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Diagnostics of antibiotic resistance
P501 Screening of ampC b-lactamases producing Escherichia coli
in stool samples
T.D. Huang, C. Bauraing, P. Bogaerts, C. Berhin, Y. Glupczynski
(Yvoir, BE)
Objectives: AmpC b-lactamases hyperproducing (ABLH) Enterobacte-
riaceae have been reported worldwide, but few data are available about
their prevalence in human clinical specimens. We aimed to investigate
the prevalence of ABLH (chromosomal or plasmid-borne) E. coli in the
faecal ﬂora of hospitalised patients.
Material and Methods: 253 consecutive faecal samples from
17 patients collected between April and July 2006 were screened for
the presence of ABLH E. coli. Samples were incubated overnight in
BHI broth containing vancomycin (20mg/L) and cefoxitin (12mg/L)
then subcultured onto CHROMagar Orientation agar (BD) plates on
which a 30mg cefoxitin disk and a 30 mg ceftazidim disk (I2A) were
placed. E. coli colonies growing close to cefoxitin and/or ceftazidim
disks were tested for antimicrobial susceptibility by disk diffusion.
Strains with reduced susceptibility to ampicillin, amoxi-clavulanate,
cefazolin and cefoxitin (compatible with a ABLH phenotype) were
further characterised by AmpC disk test, isoelectric focusing gel (IEF),
plasmid-borne ampC PCR and sequence analysis of the chromosomal
ampC promoter regions. An ABLH was deﬁned on the basis of molecular
tests (presence of a plasmidic ampC gene, a mutated ampC promoter
and/or corresponding band by IEF).
Results: 23 E. coli strains (9% of the total faecal samples) isolated
on the CHROMagar plates displayed a cephalosporinase resistance
phenotype, but only 12 were conﬁrmed as ABLH (prevalence of 6.7%
of all patients); 11 strains were chromosomal ampC hyperproducers
(prevalence of 6.2%) including 7 showing mutations at position −42 of
the promoter region; only 1 strain harboured a plasmidic CMY-2 gene.
The other 11 isolates were considered as putative penicillinase producers
associated with porin deﬁciency. Two extended-spectrum b-lactamases
(ESBL) producing E. coli strains (including one having both ampC and
ESBL enzymes) were recovered by our screening method.
Conclusion: Our screening technique appeared promising to detect
ABLH E. coli. In our study, chromosomal ampC hyperproducers E. coli
represented the major proportion (85%) of faecal carriage of ABLH
E. coli whereas plasmid-mediated ampC was encountered in only 1 of
the 12 ABLH isolates. Further studies of larger scale are needed to
characterise their prevalence.
P502 Ability of Iranian microbiology laboratories for detection
and susceptibility testing of unknown micro-organisms:
survey results of 2149 laboratories
M. Rahbar, M. Saremi, R. Sabourian, S. Hekmat yazdi (Tehran, IR)
Objective: The aim of this study was to determine ability of Iranian
microbiology laboratories for identiﬁcation and susceptibility testing of
three unknown microorganisms.
Methods: In January 17th run of proﬁciency testing of Iranian
microbiology laboratories carried out by research centre and reference
laboratories of Iran. In this survey three microorganisms including
Salmonella Para A, Stenotrophomonas maltophilia (ATCC 13637)
and Listeria monocytogenes (ATCC 7644) were submitted to 2149,
640 and 1509 laboratories respectively. All laboratories included both
hospital and non-hospital microbiology laboratories. S. para A and
S. maltophilia were sent to hospital microbiology laboratories and
S. para A and Listeria monocytogenes were sent to non-hospital
microbiology laboratories. We asked all laboratories to identify each
microorganism and susceptibility testing just for S. para A against
Ampicillin, Trimethoprim–sulfamethoxazole, Cefotaxime, Ciproﬂoxacin
and Chloramphenicol. Scoring of results performed according criteria
recommended by WHO.
Results: Of 2149 laboratories only 1491 (70%) participated in our survey
and 30% did not participated in this study. Of 1491 laboratories 513
laboratories identiﬁed S. para A correctly and obtained maximum 3 score
of points and 317 (21.2%) laboratories misidentiﬁed this microorganism.
Many laboratories had difﬁculty in identiﬁcation of S. maltophilia and
only 11% of laboratories were able in identiﬁcation of S. maltophilia and
54% of laboratories obtained zero score of points. The Third organism,
(L. monocytogenes) identiﬁed correctly by 24.6% of laboratories and
obtained the maximum score and 40.6% of laboratories were not capable
in detection of this organism. The other laboratories sent intermediate
correctly response. The results of susceptibility testing of S. para A were
relatively satisﬁed and many laboratories obtained maximum ﬁve score.
Conclusion: Our study reveals that unfortunately many microbiology
laboratories in our country are not capable in detection of microorganism
such as S. maltophilia. This problem may be due to lack of some
materials and reagents for detection of such microorganism in many
laboratories.
P503 Discrepant antimicrobial susceptibility data: an important
quality tool for the microbiological laboratory?
A. De Bel, D. Pie´rard, J. Bellen, A. Van Zeebroeck, S. Lauwers
(Brussels, BE)
Objectives: To investigate the usefulness of listings of antimicrobial
susceptibility patterns that differ in patients with several isolates of
the same species as a tool for improving the quality of antimicrobial
susceptibility tests.
Methods: A locally developed data management system was used to
detect major differences (S-R) in the antimicrobial susceptibility data
of patients with several isolates belonging to the same species. Minor
differences (S-I or I-R) were considered as not signiﬁcant and were not
taken into account. The following data were extracted from the laboratory
information system: patient name, ID number, organism ID, specimen
numbers and the results of antimicrobial susceptibility tests.
Using the pictures of disc diffusion tests stored in the SirScan®, a semi
automated image analyser coupled with an expert system, as well as
manual notes on the work lists, explanations were searched for the
discrepancies.
Results: Between 1 September 2005 and 31 August 2006, a total of
148 sets of discrepant antimicrobial susceptibility data were reviewed
on a monthly basis. In 24 cases (16.2%) discrepancies were due to a
laboratory error. An explanation was found for the discrepant patterns
in 119 cases (2 different strains, etc.) while no conclusion could be drawn
in 5 cases.
The following errors were found: erroneous reading of inhibition
diameter (n = 9), interpretation of ESBL screenings and conﬁrmation
tests (n = 5), interpretation of the D-test for the detection of inducible
resistance to clindamycin of staphylococci (n = 3), false sensitive results
to clindamycin of anaerobes when the prescribed incubation time is not
observed (n = 2), discrepancies between SirScan® results and LIS results
(n = 2), not reporting MecA PCR result (n = 1) and incorrect expert rules
n = 2).
Although the results of these surveys became available too late to lead
to useful corrections for individual patients, they enabled correction
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of systematic errors. In addition, they were discussed during technical
meetings, as an educative tool for all technologists.
Conclusion: Once a local data management system is developed, the
generation of monthly listings of discrepant antimicrobial susceptibility
data is very effortless. Systematic review of these data increases
workload for the microbiologist but is a very informative and useful
tool to improve quality. Results are used to implement corrective actions
whenever possible and as a training tool.
P504 The frequency of production of metallo-b-lactamases by hos-
pital carbapenem resistant Pseudomonas aeruginosa strains
A. Targosz, P. Nowak, A. Budak, M. Skalkowska, E. Tokarska,
D. Wlodarczyk, G. Geza (Cracow, PL)
Objectives: Pseudomonas aeruginosa is the common Gram-negative rod
associated with hospital infections. This bacterium is often multidrug
resistant. Carbapenem resistance has been observed frequently in
P. aeruginosa strains. The one form of carbapenem resistance is mediated
by metallo-b-lactamases (MBL). MBLs are Ambler class B enzymes
which hydrolyze penicillins, cephalosporins and carbapenems and are
not inhibited by site-directed b-lactam inhibitors. The aim of the study
was detection of carbapenem resistant P. aeruginosa strains producing
MBL.
Methods: Our study concerned 98 P. aeruginosa strains resistant
to imipenem and meropenem. Bacteria were isolated from clinical
specimens from patients hospitalised in different wards of Rydygier’s
Hospital in Krakow from 1st January of 2005 till 31st June 2006.
P. aeruginosa strains were identiﬁed on the basis of typical morphology
conﬁrmed by Gram-staining microscopy and biochemical tests – ID
32 GN strips using ATB system (bioMe´rieux, France). The in vitro
antimicrobial susceptibility of P. aeruginosa clinical isolates was
routinely determined using disc diffusion method according to Clinical
and Laboratory Standards Institute (CLSI) guidelines. P. aeruginosa
strains resistant to carbapenems were tested for MBL production. The
screening was carried out by two variants of the synergy disk test with
EDTA and 2-mercaptopropionic acid as MBL inhibitors and with Etest
MBL strips (AB Biodisk, Sweden).
Results: Among 98 strains resistant to imipenem and meropenem 20
produced MBL. P. aeruginosa MBL positive strains were obtained
from 9 patients hospitalised at Intensive Care Unit (19 strains) and
General Surgery Unit (1 strain). We isolated 4 strains from each of
two different patients, 3 strains from one patient, 2 strains from each
of three patients and 1 strain from each of three patients. A total of 20
MBL positive strains were collected from: respiratory track (14 strains),
urine (3 strains), wound (2 strains) and blood (1 strain). In the group of
78 P. aeruginosa strains the resistance to carbapenems was associated
with different various mechanisms.
Conclusions: Detection of carbapenem resistant P. aeruginosa strains
producing MBL is the relevant information for clinicists as well as for
Infection Control Management
P505 Screening of multidrug-resistant bacteria: clinical evaluation
of a novel chromogenic medium chromIDTM ESBL for the
screening of ESBL-producing Enterobacteriaceae
M. Husson, S. Ghiradi, M. Gerard, A. Dediste (Brussels, BE;
Craponne, FR)
Objectives: Prevention of healthcare associated infections relies on the
development and follow up of wise infection controls programmes.
Screening of extended-spectrum b-lactamase producing Enterobacteri-
aceae (ESBLE) is one of the methods to eradicate the Multi Drug
Resistant (MDR) bacteria. The aim of the study was to evaluate the
new chromogenic medium chromIDTM ESBL (bioMe´rieux, Craponne,
France) for the rapid isolation and identiﬁcation of ESBLE.
Methods: chromIDTM ESBL was compared to a home made method
combining a Mac Conkey agar plate with a disk of ceftazidime (McC).
A total of 173 at risk hospitalised patients were tested; 73 rectal swabs,
52 respiratory secretions, 48 urines were directly inoculated on the
2 media which were incubated during 18−24 hrs and 48 hrs at 35ºC-
37ºC. Typical colonies growing on chromIDTM ESBL and on McC were
identiﬁed. Conﬁrmation of the presence of ESBLs was performed using
disk diffusion methods (according to CA-SFM and/or CLSI standards).
Results: A total of 19 specimens were positive for ESBLE, corre-
sponding to 20 ESBLE strains: Escherichia coli (n = 13), Klebsiella
spp. (n = 3), Enterobacter aerogenes (n = 2), Enterobacter cloacae (n = 2).
After 24 hrs incubation, the 19 specimens were positive on chromIDTM
ESBL, whereas only 13 were positive on McC. Negative predictive
value for chromIDTM ESBL and McC was respectively 100% [97.32%;
100%] and 96% [91.37%; 98.17%], corresponding to 6 false negative
on McC. After 24 hrs, 9 specimens on chromIDTM ESBL and 17 on
McC showed a characteristic growth but were not conﬁrmed ESBL
positive (false positives). The speciﬁcity was superior for chromIDTM
ESBL than for McC (respectively 94% and 89%), with no statistical
signiﬁcant difference. Selectivity towards non ESBLE was higher for
chromIDTM ESBL.
Conclusion: The new chromIDTM ESBL, combining two chromogenic
substrates, one natural substrate and a selective agent of ESBL character,
is well positioned as a screening test in order to exclude ESBLE carriage
within 24 hrs and to participate to the development and follow up of
infection control programmes.
P506 Infections in pregnant women caused by Streptococcus
agalactiae and problems with growing MLSB-type resistance
M. Strus, M. Brzychczy-Wloch, T. Gosiewski, A. Drzewiecki, P. Kochan,
D. Pawlik, P. Heczko (Cracow, PL)
Objectives: Over the recent years in Poland one could observe
the growing numbers of pregnant women colonised with group B
streptococci (GBS). Epidemiologically speaking it raises concern,
because of severe consequences, i.e. higher number of infections and
deaths in newborns. Therefore, the main aims of this study were to:
– compare the effectiveness of GBS detection in pregnant women
using the classical culture method and a modiﬁed culture method
recommended by the CDC;
– show the frequency of GBS carriage among the populations of healthy
pregnant women versus women with high-risk pregnancy;
– examine the frequency of resistance markers to macrolides and
lincosamides (MLSB) among the GBS strains isolated from Polish
women.
Methods: The study was performed on a group of 629 women between
the II and III trimester of pregnancy. 156 women were classiﬁed
as high-risk pregnancy. The materials collected for microbiological
tests were vaginal and anal swabs. The materials were cultured on
selective media and evaluated for GBS growth. The bacteria were
identiﬁed by phenotypic methods and their identiﬁcation was conﬁrmed
by genotyping, using the ﬂuorescent in situ hybridisation (FISH) with
the Saga 67 a/b probe selective for Streptococcus agalactiae species.
MLSB-type resistance markers were also determined, their presence was
veriﬁed by looking for the erm a, b, c genes with multiplex PCR.
Results: Carriage of GBS was conﬁrmed in 13.5% of pregnant women
by using the classical culture method. Using the CDC recommended
method improved the detection to 20.8%. When using the CDC method,
it was observed that the high-risk pregnancy had higher rates of carriage
of GBS, up to 22.4%. MLSB-type resistance markers were detected in
strains isolated with the CDC recommended method.
Conclusion:
1. When comparing the effectiveness of GBS detection in pregnant
women using the classical culture method versus the CDC recommend
method, we showed improved detection (~5%) using the CDC method.
2. We showed that the frequency of GBS carriage among women with
high-risk pregnancy is 3% higher than that for healthy pregnant
women.
3. When analysing the phenotypic resistance of GBS strains to
macrolides and lincosamides, we showed an 8% more frequent
presence of the MLSB-type resistance among S. agalactiae in women
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with high-risk pregnancy (n = 156), than in women with normal
pregnancy (n = 250).
P507 A novel method for the detection of extended-spectrum
b-lactamases, metallo-b-lactamases and AmpC producing
Gram-negative bacilli in a single test: the CICA beta-test
F. M’Zali, C. Arpin, V. Dubois, C. Andre, C. Quentin (Bordeaux, FR)
Objectives: Multidrug resistant Gram-negative bacilli are emerging
pathogens. Infections caused by these organisms represent a clinical
challenge. Currently, evidence related to infectious diseases with Gram-
negative rods with extended spectrum b-lactamases (ESBLs) or metallo-
b-lactamases (MBLs) or AmpC is accumulating. A rapid, sensitive and
reliable method for their early detection is critical. The Cica beta-Test
(Kanto Chemical, Japan; Mast, UK) is a new method which uses strips
impregnated with a chromogenic cephalosporin (HMRZ-86) coupled
with each of clavulanic acid for ESBL detection, boronic acid for AmpC
detection and mercapto-acetic-acid and EDTA for detection of MBLs.
The aim of this study was to evaluate the Cica beta-Test against a large
panel of clinical strains known to harbour these enzymes singly or in
combination.
Methods: A collection of 100 epidemiologically distinct clinical isolates
from French hospitals and nursing homes were examined. The collection
includes strains of the Enterobacteriaecae family, Pseudomonads and
Acinetobacter spp. The clinical strains produce previously fully
characterised b-lactamases of TEM, SHV, CTX-M, VEB, PER, CMY,
GES, VIM, IMP and OXA families. All isolates were re-tested using
the Cica beta-Test. The test consists on paper strips each speciﬁc for
the detection of ESBLs, MBLs, AmpC and penicillinase producing
organisms. Only ESBLs and MBLs are able to hydrolyze the b-lactam
ring in HMRZ-86, resulting in a colour change from yellow to red. The
test organism is grown overnight on Muller Hinton plate. One drop of
HMRZ-86 is dispensed on each strip, then one to two colonies of the
test organism is spread on the ﬁlter pad of the Cica-Beta-Test strip. The
test is read after 2 to 15 min.
Results: All mechanisms of resistance in the clinical strains were
correctly identiﬁed. Presence of combination of mechanisms was also
picked up notably (CTX-M +AmpC), (VIM-2 + SHV-5), (VEB-1
+AmpC). In addition, the Cica beta-Test provides us with rapid
information on the resistance mechanism(s) (maximum 15 min).
Conclusion: We describe here a technically simple method for the
detection of ESBL, MBL and AmpC producing Gram-negative bacilli.
The test proved of high sensitivity and speciﬁcity and provides useful
information for targeted therapy. We recommend this test as a routine
screening method for the detection and identiﬁcation of mechanisms of
resistance in Gram-negative bacteria.
P508 Preliminary feasibility study of MIC results obtained with
Staphylococcus aureus and cefoxitin using an Investigational
Use Only MicroScan Dried Overnight Panel
K. Sei, H. Bains, B. Zimmer (West Sacramento, US)
Objectives: Accurate conﬁrmation of methicillin-resistant S. aureus
is important for clinical laboratories. The CLSI recently introduced
disk diffusion testing with cefoxitin as an alternate method to testing
with oxacillin to determine MRSA; interpretive criteria using cefoxitin
broth microdilution have not yet been established. This preliminary
feasibility study evaluated cefoxitin microdilution with S. aureus on
an Investigational Use Only (IUO) MicroScan Dried Overnight Gram
Positive panel. MIC results obtained were compared to results obtained
with cefoxitin disk diffusion, cefoxitin and oxacillin MICs using frozen
broth microdilution panels, and mecA analysis.
Methods: Thirty-nine S. aureus comprising 17 mecA positive and 22
mecA negative isolates were tested concurrently on a MicroScan IUO
Dried Overnight Gram Positive Panel and a frozen reference panel.
Both panels contained cefoxitin in doubling dilutions from 2−64 ug/mL
and linear dilutions between 4−8 ug/mL. The frozen reference panel
contained oxacillin in doubling dilutions from 0.12−64 ug/mL. Panels
were inoculated using the turbidity standard method and read visually at
24 h. Cefoxitin disk diffusion was performed as described and interpreted
by CLSI criteria. All data were analysed using mecA results as the
reference method.
Results: All mecA positive isolates gave resistant results using
the cefoxitin disk test. Reference oxacillin MICs ranged from 1–
>64 ug/mL with 2 isolates giving oxacillin MICs less than or equal to
2 ug/mL. Cefoxitin MICs on frozen panels ranged from 16−64 ug/mL;
corresponding results with MicroScan panels ranged from 7−32 ug/mL.
All 22 mecA negative isolates gave susceptible results using the cefoxitin
disk test. Reference oxacillin MICs ranged from 0.25−4 ug/mL. A total
of 20/22 cefoxitin MICs on frozen panels were 4 or 5 ug/mL; the other
2 MICs were 7 and 16 ug/mL. Corresponding results with MicroScan
panels gave 21/22 results at 4 ug/mL and 1 result at 5 ug/mL.
Conclusions: This preliminary feasibility study shows the MicroScan
IUO Dried Overnight panel correlates well with a CLSI microdilution
broth reference panel, cefoxitin disk diffusion testing, and mecA testing
for detection of MRSA.
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P509 Genotypic analysis of human Salmonella typhimurium strains
from western Kenya
D. Onyango, E.N. Waindi, R. Kakai, W. Rabsch, E. Tietye,
B. Ghebremedhin, W. Konig, B. Konig (Maseno, KE; Berlin,
Magdeburg, DE)
Salmonella spp. are recognized as some of the most common pathogens
causing enteritis worldwide. In this study we emphasized on molecular
characterisation of 20 human S. typhimurium strains from two health
centres in Western Kenya.
Identiﬁcation of S. typhimurium strains was performed using serotyping,
biochemical and distinct molecular tests including 16S rRNA sequenc-
ing. Antimicrobial screening was done using agar-disc-diffusion, E-test
and automated VITEK R 2. Molecular epidemiology and mechanisms
of resistance genes to tetracycline, ampicillin, streptomycin, gentamicin,
sulfamethoxazole and kanamycin was studied. Strain diversity was
analysed using Pulse Field Gel Electrophoresis (PFGE), ﬂuorescence
Ampliﬁed Fragment Length Polymorphism (fAFLP) and Multi-Locus-
Variable-Number-Tandem regions (MLVNTR).
All the 20 S. typhimurium isolates were resistant to ampicillin
(MIC> 256mg/L)and streptomycin (MIC, 48–256mg/L), sulfamethox-
azole (MIC> 32mg/L), chloramphenicol (MIC> 256mg/L), 14 to
gentamicin, 13 to ceferclor. 3 Salmonella strains (one S. typhimurium,
one S. enteritidis and one mixed colony) were tetracycline (MIC,
32> 256mg/L) resistant and possessed tetracyline resistance gene tetA
responsible for drug efﬂux. Ciproﬂoxacin resistance was not detected.
The molecular antimicrobial mechanism indicated resistance gene to
Grm, aadB, blaPSE1, bla TEM, aadA, and strB. The microrestriction
analysis by XbaI gave patterns A, B, C, D and E. Of the 20 typeable
isolates, 72.7% were type A, 4.5% were type B, 4.5% were type C, 4.5%
were type D, and 4.5% were type E. Phage proﬁle analysis could be
categorised into three phage types (type 1, 2, and 3) of which 3 isolates
were type 1, 8 were type 2 and 5 were type 3. 3 strains could not be
typed. Phage DT 104 was not detected. Nine isolates were positive for
class I integron (6 had 1.2Kb and 3 had 0.8Kb fragments).
Four plasmid proﬁles of 70, 55, 1.8, 1.4Kb; 70, 1.8, 1.4Kb; 70, 4.6Kb
and 60Kb were observed. Salmonella plasmid virulence factor (spv) and
invasive gene (inv) was ampliﬁed for all strains. Strains were further
subdivided Using FAFLP analysis and selected VNTR loci.
Heterogenicity among S. typhimurium strains from Western Kenya and
their difference from strains originating from other parts of Kenya and
around the world was observed. S. typhimurium isolates were resistant
to various antimicrobials. However the resistance was fairly low as
compared to the world resistance patterns.
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P510 Phenotypic and genotypic characterisation of antimicrobial
resistance in Turkish Salmonella infantis isolates from
chicken and minced meat
D. Avsaroglu, E. Junker, R. Helmuth, A. Schroeter, M. Akcelik,
F. Bozoglu, K. Noeckler, B. Guerra (Ankara, TR; Berlin, DE)
Objectives: Characterisation of the resistance (R) phenotypes and
underlying molecular mechanisms in Salmonella (S.) Infantis strains
isolated from Turkish foods.
Methods: 100 Salmonella isolates were isolated from foods bought
in free markets in Ankara (2005–2006). One of the most prevalent
serotypes was Infantis (13 isolates). Nine of these S. Infantis isolates
were considered as epidemiological unrelated strains (different isolation
date or place). The nine strains (7 from chickens and 2 from minced
meat) were tested for susceptibility to 17 antimicrobial agents by broth
microdilution. Resistant strains were screened for 16 R-genes, class 1
and 2 integrons and mutations in the quinolone-R determining regions.
Strains were typed by XbaI-PFGE and plasmid proﬁle.
Results: The strains showed two similar XbaI-PFGE-patterns (dif-
ferences affecting two bands). Six strains showed PFP1 and 3
PFP2. One big plasmid (>200 kb) was present in all of them. All
strains were multiresistant, with resistances to 7−9 antimicrobials (6−7
R-determinants). Two phenotypic R-patterns were found: [kanamycin–
neomycin–nalidixic acid–streptomycin–spectimomycin–sulfamethoxa-
zole–tetracycline–trimethoprim–sulfamethoxazole/trimethoprim] in eight
strains, and the same R-pattern without [kanamycin–neomycin] in one.
One R-determinant was responsible for each resistance: aphA1 for
kanamycin, aadA1-like for streptomycin-spectinomycin (no strA or strB
were found); sul1 for sulfamethoxazole (no sul2 or sul3 were present);
tet(A) for tetracycline (no tet(G) or tet(B)); and dfrA14 for trimethoprim
(no dfrA1, A12, A7 or A17 were present). All strains harboured a class 1
integron carrying an aadA1 gene. No class 2 integrons were detected. All
strains were resistant to nalidixic acid and showed reduced susceptibility
to ciproﬂoxacin (0.25−0.5microg/mL) conferred by mutations in the
gyrA (Ser83 to Tyr83) and parC (Thr57 to Ser57) genes. No quinolone-R
genes qnrA, qnrB or qnrS were found.
Conclusions: S. Infantis isolated from foods in Turkey exhibit a wide
repertoire of genetic elements to survive under antimicrobial pressure.
One speciﬁc PFGE-type carrying a big plasmid (>200 kb), and with the
antimicrobial multi-R pheno/genotype [KAN-NEO]-[STR-SPE]-SUL-
TET-[TMP-SXT]-NAL/aphA1-aadA1-sul1-tet(A)-dfrA14-[gyrA^Tyr83-
parC^Ser57) is widespread. Since S. Infantis frequently causes human
infections, the wide spread of such a multiresistant clone within foods
should be considered as a public concern.
P511 Salmonella enterica serotype Typhimurium DT104 as a cause
of infantile bacteraemia in Southern Mozambique
J. Ruiz, I. Mandomando, E. Macete, L. Puyol, A. Echeita, P. Alonso
(Barcelona, ES; Manhic¸a, MZ)
Objectives: To report the presence of Salmonella enterica serotype
Typhimurium DT104 as a cause of infantile bacteraemia in Southern
Mozambique.
Methods: Bacterial infections surveillance has been carried out at
Manhic¸a Health Research Centre since 1998, Maputo, Mozambique.
One hundred seventy Salmonella typhimurium isolated from under
15 children admitted at Manhic¸a District Hospital (MDH) were analysed.
Microbial identiﬁcation was performed by biochemical methods,
while serotype and phagotype were established following conventional
methodologies. Antimicrobial susceptibility levels to ampicillin (Amp),
amoxicillin plus clavulanic acid (AMC), ceftazidime (Caz) gentamicin
(Gm), streptomycin (Str) cotrimoxazole (Sxt), tetracycline (Tc), chlo-
ramphenicol (Chl), nalidixic acid (Nal) and ciproﬂoxacin (Cip) were
established by the method of Kirby-Bauer. Molecular mechanisms of
resistance to b-lactams, chloramphenicol and tetracycline as well as the
presence of type 1 integrons were detected by PCR and sequencing.
Results: Two isolates were identiﬁed as S. typhimurium DT104, which
were resistant to Amp, Str, Chl and Tc, being susceptible to Sxt, Caz,
Nal, Cip and Gm. One of the isolates was susceptible to AMC, while
the other one was intermediate. The presence of the genes carb2, ﬂoR
and tetG, as well as two integrons, that carry on the aforementioned
carb2 gene and an aadA2 respectively were detected. Presence of the
tetA, tetB, cmlA, tem-like, shv-like, oxa-1 like, oxa-2 like and oxa-5
like genes was not detected.
Conclusion: This is the ﬁrst report of multi-drug resistant Salmonella
enterica serotype Typhimurium DT104, as responsible for bacteraemia
in rural Mozambican children. Bacterial surveillance studies are need in
the country to monitor the emergence of multi-drug resistant Salmonella
including this phagotype.
P512 Dissemination of antibiotic multi-resistant Salmonella isolates
in Portuguese piggeries
P. Antunes, N. Pestana, C. Re´u, L. Peixe (Porto, PT)
Objectives: To study susceptibility to different antibiotics and to
characterise the genetic determinants of antimicrobial resistance in
Salmonella isolated from Portuguese piggery in order to assess the
contribution of this type of animal exploration to the burden of mobile
resistance genes and multidrug resistant clones previously observed in
human and food products.
Methods: Dry faeces samples collected in 2006 from 2 pig farms in
the Center and South of Portugal were positive for the presence of
Salmonella (reference method ISO 6579:2002). Antibiotic susceptibility
was study by disk diffusion method (CLSI) to 10 antimicrobial agents.
Different antibiotic resistant phenotypes were selected for further studies.
Detection and characterisation of class 1 integrons was performed by
PCR, RFLP (TaqI) and sequencing. Resistance genes were searched
by PCR. Conjugation assays and clonality analysis (PFGE-XbaI) were
performed.
Results: All the Salmonella isolates recovered were resistant to one
(tetracycline) or more antimicrobial agents (streptomycin, gentamicin,
ampicillin, nalidixic acid, chloramphenicol, tetracycline, sulfonamides
or trimethoprim). Characterisation of class 1 integrons revealed the
presence of an array of gene cassettes (dfrA12, aadA) in isolates of
S. typhimurium which also carried sul1, sul2 and sul3 genes and in
isolates of S. Rissen, carrying sul1. The isolates of both serotypes were
clonally related to strains previously observed in human and foodborne
isolates widely disseminated in Portugal. Interestingly, MDR isolates of
the S. Rissen clone were recovered from both piggeries studied. Other
resistance genes (blaTEM, aac(3)-IV, tetA) were identiﬁed in the MDR
isolates, but not integrated as gene cassettes.
Conclusion: Piggeries are in our country a source of MDR Salmonella
isolates. Intensive use of several antimicrobial agents in this type
of animal production seems to contribute to the selection of widely
disseminated MDR clones.
P513 Dissemination of a new gene cluster comprising sul3
(tnp-sul3-tnp) linked to class 1 integrons with an unusual
3′CS region (qacH) among Salmonella isolates
P. Antunes, J. Machado, L. Peixe (Porto, Lisbon, PT)
Objectives: The objective of this study was to characterise the genetic
background of sul3 gene, including their association to integron
structures, in non-typhoid Salmonella isolates, in order to explain the
dissemination of this sulfonamide resistance gene.
Methods: Forty-seven sul3-carrying Salmonella isolates from different
sources (human, food products and environment) and serotypes were
studied. Characterisation of class 1 integrons was done by PCR, RFLP
(TaqI) and sequencing. Clonality analysis (PFGE-XbaI) and location of
the sul3 gene by conjugation assays, plasmid analysis and Southern blot
hibrydisation (S1-PFGE) were performed.
Results: A gene cluster comprising sul3 and transposase-like sequences
(tnpA-sul3-orf1-IS26) was linked to class 1 integrons with an unusual
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3′CS region (qacH). Three types of elements differing in the gene
cassette array were observed: type I) 5′CS-dfrA12-orfF-aada2-cmlA1-
aadA1-qacH-tnpA-sul3 (ca. 7000 bp), located in twelve MDR isolates
(four serotypes corresponding to ﬁve clones) on large plasmids of
different sizes (100Kb, conjugation achieved in ﬁve); type II) 5′CS-
dfrA12-orfF-aadA2/1-qacH-tnpA-sul3 (ca. 4500 bp), only described in
the MDR S. Rissen clone on identical conjugative plasmids of ca.
70Kb; type III) 5′CS-estX-psp-aadA2-cmlA1-aadA1-qacH-tnpA-sul3
(ca. 7300 bp), located in thirty-two MDR S. typhimurium isolates
(corresponding to three clones) on high molecular weight plasmids of
different sizes (between 150 and 240Kb).
Conclusion: We describe the dissemination of sul3 associated with
plasmid-borne class 1 integrons containing an unusual 3′CS site. The
presence of similar sul3-integron platforms containing different gene
cassettes arrays or hybrid genes suggests evolution of the genetic
background by different recombinatorial events. The association with
epidemic plasmids and particular MDR clones of Salmonella might
contribute to the maintenance and further spread of modular antibiotic
resistance elements from food animals to hospitalised humans as reported
for other Salmonella genetic elements.
P514 Class 1 integron mediates antibiotic resistance in Aeromonas
spp. from rainbow trout farms in Australia
O. Akinbowale, H. Peng, M. Barton (Adelaide, AU)
Objectives: As part of the work carried out in response to the
Joint Expert Technical Advisory Committee on Antibiotic Resistance
(JETACAR) recommendation on antibiotic resistance surveillance, the
presence of integrons and other resistance determinants was investigated
in 90 Aeromonas isolates derived from nine freshwater trout farms in
Victoria (Australia).
Methods: Polymerase chain reaction (PCR) was carried out for the
detection of integrase genes Int1, Int2, Int3, integron variable region,
integron associated aadA gene with primers speciﬁc for the detection of
the aadA1a gene cassette and other closely related aadA gene cassettes
(with the exception of aadA4 and aadA5), streptomycin resistance genes
strA-strB, sulphonamide resistance gene sul1, quaternary ammonium
compound resistance gene qac1, beta lactamase resistance genes
blaTEM, blaSHV, and tetracycline resistance gene tetA-E and tetM.
Clonality analysis was performed by Pulse ﬁeld gel electrophoresis
(PFGE).
Results: Class 1 integrons were detected in 28 of the 90 (31%) strains
investigated. Class 2 and 3 integrons were not detected. Using primers
speciﬁc for the aadA gene, aadA gene was detected in 19 of the
27 (70%) streptomycin resistant strains. However, when the variable
region of the integron was ampliﬁed, four strains with streptomycin MIC
128mg/L and one with MIC >128mg/L gave amplicon sizes of 1000
bp each. Other strains having MIC 16mg/L did not give any amplicon
possibly due to lack of the 3′conserved segment. Sequence analysis of
the products reveals the presence of aadA2 gene. None of the strains
harboured the strA-strB genes. PFGE analysis of the ﬁve strains reveals
genetic relatedness with all ﬁve having the same banding pattern even
though they came from different farms. Sul1 gene was detected in 13 of
the 15 sulphonamide resistant strains and qac1 gene detected in 8 of the
28 integron bearing strains. TetC was detected in all and tetA in 9 of the
18 tetracycline resistant strains. No blaTEM and blaSHV was detected.
Conclusion: Although no antibiotics are licenced for use in Australian
aquaculture and there has been no information on resistance determi-
nants, our data suggests that Aeromonas carrying resistance genes as
well as integrons are present in farm raised ﬁsh and sediments and
different ﬁsh farms might share a common pool for the aadA2 gene.
P515 Analysis of antimicrobial susceptibility and virulence factors
in Helicobacter pylori clinical isolates in the United Arab
Emirates
M. Alfaresi, A. Elkouch, A. Abdulsalam (Abudhabi, AE)
Objectives: The gastric pathogen Helicobacter (H.) pylori produces
virulence factors such as CagA and VacA that are associated with
symptom severity in infected individuals. In this study, we asked whether
there is a correlation between the clarithromycin resistance status of
H. pylori clinical isolates and vacA and cagA status, as well as whether
these characteristics correlated with the clinical symptoms of gastric
disease.
Methods: DNA was extracted from antral gastric biopsy samples from
91 dyspeptic patients in the United Arab Emirates (UAE). Real-time
PCR and melting curve analysis was used to identify patients infected
with H. pylori and to further identify strains containing the A(2142/43)G
or the A(2142)C mutations that are associated with clarithromycin
resistance. PCR was also used to identify cagA- and vacA-positive
strains. Clinical examination and patient histories were used to classify
the clinical symptoms of H. pylori-infected patients.
Results: Real-time PCR analysis detected the presence of H. pylori in
55 samples (60%); further PCR analysis found that 36 of the pathogen-
positive samples (65.5%) contained at least one of three point mutations
associated with clarithromycin resistance. Patients from the UAE had
the same mutation incidence as non-UAE patients. The vacA gene
was present in 72.7% and cagA was present in 75.5% of the positive
samples. The 55 H. pylori-positive patients were clinically categorised
as having non-ulcer dyspepsia (19 patients), peptic ulcers (20 patients)
or gastroesophageal reﬂux disease (16 patients).
Conclusions: The presence of each clarithromycin-resistance inducing
mutation was largely independent of the others. The A(2142/43)G
mutations were strongly associated with the presence of both the vacA
gene and the cagA gene, and there was a strong association of the
presence of both the vacA and the cagA genes. Both genes were more
likely to be present than absent in samples from all patients, regardless
of the symptoms exhibited, but there was no correlation in the incidence
of any of the point mutations with any of the categories of clinical
symptoms.
Taken together, these results may help physicians identify patients
likely to be responsive to standard clarithromycin-based therapy, and
also underscore the value of using real-time PCR methods for rapid
identiﬁcation of clarithromycin-resistant H. pylori strains.
P516 Distribution of clarithromycin-resistant strains of
Helicobacter pylori in north-west Russia
E. Tarasova, K. Osipov, M. Suvorova (Saint-Petersburg, RU)
Objectives: Recent studies have shown that susceptibility of Helicobac-
ter pylori strains to clarithromycin strongly depends on mutations in the
gene of 23SrRNA. The level of clarithromycin resistance is constantly
increasing in the population due to accumulation of speciﬁc mutations
in the epidemic H. pylori strains. In this study we tried to assess the
distribution of clarithromycin resistant strains of Helicobacter pylori in
north-west Russia.
Material and Methods: 65 patients with H. pylori infection were
included in the study. 51 of them were children under 16 years old.
Helicobacter pylori infection was analysed by histology, rapid urease
tests and PCR employing the primers to urease C gene. From some of
the patients both antral and body of stomach biopsies were examined.
Clarithromycin resistance was assessed by polymerase chain reaction
to identify the presence of point mutations in the peptidyltransferase
region of the 23S rRNA gene previously associated with resistance to
clarithromycin. PCR products were digested with restriction enzymes
MboII, HhaI, and BsaI to detect mutations A2142G, T2717C and
A2143G
Results: Results Primary clarithromycin resistance was detected in
13 (20%) patients. The A2143G point mutation was detected in
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6 (46.1%) patients, A2142G in 3 (23.%), A2117C in 4 (30%). 12 patients
had the same mutations in antral and body stomach sections, but 1 patient
had a strain of H. pylori without any mutations in antral section and
A2142G mutation in body of stomach.
Conclusions: Our study found that clarithromycin resistance is highly
prevalent and that A2143G is the most frequent point mutation involved
in north-west Russia region. It is worth examining both antral and body
srctions of the stomach. These results suggest that the PCR is a valid
tool for rapid assessment of clarithromycin resistance in H. pylori and
that in the future it could be used directly on biopsy specimens, avoiding
the need for culture-based methods.
P517 Toxigenic status of Korean Clostridium difﬁcile isolates
H. Kim, M. Kim, C-K. Kim, D. Yong, K. Lee, Y. Chong, J-W. Park,
T.V. Riley (Seoul, Daejeon, KR; Perth, AU)
Objectives: Toxigenic strains of Clostridium difﬁcile usually produce
both toxin A and B, although toxin A variant strains (toxin A-negative,
toxin B-positive) have been responsible for C. difﬁcile associated disease
(CDAD). Some strains of C. difﬁcile also produce a binary toxin.
Recently, epidemics of CDAD with high morbidity and mortality have
been reported in Canada, the USA and Europe due to a new strain of
C. difﬁcile (PCR ribotype 027). This strain produces more toxin A and B
than other strains due to partial deletion of tcdC gene (down regulator
of production of toxin A and B) and carried binary toxin gene. The
aims of this work were to evaluate the toxigenic status of strains of
C. difﬁcile circulating in Korea and to determine whether this new strain
had arrived.
Methods: Four hundred and seven randomly selected isolates of
C. difﬁcile recovered from patients with diarrhoea in a tertiary teaching
hospital in Korea from 1980 to August 2006 were analysed. PCR was
used to amplify genes for toxin A (tcdA), toxin B (tcdB), the repeating
sequence of toxin A (tcdA rep) and binary toxin (cdtA, cdtB). PCR
ampliﬁcation of tcdC gene and PCR ribotyping were performed in binary
toxin-producing strains. The patients’ medical records were reviewed in
order to evaluate the severity of CDAD.
Results: Of the 407 strains tested, 319 (78%) were toxigenic strains.
The proportion of toxin A variant strains increased during the study
period: 1980 and 1990 (0%), 1995 (4.2%), 2002 (12.5%), 2003 (15.2%),
2004 (39.6%), 2005 (30.0%), and 2006 (28.6%). The proportion of
binary toxin-producing strains was also increased: 1980, 1990, 2002 and
2003 (0%), 1995 (2.1%), 2004 (1.9%), 2005 (2.6%) and 2006 (4.1%).
All binary toxin-producing strains were toxin A and B positive, and no
partial deletion of the tcdC genes was detected. PCR ribotyping patterns
showed that binary toxin-positive strains were unrelated. According to
medical records in binary toxin-positive cases, there was no evidence of
severe, recurrent or fatal cases.
Conclusion: Toxin A variant strains of C. difﬁcile were very prevalent
and binary toxin-producing strains started to emerge in Korea. PCR
ribotype 027 strain of C. difﬁcile was not detected in our study. Further
multicentre surveys are needed to ensure this new strain is present in
Korea.
P518 Mandatory strain sampling programme for Clostridium
difﬁcile in English NHS acute hospitals: experience from
surveillance in 2005 and options for future implementation
A. Charlett, M. Murray, B. Patel, J. Brazier, K. Wagner, A. Jones,
L. Saker, A. Pearson (London, Cardiff, UK)
Objectives: The Department of Health in England (DH) requested that
the Health Protection Agency (HPA) introduce various programmes to
examine epidemiologic trends on Clostridium difﬁcile associated disease
(CDAD). Data from the DH surveillance system suggests increasing
incidence of CDAD, with 51,690 cases reported in 2005 compared with
44,107 in 2004, representing a 17.2% increase. In addition to the national
mandatory programme for C. difﬁcile, in 2005 the HPA implemented
a random sampling scheme to monitor the frequency of C. difﬁcile
strains and examine regional variations in types of strains. This paper
describes the results of the ﬁrst year of the C. difﬁcile random sampling
programme.
Methods: 173 acute Trusts in England submitted C. difﬁcile samples to
the Anaerobe Reference Unit (ARU) in Cardiff as part of a national
sampling programme. Each acute trust was randomly allocated one
week for sampling during which they provided consecutive positive
C. difﬁcile samples (excluding multiple specimens from an outbreak)
up to a maximum of ten. C. difﬁcile isolates were identiﬁed using PCR
Ribotyping.
Results: A total of 1,004 cultures of C. difﬁcile positive stools from 143
trusts were obtained and C. difﬁcile isolates were recovered from 881
of the 1,004 samples. Results indicate wide regional variations in PCR
Ribotypes, with C. difﬁcile isolate 106 found predominantly in London
(41% of cases) and the West Midlands (40% of cases); epidemic strain
027 identiﬁed mainly in the South East (41% of cases) followed by
the West Midlands and South West (40% of cases); and isolate 001
found in Yorkshire and the Humber and the North West (48% of cases).
Results indicate that there appears to be a major shift from the observed
predominance of Ribotype 001, although previous sampling routines
focused on analysis of strains submitted from outbreaks. This study
indicates a shift in the frequency and distribution of strain types.
Conclusions: The sampling programme underscores the importance of
collecting strains for analysis by PCR Ribotying to establish whether
there has been a concomitant change in the epidemiology of C. difﬁcile.
Options for future sampling schemes for C. difﬁcile include, broadening
the sample to include patients under 65 (as these represent 22% of
the cases), over-sampling high-prevalence hospitals, instituting speciﬁc
programmes for examining hyper-endemnicity and emergent outbreaks,
and examining temporal trends.
P519 The effect of antibiotic withdrawal on the incidence of
antibiotic-resistant Campylobacter spp. in the pig gut
V.I. Enne, A.A. Delsol, P.M. Bennett (Bristol, UK)
Objectives: The fate of antibiotic-resistant bacteria in the absence of
antibiotics is poorly understood. We studied the effect of antibiotic
withdrawal on the presence of antibiotic-resistant Campylobacter spp.
in the pig gut.
Methods: After treatment with tetracycline and penicillin, 6 pigs were
placed in a bio-secure unit and antibiotics withdrawn. Faecal samples
were collected at withdrawal (t0), and once a week for 8 weeks (t1-
t8); Campylobacter spp. were isolated by plating faeces onto CCDA
medium followed by microscopic identiﬁcation. 496 Campylobacter
spp. isolates were collected, comprising approximately equal numbers
from each time point and pig. 62 of the isolates were speciated by a
multiplex PCR assay. The susceptibilities of the isolates to ampicillin,
chloramphenicol, ciproﬂoxacin, streptomycin, sulphamethoxazole and
tetracycline were determined by disc diffusion. PCR for the resistance
genes aadA, blaOXA-61 and tetO was carried out on a proportion
of isolates. RAPD PCR was used to determine relationships between
selected isolates.
Results: All 62 isolates speciated by multiplex PCR were C. coli.
The incidence of antibiotic resistance was variable from week to
week, but antibiotic withdrawal did result in some reductions in the
overall prevalence of resistance. Streptomycin resistance decreased
signiﬁcantly from 79% at t0 to 46% at t8. Ampicillin resistance also
decreased signiﬁcantly from 12% at t0 to 0% at t8, and tetracycline
resistance decreased from 90% at t0 to 44% at t8. Chloramphenicol
resistance remained low throughout the study, while ciproﬂoxacin
and sulphonamide resistances ﬂuctuated, averaging at 31% and 23%
resistance respectively. PCR indicated that approximately 75% of
streptomycin resistant isolates carried the aadA gene, approximately 90%
of tetracycline resistant isolates carried the tetO gene and approximately
60% of ampicillin resistant isolates carried the blaOXA-61 gene. RAPD
PCR revealed that at any one time the Campylobacter population was
composed of a variety of several different strains, and that the reductions
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in resistance observed were due to displacement of resistant strains by
sensitive ones.
Conclusion: Antibiotic withdrawal resulted in a reduction in the
incidence of antibiotic resistance among Campylobacter spp. from the
pig gut, although this reduction only occurred several weeks after
antibiotic withdrawal. Resistance to agents that both had and had not
been administered to the animals was reduced.
P520 Antibiotic resistance conferred by a class 1 integron and
SXT element in different Vibrio cholerae O-serotype isolated
in Algeria
H. Ammari, R. Ruimy, D. Skurnik, A. Andremont, D. Mazel, A. Guerout,
F. Assaous, K. Rahal (Algiers, DZ; Paris, FR)
Objectives: We investigated retrospectively antibiotic resistance, pres-
ence of integrons and SXT integrating conjugative element (SXT-ICE)
in Vibrio cholerae isolates from the environment and from patients in
several cities of Algeria, during the period from 1980 to 2003.
Methods: The strain collection was selected from a large number of
V. cholerae studied previously for various phenotypic and genotypic
characteristics. Single isolates differing by year, place of isolation and
phenotypic pattern of antibiotic resistance were included in this study.
Eighteen isolates (8 V. cholerae O1 and 10 V. cholerae non-O1, non-
O139) were examined for the presence of: (i) class 1, 2 or 3 integrases by
a triplex real-time PCR, (ii) SXT-ICE by PCR detection of the integrase
gene. The resistance gene cassettes content within the different class 1
integrons were determined by DNA sequencing of the variable region
located between the 5′ and 3′ conserved sequences.
Results: All V. cholerae O1 carried class 1 integron except two isolates
of 1980 and one of 1997. One isolate of 1980, and two isolates of 1981,
were found to contain two class 1 integrons carrying different cassettes
(aacC and aadA1, dfr2 and aadA6). The 1986 isolate carried also 2
integrons which respectively contained dfr15 and aadA1. A single class
1 integron was found in the isolate of 1994, which carried aadA1 only.
The SXT-ICE was only found in the isolates of 1994 and 1997.
Concerning V. cholerae non-O1, non-O139, class 1, 2 and 3 integrons
were not detected for the isolates of 1985, 1987, 1996, 1997, 1999
and 2003, of which 5 of them were only resistant to ampicillin and
one to sulfonamide. Two class 1 integrons were found in an isolate
of 2001, which respectively contained aadA7, dfr1 and orfC sequence.
Single class 1 integrons were found in three isolates, which contained
respectively dfr7, aadA1 and aadA5-dfr17. SXT-ICE was not found in
any isolate.
Conclusion: Our ﬁndings show that class 1 integrons are widespread
among different clinical and environmental V. cholerae O1 and non-
O1, non-O139 serotypes in Algeria with a high diversity of resistance
cassettes, even in a 1980 strain which appears to be the oldest available
V. cholerae O1 from Africa. The SXT-ICE was only found in V. cholerae
O1 after 1986.
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P521 Prevalence of intestinal parasitism in an urban public
hospital of Madrid
D. Monclu´s, A. Pe´rez de Ayala, J.M. Azcona, M.C. Del Rey,
M. Lo´pez-Brea (Madrid, ES)
Objective: To determine the prevalence of intestinal parasitism in adults
in a 550 beds hospital of Madrid, in a period of four years.
Material and Methods: During the years 2002–2005 a total of 13.765
stool samples from patients of the hospital and area health centres were
analysed. The average age was 44.8 years. Microscopic and macroscopic
tests were made using methods such as: fresh test with physiological
saline solution and lugol’s solution, concentration techniques with
formaldehyde-eter (Ritchie’s test), trichrome stain, Ziehl–Neelsen stain,
and Graham test for detection of oxyuros.
Results: The prevalence of the pathogens and commensal parasites was
23.51%. Of the 13,765 samples, 3,237 were positives (23.51%.), and in
686 (21% of the positives samples) we found more than one parasite,
with a total of 3,847 parasites. Blastocystis hominis was the main entero-
parasitic pathogen found (54.6%), followed by Endolimax nana (16.2%),
and Giardia intestinalis (9.5%). The Table 1 shows the parasites detected.
Conclusions: We have found low helminth prevalence compared with
protozoa probably due the geographic area and the population group.
Most of parasites were commensal or potentially pathogenic. The
prevalence of intestinal parasites in our hospital is similar to other areas
with similar characteristics.
Table 1. Parasites detected in faeces
Year G
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Total
2002 92 432 47 0 138 3 2 714
2003 72 494 142 17 191 5 2 923
2004 103 651 222 16 166 1 4 1,163
2006 100 524 214 15 182 6 6 1,047
Total 367 2,101 625 48 677 15 14 3,847
GIA LAM: Giardia lamblia; BLA HOM: Blastocystis hominis; END
NAN: Endolimax nana; ENT HIS/DIS; Entamoeba histolytica/dispar.
P522 Use of solar radiation in disinfecting contaminated drinking
water with cysts of Giardia lamblia
S. Zinyowera, N. Midzi, C. Muchaneta-Kubara, T. Simbini, T. Mduluza,
V. Robertson (Harare, ZW)
Objectives:
1. To determine whether solar radiation is capable of inactivating cysts
of Giardia lamblia.
2. To analyse use of different types of containers.
Methods: This is an experimental study. One hundred stool specimens
for the isolation of G. lamblia cysts were collected from pupils of grades
one to ﬁve from a rural primary school in Zimbabwe. Permission to
conduct the study and collect specimens from students was granted
including consent from the participants themselves. Specimens were
screened for the presence of G. lamblia. They were concentrated using
sheaters solution and puriﬁed using the discontinuos percoll gradient
centrifugation method. Protozoan parasites were then preserved in
distilled water, quantiﬁed using a hemocytometer, then stored at 4ºC.
Empty 2L polyethelyne terephthalate (PET) plastic containers were
painted black on one side including a 2L high density polypropelene
plastic containers. One thousand eight hundred millilitres of tap water
were placed in the 2L containers. Initial temperature of each container
was measured. One milliliter of the parasite suspension was added to
each bottle. The containers were shaken to aerate the water. These were
then placed outside on a black surface with the clear side facing the sun.
Temperatures were recorded hourly and at each hour, water in a PET
bottle painted black on one side would be spun at 500 g for 3 minutes
using 50ml VWR centrifuge tubes. One ml of the pooled sediment was
stained with the vital dyes 0.4% trypan blue, 0.3% Congo red and the
ﬂourogenic dyes propidium iodide (PI) and 4,6 diamidino-2-phenylindole
dihydrochloride (DAPI) were also used.
Results: When there was full sunshine 95% of parasites would be dead
after 3 hours at temperatures of 46ºC, and after 4 hours when the
temperature was above 50ºC, 100% of G. lamblia cysts were non-viable.
During cloudy conditions when the water temperature was 38ºC, 26%
of parasites were non-viable. PET bottles painted black on one side
absorbed more heat than those not painted including the high density
polypropelene plastic containers. The open PET bottles did not kill
parasites completely as the water temperature did not rise rapidly.
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Conclusion: Solar radiation is effective in killing G. lamblia cysts. More
assays need to be carried out to ﬁnd out if it is the UVA produced by
the sun or the heat from the sun that is capable of disinfecting these
parasites.
P523 Evaluation of three commercial assays for the detection of
Giardia and Cryptosporidium organisms in stool specimens
N. Dauby, C. Moens, S. Mohamed, S. Van den Wijngaert,
O. Vandenberg, A. Dediste (Brussels, BE)
Objectives: Giardia is known as the most common pathogenic intestinal
protozoa in Belgium, yet Cryptosporidium remains frequently under
diagnosed. We compared three commercial assays for the detection of
Giardia and Cryptosporidium.
Methods: Stool specimens were collected from 101 children attending a
day care centre located in Brussels. Most of those children presented
abdominal complaints and/or diarrhoea since two weeks. Therefore,
we wanted to investigate this outbreak in order to exclude a parasitic
etiology. Stool specimens were examined according to our speciﬁc
Triple-Feces-Test (TFT) protocol which consists in 3 samples collected
on 3 consecutive days (2 with SAF preservative and one fresh
specimen) examined with and without concentration techniques and a
permanent staining. In addition, a Rhodamine-auramine O staining for
Cryptosporidium is performed on the fresh specimen, with conﬁrmation
with Kinyoun carbolfuchsin acid-fast staining. Results obtained with
our protocol were compared with those from Prospect Crypto/Giardia®
(ELISA), ImmunoCard STAT® (IC) and Meriﬂuor® direct ﬂuorescent-
antibody (DFA) commercial tests, each of them performed on the
unpreserved stool specimen.
Results: Among the 101 children included in the study, 5 and 17
were infected with G. lamblia and Cryptosporidium respectively. The
sensitivity of the TFT-protocol was 100% for Giardia which was
similar to the sensitivity of the IC and ELISA tests. The speciﬁcity
of all tested methods was never lower than 97%. The sensitivity of
the IC and the ELISA for the detection of Cryptosporidium were
100% and 95.3% respectively compared to 52.9% for the microscopic
examination. When we used DFA as screening methods for the diagnosis
of Giardia or Cryptosporidium, we found a sensitivity of 80% and 82%
respectively. Speciﬁcity of the DFA was 100% and 97.6% for Giardia
and Cryptosporidium respectively.
Conclusion: Microscopy with the TFT protocol is very sensitive for
detection of Giardia but less sensitive for detection of Cryptosporidium
than the three commercial kits tested. Regarding to our results, we should
consider including ELISA or IC tests in our TFT-protocol for a more
reliable detection of Crytosporidium.
P524 The prevalence of Dientamoeba fragilis infection in patients
with suspected enteroparasitic disease in Denmark
C.R. Stensvold, M.C. Arendrup, K. Mølbak, H.V. Nielsen (Copenhagen,
DK)
A study was taken on to describe the prevalence of D. fragilis in patients
with suspected enteroparasitic disease in Denmark and the diagnostic
relevance of examining preserved rather than unpreserved stool samples.
Parasitological examination of paired stool samples from 103 patients
was completed using two different techniques: A formol ethyl-acetate
concentration technique (FECT) on unpreserved faeces and a permanent
staining technique (PST) on faeces preserved with sodium acetate-acetic
acid-formalin (SAF). Using SAF-PST and FECT, 25% and 15% of the
specimens were parasite-positive, respectively. D. fragilis was detected
only in SAF-preserved stools, and 12/103 (12%) patients were shown
to harbour the parasite, only two of which were shown also to host
other traditionally acknowledged pathogenic parasites. The present study
shows that D. fragilis is remarkably prevalent in Denmark. It conﬁrms
the relevance of examining SAF-ﬁxed stools of patients with suspected
intestinal parasitosis in settings where the examination of freshly passed,
warm stools is not an option, since at least 8/10 cases of potentially
symptomatic intestinal parasitosis go undetected using conventional
concentration and microscopy of unpreserved stools. D. fragilis was seen
mainly in patients aged 0−30 and was not associated with travel activity
less than 3 months prior to the submission of stools, suggesting endemic
occurrence in Denmark.
P525 Opportunistic properties of insect microsporidia
C. Franzen, S. Fischer, J. Scho¨lmerich, S. Schneuwly, B. Salzberger
(Regensburg, DE)
Objectives: Tubulinosema ratisbonensis is a microsporidian pathogen
of the fruit ﬂy Drosophila melanogaster belonging to the family
Tubulinosematidae. The microsporidia in this family mainly cause
infections in invertebrate hosts, but two members of this family,
Anncaliia vesicularum and Anncaliia algerae, have been found as
cause of infections in humans as well. Moreover, A. algerae could
be transmitted to immunodeﬁcient mice and grows in mammalian cell
cultures. Thus, the examination of the opportunistic properties of other
members of the family Tubulinosematidae is mandatory.
Methods: Spores of T. ratisbonensis, isolated from infected fruit
ﬂies, were inoculated on mammalian and insect cell cultures and in
immunodeﬁcient mice [NMRI (nu/nu)] (n = 24) at different locations
(tail, neck, i.p., eye, leg, oral). On day 60 post infection all mice were
euthanised and necropsied. Cultures and mice were examined by light
microscopy, scanning and transmission electron microscopy, and by PCR
and subsequent DNA sequencing.
Results: In cell cultures parasite growth was only seen in human
lung ﬁbroblasts whereas no growth was seen in Vero cells or insect
cell cultures. Transmission electron microscopy showed the typical
ultrastructure of T. ratisbonensis and scanning electron microscopy
showed oval or slightly pyriform spores with some spores having
extruded their polar tubes. Sequencing of PCR-fragments, ampliﬁed from
infected cell cultures, reveals DNA sequences that were 100% identical
with the original T. ratisbonensis rRNA sequence. All 24 mice survived
the 60 days study period without clear signs of disease. All examined
internal organs were free from microsporidia but limited growth was
seen at sites with lower body temperature (tail, leg).
Conclusion: As T. ratisbonensis is able to proliferate in mammalian
cells and in immunodeﬁcient mice at sites with lower body temperature,
it might have opportunistic properties like other members of the family
Tubulinosematidae.
P526 Clinical signiﬁcance and frequency of Blastocystis hominis
infection in primary school children in Ardabil, Iran (2003)
A. Daryani, G.H. Ettehad, N. Barmaki, M. Sharif, A. Abedi, H. Ziaei,
H. Alimohammadi (Sari, Ardabil, IR)
Objective: There is a dramatic increase in the frequency of Blastocystis
hominis infection in association with diarrhoea and distinct clinical
symptoms, especially in AIDS patients. The aim of this study was to
evaluate the frequency of this parasite, and relate personal data and the
presence of signs with the frequency of B. hominis among primary school
children.
Methods: This cross-sectional study was performed on 1070 school
children between 7−13 years old in Ardabil, Iran, 2003. A questionnaire
was completed for each child. Stool specimens were collected by
stratiﬁed random sampling and were examined for presence of B. hominis
using direct wet mount and formalin-ether concentration methods.
Results: The positive rate of B. hominis was 28.2% (302/1070). A
total of 109 cases (10.2%) showed more than ﬁve parasites per ﬁeld
at a magniﬁcation of 400x. The most common symptoms in children
who showed only B. hominis were abdominal pain (49.4%), inappetance
(35.8%), and nausea (33%).
Conclusion: As B. hominis is quite common among school children,
contaminated drinking water is suspected to be the source of infection.
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P527 Analysis of IgG and IgM in patients pre-diagnosed with
toxoplasmosis
G. So¨nmez Tamer, B. Mutlu, A. Willke (Kocaeli, TR)
Objectives: The aim of this study was to compare Toxoplasma
seropositivity among the regions of Turkey. For this purpose, we
evaluated toxoplasma IgG and IgM seroprevalans retrorespectively from
patients who applied to gynecology, neonatalogy, paediatric and other
clinics. Serum which were obtained from patients who are prediagnosed
with Toxoplasma were included to this study. These serum samples were
collected between 01.2003–10.2006.
Methods: Serums tested with Enzyme Immune Assay (Axsym, Abbot®)
for IgG and IgM. Data were collected and documented for a period of
3 years.
Results: The results obtained were evaluated in four groups: group 1
gynecology, group 2 neonatal, group 3 paediatric and group 4 others.
In 1828 serum samples, we found 32.67 IgG seropositive, 1.25% IgM
seropositive and 5.47% IgG+IgM seropositive samples. In 256 serum
samples from gynecology 47.65% were IgG seropositive, 1.95% were
IgM seropositive and 5.85% were IgG+IgM seropositive. In 239 serum
samples from paediatric clinic 50.20% were IgG seropositive, and
1.23% were IgG+IgM seropositive, but fail to ﬁnd IgM seropositive.
In 280 serum samples from neonatal clinic we found 43.57% were IgG
seropositive but fail to ﬁnd IgM and IgM+IgG seropositive samples. In
1053 serum samples from other clinics 22.13% were IgG seropositive,
1.70% were IgM seropositive and 7.79% were IgG+IgM seropositive.
Discussions: Toxoplasma IgG seroprevalance in Kocaeli region were
found to be lower than eastern and middle Anatolian parts of Turkey
where animal farming is a common practice. The results obtained from
this study may indicate that the observed differences may be related to the
high socioeconomic status of people better hygiene rules and sanitation
in Kocaeli region than other regions.
P528 Prevalence of antibodies to Trypanosoma cruzi in Latin
American immigrants in Spain
N. Portocarrero, M. Baquero, M. Gutierrez (Madrid, ES)
Introduction: Chagas’ disease is a chronic parasitic infection caused by
Trypanosoma cruzi and is endemic in Central and South America. Many
immigrants from that region now reside in Spain.
Objective: The aim of this study was to assess the prevalence
of antibodies to Trypanosoma cruzi among immigrants from Latin
American in Madrid.
Methods: A total of 320 serum samples from Latin American individuals
attending the tropical clinic at Carlos III hospital Madrid, between
January 2005 and October 2006 were analysed. T. cruzi antibodies were
identiﬁed using a commercial screening ELISA method (Biokit, Spain).
Results: Geographic distribution of the patients was: 213 Ecuador
(66.5%), 52 Colombia (16.2%), 20 Bolivia (6.2%), 9 Brazil (2.8%),
7 Peru (2.1%) and other countries of Latin American (6.2%). Eight
patients were considered reactive for antibodies to T. cruzi, most of
them from Bolivia 7/20 (35%) and one from Ecuador.
Conclusions: In this study it is worthy to note the high prevalence
among Bolivian population (35%) and our results underscore the
importance of screening of Latin American immigrants for T. cruzi
to prevent transmission possibility through blood transfusion or organ
transplantation.
P529 Clinical epidemiology and surveillance of leishmaniasis in
the Yungas of Bolivia, 2002–2005
C. Gomez, A. Rodriguez-Morales (La Paz, BO; Trujillo, VE)
Introduction: Leishmaniasis is an endemic disease in many countries in
South America, one of them Bolivia. Unfortunately is a neglected disease
with few advances in the research and development of drugs against
Leishmania spp., the etiological agent of this wide-clinical-spectrum
disease.
Objectives: For these reasons surveillance, control and prevention in
resource-limited settings where disease is present is continuously needed.
Methods: In this report we describe the clinical epidemiology and
surveillance of cases of leishmaniasis seen between 2002 and 2005,
in a programme applied in the Yungas of Bolivia. This region includes
the Departments of La Paz, Beni, Cochabamba and Santa Cruz. The
accomplishments of the programme are describe in terms of number of
communities visited for preventive activities, suspected cases ﬁnd in the
active screening, cases reported in healthcare centres, diagnostic tests
applied, conﬁrmed cases, clinical distribution (forms of leishmaniasis),
and treatments with N-metil glucamine, among others.
Results: For this period 2,606 communities were visited (mean 652
per year), detecting by active screening 2,452 suspected cases (mean
613 per year), and 334 passively (mean 83.5 per year) (p< 0.01);
5,323 tests (mean 1331 per year) were applied ﬁnding 1,845 cases
of conﬁrmed leishmaniasis (mean 461 per year) (35%, ranging 25%-
39.6%), additionally to this 12,596 diagnosed cases were referred for
treatment. From this total (14,441), 88.3% corresponded to Visceral
Leishmaniasis (AVL), 9.2% to Cutaneous Leishmaniasis (ACL) and
2.5% to Mucosal Leishmaniasis (AMCL). During this 4-year period
69,790 blisters of N-metil glucamine were applied (mean 17,448 per
year).
Conclusion: Leishmaniasis remains a major world health problem that
continues to increase in incidence. This neglected tropical disease has
strong but complex links with poverty. The burden of leishmaniasis falls
disproportionately on the poorest segments of the global population,
such as most populations in Bolivia. Public investment in treatment,
prevention and control would decrease the leishmaniasis disease burden
and help to alleviate poverty in such countries.
P530 Impact of climate variability in the occurrence of
leishmaniasis in Southern departments of Colombia
R. Cardenas, C. Sandoval, A. Rodriguez-Morales (Cucuta, Pamplona,
CO; Trujillo, VE)
Leishmaniasis are transmitted in Americas by Lutzomyia spp., mostly
in endemic zones. Previous asian, european and southamerican studies
indicated potential changes in vectors climate-related-distribution, but
impact outcomes are still need to be furtherly studied. For this reason we
report possible climatic impacts and El Nin˜o events during 1985–2002
on leishmaniasis (ATL/AVL) in 11 departments, in the southern region
of Colombia, South America. Departments included were: Amazonas
(Az), Caqueta´ (Cq), Cauca (Ca), Huila (Hu), Meta (Mt), Narin˜o (Na),
Putumayo (Py), Tolima (To), Valle (Va), Vaupes (Vp), Vichada (Vi).
Climatic data was satellitally obtained; and epidemiological from Health
Ministry. NOAA climatic classiﬁcation and SOI/ONI indexes were used
as global climate variability indicators. Yearly variations comparisons
and medians trends deviations for disease incidence and climatic
variability were made. Statistical analysis used SPSS (conf. 95%). During
this period a considerable climatic variability was present, strong El
Nin˜o during 6 years and strong La Nin˜a for 8. In this period, 19,212
leishmaniasis cases were registered in these departments (Na 18%, Cq
18%, To 16%, Va 16%, Hu 11%, Mt 8%), mean 4756.83 cases/year
(ranging in these departments from 6.89 to 192.5 cases/year). During El
Nin˜o years disease increase in a mean of 4.98% (for the whole region) in
comparison to La Nin˜a years, but this was spatially heterogeneous with
2 departments evidencing increases during El Nin˜o (Mt 6.95% and Vp
4.84%), but the rest with increase during La Nin˜a (ranging from 1.61%
to 64.41%). These differences were signiﬁcant in Va (p = 0.0092), Py
(p = 0.0001), Ca (p = 0.0313), and for the whole region (p = 0.0023) but
not in in the rest of departments (p> 0.05). Climate is changing at an
unprecedented registered-rate. Shifts in insect distribution indicate their
importance. Climate is a relevant temporospatial vectors distribution
determinant. These data and other previous presented by our group
(Am J Trop Med & Hyg 2006;75:273−7) reﬂected climate importance
on leishmaniasis incidence in different areas of Colombia, given the
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heterogeneity of impacts more temporal and spatial speciﬁc research
is needed. This opens further investigations in the area related to
forecasting and monitoring systems in public health systems to prevent
and control earlierly this emergent infectious disease.
P531 Visceral leishmaniasis – does antimony loose its efﬁciency?
G. Stevanovic, M. Pelemis, M. Pavlovic, J. Poluga, L. Lavadinovic
(Belgrade, RS)
Visceral leishmaniasis is parasitic diseases caused by Leishmania
donovani (L. infantum, L. chagasi). Reservoirs of the parasites in our
region are mostly dogs and rodents. Vector of transmission is sandﬂies.
Illness was sporadically occurred in the southern regions of our country.
Objective: The objective of this paper was to present our experience in
treatment of visceral leishmaniasis and problems in unresponsiveness to
antimony therapy.
Method: During four years period in our department we treated
22 patients safer from visceral leishmaniasis. All the patients were
citizens of Serbia and Montenegro. In endemic regions of these countries,
live 18 patients, others were been during summer period in these regions.
No one was traveled out of Europe.
Results: All the patients were adults, average age of 40.24 (range from
22−78) years, 15 of them was mails and 7 were females. Medium
duration of the illness before treatment was longer then 4 mounts. Most
of them had fever, anaemia or pancytopenia and enlargement of liver and
spleen. Diagnosis was established by serological methods and deﬁnitive
diagnosis was done by microscopic examination of bone marrow smears.
As a primary therapy we used antimony (Glukantime®) in the doses of
20mg/kg during 21−28 days. In one patient we used Pentostam®. Good
outcome we have in 17 patients. But in 5 patients in spite of therapy,
clinical ﬁndings were present. Spelnohepatomegaly was persisted, with
pancytopenia. In patients with persistent ﬁndings of parasites we repeated
therapy with antimony compounds. One of patient had good outcome, but
other 4 were needed Amphothericin B. All of them were treated during
15−28 days, given intravenously for a total dose of 20mg/kg. After two
courses of Amphothericin B therapy, only two patients had persisted
clinical ﬁndings longer then 6 months. These two patients were treated
with liposomal amphotericin B (Ambisome®) in daily dose of 2mg/kg
during 5 days. Resolution of the symptoms was achieved during ﬁrst
month after the therapy.
Conclusions: Unresponsiveness to antimony therapy is becoming
problem in Asia. In former Yugoslavia, we did not have such problems
until now. That was ﬁrst cases of visceral leishmaniasis that was
unresponsive to antimony therapy in Serbia. Favourite outcome was
achieved by use of liposomal amphothericin B.
P532 Cases of visceral leishmaniasis in a tertiary hospital in
Athens, Greece
P. Karabogia, K. Ziva, M. Orfanidou, E. Sideris, M. Karanika,
H. Malamou-Lada (Athens, GR)
Objectives: The aim of this study was to report cases of visceral
leishmaniasis in adults with emphasis to epidemiological features and
response to treatment in a tertiary hospital in Athens, Greece, during the
period 1/2005−10/2006.
Methods: During the study period, 89 patients with high fever
of unknown origin were admitted to the hospital. All of them
underwent serology testing for CMV, EBV, Rickettsiae, Coxiella burnetii,
Legionella, Brucella and Leishmania. Antibodies to Leishmania were
detected from serum by an indirect immunoﬂuorescence method (IFA,
bioMe´rieux) and the parasites were detected by direct microscopy of
bone marrow smears.
Results: Five out of 89 patients presented high titers of antibodies
to Leishmania infantum (1/640−1/1280). Direct Giemsa stain of bone
marrow smears indicated Leishmania parasites in four out of ﬁve of these
patients. The patients median age was 55 years (range 16−80 years, two
female-ﬁve male). One male patient was immigrant from Albania and
four were native Greeks. Three of them were living in Attica area and
two in urban areas of central Greece. All patients experienced symptoms
for more than one month. Fever and hepatosplenomegaly were observed
in all of the patients. The most frequent haematological ﬁnding was
thrombocytopenia, leukopenia and anaemia. One patient found to have an
underlying autoimmune disease. All patients were treated with liposomal
amphotericin B and responded well. No adverse effects were detected.
Conclusions: Visceral leishmaniasis should be included in the differen-
tial diagnosis of fever of unknown origin, especially in endemic regions
like Greece. Early diagnosis leads to more effective treatment, preventing
relapses and adverse effects.
P533 Visceral leishmaniasis cases in Romania
S. Florescu, C. Popescu, M. Cotiga, L. Raduta, R. Botgros, C. Voinea,
S. Erscoiu, E. Ceausu, P. Calistru (Bucharest, RO)
Background: Tropical diseases are no longer found only between
15 degrees northern and 15 degrees southern latitude. Increasing
travelling all around the globe made possible the import of the tropical
diseases in the temperate and cold weather regions. In such regions,
the diagnosis of tropical diseases takes longer and is more difﬁcult,
especially in the visceral leishmaniasis.
Objectives: We analysed the clinical features, the diagnosis tools and
the treatment of the imported visceral leishmaniasis in Romania.
Methods: retrospective study of 5 cases of visceral leishmaniasis
admitted between 1999–2006 in the Clinic of Infectious and Tropical
Diseases “Dr. V. Babes”.
Results: All patients were males, with age limits between 22−35 years.
They aquired the disease working in open spaces, in agriculture and
building during 3 to 12 months; 2 of them worked in Spain, 2 in
Italy and 1 in Greece. The period between the clinical onset and the
positive diagnosis ranged from 2 to 14 months, wereas the period
between the ﬁrst medical consult and the positive diagnosis ranged from
2 weeks to 12 months. All patients had fever, chills, malaise, loss of
apetite, weight loss from 6 to 20 kgs, liver and splenic enlargement
and pancytopenia. Parasitological exam of the medular aspirate showed
amastigote forms of Leishmania spp. and was the standard for positive
diagnosis. Ethiological treatment consisted of Amfotericin (4 patients)
and Pentamidin (1 patient). All patients survived.
Conclusions: Visceral leishmaniasis is a reemergent disease in Romania,
due to the masive immigration of the romanian workers, especially in the
mediteraneen region. The positive diagnosis is usually delayed because
the clinical aspect in nonspeciﬁc and aparrently sugests a haematological
malignancy; thus, clinician must be aware of the epidemiological data,
and mainly about the previous travels of the patient.
P534 Recurrent cutaneous leishmaniasis due to Leishmania
(Viannia) guyanensis after treatment with pentamidine: a
study of 7 cases and analysis of this nosological entity
J.P. Gangneux, S. Sauzet, S. Donnard, N. Meyer, A. Cornillet, F. Pratlong,
C. Guiguen (Rennes, Saint-Aubin du Cormier, Montpellier, FR)
Introduction: Localised cutaneous leishmaniasis (CL) is the most
common clinical expression of Leishmania infection in the New World.
However, various clinical presentations with therapeutic difﬁculties and
poorer prognosis exist: mucocutaneous leishmaniasis mainly due to
L. braziliensis, and diffuse cutaneous leishmaniasis due to L. mexicana
and L. amazonensis. Leishmaniasis recidivans is an unusual clinical
Old World pattern mostly associated with L. tropica. Recurrence of
CL lesions previously cured is also found in the New World CL, for
which a few authors identiﬁed a speciﬁc nosological form, known as
leishmaniasis recidiva cutis (LRC) and less than 30 cases have been
reported.
Objectives: Here, we report 7 cases of recurrent CL from French Guiana
after treatment with pentamidine, and discuss this atypical clinical
presentation.
Results: For 15 days, French military personnels spent 3 months in
French Guiana and took part in a training programme in the rainforest
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(Re´gina and Saint-Georges). 21 of them developed a CL and were
treated with Pentacarinat (3 iv or 2 im injections of 4mg pentamidine
isothionate/kg on alternate days). All lesions were cured 1 to 3 months
after the treatment had ended. For 7 patients (33%), recurrence of the
CL lesion was observed after a disease-free interval of 3 to 6 months.
For each patient, new lesions appeared on the edge of a healed scar.
Discussion: Physicians should be aware of the risk of early treatment
failure but also of recurrent form after Leishmania (Viannia) guyanensis
infections evocative of LRC. This clinical presentation stresses the need
for long-term follow-up after treatment of American CL and prompt
evaluation of speciﬁc therapeutic protocols. In our series, all recurrent
leishmaniasis were observed after treatment with Pentacarinat, and
retreatment with an intensiﬁed protocol of 4 iv injections of pentamidine
cured the disease. Less than 30 cases of LRC have been reported from
Brazil, Colombia, Peru and Ecuador, mainly caused by L. braziliensis,
L. amazonensis and L. panamensis. The mechanism of late recurring
leishmaniasis is still poorly understood. Immunological data based
on skin hypersensitivity, histopathological and immunohistochemical
ﬁndings support the concept that LRC is a late-onset reactivation after
persistence of living parasites around or in “cured” leishmaniasis by as
yet unknown stimuli and after an incomplete host immune response to
an earlier episode.
P535 Rapid epidemiological assessment of Leishmania donovani
infection in eastern Sudan: immune surveillance and
application of GIS
A. Sharief, E. Khalil, T. Theander, A. Kharazmi, S. Omer, M. Ibrahim
(Khartoum, SD; Copengahegn, DK)
This survey was based on simple in vivo and in vitro immunological
techniques combined with clinical history to obtain data about the
spectrum of L. donovani infection in communities at risk of developing
Visceral Leishmaniasis (VL). Clinical history and immunological tests
were conducted in volunteers randomly selected from villages in an
endemic area in eastern Sudan. The leishmanin skin reactivity of 5mm
was 33.3%. Children <15 years had higher leishmanin non-reactivity
(00mm) of 47.6% compared to 27% in adults. DAT results showed that
19.3% had reciprocal titers of >200 compared to 8.1% with reciprocal
titers of >200 and <3200. Titers of6400 were seen in 9% of volunteers.
Eight parasite isolates were cultured, characterised as L. donovani using
Heteroduplex analysis (HDA) and RFLP. These parasites were tested for
their in vitro sensitivities to pentostam and amphotericin B with marked
linear reduction in H3-thymidine incorporation. In the J 744-macrophage
system, the parasite survival index (PSI) was similar for both drugs.
Effect of Amphotericin B on the survival index of four L. donovani
amastigotes infecting a J774-cell line.
The use of clinical interview combined with simple immunological tests
can give valuable information about the pattern of L. donovani infection
and predict future prevalence of VL in a short time. Leishmanin non-
reactive individuals are a useful piece of data to plan for future vaccine
efﬁcacy studies. The interactive dynamic map that was produced in the
GIS can act as a nidus for development of a Leishmania network in
Sudan and the surrounding countries that are endemic for VL.
P536 Concerns on nephrotoxicity and administration schedule of
liposomal amphotericin B during treatment of a HIV-related
visceral leishmaniasis
R. Manfredi, S. Sabbatani (Bologna, IT)
Introduction: Liposomal amphotericin B (lAB) is the ﬁrst-line therapy
of HIV-related visceral leishmaniasis (VL), based on favourable
experiences, although often presented small patient (p) series, and no
agreement exists about is schedule of administration.
Case report: Despite HAART, a HIV-infected p had a limited immune
recovery (106 CD4+ cells/mL), and VL was diagnosed after a two-month
history of fever-fatigue-hepatosplenomegaly. An increasing leukopenia-
lymphopenia (3660–620 cells/mL, respectively), and anaemia, developed
subsequently. A short (6-day) course of lAB was administered at
3mg/Kg/day. Immediately after the end of therapy, moderate signs
of both kidney and haematological toxicity became apparent: increase
of creatinine and urate levels, associated with worsening anaemia-
leukopenia. Increased ﬂuid administration allowed the control of kidney
impairment, and repeated single administrations of lAB (3mg/Kg),
were performed after two and four weeks. A bone marrow biopsy
repeated 5 weeks after disclosed a complete disappearance of Leishmania
parasites, but a signiﬁcantly reduced marrow cellularity was shown (40%
versus prior 85−90%; p< 0.001).
Discussion: lAB therapy of HIV-associated VL is a real advance.
However, our report raises different problems:
1. During HIV disease, VL may mimick opportunistic infections, and
diagnosis may be hampered by a negative serology. An elevated
clinical suspicion should prompt bone marrow biopsy.
2. Kidney-haematological toxicity even after short-term (6-day) adminis-
tration of lAB recommends frequent monitoring. Nephrotoxicity must
be recognized early, while bone marrow toxicity may occur later.
3. Our treatment schedule treatment included a 6-day attack, followed
by two single doses at 14th and 28th day, but other authors delivered
3−5 further doses according to varied schedules, since no uniformly
recognized consensus exist. A standardisation of therapeutic strategies
of VL is therefore needed.
P537 Fasciolosis in Spain. Review of ten years
A. Rodrı´guez Guardado, A. Sempere, M. Rodrı´guez Pe´rez, E. Go´mez,
J. Orda´s, P. Sua´rez Leiva, J. Carto´n Sa´nchez (Oviedo, ES)
Objective: Human infections due to Fasciola hepatica (liver ﬂuke)
are common in underdeveloped countries but are rare in Europe. We
describe our experience in the diagnosis and management of fasciolosis
in Asturias, a province in the north of Spain.
Methods: We have carried out retrospective study of all the cases
diagnosed in the Hospital Universitario Central de Asturias (HUCA),
during a ten year period (1995–2005). The infection diagnosis was made
on the basis of positive serological results (titre 1/320) using indirect
haemaglutination tests and clinical manifestations pointing to fasciolosis.
Results:We found and reviewed ﬁve cases. Only one patient was female,
the mean age was 40 years (range, 34−45). The mean time from the
onset of symptoms until diagnosis was 38 days (range, 30−60). All
of them lived in a rural area and they used to eat fresh vegetables.
None presented signiﬁcant underlying diseases. Clinical manifestations
in all of them were abdominal pain, fever, malaise and weight loss. One
patient presented urticaria. Blood test of all of them showed leukocytosis,
mean 14,350 leucocytes/mm3 (range, 11,200–17,400), eosinophilia mean
32% (range, 24%-60%). Hepatic focal injury was seen by computerised
tomography in two patients. Serological results were positive in all ﬁve,
with titres in between 1/5210−1/8920. Direct microscopy examination of
stools for presence of parasite eggs was carried out in four of them, with
negative results and the duodenal aspirate examination made in one, it
was also negative. Four patients received bithionol (40mgr/Kg every two
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days during 30 days) and one patient with triclabedazole 10mg/Kg in
alone doses. One had diarrhoea after bithiolol administration but it was
not necessary to withdraw medication. Every patient recovered. During
follow up serology become negative and eosinophilia disappeared.
Conclusion: The most frequent clinical manifestations of fasciolosis
are abdominal pain, fever and weight loss. Eosinophilia is the most
frequent laboratory data. Although diagnosis may be established by
observation of parasite eggs in faeces, most of the cases can be diagnosed
by serology. Biothiolol was a very effective and safe treatment against
Fasciola hepatica.
P538 Investigation of Toxocara canis antibodies in patients with
eosinophilia and comparison of two methods: ELISA and
Western Blot
Y.A. O¨ner, E. Artinyan (Istanbul, TR)
Objectives: Eosinophylic cells, which are only present in gastrointestinal
mucosa and form a very little part of peripheric leucosites, the blood
levels are controlled districtly in healthy individuals. However, in many
diseases (allergic diseases, parasitic infections and cancer), the count
of eosinophylic cells increase meaningfully. Especially in parasitic
infections the blood counts of these cells can reach 50,000 cells/mL.
Larva migrans (visceral, ocular, cutaneous), in which eosinophilia is a
constant ﬁnding and is transmitted by pets to humans, is described as the
migration of Toxocara spp. larvas to the internal organs, eye or dermal
tissues with pathological damage. Almost in all articles and books the
primary factor of the disease is mentioned to be Toxocara canis.
Methods: The most prefered method in serological diagnosis is to
detect speciﬁc anti-Toxocara antibodies. If these antibodies are found
to be positive then it is suggested to use Western Blot technique in the
distinctive diagnosis of the illness. In our study, in a study group patients
with eosinophilia, we compared ELISA and Western Blot methods which
is found to be more speciﬁc and sensitive than ELISA.
Results: In 92 sera, 25 of them were evaluated as positive (27.2%),
ﬁve of them were evaluated as equivocal (5.4%) and ﬁnally 62 (65.3%)
of them were found to be negative with ELISA method. On the other
hand, same 92 sera were studied with Western Blot technique; 45 of
them were found to be positive with the molecular weight bands of 24,
28, 30 and 35 kDa and 47 of them were evaluated as negative while no
anti-Toxocara antibody speciﬁc molecular weight bands were formed on
the strips.
Conclusion: According to these data; when eosinophilia having blood
counts are encountered, the diagnosis probability of Toxocariasis is
very high. Moreover, our study indicated once more that in serological
diagnosis of Toxocariasis, Western Blot method is a more valuable
method with its high speciﬁcity and sensitivity than ELISA method.
Test results Serum numbers (n) %
ELISA(+) WB(+) 23 25
ELISA(−) WB(+) 17 18.5
ELISA(?) WB(+) 5 5.4
ELISA(+) WB(−) 2 2.2
ELISA(−) WB(−) 45 48.9
Total 92 100
P539 Acanthamoeba castellanii is a model for eukaryote-prokaryote
interaction and a human pathogen
H. Abd, A. Saeed, B. Advinsson, G. Sandstro¨m (Stockholm, SE)
Objectives: A. castellanii is a free-living amoeba inhabiting aquatic
environments and isolated from different environments. The aim is
to study its features, its interaction with pathogenic bacteria and its
detection from samples.
Methods: Cultivation, viable count, PCR and microscopy.
Results: A. castellanii grew tenfold and survived for more than 30 days
showing a long survival time compared to survival of macrophages. We
found that trophozoites as well as cysts emitted autoﬂuorescence helping
in the diagnosis of Acanthamoeba and its viability. It is well known that
trophozoites feed on different cells by phagocytosis. We observed that
A. castellanii could also take up trophozoite or cyst from its cell cultures.
The importance of Acanthamoeba species is their ability to be
predators or hosts to different bacteria. Our studies showed that
the facultative intracellular bacterium Francisella tularensis multiplied
inside vacuoles of A. castellanii while the extracellular bacterium
Pseudomonas aeruginosa killed this amoeba by type III secretion system
effector’s proteins. Surprisingly, Vibrio cholerae that is considered as an
extracellular bacterium multiplied in the cytoplasm of A. castellanii and
behaved same behaviour of the facultative intracellular bacteria Shigella
sonnei and S. dysenteriae.
Several Acanthamoeba species are human pathogens. The trophozoites
enter human body through respiratory tract, injured skin, invade the
central nervous system to cause granulomatous amoebic encephalitis
and colonise the cornea causing amoebic keratitis. As evidence to the
increasing importance of Acanthamoeba infections, we diagnosed the
ﬁrst Nordic case of fatal meningoencephalitis and two cases of amoebic
keratitis caused by A. castellanii.
Conclusions: Characteristics of A. castellanii such as long life because
of encystation as well as excystation, phagocytosis, autoﬂuorescence,
resistance to many antibiotics, predator, host and victim to different
bacteria, make it an ideal unicellular organism to study the interaction
between eukaryotes and prokaryotes and to be used as a powerful tool
for the culture of some intracellular bacteria in addition to its increased
role as human pathogen.
P540 Cysticercosis: correlation between serological and
radiological diagnosis
A. Rodrı´guez Guardado, E. Go´mez, M. Rodrı´guez Pe´rez, A. Sempere,
R. Lo´pez-Roger Roger, P. Sua´rez Leiva, V. Asensi A´lvarez, J.A. Carto´n
Sa´nchez (Oviedo, ES)
Objective: Human infections due to Taenia solium are common
in underdeveloped countries but they are not frequent in Europe.
We describe our experience in the diagnosis and management of
cystecercosis in Asturias, a province in northern Spain.
Methods: We have retrospectively reviewed each patient with cisticer-
cosis positive serological result in the Hospital Universitario Central
of Asturias (HUCA), during a period of six years (2000–2006). Serum
samples of each patient were tested for Taenia solium antigen, antibodies
and vesicular ﬂuid using an ELISA test. Computerised tomography or
nuclear magnetic resonance were also done on all patients.
Results: We have studied ten cases. None presented signiﬁcant
underlying diseases. Four of them were Spanish and there were six
immigrants, four from Ecuador and two from Brasil. The mean age
was 45 years (range of age 34−59). Six were female. Cephalea (three
cases), epilepsy and subcutaneous nodules (two cases) were the most
frequent symptoms. Two patients remained asymptomatic. Eosinophilia
in blood tests was not found in any of them. Faeces of each one were
examined looking for parasite eggs and were negative. Nine patients
presented Taenia solium antibodies, six were positive for vesicular ﬂuid
and one for Taenia solium antigen. Three patients were diagnosed of
neurocistycercosis, only one of them was positive to T. solium antigen.
In two cases of them the computerised tomography was negative. The
nuclear magnetic resonance was positive in the three cases Two patients
with neurocysticercosis were treated with albendazol during 30 days and
steroids in the ﬁrst seven days. One patient was treated with praziquantel
three doses during one day. All the patients cured. The rest of patients
received one doses of praziquantel (5mg/kg). All patients recovered.
Conclusions: Presence of Taenia solium antibodies in serum seems
to be useful for cysticercosis diagnosis. However, a positive antigen
result in CSF does not seem to indicate a central nervous system
infection. Nuclear magnetic resonance is more useful than computerised
Parasitology S121
tomography in neurocysticercosis diagnosis. Albendazol is a very
effective and safe treatment. Clinical and epidemiological results
consistent with neurocysticercosis are needed in order to ask for antibody
and antigen testing
P541 Clinical forms of neurocysticercosis – Our experience
S. Nikolic, G. Stevanovic, V. Peric, T. Stosic-Opincal (Belgrade, RS)
Cysticercosis is one of the commonest parasitic diseases of the central
nervous system and frequent cause of convulsions in endemic regions,
where incidence rate is about 4% of population.
Objective: The objective of our study was to analyse the clinical forms
of neurocysticercosis in patients treated at our department.
Method: The analysis of results of neuroradiological examinations (CT
scanning, MR imaging), serological tests, neurological disorders and
treatment of patients with neurocysticercosis.
Results: In the period 2000–2005, a total of 65 patients with
neurocysticercosis were treated. All patients underwent neuroradiological
examinations: endocranial CT in 40 (62%) cases, endocranial MRI in
17 (26), and both CT and MRI of the endocranium in 8 (12%) patients.
Parenchymal disease was found in 50 (78%) patients, ventricular in
8 (12%), and parenchymal and subarachnoid in 6 (9%) cases. Only one
female patient had spinal form associated with parenchymal, ventricular
and subarachnoid, and she had VP shunt implanted due to hydrocephalus.
Out of 50 patients with parenchymal disease, cystic changes were veriﬁed
in 27 (54%) cases, concurrent cysts and calciﬁcations in 15 (30%), and
only calciﬁcations in 8 (16%) cases.
Serological test results were positive in all patients with ventricular
and subarachnoid forms as well as in the female patient with spinal
cysticercosis. Out of 50 patients with parenchymal disease, 22 (44%)
had positive results of serological tests. Clinical manifestation of disease
correlated with number, extent and localisation of pathological changes.
Medicamentous treatment (Albendazole, Praziquantel) was applied in
46 (81%) out of 57 patients with active disease, while 11 (19%) cases
underwent surgical interventions (cyst extirpation, V-P shunt), followed
by medicamentous therapy. Patients with calciﬁcations were not treated.
The outcome was favourable (decrease of a number of cysts, reduction
of cyst size, cyst disappearance) in 45 patients (79%), and unchanged
ﬁndings were observed in 12 (21%) treated patients. There was no
lethal outcome. Conclusion: Parenchymal neurocysticercosis was most
prevalent in our patients (77%), while other forms of disease were
signiﬁcantly more infrequent. Active disease (parenchymal, ventricular,
subarachnoid, spinal) was detected in 57 (88%) patients. Outcome was
favourable in 45 (79%), and unchanged ﬁndings were found in 12 (21%)
treated patients. No lethal outcome was reported.
P542 Strongyloidiasis hyperinfection: diagnosis problems and
management in an intensive care unit
C. Kummerlen, I. Yalaoui, S. Barbar, H. Rahmani, P. Sauder,
M. Hasselmann (Strasbourg, FR)
Introduction: Strongyloidiasis hyperinfection (StHI) results from a
fulminant dissemination of strongyloides stercoralis larvae in the
organism. It occurs essentially in immunocompromised subjects coming
from endemic areas. Acute respiratory failure or severe neurologic
disorders may require admission in ICU and population migrations may
increase the number of StHI also in countries where S stercoralis is
usually not present. A delayed or missed diagnosis may then rise different
problems, as illustrated by this case report.
Methods: A 80 years old bosnian man, living in France for 13 years,
was admitted in the ICU for acute respiratory failure. He had a chronic
obstructive pulmonary disease (COPD) with few exacerbations in the
past years, with 2 of them accompanied by hypereosinophilia but no
speciﬁc etiology was found. He developed StHI as he was treated
with steroids. Larvae were fortuitously isolated in tracheal secretion
and also found in stool and blood. Despite adequate antihelminthic
treatment (ivermectine) and respiratory improvement, the patient died
after 4 months from irreversible hypertonia probably due to a neurologic
localisation of StHI.
Results: This observation exempliﬁes 4 key points
1. StHI has to be evoked in patients coming from endemic areas,
even years ago, specially before immunosuppressive treatment. In
Europe, South Balkan, eastern and mediterranean countries are
concerned. Early symptoms, as dysphagia and bronchospasm in our
patient, related to parasitic migration are evocative. Eosinophilia is
an alarming clue when present, but was not found.
2. Gram negative pneumonia or septicaemia are often associated and
may delay the diagnosis of StHI.
3. Microscopic identiﬁcation of larvae in the stool conﬁrms the
diagnosis, but a single examination may be insufﬁcient. A positive
serology test in a patient with a compatible history or a stay in an
endemic area are sufﬁcient grounds for empirical treatment.
4. StHI requires contact isolation and in ICU the risk of transmission
is theorically high. In this observation, despite an ignored diagnosis,
none transmission to healthcare workers was found. However, one
other patient developed eosinophilia with a positive serology.
Conclusion: In temperate non-endemic areas, StHI may be underappre-
ciated. Clinical presentation and risk factors should raise awareness of
this curable but potentially fatal parasitic infection and so facilitate early
diagnosis and treatment.
P543 Primary muscle hydatidosis of the thigh in a pregnant woman
M. Degioanni, A. Maccabruni, C. Bolla, G. Montrucchio, A. Biglino
(Asti, Pavia, IT)
Introduction: Primary skeletal muscle hydatidosis is a rare manifesta-
tion of cystic hydatid disease. We report a case of muscle hydatidosis of
the thigh observed in a pregnant woman.
Methods and Results: Our patient is a 30 years old moroccan woman
who has been immigrated to Italy for seven years ago. At the fourth
month of her third pregnancy she observed a painful swelling of the right
thigh, without any other symptoms; an ultrasonographic scan of the thigh
showed a noncalciﬁed cystic mass with little round cystic inside in the
posterior muscle compartment (diameter 13 cm). After delivery contrast
CT and MRI of right thigh were performed showing that the mass had
reached 15 cm in diameter. No additional cysts were found on CT of
the thorax, abdomen and pelvis. As hydatidosis was strongly suspected,
a speciﬁc serology was performed with positive result (IHA 1:320).
Treatment with albendazole at 400mg b.i.d. was immediately started;
two months after the ultrasonographic scan showed that the primary cyst
was smaller while all but one “daughter” cysts became smaller and oval,
with increased echogenicity. The speciﬁc antibody titer (IHA) was 1:80.
Surgical resection to remove the cyst “in toto” will be the next step of
the treatment.
Conclusion: Skeletal muscle hydatid cysts are generally misdiagnosed
as either a pyogenic infection or a malignancy. Hydatid disease should
be considered in the differential diagnosis of cystic muscular lesions
and speciﬁc serology has to be performed because routine diagnostic
procedures may not always be helpful. The correct diagnosis at the right
time allows a radical cure of the disease
P544 Fifteen-year experience with pulmonary hydatidosis: clinical
manifestation, diagnosis and treatment
B. Shariﬁ-Mood, A. Fazaeli, S. Izadi, S. Mokhtari (Tehran, IR)
Background and Objective: Hydatid disease is a major world health
problem and pulmonary hydatidosis is a widespread disease. It is
presented with different clinical manifestations. In order to determine
the most clinical manifestation, diagnostic tools and clinical outcome in
our patients, we conducted this study.
Patients and Methods: Forty-nine patients with pulmonary hydatid cysts
who were admitted to our hospital in Zahedan (Southeat of Iran) between
1990 and 2005, evaluated. We retrospectively reviewed the patients’
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symptomatology, diagnostic studies, treatment options, and morbidity
and mortality rate.
Results: The ages of the patients ranged from 16 to 68 years
(mean 43 years). Seventy-ﬁve percent of patients were from male
gender. Hemoptysis was the most common clinical presentation in
our patients. Radiological studies were the main diagnostic tool. The
correct preoperative diagnosis was made in 92% of the patients by chest
roentgenogram plus chest CT-Scan. Eighty nine percent of patients were
treated by surgical route. Only one patient was expired during surgery.
Conclusion: Upon the results emerged from this study, hemoptysis is
the most prevalent clinical manifestation in patients with pulmonary
hydatidosis and it can mimick pulmonary tuberculosis in endemic area.
P545 Praziquantel in prevention of complicated echinococcosis
relapses
S. Dautovic, N. Koluder, M. Ferhatovic, N. Mostarac, S. Kapisazovic,
H. Tanovic, A. Mesic, R. Gojak (Sarajevo, BA)
Human echinococcosis is a large therapeutical problem in all farmer
regions of the world. It is an antropozoonosis usually coincidentally
diagnosed by radiological methods. It can affect all organs, but most
frequently it affects liver. Even today this disease can cause serious
disability, when it is lately diagnosed, disseminated or when relapses
occur. When the cyst is small and accessible, total cyst and pericyst
excision is the only proper therapeutical procedure. Solitaire cyst can be
resolved by PAIR method. In complicated cases combined conservative
(albendazol)-surgical treatment is recommended (WHO). Relapses rates
are usually between 4 and 37%.
Objectives: To investigate the frequency of postoperative relapses in
our material and to investigate praziquantel efﬁciency in combined
conservative-surgical treatment.
Methods: This was an open prospective-retrospective study, started in
June, 1996. All patients with complicated or large echinococcus cysts,
treated at The Clinic for Infectious Diseases and at The Clinic for
Abdominal Surgery, Clinical Centre University of Sarajevo, in the period
of 1st June, 1996 to 1st June, 2006, were included. Praziquantel was used
in doses of 25−50mg/kg for 14 days with corticosteroids as an adjuvant
therapy. All patients were monitored clinically, so as by radiological and
serological tests after one, three, six and than every 12 months.
Results: In this period of time 70 patients were treated by combined
conservative-surgical treatment, mean age of 34.7 (4−65). There were
42 patients suffered from primary and 28 patients with echinococcosis
relapses. In 53 cases evacuation of large cysts was done and 17 patients
had cyst rupture. Our results signify that there were 12.5% of recidives
in the group of patients which was treated only by surgical treatment in
this period. In the group of patients treated by combined treatment there
were no relapses, if praziquantel antihelmintic treatment was used in pre
and postoperative period. Using praziquantel 10 days after cyst rupture
was not effective.
Conclusions: Human echinococcosis is a large public-health problem
in Bosnia and Herzegovina. Postoperative relapses in complicated cases
occur at rate of 12.5%. After combined treatment, using praziquantel,
there were no cases of relapses. Praziquantel can be an antihelmintic of
choice in prevention of complicated echinococcosis relapses in combined
treatment.
P546 Surveillance Programme in Echinococcosis and importance
in the prophylaxis and therapy of human infection
L. Junie, N. Constantea, P. Ciobanca (Cluj Napoca, RO)
Background: The human Echinococcosis is still a serious problem
for the public health, in Romania, despite the measures taken for the
prophylaxis of the disease.
Methods: There were assessed patients hospitalised in surgical clinics
between 2004–2006. The radiographic examinations, ultrasonography,
IDR Cassoni and serological test ELISA, have established the diagnosis.
Results: Most of the hydatid cysts (71.5%) were uncomplicated, but
28.5% are diagnosed due to the complications. The evolution of
uncomplicated hepatic hydatid cyst is like a biliary dyspeptic syndrome
(58%), with tumour-like signs (80%), a biliary colic (6.3%) and portal
hypertension (2.1%). Allergic reactions can occur, especially in children
(6.2%). The complications of the hydatid cyst are cholecystitis (8.4%),
jaundice (4.9%), and infectious syndrome (4.9%) and rupture (18.8%).
The rupture occurs in biliary tracts, in pleura, and in peritoneal cavity,
with the occurrence of anaphylactic shock (2.5%). In adults, hydatid
biliary tract obstruction (2.8%) and cirrhotic signs (3.8%) may occur.
Cysts in the lungs ordinarily are uncomplicated (77%) and give rise
to cough (63.6%), dyspnea (54.5%) and chest pains (36.4%). The
complications of the pulmonary hydatid cyst are ﬁssure and secondary
infection of the cyst with the occurrence of an infectious syndrome
with fever (36.4%), thoracic twinge (13.6%), sweats (4.5%), anorexia
(18.2%), asthenia (9.1%). Either surgical or drug therapy may conclude
in a favourable evolution in 90.5% of cases. The unfavourable evolutions
after surgical (9.5%) are due to the relapses (4.5%), the secondary
location (1%) and the bacterial complications (3.5%).
The echinococcosis is present in adults (46.5%) and children (53.5%),
with an alarming high incidence in children of 7 to 14 years old (70.1%).
In adults, the most common locations are the liver (83.9%), the lungs
(9.7%), and the spleen (1%). In children the most common locations
are the liver (67.7%), the lungs (27.6%), the spleen (1.9%), the kidneys
(0.9%).
Conclusions: Hepatic and pulmonary locations are frequent, leading by
their chronic evolution to tumour-like signs, severe complications (1.5%),
reserved prognosis (9.5%), and even to death (0.5%). There is an urge
for the early diagnosis of the infected patients, by the development of
the screening methods and a close collaboration among clinicians and
and laboratory doctors, for therapy and prevention of the complications.
P547 Diagnostic E. granulosus particles in hepatic cystis punctate
B. Matica, J. Granic, A. Beus, B. Desnica, K. Granic (Zagreb, HR)
Objective: Incidence of E. granulosus in Croatia is 0.9/100,000
inhabitants in year 2004, 0.46 in 2005 and 0.46 in 2006 (till 1st of
November 2006). This high incidence is a challenge for rapid and good
algorithm of diagnostic.
Material and Method: We observed 61 patients with hepatic cysts from
1.1.1999 till 1.11.2006, Patients were from age 13−63 years, female
40, male 21, ratio female:male is 1.9:1. Contents of hydatid cysts
obtained after punction under echosonographic visualisation, searched
for E. granulosus particles and vitality of protoscolices. Liquid samples
after aspiration was divided in two portions: ﬁrst part was examined
under microscopy as native specimen and after centrifugation. In second
portion 0.1ml of canine bile or 0.2% solution of sodium taurocholate
was added, incubated 48 hours at 37ºC, microscopic examined after 24
and 48 hours.
Results: In 61 contents of hepatic cysts patients serological positive
on echinococcosis (ELISA and ITF method) 37 had particles of
E. granulosus (60.66%), and 24 were negative (39.34%).
Conclusion: Examination of hepatic hydatid cysts contents evacuated
after percutaneous punction, demostrate rapid and valid diagnostic tool
that enable clinician to establish correct etiological diagnosis and/or to
evaluate results of the various therapeutic algorythm.
PAIR method (punction, aspiration, installation, repunction) is a good
diagnostic method. Evacuation of hepatic cysts contents is also a good
therapeutic procedure.
P548 Current trends in echinococcosis in Latvia
J. Keiss, V. Sondore, A. Cernusenko, L. Viksna, B. Rozentale (Riga, LV)
The objective of study was to analyse echinococcosis cases treated
in the Infectology Center of Latvia (ICL) in 1999–2005, to evaluate
echinococcosis tendencies in Latvia during this period and at present
and to deﬁne arising problems to be solved.
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Patients and Methods: Retrospective surveys of hospital records
covering years 1999–2005 have established the 32 patients (3 – men,
29 – women) with echinococcosis: in 1999 – 1, 2000 – 3, 2001 – 0,
2002 – 7, 2003 – 7, 2004 – 6, 2005 – 8 patients. All patients were rural
population, all had dogs and domestic animals and they had not left
their residence during the last 20 years. Exclusion is one patient who
lived in Kazakhstan and recently moved to Latvia. Diagnosis was based
on Echinococcus granulosus and Echinococcus sp. antibodies detection,
in all cases liver ultrasonography and computer tomography (CT) was
performed, in some cases morphological investigation of biopsy or
surgically obtained material from space occupying lesions in the liver
also was carried out.
Results: Latvia belongs to countries with a medium echinococcosis
rate, predominantly with local source of infection. Before the year 2001
a very few cases were registered, but after the year 2001 there is a
considerable increase in the number of Echinococcus infection cases,
especially during January-October, 2006, when new 14 echinococcosis
patients were treated at the ICL. We suppose the number of invaded
persons is more large. Echinococcosis shows a tendency to distribute
from the western and central to the eastern regions of Latvia. In 3 of
32 patients alveolar echinococcosis was diagnosed.
Clinically, most of patients had a discomfort in epigastrium, in 5 patients
the ﬁrst clinical symptom was itch with the following jaundice. In
6 patients the focal liver lesions were found accidentally during
the abdominal ultrasonography. In dependence on family doctors’
understanding of disease the further way of patients was different:
7 patients were forwarded to the surgical clinic, 3 – to oncological clinic
and others – to the ICL. All patients were treated with albendazole. One
patient died.
Conclusion: 1) Echinococcosis has a tendency to increase in Latvia.
2) Family doctors are often not ready to early diagnostics of
echinococcosis. 3) Cooperation with veterinarians and veterinary care
need remarkable improvement. 4) In all cases of focal affection in the
liver the serological and/or morphological tests for echinococcosis should
be performed.
P549 Epidemiological considerations about hydatid disease in
Constanta county, Romania
I. Dumitru, S. Rugina, E. Dumitru (Constanta, RO)
Introduction: Hydated disease represent a public health problem in
Constanta county because of its high prevalence and multiple health and
social implications. The high number of domestic animals (sheep, cattles,
goats) and communitarian dogs in this region are the most important
causes of this situation.
Objective: To analyse the epidemiology of hydated disease in Constanta
county.
Materials and Methods:We performed a study on 340 patients admitted
in our department of parasitology in the last 5 years. The diagnosis
was based on ELISA reaction for Echinococcus granulosus, chest x-ray,
ultrasonography and computed tomography.
Results: The prevalence of hydated disease in our region was high,
more than 50 cases/100.000 inhabitants, mainly in urban area (72%).
The prevalence was higher in women (57%), the most affected group
age was between 50 and 59 years with the highest age at diagnosis
beeing 82 years. According to race, the highest prevalence was among
romanians, followed by aromanians, turks, tatars and rroms. The epi-
demiolgical conditions were positive in the majority of cases, most of the
patients documented the contact with animals. There were nine familial
clusters. Echinococcosis had different locations, involving liver (261),
lung (87), spleen (7), kidney (6), brain (2), pericardial (2), mediastinal
(1), peritoneum (11) and retro peritoneum (3), muscles (5), bone (2),
and parotid glands (1). Secondary hydatidosis was reported in 22.18%
cases and multiple cysts were found in 35% cases with liver, pulmonary,
muscular, bone, peritoneal and parotid glands hidatidosis and multiple
locations in 17% cases. Regarding the treatment, 70% of cases were
treated with albendazole, 29% with surgery followed by albendazole
and 1% with percutaneous ultrasonography-quided puncture (PAIR).
Conclusions: The prevalence of hydated disease is high in our region.
This disease require a particularly attention and health programmes for
a better management
P550 A comparative study for the determination of IgG avidity
during a toxoplasmosis infection in pregnancy
U. Krispenz, D. Wassenberg, W. Becker, K. Pfrepper (Neuried,
Hamburg, DE)
Objectives: The comparison was made to ﬁnd out if there is a signiﬁcant
advantage for the interpretation of the time of infection during a
toxoplasmosis in pregnancy. An antigen speciﬁc line assay was used
to go further into the question if a conventional EIA using an avidity
index is sufﬁcient for the determination of the time of infection or is it
possible to obtain a signiﬁcant improvement by using an antigen speciﬁc
avidity pattern.
Methods: 180 routine samples from pregnant women were tested
positive with Abbott screening Toxo IgG and IgM and conﬁrmed
by bioMe´rieux (BM) IgG and IgM plus avidity. The samples were
tested additionally with MIKROGEN recomWell Toxoplasmosis IgG
and IgM as well as with recomLine Toxoplasmosis IgG (plus avidity)
and IgM (LTG). According to individual band and avidity patterns,
the recombinant line assay allows the differentiation into four phases:
phase 1 (acute infection, 0−3 months p.i.), phase 2 (acute infecition, 3−6
m.p.i.), phase 3 (subacute infection, 6−12 m.p.i.), and in phase 4 (latent
infection, >12 m.p.i.).
Results: In the BM avidity test 120 samples were tested with low
avidity. Running these samples with the antigen speciﬁc avidity (LTG)
the differentiation between an acute infection or a past infection can
be made more precisely: 75/120 samples were in the phase 1, 14/120
in phase 2, 19/120 in phase 3, 1/120 sample was in phase 4 and for
9/120 samples it was not possible to determine the time of infection due
to an abnormal serological pattern. With the BM assay 17 samples got
an intermediate avidity. In contrast to these 17 indeterminable samples
only one sample could not be determined with LTG due to an abnormal
serological pattern; 6/17 samples were in the acute phase 1, 7/17 in
phase 2, 2/17 in phase 3 and 1/17 sample in phase 4. A high avidity was
obtained for 43 samples with the BM avidity test.
Running these samples with the LTG 2/43 were in phase 1, 7/43 in
phase 2, 14/43 in phase 3, 16/43 in phase 4 and for 4/43 it was not
possible to determine the time of infection due to an abnormal serological
pattern.
Conclusion: The BM assay turns the user’s attention only to a low and
high avidity index. In contrast the data revealed that the recomLine
Toxoplasma enables a more precise differentiation of a Toxoplasma
infection into four speciﬁc phases. This shows deﬁnitely the advantages
of a conﬁrmation assay using recombinant antigens in a line format
especially for the avidity testing.
P551 Delayed maturation of toxoplasma immunoglobulin G avidity
in pregnant women: impact of spiramycin treatment and
gestational age
F. Peyron, M. Lefevre-Pettazzoni, M. Wallon, F. Cozon, A. Bissery,
M. Rabilloud (Lyon, FR)
Objectives: The low avidity of immunoglobulin G (IgG) has been
reported to be a useful marker of recent infection with Toxoplasma.
Nevertheless, discrepant results on the maturation of avidity over time
have been reported. The aim of this study was to investigate the
maturation of IgG avidity after Toxoplasma seroconversion during
pregnancy and to determine factors that could inﬂuence its evolution
over time.
Methods: IgG avidity was studied retrospectively in our department
data base and in 309 sera from 117 pregnant women who seroconverted
during pregnancy. Inter-patient variations in the evolution of IgG avidity
and factors that potentially inﬂuence maturation, such as gestational age
at infection and treatment with spiramycin, were investigated.
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Results: Persistent low avidity was found in some patients even after
a median follow-up period of 6 years. Avidity index of IgG was
signiﬁcantly heterogeneous and ranged from 7.8 to 35.3% for 95% of
the women 12 weeks after infection (p< 0.05). When plotted against
time after logarithmic transformation, evolution of the avidity index
displayed heterogeneous patterns with slopes between −0.017 and 0.051
for 95% of the women (p = 0.011). Maturation of avidity decreased when
gestational age at infection increased (p = 0.03) and increased when the
delay between infection and onset of treatment increased (p = 0.0003).
In conclusion, we demonstrated that maturation of Toxoplasma IgG
avidity in pregnant women is highly variable and that persistent low
avidity can be observed. Avidity evolution over time is inﬂuenced by
gestational age at maternal infection and delay in the onset of treatment.
The results of this study clearly demonstrate that, in a pregnant woman,
an acute toxoplasmic infection cannot be reliably diagnosed solely on
the basis of low avidity of immunoglobulin G.
P552 Improved performance of the automated toxoplasmosis IgG,
IgM & IgG avidity assays on the Abbott ARCHITECT
Instrument
J. Schultess, E. Sickinger, J. Dhein, M. Hausmann, D. Smith, E. Frias,
M. Palafox, J. Prostko, D. Pucci, Reno Stricker, Reto Stricker, P. Thulliez,
H. Braun (Wiesbaden, DE; Abbott Park, US; Geneva, CH; Paris, FR)
Objectives: Optimisation of IgG, IgM & IgG Avidity immunoassays as
a complete screening panel for the acute infection and immunity status
to Toxoplasma gondii.
Methods: The Toxo-IgG assay uses recombinant Toxoplasma antigens
(P30 and P35) coupled on the solid phase and a labeled anti-human
IgG antibody. The Toxo-IgM assay employs a m-capture format with an
anti-human IgM mouse monoclonal antibody bound to the solid phase
and tachyzoite lysate complexed with a labeled Anti-P30 antibody as
tracer. The Toxo IgG Avidity assay applies a comparative assay format
suppressing high avidity IgG antibodies with soluble P30 antigen in an
indirect anti-human IgG format. The avidity assay is run with automated,
sample speciﬁc dilution into a deﬁned concentration range.
The speciﬁcity of the Toxo assay panel to detect primary Toxoplasma
infections and to detect the correct immune status was determined
by testing 988 samples from different populations (518 blood donors,
220 hospitalised patients and 250 pregnant women. 165 seroconversion
panels were used to explore sensitivity. For resolution of discordant
results, a set of additional Toxo assays was tested, including the
respective AxSYM assays.
Results: In early seroconversion, the Architect Toxo IgG ranked
equivalent to AxSYM and more sensitive than other comparator assays.
It showed an excellent ability to detect past infection low level IgG’s,
equivalent or better than comparator assays, paired with high speciﬁcity
to detect immunity even on challenging specimens. The Toxo IgM assay
was found to have a relative speciﬁcity ranging from 99.7 to 100%,
for populations of random blood donors, hospital patients or pregnant
females. Its sensitivity to detect seroconversion in acute infection was
equivalent to AxSYM Toxo-M. The avidity assay found no specimen
drawn less than 4 months after infection as high avidity and showed
faster kinetics to higher avidity.
Conclusion: The fully automated Toxoplasmosis panel for the Architect
instrument is, in terms of sensitivity and speciﬁcity values, comparable
to the reference assays. In addition, a fully automated algorithm allows
the evaluation of Toxo G and Toxo IgM positive results by Toxo IgG
Avidity, to rule out acute infection with Toxoplasma in pregnant women.
P553 Evaluation of the new Vidia® toxoplasmosis IgG and IgM
assays in women of childbearing age
J. Zufferey, C. Di Mito, R. Auckenthaler (Lausanne, Geneva, CH)
Objectives: The aim of the present study was to evaluate the
performance of the new VIDIA® Toxoplasmosis IgG and IgM assays
(bioMe´rieux, France), using the VIDIA® system easy to use with a high
level of traceability, with clinical specimens prospectively collected in
women of childbearing age.
Methods: A total of 1000 fresh serum samples consecutively obtained
from 1000 women aged 18–44 years (median 30) during a period of
4 weeks were tested with ADVIA® CentaurTM Toxoplasma IgG and
IgM assays according to routine conditions. Serum aliquots stored at
+ 4ºC were blindly rechecked within 24 hours with the VIDIA system
for the same parameters. Discrepancies of results between both methods
were resolved considering avidity test, direct agglutination (Toxo-Screen
DA, bioMe´rieux), ISAGA (bioMe´rieux) and when available, the analysis
of previous drawn serum samples.
Results: Among the 1000 women screened with VIDIA, 89.4% had non
detectable IgG and IgM (T. gondii seronegative) and 8.2% had a pattern
of past acquired infection (positive IgG and no detectable IgM). Positive
IgM were detected in 1.1% of them with VIDIA system versus 2% with
ADVIA Centaur. Equivocal rate was 0.9% for VIDIA TOXO IgG and
0.5% for VIDIA TOXO IgM (versus 0.9% and 1.1%, respectively for
the compared method).
For VIDIA TOXO IgG the relative sensitivity and speciﬁcity were
96.7% and 99.7%, respectively. After the resolution of discrepancies,
the sensitivity as well as the speciﬁcity was 100%.
For VIDIA TOXO IgM the initial relative sensitivity and speciﬁcity
were 64.7% and 100%, respectively. In fact, 4 of the 6 negative samples
with VIDIA and positive with the compared method were found with
high avidity index and the remaining two samples were negative with
the reference test (ISAGA-IgM). Taking this into account, the absolute
sensitivity was found 100%.
Conclusion: The two evaluated assays VIDIA TOXO IgG and TOXO
IgM have shown an excellent sensitivity and speciﬁcity and are well
adapted to the routine screening of toxoplasmosis in pregnant women.
P554 IgG IgM Western Blot in early diagnosis of congenital
toxoplasmosis
V. Meroni, F. Genco, L. Piccoli, A. Grosso, P. Lanzarini, L. Bollani,
M. Stronati (Pavia, IT)
Introduction: Toxoplasmosis is one of the most frequent congenital
infections. Because congenital Toxoplasma infection does not usually
produce recognizable signs of infection at birth, most infected newborns
are undetected by routine clinical examinations and remain untreated.
But serious clinical sequelae such as chorioretinitis can develope later. So
the infected children must be identiﬁed and treated as early as possible.
The aim of this study was to evaluate diagnostic accuracy of IgG IgM
Western-blot (IgG IgM-WB LDBIO Lyon France) on 224 newborns at
risk of congenital toxoplasmosis.
Methods: 224 neonates born from mother with suspected or certain
infection in pregnancy were evaluated retrospectively with IgG IgM WB
(LDBIO Lyon France). Serum obtained from all the newborns at birth
was compared with maternal sample and then with sample obtained
monthly during their ﬁrst three months of life. Furthermore all the sample
were analysed with routine assays: ELISA IgG IgM, IgA(Diasorin
Saluggia Italy), IgG ELFA, IgM ISAGA (bioMe´rieux Marcy L’Etoile
France). The patients were tested with all these routine assays monthly
until seronegative and then at one year of age.
Results: At the end of the study 40 newborns were found infected. Thirty
were diagnosed at birth by the presence of IgM and/or IgA, in the other
10 diagnosis was made by antibody rebound or by IgG positivity at one
year of age.
Conclusions: IgG IgM Western blot showed a speciﬁcity (96.7) almost
superimposable to the traditional tests (98.9). Sensitivity (95) was
higher than the traditional tests (75) and the difference was statistically
signiﬁcative (P = 0.028 Yates Corrected c squared). WB let us ﬁnd out
8 infected newborns not detectable with traditional tests that could
undergone an early treatment, while 178 not infected newborns avoided
unnecessary therapy.
Parasitology S125
Table 1
IgM ISAGA+IgA ELISA IgG IGM Western blot
Pos Neg Tot Pos Neg Tot
Infected 30 2 32 38 6 44
Not infected 10 182 192 2 178 180
Tot 40 184 224 40 184 224
Sens. 75.0
(95%CI: 58.8−87.3)
Sens. 95.0
(95%CI: 83.1−99.4)*
Spec. 98.9
(95%CI: 96.1−99.3)
Spec. 96.7
(95%CI: 93.0−98.8)
Sens., sensitivity; Spec., speciﬁcity.
P555 Prevalence of Chagas’ disease in pregnant women from
Southamerica in Valencia (Spain)
A. Gil Brusola, M.J. Gimenez, Y. Garcı´a, M.D. Gomez, M. Gobernado
(Valencia, ES)
Objectives: Chagas’ disease causes high morbidity in some countries
in Southamerica. In Europe, where the triatomine vector is not found,
its way of transmission can be either mother-to-child or through organ
transplant or blood transfusion. The aim of this study was to determine
the seroprevalence of this infection in immigrants from Southamerica to
our city.
Methods: 354 sera of pregnant women from Southamerica who
attended our hospital between September 2003 and September 2005
were tested for anti-Trypanosoma cruzi antibodies (IgG) using an
enzyme-linked immunosorbent assay (ELISA). Positive sera were then
conﬁrmed with either another ELISA, a particle gel immunoassay or an
immunoﬂuorescent assay (IFA).
Results: The mean age of this group was 28. Most of them came
from Ecuador (51%), Colombia (20%) or Bolivia (17%). Infection was
conﬁrmed in nine women (2.5%). Their mean age was 29. All of them
were from Bolivia, resulting in a prevalence of 15% for women from
Bolivia. Analysis of the vertical transmission couldn’t be conducted due
to either miscarriage or lack of sera from the newborns.
Conclusions: Prevalence of Chagas’ infection is high in pregnant women
from Bolivia. Screening should be carried out in this group of patients
before delivery, for follow-up of their children in order to determine the
relevance of the disease, and to reduce the risk of transmission in case
of organ transplant or blood transfusion.
P556 Optimisation of a ﬂow cytometry protocol for detection of
Cryptosporidium parvum in hospital tap water and human
stools
J. Barbosa, S. Costa-de-Oliveira, A. Gonc¸alves Rodrigues, C. Pina-Vaz
(Porto, PT)
Cryptosporidium parvum is a waterborne agent, causing diarrhoea in
immunocompromised patients. Its diagnosis is based upon microscopic
detection of oocysts in faeces following alcohol-acid staining. This
conventional procedure presents low sensibility and speciﬁcity, being
highly dependent of the observe expertise. Our main objective was to
optimise a speciﬁc Flow Cytometric (FC) protocol for detection of
C. parvum in water and stools and to establish its sensibility limit.
C. parvum oocysts (Waterborne Inc, USA) were used for protocol optimi-
sation. FC analysis was performed using oocyst suspensions stained with
different concentrations of a speciﬁc monoclonal antibody conjugated
with R-phycoerytrin (Crypt-a-Glo, Waterbone). Serial concentrations
(2×105, 2×104, 2×103, 2×102 oocysts/mL) were later stained with
an optimised antibody concentration and analysed by FC. Speciﬁcity
and the sensibility limit of the method were established using both
prokaryotic (Escherichia coli, Sthaphylococcus aureus) and eukaryotic
microorganisms (Candida albicans, Giardia lamblia cysts). FC analysis
was repeated according of the optimised conditions, using human
stools and hospital tap water, simulating clinical and environmental
settings. Several procedures were also assayed to reduce the loss of
oocysts and improve its detection: different ﬁlters (gauze, paper ﬁlters),
centrifugation time and velocity, and distinct ﬂotation solutions (NaCl,
ZnSO4.7H2O). As the antibody concentration decreased, a decline of
peak intensity was registered. The optimal concentration of antibody was
3.0mg/mL for 105 oocysts/mL. We established a threshold of detection
of 2×103 oocysts/mL. The staining procedure was shown to be speciﬁc,
no cross-reaction occurring with bacteria, fungi or parasites. However, a
decrease in staining was seen especially when Giardia was present, but
it did not interfere with the result. Bellow threshold limit, ﬂuorescence
was not enough to allow the discrimination of oocysts. Interference of
debris was more frequently observed in faeces than in water samples.
A prolonged incubation of faeces in a ZnSO4 solution followed by
centrifugation for 10 minutes allowed a clear separation of oocysts from
debris. With the use of speciﬁc antibodies, a distinct cellular population
corresponding to oocysts could be represented in the FC histogram. This
study describes the ﬁrst optimised FC protocol for detection of C. parvum
in hospital tap water and human faeces.
P557 A multiplex microsphere-based assay for the simultaneous
detection of C. parvum, E. histolytica and G. lamblia antigen
in human faecal sample
A. Huwe, X. Su, S. Cox, H. Truong, P. Nguyen, E. Laderman, J. Groen
(Cypress, US)
Background: Cryptosporidium, Entamoeba, and Giardia are protozoan
parasites that infect the gastrointestinal tract of animals and humans by
oral-faecal transmission or through contaminated water sources. Infec-
tions may be asymptomatic or may cause a range of symptoms including
diarrhoea, fever, and vomiting. Immunocompromised individuals are
often unable to clear the parasites from their systems and ultimately
suffer severe illness and possible death. Current methods of diagnosis
include microscopy (O&P), and ELISA; these “single-plex” methods
prove to be labour intensive, and require special skills in addition to
other limitations. A high performance, multiplexed assay with the ability
to simultaneously detect the presence of all three parasites in a single
faecal sample is highly desirable. This study describes the development
of the PlexusTM Parasitic Multi-Analyte Diagnostics assay based on the
Luminex xMAPTM system (Austin, TX).
Methods: Samples: A retrospective panel of 248 human stool samples
submitted for parasite testing was collected. In addition, stool samples,
and culture supernatants of common enteric pathogens were collected for
cross-reactivity testing. PLEXUSTM Parasitic Multi-Analyte Multiplex
Assay: Monoclonal antibodies speciﬁc for each parasite were covalently
linked to microspheres. The capture microspheres were mixed with
extracted human faecal samples, washed, and incubated with polyclonal
detection antibodies speciﬁc for each parasite antigen. Finally, the
microspheres were incubated with ﬂuorescent Phycoerythrin (PE)
conjugate. The median ﬂuorescence intensity of PE measured by
the Luminex 100 System indicates the amount of antigen captured.
Reference Assay: Samples were tested by microscopy or with the
TechLabTM Cryptosporidium II, E. histolytica II, and Giardia II ELISA
systems per the manufacturer’s suggested protocol.
Results: The sensitivity of the PLEXUS Parasitic Panel compared
to ELISA was 100% (62/62) for C. parvum, 95.5% (21/22) for
E. histolytica, and 98.4% for G. lamblia. The speciﬁcity was determined
to be 100% (176/176) for all three parasites. In addition, the system does
not display cross-reactivity with any of the common enteric pathogens,
bacteria, or viruses.
Conclusion: The multiplex capability of the PLEXUSTM Parasitic Multi-
Analyte Diagnostics system offers a high performance, time-saving
alternative to microscopy and ELISA for the qualitative detection of
C. parvum, E. histolytica and G. lamblia.
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P558 Evaluation of ﬁve commercial screening assays and two
commercial immunoblots for the serological diagnosis of
Lyme borreliosis
C. Matthys, E. Petrens, E. Padalko, K. Lagrou, L. Van Renterghem
(Ghent, Leuven, BE)
Objectives: Lyme borreliosis (LB) caused by Borrelia burgorferi sensu
lato is the most common vector-born disease in North America and
Europe. According to guidelines serological diagnosis of LB should
follow a two-step procedure: a screeningtest and if reactive followed
by an immunoblot. A large variety of commercial assay is available for
the serological diagnosis of LB. We evaluated the performance of ﬁve
commercial screening assays for the detection of both IgM and IgG
antibodies to B. burgdorferi as well as of two commercial immunoblots
used as conﬁrmation of serological LB diagnosis in clinical cases of LB.
Methods: The assays tested were Quick ELISA C6 (Immunetics),
VIDAS Lyme (BioMe´rieux), Enzygnost Borreliosis IgM and IgG
(Dade Behring), Enzygnost Lyme link VlsE/IgG (Dade Behring) and
Euroimmun Anti-Borrelia IgM and IgG (Euroimmun). The testpanel
(n = 73) included sera of patients with a documented clinical history of
LB and was divided into 4 groups according to the symptoms: erythema
migrans (EM), facialis parese (FP), neuroborreliosis (NB) and other
symptoms (OS). All LB patients’ sera were also tested by two different
immunoblot (WB) assays: the Mikrogen recomblot Borrelia (Mikrogen)
and the Euroline-Western Blot (Euroimmun). Additionally, speciﬁcities
of the screening assays were evaluated by using 50 possible cross-reactive
sera.
Results: The sensitivities obtained showed that all screening assays (total
antibodies or combination of IgM and IgG assay), provided comparable
results for all 4 clinical groups ranging from 94.5% (VIDAS Lyme) to
98.6% (Quick ELISA C6). The lowest sensitivities were observed for
the group EM. The speciﬁcities ranged from 66% (VIDAS Lyme) to
96% (Quick ELISA C6). The lack of speciﬁcity seen with the VIDAS
assay was mainly caused by cross-reactivity with samples from patients
with active syphilis. The Quick ELISA C6 provided both the best
positive (97.3%) and negative (98.0%) predictive value. Considering
the conﬁrmatory tests, the Euroline WB IgG achieved the highest
sensitivities for all groups, while the Mikrogen recomblot IgM showed a
better sensitivity than the Euroline WB IgM. When combining WB IgG
and WB IgM, however, both WB had similar sensitivities.
Conclusion: The results obtained for all groups of clinical LB indicate
that the Quick ELISA assay performs better than the other 4 screening
assays. Sensitivities of Mikrogen and Euroimmun immunoblots were
similar when combining both IgM and IgG results.
Extended-spectrum b-lactamases/metallo-
b-lactamases
P559 Epidemiology of infections caused by extended-spectrum
b-lactamases producing Escherichia coli for a three-year
period
M.M. Gallardo, M.V. Garcı´a, R. Rodrı´guez, F. Ropero, E. Granados,
A. Gutierrez, A. Pinedo (Ma´laga, ES)
Objectives: For the last years we are being witness of an increase
of ESBLs productive strain isolations, making more difﬁcult managing
carrier patients. Our aim is to get to know the clinical and epidemiologic
features of the ESBLs producing E. coli in the population attending our
hospital.
Methods: A retrospective study was carried out from January 2003
to December 2005, where a total of 8623 E. coli strains were
isolated. Antimicrobial suceptibilities were carried out by the MicroScan
Walkaway® automised system and by disk difussion test and E-test.
Double-disk synergy test and E-test were used for screening ESBLs.
The results interpretation were according NCCLS guidelines.
Results: Out of the total number of isolations obtained, the percentage
of ESBLs strains was 4.5% (391) of which 59 (15.1%) were isolated
during the year 2003, 81 (20.7%) during 2004 and 351 (64.2%) during
2005. In 71.1% of the cases the origin was extrahospitalarian. Urine was
the sample where it was isolated more frequently in 67.5% of the cases
followed by exudates (18.2%)and blood (8.4%). The 391 ESBL E. coli
strains belonged to 391 patients 247 (63.1%) women and 144 (36.9%)
men with an average age of 61.8 years old (range: 1−98). Hospitalised
cases were 28.9% (113) and most of them in the internal medicine
department (45.5%), followed by the surgical department (30%) and
Intensive Care Units (24.5%). Progress of the hospitalised patients went
to resolution in 71.4% of the cases being exitus in 28.5% of them.
In reference to sensitivity, co-resistance was detected with quinolones,
fosfomycin, trimethoprim-sulfamethoxazole (TSX) and aminoglycosides,
observing that the co-resistance more frequently found was with
quinolones 71.1% followed by TSX 53.2%, aminoglycosides 20.7% and
fosfomycin 4.9%. Only 76 (19.4%) did not show co-resistance with other
groups of antibiotics. The co-resistance combination more frequently
found was ESBLs more resistant to quinolones and TSX in 46% of the
cases.
Conclusions: An important increase of ESBLs isolations have been
proven from the year 2003–2004 to the year 2005. Most of the strains
were of extrahospitalarian origin. A high level of co-resistance has
been detected among ESBLs strains, where quinolones are the antibiotic
family mostly affected.
P560 A pseudo-outbreak of a Citrobacter with an extended-
spectrum b-lactamase in a haemato-oncology ward
L. Jansen, J. Bakkers, M. Wulf (Nijmegen, NL)
Objective: To investigate a sudden increase of Citrobacter species,
which were reported to have an extended spectrum b-lactamase (ESBL)
on a haemato-oncology ward.
Design: A case-series of 16 patients colonised with a Citrobacter ESBL
between January and December 2005 were investigated. Strains were
typed by pulsed ﬁeld gel electrophoresis. On the 22 strains identiﬁed
by the automated Phoenix system as a possible ESBL, a disk diffusion
test with cefpodoxim, ceftazidim, cefotaxim combined with clavulanic
acid was performed and ESBL Etest strips were used to conﬁrm the
ESBL phenotype. In addition molecular detection of TEM, SHV, GES
and CTX-M was done.
Results: Of two 22 strains the Phoenix System indicated the resistance
pattern as ‘possible ESBL’, 9 strains had a phenotype on disk diffusion
and E-tests consistent with this result. Of these 9 strains 4 (44%) could
be conﬁrmed by PCR as ESBL positive: 2 strains with SHV, 2 with
TEM-26. 3 strains with PCR positive did had a negative disk-diffusion
test: 2 strains from one patient carried a GES, one a CTX-M.
Conclusions: The increase of reported Citrobacter ESBL was partly
due to a change in laboratory practice where all strains indicated by the
Phoenix to have a resistance pattern indicative of ESBL were reported as
such. The ‘outbreak’ was not due to a single strain and different genes
coding for ESBL were found. 4 of 9 (44%) strains with a susceptibility
pattern indicative of ESBL could be conﬁrmed by molecular techniques,
whereas 3 strains were found to contain an ESBL that did not have a
typical resistance pattern. Detection of ESBL in Gram-negative bacteria
other than E. coli and Klebsiella species remains difﬁcult and results
should be interpreted with caution.
P561 Identiﬁcation of a Pseudomonas putida isolate harbouring
blaVIM metallo-beta lactamase gene on the hands of an
intensive care unit healthcare worker
A. Bisiklis, K. Manolopoulos, K. Tomos, E. Kazakos, I. Isticoglou,
S. Alexiou-Daniel (Thessaloniki, GR)
Objectives: We sought to investigate the microbial ﬂora of the hands of
healthcare personnel working in Intensive Care Units in order to identify
potential dissemination of carbapenemase producing-Pseudomonas spp.
during routine care.
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Materials and Methods: Cotton swabs were used to obtain surveillance
cultures from the hands of 50 healthcare workers attached to Intensive
Care Units. Each culture event was performed twice – at the beginning
and at the end of their shift. Swabs were placed directly into Mueller–
Hinton broth, incubated for 24 hours at 37ºC in ambient air and
subsequently subcultured onto blood and Mc Conkey agars followed
by 18 to 24 hour-incubation under similar conditions. Initial evaluation
of growth was performed by means of Gram stain for each unique
colony morphotype present on cultures. Deﬁnite bacterial identiﬁcation
and antimicrobial susceptibility testing was achieved with the VITEK2
identiﬁcation system. Resistance to imipenem and meropenem was
further conﬁrmed by the Etest assay according to the manufacturers’
instructions and data were interpreted by applying the CLSI criteria.
Metallo-b-lactamase (MBL) phenotypes among resistant strains were
detected with the use of Etest MBL strips. Carbapenemase-resistant
isolates were subjected to PCR analysis to conﬁrm the presence of
blaVIM and blaIMP genes.
Results: During the study, two P. aeruginosa, one P. oryzihabitans and
four P. putida non-duplicate isolates were recovered. Among these, one
Ps. putida strain was characterised phenotypically as metallo-b-lactamase
producer. PCR analysis of the latter with primers for blaVIM genes
yielded a 261 bp amplicon, indicating the presence of a blaVIM allele.
Interestingly, antimicrobial susceptibility testing revealed one P. aerug-
inosa strain that showed resistance to imipenem (MIC> 32 ug/mL) and
intermediate susceptibility to meropenem (MIC= 8 ug/mL), however
MBL production could not be established by both conventional and
molecular assays.
Conclusion: Previous reports have demonstrated the existence of
blaVIM genes in Gram-negative bacilli isolated from various contam-
inated sites – inanimate objects or intact patient skin surfaces – within
hospital facilities. Our study provides further evidence regarding the role
of healthcare personnel in multidrug-resistant strains transmission and
underlines the need for continuous epidemiological surveillance, in order
to assess potential reservoirs, and implementation of preventive policies.
P562 Characterisation of an E. coli strain producer of
metallo-b-lactamase in a paediatric hospital
R. Go´mez-Gil, A. Barrios, J. Mingorance, A. Gutierrez, C. Ferna´ndez
(La Paz, ES)
Objective: Characterisation of an E. coli strain producer of metallo-
b-lactamase (MLBs) isolated in hemocultive and urocultives from a
patient with acute pielonefritis.
Material and Methods: Study of 3 isolates of E. coli from a patient of
20 days of age with acute pielonefritis, obtained ﬁrst in a hemocultive
and urocultive and the third in a new urocultive 4 months later. The
identiﬁcation and sensitivity analyses were done using Wider panels
MIC/ID Gram negatives (Soria Melguizo, S.A.®) and VITEK2 cards GN
and AST-No22 (bioMe´rieux®). Sensitivity to aztreonam was determined
by Etest.
The MLBs phenotype was settled down with EDTA-imipenem/imipenem
Etest and diffusion in Mueler-Hinton agar with an imipenem and
EDTA containing disks and with Macfarland 5 inocules. The presence
of extended-spectrum b-lactamase (ESBL) was descarded by Etest
of cefotaxime/cefotaxime-clavula´nic, ceftazidime/ceftazidime-clavula´nic
and cefepime/cefepime-clavulanic. Finally the molecular characterisation
was made by ERIC-PCR, and PCR using speciﬁc primers (blaVIM,
blaIMP)
Results: The 3 isolates corresponded to a same strain of E. coli and
had an identical antibiotype. The strain presented resistance to all the
b-lactamics, except aztreonam with CMI of 0.12mg/mL. The CMI of
imipenem was of 2mg/mL. The Etest of imipenem/imipenem-EDTA
presented a clear inhibition of the metaloenzime over more than 4
dilutions. In addition, there was resistance to gentamicin, tobramicin and
trimethoprim-sulfametoxazole. Analyses by PCR showed the presence of
a b-lactamase of the VIM family.
Conclusions: In all the isolates of enterobacteriaceae with CMI to
imipenem greater of 1mg/mL, the MLBs should be discarded even if
they seem sensible in antibiogram with CLSI cut offs
– This is the ﬁrst description in Spain of metaloenzyme of E. coli in
children.
– The association of sensitivity and the expression of the phenotype
using imipenem/imipenemEDTA with high inocules allows the
phenotypical characterisation of the enzyme
P563 Beta-lactam resistance mechanisms in clinical isolates
of Proteus spp. in Portugal: plasmid-mediated inhibitor
resistant TEM and extended-spectrum b-lactamases
V. Manageiro, N. Mendonc¸a, D. Louro, E. Ferreira, M. Canic¸a
on behalf of the Antimicrobial Resistance Surveillance Program in
Portugal (ARSIP)
Objectives: The aim of this study was to evaluate b-lactamase
mechanisms responsible for b-lactam resistance in clinical strains
of Proteus spp. isolated from hospitals covering several regions of
Portugal. The clonal diversity of amoxicillin-resistant (AML-R) isolates
of P. mirabilis was also analysed.
Methods: During a 6 months period (January to June 1999), 460
consecutive nonduplicate clinical strains of Proteus spp. (429 P. mirabilis,
29 P. vulgaris and 2 P. penneri) were isolated from patients in
16 Portuguese Hospitals and Public Health Institutions. Antibiotic
susceptibility tests were performed according to NCCLS and French
Society of Microbiology guidelines. ESBL Etest conﬁrmed ESBL
production. Isoelectric points of b-lactamases were estimated by
isoelectrofocusing. Beta-lactamase resistant genes were searched by
PCR-multiplex method and blaTEM genes were identiﬁed by nucleotide
sequencing, using speciﬁc primers. The genetic relatedness among
P. mirabilis TEM-producers (n = 42) was investigated by pulsed-ﬁeld gel
electrophoresis (PFGE).
Results: AML resistance was observed in 35% of isolates (135
P. mirabilis, 27 P. vulgaris and 1 P. penneri). AML-R P. mirabilis
strains were divided in 4 groups: non-TEM producer strains (11%), and
penicillinase (86%), IRT-type (2%) and ESBL (1%) producer strains.
The coding region of blaTEM genes identiﬁed in P. mirabilis revealed
that 76% were parental genes (blaTEM-1A, blaTEM-1B, blaTEM-1C,
blaTEM-1F or blaTEM-1G), 1% was blaESBL gene (blaTEM-10B), 3%
blaIRT-19 genes (blaTEM-74F) and 18% were non-ESBL blaTEM genes.
A new gene, named blaTEM-156A, was detected in 3% of P. mirabilis
strains. Five different promoter regions were identiﬁed among blaTEM
genes. Thirty-two PFGE proﬁle types were identiﬁed: 26 included
clones genetically unrelated and the remaining 6 included clones related/
closely related or undistinguishable (with >80% and 100% similarity,
respectively).
Conclusion: TEM-1 was the main b-lactamase produced by Proteus spp.
associated with the weak promoter P3 in the respective coding gene.
TEM-10 enzyme was responsible for the ESBL phenotype and TEM-74
(IRT-19) for the IRT phenotype in P. mirabilis. Antimicrobial resistance
to cefuroxime and narrow-spectrum cephalosporins in P. vulgaris and
P. penneri were associated with the hyperproduction of cefuroximases.
This study emphasizes the need to carefully prescribe b-lactams in
infections due to P. mirabilis.
P564 Prevalence of conﬁrmed ESBL-production among European
Enterobacteriaceae: a ten-year report from the SENTRY
Antimicrobial Surveillance Program
L. Deshpande, R. Jones, H. Sader, T. Fritsche (North Liberty, US)
Objectives: To describe the 10-year trend among European (EUR)
Enterobacteriaceae (ENT) isolates displaying phenotypic characteristics
of extended-spectrum b-lactamases (ESBL). The global emergence of
ESBLs has compromised the activity of penicillins, third- and fourth-
generation cephems and aztreonam (ATM) as empiric agents when
treating infections caused by ENT. Understanding of recommended
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ESBL detection criteria is critical for the assessment of isolate
susceptibility (S) and initiation of necessary infection control measures.
Methods: A total of 30,137 ENT isolates collected from 47 medical
centres in 18 EUR countries including Russia, were S tested as part of
the SENTRY Antimicrobial Surveillance Program (1997–2006). E. coli
(EC), K. pneumoniae (KPN), K. oxytoca (KOX) and P. mirabilis (PM)
isolates meeting ESBL-screening criteria (CLSI; MIC values 2mg/L
for ATM or ceftriaxone or ceftazidime) were conﬁrmed using ESBL
Etests (AB BIODISK) or the clavulanate (CLA) disk approximation
method. A cefepime (FEP) MIC at 4mg/L was the ESBL screening
criterion for Enterobacter spp. (ESP), Citrobacter spp. (CSP) and
Serratia spp. (SER) with conﬁrmation performed using FEP with CLA.
Results: Among the 26,858 ENT isolates examined for ESBL-
production, 2,954 (11.0%) qualiﬁed as potential ESBL producers.
A subset of 1,796 were tested using a conﬁrmatory method with
1,359 (75.7%) being positive. Conﬁrmation of screening criteria
occurred most frequently (>70%) in KPN, KOX, EC, CSP and least
often (<70%) when testing ESP, SER and PM. Among EC and KPN,
ESBL-screen positivity rates have increased from 1997–1999 to 2004–
2006 (5.5 to 8.0% and 30.0 to 35.1%, respectively). Occurrence of
ESBL-screen positive isolates that did not conﬁrm with CLA inhibition
may be attributable to other recognized R mechanisms. Conﬁrmed
ESBL-production was often associated with R to ﬂuoroquinolones and
aminoglycosides. S to carbapenems, tigecycline, and polymyxin B was
retained among ESBL-conﬁrmed isolates.
Organism
(no. tested)
ESBL screening criteria
results
ESBL conﬁrmatory test
results
No. Detected % Positive No. Tested No. (%) Positive
EC (15,026) 1,022 6.8 654 485 (74.2)
KPN (3,881) 1,034 26.6 728 648 (89.0)
KOX (1,121) 209 18.6 96 80 (83.3)
PM (1,590) 171 10.8 70 40 (57.1)
ESP (3,369) 422 12.5* 190 68 (35.8)
CSP (683) 65 9.5* 15 11 (73.3)
SER (1,188) 31 2.6* 43 27 (62.8)
Total (26,858) 2,954 11.0 1,796 1,359 (75.5)
*ESBL phenotype screening criterion of FEP4mg/L.
Conclusions: Among tested EUR ENT, ESBL-screening criteria were
most often conﬁrmed among KPN (89.0%) and KOX (83.3%) and
less so for EC (74.2%) and other species. ESBL prevalence has
increased during this 10-year study, primarily in KPN and EC. Plasmidic
movement of ESBLs between ENT species is a likely product of the
high prevalence within predominant species, a worrisome development
warranting continued longitudinal monitoring.
P565 Antimicrobial resistance comparisons amongst extended-
spectrum b-lactamase producing Klebsiella spp. phenotypes
collected from Brazilian hospitals in 2003 and 2006
C. Mendes, P. Koga, E. Sakagami, P. Turner, C. Kiffer on behalf of
the MYSTIC Group Brazil
Objective: To compare the antimicrobial resistance rates of extended-
spectrum b-lactamase (ESBL) producing Klebsiella spp. phenotypes
responsible for hospital infections in two MYSTIC editions (2003 and
2006) in Brazil.
Methods: All hospitals participating in both surveillance years were
included in the analysis. To be included, the isolates had to be
consistent with the deﬁnition of an ESBL phenotype, established
as having a minimal inhibitory concentration (MIC) to cefotaxime,
ceftazidime, and/or cefepime 1.5mg/mL determined by E-test method.
Additionally, MICs were also determined to piperacillin/tazobactam,
imipenem, meropenem, and ciproﬂoxacin. Interpretations followed the
respective year NCCLS/CLSI documents. A chi-square test was applied
to identify differences in each antimicrobial susceptibility rate among
the two studied years. P values below 0.05 were considered signiﬁcant.
Results: The same centres participating in both years (n = 19) contributed
with the selected ESBL phenotypes and the total Klebsiella spp. isolates
for the study (143/279 from 2003 and 93/170 from 2006). Then, 236
Klebsiella spp. ESBL phenotypes clinical isolates entered the analysis.
The table presents susceptibility pattern of the Klebsiella spp. ESBL
phenotypes according to the year of isolation, the chi-square and the
p value for each comparison. Both carbapenems presented elevated
susceptibility rates at both years, although a few intermediate and
resistant strains occurred. The susceptibility rate for ciproﬂoxacin did
not demonstrate any signiﬁcant change among the two years. The
susceptibility rate for piperacillin/tazobactam in 2003 was 86% and in
2006 61.3%, while the chi-square test yielded a p value <0.0001 for this
comparison.
Conclusions: The prevalence of isolation of ESBL-producing Klebsiella
spp. phenotypes has been stable over the two years in the hospitals
evaluated. Stable susceptibility rates were observed among most
antimicrobials evaluated in each year against this phenotype, with only
the carbapenems presenting virtually full and stable activity. However,
susceptibility to piperacillin/tazobactam has decreased signiﬁcantly over
the years, casting doubts on the role of this antimicrobial in empirical
therapy for the ESBL-producing phenotypes.
Susceptibility pattern of the Klebsiella spp. ESBL phenotypes according
to the year of isolation, the chi-square and the p value for each
comparison
% Susceptibility/year P value c2
2003 2006
n = 143 n = 93
Ciproﬂoxacin 73.4 80.6 0.3 1.3
Piperacillin/tazo 86 61.3 <0.0001 17.7
Imipenem 99.2 100 0.7 0.18
Meropenem 98.3 99 0.7 0.14
P566 Antibiotic resistance of community-acquired urinary tract
infections in south-east Austria. Emergence of E. coli
producing extended-spectrum b-lactamase
A. Badura, G. Feierl, A. Grisold, L. Masoud, U. Wagner-Eibel,
E. Marth (Graz, AT)
Objective: To determine antimicrobial resistance rates of the most preva-
lent Gram-negative pathogens responsible for urinary tract infections in
community patients in the region of south-east Austria during the last
5 years (2002 to 2006).
Methods: From January 2002 to October 2006, a total of 45.597 urine
samples derived from community patients suffering from urinary tract
infections from the region of south-east Austria were analysed. Species
identiﬁcation and resistance testing of nonduplicate isolates were done
in the routine microbiology laboratory of the Medical University of Graz
using conventional methods. Ambiguous results were conﬁrmed with a
VITEK2 system using the ID-GNB or ID-GN test cards (bioMe´rieux)
for identiﬁcation and the VITEK2 AST-N020 test card (bioMe´rieux) for
resistance testing. Antimicrobial susceptibility results were interpreted
using the criteria recommended by CLSI. Production of extended-
spectrum b-lactamases (ESBL) was conﬁrmed by the Etest ESBL screen
method using strips with cefotaxime, ceftazidime, and cefepime (AB
Biodisk, Solna, Sweden).
Results: E. coli was most frequently isolated (70%) followed by Proteus
spp. (14%), Klebsiella spp. (8%) and Pseudomonas aeruginosa (7%).
The proportion of ESBL-producing E. coli increased from 1 isolate
(0.03%) in 2002, 5 (0.2%) in 2003, 9 (0.3) in 2004, 27 (0.9%) in 2005 to
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52 (2.1%) in 2006. For E. coli, a signiﬁcant increase in resistance could
also be observed for ciproﬂoxacin (5% in 2002 to 12.9% in 2006),
cotrimoxazole (15.6% in 2002 to 22% in 2006) and gentamicin (1%
in 2002 to 4% in 2006). In total, 11 ESBL-producing Klebsiella spp.
were isolated, but no signiﬁcant change could be observed over the
last 5 years. Among Klebsiella isolates, resistance rates to other agents
remained stable: ciproﬂoxacin (mean 2.2%), cotrimoxazole (mean 8.8%)
and gentamicin (mean 0.7%).
Generally, resistance patterns of Proteus spp. and Pseudomonas aerug-
inosa remained constant over the study period with high proportions of
ciproﬂoxacin-resistant isolates (mean 11.3% and 14.8%, respectively).
Conclusion: Community-acquired urinary tract infections due to ESBL-
producing Enterobacteriaceae have become a serious problem worldwide
because of limited treatment options. This study conﬁrms the rapid
emergence of ESBL-producing E. coli among outpatients in the region
of south-east Austria. Further analyses concerning the spread of these
strains are urgently needed.
P567 Prevalence and antimicrobial susceptibility of extended-
spectrum b-lactamases-producing Escherichia coli isolates
from community-acquired urinary tract infections in
Madrid, Spain
J. Tamayo, B. Orden, J. Cacho, J. Cuadros, J.L. Go´mez-Garce´s,
J.I. Alo´s (Mo´stoles, Madrid, Getafe, Alcala´ de Henares, ES)
Objectives: To assess the prevalence and monitor antimicrobial sus-
ceptibility trends of extended-spectrum b-lactamases (ESBL)-producing
Escherichia coli isolates causing community-acquired urinary tract
infections in 4 Health Care Areas of Madrid, Spain: Getafe, Argu¨elles,
Alcala´ de Henares and Mo´stoles.
Materials and Methods: A total of 6,721 E. coli isolates were recovered
from November 2005 to June 2006. Of these, 279 unique ESBL-
producing E. coli strains were studied. Antimicrobial susceptibility
testing was performed by the agar dilution method according to
guidelines of the CLSI. Thirteen antimicrobial agents were tested
(see Table). Differences in antimicrobial susceptibility related to age
distribution and gender were investigated.
Antibiotic MIC (mg/L) %S %I %R
Range MIC50 MIC90
Ampicillin >16 >16 >16 0 0 100
Cefazolin >16 >16 >16 0 0 100
Cefuroxime >16 >16 >16 0 0 100
Cefotaxime 1–>16 >16 >16 – – 100
Amox/clav 4/2–>32/16 8/4 32/16 56.3 29.6 14
Piper/taz 1/4–>64/4 4/4 32/4 77.1 17.9 5.0
Imipenem 0.06–0.12 0.25 0.5 100 0 0
Ertapenem 0.008–0.12 0.03 0.06 100 0 0
Gentamycin 0.5–>8 0.5 >8 81.3 2.2 16.5
Amikacin 1–>16 2 8 99.3 0 9.7
Fosfomycin 1–>64 2 16 93.6 0 6.4
Ciproﬂoxacin 0.06–>4 >4 >4 15.5 2.5 82.0
Co-trimoxazole 0.5/9.5–>2/38 >2/38 >2/38 37.3 – 62.7
Results: The table displays the susceptibility of ESBL-producing E. coli
isolates to the 13 antimicrobial agents tested. The point prevalence of
ESBL-producing E. coli was 4.15% (279/6,721) overall, 5.97% (56/938)
in Getafe, 3.94% (75/1,903) in Argu¨elles, 3.60% (74/2,057) in Alcala´
de Henares, and 4.06% (74/1,823) in Mo´stoles.
No difference was found in antibiotic susceptibility patterns with
patients’ gender. However, pathogens resistant to co-trimoxazole or
ciproﬂoxacin were detected less frequently in patients aged <50 years
than in patients aged 50 years (for co-trimoxazole, OR= 0.43, 95%CI:
0.20–0.93, p = 0.018; for ciproﬂoxacin, OR= 0.32, 95%CI: 0.14–0.74,
p = 0.0027).
Conclusions: ESBL-producing E. coli isolates were highly prevalent
among patients with community-acquired UTI. All strains tested
were susceptible to carbapenems. Ertapenem was the most active
agent tested, with an MIC90 of 0.06mg/L, followed by imipenem
(MIC90, 0.5mg/L), amikacin (MIC90, 8mg/L), and fosfomycin (MIC90,
16mg/L). Ciproﬂoxacin and co-trimoxazole exhibited the lowest activity;
isolates from patients aged 50 years were more often resistant than
those isolated from younger patients.
P568 Virulence genes and pathogenicity islands in an
extended-spectrum b-lactamase producing Escherichia coli
strain collection from Slovenia
K. Zerjavic, T. Orazem, M. Grabnar, J. Ambrozic Avgustin (Maribor,
Ljubljana, SI)
Urinary tract infections (UTIs) belong to most common infectious
diseases, being mainly caused by uropathogenic Escherichia coli
(UPEC). UPEC strains possess several virulence factors (VFs), including
capsules, invasins, siderophores, toxins, proteases, and various types
of adhesins, that are involved in UTI pathogenesis. Some of these
VFs are encoded by speciﬁc regions of bacterial chromosome, called
pathogenicity islands (PAIs). Recent data revealed that quinolone
resistance is often associated with extended-spectrum b-lactamase
(ESBL) producing E. coli strains, which mainly belong to the non-
B2 phylogenetic group and that quinolone resistant strains have fewer
VFs than their quinolone-susceptible counterparts. The aim of this study
was to elucidate the relationship between E. coli phylogenetic groups,
virulence determinants, ciproﬂoxacin resistance and ESBL production
in E. coli strains collected between the years 2000 and 2005 at the
Institute of public health in Ljubljana. 27 strains from various sources
were studied. Twelve of them were ciproﬂoxacin-susceptible whereas
ﬁfteen were ciproﬂoxacin resistant according to the CLSI guidelines.
The phylogenetic group and the prevalence of twenty-four virulence
factor genes and gene markers for six PAIs were determined by PCR
ampliﬁcation. Fifteen strains were assigned to phylogenetic group D,
ﬁve to group B1, four to group B2 and three to group A. Gene markers
for PAI I536 and PAI III536 were not detected. Genes associated with
PAI II536, PAI IV536, PAI IIJ96 and PAI ICFT073 were detected in
11, 33, 4 and 15 percent of the strains, respectively. The most prevalent
virulence genes (occurrence between 37 and 78%) were sfa, iroN, iucD,
papG, kpsM, iha, iss and usp. Outstanding was the high prevalence of
the picU gene (100%) and the VFs associated with E. coli translocation
across the blood-brain barrier i.e. ibeA (41%) and and asl (67%) among
ciproﬂoxacin resistant strains, while some VFs, i.e. papGII, afa, hlyA,
cnfI and vat, were found exclusively among ciproﬂoxacin susceptible
strains. Our results are generally in accordance with previous reports and
indicate a distribution of UTI strains in two groups i.e. highly virulent
and low resistant, and low virulent and highly resistant, thus raising at
least two questions: (i) what are the mechanisms that allow strains from
the ﬁrst group to survive and (ii) which VFs do strains from the second
group use to cause an infection.
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P569 TEM-142: a novel extended-spectrum b-lactamase derived
from TEM-111 via an Asp238Asn substitution
B. Timmerbeil, S. Scherpe, E. Stuerenburg, P. Heisig (Hamburg, DE)
Objectives: Extended spectrum b-lactamases (ESBLs) are a group of
b-lactam hydrolysing enzymes which are able to inactivate most b-lactam
antibiotics including aztreonam and third generation cephalosporins. The
TEM family is the largest and most common ESBL family. Within this
family the subtypes differ by a few amino acid substitutions.
Four ESBL-producing Escherichia coli strains were collected from one
patient under b-lactam therapy in the period from 2001 to 2004. The b-
lactamases were determined and the strains were analysed for clonality.
S130 17th ECCMID / 25th ICC, Posters
Methods: Beta-lactamases were identiﬁed using a speciﬁc blaTEM and
blaSHV duplex PCR. Using Sanger sequencing the blaTEM subtype
was identiﬁed. Clonality analysis was performed by pulsed-ﬁeld gel
electrophoresis (PFGE) and three different ﬁngerprint PCR techniques
(RAPD-, ERIC-, RepU1b-PCR). The blaTEM-bearing plasmids were
analysed by restriction enzyme mapping. The susceptibilities of the four
strains were determined as minimal inhibitory concentrations (MICs)
according to CLSI guidelines for AMP, AMP-SUL, AMX-CLA, PIP-
SUL, PIP-TZB, CXM, CTX, CRO, CAZ, FEP, FOX, IPM, MEM, ERM,
GEN, TOB, AMK, CIP, MXF, DOX, and SXT.
Results: Four ESBL-producing Escherichia coli isolates were collected
from the same patient: E. coli Ur7883/2001, E. coli Ur6845/2003, E. coli
Ur8093/2003 and E. coli Ur11057/2004.
E. coli Ur7883/2001 was identiﬁed to produce the b-lactamase TEM-
111. The remaining three isolates are producers of TEM-142. Both
b-lactamases differ in just one amino acid position: TEM-111 (Asp238),
TEM-142 (Asn238). Results of clonality analysis provide evidence for
clonal relationship of all four strains. The blaTEM-carrying plasmids
are identical. The MICs of cefepime for the four strains has shown a
difference of two serial dilution steps (TEM-111 isolate: 2mg/L, TEM-
142 isolates: 8mg/L).
Conclusion: A novel blaTEM subtype was identiﬁed with a unique
Gly238-Asn amino acid substitution called TEM-142. The b-lactamase
is highly related to TEM-111 which was isolated from the same patient
three years earlier. All strains are clonally related and the blaTEM
containing plasmids are identical. These data suggest that TEM-111 has
acquired a point mutation to yield TEM-142. A possible driving force
for this evolution might be the selective pressure by antibiotics, like
cefepime (differences in the MIC values of cefepime were determined)
or enzyme stability.
P570 Molecular epidemiology and typing of CTX-M
extended-spectrum
L. Xu, D. Morris, K. Biernacka, N. Woodford, P. Hawkey, K. Nye
(Birmingham, UK; Galway, IE; London, UK)
Objectives: The aims of this study were to investigate the molecular
epidemiology of CTX-M Extended-Spectrum B-Lactamase-Producing
Enterobacteriaceae in both hospital and community patients in the area
served by the Heart of England NHS Foundation Trust, Birmingham.
Methods: Between January and April 2006, a total of 2529 consecutive
non-duplicate isolates of Enterobacteriaceae were processed by the
clinical service. All isolates were screened for susceptibility to
cefpodoxime by the BSAC disc diffusion method and ESBL production
conﬁrmed using cefpodoxime, cefpirome and ceftazidime with and
without clavulanate. Multiplex PCR was used to detect all blaCTX-M
genes. The blaCTX-M positive isolates were characterised by dHPLC
and results further conﬁrmed by DNA sequencing. Clonal relatedness
was identiﬁed by PFGE analysis.
Results: A total of 82 isolates (3.2%) were conﬁrmed to produce ESBL,
including 53 isolates (64.6%) from hospital and 29 isolates (35.4%)
from the community. These isolates included 64 E. coli, 15 Klebsiella
spp., 2 E. cloacae and 1 Citrobacter freundii. Multiplex PCR screening
identiﬁed a blaCTX-M gene in 76 isolates (92.7%). Multiplex PCR
screening identiﬁed a blaCTX-M gene in 76 isolates. Of these, 71
belonged to a blaCTX-M group 1, and 5 harboured a blaCTX-M group 9
gene. The dHPLC genotyping of group 1 isolates showed that all had
blaCTX-M-15 proﬁles. The 5 group 9 isolates depicted a blaCTX-M-14
chromatogram signature. DNA sequencing conﬁrmed blaCTX-M-15 in
8 representative strains of the 71 dHPLC typed CTX-M-15 isolates and
all 5 blaCTX-M-14 producers. PFGE analysis showed the 60 blaCTX-M
positive E. coli isolates to represent multiple strains among which 7
clusters of 2 or more isolates and 16 distinct strains (>85% similarity)
were observed, eight were strain A.
Conclusion: This study conﬁrms that blactx-m-15 is the commonest
cause of ESBL production in this locality. blaCTX-M-14 accounted for
6.6% of all our CTX-M producing isolates, which has not formally
reported as causing disease in the UK, it may displace blaCTX-M-15.
There was evidence of dissemination of clonally related isolates among
patients both in the hospital and the community. Strain A has been
reported to comprise 38% UK isolates, but only 13% in our study.
P571 The fate of antibiotic resistance genes in cooked meat
R. Koncan, R. Garcı´a-Albiach, D. Bravo, R. Canto´n, F. Baquero,
G. Cornaglia, R. del Campo (Verona, IT; Madrid, ES)
Background: The possibility of transfer of resistant bacteria from
animals to humans by the food chain has been demonstrated in several
works. Safe food processing implies complete microbial pathogens
elimination, but the fate of DNA encoding antibiotic resistance has not
been explored. The aim of this work was to evaluate the possibility of
detecting the aac(6’)-aph(2’) codifying aminoglycoside resistance gene
in meat after conventional cooking procedures.
Methods: 25 g of chicken, pork and beef meat were contaminated
(needle injection) with different dilutions of Enterococcus faecalis
(Delaware strain), carrying the bi-functional gene aac(6’)-aph(2”) which
confers resistance to aminoglycosides. Contaminated meat samples were
either boiled (20 min), grilled (10 min), or cooked in an owen microwave
(5 min), mimicking conventional cooking procedures. Furthermore,
samples were submitted to conventional autoclave sterilisation and high-
pressure treatment to eradicate the viable bacteria. No bacterial growth
was obtained in plates seeded with tissue samples. Total DNA was
extracted using QiaAMP extraction kit for tissues (QiaGen), and all
samples were PCR-tested by using selective primers for the aac(6’)-
aph(2’) gene. Quantitative PCR experiments were applied to determine
the bacterial DNA concentration recovered after cooking methods. A
transformation assay was performed with DNA obtained from meat and
E. faecalis JH2−2 as recipient strain.
Results: Growth of the E. faecalis Delaware strain was not detected
in any meat type after the different cooking procedures or autoclave
sterilisation, but after high-pressure treatment counts ranged from 103
to 106 CFU/mL. Positive PCR results for the bi-functional gene were
observed in all experiments, except after the autoclave treatment.
Quantitative-PCR results indicated a direct correlation between the
density of bacterial inoculum and the ampliﬁed DNA. At identical
inoculum density, higher amounts of the bifunctional gene were
recovered in the beef samples, than in the pork or chicken ones.
Transformation experiments with total DNA from samples negative in
all cases.
Conclusion: Positive ampliﬁcation for the antibiotic resistance gene
aac(6’)-aph(2”) harboured in a E. faecalis strain was obtained after
cooking contaminated meat. PCR-ampliﬁcation procedures might be
suitable to retrospectively analyse the contamination of meat samples
by antibiotic-resistant bacteria.
P572 Identiﬁcation of CTX-M-type extended-spectrum
b-lactamases in urine based on real-time PCR
C. Oxacelay, A. O¨zcan, T. Naas, P. Nordmann (Kremlin-Bicetre, FR)
Background: CTX-M extended-spectrum b-lactamases (ESBLs) are
increasingly prevalent worldwide mostly in Escherichia coli from
community-acquired urinary tract infections. Thus, availability of a fast
and reliable technique for identiﬁcation of CTX-M-enzymes is becoming
a challenge for the microbiology laboratory. We have recently developed
a powerful tool combining real-time PCR with pyrosequencing for
epidemiological studies of CTX-M-positive strains (Naas et al. AAC,
2007, in press). However, this tool required a pyrosequencing machine.
Here we report use of an alternative technique based only on real-time
PCR.
Method: A fast real-time PCR ampliﬁcation based on a LightCycler
2.0 ampliﬁcation system (Roche Diagnostic), using degenerated primers
speciﬁc for the blaCTX-M alleles coupled to a CTX-M-type-speciﬁc
detection using hybridisation probes was developed. Five well-
characterised CTX-M producers, representing each of the ﬁve groups
were used as controls. Urine samples were collected at the Biceˆtre
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Hospital (France) over a three months period. DNAs were extracted
using QiAmp Viral RNA extraction kit (Qiagen). The presence of
ESBLs were conﬁrmed by standard microbiological techniques (disk
diffusion antibiogram, synergy testing) and by standard PCR followed
by sequencing.
Results: 810 urines were collected over the studied period and
among them 36 isolates from 29 different patients had an ESBL
phenotype (prevalence rate of 3.6%). The bacterial species were: E. coli
(22/29: 77%), Klebsiella pneumoniae (2/29: 7%), Citrobacter freundii
(2/29: 7%), Providencia stuartii (1/29: 3%), Enterobacter cloacae
(1/29: 3%) and Enterobacter aerogenes (1/29: 3%). The patients were
mostly from the Nephrology (27%), Emergency (24%), Gerontology
(17%) and Urology (10%) wards. Using this PCR approach, 20 out of
29 ESBLs were identiﬁed as CTXMs. Five belonged to the CTXM-9-
and 15 to the CTXM-1-group as revealed by melting curve analysis.
Standard PCR and sequencing identiﬁed 5 CTXM-9 and 15 CTXM-
15 and the remaining 9 ESBLs were mostly of TEM-type. Patients,
with more than one ESBL positive urine were reproducibly identiﬁed as
CTX-M positive.
Conclusions: The real-time PCR is a powerful technique for a fast
identiﬁcation of CTX-M-positive isolates from urines. It has the potential
to be used in a diagnostic microbiology laboratory since up to ﬁfteen
clinical samples may be processed in less than 3 h, thus allowing a rapid
implementation of isolation measures.
P573 Evolution of bla genes from SHV family
N. Mendonc¸a, M. Canic¸a (Lisbon, PT)
Objectives: SHV (sulfhydryl variable) is the most prevalent family of
b-lactamases produced by Klebsiella pneumoniae strains, an important
mechanism of resistance to b-lactam antibiotics. The aim of the study
was to evaluate the diversity and molecular evolution of blaSHV genes
family.
Methods: PCR speciﬁc for blaSHV gene and nucleotide sequencing
were performed in 212 clinical K. pneumoniae strains isolated in
Portugal (years 1998–2005). In addition 59 blaSHV sequences were
downloaded from NCBI GenBank database. All sequences were analysed
by Bionumerics software and a speciﬁc blaSHV gene fragment of 825bp
was used to align all sequences. Phylogenetic and molecular evolutionary
analysis was conducted using MEGA software.
Results: Among the 271 sequences analysed we detected 64 different
blaSHV gene sequence frameworks (SFWs), from which 40 were here
ﬁrstly identiﬁed. The 64 SFWs emerged from the combination of
silent mutations at 38 different nucleotide positions. Silent mutations
A402→G, G705→A and C786→G may be considered hot spots, as
they appeared in a higher frequency (92%, 62% and 49%, respectively)
than others. Phylogenetic analysis showed that the SFW (named ad)
presenting those 3 mutations is a possible common ancestral.
Among the 212 blaSHV genes sequenced by us, 58 (27%) were identiﬁed
as blaSHV-11. This gene showed the highest diversity as it presented
17 different SFWs, followed by 54 (26%) blaSHV-1 genes detected
with 13 SFWs, and by 30 (14%) blaSHV-28 genes with only 2 SFWs
associated (“a” and “r”). The 111 different sequences of blaSHV genes
studied in the phylogenetic approach, presented a total of 53 non-
synonymous mutations and 38 synonymous mutations, which allowed
to the construction of an unrooted tree.
Overall, the majority of blaSHV-1 and blaSHV-11 sequence genes had
the higher number of different SFWs (18 and 20, respectively) and were
on opposite sides of the evolutionary tree, which may imply a divergent
evolution. Furthermore, the majority of extended-spectrum b-lactamase
(ESBL) coding genes (63%) could be detected within the same branch
of the unrooted tree, which may indicate a common ancestral or origin.
Conclusions: This study demonstrated that blaSHV genes descend from
a yet unidentiﬁed common ancestor. The high diversity of blaSHV genes
suggests their contribution to the rapid evolution toward blaESBL-SHV
genes coding to ESBL enzymes and thus to the emergence of resistance
to third generation cephalosporins.
P574 Emergence and dissemination of metallo-b-lactamases
producing strains in Europe: report from the SENTRY
Antimicrobial Surveillance Program
L. Deshpande, H. Sader, T. Fritsche, R. Jones (North Liberty, US)
Objective: To evaluate the emergence and dissemination of metallo-
b-lactamase (MBL) producing strains in European medical centres
participating in the SENTRY Program.
Methods: Beginning in 2000 all Gram-negative bacilli submitted to
SENTRY with decreased susceptibility to imipenem (IPM), meropenem
and ceftazidime were routinely screened for production of MBL by disk
approximation tests and/or MBL Etest (AB BIODISK) strips. Isolates
with screen-positive results were evaluated by PCR using generic primers
for IMP, VIM, SPM and GIM enzyme types. MBL gene sequencing
and molecular typing (ribotyping, PFGE) were additionally performed
to characterise MBL and to evaluate clonality.
Organism (no.) MBL
(no. of strains)
Countries
(no. of strains)
Detection year
P. aeruginosa (46) VIM-1 (32) Germany (4)/
Greece (7)/Italy
(21)
2001–2004
VIM-2 (2) France (1)/
Poland (1)
2001 and 2003
IMP-13 (6) Italy (6) 2002–2002
GIM-1 (6) Germany (6) 2002
K. pneumoniae (33) VIM-1 (33) Germany (1)/
Greece (16)/
Italy (12)/
Spain (3)/
Turkey (1)
2005–2006
E. cloacae (19) VIM-1 (7) Germany (3)/
Italy (2)/
Spain (2)
2004–2006
IMP-1 (12) Turkey (12) 2003–2004
E. aerogenes (2) VIM-1 (2) Greece (2) 2005
Acinetobacter spp. (2) IMP-2 (1) Italy (1) 2003
VIM-1 (1) Greece (1) 2003
C. koseri (1) VIM-1 (1) Italy (1) 2005
K. ozaenae (1) VIM-1 (1) Italy (1) 2005
P. mirabilis (1) VIM-1 (1) Greece (1) 2005
Results: Since 2000, 4,935 P. aeruginosa (PSA), 1,460 Acinetobacter
spp. (ASP) and 22,950 Enterobacteriaceae (ENT) have been collected
from European centres and tested for susceptibility (S) by reference
broth microdilution methods (CLSI, 2006). S rates to IMP remained
stable among PSA (75.5% in 2000 and 76.1% in 2006), but varied from
78.5% in 2000 to 51.9% in 2006 among ASP. IMP remained very active
against ENT (99.8% S in 2006), but the occurrence of strains with MIC
2mg/L increased from 0.4% in 2000 to 1.5% in 2006. A total of 105
MBL-producing strains were identiﬁed and characterised since 2000. The
most common MBL-producing species were PSA with 46 strains from
5 countries and producing 4 different MBLs; followed by K. pneumoniae
(KPN; 33 VIM-1-producing strains from 5 countries) and E. cloacae
(ECL; 19 strains, VIM-1 and IMP-1-producers from 4 countries). MBL-
producing strains were usually resistant to most antimicrobials tested.
Polymyxin B was very active against PSA (100% S) and KPN (94% S);
while tigecycline was highly active (100% S) against ASP, KPN and
ECL. Molecular typing results indicated clonal dissemination of PSA
producing VIM-1 in Germany, Greece and Italy, IMP-13 in Italy and
GIM-1 in Germany; KPN producing VIM-1 in Greece, Italy and Spain;
and IMP-1-producing ECL in Turkey. In addition, clonal diversity
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was observed among IMP-13-producing PSA from Rome, Italy; VIM-
producing KPN from Athens, Greece and ECL from Leipzig, Germany
and Madrid, Spain; and IMP-1 producing ECL from Istanbul, Turkey.
Conclusions: The emergence and dissemination of MBL-producing
strains was documented in several European countries and it is of great
concern since these enzymes were usually codiﬁed by genes located on
integrons with great mobility.
Molecular characterisation of gastro-
intestinal pathogens
P575 Comparison of four real-time PCR-based methods for the
detection of food-borne Salmonella enterica
K. Krascsenicsova, E. Kaclı´kova, T. Kuchta (Bratislava, SK)
Objectives: The aim of the study was to compare four real-time PCR-
based methods – our in-house method and three commercial kits – for
the detection of food-borne Salmonella enterica regarding sensitivity and
reliability of the results interpretation.
Methods: The next-day method for Salmonella enterica detection
developed in our laboratory utilised a two-step enrichment and our
original duplex FAM/VIC TaqMan real-time PCR. Sample preparation
prescribed for TaqMan Salmonella enterica (Applied Biosystems, Foster
City, California, USA), iQ-CheckTM Salmonella (BioRad, Marnes-la-
Coquette, France) and BACIdent Salmonella spp. (GeneScan, Freiburg,
Germany) involves a single-step enrichment in non-selective medium.
PCR detection of ABI and BacIdent kits is based on duplex
FAM/VIC TaqMan real-time PCR. The iQ-Check kit employes duplex
FAM/TexasRed Molecular Beacon-based real-time PCR. Detection limits
of PCR, as well as the detection limits of whole methods for live and
dead Salmonella cells, were determined for each method. One hundred
different food samples were analysed and 40 selected food samples were
spiked at three contamination levels (100, 101 and 102 CFU per sample)
and analysed in parallel by four methods.
Results: Detection limits of 102 CFU per ml for PCR and of 100 CFU
per sample were estimated for all presented methods. However, dead
cells were detected at a level of 103 – 104 CFU per sample by the
commercial kits utilising the single-step enrichment, which may be a
potential cause of false positive results. False negative results probably
caused by food-borne PCR inhibitors were obtained with some food
matrices.
Conclusion: Methods for the detection of Salmonella enterica utilising
an enrichment shorter than 24 h, followed by duplex real-time PCR
including an internal positive control, represent a suitable tool for
fast and reliable identiﬁcation of this food-borne pathogen. The use
of a single-step enrichment may be a disadvantage, while a two-step
enrichment facilitates a reduction in the concentration of sample-borne
PCR inhibitors as well as dead cells.
P576 Comparison of commercially available methods and in-house
real-time PCR-based method for the detection of food-borne
pathogen Listeria monocytogenes
K. Oravcova, E. Kaclikova, T. Trncikova (Bratislava, SK)
Objectives: Food-borne Listeria monocytogenes causes in susceptible
individuals serious illness listeriosis with high mortality rate. Thus
methods for its rapid identiﬁcation in foods are of importance to
determine the source and level of contamination. We compared an in-
house real-time PCR-based method and three commercially available
methods for the detection of L. monocytogenes in food regarding rapid
and unambiguous results acquisition.
Methods: All four methods tested were culture-based with the ﬁnal
identiﬁcation by real-time PCR or on chromogenic agar. Selected 40 food
samples artiﬁcially contaminated with L. monocytogenes and 12 naturally
contaminated samples were analysed using in-house method, TaqMan
Listeria monocytogenes Detection Kit (Applied Biosystems, Foster City,
CA, USA), iQ-Check Listeria monocytogenes Kit (Bio-Rad, Marnes-la-
Coquette, France) and short enrichment procedure (Oxoid, Basingstoke,
UK). Method for the next-day identiﬁcation of L. monocytogenes
developed in our laboratory consisted of two-step selective enrichment
followed by duplex real-time PCR employing TaqMan probes. Using kits,
samples were undergoing one-step selective enrichment and analysed by
duplex quantitative real-time PCR employing either dual-labeled TaqMan
DNA probes in ABI’s kit or Molecular Beacon probes in Bio-Rad’s
kit. According to Oxoid’s enrichment procedure strains were identiﬁed
on OCLA agar. Detection limits for live as well as for dead cells of
L. monocytogenes were set.
Results: Detection limits of all methods for all samples were 100 CFU
per sample with the exception of 6 samples giving false negative results
by the Oxoid’s method due to L. innocua present in the samples and
overgrowing the target L. monocytogenes. Detection limits for dead
L. monocytogenes cells were 106 CFU per sample for in-house method,
104 – 105 CFU per sample for kits.
Conclusion: Methods for L. monocytogenes identiﬁcation in foods
consisting of short enrichment and real-time PCR detection provide
a powerful tool for fast and precise epidemiological studies when
compared to only culture-based techniques. If the price of analysis is a
decisive factor our in-hause method is of preferable use. Commercially
available methods, easy to handle and data interpretation, may suffer
from possibility of false positive results due to detection of dead cells
potentially present in the food sample.
P577 Evaluation of partial rpoB and 16S rDNA sequencing for
identiﬁcation of Enterococcal species and the comparison to
phenotypic methods
G. Haase, R. Lu¨tticken, J. Weber-Heynemann, I. Ramminger,
A. Mellmann, D. Harmsen (Aachen, Mu¨nster, DE)
Objectives: Enterococci can cause a variety of serious infections in
humans and animals. As of spring 2005 this genus compromise 32
species whereas many of the newer species have not yet been included in
the database of commercially available identiﬁcation systems. Therefore,
in this study a reference databases for partial RNA polymerase B (rpoB)
and the 16S rDNA gene sequences comprising all type strains of the
genus Enterococcus was established. Subsequently, the performance
of sequence-based identiﬁcation in comparison to two commercially
available, phenotypic based identiﬁcation systems was evaluated using
44 clinical isolates.
Methods: In addition to the 32 type strains, a panel of 44 strains (mainly
human isolates compromising 9 different species) was analysed in order
to reveal the relative performance of the different identiﬁcation methods
tested. Direct sequencing was performed using ABI Prism 3100 Analyzer
(Applied Biosystems). For quality assured sequence analysis (rpoB: 551
bp, position 2491 to 3041, AF535187; 16S rDNA: 446 bp, position 54
to 510 of E. coli) the Ridom TraceEditPro version 1.0 software (Ridom
GmbH, Wu¨rzburg, Germany) was used. For phenotypic identiﬁcation
the rapid ID 32 Strep (bioMe´rieux, Nu¨rtingen, Germany) and the Gram
positive panel of the PhoenixTM system (BD, Heidelberg, Germany) were
used according to the instructions of the manufactures. ID 32 panels were
examined using the MiniAPI reader.
Results: Of the 32 type species, 28 exhibit a unique sequence in the
respective 16S rDNA/rpoB reference database whereas only the two pairs
E. porcinus/E. villorum and E. italicus/E. saccharominimus had identical
sequences. Only 7 type strains were correctly identiﬁed by ID 32 Strep or
the Phoenix system. Analyzing the 44 clinical isolates, 36 (81.8%) could
be identiﬁed univocally by sequencing (99% similarity) using the 16S
rDNA/rpoB reference database. Using the rpoB based identiﬁcation as
reference, only 25 (56.8%) and 32 (72.7%) of these strains were correctly
identiﬁed by the ID 32 Strep or Phoenix test system, respectively.
Conclusion: Sequence based identiﬁcation, in particular rpoB sequenc-
ing turned out as the most discriminatory identiﬁcation procedure for
achieving reliable species identiﬁcation of Enterococci.
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P578 Updated qnr multiplex PCR-based technique:
epidemiological survey of Qnr determinants in a collection
of ESBL-producing enterobacterial isolates from Kuwait
V. Cattoir, L. Poirel, V. Rotimi, C.-J. Soussy, P. Nordmann (Le Kremlin
Bicetre, FR; Kuwait City, KW; Cre´teil, FR)
Objective: The goal of this study was to develop a single-tube based-
PCR technique for detecting simultaneously qnrA, B and S-like genes.
This strategy was applied for screening a collection of ESBL(+)
enterobacterial isolates from Kuwait.
Material and Methods: A multiplex PCR-based technique was
developped for detection of the three known qnr genes using speciﬁc
primers. Primers were carefully designed for adaptation of variants
of these genes (qnrA1 to A5, qnrB1 to B6 and qnrS1 to S2). PCR
products were identiﬁed as qnrA, B or S according to their sizes in
ethidium bromide-stained agarose gels and thus were submitted by direct
sequencing. After its optimisation, this technique was used to screen a
collection of 63 ESBL-producing enterobacterial isolates obtained in
Kuwait from 2002 to 2004.
Results: Multiplex-PCR peformed with speciﬁc primers gave three
bands of ampliﬁcation products easily separated: 579 bp, 264 bp and
426 bp for qnrA, -B and -S genes, respectively. All positive and negative
controls were according to expected results. A qnr gene was present in
4 (6.3%) of the sixty-three enterobacterial isolates. Whereas qnrA and
qnrS were absent, qnrB was present in these four isolates corresponding
to 3 Enterobacter cloacae (strains K34, K35 and K37) and 1 Citrobacter
freundii (strain K70). After sequencing, ampliﬁcation products were
identical to qnrB2 (441/441) for K34 and K35, similar to qnrB1 (97%)
for K70, and similar to qnrB6 (89%) for K70. Analysis of deduced
protein structure of Qnr determinants from K37 and K70 strains showed
3 and 5 substitutions compared to QnrB2 and QnrB6, respectively. These
novel variants may be designated as QnrB7 and QrB8, respectively.
Conclusion: This multiplex PCR-based technique detected all variants of
the three qnr genes. Using this technique, two novel QnrB determinants
were discovered. Interestingly, no QnrA-like determinant was identiﬁed
whereas they have been reported to be associated frequently to ESBL
genes.
P579 Analysis of plasmids from multi-resistant and multi-plasmid
clinical E. coli strain CZD1527
R. Wolinowska, K. Strzezek, P. Zaleski, J. Chodnicka, A. Lakomy,
A. Demianczuk, A. Plucienniczak (Warsaw, PL)
Objectives: Clinical strain of E. coli CZD1527 is resistant to b-lactams,
aminoglycosides and tetracycline. Spontaneous changes in level of
resistance to antibiotics have been observed for this strain. Analysis
of the plasmids present in the strain has been performed in regard to
their possible involvement in that changeability of the strain antibiotic
resistance.
Methods: Transformation of laboratory E. coli strain NM522 by
electroporation. Transformation preceded by insertion of kanamycin
transposon. Antimicrobial susceptibility tested by disc-diffusion method.
PCR analysis.
Results: Total plasmid preparation obtained from E. coli CZD1527 strain
has been analysed on agarose gel and at least 8 bands can be observed.
4 of them migrate like plasmids of 4−5 kb, two bands contain very big
molecules and are localised on the top of the gel. The other bands are
less visible and placed between these two groups.
Plasmid preparation has been used to direct transformation of laboratory
strain E. coli NM522, then selection on plates with antibiotics has
been performed. Two kinds of transformants carrying big plasmids
have been obtained. Plasmids are above 100 kb and have been named
pIGT-15 and pIGAM-1, both encode resistance to b-lactams, pIGT-15
to aminoglycosides and tetracycline as well. Partial sequence of pIGT-
15 indicates that resistance to aminoglycosides and b-lactams is bound
up with class 1 integron. It shows high homology to plasmid p1658/97
from E. coli (GeneBank Acc. No NC004998). The gene of resistance to
tetracycline is located in structure of transposon T1721.
In the second step total plasmid preparation of CZD1527 strain has
been subjected to kanamycin transposon insertion and electroporation.
Two different plasmids, pIGRW12 and pIGWZ12, have been identiﬁed in
transformants. 90 colonies of 126 have been tested by PCR, no additional
plasmid has been found.
Complete nucleotide sequence of both plasmids is determined, both are
cryptic plasmids. Plasmid pIGWZ12 is 4072 bp long (GenBank Acc.
No DQ311641, Plasmid 2006, 56, 228–232), pIGRW12 is 4995 bp long
(sequence already sent to GenBank). Detailed analyses of two smallest
bands from agarose gel reveal that they are single stranded forms of
plasmids pIGWZ12 and pIGRW12.
Conclusion:
– Four plasmids have been found in clinical strain E. coli CZD1527.
– Complete sequence of two cryptic plasmids (pIGWZ12 and pIGRW12)
has been obtained.
– Partial sequence of pIGT-15 with resistance genes is being determined.
P580 Isolation EPEC strains in the region of Thrace, Greece
E. Alepopoulou, M. Panopoulou, V. Dala, A. Chatzimichail, K. Ritis,
S. Kartali (Alexandroupoli, GR)
Objective: Enteropathogenic E. coli (EPEC) is an important category of
diarrhoeagenic E. coli which links to infant diarrhoea in the developing
world and sporadic cases of diarrhoea in industrial countries. EPEC
damage the bowel mucosa with characteristic mechanism (attaching and
effacing lesion) mediated by a protein encoded by the eae chromosomal
gene.
Methods: Two hundred ﬁfteen stool specimens were examined for
EPEC. One hundred sixty ﬁve samples proceeded from patients with
diarrhoea (group A) and 50 from healthy individuals (group B). Stool
specimens or rectal swabs were inoculated on MC agar and incubated
at 37ºC overnight. Five colonies of E. coli isolated on MC agar were
picked. The biochemical identiﬁcation of the strains was performed
by automated system VITEK2 (bioMe´rieux) and serotyping by slide-
agglutination methods for serotypes O111, O55, O26, O86, O119, O127,
O125, O126, O128, O124, O114, O142 (BioRad). The presence of eae
gene was detected by PCR that contains primers for eae E. coli gene.
The PCR products 384 bp were analysed by electrophoresis in 2% agar
gel.
Results: From 215 stools 1207 strains E. coli were examined. EPEC
were recovered from 22 (10.2%) stool specimens, 11 (5.1%) of them
were from children and 8 (3.7%) from adults (group A), though 2 and 1
strain respectively from group B (control). The EPEC strains encountered
in this study belonged to 5 different serotypes of E. coli: O127−8 (36%),
O26−5 (23%), O126−4 (18%), O125−4 (18%) and O55−1 (4.5%). These
strains did not have the eae gene. However, one strain (0.6%) from
group A that yielded gene eae, did not ferment sorbitol and has been
isolated from stool of an adult patient with diarrhoea.
Conclusion: The 5.1% EPEC strains were isolated from children and
isolation rate is in agreement with those of other investigations. However,
according to the decision of the Second International Symposium on
EPEC in 1995: strains with A/E histopathology and absence of Shiga
toxin should be called EPEC. Consequently, the rate of isolation of EPEC
in this study was much lower (0.6%), as only one from the 165 samples
has the eae gene. The detection of pathogenic genes altered in high
degree the rates of isolation of EPEC and modiﬁes the epidemiologic
data of various regions.
P581 Isolation of E. coli O157:H7 and non-O157 in the region of
Thrace, Greece
E. Alepopoulou, M. Panopoulou, E. Maltezos, G. Kartalis, S. Kartali
(Alexandroupoli, GR)
Aim: The morbidity and mortality associated with several recent large
outbreaks of gastrointestinal disease caused by Shiga toxin-producing
E. coli has highlighted the threat these organisms pose to public health.
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Methods: Two hundred ﬁfteen stool specimens were examined for
EHEC. One hundred ﬁve samples proceeded from patients with
diarrhoea (group A) and 50 from healthy (group B). Stool specimens
or rectal swabs were inoculated on MC agar, CT-SMAC agar and
incubated at 37ºC overnight in aerobic conditions. For the detection
of enterohemolysin, ﬁve colonies of E. coli from MC agar and
sorbitol negative colonies from CT-SMAC were inoculated in WBA
(Washed Blood Agar) with CaCl2. For the detection of MUG activity
Tryptone X-glucuronide Agar (OXOID) was used. The biochemical
identiﬁcation of the strains was performed by automated system VITEK2
(bioMe´rieux) and serologic identiﬁcation by slide-agglutination methods
(Wellcolex * E. coli 157: H7, ABBOTT). Presence of eae, ehx, stx1,
stx2 genes was detected by multiplex PCR. The PCR products 384 bp
(eae), 534 bp (ehx), 181 bp (stx 1) and 255 bp (stx 2) were analysed by
electrophoresis in 2% agar gel.
Results: From 1207 strains isolated, 38 did not ferment sorbitol and two
of them produced small, turbid haemolytic zone on WBA with CaCl2
after overnight incubation. One strain (0.46%) was isolated from stool
of adult patient (group A), belonged to serotype O157:H7 and it did
not yield the eae, ehx, stx1, stx2 genes. From the remainder 37 strains,
two (1.2%) have stx toxin genes. These strains were serotype non –
O157:H7 E. coli and were isolated from two patients with diarrhoea.
One of them has stx 1 and stx 2 toxins genes, and the other has stx 1
and ehx genes.
Conclusion: The isolation rate of E. coli O157:H7 in the region of
Thrace, Greece is low. However, the percentage of E. coli non-O157:H7
isolated from stool of patients with diarrhoea is similar with that other
of investigations in European countries.
P582 Highly efﬁcient extraction of pathogen DNA from stool using
the NucliSENS easyMAGTM speciﬁc A 1.0.2 protocol
T. Schuurman, R.F. de Boer, P.B.H. van Deursen, P. de Bie,
A.M.D. Kooistra-Smid (Groningen, Boxtel, NL)
Objectives: The NucliSENS easyMAG is a fully automated system for
extraction of nucleic acids from a wide variety of clinical specimens.
However, the extraction of DNA from stool with the standard protocol
(Generic) has been shown to be less efﬁcient compared to other clinical
specimens. Preliminary data showed that this problem was in part related
to impaired elution of the DNA. To overcome this problem, a new
protocol, Speciﬁc A (bioMe´rieux) has been developed and validated for
use with DNA rich specimen types, such as stool.
Methods: Clinical stools (n = 94), including 43 stools positive for 1
or more intestinal pathogens, were used to challenge both extraction
protocols. Relative recovery of DNA was assessed by spiking a known
amount of HindIII-digested phage lambda DNA, and comparing the
recoveries after gel electrophoresis. Impaired elution for Generic was
assessed by a secondary elution of the DNA from the retrieved magnetic
silica. Downstream performance with the extracted DNA was assessed
with 2 internally controlled (IC) multiplex real-time PCRs each targeting
2−3 intestinal pathogens.
Results: Of the 94 stools tested, 61 showed nearly identical DNA
recoveries without impaired elution, although the DNA yield was slightly
higher with Speciﬁc A in all specimens. For the remaining 33 samples,
19 showed low DNA recovery with Generic, whereas Speciﬁc A showed
variable but improved recovery. The other 14 specimens could be
classiﬁed in three groups based on the ratio between the primary (1st) and
secondary (2nd) elution for Generic. This ratio was 1st> 2nd, 1st< 2nd,
and 1st = 2nd for 4, 4, and 6 specimens, respectively. Results of the real-
time PCRs conﬁrmed the DNA recovery results. Ct values for Speciﬁc
A were on average 0.9 and 1.1 cycles lower for IC and pathogen DNA,
respectively, compared to Generic. The distribution of all the paired Ct
values also showed a signiﬁcant difference (paired 2-sided student T-test,
p< 0.00002). When the Ct values were addressed to the DNA recovery,
the 61 specimens with nearly identical recovery showed on average 0.61
and 0.62 cycles lower Ct values with Speciﬁc A for IC and pathogen
DNA, respectively, whereas the other specimens showed on average 1.5
and 1.9 cycles lower Ct values. Inhibition was not signiﬁcantly different
between both protocols (6−7%).
Conclusion: Based on the presented data, Speciﬁc A, results in a
signiﬁcant improvement in the performance of the NucliSENS easyMAG
with stool specimens.
P583 Rapid and sensitive detection of 5 gastro-intestinal pathogens
using 2 internally controlled Multiplex real-time PCRs
T. Schuurman, R.F. de Boer, A.M.D. Kooistra-Smid (Groningen, NL)
Objectives: Traditional methods to detect gastro-intestinal pathogens
are slow, and/or lack sensitivity. Molecular detection of gastro-intestinal
pathogens has proven to be rapid and sensitive. Stool screening requires
a large throughput; however, the use of monoplex PCRs greatly limits
the capacity. Therefore, a multiplex approach is mandatory.
Methods: Real-time PCR assays for Salmonella enterica (SE),
Campylobacter jejuni (CJ), Giardia lamblia (GL), shiga toxin-
producing Escherichia coli (STEC), and Shigella spp./enteroinvasive
E. coli (SH/EIEC) were developed and subsequently multiplexed in
2 assays combining SE/CJ/GL and STEC/SH/EIEC. Both assays also
incorporated an internal control (phocin herpes virus [PhHV]). Stool
DNA was extracted with miniMAG or easyMAG (bioMe´rieux). Assays
were validated with regard to selectivity (127 strains), analytical
sensitivity (spiked faecal specimens), and clinical performance (851 stool
specimens).
Results: Both assays showed 100% selectivity with the tested panel of
strains. Analytical sensitivity was in the range of 102−4 CFU/g of stool
in both mono- and multiplex approaches. In 281 of the 851 clinical
stools, a pathogen targeted by 1 of the multiplex assays was detected
by conventional methods (culture or microscopy). Overall, the multiplex
assays showed 98.2% concordance in these 281 specimens. In the 570
stools negative for the targeted pathogens by conventional methods, an
additional 83 positive results were detected. Furthermore, 13 double
infections were detected by the multiplex assays, compared to only 3 by
conventional methods. Inhibition of the multiplex PCRs was observed
in only 4.85% and 5.43% for the SE/CJ/GL and STEC/SH/EIEC assays,
respectively.
Conclusion: Multiplex real-time PCR offers a rapid and sensitive
method for the detection of gastro-intestinal pathogens. Multiplexing
does not harm the analytical sensitivity if the assay is set-up properly.
These multiplex assays will introduce a whole new strategy in screening
stool specimens for gastro-intestinal pathogens.
P584 Molecular characterisation of Salmonella typhimurium and
Salmonella enteritidis by plasmid analysis and pulsed-ﬁeld
gel electrophoresis
Z. Aktas, M. Day, C. Bal, S. Diren, E. Threlfall (Istanbul, TR; London,
UK)
Aims: The aim of this study was to investigate clonal diversity of
S. enteritidis and S. typhimurium isolates from various clinical samples
in Turkey.
Materials and Methods: Forty-one strains of Salmonella spp. isolates
from paediatric patients in Cerrahpasa Faculty of Medicine, Istanbul,
Turkey, from 2001 to 2004 were examined for their susceptibility
to various antibiotics and the presence of antibiotic resistance genes.
Pulsed-ﬁeld gel electrophoresis and plasmid proﬁling were used to
characterise and determine possible genetic relationships between
Salmonella enterica ssp. enterica isolates of clinical isolates.
Results: All the S. enteritidis strains (n = 26) were susceptible to
antimicrobial agents tested, whereas one S. typhimurium (n = 15) was
resistant to ampicilline, four strains were resistant to ampicilline,
chloramphenicol, streptomycin, spectinomycin, sulphonamides and
tetracyclines (R-type ACSSpSuT) and the remaining other isolates were
susceptible to antimicrobial agents tested. R-type strains were positive
for the intI gene and had only one plasmid of 60Mda. Plasmid pattern
analysis permitted further differentiation of the S. enteritidis strains
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into six groups. A serovar-speciﬁc virulence plasmid of 38MDa was
detected in all of S. enteritidis strains (except one strain). Plasmids, with
molecular masses varying between 2.5 and 89MDa, were found in 12 of
the 15 of the S. typhimurium strains and ﬁve different plasmid patterns
were determined. After the XbaI macrorestriction proﬁles, we observed
23 subtypes which were grouped into ﬁve main patterns for S. enteritidis
and 15 PFGE proﬁles were observed among the S. typhimurium strains
and four patterns (I, II, III, IV) were found. Plasmids from resistant
strains were not transferred by conjugation recipient Escherichia coli
cells. Pulsed-ﬁeld gel electrophoresis and restriction enzyme digestion
analysis of DNA revealed different restriction proﬁles and sizes,
indicating these strains usually were not clonaly related whereas MDR-
S. typhimurium isolates were clonaly related.
Conclusion: Our study demonstrated the emergence of multiresistant
S. typhimurium DT104 infections in our hospital. Therefore, investigation
of the antimicrobial susceptibilities, the characteristics of resistant strains
and the molecular epidemiology of the strains is more signiﬁcant. PFGE
is more discriminatory and can be used as a conﬁrmatory method.
P585 Comparative study for conjugative plasmids carrying
CTX-M genes in Escherichia coli nosocomial isolates
N. Fursova, I. Abaev, O. Korobova, E. Pecherskikh, N. Shishkova,
S. Pryamchuk, A. Kruglov, D. Ivanov, L. Weigel, J. Rasheed (Obolensk,
Moscow, RU; Atlanta, US)
Objectives: In previous studies we have shown that CTX-M is the
most prevalent type of extended-spectrum b-lactamase (ESBL) among
recent clinical isolates of Enterobacteriaceae (2003 to 2005 isolates, 14
hospitals across Russian Federation). The blaCTX-M enzymes accounted
for 75% of ESBLs. Major groups included CTX-M-1-related enzymes
(91%) (in most cases CTX-M-15), CTX-M-9-like (7%), CTX-M-2-like
(1%), and a combination of CTX-M-1 and -9-related genes (1%). To
determine the potential for spread of CTX-M genes from isolates of
Escherichia coli, CTX-M-positive strains were analysed for plasmids,
location of CTX-M genes, and the ability to transfer plasmids with
CTX-M by conjugation.
Methods: The presence of blaCTX-M-1, blaCTX-M-2, and blaCTX-M-9
genes, as well as blaTEM and blaSHV genes, in ESBL-producing E. coli
(n = 161) isolates was analysed by PCR. Conjugations were performed
in broth using E. coli C600 (RifRAzR) recipient strain. Antimicrobial
resistance phenotypes of donors and transconjugants were determined by
disc diffusion and broth microdilution methods. Plasmids were extracted
by the alkaline hydrolysis method. blaCTX-M genes were localised to
plasmids by DNA-DNA hybridisation using high-sensitive kit Alk-Phos
(Amersham). Probes have been generated by ampliﬁcation of CTX-M
genes using universal primers.
Results: Transconjugants were identiﬁed for 35 (approx. 22%) of the
E. coli isolates including: blaCTX-M-1 gene (27), blaCTX-M-9 gene
(7), and blaCTX-M-2 gene (1). Transfer of blaCTX-M-1 was usually
observed on the same plasmid with blaTEM. In contrast, the blaCTX-
M-9 gene was frequently on a separate replicon from blaTEM (Table 1).
In addition to the ESBL genes, transconjugants acquired resistance to
doxycycline, gentamicin, amikacin, ciproﬂoxacin, and sulfonamides (in
different combinations). Clinical isolates had 1−12 plasmids of different
molecular weights. blaCTX-M genes were consistently transferred on
large plasmids (more than 100 Kb).
Donor and transconjugant strains
Total strains Successful donors Transconjugants
CTX-M1 (n = 128) CTX-M1 (n = 3) CTX-M1 (n = 3)
CTX-M1+TEM (n = 23) CTX-M1+TEM (n = 19);
CTX-M1 (n = 4)
CTX-M1+TEM+SHV (n = 1) TEM+SHV (n = 1)
CTX-M9 (n = 29) CTX-M9 (n = 1) CTX-M9 (n = 1)
CTX-M9+TEM (n = 6) CTX-M9+TEM (n = 2);
CTX-M9 (n = 4)
CTX-M2 (n = 4) CTX-M2 (n = 1) CTX-M2 (n = 1)
Conclusion: Clinical isolates of E. coli isolated in the Russian Federation
harbour CTX-M-type ESBLs that are located on high molecular
weight conjugative plasmids. In many cases genes encoding resistance
mechanisms to several groups of antimicrobial agents were located on
the same plasmid capable of horizontal transfer between bacterial strains.
These data suggest that the CTX-M-type enzymes, along with multidrug
resistance, have the potential to become a widespread problem in this
region.
P586 Phylogenetic groups, antibiotic susceptibility, bioﬁlm
formation and PFGE in Escherichia coli from
community-acquired cystitis
K. Ejrnaes, A. Reisner, B. Lundgren, S. Ferry, S. Holm, T. Monsen,
R. Lundholm, N. Frimodt-Moller (Copenhagen, Lyngby, Hvidovre,
DK; Umea˚, SE)
Objectives: To study Escherichia coli (EC) isolates from community-
acquired cystitis with respect to phylogenetic groups, antibiotic
susceptibility, bioﬁlm formation and PFGE.
Methods: A subgroup of 243 out of 1162 women with community-
acquired cystitis from a placebo-controlled comparative study of three
different dosing regimes of mecillinam was studied. We stratiﬁed patients
into two groups: 1) The mecillinam group (MG), all treated with
mecillinam and all with EC at inclusion: a group of all those having
EC at follow-up, plus a randomly selected group having negative
culture at follow-up (N= 160); and 2) the placebo group (PG), all
treated with placebo and all with EC at inclusion: a randomly selected
group having EC at follow-up and a randomly selected group having
negative culture at follow-up (N= 83). The primary infecting ECs were
studied. Susceptibility to mecillinam was tested by agar dilution; MICs
of ampicillin, cefpodoxime, chloramphenicol, ciproﬂoxacin, gentamicin,
streptomycin, sulfamethoxazole, trimethoprim and tetracycline were
tested with Sensititre. Phylogenetic grouping was determined by a triplex
PCR assay. Bioﬁlm formation was measured in 3 media (static growth,
48 hours, crystal violet staining). PFGE was done with XbaI to the
primary infecting EC and EC from follow-up.
Results: Only 20% of the strains were resistant to one or more antimi-
crobials. Susceptibility was signiﬁcantly associated with phylogenetic
group B2 for ampicillin (P = 0.048), chloramphenicol (P = 0.002), strep-
tomycin (P = 0.001), sulfamethizole (P = 0.006), trimethoprim (P = 0.013)
and tetracycline (P = 0.003). Resistance to 3 or more antimicrobials was
signiﬁcantly associated with phylogenetic group A (P = 0.033) and D
(P = 0.014). Resistance to less than 3 antimicrobials was signiﬁcantly
associated with B2 (P< 0.0001). EC causing relapse/persistence had a
higher bioﬁlm formation than those causing reinfection/cure in 2 of 3
media (P = 0.002 and P = 0.011) in the PG, but there was no signiﬁcant
difference in the MG.
Conclusion: Although representing a low-antibiotic-consumption area
(Sweden) with low resistance rates, still, antimicrobial susceptibility was
signiﬁcantly associated with phylogenetic group B2 and resistance to 3
or more antimicrobials with A and D. EC causing relapse/persistence
had a higher bioﬁlm formation capacity than those causing reinfection/
cure in the PG.
P587 Thermophilic helicase-dependent isothermal DNA
ampliﬁcation for molecular detection of Helicobacter pylori
P. Gill, H. Abdul-Tehrani, A. Ghaemi, T. Hashempour, A. Alvandi,
M. Noori-Daloii (Tehran, IR)
Objectives: Helicobacter pylori is a Gram-negative, pathogenic bac-
terium, which speciﬁcally colonises in the human gastric mucosa.
The infection with this microorganism is one of the most prevalent
infections in humans and about 50% of the adults in the industry
and more than 90% of the population in developing countries are
infected. Several PCR-based methods have been described for molecular
diagnosis of this bacterium in biological specimens. However, in this
study, we designed and developed a novel procedure for detection of ureC
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gene of Helicobacter pylori, so called thermophilic helicase-dependent
isothermal DNA ampliﬁcation, (tHDA).
Methods: Like PCR, the tHDA reaction selectively ampliﬁes a target
sequence deﬁned by two primers. However, unlike PCR, tHDA uses an
additional enzyme called thermophilic helicase to separate DNA rather
than heat. Since, this DNA ampliﬁcation is an isothermal technique,
as an advantage it does not need any thermocycler. The accuracy of
the technique was checked on DNA extracted from pure culture of
Helicobacter pylori.
Results: We obtained same results when several experiments were
performed on specimens prepared from infected gastric biopsies. All the
results were shown the equal speciﬁcity and sensitivity for this technique
in comparison to PCR.
Conclusion: THDA can be used for molecular detection of Helicobacter
pylori more cost-effectively than PCR in developing countries. Further
studies are under taken to develop this technique using ELISA and real-
time formats.
P588 Phenotypic versus genotypic identiﬁcation of bacteria in
the clinical microbiology laboratory: the possible impact on
patient care
A. Adler, V. Temper, A.E. Moses, O. Nahor, O. Zimchoni, C. Block
(Jerusalem, Rehovot, IL)
Objective: Phenotypic bacterial identiﬁcation methods have numerous
strengths but often fail because the phenotype may be variable and
subject to biases of interpretation. Sequencing of 16S rRNA and other
genes is a more accurate and objective method of identiﬁcation of
microorganisms. We report the study of the causes for phenotypic
misidentiﬁcation in four cases of severe bacterial infections and the
possible impact of these errors on patients’ care in these cases.
Methods: Phenotypic identiﬁcation was performed using conventional
manual methods and commercial identiﬁcation kits. Genotypic identi-
ﬁcation was performed by comparing an 800 bp amplicon of the 16S
rRNA gene to the GeneBank database. The impact of the phenotypic
misidentiﬁcation was assessed by reviewing the patients’ ﬁles and
questioning the Infectious Diseases specialists that were involved in these
cases.
Results: The cases summaries, the phenotypic methods and results,
the genotypic results and the possible causes for the phenotypic
misidentiﬁcation are presented in the table. The initial misidentiﬁcation
had no apparent effect on the patients’ management and outcome in the
ﬁrst two cases. In the third case, it might have led to missed diagnosis of
infectious endocarditis, to inappropriate duration of antibacterial therapy
and eventually to valvular replacement surgery. In the forth case, the
misidentiﬁcation of Brucella melitensis led to a suboptimal choice of
antibacterial therapy that might have led to persistent infection. Also,
it led to inadequate safety measures in the laboratory that resulted in
laboratory-associated brucellosis in a technician.
Case summary and
Source of isolates
Phenotypic
identiﬁcation
Phenotypic
Methods
Genotypic
identiﬁcation
Possible causes
for phenotypic
misidentiﬁcation
Pus from a brain abscess
in a two-year old girl
with congenital cyanotic
heart defect
Gemella species Manual methods Streptococcus
intermedius
Human error
Blood culture (2 sets)
from a 68-year old
female patient with
metastatic cancer
Listeria grayii Manual methods
and API
CORYNE
(bioMe´rieux)
Lactobacillus
plantarum
Pseudocatalase activity
resembling catalase led
to misidentiﬁcation by
commercial kit.
Blood and valvular tissue
from a 59-year old male
patient with infective
endocarditis
Pasteurella
haemolytica
(isolated from
blood culture;
valvular tissue
culture – no
growth)
Manual methods,
API 20E
(bioMe´rieux) and
RapID NF plus
(Remel)
Agregatibacter
(Haemophilus)
aphrophilus
(blood culture
isolate and
valvular tissue)
Erroneous
characterisation of the
isolate as “glucose
non-fermenters”
that led to selection
of inappropiate
identiﬁcation systems.
Blood culture from a
24-year old female
patient with fever and
persistent bacteraemia
Actinobacillus
ureae
VITEK1 (the
isolate was
transferred from
another hospital)
Brucella
melitensis
Inappropriate reliance
on automated
indentiﬁcation system.
Conclusion: Phenotypic misidentiﬁcation is multifactorial. It may
be caused by an unusual phenotype or by erroneous selection
or interpretation of commercial identiﬁcation systems. Since the
consequence of misidentiﬁcation might be crucial, we believe that
genotypic identiﬁcation of microorganisms should be considered in any
case of signiﬁcant infection, when the results obtained by phenotypic
methods are ambiguous or a rare organism is identiﬁed.
P589 Occurrence of AmpC chromosomally b-lactamase ACT-1
and extended spectrum b-lactamases type TEM, SHV and
CTX-M in clinical isolates of Enterobacter cloacae
M. Biendo, C. Manoliu, B. Canarelli, D. Thomas, F. Hamdad-Daoudi,
F. Rousseau, G. Laurans, F. Eb (Amiens, FR)
Objectives: The primary purpose of this investigation was, (i) to
study the main drug-resistant mechanism, (ii) to determine the genetic
relatedness of strains recovered from different separated sites using
pulsed-ﬁeld gel electrophoresis (PFGE) and, (iii) to describe the
molecular epidemiology of the outbreaks.
Methods and Results: We tested 70 consecutive nosocomial E. cloacae
isolates recovered from patients admitted in Amiens University Hospital
(61 patients), Abbeville General Hospital Center (7 patients), and
Iasi Pediatric University Hospital [(Romania) (2 patients)]. Based on
phenotypic methods, 100% of isolates produced AmpC b-lactamases,
90% produced ESBLs and 10% were ESBL-nonproducers. 100% of
AmpC producers carried AmpD enzyme and blaACT-1 while 7.2%
harboured blaFOX-5. PCR ampliﬁed, 395 pb and 1,1184 pb segments
respectively corresponding to b-lactamases with a pI of 9.0 (ACT-1),
and 7.5 (FOX-5) respectively according to IEF and sequencing results.
90% of ESBL-producers carried bla TEM-24, bla SHV-4, blaCTX-
M-1 and bla CTX-M-9. PCR ampliﬁed 972 pb, 785 pb, and 900 pb
segments respectively corresponding to b-lactamases with a pI of 6.5
(TEM-24), 7.8 (SHV-4), 8.4 (CTX-M-1) and 8.0 (CTX-M-9). The
7 ESBL-nonproducers harboured blaTEM-1 and blaSHV-1 encoding
b-lactamases with a pI of 5.4 (TEM-1) and 7.6 (SHV-1). Four isolates
for which the minimum inhibitory concentrations (MICs) of cefoxitin
(FOX), cefotaxime (CTX), ceftazidime (CAZ) and aztreonam (ATM)
were of >256 ug/mL and those of imipenem (IPM) were between
12−48 ug/mL showed a diminished level or no expression of a 37- and
38 kDa outer membrane proteins.
Conclusion: It is concluded that the high level of resistance to FOX,
CTX, CAZ and ATM and the increase of the MICs of IPM for AmpC
b-lactamase- and the ESBL-producing E. cloacae isolates studied are
associated with porin deﬁciency. PFGE analysis showed that these
isolates exhibited high genetic diversity (39 different pulsotypes). There
was great phenotypic heterogeneity (5 different biotypes), 6 b-lactam
R-patterns, and 3 aminoglycosides R-patterns.
P590 Internalin gene in natural atypically haemolytic Listeria
innocua strains suggests descent from L. monocytogenes
D. Volokhov, S. Duperrier, A. Neverov, J. George, C. Buchrieser,
A. Hitchins (Rockville, College Park US; Paris, FR)
The atypical haemolytic Listeria innocua strain, PRL/NW 15B95, was
previously shown to contain a gene cluster analogous to the pathogenicity
island 1 (LIPI 1) present in the related food-borne Gram-positive
facultative intracellular pathogen Listeria monocytogenes, which causes
human and animal listeriosis. LIPI 1 includes the hemolysin gene thus
explaining the haemolytic activity of PRL/NW 15B95. However, no other
L. monocytogenes speciﬁc virulence genes were found to be present. In
order to investigate whether any other speciﬁc L. monocytogenes genes
could be identiﬁed, a global approach using a Listeria biodiversity DNA
array was applied. According to the hybridisation results the isolate
was deﬁned as L. innocua strain of serotype 6a containing LIPI 1.
Surprisingly, evidence for the presence of the L. monocytogenes speciﬁc
inlA gene, previously thought absent, was obtained. The inlA gene
codes for the InlA protein, which enables bacterial entry into some non-
professional phagocytic cells. In depth PCR and sequence analysis of
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this region revealed that the ﬂanking background of the inlA gene was
identical to that of L. monocytogenes serotype 4b isolates. Sequence
analysis of the inlA region identiﬁed a small stretch reminiscent of the
inlB gene of L. monocytogenes. The presence of more than one cluster
of L. monocytogenes speciﬁc genes makes it less likely that PRL/NW
15B95 is simply a L. innocua strain altered by horizontal gene transfer.
More likely the atypical isolate is a relic of the evolution of L. innocua
from an ancestral L. monocytogenes, a process already postulated by
others.
P591 Denaturing high pressure liquid chromatography to detect
changes in faecal ﬂora of chickens
L.P. Randall, N.G. Coldham, M.J. Woodward (New Haw, UK)
Objectives: Recent studies have shown that it is possible to use
Denaturing High Pressure Liquid Chromatography (D-HPLC) to monitor
population dynamics of bacteria in environments such as seawater and
human faeces. Identiﬁcation of bacteria relies on separation of ampliﬁed
16S rDNA fragments by D-HPLC. The aim of this study therefore
was to determine if standard HPLC equipment (Agilent A1100 HPLC
system) ﬁtted with a Varian Helix DNA column could be used to perform
D-HPLC to monitor changes in the population dynamics of bacteria in
chicken faeces.
Methods: Methods were based on those of two previously published
papers in which D-HPLC was used to analyse communities of bacteria
in human faeces or seawater. Each method utilised different primers for
ampliﬁcation of 16S rRNA, but both previous methods used a dedicated
D-HPLC machine. In the present study, fragments of 16S rDNA were
ampliﬁed by PCR from bacterial strains (n = 16) representative of some
that would be found in faeces, to determine if the D-HPLC methods
were capable of differentiating between strains. This was coupled with
construction of distance maps for sequences of the PCR products.
Samples of healthy chicken faeces were then spiked with 0, 104 to 109
Salmonella enterica serovar Typhimurium. Bacterial DNA from faeces
was extracted using a QIAamp DNA mini stool kit and this DNA was
then used as template for ampliﬁcation of 16S rDNA prior to D-HPLC.
Figure 1. D-HPLC proﬁles of 16S products from chicken faeces.
Results: Phylogenetic trees showed that even for the smaller of the two
PCR products (194 bp), there were changes in the 16S rDNA sequences
between genera, and in most cases, between different species of the
same genera for the strains examined. Fragments from most individual
bacterial species gave rise to D-HPLC peaks with different retention
times, but when amplicons from different bacterial species were mixed,
insufﬁcient resolution was obatined. Faecal samples from chicken gave
rise to only two or three D-HPLC peaks. However, when these samples
were spiked with Salmonella Typhimurium, a new peak was detected
with a detection limit of c. 106 cfu per gram of faeces (Figure 1).
Conclusion: Standard HPLC equipment and a readily available column
can be used to perform D-HPLC to detect changes in bacterial
communities in faeces and it was possible to detect the presence of
Salmonella in the chicken faecal samples examined. Further work is
needed to determine if it is possible to optimise current methods to
improve D-HPLC resolution.
P592 Nosocomial outbreak of Sphingomonas paucimobilis
bacteraemia in an oncology and haematology unit
A. Kilic, Z. Senses, A. Kurekci, H. Aydogan, A.C. Basustaoglu (Ankara,
TR)
Objectives: The genus Sphingomonas is strictly aerobic, Gram-negative,
rod-shaped, usually yellow-pigmented, and motile bacterium with polar
ﬂagellum. Sphingomonas paucimobilis strains have been isolated from
hospital water systems, respiratory therapy equipment, and miscellaneous
clinical specimens. Within a period of one month, we isolated six
S. paucimobilis strains, including four from blood cultures of four
patients’ and two from hospital environment specimens from tap water
and bathtub in an oncology and haematology unit.
Methods: All strains were identiﬁed by conventional methods and
further by the API ID32GN system (bioMe´rieux, Marcy L’Etoile,
France) as S. paucimobilis. We described here these strains’ molecular
epidemiological analyses by pulsed ﬁeld gel electrophoresis and
antibiotic susceptibilities by E-test.
Results: Despite clinical and environmental isolates yielded three
different antibiotic resistances and pulsed ﬁeld gel electrophoresis
patterns, all clinical strains had identical by the both methods. We did
not isolate clinical strain clone in healthcare workers and environmental
samples as a source of infection.
Conclusion: It was concluded that S. paucimobilis strains could cause
a potential outbreak in oncology and haematology units. Genotyping
by PFGE is a useful identiﬁcation technique for epidemiological
investigation of outbreak caused by S. paucimobilis in oncology and
haematology units.
P593 Diversity in the content and arrangement of CTX genetic
element among toxigenic Vibrio cholerae strains isolated
during 2004–2006 in Iran
B. Bakhshi, M.R. Pourshaﬁe, F. Navabakbar, A. Tavakoli (Tehran,
Isfahan, IR)
Objectives: CTXphi is a ﬁlamentous, lysogenic bacteriophage whose
genome encodes cholera toxin, the primary virulence factor produced by
Vibrio cholerae. In regard to the diversity of the organisation of CTXphi,
two different organisational patterns have been reported. However, the
distribution and temporal changes in the content of CTX genome of
the epidemic strains are still under investigation. In this study, we
performed a molecular analysis of the CTX prophages in different
toxigenic V. cholerae O1 strains of clinical origin which were isolated
during 2004–2006 in Iran.
Methods: To assess the diversity of CTXphi, Long-PCR assay was
performed for ampliﬁcation of an approximately 6.8 kb region using
primers speciﬁc for conserved region of ig-1 which ﬂanks 3′ end of the
rstR, and the intergenic region between CTX and RTX (attB2). Ampliﬁed
fragments were subjected to RFLP analysis.
Results: The organisation of the CTXphi in the 59 V. cholerae O1 strains
revealed 3 patterns, with 6.8, 5.5, 2.7 kb in 72.9%, 27.1%, and 10.2%
of isolates, respectively. RFLP analysis of the 5.5 kb PCR products
with EcoRV, ClaI, DraI, XbaI, and BglI revealed that the diversity was
in a region between zot and attB2. PCR assays were also performed
with the primers speciﬁc for ace/attB2, zot/attB2, and ctx/attB2. In all
of the samples an approximately 1.3 kb deletion was detected in this
region. Diversity in 2.7 kb PCR products was due to different RS1-CTX
arrangement which was conﬁrmed by PCR assays using primers speciﬁc
for rstR/attB2 and ctxA/attB2. Despite of a defect in organisation of
CTXphi in 27.1% of isolates, the PCR assays revealed that these isolates
also carried intact copies of the CTXphi.
Conclusion: The results obtained by this study may suggest that the
acquisition of CTXphi by V. cholerae may have occurred multiple times
and have involved several CTXphi genotypes.
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P594 Comparison of real-time PCR and direct culture for the
detection of Campylobacter spp. from human faecal samples
K. Eastwood, H. Schuster, D. Gascoyne-Binzi (Leeds, UK)
Objectives: Campylobacter spp. are one of the major causes of food-
borne illness worldwide. Current culture techniques are slow and
labour intensive and the selective nature of media commonly used for
isolation in routine diagnostic laboratories, means that several species of
Campylobacter could be overlooked. Real-time PCR offers a speciﬁc and
rapid method for detection of Campylobacter spp. Newer, commercially
available extraction kits, can remove inhibition caused by constituents of
faecal samples effectively, but inclusion of an internal control removes
the risk of false negative results. A real-time PCR method, with an
internal control has been developed for use on chicken faecal samples.
This study was designed to evaluate the PCR assay on human faecal
samples, for use in the routine diagnostic laboratory.
Method: Human faecal samples were selected for testing using the new
real-time PCR method, following routine culture in the Leeds Teaching
Hospitals diagnostic laboratory. Brieﬂy, this involved extracting DNA
from the samples using the QIAamp DNA stool mini kit (QIAgen,
UK) before performing the PCR assay on the Mx3000p QPCR system
(Stratagene, Europe) using Brilliant R QPCR mastermix (Stratagene,
Europe). Taqman probes for Campylobacter spp. and the internal control
organism, Yersinia ruckeri, were used for detection.
Results: One hundred eighty seven faecal samples were collected
following routine culture. There were 42 Campylobacter culture positive
samples and 145 samples negative for Campylobacter on culture. Fifty
eight samples were positive for Campylobacter on PCR, and 129 were
negative. All of the culture positive samples were also PCR positive. The
sensitivity and speciﬁcity of the PCR assay in comparison to culture is
100% and 89% respectively, with a negative predictive value of 100%.
Conclusion: The real-time PCR assay is comparable with routine
culture methods for detecting Campylobacter spp. from human faecal
specimens. The assay may be more sensitive than culture, and would
make a useful screening tool.
P595 Evaluation of a new LightCycler approach for detection of
diarrhoeagenic Escherichia coli
R. Ljung, J. Eysturskard, B. Olesen, B. Bruun, D.S. Hansen (Hillerød,
DK)
Objectives: Modern laboratory diagnosis of infectious gastroenteritis
comprises the classical diarrhoeagenic E. coli: verotoxin-producing
E. coli (VTEC), enteropathogenic E. coli (EPEC), enterotoxigenic E. coli
(ETEC) and enteroinvasive E. coli (EIEC).
Our objective was to compare a novel LightCycler (LC) real-time
PCR approach to our standard identiﬁcation performed by a reference
laboratory (ref. lab.).
Methods: During 2 two-months periods, October-November 2005 and
May-June 2006, stool samples examined for diarrhoeagenic E. coli were
investigated by two different approaches: 1) the standard procedure
which was sending the sample to a reference laboratory for analysis by
conventional multiplex PCR, and 2) a new LC real-time PCR approach,
detecting the eae, vtx1, vtx2, LTI, STIa, STIb, ipaH, and 16S rDNA
(internal ampliﬁcation control) genes from over night cultures. We used
the 1.5 LC with 4.0 software, Master Mix from Roche Diagnostics, and
primers and hydrolysis probes from TIBMolbiol, Berlin. All protocols
used were previously described in the literature except for the ipaH and
16S rDNA genes which were developed in our laboratory.
Results: A total of 371 stool samples were analysed. The number of
positive samples and patients in our laboratory and at the ref. lab. were
49 and 34, and 35 and 22, respectively. From 9 of the 14 samples initially
not found positive at the ref. lab., 8 E. coli strains were isolated that
consequently conﬁrmed our results when examined by the reference
laboratory. For one patient our results could be veriﬁed, as another
sample from the patient was found positive at the ref. lab. Four samples
could not be veriﬁed as we were unable to isolate the bacteria resulting
in the positive PCR result. The number of diarrhoeagenic E. coli found
in our laboratory and at the ref. lab. (in brackets), respectively, was:
5 (3) VTEC, 6 (5) EPEC, 11 (9) ETEC, 3 (2) EIEC and 24 (16) intimin
producing E. coli (eae positive, but not belonging to the classical EPEC
O-groups).
Conclusions: A positive rate of 7% shows that detection of the classical
diarrhoeagenic E. coli is diagnostically important. Additionally 6% of
samples were positive for intimin producing E. coli, whose clinical
importens is disputed. Our results demonstrate that the new LC real-
time PCR approach is at least as sensitive (and speciﬁc) as standard
identiﬁcation in a reference laboratory, identifying totally 40% more
positive samples and 55% more patients.
P596 Detection of enteroaggregative Escherichia coli in faecal
samples from patients in the community with diarrhoea
C. Jenkins, M. Tembo, H. Chart, T. Cheasty, A.D. Phillips,
D. Tompkins, H. Smith (London, Leeds, UK)
Objectives: A PCR assay targeting the aat, aaiA and astA genes,
was used to detect Enteroaggregative Escherichia coli (EAEC) in
faecal samples from patients with community-acquired diarrhoea. Strains
harbouring one or more of these three genes were assessed for their
ability to adhere to HEp-2 cell adhesion assay to conﬁrm their EAEC
status. The aim of the study was to assess the usefulness of this PCR
for detecting typical and atypical EAEC.
Methods: Five hundred faecal samples were analysed for the presence
of EAEC, in addition to routine enteric pathogens. Nutrient broths were
inoculated with a sweep of mixed colonies from the MacConkey plates
of faecal cultures, and examined for aat, aaiA and astA genes by PCR.
In samples of mixed colonies with positive PCR result, a pure colony
pick containing either the aat, aaiA or astA genes was obtained from the
original MacConkey plate. All single colony isolates were examined by
the HEp-2 cell adherence assay, biochemically conﬁrmed as E. coli and
serotyped.
Results: The aat, aai or astA gene was found in E. coli isolates faecal
from 39 (7.8%) of 500 patients and 20 of these strains adhered to HEp-2
cells in a pattern characteristic of EAEC. Eight isolates carrying the
aai or astA gene but not the aat gene were shown to be HEp-2 cell
test-positive although 12 strains with this genotype were HEp-2 cell
test-negative. Using the HEp-2 adhesion assay as the gold standard, the
addition of primers detecting aaiA and astA to the aat PCR increased
the number of EAEC isolates detected but identiﬁed strains of E. coli
that were not EAEC.
Conclusions: The variety of genotypes exhibiting aggregative adherence
highlights the problems associated with developing a molecular
diagnostic test for EAEC. Our PCR assay detects a variety of strains
exhibiting characteristics of the EAEC group making it a useful tool for
identifying both typical and atypical EAEC.
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P597 Mixed viral infections in hospitalised children with RSV
bronchiolitis
V. Poga, K. Kallergi, A. Kossivakis, A. Pangalis, V. Syriopoulou,
M. Theodoridou, A. Mentis, M. Giannaki (Athens, GR)
Aim: The detection of mixed infections by Human Metapneumovirus
(HMPV), Rhinovirus (RV), Adenovirus (AdV) and Parainﬂuenza Virus
(PIV 1, 2, 3) in children with RSV bronchiolitis.
Material and Methods: The study group included 304 children
(7 days – 2 years old) with RSV bronchiolitis, hospitalised in two Athens
children’s hospitals during the winter period of 2005–2006. RSV antigen
was detected by two commercial kits, an immunochromatographic assay
(BD) and a direct immunoﬂuorescent assay (Meridian), in nasal aspirates
collected in the two ﬁrst days after admission in the hospital. The same
samples were tested for detection of RNA of RSV, HMPV, RV and
PIV and DNA of AdV. QIAmp Viral RNA Mini Kit and QIAmp DNA
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Mini Kit were used for viral RNA and DNA extraction, respectively.
Previously published simple and multiplex-nested RT-PCR protocols
were used for subtyping RSV A and B viruses and for the detection
of HMPV, RV, AdV and PIV 1, 2 and 3 viruses. For the detection of
AdV, a PCR protocol was used. All PCR protocols had been optimised
before their use.
Results: Two hundred eight samples out of 304 RSV-positive samples
were typed as RSVA and 96 as RSVB. Forty nine of the 304 samples,
were also positive for at least one of the other viruses checked. HMPV
was detected in 19 samples (6.3%), RV in 13 (4.3%), AdV in 10 (3.3%),
PIV1 in 5 (1.6%), PIV2 in 1 and PIV3 in 1 (0.3%). Four mixed infections
were observed in December, 8 in January, 17 in February, 13 in March,
5 in April and 5 in May.
Conclusions: Apart from RSV, another virus was also detected in 16.1%
of the children with bronchiolitis. HMPV was present in most cases
of these mixed infections (6.3%). The peak of these mixed infections
occurred in February. The clinical importance of the second virus needs
further evaluation.
P598 H5N1 diagnostics: experiences with the NucliSens EasyQ®
Inﬂuenza H5 and N1 reagents based on a real-time NASBA
assay on non-human derived specimens
G. Camenish, R. Hoop (Zurich, CH)
Objectives: The bioMe´rieux Nuclisens EasyQ® Inﬂuenza H5 and
N1 reagents allow the parallel ampliﬁcation and detection of gene
sequences of haemagglutinin subtype H5 and neuraminidase subtype N1
of Inﬂuenza A viruses from human specimens in a real-time NASBA
assay. This evaluation consists of analysis of serial dilutions of a non-
human clinical sample of H5N1 as well as a H5 transcript, other
Inﬂuenza A subtypes and avian paramyxovirus strains.
Methods: Inﬂuenza A/Duck/Switzerland/2006/V540 strain was used
for serial dilution. RNA was extracted using the RNeasy Mini Kit
(Qiagen). The extracted RNA was then submitted to H5 and N1 real-
time NASBA ampliﬁcation and detection on the bioMe´rieux Nuclisens
EasyQ® instrument using the Nuclisens EasyQ® H5 and N1 reagents
in combination with the Nuclisens EasyQ® Basic Kit v2 following the
manufacturer’s instructions (bioMe´rieux). In every run a negative control
and a H5N1 positive control (provided with the kit) were included.
Obtained data were analysed with the Nuclisens EasyQ® Analysis
software which is part of The Nuclisens EasyQ® instrument.
Results: The H5N1 strain was detected down to dilution 10−4 for H5
or 10−6 for N1 genes, respectively. HA and NA subtypes other than
H5N1 (H6, H7, H9, N2, N6, N7, N9) were not ampliﬁed. However, two
H5N9 strains could not be detected. Finally, two avian paramyxovirus-
1 strains did not show ampliﬁcation.
Conclusion: This study reveals a high sensitivity of the Nuclisens
EasyQ® Inﬂuenza H5 and N1 reagents on avian derived specimens. The
assay proves to be highly speciﬁc for the actually circulating asian clade
of H5N1. The NASBA EasyQ® H5N1 assay provides to be a suitable
platform for diagnosis of H5N1 not only for human derived probes.
P599 Use of avian inﬂuenza genodiagnostics in the Republic of
Kazakhstan
S.U. Mizanbayeva, K.S. Ospanov, S.L. Yingst, A. Garcı´a-Sastre,
M.O. Favorov, S.V. Kazakov, V.V. Zeman (Almaty, KZ; Cairo, EG;
New York, US)
A case of mass wild bird die-off was recorded in March 2006 at
the Caspian seacoast close to Aktau, the Mangustau Oblast seat, West
Kazakhstan. As a disease control measure, a number of samples were
collected to investigate the presence of inﬂuenza A virus H5 subtype.
Objectives: Determine the possible presence of inﬂuenza A virus H5
subtype in:
1. Samples obtained from patients who could have had physical contact
with wild birds and were hospitalised at the Aktau infectious disease
hospital with the ﬂu, pneumonia or acute respiratory viral infection
symptoms; and
2. Samples obtained from dead wild birds found in the vicinity of Aktau.
Methods: An RT-PCR method was used for the detection of the
inﬂuenza A virus H5 subtype RNA. The reaction protocol and Flu H5+
1456 and Flu H5–1685 primers used in the study were provided by
NAMRU-3 laboratory, Egypt, Cairo. For veriﬁcation and detection of the
inﬂuenza A virus RNA, and concurrent identiﬁcation of the H5 subtype,
we used the AmpliSens Inﬂuenza Virus A-H5/H7 test system provided
by the Epidemiological Research Institute, Moscow.
Samples Studied:
– 12 samples obtained from the tracheas, lungs, intestines, and brains
of 3 dead swans;
– 1 blood sample obtained from a live swan;
– 4 nasopharyngeal swabs obtained from patients presenting symptoms
of acute respiratory viral infection or ﬂu;
– 16 blood serum samples obtained from patients hospitalised in the
pulmıˆnology unit of the Aktau infectious-disease hospital.
Results: The RT-PCR method (based on the use of the NAMRU-3 lab,
Cairo, Egypt primers) was negative for inﬂuenza A virus H5 subtype in
the 16 blood serum samples and 4 nasopharyngeal swabs obtained from
patients. RNA from inﬂuenza A virus H5 subtype was found in the
samples obtained from tracheas, lungs, and intestines of all three birds
(swans). Identical results were obtained using the NAMRU-3 lab, Cairo,
Egypt primers and the test system provided by the Epidemiological
Research Institute, Moscow.
Conclusion: Owing to the RT-PCR method we were able to detect the
presence of the inﬂuenza A virus H5 subtype among the wild birds in
the Mangustau Oblast, the Republic of Kazakhstan.
The results obtained using the NAMRU-3 lab, Cairo, Egypt primers and
the AmpliSens Inﬂuenza Virus A-H5/H7 test system provided by the
Epidemiological Research Institute, Moscow were 100% identical. (This
project was supported by the US Department of Defense, Biological
Threat Reduction Program, Project #KZ-27.)
P600 Typing and distribution of HCV strains in South Italy
(Apulia region) by a cost-effective direct sequencing test
L. Tagliaferro, P. Menegazzi, E. Reho, O. Varnier (Lecce, IT)
Objectives: Standardisation of a rapid, direct and cost-effective test for
typing of HCV strains, by sequencing from real time PCR amplicons.
Evaluation of epidemiological distribution of HCV isolates in the
population of a southern region of Italy (Apulia).
Methods: HCV strains typing is performed by direct sequencing of
puriﬁed amplicons, using the OpenGene System (Visible Genetics, Bayer
diagn.) after removal of FRET probes.
We ampliﬁed the HCV 5′ UTR region by an “in house” rapid, single
tube LightCycler Real Time PCR with FRET technology. The accuracy
and the reproducibility of this test have been conﬁrmed by the very
low crossing point coefﬁcient of variation and standard deviation values
(3.55 and 1.03, respectively) of the used international WHO HCV human
reference standard plasma (HCV Accurun series, BBI Inc.), calculated
on more than 4,500 samples tested in 359 runs.
Results: A total of 490 HCV LightCycler amplicons were sequenced
using OpenGene System from October 2002 to November 2006. We
observed 5 of the 6 wide-world known principal HCV genotypes,
identifying 16 types and subtypes, with a homology average of 99.9%.
Along with genotypes 1−4, HCV 5 has been found in Italy as well. The
sequencer has been able to distinguish 60 different HCV isolates; 186
of 490 samples (38%) have been typed but not subtyped, because of
the presence of some undistinguishable sequences, common to several
strains.
Conclusions: This HCV sequencing test revealed an interesting cost
effectiveness, saving a lot of time and money, and was able to subtype
the 62% of observed HCV genotype, with a very high percentage of
sequence homology (99.9%). In Apulia region (southern Italy) the most
frequently observed genotypes have been 1b (35%) and 2 (28%), with a
prevalence of the K0014, HCJ5 and S83 isolates. A different subtypable
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region and an External Quality Assessment (EQA) programme for HCV
typing would be a needed addition.
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P601 Ethanol lock therapy: preliminary trial results and future
research agenda
J. Broom (Brisbane, AU)
Objectives: Pilot study: Primary aim: To evaluate the safety and efﬁcacy
of ethanol lock therapy (in conjunction with intravenous antibiotic
therapy) in the treatment of infected tunneled central venous catheters.
Prophylaxis study: Develop a clinical trial protocol to assess the efﬁcacy
of 70% ethanol lock therapy in prevention of tunneled central venous
catheter-associated blood stream infections.
Methods: Pilot study: A prospective non-randomised trial of 70%
ethanol locks to treat tunneled central venous catheter-associated blood
stream infections was performed in nineteen patients.
Proposed prophylaxis study: We have designed a prospective, ran-
domised, controlled trial of the weekly instillation of a 70% ethanol
lock vs sterile heparin saline lock in patients requiring long-term
haemodialysis via a tunneled central venous catheterm, to assess the
efﬁcacy of ethanol in preventing development of catheter-associted blood
stream infections. 56 patients will be recruited to each arm.
Pilot study: These patients had a broad range of pathogens isolated.
12/17 patients completing ethanol lock therapy retained their catheter
for greater than 14 days after the initiation of ethanol lock therapy (70%
cure rate). 5/17 patients did not retain their catheter for 14 days, but 3
of these patients had their central venous catheter removed for reasons
not attributable to recurrence of infection.
Proposed prophylaxis study: Results from the prophylactic study
outlined above will demonstrate whether ethanol lock therapy is a safe
and effective prophylactic intervention in patients requiring long-term
haemodialysis.
Conclusions: Ethanol lock therapy seems effective in treatment of
infected central venous catheters but it remains to be demonstrated to
be effective in prophylaxis. Patients requiring long-term central venous
catheterisation are a diverse group with a broad range of medical
conditions. Further larger studies need to be designed to tease out the
beneﬁts of ethanol lock therapy these diverse specialty areas.
Results from this proposed prophylaxis trial will determine whether
larger studies in more diverse patient groups are warranted to assess
ethanol lock therapy.
P602 Analysis of the effect of selected antiseptics and antibiotics
on the survival of planktonic celles and bioﬁlm cells
M. Bartoszewicz, A. Rygiel, A. Przondo-Mordarska (Wroclaw, PL)
Objectives: In the clinical practice, infections of biomaterials are still
a growing medical and economic problem. The infections are caused
both by endogenous bacterial ﬂora and by nosocomial bacteria. The
planktonic cells initiate contact with the surface of a catheter or implant.
After adhering to the surface, the bacteria start the production of
an extracellular slime forming the bioﬁlm. The bioﬁlm structure is
not homogenous and the phenotypic and biochemical properties of
the organisms forming it are different than those of their planktonic
counterparts. The above is the reason why bioﬁlm is very resistant to
antibacterial agents. The objective of the paper was to analyse the effect
of selected antibiotics and antiseptics on the degree of formation and
reduction of bioﬁlm on polystyrene plates.
Methods: A collection of strains from the Department and Institute
of Microbiology at the Wrocław Medical University was used isolated
from hospitalised patients suffering from generalised catheter-related
infections and orthopaedic implant infections as well as a model
Staphylococcus epidermidis ATCC 35984 strain. Bacterial survival
in the bioﬁlm following the application of an antiseptic or an
antibiotic was tested using the microdilution method in microtiter plates
(CLSI) and was read as MIC (Minimal Inhibitory Concentration). The
following solutions were used for antiseptics testing: 0.1% octenidine
dihydrochloride, 7.5% iodine complexed with polyvinylpyrrolidone.
Antibiotics were tested using vancomycin, clindamycin, ampicyline,
gentamicin and erytromicin in substantia
Results: In the case of antibiotics, despite the strains’ sensitivity in
planktonic cultures, after transformation into a bioﬁlm structure, the
bacteria demonstrated resistance to the tested antibiotics and the minimal
inhibitory concentrations were as much as 100 times higher than the
therapeutic dose possible to be given to the patient.
As for antiseptics, the lowest minimal inhibitory concentrations in the
bioﬁlm, in comparison with the planktonic culture, were observed with
respect to the tested strains for octenidine dihydrochloride, while the
highest ones for the analysed complexed iodine.
Conclusion: in the tested scope, octenidine dihydrochloride proved to be
the most effective agent with respect to bioﬁlm-forming bacteria, while
the tested antibiotics were not able to penetrate the bioﬁlm structure to
the extent comparable with any of the antiseptics.
P603 Detection, quantiﬁation and investigation of virulence
potential of dental-plaque formers by optic and scanning
electron microscopy and microbiological assessment tools
V. Lazar, C. Balotescu, M. Bucur, C. Dragomir, M. Burlibasa, B. Savu,
T. Traistaru (Bucharest, RO)
The aim of the present study was to investigate the dental plaque formed
on natural teeth surfaces by optic and scanning electron microscopy
(SEM), to quantify the microbial density by viable cell counts, to identify
the microbial strains recovered after culture and their pathogenicity
features.
Material and Methods: Dental plaque specimens were collected from
40 patients in duplicates. One set was ﬁxed on coverslips for SEM,
and the second was suspended in phosphate buffered saline and used
for further qualitative and quantitative microbiological tests (viable
cell counts, microbiological automatic identiﬁcation and antibiotic
susceptibility testing by VITEK system, adherence and invasion capacity
on HeLa cells by Cravioto adapted method, adherence on prostetic
substrata used in oral medicine by original experimental models for in
vitro bioﬁlm development and by slime test, production of extracellular
enzymes and exotoxins (haemolysins and other pore-forming toxins,
amylase, mucinase, gelatinase, caseinase, aesculin hydrolysis).
Results and Discussion: The scanning electron microscopy revealed
a very complex and highly organised architecture of dental plaque
(nse masses of microorganisms embedded in a microbial mathrix,
bioﬁlm thickness from 50 to 133 micrometers, presence of columns
and canalicular system). The qualitative analysis of microorganisms
in dental plaque by direct optic examination of Gram-stained smears
showed a great diversity of morphological types in 82.5% of cases,
with the constant presence of micellian hyphae, the rest of 17.5% being
monomorphous (Actinomycetae/Gram-negative cocobacilli). Two non-
cultivable spirochetae were present in 12.5% of cases. The quantitative
analysis of the dental plaque revealed comparative levels of microbial
densities (from 2.4×102 to 6.8×103 CFU/mL). Despite the great
diversity of the morphological types observed at direct microscopic
examination of the specimens, a maximum of 3 different strains/
specimen were recovered after cultivation in aerobic conditions, aspect
that is accounting for the great value of direct examination in the
investigation of the dental plaque. Out of the total number of 50 microbial
strains recovered from the analysed specimens, 50% exhibited ability to
adhere to three different polimeric inert substrata used in oral medicine.
In exchange, they showed reduced adherence and invasion capacity of
HeLa cells, as well as scared expression of soluble enzymatic factors.
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P604 Investigation of the antimicrobial activity of different
antibiotics on monospeciﬁc bioﬁlms developed in vitro
by microbial strains isolated from cardiovascular devices
associated infections
V. Lazar, C. Balotescu, M. Bucur, O. Banu, G. Dobrin, C. Bleotu,
B. Savu, I. Sandulescu, I. Stanciu, R. Cernat (Bucharest, RO)
The aim of this study was to investigate the structure of natural bioﬁlms
developed on cardiovascular devices by optic and scanning electron
microscopy (SEM), to isolate de bioﬁlm former strains and to reproduce
the development of artiﬁcial monospeciﬁc bioﬁlms on correspondent
sterile devices using three in vitro experimental models in order to select
the most effective type of treatment in controlling bioﬁlm formation on
these devices.
Material and Methods: 31 cardiovascular devices (24 central venous
catheters, 3 aortic valves, 3 draining tubes, 1 arterial catheter) taken
from patients submitted to cardiovascular surgery were examined by
optic microscopy and SEM and seeded on sheep blood agar and
nutrient broth. The antibiotic susceptibility of planktonic cells recovered
after cultivation was determined by disk diffusion and MICs were
established by broth microdillution method. The antibioresistance of
adherent cells was tested by three experimental models for in vitro
bioﬁlm development: adapted disk diffusion method with bacterial cells
embedded in the agar mathrix, development of bioﬁlm on small, sterile
device pieces immersed in nutrient agar and inclusion of bacterial cells
simultaneously with different antibiotic concentrations in agar mathrix
allowing the assessment of cel viability.
Result: The direct optic examination exhibited low predictibility of
samples positivity. The isolated microorganisms were: Staphylococcus
(S.) epidermidis (3), Acinetobacter baumannii (2) S. aureus (1), Proteus
mirabilis (1) and Klebsiella penumoniae (1). All strains proved to be
very resistant to all tested antibiotics in planktonic state, excepting
colistin, exhibiting low MICs from 0.25 to 2mg/mL. We further tested
the efﬁciency of colistin on bioﬁlm growing bacteria.
The results demonstrated that adherent bacteria exhibited a higher
resistance to colistin (reduced diameters of inhibition zones and MICs 4
to 8 times higher than their planktonic counterparts). However, colistin
proved a good penetration into bioﬁlm as demonstrated by the altered
structure and reduced thickness of the bioﬁlm revealed by SEM and by
loss of cells viability. Our results demonstrate the utility of the bioﬁlm
development experimental models in the prediction of the effective
antimicrobial agent against bioﬁlm growing bacteria and the utility of
colistin in the treatment of Gram-positive as well as Gram-negative
bioﬁlm associated infections.
P605 Bactericidal effect and diminution of bioﬁlm using Endox
endodontic system
C. Cassanelli, S. Roveta, A. Marchese, E. Debbia (Genoa, IT)
Background: Endox is an instrument used in the endodontic treatment;
its action is based on the formation of electromagnetic ﬁeld created by
high frequency alternated current. The aim of this study is to evaluate
the role cetrimide 125mg/l when bacteria are treated with Endox.
Materials and Methods: 0.1ml of cetrimide solutions 125 a˜ in NaCl
0.08M is added to 0.1ml of suspension Enterococcus faecalis ATCC
29212 bioﬁlm producers cultured in the micro-plates for 48 hours all
the cultures were treated with Endox in the presence or not of cetrimide.
Quantitative evaluation of bioﬁlm was carried out by measuring the
absorbance of the solution (A600). Survivors were determinated by
CFU/mL.
Results: The decrease of bacterial population with cetrimide was
92%, while with cetrimide and Endox was 99.99%, The consolidated
bioﬁlm was reduced 21.2% using cetrimide in conjunction with Endox,
16.2%with Endox and 9.59% using cetrimide alone.
Conclusions: Present ﬁnding indicated that cetrimide might play a role
in reducing the consolidated bioﬁlm in culture exposed with Endox.
P606 In vitro bioﬁlm-forming ability and antimicrobial resistance
of enterococci from intensive and extensive farming boilers
V. Santos, M. Oliveira, A. Fernandes, C. Carneiro, S.F. Nunes,
F. Bernardo, C.L. Vilela (Lisbon, PT; Cambridge, UK)
Objective: Enterococci remain one of the major broiler intestinal
colonisers. Antimicrobial exposure may select for resistance that may
be spread in and outside the farm environment. Bioﬁlm is a recognized
virulence factor that facilitates persistence in the host, immune evasion
and bacterial survival at high drug concentrations. This work investigated
the relation between bioﬁlm-forming ability and antimicrobial resistance
from enterococci ﬁeld isolates from broilers.
Methods: Bioﬁlm production and antimicrobial resistance of 23 isolates
from boiler faecal samples from intensive (n = 6) and extensive (n = 17)
farming were evaluated. Isolates were identiﬁed as Enterococcus faecalis
(n = 6), E. faecium (n = 15), E. durans (n = 1) and E. gallinarum
(n = 1). Direct observation of bioﬁlm in bacterial suspensions was
performed by Fluorescent In Situ Hybridisation (FISH), using two
16S rRNA oligonucleotide probes (Jansen et al., 2000; Martins da
Costa et al., 2006). Minimum Inhibitory Concentrations of vancomycin
(VAN), enroﬂoxacin (ENR), oxytetracyclin (TET) and gentamicin (GEN)
were determined by broth microdilution (Clinical Laboratory Standard
Institute guidelines). Associations between bioﬁlm production and
antimicrobial resistance and between the farming system and bioﬁlm
production or antimicrobial resistance were evaluated (Friedman and
Mann-Witney Tests).
Results: According to the FISH method, 34.78% of the enterococci
isolates could produce bioﬁlm (26.08% from intensive and 8.69%
from extensive farming). None of the isolates was resistant to VAN.
In extensive farming, resistance to ENR, TET and GEN was found
in 4.34%, 21.73%, and 13.04% of the isolates, respectively, while in
intensive farming a higher level of resistance was observed (4.35%,
39.13%, and 60.87%, respectively). No signiﬁcant association was
found between bioﬁlm production and antimicrobial resistance nor
between farming type and bioﬁlm production or antimicrobial resistance
(P> 0.05).
Conclusion: Results suggest that poultry may be colonised by bioﬁlm-
producing and antimicrobial resistant enterococci, independently of the
farming system. In vitro drug resistance could not be related to bioﬁlm
production, re-enforcing the genetic basis of resistance. Nevertheless,
bioﬁlm production should be further investigated, since it may hamper
therapy, requiring higher antimicrobial concentrations and increasing
horizontal gene transfer for resistance.
P607 Bacterial colonisation of original synthesized biomaterials in
in vivo examinations
A. Reinis, J. Kroica, J. Vetra, A. Skagers, V. Kuznecova, R. Cimdins,
L. Berzina, D. Rostoka (Riga, LV)
Objective: To examine the minimal infective dose of S. epidermidis on
different biomaterials in laboratory animal models.
Materials and Methods: Originally synthezised biomaterials –
4N bioactive glass and 4NK bioceramics were contaminated with
S.epidermidis strain ATCC 12228 in concentrations 100 CFU/mL and
1000 CFU/mL and incubated for 2 hours. After incubation period non-
attached bacteria were removed and contaminated biomaterial discs were
inoculated in animal models subdermali on left subscapular region for
2 weeks. After 2 weeks incubation in rabbit model, discs were removed,
sonicated (1 min) and vortexed (1 min). Samples were cultivated on
TSA to estimate the number of CFU per 1mm2 on the surface of both
biomaterial discs.
Results: Non-contaminated biomaterial discs (4N, 4NK) as well
as contaminated with S. epidermidis in concentration 100 CFU/mL
remained sterile. The same as bioactive glass disc 4N with S. epidermidis
in concentration 1000 CFU/mL remained sterile. The colonisation
intensity of the bioceramic glass (4NK) discs in concentration
1000 CFU/mL was 0.04 CFU per mm2.
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Conclusions: Different biomaterials have variable attachments of
S. epidermidis in laboratory animal models. The minimal infective dose
for bioactive glass 4N is 1000 CFU/mL, for bioceramic glass 4NK more
than 1000 CFU/mL.
P608 Effect of antibiotics at subMIC concentration on bioﬁlm
formation by Streptococcus pyogenes
L. Baldassarri, S. Recchia, R. Creti, M. Imperi, M. Pataracchia,
G. Oreﬁci (Rome, IT)
Objectives: To determine the effect of subMIC concentrations of
antibiotics on bioﬁlm formation by Streptococcus pyogenes.
Methods: A small collection of strains were chosen on the basis
of the genetic determinants for antibiotic resistance they carried (i.e.
susceptible, mefA+, or erm(A)-erm(B)+ strains). Four strains for each
category were selected. SubMIC concentrations were determined for
penicillin, clyndamycin and erythromycin by the microbroth dilution
methods. Ninety six wells microtiter plates were ﬁlled with serial
dilutions (1:2) of a given antibiotic; each strain was inoculated in
triplicate for each antibiotic concentration, and allowed to grow for
24 hrs. At the end of the incubation period, absorbance at 630 nm was
determined along with CFU counts. Plates were then emptied, dried, and
the bioﬁlm deposited on the well’s bottom stained with crystal violet.
Optical density at 570 nm was measured and a bioﬁlm index generated
in consideration of different growth rates.
Results: We had already determined that a majority of S. pyogenes
strains from a variety of sources are able to form bioﬁlm. In particular,
susceptible strains formed thicker bioﬁlm compared to macrolide-
resistant strains. In this study we found that subMIC concentration of
penicillin, but not erythromycin or clindamycin, were able to stimulate
bioﬁlm formation only in susceptible strains. Increase in bioﬁlm index
in three of the four susceptible strains examined reached up to 150%,
176% and 585% of the control, respectively. Bioﬁlm formation was not
affected in those strains carrying either genetic determinants of antibiotic
resistance.
Conclusion: Data obtained in this study conﬁrm that bioﬁlm may
represent a way for S. pyogenes to escape antimicrobial treatment even
when strains lack the genetic determinants for antibiotic resistance.
Penicillin treatment represents the drug of choice for eradication of
S. pyogenes in patients with recurrent infections and/or carriers. It should
however be considered that a percentage of treatment failures might still
be possible in view of this secondary effect of penicillin.
P609 Negative correlation between bioﬁlm formation and
antibiotic sensitivity in clinical isolates of clonally related
Acinetobacter baumannii
G. Fugazza, P. Landini, R. Migliavacca, M. Spalla, E. Nucleo,
A. Navarra, R. Daturi, L. Pagani (Milan, Pavia, IT)
Objectives: Acinetobacter baumannii has emerged worldwide as an
important nosocomial pathogen and an increasing number of outbreaks,
mainly in ICUs, caused by multidrug resistant (MDR) strains, has
been reported over the last years. Since bioﬁlm formation by
pathogenic bacteria might increase resistance to antimicrobial agents, we
investigated the possibility that bioﬁlm formation might be a resistance
factor in A. baumannii.
Methods: A. baumannii analysed in this study included 35 clinical
isolates, collected from 2 different hospitals in Northern Italy.
Identiﬁcation and susceptibility testing were carried out following
standard procedures. Genotyping was performed by REP-PCR and PFGE
analysis. Bioﬁlm formation was tested in two different growth media:
M9GSup, a deﬁned growth medium with glucose as main carbon source,
and LB, a rich, peptone-based medium. In addition, two different growth
temperatures were tested: 37ºC (host temperature) and 30ºC (sub-optimal
growth temperature).
Results: All isolates belonged to the same DNA group and showed either
identical or highly similar proﬁles. Consistent with the identiﬁcation
results, all strains displayed the same MDR phenotype, but were sensitive
to both tetracycline and imipenem. Four strains, chosen as representative,
were tested for bioﬁlm production and found capable of efﬁcient bioﬁlm
formation, thus suggesting that production of adhesion factor is well
conserved in this clone of A. baumannii. However, bioﬁlm formation was
greatly favoured when bacteria were grown in M9GSup; in contrast, little
bioﬁlm formation was observed in LB, possibly suggesting that adhesion
factor production might be stimulated by growth on glucose. Growth
at 30ºC resulted in slight stimulation of bioﬁlm formation compared
to growth at 37ºC in both media. Interestingly, MICs were roughly
4-fold lower in M9GSup medium for both tetracycline and imipenem,
suggesting that sensitivity to antibiotics was actually increased in
conditions favouring bioﬁlm formation.
Conclusions: Our results suggest that bioﬁlm formation by A. baumannii
does not play a major role in antibiotic resistance. Increased sensitivity
to imipenem in M9GSup medium is consistent with the reported
bactericidal effect of this antibiotic on slow-growing bacterial cells.
Future experiments will allow us to assess sensitivity of A. baumannii
bioﬁlm cells to imipenem, in order to evaluate its therapeutic potential
against bioﬁlm-related infections.
P610 Bioﬁlm formation in nosocomial pathogens of respiratory
tract
V. Hola, F. Ruzicka, R. Tejkalova, M. Votava (Brno, CZ)
Chronic infections caused by bioﬁlm-forming bacteria represent serious
medical problem nowadays. Their higher prevalence is associated with
more frequent use of artiﬁcial implants and medical devices, more fre-
quent invasive manipulation and higher number of immunocompromised
patients. The problem is much bigger on the ICUs, where the number
of immunocompromised patients is even higher. The bioﬁlm-positive
bacteria take advantage of the suppressed immunity. The artiﬁcial surface
of used implants facilitates adhesion of bacteria, which than form
bioﬁlm.
The aim of this study was to compare the ability to form bioﬁlm
in two groups of bacteria – bacteria colonising respiratory tract and
bacteria causing nosocomial infection of respiratory tract. We collected
448 strains of bacteria (ICU patients, collected from January 2006
to October 2006) which we divided into above-mentioned groups and
determined to the species level. Most of them were Gram-negative
non-fermentative bacteria, especially Pseudomonas aeruginosa and
Acinetobacter baumannii-calcoaceticus group.
In all bacteria we assessed the ability to form bioﬁlm by the modiﬁcation
of Christensen microtiter-plate method. The bioﬁlm was grown on tissue
culture microtiter plates. Each strain was cultivated simultaneously in 4
wells and the average optical density was assessed. The results were
assessed statistically by the Two-sample analysis (programme R 2.1.1)
and General Linear Models (programme Canoco 4.5). In the group of
bacteria causing nosocomial infections the bioﬁlm-forming ability was
present signiﬁcantly more often (p< 0.05).
There were differences in spatial arrangement of the ability to form
bioﬁlm as the upper and lower respiratory tract is concerned. The
differences the bioﬁlm-forming ability in particular species was not
statistically signiﬁcant.
Since the bioﬁlm-forming bacteria are difﬁcult to eradicate with
antibiotics and often cause chronic infections, their higher prevalence
in bacteria causing nosocomial respiratory tract infections may be
very problematic and the regular exchange of tracheostomic tubes and
catheters is recommended.
This work was partially supported by the grant MPO – Tandem FT-
TA3/098.
P611 Bacterial bioﬁlms in patients with chronic rhinosinusitis
E. Dworniczek, M. Fraczek, J. Kassner, R. Adamski, A. Seniuk,
I. Choroszy-Kro´l (Wroclaw, PL)
Objectives:Microbial bioﬁlms that are formed on human tissue surfaces
play a role in many chronic diseases. Existing in a bioﬁlm phenotype
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microorganisms evade host defences and are resistant to systemic and
local antibiotic therapy. Bioﬁlms have been implicated in dental and
periodontal diseases, chronic tonsilitis, otitis media. We demonstrated
that bacterial bioﬁlms are present in patients with chronic rhinosinusitis
(CRS). Although many etiological factors contributing to CRS have been
described, the role of bacteria is not well deﬁnied.
Methods:We reviewed 9 cases of CRS patients using culturing methods,
scanning (SEM) and transmission (SEM) electron microscopes. The
patients were undergoing functional endoscopic sinus surgery (FESS) or
radical antrostomy performed because of failure of past medical therapy.
Mucosal specimens and sinus lavage were taken from diseased maxillary
sinuses and cultured on media for aerobic and anaerobic bacteria and
fungi.
Microrganisms were identiﬁed by conventional biochemical tests. The
samples were prepared using standard methods for SEM and TEM. Areas
of interest were photographed.
Results: Bacterial bioﬁlms observed under electron microscope were
detected in 3 patients. Cultures of these specimens contained: Streptococ-
cus spp., Escherichia coli, Klebsiella pneumoniae, Streptococcus agalac-
tiae, Proteus mirabilis. In 2 patients neither bacteria nor fungi were
present (negative culture and microscopy). In the samples of 4 patients
Gram-negative rods, alpha-haemolytic streptococci, Propionibacterium
spp. and Corynebacterium spp. were identiﬁed. However no bioﬁlm-like
structures were observed under electron microscope.
Conclusion: Bioﬁlms were demonstrated to be present in patients un-
dergoing surgery for CRS. This is one of not numerous documentations
of bioﬁlms in association to chronic rhinosinusitis.
P612 Characterisation of bacterial isolates colonising urinary tract
catheters
X. Wang, I. Ehren, H. Lunsdorf, A. Fruth, U. Ro¨mling, A. Brauner
(Stockholm, SE; Braunschweig, Wernigerode, DE)
Objectives: To characterise bioﬁlm and related behaviours of bacteria
colonising urine catheters and urine.
Methods: Bacterial isolates were recovered and species identiﬁed from
urine and urinary catheters samples of 45 patients. All isolates were
characterised for bioﬁlm formation and related behaviour such as
expression of extracellular matrix components. Serotype was assayed.
Catheter samples were investigated by electron microscopy to analyse
bioﬁlm formation.
Results: In total 179 bacterial isolates was recovered from urine
catheter samples. Most commonly recovered species were coagulase
negative staphylococci (CNS), Enterococcus faecalis, Escherichia
coli, Staphylococcus aureus, Klebsiella pneumoniae and Pseudomonas
aeruginosa. Catheter recovered E. coli isolates were signiﬁcantly more
prevalent in patients with prostatic cancer than patients suffering
prostatic hyperplasia. Catheter recovered CNS isolates were signiﬁcantly
more prevalent in patients with short-term catheterisation than those
with long-term and more prevalence than S. aureus, E. faecalis,
Streptococci, E. cloacae and Enterobacteriaceae in patients with short-
term catheterisation. 96% of isolates showed bioﬁlm formation in vitro.
Isolates of P. aeruginosa demonstrated the highest bioﬁlm formation and
adherence capacity among investigated species. E. coli isolates recovered
from patients with catheter associated urinary tract infection formed
signiﬁcantly more bioﬁlm and adherence than E. coli isolates causing
asymptomatic colonisation. E. coli isolates with UTI-related O-antigen
formed signiﬁcantly more bioﬁlm and adherences than remaining
isolates. E. coli isolates with H antigen adhered more and expressed
more extracellular matrix than bacteria without H antigen.
Conclusions: Most isolates from catheter can form bioﬁlm in vitro.
The capacities to form bioﬁlms contribute to the virulence properties
of P. aeruginosa and E. coli by enabling colonisation of the catheter.
Although CNS is commonly found on catheter surfaces it is mainly
retrieved during short time catheterisation, which could be due to its
inability to persist urine ﬂow and over growth of other bacterial species.
The correlation found between E. coli and prostate cancer merits further
investigation.
P613 Inﬂuence of sub-inhibitory concentrations of antibiotics on
bioﬁlm formation by Salmonella typhimurium
J. Majta´n, L. Majta´nova´, V. Majta´n (Bratislava, SK)
Objectives: Salmonella typhimurium strains are important food-borne
pathogens. Numerous studies have documented the ability of Salmonella
spp. to adhere and form bioﬁlms on different surfaces. The aim of
this study was to investigate and compare the effect of sub-inhibitory
concentrations (sub-MICs) of antibiotics on bioﬁlm formation by clinical
S. typhimurium strains.
Methods: The antibiotics used in this study were gentamicin,
ciproﬂoxacin and cefotaxime. Bioﬁlm-forming abilities of three clinical
isolates of S. typhimurium (No. 18/06, 41/06, 53/06) in the presence of
sub-MICs (1/2, 1/4, 1/8, 1/16 of the MIC value) of these antibiotics were
assessed by absorbance at 570 nm of crystal violet-bound cells recovered
from 96-well tissue culture plates after growth in TSB growth medium.
Results: The effect of sub-MIC concetrations of antibiotics tested in
bioﬁlm formation was determined by the percentage of inhibition of
bioﬁlm formation. Each antibiotic had a different effect on bioﬁlm
inhibition according to the strain targeted. The most effective in all
three strains were sub-MICs of gentamicin in whole concentration range.
Sub-MICs of ciproﬂoxacin expressively inhibited bioﬁlm formation by
two strains (41/06 and 53/06). On the other hand cefotaxime markedly
stimulated bioﬁlm formation by strain 18/06 in whole concentration
range, and by 41/06 and 53/06 strains at 1/2 of the MIC.
Conclusion: These ﬁndings showed that gentamicin, ciproﬂoxacin and
cefotaxime inﬂuenced bioﬁlm formation by clinical S. typhimurium
strains at sub-MIC concentrations. This effect was dependent on the
strain and on the type of antibiotic.
P614 Slime production in blood isolates of Staphylococcus aureus
under various growth conditions
O. Aslan, B. Aksu, F. Babacan (Istanbul, TR)
Objectives: The production of bioﬁlm represents an important virulence
factor of certain strains of Staphylococcus aureus. We aimed to
investigate bioﬁlm production of blood-borne S. aureus isolates under
different growth conditions.
Methods: Total of 100 blood isolates of S. aureus were included to the
study. All the isolates were identiﬁed as S. aureus by colony morphology,
catalase and tube coagulase reactivity. Slime production of the isolates
was detected by cultivation on Congo Red Agar (CRA) plates and
quantitative microplate test. Four different Tryptic Soy Broth (TSB)
formulas were used in microplates for testing their inﬂuence on bioﬁlm
production; standard TSB, TSB supplemented with 1% glucose, iron
limited TSB (50% less than usual) and iron supplemented TSB (50%
more than usual).
Results: Only one isolate was detected as positive with three methods;
CRA and quantitative microplate method with standard TSB and iron
limited TSB. Of one hundred isolates, 8 were found positive (8%) in
glucose supplemented TSB medium which were also found positive in
iron limited TSB medium. In addition to these 8 isolates, 37 isolates
(45%) were also determined as positive in iron limited medium, but
only one isolate (1%) was detected as positive in iron supplemented
TSB.
Conclusion: Iron limited TSB medium might be the best approach to
evaluate bioﬁlm production of clinical S. aureus isolates.
P615 Adhesion of Staphylococcus epidermidis to a modiﬁed
cellulose triacetate membrane
C.I. Extremina, P.L. Granja, A. Freitas da Fonseca, A.P. Fonseca
(Porto, PT)
Objectives: There is an increase in the use of biomedical materials in
modern medicine, despite some problems resulting from this practice.
A major drawback are the biomaterial-centred infections. Adhesion of
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micoorganisms begins when they reach the biomaterial surface. This
initial step involves speciﬁc interactions between bacteria and surfaces.
A high number of the infections affecting medical devices are associated
to Staphylococcus epidermidis, which is therefore called an opportunistic
pathogen of foreign bodies. The aim of this study was to assess
the anti adhesive properties of cellulose triacetate (CTA) membranes
incorporating the antibiotic Imipenem in order to prevent Staphylococcus
epidermidis adhesion.
Methods: The materials studied were characterised in terms of surface
free energy of interaction by contact angle measurements (quantitative
measure of hydrophobicity). The antibacterial activity of the materials
was assessed in vitro by a modiﬁed Kirby Bauer test. The in vitro
adhesion of S. epidermidis RP62A expressing capsular polysaccharide/
adhesin (PS/A), the most common etiological agent of colonisation
of implantable medical devices, to CTA and to CTA with entrapped
antibiotic (CTA-Imipenem) was investigated.
Results: The thermodynamic approach showed a good correlation
between free energy of interaction between cells, materials’ surface and
water and bacterial adhesion values. CTA-Imipenem membranes showed
an anti-proliferative character, being therefore bacteriostatic. Bacterial
adhesion tests showed a statistically signiﬁcant decrease in the adhesion
of S. epidermidis to CTA-Imipenem when compared to its adhesion to
CTA alone.
Conclusion: By using the present approach it seems possible to obtain
an adequate medical device surface coated with CTA-IMP with anti-
adhesive and anti-proliferative properties.
P616 Inﬂuence of mutations in genes of the sigma B operon
on Staphylococcus epidermidis in vitro and in vivo bioﬁlm
formation
V. Pintens, C. Massonet, R. Merckx, J. Van Eldere (Leuven, BE)
Objective: To study the effect of inactivation of the regulatory gene
rsbU, the entire regulatory cascade rsbUVW and the entire sigma B
operon on Staphylococcus epidermidis bioﬁlm formation in vitro and in
vivo.
Methods: Strains used were 8400 (wild type), 8400rsbU (rsbU::erm),
8400rsbUVW (rsbUVW::erm), 8400rsbUVWsigB (rsbUVWsigB::erm),
1457 (wild type), 1457rsbU (rsbU::erm), 1457rsbUVW (rsbUVW::erm)
and 1457rsbUVWsigB (rsbUVWsigB::erm) (Mack et al. Infection.
Immun. 1992; 60: 2048; Knobloch et al. Infection. Immun. 2004;
72:3838). In vivo, catheter fragments inoculated with the different
S. epidermidis strains were implanted subcutaneously in rats as described
(S. Vandecasteele et al. Biochem Biophys Res Commun. 2002; 291: 528).
Bioﬁlm formation by the different strains was observed after one day in
vitro and in vivo. The amount of sessile bacteria in vitro was determined
at 0, 2, 6, 24, 48 and 96 hours after inoculation and in vivo catheters were
explanted 0, 4, 24, 48, 96, 336 and 504 hours after implantation. The
amount of bacteria was determined by Taqman PCR of the housekeeping
gene gmk.
Results: After one day as well in vitro as in vivo fewer catheters were
infected with rsbU and rsbUVWsigB mutants (78.87%) compared to
the wild types and rsbUVW mutants (91.42%). The amount of sessile
bacteria was also lower in the rsbU or the rsbUVWsigB mutants. In vitro
the difference was signiﬁcant from 6 hours after inoculation onwards
and in vivo from 2 days after implantation onwards. No signiﬁcant
differences were observed between rsbUVW mutants and wild type
strains.
Conclusion: Mutation of rsbUVW, a negative regulator of sigma B
activity does not increase bioﬁlm formation, relative to the wild type
strain. Similar results with regards to number of catheters colonised and
amount of sessile bacteria were obtained for wild-type strains and the
mutants with inactivation of rsbUVW.
Mutation of rsbUVWsigB reduces catheter colonisation and the number
of sessile bacteria, and the same effect was obtained with the rsbU
mutants. However, although bioﬁlm formation is reduced, there are still
adherent bacteria, suggesting alternative pathways for bioﬁlm formation.
P617 Linezolid inhibits alpha-toxin and bioﬁlm formation in
Staphylococcus aureus
K. LaPlante (Providence, US)
Objective: Bioﬁlms are important virulence factors for Staphylococcus
aureus. Alpha-toxin (hemolysin) production has been related to the
development of bioﬁlms via quorum sensing. By inhibiting alpha-toxin
production with antimicrobial agents that target various sites of protein
synthesis, we should therefore be able to effect bioﬁlm production.
Methods: We quantiﬁed bioﬁlm formation and alpha toxin production
in 5 randomly selected bioﬁlm and alpha toxin producing clinical
S. aureus strains. We used prototype high-level producers of alpha-toxin
and bioﬁlm (ATCC 10832 and ATCC 35556 respectively) as controls.
Each isolate was evaluated alone and in the presence of clindamycin,
gentamicin, linezolid, tigecycline and vancomycin at 12 the MIC.
MIC testing was determined using CLSI methodology. Antimicrobial
compounds were evaluated for their ability to inﬂuence alpha-toxin
and then bioﬁlm production. Alpha-toxin production was quantiﬁed by
collecting the supernatant of an overnight inoculated broth and assaying
the supernatant in the presence of a 2% concentrated sheep blood assay.
Bioﬁlm formation was evaluated and quantiﬁed using 12 the respective
MIC of each agent and read using the Calgary Bioﬁlm assay.
Results: Linezolid was the only agent that did not haemolyze sheep
blood erythrocytes. There was extensive haemolysis of the erythrocytes
in the presence of toxin producing S. aureus and other agents evaluated
at 12 their respective agents MIC. This may be due to linezolid’s
ability to inhibit protein synthesis at an earlier point then the other
ribosomal targeting agents. We also observed that at 12 the MIC linezolid
demonstrated signiﬁcant inhibitory effects on the production of bioﬁlm
(P = 0.002) in S. aureus.
Conclusion: Based upon these data, linezolid has merit to be investigated
further as a possible alpha toxin and bioﬁlm deterrent. Not only did this
work further validate a link between alpha-toxin and bioﬁlm formation,
but at sub-inhibitory concentrations linezolid can signiﬁcantly reduce
alpha toxin and bioﬁlm production when compared to other agents.
P618 The effect of Staphylococcus epidermidis culture supernatants
on the bioﬁlm density of other S. epidermidis strains
J.S. Cargill, M. Upton (Cambridge, Manchester, UK)
Objectives: It has been shown that staphylococcal bioﬁlm density can
be regulated by the presence of small diffusible molecules, often protein
in nature. The aim of the present study was to screen Staphylococcus
epidermidis culture supernatants for the ability to affect the bioﬁlm
density of other strains of the same organism.
Methods: Fourteen clinical strains of S. epidermidis and the control
strain RP62A were characterised as bioﬁlm-positive (optical density
(OD) at 450nm above 0.12) or negative. Overnight cultures of the strains
were suspended at a dilution of 1:100 in fresh tryptone-soya broth, and
100 microlitres added to the test wells of a sterile, ﬂat-bottomed 96-
well plate. Filtered supernatants (100 microlitres, including that from
the same strain) were then added to the wells (eight replicates), and the
plates incubated for 20 hours. The bioﬁlm density was expressed as a
ratio of the OD with that formed by 200 microlitres of the 1:100 dilution
(without supernatants). Each combination was repeated twice. Box plots
were then used to identify outlying results (greater than one interquartile
range above or below the median) which were assumed to show possible
supernatant effects. These results were then examined.
Results: All bioﬁlm-positive strains cultured with supernatants (includ-
ing that of their own strain) showed lower bioﬁlm densities than the
control 1:100 dilution. No supernatant was shown to prevent a bioﬁlm-
positive S. epidermidis strain from forming a bioﬁlm. No outlying results
were seen on the box plots to suggest a signiﬁcant reduction in bioﬁlm
density in any sample. Four outliers were seen with increased bioﬁlm
density. One remained a weak bioﬁlm former only. The remaining
samples were weakly bioﬁlm-positive in otherwise bioﬁlm-negative
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strains, although the standard deviation of the eight replicates extended
below an OD of 0.12. The results were not reproduced in both tests.
Conclusion: This simple experiment does not suggest that S. epidermidis
bioﬁlms are signiﬁcantly modiﬁed by culture supernatants produced by
other S. epidermidis strains. Lower bioﬁlm densities are produced by
bioﬁlm-positive strains when incubated with any supernatant; this may
represent an altered balance of nutrients in the supernatant compared
with fresh TSB, or may represent the presence of a general inhibitory
effect, such as acid production by S. epidermidis.
P619 Activity of daptomycin on bioﬁlms produced on plastic
support by Staphylococcus species
S. Roveta, A. Marchese, G. Schito (Genoa, IT)
Objectives: Antibiotics capable of disrupting or inhibiting the synthesis
of bioﬁlms formed by bacterial pathogens may offer therapeutic
advantages over molecules without these properties. This study assessed
the in vitro activity of the novel lipopeptide, daptomycin, against bioﬁlms
produced by staphylococcal species.
Methods: Three recently isolated slime producing strains each of
methicillin susceptible (MET-S), methicillin resistant (MET-R) S. aureus
and S. epidermidis and two bioﬁlm producing vancomycin intermediate
S. aureus (VISA) (Marchese et al., 2000) were tested. Slime formation in
96-well tissue culture plates was quantiﬁed spectrophotometrically using
a method based on that of Cramton et al. (2001).
Results: Daptomycin at concentrations achievable during therapy
(2−64mg/l) inhibited slime synthesis (>60%) in all strains. Reduction
of bioﬁlm production was >80% in both MET-S S. aureus and
S. epidermidis, and ranged from 60 to 80% in MET-R S. aureus
and from 70 to 95% in MET-R S. epidermidis. At 64mg/l, bioﬁlm
synthesis decreased by 80% in the 2 VISA isolates. Daptomycin also
disrupted the bioﬁlm both in initial (5 h) and mature (48 h) slimes.
Over 50% breakdown of preformed initial bioﬁlm was observed in all
strains. Disruption of mature bioﬁlms, however, was more variable (range
20−70%) and was both concentration- and strain-dependent.
Conclusions: Daptomycin promoted a sizable inhibition of slime
synthesis and slime disruption in both initial and mature bioﬁlms
produced on plastic support by all Staphylococcal strains studied. Bioﬁlm
present on tissues during infections is known to be thinner and less
organised. If daptomycin interacts positively with the immune defences,
its ability to interfere with the physiology of slime in vivo may be further
enhanced.
P620 Effect of linezolid and quinupristin/dalfopristin on formation
and disruption of Staphylococcus haemolyticus bioﬁlm in vitro
M. Juda, P. Helon, A. Malm (Lublin, PL)
Objectives: Staphylococcus haemolyticus belonging to coagulase nega-
tive staphylococci is the common commensal of the skin. This strain may
cause bacteraemia, especially in hospitalised patients in the presence of
indwelling medical devices. The aim of this study was to assess the effect
of linezolid and quinupristin/dalfopristin on formation and disruption of
S. haemolyticus bioﬁlm structure on polychloride vinyl (PCV) catheter
in vitro.
Methods: Four S. haemolyticus strains were isolated from patients
with lung cancer during hospitalisation (three from nasopharynx, one
from pleural drain). The routine microbiological methods were used
for their isolation and identiﬁcation. Minimal inhibitory concentration
(MIC) of linezolid and quinupristin/dalfopristin was determined by
E-test according to criteria of Clinical and Laboratory Standards (CLSI).
Modiﬁed Richard’s et al. method was used to assess of ability for
adhesion proccess and bioﬁlm formation on the PCV urological Nelaton’s
catheter in vitro. For evaluation of linezolid and quinupristin/dalfopristin
effect on formation and disruption of S. haemolyticus bioﬁlm structure
in vitro following antibiotic concentrations were used: 0.125; 0.25; 0.5;
1.0; 2.0; 4.0; 8.0; 16.0×MIC.
Results: All strains possessed strong ability to adhesion and bioﬁlm
formation on the PCV catheter in vitro. Linezolid and quinupristin/
dalfopristin inhibited adhesion process in concentrations 0.19–0.375mg/l
(0.25−0.5×MIC) and 0.125–0.75mg/l (1.0−2.0×MIC), respectively.
Linezolid effected formation of bioﬁlm in concentrations between 0.5–
0.75mg/l (0.5−1.0×MIC), while quinupristin/dalfopristin – in con-
centrations between 0.5−3.0mg/l (2.0−4.0×MIC). Drug concentrations
disrupting the mature bioﬁlm structure was higher: 1.5−2.0mg/l
(2.0×MIC) for linezolid and 1.0−6.0mg/l (8.0–16.0×MIC) for quin-
upristin/dalfopristin.
Conclusion: Our data indicate that linezolid was more effecive agent,
then quinupristin/dalfopristin in prevention of bioﬁlm formation by
S. haemolyticus strains on the PCV catheter and disruption of mature
bioﬁlm in vitro.
P621 Prevention of Pseudomonas aeruginosa bioﬁlm formation
with antibiotics used in cystic ﬁbrosis patients during early
broncopulmonary colonisation
A. Fernandez-Olmos, M. Garcı´a-Castillo, L. Maiz, A. Lamas,
F. Baquero, R. Canto´n (Madrid, ES)
Objectives: Early P. aeruginosa isolates colonising cystic ﬁbrosis (CF)
airway appear more favourable for eradication with antibiotic therapy
than those in chronically colonised patients. We study the antibiotic
susceptibilities of non-mucoid P. aeruginosa isolates recovered in early
colonisation stages of CF patients and their ability to prevent bioﬁlm
formation in these isolates.
Methods: Ciproﬂoxacin (CIP), tobramycin (TOB), ceftazidime (CAZ)
and imipenem (IMP) susceptibility of 27 non-mucoid P. aeruginosa
isolates recovered from 18 CF patients with early colonisation were
study both using a polystyrene microplate bioﬁlm susceptibility assay
(Moskowitz et al. J Clin Microbiol 2004; 42:1915−22) and the standard
microdilution method (CLSI). Bioﬁlm was formed by immersing the
pegs of a modiﬁed microtiter lid into a growth microplate, followed by
incubation. Bioﬁlm inhibitory concentration (BIC) was determined by
placing the peg lids with the bioﬁlm formed onto microplates containing
twofold diluted antibiotics. Bioﬁlm prevention concentration (BPC) was
determined after bioﬁlm was formed directly into antibiotic contact.
Optical density was measured after 6 and 24 hours of incubation.
Results: CIP, TOB, CAZ and IMP showed, respectively, the following
geometric mean values: MIC 1.3, 3.6, 12.1 and 4.9mg/L; BIC-6-h 2.7,
7.2, 149.3 and 21.8mg/L; BIC-24-h, 17.3, 37.3, 512.0 and 128.0mg/L;
BPC-6-h, 2.4, 2.7, 42.4 and 5.9mg/L; BPC-24-h, 10.3, 11.2, 339.5
and 29.6mg/L. These values showed CIP and TOB similar inhibitory
activity when P. aeruginosa growth was either sessile or planktonic at 6-h
incubation (BIC/MIC and BPC/MIC ratios of 2x). Higher concentrations
were required for all antibiotics to reach BIC and BPC after a 24-h
incubation period, with BIC/MIC ratios of 13x, 10x, 42x and 26x for
CIP, TOB, CAZ and IMP, respectively, and BPC/MIC ratios of 8x, 3x,
28x and 6x, respectively. In all cases, inhibitory effects required higher
concentrations than prevention ones.
Conclusion: Early antibiotic challenged of P. aeruginosa in CF patients
might beneﬁt of prevention of bioﬁlm formation, particularly with TOB
and CIP. Antibiotic concentration required to prevent bioﬁlm formation
was lower than that to inhibit formed bioﬁlm. The BIC and BPC
parameters have been postulated in the attempt to correlate in vitro
measurements with therapeutic outcomes in CF patients with early
P. aeruginosa colonisation bioﬁlm treatment.
P622 Penetration and activity of fosfomycin, ciproﬂoxacin,
amoxicillin plus clavulanic acid and cotrimoxazol in
Escherichia coli and Pseudomonas aeruginosa bioﬁlms
J. Rodriguez-Martinez, S. Ballesta, A. Pascual (Seville, ES)
Objectives: The aim of this study was to evaluate the penetration
and activity of four oral antimicrobial agents, commonly used to treat
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uncomplicated UTI, in E. coli and P. aeruginosa bioﬁlms on siliconised
latex urinary catheters (SL).
Methods: Strains: E. coli ATCC 25922, ESBL-producing E. coli
(urinary clinical isolate) and P. aeruginosa ATCC 27853. Bacterial
bioﬁlms: 1 cm in length segments of SL were incubated for 24 h in
broth containing 105 cfu/mL of each strain. Segments were washed
3 times with PBS to remove non-adherent bacteria. Segments containing
24 h bioﬁlms were further incubated in broth containing 10×MIC of
each antimicrobial for 24 hours. Bacterial survival was determined by
sonication of segments, dilution and colony counting. The penetration of
antimicrobials into bioﬁlms was also analysed. 24 h bioﬁlms were created
on polycarbonate membrane ﬁlters and cover with another polycarbonate
ﬁlter. A disk of known concentration for each antimicrobial was placed
on top and removed after 1, 3 and 6 hours. Drug concentrations left in
disks were measured using a bioassay method.
Results: No antimicrobial alone was able to completely sterilise the
catheter surface. For all of them, the bactericidal activity against 24 h-
bioﬁlms was higher than 96%. No differences were observed between
ESBL-producing and non-producing E. coli. The kinetics of penetration
of the four antimicrobial agents into the bacterial bioﬁlm was similar
for E. coli and P. aeruginosa. The penetration of fosfomycin and
ciproﬂoxacin was slightly slower than that of amoxicillin plus clavulanic
acid, but still more than 50% of both antimicrobials have accumulated
in bacterial bioﬁlms after 6 h incubation.
Conclusions: Fosfomycin, ciproﬂoxacin, amoxicillin plus clavulanic acid
and cotrimoxazole showed high in vitro activity against bacterial bioﬁms.
This activity could be partially due to the high accumulation into
bioﬁlms.
P624 Production of bioﬁlm and response to oxidative stress in
Pseudomonas aeruginosa in dependence on culture media
A. Hostacka, I. Ciznar (Bratislava, SK)
Objectives: P. aeruginosa as one of the most medically relevant bioﬁlm
forming bacterium is an important causative agent of many human
infections. Effect of six culture media (5 complex, 1 mineral) on
formation of bioﬁlm and response to oxidative stress in three clinical
P. aeruginosa isolates (pus, ulcer, urine) was evaluated.
Methods: Potential pathogenicity traits of clinical isolates were tested in
vitro using assay for bioﬁlm formation (microtiter plate assay with the
crystal violet) and for response to oxidative stress evoked by hydrogen
peroxide.
Results: The largest bioﬁlm forming ability of the tested strains was
observed after pre-incubation of bacteria in tryptone soya broth (TSM)
(A550 = 0.374–0.400) or in TSM supplemented with 8% glucose
(TSM+GL) (A550 = 0.358–0.384), the lowest level in mineral medium
(MM) (A550 = 0.071–0.104). The highest resistance of the tested isolates
to oxidative stress was found after cultivation in peptone water (average
of the zone of bacterial growth inhibition was 7.5mm), on the other hand,
the highest sensitive cells were observed after incubation in TSM+GL
(15.7mm) and in MM (15mm). Bacterial cells with the highest as well as
with the lowest capacity to form bioﬁlm were in average more sensitive
to hydrogen peroxide in comparison with cells growing in other tested
complex media (brain-heart infusion, Mueller-Hinton broth, peptone
water).
Conclusion: Bioﬁlm forming ability of P. aeruginosa as well as response
to oxidative stress was affected by the composition of culture media.
This work was supported by Ministry of Health of the Slovak Republic
under the project: Analysis of bioﬁlm production in nosocomial strains
as a basis to prevent infections in health institutions.
P625 Bioﬁlm formation in non-C. albicans yeasts isolated from
blood cultures
F. Ruzicka, V. Hola, P. Hamal, R. Tejkalova, I. Kocmanova, M. Votava
(Brno, Olomouc, CZ)
Although Candida albicans remains the most common fungal blood
stream pathogen, the incidence of non-albicans yeasts has been
approached to C. albicans incidence during last few decades. One of
the most important factors of their virulence is the ability to growth in
the bioﬁlm form which facilitates colonisation of indwelling implants
and defends the microbial cells against effect of the immunity system
and antifungal agents. The proof of the ability to form bioﬁlm enables to
evaluate the clinical importance and can helps to the physician to choose
appropriate strategy of therapy (e.g. removing of the focus).
The seventy-seven strains of non-C. albicans yeasts (C. parapsilosis,
32; C. tropicalis, 21; C. glabrata, 12; C. krusei, 4; C. lusitaniae, 2;
C. zeylanoides, 1; C. pelliculosa, 1; Yarrowia lipolytica, 1; Trichosporon
asahii, 3) were isolated from blood cultures during last two years (Oct.
2003 – Oct. 2006) and these strains were examined for bioﬁlm formation
in this study. The bioﬁlm formation was tested by modiﬁcation of
microtiter plate method. The yeasts were incubated in wells of microtiter
plate to form bioﬁlm. The bioﬁlm in wells was stained by means
of crystal violet. Quantity of bioﬁlm layer on the wall of each well
was evaluated spectrophotometrically. The sensitivity of some bioﬁlm-
positive strains to antifungal agents (amphotericin and voriconazole) was
evaluated by microdilution assay with colorimetric medium indicating
the fungal viability.
The thirty-seven strains (C. parapsilosis, 19; C. tropicalis, 11; C. krusei,
2; C. glabrata, 2; T. asahii, 1; C. zeylanoides, 1 and C. pellicuclosa, 1)
were positive for bioﬁlm formation. The relatively high percentage of
bioﬁlm-positive strains, especially in C. parapsilosis, and C. tropicalis,
indicates the important role of bioﬁlm formation as important virulence
factor, because these pathogens are frequently associated with indwelling
medical devices infections. Increasing incidence of these yeasts in blood
stream can be explained by high frequency of using of indwelling
medical devices in the few last decades. All tested strains growing in the
bioﬁlm showed higher resistance to all antifungal agents in comparison
with their planktonic form.
This work was supported by the grant agency IGA MZ NR/7980−3.
P626 Antifungal activity of human monocytes alone and combined
with caspofungin against Candida albicans bioﬁlm and
planktonic cells
A. Katragkou, M. Simitsopoulou, M. Dalakiouridou, E. Diza-Mataftsi,
C. Tsantali, E. Roilides (Thessaloniki, GR)
Objectives: Candida albicans (CA) forms bioﬁlms (BF) on implanted
medical devices, and most commonly on intravascular catheters. BF
constitute a niche where CA is protected from innate immunity, an
important component of which are monocytes (MNCs), and antifungal
agents. Moreover, CA BF have shown resistance to a variety of antifungal
agents but susceptibility to caspofungin (CAS). Because little is known
about the effects of host defences against Candida BF, we aimed to study
the antifungal activity of human MNCs alone or combined with CAS
against CA BF in comparison to their planktonic (PL) counterparts.
Methods: CA-M61, a documented bioﬁlm-producing CA intravascular
catheter isolate, was used. PL cells were grown in YNB at 37ºC
overnight. BF were grown on silicone elastomer disks in 96-well plates
at 37ºC with shaking for 48 h. THP1 monocytic cell line was used as
MNC source. MNCs (MNC/target ratios 1:1 and 5:1) and CAS (0.0625
and 0.015mg/l) alone or in combination were incubated with mature BF
and PL cells in RPMI-1640 with 10% fetal bovine serum at 37ºC, 5%
CO2 for 20 h. Plain BF and PL cells served as controls. Percent damage
of BF and PL cells was then assessed by XTT colorimetric micro assay
as reduction in the metabolic activity after incubation for 30 min at
450 nm with reference wavelength at 690 nm. Statistical analysis (n = 7)
included ANOVA and post hoc analysis (P< 0.05).
Results: MNC-induced BF damage was signiﬁcantly decreased com-
pared to PL cells at 5:1 ratio (mean±SE, 31.5±3.5% vs 43.6±3%,
p = 0.01) but not at 1:1 ratio. CAS-induced damage to BF was
lower than that to PL cells at 0.0625mg/l (57.7±4.1% vs 75±11%,
p< 0.001). The damage induced by MNCs at 5:1 combined with
CAS, at both concentrations, on BF was lower than that on PL
cells (71.3±5.2% vs 85±6%, p = 0.001; 65.5±9.3% vs 82.3±6.5%,
p = 0.008, respectively). While an additive effect between MNCs at 5:1
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ratio and CAS at 0.015mg/l was noted against PL cells (82.2±6.5%
vs 43.6±3%, p< 0.001 and 82.2±6.5% vs 62.8±11%, p< 0.05), no
signiﬁcant collaboration between MNCs and CAS was observed against
BF at any MNC/target ratio and any CAS concentration used.
Conclusions: C. albicans BF are more resistant than PL cells of
CA to MNCs, to CAS and to the combination of MNCs with CAS.
While MNCs and CAS exhibit an additive effect against PL, no
signiﬁcant collaboration between MNCs and CAS exists against BF. The
mechanism(s) behind resistance of CA BF to host defences need to be
determined.
P627 Effect of disinfectants and caspofungin against planktonic
and sessile cells of Candida spp.
S. Tobudic, C. Kratzer, W. Graninger, A. Georgopoulos (Vienna, AT)
Objectives: The aim of this study was to evaluate the activity of
3 different disinfectants chlorhexidine digluconate, Akacid plus® and
hydrogen peroxide compared to the antifungal caspofungin against
planktonic and sessile cells of Candida spp.
Methods: As test strains 40 clinical isolates of Candida spp. including
C. albicans, C. krusei and C. tropicalis were used. The activity of
active substances was determined against planktonic cells according to
CLSI guidelines for antifungals using broth microdilution method. For
antifungal susceptibility testing of sessile cells, isolates were incubated
overnight in yeast peptone dextrose resuspended in RPMI 1640 to a
cellular density equivalent to 1.0×106 CFU/mL. Cells were grown for
48 h in 96-well-microtiter plates, and then treated with 100 ml of Akacid
plus®, chlorhexidine and hydrogen peroxide at a ﬁnal concentration of
0.25, 0.5, 1, 2 and 4% compared to caspofungin at a concentration of 64,
128, 256 and 512mg/l for 48ºC at 35ºC. The cells were ﬁxed and stained
with crystal violet. The mean optical density was used for quantiﬁcation
using a routine microtiter-plate-reader at 490 nm. Additionally, fungal
growth following antimicrobial treatment was examined.
Results: MICs of Akacid plus® and caspofungin against planktonic
cells of Candida spp. were comparable and reached MIC values of
0.03−8mg/l, whereas MICs of chlorhexidine and hydrogen peroxide
ranged from 16 to 32mg/l and from 128 to 256mg/l. Low concentrations
of caspofungin at 64mg/l caused a 62% reduction of the sessile cells
of Candida spp. Treatment with 0.25% chlorhexidine and Akacid plus®
led to reduction of the sessile cells in 59 and 74%, whereas hydrogen
peroxide showed no effect.. No viable cells of Candida spp. were detected
in bioﬁlms treated with 0.25% Akacid plus® and chlorhexidine or 0.1%
caspofungin.
Conclusion: Caspofungin and cationic antimicrobials showed high
activity against sessile and planktonic cells of Candida spp., whereas
hydrogen peroxide was found to be ineffective.
P628 Response of Candida albicans bioﬁlms to bacterial factors
L. Rossi, S. Cagnacci, E. Tavella, O. Muratore, R. Corvo`, A. Marchese,
E. Debbia (Genoa, IT)
Introduction: Candidoses affecting immunocompromised patients are
likely to be associated with certain commensal bacteria attracted by the
inﬂammatory microenvironment. Although the precise outcome of such
a cohabitation is not known, a plausible scenario would credit bacteria
for inﬂuencing the survival of Candida spp. To gain more insights
into this aspect of fungal infection, we are looking at the response of
Candida bioﬁlms to colonisation by bacteria normally present in the
human microﬂora.
Methods: Candida albicans isolated from an immunocompromised
patient were grown in collagen gel to produce multiple bioﬁlms. Condi-
tioned media from Pseudomonas aeruginosa (CMPa), Staphylococcus
aureus (CMSa) and Lactobacillus casei (CMLc) were ﬁltrated and
freezed as stock solutions. After 5 hrs in collagen gel, nascent Candida
bioﬁlms were treated once with the several conditioned media for
approximately 10 hrs. Relevant morphological parameters were detected
and cell survival/gel was determined by the CFU test.
Results: The value of CFU in the control group was 1×107 cells/mL or
above. Conditioned media affected differently the survival of C. albicans.
Speciﬁcally, 90% of Candida cells died out following treatment with
CMPa. CMLc was somewhat less effective in that approximately 50%
of the cells survived the treatment. However, CMSa did not damage
Candida cells, that displayed a value of CFU comparable to that of the
control group. CMPa implemented ﬁlamentation of Candida bioﬁlms,
resulting in what it appeared a selective inhibition of yeast forms. CMLc
and CMSa did not interfere with this process.
Conclusions: The present results indicate that P. aeruginosa releases
factors capable of inhibiting Candida bioﬁlms in collagen gel. While
the content of CMPa was not analysed, most reports agree that
aryl homoserine lactones, quorum sensing (QS) factors regulating the
homeostasis of P. aeruginosa bioﬁlms, are mainly responsible for the
biological activity of this Gram-negative bacteria. This suggests that
certain bacterial QS factors could help to keep under control fungal
bioﬁlms, an observation worthy of further investigation. The ﬁnding
that Lactobacillus casei, a probiotic, can inhibit the growth of Candida
albicans has clinical relevance, in that the association of probiotics with
existing antimycotic drugs may provide a most effective procedure to
cure candidoses. (Supported by Pﬁzer Italia).
P629 In vitro activity of essential oils and their major components
against Candida albicans yeasts growing planktonically and
as bioﬁlms
S. Dalleau, E. Cateau, T. Berges, J. Berjeaud, C. Iimbert (Poitiers, FR)
Objectives: Candidiasis can be associated with the formation of bioﬁlms
on bioprosthetic surfaces and the intrinsic resistance of C. albicans
bioﬁlms to the most commonly used antifungal agents has been
demonstrated. In this study, we report on the antifungal activity of 13
terpenes and essential oils on C. albicans growing planktonically or as
bioﬁlms.
Methods: The strain ATCC 3153 of C. albicans was used. Nine
terpenes (carvacrol, citral, eucalyptol, eugenol, farnesol, geraniol,
linalool, menthol and thymol) and 4 essential oils (tea tree, palmarosa,
oregano and rosemary) were tested. The anti-bioﬁlm activity of the tested
compounds was evaluated using an in vitro model of C. albicans bioﬁlm
associated with polystyrene surfaces and the metabolic activity of yeasts
within the bioﬁlm was assessed with XTT method.
Results: The majority of the tested compounds showed a signiﬁcant
antifungal activity (MIC< 0.4mg/mL). Two essential oils exhibited
an “intermediate” antifungal activity – tea tree (MIC= 2.25mg/mL)
and rosemary (MIC= 1.10mg/mL) – and two terpenes (farnesol
and eucalyptol) were not efﬁcient against planktonic C. albicans
(MIC> 74mg/mL).
Citral, eugenol, palmarosa and rosemary induced a signiﬁcant inhibition
of the metabolic activity of the yeasts included in the C. albicans
bioﬁlm (p< 0.001) when added at a concentration <2.25mg/mL during
the early step of the fungal bioﬁlm growth. The concentration needed
for carvacrol, geraniol, linalool, oregano and thymol to achieve a
signiﬁcant reduction of the bioﬁlm development was <5mg/mL. The
higher efﬁcient concentrations were obtained for farnesol and menthol
and corresponded to 35.5mg/mL and 17.8mg/mL respectively.
Conclusion: This study demonstrated the efﬁciency of almost all the
tested terpenes and essential oils to inhibit the bioﬁlm growth which
could therefore represent good candidates in the prevention of bioﬁlms
associated with implanted medical devices.
P630 Aspergillus fumigatus bioﬁlms are refractory to antifungal
challenge
E. Mowat, J. Butcher, C. Williams, G. Ramage (Glasgow, UK)
Background: Aspergillus fumigatus may cause infections in im-
munocompromised patients including patients with cystic ﬁbrosis.
A. fumigatus conidia are readily inhaled and are not cleared by the innate
immune system. Respiratory infections are typiﬁed by the presence of
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dense ﬁlamentous networks of hyphae in the pulmonary cavity and
airways. These fungal mucus plugs are inherently difﬁcult to treat, and
have characteristics which resemble bioﬁlms.
Objectives: To develop an in vitro A. fumigatus bioﬁlm model to assess
the ability of antifungal agents to inhibit and/or kill these structures.
Methods: Spores were collected from AF293 and standardised at various
densities in RPMI medium and grown in 96-well polystyrene plates.
Bioﬁlm growth kinetics were then observed over 48 h (1, 2, 4, 6,
24 and 48 h) microscopically and by both metabolic (XTT) and a
biomass (crystal violet) assays. Developing bioﬁlms were visualised
using confocal laser scanning microscopy (CLSM) and electron scanning
microscopy (SEM). The speciﬁc effects of voriconazole (0.125–
256mg/mL) was also examined to measure its effectiveness pre- and
post challenge.
Results: Optimal spore concentration for conﬂuent bioﬁlms after
24 h was determined to be 1×106 spores/mL. The initial bioﬁlm
growth kinetics involved an adherence stage (0–4 h); development of a
monolayer of cells (4–8 h); and formation of a three dimensional bioﬁlm
structure after 24 h. Voriconazole and caspofungin were ineffective
against mature bioﬁlms. Amphotericin B was effective between 0.5 –
1.0mg/mL, however 90% killing was never achieved. When voriconazole
was added at the initial stages of adhesion, a dose dependant effects was
observed at therapeutic concentrations.
Conclusions: We have developed a robust reproducible in vitro
A. fumigatus bioﬁlm model was developed. Early exposure of spores
to voriconazole prevented ﬁlamentation and bioﬁlm formation. Overall
voriconazole potentially offers excellent prophylactic properties against
invasive aspergillosis.
Viral infections in the immunocompromised
host
P631 Community respiratory virus infections in patients with
haematological malignancies
V. Chebotkevich, A. Volkov (St.-Petersburg, RU)
Objectives: Viral infections are the important cause of morbidity and
mortality in immunocompromised patients (pts) with haemotological
malignancies. With regard to these agents the focus has been on herpes
viruses, particularly human Cytomegalovirus (CMV). The studying of
last decade showed that community respiratory viruses also play the
important role in serious respiratory illnesses in pts with haemoblastosis.
The current study was designed to determine the frequency and clinical
features of respiratory viral infections in pts with different forms
leukaemia.
Methods: Our study included 91 pts with different forms haemoblas-
tosis. The patients were studied during the episodes of respiratory
illnesses. Material – blood and nasal swabs were studied by means of
polymerase chain reaction (PCR) with primers to the batteries of viral
genomes: Adenoviruses, Respiratory syncytial virus (RSV), Inﬂuenza
type A and B, Parainﬂuenza type 3 and Coronaviruses.
Results: The signal of Adenoviruses was detected in nasal swabs
in 12 (13.1%) cases of respiratory illnesses, RSV in ﬁve (5.5%)
cases, Inﬂuenza A in ﬁve (5.5%) cases, Inﬂuenza B in two (2.2%),
Parainﬂuenza type 3 in eight (8/8%) and Coronaviruses in 13 (14.3%)
cases. In blood the signal of Adenoviruses was detected in 5.4% cases.
It is interesting that in all these cases the signal in nasal swab was
not founded. In one case Inﬂuenza B virus was founded simultaneously
in blood and nasal swabs. The main clinical symptoms of respiratory
illnesses were the chill (87.5%), fever (87.5%), mostly higher then 38ºC,
lymphocytosis – 43.7%. In the 50% patients respiratory illnesses were
complicated by pneumonia. We did not ﬁnd any clinical peculiarities of
the community respiratory illnesses of different viral etiology.
Conclusions: The community respiratory viral infections are serious
illnesses in pts with haemoblastosis. These infections must be controlled
as well as CMV and other herpes infections. PCR is adequate method
of monitoring viral infection in this group of patients.
P632 Viral infection is responsible for acute renal dysfunction
and chronic allograft lesions in paediatric renal-transplant
recipients: a prospective study
L. Barzon, M. Pacenti, M. De Pieri, L. Murer, G. Palu` (Padua, IT)
Objectives: Follow-up evaluation of paediatric renal-transplant recipi-
ents in order to assess the contribution of viral infection to acute and
chronic nephropathy and allograft rejection.
Methods: The presence of viral DNA (i.e., EBV, CMV, HHV6, HHV7,
HHV8, VZV, BKV, JCV, SV40 and parvovirus B19) and viral load
was prospectively investigated by quantitative real-time PCR methods
in the peripheral blood, urine, and in allograft biopsies obtained from
a series of 77 consecutive children (31F, 46 M, R/D mean age:
11.9±7.6/11.9±5.3 years) undergoing kidney transplantation in the
period 2000–2004. Immunosuppressive therapy included basiliximab,
steroids, FK506 or cyclosporinA ± mycophenolate mofetil. Follow-up
allograft biopsies were performed at the time of transplantation and
at 6, 12, and 24 months post-transplantation; diagnostic biopsies were
performed in 11 patients because of acute renal dysfunction. Virological
ﬁndings were compared with histological analysis according to Banff 97
criteria.
Results: At the time of transplantation, the allografts were positive for
parvovirus B19 in 33% of cases, HHV6 23%, BKV 5%, SV40 3%. The
cumulative incidence of chronic lesions was 29%, 52%, and 83% at 6, 12,
and 24 months post-transplantation, whereas the cumulative incidence of
viral DNA detection in biopsies was 63%, 69% and 71%, respectively
(coinfections in 25%, 22%, 24%, respectively; the most frequent: EBV,
HHV6, BKV, B19). The prevalence of viral genomes was higher in
biopsies showing acute (Banff III, IV) or chronic (Banff V) lesions than
in normal histology cases, but viral infection or histological damage did
not correlate with renal function tests. Moreover, children who developed
chronic lesions generally had early and persistent kidney infection
(especially from BKV, B19, EBV). Viral-genomes were isolated in
7/11 biopsies performed for acute renal dysfunction: 2 tubulo-intersitial
nephropathy (BKV), 3 thrombotic microangiopathy and 1 acute vascular
rejection (parvovirus B19), and 2 acute rejection (EBV). A correlation
between virological ﬁndings in biopsies and viral DNA detection in blood
and urine was observed, although the rate of positive tests was higher in
biopsies. Evalution of test predictivity is ongoing in a long-term follow-
up study.
Conclusions: Viruses not only are responsible for acute renal
dysfunction in kidney transplanted children, but also contribute to the
development of chronic allograft lesions due to persistent infection.
P633 Whole blood real-time PCR for cytomegalovirus DNA
quantiﬁcation: analysis of PCR data and pp65 antigen test
in a cohort of solid-organ transplant recipients
T. Allice, F. Cerutti, F. Pittaluga, S. Varetto, S. Gabella, A. Franchello,
M. Rinaldi, V. Ghisetti (Turin, IT)
Cytomegalovirus (CMV) is a major opportunistic agent in solid
organ transplantation (SOT). Pre-emptive therapy and a strict infection
monitoring with highly sensitive methods have signiﬁcantly decreased
CMV morbidity and mortality. Recently introduced real-time PCR tests
for routine CMV DNA quantiﬁcation require correlation studies with
pp65-antigen test as the gold standard. Moreover, there is no consensus
as the most appropriate blood compartment (i.e. whole blood, leukocytes,
plasma) for PCR test.
Aims: 1) to study the correlation between pp65-antigen test and CMV
DNA as quantiﬁed by real-time PCR in whole blood (WB) in a cohort
of SOT recipients and 2) the identify a CMV DNA cut-off level for
pre-emptive anti-CMV therapy.
Methods: WB samples (n = 397) from 41 asymptomatically infected
patients (18/41 undergoing pre-emptive therapy with ganciclovir) were
monitored the ﬁrst year after SOT by pp65 antigen test and real-time
PCR for the UL123 gene, IE1 exon 4 (Nanogen, I). Extraction was
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carried out from 220 ul of WB with a fully automated system based on
nucleic acid silica-gen afﬁnity (BioRobot 9604, Qiagen, I).
Results: Pp65 and CMV DNA were highly correlated (r = 0.750, 78%
concordant samples). CMV DNA level was much higher in pre-emptive
treated patients than in not treated ones (mean+SD: 5.8+0.8 log10
copies/mL vs. 4.5+0.6, p< 0.0001). Pre-emptive therapy was started
for pp65 values >90 positive cells, corresponding to a median CMV
DNA level of 5.6 log10 copies/mL (mean+SD: 5.4+0.8, range 3.6−6.8).
According to pp65 positive cells/200,000 examined cells of 0, 1−10,
11−50, 51–100 and >100, median levels of CMV DNA in WB were 3.8,
3.9, 4.6, 5.2 and 5.7 log10 copies/mL, respectively. A plasmid carring the
UL123 viral ampliﬁed gene was used to probe the couppled extraction
and real-time PCR platform sensitivity (100% at 3 copies/ul from the
extraction step, 100% at 2 copies/ul from the ampliﬁcation step) and
reproducibility (between assay CV% <19).
Conclusion: CMV DNA evaluation in WB by real-time PCR
signiﬁcantly simpliﬁes and accelerates the production of a reliable
quantiﬁcation for clinical purposes with a good correlation with pp65
antigen tests, excellent sensitivity and reproducibility. Levels of DNA
>5.4 log10 copies/mL that is >250,000 copies/mL are highly suggestive
of pre-emptive anti-CMV therapy.
P634 Relevance of respiratory viruses among adult immunocom-
promised patients with community-acquired pneumonia
M. Camps, T. Pumarola, A. Moreno, C. Cervera, A. Torres,
M.T. Jime´nez de Anta, M.A. Marcos (Barcelona, ES)
Background: Community-acquired pneumonia (CAP) is a serious lower
respiratory tract infection associated with signiﬁcant morbidity and
mortality in immunocompromised patients. The present study evaluated
the clinical spectrum of CAP in immunocompromised hosts, the role of
respiratory viruses (RVs), as well as the proﬁtability of viral diagnostic
methods.
Methods: Over a one-year period 92 immunocompromised patients with
CAP were prospectively evaluated for the presence of viral, bacterial and
other pathogens. A nasopharyngeal swab was collected to study RVs
which were processed by indirect immunoﬂuorescence assay (IFA), cell
culture and PCR. We deﬁned 4 groups according to aetiology of CAP:
group 1 (bacterial or Pneumocystis jiroveci), group 2 (viral), group 3
(mixed) and group 4 (unknown aetiology).
Results: In 61 (66%) of the 92 patients the aetiological diagnosis
was achieved. Respiratory infection was due to bacteria or P. jiroveci
in 38 (41%) cases of CAP, 12 (13%) were due to a virus and
11 (12%) were mixed infections. The most frequent pathogen detected
was Streptococcus pneumoniae in 29 (48%) followed by rhinovirus
(RNV) detected in 11 (18%) cases. PCR identiﬁed 95% of RVs. Medical
records did not show signiﬁcant differences among aetiological groups.
Four patients (4%) required mechanical ventilation and ﬁnally died, two
of whom had a RNV as the sole aetiological agent.
Conclusion: The high incidence of RV detected among the immunocom-
promised population studied emphasizes the need for further research on
RVs as an important pathogen involved in CAP, with PCR being the most
sensitive and rapid technique available to detect these viruses.
P635 HHV-7 primary infection in solid organ transplant recipients
A. Anton, C. Esteva, C. Cervera, T. Pumarola, A. Moreno, M.T. Jime´nez
de Anta, M.A. Marcos (Barcelona, ES)
Objectives: We aimed to study the seroprevalence of HHV-7 infection
in solid organ transplant recipients (SOTR). The incidence of HHV-7,
HHV-6, and CMV viraemia after solid organ transplantation among
HHV-7 seronegative patients who had HHV-7 seroconversion during
the ﬁrst six months of follow-up was also studied.
Methods: Ninety three SOTR (5 heart, 1 kidney-heart, 28 liver, 2
pancreas, 6 kidney-pancreas and 51 kidney) were included. Plasma and
whole blood samples were collected immediately prior to transplantation
and at 7, 14, 21, 28, 45, 60, 75, 90 and 180 days post-transplantation.
Anti-HHV-7 IgG antibodies in plasma were assessed by indirect
inmunoﬂorescence assays (Advanced Biotechnologies Inc) immediately
prior to transplantation, three and six months post-transplantation. Viral
DNA was extracted from 200 microL plasma and from 50 microL
whole blood using afﬁgene® DNA extraction kit (Sangtec, Bromma,
Sweden). An in-house SYBR Green I real-time quantitative PCR assay
was performed to detect HHV-7 DNA (detection limit: 5−10 copies/
reaction) in blood on the Mx3000P instrument (Stratagene, La Jolla,
USA). The PCR primers amplify a speciﬁc region from HHV-7 U37 gene
sequence. A standard curve was constructed from the threshold cycle
values obtained from serial diluted positive control plasmids, cloned
into pGEM-T Easy Vector. CMV viral load was determined in plasma
by the PCR kit afﬁgene® CMV VL which utilises an ELISA based
detection. HHV-6 load in whole blood was detected using the real-time
PCR system afﬁgene® HHV-6 trender on the Mx3000P instrument.
Results: Seventy-one (76%) patients had IgG antibodies against HHV-7
detected prior to transplantation. Of 22 (23%) HHV-7-seronegative
patients, 5 seroconverted, four at 3rd month and one at 6th month of
follow-up. HHV-7 DNA was detected (3rd week of follow-up) in only
one of the 5 patients who had HHV-7 seroconversion. In this patient,
HHV-6 was simultaneously detected. Of the 4 remaining patients with
HHV-7 seroconversion, HHV-6 DNA was also detected in one and CMV
DNA was detected in two, while no human beta-herpesvirus DNA was
identiﬁed in one patient.
Conclusions: While the seroprevalence of HHV-7 infection in SOTR
was high, the incidence of HHV-7 among seronegative patients who had
HHV-7 seroconverted during the ﬁrst six months of follow-up was very
low. Seroconversion may not only indicate HHV-7 replication but also
other human beta-herpesviruses viraemia. Further analysis are necessary.
P636 Stratiﬁed treatment of respiratory syncycital virus in
haematopoetic stem cell transplanted patients
N. Khanna, A. Widmer, M. Decker, I. Steffen, D. Heim, M. Weisser,
A. Gratwohl, U. Flueckiger, H.H. Hirsch (Basle, CH)
Objectives: Respiratory Syncycital Virus (RSV) causes signiﬁcant
mortality in patients after stem cell transplantation (HSCT) when
upper respiratory tract infections (RTI) progress to lower RTI and
pneumonia. Higher immunodeﬁciency (ID) is at high risk for lower
RTI. Current guidelines recommend treatment of RSV pneumonia with
ribavirin (RBV) aerosol inhalation, but impact on mortality has been
limited. We evaluated based on standardised protocol treatment using
oral or intravenous RBV (10mg/kg tid), IVIG (0.5 g/kg 3x/week) and
pavilizumab (PAB; 15mg/kg single dose i.v.) according to low or high
risk of ID.
Methods: Adult HSCT patients at the University Hospital of Basel
between February 2002 and March 2006 were included if RSV was
detected by antigen (AG), PCR or culture (Cult) in nasopharyngeal
aspirate or bronchioalveolar lavage. High ID was deﬁned as HSCT within
the last 6 months, T-cell depletion, B-cell depletion, GvHD > grade
2, leukopenia <2000/uL, lymphopenia <100/uL, or hypogammaglobuli-
naemia. Patients were stratiﬁed to Group-A: low ID or Group-B: high
ID.
Results: In the study period, 16 patients (2 autologous, 14 allogeneic
HSCT) were identiﬁed. 9 (56%) presented as outpatients. RSV infection
was detected as positive with AG+Cult+PCR in 4/16; AG+Cult 4/16;
AG+PCR 1/16; Cult+PCR 3/16; Cult 2/16; PCR 2/16. 8 (50%) had an
upper RTI, 8 (50%) lower RTI. Overall mortality of RSV was 5 (31%),
all with lower RTI. Patients in Group-A: 2 (13%); both with upper
RTI, received no treatment, and survived without developing lower
RTI. Group-B: 14 (87%); 6 with upper RTI, 1/6 received IVIG, 2/6
IVIG+RBV, and 3/6 IVIG+RBV+PAB. No lower RTI developed and all
6 patients survived. Lower RTI was found in 8/14 patients. Treatment
(survival) was as follows: 3/8 IVIG+RBV (1/3); 1/8 IVIG+PAB (1/1); 4/8
IVIG+RBV+PAB (1/4). Haemolytic anaemia resulting from oral RBV
was found in 1 patient. In group B patients, there was only a trend for
better survival using PAB, but these data are limited by small sample
size and strong impact of lower RTI.
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Conclusion: RSV infection limited to the upper RTI has a better
outcome. In patients with high ID treatment may prevent progression
to lower RTI and death. In patients with high ID and established lower
RTI intervention may be less efﬁcient. The results of PAB treatment
should be conﬁrmed in a larger trial.
P637 Quantitative CMV PCR in allogenic stem-cell transplant
patients
N. Portocarrero, A. Moriente, D. Monclus, E. Lomas, P. Sanchez,
C. Sanchez, L. Carden˜oso (Madrid, ES)
Objective: To assess the clinical value of a commercial quantitative
plasma CMV-PCR assay (COBAS AMPLICOR CMV MONITOR test,
Roche Molecular System) in allogeneic SCT patients by comparing the
results obtained with the PCR and the antigenaemia.
Methods: All patients were monitored weekly antigenaemia and PCR. A
total of 1877 blood samples from 94 patients were tested prospectively.
CMV seropositive patients (or negative with a seropositive donor< 9
received high dose of acyclovir as prophylaxis. PCR was considered
positive when more or equal 400 DNA copies/mL were detected.
Antigenaemia was considered positive when one or more positive cells
were detected.
Result: All CMV seronegative patients with a seronegative donor were
antigenaemia and PCR negative The total patients in study (94), 39 had
a positive antigenaemia and/or PCR, with a total of 71CMV infection
episodes. None developed CMV disease. PCR detected 49 out of 71
CMV episodes (69%). Overall there were 115 positive antigenaemia
(belonging to 35 patients): 65 were PCR positive, 49 PCR negative and
1 PCR inhibited. Four patients (6 episodes) had a positive PCR with
a negative antigenaemia. For samples with less than 600 copies/mL a
manual calculation of the number of copies was retrospectively done
(using a new cut-off). With this lower cut-off, PCR detected 62 out of
71 episodes (87, 4%).
Conclusion: Quantitative CMV PCR assay showed a lower sensibility
for de detection of CMV infection in allogeneic SCT compared with
antigenaemia. The PCR sensibility was increased without a decrease in
the speciﬁty, lowering the cut-off.
P638 Possible BK virus outbreak in haematopoietic stem cell
transplant recipients
M. Sonmezoglu, S. Yirmibescik, C. Obek, D. Colak, T. Kocagoz, Y. Koc
(Istanbul, Antalya, TR)
BK virus (BKV) is a human polyomavirus that has been implicated as a
common cause of late-onset haemorrhagic cystitis (HC) in patients who
have undergone bone marrow transplantation. BKV has also been shown
to be a signiﬁcant cause of tubulointerstitial nephritis, vasculopathy, and
allograft dysfunction in kidney transplant recipients.
Here we describe ﬁve cases of BKV-associated HC in hematopoietic
stem cell transplant recipients in a short period. The patients (2 chronic
myeloid leukaemia with blastic transformation, 1 Hodgkin lymphoma,
1 acute lymphocytic leukaemia and 1 thalassaemia intermedia) who
underwent allogeneic stem cell transplantation (one of them unrelated)
developed severe bladder spasms and gross hematuria 46–146 days
after receiving immunosuppressant therapy (4 days Busulfan). Physical
examination revealed marked suprapubic tenderness, continuous and
refractory haemorrhagic cystitis, which required analgesics, continuous
bladder irrigation, and blood transfusions. Weekly plasma and urine
samples were tested for BK virus DNA by polymerase chain reaction
(PCR). PCR of plasma and urine samples yielded results positive for
BKV. We administered weekly infusions of 5mg/kg cidofovir patient
in an attempt to clear viruria. Leﬂunomid were added to improve the
condition. Nephrotoxicity occurred in one patient after receiving second
dose of cidofovir and later developed renal failure and required daily
dialysis. The level of viruria persisted for 4−8 weeks after administration
of cidofovir. BKV-associated haemorrhagic cystitis is common in
patients following bone marrow transplantation and immunosuppressant
therapy. We report a possible HC outbreak due to BK virus in a bone
marrow transplant unit seen only in 2 and a half month period and ceased
thereafter.
P639 CMV monitoring of transplant patients – a ten-year
experience
M. Baier, J. Ro¨del, U. Lang, K. Boden, E. Straube (Jena, DE)
Background: To prevent CMV infection in immuno-compromised
patients, in particular after solid organ or bone marrow transplantation
regular monitoring is recommended using pp65 antigen detection for
screening and quantitative CMV PCR for conﬁrmation or in cases of
low cell count.
Methods: In our now 1375-bed-university hospital pp65 detection has
been performed since 1996. Quantitative CMV PCR was introduced in
1999. Patient data were extracted from lab database, combined with
clinical data and subsequently analysed.
Results: Till November 2006 a total of 35.741 pp65 antigen tests were
performed with a share of kidney transplant patients (NTX) of 32.7%,
respectively of liver (LTX): 22.2%, bone marrow (KMT): 18.1%, heart
transplantation (HTX): 16.4% and of other patients: 10.5%. A total of
4.424 quantitative CMV PCR tests were performed (NTX: 57.8%, LTX:
2.5%, KMT: 15.2%, HTX: 5.8%, others: 18.7%). The number of pp65
tests increased on average 13.4% per year (total: 8 in 1996, 1008 in 1997,
5200 in 2006, mean 1997–2006: 3250/year). The number of quantitative
PCR tests peaked in 2000 with 1119 tests but stabilised in the last 6 years
on 500 test/year (mean 2001–2006).
Over the 10 year observation period on average 7.9% of all pp65 tests
were positive (13.6% in 1997 and 3.64% in 2006), showing a mean
decrease in positivity rate of 12.8% per year. From NTX patients 7.9%
of samples were positive, respectively 9.3% from LTX, 7.7% from KMT,
6.9% from HTX patients and 7.6% from others. Quantitative CMV PCR
was positive on average in 10.9% of tests ranging from 4.6% in 1999
to 15.4% in 2003 with no trend in time. NTX patients were in 11.5%
PCR positive, LTX in 10.0%, KMT in 7.6%, HTX in 14.4% and others
in 9.9% respectively. In 3982 cases results obtained with both methods
were available (239 (6%) positive and 3475 (87.3%) negative in both,
190 (4.8%) were pp65 negative and PCR positive and 78 (2.0%) vice
versa). In 183 cases with 1 pp65 positive cells/100.000 leucocytes
only 60% (n = 110) were PCR positive compared to 134 cases with
>1/100.000 cells with 96% (n = 129) PCR positive results. In 40 cases
with 500 CMV copies/mL plasma 32% (n = 13) were pp65 positive
compared to 389 cases with >500 copies/mL with 58% (n = 226) positive
pp65 results.
Conclusion: In our setting CMV antigen detection and PCR was well
established as useful tools for post transplant monitoring with almost
similar sensitivity. Clinical impacts and economical aspects will be
discussed.
P640 Fatal viral opportunistic infections and Epstein-Barr virus
positive large B-cell lymphoma after alemtuzumab treatment
for a refractory Sezary syndrome
N. Roch, D. Salameire, S. Courby, F. Orsini-Piocelle,
B. Pegourie-Bandelier, R. Gressin, C. Dumontet, N. Sturm, F. Berger,
A. Toffart, J. Guellerin, G. Gereige, V. Hincky, O. Epaulard, J. Brion,
P. Pavese, S. Larrat, P. Morand, J. Stahl (Grenoble, Lyon, FR)
Objectives: Alemtuzumab (Campath-1H) is a humanised monoclonal
antibody binding to CD52, an antigen expressed on normal and malig-
nant B-lymphocytes and T-lymphocytes. This immunotherapy is effective
in the treatment of relapsed or refractory B-cell chronic lymphocytic
leukaemia. It has been used in others lymphoproliferative disorders
like Sezary syndrome, in autoimmune cytopenias, and in bone marrow
and kidney transplantations. The depletion of lymphocytes induced by
alemtuzumab can be profound within the ﬁrst month of therapy and the
reconstitution of the lymphoid cell line can be delayed for up to two
years. Infectious complications are frequent. Viral, bacterial, fungal and
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parasitic infections have been described. Cytomegalovirus reactivation is
the most common opportunistic infection and recommendations exist to
prevent this complication. Others infections were rarely reported.
Methods: We report a case of multiple opportunistic infections after
alemtuzumab treatment in a patient with refractory Sezary syndrome.
To our knowledge these have been rarely, if ever, reported before.
Results: After three weeks of treatment with alemtuzumab, cy-
tomegalovirus disease developed, successfully treated with ganciclovir.
Campylobacter septicaemia, Epstein-Barr virus positive large B-cell
lymphoma, adenoviral infection and enteroviral disease appeared
respectively at seven, eight, thirteen and eighteen weeks of treatment. In
spite of treatment with cidofovir and rituximab evolution of adenoviral
disease and Epstein-Barr virus positive large B-cell lymphoma was
fatal. The patient died four months after the start of alemtuzumab.
Lymphopenia was profound during follow-ups. To our knowledge only
two adenoviral diseases during alemtuzumab monotherapy were reported
and both were fatal. Epstein-Barr virus positive large B-cell lymphoma
after alemtuzumab treatment has been described previously in four
observations but never in patients with Sezary syndrome. Campylobacter
septicaemia and enteroviral infection have never been reported before.
Conclusion: This conﬁrms the large panel of possible infections during
treatment with alemtuzumab. This draws attention to the fact that also
viruses other than cytomegalovirus need to be considered in patients with
fever of unknown origin while on alemtuzumab treatment. Attention will
be focused on these serious complications. Report cases are necessary
for a better knowledge of possible opportunistic infections during
alemtuzumab treatment.
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P641 Invasive fungal infection as the most common cause of
cavitary lung lesions in HIV-infected patients in Taiwan
H-Y. Sun, C-C. Hung, M-Y. Chen, S-M. Hsieh, W-H. Sheng, S-C. Chang
(Taipei, TW)
Objectives: Cavitary lung lesions have not been systemically investi-
gated in patients with HIV infection before. This study aimed to analyse
the etiology of cavitary lung lesions in HIV-infected patients enrolled in
a prospective cohort study.
Methods: Medical records, radiologic and microbiologic data of cases
of cavitary lung lesions diagnosed between June 1994 and June 2006
were reviewed using a standardised case record form. During the study
period, stepwise investigations were performed to identify the aetiology
of cavitary lung lesions, which included microbiologic cultures, chest
sonography or computed tomograpgy-guided aspiration and biopsy.
Clinical samples were cultured for bacteria, fungi and mycobacteria.
Results: During the 12-year study period, 61 of 1372 (4.4%) HIV-
infected patients, 61.7% men having sex with men, 27.3% heterosexuals,
and 5.3% injecting drug users, were diagnosed with cavitary lung lesions:
7 of 175 (4.0%) in the pre-HAART era and 54 of 1197 (4.5%) in the
HAART era (p = 0.95). Of the 61 patients (56 males) with a median
age of 34 years (range, 23−81 years), CD4 count was 25×106 cells/L
(range, 1–543×106 cells/L) at the diagnosis of cavitay lung lesions.
Fungi caused 31 of the 61 (50.8%) cavitary lung lesions, followed by
bacteria (11; 18.0%), tuberculosis (7; 11.5%), and Mycobacterium avium
complex (7; 11.5%). Of the 31 cases of fungal pneumonia, 16 (51.6%)
were caused by Penicillium marneffei, 11 (35.5%) by Cryptococcus
neoformans, 3 (9.7%) by Aspergillus spp., and 1 (3.2%) by unidentiﬁed
fungus. Compared with 7 (3.5%) of 199 patients with tuberculosis
diagnosed during the study period, 16 of 31 (51.6%) patients with
P. marneffei infection and 11 of 64 (17.2%) patients with cryptococcosis
developed cavitary lung lesions (p< 0.0001). Median CD4 count of
the 7 patients with cavitary lung lesions due to tuberculosis (110×106
cells/L) was signiﬁcantly higher than that of 16 patients with P. marneffei
infection (7.5×106 cells/L) and 11 with cryptococcosis (35×106 cells/L).
Conclusion: Our ﬁndings suggest that invasive infections due to endemic
fungi were the most common cause of cavitary lung lesions in patients
at late stage of HIV infection in Taiwan.
P642 Risk of recurrent non-typhoid Salmonella bacteraemia in
HIV-infected patients in the era of highly active antiretroviral
therapy and increasing trends of quinolone resistance
C.C. Hung, M-N. Hung, P-R. Hsueh, M-Y. Chen, S-M. Hsieh,
W-H. Sheng, H-Y. Sun, S-C. Chang (Taipei, TW)
Objectives: This study aimed to assess the trends of quinolone resistance
and the risk of recurrent non-typhoid Salmonella (NTS) bacteraemia
in HIV-infected patients receiving highly active antiretroviral therapy
(HAART).
Methods: Medical records and microbiologic data of cases of NTS
bacteraemia between June 1994 and June 2006 were reviewed using a
standardised case record form. During the study period, treatment of NTS
bacteraemia was ceftriaxone for 7−14 days followed by ciproﬂoxacin as
secondary prophylaxis. While secondary ciproﬂoxacin prophylaxis for
NTS bacteraemia would not be discontinued in the pre-HAART era, the
duration of ciproﬂoxacin prophylaxis in patients receiving HAART was
at the discretion of treating physicians. End of follow-up was the date
of last clinic contact, date of death, or on 31 October, 2006, whichever
occurred ﬁrst.
Results: During the 12-year study period, 94 of 1372 (6.9%) HIV-
infected patients developed 106 episodes of NTS bacteraemia: 16 of
175 (9.1%) in the pre-HAART era and 78 of 1197 (6.5%) in the HAART
era (p = 0.27). In the pre-HAART era, 4 of 16 (25%) patients (median
CD4 count at NTS bacteraemia, 8×106 cells/L) had 7 recurrent episodes,
compared with 3 of 78 (3.8%) (median CD4, 21×106 cells/L) who had 5
recurrent episodes in the HAART era (odds ratio, 8.33 [95% CI, 1.656,
41.95]; p = 0.03). 6 patients in the HAART era died within 30 days
of NTS bacteraemia (median, 10 days; range 2−21 days). 5 recurrent
episodes occurred in 3 patients in the HAART era: 1 with primary CNS
lymphoma receiving chemotherapy and 2 without adherence to HAART.
6 of 23 NTS isolates were resistant to trimethoprim–sulfamethoxazole
[TMP-SMX] in the pre-HAART era compared with 16 of 66 isolates in
the HAART era (p = 0.99). Although none of the isolates was resistant
to ceftriaxone, 14 of 65 (21.5%) isolates in the HAART era were
resistant to ciproﬂoxacin (including 9 isolates resistant to ampicillin,
chloramphenicol, TMP-SMX) compared with 0 of 23 isolates in the
pre-HAART era (p = 0.02). Eight patients with NTS isolates resistant to
ampicillin, chloramphenicol, TMP-SMX, and quinolones who survived
NTS bacteraemia and did not receive secondary prophylaxis had no
recurrences during HAART.
Conclusion: Our ﬁndings suggest that risk of recurrent NTS bacteraemia
decreased signiﬁcantly in the HAART era, although the resistance rate
to quinolones was increasing and appropriate oral agents as secondary
prophylaxis might not be available.
P643 Causes of liver related death in HIV-infected patients in
France: mortality 2005 Survey
D. Salmon, C. Lewden, F. Bonnet, E. Rosenthal, P. Morlat, T. May,
C. Burty, D. Costagliola, E. Jougla, C. Semaille, G. Cheˆne, P. Cacoub
on behalf of Mortality 2005 Study group
Objective: To describe frequency and characteristics of liver related
death in France in HIV-infected adults and compare the results to those
of the same survey performed in 2000.
Method: Physicians involved in the management of HIV infection
and those from societies of reanimation, pneumology, hepatology and
penitentiary medicine were asked to notify deaths that occurred in 2005.
The causes of death were documented using a standardised questionnaire.
Results: The 338 participating wards notiﬁed 979 deaths (versus 964 in
2000) and documented 831 deaths with a known status for hepatitis B
and C viruses. Median age was 46 years and 75% were men. The main
underlying causes of death were AIDS-related (37%, vs 47 in 2000),
liver-related including viral hepatitis (15%, vs 13), cancer not related to
AIDS or hepatitis (17%, vs 11), cardiovascular disease (9%, vs 7), other
infections (5%, vs 7), suicide (5%, vs 4). Among the 125 deaths were
related to liver disease, 50% had an alcohol consumption >30 g/day.
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Conclusion: The proportion of liver-related deaths and particularly
hepatocellular carcinoma increased between 2000 and 2005 in HIV-
infected adults, while the proportion of AIDS related death has
decreased. This justiﬁes a more aggressive treatment of viral hepatitis C
and B, the prevention of alcohol consumption, and an early and regular
screening for hepatocellular carcinoma in case of cirrhosis.
2000 2005
No. of deaths with known status for HBV
and HCV
822 831
Death from liver disease 110 (13%) 125 (15%)
among which Hepatocellular carcinoma 17 (15%) 31 (25%)
Main cause of liver disease
HCV 72 (65%) 90 (72%)
HBV 14 (13%) 16 (13%)
HCV + HBV 16 6
Alcohol 8 8
Other – 5
Median age 41 46
Median CD4 cell count/mm3 90 165
P644 Longitudinal evaluation of the prevalence of insulin resistance
in a cohort of HIV vertically-infected children and adolescents
R. Rosso, A. Parodi, E. Repetto, C. Torrisi, C. Bernardini, F. Ginocchio,
M.P. Sormani, M. Vignolo, C. Viscoli (Genoa, IT)
Background: To assess the rate of progression insulin resistance (IR)
and the associated metabolic disturbances over a 1-year period in HIV
vertically-infected children and adolescent and to assess risk factors
associated.
Methods: 48 children (age range 6−22 years; 21 F, 27 males) were
followed over a mean period of 14 months (range 5−27). Fasting lipids
and glucose proﬁle were measured in all children. Therapy and disease
history, presence of lipodystrophy, possible co-infections, axiological
features were recorded at the baseline and at the end of the follow-up.
Results: At baseline, fasting insulin and HOMA-IR were signiﬁcantly
higher in HIV-infected patients than in healthy children and adoles-
cents (p< 0.001). Therapy duration (r = 0.281, p< 0.05), triglycerides
(r = 0.286, p< 0.05), age (r = 0.299, p< 0.05), BMI (r = 0.485, p< 0.001)
were signiﬁcant predictor variables of IR, expressed as HOMA-IR >3. At
baseline and at the end of follow-up, 36% vs. 29% of pts showed IR; and
32% vs. 33% showed dyslipidaemia (high cholesterol, or triglycerides or
both), respectively. The proportion of patients presenting lipodystrophy
remained stable (16.6%). Prospective follow-up showed no progression
at all over 1 years, in particular the number of patients with IR remained
the same but the level of mean HOMA-IR increased slightly (2.6±1.6
vs 3.8±8.1), showing no correlation with therapy duration as a whole
and particularly with PI-based HAART. HAART, deﬁned as association
of 3 antiretroviral drugs, seems not to be related with a worsening
in IR. Sex, birth weight, HCV-infection have no relation with IR, while
lipodistrophy, Tanner stage IV-V of puberty, hyper triglyceridaemia seem
to be predictor variables of IR both at baseline and at the end of follow-
up (p< 0.05).
Conclusions: In HIV-infected children IR and other metabolic com-
plications, such lipodystrophy are more likely to develop after mid-
puberty. Progression of disorders of glucose metabolism seems to be
slow but, regarding their enlarged life expectancy, efforts to prevent
the development of such complications should be targeted toward HIV-
infected children with an at least annual (using fasting glycaemia and
insulin) follow-up.
P645 Diverse dermatologic manifestations in HIV-infected patients
after highly active antiretroviral therapy
K. Jutivorakool, P. Plussind, H. Choengwiwatkit, J. Waiwarawut
(Chonburi, TH)
Objective: Highly active antiretroviral therapy (HAART) has increased
survival in HIV patients. However, there are few studies on skin
manifestations in HIV-infected patients after HAART with somewhat
conﬂicting data. The aim of this study is to evaluate the inﬂuence of
HAART on the prevalence and spectra of dermatologic disorders in HIV-
infected patients
Method: We collected data from 113 HIV-infected patients on whom
HAART was initiated in our HIV clinic between 1 June 2005 – 31
May 2006 and thus have received HAART for at least 6 months.
The primary outcomes were dermatologicmanifestations after HAART.
All diagnoses were based on patient history, physical examination,
dermatologic consultation and laboratory investigations.
Results: Dermatologic manifestations occurred in 40 patients (35.4%)
after HAART. Mean HAART duration was 55 + 61 days (range 7–
241 days). Eosinophilic folliculitis and drug eruptions were the most
common ﬁndings (N= 10, 8.8%). The next most common conditions
were mycobacterial infections (N= 4, 3.5%), non-speciﬁc dermatitis
(N = 4, 3.5%), herpes zoster infection (N= 3, 2.7%), idiopathic pruritus
(N = 3, 2.7%), lipodystrophy (N= 2, 1.8%), herpes simplex infection
(N= 2, 1.8%), histoplasmosis (N = 1, 0.9%) and psoriasis (N = 1, 0.9%).
Independent risk factors for skin manifestations after HAART by
univariate analysis were female (60% vs 30%, p = 0.003), lower nadir
CD4 counts (64.3 vs 107.8, p = 0.024) and higher percentage of
eosinophils at the time of dermatologic diagnosis (9.1% vs 5.2%,
p = 0.004). Different HAART regimens did not seem to affect the
incidence. Female sex and peripheral eosinophilia were conﬁned to
the groups of eosinophilic folliculitis and drug eruptions. There was
no signiﬁcant difference in the number of CD4 increase between
patients with or without skin manifestations. We observed ﬁve cases
of skin disorders due to opportunistic infections: four of mycobacterium
infections (inﬁltrative erythematous plaque 1, subcutaneous abscess 1,
painful erythematous nodules 1, and visible lymph node protrusion 1
and one of histoplasma lymphadenitis.
Skin manifestation group P-value
Yes (N= 40) No (N= 73)
Age (years) 36.98±9.475 39.18±9.3 0.23
Gender (M:F) 16:24 51:22 0.003*
HAART regimens (N)
1. NVP-based 14 20 0.92
2. EFV-based 14 35 0.29
3. PI-based 12 18 0.53
Nadir CD4 count (cell/ml) 64.35&±72.84 107.84±129.45 0.024*
Number of CD4 increase (cell/ml) 73.8±68.25 88.7±125.64 0.419
WBC (cell/mm3) 5951±2552 6312±3085 0.511
Percentage of eosinophils (%) 9.13±7.52 5.25±3.71 0.04*
AST (IU/dl) 92.7±235.9 39.38±21.63 0.16
ALT (IU/dl) 65.85±134.17 32.44±23.95 0.13
Conclusion: In the HAART era, eosinophilic folliculitis and drug
eruptions are the most prevalent dermatological manifestations in our
referral hospital. These are closely related to peripheral eosinophilia in
this population. Physicians initiating HAART on a female especially with
a low CD4 count should be aware of this consequence.
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P646 A prospective study of bloodstream infection in HIV-positive
patients during a 15-year period
J. Garcı´a Rodrı´guez, H. A´lvarez, B. Bun˜o, A. Marin˜o, M. Rodrı´guez,
P. Sesma (Ferrol, ES)
Objective: To know the evolution of incidence, etiology and prognostic
factors for bacteraemia infection in HIV positive patients.
Methods: Prospective study of cases of bacteraemia in our Hospital
between 1991 and 2005. Blood cultures were processed using automatic
technique and antibiotic susceptibility was determined by microdilution
according to the current recommendations from the NCCLS. In patients
with HIV positive, demographics as well as a complete set of tests
(including clinical features, risk factors to HIV infection, laboratory
studies, CD4, treatment and illness evolution) were collected in each
case. Statistical analyses were carried out with SPSS.
Results: We studied 1848 episodes of bacteraemia in adult patients,
103 (5.6%) of them in 84 HIV positive patients (incidence by 1000
hospitalised patients-year: 0.62 in pre-HAART and 0.61 in HAART-era).
The HIV transmisio´n were: intravenous drug use 77.7%, heterosexual
contact 9.7%, male homosexual contact 2.9%, blood transfusion 1%
and unknown 8.7%. Male 87 (84.5%). Mean age 34.2±7 years (range
20−59), 30.4±4.7 in the pre-HAART vs 35.8±7.3 in the HAART-
era, p< 0.05. The bacteraemia was community acquired in 82 (79.6%)
episodes. 98 (95.1%) episodes were due to monomicrobial infection.
The more frequently isolated germs were: Staphylococcus aureus 27
and Streptococcus pneumoniae 14; and the origins: endocarditis 18.4%
and pneumonia 30.1%. The CD4 cell count was <50 in 31.4% of
the patients, 50–200 in 28.6%, 201–500 in 31.4% and >500 in 8.6%.
Among 103 episodes, 17 (16.5%) patients died due to the sepsis and
8 (7.8%) cases were not linked to sepsis. Patients in the HAART-era had
more comorbidity (41/72 vs 4/31), more frecuently neutropenia (13/72
vs 1/29), pneumococcal vaccine administration (38/63 vs 4/31)and
prophylaxis with TMT-SMX (18/66 vs 2/31) than patients in the pre-
HAART era. No statistically signiﬁcant differences were observed
between the pre-HAART and the HAART-era in the isolated germs,
origins of bacteraemia, mean CD4 cells count, global mortality (7/31 vs
18/72) nor related to bacteraemia mortality (4/31 vs 13/72).
Conclusions: The incidence, etiology, origin and mortality of bacter-
aemia in HIV patients have remained stable. Patients in the HAART-
era had more frecuently associated comorbility, pneumococcal vaccine
administration an prophylaxis with TMT-SMX than those in the pre-
HAART era.
P647 Frequency of proteinuria among HIV-infected patients
A. Ramezani, M. Mohraz, M. Banifazl, L. Gachkar, F. Yaghmaie,
A. Aghakhani, N. Kalantar, K. Nemati, M. Haghighi, M. Rezaie,
A. Velayati (Tehran, IR)
Background: Nephropathies associated with human immunodeﬁciency
syndrome (HIVAN) are increasingly prevalent and associated with
proteinuria and rapid progression to end-stage renal failure. Some authors
reported, proteinuria may be an early marker of HIVAN, and screening
for its presence may be beneﬁcial. In this study we aimed to determine
the frequency of proteinuria and related risk factors in Iranian HIV
positive patients.
Methods: A total of 105 HIV positive patients were enrolled in
this study. All the patients ﬁlled out a questioner about demographic
characteristics and their high risk behaviours. Systolic and diastolic blood
pressure was examined by a physician. Patient’s blood samples were
tested for creatinine, albumin, hemoglobin, HCV Ab and HBs Ag. In
all patients CD4 counting were done by ﬂow cytometry. Urine samples
were collected and examined for detection of proteinuria. Proteinuria
was deﬁned as 1 plus in urine exam on 2 consecutive dipstick urine
analyses. Personal and lab data’s among study groups were compared
with the Chi-square using SPSS 11.5 package programme.
Results: Out of 105 HIV positive patients, 20%(n = 21) had proteinuria.
Mean age of patients with proteinuria was 35.2±9.19. There was not
any signiﬁcant difference between patients with and without proteinuria,
regarding age, sex, race, weight, risk behaviours for HIV acquisition,
disease history, staging (HIV/AIDS), concurrent drug therapy (non-
nucleoside reverse transcriptase inhibitors or protease inhibitors), systolic
and diastolic blood pressure, hemoglobin, albumin, presence of HCV Ab
and HBs Ag. Patients with proteinuria had a lower CD4 count (322.47
vs. 439.16 cells/mm3 p< 0.051) and slightly higher creatinine (1.20 vs.
0.96mg/L p = 0.054) than those without proteinuria.
Conclusion: This study showed a relatively high prevalence (20%)
of proteinuria in the HIV-seropositive population. Our study also
conﬁrmed the correlation between decreasing CD4 count and the
presence of proteinuria. But it was not demonstrated an association
between proteinuria and a positive hepatitis C antibody as reported in
previous studies.
P648 Infective endocarditis: descriptive analysis of 102 consecutive
cases. Inﬂuences of human immunodeﬁciency virus infection
in clinical evolution
E. Valencia, V. Moreno, A. Enrı´quez, L. Martı´n Carbonero, J. Gonza´lez
Lahoz (Madrid, ES)
Objective: 1) To describe the characteristics of infective endocarditis
(IE) in a group of inpatients attended in an Infectious Disease Service
during the last 14 years and 2) To analyse the inﬂuence of different
factors, HIV infection and HAART included, in the evolution of these
patients
Patients and Methods: We analysed 102 cases of IE diagnosed between
1993 and 2006. Data were collected with regard to the clinical, laboratory
and demographics characteristics of patients as well as results of blood
cultures and data on clinical outcome. We used the statistical programme
SPSS 13.0.
Results: Only four were not intravenous drug addicts (IVDA), most
of them (80%) were men and 29 (28.4%) had had a previous episode.
The onset was acute in 66 cases (64.7%), blood culture were negative
in 56 patients (54.9%) and Staphylococcus aureus was isolated in 25
episodes (24.5%). All patients were febrile and thorax radiography
showed septic emboli in 45 cases (44.1%). Affected valves were:
tricuspid 86 cases (84.3%), pulmonary 2 (2%), mitral 13 (12.7%) and
aortic 11 (10.8%). The most frequent complications were cardiac failure
(15 patients, 14.7%), renal insufﬁciency (8 patients, 7.8%) and arterial
emboli (5 patients, 4.9%). Seventy three subjects had a favourable
outcome (71.6%), 13 died (12.7%) and 16 (all of them IVDA) left the
hospital without ﬁnishing the treatment.
Seventy-eight cases had HIV infection (86.7%) and mean CD4+ was
240 cells per mm3 (range: 4–1000). Twenty two patients (21.6%) had a
concomitant opportunistic infection and only 14 (13.7%) were receiving
highly activity anti-retroviral therapy (HAART). Most of them (87.3%)
were active IVDA and 60 patients (58.8%) had hepatitis C virus (HCV)
co-infection.
The symptoms and the clinical evolution were independent from the
presence of HIV infection. Patients with left sided IE had signiﬁcantly
more cardiac failure and ventricular dysfunction than those with right
sided IE regardless HIV infection.
Conclusions: IE continue being a frequent and important problem in
IVDA with or without HIV infection. Affected valve is mainly tricuspid
and S. aureus is responsible in most of cases. In this group, HIV infection
did not inﬂuence in clinical manifestations and outcome.
P649 Cardiovascular risk evaluation in HIV-infected adults
S. Sousa, E. Valadas, J.P. Lopes Cruz, M. Doroana, L. Tavares,
L. Caldeira, N. Duarte, F. Antunes (Lisbon, PT)
Objectives: Metabolic changes caused by antiretroviral therapy may
increase risk of cardiovascular disease. The aim of this study is to
quantify cardiovascular risk (CVR) and to determine the prevalence of
CVR factors in HIV-infected adults, as well as, to suggest strategies for
decreasing CVR.
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Methods: In a cross-sectional study, HIV-infected individuals were
evaluated during a six-month period, at Hospital de Santa Maria,
Lisbon. Data collected includes: demographic variables, antiretroviral
therapy, duration of HIV infection, smoking habit, diabetes mellitus and
family history of cardiovascular disease. Height, weight, blood pressure,
total cholesterol, HDL-cholesterol, glucose and triglycerides levels were
determined. Estimates of 10-year CVR were based on Framingham’s
equation.
Results: In the 1,340 patients included: the average age was 42.1 years,
66.7% were men, 49.1% were smokers, 36% had hypertension, 4.4% had
diabetes, 15% had elevated cholesterol levels (>6.2mmol/l) and 13.5%
had low HDL-cholesterol levels (<0.9mmol/l). Estimated 10-year CVR
average was 5.2%. CVR average for patients on antiretroviral treatment
(5.86%) is almost twice than for naı¨ve patients (3.2%). An elevated CVR
(>20%) was found in 4.4% of the patients, most of them were on non-
nucleoside reverse transcriptase inhibitors or on protease inhibitors based
treatments. To stop smoking was the measure with the highest impact
on CVR decrease, followed by normalising lipid levels.
Conclusion: HIV-infected patients show several cardiovascular risk
factors. Patients should be encouraged to change their lifestyle (smoking
cessation, diet and exercise) and in some cases of important lipidaemia
changes in antiretroviral treatment should be considered.
P650 Human immunodeﬁciency virus infected patients with
community-acquired pneumonia: implication of respiratory
viruses
R. Perello, A. Moreno, C. Cervera, A. Smithson, J. Miro, L. Linares,
C. Agusti, M. Camps, M. Marcos (Barcelona, ES)
Background: Community acquired pneumonia (CAP), is an important
source of morbidity/mortality in human immunodeﬁciency virus (HIV)
infected patients. The aim of the present study is to evaluate the
implication of respiratoty viruses (RV) in CAP in HIV-infected patients.
Methods: From June 2003 to December 2005, 67 adult HIV patients
(mean age 41.39 years) with CAP were prospectively included. RV were
identiﬁed by polymerase chain reaction, cellular cultures and immunoﬂu-
orescence techniques from samples obtained by nasopharyngeal smears.
Results: A microbiological diagnostic was achieved in 48 patients.
Forty CAPs had an isolated bacterial ethiology being S. pneumoniae
the most common pathogen (85%). RV were implicated in 14 cases;
in 8 as the only pathogen and in 6 in combination with bacteria’s,
being adenovirus plus S. pneumoniae the most frequent combination.
Rhinovirus was the most common RV implicated followed by adenovirus.
No statistical signiﬁcant differences were found in CAP in which VR
were implicated compared to CAP without presence of RV regarding:
male gender (50 vs 70%; P = 0.21), mean age (40.6 vs 41 years; P = 0.92),
median CD4 cell count (229.5 vs 228.5; P = 0.75), mean logarithmic
viral charge (4.04 vs 3.68; P = 0.408), HAART (36 vs 41.5%; P = 0.694),
positive hemoculture (21.4 vs 28.3; P = 0.85), admission in ICU (7 vs
15%; P = 0.67), mechanical ventilation (7 vs 2%; P = 0.37), APACHE II
score (10.5 vs 11; P = 0.38), death (7 vs 0%; P = 0.29) and median of
hospitalisation (5 vs 7 days; P = 0.076).
Conclusions: The implication of RV in CAP of HIV infected patients
is not associated to a worst outcome.
P652 Incidence, reasons, and risk factors for hospital admissions
in patients starting their clinical management in the era of
combination antiretroviral therapy
A. Tone, N. Viget, P. Choisy, V. Baclet, F. Ajana, Y. Gerard, H. Melliez,
Y. Mouton, Y. Yazdanpanah (Tourcoing, FR)
Objective: To assess the incidence and reasons for hospital admissions
and to determine factors associated with hospitalisation in a French
clinical cohort of HIV-infected patients
Methods: We conducted our study on HIV-infected patients from the
Tourcoing AIDS Reference Center who started their clinical management
from January, 1997 to August, 2004 and followed through December,
2004. We categorised diagnoses into seven disease groups. Time to
hospital admission was calculated using the Kaplan-Meier method, from
enrolment to the ﬁrst admission. A multivariate Cox model was used
to determine independent risk factors for hospital admission among
demographic, clinical and laboratory characterises of patients at the
inclusion.
Results: Among 781 patients followed for a median period of
2.9 years (IQ25−75, 1.3−5.3), 325 patients (41.6%) experienced at
least one hospital admission, 179 (22.9%) at least two admissions,
and 112 (14.3%) at least three admissions. The risk for the hospital
admission was estimated at 33.2%, 39.3%, and 43.9% at one, two, and
three years after enrolment, respectively. The most common reasons
for hospitalisation were AIDS deﬁning illness (26.3%), non AIDS-
deﬁning infections (16.7%), neoplasms (14.3%)and toxic events related
to treatments (10.7). The less frequents reasons for hospitalisation were
the cardiovascular diseases (2.2%). In the multivariate analysis, age
>50 years (vs. <30, hazard ratios [HR], 1.7; 95% Conﬁdence Interval
[95%CI], 1.1−2.5), initial AIDS stage (HR, 8.2; 95%CI, 6.0–11.1), HIV
viral load >5 log copies/mL (vs. <4.5; HR, 1.4; 95%CI, 1.1−1.9),
viral hepatitis infection (HR, 2.0; 95%CI [1.4−2.8), and a history of
mental illness at enrollment (HR, 1.7; 95%CI, 1.2−2.4) were predictive
of hospital admission.
Conclusion: Our data indicates that in the era of combination
antiretroviral therapy, hospital admission remain substantial among HIV-
infected patients. Speciﬁc interventions should target subgroups of
patients at risk of hospital admission to reduce the occurrence of events
for which hospitalisations are required. Given the high cost of hospital
admissions, these interventions might be particularly efﬁcient and should
be prioritised.
P653 Mycobacterium tuberculosis disease in HIV-infected patients
in HAART era
J. Guardiola, L. Matas, A. Mauri, S. Herrera, M. Mateo, M. Fuster,
M. Sambeat, J. Cadafalch, P. Domingo (Barcelona, ES)
Background: The incidence and prevalence of M. tuberculosis in HIV-
infected patients remains variable. The aim of this study was to evaluate
the presence of M. tuberculosis diseases during the HAART era in our
HIV population.
Methods: We retrospectively studied all HIV-AIDS records from 1997–
2004 at a teaching-urban hospital in Barcelona (Spain). All positive
microbiologic cultures ofM. tuberculosis from our data-base and medical
records from 1997 to 2004 were reviewed.
Results: We analysed 1502 HIV-infected patients. During this period,
a total of 623 (41%) patients showed one or more microbiologically
documented infections. A total of 71/1502 (4.7%) patients showed
one or more positive cultures of M. Tuberculosis, with 132 positive
microbiological samples (30 patients had more than one site infection),
representing 11% of total prevalence of documented infections during
this period (71/623). 68.8% were men. Mean age was 40 + 9 (range:
18−79). 89% of patients were on highly-active antiretroviral therapy.
The most frequent samples isolates were: sputum 63 samples, bronchial
lavage 18 samples, urine 12 samples, adenopathy 12 samples, and
hemoculture 11 samples. 31/71 (43%) patients showed disseminated
infection.
Conclusions:
1. Almost 5% of patients had a M. tuberculosis infection.
2. M. tuberculosis constituted 11% of all infections.
3. Respiratory tract infections were the most prevalent site of infection.
4. 43% patients showed disseminated infection.
P654 Neoplasia in patients with HIV infection: effect of HAART
A.A. Garcia-Egido, M.A. Escobar, S.P. Romero, J.A. Bernal, C. Asencio,
J.L. Puerto, J. Gonzalez-Outon, F. Gomez (El Puerto Santa Maria, ES)
Surveillance data indicate that, the incidence and type of HIV related
neoplasias has changed after the introduction of HAART.
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Objective: To determine the incidence and types of cancers in the pre-
HAART and post-HAART eras, and the differences between women and
men.
Methods: Retrospective record review of HIV infected patients with
cancer from January 1991 to December 2003 at a teaching hospital.
Results: A total of 215 HIV patients with cancer were identiﬁed,
173 men (age: 38±11 years, CD4: 123±39/mL) and 42 women (age:
44±16 years, CD4: 68±27/mL), of them 90 were detected in the pre-
HAART (47%) and 102 in the post-HAART era (53%, p = n/s). AIDS
deﬁning cancers (Total: 215, 72.4%; of them 108, 77.7% in men vs. 31,
22.3% in women) were more frequent pre-HAART (Total: 76, 54.7%;
of them 60, 43% in men vs. 16, 11.5% in women) than post-HAART
(Total: 63, 45.3%; of them 48, 34.5% in men vs. 15, 10.8% in women).
Non AIDS deﬁning cancers (Total: 53, 27.6%; of them 34, 64% in
men vs. 19, 36% in women) were less frequent pre-HAART (Total:
14, 26.4%; of them 9, 17% in men vs. 5, 5.3% in women) than post-
HAART (Total: 39, 73.6%; of them 25, 47.2% in men vs. 14, 26.4% in
women). Total cancer related mortality was higher pre-HAART (61% vs
52%, p< 0.05) and in women (60% vs 55%, p = n/s) than post-HAART
(Total: 53, 27.6%; of them 36, 18.8% in men vs. 17, 8.9% in women).
AIDS deﬁning cancer related mortality was higher pre-HAART (65.8%
vs 36.5%, p< 0.01) in both sexes (p< 0.01), while non AIDS deﬁning
cancer related mortality was higher post-HAART (76.9% vs 35.7%,
p< 0.01) in both sexes (p< 0.01).
Conclusions: The incidence of non AIDS deﬁning cancer increased,
although the total incidence of HIV related neoplasia has not changed
after HAART. Total cancer related mortality is higher pre-HAART and
in women. Both sexes have a higher mortality by AIDS deﬁning cancer
pre-HAART and, by non AIDS deﬁning cancer post-HAART.
P655 Incidence and risk factor of major opportunistic infections
after initiation of antiretroviral therapy between HIV-infected
patients with baseline CD4 cell counts 50 cells/mm3 and
>50 cells/mm3
W. Manosuthi, A. Chaovavanich, S. Tansuphaswadikul, Y. Inthong,
S. Chottanapund, C. Sittibusaya, V. Moolasart, S. Sungkanuparph
(Nonthaburi, TH)
Objectives: To study incidence and risk factors for new episodes of
major opportunistic infections (OIs) after antiretroviral therapy (ART)
among HIV-infected patients.
Methods: A retrospective cohort study was conducted among naı¨ve
HIV-infected patients who were initiated ART between January 2001
and December 2003. Patients were categorised into two groups based
on baseline CD4 cell counts: group A (50 cells/mm3) and group B
(>50 cells/mm3). All patients were followed until 15 months after ART
initiation.
Results: There were 793 patients with a mean age of 35.1±7.4 years
and 56% male. Of 793 patients, 531 (67.0%) were in group A and
262 (33.0%) were in group B. Median (IQR) CD4 cell count was 13
(6−26) cells/mm3 in group A and 116 (78–167) cells/mm3 in group B.
Median (IQR) baseline plasma HIV RNA was 300,500 (138,500–
556,000) copies/mL and 185,000 (68,500–577,500) copies/mL in the
corresponding groups (P< 0.05). Group A had a higher proportion
of male, previous OIs, body weight, transaminase enzymes (P< 0.05).
Incidence of major OIs (i.e., tuberculosis, cryptococcosis, pneumocystis
pneumonia, histoplamosis and CMV disease) at 1, 3, 6, and 12 months
after ART were 2.8%, 6.6%, 8.3% and 9.8% in group A; and 1.5%, 1.9%,
3.1% and 3.5% in group B (log rank test, P = 0.002). Cox’s proportional
hazard model showed that the patients with baseline CD4 cell count 50
copies/mL was associated with high incidence of OIs after initiation of
ART (P = 0.018, HR= 4.292, 95%CI = 1.289–14.286).
Conclusions: HIV-infected patients who had baseline CD4 50
cells/mm3 had a higher probability of the occurrence of major OIs after
initiation of ART than those who had baseline CD4 >50 cells/mm3.
Closed monitoring of clinical condition is strongly recommended after
ART initiation in patients with low baseline CD4 cell counts.
P656 GB virus C infection among HIV-positive patients in Estonia
K. Denks, K. Huik, R. Avi, M. Sadam, T. Krispin, T. Karki, I. Lutsar
(Tartu, EE)
Objectives: GB virus C (GBV-C) infection is not associated with
any human disease. Some studies have shown that HIV-1 and GBV-C
coinfected patients may have improved AIDS-free survival and higher
CD4+ T-cell counts than GBV-C negative patients. The aim of current
study was to determine the GBV-C infection frequency in HIV infected
subjects in Estonia and to analyse if GBV-C infection associates with
any other parameter of the study population.
Methods: Blood samples were collected from 95 HIV positive subjects
(68 male and mean age of 28 years), between October 2005 and
September 2006. 38 subjects were prisoners. All study subjects were
infected with HIV between 2000 and 2005. 70 (74%) patients were
or had been intravenous drug users (IDU), the remaining 25 were
infected heterosexually. Among IDUs there were signiﬁcantly more men
than women; 61 (90%) vs 9 (33%) (OR= 17.4; p< 0.0001). 65 (68%)
subjects were coinfected with hepatitis C (HCV) and/or hepatitis B
virus (HBV). At the time of sampling, 14 study subjects were treated
with antiretrovirals. GBV-C infection was detected using PCR of NS5A
region [1]. The positive result was conﬁrmed and genotyped using type-
speciﬁc PCR targeting GBV-C 5′ nontranslated region [2]. PCR products
were analysed in agarose gel electrophoresis or by sequencing.
Results: GBV-C infection was detected in 33/95 (35%) subjects; the
genotype 2 was the only one found. GBV-C infection was associated with
IDU – 28 (41%) of past or current IDUs carried GBV-C infection versus
only 5 (33%) of non-IDUs (OR= 6.7; p< 0.0001). Of men, 27 (40%)
were GBV-C positive as compared with six (22%) women, but this
difference arose from IDU rather from sex. The GBV-C carriage was
not associated with HCV and/or HBV infection nor with the age. The
CD4+ T-cell number and HIV load were measured six months prior
the sampling in 55 and 43 patients, respectively. The average CD4+
T-cell count was similar in GBV-C positive and negative subjects; 289 vs
412 cells/mL, respectively. The average viral load was 50,580 copies/mL
in GBV-C negative patients vs 207,754 copies/mL in GBV-C positive
patients (p = 0.04).
Conclusion: The GBV-C infection was detected in one third of HIV-
positive patients and its presence was associated with higher HIV
loads. The relationship between GBV-C infection and IDU suggests that
GBV-C could mainly be transmitted via intravenous route.
Reference(s)
[1] George SL, Xiang J. Virology 2003; 316: 191–201.
[2] Naito H, Abe K. J Virol Methods 2001; 91: 3−9.
P657 HPV lesions in both genitalia and mouth of HIV sero-positive
male patients
E. Giovani, R. Mu¨ller, F. Aguiar, J. Melo, P. Armonia, R. Andia-Merlin
(Sa˜o Paulo, BR)
Objectives: HIV has become an important risk factor for HPV infection
and the development of HPV associated lesions. So, the aim of this
study was to correlate HPV lesions in male genitalia and in mouth of
HIV sero-positive patients.
Methods: 179 male patients were selected from the Attendance Center of
Special Patients with Venereal Diseases and HIV/Aids – SP/Brazil from
April/03 to March/06. These patients had the HPV lesions conﬁrmed
in genitalia after clinical examination, peniscopy and biopsy performed
by an Urologist. All the patients were submitted to serologic exams
(HIV/Aids), and CD4 T-lymphocyte count was carried out for those
sero-positives for HIV. The age, skin colour and exposure category were
also analysed for all patients. The whole group was sent to a dentist for
HPV lesions detection and diagnosis in oral cavity. When lesions were
diagnosed, the results were conﬁrmed by anatomy-pathological exam.
After the results, the prevalence of the lesions was tabulated and a linear
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correlation was performed. The treatment protocol used for oral lesions
was the topic administration of 75% trichloracetic acid.
Results: The mean age of the patients was 34 years, 136 (58%)
leucoderm and 43 (18%) melanoderm. 46 (26%) were HIV− (32
homosexuals and 14 heterosexuals) and 133 (74%) were HIV+ (101
homo and 32 hetero). 27 patients (15%) showed concomitants lesions
in genitalia and oral cavity and all they were HIV+ (20 homo and 7
hetero). 8 patients (30%) presented T-CD4 cells <200 for mm3 of blood,
15 (55%) presented 200 to 500 T-CD4, 4 (15%) presented T-CD4> 500.
All patients had total remission of the lesion after treatment, but for
those that showed T-CD4 cells <200, more sessions of treatment were
necessary (>4 sessions).
Conclusion: There is a positive linear correlation between HPV lesions
in male genitalia and in mouth. HIV is an important risk factor for HPV
infection and the development of HPV lesions in mouth.
P658 Clinical and paraclinical manifestations of thyroid dysfunc-
tion among patients with HIV/AIDS Tehran, Iran (2004–2005)
M. Rasoolinejad, S. Afhami, M. Izadi, M. Hajabdolbaghi,
P. Khairandish (Tehran, IR)
Objective: The aim of this study was to determine the prevalence of thy-
roid dysfunction and associated risk factors in human immunodeﬁciency
virus infected and acquired immunodeﬁciency syndrome patients.
Materials and Methods: In this cross sectional study, HIV/AIDS
patients referring to the AIDS Clinic at Imam Khomeini Hospital in
Tehran were included. All patients underwent complete history taking
and physical examination regarding signs and symptoms of thyroid
dysfunction and a sample of venous blood was drown in order to test for
free T4, free T3, and thyroid-stimulating hormone (TSH) levels. Data
on age, sex, weight variation, duration of HIV infection, CD4 cell count,
HIV–HCV co-infection, and antiretroviral treatment were also collected.
Results: Between March 2004 to March 2005, 88 patients (mean age:
35.2±6.9 years) with HIV/AIDS, consisting of 73 males and 12 females,
were included. Eighteen patients (20.5%) had abnormal thyroid function
tests at different levels: one patient (1.1%) had clinical hypothyroidism,
2 patients (2.2%) had sub-clinical hypothyroidism, 12 patients (13.6%)
had low free T4 and 3 patients (3.4%)had low free T3 levels. After
exclusion of the last 3 patients, a case-control study was conducted which
compared hypothyroid (15) with euthyroid (70) patients with respect to
other inﬂuencing factors. Univariate and also multivariate analysis did
not show any signiﬁcant relationship between the studied parameters of
age, sex, weight, CD4 count, HCV co-infection, stage of the disease
and antiretroviral therapy of HIV/AIDS patients and presence of thyroid
dysfunction.
Conclusion: According to the ﬁndings of this study hypothyroidism is
prevalent in HIV/AIDS patients therefore, it is recommended that thyroid
function should be evaluated all HIV/AIDS patients during routine
follow-ups in order to detect any abnormality and initiate appropriate
management at an earlier stage.
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P659 Susceptibility of ESBL, AmpC and K1 b-lactamase producing
Enterobacteriaceae to carbapenems in Copenhagen, Denmark
H. Fjeldsøe-Nielsen, C. Schlegel, K. Schønning, A. Friis-Møller
(Hvidovre, DK)
Objective: Carbapenems are often chosen for treatment of serious
infections with cephalosporin resistant Enterobacteriaceae. In the present
study we investigated the susceptibility of isolates of Escherichia
coli, Klebsiella pneumoniae and Klebsiella oxytoca producing ESBL
(extended-spectrum b-lactamase) and/or AmpC or chromosomal K1
b-lactamase to three different carbapenems (meropenem, ertapenem and
imipenem).
Methods: During the ﬁrst 6 months of 2006 145 isolates of
cephalosporin resistant E. coli (106), K. pneumoniae (30), K. oxytoca (9)
collected in our routine laboratory were tested by E-test for meropenem
(SRGA breakpoint 0.12/8mg/l), ertapenem (0.25/2mg/l) and imipenem
(1/8mg/l) according to Oxoid E-test technical manual. Isolates had
already been characterised as being ESBL positive, AmpC positive,
ESBL and AmpC positive, or K. oxytoca hyperproducing chromosomal
K1 b-lactamase.
Results: The isolates collected were classiﬁed as follows: 65 ESBL,
40 AmpC, 38 ESBL and AmpC, 2 K1. Meropenem had the lowest
MIC90 (minimal inhibitory concentration) values for ESBL positive and
AmpC positive E. coli and K. pneumoniae. Among these isolates the
difference between ertapenem and imipenem was minimal. However,
among isolates possessing both ESBL and AmpC b-lactamases MIC90
was highest for ertapenem compared to both meropenem and imipenem
and also compared to isolates possessing either ESBL or AmpC. When
tested for ertapenem 15 of 145 isolates had MIC values >0.25mg/l. Of
these 11 were both ESBL and AmpC positive. Among the remaining
isolates 130/145 had MIC values 0.25mg/l for ertapenem. 5/145
isolates were intermediate to meropenem all of which were both ESBL
and AmpC positive.
Conclusion: Most cephalosporin resistant Enterobacteriaceae remain
susceptible to carbapenems. However, in our study isolates harbouring
both ESBL and AmpC b-lactamases seem to be less sensitive to
ertapenem and meropenem than isolates containing either ESBL or
AmpC b-lactamases.
P660 Pseudomonas aeruginosa in German intensive care units
E. Meyer, F. Schwab, P. Gastmeier, H. Rueden, D. Jonas (Freiburg,
Berlin, Hannover, DE)
Objective: To analyse resistance data of Pseudomonas aeruginosa (PAE)
in German ICUs participating in the project SARI (Surveillance of
Antimicrobial use and antimicrobial Resistance in German Intensive
Care Units.)
Methods: From 2000–2005 resistance rates in 45 ICUs were calculated
and correlated with antibiotic use and structure parameters. Temporal
changes were tested by Wilcoxon test for paired samples.
Results: A total of 7187 PAE were included. The mean resistance rate
to imipenem was 22.9% (range 0–50.4), to piperacillin-tazobactam 21
(range 0–50.4), to ceftazidime 16.1 (0–55.6), to ciproﬂoxacin 17.1 (range
0–50.4), to meropenem 13.8 (range 0–100). At 7% resistance to amicacin
was lowest (range 0–68.6). Mean ceftazidime resistance increased
signiﬁcantly from 2000–2003 to 2004–2005 (from 14.6 to 18.8%)
whereas amicacin resistance decreased from 8.2 to 4.5%. Ceftazidime
resistance was signiﬁcantly higher in hospitals with >1000 beds and
resistance to amicacin was signiﬁcantly higher in interdisciplinary
ICUs. Carbapenem use correlated signiﬁcantly and with a correlation
coefﬁcient >0.5 with imipenem, meropenem and ceftazidime resistance
of PAE.
Conclusion: Over 20% of PAE in German ICUs are resistant to
imipenem and piperacillin-tazobactam. This has not changed over the
last 5 years. Carbapenem use and resistance correlate signiﬁcantly.
P661 ICU antimicrobial susceptibility rates among Gram-negative
bacilli isolated from infections in the USA: results from ICU
surveillance study 2005
G. Gallagher, H. Wilson, M. Abramson (West Point, US)
Background: ISS (ICU Surveillance Study) is an ongoing US
antimicrobial surveillance programme that has focused on infections
from Intensive Care Units (ICU). The objective of this analysis was to
assess antimicrobial susceptibility patterns among aerobic & facultative
Gram-negative bacilli recovered at participating sites in the USA during
2005.
Methods: 39 centres in the USA each tested the in vitro activity of
15 antimicrobial agents. Consecutive unique Gram-negative bacilli from
all body sites were tested using microdilution techniques according
to CLSI guidelines and breakpoints. Production of extended-spectrum
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b-lactamases (ESBL) was conﬁrmed in isolates with a MIC of ceftri-
axone, ceftazidime, or cefepime 2mg/mL by comparing ceftazidime,
cefotaxime, and cefepime MICs with and without clavulanate.
Results: A total of 4304 isolates were recovered from 3665 patients.
The bacteria species with a prevalence of >5.0% were P. aeruginosa
(1030 isolates; 24%), E. coli (747 isolates; 17%), K. pneumoniae (658
isolates; 15%), E. cloacae (376 isolates; 9%), A. baumannii (302 isolates;
7%), and S. marcescens (244 isolates; 6%). The percent susceptible are
reported in the table. Most prevalent body sites were respiratory isolates
(2,224; 52%), blood isolates (812; 19%), and urine isolates (574; 13%).
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Ertapenem N/A 98 89 98 N/A 96
Imipenem 76 99 93 99 78 97
Cefepime 62 91 73 70 33 91
Cefotaxime 8 95 78 62 22 78
Cefoxitin N/A 90 76 7 N/A 29
Ceftazidime 71 89 71 54 38 83
Ceftriaxone 18 89 71 54 29 86
Amp/Sulbactam 2 52 60 16 50 4
Pip/Tazobactam 81 94 78 75 38 83
Amikacin 84 98 83 96 73 96
Gentamicin 57 88 81 86 39 90
Tobramycin 73 87 74 85 63 85
Ciproﬂoxacin 60 76 76 86 37 89
Lexoﬂoxacin 60 77 79 90 38 95
Aztreonam 59 89 71 57 12 87
Conclusion: In this study, the most common Enterobacteriaceae
organisms were E. coli and K. pneumoniae. P. aeruginosa was the
predominant Non-Enterobacteriaceae. Amikacin was the most active
agent in vitro for P. aeruginosa. Ertapenem, imipenem, and amikacin
were the most reliably active drugs in vitro against Enterobacteriaceae.
P662 Affect of length of hospitalisation on susceptibility patterns
of Gram-negative bacilli isolated from intra-abdominal
infections: SMART 2005
G. Gallagher, F. Rossi, P.R. Hsueh, J. Ba´ez-Villasen˜or, H.M. Wilson,
M. Abramson (West Point, US; Taipei, TW; Sa˜o Paulo, BR)
Background: SMART (Study for Monitoring Antimicrobial Resistance
Trends) is an ongoing global antimicrobial surveillance programme
focused on clinical isolates from intra-abdominal infections (IAI).
Isolates identiﬁed after 48 hours (h) of hospitalisation have been shown
to have less susceptibility than those taken within the ﬁrst 48 h. This
2005 sub-analysis assessed susceptibility patterns among Gram-negative
bacilli from 5 regions of the world.
Methods: 50 major medical centres in North America, Latin America,
Europe, Middle East/Africa, & Asia/Paciﬁc tested the in vitro
activity of 12 antimicrobial agents. Microdilution techniques followed
CLSI guidelines. Enterobacteriaceae susceptibility rates were compared
between isolates recovered <48 h & >48 h after hospitalisation.
Results: Enterobacteriaceae were recovered from 3226 pts (3422
isolates) worldwide. 648 isolates (19%) were Inducible; 2774 (81%) were
non-Inducible Enterobacteriaceae. 238 inducible (7%) & 1423 (42%)
non-Inducible Enterobacteriaceae were recovered <48 h after hospitali-
sation. The susceptibility rates are presented in the table.
Susceptibility rate (%)
Inducible
Enterobacteriaceae*
Non-inducible
Enterobacteriaceae#
<48 h 48 h <48 h 48 h
Entrapenem 96 94 97 97
Imipenem 97 96 98 98
Cefepime 94 87 93 81
Cefotaxime 79 59 93 81
Cefoxitin 27 24 93 81
Ceftazidime 77 57 92 79
Ampicillin/Sulbactam 34 21 62 43
Piperacillin/Tazobactam 34 21 62 43
Amikacin 99 93 97 95
Ciproﬂoxacin 91 83 84 70
Levoﬂoxacin 93 88 86 72
Length of hospitalisation not reported for 6* & 33# isolates.
Conclusion: Susceptibility rates for most Enterobacteriaceae were
slightly higher for isolates recovered <48 h after hospitalisation.
Ertapenem, imipenem, & amikacin were the most active drugs in vitro
regardless of time of hospitalisation.
P663 Worldwide antimicrobial susceptibility patterns among
E. coli isolated from intra-abdominal infections (IAI): results
from SMART 2005
G. Gallagher, P.R. Hsueh, F. Baquero, D. Paterson, J. Ba´ez-Villasen˜or,
H.M. Wilson, M. Abramson (West Point, Pittsburgh, US; Taipei, TW;
Madrid, ES)
Background: SMART (Study for Monitoring Antimicrobial Resistance
Trends) is an ongoing global antimicrobial surveillance programme
focused on clinical isolates from intra-abdominal infections (IAI). The
aim of the 2005 analysis was to assess antimicrobial susceptibility
patterns among E. coli from 5 different regions of the world.
Methods: 48 centres in the North America (NA), Latin America (LA),
Europe (EU), Middle East/Africa (ME/A), & Asia/Paciﬁc (A/P) tested
the in vitro activity of 12 antimicrobial agents Microdilution techniques
followed CLSI guidelines. E. coli were screened for extended-spectrum
b-lactamase (ESBL) production by ceftriaxone, cefotaxime, cefepime,
or ceftazidime MIC greater than or equal to 2 ug/mL & conﬁrmed by
comparing ceftazidime, cefotaxime, and cefepime MICs ± clavulanate.
NA
N=156
LA
N=190
EU
N=1036
M E/A
N=32
A/P
N= 438
Ertapenem 100 >99 >99 97 90
Imipenem 100 100 >99 100 90
Ceftriaxone 97 89 93 91 68
Ceftazidime 97 90 92 91 68
Cefotaxime 97 91 94 91 71
Cefoxitin 94 95 94 84 77
Cefepime 99 91 94 91 71
Ampicillin-Sulbactam 60 43 48 34 36
Piperacillin-Tazobactam 96 96 95 88 82
Amikacin 99 98 >99 97 87
Ciproﬂoxacin 84 75 82 75 56
Levoﬂoxacin 84 77 83 75 58
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Results: E. coli was recovered from 1852 patients of the study’s
3553 patients (3805 isolates) worldwide. % susceptibilities are reported
by region in the table. ESBL-producing E. coli constituted 1%, 9%, 4%,
9%, & 21% of isolates from NA, LA, EU, ME/A, & A/P, respectively.
53% (979/1852) were recovered <48 hrs of hospitalisation. Of those,
3% (32/979) were ESBL producers.
Conclusion: Prevalence of ESBL-producing strains may affect choice of
empirical therapy. Many ESBL-producing E. coli may have been hospital
acquired. Overall, ertapenem, imipenem, and amikacin were the most
reliably active drugs in vitro against E. coli.
P664 Antimicrobial susceptibility patterns of inducible
Enterobacteriaceae isolated from intraabdominal infections
in Europe: results from SMART 2005
G. Gallagher, F. Baquero, F. Rossi, J. Ba´ez-Villasen˜or, H.M. Wilson,
M. Abramson (West Point, US; Madrid, ES; Sa˜o Paulo, BR)
Background: SMART (Study for Monitoring Antimicrobial Resistance
Trends) is an ongoing global antimicrobial surveillance programme
focused on clinical isolates from intraabdominal infections (IAI). The
2005 analysis assessed antimicrobial susceptibility patterns among
inducible Enterobacteriaceae from Europe.
Methods: 25 European sites tested the in vitro activity of 12 an-
timicrobial agents. Microdilution techniques followed CLSI guidelines.
All Enterobacter, Serratia, Citrobacter, Providencia spp., Morganella
morganii, Hafnia alvei, & Proteus vulgaris were considered to have
inducible b-lactamases for this study.
Results: Inducible Enterobacteriaceae were recovered from 19% of pts
(347/1820); 18% (350/1964) of the total isolates. 42% (145) of these
isolates were recovered <48 hrs of hospitalisation. Enterobacter spp.
(46%), Citrobacter spp. (25%), M. morganii (12%) & Serratia spp. (6%)
were the most common isolates. Susceptibility rates are listed in the table.
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E
nt
er
ob
ac
te
r
sp
p.
N
=
16
2
C
it
ro
ba
ct
er
sp
p.
N
=
86
M
or
ga
ne
ll
a
m
or
ga
ni
i
N
=
43
Se
rr
at
ia
sp
p.
N
=
20
N = 162 N= 86 N= 43 N= 20
Ertapenem 96 99 100 100
Imipenem 98 99 100 100
Cefoxitin 5 20 70 35
Ceftriaxone 59 64 95 90
Ceftazidime 57 61 86 100
Cefotaxime 61 69 88 90
Cefepime 91 98 100 100
Ampicillin-Sulbactam 20 48 9 10
Piperacillin-Tazobactam 79 84 100 90
Amikacin 98 99 100 100
Ciproﬂoxacin 90 88 88 95
Levoﬂoxacin 93 94 93 95
Conclusion: The majority of isolates were recorded >48 hrs of
hospitalisation. Enterobacter species were the most common isolates.
Cefoxitin & ampicillin-sulbactam were the least active agents; er-
tapenem, imipenem & amikacin were the most active agents in vitro.
P665 Multicentre surveillance of Pseudomonas aeruginosa
susceptibility patterns in nosocomial infections
J. Van Eldere, I. Devenijns (Leuven, BE)
Objectives: To determine susceptibility rates and patterns of nosocomi-
ally acquired Pseudomonas aeruginosa from Belgian hospitals against
commonly used antibiotics and compare these data with data from a
similar surveillance study performed 5 years earlier.
Methods: 1250 strains from 40 Belgian hospitals were collected in
2005. Only clinically signiﬁcant non-duplicated isolates from blood,
deep respiratory samples, sterile body ﬂuids and urine samples taken
>48 hrs after admission were included. All strains were centralised in
a single lab, re-identiﬁed and MIC values were determined with an
agar-dilution method according to CLSI guidelines against the following
antibiotics: piperacillin-tazobactam (P-T), aztreonam (AZ), ceftazidime
(CT), cefepime (CP), meropenem (ME), amikacin (AK), tobramycin
(TB), gentamicin (GN), ciproﬂoxacin (CF), levoﬂoxacin (LF).
Results: Applying CLSI breakpoints, susceptibility rates in decreasing
order were 91% for P-T, 90% for AK, 88% for ME, 84% for CT and
TB, 80% for CP, 77% for GN and CF, 72% for LF and 65% for AZ.
Corresponding MIC50 and MIC90 values were respectively 8/64 for
P-T, 4/16 for AK, 1/8 for ME, 2/32 for CT, 1/128 for TB, 4/16 for CP,
2/64 for GN, 0.25/32 for CF, 1/32 for LF and 8/32 for AZ. Signiﬁcant
differences were observed between hospitals but not according to sample
origin. Compared to a similar 1999 survey, there was a signiﬁcantly
increased susceptibility to all b-lactam antibiotics and ﬂuoroquinolones,
whereas susceptibility to aminoglycosides remained stable. Beta-lactam
and ﬂuoroquinolone MIC distribution curves showed a clear shift to the
left between 1999 and 2005.
Conclusion: Resistance to b-lactams and ﬂuoroquinolones has decreased
compared to 5 years ago. In spite of reduced overall resistance, no single
anti-pseudomonas antibiotic has sufﬁciently high susceptibility levels to
warrant monotherapy for nosocomial P. aeruginosa infections.
P666 Comparative in vitro activity of tigecycline against ICU- and
non-ICU isolates of ﬁve clinically important Gram-negative
pathogens: results of the German T.E.S.T. Surveillance
Programme 2005
M. Kresken, J. Brauers, H. Geiss, E. Halle, E. Leitner, G. Peters,
H. Seifert on behalf of the German T.E.S.T. Surveillance Programme
Objectives: Tigecycline (TGC), the ﬁrst glycylcycline antibacterial
agent, has been shown to be highly effective against a wide range of
bacteria including multiple resistant Gram-negative pathogens such as
extended-spectrum b-lactamase (ESBL)-producing Enterobacteriaceae.
G.-T.E.S.T. is a surveillance programme comprising 15 German
laboratories which monitors the susceptibility of bacterial pathogens to
TGC. The objective of this study was to evaluate the in vitro activity
of TGC against both ICU- and non-ICU isolates of Acinetobacter
baumannii (Ab), Stenotrophomonas maltophilia (Sm) and three major
members of the family Enterobacteriaceae.
Methods: A total of 410 ICU isolates (36 Ab, 120 Enterobacter spp.
[En], 93 Escherichia coli [Ec], 87 Klebsiella spp. [Kl], 74 Sm) and
679 non-ICU isolates (93 Ab, 140 En, 187 Ec, 181 Kl, 78 Sm) were
tested against TGC, doxycycline (DOX), ciproﬂoxacin (CIP), cefotaxime
(CTX), imipenem (IMP), piperacillin-tazobactam (P/T) and other drugs.
MICs were determined by broth microdilution according to German DIN
guidelines in a central laboratory. The MICs of TGC were interpreted
by both EUCAST and FDA criteria. DIN breakpoints were applied to
the other drugs.
Results: TCG exhibited comparable activity against ICU- and non-ICU
isolates of all ﬁve organisms tested. MIC50/90 values for ICU- vs non-
ICU isolates were 0.25/0.5 vs 0.25/0.5 for Ab, 0.5/1 vs 0.5/2 for En,
0.125/0.25 vs 0.125/0.25 for Ec, 0.5/4 vs 0.5/2 for Kl, and 0.5/2 vs
0.5/1 for Sm, respectively. In contrast, resistance to CTX and/or P/T in
En and Kl was more frequently distributed among ICU- than non-ICU
isolates. Overall, susceptibility rates for ICU/non-ICU isolates (%) were
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as follows: Ab – TGC (no breakpoints available, n. b. a.), DOX 97/90,
CIP 69/71, CTX 0/5, IMP 94/100, P/T 64/69, En – TGC EUCAST:93/88
FDA:93/94, DOX 33/29, CIP 94/94, CTX 53/74, IMP 100/100, P/T
58/69, Ec – TGC EUCAST:100/100 FDA:100/100, DOX 47/47, CIP
76/79, CTX 95/94, IMP 100/100, P/T 88/94, Kl – TGC EUCAST:82/88
FDA:90/91, DOX 59/66, CIP 89/93, CTX 93/97, IMP 99/100, P/T 74/96,
and Sm – TGC (n. b. a.), DOX 34/38, CIP 82/79, CTX 0/1, IMP 0/1,
P/T 0/1.
Conclusion: TGC demonstrated excellent in vitro activity against major
Gram-negative pathogens, with almost equivalent activity against strains
from ICU- and non-ICU patients. TGC seems to be a useful drug for
the treatment of infections caused by clinically important Gram-negative
bacteria, even in patients on intensive care units.
P667 Assessment of the polymyxin B antimicrobial activity tested
against 26,921 clinical strains of Gram-negative bacilli
collected in Europe: report from 10 years of the SENTRY
Antimicrobial Surveillance Program
H. Sader, T. Fritsche, M. Janechek, R. Jones (North Liberty, US)
Objective: To evaluate the in vitro activity of polymyxin B tested against
Gram-negative organisms isolated from patients hospitalised in European
medical centres. Emergence of multidrug-resistant (MDR) P. aeruginosa,
Acinetobacter spp. and K. pneumoniae isolates causing life-threatening
infections has restored the potential therapeutic indication for the
parenteral use of the polymyxin class (polymyxin B or colistin).
Methods: A total of 26,921 Gram-negative bacilli isolated from diverse
sites of infection were tested for susceptibility (S) against polymyxin B
by reference broth microdilution method and the results were interpreted
according to the S breakpoint established by the CLSI (2007) for
Acinetobacter spp. and P. aeruginosa (2mg/L). The isolates were
collected through the SENTRY Antimicrobial Surveillance Program
between 2001 and 2006 in 34 medical centres located in 12 European
countries, Turkey and Israel. Concurrent quality control was obtained
and all results were within CLSI ranges.
Results: Polymyxin B showed excellent potency and spectrum against
4,137 P. aeruginosa (MIC90, 2mg/L; 99.5% S) and 1,191 Acinetobacter
spp. strains (MIC90, 1mg/L; 97.9% S). Among other non-fermentative
Gram-negative bacilli, polymyxin B S rates were 92.9% for other
Pseudomonas spp., 88.5% for Aeromonas spp., 78.8% for S. maltophilia,
but only 25.0% for Burkholderia cepacia. Against Enterobacteriaceae,
polymyxin B showed excellent activity overall (MIC90, 1mg/L;
>98% S) against Citrobacter spp., E. coli and Klebsiella spp.; but
inconsistent activity against Enterobacter spp. (MIC50, 1mg/L;
83.3% susceptible) and Salmonella spp. (MIC50, 2mg/L, 65.5% S).
Very limited activity (MIC50, >8mg/L) against Serratia spp. (6.2%
susceptible), indole-positive Proteus (1.5% susceptible) and Proteus
mirabilis (0.8% susceptible) was documented for polymyxin B.
Conclusions: Polymyxin B was highly active against Acinetobacter
spp., P. aeruginosa and Klebsiella spp., including MDR strains. The
emergence of acquired resistance to polymyxin B (also colistin) is of
great concern since these agents are typically regarded as agents of last
resort when no therapeutic options remain. Prudent use of this class is
recommended guided by recently developed in vitro testing guidelines
(M7-A7, M100-S17).
P668 Antimicrobial resistance and prevailing resistance mech-
anisms among problematic clinical isolates of Pseudomonas
aeruginosa from the university hospitals in Soﬁa, Bulgaria
T. Strateva, V. Ouzounova-Raykova, B. Markova, Y. Marteva-Proevska,
I. Mitov (Soﬁa, BG)
Objectives: To assess the current levels of antimicrobial susceptibility
and to evaluate the resistance mechanisms to antipseudomonal antimi-
crobial agents among Bulgarian nosocomial isolates of Pseudomonas
aeruginosa.
Methods: A total of 203 clinical isolates of P. aeruginosa, resistant
to one or more of the following groups of antimicrobials –
extended-spectrum cephalosporins, carbapenems, aminoglycosides, ﬂu-
oroquinolones, were collected from 5 University hospitals in Soﬁa
during 2001–2006. Antimicrobial susceptibilities were detected by
the disk diffusion method and Etest (AB Biodisk, Solna, Sweden).
The resistance mechanisms were studied with phenotypic methods as
previously described by Jarlier V. et al., Lee K. et al. and Miller G. et al.
Polymerase chain reaction and sequencing of genes, encoding Ambler
class A, B and D b-lactamases, were performed.
Results: The antibiotic resistance rates were: to carbenicillin – 93.1%,
azlocillin – 91.6%, piperacillin – 86.2%, piperacillin/tazobactam –
56.8%, ceftazidime – 45.8%, cefoperazone – 86.2%, cefepime –
48.9%, cefpirome – 58.2%, aztreonam – 49.8%, imipenem – 42.3%,
meropenem – 45.5%, amikacin – 59.1%, gentamicin – 79.7%,
tobramycin – 89.6%, netilmicin – 69.6%, and ciproﬂoxacin – 80.3%. 101
of the studied P. aeruginosa isolates (49.8%) were multidrug-resistant.
Structural genes encoding Ambler class A and class D b-lactamases
showed the following frequency: blaVEB-1 – 33.1%, blaPSE-1 – 22.5%,
blaPER-1 – 0%, blaOXA-groupI – 41.3%, and blaOXA-groupII – 8.8%.
IMP- and VIM-type carbapenemases from molecular class B were not
detected.
Conclusions: The studied clinical stains of P. aeruginosa were
problematic nosocomial pathogens. VEB-1 ESBLs appear to have a
signiﬁcant presence among the clinical P. aeruginosa isolates from Soﬁa.
The carbapenem resistance was related to non-enzymatic mechanisms
such as OprD deﬁciency and active efﬂux.
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P669 Epidemiology and genotypes of plasmid-mediated AmpC
b-lactamase produced by clinical isolates of Klebsiella
pneumoniae in Korea
W. Song, C.H. Lee, J.S. Kim, H.S. Kim, Y. Uh, J. Lee, K. Lee (Seoul,
Choongju, Wonju, Daegeon, KR)
Objectives: Plasmid-mediated AmpC b-lactamases (pAmpCs) are
cephalosporinases that confer resistance to a wide variety of b-lactam
drugs and that may thereby create serious therapeutic problems. The
pAmpC-producing organisms are a major concern in nosocomial
infections and should therefore be monitored in surveillance studies.
The present study was conducted to determine the epidemiology
and genotypic distributions of pAmpCs among Klebsiella pneumoniae
isolates in Korea.
Methods: During the period May to July 2004, 60 cefoxitin non-
susceptible isolates of 735 consecutive, nonrepeat isolates of K. pneu-
moniae at ﬁve Korean university hospitals were tested for antimicrobial
susceptibility by broth microdilution methodology. The cefoxitin non-
susceptible isolates were further investigated by AmpC disk tests,
double disk synergy and antagonism tests, isoelectric focusing, multiplex
AmpC PCR, allele-speciﬁc PCR, DNA sequencing, and pulsed-ﬁeld gel
electrophoresis (PFGE)
Results: pAmpC producers were found at all the 5 sites in 48/735
K. pneumoniae (6.5%). Thirty-one of 48 pAmpC producers (64.6%)
also positive tested by double disk synergy tests for extended-spectrum
b-lactamases. Susceptibilities of the pAmpC producers were as follows:
ceftazidime 2%, aztreonam 19%, cefepime 49%, and imipenem 96%.
Among the 48 K. pneumoniae isolates, there were 47 DHA-1 and 1
CMY-1 b-lactamase. Ten PFGE patterns were shown by the DHA-1-
producing K. pneumoniae isolates.
Conclusion: pAmpC producers widespread among Korean medical
institutions. A DHA-1 type in K. pneumoniae was the predominant
enzyme detected. Overall, despite many different PFGE patterns of the
pAmpC producers, some outbreak and epidemic clones appear to be
prevalent according to the hospitals in Korea. Prevention of the spread
of pAmpC producers requires clinical laboratories test for this resistance
mechanism.
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P670 Molecular epidemiology of VIM-1 producing Klebsiella
pneumoniae isolates
E. Kraniotaki, E. Platsouka, E. Belesiotou, M. Nepka, Z. Psaroudaki,
A. Argyropoulou, O. Paniara (Athens, GR)
Objectives: This study was performed to investigate the molecular epi-
demiology of MBL producing blood isolates of Klebsiella pneumoniae,
collected in our tertiary care hospital in the two-year period 2005–2006.
Methods: All consecutive K. pneumoniae isolates from blood cultures
of 140 inpatients (49 in medical wards, 17 in surgical wards, 74 in
ICUs) were tested. They were identiﬁed by standard methods and MICs
were determined by the broth microdilution method, according to CLSI
guidelines. MBL production was screened by Etest MBL. blaVIM-1
alleles were detected by PCR. The clonality of the VIM-1 positive
isolates was examined by PFGE, using the restriction enzyme XbaI.
Results: Seventy out of one hundred forty isolates were found to
produce an MBL activity by the Etest. The MICs of imipenem(IMI)and
meropenem (MER) of the above MBL(+) isolates ranged from 0.5 to
16mg/mL. The same seventy isolates, 50% of the total K. pneumoniae
blood isolates, were found positive for the presence of the blaVIM-1
gene. PFGE results revealed four distinct genotypes among the
MBL(+)isolates.
Conclusion: The presence of the blaVIM-1 gene in 50% of our
K. pneumoniae blood isolates is high. The fact that four distinct
genotypes were involved in the nosocomial spread of the MBL resistance,
indicates horizontal transfer of the blaVIM-1 gene. Continuous
surveillance and control measures, comprising molecular investigation
methods, are necessary in order to eliminate the MBLs.
P671 Emergence of Klebsiella pneumoniae with an AmpC and
blaSHV-11 in a Belgian hospital
T. Vanwynsberghe, A. Boel, R. Cartuyvels, M. Raymaekers, H. De
Beenhouwer (Aalst, Hasselt, BE)
Objectives: From August to October 2006 we observed 12 unrelated
clinical isolates of Klebsiella pneumoniae expressing an unusual
antibiotic susceptibility pattern. Characterisation of these strains was
performed.
Methods: Isolates were found in routine because of ﬂagging by
Phoenix® (BD) as “possible extended-spectrum be`ta-lactamases (ESBL)
positive”. Identiﬁcation was conﬁrmed by 16S rDNA sequencing.
Control testing for ESBL was done with a modiﬁed double-disk synergy
method also including cefoxitin. In order to verify the presence of
an AmpC b-lactamase, the AmpC disk test presented by Black et al
(2005), was performed. The clinical isolates were examined for the
presence of blaTEM, blaTEM-24, blaSHV and blaCTX-M by polymerase
chain reaction (PCR), using consensus primers for the different genes.
Furthermore typing with pulsed ﬁeld gel electrophoresis was performed.
Results: Strains were conﬁrmed as Klebsiella pneumoniae. All were
cefoxitin-resistant. A resistance-induction phenomenon potentiated by
amoxicillin-clavulanic acid was observed with cefotaxime and aztre-
onam. Besides that, scattered colonies were found in the inhibition zones
of ceftazidime, ceftriaxone, aztreonam, cefotaxime, and amoxicillin-
clavulanic acid, but not for cefepime. On the other hand the cefepime
inhibition zone showed a phantom zone in the neighbourhood of
amoxicillin-clavulanic acid.
The cefoxitin-resistance leads to only a few possible causes of
the expressed pattern: porin loss, AmpC b-lactamase production, or
carbapenemase production (metallo-b-lactamase) are all described. In
these strains the AmpC disk test was positive pointing to the presence of
an AmpC b-lactamase. Furthermore the molecular investigation showed
the presence of the blaSHV-11 gene, a gene which is not classiﬁed as
an ESBL-producing gene.
Strains of Klebsiella pneumoniae containing SHV-11 and an AmpC
b-lactamase are rare and have been described mainly in Taiwan. Until
now strains producing these enzymes have been found rarely on
other continents. However in the Far East the prevalence of AmpC
b-lactamases in Klebsiella pneumoniae is rising.
Characteristics of the ﬁrst strain discovered
Ref. nr. AMC ATM CAZ CRO CTX FEP FOX
MIC Ø MIC Ø MIC Ø MIC Ø MIC Ø MIC Ø MIC Ø
67224 >16 11a 2 23a >16 20a 2 26 – 23a,b 2 29c – 6
MIC in mg/mL; inhibition zone (Ø) in mm. AMC: amoxicillin-clavulanic
acid; ATM: aztreonam; CAZ: ceftazidim; CRO: ceftriaxone; CTX: cefotaxime;
FEP: cefepime; FOX: cefoxitin.
aScattered colonies in the inhibition zone; bﬂattening of the inhibition zone towards
AMC; cphantom zone present towards AMC.
Conclusion: Based on the phenotype and the molecular ﬁndings an
AmpC b-lactamase together with SHV-11 is very suggestive. Strains of
Klebsiella pneumoniae harbouring the combination of the blaSHV-11
gene and an AmpC gene are infrequently found in Europe.
P672 Spread of extended-spectrum b-lactamases among clinical
Klebsiella pneumoniae isolates from an Algerian hospital
N. Ramdani-Bouguessa, J. Leita˜o, E. Ferreira, M. Tazir, M. Canic¸a
(Algiers, DZ; Lisbon, PT)
Objectives: Extended-spectrum b-lactamases (ESBLs) are a cause of
resistance to third-generation cephalosporins and aztreonam in Klebsiella
pneumoniae pathogens, which have an important role in nosocomial
infections. The aim of this study was the characterisation of resistance
mechanisms in clinical K. pneumoniae strains from an Algerian hospital.
Methods: Thirty six clinical K. pneumoniae isolates were selected for
this study among a total of 131 Klebsiella spp. ESBL producer strains,
collected among January and June 2005 from different specimens. MICs
were determined by microdilution broth method. PCR and sequencing
were used to screen and identify blaTEM, blaSHV, blaOXA, ampC
and blaCTX-M genes. Environmental context of blaCTX-M genes
was also analysed by PCR, searching for ISEcp1, IS26 and IS903
insertion sequences (IS). Biochemical characterisation was performed
by isoelectric focusing (IEF). Genetic relatedness among strains was
analysed by pulsed-ﬁeld gel electrophoresis (PFGE).
Results: Of a total of 36 isolates, 32 (89%) were multidrug-
resistant (MDR): 30 (94%) were resistant to b-lactam, aminoglycoside
and trimethopim-sulfamethoxazole families, and 2 (6%) also to
ﬂuoroquinolones. Molecular characterisation revealed the presence of
blaTEM-type (n = 33), blaSHV-1 (n = 7), blaSHV-11 (n = 11), blaSHV-
28 (n = 1), blaSHV-33 (n = 1), blaSHV-type with G794→T mutation
(n = 3) or with A299→G mutation (n = 1), other blaSHV-type (n = 11),
blaCTX-M-3 (n = 10), blaCTX-M-14 (n = 1) and blaCTX-M-15 (n = 20)
genes. The novel blaSHV-100 gene was also identiﬁed. ISEcp1 (n = 29)
elements were detected upstream of blaCTX-M genes and IS26 (n = 14)
were also downstream. IS903 (n = 2) were detected downstream of those
genes. IEF conﬁrmed strains as ESBL producers. PFGE analysis revealed
a high clonal heterogeneity, with 16 unique proﬁle types and genetically
related or closely related (>80% similarity) strains forming clusters I to
VII.
Conclusions: K. pneumoniae strains from Algeria showed to be ESBL
producers mainly due to CTX-M (83%) enzymes, however, 19% were
simultaneous ESBL producers from SHV family. The presence of IS
elements in ESBL (CTX-M)-producing K. pneumoniae strains suggests
their important role in the dissemination of these enzymes. Overall,
the presence of IS and the ﬁrst report of CTX-M-14 enzyme in this
country, as well as the new SHV-100 enzyme and the concomitant
MDR phenotypes constitute a microbial threat, as they contribute to
the reducing therapeutic choices.
Beta-lactamases in epidemic Gram-negatives S161
P673 Description of blaTEM-48 ESBL gene carried in addition to
blaSHV-5 gene within the same megaplasmid of nosocomial
Klebsiella pneumoniae strains
M. Alca´ntar-Curiel, J. Ortı´z, R. Morﬁn, C. Gayosso, S. Esparza,
A. Carlos, E. Rodrı´guez-Noriega, J. Santos, C. Alpuche-Aranda
(Mexico, Jalisco, MX)
Background: Prevalence of ESBL-producing Klebsiella pneumoniae
(Kpn) and other Gram-negatives in the United States of America (USA)
is relatively lower compare to Mexico. The most common ESBLs (85%)
described in Me´xico are SHV-5 and TLA-1 and in contrast to US there
was no description of TEM ESBLs in Mexico before.
Methods: We collected nosocomial Kpn strains isolated over a
45 month period in a Mexican Hosp. Antimicrobial susceptibility
patterns were determined by diffusion and dilution methods. Genotyping
was determined by PFGE. E-test, isoelectrical point focusing (pI) and
kinetic studies by spectrophotometric assay were used to deﬁne ESBL
production. Conjugation, restriction endonuclease and Southern blot
were used to characterise plasmids. PCR and sequencing analysis were
used to molecular characterise ESBLs.
Results: Sixty two per cent of the 168 Kpn strains collected were
ESBL producers and they were part of 23 different clones. ESBL in
addition to other antibacterial resistance phenotype were transferred by
conjugation of one plasmid. Most of the clones produced ESBLs with
pI 7.5 and 8.2 and only two (G18 and G56) produced ESBL pI 6.0, 7.5
and 8.2. Those with pI 6.0 and 8.2 were transferred in the same identical
megaplasmid in both clones. ESBL pI 8.2 corresponded to SHV-5. ESBL
pI 6.0 preferentially hydrolyzed cefotaxime and it was PCR ampliﬁed
by blaTEM speciﬁc primers. The deduced protein sequences showed to
be 100% identical to blaTEM-48.
Conclusion: Prevalence of ESBL-producing Kpn strains in Mexico is
very high mostly related to blaSHV-5 gene carried in a plasmid. However
blaTEM genes can also be present in these plasmids. This is the ﬁrst
report of an ESBL-TEM family produced in Mexico.
P674 ESBL evolution in Italy: rapid regional spread of a multidrug-
resistant Klebsiella pneumoniae strain producing CTX-M-15
C. Mugnaioli, E. Manso, G. Rossolini (Siena, Ancona, IT)
Objectives: Extended-spectrum b-lactamases (ESBLs) play a cru-
cial role as emerging resistance determinants to expanded-spectrum
cephalosporins in Enterobacteriaceae. The CTX-M-type ESBLs have
recently undergone a massive spread in several settings, showing a
remarkable potential for dissemination. In Italy, we have recently
observed a remarkable countrywide dissemination of these enzymes in
Escherichia coli (54.8% of ESBL producers) while their prevalence in
Klebsiella pneumoniae was found to be much more limited (12.3% of
ESBL producers). Here we describe the occurrence of a rapid regional
spread of a multidrug resistant (MDR) K. pneumoniae strain producing
CTX-M-15.
Methods: susceptibility testing was carried out as recommended by
CLSI. Genomic relatedness among the isolates was investigated by
RAPD proﬁling. ESBL determinants were detected by PCR, and the
DNA sequence was determined by direct amplicon sequencing. Transfer
of resistance genes by conjugation was assayed by mating experiments.
Plasmids were characterised by RFLP analysis.
Results: during the period October 2005 – June 2006, 65 consecutive
nonreplicate ESBL-positive isolates of K. pneumoniae showing an MDR
phenotype including b-lactams (except carbapenems), aminoglycosides
and ﬂuoroquinolones were referred to the regional Clinical Microbiology
Laboratory of the Marche region (central Italy) from 8 different hospitals.
Most isolates were from ICUs, but some were from medical and surgical
wards. RAPD analyses revealed clonal relatedness among isolates, all of
which were found to carry the blaCTX-M-15 ESBL gene. The gene was
carried on a conjugative plasmid that could be efﬁciently transferred to
E. coli (conjugation frequencies in the order of 10−4 transconjugants per
recipient). Plasmid analysis revealed apparent identity among CTX-M-
15-encoding plasmids from all the isolates.
Conclusion: Results of this study underscore the ability for rapid
multifocal spreading of MDR clones of K. pneumoniae that have
acquired the CTX-M-15 determinant.
P675 High frequency of CTX-M genes among ESBL-producing
Klebsiella pneumoniae in a university hospital in Belgium
H. Rodriguez-Villalobos, C. Laurent, R. Castany-Prado, A. Deplano,
B. Byl, R. de Mendonc¸a, M.J. Struelens (Brussels, BE)
Objectives: CTX-M enzymes are emerging in Europe and have become
prevalent in many institutions among E. cloacae and E. coli but
less frequently in K. pneumoniae. We investigated the molecular
epidemiology of ESBL-producing K. pneumoniae (ESBL-KP) isolates
over a 6 year period in a university hospital in Brussels, Belgium.
Methods: In 2000–2005, ESBL production was screened by double-disk
synergy test. ESBLs were characterised by multiplex PCR for bla genes
of the SHV, TEM and CTX-M family and DNA sequencing. MIC of
12 antimicrobials was tested by agar dilution. ESBL-producing strains
were screened for class I and II integrase by PCR. Strains from a cluster
in 2005 were genotyped by ERIC2-PCR. The clinical charts of patients
were retrospectively reviewed.
Results: Strains (n = 137) were isolated from 84 males and 53 females
with a mean age of 56 years (1−96). Charts (n = 96) patients showed
that acquisition was either nosocomial (45% of them originated from
ICU) or from previous contact with our institution or from other care
centres. Incidence density (cases/10.000 pts-day) since 2000 to 2005
were 0.87, 0.80, 0.16, 0.61, 0.84 and 2.85 respectively. Isolates included
screening isolates from rectal swabs (40%), clinical isolates from urinary
tract (24%), respiratory tract (15%), wounds (7%), blood (4%) and other
sites (10%). Sixty-ﬁve percent of isolates harboured CTX-M enzymes:
CTX-M group 1 in 83%, CTX-M group 2 in 5% and CTX-M group 9 in
13%. The mean proportion of ESBL-KP harbouring bla CTX-M genes
by year was 44% (0% in 2002 to 73% in 2005). SHV and TEM ESBLs
were harboured by 25% and 4% of strains respectively. Class I integrase
was detected in 91% of strains. ERIC typing showed 3 major types (11
to 21 pts) sharing close spatio-temporal linkage (2 harbouring CTX-
M-15 enzymes) in 2005. The proportion of non-susceptible isolates
were: temocillin 9%, ceftazidime 79%, cefepime 45%, piperacillin-
tazobactam 35%, cotrimoxazole 82%, ciproﬂoxacin 43%, gentamicin
48%, tobramycin 61%, and amikacin 22%. Meropenem showed good
activity with MIC50 of 0.06 and MIC90 of 0.25mg/L.
Conclusion: Since 2000 ESBL-KP isolates in our institution frequently
harboured bla CTX-M genes with predominance of group 1. Integrons
of class I were present in the majority of these strains. Two CTX-
M-15 clones were associated with one outbreak in ICU during 2005.
Co-resistance to aminoglycosides and quinolones was frequent but no
resistance to meropenem was observed.
P676 Epidemiology of hospital-acquired Klebsiella pneumoniae
producing CTX-M b-lactamases in Slovenia
K. Mesˇko Meglic, S. Koren, M.F.I. Palepou, E. Karisik, D.M. Livermore,
A. Andlovic, S. Jeverica, V. Krizˇan-Hergouth, M. Mueller-Premru,
K. Seme, N. Woodford on behalf of the Slovenian ESBL Study Group
Objectives: The epidemiology of extended-spectrum b-lactamases
(ESBLs) has changed dramatically, with the emergence of CTX-M
enzymes. They have accumulated rapidly in Escherichia coli, including
those from the community. Less has been reported on the spread
of CTX-M ESBLs in K. pneumoniae though evidence suggests they
are replacing TEM/SHV ESBLs, e.g. in the UK. We investigate the
emergence and epidemiology of CTX-M ESBLs in K. pneumoniae in
Slovenian hospitals.
Methods: From January 2005 to May 2006, isolates of ESBL-producing
K. pneumoniae causing nosocomial infections and/or colonisation were
collected at 11 hospitals in Slovenia (one isolate per patient). ESBL
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production was detected by double-disc synergy tests and ESBL Etests.
MICs were determined and interpreted according to CLSI criteria.
Isolates were screened for blaCTX-M genes using multiplex PCR and
were compared by PFGE of XbaI-digested genomic DNA. Data were
analysed using BioNumerics software.
Results: A total of 177 ESBL-producing K. pneumoniae isolates were
collected. Of these, 60 (33.9%), from 8 hospitals, were positive for
blaCTX-M, all with group-1 enzymes. Clonal relationships among these
60 isolates were studied in comparison with 27 CTX-M-negative strains
from the same hospitals. The isolates represented multiple strains, but
several clusters of related isolates (>80% similarity) were observed,
some of them including isolates from more than one centre. The largest
cluster consisted of 26 clonally-related isolates with group-1 CTX-M
enzymes, 24 of them from one hospital. This outbreak needs further
investigation. Two isolates of this outbreak strain were identiﬁed in
further hospitals, suggesting inter-site transmission. Most isolates had
substantial resistance to both cefotaxime (>128mg/L) and ceftazidime
(>16mg/L), possibly indicating CTX-M-15.
Conclusion: K. pneumoniae with CTX-M enzymes are an emerging
problem in Slovenian hospitals, but currently represent a minority of
ESBL producers of this species. This contrasts with the dominance of
CTX-M enzymes among ESBL-producing E. coli in most European
countries. The epidemiology of K. pneumoniae with CTX-M enzymes
was complex, with the spread of several strains within and between
hospitals. Since K. pneumoniae is an important hospital pathogen this
worrying development merits closer monitoring.
P677 Characterisation of PER-1 extended-spectrum b-lactamase
producing P. aeruginosa clinical isolates from Hungary and
Serbia
B. Libisch, Z. Lepsanovic, B. Krucso, M. Muzslay, B. Tomanovic,
Z. Nonkovic, V. Mirovic, G. Szabo, B. Balogh, M. Fu¨zi (Budapest,
HU; Belgrade, RS)
Objectives: The aim of our study was to assess the contribution of
ESBLs to the MDR phenotype among P. aeruginosa clinical isolates
from Hungary and Serbia and to examine their molecular epidemiology.
Methods: The double-disk synergy test was performed with cefepime,
ceftazidime and amoxicillin-clavulanic acid disks on MH agar plates for
phenotypic ESBL screening. The positive isolates were characterised by
serotyping, RAPD and PFGE analysis and submitted to PCR reactions
using blaPER, blaVEB, blaGES and class 1 integron speciﬁc primers.
The full length of the coding region of the identiﬁed blaPER genes were
sequenced. Mating out assays were carried out on MH agar plates and
transconjugants were selected on plates containing 16mg/l ceftazidime
and 300mg/l rifampicin using the P. putida strain UWC1 as recipient.
Results: A strain collection of MDR P. aeruginosa representing all
geographical regions of Hungary and one Belgrade hospital was screened
by phenotypic methods. This work yielded 4 positive P. aeruginosa
isolates from the Belgrade hospital in Serbia and 2 isolates from two
different hospitals in Budapest, Hungary. PCR experiments revealed
the presence of blaPER genes in all six isolates and indicated that
these genes are not located on class 1 integrons. Sequencing of their
coding region identiﬁed the PER-1 allele in every case. All isolates
belonged to serotype O11. The four positive isolates from the same
Belgrade hospital are clonally related by both PFGE and RAPD thus
represent a cluster of PER-1 positive infections. While macrorestriction
proﬁling could not establish genetic relatedness between the isolates from
Budapest and Belgrade using an 80% cut off value, RAPD indicated a
potential clonal relationship between them with the Dice coefﬁcients
 89%. Interestingly, one of the PER-1 isolates from Budapest was
cultured from the nasal swab sample of a Romanian citizen on admission
to the hospital. This observation raises the possibility that this strain
was imported to Hungary from abroad. The PER-1 gene proved to be
transferable by in vitro conjugation experiments for both strains from
Hungary.
Conclusions: This is the ﬁrst report of ESBL-producing Pseudomonas
spp. from Serbia and Hungary. Our results indicate that ESBL producers
occur only sporadically among P. aeruginosa clinical isolates in Hungary
while a cluster of PER-1 positive infections was identiﬁed in the
Belgrade hospital.
P678 Characterisation VIM-1-producing Pseudomonas aeruginosa,
Enterobacter cloacae and Klebsiella pneumoniae strains from
Germany: report from SENTRY Antimicrobial Surveillance
Program
L. Deshpande, A. Rodloff, G. Just-Nuebling, R. Jones, H. Sader (North
Liberty, US; Frankfurt, Leipzig, DE)
Objective: To characterise carbapenem (CARB)-resistant P. aeruginosa
(PSA) and Enterobacteriaceae strains isolated in German medical centres
participating in the SENTRY Program. The GIM class of metallo-
b-lactamases (MBL) was originally described by our programme in
clinical isolates from Germany and has not been observed again or
in other nations. In Germany, MBL-producing strains are still rare in
contrast to other European countries.
Methods: From 2000 to 2006, a total of 8,846 isolates were submitted to
the SENTRY Program monitor from six German centres, including 596
PSA, 256 E. cloacae (ECL) and 348 K. pneumoniae (KPN). The isolates
were tested for susceptibility (S) by reference (CLSI) broth microdilution
methods and those with decreased S to imipenem (IPM), meropenem
and ceftazidime were routinely screened for MBL production by disk
approximation tests and/or MBL Etest (AB BIODISK) strips. Isolates
with screen-positive results were conﬁrmed by PCR using generic
primers for IMP, VIM, SPM and GIM enzyme types. MBL gene
sequencing and molecular typing (automated ribotyping, PFGE) were
additionally performed to characterise MBL and to evaluate clonality.
Results: Decreased S to CARB (IMP MIC, 2mg/L) was observed in
3 ECL (1.2%) and 1 KPN (0.3%) strains, while 77 PSA (13.1%) were R
to IPM (MIC, 16mg/L). Among IPM-R PSA, 10 strains had a positive
MBL screen test and were PCR-positive for blaGIM-1 (6 strains from
Du¨sseldorf described in 2002) or blaVIM-1 (4 strains from Frankfurt
isolated in 2005–2006). The ECL and KPN strains were from Leipzig
(2005 and 2006) and PCR-positive for blaVIM-1. The blaVIM-1 was
located within a class 1 integron for all VIM-1-producing strains. VIM-
1-producing PSA showed identical/similar PFGE patterns, while the ECL
strains each had a distinct molecular typing pattern.
Distribution of MBL types in German samples (2000–2006)
MBL-type Location (no.) Species (no.) No. of PFGE patterns
GIM-1 Du¨sseldurf (6) P. aeruginosa (6) 1
VIM-1 Frankfurt (4) P. aeruginosa (4) 1
Leipzig (4) E. cloacae (3) 3
K. pneumoniae (1) 1
Conclusions: blaVIM-1 has emerged and is rapidly disseminating as
clones and also among clonally unrelated strains in diverse areas of
Germany. Long-term surveillance and continued screening for MBL
genes among isolates with decreased S to CARBs will be essential to
control of dissemination by this important R mechanism.
P679 Dissemination of a CMY-16 producing clone of P. mirabilis in
long-term care and rehabilitation facilities of northern Italy
E. Nucleo, R. Migliavacca, M. Spalla, C. Terulla, M. Debiaggi,
M. Balzaretti, A. Migliavacca, A. Navarra, L. Pagani (Pavia, Milan, IT)
Background: The use of cephamycins and b-lactam-inhibitor combina-
tions to counter the threat of extended-spectrum b-lactamases (ESBLs)
mediated resistance determined a shift toward non-ESBL phenotypes
in species without inducible chromosomal AmpCs. The CMY-LAT-type
enzymes are a group of molecular acquired class C b-lactamases (CBLs)
that exhibit a broader spectrum of resistance than classical ESBLs.
Epidemiology of vancomycin-resistant enterococci S163
Methods: 204 non-repetitive P. mirabilis isolates intermediate/resistant
to cefotaxime, collected from May 2003 to March 2006 from inpatients
in three Long Term Care and Rehabilitation facilities of Northern Italy
(ASP S. Margherita, IRCCS S. Maugeri and ASP P. Redaelli), were
included in the study. The isolates were recovered from urinary tract.
The production of an ESBL activity was screened by the CLSI diffusion
test; IEF of crude bacterial lysates was performed to detect the pIs of
b-lactamase bands. The nature of the resistance genes and the clonal
relationships between the strains, were studied by molecular techniques
such as ampliﬁcation, sequencing and PFGE (SﬁI).
Results: 18/204 (8.8%) strains showed an AmpC phenotype. Analytical
IEF revealed the presence of 2 b-lactamase bands, of pI 5.4 and >8.4
respectively, in all the isolates. The pI 5.4 band was unable to hydrolyze
extended-spectrum cephalosporins (CTX, CAZ, FEP), monobactams
(ATM) and cefoxitin (FOX) and was likely contributed by a TEM-
type enzyme. The alkaline pI band was active against both FOX, CTX
and CAZ, suggesting the presence of an acquired CBL. PCR and
sequencing revealed the occurrence of the CMY-16 enzyme, a variant
of the CMY/LAT lineage. All the 18 CMY-16 producers were clonally
related. The incidence of CMY genes within the three hospitals was:
10/64 (15.6%) at ASP S. Margherita; 2/15 (13.3%) at IRCCS S. Maugeri;
6/125 (4.8%) at ASP Redaelli respectively.
Conclusion: Resistance of P. mirabilis to expanded-spectrum
cephalosporins is an increasing problem in several settings. Acquired
AmpC-type b-lactamases are overall less common than class A ESBLs,
but emergence of these enzymes in P. mirabilis has been reported in
some areas. This report focus on the increasing diffusion of an AmpC-
type variant in P. mirabilis; the clinical strains investigated in this work
were all clonally related, and shared a common structure of genetic
environment of CMY-16 determinant, suggesting a worrisome vertical
spread of diffusion.
P680 Occurrence of metallo-b-lactamases in Pseudomonas
aeruginosa clinical isolates resistant to carbapenems
D. Vitti, E. Protonotariou, D. Soﬁanou (Thessaloniki, GR)
Objectives: The main mechanism of resistance to carbapenems is
the production of metallo-b-lactamases (MBLs). These enzymes are
plasmid-mediated and their spread in P. aeruginosa has become of great
concern. The aim of this study was to determine the occurrence of
MBLs in clinical isolates of P. aeruginosa resistant to carbapenems in
our hospital.
Methods: A total of 36 nonrepetitive strains of P. aeruginosa
resistant to carbapenems were obtained from clinical specimens
between February 2003 to November 2005. The identiﬁcation and
susceptibility testing were performed by the VITEK-2 automated system
(bioMe´rieux, France). Imipenem (IMP) and Meropenem (MER) MICs
were determined by E-test. EDTA-IMP double disc synergy test was
carried out for screening of MBLs production. All isolates were subjected
to PCR assay with speciﬁc primers and DNA sequencing. Pulsed-ﬁeld
gel electrophoresis (PFGE) was used to delineate clonal relationship
between strains.
Results: Among the 36 carbapenem-resistant isolates of P. aeruginosa,
18 were positive by PCR for the presence of blaVIM. All these isolates
had MIC of IMP and MER >32mg/mL and showed a synergy between
EDTA-IMP. Sequence analysis of PCR product revealed the presence
of VIM-2 gene. Eight VIM producing strains harboured also a blaSHV
gene and gave a synergy using disks of amoxicillin+clavulanate and 3rd
generation cefalosporins. Phylogenetic tree using UPGMA (pairwise-
unweighted) algorithm with QuantityOne Software (BIORAD), revealed
different PFGE patterns with predominance of type A that comprised 5
isolates.
Conclusions: This study illustrates the spread of genes encoding MBLs
in P. aeruginosa. High percentage of MBLs-producing strains were,
in addition, SHV-producers. Appropriate control measures including
introduction of MBL screening in regular basis, are necessary in order
to prevent wider dissemination of these genes.
Epidemiology of vancomycin-resistant
enterococci
P681 Emergence of worldwide epidemic clones of vancomycin-
resistant Enterococcus faecium in a Northern Spain hospital
M. Romo, H. Tomita, Y. Ike, L. Martı´nez-Martı´nez, M. Francia
(Santander, ES; Maebashi, JP)
Objectives: Vancomycin-resistant enterococcal outbreaks are unusual
in Spain. However, between October 2002 and April 2004, 31 clinical
isolates of VanA E. faecium were reported in our hospital. These isolates
showed high-level resistance to ampicillin, erythromycin, ciproﬂoxacin
and aminoglycosides. Preliminary PFGE typing indicated the presence
of two different patterns. The objective of this study was to determine
the genetic lineages from which our isolates were derived along
with the conjugative elements involved in the vancomycin resistance
dissemination in our institution.
Methods: E. faecium isolates were genotyped by MultiLocus Sequence
Typing (MLST). The clonal relationship between the isolates was
analysed by the allelic proﬁles of the sequence types (STs) through
the web site (http://www.mlst.net). Southern Hybridisation methods
using a digoxigenin-based nonradioisotope system (Boehringer GmbH,
Mannheim, Germany) and standard protocols were performed to
determine the presence of pMG1-like plasmids.
Results: Among the 31 E. faecium isolates, two STs were identiﬁed,
ST132 (representing 85% of the isolates) and ST18 (15%), being
coincidental with the two PFGE patterns previously shown. Analysis
of the allelic proﬁle of the STs suggested all the isolates be assigned to
clonal complex 17, with each ST being a double locus variant of ST17,
a well-known world wide epidemic strain. ST132 strains were shown
to harbour the highly conjugative pMG1-like plasmids, frequently found
in vancomycin resistant E. faecium clinical isolates in Japan and USA.
pMG1 was absent from ST18 isolates.
Conclusions: Our data suggested the outbreak occurred in our
hospital was caused by two hospital adapted multi-resistant E. faecium
clones forming part of the major circulating epidemic lineage in the
world. pMG1-like plasmids appear to be involved in the vancomycin
dissemination, at least in our predominant clone.
P682 Increase of VRE in a German university hospital
A. Kola, F. Schwab, I. Chaberny, S. Suerbaum, P. Gastmeier (Hannover,
Berlin, DE)
Objective: To analyse the epidemiology of vancomycin-resistant
E. faecium (VREfm) at Hannover Medical School (MHH), a 1400 bed
university hospital with 40000 admitted patients per year. Starting in
2004, an increase of VREfm was observed: The proportion of VREfm
raised from 1.2% (ﬁrst half-year of 2004) to 31.5% (ﬁrst half-year of
2006) in spite of isolation precautions.
Methods: VREfm were typed by PFGE (SmaI-restriction). PFGE
proﬁles yielding a similarity of >80% using the Dice coefﬁcient (<4
different fragments) were considered as clonally related. The simple
diversity index SD (different genotypes//N isolates ° 100) was calculated.
Results were compared to those obtained for 239 isolates of Vancomycin-
susceptible E. faecium (VSEfm). In addition, multiple-locus variable-
number tandem repeat analysis (MLVA) was performed. Typing results
and conventional epidemiology were applied for transmission analysis.
Results: Excluding copy-strains, 171 isolates of 166 patients hospitalised
on 30 wards were analysed: PFGE revealed 57 different genotypes, of
which 36 were unique and 21 appeared in clusters of 2 – 31 isolates
belonging to the same type. The most frequent genotype was present on
14 wards. With the exception of three clusters of 2, 3 and 5 isolates,
there was no genotype that was related to a speciﬁc ward. Sixty-
one patients (37%) with VREfm were in the general surgery unit and
38 patients (23%) in the haematological oncology unit. In these units,
30% of VREfm were due to patient-to-patient transmissions. SD was
signiﬁcantly different between VREfm and VSEfm (33.3 vs. 44.8, RR
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VREfm/VSEfm = 0.745, CI95: 0.58–0.96, p = 0.024), as were the cluster
sizes (number of isolates belonging to one genotype) of VREfm and of
VSEfm (mean: 6.47 vs. 4.77, median: 3 vs. 2, p = 0.028). MLVA-analysis
of the most prominent PFGE-cluster revealed the involvement of the
epidemic clonal complex-17 (MT 1, MT 3 and MT 7).
Conclusion: The lower SD and the greater median cluster size of VREfm
express a higher genetic relationship of VREfm in comparison to VSEfm.
Considering the 36 unique genotypes and the occurrence of identical
genotypes on different wards without epidemiological linkage, this is
not explained by simple patient-to-patient transmission of VREfm, which
accounted for approximately 30% of VREfm. Further analysis has to be
done to clarify the causes of the increase in VREfm at MHH.
P683 Molecular characterisation of vancomycin-resistant
Enterococcus isolates in clinical samples from Chile
G. Saavedra, J. Hormaza´bal, A. Maldonado, J. Mota, F. Baquero,
J. Silva, R. del Campo (Panama´, PA; Santiago de Chile, CL; Madrid,
ES; Antofagasta, CL)
Objectives: The aim of this work was to characterise a collection of
vancomycin-resistant isolates recovered from clinical samples in Chile.
Methods: A total of 70 vancomycin resistant enterococal strains
recovered during 2003–2005 was included (10 E. faecalis and 60
E. faecium). Strains were recovered from different samples (34 faecal
swabs, 15 urine, 6 exudates, 3 blood and 12 others) corresponding to
unrelated patients attended in 16 different hospitals corresponding to
four regions of Chile. All strains presented vancomycin-resistance and
were sent to the National Reference Institute. Susceptibility to several
antimicrobial agents was tested using the microdilution test. Clonal
relationships were studied by PFGE-SmaI assays, and presence of the
vanA or vanB genes were demonstrated by PCR experiments. Amplicons
were puriﬁed and sequenced. Presence of ace, agg, cylA, esp, efaA and
gelE genes was also investigated in the different clones detected.
Results: All strains were resolved into 7 different clones (2 E. faecalis
and 5 E. faecium) showing resistance to vancomycin, and susceptibility to
teicoplanin. Resistance to macrolides, tetracycline, quinolones, b-lactams
(only in E. faecium clones), and high level resistance to aminoglycosides
was observed in all enterococcal clones. Positive ampliﬁcation with the
generic vanB primers was observed, and the sequences correspond to
the previously described vanB2 variant. Presence of ace, agg, cylA, esp,
efaA and gelE genes was only detected in the E. faecalis clones.
Conclusions: vanB2-containing E. faecium and E. faecalis clones have
been isolates dispersed in 16 different hospitals in Chile.
P684 Molecular epidemiology of vancomycin-resistant enterococci
isolated in 2003–2005 in a large teaching hospital in Warsaw
W. Grzybowska, G. Mlynarczyk, A. Mlynarczyk, A. Mrowka, S. Tyski,
M. Luczak (Warsaw, PL)
Objectives: Enterococcal infections caused by multiresistant bacteria
might constitute a severe problem for patients with serious diseases.
Glycopeptides are the most frequently used antibiotics in such cases.
In the investigated hospital, vancomycin resistant enterococci (VRE) did
not occur frequently up to the 2003. A signiﬁcant increase in the number
of VRE isolated recently has suggested a possibility of an outbreak.
The aim of this study was to perform epidemiological analysis of VRE
strains isolated from clinical materials of hospitalised patients.
Methods: All VRE strains originated from patients of the investigated
hospital and were isolated in the years 2003–2005. Strains were initially
identiﬁed in the Diagnostic Laboratory of Microbiology Department.
Identiﬁcation was performed by API ID32 Strep and the susceptibility
was tested by ATB Entero. Vancomycin resistant or intermediate isolates
were checked by E-tests. All resistant strains were analysed for the
presence of vanA, van B, vanD or vanG ligase genes by PCR. The
identiﬁcation of the strains was proven by PCR with application of
the ddl primers. Only one VRE isolate from one patient was taken
to epidemiological analysis. Strains were compared on the basis of
differences in patterns obtained by PFGE of SmaI-restricted whole
genomes analysis.
Results: Although the frequency of enterococci isolation in our
laboratory was usually about 1000 strains per year, until the 2003, VRE
occurred sporadically. In 2003 they appeared in one of internal wards,
and were isolated from urine (9 patients) and from blood (1 patient).
In 2004 VRE were isolated from 9 patients of the same ward and
appeared in The Intensive Therapy Unit (OIOT) (2 patients) and in
surgery (2 patients). In 2005 VRE were isolated from 11 patients of
internal ward, from one patient of OIOT and from 21 patients of surgery.
All together 53 VRE isolates were available for PFGE examination
(12 E. faecalis, 41 E. faecium). All examined strains possessed vanA
determinant of resistance. PFGE analysis revealed that most E. faecium
strains belonged to one of the 3 clusters. The same strains occurred in
three wards of the hospital. The PFGE relationship analysis between
isolated E. faecium and between E. faecalis strains showed their high
similarity: 75% and 82%, respectively.
Conclusion: The PFGE and SmaI restrictase turned out to be very useful
for epidemiological analysis of enterococci.
P685 Molecular characterisation of vancomycin-resistant Ente-
rococcus faecium isolated from German hospitals between
1991 and 2006 reveals differences in emergence and spread
G. Werner, I. Klare, W. Witte (Wernigerode, DE)
Objectives: To investigate the molecular background of vanA-type
glycopeptide resistance in 57 clinical vancomycin-resistant Enterococcus
faecium (VREF) from 29 German hospitals of three separate periods
(group I, 1991–1995; II, 1996–1999; III, 2004–2006).
Methods: Isolates were characterised by multi-locus sequence typing
(MLST), SmaI macrorestriction analysis in pulsed-ﬁeld gel electrophore-
sis (PFGE), and multiple-locus variable-number tandem repeat analysis
(MLVA). Phylogenetic relatedness between strains was identiﬁed using
BioNumerics and eBURST software. Distribution of virulence genes esp
and hylEfm was investigated by PCR. The structure of the vanA gene
clusters was investigated by PCR, long PCR, sequencing and Southern
hybridisations.
Results: Group I isolates (n = 6) are quite diverse by different typing
methods, lack mostly any of the investigated virulence genes, and
possess all an identical vanA cluster type. Two and all group II and III
isolates belong to the clonal complex of hospital-adapted strain types
(MLST CC17, MLVA C1). Isolates of group II (n = 8) are identical by
MLST (ST-117), PFGE and MLVA (MT-12), harbour all the esp but
not the hylEfm gene and possess an identical or slightly modiﬁed vanA
cluster type (insertion of ISEf1). Group III VREF (n = 43) are rather
diverse constituting different strain types, different virulence markers
and vanA clusters. Within this diversity we found supportive data for
a dissemination of related VREF among various hospitals and spread
of identical vanA gene clusters into different strain types within single
hospitals.
Conclusions: Our data suggest that VREF from the three periods
investigated here have evolved differently. The increase in the rates of
VREF among German hospital patients within the last two years might
be rather complex and due to different molecular events and scenarios.
P686 Nosocomial outbreak of vancomycin-resistant Enterococcus
faecium at a Turkish University Hospital
A. Ozcan, B. Ozhak Baysan, D. Ogunc, D. Inan, T. Naas, D. Colak,
P. Nordmann (Antalya, TR; Kremlin-Bicetre, FR)
Objectives: Vancomycin-resistant enterococci (VRE) are widespread
worldwide. Despite growing concern about VRE as nosocomial
pathogens, especially in the USA, they are rarely isolated in Turkish
hospitals. In 2001, unrelated VRE isolates were ﬁrst described in Turkey
(Colak D, JAC, 2002, 50:397–401.). Here we report the emergence of
a novel VRE clone responsible of a nosocomial outbreak at a Turkish
University Hospital.
Epidemiology of vancomycin-resistant enterococci S165
Methods: Strains correspond to either clinical samples or rectal swab
specimens for analysing carriage. Identiﬁcation, susceptibility testing,
molecular characterisation and molecular comparison of the strains
(PFGE and MLST) were performed according to standard techniques.
Virulence genes were searched for by PCR.
Results: Thirty six VRE were isolated from ten patients between
June 2005 and January 2006, of whom nine were hospitalised at
the Department of Pediatrics and one of them at the Department of
Haematology. Six patients were carriers, two had urinary tract infections
and two patients had bloodstream infections. All isolates were E. faecium
and expressed high level glycopeptide resistance (MIC for vancomycin:
>256mg/L and for teicoplanin: >48mg/L). These strains were also
resistant to ampicillin, clindamycin, erythromycin and displayed high-
level resistance to gentamicin, kanamycin and streptomycin whereas they
remained susceptible to levoﬂoxacin, linezolid, and tigecycline.
PFGE analysis revealed that these 36 E. faecium isolates were clonally
related, except for four isolates (three from patient 9 and one from
patient 10). The epidemic clone was found in all 10 patients. They were
all of vanA genotype, and esp positive. The vanA gene was part of a
vanA-type operon for expression of resistance located on a transposon
similar to Tn1546 in the VanA prototype strain E. faecium BM4147,
except for the presence of Insertion Sequences.
Conclusion: This work further reports emergence of VRE in Turkey as
observed now in many European countries. Implementation of stringent
hand disinfection and environmental disinfection policies, as well as
measures for patient isolation contained this outbreak of VRE, and since
February 2006 no new VanA E. faecium strains was isolated from these
units.
P687 Vancomycin-resistant Enterococcus faecium emergence during
a nosocomial outbreak of Clostridium difﬁcile diarrhoea
A. Moreno, A. del Rio, D. Pereda, A. Cangussu, M. Tuset, M. Castella´,
C. Cervera, L. Linares, J. Martinez, C. Mestres, J. Vila (Barcelona, ES)
Objectives: Vancomycin-resistant Enterococcus faecium (VRE) have
been recognized as microorganisms capable of causing epidemics in
critically ill patients; however, in our institution are very infrequent. For
this reason, we describe three cases involving VRE infection during a
nosocomial outbreak of Clostridium difﬁcile diarrhoea in patients with
vascular diseases.
Methods; From January to April 2006, 45 patients admitted from the
vascular surgery department developed diarrhoea. Faeces samples were
taken from these patients in order to determine cultures, parasites and
toxins of C. difﬁcile. Data related to the diarrhoea outbreak and the
appearance of Vancomycin-resistant Enterococcus faecium strains in this
population were recorded.
Results: We included 45 patients with diarrhoea, 31 of whom were
men (70%), with a mean age of 70 years (SD 10). Median length of
stay was 16 days (IQR 8;31). Thirty patients (66%) received antibiotics
due to surgical wound infection prior to the diarrhoea, 15 received
vancomycin during 3 days (IQR 1; 10) and 26 received quinolones during
7 days (IQR 2.7; 10.2). Six patients died (13%) due to other causes
not related to the diarrhoea. All bacterial cultures and parasites from
faeces were negative. Nineteen cases (42%) had a positive C. difﬁcile
toxin. Thirteen patients received oral vancomycin (29%) and 32 (71%)
oral metronidazole. Median length of stay of patients with C. difﬁcile
diarrhoea was 18 days (IQ 9; 27) vs. 12 (IQ 7; 38) days of patients
without a C. difﬁcile diagnosis (p=NS). In 54% of patients that received
quinolones prior to the diarrhoea, a positive C. difﬁcile toxin was
found (p = 0.07). Three patients had a VRE surgical infection developed
during the diarrhoea treatment. Three out of 23 patients that received
vancomycin developed VRE (13%), one before diarrhoea and two as a
result of C. difﬁcile diarrhoea.
Conclusions: During a nosocomial outbreak of C. difﬁcile diarrhoea,
three Vancomycin-resistant Enterococcus faecium strains were isolated
in patients with surgical wound infection. These three patients had been
treated with vancomycin. Therefore we suggest not using this drug as
initial treatment for nosocomial C. difﬁcile diarrhoea.
P688 Interhospital dissemination of glycopeptide resistance among
enterococcal clinical isolates from Portugal is associated to
spread of epidemic pMG1-like plasmids carrying diverse
Tn1546 variants
A. Freitas, C. Novais, T.M. Coque, L. Peixe (Porto, PT; Madrid, ES)
Objectives: Vancomycin resistant enterococci (VRE) are increasing in
European hospitals, Portugal having one of the highest VRE rates. Our
objective was to characterise the genetic context of representative clinical
strains in order to understand the role of horizontal gene transfer in the
dramatic recent spread of VRE in our area.
Methods: We analysed 43 E. faecium and 21 E. faecalis isolates (37
PFGE types) collected from 3 Portuguese hospitals in different regions
(1996–2003). Susceptibility to 13 antibiotics was studied by standard
agar dilution method. Clonality was established by PFGE and transfer of
vancomycin resistance was achieved by broth and ﬁlter matings. Tn1546
backbone was determined by overlapping PCR and Tn1546 location
was identiﬁed by Southern hybridisation of I-CeuI and/or S1 nuclease-
digested genomic DNA. Plasmids characterisation included comparison
of EcoRI-RFLP patterns and hybridisation with probes for vanA and
pMG1, pAD1 and pAMb1 plasmids.
Results: Fourteen Tn1546 types, mostly containing ISEf1 or IS1216V
within vanX-vanY region, and located on conjugative plasmids of
variable size (50–225 kb) were identiﬁed. Two Tn1546 types represent
56% of the cases (PP4 and PP5). Plasmids of 80−95 kb showing similar
EcoRI-RFLP patterns and related 4 ISEf1-Tn1546 variants (types PP4,
PP5, PP9 and PP24) were collected from 21 strains of 3 hospitals during
7 years. Plasmids of 45–110 kb corresponding to 7 unrelated patterns
harbouring IS1216V-Tn1546 variants (4 Tn1546 types) were collected
from 12 strains of 3 hospitals during 2 years. All of them showed
homology with known pMG1 enterococcal plasmid by hybridisation.
Conclusions: Persistent epidemic plasmids highly related to the
wordlwide spread pMG1 have a signiﬁcantly role in intra and
interhospital dissemination of VRE in Portugal. The Tn1546 diversity
found among related plasmids suggests evolution of speciﬁc elements
by different genetic events.
P689 Genotypic characterisation by PFGE and ribotyping of
clinical isolates of vancomycin-resistant enterococci in Iran
S. Eshraghi, M. Pourshaﬁe (Tehran, IR)
Objectives: Vancomycin resistant enterococci (VRE) is becoming a
major concern in the clinical settings as the rate of occurrence of
Enterococcus spp. is increasing. Epidemiological knowledge of the
clonal dissemination of vancomycin resistant. enterococci (VRE) spp.
is fundamental for the implementation of control measures. This study
conceived to provide information on the diversity of vancomycin resistant
enterococci in Iran.
Methods: The clinical enterococcal isolates which were collected
sporadically from the hospitalised patients and outpatients in three
major hospitals in Tehran. A single specimen was obtained from each
patient. The susceptibility tests of the isolates were performed and
interpreted according to the guidelines from the Clinical and Laboratory
Standards Institute (CLSI). The structures of Tn1546 like elements were
analysed by long PCR-RFLP using a single primer targeting the inverted
repeat sequence of Tn1546. All of isolates were typed by Pulsed-ﬁeld
Gel Electrophoresis (PFGE) using SmaI and ribotyping using EcoRI
restriction enzymes.
Results: Fifty (5.7%) VRE isolates were obtained out of nine hundred
enterococci spp. samples were collected. All VRE isolates showed a
high level vancomycin resistance and harboured vanA gene. Antibiotic
susceptibility tests showed that the isolates were resistant to ampicillin
(98%), ciproﬂoxacin (92%), gentamicin (96%), erythromycin (92%),
tetrracyclin (28%), and chloramphenicol (4%). L-PCR-RFLP revealed
the presence of two groups among the 50 human strains tested.
Genotyping by PFGE using SmaI and ribotyping using EcoRI restriction
enzyme grouped the isolates into 18 and 12 types, respectively.
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Conclusion: The results indicated that the clinical VRE strains are highly
diverse in term of bacterial clonality. But it was shown that different
VRE isolated from patients’ samples carried a similar Tn1546 with same
genomic structure.
P690 Clonal diversity of vancomycin-resistant Enterococcus faecium
isolated from three university hospitals in Daegu, Korea
D.T. Cho, J.Y. Oh (Daegu, KR)
Objectives: To determine the evidence for molecular epidemiology
by genetic characterisation of related resistant genes and virulence
associated genes in high-level glycopeptide and aminoglycoside resistant
clinical isolates of Enterococus faecium.
Methods: Species identiﬁcation of a total of 58 vancomycin-resistant
E. faecium (VREFM) was conﬁrmed by ddl gene PCR. Conjugal transfer
of resistance was done by ﬁlter mating. Vancomycin resistance gene
(van), aminoglycoside resistance genes and ﬁve virulence genes were
detected by multiplex PCR. Mapping of transposon Tn1546 structure by
PCR, pulse-ﬁeld gel electrophoresis (PFGE) and multi-locus sequence
typing (MLST) were attempted for clustering of isolates to study clonal
diversity and genetic relatedness.
Results: All isolates carried vanA gene. The aac6-aph2 gene was
detected in 53 (91.4%) of isolates and 27 (46.6%) showed aadE gene.
Macrolide resistance gene ermA was detected in 3 (5.2%) VREFM
isolates while 55 (94.8%) showed ermB. Virulence associated genes, esp
and hyl were detected in all 58 VREFM and in 34 (58.6%) respectively.
Other virulence genes asa1, gelE and cylA were not detected. Virulence
gene hyl was transferred by conjugation with vanA and gentamicin-
resistance gene. Eleven types of (A to H) transposon Tn1546-like
element were obtained by PCR mapping. Insertion sequence IS1216 in
the vanX-vanY intergenic region in Tn1546 structure were conﬁrmed in
49 strains (A to F). Six clusters could be estimated by PFGE analysis.
MLSTs of 58 VREFM isolates showed 11 different sequence types (ST).
Thirty-eight (65.5%) of 58 strains belonged to clonal complex CC78
and then these were subdivided into three types; ST192 (32.8%), ST203
(19.0%) and ST78 (13.8%). ST203 was detected in all three university
hospitals but ST192 and ST78 were present only in KNU-hospital.
Conclusion: Vancomycin resistance gene, vanA and aminoglycoside
resistance gene were located in conjugally transferable plasmid which
carried Tn1546-like element and virulence gene hyl. Clustering based
on PFGE analysis showed relatively more close relatedness with Tn1546
type and MLST than those relatedness between Tn1546 type and
MLST. Genomic evolution of nosocomial isolates of VREFM could
be conﬁrmed through molecular characterisation, including PFGE,
transposon typing and MLST.
P691 Vancomycin-resistant enterococci still persist in slaughtered
poultry in Hungary 8 years after the ban on avoparcin
A. Ghidan, O. Dobay, E. Kaszanyitzky, P. Samu, S. Amyes, K. Nagy,
F. Rozgonyi (Budapest, HU; Edinburgh, UK)
Objectives: Vancomycin-resistant enterococci (VRE) are one of the
major problems in the ﬁeld of antibiotic resistance. Fortunately, the
proportion of human VRE isolates remains very low in Hungary;
however, VREs persist in animal samples. In this report we examined
the glycopeptide susceptibility of enterococci, isolated in 2005, from
slaughtered animals, within the conﬁnes of Hungarian Antibiotic
Resistance Monitoring System. We determined the presence of the van
genes and their genetic relatedness in enterococci from poultry.
Methods: Enterococcus sp. (n = 175) were collected from intestinal
samples of slaughtered poultry in 2005. The origin of the samples was
registered at county level. After screening the strains with 30 microgram
vancomycin disc 19 (86%) intermediate resistant and 4 (3%) resistant
strains were found. The MICs of vancomycin and teicoplanin were
determined by agar dilution. The presence of the van genes was detected
by PCR. The identity of the van gene carrying strains was identiﬁed by
PCR using genus-speciﬁc and species-speciﬁc primers. The potential
similarities of these strains was determined by PFGE (digesting with
SmaI).
Results: The distribution of MICs among 23 enterococcus strains which
were intermediate or resistant to vancomycin were 0.25mg/L (4.4%),
2mg/L (8.6%), 4mg/L (8.6%), 8mg/L (61%), 16mg/L (8.6%) and
256mg/L (8.6%). The MICs of teicoplanin were 0.25mg/L (4.3%),
1mg/L (8.6%), 4mg/L (78.3%), 16mg/L (4.3%), and 256mg/L (4.3%).
The two most vancomycin-resistant strains were vanA carriers (1
E. faecalis and 1 E. faecium). No strains carried vanB, vanC1 or
vanC2. The E. faecalis strain had high resistance to both glycopep-
tides (MICs = 256mg/L) and the E. faecium had high resistance to
vancomycin (MIC= 256mg/L) and intermediate resistance to teicoplanin
(MIC= 16mg/L). These strains originated from two different counties of
Hungary. These 23 strains were not closely related to one another.
Conclusion: Avoparcin was used as a growth promoter for broiler
chickens since 1989 but was banned in 1998. Despite this prohibition,
the VRE strains only disappeared in 2003. However, in 2004 strains
only with higher MICs to vancomycin were detected and, in 2005, two
strains were vanA positive. The farms that produced these strains can be
reservoirs of VRE and the affected farms should change the technology
of disinfection and breeding in order to prevent the emergence of high
numbers of human VRE isolates in Hungary.
P692 A two-year study of antibiotic resistance in Enterococci
isolated from food, abattoirs and farms in Scotland and its
link to hospital-acquired infections
L. Vali, A. Hamouda, A. Mateus, D.J. Walker, J. Dave, A. Gibb,
S.G.B. Amyes (Edinburgh, Glasgow, UK)
Objective: To establish whether there is any signiﬁcant link between
enterococci originated from animals and the clinical human strains,
indicating animals infecting human populations in hospitals.
Methods: From 2004–2006 a total of 55 different food stuff including
dairy and meat products from commercial outlets, 100 faecal samples
from cattle on Scottish beef cattle farms, and from abattoirs; 100 faecal,
460 nostril, skin, and ear swab samples collected from pigs, cattle and
sheep. Fifty clinical E. faecium and E. faecalis were isolated from
hospitalised patients from two hospitals in Edinburgh. Selective media
was used for isolation followed by phenotypic and genotypic species
characterisations. The minimum inhibitory concentrations of antibiotics
were determined by the agar dilution method. PCR and sequencing
determined the van genes responsible for vancomycin resistance. Pulsed-
ﬁeld gel electrophoresis (PFGE) was used for molecular typing of the
strains, and the presence of esp virulence gene was determined by PCR.
Results: Enterococci were isolated from 20 food, 50 faecal samples,
and 27 swab samples. In total 14 strains were resistant to vancomycin,
of which 5 were highly resistant to vancomycin (MIC> 32) and
teicoplanin (MIC> 16). vanA and vanC1 genes were detected in 10 and
7 strains respectively. PFGE demonstrated that there is diversity within
enterococci population isolated from animals and humans; suggesting
the host speciﬁcity. However closely related clones were identiﬁed
from outlet food and the clinical strains; suggesting the possibility of
contamination by food handlers. esp gene was not detected in enterococci
obtained from animal sources.
Conclusion: Host speciﬁcity of enterococci suggests that animal strains
do not generally impose a serious threat to nosocomial infections in
clinical settings. In hospitalised patients the threat of infections is caused
by bacteria that largely spread clonally. Moreover the presence of esp
gene that identiﬁes the successful nosocomial clones was not detected in
any of the strains from the animal origin. Although the presence of van
genes causes concern regarding the spread and transfer of vancomycin
resistance, it is unlikely that resistance in hospital acquired infections is
caused by animal strains. Enterococci may spread from food to humans
only if the foodstuff is contaminated through human handling. Safe food
handling is therefore crucial especially to high risk patients in hospitals.
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P693 Epidemiology of multiresistant Enterococcus faecalis and
Enterococcus faecium collected during 2004 to 2006 in a
Lisbon hospital
R. Pires, M. Pereira, P. Rodrigues, S. Carvalho, T. Ferreira, R. Mato
(Oeiras, Lisbon, PT)
Objectives: Determination of the prevalence, evolution of antimicrobial
resistance, and clonality of high-level gentamicin (HLGR) and glycopep-
tide resistant (GR) E. faecalis (E.ﬂ) and E. faecium (E.fm) recovered
from infection products during 2004 to 2006 in a public community
(350-beds) Lisbon hospital.
Methods: Microbial identiﬁcation and antimicrobial susceptibility
testing were performed using the VITEK2 system. HLGR and GR
E.ﬂ and E.fm were conﬁrmed by PCR detection of aac(6’)-aph(2”)
and vanA/B/C1/C2 genes and clones were assessed by SmaI-PFGE and
carriage of the esp gene. Multiplex-PCR was used to detect the cylA,
asaI, gelE and hyl virulence genes among GR isolates.
Results: A total of 403 isolates were recovered during 2004–2006.
The prevalence of E.ﬂ and other enterococcal species (E. durans,
E. casseliﬂavus, E. avium by decreasing order of frequency) increased
from 68 to 81% and from 0.6 to 6%, respectively, while E.fm decreased
from 30 to 11%. HLGR-E.ﬂ increased from 31 to 41% and resistance to
ampicillin-Amp (4%), ciproﬂoxacin-Cip (40%), erythromycin-E (89%),
and vancomycin-Va (1%) remained stable. Most (90%) of the E.fm were
resistant to Amp, Cip and E, and resistance to Va decreased from 14 to
8%. HLGR-E.fm increased from 62 to 77%.
All HLGR isolates (n = 162) carried the aac(6’)-aph(2”) genes. GR-E.ﬂ
(n = 3) and GR-E.fm (n = 5) were vanA-positive. HLGR-E.ﬂ (n = 107)
were of 27 PFGE patterns. PFGE-AO was prevalent (n = 53) and
increased in prevalence during the study period (37.5% to 61.5%). esp-
positive HLGR-E.ﬂ increased from 25 to 82%, in parallel with the
increment of esp-positive HLGR-E.ﬂ PFGE-AO from 8 to 92%. PFGE-
AO also included GR-E.ﬂ isolates positive for cylA, asaI, gelE and one
isolate was also esp-positive. HLGR-E.fm (n = 55) were of 11 PFGE
types. Three major clones (PFGE-a, -o and -c) coexisted in 2004. PFGE-a
decreased from 2005 (76%) to 2006 (20%) while PFGE-c emerged as
dominant (50%). The esp gene increased from 68 to 90%. GR-E.fm were
of PFGE-a, -o (two esp-positive isolates), -c and -d (all esp-negative,
HLG susceptible). PFGE-o and -c isolates carried only gelE.
Conclusions: Enterococcal infections mainly by HLGR-E.ﬂ and E.fm
seem to be increasing. The prevalence of GR strains was lower that the
published data. One major E.ﬂ nosocomial clone is acquiring virulence
traits over time. To our best knowledge this is the ﬁrst molecular
epidemiological study of enterococcal infections from a Portuguese
hospital.
P694 Nationwide increase of invasive ampicillin resistant
Enterococcus faecium in the Netherlands
J. Top, R. Willems, S. van der Velden, M. Asbroek, M. Bonten (Utrecht,
NL)
Objectives: We recently described an increase in the proportion
of invasive enterococcal infections caused by ampicillin resistant
Enterococcus faecium (AREfm) from 2% in 1994 to 32% in 2005 and
a partially replacement of ampicillin-susceptible (ampS) E. faecalis by
E. faecium (75% AREfm) among enterococcal bloodstream infections
in our hospital (Top et al., CMI in press). In our hospital all AREfm
belonged to CC17 E. faecium, a clonal complex associated with
nosocomial outbreaks worldwide. A nationwide study was initiated to
determine whether these ecological changes had also occurred in other
hospitals in the Netherlands.
Methods: All 66 microbiology laboratories serving all hospitals of
the country were asked to provide data on annual numbers of all
invasive ampicillin resistant (ampR) enterococcal isolates and the ﬁrst
30 enterococcal blood stream isolates (1 per patient) from 1994
until 2006. Multiplex PCR based on the ddl gene was performed to
distinguish E. faecium and E. faecalis and susceptibility to ampicillin
was determined.
Results: Thirty labs (45.5%) provided data, and 8 (12%) labs also
provided isolates. The mean number of invasive ampR enterococcal
isolates increased from 5 in 1994 to 25 in 2005. This increase was
more pronounced in academic and large non-academic hospitals (>500
beds); from 5 in 1994 to 45 in 2005 in academic hospitals and from 4
in 1994 to 19 in 2005 in non-academic hospitals. Among enterococcal
blood isolates proportions AREfm increased from 13% in 1993 to 40% in
2006; from 13% in 1993 to 51% in 2006 in academic hospitals and from
13% in 1999 to 26% in 2006 in non-academic hospitals. All E. faecalis
isolates were ampicillin susceptible, while 75% of the E. faecium isolates
were ampicillin resistant.
Conclusions: In the Netherlands invasive AREfm increased nationwide
and have partially replaced ampS E. faecalis. The difference in
prevalence among academic and non-academic hospitals probably
reﬂects differences in patient population with haematology and transplant
patients having the highest risks for AREfm bacteraemia being over
represented in academic hospitals. All E. faecium isolates will be
genotyped to determine the molecular epidemiology of AREfm in the
Netherlands.
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P695 Susceptibility of streptococci to antibiotics and biocides
isolated from Saudi Arabia and UK
A.M. Al-Qorashi (Dammam, SA)
The assessment of the in vitro activities of 16 antibiotics, 10 biocides and
6 metallic compounds against clinical isolates of Streptococcus pyogenes
(group A) from UK and Saudi Arabia and its control strains from UK.
16 antibiotics (benzypenicillin, erythromycin, lincomycin, methicillin,
rifampicine, trimethoprim, vancomycin, ampicillin, chloramphenicol,
fucidic acid, gentamicion, kanamycin, nalaedixic acid, novobiocin
and streptomycin), 10 biocides (3 phenolics: chlorocresol, cresol,
phenol; 4 parabens: methyl, ethyl, butyl and propyl esters of para-
4-hydroxybenzoic acid); a bisbiguanide: chlorhexidine diacetatate;
2 quaternary ammonium compounds: cetylpyridinium chloride and
benzethonium chloride) and 6 metallic compounds (mercuric chloride,
phenylmercuric nitrate, cadmium chloride, cupric chloride, zinc chloride
and silver nitrate) were tested against controls and clinical isolates of
Streptococcus pyogenes (group A) from the university hospital of Wales
UK as well as clinical isolates from King Fahd University Hospital, Al-
Khobar and King Abdulaziz University Hospital, Jaddah, Saudi Arabia
by the disc diffusion method and the determination of minimal inhibitory
concentration (MIC).
All strains of Streptococcus pyogenes (group A) were b-lactamase-
negative. All British strains were sensitive to all of the antibiotics
tested, except gentamicin and streptomycin. Some of the Saudi strains
were resistant to gentamicin and erythromycin and all were resistant
to lincomycin. The British and Saudi Arabian strains showed the same
order of response to phenols and parabens. Similarly, the British and
Saudi Arabian strains were equally sensitivity to phenylmercuric nitrate,
however, response to other metallic compounds were variable.
P696 In vitro activity of fosfomycin tromethamine and linezolid
against clinical vancomycin-resistant Enterococcus faecium
isolates
F. Cilli, H. Pullukcu, S. Aydemir, O. Sipahi, M. Tasbakan, A. Turhan,
S. Ulusoy (Izmir, TR)
Objectives: Infections with vancomycin resistant enterococci are
emerging problems. The aim of this study was investigate the in vitro
effect of fosfomycin tromathanole and linezolid against 117 vancomycin-
resistant isolates of Enterococcus faecium.
Method: MIC of fosfomycin and linezolid were determined by E test
(Biodisk, Sweden). A 0.5 McFarland suspension of the microorganism in
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0.9% saline was inoculated into Mueller-Hinton agar (Oxoid, England).
E test strips were placed on the culture plates and the MIC read after
24 h. Since E test strips for fosfomycin contained glucose-6-phosphate,
extra supplementation of the compound in the culture medium was not
done. The readings were tabulated and the MIC50 and MIC90 values
determined. The breakpoint criteria to determine susceptibility were
based on the CLSI. All isolates were Enterococcus faecium (89 from
rectal swabs, 24 from hemoculture, 3 from tissue biopsy culture, 1 from
urine culture).
Results: The MIC90 and MIC50 of fosfomycin were 192mg/L and
512mg/L and for linezolid 1mg/L and 2mg/L, respectively. Overall MIC
for linezolid ranged between 0.5−3mg/dl.
Conclusion: Linezolid but not fosfomycin tromethanol had good in vitro
activity against 117 isolates of vancomycin resistant E. faecium.
P697 In vitro activity of daptomycin and linezolid against
vancomycin-resistant Gram-positive pathogens from cancer
patients
R. Prince, E. Coyle, K. Rolston, M. Kapadia, A. Kaur, S. McCauley
(Houston, US)
Objectives: To compare the in-vitro activity of daptomycin (DAP)
and linezolid (LIN) to vancomycin (VAN) against Van-resistant Gram-
positive (GP) organisms isolated from cancer patients.
Background: GP organisms cause 40−70% of documented bacterial
infections in cancer patients. VAN has been the drug of choice for the
treatment of GP infections in such patients. Although uncommon, VAN-
resistant organisms are being isolated with increasing frequency and
alternative agents need to be evaluated in this setting.
Methods: The organisms were isolated between January 2004 and
September 2006 and >90% were from blood cultures. E-testTM strips
(AB Biodisk, Solna, Sweden) were used for susceptibility testing.
S. aureus ATC-29213 was used as the control strain.
Results: MIC50, MIC90 values (if >10 strains were tested) and range
of activity (in mg/mL) are shown in the Table below.
Agent MIC (mg/mL)
MIC50 MIC90 Range
VAN-resistant enterococci (34) DAP 1.0 3.0 0.25−30
LIN 1.5 1.5 0.38−2.0
VAN >256 >256 >256
Leuconostoc spp. (7) DAP 0.064–0.38
LIN 2.0−8.0
VAN >256 >256 >256
Pediococcus spp. (5) DAP 0.25−1.0
LIN 4.0−8.0
VAN >256 >256 >256
Conclusions: Daptomycin appears to have excellent in-vitro activity
against most VAN-resistant organisms. It also has better bactericidal
activity than VAN and LIN (data not shown). LIN has excellent activity
against VRE but appears to be less potent against Leuconostoc and
Pediococcus spp. The clinical potential of these agents needs to be
evaluated, although infections caused by some of these pathogens are
rare.
P698 VITEK diagnostics of Enterococcus species in urine samples
V. Vuksanovic (Podgorica, ME)
Objectives: Urinary infections (UTI) are common in patients with
anatomically normal urinary tract, manifested as a no complicated
infections, where Escherichia coli is the most frequent aetiological
cause. In UTI, with structional or functional abnormality of urinary
tract, the resistant enterobacteria, enterococci and Candida are more
common aetiological cause. Enterococci as a opportunistic pathogens can
cause severe urinary infection, infections of surgery wounds, bacteraemia
and bacterial endocarditis. As the high resistance of micro organisms
to antibiotics has been registered the aim of this work is to examine
sensitivity of enterococci originated from patients’ urine.
Methods: After isolation in blood agar, identiﬁcation and sensitivity of
67 enterococci was done by using VITEK2 system (bioMe´rieux). Out of
these patients 42 were hospitalised in Clinical Centre Podgorica, and 25
samples were taken from patients visited outpatient healthcare services.
Results: Out of 62 isolated enterococci, 63% (42) were from hospitalised
patients, and E. faecium was identiﬁed in 50% (21) cases. This was
not case with urine samples taken from patients who visited outpatient
healthcare services, where E. faecium was isolated in only 4% (1) of
cases. All types of E. faecalis showed sensitivity in over 95% of cases
to beta lactamic antibiotics: ampicilin 95%, ampicilin sulbactam 98%
and imipenem 95%, as well as to linezolid 95% and glycopeptides
(teicoplanin and vancomycin 98%). Lower percentage of sensitivity
was found in quinolones (73%). The highest resistance of E. faecalis
was to tetracycline 72% (37), while half of the types were resistant
to erythromycin 51% and gentamycin 53%. Although E. faecium is
normally resistant to beta lactamic antibiotics, one urine sample had wild
phenotype sensitive to ampicilin, ampicilin sulbactam and imipenem.
E. faecium showed resistance to ciproﬂoxacin in over of 80% cases
(86%), erythromycin 86% and gentamycin 82%, while sensitivity to
linezolid, teicoplanin and vancomycin was registred in 90% of cases.
Conclusion: This study shows that E. faecalis is the most sensitive to
penicillin preparations and it is still drug of ﬁrst choice in our region.
Drugs of choice for E. faecium are linezolid, teicoplanin and vancomycin,
in infections of hospitalised patients caused by enterococci. The ﬁnal
identiﬁcation of enterococci and antibiogram is mandatory procedure, if
it is available, in treatment of urinary infections
P699 Antimicrobial effects of non-antibiotics on resistant
Gram-positive bacteria
O. Hendricks, T. Butterworth, J. Christensen, H. Sahly, R. Podschun,
J. Kristiansen (Sønderborg, Copenhagen, DK; Kiel, DE)
Objectives: Psychotropic therapeutics, especially the phenothiazines
are employed for the treatment of psychosis though they exhibit the
additional property of an anti-microbial activity. We deﬁned MICs for
selected compounds on clinically relevante Gram-positive bacteria. The
evaluation of the combined effect of these compounds and conventional
antibiotics of clinical relevance showed a signiﬁcant synergistic effect.
As intracellular survival of Gram positive species is another possible
explanation for the insufﬁciency of antibiotic treatment, we investigated
the inﬂuence of phenothiazines on bacterial invasion in human epithelial
cell lines. The project investigates the anti-microbial activity of
Non-antibiotics against clinically relevant Gram-positiv bacteria, e.g.
staphylococci, streptococci and enterococci.
Methods: Agardilution, Microdilution, Human ephitelcell-models
A-549, HCT-8, T-24.
Results: All Gram-positive bacterial strains, regardless of their
susceptibility to regularly used antibiotics, were inhibited by the
testsubstances at concentrations of 8–64 g/L. Combination of the
antibiotics and the choosen testcompounds at subinhibitory concentration
demonstrated a restored activity for the investigated antibiotics. We
documented interference of our test-compounds with efﬂux based
multidrug resistance. Furthermore, we recorded a signiﬁcant reduction
of the mean bacterial invasion ability in the investigated cell lines in the
presence of selected agents. Overall, these results indicated a signiﬁcant
reduction of the mean invasion ability of the Gram-positive bacteria in all
epithelial cell lines (18.9%±1.8) as compared to the invasion in absence
of the substance (52.1%±4.4) (p< 0.0001).
Conclusions: The present experiment shows that phenothiazine
derivates, especially thioridazine, have an antimicrobial effect against the
investigated strains. Our studies offer new information on the effect of
phenothiazines on Resistant Gram-positive bacteria. The anti-microbial
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activity of these compounds may have a place in the treatment of
infections where the possibilities for current antibiotic treatment are
limited.
P700 Comparison of antibiotics susceptibility of different
vancomycin-resistant Enterococcus faecium clones
A. Mironova, G. Kliasova, A. Brilliantova (Moscow, RU)
Background: The aim of this study was to compare the antibiotic re-
sistance between different clones of vancomycin-resistant Enterococcus
faecium (VREF).
Methods: A total of 123 isolates were collected from patients with
haematological malignancies during May 2003 to September 2006.
Minimal Inhibitory Concentrations (MICs) were determined by broth
microdilution method (CLSI). Resistance genes were detected by PCR.
Macrorestriction analysis of SmaI digests was performed by pulsed-ﬁeld
gel electrophoresis.
Results: PFGE typing revealed 21 strain types of VREF. 78 (69%)
isolates belonged to type A and 12 (11%) – to type F. The remaining
24 VanA isolates were distributed among 17 different PFGE types.
All strains were resistant to ampicillin, penicillin, erythromycin, lev-
oﬂoxacin, streptomycin and gentamicin (high-level resistance). Different
resistance levels to chloramphenicol and tetracycline were exhibited
among PFGE types. Tetracycline susceptibility was 82% (64/78) for
type A isolates, 50% (6/12) for type F and 83% (20/24) for the
strains, belonged to the other 17 different PFGE types. Chloramphenicol
susceptibility was 45% (35/78) for type A isolates, 25% (3/12) for
type F and 54% (13/24) for the other strains. During the period of
investigation from 2004 to 2006 the number of clone A isolates with
intermediate susceptibility to teicoplanin increased from 18% (5/28) in
2005 to 82% (36/44) in 2006, with susceptibility to chloramphenicol
increased from 32% (9/28) in 2005 to 59% (26/44) in 2006. Linesolide
was highly active against all investigated VREF strains. The distribution
of linesolide MICs in all VREF was unchanged during 2004 to 2006
(MIC90 = 2mg/L).
Conclusion: VREF presented high resistance rates to the antibiotics
tested. Linesolide is uniformly active against all VREF regardless of
phenotype and PFGE type. Differences between PFGE types were
discovered to compare resistant to chloramphenicol and tetracycline.
P701 Comparison of baseline proﬁles of RO4908463 (CS-023)
against recent isolates of target Gram-positive pathogens
exhibiting key resistance phenotypes obtained from Europe
and USA 2003–2006
D. Sahm, N. Brown, M. Jones, D. Draghi, B. Dannemann (Herndon,
US; Breda, NL; Nutley, US)
Objectives: RO4908463 (CS-023) is a carbapenem that has activity
against a broad spectrum of bacterial pathogens including MRSA and
P. aeruginosa and is under development for lower respiratory tract
infections and complicated skin and skin structure infections. Because
susceptibility proﬁles of target organisms obtained from different
geographic areas can vary, this study was done to compare the current
activity of RO49 against key Gram-positive pathogens isolated from
Europe (EU) and from the United States of America (USA).
Methods: RO4908463 and other agents were tested by broth microdi-
lution (CLSI; M7-A7, 2006) against a total of 1,231 Gram-positive
bacteria, isolated from the EU (n = 599) and USA (n = 632), that included
S. aureus (SA), S. epidermidis (SE), E. faecalis (EF), E. faecium (EM),
S. pneumoniae (SP), S. pyogenes (SY), and S. agalactiae (SG). The
EU isolates were from 14 different countries and the US isolates were
collected from across all 9 US Census Bureau Regions collected during
2003–2006 (11 isolates dating pre-2003).
Results: See the table.
Organism Phenotypea RO4908463 MIC parameter (mg/L)
EU USA
Total n Range MIC90 Total n Range MIC90
S. aureus All 312 0.06–>32 16 333 0.06−32 4
MRSA 161 0.5–>32 16 172 0.25−32 4
MSSA 151 0.06−2 0.25 161 0.06−2 0.25
S. epidermidis All 56 0.06−16 1 56 0.03−8 4
MRSE 23 0.06−16 4 29 0.06−8 4
MSSE 33 0.06–0.06 0.06 27 0.03–0.12 0.12
E. faecalis 51 0.06–>32 4 54 0.03−4 4
E. faecium 30 4–>32 >32 30 0.06–>32 >32
S. pneumoniae All 52 0.008−1 0.5 55 0.008−1 1
PEN-S 32 0.008–0.03 0.008 32 0.008–0.03 0.015
PEN-NS 20 0.03−1 0.5 23 0.25−1 1
S. pyogenes 47 0.008–0.015 0.015 51 0.008–0.06 0.015
S. agalactiae 51 0.015–0.06 0.06 53 0.03–0.06 0.06
aMR, methicillin-resistant; MS, methicillin-susceptible; PEN, penicillin; S, susceptible; NS, non-susceptible.
Conclusion: RO4908463 demonstrated good in vitro activity against
most Gram-positive pathogens, including MRSA. The level of
RO4908463 activity was comparable regardless of the geographic source
of the strains, although for MRSA MIC90 and range was higher among
the EU strains than those from the USA. The reason for this difference
is currently unknown, but studies are underway to conﬁrm the higher
MIC phenotype and determine if there may be a clonal relationship
among the EU strains that exhibited the higher MIC. These data
obtained with strains from widely distributed geographic areas indicate
that RO4908463 has potent anti-Gram-positive activity and provides
an important baseline for detecting any changes in the activity of
RO4908463 as clinical development continues.
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P702 Synergistic effect of lactoferricin/amoxicillin associations
against “two canine” amoxicillin-resistant Staphylococcus
intermedius strains
P. Butty, B. Manco, L. Florent (Libourne, FR)
Objectives: The bacteriostatic and bactericidal effects of lactoferricin/
amoxicillin combinations against two S. intermedius strains (00-A519
and 00–5191) isolated from a dog infected by pyoderma and resistant
to amoxicillin were compared to the effect of lactoferrin/amoxicillin
combinations. The synergistic, addition or antagonistic activity was
determined by calculating the fractional inhibitory concentration (FIC)
index. The FIC-index value related to synergism must be 0.5 or less when
the concentration for each antimicrobial and for the most favourable
point is at least 4 times below the MIC obtained for each antimicrobial
used alone.
Methods: Checkerboard array technique in liquid medium was used to
assess the bacteriostatic activity of these combinations. The bactericidal
activity was tested by sub-cultures on agar free-drug medium from
the combination inhibitory concentrations. The concentrations tested for
each antimicrobial were ranged from ﬁve dilutions below the minimal
inhibitory concentration (MIC) to twice the MIC for amoxicillin and
to the maximum possible concentration for lactoferricin and lactoferrin
depending of their respective solubility.
Results: The tested strains showed a lactoferricin MIC of 1,280 mg/mL, a
lactoferrin MIC equal to 51,200mg/mL and an amoxicillin MIC ranging
from 64–512mg/mL. Lactoferricin/amoxicillin combinations showed
synergic effect with FIC-index between 0.16 and 0.27 and amoxicillin
MIC was reduced to 8mg/mL. Concerning the lactoferrin/amoxicillin
combinations, the synergistic effect was observed with FIC-index equal
to 0.25. The respective concentrations of the lactoferricin/amoxicillin and
lactoferrin/amoxicillin combinations showing the bacteriostatic effect
correspond also to a bactericidal effect.
Conclusion: Considering that lactoferricin represents the puriﬁed active
fraction of the lactoferrin in our approach, lactoferricin could be a good
alternative to maximise the antibacterial activity of amoxicillin against
emerging antibioresistant strains of canine S. intermedius.
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P703 Comparative activity of moxiﬂoxacin vs. trimethoprim-
sulfamethoxazole, cloxacillin, linezolid, clindamycin, and
ciproﬂoxacin against intracellular methicillin-sensitive and
community-acquired methicillin-resistant S. aureus
S. Lemaire, F. Van Bambeke, P. Tulkens, Y. Glupczynski (Brussels, BE)
Objectives: Recurrence and persistence of S. aureus infection is often
ascribed to intracellular bacterial persistence, which may also be a cause
of emergence of resistance. We showed that the activity of antibiotics is
always weaker when tested against intracellular bacteria in comparison to
those growing in broth (AAC 2006, 50:841–851). In this context, we have
examined the intraphagocytic activity of moxiﬂoxacin (MXF; recently
approved for skin and soft-tissues infections) against fully sensitive
S. aureus (MSSA) and community-acquired methicillin-resistant S. au-
reus (CA-MRSA), in comparison with (i) antibiotics commonly used for
the treatment of CA-MRSA infections (trimethoprim-sulfamethoxazole
[TMP-SMX], cloxacillin [CLX], linezolid [LNZ], clindamycin [CLI]),
and (ii) ciproﬂoxacin (CIP).
Methods: MSSA (ATCC 25923) and CA-MRSA (NRS 192) were used.
MICs were determined by microdilution in MH broth according to CLSI
guidelines with a 10e5 cfu/mL original inoculum. Intracellular activity
was assessed on infected THP-1 macrophages (as described in details
in AAC 2006, 50:841–851) after 24 h exposure to drug concentrations
corresponding to their respective human Cmax (see Table). Controls
cells (no antibiotic added) were incubated with gentamicin [0.5×MIC]
to prevent extracellular growth (see validation in AAC 2006, 50: 841–
851).
Results: The table shows the MICs of each drug, together with
their corresponding intracellular activity (change in cfu from post-
phagocytosis inoculum).
Drugs (Cmax*) ATCC 25923 (MSSA) NRS 192 (CA-MRSA)
MIC
(mg/L)
intracell.
activity
(D log cfu)
MIC
(mg/L)
intracell.
activity
(D log cfu)
TMP-SMX (25) 1 +0.6±0.1 1−2 +0.7±0.0
CLX (8) 0.125 −0.8±0.1 0.5−1 −0.07±0.1
LNZ (21) 1 −0.7±0.1 2 −0.7±0.1
CLI (12) 0.06 −1.0±0.1 0.125 −0.9±0.1
CIP (4) 0.125 −1.3±0.1 0.5 −1.4±0.1
MXF (4) 0.03 −2.0±0.0 0.03 −1.8±0.1
*As commonly observed in humans after conventional administration
and used as extracellular concentration (total drug) to assess intracellular
activity.
Conclusions: All antibiotics tested, with the exception TPM-SMX,
allowed for a reduction of the intracellular inoculum, but MXF
demonstrated the largest effect (~2 log decrease), but this could be due,
partly, to its low MIC towards the strains examined.
P704 Susceptibility of Staphylococcus aureus bioﬁlms to
vancomycin and gentamicin
D. Kotulova, L. Slobodnikova, A. Longauerova (Bratislava, SK)
Objectives: To determine changes in MBIC (microbial bioﬁlm inhibitory
concentration) and MBEC (microbial bioﬁlm eradicating concentration)
to vancomycin and gentamicin in comparison with MIC (minimum
inhibitory concentration) of a planktonic form of S. aureus strains,
isolated from indwelling medical devices of patients of the Bratislava
Teaching Hospital.
Patients and Methods: Fifteen S. aureus strains isolated from central
venous catheters, intratracheal cannulae and surgical drains from patients
of the Teaching Hospital were investigated. The strains were identiﬁed
by standard microbiological methods. Antimicrobial susceptibility was
tested by the disc diffusion method according to NCCLS 2004 and 2005,
respectively. MIC values to vancomycin and gentamicin were established
by broth dilution according to NCCLS 2004, 2005 and, to vancomycin
by E test, as well. Bioﬁlm production was detected by the Christensen
and microtitre bioﬁlm methods. MBIC and MBEC were detected in
microtitre plates using different concentrations of the investigated drugs,
equal or higher than MIC detected in a planktonic form.
Results: Of the 15 investigated strains, 4 were methicillin resistant,
but susceptible to vancomycin and gentamicin. When using Christensen
method, a weaker bioﬁlm production was detected in all of the tested
strains in comparison with the microtitre method. No differences were
found between vancomycin MIC (median 2mg/L) and MBIC (median
2mg/L). However, the concentration required for bioﬁlm eradication was
higher in all tested strains – MBEC values were 4mg/L (S) in two strains,
8–16mg/L (I) in ten strains, and 32mg/L (R) in two strains.
While investigating the effects of gentamicin, it was found that in
comparison with MIC (median 1mg/L), the MBICs were increased in
14 strains (median 2.7mg/L). MBEC values were increased only in two
strains – to 4mg/L.
Conclusions: Our preliminary results validated the fact that determining
bacterial susceptibility in a planktonic form is insufﬁcient in efforts to
successfully eradicate S. aureus bioﬁlms on biomaterials: MBIC and
MBEC values should be determined. Such results may help physicians
in administration of drugs in correct doses to individual patients.
Standardisation of this susceptibility testing method will be necessary in
the future, due to the increasing incidence of indwelling and implanted
medical devices infections.
P705 Activity of moxiﬂoxacin and cefuroxime against MSSA in
time-kill and in vitro PK/PD studies
R. Endermann, G. Weskott, A. Pickbrenner, J. Schuhmacher, I. Knezˇevic
(Wuppertal, DE)
Objectives: Methicillin-susceptible Staphylococcus aureus (MSSA) is
frequently involved in complicated skin and skin structure infections
(cSSSI). Moxiﬂoxacin (MXF) and cefuroxime (CXM) have been
approved for this indication. This study compares bactericidal activity of
MXF and CXM against three MSSA strains. Both agents were compared
in time-kill experiments and in a hollow ﬁbre pharmacokinetic (PK)
model.
Methods: MIC values were determined by the broth microdilution
method. MIC and time-kill experiments were performed according
to CLSI guidelines. The MSSA strain DSM 11823 and a recent
clinical isolate, HF 1012717 were used for the time kill experiments
at concentrations of 0.25–16 times the MIC. Using the hollow ﬁbre
PK model, the strains ATCC 29213 and HF 1012717 were exposed to
free drug serum concentrations according to human PK after a dose of
MXF 400mg IV (Cmax 2.2mg/L, T1/2 13 h) or CXM 1500mg t.i.d.
(Cmax 70mg/L, T1/2 1.5 h). For the PK model an initial inoculum of
108 CFU/mL was used. Antibiotic concentrations were conﬁrmed by
bioassay and HPLC. Antibacterial effect was measured over time and
speciﬁcally by time to 3-log reduction (bactericidal kill) in viable counts.
Results: The MIC for CXM was 2mg/L for all three test strains and
for MXF was 0.06mg/L for ATCC 29213 or 0.03mg/L for HF 1012717
and DSM 11823. In time-kill experiments, exposure to MXF and CXM
at 1–16 times the MIC led to bactericidal kill of strain DSM 11823.
With MXF, 3-log kill was achieved earlier than with CXM (1 vs 3 h at 8
times the MIC). Against the clinical isolate HF 1012717, MXF showed
a bactericidal kill at 4–16 times the MIC, while CXM achieved at best
a 2-log reduction at 16 times the MIC. In the hollow ﬁbre PK model
3-log kill was achieved for both strains (HF 1012717 and ATCC 29213)
at 1.5–2 h for MXF. When CXM PK was simulated, 3-log kill was noted
at 4.5–6 h for ATCC 29213 and at 7–10 h for HF 1012717. There was
no regrowth for any strain or regimen after 24 h, and the MICs of the
isolated colonies at 24 h were not elevated.
Conclusions: MXF and CXM were bactericidal against all three MSSA
strains when tested in time-kill experiments and in a hollow ﬁbre PK
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model. With regard to time to 3-log reduction, MXF was more effective
than CXM in both models.
P706 The evaluation of the bactericidal activity of daptomycin,
vancomycin and linezolid and determination of the
interactions of these antimicrobials with gentamicin or
rifampin against S. aureus
H. Sader, T. Fritsche, R. Jones (North Liberty, US)
Objective: To determine the bactericidal activities of daptomycin (DAP),
vancomycin (VAN) and linezolid (LZD), and the drug interaction
categories for these 3 antimicrobials combined with each other or tested
with gentamicin (GEN) or rifampin (RIF) against S. aureus strains.
Methods: Minimum inhibitory concentrations (MIC) were determined
by CLSI broth microdilution methods. Bactericidal activity (MBC) was
evaluated on 207 S. aureus (101 wild-type [WT] oxacillin-resistant
[MRSA], 64 VAN-heteroresistant [hVISA], 37 VAN-intermediate
[VISA] and 5 VAN-resistant [VRSA]) by plating the entire broth content
from the well onto appropriate growth media. Quantitative colony counts
were performed and compared to the initial inoculum. Checkerboard
synergy tests were performed on 18 S. aureus (15 MRSA) using broth
microdilution trays containing 2 agents in 2-fold dilutions dispensed in
a checkerboard format. DAP, VAN and LZD were combined with each
other and with GEN or RIF, resulting in 9 combinations. The fractional
inhibitory concentration (FIC) was calculated for each agent and the
summation of both FICs was used to classify the combined activity of
antimicrobials as synergistic (SYN; 0.5), partially synergistic (PSYN;
>0.5 and <1), additive (ADD; 1), indifferent (IND; >1 and <4) and
antagonistic (ANT; 4).
Results: DAP was bactericidal against all S. aureus groups while VAN
MBC/MIC ratios consistent with tolerance were observed at a rate of
14.9; 68.8; and 86.5% for WT-MRSA, hVISA and VISA respectively,
and LZD MBC/MIC ratios consistent with tolerance were observed at
a rate of 99.0%; 100.0%; 94.6% and 100.0% for WT-MRSA, hVISA,
VISA and VRSA respectively. Checkerboard results showed no ANT
or SYN with any of the antimicrobial combinations evaluated. The
majority of strains (77.8%) showed PSYN (50.0%) or ADD (28.8%)
interactions when DAP was combined with GEN; while ADD and IND
effects predominated when DAP was combined with LZD (94.4%), RIF
(88.9%) or VAN (72.2%). All isolates showed IND effect when LZD was
combined with GEN. VAN combinations exhibited predominant ADD
(16.7–38.9%) or IND interactions (44.4–77.8%).
MBC results for daptomycin, linezolid and vancomycin tested against S. aureus.
Antimicrobial agent No. of isolates (cumulative %) with MBC at:
0.12 0.25 0.5 1 2 4 8 16 32
Daptomycin
MRSA-WT (101) 0 (0) 29 (29) 64 (92) 7 (99) 1 (100) – – – –
hVISA (64)c 0 (0) 1 (2) 32 (52) 30 (98) 1 (100) – – – –
VISA (37) 0 (0) 0 (0) 2 (5) 23 (65) 9 (92) 3 (100) – – –
VRSA (5) 0 (0) 0 (0) 4 (80) 1 (100) – – – – –
Linezolid
MRSA-WT (101)a 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (1) 0 (1) 100 (100)
hVISA (64)c 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 64 (100)
VISA (37) 0 (0) 0 (0) 0 (0) 0 (0) 2 (5) 0 (5) 0 (5) 0 (5) 35 (100)
VRSA (5) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 5 (100)
Vancomycinb
MRSA-WT (101) NTc NT 2 (2) 38 (40) 23 (62) 9 (71) 14 (85) 3 (88) 12 (100)
hVISA (64)c NT NT 0 (0) 3 (3.0) 9 (12) 3 (17) 2 (20) 4 (24) 43 (100)
VISA (37) NT NT 0 (0) 0 (0) 0 (0) 2 (5) 1 (8) 0 (8) 34 (100)
aClinical MRSA isolates with vancomycin MIC 2mg/L (homogeneous populations) collected from medical
centres worldwide in 2003.
bMBC was not evaluated on VRSA strains (ﬁve strains with vancomycin MIC> 32mg/L).
cNT, not tested.
Conclusions: DAP was the only agent highly bactericidal against
S. aureus strains, independent of their susceptibility to VAN. The
combinations of DAP with any other agent were never antagonistic.
DAP with GEN and LZD with RIF generally exhibited a PSYN or ADD
interaction; while IND and ADD interactions predominated among all
other combinations.
P707 Reduced efﬁcacy of chlorhexidine against clinical MRSA
residues compared to standard strains
S. Davies, L. Vali, S. Amyes (Edinburgh, UK)
Objectives: To determine whether sub-inhibitory concentrations of
chlorhexidine acetate (CHX) are effective against surface dried MRSA
and whether there are differences in the susceptibility of clinical strains
compared to control EMRSA 16 and Staphylococcus aureus strains.
Methods: A surface disinfectant test was performed as follows: Washed
bacterial suspensions (overnight growth in nutrient broth, washed three
times in saline) of control strains (EMRSA 16 and S. aureus NCTC
6571) and clinical MRSA were dried onto surfaces for 2 and 24 hours.
After drying, a sub-inhibitory concentration of chlorhexidine diacetate
(CHX) was added. Following a 5 minute contact time, neutraliser was
added and the cells resuspended for 5 minutes using magnetic followers.
Enumeration was performed using the drop-counting method (serial
dilution in SDW followed by 3×10 ul drops of each dilution on nutrient
agar plates). Microbiocidal effect (log reduction in CFU/mL following
CHX exposure) was determined by evaluating triplicate counts against a
control without CHX for each isolate, enabling the results from different
isolates to be compared.
Results: CHX was more effective after longer bacterial drying times
(ﬁgure).
Mean microbiocidal effect of CHX on bacterial residues.
This difference was more pronounced in the control EMRSA 16 (C)
and NCTC 6571 (S) strains than in the clinical isolates (LF26, LF67
and LF93), in which the effectiveness of CHX after 24 hours bacterial
drying time was not greatly increased. At both drying times, CHX was
less effective on the clinical isolates than the control strains. Even after
24 hours bacterial drying, there was less than a 3-log CFU/mL reduction
in the clinical isolates following exposure to CHX.
Conclusions: These results suggest that sub-inhibitory concentrations
of CHX, as might occur during misuse of biocides in hospitals, are
minimally effective against clinical isolates of MRSA, and may therefore
lead to selection of reduced susceptibility MRSA isolates in the clinical
environment. The difference between CHX efﬁciency against control
strains compared to clinical isolates has implications for the tested
efﬁcacy of biocides, as it may be that clinical strains are less susceptible
than efﬁcacy testing on standard strains would imply.
P708 Bactericidal activity of moxiﬂoxacin against Staphylococcus
aureus and S. epidermidis at concentrations simulating bone
penetration
J. LeBlanc, S. Campbell, R.J. Davidson (Halifax, CA)
Objectives: Staphylococcal osteomyelitis is frequently managed with a
combination of ciproﬂoxacin and rifampin, the combination preventing
the emergence of resistance to either agent. Moxiﬂoxacin has
signiﬁcantly enhanced activity against Gram-positive bacteria including
Staphylococcus spp. We describe a series of pharmacodynamic exper-
iments designed to investigate the bactericidal activity of moxiﬂoxacin
against S. aureus and S. epidermidis at concentrations simulating bone
penetration.
Methods: Eight ﬂuoroquinolone susceptible isolates (4 S. aureus
and 4 S. epidermidis) were challenged with moxiﬂoxacin in a
pharmacodynamic model utilising Mueller-Hinton broth. Cultures were
inoculated at a density of 1×107 cfu/mL, incubated at 35ºC, and
examined for viable growth at 0, 1, 2, 4, 6, 12, and 24 h after exposure to
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moxiﬂoxacin at concentrations simulating bone penetration (1.8mg/mL).
The model also simulated the elimination of moxiﬂoxacin over a 24 h
dosing interval. The moxiﬂoxacin MICs of S. aureus and S. epidermidis
ranged between 0.03 and 0.12 mg/mL for both species. All isolates were
screened by PCR and parC/gyrA DNA sequencing to ensure the absence
of target site mutations prior to initiating the experiments.
Results:Moxiﬂoxacin was rapidly bactericidal against all 8 staphylococ-
cal isolates. For S. aureus, a 4 log decrease in the viable colony count
was observed after 1 h exposure in all 4 strains and complete eradication
was achieved in 4 h. For S. epidermidis, a 3 log decrease in the viable
colony count was observed after 1 h exposure in 2 strains and a 4 log
decrease in the remaining 2 strains. Complete eradication was achieved
in 3 strains after 4 h and 6 h in the remaining strain. Despite simulating
elimination of moxiﬂoxacin over a 24 h dosing interval, we failed to
detect re-growth in any of the isolates.
Conclusions: Moxiﬂoxacin was very rapidly bactericidal against both
S. aureus and S. epidermidis at concentrations achievable in bone.
Complete eradication was achieved after 4 h in the majority of isolates
and re-growth was not detected in any isolate even after 24 h. Our
ﬁndings suggest that moxiﬂoxacin may be an excellent choice in the
management of osteomyelitis.
P709 Differences in antibiotic resistance between MRSA and
MSSA strains isolated in Hungary, Austria and Macedonia
A. Horva´th, G. Malmos, N. Pesti, K. Kristo´f, K. Nagy, Z. Cekovska,
G. Kotola´csi, R. Gattringer, W. Graninger, F. Rozgonyi (Budapest,
HU; Skopje, MK; Vienna, AT)
Objectives: The aim of the study was to compare the quantitative
susceptibility of methicillin-resistant (MRSA) and methicillin-sensitive
(MSSA) strains of Staphylococcus aureus to antistaphylococcal agents.
Antimicrobial sensitivity of 123 MSSA and 158 MRSA strains isolated
in Hungary, 115 MSSA and 40 MRSA strains isolated in Austria and
72 MRSA strains isolated in Macedonia were tested.
Methods: Identiﬁcation of S. aureus strains was performed by classical
and molecular methods (presence of catalase, clumping factor, nucA
and 23S rDNA genes). The mecA gene was detected by polymerase
chain reaction (PCR). Minimum inhibitory concentrations (MICs) of
antibiotics were determined by broth microdilution method according
to NCCLS/CLSI recommendations. PFGE analysis of the strains is in
process.
Results: All tested strains were sensitive to vancomycin. Majority of
Hungarian and Austrian MRSA strains were sensitive to amikacin, while
70.8% of Macedonian strains were resistant. Resistance of Austrian and
Macedonian MRSA strains to gentamicin exceeded 90%, Hungarian
MRSA strains were gentamicin resistant in 73.7%. None of the MRSA
strains were sensitive to clindamycin. To clarithromycin, ciproﬂoxacin,
levoﬂoxacin and moxiﬂoxacin more than 90% of MRSA strains were
resistant.
All tested MRSA strains were multidrug resistant. The most frequent re-
sistance phenotype of Hungarian and Austrian strains was the resistance
to gentamicin, clindamycin, clarithromycin and to ﬂuoroquinolones. The
most common phenotype of Macedonian strains was the resistance to
these antibiotics and amikacin as well.
Both Hungarian and Austrian MSSA strains were mainly sensitive
to aminoglycosides. While MSSA strains were mostly sensitive to
clarithromycin, resistance of Hungarian and Austrian MSSA strains to
clindamycin were 69% and 77%, respectively. The vast majority of
MSSA strains were sensitive to all 3 tested ﬂuoroquinolones, Austrian
strains were less sensitive than Hungarians.
Conclusion: Resistance rates and degrees of MRSA strains to a
variety of antimicrobials were signiﬁcantly higher than those of the
MSSA strains. Therapeutic options differ according to countries. In
MSSA infections all antistaphylococcal drugs except for penicillin and
clindamycin can be used, while in MRSA infections for empiric therapy
only vancomycin and teicoplanin is recommended.
Supported by OTKA No.: T 46186 and O¨AAD-Te´T grant No. A-19/02
P710 Baseline activity of ceftobiprole against methicillin-
susceptible and -resistant staphylococcal clinical isolates
from Europe collected in 2005–2006
T. Davies, D. Sahm, R. Flamm, K. Bush (Raritan, Herndon, US)
Objectives: Ceftobiprole is an investigational parenteral cephalosporin
that is distinguished from currently marketed cephalosporins by its
antimicrobial activity against methicillin-resistant (MR) staphylococcal
isolates. It is currently under clinical development for pneumonia
and complicated skin and skin structure infections. The activity of
ceftobiprole and comparators was tested against methicillin-susceptible
(MS) and -resistant (MR) staphylococcal isolates from Europe to
establish a baseline for longitudinal tracking.
Methods: A total of 1203 S. aureus (SA), 214 S. epidermidis (SE),
and 125 other coagulase-negative staphylococci (CoNS), primarily
S. haemolyticus, S. sciuri, S. saprophyticus, and S. simulans, were
collected from 31 cites in 13 European countries during 2005–2006.
Ceftobiprole (BPR), clindamycin (CLI), erythromycin (ERY), gentam-
icin (GEN), linezolid (LZD), oxacillin, trimethoprim-sulfamethoxazole
(SXT), and vancomycin (VAN) MICs were determined by broth
microdilution according to CLSI methods.
Results: Against MSSA, SXT had the lowest MIC90 (0.25mg/L)
followed by BPR and GEN (0.5mg/L). The SXT MIC90 (0.25mg/L)
was also the lowest for MRSA. BPR, LZD, and VAN had MIC90s of
2mg/L for MRSA. SXT was signiﬁcantly less active against SE and
other CoNS. BPR and GEN were the most active agents tested against
MSSE and MSCoNS with MIC90s of 0.12 to 0.25mg/L. For MRSE and
MRCoNS BPR, VAN, and LZD had the lowest MIC90s of 1 to 2mg/L.
Organism N MIC50/MIC90 (mg/L)
BPR VAN LZD GEN ERY SXT
All SA 1203 0.5/2 1/1 2/2 0.25/>16 >8/>8 0.25/0.25
MSSA 404 0.25/0.5 1/1 2/2 0.25/0.5 0.5/>8 0.25/0.25
MRSA 799 1/2 1/2 2/2 0.5/>16 >8/>8 0.25/0.25
All SE 214 1/1 2/2 1/2 0.06/>16 >8/>8 0.25>4
MSSE 69 0.12/0.25 2/2 1/1 0.06/0.12 0.25/>8 0.25/4
MRSE 115 1/2 2/2 1/1 16/>16 >8/>8 2/>4
All CoNSa 125 0.5/2 2/2 1/2 0.06/>16 >8/>8 0.25/>4
MSCoNS 32 0.12/0.25 2/1 1/1 0.06/0.12 0.25/>8 0.25/>4
MRCoNS 93 1/2 2/2 1/2 2/>16 >8/>8 0.5/>4
aExcluding SE.
Conclusion: Ceftobiprole had excellent activity against methicillin-
susceptible and -resistant staphylococci, similar to or slightly better than
linezolid and vancomycin. Ceftobiprole MICs were lower in methicillin-
susceptible isolates compared to MR strains; however, the ceftobiprole
MIC rarely exceeded 2mg/L.
Surveillance and epidemiology of bacterial
infections in immunocompromised patients
P711 Legionnaires’ disease in solid-organ transplant recipients
revisited
C. Garcia-Vidal, C. Gudiol, R. Verdaguer, N. Ferna´ndez-Sabe´,
J. Carratala` (Barcelona, ES)
Objectives: We aimed to ascertain the incidence, characteristics, and
outcome of Legionnaires’ disease (LD) in solid-organ transplant (SOT)
recipients. We also looked at differences on time to diagnosis between
cases identiﬁed by urine antigen and cases documented when this test
was not available.
Methods: We reviewed medical charts of all cases of LD occurring in
SOT recipients from 1985 to 2006. Since 1997 urine antigen testing
was routinely performed whenever a SOT recipient presented with
pneumonia. Information concerning clinical characteristics, diagnosis,
treatment, and outcome was collected.
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Results: Among 2,789 SOT recipients, 12 (0.4%) cases of LD were
diagnosed. The incidence according to the type of allograft received
was as follows: 0.8% (2 of 246) for heart recipients, 0.5% (8 of 1560)
for kidney recipients, and 0.2% (2 of 983) for liver recipients. Ten
patients were males (83%), with a mean age of 47.8 years (range, 26–
65 years). All patients were receiving more than one immunosuppressive
drug by the time of diagnosis: corticoesteroids (10), cyclosporine (9),
mycophenolate mofetil (5), rapamycin (2), tacrolimus (2), and other
agents (2). Nine cases were community-acquired. The mean time to
the development of LD was 1046 days (range, 31–2920 days). Among
all patients, 25% had early-onset LD (3 months after SOT) and 75%
had late-onset LD (>3 months). LD occurred in the setting of transplant
rejection in 50% of cases. Patients frequently had high fever (62%),
chills (70%), and multilobar pneumonia (44%). Pleural effusion and
hyponatraemia were also relatively common. Microbiological diagnosis
was established by bronchoalveolar lavage (4), transthoracic needle
aspiration (3), tracheal aspirate (2), and/or urine antigen test (4).
Legionella pneumophila was the species identiﬁed in all cases. Two
patients had dual infection (cytomegalovirus viraemia 1, and nocardiosis
1). The mean time to diagnosis was shorter for cases identiﬁed by urine
antigen testing than for the remaining cases (1.3 days vs. 8.5 days;
p = 0.005). Eight patients were given erythromycin (plus rifampin in
4 cases) and 4 patients received levoﬂoxacin. Overall case fatality-rate
was 17%.
Conclusion: The incidence of LD among SOT recipients is relatively
low but it causes signiﬁcant mortality. LD occurs mainly as a
late complication of transplantation involving patients with allograft
rejection. Urinary antigen testing has improved early recognition of
cases.
P712 Risk factors for Nocardia infection in organ transplant recip-
ients: a matched case-control study over an 11-year period
A. Peleg, S. Husain, Z. Qureshi, F. Silveira, M. Sarumi, K. Shutt,
E. Kwak, D. Paterson (Boston, Pittsburgh, US)
Objectives: Risk factors for Nocardia infection in organ transplant
recipients have not been formally assessed in the current era of
transplantation. Our objectives were to systematically assess these risk
factors and to describe the clinical, radiological and microbiological
characteristics of the largest number of Nocardia infections across the
broadest range of organ transplant recipients yet reported from a single
institution.
Methods: We performed a matched case-control study (1:2 ratio)
from January 1995 through December 2005. Controls were matched
for transplant type and timing. Univariate matched odds ratios and
conditional logistic regression were performed to identify independent
risk factors. Clinical and microbiological characteristics of all cases were
reviewed.
Results: Thirty-ﬁve cases (0.6%) of Nocardia infection were identiﬁed
from 5126 organ transplant recipients. The highest frequency was in
lung recipients (18/521 [3.5%]), followed by heart (10/392 [2.5%]),
intestinal (2/155 [1.3%]), kidney (3/1717 [0.2%]) and liver (2/1840
[0.1%]) recipients. Compared to 70 matched controls, high dose steroids
(OR 27 [3.2–235], P = 0.003) and CMV disease (OR 6.9 [1.02–46],
P = 0.047) in the preceding 6 months, and a high median calcineurin
inhibitor level in the preceding 30 days (OR 5.8 [1.5–22], P = 0.012),
were independent risk factors for Nocardia infection. The majority
of cases had pulmonary disease only (27 [77%]). Seven recipients
(20%) had disseminated disease. Nocardia nova was the most common
species (17 isolates [49%]), followed by N. farcinica (9 isolates [28%]),
N. asteroides (8 isolates [23%]) and N. brasiliensis (1 isolate [3%]). Of
the 35 cases, 24 (69%) were receiving trimethoprim-sulfamethoxazole
for PCP prophylaxis. Thirty-one cases (89%) were cured of their
Nocardia infection.
Conclusions: High dose steroids, CMV disease and high levels
of calcineurin inhibitors are independent risk factors for Nocardia
infection in organ transplantation. Our study provides insights into the
epidemiology of Nocardia infection over the current era, a time where
immunosuppressive and prophylactic regimens have greatly evolved.
P713 Risk factor analysis of blood stream infection and pneumonia
in neutropenic patients after peripheral blood stem-cell
transplantation
E. Meyer, J. Beyersmann, H. Bertz, S. Wenzler-Roettele, R. Babikir,
M. Schumacher, F. Daschner, H. Rueden, M. Dettenkofer and the
ONKO-KISS study group
Objectives: To analyse risk factors for blood stream infection (BSI)
and pneumonia in neutropenic patients who have undergone peripheral
blood stem cell transplantation (PBSCT). Data taken from the ONKO-
KISS (Hospital Infection Surveillance System for Patients with
Hematologic/Oncologic Malignancies) multicentre surveillance project.
Methods: Infections were identiﬁed using CDC deﬁnitions (laboratory-
conﬁrmed BSI) and modiﬁed criteria for pneumonia in neutropenic
patients. The multivariate analysis was performed using the Fine-Gray
regression model for the cumulative incidences of the competing events
‘infection’, ‘death’ and ‘end of neutropenia’. The risk factors investigated
were: sex, age, underlying disease (early and advanced disease), and type
of transplant (autologous or allogeneic, related donor or unrelated donor).
Results: From 1/2000 to 6/2004, a total of 1699 patients in 20
hospitals were investigated. In the multivariate analysis, male patients
had a signiﬁcantly higher risk of acquiring BSI than female patients
(p = 0.002). The risk of acquiring BSI is highest in patients with advanced
acute myeloid leukaemia (AML). In the univariate and multivariate
analysis, unrelated donor allogeneic transplantation constituted a risk
factor for pneumonia (p = 0.012).
Conclusion: ONKO-KISS provides reference data on the incidence of
pneumonia and BSI. The increased risk for BSI in males and patients
with advanced AML, and the increased risk for pneumonia in unrelated
donor allogeneic PBSCT patients should be targeted to prevent infections
in these higher risk groups.
P714 Surveillance of nosocomial sepsis and pneumonia in patients
with haematologic stem-cell transplantation: ﬁve years of
‘ONKO-KISS’
M. Dettenkofer, R. Babikir, H. Bertz, E. Meyer, H. Ru¨den, F. Daschner
and the ONKO-KISS Study Group
For surveillance of nosocomial bloodstream infections (BSI) and
pneumonia during neutropenia in adult patients undergoing bone marrow
transplantation (BMT) or peripheral blood-stem cell transplantation
(PBSCT), in the year 2000 an ongoing multicentre surveillance project
was initiated by the German National Reference Centre for Surveillance
of Nosocomial Infections (ONKO-KISS).
Methods: Nosocomial Infections are identiﬁed using CDC deﬁnitions
for laboratory-conﬁrmed BSI and modiﬁed criteria for pneumonia in
neutropenic patients [for detailed information in German language see
http://www.nrz-hygiene.de/surveillance/onko.htm].
Results: Over the 60-month period up to June 2006, 4,203 patients
with 62,338 neutropenic days were investigated (26 centres in German-
speaking countries). Of this number, 2,492 (59%) had undergone
allogeneic and 1,711 (41%) autologous BMT or PBSCT. The mean
length of neutropenia was 14.8 days (9.4 d after autologous and 18.6 d
after allogeneic transplantation). In total, 776 bloodstream infections
and 353 cases of pneumonia were identiﬁed. The site-speciﬁc incidence
densities (pooled mean) were: 12.4 BSIs per 1,000 neutropenic days
(10.6 for allogeneic vs. 17.8 for autologous transplantations) and
5.7 cases of pneumonia per 1,000 neutropenic days (5.8 for allogeneic
vs. 5.3 for autologous transplantations). There was a trend toward lower
incidence densities over the ﬁve years. Following allogeneic transplan-
tation, 19.7 BSI/100 patients and 10.8 cases of pneumonia/100 patients
occurred, whereas following autologous transplantation 16.7 cases of
BSI/100 patients and 5.0 cases of pneumonia/100 patients were observed.
The main pathogens associated with BSI were coagulase-negative
staphylococci (52%).
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Conclusions: The ongoing ONKO-KISS project adds to improving the
quality of care in HSCT-patients. Since 2006, surveillance has been
extended to neutropenic patients with acute leukaemia to allow centres
that do not perform HSCT to participate.
P715 Trends in bacteraemia due to Pseudomonas aeruginosa:
comparison between oncohaematologic and non-
oncohaematologic patients
P. Martin-Davila, G. Ayala, E. Fernandez-Cofrades, J. Fortun, E. Loza,
J. Lopez-Martin, J. Lopez-Jimenez, R. Canton, F. Baquero, S. Moreno
(Madrid, ES)
Objectives: To review epidemiological aspects of P. aeruginosa. (PA)
bacteraemia, prognostic factors, and changes in their antimicrobial (Ab)
susceptibility patterns in oncohaematologic (OH) and non-OH patients.
Methods: A retrospective review during a 10-year period (1996–2005)
in our institution was performed including all episodes with at least one
positive blood culture yielding PA from patients with diagnosis of active
cancer, receiving or not chemotherapy at bacteriemic episode (OH group)
and non-OH patients. Clinical, microbiological and epidemiological data
were obtained and compared. Bacteraemia was considered nosocomial
if the diagnosis was done 72 h after hospital admission and no
evidence of bacteraemia was present at the time of admission. Also
patients diagnosed after discharge within 60 days of a previous hospital
admission.
Results: From Jan-96 to Dec-05 a total of 354 episodes of PA
bacteraemia were identiﬁed, 342 for full-analysis (125 episodes
occurring in OH patients). Total PA bacteraemia episodes per year
remains stable but time trends analysis showed an increased rate of
episodes occurring in OH patients. Mean ages were similar in both
groups (61 vs 60 years). Mean time from hospital admission to
bacteraemia was 16 days in OH vs. 24 days in non-OH (p = 0.04).
Bacteraemia was considered nosocomial-acquired in 86% of OH and
83% of non-OH groups. Patients staying at ICU during bacteraemia were
4% in OH and 45.5% in non-OH patients (p< 0.001). Ab susceptibility
proﬁles are shown in the table.
No signiﬁcant differences were found when compared Ab susceptibilities
between both groups, but a general decrease in susceptibility was
observed. In 2005, 10% of isolates were multidrug-resistant (3
Ab groups) in OH and non-OH patients Mortality at 30 days after
bacteraemia was similar in both groups (38% vs 31%, p =NS).
Ab susceptibility proﬁlesa
19
96
19
97
19
98
19
99
20
00
20
01
20
02
20
03
20
04
20
05
% CAZ OH 0 0 0 0 10 0 0 9 6 10
Non-OH 12 11 0 0 4.5 11.5 11.5 18 12 5
% FQ OH 0 0 0 0 0 0 12.5 9 33 34.5
Non-OH 4 11 0 0 14 4 19 18 32 35
% AG OH 0 17 9 0 20 0 0 9 28 31
Non-OH 4 9 0 0 4.5 0 8 0 16 32.5
% Carbapenems OH 0 0 0 0 0 11 12.5 4 11 14
Non-OH 4 11 0 0 9 19 38.5 18 28 15
% Colistin OH 0 0 0 0 0 0 0 0 0 3
4 0 0 0 0 0 0 0 8 0
% Non-resistance OH 100 83 82 100 80 89 87.5 74 56 55
Non-OH 76 57 0 0 82 73 50 59 44 55
% R to 3 groups OH 0 0 0 0 0 0 0 0 6 10
Non-OH 0 3 0 0 4.5 0 11.5 4.5 12 10
aNo. of isolates: 125OH, 217Non-OH.
Conclusions: Bacteraemia due to PA increased in OH patients. Analysis
of Ab susceptibility patterns showed an increase in resistance to
ciproﬂoxacin, aminoglycosides and, to a lesser degree, to carbapenems
in both studied groups. Mortality remains high in both groups.
P716 Febrile neutropenia in children with cancer; a retrospective
Norwegian multicentre study
N. Stabell, E. Nordal, K. Wiger, B. Lund, E. Stensvold, A. Taxt,
F. Buhring, M. Greve-Isdahl, H. Fornebo, G. Simonsen, C. Klingenberg
(Tromsø, Oslo, Trondheim, Bergen, Stavanger, Tønsberg, NO)
Objectives: Febrile neutropenia (FN) is a frequent and potentially life-
threatening complication in children with cancer under chemotherapy.
Empirical antibiotic therapy of FN in Norway differs from international
guidelines with ampicillin or benzyl penicillin combined with an
aminoglycoside commonly being used as ﬁrst line treatment.
Methods: During a 2-year period we retrospectively reviewed clinical
and laboratory data on FN episodes in children with cancer below
16 years of age at seven hospitals in Norway. Empirical antibiotic therapy
was aggregated into two groups; (i) benzyl penicillin or ampicillin in
combination with an aminoglycoside (Regimen A) and (ii) monotherapy
with a third generation cephalosporin or a combination of a third
generation cephalosporin with other agents (Regimen B).
Results: 95 patients (52.6% boys) with a total of 236 FN episodes were
included. Baseline clinical parameters including degree of neutropenia
were similar in both treatment groups. Time to defervescence was shorter
in patients receiving Regimen A (136 episodes, median 1 day) than
in Regimen B (100 episodes, median 2 days) (p = 0.026). There were
no statistically signiﬁcant differences regarding duration of neutropenia,
duration of antibiotic therapy, change of ﬁrst-line empirical antibiotic
therapy, subsequent number of changes of therapy, and frequency of
positive blood cultures. Thirty-nine of 236 episodes (17%) revealed
positive blood cultures. Children with leukaemia had higher rates of
blood culture positive FN episodes (30/141, 21%) compared to children
with other cancer diagnoses (9/95, 9%) (p = 0.017). Twenty-eight (72%)
bacterial isolates were Gram-positive species. High rates of resistance
to penicillin and ampicillin were found in both Gram-positive and
Gram-negative species (19/39, 49%). All Gram-negative isolates were
susceptible to aminoglycosides. Only coagulase negative staphylococci
were frequently resistant to both b-lactams and aminoglycosides. One
infection-related death occurred during the study period, a child who
died of candida sepsis.
Conclusion: Our data indicate that ampicillin or benzyl penicillin
combined with an aminoglycoside is not inferior to a regimen based on
third generation cephalosporins for the empirical treatment of paediatric
febrile neutropenia in Norway.
P717 Bacteraemia and fungaemia in haematologic patients
G. Kliasova, L. Speranskaya, E. Trushina, A. Mironova, M. Maschan,
S. Vereschagina, L. Kaporskaja, N. Yuritcina, T. Pospelova,
L. Krainova, A. Brilliantova, O. Markina (Moscow, Irkutsk, Samara,
Novosibirsk, Ekaterinburg, RU)
Objectives: To evaluate the frequency of pathogens isolated from
bloodstream of haematologic patients hospitalised at seven medical
centres of Russia.
Methods: During the period from 01 January 2003 to 10 November 2006
we performed a prospective study of all clinically signiﬁcant bloodstream
pathogens. Coagulase-negative staphylococci, Corynebacterium spp.
were evaluated in the cases of isolation from two separate blood cultures.
Results: A total of 882 bloodstream isolates were recovered from
654 patients. Age of patients ranged from 5 months to 88 years
old, most patients (49%) had leukaemia. 440 (50%) episodes were
caused by Gram-negative bacilli, 390 (44%) by Gram-positive bacteria,
50 (5.8%) by fungi and 2 (0.2%) by anaerobic bacteria. In 5%
of patients, the ﬁrst episode of bacteraemia was polymicrobial. The
most frequent pathogens were E. coli (20%), coagulase negative
staphylococci (18%, CoNS), Enterococcus spp. (10%), P. aeruginosa
(7.5%), K. pneumoniae (7%), Viridans streptococci (7%). The prevalence
of ESBL-producing strains ranged from 34% (59/175) for E. coli to
58.5% (38/65) for K. pneumoniae. Incidence of Acinetobacter spp.
was 4% (n = 33), Stenotrophomonas maltophilia – 3% (n = 24). Among
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Enterococcus spp. isolates, E. faecium (69%) was predominant. One
isolate of E. faecium was resistant to vancomycin (vancomycin MICs –
512mg/mL, teicoplanin MICs – 32mg/mL). Oxacillin-resistance rates
were 23% and 79% among S. aureus and CoNS, respectively, isolates. 50
episodes of fungaemia included Paecilomyces javanicus (2), Fusarium
spp. (1), C. neoformans (1), G. capitatum (1), C. albicans (11), Candida
non-albicans (34).
Conclusions: Gram-negative bacilli were predominant in bloodstream
infections among haematologic patients. Fungi were isolated from blood
rarely but the broad spectrum of pathogens was the cause of fungaemia.
P718 Bloodstream infections complicating orthotopic liver
transplant: comparison between the recipients from cadaver
and living donors
A. Bedini, C. Venturelli, M. Codeluppi, S. Cocchi, F. Prati,
F. Di Benedetto, M. Masetti, C. Mussini, G. Guaraldi, V. Borghi,
F. Rumpianesi, G.E. Gerunda, R. Esposito (Modena, IT)
Objective: We evaluated the incidence, the prevalence of the microor-
ganisms isolated and the impact on the survival of the bloodstream
infections (BSIs) in two groups of patients: recipients of orthotopic liver
transplant (OLT) from cadaveric donor (group A) and from living donor
(group B).
Methods: Between October 2001 and September 2006, all the episodes
of BSIs that occurred in the ﬁrst year after OLT in 205 patients were
evaluated. One hundred seventy (82.9%) patients received OLT from
cadaveric donor and 32 (15.6%) from living donor.
Results: During the study period, 91 episodes of BSI occurred in
205 patients with an incidence rate of 0.44 episodes per patients. The
patients of group B had a higher incidence of BSIs than the patients
of group A (40.0% and 19.4%, respectively; p = 0.008). No differences
in the prevalence of the microorganisms isolated were observed between
the 2 groups (group A: Gram positives 49%; Gram negatives 42%; fungi:
9%; group B: Gram positives 41%; Gram negatives 50%; fungi: 9%).
The episodes of BSI occurred within the ﬁrst 2 months after transplant
in the 50.8% in the group A and 42.4% in the group B (p = n.s.). The
crude 30-day mortality rate was 21.2% in the group A and 14.2% in
the group B (p = n.s). Survival rate 1 year after OLT was 80.0% in
the patients from both groups. Considering the patients all together, we
observed that 1-year survival of the patients with BSIs was lower than
those without BSIs (p = 0.0001).
Conclusions: In our population, the patients receiving OLT from living
donor had a higher risk of BSIs than recipients of OLT from cadaveric
donor. These data could be due to the higher complexity of surgical
interventions used in OLT from living donor. Notwithstanding of this,
the 30-day mortality rate resulted lower in the group B and the survival
at 1 year after OLT resulted the same in both groups. The results of this
study conﬁrm that BSIs affect the survival of OLT patients, particularly
during the ﬁrst 1 year after transplantation.
P719 First reported case of human infection with Psychrobacter
submarinus
S. Musaad, N.D. Smith, A. English, D. Gascoyne-Binzi, A. Glaser,
R. Phillips, N. Young (Leeds, UK)
We present the ﬁrst reported human infection involving Psychrobacter
submarinus. This was from a case of suspected line infection in a
7 year old, male, Caucasian child who was diagnosed 3 months prior
to this episode with widespread Burkitts lymphoma in association with
high Epstein Barr virus titres. He made a good symptomatic response
to standard chemotherapy. Following his ﬁfth course of intensive
myelosuppressive therapy, he was admitted on day 20 with fever,
abdominal pain and tenderness. These symptoms settled with observation
and antibiotic therapy as detailed below.
Luminal blood cultures revealed mixed streptococci and Gram-negative
coccobacilli (GNCB).
The child clinically improved on iv cefuroxime and the focus of the
infection was thought to be his line. Further luminal blood cultures
revealed only enterococci after a repeat fever spike 3 days later. The
child was switched and responded well to vancomycin, tobramycin and
piperacillin/tazobactam treatment.
The GNCB grew on blood agar after 6 days in CO2 at 37ºC, was
oxidase positive and was sensitive to most anti Gram-negative antibiotics
including amoxicillin, cefuroxime and tobramycin. It failed to identify
by conventional methods so was submitted for PCR and sequencing (in
both directions) of the 16S ribosomal gene. Using the GenBank database,
it was found to have 98.5% similarity with Psychrobacter submarinus.
The genus Psychrobacter was ﬁrst described in 1986 and belongs to
the family Moraxellaeceae. Members of this genus have been isolated
from sea water, skins of ﬁsh and other marine life. P. submarinus is a
new species described in 2002 as a marine organism. It is a GNCB and
is catalase and oxidase positive. Some isolated case reports have been
described as being caused by Psychrobacter spp. (in an AIDS patient in
1994, meningitis in a neonate in 1991 and an ocular infection in 1990).
Recently (2006), a surgical wound infection due to Psychrobacter spp.
and a bacteraemia in a cirrhotic patient due to P. phenylpyruvicus were
described.
This is the ﬁrst reported case of P. submarinus in humans and involved
a line infection in an immunocompromised patient.
P720 Successful treatment of a linezolid- and vancomycin-resistant
Enterococcus faecium sepsis with daptomycin plus
doxycycline in an allogenic stem cell transplant recipient
J. Dahlke, I. Sobottka, H. Rhode, G. Franke, T. Zabelina, H. Lellek,
A. Muth, C. Wolschke, A. Zander, N. Kro¨ger (Hamburg, DE)
Background: Nosocomial bacteraemia is a major cause of morbidity
in patients with cancer. Of major concern is the growing resistance
of Enterococci such as E. faecium to multiple antibiotic agents. While
vancomycin-resistant E. faecium (VRE) remains a problem in treatment,
the linezolid- and vancomycin-resistant E. faecium (LRVRE) comes into
focus.
Case: During induction chemotherapy a 41-year-old woman with CML
developed fever and inﬂammation of the colon with severe diarrhoea.
Neutropenic fever was treated with vancomycin and imipenem but
fever persisted. Blood- and urine culture yielded Enterococci: VRE
with additional resistance to ampicillin-, erythromycin-, clindamycin and
ﬂourquinolones but susceptibility to linezolid and tetracycline. Treatment
with linezolid was successful with recovery of the intestinal mucosa.
However the patient remained in neutropenia and bone marrow showed
persistent leukaemia. The patient was transferred to BMT-department
for allogeneic stem cell transplantation (SCT). During pretransplant
conditioning the patient remained neutropenic and developed fever
and an increase of CRP. Neutropenic fever persisted under antibiotic
therapy of linezolid in combination with ceftazidim and tobramycin.
The CT of the abdomen detected a perianal abscess. The further clinical
courses showed a clinical picture deteriorated with critically systemic
inﬂammatory response. Blood cultures obtained at day 5 and 1 before
SCT as well as genital and anal smears were positive for VRE again
that however since then emerged as resistant to linezolid additionally. So
far the LRVRE isolates were susceptible to tetracycline only. In view of
the critical state of the patient we decided to combine tetracycline with
daptomycin (4mg/kg) that subsequently was found to be effective also.
Within the next three days the patient became apyrexial and the CRP
fell rapidly. Blood- and stool cultures obtained regularly after starting
daptomycin/tetracycline did not yield LRVRE. The perianal abscess
resolved completely.
Conclusions: This is the ﬁrst report of a LRVRE strain isolated
in Germany that successfully could be treated with the combination
of daptomycin and doxycycline. The case presented emphasizes that
daptomycin should be considered as therapeutic option for severe
infections with multiresistant organisms such as LRVRE.
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P721 Pulmonary nocardiosis in a tertiary care hospital: 8-year
experience (1999–2006)
E. Papaefstathiou, M. Kanellopoulou, N. Skarmoutsou, M. Martsoukou,
P. Katiska, E. Papafrangas, A. Tsakris (Athens, GR)
Objectives: Pulmonary nocardiosis (PN) is a subacute or indolent
pneumonia caused by aerobic actinomycetes of the genus Nocardia.
The disease is difﬁcult to diagnose and therefore its incidence is not well
established. We report our experience on PN in a case study conducted
in our hospital (108 pulmonary beds) during a period of eight years
(1999–2006).
Methods: Sputa of all admitted patients were smeared, stained by Gram
and ZN and plated in appropriate media. The identiﬁcation of Nocardia
species was performed by drug susceptibility patterns (MIC, E-test,
Disk diffusion method) in conjunction with the proﬁles of conventional
biochemical assays. Information was collected on demographic data,
clinical details, underlying diseases and immunosuppressive therapy.
Results: Thenty-nine patients with PN were studied (17 males and
12 females; mean age 52 y). Pathogens were N. asteroides I, II,
VI (22/29), N. farcinica (6/29) and N. transvalensis complex (1/29).
Underlying diseases included haematological and other malignancies
(11 cases), cystic ﬁbrosis (10 cases), COPD (3 cases), multiple sclerosis
(2 cases), diabetes mellitus (3 cases). Diabetes mellitus was concomitant
underlying disease in cystic ﬁbrosis (2 cases) and haematological
malignancies (3 cases). Seven patients had received steroid treatment.
Therapy with TMP/SMX (20/29) or with the combination of imipenem
and amikacin (9/29) was given to the patients for 2 to 6 months. In all
but seven cystic ﬁbrosis patients, treatment resulted in microbiological
eradication of the pathogen.
Conclusion: PN is an infrequent infection that mainly affects
immunocompromised patients. In our study, several Nocardia species
were identiﬁed among patients with various predisposing diseases. To
our experience direct Gram-stain in sputum smears was found useful
to drive the diagnosis of PN, particularly in patients with underlying
diseases and a clinical suspicious of the disease.
P722 Clonal dissemination of Gram-negative bacteria causing
bloodstream infections in patients with haematological
malignancies
A. Brilliantova, G. Kliasova, A. Mironova, S. Sidorenko (Moscow, RU)
Objectives: The purpose of the study was to investigate the clonal
dissemination of Gram-negative strains causing bloodstream infections
in one haematological centre.
Methods: A total of 141 Gram-negative strains, which included
E. coli (n = 80), Enterobacter spp. (n = 15), K. pneumonia (n = 27) and
P. aeruginosa (n = 19) isolated from blood of haematological patients
form January 2003 to December 2005, were analysed by pulsed-ﬁeld gel
electrophoresis (PFGE). Genomic DNA of E. cloacae, and P. aeruginosa
isolates was digested with SpeI enzyme, K. pneumonia and E. coli
DNA – with XbaI and NotI enzymes respectively. Interpretative criteria
used were those described by F. Tenover et al.
Results: Genotyping of P. aeruginosa strains revealed 15 different PFGE
types, 37% (7/19) of P. aeruginosa isolates belonged to three closely
related clonal types. Enterobacter spp. isolates represented 12 PFGE
types, among them 33% (5/15) were genetically related and arouse from
two clones. Isolates of K. pneumonia were grouped into 23 PFGE types,
26% (7/27) of isolates belonged to three closely related clonal types.
E. coli isolates belonged to 79 different PFGE types and showed the
highest level of clonal diversity. Only 3% of E. coli (2/80) isolates
were clonally related, which differed signiﬁcantly from the amount of
clonally related isolates of P. aeruginosa (37%), Enterobacter spp.(33%),
K. pneumonia (26%), p< 0.001.
Conclusion: E. coli isolates demonstrated signiﬁcantly higher clonal
diversity than other Gram-negative bacteria isolated from blood.
We suppose that the majority of E. coli bloodstream infections in
haematological patients are of endogenous origin. Infections caused by
other Enterobacteriaceae and P. aeruginosa are more likely to be acquired
from hospital environment.
P723 Diagnostic relevance of interleukin-6 and tumour necrosis
factor alpha in discriminating high-risk and low-risk groups
in febrile
M. Parsa, S. Najjar najaﬁ, N. Jonaidi jafari, M. Mohraz, A. Ghavam
zadeh, B. Bahar, M. Izadi, H. Radfar, H. Ghofrani (Tehran, IR)
Objectives: Early diagnosis of serious infection in an important issue
in feverish patients with neutropenia. Identifying serum markers of
immunologic response may be useful for distinguish patients with high
risk or low risk. Serum IL-6 and TNF-alpha have shown to increase in
response to sepsis and infection in non-neutropenic patients. The present
study was designed to determine diagnostic value of IL-6 and TNF-alpha
in patients with fever and neutropenia.
Methods: This is a prospective study of 133 patients admitted to two
university hospital in Tehran, Iran with fever and neutropenia. Patients
were divided two groups as low risk and high-risk groups. Cytokines
level compared with Mann-Whitney test in study groups of patients and
ROC curves used to determine best cut-off points level for cytokines
discriminating risk groups.
Results: Mean age of patients was 26.8±2.5 years and 7.5% of patients
allocated in low risk group. The mean IL-6 and TNF-alpha serum
level below 17 pg/mL was deﬁned as best cut-off point determining low
risk group patients with sensitivity and speciﬁcity of 70% and 67.5%
respectively. However, we cannot deﬁne a statistically signiﬁcant cut-off
point for TNF-alpha to use as a diagnostic test.13.5% of patients of
our study have positive blood cultures (6% Gram-negative, 6% Gram-
positive, 1.5% fungi), but no statistical difference had found in serum
IL-6 and TNF-alpha levels in blood culture groups.
Conclusion: Despite our ﬁndings about IL-6 diagnostic value in
neutropenic patients with fever and its advantages in discriminating risk
groups of patients it seem necessary to design a randomised controlled
trial before use of this marker.
P724 Serum levels of IL-6, IL-8 and IL-10 at fever onset
in neutropenic patients: a rapid test for the prediction
of Gram-negative bacteraemia? Results of an EORTC
Infectious Disease Group multicentre study
H. Akan, M. Paesmans, O. Marchetti, W.V. Kern on behalf of the
EORTC Infectious Disease Group
Objectives: Previous studies have suggested that serum or plasma levels
of cytokines such as IL-6 or TNF-alpha may have prognostic value in
patients with severe sepsis. These and other cytokines have also been
studied in febrile neutropenic patients, but the test characteristics for
prediction of outcomes in this setting have been variable. We wondered
whether the levels of IL-6, IL-8 or IL-10 in samples obtained at
fever onset were helpful in predicting bacteraemia in general or, more
speciﬁcally, Gram-negative bacteraemia (GNB).
Methods: Blood samples were obtained from 573 patients with fever
and neutropenia who were included in a multicentre therapeutic trial of
the EORTC (EORTC-IDG Trial 46971). The samples were collected at
fever onset, centrifuged within 1 hour, frozen and shipped to a central
facility where they were stored at −70ºC until testing. The cytokine
concentrations were measured in duplicate by an immunoluminiscence
assay (Immulite) allowing single serum sample measurements within
~45 min.
Results: Most patients had acute leukaemia. Their median age was
46 years (range, 2−86). Fifteen percent of the patients had GNB
(anaerobes excluded), and eight percent died. For all three cytokines,
there was a signiﬁcant correlation between serum concentrations and
length of fever. Levels of the three cytokines were higher in patients who
failed initial empirical therapy because of clinical deterioration. They
were highest in the subgroup of patients with GNB. The areas under the
receiver operating characteristic curve (AUROCs) for the prediction of
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bloodstream infection (any organism) was best for IL-10 (0.73; 95% CI,
0.68–0.78) but the differences between IL-10 and IL-6 or IL-8 AUROCs
were small and statistically nonsigniﬁcant. Similarly, the AUROC for the
prediction of GNB was better for IL-10 (0.82; 95% CI, 0.77–0.87) than
for IL-8 (0.75; 95% CI, 0.69–0.81) and IL-6 (0.73; 95% CI, 0.67–0.80).
At speciﬁcity levels of 95%, sensitivities of the three cytokine assays,
however, were <50% for the prediction of bacteraemia or GNB.
Conclusion: We conclude that a single serum sample analysis for
measurement of one of these interleukins at the onset of febrile
neutropenia currently has limited predictive value.
P725 European survey on the use of antibacterial prophylaxis in
neutropenic cancer patients: a joint project of the EORTC
and the EBMT
H. Akan, O. Marchetti, C. Cordonnier, T. Calandra for the Infectious
Diseases Group of the European Organization for Research and
Treatment of Cancer (EORTC-IDG) and the Infectious Diseases
Working Party of the European Group for Blood and Marrow
Transplantation (EBMT-IDWP)
Background: Bacterial infections are frequently observed in neutropenic
cancer patients. The use of antibacterial prophylaxis (Px) for prevention
of these complications may differ among centres due to the emergence
of bacterial resistance and the uncertain impact on infectious morbidity
and mortality. Few data are available on the use of antibacterial Px in
onco-haematological patients in Europe.
Objective: To conduct an European survey on the use of antibacterial
Px in neutropenic cancer patients.
Methods: A questionnaire on antibacterial prophylaxis was distributed in
2004–2005 to all members of the EORTC-IDG and EBMT-IDWP. Four
clinical settings were studied: short-duration neutropenia (<10 d) in solid
tumours/haematological malignancies, long-lasting neutropenia (>10 d)
in acute leukaemia, autologous hematopoietic stem cell transplant
(HSCT) and allogeneic HSCT.
Results: 105 out of 586 EBMT centres reached by web page and
32 EORTC-IDG members reached by e-mail (70% university, 16%
university-afﬁliated and 14% community or private hospitals) from 25
European countries participated in the survey. Specialties of investigators
were: 86% haematology–oncology, 9% infectious diseases, and 5%
other. 62% of responding investigators were involved in patients care as
primary physicians, 26% as consultants, while 12% were not in charge
of this type of patients. Assessment of the risk of bacterial infections
and use of antibacterial prophylaxis in the 4 patient populations. Median
(range) daily dose of ciproﬂoxacin: 1000mg (500–1500). Px was given
orally in 100% of the patients with neutropenia < or > 10 days and in
autologous HSCT, while it was given i.v. in 6.5% of allogeneic HSCT.
Neutropenia HSCT
<10 d
(n = 97)
>10 d
(n = 101)
Autologous
(n = 101)
Allogeneic
(n = 100)
Proportion of investigators
estimating that patients are
at high risk of bacterial
infections
9% 78% 51% 80%
Proportion of patients
receiving antibacterial Px
19% 51% 50% 76%
Antibiotics used for Px:
Ciproﬂoxacin 55% 52% 56% 53%
Other ﬂuoroquinolone 19% 20% 18% 22%
Cotrimoxazole 23% 15% 18% 22%
Selective digestive 3% 10% 7% 11%
decontamination
Conclusions: In Europe, antibacterial prophylaxis is used routinely
in 50% to 76% of neutropenic cancer patients with long-duration
neutropenia. Oral ﬂuoroquinolones, mostly ciproﬂoxacin, are the agents
used most commonly.
P726 Usefulness of a general chemotherapy myelotoxicity score to
predict febrile neutropenia in haematological cancers
A. Georgala, M. Paesmans, A. Schwarzbold, F. Muanza, M. Aoun,
A. Ferrant, D. Bron, J. Klastersky, M. Moreau (Brussels, BE)
Introduction: Chemotherapy-induced neutropenia is the most common
adverse effect of chemotherapy and is often complicated by febrile
neutropenia (FN). In many institutions, the decision to give granulocyte
colony-stimulating factors as prophylaxis is mainly based on the
myelosuppressive potential of the chemotherapy regimen (CR) but clear
regimen-speciﬁc risks are not deﬁned. The objective of this study is
to validate a classiﬁcation of aggressiveness of a CR and to evaluate
its usefulness in a risk prediction model of FN in patients with
haematological cancers (HC) at the beginning of a chemotherapy cycle.
Methodology: Patients aged above 16 years, diagnosed with HC of
any type were prospectively enrolled and followed in the “Institut Jules
Bordet” and the “Universite´ Catholique de Louvain” between 2001 and
2005. Out of the 266 enrolled patients, 22.9%, 43.6% and 33.5% were
followed respectively during one cycle, 2 to 4 cycles and more than
4 cycles, totalising 1053 cycles. Relevant patient’s information were
collected at the beginning of the ﬁrst cycle (sex, age, diagnosis and
concomitant diseases). At the beginning of each cycle, the CR score
was computed, a blood examination performed and the temperature
measured. In the follow-up, the number of days of FN (neutrophils
<500/ml and fever) were counted. This outcome was dichotomised (no
FN vs 1 day of FN). Generalised Estimating Equations (GEE) was
used for the analysis as it takes into account the correlation structure
between the outcome as well as the covariates within the same patient.
Results: In 35.3% of the cycles, patients experienced FN. In the
ﬁnal model, aggressive CR is the major predictor of FN (OR 4.4
[2.7−7.0]), compared to those not receiving an aggressive CR. The
other independent predictors are a diagnosis of “myeloid tumour”
(2.9 [1.7−5.1], a baseline monocyte count <150/ml (2.3 [1.4−3.8]), an
involvement of bone marrow (2.1 [1.4−3.2]), the ﬁrst cycle in the same
treatment line (2.2 [1.5−3.2]) and a baseline hemoglobin dosage <12 gr/l
(1.7 [1.0−2.7]). Using the estimates of the regression coefﬁcients, a rule
of prediction of FN was computed (sensitivity: 82.2%, speciﬁcity: 78.1%,
positive predictive value: 68.5% and negative predictive value: 88.4%).
Conclusions: Further studies are needed to validate this score as well
as investigating new factors in order to be able to better predict FN.
P727 The use of cepfoperazone/sulbactam in oesophageal
cancer patients after Lewis-Tanner oesophagectomy via an
abdominal-right thoracotomy approach
Z. Volkova (Moscow, RU)
Objective: The aim of the study was the comparison of two
regimens of cefoperazone/sulbactam (CS) in oesophageal cancer patients
(pts) undergoing Lewis-Tanner oesophagectomy via an abdominal-
right thoracotomy approach for prevention of postoperative infectious
complications.
Materials and Methods: 64 oesophageal cancer pts were studied. Group
(gr) A (31 pts) received preventive therapy with CS 4 g/day for 5 days.
Gr B (33 pts) received preventive therapy with CS 8 g/day for 5 days.
First dose of CS started 1 hour before operation. Both groups were
comparable (p> 0.05) for the main parameters (underlying diseases,
age, weight, cancer diseases, a˜-therapy, chemotherapy). Bacteriological
analyses were made with automatic systems: “ATB-Expression“ and
“VITEK2“ (“BioMerioux“, France).
Results: 11 (35.5%) pts of gr A had infectious complications during
ﬁrst 7 days after operation: sepsis, septic shock – in 2/31 (6.5%) pts;
pneumonia in – 11/31 (35.5%) pts; supperative tracheobronchitis in –
7/31 (22.6%), pleural abscess in 1/31 (3.2%) pts. 9 (29.0%) pts had
two or more infections: pneumonia and bronchitis in – 6/9 (66.7%) pts;
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sepsis, septic shock and pneumonia in – 2/9 (22.2%) pts; pneumonia,
abscess and pleural empyema in – 1/9 (11.1%). Only 4/33 (12.1%) pts
of gr B (p< 0.05) had infections complications during ﬁrst 7 days after
operation. 4/33 (12.1%) pts – pneumonia; 1/33 (3.0%) pts – pneumonia
and bronchitis.
67.9% of strains were Gram-negative rods: 28.4% – P. aeruginosa,
13.3% – S. malthophilia, 9.8% – K. pneumoniae, 7.4% – E. coli.
59% strains of P. aeruginosa was multiresistant. Nosocomial microﬂora
contaminated pts after 13–14 days postoperation. The pneumonia cases
was found 2.8 times more often in gr A vs gr B (p< 0.05) and it was
assiciated with sepsis, septic chock in 2/13 (15.4%) pts vs 0% pts in
group A and B, respectively.
Conclusion: Preventive therapy with cefoperazone/sulbactam 8 g per
day, in oesophageal cancer patients after Lewis-Tanner oesophagectomy
via an abdominal-right thoracotomy approach reduced the rate of
infectious complications in early postoperative period.
P728 Initial experience with ertapenem in clinical practice:
treatment of twenty patients with chemotherapy-induced
low-risk febrile neutropenia in an outpatient setting
F. Krasniqi, A. Ho, G. Egerer (Heidelberg, DE)
Objectives: Ertapenem is a novel, once-a-day parenteral carbapenem
with a broad spectrum, including extended-spectrum b-lactamases
(ESBL) producers and AmpC producing enterobacteriaceae. An obser-
vational study was performed in low-risk (deﬁned by the AGIHO) cancer
patients with chemotherapy-induced febrile neutropenia to determine the
safety and efﬁcacy of ertapenem given in an outpatient setting.
Material and Methods: In a prospective observational study carried out
between December 2005 and September 2006 20 febrile episodes were
recorded. Inclusion criteria were neutropenia (neutrophil count <500/mL
or <1000/mL with predicted decline to 500/mL within the next 2 days)
and fever (38.3ºC). Patients with acute leukaemia (n = 7), multiple
myeloma (n = 5), high-grade Non-Hodgkin-Lymphoma (n = 4), low-grade
Non-Hodgkin-Lymphoma (n = 3) and Hodgkin‘s disease (n = 1) were
enrolled with a median age of 58 years (range 25−74) and a median
Karnofsky-performance-score of 8.0 (range 7.0–10.0).
The causes of fever were: FUO in 10 patients, clinically deﬁned infection
(CDI) in 6 patients and 4 patients with MDI and CDI. All patients were
initially treated with an empirical treatment with ertapenem 1 g per day,
either alone (n = 8) or in combination with other agents (n = 12).
Results: The initial treatment with ertapenem was successful in
14 patients, who were treated in an outpatient setting. However admission
to hospital was necessary for another 6 patients, two of whom
died (one of mykoplasmapneumonia, another one of septicaemia with
Enterococcus faecium).
Conclusion: Ertapenem is effective and safe in patients with febrile
neutropenia. In terms of increasing Gram-negative multi-drug resistance
ertapenem is an effective, safe and economic option for the treatment of
low-risk febrile neutropenia. However, further studies are necessary.
P729 Tigecycline usage in cancer patients with refractory
pneumonia: a report on 38 cases. A single-institution study
R. Chemaly, R. Hachem, S. Hanmod, J. Adachi, H. Hogan, V. Mulanovich,
D. Kontoyiannis, A. Safdar, I. Raad, K. Rolston (Houston, US)
Background: Tigecycline (TG), ﬁrst in a new class of Glycylclines, is
a novel agent approved for treatment of complicated soft tissue and
intraabdominal infections in adults. Clinical data on the safety and
efﬁcacy of TG in cancer pts with pneumonia is lacking.
Methods: We reviewed records of cancer pts with pneumonia treated
with TG for >72 h between Sept’05 and Sept’06. Data collection
included demographics, cancer type, indication for TG, side effects and
outcome.
Results: Thirty-eight pts with pneumonia were identiﬁed, 4 (10%) of
them had ventilator-associated pneumonia. Median age was 56 years
(23−79 y). Most pts (28, 74%) had haematologic malignancies,
including 14 allogeneic HSCT pts; 13 pts (34%) were neutropenic
(ANC< 500/mm3). Twenty-six pts (68%) were in the ICU of whom
18 (69%) required ventilator support after development of pneumonia.
Thirty-six (95%) pts received TG as second line agent (after failure
of other broad-spectrum antibiotics) and in combination with an
anti-pseudomonal drug(s) and the remaining 2 pts received it as a
ﬁrst line agent because of allergy to vancomycin and/or b-lactams.
Median duration of therapy was 11 d (4−35 d). Twenty-eight pts (74%)
received TG for refractory pneumonia of unknown etiology and 10 pts
(26%) for microbiologically documented pneumonia with multi-drug
resistant organisms (MDRO) [MRSA, S. maltophilia, E. coli, VRE,
and Acinetobacter]. Clinical response was noted in 24 pts (63%);
including 4 of the 5 pts who had associated bacteraemia and 2 pts with
associated intra-abdominal infections. Eight of the 10 (80%) patients
who had microbiologically documented pneumonia responded to the
treatment. The remainder 14 pts died (37%). The cause of death was
multi-organ failure and pneumonia of unknown etiology in 10 pts;
MDR P. Aeuroginosa bacteraemia, aspergillosis, S. maltophilia and VRE
pneumonia in 1 each. Of the 9 pts who were not on anti-emetics and
were not intubated, only 1 developed mild nausea. Diarrhoea was noted
in 1 pt.
Conclusions: Combination of TG with anti-pseudomonal drug(s)
appears to be an appropriate choice for treatment of refractory
pneumonia secondary or not to MDRO (excluding P. aeuroginosa) in
cancer patients, including HSCT recipients.
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P730 Resistance of Streptococcus pneumoniae to widely used
antibiotics in a training hospital in Ankara, Turkey
N. Balaban, I. Mumcuoglu, N. Hayirlioglu, Z. Karahan, N. Sultan,
H. Bodur (Ankara, TR)
Objectives: The worldwide increase of resistance to widely used
antibiotics in S. pneumoniae treatment has become a serious problem
within the last 20 years. The aim of this study was to determine
the antimicrobial susceptibility of clinical S. pneumoniae isolates to
penicillin and other widely used antibiotics.
Methods: Seventyeight S. pneumoniae strains were isolated from clinical
samples between June 2004 and May 2005 at the Department of
Microbiology and Clinical Microbiology in Ankara Numune Training
and Research Hospital and Gazi University Hospital. 57 (73.1%) of the
strains were isolated from sputum and 21 (26.9%) from sterile body
sites. Identiﬁcation of the S. pneumoniae strains was performed by Gram
stain, colony morphology, optochin sensitivity and bile solubility tests.
Susceptibility of the strains to penicillin, erythromycin, azithromycin,
trimethoprim-sulfamethoxazole, cefotaxime, cefuroxime, doxycycline,
oﬂoxacin and levoﬂoxacin were determined by the E test method
(AB-Biodisk, Sweeden). Results were evaluated according to the CLSI
standards. S. pneumoniae ATCC 49619 was used as the quality control
strain.
Results: The rates of penicilin resistance and intermediate resistance
were 7.7% and 21.8% respectively. All resistant strains were isolated
from sputum. The resistance rates for trimethoprim-sulfametaxazole,
azithromycin and erithromycin were 28.2%, 16.7% and 14.1%. 98.7%
of the pneumococcal isolates were susceptible to both levoﬂoxacin and
cefotaxime. All penicillin resistant isolates and 82.4% of the intermediate
resistant isolates were resistant to at least two antimicrobial agents.
Conclusion: Increasing rates of penicillin resistant S. pneumoniae
(PRSP) has been shown in Turkey in recent studies. Knowing
penicillin resistance rates of the isolates is important for planning
empirical antimicrobial therapy in pneumococcal infections such
as community acquired pneumonia and meningitidis. It is worth
reminding the clinicians about the fact that, PRSP may cause treatment
failure in respiratory tract infections as they are usually resistant to
many commonly used antimicrobial agents such as macrolides and
trimethoprim-sulfametaxazole.
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P731 S. pneumoniae resistance patterns in a chest diseases
hospital, for the decade 1997–2006
M. Makarona, H. Moraitou, N. Tsagarakis, S. Karabela, A. Gioga,
I. Kouseris, V. Spyropoulos, S. Triantafyllou, A. Pefanis, S. Kanavaki
(Athens, GR)
Objectives: The aim of this study was to investigate the resistant patterns
of S. pneumoniae strains isolated in ‘Sotiria’ Chest Diseases Hospital
from 1997 to 2006, a period covering the last decade.
Material and Methods: A total of 480 S. pneumoniae strains were
isolated in our laboratory during the last decade. Most of them (373/480,
77.7%) derived from sputum samples, while 107/480 (22.3%) derived
from different invasive infection sites, such as blood (61/480, 12.7%),
pleural effusion (35/480, 7.29%) and CSF (5/480, 1.04%).
Culture and susceptibility tests were performed according to NCCLS
2004 guidelines. All strains were tested by Kirby-Bauer disk diffusion
method for penicillin, erythromycin, tetracycline, co-trimoxazole,
ciproﬂoxacin and cefotaxime susceptibility. Oxacillin 1mg/mL disks
checked resistance to penicillin. Zone diameter 20mm indicated
Penicillin susceptible strains (PSSP) and 19mm penicillin non-
susceptible (PNSP). Penicillin MIC for PNSP strains was determined
by E-test, according to NCCLS 2004 guidelines.
Results: Regarding penicillin, 366/480 (76.25%) were PSSP strains and
114/480 (23.75%) were PNSP. A number of 92/114 (80.7%) showed
intermediate resistance and 22/114 (19.3%) resistance. Most of the
PNSPs (90/114, 78.9%) derived from sputum cultures. It is worthy of
remark that 81/114 (71.0%) of PNSPs and 76/366 (20.7%) of PSSPs
conferred resistance also to Erythromycin. Erythromycin resistance rates
remained stable around 30% throughout the decade. Erythromycin MIC
was performed on 108 strains and 48/108 (44.4%) showed high levels
of resistance (MIC 128mg/mL). Tetracycline resistance rate was at
14.6%. Cefotaxime resistance rate was at 1.0% and Ciproﬂoxacin at
2.0%. 96/480 (20.0%) strains proved multi-drug resistant (MDR), while
76/96 (79.0%) were PNSPs.
Discussion: All medical practitioners should be aware of current
S. pneumoniae resistance rates, before empirical treatment is offered
to community-acquired respiratory system infections.
P732 Comparison between respiratory and blood isolates of
community-acquired Streptococcus pneumoniae from the UK
and Ireland: resistance and serotypes
R. Reynolds, D. Felmingham, R. Hope for the BSAC Working Parties
on Resistance Surveillance
Objective: Results from the BSAC Respiratory and Bacteraemia Resis-
tance Surveillance Programmes were compared to identify differences
between respiratory and blood isolates of S. pneumoniae.
Methods: 31 centres collected 5083 community-acquired lower
respiratory S. pneumoniae from 1999/2000 to 2005/06; 29 centres
collected 1157 isolates from blood from 2001 to 2005. Ten of these
centres contributed to both programmes. MICs were measured by
BSAC methods in two central laboratories, one for each programme.
Respiratory isolates from 2005/06 and all blood isolates were serotyped.
The 285 blood isolates taken >48 hours after hospital admission differed
from presumed community-acquired blood isolates in penicillin non-
susceptibility (11% vs. 5%), patient age and sex, and were excluded
from the results below. Logistic and multinomial logit models used robust
errors to account for clustering of effects by centre.
Results: The top ten serotypes in blood were 14, 1, 9V, 23F, 8, 4, 3,
19F, 6B, 22F (total 70%); this distribution did not vary signiﬁcantly over
5 years. The distribution was different in respiratory isolates: the top ten
were 19F, 23F, 6B, 3, 6A, 9V, 14, 11, 15, 19A (total 63%). Serotype
distributions varied with age group but not with sex or care setting
(community vs. hospital), and prevalence of penicillin non-susceptibility
varied between serotypes.
Penicillin non-susceptibility was more prevalent in respiratory than in
blood isolates; this difference was apparent in each age group, sex and
care setting, and within some common serotypes. Care setting and isolate
source (respiratory vs. blood) were signiﬁcant independent predictors of
penicillin non-susceptibility; sex and age group were not. The role of
serotype distribution is uncertain, as serotypes were too numerous to
include satisfactorily in models, but it is unlikely to explain these effects
completely since differences could be seen within some major serotypes.
Conclusion: Penicillin non-susceptibility is uncommon in community-
acquired S. pneumoniae in the UK and Ireland. It is more common in
isolates from lower respiratory sources than those from blood, but some
caution in interpretation is required as few centres contributed both blood
and respiratory isolates. The serotype distribution of blood isolates was
stable over 5 years. These results provide a baseline for comparison
should serotype distributions and associated resistance change with
future use of the 7-valent conjugate vaccine.
S. pneumoniae penicillin non-susceptibility
Non-susceptible
Respiratory Blood
N %PEN-NS N %PEN-NS
All isolates 5065 8.3 843 4.7
Care setting
community 2023 6.4 162 4.3
hospital (<48 hours) 3042 9.5 681 4.8
Age
0−19 481 8.9 114 6.1
20−59 1837 6.8 275 4.0
60 2742 9.2 447 4.9
Gender
female 2074 7.0 406 4.9
male 2989 9.1 434 4.6
Serotype
14 38 34 135 3
23F 72 6 60 3
19F 83 10 43 2
9V 39 31 67 34
3 51 0 46 0
1 11 0 74 0
6B 53 9 32 6
P733 The ﬁrst nationwide surveillance of bacterial respiratory
pathogens conducted by the Japanese Society of
Chemotherapy
Y. Niki, S. Kohno, N. Aoki, A. Watanabe, M. Yagisawa, J. Sato, H. Hanaki
on behalf of the JSC Surveillance Committee & The Kitasato Institute
Objectives: The main approach in the control of antibiotic-resistant
infections is through the precise usage of speciﬁc antimicrobial agents.
Comprehensive data on susceptibilities of the major pathogens to
currently available agents is currently lacking. In 2006 the Japanese
Society of Chemotherapy (JSC) initiated a nationwide study of major
bacterial RTI pathogens (Staphylococcus aureus, Streptococcus pneu-
moniae, Streptococcus pyogenes, Haemophilus inﬂuenzae, Moraxella
catarrhalis, Klebsiella pneumoniae and Pseudomonas aeruginosa) in
Japan.
Methods: A total of 924 clinical isolates from well-diagnosed adult
RTI patients were obtained from 34 hospitals throughout Japan
between January and April 2006. Susceptibility of these strains to 40
antimicrobial agents was tested at the central laboratory according to
CLSI standards for broth microdilution method. Beta-lactamases were
detected by the Nitroceﬁn disc method. Extended-spectrum b-lactamase
(ESBL) and metallo-b-lactamase (MBL) were detected by the Cica-Beta
Test (Kanto Chemical, Tokyo).
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Results: See the table. One MBL-producing multi-drug resistant
P. aeruginosa was found among 143 strains, and two ESBL-producing
K. pneumoniae were found among 74 strains.
Strain No. of strains Antimicrobial agent % resistance
S. aureus (MRSA) 205 methicillin 63.4*
vancomycin 0
teicoplanin 0
linezolid 0
S. pneumoniae 200 penicillin 39a
erythromycin 73
H. inﬂuenzae 165 ampicillin (also
b-lactamase negative)
29.1
a4% resistant, 35% intermediate.
Conclusion: In the ﬁrst nationwide surveillance of bacterial respiratory
pathogens, valuable data on resistance patterns to currently available
antimicrobial agents were elucidated. JSC intend to update this data
annually to promote precise usage of antimicrobial agents. We also intend
to extend the study to include uropathogens.
P734 Nosocomial outbreak of telithromycin- and ﬂuoroquinolone-
resistant Streptococcus pneumoniae in a Japanese hospital
T. Muratani, T. Kobayashi, T. Matsumoto on behalf of the Hibiki
Research Group for Clinical Microbiology
Background: Streptococcus pneumoniae is a major pathogen causing
community-acquired pneumonia and acute bronchitis. Amoxicillin,
macrolides, and ﬂuoroquinolones have been used in clinically, because
of their potent activity against S. pneumoniae. Recently, the resistant
isolates to b-lactams including amoxicillin and macrolides, such as
erythromycin, clarithromycin, rokitamycin, azithromycin have accounted
for majority in clinical isolates. But telithromycin and ﬂuoroquinolone
have kept potent activity. We isolated high resistant isolates to
telithromycin and ﬂuoroquinolones in 2004 and 2006. The aim of the
this study is to analyse these resistant isolates.
Materials and Methods: The resistant isolates to telithromycin and
levoﬂoxacin were isolated from 2 patients in 2004, and 9 patients in
2006 from a same hospital. The MICs of various antimicrobials against
the isolates were determined by the two-fold serial agar dilution method.
PCR and DNA sequencing technique were used to analyse mechanism
of resistance to telithromycin. PFGE technique was performed to analyse
clonal spread.
Results: The MICs of levoﬂoxacin and telithromycin were 8−16 and
16−32mg/L, respectively. According to PCR results these isolates had
ermB, but didn’t have mefA, mefE, ermTR. The DNA sequence of 23S
rRNA, rplD and rplV of these resistant isolates were the same as the
susceptible strain. The ermB of resistant isolates had an amino acid
change (Asn100Ser), and 1 or 2 mutations in upstream base sequence.
PFGE technique using SmaI digested DNA of resistants was performed
against 7 isolates. The results revealed the 7 resistant isolates were the
same clone.
Conclusions: We isolated 11 telithromycin and ﬂuoroquinolone high
resistant S. pneumoniae. The mechanisms of resistance to telithromycin
were considered mutated ermB with changed upstream base sequence. It
was considered that the 11 resistant isolates were spread by nosocomial
infection. We must minimise the spread of such resistant S. pneumoniae.
P735 Prevalence and antimicrobial susceptibility proﬁles of leading
nosocomial pneumonia pathogens: the ten-year report from
the European SENTRY Antimicrobial Surveillance Program
T. Fritsche, H. Sader, P. Strabala, R. Jones (North Liberty, US)
Objectives: To present a 10-year summary of bacterial pathogens
(prevalence and antimicrobial susceptibility [S] trends; SENTRY
Antimicrobial Surveillance Program) recovered from European patients
hospitalised with pneumonia (HAP). The emergence of resistance (R)
among pathogens responsible for HAP is changing approaches to
empiric therapy, with increasing dependence on carbapenems (CARB),
ﬂuoroquinolones (FQ), and b-lactamase inhibitor combinations.
Methods: Non-duplicate, clinically-signiﬁcant pneumonia isolates
(10,780) were collected from 25 medical centres in Europe participating
in the SENTRY Program from 1997–2006. Identiﬁcations were
conﬁrmed by the central monitoring laboratory and all isolates were S
tested using CLSI methods and interpretive criteria (M100-S17) against
commonly used antimicrobial agents used for the empiric or directed
therapy of HAP.
Results: Ranking European HAP pathogens between the years 1997–
2006 included S. aureus (SA) > P. aeruginosa (PSA) > Klebsiella spp.
(KSP) > E. coli (EC) > Enterobacter (ESP) > Acinetobacter (ASP) >
Serratia spp. > S. maltophilia. MRSA rates have remained essentially
unchanged during the study, although dramatic differences were noted
between nations. R-emergence is most notable among Gram-negative
bacilli, especially ASP, where R increases have been seen in all sampling
periods for CARB, cephalosporins, FQ and aminoglycosides. Modest
increases in R have also been detected with PSA (imipenem [IPM],
FQ), KSP (ceftazidime [CAZ], FQ, amikacin [AMK]), EC (FQ), and
ESP (CAZ, FQ). ESBL-phenotype rates for KSP have more than doubled
(>27%) since the start of the Program and are also of concern among
EC (9.7%). IPM-R isolates are sporadically detected among KSP and
ESP, usually due to the presence of metallo-carbapenemases (VIM-1;
Italy, Greece and Turkey).
Organism % Inhibited at CLSI Breakpoints
(R pattern) 1997–1999 2000–2002 2004–2006
S. aureus (SA; 2,456)
Methicillin-R (MRSA) 37.3 39.6 38.3
P. aeruginosa (PSA; 2,377)
IPM-NSa 23.6 25.1 29.3
CAZ-R 15.2 21.1 19.3
LEV-R 21.2 25.1 28.6
AMK-R 8.7 8.2 7.5
Klebsiella spp. (KSP; 956)
IPM-NSa 0.0 0.0 0.4
CAZ-R 10.2 (13.6)b 12.4 (19.4)b 17.0 (27.1)b
LEV-R 2.4 2.3 12.6
AMK-R 1.0 2.6 5.4
E. coli (EC; 847)
CAZ-R 1.7 (6.8) 3.1 (8.2) 3.6 (9.7)
LEV-R 4.0 7.4 17.9
Enterobacter spp. (ESP; 748)
IPM-NSa 0.5 0.3 1.1
CAZ-R 21.9 24.5 30.7
LEV-R 7.1 7.8 17.0
Acinetobacter (ASP; 568)
IMP-NSa 33.3 20.9 47.5
CAZ-R 37.9 59.6 69.1
LEV-R 45.2 51.7 68.3
AMK-R 45.9 53.1 62.2
aNS, non-susceptible; bNumber in parentheses reﬂects the ESBL-
phenotype rate (MIC values 2mg/L).
Conclusions: The SENTRY Program has documented emerging HAP
pathogens and changing susceptibility proﬁles within European medical
canters for 10 years. During this time, dramatic changes have been noted
with declining S among widely used classes including the cephalosporins
(Enterobacteriaceae [ENT]), CARB (PSA), and FQ (ENT, PSA and
ASP); marked declines in S to all tested agents were noted with ASP.
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Changing patient demographics, antimicrobial usage and recognition of
R genotypes with highly mobile genetic elements (class 1 integrons)
within hospital environments have altered antibiograms, resulting in
continued R emergence among HAP pathogens.
P736 In vitro synergism between rokitamycin and cotrimoxazole
against S. pyogenes and S. pneumoniae
S. Roveta, A. Marchese, E.A. Debbia, R. Bandettini (Genoa, IT)
Objectives: Using standard susceptibility tests (CLSI, 2005), synergism
between cotrimoxazole (SXT) and rokitamycin (ROK) was observed on
S. pyogenes and S. pneumoniae. The aim of this study was to conﬁrm
this phenomenon on a large number of isolates, displaying different
macrolide resistance phenotypes, employing time-kill tests.
Methods: Synergism between SXT and ROK on 100 S. pyogenes and
100 S. pneumoniae recently isolated was detected by a double-disk
screening test. Time kill experiments were performed on representative
strains adopting standard procedures (CLSI 2005).
Results: The combination of SXT plus ROK reacted synergistically
against 93% S. pyogenes strains and 51% S. pneumoniae strains. On
pneumococci SXT-S this percentage arise to 64%, while, on SXT-R it
was 29%. In no instances antagonism was demonstrated. Synergism was
not observed against S. pyogenes strains showing cMLSB phenotype.
In S. pneumoniae no relationship between different mechanisms of
macrolide resistance and the results of interactions was found. Results of
time-kill experiments conﬁrmed those obtained with double-disk assay
in all the strains tested.
Conclusion: Synergism between SXT and ROK was more frequently
encountered among S. pyogenes than S. pneumoniae strains. Different
macrolide-resistance mechanisms (reduced binding due to modiﬁcation
of the 50S subunit or efﬂux pump) among the various bacteria may
eplain the observed differences
P737 Current susceptibility patterns for Streptococcus pneumoniae
and Haemophilus inﬂuenzae isolates from Europe: ﬁndings
of the 2005–2006 GLOBAL Surveillance Program
M. Jones, N. Brown, D. Draghi, C. Thornsberry, D. Sahm (Breda,
NL; Herndon, US)
Objective: Multi-drug resistant (MDR) has become problematic for
clinicians treating infections caused by S. pneumoniae (SP). Monitoring
susceptibility patterns along with geographic trends for MDR prevalence
can be useful. H. inﬂuenzae (HI) commonly associated with community-
acquired respiratory tract infections can become resistant (R) to
commonly prescribed agents and these resistance rates can vary
according to regional distributions. The GLOBAL Surveillance initiative
was undertaken to track resistance patterns among common respiratory
pathogens.
Methods: During ‘05-‘06, 1542 SP and 1579 HI were collected from 5
countries in Europe (EU; France [FR], Germany [GE], Italy [IT], Spain
[SP], and the United Kingdom [UK]. All isolates were centrally tested
by broth microdilution (CLSI M7-A6, 2003) and results were interpreted
according to CLSI M100-S15, 2005. For SP, MDR was deﬁned as R to
2 agents of the following agents: penicillin (PEN), cefuroxime (CFX),
azithromycin (AZI), and trimethoprim-sulfamethoxazole (SXT).
Results: For all countries combined the prevalence of MDR SP was
18.7%; the most common MDR phenotype was R to PEN, AZI, CFX,
and SXT. LFX-R was not commonly associated with MDR; 98.6% of
MDR were LFX-susceptible (S). By country, the MDR rates (%) were as
follows: 33.2 FR, 28.5 SP, 17.6 GE, 13.4 IT, and 4.3 UK. In each of those
countries, LFX S rates among MDR SP remained high ranging from
96.6% (GE) to 100% (IT and UK). Overall, there were 61% of isolate
pan-S; 20.4% 1-drug R; 5.3% 2-drug R; 7.3% 3-drug R; and 6% 4-drug
R. For all countries combined 219 HI isolates were b-lactamase (BL)
positive (13.9%) and 1360 isolates were BL-negative (86.1%). Overall
MIC90s (mg/L), were >8 for ampicillin (AMP), 0.015 for LFX, and
>4 for SXT. By country LFX retained potent activity against HI, based
on MIC90s (0.015mg/L for all) and %S (100% for all). Only 1 isolate
was encountered that was BL-negative AMP-resistant (BLNAR), which
came from Italy.
Conclusions: The MDR rates among SP varied by country studied;
however, most frequently involved resistance to three classes of agents
including b-lactams, macrolides, and SXT. Susceptibility to LFX remains
high among SP. Among HI, resistance to SXT and AMP (b-lactamase-
mediated) is prevalent throughout EU. In contrast, current susceptibility
to LFX remains high throughout EU. Continued surveillance is warranted
to monitor any changes that may occur among the bacterial landscape.
P738 Respiratory tract isolates of Streptococcus pneumoniae – sus-
ceptibility to antimicrobial agents in Slovenia, 2002 and 2004
I. Sˇtrumbelj, T. Orazˇem, T. Franko-Kancler, V. Bozˇanic, I. Grmek
Kosˇnik, M. Kavcic, L. Sarjanovic, T. Harlander (Murska Sobota,
Ljubljana, Maribor, Celje, Kranj, Koper, Nova Gorica, Novo Mesto, SI)
Objectives: To determine and compare rates of susceptibility to
selected antimicrobial agents in respiratory tract isolates of Streptococcus
pneumoniae in Slovenia in 2002 and 2004.
Methods: Non-duplicated isolates of Streptococcus pneumoniae from
respiratory tract from 2002 and 2004 were identiﬁed by standard methods
in eight Slovenian laboratories. Oxacillin zones and susceptibility to
seven non-betalactam antimicrobials were determined by NCCLS disc-
diffusion procedure. Isolates with oxacillin inhibition zone less than
20mm were tested by Etest: MICs for penicillin and cefotaxime were
interpreted according to NCCLS criteria for isolates from respiratory
tract. Results from 2002 and 2004 were compared (chi-square test,
statistical signiﬁcance: p< 0.05).
Results: Number of isolates in 2002 and 2004 was 850 and 976,
respectively. All isolates were susceptible to vancomycin. Rates of
susceptibility in years 2002 and 2004, respectively, were: to penicillin
81% and 76%, to cefotaxime 99% and 100%, to erythromycin 87% and
80%, to clindamycin 90% and 84%, to trimethoprim-sulfamethoxazole
70% and 63%, to tetracycline 85% and 82%, to levoﬂoxacin and
moxiﬂoxacin 99.8% and 99.8%. Differences between 2002 and 2004
were statistically signiﬁcant for penicillin, erythromycin, clindamycin,
trimethoprim-sulfamethoxazole and tetracycline.
Conclusion: Susceptibility to ﬁve antimicrobial agents decreased from
2002 to 2004 in Slovenian S. pneumoniae respiratory tract isolates.
Surveillance and actions to decrease resistance are necessary.
P739 Reversibility of antimicrobial resistance in respiratory
isolates in HIV-positive Cambodian children after 36 months
of HAART
E. Kalavsky, P. Beno, A. Shahum, J. Benca, L. Seng Duong,
A. Augustinova, Z. Havlikova, A. Liskova, V. Krcmery (Bratislava,
Trnava, SK; Phnom Penh, KH)
Objective: Aim of this study was to assess, if restauration of the immune
system after 36 months treatment with HAART in cambodian children
has an impact on antibiotic resistance and its reversibility.
Methods: Study participants were HIV positive cambodian children
treated with HAART stavudine, lamivudine and nevirapine or efavirenz.
Respiratory tract isolates (nose, pharyngeal, ear svabs) from 32
cambodian previously ART naive children 3−11 years old were assessed
every 3 months within 36 months of HAART.
Results: Analysing relationship between duration of HAART, and
colonisation with any speciﬁc resistance pattern, MRSA appeared to
emerge after 6−12 months of HAART in comparison to pre-HAART
period (was 90−93% after 9−12 months vs 50% in HAART naive,
P< 0.01). Presence of multiresistant Klebsiella, and Enterobacter spp.
was high already at baseline and in ﬁrst months of HAART and
the proportion of multiresistant Gram-negative bacteria (MR GNB)
decreased later to 0 and 20% (P< 0.02). Susceptibility of both Gram-
negative and Gram-positive bacteria showed biphasic but increasing
tendency. Proportion of MR GNB decreased from 21/23 (90%) in the
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ﬁrst 6 months of HAART, to 0−11% in those receiving HAART for
15−18 months and to 20−50% after 33 months of HAART. Reversibility
of MR in GNB took 15−18 months. However, the baseline of resistance
in GNB were relatively high. Proportion of MRSA increased from
50−55% in ﬁrst 6 months to 93–85.7% after 9−18 months but than
decreased to 20−33% after 36 months of HAART. Emergence of MRSA
was slower. Reversibility of MR in Staphylococcus aureus was longer
and took approximately 24−30 months. Ratio of Gram-positive to Gram-
negative decreased from 1:3.9 (HAART naive) to 1:1.1 (30−36 month
of HAART).
Conclusion: Reversibility of resistance among isolates from respiratory
system was probably due to the reconstitution of their immune system
due to the HAART and therefore less exposition with therapeutic ATB.
In MRSA, the reversibility of resistance took 15−21 months and was
slower than in MR Gram-negative bacilli (Klebsiella, Enterobacter)
where the increase of susceptibility (and the decrease of resistance) took
9−12 months. Prophylactic administration of cotrimoxazol 3x weekly did
not affect the reversibility of resistance and seems to be less promotive
for antibiotic resistance.
P740 Changes in the catchment population – changes in the rate
of penicillin-resistant Streptococcus pneumoniae strains?
E. Hajdu, M. Matuz, R. Benko, A. Ordas, E. Nagy (Szeged, HU)
Objectives: The catchment population of our laboratory has changed
during the years. We analysed whether this change had any impact on
penicillin resistance rates of S. pneumoniae strains.
Methods: We included in our analysis the S. pneumoniae isolates
if the symptoms or the source of the isolate proved of its clinical
relevance. According to the changes in the catchment population
(between 1998 and 2001 we provided our service exclusively for the
in- and outpatient departments of the university hospital while from the
year 2002 increasing number of general practitioners sent samples to
our laboratory) we set up two time periods: Period I (1998–2001) and
Period II (2002–2005). Isolation and identiﬁcation were carried out by
conventional methods.
All resistance data were collected from our laboratory database
system. The same methodology was used to detect penicillin resistance
throughout the study. The susceptibility of isolates was determined by
using the breakpoints recommended in the NCCLS/CLSI guidelines.
MIC determination was carried out by using the E test. Repeat isolates
from individual patients were excluded. Differences in the distribution of
resistance patterns between the two time periods were analysed by chi-
square test and Fisher’s exact test, using the SPSS programme package
(version 13.0). A P value <0.05 was considered to be statistically
signiﬁcant.
Results: Our results are summarised in the table.
Age group S. pneumoniae isolates P value
Total number Number of penicillin-resistant isolates
HR* LR**
Period I Period II Period I Period II Period I Period II
In-patients
0−2 158 335 32 (20) 13 (4) 58 (37) 180 (54) <0.001
3−14 193 297 26 (13) 7 (2) 68 (35) 129 (43) <0.001
15−65 85 103 7 (8) 3 (3) 22 (26) 28 (27) 0.270
>65 41 55 4 (10) 1 (2) 12 (29) 11 (20) 0.097
All 477 790 69 (14) 24 (3) 160 (34) 348 (44) <0.001
Outpatients
0−2 115 373 24 (21) 9 (2) 36 (31) 208 (56) <0.001
3−14 181 545 12 (7) 9 (2) 55 (30) 297 (53) 0.001
15−65 84 92 1 (1) 1 (1) 16 (19) 25 (27) 0.444
>65 4 9 0 (0) 0 (0) 0 (0) 2 (0) 0.304
All 384 1019 37 (10) 19 (2) 107 (28) 522 (51) <0.001
*HR: high level of resistance; **LR: low level of resistance including resistant (R)
and intermediate resistant (IR) strains.
Conclusion: Contradictory publications exist about the rate of penicillin
resistance among S. pneumoniae isolates in Hungary [1,2]. In our
study the rate of penicillin resistance was found to be low and further
decreasing was observed with the change of the catchment population.
The importance of taking into account the used methodology for
detecting resistance and the origin of the isolates (inpatient vs. outpatient)
is highlighted by our study.
Reference(s)
[1] Marton A. Epidemiology of resistant pneumococci in Hungary.
Microb Drug Resist 1: 127–130, 1995.
[2] Dobay O et al. Antimicrobial susceptibility and serotypes of
Streptococcus pneumoniae isolates from Hungary J Antimicrob
Chemother 51: 887–893, 2003.
P741 Prevalence and mechanisms of Streptococcus pyogenes
resistance to macrolides in Moscow, Russian Federation
S.A. Grudinina, O.Y. Filimonova, E.N. Ilina, S.V. Sidorenko (Moscow, RU)
Objectives: Streptococcus pyogenes (Spy) is a leading cause of bacterial
pharyngitis in humans it is also implicated in some life-threatening
infections in last years. Although Spy isolates are fully susceptible
penicillin G, macrolides are recommended for some groups of patients.
However Spy resistance to macrolides due to ribosomal methylation or
efﬂux is increasing. The objective of the study was to determine the
prevalence and mechanisms of resistance among Spy to macrolides in
Moscow region.
Methods: Clinically signiﬁcant Spy isolates were prospectively collected
in Moscow region from adult and paediatric patients with upper
respiratory tract and skin and soft tissues infections during 2002–2005.
The species identity and purity of all isolates was conﬁrmed in central
laboratory. MICs of erythromycin, clindamycin and telithromycin were
determined using a broth microdilution method as recommended by
CLSI. The erm and mef genes were ampliﬁed using speciﬁc primers.
Discrimination of mef genes subclasses was carried out in thermocyclic
primer extension reaction, followed by mass-spectrometric detection of
the products. Sequencing of selected mef genes was performed using
ABI Prism 3100 Genetic Analyzer (Applied Biosystems, USA).
Results: Trends in resistance prevalence (% of nonsusceptible isolates)
among Spy during the study period are presented in the Table.
Year (number of isolates)
Antibiotic 2002
(n = 194)
2003
(n = 175)
2004
(n = 189)
2005
(n = 158)
Erythromycin 6.7% 4.6% 7.4% 11.4%
Clindamycin 0.5% 0% 1.1% 1.3%
Telithromycin 0 0 0 0
Thirty erythromycin-nonsusceptible isolates were available for molecular
studies. ermA genes were detected in three isolates, and ermB in
one. All these isolates demonstrated MLS phenotype. Thirteen isolates
demonstrating M phenotype were mef positive in PCR with speciﬁc
primers. All mef genes were recognized as mef(I) subclass in primer
extension reaction, and in 10 isolates presence of mef genes was
conﬁrmed by sequencing. No resistant determinants were detected in
13 isolates, demonstrating M phenotype.
Conclusions: Prevalence of macrolide resistance among Spy isolates
in Russia is similar to other regions of Central and Eastern Europe.
Efﬂux mediated by mef genes which belong to recently described mef(I)
subclass is predominant mechanism of resistance.
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P742 Microbial and antimicrobial susceptibility patterns from
patients with chronic otitis media in Ardebil, Iran
G.H. Ettehad, S. Refahi, A. Nemmati, A. Pirzadeh, Z. Tazakori
(Ardebil, IR)
Objective of this study is to identify the commonest microorganisms
associated with chronic suppurative otitis media (CSOM) and their
antimicrobial sensitivities. This study was carried out from 2003 – 2004
at the Department of ear and nose and throat of Ardebil University
of medical sciences. Sixty one patients with chronic suppurative otitis
media were prospectively studied. They had chronic ear discharge and
had not received antibiotics for the previous ﬁve days. Also they
had no cholesteatoma. Swabs were taken, and cultured for bacteria.
Bacteriological specimens were processed and identiﬁed with standard
cultures. Antimicrobial susceptibility of these bacterial isolates was
assessed by an agar disc diffusion method. Isolates were tested against 10
antibiotics: The most frequently isolated organism in chronic suppurative
otitis media was Staphylococcus aureus 19 (31.15%), followed by
Pseudomonas aeruginosa 16 (26.23%) and Proteus sp. 12 (19.67). Fungi
accounted for 4 (6.56%) of the isolates. Sensitivity results showed
majority of isolates were susceptible to Ciproﬂoxacin (85.71%), and
resistant to Penicillin (84.97%). In conclusion, the in vitro susceptibility
results indicate that Ciproﬂoxacin can be an effective antibiotic in the
treatment of active chronic suppurative otitis media.
P743 Antimicrobial resistance of Streptococcus pneumoniae strains
to penicillin and ceftriaxone, isolated in the Nisˇ district,
Romania during 1999–2006
S. Mladenovic-Antic, B. Kocic, P. Stojanovic, S. Ivic, V. Mladenovic
(Nis, RS)
Streptococcus pneumoniae has shown an increase in resistance to
anitimicrobial drugs which signiﬁcantly hinders therapy.
Objectives: To determine the level of resistance to penicillin and
ceftriaxon, and to study it in relation to its resistance in other European
countries.
Methods: In the period between January 1999–December 2003 and
January 2005–September 2006, 523 isolates of S. pneumoniae of various
origins were studied. They were identiﬁed by means of morphological,
cultural and antigen characteristics, and tested by the agar–dilution
method, to indicate their response to penicillin and ceftriaxon according
to the recommendations of the Clinical Laboratory Standards Institute.
Results: In the ﬁrst period, from the 320 S. pneumoniae obtained
from various clinical material, the greatest percentage was found in the
population of children under the age of 15 (84, 07%). The nose smear
(81, 4%) and aspirate (7, 51%) were the most frequent. Testing their
sensitivity gave the following results: 68, 2% of the isolates showed
a reduced sensitivity to penicillin (21, 3% were resistant and 46, 9%
intermediate), and 19, 4% showed a reduced sensitivity to ceftriaxon –
I (9, 4%) and R (10%). In the second period of investigation, 203
isolates of S. pneumoniae of various origins were studied. The greatest
percentage was found in the population of children under the age of 15
(68, 9%). The nose smear (68, 9%) and aspirate (12, 3%) were the most
frequent. Testing their sensitivity gave the following results: 79, 4% of
the isolates showed a reduced sensitivity to penicillin (27% resistant and
52,4% intermediate). Among this isolates, 6, 9% had MIC 4mg/mL –
HLR isolates. 18, 67% showed a reduced sensitivity to ceftriaxon –
I (10, 3%) and R (8, 37, 0%).
Conclusion: The level of resistance and percentage of highly resistant
isolates (MIC 4mg/mL) 6, 9% rank us among those European countries
with the highest rate of resistance to penicillin. The level of resistance to
penicillin is the highest among the isolates obtained from children under
the age of 15 (28%). In the case of ceftriaxon, the level of resistance is
highest among hospital isolates (8%), while the percentage of isolates
which are resistant (8, 37%) and intermediary (10, 3%) to ceftriaxon.
The level of resistance to penicillin is signiﬁcantly higher among the
isolates from the second period of investigation than among the isolates
obtained from children, p 0.001).
P744 Changes in United States regional variations in penicillin-
resistant rates of Streptococcus pneumoniae, 1999 to 2006
S. Bouchillon, B. Johnson, R. Badal, M. Hackel, J. Johnson, D. Hoban,
M. Dowzicky (Schaumburg, Collegeville, US)
Background: The percentage rates of penicillin-resistant (PenR)
S. pneumoniae (SPN) vary by country and region. Earlier studies have
documented US regional variations in PenR SPN. The purpose of this
study was to determine changes in regional variations, if any, of PenR
and PenNS strains of SPN, and the current activity of tigecycline
(TIG), amoxicillin-clavulanic acid (AC), ceftriaxone (CFX), levoﬂoxacin
(LEV), linezolid (LNZ), and vancomycin (VAN) to PenR isolates.
Methods: 2,071 clinically relevant isolates of SPN were collected from
patients in 172 hospitals from 2004–2006. MIC’s to all agents tested
were determined by broth microdilution and interpreted following CLSI
guidelines. Regions are deﬁned by the CDC.
Results: PenNS rate was 42.2% for all regions varying from a high of
62.5% (East South Central) to a low of 31.2% (Paciﬁc). PenR decreased
in all regions but one (New England) with a corresponding increase in
PenI rates in all regions. Regional changes from 1999–2000 to 2004–
2006 are noted. Tigecycline and vancomycin had the lowest MIC90s
(mg/mL) against PenR SPN at 0.25 and 0.5, respectively, followed by
LEV and LNZ at 1, and CFX at 2.
Regions Pen I+R (%) Net Gain/(Loss)
1999−2000
n = 1948/4751
2004−2006
n = 873/2071
(%)
All regions 41.0 42.2 1.2
East North Central 38.7 41.7 3.0
East South Central 53.3 62.5 9.2
Middle Atlantic 36.9 37.6 0.7
Mountain 41.1 37.1 (4.0)
New England 26.1 35.1 9.0
Paciﬁc 34.6 31.2 (3.4)
South Atlantic 47.9 45.3 (2.6)
West North Central 37.1 45.3 8.2
West South Central 47.5 45.1 (2.4)
Conclusions: PenNS for SPN has increased slightly since 1999, with
large increases in levels of PenI in almost all regions, but signiﬁcant
decreases in PenR levels. VAN, LNZ, LEV and TIG MIC90 values
remain unaffected by pen phenotypes.
P745 Antimicrobial susceptibility among clinical isolates of
Haemophilus inﬂuenzae in a tertiary hospital in Greece
D. Kofteridis, G. Notas, S. Maraki, G. Samonis (Heraklion, GR)
Objectives: Haemophilus inﬂuenzae (HI) is an important human
pathogen as well as a commensal of the respiratory tract of children
and adults. The increasing antimicrobial resistance of this organism is
a matter of concern. The antimicrobial resistance of HI strains isolated
from patients of the University Hospital of Heraklion, Crete, Greece
during a 10-year period was investigated.
Materials and Methods: A total of 930 clinical strains of HI
were isolated from various clinical specimens, between January 1996
and December 2005. The strains were characterised according to the
production of b-lactamase, and their in vitro susceptibilities to 24
antimicrobial agents on the basis of the current Clinical and Laboratory
Standards Institute guidelines.
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Results: Overall, 9.5% of the isolates were producing b-lactamase.
An increase in penicillin resistance from 31% in 1996 to 77% in
2005 was observed with an overall resistance of 50%. No increase
in amoxicillin and amoxicillin-clavulanate resistance was observed with
overall resistance of 11% and 0.6%, respectively. A high percentage of
b-lactamase producing strains were isolated from ophthalmic specimens
(36.5%), while most penicillin resistant ones from ear, ophthalmic and
bronchoalveolar lavage (71, 77 and 64%, respectively). Some uncommon
strains such as 2 b-lactamase negative-ampicillin resistant (BLNAR), and
4 b-lactamase positive-amoxicillin-clavulanate resistant (BLPACR) were
identiﬁed. BLNAR represented 0.22% and BLPACR 0.44% of all studied
isolates. A signiﬁcant increase in tetracycline resistance from 1.6% in
1996 to 38% in 2005 was observed, being most prominent during the
last years. Resistance to erythromycin was 99% and remained steady and
high during all the study period. Newer macrolides were not included
in the investigation. Resistance to quinolones was extremely low during
all years (0.8% for oﬂoxacin, and 0.2% for ciproﬂoxacin). Resistance
to other non-b-lactam agents varied from 37.5% for trimethoprim-
sulfamethoxazole to 2.6% for rifampin and 0.4% for chloramphenicol.
Conclusions: An increase in penicillin resistance during the study
period was observed among HI isolates, as opposed to amoxicillin
and amoxicillin-clavulanate resistance that remained unchanged. Among
non b-lactams increased resistance was observed to tetracycline and
trimethoprim-sulfamethoxazole.
P746 Bacteriological efﬁcacy of azithromycin on non-typeable
Haemophilus inﬂuenzae adhered to and entered cultured
human epithelial cells
N. Yamanaka, M. Hotomi, K. Fujihara, S. Tamura, T. Tomita, S. Saito
(Wakayama, JP)
Objectives: Nontypeable Haemophilus inﬂuenzae (NTHi) is a respira-
tory tract pathogen that is not traditionally regarded as an intracellular
bacterium. However, NTHi was shown to reside and replicate
intracellulary in human macrophage-like cells found subepithelially in
human adenoid tissue. The possibility that NTHi might be shielded from
the local immune response and antibiotics by entering macrophages and
epithelial cells may explain the persistence of NTHi in prolonged otitis
media, sinusitis and bronchitis. The aim of the present study was to
study bacteriological efﬁcacy of azithromycin on NTHi adhered to and
internalised by cultured human epithelial cells.
Methods: Clinical isolates of NTHi and the human carcinoma epithelial
cell lines, Hep2 and Detroit562, were used in this study. Bacteriological
efﬁcacies of azithromycin(AZM) and ceftriaxon(CTRX) were studied in
adherence and internalisation assay. In adherence assay for NTHi, after
separating the extracellular nonadhered bacteria in supernatant, 1MBC
of AZM and CTRX were added to the well with NTHi adhered to Hep2
cells. The number of adhered and intracellular NTHi was determined
the following day. To examin internalisation and penetration activity of
NTHi, we used 24 well multiplate with transwell polyester membrane
ﬁlters cultured with Detroit562 cells. Bacterial suspension of NTHi
was added to monolayer cells pre-treated with various concentrations of
AZM, followed by overnight incubation, and internalised bacteria after
the mechanical lysis and penetrated bacteria in the lower chamber were
counted.
Results: CTRX did not show bacteriocidal effect on adhered and
intracellular NTHi even after 12 h incubation. On the other hand, AZM
showed marked bacteriocidal effect on adhered and intracellular NTHi
as well as extracellular bacteria after 4 h incubation. AZM higher than
10 ug/mL incubated with monolayer Detroid562 cells showed marked
bacteriocidal effects on both internalised and penetrated NTHi and no
viable bacterium was determined.
Conclusion: In the present study, we observed a wide spectrum in the
level of NTHi adherence, internalisation and penetration. AZM showed
marked bacteriological efﬁcacy on NTHi adhered to, internalised by,
and penetrated with cultured human epithelial cells, in contrast with
CTRX which was bacteriocidal only to extracellular NTHi. These data
suggest that AZM may be of high therapeutic signiﬁcance on prolonged
respiratory tract infections due to NTHi.
P747 Comparative minimum inhibitory concentration and mutant
prevention concentration of azithromycin, cefuroxime,
gemiﬂoxacin, moxiﬂoxacin and telithromycin against clinical
isolates of Haemophilus inﬂuenzae
J. Blondeau, S. Borsos (Saskatoon, CA)
Objective: Haemophilus inﬂuenzae (HI) is an important and prevalent
respiratory pathogen; it is the most prevalent bacterial cause of acute
exacerbations of chronic bronchitis (AECB). Beta-lactam, macrolide
and quinolone compounds are used for AECB therapy, however, little
is known about the resistance selection potential of these compounds
with HI. We tested azithromycin (AZI), cefuroxime (CFX), gemiﬂoxacin
(GEM), moxiﬂoxacin (MXF) and telithromycin (TEL) by minimum
inhibitory concentration (MIC) and mutant prevention concentration
(MPC) against clinical isolates of HI.
Methods: For MIC testing, the recommended procedure of the Clinical
and Laboratory Standards Institute (CLSI) were followed using 105
CFU/mL of organism in brain heart infusion broth and 5% Fildes
exposed to doubling-drug concentrations and incubation in optimal
atmosphere and temperature. For MPC testing, 109 CFU were exposed
to doubling-drug concentrations on Haemophilus test medium agar plates
and incubated for 24−48 h. The concentration preventing growth was
either the MIC or MPC depending on the method used.
Results: MIC and MPC data for the antimicrobials vs HI (n = 42−45)
are shown in the Table. For GEM and MXF, MIC and MPC values
for all strains were below the susceptibility breakpoint as compared to
100% and 0% for AZI, 100% and 0% for CFX and 96.3% and 20% for
TEL.
MIC (mg/L) MPC (mg/L)
MIC50 MIC90 Range MPC50 MPC90 Range
AZI 1 2 0.5−2 16 32 8−64
CFX 0.5 0.5 0.25−2 >16 >16 >16
GEM 0.004 0.008 0.002–0.016 0.063 0.125 0.016–0.125
MXF 0.016 0.031 0.008–0.031 0.125 0.25 0.031−0.5
TEL 2 2 1−8 8 16 2−32
Conclusions: MPC values were low for GEM and MXF and below
susceptibility breakpoints for 100% of isolates tested suggesting a
low propensity of these compounds to select for resistance from high
density inocula. MPC values for AZI and CFX were elevated beyond
susceptibility breakpoints, however, the mechanism of this observation
remains unknown. For TEL, MPC values were above the susceptibility
breakpoint for 80% of isolates tested.
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P748 EARSS results: S. pneumoniae resistance related to
serogroups?
M.E.A. de Kraker, G. Kahlmeter, N. van de Sande-Bruinsma,
E.W. Tiemersma, J.C.M. Monen, H. Grundmann and EARSS participants
Objective: Since three years the European Antimicrobial Resistance
Surveillance System (EARSS) has, next to resistance data, been
collecting serotype information for S. pneumoniae isolates (SPN). We
analysed the relationship between penicillin and erythromycin resistance
and serotype among SPN isolates.
Methods: Since 1999, EARSS collects routine antimicrobial suscepti-
bility test data amongst others from invasive SPN isolates. According to
standard protocols, macrolide (ery) and b-lactam (pen) susceptibility are
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reported. Serotype data is reported according to the Danish Kauffman-
Lund scheme. We chose two countries that represented a low and a
high endemic situation and that reported serotype information for most
SPN isolates in the database. We compared resistance rates among the
most common serogroups between the high and low endemic country by
chi-square test.
Results: The total number of SPN isolates with serogroup information
over those tested for both antimicobial groups in 2005 was 1536/1539 for
the high endemic country and 1182/1373 for the low endemic country.
Pen resistance was reported 4% for the low endemic country and 12%
for the high endemic country, ery resistance 11% versus 31% and
dual resistance 1 versus 9%. The six most common serogroups in both
countries were 1, 6, 9, 14, 19 and 23. Ery resistance was higher in the
high endemic country for all six serogroups (p< 0.01), pen resistance
was signiﬁcantly higher for serogroups 14, 19, 23 compared to the low
endemic country.
Conclusion: Irrespective of serogroup, pen and ery resistance were
higher for the high endemic country. This indicates that resistance in SPN
is not based on the expansion of particular clones, but rather inﬂuenced
by antimicrobial consumption.
P749 Serotype distribution and antimicrobial resistance of
Streptococcus pneumoniae isolates from ocular infections
S. Maraki, E. Nioti, A. Georgiladakis, Z. Gitti, I. Neonakis,
M. Katrinaki, Y. Tselentis (Heraklion, Crete, GR)
Objective: To determine the antimicrobial susceptibilities and serotypes
of Streptococcus pneumoniae recovered from ocular and periocular
infections from 1997 through 2006 in the University Hospital of Crete,
Greece.
Material and Methods: A total of ninety Streptococcus pneumoniae
isolates were studied. Pneumococci were identiﬁed by using standard
techniques, including Gram stain characteristics, colonial morphology,
optochin susceptibility, and bile solubility. Susceptibility tests were done
by the E-test method according to manufacturer’s recommendations
and were interpreted according to the CLSI guidelines. The following
antibiotics were tested: penicillin G, cefuroxime, cefotaxime, ceftriax-
one, cefepime, imipenem, meropenem, erythromycin, clarithromycin,
clindamycin, ciproﬂoxacin, levoﬂoxacin, sparﬂoxacin, moxiﬂoxacin,
chloramphenicol, tetracycline, trimethoprim/sulfamethoxazole, and van-
comycin. Serotyping was performed by the capsular swelling method
with speciﬁc antisera.
Results: Fourteen isolates (15.5%) showed intermediate resistance
and 7 (7.8%) high-level resistance to penicillin. Erythromycin, clar-
ithromycin, clindamycin, chloramphenicol, tetracycline, and trimetho-
prim/sulfamethoxazole resistance rates were 32.2, 32.2, 14.4, 1.1, 25.6
and 15.6%, respectively. All isolates were sensitive to vancomycin and
to all 4 quinolones tested. The most prevalent serotype was 19, followed
by 6, 9 and 14.
Conclusion: The increased resistance rates of S. pneumoniae to
penicillin, macrolides and other antibiotics indicate the importance of
performing antimicrobial susceptibility testing in order to determine the
appropriate therapy. Fluoroquinolones are highly active in vitro against
ocular pneumococcal isolates including penicillin resistant strains and
may offer enhanced coverage for these organisms.
P750 Regional differences in pneumococcal serotype distribution
in Germany
I. Seegmu¨ller, M. van der Linden, C. Heeg, R. Reinert (Aachen, DE)
Objectives: The German National Reference Centre for Streptococci
collects S. pneumoniae isolates from allover the country. Together with
the isolates we receive epidemiological data concerning the residence of
the patient, the federal state the patient lives in and the federal state of
the centre which sent the isolate. Taking into account the longstanding
coexistence of two german states we wanted to know whether this
separation has a still lasting effect on serotype distribution. We wanted to
know whether there is a difference in the serotype distribution between
the eastern federal states and the western federal states and if so whether
it changes with time.
Methods: Between 2000 and 2005 we received 3678 S. pneumoniae
isolates of which we have information on serotype and the federal state
of patients residence and/or on the federal state of the centre which sent
the isolates.
First we determined the ﬁve most common serotypes of all samples sent.
Afterwards we divided the German federal states into belonging to the
western or eastern part of the country, resulting in 10 western states and
6 eastern states (including the city and state of Berlin). Thereafter we
split the time period between 2000 and 2005 into two separate periods
(2000–2002, 2003–2005) and calculated whether there was a difference
in the relative amounts of the ﬁve most common serotypes changing
with time.
Results: The ﬁve most common serotypes among the 3678 isolates taken
into account are 14, 23F, 6B, 19F and 3 of which serotype 14 (21.6%)
is by far the most common one. Between 2000–2002 (2003–2005) we
received 1643 (2143) samples of which 184 (241) were sent from the
eastern part of Germany and 1459 (1902) from the western part of
Germany. The relative amount of serotype 14 was stable in western
Germany (20.2% vs 20.1%) but changed dramatically in eastern parts
of Germany (37.5% vs 24.9%).
Conclusions: Serotype distribution is different in eastern and western
parts of Germany and it is dramatically changing.
P751 Epidemiology of invasive Streptococcus pneumoniae in
Taiwan, 2001–2003
C-J. Chen, Y-C. Huang, L-H. Su, T-Y. Lin (Taoyuan, TW)
Objectives: To characterise the microbiological features of Streptococ-
cus pneumoniae invasive isolates from a tertiary care hospital in Taiwan
before the introduction of 7-valent pneumococcal conjugate vaccine
(PCV).
Methods: Between January 2001 and December 2003, a total of 272
invasive isolates (115 from children and 157 from adults) were collected
from the clinical microbiologic laboratory of Chang Gung Memorial
Hospital. The susceptibilities to various antibiotics, the serotypes and
pulsed ﬁeld gel electrophoresis (PFGE) typing were determined in all
isolates.
Results: Of 272 isolates, 12 serogroups (18 serotypes) and 78
PFGE types were identiﬁed. The most frequent serotypes were types
14 (30.1%), followed by 23F (20.6%), 6B (16.2), 19F (7.4%), 3 (5.9%)
and 9V (4.0%). The serotype distributions were similar in children and
adults, except for serotype 9V, which was identiﬁed exclusively in adult
isolates. The genotypes of isolates were diverse and a variety of PFGE
types were identiﬁed in isolates with same serotype. However, it was
not uncommon to identify predominant clones of isolates in each of
the six most common serotypes. The non-susceptible rate to penicillin
was 73.9% and the incidence of high-level resistance (MIC 2 ug/mL)
was 43.4%. The isolates also demonstrated high rate of resistance to
erythromycin (91.2%), cefuroxime (55.5%) and ceftriaxone (29.0%). The
isolates expressing PCV-serotypes comprised 95.0% of the penicillin-
non-susceptible strains. When compared to the isolates from adults,
the isolates from children had a signiﬁcant higher rate of resistance
to penicillin (80.9% vs. 68.8%, p = 0.025) and erythromycin (95.7% vs.
87.9%, p = 0.0259) but a lower resistant rate to ceftriaxone (21.7% vs.
37.4%, p = 0.0231). The coverage of 23-valent polysaccharide vaccine
and 7-valent PCV of the serotypes was 91.5% and 83.0%, respectively,
in children; and 85.7% and 78.6%, respectively, in adults.
Conclusion: In Taiwan, the invasive isolates of S. pneumoniae harboured
high-level resistances to macrolide and b-lactams and exhibited distinct
resistant proﬁle between strains from children and adults. The current
commercial pneumococcal vaccines had adequate coverage of the
serotypes among the pneumococcal invasive diseases.
S186 17th ECCMID / 25th ICC, Posters
P752 5-year study of resistance, serotype and genetic diversity of
resistant Streptococcus pneumoniae strains isolated in West
Pomerania region of Poland
M. Nowosiad, S. Giedrys-Kalemba (Szczecin, PL)
Objectives: Streptococcus pneumoniae is responsible for the majority
of upper respiratory tract infection incidents and some invasive diseases.
Abuse of antibiotics in empirical ambulatory practice caused an abrupt
increase in antibiotics resistance as well as clonal spread of resistant
strains in recent years. This explains the importance of epidemiological
studies and searching for new antipneumococcal agents of which
vaccination seems to be the most effective. The aim of this study was to
analyse resistance patterns, serotypes and genetic diversity of resistant
S.p. strains isolated in our region during a 5-year period (2001–2005).
Methods: Using E-test method and the CLSI criteria for ben-
zylpenicillin(P), erythromycin(E), clindamycin(L), tetracycline(T), cot-
rimoxazole(S), ceftriaxone(C), chloramphenicol(H), vankomycin(V),
imipenem(I), 158 strains resistant or intermediate to at least one drug
were obtained. Strains were serotyped with the reference antisera kit
from the Statens Serum Insitut (Copenhagen). Molecular typing was
performed using PFGE method with SmaI restriction enzyme and
analysed with Molecular Analyst (BioRad) software. The resistance
pattern, serotype and PFGE proﬁle was determined for each strain.
Results: Resistance to 8 out of the 9 antibiotics (except vancomycin)
has been observed and resistance to cotrimoxazole was the most frequent
(86.7%). Strains showed 32 different resistance patterns. The dominant
four: TSH (15.2% strains), S, ELTS, PSI concerned 48% of strains.
Resistance degree reached 8 drugs (0.6% strains) and 53.8% of strains
were MDR. Strains belonged to 13 serotypes and 11 of them are
found in the 23-valent vaccine and cover 83.5% of strains. The most
frequent serotype was 19F (22.2%). We have found 70 PFGE proﬁles:
44 unique and 26 clusters (A-Z) consisting of 2−30 strains with similarity
exceeding 87%. The most numerous cluster I consists of 30 strains that
were isolated over the 5 years of the study and showed the same or very
similar resistant patterns: TSH (70%), SH, TH, T, H, S and serotype 19F.
Conclusions: Population of resistant S.p. strains in our region presents
high genetic diversity and numerous different resistance patterns. They
do not show many serotypes and majority of resistant strains are still
covered by the 23-valent vaccine. The I cluster presents the most clonal
spread and doesn’t show similarity to any of the international clones.
P753 Antimicrobial resistance within Streptococcus pneumoniae
isolates from eastern and southern Mediterranean countries
M.A. Borg, E.A. Scicluna, E.W. Tiemersma, M. de Kraker, N. van de
Sande-Bruinsma, J. Monen, H. Grundmann and ARMed Project
Collaborators
Objective: Streptococcus pneumoniae is a common cause of invasive
disease, such as meningitis, sepsis and pneumonia. Treatment of
these serious conditions is compromised by antimicrobial resistance
which has been identiﬁed to be particularly prevalent some Northern
Mediterranean countries, including France and Spain. Information about
the prevalence of antimicrobial resistance in the countries of the
southern and eastern Mediterranean has, however, been sparse. The
Antibiotic Resistance Surveillance and Control in the Mediterranean
Region (ARMed) project [www.slh.gov.mt/armed] provided a ﬁrst time
opportunity for a longitudinal multi-year study of trends of antimicrobial
resistance amongst this species within countries of the southern and
eastern Mediterranean.
Methods: ARMed used almost identical protocols to those adopted and
validated by the European Antimicrobial Resistance Surveillance System
(EARSS) and collected susceptibility test results from invasive isolates
of S. pneumoniae routinely isolated from clinical samples of blood and
cerebrospinal ﬂuid in the participating laboratories situated in Algeria,
Cyprus, Egypt, Jordan, Lebanon, Malta, Morocco, Tunisia and Turkey.
Results: In total, 1298 S. pneumoniae invasive isolates were reported to
ARMed from 2003 to 2005. Overall 27% of these isolates were reported
non-susceptible (intermediate or resistant) to penicillin (PNSP). In 2005,
the lowest proportions of PNSP were found in Malta (15%, n = 13)
and Morocco (17%, n = 42). The highest proportions of PNSP were
reported from Algeria (44%, n = 71). In 2005, the lowest proportions
of erythromycin non-susceptibility (ENSP) were found in Turkey (10%,
n = 98) and Morocco (12%, n = 41). The highest proportions of ENSP
were reported from Malta (46%, n = 13) and Tunisia (39%, n = 33). In
2005, the highest evidence of dual resistance to both penicillin and
erythromycin was seen from Tunisia (24.2%, n = 33) with the lowest
proportion reported from Egypt (2.5%, n = 121) and Malta (0%, n = 13).
A signiﬁcant increase was seen in Turkish laboratories (3% in 2003 to
10% in 2005).
Conclusion: ARMed countries showed a greater prevalence of penicillin
resistance in S. pneumoniae than their northern European Mediterranean
counterparts. However, with the exception of Tunisia, erythromycin
susceptibility was greater and less instances of multiple resistance were
identiﬁed in the southern and eastern Mediterranean centres.
P754 Analysis of in vitro Streptococcus pneumoniae non-
susceptibility to several antimicrobial agents in a children’s
hospital in Turkey (1997–2005)
D. Gur, B. Guciz Dogan (Ankara, TR)
Objectives: The trends in resistance to nine antimicrobial agents in
Streptococcus pneumoniae (SP) isolated in a nine-year period in a
university hospital were evaluated.
Methods: A total number of 1406 clinical isolates of SP iso-
lated between january 1997 and december 2005 were included for
evaluation. Susceptibility tests were performed following the CLSI
guidelines. Susceptibilities to penicillin (PEN) and cefotaxime (CTX)
were determined with E-test and disk diffusion method was used
for erythromycin (ERY), chloramphenicol (CHL), oﬂoxacin (OFX),
levoﬂoxacin (LEV), trimethoprim/sulfamethoxazole (T/S), tetracycline
(TET) and vancomycin (VAN). Rates of resistance to antimicrobial
agents were evaluated by year for each group of specimens (respiratory
tract, CSF and blood). Annual mean MIC and inhibition zone diameter
values were compared for each antimicrobial agent in each group of
specimens.
Results: PEN non-susceptible isolates were 36.9% in 1997 and increased
to 40.9% in 2005 (p = 0.052). Overall 2.4% of the isolates were
highly and 30.0% were intermediately resistant. There was a signiﬁcant
increase in the mean MIC’s of PEN over the years (p = 0.031). ERY
resistance increased from 5.0% to 27.6% in (p = 0.000). Dual resistance
to PEN+ERY increased from 5.0% to 20.5% (p = 0.000). Resistance to
T/S increased from 51.9% to 62.6% and to TET increased from 8.0%
to 25.7%. Overall two isolates were intermediately resistant to LEV and
all were susceptible to VAN.
Conclusion: Resistance rates to PEN has not increased over the years,
however, mean MIC’s for penicillin and resistance rates for ERY, TET,
CHL, T/S have increased signiﬁcantly in nine years.
P755 Rapid variations in the macrolide resistance frequency,
phenotypes and clones of group A streptococci from
pharyngeal colonisation and infections, 2000 to 2006
D. Rolo, S. Custo´dio, A. Nunes, R. Cabral, M. Rato, V. Oliveira,
D.A. Tavares, R. Pires, A. Morais, M.C. Faria, R.M. Barros, I. Peres,
G. Trigueiro, C. Cardoso, J.G. Marques, I. Santos-Sanches (Caparica,
Oeiras, Covilha˜, Lisbon, Miraﬂores, PT)
Objectives: To compare the macrolide resistance frequencies, pheno-
types, clones and population structure among isolates of Group A
streptococci (GAS) from pharyngeal colonisation and infections over
time.
Methods: A total of 1,425 GAS collected during 2000–2006 in Portugal
from asymptomatic pharyngeal carriage (CA, n = 938) and tonsillitis/
pharyngitis (TS, n = 487) of children and adults were tested for macrolide
resistance frequency and phenotypes (M or MLSB) by disk diffusion.
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The macrolide-resistant (MR) isolates from CA (n = 153) and TS
(n = 101) were characterised for serologic T-types and for SmaI or SﬁI
DNA-band Pulsed-Field Gel Electrophoresis (PFGE) patterns. Isolates of
major PFGE patterns were tested by PCR and sequencing for emm-types
and for sequence types (ST) by Multi Locus Sequence Typing (MLST).
Results: Resistance to macrolides gradually increased since 2000 (12%)
to 2003 (43%) and decreased since 2004 (21%) to 2006 (13%) in TS
isolates and the same trend was observed in CA isolates: an increase
since 2000 (9%) to 2003 (28%) and a decrease until 2006 (14%). The
M phenotype among CA isolates increased rapidly from 40% in 2000 to
88% in 2001, became stable (>80%) during 2000/04 and was undetected
in 2005/06, while among TS isolates was almost constant from 2000/05
(>50%) and decreased to 17% in 2006. In parallel, the MLSB phenotype
became dominant in 2005/06. Most (76%) of the MR isolates were of
three M phenotype international lineages that emerged among isolates
of both origins in different years: ST39 (PFGE AA-emm4,emm75-
T8.25Imp19,T4,others), ST36 (PFGE R-emm12-T12,others) and ST28
(PFGE Z-emm1-T1). ST28 emerged in 2000/01, was dominant in
2001 (71%) and disappeared in 2003. ST39 and ST36 emerged in
2001/02, were dominant in 2003 (c.a.40%) and disappeared in 2005/06.
One MLSB phenotype lineage, ST52 (PFGE F or PFGE AK-emm28-
T28), resistant to bacitracin and also seen as epidemic worldwide
emerged in 2000/02 and in 2006 included all the MLSB isolates from
CA and TS.
Conclusions: The epidemiology of GAS from throat colonisation and
infection underwent major shifts during 2000–2006, which included:
(i) decrease in macrolide resistance since 2003 to 2006; (ii) inversions of
macrolide resistance phenotypes in 2000 and 2005; (iii) ﬂuctuation and
replacement of major macrolide-resistant clones. In this study, lineage
ST52 of MLSB phenotype recognized as capable of causing a broad
range of streptococcal infections was ﬁrst detected in carriers.
P756 Epidemiology of invasive Streptococcus pyogenes infections
in Germany
R. Wahl, R. Lu¨tticken, S. Stanzel, M. van der Linden, R. Reinert
(Aachen, DE)
Objectives: This study sought to identify epidemiological markers of
invasive S. pyogenes disease in Germany.
Methods: A nationwide laboratory-based surveillance study of invasive
S. pyogenes infections was conducted in Germany from 1996 until
2002. Demographic and clinical information on the invasive cases were
obtained from medical ﬁles. 464 isolates from 475 patients were available
for emm typing and characterisation of pathogenicity factors. Isolates
were identiﬁed by their haemolysis on sheep blood agar, Lanceﬁeld
grouping, using a commercially available agglutination technique and
standard biochemical procedures. The presence of emm genes was
determined by PCR using ’all M’ primers following a previously
published protocol. The presence of the genes speA, speC, speF, or
ssa was determined by PCR. Multiple logistic regression analysis was
performed to determine risk factors for fatal outcome.
Results: Invasive isolates were obtained from 475 patients, with
251 (52.8%) isolates cultured from blood. The most frequent emm types
were emm 1 (36.4%), emm 28 (8.8%) and emm 3 (8%). The genes
speA and speC and ssa were present at variable frequencies in different
emm types. The highest rate of speA and speC were found in emm
1 (93.6%) and emm 4 (94.7%), respectively. The number of the annual
estimated incidence of invasive GAS disease was at least 0.1 cases
per 100,000 persons. Complete clinical information was available in
165 cases. The overall case fatality rate was 40.6% and highest in the age
group 60−69 years (65.2%). Shock, age 30 years and adult respiratory
distress syndrome (ARDS) were predictors of fatal outcome in a multiple
logistic regression analysis. 6.7% of the cases were categorised as
having been nosocomially acquired. Nine cases of puerperal sepsis were
observed.
Conclusions: The study underscores the importance of invasive
S. pyogenes disease in Germany. Chemoprophylaxis of selected contacts
of patients with invasive infection, infection control, and prompt
investigation of outbreaks in hospitals and nursing homes are possible
measures to reduce the high burden of S. pyogenes disease.
P757 Antimicrobial resistance of S. pyogenes in Russia: results of
prospective multicentre study PEHASus
R. Kozlov, O. Sivaja (Smolensk, RU)
Objective: S. pyogenes (GAS) is the one of the common bacterial
pathogens casing community-acquired infections (tonsillopharyngitis,
skin and skin structure infections). In addition it might cause
streptococcal toxic shock syndrome and also necrotising fasciitis,
incidence of which is increasing in Russia. Therefore it is signiﬁcant
to determine the most active antimicrobials against S. pyogenes.
Methods: The study was conducted in 16 centres in 2001–2003
and 13 centres in 2004–2005 of Russia. Identiﬁcation of the strains
were done on the basis of colony morphology, Gram stain, bacitracin
(0.02 IU) susceptibility and latex agglutination tests. Susceptibility
to 13 antimicrobials was performed in central laboratory by broth
microdilution method. Breakpoints were those of NCCLS (2005) except
for SPI (<1; >4mg/L) and MID (<1; >4mg/L).
Results: A total of 1,057 in non-duplicate clinical isolates of S. pyogenes
were included in this study.
2001–2003, n = 683 2004–2005, n = 374
I/R (%) MIC90 (mg/L) I/R (%) MIC90 (mg/L)
Penicillin G 0 0.06 0 0.008
Erythromycin 2.9/5.3 5.3 4.0/4.8 0.25
Clarithromycin 3.1/3.8 1.2 1.6/2.9 0.125
Azithromycin 0.4/8.3 8.3 4.4/5.3 0.06
Midecamycin 2.0/0 0.5 0/0.3 0.25
Spiramycin 2.0/0 0.5 0/0.3 0.5
Clindamycin 0/0.7 0.03 0.3/0.3 0.03
Levoﬂoxacin 0 0.5 0 1
Moxiﬂoxacin 0 0.25 0 0.25
Linezolid 0 1 0 0.5
Chloramphenicol 1.0/13.0 16 0.8/12.6 16
Tetracycline 1.6/44.5 32 4.0/43.1 32
Conclusions: Expectedly, there were no non-susceptible strains to
penicillin G, levoﬂoxacin, moxiﬂoxacin and linezolid. Percentage of
non-susceptibility to erythromycin, clarithromycin, azithromycin and
clindamycin was less than 10% and relatively stable during the study
period. Midecamycin and spiramycin possessed the higher in vitro
activity in comparison with 14- and 15-membered macrolides suggesting
efﬂux as main mechanism of resistance. The highest non-susceptibility
was observed to chloramphenicol and tetracycline that compromises their
potential for usage for treatment of streptococcal infections.
P758 Differences in the epidemiology of paediatric and adult Strep-
tococcus pyogenes invasive infections in Greece, 2003–2005
A. Stathi, J. Papaparaskevas, L. Zachariadou, A. Pangalis, P. Tassios,
A. Tseleni-Kotsowili, N. Legakis for The Hellenic Strep-EURO Study
Group
Objectives: To investigate possible clinical and epidemiological
differences in Streptococcus pyogenes invasive infections (iGAS) among
the adult and paediatric populations in Greece.
Materials and Methods: A total of 101 cases of iGAS infections during
2003–2005 were studied. Epidemiological and clinical information
collected included: age, gender, specimen type, date of isolation, clinical
manifestation, treatment, outcome, and risk factors. All isolates were
typed by emm gene sequencing.
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Results: Children represented 68 (67.3%) of the cases, and adults
33 (32.7%). The male to female distribution was 37 (54%) to 31 (46%)
in children, and 24 (73%) to 9 (27%) in adults. Age range was
0.5−14 years (mean 5.3) in children, and 22−90 years (mean 51.3) in
adults. Annual incidence was 0.8 cases/100,000 inhabitants/year. Blood
and deep abscesses were the most frequent sites of isolation (41.6 and
35.6%, respectively). A second isolation site was found in 21% of the
cases. Bactaeraemia was a more frequent clinical manifestation among
adults (p = 0.054). Varicella infection was detected as a risk factor only
among children (23%), though a marked decrease was recorded during
2005 (7%, compared to 20% and 30% for 2003 and 2004, respectively),
when trauma emerged as the predominant risk factor in children (39% –
compared to 11% and 6% in 2003 and 2004, respectively). Trauma was
overall the main risk factor among adults (11%). Immunosupression was
more frequent among adults than children (5 and 0.8%, respectively),
whilst surgery was required more frequently among children (p = 0.003).
Only 2 cases were fatal, both paediatric, presented with meningitis and
STSS (paediatric case fatality rate: 3%). The most frequent (>5%) emm
types were 1 (26.7%) and 12 (8.9%). Some emm types were exclusively
observed in adult (11, 19, 50, 80, 101, 108, 113, and 117), or paediatric
isolates (22, 75, 77, 78, 83, and 115).
Conclusions: In addition to distinct emm-types affecting either the adult
or the paediatric population, there were also differences in clinical
manifestations, and predisposing factors between iGAS in adult and
paediatric infections in Greece.
Acknowledgments: Strep-EURO project is funded by the European
Commission (QLK2-CT-2002–01398).
M. Foustoukou, A. Avlamis, H. Malamou-Ladas, E. Papafrangas, A.
Bethimouti, G. Kouppari, B. Gizaris, S. Levidiotou-Stefanou, O. Paniara,
A. Halakatevaki, A. Perogambros, A. Vogiatzi, V. Petroxeilou-Pashou and
M. Iordanidou.
P759 High-level multidrug-resistance among viridians group
streptococci isolated from Turkey: report from the SENTRY
Antimicrobial Surveillance Program
D. Biedenbach, D. Gur, V. Korten, G. Soyletir, R. Jones (North Liberty,
US; Ankara, Istanbul, TR)
Objectives: Viridans group streptococci (VGS) are composed of
numerous species which are usually considered as harmless commensal
of the oral cavity, gastrointestinal and female genital tract. However, VGS
can cause invasive disease including endocarditis, deep abscesses, and
bacteraemia, and are especially problematic among neutropenic patients.
The SENTRY Program has monitored VGS in Europe (EUR) since
1997 including centres in Turkey. After ten years of monitoring these
sites, it was observed that VGS from Turkey were markedly more MDR
compared to other EUR sites and this study documents the MDR patterns
detected.
Methods: A total of 1,361 isolates of VGS were collected from EUR
sites (1997–2006) of which 119 strains were from Turkey. Isolates were
identiﬁed to species level by participants and referred to a central
laboratory for conﬁrmation using bile solubility, colony morphology
and commercial kits when needed. The majority of VGS from Turkey
were included in the S. mitis group. The susceptibility (S) proﬁle
was determined using broth microdilution methods in lysed-horse
blood supplemented CAMHB according to CLSI recommendations/
interpretations (2006). A subset of 18 strains that were high-level
resistant (R) to penicillin (PEN) and mupirocin (MUP) were tested for
clonality using PFGE.
Results: The table showing R-proﬁles among 10 antimicrobials for
strains collected in Turkey compared to centres in EUR. PEN non-S was
69.8% in Turkey (approx. 60% of these were non-S to ceftriaxone [CRO]
or cefepime [FEP]) compared to VGS isolated in EUR at 25% PEN
non-S; 30% non-S to CRO and FEP. Erythromycin (ERY)-R was also
greater in Turkey (53.8%) compared to EUR (28.3%) with a constitutive
clindamycin (CC)-R rate of 56 and 35%, respectively. R to levoﬂoxacin
(LEV) was two-fold higher, tetracycline (TET)-R was nearly double,
and strains R to quin/dalfo (Q/D) and MUP were rarely isolated outside
Turkey. PFGE revealed clonally related strains within this population of
unusually R patterns.
MDR patterns of Turkish viridans-group streptococci
VGS/Antimicrobial
agent
Turkey
(n = 119)
Europe and Israel
(n = 1,242)
% Inter-
mediatea
% Ra % Inter-
mediatea
% Ra
PEN 32.8 37.0 19.6 5.0
CRO 5.8 36.5 3.9 3.3
FEP 10.9 30.3 4.6 3.6
ERY 5.9 53.8 4.0 28.3
CC 0.0 30.3 1.0 9.8
LEV 0.0 3.4 0.6 1.5
TET 3.4 51.3 2.0 28.9
Q/D 5.9 1.7 0.9 0.0
Imipenem – 35.6b – 3.1b
MUP – 18.0c – 1.0c
a% based upon published CLSI S ranges (M100-S16); b% of iso-
lates 1mg/L; c% of isolates 16mg/L.
Conclusions: This study documents signiﬁcant variability among the
S proﬁle of Turkish VGS compared to strains from adjacent EUR
nations. The percentage of strains from Turkey that were R to commonly
prescribed antimicrobial agents such as b-lactams and macrolides
was alarming as was the R rate to ﬂuoroquinolones, TET, Q/D and
MUP. Continued monitoring of VGS will be necessary because of the
geographic variability in R for this increasingly important pathogen.
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P760 Emergence of PCR-ribotype 027 Clostridium difﬁcile-
associated disease, Northern France, 2006
B. Coignard, F. Barbut, K. Blanckaert, J. Thiolet, A. Carbonne,
P. Astagneau, J. Petit, M. Popoff, J. Desenclos (Saint-Maurice, Paris,
Lille, FR)
Background: Clostridium difﬁcile (CD)-associated disease (CDAD) has
been recognized as an increasing cause of nosocomial infections (NI)
since 2003 when a 027 epidemic strain emerged in Northern America
and Europe. To timely detect and control CDAD clusters in France,
the Institut de Veille Sanitaire (InVS) and regional infection control
coordinating centres (CClin) strengthened the surveillance of NI and
set up with the Anaerobe national reference centre (NRC) a network
of regional laboratories to characterise CD isolates. We describe the
introduction and spread of 027 CDAD in northern France in 2006.
Methods: Using ECDC case deﬁnitions, CDAD were notiﬁed by
healthcare facilities (HCF) to CClin and district health departments
through the mandatory national NI early warning and response system.
CD strains were sent to the regional laboratories and NRC for
conﬁrmatory testing and PCR-ribotyping. CClin assisted HCF in the
investigation and implementation of control measures. InVS coordinated
the investigation and centralised epidemiological and microbiological
data.
Results: The ﬁrst cluster of 027 CDAD occurred in a HCF of the Nord
– Pas de Calais region in April 2006 and accounted for 41 cases. Until
November 2006, 30 HCF and 3 nursing homes (NH) notiﬁed 400 CDAD
cases: 23 facilities had clusters of which 7 with 10 cases or more. Among
387 cases diagnosed in HCF, 328 (85%) were healthcare-associated and
54 (14%) community-acquired. Cases occurred mostly among elderly
patients in geriatric or rehabilitation wards; 105 (27%) patients died;
22 (6%) deaths were attributed to CDAD. Of 236 C. difﬁcile strains
obtained from stool, 167 (71%) (31 HCF and 2 NH) belonged to the
027 epidemic strain. As of November 7th, 6 clusters were still considered
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as active. Intensive control measures were needed and included contact
precautions, reinforcement of handwashing, glove use, environmental
cleaning, and patients’ isolation/cohorting. In other French regions, 49
HCF notiﬁed 138 cases with 60 strains sent for typing: none belonged
to the 027 epidemic strain.
Conclusion: Our data conﬁrm the emergence and spread of the 027
epidemic strain in France, which is presently clustered in the Northern
region. This is probably related to close relationships with Northern
Europe countries previously affected by this strain (United Kingdom,
Belgium and The Netherlands). Control of 027 CDAD needs timely,
organised and intensive surveillance and infection control resources.
P761 Succesful control of Clostridium difﬁcile type 027 outbreak
by cohort isolation of infected patients
A.A. Bentohami, C.C.M. Nolte, C.M.F. Verberg, M. Tensen,
E.F.P. IJzerman, G. Heuff, E.J. Kuijper (Hoofddorp, Leiden, NL)
Objectives: Since 2005, outbreaks due the hypervirulent C. difﬁcile
type 027 have been recognized in the western part of the Netherlands.
The outbreaks are difﬁcult to control and advises are contradictory with
respect to isolation protocols. We performed a prospective comparative
study of cohort isolation with isolation of a patient in a single room to
the incidence of CDAD.
Methods: From January until December 2005, an outbreak of CDAD
occurred in a 400 beds general hospital encompassing 129 patients in
total. The mortality attributable to CDAD was 3.1%. Of 17 availabe
strains, 12 (71%) belonged to PCR ribotype 027. The departments of
Internal Medicine (81 beds) and Surgery (76 beds) were the two most
affected departments with 42 and 60 patients, respectively. At week
18, cohort isolation was introduced at the Surgery department, whereas
isolation on a single room was continued at the Internal Medicine.
Patients were isolated on a clinical suspicion of CDAD and/or a positive
toxin test of a faeces sample by enzyme immunoassay. Data on the
antibiotic use were obtained from the pharmacy database and calculated
as daily deﬁned doses (DDD). Patients characteristics were obtained
using a home made standardised questionnaire.
Results: Before week 18 of the outbreak, the incidence of CDAD was
38.5 per 1000 admissions at the Department of Internal medicine and
35.4 per 1000 admission at the Surgery department. The construction
of both departments was identical. Patients did not differ in mean
age, gender, classiﬁcation of American Society of Anesthesiology
characteristics, previous antibiotic use and days of admission before
CDAD developed. After introduction of cohort isolation, the incidence
decreased in the following 20 weeks to 4.4 per 1000 admissions whereas
the incidence remained unchanged to 39.8 per 1000 admission at the
Internal Medicine. Patients with CDAD after week 18 did not differ from
patients with CDAD before week 18. Environmental disinfection with
hypochlorite was similar at the two departments, as were handhygiene
with water and soap and the use of protective clothing. DDD of
cephalosporines and ﬂuoroquinolones were 463 and 1281 at the Internal
Medicine per 12 months and 463 and 1134 at the Surgery department.
Conclusion: In contrast with isolation on a single room, cohort isolation
resulted in a rapid decrease of the incidence of CDAD during an outbreak
of the hypervirulent type 027.
P762 Clinical features of Clostridium difﬁcile-associated disease
and molecular characterisation of the isolated strains in a
cohort of Danish hospitalised patients
L. Søes, I. Brock, S. Persson, K.E.P. Olsen, M. Kemp (Copenhagen, DK)
Objective: Recently outbreaks of severe cases of Clostridium difﬁcile
associated disease (CDAD) due to bacteria with increased virulence have
been reported in hospitals in North America and in parts of Europe.
These virulent strains have been associated with increased production
of toxin A (TcdA) and toxin B (TcdB) and production of binary toxin
(CDT). Furthermore a deletion in the toxinregulating gene tcdC has
been reported in these virulent strains. These ﬁndings have emphasized
the importance of an ongoing surveillance of CDAD. At Statens Serum
Institut a multiplex-PCR method for the simultaneously detection of
C. difﬁcile toxin genes has been developed for this purpose. The aim
of this study was to determine the toxin proﬁle of the strains involved in
CDAD in a Danish cohort and to compare the toxin proﬁles to clinical
features.
Methods: A questionnaire was devised to reveal clinical features such
as severity of disease, symptoms, predisposing illnesses and prior use of
antibiotics. During a period of 6 months stool samples positive in culture
for C. difﬁcile were recorded and the local hospital ward contacted to ﬁll
out the questionnaire by an interview. The isolates were then analysed
by PCR for detection of the toxin genes: tcdA, tcdB and cdtA/cdtB.
Furthermore PCR was applied for detection of deletions in the tcdA and
a sequencing based method was applied to reveal deletions in the tcdC
regulatory gene.
Results: 104 new cases of CDAD were diagnosed by stool culture, and
at present 89 clinical charts could be reviewed. Age ranged from 1 month
to 93 years with 8 patients less than 3 years old. Excluding these, mean
age was 66 years. Male/female ratio was 44/56%. Contributing factors,
such as haematological malignancies, preexisting renal insufﬁciency,
malignant solid tumours or inﬂammatory bowel disease, were seen in
52% of the patients. Immunosuppressive agents were used in one third
of the patients. Bloody stools were seen in about one ﬁfth of the patients
and endoscopy was performed in 12%. According to preliminary results
three quarters of the patients received antibiotics prior to symptoms
and positive culture. Clinical isolates were studied and the toxin proﬁle
investigated as well as deletion studies.
Conclusion: Among other characteristics, these clinical features will be
compared to toxin proﬁles of the isolates and observed deletions in tcdA
and tcdC in order to evaluate the pathogenic potential of the isolated
C. difﬁcile.
P763 Epidemiological investigation of Clostridium difﬁcile
associated diarrhoea in a tertiary care hospital
V. Mela, K. Dimarogona, A. Pantazatou, D. Rebelou, A. Katsandri,
J. Papaparaskevas, A. Avlamis (Athens, GR)
Objective: To investigate for epidemiological differences among patients
with various underline disease severity, that were diagnosed and treated
for Clostridium difﬁcile associated diarrhoea (CDAD).
Materials and Methods: During the period March 2005-May 2006,
out of a total of 640 specimens submitted for investigation of CDAD,
65 were culture-positive for C. difﬁcile, of which 33 were also positive
for toxin A and B. Culture for C. difﬁcile was performed on cefoxitine-
cycloserine-fructose agar after alcohol shock treatment of the specimen.
Toxin A and B production was investigated by a commercially available
enzyme immunoassay (Kytolone A+B kit, Meridian). Epidemiological
and clinical information collected included: age, gender, type of ward,
nosocomial acquisition of diarrhoea or not, duration of symptoms,
classiﬁcation of underlying disease according to Mac Cabe score (cases
with score A were designated as group A, and those with scores
B+C as group B), prior antimicrobial therapy or hospitalisation, CDAD
treatment, and outcome. Statistical analysis was performed with the SPSS
13.0 programme using the x2 procedure.
Results: Among the 65 patients, 34 (52%) were women. The majority
(45/65, 69%) were admitted in internal medicine wards, and previous
hospitalisation was identiﬁed in 44 patients (68%). CDAD treatment
received 40 patients (62%). Improvement was detected in 50 patients
(77%). Nosocomial acquisition (>48 h from admission) was identiﬁed
in 55 patients (85%) and was associated with group B cases (p = 0.001).
Previous hospitalisation among group B patients was associated with
positive toxin production (p = 0.036). Group B patients who received
treatment for CDAD were more frequently improved than patients
without treatment (p = 0.024), an association that was not detected among
group A patients. Increased length of diarrhoea (>7 days) affected
negatively the outcome of CDAD among group B patients (p = 0.009),
but not among group A patients. Prior quinolone and prior 4th generation
cephalosporin therapy was associated with increased length of diarrhoea
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(>7 days) among group B (p = 0.040 and 0.019, respectively) but not
among group A patients.
Conclusions: Differences were detected between the two groups of
patients regarding nosocomial acquisition, prior hospitalisation, prior
antimicrobial therapy, length of diarrhoea, and ﬁnal outcome. These
differences are considered useful for optimisation of measures for
prevention, control and treatment of CDAD.
P764 Mortality of patients with antibiotic-associated diarrhoea –
the impact of Clostridium difﬁcile
J. Bishara, S. Pitlik, Z. Samra (Petah-Tiqva, IL)
Background: Clostridium difﬁcile infection is implicated in 20 to
30% of cases of antibiotic-associated diarrhoea. Previous studies have
shown conﬂicting results relating to mortality attributable to C. difﬁcile
infection. The objective of this study was to determine the impact of
C. difﬁcile infection on short- and long-term mortality in hospitalised
patients with antibiotic-associated diarrhoea.
Methods: All patients hospitalised from October 2003 to January 2004
who had antibiotic-associated diarrhoea and underwent stool enzyme
immunoassay for C. difﬁcile TOX A/B were followed prospectively. For
univariate survival analysis the Kaplan-Meier and the log-rank test were
used. The Cox regression model was used for multivariate analysis of
28-day and long-term mortality.
Results: Fifty-two (24%) of the 217 patients who met the study
criteria were positive for C. difﬁcile TOX A/B. The crude 28-day and
long-term mortality rates of the entire cohort were 12.4% and 56%,
respectively. On Cox regression analysis, hypoalbuminaemia, impaired
functional capacity, and elevated serum urea levels were found to be
the only independent and signiﬁcant variables associated with long-term
mortality. C. difﬁcile toxin positivity per se was not associated with
increased short- or long-term mortality rates.
Conclusions: Antibiotic-associated diarrhoea is associated with high
rates of short- and long term mortality. Hypoalbuminaemia, renal failure,
and impaired function capacity predict mortality. C. difﬁcile involvement
by itself does not further increase the risk of death in these patients.
P765 Co-existence of Clostridium difﬁcile and vancomycin-resistant
enterococci in stool samples, in a tertiary hospital in Greece,
during a one-year period
M. Orfanidou, E. Vagiakou, P. Karabogia, M. Karanika, A. Strouza,
H. Malamou-Lada (Athens, GR)
Objectives: The surveillance of vancomycin resistant enterococci (VRE)
from stool specimens submitted for Clostridium difﬁcile (Cd) testing, in
a tertiary Hospital in Athens, Greece, during one year period (6/2005 –
6/2006)
Methods: During the study period 553 stool samples from patients with
hospital acquired diarrhoea were examined for both Cd and VRE using
cycloserine cefoxitin blood agar (BD) and esculin azide agar with 6mg/L
vancomycin (VA), respectively. Cd strains were identiﬁed by rapid ANA
II (Remel, Lenexa) and latex test (Culturette, BD). VRE strains were
identiﬁed by VITEK2 (bioMe´rieux). Toxin A was detected from Cd
strains by an ELISA (Vidas, bioMe´rieux) and a chromatographic assay
(ColorPak, BD). Both toxins A&B were detected by an EIA (Premier
Toxins A&B, Meridian).
Results: Cd strains were isolated in 67/553 (12%) and VRE in
125/553 (22.6%) faecal specimens. Co-existence of Cd and VRE was
observed in 17/67 (25.4%) specimens. Toxin A+B+ producers were
9/17, A-B+ 5/17 and A-B− 3/17 Cd strains. These 17 specimens were
obtained from patients of Internal Medicine, Gastroenterology, Surgical,
Hematology and Nephrology department. The mean age was 66.7 years
(range 44−83 years). The underlying diseases were: diabetes mellitus,
cancer, Crohn’s disease and operation during the past six months. All
of the patients were under antibiotic therapy, mainly with b-lactams and
glycopeptides, during their hospitalisation. All of Cd-positive patients
were treated with metronidazole (MTZ), with the exception of one
patient who presented pseudomembranous colitis and to whom MTZ was
given simultaneously with VA. None of the 17 patients presented VRE
bacteraemia. Interestingly, 7/67 Cd-positive patients who were treated
successfully for their intestinal infection (ﬁve with MTZ and two with
VA) presented VRE in their stool samples after their treatment.
Conclusions: In our hospital co-existence of Cd and VRE is high.
This may result in the emergence of vancomycin resistant Cd posing
new challenges in the management of hospital associated diarrhoea.
So appropriate antibiotic policy and strict enteric precautions should
be implemented to break the vicious circle between these two bacteria.
P766 Clostridium difﬁcile in Australia
B. Elliott, B. Chang, T. Riley (Perth, AU)
Background: Clostridium difﬁcile is an important nosocomial pathogen.
Toxigenic strains usually produce toxins A and B, which are primary
virulence factors of C. difﬁcile. Some strains produce an additional toxin,
an adenosine-diphosphate ribosyltransferase known as binary toxin, the
role of which in pathogenicity is unknown. There has been concern about
the recent emergence of a hypervirulent ﬂuoroquinolone-resistant strain
(PCR ribotype 027) in North America and Europe.
Objectives: To determine the circulating molecular types of C. difﬁcile
in Australia, and the prevalence of different toxin genotypes including
binary-toxin positive strains. The extent of antimicrobial resistance was
also investigated.
Methods: A total of 115 recent Western Australian (WA) clinical isolates
was examined and compared to 34 clinical isolates from the Eastern
States (ES) of Australia and a PCR ribotype 027 isolate. PCR was used
to detect C. difﬁcile toxin genes and PCR ribotyping to type isolates.
Results: Of the WA isolates, 10 of 103 (10%) were toxin A-negative,
B-positive while 21 of 103 (20%) were non-toxigenic. Only 1 of 33 (3%)
ES isolates was toxin A-negative, B-positive, while 4 of 33 (12%) were
non-toxigenic. These differences were not statistically signiﬁcant. Binary
toxin genes were detected in 17 of 103 (17%) WA isolates, but only
3 of 33 (9%) ES isolates. Two toxin A-negative, B-negative strains
possessing binary toxin genes were detected in WA. Computer analysis of
ribotyping patterns divided 95 Australian isolates into 51 PCR ribotypes.
No isolate with a ribotyping pattern matching that of PCR ribotype 027
was found. Little antimicrobial resistance was found in WA C. difﬁcile
isolates. Fluoroquinolone resistance was detected in one WA and one ES
isolate. Clindamycin resistance was detected in 6 WA isolates (6%). No
metronidazole or vancomycin resistance was detected.
Conclusions: Clinical isolates of C. difﬁcile in WA are diverse with
respect to both their toxin genotype and PCR ribotype. Antimicrobial
resistance, including ﬂuoroquinolone resistance, is low in WA, possibly
as a reﬂection of restricted antimicrobial usage. The PCR ribotype 027
strain was not detected.
P767 Quantiﬁcation of Clostridium difﬁcile by real-time PCR in
hospital environmental samples
C. Nonnenmacher, R. Kropatsch, S. Schumacher, R. Mutters (Marburg,
DE)
Objective: The aim of this study was to detect and quantify Clostridium
difﬁcile in environmental samples obtained in hospital units where
Clostridium difﬁcile symptomatic patients were hospitalysed.
Methods: A real-time PCR assay was established for the detection and
quantiﬁcation of C. difﬁcile in environmental samples. Quantiﬁcation
was performed with speciﬁc 16S rRNA target sequences using
double ﬂuorescence labeled probes. 221 samples were collected from
environmental sites considered to be commonly exposed to patients and
healthcare staff from the hospital settings. Sampling was performed with
sterile cotton wool swabs moistened with 0.25% Ringer’s solution. The
samples were placed immediately in a Schaedler boullion and incubated
under anerobic conditions for 3 days, and subsequently DNA extraction
was performed.
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Results: The sites sampled comprised bed frames, commodes, toilet
environment, patient side room, ﬂoors, staff and patient hands. 86 isolates
(40.6%) recovered from the hospital environment were positive for the
presence of Clostridium difﬁcile. Quantiﬁcation of the positive samples
ranged from 6.7×104 cells/mL to 1.0×103 cells/mL with the higher
numbers of of C. difﬁcile being found in the hands of patients and staff,
staff gloves and in the toilets.
Conclusion: Considering the importance of staff and the inanimate
hospital environment as a potential source of C. difﬁcile, close attention
should be paid to the hygiene of the clinical settings.
Infection control: surveillance and
networking
P768 WHO ﬁrst Global Patient Safety Challenge: current
achievements
B. Allegranzi, A. Leotsakos, J. Storr, G. Dziekan, L. Donaldson,
D. Pittet (Geneva, CH)
Objective: The WHO World Alliance for Patient Safety identiﬁed
healthcare-associated infection (HAI) as the topic of the ﬁrst Global
Patient Safety Challenge (GPSC). The GPSC aims at reducing HAI
worldwide by strengthening integrated actions in the areas of blood
safety, injection safety, clinical procedure safety, and water, sanitation
and waste management safety, with the promotion of hand hygiene (HH)
in healthcare as the cornerstone.
Methods: The GPSC team, supported by a core group of renowned
international experts and WHO collaborating partners, identiﬁed the
following key success factors: 1) raise global awareness about the
importance of HAI as a priority patient safety issue; 2) catalyze country
commitment to actually face this problem; 3) prepare evidence-based
guidelines for HH improvement in healthcare; 4) design and pilot test
a strategy to translate into practice the GPSC, in particular the newly
produced guidelines.
Results: Over the past 12 months, a formal statement has been signed
by 35 Ministries of Health as a pledge of their support to implement
actions to reduce HAI. Twenty additional countries have planned to sign
the pledge by 2007, leading to 75% coverage of the world population.
Following the pledge, 13 countries have recently documented their
actual progress, including establishment of new policies, resources,
national campaigns and guidelines, training programmes and surveillance
systems. A dedicated web page has been constructed as well as a database
of more than 2,000 contacts in the ﬁeld of patient safety and infection
control acting as stakeholders worldwide. A multimodal strategy is
proposed by WHO to improve HH in healthcare settings together with
other infection control interventions. The implementation is supported
by a range of practical tools of different types to address different
targets: operational, advocacy and information, monitoring, HH product
procurement, education, impact evaluation. A test phase is currently
ongoing in several sites.
Conclusions: In only one year of work, the GPSC has attained several
achievements related to pre-established key success factors. The aim of
the ongoing testing of the GPSC implementation strategy is to obtain
feedback about feasibility, acceptability and sustainability in healthcare
settings worldwide. The combined efforts expected under the GPSC have
the potential to save millions of lives and engender major cost savings
by improvement of basic procedures such as HH.
P769 National Resource for Infection Control (www.nric.org.uk):
meeting a need?
S. Wiseman, P. Kostkova, F. Hansraj (London, UK)
The National Resource for Infection Control (NRIC) was launched
in May 2005 in response to National Audit Ofﬁce (2000/04)
recommendations for a national infection control manual. The project
funded by the Department of Health (UK) and endorsed by the UK
National electronic Library of Infection (www.neli.org.uk) has also
been timely in assisting infection control professionals in reviewing/
updating their local evidence based infection control policies, now a
statutory requirement under the Health Act: Code of Practice (2006)
National policy and guidance documents are available on NRIC, with
level of evidence for each resource clearly noted, documents are
organised by settings, clinical practice tasks, modes of transmission
and diseases, organisms. Eighteen months on are we succeeding? A
preliminary evaluation study investigating the NRIC web server logs,
search keywords used and user feedback survey analysis demonstrates
over 2000 distinct users and thousands of hits per month. Geographical
distribution demonstrates 32% of users are from the UK, and 68% users
from non-UK countries (see Table 1).
On average, users spent 2.32 sec on NRIC and visit 3.44 pages; 25.0%
visit NRIC page from other NRIC page, 21.3% come from Google,
6.4% from NeLI, 2.3% from Department for Health, UK website, 5.3%
from other search engines. User feedback has been positive indicating
increasing need for evidence-based knowledge accessed online. NRIC
has now received a ‘face lift’, adding several useful tools for easier
access to other information such as News, upcoming events and over
1000 infection control professionals have signed up for the monthly
eNewsletter. Whilst valid for research the impact of NRIC/NeLI on
public/professionals knowledge, attitudes and subsequent patient care
also needs to be evaluated. Preliminary research has indicated the
potential of these resources to impact on patient care by changing
knowledge & attitudes. Further research is needed to see if these
resources are inﬂuencing clinical outcomes, policy writing and the rise in
shared internet-based infection control manuals by UK healthcare trusts
or whether NRIC needs to develop a wider remit. This presentation will
describe the progress made, the detailed results of the user evaluation
and outline a research protocol for a review of NRIC users, changes
in attitudes/knowledge following use and cost effectiveness in terms
of impact on decision making in policy development and subsequent
practice. Ref-NRIC
P770 Surveillance of surgical site infections after ambulatory
surgery
A. Blaich, R. Babikir, E. Meyer, P. Gastmeier, M. Dettenkofer
(Freiburg, Hannover, DE)
Objective: For patients ambulatory surgery must not be associated
with an higher risk for surgical site infections (SSI) than in hospital
settings. Several studies have demonstrated that SSI result in considerable
morbidity and excess healthcare costs, mostly from extended duration of
hospitalisation and antibiotic use. Surveillance programmes have been
shown to reduce the risk of SSI in surgical patients and are strongly
recommended for prevention.
Methods: In 2002 the German National Reference Center for
Surveillance of Nosocomial Infections established a surveillance module
in order to provide sound data for prevention and control of SSI
in ambulatory surgery (AMBU-KISS). Until today the project centre
(Institute of Enviromental Medicine and Hospital Epidemiology at the
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University Medical Center Freiburg, Germany) has analysed data of
101,584 procedures for a total of 8 operative indicator procedures from
135 participating institutions. Three of these indicator procedures were
compared with corresponding procedures of the OP-KISS modul (SSI
Surveillance in hospital settings). Included in the comparison were SSI
of the OP-KISS modul in patients with arthroscopic surgery of the knee,
inguinal hernias (risk group 0) and in patients with vein – stripping (risk
group 0, 1, 2 and 3).
Results: Results obtained for three indicator procedures show a
signiﬁcant difference in SSI rates for ambulatory surgery institutions
and hospital settings (OP – KISS). The arithmetic mean values of SSI
rates in arthroscopic surgery of the knee are 0.09% in AMBU KISS
and 0.18% in OP–KISS. For inguinal hernias, the respective rates are
0.35% versus 0.68%, and for vein-stripping 0.27% versus 0.84%. The
arithmetic mean values of SSI rates in ambulatory surgery are 0.14%
for orchidotomy and 0% for lumbar intervertebral disc operations, breast
excisions, breast enlargements and nasal septum operations.
Conclusion: The results display that AMBU – KISS is suitable to assess
the frequency of SSI in outpatient institutions and that there is a lower
risk to contract SSI than in hospital settings. However, these data have
to be subject of validation. In ambulatory surgery a highly experienced
team is active. The resulting shorter duration of the operative procedures
and a more gentle technique may be important reasons for the lower rates
in ambulatory surgery.
P771 Are our mobile phones clean?
F. Ulger, S. Esen, A. Dilek, K. Yanik, M. Gunaydin, H. Leblebicioglu
(Samsun, TR)
Objective: Inanimate objects can be contaminated with epidemiolog-
ically important nosocomial pathogens. Cellular phones are widely
used non medical devices by healthcare workers. In this study the
contamination rates of health care worker’s (HCW) mobile phones were
evaluated and the relationship with the contaminated hands of healthcare
workers were investigated.
Material and Methods: A total of 200 HCWs included in the study.
Microbial samples were collected from mobile phones and dominant
hands of HCWs. For each HCW, a sterile swab moistened with sterile
water was rotated over the surface of both sides of his/her phone, a
second swab for the sampling of the dominant hand and both swabs
were immediately streaked on to two plates that consist of blood agar
supplemented with 5% deﬁbrinated sheep blood and eosin methylene
blue agar. Plates were incubated aerobically at 37ºC for 24 h. Oxacillin
sensitivity of the staphylococci and ceftazidime sensitivity of the Gram-
negative isolates were investigated by disk diffusion method.
Types of bacteria isolated from phones and hands of HCWs
Bacteria Mobile phones
(n = 200)
Dominant hands of
HCWs (n = 200)
CoNSa 181 193
Staphylococcus aureus 50 53
Moulds 20 19
Nonenteric Gram-negatives 19 26
Coliforms 15 12
Streptococci 12 18
Enterococcus spp. 7 9
Yeasts 3 3
aCoNS: Coagulase-negative staphylococci.
Results: In total, 94.5% of phones demonstrated evidence of bacterial
contamination. The distribution of the isolated microorganisms was
similar to hand isolates. Some of the mobile phones sampled grew
bacteria that are known to cause nosocomial infections (Table). It was
found that 49.0% of phones grew one bacterial species, 34.0% grew
two different species and 11.5% grew three or more different species.
52.0% of the S. aureus strains that were isolated from mobile phones and
37.7% of the strains from the hands were resistant to methicillin. 31.3%
of the Gram-negative strains that were isolated from mobile phones and
39.5% of the strains from the hands were resistant to ceftazidime.
Conclusions: This study demonstrates that mobile phones may be
contaminated by the hands of HCWs. In this study, some of the
contaminated microorganisms were epidemiologically important noso-
comial drug resistant pathogens. Development of effective preventive
strategies such as regular decontamination of mobile phones with alcohol
disinfectant wipes can reduce cross-infection related with this frequently
used devices in healthcare settings.
Malaria
P772 Sociodemographic and spatial inﬂuences on the malaria
incidence of infants in the Ashanti Region/Ghana
B. Kreuels, R. Kobbe, S. Adjei, O. Adjei on behalf of the Agona IPTi
Trial Team
Introduction: Malaria incidence rates have been shown to vary greatly
over short distances and periods of time in areas of low to medium
transmission. In areas of high, perennial transmission, due to early
acquired immunity malaria incidence variation is considered to be far
less various. However in small children who have not yet developed
immunity this is not necessarily true.
Methods: We recruited a group of 535 children from 9 villages in an
area of high transmission in Ghana at the age of 3 months and followed
them monthly over a period of 21 months. Malaria was deﬁned as
a new fever episode together with a positive thick smear of at least
500 parasites/ml. Socio-economic characteristics were evaluated with
the help of a questionnaire on recruitment. Geographical characteristics
of the villages and distances of households to the forest fringe were
analysed on satellite images with a Geographic Information System
(GIS). Ecological analyses and multivariate Poisson regressions were
performed to determine the most important factors responsible for the
spatial variation of malaria incidence.
Results: Malaria incidence in the study area was highly heterogeneous
between the 9 villages with a variation of 0.83–2.20 episodes per person
year at risk. Incidence rates were strongly correlated to village area
(r2 = 0.74) and village population (r2 = 0.68) while altitude variation in
the study area was low and did not correlate to incidence rates. We found
signiﬁcant lower malaria incidences in children born in May (p< 0.001),
September (p< 0.01) or October (p< 0.01), in children with literate
mothers (p< 0.02), in those with use of bednets (p< 0.001) and window-
screens (p< 0.001), and those born into families with a higher ﬁnancial
status (p< 0.01). On the other hand malaria incidence was higher in
children of Northern Ghanaian ethnicity (p< 0.001) and children whose
mothers worked as farmers (p< 0.01). An independent and strongly
signiﬁcant inﬂuence could be seen for the distance of the household
from the forest fringe with a linear rate reduction of 0.2 episodes every
50 meters further away from the forest (p< 0.001).
Conclusion: Our results indicate that the variation of malaria incidence
rates in children from rural areas of high transmission may have been
underestimated in the past. Taking this variation into account when
designing new and implementing current intervention measures could
possibly increase their efﬁciency and cost-effectiveness.
P773 Trend in malaria vector resistance or susceptibility to
insecticides in Cameroon
J. Etang, P. Nwane, M. Chouaibou, L. Manga, P. Awono-Ambene,
C. Antonio-Nkondjio, E. Fondjo, F. Simard (Yaounde, Brazzaville, CM)
Objectives: The National Strategic Plan for Malaria Prevention in
Cameroon mainly releases on vector control by Insecticide treated nets
and indoor residual spraying. Vector resistance to insecticides is therefore
seen as a threat for interventions.
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The objectives of the study were: (1) to evaluate the susceptibility of
malaria vectors to insecticides used in vector control, (2) to identify
involved resistance mechanisms and their distribution.
Methodology: A large scale programme was conducted in Cameroon
from 2002 to 2006, using WHO protocol for adult bioassays as well as
molecular and biochemical analyses, to evaluate susceptibility to DDT
and pyrethroid insecticides in 45 ﬁeld populations of Anopheles gambiae
Giles and An. arabiensis Patton, 3 populations of An. funestus Giles, 2
populations of An. nili Theobald and 2 populations of An. moucheti
Evans. These anopheline species are the major malaria vectors in
Cameroon (300 infected bites/man/year).
Results: An. funestus, An. nili and An. moucheti were found susceptible
to all insecticides, with almost 100% mortality rates. However, different
patterns of resistance were seen in An. gambiae M and S molecular
forms, and An. arabiensis. In the southern equatorial region, An. gambiae
displayed resistance to DDT (30−60% mortality rate), sometimes
coupled with resistance to pyrethroids (60−80% mortality rates). This
resistance was mainly due to target site insensitivity resulting from
a single nucleotide polymorphism in the gene encoding subunit 2
of the sodium channel. This mutation, known as kdr mutation, leads
to substitution of Leucine (TTA) amino acid to Phenylalanine (TTT)
or Serine (TCA). Both mutations were broadly distributed in the
S molecular form, but slightly in the M form. A polymorphism was
seen in discriminative nucleotides between M and S, at positions 702
and 703 of the subunit 1 of the sodium channel, but not at position 896,
suggesting 3 independent mutational events and introgession between
M and S forms. In the northern part of the country, both An. gambiae
S form and An. arabiensis displayed low level resistance to pyrethroids
and sometimes to DDT (80–100% mortality rates). This resistance was
attributed to elevated activity of esterases or oxidases rather than kdr
mutations.
Conclusion: This is the ﬁrst report of the distribution of kdr mutations
in Cameroon. Current data will enable the National Malaria Control
Programme to elaborate strategies for effective malaria prevention in
Cameroon.
P774 Malaria cases in Turkey: do climatic changes play any role?
O¨. Ergo¨nu¨l, A. Azap, S. Akgu¨ndu¨z (Istanbul, Ankara, TR)
Introduction: Malaria is one of the vector borne infectious diseases that
was affected by climatic changes.
Objective: To demonstrate the effects of temperature and rainfall on
malaria cases in Turkey.
Methods: The data was obtained from two sources: Number of the
malaria cases in the last 30 years from the Ministry of Health (MOH)
of Turkey and the changes in the temperature and rainfall in the last
70 years from The Research Unit in Turkish State Meteorological
Service. Temperature and rainfall variations and trends for Turkey were
analysed by using a data set including monthly averages of daily mean,
and minimum temperatures. Non-parametric Kruskal-Wallis (K-W) test
was performed in order to detect homogeneity in mean annual series.
The non-parametric Mann-Kendall (M-K) rank correlation test was used
to detect any possible trend in temperature series, and to test whether
or not such trends are statistically signiﬁcant. The Cramer test was used
to detect the difference in temperature and rainfall between given time
periods and the longer period.
Results: In recent 35 years, there were two important peaks of malaria
cases in Turkey, one is at the 1977–1984 period, and the other is at
the 1993–1999 period. The mean temperature in 1977–1987 period was
signiﬁcantly higher than mean temperature between 1930 and 2004
in some provinces where malaria incidence was high. Malaria cases
increased in parallel to the increase in mean temperature within certain
time intervals in certain provinces. Although no signiﬁcant decrease
in temperature was observed, the incidence of malaria has declined
signiﬁcantly after year 2000. Extensive control efforts implemented by
local and governmental healthcare authorities might contribute to the
decline of malaria cases. No association was found between rainfall and
the incidence of malaria in any region for any time period.
Conclusion: Although climatic changes may play some role on the
incidence of malaria, preventive efforts for controlling malaria have a
substantial impact.
P775 Effects of intermittent preventive anti-malarial treatment of
infants in a holoendemic area
R. Kobbe, S. Adjei, O. Adjei, J. May on behalf of the Agona IPTi
Trial Team
Background: Intermittent preventive antimalarial treatment of infants
(IPTi) with sulfadoxine-pyrimethamine reduces falciparum malaria and
anaemia in areas of moderate and seasonal transmission. To date, IPTi
has not been assessed in areas of intense perennial malaria transmission.
We investigated the protective efﬁcacy of IPTi in a holoendemic area of
perennial high transmission and analysed the time-dependency as well
as the therapeutic and prophylactic fraction of the effects.
Methods: A randomised, double-blinded, placebo-controlled trial on
IPTi with sulfadoxine-pyrimethamine at three, nine and ﬁfteen months
of age was conducted with 1070 children in an area holoendemic for
malaria inthe Ashanti Region, Ghana. Participants were monitored for
21 months after recruitment by active follow-ups and passive case
detection. Primary endpoint was the reduction of malaria incidence.
Additional outcome measures were incidence of anaemia, number of
outpatient visits, frequency of hospital admissions, and mortality.
Results: Overall protective efﬁcacy against malaria episodes was
20% (95% CI: 11%–29%; p< 0.001). The frequency of malaria
episodes was reduced after the ﬁrst two sulfadoxine-pyrimethamine
applications (protective efﬁcacy 23%; 95% CI: 6%–36%; p = 0.01
and 17%; 95% CI: 1%–30%; p = 0.04, respectively). After the third
sulfadoxine-pyrimethamine administration at month 15, however, no
further protection was achieved. Stratiﬁed analyses for six-months
periods after each treatment were performed. Protection against the ﬁrst
or single episode of anaemia was only signiﬁcant after the ﬁrst IPTi
dose (30%; 95% CI: 5%–49%; p = 0.02) and the frequency of anaemia
episodes increased during the rebound period (−24%; 95% CI: −50%–
−2%; p = 0.03). For all IPTi applications the prophylactic effects clearly
exceeded the therapeutic effects.
Conclusion: In an area of intense perennial malaria transmission, the
protective efﬁcacy of sulfadoxine-pyrimethamine based IPTi is age-
dependent and based on the prophylactic effects of the antimalarial drug.
P776 Clinical symptoms, treatment and outcome of Highlands
malaria in Eldoret (2,400m a.s.l.) and comparison to malaria
in hyper-immune population in endemic region of South
Sudan
A. Farkasova, S. Seckova, Z. Nagyova, A. Kolenova, P. Olejcekova,
I. Sabo, L. Gabrhelova, V. Krcmery, P. Kisac, E. Kalavsky, M. Kiwou,
M. Taziarova, P. Bukovinova, M. Ocenas, J. Kralova, K. Kutna,
J. Mykyta, M. Velganova, A. Augustinova, M. Pivarnik, M. Duris,
L. Uhercik, J. Benca, T. Pastekova (Trnava, Bratislava, SK; Eldored, KE)
Aim of the study and Introduction: Malaria should not be present in
altitudes more than 1,800m a.s.l. However due to global warming, so
called Highlands malaria (HM) sporadically occurs up to 2,000m a.s.l.
The purpose of this study is compare of clinical picture and prognosis
of HM and compare it to malaria in endemic region of South Sudan
(endemic malaria – EM) among hyper-immune population.
Patients and Methods: Analysis of HM from November 2005 to
November 2006 were reviewed (64 cases), symptoms, therapy and
outcome were compared to 215 cases of EM occurring in Gordhim,
South Sudan, where malaria is endemic. Imported cases from Rift Valley
to Eldoret were excluded.
Results: Analysis of 64 cases of sporadic HM showed mild clinical
picture – fever 100%, chills up to 80%, headache 15%, gastrointestinal
symptoms were present in 35.6%, respiratory symptoms in 64.4%. Only
1 case (1.6%) of cerebral malaria occurred. Amodiaquine in 81% and
amodiaquine/arthesunate in 19% were used for therapy with only 1
failure.
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Analysis of 215 cases of EM showed more severe symptoms: 58 (27%)
had severe clinical course, 10 patients (4.7%) cerebral, 1 patient
(0.5%) lung edema, severe anaemia with hemoglobinuria 21.8%, seizures
8 patients (3.7%), severe hypoglycaemia 12 (5.75%). Amodiaquine plus
artesunate was used for therapy, in some cases, arthemeter or/and quinine
were prescribed. 17 patients in Sudan (4%) died, mostly on CNS and
respiratory failure due to cerebral malaria and/or severe anaemia.
Conclusion: Sporadic malaria occurs also in heights up to 2,400m a.s.l.
We documented 64 cases of non-imported malaria in population living
above 2,000m a.s.l., probably due to global warming in Equatorial
Africa. Clinical symptoms despite of high immunity among population
were much severe in endemic area of South Sudan (27%) including 17
deaths (4%) in comparison to no deaths and 1.6% occurrence of severe
malaria in semi-immune population of Eldoret (Highlands malaria).
P777 The risks of reintroduction of malaria into Belgrade area,
Serbia
Z. Dakic, N. Stajkovic, Z. Kulisic, M. Pelemis, J. Poluga, M. Cobeljic,
I. Ofori-Belic, D. Tomic, M. Pavlovic (Belgrade, RS)
Objectives: Since 1974, when the WHO ofﬁcially declared Serbia
malaria-free, only imported cases of malaria have occurred. The
population of mosquitoes has generally been reduced by the campaign
of malaria eradication and frequent insecticide use. During the 1990s,
severe ﬁnancial constraints contributed to the suspension of the vector-
control. Most patients with imported malaria are treated in Belgrade.
Methods: The pattern of imported malaria was monitored during the
period 1994 to 2005 in Belgrade, as a whole and available data on
the presence of the potential vectors for malaria are presented for
comparison.
Results: The mosquitoes present in Belgrade include 20 species of
mosquitoes family of Culicidae. In centre of city the molestants are
distributed. Before eradication, the main vectors of malaria in Belgrade’s
area were Anopheles maculipennis s. s., and secondary vectors were
An. messeae and An. atroparvus. Mainly in the areas of the river Danube
and Sava basin, they have recolonised their previous habitats. But, the
relation between the species of An. maculipennis complex has changed.
An. maculipennis s. s. is very rare now, while there is a constant increase
of An. atroparvus.
From 1994 to 2005, a total of 166 imported cases of malaria were
treated in Belgrade. Most patients were treated in the Institute for
Infectious and Tropical Diseases (96%), and others in Military Medical
Academy. The vast majority of malaria infections in our patients were
due to P. falciparum alone or in mixed infections (67%). Of all imported
cases during the period theoretically favourable to transmission (n = 63),
only one third of them (n = 18) were gametocyte carriers. Of these 18
gametocyte carriers, 67% were of P. falciparum, and 33% of P. vivax.
Most of them were imported from Africa, only 1 from Asia. The length
of potential exposure of gametocyte carriers to mosquitoes is very low.
All patients are treated in 2 hospitals in the centre of city, and that limits
mosquito-human contact.
Conclusion: From 2000, when travel restrictions stopped, there has not
been a signiﬁcant increase in the total number of imported malaria
cases. Belgrade’s vulnerability is low because of the low presence
of gametocyte carriers during June-September. The three species of
the Anopheles maculipennis complex, particularly An. messeae and
An. atroparvus, are considered as potential vectors of malaria in
Belgrade. Their roles as vectors requires additional investigation.
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P778 A novel not b-lactam inhibitor of DD-peptidase 64–575
J. Solecka, A. Rajnisz, A. Laudy, W. Kurzatkowski (Warsaw, PL)
Objectives: The increasing bacterial resistance to antibiotics is at
present a great therapeutic problem. Multi-resistant pathogenic bacteria
occur more and more frequently. The solution of this problem involves
screening for microorganisms producing novel antimicrobial drugs.
Streptomycetes are very well known producers of antibiotic. The purpose
of this work was search for novel antimicrobial agents (inhibitors of DD-
peptidases).
Methods: 1) Screening for Streptomyces producing exocellular inhibitors
of DD-carboxypeptidase/transpeptidase 64–575 (DD-peptidase 64–575).
After cultivation in liquid medium, supernatants of 110 Streptomyces
strains (strain collections: IAUR, ISP, IMAN) were tested for DD-
peptidase 64–575 inhibition (mode of action of b-lactams antibiotics)
(Solecka J et al., Acta Pol Pharm, 2003; 60: 115−8). 2) Assay the
supernatant stability of DD-peptidase 64–575 inhibitors after class A
b-lactamase incubation. 3) Puriﬁcation of inhibitors: acetone protein
precipitation from the culture supernatant, use of Strongly Basic
Anion Exchanging Resin column (acetic acid pH modiﬁcation) and RP
HPLC with C18 modiﬁed columns (Atlantis, Waters)(eluent: TFA and
acetonitrile; gradient methods). 4) Structural elucidation was conducted
using the following methods: HPLC-MS, MS/MS, LR-MS, IR, 1H, 13C
and 2D NMR. 5) Antimicrobial activity assay: dilution method was used.
Results: After 48 h of cultivation the supernatant of the Streptomyces sp.
1 strain showed 90% of the DD-peptidase 64–575 inhibition. This strain
was selected to further experimentation. The most inhibiting compound –
AR1 (not degraded by penicillinase) was puriﬁed to one peak. Molecular
weight of AR1 is 207.2Da. It is an aromatic not b-lactam compound.
The AR1 DD-peptidase 64–575 inhibition is expressed by the value
of ID50(M) = 0.12×10−2. AR1 showed antibacterial activity against
Proteus vulgaris NCTC 4635 and Staphylococcus aureus NCTC 4163.
Conclusions: A novel non b-lactam inhibitor of DD-peptidase 64–575
with antimicrobial activity was isolated. Further experiments should be
done to synthesize the AR1 compound and to continue the chemical
characterisation.
Grant no. 3P0 5F 033 24, Ministry of Education and Science, Warsaw,
Poland.
P779 Pharmacokinetics of ceftobiprole following single and multiple
intravenous infusions administered to healthy subjects
B. Murthy, D. Skee, D. Wexler, D. Balis, I. Chang, D. Desai-Kreiger,
G. Noel (Raritan, US)
Objectives: Ceftobiprole, an investigational broad-spectrum cephalo-
sporin with activity against methicillin-resistant staphylococci, is
currently in late stage clinical development. The purpose of this study
was to evaluate the single- and multiple-dose pharmacokinetics (PK) of
ceftobiprole 500mg q8h given as a 2-h infusion.
Methods: This was a single-centre, open-label study in 28 healthy adult
males and females. Subjects received a single infusion on Day 1 and
multiple infusions on Days 3 through 5. Serial blood and urine samples
were collected through 24 h after the start of infusion on Days 1 and
5 for estimation of ceftobiprole medocaril (prodrug), ceftobiprole, and
open-ring metabolite (M1) via an LC-MS/MS method. PK parameters
were estimated using model-independent methods.
Results: PK parameter estimates for ceftobiprole and M1 are shown in
the table. Plasma concentrations of the prodrug were measurable only
during the infusion, indicating instantaneous conversion to ceftobiprole.
Systemic exposure of ceftobiprole was comparable between Days 1 and
5 with minimal accumulation. Clearance (CL) remained unchanged from
Day 1 to Day 5. Ceftobiprole was primarily excreted unchanged in the
urine (83%). Systemic exposure of M1 increased from Day 1 to 5 with
an accumulation index of 1.5. Elimination half-life of M1 was 5−6 h.
Less than 7% of ceftobiprole is excreted in the urine as the open-ring
metabolite. Systemic exposure of ceftobiprole and M1 was higher in
females compared to males, which normalised upon correction for body
weight. On Day 5, approximately 100% of the dose was excreted in the
urine as the prodrug, ceftobiprole, and M1. No subject had a serious
adverse event. No subjects were withdrawn from the study due to an
adverse event.
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Parameter Ceftobiprole M1
Day 1 Day 5 Day 1 Day 5
Cmax (mg/L) 29.2 (5.52) 33.0 (4.83) 0.804 (0.214) 1.07 (0.254)
AUC0−8h (mg·h/L) 90.0 (12.4) 102 (11.9) 3.68 (0.882) 5.45 (1.35)
t1/2 (h) 3.1 (0.3) 3.3 (0.3) 4.7 (0.8) 5.8 (0.9)
CL (L/h) 4.89 (0.687) 4.98 (0.582) – –
Conclusion: The pharmacokinetics of the ceftobiprole 500mg q8h
regimen given as a 2-h infusion are similar to results previously reported
with no accumulation observed. The majority of the administered dose
was recovered in the urine. This regimen was safe and well tolerated.
P780 Activity of ceftobiprole tested against contemporary
European Enterobacteriaceae and Pseudomonas aeruginosa
(2005–2006)
T. Fritsche, H. Sader, P. Strabala, R. Jones (North Liberty, US)
Objectives: To present results assessing in vitro potency of ceftobiprole
(BPR) against the most commonly occurring Enterobacteriaceae (ENT)
and non-fermentative Gram-negative bacilli isolates in Europe. BPR,
an investigational parenteral cephalosporin, is currently in clinical trials
for complicated skin and skin structure infections and nosocomial
pneumonia. This agent is unique amongst its class, being active against
methicillin-resistant S. aureus (MRSA) as well as other Gram-positive
and -negative pathogens, making it an attractive candidate for broad-
spectrum therapy.
Methods: Non-duplicate clinically-signiﬁcant isolates of ENT (3,399),
P. aeruginosa (PSA; 666) and Acinetobacter spp. (ASP; 230) were
collected from 25 medical centres in Europe participating in a
BPR surveillance programme during 2005–2006. Identiﬁcations were
conﬁrmed by the central monitoring laboratory and all isolates
were susceptibility (S) tested using CLSI methods against BPR and
comparators including ceftazidime (CAZ) and cefepime (FEP).
Results: BPR, CAZ and FEP results are listed in the Table. BPR
was similar in potency to the third- and fourth-generation cephems
(MIC50 values, 1mg/L) for all tested ENT. Coverage against EC
was nearly identical for the three agents (Table; 94−95% inhibited
at 4mg/L). Whereas FEP provided enhanced coverage against KSP
(88% at 8mg/L vs. 76−81% for BPR and CAZ), BPR and FEP
were superior to CAZ against ESP and CIT. All were equally active
against PM, SER and Salmonella spp. Against PSA, BPR was equal
in potency to CAZ (MIC50, 2mg/L) and two-fold more potent than
FEP, although % inhibited for these agents at 2/4/8mg/L was similar
(49−54/65−70/76−80%, respectively). None of these agents inhibited
>45% of ASP at 8mg/L.
Species (no. tested) MIC90 (% at 2/4/8mg/L)
BPR CAZ FEP
E. coli (EC; 1889) 0.06 (94/94/94) 1 (94/95/96) 0.25 (95/95/96)
Klebsiella spp.
(KSP; 624)
>8 (75/75/76) >16 (78/79/81) 16 (82/85/88)
Enterobacter spp.
(ESP; 381)
>8 (81/84/88) >16 (66/68/69) 4 (89/94/96)
Citrobacter spp.
(CIT; 79)
1 (99/99/99) >16 (72/73/76) 1 (99/99/99)
P. mirabilis
(PM; 143)
0.06 (96/96/96) 1 (96/97/98) 0.12 (97/97/97)
Serratia spp.
(SER; 142)
0.5 (96/96/96) <1 (96/96/97) 0.5 (98/98/98)
PSA (666) >8 (54/65/79) >16 (57/70/76) 16 (49/65/80)
ASP (230) >8 (37/39/40) >16 (12/31/37) >16 (22/33/45)
Conclusions: BPR is a new anti-MRSA b-lactam with recognized
activity against the most commonly occurring ENT and PSA, similar
to that of extended-spectrum cephems. These characteristics warrant
continued evaluation of BPR as empiric therapy for severe pneumonia,
especially in those European institutions/regions where MRSA and PSA
may be prevalent.
P781 Activity of ceftobiprole tested against staphylococcal and
streptococcal isolates recovered from patients in European
medical centres (2005–2006)
T. Fritsche, H. Sader, P. Strabala, R. Jones (North Liberty, US)
Objectives: To present in vitro potency of ceftobiprole (BPR) against
staphylococci and streptococci originating from European (EUR) patients
in 2005 and 2006. BPR, an investigational parenteral cephalosporin
with a broad spectrum against Gram-negative and -positive pathogens,
including MRSA, is currently in clinical trials targeting complicated skin
and skin structure infections (cSSSI) and nosocomial pneumonia (NP).
Methods: Non-duplicate clinically-signiﬁcant isolates (4,957 isolates)
of S. aureus (SA; oxacillin-susceptible [OXA-S] and – resistant
[R]), coagulase-negative staphylococci (CoNS; OX-S And OX-R),
S. pneumoniae (SPN; penicillin (PEN)-S and PEN-R), viridans group
streptococci (VGS), beta-haemolytic streptococci (BHS) were submitted
from 25 medical centres in EUR participating in BPR surveillance
(2005–2006). Central laboratory processing included identiﬁcation
conﬁrmation and susceptibility (S) testing to BPR and other comparative
b-lactams using CLSI reference methods and interpretive criteria.
Results: BPR inhibited 100 and >99% of tested S. aureus and CoNS
at 4mg/L, respectively, and all SPN and BHS at 0.5mg/L. While
MIC90 values for OXA-R strains were four-and eight-fold higher for
SA and CoNS, respectively, published PK/PD characteristics suggest
that target attainment for both OXA-S and -R populations would be
achievable. BPR potency against OXA-S and OXA-R SA from North
America and Latin America were nearly identical to those presented
here for EUR (MIC50/90, 0.25/0.5 and 1−2/2mg/L, respectively). All
streptococci were readily inhibited by BPR (MIC90 values 0.5mg/L);
only VGS included strains with elevated MIC values (6% at >0.5mg/L).
BPR potency against SPN was equivalent to that of imipenem (MIC90,
0.25mg/L). While BPR is generally inactive against E. faecium, the
majority of E. faecalis strains (93% of 720 isolates) were inhibited at
4mg/L (data not shown).
Organism (no. tested) BPR MIC (mg/L) Cum. % inhibited at MIC (mg/L)
50% 90% 0.12 0.25 0.5 1 2 4
S. aureus (SA)
OXA-S (1,197) 0.25 0.5 3 74 >99 >99 100
OXA-R (781) 1 2 <1 <1 16 65 96 100
CoNS
OXA-S (324) 0.12 0.25 68 97 100
OXA-R (826) 1 2 1 7 42 81 93 >99
S. pneumoniae (SPN)
PEN-S (141) 0.06 0.06 100
PEN-R (169) 0.25 0.5 1 55 100
VGS (289) 0.06 0.25 89 92 94 95 96 97
BSH (510) 0.06 0.06 >99 100
Conclusions: BPR displayed a, antibacterial spectrum of activity against
EUR pathogens responsible for cSSSI and NP, including OXA-R SA and
OXA-R CoNS. BPR was also among the most active b-lactams tested
against SPN, equivalent in potency to the carbapenems.
P782 Dalbavancin activity tested against rarely isolated
Gram-positive organism species from Europe
R. Jones, H. Sader, T. Fritsche, M. Stilwell (North Liberty, US)
Objectives: To determine the in vitro dalbavancin activity against
European isolates of Gram-positive species that may rarely be
pathogens in signiﬁcant infections. A large surveillance platform was
utilised (SENTRY Antimicrobial Surveillance Program) to evaluate over
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1,300 strains (10 isolates/species) tested by reference (CLSI) methods
against dalbavancin and selected comparators.
Methods: A total of 1,314 strains were available for dalbavancin testing,
all isolated since 2003. Only those species (26) with at least 10 isolates
were considered representative. A total of 30 locations contributed strains
from 13 countries, all tested by broth microdilution method (CLSI) with
appropriate solvents and polysorbate-80 (0.002%). Quality control results
with S. aureus ATCC 29213, E. faecalis ATCC 29212 and S. pneumoniae
ATCC 49619 were within published ranges.
Results: The distribution of tested strains was: Bacillus spp. (19),
Corynebacterium spp. (31), enterococci other than E. faecalis/faecium
(82; 4 species), Listeria spp. (24), CoNS (699, 8 species), Micrococcus
spp. (21) and streptococci not pneumococci or beta-haemolytic (439;
10 species). The overall dalbavancin MIC50 was 0.03mg/L and
the MIC90 results ranged from 0.03 (streptococci, micrococci) to
0.25mg/L (S. haemolyticus and S. warnerii). These results were
comparable to the MIC90 results for the most studied dalbavancin-
indicated species (beta-haemolytic streptococci and S. aureus; MICs,
0.03–0.06mg/L). Examples of speciﬁc species (50 strains) and their
MIC90 (in mg/L) are: Staphylococcus capitis (0.06), S. hominis (0.06),
Streptococcus anginosus (0.03), S. bovis (0.06), S. mitis (0.03),
S. oralis (0.06) and S. parasanguis (0.03). All four enterococcal species
(avium, casseliﬂavus, durans, and gallinarum) had the same MIC90 at
0.12mg/L.
Activity of dalbavancin against 1,314 uncommonly isolated Gram-
positive species (Europe 2002–2006)
Organism (no. tested) MIC (mg/L)
50% 90% Range
B. cereus (19) 0.03 0.12 0.03–0.12
Corynebacterium spp. (31) 0.06 0.12 0.03–0.25
Enterococci (82; 4 spp.) 0.06 0.12 0.03–0.25
L. monocytogenes (24) 0.06 0.06 0.03–0.06
M. luteus (21) 0.03 0.03 0.03–0.06
CoNS (699; 8 spp.) 0.03 0.12 0.03−0.5
Streptococci (439; 10 spp.) 0.03 0.03 0.03–0.06
Conclusions: Dalbavancin exhibited a wide and potent spectrum of
activity (MIC90 range, 0.03–0.25mg/L) against European strains of 26
rarely isolated Gram-positive organisms other than the usual indicated
species (e.g. S. aureus or S. pyogenes). Generally, the most dalbavancin-
susceptible organisms were streptococci species (viridians group) and
M. luteus; while S. haemolyticus showed the most elevated MIC values
(0.5mg/L). Dalbavancin demonstrated a wide potential application as
therapy for Gram-positive infections encountered in European medical
centres.
P783 QT/QTc assessment of ceftobiprole in a single-dose study
D. Balis, R. Strauss, B. Murthy, H. Tiian, G. Noel (Raritan, US)
Objectives: Delayed cardiac repolarisation is a potential side effect of
some non-antiarrhythmic drugs. Because delayed cardiac repolarisation
has been associated with the increased risk of serious and potentially
life-threatening arrhythmia, rigorous characterisation of a drug’s effect
on the QT/QTc interval is warranted. The current study was conducted
to evaluate the effects of ceftobiprole on QT/QTc interval.
Methods: This was a randomised, double-blind, placebo- and positive-
controlled, double-dummy, 4-way crossover, single-centre study of
ceftobiprole medocaril at therapeutic (500mg) and supratherapeutic
(1000mg) doses intravenously infused over 2 h in healthy adult
volunteers. Sixty subjects received either a single dose of ceftobiprole
medocaril (500mg or 1000mg) or matching placebo intravenous (i.v.)
infusion on Day 1. In addition, the subjects received either a single dose
of moxiﬂoxacin 400mg as a positive control or a matching placebo as
oral administration prior to i.v. infusion on Day 1. Serial 12-lead ECGs
were measured on Day –1 (baseline) and Day 1 (post-dose). Fridericia
correction was used as the primary correction method for statistical
evaluation of serial ECG data.
Results: The upper limits of the 90% conﬁdence intervals for difference
in mean change in QTcF (QTc interval using Fridericia correction
formula) between ceftobiprole 1000mg and placebo (change in QTcF)
were below 10ms at all time points. The same result was demonstrated
for change in QTcF between ceftobiprole 500mg and placebo. Therefore,
this analysis establishes the noninferiority of ceftobiprole to placebo
with respect to QT/QTc interval duration. The lower limit of 90%
conﬁdence intervals for the difference in mean change in QTcF between
moxiﬂoxacin and placebo was above zero for all time points between
1.25 and 24 h, with a mean difference of 5.5ms to 13.1ms. Results
from this analysis establish assay sensitivity.
Conclusion: In this QT/QTc study conducted in healthy adult subjects,
the effect of single i.v. administrations of ceftobiprole at therapeutic
(500mg) and supratherapeutic (1000mg) doses on QT/QTc prolongation
was comparable to placebo.
P784 In vitro activity of ceftobiprole, dalbavancin and tigecycline
against methicillin-resistant Staphylococcus aureus strains
from hospitalised patients in Belgium
O. Denis, C. Nonhoff, A. Deplano, M. Hallin, R. De Ryck, S. Rottiers,
S. Crevecoeur, M.J. Struelens (Brussels, BE)
Background: The in-vitro activity of 20 antimicrobial agents including
ceftobiprole, dalbavancin, tigecycline was tested against methicillin-
resistant Staphylococcus aureus (MRSA) strains collected during a
national survey conducted in 2005 in Belgian hospitals.
Methods: 335 MRSA strains from 116 hospitals were identiﬁed by
PCR for 16S rRNA, nuc and mecA genes. Strains were genotyped
by spa typing, SCCmec type. MICs of 20 antimicrobials were
determined by agar dilution method according to CLSI. Resistance genes
for aminoglycosides and macrolides-lincosamides-streptogramins were
tested by PCR.
Results: By molecular typing, 80% of MRSA strains belonged to
5 epidemic genotypes: spa CC38-SCCmec IV (45%), spa CC8-
SCCmec IV (21%), spa CC2-SCCmec II (9%), spa CC2-SCCmec
IV (4%), spa CC790-SCCmec IV (4%). The proportion of MRSA
strains resistant to aminoglycosides ranged from 2% for gentamicin
to 41% for tobramycin; 54% were resistant to erythromycin and
39% to clindamycin. 90% of isolates were susceptible to minocycline
and 85% to tetracycline. More than 95% of strains were susceptible
to fusidic acid, rifampin and cotrimoxazole. 93% of isolates were
resistant to ciproﬂoxacin and moxiﬂoxacin. 2.7% of strains were high
level resistant (MIC> 524mg/l) to mupirocin. No strains resistant to
glycopeptides, dalbavancin, linezolid, tigecycline or ceftobiprole were
detected. Resistance to aminoglycosides was mainly encoded by ant4
gene and to MLS by ermA and ermC genes. The table shows MIC
distributions for the new agents.
Antimicrobial agent MIC (mg/L)
MIC50 MIC90 Range
Dalbavancin 0.12 0.12 0.06−1
Tigecycline 0.25 0.25 0.06−0.5
Ceftobiprole 1 2 0.5−4
Vancomycin 0.5 1 0.25−1
Conclusion: Ceftobiprole, dalbavancin and tigecycline showed excellent
antibacterial activity against recent isolates of sporadic and epidemic
multi-drug resistant MRSA clones from hospitalised patients in Belgium.
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P785 In vitro activitiy of dalbavancin against clinical
vancomycin-resistant enterococci isolates
B. Saager, M. Horstkotte, H. Rohde, I. Sobottka, P. Heisig (Hamburg,
DE)
Objectives: Dalbavancin is a lipoglycopeptide holding bactericidal
antimicrobial activity against Gram-positive bacteria bringing forth
noscomial infections, e.g. methicillin-resistant Staphylococcus aureus
(MRSA). It is currently being ﬁled for FDA approval for complicated
skin and skin structure infections. The mechanism of action of
lipoglycopeptides is similiar to other glycopeptides (e.g. teicoplanin or
vancomycin) by inhibiton of cell-wall synthesis through binding to the
terminal D-alanyl-D-alanine of nascent peptidoglycan chains. A col-
lection of genotypically characterised vancomycin-resistant enterococci
(VRE) was tested towards their susceptibility with a view to compare
the activity of dalbavancin with recently approved and other clinical well
proven antibiotics.
Methods: A number of 61 strains previously described as VRE isolated
at the University Medical Center Hamburg – Eppendorf (Germany)
between 1995 and 2006 was chosen for susceptibility testing. MICs of
dalbavancin, daptomycin, linezolid, teicoplanin, vancomycin, ampicillin,
and gentamicin were determined by broth microdilution according to
CLSI guidelines. Characterisation of clinically relevant glycopeptide
genotypes (vanA, vanB, vanC1, vanC2/3) and species identiﬁcation for
enterococci were done by polymerase chain reaction.
Results: A number of 57 isolates were resistant to vancomycin, while
4 four isolates showed susceptibility or intermediate susceptibility to
vancomycin. MICs ranged from 4 to >256 for vancomycin and from 16
to 256 for teicoplanin. Corresponding MIC90 values were >256 and 256
for vancoymcin and teicoplanin, respectively. Determination of MICs for
dalbavancin showed values ranging from 0.03 to >32 with a MIC90
of 16. The MIC90 values for daptomycin and linezolid were 4 and 2
respectively, MICs were ranging from 0.016 to 4 for daptomycin and
from 1 to 16 for linezolid.
Conclusion: In comparison to the well established antibiotics van-
comycin and teicoplanin, dalbavancin shows improved in vitro activity
against the tested isolates. With regard to the newer antimicrobial agents
introducing new mechanism of actions, daptomycin and linezolid, the
in vitro activity of dalbavancin was comparable. Thus, dalbavancin is
a potential drug for the treatment of VRE, with its awaiting approval
hopefully supplementing the arsenal of antimicrobial drugs for the
treatment of nosocomial infections.
P786 Susceptibility of Staphylococcus aureus, Enterococcus faecium
and Enterococcus faecalis to daptomycin at a university
medical centre Hamburg-Eppendorf, Germany
B. Saager, M. Horstkotte, H. Rohde, I. Sobottka, P. Heisig (Hamburg,
DE)
Objectives: Daptomycin (Cubicin®) is the ﬁrst lipopeptide bactericidal
antimicrobial agent and introduces a new mechanism of action against
Gram-positive bacteria. By binding to and integrating into bacterial
membranes it causes a rapid depolarisation of membrane potential
resulting in the inhibition of metabolism and ultimately in cell death.
Being approved for the treatment of complicated skin and skin structure
infections due to S. aureus, including methicillin resistant S. aureus
(MRSA) and E. faecalis, daptomycin presents a promising therapeutical
option for treatment of noscomial Gram-positive pathogens.
To investigate the susceptibility of daptomycin facing isolates with
multiple resistance phenotype in vitro, clinical isolates of S. aureus,
E. faecium and E. faecalis were chosen for susceptibility testing against
daptomycin and established clinically important antibiotics.
Methods: 285 strains being isolated at the University Medical Center
Hamburg – Eppendorf (Germany) between 2004 and 2006 were chosen
for susceptibilty testing. This collective comprised 221 isolates of
S. aureus including 15.4% MRSA, 41 isolates of E. faecalis and
23 isolates of E. faecium with two isolate of E. faecium being
resistant to vancomycin. MICs of daptomycin, penicillin, oxacillin,
erythromycin, ciproﬂoxacin, gatiﬂoxacin, moxiﬂoxacin, sparﬂoxacin
gentamicin, linezolid, teicoplanin, and vancomycin were determined for
S. aureus and those of daptomycin, ampicillin, linezolid, teicoplanin,
vancomycin and gentamicin for E. faecalis and E. faecium by broth
microdilution according to CLSI guidelines.
Results: All strains tested of S. aureus were susceptible to daptomycin
(MICs 1mg/mL) as well as all strains of E. faecium and E. faecalis
(MICs 4mg/mL). MICs were ranging between 0.03−1 for S. aureus
and 0.25−4 and 0.5−4 for E. faecalis and E. faecium, respectively.
MIC90 values were 0.5 (S. aureus), 2 (E. faecalis) and 4 (E. faecium).
A total number of 25 S. aureus (11.3%) isolates with multiple resistant
phenoytpe were found showing resistance to ciproﬂoxacin, erythromycin
and oxacillin.
Conclusion: Our data show that daptomycin offers good in vitro activity
against S. aureus, E. faecalis and E. faecium, including isolates with
multiple-resistant phenotype.
P787 Comparative in vitro activity of dalbavancin against clinical
isolates of vanA, vanB, and vanC enterococci
E. Cercenado, O. Cuevas, M. Marin, M.J. Goyanes, E. Bouza (Madrid,
ES)
Objectives: Dalbavancin (DAL) is a new lipoglycopeptide with activity
against Gram-positive microorganisms. Its half-life of 8.5 days enables
once-weekly dosing. In this study we compared the activity of DAL with
other agents against clinical isolates of vancomycin-resistant enterococci
(VRE).
Methods: We tested a total of 238 well characterised non-duplicate
clinical isolates of VRE recovered from patients at our institution. Origin
of isolates were: wounds (69 isolates), urine (45), blood (38), peritoneal
ﬂuid (24), abscesses (17), other sterile ﬂuids (12), intravascular catheter
(12), and others (21). Multiplex PCR was used to detect vanA, vanB,
vanC-1, and vanC-2 genes. The isolates were 83 E. faecalis (64 vanA,
19 vanB), 80 E. faecium (37 vanA, 43 vanB), 50 E. gallinarum (vanC1),
and 25 E. casseliﬂavus (vanC2). Susceptibility testing was performed by
the broth microdilution method in cation-adjusted Mueller-Hinton broth
following CLSI guidelines. The antimicrobial agents evaluated were:
dalbavancin (DAL), vancomycin (VAN), teicoplanin (TEI), and linezolid
(LZD). E. faecalis ATCC 29212 and S. aureus ATCC 29213 were used
as control strains.
Results: The MIC50, MIC90, and MIC range values (mg/L) are
summarised in the table.
Organisms and type (No.) Antimicrobials MIC (mg/L)
MIC50 MIC90 Range
VanA VRE (101) Dalbavancin 8 64 0.12−64
Vancomycin 512 1,024 256–1,024
Teicoplanin 64 128 32–128
Linezolid 1 2 1−2
VanB VRE (62) Dalbavancin 0.12 1 0.12−2
Vancomycin 32 512 16–1,024
Teicoplanin 0.5 0.5 0.12−1
Linezolid 1 2 1−2
VanC VRE (75) Dalbavancin 0.12 0.12 0.12−0.5
Vancomycin 8 16 4−16
Teicoplanin 0.25 0.5 0.12−0.5
Linezolid 1 2 1−2
Conclusions: Dalbavancin was more active than comparator glycopep-
tides and presented good activity against vanB, and vanC enterococci,
however, it was inactive against vanA enterococci.
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P788 Efﬁcacy and safety of Uro-vaxom treatment for patients
with recurrent cystitis: open multicentre study
U-S. Ha, S-G.C. Chang, H.K. Park, S.J. Yoon, Y-H. Cho (Suwon,
Seoul, Incheon, KR)
Objectives: To investigate the efﬁcacy and safety of the immunothera-
peutic Uro-vaxom in uncomplicated recurrent cystitis in female patients
only.
Methods: Adult female patients could enroll in this multicentre, open-
label study if they had acute cystitis at the enrollment visit and positive
results of urine culture (103 CFU/mL). Patients were treated for
3 months with one capsule daily of Uro-vaxom after antibiotic therapy
and observed for further 3 months. Primary efﬁcacy criteria were cystitis
recurrence rates over 6 months, distribution of cystitis and proportion of
patients of cystitis.
Results: A total of 50 patients were evaluated. During the 6-month trial
the number of recurrences from cystitis was signiﬁcantly reduced in
comparison with the 6-month pretrial period (on the average 0.64 as
compared to 3.0 recurrences, p< 0.001). The case for the incidence of
frequency, urgency and dysuria was remained low until the end of the
trial. Uro-vaxom was well tolerated: side-effects were mentioned in 8%
of the 50 patients, in the absence of case leading to treatment withdrawal.
Conclusions: Uro-vaxom signiﬁcantly reduced the incidence of cystitis
during the 6 months of the study including 3 months of treatment.
These results demonstrate that Uro-vaxom is a valuable product for the
prophylaxis of recurrent cystitis.
P789 A comparison of the CLSI (formerly NCCLS), EUCAST and
various EU country standard methods for the susceptibility
testing of retapamulin, a novel pleuromutilin
L. Williams, A. Colclough, D. Felmingham (London, UK)
Objective and Methods: Retapamulin[RE] is the ﬁrst semi-synthetic
pleuromutilin formulated as a topical antibacterial for treating skin
infections. In this study, minimum inhibitory concentrations (MIC)
and inhibition zone diameters of RE were determined for selected
populations of Staphylococcus aureus [SA] (1000 isolates) and
Streptococcus pyogenes [SP] (503) using CLSI standard methods and
compared with various methods used in EU countries including those
deﬁned by EUCAST, DIN, SRGA, BSAC and the CA-SFM.
Results: For isolates of SA, there was very good correlation between
MICs of RE determined by broth microdilution using CLSI, with those
by EUCAST, DIN and SRGA methods (median MIC 0.06mg/L for
all methods; >90% of results within ±1 doubling dilution of each
other). Similar results were observed when MICs of RE determined
by agar dilution using CLSI, were compared to those determined by
EUCAST, DIN, SRGA, BSAC and CA-SFM methods. Close agreement
was observed between inhibition zone diameters (median diameters
within 1mm) using CLSI compared to DIN, SRGA, BSAC and CA-
SFM methods. For isolates of SP, MICs of RE determined using the
broth microdilution methods of the CLSI, EUCAST, DIN and SRGA
were all in close agreement (median MIC 0.015–0.03mg/L; >95% of
results within ±2 doubling dilutions). For agar dilution, there was also
good correlation between MICs determined using CLSI compared to
EUCAST, SRGA, BSAC and CA-SFM (median MIC 0.06mg/L for
all methods; >95% of results within ±1 doubling dilution). However,
there was poor agreement between MICs obtained by the CLSI and
DIN agar dilution methods. It is possible that the difference in the
recommended amount of lysed horse blood (2% for DIN and 5% for
CLSI) had an impact, because the median MIC by the DIN method
(0.015mg/L) was four-fold lower than by CLSI and only 44.73% of
results within ±2 doubling dilutions of each other. Consistent with
these results, inhibition zone diameters obtained using CLSI, SRGA,
BSAC and CA-SFM correlated well (median values 20−22mm) but
those produced using the DIN method were appreciably larger (median
29mm).
Conclusion: Minor differences were seen for both SA and SP, in
MICs and inhibition zone diameters determined by the various methods
examined in this study and such differences are unlikely to affect
qualitative interpretation of MICs. The differences noted between CLSI
and DIN methods warrant further investigation.
P790 In vitro activity of retapamulin, a novel pleuromutilin,
against Staphylococcus spp. (n = 1413) and Streptococcus
pyogenes (n = 503) from 26 European centres
L. Williams, J. Northwood, N. Crowhurst, D. Felmingham (London, UK)
Background and Objectives: Retapamulin (RE) is the ﬁrst agent of
the novel pleuromutilin class, formulated as a semi-synthetic topical
antibacterial for treating skin infections. It has a unique mode of action,
a low potential for the development of resistance and no target speciﬁc
cross-resistance to other antibacterial classes. The in vitro activity of RE
against Staphylococcus spp. (n = 1413) and Streptococcus pyogenes (SP)
(n = 503) collected from 26 centres in 14 European countries (January
2003 – March 2005) was compared with that of erythromycin (ERY),
fusidic acid (FUS), gentamicin (GEN) and mupirocin (MUP).
Methods: All testing was conducted using CLSI methods.
Results: MIC90 of RE, ERY, FUS, GEN and MUP for isolates
of S. aureus (SA), S. epidermidis (SE), other coagulase-negative
staphylococci (CNS) and SP are shown in the table. 99.9% of the isolates
of Staphylococcus spp. were inhibited by 2mg/L RE this activity being
unaffected by resistance to methicillin, ERY, FUS or MUP (MIC90 range
0.06−0.5mg/L). All isolates of SP were inhibited by 0.06mg/L (MIC90
0.03mg/L).
MIC90 (mg/L)
Species Phenotype (n) RE ERY FUS GEN MUP
SA All isolates (1048) 0.12 128 4 64 0.5
MRSA (318) 0.12 128 64 64 16
ERYR (369) 0.12 128 8 64 16
FUSR (144) 0.12 128 64 64 0.25
MUPR (76) 0.12 128 0.25 65 0.25
SE All isolates (256) 0.06 128 16 64 128
MRSE (178) 0.12 128 16 64 128
ERYR (159) 0.06 128 16 64 128
FUSR (89) 0.12 128 32 64 128
MUPR (73) 0.06 128 16 64 128
Other CNS All isolates (109) 0.25 128 8 4 128
MRCNS (75) 0.25 128 8 4 128
ERYR (49) 0.12 128 8 16 128
FUSR (56) 0.5 128 16 2 4
MUPR (12) 0.25 128 16 4 128
SP All isolates (503) 0.03 16 8 8 0.12
ERYR (94) 0.03 128 8 8 0.25
Conclusions: RE was the most potent agent tested in vitro and has
excellent activity against Staphylococcus spp. (including those isolates
resistant to either MET, ERY, FUS or MUP) and Streptococcus pyogenes
(including ERY-resistant strains). It has potential for the topical therapy
of uncomplicated skin infections involving these organisms.
P791 Novel small-molecule inhibitors of gyrase B: antibacterial
activity in vitro and in murine models of infection
D. Haydon, P. Lancett, J. Bennett, L. Czaplewski (Oxford, UK)
Objectives: The bacterial type II topoisomerases, DNA gyrase and
topoisomerase IV, are well-validated targets for antibacterial therapy.
A series of novel compounds have been synthesized that inhibit the
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ATPase activity of these enzymes. The objective of this work was
to explore the structure activity relationships (SAR) of the series and
to progress the compounds through preclinical development towards
candidate nomination.
Methods: The biochemical activity of compounds was determined using
an in vitro ATPase assay. Minimal inhibitory concentrations (MIC)
were determined using the CLSI broth microdilution method. Resistance
frequency, time-kill and post-antibiotic effect were investigated using
standard microbiological methods. The ADMET proﬁle of various
compounds was evaluated using in vitro methodology. Compounds from
the series were evaluated in acute systemic infection models in mice.
Results: A medicinal chemistry programme to explore the SAR of the
compound series resulted in the synthesis of potent derivatives that have
on-target activity against a range of species. Compounds within the series
have nanomolar IC50s against gyrase and topo IV ATPase and single-
digit, or better, microgram/mL MICs against S. aureus, E. faecalis,
S. pneumoniae, M. catarrhalis and H. inﬂuenzae. The spontaneous
resistance frequency observed for the series is low, consistent with dual
targeting of DNA gyrase and topo IV. The compounds have a cidal mode
of action with a time, but not concentration, dependant kill and no post-
antibiotic effect. The protein binding, cytotoxicity, chemical, plasma and
microsomal stability, Caco-2 permeability, cytochrome P450 and hERG
ion channel activities of the series have been explored.
Selected derivatives have been characterised in vivo. The compounds
were well tolerated and there was good bioavailability following IP
or oral administration. Selected compounds demonstrated efﬁcacy in
murine septicaemia models of staphylococcal infection.
Conclusion: The properties of the inhibitors are consistent with a
compound series capable of optimisation into an antibiotic targeting both
respiratory tract and drug-resistant Gram-positive infections.
P792 Comparative activity of tigecycline, cefepime and imipenem
against clinical isolates of Klebsiella pneumoniae producing
extended spectrum b-lactamases, plasmid-mediated
AmpC-type b-lactamases or both, associated or not with
porin deﬁciency
M. Conejo, J. Herna´ndez, A. Pasual (Seville, ES)
Objective: To study the in-vitro activity of tigecycline against
clinical isolates of Klebsiella pneumoniae producing extended spec-
trum b-lactamases (ESBL), plasmid-mediated AmpC-type b-lactamases
(pACBL) or both, associated or not with porin (POR) deﬁciency.
Methods: Fifty K. pneumoniae clinical strains were studied, including 2
ESBL−/pACBL−/POR−, 10 ESBL+/POR+, 12 ESBL+/pACBL−/POR−,
18 ESBL−/pACBL+/POR+, 1 ESBL−/pACBL+/POR−, 4 ESBL+/
pACBL+/POR+, and 3 ESBL+/pACBL+/POR−. Antimicrobial suscep-
tibilities to tigecycline, cefepime and imipenem were determined by
broth microdilution (CLSI guidelines) with standard and 10-fold higher
inocula. The inoculum effect was deﬁned as an eight-fold or greater MIC
increase on testing with the highest inoculum.
Results: The MIC50 of tigecycline, cefepime and imipenem were 0.25,
2 and 0.5mg/L respectively, the MIC90 were 1, 128 and 1mg/L,
respectively and the percentages of susceptible isolates were 98, 80
and 94%, respectively. Tigecycline was the most active drug, with
no resistance detected and only one isolate with a MIC of 4mg/L
(1 isolate ESBL−/pACBL−/POR−). No inoculum effect was observed
with this antimicrobial agent. Imipenem showed excellent activity, except
for the group ESBL+/pACBL+/POR−, and inoculum effect was only
observed in pACBL+ strains. Cefepime was the least active drug,
and inoculum effect was very frequently observed among ESBL+ and
pACBL+ isolates.
Conclusions: Tigecycline showed excellent activity against clinical
isolates of Klebsiella pneumoniae producing ESBL, pACBL or both,
associated or not with POR deﬁciency. Its activity was comparable to that
of imipenem against isolates producing ESBL, and higher than imipenem
against pACBL producers.
P793 Pharmacokinetic/pharmacodynamic modelling of the plasma
bactericidal activity of NXL103 against Streptococcus
pneumoniae and Staphylococcus aureus in phase I studies
H. Merdjan, J. Lowther, A-M. Girard, C. Delachaume, M. Rangaraju
(Romainville, FR)
Objective: NXL103 is a novel oral streptogramin antibiotic associating
2 components RPR202868 (PI) and RPR132552 (PII). The objective
of this study was to characterise the relationship between the plasma
bactericidal activity against S. pneumoniae and S. aureus strains, and
PI and PII plasma concentrations measured in samples collected in 2
phase I studies.
Methods: The dataset for building the PK/PD model was composed
of 1067 plasma samples from a phase I repeated (10-day) oral
administration study in healthy male volunteers. Four cohorts of
10 subjects (8 received NXL103 and 2 placebo) received 0.5 g bid,
0.75 g bid, 1.5 g oad, or 1 g bid. Blood samples were taken on 7
occasions from day 1 to day 11. PI and PII concentrations were measured
in plasma by LC-MS/MS. Separate aliquots of the same samples
were serially diluted into a growth medium/control plasma mixture,
and incubated with S. pneumoniae (030MV1 strain) and S. aureus
(011HT18 strain) to measure bactericidal activity. For the purpose of
PK/PD modelling, cidality data were recoded as 0 (no activity) or 1
(cidal activity), irrespective of the intensity of effect. Fits were performed
using WinNonlin®.
Results: The model predicted bactericidal activity on S. pneumoniae
if both PI and PII were more than 0.175mg/L and 0.523mg/L,
respectively. Breakpoints for S. aureus were 0.123mg/L and 0.081mg/L,
respectively. The descriptive performance of the model was 93.5%
and 83.9% accurate against S. pneumoniae and S. aureus, respectively.
The predictive performance of the model was assessed on a separate
validation dataset composed of 416 human plasma samples collected in
a previous study, where 32 healthy male volunteers received a single oral
dose of either 0.5 g, 1 g, 1.5 g or 2 g of NXL103. Plasma concentrations
of PI and PII, and bactericidal activity were measured as above. Model-
predictions were 91.8% and 93.5% accurate against S. pneumoniae and
S. aureus, respectively, the remainder being evenly distributed between
false positive and false negative predictions.
Conclusion: A PK/PD model was built that predicts the plasma
bactericidal activity against two pathogens of therapeutic interest. These
results should be taken into account in deﬁning dose(s) for phase II
trial(s).
P794 The efﬁcacy of ceftazidime combined with NXL104, a novel
b-lactamase inhibitor, in a mouse model of kidney infections
induced by b-lactamase producing Enterobacteriaceae
M. Borgonovi, C. Miossec, J. Lowther (Romainville, FR)
Objectives: NXL104 is a novel b-lactamase inhibitor that has been
shown in vitro and in vivo to inhibit both class A and class C
b-lactamases. The occurrence of Enterobacteriaceae producing extended-
spectrum b-lactamases and AmpC enzymes needs to be considered in
the therapy of complicated urinary tract infections (UTI). The aim of
the study was to demonstrate in a murine model that the combination
of ceftazidime (CAZ) with NXL104 restored the bactericidal efﬁcacy of
CAZ against strains refractive to CAZ alone due to b-lactamases.
Methods: Kidney infections were induced in immunodepressed,
anaesthetised male CD1 mice by direct injection of 104 cells in 0.02
ml of exponentially growing culture by 25 gauge needle. Typically the
kidney bacterial burden increased by 1.5log10 within 48 hours. Therapy
commenced subcutaneously 4 hours after infection bid for 2 days.
Bacteria were enumerated in the kidneys of treated and control mice
48 hours post infection.
Results: CAZ alone was ineffective against all 6 strains tested compared
to the non-treated control group. The combination CAZ/NXL104 (4:1)
was effective in a dose range 10−25mg/kg in reducing the inoculum
and preventing proliferation of Escherichia coli (one ClassA and one
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AmpC), Enterobacter cloacae (AmpC), Klebsiella pneumoniae (ClassA
+ AmpC), Morganella morganii (AmpC) and Citrobacter freundii
(AmpC). In each case CAZ/NXL104 was signiﬁcantly effective, reducing
bacterial kidney burden by 2.6 to 4.5log10 compared to the CAZ treated
group (p< 0.05, Bonferroni).
Conclusion: The combination CAZ/NXL104 (4:1) was effective against
representative strains of CAZ-resistant Enterobacteriaceae species in
a murine kidney infection model. This combination could represent
a useful therapeutic option for the treatment of infections due to
b-lactamase producing Enterobacteriaceae species, which are increasing
in frequency in complicated UTI.
P795 Tolevamer, a novel toxin-binding polymer, neutralises the
large clostridial toxins from the B1/027 epidemic strain of
Clostridium difﬁcile
R. Barker, P. Hinkson, J. Klinger, D. Davidson (Waltham, US)
The incidence of C. difﬁcile-associated diarrhoea (CDAD) has more
than doubled over the past decade, accompanied by an increase in
the proportion of isolates associated with the epidemic strain BI/027.
The BI/027 epidemic is associated with greater morbidity and mortality
than previously seen with CDAD, and this strain has been shown to
produce high levels of the large clostridial toxins in vitro, perhaps
due to a mutation in the tcdC gene, a putative negative regulator of
toxin production. Tolevamer is a non-antibiotic polymer that is being
developed as a novel therapy for CDAD. Previous studies have shown
that tolevamer binds toxins A and B (CdtA and CdtB) in vitro, preventing
cell-rounding in the Vero cell cytotoxicity assay. Furthermore, tolevamer
prevented mortality in a hamster model, and most importantly, was not
inferior to vancomycin with respect to resolving diarrhoea in a phase II
clinical study.
Objectives: Given their virulence and rising incidence, the capacity of
tolevamer to neutralise CdtA and CdtB from BI/027 isolates obtained
from different geographic areas was assessed.
Methods: Cultures were grown in broth culture for 48 hr, the supernatant
was removed, centrifuged, and sterile ﬁltered. Supernatants were diluted
onto conﬂuent Vero cell monolayers and toxin titre was determined
by microscopic examination of cell morphology after 24 hr. The titre
used for tolevamer neutralisation studies was deﬁned as 2-fold greater
than the minimum concentration required for 100% cell rounding. For
toxin neutralisation studies, dilutions of tolevamer were added to Vero
cell monolayers in combination with tittered supernatants; cells were
incubated 24 hr and then were assessed microscopically. Neutralisation
was deﬁned as that concentration of tolevamer that prevented >90%
cell-rounding.
Results: Titred supernatants from all strains tested were neutralised by
the same concentration of tolevamer.
Conclusions: Tolevamer neutralises the large clostridial toxins from the
epidemic BI/027 strain as well as it does toxins from other C. difﬁcile
strains.
P796 In vitro and in vivo pharmacokinetics of 2-methylamino-
benzodiazepines to treat Helicobacter pylori infections
J. Newman, M. Rooney, B. de Jonge, A. Kutschke, C. Cederberg
(Waltham, US; Molndal, SE)
Objectives: 2-Methylamino-benzodiazepines were identiﬁed as selective
H. pylori inhibitors that suppress growth through MurI, an enzyme
essential for peptidoglycan synthesis. We describe the pharmacokinetics
of these analogs and the pharmacodynamic parameters required for
gastric H. pylori monotherapy.
Methods: In vitro kinetics were determined upon exposure to cells to
various concentrations of compound. In vivo pharmacokinetics were
determined after intravenous and oral dosing in rats and mice. Drug
levels were measured in plasma and gastric juice by LC-MS/MS. In
vivo efﬁcacy against H. pylori was assessed in a 4-day mouse model.
Pharmacodynamics for amoxicillin were determined in this model as a
comparator, since it also blocks cell-wall biosynthesis with slow killing
kinetics.
Results: 2-Methylamino-benzodiazepines were determined to be cidal
agents in vitro with slow killing kinetics. They exhibited moderate
clearance in rats (~20ml/min/kg) and moderate bioavailability (~40%).
In addition, these compounds were detected in rat gastric juice after
i.v. dosing, indicating penetration to the site of infection. Analysis of
amoxicillin efﬁcacy in mice, and correlation to plasma drug levels,
indicated that T>MIC for 24 hours was the index associated with
suppression of infection. Therefore, benzodiazepines were administered
to mice in various dosing schedules designed to exceed the MIC for
the full 4-day course of therapy. Multiple daily dosing, and use of a
metabolism inhibitor, produced drug levels above the MIC for most of
day 1, but levels were lower on days 2−4. Consequently, no suppression
of infection was observed.
Conclusions: Analogs in this series exhibit suitable in vitro killing
kinetics with good PK properties in rodents, but efﬁcacy against H. pylori
was hampered by sub-optimal exposure.
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P797 Correlation of C-reactive protein to complications and out-
come during the intensive care unit course of sepsis patients
O. Alici, N. Bavbek, A. Kargili, A. Kaya, F. Karakurt, A. Kosar
(Ankara, TR)
Purpose: Elevated concentrations of CRP have been reported to be
in correlation with increased risk of death in different patient groups.
There are conﬂicting results about the prognostic role of CRP in sepsis
patients. To determine the prognostic informative value of CRP in
patients admitted to the ICU with sepsis, 213 patients hospitalised in
our unit were retrospectively studied.
Materials and Methods: Demographic data, comorbid diseases,
all clinical, microbiological, and laboratory data were registered
retrospectively. Plasma levels of CRP on days 1, 3, 5 and 7 were
registered.
Results: The overall mortality rate was 37%. Nonsurvivors had
signiﬁcantly higher CRP levels than survivors on the 3rd day
(150.8±21.9mg/L vs 96.4±6.5mg/L, p = 0.002). Survivors had signiﬁ-
cantly lower CRP levels on the 3rd day than the 1st day (96.4±6.5mg/L
vs 160.2±11.8mg/L, p = 0.000) while nonsurvivors had signiﬁcantly
higher CRP levels on the 3rd day than the 1st day 150.8±21.9mg/L vs
130.9±17.3mg/L, p = 0.000). In patients with sepsis, age and diabetes
mellitus were the important prognostic variables for intensive care unit
mortality.
Conclusions: In sepsis, progressively increasing concentrations of CRP
are correlated with increased risk of organ failure and death. Serial
measurements are helpful to identify these patients who require more
intensive treatment to prevent complications.
P798 The investigation of correlation between serum cytokine
levels, C-reactive protein and erythrocyte sedimentation rate
in acute brucellosis
N. Ates Arica, F.S. Erdinc, G. Tuncer Ertem, C. Bulut, M.A. Yetkin,
U. Onde, B. Oral, A.P. Demiro¨z (Ankara, TR)
Objectives: Cytokines are thought to have an important role in the
pathogenesis of brucellosis and the T helper 1/T helper 2 balance may
be involved in the susceptibility or resistance to the disease. Effective
immune response is mediated by T helper 1 cells in brucellosis. The aim
of this study was to detect serum interferon gamma (IFN-g), interleukin-6
(IL-6) and interleukin-12 (IL-12) levels in patients with acute brucellosis
and to investigate the correlation between those cytokines, C-reactive
protein (CRP) and erythrocyte sedimentation rate (ESR).
Methods: Fifty patients with acute brucellosis followed between August
2002 and August 2006 in Ankara Research and Training Hospital
Infectious Diseases and Clinical Microbiology Department were included
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in to the study. The control group included 31 healthy persons. Serum
cytokine levels were measured by ELISA method. ESR values were
determined by Westergren method and CRP levels were determined by
nephelometric method. Data were analysed with SPSS 13.0 for Windows.
Results: The mean serum levels in patients with acute brucellosis
and control group were as follows; IFN-g; 14.2 pg/mL and 0.4 pg/mL
(p = 0.021), IL-6; 44.7 pg/mL and 2.4 pg/mL (p = 0.012) and IL-12;
176.0 pg/mL and 76.9 pg/mL (p = 0.001), respectively. The difference
between two groups was stastically signiﬁcant (p< 0.05).
In acute brucellosis group, for CRP, we found positive correlation with
IFN-g, IL-12 and ESR (r = 0.31, p< 0.05; r = 0.31, p< 0.05; r = 0.53,
p< 0.01, respectively). Also there was a positive correlation between
IL-12 and IFN-g (r = 0.62, p< 0.01). There was no signiﬁcant correlation
between ESR and the cytokines. For IL-6, there was not any signiﬁcant
correlation with the other parameters.
Conclusion: In conclusion, our study is in accordance with the results
of the previous studies suggesting that immunity against brucellosis is
mediated by T helper 1 cells. CRP and ESR are proved parameters to be
related with acute brucellosis. Signiﬁcantly high IFN-g, IL-6 and IL-12
levels in acute brucellosis might imply the role of the cytokines in the
pathogenesis of brucellosis.
P799 Phagocyte Fcg receptors expression in bacteraemia
A.A. Garcia-Egido, M.A. Escobar, F.J. Fernandez, F.M. Gomez-Soto,
P. Ruiz, M. Rosety, C. Rivera, F. Gomez (El Puerto Santa Maria, ES)
Early markers of bacteraemia are useful for prognosis and, in decision
making for i.v. antibiotic therapy.
Objectives: To assess the diagnostic power of the surface expression of
Fc receptors for IgG (FcgRs) for the prediction of bacteraemia in febrile
patients.
Methods: We performed a 4 year prospective case-control study on 166
consecutive patients (pts) with an episode of bacteraemia as compared to
174 randomly selected concurrent febrile pts with negative blood cultures
(control). Demographic and clinical data were collected by chart review
and/or questioning their attending physicians. Plasma levels of C-reactive
protein (CRP), TNFg, IL-1a, IL-6, IL-8 and IL-10 were determined. The
surface expression of Fc receptors for IgG (FcgRs): FcgRI, FcgRII and
FcgRIII on peripheral blood monocytes (M) and granulocytes (G) was
assessed by ﬂow cytometry. These studies were done concomitantly with
blood cultures.
Results: Both groups were not different for age, gender, previous
administration of immunosupressants or antibiotics, clinical severity
index or comorbid conditions. In univariate analysis, cases had
signiﬁcantly higher levels of CRP (p< 0.001), TNFg (p< 0.001), IL-1a
(p< 0.001) and IL-6 (p< 0.01) than controls. The expression of FcgRIIA
and FcgRIII by M and, that of FcgRI on G was signiﬁcantly enhanced
(p< 0.001) in bacteriemic patients as compared to culture-negative
febrile pts; while the expression of FcgRIIB by either M or G was
signiﬁcantly decreased (p< 0.03). Setting a cut-off value =25% of the
mean ﬂuorescence intensity over controls for FcgRs surface expression
and, assuming a prevalence of bacteraemia of 5−10% among hospitalised
patients undergoing blood cultures, results in a sensitivity, speciﬁcity,
positive and, negative predictive values of: 77%, 97%, 74%, and 98%,
respectively for M-FcgRIIA, 73%, 96%, 74% and 97%, respectively for
M-FcgRIII, 58%, 93%, 49% and 95%, respectively for G-FcgRI and,
71%, 91%, 57% and 83%, respectively for G-FcgRIIB.
Conclusions: Our results suggest that the surface expression of Fc
receptors for IgG on peripheral blood monocytes and granulocytes may
help clinicians to rule out bacteraemia in febrile patients.
P800 Modiﬁcation of a haemolytic assay for the measurement
of functional human mannose-binding lectin by classical
pathway inhibition
B.A.W. de Jong, B.L. Herpers, B. Dekker, P.C. Aerts, H. van Dijk,
G.T. Rijkers, H. van Velzen-Blad (Nieuwegein, Utrecht, NL)
Objective: Low levels of functional mannose-binding lectin (MBL),
impairing early complement activation via the lectin pathway, have
been associated with disease. Therefore, diagnostic procedures for MBL
levels and lectin pathway activity are widely performed. In a previously
described assay MBL levels are measured by bystander-haemolysis
after binding mannan on Saccharomyces cerevisiae (Kuipers et al,
2002). All down-stream complement components are provided by MBL-
deﬁcient serum. As both the ligand-binding and complement-activating
properties are assessed simultaneously without interference of down-
stream deﬁciencies, this is the only assay to quantitatively measure
the level of functional MBL. Interference by classical pathway activity
has been postulated, for example by C1q-binding immune complex
formation of antibodies to S. cerevisiae (ASCA). Here we describe the
classical pathway interference in the haemolytic MBL assay and the
modiﬁcation of this assay to prevent this artifact.
Methods: To determine the minimal inhibitory concentration, classical
pathway activity was inhibited in a CH50 assay by preincubation of
three 1:10 diluted ASCA-positive test sera with 0−150 ug/mL anti-C1q
monoclonal antibodies. To examine the interference of classical pathway
activity in the functional MBL assay, haemolytic activity was assessed
in the MBL assay in absence and presence of 50 ug/mL anti-C1q in the
three ASCA-positive sera and in 35 selected sera of donors with known
genotypes.
Results: Anti-C1q inhibited all classical pathway activity dose-
dependently, with full inhibition at 50 ug/mL. In three selected ASCA-
positive sera, anti-C1q decreased haemolysis in the MBL assay in two
samples (ﬁgure 1a).
Figure 1. Effect of anti-C1q on haemolysis in the haemolytic MBL
assay in (a) three selected ASCA-positive sera and (b) 35 sera of known
genotypes.
Most of the 35 selected sera did not show a signiﬁcant difference with or
without anti-C1q (ﬁgure 1b). A striking effect was found in some sera
from donors with deﬁcient genotypes XA/0 and 0/0, where anti-C1q
decreased haemolytic activity completely.
Conclusion: The haemolytic MBL assay is designed to measure
functional MBL levels by its ability to bind its ligand and activating
complement, without interference of down-stream deﬁciencies. However,
in some samples classical pathway activity can interfere with this
functional MBL measurement, either via ASCA or other C1q-binding
immune complex formation. This interference can and should be
inhibited by anti-C1q to prevent that MBL deﬁciency is overlooked and
patients are misdiagnosed.
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Antimicrobial effects and mechanisms
P801 Eradication of induced mouse ﬁbrosarcoma with combination
of verotoxin1 and monophosphoryl lipid A
H. Hosain Zadegan, M. Sattari, Z. Mohammad Hasan, A. Allameh
(Khorram Abad, Tehran, IR)
Objectives: Because of disadvantages of routine cancer therapies
such as chemotherapy and radiotherapy, four essential approaches of
different microbial metabolites have been used recently in treatment
of cancers. These are enterotoxins, bacterial proteins, recombinant
toxins, and combination therapies. Antitumour effects of verotoxin1
have known from several years ago, that produced from some kinds of
Escherichia coli. Our purpose was to study the synergistic cytotoxicity
of verotoxin1 and monophosphoryl lipidA (MPL) a nontoxic derivative
of lipopolysaccharide on induced ﬁbrosarcoma of Balb/c.
Methods: For determining treatment doses of Verotoxin1 and MPL on
animals, lethal dose 50 percent of them calculated with Reed & Munch
method. Then intradermal tumours (mean diameter of 0/7−1 centimeter)
induced with WEHI-164 cells on back of animals, and divided in four
groups. Group 1 used as control, and groups 2, 3, 4 injected with MPL,
verotoxin1, and combinations of MPL and verotoxin1 respectively. After
treatment, eradication or decrease in volume of tumours monitored daily
and compared in 4 groups.
Results: verotoxin1 like standard vero cell line indicated cytotoxicity
on WEHI-164 line in In vitro experiments. Simultaneous treatment of
tumours with verotoxin1 & MPL eradicated malignant ﬁbrosarcoms
of balb/c. Animals of control group died after severe weight loss in
comparison.
Conclusion: Our results indicate that verotoxin1 have synergistic effects
with MPL in eradication of malignant ﬁbrosarcomas of Balb/c. And
after further studies, it can be used for treatment of different tumours.
Application of tow microbial metabolite as a treatment of tumours
proposed and studies ﬁrstly in this study. On the other hand results
indicate that tow factors have synergy in pathogenesis of verotoxigenic
E. coli infections.
P802 Effect of Berberis aetnensis C. Presl extract on tissue
transglutaminase expression in primary astroglial cell
cultures exposed to glutamate
A. Campisi, A. Speciale, R. Acquaviva, G. Raciti, I. Barbagallo,
S. Puglisi, L. Iauk (Catania, IT)
Berberis aetnensis C. Presl (Berberidaceae) is a bushy spiny shrub
presents on Mount Etna (Sicily). It contains several alkaloids showing
several pharmacological properties (febrifugal, hypotensive, immunos-
timulating, antinﬂammatory). It is well known that excitotoxicity is a
common feature in various neurological disorders. The excitotoxicity,
increasing the intracellular calcium levels and activating speciﬁc
genes, results in synthesis of several enzymes involved in cellular
stress response, including tissue transglutaminase (TG-2). This is a
multifunctional protein implicated in numerous cellular processes, as
well as cellular differentiation, signal transduction, cell survival, and
apoptosis. In previous researches, we demonstrated that the alterations
of cellular redox state, evoked by glutamate in primary astrocyte cultures,
are associated with the increase of TG-2 expression, and its effects were
reduced by the antioxidant treatments.
In this study, we investigated the protective effects of B. aetnensis extract
in glutamate-evoked TG-2 up-regulation in primary rat astroglial cell
cultures.
Primary rat astroglial cell cultures were prepared from newborn albino
cerebral cortex (1–2-day-old Wistar strain), maintained in cultures for
two weeks, and exposed to 500mM of glutamate for 24 hrs. Some
cultures were also treated with the methanolic extract of plant roots
at different concentrations and then exposed to the neurotransmitter.
The exposure of the astroglial cell cultures to glutamate caused a dose-
dependent depletion of the glutathione levels, increased the reactive
oxygen species (ROS) production and induced DNA fragmentation. The
treatment of the cells with B. aetnensis extracts recovered the oxidative
status and reduced the glutamate-increased of TG-2 expression.
These data suggest that B. aetnensis, preventing TG-2 up-regulation and
reducing the oxidative stress induced by glutamate in primary astroglial
cell cultures, may represent a new strategies in the neuropathological
conditions associated to excitotoxicity.
P803 Different antimicrobial activity of beta defensins and colonic
biopsy extracts against aerobic and anaerobic bacterial
strains of the gastrointestinal tract
S. Nuding, L. Zabel, K. Fellermann, J. Wehkamp, H.A.G. Mueller,
E.F. Stange (Stuttgart, Goppingen, DE)
Objectives: The human gastrointestinal tract harbours a variety of
aerobic and anaerobic microorganisms. To prevent colonisation and
invasion of bacteria, the intestinal mucosa synthesizes antimicrobial
peptides such as the cationic defensins. Based on RT-PCR and western
blot, we determined a high induction of beta defensins in ulcerative
colitis, whereas beta defensins in Crohn’s disease were less induced. To
elucidate possible functional consequences for the intestinal barrier, we
investigated the antimicrobial activity of defensins and cationic protein
extracts, taken from the colon of patients with Crohn’s disease, ulcerative
colitis or controls, against bacteria of the intestinal ﬂora.
Methods: To quantitate the antimicrobial activity, we established a ﬂow
cytometric assay with the membrane potential sensitive dye bis-(1,3-
dibutylbarbituric acid) trimethine oxonol. Depolarisation of the bacterial
cell membrane caused by antimicrobial peptides leads to an uptake of
the dye followed by an increasing green ﬂuorescence. We tested the
antibacterial activity of the constitutive human beta defensin HBD-1,
the inducible defensin HBD-3 and cationic biopsy extracts of 22 patients
with colonic Crohn’s disease, 32 with ulcerative colitis and 13 controls
against ATCC strains of Escherichia coli and Staphylococcus aureus and
a clinical isolate of Bacteroides vulgatus.
Results: In populations of the aerobic strains E. coli and S. aureus
as well as the anaerobic strain B. vulgatus 80% of the bacteria were
killed by 2.5−5mg HBD-3/mL. In contrast, HBD-1 in concentrations up
to 15mg/mL, which kill E. coli and S. aureus, exerted no bactericidal
effect against B. vulgatus. The antimicrobial activity of cationic biopsy
extracts was signiﬁcantly diminished in extracts of patients with Crohn’s
disease against E. coli and B. vulgatus compared to ulcerative colitis.
The activity in extracts of Crohn’s disease against S. aureus was also
reduced, but the differences versus controls and ulcerative colitis were
less pronounced.
Conclusion: The viability of B. vulgatus is not inﬂuenced by the
constitutive HBD-1, this is in concordance with its augmented presence
in the normal intestinal ﬂora. The inducible defensin HBD-3 is a potent
antimicrobial peptide against all 3 strains tested. The lower antimicrobial
activity in extracts of Crohn’s disease corresponds well to the deﬁcient
beta defensin induction. The impact of other antimicrobial peptides must
still be clariﬁed.
P804 Inhibitory effect of Melaleuca alternifolia (tea tree oil) on
inﬂuenza A/PR/8 virus replication
R. Timpanaro, A. Garozzo, B. Bisignano, A. Stivala, P.M. Furneri,
G. Tempera, A. Castro (Catania, IT)
Objectives: The Melaleuca alternifolia (Tea Tree) is a coniferous tree
found in tropical regions, whose needles contain an essential oil that
is used in medical and cosmetic products. The Tea Tree Oil (TTO)
consists of about 50% oxygenated monoterpenes and 50% terpene
hydrocarbons, terpinen-4-ol is the main active component. TTO has a
wide spectrum of antimicrobial activity against bacteria, yeasts and fungi.
The antimicrobial activity has been principally attributed to terpinen-4-
ol. The aim of this study was to investigate the antiviral activity and the
mechanism of action of Tea Tree Oil and its components, terpinen-4-ol,
g-terpinene, p-cymene, a-terpinene, terpinolene and a-terpineol, against
Inﬂuenza A/PR/8 virus subtype H1N1 in MDCK cells.
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Methods: The inhibitory effect was studied by measuring hemoagglu-
tinin units (HAU) and 50% cytopathic effect (CPE50). In order to study
the mode of action of the TTO, we carried out a series of experiments,
including virucidal assay, pre-treatment assay, inhibition of attachment
assay and time of addition assay.
Results: The TTO, the terpinen-4-ol, the terpinolene, the a-terpineol
were found to have an inhibitory effect on inﬂuenza virus replication
at doses below the cytotoxic dose. No of the tested compounds showed
virucidal activity nor any protective action for the MDCK cells.
The effect of compound on different steps of the replicative cycle of
inﬂuenza virus in MDCK cells was studied by adding compound at
various times after infection (0, 1, 2, 4, 6 and 9 h). Viral replication,
assessed as HAU/mL and CPE50 24 h after infection, revealed that this
was signiﬁcantly inhibited only if TTO was added within 2 h of infection,
indicating an interference with an early step of the viral replicative
cycle of Inﬂuenza virus. The inﬂuence of the compound on the virus
adsorption step, studied by the infective centre assays, indicated that
TTO did not interfere with cellular attachment of virus.
Conclusion: These data suggest that TTO interferes with an early events
of Inﬂuenza virus replication, after viral adsorption. Further studies are
necessary to understand the precise mode of action of this compound.
P805 Essential oil composition and antibacterial effects of
Ziziphora clinopodioides
M. Chitsaz, M. Barton, M. Bazargan, M. Kamalinejad (Tehran, IR;
Adelaide, AU)
Background: The plant of Ziziphora clinopodioides (LAM), which is
habitant of Iran, has been used in Iranian Traditional Medicine for
treatment of some infectious conditions. In this survey, its antibacterial
effects were examined against some bacterial species.
Methods: Hydro-alcoholic extract of plant obtained by solvent
(methanol 70%) and essential oil obtained by hydro-distillation
procedure. The methanolic extract and essential oil were tested
against Staphylococcus aureus (ATCC25923), Streptococcus pyogenes
(PTCC1470), Escherichia coli (ATCC25922), Salmonella typhimurium
(PTCC1609), Klebsiella pneumoniae (PTCC1053), and Pseudomonas
aeruginosa (ATCC27853). Standard agar diffusion method was used
for antimicrobial assay of methanolic extract and essential oil. MIC
and MBC were determined by using macrobroth dilution method.
Compounds of essential oil separated and identiﬁed by GC and GC/MS
analysis.
Results: The growth of Gram-positive organisms (S. aureus and
S. pyogenes) were inhibited by methanolic extract at a concentration of
25mg/well, but it did not inhibit any of the tested Gram-negative species.
Essential oil halted the growth of all tested Gram-positive and Gram-
negative organisms, with highest effect on S. typhimurium (with MIC
and MBC of 225micg/mL). Gas chromatographic analysis revealed 22
different compounds in essential oil which ﬁve of them comprise more
than 73% of oil and pulegon is the highest one.
Conclusion: The results suggest that Ziziphora clinopodioides has potent
antibacterial effects on some Gram-positive and Gram-negative bacterial
species especially on Salmonella typhimurium.
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P806 Assessment of tryptophan metabolism and cytokine proﬁle
in cerebrospinal ﬂuid samples from patients with bacterial
meningitis
L.G. Coutinho, C.L. Bellac, D. Grandgirard, M. Wittwer, R.S. Coimbra,
S. Christen, L.F. Agnez-Lima, L.A. Marinho, S.L. Leib (Berne, CH)
Objectives: Activation of the kynurenine (KYN) pathway (KP) has been
observed in experimental bacterial meningitis (BM). Here we assessed
the association of chemo-/cytokine levels with the concentration of KP
metabolites in CSF and plasma samples from patients with BM.
Methods: CSF samples were collected from 22 hospitalised patients.
Nine patients were diagnosed with bacterial meningitis, 6 patients
with viral meningitis and 7 patients with non-infectious neurological
disorders. Microsphere-based multiplex assays (Lincoplex®, Linco
Research Inc., St Charles, MA, USA) was used to assess the
concentrations of 14 chemo-/cytokines separately in CSF and serum.
The CSF and serum concentration of metabolites from the kynurenine
pathway was assessed by high pressure liquid chromatography.
Results: The concentration of TNF-a, IL-6, IL-1b, IFN-g, IL-10, IL-1
receptor antagonist, MIP-1a, MIP-1b, MCP-1 and G-CSF were 100-fold
higher in CSF from patients with BM compared to the two other groups.
In all CSF samples the concentration of IL-2, IL-12(p70), IL-4 and GM-
CSF was below the detection limit.
In plasma samples the concentrations of IL-6, IL-10, IL-1 receptor
antagonist, MCP-1 and G-CSF were signiﬁcantly increased in patients
with BM. The concentrations of the KP metabolites kynurenine,
anthranilic acid and kynurenic acid were 10-fold higher in CSF of
patients with BM compared to the other two groups. In contrast to what
was found in CSF, the concentrations of KP metabolites in the plasma
were not signiﬁcantly different between the three groups. Tryptophan
levels in plasma samples were higher than in CSF samples and were
signiﬁcantly decreased in patients with BM.
Conclusion: BM is associated with increased levels of pro-inﬂammatory
cytokines and KP metabolites. This increase in KP metabolites is
most likely due to activation of KP by IFN-g and TNF-alpha. Based
on the comparison of tryptophan and KP metabolite concentrations
between plasma and CSF samples we conclude that the activation of
the tryptophan pathway upon BM occurs within the brain.
P807 Characterisation of the soluble domain of nitrite reductase
from Neisseria meningitidis strains
P. Stefanelli, G. Colotti, A. Neri, M.L. Salucci, R. Miccoli, L. Di
Leandro, R. Ippoliti (Rome, L’Aquila, IT)
Objectives: The objective of the study was to characterise the molecular
and biochemical properties of the soluble domain of the AniA protein
of N. meningitidis serogroup B MC58, and thereafter evaluate genomic
conservation and protein expression in a panel of N. meningitidis clinical
isolates.
Methods: The soluble domain of the aniA gene of N. meningitidisMC58
was cloned and expressed in E. coli following standard procedures.
Nitrite consumption was evaluated by the Griess method at different
time points. For the pH dependence, the experiments were performed
using different buffers 20mM acetate buffer in the range 4.5−5.5, 20mM
Hepes buffer in the range 5.5−6.6, and 20mM phosphate buffer in the
range 6.5−7.5. Direct Nitrogen Oxide production was recorded by a
speciﬁc electrode (WPI, UK). A total of 11 N. meningitidis strains, 7
disease-associated and 4 carriers, were cultured with 5% CO2 at 37ºC
on Thayer-Martin plates. The aniA sequences were analyzed with the
BLAST programme. The antisera was prepared with 1.5mg of puriﬁed
protein to immunise New Zealand rabbits, Charles River and used to
perform western-blot analysis.
Results: The biochemical results show an ordered mechanism for the
catalysis, since the binding of nitrite needed to induce electron transfer
from the type I to the type II Cu-site. Furthermore sAniA shows a
dependence of the catalytic activity upon acidiﬁcation. Sequence analysis
of the coding region of the gene in 11 N. meningitidis strains showed
that, notwithstanding a high degree of gene sequence similarity among
them, two gene variants were found due to insertions or deletions. In 1
disease associated strain a 9-residue insertion was located close to the
catalytic site. No ampliﬁcation was obtained in 2 carried strains due to
the presence of a gene for a transposase protein. The AniA was expressed
in all the strains, except for two with no ampliﬁcation reaction.
Conclusion: These preliminary results describe the basic biochemical
properties of the sAniA from N. meningitidis MC58, in particular its pH
dependence. The conservation of the gene among the majority of the
examined strains suggests that preservation of its integrity is important
for bacterial survival. However, further investigation will be performed
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to understand how ani A gene variations in the two carrier strains could
affect the enzymatic activity of the protein.
P808 Distinct Neisseria meningitidis isolates display different
cytokine induction capacities in an ex vivo whole-blood model
A. Fiserova, O. Beran, J. Kalmusova, M. Musilek, P. Kriz, M. Holub
(Prague, CZ)
Objectives: The aim of the present study was to examine the cytokine
induction capacities of heat-inactivated Neisseria meningitidis isolates
from patients with distinct courses of invasive meningococcal disease
(IMD) in an ex vivo whole-blood model.
Methods: Three healthy adult volunteers with negative antimeningococ-
cal anti-B and anti-C antibodies (as detected by serum bactericidal assay)
were selected for whole blood-model. Reﬂudan®-anticoagulated whole
blood (0.05mg/mL) and heat-inactivated bacteria at a ﬁnal concentration
of 106 CFU/mL in blood samples were incubated for 4 hr at 37ºC under
constant shaking. Flow cytometric quantiﬁcation of tumour necrosis
factor (TNF)-a, interleukin(IL)-1b, IL-6, IL-8, IL-10, and IL-12p70
levels in supernatants was performed using cytometric bead array.
Results are summarised in the table, n = 6 (each donor in two independent
experiments). There are statistically signiﬁcant differences between
strains 137/05 vs. (versus) 285/05, 137/05 vs. 113/04, 137/05 vs. 171/05,
285/05 vs. 109/05, 113/04 vs. 109/05, and 109/05 vs. 171/05 in TNF-a,
IL-1b, and IL-6 production (P< 0.01) except for strains 113/04 vs. 109/5
in IL-1b production (P< 0.05).
Neisseria meningitidis strains and
clinical parameters of IMD
TNF-a
(ng/mL)
IL-1b
(ng/mL)
IL-6
(ng/mL)
137/05 group C strain
(C:NT:P1.2,5; ST-11 HC) M+S,
APACHE 14, SOFA 3, moderate course
3,724
±1,326
5,844
±3,556
8,071
±7,138
285/05 group B strain
(B:1:NST; ST-41/44 complex) M+S,
APACHE 10, SOFA 4, mild course
13,540
±4,038
18,773
±4,223
45,319
±14,563
113/04 group B strain
(B:22:P1.14; ST-18 HC) SS+WFS,
APACHE 25, SOFA 12, severe course
10,908
±3,043
15,661
±6,283
37,123
±14,575
109/05 group B strain
(B:NT:NST; ST-919, not HC) M+S,
APACHE 17, SOFA 6, mild course
3,399
±1,999
6,664
±4,290
10,493
±7,686
171/05 group B strain
(B:15:P1.4; ST-5126, not HC) M,
APACHE 11, SOFA 3, mild course
14,043
±4,103
19,862
±9,660
46,854
±14,629
HC: hypervirulent complex; IMD: invasive meningococcal disease; M: meningitis;
S: sepsis; SS: septic shock; WFS: Waterhouse–Friderichsen syndrome.
Data are expressed as mean±SD.
Conclusion: N. meningitidis isolates display different cytokine-
stimulating potential in whole-blood model. The cause might be in
differences in the quantity and quality of bacteria structural components
and remains to be solved.
Acknowledgement: The study is supported by grants MSM 0021620806
and IGA NR/8014−3.
P809 Roles of uropathogenic Escherichia coli pili in pathogenesis
of urinary tract infection
S. Najar Peerayeh, N. Nooritalab, M. Sattari (Tehran, IR)
Introduction: Urinary tract infections (UTI) are one of the most
common infectious diseases in man with a prevalence strongly inﬂuenced
by gender and age. Uropathogenic E. coli (UPEC) strains account for
90% of all UTI and up to 50% of all nosocomial UTI. Infection is
initiated when UPEC binds to the superﬁcial epithelial cells by type 1
pili. In addition to attachment, the presence of type 1 pili can lead to
bacterial invasion to bladder epithelial cells. However, P piliation of
UPEC is characteristic of strains causing upper urinary tract infection as
well as pyelonephritis leading to urosepsis. In this study we determine
the roles of type 1 and P pili in interaction of UPEC with human
polymorphonuclear leukocyts (PMNS).
Materials and Methods: Type 1 and P piliated and unpiliated
strains (obtained by growth at a pilus-restrictive temperature) of
UPEC were used for determining the effects of these adhesins on
migration of neutrophils towards bacteria in Boyden chamber. The
lectinophagocytosis and intracellular killing of bacteria with puriﬁed
human neutrophils were estimated by counting of the number of viable
bacteria in 45 min.
Results: Type 1 piliated UPEC stimulated signiﬁcantly greater
chemotaxis than did P piliated, unpiliated bacteria and bacteria in which
the piliation was suppressed. Phagocytosis of type 1 piliated UPEC
occurred in the direct and opsonin-independent manner. In contrast, P
piliated and unpiliated bacteria failed to bind to PMNS.
Conclusion: The results indicated that type 1 pili have a chemotatic
effect, and there was a positive correlation between type 1 piliation and
bacterial killing by PMNS. In contrast, PMNS did not chemotaxis to
UPEC with type P pili, and unable to react with these bacteria. Therefore
the expression of type P pili is critical to UPEC establishment in upper
urinary tract.
P810 Salmonella ability to use B-lymphocytes as a reservoir is
due to overcoming bactericidal mechanisms, in addition to
inability to produce inﬂammatory cytokines
R. Rosales-Reyes, A. Pe´rez-Lo´pez, M. Ramı´rez-Aguilar, V. Ortiz-
Navarrete, M. Urba´n-Reyes, C. Alpuche-Aranda (Mexico City, MX)
The ability of Salmonella to survive and replicate within macrophages
and dendritic cells is a relevant pathogenic factor to develop disseminated
disease. It has also been shown that Salmonella is able to infect B cells
in vitro and in vivo. In the mouse model, Salmonella is localised inside
B cells (CD19+, B220+) and macrophages (Mac1+) of spleen and bone
marrow after 60 days of initial infection.
Objectives: To identify B-Lymphocytes ability to produce bactericidal
mechanisms and inﬂammatory cytokines proﬁle against Salmonella
infection.
Methods: Intracellular Salmonella were detected by FACS and UFCs.
The nitrogen intermediates reactive (NIR) were quantiﬁed by Griess
method. The cytotoxicity (ctx) was assay by LDH quantiﬁcation. TNF-a
and IL-1b were detected by ELISA.
Results: The efﬁciency of Salmonella uptake by B cells increased
10 times when the bacterium was opsonised with speciﬁc IgG
anti-Salmonella Ab. In addition, the intracellular bacteria were not
ctx on infected B cells (even MOI of 1:50) as macrophages
(10% vs 38% respectability). Salmonella survives more efﬁciently
in B cells than macrophages at 24 hours post-infection. On the
other hand, these Salmonella infected B cells were able to pro-
duce NIRs (14.05±3.61microM without infection, 29.33±3.33microM
with MOI = 50, 75.72±1.39microM with MOI = 100) in response to
magnitude of infection as macrophages (9.33±1.67microM without
infection, 89.33±1.11microM with MOI = 50 and 116.27±1.39microM
with MOI = 100). Infected B cells are not able to produce IL-1b by
inﬂamosome complex as macrophages (non detected vs 20000 pg/mL
respectively).
Conclusions: Salmonella internalisation by B cells is favoured by Fc
receptor phagocytosis and is able to survive and evade the bactericidal
effect of NIRs. The infected B cells are not able to produce inﬂammatory
cytokines by inﬂamosome complex (such as IL-1beta) involved in
recruitment of effectors immune cells. These data suggest that B cells
are a “safe” intracellular reservoir for Salmonella and perhaps they are
also a mechanism of transportation and evading effectors immune cells
during in vivo infection.
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P811 The role of typical and atypical enteropathogenic Escherichia
coli in diarrhoea
M.Y. Alikhani, M.M. Aslani, A. Mirsalehian, B. Fatollahzadeh
(Hamadan, Tehran, IR)
Objectives: Infectious diarrhoea is one of the world’s leading causes of
morbidity and mortality, resulting in about two million deaths per year.
Enteropathogenic Escherichia coli (EPEC) is a major cause of infantile
diarrhoea in developing countries. The present study was performed
to investigate the contribution of typical and atypical enteropathogenic
Escherichia coli (EPEC) as a cause of infectious diarrhoea in Iranian
children less than 10 years of age.
Methods: A total of 1355 children were chosen for the presence of
EPEC in their faeces. The samples were cultured for enteric pathogen
by standard methods. Strains biochemically identiﬁed as Escherichia coli
were selected and Serogroups of lactose positive and lactose negative
E. coli strains were determined by slide agglutination tests. EPEC
isolates was examined by PCR with the speciﬁc primers for the following
virulence genes: eaeA, bfpA and stx.
Results: During the summer months, 247 specimens from children
with diarrhoea, and 1108 from asymptomatic cases were analyzed for
the presence of typical and atypical EPEC. Potential enteric pathogens
were identiﬁed in 140 patients (56.7%). EPEC was the most frequently
identiﬁed agent (111 patients). EPEC isolates were examined for the
presence of the eaeA, bfpA and stx genes by PCR. EPEC isolates were
classiﬁed as typical (eaeA+, bfpA+, stx−) or atypical (eaeA+, stx− or
bfpA+, stx−). The results obtained indicated that typical EPEC was
diagnosed in 35 patient (11.8%) compared to 8 (0.4%) of asymptomatic
persons (P< 0.05). Atypical EPEC strains were isolated in 23 patients
(9.3%) compared to 13 (1.2%) of the healthy cases (P< 0.05).
Conclusion: Detection of the eaeA and bfpA genes is a useful method
for identiﬁcation and differentiation between typical and atypical EPEC
strains. Typical and atypical EPEC were prevalent in children with
diarrhoea than healthy cases. Our data suggest that typical and atypical
EPEC are important causes of diarrhoea in Iranian children.
P812 Haemoglobin-binding activity and haemoglobin-binding
protein of Prevotella nigrescens
S. Fujimura (Shiojiri, JP)
Objectives: Prevotella nigrescens, a Gram-negative, black-pigmented,
anaerobic rod is implicated as an etiological agent of periodontitis as
Porphyromonas gingivalis or Prevotella intermedia. These periodon-
topathogens, however, lack iron-chelating systems (siderophores) which
overcome a deﬁciency of iron. Based on the assumption that P. nigrescens
acquires iron from haemoglobin derived from erythrocytes in periodontal
lesions, we examined the binding activity of the envelope of P. nigrescens
to haemoglobin and efforts were made to isolate haemoglobin-binding
protein (HbBP).
Methods: P. nigrescens ATCC33563 was cultured anaerobically in a
glove box in Trypticase-base medium containing haemin and menadione.
The envelope was prepared by ultrasonic treatment of cells and
centrifugation at 120,000 g and solubilised using a detergent (CHAPS).
Insoluble material of the envelope was used as the outer membrane.
Binding of haemoproteins including haemoglobin to the envelope was
tested by photometrically. Dot blot assay was employed to conﬁrm
the binding of HbBP and haemoglobin using peroxidase-labelled
haemoglobin on nitrocellulose membranes.
Results: Binding of the envelope to haemoglobin occurred in a strictly
pH-dependent manner; the binding was observed at pH 4.5 to 5.5, but
was not in the neutral and alkaline buffers. Furthermore, haemoglobin
bound to the envelope dissociated in the high pH buffers. The same level
of haemoglobin binding activity was observed in the whole cell, but the
outer membrane demonstrated only one third the activity of the envelope.
Other haemoproteins such as myoglobin, cytochrome c and catalase also
were found to bind to the envelope. We hypothesised the existence of
haemoglobin-binding protein (HbBP) in the envelope responsible for this
binding, and proved its presence by dot blot method. HbBP was puriﬁed
from the solubilised material of the envelope by the combination of
ion-exchange chromatography, afﬁnity chromatography and isoelectric
focusing.
Conclusion: Binding of the envelope of P. nigrescens to haemoproteins
including haemoglobin was conﬁrmed and haemoglobin-binding protein
in the envelope was isolated.
P813 Alterations of serum lipoproteins in patients with acute
brucellosis
F. Apostolou, A. Kostoula, E. Liberopoulos, I. Gazi, A. Spyrou,
E. Tsianos, E. Bairaktari, A. Tselepis, M. Elisaf (Ioannina, GR)
Objectives: Changes in serum lipid parameters are observed during
inﬂammation. These changes may be associated with the pathogenesis of
atherosclerosis. There are no data on the possible effect of acute infection
with Brucella on serum lipoproteins.
Methods: Serum lipid parameters were determined in 28 patients
(18 male and 10 female, aged 52.9±14.6 years) with acute brucellosis
on admission and 4 months after the initiation of appropriate treatment.
Furthermore, 24 matched controls were studied. Fasting levels of
total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C),
triglycerides, apolipoproteins (Apo) AE´, B, E and lipoprotein (a) [Lp(a)]
were measured. Low-density lipoprotein (LDL) subclass analysis was
performed by use of the Lipoprint LDL System.
Results: On admission, patients exhibited signiﬁcantly lower levels
of TC, HDL-C, LDL-C and ApoAI compared with controls, while
there were no signiﬁcant differences in TG, ApoB, ApoA˚ and Lp(a)
levels. Furthermore, mean LDL particle diameter was signiﬁcantly lower
in patients compared with controls. Of interest, small dense LDL-C
(sdLDL-C) levels as well as the sdLDL-C/LDL-C, LDL-C/HDL-C and
ApoB/ApoAI ratios were signiﬁcantly higher in patients compared with
controls.
Four months after treatment initiation, a signiﬁcant increase in levels of
TC (by 23%), HDL-C (by 37%), LDL-C (by 23%), and ApoAI (by 39%)
was noticed. On the other hand, levels of TG, ApoB, ApoE and Lp(a)
were not signiﬁcantly altered. Furthermore, sdLDL-C levels, the sdLDL-
C/LDL-C ratio, the LDL-C/HDL-C ratio and the mean LDL particle
diameter were not signiﬁcantly changed. However, the ApoB/ApoAI ratio
was signiﬁcantly decreased.
Conclusions: Signiﬁcant quantitative and qualitative alterations of serum
lipoproteins were seen during acute infection with Brucella. These
changes were not fully restored 4 months after treatment initiation.
P814 Association of FCgamma RIIA polymorphism with
brucellosis
A. Raﬁei, R. Ghasemian, Z. Hosseini khah, A. Ajami (Mazandaran, IR)
Background and Purpose: Brucellosis is a major bacterial zoonosis
of global importance. Effective host defence against brucella depends
on immunoglobulin G-mediated phagocytosis of the bacteria and it has
been shown that the FC RIIA polymorphism (FCgamma RIIA-R131
vs FCgamma RIIA –H131) determines the capacity of immunoglobulin
G-mediated phagocytosis via this receptor. The aim of the study
was evaluation of FCgamma RIIA polymorphism in patients with
brucellosis and reveals any relation between this polymorphism and
disease progression.
Materials and Methods: In this study we evaluated FCgamma
RIIA polymorphisms (R/R131, R/H131, H/H131) in 67 patients with
serologically proven brucellosis and 67 age, gender and geographical
healthy volunteers. FCgamma RIIA polymorphism was determined using
a polymerase chain reaction (SSCP-PCR).
Results: The frequency of FCgamma RIIA-R/R131 genotype was higher
in patients with brucellosis compared Controls (47.8% vs 28.4%).
This genotype has an OR= 2.1, 95%CI = 1.3–4.2, P = 0.039) Signiﬁcant
correlation with brucellosis. But we did not ﬁnd a signiﬁcant difference
between patients with brucellosis and controls (P = 0.2).
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Although the frequency of FCgamma RIIA-R/R131 was higher in
patients with brucellosis compared controls, we did not ﬁnd any
statistically differences (53.8% vs46.3%, P = 0.2). As a result there was
no signiﬁcant association between FCgamma RIIA genotype and severity
of brucellosis.
P815 Haemophilus inﬂuenzae survival during complement-
mediated attacks is promoted by Moraxella catarrhalis outer
membrane vesicles
T.T. Tan, M. Mo¨rgelin, A. Forsgren, K. Riesbeck (Malmo¨, Lund, SE)
Objectives: Moraxella catarrhalis causes respiratory tract infections in
children and adults with COPD. It is often isolated as a co-pathogen with
Haemophilus inﬂuenzae. The underlying mechanism for this cohabitation
is unclear. The aim of this study was to investigate if M. catarrhalis is
able to contribute to the survival of H. inﬂuenzae in human serum.
Methods: The M. catarrhalis ubiquitous surface proteins (Usp) A1
and A2 are known to contribute to M. catarrhalis serum resistance
by interactions with various complement proteins. M. catarrhalis also
secretes outer membrane vesicles (blebs) in vitro. Hence, we examined
nasopharyngeal samples of a 9-year old child who had grown pure
cultures of M. catarrhalis during an episode of sinusitis. Both electron
microscopy and gold labeled anti-UspA1 and A2 antibodies were used
to analyse the samples. The effect of M. catarrhalis blebs on the
bacteriolytic activity of human serum against H. inﬂuenzae was examined
by incubating blebs with serum before performing bactericidal assays.
The interaction of these blebs with the complement system was further
documented by dot-blot assays.
Results: Blebs carrying Usp A1/A2 are secreted both in vivo and in
vitro. These blebs do carry UspA1 and A2 and they absorb the third
component of complement system (C3), counteracting the complement
cascade directed against H. inﬂuenzae. An improved survival was evident
in all clinical strains (n = 5) of H. inﬂuenzae tested. In contrast, UspA1/2
deﬁcient blebs are much weaker inhibitors of the complement-dependent
killing of H. inﬂuenzae.
Conclusion: Our results suggest a novel strategy in which pathogens
collaborate to conquer innate immunity and that the M. catarrhalis
vaccine candidates, UspA1/A2 play a major role in this interaction.
P816 Does Pseudomonas aeruginosa need free living amoebae in
environment?
C. Roger, S. Bouyer, Y. Hechard, C. Imbert, M. Rodier (Poitiers, FR)
Objectives: According to most authors, amoebae of genus Acan-
thamoeba do not play an important role as reservoirs for Pseudomonas
aeruginosa, frequently isolated from hospital water. In our hospital,
beside Acanthamoeba, amoebae of genus Hartmanella are also often
recovered from water taps. We investigated in this work the ability for
H. vermiformis to allow growth and/or survival of P. aeruginosa.
Methods: Trophozoites of H. vermiformis ATCC 50256 (5.105/mL) were
incubated with 5.104/mL bacteria (MOI = 0.1) of three P. aeruginosa
strains (ATCC 1111, one strain from a patient and one environmental
strain from hospital water). The mixture was incubated in PBS at 27ºC
during 24, 48 and 72 h. Each P. aeruginosa strain was also cocultivated
with trophozoites of A. castellanii (ATCC 30234), A. polyphaga (ATCC
30461) and A. culbertsoni (ATCC 30171) in the same conditions.
Controls were realised by incubating bacteria in PBS without amoebae.
After incubation and before plating on Mueller Hinton medium, the
mixture was passed through a 27 gauges needle ﬁve times to ensure
lysis of amoebae. Dilutions of the lysate were plated to determine CFU.
All the experiments have been made three times, each time in triplicate.
To visualise the potential interactions between bacteria and amoebae,
transmission electron microscopy was used.
Results: In this study, we have shown that there was neither growth
nor survival of P. aeruginosa in the free living amoebae used. No
internalisation of the bacteria was shown by transmission electron
microscopy.
Conclusion: In our conditions, neither the H. vermiformis strain nor the
Acanthamoeba strains were able to allow the survival and the growth of
the three strains of P. aeruginosa used. Further studies are nevertheless
necessary to conﬁrm that most of the P. aeruginosa strains do not need
reservoirs to survive in water.
P817 Efﬂux pump inhibitors reduce the invasiveness of
Pseudomonas aeruginosa
Y. Hirakata, A. Kondo, K. Hoshino, T. Miyazaki, S. Kurihara,
K. Izumikawa, M. Seki, K. Yanagihara, Y. Miyazaki, S. Kamihira,
S. Kohno (Nagasaki, Tokyo, JP)
Objectives: We have recently shown a mexAB-oprM deletion strain
(delta-ABM) derived from P. aeruginosa PAO1 was compromised in
its capacity to invade or transmigrate into MDCK cells (Hirakata Y,
et al. J Exp Med 2002; 196: 109). These data suggest that P. aeruginosa
exports invasion determinants predominantly using MexAB-OprM efﬂux
system. On the other hand, multi-drug efﬂux systems are thought to
contribute to the intrinsic resistance of a number of the antimicrobials.
MexAB-OprM is known to be constitutively expressed in P. aeruginosa
PAO1. We studied the inﬂuence of efﬂux pump inhibitors (EPIs), broad-
spectrum efﬂux inhibitor MC-207,110 and MexAB-OprM speciﬁc efﬂux
pump inhibitor (ABS-EPI) D13–9001, on the P. aeruginosa invasion
using the Madin-Darby canine kidney (MDCK) epithelial cell monolayer
penetration assay model.
Methods: P. aeruginosa PAO1, its delta-ABM mutant, nalB (MexAB-
OprM overproducing strain) mutant, and nfxB (MexCD-OprJ overpro-
ducing strain) mutant were used in this study. Broad-spectrum EPI, Phe-
Arg b-naphthylamide (MC-207,110) and MexAB-OprM-speciﬁc efﬂux
pump inhibitor (ABS-EPI) D13–9001 were used. MDCK cell monolayer
penetration assay was performed as reported previously (Hirakata Y, et al.
J Infect Dis 2000; 181: 765). Bacterial strains were cultured together
with several concentrations of EPIs in LB broth overnight at 37ºC with
vigorous shaking. The bacteria in the baso-lateral medium were counted
by plating at timed intervals.
Results: The invasiveness of PAO1 wild-type (WT) and nalB (MexAB-
OprM overproducing strain) was concentration-dependently inhibited in
the presence of EPIs. However, the invasiveness of nfxB (MexCD-OprJ
overproducing strain) was not reduced in the presence of EPIs.
Conclusion: The ﬁndings support that invasion determinant(s) are
predominantly exported by P. aeruginosa via MexAB-OprM, and that
the EPIs are useful to reduce not only antimicrobial resistance but also
the invasiveness of P. aeruginosa.
P818 Qnr prevalence and their association with orf513 in Enter-
obacter cloacae, Enterobacter aerogenes, Citrobacter freundii,
and Serratia marcescens: a multicentre study from Korea
Y.J. Park, J.K. Yu, E.J. Oh, J.J. Park, G.J. Woo (Seoul, KR)
Objectives: In this study, we investigated the prevalence of all known
qnr determinants (qnrA, qnrB and qnrS) in Enterobacter cloacae,
Enterobacter aerogenes, Citrobacter freundii, and Serratia marcescens
collected from various parts of Korea, their distribution of quinolone
(ciproﬂoxacin and nalidixic acid) MICs and association with orf513and
orf 1005.
Methods: A total of 644 consecutive, non-duplicate isolates, including
E. cloacae (186), E. aerogenes (154), C. freundii (138), and
S. marcescens (166), were collected from clinical specimens at 12
clinical laboratories. The MICs of ciproﬂoxacin (CIP) (0.062−1mg/L)
and nalidixic acid (NAL) (4−32mg/L) were determined by an agar
dilution method as described in CLSI guideline (2003). For isolates
with cinproﬂoxacin MICs of 0.25mg/L or nalidixic acid MICs of
16mg/L, qnr determinants were screened by PCR using primers
reported previously:
for qnrA;
qnrA-F, atttctcacgccaggatttg-3′,
qnrA-R, 5′-gatcggcaaaggttaggtca-3′,
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for qnrB;
qnrB-F, 5′-gatcgtgaaagccagaaagg-3′,
qnrB-R, 5′-acgatgcctggtagttgtcc-3′,
for qnrS;
qnrS-F, 5′-acgacattcgtcaactgcaa-3′,
qnrS-R, 5′-taaattggcaccctgtaggc-3′,
for orf513;
orf513-F, 5′-aag gaacgccacggcgagtcaa-3′,
orf513-R, 5′-tgcaaagacgccgtggaagc-3′,
for orf1005;
orf1005-F, 5′-ctt ggtattcgaagctggtc-3′,
orf1005-R, 5′-ctaccgtttgcaacagtaag-3′.
Strains positive for qnrA were generous gifts from Professor Nordmann
and Professor Kim and positive control strains for qnrB, qnrS were from
Professor Jacoby (Lahey clinic).
Results: Of the total of 644 isolates, 47.9% (89/186) of E. cloacae,
16.9% (26/154) of E. aerogenes, 47.1% (65/138) of C. freundii,
and 66.3% (110/166) of S. marcescens showed cinproﬂoxacin MICs
of 0.25mg/L or nalidixic acid MICs of 16mg/L. Of them, 54
E. cloacae, 8 E. aerogenes, 42 C. freundii and two S. marcescens isolates
harboured qnr determinants. One E. cloacae harboured both qnrA and
qnrB. Almost all (93.5%) of the qnrA producers and about half (47.8%)
of the qnrB producers harboured orf513.
None of the qnrB producers harboured orf1005. The occurrences of qnr
determinants did not show relationship with quinolone MICs in either
E. cloacae or C. freundii (Fig. 1).
% of qnr in ECL
Conclusion: The prevalence of qnr determinants was very high among
E. cloacae and C. freundii, but very low in S. marcescens. In E. cloacae
and E. aerogenes, proportion of qnrA and qnrB was similar, but qnrB
was predominant in C. freundii.
P819 Characteristics of phylogenetic group D Escherichia coli
isolates from bacteraemia
S. Soto, S. Martı´, J. Sa´nchez-Ce´spedes, J. Martı´nez, J. Mensa, J. Vila
(Barcelona, ES)
Objective: The most frequent cause of Gram-negative extraintestinal
bacterial infections, such as bacteraemia, is Escherichia coli. In our
hospital 50% of E. coli strains most frequently isolated as a cause of
bacteraemia belonged to phylogenetic group D, in contrast to the data
found by other research groups. The aim of our study was to characterise
phylogenetic group D bacteraemic E. coli isolates by analysing the
epidemiological relationship, the virulence proﬁles, and the capacity to
form “in vitro” bioﬁlm and compare bacteraemic group D E. coli from
a urinary focus with those from another focus.
Methods: Ninety-nine E. coli blood isolates belonged to phylogenetic
group D collected from patients with bacteraemia in the Hospital
Clinic of Barcelona were included in the study. The epidemiological
relationship was analysed by REP-PCR. The presence of VFs was
determined by PCR using speciﬁc primers. Bioﬁlm assay was carried
out using minimal glucose medium (M63).
Results: Yersiniobactin, type 1 ﬁmbriae, and the Ag43 were the VFs
most frequently found (78%, 73%, and 71%, respectively). When the
comparison of blood isolates from a urinary focus with blood isolates
from an other focus (intra-abdominal, pneumonia, venous catheter, skin
and soft tissue infections, and unknown source) was made, several
observations are of note: (i) the isolates from a non-urinary focus
tended to be more resistant to nalidixic acid (p = 0.09); (ii) there were
signiﬁcant differences in the presence of several VFs between the two
groups of isolates. In fact, E. coli isolates from a urine focus frequently
presented: hlyA, cnf1, malX, and P-ﬁmbriae-related genes (papA, papC,
papG, and papEF) (p = 0.01, 0.02, 0.006, 0.03, 0.001, 0.02, and 0.00001,
respectively).
Conclusion: The phylogenetic group D was the most predominant
among the E. coli isolates causing bacteraemia in our region. The
virulence capacity was related to the original foci of the isolates, with the
blood isolates from a urinary focus being more virulent probably because
the UPEC isolates causing bacteraemia need to invade the kidney and
then disseminate to the bloodstream.
P820 Escherichia coli virulence factors in chronic bacterial
prostatitis
J. Vranes, A. Antolovic-Pozgain, M. Senjug, B. Bedenic (Zagreb, Osijek,
HR)
Objectives: Urinary tract infection (UTI) is the principal extraintestinal
syndrome caused by Escherichia coli. Although most common among
women, it is also signiﬁcant problem among men, who can experience
cystitis, pyelonephritis and prostatitis. Better enderstanding of the
pathogenesis of UTI and prostatitis in men is necessary to guide the
development of effective preventive measures. The aim of this study was
to determine the prevalence of various virulence factors among E. coli
strains causing chronic prostatitis (CPR, n = 25) and compare them with
the strains isolated in acute (AP, n = 23) and chronic pyelonephritis (CP,
n = 22), acute cystitis (AC, n = 22), and asymptomatic bacteriuria (ABU,
n = 18).
Methods: Total of 110 E. coli strains were isolated from 110 patients
who presented with one of ﬁve clinical syndromes. Bacterial suscep-
tibility to serum killing was measured by assessing bacterial regrowth
after incubation in normal human serum. The expression of adhesins
was deﬁned by hemagglutination and inhibition of hemagglutination
in microtiter plates. Serotyping was performed on glass slides and the
production of hemolysin was tested on human blood agar plates.
Results: The most virulent strains were isolated from patients with AP,
followed by strains isolated from patients with CPR. Strains isolated
from patients with CPR were signiﬁcantly more often resistant to the
bactericidal activity of serum (BAS), signiﬁcantly more often produced
hemolysin and signiﬁcantly more often expressed adhesins (p< 0.01)
than did ABU and CP strains. P-ﬁmbriated strains were most commonly
detected in the AP and CPR groups, although AP strains expressed
P-ﬁmbriae signiﬁcantly more often than did CPR strains (p< 0.05). CPR
and AP groups of strains were signiﬁcantly more often resistant to BAS
than strains isolated in other diagnostic groups (p< 0.01). There were
signiﬁcant correlations between resistance of E. coli strains to BAS and
expression of mannose-resistant adhesins (C = 0.365). The difference in
antigenic structure did not inﬂuence on serum sensitivity of the strains.
Conclusion: E. coli virulence factors such as adhesins, hemolysin and
serum resistance may have important roles in the pathogenesis of chronic
prostatitis.
P821 Urease-like IgG activity in H. pylori-positive patients with
duodenal ulcer
M. Konorev, I. Generalov, V. Okulich (Vitebsk, BY)
Objectives: To investigate the urease-like IgG activity in Hp-positive
patients with duodenal ulcer.
Methods: Randomly selected 37 Hp-positive duodenal ulcer patients and
40 Hp-negative patients with gastritis in the age of range 21−61 years
were examined. Identiﬁcation of H. pylori (Hp) was performed by rapid
urease test, morphological method, ELISA. Serum IgG were puriﬁed
from serum of patients according to Paul et al. Conﬁrmation of IgG
purity was made by size-exclusion Toyopearl HW 55 chromatography
or Diasorb Diol 400 HPLC in acid glycine-HCl buffer, 0.05M, pH 2.8
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and by SDS-polyacrylamide gradient gel electrophoresis. For detection
of urease IgG activity 0.1ml IgG (1.5mg/mL) and 0.1ml substrate
solution (20 g/L urea (Serva) with 2 g/L NaN3 in 0.1ml FBB 0.1M,
pH 8.2) were mixed. Control tests include 0.1ml albumin (1.5mg/mL) or
0.1ml NaCl (9.0mg/mL) and 0.1ml substrate solution. The samples were
incubated at least for 120 hours (t = 37ºC) to attain reliable differences
between experimental and control tests. The control of sterility of
IgG preparations, albumin, substrate, experimental and control tests
did’t reveal any bacterial contamination (estimated in 72, 120 and
148 hours). The fall of urea concentration (in mM) was assessed by
enzymatic urea reagent (BUN Reagent, ECO-MED-POLL, Austria) with
spectrophotometer “Spectrum II” detection (Abbott, USA; l= 340 nm).
Conversion of results into international units of activity (pikoCatals) was
carried out according to regression equation Y= 4.6X (in pCat), where
X is the quantity of hydrolyzed urea (mM).
Results: All Hp-negative patients didn’t have Hp in the stomach and
demonstrated the negative rapid urease test. IgG fractions of all Hp-
negative patients were lack of urease activity (P> 0.05); at the same
time they didn’t contain IgG antibodies to Hp by the ELISA test. All Hp-
positive patients had Hp in the stomach, serum IgG antibodies to Hp, and
demonstrated the positive rapid urease test. IgG fraction of 28 patients
with Hp infection and duodenal ulcer showed the high incidence and
levels of urease-like IgG activity (75.7%; 4.6±1.4 pCat; P< 0.01) and
possessed IgG antibodies to Hp, determined by the ELISA test (2.4±0.2
ISR value).
Conclusion: Serum IgG fractions of Hp-positive patients with duodenal
ulcer demonstrate the discernible levels of urease-like Ig activity. The
latter is expected to be an intrinsic property of IgGs, as far as the enzyme
urease is not produced by mammalian cells.
P822 Evidence for the role of Haemophilus inﬂuenzae in the
pathogenesis of recurrent tonsillitis
C. Skoulakis, E. Tigiroglou, E. Malli, D. Klapsa, C. Papadakis,
E. Petinaki (Volos, Larissa, GR)
Objectives: Frequently, cultures of tonsils from patients with recurrent
tonsillitis did not reveal the presence of pathogenic bacteria such as
S. pyogenes. The bacteria probably enter into the core and conventional
methods failed to detect them. In this study, the tonsils of 60 patients
undergoing tonsillectomy were studied in order to determine the
correlation between bacteria isolated from tonsillar surface and core
using conventional and molecular methods.
Methods: Sixty tonsillar tissues, from patients with recurrent tonsillitis
(n: 29), as well from individuals undergoing tonsillectomy for snoring
or sleep apnea (control group, n: 31), were collected. Samples from
both surface and core were cultured, while the identiﬁcation of bacteria
isolated was done using conventional methods. In addition, DNA was
extracted from specimens obtained exclusively from tonsil core using a
commercial kit (QIAGEN), and then it was PCR ampliﬁed with a pair
of primers targeting the 16SrRNA gene, followed by sequence analysis.
The viability of microorganisms were detected by RT-PCR, after RNA
extraction, by using speciﬁc primers for bacteria whom DNAs were
detected.
Results: Among patients with recurrent tonsillitis, 25% of the surface
cultures did not grow any bacteria, while 75% showed the presence
of Streptococcus mitis and oralis; in some cases we observed
the co-existence of Staphylococcus aureus (17%) and Haemophilus
parainﬂuenzae (20%). On the other hand, the core cultures were negative
for bacteria. However, into the core of nineteen tonsils, molecular
methods revealed the presence of mRNA of S. pyogenes in three cases
(10.3%) and H. inﬂuenzae in sixteen cases (55%) conﬁrming their
viability. Among the control group, surface cultures showed the presence
of Streptococcus mitis and S. oralis (72%), with the co-existence of
Staphylococcus aureus (5%) and Haemophilus parainﬂuenzae (20%),
while the core cultures remained negative. No bacterial DNAs were
detected in the core of the control group.
Conclusions: The high incidence of H. inﬂuenzae isolated in patients
with recurrent tonsillitis, comparing to the control group, suggests the
potential pathogenic role of this bacterium in this type of infection.
In vitro susceptibility of glycolipopeptides
P823 Europe surveillance initiative proﬁling the activity of
telavancin against streptococci by specimen source from 2004
to 2005
D. Draghi, B. Benton, M. Jones, K. Krause, C. Thornsberry, D. Sahm
(Herndon, South San Francisco, US; Breda, NL)
Objectives: Telavancin (TLV) is a novel, rapidly bactericidal lipo-
glycopeptide with potent activity against a wide spectrum of Gram-
positive bacteria. TLV has recently completed two Phase 3 clinical
trials for the treatment of complicated skin and skin structure infections.
Ongoing trials are assessing TLV for the treatment of hospital-acquired
pneumonia. The current study was performed to establish a baseline of
TLV activity versus recent isolates of various streptococcal species that
may be encountered in the clinical setting.
Methods: During 2004–2005, 168 Streptococcus pneumoniae (SP),
67 viridans streptococci (VGS) and 106 b-haemolytic streptococci
(BS; including 46 S. pyogenes, 42 S. agalactiae and 18 Group C,
G and F streptococci) were collected from Europe (33 hospital sites
in 14 countries). Isolates were centrally tested by broth microdilution
according to Clinical and Laboratory Standards Institute (CLSI)
methodology (M7-A7) against TLV and comparators. Isolates were
analysed in groups by specimen source (SPEC), which included blood,
lower respiratory tract, upper respiratory tract and skin structure.
Results: The table shows the activity of TLV against the different
streptococcal isolates.
Activity of telavancin against Streptococcus pneumoniae (SP), viridans
streptococci (VGS) and b-haemolytic streptococci (BS) isolates
Organism Specimen Phenotypeb No. of MIC (mg/L)
sourcea isolates Range MIC90
SP Blood All 52 0.001–0.06 0.03
PEN-S 44 0.001–0.06 0.03
PEN-NS 8 0.015–0.03 NAc
LRT All 67 0.002–0.03 0.03
PEN-S 42 0.002–0.03 0.03
PEN-NS 25 0.015–0.03 0.03
URT All 49 0.008–0.03 0.03
PEN-S 35 0.008–0.03 0.03
PEN-NS 14 0.015–0.03 0.03
VGS Blood All 40 0.03−0.5 0.12
ERY-S 21 0.03−0.5 0.12
ERY-NS 19 0.03–0.12 0.12
SST All 27 0.015−0.5 0.06
ERY-S 17 0.03–
0.06−0.06
ERY-NS 10 0.015−0.5 0.06
BS Blood All 26 0.001–0.25 0.06
ERY-S 21 0.015–0.25 0.06
ERY-NS 5 0.001–0.06 Nac
SST All 80 0.002–0.12 0.06
ERY-S 59 0.002–0.12 0.06
ERY-NS 21 0.015–0.12 0.06
aLRT, lower respiratory tract; URT, upper respiratory tract; SST, skin
structure.
bPEN-S/PEN-NS, penicillin-susceptible/nonsusceptible; ERY-S/ERY-NS,
erythromycin-susceptible/nonsusceptible.
cNA, not available; MIC90 values were not determined for <10 isolates.
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Conclusion: TLV demonstrated potent activity against all streptococcal
species and groups encountered in this surveillance initiative, regardless
of resistance to other antimicrobial classes. TLV MIC90 values for each
streptococcal group were equivalent or within one doubling dilution
when studied by SPEC. This baseline evaluation provides a useful
benchmark of TLV activity as clinical development and use progresses.
P824 Europe surveillance initiative proﬁling the anti-staphylococcal
activity of telavancin by specimen source from 2004 to 2005
D. Draghi, B. Benton, M. Jones, K. Krause, C. Thornsberry, D. Sahm
(Herndon, South San Francisco, US; Breda, NL)
Objectives: The increase and spread of methicillin (oxacillin)-resistant
staphylococci present challenges for clinicians. Telavancin (TLV), a
novel, rapidly bactericidal lipoglycopeptide, has recently completed two
Phase 3 clinical trials for the treatment of complicated skin and skin
structure infections. Ongoing trials are assessing TLV for the treatment
of hospital-acquired pneumonia. Surveillance was initiated to establish
a baseline for the activity of TLV against recent staphylococcal isolates,
according to specimen source (SPEC).
Methods: Overall, 1721 Staphylococcus aureus (SA) and 226 coagulase-
negative staphylococcus (CoNS) isolates were collected from Europe (33
hospital sites in 14 countries) during 2004–2005. Isolates were centrally
tested by broth microdilution according to Clinical and Laboratory
Standards Institute (CLSI) methodology (M7-A7) against TLV and
comparators. Isolates were analysed in groups by SPEC, which included
blood, skin structure, upper respiratory tract (SA only) and lower
respiratory tract (SA only).
Results: The oxacillin-resistance (OX-R) rate for all SA was 30.5% and
the OX-R rate for CoNS was 73.5%. The activity of TLV against the
SA and CoNS isolates is shown in the Table. Based on MIC90 values,
TLV (0.5mg/L) was 16 times more potent than teicoplanin (TEI; 8mg/L)
against CoNS. Additionally, MIC ranges for TLV (0.06−2mg/L) were
lower compared with TEI (0.25−32mg/L).
Activity of telavancin against Staphylococcus aureus (SA) and
coagulase-negative staphylococci (CoNS) isolates
Organism Specimen Phenotypeb No. of MIC (mg/L)
sourcea isolates Range MIC90
SA SST All 951 0.015−1 0.25
OX-S 709 0.015−1 0.25
OX-R 242 0.06−1 0.5
Blood All 365 0.06−1 0.25
OX-S 235 0.06−1 0.25
OX-R 130 0.12−1 0.5
LRT All 349 0.015−1 0.5
OX-S 209 0.015−1 0.25
OX-R 140 0.12−1 0.5
URT All 17 0.12−0.5 0.5
OX-S 16 0.12−0.5 0.25
OX-R 1 0.5−0.5 NAd
CoNS SST All 25 0.06–0.25 0.25
OX-S 10 0.06–0.25 0.25
OX-R 15 0.12–0.25 0.25
Blood All 190 0.06−2 0.5
OX-S 48 0.12−2 0.5
OX-R 142 0.06−2 0.5
aSST, skin structure; LRT, lower respiratory tract; URT, upper respiratory
tract.
bOX-R, oxacillin-resistant; OX-S, oxacillin-susceptible.
c39 SA isolates and 11 CoNS isolates were from an unknown or other
source.
dNot available; MIC90 values were not determined for <10 isolates.
Conclusion: TLV demonstrated potent activity against all SA and CoNS
isolates, regardless of SPEC or resistance to oxacillin or TEI. This
evaluation of TLV activity will provide a baseline for comparison of
in vitro activity as clinical development and use progresses.
P825 Comparative activity of telavancin against Gram-positive
pathogens using European and CLSI susceptibility testing
methods
D. Farrell, A. Colclough, L. Williams (London, UK)
Objectives: Telavancin (TLV) is a novel lipoglycopeptide antibiotic that
is in late stage development for the treatment of serious infections in
humans caused by Gram-positive bacterial pathogens. In this study, the
in vitro activity of TLV was determined using the Clinical and Laboratory
Standards Institute (CLSI) reference methodology and 5 European
guidelines (Deutsches Institut fu¨r Normung [DIN], European Committee
on Antimicrobial Susceptibility Testing [EUCAST], Swedish Reference
Group for Antibiotics [SRGA], British Society for Antimicrobial
Chemotherapy [BSAC] and Comite´ de l’Antibiogramme de la Socie´te´
Franc¸aise de Microbiologie [CASFM]).
Methods:MICs for TLV versus 478 bacterial isolates (150 staphylococci
[STA], 206 streptococci [STR], 102 enterococci [ENT] and 20
Corynebacterium jeikeium [CJ]) were determined under 6 experimental
conditions representing 4 microbroth dilution (MD) and 6 agar dilution
(AD) MIC methods.
Results: The MIC range and mode for each of the 6 experimental
methods are shown in the Table. Against staphylococci, consistent results
were obtained among all methodologies used. The MIC distribution for
ENT was bimodal, with VanA phenotype Enterococcus faecalis being
responsible for the higher mode. The greatest inter-method variability
was found for STR, with 2 of the AD methods having modal values 4
to 8 times higher than the other methods.
MIC range and mode for telavancin Gram-positive pathogens using 6
CLSI and European susceptibility testing methods
Telavancin MIC range (mode) mg/L
Methoda STA ENT STR CJ
1 (MD) 0.015−1
(0.12)
0.015−8
(0.25 and 4b)
0.004–0.25
(0.015)
0.008–0.03
(0.015)
2 (MD) 0.03−1
(0.12)
0.03−8
(0.06 and 4b)
0.008–0.25
(0.03)
0.015–0.06
(0.03)
3 (AD) 0.06−2
(0.12)
0.03−4
(0.06 and 2b)
0.015–0.12
(0.12)
0.015–0.12
(0.06)
4 (AD) 0.03−1
(0.12)
0.03−4
(0.06 and 4b)
0.015–0.12
(0.03)
0.015–0.03
(0.03)
5 (AD) 0.03−1
(0.06)
0.03−4
(0.06 and 2b)
0.015–0.06
(0.03)
0.015–0.03
(0.015)
6 (AD) 0.06−2
(0.12)
0.03−4
(0.06 and 2b)
0.015–0.12
(0.12)
0.015–0.06
(0.03)
,NL> aMethods: 1. CLSI-DIN-EUCAST (MD); 2. SRGA (MD); 3. DIN
(AD); 4. BSAC (AD); 5, SRGA (AD); 6. CLSI-CASFM-EUCAST (AD).
bE. faecalis with VanA phenotype.
Conclusion: There was very good correlation between all methods and
between MD and AD. These results will be useful when establishing
TLV breakpoints in countries using these susceptibility testing methods.
P826 Europe surveillance initiative proﬁling the anti-enterococcal
activity of telavancin by specimen source from 2004 to 2005
D. Sahm, D. Draghi, B. Benton, M. Jones, K. Krause, C. Thornsberry
(Herndon, South San Francisco, US; Breda, NL)
Objectives: Enterococci are frequently associated with hospital-based
infections, including bacteraemia. Telavancin (TLV), a novel, rapidly
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bactericidal lipoglycopeptide, has recently completed two Phase 3
clinical trials for the treatment of complicated skin and skin structure
infections. Ongoing trials are assessing TLV for the treatment of hospital-
acquired pneumonia. Because TLV will be used in the hospital setting,
proﬁling its activity against enterococci is important.
Methods: A total of 434 Enterococcus faecalis (EF) and 348 E. faecium
(EM) isolates were collected from Europe (35 hospital sites in
14 countries) during 2004–2005. Isolates were centrally tested by broth
microdilution according to Clinical and Laboratory Standards Institute
(CLSI) methodology (M7-A7) against TLV and comparators. Results
were analysed according to blood and non-blood specimen sources
(SPECs).
Results: The vancomycin-nonsusceptible (VAN-NS) rate for all EF was
5.5% and the VAN-NS rate for EM was 22.7%. The activity of TLV
against the EF and EM isolates is shown in the Table.
Conclusion: TLV demonstrated potent activity against all EF and EM
isolates, regardless of SPEC. Based on MIC90 values, TLV was 16-fold
more potent against vancomycin-susceptible (VAN-S) isolates compared
with VAN-NS isolates among EF and EM. This evaluation of TLV
activity will provide a baseline for comparison of in vitro activity as
clinical development and use continues.
Activity of telavancin against Enterococcus faecalis (EF) and E. faecium
(EM) isolates
Organism Specimen Phenotypea No. of MIC (mg/L)
source isolates Range MIC90
EF Blood All 181 0.06−8 1
VAN-S 164 0.06−2 0.5
VAN-NS 17 4−8 8
Non-blood All 253 0.06−8 0.5
VAN-S 246 0.06−8 0.5
VAN-NS 7 0.5−8 8
EM Blood All 144 0.03−8 4
VAN-S 100 0.03−2 0.25
VAN-NS 44 0.12−8 4
Non-blood All 204 0.03−8 2
VAN-S 169 0.03−2 0.25
VAN-NS 35 0.12−8 4
aVAN-S/VAN-NS, vancomycin-susceptible/nonsusceptible.
P827 Inﬂuence of polysorbate 80 on susceptibility of Gram-positive
bacteria to oritavancin
F.F. Arhin, I. Sarmiento, A. Belley, G. McKay, D. Draghi, P. Grover,
D. Sahm, T.J. Parr Jr., G. Moeck (Saint Laurent, CA; Herndon, US)
Objectives: Oritavancin (ORI) is a lipoglycopeptide (LG) with activity
against Gram-positive bacteria. Broth microdilution (BMD) assays
with dalbavancin, another LG, require 0.002% polysorbate 80 (P80).
Following initial observations that P80 reduced ORI BMD minimum
inhibitory concentrations (MICs) for reference strains of Staphylococcus
aureus (Sa) ATCC 29213 and Enterococcus faecalis (Ef) ATCC 29212
but not for Streptococcus pneumoniae (Sp) ATCC 49619, we examined
the effect of P80 on ORI MICs for 301 clinical isolates of these three
genera.
Methods: BMD assays were conducted on clinical isolates of Sa (n = 76),
coagulase-negative staphylococci (CNS; n = 26), Ef (n = 70), E. faecium
(Em; n = 30), Sp (n = 19), S. agalactiae (n = 29), S. pyogenes (n = 29),
Groups C and G streptococci (n = 8), and Viridans Group streptococci
(n = 14), either following CLSI guidelines (no P80) or with P80, in
parallel. When tested in the presence of P80, ORI, vancomycin (VAN)
and teicoplanin (TEI) were dissolved in 0.002% P80 and maintained in
0.002% P80 thereafter. Reference strains of Sa, Ef and Sp were tested
concurrently.
MIC range (MIC 90a ), mg/L
ORI ORI+P80 TEI TEI+P80 VAN VAN+P80
Enterococci
E. faecalis
(n = 70)
0.12−4 (2) 0.008−0.5
(0.12)
0.06−64 (0.5) 0.06−64
(0.12)
0.12–>256
(2)
0.5–>256
(2)
E. faecium
(n = 30)
0.12−4 (4) 0.004−0.5
(0.25)
0.12–256
(64)
0.06–128
(128)
0.25–>256
(>256)
0.25–>256
(>256)
Staphylococci
S. aureus
(n = 76)
1−8 (4) 0.015–0.25
(0.12)
0.12−1 (0.5) 0.12−2
(0.5)
0.5−1 (1) 0.5−16 (1)
CNS (n = 26) 0.12−8 (4) 0.008−0.5
(0.25)
0.12−4 (2) 0.06−4 (2) 0.5−2 (1) 0.5−2 (2)
Streptococci
S. agalactiae
(n = 29)
0.03−0.5 (0.25) 0.03−0.5
(0.25)
0.03–0.12
(0.06)
0.03–0.12
(0.06)
0.25−0.5
(0.5)
0.25−0.5
(0.5)
S. pneumoniae
(n = 19)
0.00025–0.004
(0.004)
0.0005–0.004
(0.004)
0.015–0.06
(0.06)
0.015–0.06
(0.06)
0.12−0.5
(0.25)
0.12−0.5
(0.25)
S. pyogenes
(n = 29)
0.015−0.5
(0.25)
0.015−0.5
(0.25)
0.001–0.25
(0.06)
0.015–0.06
(0.03)
0.25−0.5
(0.25)
0.25−0.5
(0.25)
Group C and G
(n = 8)
0.004−1 (na) 0.004−1 (na) 0.03–0.06
(na)
0.03–0.06
(na)
0.25−0.5
(na)
0.25−0.5
(na)
Viridans group
(n = 14)
0.004−2 (1) 0.004−2 (1) 0.002–0.12
(0.06)
0.002–0.25
(0.12)
0.25−1
(0.5)
0.25−0.5
(0.5)
ana, MIC 90 was not calculated for groups containing less than 10 isolates; P80: polysorbate 80.
Results: P80 reduced ORI MIC90s by 16- to 32-fold for enterococci
and staphylococci. In contrast, TEI and VAN MIC90s were identical (the
same or within one doubling dilution) with and without P80 with the
exception of a 4-fold reduced TEI MIC90 for Ef with P80. P80 did
not change MIC90s for any agent against streptococci grown in cation-
adjusted Mueller-Hinton broth containing 2% lysed horse blood (LHB).
Conclusions: Signiﬁcant (16- to 32-fold) reductions in ORI MIC90s were
observed for enterococci and staphylococci with P80. A modest (4-fold)
reduction in TEI MIC90 was observed for Ef +P80. ORI MICs ± P80
for streptococci were identical in the CLSI-recommended medium which
contains LHB. Companion binding studies promote the idea that LHB
may substitute for P80, which may help to explain the observed lack of
shift in ORI MICs with P80 for streptococci.
P828 Activity of daptomycin against coryneform bacteria isolated
from clinical samples
C. Salas, J. Calvo, L. Martı´nez-Martı´nez (Santander, ES)
Objectives: To evaluate the activity of Daptomycin (DAP) and six other
agents against coryneform bacteria of clinical origin.
Methods: We evaluated 179 clinical isolates (1 per patient) including
Corynebacterium striatum [Cstr (58)], C. amycolatum [Camy (25)],
C. jeikeium [Cjei (25)], C. pseudodiphtheriticum [Cpse (21)], Listeria
monocytogenes [Lmon (24)] and Arcanobacterium haemolyticum [Ahae
(26)]. A microdilution assay, according to CLSI guidelines (M45-P),
was used. The following antimicrobials were included: Clindamycin
(CLI), Vancomycin (VAN), Teicoplanin (TEC), Linezolid (LNZ) and
Quinupristin-dalfopristin (QDA). For DAP, Mueller-Hinton broth with
3% laked horse blood was supplemented with 50mg/L of Ca++.
S. pneumoniae ATCC 49619, S. aureus ATCC 29213 and E. faecalis
ATCC 29212 were used as reference control strains.
Results: MICs 50/90 (mg/L) values are presented in table 1.
Table 1
Antimicrobial MIC50/MIC90
Cstr Camy Cjei Cpse Lmon Ahae
CLI 32/>32 >32/>32 >32/>32 >32/>32 0.5/1 0.015/0.015
VAN 0.25/0.5 0.25/0.5 0.06/0.25 0.25/0.25 0.5/1 0.25/0.5
TEC 0.06/0.12 0.12/0.25 0.06/0.12 0.06/0.25 0.06/0.25 0.06/0.06
LNZ 0.25/0.5 0.12/0.25 0.25/0.5 0.25/0.5 2/4 0.25/0.5
QDA 0.12/0.5 0.06/0.25 0.25/1 0.06/0.06 0.5/1 0.06/0.06
DP 0.06/0.5 0.06/0.06 0.25/0.25 0.06/0.06 2/4 0.5/0.5
Conclusions: Daptomycin has a good in vitro activity against
C. striatum, C. amycolatum, C. jeikeium, C. pseudodiphtheriticum and
A. haemolyticum, and presented reduced activity against L. monocyto-
genes. Teicoplanin, Vancomycin, Linezolid and Quinupristin-dalfopristin
are also active against these organisms. Clindamycin was poorly active,
in vitro, except against A. haemolyticum and L. monocytogenes.
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P829 Intracellular activity of daptomycin against methicillin-
sensitive, methicillin-resistant and vancomycin-intermediate
S. aureus
S. Lemaire, F. Van Bambeke, P. Tulkens (Brussels, BE)
Objectives: Relapsing and chronic S. aureus infections have been
associated with intracellular bacterial persistence. The activity of
antibiotics may differ markedly between the extracellular and the
intracellular milieus, and intracellular activity needs, therefore, to be
assessed in speciﬁc models. Daptomycin (DAP) is a cyclic lipopeptide
with fast and extensive bactericidal activity against extracellular forms
of S. aureus. Our aim was to examine its intracellular activity in a
newly developed model of human macrophages allowing for extended
exposure periods (AAC 2006; 50:841–851), and using strains with
different resistance phenotypes of clinical signiﬁcance.
Methods: MSSA (ATCC 25923), MRSA (ATCC 33591) and VISA
(NRS 23) were used. MICs were determined in MH broth (supplemented
with 50mg/L of Ca2+) by microdilution method. Infection of THP-1
macrophages was performed as described previously (AAC 2006;
50:841–851). Intracellular localisation of the bacteria was examined
by confocal and electron microscopy. Activity was measured after 24 h
exposure to a DAP concentration corresponding to its reported human
Cmax (77mg/L), in comparison with controls (cells incubated with
gentamin [0.5×MIC] to prevent extracellular growth; see AAC 2006,
50:841–851 for validation).
Results: In controls, phagocytised bacteria were seen sojourning and
multiplying in membrane-bounded vacuoles (phagolysosomes). MICs
(broth) and intracellular changes in cfu are shown in the table.
Strains MIC (mg/L) log10 intracell. change in cfu
(±SD)a
controls + DAP (77mg/L)
MSSA 0.125 +1.30±0.05 −1.66±0.07
MRSAb 0.125 +1.63±0.13 −1.46±0.07
VISA 0.5 +1.39±0.05 −1.30±0.05
acompared to the original inoculum (approx. 106 cfu/mg cell protein).
bHospital-acquired.
Conclusions: DAP shows intracellular activity against MSSA, MRSA
and VISA.
P830 Assessing the in vitro activity of daptomycin against
well-characterised methicillin-resistant Staphylococcus aureus
strains representing different spa types
K. Becker, B. Gru¨nastel, A. Mellmann, G. Peters, C. von Eiff (Mu¨nster,
DE)
Objectives: Daptomycin is a recently introduced cyclic lipopeptide
antibiotic that is rapidly bactericidal in vitro against a broad spectrum of
Gram-positive bacteria including multi-resistant strains. The purpose of
the present study was to assess the in vitro activity of daptomycin against
a well-characterised collection of methicillin-resistant Staphylococcus
aureus (MRSA) isolates collected in multi-centre studies.
Methods: The MicroScan WalkAway-96 system for Gram-positive (GP)
organisms (Dade Behring) was used to assess the in vitro activity of
daptomycin against MRSA strains. For this purpose, clinical MRSA
strains of different geographic origin and different clonality were
included. To determine the clonal lineages of MRSA strains, the repeat
region of the spa gene was ampliﬁed by PCR. spa types were determined
using the Ridom StaphType software version 1.3.
Results: All MRSA strains tested were susceptible to daptomycin. The
MIC for all strains tested was 1mg/l (MIC90 1mg/l). These MRSA
strains representing 100 different spa types comprised the most common
European spa types, such as t003, t032, t008, t002, t044, t001, t004, and
t037, as well as a broad range of rarely occurring types. Daptomycin
was also active towards those strains harbouring the Panton Valentine
leukocidin (PVL) encoding genes.
Conclusion: Daptomycin was shown to be potent against all MRSA
strains tested representing the most common European MRSA lineages.
P831 In vitro activities of daptomycin against isolates of Gram-
positive organisms causing skin and soft tissue infections,
compared to vancomycin, linezolid, and teicoplanin
J. Fairest (London, UK)
Objectives: Gram-positive pathogens are a major cause of skin and soft
tissue infection (SSTI), and daptomycin is a new novel drug developed
primarily for the treatment of SSTIs.
The aim of this study was to compare daptomycin with the current
conventional antimicrobials used to treat SSTIs (vancomycin, linezolid,
and teicoplanin).
Methods: In total 260 isolates were collected comprising of 20
Staphylococcus aureus, 50 Staphylococcus epidermidis, 50 MRSA,
50 Enterococci, 10 Vancomycin-Resistant Enterococci (VRE), and
50 group A Streptococci (S. pyogenes), over a period of one month.
Minimum inhibitory concentrations (MICs) were obtained using two
different methods, the E-test method and the broth microdilution method.
Data analysis was carried out using the paired t-test to compare mean
MICs obtained from both tests.
Results: All isolates proved to be highly susceptible to daptomycin. Low
mean MICs were obtained with daptomycin against the staphylococci
(0.24 ul/mL for S. aureus, 0.32 ul/mL for S. epidermidis, and
0.18 ul/mL for MRSA). Higher mean MICs (1.13 ul/mL) were found with
daptomycin against the enterococci. Daptomycin was found to be highly
active against VRE, with a mean MIC of 1.78 ul/mL. However, linezolid
had a lower mean MIC of 0.54 ul/mL. For the group A streptococci
(S. pyogenes) daptomycin had the lowest mean MIC (0.07 ul/mL)
compared to the other antimicrobials.
Conclusion: Overall, daptomycin has proved to be highly effective
agent against most Gram-positive organisms responsible for SSTIs.
Daptomycin was found to be comparable to linezolid, however superior
to vancomycin and teicoplanin in most cases. Daptomycin appears to be
a useful alternative in the treatment of SSTIs, especially when multi-drug
resistant organisms such as MRSA and VRE are encountered.
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P832 Temporal trends in the methodological quality of randomised
controlled trials of antimicrobial agents
M.E. Falagas, E. Pitsouni, I. Bliziotis (Athens, GR)
Objective: The aim of this study was to investigate the potential
improvement of the methodological quality of RCTs of antimicrobial
agents published during the last 30 years.
Methods: We randomly selected from the Cochrane Central Register
of Controlled Trials database 70 RCTs of antibacterial agents that were
published during a 30-year study period (1975–2005); speciﬁcally we
randomly selected 10 RCTs published during each of the following years:
1975, 1980, 1985, 1990, 1995, 2000, and 2005. In each of the selected
RCTs we searched for information regarding quality of randomisation,
double blinding, quality of the blinding, description of withdrawals or
dropouts, eligibility of the study group, interventions, outcomes, baseline
data, allocation concealment, adverse events, statistical signiﬁcance, and
reporting of conﬂicts of interest and funding of the research. We graded
the methodological quality of the reviewed RCTs to evaluate trends for
possible improvement.
Results: No improvement was noted in most of the analyzed
methodological aspects of the RCTs during the 30-year study period.
Quality of randomisation, double blinding, quality of the blinding, and
allocation concealment were rather scarce among the reviewed RCTs,
without observing a trend for improvement during the study period. We
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noted improvement in reporting and analyzing baseline data as well as in
reporting the presence or not of statistical signiﬁcance and the statistical
cut off of signiﬁcance. In only 2 of the reviewed 70 RCTs all 12 of the
examined methodological quality aspects were met.
Conclusion: We did not observe considerable overall improvement in
the quality of the methodology of RCTs on antibacterial agents during
the last 30 years. The methodological quality aspects that need the
most improvement are these that ensure (when present) minimisation
of various types of biases.
P833 Intravenous therapy with doripenem versus levoﬂoxacin with
an option for oral step-down therapy in the treatment of
complicated urinary tract infections and pyelonephritis
K. Naber, R. Redman, P. Kotey, L. Llorens, K. Kaniga (Munich, DE;
Mountain View, Raritan, US)
Objective: Doripenem (DOR) is an investigational carbapenem with
broad-spectrum activity against common pathogens of complicated
urinary tract infections (cUTIs). This study evaluated the efﬁcacy and
safety of DOR for the treatment of complicated lower UTIs and
pyelonephritis (complicated and uncomplicated) in a large, multinational
phase 3 study.
Methods: This randomised, double-blind, double-dummy, multicentre
study compared DOR (500mg q8h) with levoﬂoxacin (LVX) (250mg
q24h) in the treatment of cUTIs in adults. Both study drugs were
administered as 60-min IV infusions. After 9 or more doses of IV drug
therapy, subjects could be switched to oral therapy with LVX (250mg
q24h). Total duration of study therapy was 10 days. Non-inferiority of
DOR to LVX was evaluated with respect to microbiologic response in
patients who were microbiologically evaluable at the test of cure (ME
at TOC) visit (6−9 days after completion of study drug therapy). Non-
inferiority was deﬁned as a lower limit of the 95% conﬁdence interval
(CI) for the difference in response rates greater than −10%. The primary
end point was the microbiological cure rate at the TOC visit; this was
evaluated in subjects who were ME at TOC, and as a co-primary analysis
in the microbiological modiﬁed intent-to-treat (mMITT) population. A
key secondary end point was clinical cure in the clinically evaluable
(CE) at TOC analysis set.
Results: A total of 753 patients were randomised; 376 received DOR
and 372 received LVX. The microbiologic cure rate in the ME at TOC
population was 82.1% (230/280) for DOR and 83.4% (221/265) for
LVX (95%CI: −8.0, 5.5). The microbiologic cure rates in the mMITT
population were 79.2% (259/327) and 78.2% (251/321), respectively
(95%CI: −5.6, 7.6). The clinical cure in the CE at TOC population
was 95.1% (272/286) for DOR and 90.2% (240/266) for LVX (95%CI:
0.2, 9.6). DOR was effective against major causative organisms of
cUTIs, including Escherichia coli, Proteus mirabilis, and Klebsiella
pneumoniae. Gastrointestinal disorders were most commonly reported
as adverse events, occurring in 25% of DOR- and 27% of LVX-treated
patients. Headache was also frequently reported (16%, DOR; 15%,
LVX). No seizures were reported in patients receiving DOR.
Conclusion: DOR was microbiologically and clinically effective and
therapeutically non-inferior to LVX in this study for the treatment of
cUTIs and was generally safe and well-tolerated, with an AE proﬁle
similar to that of LVX.
P834 Treatment of complicated intra-abdominal infections:
doripenem versus meropenem
C. Lucasti, A. Jasovich, O. Umeh, J. Jiang, K. Kaniga (Somers Point,
US; Buenos Aires, AR; Mountain View, Raritan, US)
Objective: Doripenem (DOR) is an investigational carbapenem with
broad-spectrum activity against common causes of complicated intra-
abdominal infections (cIAIs), such as Enterobacteriaceae and anaerobes.
This study evaluated the efﬁcacy and safety of DOR for the treatment
of cIAIs in a large phase 3 study (DORI 07).
Methods: This phase 3, randomised, double-blind, double-dummy,
multicentre study compared IV DOR (500mg q8h over 60 min) with
IV meropenem (MER) (1 g q8h administered as a bolus over 3−5 min)
in the treatment of adults with cIAIs. Subjects could be switched to oral
amoxicillin/clavulanate after 9 or more doses of DOR or MER. Total
duration of study therapy was 5−14 days. Non-inferiority of DOR to
MER was inferred if the lower limit of the 2-sided 95% conﬁdence
interval (CI) for the difference in clinical cure rates (doripenem minus
meropenem) was greater than or equal to −15%. The primary efﬁcacy
end points included clinical cure rate at the test of cure (TOC) visit
(21−60 days post therapy) in subjects who were microbiologically
evaluable (ME) at TOC, and the clinical cure rate occurring up to 60 days
after the last dose of study drug therapy in the microbiological modiﬁed
intent-to-treat (mMITT) population.
Results: A total of 476 patients were randomised; 237 received DOR
and 239 received MER. The clinical cure rate at the TOC visit
in the ME at TOC population was 85.9% (140/163) for DOR and
85.3% (133/156) for MER (95%CI: −7.7, 9.0). The clinical cure rates
in the mMITT population were 77.9% (152/195) and 78.9% (150/190),
respectively (95%CI: −9.7, 7.7). DOR was microbiologically effective
against major causative organisms of cIAIs, including Escherichia
coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Streptococcus
intermedius, Enterococcus faecalis, Bacteroides caccae, Bacteroides
thetaiotaomicron, Bacteroides fragilis, and Bacteroides uniformis. The
most common study drug-related adverse events reported were nausea
(DOR, 6.8%; MER, 1.3%), diarrhoea (DOR, 6.4%; MER, 4.7%), and
phlebitis (DOR, 3.4%; MER, 2.1%). No seizures were reported.
Conclusion: For the treatment of cIAIs, DOR was generally well-
tolerated and therapeutically non-inferior to MER at the doses studied.
P835 Adequacy and efﬁcacy of initial empiric antibiotic treatments
in severe nosocomial infections in ICU departments: results
of multicentre randomised study
S. Yakovlev, V. Beloborodov, S. Sidorenko, A. Ovechkin, V. Yakovlev
(Moscow, RU)
Objectives: The incidence of nosocomial infections due to multi-
drug resistant pathogens especially ESBL-producing microorganisms
has increased markedly in recent years in most ICU departments.
The resistant pathogens are the main reason of empiric antimicrobial
treatment failure. In this open randomised multicentre study, the
adequacy and effectiveness of meropenem monotherapy was compared
with traditional cephalosporins or ﬂuoroquinolones plus aminoglycoside
combination for initial empiric antibiotic therapy of severe infections in
ICU departments.
Methods: This multicentre study was conducted in 18 ICU departments
in 15 cities of Russia. The adult patients with conﬁrmed nosocomial
infection (pneumonia or intra-abdominal) were randomly allocated to
one of two treatment arms: meropenem (MER) IV 0.5−1 g TID as
monotherapy or conventional combination treatment (CT) with 3rd or
4th generation cephalosporin or ﬂuoroquinolone (ciproﬂoxacin, oﬂoxacin
or levoﬂoxacin) plus aminoglycoside and ± metronidazole. Only the
patients with severe infection (clinical signs of severe sepsis and
APACHE II score 15−25) were included. The initial therapy was empiric
provided the adequate samples for bacteriological investigation.
Results: Of a total of 166 patients enrolled, 135 were clinically
evaluable: 62 in the MER arm and 73 in CT arm; 102 patients
were microbiology evaluable. Baseline demographic and disease
characteristics as well as the severity of infection were similar for
both treatment groups. At the TOC assessment, 50 of 62 (80.6%)
clinically evaluable patients in the MER group and 34 of 73 (46.6%)
in the CT group had a favourable clinical response (P< 0.01). The
bacteriological efﬁcacy was also better after MER therapy – 89.6 and
48.1%, respectively (P< 0.001). The microbiological eradication rates
was signiﬁcantly higher in the MER group for P. aeruginosa (88 and
40%, P = 0.007), E. coli (100 and 46.7%, P = 0.003) and Acinetobacter
spp. (90.9 and 40.0%, P = 0.02). The adequacy of empiric therapy was
2.7 times higher in MER group (P< 0.001). The cost-effectiveness ratio
for MER therapy was signiﬁcantly lower than for CT (2031 and 4483
per cured patient taking into consideration only direct medical cost).
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Conclusion: Empiric meropenem monotherapy of severe infections
in ICU appears to be more adequate and more cost-effective than
conventional combination therapy with broad-spectrum antibiotics.
P836 Efﬁcacy and safety of colistin
A. Levcovich, Y. Lischenski, P. Leon, S. Lev, R. Hazzan, M. Chowers,
J. Bishara, L. Leibovici, M. Paul (Petah Tikva, Kfar Saba, IL)
Objectives: The use of colistin decreased substantially in the 1970s
following reports of renal failure and neuropathy. The appearance
of highly resistant Gram-negative bacteria in hospitals, such as
Acinetobacter baumannii, Pseudomonas spp. and Klebsiella spp.,
rendered colistin a drug of last resort for patients infected with these
bacteria. The objectives of this study were to establish the safety and
efﬁcacy proﬁle of colistin, in comparison to carbapenems and ampicillin-
sulbactam.
Methods: Prospective observational cohort study including all adult
patients treated with colistin, imipenem, meropenem or ampicillin/
sulbactam with bacteraemia or fulﬁlling CDC diagnostic criteria
for pneumonia, urinary tract infection, meningitis, catheter-related or
catheter-associated infections. We compared outcomes for colistin vs.
comparator antibiotics. Data were collected at the time of infection
presentation with follow-up of 30 days. Mortality was deﬁned as 30-
day all-cause mortality. Renal failure was deﬁned as 50% increase of
creatinine levels from baseline and above 1.4mg/dL at 2 weeks follow-
up.
Baseline patient characteristics Colistin Comparators P-value
No patients 31 44
Female gender 14 (45.2%) 19 (43.2%) 0.86
Age (mean, SD) 68 (±16) 57 (±20) 0.029
Service
Internal medicine 12 (38.7%) 14 (31.8%) 0.29a
Surgery 4 (12.9%) 14 (31.8%)
ICU 15 (48.4%) 16 (36.4%)
Baseline functional status (full
activity)
17 (54.8%) 31 (70.5%) 0.17
Central line 10 (32.3%) 19 (43.2%) 0.34
Mechanical ventilation 18 (58.1%) 25 (56.8%) 0.91
Recent invasive procedure 18 (58.1%) 29 (65.9%) 0.49
Charison score (median, range) 2 (1−6) 1 (1−7) 0.31
McCabe score
1 17 (54.8%) 32 (72.7%) 0.11b
2 7 8
3 7 4
SOFA score (median, range) 4 (1−14) 4 (1−14) 0.68
Chronic renal failure 10 (32.3%) 11 (25%) 0.49
Albumin g/dL (mean, SD) 2.2 (±0.46) 2.4 (±0.66) 0.33
WBC K/micl (mean, SD) 16.587 (±9.6) 14.294 (±8.4) 0.28
Bacteraemia 12 (38.7%) 13 (29.5%) 0.41
aFor ICU vs. others; bfor 1 vs. others.
Results: Data were collected between March to October 2006 in
2 medical centres in Israel; 31 patients were treated with colistin
and 44 with comparator antibiotics (meropenem 12, imipenem 15,
ampicillin-sulbactam 17). All infections were healthcare associated
(median time in hospital before infection 17 days, 0−34). Prior
antibiotic treatment was administered to 27 patients with colistin vs.
38 patients with comparator antibiotics. Treatment was administered
for microbiologically documented infections in all but 2 patients.
Acinetobacter, Klebsiella and Pseudomonas spp. were implicated in
56%, 56% and 31% of infections, respectively. Colistin was administered
as single drug to 27/31 colistin-treated patients; bacteria were susceptible
only to colistin in 23/3. Baseline patient characteristics and outcomes are
shown in the table. Mortality was signiﬁcantly higher with colistin vs.
comparators, 48% vs. 20%, p = 0.01. A multivariate analysis including
75 patients and the variables age, McCabe score, independent functional
status and treatment arm as covariates, revealed that colistin remained
signiﬁcantly associated with 30-day mortality (p = 0.03).
Conclusions: Treatment with colistin was associated with a signiﬁcantly
higher mortality rate at 30 days and a non-signiﬁcantly higher rate of
renal failure development. Higher-risk patients were treated with colistin.
P837 Clinical factors associated with daptomycin outcomes in skin
and soft-tissue infections
K. Lamp, L. Friedrich, K. Lindﬁeld (Lexington, US)
Objectives: To examine the impact of multiple clinical factors on
daptomycin (DAP) clinical outcomes in patients (pts) with skin and soft-
tissue infections (SSTI).
Methods: The Cubicin® Outcomes Registry and Experience (CORE^sm
2005) is a multicentre (52 US institutions), retrospective study
evaluating DAP outcomes. Pts unevaluable for outcome were excluded.
Factors that may impact clinical outcomes (initial creatinine clearance
[CrCl] <30mL/min, dialysis, complicated SSTI [cSSTI], bacteraemia,
methicillin-resistant Staphylococcus aureus [MRSA], sepsis, ICU stay,
diabetes, cancer history, chronic kidney disease, age 66 yrs, concomi-
tant antibiotic (abx) use, community location, prior abx category) were
investigated in a multivariate logistic regression analysis (MV). Prior abx
categories were deﬁned as: no prior abx (DAP ﬁrst line, FL), DAP after
vancomycin (VAN) failure (VF), after VAN without VAN failure (VNF),
after non-VAN failure (NVF), and after non-VAN without non-VAN
failure (NVNF). Prior abx failure was determined by the investigator.
Results: There were 486 evaluable pts with SSTI including noncatheter-
related bacteraemia. The number of pts in prior abx categories were FL
(n = 127, 26%), VF (n = 56, 12%), VNF (n = 121, 25%), NVF (n = 86,
18%), NVNF (n = 96, 20%). Pts were 51% female, 21% 66 yrs,
12% with CrCl <30mL/min or dialysis, 57% were in the community
2 days prior to DAP. The population consisted of 70% cSSTI, 30%
uncomplicated SSTI and 5% of all pts had bacteraemia. The most
common pathogen cultured was MRSA, 52%. The median DAP dose
(4mg/kg) and duration (12 days) did not differ by prior abx category.
Overall, 94% of pts achieved clinical success after DAP therapy. By
logistic regression DAP success rates were higher for FL than VF (98%
vs. 88%, P = 0.018). The presence of an initial low CrCl (P = 0.015),
ICU stay (P = 0.007) and sepsis (P = 0.009) were signiﬁcant predictors
of lower DAP success in MV. There was a trend that VF (P = 0.07) or
NVF (P = 0.07) were associated with lower DAP success.
Conclusion: In almost 500 SSTI pts treated with DAP, clinical success
rates exceeded 90%. In the MV, a low initial CrCl, ICU stay or presence
of sepsis were associated with lower DAP success which is consistent
for markers of severity of illness. Prior abx category, in the presence of
other patient factors, in MV resulted in the observation that DAP success
was independent of the prior abx. Further studies are needed to conﬁrm
these ﬁndings.
P838 Clinical experience trends with daptomycin in the ﬁrst two
years: report from a registry
K. Lamp, L. Friedrich (Lexington, US)
Objectives: To describe trends in the use of daptomycin (DAP) in the
United States during the ﬁrst two years on the market.
Methods: The Cubicin® Outcomes Registry and Experience (CORESM)
collected data in 2004 and 2005 at 45 and 52 US institutions, respectively.
CORESM is a retrospective, observational chart review evaluating
outcomes of DAP patients (pts). Investigators collected demographic,
disease state, clinical and microbiological data; outcomes were assessed
using standard deﬁnitions.
Results: There were 1160 and 1172 pts enrolled in CORESM 2004
and 2005, respectively. Pts with more than one infection type were
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stratiﬁed by severity of infection (endocarditis > osteomyelitis >
bacteraemia > other [foreign body, septic arthritis, pyelonephritis/UTI,
CNS, necrotising infection] > complicated skin and soft-tissue, cSSTI >
uncomplicated skin and soft-tissue, uSSTI). The patients in 2004/2005
(%/%) by infection type were: endocarditis (4/3), osteomyelitis (12/12),
bacteraemia (19/25, P< 0.01), other (15/15), cSSSI (32/33), uSSSI
(18/12, P< 0.01). These ﬁndings were consistent even if restricted to sites
participating in both years. Pt gender, age ranges and location 48 hours
prior to starting DAP were similar for both years. The percentage of
pts with an initial creatinine clearance <30mL/min was higher in 2004
(30% vs. 18%, P< 0.001). Overall, DAP was used as initial therapy in
24% of pts. Staphylococcus aureus was the most common pathogen,
isolated in approximately one-half of patients (methicillin-resistant >
methicillin-susceptible), followed by coagulase-negative staphylococci
and vancomycin-resistant enterococci. The mean DAP dose was higher
for all infection types in 2005; however, the median dose differed only for
bacteraemia and other infections (P< 0.05). The median DAP duration
was 13 days for both years. Clinical outcomes for 2004/2005 (%/%) were
success, cure plus improved, (80/75), failure (5/6), and nonevaluable
(15/19).
Conclusion: DAP was primarily used to treat SSTI. In 2005, DAP was
used in more pts with bacteraemia and at higher doses, which may reﬂect
the release of data from a phase 3 study in S. aureus bacteraemia and
endocarditis. In a population of pts with a high rate of previous antibiotic
use (76%), DAP was associated with good clinical outcomes. Further
studies are needed to describe the effectiveness of DAP.
P839 Daptomycin is clinically more rapidly effective than
comparator for treatment of complicated skin and
skin-structure infections
L. Friedrich, J. Krige, K. Lindﬁeld, C. Otradovec, W. Martone, D. Katz,
F. Tally (Mt. Pleasant, US; Cape Town, ZA; Lexington, US)
Objective: To compare rapidity of clinical response between daptomycin
(DAP) and comparator (COMP) (vancomycin, semi-synthetic penicillin)
in South African (SA) patients from 2 large randomised, blinded studies.
Methods: A subset of clinically evaluable SA patients comparing DAP
to COMP for complicated skin and skin-structure infections (cSSSI)
treatment with either 0 or 1 clinical comorbidity were studied. Patients
were evaluated at baseline, on therapy (day 3−4), end of therapy (EOT),
and test of cure (TOC). Clinical symptom (edema, erythema, ﬂuctuance,
induration, necrotic tissue, purulent drainage, tenderness, ulceration)
severity was assessed as none, mild, moderate, or severe by a blinded
investigator at each visit. These assessments were combined into 2
categories (none/mild and moderate/severe) and tallied for each visit.
The Mantel-Haenszel chi-square was used to assess overall differences
between DAP and COMP symptom severity at any visit with chi-square
tests to determine the source(s) of the overall effect for each symptom
at each visit. Nonparametric tests were used for all other comparisons.
A P< 0.05 was statistically signiﬁcant and 0.05 P< 0.10 marginal.
Results: Of 356 clinically evaluable patients, 326 (92%) had 0 or
1 clinical comorbidity and were eligible for analysis (DAP= 174,
COMP= 152). Common comorbidities included SIRS (~30%), diabetes
(7%-9%), and peripheral vascular disease (2%-3%); there were no
demographic differences between groups. Wound infection (~50%) and
major abscess (~20%) were most common. Diabetic ulcer occurred
in 3% of each group. Staphylococci and Streptococci were the most
common pathogens. Only 4% of COMP patients received vancomycin.
Clinical success was 93% for DAP and 95% for COMP. DAP patients
had a shorter median duration of therapy (7 [3−15] vs. 8 [3−17] days,
P< 0.0001). Overall, DAP patients improved more quickly (P = 0.038).
No differences in symptom severity were noted between DAP and
COMP at baseline. DAP symptom severity signiﬁcantly decreased by day
3−4 for induration (P = 0.027), erythema (P = 0.048) and marginally for
edema (P = 0.096) and necrotic tissue (P = 0.097). At EOT, DAP showed a
signiﬁcant decrease in severity for induration (P = 0.043) and a marginal
decrease in tenderness (P = 0.056). At TOC, the decrease in severity for
DAP for induration was still evident (P = 0.031).
Conclusion: DAP length of therapy was signiﬁcantly shorter and
produced a more rapid clinical response than COMP as evidenced by a
signiﬁcant decrease in the severity of clinical symptoms.
P840 Hospital length of stay in patients with methicillin-resistant
Staphylococcus aureus infections: retrospective analysis of a
clinical study comparing tigecycline and vancomycin
R. Mallick, S. Sun (Collegeville, US)
Objective: Using data from a recent clinical study, to investigate which
presenting characteristics were risk factors for prolonged length of stay
(LOS) in hospitalised patients treated for serious infections involving
MRSA.
Method: For this analysis, data from patients with MRSA in a
multinational, double-blind clinical study conducted in patients with
conﬁrmed serious infections involving resistant Gram-positive pathogens
(MRSA and vancomycin-resistant enterococci [VRE]) was extracted.
In the study, patients with MRSA were randomly assigned in a 3:1
ratio to receive IV tigecycline or vancomycin. Treatment duration
was to be 7−28 days, depending on site and severity of the
infection. Hospital length of stay was based on additional systemic
evaluation. We (a) summarised baseline characteristics and (b) estimated
multiple regression models – adjusting for hospital death and study
discontinuation as necessary – to identify risk factors for prolonged LOS.
Results: Among patients with MRSA infections who met minimal
disease criteria (n = 133) and had complete hospitalisation data (n = 131),
diabetes (20.7%) and peripheral vascular disease (PVD) (17.4%)
were leading co-morbidities. Complicated skin and skin structure
infections (69.5%), complicated intra-abdominal infections (16.0%)
and bacteraemia – including catheter-related bacteraemia – (9.9%)
constituted the most common infection types. Mean APACHE severity
score was 7.9; 9.9% of patients had an APACHE score >15. Mean
duration of IV antibiotic therapy was 12.1 days, mean LOS was
15.0 days, re-hospitalisation rate was 9.2%, mortality rate was 3.8%.
Bacteraemia (+4.8 days; p = 0.0014) and peripheral vascular disease
(+2.7 days; p = 0.029) were notably associated with prolonged IV
treatment duration. An APACHE score >15 was associated with a
substantial impact (+15.8 days; p< 0.0001) on hospital LOS. There was
no signiﬁcant difference between the tigecycline and vancomycin groups
in IV treatment duration, LOS, re-hospitalisation rate or mortality rate.
Conclusions: In this retrospective analysis of a clinical study in
patients with selected serious infections involving MRSA, bacteraemia
and peripheral vascular disease emerged as presenting risk factors for
prolonged IV antibiotic treatment, and an APACHE score >15 for
prolonged hospitalisation; there were no signiﬁcant differences between
tigecycline and vancomycin.
P841 Duration of hospital length of stay in patients with
community-acquired pneumonia treated in European
centres: retrospective analysis of a clinical study comparing
tigecycline and levoﬂoxacin
R. Mallick, S. Sun (Collegeville, US)
Objective: To investigate risk factors for prolonged length of stay (LOS)
in hospitalised CAP patients (pts) in European centres.
Method: Data from European centres in a double-blind clinical study
among hospitalised pts with CAP who were stratiﬁed by the FINE
Pneumonia Severity Index and randomised to receive intravenous (IV)
tigecycline or IV levoﬂoxacin, was retrospectively analyzed. Treatment
termination was based on resolution of infection symptoms and hospital
discharge on additional systemic evaluation. We (a) summarised baseline
characteristics and (b) estimated multiple regression models – adjusting
for hospital death and study discontinuation as necessary – to identify
risk factors for prolonged LOS.
Results: Among 345 pts (23.2% age >65 yrs) hospitalised for CAP in
European centres, diabetes (10.1%) and COPD (8.1%) were leading
co-morbidities; 57.1% of pts were past or current smokers. Median
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FINE category and CURB-65 severity index scores were 3 (range
1−5) and 1 (range 0−4) respectively. Blood urea nitrogen (BUN)
concentration >7mmol/L (22.0% of pts) and respiratory rate >30/minute
(18.0% of pts) were most common severity components. Among
246 pts with known microbiology, Streptococcus pneumoniae (41.5%)
and Mycoplasma pneumoniae (28.1%) were leading pathogens; 42.7%
of pts had a poly-microbial infection. Among all pts, mean duration of
IV antibiotic therapy was 10.0 days; mean LOS was 13.8 days. Alcohol
abuse (hazard ratio [HR] = 0.47; p = 0.0039), co-morbid liver disease
(HR= 0.60; p = 0.0485) and BUN >7mmol/L (HR= 0.74; p = 0.0282)
were associated with slower hospital discharge rates (prolonged LOS).
Among the 246 pts with known microbiology, presence of a poly-
microbial infection (HR= 0.69; p = 0.007), Legionella pneumoniae
(HR= 0.41; p = 0.005), or Haemophilus inﬂuenzae (HR= 0.57; p = 0.013)
was associated with prolonged LOS, as was absence of cure (HR= 0.28;
p< 0.0001). There was no signiﬁcant difference between the tigecycline
and levoﬂoxacin groups in LOS, however, tigecycline was associated
with a slight trend towards a lower re-hospitalisation rate (tigecycline
0.6%, levoﬂoxacin 4.1%; p = 0.067).
Conclusions: Co-existing liver disease, alcohol abuse, abnormal blood
urea nitrogen, and among pts with known microbiology, presence of poly-
microbial infections, Legionella pneumoniae or Haemophilus inﬂuenzae
emerged as risk factors for prolonged hospitalisation; there were no
differences between tigecycline and levoﬂoxacin.
P842 An open-label, randomised, comparative study of the
patient compliance, efﬁcacy and safety of treatment with
clarithromycin extended-release versus clarithromycin
immediate-release for the treatment of acute bacterial
exacerbation of chronic bronchitis
P. Kardas (Lodz, PL)
Objectives: The aim of this study was to compare patient compliance as
well as the efﬁcacy and safety of clarithromycin extended-release (ER)
tablets administered once daily (QD) and immediate-release (IR) tablets
administered twice daily (BID).
Methods: This was an open-label, randomised, comparative study in
adult outpatients (age  60 years) with a diagnosis of acute bacterial
exacerbation of chronic bronchitis (ABECB). Eligible patients were
randomised 1:1 to receive either 1 clarithromycin ER 500-mg tablet
QD for 7 days or 1 clarithromycin IR 250-mg tablet BID for 7 days.
Studied drugs were given to the patients in excessive number in MEMS 6
containers, which enabled precise electronic measurement of compliance
parameters. Clinical response was assessed at day 7 and at the test-of-
cure visit (study day 21). For the assessment of patient compliance, the
overall compliance (deﬁned with the ratio of the number of container
openings to the number of prescribed doses), as well as days with correct
number of doses taken, were employed. Safety was assessed based on
the incidence of study drug-related adverse events.
Results: A total of 122 patients were randomised (60 to ER and 62 to IR
group). Clinical cure rates were similar for evaluable patients treated with
ER (94.5%, 52/55) and those treated with IR (88.1%, 52/59) (P> 0.05).
Mean overall compliance was 94.3% in the ER group and 82.3% in
the IR group, and the mean days with correct number of doses taken
was 80.2% and 70.3% for the respective treatment groups (P< 0.001).
The incidence of adverse events was 8% (5/60) in the ER group and
8% (5/62) in the IR group.
Conclusion: Clarithromycin ER 500-mg tablets QD for 7 days were
equally effective and well tolerated as clarithromycin IR 250-mg tablets
BID for 7 days in treating adults with ABECB, and were associated with
signiﬁcantly higher rates of patient compliance.
P843 Effectiveness of linezolid in nosocomial and severe
community-acquired pneumonia: meta-analysis
O. Yeniova, S. Ascioglu (Ankara, TR; Boston, US)
Objective: To review the evidence for the effectiveness of linezolid
treatment in patients with nosocomial or severe community acquired
pneumonia (CAP).
Methods: We searched PubMed and Cochrane databases (January 1990
to 31 October 2006) using linezolid and pneumonia as text words,
also hand searched the bibliographies of published studies. We tried
to be inclusive in our inclusion criteria due to scarcity of studies in
this area. Studies met our inclusion criteria if they were randomised
controlled trials or observational studies comparing linezolid with a
suitable comparator in adult patients with pneumonia. Pooled estimates
of the risk ratio (RR) for successful outcome were obtained using a
ﬁxed effects model. Test of heterogeneity was not signiﬁcant (MH test,
p = 0.950).
Results: Our search yielded a total of 117 references. After we
examined all abstracts, we identiﬁed 6 randomised controlled trials.
There weren’t any observational studies or non-randomised trials which
met our inclusion criteria. Only 2 of the included trials had a primary
objective of evaluating effectiveness in nosocomial pneumonia patients,
3 trials had subgroups of nosocomial pneumonia patients and 1 trial
included hospitalised patients with severe CAP. In all but 1 of the
studies comparator drug was a glycopeptide (2 studies teicoplanin,
3 vancomycin), in the severe CAP study only, comparator drug was
ceftriaxone. The pooled analysis of all trials showed that linezolid was
not associated with a signiﬁcantly better outcome than the comparator
treatments (RR: 1.05, 95%CI: 0.98–1.12) (Figure). We did a sensitivity
analysis including only nosocomial pneumonia studies; omission of the
CAP study which appeared to be the one that dominated the other trials
attenuated the effect estimate (RR: 1.02, 95%CI: 0.92–1.13). Our sample
size was too small to evaluate publication bias.
Conclusions: Linezolid had a very small favourable effect on the
outcome of patients with severe CAP and nosocomial pneumonia and this
result wasn’t statistically signiﬁcant. Future trials addressing linezolid
treatment in these patient groups are urgently needed.
P844 The ATLAS studies: double-blind, randomised, active
controlled, multinational Phase 3 trials comparing telavancin
with vancomycin for the treatment of complicated skin and
skin structure infections
G.R. Corey, M.E. Stryjewski, V.G. Fowler Jr, V. Skerk, A. Hopkins,
M.M. Kitt, S.L. Barriere for the ATLAS Study Group
Objectives: Methicillin-resistant Staphylococcus aureus (MRSA) is a
common pathogen isolated from complicated skin and skin structure
infections (cSSSI). Telavancin is a novel, rapidly bactericidal lipogly-
copeptide with a multifunctional mechanism of action against Gram-
positive pathogens, including MRSA. The ATLAS trials compared the
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efﬁcacy and safety of telavancin with vancomycin for the treatment of
cSSSI, especially in patients with infections due to MRSA.
Methods: ATLAS 1 and 2 were identical double-blind, randomised,
active controlled, multinational Phase 3 trials. Patients were 18 years
of age or older with suspected or conﬁrmed MRSA resulting in cSSSI
(major abscess, infected burn, deep/extensive cellulitis, infected ulcer or
wound infection) requiring 7 days of IV antibiotic therapy. Patients
received telavancin 10mg/kg administered IV once daily or vancomycin
1 g IV once every 12 h for 7−14 days. Efﬁcacy was assessed as the
clinical cure at the test-of-cure visit (7−14 days after administration of
the last dose of study drug) in the combined population. Safety was also
assessed.
Results: A total of 928 patients received telavancin (n = 745 clinically
evaluable; n = 278 clinically evaluable with MRSA) and 939 received
vancomycin (n = 744 clinically evaluable; n = 301 clinically evaluable
with MRSA). Clinical cure at the test-of-cure visit was similar for the two
drugs in the combined clinically evaluable population (telavancin, 88.3%;
vancomycin, 87.1%; difference, 1.2% [95%CI, −2.1, 4.6]). Clinical
cure was also comparable in clinically evaluable patients with MRSA
infections (telavancin, 90.6%; vancomycin 86.4%; difference, 4.1%
[95%CI, −1.1, 9.3]), regardless of diabetes status, gender, race, type of
cSSSI or body mass index. Serious adverse events and discontinuations
due to adverse events were slightly greater in the telavancin group. The
most common adverse events associated with telavancin were generally
mild and transient taste disturbance, nausea, vomiting and foamy urine.
Renal adverse events were infrequent, but were greater with telavancin
than vancomycin (3% vs 1%).
Clinical cure and microbiological eradication at test-of-cure clinic visit
Endpoint Cure rate
Telavancin,
n (%)
Vancomycin,
n (%)
Difference,
% (95%CI)
Clinical cure
All-treated population 710/928
(76.5)
697/939
(74.2)
2.3
(−1.6, 6.2)
Clinically evaluable
population
658/745
(88.3)
648/744
(87.1)
1.2
(−2.1, 4.6)
(MRSA) 252/278
(90.6)
260/301
(86.4)
4.1
(−1.1, 9.3)
Microbiological eradication
Modiﬁed all-treated
population
527/680
(77.5)
526/703
(74.8)
2.7
(−1.8, 7.2)
Microbiologically evaluable
population
473/527
(89.8)
468/536
(87.3)
2.4
(−1.4, 6.2)
(MRSA) 250/278
(89.9)
257/301
(85.4)
4.4
(−0.9, 9.8)
Overall therapeutic response (cure + eradication)
Modiﬁed all-treated
population
516/680
(75.9)
515/703
(73.3)
2.6
(−2.0, 7.2)
Microbiologically evaluable
population
467/527
(88.6)
462/536
(86.2)
2.4
(−1.6, 6.4)
(MRSA) 250/278
(89.8)
255/301
(84.7)
5.1 (−0.3,
10.5)
Conclusion: Combined data from ATLAS 1 and 2 have consistently
shown that telavancin is non-inferior to vancomycin for the treatment of
patients with a cSSSI, including those caused by MRSA. Telavancin had
an acceptable adverse event proﬁle for the treatment of serious infections
due to resistant bacteria.
P845 ATLAS 1: the ﬁrst Phase 3 study evaluating the new
lipoglycopeptide, telavancin, for the treatment of patients
with complicated skin and skin structure infections
G.R. Corey, M.E. Stryjewski, W.D. O’Riordan, V.G. Fowler Jr., D.P. Ross,
A. Hopkins, M.M. Kitt, S.L. Barriere for the ATLAS Study Group
Objectives: Recent publications have highlighted the critical shortage
of new antimicrobial agents currently in Phase 2/3 development [1].
Telavancin, a novel, rapidly bactericidal lipoglycopeptide with a
multifunctional mechanism of action against Gram-positive pathogens,
was recently evaluated in two parallel Phase 3 studies involving patients
with complicated skin and skin structure infections (cSSSIs). Here we
report results from the ﬁrst of these trials, ATLAS 1.
Methods: ATLAS 1 was a double-blind, randomised, active controlled,
multinational study comparing the efﬁcacy and safety of telavancin
(10mg/kg IV q 24 h) with vancomycin (1 g IV q 12 h). Eligible patients
included men and women, aged 18 years or older, with a cSSSI (major
abscess, infected burn, deep/extensive cellulitis, infected ulcer or wound
infection) requiring 7 to 14 days of IV antibiotic therapy. The primary
endpoint, clinical response at the test-of-cure visit (TOC; 7−14 days after
administration of the last dose of study medication), was evaluated using
non-inferiority (delta deﬁned as 10%). Secondary objectives included
cure rates by pathogen and microbiological eradication. Safety was also
evaluated.
Clinical cure and microbiological eradication at test-of-cure clinic visit
Endpoint Cure rate
Telavancin,
n (%)
Vancomycin,
n (%)
Difference,
% (95%CI)
Clinical cure
All-treated population 323/426
(75.8)
321/429
(74.8)
1.0
(−4.8, 6.8)
Clinically evaluable
population
304/346
(87.9)
302/349
(86.5)
1.3
(−3.6, 6.3)
Clinically evaluable
population (MRSA)
101/116
(87.1)
118/138
(85.5)
1.6
(−6.9, 10.0)
Microbiological eradication
Modiﬁed all-treated
population
240/307
(78.2)
241/322
(74.8)
3.3
(−3.3, 10.0)
Microbiologically evaluable
population
212/237
(89.5)
219/255
(85.9)
3.6
(−2.2, 9.4)
Microbiologically evaluable
population (MRSA)
101/116
(87.1)
117/138
(84.8)
2.3
(−6.3, 10.8)
Overall therapeutic response (cure + eradication)
Modiﬁed all-treated
population
235/307
(76.5)
239/322
(74.2)
2.3
(−4.4, 9.1)
Microbiologically evaluable
population
210/237
(88.6)
218/255
(85.5)
3.1
(−2.8, 9.0)
Microbiologically evaluable
population (MRSA)
101/116
(87.1)
117/138
(84.8)
2.3
(−6.3, 10.8)
Results: Among all patients treated with telavancin (n = 426) or
vancomycin (n = 429), 81% were clinically evaluable (CE; 346 and
349, respectively) and over 70% of the CE population was also
microbiologically evaluable (237 and 255, respectively). Clinical cure
at the TOC visit was similar for the two treatment groups (Table),
thus demonstrating non-inferiority for telavancin relative to vancomycin
in this study. The safety proﬁle of telavancin was acceptable for the
treatment of serious infections due to resistant bacteria. Discontinuations
due to adverse events were reported for 7% of telavancin-treated patients
and 5% of vancomycin-treated patients.
Conclusion: Telavancin is a novel lipoglycopeptide that acts by
inhibiting bacterial cell wall synthesis and disrupting the functional
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integrity of the bacterial plasma membrane. The results of ATLAS 1,
the ﬁrst of two parallel, Phase 3 studies evaluating telavancin for the
treatment of serious skin infections, consistently favoured telavancin
compared with vancomycin.
Reference(s)
[1] Talbot et al. Clinical Infectious Diseases. 2006; 42: 657–668.
P846 ATLAS 2: a double-blind, randomised, active controlled,
multinational Phase 3 study comparing telavancin with
vancomycin for the treatment of patients with complicated
skin and skin structure infections
G.R. Corey, M.E. Stryjewski, V.G. Fowler Jr., O. Teglia, A. Hopkins,
M.M. Kitt, S.L. Barriere for the ATLAS Study Group
Objectives: Telavancin is a novel, rapidly bactericidal lipoglycopeptide
with activity against Gram-positive pathogens, including methicillin-
resistant Staphylococcus aureus (MRSA). It has a multifunctional
mechanism of action, which includes inhibiting cell wall synthesis
and disrupting plasma membrane functional integrity. The efﬁcacy and
safety of telavancin vs vancomycin have been compared in patients with
complicated skin and skin structure infections (cSSSIs) in two Phase 3
studies. Here we report results from the second of these trials, ATLAS
2.
Methods: ATLAS 2 was a double-blind, randomised, active controlled,
multinational study involving men and women, aged 18 years or older.
Patients had a cSSSI (major abscess, infected burn, deep/extensive
cellulitis, infected ulcer or wound infection) requiring 7 days of IV
antibiotic therapy. Patients were randomised to IV infusions of telavancin
10mg/kg once daily or vancomycin 1 g once every 12 h for 7−14 days.
The primary efﬁcacy endpoint was the clinical response at the test-of-
cure visit (7−14 days after the last dose of study drug), evaluated using
non-inferiority criteria (with a non-inferiority delta of 10%). Secondary
endpoints included clinical cure in patients with MRSA infections,
clinical cure by pathogen and microbiological eradication. Safety was
also evaluated.
Clinical cure and microbiological eradication at test-of-cure clinic visit
Endpoint Cure rate
Telavancin,
n (%)
Vancomycin,
n (%)
Difference,
% (95%CI)
Clinical cure
All-treated population 387/502
(77.1)
376/510
(73.7)
3.4
(−1.9, 8.7)
Clinically evaluable
population
354/399
(88.7)
346/395
(87.6)
1.1
(−3.4, 5.6)
Clinically evaluable
population (MRSA)
151/162
(93.2)
142/163
(87.1)
6.1
(−0.3, 12.5)
Microbiological eradication
Modiﬁed all-treated
population
287/373
(76.9)
285/38
(74.8)
2.1
(−4.0, 8.2)
Microbiologically evaluable
population
261/290
(90.0)
249/281
(88.6)
1.4
(−3.7, 6.5)
Microbiologically evaluable
population (MRSA)
149/162
(92.0)
140/163
(85.9)
6.1
(−0.7, 12.9)
Overall therapeutic response (cure + eradication)
Modiﬁed all-treated
population
281/373
(75.3)
276/381
(72.4)
2.9
(−3.4, 9.2)
Microbiologically evaluable
population
257/290
(88.6)
244/281
(86.8)
1.8
(−3.6, 7.2)
Microbiologically evaluable
population (MRSA)
149/162
(92.0)
138/163
(84.7)
7.3
(0.4, 14.2)
Results: A total of 502 patients received telavancin (n = 399 clinically
evaluable; n = 290 microbiologically evaluable; n = 204 with MRSA)
and 510 received vancomycin (n = 395 clinically evaluable; n = 281
microbiologically evaluable; n = 202 with MRSA). Clinical cure and
eradication at the test-of-cure visit were similar for the two treatments
(Table), demonstrating the non-inferiority of telavancin vs vancomycin,
since the lower bound of the 95% conﬁdence interval was greater than
−10%. Telavancin achieved a higher overall therapeutic response (cure
+ eradication) than vancomycin. Adverse events were comparable in the
two treatment arms. Overall, 43 (8.6%) telavancin-treated patients and 28
(5.5%) vancomycin-treated patients discontinued due to adverse events.
Conclusion: In the ATLAS 2 study, telavancin was found to be effective
for the treatment of patients with cSSSIs, including those caused by
MRSA. The results, including overall therapeutic response, consistently
favoured telavancin compared with vancomycin. Telavancin also had an
acceptable adverse event proﬁle for the treatment of serious infections
due to resistant bacteria.
P847 Activity of telavancin against Staphylococcus aureus isolates
carrying the Panton-Valentine leukocidin gene in the ATLAS
studies
V.G. Fowler Jr., T. Rude, C. Nelson, M.E. Stryjewski, M.M. Kitt,
S.L. Barriere, D. Friedland, G.R. Corey (Durham, South San Francisco,
US)
Objectives: Telavancin (TLV) is a novel, rapidly bactericidal lipo-
glycopeptide antibiotic with a unique, multifunctional mechanism of
action against a broad range of Gram-positive pathogens. TLV was
recently evaluated in two large, international, Phase 3 studies (ATLAS 1
and 2) involving patients with complicated skin and skin structure
infections (cSSSI). Panton-Valentine leukocidin (PVL) is a highly potent
cytotoxin which is increasingly associated with community-acquired
methicillin-resistant Staphylococcus aureus (MRSA) infections. This
analysis examined PVL gene prevalence in S. aureus isolates from
patients with cSSSI enrolled in ATLAS 1 and 2.
Methods: ATLAS 1 and 2 were identical, double-blind, randomised,
active-controlled, multinational, Phase 3 studies. Patients were 18 years
of age with a cSSSI (major abscess, infected burn, deep/extensive
cellulitis, infected ulcer or wound infection) caused by a Gram-positive
pathogen and required 7 days of IV antibiotic therapy. Patients were
randomised to TLV (10mg/kg administered IV q 24 h) or vancomycin
(1 g IV q 12 h). Clinical cure was determined at the test-of-cure
(TOC) visit (7−14 days after administration of the last dose of study
medication). S. aureus isolates were screened for PVL genes (lukS-PV
and lukF-PV) by PCR methods.
Results: Isolates from a total of 870 clinically evaluable patients in the
two studies were available for analysis (543 MRSA; 327 methicillin-
sensitive S. aureus [MSSA]). The PVL gene was detected in isolates
from 557/870 (64%) patients. Rates of PVL-positivity were higher in
patients with MRSA isolates (459/543 [85%]) than MSSA isolates
(98/327 [30%]). Clinical cure at the TOC visit was similar for TLV
and vancomycin in the combined ATLAS 1 and 2 microbiologically
evaluable populations, regardless of PVL status (Figure).
Overall treatment difference in clinical response at test-of-cure by
pathogen PVL characteristics; ATLAS 1 and ATLAS 2 combined, CE
population. *Weighting for point difference was bazed on the size of
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ATLAS 1 and ATLAS 2 trials. Percentages shown to the right were not
weighted.
Conclusion: The PVL gene was present in a large proportion of S. aureus
isolates from cSSSI patients in the ATLAS studies. PVL status did not
seem to inﬂuence the outcome of treatment. In these studies, TLV was
effective in the treatment of cSSSI caused by S. aureus, including strains
carrying the PVL gene.
P848 Efﬁcacy of tigecycline (TGC) compared with
levoﬂoxacin (LEV) for treating Streptococcus pneumoniae
bacteraemia in patients (pts) hospitalised with
community-acquired pneumonia (CAP)
N. Dartois, G. Dukart, C.A. Cooper, N. Castaing, H. Gandjini on
behalf of the 308 and 313 Study Groups
Objective: Tigecycline (TGC), a ﬁrst-in-class glycylcycline approved for
treating complicated skin/skin structure and intra-abdominal infections,
has an expanded spectrum of activity against Gram-positive, Gram-
negative and atypical bacteria including some resistant strains. CAP pts
with Streptococcus pneumoniae bacteraemia frequently have more severe
disease and increased mortality than pts without bacteraemia. We
evaluated the efﬁcacy and safety of TGC vs. levoﬂoxacin (LEV) in a
subset of hospitalised CAP pts with pneumococcal bacteraemia.
Method: Two Phase 3, multicentre, double blind studies were conducted
in hospitalised CAP pts. Pts were randomised to receive IV TGC (100mg
then 50mg ql2h) or IV LEV (500mg q24h or q12h). In 1 study, pts
could be switched to oral LEV after 3 days of IV dosing. Clinical
response was evaluated at test-of-cure (TOC). Results are presented for
the microbiologically evaluable (ME) and microbiologic modiﬁed intent-
to-treat (m-mITT) populations.
Results: 846 pts received at least 1 dose of study drug in these
2 trials. Of the 345 ME and 457 m-mITT pts, 40 (11.6%) and
50 (10.9%) pts, respectively, had S. pneumoniae (sp.) bacteraemia.
At TOC (ME population), TGC cured 20/22 (90.9%)and LEV cured
13/18 (72.2%) – absolute difference TGC–LEV, 18.7% (95%CI
−8.8, 45.6). The cure rate for TGC in sp. bacteraemic pts was similar
to that of TGC in ME pts without sp. bacteraemia (127/138, 92.0%).
The cure rate for LEV in bacteraemic pts (ME) was numerically lower
than that for LEV pts without bacteraemia (146/159, 91.8%). In the
m-mITT population, TGC cured 22/27 (81.5%) and LEV cured 15/23 pts
(65.2%) – absolute difference TGC–LEV 16.3% (95%CI −10.5, 41.4).
Again, the cure rate for TGC in sp. bacteraemic pts was similar
to that achieved by TGC in pts without sp. bacteraemia (162/189,
85.7%), whereas the cure rate for LEV was lower in bacteraemic
vs. non-bacteraemic pts (177/203, 87.2%). The minimum inhibitory
concentration (MIC) of TGC for S. pneumoniae blood isolates ranged
from 0.03–0.12mg/mL, whereas the MIC of LEV for these isolates
ranged from 0.5−1.0mg/mL.
Conclusions: In these 2 studies, TGC appeared safe and achieved
cure rates similar to LEV in hospitalised pts with CAP. Further, in a
subset of pts with S. pneumoniae bacteraemia, TGC achieved cure rates
similar to those in TGC-treated CAP pts without bacteraemia. Finally,
TGC achieved a numerically higher cure rate than LEV, although the
difference was not statistically signiﬁcant.
P849 Efﬁcacy of tigecycline versus levoﬂoxacin in patients
hospitalised with community-acquired pneumonia: analysis
of risk factors
N. Dartois, G. Dukart, C. Cooper, N. Castaing, I. Gandjini, D. Sarkozy
on behalf of the 308 and 313 Study Groups
Objective: The initial severity of community-acquired pneumonia (CAP)
and eventual clinical outcome may be inﬂuenced by a number of risk
factors. Tigecycline (TGC), a ﬁrst-in-class glycylcycline approved for
treating complicated skin/skin structure and intra-abdominal infections,
exhibits expanded activity against Gram-positive, Gram-negative and
atypical bacteria and some resistant strains. The efﬁcacy of TGC vs
levoﬂoxacin (LEV) was studied in hospitalised pts with CAP. In addition
to overall response, exploratory analyses were performed evaluating
response to treatment for a variety of risk factors.
Method: Two Phase 3, multicentre, double blind studies were conducted
in hospitalised pts with CAP who were randomised to receive IV
TGC (100mg initially then 50mg ql2h) or IV LEV (500mg q24h or
q12h). In 1 study, pts could be switched to oral LEV after 3 days
of IV dosing. At randomisation, pts were stratiﬁed by: geographic
location in 1 study and by Fine Pneumonia Severity Index in both
studies. Clinical response was evaluated at test-of-cure. Risk factors,
such as age, Fine Pneumonia Severity Index and estimated CURB-65
scores, and co-morbidities including diabetes (DM), chronic obstructive
pulmonary disease, congestive heart failure (CHF) and cerebrovascular
disease (CVD) were evaluated. Results will be presented for the clinically
evaluable (CE) population.
Results: 846 pts received at least 1 dose of study drug in these 2 trials
and the CE population consisted of 574 pts (TGC= 282, LEV= 292).
Overall, the cure rates (CE) for TGC (253/282 pts, 89.7%) were similar to
LEV (252/292, 86.3%). Although the number of pts was small for some
subgroups, a statistically signiﬁcant subgroup by treatment interaction
was observed for some factors, such as age <55 vs. 55 and presence
or absence of CVD, CHF, and DM. The cure rates for TGC pts were
generally consistent across the subgroups, while those for LEV were
more variable. Failure analysis revealed no signiﬁcant risk factors for
TGC pts, whereas multilobar disease, prior antibiotic failures, creatinine
clearance (70mL/min), and geographic region (Western Europe and
US/Canada) were signiﬁcant risk factors for LEV.
Conclusions: In both studies, TGC appeared safe and achieved cure rates
similar to LEV in hospitalised pts with CAP. The cure rates for TGC pts
were generally consistent across the subgroups. Further, in an analysis
of risk factors, which contributed to failure of the study regimen, no
prognostic factors were identiﬁed for TGC treated subjects.
P850 Comparison of clinical outcomes in patients with Staphylo-
coccus aureus bacteraemia and endocarditis presenting with
or without systemic inﬂammatory response syndrome
Z. Kanafani, G. Vigliani, H. Boucher, H. Chambers, M. Rupp,
S. Nasraway, S. Rehm, M. Campion, E. Abrutyn, A. Karchmer,
D. Levine, G. Fatkenheuer, H. Brodt, T. Wolf, R. Corey (Durham,
Lexington, Boston, San Francisco, Omaha, Cleveland, Philadelphia,
Detroit, US; Cologne, Frankfurt, DE)
Objectives: S. aureus is a unique pathogen with an ability to invade
normal tissues including normal heart valves. Determining the optimal
length of therapy (LOT) at onset of S. aureus bacteraemia (SAB) is
therefore difﬁcult. In addition, the effect of the systemic inﬂammatory
response syndrome (SIRS) on the outcome of patients with documented
SAB (SIRS + SAB = sepsis) has not been determined. We evaluated
the ﬁnal diagnosis and outcomes in patients with documented SAB
enrolled in the recently reported SAB/S. aureus infective endocarditis
(SAIE) daptomycin trial who presented with and without SIRS (sepsis)
at baseline.
Methods: The SAB/SAIE daptomycin trial was a randomised study
conducted between August 2002 and February 2005 in 44 sites in
the United States and Europe. Eligible patients had 1 positive
blood cultures for S. aureus within two days of enrolment. Patients
were randomised to daptomycin 6mg/kg/d or combination of either
vancomycin 1 g every 12 hours or antistaphylococcal penicillin 2 g
every 4 hours, both with gentamicin 1mg/kg every 8 hours for 4 days.
Investigators determined the duration of treatment based on the working
diagnosis. Final diagnosis and outcome at the end of therapy (EOT)
and test of cure (TOC) were determined by an adjudication committee
blinded to treatment group assignment. SIRS was considered present at
baseline if patients met 2 or more of the following criteria: temperature
<36ºC or >38ºC, heart rate >90 bpm, respiratory rate >20 breaths/min,
WBC <4,000 mm3 or 12,000/mm3 or bands >10%.
Results: One hundred and seventy-six of the 235 patients enrolled with
SAB (75%) met SIRS criteria. The proportion with MRSA was similar
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in 38.6% patients with and 35.6% without SIRS. Complicated SAB
or SAIE was the ﬁnal diagnosis in 133/176 (75.6%) with SIRS and
41/59 (69.5%) without SIRS. Patients with and without SIRS had similar
success rates at EOT (78.4 vs 71.2%) and TOC (71.0 vs 64.4%) and
similar mortality by 42 days after treatment (11.4 vs 11.9%).
Conclusion: SAB is associated with a high rate of complicated disease
and SAIE irrespective of the presence of SIRS at baseline. The absence
of SIRS is not a useful predictor of outcome and should not be used to
limit duration of therapy in patients with SAB.
Final diagnosis SIRS (N= 176) n (%) No SIRS (N= 59) n (%)
R-sided IE 29 (16.5) 6 (10.2)
L-sided IE 14 (8.0) 4 (6.8)
Complicated SAB 90 (51.1) 31 (52.5)
Uncomplicated SAB 43 (24.4) 18 (30.5)
P851 The eradication of MRSA nasal carrier status by mupirocin
pomadeand the effect of eradication on the prevelance of
MRSA infection
H. Irmak, S. Cesur, F. Yildiz, C. Bulut, S. Kinikli, Z. Aygu¨n,
A.P. Demiro¨z (Ankara, TR)
Objectives: The aim of this study is to compare the rate of eradication
of MRSA carrier status in hospital staff with mupirocin with placebo
and to establish the effect of eradication on the prevalance of MRSA
infection.
Methods: This study was carried out in Infectious Diseases and Clinical
Microbiology Department of Ankara Training and Research Hospital.
Totally eigty-eight hospital staff, 44 of them in mupirocin grup
(20 MRSA nasal carriers, 24 MSSA nasal carriers) and further 44
hospital staff, who are MSSA carriers and administered placebo as
control group, were included in the study. Informed consent of the
patients and approval of ethics committee was obtained. Control group
received only placebo.
MRSA prevalance in the three months before administration of
mupirocin and the prevalance in the three months following adminis-
tration were calculated.
Mupirocin pomad was applied three times a day for 5 days to the nose.
6th day, 1 month and 2 months after application, nasal cultures from
obtained form the staff applied muciporin and those receiving placebo
and eradication rates established. and compared statistically. In statistical
analysis Chi-square and Fisher’s Exact tests were used.
Results: Eradication rates were found to be respectively 91.7%, 66.6%
and 58.3% after 6 days, 1 month and 2 months in mupirocin group while
they were 4.5%, 6.8% and 11.4% respecively in the control group. In
the mupirocin group, resistance developed against mupirocin in 2 (4.5%)
hospital staff. In another 6 (13.6%) hospital staff receiving mupirocin,
side effects such as feeling of burning developed in the nose. After
treatment ended, these complaints resolved spontaneously.
When the eradication rates at 6 days, 1 month and 2 months were
compared between two groups, statistically signiﬁcant difference was
found (p< 0.001). While MRSA infection prevalence was 9.6% (12/125)
in the three months before application of mupirocin, it was 6.8% (8/118)
in the the three months after application., with no statistically signiﬁcant
difference (p> 0.05).
Conclusion: In conclusion, although the eradication of nasal carrier
status of MRSA is higher with mupirocin compared with placebo,
mupirocin per se is not adequate in the reductionof the prevalence of
MRSA infection. In order to reduce the prevalance of MRSA infection,
all infection control measures for MRSA infection (isolation, contact
isolation, hand washing, laboratory based surveillance) and training of
the staff are required.
P852 A multicentre, double-blind, randomised clinical trial of par-
enteral cefepime in the treatment of acute bacterial infections
X.J. Lu (Chengdu, CN)
Objective: To evaluate the clinical efﬁcacy and safety of domestic
injectable cefepime for the treatment of acute moderate and severe
bacterial infections.
Methods: A multicentre double-blind randomised clinical trial was
conducted comparing the efﬁcacy and safety of domestic injectable
cefepime with imported one (Maxipime). Cefepime was administered
intravenously at a dose of 1−2 g twice daily for 7 to 14 days.
Results: A total of 211 patients were enrolled in the study. There were
109 patients who enrolled in FAS analysis and 104 in PPS analysis
in treatment group, while 108 patients were enrolled in FAS analysis
and 107 patients were eligible for PPS analysis in control group. At
the end of treatment, the cure rate and effective rate were 42.30% and
84.61% in trial group; while 48.59% and 79.43% in control group.
The bacterial eradication rates were 91.3% and 86.7%, respectively.
There was no statistical difference between the two groups (P> 0.05).
Adverse reactions were observed in 8.93% and 5.41% of patients in
the two groups, dominated by skin rash (1/112), temporary acidophilia
(2/112; 2/111) and mild elevated transaminases (4/112; 2/111).
Conclusion: Domestic injectable cefepime is effective and safe for the
treatment of acute moderate and severe bacterial infections.
P853 Efﬁcacy and tolerance of linezolid-rifampicin combination
prolonged oral therapy for bone and joint infections
E. Senneville, L. Legout, X. Lemaire, C. Dehecq, E. Beltrand, C. Loiez,
H. Migaud, Y. Yazdanpanah (Tourcoing, Lille, FR)
Objectives: To evaluate the efﬁcacy and safety of linezolid-rifampicin
combination (LRC) in the treatment of bone and joint infections.
Methods: The records for patients treated with LRC for more than
4 weeks because of chronic bone and joint infections were reviewed
for clinical outcome and tolerance. Primary end points were the clinical
outcome at follow-up after the end of treatment (F-EOT), and the
occurrence of adverse effects.
Results: Between June 1999 and July 2005, 29 adult patients with
18 infected orthopaedic devices including 11 prosthetic joints, and
11 chronic osteomyelitis, were eligible for the study. Pathogens were
predominantly methicillin-resistant staphylococci (16/30 strains, 53.3%).
The mean treatment duration was 17.8±7.5 weeks. Patients were given
intravenous therapy for 6−8 days as inpatients, and then, as outpatients,
were changed to oral therapy with weekly haematological monitoring.
Reversible anaemia (haemoglobin <90 g/L) was reported in 6 patients
(20.7%), of whom 4 had to receive blood transfusions. Mean time from
treatment initiation to anaemia onset was 7.5 weeks (range 4−11). No
other LRC-related haematological toxicity episodes (i.e. leukopenia and
thrombocytopenia) were recorded. Five patients (17.2%) had to stop the
antibiotic treatment because of the occurrence of serious adverse effects
(anaemia = 4, and peripheral neuropathy = 1). In the 10 patients who had
two-stage exchange of prosthetic device, no linezolid-resistant strains
grew from the samples taken during reimplantation of the prosthesis.
At the end of treatment, 26 patients (89.6%) were cured. During the
post-treatment follow-up (median duration: 17 months, range: 12−36),
1 patient experienced relapses of infection, resulting in an overall success
rate of 25/29 (86.2%).
Conclusions: LRC prolonged oral therapy seems effective for treating
patients with resistant Gram-positive cocci bone and joint infections,
including infected orthopaedic devices. However, close haematological
and neurological monitoring of patients receiving LRC prolonged therapy
is needed in order to reduce the occurrence of severe adverse effects.
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P854 Efﬁcacy of gentamicin for 5 days plus doxycycline for eight
weeks versus streptomycin for 2 weeks plus doxycycline for
45 days in the treatment of human brucellosis
M.R. Hasanjani Roushan, M.J. Soleimani Amiri, N. Janmohammadi,
S. Soleimani Amiri (Babol, IR)
Objectives: Regimen of choice and duration of therapy in human
brucellosis is unknown. The purpose of this study was to evaluate the
efﬁcacy of gentamicin for 5 days plus doxycycline for 8 weeks versus
streptomycin for 2 weeks plus doxycycline for 45 days in the treatment
of human brucellosis
Methods: From April 2005 to October 2006, this comparative clinical
study was conducted to compare the efﬁcacy of gentamicin for 5 days
plus doxycycline 100mg twice daily for 8 weeks (regimen GD) versus
streptomycin 1 gr for 2 weeks plus the same dose of doxycycline
(regimen SD) for 45 days at the department of infectious diseases, in
Babol, Iran. All cases were followed for 12 months after cessation of
therapy.
Results: Forty-nine cases with the mean age of 34±14 years and 44 cases
with the mean age of 36.5±15.3 years were treated by GD and SD
regimens, respectively. The clinical manifestations and laboratory test
results in these two treated groups were similar. Relapse was seen in
2 (4.1%) cases treated by regimen GD and in 2 (4.5%) cases treated by
regimen SD (p> 0.05). Cure rate with regimen GD was 95.9% and with
regimen SD was 95.5% (p> 0.05). Both regimens of therapy were well
tolerated.
Conclusion: The result of this study shows that gentamicin for 5 days
plus doxycycline for 8 weeks is as effective as standard regimen for
therapy of human brucellosis.
P855 Effectiveness and tolerability of amoxycillin and
azithromycin in treatment of patients with mild-to-moderate
community-acquired pneumonias in outpatient settings
A. Kondratenko, I. Bereznyakov, V. Pozhar (Kharkiv, UA)
Background: Although amoxycillin and azithromycin are recommended
in Ukraine as ﬁrst-line antibiotics to treat adult outpatients with
community-acquired pneumonias (CAP), there are no direct comparisons
between these antibiotics.
Objective: to compare an effectiveness and tolerability of amoxycillin
and azithromycin in outpatients with CAP conﬁrmed by chest X-ray with
no co-morbidities and other modifying factors and no bacterial sample
requirements for patient (pt) inclusion.
Methods: We performed a randomised open-label study in outpatients
with mild-to-moderate CAP aged 18−60 years. 56 pts with CAP
conﬁrmed clinically and by chest X-ray were randomly assigned for
treatment with amoxycillin (0.5 g tid po for 7−10 days), 45 pts were
assigned for treatment with azithromycin (0.5 g qd po for 3 days or 0.5 g
po x 1, than 0.25 g/d for 4 days). Dynamics of clinical, objective and
laboratory data was estimated in 48−72 hours, 7±1 and 12±2 days after
the beginning of treatment.
Results: Adverse reactions were registered in 1 pt (2.2%) from
azithromycin group and 2 pts (3.6%) from amoxycillin group; initial
antibiotic was changed in 1 case in the last group. Clinical recovery
with chest X-ray conﬁrmation (i.e. excellent results) were registered
in 20 pts (35.7%) from amoxycillin group and 15 pts (33.3%) from
azithromycin group, clinical recovery with no chest X-ray conﬁrmation
(i.e. good results) were determined in 11 (19.6%) and 7 pts (15.6%)
respectively. Satisfactory results (i.e. clinical improvement) were deﬁned
in 13 (23.2%) and 17 pts (37.8%) correspondingly. In 4 cases (7.1%)
from amoxycillin group and 3 cases (6.7%) from azithromycin group
it was not possible to estimate results. Unsatisfactory results of
therapy were documented in 2 pts (4.4%) from azithromycin group and
8 pts (14.3%) from amoxycillin group.
Conclusion: in 12±2 days of outpatient treatment positive results were
reached in 78.5% cases in amoxycillin group and 86.7% cases in
azithromycin group. There was a similar tolerability of both regimens of
treatment.
P856 Comparison of ornidazole and metronidazole in the
treatment of trichomoniasis in men
A. Khryanin, O. Reshetnikov (Novosibirsk, RU)
Objective: Trichomonas vaginalis is a globally common sexually
transmitted human parasite. Many strains of T. vaginalis from around
the world have been described to be resistant to the current drug
of choice, metronidazole. The aim of the study was to compare
efﬁcacy of metronidazole and ornidazole in the treatment of urogenital
trichomoniasis in men.
Methods: A series of consecutive outpatients attending our STD clinic
in 2000–2004 were included in the study. Four hundred twenty seven
men aged from 20 to 48 years were randomly assigned to receive
either 250mg metronidazole t.i.d. over 10 days (210 subjects) or 500mg
ornidazole (Tiberal®) b.i.d. over 10 days (217 subjects). Clinical efﬁcacy
was assessed 1, 2 and 3 weeks after end of treatment regimen as well as
microbiological efﬁcacy with microscopy and culture.
Results: Clinical efﬁcacy of metronidazole or ornidazole after 3 weeks
was 57.6% and 94.5%, microbiological efﬁcacy – 77.1% and 98.2%,
respectively. Side effects were reported by 59.0% metronidazole arm
versus only 3.7% in ornidazole arm.
Conclusion: Thus, ornidazole is more effective and safe medication than
metronidazole in the treatment of T. vaginalis infection in males.
P857 Clindamycin/aminoglycoside versus b-lactam monotherapy
for the treatment of intra-abdominal infections: a
meta-analysis of randomised controlled trials
M.E. Falagas, D.K. Matthaiou, E.A. Karveli, G. Peppas (Athens, GR)
Objective: We sought to compare the effectiveness and safety of
clindamycin/aminoglycoside combination therapy with broad-spectrum
b-lactam monotherapy in patients with intra-abdominal infections
by performing a meta-analysis of the available relevant randomised
controlled trials (RCTs).
Methods: The studies for our meta-analysis were retrieved from
searches of the PubMed database and reviewed by two indepen-
dent reviewers. We considered a study eligible if: (1) it was a
RCT comparing clindamycin/aminoglycoside combination therapy with
b-lactam monotherapy for the treatment of patients with intra-abdominal
infections, (2) reported data regarding the effectiveness of the treatment,
mortality, and/or adverse effects, (3) included at least 10 evaluable
patients, and (4) at least 70% of the study population had an intra-
abdominal infection.
Results: A total of 28 RCTs were included in the analysis. Beta-lactam
monotherapy was more effective regarding cure of the infection than
clindamycin/aminoglycoside combination (3,177 clinically evaluable
patients, ﬁxed effects model, OR= 0.67, 95%CI 0.55 to 0.81, p< 0.001).
The same result was found in several subset sensitivity analyses. There
was no difference in all-cause mortality and attributable to infection
mortality [2,382 intention-to-treat (ITT) patients, ﬁxed effects model,
OR= 1.25, 95%CI 0.74 to 2.11 and 1,976 ITT patients, ﬁxed effects
model, OR= 1.19, 95%CI 0.59 to 2.41, respectively]. There was no
difference regarding overall adverse effects and ototoxicity (1,460 ITT
patients, ﬁxed effects model, OR= 1.05, 95%CI 0.80 to 1.37, and 1,404
ITT patients, ﬁxed effects model, OR= 3.22, 95%CI 0.72 to 14.45,
respectively). However, treatment with clindamycin/aminoglycoside was
more likely to be associated with nephrotoxicity compared to b-lactam
(3,065 ITT patients, ﬁxed effects model, OR= 3.7, 95%CI 2.09 to 6.57,
p< 0.001). On the other hand, clindamycin/aminoglycoside was less
likely to be associated with antibiotic associated diarrhoea compared
to b-lactam (3,050 ITT patients, ﬁxed effects model, OR= 0.68,
95%CI 0.46 to 1, p = 0.051).
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Conclusion: The results of our meta-analysis suggest that b-lactams are
more effective in the treatment of intra-abdominal infections compared
to clindamycin/aminoglycoside combination.
P858 Beta-lactam alone compared to b-lactam-macrolide
combination therapy for community-acquired pneumonia:
prospective, observational study using a propensity score
M. Paul, A. Nielsen, A. Gafter-Gvili, E. Tacconelli, S. Andreassen,
N. Almanasreh, E. Goldberg, R. Cauda, U. Frank, L. Leibovici for
the TREAT Study Group
Objectives: Observational studies have shown improved outcomes for
patients treated with b-lactam (BL)-macrolide combinations compared
to single BL treatment for CAP. However patients treated for an atypical
pathogen are probably a-priori different from patients treated with a BL
drug alone. Physicians are likely to reﬂect in their choice of treatment
common wisdom as to the presentation of “atypical” pathogens. We used
a propensity score to adjust for these differences and compared treatment
groups.
Methods: Patients were enrolled as part a multicentre trial assessing a
decision support system for antibiotic treatment in Israel, Germany and
Italy. We compared all 30-day mortality for patients with radiologically
proven CAP treated empirically with BL alone vs. combination therapy.
Baseline characteristic of the two treatment groups were used to
develop a propensity score for combination therapy and comparisons
were matched by patients’ propensity score. In addition, we used the
propensity score as a covariate in a logistic model for mortality.
Results: Patients treated with BLs alone (N= 169) were older (mean
age 70.6±17.3 vs. 65.0±19.6 years), more often residents of nursing
homes (9% vs 4%), bed-ridden (60% vs. 40%), had a higher chronic
diseases score and a different clinical presentation compared to patients
given combination therapy (N= 282). Accordingly, the propensity
scores differed markedly, 0.179±0.139 vs. 0.074±0.103, p< 0.001,
respectively. Unadjusted fatality was signiﬁcantly higher with BL
monotherapy 22% vs. 7% (p< 0.001) and remained signiﬁcantly higher
on multivariate analysis without adjusting for the propensity score. Only
27 patients in the BL group could be matched to (27) patients in the
BL-macrolide group using the propensity score with a precision of 3
ﬁgures after the decimal point. Among these patients, mortality was
identical in the two study groups, 3 demises each (11%, p = 1.0, OR= 1.0,
95%CI 0.2–5.5). A multivariable analysis for mortality, adjusting for
the propensity score showed no signiﬁcant difference between the study
groups (OR= 0.84, 95%CI 0.27–2.51).
Conclusions: Patients given single BL treatment for CAP are markedly
different from patients given combination therapy. Only a small
percentage of patients could be matched using a propensity score and
when matched mortality is identical. Classical multivariable techniques
may not adjust correctly for these differences.
P859 Comparison of 2 options for antibacterial treatment of
tularaemia type B
A. Stepanyan (Yerevan, AM)
Objectives: To compare the effect of antibacterial treatment with
streptomycin or tetracycline on lymphadenitis during the Francisella
tularensis type B infection.
Methods: This was a randomised clinical trial using indicated antibiotics
for this infection. Thirty male military personnel with tularaemia type B,
aged 18 to 20 years, were randomly prescribed to get either streptomycin
1.0×2 i.m. (14 patients) or tetracycline hydrochloride 0.5×4 p.o.
(16 patients) for 10 days. All the cases were mild to moderate and
presented as pharyngeal-bubonic or ocular-bubonic forms during the
ﬁrst week of disease. No antibiotic has been taken before admission
to the hospital. Patients stayed at the hospital until the resolution or
sclerosis of lymph node or healing of ﬁstula after suppuration. In the
case of suppuration (determined by ﬂuctuation of node), early surgical
drainage was performed, after test puncture. Sclerosis of lymph node was
deﬁned as no suppuration occurred during the ﬁrst 3 weeks in hospital.
From previous own experience it was observed that ﬂuctuation usually
occurs within the ﬁrst 4 weeks of disease and if not so it will develop to
sclerosis. The outcomes of study were the duration of stay in the hospital
and the resolution/suppuration or sclerosis of lymph node. The t test was
used for signiﬁcance of difference for hospital stay and chi squared test
for lymphadenitis outcomes.
Results: Patients in the tetracycline group stayed in the hospital
20±2.1 days, while patients receiving streptomycin 28±3.4 days
(P< 0.01). In 14 patients of tetracycline group (87.5%) and 12 patients
of streptomycin group (85.7%) resolution or suppuration of lymph nodes
were observed (P> 0.05). All the suppurations occurred in the 2nd or
3rd weeks of hospital stay. In other cases sclerotic lymph node remained.
Discussion: Tularaemia type B infection is mild to moderate infection,
which causes signiﬁcant lymphadenitis. The outcomes of bubo are
resolution, suppuration or sclerosis. First two outcomes are favourable,
because simple surgery or no surgery is required for complete recovery.
Unlike it, sclerotic lymph node remains in the subcutaneous tissue in
the third case, which needs cosmetic surgery. Treatment by tetracycline
leaded to shorter hospital stay but there was no signiﬁcant difference for
bubo outcomes.
It can be concluded that using tetracycline in the case of mild to moderate
tularaemia type B reduces the time necessary for hospital stay or medical
care.
P860 Efﬁcacy and safety of gatiﬂoxacin for chronic prostatitis
(NIH category II or IIIa) in Korea
S. Lee, M. Kim, C. Kim, B. Shim, D. Kim, C. Han, Y. Ha, Y. Cho
(Busan, Seoul, Gwangju, Daegu, KR)
Objectives: The objective of this study was to investigate the efﬁcacy
and safety of gatiﬂoxacin for patients with chronic prostatitis (NIH
category II or IIIa) in Korean urologic practice.
Materials and Methods: A total of 16 outpatient urology clinics
at tertiary care medical centres in Korea participated. Gatiﬂoxacin
(400mg/day) treatment (S.D.) of 149 patients (20 patients with
category II and 129 patients with category IIIa) with prostatitis, mean
age 45.8 (13.3) years, was carried out for 41.7 (33.1) days. A 4-glass test
according to Meares and Stamey or two glass test was carried out at study
entry and one month after the end of treatment. Clinical response, safety
and bacteriological response were assessed before treatment (within
48 hours of initiation of the study medication) and at one month after
treatment completion.
Results: In a total of 149 patients, the total NIH-CPSI score
was signiﬁcantly reduced from 20.5 to 10.0 (response rate 86.7%;
95%CI 80.2−93.2%) (p< 0.05). Sub-scores of pain, urinary symptoms
and impact on the quality of life were also signiﬁcantly reduced from
8.9 to 3.8 (response rate 83.8%; 95%CI 76.8−90.9%), from 4.2 to 2.0
(response rate 73.3%; 95%CI 64.9−81.8%) and from 7.4 to 4.2 (response
rate 79.0%; 95%CI 71.3−86.8%), respectively (p< 0.05). In terms of the
overall clinical efﬁcacy assessment by investigators, out of 149 patients
with prostatitis, 71.2% were assessed to be responders. Bacteriological
studies in expressed prostatic secretion (EPS) or post prostate massage
urine (VB3) at 1 month after treatment completion demonstrated that
the overall eradication rates of pathogens was 85% and the pyuria (more
than 10 WBC/HPF) rates in the NIH category II and IIIa were 35% and
18.6%, respectively (overall rate 20.8%). There were 16.1% of patients
that presented with some adverse events considered by investigators to
be related to the drug. The majority of adverse events were considered
to be of mild (87.5%) or moderate (8.3%) intensity.
Conclusions: These results suggest that gatiﬂoxacin in Korean urologic
practice is well tolerated and improves the clinical outcomes in the
patients with chronic prostatitis (NIH category II or IIIa).
S222 17th ECCMID / 25th ICC, Posters
Antibiotic resistance mechanisms
P861 ECL-1, a novel plasmid-mediated class A b-lactamase with
carbenicillinase characteristics from Escherichia coli
C. Papagiannitsis, A. Loli, L.S. Tzouvelekis, E. Tzelepi, G. Arlet,
V. Miriagou (Athens, GR; Paris, FR)
Objectives: Characterisation of a novel class A b-lactamase (ECL-1)
encoded by an 80-kb self-transferable plasmid from Escherichia coli.
Methods: E. coli EC-3521r was isolated in 2002 from a urine sample
of a patient treated in a general hospital. MICs of b-lactam antibiotics
were determined by agar dilution. Isoelectric points of the produced
b-lactamases were determined by IEF of cell extracts. Hydrolysis rates
of b-lactams and inhibitory activity of clavulanic acid, tazobactam, and
sulbactam, were determined by UV spectrophotometry. Bla-genes were
identiﬁed by PCR. Mating experiments were performed in mixed broth
cultures. Bla gene encoding fragments were cloned into the pBCSK(+)
vector and the nucleotide sequences of inserts were determined.
Results: By PCR screening, the E. coli EC-3521r isolate was found to be
positive for blaACC and blaTEM. Analysis of the b-lactamase content
by IEF, indicated production of three main b-lactamase species with
isoelectric points (pIs) of 7.8 corresponding to ACC-1, 5.4 (TEM-1) and
5.8. Identities of the former two enzymes were conﬁrmed by sequencing
of PCR products. Beta-lactam resistance was transferred by an 80-kb
plasmid (pR3521) that encoded all three b-lactamases.
A cloned fragment of pR3521 encoded production of the b-lactamase
with a pI of 5.8 and mediated resistance to penicillins but not
cephalosporins. The respective recombinant plasmid carried a 3,833-
bp Sau3A fragment containing an ORF of 867-bp homologous to the
orf1 observed in ACC-1-encoding plasmids. This orf did not exhibit
signiﬁcant homology with any known sequence. However, the deduced
polypeptide (288aa) possessed the typical motifs of a class A b-lactamase
and was designated blaECL-1. ECL-1 exhibited 51% amino acid
sequence identity with the chromosomal carbenicillinases of the RTG.
The enzyme was effective against ampicillin and carbenicillin while the
relative hydrolysis rates of oxacillin, cephalothin and cephaloridine were
low. Tazobactam was the most potent inhibitor of ECL-1 followed by
clavulanic acid and sulbactam.
Conclusion: The ECL-1 is a novel class A b-lactamase of unknown
origin, that is functionally and phylogenetically related to the RTG
subgroup of the CARB b-lactamases.
P862 Prevalence and molecular epidemiology of CTX-M
b-lactamases in Croatia
B. Bedenic, M. Tonkic, I. Jajic-Bencic, S. Kalenic, A. Baraniak, J. Fiett,
M. Gniadkowski (Zagreb, Split, HR; Warshaw, PL)
Objectives: The aim of this study was to characterise b-lactamases
produced by these isolates.
Methods: Eleven E. coli strains were isolated from two hospitals in
Zagreb and one in Split. Extended-spectrum b-lactamases (ESBL) were
detected by double-disk synergy test and CLSI combined disk test.
Susceptibility to a wide range of antibiotics was determined by the broth
microdilution method according to CLSI. ESBLs were characterised by
isoelectric focusing, substrate proﬁle determination, PCR and sequencing
of blaCTX-M genes. The two latter approaches were also used to study
the genetic environment of the genes. Genetic relatedness between the
strains was tested by PFGE.
Results: Despite some similarities, susceptibility testing revealed
signiﬁcant differences between the groups of isolates identiﬁed in the
three hospitals.
All of the isolates produced b-lactamases with high pI values, either 8.9
in the case of the isolates from the University Hospital Center Zagreb
or 8.4 in the case of the all remaining isolates. PCR for blaCTX-M
genes was positive and sequencing these identiﬁed the pI 8.9 enzymes as
CTX-M-15, whereas those with a pI of 8.4 as CTX-M-3 b-lactamase. An
insertion sequence ISFcp1 was identiﬁed 48 bp upstream of all blaCTX-
M-15 producers and 128 bp upstream of one blaCTX-M-3 gene, whereas
the remaining blaCTX-M-3 genes were accompanied by the IS26
element. The ﬁve CTX-M-15-producing isolates were indistinguishable
in the PFGE analysis, and different from the all remaining isolates. The
group of CTX-M-3 producers from Split was much more diverse with
only two isolates that were clonally related to each other. The isolate
from the Sisters of Mercy Hospital in Zagreb was unrelated to any other
study isolate.
Conclusions: This study reported the appearance of CTX-M-3 and
CTX-M-15 in clinical isolates of E. coli from Croatia. Despite the
high similarity of these enzymes, differences in the genetic context of
their genes indicated that they emerged independently on each other.
Moreover, it is possible that there were also two different origins of
CTX-M-3, which altogether is striking considering the relative small
geographic region of the isolates identiﬁcation. CTX-M-15 producers
disseminated in the hospital in Zagreb by clonal spread, whereas in Split
the blaCTX-M-3 gene was probably horizontally transmitted between
non-related strains. CTX-M b-lactamases are still rare in Croatia.
P863 A single-tube real-time PCR and melting-curve analysis
for detection and characterisation of TEM-type
extended-spectrum b-lactamases
A. Nikulin, Y. Alexeev, M. Edelstein (Smolensk, Moscow, RU)
Objectives: ESBLs of the TEM-type are among the most common
plasmid-mediated enzymes conferring resistance to oxyimino-b-lactams
in Enterobacteriaceae. Despite the overall diversity, all the known TEMs
capable of hydrolising oxyimino-b-lactams differ from TEM-1 and
TEM-2 penicillinases in at least one of the three aa positions: 104, 164,
and 238, suggesting their importance for ESBL activity. Here we describe
a simple and rapid method for identifying mutations at these positions
in a single real-time PCR reaction.
Methods: The proposed method utilises asymmetric ampliﬁcation of
three ultrashort (50−63 nt) fragments of blaTEM genes encompassing
the key mutation sites. Each fragment is ampliﬁed using one excess
primer internally labeled with the BHQ quencher in the presence of 3′-
ﬂuorophore-labeled probe that covers the mutation site and anneals to
the extension product of the BHQ-labeled primer just 1 to 3 nucleotides
apart from its 3′-end. Thus, binding of the probe to its target brings the
ﬂuorophore and quencher into close contact and results in ﬂuorescence
quenching. Owing to this design, several nucleotide polymorphisms
(SNPs) in each site can be discerned using post-PCR melting curve
analysis. When the probe is fully complementary to the product, it melts
at higher temperature, if an SNP is present, the melting temperature (Tm)
speciﬁcally decreases depending on the type and position of mutation. In
this study, three probes were designed to match the blaTEM-1 sequences
at codons 104, 164, and 237–240, respectively, and one probe was
designed to match the mutant codon (AAG) for Lys240. The probes
were labeled with different dyes to allow multiplex detection in the same
reaction.
Results: The applicability of the real-time PCR method described herein
for detection of SNPs associated with ESBL activity was evaluated
using a collection of 20 laboratory and 100 clinical strains producing
TEM-1, TEM-2 (non-ESBL controls), and various TEM-type ESBLs
carrying the following mutations: E104K, R164C, R164H, R164S,
A237T, G238S and G240K. All of these mutations were successfully
detected and discriminated from the wild-type sequences according to
speciﬁc Tm-s. Most notably, the proposed design of primers and probes
made possible an unambiguous identiﬁcation of key mutations regardless
of the presence of closely spaced silent SNPs.
Conclusion: The simplicity and rapidity of the described method make
it useful for epidemiological studies on TEM ESBLs.
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P864 Complete nucleotide sequence of pEK499, a multidrug-
resistance plasmid from the UK’s most prevalent Escherichia
coli strain with CTX-M-15 b-lactamase
E. Karisik, A. Underwood, M.J. Ellington, D.M. Livermore,
N. Woodford (London, UK)
Objectives: Multi-resistant E. coli with CTX-M (mostly CTX-M-15)
b-lactamases are prevalent in the UK, with several epidemic strains and
many unrelated producers. Strain A is the most widespread producer
clone, recorded from >45 centres. We report the complete nucleotide
sequence of pEK499, a multi-resistance plasmid encoding CTX-M-15
enzyme in epidemic strain A.
Method: pEK499 was randomly sheared and the 2−3 kb fraction was
cloned into the pGEM-Teasy vector, prior to transformation into E. coli
DH10b. Inserts were sequenced by dye terminator chemistry. Sequences
were assembled using the Staden Package. Combinatorial PCRs, directed
PCRs, and walking reads on selected clones were used to assemble the
sequences and to ﬁll-in gaps.
Results: pEK499 was found to be a circular molecule of 117,536 bp
belonging to incompatibility group FII. It harboured up to 185 predicted
genes and encoded multi-resistance and virulence factors. With the
exception of blaTEM-1, all antibiotic resistance genes were clustered in
a 25-kb region. They included blaCTX-M-15 and blaOXA-1 as well as
genes conferring resistance to aminoglycosides and ciproﬂoxacin (aac6’-
Ib-cr), macrolides [mph(A)], chloramphenicol (catB3) and tetracycline
[tet(A)]. A 1.8-kb class I integron was present within the multi-resistance
region; this carried dfrA17 and aadA5, encoding trimethoprim and
streptomycin resistance respectively, also sulI encoding sulphonamide
resistance. Virulence-associated genes present on pEK499 included the
serum survival gene traT, as well as vagC/D. pEK499 also encoded the
F-plasmid-derived CcdA/B toxin/antitoxin addiction system.
Conclusion: Plasmid pEK499 harboured 10 antibiotic resistance genes
affecting 8 antibiotic classes, along with different virulence determinants.
It may contribute towards the epidemiological success of E. coli strain
A in the UK. The toxin/antitoxin addiction system will ensure its
maintenance in the absence of antibiotic pressure.
P865 A new metallo-b-lactamase gene (blaIMP-22) harboured in
class 1 integron from Pseudomonas ﬂuorescens
C. Pellegrini, G. Celenza, P. Mercuri, M. Galleni, B. Segatore,
G. Amicosante, M. Perilli (L’Aquila, IT; Lie`ge, BE)
Objectives: Intensive use of b-lactams in human and animals practice
promoted spreading and evolution of resistance determinants also among
environmental bacteria. These bacteria represent an important reservoir
of mobile metallo-b-lactamase determinants.
Methods: Pseudomonas ﬂuorescens was isolated from environment
samples derived from efﬂuent of urban sewage. PCR experiments using
speciﬁc primers for blaIMP and blaVIM genes were performed on
genomic DNA of P. ﬂuorescens. The presence of mobile elements such
as integrons was investigated by PCR using the speciﬁc primers for
5′CS and 3′CS region. The nucleotide sequence was submitted to the
EMBL/GenBank whit accession number DQ361087. The blaIMP-22
gene was cloned in pBC-SK vector to yield the recombinant plasmid
pBC-IMP22. In vitro susceptibility of E. coli HB101 harbouring the
pBC-IMP-22 plasmid versus different antibiotics was investigated.
Results: P. ﬂuorescens was highly resistant to imipenem (32 mg/mL),
meropenem (32mg/mL), cefotaxime (>128mg/mL) and ceftazidime
(>64mg/mL) and susceptible to penicillins (piperacillin, MIC= 16mg/
mL; amoxicillin, MIC= 8mg/mL). The blaIMP gene-isolated by PCR
revealed an ORF of 741 bp that encode for a pre-protein of 246 amino-
acid, named IMP-22. Compared to other known IMP b-lactamases, the
IMP-22 enzyme is quite divergent from other IMP variants: its closest
relative is IMP-16 (94% sequence identity) and IMP-1 is 85% identical
to IMP-22. The IMP-22 shows three unique substitutions at the following
positions: E104D, K108Q and E174V (EBL numbering). Sequence
mapping obtained from PCR products, carried out using 5′CS for and
3′CS rev primers and P. ﬂuorescens genomic DNA, demonstrated that
blaIMP-22 is located in a class 1 integron. The genetic context in which
was located blaIMP-22 is upstream represented by typical structure of
5′CS region whereas the 3′CS region is represented by qaEDelta and
sul. Downstream the blaIMP-22 gene cassette an ORF of 327 bp was
found. The amino acid translation of this last region corresponds to a
putative unknown protein.
Conclusion: Detection of a new metallo-b-lactamse in environmental
strain is very interesting but not rare. In this case blaIMP-22 gene was
harboured by a class 1 integron whose structure is typical of most of
integrons found in clinical isolates, but not in environmental bacteria.
P866 Mutators are not responsible for the association between
b-lactam and quinolone resistance in Escherichia coli with
AmpC hyperproduction phenotype
M. Conejo, G. Amblar, E. Perea, L. Martı´nez-Martı´nez (Seville, ES)
Objective: Clinical isolates of Esherichia coli (Eco) resistant to
quinolones displaying an AmpC hyperproduction phenotype (resistance
to both cefoxitin and amoxicillin-clavulanate in the absence of
extended-spectrum b-lactamases) have been increasingly observed in our
institution. The aim of this study was to determine if the frequency of
hypermutable strains is higher in this group of organisms than in isolates
without combined resistance to both quinolones and b-lactams.
Method: Rifampin (Rif) resistance mutation frequency (MF) was studied
in 97 Eco isolates from the Univ. Hosp. V. Macarena, Seville, Spain,
including 60 isolates showing an AmpC hyperproduction phenotype
resulting from several point mutations in the promoter and or the
attenuator of the chromosomal ampC gene (ACBL+) and co-resistance
to ciproﬂoxacin and nalidixic acid (QUINR), 9 isolates ACBL+ and
susceptible to both quinolones (QUINS), and 28 isolates susceptible to
both cefoxitin and amoxicillin-clavulanate (ACBL−) and either QUINR
or QUINS (15 and 13 strains respectively). Three Luria-Bertani (LB)
tubes for each strain were inoculated with an independent colony from
a blood agar plate. After 24 h of incubation, appropriate dilutions were
seeded onto LB agar plates with and without Rif (100mg/L), and colony
counts were performed after 48 h. MFs were reported as a proportion
of the number of Rif-resistant colonies to the total viable count. The
results were the mean value obtained in three independent experiments
that were repeated in cases of discrepancies. Eco AB1157 mutS::Tn10,
with a defective mutS gene, was used as a strong mutator control, and
Eco ATCC25922 as a non hypermutable control. Statistical differences
were determined by the chi-square test (p< 0.05: signiﬁcant).
Results: Strains were considered non hypermutable when the MF was
<4×10−8, weak mutators if 4×10−8MF< 4×10−7 and strong mutators
if MF 4×10−7. Of the 97 strains, 65 were non hypermutable, 29 were
weak mutators and 3 were strong mutators. Hypermutable strains were
detected in higher proportions in the isolates with ACBL+QUINS and
ACBL-QUINR (54.5% and 40%, respectively) than in isolates with
ACBL+QUINR (29.7%). Among ACBL-QUINS isolates only 15% were
hypermutable. No signiﬁcant differences were observed among groups.
Conclusion: Hypermutability could not explain the association between
b-lactam and quinolone resistance in clinical isolates of Eco with AmpC
hyperproduction phenotype.
P867 Carbapenem resistance mechanisms in Norwegian clinical
isolates of Pseudomonas aeruginosa
Ø. Samuelsen, L. Buarø, B. Aasnæs, C.G. Giske, B. Haldorsen,
G.S. Simonsen, T.M. Leegaard, A. Sundsfjord (Tromsø, NO; Stockholm,
SE; Oslo, NO)
Objectives: The objective of the study was to investigate resistance
mechanisms to carbapenems and evaluate phenotypic selection criteria
for metallo-b-lactamase (MBL) testing in carbapenem resistant clinical
isolates of P. aeruginosa in a low-prevalence country like Norway.
Methods: 31/138 imipenem resistant P. aeruginosa clinical isolates from
Norwegian hospitals (year 2004 to 2006) with a positive MBL Etest
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(IP/IPI ratio of 8 and/or ellipse/phantom zone) were retested at the
Reference Centre. A broad spectrum b-lactam MIC screen by Etest was
also done. Veriﬁcation of MBL presence was done by PCR (blaIMP and
blaVIM) and by spectrophotometric analysis of imipenem hydrolysis by
crude cell extracts. As part of an ongoing study a subset of the strains
(n = 10) was evaluated for changes in the transcription of oprD and mexB
by quantitative RT-PCR.
Results: Of the 31 MBL Etest positive isolates 7 were positive upon
retesting. Interestingly, the IP MIC was reproducible while the IPI
MIC was consistently increased, often by more than 2-fold dilutions.
MBL production was veriﬁed in two isolates by PCR and hydrolysis
of imipenem, resulting in 29 and 5 false-positive isolates in the initial
and retesting respectively. Analysis of the resistance proﬁle of the
isolates showed that additional selection criteria for MBL testing such as
resistance to meropenem and/or ceftazidime using EUCAST breakpoints
would reduce the number of false positives further. qRT-PCR on the
subset of the isolates (n = 10) revealed a signiﬁcant downregulation of
oprD (n = 6) and/or upregulation of mexB (n = 4) in the tested isolates.
Conclusions: (i) In this study MBL Etest results were difﬁcult to
reproduce and overestimated the presence of MBL in a low prevalence
country like Norway. (ii) Additional selection criteria such as meropenem
and/or ceftazidime resistance will reduce false-positive results and should
be considered before more labour intensive analysis are performed.
(iii) Gene transcription analyses indicate that decreased permeability
and efﬂux are more prevalent mechanisms than MBL production
in carbapenem resistant Norwegian P. aeruginosa isolates. (iv) False
positive test results are probably due to the permeabilising effect of
EDTA.
P868 Occurrence of OXA-58 and an OXA-58 variant in
Acinetobacter baumannii isolates from blood cultures in a
university hospital in Athens, Greece
I. Galani, V. Sakka, L. Galani, M. Souli, Z. Chryssouli, H. Giamarellou
(Athens, GR)
Objectives: Imipenem (IMP)-resistant A. baumannii isolates, collected
from blood cultures of hospitalised patients in the University General
Hospital “Attikon”, between September 2004 – May 2005, were studied
for their clonality and carbapenemase content.
Methods: Susceptibility to antimicrobials was determined using a broth
microdilution method and E-test. Bacterial clones were identiﬁed by
PFGE with ApaI. Metallo-b-lactamases were detected by the IMP-
EDTA disc synergy test and by PCR with primers speciﬁc for blaVIM.
Multiplex PCR with primers amplifying blaOXA-23-like, blaOXA-24-
like, blaOXA-51-like and blaOXA-58-like, was performed according to
Woodford et al (Int J Antimicrob Agents 2006; 27:351–353). Sequencing
of cloned PCR products was performed by MWG-THE Genomic
Company. Sequence similarity searches were carried out with the BLAST
programme found at the website of the NCBI.
Results: Twenty-seven non-repetitive IMP-resistant isolates, 70.2% of
all A. baumannii strains isolated from blood cultures, were tested. All
isolates presented a multi-resistance pattern, with all being susceptible
to colistin (MICs: 0.125–0.75) and 33% being susceptible also to
ampicillin/sulbactam. A. baumannii isolates were distributed into seven
genotypes by PFGE proﬁles, with 12, 4, 4, 3, 2, 1, and 1 strains in
each group. The three genotype-groups of 12 and 4 isolates were further
divided into 2 subgroups. None of the isolates was positive for metallo-
b-lactamase production by IMP-EDTA synergy test or PCR. Multiplex
PCR for OXA-type carbapenemases revealed the presence of blaOXA-
51-like, which is believed to be intrinsic to A. baumannii and blaOXA-
58-like in all isolates. Sequencing of blaOXA-58 PCR amplicon revealed
the presence of the blaOXA-58 in most of the isolates but also the
existence of a novel variant of OXA-58 in which an A to G substitution
revealed a Thr to Ala amino acid change.
Conclusions: Several clones of IMP-resistant A. baumannii producing
both blaOXA-58 and naturally occurring blaOXA-51-like have emerged
as important bloodstream pathogens in our hospital. This observation
emphasizes the importance of both the restriction of carbapenem usage
as well as of the strict implementation of hand hygiene techniques for
the containment of this emerging threat.
P869 Spread of clinical extended-spectrum b-lactamase
(CTX-M)-producing Escherichia coli in Portugal
J. Leita˜o, N. Mendonc¸a, V. Manageiro, D. Louro, E. Ferreira,
M. Canic¸a on behalf of the Antimicrobial Resistance Surveillance
Program in Portugal (ARSIP)
Objectives: CTX-M extended-spectrum b-lactamases, which had a rapid
growing and geographic dissemination, are the main recent cause of
resistance to third-generation cephalosporins. The aim of this study
was to characterise the resistance mechanisms to b-lactam antibiotics
of clinical Escherichia coli strains, using phenotypic, biochemical and
molecular approaches.
Methods: During a 2-year period, started on March 2004, 181
nonrepetitive E. coli strains were isolated as ESBL producers from
different clinical specimens at 9 hospitals from 3 different Portuguese
regions. In this work, were only investigated the ESBL (CTX-M)-
producing strains. Antimicrobial susceptibility was performed by broth-
microdilution method. PCR and sequencing were used to screen
and identify blaTEM, blaSHV, blaOXA, ampC and blaCTX-M genes.
Biochemical characterisation was performed by isoelectric focusing. The
genetic environment of blaCTX-M was characterised by PCR, regarding
for ISEcp1, IS26 and IS903 elements. Strains were subtyped by using
PFGE.
Results: Of the 181 strains 119 (66%) were CTX-M producers.
Susceptibility towards b-lactams conﬁrmed all isolates as ESBL
producers, also suggesting CTX-M enzymes expression, which was
corroborated by pI values. More than 98% of strains producing CTX-M
group-1 were resistant to cefotaxime and ceftazidime, while all CTX-M
group-9 producers were resistance to cefotaxime and 11% resistant to
ceftazidime. Overall, multidrug-resistant (92%) strains were predominant
in outpatients (50%) than inpatients (37%). PCR-sequence analysis
conﬁrmed the presence of blaCTX-M-15 (n = 110) and blaCTX-M-32
(n = 1) genes from CTX-M-1 group, blaCTX-M-14 (n = 9) genes from
CTX-M-9 group, blaTEM-1 (n = 104) and blaOXA-30 (n = 101). No
strain carried the blaSHV gene. ISEcp1 elements were found upstream
of all blaCTX-M genes and IS903 was detected downstream of one
blaCTX-M-14 gene. Genetic relatedness analysis revealed 5 clusters and
indicated that 76% of all isolates (from cluster IV) corresponded to a
single epidemic strain.
Conclusions: Our work conﬁrms the geographic spread in Portugal of
CTX-M-type b-lactamases, mainly CTX-M-15, and suggests that the
horizontal transfer of blaCTX-M genes, mediated by plasmids and/or
mobile elements, contribute to the dissemination of those enzymes
to community and hospital environments. Given the potent extended-
spectrum activity of these enzymes, their continuous spread would have
a distressing development.
P870 GES-1 and TEM-1-like b-lactamases of Pseudomonas aerug-
inosa strains isolated from patients in two Warsaw hospitals
A.E. Laudy, A. Cieloch, D. Dzierzanowska, S. Tyski, J. Patzer (Warsaw,
PL)
Objectives: Ambler class A extended-spectrum b-lactamases are
produced not only by Enterobacteriaceae family rods but also by
P. aeruginosa strains isolated from clinical materials of hospitalised
patients world wide. Recently, the presence of PER-1 enzymes produced
by P. aeruginosa isolated in Poland has been described.
The aim of the study was to identify strains producing TEM-, SHV-,
GES- and VEB-type ESBLs, among P. aeruginosa isolated in Warsaw
hospitals.
Methods: The analysed 35 P. aeruginosa strains were isolated from
clinical materials of patients in two Warsaw hospitals. The presence
of ESBL in the strains was detected by a double-discs synergy test
with inhibitors: clavulanic acid, sulbactam, tazobactam and imipenem.
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The antibiotics MICs value were determined by agar dilution methods,
according to CLSI recommendation. The presence of class 1 integron
and genes coding ESBL-type enzymes among P. aeruginosa was detected
by PCR. Gene cassettes were identiﬁed by sequencing of the obtained
amplicons.
Results: The ESBL-type enzymes were detected among 12 strains,
by double-discs synergy test with inhibitors of serine b-lactamases.
However, this test showed to be not useful for detection of ESBLs
in the remaining 23 isolates. Three out of 23 strains were resistant to
all b-lactams. In 2 isolates the gene coding class A b-lactamases was
identiﬁed – blaGES-1 in a strain from hospital A and blaTEM-1-like in
a strain received from hospital B. The clinical isolate producing GES-1
exhibited the inhibitor-sensitive phenotype. The synergy pattern between
inhibitors (clavulanic acid or imipenem) and ceftazidime, cefepime
or aztreonam was observed, as well as resistance to gentamicin and
all b-lactams except imipenem. The gene blaGES-1 is located on the
variable region of class 1 integron. The other strain, producing TEM-
1-like enzyme, was resistant to all b-lactams and no synergy between
inhibitors and b-lactams was observed. Additionally in case of this strain
no VIM-type metallo-enzymes were found.
Conclusion: GES-1 and TEM-1-like b-lactamases producing P. aerug-
inosa strains were identiﬁed the ﬁrst time in Poland. The double-discs
synergy test was not useful for detection of all Ambler class A ESBLs
among P. aeruginosa isolates.
P871 Phenotypic detection of AmpC in E. coli: comparison of
cloxacillin, boronic acid and EDTA disk synergy assays
C. Giske, B. Haldorsen, E. Lundblad, B. Aasnæs, G. Simonsen,
A. Sundsfjord (Stockholm, SE; Tromsø, NO)
Objectives: Disk synergy tests using cephalosporins ± boronic acid
or cloxacillin have been found to be both sensitive and speciﬁc for
phenotypic detection of chromosomal hyperproduction of AmpC and
plasmid-mediated AmpC in E. coli. Also, an assay based on EDTA
permeabilisation followed by analysis of distortion of cefoxitin inhibiton
zone has been described. The purpose of this study was to compare
the three methods against a previously characterised strain collection of
E. coli either hyperproducing chromosomal AmpC or featuring plasmid-
mediated AmpC.
Materials: A collection of 23 isolates from 12 different Norwegian
laboratories were characterised with respect to hyperproduction of
chromosomal AmpC (mediated by promotor mutations) and the presence
of plasmid-mediated AmpC b-lactamases. Control strains of Enter-
obacteriaceae with deﬁned plasmid-mediated AmpC or hyperproducing
chromosomal AmpC as well as negative controls (ESBL-producers
and wild-type E. coli) were included. Thirteen isolates were AmpC
hyperproducers, whereas CMY b-lactamases were detected in 10 isolates.
All isolates were subjected to disk synergy testing using cefoxitin,
cefotaxime and ceftazidime ± boronic acid (400 ug) or cloxacillin
(750 ug). A zone diameter difference of 5mm was considered
indicative of AmpC production.
Results: Synergy between cefoxitin and cloxacillin was found in all
isolates, while synergy between cefoxitin and boronic acid could be
demonstrated in all but two isolates. However, the latter two isolates
were positive when results obtained with cefotaxime and ceftazidime ±
boronic acid were taken into consideration. The EDTA test was negative
in two isolates hyperproducing chromosomal AmpC.
Conclusions: The cefoxitin ± cloxacillin assay correctly identiﬁed all
AmpC hyperproducers and CMY-producers. The cefoxitin ± boronic
acid assay failed to identify two isolates, but both of these were positive
with cefotaxime and ceftazidime ± boronic acid. This is in agreement
with earlier observations that synergy between cefoxitin and boronic acid
can sometimes be masked in strains featuring porin defects. Although
the strain collection is relatively small the results indicate that cefoxitin
± cloxacillin may be promising as a stand alone test for phenotypic
detection of AmpC production in E. coli. Further studies are warranted
to determine whether cefotaxime and ceftazidime should be included in
the cloxacillin assay.
P872 Extended-spectrum b-lactamase among non-typhoidic
Salmonella in paediatric unit of Algerian hospital
M. Ouar-Korichi, F. Assaous, L. Gilly, G. Paul, K. Rahal (Algiers,
DZ; Paris, FR)
Objectives: The purpose of this work is to characterise the different
types of extended-spectrum b-lactamases (ESBL’s) produced by non
typhoidic Salmonella and to study their evolution from 1989 to 2005.
Methods: From 1989 to 2005, 240 of non typhoidic Salmonella
producing ESBL’s were recovered from patient of multiple outbreaks
(n = 28) in paediatric unit from 13 hospitals. ESBL’s were detected by
disc diffusion method and conﬁrmed with MIC s of cefotaxime (CTX)
and ceftazidime (CAZ) plus clavulanate, sulbactam and tazobactam by
microdilution broth method. Isoelectric focusing was used to characterise
Pi of b-lactamases. PCR was performed with speciﬁc primers to type
b-lactamase genes like bla TEM, bla SHV, bla CTX-M. The sequencing
of the gene was used to identify the speciﬁc type of the b-lactamase.
Results: 240 strains were conﬁrmed as ESBL’s producers with the disc
diffusion methods and the MIC’s. The serotypes of the Salmonella
enterica were: m’bandaka (n = 136), brunei (n = 40), kedougou (n = 29),
seftemberg (n = 28), typhimurium (n = 7). These Salmonella were isolated
from following biological products: stool (n = 217), blood (n = 15), urine
(n = 5), tear ﬂuid (n = 1), pus (n = 1), physiological water (n = 1).
The strains of 18 outbreaks had the gene bla TEM. The sequencing of
the gene was made for 9 outbreaks and the results revealed that the
strains encoded for different enzymes TEM-1 (Pi 5.4), TEM 25 (Pi 5.4)
and TEM 110 (Pi 5.4) in the outbreak’s in 1989–1990, TEM 25 (Pi 5.4)
in 1991, TEM 47 (Pi 6) in the years 1993, 1994, 1995, 1999 and TEM
19 (Pi 5.4) in 1994. But since 2001 we characterised strains with CTX-
M15 (Pi 8.8) extended-spectrum b-lactamase and CTX-M 3 (Pi 8.4) in 3
outbreaks in 2004–2005. In our study no strains produced SHV extended
b-lactamase.
Conclusion: Our study showed an evolution with different TEM ESBL’s
before 2001 and after that we found only CTX-M like CTX-M3 and
CTX-M 15.
P873 Prevalence of plasmid-mediated quinolone resistance
determinants: qnrA, qnrB and qnrS in extended-spectrum
b-lactamase producing Enterobacteriaceae strains in Hungary
D. Szabo´, N. Pesti, K. Kristo´f, L. Ro´kusz, J. Szentandra´ssy, K. Katona,
K. Nagy (Budapest, HU)
Objectives: To determine the prevalence of the plasmid-mediated
quinolone resistance genes: qnrA, qnrB and qnrS in a selected collection
of extended-spectrum b-lactamase(ESBL)-producing Enterobacteriaceae
strains.
Methods: A total of 92 non-repetitive ESBL-producing Klebsiella
spp., 58 ESBL-producing Enterobacter spp., and 20 ESBL-producing
E. coli isolates were collected from seven different hospitals of
Budapest, Hungary. The minimum inhibitory concentrations (MICs)
of ciproﬂoxacin, levoﬂoxacin and moxiﬂoxacin were determined by
microdilution technique according to the Clinical and Laboratory
Standards Institute (CLSI). All the isolates were screened for the
presence of the qnrA, qnrB and qnrS genes by PCR.
Results: 75% (15/20) of the ESBL-producing E. coli isolates were
resistant to all the three ﬂuoroquinolones. QnrA gene was detected
only in one strain and none of them harboured qnrB gene. QnrS was
present also in one strain (5%). 84% (49/58) of the ESBL-producing
Enterobacter. isolates were resistant to all the three ﬂuoroquinolones.
Three Enterobacter strains were qnrA positive (5%), 19 strains were
qnrB positive (33%), and two strains were qnrS positive (3%). Among
the Klebsiella isolates 55/97 (56%) were resistant to all the three
ﬂuroquinolones. Five Klebsiella strains were qnrA positive (5%), and two
strains were qnrB positive (2%) and one strain were qnrS positive (1%).
One qnrA positive Enterobacter strain, one qnrA positive Klebsiella
strain and two qnrB positive Enterobacter strains were susceptible to the
quinolones based on their MIC values. One qnrB positive Enterobacter
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strain and the qnrS positive Klebsiella strain’s MIC values belonged to
the intermediate range.
Conclusion: This is the ﬁrst report of qnr-positive ESBL-producing
Enterobacteriaceae strains in Hungary. The prevalance of qnrA and qnrS
gene was similar to the international studies, but the prevalence of
the qnrB gene was high among Enterobacter. suggesting widespread
distribution of plasmids conferring resistance to extended-spectrum
cephalosporins and quinolones in clinical isolates.
P874 Quinolone-resistant Brucella selection by treatment with ﬂu-
oroquinolones in a macrophage infection experimental model
R. Rodrı´guez Tarazona, J. Mun˜oz Bellido, J. Garcı´a Rodrı´guez
(Salamanca, ES)
Background: Brucellosis remains an important public health problem
in wide areas around the world. Classical treatments, though quite
effective, are not exempt of side effects. Fluoroquinolones (FQ) were
proposed years ago as a possible alternative, but the treatment failures
rate was unacceptable. A reduced activity of FQ due to the low pH in
the phagolysosome has been proposed, but not deﬁnitively demonstrated.
The possibility of failures as a consequence of resistant mutants selection
has not been explored. We have studied the emergence of FQ-resistant
Brucellae after experimental infection of macrophages cultures and
treatment with FQs.
Methods: We infected dog macrophages cultures with a B. melitensis
type strain, according previously described methods. Macrophage
cultures were infected with B. melitensis, opsonised with speciﬁc
antibodies. After 1 hour incubation to allow Brucellae to penetrate
into the macrophages, extracellular microorganisms were killed by
adding gentamicin. Then, ciproﬂoxacin (CIP), levoﬂoxacin (LEV) or
moxiﬂoxacin (MOX) were added. After 2 hours, cultures were lysed
and spread onto Brucella agar with CIP, LEV or MOX at 4x wild type
B. melitensis MIC. MICs of CIP, LEV and MOXI were determined for
the colonies grown on plates. When a signiﬁcant increase of resistance
was conﬁrmed, the gyrA and parC regions similar to regions containing
the QRDR in E. coli were ampliﬁed and sequenced.
Results: MICS of CIP, LEV and MOX for the original strain were
0.2, 0.1 and 0.2mg/mL respectively. MOX did not selected any resistant
strain. CIP and LEV selected resistant isolates with a high frequency,
around 1×10−4. Most of these resistant isolates showed increased MICs
for all the ﬂuoroquinolones tested, MICs ranging between 2−4mg/mL
for CIP, 1−2mg/mL for LEV and 2−8mg/mL for MOX. One isolate
showed signiﬁcant MICs increases only for MOX (2mg/mL). gyrA and
parC regions sequencing did not show signiﬁcant changes, and MICs in
presence of reserpine did not show differences as compared to antibiotics
alone.
Conclusions: The treatment with FQs in macrophage cultures infected
with Brucella select resistant strains with a high frequency. This fact
might play an important role in treatment failures of brucellosis with
FQs.
P875 Development of multidrug efﬂux mediated ﬂuoroquinolone
resistance in Salmonella hadar
S. Schmidt, P. Heisig (Hamburg, DE)
Objectives: Fluoroquinolones (FQs) are often the antibiotics of choice
to combat gastrointestinal, respiratory and urinary tract infections as well
as infections of the skin and soft tissue. However, bacterial resistance
is becoming an increasing problem. Resistance to FQs is acquired by
alterations of the target (mutations in type II topoisomerase genes gyrAB,
parC) as well as by decreased uptake and increased efﬂux. Multi-drug
efﬂux in E. coli is known to be due to elevated expression of several
RND-type efﬂux pumps like AcrAB-TolC. Enhanced expression of efﬂux
systems can be a result of mutations in local repressor genes or an altered
expression of global regulators like marA.
For investigating the development of multi-drug efﬂux mediated FQ
resistance in S. hadar a selection experiment has been performed and the
resulting ﬁrst and second step mutants have been analysed by sequencing
of target genes, performing susceptibility testings as well as quantitative
real-time PCR to determine putative expression changes of efﬂux pumps
and global regulators.
Methods: For in vitro selection of FQ resistant mutants S. hadar
was plated on ciproﬂoxacin and sparﬂoxacin (2−8×MIC). Susceptibility
testing of representative mutants was done according to CLSI-guidelines
using phe-arg-g-naphthylamide as efﬂux pump inhibitor (EPI). For qrt-
PCR total RNA was isolated, reverse transcription was done using gene
speciﬁc primers and expression changes were determined using SYBR
Green.
Results: First step selection mutants show elevated MICs (4−6 dilution
steps) to several FQs which are due to mutations in gyrA. Second
step mutants are even more resistant (8 dilution steps) without having
additional mutations in the target genes. An MIC-decrease of 3 dilution
steps in the presence of an EPI indicates that elevated efﬂux is
responsible for the increase in resistance in the second step mutants.
qrt-PCR experiments show that expression of efﬂux-pumps acrAB-tolC,
acrEF-tolC, mdtABC-tolC and ydhE as well as global regulators marA
and rma is elevated.
Conclusions: In S. hadar elevated expression of several efﬂux pumps as
well as global regulators add to the resistance phenotype. Still unknown
is the complex interplay between regulators and efﬂux pumps. However
insight is essential for the development of new chemotherapeutics acting
on the level of bacterial efﬂux.
P876 Fluoroquinolone resistance in Clostridium difﬁcile Italian
clinical isolates
P. Spigaglia, F. Barbanti, P. Mastrantonio on behalf of ESCMID Study
Group on Clostridium difﬁcile
Objectives: Decreased susceptibility to ﬂuoroquinolones in Clostridium
difﬁcile has been recently described. In particular, the epidemic strain
NAP1/027 shows to be resistant to moxiﬂoxacin and levoﬂoxacin. Since
no data are available in our Country, the aim of this study was to
evaluate the minimal inhibitory concentrations (MICs) to ciproﬂoxacin
and moxiﬂoxacin of 60 C. difﬁcile clinical isolates and to investigate the
mechanism of resistance.
Methods: Sixty C. difﬁcile isolates, collected between 1987 and
2005 from different Italian hospitals, were examined. MICs were
determined using both the agar dilution technique performed on
Muller Hilton plates and the E-test. E-test was performed on
pre-reduced brucella agar plates containing vitamin K1, hemin,
and 5% deﬁbrinated sheep red blood cells. The breakpoints for
ciproﬂoxacin and moxiﬂoxacin were 16mg/L and 4mg/L, re-
spectively. The quinolone resistance-determining region of gyrA was
ampliﬁed using the primers 5-AA TGAGTGTTATAGCTGGACG-3 and
5-TCTTTTAACGACTCATCAAAGT T-3, whereas that of gyrB was
ampliﬁed using the primers 5-AGTTGATGAACTGGGGTCTT-3 and
5-TCAAAATCTT CTCCAATACCA-3. Both strands of the ampliﬁed
fragments were sequenced.
Results: 16 of the 60 isolates (27%) were highly resistant to both
ciproﬂoxacin and moxiﬂoxacin by both methods, except for two strains
showing MICs = 16mg/L for ciproﬂoxacin by agar dilution method and
one strain showing a MIC= 4mg/L for moxiﬂoxacin by E-test. The
majority of resistant strains were isolated after 1999. All resistant strains,
except one, showed amino acid substitutions in gyrA or/and gyrB. Two
amino acid substitutions were found in gyrA: from Thr82 to Ile and
from Gly113 to Glu. Four different amino acid substitutions were found
in gyrB: from Ser416 to Ala, from Asp426 to Asn, from Arg447 to Lys
and Asp481 to Asn. The amino acid substitutions regarding Gly113 in
gyrA, Ser416, Arg447 and Asp481 in gyrB have been not yet described
in C. difﬁcile. In gyrA, the substitutions of Gly113 and Thr82 were
always observed together. Substitutions of Ser416 and Asp481 in gyrB
were found only in strains showing amino acid substitutions in gyrA.
Conclusions: This study shows an increase of C. difﬁcile isolates
resistant to ciproﬂoxacin and moxiﬂoxacin in Italy since 1999 and
indicates the necessity of further studies to investigate the possible
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association of the different amino acid substitutions with resistance
patterns to other ﬂuoroquinolones.
P877 The impact of a drastic change in selection pressure on
trimethoprim resistance genes in clinical Escherichia coli
isolates
A. Motakeﬁ, M. Sundqvist, G. Kahlmeter, M. Grape (Stockholm, Va¨xjo¨,
SE)
Objectives: A rapid increase in resistance against trimethoprim (TRI)
has been observed during the last ten years. The main mechanism of
TRI-resistance is the integron-carried dihydrofolate reductase genes (dfr-
genes). During 2 years (from Oct 1, 2004) an intervention project was
carried out in the county of Kronoberg, Sweden, the TRICK study,
where the use of trimethoprim and cotrimoxazole was reduced by 85%.
By monitoring the effect of the intervention on the distribution of the
ﬁve most common dfr-genes (dfrA1, dfrA5, dfrA7, dfrA12 and dfrA17)
we describe changes in the mechanisms of resistance development and
reversibility.
Methods: Before, during and after the intervention 100 consecutive
clinical urinary E. coli isolates resistant to TRI were collected. Two
multiplex PCR (mPCR) protocols using similar primers were developed,
one conventional mPCR and one real-time mPCR respectively. The ﬁrst
ten PCR-products of each dfr-gene were sequenzed to validate the PCR
methods. Both protocols were run on each isolate and the results were
compared. The frequency of the ﬁve different dfr genes, were then
determined as well as the distribution of these genes at each timepoint.
Results: The ﬁve selected dfr-genes were responsible for 86% of TRI
resistance prior to and at mid-point of the intervention. dfrA1 was the
most prevalent gene amongst the selected ﬁve genes. The distribution
in the isolates collected prior to the intervention was; 39% dfrA1, 21%
dfrA5, 2% dfrA7, 7% dfrA12 and 31% dfrA17. At mid-point only small
shifts in the proportions of the ﬁve selected genes were seen 37% dfrA1,
15% dfrA5, 6% dfrA7, 2% dfrA12 and 27% dfrA17.
Conclusion: A high proportion of the isolates carried the ﬁve selected
genes indicating that the selection of genes was relevant. 12 months of
substantially reduced TRI consumption did not affect the distribution of
dfr-genes to any signiﬁcant extent. This implies that other factors than
use of trimethoprim are of importance for determining the distribution of
genetic elements encoding TRI resistance. The modest changes observed
in the distribution of the ﬁve dfr-genes are being investigated further as
are the hundred strains collected at the end of the intervention.
P878 First detection of invasive non-typeable Haemophilus inﬂuen-
zae strains with heterogeneous resistance to imipenem in Italy
M. Cerquetti, R. Cardines, M. Giufre`, P. Mastrantonio (Rome, IT)
Objectives: Carbapenems are considered an useful alternative to third-
generation cephalosporins in treating invasive infections caused by
ampicillin-resistant Haemophilus inﬂuenzae isolates. Here we report
the detection of two nontypeable H. inﬂuenzae (NTHi) strains with
heterogeneous resistance to imipenem. The resistance mechanisms were
investigated.
Methods: NTHi strains 183 and 184 were isolated from elderly patients
with meningitis. MICs were determined by E-test. Genetic relatedness
between the isolates was examined by PFGE. The sequences of the
ftsI gene encoding the penicillin-binding protein (PBP) 3 and of the
dacB gene encoding PBP 4 were determined. Rd strain was transformed
with the PCR-ampliﬁed ftsI gene from strain 183. The imipenem
susceptibilities of the Rd-transformant and of strains Rd and 183
were compared by population analysis. To investigate the presence of
additional mechanisms, the acrR regulatory gene of the AcrAB efﬂux
pump was sequenced.
Results: By E-test, strains 183 and 184 showed MICs ranging from
4mg/L to 6mg/L, respectively, but colonies grew inside the inhibition
zone up to 32mg/L in both strains. By PFGE, the two isolates appeared
closely related. Analysis of the deduced amino acid sequences of PBP3
transpeptidase region revealed the presence of 6 common amino acid
substitutions in both strains plus an additional one unique for strain
183, compared to the Rd strain. This pattern of amino acid changes
was not found in a group of imipenem-susceptible strains. Conversely,
no relationship between amino acid substitution patterns in PBP4 and
imipenem susceptibility was observed. Replacement of the ftsI gene
in the Rd strain (MIC of imipenem = 0.094mg/L) with the ftsI from
183 resulted in a transformant with a imipenem MIC ranging from
1.00mg/L to 1.50mg/L. When strains 183 and Rd-transformant were
examined by the quantitative method of population analysis, both were
heterogeneously resistant to imipenem and contained subpopulations
growing up to 32mg/L, at frequency of 10−5 and 10−8, respectively.
No subpopulations were detected in Rd strain above 2mg/L. No change
in sequence of the acrR regulatory gene was found.
Conclusion: To our knowledge, this is the ﬁrst report of H. inﬂuenzae
strains showing heterogeneous resistance to imipenem in a clinical
setting in Italy. Although the resistant phenotype seems to partly depend
on PBP3 mutations, additional mechanisms could be involved.
P879 Cloning of a mdfA-like gene, encoding an efﬂux pump of
an Acinetobacter baumannii clinical isolate
S. Marti, J. Sanchez-Cespedes, J.M. Sierra, M. Ruiz, S.M. Soto, J. Vila
(Barcelona, ES)
Objectives: Acinetobacter baumannii is an important cause of noso-
comial infection over the world; the increasing multiresistance of this
microorganism is becoming a problem. An important way of acquiring
this multiresistance is by overexpressing antimicrobial efﬂux pumps. The
objective was to clone and characterise a mdfA-like gene encoding an
efﬂux pump.
Methods: The search for efﬂux pumps was done by designing primers
homologous to well characterised efﬂux pumps in other microorganisms.
We compared the homology between the gene mdfA in Escherichia coli
and the ORF57 of Acinetobacter calcoaceticus (presumably mdfA). A
set of primers was designed in the areas of higher homology between
these two genes. A small portion of the mdfA gene was ampliﬁed and
sequenced. In order to obtain the whole gene, the genomic DNA of
A. baumannii strain RUH134 was digested with MspI, a high frequency
cutting restriction enzyme. The fragments obtained were auto ligated
and the piece of DNA containing the mdfA gene was detected by PCR.
Afterwards, this fragment of DNA was sequenced to obtain the complete
gene sequence.
Results: The whole mdfA gene of A. baumannii strain RUH134 was
sequenced. This gene had 1,230 nucleotides and it showed a 51.6%
homology with the gene in Escherichia coli, and a 71.1% homology
with Acinetobacter calcoaceticus ADP1. As regard to amino acids, the
gene had a 42.7% homology with E. coli and a 76.5% homology with
A. calcoaceticus ADP1. The prevalence of this gene was analysed in a
group of sixty-four epidemiologically unrelated strains collected from
Spanish hospitals in the year 2000. All the strains were positive for the
gene mdfA and therefore, this suggests that the gene mdfA is present in
the bacterial genome and not associated to a plasmid.
Conclusion: The mdfA gene codifying a putative multidrug efﬂux pump
was identiﬁed and completely sequenced in one strain of A. baumannii.
This gene also appeared in all the strains from a collection of
A. baumannii obtained from Spanish hospitals suggesting a genomic
implication. Further analyses will be necessary to determine the function
of this gene and the involvement in acquiring antimicrobial resistance.
P880 Single-step selection of double mutations leading to
high antibiotic-resistance in hyper-mutable Pseudomonas
aeruginosa
M. Garcı´a-Castillo, M.I. Morosini, A. Oliver, F. Baquero, J.L. Martı´nez,
R. Canto´n (Madrid, Palma de Mallorca, ES)
Objective: To determine the resistance mechanisms in single-step
variants from PAO1deltamutS P. aeruginosa and those derived from the
isogenic wild-type strain.
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Methods: Both the PAO1deltamutS and the wild-type PAO1 P. aerug-
inosa strains (5×109−1×1010 cfu/mL) were exposed to agar plates
containing different antibiotic concentrations (range 0.25–256mg/L) of
tobramycin (TOB), ceftazidime (CAZ), imipenem (IMP), ciproﬂoxacin
(CIP), and levoﬂoxacin (LEV). Sixty ﬁve mutants recovered from plates
immediately below the mutant prevention concentration were selected
and susceptibility (standard CLSI agar dilution) to different antibiotics
was determined. Topoisomerase (II and IV) mutations, expression of
efﬂux pumps (MexAB-OprM, MexCD-OprJ, and MexXY) and AmpC
b-lactamase, and OprD deﬁciency were analyzed in selected mutants.
Results: The original PAO1deltamutS strain was less susceptible than
its parental wild-type PAO1 strain for CAZ (8 and 1mg/L, respectively)
and TOB (2 and 0.5mg/L). Mutants derived form the PAO1deltamutS
strain were obtained in plates with higher CAZ, IMP, or TOB antibiotic
concentrations (1−2 log dilutions) than those permitting the growth
of mutants originated in normo-mutable PAO1 strain. Indeed mutants
obtained from PAO1deltamutS strain were regularly less susceptible
(1−4 log dilutions) than those selected form the wild-type PAO1 strain.
Mutants selected on CAZ and IMP have reduced susceptibility restricted
to b-lactam antibiotics. In these mutants, the MICs and enzymatic
activity were compatible with a higher production of chromosomal
AmpC enzyme in the case of CAZ selected mutants, whereas AmpC
hyper-production superimposed with OprD reduction was observed in
the case of IMP. In mutants selected with CIP or LEV, overproduction of
efﬂux pumps was mainly observed with PAO1 strain and overproduction
of pumps superimposed with gyrA mutations with PAO1deltamutS strain.
Conclusions: The higher antibiotic resistance levels of mutants derived
from dense populations of PAO1deltamutS P. aeruginosa when compared
with those from the corresponding normo-mutable PAO1 wild-type strain
might result from the selection of cells carrying double mutations.
Hyper-mutable strains contribute to the single-step selection of variants
with higher levels of antibiotic resistance.
P881 Altered outer membrane protein proﬁles of Pseudomonas
aeruginosa highly susceptible to the efﬂux pump inhibitor
Phe-Arg-b-naphthylamide
A.B. Campo-Esquisabel, S. Martı´, J.M. Sierra, L. Martinez-Martinez,
J. Vila (Santander, Barcelona, ES)
Objective:Multidrug efﬂlux systems play an important role in resistance
of P. aeruginosa (Pae) to several antibiotics. Phe-Arg-b-naphthylamide
(PAN) is usually able to inhibit these systems. When evaluating the
relevance of efﬂux in some clinical isolates of Pae we noticed that some
of them were inhibited by low concentration of PAN alone. We have
evaluated OMP expression in Pae highly susceptible to PAN.
Methods: Three Pae clinical isolates (HUMV1, HUMV2 and HUMV3)
for which MIC of FEP was at least 2 times higher than that of CAZ
were selected among a collection of 20 isolates with a similar phenotype.
MICs of PAN and of FEP in the absence and in the presence of 20mg/l
of PAN were determined by reference microdilution (CLSI guidelines).
The study of clonal relation between the isolates was performed by
pulsed-ﬁeld gel electrophoresis (PFGE) digested with SpeI. Fractions of
enriched cell envelope proteins from the three organisms grown in media
without or with subMIC of PAN proﬁles were characterised by SDS-
PAGE. Proteins were further analysed by MALDI-TOF mass spectometry
after in-gel trypsin digestion.
Results: MICs (mg/l) of FEP for HUMV1, HUMV2 and HUMV3 were
64, 32 and 16mg/l, respectively. MIC of FEP+PAN for HUMV3 was
4mg/l, but HUMV1 and HUMV2 did not grow in the presence of 20mg/l
of PAN. In fact, MICs of PAN alone for HUMV1 and HUMV2 were
4 and 2mg/l, respectively. The PFGE proﬁle for HUMV1 and HUMV3
was identical, and their corresponding protein proﬁles differed in three
proteins identiﬁed as: major outer membrane lipoprotein I (present in
HUMV3, absent in HUMV1), 30S ribosomal protein S16 (reduced
expression in HUMV1) and lisozyme (present in HUMV1, absent in
HUMV3). Major outer membrane lipoprotein I was also absent in the
PAN-susceptible HUMV2 isolate.
Conclusions: Hypersusceptibility of two P. aeruginosa strains to the
efﬂux pump inhibitor Phe-Arg-b-naphthylamide was linked to loss of
major outer membrane lipoprotein I.
P882 Biological cost of resistance to fosfomycin in Escherichia coli
isolates
J.I. Alo´s, P. Garcı´a-Pen˜a, J. Tamayo (Mo´stoles, ES)
Fosfomycin is a bactericidal antibiotic that acts by inhibiting the cell
wall, and which is used mainly in the treatment of uncomplicated
urinary tract infections (UTI). Resistance to fosfomycin develops rapidly
in experimental conditions, although despite its frequent use in UTI,
resistance in E. coli, the main uropathogen, is very low (1−3%), and has
remained so for many years. The objective of this study was to ascertain
whether E. coli fosfomycin-resistant strains have less ﬁtness than those
that are fosfomycin-sensitive in competing, and would therefore tend to
disappear in their competition with fosfomycin-sensitive strains in the
absence of antibiotics.
Methods: Fosfomycin-resistant strains (n = 8) with different phenotypes
of resistance to other antibiotics. All but one were lactose (+).
Fosfomycin-resistant strains (n = 13) that had same phenotypes of
resistance to other antibiotics as the resistant strains and which
furthermore had the opposite pattern of lactose fermentation.
Thirty-three (33) competition experiments by pairs of strains were
conducted (Fosfomycin-R versus Fosfomycin-S with the rest of resistance
determinants being equal and with a different lactose fermentation
capacity to perform the differential counts in MacConkey agar). The
experiments were performed in nutrient broth (NB). Equal amounts of
the strains were challenged (approx. 50% and approx. 50%) for 4 days,
with a daily change to a new medium. Five differential counts were
performed (days 0, 1, 2, 3, and 4). The 33 experiments were performed
in duplicate, and the mean of both results are presented below.
Results: In 20 experiments (60.6%) there was a relative increase in the
fosfomycin-sensitive strain that translated into a count of >60% (between
65%-99%) on the fourth day. In 6 experiments (18.2%) there was a
relative increase in the fosfomycin-resistant strain that translated into a
count of >60% (between 65%-75%) on the fourth day. In 7 experiments
(21.2%), on the fourth day none of the strains reached 60%. When the
data of the 26 (20+6) experiments in which there were changes were
analysed by the Chi2 test there was an statistically signiﬁcant difference
(P = 0.044).
Conclusions:
• Resistance to fosfomycin entails a biological cost (less ﬁtness) for the
majority of the E. coli strains assayed.
• This biological cost hinders their competition with fosfomycin-
sensitive strains in the normal intestinal ﬂora, which would make them
less likely to cause UTI.
P883 Antibiotic resistance of enterococci isolated from blood
cultures during 2003–2006
U. Arslan, B. Feyzioglu, E.B. Uysal, E.I. Tuncer, D. Findik (Konya, TR)
Objectives: Enterecocci have become a signiﬁcant problem due to
their aetiologic role in bacterial infections. An alarming problem is
the increasing rate of enterococci resistant to vancomycin (VRE) and
therefore the source and spreading of these strains are very important
epidemiological problems. The aim of the study was to evaluate antibiotic
resistance and monitoring of VRE isolated from blood cultures during
July 2003 – October 2006 in our hospital.
Methods: A total of 138 strains of enterococci were isolated from
blood cultures. The identiﬁcation of the isolated bacteria was performed
by conventional methods and bioMe´rieux API 20 STREP test (Marcy
I’Etoile, France). The susceptibility testing was carried out by disc-
diffusion method and Etest. Determination of glycopeptide resistance
genotypes (van A, van B, van C1, van C2/3) of VRE was performed
by GenoType Enterococcus assay (Hain Lifescience GmbH, Nehren,
Germany).
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Results: Of the 138 enterococci strains isolated 72 strains were
E. faecium, 59 E. faecalis, ﬁve E. gallinarum, two E. casseliﬂavus.
123 (89.1%) enterococ strains were isolated from inpatients. 53 (38.4%)
of them were isolated from intensive care units, 40 (29%) from medical
units, 28 (20.3%) from paediatric units, 17 (12.3%) from surgery units.
A total of 108 strains were resistant to ampicillin (78.3%), 58 to high
level gentamycin (42.0%) and 9 to vancomycin and teicoplanin (6.5%).
All of VRE strains was identiﬁed as E. faecium. All of the VRE strains
were susceptible only to linezolide. VRE showing high resistance to
vancomycin and teicoplanin suggest the presence of Van A phenotype.
In all of the VRE strains with glycopeptide resistance genotypes we
detected Van A genotype.
Conclusion: This study indicates that in our hospital Enterecoccus
spp. shows high resistance to high level aminoglycosides and to
aminopenicillins and VRE strains carry Van A gene.
P884 Effect of multiple passages of S. typhimurium in the presence
of disinfectants on susceptibility to antimicrobials, on
persistence in the one-day-old chick model and efﬂux systems
M. Bagnall, L. Randall, N. Coldham, A. Karatzas, T. Humphrey,
L. Piddock, M. Woodward (Addlestone, Bristol, Birmingham, UK)
Objectives: Reduced susceptibility to certain disinfectants has been
linked with reduced susceptibility to some antibiotics. If persistence and
accumulation of such mutants persist within the food chain this would be
of concern. In this study, mutants derived from Salmonella typhimurium
following multiple exposures to two different farm disinfectants (either
a combination formaldehyde, glutaraldehyde and quaternary ammonium
compound aldehyde-based disinfectant (F/G/QAC) or an oxidising
compound disinfectant (OXC) disinfectant) were analysed for their
susceptibility to antimicrobials and ﬁtness in the day old chick model.
The proteomes were also compared and molecular ﬂux investigated using
the ﬂuorescent dye bisbenzimide (H33342).
Methods: Minimum Inhibitory Concentrations (MIC) of various
disinfectants and antibiotics were determined by the BSAC agar dilution
method. In competitive index experiments one-day-old chicks were
infected by oral gavage (c.104 cfu per bird, c.1:1 mix of mutant and
parent strain). Infection was monitored by cloacal swabbing at 3, 10, 17,
24, 31 and 35 days post-infection. Infection was calculated as cfu/g of
faecal matter. In conjunction with the cloacal swabs 5 birds/group were
sacriﬁced at 7, 14, 21 and 28 days post-infection and the caecal contents
enumerated as previously described. Proteomes were determined by 2D-
LC-MS and uptake of bisbenzimide (2.5mM) using a ﬂuorescent plate
reader in a 96 well format at 350 and 460 nm respectively.
Results: The mutant strains were signiﬁcantly less able to persist in
the one-day-old chick model than their parent strains. Both mutants
showed reduced susceptibility (circa x 4) to some clinical antibiotics (cip,
chlor, tet and amp) and were also cyclohexane resistant. This suggests
that the mechanism of resistance is due to up-regulated efﬂux and/or
reduced porins. The proteomics conﬁrmed increased expression of the
AcrAB/TolC efﬂux pump. Reduced uptake of the dye bisbenzimide was
consistent with these changes in protein expression.
Conclusions: Repeated exposure of Salmonella Typhimurium to
disinfectants gave rise to mutants with reduced susceptibility to
disinfectants and/or antibiotics. This was coupled with increased efﬂux,
as measured by bisbenzimide uptake assays, and increased differences
in key efﬂux proteins.
P885 Investigation of autolysin and autolysis of glycopeptide-
intermediate Staphylococcus aureus induced from
methicillin-resistant Staphylococcus aureus
J.I. Yoo, E.J. Park, J.S. Yoo, K.M. Lee, G.T. Chung, Y.S. Lee (Seoul, KR)
Background: Methicillin-resistant Staphylococcus aureus are the most
important pathogens causing nosocomial infections. The glycopeptide
antibiotics has been used successfully for the treatment of serious
infections caused by MRSA for several decades. However, clinical
isolates with reduced susceptibility to glycopeptide antibiotics have
arisen during long-term vancomycin therapy in various contries around
the world since 1997. The efﬁcacy of vancomycin has been limited by
the emergence of both GISA and VRSA in clinical isolates. In this study,
we induced GISA phenotype from vancomycin susceptible strains and
investigated characteristics of autolysis and autolysin.
Methods: The 6 MRSA clinical strains showing prevalent PFGE types in
Korea were selected to induce resistance. The agr types were determined
with agr group speciﬁc primers by multiplex PCR. Strains were grown
in TSB in the presence of vancomycin at 1 to 2 ug/mL or were above
the MIC for a given strain and induced to 4 ug/mL and 8 ug/mL MICs,
continuously. The change of autolysis was quantitated as percentage of
the initial OD600 remaining at each sampling time point. The autolysin
was analyzed with intracellular protein and extracellular protein from
GISA strain. The function of the agr operon in GISA strains was
measured by d-hemolysin production experiment.
Results: All of 6 strains showed 3 different agr types (I, II, III) and
all strains were induced to MICs 4−8 ug/mL. All induced GISA strains
showed a slower rate of autolysis than did their parents. And two isolates
among GISA strains showed decreased d-hemolysin expression (the other
4 strains had no d-hemolysin activity in their parents). The expression of
major intracellular autolysin (53 kDa) was decreased in GISA strains and
the other 3 or 4 autolysin bands were shown. In extracellular proteins,
the expression of 53 kDa autolysin was also decreased but that of 37 kDa
autolysin was increased in 2 GISA strains.
Conclusion: The reduction of autolytic activity and d-hemolysin activity
in GISA strains is supposed that the agr operon has relation with the
activity of autolysin. Among the several autolysin, 53 kDa and 37 kDa
autolysins are play a role in GISA strains. And also, the autolysin activity
is reduced against vancomycin to tolerate the antibiotic stress.
P886 Macrolide resistance in Streptococcus spp. and Enterococcus
spp. clinical isolates: phenotypic and genotypic analysis
J. Perez, E. Culebras, M. Gomez, J. Picazo (Madrid, ES)
Objectives: The growing number of macrolide resistant strains of
Enterococcus spp. and Streptococcus spp. is an increasing problem
worldwide. In this study we evaluated 44 clinical isolates of both genera
obtained at Microbiology Department of Hospital Clı´nico San Carlos.
All of these macrolide resistant strains were tested for their antimicrobial
susceptibility, resistance phenotypes and genotypes.
Methods: A total of 25 Streptococcus spp. (10 S. pyogenes, 10
S. agalactiae, 5 group G Streptococcus and 1 S. pneumoniae) and
19 Enterococcus spp. (10 E. faecalis, 7 E. faecium, 1 E. gallinarum
and 1 E. avium) clinical isolates resistant to erythromycin and/or
clindamicin were included. Organisms were collected at the Hospital
Clı´nico San Carlos from January to June of 2006. All strains were
identiﬁed by standard methods and by the Rapid ID32 Strep system.
Susceptibility to penicillin (P), erythromycin (ER), clindamycin (CC),
clarithromycin (CL), azithromycin (AZ), josamycin (J), telithromycin
(TL), Quinupristin/Dalfopristin (Q/D), gentamicin (G), tetracycline (T),
minocycline (M) and tigecycline (TG) was determined by the agar
dilution methods. The presence of erm(A), erm(B) and mefA/E genes
was determined by PCR ampliﬁcation with speciﬁc primers.
Results: In general, Enterococcus spp. were more resistant than
Streptococcus spp. Of the 25 Streptococcus spp. studied, 68%, 36%,
8% and 8% were resistant to CC, T, Q/D and TL respectively. The
Enterococcus spp. clinical isolates show TL MICs ranged between 
0.006 and 4mg/L, and Q/D ranged between 0.006 and >256mg/L.
68% and 58% of Enterococcus spp. were resistant to ER and T
respectively. All strains remain susceptible to TG. There was 22 strains
with erm(B) gene alone (5 S. agalactiae, 5 S. pyogenes, 1 S. pneumoniae,
6 E. faecalis, 4 E. faecium and 1 E. gallinarum). erm(A) alone was
present in 5 strains (4 group G Streptococcus and 1 S. agalactiae), in 3
of these strains MIC to CC was higher than MIC to ER. The mefA/E gene
was ampliﬁed in all strains with M phenotype. Three strains harboured
erm(A) and erm(B) both genes. We were no able to detected any of the
studied gene in 13 strains.
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Conclusions: 1) erm(B) was the most prevalent gene in our clinical
isolates; 2) A bimodal distribution of ER MICs was noted in erm(A)
isolales. 3) All clinical isolates resistant to TL harboured erm(B) gene.
4) Resistance to Q/D is common in our E. faecium.
P887 Linezolid resistance in clinical isolates of Staphylococcus
haemolyticus
J. Calvo, M. Cano, M. Marı´n, E. Cercenado, L. Martinez-Martinez
(Santander, Madrid, ES)
Objectives: To characterise four isolates of linezolid-resistant
S. haemolyticus obtained from different patients.
Methods: Identiﬁcation and preliminary susceptibility testing of organ-
isms were performed with the WalkAway system. Linezolid MICs were
determined by reference microdilution and Etest assays, according to
CLSI guidelines and manufacturer’s instructions, respectively. Detection
of the G2576T mutation was performed by PCR ampliﬁcation and
sequencing of the domain V of 23S rRNA gene (Tsiodras et al, Lancet
2001). Clonal relationship of the isolates was examined by PFGE of
SmaI macrorestricted genomic fragments.
Results: Four linezolid-resistant S. haemolyticus isolated in pure cultures
from blood samples (n = 3) or bile (n = 1) were identiﬁed among
17 organisms of this species obtained in our laboratory in the period
March-April 2006. All four isolates were from different patients admitted
to ICUs of our hospital. Reference MICs of linezolid were 64mg/L
for 3 isolates and 128 for the other one. Etest yielded one twofold
dilution lower in all isolates. The G2576T mutation was detected in
all four isolates and all of them were homozygous. Similar resistance
phenotype (WalkAway) was observed for all 4 isolates, being resistant
to oxacillin, teicoplanin, ciproﬂoxacin, clindamycin, erythromycin, gen-
tamicin, tobramycin, amikacin, rifampin, trimethoprim-sulfamethoxazol
and susceptible to vancomycin, tetracycline and quinupristin-dalfopristin.
Two closely related PFGE-patterns were observed for the 4 isolates, each
one corresponding to two isolates.
Conclusions: We have identiﬁed the emergence of multiresistant
S. haemolyticus isolates presenting homozygous resistance to linezolid.
P888 Macrolide efﬂux pumps mef(E) and mef(I) detected in
clinical isolates of S. pyogenes isolated from PROTEKT
1999–2005 and PROTEKT US 1999–2004
J. Northwood, L. Cossins, M. Coley, A. Pantosti, M. Del Grosso,
D. Farrell (London, UK; Rome, IT)
Objectives: To determine the presence of the macrolide efﬂux
mechanism of resistance, mef(A) subclass mef(E), in community-
acquired lower respiratory tract infections of Streptococcus pyogenes,
from a global collection of clinical isolates (n = 28,892) 1999–2005.
Methods: Isolates of S. pyogenes with MIC values demonstrating the
M phenotype of resistance to macrolides were screened for the mef(E)
gene using a novel TaqManTM assay designed for this project. Isolates
which were positive for the presence of mef(E) using the TaqManTM
assay were conﬁrmed by di-deoxy sequencing of a 300 bp segment of
the mef(E) gene.
Results: Twenty-Two isolates (0.07%) were considered to be mef(E)
although 3 isolates had 1 amino acid substitution from mef(E): M30I
and 1 isolate had 3 amino acid substitutions from mef(E): C97V, M104I,
and I105V (5 SNPs). These isolates may have additional substitutions
outside of the 300 bp region examined, and further sequence analysis
of the mef gene is required. Five isolates (0.02%) of S. pyogenes were
consider to have the mef(A) subclass mef(I) gene present, all of these
isolates had 1 amino acid substitution from mef(I): K39R. One isolate
was considered to be a novel subclass of mef(A) due to the following
variations: mef(A) 4 amino acid substitutions L52V, S89A, T92A and
A125S; mef(E) 5 amino acid substitutions I59V, L60F, C97Y, I105V
and A125S; mef(I) 4 amino acid substitutions L96F, V107I, V114I and
A125S and mef(O) 3 amino acid substitutions L96F, V107I, A125S (14
SNPs). There was a global distribution of mef(E) in S. pyogenes whereas
4 out of the 5 isolates positive for mef(I) came from Belgium.
Conclusions: This study deﬁnitively shows the presence of mef(E)
in S. pyogenes and its global distribution, the previously un-described
presence of mef(I) in S. pyogenes and the presence of a novel subclass
of mef(A).
P889 Emergence of linezolid-resistant Enterococcus faecalis in
Spain and rapid characterisation by real-time PCR
E. Cercenado, M. Marin, O. Cuevas, E. Bouza (Madrid, ES)
Objectives: Linezolid was introduced in our institution in 2004. From
May 2005 to September 2006 we determined the in vitro activity
of linezolid against all staphylococci and enterococci isolated in our
laboratory. We characterise the ﬁrst linezolid-resistant (LNZ-R) clinical
isolates of Enterococcus faecalis in Spain.
Methods: MICs were determined by the broth microdilution method
using commercialised MicroScan panels (Dade-Behring). CLSI guide-
lines (2006) were followed for determination of breakpoints. LNZ-R
isolates were conﬁrmed by E-test. Detection of the G2576T mutation
was performed by PCR and sequenciation of the 23S rRNA gene, as
well as by real-time PCR (Woodford et al; JCM 2002; 40: 4298–4300)
using a ﬂuorescent dye-labeled detection probe.
Results: Over the period of study, we tested 6,214 staphylococci
(3,817 S. aureus; 2,407 coagulase-negative staphylococci), and 1,850
enterococci (1,439 E. faecalis; 340 E. faecium; 71 other species).
All staphylococci were susceptible to linezolid (MIC 4mg/L). Three
E. faecalis isolates (0.16%) were LNZ-R (MICs 64, and 128mg/L; 2
and 1 isolate, respectively. The isolates were recovered in 2006 and
corresponded to 3 patients hospitalised in different wards that received
linezolid for >15 days previous to the isolation of the LNZ-R isolates.
PCR and sequenciation detected the G2576T mutation only in 2 isolates
(MICs 64mg/L). Real-time PCR was positive in all 3 isolates, being
one strain (MIC= 128mg/L) heterozygous, and the other 2 homozygous.
Results were obtained in less than 2 h. The G2576T mutation in
the heterozygous strain was not detected by PCR ampliﬁcation and
sequencing of the 23S rRNA gene.
Conclusions:We characterise for the ﬁrst time in Spain the emergence of
LNZ-R E. faecalis isolates in patients previously treated with linezolid.
Since the G2576T mutation was not detected in the heterozygous isolate
by PCR and sequencing, the real-time PCR must be the method of choice
for the characterisation of this emergent resistance mechanism.
P890 Linezolid resistance in a Staphylococcus haemolyticus strain
isolated in an intensive care unit
A. Mazzariol, G. Lo Cascio, R. Koncan, L. Maccacaro, R. Fontana,
G. Cornaglia (Verona, IT)
Objectives: Although even recent reports conﬁrm resistance to linezolid
to be minimal among coagulase-negative staphylococci, and virtually
conﬁned to a few cases of Staphylococcus epidermidis encountered
in the USA, a number of documented cases have occurred in South
America and Europe, too. In a recent report from intensive care units
(ICUs) in Madrid, Spain, variable resistance percentages were found in
Staphylococcus epidermidis (0.81%), Staphylococcus hominis (0.71%),
and most noticeably Staphylococcus haemolyticus (6.84%).
A 65-year-old male patient was admitted to the ICU of the Verona
University Hospital on 1 August 2006, after extensive surgery for acute
pancreatitis. Empirical therapy with teicoplanin (600mg) was started
on admission. On the 16th day of therapy, a strain of S. haemolyticus
was isolated from the blood culture. The strain proved intermediate
to teicoplanin (MIC, 16mg/L), which was immediately suspended and
replaced with linezolid (MIC, 0.25mg/L). After a further 8 days, a
new blood culture showed that the same strain had become resistant
to linezolid (MIC, 32mg/L).
Methods: Antimicrobial susceptibility testing was routinely performed
by diffusion test according to the latest CLSI documents. The MICs to
all antibiotics were determined by means of the E-test and conﬁrmed by
dilution tests. PFGE was carried out by standard procedures.
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Results:MICs for recently released anti-staphylococcal compounds were
as follows: daptomycin, 0.12mg/L; quinopristin/dalfopristin, 0.5mg/L;
telavancin, 0.12mg/L; tigecycline, 1mg/L.
After serial passage on antibiotic-free medium, the isolate’s resistance
to high concentrations of linezolid was unvaried. Compared with two
linezolid-susceptible S. haemolyticus strains, isolated from the same ICU
in the same time period, the linezolid-resistant isolate demonstrated a
signiﬁcant difference in its in-vitro growth characteristics. PFGE of the
two linezolid-susceptible strains would suggest a clonal relationship with
the linezolid-resistant one. Further resistance characterisation and clonal
analysis are ongoing.
Conclusions: After three years of linezolid use, multifocal emergence
of linezolid resistance in coagulase-negative staphylococci has become
an important matter of concern and involves species other than
S. epidermidis. Because of the paucity of newer effective antimicrobial
agents, this fact mandates stricter control over the use of this antibiotic
to preserve its clinical utility.
P891 Mycobacterium leprae DNA gyrase: expression, puriﬁcation,
inhibition by quinolones and functional analysis of two
mutant enzymes
S. Matrat, S. Petrella, E. Cambau, W. Sougakoff, V. Jarlier, A. Aubry
(Paris, FR)
Objectives: M. leprae is still uncultivable in vitro and evaluation of
antibiotic activity against this bacteria relies mainly on the mouse foot
pad model that requires 8 to 12 months experiments. It is therefore
important to establish an in vitro approach allowing to test rapidly
the efﬁciency of quinolones against wild type and quinolone resistant
mutants of M. leprae. Mutations in the DNA gyrase (the sole target
of quinolones in M. leprae) was previously described. The aim of the
present study was to purify the DNA gyrase of M. leprae in order (i) to
test the ability of quinolones to inhibit this enzyme and (ii) to study the
implication of gyrase mutations in the resistance of M. leprae clinical
isolates to quinolones.
Methods:We separately overexpressed in Escherichia coli the M. leprae
GyrA and GyrB subunits as His-Tagged proteins using pET plasmids
harbouring the gyrA and gyrB genes. Two mutant enzymes (A91V in
GyrA and D205N in GyrB, corresponding to amino acids GyrA 83 and
GyrB 183 in E. coli numbering system), representing mutations found
in M. leprae clinical isolates (Cambau et al., Lancet, 1997; Kim et al.,
FEMS, 2003), were introduced by site directed mutagenesis. Wild type
and mutant subunits were puriﬁed by nickel chelate chromatography.
The drug concentrations that induced 25% of DNA cleavage (CC25)
were measured for 3 quinolones (MXF, OFX and LVX).
Results: The soluble 97.5-kDa GyrA and 74.5-kDa GyrB wild type and
mutant subunits obtained after puriﬁcation were mixed to reconstitute
enzymes showing a DNA supercoiling activity. The CC25s of the GyrB
mutant D205N were similar to those found with the wild type subunit. In
contrast, the CC25s of OFX, LVX and MXF for the GyrA mutant A91V
were 4-, 6- and 20-fold higher than the wild type ones respectively.
Conclusion: Our results show that mutation D205N in GyrB is not
involved in acquired resistance ofM. leprae to quinolones whereas A91V
in GyrA is involved in quinolone resistance of M. leprae. In addition, we
showed that drug-induced DNA cleavage assays from puriﬁed wild type
and mutant M. leprae DNA gyrases represent a safe, quick and useful
screening test for identifying quinolones with potential activity against
M. leprae and related multidrug resistant strains.
P892 Genetic basis of macrolide and lincosamide resistance among
staphylococcal clinical isolates in a cancer centre
V. Kolliou, M. Lymperopoulou, M. Tsaparli, A. Markogiannakis,
E.N. Manolis, N.J. Legakis, A. Tsakris (Athens, Piraeus, GR)
Objectives: To investigate the incidence of macrolide and lincosamide
resistance phenotypes and the distribution of the related resistance genes
among staphylococcal isolates collected in a cancer hospital in Greece.
Materials and Methods: The study included 148 Staphylococcus aureus
and 24 cogulase-negative staphylococci (CNS) clinical isolates recovered
during 2002–2004 from separate patients in the Metaxa Cancer Hospital.
MICs of erythromycin, clindamycin and oxacillin were tested by an agar
dilution method. The macrolide-lincosamide-streptogramin B (MLSB),
macrolide-streptogramin B (MS) and lincosamide (L) phenotypes
were screened by the disk approximation test with erythromycin and
clindamycin. Detection of the genes encoding resistance to macrolides
and lincosamides was performed by PCR, while clonal strains were
identiﬁed by PFGE analysis of SmaI-digested DNA.
Results: One hundred-one (68.2%) of the S. aureus isolates were
characterised as MRSA and 19 (79.2%) of the CNS as MRCNS. Seventy-
six (44.2%) staphylococcal isolates (56 S. aureus and 20 CNS isolates)
exhibited resistance or intermediate level of resistance to at least one
of erythromycin and clindamycin. The MLSB constitutive phenotype
was detected in as many as 69 (90.8%) isolates, followed by the MLSB
inducible phenotype (4 isolates; 5.3%), the MSB phenotype (2 isolates;
2.6%) and the L phenotype (one isolate; 1.3%). The ermA gene was
identiﬁed in 69.7% of the isolates, while less frequently were identiﬁed
the ermC gene (17.1% of isolates), the combination of ermC and msrA/B
genes (6.6% of isolates), the msrA/B gene (1.3% of isolates) and the
lnuA/A′ gene (1.3% of isolates). In 3 (3.9%) isolates resistance genes
were not detected. PFGE showed the dissemination of two major clonal
types among S. aureus isolates.
Conclusions: The data indicate that in the cancer centre of this study the
overall macrolide and lincosamide resistance is driven by the epidemic
spread of the MLSB constitutive phenotype among clonal staphylococcal
isolates containing either ermA or ermC gene.
P893 Prevalence and genetic background of ﬂuoroquinolone
resistance in clinical isolates of Proteus mirabilis
R. Nakano, M. Abe, M. Inoue, R. Okamoto (Sagamihara, Kanagawa, JP)
Objectives: Fluoroquinolone (FQ) resistance among Enterobacteriaceae
was reported increasingly. It occurs primarily through mutation in the
QRDRs of the DNA gyrase (gyrA and gyrB) and topoisomerase IV (parC
and parE). In this study, we carried out a survey to assess the prevalence
of the FQ resistant P. mirabilis and investigate the mechanism of the
resistance.
Methods: 1855 isolates of P. mirabilis were collected from 7
different hospitals in Kanagawa Prefecture, Japan in 2000–2005. The
susceptibility of levoﬂoxacin (LVFX) was determined by the agar
dilution method according to the CLSI guidelines. DNA sequences
of the QRDRs of gyrA, gyrB, parC, and parE in 50 clinical isolates
with susceptibility or resistance to LVFX were determined by PCR and
sequencing.
Results: Of the 297 strains were found to resistant to LVFX
(MIC> 2mg/mL). It was gradually increase the incidence in 2000–2004
and was signiﬁcantly increased 45.9% in 2005. The DNA sequences
of the QRDRs of P. mirabilis were identiﬁed. Susceptibility strains
(MIC, 0.125 to 2mg/mL) and MIC 4mg/mL strains showed change in
gyrA (S83I) and parC (S80I). Low-level resistant strains (MIC, 8 to
16mg/mL) showed change in gyrA (S83I), gyrB (S464Y or E467D),
and parC (S80I). High-level resistant strains (MIC, 32 to 256mg/mL)
showed change in gyrA (S83I+E87K), parC (S80I), and parE (D420N).
Highest-level resistant strains (MIC, 512mg/mL) strains showed change
in gyrA (S83I+E87G), gyrB (S464F), parC (S80I), and parE (D420N).
Conclusion: The prevalence of LVFX resistant P. mirabilis was steadily
increasing in Japan. Susceptibility proﬁles for LVFX were correlated
with amino acid changes in QRDRs. Low-level resistant strains (MIC, 8
to 16mg/mL) were associated with mutation in gyrB (S464Y or E467D).
High-level resistant strains (MIC, 32 to 256mg/mL) were associated with
mutations in gyrA (E87K) and parE (D420N). Highest-level resistant
strains (MIC, 512mg/mL) were associated with mutations in gyrA
(E87G), gyrB (S464F), and parE (D420N).
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P894 Characterisation of insertion sequence, conjugative
transferase gene and mupA gene of mupR plasmid from
MuH methicillin-resistant staphylococci
J.I. Yoo, G.T. Chung, E.S. Shin, Y.S. Lee (Seoul, KR)
Objectives: Mupirocin has been used to eliminate the carriage of
S. aureus and prevent staphylococcal infections. However, mupirocin-
resistant S. aureus has been increased and the high level mupirocin
resistance (MuH) is associated with an isoleucyl tRNA synthetase that
is encoded by a novel plasmid-encoded gene, mupA. In this study,
we investigated transferable mupirocin resistance element containing
insertion sequence (IS), trs and mupA gene of mupR plasmid from MuH
methicillin resistant staphylococci isolates.
Methods: Against 680 staphylococci isolates from tertiary hospitals,
antimicrobial susceptibility test including mupirocin was done by disk
diffusion and MIC of mupirocin was determined by E-test method. The
plasmid-encoded mupA gene was detected by PCR. The mupA-IS and
trsLM-mupA speciﬁc primers were used to identify the presence and
genetic location of IS element, trs and mupA gene.
Results: 12 MuH-staphylococci isolates with different PFGE patterns
were selected from hospitals (680 isolates) and long-term care facilities
(407 isolates) in Korea. MuH MRSA (8 isolates), MuH S. haemolyticus
(2 isolates), MuH S. hominis (1 isolates) and MuH S. epidermidis
(1 isolates) were identiﬁed. The trsLM-mupA PCR showed 4 different
products such as 7,033 bp (6 isolates), 5,024 bp (3 isolates), 4,530 bp
(2 isolates) and 6,105 bp (1 isolates). IS sequence of all 12 isolates
identiﬁed to have IS257 sequences except 2 nucleotide substitution
(A174G, A536G) and one thymine nucleotide deletion at 644 nucleotide.
The mupA was ﬂanked by two directly repeated IS257 like sequences.
The sequences of trsLM were also different in 68 nucleotide site
compared to previously reported trsLM sequences.
Conclusion: The high-level mupirocin resistant staphylococci isolated
from Korea hospitals had different IS257 sequences and trsLM
sequences. Because sequences of all MuH isolates showed the same
sequences, the IS257 like sequences and trsLM sequences is typical in
Korean isolates. According to the trsLM-mupA sequence analysis, there
was no speciﬁc difference between MRSA and MRCNS. It indicated the
possibility of mupA transfer from MRSA to MRCNS and vice versa.
And also the sequence relation of trs, IS and mupA against MRCNS is
the ﬁrst report in the world.
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P895 Evaluation of a real-time PCR assay and an multiplex-reverse
hybridisation system for the detection of methicillin-resistant
Staphylococcus aureus
M. Ieven, M. Michiels, H. Jansens, H. Goossens (Edegem, BE)
Objective: To evaluate the performance of a commercial multiplex
PCR – reverse hybridisation system, Hyplex StaphyloResist® (BAG
Germany distributed in the Benelux by AlphaOmega instruments), and
a real-time PCR assay for the detection of MRSA from 24 hours
enrichment broths compared to the routine culture method.
Methods: A total of 500 enrichment broths from MRSA screenings were
included in the study. On arrival in the lab, swabs were cultured by direct
plating and subsequently put in MRSA enrichment broth. After 24 hours
incubation the broth was subcultured on routine media and MRSA was
identiﬁed by conventional methods. A broth sample was taken for DNA
extraction and two PCR assays. The Hyplex StaphyloResist® consists of
a multiplex PCR amplifying simultaneously mecA gene, coagulase gene
and a “housekeeping” gene. Specimens were processed according to the
manufacturer’s instructions. For the real-time PCR assay specimens were
extracted using the Qiagen blood mini kit with consecutive detection of
mecA, nuc and SCCmec genes, according to a modiﬁed protocol by
Huletsky et al (JCM 2004; 42: 1875−84). PCR results were considered
positive if conﬁrmed by culture or the second PCR.
Results: In total 78 (16%) of the 500 MRSA enrichment broths tested
were culture and both PCRs positive, 6 were culture negative and both
PCRs positive, 1 was culture positive and both PCRs negative. 6 broths
were culture positive and one PCR negative (5 real-time PCR assay, 1
Hyplex StaphyloResist® assay) and 28 broths were culture negative and
one PCR negative (14 real-time PCR assay, 14 Hyplex StaphyloResist®
assay). The sensitivity, speciﬁcity and negative and positive preditive
values of the Hyplex StaphyloResist® assay for the detection of MRSA
from broth were 98%, 96%, 99% and 83% and 93%, 96%, 98% and 83%
for the real-time PCR assay, respectively. Both PCR assays provided
same day results on 24 hours enrichment broths compared to 48 to
96 hours for routine culture method. The time needed to complete the
Hyplex StaphyloResist® and real-time PCR assays were 3 hrs 25 min
and 2 hrs 30 min with a hands-on time of 1 hrs 30 min and 1 hrs 15 min,
respectively.
Conclusion: There is no signiﬁcant difference in sensitivity and
speciﬁcity between the Hyplex StaphyloResist® assay and the real-time
assay for the detection of MRSA from enrichment broth. More than
90% of MRSA positives can be identiﬁed after one day by either PCR
if performed on MRSA enrichment broth.
P896 Comparison of NucliSens easyMAG and Qiagen nucleic acid
extraction using screening broths for the detection of MRSA
M. Ieven, M. Michiels, K. Bergs, D. Ursi, H. Goossens (Edegem, BE)
Background: The NucliSens easyMAG platform (bioMe´rieux) is a
second generation system for automated isolation of nucleic acids (NA)
from clinical samples, based upon silica extraction technology. Currently,
no data are available on the NucliSens easyMAG for the extraction of
MRSA DNA from screening samples.
Objectives: To evaluate the performance and user convenience of
the NucliSens easyMAG platform for NA extraction from MRSA
enrichment broths compared to manual Qiagen extraction.
Materials and Methods: 500 enrichment broths from MRSA screenings
were included in the study: on arrival in the lab, swabs were cultured
by direct plating and enrichment cultures. 200ml broth was used for NA
extraction using the Qiagen blood mini kit and 1ml broth was frozen.
NAs extracts were analysed by real-time PCR targeting the mecA, nuc
and SCCmec genes for the detection of MRSA DNA. 60 broths proven
positive by culture and/or PCR were retrospectively extracted using the
NucliSens easyMAG protocol on 200ml of the frozen aliquots. An equal
number of negative samples were analysed by the same extraction and
PCR protocol.
Results: The real-time PCR detected MRSA DNA in 60 enrichment
broths as well after Qiagen as after easyMAG extraction. In 49, 48 and
48 of the extracted MRSA positive broths Icycler Ct values for detection
of SCCmec, mecA and nuc genes respectively were lower after NucliSens
easyMAG extraction compared to the values after Qiagen extraction with
a mean Ct difference of 3.02, 1.79 and 2.04. If the Ct values after
Qiagen extraction were lower than after NucliSens easyMAG extraction,
which was the case in less than 10 of the extracted broths, the mean Ct
difference was minimal: 1.2, 1.3 and 1.2 for the detection of SCCmec,
mecA and nuc genes, respectively. For all 60 negative broths, both
NucliSens easyMAG and Qiagen produced clear cut negative results.
The time needed for the Nuclisens easyMAG extraction procedure was
40 minutes for 24 samples, with a hands-on time of less than 20 min,
compared to 85 minutes for Qiagen extraction.
Conclusion: In this study the Nuclisens easyMAG extracted more
efﬁciently the MRSA DNA of the enrichment broths by showing on
average lower and higher Ct values for respectively MRSA positive and
negative samples in the real-time PCR assays. The instrument features
user-friendly, intuitive software, and delivers high throughput capabilities
with 40 minutes turn-around-times.
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P897 Expression of icaA and icaD genes by quantitative
real-time PCR in correlation to bioﬁlm synthesis among
methicillin-resistant coagulase-negative staphylococci
A. Foka, V. Chini, E. Petinaki, G. Dimitracopoulos, I. Spiliopoulou
(Patras, GR)
Objectives: Among pathogens causing hospital infections methicillin-
resistant coagulase–negative staphylococci (MR-CNS) have become
predominant, especially in neonatal intensive care units (nICU). This
results their ability to form bioﬁlm, especially among patients with
invasive procedures. The purpose of the present study was to investigate
slime production in correlation to the presence and expression of ica
operon among MR-CNS isolated from different patients hospitalised in
a nICU.
Methods: During a two-year period 132 (MR-CNS) were isolated from
different inpatients at the nICU. Bioﬁlm production was detected by
the qualitative and quantitative methods. PCR was performed for the
detection of the four genes of the ica operon, (icaA, icaD, icaB, icaC)
and of the insertion sequence element IS256. Fourteen representative
strains, 11 slime-positive and three slime-negative, were selected for
reverse transcription quantitative relative Real time PCR (qRT-PCR) for
the detection of the expression levels of icaA and icaD genes. Total RNA
was isolated by the Trizol method, and a part of the 23S rRNA was used
as the reference gene in the relative quantiﬁcation of ica genes using the
SYBR® Green I chemistry; results were calculated by the Pfafﬂ method.
Results: Both methods for bioﬂilm formation revealed that 117 (89%)
isolates were bioﬁlm-positive. PCR showed a variation of possession of
ica genes. The selected 14 strains were positive for icaA and icaD by
PCR screening. Seven out of the 11 slime-positive strains carried also
IS256. Among them, two showed high, two medium and three strains low
expression levels of both ica genes by qRT-PCR. In the remaining four
slime-positive strains that did not carry IS256, two showed medium and
two low expression levels of both ica genes. Two out of the three slime-
negative MR-CNS possessed IS256 and all three had low expression
levels of ica genes.
Conclusions: The majority of MR-CNS associated with infections in the
nICU produced bioﬁlm. The insertion sequence element IS256 does not
always inactivate the expression of ica operon. Other factors are involved
in bioﬁlm formation.
P898 StaphPlex System for rapid and simultaneous identiﬁcation,
antibiotic resistance determination and Panton-Valentine
leukocidin detection of staphylococci from positive blood
cultures
Y.W. Tang, A. Kilic, Q. Yang, H.J. Li, R.S. Miller, M. McCormac,
K.D. Tracy, C.W. Stratton, J. Han (Nashville, Huntsville, US)
Objectives: Current phenotypic methods take several days for identiﬁ-
cation and antimicrobial susceptibility testing of staphylococcal isolates
after Gram-positive cocci in clusters (GPCC) are seen in positive
blood cultures. We developed and validated a StaphPlex system that
ampliﬁes and detects 18 gene targets simultaneously in one reaction for
identiﬁcation, Panton-Valentine leukocidin (PVL) gene detection, and
antimicrobial resistance determination of staphylococci.
Methods:We collected positive blood culture specimens in which GPCC
were seen and compared the results of the StaphPlex System with
staphylococcal identiﬁcation and antimicrobial resistance determination
obtained by phenotypic methods.
Results: Among a total of 360 GPCC specimens, 265 (73.6%),
41 (11.4%), 32 (8.9%), 11 (3.1%), and 11 (3.1%) were identi-
ﬁed as coagulase-negative Staphylococci (CoNS), methicillin-resistant
Staphylococcus aureus (MRSA), methicillin-susceptible S. aureus
(MSSA), mixed infections of CoNS and MRSA, and non-staphylococci,
respectively. The total agreement rate was 91.9% in comparison with
those identiﬁed by conventional phenotypic methods. The 277 CoNS
specimens were further speciated to 205 (74.0%) Staphylococcus epider-
midis, 9 (3.3%) Staphylococcus haemolyticus, 25 (9.0%) Staphylococcus
hominis, 1 (0.4%) Staphylococcus lugdunensis, and 37 (13.4%) other
CoNS with an accordance rate of 84.6% when compared to an API
STAPH identiﬁcation. High speciﬁcity and low sensitivity were noticed
when aacA, ermA, ermC, tetM and tetK genes were detected to predict
in vitro antimicrobial susceptibilities. The StaphPlex system presented
a sensitivity of 100.0% and speciﬁcity ranged from 95.5% to 100.0%
when used for staphylococcal cassette chromosome mec typing and PVL
gene detection.
Conclusion: StaphPlex provides accurate and relevant staphylococcal
identiﬁcation, PVL gene detection, and antimicrobial resistance deter-
mination within ﬁve hours, which signiﬁcantly shortens the time usually
needed for phenotypic identiﬁcation and antimicrobial susceptibility
testing.
P899 Comparison of enterotoxin genes in Staphylococcus aureus
from nasal carriage and bacteraemia
J.Y. Baek, K.S. Ko, K.R. Peck, J.H. Song (Seoul, KR)
Background and Objective: The prevalence of enterotoxin genes within
S. aureus isolated in Korea including both in community-setting and in
hospital-setting has not been reported.
Material and Methods:We analyzed 95 S. aureus colonisers (18 MRSA
and 77 MSSA) isolated from children attending outpatient clinics and
70 S. aureus isolates (36 MRSA and 34 MSSA) from patients with
bacteraemia. spa typing, multilocus sequence typing, and SCCmec typing
were performed to characterise S. aureus isolates. Enterotoxin genes (sea,
seb, sec, sed, see, seg, seh, sei, sek, and tst) and pvl gene were assayed
by method of PCR.
Results: The most common enterotoxin genes were seg, sei, and tst in
both nasal carriage strains and S. aureus from bacteraemia (60.0% and
58.6% for seg, 69.5% and 55.7% for sei, and 52.6% and 42.9% for tst,
respectively). Possession rate of enterotoxin genes was not signiﬁcantly
different between isolates from nasal carriage and bacteraemia, except
for sec and seh genes. While only two isolates of nasal carriage (2.1%)
were carrying sec gene, 34.3% of isolates from bacteraemia were
positive. Interestingly, sec gene was found only in MRSA isolates. For
seh gene, it was positive in 30.5% of nasal carriage strains, but only
8.6% of bacteraemia strains possessed it. No isolates contain pvl gene.
While the most prevalent clone was ST30 (spa motif, WG/FKAOMQ)
(34/95 isolates, 35.8%) in nasal carriage, ST5 (spa motif, DMGMK) was
the most frequently found clone in bacteraemia strains (24/70 isolates,
34.3%). Bacteraemia strains belonging to the same clone have the similar
enterotoxin gene pattern, but it did not in nasal carriage strains.
Conclusion: S. aureus isolates from bacteraemia and nasal carriage
showed different genetic backgrounds, that is, no close relation each
other. There was no evidence that S. aureus isolates from bacteraemia
possessed more enterotoxins genes than nasal carriage.
P900 Performance of the GeneXpert® system for detection of
methicillin-resistant Staphylococcus aureus including the
non-typeable clone from animal origin
M.W.M. Wassenberg, S. Nijssen, X.W. Huijsdens, A.M.C. Bergmans,
C.M.J.E. Vandenbroucke-Grauls, M.J.M. Bonten, J.A.J.W. Kluytmans
(Utrecht, Breda, Bilthoven, Amsterdam, NL)
Objectives: The rapid and accurate identiﬁcation of methicillin-resistant
Staphylococcus aureus (MRSA) is of great importance to control the
spread of MRSA. Since 2003 a MRSA clone from animal origin is
observed with rapidly increasing prevalence in the Netherlands and this
isolate is non-typable (NT) with SmaI PFGE. The recently developed
GeneXpert® system allows molecular detection of MRSA with a simple
procedure in 75 minutes.
The objective of this study was to assess the in vitro sensitivity of the
Xpert MRSA Assay performed in the GeneXpert® system to detect
MRSA including NT-MRSA isolates.
Methods: A collection consisting of 35 NT-MRSA and 73 typable
MRSA strains isolated from humans in the period January 2003 to
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September 2005 was used. The typable strains were obtained from the
same area and time period as the NT-MRSA. All strains were coded
during testing. The GeneXpert® was performed on fresh cultures of the
isolates and according to the manufacturer’s protocol.
Results: 108 MRSA isolates were tested. In 4 cases there was an invalid
result or technical error. Of the remaining 104 isolates, 99 (95%) were
detected with the GeneXpert®. The sensitivity among NT-MRSA isolates
was 31 of 35 (89%) and among the other strains 68/69 (99%). Four of the
5 false negative MRSA isolates had SCCmec type III. Of the 76 strains
that were SCCmec typed, 14 had SCCmec type III (18%).
Conclusion: This study demonstrates that the GeneXpert® is a rapid
and reliable system for detecting MRSA in vitro. The assay is also
able to detect NT-MRSA. Clinical studies are required to determine the
reliability of the GeneXpert® to detect MRSA from clinical samples. The
majority of the strains that were not detected were of SCCmec type III.
This should be studied in more detail.
P901 A new automated magnetic bead based nucleic acid sample
preparation directly from nasal swabs for MRSA diagnostics
T.E. Kolpus, H.K. Høidal Berthelsen, M. Lorentzen, U.H. Refseth
(Oslo, NO)
Objectives: The term MRSA (methicillin resistant Staphylococcus
aureus) is used to describe Staphylococcus aureus that is resistant to
commonly used antibiotics. The bacterium is known to mainly colonise
the nostrils, but the respiratory tract, open wounds, catheters and urinary
tract are also potential sites of infection. It is believed that as many as
53 million people carry MRSA. The traditional method of testing for
MRSA is both cumbersome and time consuming, and can take several
days before a result can be reported.
We have developed a unique principle for bacterial DNA extraction
directly from nasal swabs. Collection and transport systems from
alternative manufacturers have been successfully tested, such as rayon
and nylon swabs in Liquid Stuart or Amies (liquid and gel) Transport
Medium. The dimensions of many types of transport tubes limits full
automation because they are unsuitable for insertion into the automation
instruments, which necessitates manual transfer of sample into sample
preparation tubes. In this study we present results of a fully automated
BUGS’ n BEADS system for bacterial DNA isolation, using swab and
transport devices manufactured by Copan, Brescia, Italy.
Methods: The specimen is collected from the patient using a ﬂocked
nylon swab that is submerged into a polypropylene screw-cap tube
containing 1ml of Liquid Amies Transport Medium following transport
to the test laboratory, the tube is vortexed, the swab removed and the tube
is placed straight into the automation instrument to serve as the primary
tube for automated transfer of sample into the sample preparation tube.
Microbial contents remaining in the primary tube after withdrawal of
sample for BUGS’ n BEADS may be used for cultivation.
Results: Automated BUGS’ n BEADS extraction of MRSA DNA
directly from swab was achieved using automation instrument compatible
polypropylene screw-cap tubes containing Liquid Amies Transport
Medium, in combination with ﬂocked nylon swabs (Copan, Brescia,
Italy). The obtained sensitivity was 150 cfu MRSA per swab.
Conclusions: MRSA is detected directly from swab without prior
cultivation, at a sensitivity of about 150 cfu per swab, using Copan
swab and transport tubes in fully automated BUGS’ n BEADS sample
preparation.
P902 Development of a multiplex real-time PCR for detection
of methicillin-resistant Staphylococcus aureus and
Panton-Valentine leukocidin directly from clinical samples
L. Renwick, A. Hardie, E.K. Girvan, A.P. Gibb, D. Morrison, J. Dave,
K.E. Templeton (Edinburgh, Glasgow, UK)
Objectives: Methicillin-resistant Staphylococcus aureus (MRSA) is
a major pathogen responsible for signiﬁcant numbers of healthcare
associated infections. Isolates containing Panton-Valentine leukocidin
(PVL) that cause severe skin infections are emerging as a problem in
the community. Rapid, PCR-based detection of MRSA in screening and
wound swabs would be an invaluable tool in a diagnostic laboratory. The
aim of this study is to develop a novel multiplex real-time PCR assay
for detection of MRSA and PVL directly from clinical samples.
Methods: Individual assays for MRSA (SCCmec) and PVL (LukF
and LukS) were optimised and combined and the new multiplex assay
evaluated with screening and wound swabs. Swabs (n = 240) from all
S. aureus positive patients taken during May and June 2006 were
collected and tested by multiplex PCR. All PVL positives were conﬁrmed
by second PCR.
Results: MRSA and PVL positive isolates were detected by the assay
with an analytical sensitivity of 100 cells/reaction. No other bacterial
species were ampliﬁed. Five of 240 swabs (2.1%) were positive for PVL.
All ﬁve were independently conﬁrmed by different PCR in the Scottish
MRSA reference Laboratory. Three PVL positives were methicillin-
sensitive S. aureus and two were MRSA. Each positive specimen was
collected from a patient with a skin infection at an outpatient clinic or
within 24 hours of admission to hospital.
Conclusion: This assay is a powerful, sensitive diagnostic tool giving
rapid results and could allow timelier treatment and infection control
decisions to be taken. It can also provide valuable epidemiological
information.
P903 Methicillin-resistant Staphylococcus aureus strains from
animal origin are recognized by IDI-MRSA PCR
R. Roosendaal, J.A.J.W. Kluytmans, J.H.C. Woudenberg, X. Huijsdens,
C.M.J.E. Vandenbroucke-Grauls (Amsterdam, Bilthoven, NL)
Objectives: The Netherlands is one of few countries in the world that
is able to keep the prevalence of MRSA low, grace to a very stringent
infection control policy. Recently, however, a new problem has emerged:
a high percentage of pig-farmers appears colonised with MRSA strains
that are non-typable in pulse ﬁeld electrophoresis (PFGE). These strains
have also been detected in large numbers of pig-farms and pigs. Because
these strains represent a new threat to our national policy, we determined
whether these strains of animal origin can also be rapidly recognized by
the PCR assay described by Huletsky et al [1], and marketed as IDI-
MRSA Test by Becton Dickinson.
Methods: MRSA strains collected at the RIVM between January 2003
and September 2005 and deﬁned as “non-typable” by routine PFGE were
tested with the IDI-MRSA test. In addition, the presence of the mecA-
gene was determined. SCCmec type and spa type were determined in a
previous study at the RIVM.
Results: The IDI-MRSA identiﬁed correctly 29/33 strains (86.2%). Of
these, 28 were of MLST sequence type (ST) 398, and one ST 752 (a
single locus variant of ST 398). Furthermore, spa types t034 (5 strains),
t108 (14 strains), t011(8 strains), t571 (2 strains) and SCCmec types V
(21 strains), IVa (3 strains), and III (4 strains) were detected in the 29
correctly identiﬁed strains. In one strain the SCCmec type could not be
determined.
The four misidentiﬁed strains were MLST ST398 (3 strains) and ST753
(1 strain). The spa types were t034 (1 strain), t567 (2 strains) and t898
(1 strain). The SSCmec types were all type III in these four strains, hence
half of the strains with this SSCmec (4/8) were not correctly identiﬁed
by the IDI-MRSA test.
Conclusion: The IDI-MRSA performs well with MRSA strains of
animal origin. We hypothesise that the strains that are not recognized
harbour point mutations at critical sites in SCCmec. This is currently
under investigation.
Reference(s)
[1] Huletsky A, R. Giroux, V. Rossbach, M. Gagnon, M. Vaillancourt,
M. Bernier, F. Gagnon, K. Truchon, M. Bastien, F. J. Picard, A.
van Belkum, M. Ouellette, P. H. Roy, and M. G. Bergeron. New
Real-Time PCR Assay for Rapid Detection of Methicillin-Resistant
Staphylococcus aureus Directly from Specimens Containing a
Mixture of Staphylococci. J. Clin. Microbiol. 2004 42: 1875–1884.
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P904 Comparison of culture and real-time PCR for point
prevalence surveillance of methicillin-resistant Staphylococcus
aureus in a large public teaching hospital
D. Fuller, S. Wilson, R. Buckner, M. Commiskey, K. Prugh,
C. Miramonti, G. Huffman, H. Cui, T. Davis (Indianapolis, US)
Objective: Controlling MRSA is a primary focus of most hospital
infection control programmes. Currently, the standard surveillance
method for detecting MRSA is culture, which is very laborious and
time intensive. A rapid and more sensitive method to screen for MRSA
will represent a deﬁnite advantage for infection control programmes.
The objective of this pilot study is to evaluate the prevalence of MRSA
colonisation in patients at Wishard Health Services (Indianapolis, IN)
using conventional culture and real-time PCR (RT-PCR) technology.
Methods:We conducted a prevalence survey of all inpatients at Wishard
excluding children and prisoners. A total of 259 subjects were tested to
establish MRSA prevalence. Anterior nares specimens were collected
from each subject using a double swab set. One swab from each set pair
was streaked to conventional agar media for culture and RT-PCR testing
was performed on the other swab from each swab set pair. Cultures
positive for SA were then tested for oxacillin sensitivity. Discrepant
results were resolved by retesting the culture swab using PCR technology
and by retesting the RT-PCR swab with an alternative ampliﬁcation assay
(Analyte Speciﬁc Reagent). Percent agreement was calculated in which
a true positive was deﬁned as (a) culture positive or (b) any 2 positive
PCR results.
Results: Of the 259 subjects tested, 183 (71%) were negative for MRSA
with both conventional culture and RT-PCR while 57 were positive with
both methods. Nineteen subjects had discrepant results (17 were RT-PCR
positive/culture negative and 2 were RT-PCR negative/culture positive).
All discrepant results were resolved after retesting and showed 100%
agreement.
Conclusions: RT-PCR technology proved to be much more sensitive
than conventional culture methods for detection of MRSA. This patient
population had an overall MRSA prevalence rate of 29% (74/259). Using
culture only instead of PCR technology would have missed 23% (17/74)
of MRSA colonised patients which has profound implications for
infection control.
P905 Low speciﬁcity of GenoType® MRSA Direct test when result
interpretation is restricted to hybridisation of PCR products
S. Borgmann, A. Kick, M. Schuierer, A. Reber, H. Gruber, K. Beyser,
R. Abel, A. Lindauer (Weiden, Bayreuth, DE)
Objectives: Identiﬁcation of MRSA bearing patients might be
accelerated by performing PCR from primary materials (swabs,
etc.) circumventing bacterial culture. Recently, Robert-Koch-Institute
recommended GenoType® MRSA Direct test (Hain, Nehren, Germany)
to reveal MRSA colonisation. In our lab this test has been performed
since January 2006 servicing more than 40 hospitals in Northern Bavaria
with microbiological analyses. Here we present data covering all PCR
examinations collected over a time period between April and October
2006.
Methods: MRSA PCR and hybridisation of PCR products against
speciﬁc probes linked to nitrocellulose strips were performed according
to the manufacturers’ recommendations. In addition, all PCR products
were examined by agarose gel electrophoresis. All results were
documented and compared to those of bacterial cultures performed
within the following 7 days.
Results: A total of 861 samples was examined by PCR out of which
457 samples were grown and characterised through microbiological
routine within the next 7 days (Table 1).
Among the cohort of PCR negative MRSA samples only 2% showed
bacterial growth (column 2). Hybridisation positive MRSA without
detectable PCR products on agarose gels (column 3) could be grown
in bacterial cultures in only 14% of the samples, suggesting a high
percentage of false positive PCR results. Even with a detectable PCR
product on an agarose gel combined with a positive hybridisation signal
(column 4) growth of MRSA was observed in only 71% of the samples.
Since this result also indicates a low speciﬁcity these 25 cases were
backtracked in more detail. Eventually there were only 5 cases left for a
fair comparison of positive PCR results versus negative bacterial growth
results suggesting speciﬁcity higher than 90%.
Table 1. Summary of MRSA direct PCR and bacterial culture resultsa
Culture Gel− Hyb− Gel− Hyb+ Gel+ Hyb+
n.d. 376 5 23
+ 7 2 60
− 351 12 25
aGel: results of agarose gel electrophoresis. Hyb: results of hybridisation
reaction; n.d., not done.
Conclusion: GenoType® MRSA Direct test is a sensitive tool for
identifying MRSA bearing patients. However, interpretation of PCR
results needs to be based on hybridisation combined with agarose gel
electrophoresis.
P906 Evaluation of the IDI-MRSA assay for detection of
methicillin-resistant Staphylococcus aureus from clinical
specimens
K. Lucke, M. Hombach, G.E. Pfyffer (Lucerne, CH)
Persistent spread of methicillin-resistant Staphylococcus aureus (MRSA)
in hospitals and other healthcare facilities requires suitable and efﬁcient
infection control strategies. Early detection of MRSA carriers and
the rapid availability of diagnostic results are paramount for the
implementation of efﬁcient control measures. To determine the beneﬁt
of a recently developed molecular technique 691 high risk patients were
screened for carriage of MRSA by real time PCR using the commercially
available IDI-MRSA assay (GenOhm, San Diego, CA). Its efﬁcacy
as a screening test was assessed by analysing nasal, inguinal, rectal,
and vaginal swabs as well as swabs from axilla, wound and throat.
In addition, backup cultures for all specimens were done in parallel.
Thirty-two of 691 specimens were both PCR and culture positive, while
633 specimens were negative with both methods. Sixteen specimens
were PCR positive but culture negative, whereas 8 specimens were PCR
negative but culture positive. For two specimens the PCR reaction was
inhibited. Among the 16 specimens with a false susceptible PCR result
10 contained a methicillin-susceptible Staphylococcus aureus strain, but
no MRSA. Overall sensitivity, speciﬁcity, positive predictive value (PPV)
and negative predictive value (NPV) of the IDI-MRSA assay were 80.0%,
97.5%, 66.6%, and 98.8%, respectively.
In addition, our study demonstrates that the test is also applicable for
specimens other than nasal swabs. With its excellent NPV the IDI-MRSA
is a perfect screening test for a rapid exclusion of MRSA carriers.
However, due to the incidence of false positive results we strongly
recommend backup cultures. Taking into account the high cost for patient
isolation and other infection control measures and in particular, the
prevention of pathogen transmission within the hospital the expenses
for the IDI-MRSA assay are more than paid off.
P907 Rapid detection of methicillin-resistant Staphylococcus
aureus by real-time PCR from clinical specimens
B. Jovanic, B. Jobst, C. Schmidt, T. Miethke (Munich, DE)
To avoid spread of methicillin-resistant Staphylococcus aureus (MRSA)
within the clinic rapid detection of the bacterium is desirable. Culture
based methods require up to 5 days to identify MRSA from patient
specimens. In order to replace this time consuming method a real time
PCR was developed by our group to rapidly identify MRSA within
3 hours (Hagen et al. 2006, Int. J. Med. Microbiol. 295:77). The real time
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PCR assay targets the 3′ integration site of the staphylococcal cassette
chromosome mec (SCCmec) at the orfX locus.
In the present study we improved our real time PCR to detect in
addition to SCCmec types I–IV the type V cassette. We demonstrate
here that 226 MRSA, 111 methicillin-sensible Staphylococcus aureus
(MSSA), 50 methicillin-resistant coagulase-negative Staphylococci and
12 methicillin-sensible coagulase-negative Staphylococci were correctly
identiﬁed. However, 3 MSSA were false positive and the reason for this
observation remains currently unknown.
Furthermore, we evaluated our method with nasal and wound swabs from
patients. In our ongoing clinical study we have analyzed 519 swabs
by culture and PCR. 489 swabs were negative in both experimental
procedures. All together 30 swabs contained MRSA. 15 swabs had
positive results in PCR and culture method, 8 swabs were only in PCR
positive and 7 only by culture. The swabs, which were only positive in
PCR, were conﬁrmed to be MRSA-positive in an independent PCR-assay
detecting mecA and a Staphylococcus aureus-speciﬁc gene. To rule out
the possibility that our SCCmec-PCR was unable to detect the 7 MRSA-
strains that were only positive in culture, we repeated the PCR-assay in
5 out the 7 cases (in 2 cases the strains were unfortunately not available)
from colony material. In all 5 cases the SCCmec-PCR was positive.
The earlier analysis (3 hours versus at least 5 days) brings an overall
cost reduction in the clinic because hygiene measures can be employed
quicker and the spread of MRSA thus prevented. Isolation measures
of patients with former MRSA-carriage can be ﬁnished sooner, if the
SCCmec-PCR assay is negative.
In conclusion the SCCmec-PCR is a reliable and time saving detection
method for MRSA in the clinic and our studies show that this PCR assay
equals the accuracy of culture.
P908 The ability of a rapid PCR-based method to identify surgical
patients colonised with methicillin-resistant Staphylococcus
aureus
K.J. Hardy, S. Gossain, C. McMurray, S. Shabir, I. Alobwede,
A. Williams, N. Athamneh, P.M. Hawkey (Birmingham, UK)
Objectives: To determine the ability of the rapid IDI MRSA PCR based
assay to identify surgical patients colonised with MRSA compared to
conventional culture methods.
Methods: During a 9 month period all patients admitted to 4 surgical
wards had nasal swabs taken for detection of MRSA on admission and
every 4 days subsequently. Each swab was plated directly onto MRSA
ID agar and then tested using the IDI MRSA assay. Additionally all
swabs were placed in brain heart infusion broth incubated overnight
and subcultured onto MRSA ID and Baird Parker agar for detection of
MRSA and MSSA respectively.
Results: A total of 7545 nasal samples were examined from
3769 patients. Seven hundred and ﬁfty six samples were positive by
the IDI MRSA assay, of which MRSA was isolated on direct culture
from 374 (49.5%). Of the 382 samples that were negative on direct
culture, MRSA was isolated on broth enrichment from 138 samples,
and MSSA from 42 samples. Of the 244 samples that were IDI MRSA
assay positive but did not have MRSA isolated, 77 (31.6%) came from
patients that had previous or subsequent samples from which MRSA
was isolated. When individual patients are examined a total of 465 of
the 3769 patients (12.3%) sampled had at least one sample that was
positive by the IDI MRSA assay, of which 254 (54.6%) were positive by
direct culture. An additional 76 patients had MRSA isolated from broth
enrichment, but a total of 135 patients (29%) were only ever found to
be positive by the IDI MRSA assay and did not have MRSA isolated
using culture. Overall the IDI MRSA assay has a sensitivity of 97%, a
speciﬁcity of 96.1%, NPV of 99.7% and a PPV of 71%.
Conclusion: The IDI MRSA assay provides a rapid and sensitive way
of screening surgical patients for MRSA, with a very high negative
predictive value. The increased number of patients identiﬁed as colonised
with MRSA using the IDI MRSA assay compared to conventional
culture, may be due to the increased sensitivity of PCR compared to
culture. Rapid and sensitive identiﬁcation of surgical patients colonised
with MRSA aids in the prompt decolonisation and isolation of patients.
P909 Genome variability of methicillin-resistant Staphylococcus
aureus as revealed by comparative genome hybridisation
with a multi-strain microarray
G. Kuhn, T. Koessler, P. Francois, A. Huyghe, J. Schrenzel, P. Francioli,
D.S. Blanc (Lausanne, Geneva, CH)
Objectives: Using comparative genome hybridisation (CGH), we ﬁrstly
aimed to analyse core and accessory genome compartments in a diverse
collection of Methicillin resistant S. aureus (MRSA). Secondly, we aimed
to know whether genetic elements have speciﬁcally been gained or lost
during evolution of S. aureus Clonal Complexes (CC’s).
Methods: Our collection comprised 21 MRSA isolates of 5 different
CC’s. It included 1 isolate of CC1, 6 isolates of CC5, 7 isolates of CC8,
1 isolate of CC22, 7 isolates of CC45 and 2 singletons (ST 80 and
15). CGH was performed on a multi-strain oligonucleotide microarray.
It comprised probes for S. aureus strains N315, Mu50, COL, and MW2
covering 99% of all genomes with 2535, 2663, 2633, and 2625 genes
respectively. Based on genome sequences of all 4 strains, 2019 genes
are core. Oligonucleotide probes included common probes targeted at
conserved gene regions (based on alignment of orthologs of all 4 strains)
and speciﬁc probes targeted at variable gene regions. Common probes
were designed to avoid absence of signals in CGH due to sequence
variation. For analysis of S. aureus CC evolution we subtracted isolates
of CC5, CC8, or CC45 from all other isolates.
Results and Discussion: CGH of DNA from 21 strains to common
probes showed that the core genome comprised only 1851 genes.
Interestingly, we noted that a considerable number of genes, which
were located on mobile genetic elements, were present in all strains.
In contrast to this, other genes, which were clearly not associated with
mobile genetic elements, were variably lost.
A phylogenetic analysis based on presence and absence of accessory
genes was performed and showed a weak congruence with CC groups
and this was especially true for isolates of CC8. In line with this
observation, we did not ﬁnd genes which were speciﬁcally associated
with either CC5, CC8, or CC45. This was in contradiction to previous
studies using CGH.
Conclusions: By performing CGH analysis on 21 genetically diverse
strains using a microarray which comprised a set of common probes we
were able to clearly differentiate core and accessory genes. Our results
show that accessory genes are not useful for phylogenetic analyses.
P910 Rule-out Staphylococcus aureus, including MRSA, directly
from primary swab cultures using S. aureus PNA FISH
A. Voss, M. Wulf, M. Sørum, R. Skov, K.G. Madsen (Nijmegen, NL;
Copenhagen, Vedbæk, DK)
Objectives: In July 2006, we performed a study among veterinarians
attending the International Pig Veterinary Society Congress (IPVS) in
Copenhagen. This study was set-up to screen the attendees for MRSA
carriership and at the same time to validate S. aureus PNA FISH
(AdvanDx Inc.) as a rapid rule-out test from primary swab cultures.
S. aureus PNA FISH is a rapid molecular diagnostic test with a 2.5 hours
turn-around time once culture swab culture reach the laboratory.
Methods: 264 swabs from the anterior nares and throat (combined
culture) were collected from participants at the IPVS Congress.
The swabs were transported to Statens Serum Institut for over-night
enrichment in salt-enriched semi-selective nutrient broth. One ml of
this primary swab culture was frozen and shipped to Nijmegen, The
Netherlands for analysis by S. aureus PNA FISH. Subsequently, the broth
was subcultured on blood agar and MRSA-ID agar plates (bioMe´rieux).
Staphylococcus aureus was identiﬁed by colony morphology and tube
coagulase test. Oxacillin-resistance was determined by cefoxitine-disc-
diffusion according to CLSI criteria and conﬁrmed by in-house mecA
PCR.
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Results: 34 of the 264 samples were MRSA-positive according to the
above mentioned method. Using S. aureus PNA FISH, 112 of the samples
were positive for S. aureus, including 32 of the 34 MRSA-positive
samples. Two MRSA’s were found S. aureus PNA FISH false negative.
The 80 false positive S. aureus PNA FISH results were presumably
caused by the presence of methicillin-susceptible S. aureus. The
sensitivity, speciﬁcity, positive predicted value and negative predicted
value (NPV) of S. aureus PNA FISH for MRSA were 94.1%, 65.2%,
28.5%, and 98.7%, respectively, such that after only 24 hours, 150 out of
the 264 samples could be ruled out as being non-S. aureus and therefore
also non-MRSA’s.
Conclusion: The high NPV (98.7%) of S. aureus PNA FISH suggest
that this test could be a rapid method to rule-out MRSA directly from
primary surveillance swab cultures. Using this rapid test as a pre-screen,
only the minority of samples that yield a positive S. aureus PNA FISH
result would require continued isolation and testing using conventional
screening and/or other MRSA speciﬁc rapid diagnostic tests.
Molecular detection of sexually transmitted
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P911 The Becton Dickinson ProbeTec ET system detects
Chlamydia trachomatis and Neisseria gonorrhoeae from male
“self collected” glans/urethral dry swab specimens thus
advancing the potential for prevention and control through
“home collection”
D.V. Ferrero, D.E. Schultz, N. Burgess, S.A. Willis, G.M. Ferrero
(Stockton, Santa Clara, US)
Nucleic Acid Ampliﬁcation Tests (NAATs) have proven to be useful
tools in identifying cases of Chlamydia trachomatis (CT) and Neisseria
gonorrhoeae (NG) throughout the world. Unfortunately, infection rates
continue to increase. Increasing CT rates and ever-present NG infections
in women, have given rise to consideration of male CT/NG screening
programmes in order to address the male reservoir. Because, current
efforts have not adequately controlled these diseases, Public Health
Ofﬁcials must consider other means. Home collection may be a viable
mechanism for reaching certain populations that in the past have not
been accessed. Effortlessly collected, non-invasive, self-collected male
specimens that are stable and easy to transport would enhance the
success of male screening programmes. We designed a study to consider
the effectiveness of male dry noninvasive self collected glans/urethral
swab (SCS) specimens to detect CT and NG when compared to
clinician collected swab (CCS) specimens and ﬁrst catch urine (FCU)
specimens. 284 male patients attending an STD clinic were tested
for CT and NG using CCS, FCU and SCS. All patients enrolled
signed an approved Investigational Review Board (IRB) consent. The
three specimens collected per patient were processed according to the
manufacturer’s recommended procedure using the Becton Dickinson
ProbeTec system. There were a total of 51 specimens detected positive
for either CT or NG. The CT prevalence was 12.0%. The NG prevalence
was 5.6%. The overall sensitivity of SCS was 91% with a speciﬁcity
of 99%. Sensitivity and speciﬁcity were based on an infected patient
status of any two or more results being considered true results. There
was an overall SCS agreement of 97.5% with CCS specimens and
98.1% with FCU specimens. Male dry self-collected glans/urethral swab
specimens are a viable specimen choice. Dry swab specimens are easy to
collect, transport and test using the Becton Dickinson ProbeTec system.
The BD ProbeTec system showed high sensitivity and speciﬁcity for
detection of CT/NG and high agreement when compared to CCS or FCU
specimens. Simpler methods of collection and transport that produce
reliable test results may increase the potential for screening difﬁcult to
test populations. This study is particularly important as the data indicates
there is potential for NAATs to adequately detect CT and NG in male
SCS in many venues including one’s own home.
P912 Molecular genetic-based diagnosis of sexually transmitted
Mycoplasma and Ureaplasma using an ELISA-based
Multiplex PCR system
R. Rabhofer, F. Schwarzmann, S. Hofstetter, F-W. Tiller (Munich, DE)
Mycoplasmatales are the causative agents of a number of non-chlamydial
non-gonococcal infections in the urogenital tract. It was shown further
that neonates become infected during delivery resulting in colonisation
of the respiratory tract leading to pneumonia and meningitis. Diagnosis
of Mycoplasmatales in clinical samples by culture is difﬁcult and time-
consuming. Thus, we have evaluated the molecular genetic-based hyplex
STD ID system for the rapid and reliable detection of U. urealyticum/
U. parvum, M. hominis, and M. genitalium.
Twenty-two vaginal, 3 cervical, 1 urethral and 14 glans swabs
as well as 6 ejaculate and 46 urine samples were selected from
46 patients presenting with acute clinical symptoms of inﬂammation
characteristic for chlamydial or mycoplasmal infections. DNA was
extracted automatically using MagNA Pure technology and samples were
analysed in parallel using the molecular genetic hyplex technology and
culture.
Using the hyplex system, the pathogen-speciﬁc DNA was ampliﬁed
by multiplex PCR and subsequently detected by hybridisation to
immobilised Mycoplasma/Ureaplasma-speciﬁc probes in an ELISA-
based format with colour-coded wells.
21.3% (10/46) of the samples were identiﬁed positive for Mycoplasma
or Ureaplasma by bacterial culture and 32.6% (15/46) by the molecular
genetic assay. In 2/46 samples bacterial growth was detected by culture,
however, interpretation was not possible. The respective samples scored
positive for both Mycoplasma and Ureaplasma by the molecular genetic
assay. In 73.9% (34/46) of the samples culture was negative whereas
the molecular genetic-approach did detect neither Mycoplasma nor
Ureaplasma only in 67.4% (31/46) of the samples.
14/15 positive samples were vaginal or cervical swabs whereas
13/14 glans swabs and 6/6 ejaculate samples were negative. 12/15 pa-
tients’ positive swabs were conﬁrmed with corresponding positive urine
samples. 3/15 positive swabs could not be conﬁrmed in the urine whereas
2/11 negative glans swabs were re-tested positive.
In conclusion, the hyplex STD ID system proved to be a fast and reliable
tool for the diagnosis of Mycoplasma or Ureaplasma. In comparison to
the standard culture the sensitivity of the molecular genetic hyplex assay
was 100%, speciﬁcity was 91.2%, NPV was 100%, and PPV was 80%.
Nevertheless, urines should be handled with caution keeping in mind
that large volumes may result in inappropriate dilution and probably
false negative results.
P913 High throughput-screening for Chlamydia trachomatis in uro-
genital clinical samples using an ELISA-based PCR-system
F. Schwarzmann, S. Fesenmeir, R. Rabhofer, S. Hofstetter, F-W. Tiller
(Munich, DE)
Screening of asymptomatic women has been shown to reduce signiﬁ-
cantly the incidence of severe ascending infections caused by Chlamydia
trachomatis. The enzyme immunoassay is used most commonly for
diagnosis but lacks the sensitivity required for screening. Thus, we tested
the hyplex STD Chlamydia PCR-ELISA-System as a cost-effective and
sensitive tool for high throughput applications.
217 urogenital swabs, 22 urine and 11 ejaculate samples were randomly
selected and DNA was extracted automatically using MagNA Pure
technology. The samples were analysed in parallel using the hyplex
technology and the Cobas Amplicor system as a gold standard. Using
the hyplex system, the target-DNA was ampliﬁed by conventional PCR
and subsequently the Chlamydia-speciﬁc products were detected by
hybridisation to immobilised probes in an ELISA-based format with
colour-coded wells.
9.2% (20/217) of the urogenital swabs, 0% (0/22) of the urine samples,
and 0% (0/11) of the ejaculate samples were identiﬁed positive using
the hyplex system. There was an overall concordance of 100% with
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the gold standard. 88.9% (193/217) of the swabs, 86.4% (19/22) of
the urine samples and 100% (11/11) of the ejaculate samples were
identiﬁed negative both using the hyplex system and the Amplicor
system. However, 1.9% (4/217) of the swabs and 13.6% (3/22) of the
urine samples, which were identiﬁed negative by the Amplicor system,
were excluded from the analysis by the hyplex system due to missing
internal control (IC), which uses a bacterial house-keeping gene to detect
inhibition as well as insufﬁcient quality of the sample. In conclusion,
testing urogenital swabs, urine and ejaculate samples the hyplex assay
showed 100% concordance in clinical sensitivity compared to the gold
standard. Referring to the negative results, there was a concordance
of 97.9%, 86.4%, and 100% for swabs, urine and ejaculate samples,
respectively. This was exclusively due to “invalid” IC results of the
hyplex test, supposedly related to differences in the type of IC. Although
there was not sufﬁcient material available for retesting, we suppose that
the observed differences were due to efﬁcient detection of insufﬁcient
sample quality by the hyplex IC. In conjunction with an ELISA-processor
the recently CE-certiﬁed hyplex ELISA-based PCR-assay is a cost-
effective alternative to well established systems allowing analysis of up
to 96 samples for C. trachomatis DNA within four hours of time.
P914 Sequencing of Treponema pallidum ssp. pertenue Samoa D
genome
P. Matejkova, M. Strouhal, D. Sˇmajs, S.J. Norris, G.M. Weinstock
(Brno, CZ; Houston, US)
Objectives: Treponema pallidum ssp. pertenue (TPE) causes endemic
treponematosis yaws. Genome of this pathogen was shown to be 99%
identical to Treponema pallidum ssp. pallidum (TPA), the causative
agent of syphilis. Although syphilis and yaws have different clinical
manifestation, the pathogens are microscopically and serologically
indistinguishable. Genome scale approaches (microarray hybridisations
and whole genome ﬁngerprinting – WGF) showed that there are no
gene deletions and multiplications and no large indels. Relatively subtle
genetic differences responsible for different pathogenesis of syphilis and
yaws thus require complete genome sequence of TPE.
Methods: Comparative genome sequencing (CGS) is a technique based
on hybridisation of the test and the reference genomic DNA to the
oligonucleotide chip and has two stages. In the ﬁrst stage, heterologous
regions of the test genome were mapped and in the second step, positions
of single nucleotide polymorﬁsms (SNPs) in the test genome were
revealed. Additional regions containing clustered SNPs and indels were
subjected to dideoxyterminator (DDT) sequencing. Physical map of
complete genome sequence obtained by combination of CGS and DDT
of heterologous regions was conﬁrmed by WGF.
Results: CGS together with DDT sequencing and WGF was employed
to obtain complete genome sequence of TPE Samoa D strain. The
unﬁnished complete genome sequence comprised 1 linear contig.
CGS revealed 904 SNPs and 84 regions were suggested for DDT
sequencing. DDT sequencing of these regions revealed more than
additional 500 SNPs and 85 indels in the length range of 1 303 bp.
WGF was used to verify the assembly of the genomic sequence and to
conclude the exact number of repeats in 2 tandem repeat regions and
in additional 4 regions comprising T. pallidum repeat (tpr) genes and
hypothetical genes in their vicinity. In silico proteome analysis revealed
that more than 300 proteins (out of 1039 proteins predicted in TPA
Nichols strain) were affected by sequence changes.
Conclusion: The genome sequence of yaws treponeme was used to
deﬁne intersubspecies difference between TPE and TPA.
This work was supported by the grants from the Internal Grant Agency
of the Ministry of Health of the Czech Republic (NR/8967−4/2006) and
from the Grant Agency of the Czech Republic (310/04/0021).
P915 Comparative genomics of closely related treponemal strains
M. Strouhal, P. Matejkova, D. Sˇmajs, E. Sodergren, S.J. Norris,
G.M. Weinstock (Brno, CZ; Houston, US)
Objectives: Genus Treponema includes several pathogenic spirochetes:
Treponema pallidum ssp. pallidum (TPA) is the causative agent of
sexually transmitted syphilis, Treponema pallidum ssp. pertenue (TPE)
causes endemic non-veneral treponemal infections and T. paraluiscuni-
culi (TPAR) is the etiologic agent of veneral syphilis in rabbits and does
not infect humans. These treponemes cannot be continuously cultivated
under in vitro conditions and are indistinguishable by morphological and
serological methods. In this study, genomes of closely related treponemes
were compared.
Methods: Whole genome ﬁngerprinting (WGF) was used to compare
four treponemal strains including Nichols (TPA), SS14 (TPA), Samoa
D (TPE) and Cuniculi A (TPAR). The genomes of analysed strains
were divided into 97 overlapping intervals covering the whole genome
and each of these segments was ampliﬁed and digested by restriction
enzymes BamH I, EcoR I and Hind III. The resulting restiction proﬁles
were used for identiﬁcation of heterologous regions in chromosomal
DNA.
Results: When compared to the Nichols genome the prominent indels
and sequence changes were preferentially localised in tpr genes (tprD –
TP0131, tprE – TP0313, tprF – TP0316, tprG – TP0317, tprI –
TP0620, tprJ – TP0621, tprK – TP0897 and tprL – TP1031) and
in the hypothetical genes in the vicinity of tpr genes. Differences
in number of tandem repetitions within the gene TP470 and genes
TP0433−4 (hypothetical genes) were detected in all analysed strains. In
the second case fusion of both genes (TP0433−4) resulted in one acidic
repeat protein gene (arp gene). Altogether, 2 deletions and 2 insertions,
7 deletions and 3 insertions, 12 deletions and 7 insertions were found in
the strains SS14, Samoa D and Cuniculi A, respectively.
Conclusions: In this study, WGF was shown to be essential approach for
veriﬁcation of the whole genome assembly based on comparative genome
sequencing and dideoxyterminator sequencing data. During completion
of the SS14 and Samoa D genome sequences, tandem repeat regions
and regions comprising paralogous genes were selectively identiﬁed by
WGF.
This work was supported by the grants from the Internal Grant Agency
of the Ministry of Health of the Czech Republic (NR/8967−4/2006) and
from the Grant Agency of the Czech Republic (310/04/0021).
P916 Treponema pallidum in the vitreous tap
M. Mu¨ller, I. Ewert, F. Hansmann, C. Tiemann, H. Hagedorn, J. Roider,
H. Hoerauf, H. Laqua, W. Solbach (Lubeck, Herford, Kiel, DE)
Background: Syphilis of the eye still poses a clinical challenge due
the chameleonic behaviour of the disease. As the serodiagnosis has
signiﬁcant limitations, the direct detection of Treponema pallidum (TP)
in the vitreous of the eye represents a desirable diagnostic tool.
Methods: Real-time polymerase chain reaction (PCR) for the detection
of TP was applied in specimens from diagnostic vitrectomies of
2 patients with acute chorioretinitis. Qualitative veriﬁcation of TP
by real-time PCR and melting point analysis according a modiﬁed
protocol was ruled out. Patients underwent complete serological work-
up (TP antibodies, immunoblot, antilipoidal antibodies), ophthalmologic
examination with fundus photographs, ﬂuorescein angiography, antibiotic
treatment and follow-up.
Results: In 2 cases of acute chorioretinitis of unknown origin, real-
time PCR of vitreous specimens of both patients provided evidence of
TP and was 100% speciﬁc. Initial diagnosis of presumed viral retinitis
was ruled out by PCR of vitreous specimen. Patients were treated with
systemic antibiotics and showed prompt improvement in visual function
and resolution of fundus lesions.
Conclusions: In cases of acute chorioretinitis the use of PCR-based
assays of vitreous specimens in the diagnostic evaluation of patients
is advisable. With real-time PCR, detection of TP in the vitreous was
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possible and delivered a sensitive, quick and inexpensive answer in a
disease rather difﬁcult to assess. Although syphilitic chorioretinitis is a
rare disease, PCR should include search for TP, as diagnostic dilemmas
prolong deﬁnitive treatment in a sight threatening disease.
P917 A new fast automated magnetic bead based nucleic acid
sample preparation for STI diagnostics combined with BD
ProbeTecTM ET
T. Engen, M. Angle`s d’Auriac, S. Harja, M. Tauvo-Kallio,
K. Rantakokko-Jalava, U. Refseth (Oslo, NO; Turku, FI)
Objectives: Chlamydia trachomatis is a leading cause of sexually
transmitted disease worldwide. Current NAAT methods on urine samples
require substantial cumbersome manual handling, centrifugation and lead
to inhibition with a signiﬁcant number of samples, further requiring
costly retesting. Automation of the sample preparation will reduce hands-
on time, the risk of cross-contamination, increase reproducibility and
sample throughput. Here, we present a new rapid automated magnetic
sample preparation method for C. trachomatis from urine samples
compared with the manual BD ProbeTecTM ET (Becton Dickinson)
sample preparation, both combined with the SDA detection system of
BD ProbeTecTM ET. The new rapid method uses the same Bacteria
Binding Beads as the validated BUGS’n BEADSTM (BnB, Genpoint
AS, Norway) on a customised Tecan MiniPrep 75 instrument. This new
method called BUGS’n BEADS STI-fast, includes no active lysis, uses
no hazardous or inhibiting reagents and is faster.
Methods: C. trachomatis was isolated in parallel from urine samples
using BD ProbeTecTM ET sample preparation and BUGS’n BEADS STI
–fast, both combined with the BD ProbeTecTM ET detection system. The
ampliﬁcation control (AC) in the BD ProbeTecTM ET kit was included
to reveal any potential inhibition. Discrepant results were resolved by
repeating both methods in duplicate.
Results: Based on the 442 specimens processed so far, it seems that
sensitivity is improved using this new and faster sample preparation
system obtaining 97.4% compared to 84.6% using the BD ProbeTecTM
ET sample preparation. Meanwhile, speciﬁcity remained excellent of
100% for both methods. The average signal to noise ratio for positive
samples is about 20000 MOTA units higher for BUGS’n BEADS STI
–fast suggesting that the new method increases the end result robustness
for BD ProbeTecTM ET. In addition, inhibition was observed for the BD
ProbeTecTM ET sample preparation at the rate of about 1.5%, whereas
no inhibition has been observed using the new method. The automated
isolation of 48 samples including primary sample transfer to robot tubes
and transfer of ﬁnished isolated sample to BD priming wells takes close
to 1.5 hours.
Conclusions: This new robust and faster DNA preparation method
avoids inhibition, increases throughput, reduces hands-on time and uses
no hazardous reagents while obtaining comparable sensitivity with the
standard BD protocol.
P918 Evaluation of the Abbott M2000 sp/rt real-time PCR on
Chlamydia trachomatis and Neisseria gonorrhoeae using urine
samples, and comparison with the Roche Cobas Amplicor
Ctr/Ngo PCR assays
D. Luijt, J. Schirm (Groningen, NL)
Objectives: Chlamydia trachomatis (Ctr) and Neisseria gonorrhoeae
(Ngo) are the most common micro organisms diagnosed in sexually
transmitted diseases. Nowadays laboratory diagnosis of Ctr and Ngo
is mainly based on molecular methods. The aim of this study was
to evaluate the recently introduced ABBOTT M2000 sp/rt real-time
Ctr/Ngo PCR assay in urine specimens, and to make a comparison with
the ROCHE COBAS AMPLICOR (CA) Ctr/Ngo PCR test.
Methods and Materials: Dilutions of positive control stocks in urine
and QCMD quality control panels were used for the analytical sensitivity
testing. In addition 846 clinical urine samples were tested prospectively.
Positive results of the CA Ngo assay were conﬁrmed with a speciﬁc
real-time in-house PCR using the opa gene.
Results: For both Ctr and Ngo the dilution series showed a higher
sensitivity for the M2000 assay than for the CA assay. In the QCMD
panels the M2000 assay had a 100% performance, whereas the CA
assay missed the sample with the lowest copy number of both Ctr and
Ngo. In the prospective study 5 (0.6%) samples were inhibited in the
M2000 assay and 20 (2.4%) samples were inhibited in the CA assay.
Of the remaining 821 urine samples 61 were positive and 749 negative
for Ctr in both assays. Of the 11 discrepant samples 8 were positive
with the Ctr M2000-positive/CA-negative, and 3 were Ctr CA-positive/
M2000-negative. The 8 M2000-positive/CA-negative samples were all
weak positive. Because of the higher analytical sensitivity of the M2000
assay these samples were presumable true Ctr positive samples. The 3 Ctr
CA-positive/M2000-negative samples were all negative after retesting in
the CA assay.
For Ngo 5 samples were positive and 799 samples negative in both
assays. All 5 positive samples were also positive in the Ngo speciﬁc
real-time conﬁrmation assay. The other 17 discrepant samples were all
positive in the CA assay but negative in the M2000 assay. All these
17 samples were negative in the real-time in-house PCR conﬁrmation
assay.
Conclusions: In conclusion, the M2000 assays for both Ctr and Ngo are
sensitive and speciﬁc assays, with a very low inhibition rate. For Ngo
the M2000 the assay is a more speciﬁc test than the Ngo CA assay. The
ABBOTT M 2000sp/rt system is very suitable for routine diagnostic
laboratories because of the automation, the high throughput, and the
good speciﬁcity.
P919 Specimen pooling for the detection of Chlamydia trachomatis
and Neisseria gonorrhoeae in urogenital specimens
M. Altwegg, O. Su¨ess, K. Jaton, G. Greub, K. Egli (Lucerne, Lausanne,
CH)
Objectives: To test whether pooling of 3 clinical specimens in
combination with automated DNA extraction and a home-brew duplex
test for the detection of Chlamydia trachomatis (CT) and Neisseria
gonorrhoeae (NG) performs similarly as a well established commercial
system with individual specimens and thus might help reducing costs
for analysis.
Methods: 231 clinical specimens (swabs in Roche transport medium,
native urines) were analyzed for CT and NG using the CobasAmplicor
system (Roche). Inhibited specimens were retested after DNA extraction
and NG+ specimens were conﬁrmed using an independent test. The
same specimens were further analyzed individually (N = 99) and pooled
(N= 231; 3 consecutive specimens per pool). This included DNA
extraction using the easyMAG system (bioMe´rieux) and analysis with a
home-brew duplex test for CT and NG (5′exonuclease format) on the
LightCycler (LC; Roche). In case of a positive result for a given pool,
the 3 specimens were analyzed individually using the same system. The
volumes of clinical specimens analyzed per PCR on the Cobas were
50ul and 25ul for urines and swabs, respectively, 29ul for individual
and 18ul for pooled specimens in our own assay. Inhibition of PCR was
determined using the internal ampliﬁcation control on the Cobas and an
external control on the LC.
Results: Of the 231 specimens, 4 were CT+, 1 NG+ and 2 CT+/NG+.
An additional 2 specimens were false positive for NG on the Cobas.
All pools gave the expected result when tested by home-brew PCR.
Analysis of individual specimens from positive pools correctly identiﬁed
the positive specimens (which were all in separate pools). The 2 false
positive NG specimens did not result in a positive pool signal. Inhibition
occurred in 19/231 (8.2%) of the individual specimens tested on the
Cobas, in 1/99 (1.0%) individual specimens and in 2/73 (2.7%) pools
tested on the LC. No inhibition was detected when the members of
inhibitory pools were individually extracted and tested on the LC.
Conclusions: Pooling of urogenital specimens is a promising strategy
to reduce costs for CT/NG testing. Because of the small number of
positive results the sensitivity of this procedure requires conﬁrmation.
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Optimal pool sizes depend on the number of specimens to be analyzed
and on the prevalence of the two organisms. Ampliﬁcation controls
are recommended for pools, however, this may not be necessary for
individual specimens because for those the use of automated DNA
extraction results in an inhibition rate of only 1%.
P920 Screening for Chlamydia trachomatis in women attending
outpatient clinic in Lithuania
D. Ambrasiene, R. Mikalauskas (Kaunas, Vilnius, LT)
Chlamydia trachomatis (C. trachomatis) is associated with a spectrum of
diseases. The most well-known is the sexually transmitted disease (STD)
commonly referred to as “chlamydia”. This pathogen causes genital
tract infection in both men and women, leading to sometimes serious
consequences such as infertility, ectopic pregnancy and chronic pelvic
pain. Infection with C. trachomatis is often asymptomatic, delaying its
diagnosis and treatment. The present study was initiated to determine the
prevalence of sexually transmitted pathogen C. trachomatis in Lithuanian
females.
Objectives: The aim of this study was to determinate the incidence
of C. trachomatis in asymptomatic women who attended the outpatient
clinic, for their routine annual visit.
Material and Methods: The study was carried out in Biomedical
Research Centre using highly sensitive nucleic acid ampliﬁcation
technique where this method was successfully introduced in 2001. A
total of 827 women were studied for presence of C. trachomatis by
PCR method. The vaginal and/or cervical swabs specimens have been
collected from each patient. DNA was extracted from clinical samples
by using rapid in-house procedures. The presence C. trachomatis was
determined by using in house PCR with speciﬁc primers. Five age groups
were studied: group A – under 20 years (n = 46), group B – 21−30 years
(n = 415), group C – 31−40 years (n = 205), group D – 41−50 years
(n = 126), group E – 51−60 years (n = 35).
Results: C. trachomatis infection was detected in 60 out of 833 samples
(7.2%). The prevalence of C. trachomatis genital infection in the studied
groups were: group A – 24.3% (46/9), group B – 8.6% (415/33),
group C – 4.6% (205/9), group D – 6.8% (126/8), group E – 2.9% (35/1).
Conclusion: The C. trachomatis infection is common and largely
asymptomatic. Therefore, early detection strategies of C. trachomatis
with screening programmes among young women are important in
prevention and control of target infection.
P921 Utility of molecular methods in the diagnosis of infections
related to abnormal vaginal discharge
L. Garcı´a-Agudo, M. Roman-Enry, J.R. Leo´n, I. Jesus de la Calle,
M. Rodriguez-Iglesias (Cadiz, ES)
Objective: Abnormal vaginal discharge is among the most common
causes women ask for medical advice, resulting in 5 to 10 million visits
annually. The principal diseases associated with vaginitis, in order of
frequency, are bacterial vaginosis (BV), vulvovaginal candidosis and
trichomoniasis. We evaluated a DNA hybridisation test for simultaneous
molecular detection of Gardnerella vaginalis, Candida spp. and
Trichomonas vaginalis, as an alternative to conventional microbiological
methods.
Methods: We analysed 273 vaginal samples from symptomatic women
attending the outpatient clinic of Gynecology at our hospital. We
obtained two swabs from each woman, one for mycological culture and
the other for wet mount, Gram stain and molecular detection. Wet mounts
were examined for the presence of motile trichomonads and Gram smears
were evaluated according to Nugent criteria, considering intermediate
ﬂora as negative for BV. DNA hybridisation method (Afﬁrm VPIII,
Becton Dickinson) was performed as described by the manufacturer.
The sensitivity cutoff indicates nucleic acid estimation equal or more
than 2×105 CFU of G. vaginalis, 1×104 cells of Candida spp. and/or
5×103 of T. vaginalis.
Results: Of the 273 patients, 34 had Gram smear compatible with BV.
Ten patients demonstrated intermediate Gram stain. G. vaginalis was
detected by hybridisation method in 27 of 34 specimens positive for BV
by Gram stain. Compared to the Gram stain, the DNA hybridisation test
had a sensitivity of 79%, a speciﬁcity of 79%, a positive predictive value
of 35% and a negative predictive value of 96%. Seventy-two women
presented a positive mycological culture for Candida spp. Fifty-seven of
them were positive by hybridisation. Compared to mycological culture,
the molecular technique had a sensitivity of 79%, a speciﬁcity of 92%,
a positive predictive value of 78% and a negative predictive value of
92%. There was only a positive wet mount for T. vaginalis which was
conﬁrmed by hybridisation.
Conclusion: Although we count with several laboratory methods to
diagnose vaginitis, there is a need for a rapid and highly selective tool
to help distinguish them and establish the appropriate treatment. Afﬁrm
VPIII test correlates well, resulting more objective than Gram stain and
faster than mycological culture, although it is more expensive. Its high
negative predictive value compared with any of the other diagnostic
methods, permits its use as a screening test.
P922 Evaluation of the role of Chlamydia trachomatis in chronic
prostatic infection
V. Ouzounova-Raykova, G. Mizgova, E. Ouzounova, I. Mitov (Soﬁa, BG)
Objectives: Urinary tract infection (UTI) is one of the most common
reason for adults to refer to a medical specialist. Half of all men
experience symptoms of prostatitis at some time in their life. The most
frequently recognized causes of prostatitis are classical urinary tract
pathogens rather than sexually transmitted pathogens. They are the reason
for the so called acute or chronic bacterial prostatitis. According to the
NIH consensus classiﬁcation of prostatitis there is established category
of chronic prostatitis/chronic pelvic pain syndrome (CPPS). Opinion
among researchers is divided as to whether Chlamydia trachomatis,
which cannot be cultured on conventional bacteriological culture media,
is a causative organism of chronic prostatitis.
Our study was designed to establish the prevalence of C. trachomatis in
men with chronic prostatitis and to evaluate the role of the bacterium
as possible etiological agent of chronic prostatitis syndrome. From
December 2005 to September 2006 a total of 236 men were enrolled
in the study and evaluated for the syndrome of chronic prostatitis.
Methods: Diagnosis of chronic prostatitis was made using medical
histories, physical examinations, scoring with Prostate Symptom Score
Index (PSSI) and NIH Chronic Prostatitis Symptom Index (CPSI),
pre-massage and post-massage test (PPMT), culture and microscopic
examinations of prostatic ﬂuids and urine. In all cases with suspicion of
CPPS culture and PCR of urethral smears were performed.
Results: Based on laboratory ﬁndings 195 patients (82.6%) were
diagnosed with chronic bacterial prostatitis caused by one or more of the
following pathogens – Enterococus spp., S. aureus, E. coli, T. vaginalis,
P. mirabilis. 41 men (17.4%) were examined for C. trachomatis infection
and 5 (12.2%) of them resulted positive either on PCR and culture.
Conclusion: C. trachomatis is frequent cause for STDs in European
countries. Diseases caused by C. trachomatis range from asymptomatic
to those with severe sequelae. Especially in prostatitis the exact role
is still under debate. The found prevalence of C. trachomatis in men
with CPPS in this study resulted comparable or a little higher to that
in health population. It is important to continue with the investigation
including more patients for a longer period. In our opinion although the
role of C. trachomatis in pathogenesis of prostatitis remains speculative,
however, testing for infections is highly recommended.
P923 Detection of Ureaplasma urealyticum biovars in semen of
infertile men by polymerase chain reaction
H. Zeighami, S. Najar Peerayeh, R. Salman Yazdi (Tehran, IR)
Introduction: Ureaplasma urealyticum can be produce disorders such as
non gonococal urethritis, epididymitis, prostatitis, in men and immature
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neonatal birth, abortion and fallopian infection in female. Ureaplasma
urealyticum can be effect in fertility rate in both sexes. Ureaplasma
urealyticum have a two biovars and 14 serovars. Biovar 1 (Parvum biovar)
has serotypes 1, 3, 6 and 14 and biovar 2 (Urealyticum) include serovars
2, 4, 5, 6, 7, 8, 9, 10, 11, 12 and 14. These bacteria can be present in
healthy and patient people but it is important that speciﬁc biovar may be
effect on diseases. Therefore in this study, we investigated frequency of
Ureaplasma urealyticum in infertile and healthy men by PCR method,
and then detect responsible biovars in semen of theirs.
Materials and Methods: In this study semen samples were obtained
from 100 infertile and 100 healthy men with age between 22−55 years.
After collection of samples, spermogram test were made. Samples DNA
extracted by Cadieux method. For all extracted DNA, PCR by genus
primer for Ureaplasma urealyticum (U4, U5) that based on Urease gene
were done. For all positive PCR samples PCR by biovars speciﬁc primers
(UMS263, UMA61) for urealyticum biovar and (UMA57, UMS222) for
parvum biovar which based on 5′ end of MBA gene were done.
Results: From 100 infertile men in 12% and in healthy men in 3%
U. urealyticum was detected (p< 0.05). From 12 positive samples in
infertile men in 9% urealyticum biovar and 3% parvum biovar were seen.
In 3% of healthy men in 2% parvum biovar and 1% urealyticum biovar
were detected. Spermogram test and most semen parameters decrease in
men with positive PCR test and in men with uealyticum biovar disorders
such as varicocele, azoospermia, abortion in wife and etc were seen.
Conclusion: Results of this study showed that differences in frequency
of this bacteria in two groups was signiﬁcant (p< 0.05). Furthermore
urealyticum biovar in dominant biovar in infertile men (such other
studies) and may be urealyticum biovar have a high potency than parvum
biovar for produce disease.
P924 Comparison of DiaSorin Liaison® and Architect®
immunoassay systems for syphilis screening
L. Grassi, D. Campisi, M.R. Sarcinelli, I. Papagni, R. Frigato (Milan, IT)
Objectives: Syphilis, which is caused by the spirochete Treponema
pallidum is a chronic bacterial infection that remains a public health
concern worldwide. As the World Health Organization estimated,
venereal syphilis is rapidly increasing in USA and in Europe. The
laboratory diagnosis of syphilis is a crucial point in the epidemiological
and diagnostic evaluation of the diseases.
Aim of the present study was to compare the performance of two
automated immunoassay systems for Syphilis immunoassay in blood
donors and random clinical specimens sent to the laboratory for
Treponema pallidum screening.
Methods: Study group: 419 blood donors serum samples and 458
random specimens sent to the laboratory for Treponema pallidum
screening. The following tests were used: TPPA (Fujirebio, Tokio,
Japan), Syphilis TP Architect® (Abbott Diagnostics, Weisbaden,
Germany), Treponema Screen LIAISON® (DiaSorin S.p.A, Saluggia,
Italy) were used on all specimen from blood donors. Random clinical
samples were tested with all the kits as above and with RPR (Alfa
Wasserman). Samples with discordant results were tested by Western
blot (Mikrogen).
Specimens were graded as reactive, non-reactive or equivocal in
accordance with the manufacturer’s interpretation criteria.
Results: Blood donors serum samples: All results from the 419 blood
donors samples showed complete agreement between Syphilis TP
Architect® and Treponema Screen LIAISON® on blood donors samples.
Random clinical specimens: The agreement between Syphilis TP
Architect® and Treponema Screen LIAISON® was 99.6%: two samples
positive with Architect® were negative with Liaison. These 2 samples
were further analyzed by all the methods and they were scored as
negative.
Conclusions: The performance evaluation data demonstrate that both
automated immunoassay LIAISON® Treponema Screen and Syphilis TP
Architect® have equivalent performance.
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P925 Evolution of antimicrobial susceptibility of Campylobacter
jejuni strains isolated from hospitalised children in Athens,
Greece
H. Papavasileiou, K. Papavasileiou, S. Chatzipanagiotou, A. Makri,
I. Andrianopoulou, A. Voyatzi (Athens, GR)
Objective: To investigate the current epidemiology and the antimicrobial
susceptibility of Campylobacter jejuni strains, isolated from children
with gastroenteritis.
Material and Methods: 170 strains were isolated from stools of
children aged up to 14 years during a two year period (2004–2005).
The specimens were plated on charcoal, blood free, selective medium
(oxoid, UK) and incubated for 48 h at 42ºC in a microaerophilic
atmosphere (BBL). The identiﬁcation was performed by typical
growth, microscopic examination, hippurate hydrolysis, positive catalase
and oxidase reactions. For the susceptibility of Campylobacter the
diffusion disk method was used and the determination of MIC was
performed by E-test, (AB, Biodisk, Solna Sweden) for the following
antibiotics: erythromycin, amoxicillin + clavulanic acid, ampicillin,
gentamicin, tetracycline, ciproﬂoxacin, clindamycin. As control, the
ATCC33560 strain was used. Results were interpreted according to
the criteria of the NCCLS for Enterobacteriaceae. The serotyping was
performed, based on Penner’s heat-stable (HS) serogroups, in the Greek
reference laboratory.
Results: From the 170 strains of C. jejuni isolated from gastroenteritic
cases, 30% showed resistance to ciproﬂoxacin (MIC 4mg/l), 55% to
tetracycline (MIC> 8mg/l), 13% to clindamycin (MIC 8mg/l), 4% to
ampicillin (MIC> 16mg/l), 6% to erythromycin (MIC 8mg/l) and 4%
to amoxicillin + clavulanic acid (MIC 16/8mg/l). In gentamicin all
strains were sensitive.
The MIC50 and MIC90 of the strains are shown in the table.
Strain MIC (mg/L)
MIC50 MIC90
Erythromycin 0.50 2
Ciproﬂoxacin 0.50 >32
Gentamicin 0.50 0.50
Clindamycin 0.25 32
Tetracycline 16,256
Ampicillin 2 4
Co-amoxiclav 0.50 2
Most of the strains resistant to ciproﬂoxacin were also to tetracycline.
Only two strains found to be multiresistant. Two serotypes were more
predominant: HS: 4, 13, 16, 43, 50 and HS: 1,44, while a signiﬁcant
number of strains was non-typeable (NT).
Conclusion: Resistance of C. jejuni to erythromycin, ampicillin,
amoxicillin + clavulanic acid, still remains low, whereas to tetracycline
and ciproﬂoxacin increases. As long as resistance of C. jejuni to
quinolones increases, veriﬁcation of antimicrobial susceptibility is
suggested as a routine practice in laboratories.
P926 Prevalence of antimicrobial resistance among Polish
Campylobacter jejuni and Campylobacter coli strains isolated
from humans and chicken meat
E. Rozynek, K. Dzierzanowska-Fangrat, D. Korsak, S. Wardak, J. Szych,
D. Dzierzanowska (Warsaw, PL)
Objectives: Campylobacter jejuni and Campylobacter coli have been
recognized as a major cause of foodborne bacterial gastrointestinal
infections in humans. Campylobacteriosis is often associated with
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handling raw poultry or eating undercooked poultry meat. Many studies
have shown an increasing antibiotic resistance among poultry and human
strains of Campylobacter.
The aim of this study was to compare the prevalence of antimicrobial
resistance among C. jejuni and C. coli strains isolated from children
with diarrhoea and from chicken meat in central Poland.
Methods: All isolates were collected during 2003–2005. Samples of
chicken meat were obtained from selected supermarkets in Warsaw.
Isolation of Campylobacter sp. from chicken meat was performed
according to the ISO10272 guidelines. Campylobacter strains isolated
from children with diarrhoea were identiﬁed according to the WHO
procedure. Species identiﬁcation was conﬁrmed by the PCR method.
Susceptibility to nalidixic acid, ciproﬂoxacin, tetracycline, erythromycin,
gentamycin and ampicilin was determined by the E-test method.
Results: A total of 203 Campylobacter sp. strains were isolated.
Resistance to tetracycline in all strains did not exceed 30%, but the
resistance in chicken isolates increased from 0% in 2003 to 17.3% in
2005 (p< 0.05). Tetracycline had lower activity against human C. jejuni
strains comparing to chicken isolates. Ampicillin and ciproﬂoxacin
showed low activity against both C. jejuni and C. coli strains, regardless
of their origin. Resistance to ampicillin rose from 8% in 2003 to 35.4% in
2005 (p< 0.05) in human isolates, and from 5.8% to 30.4% in chicken
strains (p< 0.05). High rates of ciproﬂoxacin resistance (>40%) were
noted in both human and chicken isolates and they did not change
signiﬁcantly in the study period. Only one human C. jejuni strain was
resistant to erythromycin and azithromycin. Resistance to gentamycin
was detected in three C. jejuni strains isolated from children and in
one chicken strain. Double resistance was detected twice as frequently
in child isolates comparing to chicken strains (37% versus 16.7%,
respectively).
Conclusion: Differences in resistance patterns between human and
chicken strains may indicate that chickens are not the main source of
Campylobacter infection in Polish children.
P927 Ten years of surveillance on antimicrobial resistance in
non-typhoidal Salmonella from humans in a Spanish
hospital: 1996–2005
C. Rodriguez-Avial, O. Lo´pez, I. Rodriguez-Avial, J. Picazo (Madrid, ES)
Objectives: In the present work we studied the evolution of resistance
and the serotypes of nontyphoidal Salmonella isolated during ten years
in a hospital of Madrid.
Methods: From 1996 thought 2005 a total of 1647 nontyphoidal
Salmonella strains were isolated from stools. The identiﬁcation and
susceptibility to 14 antibiotics were performed by a microdilution method
(Wyder system). All strains were serotyped using the somatic and
ﬂagellar antigens following the Kauffman-White Scheme.
Results: Of the 1647 isolates, 25 different serotypes were identiﬁed. The
most common were S. Enteritidis (76.5%), S. typhimurium (19.5%) and
S. Hadar (2%). Overall, 43, 7% of the strains were susceptible to all
antibiotics tested. The more relevant antimicrobial resistance rates were:
nalidixic-acid (Na) 30, 5%, amoxicilin (A) 22%, chloranphenicol (CL)
9%, gentamycine (G), tobramycin (T) 4, 7%, and cotrimoxazol (SXT)
4.7%. Resistance to Na increased from 13% in 1996 to 38, 5% in 2005.
No resistance to ciproﬂoxacin (CP) was detected, although decreased
susceptibility (CMI> 0.12mg/L) was observed in 89% of Na resistant
strains Resistance to CL decreased from 20% in 1996 to 10.5% in 2005
and was associated with S. typhimurium. In 2004 cefoxatime (CTX),
ceftazidime (TAZ) and cefoxitin (CX) resistance was observed in four S.
Heidelberg strains, all expressed a b-lactamase of pI 8.9 with amplicons
showing a high level of homology with CMY-2. The most frequent
resistance association was A+ Na (5.5%). Six strains (6 S. typhimurium)
were resistant to A+Na+SXT+CL and eleven strains (8 S. typhimurium)
to A+SXT+G+CL.
Conclusions: S. enteritidis was the most frequent serotype isolated,
which showed an increase from 63% in 1996 to 76, 5% in 2005.
S. typhimurium was associated with multidrug resistance. Resistance to
NA with decreased susceptibility to ciproﬂoxacin was associated with
S. Enteritidis and S. Hadar serotypes. In 2004 four S. Heidelbeg strains
were CMY-2 b-lactamase producers.
P928 Report of the susceptibility pattern and toxigenicity of
Clostridium difﬁcile strains isolated from patients in a
tertiary hospital in Greece during four years
M. Orfanidou, H. Kafkoula-Alevizou, E. Vagiakou, H. Tzoumakidou,
A. Strouza, H. Malamou-Lada (Athens, GR)
Objective: To report the susceptibility pattern and toxigenicity of
Clostridium difﬁcile (Cd) strains isolated from hospitalised patients
suffering from Cd associated diarrhoea, in a tertiary hospital in Athens,
Greece, during four years period (3/02–3/06).
Methods: During the study period 2035 stool samples were examined for
C.d. using cycloserine cefoxitin fructose agar with 5% egg yolk (CCFA)
and cycloserine cefoxitin blood agar (BD). The strains were identiﬁed by
rapid ANA II (Remel, Lenexa) and latex test (Culturette, BD). Toxin A
was detected from C.d. strains by an ELISA (Vidas, bioMe´rieux) and a
chromatographic assay (ColorPac, BD). Both toxins A&B were detected
by an EIA (Premier Toxins A&B, Meridian) and a chromatographic assay
(Immunocard Toxins A&B, Meridian). Antibiotic susceptibility testing
was performed by E-test (AB Biodisk, Solna).
Results: C.d. strains were isolated in 171/2035 (8.4%) stool specimens.
Toxin A was detected in 133/171 (77.8%) strains, toxin B in
22/171 (12.9%) and A−B in 16/171 (9.3%) strains. The resistance
rate of the isolated C.d. strains to penicillin (PEN) was 78.8% (MICs
0.016->32mg/L), clindamycin (DA) 55.6% (MICs 0.094->256mg/L),
tetracycline (TE) 33.4% (MICs 0.023−96mg/L), while no resistance was
observed to metronidazole (MTZ) (MICs 0.016–0.38mg/L), vancomycin
(VA) (MICs 0.032−4mg/L) and piperacillin/tazobactam (TZP) (MICs
0.75−16mg/L), although one strain presented to VA a high level MIC
of 4mg/L. Especially for meropenem (MP) the resistance rate was 7.6%
(MICs 0.016->32mg/L), while 67 strains were tested also to ertapenem
(ERT) and were found to be resistant 20% of them (MICs 0.094-
>32mg/L). The MICs range of moxiﬂoxacin (MOX) and erythromycin
(ERY) for 80 C.d. strains was found to be 0.25->32mg/L and 0.125-
>256mg/L and their resistance rate was 31.2% and 46% respectively.
Linezolid (LZ) was tested in 100 strains and all were found susceptible
(MICs 0.5−4mg/L). All strains that produced toxin B were found
resistant to PEN, DA and ERY (MICs 1.5->32mg/L, >256mg/L, 12-
>256mg/L respectively).
Conclusions:
– The most common toxin detected remains toxin A but there is an up
going presence of toxin B
– There is a high resistance rate to PEN, DA, ERY, TE and MOX, while
there is still no resistance to MTZ and VA
– A new resistance in MP and ERT is being revealed with meropenem
being more effective. No resistance was found to LZ.
P929 Primary and secondary resistance of Helicobacter pylori
to metronidazole and azithromycin in the northern part of
Croatia
Z. Marusˇic, V. Plecko, M. Katicic, L. Zˇele-Starcevic, A. Budimir,
B. Bedenic, A. Presecki Stanko, Z. Bosˇnjak, S. Kalenic (Zagreb, HR)
Objectives: The aim of this study was to assess primary and secondary
antibiotic resistance rates in Helicobacter pylori isolates over a period
of three and a half years (2003–2005 and the ﬁrst 6 months of 2006).
Methods: A total of 378 H. pylori from 347 patients were isolated
from 1211 gastric biopsies taken from patients visiting CHC Zagreb
and CHC Merkur in Zagreb, Croatia. Isolates from January 1st 2003 to
July 1st 2006 were included in the study. From each patient 4 gastric
biopsies were taken for histology and 2 were sent to the Department
for Clinical and Molecular Microbiology CHC Zagreb for culture and
determination of antibiotic activity against H. pylori by means of agar
dilution. Susceptibility to clarithromycin, azithromycin, metronidazole,
tetracycline and amoxicillin was determined. Primary resistance was
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assessed in H. pylori strains isolated before the ﬁrst eradication therapy.
Secondary resistance was assessed in H. pylori strains repeatedly isolated
after treatment failure.
Results: Resistance of H. pylori to amoxicillin and tetracycline was
not detected. Clarithromycin and azithromycin showed a common
resistance pattern in all tested isolates. Among the 342 pre-therapy
isolates, 124 (36.25%) were susceptible to all antibiotics tested. Primary
resistance to macrolids was detected in 167 (48.83%) strains and
192 (56.14%) strains were resistant to metronidazole. The mean dual
resistance rate (resistance to both macrolids and metronidazole) was
37.72% (129/342). Among the 36 isolates cultured after unsuccessful
therapy, only 1 was susceptible to all antibiotics tested (2.78%),
2 (5.56%) were resistant only to macrolids and 5 (13.89%) were resistant
only to metronidazole. The dual resistance rate was 77.78% (28/36).
Among the macrolid resistant strains, therapy-induced resistance was
determined in 30.0% (9/30), while the rest (21/30) was attributed
to primary resistance. Therapy-induced resistance was determined in
21% (7/33) of the metronidazole resistant strains.
Conclusions: The resistance rates to metronidazole and macrolids and
dual resistance rates are high among H. pylori in northern Croatia. There
are increased rates of resistance to macrolids and metronidazole among
post-therapy isolates which can mainly be attributed to pre-existing
primary resistance and in part to therapy-induced resistance.
P930 Primary and secondary resistance to metronidazole and
clarithromycin in Spanish Helicobacter pylori clinical isolates
obtained from children
L. Cibrelus, T. Alarcon, P. Urruzuno, M. Martinez, A. Perez De Ayala,
J. Diaz-Regan˜on, M. Lopez-Brea (Madrid, ES)
Objective: To determine the primary and secondary resistance to
metronidazole and clarithromycin in Spanish Helicobacter pylori (HP)
clinical isolates obtained from paediatric patients from January 2002 to
June 2006.
Methods: Samples were collected from gastric biopsies of symptomatic
paediatric patients and H. pylori cultured as previously described.
Resistance was determined by E-test. Strains were considered resistant
if MIC 2mg/l for amoxicillin, 4mg/l for tetracyclin, 8mg/l for
metronidazole and 1mg/l for clarithromycin and intermediate if
MIC= 0.5mg/l for clarithromycin, Medical record were retrospectively
reviewed to get histories. Statistical analysis was based on chi2 tests
using Stata software. Signiﬁcance was construed for p< 0.05.
Results: 101 patients were included: 38 males and 63 females (gender
ratio M/F = 0.6). They were aged 10 years in average (standard
deviation 3.3, ranges 4−18 years). Thirty-ﬁve patients (34.7%) had
history of treatment failure, and were therefore considered as secondary
HP-infection, with no statistical difference in distribution of gender
(0.5 M/F ratio for patients with history of treatment failure versus 0.7
without, p = 0.61) or class breaks of age (45.7% (n = 16) over 12 among
patients with history of treatment failure versus 27.0% (n = 17) without,
p = 0.06).
All strains were susceptible to amoxicillin and tetracycline, 35.7%
(n = 35) were resistant to metronidazole, 54.6% (n = 54) to clarithromycin
and 2.0% (n = 2) were intermediate to clarithromycin. Double resistance
to metronidazole and clarithromycin rated to 17.2% (n = 17). Primary
and secondary resistance rates to metronidazole and clarithromycin
(including double resistance) are detailed in the table.
Antibiotic Primary
resistancea,
n (%)
Secondary
resistancea,
n (%)
RRb p
Metronidazole 21 (32.8%) 14 (41.2%) 1.3 0.41
Clarithromycin 32 (49.2%) 24 (70.6%) 1.4 0.04
Double resistance 10 (15.4%) 9 (26.5%) 1.7 0.18
aIntermediate strains to clarithromycin were considered as resistant.
bRR of resistance in case of treatment failure.
Conclusion: Resistance to clarithromycin (56.6%) was higher than to
metronidzole (35.7%) in the HP strains studied herein. Clarithromycin
resistance was very high even in strains from paediatric patients not
previously treated for HP infection (49.2%).
Acknowledgement: The study was supported by FIS PI 052452.
P931 Susceptibility of micro-organisms causing bacterial
gastroenteritis in a Spanish hospital
M. Quiles, S. Garcia-Bujalance, J. Mingorance, R. Go´mez, A. Gutierrez
(Madrid, ES)
Objective: To study the antimicrobial resistance of Salmonella sp.,
Shigella sp., Aeromonas sp., Yersinia sp., and Campylobacter sp.,
isolated from clinical samples.
Material and Methods: 5504 strains isolated from stool samples
between January 2000 to December 2005 were studied. The isolates
were cultured on the selective media routinely used for the study
of enteric pathogens. Identiﬁcation was made according to standard
microbiological procedures. Antimicrobial susceptibility was performed
by the broth microdilution method using an automated system (Wider®).
The antimicrobials studied were amoxicillin (Amx), amoxicillin-
clavulanate (A/C), cotrimoxazole (Cotr), ciproﬂoxacin (Cipr) and
clarithromycin (Clar) (for Campylobacter sp. only)
Results: The 5504 strains studied accounted for 15.86% of the total of
stool samples analyzed. The isolates were as follows: Campylobacter
sp (2415 strains), Salmonella sp. (2309 strains), Aeromonas sp.
(191 strains), Yersinia enterocolitica 0.3 (89 strains) and Shigella sp.
(50 strains). The Campylobacter sp. resistance rate were 86.6% to Cipr,
1.98% to Clar and 0.2% to Amx. The Salmonella enterica ssp. enterica
resistance rate were 44.16% to Amx, 9.12% to Cotr, 0.72% to A/C and
0.63% to Cipr. The Aeromonas sp. resistance rate were 86% to Amx,
14.6% to Cotr, 7.3% to A/C and 0% to Cipr. Aeromonas hydrophila
and Aeromonas veronii var. sobria were the most resistant species. The
Yerisinia entercolitica 0.3 resistance rate were 100% to Amx, 13.5% to
Cotr, 1.12% to A/C and 0% to Cipr. The Shigella sp. resistance rate were
74% to Cotr, 26% to Amx, 2% to A/C and 0% to Cipr.
Conclusion: Our results show that all the isolates of Aeromonas,
Yersinia and Shigella and most of Salmonella (except two strains)
were susceptible to ciproﬂoxacin conﬁrming that it is the empirical
ﬁrst-line treatment of bacterial gastroenteritis. Campylobacter sp. keeps
susceptibility to clarithromycin but there was a trend to increasing levels
of resistance to ciproﬂoxacin, reaching a 92.43% in 2005.
P932 Evolution of susceptibility of non-typhi Salmonella in
Spanish hospital: six years of surveillance
M.I. Quiles, S. Garcia-Bujalance, J. Mingorance, R. Gomez-Gil,
A. Gutierrez (Madrid, ES)
Objective: To study the evolution of the antimicrobial resistance of non-
typhi Salmonella in a Spanish Hospital during the last ﬁve years (2000–
2005).
Materials and Methods: We studied 2309 Salmonella enterica ssp.
enterica (designated ssp. I) isolated from clinical samples. All strains
were isolated in the culture media routinely used for the isolation
of enteric pathogens. Identiﬁcation was made according to standard
microbiological procedures and was conﬁrmed by serotyping with
commercial antisera (Difco Laboratories). Antimicrobial susceptibility
was performed by the broth microdilution method using an automated
system (Wider®). The antimicrobials studied were amoxicillin (Amx),
amoxicillin-clavulanate (A/C), cotrimoxazole (Cotr) and ciproﬂoxacin
(Cipr). The majority of the isolates (90%) belonged to serotypes 0:4 (B)
and 0:9 (D1), and therefore only these have been included in this study.
Results: See Tables 1 and 2.
Conclusions: 1) There is a strong relationship between serotype and
antimicrobial resistance, being serotype 0:4(B) more resistant than 0:9
(D1). 2) In spite of the low resistance rate of serotype 0:4(B) to A/C there
were high level (range 17−31%) of moderately resistant (intermediate)
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strains. 3) Resistance to Cotr was low in serotype 0:9(D1) and moderate
(range 13% to 23%) in serotype 0:4(B). 4) In 2004 and 2005 appeared
two strains of serotype 0:4(B) resistant to Cipr, probably in relation with
a high frequency of using these antibiotics as ﬁrst choice drugs in the
treatment of acute diarrhoea in adults.
Table 1. Evolution of number of isolates by serotype
2000 2001 2002 2003 2004 2005
0:4B 77 75 78 61 80 79
0:9D 236 311 323 274 295 151
Table 2. Evolution of resistance (%) to different antimicrobial agents by
serotype
2000 2001 2002 2003 2004 2005
AMX 0:4B 80.52 68 85.9 75.41 71.25 51.9
0:9D 17.37 8.7 14 17.15 8.13 4
A/C 0:4B 1.3 0 2.56 3.3 0 0
0:9D 0.85 0 0.31 0 0.33 0
COTR 0:4B 23.37 13.33 19.23 27.9 10 12.65
0:9D 0.42 0.64 0.31 0.36 0.7 1.32
CIPRO 0:4B 0 0 0 0 1.25 1.26
0:9D 0 0 0 0 0 0
P933 Emergence of resistance to new antimicrobials detected
among Shigella isolates in Finland
K. Haukka, A. Siitonen (Helsinki, FI)
Objectives: In Finland most cases of shigellosis are related to traveling
abroad. Shigella strains have rapidly evolved resistance to the commonly
used antimicrobials. We studied the geographical resistance patterns
and emerging new resistances to antimicrobials among Shigella strains
isolated from patients in Finland between 1990 and 2005.
Methods: Antimicrobial drug resistance of 1834 Shigella strains isolated
from Finnish patients during 1990–2005 was studied by diffusion
method using discs for 12 antimicrobial agents. Since 2000, E-test for
ciproﬂoxacin MIC determination has been done to the nalidixic acid
resistant isolates (n = 65).
Results: The proportion of strains resistant to the studied antimicrobials
increased during the study period. However, the frequencies of resistance
differed between S. sonnei and the other Shigella serogroups. The
proportion of multiresistant strains (resistant to at least 4 antimicrobials)
was highest among the strains imported from China and India. Resistance
to nalidixic acid has become common (87% in 2005) among the strains
from the Far-East. In general, only one strain resistant to nalidixic acid
per year has been obtained from the other geographical areas. In 2000–
2001, susceptibility to ciproﬂoxacin had decreased (MIC 0.125mg/L)
in 44% and in 2004–2005 even in 83% of the nalidixic acid resistant
strains. First three isolates, fully resistant to ciproﬂoxasin by the disc
diffusion method were obtained during 2004–2005. By mid-November
2006, three more ciproﬂoxasin resistant isolates have been detected.
All these six isolates belonged to the S. ﬂexneri 2a serotype (MICs
3 – 32 mg/L), and most of them originated from India. Also six
gentamicin, two cefotaxime and several mecillinam resistant strains have
been encountered during the recent years.
Conclusion: The proportion of multiresistant Shigella strains is growing
and, moreover, resistance to several new antimicrobials is emerging.
The antimicrobial resistance patterns detected among the isolates
from Finnish travelers reﬂect the resistance situation and usage of
antimicrobials in the countries the infections were obtained from.
Fluorokinolones, especially ciproﬂoxasin, are the drug of choice when
treatment is needed. Unfortunately, Shigella strains seem to be rapidly
evolving resistance to this group of antimicrobials as well. South and
East Asia seem to be the areas where the new resistances emerge.
P934 Characterisation of multi-resistant Helicobacter pylori
emerging in the UK
S.A. Chisholm, R.J. Owen (London, UK)
Objectives: To identify and characterise multi drug resistant (MDR)
Helicobacter pylori in the UK. Only four antibiotics, metronidazole
(MTZ), clarithromycin (CLA), tetracycline (TET) and amoxicillin
(AMX) are recommended for H. pylori eradication. MTZ and CLA
resistance rates account for 33% and 11% of H. pylori recovered pre-
treatment in the UK, with signiﬁcantly higher rates observed post-
treatment. Resistance to these agents substantially reduces eradication
efﬁcacy. In contrast TET and AMX resistance is rarely observed and
MDR (resistant to three or more drugs) H. pylori have not been reported
in the UK.
Methods: Antibiotic susceptibility data for all isolates referred to our
reference unit from 2000 to date were examined for multi-resistance. As
ﬂuoroquinolones and rifamycins are used to treat refractive infection,
additional susceptibilities to ciproﬂoxacin (CIP) and rifampicin (RIF)
were tested. Antibiotic susceptibilities were re-tested for eight single
colony picks (scps) for each MDR isolate. All scps were screened for
mutations associated with CLA, TET and CIP resistance by real-time
PCR or sequencing.
Results: Since 2004, eight isolates of H. pylori with atypical MDR pro-
ﬁles were identiﬁed. All had originated from patients in Southeast Eng-
land, of whom seven had failed prior eradication therapy. The incidence
of MDR strains increased annually, with four examples observed in 2006.
Seven resistance proﬁles were identiﬁed: MTZ/CLA/TET/AMX (n = 2),
MTZ/CLA/AMX (n = 1), MTZ/CLA/TET (n = 1), CLA/TET/AMX/CIP
(n = 1), MTZ/CLA/TET/CIP (n = 1), MTZ/CLA/AMX/CIP (n = 1),
MTZ/CLA/TET/AMX/CIP (n = 1). Re-testing scps for each isolate
conﬁrmed the MDR proﬁles in ﬁve cases. Repeat testing failed to
conﬁrm CIP resistance in two cases and AMX resistance (known to be
unstable) in one case. All CLA, TET and CIP resistant isolates contained
mutations in the 23S rRNA, 16S rRNA and gyrA genes, respectively.
Conclusions: Multi-resistance in H. pylori is extremely rare in Europe
and has not been documented previously in the UK. We suggest that
this may be an emerging problem. Further characterisation of scps
conﬁrmed that most were genuine MDR strains and not examples of
mixed infections. While the clinical impact of these rare MDR strains is
unknown, this study highlights the importance of continued surveillance
of antibiotic resistance in H. pylori.
Bloodstream infections
P935 Time-to-positivity of aerobic blood cultures by using BacTec
9120 blood culture system
St. Fokas, Sp. Fokas, G. Altouvas, M. Tsironi, S. Kaptanis, M. Kalkani,
M. Dionysopoulou (Eghio, Sparta, GR)
Objectives: The aim of this study was to determine the time to detection
of positive aerobic blood cultures with the BACTEC 9120 system.
Methods: We retrospectively analyzed the data of 3250 aerobic blood
cultures incubated for a period of 7 days in the BACTEC 9120 system
from June 2004 to June 2006. Blood samples were drawn from peripheral
veins and were inoculated into two aerobic/F bottles for each blood
culture. Whenever there was a sign of positive culture the detection
time, measured in hours, was documented for each bottle. Negative
blood cultures from patients with clinical evidence of brucellosis were
subcultured blindly.
Results: A total of 247 (7.6%) positive cultures were detected and
62 (1.9%) of them were clinically insigniﬁcant. Gram-negative organisms
were recovered more frequently than Gram-positives in true bacteraemias
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(78%, 144/185 strains versus 22%, 41/185 strains) while CoNS were the
most common contaminants. The mean detection time for all microbes
(435 isolates) was 24.13 h (range 2.88 h to 122 h) and 72% (313/435)
of them were detected within the ﬁrst 24 h of incubation. The mean
detection times for the Gram-negative and Gram-positive bacteria were
31.08 h and 21.9 h respectively (E. coli 9.3 h, Proteus spp. 9.2 h,
Klebsiella spp. 9.2 h, P. aeruginosa 14.2 h, Brucella melitensis 65.39 h,
S. aureus 15.5 h, CoNS 23.6 h, S. pneumoniae 10 h, Enterococcus spp.
19.8 h, Streptococcus spp. 36.6 h, Candida spp. 15.6 h).
Conclusions: The recovery time of Enterobacteriaceae (9.2 h) was
signiﬁcantly shorter of Gram-positive bacteria and 85% of Enterobac-
teriaceae were isolated within the ﬁrst 24 h. All pathogenic microbes,
including Brucella spp. were recovered within 5 days of incubation and
the detection times of clinically signiﬁcant isolates were shorter than
contaminants. A protocol of 5-days incubation period is possible to apply
with the BACTEC 9120.
P936 Is there any relation between time to positivity in blood
cultures and source of infection in patients with Enterococcus
spp. bacteraemia?
J. Alava, C. Ezpeleta, G. Ezpeleta, V. Cabezas, I. Atutxa, C. Busto,
E. Gomez, J. Unzaga, R. Cisterna (Bilbao, ES)
Objective: The aim of this study is to know if, like in other
bacteraemias, the time between blood culture incubation and growth
detection measured by the time to positivity in a continuously monitored
system correlates with the source of infection and the outcome of the
patient who suffers and enterococcal bacteraemia.
Methods: We performed a retrospective, observational study involving
adult inpatients that had Enterococcus spp. bacteraemia between 1
October 2003 and 30 September 2006 at a University hospital.
Measurements included time to positivity in initial blood culture series,
duration of bacteraemia episode, gender, age, rate of metastatic infection,
and outcome.
Results: A total of 38 Enterococcus spp. bacteraemias (>1 positive
blood culture result) were reported for patients with ages between
1 day–94 years (median age, 69 years); 5 (13.15%) bacteraemias were
associated with endocarditis. The microbiological documentation of the
source of infection was achieved only in half of the cases. The mortality
rate was 21.8%.
The duration of bacteraemia was 1–47 days (median duration, 8 days;
average duration 11.65 days). The time to positivity ranged from
40 minutes to 1 day (median time to positivity, 8.45 h). There was
signiﬁcantly shorter for patients with an endocarditis or catheter related
infection, compared with the other sources of bacteraemia (p = 0.05) but
no statistical difference was observed when both endovascular sources of
infections were compared. Analysis using logistic regression found that a
short time to positivity was an independent predictor of an endovascular
source of infection but not the outcome of the patient. In fact, all the
deaths recorded in this study were non-infection related.
Conclusions: Time to positivity in Enterococcus spp. bacteraemia may
provide useful diagnostic information of the source of infection but not
prognostic information. Meanwhile due to the reduced number of cases
further studies are needed.
P937 Time to positivity in blood cultures of patients with
Staphylococcus aureus bacteraemia: possible correlation with
the source of infection
C. Ezpeleta, J.A. Alava, G. Ezpeleta, V. Cabezas, I. Atutxa, C. Busto,
E. Gomez, J. Unzaga, R. Cisterna (Bilbao, ES)
Objective: The aim of this study is to asses if the time between
blood culture incubation and growth detection in Staphylococcus aureus
bacteraemia measured by the time to positivity in a continuously
monitored system correlates with the source of infection and the outcome
of the patient.
Methods: We performed a retrospective, observational study involving
adult inpatients who had S. aureus bacteraemia between 1 October 2002
and 30 September 2006 at a University hospital. Measurements included
time to positivity in initial blood culture series, duration of bacteraemia
episode, gender, age, rate of metastatic infection, and outcome.
Results: A total of 211 S. aureus bacteraemias (>1 positive blood
culture result) were reported for patients with ages between 7–94 years
(median age, 69 years); 21 (9.95%) bacteraemias were associated
with endocarditis. The microbiological documentation of the source of
bacteraemia was achieved only in half of the cases. The mortality rate
was 21.8%.
The duration of bacteraemia was 1–60 days (median duration, 8 days;
average duration 9.8 days). The time to positivity ranged from 40 minutes
to 3 days (median time to positivity, 11.19 h) and was signiﬁcantly
shorter for patients with an endovascular source of infection (endocarditis
or catheter related infection), compared with the other sources of
bacteraemia (p = 0.001). Analysis of the data using logistic regression
revealed that a time to positivity shorter than 10 hours, was an
independent predictor of an endovascular source of infection and
outcome of the patient.
Conclusions: Time to positivity in S. aureus bacteraemia may provide
useful diagnostic and prognostic information. Growth of S. aureus within
10 h after the initiation of incubation may identify patients with a high
risk of fatal infection. Meanwhile due to the reduced number of cases
further studies are needed.
P938 Time-to-report blood culture Gram stain and tentative
susceptibility result
G. Just-Nu¨bling, S. Franck, M. Hahn, V. Rickerts, P.M. Shah (Frankfurt
am Main, DE)
Objective: Rapid detection of pathogens in blood culture bottles shortens
hospitalisation (Beekmann et al.) and appropriate empirical antimicrobial
treatment improves outcome. (Behrendt et al. Hautala et al.) How long
does it take to report Gram stain result, tentative categorisation (TC)
“susceptible, intermediate or resistant” from directly inoculated agar
plates and how often were very major (VME), major (ME) or minor
errors (mE) when TC results were compared to the ﬁnal susceptibility
results?
Method: Bactec bottles (Plus aerobic/anaerobic) were inoculated on the
wards as recommended by the manufacturer. All bottles were incubated
in the BACTEC 9120/9140. When growth was reported to the laboratory
personnel a Gram stain was performed and an aliquot was streaked on
blood and chocolate agar plates. Depending on the Gram stain result
appropriate antibiotic disks were placed on additional Mu¨ller-Hinton or
Columbia blood agar plates and TC was judged by using agar diffusion
method.. The Gram stain result was reported to the clinician. Tentative
susceptibility was interpreted after6−8 hours of incubation and TC was
compared with the ﬁnal categorisation obtained from MIC determined
using the E-Test method.
Results: 141 blood culture bottles were prospectively studied. Gram
stain results were available in 0.6 (standard deviation [SD] 0.6, range
3.6–0.1) hours and it took 0.9 (SD 0.7, range 3.3–0.1) hours to report
the result to the attending physician. 2,538 antibiotic interpretations (TC)
were available within 22.5 (SD 16.4, range 97.8–5.1) hours. VME were
seen in 9 (0.35%), ME in 4 (0.16%) and mE in 27 (1.06%).
Conclusions: Gram stain result and direct susceptibility result are
available within 23.1 hours and can be safely used to modify empirical
treatment, as very major or major errors were recorded in less than 1%.
Reference(s)
Beekmann, S.E., et al. Effects of rapid detection of bloodstream
infections on length of hospitalisation and hospital charges. J Clin
Microbiol 41 (2003): 3119−25.
Behrendt, G., et al. Inﬂuence of antimicrobial treatment on mortality in
septicaemia. J Chemother 11 (1999): 179−86.
Hautala, T., et al. Blood culture Gram stain and clinical categorization
based empirical antimicrobial therapy of bloodstream infection.
Int J Antimicrob Agents 25(4) (2005): 329−33.
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P939 Effectiveness of the lysis centrifugation method isolator 10
system compared to BacT/Alert 3D in detecting bacteraemia
K. Kharazmi, C. Kratzer, G. Tucek, M. Klimpﬁnger, A. Georgopoulos
(Vienna, AT)
Objectives: Aim of this study was to compare the effectiveness of
the lysis centrifugation method Isolator 10 system to the conventional
BacT/Alert 3D system in diagnosis of bacteraemia.
Methods: 300 hospitalised patients with fever of unknown origin were
included in the present study. At three different times, especially when
patients’ blood temperature was rising, one blood sample was taken
and divided among the aerobic, the anaerobic BacT/Alert bottle and the
Isolator 10 tube.
Results: 129 bacterial and 4 fungal isolates were recovered by using
both methods. Isolator 10 System showed a higher detection rate of
31.7% compared to 14% of the BacT/Alert 3D (c2 test p< 0.001).
The Isolator 10 system recovered signiﬁcantly more coagulase-negative
staphylococci, viridans streptococci, pneumococci, non-fermenters and
fungi, but no obligate anaerobic bacteria were identiﬁed. A strong
positive correlation (Spearman = 0.76, T-test p< 0.001) between the
microbial counts detected by Isolator 10 system and a positive
BacT/Alert blood culture was found. All Isolator cultures with a
microbial count >12 cfu/mL were also positive using BacT/Alert,
whereas microbial counts <5 cfu/mL were not detectable by the
conventional blood culture system. Isolator 10 system required 8 to
22 hours to detect staphylococci, Enterobacteriaceae and non-fermenters
compared to 21 to 24 hours with BacT Alert. A time range till 48 hours
was needed to detect streptococci by using both blood culture systems.
Conclusion: Isolator 10 system showed high effectiveness in detecting
pathogens with low microbial counts. Due to high potentiality of
contamination and poor recovery of anaerobic bacteria by Isolator 10
system, the combination of both blood culture methods could optimise
the diagnosis of bacteraemia.
P940 First notiﬁcation of positive blood cultures: can we rely on
the Gram stain?
M. Søgaard, M. Nørgaard, H. Schønheyder (Aalborg, DK)
Objectives: When blood cultures (BCs) turn positive the attending
physicians are usually notiﬁed immediately about Gram stain ﬁndings.
Despite the implications for antibiotic treatment and other therapeutic
interventions, information on the accuracy of Gram staining is very
limited. In this study we examined the accuracy of the preliminary BC
reports based on wet-mount microscopy and Gram stain.
Methods: Observational study in North Jutland County, Denmark
including the years 1996, 2000, 2001, and 2003. We retrieved data
from the County Bacteraemia Registry, the departmental information
system, and technicians’ laboratory notes. The study was restricted
to BCs with one morphological type; for patients with bacteraemia
only the ﬁrst positive BC was included. We deﬁned 6 morphological
groups: Gram-positive cocci in clusters, Gram-positive cocci in chains
or diplococci, Gram-positive rods, Gram-negative cocci, Gram-negative
rods, and yeasts. The sensitivity, speciﬁcity, positive (PPV) and negative
(NPV) predictive values were estimated for each group using the species
diagnosis as reference. We also evaluated Gram stain and wet-mount
ﬁndings for the most frequent bacterial species/groups.
Results: A total of 5833 positive BCs were obtained during the
four study years. The Table shows the distribution, sensitivity,
speciﬁcity, PPV and NPV for the deﬁned morphological groups. The
sensitivity for the most frequent pathogens was in the range 88.2–
100% with non-haemolytic streptococci being one notable exception
(sensitivity 88.2%; 95%CI 82.6−92.4%). Wet-mount reports were more
inaccurate (sensitivity 30−70% for species with peritrichous motility).
Enterobacteriaceae (Salmonella spp. being most prominent) accounted
for 25% of the bacteria with a report of polar motility.
Cocci Rods Yeasts
Gram(+) Gram(−) Gram(+) Gram(−)
clusters chains/
diplococci
Number (%) 2088 (36%) 826 (14%) 35 (0.6%) 612 (10%) 2180 (37%) 92 (1.6%)
Correct evaluation 2082/2088 794/826 33/35 566/612 2151/2180 90/92
Sensitivitya 99.7
(99.4−99.9)
96.1
(94.6−97.3)
94.3
(80.1−99.3)
92.5
(90.1−94.4)
98.7
(98.1−99.1)
97.8
(92.4−99.7)
Speciﬁcitya 99.1
(98.7−99.4)
99.8
(99.6−99.9)
100
(99.9–100)
99.7
(99.5−99.8)
99.1
(98.7−99.4)
100
(99.9–100)
PPVa 98.4
(97.8−98.9)
98.6
(97.6−99.3)
94.3
(80.1−99.3)
97.1
(95.4−98.3)
98.4
(97.8−98.9)
100
(96.0–100)
NPVa 99.8
(99.7−99.9)
99.4
(99.1−99.6)
100
(99.9–100)
99.1
(98.8−99.4)
99.2
(98.9−99.5)
100
(99.9–100)
a95%CI in parentheses.
Conclusion: We demonstrated a high accuracy of Gram stain reports.
Non-haemolytic streptococci formed an exception, which probably
reﬂected this group’s taxonomic heterogeneity. Wet-mount microscopy
was generally less accurate.
P941 An evaluation of the rapid transport of BacT/ALERT blood
culture bottles via a vacuum sample transport system at a
UK regional hospital
L. Joslin (Exeter, UK)
Objectives: Blood cultures should be transported to the laboratory as
quickly as possible, preferably within two hours [1]. The location of the
laboratory, in relation to hospital wards at the Royal Devon and Exeter
Hospital, meant that the deliveries of blood cultures were sometimes
delayed by up to 15 hours. The objective of the study was to evaluate
the possibility of rapidly transporting BacT/ALERT polycarbonate blood
culture bottles to the laboratory via a vacuum sample transport system.
Methods: A two phase evaluation proticol was followed. We investigated
the robustness of the polycarbonate bottles both experimentally and in
routine use.
Experimental evaluation: Fifty uninoculated BacT/ALERT PF bottles
and BacT/ALERT SA and SN bottle pairs were transported from hospital
wards to the microbiology laboratory. To apply stress greater than that
expected in routine use each culture bottle travelled eight stop/start
journeys over a total distance of four miles. Bottles were placed in
sample collection bags only, supplemental bottle transport devices or
padding were not included. Bottles were visually inspected for leaks and
cracks at the end of each run.
Routine use evaluation: The transport of approximately 28,000 blood
culture sets via a vacuum transport system was monitored over a two-year
period. The incidence of cracks or leaks were monitored and recorded.
Results: Experimental evaluation: On inspection, cracks or leaks were
not detected in 49 BacT/ALERT PF bottles and 50 BacT/ALERT SA and
SN paired bottles. One PF bottle was ‘lost’ within the vacuum transport
system and was not returned to the laboratory for investigation.
Routine use evaluation: Over a two-year period approximately
28,000 blood culture sets have been received by the laboratory the
majority if which arrived via vacuum tube. No incidences of cracks
or leaks in the polycarbonate blood culture bottles have been reported.
Conclusion: The routine transport of polycarbonate BacT/ALERT blood
cultures via rapid vacuum transport systems was demonstrated to be a
viable option. Blood cultures can be received to the laboratory within
minutes rather than hours potentially decreasing the time to report both
positive and negative culture results.
Reference(s)
[1] Baron E.J., Weinstein M.P., Dunne W.M., Yagupsky P., Welch D.F.,
Wilson D.M. Cumitech Blood Cultures IV. ASM Press 2005.
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P942 Time to positivity of blood cultures in patients Escherichia
coli bacteraemia
G. Peralta, B. Ceballos, L. Garcı´a-Maurin˜o, M.P. Roiz, J.C. Garrido,
I. De Benito, L. Ansorena, M.B. Sanchez (Torrelavega, ES)
Objectives: Bacterial blood concentration is associated with prognosis
of patients with bacteraemia caused by some microorganisms. However
quantitative blood cultures are not performed in clinical practice. Time
from the starting of incubation to a positive reading of blood cultures
has been considered a surrogate marker of bacterial blood concentration
and can be associated with prognosis. We analyze time to positivity
(ttp) relationships with clinical parameters in patients with E. coli
bacteraemia.
Methods: charts of all patients with monomicrobial E. coli bacteraemia
attended at our hospital between January 1997 and December 2004 were
identiﬁed by using the Microbiology laboratory database and reviewed.
BacT/ALERT (bioMe´rieux) microbial detection system, was used for
blood cultures and TTP detection. When multiple cultures were positive
only the shortest TTP was selected for the analysis. Mann-Whiney U
test was used for the comparison of median values, chi square test and
Fisher‘s exact test for the comparison of categorical data.
Results: during the study period we identiﬁed 567 cases of E. coli
monomicrobial bacteraemia, with a mortality of 4.9%. Median (in-
terquartile range) TTP was: 11.3 h (10.2 h–11.8 h). Signiﬁcant correlation
among TTP and the number of positive blood cultures was found
(Spearman‘s coefﬁcient = −0.5, p< 0.0001). No differences in TTP were
detected depending on the comorbidities, or nosocomial or postsurgical
acquisition. However TTP was longer in patients treated with antibiotics
when blood cultures were performed (21.2 h±27.4 h vs 14.01 h±12.06 h,
p = 0.01), and shorter in patients with a non urinary origin of the
bacteraemia (12.5±10.1 h vs 16±16.8 h, p< 0.0001), severe sepsis or
shock (9.7±3.3 h vs 15.2±1.3 h, p< 0.0001), or patients who died
(10.7±5.4 h vs 14.9±15 h, p = 0.006). ROC analysis revealed that a
time to positivity of 10.4 h was associated with the best sensitivity and
speciﬁcity for predicting dead (70% and 59%, respectively).
Conclusions: in patients with E. coli bacteraemia TTP is inﬂuenced by
antibiotic treatment and has relationship with relevant clinical parameters
as the origin of the bacteraemia, the presence of severe sepsis or shock
and with the outcome. Its usefulness as a prognostic marker should be
explored.
P943 Time to positivity of BACTEC blood culture bottles
S. Baka, I. Logginidis, V. Efstratiou, E. Panagiotopoulou, G. Kaparos,
K. Gerolymatos, E. Kouskouni (Athens, GR)
Objective: The aim of this study was to detect how long it takes for blood
cultures to become positive when using the BACTEC system bottles.
Methods: Using a continuously monitoring blood culture system
(BACTEC 9050, Becton Dickinson, USA) we determined the time to
positivity of blood cultures obtained from the patients of our hospital.
We processed a total of 2125 blood culture sets and detected 420 (19.7%)
positive blood cultures.
Results: Out of the 420 positive blood cultures we recovered 1
pathogen from 392 (93.3%) and 2 pathogens from 28 (6.7%) of
them. Four hundred and forty-eight clinically signiﬁcant pathogens
were identiﬁed in the following order: 185 (41.3%) Gram-negative
rods, 153 (34.1%) staphylococci [131 (29.2%) coagulase-negative
staphylococci and 22 (4.9%) Staphylococcus aureus], 51 (11.4%)
streptococci, 49 (10.9%) yeasts, 8 (1.8%) anaerobes and 2 (0.5%) Gram-
positive rods. Two hundred and twenty-eight (54.3%) blood cultures were
obtained from ICU patients, 183 (43.6%) from surgical patients, 7 (1.7%)
from OB-GYN patients and only 2 (0.4%) from neonates. In respect to
the time to detection or to positivity 274 (65.2%) blood cultures turned
positive during the ﬁrst 24 h of incubation, 119 (28.3%) up to 48 h,
21 (5.0%) in 72 h, while 4 (1.0%) and 2 (0.5%) were positive after 4
and 5 days of incubation, respectively.
Conclusions: The time to positivity for 65.2% of our positive blood
cultures was up to 24 h, while in the ﬁrst 2 days of incubation a total
of 93.5% of the positive cultures were detected. Although we maintain
the recommended period (7 days for aerobic and anaerobic bottles and
14 days for mycosis bottles), we could consider reducing the incubation
time to 5 days (at least for the aerobic and anaerobic bottles) since all
our blood cultures turned positive during the ﬁrst 5 days.
P944 Bacteraemia caused by high-level gentamicin-resistant
Enterococcus: risk factors, clinical features and outcomes
H.C. Jang, W. Park, C-I. Kang, S. Kim, C. Lee, S-W. Park, E. Kim,
H-B. Kim, N-J. Kim, E-C. Kim, M-D. Oh, K-W. Choe (Seoul, Jeonju,
Cheonan, Kyongju, KR)
Objectives: High-level gentamicin resistance (HLGR) was increased in
enterococci since 1980, but there were few studies about the impact of
HLGR on clinical features and outcomes. So, we performed this study to
determine the risk factors, clinical features and outcomes of bacteraemia
due to enterococcus with HLGR.
Methods: All patients with blood cultures positive for E. faecalis and
E. faecium during the period of January 1999 – August 2003 (inclusive)
were identiﬁed from a retrospective review of the Clinical Laboratory
Records at Seoul National University Hospital in Korea. HLGR was
determined by using disk diffusion method with 120 ug gentamicin disc
(Oxoid), following the recommendation of the NCCLS.
Patients who had bacteraemia due to enterococcus without HLGR
(Group 1) were compared with patients who had bacteraemia due to
enterococcus with HLGR (Group 2). Statistical analysis of the data
was performed using SPSS for Windows, version 11.0 (SPSS). Logistic
regression analysis was done for multivariate analysis.
Clinical features of 215 patients with enterococcal bacteraemia
HLGR+
(N= 79)
HLGR−
(N= 136)
n % n % P value
Demographic data
Male gender 52 66 92 68 NS
Age 58.1(±14.2) 56.2(±16.8) NS
Underlying disease
Haematologic disease 4 5 27 20 0.002
Neutropenia 4 5 39 29 <0.001
Cancer 42 53 70 51 NS
Kidney disease 2 3 8 6 NS
Urologic disease 5 6 7 5 NS
Biliary disease 9 11 9 7 NS
GI disease 5 6 6 4 N
Infection site
Vascular catheter 2 3 12 9 NS
Infective endocarditis 6 8 3 2 NS
Urinary tract 12 15 20 15 NS
GI (except biliary tract) 13 16 35 26 NS
Biliary tract 35 44 33 24 0.004
Other status
B. faecium infection 45 57 105 77 0.003
Nosocomial infection 51 65 115 85 0.001
Polymicrobial infection 30 38 22 16 <0.001
ICU stay at culture 7 9 36 26 0.002
Appropriate treatment 42 53 54 40 NS
APACHE II scores 14.4(±7.3) 20.7(±8.3) <0.001
Outcome
14-day mortality 12 15 50 37 0.001
30-day mortality 17 22 66 49 0.002
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Results: 215 cases of clinically signiﬁcant E. faecalis and E. faecium
bacteraemia were identiﬁed. 136 (63.3%) were caused by enterococci
with HLGR. Hospital acquired infection, monomicrobial bacteraemia,
E. faecium bacteraemia, underlying haematologic malignancy and
neutropenia were more common in Group 2 than in Group 1 (p< 0.05).
Biliary tract infection was less common in Group 2 than in Group 1
(p< 0.05). Independent factors for occurrence of HLGR enterococcal
bacteraemia were ICU stay at culture, 3rd generation cephalosporin use
and monomicrobial infection (p< 0.05). 14-day and 30-day mortality
in Group 2 were higher than in Group 1 in univariate analysis
(p< 0.05). But HLGR was not an independent risk factor for mortality
in multivariate analysis.
Conclusion: Independent factors for occurrence of HLGR enterococcal
bacteraemia were ICU stay at culture, 3rd generation cephalosporin use
and monomicrobial infection. HLGR was not an independent risk factor
for mortality.
P945 Occurrence of virulence determinants, antibiotic resistance
in Swedish Enterococcus faecium blood-culture isolates
during a six-year period
H. Billstro¨m, A˚. Sullivan, B. Lund (Stockholm, SE)
Background: Recently the isolation ratio between E. faecalis and
E. faecium causing infections has shifted from 10:1 to 3:1. Suggested
explanation for this has been the increasing antibiotic resistance
in E. faecium. However, changes in virulence cannot be excluded.
Evidences are now emerging indicating a nosocomial origin of these
infections.
Objectives: To detect the presence of virulence determinants in
E. faecium infectious isolates and determine changes in frequencies
over time. Furthermore, to investigate the levels of antibiotic resistance
towards clinically relevant antibiotics and possible genetic relationships
between isolates with suspected clonality.
Methods: A total of 278 strains E. faecium isolated from bacteraemia
patients during year 2000 to 2006 at the Karolinska University Hospital,
Huddinge were used. All isolates were screened for the seven virulence
genes, aggregation substance (asa1), cytolysin (cylA), collagen binding
protein (ace), E. faecalis endocarditis antigen (efafm), enterococcal
surface protein (espfm), gelatinase (gelE), and hyaluronidase (hylfm),
using PCR. Minimal inhibitory concentrations were determined towards
ampicillin, ciproﬂoxacin, daptomycin, gentamicin, linezolid and van-
comycin using agar dilution. PFGE was used to detection possible
identical clones.
Results: A total of 54.3% of the isolates was esp-positive. In 14 of
the isolates, hyl was found. 2% of the isolates harboured one or more
of ace, asa1, efaAfm and gelE. None of the isolates were cytolysin
positive. Ampicillin, ciproﬂoxacin and imipenem resistance were high,
76%, 90% and 80% respectively, while low frequencies were found for
vancomycin (4.7%) and gentamicin (1.8%). Resistance towards linezolid
and daptomycin was not found.
Discussion: During the course of this 6-year study, the levels of antibiotic
resistance seem to be stable. The occurrence of espfm and hylfm also
appear to be constant. The more rare virulence determinants, exclusively
found during the last two study years, might indicate that an increase
is occurring. The high frequency of espfm and antibiotic resistance
suggests that these factors are of importance for infection development.
However, if this is the case further unknown traits probably exist since
a signiﬁcant part of the isolates lacks all the investigated determinants.
P946 Recurrent cases of Escherichia coli bacteraemia in the
county of Funen, Denmark in 1996–2001
B. Olesen, E.M. Nielsen, P. Søgaard, F. Scheutz, H.J. Kolmos,
B.G. Bruun (Hillerød, Copenhagen, Odense, DK)
Objectives: To characterise a cohort of recurrent E. coli bacteraemia
bacteriologically and epidemiologically with emphasis on differences
between cases of relapse and re-infection.
Methods: The following deﬁnitions were used:
– An episode of bacteraemia was deﬁned as the presence of E. coli in
a blood culture set.
– Recurrence occurred when an isolate was obtained from an episode
taking place more than 4 weeks after the ﬁrst episode.
– Polymicrobial bacteraemia occurred when more than one clinically
relevant species or two different strains of E. coli were present in the
same blood culture.
– A recurrent infection with the same strain was deﬁned as a relapse
and was assumed when the PFGE proﬁles were indistinguishable or
had <4-fragment difference.
– All other cases were considered to be re-infections.
All isolates were serotyped and typed by Pulsed-Field Gel Electrophore-
sis (PFGE) with XbaI.
Results: Out of a total of 1,648 patients with E. coli bacteraemia,
106 patients (6.4%) suffered (a) recurrence(s) during the 6-year study
period: 191 isolates from 89 patients were available for examination.
79 of these patients had 2 episodes of bacteraemia, 8 patients had 3,
1 patient had 4 and 1 patient had 5 episodes. Three patients were found
in both the relapse and re-infection group.
“The relapse group”: 48 patients had 102 recurrent episodes with 48 sets
of identical strains:
• The isolates comprised 18 different O groups.
• Thirteen strains (27%) possessed capsular antigen K1 and 12 (25%)
capsular antigen K5.
• The median time between episodes was 95 days (range 28–1278).]
• Four episodes (4%) were polymicrobial.
“The re-infection group”: 44 patients had 89 recurrent episodes with 89
different isolates:
– The isolates comprised 30 different O groups.
– Five strains (6%) possessed capsular antigen K5 and two strains (2%)
capsular antigen K1.
– The median time between episodes was 222 days (range 40–2011).
– Fourteen episodes (16%) were polymicrobial.
Conclusions: 6.4% of 1,648 patients with E. coli bacteraemia suffered
(a) recurrence(s) during the 6-year study period. 54% of 89 patients had
a relapse with the same strain. O6:K5:[H1] was the single most common
serotype in both groups. Characteristics of cases of relapse compared to
re-infections were: signiﬁcantly higher frequency of possession of K1
or K5 capsular antigen, shorter median time between recurrences, and
lower frequency of polymicrobial bacteraemia.
P947 Bacteraemia due to extended-spectrum b-lactamase
producing Enterobacteriaceae in a tertiary care hospital in
Salford, UK: one-year retrospective study
S. Ambalkar, K. Ryan, P.R. Chadwick, C.P.K. Subudhi (Salford, UK)
Objectives: Extended-spectrum b-lactamase (ESBL) producing strains
of Enterobacteriaceae have caused major therapeutic problems world-
wide since the majority of these are resistant to multiple antibiotics.
This retrospective observational study was conducted to determine the
prevalence, antibiotic susceptibility pattern and outcome of treatment of
ESBL-producing Enterobacteriaceae isolated from blood culture over a
one year period.
Methods: The laboratory database was used to identify patients who had
positive blood cultures for Enterobacteriaceae during the period October
2004 to September 2005. Case notes and electronic patient records
were reviewed to determine the outcome of episodes of bacteraemia
in patients due to ESBL producers. Antibiotic susceptibility pattern of
ESBL positive isolates were analysed to determine the prevalence of
co-resistance to ciproﬂoxacin, gentamicin and piperacillin-tazobactam.
Results: There were 220 patients who had positive blood cultures for
Enterobacteriaceae during this period. Approximately 10% (23/220)
of these patients had ESBL-producing isolates. Bacteraemia due to
ESBL-producing organisms in this study was healthcare-associated in
all 23 patients (100%). 70% of these patients were aged more than
65 years. E. coli was the most common (70%) isolate amongst the ESBL-
producing organisms. All the ESBL-producing isolates were susceptible
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to carbapenems. Resistance to ciproﬂoxacin, gentamicin and piperacillin-
tazobactam was present in 80% (19/23), 55% (12/23) and 24% (5/23) of
these isolates respectively. Majority (72%) of patients had inappropriate
empirical antibiotic therapy with ceftriaxone. There was 48% (11/23)
30 day associated mortality amongst patients with bacteraemia due to
ESBL-producing organisms.
Conclusions: ESBL-producing strains of Enterobacteriaceae are a
signiﬁcant cause of healthcare-associated blood stream infections. They
carry a high risk of mortality. Empirical treatment of sepsis caused by
Enterobacteriaceae needs to be reconsidered in areas where there is high
prevalence of ESBL producers as there are therapeutic implications due
to co-resistance to multiple antibiotics.
P948 Risk factors and outcome of bloodstream infections caused
by enterobacteria producing extended-spectrum b-lactamases
A. Endimiani, F. Luzzaro, A. Toniolo (Varese, IT)
Objectives: Enterobacteria-induced bloodstream infections (BSI) rep-
resent a common clinical entity. This study was initiated to evaluate
risk factors and outcome of BSI episodes caused by members of the
Enterobacteriaceae family producing extended-spectrum b-lactamases
(ESBLs).
Methods: Two-hundred-eighteen BSI episodes caused by enterobacteria
occurring at the Ospedale di Circolo (Varese, Italy) from 1997 to 2005
have been analyzed. ESBL production was assessed by phenotypic and
molecular methods. Clinical records of BSI-patients were examined
retrospectively: demographic data, underlying diseases (McCabe and
Jackson classiﬁcation scheme and Charlson weighted index), risk factors,
antimicrobial therapy, treatment outcome and clinical outcome were
investigated. Cases due to ESBL-positive strains were compared to
those due to ESBL-negative strains. Student’s unpaired t-test and Mann-
Whitney U-test were used to compare continuous and not normally
distributed continuous variables. The Chi-square test was used to
compare the treatment and clinical outcome.
Results: Ninety-eight isolates were shown to produce ESBLs (mainly
TEM-52/92, CTX-M-1 and SHV-12). Compared with the ESBL-negative
group, ICU stay, use of bladder and intravascular catheters, previous
surgery, previous use of antibiotics, and intubation were signiﬁcant risk
factors for BSI due to ESBL-positive isolates (all P< 0.01). BSI cases
due to ESBL-positive enterobacteria were more frequently associated to
lower respiratory tract infections than those due to ESBL-negative strains
(32.7% and 8.3%, respectively; P< 0.01). Compared with cases due to
ESBL-negative isolates, those caused by ESBL-positive strains showed
higher mean hospital stay (74.4 and 33.4 days, respectively; P< 0.01) and
crude mortality rate (26.5% and 8.3%, respectively; P< 0.01). Empirical
treatment was more frequently adequate among patients with BSI due to
ESBL-negative than in the case of ESBL-positive isolates (76.7% and
49.0%, respectively; P< 0.01). BSI cases due to ESBL-negative isolates
responded to therapy more frequently than those due to ESBL-positive
strains (81.3% and 62.5%, respectively; P< 0.10).
Conclusion: Therapeutic failure and high mortality rate are a common
feature of BSI episodes caused by ESBL-positive enterobacteria. Prompt
recognition of ESBL-positive strains appears critical for the clinical
management of patients with systemic enterobacterial infections.
P949 High rate of extended-spectrum b-lactamases among Enter-
obacteriaceae blood-culture isolates from Bulgarian hospitals
E. Keuleyan, R. Markovska, I. Schneider, T. Kantardjiev, M. Sredkova,
D. Ivanova, K. Rachkova, B. Markova, E. Dragijeva, I. Mitov,
A. Bauernfeind (Soﬁa, BG; Munich, DE; Pleven, Stara Zagora, BG)
Objectives: (1) To reveal the rate of ESBL producers among bacteraemia
isolates. (2) To characterise the spectrum of ESBL genes and their
possible spread.
Methods: Surveillance data have been obtained through the national
programme BulStar since 1998. Eight hospitals from three towns
provided 71 bacteraemia isolates in an ESBLs survey, conducted from
1996 to 2003. The Medical Institute-Ministry of the Interior (MIMI)
served as a referral centre. ESBLs were determined and characterised
by double disk synergy-, disk diffusion conﬁrmatory- (CLSI, 2005)
tests; conjugation was performed on solid medium; Isoelectric focusing
and bioassay were followed by ESBL-group speciﬁc PCR and nucleic
acid sequencing; RAPD was carried out to detect epidemiological
relationships.
Results: ESBLs, 3% among Enterobacteriaceae from septicaemia in
1998, augmented up to 15% in E. coli, 35% in K. pneumoniae and
24% in S. marcescens during 2004 (BulStar); their rate at MIMI from
2003 to 2005 was: 6% – E. coli, 50% – K. pneumoniae and 33% –
S. marcescens. The survey on ESBLs revealed the incidence of 3 groups:
SHV-, TEM- and CTX-M; and 5 particular enzymes: SHV-12 (47%),
SHV-2 (4%), TEM-3-like (19%), CTX-M-3 (14%) and CTX-M-15 (9%);
5 strains produced 2 ESBLs. The majority of the pathogens from MIMI
and other Soﬁa hospitals produced SHV-12; TEM-3-like was found
at the medical centre-Pleven. K. pneumoniae, the predominant species
collected (60% of all blood-culture isolates), produced most frequently
SHV-12 (29 out of 42 strains), followed by TEM-3-like (6), CTX-M-
15 (3), CTX-M-3 and SHV-2 (by 1). Among 11 E. coli, CTX-M-
15 ESBLs were most common (4), followed by TEM-3-like (2) and
5 strains produced combinations of 2 enzymes. S. marcescens (7 strains)
produced CTX-M-3 (3), SHV-12 (2) and SHV-2 (2). Two small outbreaks
and one larger could be identiﬁed. Most of the strains showed multiple
resistance, e.g. 74% to aminoglycosides and ciproﬂoxacin, however they
were susceptible to carbapenems.
Conclusion: A high proportion of Enterobacteriaceae strains (3−50%)
isolated from patients with bacteraemia were shown to elaborate ESBLs
from three groups, ﬁve different enzymes, which is worrying and
represents one of the highest percentage in Europe. Strong attention
should be paid at national and hospital level towards antibiotic use and
Infection control.
P950 Quantifying the relationship between Staphylococcus aureus
bacteraemia and Staphylococcus aureus bacteriuria
M. Ekkelenkamp, J. Verhoef, M. Bonten (Utrecht, NL)
Objectives: Common belief is that Staphylococcus aureus bacteraemia
(SAB) causes S. aureus bacteriuria, especially in the case of endocarditis.
Evidence for this theory is however limited. We hypothesised that if SAB
truly causes S. aureus bacteriuria this phenomenon would be observed
also in patients without urinary tract infection (UTI) and without risk
factors for urinary colonisation with S. aureus (speciﬁcally the presence
of urinary catheters and oliguria).
Methods:We conducted a retrospective cohort study over a 5-year period
to assess the frequency of S. aureus bacteriuria in patients with SAB. We
analyzed the diagnosis of these patients and determined whether they had
risk factors for colonisation or whether the S. aureus bacteriuria could
solely be attributed to SAB.
Results: In the ﬁve-year period, 515 patients had demonstrated SAB.
From 164 patients urine cultures had been taken concomitantly with the
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blood cultures and of these, 23 patients had S. aureus bacteriuria. In all
23 patients the bacteriuria could be explained either by UTI, the presence
of urinary catheters or oliguria.
Conclusion: If SAB caused S. aureus bacteriuria, it was a very
infrequent event in this study. Nearly all cases of S. aureus bacteriuria
in patients with SAB could be explained by the presence of risk factors
for colonisation or simply reﬂected a urinary tract infection.
P951 Trends in nosocomial bacteraemias: results from a university
hospital in the Netherlands
H.S.M. Ammerlaan, A. Troelstra, H. Blok, M.J.M. Bonten (Utrecht, NL)
Objective: To evaluate the burden (morbidity and mortality) of
nosocomial bacteraemias (NB) in a MRSA-free hospital.
Methods: The UMC Utrecht is a 997-bed tertiary care centre with
about 21,100 admissions annually. We analyzed all patients admitted
between January 1996 and December 2005, aged 18. Day-care
admissions and those treated in psychiatry were excluded. The hospitals’
microbiological database was linked to the patient-administrative system,
thereby providing all blood culture results and data on gender, date of
birth, department, length of stay, and mortality at hospital discharge.
NB was deﬁned as isolation of bacteria or yeast from 1 blood
culture set >2 days after hospital admission, with only the ﬁrst episode
analyzed. Skin organisms commonly associated with contamination,
were excluded. Annual incidence and mortality rates of NB were
calculated, with subgroup analysis for different micro-organisms.
Results: 1,769 episodes of NB were identiﬁed, with incidence rates
increasing from 89.9 per 100,000 patient-days in 1996 to 112.6 in 2005,
due to an increase in both Gram-positive and Gram-negative infections.
The RR of male on acquiring NB was 1.6 compared to female. The
RR of patients in the ICU was 6.0 compared to the other departments.
In this period no trend towards increasing resistance was found, accept
for a striking increase of amoxicillin resistance among Enterococcus
species in the 2nd half of the study from 12.1% to 46.6% (p = 0.001).
The length of stay (LOS) within the hospital decreased from 10.7
(95%CI: 10.6−10.8) in 1995 to 7.9 (95%CI: 7.8−7.9) days in 2005. The
average LOS for patients with NB did not change between 1995 and 2004
(50.4 days (95%CI: 48.0−52.7)), but decreased in 2005 to 41.5 days
(95%CI: 36.2−46.8). Average LOS for patients with NB ranged from
39.6 days (95%CI: 24.6−54.5) for Morganella morganii to 73.7 days
(95%CI: 49.2−98.1) for Serratia species. Overall hospital mortality for
patients with NB was 26.4% (ranging from 12.0% for Acinetobacter
species to 52.1% for Candida). The RR to die in the hospital for patients
with NB was 8.5 when compared to non-affected patients. This did not
change signiﬁcantly from 1996 to 2005.
Conclusion: The burden of nosocomial bacteraemias did not change
signiﬁcantly over the past 10 years within the UMC Utrecht. While the
mean LOS within the hospital decreases, the incidence rate of HAB
increases, suggesting an increasing severity of illness of hospitalised
patients.
P952 Epidemiology and outcome of primary and secondary
community-acquired bacteraemia in adult patients
M. Ortega, M. Almela, J. Martı´nez, F. Marco, A. Soriano, J. Lo´pez,
M. Sa´nchez, A. Mun˜oz, J. Mensa (Barcelona, ES)
Objectives: To know the associated factors and outcome of community-
acquired primary bacteraemia (PB); to describe the most frequently
isolated microorganisms, its antibiotic resistance pattern and to guide
the most adequate antibiotic treatment.
Patients and Methods: 1640 community-acquired bacteraemias in
non-neutropenic adults were consecutively enrolled from January 2003
to May 2006 and prospectively followed up. Non-conditional logistic
regression methods were used with PB and death as dependent variables.
Results: 1440 were secondary bacteraemia (SB) and 200 (12%) were
PB. The independent factors associated with PB were: male gender
(OR: 1.69, 95%CI: 1.27–2.25, p = 0.001), ultimately or rapidly fatal
prognosis of underlying disease (OR: 2.48, 95%CI: 1.84–3.34, p = 0.001)
and incorrect empirical antibiotic therapy (OR: 2.33, 95%CI: 1.61–3.33,
p = 0.001). The most frequently isolated microorganisms in PB were
E. coli and other enterobacterias (26% and 22%) and S. aureus (15%).
There were 28% and 37% of ciproﬂoxacin resistant E. coli strains in
SB and PB, respectively (p = 0.2). Mortality was signiﬁcantly higher in
PB cases (13% vs 8%, p = 0.04). The independent factors associated
with mortality in PB were: ultimately or rapidly fatal prognosis of
underlying disease (OR: 2.1, 95%CI: 1.41–3.13, p = 0.001) lack of fever
at the moment of bacteraemia (OR: 2.38, 95%CI: 1.18–4.76, p = 0.02)
and incorrect empirical antibiotic therapy (OR: 2.01, 95%CI: 1.22–3.33,
p = 0.006).
Conclusions: The initial empiric antibiotic treatment is more frequently
incorrect in PB than in SB and this is a predictor factor for mortality in
PB. The resistance pattern of E. coli, other enterobacterias and S. aureus
in every setting should guide the most appropriated empirical treatment
for PB.
P953 A six-year surveillance of the epidemiology and aetiology of
the bacteriaemias at a Milan hospital. The clinical relevance
of haemoculture
M. Cainarca, C. Tarricone, R. Ranieri, C. Erba, A. D’Arminio
Monforte, G. Melzi d’Eril (Milan, IT)
Objectives: In recent years, hospitalised patients are at increasing risk
of acquiring a nosocomial infection, mainly due to the widespread
use of invasive procedures. Haemocolture is considered as the gold
standard for deﬁning and treating a patient at high risk for developing
a bacteraemia. Our aim was to perform a six-year surveillance of
the infectious events, nosocomial and community bacteraemias and
pseudobacteraemias occurring at San Paolo Hospital (about 500 beds
for admissions).
Methods: We performed a retrospective collection of infectious events,
bacteraemias and pseudobacteraemias during the period between 2000
and 2005. The bacterial strains were identiﬁed by the instrument
VITEK2 (bioMe´rieux).
Results: The number of infectious events remained stable overtime
(from 893 in 2000 to 891 in 2005), as well as the number of colture
isolates/infectious events (from 133 in 2000 to 133 in 2005). The
most frequent isolated bacteria was Staphylococcus aureus (21.1%),
followed by Escherichia coli (20.5%), enterococci (9.2%) and negative
coagulase staphylococci (8.35%). Nosocomial bacteraemias were mainly
due to Staphylococcus aureus (23.2%); on the contrary Escherichia coli
was the most frequent agent in community bacteraemias (23%). The
mean percentage of the bacteraemias/infectious events in the period
2000–2005 was 14% with a difference between the surgical department
(18.7%) and medical department (15.7%). The rate of nosocomial
bacteraemias (2.76/1000 admissions) and community bacteraemias
(4.08/1000 admissions) did not vary during the period of surveillance.
Conclusion: Our data conﬁrm that Staphylococcus aureus is the
main responsible bacteria for nosocomial infections as Escherichia
coli is in community bacteraemias. The steadiness of the number
of isolates/infectious events and the rate of nosocomial bacteraemias
suggest the need of an educational interventions to remark the role of
the haemocolture in deﬁnining bacteraemias and the establishment of
approaches to reduce the incidence of hospital acquired infections.
P954 Predictors of positive blood culture in an emergency service.
A prospective study
B. Ceballos, G. Peralta, L. Ansorena, M. Rodriguez-Lera, M. Roiz,
M. Sa´nchez (Torrelavega, ES)
Objectives: The microbiology laboratory is of limited usefulness for
bloodstream infection detection, because only a low proportion of blood
cultures have positive results, and the ﬁnal results take at least 24 h to be
known. We design a prospective study to develop a prediction model for
bacteraemia, based on clinical data of patients assisted in an Emergency
Service.
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Methods: The study was developed in a 250 bed community teaching
hospital placed in the North of Spain with around 65,000 presentations
to the emergency service annually. All patients to whom blood cultures
were performed from January to June 2006 were recruited for the study.
Univariate analyses and stepwise logistic regression were performed to
identify factors associated with bacteraemia.
Results: Blood cultures were performed in 390 patients in the period of
study. Bacteraemia was detected in 60 (15.4%). Isolated microorganisms
were E. coli in 35 (9%), S. aureus in 3 (0.8%), S. agalactiae in 2 (0.5%),
P. aeruginosa in 2 (0.5%), Listeria spp. in 2 (0.5%), and others in
16 (4.1%). No signiﬁcant differences among patients with positive and
negative blood cultures in age, gender, proportion of comorbibities (renal
chronic failure, cardiac failure, diabetes, dementia, immunosuppression,
cirrhosis, neoplasia), Charlson index score, or clinical manifestations
(presence of chills, or vomiting, and mean systolic blood pressure)
were detected. However patients with positive blood cultures had
shorter duration of the acute illness (29.3±32.5 h vs 59.4±85.7 h), more
frequently had no previous antibiotic treatment (96.7% vs 84.2%), more
frequently had temperature higher than 38ºC (60% vs 40.2%), severe
sepsis (21.7% vs 7.9%) or altered consciousness (20% vs 6.7%). In a
logistic regression model the predictors of bacteraemia were absence
of previous antibiotic treatment (OR: 4.87, 95CI: 1.12−21.17), altered
consciousness at arrival (OR: 3.85, 95CI: 1.55–9.54) and the presence
of fever (OR: 2.18, 95CI: 1.16–3.97).
Conclusions: Several clinical parameters can be useful for predict
bacteraemia in an Emergency service. The absence of previous antibiotic
administration, altered consciousness at arrival, and the presence of fever
are associated with a higher risk of bacteraemia
P955 Epidemiological characteristics of nosocomial blood
infections at a clinical centre, Belgrade, Serbia in 2005
B. Jovanovic, V. Mioljevic, S. Jovanovic, N. Mazic, I. Palibrk (Belgrade,
RS)
Introduction: Nosocomial bloodstream infections (BSI) represent actual
and one of the most severe medical problems due to their frequency,
prolonged hospitalisation and increase of medical costs. Their incidence
varies depending on the characteristics of the observed patients and
department, ranging between 1.3 and 18.4 per 1000 patient days.
Major causes of BSI include coagulase-negative staphylocci(CNS),
Staphylococcus aureus, Enterococcus spp. and Candida spp.
Purpose: Determining of BSI incidence and distribution of BSI causes
in percentages in patients hospitalised for more than 48 hours at the
Institute of Digestive Diseases in 2005.
Methods: BSI incidence is calculated using Atlanta CDC methodology.
Cultivation, isolation, identiﬁcation and susceptibility tests of the
causative organisms obtained from the patient material was carried
out using standard microbiological methods in the Microbiological
Laboratory within the Emergency Center of the Clinical Center of Serbia.
Results: BSI incidence at the Institute of Digestive Surgery was 5.76
per 1000 patient days. One third (28%) of all blood infections veriﬁed in
the laboratory was caused by CNS, followed by Klebsiella spp. (14%),
Staphylococcus aureus and Candida spp. (12.5%). Methicillin resistance
was evidenced in 80% of CNS isolates and 90% of Staphylococcus
aureus isolates. ESBL was produced by 18% of Klebsiella spp. isolates.
Conclusion: The incidence of BSI recorded at the Institute of Digestive
Diseases in 2005 was 5.76 per 1000 patient days. One third of all blood
infections veriﬁed in the laboratory at the Institute during 2005, was
caused by CNS, followed by Klebsiella spp., Staphylococcus aureus
and Candida spp. All the isolates show high degree of resistance
to antimicrobial drugs. Epidemiological surveillance of BSI enables
insight into epidemiology of BSI, monitoring of resistance of causative
organisms and application of the speciﬁc preventive measures against
the infections.
P956 Surveillance of nosocomial sepsis and identifcation of relevant
risk factors in neutropenic haematology-oncology patients
F. Tabibnia, F. Mattner, A. Ganser, P. Gastmeier, I. Chaberny
(Hannover, DE)
Objectives: Implementation of a prospective surveillance and identiﬁca-
tion of risk factors concerning nosocomial bloodstream infections (BSI)
during neutropenia in adult patients of a haematology–oncology unit
after hematopoetic stem cell transplantation or high dose chemotherapy
(CT).
Methods: BSIs were identiﬁed using CDC deﬁnitions (laboratory
conﬁrmed BSI) in neutropenic patients (NPs) with haematological and
solid malignancies (absolute neutrophile counts <1000/mm3). Recorded
risk factors (RFs): Age, gender, diagnosis, type of transplantation
(autologous, allogeneic sibling donor, matched unrelated donor), type
of central access (CVC, Port) or use of peripheral access, fever days.
Uni- and multivariate analyses were used to determine RFs.
Results: During the 12-month period of the study 202 patients with
2,843 neutropenic days (NDs) were investigated. 41 patients received
autologous transplant (345 NDs), 161 were treated for other reasons
(2,498 NDs). The median age was 49.5 years (17−77). The mean number
of NDs (range: 2−72) was 14.1 (15.5 and 8.4 after CT and autologous
transplantation (AT), respectively). A total of 37 BSIs were diagnosed.
The incidence densities were 13.0 BSIs/1,000 NDs (10.2 and 23.2 after
CT and AT, respectively) or a rate of 18.3 BSIs/100 NPs (18.0 and 19.5
after CT and AT, respectively). The main pathogens were coagulase-
negative staphylococci (36.4%), Gram-negative rods (31.8%) and Gram-
positive cocci (20.5%). The shortest mean duration of neutropenia until
development of BSI among the pathogens was found for Gram-negative
rods counting 5 days. The mean length of fever was 4 days (with BSI
8 days). On univariate analysis, the duration of fever (p< 0.001) and of
neutropenia (p< 0.001) was signiﬁcantly associated with development
of BSI. On multivariate analysis, the independent RFs for BSI were the
number of fever days (Hazards ratio 1.2 increased risk/day) and use of
CVC (Odds ratio [OR], 6.4; 95% conﬁdence intervall, 1.5−27.7, Hazards
ratio 5.8).
Conclusions: The study shows and conﬁrms that the use of CVC is a
major RF for nosocomial BSIs in NPs. The incidence of BSI/1000 NDs
was higher among AT recipients of this study than of the participating
hospitals of ONKO-KISS (pooled data: 17.8). Compared to the results in
former studys (Dettenkofer et al., CID 2005;40:926−31) a higher share
of Gram-negative rods (31.8% vs. 15%) was found associated with BSI.
P957 The inﬂuence of antimicrobial resistance on mortality in
critically ill patients with bacteraemia
J.Y. Choi, Y.K. Kim, M.S. Kim, Y.S. Park, Y.G. Song, D. Yong, K. Lee,
J.M. Kim (Seoul, KR)
Background: Among all hospitalised patients, ICU patients are at
greatest risk for nosocomial infections. Predominant pathogens include
Pseudomonas aeruginosa, Enterobacter cloacae, Staphylococcus aureus,
Enterococci, and Candida spp. They are more likely to be resistant to
antimicrobial agents than are isolates from elsewhere in the hospital.
The isolation of antimicrobial resistant pathogens increase the risk
of inadequate antimicrobial therapy. However, clinical importance of
antimicrobial resistance, as a risk factor for hospital mortality and other
adverse clinical outcomes, has not been systematically evaluated in the
ICU setting. The objective of this study was to evaluate the effects of
the isolation of antimicrobial resistant pathogens on clinical outcomes
among ICU patients with bacteraemia.
Methods: A retrospective cohort study was performed to identify risk
factors for mortality in ICU patients with bacteraemia. Data from
76 patients with bacteraemia who admitted between January 2004 and
December 2004 at ICU of Severance Hospital, Yonsei University College
of Medicine in Seoul, Korea, a 1,300-bed tertiary-care teaching hospital,
were analyzed to identify risk factors for in-hospital mortality. ICU
patients with antimicrobial resistant pathogens such as MRSA, VRE,
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MDR P. aeruginosa, MDR A. baumannii, ESBL-producing E. coli,
ESBL-producing Klebsiella sp., 3rd cephalosporin resistant Enterobacter
sp were deﬁned patients with antimicrobial resistant pathogens.
Results: The mean age of the 76 enrolled patients was 60 years,
and mortality rate was 76.3% (58 of 76 patients). Univariate analysis
revealed that the risk factors for mortality included; age, shock, elevated
creatinine, duration from admission to bacteraemia and patients with
antimicrobial resistant pathogens. Multivariate analysis revealed that the
independent risk factors for mortality were age, elevated creatinine,
duration from admission to bacteraemia and patients with antimicrobial
resistant pathogens.
Conclusion: Isolation of antimicrobial resistant pathogens was indepen-
dently associated with in-hospital mortality among critically ill patients
with bacteraemia in ICU setting.
P958 Risk factors for inadequate antimicrobial treatment in
patients with bloodstream infection
J. Valle´s, E. Calbo, E. Anoro, D. Fontanals, M. Xercavins, E. Espejo,
G. Serrate, M. Morera, N. Freixas, B. Font, F. Bella, F. Segura,
X. Garau (Sabadell, Terrassa, ES)
Objective: Analyse the risk factors for ineffective antimicrobial therapy
in patients with bloodstream infections (BI).
Methods: Prospective cohort study of adults with BI at three hospitals
during one year. BI was deﬁned as nosocomial-acquired (NA),
community-acquired (CA), and healthcare-associated (HA).
Results: Of 1157 BI, 581 (50.2%) were CA, 295 (25.5%) were NA,
and 281 (24.3%) were HA. Patients with NA received inadequate
antimicrobial therapy in 28% of episodes, compared with 8% in CA
(OR: 4.27; 95%CI, 2.8−6.3; p< 0.001). Patients with HA received inad-
equate therapy in 16% of episodes compared with 8% in CA (OR: 2.07;
95%CI, 1.3−3.2; p = 0.001). The difference between NA and HA
episodes (28% vs 16%) was also different (OR: 2.06; 95%CI, 1.3−3.1;
p = 0.001). Mortality among patients with adequate treatment was 18%
vs 34% with inadequate treatment (p< 0.001). Multivariate logistic
regression using community-acquired status as reference, identiﬁed NA
episodes (OR, 1.7; 95%CI, 1.1−2.7), and BI of unknown origin (OR, 2.3;
95%CI, 1.4−3.7) as independent predictors of inadequate therapy.
C. albicans (OR, 13.9; 95%CI, 3.7−52.2), methicillin-resistant S. aureus
(OR, 6.9; 95%CI, 2.4−19.6), P. aeruginosa (OR, 2.4; 95%CI, 1.3−4.3),
and coagulase-negative staphylococci (OR, 1.9; 95%CI, 1.06−3.5) were
associated with an increased likelihood of receiving inadequate therapy.
Infection due to S. pneumoniae (OR, 0.14; 95%CI, 0.03–0.59) and
E. coli (OR, 0.2; 95%CI, 0.1−0.3) were associated with a decreased
risk of ineffective therapy.
Conclusions: Among patients treated for BI, nosocomial-acquired
episodes, unknown origin of infection, and infection due to multiresistant
pathogens were an independent predictor of inadequate antimicrobial
therapy.
P959 Serum total cholesterol as a predictor for clinical outcome
of bacteraemia
T. Kitazawa, Y. Ota, K. Tatusno, S. Okugawa, A. Fukushima,
S. Yanagimoto, K. Tsukada, K. Koike (Tokyo, JP)
Objectives: Infection and inﬂammation induce the acute phase response,
leading to multiple alterations in lipid metabolism. There have been few
reports, however, about changes in blood cholesterol levels at the onset
of bloodstream infection (BSI) and association between the changes and
prognosis of the BSI. The aim of this study was to elucidate the factors
which were related with the changes in blood cholesterol levels at the
onset of BSI. In addition, it was also examined whether the changes or
the levels of the serum cholesterol were associated with the prognosis
of bacteraemia.
Methods: From April 2003 to March 2006, all the patients aged
20 years whose blood cultures were positive at the University of Tokyo
Hospital were enrolled in this study. We selected the patients whose
cholesterol levels were tested during both of the two periods; the ﬁrst
period, between 30 days and 10 days before the onset of BSI, and the
second period, 2 days from the onset. A retrospective chart review was
performed to collect demographics including medical history, invasive
procedures and medications.
Results: Average total cholesterol levels before the onset of bacteraemia
was 168.9±46.7mg/dL, and decreased to 135.7±45.0mg/dL at the onset
of bacteraemia, with statistical signiﬁcance (p< 0.001). Non-survivors
had lower cholesterol levels than survivors, before the onset of BSI
(130±45 vs 172±46, p = 0.022) and at the onset of BSI (103±40
vs 138±45, p = 0.044). The lower cholesterol group had higher 30-
day mortality than the higher cholesterol group, but not signiﬁcantly
(p = 0.10). The lower cholesterol group had longer durations of treatment
than the higher cholesterol group with statistically signiﬁcant (P = 0.042).
Conclusion: Serum cholesterol level at the onset of BSI is an important
predictor for the outcome of BSI.
P960 Prospective evaluation of risk factors for catheter-related
bloodstream infections in two Swiss hospitals
A. Templeton, G. Rettenmund, B. Scho¨bi, K. Diethelm, M. Schlegel,
F. Fleisch, S. Henz, G. Eich (St. Gallen, Zurich, CH)
Background and Objectives: Catheter related bloodstream infections
(CRBSI) are a leading cause of nosocomial infections associated with
signiﬁcant mortality and costs. The objective of this study was to
determine the rate of CRBSI in two large Swiss hospitals and to identify
risk factors for this condition.
Methods: During one year all central venous catheters (CVC) inserted
in patients admitted for visceral, orthopaedic, or urologic surgery to
the cantonal hospital St. Gallen and all CVCs inserted in patients
at the cantonal hospital Chur were included in the study. Catheters
were followed for the duration of their insertion. Blood cultures and
semiquantitative cultures from catheters were drawn in the presence
of local or systemic signs of infection. Primary endpoint was CRBSI.
CRBSI was deﬁned as deﬁnite if (a) the same pathogen grew in at
least one blood culture and from the distal segment of the catheter or
(b) the same pathogen grew in at least one peripherally and centrally
drawn blood culture and the differential time to positivity of central
blood culture vs. peripheral blood culture was >120 minutes. CRBSI was
deﬁned as probable when at least one blood culture was positive with a
recognized pathogen in the absence of an other site of infection. Data
were analysed using univariate and multivariate time-to-event methods.
Results: During the study period 1396 CVCs in 1162 patients were
prospectively studied. Incidence density of all CRBSIs (deﬁnite n = 29,
probable n = 7) was 2.51 (95%CI; 1.81–3.49) per 1’000 catheter-days.
The lowest rate of CRBSI was found in subclavian catheters, the
adjusted hazard ratio (HR) for jugular catheters was 2.2 (95%CI: 1.1–
4.3; p = 0.03) and for femoral catheters 2.9 (95%CI: 0.6–14.4; p = 0.19).
Each additional lumen increased the risk (HR= 4.4, 95%CI: 2.5–7.7,
p< 0.001), whereas the blocking of additional lumens was protective
(HR= 0.3, 95%CI: 0.1–0.7, p = 0.006). The most commonly isolated
organism were coagulase negative staphylococci with a rate of 28%.
Conclusion: Number of lumens and site of access were independent
risk factors for catheter-associated blood-stream infections. The use of
catheters with multiple lumens should therefore be restricted as far as
possible. If a catheter cannot be removed, the permanent closure of
unneeded lumens may reduce the risk of CRBSI.
P961 Septicaemia secondary to Vibrio vulniﬁcus
I. Villamil-Cajoto, L. Rodriguez-Otero, S. Cortizo, M.A. Garcia-Zabarte,
A. Aguilera-Guirao, M. Trevin˜o-Castellano (Santiago de Compostela,
ES)
Introduction: Vibrio vulniﬁcus is a halophilic species which has demon-
strated its pathogenic power by causing septicaemia and bacteraemia in
patients who had ingested contaminated seafood (especially raw oysters)
and infections of soft tissues exposed to sea water. The mortality rate
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in the case of septicaemia can reach values higher than 50%. Hepatic
diseases and inmunodepression are the main risk factors.
Clinical case: A 37 years old male arrives at the emergency service of
the hospital because of a temperature of 38.4ºC, local pain and a one
week old inﬂammation in the right lower limb. Physical examination
revealed an oedematous and erithematous infected wound in the external
malleolar region of the right lower limb which was caused by a sharp
vegetal object and which got considerably worse after swimming in the
sea. The hemogramme showed 18.500 neutrophilic leukocytes (91%).
VHS 72mm. Coagulation tests revealed a protrombine time of 33%,
INR of 2.6, ﬁbrinogen level of 585mg/dl and an activated partial
thromboplastin time of 43 seconds. The patient was diagnosed with
cellulitis and lymphangitis in the right lower limb. The molecular analysis
of the HFE gen revealed a heterozygosis of the C282Y mutation. Six
days after the admission to hospital the blood cultures became positive.
The biochemical identiﬁcation of the colony was realised by the API 20
NE system (bioMe´rieux, Marcy l’Etoile, France).
The result obtained showed the numeric code 7−6-3−0-0−4-4 which
could be identiﬁed as Vibrio vulniﬁcus with a T-value of 0.51. The
isolated strain was resistant to ampicillin and amoxicillin-clavulanic and
sensitive to third and fourth-generation cephalosporins, monobactams,
carbapenems, tetracycline, cotrimoxazole, and ﬂuorquinolones. On the
10th hospital day and after a favourable clinical progress the patient was
discharged.
Conclusions: Vibrio vulniﬁcus shows high afﬁnity for iron, which can
explain its connection to diseases with increased iron deposit, such as
chronic liver problems caused by hemochromatosis. Our group describes
the second case exposed in scientiﬁc literature of a patient whose
biochemical markers for iron metabolism show normal values and who
is carrier of heterozygosis of the C282Y mutation in the HFE gen of the
hemochromatosis.
P962 Mannose-binding lectin promoter gene variants in Korean
patient with bacteraemia
Y.S. Park, J.Y. Choi, S.Y. Shin, M.S. Kim, Y.H. Kim, Y.G. Song,
J.M. Kim (Seoul, KR)
Mannose-binding lectin is a calcium-dependent, liver-derived serum
protein involved in innate immune defence. Variant alleles causing low
serum levels of functional mannose-binding lectin have been shown to
be associated with an increased risk of infections. Also, there is the
existence of additional polymorphisms at positions −550 (H/L variants)
and −221 (Y/X variants) in promoter regions of the gene.
Blood samples were obtained from patients with bacteraemia, at
Severance hospital between March, 2003 and September, 2004. For
inclusion, patients were required to have at least one positive blood
culture results. PCRs were performed using genomic DNA and DNA
sequence analysis of the MBL promoter region was performed on PCR
products (spanning position −801 to +77 of the MBL gene).
Each allele H, L, Y, X has 0.37, 0.63, 0.58, 0.42, of frequency,
respectively and Haplotype HY, LY, HX, LX has 0.26, 0.32, 0.11, 0.32
of frequency. Correlation with SAPS II score is shown in Table 1.
Table 1.
total H/Y L/Y L or H/X
SAPS II score 37.7±15.4 36.9±15.1 38.4±16.3 42.1±10.6
Mortality predicted 20.8% 19.3% 22.6% 28.7%
Mortality observed 27.1% (16) 26.7% (5) 21.1% (4) 28.0% (7)
The promoter haplotypes, HY, LY, and LX, have been known to
associations with high, medium, and low levels of MBL serum
concentrations, respectively. These gene and haplotypes frequencies
in these bacteraemic patients were relatively similar to other normal
Caucasoid. So, we need to examine Korean normal population and
linkage disequilibrium between promoter and structural variants.
Fungal infections in the immunocompromised
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P963 Empirical antifungal therapy in febrile neutropenic
patients – systematic review
E. Goldberg, A. Gafter-Gvili, M. Paul, E. Robenshtok, L. Vidal,
L. Leibovici (Petah-Tikva, IL)
Objectives: The practice of administering empirical antifungal therapy
to persistently febrile neutropenic patients has become a standard of
care. This study aims to evaluate if empiric antifungal treatment reduces
mortality and prevents invasive fungal infections (IFI).
Methods: Systematic review and meta-analysis including randomised
controlled trials (RCTs) comparing empirical antifungal treatment
with placebo or no intervention (control), or another regimen, in
persistently neutropenic patients. Search was conducted until 2006.
Outcomes assessed were: All-cause mortality, documented IFI, fungal-
related mortality, composite failure, invasive mould infections, invasive
yeast infections, resolution of fever during neutropenia, adverse events.
Relative risks (RR) with 95% conﬁdence intervals (CIs) were estimated
and pooled.
Results: Our search yielded 25 trials, 5 of which compared polyenes
or azoles to control, and 20 compared between different regimens of
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polyenes, azoles or glucan synthesis inhibitors. Compared to control,
there was no difference in all-cause mortality (RR 0.93; 95%CI 0.55–
1.58, 5 trials, Fig.1). The risk for developing documented IFI was
lower (RR 0.30; 95%CI 0.11–0.84, 4 trials, 4 events in the treatment
group versus 15 in the control). When azoles (ﬂuconazole, ketoconazole,
itraconazole, voriconazole) were compared to polyenes (amphotericin B
in 7 trials, liposomal ampho B in 1 trial) there was a trend in favour
of azoles for decreased all-cause mortality (RR 0.88; 95%CI 0.71–1.08,
8 trials) and for decreased documented IFI (RR 0.67; 95%CI 0.44–
1.02, 7 trials). Adverse events which required discontinuation were less
frequent in the azole group (RR 0.52; 95%CI 0.39–0.69, 6 trials).
Conclusions: Our review demonstrates that empirical antifungal therapy
does not reduce mortality. Although it reduces IFI, data are based
on a small number of trials and events. Future trials should pursue
a pre-emptive approach using improved diagnostic tools (such as
galactomannan testing, high resolution CT), to identify the patients for
whom antifungal treatment is warranted. The use of amphotericin B as
empirical therapy seems unwarranted since it appears to be less effective
than azoles, with no mortality beneﬁt and an increased rate of side effects
P964 Antifungal prophylaxis for patients undergoing chemotherapy
or haematopoeitic stem cell transplantation – meta-analysis
E. Robenshtok, A. Gafter-Gvili, M. Paul, E. Goldberg, L. Vidal,
L. Leibovici (Petah-Tikva, IL)
Objectives: Fungal infections are a major cause of morbidity and
mortality following intensive chemotherapy. This study aims to evaluate
the prophylactic use of antifungal agents to prevent invasive fungal
infections (IFI) and mortality in patients with malignancies or
hematopoeitic stem cell transplantation (HSCT).
Methods: Systematic review and meta-analysis including randomised
controlled trials (RCTs) comparing prophylactic antifungal treatment
with placebo, no intervention, or oral polyenes in patients following
chemotherapy or hematopoeitic stem cell transplantation (HSCT). Search
was conducted until 2006. Primary outcomes were: all cause 30-day
mortality, fungal related mortality, and invasive fungal infections (IFI).
Relative risks (RR) with 95% conﬁdence intervals (CIs) were estimated
and pooled.
Results: Forty-nine RCTs were included in the analysis. Azoles (ﬂucona-
zole, itraconazole, ketoconazole) or intravenous polyenes (Amphotericin
B or liposomal Ampho B) were compared with placebo or no treatment in
29 trials, and with oral polyenes in 20 trials. Compared to control or oral
polyene, there was a signiﬁcant reduction in 30 day all-cause mortality
(RR 0.80; 95%CI 0.70–0.91, ﬁg.1), fungal related mortality (RR 0.55;
95%CI 0.41–0.74), and documented IFIs (RR 0.49; 95%CI 0.40–0.60).
Overall mortality was signiﬁcantly reduced in HSCT recipients (RR 0.77;
95%CI 0.40–0.97, 9 trials, 1096 patients), and there was a strong trend
toward reduced mortality in leukaemia patients (RR 0.84; 95%CI 0.70–
1.02, 26 trials, 3497 patients). There was a signiﬁcant reduction in
IFIs and fungal related mortality in all patient subgroups (HSCT, acute
leukaemia, others).
Conclusions: Our review demonstrates that prophylactic antifungal
therapy reduces overall mortality, fungal related mortality, and invasive
fungal infections following chemotherapy or HSCT. This is the most
updated systematic review of antifungal prophylaxis and the ﬁrst to
demonstrate a reduction in mortality. Prophylactic antifungals should be
administered routinely to HSCT patients as recommended by guidelines,
and should probably be considered for acute leukaemia patients.
P965 Prospective, multicentre study of caspofungin for prophylaxis
in high-risk liver transplantation
J. Fortu´n, M. Montejo, P. Martı´n-Da´vila, P. Mun˜oz, J.M. Cisneros,
C. Arago´n, M. Blanes, A. Ramos, J. Gavalda´, R. San Juan, P. Llinares
on behalf of the Spanish Transplantation Infection Study Group
(GESITRA-SEIMC)
Objective: There is signiﬁcant morbidity and mortality related to inva-
sive fungal infections (IFI) in patients undergoing liver transplantation
(LT). Prevention remains elusive, especially for IFI caused by moulds.
The aim of this study was to evaluate the efﬁcacy and safety of
caspofungin (CAS) as prophylaxis for IFI in the subset of LT recipients
at high risk of developing IFI (HR-LT) (study sponsored by GESITRA,
funded by MSD Spain).
Methods: A prospective, non-comparative, open label trial was
conducted in HR-LT adult patients who received CAS prophylaxis.
HR-LT included second LT due to primary dysfunction of a previous
graft, renal failure and/or kidney replacement techniques, LT post-
fulminant hepatitis, or the coincidence of 2 of the following: all-other-
cause second LT, fungal colonisation, high transfusion requirements,
choledocojejunostomy, biliary leak, or reintervention. Patients were
expected to receive CAS at 50mg qD (with 70mg load) for 21 days. A
succesful treatment outcome was deﬁned as the absence of breakthrough
IFI (proven or probable per EORTC/MSG criteria) during the ﬁrst
100 days after the onset of caspofungin in the absence of premature
discontinuation of prophylaxis because of toxicity or lack of efﬁcacy.
Results: An interim analysis was performed on the ﬁrst 41 patients
enrolled in the study (enrollment plan: 70 patients). The median duration
of CAS prophylaxis was 21 days (range, 5−54). The dose of CAS was
lowered to 35mg qD due to LT-related liver dysfunction in 16 (39.0%)
patients. Four (9.8%) more patients discontinued CAS due to drug-
related altered liver function tests after 8 to 19 days of therapy. CAS was
otherwise well tolerated. Eight (19.5%) patients died of CAS-unrelated,
LT-related complications other than IFI. Among survivors (up to 100-day
follow-up), one (2.4%) patient experienced an invasive Mucor surgical
wound infection 41 days post-CAS prophylaxis. No other patient met
diagnostic criteria for possible, probable or proven IFI during CAS
therapy or during the predeﬁned 100-day follow-up period post-CAS
discontinuation. Thus, the overall incidence of documented IFI was
1/41 (2.4%). Overall, CAS prophylaxis was successful in 36 patients
(87.8%).
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Conclusion: In this interim analysis, the outcome of CAS prophylaxis
was successful in 87.8% (36/41) of the patients, with an overall incidence
of documented IFI of 2.4% (1/41). These results suggest promise for the
prophylactic use of CAS in HR-LT recipients.
P966 Prophylaxis for Pneumocystis pneumonia in non-HIV
immunocompromised patients: systematic review and
meta-analysis
H. Green, M. Paul, L. Vidal, L. Leibovici (Petah Tikva, IL)
Objectives: Pneumocystis pneumonia (PCP) is associated with signiﬁ-
cant mortality and morbidity among immunocompromised patients. Data
on the beneﬁt of PCP prophylaxis are available for HIV patients, but were
not previously quantiﬁed for non-HIV immunocompromised patients.
We performed a systematic review and meta-analysis to assess the
effectiveness of PCP prophylaxis among non-HIV immunocompromised
patients.
Methods: We searched for randomised controlled trials comparing
prophylaxis using an antibiotic effective against Pneumocystis jirovecii
(formerly P. carinii) versus placebo, no intervention or an antibiotic/s
with no activity against P. jirovecii, among immunocompromised
patients and assessing clinical PCP infections as an outcome. In
addition, we included trials comparing different PCP prophylaxis
regimens or administration schedules. The search included CENTRAL,
PubMed, LILACS and relevant conference proceedings. No language,
year or publication status restrictions were applied. Two reviewers
independently searched, ﬁltered the trials and extracted data and
performed methodological quality assessment. Relative risks (RR) with
95% conﬁdence intervals (CI) are reported. Meta-analysis was performed
using the random effects model.
Results: 12 randomised trials performed between 1974–1997 were
identiﬁed, including 1245 patients (50% children) with haematological
cancer, bone marrow or solid organ transplantation. Compared to no
PCP prophylaxis, there was a 91% reduction in the occurrence of
PCP in patients receiving prophylaxis with cotrimoxazole, RR 0.09
(95%CI 0.02–0.32), numbers needed to treat 15 patients, with no
heterogeneity (Figure). No signiﬁcant reduction was found in all cause
mortality. PCP-related mortality was signiﬁcantly reduced, RR 0.17
(95%CI 0.03–0.94). Adverse events requiring discontinuation occurred
in 3.1% of adults and 0% of children and all were reversible.
No differences between once daily and thrice weekly administration
schedules were found.
Conclusions: Balanced against severe adverse events, PCP prophylaxis
is warranted when the prevalence of PCP in the treated population is
above 3% for adults. The expected NNT to prevent one PCP with this
baseline probability is 35 patients. Adverse events are less frequent in
children, thus prophylaxis might be warranted with lower PCP prevalence
rates.
P967 Association between systemic inﬂammation and Pneumocystis
jirovecii colonisation in patients with chronic obstructive
pulmonary disease
R. Morilla, L. Rivero, F. Mun˜oz-Lobato, M. Montes-Cano, V. Friaza,
N. Respaldiza, F. Medrano, J. Varela, E. Caldero´n, C. de la Horra
(Seville, ES)
Objectives: Chronic obstructive pulmonary disease (COPD) is char-
acterised by signiﬁcant chronic inﬂammation in the pulmonary
compartment as well as in the circulation. Smoking is considered the
major cause of the disease. However, only a small portion of all smokers
develops the disease. In COPD, airway and systemic inﬂammatory
markers increase over time and high levels of these markers are
associated with a faster decline in lung function. Interest has focused
on the potential role of infectious agents as cofactors in accelerating
the progression of airway obstruction through increasing inﬂammatory
response. It is known that Pneumocystis jirovecii “carriers” is present
among COPD patients. In animal models, Pneumocystis causes an
increase in proinﬂammatory cytokines. All these evidences raises the
possibility that P. jirovecii colonisation might inﬂuence the natural
history of this disease. This study was undertaken to identify possible
inﬂammatory changes induced by P. jirovecii in COPD patients
Methods: The study included 51 COPD patients. The identiﬁcation
of P. jirovecii was performed by Nested PCR of respiratory samples.
Inﬂammatory responses were analyzed by ELISA commercials Kit
(R&D systems) for IL-8, IL-6, and TNF-a in serum samples.
Results: Of the 51 individuals with COPD included in the study,
28 (54%) had P. jirovecii colonisation. No other infection were detected.
No differences were detected due to age, gender, smoking habit, and
functional respiratory parameters (FEV-1%) when comparing P. jirovecii
carriers with non-carriers. However, patients with COPD colonised by
P. jirovecii showed a higher level of proinﬂammatory cytokine than non
colonised subjects (Table).
Conclusions: Pneumocystis jirovecii colonisation is associated with
higher proinﬂammatory cytokines levels. These ﬁndings suggest that
P. jirovecii is an infectious agent that may play a role in the
pathophysiology of COPD.
This work was funded by research grants SAF2003–06061 and FIS CP-
04/217.
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Serum cytokine levels in chronic obstructive pulmonary disease patients
with and without Pneumocystis jirovecii colonisation
Cytokine level
(pg/mL)
COPD without/with
P. jirovecii colonisation
P-value
(Student’s T)
Without (N = 23) With (N= 28)
IL-8 (mean±SD) 13.89±13.87 21.26±9.25 0.028
TNF-a (mean±SD) 3.57±2.03 8.15±10.6 0.047
IL-6 (mean±SD) 5.34±5.45 16.95±25.06 0.038
P968 Pulmonary surfactant-associated protein alterations in
subjects colonised by Pneumocystis jirovecii with idiopathic
interstitial pneumonia
V. Friaza, C. de la Horra, N. Respaldiza, M.A. Montes-Cano,
F. Munoz-Lobato, R. Morilla, L. Rivero, J. Martin-Juan, J.M. Varela,
E. Rodriguez-Becerra, F.J. Medrano, E.J. Calderon (Seville, ES)
Background: Idiopathic Interstitial Pneumonia (IIP) is a heterogeneous
group of poorly understood diseases with uncertain etiology. All of them
feature an initial inﬂammatory response that can lead to pulmonary
ﬁbrosis in some cases. This initial inﬂammatory response could be
somehow trigger by an infectious agent. It is well known that pulmonary
surfactant-associated proteins SP-A and SP-D play an important role in
lung host defence. In the same manner, there are evidences that SP-A
and SP-D regulate NF-kB and, by this pathway, are able to enhance
or suppress inﬂammatory mediators production. It had been previously
reported in vitro and in animal models, that Pneumocystis binds to
surfactant proteins and could alter their expression and distribution.
Objectives: To identify possible alterations in Pulmonary Surfactant-
associated Protein components in IIP Pneumocystis colonised patients.
Patients and Methods: Bronchoalveolar lavage ﬂuid (BALF) from
40 IIP patients was collected and the identiﬁcation of P. jirovecii was
performed by mt LSU RNAr gene Nested-PCR. SP-A levels were
determined by western-blotting following densitometry analysis using
1D Manager Software. SP-D was assayed by commercial available
ELISA Kits (Human SP-D ELISA BioVendor). All data obtained were
normalised with total protein concentration (quickstart Bradford dye
reagent, Biorad) of each sample.
Results: P. jirovecii was identiﬁed in 14 out of 40 (35%) IIP patients.
The results obtained for surfactant-associated proteins are showed in the
following table:
IIP colonised IIP non-colonised p
SP-A (CN*/mg prot) 11.77 15.25 0.295
SP-D (ng/mg prot) 406.24 904.86 0.026
aNormalised relative concentration.
Conclusions:
1. A high P. jirovecii colonisation rate in IIP patients has been found.
2. There is a statistical signiﬁcant SP-D decrease in colonised IIP
patients.
3. P. jirovecii could play a role in the physiopathology of this disease
through interaction with pulmonary surfactant-associated proteins.
P969 Mucocutaneous manifestations of disseminated
histoplasmosis in AIDS patients: special aspects in a Latin
American population
V. Cunha, T. Cestari, M. Zampese, L. Goldani (Porto Alegre, BR)
Objectives: Mucocutaneous lesions in HIV-infected patients with dis-
seminated histoplasmosis have a wide spectrum of clinical manifestations
making the diagnosis very difﬁcult. Studies have been restricted to case
reports and series with small number of patients not speciﬁcally focusing
on dermatological aspects of histoplasmosis. The authors describe the
mucocutaneous lesions of disseminated histoplasmosis found on 36 HIV-
infected patients with special attention to its morphology and clinical
distribution. Diagnostic, clinical, and therapeutic implications were also
analyzed in this study.
Methods: A retrospective and prospective study in 36 HIV-infected
patients with mucocutaneous histoplasmosis in a tertiary-care hospital
in Brazil.
Results: Eleven patients (30%) were taking antiretrovirals when
diagnosed and their CD4+ cell counts ranged from 2 to 103 cells/mm3.
The average number of lesions was 3 per patient, and each patient
presented 1 to 7 different morphological types of lesions. Despite the
variability of the lesions, papules (50%) and crusted papules (64%),
and oral mucosa erosions or/and ulcers (58%) were the most frequent
dermatolological lesions. A diffuse pattern of distribution of the skin
lesions was found in 58% of the cases. There was a signiﬁcant
association between the CD4+ cell counts and the morphological
variability of lesions per patient. Polymorphism of lesions was associated
with higher counts of CD4+ cells.
Conclusion: Papules with or without crusts, and mucous erosions or
ulcers in HIV-infected patients, along with general symptoms such as
fever, malaise, anorexia, weight loss and fatigue, and CD4+ cell counts
lower than 50 cells/mm3, are highly suspicious for histoplasmosis. In
spite of being easily confused with other dermatological conditions,
it is important to raise the possibility of histoplasmosis, especially in
patients who live in endemic regions. Biopsy with microscopy and
cultures of muco-cutaneous lesions are important tools for deﬁnitive
diagnosis. Physicians caring for HIV-infected patients should be aware
of the wide spectrum of dermatological lesions observed in disseminated
histoplasmosis, besides the importance to detect and isolate the fungus
in mucocutaneous tissues.
P970 Itraconazole does not affect the pharmacokinetics of
micafungin (FK463)
N. Undre, P. Stevenson, A. Brooks (Munich, DE; Leeds, UK)
Objectives: To determine the pharmacokinetic interaction of intravenous
micafungin and oral itraconazole following repeated administration to
healthy male subjects.
Methods: This was an open-label non-randomised study in 24 healthy
male subjects aged between 18 and 55 years. Single doses of 200mg
micafungin were administered as a 1-hour infusion on Days 1 to 5 and
on Days 31 to 35. Oral doses of itraconazole (200mg) were administered
twice daily on Days 19 and 20 and once daily on Days 21 to 35.
Subjects then received concurrent daily administration of micafungin
and itraconazole for 5 days. Pharmacokinetics were evaluated on Day 5
(micafungin alone), Day 30 (itraconazole alone) and Day 35 (micafungin
and itraconazole).
Results: Repeated daily administration of itraconazole had no effect on
the extent of systemic exposure to micafungin as measured by AUC0−24
and Cmax, compared with that observed following administration of
micafungin alone. The geometric mean ratio (90% CI) for micafungin
plasma AUC0−24 and Cmax on the day of co-administration relative
to administration alone were 0.958 (0.937, 0.980) and 0.991 (0.962,
1.02), respectively. Systemic exposure (AUC0−24) to itraconazole and
hydroxyitraconazole, at steady state, showed a 22% and 20% increase,
respectively, following co-administration of micafungin with itraconazole
compared with itraconazole administered alone. The majority of adverse
events reported during the study were mild in severity, and none were
serious or severe.
Conclusion: There was no discernible inﬂuence of repeated daily
administration of itraconazole on the pharmacokinetics of micafungin.
The AUC0−24 of itraconazole and hydroxyitraconazole at steady
state was approximately 20% higher following co-administration of
micafungin with itraconazole compared with itraconazole administered
alone. Repeated intravenous doses of micafungin were safe and well
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tolerated. No dose adjustments of either micafungin or itraconazole are
required when the two compounds are co-administered.
P971 Amphotericin B does not affect the pharmacokinetics of
micafungin (FK463)
N. Undre, P. Stevenson, D. Wilbraham (Munich, DE; London, UK)
Objectives: To investigate the pharmacokinetic interaction of intra-
venous (i.v.) micafungin (MICA) when given concomitantly with
amphotericin B (AmB) following repeated administration to healthy male
subjects.
Methods: This was an open-label non-randomised study. A total of
26 healthy male subjects aged between 18 and 55 years received a
daily i.v. infusion of MICA (200mg) over 1 hour for 5 days. After a
3-day washout, subjects received a daily 4-hour i.v. infusion of AmB
(250mg/kg/day) for 5 days. Subjects then received concurrent daily
administration of MICA (200mg) and AmB (250mg/kg/day) for 5 days.
Results: Following repeated once-daily i.v. co-administration of MICA
and AmB, there was no difference in the extent of systemic exposure to
MICA, as measured by AUC0−24 and Cmax, compared to that observed
following administration of MICA alone. The geometric mean ratio
(90% CI) for MICA plasma AUC0−24 and Cmax after 5 days of co-
administration relative to administration alone were 0.98 (0.93, 1.03) and
1.02 (0.99, 1.06), respectively. The systemic exposure to AmB increased
over time by approximately 30%. This accumulation was expected based
on its long half-life. These data suggest that repeated administration of
MICA does not affect the pharmacokinetics of AmB.
Conclusion: There was no discernible pharmacokinetic interaction
between MICA and AmB following repeated daily co-administration
of both medications. Repeated i.v. doses of MICA were safe and
well tolerated. Concurrent dosing with MICA and AmB was less well
tolerated than either drug alone, probably owing to an accumulation of
AmB towards steady state.
P972 A review of the safety of micafungin compared with
liposomal amphotericin B in a large, phase III trial in
patients with invasive candidiasis and candidaemia
A.J. Ullmann, J. De Waele, R. Betts, C. Rotstein, M. Nucci,
O.A. Cornely (Mainz, DE; Ghent, BE; Rochester, US; Hamilton, CA;
Rio de Janeiro, BR; Cologne, DE)
Objective: Liposomal amphotericin B (L-AmB) is associated with
nephrotoxicity. The objective of this review is to present data on the
safety proﬁle of micafungin (MICA) compared with L-AmB in patients
with invasive candidiasis and candidaemia.
Methods: In a phase III, randomised, double-blind study, patients with
conﬁrmed candidaemia or invasive candidiasis were randomised 1:1
to receive MICA (100mg/day) or L-AmB (3mg/kg/day). Safety was
assessed in terms of observed adverse events (AEs) of any causality and
AEs related to treatment. There were two predeﬁned safety endpoints:
estimated glomerular ﬁltration rate (eGFR) and incidence of infusion-
related reactions.
Results: In the adult population, the treatment groups (MICA: n = 264;
L-AmB: n = 267) were well balanced at baseline with respect to age,
gender and race. Neutropenia was present at baseline in 12.9% of
MICA and 10.5% of L-AmB patients. At baseline, APACHE II scores
of 20 were recorded in 72.5% of MICA patients and 76.0% of L-AmB
patients. Treatment groups were well balanced with regard to underlying
conditions, the most common being haematological disorders, solid
organ tumours and diabetes mellitus. Mean treatment days for MICA
and L-AmB were 14.1±8.0 and 13.9±8.5 days, respectively. AEs (any
causality) were seen in 92.8% of MICA patients and 94.4% of L-AmB
patients. Common treatment-related AEs are summarised in the table.
Treatment-related renal AEs with respect to creatinine increase were
seen signiﬁcantly less often with MICA than with L-AmB (p< 0.05),
and a lower incidence of chills and back pain was observed with
MICA compared with L-AmB (p< 0.05). On the predeﬁned safety
endpoint of eGFR, the mean peak decrease compared with baseline was
−1.3ml/min/1.73m2 for MICA and −19.1ml/min/1.73m2 for L-AmB, a
difference which was statistically signiﬁcant (p< 0.001). Furthermore,
88.0% of L-AmB patients experienced a decrease in eGFR during
week 1. Signiﬁcantly fewer MICA patients than L-AmB patients
experienced treatment-related infusion-related reactions (MICA 17.0%
versus L-AmB 28.8%; p 0.001).
Common treatment-related AEs (>3 patients in either group)
MICA (N= 264),
n (%)
L-AmB (N= 267),
n (%)
P-value
Fever 23 (8.7) 36 (13.5) NS
Chills 3 (0.8) 17 (6.4) <0.05*
Back pain 1 (0.4) 12 (4.5) <0.05*
Nausea 12 (4.5) 10 (3.7) NS
LFT abnormal 11 (4.2) 5 (1.9) NS
Vomiting 9 (3.4) 9 (3.4) NS
Hypokalaemia 18 (6.8) 32 (12.0) NS
Increased creatinine 5 (1.9) 17 (6.4) <0.05*
Increased SGPT 5 (1.9) 1 (0.4) NS
Increased LD 4 (1.5) 3 (1.1) NS
Dyspnoea 3 (1.1) 6 (2.2) NS
Rash 4 (1.5) 7 (2.6) NS
Skin erythema 1 (0.4) 4 (1.5) NS
NS: not signiﬁcant; *Fisher exact test.
Conclusion: This study showed overall safety advantages for MICA
over L-AmB in the treatment of invasive candidiasis/candidaemia, with
signiﬁcant differences in eGFR and in acute infusion-related reactions.
P973 An analysis of the efﬁcacy of micafungin in Candida infections
caused by non-albicans Candida species in phase III trials
O.A. Cornely, J. De Waele, R. Betts, C. Rotstein, M. Nucci, L. Kovanda,
C. Wu, A.J. Ullmann (Cologne, DE; Ghent, BE; Rochester, US;
Ontario, CA; Rio de Janeiro, BR; Deerﬁeld, US; Mainz, DE)
Objective: In recent years, the prevalence of non-albicans Candida
species has increased. Some antifungal agents, such as ﬂuconazole, are
limited by intrinsic and acquired resistance in non-albicans Candida
species. The objective of this study is to evaluate the efﬁcacy of
micafungin (MICA) against fungal infections caused by non-albicans
Candida species in two comparative phase III trials.
Methods: Two phase III, randomised, multicentre, active-controlled
trials conducted in patients with invasive candidiasis/candidaemia were
examined to assess the efﬁcacy of MICA in non-albicans Candida
infections. Both studies were conducted in adult patients with conﬁrmed
Candida infection at baseline. One trial compared MICA at 100mg/day
(MICA100) with liposomal amphotericin B (L-AmB) at 3mg/kg/day; the
other trial compared MICA100 and MICA at 150mg/day (MICA150)
with caspofungin (CAS) at 50mg/day (70mg loading dose on Day 1).
The primary efﬁcacy endpoint was treatment success at the end of
therapy, deﬁned as both positive clinical and positive mycological
response as assessed by the investigator.
Results: The primary efﬁcacy population (per protocol set; PPS) of
the two-arm trial included 392 patients (MICA100: n = 202; L-AmB:
n = 190). In the three-arm trial, the primary efﬁcacy population was the
full analysis set (FAS), which included 593 patients (MICA100: n = 191;
MICA150: n = 199; CAS: n = 188). The key efﬁcacy results are shown
in the table. In the two-arm trial, MICA showed equivalent treatment
success rates to L-AmB in all Candida species isolated. A similar result
was seen in the three-arm trial, with the two MICA doses being at
least as effective as CAS for all species isolated. There were no marked
differences in treatment success with MICA between infections caused
by C. albicans and those caused by non-albicans Candida species.
S258 17th ECCMID / 25th ICC, Posters
Conclusion: MICA demonstrated broad-spectrum efﬁcacy against
Candida infections. MICA is a valuable treatment option in invasive
candidiasis and candidaemia.
Treatment success, n (%)
Two-arm trial (PPS) Three-arm trial (FAS)
MICA100 L-AmB MICA100 MICA150 CAS
C. albicans 76/86
(88.4)
75/84
(89.3)
71/93
(76.3)
71/102
(69.6)
62/84
(73.8)
Non-albicans
Candida species
113/126
(89.7)
100/112
(89.3)
84/111
(75.7)
74/107
(69.2)
85/122
(69.7)
C. glabrata 19/23
(82.6)
12/15
(80.0)
24/28
(85.6)
30/34
(88.2)
22/33
(66.7)
C. tropicalis 48/52
(92.3)
41/43
(95.3)
21/31
(67.7)
20/33
(60.6)
24/32
(75.0)
C. parapsilosis 33/37
(89.2)
26/30
(86.7)
23/30
(76.7)
15/21
(71.4)
27/42
(64.3)
C. krusei 5/6 (83.3) 6/7 (85.7) 6/8 (75.0) 5/8 (62.5) 3/4 (75.0)
C. guilliermondii 4/4 (100) 4/4 (100) 3/3 (100) 2/2 (100) 1/1 (100)
C. lusitaniae 1/1 (100) 2/2 (100) 3/3 (100) 0/1 3/3 (100)
C. famata 3/3 (100) 1/1 (100) – – –
Only Candida species observed in 3 patients in either study are included in the
table. Patients could be diagnosed with more than one organism at baseline.
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P974 Antifungal chemoprophylaxis in the very low birth weight
neonates: a prospective randomised controlled study
N. Klimko, A. Kolbin, N. Shabalov (Saint-Petersburg, RU)
Objectives: Invasive candidiasis is associated with high morbidity and
mortality in preterm neonates. We have carried out analysis of clinical
efﬁcacy and safety of ﬂuconazole as used for prophylaxis of invasive
candidiasis in the very low birth weight neonates.
Methods: We conducted a prospective, analytical, randomised, non-
parallel, controlled, clinical trial over 12-month period in 104 preterm
neonates with birth weight <1500 g. Historical control group consist
of 249 preterm neonates with birth weight <1500 g. The 104 neonates
were randomly assigned during the ﬁrst ﬁve days of life to receive either
intravenous ﬂuconazole at a dose of 3mg/kg or at a dose of 6mg/kg. On
an average, one course of prophylaxis required 14 or 15 administrations
of ﬂuconazole in the course of 30 days.
Results: Analysis of the effect of the studied antifungal prophylaxis on
the incidence of invasive candidiasis in very low birth weight neonates
has not revealed any signiﬁcant differences between the used doses
((3mg/kg and 6mg/kg) of ﬂuconazole (2% vs 3.7%, p = 0.67). On the
other hand, the prophylactic use of ﬂuconazole in the speciﬁed doses
was accompanied by signiﬁcant decrease in the invasive candidiasis
incidence as compared to control group (2.9% vs 10.8%, p = 0.004).
The study has demonstrated that the prophylactic use of ﬂuconazole at
a dose of 3 or 6mg/kg was accompanied by a signiﬁcant decrease in
mortality due to invasive candidiasis (0% vs 10%, p< 0.001). No pt had
a serious AE or discontinued ﬂuconazole due to toxicity. Evaluation of
the isolated Candida species has shown that C. albicans dominated in
both the prophylactic groups and the control group. In the course of the
study, no effects of the speciﬁed doses of ﬂuconazole prophylaxis on the
selection of resistant strains of Candida were revealed.
Conclusion: Prophylactic use of ﬂuconazole at a dose of 3 in the very
low birth weight newborns is safe and decrease incidence of invasive
candidiasis and attributable mortality.
P975 Liposomal amphotericin B followed by voriconazole for
secondary antifungal prophylaxis in paediatric allogeneic
haematopoietic stem cell recipients
K. Allinson, H. Kolve, H.G. Gumbinger, H.J. Vormoor, K. Ehlert,
A.H. Groll (Mu¨nster, DE)
Objectives: Presumed or proven invasive pulmonary aspergillosis
(IPA) is an important cause of infectious morbidity in patients with
acute leukaemia. Although prior IPA is no longer a contraindication
for subsequent allogeneic hematopoietic stem cell transplantation
(HSCT), its successful management during granulocytopenia and
immunosuppression remains challenging.
Methods: In the absence of an evidence-based approach, 11 adolescents
(11 to 18 yrs) with acute leukaemia and a history of antecedent possible
(4) or probable (7; modiﬁed EORTC/MSG criteria, Herbrecht et al. 02)
IPA received liposomal amphotericin B (LAMB; 1mg/kg QD) from
the start of the conditioning regimen until engraftment and ability to
take oral medication, followed by oral voriconazole (VCZ; 200mg BID)
until the end of the at-risk period. Nine patients had a good partial
(>50% reduction in pulmonary inﬁltrates), and two a complete response
to standard antifungal agents prior to admission for HSCT.
Results: Granulocyte engraftment occurred after a median of 16 days
(r, 13−22). In addition to standard post transplant immunosuppression
with methotrexate and cyclosporin A, 3 patients received short (<14),
and 4 prolonged courses (r, 32−89 days) of methylprednisolon for acute
grade I or II GVHD. The median duration of IV treatment with LAMB
was 30 days (r, 19−36), followed by a median of 152 days (r, 19–
210) of oral VCZ. LAMB was discontinued early in 1 patient and VCZ
was transiently or permanently discontinued due to adverse events/new
contraindications in 2 and 2 patients, respectively. At +180 days post
transplant, 8 patients were alive, 6 with complete, and 1 each with
near complete and ongoing resolution of pulmonary inﬁltrates; all but
one were in continuing haematological remission. Three patients had
succumbed either to recurrent leukaemia (2) or refractory graft failure
(1); while one of these patient had maintained a complete response, 2
died with secondary possible (1) or probable (1) IPA. Both patients had
discontinued VCZ early and developed IPA in lung areas involved during
the primary episode.
Conclusions: This paediatric series supports the notion that successful
secondary antifungal prophylaxis for possible or probable IPA can be
safely and effectively achieved in allogeneic HSCT. In the absence of
chronic GVHD, reactivation or breakthrough infection appeared to be
associated with recurrent leukaemia/graft failure and shorter duration of
post-engraftment prophylaxis.
P976 Prospective, randomised, double-blind, placebo-controlled
phase III trial on voriconazole as primary antifungal
prophylaxis during induction chemotherapy for acute
myelogenous leukaemia
J. Vehreschild, S. Mousset, M. Hummel, D. Arenz, G. Wassmer,
U. Harnischmacher, A. Ullmann, D. Buchheidt, A. Bo¨hme, O. Cornely
(Cologne, Frankfurt, Mannheim, Mainz, DE)
Background: Invasive fungal infections remain a frequent cause
of morbidity and mortality in long-term neutropenic patients. The
availability of tolerable broad-spectrum antifungals like voriconazole
reignited the discussion about the best timing of antifungal therapy.
We therefore conducted a trial to analyze the efﬁcacy and safety
of voriconazole in the prevention of lung inﬁltrates during induction
chemotherapy for acute myelogenous leukaemia (AML).
Methods: Prospective, randomised, double-blind, placebo-controlled
phase III trial in AML patients undergoing ﬁrst remission induction
chemotherapy. Voriconazole 200mg BID or placebo were administered
until detection of a lung inﬁltrate or end of neutropenia. Primary
objective was the incidence of lung inﬁltrates until day 21, i.e. the start
of 2nd induction chemotherapy.
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Results: 25 patients were randomised to voriconazole (N = 10) or
placebo (N= 15). Incidence of lung inﬁltrates until day 21 was 0 (0%)
in the voriconazole vs. 5 (33%) in the placebo treatment arm (chi2
test, p = 0.04). Incidences of chronic disseminated candidiasis at 4 week
follow-up was 0 (0%) in the voriconazole vs. 4 (27%) in the placebo
treatment group (chi2 test, p = 0.07).
Conclusion: In this randomised, double-blind, placebo-controlled trial
voriconazole 200 mg BID PO reduced the incidence of lung inﬁltrates
during AML induction chemotherapy. There was a trend towards a lower
incidence of chronic disseminated candidiasis in the voriconazole arm.
P977 Safety and tolerability of voriconazole compared to
amphotericin B followed by ﬂuconazole in patients with
candidaemia and baseline renal insufﬁciency
A.M.L. Oude Lashof, J.D. Sobel, M. Ruhnke, P.G. Pappas, C. Viscoli,
H.T. Schlamm, J.H. Rex, B.J. Kullberg (Nijmegen, NL; Berlin, DE;
Genoa, IT; Birmingham, New York, Houston, Detroit, US)
Background: Acutely ill patients with candidaemia frequently have
other co-morbidities such as renal insufﬁciency. Voriconazole is approved
for treatment of candidaemia in non-neutropenic patients but use of the
intravenous formulation with sulfobutyl ether b-cyclodextrin (SBECD)
is restricted in patients with renal insufﬁciency. We evaluated the
use of i.v. voriconazole (formulated with SBECD) in candidaemic
patients with moderate to severe renal insufﬁciency, and we compared
treatment outcome and safety to patients who received a short course of
amphotericin B followed by ﬂuconazole (AmB/ﬂu).
Methods: We retrospectively reviewed data from the previously
published trial (Lancet 2005; 366: 1435−42) of voriconazole compared
to a regimen of AmB followed by ﬂuconazole for ﬁrst-line treatment
of candidaemia in 370 non-neutropenic patients. From this database we
collected treatment outcome, survival, safety, and tolerability data from
the patients with moderate to severe renal insufﬁciency at study entry,
deﬁned as a baseline creatinine clearance of 30−50ml/min (moderate)
or <30ml/min (severe).
Results: 58 patients were included; 41 were randomised to intravenous
voriconazole with moderate (32) or severe (9) renal impairment at
baseline, and 17 patients were randomised to amphotericin B with
moderate (13) or severe (4) renal impairment. Median duration of
treatment was 14 days for voriconazole (of which 7 days iv) and
3 days for AmB, followed by 11 days of ﬂu. Despite the short duration
of exposure, worsening of renal function or newly emerged renal
adverse events were reported in 53% of amphotericin B-treated patients
compared to 39% of voriconazole-treated patients.
During treatment, median serum creatinine decreased in the voriconazole
arm, whereas creatinine increased in the AmB/ﬂu arm, before return to
baseline at week 3. Outcome at end of therapy was successful in 63.4%
on voriconazole and 64.7% on AmB/ﬂu, and sustained success rate at
12wks follow-up was 31.7% (voriconazole) vs. 23.5% (AmB/ﬂu). All-
cause mortality at 14 weeks was 49% in the voriconazole arm compared
to 65% in the amphotericin B arm.
Conclusions: Intravenous voriconazole (with SBECD) was effective in
patients with moderate to severe renal insufﬁciency and candidaemia,
and tended to be associated with less acute renal toxicity and improved
survival compared to a short course of conventional amphotericin B.
P978 Efﬁcacy and safety of caspofungin in solid organ transplant
recipients
J. Petrovic, A. Ngai, S. Bradshaw, A. Williams-Diaz, A. Taylor,
C. Sable, N. Kartsonis (Rome, IT; West Point, US)
Objective: Efﬁcacy & safety data for the echinocandins in solid organ
transplant (SOT) recipients are limited. We reviewed the experience from
all SOT patients (pts) receiving caspofungin (CAS) therapy (Rx) for an
invasive fungal infection (IFI).
Methods: Data in SOT pts receiving CAS are available from 3 clinical
trials, including 2 noncomparative clinical trials (a salvage invasive
aspergillosis [IA] study [Protocol 019, P019] & a non-fungemic invasive
candidiasis [IC] study [P045]) & 1 comparator-controlled study (CAS
vs. amphotericin B [AmB] in IC [P014]). CAS was administered at
doses ranging from 50 to 100mg/day. Efﬁcacy was assessed in all pts
at end of CAS Rx (EOT). For IC pts, a favourable overall response
required complete symptom/sign resolution & Candida eradication (or
radiographic resolution). For IA pts, a favourable response required
clinically meaningful improvement in attributable symptoms/signs &
relevant radiographic ﬁndings. Adverse events (AE) & lab data were
collected from all pts. Investigators identiﬁed the seriousness, causality,
& action on study Rx for all clinical & lab AE noted during Rx & for
14 days postRx.
Results: 22 SOT pts, aged 34−67 years, were identiﬁed. All had proven
IC (6 pts) or proven/probable IA (16 pts) & received 1 dose of CAS
Rx. IC: Mean APACHE II score was 18 (range 6−27). All pts received
CAS as primary Rx. Sites of IC included blood (4), peritoneal ﬂuid (1),
& liver abscess (1). CAS success at EOT was 83% (5/6), with responses
seen across Candida spp. Success by SOT type was kidney 4/5 & liver
1/1. IA: All 16 pts had pulmonary IA (4 deﬁnite, 12 probable) & received
CAS as salvage Rx. CAS success at EOT was 50% (8/16), with responses
seen for both deﬁnite (3/4) & probable IA (5/12). Success by SOT type
was: heart 2/2, heart/lung 0/2, kidney 3/3, liver 1/3, & lung 2/6. Outcome
was not inﬂuenced by CAS dose. Safety: CAS, dosed for 2 to 162 (mean
36.8) days, was well tolerated. No pt had a serious drug-related (DR)
adverse event (AE) or discontinued CAS due to toxicity. Incidence of
DR clinical AE was 9% & DR lab AE 23%. The 30-day overall mortality
was 32% (IC 0% & IA 41%).
Conclusion: Based on the limited data, CAS appears to be an effective
& well tolerated option for the treatment of IC & IA in SOT recipients.
P979 Safety of high-dose caspofungin in 80 cancer patients and
haematopoietic stem cell transplant recipients with invasive
fungal infections
A. Safdar, G. Rodriguez, F. Al Akhrass, D. Kontoyiannis, H. Kantarjian,
R. Champlin, I. Raad (Houston, US)
Background: We recently reported safety of high-dose caspofungin
(HD-CAP) (100 mg daily) in 34 cancer patients (Safdar A, et al. ICAAC
2005). This study was performed to evaluate safety of HD-CAP in
additional 80 patients at our cancer centre.
Methods: Retrospective review of adverse events (AE) was undertaken
after obtaining IRB approval in patients who have received 3 or more
days of HD-CAP between August 2004 and April 2006. All values are
given in median ± standard deviations.
Results: Leukaemia was common underlying malignancy (63%) and
age was 52±14 years. Over half of the patients (54%) had refractory
or relapsed cancer. Among 37 (46%) haematopoietic stem cell
transplant (HSCT) recipients, 29 (36%) had received allogeneic graft
transplantation; 12 of 17 patients with GVHD were receiving treatment
for chronic GVHD. APACHE II score was 12±5 (range, 2 to 25) and 34%
had proven invasive fungal infections (IFI). Ninety-one percent received
HD-CAP in combination with another antifungal agent including,
voriconazole (34%) and AmBisome (36%). The duration of HD-CAP
was 12±24 (range, 3 to 161) doses. In attached table, interval increase in
values between start and end of HD-CAP therapy are shown. In 2 patients
(3%) serum bilirubin level doubled after receiving 5 and 22 doses of HD-
CAP therapy; levels return to normal after treatment was discontinued.
One patient (1%) developed reversible paresthesia.
Parameter <4 week
therapy
4−23 weeks
therapy
P value
Creatinine (mg/dL) 0.5±0.7 0.2±0.3 0.8
Total bilirubin (mg/dL) 0.2±0.9 0.5±1.8 0.9
Alanine aminotransferase (IU/L) 4±10 38±29 0.6
Alkaline phosphatase (IU/L) 46±201 26±39 0.3
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Conclusions: Extended therapy with HD-CAP was tolerated without
serious hepatic or renal impairment. Reversible hyperbilirubinaemia may
infrequently occur during HD-CAP therapy.
P980 Liposomal amphotericin B standard dose in combination with
caspofungin versus liposomal amphotericin B high dose regi-
men for the treatment of invasive aspergillosis in immunocom-
promised patients: randomised pilot study (Combistrat Trial)
D. Caillot, A. Thie´baut, R. Herbrecht, A. Pigneux, S. de Botton, M. Attal,
F. Bernard, J. Larche´, S. Alfandari, F. Monchecourt, L. Mahi (France,
Lyon, Strasbourg, Bordeaux, Lille, Montpellier, Nancy, Paris, FR)
Objectives: Antifungal Monotherapy for Invasive Aspergillosis (IA)
treatment is still associated with substantial mortality. Preclinical studies
data suggest that combination therapy with polyenes and echinocandins
may have additive activity against Aspergillus species.
Methods: We assessed the efﬁcacy of Liposomal Amphotericin B stan-
dard dose (3mg/kg/d) in combination with caspofungin standard dose
(COMBO) versus Liposomal Amphotericin B high dose (10mg/kg/d)
regimen (L-AMB HD). Modiﬁed EORTC-MSG criteria were used
to include patients with proven or probable IA. Study drug was
administered until investigator-deﬁned end of treatment (EOT). The
primary endpoint was favourable overall response (FOR) deﬁned as
partial or complete response assessed at EOT. Survival was followed up
to 12 weeks. Centrally data review committee conﬁrmed IA diagnosis.
Results: 30 patients with pulmonary IA diagnosis were assessed: 15
received COMBO and 15 L-AMB HD. Groups were well matched in
terms of demographics and neutropenia. Median duration of study drug
treatment was COMBO 18 days [10−35] and L-AMB HD 17 days
[4−24]. At EOT, FOR was COMBO 67% vs. L-AMB HD 27%
(p = 0.028). At week 12, FOR was 80% for COMBO and 67% for
L-AMB HD (NS) and survival 100% COMBO vs. 86.7% L-AMB HD
(NS). Infusion related reactions were observed in 3 L-AMB HD patients
(20%) (Flush, cervical or thoracic pain, chills, nausea). Nephrotoxicity
(serum creatinine >2x baseline) occurred in 4 L-AMB HD patients
(23%) vs. 1 COMBO (7%). Hypokalaemia (K+< 3.0mmol/L) developed
in 3 L-AMB HD (20%) vs. 2 COMBO (13%).
Assessment of volume and number of lesions observed in chest CT-Scan
showed an increase and worsening at day 7 then a decrease until EOT
(see Table1). These data support the initial diagnosis and allowed an
optimal follow up of the pulmonary IA.
Table 1. Characteristics of chest CT-scan evolution
Screening D7 D14 EOT
Numbers of patients
with reviewed scan
29 25 13 25
Median number of IA
lesions (range)
2.0
(1.0; 12.0)
3.0 (1.0; 10.0) 2.0
(1.0; 10.0)
2.0 (0.0; 7.0)
Median volume of IA
lesion (cm3) (range)
20.8
(0.9; 216.8)
48.5
(3.0; 471.8)
33.0
(9.3; 361.2)
25.5
(1.9; 216.6)
Median volume of
lesions/screening (%)
100 165.8
(27.1; 5110.9)
143.7
(9.8; 1323.5)
75.3
(4.5; 23113.1)
Conclusion: In immunocompromised patients with underlying haema-
tological malignancies, Liposomal Amphotericin B at 3mg/kg/d in
combination with caspofungin showed promising results in initial
treatment of invasive aspergillosis. A large randomised controlled trial is
required to conﬁrm these data. In addition the systematic use of chest CT-
Scan appeared to be a useful tool to follow the evolution of pulmonary
IA.
P981 Efﬁcacy of micafungin in patients with deep, invasive
Candida infections
A.J. Ullmann, J. De Waele, R. Betts, C. Rotstein, M. Nucci, L. Kovanda,
C. Wu, D. Buell, H. Diekmann, S. Koblinger, O.A. Cornely (Mainz,
DE; Ghent, BE; Rochester, US; Hamilton, CA; Rio de Janeiro, BR;
Deerﬁeld, US; Munich, Cologne, DE)
Objectives: The objective of this study was a post hoc analysis of
efﬁcacy data from two double-blind, randomised, phase III trials with the
echinocandin micafungin (MICA) in patients with invasive candidiasis
(IC).
Methods: We reviewed data on patients with a baseline diagnosis of
IC other than candidaemia enrolled in two double-blind, randomised,
phase III MICA trials. A three-arm trial compared intravenous MICA
100mg/day (MICA100) or 150mg/day (MICA150) with intravenous
caspofungin (CAS) (70mg/day loading followed by 50mg/day). A two-
arm trial compared MICA100 with liposomal amphotericin B (L-AmB)
3mg/kg/day. The studies shared similar endpoints: the primary efﬁcacy
endpoint was treatment success at the end of therapy, deﬁned as both
clinical and mycological response as assessed by the investigator. In
this analysis, we reviewed data from the modiﬁed full analysis set
(mFAS) for each of the trials, which for the three-arm trial included all
randomised patients who received at least one dose of study drug and
had documented Candida infection at baseline, conﬁrmed by the data
review panel. In this trial, the mFAS excluded patients with Candida-
associated endocarditis, osteomyelitis or meningitis. For the two-arm
trial, the mFAS included all patients who received at least one dose of
study drug and had a conﬁrmed diagnosis of IC or candidaemia.
Results: IC was observed in 85 of 578 patients (14.7%) in the three-arm
trial and in 84 of 494 patients (17.0%) in the two-arm trial. Treatment
success rates by infection site are shown in the table. MICA150
disseminated results were inﬂuenced by APACHE scores (2, 13, 14 for
successes vs 12, 13, 16, 21, 23, 26, 29, 33 for failures). Otherwise, MICA
was at least as effective as CAS in the three-arm trial in IC patients and
not affected by the site of infection. In the two-arm trial, MICA was
at least as effective as L-AmB in IC patients, and showed consistent
efﬁcacy independent of the infection site.
Infection site Treatment success (%)
Three-arm trial Two-arm trial Pooled data on
MICA100
(n = 199)
MICA150
(n = 191)
CAS
(n = 188)
MICA100
(n = 247)
L-AmB
(n = 247
MICA 100
Invasive
candidiasis
22/28
(78.6)
16/30
(53.3)
17/26 (65.4) 28/40
(70.0)
22/38
(57.9)
50/68 (73.5)
Abscess 5/5 (100) 5/6 (83.3) 6/9 (66.7) 5/5 (100) 4/6 (66.7) 10/10 (100)
Bone – – – – 1/1 (100) –
Chorioretinitis 0/2 1/1 (100) – – – 0/2
Disseminated 6/8 (75.0) 3/11 (27.3) 5/8 (62.5) 7/10 (70.0) 6/10 (60.0) 13/18 (72.2)
Endocardium – – –1/2 (50.0) 3/5 (60.0) 12 (50.0)
Endophthalmitis 4/4 (100) 1/3 (33.3) 1/1 (100) – – 4/4 (100)
Kidney – – – – 0/1 –
Organ –1/1 (100) – – – –
Other 3/3 (100) 1/1 (100) 3/3 (100) 1/3 (33.3) 0/1 4/6 (66.7)
Peritonitis 4/6 (66.7) 4/7 (57.1) 2/5 (40.0) 14/20
(70.0)
8/14 (57.1) 18/26 (69.2)
Conclusion: In these trials, MICA was associated with efﬁcacy
comparable to both CAS and L-AmB in patients with IC and thus
represents a valuable treatment option.
P982 Invasive cryptococcosis associated with treatment with
adalimumab, a tumour necrosis factor alpha-antagonist agent
J.P. Horcajada, J.L. Pen˜a, V.M. Martinez-Taboada, T. Pina, I. Belaustegui,
M.E. Cano, J.D. Garcı´a-Palomo, M.C. Farin˜as (Santander, ES)
Objectives: Adalimumab is a human monoclonal anti-TNF-alpha
antibody approved in 2002 for treatment of rheumatoid arthritis (RA).
There is some evidence of an increased risk of serious infections in
patients treated with anti-TNF antibody therapy. We report the ﬁrst case
of invasive cryptococosis in a patient under adalimumab therapy for RA.
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Methods: Chart review and case report.
Results: A 69-year-old caucasian woman with RA was referred for
severe acute inﬂammation of the second ﬁnger of the left hand. She
was receiving adalimumab 40mg sq every other week since a year
ago. Examination revealed severe tenosynovitis of the digital ﬂexor
tendon with intense edema and compartimental signs. Early surgical
decompression was performed. Intraoperative ﬁndings were extensive
subcutaneous celullitis with inﬁltration of both vasculonervous bundles,
and ﬂexor tendon synovitis. Culture of extracted material identiﬁed
Cryptococcus neoformans susceptible to amphotericin B, azoles and
ﬂucytosine, in four separated samples, including biopsy of subcutaneous
tissue. Cerebrospinal ﬂuid analysis was normal. Serum cryptococcal
latex and HIV serology were negative. Nuclear Magnetic Resonance
of the ﬁnger did not show arthritis nor osteomyelitis. Adalimumab
therapy was discontinued. Intravenous liposomal amphotericin-B 300mg
qd and intravenous ﬂucytosine 2.5 gr every 8 hours were administered
for 7 days. Once systemic and central nervous system involvement
were discarded, therapy was changed to intravenous ﬂuconazole 400mg
bid, with a slow clinical response, but with reduction of inﬂammatory
signs. However as the extent of residual soft tissue necrosis was
very important reconstructive surgical solution was rejected and
amputation of the second ﬁnger was performed on the third week after
admission. Pathologic exam revealed chronic necrotising granulomatous
inﬂammation with typical encapsulated fungal forms of Cryptococcus
spp. inside multinucleated giant cells These forms were observed with
hematoxillin-eosin and Mayer mucicarmine staining.
Conclusions: The ﬁrst case of cryptococosis in a patient taking
adalimumab is reported. Local manifestations were severe and response
to antifungal drugs was slow, with loss of the affected ﬁnger. Active
surveillance is required to detect severe opportunistic infections in these
patients in order to start antimicrobial therapy earlier.
P983 Is the determination of galactomannan in non-haematological
patients helpful for the diagnosis of invasive aspergillosis?
The value of determination in serum of patients with clinical
isolation of aspergillus
J. Guinea, J. Jensen, M. Rivera, R. Alonso, T. Pela´ez, P. Mun˜oz,
M. Torres-Narbona, E. Bouza (Madrid, ES)
Objectives: Haematological patients have traditionally been the highest
risk population for developing invasive aspergillosis (IA) and the
detection of galactomannan (GM) in serum in these patients has been
widely evaluated. However, the value of the test in non-haematological
patients has received little attention. We studied the value of detecting
GM in the serum of non-haematological patients with isolation of
Aspergillus in clinical samples for the diagnosis of IA.
Methods:We followed up those patients admitted to non-haematological
wards with one or more clinical isolations of Aspergillus in our institution
from March 2003 to August 2006. The patients were classiﬁed according
to EORTC standards (Ascioglu, CID 2002). A serum sample for GM
detection was requested under non-surveillance conditions in those
patients with a positive culture for Aspergillus. GM was detected by
the Platelia Aspergillus test (Bio-Rad). A detection of GM 1 ng/mL
was considered positive.
Results: During the study period, 75 different patients had an isolate of
Aspergillus and a serum sample processed for GM detection. Admitted
patients were located as follows: intensive care units 28 (37.3%), medical
wards 38 (50.7%), and surgical wards 9 (12%). Of the 75 patients
studied, 11 (14.7%) had proven or probable invasive aspergillosis. The
underlying conditions of the patients were COPD 5 (50%), HIV infection
1 (10%), lymphoma 1 (10%), liver transplant 1 (10%), solid malignancies
1 (10%) and corticosteroid treatment 1 (10%). The sensitivity, speciﬁcity,
positive predictive value (PPV) and negative predictive value (NPV) of
the detection of GM in serum for the diagnosis of IA were 50%, 98.5%,
83.3% and 92.7%, respectively (P< 0.001).
Conclusions: The detection of GM in the sera of non-haematological
patients with a clinical isolate of Aspergillus is useful for the diagnosis of
IA with PPV and NPV above 83% and 92%, respectively. Jesu´s Guinea
Pharm D, PhD, is contracted by the Fondo de Investigacio´n Sanitaria
(FIS), contract number CM05/00171.
P984 111-indium labelled leukocyte renal scintigraphy in patients
with candiduria: preliminary results of a prospective study
M. Gutie´rrez-Cuadra, J.P. Horcajada, I. Martı´nez, C. Salas,
D. Garcı´a-Palomo, J.M. Carril, M.C. Farin˜as (Santander, ES)
Objectives: to study possible renal parenchyma involvement in patients
with candiduria by means of 111-Indium labelled leukocyte scintigraphy.
Methods: prospective study of all candidurias detected between March
2006 and October 2006 in an university tertiary care hospital. Candiduria
was deﬁned as the presence of >10.000 CFU/mL of Candida sp. in urine
culture. A second urine culture with Candida sp. and/or an urinalysis
with abundant yeasts was needed to include the patients. Exclusion
criteria: presence of bacteria in urine culture, ICU patients, advanced
nephropathy, antifungal treatment, and pregnancy. 111-Indium labelled
leukocyte scintigraphy was performed 24−48 h. after conﬁrmation of
candiduria. Positive scintigraphy was considered when renal area uptake
was higher than the background. A renal CT scan was performed in
patients with positive scintigraphy. Patients with positive scintigraphy
were treated with oral ﬂuconazole 200mg qd for 14 days. A control
scintigraphy was performed one month later.
Results: 192 candidurias in 153 patients were analyzed. 139 episodes
were excluded and in the rest 53 candiduria was conﬁrmed in 13 patients.
Scintigraphy was performed in 8 patients. 5 were men and 3 women.
Mean age was 68 years. Urinary tract symptoms were absent in all
studied patients. 4 (50%) showed bilateral renal uptake before antifungal
treatment. CT scan was performed in 2 of them and it was normal.
Control scintigrapy after treatment was positive in the 3 patients in
which it was performed. Positive and negative patients were comparable
in terms of baseline conditions and the presence of indwelling urinary
catheters. 3 (75%) of positive patients and 1 (25%) of the negative
patients had low-grade fever (p = 0.2).
Conclusions: Half of the studied patients with candiduria showed renal
uptake in 111-Indium labelled leukocyte scintigraphy. Uptake persisted
one month later and after antifungal treatment. Although more data are
needed, subclinical pyelonephritis could be very frequent in patients with
candiduria. This could explain the high frequency of recurrencies in these
patients and could have therapeutical implications.
P985 Pharmacokinetic interaction and dose adjustment for
combined use of voriconazole and efavirenz
B. Damle, R. LaBadie, P. Crownover, P. Glue (New York City, US)
Objectives: Efavirenz (EFV) is an inducer of CYP450 isozymes
while voriconazole (VORI) is a substrate and inhibitor of CYP450s.
Coadministration of standard doses of VORI and EFV results in a
substantial decrease in VORI levels while increasing EFV levels. Hence
concomitant use of standard doses of VORI and EFV is contraindicated.
Our aim was to determine dose adjustments for coadministration
of VORI and EFV that result in exposures similar to respective
monotherapy.
Methods: This study used an open-label, four-treatment, multiple-dose,
ﬁxed-sequence design in 16 healthy males. Steady-state PK parameters
were assessed following two different test combinations (VORI 300mg
q12h + EFV 300mg q24h and VORI 400mg q12h + EFV 300mg
q24h). These parameters were compared to steady-state PK parameters
for reference monotherapy with VORI 200mg q12h or EFV 600mg
q24h, using an ANOVA model to determine point estimates and 90% CI.
VORI and EFV levels were determined by validated LC/MS/MS and
HPLC/UV assays, respectively. PK parameters were determined by non-
compartmental analyses.
Results: PK parameters are listed in the table, presented as the mean ratio
for each test combination relative to respective reference monotherapy.
VORI 300mg + EFV 300mg resulted in a signiﬁcant decrease in
VORI AUC (−55%) and Cmax (−36%), making it an unsuitable dose
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combination. Dosing of VORI 400mg + EFV 300mg resulted in a minor
decrease in VORI AUC (−7%) and increased Cmax (23%), while slightly
increasing EFV AUC (17%) and not changing Cmax. VORI and EFV,
administered alone or combined, were safe and well tolerated.
Conclusions: These data suggest that systemic exposures similar to those
seen with monotherapy can be attained during coadministration with
VORI and EFV by making adjustment to the dose regimen. To achieve
exposure levels similar to monotherapy, VORI dose should be increased
to 400mg q12h and EFV dose should be decreased to 300mg q24h
when the two drugs are coadministered.
Geometric mean ratio (90%CI)
Parameter VORI 300mg +
EFV 300mg
VORI 400mg +
EFV 300mg
VORI Cmax 64% (51, 79) 123% (99, 153)
VORI AUC 45% (38, 55) 93% (77, 113)
EFV Cmax 86% (79, 93) 96% (88, 104)
EFV AUC 101% (92, 111) 117% (106, 129)
P986 Anidulafungin: pharmacokinetics and tissue distribution in
rats
B. Damle, M. Stogniew, J. Dowell (New York City, US)
Objectives: Anidulafungin (ANID), a novel echinocandin antifungal
agent, is used in the treatment of oesophageal candidiasis and
candidaemia. For systemic fungal infection, drug levels in the infected
tissues are crucial for pharmacodynamic activity. Little is known about
the tissue distribution of ANID, so this study was conducted to assess
the pharmacokinetics and tissue distribution of ANID in rats.
Methods: Male F344 rats were given a single IV bolus dose of
14C-ANID (5mg/kg). Plasma and tissue (kidney, liver, lung, spleen,
quadricep, skin) samples were collected at 0, 0.083, 0.5, 1, 2, 4, 8,
24, 48 and 72 h after dosing (n = 3 rats/time), and the levels of parent
drug by HPLC/UV and total radioactivity were determined. Additionally,
whole blood and cerebrospinal ﬂuid samples were collected and analysed
for total radioactivity. In another study, distribution of radioactivity was
assessed in rats by whole body autoradiography for up to 168 h after a
single dose.
Results: Pharmacokinetics of ANID (ie, parent drug) are given below
(Table).
Tissue AUC (0−∞)
(ng×h/gm or mL)
Cmax (ng/gm or
mL)
Tmax
(h)
T1/2
(h)
Kidney 658,926.9 16,087.9 0.5 32.3
Liver 767,221.0 15,854.5 0.083 33.9
Lung 638,209.7 31,105.8 0.083 24.4
Quadriceps 57,349.2 3,839.7 0.5 17.1
Plasma 61,643.8 5,253.6 0.083 18.5
Skin 124,106.6 4,021.0 0.5 28.2
Spleen 567,950.4 24,195.6 0.5 25.2
Parent drug distributed rapidly into the tissues (Tmax 0.5 h). Based
on T1/2 values, the elimination of parent drug from most tissues was
slower than from plasma. The AUC of parent drug in liver, lung, kidney,
and spleen was 12.4-, 10.4-, 10.7-, and 9.2-fold greater than in plasma.
The tissue/AUC ratio of parent drug in skin and quadriceps was 2.0 and
0.9, respectively. Levels of drug-derived radioactivity, which represents
parent drug and degradation products, were approximately 2- to 3-fold
higher than parent drug in plasma and tissues. Drug-derived radioactivity
was eliminated from plasma (T1/2 = 37.4 h) and tissues (T1/2 = 37.5
to 69.2 h) at a slower rate compared to parent drug. Cerebrospinal
ﬂuid had minimal (0.4%) radioactivity relative to whole blood. In the
autoradiography study, high levels of radioactivity were observed in the
adrenal gland, bone marrow, caecal and intestinal walls, kidney, liver,
lung, lymph nodes, salivary gland, spleen, stomach wall, and thyroid
glands.
Conclusion: Following IV administration in rats, ANID distributes well
into the tissues that are considered clinically relevant for systemic fungal
infection.
P987 Steady-state bioavailability of oral isavuconazole in healthy
volunteers
A. Schmitt-Hoffmann, B. Roos, M. Heep (Basle, CH)
Objectives: This was a double-blind, randomised, parallel-group,
multiple-dose, placebo- and active-controlled study carried out with 80
male and female subjects at a single study centre. The primary objective
of the study was to determine whether isavuconazole (BAL4815) affects
cardiac repolarisation, assessed by measurement of the QT interval.
Because pharmacokinetics of isavuconazole were also evaluated after
oral and intravenous administration, a sub-analysis was carried out to
estimate oral bioavailability.
Methods: Subjects received 400 mg oral moxiﬂoxacin on day 1 as a
positive control. Afterwards, the 39 male and female subjects in the
verum group received isavuconazole at loading doses of 400, 300,
200mg orally (days 4−6) followed by maintenance doses of 100mg
orally (days 7−10) and 100mg intravenously (day 11), and loading
doses of 300, 250, 200mg orally (days 12−14) followed by maintenance
doses of 150mg orally (days 15−18) and 150mg intravenously (day 19).
Serial blood samples on days 10, 11, 18 and 19 and pre-dose (trough)
samples on days 6, 7, 8, 9, 10, 14, 15, 16, 17 and 18 were obtained.
Pharmacokinetic parameters on days 10, 11, 18 and 19 were derived by
non-compartmental analysis using WinNonlin Version 4.0.1.
Results: The mean trough levels of isavuconazole indicated that,
after the loading doses, steady-state was achieved for the two
maintenance doses. Mean trough levels of 2024±552.7 ng/mL and
1954±590.0 ng/mL were observed on days 7 and 10, respectively during
the 100mg maintenance oral dose sequence. The corresponding values
for the 150mg maintenance sequence were 2886±843.3 ng/mL and
2815±737.6 ng/mL on days 15 and 18.
The mean AUC0−24h were 46956 (day 10) and 46976 ng.h/mL (day 11)
after 100mg orally and intravenously, respectively. The corresponding
AUC-values on days 18 and 19 were 73016 and 71109 ng.h/mL
after 150mg orally and intravenous, respectively. The mean within-
subject bioavailability of oral isavuconazole for the 100mg dose was
100±8.63% and for the 150mg dose was 102±13.2%.
Conclusion: Stable and dose proportional levels were achieved
for oral once daily maintenance doses of 100mg and 150mg of
isavuconazole. Comparison of the pharmacokinetic proﬁles following
oral and intravenous dosing at steady state demonstrated complete
bioavailability of isavuconazole oral formulation.
P988 Pharmakokinetics of voriconazole in an intensive care unit
patient with liver cirrhosis
S. Weiler, R. Bellmann-Weiler, R. Bellmann (Innsbruck, AT)
Objectives: Voriconazole (VRC) is a second-generation triazole with
a broad antimycotic spectrum including non-albicans Candida and
Aspergillus species. Oral and parenteral formulations have similar phar-
macokinetics, however interpatient variation in plasma concentrations is
considerable. Plasma concentrations of >6mg/mL were associated with
occasional liver function abnormalities. Neurologic toxicity was found
in 50% of the patients with peak levels >5.5mg/mL.
Methods: We report a 45 year old male (body weight 100 kg) suffering
from a fatty liver cirrhosis, who was admitted to the ICU because of
unconsciousness. The patient had received an oral dose of 2mg/kg bid of
VRC for 30 days for pulmonary aspergillosis. In addition, he was treated
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with pantoprazole, risperidone, vancomycin, naloxon and furosemid.
VRC plasma concentrations were determined starting 15 hours after the
last intake, using a quantitative analysis via HPLC and UV detection.
Pharmacokinetic parameters were calculated with Kinetica 2000 using a
non-compartmental model.
Results: The plasma level determined at admission amounted
13.9mg/mL. Therefore VRC therapy was discontinued. The patient’s
condition, particularly CNS symptoms, gradually improved while VRC
levels slowly declined and he could be transferred to the ward after
2 days (VRC concentration ~10mg/mL). A half life of 53.1 h (in healthy
volunteers: 4.71 h), an apparent volume of distribution at steady state
of 0.132 L/kg (in healthy volunteers: 2.04 L/kg) and a VRC clearance
as low as 1.39mL/h/kg (in healthy volunteers: 253.94mL/h/kg) were
calculated. Even after 11 days VRC was detectable (0.66 mg/mL).
Conclusion: The elimination of VRC appears to be markedly prolonged
in severe liver cirrhosis leading to potentially toxic plasma levels.
Therapeutic drug monitoring of plasma concentrations could greatly
improve therapeutic safety.
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P989 Identiﬁcation and antimicrobial susceptibility of viridans
streptococci isolated from blood cultures in Leipzig, Germany
C. Friedrichs, K. Fickweiler, P. Nitsche-Schmitz, S. Chhatwal,
A. Rodloff (Leipzig, Braunschweig, DE)
Objectives: Viridans streptococci (VS) are commensal bacteria of
the human oral cavity, the respiratory, the gastrointestinal and the
genitourinary tract. On the other hand, they are responsible for several
systemic diseases including bacteraemia. The aim of the present study
was to identify clinically relevant VS isolated from blood cultures to the
species level, determine their susceptibilities to different antimicrobial
agents and analyse the macrolide resistance mechanisms.
Methods: A total of 51 strains of VS were recovered from blood
cultures from March 2004 to July 2006. The isolates were identiﬁed
with phenotypic and genotypic methods. Phenotypic classiﬁcation of
erythromycin resistance were determined by double-disk diffusion test.
All strains were characterised by PCR to detect the presence of mef(A),
erm(B) and erm(A) genes.
Results: 37 strains were identiﬁed as mitis group; 10 as anginosus
group and 4 strains as salivarius group by PCR. The comparison
of the species identiﬁcation results of the phenotypic and genotypic
identiﬁcation systems showed a consistency of 94% on the group level.
Macrolide resistance was found in nearly 40% of all strains with typical
resistance mechanism and only one S. salivarius showed a high penicillin
resistance.
Conclusions: The present study has shown a preponderance of mitis
group species and indicate that the ID 32 STREP is an acceptable method
for the identiﬁcation VS on a group level while the species-speciﬁc
differentiations were not reliable. The differentiation of the mitis group
species still remained difﬁcult. The high macrolide resistance indicate
that macrolides can not be considered an optimal alternative to penicillin
in the treatment of VS infections.
P990 Presence of plasmid pA15 correlates with prevalence of
constitutive MLSB resistance in group A Streptococci
isolates at a university hospital in southern Taiwan
Y-F. Liu, H-M. Fu, H-M. Wu, R.P. Janapatle, C-H. Wang, J-J. Wu
(Tainan, TW)
Background: In streptococci resistance gene erm mediates high level
macrolide, lincosamide and group B streptogramins (MLSB) resistance.
In mid 1990s constitutive MLSB resistance phenotype was replaced by
M phenotype in group A streptococci (GAS) clinical isolates in southern
Taiwan. Our lab collection of GAS isolates from 1990 to 2006 consists of
the 215 erythromycin resistance isolates, 56 were with MIC 256mg/mL
and 159 with MIC< 256mg/mL.
Objective: To determine the mechanism and prevalence rate of
erythromycin resistance mediated by plasmid and transferability of the
plasmid.
Methods: Colony blot hybridisation, PCR, plasmid curing and
transformation and PFGE techniques were used in our study.
Results: By using zeta gene of GAS plasmid pSM19035 as a probe and
restriction enzyme digestion analysis we found that in the 56 isolates
with high erythromycin resistance 53 isolates harbour a plasmid, pA15,
of 19 kb, in one isolate a plasmid pA768, of 16 kb was detected and in the
remaining two isolates plasmid was not detected. We observed that ermB
was on pA15 and it confers constitutive MLSB resistance phenotype.
Prevalence rate of the pA15 harbouring erythromycin resistance isolates
was high in 1993 (60%), 1994 (36%) and 1996 (33%), but the plasmid
could not be detected from 2004 to 2006. To link the high level resistance
to the pA15, clinical isolate A15 was selected and pA15 was cured by
novobiocin. In the plasmid cured isolate SW503, the erythromycin MIC
decreased from 256mg/mL to 0.032mg/mL. By electroporation pA15
was introduced into plasmid cured erythromycin sensitive isolate and we
found that high level erythromycin resistance was restored. Interestingly,
pA15 was also transferred to GBS and GCS by electroporation, acquiring
erythromycin resistance. In all the pA15 containing isolates emm1 type
was present and pulse type J was predominant (48 of 54 isolates) which
demonstrates that these isolates had evolved from a single clone.
Conclusion: the plasmid pA15 mediated cMLSB resistance in mid
1990s, but pA15 cannot be detected from 2004 in the clinical isolates,
which correlates with the absence of cMLSB resistance in this region.
P991 Serotypes distribution and gene homology of penicillin-
nonsusceptible Streptococcus pneumoniae isolated from
children in Beijing, China, 2000–2004
K. Yao, X. Shen, S. Yu, Y. Yang (Beijing, CN)
Objective: The study was designed to investigate the situation of antibi-
otic resistance and serotypes distribution, as well as the genetic homology
of penicillin-nonsusceptible Streptococcus pneumoniae (PNSP) isolated
from children in Beijing, China from 2000 to 2004.
Method: Nasopharageal swab specimens were collected from children
up to 5-year-old with upper respiratory infection. The antibiotic
susceptibility was tested by E-test MIC method. The serotypes were
tested by simpliﬁed chessboard system. Chromosomal macrorestriction
patterns of the strains isolated from 2000 to 2002 were detected by
PFGE.
Results: One hundred and twenty-nine PNSP strains were collected.
Seven serotypes were identiﬁed, which covered 104 strains. The other
25 strains could not typed by the system. There were 99 strains (76.7%)
covered by the common serotypes 19, 23, 6 and 14. From 2000 to 2004,
the isolates of serotype 19 with higher penicillin MIC was increasing
when the isolates of serogroup 23 with lower penicillin MIC was
decreasing. The covering rate of the heptavalent conjugate vaccine in
total strains was about 76.7%. Two clones, P.01 and P.02, deﬁned by the
PFGE detection, were founded in the serogroup 23. The strains included
in the two types, which accounted for 70.8% (17/24) of the group, were
isolated mainly in 2000 and 2001 and 0.19mg/mL for penicillin MIC
value. Meanwhile, about 62.5% of serogroup 19 strains were0.5mg/mL
for penicillin MIC value, and 62.5% of the group were nonsusceptible to
cefrotaxime, cefaclor and/or cefrotriaxone. Three clones, P.03, P.04 and
P.05, were founded in the serogroup 19. The strains covered by the P.03,
which accounted for 31.3% (5/16) of the group were isolated mainly in
2002 and most of them were resistant to penicillin.
Conclusions: The data on serotype prevalence could be a useful guide to
application of the vaccine, which should be an effective way in Beijing
to control the carriage, infection and spreading of PNSP. The higher
penicillin resistant clones isolated in latest period are not developed
from the lower resistant clones spreading in the early study stage.
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P992 Streptococcus pneumoniae strains isolated from laboratory
animals and pets
M. van der Linden, A. Al-Lahham, I. Seegmu¨ller, W. Nicklas, P. Kopp,
R. Reinert (Aachen, DE; Amman, JO; Heidelberg, Ludwigsburg, DE)
Objectives: Streptococcus pneumoniae is the major causative pathogen
of many childhood community-acquired respiratory tract infections
(RTIs), including community-acquired pneumonia, acute otitis media
and acute maxillary sinusitis. In the present study S. pneumoniae
strains isolated from mastomys, guinea pigs, mice, rats and a cat were
characterised.
Methods: Species diagnosis was performed using optochin- and bile
solubility testing. Serotyping was performed using the Neufeld Quellung
reaction. MICs to antibiotics were determined with the microdilution
method according to the CLSI recommendations. Multilocus Sequence
Typing was performed according to standard methods.
Results: Between 1986 and 2006 S. pneumoniae was isolated from 33
laboratory animals during routine control checks in the animal facility
in the German Cancer Research Center and 2 pets treated in a medical
veterinary laboratory. Isolates were obtained from mastomys (n = 24),
rats (n = 4), guinea pigs (n = 3), mice (n = 3) and a cat. S. pneumoniae
were isolated from nose, lung, trachea, abdomen and eye. Only four
animals showed disease symptoms. Two guinea pigs were C4-immune
deﬁcient and suffered from severe peritonitis. The third guinea pig and
the cat were pets and had severe respiratory problems. Serotypes detected
were: 14 (n = 29), 19F (n = 3), 33A (n = 2) and 7C (n = 1). One isolate
was rough and two were non typable. The guinea pigs isolates had
serotypes 19F. All isolates were sensitive to penicillin, telithromycin
and levoﬂoxacin. One isolate was clarithromycin resistant. Twenty-six
isolates were ST 15 (serotype 14 and n.t.) a sequence type commonly
found in human isolates. The cat isolate was ST 180 (serotype 3). Twelve
isolates had new MLS-types, seven of which are close variants of known
MLSTs. The three guinea pig isolates showed the same completely new
combination of known alleles.
Conclusions: S. pneumoniae strains could be routinely isolated from
non-human hosts, showing animals to be a reservoir for S. pneumoniae.
P993 High prevalence and persistence of the Streptococcus
pneumoniae Taiwan19F-14 clone among children in Greece
A. Mavroidi, I. Paraskakis, A. Pangalis, E. Kirikou, A. Charisiadou,
T. Athanasiou, P. Tassios, L. Tzouvelekis (London, UK; Athens, GR)
Objectives: Molecular characterisation of the multi-drug resistant
serotype 19F Streptococcus pneumoniae strains, prevalent amongst
Greek children during 2001–2006, i.e. before and after introduction of
the heptavalent vaccine in 2004.
Methods: A representative subset of 143 of 241 (34%) serotype 19F
pneumococci from invasive (IPD), non-invasive infections (NIPD)
and healthy children during January 2001–April 2006 were studied
with respect to antimicrobial susceptibility (penicillin, amoxicillin,
cefotaxime, erythromycin, clindamycin, co-trimoxazole, tetracycline,
chloramphenicol, rifampicin, oﬂoxacin), by disk diffusion and E-test,
and subtyped by PFGE and MLST.
Results: Serotype 19F – representing 31.8% and 26.0% of all
pneumococcal isolates from children during 2001–2004 and 2005–2006,
respectively – was a leading cause of NIPD in both periods, and more
important in IPD in the second (19% vs. 6.5%; chi2 = 6.51, p< 0.02).
Apart from 18 fully susceptible isolates, the remaining 125 (87.4%) were
resistant to three or more antimicrobial classes (MDR). PFGE yielded
18 types (a total of 55 subtypes); 93% of all isolates belonged to only
eight types. The dominant type, G (110 isolates, of which 55 belonged
to one of 30 subtypes), had been seen ﬁrst in 1996, in a common
UK-Greek erythromycin-resistant clone. All type G isolates were MDR
(including resistant to erythromycin and non-susceptible to penicillin
(PNS)), in contrast to only 15 (45%) of the remaining 33 isolates
(chi2 = 68.64, p< 0.001). Thirteen (12%) of the PNS isolates also showed
decreased susceptibility or resistance to cefotaxime (MIC 2−8mg/L).
MLST followed by eBURST analysis identiﬁed 12 STs – of which
ﬁve were novel – grouped in six clonal complexes (CC). PFGE type G
isolates were either ST236, corresponding to the Taiwan19F-14 (CC271)
international clone, or one of four new single locus variants (SLV). A
novel SLV of ST177 was also found.
Conclusion: First observed in Greece in 1996, the Taiwan19F-14
(CC271) international clone – so far considered minor in Europe – has
now become dominant amongst Greek paediatric S. pneumoniae, even
after introduction of the heptavalent vaccine in 2004. Over 75% of these
isolates belonged to CC271 and a single PFGE type, yet both phenotypic
and genotypic variation suggest a locally actively evolving clone.
P994 Characterisation of ﬂuoroquinolone non-susceptible clinical
isolates of Streptococcus pneumoniae in Germany: 1992–2005
A. Al-Lahham, M. van der Linden, C. Heeg, I. Seegmueller, R. Reinert
(Amman, JO; Aachen, DE)
Objectives: S. pneumoniae belongs to the main human infectious agents
worldwide. In several nationwide studies on resistance development in
pneumococcal disease ﬂuoroquinolone resistant pneumococcal isolates
were collected and charachterised.
Methods: Strains were serotyped using Neufeld’s Quellungreaction
and MICs of penicillin G (PEN), cefotaxime (CEF), amoxicillen
(AMOX), erythromycin A (ERY), clindamycin (CLI), tetracycline
(TET), ciproﬂoxacin (CIP), levoﬂoxacin (LEV), sparﬂoxacin (SPA),
grepaﬂoxacin (GRE), clinaﬂoxacin (CLX), moxiﬂoxacin (MOX), gat-
iﬂoxacin (GAT) and gemiﬂoxacin (GEM) were determined using the
microdilution method according to the CLSI guidelines. Fluoroquinolone
resistant genotypes were checked using PCR followed by DNA-
sequencing of gyrA, gyrB, parC and parE according to standard methods.
MLST was performed according to standard methods.
Results: Between Jan. 1992 and Dec. 2005, 13.230 isolates from 315
laboratories were included in this study. A total of 42 ﬂuoroquinolone
resistant strains (MIC CIP >2mg/mL) were identiﬁed (0.2−1.2%). The
predominant serotypes were 6A (14.3%), 6B (11.9%) and 9V, 23F
and 11A (7.1% each). MIC50 and MIC90 for 17 different antibiotics
were as follows (mg/mL): Penicillin (0.016, 1), cefotaxime (0.016, 1),
amoxicillin (0.016, 0.5), erythromycin (0.125, 32), clindamycin (0.125,
32), tetracycline (0.5, 32), chloramphenicole (<4, <4), telithromycin
(0.016, 0.016), quinupristin-dalfopristin (1, 1), ciproﬂoxacin (16, >32),
levoﬂoxacin (4, 32), sparﬂoxacin (4, 32), grepaﬂoxacin (1, 32),
clinaﬂoxacin (0.25, 0.5), moxiﬂoxacin (0.25, 4), gatiﬂoxacin (1, 4) and
gemiﬂoxacin (0.125, 2). Predominant mutations were S81F (11.9%) and
S114G (11.9%) for gyr(A), S79F (33.3%) and S79Y (23.8%) for par(C)
and I460V (47.8%) for par(E). One isolate possesses a combination of
both gyr(A) (E85G) and gyr(B) (R571T) mutations. A fourfold reduction
of the ciproﬂoxacin MIC in the presence of reserpine was only observed
in 14 isolates. In multi locus sequence typing, 4 clones were observed
for the ﬁrst time in Germany ST1551, ST1983, ST2007, and ST2008.
Conclusions: The overall incidence of ﬂuoroquinolone resistance in
Germany remains low, nevertheless the spread of FQ resistance to multi-
drug resistant clones with worldwide distribution is worrisome. A clonal
relatedness of strains could not be afﬁrmed using MLST.
P995 Characterisation of the genetic structure of the invasive
macrolide-resistant pneumococci in Portugal
R. Dias, D. Fe´lix, C. Pissarra, M. Canic¸a on behalf of the
Antimicrobial Resistance Surveillance Program in Portugal (ARSIP)
Objectives: The Streptococcus pneumoniae resistant to macrolides had
increased consistently in Portugal since 1997, mainly associated to the
consumption of that drug. To a better understand about the increase of
this resistance, a molecular study was undertaken to characterise the
genetic structure of the macrolide resistant strains.
Methods: A total of 191 invasive S. pneumoniae strains resistant to
macrolides were recovered from 1994 to 2004 in 24 hospitals and
public health institutions across Portugal. Genetic characterisation was
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undertaken by PFGE (n = 186) and MLST (n = 73). Genetic Clustering
was performed by PFGE; one strain from each cluster was randomly
chosen to be further characterised by MLST (with selection of a greater
number of isolates for larger PFGE clusters). Linage assignment was
performed by e-BURST analysis.
Results: The combination of PFGE and MLST data, permitted to
identify the genetic lineages of the majority of macrolide resistant
isolates. We found 41 Sequence Types (ST) integrated in 16 clonal
complexes (CC) and 4 singletons. In this study, 24 STs were also found
elsewhere and 17 were described only in Portugal including 13 novel STs.
Seven Pneumococcal Molecular Epidemiology Network (PMEN) clones
were found and 10 STs were Single Locus Variant of PMEN clones.
In the period 1994–1998, were found different CCs, with the following
putative founders: ST156, ST15, ST90, ST63, ST81, ST315, and ST97.
In the following years (1999–2004), in which was observed an increase
of macrolide resistance, we identiﬁed the main previous CCs, and the
emergence of new ones, with the following putative founders: ST230,
ST177, ST717, ST193, ST176, ST90, ST180, ST191, ST88 and ST271.
It was also observed the emergence of new single genetic lineages such
as: ST2360, ST2357 and ST2359. However, in the period 2002–2004
the ST180 and ST191 disappeared and the number of isolates from the
ST315 decreased signiﬁcantly. Among the CCs, which emerged within
the macrolide resistance, 5 were described as susceptible in the earlier
years; 2 were described internationally in resistant strains and 3 were
described in both susceptible and resistant strains.
Conclusion: Our results suggest that macrolide resistance among
pneumococci increased in Portugal due to the expansion of clonal
complexes (which appeared before the emergence of macrolide), and
due to the acquisition of resistance by susceptible circulating clones and
to the import of international resistant clones.
P996 Pneumococcal invasive isolates of non-vaccine serotypes in
Italy, 1999–2003 (pre-vaccine era)
G. Gherardi, M. Monaco, R. Camilli, F. D’Ambrosio, P. D’Ancona,
R. Manganelli, G. Dicuonzo, A. Pantosti (Rome, Padua, IT)
Objectives: The introduction of the 7-valent conjugate vaccine (PCV7)
for children has caused a dramatic decrease of pneumococcal infections
due to vaccine serotypes (VS) and a relative increase of infections due to
vaccine-related (VRS) or non-vaccine serotypes (NVS). The aim of this
study was to characterise invasive pneumococci belonging to serotypes
non included in PCV7 before the implementation of this vaccine in Italy.
Methods: All pneumococcal invasive isolates recovered from children
and adults in an Italian nation-wide surveillance in 1999–2003 were
studied. All isolates were serotyped and examined for susceptibility
to penicillin, cefotaxime, erythromycin, clindamycin, tetracycline and
chloramphenicol following the CLSI standard procedures. Pulsed-Field
Gel Electrophoresis and Multilocus Sequence Typing (MLST) were
used to deﬁne clonal groups among penicillin non-susceptible (PNSSP)
and/or multi-drug resistant isolates and selected susceptible isolates.
The sequence types (ST) were related to those reported in the MLST
website (www.mlst.net) and described in the Pneumococcal Molecular
Epidemiology Network (PMEN) as international clones.
Results: Among 790 invasive isolates, mostly obtained from adult
patients, 392 (49.6%) belonged to VS; the other group included isolates
belonging to VRS (93 isolates), to NVS (297 isolates) or that were non-
typable (8 isolates). Among these isolates, 19 (5.7%) were PNSSP, all
in the intermediate range, and 63 (15.8%) were erythromycin-resistant.
The most prevalent serotypes, were 6A, and 19A among VRS and 1,
3, 7F, 8, 10A, 11A, 12F, 15B/C, 20 and 22F among NVS. Among the
PNSSP the most frequent serotypes were 19A and 35F (5 isolates each).
Several PMEN clones were identiﬁed, such as Sweden15A-25/ST63,
Greece21−30/ST193, Netherlands3−31/ST180, Netherlands8−33/ST53,
Netherlands15B-37/ST199, Netherlands7F-39/ST191 and Sweden1−40/
ST304. Some cases of capsular switching were detected. Some isolates
belonged to clonal groups that had not been previously identiﬁed, such
as serotype 15B/C isolates (ST1577) and serotype 6A isolates (ST675
and ST1833).
Conclusions: In the pre-vaccine era, serotypes not contained in PCV7
(VRS or NVS) show a lower rate of penicillin or erythromycin resistance
than VS. Both international clones and newly-described clones were
detected and capsular switching was observed. Future monitoring of
serotypes and clones in the vaccine era is of paramount importance.
P997 Population structure of Spanish mef-PCR positive
Streptococcus pneumoniae clinical isolates
E. Go´mez G-de la Pedrosa, M. van der Linden, M.I. Morosini,
J.C. Gala´n, F. Baquero, R.R. Reinert, R. Canto´n (Madrid, ES; Aachen,
DE)
Objectives: To determine the population structure of a collection of
mef-PCR positive Streptococcus pneumoniae clinical isolates recovered
in different Spanish hospitals. Prevalence of associated erythromycin
resistance determinants and phenotypes were also screened.
Methods: A PCR assay was performed to identify erythromycin
resistance genes (ermB or mef) in a collection of 712 clinical isolates
recovered in Spain from 1999 through 2003. All mef-PCR positive
S. pneumoniae strains (n = 46) were selected for further population
structure analysis (serotyping with Neufeld’s Quellung method, PFGE
with SmaI digestion, and MLST with the standard 7 housekeeping
loci scheme). Susceptibility testing was performed by the standard
microdilution technique (CLSI) and resistance phenotypes by diffusion
assay using commercial erythromycin, clindamycin, and rokitamycin
disks. A multiplex-PCR was designed to distinguish between mef(A)
and mef(E). msr(D) determinant (mel gene) was also detected by PCR.
Results: Resistance values among 46 selected mef positive isolates were:
penicillin, 67.3% (intermediate + resistant), clindamycin, 52.2%, and
tetracycline 56.5%. No telithromycin resistance was found (MIC range,
0.03−1mg/L) but one isolate was resistant to levoﬂoxacin (MIC, 8mg/L).
Interestingly, 4 mef positive isolates (8.7%) showed erythromycin
MICs in the susceptible range (0.12mg/L), but increased 32mg/L
endowing the M phenotype when plated on increased concentrations of
erythromycin. The M and MLSB phenotypes in erythromycin resistant
isolates were observed in 45.2% and 54.72% of isolates, respectively.
The presence of both erm and mef determinants was found in 50%
of isolates. All mef determinants belonged to mef(E) subclass and
all isolates presented the msr(D) gene. Serotype distribution was as
follows: 14, 21.7%; 19F, 19.5%; 19A, 15.2%; 6B, 6.5%; 9V 6.5%; and
others, 30.6%. Most isolates belonging to the same serotype showed
similar PFGE patterns. England^14−9 and Taiwan^19F-14 multiresistant
clonal complexes were represented within mef positive isolates and
Spain^23F-1, Poland^6B-20, Sweden^15A-25 and Spain 6B among erm
and mef positive isolates.
Conclusions: A high proportion of S. pneumoniae isolates harbouring
the mef gene in our collection also presents the ermB determinant.
Nearly all of them displayed the MLSB phenotype. A complex
population structure was found in our mef positive S. pneumoniae
collection.
P998 Antimicrobial resistance patterns and genotypes of
Streptococcus agalactiae and Streptococcus dysgalactiae ssp.
dysgalactiae from bovine mastitis in Portuguese dairy farms
M. Rato, D. Rolo, R. Bexiga, S.F. Nunes, L.M. Cavaco, C.L. Vilela,
I. Santos-Sanches (Caparica, PT; Glasgow, Cambridge, UK; Lisbon, PT)
Objectives: To evaluate the proﬁles of antimicrobial (ATB) resistance
and genotypes of the contagious bovine mastitis pathogen Streptococcus
agalactiae (GBS) and of Streptococcus dysgalactiae ssp. dysgalactiae
(GCS), which is considered to be either a contagious or an environmental
bovine pathogen.
Methods: Among 459 milk samples collected during 2002/2003 from
mastitis quarters of 377 bovines in 11 Portuguese herds, 13.9% of
the bacteria were GBS and 3.7% were GCS. A total of 32 GBS
and 17 GCS of these ﬁeld isolates were studied. ATB resistance was
evaluated by disk diffusion against macrolides-M (erythromycin-E),
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lincosamides-L (pirlimycin-PRL) and tetracycline-T. The ATB resistance
genes tet(M), tet(O), tet(W), tet(L), tet(Q), tet(K), tet(S), mef(A), erm(A)
and erm(B) were detected by PCR. The human pathogen S. pyogenes
(GAS) virulence phage-encoded speA, speC and ssa genes were also
tested by PCR in all GCS. Clonality among isolates was evaluated
by pulsed ﬁeld gel electrophoresis (PFGE). GBS representative clones,
deﬁned by PFGE, were further characterised by Multi Locus Sequence
Typing for identiﬁcation of Sequence Types (ST) and of Single and
Double Locus Variants (SLV and DLV) of ST common in human isolates.
Results: Resistance to E was 21.9% in GBS and 23.5% in GCS, while
resistance to PRL was 21.9% in GBS and 35.3% in GCS. Resistance to
T was 65.6% in GBS and 100% in GCS. Three GCS resistant to E and
T carry erm(B)/tet(O), six GBS carry erm(B)/tet(O)/tet(K) and one GCS
carries erm(A)/tet(M). Most (79%) GCS and GBS resistant only to T
carry tet(M), tet(O), tet(K) or tet(S). Out of the 20 GBS clones, six were
herd-speciﬁc and none was disseminated in more than one herd. Out of
the 15 GCS clones only one was herd-speciﬁc and one was disseminated
in two herds. Among the 17 GCS, 29.4% are speC-positive and all are
speA/ssa-negative. The six GBS representative strains were of ST-2 and
ST-61. ST-2 is a SLV of ST-1 and ST-61 is a DLV of ST-17 and ST-18,
all of human origin.
Conclusion: Results conﬁrmed the contagious nature of GBS and
suggested an environmental origin of GCS in the Portuguese herds.
A putative novel phenotype of susceptibility to M and resistance to
L was detected in GCS. To our knowledge, tet(S) and tet(K) genes,
detected among this collection, were not reported yet in bovine GBS and
GCS. The ﬁnding of speC in bovine GCS suggests that GAS prophages
may also be critical contributors to animal GCS genetic diversity and
virulence.
P999 Molecular characterisation of Streptococcus pneumoniae
strains isolated from children with acute otitis media in
Barcelona (1992–2005)
C. Ardanuy, A. Gene´, L. Calatayud, E. Palacı´n, A. Fenoll, J. Lin˜ares
(Barcelona, Esplugues de Llobregat, Majadahonda, ES)
Objectives: S. pneumoniae (Spn) is a frequent cause of acute otitis
media (AOM) in children. The aims of this study were: (a) To analyse
the distribution of Spn clones causing AOM in children in Barcelona
(1992–2005). (b) To analyse the impact of the heptavalent pneumococcal
conjugated vaccine (PCV7).
Methods: Three hundred and twenty pneumococci isolated from children
(1992–2005) with AOM were studied. Serotyping was performed by
Quellung reaction. The antibiotic susceptibility was performed by agar
dilution and disk-diffusion methods to penicillin (PEN), erythromycin,
clindamycin, tetracycline, chloramphenicol and cotrimoxazole. The
isolates were typed by PFGE (SmaI and/or ApaI). Representative isolates
of each dominant clone were studied by MLST.
Results: The most frequent serogroups were: 19 (31%), 6 (23%),
14 (14%), 23 (11%) and 3 (6%). Among 300 pneumococci studied
by PFGE, 114 different band patterns were found. Four multiresistant
clones, Spain6B-2 (14%), Spain9V-3 (12%), clone ST88 of serotype 19F
(9%) and Spain23F-1 (9%) accounted for 44% of strains. Among
221 PEN-R Spn, 66 different PFGE patterns were found. Eight
of them (Spain6B-2, Spain9V-3, ST88 clone of serotype 19F,
Spain23F-1, Sweden15A-25, Spain14−5, Poland6B-20, and ST276 clone
of serotype 19A) accounted for 73.7% of PEN-R strains. Among
79 PEN-S strains, 52 PFGE patterns were found, 39 (49%) of
them had a single isolate. Multidrug-resistance was observed in 81%
of PEN-R strains and 17% of PEN-S strains (p< 0.001). Capsular
switching was observed in three clones: Spain9V-3 (25/36 were
serotype 14 and 1/36 was serogroup 19); Spain23F-1 clone (3/26 were
serogroup 19); Sweden15A-25 clone (10/13 were serogroup 19 and 1/13
was serotype 23F). Comparing 1996–2000 and 2001–2005 periods the
following changes were observed: (1) A decrease in the rate of PEN-R
isolates (76% vs 61%). (2) A decrease in the vaccine serotypes (6B,
14, 23F). (3) An increase in the vaccine-related serotype 19A. (4) A
signiﬁcant decrease of Spain6B-2 clone (17% vs 4%), Spain23F-1 clone
(11.0 vs 1.3) and ST88 clone of serotype 19F (9% vs. 4%) observed.
(5) The emergence of a new clone related to serotype 19A (ST276) (0%
vs 5%).
Conclusion: The proportion of episodes of AOM caused by PEN-R Spn
decreased after the introduction of the PCV7 in Barcelona, coinciding
with a decrease of multiR clones of vaccine related serotypes. Capsular
switching was frequently observed.
P1000 Molecular characterisation of penicillin non-susceptible
invasive strains of Streptococcus pneumoniae prevalent in
the Czech Republic
V. Jakubu, H. Zemlickova, P. Urbaskova, J. Kasik (Prague, CZ)
Objectives: To study the clonal diversity of penicillin non-susceptible
invasive strains of S. pneumoniae isolated in the Czech Republic. By
use of multilocus sequence typing (MLST) the present study allow to
determine the epidemiological relationship between the various PNSP
serotypes and establish the prevalence of international penicillin-resistant
clones in the Czech Republic.
Methods: All strains (n = 1054) isolated from blood or cerebrospinal
ﬂuid between 1996 to 2004 were submitted to the National Institute
of Public Health by 63 microbiology labs from 45 cities. Serotyping
was performed by Quellung reaction and the minimal inhibitory
concentrations (MICs) of penicillin, erythromycin, tetracycline and
chloramphenicol were determined by CLSI broth microdilution method
among all submitted strains. All viable PNSP isolates (n = 37) were
analysed further by MLST.
Results: Overall 38 (3.5%) of strains had reduced susceptibility to
penicillin but only ﬁve of these were highly resistant. The prevalence
rate of invasive S. pneumoniae strains with reduced susceptibility to
penicillin remains stable for the study period. The PNSP serotypes were
as follows: 9V (26), 23F (4), 14 (3), 6B (2), 19A (1), 19F (1) and 22F (1).
Except of decreased susceptibility to penicillin, some strains were also
concomitantly resistant to other antibiotics tested. Twelve (31.6%) of
PNSP strains were resistant to erythromycin, ﬁve (13.2% both) of strains
were resistant to tetracycline and chloramphenicol. MLST typing has
been performed on 37 of viable PNSP isolates. Isolates harbouring STs
identical to that of two globally spread penicillin resistant clones of
S. pneumoniae, Spain^9V-3 and Spain^23F-1, were detected among
isolates of serotype 9V, 14, 22F and 23F, respectively. Sequence type
(ST) 271, the single locus variant (SLV) of the Taiwan^19F-14 clone
(ST 236) was found in one isolate of 19F serotype. Two 6B isolates
were not related to any major international drug-resistant clones already
described.
Conclusion: Despite the low prevalence of penicillin non-susceptible
S. pneumoniae in the Czech Republic, multidrug resistant clones, which
attribute to high rates of resistance to b-lactams in many countries, were
identiﬁed in our country. The Spain^9V-3 clone (ST 156) to have a
major contribution among our invasive PNSP. Apparently, the genetic
background of this clone is not restricted to serotype 9V, but is also
disseminated within serotype 14 and 22F.
P1001 Clonal relationships of Streptococcus pneumoniae isolates
harbouring multiple antibiotic resistance from Belgium
F.P. O’Hara, J. Van Eldere, R. Mera, L. Miller, J. Poupard,
H. Amrine-Madsen (Collegeville, US; Leuven, BE; Research Triangle
Park, Philadelphia, US)
Objectives: Antibiotic resistance has been increasing in many European
countries and strains that are non-susceptible to two or more classes of
antibiotics (multiple resistance or MR) are particularly troubling. In order
to better understand the evolution of resistance in S. pneumoniae, we
have identiﬁed and characterised the clones present in isolates obtained
from a surveillance dataset collected in Belgium.
Methods: A sample of 190 S. pneumoniae isolates from 1997–2004
was selected at random from the larger Belgian surveillance set. For
each isolate, PCR was performed on seven housekeeping genes based on
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the universal Multi Locus Sequence Typing methods. Internal fragments
were sequenced, compared to published alleles, and assigned allele
numbers. Allele numbers were used to generate allelic proﬁles, which
were compared to published allelic proﬁles to determine a sequence
type (ST). The eBURST algorithm was used to assign STs to clonal
complexes (CCs).
Results: The 190 isolates contain 95 unique STs which are divided into
17 CCs and 44 singletons. The 62 MR isolates represent 31 sequence
types, but half of these are found within two major clonal complexes
(CC156 and CC81). MR is not evenly distributed among CCs; within
CCs, the rate of MR varies from 0% (CC53) to 100% (CC81). The clonal
composition of the S. pneumoniae population changed over time. In
1997–1999, two CCs, CC156 (representing the PMEN clone Spain9V-3)
and CC81 (representing the PMEN clone Spain23F-1), accounted for
25.8% and 13.4% of all isolates, respectively. By 2001–2004, the
frequencies of these CCs had dropped to 7.5% and 3.2%. In 1997–1999,
CC81 and CC156 accounted for 67.6% of all MR isolates. In 2001–
2004, those CCs accounted for only 28.6% of MR isolates. The clonal
structure of the different serotype groups varied. Of the 10 most common
serotype groups, four were highly clonal, while six contained a variety
of CCs representing genetically diverse STs. For example, serogroup 19
covered 7 CCs while serogroup 8 covered 1 CC. MR was much higher in
the genetically diverse serotype groups (48.4%) than in those that were
highly clonal (4.3%).
Conclusions: The PMEN clones Spain9V-3 and Spain 23F-1 decreased
from 1997–2004 in Belgium despite the level of MR increasing over
time. The frequency of CCs that harbour MR changes over time.
Serotype groups that are genetically diverse such as 19 are more likely
to harbour MR.
P1002 Streptococcus pneumoniae clonal relationships over time in
isolates from Belgian provinces bordering countries with
low and high levels of antibiotic resistance
H. Amrine-Madsen, J. Van Eldere, R. Mera, L. Miller, J. Poupard,
F.P. O’Hara (Research Triangle Park, US; Leuven, BE; Collegeville,
Philadelphia, US)
Objectives: Belgium is located between countries with low (Nether-
lands) or high (France) levels of antibiotic resistance. Border provinces
from Belgium afford a unique opportunity to look at the clonal structure
of isolates with non-susceptibility to two or more antibiotic classes
(multiple resistance) across time and place. The clonal distribution of
S. pneumoniae was analyzed in a sample of isolates collected from 1997–
2004 in Limburg which borders the Netherlands and West-Vlaanderen
which borders France.
Methods: A sample of 190 S. pneumoniae isolates collected in the
provinces of Limburg and West-Vlaanderen was selected at random
from a larger Belgian surveillance set. For each isolate, PCR was
performed on seven housekeeping genes based on the universal Multi
Locus Sequence Typing methods. Internal fragments were sequenced,
compared to published alleles, and assigned allele numbers. Allele
numbers were used to generate allelic proﬁles, which were compared
to published allelic proﬁles to determine a sequence type (ST). The
eBURST algorithm in conjunction with phylogenetic trees was used to
assign STs to clonal groups.
Results: The 190 isolates contain 95 unique STs which are divided into
24 clonal groups. More than half of all isolates are contained within
the 8 largest clonal groups. The vast majority of the clonal groups
occur in both Limburg and West-Vlaanderen, however, the frequency
of clones in each province is different. For example, clonal group 17
(representing the PMEN clone Spain 23F-1) is more likely to be present
in West-Vlaanderen (94%) than in Limburg (6%) as is clonal group 1
(representing the PMEN clone Spain 9V-3). The distribution of multiple
resistance (MR) varies across provinces and across clones with West-
Vlaanderen harbouring 77.4% of the MR and Limburg only 22.6%. The
variation in clonal group proportions explains much of the variation in
MR levels between the provinces.
Conclusions: Although the same clonal complexes of S. pneumoniae
are circulating in both Limburg and West-Vlaanderen, the frequency
of clones varies signiﬁcantly between the two provinces. A higher
proportion of clonal groups harbouring MR such as Spain 23F-1 and
Spain 9V-3 is seen in the Belgian province of West-Vlaanderen which
borders France than in the Belgian province of Limburg which borders
the Netherlands. There is evidence of a ﬂow of clones and resistance
from West-Vlaanderen to Limburg.
P1003 Macrolide resistance in Streptococcus pyogenes in the
United Kingdom is encoded by a variety of resistance
determinants associated with a small number of clones
G. Moore, K. McGregor (Slough, UK)
Objective: Identify and characterise the elements that harbour resistance
genes in a collection of Streptococcus pyogenes from the United
Kingdom.
Methods: The minimum inhibitory concentration of 17 antimicrobial
agents was determined by agar dilution for 119 S. pyogenes isolates
which had previously been characterised by MLST. PCR ampliﬁcation of
fragments of published resistance genes, their ﬂanking genes, resistance
element junction regions and chromosomal insertion sites was performed
using speciﬁc primers.
Results: The majority (77%) of isolates were susceptible to all of the
agents tested. Six isolates (5%) were resistant to erythromycin. Of
these, two isolates (both ST150, tetracycline susceptible and with a
M macrolide-resistance phenotype) harboured a mef(A) gene within a
Tn1207.3 element that had been inserted into the chromosomal comEC
gene. One isolate (ST36, and carrying tet(M)) demonstrated a cMLS
phenotype that was encoded by an erm(B) gene. The remaining three
isolates (one ST63-tet(O), two ST89-tet(M)) carried an erm(A) (subclass
erm(TR)) gene which gave rise to the iMLS phenotype. Analysis of the
genes ﬂanking the erm(TR) gene revealed that the two ST89 isolates
contain an element similar to the 48,853-bp erm(TR)-containing element
present in the genome of US isolate MGAS10750 (ST39). However,
while the ST63 isolate had the same DNA directly downstream of
erm(TR), the upstream DNA differed. Furthermore, unlike the US
isolate, the erm(TR) element in the UK strains did not insert into the
chromosomal hsdM gene. Twenty isolates were resistant to tetracycline
and erythromycin susceptible. A single ST63 isolate harboured tet(O),
and 19 isolates (representing 14 STs) harboured tet(M). Four isolates
(ST117-tet(M)) were resistant to rifampicin.
Conclusion: In this collection of S. pyogenes, macrolide resistance was
associated with four distinct resistance elements, including a previously
undescribed erm(TR)-containing element. The association of macrolide
resistance with a relatively small number of clones, in the UK and
other European countries, suggests that these clones may have a greater
propensity for acquiring resistance elements.
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P1004 Comparison of Acinetobacter baumannii from human and
animal isolates by pulsed-ﬁeld gel electrophoresis in Scotland
A. Hamouda, L. Vali, D. Walker, A. Mateus, J. Dave, A. Gibb,
S. Dancer (Edinburgh, Glasgow, UK)
Objectives: Several studies have shown that ﬂuoroquinolone (FQ) use
in food animals contributes to the selection of antimicrobial resistance
in zoonotic bacteria and poses a risk to humans. However, the main
problem in hospitals is not zoonotic bacteria but other species such
as Acinetobacter baumannii, Pseudomonas aeruginosa, and Methicillin
resistant Staphylococcus aureus. Preserving the efﬁcacy of FQ in the
treatment of A. baumannii infections in human is essential to reduce
the current dependence on the carbapenems. The purpose of this study
was to investigate a possible link between ciproﬂoxacin resistance in
A. baumannii clinical and animal isolates.
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Methods: A total of 264 samples collected from pig, cattle and sheep
were screened for A. baumannii. Five clinical isolates were obtained
from two Scottish hospitals. Acinetobacter selective medium was used
for isolation of this species. Suspected isolates were phenotypically
characterised by the API 20NE test, and identiﬁcation to the species level
was carried out by restriction analysis of the 16S-23S rRNA intergenic
spacer sequences (RAI16rRNA). The minimum inhibitory concentration
of antibiotics was determined by the agar dilution method following the
BSAC Guidelines. Pulsed-ﬁeld gel electrophoresis (PFGE) typing was
performed using ApaI restriction endonuclease.
Results: Out of 264 animal samples processed, 18 were conﬁrmed
as A. baumannii by RAI16rRNA. Two isolates were resistant to
ciproﬂoxacin and two were resistant to gentamicin. All isolates were
resistant to ampicillin, trimethoprim, chloramphenicol and tetracycline
but were sensitive to imipenem. Dendrogramme analysis showed that
most (8 out 9 and 6 out 8) A. baumannii isolated from pig and cattle
faecal samples respectively, fell into one major cluster. The clinical
isolates grouped in two different clusters and were much more closely
related to each other than to those of the animal isolate clusters.
Conclusion: This study has shown that PFGE revealed a certain degree
of heterogeneity among ciproﬂoxacin-resistant-A. baumannii from both
animal and human isolates, and that they were genetically different. It
has also shown that there was no correlation between PFGE proﬁle and
ciproﬂoxacin resistance in both animal and clinical isolates.
P1005 Resident OXA-51-like carbapenemases in Acinetobacter
baumannii: a useful marker for genotyping?
T. Giani, M.M. D’Andrea, R. Migliavacca, M. Spalla, E. Nucleo,
G. Fina, F. Luzzaro, L. Pagani, G.M. Rossolini (Siena, Pavia, Varese, IT)
Objectives: Multi drug resistant (MDR) Acinetobacter baumannii is a
problem of a great concern in nosocomial settings. Hospital outbreaks
have been described worldwide and this organism has become endemic in
some areas. Comparison of isolates obtained from different investigators
is not straightforward, mostly because requires the interchange of
isolates between laboratories and the standardisation of the genotyping
techniques used. Recently resident blaOXA-51 type determinants have
been proposed as a convenient marker for species identiﬁcation, in
alternative to previous molecular approaches. The aim of this study was
to investigate the correlation between OXA-51-like carbapenemases and
genotypes in a collection of A. baumannii isolates from Italian hospitals.
Methods: A. baumannii analyzed in this work included 151 clinical
isolates, collected from 14 different Italian hospitals. Identiﬁcation and
susceptibility testing were carried out following standard procedures.
Genotyping was carried out by RAPD, REP-PCR and PFGE analysis.
OXA-51-like determinants were investigated by PCR, followed by direct
amplicon sequencing.
Results: Genotyping analysis deﬁned 5 major clusters of MDR
A. baumannii, with consistent results using the various typing methods.
Each cluster was characterised by a speciﬁc resident blaOXA-51-
type carbapenemase, namely OXA-66, OXA-69, OXA-90, OXA-98 and
OXA-100. The last three are new variants which differ from OXA-51
by 4, 7 and 6 amino acids respectively.
Conclusions: Consistent relationship between the blaOXA-51-like
variants and genotyping results was found. Present results suggest that
OXA-51 typing could be a useful marker for genotyping of A. baumannii
clinical isolates.
This work was funded in part by the research grant “MIUR-PRIN
2005061894_004”.
P1006 Imported cases of carbapenem-resistant Acinetobacter
baumannii producing OXA-23 carbapenemase in Belgium:
characterisation and unusual loss of resistance
P. Bogaerts, T. Naas, C. Bauraing, A. Deplano, D. Pie´rard,
P. Nordmann, Y. Glupczynski (Yvoir, BE; Paris, FR; Brussels, BE)
Objectives: International travel contributes to the worldwide spread
of multi-drug resistant (MDR) bacterial strains. Carbapenems are
the drugs of choice for the treatment of nosocomial infections
due to MDR Acinetobacter baumannii (Ab). However, their efﬁcacy
is actually compromised through the emergence of carbapenem-
hydrolysing b-lactamases (CHBL) in that species. We report here, three
independent cases of CHBL OXA-23-producing Ab strains documented
after international travel and the unusual spontaneous loss of OXA-23
gene in the absence of any antibiotic treatment.
Methods: Over the last 24 months, three severely injured patients were
transferred from Cairo (Egypt), Cape Town and Johannesburg (South
Africa) to three unrelated hospitals in Belgium. Carbapenem-resistant
clinical isolates of Ab were recovered upon patient arrival and for one
patient 3 sequential isolates were obtained. The ﬁve strains were referred
centrally for molecular investigation of their resistance mechanism,
using DNA analysis, isoelectric focusing (IEF), conjugation assays and
PFGE. BlaIMP, blaVIM, blaOXA-23-like, blaOXA-26-like, blaOXA-51-
like, blaOXA-58 genes, blaTEM gene, blaAmpC and the presence of
ISAba1 inserted upstream of different genes were sought by PCR.
Results: All 5 MDR-Ab isolates were positive blaOXA-51-like and
blaAmpC genes and all but one were positive for blaOXA-23-like
genes. ISAba1 was detected upstream of blaAmpC, blaOXA-23-like and
blaOXA-51-like in 5, 4 and 1 isolates respectively. blaTEM was detected
in two isolates. Sequencing of the amplicons revealed identical blaOXA-
23 gene but different blaAmpC and blaOXA-51-like genes. Ab isolates
from the different patients were unrelated as shown by PFGE. For one
patient with a diagnosis of complicated urinary tract infection, the three
consecutive isolates presented identical PFGE patterns, though only the
two ﬁrst isolates were found blaOXA-23-positive. The third isolate was
susceptible to carbapenem by loss of the blaOXA-23 gene allowing the
patient to be successfully treated by meropenem.
Conclusions: Our data further support the role of inter-country transfer
in the spread of MDR-Ab and underline the importance of ISAba1
in the expression of b-lactam resistance genes. The spontaneous loss
of carbapenem resistance along with blaOXA-23 gene in the absence
of antibiotic treatment highlights the importance of judicious and well
controlled usage of antibiotics for such MDR isolates.
P1007 Plasmid location of blaOXA-40 gene in Acinetobacter
baumannii and Acinetobacter haemolyticus
S. Quinteira, F. Grosso, L. Peixe (Porto, PT)
Objectives: The aim of this work was to investigate the location and
genetic background of the carbapenem-hydrolysing oxacillinase gene
blaOXA-40 in Acinetobacter spp. isolated from a University Hospital
with a high rate of imipenem resistance, mainly due to the endemic
presence of the Iberian A. baumannii blaOXA-40 producing clone.
Methods: An isolate of A. baumannii and two A. haemolyticus
producing OXA-40 recovered from a University Hospital were studied.
Susceptibility to antibiotics was determined by standard agar diffusion
method and Etest. Carbapenemase producing strains were detected by a
bioassay using imipenem discs (10mg) with enzymatic extracts. Clonality
was established by PFGE. The presence and sequencing of blaOXA
gene was determined using the blaOXA-24-like primers. Sequencing of
ﬂanking regions of blaOXA-40 was conducted in plasmidic extracts.
Hybridisation assays were performed using blaOXA-40 probe after S1
nuclease digestion and plasmidic extraction. Furthermore, transfer of
resistance by conjugation and transformation assays was also attempted.
Results: The A. baumannii and the two A. haemolyticus isolates
presented resistance to imipenem, meropenem, ertapenem (MIC of
32mg/mL), to amoxicillin and its association with clavulanic acid, ure-
idopenicillins and their associations (MIC of 256mg/mL). Resistance
to ceftazidime, cefepime and aztreonam (MIC of 256mg/mL) was only
observed in the A. baumannii isolate.
Hybridisation experiments with blaOXA-40 probe in S1 nuclease
resulting bands and in plasmids extracts revealed a plasmid of about
30Kb carrying blaOXA-40 in the A. baumannii and the two clonally
related A. haemolyticus. These plasmids showed an identical sequence
upstream of blaOXA-40.
Epidemiology of resistant non-fermenters S269
Attempts to transfer resistance by conjugation of plasmid DNA into
either an A. baumannii or an E. coli recipient were unsuccessful.
Conclusions: In this study we describe a plasmidic location for the
blaOXA-40 gene in both an A. baumannii and A. haemolyticus isolates.
Although the spreading of OXA-40, both in the Iberian Peninsula and
France, has been correlated with the progressive dissemination of a single
A. baumannii clone, the observation of this enzyme in different genomic
species could be explained by a plasmid location.
The plasmid-mediated OXA-40 described in this study could contribute
to a rapid spread of carbapenem-resistance in Acinetobacter spp.
P1008 Epidemiology and mechanism of resistance of an outbreak
of multidrug-resistant Acinetobacter baumannii at in a
Lebanese hospital
A. Di Popolo, A.U. Khan, Z. Daoud, M. Bagattini, C. Aﬁf, M. Triassi,
N.I. Hakime´, R. Zarrilli (Naples, IT; Aligarh, IN; Beirut, LB)
An epidemiological study to investigate an outbreak of multidrug-
resistant Acinetobacter baumannii conducted at the Saint George
University Hospital, Beirut, Lebanon. The ﬁrst cases were observed in
November 2004, when A. baumannii was isolated from 17 patients, 11
from medical-surgical intensive care unit (ICU), 6 from other wards.
Since then, more than 30 cases were identiﬁed and the strain of
Acinetobacter baumannii became a frequent isolate in our lab.
Epidemiological data
Nr. Date of
admission
Date of
discharge
Age Gender Transfer
to ICU
(duration)
Intubation
(duration)
Recent
surgery
Previous
therapy
Clinical
presentation
of culprit
A. baumannii
1 25/11/04 16/11/05 35 M 26/11/04
(27 days)
Yes
(14 days)
Yes No previous
therapy
Effusion
2 06/12/04 26/01/05 85 M 06/12/04
(14 days)
Yes
(19 days)
No No previous
therapy
Pneumonia
(RTI)
3 18/12/04 27/12/04 77 M No No Yes No previous
therapy
Bacteraemia
(BSI)
4 14/12/04 26/12/04 64 M 14/12/04
(13 days)
Yes
(13 days)
Yes No previous
therapy
Pneumonia
(RTI)
5 05/01/05 Still in
hospital
44 F 05/01/05
(17 days)
Yes
(15 days)
Yes Antibiotic
Prophylaxis
Pneumonia
(RTI)
6 02/01/05 27/01/05 17 M 03/01/05
(11 days)
Yes
(8 days)
No No previous
therapy
Pneumonia
(RTI)
7 18/12/05 Still in
hospital
30 M Not in ICU No Yes Antibiotic
treatment
Abscess
8 27/11/04 08/02/05 66 M 27/01/05
(21 days)
Yes
(3 days)
Yes Antibiotic
treatment
Pneumonia
(RTI)
9 16/01/05 06/02/05 70 F 19/01/05
(14 days)
Yes
(9 days)
No Corticosteroids Pneumonia
(RTI)
10 15/02/05 23/02/05 86 M No Yes
(5 days)
Yes Corticosteroids Pneumonia
(RTI)
11 05/02/05 04/03/05 88 F 05/02/05
(10 days)
Yes
(2 days)
Yes Antibiotic
treatment
Pneumonia
(RTI)
12 29/01/05 Still in
hospital
79 F No No No No previous
therapy
UTI
13 02/02/05 17/03/05 75 F Yes (16 days) Yes
(15 days)
No Corticosteroids Pneumonia
(RTI)
14 14/03/05 Still in
hospital
57 M 14/03/05
(11 days)
Yes
(9 days)
No No previous
therapy
Wound
Infection
(SSI)
15 24/03/05 67 M No No Yes Antibiotic
treatment
Wound
Infection
(SSI)
16 24/09/04 26/01/04 64 F 24/09/04
(60 days)
Yes
(55 days)
Yes No previous
therapy
Pneumonia
(RTI)
17 01/04/05 Still in
hospital
71 M No No Yes Antibiotic
treatment
Pneumonia
(RTI)
Genotype analysis of all A. baumannii strains isolated during the
outbreak identiﬁed one major PFGE type B, that differed in more
than 6 bands from one additional strain isolated from ICU of the
hospital six months before (PFGE type A). All A. baumannii strains
of PFGE type B showed an identical multi-resistant antibiotype,
being susceptible to colistin and trimetropim-sulphomethoxazole, of
intermediate susceptibility to ampicillin-sulbactam and meropenem,
while resistant to all other antimicrobial tested. In these isolates,
inhibition of OXA enzymes by 200mM of NaCl reduced imipenem MIC
by up to 8-fold. Molecular analysis of antimicrobial resistance genes
showed that all epidemic A. baumannii strains harboured in their genomic
DNA a class 1 integron containing the aacA4, orfX, and blaOXA-20 gene
cassettes, an ampC gene and a blaoxa-51-like allele. Moreover, a blaoxa-
58 gene surrounded by regulatory insertion sequence elements ISAba1
and ISAba3 was identiﬁed in a 21 kb plasmid DNA from A. baumannii
strains of PFGE type B, but not PFGE type A. No ampliﬁcation products
were obtained from genomic DNA of epidemic strains of PFGE type B
for blaIMP-type, blaVIM-type or blaSIM-type metallo-b-lactamase genes
or blaoxa-23 or blaoxa-24 carbapenem-hydrolysing oxacillinases. Also,
both carbapenem-susceptible A. baumannii strains of PFGE type A and
carbapenem-resistant strains of PFGE type B expressed 26-kDa outer
membrane protein CarO. Conjugation experiments demonstrated that
resistance to imipenem, along with the blaoxa-58 gene, was transferred
from A. baumannii strains of PFGE type B to those of PFGE type A.
The selection and the spread between different wards of a single
A. baumannii clone producing OXA-58 carbapenem-hydrolysing oxacil-
linase were responsible for the increase of A. baumannii infections
that occurred in Saint George University Hospital of Beirut, Lebanon.
The epidemiologic pattern of the resistant organism vary from hospital
to hospital, and control measures or therapeutic approaches should be
customised to each institution.
P1009 Carbapenemase producing clinical isolates among
non-fermenting bacteria from a tertiary hospital
D. Perimeni, K. Trifynopoulou, P. Giakouppi, S. Vourli, A. Alevizos,
O. Zarkotou, I. Tsimettas, D. Gianneli, V. Kalapothaki, A. Vatopoulos
(Athens, Piraeus, GR)
Objectives: The aim of our study was to investigate the distribution of
metallo-b-lactamase producing strains and their molecular characteristics
in non fermenting bacteria isolated from clinical specimens from a
tertiary General Hospital in Piraeus, Greece in an 18-month period.
Methods: 110 strains of Pseudomonas aeruginosa and 57 strains of
Acinetobacter calcoaceticus baumannii have been obtained mainly from
blood and wound cultures, between 2002 and 2004. Antibiotic resistance
was identiﬁed by disc diffusion tests and by determination of the MICs.
All carbapenem-resistant P. aeruginosa and A. baumannii isolates were
tested for the possible presence of MBL by placing a home-made disc
containing 750 g EDTA 20mm away from one containing imipenem
10mg, conﬁrmed with E-test MBL combination strips when the
expansion was marginal. The presence of the carbapenemase-encoding
genes blaVIM-1 and blaVIM-2 was tested by PCR. Genomic DNA of
the blaVIM producing P. aeruginosa isolates, was digested with SpeI
enzyme and processed for typing by Pulsed-ﬁeld gel electrophoresis.
Results: 49 (44.5%) of P. aeruginosa and 24 (42%) of A. calco.
baumannii isolates were carbapenem resistant. Of those, after further
testing, 19 P. aeruginosa isolates were found to contain a blaVIM
gene, while no A. calco. baumannii strain carried a metallo-b-lactamase.
18 P. aeruginosa isolates carried a blaVIM-2 gene and PFGE analysis
showed a single pattern with two subtypes, while one strain carried a
blaVIM-1 gene. All blaVIM genes were located in class 1 integrons.
Conclusion: Almost 39% of the carbapenem resistant P. aeruginosa
isolates were blaVIM positive, while carbapenemase production did not
seem to contribute in the resistance of infections caused by carbapenem
resistant A. baumannii isolates in our hospital. The clonality of blaVIM-2
P. aeruginosa isolates implies that strict measures should be implemented
in order to control the further spread of resistance.
P1010 Increasing diversity of metallo-b-lactamases produced by
Gram-negative bacilli at a Korean hospital in 2006
C.K. Kim, E.M. Ko, J.H. Yum, D. Yong, K. Lee, Y. Chong (Seoul, KR)
Objectives: Carbapenems have been the most successful b-lactam
antibiotics in evading bacterial resistance. However, carbapenem-
resistant Gram-negative bacilli (GNB), particularly Pseudomonas spp.
and Acinetobacter spp., have been increasingly isolated at a Korean
hospital, and some of them produced VIM-2, IMP-1 and SIM-1 type
metallo-b-lactamases (MBLs). We determined trend of isolation of MBL
producing GNB in 2006.
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Methods: GNB were isolated from January to September, 2006, from
clinical specimens at a tertiary-care hospital in Seoul, Korea. Imipenem
susceptibility was tested by the CLSI disk diffusion test. Imipenem-
nonsusceptible isolates were screened for MBL production by the
imipenem-disk Hodge (cloverleaf) test, and a double disk synergy test
using imipenem disks and EDTA (750 ug) plus sodium mercaptoacetic
acid (SMA, 2mg)-containing disks. Screening-positive isolates were
further tested by PCR to detect blaIMP-1, blaSIM-1 and blaVIM-2
alleles.
Results: Alleles of MBL gene were detected in 13.4% (81 of 603) of
imipenem-nonsusceptible GNB isolates. It was interesting that 86.4%
(19 of 22) of imipenem-nonsusceptible P. putida isolate had MBL
genes. The types detected were blaVIM-2 in 50, blaIMP-1 in 26, and
blaSIM-1 in 5 isolates. Relatively more prevalent MBL types were
blaVIM-2 in P. aeruginosa (71.9%) and in P. putida (100%), blaIMP-1
in Acinetobacter sp. (56%). blaSIM-1 was detected only in A. baumannii
isolates. blaVIM-2 was detected ﬁrst time in one Ralstonia pickettii
isolate. Relative increase in blaIMP-1 was observed in P. aeruginosa,
blaIMP-1 and blaSIM-1 in Acinetobacter spp. The MBL types in
P. putida remained to be only blaVIM-2. MBL gene was not detected
in any of the imipenem-nonsusceptible isolates of 3 Achromobacter
xylosoxidans ssp. xylosoxydans, one each of Alcaligenes faecalis,
Enterobacter cloacae, Proteus mirabilis, Providencia rettgeri, and 4
Klebsiella pneumoniae. MBL-producing GNB were mostly isolated from
urine (42; 51.9%) and sputum (23; 28.4%), but 4 (4.9%) were from
blood.
Conclusion: MBL genes were detected in 13.4% of 603 imipenem-
nonsusceptible GNB isolates. Increasing diversity of MBL gene types
was noted in Acinetobacter spp. from which all three types of MBL
genes including blaSIM-1were detected.
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P1011 Carbapenem resistance in an epidemic CTX-M-15
b-lactamase-producing Escherichia coli strain in the United
Kingdom
E. Karisik, M.J. Ellington, R. Pike, M.F. Palepou, S. Mushtaq,
J.S. Cheesbrough, P. Wilkinson, D.M. Livermore, N. Woodford (London,
Preston, UK)
Objectives: E. coli strain A is the most widespread lineage with CTX-
M-15 b-lactamase in the UK, and is dominant among ESBL producers in
some locales. Cephalosporin MICs are lower than for most other isolates
with CTX-M-15 enzyme, owing to an IS26 element between blaCTX-
M-15 and its normal promoter. In one locale, this strain has additionally
acquired a CIT-type AmpC b-lactamase, conferring resistance to all
b-lactams except carbapenems and temocillin. We report here a further
variant from this centre, with ertapenem resistance.
Method: MICs were determined by BSAC methodology. XbaI-digested
genomic DNA proﬁles were compared by PFGE. Culture sonicates
were used for outer membrane protein (OMP) proﬁling by SDS-PAGE.
Beta-lactamase-encoding genes, including blaCTX-M and blaCIT, were
identiﬁed by PCR.
Results: An ertapenem-resistant E. coli (MIC 4mg/L) was isolated from
a catheter urine specimen from an 86-year-old female nursing-home
resident. She had had a catheter in situ for over 4 years, but had no
recent hospital admissions and minimal exposure to antibiotics, with
just one course of oral cephalexin in the preceding 12 months. None
of the other residents had received carbapenems in the home, though
they may have done so during periodic hospitalisations. This isolate
was resistant to most b-lactams including cephalosporin/clavulanate
combinations, ﬂuoroquinolones, and to aminoglycosides except gentam-
icin (MIC 1mg/L). Susceptibility to imipenem (MIC 1mg/L) and to
meropenem (MIC 0.5mg/L) were reduced compared with typical E. coli
strain A isolates. blaCTX-M-15 linked to IS26 was identiﬁed by PCR,
and PFGE conﬁrmed this isolate as being strain A. blaCIT was also
detected by PCR, correlating with the lack of cephalosporin/clavulanate
synergy. SDS-PAGE showed loss of OmpC.
Conclusion: We report ertapenem resistance in a representative of the
most successful CTX-M-15 b-lactamase-producing E. coli strain in
the UK; this may be explained by the loss of OmpC, together with
the production of AmpC and CTX-M-15 enzymes. The continuous
adaptation of epidemic strain A remains alarming, as treatment options
are further reduced.
P1012 First cases of infection with Escherichia coli containing
plasmid-mediated ﬂuoroquinolone resistance (qnrA and
qnrS) in Scandinavia
L.M. Cavaco, D.S. Hansen, F.M. Aarestrup, N. Frimodt-Møller
(Copenhagen, DK)
Objectives: To investigate plasmid mediated ﬂouroquinolone resistance
in human and animal E. coli strains in Denmark.
Methods: Escherichia coli strains from humans and swine in Denmark
were selected based on nalidixic acid resistance (MIC 32mg/L) or
low level resistance to ciproﬂoxacin (MIC 0.125mg/L). Screening for
qnrA, qnrB and qnrS genes was performed by PCR in pooled samples, on
strains with PCR positive strains were further tested for resistance genes
and transfer studies performed. Chromosomal mutations were detected
by PCR and sequencing of QRDR (quinolone resistance determining
regions) of topoisomerase genes.
Clinical data for each case was collected from the patient records.
Results: By screening of 130 strains by PCR for qnr genes, two positive
isolates were identiﬁed, one strain (H88) contained the qnrS gene,
another the qnrA gene (H93). Both strains showed low level ciproﬂoxacin
resistance (MICs = 0.5mg/L), although susceptible to nalidixic acid
(MICs = 4−8mg/L).
First case was an 88 year old woman who previously treated for breast
cancer, with recurrent pneumonia, that was admitted to the hospital on
suspicion of pneumonia and cystitis. An urine culture showed growth of
105 CFU/mL of an ESBL-producing multi-resistant E. coli (H88). The
patient was treated successfully with mecillinam orally and was returned
to the nursing home.
Second case was a 72 year old man with septicaemia and colon
cancer. From blood, an ESBL-producing multiresistant E. coli (H93)
was cultured. The patient was treated with i.v. piperacillin+tazobactam
and ciproﬂoxacin, on which he improved clinically and became afebrile.
During the subsequent months he deteriorated and ﬁnally succumbed to
his cancer disease.
Conclusion: These are to our best knowledge the ﬁrst two cases
of infections with plasmid mediated ﬂuoroquinolone resistant strains
reported from Denmark as well as from Scandinavia. In both cases
the isolates were ESBL-producing multi-resistant strains. The clinical
impact of this low level ﬂuoroquinolone resistance is difﬁcult to
assess, as the one patient treated with ciproﬂoxacin also received
piperacillin+tazobactam towards which the strain was found susceptible.
Further studies on optimisation of treatment in these cases are needed,
to avoid treatment failures and/or spread of resistance.
P1013 Detection and characterisation of ESBLs in German
Escherichia coli, isolated from animal, foods, and human
origin between 2001–2006
B. Guerra, M.D. Avsaroglu, E. Junker, A. Schroeter, L. Beutin,
R. Helmuth (Berlin, DE; Ankara, TR)
Objectives: Detection and characterisation of ESBLs in E. coli isolates,
from animal, foods, and human origin and isolated between 2001–2006.
Characterisation of the host structures.
Methods: About 2000 E. coli isolates (2001–2006) mostly from animal
and food origin have been analysed in the NRL-Salm (BfR) for
their susceptibility to 17 antimicrobial agents (including the b-lactams
ampicillin and ceftiofur, and amoxycillin/clavulanic acid) by broth
microdilution. Isolates showing ceftiofur-R were further tested for a
panel of 11 b-lactams by disc diffusion. According to the R-patterns
found, the strains were screened for different ESBL genes. The complete
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R-repertoire of the strains was characterised by molecular methods
(R-genes, class 1 and 2 integrons and mutations in the quinolone-R
determining regions). Strains were typed by XbaI-PFGE and plasmid
proﬁle analysis. Location of ESBLs was determined by hybridisation.
Results: Only two isolates were completely resistant (MIC 8mg/mL)
to ceftiofur. Three isolates showed intermediate resistance values
(MIC= 1−2mg/mL) and their resistance phenotypes to other b-lactams
indicated mechanisms different than ESBLs. The two resistant isolates
showed resistance patterns which suggested the presence of CTX-M
enzymes (cefotaxime 22 and 21mm, ceftriazone 20 and 17mm,
cefuroxime-R, cefpodoxime-R, aztreonam 25 and 26mm, respectively).
After PCR and sequencing CTX-M15 was found in one human
isolate (Ont:H4) which also showed resistance to kanamycin-neomycin,
nalidixic acid, ciproﬂoxacin, streptomycin, spectinomycin, sulfadiazine,
tetracycline, trimethoprim and trimethoprim/sulfamethoxazole. The other
isolate (Ont:H−) was isolated from milk from a cow with mastitis,
and carried CTX-M1. The strains showed different PFGE patterns
and plasmid proﬁles. Both CTX-M15 and CTX-M1 were located on
big plasmids (aprox. sizes 160–180 kb). These plasmids could not be
transferred.
Conclusions:While in many countries the presence and spread of ESBLs
is of concern, their prevalence still remains low among German E. coli
isolates. However, presence of ESBLs in multiresistant strains (more than
7 different classes of antimicrobials) including ﬂuoroquinolone resistance
is worrying and should be prevented by prudent use of extended-
spectrum b-lactams.
P1014 Characterisation of Escherichia coli isolates producing
extended-spectrum b-lactamases from a hospital and its
surrounding healthcare centres in Stockholm
H. Fang, F. Ataker, K. Dornbusch (Stockholm, SE)
Objectives: Nosocomial outbreaks of Escherichia coli producing
extended-spectrum b-lactamases (ESBLs) were observed at South
General Hospital and its surrounding healthcare centres in Stockholm
in 2002. One of the endemic clones had already circulated in the area
as early as 2001. In recent years, the number of new ESBL-cases has
increased. The present study is aimed at identifying b-lactamase genes
and investigating clonal diversity among the ESBL strains detected in
the area during the period 2001 to 2006.
Methods: Consecutive, non-repeated ESBL-producing E. coli isolates
from South General Hospital and its surrounding healthcare centres
in Stockholm were included in the study. The presence of ESBL was
ﬁrst phenotypically determined by either the double-disk method or
Etest. Then all the isolates were subjected to a multiplex PCR assay
targeting SHV, TEM, CTX-M and OXA type b-lactamases, and analysed
by pulsed-ﬁeld gel electrophoresis (PFGE). At least one isolate of each
genotype, as determined by the PFGE pattern combined with the PCR
proﬁle of b-lactamase genes, was further analysed by sequencing the
speciﬁc b-lactamase genes.
Results: Eighty-one strains were collected during the period 2001 to
Oct. 2006, while 53% (43/81) of them were isolated during the latest
two years. CTX-M gene was present in 93% (75/81) of the strains,
followed by TEM (64%) and OXA (59%). Among the strains tested,
three types of CTX-M ESBLs were identiﬁed, belonging to CTX-M-
1 group, CTX-M-2 group and CTX-M-9 group, respectively. It was
common that one strain harboured two or three different b-lactamase
genes. The nosocomial outbreaks in the area in 2002 were represented by
two clones, clone 1 and clone 2. Both clones produced CTX-M-1 group
ESBLs. The initial clone 1 isolates in 2001 harboured three b-lactamase
genes (TEM, CTX-M and OXA). In 2002, one of the clone 1 ESBL
strains was found to have lost the TEM b-lactamase gene. Moreover,
isolates of clone 1 losing both TEM and OXA genes were then detected
in 2004.
Conclusion: The frequency of ESBL-producing E. coli has increased in
Stockholm. CTX-M ESBLs were the main type of b-lactamases produced
by the strains. One endemic ESBL-E. coli clone was persistent in the
area through the years.
P1015 Genetic diversity of SHV-12 producing isolates from the
community and nosocomial settings (Madrid, Spain)
A. Valverde, R. Canton, A. Novais, F. Baquero, T. Coque (Madrid, ES)
Objectives: To study the epidemiological features and diversity of
genetic elements surrounding blaSHV-12 in isolates harbouring this
enzyme from hospitalised and non-hospitalised patients, and non clinical
samples from healthy volunteers, environment and food.
Methods: Forty three producing SHV-12 isolates (28 Escherichia coli
and 15 Klebsiella pneumoniae) obtained from 1999 to 2005 were
studied. Clonal relatedness was established by XbaI-PFGE. Phylogenetic
groups among E. coli isolates were identiﬁed by a multiplex PCR
assay. Transfer of bla genes was searched by broth and ﬁlter mating.
Plasmid characterisation was accomplished by Barton’s method, RFLP
and incompatibility group was identiﬁed by the method described by
Carattoli et al. Presence of IS26 and its association with blaSHV-12
was elucidated by PCR. Presence of integrons and associated gene
cassettes within the variable region was determined by PCR and further
sequencing.
Results: SHV-12 isolates were recovered from hospitalised (32.5%
medical, 11.7% surgery and 9.3% ICU) and community patients (28%),
healthy volunteers (14%) and environmental samples (4.5%). Fifty
four percent of isolates were resistant to ciproﬂoxacin and/or nalidixic
ac., whereas 90% were resistant to sulphonamide. E. coli isolates
belonged to phylogenetic groups D (46%), A (43%) and B1 (11%). High
clonal diversity was observed in E. coli isolates (D = 0.99) while most
K. pneumoniae isolates belonged to a single epidemic clone recovered
from 2001 to 2003. Most isolates were able to transfer blaSHV-12
gene (83%), located in plasmids of 48, 97 and 145 kb. Analysis of
incompatibility groups showed the predominance of IncI1 and IncN
plasmids with a no clear trend of dominance in different settings. A
high diversity of resistance gene cassettes within the integron variable
region was found (dhfr1-aadA1, sat, aacA4-qacEdelta1, IS1-orf, dhfr16-
aadA2). Presence of IS26 was detected in most of SHV-12-isolates.
Conclusions: Strains producing blaSHV-12 were found both in the
nosocomial (mainly associated to an epidemic K. pneumoniae clone) and
in the community (mainly associated to different E. coli clones) settings.
Presence of integrons with different genes cassettes in conjugative
plasmid might contribute to the dissemination and persistence of this
enzyme.
P1016 Most Escherichia coli strains overproducing AmpC
b-lactamase belong to phylogroup A
S. Corvec, A. Prodhomme, C. Giraudeau, A. Reynaud, N. Caroff
(Nantes, FR)
Objectives: AmpC overproducers represent about 1% of the E. coli
strains isolated from clinical specimens in our hospital. Overproduction
of AmpC enzyme is mostly caused by mutations in the ampC promoter,
particularly at position −42. The aim of this study was the classiﬁcation
of the strains presenting this speciﬁc resistance mechanisms in the
different phylogenetic groups.
Methods: 54 E. coli strains, isolated over a 12-year period, and previ-
ously identiﬁed as AmpC overproducers by increased MICs for third-
generation cephalosporins without ESBL production (negative double
disk synergy test) and spectrophotometric data were phylogrouped by
multiplex PCR. As a comparison, 82 E. coli clinical isolates, susceptible
to all b-lactams were also tested by the same method. The ampC
promoter sequence was determined for all these isolates. ERIC-2 PCR
was used to compare the isolates.
Results: 45 (83%) of the 54 AmpC overproducers tested belonged to
phylogroup A. Among the 43 isolates presenting a −42 mutation in the
ampC promoter, 37 (86%) belonged to phylogroup A, 5 to phylogroup B1
and one to phylogroup D. Among the 6 isolates presenting mutations
at position −32 (box-35) in the promoter, 5 were from phylogroup A.
Three other isolates, which were also from phylogroup A, harboured a
−11 mutation. These −32, −42 and −11 mutations, responsible for AmpC
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overproduction were usually associated with DNA polymorphisms at
position −88, −82, −18, +1 and +58 in the ampC promoter.
In the control susceptible isolates, these polymorphisms were detected
in 10 ampC promoters (8 phylogroup B1 and 2 phylogroup A). These
polymorphisms were never associated with the main phylogroup B2,
representing 70% of the isolates.
Conclusion: In this study, a well-known chromosomal mechanism of
resistance, overproduction of AmpC cephalosporinase, was clearly linked
to E. coli phylogroupA. The strains belonging to this phylogroup are
usually considered as less virulent. Studies of virulence factors from
these AmpC overproducing strains are in progress in our lab.
P1017 The ﬁrst identiﬁcation of an extended-spectrum b-lactamase-
producing Escherichia coli from Norwegian livestock
M. Sunde, H. Tharaldsen, H. Solheim, M. Norstro¨m (Oslo, NO)
Objectives: Until now no ESBL-producing bacteria from Norwegian
livestock have been detected. The situation regarding antimicrobial
resistance in food producing animals in Norway is very good in an
international perspective. The frequencies of resistance are low to
moderate and the situation has been stable since the start of the
monitoring programme (NORM-VET) in year 2000. The NORM-VET
2006 programme susceptibility tested 250 E. coli isolates from faecal
samples from broilers collected within the Norwegian salmonella control
programme, as well as 150 E. coli isolates from broiler meat (retail
stores). One E. coli isolate from a faecal sample showed reduced
susceptibility to cephalosporins (MIC ceftiofur 4mg/L, MIC cefotaxime
1mg/L), this isolate was subjected to further investigations.
Methods: Rosco synergi test and Etest® ESBL tests were carried out.
Polymerase chain reaction (PCR) and sequencing was performed for
detection of genes encoding ESBL, conjugation was carried out in broth
with E. coli DH5a´ as recipient strain.
Results: The strain was positive in the ESBL tests. The b-lactamase pro-
duced was not resistant to clavulanic acid. Further investigations showed
the presence of the blaTEM-20 gene. Resistance to cephalosporins was
transferred when conjugation was carried out, indicating that blaTEM-20
was located on a mobile DNA element.
The ﬁnding of an ESBL positive E. coli from the faecal ﬂora of a broiler
on a Norwegian farm is surprising. Cephalosporins are not used in the
Norwegian broiler production and the presence of selection pressure is
therefore absent. Interview with the farmer conﬁrmed that there had been
no use of cephalosporins to any animals or humans at the farm.
The origin of the strain (or the plasmid encoding resistance to
cephalosporins) is unknown. One explanation might be that the strain
(or the plasmid) could be part of the normal ﬂora of imported animals
taken into Norway for breeding purposes.
Conclusion: ESBL-producing E. coli can be present in the normal ﬂora
of a healthy domestic animal not exposed to the antimicrobial agent
in question. Furthermore, genes encoding ESBL can probably maintain
within a bacterial population without the involvement of direct selection
force.
P1018 Relationship between clonal variability, phylogenetic groups
and multiresistance amoung extraintestinal isolates of
Escherichia coli lacking extended-spectrum b-lactamases
B. Ruiz Del Castillo, L. Martinez-Martinez (Santander, ES)
Objectives: To evaluate the clonal relationship among multiresistant
clinical isolates of E. coli not producing ESBL and to determine the
phylogenetic group of these isolates.
Methods: E. coli(n = 100) obtained consecutively from clinical samples
(1 per patient), resistant to at least three of the following agents:
amoxicillin (AMX), amoxicillin-clavulanate (AMC), nalidixic acid
(NAL), gentamicin (GEN) and cotrimoxazole (SXT) and not producing
ESBL, have been studied. Preliminary identiﬁcation and susceptibility
testing was done with the WalkAway system (Dade Behring). MICs were
conﬁrmed by reference microdilution (CLSI guidelines). Phylogenetic
groups were deﬁned by a multiplex PCR (Clermont et al. Appl.
Environm. Microbiol 2000: 4555), using 5 E. coli strains from the
ECOR collection as controls. Clonal relationship was evaluated by
REP-PCR using primers REP1(5′IIIGCGCCGICATCAGGC-3′) and
REP-2 (5′ACGTCTTATCAGGCCTAC-3′). Haemolysis production was
assessed in sheep blood agar.
Results: Organisms were obtained from urine (79) or from other samples
(21). Sixty-one isolates were from samples of patients admitted to the
hospital and 39 from outpatients. Percentages of resistant+intermediate
organisms were: AMX (92%), AMC (41%), GEN (96%), NAL (98%),
SXT (96%). Forty-ﬁve isolates were in phylogenetic group D, 26 in
group A, 12 in group B1 and 17 in group B2. Forty REP-PCR patterns
were observed, with 24 patterns including one single isolate. Patterns I,
II, XXIII and XXIV included 18 (all group D; 9 from inpatients), 14
(all group B2; 9 from inpatients), 8 (all group D and from neonates) and
4 (all group A; 1 from inpatient) isolates, respectively. All organisms
were non-haemolytic. The more frequent phenotypes of resistance were
AMX/GEN/NAL/SXT(AGNS; n = 49)and AMX/AMC/GEN/NAL/SXT
(ACGNS; n = 38). AGNS/ACGNS resistant isolates included 17/21, 16/8,
8/7, and 8/2 organisms in groups D, A, B2 and B1.
Conclusions: A great clonal variability among multiresistant ESBL-
negative extraintestinal E. coli has been observed, but some clones are
distributed in both hospitalised and non-hospitalised patients. While most
isolates correspond to phylogenetic group D, almost one third of them
are of groups A and B1, being isolates of group B2 the less frequent
ones.
P1019 Epidemiology and molecular characterisation of clinical
isolates of Escherichia coli producing extended-spectrum
b-lactamases from Rome, Italy
A. Carattoli, A. Garcia, P. Varesi, D. Fortini, S. Gerardi, A. Penni,
C. Mancini, A. Giordano (Rome, IT)
Objectives: Extended-spectrum b-lactamase (ESBL)-producing Es-
cherichia coli are an emergent cause of infections in the Policlinico
Umberto I, a large University hospital of Rome (1500 beds), making
more difﬁcult managing carrier patients. Our aim is to analyse the
epidemiology and to characterise the E. coli ESBL producers in the
population attending our hospital.
Methods: A perspective study was carried out from 1st April to
15th September 2006. A total number of 5674 various clinical samples
were sent for bacterial isolation to the Microbiology Laboratory from 51
different wards, for suspected hospital acquired infections. 209 E. coli
strains were isolated from 166 inpatients. Antimicrobial susceptibilities
were carried out by the VITEK2 system. Double-disk synergy test
were used for the conﬁrmation of ESBL producers. ESBL genes were
characterised by PCR and sequencing. Clonal relationships among
the isolates were determined by ERIC-PCR. Plasmid extraction was
performed by alkaline lyses. Plasmids were typed by the PCR-based
replicon typing method.
Results: A total of 51 non-repetitive (one for each patient) E. coli ESBL
positive strains were obtained indicating a prevalence of 30% (51/166)
of E. coli ESBL producers in our hospital. 29 isolates were genotyped
by ERIC-PCR and analysed for the SHV-, TEM-, CTX-M-type ESBL
genes. Nine different clonal lineages were evidenced and two slightly
prevalent clones were identiﬁed. The most diffused ESBL was CTX-
M-15, being detected in 27/29 E. coli strains of different genotypes.
The two strains lacking the CTX-M-15 were SHV-12 producers. Three
strains carried both the SHV-11 and CTX-M-15. Most of the strains
were also positive for the blaTEM gene (22/29). The blaCTX-M-15
was detected on similar plasmids in all selected isolates and their
transconjugants, belonging to the FII incompatibility group. Further
plasmid characterisation is under way.
Conclusion: The eruptive worldwide dissemination of the CTX-M-15 in
geographically distinct hospitals emphasizes the necessity of immediate
intervention and epidemiological monitoring. E. coli with CTX-M-15 are
a major problem in the our hospital causing outbreak as well as many
sporadic infections. The impressive prevalence of this genetic trait in our
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hospital seems associated to the diffusion of epidemic plasmids and the
current knowledge on the spread of these plasmids is still limited but it
should be taken into account for the design of control measures.
P1020 Genotypic characterisation of Norwegian Escherichia coli
clinical isolates with an AmpC-resistance proﬁle
B. Haldorsen, B. Aasnaes, K. Dahl, A-M. Hanssen, G. Simonsen,
T.R. Walsh, M.A. Toleman, A. Sundsfjord, E. Lundblad (Tromso, NO;
Cardiff, UK)
Introduction: Resistance to extended-spectrum cephalosporins in E. coli
can be meditated by mobile AmpC-type b-lactamases and over-
expression of native AmpC enzymes normally repressed. Herein, we
describe a full genetic characterisation of AmpC-mediated resistance
and report novel insertion promoter sequences.
Methods: The Norwegian Reference Centre for Detection of Antimi-
crobial Resistance (K-res) received 414 clinical isolates of E. coli
from different Norwegian laboratories with a reduced susceptibility to
third-generation cephalosporins, over a 2-year period 2003–2005. Of
these, 23 isolates showed an AmpC-mediated phenotype using substrate
proﬁling. Strains were molecularly characterised and typed by IEF and
PFGE. AmpC-type b-lactamase genes and adjacent sequences were
analysed using PCR, sequence analysis, endonuclease plasmid analysis
and hybridisation.
Results: The 23 isolates all possessed pI values of pI 9.0−9.2 indicative
of AmpC expression. Multiplex blaampC-PCR and southern blot analysis
of S1 nuclease digested total DNA separated by PFGE, suggests that 10
of the 23 E. coli isolates have the blaampC gene located on plasmids.
Sequencing analysis showed that 9 of these had the blaCMY-2 gene,
while one strain had the blaCMY-7 gene. All plasmid-mediated blaampC
genes were found to be linked to an insertion sequence ISEcp1-like
element by an ISEcp1-blaampC gene linkage PCR. The bla CMY-2
genes possessed blc, sugE and dsbC downstream suggesting that they
belong to Type 1 and Type 2. The 13 non-plasmid mediated blaampC
strains, revealed promoter and attenuator alterations compared to E. coli
wild-type promoters. Two blaampC promoter regions were interrupted
by the insertion sequence ISEc10 of the IS21-family. PFGE analysis
suggests that the majority of the 23 E. coli isolates are unrelated.
Conclusion: These ﬁndings suggest there are two different populations
of AmpC-type resistant E. coli clinical isolates in Norway – plasmid-
mediated blaCMY genes and cognate AmpC promoter mutations. The
genetic context of the blaCMY gene suggests they are identical to
international strains.
P1021 A comparison of antimicrobial susceptibility in non-clinical
and clinical isolates of Escherichia coli
M. Sjo¨lund, J. Bonnedahl, S. Bengtsson, G. Kahlmeter (Va¨xjo¨, Kalmar,
SE)
Objectives: The frequent use of antimicrobial agents during the last
decades has resulted in an increased selective pressure, driving resistance
development in pathogenic, commensal as well as environmental
microorganisms. To assess the effect of the host’s environment and the
role that human use of antimicrobials play in selecting for resistance
in the normal microbiota, we have performed a unique comparison of
antimicrobial susceptibility in isolates of E. coli originating from two
widely different areas – one area with a standard use of antimicrobial
agents, County of Kronoberg, Sweden, and one area totally devoid of
antimicrobial agents; the Arctic.
Methods: In 2005, the Swedish Polar Research Secretariat organised
a scientiﬁc expedition to the Arctic. During this expedition, cloacal
swabs from Arctic birds were collected at three different geographical
regions; Northern Siberia, Alaska and Greenland. In the present study,
97 E. coli isolates from birds, and 100 clinical isolates from blood
cultures performed at Va¨xjo¨ hospital in 2004–2005, were included. The
antimicrobial susceptibility to 17 antimicrobial agents was determined
by disk diffusion. In addition, 25 copies of E. coli ATCC 25922 were
included and served as quality-control in a blinded fashion. For each
antimicrobial agent, zone inhibition histograms were established. The
wild type distributions were deﬁned by the median zone diameter and
the NRI (Normalised Resistance Interpretation) value.
Results: The wild type distributions of avian and clinical isolates
of E. coli showed complete agreement. Among the avian isolates,
resistance (deﬁned by the epidemiological cut-off) occurred most often
to ampicillin, sulfamethoxazole, trimethoprim, chloramphenicol and
tetracycline. Among the clinical isolates, resistance was most common
to ampicillin, nalidixic acid, streptomycin, sulphamethoxazole and
trimethoprim. The most pronounced difference between human and avian
isolates was observed for ﬂuoroquinolone resistance.
Conclusion: The wild type distributions of avian and clinical patient
isolates of E. coli are identical. However, clinical isolates of E. coli
were, as expected, signiﬁcantly more often resistant although resistance
as well as multi-drug resistance was observed among the avian isolates.
P1022 Prevalence and molecular epidemiology of CTX-M extended-
spectrum b-lactamase-producing Escherichia coli and Kleb-
siella pneumoniae isolates in a Portuguese university hospital
G.J. Da Silva, A.T. Simo˜es, A. Tavares, L. Boaventura, C. Vital,
G. Ribeiro (Coimbra, PT)
During the past decade CTX-M extended-spectrum b-lactamases (ESBL)
emerged in many countries. In Portugal only sporadic CTX-M-producers
isolates has been reported.
Objectives: The aim of the study was to investigate the prevalence
of CTX-M producers among ESBL-producing isolates of Escherichia
coli and Klebsiella pneumoniae as well as the molecular epidemiology
and the mechanism of dissemination of these emerging resistance
determinants.
Methods: Between November 2003 and February 2004 nonduplicate
isolates of E. coli (n = 25) and K. pneumoniae (n = 17) collected in the
University Hospitals of Coimbra were screened for CTX-M, TEM and
SHV enzymes production. They were identiﬁed as ESBL producers by
the automatic VITEK2 AES. ESBL production was further conﬁrmed by
ESBL E-test strips and disk diffusion synergy test. CTX-M alleles were
detected in whole DNA and plasmids by PCR with speciﬁc primers for
phylogenetic groups 1, 2 and 9. Transfer of blaCTX determinants was
assayed by conjugation using E. coli K102 (NalRRifR) as recipient cell.
Genetic relatedness was assessed by RAPD.
Results: ESBL production was conﬁrmed for ALL isolates by the
synergy method using CAZ, CTX, AZT, CPM and AMC. These results
were corroborated by E-test ESBL strips except for 3 K. pneumoniae
isolates. Only CTX-M-1 cluster enzymes were detected: 23 (92%) E. coli
and 2 (11.7%) K. pneumoniae isolates. TEM determinants were ampliﬁed
in the CTX-M-negative E. coli isolates. None E. coli expressed SHV
enzymes. The nature of these determinants was not further determined.
Two major lineages were observed among E. coli isolates by RAPD.
Clone A included the majority of the isolates (72%) while clone B
comprise 7 isolates with minor band variations. By sequence analysis
we found CTX-M-15 in clone A and CTX-M-1 in 2 isolates of clone B.
CTX-M-1 was detected in one of the CTX-M-positive K. pneumoniae
isolates. The other, a mutant found in the inhibition zone of cefotaxime
disk, exhibited a CTX-M-15. The determinants were carried by plasmids
>10 kb and it was possible to transfer blaCTX-M-1 determinant, but no
transconjugants were obtained with transference of blaCTX-M-15.
Conclusions: A prevalence of the emergent CTX-M-15 was observed
mainly in E. coli isolates from urinary tract infections. The lower
genotypic diversity among E. coli CTX-M-15 producers and lower
propensity of transfer by conjugation of blaCTX-M-15 suggest that
dissemination of CTX-M-15 was more related to clonal expansion.
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P1023 Clonality and presence of antibiotic resistance genes of
E. coli isolated in recurrent urinary tract infections
K. Truusalu, E. Sepp, J. Shchepetova, S. Koljalg, I. Vainuma¨e, K. Stroo,
K. Sepp, M. Mikelsaar (Tartu, EE)
E. coli is the main causative agent of recurrent urinary tract infections
(rUTI). The antibacterial treatment can facilitate the transmission of
resistance gene cassettes e.g. integrons and sul genes encoding resistance
to sulfamethoxazole (SMX). However, it is not known if the persistence
of clonal isolates can be predicted by antibiotic resistance pattern. We
aimed to investigate the molecular identity of consecutive E. coli strains
in rUTI patients and its association with geno- and/or phenotypically
changed antibiotic resistance pattern.
Material and Methods: A total of 22 E. coli strains were isolated from
urine of 8 children (aged 2mo – 8 y) out of 64 with phenotypically
changed antibiotic resistance pattern in 2−4 episodes of rUTI. The
index episode was acute pyelonephritis but in recurrences cystitis
was also found. During consecutive UTI episodes the changes in
antibiotic resistance to trimetroprim-sulfamethoxazole (TMP-SMX) in
3, to ampicillin in 2, to cefuroxime in 1 and to a combination of
both TMP-SMX and ampicillin in 2 patients were detected with disk-
diffusion method. The MIC values to ampicillin, cefuroxime, cefotaxime,
meropenem, gentamicin, ciproﬂoxacin and SMX were measured by
E-test. Microbial DNA was extracted using QIAamp DNA Mini Kit.
Genes of Int1, sul1, sul2 and sul3 were detected by PCR. Pulsed Field
Gel Electrophoresis (PFGE) with Qiagen kit was applied to detect E. coli
strain identity.
Results: In three patients index case and recurrences had similar PFGE
patterns while in remaining 5 patients they varied. There was no
relationship between clonality and phenotypically expressed changed
antibiotic resistance and the presence of resistance genes. Eight strains
isolated from six patients contained intI gene and the MIC values
to cefuroxime were higher than in intI negative strains (p = 0.003).
Phenotypical resistance to TMP-SMX was found in 6/22 strains, while
sul genes were present in 17/22 strains (p = 0.001). The MIC to SMX
was higher in sul positive than in sul negative strains (p = 0.001).
Conclusions: RUTI episodes are more frequently due to different
individual clones than one persisting clone. Persistence of particular
rUTI causing E. coli clones can not be detected by the stability of either
phenotypic nor genotypic resistance pattern.
P1024 Mechanisms of resistance in multiple-antibiotic-resistant
Escherichia coli strains isolated from drinking and
recreational, salmaster waters
R. Cernat, C. Balotescu, D. Ivanescu, D. Nedelcu, V. Lazar, M. Bucur,
D. Valeanu, R. Tudorache, M. Mitache, M. Dragoescu (Bucharest, RO)
Aim: To delineate the clonal diversity and transmission patterns, and to
investigate the occurrence and distribution of various resistance genes in
multiple antibiotic resistant E. coli strains isolated from various aquatic
sources.
Methods: 100 environmental Escherichia coli isolated from drinking
water (50) and marine water (50) in Constanta and Bucharest were
previously characterised for their virulence, pathogenicity, antibiotic
resistance and plasmid proﬁle. 30 strains from this group showed
multiple-antibiotic resistance and have been further investigated by PCR,
multiplex PCR and sequencing, for the presence of TEM-, SHV- and
CTX-M-like extended-spectrum b-lactamases, blaIMP1, blaOXA, sul1,
sul2 and sul3 genes, dfr-A like genes, tet efﬂux resistance genes, class 1,
class 2 and class 3 integrons with the corresponding gene cassettes,
respectively. Clonal diversity was assessed through PFGE of XbaI-
digested genomic DNA.
Results: E. coli isolates showed 16 unrelated PFGE patterns. All
strains were ampicillin resistant, blaTEM1a and blaTEM1b genes being
identiﬁed in 40% of the strains while group 1 and group 8 of blaCTX-M
genes were present in 90% of the strains. Most of the retrieved
sequences were identical or very similar to b-lactamase genes previously
characterised from clinical isolates. None of blaSHV, blaOXA and
blaIMP1 genes retrieved. 20% of E. coli strains were kanamycin resistant,
and the aphA1 and aphA2 genes were detected. The tetA, tetB and tetD
genes were found in all the strains. A relatively high prevalence has
been also obtained for dfrA17 (70%), dfrA12 (50%), sul1 (50%) and
sul2 (60%) genes. Class 1 integrons were the only found in resistant
bacteria and harboured 6 different cassette arrays, most common being
dfrA17-aadA5.
Conclusions: All aquatic multiresistant E. coli strains showed a wide
viariety of antibiotic resistance genes. Therefore, the aquatic ecosystem
may play a key role as acceptor and donor of transmissible antimicrobial
resistance mechanisms. The inclusion of some resistance genes inside
class 1 integrons constitutes an effective means to spread antibiotic
resistance among bacteria from different ecosystems.
P1025 Isolation of quinolone-resistant CTX-M-producing
Escherichia coli from raw chicken meat sold in retail outlets
in the West Midlands, UK
V. Ensor, R. Warren, P. O’Neill, V. Butler, J. Taylor, K. Nye, M. Harvey,
D. Livermore, N. Woodford, P. Hawkey (Birmingham, Shrewsbury,
Colindale, London, UK)
Objectives: To identify genotypes of CTX-M b-lactamase-producing
Escherichia coli isolated from raw chicken on sale in the UK West
Midlands.
Methods: Fresh and frozen raw chicken ﬁllets (originating from the
UK and other countries) were purchased from 18 different retail outlets,
including 13 major supermarkets in Shropshire and around Birmingham,
UK. Samples were cultured onto CLED agar with 8mg/L ciproﬂoxacin.
A cefpodoxime disc (30mg) was placed on the agar surface. Resistant
colonies identiﬁed as E. coli using chromogenic agar were investigated
for ESBL production using the combination disc test; those found
positive isolates were screened for blaCTX-M by multiplex PCR. Reverse
line hybridisation was used to identify blaCTX-M genotypes.
Results: See Table 1.
Table 1. CTX-M-producing E. coli isolated from chicken meat by
country
Origin Total positive/tested CTX-M enzyme present
C
T
X
-M
-1
C
T
X
-M
-2
C
T
X
-M
-8
C
T
X
-M
-1
4
British 1/62 1 0 0 0
Irish 0/3 0 0 0 0
Brazil 5/10 0 5 0 0
Brazil/Poland/Francea 3/4 0 3 0 0
Poland 0/4 0 0 0 0
Netherlands 2/2 0 2 0 0
Spain 0/1 0 0 0 0
France 0/1 0 0 0 0
Denmark 0/1 0 0 0 0
German 0/1 0 0 0 0
Unknown 6/40b 0 1 1 4c
Total 17/129 1 11 1 4
aPrecise country of origin not stated on packaging.
bCountry of origin not identiﬁed on packaging.
cAll chicken meat containing E. coli with CTX-M-14 was purchases
from 2 major supermarkets and was processed at 2 UK cutting stations.
Conclusions: E. coli with CTX-M enzymes were infrequently isolated
from chicken meat originating from EU countries, except that from
the Netherlands. CTX-M-15, the predominant ESBL type in clinical
isolates in the UK (and many other countries), was not found, suggesting
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contaminated chicken is an unlikely continuing source for current human
gut colonisation with this type.
E. coli with CTX-M-2 were isolated from 2/2 and 5/10 chicken meat
samples originating from the Netherlands and Brazil, respectively; CTX-
M-2 is the most common CTX-M type from clinical E. coli in Brazil
but is rare in clinical disease in the UK, although it has been isolated
from faecal samples. CTX-M-14 is the second commonest UK isolate
and common in other EU countries.
Analysis was complicated by the fact that countries of origin of 40
raw chicken samples was not identiﬁable on packaging, however, it
was apparent that there may be signiﬁcant differences in the CTX-M
enzyme found in chicken originating from different countries. Our
ﬁndings suggest that chicken meat may be a potential source of bowel
colonisation with E. coli producing CTX-M enzymes, but do not identify
a link to the main CTX-M type (CTX-M-15) from clinical infections in
the UK.
P1026 Occurrence and diversity of genetic resistance determinants
among Enterobacteriaceae clinical isolates in Aveiro,
Portugal
S. Ferreira, M. Toleman, T. Walsh, S. Mendo (Aveiro, PT; Cardiff, UK)
Objectives: The aim of the present study was to assess the occurrence of
antimicrobial resistance determinants and their genetic apparatus among
clinical isolates from Aveiro, Portugal.
Methods: The isolates population was composed by Escherichia coli,
Klebsiella pneumonia, Pseudomonas aeruginosa, Providencia stuar-
tii, Stenotrophomonas maltophilia, Citrobacter freundii, Enterobacter
cloacae, Enterobacter aerogenes, Morganella morganii and Proteus
mirabilis. PCR, sequencing and sequence analysis was used to assess
b-lactamase encoding sequences, class 1 and class 2 integrases, integron
variable regions and ISCR elements. The Biological Sequence Alignment
Editor, BioEdit version 7.0.0 was used for DNA and amino acid sequence
alignments. Sequences obtained were compared with others deposited in
the EMBL Genebank.
Results: PCR speciﬁc for CTX-M encoding sequence showed the
presence of this gene in 33.3% of the isolates bearing an ESBL. The
intI1 gene was present in 20.7% of the Enterobacteriaceae isolates. The
intI2 gene was present in 3 isolates possessing the same cassette array
(dfrA1, sat1, aadA1). A total of 14 cassettes included in 6 different
cassette arrays were identiﬁed – the most frequently found genes were
aadA variants. The ISCR elements were present in 8.1% of the isolates
and were present in 9 E. coli strains and 1 Enterobacter cloacae.
Conclusion: This is the ﬁrst report of ISCR elements from Portugal and
as they are intrinsically linked to antibiotic resistant genes, their high
incidence, particularly among E. coli strains, is disconcerting. The high
percentage of CTX-M genes conﬁrms that these have now become the
dominant ESBL genotype within this region.
P1027 Plasmid-mediated AmpC b-lactamases in Enterobacteri-
aceae lacking a chromosomal ampC gene and E. coli: preva-
lence at a Swiss university hospital and distribution of the
different molecular types in the northern part of Switzerland
H. Adler, L. Fenner, D. Hohler, R. Frei (Basle, CH)
Objectives: (1) to determine the prevalence of plasmid-mediated AmpC
b-lactamases in isolates of Enterobacteriaceae lacking a chromosomal
ampC gene and E. coli at the University Hospital Basel. (2) to determine
which types of plasmid-mediated AmpC b-lactamases occur in the
northern part of Switzerland.
Methods: Between January 27 and September 27, 2006, a total of
2,100 consecutive clinical isolates of E. coli and Enterobacteriaceae
naturally lacking a chromosomal ampC gene were screened for resistance
to cefoxitin with the disk diffusion test. Furthermore, clinical isolates
suspected to harbour a plasmid-mediated AmpC b-lactamase were
collected from laboratories in the northern part of Switzerland. Multiplex
AmpC PCR (Perez-Perez and Hanson, 2002, J Clin Microbiol 40:
2153−62) was performed on all cefoxitin-resistant isolates. The ampC
genes of the PCR-positive isolates were sequenced.
Results: (1) One hundred of the consecutive clinical isolates were
cefoxitin-resistant. Plasmid mediated AmpC b-lactamases were found in
three isolates of E. coli. Thus, the prevalence of plasmid-mediated AmpC
b-lactamases was 0.14%. (2) Plasmid-mediated AmpC b-lactamases
were found in 16 isolates from 5 laboratories in the northerm part of
Switzerland. Thirteen of the isolates were E. coli, 2 were Klebsiella
pneumoniae and one was Proteus mirabilis. CMY-2 and CMY-2 like
AmpC b-lactamases were detected in 11 isolates of E. coli, 2 isolates of
K. pneumoniae and one isolate of P. mirabilis. DHA-1 was detected in
2 isolates of E. coli.
Conclusion: (1) The prevalence of 0.14% of plasmid-mediated AmpC
b-lactamases in Enterobacteriaceae lacking a chromosomal ampC-gene
plus E. coli at the University Hospital Basel is very low. (2) CMY-2 and
CMY-2 like AmpC b-lactamases are the predominant plasmid-mediated
AmpC b-lactamases (87.5%) in the northern part of Switzerland. DHA-1
was the only other AmpC b-lactamase that was found (12.5%).
P1028 Countrywide spread of CTX-M-3 and CTX-M-15
extended-spectrum b-lactamases among Enterobacteriaceae
in Bulgaria
R. Markovska, I. Schneider, E. Keuleyan, M. Sredkova, D. Ivanova,
K. Rachkova, B. Markova, T. Kostyanev, E. Savov, I. Mitov,
A. Bauernfeind (Soﬁa, BG; Munich, DE; Pleven, Stara Zagora, BG)
Objectives: (1) To characterise the distribution of CTX-M producing
isolates among eight clinical centres from three towns in Bulgaria. (2) To
investigate their epidemiology and mechanism of spread.
Methods: Antibiotic susceptibility was determined by disc diffusion
method (CLSI standards 2005). The extended-spectrum b-lactamase
(ESBL) production was conﬁrmed by CLSI double disc ESBL
conﬁrmatory method. Conjugation was performed on solid medium.
Isoelectric focusing, followed by bioassay, ESBL-group speciﬁc PCR and
sequencing of ESBL genes of representative isolates were carried out.
RAPD with ERIC-1A and ERIC-2 primers and plasmid ﬁngerprinting
with PstI restriction were performed with representative strains.
Results: During a survey on ESBLs in Bulgaria from 1996 to 2003,
CTX-M-type ESBL-producing Klebsiella spp. (47), E. coli (113),
S. marcescens (9), Enterobacter. (5), C. freundii (6) from eight centres
in three different towns were detected. The most widespread enzyme was
CTX-M-15 (in all centres), followed by CTX-M-3 (in six centres). CTX-
M-15 was produced mainly from E. coli strains (83%) and associated
with urinary tract infections (49%). CTX-M-3 was produced from
K. pneumoniae – in 52%. The rate of CTX-M enzyme harbouring strains
has increased rapidly after ﬁrst detection in 2001 to 56% in 2003.
Resistance of CTX-M-3 producing strains was: AUG – 39%, TOB –
89%, GEN – 100%, AMI – 87%, CIP – 0%, TET – 33%, SXT – 85%
and CHL – 26%.
For CTX-M-15 producers the resistance was: AUG – 87%, TOB – 95%,
GEN – 88%, CIP – 84%, TET – 94%, SXT – 52% and CHL – 51%.
Epidemiological analysis by RAPD revealed a broader diversity of
RAPD-types among CTX-M-3 producing strains in comparison with
CTX-M-15 producers. The PstI plasmid ﬁngerprinting showed a broader
variety of CTX-M-15 encoding plasmids than CTX-M-3 harbouring
plasmids. One of CTX-M-3 carrying plasmid was dominant, we detected
it in four different bacterial species, isolated from patients in three towns.
Conclusions: In eight clinical centres in three Bulgarian towns CTX-M-
15 and CTX-M-3 were the only CTX-M-type b-lactamases found. Our
data suggest that plasmid transfer is the main mechanism of CTX-M-3
spread, while for CTX-M-15 producers spread by clonal dissemination
is more prevalent.
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P1029 Explosive emergence of CTX-M-15 extended-spectrum
b-lactamase in Enterobacteriaceae in Kuwait
L. Poirel, V. Rotimi, S. Bernabeu, W. Jamal, P. Nordmann (Le Kremlin
Bicetre, FR; Kuwait City, KW)
Objectives: Emergence of expanded-spectrum b-lactamases (ESBL) of
the CTX-M group in Enterobacteriaceae has been reported worldwide.
Our goal was to identify ESBL genes from a collection of clinically-
signiﬁcant ESBL-producing enterobacterial isolates recovered from the
Mubarak hospital in Kuwait City, Kuwait from 2002 to 2004.
Methods: PCR with primers speciﬁc for several ESBL genes (blaTEM,
blaSHV, blaCTX-M, blaVEB, and blaPER) were used for screening
followed by sequencing of PCR products. Primers speciﬁc for mobile
elements known to be at the origin of blaCTX-M genes acquisition were
also used. Strains (one per patient) were collected during a three-year
period. ESBL production was suggested by results of liquid medium
VITEK2 analyzer and conﬁrmed by synergy tests performed on solid
agar plates. Plasmid proﬁles analysis was determined by the Kieser
method followed by Southern hybridisation with blaCTX-M speciﬁc
probes.
Results: 598 enterobacterial isolates were recovered during the studied
period with 63 ESBL-producers (10.5%). Noteworthy, in 2002 and
2003 respectively, only 2 out of 57 (3.5%) and 6 out of 265 (2.3%)
enterobacterial isolates were ESBL producers, whereas they were 55
out of 276 (20%) in 2004. ESBL producers were mostly Escherichia
coli (n = 29), Klebsiella pneumoniae (n = 19). In addition, there were
several Enterobacter cloacae (n = 4), Enterobacter aerogenes (n = 3),
Proteus mirabilis (n = 6), Citrobacter freundii (n = 2) and Serratia
marcescens (n = 1). They were from different hospital units, but mostly
from Medicine, Surgery and Nephrology departments. The ESBL
determinants were mostly of the CTX-M group (50 out of 63), with
CTX-M-15 being the main ESBL (46 out of 50). Insertion sequence
ISEcp1 was identiﬁed systematically upstream of the blaCTX-M-15
gene. The other CTX-M variants were CTX-M-2 and CTX-M-9. The
other ESBL-type were mostly SHV-type enzymes, and one isolate was
VEB-1 positive.
An heterogeneous pattern of blaCTX-M-borne plasmids was observed
that indicated that the dissemination of those resistance determinants
were not related to dissemination of a single plasmid.
Conclusion: This study constitutes the ﬁrst survey on ESBL spread
in Kuwait. Dissemination of CTX-M-15 producers was identiﬁed as
observed worldwide with a threatening increasing detection rate.
P1030 Low prevalence of TEM-type ESBLs among nosocomial
strains of Enterobacteriaceae in Russia
L.N. Ikryannikova, E. Shitikov, E.N. Ilina, M.V. Edelstein, V.M. Govorun
(Moscow, Smolensk, RU)
Objectives: Production of extended-spectrum b-lactamases (ESBLs) in
Enterobacteriaceae is one of the most prevalent mechanisms of resistance
to oxyimino-b-lactams. Among others enzymes, the numerous mutant
variants of TEM-type penicillinases (e.g. TEM-1 and TEM-2) possess
ESBL phenotype. In this study we evaluated a contribution of TEM-
type ESBLs to the development of resistance to oxyimino-b-lactams in
nosocomial strains of Enterobacteriaceae collected in Russian Federation.
Methods: A total of 718 ESBL-producing nosocomial isolates of 10
different genera of the family Enterobacteriaceae, mainly Klebsiella
pneumoniae (47.4%) and Escherichia coli (40.5%), collected in the
hospitals from Central (n = 235), North-West (n = 52), Volga (n = 39),
South (n = 95), Ural (n = 62), Siberian (n = 175) and Far-Eastern (59)
regions of Russian Federation as part of the national surveillance
of antimicrobial resistance in ICU pathogens in 2002–2004 were
investigated. The ESBL phenotype of these isolates was inferred based
on the MIC of at least one of the oxyimino-cephalosporins (cefotaxime,
ceftazidime and cefepime) 2mg/L and positive results of the MIC
synergy test (according to CLSI), or of the double-disk synergy with
clavulanic acid. The complete coding sequences of TEM b-lactamase-
coding genes were ampliﬁed by PCR and directly sequenced using the
automated ﬂuorescent dideoxy terminator sequencing.
Results: Three hundred and seventy three (51.9%) of the studied isolates
were PCR-positive for blaTEM genes. Of these, 372 were found to
possess TEM-penicillinase genes, including 368 – TEM-1 (98.7%), two –
TEM-2, one – TEM-57 (Gly92Asp), and one – TEM-117 (Leu21Phe).
Only one strain had a single Arg164His substitution consistent with the
TEM-29 ESBL.
Conclusion: This is a ﬁrst report of a distribution of TEM-type ESBLs
in Russian nosocomial strains of Enterobacteriaceae expressing ESBL
phenotype. Our results show that TEM-type ESBLs are not a common
cause of resistance in Russian Federation.
P1031 Prevalence of faecal carriage of metallo-b-lactamase
producing Enterobacteriaceae in a Spanish hospital
T. Curiao, M. Tato, A. Valverde, A. Novais, F. Baquero, T.M. Coque,
R. Canton (Madrid, ES)
Background:Metallo-b-lactamase (MBL) producing Enterobacteriaceae
have been recognized in different European countries, including Greece,
France, and Spain. We recently described a polyclonal outbreak involving
these isolates in our hospital in Madrid (Tato et al. 46th ICAAC, 2006;
abstract C2−66). In this study we investigated the intestinal colonisation
by MBL producing isolates of hospitalised and ambulatory patients in
our geographic area.
Methods: A total of 600 faecal samples from 569 hospitalised (20%) and
ambulatory (80%) patients who attended in our hospital (January-April
2006) were studied. Aliquots of saline faecal suspension were cultured in
MacConkey supplemented with ceftazidime (4mg/L) agar plates and in
Luria-Bertani (LB) supplemented with imipenem (2mg/L) broth. Isolates
from positive cultures were screened for MBL production by a double
disk synergy test (DDST) using imipenem (10mg), ceftazidime (30mg)
and EDTA (1900mg) disks. Bacterial identiﬁcation and antimicrobial
susceptibility were performed using the WIDER system (Fco. Soria
Melguizo, Madrid, Spain). MLB characterisation (blaVIM and blaIMP
PCR, sequencing, and IEF) and PFGE were performed in isolates with
positive DDST.
Results: A positive faecal carriage with MLB producing isolates was
observed in four patients (0.7%) hospitalised (3.5%) at surgical (n = 1)
and medical (n = 1) wards and ICUs (n = 2). No colonised patients were
detected in outpatients. Proposed method for detection of MBL producers
was efﬁcient. All MBL producers were recovered on both supplemented
MacConkey agar plates and LB broth and identiﬁed as Enterobacter
cloacae (n = 2) and Klebsiella pneumoniae (n = 2). All of them produced
VIM-2 enzyme and belonged to epidemic clones detected in our hospital.
Unlike E. cloacae, patients with K. pneumoniae colonisation were also
infected by this clone.
Conclusions: MBL (VIM-2) producing Enterobacteriaceae have
emerged in our geographic area in hospitalised patients. Prevalence of
colonised patients (3.5%) in our institution represents a clinical concern
for the maintenance of epidemic clones and source for infections.
Intervention strategies of containment of MBL producing isolates should
include faecal carriage studies.
P1032 Extended-spectrum b-lactamase producing
Enterobacteriaceae in a Swiss university hospital:
molecular characterisation and susceptibility to ertapenem
T. Bruderer, A.F. Widmer, M. Flury, S. Oezcan, M. Jutzi, R. Frei
(Basle, CH)
Objectives: First, to determine the molecular types of extended-spectrum
b-lactamases (ESBLs) in Enterobacteriaceae at the University Hospital
Basel, Switzerland. Secondly, to assess the activity of ertapenem against
ESBL-producing strains.
Methods: Between 1/1/2003 and 31/12/2005, all consecutive clinical
Enterobacteriaceae isolates were screened by use of 4 ESBL markers
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(ceftazidime, ceftriaxone, cefpodoxime, and aztreonam) according to
Clinical and Laboratory Standards Institute (CLSI) guidelines. As
phenotypic conﬁrmatory test, three different ESBL Etest strips (AB
Biodisk, Sweden) were used, i.e., ceftazidime, cefotaxime, and cefepime,
each with and without clavulanic acid. Repetitive patient isolates and
K1 hyperproducing Klebsiella oxytoca were excluded. To determine
the molecular types, PCR amplifying SHV, TEM, and CTX-M genes
was performed and amplicons were sequenced. Minimal inhibitory
concentrations (MICs) of ertapenem were determined by Etest and
interpreted according to the standards of CLSI.
Results: Among 8,384 isolates screened, 57 (0.68%) phenotypically
conﬁrmed ESBLs were identiﬁed. The ESBL rate was 1.1% and 3.4%
in Escherichia coli and Klebsiella pneumoniae, respectively. Among
ESBL strains, 59.6% were E. coli, 31.6% K. pneumoniae, and 8.8%
other genera. The majority (49.1%) of ESBL strains was found in urine
samples. PCR and DNA sequencing analysis demonstrated that 61.4%
of the ESBL strains expressed a CTX-M type, 15.8% an SHV ESBL
type, and 5.3% a TEM ESBL type. CTX-M-15 was the predominant
(29.8%) b-lactamase followed by CTX-M-3 and SHV-12. There was no
epidemiological and microbiological evidence for an outbreak situation.
In 9 strains, no CTX-M, SHV or TEM ESBL could be detected.
The MIC50 and MIC90 of ertapenem were 0.06mg/l and 0.25mg/l,
respectively. Overall, 98.2% of the strains were susceptible to ertapenem
(MIC 2mg/l).
Conclusions: Despite an extensive screening strategy, the prevalence
of ESBLs is low in our medical institution. The distribution of the
ESBL types is similar to the distribution in institutions with high
ESBL prevalence, being CTX-M the predominant ESBL class. The
new compound ertapenem is highly active against the ESBL-producing
Enterobacteriaceae tested.
P1033 Prevalence of the plasmid-mediated quinolone resistance
determinants qnrA, qnrB and qnrS in Enterobacteriaceae
isolates causing bacteraemia
J. Sanchez-Cespedes, S. Marti, M. Ruiz, S.M. Soto, M. Almela,
F. Marco, J. Vila (Barcelona, ES)
Objectives: The main objective of this study was to investigate the
prevalence of the qnrA, qnrB and qnrS genes in Enterobacteriaceae
isolates causing bacteraemia.
Methods: Hundred and ninety-ﬁve Enterobacteriaceae isolates from
blood samples were collected: 54 Klebsiella pneumoniae (27.7%),
28 Proteus mirabilis (14.4%), 25 Enterobacter cloacae (12.8%),
22 Serratia marcescens (11.3%), 21 Salmonella enteritidis (10.8%),
16 Klebsiella oxytoca (8.2%), 8 Salmonella typhimurium (4%),
6 Enterobacter aerogenes (3%), 5 Citrobacter freundii (2.6%), 4
Citrobacter koseri (2%), 3 Morganella morganii (1.5%), 2 Pantoea
agglomerans (1%) and 1 Citrobacter werkmanii (0.5%). Screening of the
qnrA, qnrB and qnrS genes was performed by multiplex PCR using a
cocktail of speciﬁc primers. Bacterial strains positive for each qnr gene
were used as positive controls, and were run in each batch of tested
samples. Positive reactions were conﬁrmed by direct sequencing of the
PCR products. The sequences obtained were compared in the GenBank
to determine the correspondent qnr variant. In order to characterise the
genetic environment of these QNR determinants a PCR with an universal
integron primer and a qnr multiplex primer was also performed.
Results: Five isolates (3%) carrying a qnr gene were found. Four of
them corresponded to qnrB and the other one to qnrS; qnrA was not
detected. The qnrS determinant corresponded to the variant qnrS2 and
was found in K. pneumoniae 46408. Two variants of the qnrB gene
were detected: qnrB2 in C. freundii 62778, C. freundii 21112 and 14.0
and qnrB6 in C. freundii 72857. The three isolates of C. freundii were
not epidemiologically related by REP-PCR. Results of the PCR with
the combination of integron and qnr primers showed that the qnrB2
determinant in the isolate C. werkmanii 14.0 was integrated in a qnr-
containing complex sul1-type integron.
Conclusions: In our Hospital, the prevalence of the qnrB gene was
higher than for the qnrA and qnrS determinants, differing to the situation
in Spain where the qnrB determinant had not been detected until now.
Also it is important to mention the high prevalence of the qnr gene in
C. freundii (60% of the ﬁve studied isolates) and the presence of this
gene in C. werkmanii given that this is the ﬁrst time that the presence
of a qnrB determinant has been reported in these species.
P1034 International dissemination of extended-spectrum
b-lactamase TEM-24 among Enterobacteriaceae species is
caused by spread of both epidemic IncA/C2 plasmid and
strains
A. Novais, R. Canto´n, E. Machado, L. Peixe, F. Baquero, T.M. Coque
(Madrid, ES; Oporto, PT)
Objectives: TEM-24 is one of the TEM-type ESBL most widespread in
Europe. The aim of this study was to characterise TEM-24-producing
Enterobacteriaceae isolates recovered in different European countries and
genetic elements participating on this ESBL dissemination.
Methods: Twenty ﬁve TEM-24-producing isolates recovered during
a period of six years (1998–2004) from Spain (n = 11), Portugal
(n = 11), and France (n = 3) were studied. Only one isolate/phenotype was
included. They were Escherichia coli and Klebsiella pneumoniae (n = 6
each), and Enterobacter aerogenes (n = 13). Isolates were obtained from
patients at medical wards (57.1%), ICUs (19.1%), surgical wards (9.5%),
and 14.3% were outpatients. ESBL characterisation was performed by
IEF, PCR and further sequencing. Relationship among isolates was
established by PFGE and E. coli phylogenetic groups were searched
as reported. Antibiotic susceptibility testing and conjugation assays
were performed using standard methods. Integrons were determined as
described. Plasmid characterisation included analysis of RFLP patterns
and determination of incompatibility group by PCR, hybridisation and
sequencing.
Results: E. coli isolates (n = 6) were assigned to six PFGE types whereas
K. pneumoniae and E. aerogenes isolates were each associated with
an epidemic clone. E. coli isolates belong to phylogroups D (75%)
and A (25%). Most strains were resistant to tobramycin, amikacin and
nalidixic acid. blaTEM-24 was located in a 170kb-IncA/C2 conjugative
plasmid in all cases. Related plasmid RFLP patterns were observed
among distinct Enterobacterial isolates, suggesting a common plasmid
background involved in TEM-24 dissemination. This plasmid contain
class 1 integron carrying aacA4 gene cassette.
Conclusions: Intercountry spread of blaTEM-24 is determined either
by E. aerogenes or K. pneumoniae epidemic strains or by epidemic
plasmids among Enterobacteriaceae species. Location on broad host
range IncA/C2 plasmid might enables further transmission to other hosts.
P1035 ESBL-producing Enterobacteriaceae from non-human
sources (poultry and swine) in Portugal
E. Machado, T. Coque, R. Canto´n, F. Baquero, J. Silva, J.C. Sousa,
L. Peixe (Porto, PT; Madrid, ES; Fafe, PT)
Objectives: To investigate the occurrence and diversity of ESBL-
producing Enterobacteriaceae among healthy animals and raw poultry
meat samples from Portugal.
Methods: We studied (i) 35 faeces samples from healthy swines (HS)
in 1998 and 2004, (ii) 20 samples from uncooked poultry carcasses
(PM) of two poultry retail markets (2003), and (iii) 20 faecal samples
from healthy poultry (HP) in 2004 (n = 20). HS and HP were from
distant geographic farms. Animals were not exposed to antibiotics
in the 3 months preceding sample recovery. Samples were plated on
MacConkey agar with ceftazidime (1mg/L) or cefotaxime (1mg/L).
ESBL characterisation was accomplished by double disk diffusion, PCR,
and sequencing. Bacterial identiﬁcation was performed using API ID
32GN and antibiotic susceptibility tested by the disk diffusion method
(CLSI). Clonal relatedness was established by RAPD and E. coli
phylogenetic groups were identiﬁed by a multiplex PCR. Conjugation
experiments were performed as described.
Results: ESBL were identiﬁed in PM (60%, 12/20), HS (5.7%, 2/35) and
HP (10%, 2/20). ESBL-producing isolates were identiﬁed as C. freundii
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(2HS), E. coli (n = 12; 2HP, 10 PM) and K. pneumoniae (n = 4; 4PM), and
ESBLs as TEM-52 (n = 12), SHV-2 (n = 3), SHV-12 (n = 2), and CTX-
M-1 (n = 1). TEM-52 was found among E. coli. SHV-2 only detected
in K. pneumoniae, SHV-12 only observed among C. freundii isolates
and CTX-M-1 in one E. coli. Isolates showed decreased susceptibility
patterns to other antimicrobial classes. Most bla genes were transferred
by conjugation. RAPD analysis revealed that 2 TEM-52-producing
E. coli from PM, 2 TEM-52-producing E. coli from HP, 2 SHV-2-
producing K. pneumoniae and 2 SHV-12-producing C. freundii were
clonally related (4 distinct RAPD-types). The remaining isolates showed
unique RAPD patterns. These isolates and ESBL-producing clinical
isolates spreading in Portuguese hospitals during 2003 and 2004 were
clonally unrelated. E. coli phylogenetic group A was predominant
(58.3%). Less represented phylogroups were D (33.3%) or B1 (8.3%).
Conclusions: This work constitutes the ﬁrst report of some ESBLs
from Enterobacteriaceae from livestock. The frequent presence of ESBL-
producing Enterobacteriaceae in poultry meat in Portugal highlights the
risk of transmission to humans via food chain. Horizontal gene transfer
could be responsible for ESBL dissemination in our country.
P1036 Clinical urinary tract isolates of Enterobacteriaceae in
the Arkhangelsk region, Russian Federation: antimicrobial
resistance proﬁles and characterisation of ESBL-strains
V. Vorobieva, T. Bazhukova, N. Semenova, B.C. Haldorsen, A. Bettina,
G. Simonsen, A. Sundsfjord (Tromso, NO; Arkhangelsk, RU)
Objectives: (i) Antimicrobial resistance in urinary tract isolates of
Enterobacteriaceae in the Arkhangelsk, Russia. (ii) The molecular
epidemiology of ESBL-strains.
Material and Methods: A total of 136 non-duplicate urinary isolates of
Enterobacteriaceae were collected from September 2005 to September
2006; 112 (82%) and 24 (18%) strains from in- and out-patients
were identiﬁed with standard microbiological methods. Antimicrobial
susceptibility testing was performed by agar disc diffusion (AB,
BIODISK, Solna, Sweden) to 15 different antibiotics. Clinical strains
with reduced susceptibility to oxyimino-cephalosporins were analysed
by oxyimino-cephalosporin Etests, blaTEM/SHV/CTX-M ESBL-genes,
inhibitor-based AmpC-detection (boronic acid), ESBL phenotypic tests
(ESBL Etest; combined disk method), susceptibility to non-betalactam
antibiotics by VITEK2 (bioMe´rieux, France). Interpretation criteria
were according to EUCAST and NWGA. Strains with resistance and
intermediate susceptibility were classiﬁed as non-susceptible.
Results: The rates of non-susceptibility to 110 (81%) Escherichia coli,
16 (12%) Klebsiella pneumoniae, 10 (7%) other Enterobacteriaceae
were: ampicillin 99%, cefuroxim 98%, trimethoprim 32%, trimethoprim-
sulfamethoxazole 32%, piperacillin-tazobactam 24%, nalidixic acid 23%,
ciproﬂoxacin 21%, gentamicin 21%, aztreonam 20%, ceftazidime 19%,
cefotaxime 18%, mecillinam 19%, nitrofurantoin 16%; meropenem 0%.
Twenty-ﬁve (18%) clinical strains of Enterobacteriaceae: E. coli (n = 17),
K. pneumoniae (n = 5), Enterobacter cloacae (n = 2), Serratia marcescens
(n = 1) with reduced susceptibility to oxyimino-cephalosporins were
detected among 22 (88%) and 3 (12%) in- and out-patients. Twenty-
four were conﬁrmed as ESBL-positive by blaTEM/SHV/CTX-M PCR;
24 blaCTX-M (E. coli n = 16; K. pneumoniae n = 5; E. cloacae n = 2;
S. marcescens n = 1), blaSHV (E. coli n = 3; K. pneumoniae n = 5),
blaTEM (E. coli n = 12; E. cloacae n = 2; S. marcescens n = 1). Sequence
typing of amplicons is ongoing.
Conclusions: (i) High non-susceptibility rates to b-lactam and non-
b-lactam antibiotics are found. (ii) ESBL-production was detected
in 16/110 (15%), 5/16 (31%), 3/10 (30%) isolates of E. coli,
K. pneumoniae, and other Enterobacteriaceae from 22 (92%) and 2 (8%)
in- and out-patient. (iii) blaCTX-M was the most prevalent ESBL-
type. (iv) Inhibitor-based detection of AmpC-production in E. coli
and K. pneumoniae strains with reduced susceptibility to oxyimino-
cephalosporins was negative.
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P1037 Evaluation of PlateliaTM Dengue NS1 Antigen assay for
early diagnosis of acute dengue infection
M. Tabouret, C. Salanon, P. Sarfati (Marnes la Coquette, FR)
Objectives: In tropical and subtropical region, endemic dengue disease
is the most important arbovirosis in terms of morbidity and mortality. To
implement appropriate treatment, there is a need for a direct, rapid and
speciﬁc detection test during the acute phase of the infection. For that
purpose, viral culture or nucleic acid detection (performed mainly in
reference laboratories) require specialised environment but sometimes
with delays to report results. Dengue speciﬁc antibodies detection is
commonly used even if these antibodies appear several days after onset
of symptoms. The objective of the study is to evaluate the performances
of PlateliaTM Dengue NS1 Ag (Bio-Rad Laboratories) for early diagnosis
of acute dengue infection.
Methods: PlateliaTM Dengue NS1 Ag is a one step sandwich ELISA
assay for qualitative detection of Dengue virus NS1 antigen in human
serum or plasma. Speciﬁcity and sensitivity were determined on 554
healthy blood donors and 297 dengue virus infected patients with
accessible clinical information. 157 infected patients (52.9%) were
selected based on positive PCR results and because the delay after onset
fever was available. Serological status was determined using Dengue IgG
indirect and Dengue IgM Capture Panbio assays.
Results: All 554 sera from blood donors were found negative for
NS1 giving a speciﬁcity of 100%. Sensitivity of NS1 was 91.0% on
the 157 PCR positive samples with no signiﬁcant difference observed
between the 4 dengue virus serotypes. NS1 sensitivity was signiﬁcantly
higher (98.5%) in patients with primary dengue infection (PCR+/IgG−)
compared to 85.6% in patients with secondary (PCR+/IgG+) dengue
infection (Chi2, p< 0.05). During the ﬁrst 5 days after clinical onset,
detection rates ranged from 100.0 to 87.0% for NS1 Ag and from 0.0 to
30.8% for IgM serology. When considering all dengue infected patients,
NS1 sensitivity was signiﬁcantly higher for IgM negative (88.7%) than
for IgM positive (66.2%) samples (Chi2, p< 0.0001).
Conclusion: PlateliaTM Dengue NS1 Ag assay is an easy-to-use ELISA
for dengue antigen detection. The assay allows early and speciﬁc
diagnosis of both primary and secondary dengue acute infections. This
new test should be considered in diagnostic algorithms to improve patient
care monitoring.
P1038 Seroprevalence of IgG antibodies against ﬂaviviruses in
German soldiers
S. Friedewald, A. Ja¨ger, M. Faulde, S. Essbauer, M. Pfeffer, R. Wo¨lfel,
G. Dobler (Munich, Koblenz, DE)
Objectives: West Nil virus (WNV) is an emerging pathogen causing
increasing numbers of epidemics and human cases in Europe, Africa,
Asia and America. While WNV was detected in France, Slovak and
Czech Republic, there is no evidence for circulation of this ﬂavivirus in
Germany thus far. Seroepidemiological studies for a particular ﬂavivirus
infection are hampered because of cross-reacting antibodies against
other autochthonous or travel-related and vaccination-induced ﬂavivirus
antibodies, e.g. tick borne encephalitis virus (TBEV) Dengue virus
(DENV), Japanese encephalitis virus (JEV). Hence two commercially
available ELISA assays for the speciﬁc detection of antibodies against
WNV were compared using well deﬁned sera from German soldiers.
Methods: 715 sera from soldiers of different parts of Germany were
tested for IgG antibodies (AB) against WNV using a commercial ELISA
(Focus Diagnostics, USA). Reactive sera were retested in a second
WNV AB ELISA, against DENV AB and TBEV AB (all Euroimmun,
Germany). Positive sera were also tested for avidity (Euroimmun,
Germany) to detect possible reduction of cross reactivity of AB. All
tests were conducted according to the manufacturers’ instructions.
Results: 142/715 sera (19.9%) reacted positive in the WNV AB ELISA
(Focus Diagnostics). Re-testing by WNV AB ELISA (Euroimmun)
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showed positive results in 73 of these 142 sera. However 123/142
sera reacted positive in TBEV AB ELISA and 59/142 sera showed
positive results in DENV AB ELISA. Results of only 6/715 sera (0.8%)
were consistent with past WNV or DENV infection. These results are
consistent with data of earlier studies and it can be assumed that these 6
soldiers acquired a WNV or DENV during travelling in endemic areas.
The use of WNV AB avidity test did not reduce cross-reactivity.
Conclusions: Our data do not provide any evidence for autochthonous
human WNV infection in Germany. However, huge differences in
sensitivity and speciﬁcity of two commercial ELISA assays were
found with the ELISA (Focus Diagnostics) showing the lowest
speciﬁcity. The second ELISA (Euroimmun) showed higher speciﬁcity.
The use of avidity testing had no effect on cross-reactivity at all.
Only 6/715 sera showed evidence of past infection with WNV or
DENV. In seroepidemiological studies or in serological diagnosis of
WNV infections or vaccinations against other ﬂaviviruses have to be
excluded using tests with higher speciﬁcity, i.e. immunoﬂuorescence and
neutralisation test.
P1039 Antibody response in Crimean-Congo haemorrhagic fever,
and association between antibodies and clinical outcome
Z. O¨zkurt, K. O¨zden, A. Kadanali, S. Erol, N. Yilmaz, M. Parlak
(Erzurum, Ankara, TR)
Objectives: Crimean-Congo haemorrhagic fever is a serious viral
disease. Fatality rate of the disease has been reported as 5−50%. The
neutralising antibody response is weak and difﬁcult to demonstrate in
CCHF infection. In this study we aimed detection of antibody response
in the disease and association between clinical outcome.
Methods: We evaluated 90 conﬁrmed CCHF cases. Microbiological
diagnosis and conﬁrmation of the disease were made by demonstrating
seroconversion, by IgM antibody, and/or polymerase chain reaction
(PCR). IgM and IgG antibodies were detected by ELISA.
Results: Anti-CCHFV IgM antibody was detected in 4 of 10 (40%)
fatal cases versus 54 of 90 (60%) survivors (p< 0.05). Anti-CCHFV
IgG antibody was not detected in any fatal case (0/10) but it was found
positive in 35 of 76 (46%) survivors (p< 0.05).
Conclusion: These data show that antibody response is low in fatal cases
than those of survivors. Neutralising activity may have an important role
of limitation of the disease, and the value of immune sera in therapy
should be investigated in further studies.
P1040 Clinical and laboratory features of Crimean-Congo
haemorrhagic fever: predictors of fatality
M.A. Cevik, A. Erbay, H. Bodur, E. Gulderen, A. Bastug, A. Kubar,
E. Akinci (Ankara, TR)
Objectives: To determine the predictors of fatality among patients with
Crimean-Congo haemorrhagic fever (CCHF) based on epidemiological,
clinical and laboratory ﬁndings.
Methods: Among the patients who were referred from surrounding
hospitals to Ankara Numune Education and Research Hospital as a
possible CCHF case during the spring and summer of 2003–2006,
patients with IgM antibodies or PCR results positive for CCHF virus
in blood and who had received only supportive treatment were included
to the study.
Results: Sixty-nine patients were admitted from various cities of north-
east of central Anatolia and the southern parts of the Black Sea
region. Male patients accounted for 45 (65%) of the patients and
the mean age was 50 years. Eleven (15.9%) cases were died with
massive haemorrhage. The age, gender, days from the appearance of
symptoms to admission and initial complaints were similar between
fatal and survived cases (p> 0.05). Forty patients were IgM-positive, and
50 patients were PCR-positive. Among the clinical ﬁndings, ecchymosis
(p = 0.007), hematoma (p = 0.023), haematemesis (p = 0.030), melaena
(p< 0.001) and somnolence (p< 0.001) were more common among fatal
cases. Almost all of the patients had leukopenia, thrombocytopenia,
and elevated AST, ALT, LDH and CPK levels at admission. Mean
thrombocyte level was 47000/mm3 in survived patients and 12000/mm3
in died patients (p = 0.003). Among the fatal cases the mean PT
(18 s vs. 13 s; p< 0.001) and mean aPTT were longer (69 s vs. 43 s;
p = 0.001), the mean ALT (1688 vs. 293; p< 0.001) and the mean
AST (3028 vs. 634; p< 0.001) were higher. All patients received
intensive clinical supportive measures, including platelets, fresh frozen
plasma, and packed erythrocyte infusions, when indicated. None of the
patients received ribavirin. Fatal patients received signiﬁcantly more
fresh frozen plasma (p< 0.001) and thrombocyte suspensions (p = 0.017)
than survived patients. Cox proportional hazard model was used for
fatality analysis, the starting time point was beginning of the complaints,
and the ending time point was either death or discharge from the
hospital. Thrombocytopenia of <20000/mm3 (hazard rate [HR], 9.8;
95% conﬁdence interval [CI], 1.17−81.4; p = 0.035) and somnolence
(HR, 5; 95%CI, 1.4−17.5; p = 0.012) were independently associated with
mortality.
Conclusion: Thrombocytopenia of <20000/mm3 and somnolence were
independent predictors of fatality among patients with CCHF.
P1041 Crimean-Congo haemorrhagic fever infection among
children
G. Tanir, O. Ergonul, N. Tuygun, P. Golabi, V. Korten (Ankara,
Istanbul, TR)
Objective: The epidemiological, clinical, and laboratory ﬁndings of the
children diagnosed as Crimean-Congo haemorrhagic fever (CCHF) were
described.
Methods: The children infected with CCHF virus in 2005 and 2006, and
hospitalised in Ankara Dr. Sami Ulus Children’s Hospital and Marmara
University Hospital were included. All the patients had positive results
of IgM and/or PCR results for CCHF virus in their blood.
Results: Thirteen cases were included, and all were from the
northeastern Anatolia and the southern parts of Black sea region. The
mean age was 8 (3−13), the rate of males was 62%. The majority (77%)
of the cases had the history of tick bite. There was only one fatal case.
All the patients had the history of fever. Rash (58%), myalgia (50%), and
abdominal pain (40%) were common. The mean AST and ALT levels on
the admission were 141 U/l and 85 U/l. The mean platelet count was on
admission was 117000/mm3, and the lowest was 16100. The mean of the
lowest white blood cell count was 3200/mm3. The mean of the highest
lactate dehydrogenase was 925 IU/L. Ribavirin was given to three cases.
Conclusions: CCHF among children was not reported in detail before.
Despite one fatal case, the clinical course of the infection among the
children was milder and the duration of illness was shorter compared to
adult cases.
P1042 Sero epidemiology of Crimean-Congo haemorrhagic fever
in domestic animals in central area of Iran
M. Izadi, H. Salehi, K. Mostafavi, S. Chinikar, B. Ataei, F. Khorvash,
M. Darvish, N. Jonaidi jafari (Tehran, Isfahan, IR)
Objectives: Crimean-Congo Haemorrhagic Fever is a viral zoonotic
infection which several cases of that have been reported in Iran and
during these recent years the nature of the pathogen has been revealed.
The purpose of this study was determination of the seroprevalence of
CCHF IgG among local and imported domestic animals of the Isfahan
province during the year 2004.
Methods: This cross sectional study has been performed among 232
animals regarding to the presence of IgG antibody of Crimean-Congo
Haemorrhagic Fever. The study was made with the special helps of
Arbovirus laboratory Pasteur Institute of Iran on 2004.
Results: 88 (37.9%) of animals had seropositive results in which the
most prevalent was within ovine (53.3%) and after that bovine (38.5%)
and caprine (18.6%). With increasing age, the chance of seropositivity
was increased and the most common range of age belonged to 4−5 years
old animals. The most infected grassland was Borkhar region and after
that Qom, Natanz, Fereydan, Falavarjan and Isfahan, respectively. No
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infected case was noticed among animals belonging to the Kordestan
region grasslands.
Conclusion: The results of this study revealed the endemic spreading of
CCHF in the animals in Isfahan province and it needs special attention
to prevent the infection in the communities and occupational exposure.
P1043 Risk factors among patients with Crimean-Congo
haemorrhagic fever
N. Tasdelen Fisgin, E. Tanyel, N. Tulek (Samsun, TR)
Objectives: Crimean-Congo haemorrhagic fever (CCHF) is a potentially
fatal disease caused by Nairovirus in the Bunyaviridae family.
Methods: Between 2004 and 2006, patients with typical clinical ﬁndings
and positive IgM for CCHFV in blood sample were enrolled in the study.
Patients were divided 2 subgroup; group I (n: 19) alive patients, group II
(n: 5) excites patients. Risk factors including demographic and laboratory
data were investigated among 24 patients with CCHF.
Results: The median platelet count was signiﬁcantly lower in excitus
group (9400/mm3) when compared to alive group (43942/mm3).
Aspartate transferase (AST) and alanin transferase (ALT) levels were
signiﬁcantly higher in excites group (AST: 2555 U/L, ALT: 1675 U/L)
when compared to alive group (AST: 667U/L, ALT: 295U/L).
Conclusion: Low platelet count, increased AST and ALT levels could
be poor prognostic factors in patients with CCHF
P1044 Serology and immunological study on the infectivity of host
animals and ticks (Ixodidae, Argasidae) to CCHF virus in
Ardabil Province, Iran
Z. Telmadarraiy, S. Chinikar, H. Vatandoost, K. Holakoui, F. Faghihi,
Z. Zarei, M. Oshaghi (Tehran, IR)
Ardabil province is located in North western Iran. The main activities of
people in this region is agriculture and cattle rearing. A comprehensive
study was carried out in year 2004–2005 for determination of presence
in virus in ticks and antibody against CCHF in their hosts. The villages
selected randomly and ticks with their host sampled according to
standard method. Results showed that the majority of ticks host were
cow, sheep, goat, camel, poultry, and buffalo, At the same time all the
collected ticks were searched for the presence of CCHF virus using RT-
PCR method. Among 56 sera of cow and sheep and 3 goats, it is found
that 48.7% of sheep, 21.4% of cow and 33.3% of goats was found IgG
positive. Different species of soft and hard ticks including Rhipicephalus,
Hyalomma, Argas and Ornithodoros was collected from various types
of houses, stable and animal shelters.
Results of RT-PCR revealed that 33.3% of Hyalomma collected from
buffalo was positive to virus, Rhipicephalus bursa and Hyalomma
was found positive when they were collected from camel. The ﬁgures
for Rhipicephalus bursa on goat was 40%. Argas reﬂexus which
was collected on poultry was not infected to CCHF virus. The main
species of infected ticks to CCHF was: Rhipicephalus bursa, Haylomma
aegypticom, Hyalomma asiaticum, Hylaomma detritum, Hyalomma
marginatum, Hyalomma shculzei and Ornithodoros lahorensis.
P1045 Clinico-epidemiologic feature and outcome analysis of
Crimean-Congo haemorraghic fever in Iran (1999–2006)
M. Mardani, M. Goya, M. Zainali, M. Keshtkar Jahromi (Tehran, IR)
Background: Crimean Congo Haemorrhagic Fever (CCHF) is a tick
borne viral disease reported from more than 30 countries in Africa, Asia,
southeast Europe, and the Middle East. The disease has been reported
in Iran since 1999. This study is performed to deﬁne the last data of
CCHF cases in Iran.
Methods: Based on records of Ministry of Health of Iran, the
epidemiological features and clinico-epidemiological manifestations of
conﬁrmed cases since 1999 upto 2006 in Iran have been studied.
Results: 287 out of 666 probable cases were conﬁrmed to have
CCHF by positive IgM and/or IgG for CCHF virus. The disease was
more prevalent in middle aged men. The maximum incidence was in
August and September. The clinical ﬁndings were severe headache,
myalgia, nausa and fever. Epistaxiy, bleeding from the gums, nose
and venopuncture sites, petechia, purpura, melena and hematemesis
were common. Large ecchymotic areas developed on trunks, arms and
legs. The most common laboratory ﬁndings were hematuria, proteinuria,
prolonged partia thromboplastin time and AST greater than 100 IU/dl.
Most of patients received oral Ribavirin in addition to supportive care
including volume expanding intravenous ﬂuids, packed cells, fresh frozen
plasma and platelet, management of shock and renal failure and intensive
care. 51 conﬁrmed patients died (Mortality rate = 17.7%). The cause of
death in the most of patients was intractable haemorrhage, multiorgan
failure and shock.
Conclusion: It should be noted that case fatality rate has been increased
despite the decrease in the incidence of disease recently and providing
laboratory facilities in order to have rapid and accurate diagnosis for
early treatment of the disease in endemic areas such as our country
(Iran) is a priority.
P1046 Reappearance of CCHF and other tick-borne arboviruses
in the Syrdarya region of the Republic of Uzbekistan
A. Kadyrov, D. Shermukhamedova, N. Komilov, S. Umurzakov,
E. Bryanseva, M. Nazarbekova (Tashkent, UZ)
Objective: In the Syrdarya region of Uzbekistan, vast virgin lands were
cultivated for agriculture during the last half of the 20th Century. As
a result, natural-foci of arbovirus infections apparently disappeared. For
example, there were not any cases of Crimean Congo Haemorrhagic
Fever (CCHF) reported there in the last 35 years. However; since 2001,
lethal cases of CCHF have been registered annually. It has become
necessary to reevaluate the presence of, and determine the prevalence
of human illness caused by such tick-borne arboviruses in the Syrdarya
region.
Methods: Specimens were collected during the spring and summer of
2001–2004. The collected ﬁeld material included: serum of patients with
febrile illness of unknown etiology (n = 1238), serum of patients with
suspicion of CCHF (n = 167 paired sera), serum from apparently healthy
people (n = 3630), serum from contacts of suspected CCHF patients
(n = 201), serum of cattle (n = 650), serum of other animals (n = 131), and
Hyalomma spp. (H. spp.) ticks (n = 1130). Diagnostic assays for CCHF,
Karshi, Tamdy, and Syrdarya Valley Fever viruses (SDVF) included:
precipitation reaction in agar (RDPA), complement ﬁxation (CFR), and
indirect hemaglutination (IH).
Results: Among the patients with fevers of unknown etiology, CCHF
was detected in 8, Tamdy in 9, Karshi in 24, SDVF in 5, and a
mixed infection was detected in 5 patientsy Among healthy people we
detected precipitating antibodies against CCHF virus in 11 samples.
Antigens of CCHF, Karshi, Tamdy, and SDVF viruses were detected in
H. anatolicum and H. detriticum. Infection of ticks with these viruses was
relatively stable during the study period (19.7% (2001), 53.8% (2002),
21.7% (2003), 25% (2004). In cattle, precipitating antibodies against
CCHF were detected in 8.6%, Karshi in 7.2%, Tamdy in 5.7%, and
SDVF in 4.6% of samples.
Conclusions: Tick-borne arbovirus foci were detected in the Syrdarya
region. H. anatolicum and H. detriticum are known to parasitise domestic
animals and livestock, and are therefore likely contact humans and act as
putative vectors for CCHF. Detection of antibodies against CCHF virus
among healthy people – 0.35%, shows, that inapparent illness due to
infection with CCHF is very low.
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P1047 The situation of Crimean-Congo haemorrhagic fever in the
last years in Iran
S. Chinikar, F. Ahmadnejad, A. Fayaz, N. Hosseini, N. Afzali,
M. Gooya, M. Zeinali, B. Hooshmand, A. Lundkvist, M. Nilsson,
A. Mirazimi, R. Flick, A. Grolla, H. Feldmann, M. Bouloy (Tehran,
IR; Stockholm, SE; Galveston, US; Winnipeg, CA; Paris, FR)
Objectives: Crimean-Congo haemorrhagic fever (CCHF) is an acute
zoonotic tick-borne viral disease caused by the CCHF virus. The virus
belongs to the genus Nairovirus (family Bunyaviridae) and causes severe
haemorrhagic symptoms in man with a mortality rate of 10–50%.
Humans are usually infected with CCHF virus either through the bite
of infected ticks or by direct contact with virus contaminated tissues or
blood.
Methods: From June 2000 to August 2006, sera were collected
from Iranian suspected patients for CCHF and have been sent to the
Arboviruses Lab (National Center) of the Pasteur Institute of Iran. The
sera have been analyzed with speciﬁc ELISA for detecting antibodies
(IgM and IgG), and also with RT-PCR to investigate the genome of the
virus.
Results: Between 854 suspected human cases, 335 were conﬁrmed cases.
Between the 335 cases, 298 were IgM positive and 37 cases only RT-PCR
positive. Between the 298 IgM positive, 75 persons were also RT-PCR
positive. The number of suspected, conﬁrmed and dead cases according
to the year respectively is as follows: 2000 (55, 20, 4), 2001 (167, 66,
11), 2002 (247, 111, 14), 2003 (144, 57, 12), 2004 (82, 26, 6), 2005 (84,
18, 7), up to August 2006 (75, 37, 3).
54.3% of the positive cases were in the age range 21−40 years. The
Sistan-Baluchestan province, by having 64.8% of positive cases, was
the most infected province and the Isfahan province (10.4%) and Fars
province (5.7%) were the second and third infected province. The most
exposed professions were: Farmer (19.4%), worker (18.2%), housewife
(19%) and butcher (12.5%).
Conclusion: CCHF is the most important haemorrhagic fever in most
parts of Iran and conﬁrmed cases have been found in 21 provinces of
Iran. The most infected province is Sistan-Baluchistan in the southeast
of Iran near the border of Pakistan and Afghanistan where the disease
is endemic.
As the most involved age range are people between 21−40 years old
and the majority of conﬁrmed cases professions in Iran are related to
animals; such as farmer, slaughterer and butcher, so informing the high-
risk groups about the transmission routes of the disease is very useful.
P1048 Pandemic ﬂu preparedness – role of antibiotics
E. McIntosh, D. Wu, P. Paradiso, H. Tucker, B. Burlington, R. Brenner,
J. Clarke, J. Cooke, P. Puz, M. Temple, D. Papiernik, R. Mallick,
A. Kuznik, L. Barrett, A. Woodrow (Maidenhead, UK; Collegeville, US)
Objectives: This work analyses the potential role of antibiotics in
pandemic ﬂu preparedness using examples drawn from past pandemics,
interpandemic ﬂu and SARS, and makes recommendations to improve
antibiotic availability in the event of a pandemic.
Methods: Commercial data for antibiotic sales during interpandemic ﬂu
and SARS was obtained. The following assumptions were made: 50%
of the population would be affected by pandemic ﬂu, 10% would be
diagnosed with post-ﬂu bacterial CAP, 20% of those will be hospitalised
and 85% would require IV antibiotics. It was also assumed that 20%
would be infected by MRSA and that 30% of the patients would ideally
received ICU management.
Results: Sales of some IV antibiotics were found to follow the ﬂu season
by up to 3 weeks. The sales of 7 IV antibiotics were signiﬁcantly related
to the number of individuals testing positive for ﬂu, an overall 4.1%
incremental effect. About 40 to 60% of hospitalisations in the USA
(350,000 to 1.2 million) for secondary CAP are projected to optimally
warrant IV antibiotic therapy with coverage for MRSA. In a “moderate”
pandemic there would be 209 thousand and in a “severe” pandemic
1.9 million ﬂu-related deaths in the USA alone. In Hong Kong there
was a very sharp rise in antibiotic use associated with SARS.
The expected successes of the following antibiotics in ﬂu-related CAP
are: ceftriaxone 39.3%, piperacillin/tazobactam 39.9%, azithromycin +
ceftriaxone 63.8%, vancomycin + azithromycin + ceftriaxone 79.5%,
levoﬂoxacin 79.6%, ceftriaxone + levoﬂoxacin 80.8%, azithromycin +
ceftriaxone + levoﬂoxacin 80.8%, piperacillin/tazobactam + levoﬂoxacin
83.1%, tigecycline 85.1%, vancomycin + levoﬂoxacin 93.2%.
Conclusions: In a ﬂu pandemic, there will be a requirement for broad-
spectrum hospital intravenous antibiotics to cover common pathogens,
especially those resistant to conventional antibiotics. Further efforts
should be made to incorporate antibiotic preparedness into pandemic
ﬂu preparedness plans.
P1050 Estimation of the incubation period for pandemic inﬂuenza
during 1918−19
H. Nishiura (Tu¨bingen, DE)
Background: The incubation period of inﬂuenza has not been precisely
understood and is yet to be clariﬁed.
Methods: This study reassessed an epidemiologic record of pandemic
inﬂuenza observed on the ocean during voyages. The original data is
based on observations of 92 voyages from 1918−19, departing from
several ports in Australia with incubating individuals. Although infection
event is not directly observable, the incidence (i.e., time of onset) is
recorded according to the date after departure. Whereas Dr. Anderson
Gray McKendrick (1876–1943) previously used a daily probability of
onset to infer the incubation period, I show how to interpret the data and
improve the estimation method assuming lognormal distribution for the
incubation period.
Results: Maximum likelihood estimates of the mean incubation period
and coefﬁcient of variation were 1.34 days and 53.1%, respectively. The
estimate was roughly consistent with the suggestion of Dr. McKendrick
proposing 32.71 hours as the mean. An explicit distribution of the
incubation period was obtained. Dr. McKendrick’s method appeared to
have assumed the complementary cumulative distribution function for
the observed data.
Conclusions: Although it is often difﬁcult to determine the incubation
period without explicit information of the time of exposure, a hint to
limit most probable time of exposure enables the estimation. Whereas the
precision might be still limited, the length and variance of the incubation
period would be directly relevant to public health interventions (i.e.,
determination of the time to quarantine exposed individuals).
P1051 New emerging human infection caused by Bartonella
vinsonii ssp. arupensis in Russia
A. Kruglov, G. Barmina, V. Osadchaya, G. Frolova, A. Markov,
G. Smirnov, V. Bashkirov, M. Kirillov, M. Kosoy (Moscow, RU; Ft.
Collins, US)
Objective: First case of human illness caused Bartonella vinsonii ssp.
arupensis was described in Wyoming, 1999. The cattle rancher suffered
from bacteraemia and high fever. The second case was recorded in France
in 2005 where a patient was hospitalised with endocarditis.
Methods: Surveyed 95 patients with infective endocarditis (IE) and
a fever of unknown origin (FUO) in the clinics of Moscow Medical
Academy during 2004–2006 years. The basic lab methods of research
were: inoculation of blood samples to Vero E6 cell culture and incubation
at 37ºC for 10 days; culturing of samples on plates with hard medium
in an atmosphere of 5% CO2; estimation of antibody titers by indirect
immunoﬂuorescence (IFA; PCR with genus-speciﬁc primers; RFLP and
sequence of obtained amplicones.
Results: High frequency of the positive serological reactions to
bartonellae antigenes was detected (10.3% – IE, 5.1% – FUO). Two
cases of cultural positive B. vinsonii ssp. arupensis infections were
detected. Both patients were young women. First had FUO. Second –
IE. Blood samples from the patients were obtained on day 39 (1st case)
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and on day 73 (2nd case) after admission. Main clinical manifestations
of the illness were: the acute onset of disease and the symptoms
of expressed intoxication. The patients did not have typical clinical
attributes of classical Bartonella infection; the inﬂammation traits in
blood were slightly expressed, and low-grade bacteraemia symptoms
were observed; the disease had positive dynamics of after the nonspeciﬁc
antibacterial therapy. Typical colonies appeared on agar plates after
7 days of incubation at 37ºC in 5% CO2 atmosphere. Small Gram-
negative bacteria were seen after staining. Biochemical properties and
antimicrobial susceptibility of the both strains were studied and found
typical for Bartonella genus. Antibodies titers to B. vinsonii in serum of
both patients were 1/64.
In both cases PCR from bacterial isolates with Bartonella-speciﬁc
primers resulted in strong positive signals with 5 targets such as partial
sequences of the gltA, ribC, ftsZ, 23S rRNA, and sucB genes. RFLP and
sequence analysis demonstrated that both strains belong to B. vinsonii
ssp. arupensis.
Conclusion: The high frequency of positive serological reactions to
Bartonella amongst patients with IE was detected. This is a ﬁrst report
about the bartonelloses caused by B. vinsonii ssp. arupensis in humans
in Russia.
P1052 Epidemiological, clinical and serological features of human
leptospirosis in Bulgaria in 2005
E. Taseva, I. Christova, T. Gladnishka (Soﬁa, BG)
Objectives: Leptospirosis is a worldwide distributed zoonosis that affects
humans and is now identiﬁed as one of the emerging infectious diseases.
The present study aims to summarise incidence, epidemiology, clinical
symptoms, circulating serovars, mode of transmission, and source of
infection in laboratory conﬁrmed human leptospirosis cases reported to
the Bulgarian Ministry of Health for 2005 year.
Methods: All patients were diagnosed using the reference method for
serological diagnosis, i.e. microscopic agglutination assay. Suspensions
of live serovars from 9 different Leptospira serogroups were used as
antigens.
Results: A total of 43 conﬁrmed and reported leptospirosis cases for
2005 year, were analyzed. The average incidence of the disease was
0.55/100 000. The overall fatality rate was 11.63%, which is higher than
in the previous study. The most cases were reported from north-eastern
regions (Shumen – 27.91%) and north-western (Montana – 11.63% and
Lovech – 9.30%) regions of the country. The disease affected mainly
men. Cases occurred in all age groups, but were more common the
men of working age (51−60 years) – 31.75%. The typical leptospiral
seasonal course, with a peak in October, was observed. The infection
was acquired through occupational (48.84%), recreational (30.24%) and
accidental (20.93%) exposure. The most frequently reported symptoms
were fever (38.46%), icterus (36.54%), myalgia, headache, hepatomegaly
and splenomegaly. Serovars belonging to 6 different serogroups caused
infection during the study period. Two serogroups, Icterohaemorrhagiae
(48.70%) and Pomona (32.17%) accounted for most of leptospirosis
cases. The third main cause of infection was serogroups Bataviae and
Sejroe (6.96%).
Conclusions: The analysis of the data showed that measures for rodent
control are still inefﬁcient. Clinical data showed prevalence of the icteric
clinical form of the disease and serological ﬁnding revealed prevalence of
serogroup Icterohaemorrhagiae. Knowledge of epidemiological, clinical,
and serological features of leptospirosis is an appropriate base to outline
measures for successful prevention and early diagnosis of the disease.
P1053 Epidemiology of human leptospirosis in Malaysia
A. Fairuz, B. Abdul Rani, M. Ayu, I. Hishamshah (Kuala Lumpur, MY)
Leptospirosis is endemic in Malaysia. The epidemiological data for the
past decade is very limited and the true disease burden in Malaysia is
unknown. A hospital based study was carried out to estimate the most
recent incidence and prevalence rates of the disease and also to descibe
some epidemiological characteristics of the disease in Malaysia.
All sera of patients suspected to have leptospirosis admitted to the
hospitals in Malaysia were tested for presence of antibody to leptospira.
Isolation of leptospires and Polymerase chain reactions were also carried
out to augment the diagnotic sensitivity. The clinical data of patients
conﬁrmed to have leptospirosis were obtained from their clinical case
notes.
A total number of 5652 sera were received throughout 2003 till 2005 and
1060 were conﬁrmed positive leptospirosis. The annual incidence rates
for 2003, 2004 and 2005 were 0.9, 1.18 and 2.13 per 100000 population
respectively. The case fatality rate 10.2%. The cases occurred throughout
the year but there were more cases during the intermonsoon period that
is between June to September and December to January. The male to
female ratio was 4:1. The mean age of patients was 40.1±19. Ninety
ﬁve percent of the cases were those in the productive ages between
20−60 years old. The disease was most common amongst the Malays,
the largest ethnic group in Malaysia. The common clinical features
were fever (98%), chills (64.2%), Jaundice (44%), Abdominal pain
(42.9%), cough (56.5%) and hepatomegaly (40.5%). The most worrying
trend is the increasing number of cases(50.8%) with severe pulmonary
involvement which include pneumonia, pulmonary haemorrhage, ARDS,
and pulmonary failure. Pulmonary failure was the major contributory
factor causing death in 85% of the fatal cases.
In conclusion, leptospirosis still remain to be a signiﬁcant cause of
morbidity and mortality. There should be a concerted effort to assess
the health as well as economic impact of leptospirosis in this country.
A comprehensive database needs to be created in order to obtain more
data on the current trend of leptospirosis in Malaysia. Research in this
ﬁeld should also be done via collaborative efforts between the human
and veterinary health institutions to address major issues related to the
disease and facilitate in designing of strategies for control and prevention
of the disease in this country.
P1054 Tularaemia outbreak due to consumption of natural spring
water in Karamu¨rsel, Turkey
M. Meric, M. Sayan, A. Willke, S. Gedikoglu (Kocaeli, Bursa, TR)
Objective: To describe a recent tularaemia outbreak resulted from
consumption of spring water in a village of Karamu¨rsel/Turkey and to
present the anti-epidemic measures implemented.
Methods: After diagnosis as oropharyngeal tularaemia of two patients
come from the village, a ﬁeld investigation was performed at the
region in March 2005. Clinical samples from the patients and water
samples from the natural spring water were obtained and microbiological
investigation was performed. A questionnaire designed to determine the
risk factors for the infection.
Results: Totally 17 patients were diagnosed as tularaemia with their
clinics and serological results. The patients were treated with strepto-
mycin, or ciproﬂoxacin, or doxycycline, or streptomycin+ doxycycline.
All the patients recovered. Francisella tularensis PCR was found to be
positive in water samples. After then spring water collected in a storage,
chlorinated and then allowed to delivery. The outbreak was controled
after hygienic measures.
Conclusion: Oropharyngeal tularaemia is dominant in our region
and Turkey which could be associated with the consumption of the
contaminated water. In this small outbreak, we showed the F. tularensis
DNA by real-time PCR assay. After establishing hygienic regulations the
outbreak was stopped. Surveillance and early alert system for tularaemia
and ﬁeld investigation teams are nessesary for detection and prevention
of the outbreaks.
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P1055 First case of nosocomial Clostridium difﬁcile toxinotype III,
PCR-ribotype 027-associated disease in Switzerland
A.F. Widmer, L. Fenner, M. Rupnik, A. Trampuz, R. Frei (Basle, CH;
Maribor, SI)
Objectives: to describe the ﬁrst case of Clostridium difﬁcile tox-
inotype III, PCR-ribotype 027-associated disease in Switzerland,
characterised by an 18 bp deletion in the tcdC gene and increased
production of toxins A and B in vitro.
Methods: Since 2001, stool specimens are processed by testing for toxin
A/B, and a routine culture for C. difﬁcile is performed, followed by
repeated toxin testing from the isolate. All isolates are saved and stored
at −70ºC, and patient data are stored in a standardised database.
A random sample of all isolates from 2003–2005 were screened for
toxinotype III (Rupnik M J Clin Microbiol. 1998). and underwent
ribotyping (Stubs et al. J Clin Microbiol. 1999). Regulator of toxin
production (TcdC) was analyzed using the method by Spigaglia P. J. Clin.
Microbiol 2002. A total of 388 cultures were positive for C. difﬁcile
during the study period. Of those, 102 isolates were further analyzed
with the methods mentioned above.
Results: One 73 year old patient with advanced lymphoma was positive
for Clostridium difﬁcile toxinotype III, PCR-ribotype 027-associated
disease. She had 2 relapses and suffered from prolonged disease over
three months, only partly responding to metronidazole. The isolate was
resistant to ciproﬂoxacin, levoﬂoxacin and susceptible to moxiﬂoxacin
(MIC 0.75mg/L). The strain had an MIC of clindamycin 3mg/L,
metronidazole 0.125mg/L and vancomycin 0.75mg/L. It was positive
for binary toxins cdtA and cdtB, and showed a 18 bp deletion in tcdC
gene. In addition, the strain exhibited a single nucleotide mutation at
position 117, likely a more speciﬁc marker for highly-virulent epidemic
C. difﬁcile. No evidence for spread of this strain was observed during a
one year follow-up in our institution.
Conclusions: This is the ﬁrst documentation of the highly virulent strain
of C. difﬁcile in Switzerland. This strain demonstrates all characteristics
of the epidemic strain observed in Canada, USA and few other European
countries.
P1056 Emergence of a new epidemic Clostridium difﬁcile strain
(ribotype 017) resistant to newer ﬂuoroquinolones in Poland
H. Pituch, D. Wultanska, P. Obuch-Woszczatynski, G. Nurzynska,
W. van Leeuwen, F. Meisel-Mikolajczyk, M. Luczak, A. van Belkum
(Warsaw, PL; Rotterdam, NL)
Outbreaks due to new hypervirulent C. difﬁcile (ribotype 027,
toxinotype III) strains that are highly resistant to ﬂuoroquinolones were
detected in The Netherlands between April 2005 and February 2006.
One hospital in The Netherlands experienced an outbreak due to a
toxin A negative C. difﬁcile strains (ribotype 017 toxinotype VIII).
Toxin A negative/toxin B positive C. difﬁcile, PCR ribotype 017 strains
lack a part of the toxin A gene and were ﬁrst recognized as a cause of
CDAD in Poland in 1995. Between 2001 and 2005 a growing epidemic of
C. difﬁcile-associated diarrhoea (CDAD) caused by toxin variant strains
producing only toxin B (A−B+) was noted in our Polish university
hospital. All C. difﬁcile strains ribotype 017 isolated before 2001 were
susceptible to the newer ﬂuoroquinolones. The new Polish A−B+ isolates
belonging to PCR ribotype 017 have a characteristic antimicrobial
susceptibility pattern, since they are highly resistant to ciproﬂoxacin,
moxiﬂoxacin, gatiﬂoxacin and show resistance to clindamycin and
erythromycin (MLSB type resistance). Macrolide, lincosamide, and
streprogramin B resistance is due to the presence of an ermB gene. All
PCR ribotype 017 strains were resistant to gatiﬂoxacin and moxiﬂoxacin,
but not the historical isolates (obtained before 2001). Exposure of
patients to ﬂuoroquinolones in Poland is recognized as a risk factor
for CDAD caused by C. difﬁcile strains ribotype 017.
This work was supported by Polish Ministry of Education and Science,
Grant No. 2 P05D 074 27.
P1057 Transfusion-transmitted virus, injection drug users, hepatitis
A. Soudbakhsh, M. Hajabdolbaghi, M. Mohraz, M. Abdollahi Nami,
P. Khairandish, H. Emadi Koochak (Tehran, IR)
Objective: Transfusion-Transmitted Virus (TTV) is a nonenveloped,
single-stranded and circular DNA virus which is belongs to the genus
Anellovirus of circuviridae family. It was discovered by Nishizawa in
1997. One of the most important ways of transmission is use of common
syringes. An increase in the population of Injection drug users (IDU) can
be dangerous to other persons who are not IDUs. The objective of this
study was to determine the prevalence of TTV in the IDU population of
Iran.
Materials and Methods: In this cross-sectional study which was
performed at the Infectious ward of Imam Khomeini hospital, 60 IDU
patients were studied. Blood samples were dispatched to the lab in
citrated test tubes for Virus isolation, using the boiling method, and
then PCB assay performed based on available primers. The patient’s
information gathered by interview and questionnaire methods. Statistical
tests such as Pearson Chi-Square, Mann Whitey and T-test used to
analyze these data.
Results: All our 60 patients were men and their age average was
35.3 years (SD±9.68). Twenty-six patients had positive TTV PCR and
92.3% of them had history of imprisonment. Of these 26 patients, 88.5%
had positive HCV Ab, 65.4% had positive HIV Ab and 30.8% had
positive HBS Ag. In the 60 patients studied, 80% had positive HCV Ab,
71.7% had positive HIV Ab, 43% had TTV PCR and 26.7% had positive
HBS Ag.
Out of 26 patients who had TTV, 34.60% of them had no overt sickness
and 11.5% of them displayed signs of hepatitis (fever, abdominal pain,
nausea, vomiting, right upper quadrant tenderness and icter). Liver
function test was abnormal in 34.6% The average years of injection
in the 26 TTV patients was 9 years (SD±7.16) and the patient’s age
average was 36.35 years (SD±9.2).
Conclusion: One of the most important ways of TTV infection is needle
sharing. By this rout chance of TTV infection is less than HIV and HCV
but more than HBV. Due to the high prevalence of TTV infection in the
IDU population in our country and the fact that this population is not
limited and there is no comprehensive information about pathogenesis
of this virus, which is faecal–oral, there is a need to make plans and
adopt policies to decrease the danger of transmission of this virus to
healthcare workers and their families as well as other near relatives.
P1058 Detection of toxigenic Vibrio cholerae O1 from a freshwater
lake near Tbilisi, Georgia: a potential source for disease
M. Tediashvili, C.A. Whitehouse, A. Huq, E. Jaiani, T. Kokashvili,
N. Janelidze, C. Grim, R.R. Colwell (Tbilisi, GE; Fort Detrick,
Baltimore, US)
Objectives: Strategies for the prevention and control of cholera and
other vibrio-related infections depend on regular monitoring of natural
aquatic environments, as well as understanding the origin, pathogenicity,
transmission dynamics, and other characteristics associated with the
occurrence and spread of epidemic strains. As part of ongoing studies
to examine the presence and diversity of pathogenic Vibrio spp. in
aquatic environments in Georgia, we sampled three freshwater lakes,
Lisi, Kumisi, and Tbilisi Sea near Tbilisi.
Methods: Lakes were monitored for various biological and physical-
chemical characteristics including temperature, pH, and salinity. Samples
were taken from 2 sites from each lake biweekly from May to October
2006. Because Vibrio spp. can survive in the environment in a viable
but nonculturable state, direct detection methods, such as PCR and direct
ﬂuorescent antibody (DFA) assays were used.
Results: Of 375 bacterial isolates obtained, 191 were presumptively
identiﬁed as Vibrio spp. by growth on selective media and typical
biochemical proﬁle. Complete characterisation of these isolates is
ongoing. Total DNA was extracted from water samples and tested
for the presence of V. cholerae and selected virulence factor genes.
S284 17th ECCMID / 25th ICC, Posters
Samples from Lisi Lake were positive for V. cholerae-speciﬁc ISR rRNA
(encoding the intergenic spacer region of the 16S-23S rRNA gene), ctxA,
tcpA, zot, ompU, and toxR by PCR. Furthermore, DFA testing, using
antibodies speciﬁc for either the O1 or O139 serotypes, were positive for
V. cholerae O1. None of the samples tested were positive for V. cholerae
O139.
Conclusion: These data provide initial evidence for an environmental
reservoir for toxigenic V. cholerae O1 in a freshwater lake in Georgia.
Since this lake is often used for recreational purposes, it should be
considered a potential source for disease.
P1059 Detection of Dobrava hantavirus infections in rodents
(Apodemus agrarius, A. ﬂavicollis) in the Transdanubian
region of Hungary
F. Jakab, G. Horva´th, E. Ferenczi, G. Szucs (Pe´cs, Budapest, HU)
Background: Dobrava hantaviruses belong to the genus Hantavirus,
family Bunyaviridae and carried by striped ﬁeld (Apodemus agrarius)
and yellow necked (Apodemus ﬂavicollis) mice. Dobrava hantavirus
causes severe haemorrhagic fever with renal syndrome (HFRS) in many
European countries.
Objectives: The goal of this pilot study was to determine the prevalence
of Dobrava hantavirus in A. ﬂavicollis, A. agrarius, A. sylvaticus rodents
in the Transdanubian region of Hungary.
Methods: The rodents were trapped in three different location of
the Transdanubian region of Hungary (Gye´ke´nyes, Go¨rcso¨ny and Kis-
Balaton area) during the summer and autumn seasons of 2005. The
rodents were dissected and lung tissues were used for hantavirus
detection. The viral RNA was extracted from lung suspensions with
TRIzol reagent according to the manufacturer’s recommendation.
Dobrava hantaviruses were detected by SYBR Green-based real-time
PCR, using newly designed virus speciﬁc primers. Positive samples were
selected for sequence and phylogenetic analysis.
Results: During the study period 22 Apodemus sp. (11 A. agrarius,
10 A. ﬂavicollis and 1 A. sylvaticus) were tested for the presence of
hantaviruses. Out of the 22 Apodemus rodents 3 A. agrarius were
infected with Dobrava hantavirus. Based on the phylogenetic analysis at
least two genetic lineages circulate and represent in the region, according
to the different geographic locations.
Conclusion: In this study we reported the occurrence of Dobrava
hantaviruses in the Transdanubian region of Hungary. Based on the
clinical experience and our new data from the region we concluded that
extended reservoir studies as well as serological investigations might be
important in the future.
P1060 Burden of zoonotic diseases in Venezuela during 2004 and
2005
J. Benitez, A. Rodriguez-Morales (Maracay, Trujillo, VE)
Introduction: Emerging zoonotic diseases have assumed increasing
importance in public and animal health, as the last few years have seen
a steady stream of new diseases, each emerging from an unsuspected
quarter and causing severe problems for animals and humans.
Objectives: For this reason surveillance, analyses, prevention and control
of these diseases are of utmost importance. In this report we described
the importance and burden of zoonotic diseases in Venezuela during
2004 and 2005.
Methods: Records reported from different divisions and states to the
Ministry of Health compiled and summarised are analyzed for years 2004
and 2005. Zoonoses included are: rabies, equine encephalitis, leptospiro-
sis, leishmaniasis, cysticercosis, teniasis, brucellosis, toxoplasmosis and
yellow fever.
Results: During this period 3,859 cases of suspected zoonotic diseases
were recorded, being conﬁrmed 52.8%, 772/2031 in year 2004 (38%)
and 1265/1828 in year 2005 (69%). Leishmaniasis was the ﬁrst in
incidence among this group, 458 cases (22.5%) (p< 0.05) [63 (3.1%)
in humans], followed by rabies with 299 cases (14.7%) [5 (0.2%) in
humans], 175 (8.6%) cases of cysticercosis in humans, 97 (4.8%) cases
of leptospirosis in humans, 39 (1.9%) cases of brucellosis in humans,
VEE 20 cases (1%), EEE 13 cases (0.6%), 18 cases of teniasis, 17 of
yellow fever and 14 of toxoplasmosis.
Conclusion: The reasons for zoonoses emergence are multiple being
the expansion of the human population, animals’ mobilisation and
close human contact, the most important. Current issues such as
the increasing movement of a variety of animal species, ecological
disruption, uncultivatable organisms, and terrorism, all imply that
emerging zoonotic diseases will in all probability, not only continue
to occur, but will increase in the rate of their emergence. The recurring
nature of the crises dictates that closer integration of veterinary and
medical communities is warranted, along with improved education of the
general public and policy makers to reduce the impact of this important
public health problem.
P1061 International Circumpolar Surveillance interlaboratory
quality control programme, 1999–2004
T. Zulz, A. Reasonover, M. Lovgren, L. Jette, M.S. Kaltoft, M. Bruce,
A.J. Parkinson (Anchorage, US; Edmonton, Sainte-Anne-de-Bellevue,
CA; Copenhagen, DK)
Background: The International Circumpolar Surveillance (ICS) system
conducts population-based surveillance of invasive pneumococcal
disease in Finland, Greenland, N. Canada (N Can), N. Sweden,
Norway and in the U.S. Arctic (AK). Reference laboratories in N. Can
[National Centre for Streptococcus (NCS) and Laboratoire de sante´
publique du Que´bec (LSPQ)] and AK [Arctic Investigations Program
(AIP)] began an interlaboratory quality control (QC) programme in
1999 for pneumococcal serotyping and antibiotic susceptibility testing.
Staten Serum Institute (SSI) in Copenhagen, Denmark, joined the QC
programme in 2004. The objectives of the QC programme were to
provide participating laboratories with external proﬁciency testing that
monitors routine protocols as they are applied to the characterisation
of Streptococcus pneumoniae (Sp), to identify and correct potential
problems and to continually improve services.
Methods: Each participating laboratory sent one panel per year. A
panel contained 7 Sp isolates with a variety of serotypes and antibiotic
resistance patterns. Pneumococcal type speciﬁc antisera from SSI was
used at AIP, NCS and SSI to classify all 90 Sp serotypes; LSPQ
maintained antisera to the most common serotypes and less common
ones were referred to NCS. Minimum inhibitory concentrations were
determined for each isolate for those antibiotics routinely tested in
each lab. Results were considered to be in agreement if within one
log(2) of each other. Each lab submitted a completed standard form
to the distributing laboratory where a summary report was prepared that
included discussion of any problems encountered.
Results: A total of 18 panels were tested. The overall serotype agreement
was 91% (range 87.5% – 100%); there were only 2 (11%) out of the 18
panels with less than 100% agreement. Overall antibiotic susceptibility
correlation was 96.3% (range 83%–99%) with 8 or 9 antibiotics tested
per panel. Delays encountered during shipment of panels during 2001
prompted labs to consider using charcoal culturettes or to lyophilise the
cultures for future shipments to maintain isolate viability.
Conclusion: The ICS QC programme is a successful international
interlaboratory quality control testing programme. Correlation of
serotyping and antibiotic susceptibility testing was high. The QC
programme should be expanded to other participating regions in ICS
to ensure interlaboratory comparability.
P1062 Brucellosis in Thailand: emerging and enigmatic
W. Kulwichit, B.K. De, O. Putcharoen, S. Nilgate, N. Hiransuthikul
(Bangkok, TH; Atlanta, US)
Objectives: Brucellosis is a worldwide emerging disease. As per a
recently-updated global map, our country belongs to the group of
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‘nonendemic/no data’, with fewer than 10 human cases. Our cases may
be low in number, but certainly not in clinical attractiveness.
Methods: We gathered data of interesting cases of brucellosis in the
past few years. CASE 1&2 are spouses who suffered from systemic
brucellosis several months apart. Epidemiologic investigation pointed
towards a probable sexual transmission. The isolates were examined at
the US CDC by standard phenotypic assays, AMOS PCR, and multiple-
locus variable-number tandem repeat (VNTR) analysis (MLVA) with 7
Brucella species as controls. CASE 3 developed vertebral osteomyelitis
and psoas abscess following back injury, compatible with the principle
of locus minoris resistentiae.
Results: CASE 1&2 – The 37-year-old husband had been exposed
to goats and drinking unpasteurised goat milk. Blood cultures grew
Brucella melitensis. Four months after his ‘recovery’, his wife started a
prolonged febrile illness. Blood cultures grew B. melitensis. Periodically
visited by her husband, the wife lived in the national capital with no
history of goat exposure or goat milk consumption. Isolates from the
couple (BM1 & BM2) were identical phenotypically and identiﬁed as
Brucella melitensis biovar 2. AMOS PCR revealed that both isolates
co-migrated with a reference strain of B. melitensis. MLVA targeting 15
loci exhibited same-size amplicons for 14 of them, and allele sizes of
631 and 638 for each isolate for the other locus (Figure).
CASE 3, a farmer presented with lumbosacral osteomyelitis and right
psoas abscess by Brucella abortus. She had consumed raw beef for years
without a previous problem. A few weeks prior to this illness, however,
she had been kicked by a cow and fell to the ground, hurting the lower
back area for about a week. This reminds us of locus minoris resistentiae,
or a place of less resistance.
Conclusion: For case 1&2, both isolates were very similar and probably
originated from a single source. With epidemiologic data, the organism
could be transmitted from husband to wife, probably sexually. Case 3
is an example of food-borne zoonosis induced by physical injury.
Brucellosis is not only emerging, it also demonstrates an ability to
manifest and be transmitted in an extended spectrum. Clinicians need to
maintain a suspicious mind to cope with the current world of dynamic
infectious diseases.
P1063 Performance evaluation of a novel enzyme immunoassay for
detection of human metapneumovirus
M. Sheridan (Dublin, IE)
Objectives: Human Metapneumovirus (hMPV) is a causative agent
of acute respiratory tract infections and is emerging as a signiﬁcant
cause of hospitalisation for such infections in young children and the
immunocompromised worldwide. Here we describe the performance
evaluation of an antigen detection enzyme immunoassay (EIA) system
based on a unique combination of monoclonal antibodies directed to
major hMPV proteins.
Methods: The diagnostic performance characteristics (sensitivity and
speciﬁcity) of the hMPV EIA were evaluated using panels of conﬁrmed
hMPV positive or negative respiratory samples that were recovered from
patients by a range of typical collection methods. Analytical performance
parameters were estimated using viral cultures of known TCID50.
Analytical speciﬁcity was evaluated by testing panels of potentially
interfering viruses, bacteria and medications.
Results: The EIA exhibited close correlation to PCR in terms of
diagnostic sensitivity. A high level of speciﬁcity was demonstrated
against a panel of potentially cross-reactive, non-hMPV, specimens. The
EIA was found to be reactive with hMPV subgroups 1 and 2 of genotypes
A and B from viral culture.
Conclusions: The hMPV antigen detection EIA is comparable to PCR
in terms of key diagnostic performance characteristics is an easy-to-
use, cost-effective alternative to PCR suitable for use in the clinical
laboratory.
P1064 Fusobacterium necrophorum infections in Denmark from
1998 to 2001 – a prospective epidemiological and clinical
survey
L.H. Kristensen, J. Prag (Viborg, DK)
Objectives: The aim of this study was to describe the epidemiology and
clinical spectrum of F. necrophorum infections.
Methods: In a prospective countrywide 3-year-study in Denmark from
1998 to 2001 a total of 391 human isolates of F. necrophorum were
registered and epidemiological and clinical data collected from the
clinical records.
Results: Fifty-seven patients had Lemierre’s syndrome, which gave
an incidence of Lemierre’s syndrome of at least 3.5 per mill. per
year, without any increase during the study period or seasonal
variation. Lemierre’s syndrome was seen in 5 small children with otitis
media, 38 youngsters with tonsillitis and 7 young adults with e.g.
parapharyngeal abscess, meningitis or sinusitis and 7 elderly adults with
presumably primary head focus. The patients with Lemierre’s syndrome
were previously healthy. They were obviously sick on admission with
leukocytosis, band neutrophilia, elevated C-reactive protein, metastatic
infections especially to the lungs and rapid progress, if they were not
immediately treated with long-term antibiotics, often combined with
surgery/drainage. Nine percent died.
Disseminated F. necrophorum infections caudally of the head were
seen in 36 elderly patients, who often had predisposing diseases,
e.g. abdominal or urogenital cancers. They had a mortality of 28%,
predominantly due to age and predisposing diseases rather than the
infection.
Localised F. necrophorum infections in the head were seen in
215 youngsters with peritonsillar abscess, 7 small children with otitis
media, 9 small children with solitary abscess formation in cervical
lymphadenitis, 26 youngsters with tonsillitis and 10 middle-aged with
sinusitis or tooth problems. F. necrophorum was found in 20% of all
peritonsillar cases cultured on routine anaerobic media. All localised
cases were previously healthy. They were clearly less sick on admission
than the patients with Lemierre’s syndrome, and all recovered without
sequelae.
Conclusion: The incidence of Lemierre’s syndrome may be higher than
previous thought. F. necrophorum seems to play a role in tonsillitis.
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Increased awareness of Lemierre’s syndrome by the clinicians and the
clinical microbiologists is mandatory, along with long-term antibiotic
therapy, often combined with aggressive surgery and repeated drainage,
to lower mortality and morbidity.
Table 1. Prospective study of Fusobacterium necrophorum infections in
Denmark, 1998–2001
Male Female Total no. Mortality
no. (%)
Lemierre’s syndrome 33 24 57 5 (9%)
Other disseminated cases 24 12 36 10 (28%)
Local infections
In the head and neck 160 107 267 0
Caudally from the head 13 9 22 0
Unknown primary focus 5 1 6 1 (17%)
No signs of infection 1 2 3 0
Total 236 155 391 16 (4%)
P1065 S. agalactiae invasive infections in male adults
M. Makarona, N. Tsagarakis, H. Moraitou, N. Kentrou, A. Gioga,
C. Kapotis, A. Pefanis, S. Kanavaki (Athens, GR)
Objectives: To investigate S. agalactiae invasive infections in our
hospital. In particular, S. agalactiae has been considered a major
pathogen in neonates and pregnant women. However, there is
accumulating concern about its signiﬁcance in non-pregnant adults,
because it has been recently recognized as an important and increasingly
common cause of invasive diseases in the previous. Speciﬁcally, it
can cause disease in adult patients with underlying medical conditions,
including diabetes mellitus, malignancies and liver disease. Skin and
soft tissue infections are common presentations of invasive S. agalactiae
infections, while nosocomial infections and polymicrobial bacteraemia
occur in a signiﬁcant proportion of patients. The annual incidence of
invasive disease has been estimated at 4.4 per 100,000 non-pregnant
adults, whereas the incidence of infections due to S. agalactiae has
increased among diabetic patients. Mortality rates in invasive diseases
are particularly high (20−70%).
Materials: We retrospectively studied 9 cases of systemic infections due
to S. agalactiae in male adults, during the last ﬁve-year period.
Results: From a total of nine cases of S. agalactiae infection, 6 (66.6%)
concerned male patients that had all been hospitalised within this
recent year, 2006, in various departments of our hospital. S. agalactiae
was isolated and identiﬁed in various clinical specimens: blood, pus,
cerebrospinal ﬂuid, sputum, urine, pleural effusion and synovial ﬂuid.
Five out of nine strains (56%) were responsible for bacteraemia, from
which 2/5 where responsible for bacteraemia only, 2/5 for bacteraemia as
well as for diabetic foot, while 1/5 was simultaneously isolated in blood
and cerebrospinal ﬂuid. Among the others, 1/9 (11.1%) was isolated from
pleural effusion, 1/9 (11.1%) from synovial ﬂuid, 1/9 (11.1%) from urine
and 1/9 (11.1%) from sputum. Eight out of nine patients (88.9%) were
suffering from a serious underlying disease: 4 from diabetes mellitus,
2 from diabetes mellitus and malignancy, 1 had malignancy only, 1
suffered from chronic renal failure, while only 1 had a free previous
medical history. One patient died, while all the rest had an improved
clinical outcome.
Conclusion: S. agalactiae invasive infections seem to gain ground as
a signiﬁcant problem in male adults, especially in those with chronic
diseases, such as diabetes mellitus. Efforts should be made to be
identiﬁed and treated early for a successful clinical outcome.
P1066 Nineteen cases of Actinobaculum schaalii identiﬁed in
Viborg County, Denmark
T.F. Jakobsen, H.L. Nielsen, K.M. Søby, J. Prag (Viborg, DK)
Objectives: Actinobaculum schaalii is a Gram-positive, non-spore-
forming, facultative anaerobic, catalase-negative, rod-shaped bacillus,
usually associated with urinary tract infection, and human infections
are currently limited to a few reports. A. schaalii was identiﬁed in
blood and/or urine from 18 patients in 18 months by the Department
of Clinical Microbiology at Viborg Hospital, Denmark. Nine cases with
clear pathological ﬁndings are described.
Methods: In our department urine cultures are routinely incubated in a
CO2-enriched atmosphere and this practice has proved to facilitate the
ﬁnding of A. schaalii, since it grows poorly or not at all in ambient air.
Identiﬁcation of A. schaalii is initially done by use of the API Coryne and
Rapid ID32A test systems eventually followed by 16S rRNA sequencing
to verify the identity of isolated bacteria for publication.
Results: Between February 2005 and July 2006, we identiﬁed A. schaalii
in blood and urine from 18 patients (age range 60−92 years) in Viborg
County, with a population of 230,000. Clinical data and predisposing
conditions from nine patients are summarised in Table 1.
Although A. schaalii was found in urine from the remaining 9 patients
as well, they had no clear clinical symptoms of urinary tract infection at
the time of sampling. The asymptomatic patients suffered from recurrent
UTIs and/or conditions, such as prostate cancer, urethrastenosis,
cystocele and diabetes mellitus, that may predispose bacteuria.
Table 1. In vitro activities of some antibiotics against multi-resistant bloodstream
infections of Acinetobacter spp.
Antibiotics MIC % Resistance
MIC50 MIC90 Range 1996–2000
(n = 60)
2001–2005
(n = 104)
Amikacin 128 256 0.25–256 86.0 74.0
Netilmicin 4 32 0.125−64 46.7 25.0
Imipenem 32 >32 0.064->32 65.0 63.5
Piperacillin-tazobactam 256 >256 0.016->256 81.7 84.6
Cefoperazone-sulbactam 256 256 0.125->256 68.3 63.5
Colistine 2 1024 0.19–1024 63.3 25.0
Tigecycline 1 2 0.047−16 1.0
Ciproﬂoxacin 32 >32 0.064->32 66.7 83.7
Tetracycline 32 256 0.125->256 91.7 86.5
Conclusion: Our ﬁndings conﬁrm the importance of A. schaalii as
a pathogen in UTIs as it can cause serious infections, such as
pyleonephritis and urosepsis, but may also be present in cystitis as well
as in asymptomatic bacteuria. The fact that A. schaalii was found in a
patient in Viborg each month strongly suggests that A. schaalii infections
are more common than previously recognized. Clinicians should be
aware of A. schaalii in cases of unexplained pyuria, especially if the
initial microscopic bacterial ﬁndings differ from the growth results under
aerobic conditions.
P1067 Fusobacterium necrophorum severe sepsis associated with
Lemierre’s syndrome and pulmonary metastatic septic
embolisation
G. Magnani, E. Gabbi, A. Catania, L. Ricci, C. Guidetti, L. Vecchia
(Reggio Emilia, IT)
Objectives: Fusobacterium necrophorum is an unusual but potentially
lethal pathogen, associated with Lemierre’s syndrome, an oropharyngeal
infection complicated by internal jugular vein (IJV) thrombophlebitis
and metastatic septic embolisation. We report a case of this disease with
a secondary pulmonary abscess, following F. necrophorum severe sepsis.
Case report: A 34-year-old female was admitted because of fever,
abdominal pain and diarrhoea. She referred an acute tonsillitis 2 weeks
before. Tonsils hypertrophy, but normal aspect of the neck was observed.
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Laboratory analysis demonstrated WBC 12.4×109/L (85% N), platelets
97×109/L, C-reactive protein 27.41mg/dl and procalcitonin 9.06 ng/mL.
Abdominal US showed splenomegaly and slight peritoneal ﬂuid. Normal
was chest x-ray. Empirical therapy with ceftriaxone 2 gr qd was initiated,
but 24 hours later her clinical conditions worsened with hypotension
(90/40mmHg) and respiratory distress. Auscultation revealed bilateral
chest crepitations and thoracic radiograph conﬁrmed focal inﬁltrates and
slight pleural ﬂuid. Multiple blood cultures yielded b-lactamase negative
F. necrophorum, susceptible in vitro to penicillin, metronidazole and
clindamycin. So, metronidazole 500mg i.v. qid was added. Six day after
the admission, she developed painful left upper neck mass along anterior
border of the sternocleidomastoid muscle. The ultrasound and the CT
scan of the neck demonstrated a parapharingeal inﬁltrate with thrombosis
of left IJV. The surgical approach was excluded. Anticoagulant treatment
with warfarin was started, but ten day into therapy she worsened
with dyspnoea and left pleuritic chest pain. The CT scan revealed an
abscess of 3×3 cm in size in the left paramediastinal side with pleuric
effusion. Surgical drainage revealed a purulent material, negative at the
bacterial cultures. The patient completed a 4-week course of intravenous
antibiotics; and was discharged 30 days after hospitalisation.
Results and Conclusions: We describe a case Lemmiere’s syndrome,
complicated by lung abscess and empyema, due to F. necrophorum.
Note-worthy, the postanginal sepsis developed after two week from the
initial episode of oropharingeal infection. Moreover, F. necrophorum
was isolated from the blood several days before the initiation of the
typical manifestation, underlining the importance of culture of anaerobic
bacteria and the interdisciplinary collaboration
P1068 From insects to man: identiﬁcation of virulence factors
involved in the adaptation of the emerging pathogen
Photorhabdus asymbiotica to human hosts
M. Forquin, J. Esque, A. Pimenta (Cergy Pontoise, FR)
Photorhabdus are entomopathogenic bacteria currently used for the
biological control of crop pests. Recently, an increasing number of
Photorhabdus strains have been isolated from human clinical specimens,
associated with locally invasive soft tissue infections and disseminated
bacteraemia.
Objectives: In view of their growing use in biological control, which
increases the human potential rate of exposure to these pathogens, we
undertook a comparative study between insect and human pathogenic
strains of Photorhabdus, in an attempt to understand the genetic
mechanisms involved in their recently acquired capacity to infect
humans.
Methods: Three Photorhabdus strains, two human (P. asymbiotica SN
and ATCC43949) and one insect pathogen (Photorhabdus sp Q617),
were tested for their ability to bind to two major components of the
human extracellular matrix (ECM), ﬁbronectin (Fn) and vitronectin (Vn),
to infect or invade human epithelial cells in culture, and to interact with
the cellular cytoskeleton. Adherence, infection and invasion experiments
were performed in 96-well microtiter plates coated either with Fn, Vn or
with monolayers of human epithelial HaCaT cells. Bacterial invasion was
quantiﬁed by the gentamicin survival assay. In inhibition assays, anti-Fn,
anti-Vn antibodies, or genistein were added to epithelial cell monolayers.
For immunoﬂuorescence, HaCaT monolayers on glass coverslips were
infected and labelled with phalloidine-TRITC and DAPI.
Results: Only P. asymbiotica human pathogenic isolates ATCC43949
and SN were able to adhere to human ﬁbronectin and/or vitronectin,
and to infect/invade HaCaT cells. This was inhibited in the presence
of antibodies against human Fn or Vn. Only strain ATCC43949
induced cytotoxic effects after 6h co-culture with human cells.
Cytoskeleton involvement in the P. asymbiotica infective process was
indicated by blockage of infection and invasion by genistein, and by
immunoﬂuorescence analysis of infected cells.
Conclusion: The acquisition of virulence factors enabling P. asymbiotica
to interact with human ECM and to human cells is a key factor in its
evolution towards the colonisation of human hosts. ECM proteins are
involved in the primary events during P. asymbiotica colonisation of
human epithelial tissues, and the host cytoskeleton is solicited during
the P. asymbiotica-epithelial cells interaction. Possible mechanisms used
by P. asymbiotica to colonise human tissues are discussed.
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P1069 Clustered epitopes within the Gag-env HIV-1 fusion
proteins DNA vaccine enhance immune responses in mice
F. Roodbari, F. Sabahi, M.N. Sarbolouki, F. Barkhordary, M.A. Mahdavi,
R. Sarami Forooshani, T. Bamdad, A. Adeli, F. Mahboudi (Tehran, IR)
Objectives: The global HIV epidemic continues to expand and
exceeding previous predictions. An effective vaccine represents the best
hope to curtail the HIV epidemic. DNA vaccines induce conformational-
dependent humoral and cellular response and mimic live vaccines
without their pathogenic potential. The importance of CD8+ CTL
responses in controlling HIV and SIV viraemia has led to a series of
vaccine candidates that effectively induce these responses. It is now
widely believed that an HIV vaccine strategy must stimulate both a
strong humoral (antibody) as well as cell-mediated (CTL) immune
response. Neutralising antibodies reduce viral burden by latching onto
and destroying HIV circulating in body ﬂuids. CTLs eliminate HIV-
infected cells, thereby inhibiting viral replication. Both types of immune
response are invoked by the presence of antigens, such as HIV envelope
glycoproteins, in the body.
The P24 and gp41 play many of important roles in host-virus-interaction
and pathogenesis. These proteins are considered as attractive vaccine
candidate in which their immungenecity and immunomodulatory effects
have been conﬁrmed.
Methods: In this study, an expression vector (PCDNA3.1 hygro)
containing P24-gp41 immunogenic sequences under the control of IE
HCMV promoter was designed. The expression of the recombinant
peptides was analyzed in an eukaryotic systems, COS-7 and Hela
cells. Immunoﬂuorescence and western blotting conﬁrmed the presence
of expressed proteins The cited P24-gp41 fusion gene that is able
to express in a proper folding form. This fusion gene was studied
as DNA vaccine in mice(BALB/c) for evaluation and generation of
effective immune responses. For immunising, we used dendrosome, a
novel family of vehicles for transfection and therapy. Some groups of
mice were immunised with our construct and pCAGGS-IL-12 as co-
injection. Humoral response and IFN-g and IL-2 was detected by ELISA.
Lymphoprolifration assay was detected by MTT.
Results: ELISA and MTT assays conﬁrmed, the cited P24-gp41 fusion
gene that is able to enhance immune responses in mice.
Conclusions: Our construct is a good candidate for DNA vaccine against
HIV-1.OF course, it needs much more research for clearing some things
that they are unclear.
P1070 Susceptibility to rubella in females born 1996–2003: a
potential congenital rubella syndrome iceberg?
A. Vyse, R. Pebody, L. Hesketh (London, Preston, UK)
Objectives: Rubella immunisation programmes are designed to prevent
maternal infections and thus congenital rubella infection. Since 1970 the
UK has implemented both selective and universal rubella vaccination
strategies. The WHO European Regional Ofﬁce has established a
target to eliminate rubella from Europe by 2010 and recommends
susceptibility among women of childbearing age to be <5%. Whilst
rubella infection has rarely occurred in the UK since 1996, decreasing
MMR uptake in infants since the late 1990s and increased immigration
from countries without routine rubella vaccination programmes suggest
rubella susceptibility at the population level should be reviewed.
Methods: A total of 2883 serum samples collected in 2004 across the
complete age range reﬂecting the general population were screened for
rubella speciﬁc IgG by ELISA (Behring Enzygnost). Serological data
were stratiﬁed by birth cohort and gender and described using a four
component mixture model, exploiting differences in the distribution
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of quantitative results in samples from previously infected, previously
vaccinated and previously unexposed individuals. Vaccine coverage data
for MMR and laboratory conﬁrmations of rubella obtained in 2004 were
included.
Results: During 2004 only 14 cases of rubella were laboratory conﬁrmed
(ages <1->35 yrs) and vaccine coverage for MMR was estimated to be
~80% by the second birthday for those born 2000–2003. Serological
estimates of susceptibility to rubella in males and females born 2000–
2003 reﬂected vaccine coverage estimates. Whilst serological estimates
of rubella susceptibility in females of childbearing age were very low
(0−2%) in 2004, susceptibility in females born 1996–1999 who have
had opportunity for a second dose of MMR was estimated at 9%.
Susceptibility estimates were also high in males born 1956–1980 (range
7%-12%).
Conclusions: Most rubella susceptibility is found in those born post
1995 reﬂecting the current suboptimal uptake of MMR, and in males
born 1956–1980 who have never had an opportunity for vaccination
and not yet acquired the infection naturally. Susceptibility in women of
childbearing age is currently estimated to be very low in the general
population. It is important that those females born 2000–2003 receive a
second dose of MMR and those females born 1996–1996 who are now
too old to receive a routine second dose should be further monitored, to
ensure low susceptibility levels are obtained in these cohorts before they
reach childbearing age.
P1071 Measles sero-epidemiology in England in 2004
R. Pebody, A. Vyse, L. Hesketh (London, Preston, UK)
Objectives: The WHO European Regional Ofﬁce has established a target
of measles elimination by 2010. Since the late 1990s uptake of MMR
in infants in the UK has declined, and recently the UK has experienced
localised measles outbreaks, particularly during 2006. The aim of this
study was to measure susceptibility to measles in the general population
of England to assess progress towards measles elimination.
Methods: A total of 2883 serum samples collected in 2004 across the
complete age range reﬂecting the general population were screened for
measles speciﬁc IgG by ELISA (Behring Enzygnost). Serological data
were stratiﬁed by birth cohort and described using a ﬁve component
mixture model, exploiting differences in the distribution of quantitative
results in samples from previously infected, previously vaccinated and
previously unexposed individuals. Susceptibility was compared to WHO
age-speciﬁc measles susceptibility targets of <15% in 1−4 year olds,
<10% in those aged 5−9 years and <5% in those aged >10 years.
Historical vaccine coverage data for MMR and laboratory conﬁrmations
of measles were also analysed.
Results: During 2004 vaccine coverage for MMR was estimated to
be ~80% by the second birthday in those born 2000–2003. Reported
laboratory conﬁrmed cases stand at 191 in 2004 (51% in those aged
<5 years), 77 in 2005 (56% in those aged <5 years) and 438 during
the ﬁrst ﬁve months of 2006. The serological estimates of measles
susceptibility in 2004 were 21% in those born 2000–2003, 5% in those
born 1996–1999, 8% in those born 1991–1994, 3% in those born 1986–
1990 and <3% in those born before 1986. A similar study carried out
using samples collected in 2000 estimated measles susceptibility in those
born 1996–1999 to be 21%.
Conclusions: Compared to the WHO age-speciﬁc targets measles
susceptibility in pre-school aged children is high but is within acceptable
limits for older age groups, congruent with the low uptake of ﬁrst dose
MMR that has been observed. This highlights the potential for measles
outbreaks in this age-group and is consistent with recent laboratory
conﬁrmations, indicating the need to improve ﬁrst dose MMR vaccine
coverage. In 2004 the estimate of measles susceptibility in those born
1996–1999 was considerably lower than the estimate made in 2000 for
this cohort before they had opportunity for a second dose of MMR,
reinforcing the value of including a second dose in the programme at
school entry.
P1072 Interpreting the mumps epidemic in England in the early
21st century: a disease iceberg that is likely to continue?
A. Vyse, R. Pebody, L. Hesketh (London, Preston, UK)
Objectives: Currently in the United Kingdom, outbreaks of mumps are
running at their highest level since the introduction of MMR vaccine in
1988. These have mainly affected young adults attending tertiary-level
educational institutions, many of whom have had opportunity for at least
one dose of MMR vaccine. This study draws on key surveillance data
to investigate underlying reasons behind this epidemic.
Methods: A total of 2883 serum samples collected in 2004 across the
complete age range reﬂecting the general population were screened for
mumps speciﬁc IgG by ELISA (Behring Enzygnost). Serological data
were stratiﬁed by birth cohort and described using a four component
mixture model, exploiting differences in the distribution of quantitative
results in samples from previously infected, previously vaccinated and
previously unexposed individuals as the basis for analysis. Comparison
was made with vaccine coverage data for MMR and laboratory
conﬁrmations of mumps obtained in 2004.
Results: During 2004, 8130 cases of mumps were laboratory conﬁrmed
with ~80% in those born 1980–1989 and <1% in those born 2000–2003.
Vaccine coverage for MMR was estimated to be ~80% by the second
birthday for those born 2000–2003. Serological estimates of those with
no evidence of mumps speciﬁc IgG were highest in those born 2000–
2003 (15%) and low in all other birth cohorts/age groups (0%-3%).
Strongest antibody responses occurred in older age groups (born pre-
1980) most likely to have experienced natural mumps infection. Large
proportions of those born 1981–2003 were estimated to have only low
levels of mumps antibody. Those born 1986–2003 have had opportunity
for at least one dose of MMR, with those born 1991–1999 opportunity
for a second dose. There was no evidence that an opportunity for a
second dose of MMR boosted mumps IgG levels.
Conclusions: The current mumps epidemic is occurring in a cohort
where few have no evidence of mumps speciﬁc IgG but large proportions
are estimated to have only low levels of antibody, suggesting a lack
of protection. Behavioural mixing patterns, transmissibility of the virus
and the relative proportions with low or no mumps antibody are likely
to combine to determine where the burden of infection lies. Similar
proportions observed with low IgG levels in those born 1991–2003 may
therefore fuel future mumps outbreaks as they enter tertiary educational
settings, suggesting mumps may be an ongoing problem in the UK.
P1073 Outcome of pregnancy in pregnant women vaccinated in
the mass campaign against measles/rubella in Tehran, Iran
H. Emadi, M. Hajabdolbaghi, M. Rasoolinejad, S. Jafari,
P. Khairandish, L. Taheri, A. Karami (Tehran, IR)
Introduction: Rubella is one of the most important diseases in
pregnancy because of its ability to cause fetal malformations. Fetuses
of women who acquire rubella in the ﬁrst trimester of pregnancy may
have congenital rubella syndrome (CRS) which includes sensorineural
deafness, cataracts, microphtalmos, glaucoma, microcephalos, and other
problems. Pregnancy is a contraindication for rubella vaccination
because of concerns regarding the theoretical possibility of adverse
effects on the developing fetus. To decrease the chance of acquiring
this infection during pregnancy, mass campaign for measles/rubella
vaccination was performed in December 2003 throughout Iran. During
this time period, there were women who received this vaccine during
pregnancy mistakenly as they were not aware of their pregnancy at the
time of vaccination. In this study, we have followed these women who
referred to the infectious disease clinic at Imam Khomeini Hospital to
determine the outcome of pregnancy.
Materials and Methods: Women with history of rubella vaccination
that were possibly pregnant and had referred to the infectious disease
clinic at Imam Khomeini Hospital were included. Pregnancy test and
anti-rubella IgG avidity were performed in all cases. According to the
result of the avidity test, they were grouped into two groups:
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1. High avidity (titer higher than 53% which is indicative of immunity)
2. Low avidity (titer lower than 53% which is indicative of susceptibility)
Neonates born from susceptible women were tested for rubella-speciﬁc
IgM in cord blood sera.
Results: Out of 325 women, 3 were excluded because they were not
actually pregnant and the outcomes of conception were known only for
235 of the 322 pregnancies. Two-hundred-ﬁve (87.2%) had high avidity
and 30 (12.8%) had a low avidity titer. The outcome of pregnancy in the
two groups is depicted in the graph.
Discussion: In this study rubella vaccination did not increase the rate of
still birth, congenital malformation and abortions in rubella susceptible
vaccinated mothers as compared to immune mothers.
There was also no signiﬁcant difference in still birth, congenital
malformation and abortions between non-vaccinated and vaccinated
pregnant women.
P1074 Evaluation of seroconversion to measles vaccine in
vaccinated infants in Ibadan, Nigeria
O.M. Akinloye, O. Oyedele, O. Akinloye, F. Adu (Shagamu, Ibadan,
Osogbo, NG)
Objectives: Measles account for more mortality than any other vaccine
preventable diseases and responsible for over 10% deaths of children
aged below 5 years worldwide. The use of measles vaccine over the last
30 years has however reduced global measles morbidity and mortality.
This study was designed to investigate the efﬁcacy of vaccination in
Nigeria and to determine if the presence or absence of maternal antibody
at the time of vaccination had any inﬂuence on the level of IgG produced
after vaccination.
Methods: Using ELISA kits, the level of maternally derived IgG was
determined in 24 infants at age of nine months who reported at the
vaccination centre and 6 cord blood samples from the maternity ward of
University College Hospital, Ibadan as control group. The children were
bled prior to vaccination and six weeks after vaccination.
Results: Five of the infants had protective levels of maternally derived
IgG while 19 had lost it at the time of sample collection while the
control group shows high IgG levels. Six weeks after vaccination all
the infants tested had post vaccination protective levels of measles IgG
(400–21966 mlU/mL). However, we observed a drop in the IgG level of
children with high maternal antibody level after vaccination, although
the post-vaccination IgG levels were still higher than others. One of
the infants had a dramatic rise in post vaccination IgG (from 367 to
21966 mlU/mL) this prompted the evaluation of pre and post vaccination
measles IgM. Two of the children had detectable measles IgM before
vaccination and 4 children after vaccination.
Conclusion: It is concluded from this study that there is a high vaccine
efﬁcacy with measles vaccination in Nigerian infants. The presence of
measles IgM in some children reporting for vaccination shows possibility
of recent exposure before vaccination. Sustenance of measles vaccine
coverage may therefore result to eradication of measles from Nigeria
population.
P1075 Mumps outbreak in a highly vaccinated school population:
a question of vaccine failure?
D. Park, J. Kim, M. Nam, H. Kim, J. Sohn, K. Song, M. Kim (Ansan,
Seoul, KR)
Objective: Despite MMR vaccination, mumps epidemics have increased.
The aim of this study is to describe and identify possible reasons for
mumps outbreak in a highly vaccinated high school population.
Methods: Survey and cohort study of 41 students in a class of high
school, Gyeonggi province, Korea were carried out from Mar. to Apr.,
2006. Mumps was clinically diagnosed as an illness with 2 or more days
of parotid or any other salivary gland swelling. Vaccination records were
achieved by questionnaire. Serologic screening study for mumps IgG and
IgM antibody (Ab) and mumps IgG avidity test was done with serum
samples collected from 2−5 weeks after onset of symptoms. Virus culture
and PCR detection for the mumps virus from throat swab specimen, and
sequence analysis were performed.
Results: Clinical mumps developed in 15 students (attack rate, 36.6%).
Among them, 11 patients had been vaccinated single dose, 3 had
second dose, and 1 had not. Twenty six students had not developed
clinical illness, of which 23 had been vaccinated single dose, 2 had
second dose, and 1 is unknown. All of 41 students had mumps
IgG Ab. Two of 15 patients had IgM Ab. Virus was isolated in
3 patients. Sequence analysis of virus isolated revealed 99% similarity
with Dg1062/Korea/98 strain. Among 15 patients, 11 vaccinated patients
have been considered as secondary vaccine failure with high IgG
titer and high avidity index (AI, ±32%), an unvaccinated patient as
primary infection with high IgG titer and low AI, and 3 vaccinated
patients as other infections with low IgG titer and low AI. Among 26
healthy students, 5 vaccinated patients were retrospectively diagnosed as
inapparent infection with high IgG titer and high AI, one student as past
infection with high IgG titer and high AI, and the remaining students
showed low IgG titer and low AI.
Conclusions: The overall attack rate of this study is higher than rates
of previous reports for a population with vaccine coverage. Secondary
vaccine failure did play an important role in this mumps outbreak.
Additionally, booster immunisation for mumps should be considered in
immunised adolescent persons to prevent further outbreaks.
P1076 Immunological evaluation of Vi-CPS-BSA conjugate of
Salmonella typhi
H. Ahmadi, B. Tabaraiee, S. Siadat, F. Poor Mirza Gholi, D. Norouzian
Shamasbi, M. Hedayati (Tehran, IR)
Introduction: The role of Vi-capsular polysaccharide (Vi-CPS) in
human immunity against infection caused by Salmonella typhi is well
known. Puriﬁed Vi-CPS can be regarded as a reliable immunogen to
control typhoid fever in man. Moreover BSA can be selected as a
T-dependent macro-carrier protein in order to conjugate with Vi-CPS.
Methods: Vi-CPS was extracted from standard strain of Salmonella
typhi Ty6s (CSBPI-B-191) according previously described, by Ahmadi
et al, 1999. The Vi-CPS of Salmonella typhi Ty6s was conjugated to
Bovine Serum Albumin (BSA-Sigma) according to Mattox et al, 1989.
The conjugate was prepared with 1-ethyl-3-(3-dimethylamino-propyl)
carbodiimide (EDAC). The conjugate, Vi-CPS and BSA were injected
intramuscularly into three group of three rabbit with boosters on days
15, 30 after the primary immunisation. The serum collected on days
0, 15, 30, 45 and 180 were tested by Passive Hemaglutination test for
evaluation of antibody production responses in rabbit model.
Results: In comparison puriﬁed Vi-CPS with Vi-CPS-BSA conjugate,
the titer of hemagglutination passive of anti Vi-CPS-BSA conjugate was
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512 which shows 30 times increase in titer when 3 I/M injection of 50 mg
of conjugate were given to animals.
Discussion: This ﬁnding reveals that I/M injection of covalently bound
puriﬁed Vi-CPS to a T-dependent proteins elicited much higher levels
of antibodies than Vi-CPS alone besides, this conjugate it induce a
booster responses in human. But, unfortunately the level of conjugation
in this process is low due to les number of protein binding sites on
Vi-molecules.
Though the Vi-CPS conjugates elicits higher levels of antibodies,
immunoprophylactic activities of the conjugate must be as curtained by
clinical evaluation and more research should be conducted to increase
the degree of conjugation of the two macromolecules.
P1077 Immunogenicity of tetanus component in monovalent and
combined vaccines
W. Janaszek-Seydlitz, B. Bucholc, U. Czajka, A. Wiatrzyk (Warsaw, PL)
Objectives: Vaccination with combined vaccines is without any doubt
beneﬁcial, allowing for decreasing number of injections and costs
connected with vaccination. However, there is a possibility that the
interaction between components of combined vaccines may inﬂuence
their immunogenicity and reactogenicity. The immunogenicity of tetanus
component in monovalent tetanus toxoid adsorbed and combined
vaccines DTP and DTP+IPV was evaluated on Balb/c mice.
Methods: Animals: Six weeks old Balb/c mice were immunised with
tetanus toxoid adsorbed; DTP or DTP+IPV. Animals (10 mice in each
group) were injected subcutaneously three times with dose 0.25ml at
6 weeks intervals. Control was unvaccinated.
Enzyme-linked immunosorbent assay (ELISA): The antibody responses
to tetanus toxoid in sera 14 days after the immunisation were determined
using in house ELISA method. The level of antibodies was expressed in
arbitrary units.
Production of IFN-g and IL-5: The levels of IFN-g and IL-5 were
evaluated in supernatants of cell culture of splenocytes stimulated by
non-adsorbed tetanus toxoid or PHA.
Results: Geometric mean titre for anti-tetanus antibodies evaluated
14 days after the immunisation in animals vaccinated with tetanus toxoid
adsorbed was lower (2650.2 a.u./mL) than in animals vaccinated with
DTP (3968.6 a.u./mL) or DTP+IPV (4070.7 a.u./mL). There was no
statistical differences between groups of animals receiving only DTP
or simultaneously DTP and IPV. The mean concentration of IFN-g
in supernatants from speciﬁc stimulated cell cultures derived from
animals vaccinated with tetanus toxoid was 720.45 pg/mL, from animals
vaccinated with DTP – 2579.7 pg/mL and from animals vaccinated with
DTP+IPV 1812.05 pg/mL.
The mean concentrations of IL-5 are about 20-times lower than
concentration of IFN-g in cell cultures of splenocytes derived from all
evaluated groups of animals.
Conclusions: Whole-cell pertussis component inﬂuences as adjuvant on
tetanus component in combined vaccines. Simultaneously administrated
IPV vaccine not inﬂuences on immunogenicity of tetanus component.
Pertussis component signiﬁcantly increases level of speciﬁc tetanus
antibodies and production of IFN-g in cell cultures derived from
vaccinated animals.
P1078 Vaccination of healthcare workers against hepatitis B virus
in a teaching hospital
C. Ataman Hatipoglu, M.A. Yetkin, F. Ergin, K. Ipekkan, F.S. Erdinc,
C. Bulut, N. Tulek, G. Demir, Y. Yigit, A.P. Demiroz (Ankara, Samsun, TR)
Objectives: Hepatitis B virus infection which can be prevented by
active immunisation is one of the common health problems among the
healthcare workers (HCW). The aim of this study was to vaccinate our
HCWs in order to protect them against hepatitis B virus.
Methods: A total of 1009 HCWs who were working in Ankara Teaching
and Research Hospital during January 2002-June 2006 were included
into the study. HBsAg and antiHBs results, demographic data (gender,
age, occupation and department) and immune status against hepatitis B
virus were recorded for each HCW. HCWs that were negative for HBsAg
and antiHBs were included into the vaccination programme.
Results: Among 1009 HCWs, 448 were male (44.4%), 561 female
(55.6%) and the mean age was 32.02±7.74 years. Of the HCWs,
209 were working as doctors (20.7%), 246 as nurses (24.4%), 322 as
domestic workers (31.9%) and 232 (23.0%) as other works (laboratory
technician, radiology technician, ofﬁcer, etc). Thirty-one percent of
HCWs were working in the surgical departments whereas 20.6% of
them in internal medicine departments. The rest of them were working
in laboratories, emergency department, outpatient clinics and various
other parts of the hospital with a rate of 8.4%, 7.4%, 7.3% and 25.5%,
respectively. HBsAg was negative in all HCWs. AntiHBs was positive
in 439 (43.5%) and negative in 570 (56.5%). A total of 570 HCWs
were included in the vaccination programme. One hundred and ﬁfteen
(20.2%) were vaccinated with three-dose regimen in 0, 1 and 6 months,
349 (61.2%) with four-dose regimen in 0, 1, 2 and 12 months and
106 (18.6%) with single booster dose with yeast derived hepatitis B
vaccine (Euvax-B, LG Chemical, S. Corea). Four hundred and sixty-
nine of 1009 HCWs had a history of vaccination before, 170 (36.3%) of
them had negative value of antiHBs at the time of the study. These
170 HCWs were vaccinated with a single dose hepatitis B vaccine.
One hundred and six of them became positive for anti HBs after
this vaccination. A complete vaccination schedule was applied to the
remaining 64 HCWs who were negative after a single dose. Three
hundred and sixty HCWs (63.1%) were compatible with the vaccination
programme whereas 210 (36.9%) of them were incompatible.
Conclusion: We think that systematic surveillance and vaccination
against hepatitis B will reduce the risk of transmission of this infection
to the HCWs.
P1079 Comparing the immunogenecity of hepatitis B vaccine in
two different methods of intramuscular and intradermal
injection in infants of Bandar Abbas city, Iran
P. Davoodian, M. Jamshidi, Z. Shamandi, K. Kargar, K. Mahouri
(Bandar Abbas, IR)
Objectives: The efﬁcacy and safety of recombinant DNA hepatitis B
vaccine is well known. However, few data are available on comparasion
of different injection methods of interadermal and intra muscular.
This study aimed to make a comparasion between immunogenicity of
these two methods of injection in infants.
Methods: In a clinical trial 47 cases entered the study who were infants
randomly selected and received Intra-dermal(ID) immunisation against
Hepatitis B at the ages of 0, 1.5 and 9 months old. The blood samples
were obtained from our cases at the age of one year. The control group
was consisted of 100 blood samples which were obtained from 1 year old
infants who had given blood sample for other purposes. These infants
were immunised according to the national vaccination routines applying
intra-mascular(IM) injection method, 3 times (0, 1.5 and 9 months old),
against HBV. After collecting the blood samples from case and control
groups all samples were tested with ELISA method to determine anti-
HBs Ab level.
Results: 84% of cases in IM and 87/3% in ID method had protective
immunity (p = 0.791). In IM method 41.7% of cases had complete
immunity whereas only 19.5% of those with ID method had complete
immunity against HBV (p = 0.024). There was no relation between
gender and Ab level in any of the injection methods.
Conclusion: We found out that both IM and ID methods have the
same immunogenecity feature but IM method resulted in more complete
immunity in infants.
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P1080 Enzyme-linked Immunospot testing to assess the
cell-mediated immune response to anthrax vaccine
precipitated booster vaccination
M. Hepburn, J. Eyles, G. Paterson, E. Dyson, A. Simpson (Porton
Down, UK)
Objectives: Vaccination remains one of the crucial countermeasure
strategies against the intentional use of Bacillus anthracis. Assessment of
the cell-mediated immune response to the licensed UK vaccine, Anthrax
Vaccine Precipitated (AVP), particularly in persons receiving a booster
vaccination, is needed for determining the optimal utilisation of this
vaccine. We are conducting a prospective, observational study using
an Enzyme-Linked Immunospot (ELISPOT) assay to assess the cell-
mediated immune response before and after booster vaccination.
Methods: Laboratory workers scheduled to receive their yearly AVP
booster vaccination had blood samples obtained before vaccination, then
at 1, 2, 4 and 8 weeks after vaccination. Peripheral blood mononuclear
cells were extracted from whole blood samples, and BDTM ELISPOT
kits (Becton Dickinson) for IFN-g, IL-4 and IL-5 were used to assess
cellular responses to antigen-speciﬁc stimulation (5×105 cells per well).
Antigens included protective antigen (PA), lethal factor (LF), and edema
factor (EF), with concanavalin-A as a positive control, and tetanus toxoid
as an additional control. A positive response was deﬁned as a stimulation
index greater than three times the number of positive cells in the medium
only (negative control) wells.
Results: Prior to booster vaccination, the following number of subjects
had positive responses with IFN-g: 2/5 for PA stimulation, 3/4 for LF,
and 2/5 for EF. Two subjects had more than a three-fold increase in
their IFN-g spot counts with PA stimulation by day 56 after vaccination
(compared to pre-vaccination spot counts), while three other subjects
had no change. These subjects had similar trends in IFN-g spot counts
with LF and EF stimulation. Four subjects had low baseline responses
to IL-5 and IL-4 across all of the anthrax antigens, with some increase
in IL-5 noted after vaccination but minimal changes observed in IL-4
counts.
Conclusions: In this ongoing study, cell-mediated responses to anthrax
antigens were measurable in approximately 12 of subjects one year after
their last anthrax vaccination. Some subjects were observed to have a
substantial increase in their cell-mediated response to these antigens,
while other subjects had no response. Further testing is needed to assess
the factors that inﬂuence these immune responses.
P1081 Preparation of the herpes simplex virus type 2
glycoprotein D subunit and DNA vaccines and evaluation
of their efﬁcacy in guinea pigs
F. Fotouhi, H. Soleimanjahi, M. Roostaee, A. Dalimi (Tehran, IR)
Objective: Herpes simplex virus type 2 (HSV-2) is highly prevalent
world-wide and major cause of genital herpes in humans. The life-long
nature of infection, the increasing prevalence of genital herpes, and the
disease severity in neonates and immunocompromised individuals imply
that vaccination is the best strategy for controlling the spread of infection
and limiting HSV disease. Herpes simplex virus glycoprotein D (gD) is
one of the most important viral immunogen which has an essential role in
virus infectivity and can induce humoral and cellular immune responses.
In this study, full length HSV-gD2 gene was used to develop DNA and
subunit vaccines. Their immunogenicity and protectivity was evaluated
in a genital guinea pig model.
Method: In the ﬁrst step, an Iranian isolate of HSV-2 was propagated
in HeLa cell line and its DNA was extracted and used as template
in polymerase chain reactions (PCR), to amplify gD2 gene. The
PCR product was conﬁrmed by restriction enzyme analysis, cloned
into a cloning vector and then sequenced. The gene of interest was
subcloned into an eukaryotic expression vector (pcDNA3) to construct
DNA vaccine which was transfected into mammalian cells and protein
expression was conﬁrmed using indirect immunoﬂoerscent test. In the
next step, the gD2 gene was subcloned into a donor plasmid to construct
recombinant baculovirus and express the desired protein in insect cells
as sununit vaccine which was conﬁrmed with SDS-PAGE and western
blot analysis. In the last stage, the prepared vaccines were used alone or
in combination to immunise guinea pigs.
Results: Immunisation with the above materials elicited potent humoral
responses as measured by neutralisation test and ELISA, protected
guinea pigs from induced HSV-2 genital disease and decreased viral
replication in genital tract as much as that achieved with live HSV-2.
The results also showed that DNA priming-protein boosting induced a
neutralising antibody titer higher than that obtained with DNA-DNA
vaccination.
Conclusion: Although immunisation with recombinant DNAs encoding
antigenic proteins can induce cellular and humoral responses by
providing antigen expression in vivo, but higher immune response has
been shown to occur when the recombinant proteins followed DNA
inoculation. The ﬁndings conﬁrmed that vaccine formulation containing
gD2 protein and pcDNA-gD2 is more effective than DNA alone.
P1082 Concomitant administration of Zostavax® and inﬂuenza
vaccine in adults 50 years old
B. Kerzner, A. Murray, E. Cheng, R. Iﬂe, P. Harvey, M. Tomlinson,
K. Rarrick, J. Barben, J. Stek, M. Chung, J. Xu, I. Chan, K. Schlienger,
F. Scho¨del, J. Silber (Baltimore, Greensboro, Brooklyn, US;
Waterland-Oost, NL; Surrey, Ledbury, UK; North Wales, US)
Background: Zostavax® is licensed for prevention of herpes zoster
(HZ) and its complications. This study evaluated Zostavax® administered
concomitantly with inﬂuenza (ﬂu) vaccine in adults 50 yrs old.
Methods: Randomised, double-blind, placebo-controlled study. Eval-
uated safety and immunogenicity proﬁles of Zostavax® given con-
comitantly or sequentially with ﬂu vaccine. Primary safety endpoints:
incidence of vaccine-related serious adverse experiences (AEs) within
28 days postvaccination (PV); and vaccination report card prompted
systemic and injection-site AEs. Primary immunogenicity endpoints:
geometric mean titer (GMT) and geometric mean fold rise (GMFR) of
varicella-zoster virus (VZV) antibody (Ab) at 4wks PV by glycoprotein
enzyme-linked immunosorbent assay (gpELISA); and GMT of ﬂu Ab
for the 3 vaccine strains at 4wks PV by hemagglutination inhibition
assay. Secondary immunogenicity endpoint: ﬂu seroconversion rates
(titer 1:40 4wks PV in baseline seronegative subjects).
Results: No serious AEs related to Zostavax® were observed during
the study. VZV Ab GMTs 4wks PV for the concomitant (N = 382)
and nonconcomitant (N = 380) groups were 554 and 597, respectively.
Estimated VZV GMT ratio was 0.9 (95%CI, 0.8, 1.0), indicating non-
inferior (p< 0.001 that decrease is <1.5 fold) responses. Estimated VZV
GMFR from baseline in the concomitant group was 2.1 (95%CI: 2.0,
2.3), indicating acceptable range of fold-rise. Estimated GMT ratios
(concomitant/nonconcomitant) for ﬂu strains AH1N1, AH3N2, and B
were 0.9 (95%CI: 0.8 to 1.1), 1.1 (95%CI: 0.9 to 1.3), and 0.9 (95%CI:
0.8 to 1.1), respectively. Seroconversion rates for each of the 3 ﬂu strains
were comparable across the 2 groups, with >85% of subjects achieving
1:40 PV Ab titers, meeting EMEA criteria.
Conclusions: ZOSTAVAX® and ﬂu vaccine administered concomitantly
are generally well tolerated in adults 50 yrs old. VZV and ﬂu Ab
responses were similar whether Zostavax® and ﬂu vaccine were given
concomitantly or sequentially.
P1083 Investigation of IFN-g and IL4 cytokine responses in
vaccinated mice with DNA vaccine containing E7 gene of
human papillomavirus type 16
Z. Meshkat, H. Soleimanjahi, Z. Hassan, M. Mahmoudi, H. Mirshahabi,
M. Meshkat (Tehran, Mashhad, IR)
Objectives: Papillomaviruses are small, non-enveloped viruses, their
sizes is 55 nm in diameter, and widely induce cervical cancer. Cervical
cancer is the second most common malignancy in women, and
an estimated 470,000 new cases are diagnosed annually. Human
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Papillomaviruses (HPVs), particularly HPV 16, are associated with most
cervical cancers. For immunotherapy of HPV16 associated disease, the
E7 gene is considered a prime candidate, as it is expressed in all HPV16-
positive tumours.
Methods: Previously, we designed and constructed an expression vector
containing E7 gene of HPV16 as a DNA vaccine. In this study, we used
the vaccine and injected it to BALB/c mice for evaluation of cytokine
responses. IFN-g and IL4 production were measured in the mice by
ELISA.
Results and Conclusion: Our results showed the vaccine can induce
production of IFN-g but not IL4. Therefore, the mice immune system
showed CD8 than CD4 responses. It is very important in cancer therapy
because CD8 responses can eliminate tumour cells.
P1084 Long-term public health effects of vaccination against
cervical cancer in Germany: results from a Markov model
T. Schwarz, A. Schneider, R. Rogoza, N. Ferko, T. Hammerschmidt,
U. Siebert (Wu¨rzburg, Berlin, DE; Burlington, CA; Munich, DE; Hall
i.T., AT)
Objective: To assess the public health impact of vaccinating 10 year
old girls with an HPV-vaccine on precancerous cervical lesions
(CIN=cervical intraepithelial neoplasia) and invasive cervical cancer
(ICC) in Germany.
Methods: A Markov model which replicates natural history of HPV
infection to ICC is calibrated for Germany in order to reﬂect the
current German epidemiologic situation and screening/treatment patterns
using German cancer registry data, literature data and ofﬁcial statistics.
Vaccination added to routine cervical cancer screening is compared with
screening alone. Screening is maintained constant (~47% of the German
women aged 20 years and older screened each year). A cohort of 399,400
ten year old girls is completely vaccinated. The vaccine covers HPV-
genotypes 16 and 18. Based on clinical evidence, it is assumed to provide
95% protection against HPV-16 and HPV-18 as well as cross protection
against related genotypes HPV-45 (90%) and HPV-31 (50%) (Harper et
al. 2006). Sensitivity analysis is performed.
Results: The screening alone strategy results in 9,088 detected CIN1
lesions (4,239 (46.6%) due to oncogenic HPV), 3,181 treated CIN1
lesions (1,484 (46.7%) due to oncogenic HPV), 40,023 detected CIN2/3
lesions (29,014 (72.5%) due to oncogenic HPV), 39,253 treated CIN2/3
lesions (28,464 (72.5%) due to oncogenic HPV), 4,425 ICC cases
and 1,139 ICC-related death. Adding vaccination to screening reduces
the number of treated CIN1 by 853 (−26.8% of any cases/−57.5%
of cases due to oncogenic HPV), treated CIN2/3 by 16.808 (−42.8%
of any cases/−59.1% of cases due to oncogenic HPV), ICC cases by
3,462 (−78.2%) and ICC deaths by 885 (−77.7%). 27.8%, 14.2%, and
5.1% of the overall effectiveness against CIN 1, CIN2/3, and ICC,
respectively, can be attributed to cross protection.
The model is most sensitive regarding variations in age at vaccination,
vaccination coverage and screening interval, but less sensitive against
variations on vaccine efﬁcacy, cross protection, or a theoretically possible
waning of immunity.
Conclusions: Despite opportunistic cervical cancer screening, a high
disease burden from precancerous lesions and invasive cervical
cancer including related mortality remains in Germany. Adding HPV
vaccination can signiﬁcantly reduce this burden. Cross protection plays
a remarkable role in the primary prevention of cervical cancer and
precancerous lesions.
P1085 Administration of DNA vaccine containing E6 gene of
HPV16 in order to evaluate cellular immunity
H. Soleimanjahi, Z. Hassan, Z. Poorpak, Z. Meshkat, H. Mirshahabi,
M. Meshkat (Tehran, Mashhad, IR)
Objective: Cervical cancer is the second most common cause of
cancer deaths in women worldwide. Human papillomaviruses (HPVs)
are thought to be the primary causative agent in >90% of cervical
cancers, with HPV 16 being the type most frequently found in these
tumours. HPVs are thought to induce cervical carcinoma most likely
through the expression of E6 and E7 genes presumably by inactivating
the tumour suppressor protein, p53 and p Rb, respectively. E6 is a
multifunctional protein that affects cell growth and proliferation. The E6-
mediated activities include cell immortalisation, transformation, tumour
formation, and apoptosis. E6 and E7 oncoproteins are the most logical
target molecules for therapeutic vaccines. In the present study E6 was
chosen as target gene in order to evaluate CMI responses.
Methods: The HPV16 E6 ORF was obtained by PCR ampliﬁcation using
designed speciﬁc primers and cloned into pcDNA3 expression vector.
The constructed was used for immunisation of mice after conﬁrmation.
Animal receiving to injection of target expression vector (pcDNA3-
HPV16 E6) and pcDNA3 vector as a negative control were evaluated
for speciﬁc T helper immune responses.
Results: Mice receiving pcDNA3-HPV16 E6 demonstrated high level
production of IFN-g versus negative control group where as IL4
production was not statistically signiﬁcant.
Conclusion: Based on the results, the injection of pcDNA3-HPV16 E6
examination plasmid could efﬁciently induce IFN-g, an indicator of Th1
responses, with has an important role in cancer therapy. The ability of
the vaccine to elicit speciﬁc T cell responses and modulate a relevant
cytokine secretion pattern is the key to DNA vaccine efﬁcacy.
P1086 Serum bactericidal antibody titres against serogroup C
meningococci in Turkish children: serological basis of the
need for conjugated meningococcal vaccine
I. Yildirim, M. Ceyhan, P. Balmer, N. Andrews, R. Borrow, A. Aydogan,
C. Ecevit, M. Turgut, N. Kurt, G. Uysal (Ankara, TR; Manchester,
London, UK)
Like many other developing countries; there is no accurate information
about the distribution of Neisseria meningitidis serogroups and the
potential need for a conjugated meningococcal C vaccination programme
in Turkey. To evaluate the need for this vaccine in our country we
collected serum samples from four health centres located in different
geographic regions and stratiﬁed according to age. Sera were tested
for serum bactericidal antibodies (SBA) to serogroup C meningococci
using rabbit serum as the complement source. It was observed that
98 (29.8%) and 40 (12.2%) of 329 individuals within the study
population achieved SBA titer of >8 and >128, respectively. Overall;
at least 70.2% of the population are susceptible (SBA titer <8) to
meningoccal serogroup C disease. The rate of susceptibility was highest
in infants aged 7−12 months and young children (1–4 years). Although
the true incidence of meningococcal serogroup C disease is not well-
known in Turkey, conjugated meningococcal C vaccine should be in
mind as candidate vaccine for routine immunisation schedule given the
high rate of susceptibility of the Turkish population.
P1087 Comparison among opsonic activity and serum bactericidal
activity against Meningococci in rabbit sera from vaccines
after immunisation with the Neisseria meningitidis
serogroup A capsular polysaccharide-serogroup B outer
membrane vesicle conjugate vaccine
S. Siadat, H. Najaﬁ Barzegar, Q. Behzadiyannejad, B. Tabaraiee,
H. Ahmadi, D. Nourouzian Shamasbi, S. Najar Peerayeh, M. Nejati,
M. Zangeneh, B. Adibi Motlagh (Tehran, IR)
Introduction: Production of effective vaccine formulations is dependent
on the availability of assays for the measurement of protective immune
responses. Antibody- and complement-mediated phagocytosis is the
main defence mechanism against Neisseria meningitidis.
Methods: Therefore, a newly developed phagocytosis assay based on
ﬂow cytometry (ﬂow assay) and the serum bactericidal assay (SBA) were
using sera obtained from rabbit postvaccination with a bivalent conjugate
of Neisseria meningitidis serogroup A capsular polysaccharide (CPSA)
to serogroup B outer membrane vesicle containing PorA (OMV-PorA),
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an OMV-PorA of Neisseria meningitidis serogroup B and the CPSA
(as control), was done in order to evaluation of the potential efﬁcacy
of (experimental) meningococcal vaccines. The conjugate and control
were injected intramuscularly into groups of ﬁve rabbit with boosters
on days 14, 28 and 42 after the primary immunisation. The following
groups were used as control: 1: CPSA; 2: OMV-PorA; 3: normal saline.
The serum on days 0, 14, 28, 42 and 56 were collected and stored at
−20ºC for next analysis.
Phagocytic function of and intracellular oxidative burst generation by
rabbit PMN, against Neisseria meningitidis serogroup A and B, were
measured with ﬂow cytometer (Coulter Epics-XL-Proﬁle USA), using
dihydrorhodamine-123 as probes, respectively. In these experiments
non-heat-inactivated standard strain Neisseria meningitidis serogroup A
(CSBPI, G-243) and B (CSBPI, G-245) were used. SBA titers are given
as reciprocal Log2 values of the dilution giving at least 50% killing of
the inoculum measured as colony forming units.
Results: The results of SBA titers and quantitative ﬂow cytometric anal-
ysis of rabbit PMN function in hyperimmun sera with the glycoprotein
conjugate revealed a highly signiﬁcant increase in opsonophagocytic
responses and bactericidal antibody against serogroup A meningococci
after 56 day in comparison with the CPSA and OMV-PorA control
group (P< 0.05). Opsonophagocytic responses and bactericidal activity
against serogroup B meningococci of the conjugate showed no signiﬁcant
difference in comparison with the OMV-PorA containing control
(P> 0.05).
Conclusion: Both SBA and opsonic activity are crucial for the protection
against meningococcal disease, Our results indicated that the CPSA–
OMV-PorA conjugate could be as a candidate for bivalent vaccine toward
serogroup A and B meningococci.
P1088 Evaluation of serum bactericidal activity speciﬁc
for Neisseria meningitidis serogroup A and B: effect
of immunisation with N. meningitidis serogroup A
polysaccharide and serogroup B outer membrane vesicle
conjugate as a bivalent vaccine candidate
B. Adibi Motlagh, S.D. Siadat, Q. Behzadiyannejad, B. Tabaraiee,
H. Ahmadi, S. Najar Peerayeh, D. Nourouzian Shamasbi, M. Nejati,
M.H. Hedayati, A. Moshiri (Tehran, IR)
Objective: Bacterial meningitis caused by different groups of Neisseria
meningitidis is still one of the Serious health problems world wide.
The serum bactericidal assay (SBA) to meningococci is the most
important test in immunological evaluation of meningococcal infection
after vaccination. The SBA has been adapted as the gold standard for
immunity against different serogroups of Neisseria meningitides after
immunisation.
Methods: Neisseria meningitidis serogroup A capsular polysaccharide
(CPSA) was conjugated to serogroup B OMV-PorA in order to test the
possibility of obtaining a bivalent serogroup A and B meningococcus
immunogen. The conjugate was prepared with adipic acid hydrazid
(ADH) and 1-ethyl-3-(3-dimethylamino-propyl)carbodiimide (EDAC).
The conjugate and control were injected intramuscularlly into groups
of ﬁve rabbit with boosters on days 14, 28 and 42 after the primary
immunisation. The following groups were used as control: (1) CPSA
plus OMV-PorA; (2) CPSA; (3) OMV-PorA; and (4) normal saline. The
serum collected on days 0, 14, 28, 42 and 56 were tested by complement
mediated bactericidal assay according to the World Health Organization
protocol.
Results: The results of SBA in the glycoprotein conjugate group revealed
a signiﬁcant increase in serum bactericidal titer against serogroup A
meningococci after 56 day in comparison with the CPSA and OMV-
PorA control group. Bactericidal titer against serogroup B meningococci
of the conjugate showed no signiﬁcant difference in comparison with the
OMV-PorA containing control.
Conclusion: The results indicate that when polysaccharide A and OMV
are in a covalent conjugate form, the complex is able to induce a high
level of bactericidal antibody response. Therefore, this paper shows
that the CPSA–OMV-PorA conjugate could be a candidate for bivalent
Vaccine toward serogroup A and B meningococci.
P1089 Comparative studies of conjugated capsular polysaccharide
of Neisseria meningitidis serogroup A with outer membrane
vesicle of N. meningitidis serogroup B
S.D. Siadat, D. Nourouzian Shamasbi, B. Tabaraiee, H. Ahmadi,
Q. Behzadiyannejad, S. Najar Peerayeh, B. Adibi Motlagh, M. Nejati,
M.H. Hedayati (Tehran, IR)
Objective: Many strategies are being explored to manipulate the
immune system of humans/animals to ﬁght better against a pathogenic
organisms. The incidence of endemic meningitis and the frequency of
epidemic meningitis caused by group A Neisseria meningitidis (GAM)
are increasing in Africa and Asia. Although GAMP vaccine confers
immunity at all ages, the improved immunogenicity of a conjugate and its
compatibility with the World Health Organization’s extended programme
on immunisation offers advantages over GAMP alone. Henceforth,
disease caused by serogroup B strains remains an unsolved health
problem in many part of the world and the lack of a serogroup B
meningococcal vaccine is a serious public health limitation since these
strains account for approximately one-third of meningococcal disease in
North America and up to 80% in North Europe.
Method: In this study, polysaccharide from Neisseria meningitides
serogroup A was puriﬁed according to the World Health Organization
protocol. Then outer membrane vesicle (OMV) of serogroup B
meningococci was also extracted by deoxycholate reagent using
ultracentrifuge. Conjugates of group A meningococcal polysaccharide
(GAMP) bound to OMV, with adipic acid dihydrazide (ADH) as a
linker and 1-ethyl-3-(3 dimethylaminopropyl) carbodiimide (EDAC) as
a coupling agent, were synthesized and characterised. The obtained
polysaccharide was activated by cyanogens bromide (CNBr) and
1-cyano-4(dimethylamino)pridium tetraﬂoroborate (CDAP) separately.
First ADH with EDAC was bound to GAMP activated with CNBr to
form GAMPCNBr AH. Second ADH with EDAC was bound to GAMP
activated with CDAP to form GAMPCDAP AH. Then these derivatives
were conjugated to OMV by EDAC to form GAMPCNBr AH-OMV and
GAMPCDAPAH-OMV.
Result: Thus, GAMPCDAPAH-OMV with immunogenicities improved
over that of GAMP have been prepared and standardised. The yields
of GAMPCDAPAH-OMV was 45 to 48%. GAMPCDAPAH-OMV was
higher than that of the other conjugate (15−17%). The glycoconjugates
were shown to induce hyperimmunity in rabbits and formed antibodies
against the above mentioned conjugates were detected by immune
diffusion technique.
Conclusion: The average yield of conjugation should be improved
through a useful activating reagent.CDPA seemed to be a more useful
activating reagent, because the treated GAMP had a higher molecular
weight and content of O-acetyl than other activator(CNBr). Therefore,
the development of a A/B bivalent anti-meningococcal vaccine could be
a good candidate.
P1090 Development of novel recombinant group B streptococcal
vaccine based on surface expressed polypeptides
A. Suvorov, L. Meringova, K. Grabovskaya, A. Simbirtcev, G. Leontieva,
E. Vorobieva, I. Koroleva, A. Totolian (St. Petersburg, RU)
Objectives: Group B streptococcus (GBS) being a common cause of
newborn mortality raises numerous problems to the healthcare system
due to extremely high level of carriage and inefﬁciency of conventional
antibiotic therapy. Recently several attempts to generate GBS vaccine
had been made in different laboratories however at present there is no
GBS vaccine on the market. Employing the strategy of cloning of the
epitope containing regions of the surface expressed polypeptides several
constructs had been made and the resultunt products were tested for
immunogenicity and protection.
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Goals of investigation: Analysis GBS surface proteins as vaccine
component against infection.
Materials and Methods: GBS gene fragments encoding for proteins
Bac, ScaAB, GS and ScpB had been cloned from the strains 090R
(1a) and 219 (1bc) and expressed in E. coli. Afﬁnity puriﬁed
polypeptides were used for immunisation of mice and rabbits. Mice
antibodies were used for protection and antibody dynamics studies. For
opsonophagocytosis assay serum from mice or rabbits had been used.
Four different types of adjuvants (Feund, Alum, Bestim and IfnG) had
been used for stimulating immune response. Evaluation of the results
of immunisation had been done by ELISA with the following computer
analysis.
Results: It was determined that protein antigens depending on their kind
and molecular weight differ dramatically regarding the immune response
and protective force. Interestingly, in spite of the correlation between
the antibody titer and the level of protection antibodies to some of the
peptides were protective with relatively small concentrations of speciﬁc
IgG. We could determine protective antibody titers for the most of the
peptides. Results of in vitro opsonophagocytosis assay well correlated
with data obtained after mice protection experiments. Alum and Freund
adjuvants were providing most effective immune response stimulation.
Results of the analysis allowed selecting most promising peptide antigens
for the future vaccine development. Study had been supported by RFFI
grants 06−04–08026 and 06−04–48949.
P1091 Trends in pneumococcal bacteraemia in adults after the
beginning of a pneumococcal vaccination programme
G. Peralta, B. Ceballos, M. Sanchez, C. Farin˜as, I. De Benito, M. Roiz,
L. Ansorena (Torrelavega, ES)
Objectives: In Cantabria (Spain) a polysaccharide pneumococcal
vaccination programme has been initiated in the year 2000, directed to
people older than 65 years and/or with speciﬁc comorbidities. We analyze
changes in incidence and characteristics of pneumococcal bacteraemia
(PB) in our hospital after the beginning of the pneumococcal vaccination
programme.
Methods: Retrospective review of all charts of patients with PB
identiﬁed by using the microbiology database, attended in our hospital
from January 1997 to December 2005. We compared the periods 1997–
2000 (prevaccination) and 2001–2005 (postvaccination). In statistical
analyses, Mann-Whitney U test was used for the comparison of mean
values and Chi-square test for the comparison of categorical data.
Prevaccine
(N= 65)
Postvaccine
(N= 53)
p
Age (years±SD) 65±17.8 63.4±20.2 0.9
Diabetes n (%) 6 (9.2) 5 (9.4) 0.61
Immunosuppression n (%) 5 (7.7) 1 (1.9) 0.16
Cirrhosis n (%) 9 (9.2) 2 (3.8) 0.21
Renal Chronic failure n (%) 1 (1.5) 0 0.56
Charlson index 0.74±0.94 0.94±1.14 0.49
Pneumonia n (%) 54 (83) 41 (77) 0.3
Meningitis n (%) 4 (6.2) 6 (11.3) 0.25
Exitus n (%) 6 (9.2) 7 (13.2) 0.35
Penicillin susceptible n (%) 50 (76.9) 50 (94.3) 0.007
Incidence× 106 year 9.22±3.48 6.12±2.04 0.14
BP× 103/hospital admissions 2.13±0.17 1.14±0.39 0.03
BP× 103/blood cultures 10.54±3.56 4.96±1.6 0.02
Results: In the period of study we detected 118 PB. The annual
incidence 8.2 cases per 100000 population. No signiﬁcant differences
were detected among prevaccine and postvaccine periods in the age,
the presence of any comorbidity, the origin of the bacteraemia or the
outcome of patients with PB. A decrease in the proportion of PB caused
by penicillin non-susceptible pneumococci in the postvaccination period
was detected. Although no signiﬁcant difference was detected in the
global PB incidence among prevaccine and postvaccine period, both
the number of annual PB respect to the hospital admissions and the
number of annual PB respect blood cultures performed diminished in
the postvaccine period.
Conclusions: Our data suggest that PB has decreased after the beginning
of a pneumococcal vaccination programme, with an associated decline
in penicillin non-susceptibility. No change in other characteristics of
patients with PB has detected after the beginning of the programme.
P1092 Effect of the introduction of the pneumococcal conjugate
vaccine on invasive disease produced by Streptococcus
pneumoniae
E. Cercenado, O. Cuevas, A. Fenoll, M. Marin, D. Vicioso, E. Bouza
(Madrid, Majadahonda, ES)
Objectives: The heptavalent pneumococcal conjugate vaccine (PCV7)
reduces carriage of pneumococci and prevents the disease. The PCV7
was licensed in Spain in 2001. We evaluate the effect of PCV7 on
invasive disease and the impact of non-PCV7 serotypes in the area cared
for our institution.
Methods: We identiﬁed episodes of bacteraemia and meningitis due to
pneumococci in patients admitted to our institution from 1999 to 2005.
Serotype distribution and antibiotic resistance were compared.
Results: A total of 726 episodes of bacteraemia (9% children) and
46 cases of meningitis (22% children) were identiﬁed. Over the period
of study, the most frequent serotypes were 14 (10.2%); 3 (9%);
19 (8.9%); 8 (8.5%); 1 (7.2%); 4 (6.6%); and 23F (3.5%). By comparing
data from 1999–2001, with data from 2002–2005, the percentage of
isolates non-susceptible to penicillin showed a slight decrease (from
31.47% to 30.2%) and isolates resistant to erythromycin increased
(from 17% to 24.3%). The incidence of pneumococcal bacteraemia was
unchanged (from 1.90 cases to 1.92 cases/1,000 admissions). Vaccine
serotypes caused 38% of episodes of bacteraemia and meningitis in the
ﬁrst period, compared with 27.4% of episodes in the second period
(p = 0.037). Infections due to vaccine serotypes 4, 9V, and 23F decreased
signiﬁcantly during the second period (p< 0.002) but not these caused by
serotypes 6B, 14, 18C, and 19F. The percentage of episodes of invasive
disease caused by vaccine-related serotypes (same serogroup but not the
same serotype as PCV7) showed a tendency towards the increase from
10% of episodes in the ﬁrst period to 14%of episodes in the second
(p = 0.135). Episodes due to VRST 19A increased (p< 0.001). Infections
caused by non-PCV7 serotypes 1 and 8 increased from 11% to 19%
(p< 0.05). In 2005, all invasive infections in children were produced by
non-vaccine serotypes, and the estimated coverage of the PCV7 in adults
was 23.6%.
Conclusions: The overall incidence of invasive pneumococcal disease
and the rate of antibiotic-resistant invasive infections has not decreased
in our area after the introduction of the PCV7. There were signiﬁcant
decreases in the incidence of invasive infections caused by several
vaccine serotypes, however, invasive infections due to vaccine-related
serotype 19A, and to non-vaccine serotypes increased.
P1093 Immune response to serotype 19A induced by serotype 19F
in pneumococcal protein conjugate vaccine
H.J. Lee, S.Y. Lim, K.-H. Kim (Seoul, KR)
Objectives: Pneumococcal 19F and 19A are important serotypes in
invasive infection worldwide as well as in Korea. Pneumococcal
vaccine containing 19F seemed to be protective against infection by
19A serotype. To elucidate immunogenicity to 19A serotyppe by 19F
polysaccharide in pneumococcal conjugate vaccine, we studied antibody
titer and opsonisation titer to 19F and 19A.
Methods: Twenty healthy adults were immunised with 7-valent
pneumococcal conjugate vaccine which contained 19F polysaccharide
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antigen. Antibody titers and opsonisation titers to 19F and 19A serotypes
were studied in preimmune and postimmue sera.
Results: Geometric mean titer of antibody to 19F serotype was increased
signiﬁcantly from 3.66 (95%CI 2.57, 5.13) mg/mL to 12.60 (95%CI
6.76, 23.44) mg/mL after immunisation. Geometric mean antibody titer
to 19A serotype also increased from 4.43 (95%CI 3.02, 6.46) mg/mL to
8.43 (95%CI 4.90, 14.45) mg/m (P> 0.05). Antibody titer to 19F and
19A were not signiﬁcantly different in preimmune sera. In postimmune
sera, antibody titers to 19F were signiﬁcantly different with those to
19A. Geometric mean opsonisation titer to 19F and 19A were increase
from 30.74 (95%CI 13.18, 70.79) and 72.32 (95%CI 24.84, 181.97)
to 1142.00 (95%CI 630.96, 2089.30) (P< 0.05) and 948.41 (95%CI
512.86, 1737.80), respectively. Opsonisation titers were not signiﬁcantly
different between 19F and 19A after immunisation.
Conclusion: 19F polysaccharide in pneumococcal conjugate vaccine
elicited antibody responses to 19A serotype, quantitatively and
qualitatively in healthy adults. Further studies are needed in children
and elderly people.
P1094 Prophylactic potential of high molecular weight antigenic
fractions of a recent clinical isolate of L. donovani against
experimental visceral leishmaniasis
P. Tripathi, S. Naik (New Delhi, Lucknow, IN)
Objectives: Identiﬁcation of potential T cell stimulatory antigens of a
recent clinical isolate of L. donovani against Visceral Leishmaniasis (VL)
for prophylactic efﬁcacy in hamster model of VL.
Methods:We have recently reported the presence of T cell immunostim-
ulatory antigens in the high molecular weight (MW) fractions (F1-F4;
MW range 134−64.2Kd) of whole LD antigen [strain 2001; (F1-F11;
MW range 139−24Kd)], which stimulated variable amounts of IFN-g,
IL-12 and IL-10 in exposed immune individuals. The present study was
undertaken to evaluate high molecular weight antigenic fractions of LD
for potential protective efﬁcacy. The high molecular weight region of
the parasite was resolved into ﬁve antigenic fractions (Prep A-E; MW
range >100−60Kd) using continuous elution gel electrophoresis. Prior
to in vivo protection studies in hamsters, these fractions were used to
evaluate in vitro cellular responses (deﬁned by their ability to induce in
vitro T-cell proliferation and induction of cytokines: IFN-g, IL-12 and
IL-10) in eight leishmania exposed individuals. The protective efﬁcacy
of prep A+B, C, D and E in combination with BCG was evaluated in
inbred hamsters using standard immunisation protocol.
Results: Proliferative responses were seen in all eight of 8 exposed
individuals to prep D and E, 5 of 8 individuals to prep B and C and
3 of 8 to prep A. The median proliferative responses of eight exposed
individuals to prep D (median SI: 5.2 [range 3.9−7.1]) and E (median
SI: 5.6 [range 4.4−8.2]) were signiﬁcantly higher than to fraction A
(median SI: 0.2 [range 0.1−7.2]; P< 0.05) but not to prep B and C.
However, prep A-E induced equivalent levels of IFN-g, IL-10 and IL-12
cytokines. Fractions D and E also exhibited marked parasite inhibition
in spleen (52.5% and 73.7%) and liver (65% and 80.2%) as compared to
prep A+B (23% in spleen and 24% in liver) and prep C (38% in spleen
and 24% in liver). Prep D and E vaccinated animals showed higher
in vitro stimulatory responses (Mean SI: 6.6 and 8.8) and nitric oxide
(NO) induction (mean NO levels: 6.4 and 10.7 mg/mL) against whole
cell extract as compared to other groups. The protection also correlated
with presence of suppressed leishmania speciﬁc IgG levels in prep D
and E immunised hamsters.
Conclusions: These studies indicate the presence of immunostimulatory
and protective molecules in 60−80Kd region of LD, which may be
further exploited for developing a subunit vaccine.
P1095 Dose sparing with intradermal injection of inﬂuenza vaccine
M. Metanat, M. Salehi, B. Shariﬁ-Mood, M. Safai (Tehran, IR)
Objective: The most effective measure available for the control of
inﬂuenza is the annual administration of inactivated inﬂuenza vaccine.
Inactivated inﬂuenza vaccine has been shown to be effective in the
prevention of inﬂuenza A and relatively high efﬁcacy(70% to 90%), is
observed in healthy young people, who were vaccinated intramuscularly
with dose of 15mg of antigen. Intradermal admiminstration of antigens is
expected to facilitate their exposure to antigens – presenting cells, such
as maorophages and dendritc cells, which are present at higher level
in skin than in muscle. Therefore, intradermal vaccination may induce
similar serum antibody responses with a smaller quantity of antigen.
Dose sparing with intradermal administration could be used to expand
the supplies of inﬂuenza vaccine.
In order to determine the antibody response of an intradermal injection
of trivalent inactivated inﬂuenza vaccine, with 40 percent of the usual
dose and then to compare with the immunogenicity and safety of usual
inﬂuenza vaccine, we conducted this study.
Materials and Methods: In this randomised control trial, we evaluated
the antibody response of intradermal vaccine among 97 cases who were
selected randomly from healthcare workers and then results compared
with results in 94 cases of healthcare workers who were received
intramuscular inﬂuenza vaccine with usual dose. One hundred ninety
one cases with age range of 22−50 years, have been vaccinated by
one experienced person then blood samples were evaluated for titers of
hemagglutination – inhibition (HAI) antibody before and after injection
of vaccine. Also, local and systemic adverse events assessed.
Results: Our study showed that there was no signiﬁcant difference
in seroconversion and seroprotection rates after vaccination, between
two groups (p> 0.05). Local reactions (induration and redness) were
signiﬁcantly more common, among recipients of intradermal injections
than among recipients of intramuscular injection, but such reactions were
mild and transient.
Conclusions: We conclude that reduced dose of inﬂuenza vaccine given
by the intradermal route in healthy adults was safe and immunogenic,
similarly to intramuscular injection with usual dose and dose sparing
with intradermal injection could be to increase the number of available
doses of vaccine.
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P1096 Outpatient antibiotic utilisation in the city of Zagreb in 2005
D. Sˇtimac, J. Culig, I. Vukusˇic, Z. Sˇostar, M. Bucalic (Zagreb, HR)
Objective: According to ﬁnancial indicators, antibiotics ranked fourth,
accounting for a high share of 9.44% in the overall drug utilisation in
the City of Zagreb. The aim was to identify the causes of such a high
utilisation and distribution within the group of antibiotics (J01).
Methods: Data on the number of packages and wholesale price were
obtained from all pharmacies in the City of Zagreb for each individual
drug registered in Croatia. Based on these data, the number of deﬁned
daily doses (DDD) and DDD per 1000 Zagreb inhabitants per day
(DDD/1000/day) in 2005 were calculated for each individual drug at all
levels of the Anatomic-Therapeutic-Chemical (ATC) drug classiﬁcation
system.
Results: In the City of Zagreb, total utilisation of antibiotics in 2005 was
34.62 DDD/1000/day, yielding a 16% increase from the preceding year.
B-Lactam antimicrobials, penicillins (J01C) accounted for more than
a half of total antibiotic utilisation with 17.99 DDD/1000/day. Within
J01C group, J01CR subgroup of penicillin combinations including
b-lactamase inhibitors accounted for 53%. The entire consumption
of the latter referred to a combination of amoxicillin and clavulanic
acid, the most frequently prescribed antibiotic in the City of Zagreb
with 9.61 DDD/1000/day. The subgroup of broad-spectrum penicillins
(J01CA), led by amoxicillin with 4.33 DDD/1000/day, accounted for
25% of penicillin utilisation, followed by J01CE with 21%, J01D
with 13.85% (predominated by second generation cephalosporins), J01F
with 12.34% (predominated by azithromycin with 2.27 DDD/1000/day),
J01A (systemic anti-infective agents) with 7.82% (predominated by
doxycycline with 2.71 DDD/1000/day, J01M (quinolones) with 6.23%
(predominated by norﬂoxacin with 1.6 DDD/1000/day), J01E with
S296 17th ECCMID / 25th ICC, Posters
4.76%, J01X with 2.61%, and J01G (aminoglycosides) with the lowest
rate of 0.42%.
Conclusion: Broad-spectrum antibiotics predominated in the utilisation
of antibiotics. Amoxicillin with clavulanic acid accounted for almost one
third (28.26%) of antibiotic utilisation in the City of Zagreb, in spite of
the guidelines preferring the use of narrow-spectrum antibiotics. The
rather frequent empiric prescribing of broad-spectrum antibiotics entails
the pending risk of the microorganism resistance associated with an
array of unfavourable consequences for both the patients and healthcare
system in general, ultimately resulting in treatment cost increase and
therapeutic inefﬁciency.
P1097 Trends in antibiotic consumption over a 7-year period in
a general hospital, Athens, Greece
C. Loupa, I. Tzannou, V. Tsolaki, K.J. Karnezi, A. Dimizas, M. Lelekis
(Athens, GR)
Objective: The aim of the present study was to record the trends in
antibiotic consumption in our 300-bed general hospital over a 7 year
period.
Methods: Antibiotic consumption for the period 1999 to 2005
was studied retrospectively using data from the pharmacy computer.
Antibiotic use was calculated in DDDs per 1000 patient days (ABC
Calc 3.0). We used linear regression for statistical analysis (SPSS 11.5).
Results: Antibiotic consumption was 572, 647, 678, 675, 710, 785 and
892 DDDs/1000 patient days (years 1999, 2000, 2001, 2002, 2003, 2004,
2005 respectively) and the trend was signiﬁcant (p = 0.001). Concerning
consumption of major classes of antibiotics, only penicillins had a
decrease (from 83.4 to 67.9). The consumption of other classes of
antibiotics had the following trend over time: cephalosporins/aztreonam
from 152.6 to 253.8 (p =NS), penicillins+inhibitors from 133.9 to 209.1
(p = 0.034), carbapenems from 3.8 to 15.2 (p = 0.029), aminoglycosides
from 45.4 to 46.1 (p =NS), macrolides from 35.9 to 81.8 (p =NS),
quinolones from 28.6 to 109.7 (p = 0.001) and glycopeptides from 1.3
to 18 (p = 0.014). It is worth noting that consumption of carbapenems,
quinolones and glycopeptides had the above mentioned signiﬁcant
increase despite the fact that these antibiotics are included in the
restricted list antibiotics since late ‘80s, together with 3rd-4th generation
cephalosporins/monobactams. The heavily marketed, newly introduced in
Greek market ertapenem and “respiratory quinolones” are at least partly
responsible for the signiﬁcant increase in carbapenem and quinolone
consumption respectively. Furthermore, due to high prevalence of
MRSA and MRSE strains in our hospital, glycopeptides are currently
widely used for treatment of staphylococcal infections as well as for
chemoprophylaxis in serious operations such as hip replacement.
Conclusions: During the study period, consumption increased signiﬁ-
cantly for almost all major classes of antibiotics, including ones under
restriction. It is obvious that besides the existence of a restriction
policy, additional measures are needed in order to control the increasing
antibiotic consumption. The impact of this increase on resistance is
currently under investigation.
P1098 Ambulatory care self-medication with antibiotics within
countries in the south-eastern Mediterranean region:
results from the ARMed project
E.A. Scicluna, M.A. Borg and ARMed Project Collaborators
Objective: Until recently, data on the degree of self medication with
antibiotics in the southern and eastern Mediterranean was unavailable,
contrary to the situation in the northern part of this region, where data
has already been published. The ARMed project aimed to ﬁll in this
void and elucidate the situation in the countries under study.
Methods: Short structured interviews were held in out-patient clinics or
primary health centres in Cyprus, Egypt, Jordan, Lebanon, Libya, Tunisia
and Turkey between November 2004 and July 2005, using the country’s
own language. One person accompanying a patient was approached and,
after approval, asked to correctly deﬁne an antibiotic. If the reply was
in the afﬁrmative, the full interview were then conducted,
Results: A total of 2109 subjects were approached and 1705
completed the full interview. Actual self-medication was reported by
326 respondents, which ranged from 0% in Cyprus to 37% (95%CI:
28.3% – 45.6%) in Lebanon. In the total group of antibiotic users, there
was no association between self-medication and either gender or age,
and a borderline association (p = 0.049) with education level. At the
country speciﬁc level, self-medication was associated with age in Jordan
(p = 0.016) and in Lebanon (p< 0.001) only. Self-medication increased
with age in both countries. There was no association with gender or
education level in any of the participating countries.
Intended self-medication ranged from 1.3% (95%CI: 0% – 3%) in
Cyprus to 70.7% (95%CI: 64% – 77%) in Jordan and for children
ranged from 0% in Cyprus and 62% (95%CI: 55%, 69%) in Jordan.
Upper respiratory tract infections were the most frequent reason for
intended self-medication. Almost half of interviewees (48.4%) reported
that they had antibiotics at home, reaching 60% (95%CI: 51% – 69%)
in Lebanon. We found a statistically signiﬁcant association between
antibiotic hoarders and intended users of antibiotics for self-medication
in all the participating countries, except Cyprus.
Conclusion: Ambulatory care consumption of antibiotics without
prescription is signiﬁcant in many southern and eastern Mediterranean
countries and appears higher than that previously reported by other
European counterparts in the region. Actual self-medication with
antibiotics is strongly predicted by intended self-medication, which exists
at much higher levels, implying that the public health risk is higher than
indicated by actual self-medication rates.
P1099 Using directed graphs for examining transitions in
antibiotic usage
S. Natsch, F. Baart, P. van der Linden, H. de Neeling on behalf of
the SWAB’s working group on Surveillance of Antimicrobial Use
Objective: to develop a method to analyse consecutive prescriptions for
antibiotics. To describe how animated directed graphs can be used to
gain insight into the subsequent use of antibiotics.
Method: The database of the Dutch Foundation of Pharmaceutical
Statistics was used for this study, consisting of 10 million prescriptions
from 2 million patients from 2000 to 2004. The prescriptions were sorted
by patient and prescription date. These series were transformed into four
kinds of transitions. First the transition from no antibiotic to an antibiotic,
second from an antibiotic to no antibiotic, third from one antibiotic to
the same antibiotic and fourth from an antibiotic to another antibiotic.
Results: A graph was created for each month in the 5 year period. The
resulting 60 graphs were rendered into an animation. It can be viewed
at www.swab.nl/wool/faster_transitions.svg. This animation shows that
if a patient started using an antibiotic, it was most often amoxicillin.
Doxycycline, amoxicillin and amoxicillin/clavulanic acid were often
prescribed two or more times in a row. The most frequent transition was
from amoxicillin to amoxicillin/clavulanic acid. Among the antibiotics
used primarily for urinary tract infections, nitrofurantoin is most often
used as ﬁrst choice. Norﬂoxacin was the most prominent secondary drug
subsequent to nitrofurantoin.
Conclusions: The method will allow more in-depth analysis of patterns
of usage, choices for ﬁrst and second-line treatments and adherence to
guidelines and policies. A big advantage is the possibility for detection
of changes over time as well as seasonal inﬂuences. In the future,
linking these data to surveillance of antimicrobial resistance data will
provide further insight into the relationship between antibiotic usage and
development of resistance.
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P1100 ESAC II hospital care subproject 2005–2007: improving
quality indicators of hospital antibiotic prescribing within
standardised data, longitudinal study
F. Ansari, H. Goossens, P. Davey on behalf of the ESAC II HC
Subproject Working Group
Objectives: The ESAC I project demonstrated the lack of uniﬁed hospital
information on antibiotic use and standardised denominator of clinical
activity across Europe. In 2004 DG SANCO supported the ESAC
II Hospital Care subproject to improve the knowledge of antibiotic
consumption, to consolidate the continuous collection of comprehensive
data, to develop and validate health indicators based on antibiotic
consumption data, and to use a set of core indicators to provide feedback
to the participating countries. The ESAC II HC subproject consists of
Longitudinal Survey and Point Prevalence Survey. By the end of the
project we wish to produce standardised data from at least one hospital
per country and to develop a strategy for regional and national roll outs.
The main objective of longitudinal survey is to establish a platform
for statistical analysis of time trends within and between the hospitals
and countries and to compare results using bed days or admissions as
denominators.
Methods: Monthly data were collected from each hospital for a 6-year
period from 2000 for antibacterials dispensed to inpatient destinations
in DDD as numerator, and bed days and admissions as denominators.
Databases were assigned for ATC/DDD and analysed centrally in
Dundee. Statistical analysis was conducted using regression modelling
of time series.
Results: We have analysed longitudinal data from 14 hospitals so far. In
11 hospitals the direction of time trends was the same using bed-days or
admissions (increasing in 8 which were signiﬁcant for 3, decreasing in
3). In the 3 remaining hospitals the trends were different; DDD/100 bed
days showed increase over time whereas DDD/100 admissions showed
a decrease. In 3 hospitals there was signiﬁcant increase over time in
DDD/100 bed days whereas there was a non-signiﬁcant increase in
DDD/100 admissions. The proportion of parenteral antibacterials used
in 15 hospitals in 2005 was 8−78% and the rank order of parenteral use
was very different from total use.
Conclusion: The results show similar signiﬁcant trends with the 2
denominators in 6 of the 14 hospitals. Using additional denominators
of clinical activity especially in longitudinal studies could provide set of
indicators of prescribing quality and resource use. Including prescription
at discharge in some hospitals might explain differences in use of
parenteral antibacterials from total use.
Parenteral use might be a more meaningful indicator of inpatient
treatment than total use.
P1101 A comparative study on the antibiotic consumption of two
Hungarian county hospitals
I. Alma´si, G. Terna´k, F. Rozgonyi (Szeksza´rd, Pe´cs, Budapest, HU)
Objectives: The aim of this study was to analyse the changes in the
antibiotic consumptions and indications of antibiotic prescription in two
similar size hospitals in order to see the quality of antibiotic usage.
Methods: Case histories and the conditions of antibiotic treatment
of patients such as considerations of indication, choice and name of
antibiotics, treating dose and durations, microbiological examinations,
etc were put in a computer database. Date of patients discharged from
the hospitals in January 1995 and 2005, respectively, were analysed and
compared in both hospitals. An antibiotic policy and infection control
was implemented in both hospitals in 1995.
Results: Data of 2230 and 3031 patients from Hospital 1 (H1) and
data of 1240 and 1809 patients from Hospital 2 (H2) in the year
1995 and 2005 were compared. Here we focus on the features of the
antibiotic consumption. In the two periods, systemic antibiotic treatment
was given to 24.7% and 18.4% of the patients in H1, while to 28.7%
and 27.5% of the patients in H2. Surgical proplylaxis became the most
frequent indication for antibiotic treatment: from 11.7% to 34.7% in
H1, and from 6.7% to 35.6% in H2. Lower respiratory and urinary
tract infections, respectively, were the next frequent indications. Rates
of fever or unidentiﬁed indications for antibiotic treatment decreased
remarkably. The usage of b-lactams increased in both H1 and H2:
from 55.2% to 68.2% and from 51.0% to 58.2%. The usage of an
aminopenicillin+b-lactamase inhibitor increased signiﬁcantly: from 3.5%
to 30.1% in H1 and from 5.5% to 36.5% in H2. The rates of both the
prescription of multiple antibiotics under the same hospital stay and
the combined antibiotic therapy decreased in both hospitals: from 33.8
to 24.0% in H1 and from 36.0% to 22.9% in H2 (concerning No. of
patients), as well as from 16.0% to 11.2% in H1 and from 13.9% to
12.6% in H2 (concerning antibiotic courses).
Conclusion: The antibiotic policy and infection control guidelines were
followed by the clinicians in both hospitals. These resulted in a better
structure of the antibiotic consumption. These were mainly due to the
more appropiate surgical antibiotic prophylaxis during the ten years.
P1102 Population approach to antibiotic use for children in
Lithuania
A. Berzanskyte, R. Valinteliene (Vilnius, LT)
Survey in 18 European countries and Israel revealed Lithuania as the
country with the highest rate of self-medication (22% of all respondents).
It prevailed in almost the half of questioned residents, who used
antibiotics during the last 12 months. However this ﬁgure reﬂected adults
approach only towards their selves.
Objective: The aim was to ﬁnd out if the attitudes of population about
antibiotic use for children are different.
Methods: The study was performed as part of European survey – Self-
Medication with Antibiotics and Resistance Levels in Europe (SAR
project). 3000 questionnaires were sent by mail to one urban and one
rural area. Response rate after reminders reached 25.4%.
Results: 3.9% of complete sample self-medicated their kids, what was
much more seldom than in adults (22%). In general there were 181
of the responders, who mentioned about children up to 16 years old
living together. During the last 12 months 59.6% of them pointed about
used antibiotics for children. 86.9% of the latter used prescriptions,
but nearly one third (27.1%) did not. Rural people tended to give
antibiotics without consulting the doctor more often than urban people –
relatively 31.3% and 22.5%, concerning gender – men more often
than women – 36.5% and 14%. However only 1 person mentioned
about intended self-medication for the children. The most frequent
diseases for which children were self-medicated corresponded to the ones
among adults – tonsillitis (28.2%), upper respiratory infections (23.6%),
bronchitis (16.4%). 86.2% of self-medicators indicated pharmacy as the
most often source to get antibiotics without prescription, 17.2% from
leftovers, 3.4% from family members and friends.
Conclusion: All the determinants and tendencies in self-medication
with antibiotics for children are mostly the same as in adults. However
the general numbers, particularly intended self-medication, are lower.
Although Lithuanian people consider antibiotics as “universal” drug,
they are still cautious concerning children treatment with them. It proves
need of education in this area.
P1103 Variability in the number and pattern of the most frequently
used antibiotics to treat outpatients in 28 European countries
A. Muller, M. Ferech, S. Coenen, E. Hendrickx, D.L. Monnet,
H. Goossens on behalf of the ESAC project
Objectives: Studies have shown country differences in outpatient use and
class distribution of antibiotics. However, most of the use is constituted
by a limited number of antibiotics, which may differ among countries.
The objective of this study was to identify similarities or differences in
the patterns of the most used antibiotics among European countries.
Methods: Data on outpatient antibiotic use were collected from 28
European countries in the ESAC network. For each country and each
of the 210 antibiotics (ATC J01, WHO, 2005), we calculated the no.
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of Deﬁned Daily Doses (DDD). Antibiotics representing 90% of total
no. DDD of a country (DU90%) were labeled “routinely used”. A
hierarchical cluster analysis was performed to study the similarity of
the antibiotics that were routinely used in these countries.
Results: In 2004, the total no. of different antibiotics used in outpatients
in Europe was an average of 57 (min: 33 in Iceland, max: 94 in
Italy and Germany). The no. routinely used antibiotics was an average
of 14 (min: 9 in Slovenia and Israel, max: 21 in France). Two
antibiotics, i.e. amoxicillin (J01CA04) and doxycycline (J01AA02), were
routinely used in all countries. Five other antibiotics, i.e. amoxicillin and
enzyme inhibitor (J01CR02), ciproﬂoxacin (J01MA02), clarithromycin
(J01FA09), azithromycin (J01FA10) and sulfamethoxazole+trimethoprim
(J01EE01) were routinely used in more than 2/3 of the countries and 25
in only one country. The three mostly used antibiotics represented an
average of 52% of the total no. DDD (min: 35% in Finland, max: 64%
in Israel). Clustering of countries according to routinely used antibiotics
is presented in the Figure.
Conclusion: There were remarkable differences in the no. and pattern
of antibiotics routinely used to treat outpatients in Europe. This inter-
country variability may reﬂect cultural differences as well as national
drug policies.
P1104 Antimicrobial consumption in Southern and Eastern
Mediterranean hospitals: ﬁnal results from the ARMed
Project
P. Zarb, M.A. Borg, M. Ferech, H. Goossens (Gwardamangia, MT;
Antwerp, BE)
Objectives: Data on antimicrobial consumption in southern and eastern
Mediterranean countries has been sorely lacking. The Antibiotic
Resistance Surveillance and Control in the Mediterranean Region
(ARMed) project addressed this by studying antibiotic use in hospitals
in the region.
Methods: Data was collected prospectively for 2 years: 2004–2005,
using Anatomical Therapeutic Chemical (ATC) classiﬁcation from 24
hospitals: Cyprus (5); Egypt (8); Jordan (1); Malta (1); Tunisia (3);
Turkey (6). Deﬁned Daily Doses was used as numerator, and 100-
occupied-bed-days as denominator (DDD/100BD).
Results: Overall consumption exhibited a median of 84.3 DDD/100BD
(IQR 43.0–310) with a range of 22.8 to 1900 (a bone marrow transplant
centre) DDD/100BD. The ARMed median correlates well with the
Antimicrobial Resistance Prevention and Control (ARPAC) median of
82 DDD/100BD for Southern European Hospitals.
Penicillins were the most commonly consumed antibiotics, (range
2.45–1465.3, median 28.8, IQR 12.6–120.9, DDD/100beddays): broad-
spectrum penicillins (amoxicillin and ampicillin) were predominant in
Cyprus, Egypt, Jordan and Tunisia as opposed to combinations with
b-lactamase inhibitors in Malta and Turkey. Considerable variability
was evident for cephalosporins (range 2.67–167.7, median 16.21, IQR
10.34−38.21, DDD/100BD). Hospitals in Cyprus utilised mainly 1st
generation, Jordan and Malta 2nd generation and 3rd generation in
Egypt, Tunisia and Turkey.
Remarkable variability in patterns of use was evident between hospitals
in the same country, especially in Egypt, as well as between countries.
The specialised hospitals in ARMed contributed to a predominance of
high consumption outliers (>120DDD/100BD), (10/23), as opposed to
ARPAC Southern European hospitals (2/28).
In 2005, antibiotic use increased in 14 hospitals (inter-year change
from −41% to +127%). Contrarily, the proportion of parenteral drugs
decreased in all countries (range: −10% to −32%).
Conclusion: The variations observed are likely to be the consequence of
multifactorial causes: the range of antibiotics licensed; national/hospital
formulary; type/size of hospital, as well as region speciﬁc drug
supply mechanisms (donations, purchase outside hospital). However, in
comparison with available European data, the region seems to utilise
a higher quantity of broad-spectrum antimicrobials. This could be a
risk factor for the high prevalence of resistance already documented by
ARMed.
P1105 Shortage of antimicrobial agents in Europe: results of an
international survey
S. Harbarth, P.M. Filius, S. Natsch, F. Mackenzie, I. Gyssens on behalf
of the ESCMID Study Group on Antibiotic Policies (ESGAP)
Objectives: There is little information available regarding the shortage
of antimicrobial agents in Europe. This survey attempted to determine to
what extent shortages have already inﬂuenced prescribing in European
hospitals.
Methods: The study was conducted as an international, 9-item survey
sent out via email in October 2006 to 360 hospitals throughout Europe.
The subjects were infectious disease physicians, clinical microbiologists
or pharmacists. Data were entered in a spreadsheet, checked for accuracy,
and transported to SPSS for descriptive analysis.
Results: Participants from 23 countries and 55 hospitals responded.
38/55 (69%) of the respondents had experienced a shortage of
antimicrobial agents within the last 12 months. Shortages were
not evenly distributed among countries. Only 4 countries did not
report any shortage. The most frequently affected agents were
cefepime (n = 15); mupirocin ointment (n = 15); meropenem (n = 13);
piperacillin/tazobactam (n = 11) and piperacillin alone (n = 4); semi-
synthetic penicillins (n = 7); aztreonam (n = 6); and 1st- or 2nd-generation
cephalosporins (n = 5). Shortages of penicillin, ampicillin, colistin,
doxycycline, rifampicin, vancomycin, nitrofurantoin, fosfomycin, am-
photericin B, amikacin and tobramycin occurred less frequently. There
was great variability in the duration of the shortages (range: 1 week –
18 months). Substitutes were either more expensive (e.g. carbapenems
instead of cefepime), more broad-spectrum (e.g. cefuroxim, ceftriaxone
or co-amoxiclav instead of oxacillin and penicillin), or less efﬁcacious
(e.g. neomycin and chlorhexidine instead of mupirocin ointment).
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19 hospitals (35%) had trouble ﬁnding equivalent drugs for substitution.
Only 10 hospitals reported that they had always been adequately
informed by the producer or distributor about the shortage.
Conclusions: A substantial number of hospital pharmacies in Europe
have experienced antimicrobial drug shortages within the last 12 months.
Shortage of meropenem, mupirocin and cefepime were considered
to have the largest impact on patient care. Shortage-triggered policy
changes may negatively affect antimicrobial prescribing patterns and
expenses. This survey provides important information that will guide
further ESGAP initiatives to document and ultimately prevent shortages.
P1106 Hospital consumption of antibacterials for systemic use in
Slovenia in 2005
M. Cizman on behalf of the Slovenian ESAC group
Objective: To collect data on Hospital consumption (HC) of antibiotics
in all Slovenian hospitals and departments aggregated at national level
in the year 2005.
Methods: Consumption data of systemic antibiotics in anatomical
therapeutic chemical (ATC) (WHO version 2006) class J01 were
collected, expressed in Deﬁned Daily Doses (DDD). The consumption
was expressed in DDD per 100 bed-days. Hospital pharmacist provided
the data in the number of packages. The coverage of bed days were in
all three years 100%.
Results: The results are shown in Tables 1 and 2.
Table 1. Hospital use (DDD/100 Bed-days) of antibacterials in Slovenian
hospitals (n = 29) by type of hospital
Departments/units General hospitals mean
(min–max)
UMC
Medical (n = 10) 66.71 (45.29−85.40) 80.40
Surgical (n = 10) 56.38 (39.28−75.84) 80.85
Paediatric (n = 11) 41.88 (33.24−63.09) 44.45
Medical ICU (n = 6) 143.46 (45.56–221.93) 136.23
Surgical ICU (n = 6) 199.0 (132.97–261.82) 238.33
Medical and surgical ICU (n = 2) 152.42 (146.76–178.07) –
Gynaecological (n = 10) 30.71 (16.81−46.85) 22.08
Table 2. Hospital use (DDD/100 bed-days) of antibacterials in UMC
(teaching hospital) and departments of general hospitals in Slovenia in
2005
Type of hospital 2005 mean
UMC (teaching (n = 1) 61.17
General (n = 11) 58.80 (42.66−77.47)
Orthopaedic (n = 1) 32.61
Private (n = 3) 32.61
Maternity (n = 2) 27.07 (25.81−28.33)
Lung (n = 2) 68.23 (58.50−77.96)
Psychiatric (n = 5) 6.96 (6.23–7.15)
Nursery (n = 1) 28.42
Rehabilitation centres (n = 2) 8.06 (6.42–9.75)
Oncology Institute (n = 1) 51.51
Conclusion: total consumption of antibacterials in Slovenia is moderate.
High variations of antibacterials use was found among similar types of
some hospitals and departments. The data provide the rationale for an
intervention.
P1107 Antibiotic use in German intensive care units
E. Meyer, F. Schwab, P. Gastmeier, H. Rueden, D. Jonas (Freiburg,
Berlin, Hannover, DE)
Objective: To analyse antibiotic use in German ICUs participating in
the project SARI (Surveillance of Antimicrobial use and antimicrobial
Resistance in German Intensive Care Units).
Methods: Antibiotic use density (AD) was calculated in deﬁned daily
doses (DDD)/1000 patient days. DDDs according to the WHO in 2006
include 81 single antibiotics and 25 antibiotic groups.
Results: In 2005 mean AD was 1282 DDD/1000 pd in 43 ICUs.
AD ranged from 559 to 2409. The top 3 antibiotic groups used
were quinolones, the ﬁxed combination of penicillins with lactamase
inhibitor and 3rd generation cephalosporins (AD 165, 150 and 110,
respectively); The top 3 single antibiotics were ciproﬂoxacin, cefuroxim
and ampicillin-sulbactam (114, 89 and 74, respectively). The median of
single antibiotics used was 27 (range 13−21). This did not differ by
type or size (>1000 beds) of hospital or by type of ICU. Antibiotic
use did not change signiﬁcantly from 2000–2002 to 2002–2005 with
the exception of a switch from the ﬁxed combination penicillins with
lactamase inhibitor to the free combination.
Conclusion: Antibiotic use in German ICUs is highly heterogeneous, but
does not differ by type or size of hospital. Quinolones are the antibiotic
group with the highest use.
P1108 Antimicrobial consumption and resistance in Staphylococcus
aureus and Pseudomonas aeruginosa isolates from 47
French hospitals
A. Rogues, C. Dumartin, H. Boulestreau, A. Venier, J. Gachie,
N. Marty, P. Parneix (Bordeaux, Toulouse, FR)
Objective: To investigate relationships between antimicrobial con-
sumption and resistance in Staphylococcus aureus and Pseudomonas
aeruginosa isolates from hospitals.
Methods: Hospital were asked to collect consecutive S. aureus and
P. aeruginosa (Pa) isolates, consumption of antibiotics (J01A) and
hospital characteristics (size, length of stay, number of beds: total and for
each hospital areas) during one year. For methicillin-resistant S. aureus
(MRSA) and for ceftazidime, ciproﬂoxacin and imipenem susceptibility
of Pa, resistance (R) were expressed as percentage of nonsusceptible
isolates and as incidence [nonsusceptible isolates per 1000 patient-days
(PD)]. Antimicrobial consumption were expressed as number of deﬁned
daily doses per 1,000 PD). Association between continuous variables was
tested in univariate analysis with the Spearman correlation test. Multiple
linear regression was performed to control for hospital characteristics.
Results: Data were obtained from 47 hospitals with a total of 12188
S. aureus and 6370 P. aeruginosa tested. Resistance in percentage
and incidence were, respectively, MRSA:42% and 0.8, ciproﬂoxacinR
Pa:43% and 0.9, ceftazidimeR Pa:16% and 0.2, imipenemR Pa:14%
and 0.2. In the multivariate analysis, signiﬁcant association with
antimicrobial consumption was less frequent with percentage than with
incidence of resistance. The incidence of MRSA increased with use of
ciproﬂoxacin and levoﬂoxacin and with percentage of beds of intensive
care in the hospital (R2a:0.30. Total antibiotic consumption minus
glycopeptides explained 13% of the variance of MRSA incidence.
For P. aeruginosa, incidence of ceftazidime resistance were higher
in hospitals with higher consumption of ceftazidime, levoﬂoxacin
and gentamicin (R2a:0.37). The incidence of ciproﬂoxacin resistance
increased with use of ﬂuoroquinolones and percentage of beds of
intensive care in the hospital (R2a:0.35). There was a positive and
independent association between the incidence of imipenemR and
consumption of carbapenem, cefotaxime, and macrolides (R2a:0.41).
Conclusion: A signiﬁcant relationship occurred between ﬂuoro-
quinolone use and resistance in S. aureus and Pa isolates. After adjusting
for hospital characteristics, the associations between antimicrobial
consumption and resistance found in our ecologic study were consistent
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with those observed on an individual patient level. Percentage of
resistance was less interesting than incidence to study those relations.
In vitro antibacterial susceptibility
P1109 Antimicrobial and antioxidant actions of the clubmoss
Lycopodium clavatum L.
B. O¨zc¸elik, I. Orhan, S. Aslan, M. Kartal, T. Karaoglu, B. Sener,
M. Choudhary (Etiler, Ankara, TR; Karachi, PK)
Purpose of the present study was to evaluate antioxidant, antibacterial,
antifungal, and antiviral activities of the petroleum ether, chloroform,
ethyl acetate and methanol extracts as well as the alkaloid fraction of
Lycopodium clavatum L. (LC).
Antioxidant activity of the LC extracts was evaluated by 1,1-diphenyl-2-
picrylhydrazyl (DPPH) radical-scavenging method at 0.2mg/mL using
microplate-reader assay. Antiviral assessment of LC extracts was
evaluated towards the DNA virus Herpes simplex and the RNA
virus Parainﬂuenza using Madin-Darby Bovine Kidney and Vero cell
lines. Antibacterial and antifungal activities of the extracts were tested
against standard and isolated strains of the bacteria Escherichia coli,
Pseudomonas aeruginosa, Proteus mirabilis, Acinetobacter baumannii,
Klebsiella pneumoniae, Staphylococcus aureus, Bacillus subtilis, as well
as the fungi C. albicans and C. parapsilosis. We evaluated the in vitro
activity with standard antimicrobial powders as ketoconazole, ﬂucona-
zole, amphotericin B, ﬂucytosine, voriconazole (triazole derivative), and
caspofungin (echinocandin).
All of the extracts possessed noteworthy activity against ATCC strain of
S. aureus (4mg/mL), while the LC extracts showed reasonable antifungal
effect. On the other hand, we found that only the chloroform extract
was active against HSV (16−8mg/mL), while petroleum ether and
alkaloid extracts inhibited potently PI-3 (16−4mg/mL and 32−4mg/mL,
respectively). However, all of the extracts had insigniﬁcant antiradical
effect on DPPH. In addition, we also analysed the content of the alkaloid
fraction of the plant by capillary gas chromatography-mass spectrometry
(GC-MS) and identiﬁed lycopodine as the major alkaloid.
P1110 In vitro study of antibiotic diffusion from bioceramic
cylinders (hydroxyapatite and wollastonite)
M. Jorge, R. Seoane, F. Guitian, A. Perez-Estevez, M. Trevino-Castellano,
L. Moldes-Suarez, C. Garcia-Riestra (Santiago de Compostela, ES)
Objectives: The use of antibiotics embedded in biomaterials is very
common in orthopaedic surgery. The aim of the present study is to
evaluate the delivery kinetics of teicoplanin from bioceramic cylinders
vs two control antibiotics (oﬂoxacin and ceftriaxone).
Methods: Cylinders of hydroxyapatite (HA) and wollastonite (WA)
100mg, 9mm diameter and 3mm thick, containing 3% each antibiotic
were made at the Ceramic Institute of University of Santiago. Delivery
was evaluated by bioassay using Mueller-Hinton plates inoculated with
Bacillus subtilis ATCC6633 spores. Inhibition diameters were measured
daily. Once measured cylinders were transferred to new plates ever on
the same side. When no inhibition could be detected cylinders were
deposited on the other side. The residual activity was evaluated by
extraction with PBS from cylinders no longer active. Delivered amounts
were calculated by interpolation with standard curves made with paper
disks containing known amounts of antibiotic.
Results: Results show a clear difference in delivery patterns from
the two assayed bioceramics. Ceftriaxone delivery was quicker from
hydroxyapatite opposite to observed with oﬂoxacin and teicoplanin.
According to this fact ceftriaxone cylinders showed activity for 19
days from HA and 38 days from WA; on the contrary, teicoplanin and
oﬂoxacin showed longer activity from HA, specially oﬂoxacin (50 days
from HA vs. 26 days from WA).
Conclusions:
1. Hydroxyapatite delivers high levels of antibiotic for long periods and
appears to be better material than wollastonite to carry antibiotics.
2. Wollastonite allows a quick delivery of both teicoplanin and oﬂoxacin.
Nevertheless, ceftriaxone delivery was longer from this bioceramic.
3. The different delivery patterns detected suggest that bioceramic
election could depend of antibiotic selected and desired delivery
pattern.
P1111 Comparative in vitro susceptibility of bacterial isolates
from Tbilisi maternity hospitals to antibiotics, speciﬁc
bacteriophages and plant antibacterials
S. Tsertsvadze, M. Mshvildadze, A. Tskhvediani, N. Mitaishvili,
T. Koberidze, M. Tediashvili, I. Davitaia (Tbilisi, GE)
Broad-spectrum antibiotics still remain the major treatments for
neonatal bacterial infections. The same time occurrence of resistant
bacterial strains increases every year. Application of bacteriophages and
antibacterial substances of plant origin may be considered as effective
alernative strategy.
The aim of the study was to isolate and study the bacterial microﬂora
in neonatal departments and to perform screening of isolated strains
on susceptibility to antibiotics, bacteriophages and tea antibacterials
(TAB). Specimens were collected at neonatology departments of A
and B maternity hospitals in Tbilisi during 4 months period in 2006.
Women’s vaginal microﬂora was studied before labour, while smears
from the neonates oral cavity and nose were taken immediately after
birth and within 24, 48, 72 and 96 hours. Processing of specimens was
performed by standard bacteriological methods followed by identiﬁcation
using API-tests (bioMe´rieux, France). Sensitivity of the isolated strains
to 12 antibiotics and 3 TAB preparaions was studied by disc diffusion
and serial dilution methods. Lytic efﬁcacy of speciﬁc phage clones as
well as to mono- and complex bacteriophages (Pyophage, Intestyphage,
Enterophage, SPS-phage, production of the Eliava IBMV) was estimated
by spot test followed by titration using double layer method.
Specimens were taken from 32 mothers and newborns in parallel with
collecting material from hospital environment. 128 bacterial isolates were
characterised to reveal the prevalent microﬂora, the focus was made on
isolation and identiﬁcation of Staphylococcus spp., Streptococcus spp.,
Pseudomonas aeruginosa and Klebsiella spp. Resistance to 2−5
antibiotics was registered in >60% of isolated strains while susceptibility
to different bacteriophages varied signiﬁcantly within different bacterial
groups and comprised in average 45%. It must be stressed that no
correlation between phage- and antibiotic resistance was observed.
High efﬁcacy of experimental TAB preparations (Institute of Plant
Biochemistry, Georgia) was shown as well, especially in case of Gram-
positive bacteria.
P1112 Effect of polysorbate 80 on oritavancin binding to plastic
surfaces – implications for susceptibility testing
F.F. Arhin, I. Sarmiento, T.J. Parr Jr., G. Moeck (Saint Laurent, CA)
Objectives: Oritavancin (ORI) is a lipoglycopeptide (LG) with activity
against most Gram-positive bacteria including drug-resistant pathogens.
Broth microdilution (BMD) assays with dalbavancin, another LG, require
addition of 0.002% polysorbate 80 (P80). To investigate whether P80
affects ORI susceptibility test results, we performed BMD assays for
ORI with and without P80 and quantitated 14C-ORI recovery from assay
plates containing cation-adjusted Mueller Hinton Broth (CAMHB) ±
P80.
Methods: For recovery assays, 14C-ORI and 14C-ciproﬂoxacin (14C-
CIP) were dissolved in water ± P80, diluted in CAMHB or CAMHB
plus 2% lysed horse blood (LHB) ± P80, and dispensed into 96-well
polystyrene plates (Sensititre) without cells. Recovery of radiolabeled
agents was assessed by scintillation counting of supernatant over time to
yield residual counts relative to input label at time 0. BMD assays with
Staphylococcus aureus ATCC29213, Enterococcus faecalis ATCC29212
and Streptococcus pneumoniae ATCC49619 followed CLSI guidelines.
P80, where present, was at 0.002%.
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Results: In the absence of P80, 14C-ORI was rapidly lost from solution:
at 1mg/L, <10% of input ORI was recovered at 1 h. ORI loss was
concentration dependent: proportionately greater losses were observed
at lower ORI concentrations, suggesting saturable binding of ORI to
surfaces. Inclusion of P80 or LHB promoted recovery of 80–100% of
14C-ORI at all concentrations tested up to 24 h. Quantitative recovery
of input 14C-CIP +/− P80 was observed for all concentrations and time
points tested. Concordantly, minimal inhibitory concentrations (MICs)
of ORI for S. aureus and E. faecalis were 16- to 32-fold lower in the
presence of P80 whereas P80 had no impact on MICs of vancomycin,
teicoplanin or CIP. Assay plates with low-binding surfaces afforded 4- to
8-fold reductions in ORI MICs without P80, suggesting that ORI binding
to plastic in the absence of P80 may underestimate in vitro potency. ORI
MICs for S. pneumoniae tested in CLSI-recommended CAMHB + 2%
LHB were identical ± P80.
Conclusions: ORI exhibits rapid, saturable binding to susceptibility
test plates. P80 minimises binding of ORI to microtitre plate surfaces,
thereby maintaining ORI available in solution for growth inhibition. 2%
LHB in CAMHB promoted ORI recovery, helping to explain the lack
of ORI MIC shifts for S. pneumoniae with P80. Current literature MIC
data for ORI signiﬁcantly underestimates ORI in vitro potency.
P1113 Antimicrobial susceptibility of anaerobic and facultative
aerobic bacteria isolated from pus specimens of orofacial
infections and b-lactamase production
G. Blandino, I. Milazzo, D. Fazio, S. Puglisi, A. Speciale (Catania, IT)
Objectives: Informations on susceptibility of the microorganisms
involved in oro-facial infections can be useful for an effective antibiotic
therapy. In the study we determine the antimicrobial susceptibility of 235
anaerobic and facultative aerobic bacteria isolated from pus specimens
of orofacial infections during 2006 and the b-lactamase production.
Methods: The bacteria isolated from pus specimens were identiﬁcated
using conventional methods and packages system. Minimum inhibition
concentrations (MICs) were determined by the microdilution method
in accordance with the guidelines ofthe NCCLS (1997) (anaerobic and
facultative aerobic bacteria) and the CLSI (2005) (viridans streptococci).
Results: The table shows bacteria isolated, b-lactamase production,
antimicrobials tested, and percentages of susceptibility.
Conclusion: Based on our ﬁndings amoxicillin-clavulanate and ce-
foxitin, and to less extent clindamycin and levoﬂoxacin, remain good
empirical choices against the polymicrobial aetiology of oro-facial
infections, where anaerobes and viridans streptococci are predominant.
Species (# b-lactamase+a/# isolates) Susceptibility (%)b
P A/C CX IP E DA LEV MTZ
Viridans streptococci (0/18) 100 – 100c 100 83.3 88.8 100 –
G. morbillorum(0/5) 100 – 100 100 100 100 100 100
Actinomyces sp. (0/35) 97.1 – 100 100 85.7 94.2 100 40
Peptostreptococcus sp. (0/60) 93.3 – 93.3 100 53.3 93.3 100 100
Eubacterium sp. (0/6) 83.3 – 100 100 83.3 100 100 100
Propionibacterium sp. (0/2) 100 – 100 100 100 100 100 0
P. gingivalis (2/32) 93.7 100 100 100 90.6 93.7 93.7 100
Prevotella sp. (8/30) 73.3 100 100 100 90 100 93.3 100
F. nucleatum (1/18) 94.4 100 100 100 38.8 100 100 100
C. rectus (0/7) 100 100 100 100 85.7 100 100 100
B. forsythus (3/9) 66.6 100 100 100 88.8 100 100 100
B. ureolyticus (1/7) 85.7 100 100 100 42.8 85.7 100 100
Veillonella sp. (1/6) 83.3 100 100 100 83.3 100 100 100
aNitroceﬁn test (penicillin MIC 0.25mg/L).
bP: penicillin; A/C: amoxiclav, CX: cefoxitin; IP: imipenem, E: erythromycin;
DA: clindamycin; LEV: levoﬂoxacin, MET: metronidazole.
cCefotaxime.
P1114 Increase of antimicrobial activity of b-lactam antibiotics in
combination with sodium dioctylsulfosuccinate
S. Roveta, A. Marchese, E. Debbia (Genoa, IT)
Objectives: Previous studies (Simonetti et al., 2004) demonstrated that
the dioctyl ester of sodium sulfosuccinate, Sodium dioctylsulfosuccinate
(SDSS), at sub-inhibitory concentration, increases the activity of some
antimicrobial agents. In the present study we attempted to examine the
effect of SDSS in combination with various b-lactam antibiotics on the
viabiliy of some bacterial species.
Methods: b-lactam resistant strains of Escherichia coli, Klebsiella
pneumoniae, Enterobacter cloacae, Pseudomonas aeruginosa, Staphy-
lococcus aureus and Enterococcus faecium (10 of each specie) were
employed in this study. The antibiotics tested in combination with
the surfactant were ampicillin (AMP), ceftazidime (CAZ), ceftriaxone
(CRO), aztreonam (ATM) and imipenem (IPM). Preliminary screening
to verify increasing of antibiotic activity by SDSS (ranging from 250 to
2,000mg/L) was performed employing a disk-diffusion test. Time kill
experiments (CLSI 2006) were performed on representative strains of
E. coli, P. aeruginosa, S. aureus and E. faecium (1 strain each) employing
selected antibiotics (AMP, CAZ, IPM) in association with 1,000mg/L
of surfactant.
Results: In preliminary screening SDSS extended the inhibition zones
of the antibiotic disks in both Gram-negative and positive strains. The
time-kill results conﬁrmed those obtained with the disk-diffusion assay.
The association of surfactant with a b-lactam antibiotic produced, in
all strains tested, signiﬁcative reductions of CFU/mL in comparison
to each compound alone. SDSS in combination with AMP produced
reductions greater than 104 CFU/mL in both E. coli and E. faecium. The
surfactant associated with CAZ and with IPM was tested on S. aureus
and P. aeruginosa respectively. Synergistic effect was noted against
both pathogens. The best result was obtained against S. aureus with
a reduction of 105 CFU/mL within 2 hours. No bactericidal activity was
observed on the microorganisms tested employing SDSS alone.
Conclusion: SDSS is able to increase the antimicrobial activity of
b-lactams on both Gram-negative and Gram-positive b-lactam resistant
microorganisms. This phenomenon might be explained by interferences
with transmembrane proteins, alterations of bacterial membrane or
increase in cell permeability. These results suggests a new approach
to the drug use in topical formulations with a signiﬁcant improvement
of antibiotic activity and a reduction of allergic and toxic reactions.
P1115 Evaluation of the efﬁcacy of disinfectants used in hospital
aseptic dispensing against Bacillus spores
M. Mehmi, J. Smith, P. Lambert (Birmingham, UK)
Objectives: To evaluate disinfectants currently used for transfer
sanitisation in hospital aseptic dispensing processes. These disinfectants
were assessed for efﬁcacy against spores of Bacillus subtilis ATCC6633
in suspension and carrier tests. Techniques of disinfectant application
such as spraying, wiping or both were investigated.
Methods: Suspension testing: An aqueous spore suspension of B. subtilis
ATCC6633 was added to the disinfectant solution for a 2 minute contact
time. The mixture was then neutralised, exposed to germinant solution
and viable numbers determined by plating.
Hard-surface testing: Stainless steel carriers were aseptically inoculated
with B. subtilis ATCC6633 spores. After drying the carriers were
sprayed, wiped, or sprayed and then wiped with disinfectant. After 2
minutes any surviving spores were recovered by agitation following
neutralisation. Recovered spores were exposed to germinant solution and
a dilution series was carried out.
Time-kill testing: As the suspension test, but samples were removed
and enumerated over 24 hours. All dilutions were plated out onto
tryptone soya agar and incubated overnight at 37ºC. Any resulting colony
forming units observed were counted. A control was used in each of the
experiments.
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Results: Of the 6 disinfectants tested a quaternary ammonium
compound/chlorine dioxide formulation and 6% hydrogen peroxide were
the more consistently effective biocides (approximate log 2 reduction
after 24 hours). The disinfection method found to be the most effective
in killing of the Bacillus spores was spraying followed by wiping, with
the least effective being spraying alone. Overall, wiping as a method
of disinfection was found to be very effective, with all disinfectants
achieving similar reductions in spore levels. Disinfectants generally
performed better in the carrier tests than the suspension tests. For carrier
tests, spraying alone with a disinfectant was not as effective as wiping
alone, or both spraying and wiping.
Conclusion: Disinfectant efﬁcacy increased on an increase in contact
time. However, longer contact times are not feasible and therefore
a compromise may be required. The results obtained re-enforce
research that indicates the insufﬁciency of current aseptic transfer
disinfection protocols. Spores are very hard to kill with the use of
chemical disinfectants currently available and therefore other methods
of disinfection such as rapid gassing techniques need to be considered.
P1116 Antimicrobial activity of ozonised water and 0.9% NaCl
E. Bocian, D. Bialoszewski, B. Bukowska, M. Czajkowska, S. Tyski
(Warsaw, PL)
Objectives: Antimicrobial activity of ozon is widely known and such
property is sometimes utilised e.g. for water disinfection and for
production of water intended for human consumption. However, in such
application ozon concentration is rather low and bactericidal effect is
not very high. Specially developed apparatus which allows ozon “in
statu nascendi” production from oxygen and preparation of ozonised
solutions, has been applied in this study. Ozonised water and 0.9% NaCl
were prepared and such obtained solutions might be used as antiseptic
and disinfectant agents, during surgical operations.
The aim of this study was to analyse bactericidal and yeasticidal activity
of ozonised water and 0.9% NaCl, according to European standards EN
1040 and EN 1275.
Materials and Methods: Two European standards designated for
estimation of antimicrobial activity of antiseptics and disinfectants were
applied to analyse basic bactericidal activity – EN 1040 and basic
yeasticidal activity EN 1275.
Freshly obtained ozonised water and phosphate saline were mixed
with microbial cells suspensions (bacteria: 108 cfu/mL, yeasts: 107
cfu/mL). Test microbial strains: S. aureus ATCC6538, P. aeruginosa
ATCC15442, E. coli ATCC10538, Enterococcus hirae ATCC10541 and
C. albicans ATCC10231 were used in order to analyse bactericidal
and yeasticidal activity. Different contact times were applied and log
reduction factors of viable bacteria count and viable yeast count, were
calculated. Ozone concentration in tested liquids was also determined
by titration. Chemically obtained data were compared with antimicrobial
effect.
Results: It was shown, that 20min of contact time caused at least a 105
log reduction in viable bacterial cells count of all tested strains and at
least 104 log reduction in viable yeast cells count. Neutralisation method
was effective in ozone antimicrobial effect liquidation. Test method was
validated.
It means that prepared ozonised liquids complied the EN Standards:
basic bactericidal and basic yeasticidal activities.
Conclusion: Applied apparatus produced high ozon concentration
solutions and freshly prepared ozonised water and 0.9% NaCl, which
could be used as effective antiseptic and disinfection preparations.
P1117 Qualitative and quantitative evaluation of micro-organisms
present in excised human skin used for ex vivo assessment
of topical antimicrobials
T.J. Karpanen, T. Worthington, B. Conway, P.A. Lambert (Birmingham,
UK)
Introduction: Efﬁcacy of topical antimicrobial agents is frequently
assessed in vitro using suspension or carrier tests. Evaluation of the
efﬁcacy of antimicrobials applied topically should ideally incorporate in
vivo studies, however these are often laborious and human volunteers
are required. A method which overcomes the problems associated with
in vivo studies is ex vivo assessment whereby excised skin is inoculated
with microorganisms in laboratory conditions. However, the number and
type of microorganisms already present in skin models used for ex vivo
assays should be taken into consideration when evaluating antimicrobial
efﬁcacy data.
Objectives: Qualitative and quantitative assessment of the microbial load
of excised human skin.
Methods: Full thickness human skin was obtained from ten patients
undergoing breast reduction. Full thickness skin samples were cut
aseptically to 2 cm× 2 cm squares in duplicate, weighed, diluted 1:10
with sterile phosphate buffered saline and ground in a stomacher. For
quantitative assessment the suspensions were serially diluted and 1mL
aliquoted in duplicate into pour plates with molten 5% blood agar. For
qualitative evaluation 100 microliters of suspensions were aliquoted in
duplicate onto 5% blood agar. All the culture plates were incubated at
37ºC in aerobic and anaerobic conditions for 48 hours. Microorganisms
recovered were identiﬁed by VITEK compact 2 bacterial identiﬁcation
system (bioMe´rieux, Basingstoke, UK).
Results: All excised skin samples were contaminated with microor-
ganisms [mean aerobic count 2,219 CFU/g (range 7–8,230), and
mean anaerobic count 8,573 CFU/g (range 14–37,205)]. There was
no correlation between weight of the skin sample and microbial
load. The most common microorganisms recovered from the skin
samples were Staphylococcus epidermidis and other coagulase negative
staphylococci. Other organisms recovered include Kocuria spp., Bacillus
spp., Acinetobacter spp., Klebsiella spp. and Rhizobium spp.
Conclusion: These results highlight the importance of taking into
account the resident and contaminating microbial ﬂora of excised human
skin when undertaking ex vivo antimicrobial studies which use artiﬁcial
microbial inoculation of the skin in laboratory.
P1118 Antimicrobial susceptibility of Nocardia spp. – experience
in England and Wales
R.L.R. Hill, R. Pike, M. Warner (London, UK)
Objectives: Nocardia are responsible for a variety of cutaneous, lung
and central nervous system infections. Although antibiotic therapy with
co-trimoxazole is put forward as the treatment of choice, the reliability
of such an agent is uncertain. We have therefore investigated the
susceptibility of patient-isolates from a variety of lesions.
Methods: During 2004−06, all Nocardia spp. referred to the Antibiotic
Resistance Evaluation Unit, a national reference service for England and
Wales, were characterised by MIC proﬁling. Demographic and clinical
data were also collated.
Results: Of 48 referred patient-isolates, 22 were unspeciated whilst
there were 7 each of N. farcinica and N. cyriacigeorgica. There were
three N. asteroides; other species amounted to 1 or 2 isolates each.
MICs of co-trimoxazole were 0.25–0.03 for N. farcinica (sensitive),
0.03−32 for N. cyriacigeorgica (2/7 isolates resistant), 4−>256 for
N. asteroides (3/3 resistant), 0.25−>32 for other speciated isolates (3/12
resistant) and 0.06−>32 for unspeciated Nocardia (18/29 resistant),
Overall, 26/58 (44.8%) Nocardia spp. were resistant to co-trimoxazole.
Of other antibiotics, 5/48 (10.4%) isolates were resistant to linezolid
(MICs 0.25−64), 24/48 (50%) resistant to Amikacin, 8/48 (16.7%)
resistant to imipenem.
The majority of patients were male (36, 75%); ages ranged from 28
to 87y. 27.1% presented with cerebral abscesses, followed by 18.9%
with lung lesions. Other abscesses accounted for 12.6% whilst Nocardia
were isolated from blood in 10.4%. Skin/wound infections accounted
for 8.3% isolates, whilst eye lesions, multiple abscesses, synovial ﬂuid
and osteolysis accounted for 6.3, 4.1, 4.1%, respectively. Of 6 isolates
from cerebral abscesses tested for susceptibility to moxiﬂoxacin, MICs
were 0.25−4 (66.6% sensitive). Only one isolate from cerebral pus
was sensitive to doxycycline but only one was resistant to linezolid
(MIC= 64); 2 were resistant to co-trimoxazole (MIC 4−>32).
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Conclusion: Whilst about half of all isolates were resistant to co-
trimoxazole, susceptibility amongst isolates from cerebral abscesses
was more common. Overall, linezolid was the most reliably active
agent although moxiﬂoxacin may be useful for cerebral abscesses. The
variability in antibiotic susceptibility highlights the need for continued
surveillance of the susceptibility of these organisms to determine
effective therapeutic strategies.
P1119 Antimicrobial effect of antibacterial essential oils and three
common antiseptic products
J. Karbach, S. Ko¨nigkamp, P. Warnke, E. Behrens, B. Al-Nawas (Mainz,
Kiel, DE)
Objectives: Essential oils are used in cosmetics and healthcare products
and have re-emerged as an effective antiseptic in patients with incurable
head and neck cancer and associated malodorous necrotic ulcerations.
The aim of the study was to evaluate the antimicrobial effect of a
combination of the oils compared to a single application and standard
antiseptics.
Methods: The efﬁcacy of different oils was evaluated by agar
diffusion test. Tea tree oil (TTO), Eucalyptus oil (EO), Lemon
grass oil (LMO), and one Eucalyptus-based oil mixture (KM-PT
70, Klonemax®, Central Tilba, NSW, Australia) were tested and
the results were compared with Paroex® (Chlorhexidindigluconat
0.2%, CHX), Octenisept® (octenidine dihydrochloride 0.1 g/100mL)
and Betaisodona® (Povidon-Iod 10 g/100mL). 10 different cultured
aerobic and facultative anaerobic bacteria and two yeasts were tested
for the ability for proliferation (L. buchneri, L. brevis, S. gordonii,
S. mutans, S. aureus, S. epidermidis, E. faecium, E. faecalis, M. micros,
A. actinomycetemcomitans, C. albicans, C. glabrata).
Results: The results of the agar diffusion tests are shown in Table 1. In
the common antiseptic group Paroex® showed the highest antimicrobial
effect. All tested oils also have antimicrobial effects against the biological
indicators. The four oils showed a signiﬁcantly higher antimicrobial
effect compared to Betaisodona® (p = 0.001). Lemon grass oil (p = 0.005)
and the mixture of oils (p = 0.039) had also a higher antimicrobial
effect than Octenisept®, Lemon grass oil (p = 0.021) revealed a higher
effect than Paroex®. Eucalyptus oil (p = 0.018) had a lower success
than Paroex®. The four tested oils prevented bacterial growth similar
to Paroex®. The results of Leman grass oil showed the best inhibitory
effect of all tested products.
Table 1. Diameter of the inhibition area of different pathogens [mm]
Mean Standard deviation Minimum Maximum
TTO 14 7 8 36
EO 12 4 9 22
LGO 22 9 11 39
Mixture 16 8 11 39
40% alcohol 6 0 6 6
Paroex® 15 3 11 20
Octenisept® 12 2 10 16
Betaisodona® 7 2 6 12
Conclusion: The tested oils prevent bacterial growth in our in-vitro
study and exhibit potency comparable to three well known standard
products. In the agar diffusion test, the size of the microbial inhibition
zone depends on the solubility and diffusion of the test substance and
therefore, they may not express its full effective potential. The efﬁcacy of
the tested oily lipophyle and alcoholic hydrophyle antimicrobial agents
and the results in antiseptic reaction should be evaluated in further
studies.
P1120 Antimicrobial susceptibility testing for Mycobacterium
kansasii in Taiwan
T.S. Wu, M.H. Lee, H.S. Leu, T.L. Wu, P.C. Chiang, C.H. Chiu
(Taoyuan Hsien, TW)
Objectives: Although Mycobacterium kansasii had been found for
decades, infections cause by this organism is newly emerging in Taiwan.
We know some ﬁrst-line antituberculous agents such as isoniazid,
rifampin, and ethambutol are effective to treat M. kansasii infections,
but we want to explore the efﬁcacy of other antimycobacterial agents.
Methods: Bacterial strains: Thirty seven clinical isolates were collected
from August, 1999 to January, 2003 at the Clinical Mycobacteriology
Laboratory of Lin-Kou Chang Gung Medical Centre, Taoyuan, Taiwan.
They are stored in skim milk containing 50% glycerol at −70ºC until
they are subcultivated.
PRA (PCR-restriction enzyme analysis): We differentiate M. kansasii
from other mycobacterial species by using molecular biology methods
described by Telenti et al.
Susceptibility tests: We use 96 wells plates for microdilution methods
of susceptibility tests described by Wallace et al. We made bacterial
7H9 broth equal to 0.5 McFarland turbidity, then diluted to 1:1,000,
and delivered 0.01mL into each well containing 0.1mL broth. Each
antimicrobial agent was added by twofold dilution by sequence.
Breakpoints: Isoniazid (INH) >1mg/mL; rifampin (RIF) >1mg/mL;
rifabutin (RFN) >2mg/mL; ethambutol (EMB) >5mg/mL; Clar-
ithromycin (CLR) >16mg/mL; ciproﬂoxacin (CIP) >2mg/mL; moxi-
ﬂoxacin (MFX) >2mg/mL; streptomycin (SM) >10mg/mL; amikacin
(AN) >32mg/mL; sulfamethoxazole >32mg/mL.
Results: The most active antibiotic is clarithromycin, the least
is ethambutol. The intermediate sensitive antimicrobial agents are
isoniazid, ciproﬂoxacin, and moxifoxacin; others are between 80% to
90% sensitive.
Conclusion: Ethambutol should not be contained in ﬁrst-line antimy-
cobacterial agents because most of M. kansasii isolates are resistant
to ethambutol in Taiwan. M. kansasii isolates is not so sensitive
to newer ﬂuoroquinolones because they are 70% and 55% sensitive
to ciproﬂoxacin or moxiﬂoxacin respectively. The ﬁrst line anti-
mycobacterial regimens for M. kansasii infections should contain of
clarithromycin, isoniazid, and rifampin at least. The alternative drugs
for M. kansasii infections are rifabutin, aminoglycosides (streptomycin
or amikacin), and sulfamethoxazole. The results of susceptibility tests
are variable among nations; we must choose the correct drugs to improve
the mortality and morbidity of patients according to local susceptibility
tests data.
Susceptibility testing for M. kansasii isolates
Antimicrobial agent Sensitivity MIC (mg/L)
(%) MIC50 MIC90 Range
INH 64.86 1 >32 0.25–>32
RIF 81.08 0.5 16 0.125–16
RFN 97.30 0.125 0.5 0.125–4
EMBa 12.12 8 16 4–>64
CLR 100 2 4 0.5−8
CIP 70.27 1 8 0. 5–>16
MFXa 54.55 2 >8 0.06–>8
SM 94.59 4 8 0. 5–>64
AN 97.30 8 8 1–>64
SXT 81.08 4 128 1–>128
aOnly 33 isolates were done.
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P1121 Patterns of susceptibility of Gram-negatives/positives
isolated in the United Kingdom and Ireland
B. Johnson, S. Bouchillon, M. Hackel, R. Badal, J. Johnson, D. Hoban,
M. Dowzicky (Schaumburg, Collegeville, US)
Background: The rapid emergence of multi-drug resistant pathogens
has undermined the efﬁcacy of many widely used broad spectrum
antibacterials and prompted the development of newer antimicrobials.
Tigecycline is a new glycylcycline shown to have broad spectrum
activity against many hospital pathogens. The purpose of this study was
to examine the activity of tigecycline and comparators to nosocomial
pathogens isolated in the UK and Ireland between 2004−06.
Methods: A total of 1,131 nosocomial pathogens were identiﬁed at each
site and conﬁrmed at a reference laboratory. MICs were determined at
each site utilising supplied broth microdilution panels and interpreted
according to EUCAST guidelines.
Results: See the tables:
E. coli, K. oxytoca/
pneumoniae (n = 294)
Acinetobacter
spp. (n = 86)
P. aeruginosa
(n = 119)
%S MIC90 %S MIC90 %S MIC90
Tigecycline 95.2 1 n/a 1 n/a 16
Amikacin 99.7 4 88.4 16 93.3 8
Cefepime 86.1 4 n/a 32 83.2 32
Imipenem 100 0.5 91.9 2 89.1 8
Levoﬂoxacin 79.3 >8 76.7 8 65.5 >8
Minocycline n/a 8 n/a 4 n/a >16
Pip/Tazo n/a 16 n/a >128 n/a 64
S. aureus
(n = 136)
Enterococcus
spp. (n = 79)
S. pneumoniae
(n = 79)
%S MIC90 %S MIC90 %S MIC90
Tigecycline 100 0.26 100 0.25 n/a 0.5
Levoﬂoxacin 75.7 8 n/a >32 100 1
Linezolid 100 4 100 2 100 1
Minocycline n/a 0.6 n/a >8 n/a 2
Vancomycin 100 1 92.4 2 100 0.5
n/a: breakpoints not yet available.
Conclusions: Tigecycline was as active as comparator agents against
most Enterobacteriaceae spp., displayed the lowest MICs against
Acinetobacter spp., and had minimal activity against P. aeruginosa.
Against Gram-positives, tigecycline was as active as vancomycin and
linezolid, and superior to levoﬂoxacin or minocycline.
P1122 In vitro susceptibility of Actinobaculum spp. isolated from
urinary tract infections against nine antibiotics
T. Schu¨lin-Casonato, F. D’Ancona, H. Willemse, P. Sturm (Nijmegen, NL)
Introduction: Gram-positive rods have been described as cause of uri-
nary tract infections (UTI) and urosepsis. Recently, with more sensitive
detection and more advanced identiﬁcation methods, Actinobaculum spp.
have been identiﬁed to cause UTIs and urosepsis. The majority of UTIs is
treated without microbiological diagnosis with antibiotics (AB) directed
against Gram-negative rods.
Material and Methods: We tested the susceptibility of 21 Actinobacu-
lum spp. isolated from urine for 9 antibiotics which are used as empirical
therapy in UTIs or have known activity against Gram-positive organisms.
MICs for 9 antibiotics (penicillin [PEN], ceftriaxone [CRO], moxi-
ﬂoxacin [MOX], ciproﬂoxacin [CIP], clindamycin [CLI], erythromycin A
[ERY], vancomycin [VAN], tetracycline [TET], nitrofurantoin [NFT]) of
21 unique strains of Actinobaculum spp. (17 A. schaalii, 1 A. massiliae,
1 A. urinale and 2 A. species) isolated over a two-year period from
urinary tract infections were determined by means of agar-dilution
technique on lysed sheep blood agar with a ﬁnal inoculum of 5×104 CFU
per spot. Plates were incubated for 18 hours under anaerobic conditions.
Results: Distribution of MICs are presented in table 1.
Table 1. Number of strains for different MICs:
Agent MIC (mg/L)
<0.015 0.015 0.03 0.06 0.125 0.25 0.5 1 2 4 8 16 32 >32
PEN – 21 – – – – – – – – – – – –
CRO – – 10 6 5 – – – – – – – – –
CLI – – – – 1 3 3 11 2 – – – – 1
ERY – 18 1 1 – – – – – 1 – – – –
TET – – – 3 4 11 2 1 – – – – – –
MOX – – – – – 1 6 13 1 – – – – –
CIP – – – – – – – 1 4 14 – 1 1 –
VAN – – – – 5 16 – – – – – – – –
NFT – – – – – – 1 1 13 5 – 1 – –
Discussion: PEN and ERY were the agents with the lowest MICs.
MICs for CRO, a third generation cephalosporin, which is often used as
empirical therapy in urosepsis, were also in the range of available urine
concentrations of this drug. Interestingly, one strain was resistant for CLI
and ERY, which is suggestive for an MLSb resistance mechanism. MICs
for CIP, frequently used in UTIs, were between 1 and 32mg/L, which
makes it less useful to treat UTIs due to Actinobaculum species. MICs
for MOX were lower, but this drug does not reach high concentrations
in urine.
Actinobaculum spp. can be a cause of UTIs and should be considered in
patients who do not respond to therapy with antimicrobial agents directed
solely against Gram-negative bacteria.
P1123 Antimicrobial susceptibility and phage types of Salmonella
typhimurium human strains isolated during 2002–2005 in
the Slovak Republic
L. Majta´nova´, V. Majta´n (Bratislava, SK)
Objectives: Salmonella Typhimurium is a common cause of human
salmonellosis in many countries. This is the second most common
salmonella serovar isolated from human sources. The extensive use
of antimicrobials in human and veterinary medicine has led to an
increase in multidrug resistance strains (MDR). A MDR S. Typhimurium
strain, with deﬁnitive phage type 104 (DT104), has emerged and spread
over the world since 1984. The aim of this study was to analyse the
antimicrobial resistance patterns of 330 S. Typhimurium human isolates
and to investigate the distribution of their phage types.
Methods: Antimicrobial susceptibility tests were performed by disk-
diffusion method using 10 different antibiotic disks according to the
method of CLSI/NCCLS. Phage types were determined by the extended
phage typing scheme of Anderson et al. (1977).
Results: Of total 330 strains analysed, MDR was identiﬁed in
192 (58.2%) isolates. They were the most frequently resistant to
ampicillin, streptomycin, sulﬁsoxazole, tetracycline, chloramphenicol,
sulfamethoxazole-trimethoprim and trimethoprim. None of the all
isolates were resistant to ceftriaxone and only one isolate was resistant
to ciproﬂoxacine. Three hundred and thirty strains encompassed 25
deﬁnitive phage types, 38 strains were atypical types (RDNC) and
76 ones were untypable. The predominant phage types were DT104
(22.4%), DT20a (22.1%) and DT120 (5.6%).
Conclusion: The strains studied expressed MDR and belonged to differ-
ent phage types. The MDR was ascertained mainly in the predominant
phage types DT104, DT20a, DT120 and also in untypable strains
originating from sporadic cases of infection. Continual surrveillance is
necessary to monitor the dissemination of these and similar MDR strains
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as well as their phage types in order to implement appropriate control
measures.
P1124 In vitro antimicrobial activity of azithromycin against
Mycoplasma genitalium and the bacteriological efﬁcacy in
male M. genitalium-positive non-gonococcal urethritis
M. Yasuda, N. Hagiwara, M. Ito, S. Ishihara, S. Maeda, S. Ito,
H. Narita, T. Deguchi (Gifu, Minokamo, Toyota, Sendai, Nagoya, JP)
Objectives: Many studies have shown Mycoplasma genitalium to be
a pathogen responsible for non-gonococcal urethritis (NGU). However,
there are no published guidelines or recommendations for treating
M. genitalium-positive NGU. So dosing regimens of antimicrobial
agents active against Chlamydia trachomatis are usually used to
treat M. genitalium-positive NGU. In the CDC and EAU guidelines,
azithromycin or doxycycline treatment is recommended for management
of patients with NGU. Thus we investigated the minimal inhibitory
concentration (MIC)s of azithromycin and other antimicrobial agents
for M. genitalium and whether azithromycin are clinically efﬁcacious as
antibacterial therapy against M. genitalium.
Methods: Seven strains of M. genitalium were obtained from the
American Type Culture Collection. Susceptibility testing was performed
by the broth microdilution method in 96-well microtiter plates with SP-4
medium. We then enrolled a total of 19 men with M. genitalium-positive
NGU who were treated with azithromycin 1,000mg orally as single dose.
PCR-based assay was performed to evaluate the microbiological efﬁcacy
of eradication therapy in these patients.
Results: Azithromycin (MIC range: 0.004–0.008mg/L) and clar-
ithromycin (MIC range: 0.008–0.015mg/L) were very active against
M. genitalium. Doxycycline (MIC range: 0.06–0.125mg/L) and minocy-
cline (MIC range: 0.06–0.125mg/L) had a moderate activities against
M. genitalium-positive non-gonococcal urethritis. Gatiﬂoxacin (MIC
range: 0.125–0.25mg/L) and sparﬂoxacin (MIC: 0.25mg/L) were more
active than levoﬂoxacin (MIC: 1.0mg/L). In 17 of 19 (89.5%) patients
treated with azithromycin,M. genitalium was eradicated from the urethra.
Conclusions: Susceptibility testing suggests that azithromycin are
suitable for treating M. genitalium-positive NGU. Clinical results suggest
that azithromycin given orally at 1,000mg as single dose is useful in
treating M. genitalium-positive NGU.
P1125 Susceptibility pattern of Escherichia coli associated urinary
tract infection: a comparison between spinal cord and
nosocomial induced UTIs
F. Khorvash, K. Mostafavizadeh, S. Mobasherizadeh, A. Javadi,
M. Behjati (Isfahan, IR)
Evolving resistant uropathogenes have been associated with the elevated
risk of morbidity and mortality, both in nosocomial and spinal
cord (SCI) associated urinary tract infections (UTI). Both of these
complicated UTIs have concomitant risk factors for UTI conﬂiction, as
urinary catheterisation, probable poor hygiene, prolonged or intermittent
antibiotic consumption and others. Regarding to this susceptibility,
antibiotic resistance emerges, so more clinicoepidemiological studies are
needed to facilitate empirical therapy and decrease time and costs toward
diagnosis and treatment.
Method and Material: During 18 months period of this study (2005
and early 2006) 100 and 80 E. coli specimens from cases of diagnosed
nosocomial UTI and spinal cord injury associated (SCI) UTI have been
isolated by standard microbiological methods respectively. MIC of 10
antibiotics on isolated bacteria was determined by gradient concentration
method (E-Test®; AB BIODISK Co. Sweden). Quality control was tested
by E. coli ATCC25922. Data was analysed by SPSS 13 and Whonet 5
software.
Results: Antibiotic resistant uropathogenes were more prevalent among
nosocomial UTIs rather than SCI associated UTI (P< 0.05). According
to break point used for susceptibility meet CLSI M7-A6 (Clinical and
Laboratory Standard Institute) criteria, resistance of isolated E. coli
in nosocomial and SCI associated UTIs was 13.9% and 5.9% in
amikacin (P< 0.01), 65% and 40.5% in ceftazidim (P< 0.05), 69.8%
and 32.4% in ceftriaxone (P< 0.005), 50% and 41.2% in ciproﬂoxacin
(P< 0.05), 56.9% and 13.6% in gentamicin (P< 0.005), 2.1% and 0% in
imipenem (P< 0.005), 3.9% and 0% in meropenem (P< 0.005), 73.6%
and 63.6% in trimethoprim/Sulfamethoxazole (P< 0.05) respectively.
Only resistance to nalidixic acid was mildly higher in SCI E. coli
(79.1%, 73.6%). MIC50 of all antibiotics were higher in nosocomial
E. coli (p< 0.05).
Conclusion: Despite more risk factors for antibiotic resistant E. coli
in SCI population, the emerged antibiotic resistant E. coli was more
diagnosed in nosocomial UTIs. Although this difference can be attributed
to the hospital environment, more studies are needed to uncover the
causes of these ﬁndings.
P1126 Emergence of Salmonella spp. isolates with reduced
susceptibility to ciproﬂoxacin in Kuwait and the
United Arab Emirates
V.O. Rotimi, W.Y. Jamal, T. Pal, A. Sonnevend, T.S. Dimitrov,
M.J. Albert (Safat, KW; Al Ain, AE; Andolus, KW)
Objective: Kuwait and UAE are of sentinel signiﬁcance in the context
of global epidemiology of antimicrobial resistance because of a large
expatriate population of workers from different parts of the world. Our
main objective was to evaluate the antimicrobial susceptibility of clinical
isolates of Salmonella spp. in these countries over a 2-year period and
determine the extent of resistance problem.
Methods: A total of 410 Salmonella spp. isolated from symptomatic
patients in various hospitals in Kuwait and UAE, were studied.
The problem of drug resistance was investigated by determining the
antimicrobial susceptibility of 410 Salmonella spp. from both countries
by the E-test method.
Results: The MIC90s of amikacin, cefotaxime, ceftriaxone and
ciproﬂoxacin were 1.9, 0.47, 0.47, and 0.14 mg/mL, respectively (Kuwait
isolates), and 2.5, 0.22, 0.22, and 0.056mg/mL, respectively (UAE).
Resistance rates among Kuwait and UAE isolates to ampicillin were
25.1% and 15.5%, cefotaxime/ceftriaxone 1.6% and 1.6%, ciproﬂoxacin
1.2% and 0.8%, chloramphenicol 5.6% and 5.7%, and trimethoprim
25.5% and 7.4%, respectively. In Kuwait and UAE, 14.2% and 7.3%
of the non-typhoidal Salmonella, respectively, and 44% of S. Typhi
and 46.7% S. Paratyphi demonstrated reduced susceptibility (MIC;
0.125−0.5mg/mL) to ciproﬂoxacin.
Conclusion: A large number of Salmonella spp. isolates, many of which
were multi-drug resistant, were resistant to the ﬁrst-line antibiotics.
A high proportion of isolates also exhibited reduced quinolone
susceptibility, a phenomenon that appears to be spreading rapidly
throughout the world.
P1127 Enhancement of antimicrobial activities of cefteram
or clavulanic acid/amoxicillin against ceﬁxime-resistant
Neisseria gonorrhoeae in the presence of clarithromycin or
azithromycin
H. Kiyota, S. Onodera (Tokyo, JP)
We investigated the enhancement of antimicrobial activities of b-lactams
against ceﬁxime (CFIX)-resistant Neisseria gonorrhoeae in the presence
of macrolides. Ten strains of CFIX-resistant N. gonorrhoeae, isolated
from the patients with male urethritis between 2000 and 2003 at
Jikei University Afﬁliated Hospital and its related clinics in the Tokyo
metropolitan area, were tested. The fractional inhibitory concentrations
of clavulanic acid/amoxicillin (CVA/AMPC), CFIX, or cefteram (CFTM)
in the presence of clarithromycin (CAM) or azithromycin (AZM)
against these strains were determined. Synergism, partial synergism or
additivity between CVA/AMPC or CFTM and macrolides against 9
strains were recognized. Additivity or partial synergism between CFTM
and macrolides against 9 or 10 strains were also recognized. On the other
hand, antagonism between CFIX and macrolides was recognized. These
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results indicate that the combination of antimicrobial chemotherapy
of CFTM or CVA/AMPC with macrolides is a possible alternative
treatments against CFIX-resistant N. gonorrhoeae infections.
P1128 Microbial diversity and resistance of pathogens in prostatitis
M.S. Lapatschek, A. Hartinger (Munich, DE)
Objectives: Only very few types of antibiotics are efﬁcient for the
treatment of acute and chronic prostatitis. Moxiﬂoxacin is a new
ﬂuoroquinolon with an extended antibacterial spectrum including Gram-
positive bacteria and anaerobes. In this study we determined the activity
of moxiﬂoxacin against pathogens isolated from 100 patients with
prostatitis in comparison with other antibiotics used for the treatment
of this disease.
Methods: Prostatic ﬂuid of patients suffering from clinically diagnosed
prostatitis was cultured for potentially pathogenic microbes. In addition,
a PCR for the detection of Chlamydia trachomatis and Neisseria
gonorrhoeae was performed. The conventionally cultured bacteria
were tested for resistance by Etest against ampicillin, ampicillin/
sulbactam, sulfamethoxazole/trimethoprim, doxycycline, levoﬂoxacin
and moxiﬂoxacin.
Results: We received 147 specimens from 100 patients. We were
able to cultivate 93 potential pathogens, distributed over 21 different
species; 33% of these isolates were Gram-positive cocci, 45% Gram-
negative rods and 2% anaerobic Gram-negative rods. Chlamydia and
Gonococci were not found. The results of the sensitivity testing show an
overall sensitivity of 59% for ampicillin, 83% for ampicillin/sulbactam,
79% for sulfamethoxazole/trimethoprim, 48% for doxycycline, 92% for
levoﬂoxacin and 91% for moxiﬂoxacin.
Conclusions: Prostatitis is caused by a broad spectrum of different
pathogens. Ampicillin without inhibitor, sulfamethoxazole/trimethoprim
and doxycycline are not covering a sufﬁcient spectrum of bacteria
for calculated monotherapy. Ampicillin/sulbactam, levoﬂoxacin and
moxiﬂoxacin have a comparable overall in vitro activity towards
potentially pathogenic bacteria. Thus, moxiﬂoxacin seems to be a feasible
alternative for the treatment of prostatitis presuming a good tissue
penetration into the prostate gland.
P1129 Antimicrobial susceptibility of gonococci isolated in Greece
in 2005. Dramatic increase in quinolone resistance rate due
to a single serovar
M. Stathi, H. Avgerinou, V. Miriagou, A. Flemetakis, M. Daniilidou,
K. Kyriakis, E. Tzelepi (Athens, Thessaloniki, GR)
Objectives: Surveillance of antibiotic susceptibility trends of gonorrhoea
in Greece.
Methods: Microbiological and epidemiological data for 168 gonococci
received by the Greek National Reference Centre for Neisseria
gonorrhoeae during the year 2005 were evaluated. The strains were
isolated consecutively from gonorrhoea cases attended either the Andreas
Sygros STD Hospital in Athens (90%) or other hospitals throughout
Greece (10%). Susceptibilities of the isolates were determined in terms of
Minimal Inhibitory Concentrations (MICs) of eight antimicrobial agents
using Etest strips (AB Biodisk). Serological classiﬁcation was performed
with the Phadebact GC Serovar Test (Boule Diagnostics). Plasmid
content analysis was performed for penicillinase producing strains
(PPNG) and for strains exhibiting tetracycline MICs >8mg/L (TRNG).
Epidemiological data were obtained through a standard questionnaire,
which included demographic data and information for sexual behaviour
and source of infection.
Results: Only cefotaxime and spectinomycin were fully active against
all of the 168 isolates. Whereas, high rates of resistance (R) and
intermediate susceptibility (I) were observed for penicillin G (R 23.2%,
I 70.8%), tetracycline (R 30.4%, I 68.4%), erythromycin (R 45.2%,
I 50.6%), chloramphenicol (R 39.9%, I 56.5%), norﬂoxacin (R 33.3%)
and ciproﬂoxacin (R 33.3%, I 0.6%). PPNG and/or TRNG isolates
accounted for 5.4% of the total sample, including four strains that were
simultaneously quinolone-resistant (QRNG). The isolation frequency of
QRNG strains (33.3%) was found dramatically raised as compared to
the rate of 11.3% which was recorded in the previous year. Serotyping
results revealed a strong association (P< 0.001) of quinolone resistance
with a single serovar (Bropyst), present in 75% of the QRNG isolates.
Interestingly, Bropyst/QRNG isolates exhibited cross-resistance to all
antibiotics tested, except cefotaxime and spectinomycin. Information
ensued by the questionnaires indicated that QRNG/Bropyst isolates
derived from cases of infection acquired within Greece.
Conclusion: Resistance proﬁles in the Greek gonococcal sample of
2005 point out as drugs of choice for the treatment of gonorrhoea
3rd generation cephalosporins and spectinomycin. Typing results and
epidemiological data suggest that triplication in QRNG frequency
observed between 2004 and 2005 is probably due to a single, endemic
strain.
P1130 The panhellenic study on the antimicrobial susceptibility of
community-acquired uropathogens: preliminary data report
I. Katsarolis, G. Poulakou, S. Athanasia, F.V. Kontopidou,
P. Panagopoulos, E. Karaiskos, D. Voutsinas, L. Zarkotou, P. Gavra,
G. Koratzanis, M. Kanellopoulou, G. Adamis, E. Vagiakou,
I. Matthaiopoulou, E. Vogiatzi, P. Perdikaki, G. Panou, E. Kremastinou,
H. Giamarellou (Haidari, Piraeus, Marousi, Athens, Tripoli, Nafpaktos,
Astros Kynourias, Karpenissi, GR)
Purpose: To present preliminary microbiological data from the ﬁrst
panhellenic survey investigating the prevalence and susceptibility of
pathogens causing community-acquired acute uncomplicated urinary
tract infections in 2005, with a view to guide empirical treatment.
Methods: Midstream urine samples were cultured from women <65
years, without known complicating factors, presenting with symptoms
of acute cystitis at public and private community healthcare centres
across Greece in 2005. Pathogens were identiﬁed and tested for their
susceptibility to 13 antimicrobials by disk diffusion assay, using CLSI
2005 methodology and breakpoints. Patients with known complicating
factors (urinary tract abnormalities, comorbidities, pregnancy, recent
hospitalisation, antibiotic usage or UTI history in the past 2 weeks)
were excluded.
Results: Preliminary microbiological data (March–July 2005) were
derived from 418 consecutive positive cultures from women with
acute uncomplicated cystitis, out of 1,532 patients tested in the same
period. Escherichia coli accounted for 78.7% of isolates, Proteus
mirabilis 8.9% and Klebsiella pneumoniae 2.4%. Staphylococcus
saprophyticus was isolated in only two cases. Full susceptibility to
all investigated antimicrobials was recorded among 39.2% of E. coli
isolates, whereas resistance was most common to ampicillin (27.1%)
and cephalothin (24.8%), followed by cotrimoxazole (21.1%), ni-
trofurantoin (19%) and amoxicillin/clavulanate (7.7%). Resistance to
nalidixic acid and ciproﬂoxacin, fosfomycin and cefuroxime was
7.8%, 4%, 3.1% and 2.1%, respectively. Proteus mirabilis resistance
rates per antimicrobial were: ampicillin (25%), cotrimoxazole (27.8%),
nalidixic acid/ciproﬂoxacin (10.8/0.0%), amoxicillin/clavulanate (5.4%)
and cefuroxime (2.7%). Gentamycin resistance rates for E. coli and
P. mirabilis were similar (2.2/2.8% respectively). No ESBL-producing
strains were detected.
Conclusions: From the up till now analysed preliminary data, it
is evident that: (1) Empirical use of ﬁrst-line antimicrobials in
uncomplicated community-acquired UTIs, such as ampicillin, cotrimox-
azole and nitrofurantoin, should be reevaluated, due to high rates of
resistance. (2) Quinolones are still highly efﬁcacious in this setting,
but increasing resistance rates may advocate caution in their use
in uncomplicated infections. (3) Low-level resistance to amoxicillin/
clavulanate, cefuroxime and fosfomycin must be taken into account in
the empirical treatment strategy.
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P1131 Antimicrobial susceptibilities and prevalence of qnrA in
UTI isolates from hospital and the community
P.G. Higgins, M. Lohr, F. Wisplinghoff, H. Seifert, H. Wisplinghoff
(Cologne, DE)
Objectives: To determine the prevalence of the quinolone resistance gene
qnrA and to compare species distribution and antimicrobial susceptibility
of nosocomial and community acquired urinary tract infections.
Methods: Over a three-month period, isolates were prospectively col-
lected from hospitals and private practices in the Cologne metropolitan
area. 557 Gram-negative isolates were included in the study. Species
identiﬁcation and antimicrobial susceptibility testing were performed
using the VITEK Two and the MicroScan-Walkaway system. Presence
of qnrA was investigated by PCR.
Results: E. coli was most the commonly isolated organism, accounting
for 59% of all isolates, followed by Klebsiella spp. and Pseudomonas
aeruginosa (13% and 8% respectively). Species distribution was similar
in nosocomial and community acquired UTI, except for Klebsiella spp.
and Morganella morganii that were more commonly seen in nosocomial
UTI, while E. coli was more frequently observed in community
acquired UTI. Prevalence of qnrA was low; the gene was detected in
2 Enterobacter cloacae isolates, both from nosocomial UTIs. One of
these strains showed intermediate resistance to ciproﬂoxacin while the
other was fully susceptible. Nosocomial isolates were in general more
resistant to the antimicrobial agents than the community isolates. For
example, 90% of P. aeruginosa from the community were susceptible to
ceftazidime and imipenem compared to 83% and 71% respectively of
the hospital isolates. Also 93% of community E. coli were susceptible
to cefuroxime compared to 78% of hospital isolates. Of note, 88% of
nosocomial Proteus species were susceptible to ciproﬂoxacin compared
to only 59% in community isolates.
Conclusions: As expected, nosocomial Gram-negative UTI pathogens
are less susceptible to antimicrobials compared to those that are
community acquired. However, the notable exception to this is
ciproﬂoxacin activity against Proteus species. The qnrA gene is still
rarely found in Germany and to date has not been found in community
isolates.
P1132 Occurrence and susceptibility rates among urinary tract
infection pathogens from Europe: a seven-year report
from the SENTRY Antimicrobial Surveillance Program
(1997–2000, 2003)
G. Moet, M. Stilwell, R. Jones (North Liberty, US)
Objectives: To report the occurrence and susceptibility (S) rates for
pathogens causing urinary tract infection (UTI) isolated from medical
centres in Europe, Turkey, and Israel. The S rates were compared
by CLSI and EUCAST breakpoints. The SENTRY Antimicrobial
Surveillance Program was utilised as the platform for collecting urine
culture isolates during 5 years out of 10 year period that the programme
has been in existence.
Methods: A total of 4,507 strains (50 consecutive, non-duplicate per
site) were collected from 42 medical centres in 19 countries in Europe,
Turkey and Israel (1997–2000, 2003). During the 5 years 31 locations
participated in 3 or more years. All isolate identiﬁcations were conﬁrmed
and S testing performed in a central laboratory using reference broth
microdilution methods (M7-A7) and interpretive criteria of CLSI and
EUCAST (2006). ESBL phenotype rates were as determined by CLSI
criteria.
Results: The 5 most frequent pathogens accounted for 83.3% of the
total CA-UTI and the top 7 for 90.0%. These 7 pathogens displayed
little change in occurrence rates over the 7 year period. Escherichia coli
remained the dominant UTI pathogen at nearly 50% while enterococci
showed a slight decrease from 11.7 to 10.1%. Variations in 1999
were greater due to only 9 participating sites (small sample size).
Among commonly isolated Enterobacteriaceae, carbapenems were the
most active agents ranging from 99.1% to 100.0% S; lower S was
noted for ciproﬂoxacin (77−89%) and trimethoprim/sulfamethoxazole
(T/S; 63−78%). Ceftazidime S rates for Klebsiella, E. coli, and Proteus
mirabilis were 80.7, 97.2, 95.5% (CLSI) and lower at 76.9, 94.7,
92.5% (EUCAST), respectively. ESBL phenotype rates were 24.0, 5.3,
and 7.2% for the same organism groups. Polymyxin B was active
against Pseudomonas aeruginosa at 99% S, followed by carbapenems
and piperacillin/tazobactam at 84% and amikacin at 83%. Vancomycin,
teicoplanin, and linezolid remained active against enterococci (99% S).
Variation of rank order in SENTRY Program UTI pathogens by year for Europe
Rank Organism All years 1997 1998 1999 2000 2003
1 E. coli 2,175(48.3) 505(51.0) 548(48.0) 68(39.5) 361(46.1) 693(48.8)
2 Enterococci 510(11.3) 116(11.7) 127(11.1) 23(13.4) 100(12.8) 144(10.1)
3 Klebsiella spp. 445(9.9) 83(8.4) 120(10.5) 25(11.6) 69(8.8) 153(10.8)
4 P. aeruginosa 355(7.9) 65(6.6) 91(8.0) 16(9.3) 71(9.1) 112(7.9)
5 P. mirabilis 265(5.9) 52(5.2) 70(6.1) 3(1.7) 56(7.2) 84(5.9)
6 Enterobacter spp. 194(4.3) 49(4.9) 36(3.2) 11(6.4) 33(4.2) 65(4.6)
7 Indole + Proteus spp. 109(2.4) 21(2.1) 31(2.7) 5(2.9) 27(3.1) 28(2.0)
Total 4,507 991 1,142 172a 783 1,419
aSmall sample.
Conclusions: This comprehensive report from the SENTRY Program
covering 7 years of UTI sampling in Europe, reports minor variation
in the most common pathogens between the sample intervals but with
signiﬁcant S differences noted among monitored countries. Emerging
resistance is limiting the usefulness of commonly prescribed UTI agents
including T/S and FQ, forcing reliance on more potent parenteral broad-
spectrum agents and the additional problems inherent in their use.
P1133 Increasing ciproﬂoxacine resistance in the bacteria isolated
from urine samples: 1999–2004
O. Alici, Z. Acikgoz, S. Gocer, S. Gamberzade, M. Karahocagil
(Ankara, TR)
Purpose: The aim of the study was to determine the ciproﬂoxacin
resistance of various bacterial species responsible for UTIs according
to IDSA guidelines for UTIs between 1999 and 2004, retrospectively.
Materials and Methods: Overall 3,520 unduplicated urinary isolates
were screened for their ciproﬂoxacin resistance between 1999 and 2004,
retrospectively. Of the isolates 3,276 (93.1%) were from outpatients
and 244 (6.9%) from the hospitalised ones. The screening was made
regardless of age, gender and other demographic parameters. The
isolates were identiﬁed by using conventional biochemical tests and
the semi automated API systems (bioMe´rieux, France) when it was
required. Antimicrobial susceptibility assays were performed using the
disc diffusion method according to the recommendations of Clinical and
Laboratory Standards Institute (CLSI) criteria. The data were analysed
by Chi-square test in SPSS 10.0 programme and p values lower than
0.05 were considered signiﬁcant.
Results: Of the screened isolates 3,216 (91.4%) were Gram negative
bacilli and 304 (8.6%) were Gram positive cocci. Totally 29.9% (73/244)
of in-patients isolates and 11.8% (281/2,376) of outpatient isolates
had ciproﬂoxacin resistance. Out-patient and in-patient distributions of
the resistant isolates according to main microorganism groups were
as follows: For Gram positives 34.7% (n.8) and 65.3% (n.15); for
Gram negatives 19.6% (n.65) and 80.4% (n.266), respectively. While
there was no statistically signiﬁcant difference between Gram positive
and Gram negative microorganisms in terms of ciproﬂoxacin resistance
(p> .05), the resistance rates of isolates from in-patients and out-patients
differed signiﬁcantly (p< 0.001). Ciproﬂoxacin resistance rates over the
six years (1999–2004) were: 3.3% (17/509), 4.2 (33/551), 6.7 (40/593),
13% (102/786), 16.1% (124/768) and 15.3% (48/313) respectively. the
differences between 1999 and 2001, 1999 and 2002, 2000 and 2001,
2000 and 2002 and 2001 and 2002 were signiﬁcant (p< 0.05).
Conclusions: We concluded that a prominent increase in ciproﬂoxacin
resistance has emerged in bacteria isolated as UTI agents, especially in
E. coli. This problem of resistance is a considerable issue for in-patients
and has the potential to affect out-patients in long term periods.
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Table 1. Distribution of bacterial species and their ciproﬂoxacin
resistance rates
Species No. of isolates Resistance
n (%)
E. coli 2,444 305 12.5
Klebsiella spp. 480 21 4.4
Proteus spp. 190 – –
Enterococcus spp. 137 18 13.1
Gr. B streptococci 85 1 1.1
Staphylococcus spp.a 82 4 4.9
Enterobacter spp. 51 – –
Pseudomonas spp. 51 5 9.8
Total 3,520 354 10.1
aIncluding Staphylococcus aureus and coagulase-negative staphylococci.
P1134 Antimicrobial resistance of Mycoplasma hominis and Ure-
aplasma urealyticum among women with vaginal discharge
A. Kurti, G. Mulliqi-Osmani, L. Raka, L. Berisha, A. Jaka, X. Jakupi,
L. Begolli (Pristina, Kosovo, RS)
Objectives: The aim of study was to isolate Mycoplasma hominis (Mh)
and Ureaplasma urealyticum (Uu) and determine the antimicrobial
resistance in cervico-vaginal samples of women, who had complaints
of vaginal discharge, using Mycoplasma IST 2 (bioMe´rieux).
Methods: There were 471 patients with vaginal discharge included in
the study. Vaginal samples were taken from endocervikal region after
exocervikal mucus had been swabbed clean. Mycoplasma IST 2 used
for investigation of Mh and Uu provided information about the presence
or absence of Mh and Uu and also their antimicrobial susceptibility
to doxycycline, josamycin, oﬂoksacin, erythromycin, tetracycline,
ciproﬂoxacin, azythromycin, clarythromycin and pristinamycin.
Results: Uu has been isolated in 235 (49.90%) patients, while Mh has
been isolated in 42 (8.91%) of them. Uu and Mh have been both isolated
in 36 (7.46%) of the patients.
The Uu has shown the lowest sensitivity in ciproﬂoxacin with 98
(41.70%) of isolates being resistant. The isolates of Mh and the mixt
Mh/Uu isolates have shown low sensitivity on Erythromicin with 6
(100%) and 27 (75%) respectively being resistant.
Conclusion: A higher prevalence of Uu versus Mh is noted in the vaginal
swabs as well as higher resistance in the chinolone. In addition, Mh and
mixed isolates are more resistant in macrolides further explaining that
the macrolide resistence is attributed to Mh.
P1135 Ten-year surveillance of antimicrobial susceptibility of
community-acquired uropathogens in northern Israel
R. Wasseem, B. Chazan, M. Elias, R. Colodner, R. Raz (Afula, IL)
Background: Community acquired urinary tract infection (CA-UTI) is
very common. Knowing local antibiotic sensitivity patterns is essential
for empiric therapy.
Aim: Compare susceptibility patterns of community acquired
uropathogens in northern Israel over a 10 year period.
Methods: All community urinary isolates processed by our laboratory
during 1995, 1999, 2002 and 2005 were included. Distribution and
susceptibility of Gram negative isolates were assessed. Antibiotic
Consumption over 2000–2005 was evaluated.
Results: Over the study years approximately 10% of cultures grew
Gram-negative isolates. E. coli remained the leading uropathogen (61%)
without a signiﬁcant change in the prevalence of other Gram-negative
isolates. The susceptibility rates of E. coli for ampicillin (45%),
cefuroxime (97%) and ceftriaxone (98%) remained stable. Susceptibility
to amoxicillin-clavulanate (89% vs. 96%), TMP-SXZ (70.99% vs.
71.88%) and nitrofurantoin (93.9% vs. 97%) increased signiﬁcantly.
However, susceptibility of E. coli and other Gram–negative pathogens
to ciproﬂoxacin (~94% vs. ~89.5%) decreased signiﬁcantly. MIC90 of
E. coli for amoxicillin-clavulanate, cephalothin, cefuroxime, ceftriaxone
and ciproﬂoxacin remained stable. A signiﬁcant decrease in the use
nitrofurantoin and TMP-SMX and a signiﬁcant increase in the use of
ampicillin, cephalothin and ceftriaxone were seen by DDD/1,000/day.
Conclusions: Over a 10-year period susceptibility of E. coli and other
Gram negative uropathogens responsible for CA-UTI in northern Israel
has mostly remained stable or showed a small increase. However,
there was a constant decrease in susceptibility of uropathogens to
ﬂuroquinolones.
We didn’t ﬁnd a marked correlation between bacterial susceptibility and
antibiotic consumption.
P1136 Community coliforms in Cambridgeshire: resistance
patterns in urinary isolates from 1997 to 2006
J.S. Cargill, H.A. Payne, D.A. Enoch, H. Ludlam, N.M. Brown
(Cambridge, UK)
Objective: To demonstrate variations in resistance patterns for urinary
isolates in the community over a 9 year period to the end of June 2006.
Methods: The laboratory results database was searched for urine
samples obtained from general practice patients, and the susceptibility
rates to ampicillin (AMP), co-amoxiclav (AMC), cephalexin (CLN),
norﬂoxacin (NOR) and trimethoprim (TMP) against selected Enter-
obacteriaceae (grouped as Escherichia coli, Citrobacter–Enterobacter–
Klebsiella–Serratia spp. [CEKS] and Proteus–Providencia–Morganella
spp. [PPM]) were examined. Susceptibility was assessed by a breakpoint
method prior to 1998 and by BSAC methods since. Resistance
to cefpodoxime was introduced as a marker for extended-spectrum
b-lactamase production in September 2005, and the resistance rates to
this are also included.
Results: Of 58,823 positive isolates identiﬁed, 48,317 (82.1%) were
E. coli, and so the resistance patterns are dominated by changes in this
organism. Table 1 shows antibiotic susceptibilities at selected time points,
showing that overall sensitivities to CLN have remained stable over the
study period, while AMC (and AMP) sensitivity shows a cycling pattern.
TMP showed constant susceptibilities until 2002, followed by a decline,
while NOR has shown a gradual decrease in susceptibility throughout
the time period, with an acceleration in resistance rates after 2004.
For E. coli NOR sensitivity ﬁrst dropped below 95% in early 2003, and
below 90% in early 2005. For CEKS these levels were reached in early
2002 and late 2004 respectively, and for PPM late 2000 and early 2006
respectively. For E. coli TMP sensitivity dropped below 75% for the ﬁrst
time in early 2005, having been below 85% throughout the study period.
For CEKS TMP sensitivity dropped below 85% for the ﬁrst time in late
1998, recovering to 85−93% with a drop below 80% in early 2004, while
for PPM TMP has shown less than 75% sensitivity rates throughout the
study period.
Cefpodoxime resistance is present in 2.7−4.1% of E. coli, 7.6–12.1% of
CEKS and 0.0−2.2% of PPM per quarter.
OveralI susceptibility rates (% of isolates)
Jul–Dec Jan–Jun Jul–Dec Jan–Jun Jul–Dec Jan–Jun Jan–Jun
1997 1999 2000 2002 2003 2005 2006
Ampicillin 55.7 54.7 57.3 57.2 57.4 49.7 51.1
Co-amoxiclav 84.7 89.0 93.9 90.6 89.8 83.4 93.3
Cefalexin 94.4 93.9 92.5 95.2 96.5 95.9 94.8
Norﬂoxacin 98.5 98.2 96.8 96.4 93.6 90.4 87.3
Trimethoprim 78.8 79.3 80.0 82.2 78.4 76.0 74.7
Conclusions: The resistance rates to antibiotics commonly prescribed in
the community for urinary tract infection is increasing. This is potentially
serious in cases of complicated or ascending infections. Local resistance
rates should be taken into account when preparing empirical treatment
guidelines, both for community and hospital use.
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P1137 Prevalence of syphilis and an examination of two syphilis
rapid tests in the MCA, Cameroon
F. Oudenaarden, M. Siemerink (Rotterdam, NL)
Objectives: A two-fold cross-sectional ﬁeld study was performed
at Manyemen Presbyterian Medical Institutions, Cameroon. First, the
prevalence of syphilis among people in the reproductive age (men: 15−60
years, women: 15−50 years) living in the Manyemen Catchment Area
(MCA) was assessed. Second, the Abbott determine Syphilis TP® rapid
test (Abbott test) was compared to the syphilis rapid test that is presently
used in the MCA (local test).
Methods: The studied population was tested on syphilis with two
different rapid tests: the Abbott test and the local test. People with at least
one positive test were treated with benzathin penicillin. A questionnaire
was used to obtain additional information about the studied population.
Blood was collected on ﬁlter paper in order to perform the FTA-abs
test in The Netherlands, which was used both for determination of the
prevalence and as a conﬁrmation test in order to differentiate between
the two rapid tests. All positive blood samples according to the rapid
tests performed in Cameroon, and a control group of randomly selected
negative blood samples were (re)tested with the FTA-abs test.
Results: A total of 1,128 (539 men and 589 women) participated in this
study. Of this population, 114 people (10.1%) had at least one positive
rapid test. After cross-reference using FTA-abs a syphilis prevalence of
only 2.9% was determined for the MCA.
The Abbott test has a greater positive predictive value (18% versus 16%)
and a slightly greater speciﬁcity (93% versus 92%). The local rapid
test on the other hand is more sensitive (52% versus 48%). Using the
ASSURED method, the Abbott test showed advantages over the local
test mainly in affordability, user-friendliness, and robustness.
Conclusions: This study shows that the syphilis prevalences world-wide
might be much lower than is believed at this moment. The striking higher
number of positives that was found using the rapid tests can be explained
by the appearance of false positive tests due to cross-reactions that have
occurred in these non-speciﬁc rapid tests.
The Abbott test can be considered superior to the currently used local
test, although the local test is slightly more sensitive. However, the
Abbott test has many advantages over the local test in the ﬁeld. Hospitals
and health centres in the MCA are advised to switch to the Abbott test.
P1138 Rash and fever in adults: the aetiology and clinical features
F. Tabak, A. Murtezaoglu, R. Ozaras, B. Mete, O. Tabak, A. Mert,
R. Ozturk (Istanbul, TR)
The patient with fever and rash often poses an urgent diagnostic and
therapeutic challenge for the clinician. The nonspeciﬁcity of many fever
and rash syndromes mandates a systemic approach to diagnosis that
includes a thorough history and physical exam as well as appropriate
use of laboratory tests.
In this study, we aimed to determine the aetiology of fever and rash in
100 consecutive adult patients followed-up as in- or out-patients between
May 2001 and April 2004 prospectively. Median age of the cases was 35
(range: 14−79); 45 were female and 55 male. The patients were divided
into three groups according to the aetiology of fever and rash: infectious
causes (50%), non-infectious causes (40%) and undiagnosed ones (10%).
The most common type of rash was maculopapular and the most common
ﬁve causes were measles, cutaneous drug reactions, varicella, adult-onset
Still’s disease and rickettsial disease. Viral diseases among infectious
causes and cutaneous drug reactions among noninfectious causes were
determined as the leading aetiologies among the aetiologies of fever and
rash in adults.
Headache and conjunctivitis did relate strongly with infectious causes
(p = 0.012, p = 0.011, respectively) and drug use and arthritis did so with
non-infectious causes (p = 0.010, p = 0.037, respectively). The laboratory
studies did not predict the aetiological categories. However, the increase
in levels of acute phase reactants was greater in bacterial diseases when
compared with those in viral diseases (ESR, p = 0.015; CRP, p = 0.006).
The mortality rate was 5% and the causes of death were as follows: toxic
epidermal necrolysis (2), adult-onset Still’s disease (1), staphylococcal
toxic shock syndrome (1) and graft-versus-host disease (1).
The main aetiologies of the patients admitted with rash and fever
are measles, drug reactions, varicella, adult-onset Still’s disease and
rickettsial disease. However the diagnosis for every case includes use
of epidemiology, detailed history, physical exam, and appropriate use of
laboratory tests.
P1139 Presence of STa, STb and LT enterotoxin genes in Klebsiella
strains isolated in different hospitals from gastrointestinal
tracts
B. Maczyn˜ska, U. Kasprzykowska, A. Zychowicz,
A. Przondo-Mordarska, M. Bartoszewicz, D. Smutnicka (Wroclaw, PL)
Objectives: Klebsiella infections pose a signiﬁcant problem, especially
in paediatric wards where they can cause various nosocomial infections,
such as serious diarrhoea in children and infants. Due to the fact that the
microbes can also constitute normal ﬂora of the alimentary canal, the key
factor in considering them as an aetiological factor in diarrhoea is the
determination of the presence of heat-stable and heat-labile enterotoxins.
Therefore, the purpose of the paper was to investigate the genetic basis
of the expression of enterotoxins (STa, STb and LT) among the selected
strains isolated from diarrhoea cases in the hospitalised children. Because
enterotoxin genes are encoded on the plasmids, which facilitates their
transmission and spreading in nosocomial strains of Enterobacteriaceae,
the paper also aimed to determine the frequency of occurrence of these
genes in the Klebsiella species isolated in various clinical centres in
Poland.
Methods: The research included 61 clinical Klebsiella strains isolated
from faeces samples taken from children with diarrhoea symptoms
hospitalised in various paediatric wards. Klebsiella strains not originating
from diarrhoea cases but isolated from the blood and respiratory tract of
hospitalised patients served as a control group. The presence of genes
encoding ST and LT enterotoxins was detected using the PCR method
with primers designed for sta, stb and lth genes described for E. coli.
Results: Research conducted indicates that in the plasmid DNA of
the majority (85%) of Klebsiella strains isolated from diarrhoea cases,
enterotoxin-encoding genes (sta, stb, lth) were detected. The 43% of the
strains had genes for one enterotoxin, 39% genes for two endotoxins and
3% of strains showed the presence of three genes (sta, stb, lth). In the
Klebsiella strains isolated from blood and the respiratory tract (negative
controls), no sta, stb or lth genes were found.
Conclusions: The presence of enterotoxin-encoding genes have very
important signiﬁcance in diagnosing of aetiological agent of children
diarrhoea. A direct correlation was shown between the frequency of
individual gene detection and the clinical centre in which the given strain
was isolated. Detection of enterotoxin-encoding genes in Klebsiella
using the PCR method was regarded as useful in routine diagnosing
of Klebsiella related diarrhoea cases.
P1140 Immunoreactivity studies on synthetic peptides deriving
from variable domain IV of Chlamydia trachomatis major
outer membrane protein
S. Klimashevskaya, T. Ulanova, A. Burkov, A. Obriadina (Nizhnij
Novgorod, RU)
Objectives: The amino acid sequence of the major outer membrane pro-
teins (MOMPs) from Chlamydia trachomatis serovars are predominantly
conserved, but have four variable domains (VDs). The major neutralising
and serotyping antigenic determinants are located in VD-I, VD-II and
VD-IV.
The aim of this study was to identify the location of immunodominant
regions and to study the relationship between the sequence heterogeneity
S310 17th ECCMID / 25th ICC, Posters
and immunoreactivity by detecting antigenic reactivity of synthetic
peptides derived from VD-I, VD-II and VD-IV of the C. trachomatis
MOMP.
Methods: Unique 25-mer long (n = 281) overlapped by 4aa peptides
derived from VD-I (aa65–127), VD-II (aa139–202) and VD-IV (aa286–
362) sequences corresponding to 9 different C. trachomatis serovars (A,
C, D, E, F, H, L1, L2, L3) were designed and synthesized. The antigenic
reactivity was detected by indirect enzyme immunoassay with known
anti-C. trachomatis positive (N= 30) and negative (N= 30) sera.
Results: A strong antigenic region was identiﬁed within the MOMP
VD IV at amino acids 302–345. The percent amino acid homology
between different serovar sequences encompassing this region varied
from 43.2% to 95.5%. All except one peptide (serovar C) contained the
common motif TTTLNPTIA previously described as the minimal size
of the antigenic epitope. However, the range of immunoreactivity with
positive serum specimens varied from 50% to 93% for peptides with the
common sequence and was 25% for synthetic peptide with substitution
of two amino acids in this sequence. The most immunoreactive peptide
(QPKSATAIFDTTTLNPTIAGAGDVK) detected 93% of the positive
sera with the highest signal to cutoff ratio. This peptide was derived
from the C. trachomatis serovar E.
Conclusion: The reactivity of the antigenic epitopes (s) may be
differentially affected by neighbouring amino acids. Diagnostic test
development requires careful selection of sequence variants, but the
length and exact position of diagnostic targets also must be chosen
carefully.
P1141 Rapid diagnosis of experimental meningitis by measuring
bacterial heat ﬂow in cerebrospinal ﬂuid samples
A. Trampuz, A. Steinhuber, M. Wittwer, S.L. Leib (Basle, Berne, CH)
Background: Rapid diagnosis and therapy improves the outcome of
bacterial meningitis. Growth of microorganisms generates heat ﬂow that
can be detected by calorimetry. Here we used isothemal calorimetry
(detection limit ~0.3mW) to assess bacterial growth in cerebrospinal
ﬂuid (CSF) from rats with pneumococcal or meningococcal meningitis.
Methods: 11-days-old Sprague-Dawley rats were infected intracister-
nally with 10mL saline containing 1×107 cfu/mL S. pneumoniae (n = 5)
or 1×109 cfu/mL N. meningitidis (n = 5). Controls were injected with
heat-inactivated N. meningitidis (n = 2) or sterile saline (n = 2). CSF was
obtained at 18 h after infection and cultured quantitatively (5mL). For
calorimetry, 10mL of CSF were added to 3mL brain heart infusion for
S. pneumoniae or tryptic soy broth for N. meningitidis. Heat ﬂow was
monitored at 37ºC for 4 days using a 48-channel microcalorimeter (3102
TAM III, Thermometric, Ja¨rfa¨lla, Sweden). Serial dilutions of known
bacterial counts were used to determine the calorimetric detection limit.
Positivity was deﬁned as heat ﬂow 10mW; time to positivity (TTP)
was calculated from the start of calorimetric measurement.
Results: The table shows mean values ± SD of CSF bacterial counts at
18 h after infection, calorimetric TTP and peak heat ﬂow. The distinct
heat ﬂow curves were characteristic for the causative pathogen und
independent from the initial concentration. The calorimetric detection
limit per mL was 2 cfu S. pneumoniae (TTP = 13.9 h) and 4 cfu
N. meningitidis (TTP = 19.5 h).
Conclusion: Microcalorimetry is a rapid and sensitive method for the
diagnosis of bacterial meningitis, allowing detection and potentially
identiﬁcation of pathogens from 10mL CSF in <2 h.
Intracisternal injection Bacterial count in
CSF (cfu/mL)
Calorimetric
TTP (h)
Peak
heat ﬂow
(mW)
S. pneumoniae (n = 5) 1.5×108 ± 5.5×107 1.5±0.2 331±31
N. meningitidis (n = 5) 1.3×106 ± 2.6×105 1.7±0.3 79±9
heat-inactivated (n = 2) 0 Negative <10
Saline control (n = 2) 0 Negative <10
P1142 Identiﬁcation of Helicobacter pylori in gastric biopsy and
resection specimens
T. Babic, H. Basic, B. Kocic, P. Stojanovic, B. Miljkovic Selimovic
(Nis, RS)
Objectives: To compare the sensitivity of detecting H. pylori in gastric
biopsy and resection specimens using classical morphologically oriented
detection methods (haematoxylin and eosin (HE) stain, modiﬁed Giemsa
stain) with immunohistochemistry using a commercially available anti-
H. pylori antibody (Dako, Denmark).
Methods: Gastric antral biopsy specimens showing chronic gastritis
(26 cases) together with tissue blocks from gastrectomy specimens
for duodenal ulcer were histology reviewed. The parafﬁn sections
were stained with traditional histological HE and modiﬁed Giemsa
and immunoenzymatic by alkaline phosphatase antialkaline phosphatase
(APAAP) method for the identiﬁcation of H. pylori.
Results: The presence of chronic gastritis was conﬁrmed in the 26 gastric
biopsy specimens. A diagnosis of duodenal ulcer was conﬁrmed in the
mucosa from the gastrectomy specimens. The HE, modiﬁed Giemsa
and immunoenzymatic treated sections were carefully examined for
the presence of H. pylori. HE-stained H. pylori appeared as slightly
basophilic, spiral-shaped organisms attached to the apical surface of the
surface mucus cells. However, curved bacteria were only detected when
found in great numbers. Using a modiﬁed Giemsa stain, the spiral-
shaped bacteria of H. pylori stained blue, were attached to the brush
border of the gastric foveolar epithelial cells and inside gastric pits. In
some cases masked bacteria hidden within mucus were obvious only
in immunostained preparations (red deposits). In addition, on sections
stained with modiﬁed Giemsa coccoid forms, which were particularly
seen in secions from resection specimens, caused some uncertainty.
These coccoid H. pylori were obvious in immunostained preparations.
Immunoenzymatic staining can be performed on cryostat and parafﬁn
tissue sections, but reaction was more intense and diffuse in a cryostatic
sections. H. pylori was identiﬁed in 34.6% sections stained with HE,
but it could be identiﬁed with greater frequency in sections stained with
modiﬁed Giemsa (73.0%). It could be detected at a still greater frequency
in staining with APAAP (92.3%). Immunohistochemistry was positive
in all cases in which H. pylori was detected by other methods.
Conclusion: Immunohistochemical identiﬁcation of Helicobacter pylori
by the APAAP procedure is a highly sensitive and easy to use method
for detecting this organism.
P1143 Gastric juice urease test for Helicobacter pylori detection
P. Pirpiris, P. Sergouniotis, F. Sergouniotis, E. Papoylia (Amﬁssa, GR)
Objectives: The purpose of our study was to demonstrate the
sensititivity, speciﬁcity and accuracy of gastric juice urease test and anti
H. pylori IgG antibodies compared to the histological examination for
HP.
Methods: We studied 55 patients age range 20−85 years, during the
years 2005 and 2006. Forty-eight out of 55 patients underwent upper
gastrointestinal endoscopy and had up to three gastric biopsy specimens
taken for histological examination for HP. For each patient, 2−3mL
gastric juice was collected and 1mL in the supernatant was tested for
rapid urease reaction. We use per os thin “paediatric” Levin Nº10 or
Nº11 or the gastroscopio to obtain gastric juice samples. Also blood
samples were taken for the estimation of anti H. pylori IgG antibodies.
Results: The results are shown in Table 1. Based on histology, the
sensitivity of gastric juice urease test was found 97.4%, speciﬁcity
77.8%, positive predictive value 95% and negative predictive value
87.5% (48 patients) and for anti H. pylori IgG antibodies 65.0%, 83.3%,
92.8%, 41.6%, respectively (26 patients).
Conclusions: It seems that the gastric juice urease test is an alternative
non-invasive method by using Levin for the collection, to the invasive
gastric biopsy specimens with little inconvenience to the patient,
accurate, simple, cheap, rapid and reliable method for the detection
of H. pylori. It should be used for detecting H. pylori infection in
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patients with coagulopathy, in children under the age of 5 years, for large
epidemiologic studies, for the conﬁrmation of H. pylori eradication and
in several cases where 13-C-urea breath test contraindicated. In contrast
the anti H. pylori IgG antibodies test has a low sensitivity and the results
should always be interpreted in connection with other methods.
Table 1
Gastric juice CLO test Biopsy Anti H. pylori IgG
Positive 45 39 17
Negative 10 9 15
Total 55 48 32
P1144 Antibody decay proﬁles during Yersinia enterocolitica O:3
infections: a follow-up study of 94 patients
E. Rasmussen, P. Schiellerup, T. Dalby, K. Krogfelt (Copenhagen, DK)
Objective: An enzyme-linked immunosorbent assay (ELISA) was
employed to measure immunoglobulin G (IgG), IgM and IgA classes
of human serum antibody in sera from adult Danish patients with a
culture proven Yersinia enterocolitica O:3 infection at various intervals
after debut of symptoms.
Methods: Yersinia enterocolitica O:3 LPS was used as coating antigen
in the ELISA test. A total of 220 sera drawn between 19 and 1,038 days
after onset of disease from 94 patients with veriﬁed Yersinia enteritis
were examined. A control group of 100 sera from healthy Danish blood-
donors were tested to determine the cut-off for negative results.
Results:With a 95th percentile of speciﬁcity, measurement of IgG, IgM,
and IgA speciﬁc for Yersinia enterocolitica O:3 LPS within a month
after infection showed a sensitivity of 50%, 100% and 83% respectively.
31 to 60 days after infection a sensitivity of 79% was found when
combining all three immunoglobulin classes (IgG 40%, IgM 77% and
IgA 56%) whereas a combined sensitivity of 61% was found 61 to
90 days after infection (IgG 29%, IgM 61% and IgA 25%). At 91
to 180 days after infection the combined sensitivity were 51% (IgG
38%, IgM 32% and IgA 30%). The antibody decay proﬁles for the three
different immunoglobulin classes for the individual patients exhibited a
large degree of variation.
Conclusion: At follow up of the patients, IgM and IgA levels were
elevated up to 2 months from onset of infection. IgG levels were not
elevated during infection, the highest sensitivity 50% was found within a
month from infection. A rapid decrease in antibodies speciﬁc for Yersinia
enterocolitica O:3 were shown. Elevated levels of antibodies in serum
following Yersinia gastroenteritis were limited to the two ﬁrst months
after infection.
P1145 Development of hybridomas secreted Streptococcus suis
2 serotype-speciﬁc monoclone antibody
X.Z. Pan, J.C. Ge, C.J. Wang, X.F. Li, F. Zheng, J.Q. Tang (Nanjing, CN)
Objective: For the development of a diagnostic reagent and vaccine
of Streptococcus suis (S. suis), monoclonal antibodies (MAbs) against
S. suis were obtained by the fusion of SP2/0 murine myeloma cells
and spleen cells from BALB/c mice immunised with a whole-bacterial-
antigen of S. suis ZY/H33 (serotype 2).
Methods: Formalin-killed, 12 h cultures of ZY/H33 strain were used to
immunise mice. After the booster inoculation, the spleen of the mouse
was recovered and fused with myeloma cell line SP2/0. Hybridoma
supernatants were screened for S. suis type 2 antibodies by the indirect
ELISA. The isotypes of MAbs were determined. For Western blot,
the sample of sonicated bacteria antigen was subjected to 12% SDS-
PAGE, then transferred to nitrocellulose membrane. After blocked with
5% skim milk, the membrane was incubated with anti-S. suis type 2
(ZY/H33) ascite ﬂuid in a 1:100 dilution in TBST for 1 h, followed
by the incubation with HRP-conjugated anti-mouse antibody IgG in a
1:5,000 dilution in TBST for another 1 h. After washings in TBST and
using DAB as substrate, the reacting bands were visualised.
Results: A total of 201 hybridomas were tested in ELISA, out of
which 6 hybridomas, namely 1A8, 1B4, 2A9, 3C2, 4B4, and 4B9,
showing a positive reaction were selected for further characterisation.
The immunoglobulin classes of Mabs 1B4, 2A9, 4B4 and 1A8, 4B9, 3C2
were IgM and IgG3, respectively.
In the Western blot, MAb 2A9 reacted with a major band of an estimated
molecular mass of 90 kDa. As show in Fig. 1, MAb 2A9 reacted with
a single 90 kDa protein of S. suis type 2 such as ZY/H33, Habb
and S10, while S. suis type 3, S. faecalis, Pneumococcal Pneumonia
without reaction. And in the following test, all S. suis type 2 including
international and Chinese isolates were shown to react with MAb 2A9
using immunoblotting, while negative results were obtained in the other
serotypes of S. suis and non-S. suis strains.
Conclusion: In conclusion, 2A9 is a serotype-speciﬁc monoclone
antibody. It is a robust tool for S. suis type 2 test.
P1146 Fine-needle aspiration has a very low sensitivity in the
diagnosis of tuberculous cervical lymphadenitis in Iran
M. Hasibi, J. Rezaei, Z. Madani Kermani, M. Asadollahi, M. Abouzari,
A. Rashidi (Tehran, IR)
Objectives: To assess the issue of ﬁne-needle aspiration (FNA)
sensitivity for early tuberculous cervical lymphadenitis in Iran for the
ﬁrst time.
Methods: The results of FNA in 46 consecutive patients (12 Afghan, 34
Iranian) with cervical lymphadenopathy who had a deﬁnitive diagnosis
of tuberculous cervical lymphadenitis were retrospectively evaluated.
Deﬁnitive diagnosis was established on the presence of caseous necrosis
with epitheloid-cell granulomas at histopathologic evaluation of the
nodes after excisional biopsy. Smear (with Giemsa staining) and culture
(with Ziehl–Neelsen’s staining) for acid-fast bacilli on FNA specimens
were available in 35 and 29 cases, respectively. All patients had a
negative serology for HIV infection. A skin tuberculin test (PPD) had
been performed on all patients.
Results: There were 13 males and 33 females ranging in age from 12
to 70 years with a mean age of 39.6 years. Lymphadenopathy ranged
in duration from 15 days to 2 years with a mean of 55 days. PPD test,
smear and culture were positive in 41 (89%), 1 (2.8%) and 1 (3.4%)
cases, respectively. FNA results were nonspeciﬁc acute and/or chronic
inﬂammation without necrosis or granuloma in 34 (73.9%), granuloma
without necrosis in 3 (6.5%), malignancy in 5 (10.8%) and granuloma
with caseous necrosis in 4 (8.7%) patients. Based on these results, if one
deﬁnes a positive test as one revealing granuloma with caseous necrosis
which is the characteristic ﬁnding of tuberculous lymphadenitis, then
the sensitivity of FNA will be only 8.7%. Even if we regard the samples
with granuloma but without necrosis as positive, the sensitivity will still
be only slightly higher than 15%. Of particular note, more than 84% of
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samples did not show a granuloma, which made TB involvement seem
less likely. Also, smear and culture could not increase the sensitivity
signiﬁcantly, each being positive in less than 4% of patients only.
Conclusion: The advantages of an early deﬁnite diagnosis even with
the aid of an invasive procedure such as excisional biopsy should be
carefully assessed against the disadvantages of high false negative rates
obtained from a relatively non-invasive procedure like FNA.
P1147 Prevention of perinatal GBS infections: impact of
ChromID® StreptoB, a new chromogenic medium on
suscpetibility testing
W. Chaker, S. van den Wijngaert, A. Dediste (Brussels, BE)
Objective: Compare the results of antimicrobial susceptibility testing
(AST) of Group B Streptococcus (GBS) by disk diffusion performed on
the colonies directly picked from chromID® Strepto B agar (bioMe´rieux)
with AST performed on colonies grown on Columbia agar with sheep
blood supplemented with nalidixic acid (CNA).
Material and Methods: ASTs were performed on Mueller Hinton
II agar enriched with 5% sheep blood (MHB) inoculated with a
0.5 McFarland suspension and incubated overnight at 37ºC in 5%
CO2. The Kirby-Bauer disk diffusion AST method was performed for
penicillin, vancomycin, erythromycin, clindamycin, and levoﬂoxacin.
Zone diameters were measured, and the GBS were categorised as
susceptible (S), intermediate (I) or resistant (R) according to CLSI
guidelines (supplement M100-S14). Antimicrobial disks and plates were
provided by Oxoid and CNA agar plates by bioMe´rieux.
Results: For the 18 strains preliminarily tested, we observed an overall
concordance of 100% for penicillin, vancomycin, clindamycin and
levoﬂoxacin independently from the susceptibility or resistance of the
bacteria to the antibiotic. The same diffusion-zone was observed with
clindamycin by using both methods for the GBS strain that harboured
the MLSb resistance. With erythromycin, only one minor discrepancy
has been obtained (I vs. S) with respective diameters of 20 and 22mm
with colonies from chromID® Strepto B agar and CNA.
Conclusions: These ﬁrst results are promising and will be conﬁrmed by
extending the sample size. This methodology with chromID® Strepto B
agar directly associated with AST could avoid subculture on blood agar
and permit an earlier result for the clinicians.
P1148 Impact on viral pathogen yield of the absence of cells in
nasopharyngeal aspirate specimens
D. Pie´rard, D. Stevens, J. Mignolet, L. Moriau, K. Vergalle, S. Lauwers
(Brussels, BE)
Objectives: To evaluate the impact of the absence of cellular material
on the pathogen yield in nasopharyngeal aspirate specimens (NFAS)
submitted for viral examination, as possible criterion for specimen
rejection.
Methods: To check for the presence of a visible cell pellet, all NFAS
submitted during winter 2005−06 were centrifugated after mixing with
DMEM with 2% fetal calf serum and vortexing (and removal of
excessive mucus if needed), before being resuspended and processed.
Specimens showing a pellet were classiﬁed as C+, those without as C−.
All specimens were examined by RSV Respi-Strip® antigen test (Coris,
Gembloux, BE), by a multiplex in-house PCR protocol for respiratory
viruses and by viral isolation on cell culture. Results were compared for
C− and C+ specimens.
Results: Out of 634 samples, 537 were C+ and 97 C−. RSV antigen
detection was positive in 33% C+ and 19% C− (p = 0.005). PCR was
positive for RSV in 42% C+ and 30% C− (p = 0.029), for any virus
in 59% C+ and 43% C− (p = 0.005). Culture was positive for RSV in
26% C+ and 16% C− (p = 0.021) and for any virus in 33% C+ and
19% C− (p = 0.005).
Conclusion: If we assume that the percentage of truly infected patients is
similar in those with C− and C+ specimens, we conclude that the yield of
viral pathogens is signiﬁcantly diminished in C− samples, culture being
mostly inﬂuenced, followed by antigen detection and PCR. However,
since it is generally not possible to obtain a replacement sample, rejecting
those samples could have a negative impact on patient care.
P1149 Evaluation of a new automated urine cell analyser (Sysmex
UF-1000i) for bacteriological urinalysis
H. von Wulffen (Hamburg, DE)
Objectives: We wanted to assess to what extent the UF-1000i
(SYSMEX) automated urine cell analyser can support bacteriological
urinalysis, in particular to ﬁnd answers to the following questions:
can it replace Gram stain? Can we dispense with culture in case of
negative results for bacteria, leukocytes and yeast-like cells? Is there
a suitable cut-off for number of bacteria to select urine specimens for
direct susceptibility testing?
Methods: Urine specimens with a request for urine culture were
processed using the UF-1000i in parallel with Gram stain and culturing
overnight of 0.001mL undiluted urine each onto UTI, CNA, and
Sabouraud agar using calibrated loops. Specimens were also tested for
inhibitory activity using spore plates.
Results: To select out negative specimens UF-1000i results were
considered positive if white blood cells exceeded 20/ml and/or bacterial
particles were counted over 50/ml and/or yeast-like cells exceeded 25/ml.
In comparison, cultures yielding organisms at 103 CFU/mL or higher
were considered positive. On this basis out of 363 urine specimens
evaluated 42% of the UF-1000i results were true positive, 30% true
negative, 22% false positive, and 6% false negative. However, only 2/24
false negative results yielded 106 CFU/mL, all others had 104 CFU/mL
or lower, most of them with mixed ﬂora, thus reducing signiﬁcantly
false negative results to less than 0.6%. Only looking at the specimens
without inhibitory activity (n = 232) and using a cut-off of 105 CFU/mL
or higher for predicting a urinary tract infection, the UF-1000i yielded a
sensitivity of 97.6%, a speciﬁcity of 86.7%, a positive predictive value
of 80.0%, and a negative predictive value of 98.5% when using a cut-off
of 100 bacterial particles/ml. This cut-off also proved useful for selecting
those specimens suitable for direct susceptibility testing.
Conclusions: For our purposes the UF-1000i could replace Gram stain
of urine specimens and thereby reduce time-consuming microscopy.
The low rate of truly false negative results around 0.6% appears
to be tolerable and would allow dispensing with culture in case of
negative UF-1000i results and thus further reduce workload in the
laboratory. Specimens from certain patients (e.g. haematology patients
with cytopenia) or certain materials (e.g. suprapubic bladder aspirates)
should be cultured in any case.
P1150 Community-acquired Legionnaire’s disease in the urinary
antigen era
G. Tolchinsky, L. Mateu, M. Pedro-Botet, N. Sopena, M. Garcia-Nun˜ez,
M. Sabria, C. Rey-Joly (Barcelona, ES)
Objectives: At present urinary antigen detection is the hallmark of
the diagnosis of Legionnaires’ disease and may have inﬂuenced the
demographic and the clinical data of this disease. The aim of this study
was to describe demographic data, risk factors, clinical characteristics
and outcome of patients with community-acquired pneumonia (CAP) by
Legionella pneumophila serogroup 1 diagnosed using urinary antigen
test.
Method: Patients were selected from a database of Legionella
pneumonia prospectively collected from 1983 to 2006 in a 630-bed
university hospital. Only patients with CAP diagnosed by Legionella
urinary antigen detection were included.
Results: We studied 168 patients, most cases (97.1%) being sporadic.
Males predominated (81%) with a mean age of 57.5 years (range 19−95
years). 85.1% had at least one risk factor, smoking habit (48.2%),
alcohol intake (24.4%) or underlying diseases (56.5%) including
chronic respiratory diseases (18%), diabetes (16.1%), cancer (10%),
immunosuppressive therapy (9.5%) and HIV (9.5%). At presentation
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94% had fever, 69.6% cough, 44.6% dyspnea and 42.9% expectoration.
48.8% presented neurological (35.1%) or gastrointestinal (26.8%)
symptoms. Analytical data showed leucocytosis (46%), increased AST
(42%), hyponatraemia (20.5%) and increased creatine phosphokinase
(24.1%). 48.2% patients (81/130) had Fine score  III. 92% were
hospitalised, 17.3% being admitted to the ICU and 13% needing
mechanical ventilation. 32.1% had received previous b-lactams and 34%
began appropriate treatment within the ﬁrst 3 days of symptom onset.
Complications occurred in 84 patients (50%), with respiratory failure
(46%), renal insufﬁciency (10.7%) and septic shock (8.4%) being of
note. Radiological complications appeared in up to 17.5%, the most
frequent being pleural effusion in 13.1% and bilateral progression in
16 (9.5%). 15 patients (8.9%) died due to the pneumonia and only one
patient relapsed.
Conclusion: Nearly 15% of patients with Legionella CAP had no risk
factor and almost 50% no underlying diseases. When faced with CAP, the
“atypical pneumonia” syndrome should still suggest Legionella infection.
Legionella CAP continues to be a severe disease based on hospitalisation,
respiratory failure and ICU admission.
P1151 Utility and clinical impact on the reported aetiology of a
urinary antigen-detection test for Streptococcus pneumoniae
in community-acquired pneumonia at the emergency
department
G. Ezpeleta, C. Ezpeleta, J.A. Alava, J. Unzaga, V. Cabezas,
I. Gerediaga, B. Amezua, R. Blanco, R. Cisterna (Bilbao, ES)
Objectives: The diagnosis of severe pneumococcal infections is
inadequate, relying heavily on culture of Streptococcus pneumoniae from
blood or other normally sterile ﬂuids, and is severely limited by prior
administration of antibiotics. We evaluated prospectively the Binax NOW
S. pneumoniae urinary antigen test, a rapid immunochromatographic
(ICT) assay, for the diagnosis of bacteraemic pneumococcal infections in
adult patients with community lower respiratory tract infection (CLRTI)
at the emergency room.
Methods: One thousand, two hundred and thirty three adult patients
with CLRTI who were admitted to the hospital were studied prospectively
between January 2004 and September 2006. The ICT test was performed
on fresh unconcentrated urine following the manufacturer instructions.
The results of the ICT test were compared with blood culture ones, and
sensibility, speciﬁcity and likehood positive and negative ratios were
calculated.
Results: The ICT assay was positive in 298 (24.15%) of 1,233 patients
enrolled into the study and in 78 (79.59%) of 98 patients with
pneumococcal pneumonia conﬁrmed by conventional methods. The test
revealed a sensitivity of 75.9% (71.2–83.1) and a speciﬁcity of 94.0%
using conventional microbiological criteria as the gold standard. The
likehood positive ratio value was 12.65, and the negative one was 3.9.
The diagnostic yield of pneumococcal pneumonia was increased using
ICT combined with conventional methods. Antigen was still detectable
in 53% of patients during treatment
Conclusion: The ICT to detect S. pneumoniae urinary antigen is
therefore a rapid and useful method for diagnosing pneumococcal
pneumonia. Detection of urinary antigen is a valuable, sensitive, and
rapid test for the early diagnosis of bacteraemic pneumococcal infections
in adult patients, even after antibiotic treatment has commenced
P1152 Sampling respiratory epithelial cells by nasal or
nasopharyngeal ﬂocked swabs
S. Castriciano, G. So, S. Buracond, M. Savarese, D. Triva, M. Smieja
(Brescia, IT; Hamilton, CA)
Objective: Nasal swab (NS) collection is less invasive than nasopharyn-
geal swab (NPS) collection, and may facilitate wider surveillance and
diagnosis of respiratory viral infections. We studied NS collection of two
new swab designs to determine whether NS could sample respiratory
epithelial cells as well as NPS.
Methods: A total of 52 volunteers were studied. 17 had one Copan
pernasal Flocked Swab NPS and three different Copan Nasal Flocked
Swabs (regular, round, and ﬂat) administered and collected by a
physician or trained research staff. The remaining 35 subjects had 3 NS
performed without an NPS. For all individuals, the order of the three
NS was randomised, while the NPS was done last for the subgroup
of 17 volunteers. The swabs were placed in a 1-mL tube of Copan
Universal Transport Medium, vortexed, and centrifuged, with the residual
cell pellets resuspended in 1mL of PBS. 25mL of suspension were
placed in wells on a glass slide, dried, ﬁxed and counterstained with
FITC labelled monoclonal antibody. Respiratory epithelial cells were
quantitated using a ﬂuorescent microscope at 400× magniﬁcation by an
experienced microscopist blinded to swab type while enumerating. An
average count from 4 ﬁelds was calculated when 10 or more epithelial
cells were present per high-powered ﬁeld (hpf); 10 ﬁelds were averaged
if there was fewer than 10 cells/hpf.
Results: Among the 17 subjects with parallel NS and NPS specimens,
mean(SD) cells yields were: 73.3(31.2), 83.1(35.5), and 92.5(35.1)
cells/hpf for the regular, round, and ﬂat NS, respectively; and 105.9(44.0)
cells/hpf for NPS. The difference between the regular NS and NPS
was statistically signiﬁcant (P = 0.02), whereas the two new NS designs
(round and ﬂat) were not different from the NPS (P = 0.11 and 0.34,
respectively). Among all 52 subjects, the mean(SD) cell yields were
65.2(31.3), 81.8(42.4), and 81.8(41.7) for regular, round, and ﬂat
swabs, respectively. The two new NS designs improved cell yield
by 16.5 cells/hpf (95%CI: 8.0, 25.0, P< 0.001) compared with the
regular NS. The 3 NS swabs were equally well tolerated and caused
less discomfort than the NPS.
Conclusions: An improved ﬂocked design for NS allows sampling
equivalent to NPS with less discomfort. If validated in symptomatic
patients, this will have important implications for surveillance swabbing
or diagnosis in patients currently not beneﬁting from respiratory
diagnostics.
P1153 Comparative study of Copan Venturi Transystem and
Medical Wire and Equipment Transwab microbiological
swabs, using the roll-plate method
K. Birrell (Hastings, NZ)
Objectives: To compare/contrast Copan with Medical Wire and
Equipment (MWE) swabs to determine the differences/similarities in
numbers of organisms retrieved from each swab type. Swabs which
maintain viability of organisms are preferable over those which do
not (avoiding overgrowth). Systems maintaining organisms for extended
time, without overgrowth, are beneﬁcial due to potentially prolonged
transport times for example. The systems which best maintain organisms,
representing the clinical picture will aid the laboratory in the correct
determination of results.
Methods: The roll-plate method was used in these viability and
overgrowth studies. This is qualitative/semi-quantitative method rather
than quantitative (the elution method). Many clinical laboratories
use the roll-plate method to directly inoculate media. Organisms
tested: Streptococcus pyogenes ATCC19615, Streptococcus pneumoniae
ATCC6305, Pseudomonas aeruginosa ATCC27853, Haemophilus in-
ﬂuenzae ATCC10211, Neisseria gonorrhoeae ATCC43069, Escherichia
coli ATCC25922 and Candida albicans ATCC60193. This study was
performed following the Clinical and Laboratory Standards Institute
(CLSI) Quality Control of Microbiological Transport Systems; Approved
Standard M40-A (Volume 23, Number 34).
Results: A signiﬁcant variance in the number of colony forming units
(CFU) was seen between the systems. In most cases twice as many CFU
were released by the MWE Transwab than by the Copan Transystem.
Two of the organisms tested showed a greater than a four-fold difference
between the release of CFU from the Copan Transystem and the MWE
Transwab.
Conclusions: The MWE Transwab performed better in this study. Both
systems employed Amies Clear media. A possible reason for the results
may involve the amount of media; the MWE Transwab released more
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transport media from the system onto the agar plates than the Copan
Venturi Transystem swabs. The weave of the MWE swab tips tends to
open after the swab had been in the transport media aiding in media
transfer. In contrast there was very little change in the weave of the
Copan Transystem swab tips. This is potentially a factor in the difference
between the results obtained in this study.
P1154 Rapid pathogen identiﬁcation by MALDI-TOF mass
spectrometry/SARAMIS database in clinical microbiological
routine diagnostics
J. Gielen, M. Erhard, W. Kallow, M. Kro¨nke, O. Krut (Cologne,
Potsdam, DE)
Automated identiﬁcation systems are commonly used in medium-
to-high-throughput clinical microbiology laboratories. However, such
systems are relatively slow because they depend on a bacterial growth
and metabolic activity. Bacterial identiﬁcation by mass spectrometry
provides a promising way to accelerate pathogen identiﬁcation,
since it can be performed in a few minutes. In this study we
compared performance of mass ﬁngerprinting with established methods
(VITEK2/API, BioMe´rieux) in the clinical microbiology laboratory
settings. A part of a colony grown on solid culture medium was
transferred on the sample plate of a MALDI-TOF apparatus, disrupted
by addition of matrix followed by the generation of mass spectra.
The acquired spectrum was used for a search in the SARAMIS
database (Anagnostec), which holds reference spectra for common
pathogens. Within three months we investigated 1,616 independent
pathogen isolates representing more then 50 bacterial and fungal species.
MALDI/SARAMIS correctly identiﬁed 94% and 96% of samples to
species and genus level, respectively. The most exact identiﬁcation
was achieved for Staphylococci (99%) and Enterobacteriaceae (98%),
followed by nonfermenter (92%) and Streptococci (91%). Remarkably,
MALDI/SARAMIS method produced no misidentiﬁcations. The rate of
samples identiﬁed as “unknown” was about 3%. In 22 cases where
results of MALDI/SARAMIS identiﬁcation were in discrepancy with
VITEK the correctness of the mass spectrometry method was conﬁrmed
by sequencing. The typical time for the measurement and identiﬁcation
of a single isolate was about 3−5 minutes. In conclusion, the application
of MALDI-TOF/SARAMIS represent a simple, rapid, robust and in the
long run inexpensive method for the bacterial and fungal identiﬁcation
in the clinical microbiological routine laboratory.
P1155 Flow-cytometric assay to detect group B streptococci in
vaginal swabs
L. Zabel, M. Anliker, S. Nuding, H. Mu¨ller (Goppingen, Stuttgart, DE)
Objectives: Group B streptococci (GBS) are the leading cause of
neonatal sepsis in the USA and appear to be a growing problem
world-wide. The CDC guidelines and the German AWMF guidelines
recommend screening pregnant women for GBS. Collection of cultures
between 35 and 37 weeks gestation is recommended to improve the
sensitivity and speciﬁcity of detection of women who remain colonised at
the time of delivery. Women at risk should receive antibiotic prophylaxis
during delivery. The screening-cultures from vaginal swabs require at
least two days for culture and identiﬁcation. Unfortunately many women
are hospitalised for delivery, when the woman is already in labour and
a screening result is not available by the time.
Methods: Using ﬂow-cytometry and a monoclonal mouse antibody
(C55560M Dunn laboratories, Germany) directed against GBS an assay
was established, which detected GBS from liquid cultures (Todd Hewitt
broth) of vaginal swabs after a short incubation time of 90min. Results
were received within 2.5 hours. The assay was applied to 121 vaginal
swabs of women selected independent of diagnosis or hospitalisation and
compared to conventional culture methods.
Results: The detection limit was determined to be approximately
1.88×103 cfu/mL, using serial dilutions of the reference strain Strep-
tococcus agalactiae ATCC13813.
A total of 15 (12.4%) were identiﬁed as carriers of BGS by both, culture
and ﬂow-cytometry. Taking only the culture into account, 18 (14.9%) of
the vaginal specimens were positive for GBS. Flow-cytometric analysis
showed a more increased positivity rate with 44 (36.4%) GBS-positive
specimens.
Conclusion: The ﬂow-cytometric assay provided physicians with results
within 2−3 hours and was more sensitive than conventional culture. It
therefore may be used to detect GBS in sufﬁcient time, even if the patient
is already in labour.
P1156 Phenotypic characteristics of 357 consecutively collected
human isolates of Fusobacterium necrophorum ssp.
funduliforme from Denmark
A. Jensen, L.H. Kristensen, J. Prag (Viborg, DK)
Objectives: Fusobacterium necrophorum causes severe infections like
Lemierre’s syndrome. However, F. necrophorum is often not correctly
identiﬁed or the identiﬁcation process may be very slow. The aim of this
study was to phenotypic characterise human isolates of F. necrophorum
for the purpose of establishing a rapid procedure for identiﬁcation of
F. necrophorum. In addition, we examined whether there were any
variation in phenotypic characters between strains causing Lemierre’s
syndrome and strains causing localised infections.
Table 1. Phenotypic characteristics of Fusobacterium necrophorum ssp.
funduliforme and F. necrophorum ssp. necrophorum from 357 human
isolates, four animal isolates and the type strains of ssp. necrophorum
ATCC252S6 and ssp. funduliforme ATCC51357.
Characteristic Subspecies
funduliformea necrophorumb
Routine phenotypic characters n = 358 n = 5
Colony margins Entire Irregular
Colony surface Glistening Dull
Colony elevation Pulvinate Convex
Colony consistency Creamy Waxy
Cellular morphology Coccoid
pleomorphic
rods
Pleomorphic
rods
Gram stain ÷ ÷
Smell of butyric acid + +
Fluorescence in Wood’s light + +
b-haemolysi s on horse blood + +
Metronidazole susceptible + +
Kanamycin susceptible + +
Penicillin susceptible + +
Additional phenotypic characters n = 41 n = 5
Catalase ÷ ÷
Indole + +
Lipase + +
b-galactosidase ÷ ÷
DNase + +
Fermentation of mannose ÷ ÷
Fermentation of fructose ÷ ÷
Fermentation of glucose + +
Hydrolysis of esculin ÷ ÷
Propionic acid from lactate (GLC) + +
Propionic acid from threonine (GLC) + +
Butyric acid from glucose (GLC) + +
Chicken erythrocyte agglutination ÷ +
Human erythrocyte agglutination ÷ +
a356 human isolates, 1 type strain, 1 animal isolate; b1 human isolate,
1 type strain, 3 animal isolates.
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Methods: Three-hundred and ﬁfty-seven clinical isolates of Fusobac-
terium necrophorum from human infections were collected from all
16 clinical microbiological departments in Denmark and identiﬁed by
routine phenotypic characters through a three year period. In addition
the ﬁrst 40 isolates collected were subjected to an extended phenotypic
characterisation. Fifty-three isolates were from conﬁrmed Lemierre’s
syndrome cases, 249 from localised infections in the head and neck,
including cases of tonsillitis and peritonsillar abscesses and 55 isolates
were from other localised F. necrophorum infections.
Results: All human isolates, but one, which differed in cellular and
colony morphology, were identical in all phenotypic characters used in
routine identiﬁcation (Table 1). The ﬁrst 40 isolates that were subjected
an extended phenotypic characterisation were identical. However the
isolate, which differed in routine characters, agglutinated chicken and
human erythrocytes (Table 1). All isolates, but the outlier, were identiﬁed
as F. necrophorum ssp. funduliforme. The outlier was identiﬁed as
F. necrophorum ssp. necrophorum.
Conclusion: F. necrophorum may be identiﬁed and differentiated
from other Fusobacterium spp. in less than 72 hours reliable on
basis of cellular and colony morphology, Gram stain, sensitivity to
kanamycin and metronidazole, the smell of butyric acid, chartreuse
colour ﬂuorescence and beta-haemolysis on horse blood agar. Subspecies
funduliforme can be differentiated from ssp. necrophorum on basis of
cellular and colonial morphology and the agglutination of human and
chicken erythrocytes. Human isolates of F. necrophorum infections in
Denmark are phenotypic identical with no differences between isolates
from Lemierre’s syndrome and other localised infections.
P1157 Diroﬁlaria and Wolbachia antigens to detect naturally
acquired diroﬁlariosis in usual and occasional hosts
S. Gabrielli, G. Cancrini (Rome, IT)
Zoonotic diroﬁlarioses are mosquito-borne diseases due to several
species of animal ﬁlarial worms present in many regions of the world.
Diroﬁlaria immitis and D. repens are usual parasites of dogs and
other carnivores that develop heartworm disease and subcutaneous
diroﬁlariosis, respectively. Humans, unsuitable hosts, are occasionally
infected, and develop abortive infections or syndromes due to migrating
larvae that cause pulmonary nodules (mainly if the worm is D. immitis),
and ocular pathologies or subcutaneous lesions (mainly if the worm is
D. repens). These lesions always give rise to the suspicion of a tumour,
so requiring, as primary measure, differential diagnosis. Diroﬁlariosis
is easily diagnosed in dogs by microscopy/molecular methods, or by
serology, whereas in humans it is possible only by microscopy/molecular
methods applied to the worm surgically removed, due to the lack of
reliable serological tests.
Recent researches evidenced that most pathogenic ﬁlariae, diroﬁlariae
included, harbour bacterial endosymbionts belonging to the genus
Wolbachia as stable components of the body. Experimental infections
suggested that the continuous release of bacterial antigens could
stimulate the host immune response and even switch the response
against Wolbachia rather than against the worm. Moreover, it has
been hypothesised a possible role of these bacteria in the ﬁlariosis
pathogenesis. Aim of the present study was to conﬁrm in humans and
dogs naturally infected by D. repens and D. immitis the hypothesis that
also Wolbachia-derived proteins can be antigenic, to compare response
patterns against Diroﬁlaria and Wolbachia antigens in suitable and
unsuitable hosts, and to evaluate the possible use of an ELISA test to
diagnose human diroﬁlariosis before surgery.
To evaluate the antibody response against ﬁlarial polypeptides and
Wolbachia surface protein we tested the sera of 86 dogs and 88 humans
positive for the two diroﬁlariae, and showing different clinical status. The
response against ﬁlarial polypeptides was mainly observed in humans
affected by D. repens (both ocular and abortive infections), and in
dogs with chronic disease. As far the anti-Wolbachia response, it was
evidenced mainly in dogs affected by heartworm occult disease and
in humans with pulmonary nodules (coin lesions), so conﬁrming, in
natural infections, its relationship with severe pathology, and suggesting
a possible diagnostic use of the test developed.
P1158 Helcococcus kunzii isolation from prosthetic joint infection
M. Balejova´, M. Fialova´, N. Piskunova´, P. Trubac, J. Motlova´ (Ceske´
Budejovice, Prague, CZ)
Objective: Identiﬁcation of a rare isolate – Helcococcus kunzii – from
prosthetic joint infection is presented.
Methods: Perioperative specimens from prosthetic joint infection were
processed according to standard laboratory practice. Tissue specimens
were homogenised in thioglycolate broth, components of explanted
prosthesis were sonicated in Ringer solution. Homogenised and sonicated
ﬂuids were centrifuged and the sediment used for Gram staining and
culture. Culture media, both solid and liquid, were incubated at 35−37ºC
aerobically and anaerobically for 7 days, while daily examined. The
identiﬁcation of the microorganism was performed by conventional
methods and API 20 Strep set (bioMe´rieux). DNA sequencing of the
16S rRNA gene was performed using ABI Prism 310 Genetic Analyser
(Applied Biosystems, Foster City, CA, USA). Nucleotide sequences were
analysed with MegAlign software (DNASTAR, Regent St. Madison,
WI, USA) and aligned to EMBL/GenBank. Antimicrobial susceptibility
testing was determined using disc diffusion method and E-test system
(AB Biodisk).
Results: Direct smear examination from the tissue specimen showed
only erythrocytes. After 72-hour of incubation, growth of pinpoint,
translucent, non-haemolytic colonies appeared on 5% sheep blood agar.
A subculture from the thioglycolate broth yielded the same bacterial
growth. A Gram stain of the isolate revealed Gram-positive cocci of
various sizes in clusters. The identiﬁcation in API 20 Strep (bioMe´rieux)
resulted in proﬁle no. 4102411 – Aerococcus viridans (75.6%). DNA
sequencing of the 16S rRNA gene of the isolate showed 99.8% similarity
with H. kunzii. The strain was susceptible to ampicillin, erythromycin,
clindamycin, vancomycin, rifampin and resistant to ciproﬂoxacin,
gentamicin. The MICs of penicillin and clindamycin, determined by the
E-test system were 0.500 and 0.032mg/L, respectively.
Conclusions: H. kunzii is a rare isolate in clinical specimens.
Identiﬁcation of this bacterium on the basis of phenotypic tests is
difﬁcult. Absence in databases in the most of the commercial products
makes impossible to identify this organism by those means. DNA
sequencing of the 16S rRNA gene identiﬁed the aetiologic agent of
prosthetic joint infection in our case.
P1159 In vitro evaluation of hand-held test kits, immunoﬂuores-
cence microscopy, ELISA, and ﬂow cytometric analysis for
the rapid presumptive identiﬁcation of Yersinia pestis
H. Tomaso, P. Thullier, E. Seibold, V. Guglielmo, A. Buckendahl,
L. Rahalison, H. Neubauer, H. Scholz, W. Splettstoesser (Munich,
DE; Grenoble, FR; Antananarivo, MG; Jena, DE)
Plague caused by Yersinia pestis is a zoonosis mainly circulating among
rodents and their ﬂeas, which can transmit the disease to humans. Due to
the continuing threat of outbreaks in endemic regions and the potential
use of Y. pestis as a biological agent rapid diagnostic tools are needed.
The aim of this study was to evaluate the performance of immunological
assays targeting the fraction 1 capsular antigen (F1 CA) for the rapid
identiﬁcation of Y. pestis.
An in house developed immunochromatographic test strip (ICT),
the Plague BioThreat AlertTM test strip (BTA; Tetracore, USA),
ABICAPTM columns (Senova, Germany), an ELISA (Seramun,
Germany), immunoﬂuorescence microscopy and ﬂow cytometric analysis
were compared. The speciﬁcity of the assays was determined using
a representative collection of Y. pestis strains and clinically relevant
bacteria. Detection limits were assessed using serial dilutions of F1
CA. Additionally, ease of handling, costs, and turn-around time were
evaluated. All assays identiﬁed Y. pestis isolates correctly and detected
no other bacteria. The in-house developed ICT strip proved to be speciﬁc,
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highly sensitive detecting 3.3 ng of F1 CA and was the most convenient
and economic test. In contrast to immunoﬂuorescence microscopy,
ELISA can be used as a screening tool and for quantiﬁcation of F1
CA. Flow cytometric analysis is sophisticated and too expensive for
laboratories in most areas where plague is endemic. Commercially
available products will become more attractive when certiﬁed for
diagnostic purposes and available at lower costs.
P1160 Development of a rapid ﬂuorescence assay in 96 well plate as-
say for multiple antibiotic resistant Salmonella typhimurium
N. Coldham, L. Randall, L. Piddock, M. Woodward (Surrey, UK)
Objectives: Multiple antibiotic resistant (MAR) mutants of Salmonella
enterica and E. coli are characterised by MIC increases of 2−8 fold
to unrelated antibiotics including tetracycline, chloramphenicol, some
penicillins and quinolones. They have been associated with clinical
disease in their own right and provide a platform for progression to
high level antibiotic resistance. Previous studies have indicated that
the AcrA/B-TolC efﬂux pump system and certain porins cooperate
to reduce the uptake of antibiotics and are important effectors of
MAR. Many substrates of AcrA/B-TolC are divalent cations and
include ﬂuoroquinolone antibiotics and ethidium bromide. In the present
study, intracellular concentration of the ﬂuorescent probe bis benzimide
(H33342) was evaluated as a rapid single test for MAR Salmonella
Typhimurium.
Methods: S. Typhimurium (SL1344), isogenic MAR mutants (n = 4) and
isogenic mutants with deﬁned deletions in acrB, tolC, ompC and ompF
were cultured overnight in LB broth and diluted with phosphate buffered
saline to an optical density of 0.1 (600 nm). The strains were incubated
in 96 plate wells with bis benzimide (2.5mM) and the ﬂuorescence
recorded for 30 minutes using a Fluostar plate reader at excitation and
emission wavelengths of 350 and 460 nm respectively. Sensitivity of
these strains to the efﬂux pump inhibitors Phe-Arg-b-naphthylamide
(166 ug/mL) and carbonyl cyanide m-chlorophenylhydrazone (2 ug/mL)
was also evaluated. The cyclohexane tolerance of all strains was also
determined.
Results: Only the MAR mutants were tolerant to cyclohexane.
Signiﬁcantly (P< 0.0001) reduced uptake of bis benzimide was observed
by the MAR mutants and strains with deﬁned gene deletions in ompC
and ompF compared to their parent (SL1344). The uptake of bis
benzimide was unchanged in the acrB deletion mutant presumably due
to increased compensatory expression of AcrE and AcrF efﬂux pump
proteins. Increased uptake of bis benzimide was observed in the tolC
gene deletion mutant and heat inactivated controls. Uptake by all strains
was inhibited by the efﬂux pump inhibitors. Reduced sensitivity of the
MAR mutants to CCCP further ampliﬁed the difference in bis benzimide
uptake compared to the parent strain.
Conclusion: A rapid test in 96 well plate format has been developed
and partially validated for the detection of MAR mutants. Differential
sensitivity to efﬂux pump inhibitors enables further concurrent test
ampliﬁcation and phenotypic analysis.
P1161 Comparison of selective media for the detection and
enumeration of lactobacilli and biﬁdobacteria from human
faecal samples
V. Vankerckhoven, C. Lammens, O. Chonan, K. Oishi, H. Goossens
(Wilrijk, Ghent, BE)
Objectives:Methods for the detection and enumeration of faecal bacteria
should be properly validated. The aim of this study was to compare
selective media for the enumeration of lactobacilli and biﬁdobacteria
from human faecal samples.
Methods: Serial dilutions of 15 human faecal samples were plated,
using the spiral enter apparatus Eddy Jet, on two commonly used
selective media, LAMVAB and LBS for the detection and enumeration of
lactobacilli, and transgalactosyloligosaccharide agar (TOS) and modiﬁed
TPY agar (MTPY) for biﬁdobacteria. Colonies were counted based on
colony morphology and Gram stain after a 72 h anaerobic incubation at
37ºC. The number of lactobacilli and biﬁdobacteria per gram wet weight
of faeces was estimated from the number of colonies.
Results: Total colony counts ranged from <2.0 to 5.8 log10 cfu/g faeces
for LAMVAB and from <2.0 to 5.5 log10 cfu/g faeces for LBS. Mean
bacterial counts for lactobacilli were 5.0 log10 cfu/g faeces on LAMVAB
compared to 4.9 log10 cfu/g faeces on LBS (P> .05). Using LAMVAB,
lactobacilli were found in 11 of 15 (73%) faecal samples compared to
9 of 15 (60%) using LBS (P> .05). For the biﬁdobacteria, total colony
counts ranged from 7.1 to 9.6 log10 cfu/g faeces for TOS and from
7.0 to 9.4 log10 cfu/g faeces for MTPY. Mean bacterial counts for
biﬁdobacteria were 8.3 log10 cfu/g faeces on both TOS and MTPY
(P> .05). Biﬁdobacteria were found in all (100%) faecal samples using
both media (P> .05).
Conclusions: It can be concluded that both lactobacilli and biﬁdobacteria
could reliably be detected on each of the two selective media. For
lactobacilli, LAMVAB and LBS showed comparable results and could
be used to quantify lactobacilli in human faeces. The same holds for the
media TOS and MTPY, which showed comparable results and could be
used for the quantiﬁcation of biﬁdobacteria from human faecal samples.
P1162 Retrospective analysis of Staphylococcus lugdunensis isolates
K. Chatzigeorgiou, N. Siafakas, A. Tarpatzi, S. Chaniotaki,
S. Kouvardas, L. Zerva (Athens, GR)
Objectives: Staphylococcus lugdunensis is an emerging pathogen of
a yet undeﬁned clinical importance. The aim of the present study
was the retrospective analysis of all S. lugdunensis isolates recovered
in a Microbiology Laboratory and the assessment of their clinical
signiﬁcance.
Methods: Twenty-ﬁve Gram (+) cocci initially identiﬁed by Phoenix
(Becton Dickinson) as S. lugdunensis during a 31 month period were
obtained from 12 patients. Thus, 12 strains (1 strain per patient)
were thawed and retested by Phoenix. API Staph system (bioMe´rieux),
16S rRNA gene sequencing, ornithine decarboxylase (ODC), PYR
(Remel), slide (BD) and tube (Remel) coagulase tests were additionally
performed. Susceptibility tests included disk diffusion (penicillin,
oxacillin, cefoxitin, vancomycin, teicoplanin, tetracycline, gentamicin,
erythromycin, clindamycin, ciproﬂoxacin, norﬂoxacin, rifampin and
nitrofurantoin), E-test (penicillin and oxacillin), mecA gene (PCR)
and PBP2a protein (slide latex, bioMe´rieux) detection and b-lactamase
production (Oxoid). All relevant clinical information was retrieved from
the medical records.
Results: By 16S rRNA sequencing, 10 of the 12 strains were identiﬁed
as S. lugdunensis; the rest were not further considered. API Staph testing
produced identical results with sequencing, while Phoenix misidentiﬁed
1 as S. capitis ssp. ureolyticus. All were ODC and PYR (+), tube
coagulase (−) and half bound coagulase (+). All were mecA and
PBP2a (−) and one produced b-lactamase. They all exhibited a multi-
susceptible phenotype except for 1 gentamicin- and 1 quinolone-resistant
strain. Clinical presentation included 1 case of endocarditis and 2
bacteraemias with excellent clinical outcome. The other isolates were
obtained from pus (6 cases) or urine (1 case) specimens and their
clinical signiﬁcance was doubtful. Finally, analysis of laboratory records
demonstrated that S. lugdunensis represented 1.3% of all coagulase
negative isolates.
Conclusion: S. lugdunensis can be misidentiﬁed during routine
laboratory practice and supplementary biochemical asays, especially
ODC and PYR, are crucial for its recognition. It is rather a multi-
susceptible species and may cause severe infections, albeit with good
prognosis, or simply represent a contaminant.
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P1163 Emergence of optochin resistance among Streptococcus
pneumoniae in Portugal
S. Aguiar, M.J. Frias, L. Santos, J. Melo-Cristino, M. Ramirez (Lisbon,
PT)
Objective: Characterise optochin-resistant strains of Streptococcus
pneumoniae associated with pneumococcal infections in Portugal.
Methods: All strains submitted to our laboratory during 1999–2003
were optochin susceptible. Since then, 2 isolates (0.3%) in 2004
and 30 isolates (3.2%) in 2005, recovered from 10 geographically
dispersed hospitals, were optochin-resistant. These 32 optochin-resistant
S. pneumoniae strains consisted of mixed populations of optochin-
susceptible and optochin-resistant isolates. For each isolate, both
optochin-resistant and susceptible subpopulations were characterised
using a combination of bile solubility, antimicrobial susceptibility,
serotyping and macrorestriction proﬁling, using SmaI and pulsed ﬁeld
gel electrophoresis (PFGE). The BioNumerics software was used to
make UPMGA (unweighed pair group method with arithmetic mean)
dendrograms of PFGE patterns. The Dice similarity coefﬁcient was
used with optimisation and position tolerance settings of 1.0 and 1.5%,
respectively.
Results: Subculture of individual colonies of each strain exposed a
uniformly optochin-resistant subpopulation and a uniformly optochin-
susceptible subpopulation. The optochin-resistant subpopulations were
bile soluble and reacted with sera targeting pneumococcal capsular
polysaccharides, conﬁrming their identiﬁcation as S. pneumoniae.
The antimicrobial susceptibility proﬁle and serotype was identical in
both optochin-susceptible and resistant subpopulations suggesting that
they corresponded to variants of the same clone. PFGE analysis of
each subpopulations revealed indistinguishable PFGE proﬁles, further
supporting the suggestion that these constitute two variants of the
same strain. The 32 strains included in this study presented 19
different serotypes, all previously found among invasive and colonisation
pneumococcal strains in Portugal. Furthermore, the diversity of PFGE
proﬁles observed and the identiﬁcation of internationally disseminated
clones (ex: clone England14−9) excludes a clonal origin for these strains.
Conclusion: Accurate identiﬁcation of S. pneumoniae isolates is
essential for the correct diagnosis and adequate therapy of patients
with pneumococcal infections. In view of the ﬁndings described
here we recommend that at least the bile solubility test should be
routinely performed in cases of suspected pneumococcal ethiology,
even if the isolates are optochin-resistant, to exclude the possibility of
S. pneumoniae.
P1164 Evaluation of 4 chromogenic media for detection and
identiﬁcation of clinically relevant yeasts
M. Ieven, Z. Wouters, E. Vercauteren, H. Goossens (Edegem, BE)
Background: Rapid detection and identiﬁcation of yeasts is essential for
an immediate and correct therapeutic management.
Objectives: Four commercially available chromogenic agars for the
detection and identiﬁcation of yeasts were evaluated on strains and
directly on clinical specimens.
Methods: A total of 94 well characterised clinical isolates were included
(31 C. albicans, 22 C. glabrata, 9 C. parapsilosis, 6 C. krusei,
8 C. tropicalis, 5 C. dubliniensis, 1 C. guilliermondii, 5 Cryptococcus
neoformans, 3 Geotrichum spp. and 1 Saccharomyces cerevisiae) as well
as 100 clinical specimens, identiﬁed positive for yeasts by conventional
methods, including a wide range of sample types (wound swabs, sputa,
urine blood cultures). All isolates and clinical specimens were cultured
onto Candida ID2 (bioMe´rieux), Oxoid Chromogenic Candida Agar
(OCCA, Oxoid) BD CHROMagar Candida (Becton Dickinson) and
Cromogen Candida (Biomedics) and examined after both 24 h and 48 h
incubation at 37ºC or 30ºC for the OCCA agar. Conventional non-
chromogenic media, commercial identiﬁcation systems and biochemical
tests were used as gold standard to compare the results of the
chromogenic media.
Results: The sensitivity for identiﬁcation of isolates of C. albicans
on chromogenic media varied between 13% and 100% after 24 h
and increased to 97%-100% for all four media after 48 h. Both
BD CHROMagar Candida and OCCA media correctly identiﬁed all
C. albicans, C. krusei, C. tropicalis and C. dubliniensis after 48 h.
Sensitivity for identiﬁcation of C. glabrata, the second most prevalent
species recovered from all clinical specimens, was 100% and 95.5%
for OCCA and BD CHROMagar Candida respectively. Speciﬁcity for
all 4 media was 100%: no single isolate was misidentiﬁed. The table
presents sensitivity (%) for isolation and identiﬁcation directly from
clinical specimens.
Sensitivity for isolation and identiﬁcation directly from clinical
specimens
Species (n = 114) Sensitivity (%)a
OCCA BD
CHROMagar
Cromogen
Candida
Candida ID2
C. albicans 91 82 84 96
C. glabrata 94 80 NA NA
C. krusei 100 100 100 100
C. tropicalis 100 100 100 NA
C. parapsilosis 67 NA NA NA
aNA, not applicable.
Conclusions: C. albicans was detected and identiﬁed with the highest
sensitivity on the Candida ID2 but the OCCA chromogenic agar allowed
to isolate and identify 98.2% of all species isolated from clinical samples
with sensitivities varying between 91% and 100%.
P1165 Evaluation of various carbon sources on conidia production
among clinical isolated moulds
P. Santanirand, S. Thanavanitnam, P. Chongtrakool, K. Angkananukool
(Bangkok, TH)
Differentiation of conidia structure is one of the keys for fungal
identiﬁcation. The conventional slide culture technique has difﬁculty in
certain culture conditions particularly in humidity levels which lead to
uncertainty in sporulation. A new slide culture technique performed in
24-well tissue culture plate was introduced in order to overcome previous
limitations. It showed several advantages over the conventional method,
including simplicity and convenience in procedures, using less time
and space, better humidity control and higher safety for workers. The
latter advantage was due to double-coverglass technique. Apart from the
adaptation of slide culture technique, the correlation of sporulation time
and colony size or incubation period was studied. Fifty seven isolates
of dermatophytes and forty eight black moulds from 16 genera were
tested. In dermatophytes, approximately 90% of the isolates produced
conidia when colony diameter reached 3 cm. which was equally to 7
days of incubation. For rapid and slow grower black moulds, the colony
diameter of 1.4 cm. (or 5 days of incubation) and 6 cm. (or 6 days of
incubation), respectively, were the optimal sporulation time. Lastly, the
effect of various carbon sources on sporulation was studied. Among
various ﬂours, rice, brown rice and glutinous rice have showed the most
promise in inducing conidia production. Therefore, these 3 ﬂours were
combined in a new media called triple ﬂours agar (TFA). A comparison
of TFA and potato dextrose agar and Sabouraud dextrose agar (SDA) in
the dermatophyte group showed no differences but TFA was signiﬁcantly
better than SDA in the induction of sporulation in black moulds. Addition
of fatty acids into TFA did not enhance induction capacity of sporulation
in black moulds and dermatophytes. However, Nigrospora spp. responded
to fatty acids addition by producing of signiﬁcantly larger amount of
conidia compared to TFA alone.
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P1166 Diagnostics of fungal infections in the Nordic countries: we
still need to improve!
M.C. Arendrup, E. Chryssanthou, P. Gaustad, P. Sandven, M. Koskela,
V. Fernandez on behalf of the Nordic Reference Group for Methods
in Medical Mycology (NRMM)
Objectives: A Nordic External Quality Assessment programme in
medical mycology was established in 2005. In order to monitor not
“best practice” but the level of routine diagnostics, the specimens were
designed to resemble clinical samples and laboratories were asked to
handle the samples like routine samples.
Methods: Five simulated clinical samples were distributed to 59
participating Nordic laboratories of clinical microbiology. The specimens
contained the following microorganisms: (1) Candida glabrata and
C. albicans in a ratio of 1:20; (2) Cryptococcus neoformans;
(3) Aspergillus fumigatus, C. albicans and Enterobacter cloacae;
(4) C. tropicalis, Klebsiella pneumoniae and Enterococcus faecium,
(5) None.
Results: Sixty-six percent of the laboratories failed to detect the
C. glabrata isolate in sample 1. Thirty-four percent of the laboratories
reporting susceptibility results incorrectly reported the Cryptococcus
neoformans isolate as ﬂuconazole susceptible. Twenty-four percent of
the laboratories failed to detect Aspergillus fumigatus in specimen 3
although the accompanying clinical information notiﬁed that it was a
BAL sample from a neutropenic patient in an ICU.
Conclusion: This distribution of simulated clinical samples illustrates
that the traditional quality assessment programmes may give a false
sense of well performance, that mycological diagnosis is difﬁcult, and
that there is a need of further improvement and attention.
Viral serology
P1167 Evaluation of InﬂuA&B Respi-Strip for the rapid detection
of inﬂuenza A and B viruses in respiratory samples
S. Degallaix, L. Denorme, O. Lefe`vre, V. Labrune, T. Laurent,
T. Leclipteux, P. Mertens (Gembloux, BE)
Inﬂuenza virus is the causative agent of ﬂu, a highly contagious infection
of the upper respiratory tract. Flu is characterised by the antigen
variability, the seasonality and the impact on the general population.
There are two main (A and B) types of inﬂuenza viruses. H1N1, H2N2
and H3N2 InfA subtypes as well as InfB strains can cause outbreaks
of variable intensity annually in humans. Although inﬂuenza A are the
most prevalent, type B viruses can represent up to 50% of circulating
virus during one season, and is often more abundant at the end of the
season.
Flu is most often a mild viral infection, but inﬂuenza can cause severe
complications such as bronchitis or pneumonia, particularly in children
and elderly people. Antivirals are available, but these treatments are
effective only if administered early requiring a rapid diagnostic test.
There are many other viral infections that can mimic inﬂuenza making
laboratory tests necessary to distinguish it from other acute respiratory
infections. The widespread of H5N1 wildbird strains that can infect
humans and the threat of a pandemic makes the rapid diagnosis still
more valuable.
We have developed a new rapid dipstick test (InﬂuA&B Respi-Strip)
based on monoclonal antibodies (MAb) directed agaisnt non-variable
proteins of inﬂuenza A and B viruses. The ﬁnal device has two sides, one
for the detection of inﬂuenza A and the opposite side for the detection
of inﬂuenza B. For each virus, MAbs are coated on the nitrocellulose,
while other Mabs are conjugated to colloidal gold particles. A build-in
control is used as migration control.
An evaluation on 113 frozen nasopharyngeal samples has been conducted
to compare the InﬂuA&B Respi-Strip to a market leader rapid
immunochromatographic test (Test N), with RT-PCR as the reference
method. Both tests showed excellent speciﬁcities for both InfA and
InfB detection (98.6–100%). InﬂuA&B Respi-Strip was slightly more
sensitive than Test N, for both InfA and InfB detection. InﬂuA&B Respi-
Strip will be further validated on fresh samples during the epidemic
season.
In conclusion, the Coris’ Inﬂu-A&B Respi-Strip shows sensitivity and
speciﬁcity comparable to one of the bests currently available rapid tests.
The use of this test for diagnosis of inﬂuenza disease should enhance
patient healthcare by enabling rapid and appropriate use of antiviral
treatments and lowering inappropriate use of preventive antibiotic
treatment still often prescribed by mistake.
P1168 Evaluation of an automated chemiluminescent immunoassay
for the detection of anti-rubella virus IgM antibodies
B. Pustowoit, U.G. Liebert (Leipzig, DE)
Background and Objectives: Rubella, commonly known as German
measles, occurs worldwide. In an acute rubella infection acquired either
naturally or via vaccination, IgM antibodies appear in the patient serum
at the onset of clinical illness and persist for a period of 4 to 5 weeks.
However, low IgM levels may not necessarily indicate a recent rubella
infection. A fully automated assay for the qualitative detection of anti-
Rubella IgM in human serum developed on the Access® immunoassay
systems (Beckman Coulter Inc.) was studied including clinical speciﬁcity
and sensitivity as well as performance with potential cross reactivity
panels. A study was performed with a panel named “long persistent
Rubella IgM” referring to positive results obtained with other anti-
Rubella IgM method but not considered as acute infection or recent
vaccination.
Methods: The speciﬁcity was studied with a population of 96 samples
considered negative in IgM (>360 days after exanthema or vaccination).
Sensitivity was studied with 31 samples from a Rubella outbreak and
12 samples from recently vaccinated people. The evaluation of potential
cross reactivity was based on 30 samples from individuals who had
serological evidence of acute infections with Mumps (n = 9), EBV (n = 5),
CMV (n = 3), Inﬂuenza A (n = 4) and other pathogenic microorganisms
(n = 10). “Long persistent IgM” were studied with samples from persons
with positive IgM with an other method but with high level of IgG
avidity and/or presence of E2 band in native immunoblot (inconsistent
with acute Rubella). Discrepant results were conﬁrmed using additional
EIA tests, avidity of anti-Rubella IgG as well as native immunoblot test
for determination of IgG antibodies against Rubella virus proteins.
Results: In this study, Access®Rubella IgM exhibited a speciﬁcity of
98.09% and a sensitivity of 97.61%. A sensitivity of 100% was noted
with seroconversion panels. Two samples (one positive in anti-E. coli and
one positive in Inﬂuenza A IgA) presented a cross-reaction. Referring to
the “long persistent” rubella IgM panel, 8 samples were negative with
Access Rubella IgM in accordance with the sample status (no acute
infection or recent vaccination).
Conclusion: The Access® anti-Rubella IgM assay combines clinical
performance, with good sensitivity, speciﬁcity with the advantage of
a rapid, automated, random access immunoassay system.
P1169 Evaluation of a fully automated Multiplexed Bead assay for
assessment of Epstein-Barr virus immunologic status
M. Baccard, J.M. Seigneurin (Grenoble, FR)
Detection of clinically relevant circulating Epstein-Barr virus (EBV)
speciﬁc and heterophile antibodies in serum are essential for the
diagnosis of EBV infection and determination of the patient EBV
serology status. Currently, speciﬁc serological assays using either indirect
immunoﬂuorescence or enzyme-linked immunosorbent (ELISA) are
performed to evaluate the status of Epstein-Barr virus (EBV) infection in
humans. Even if reliable, these methods are limited to testing an antibody
response to a single viral antigen per reaction, thus necessitating a panel
of assays to complete the evaluation.
The aim of this study was to evaluate the performance of the BioPlex
2200 EBV IgG and IgM Panels (Bio-Rad Laboratories, Hercules, CA),
a new fully automated multiplex method that can simultaneously detect
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in a single tube VCA, EBNA-1 and EA-D IgG and VCA IgM and
heterophile antibodies.
610 serum samples from 508 patients including seronegative and positive
clinically documented samples (119 Infectious Mononucleosis [IM] and
other stages of the infection) were tested both with the BioPlex 2200
panels and the assays routinely used in the lab.
Speciﬁcity on negative samples was 98.2% and ranged from 96 to
100% on clinical samples depending on the analyte. The clinical
sensitivity on acute and IM samples was up to 95% for VCA IgM
and 96.4% for heterophile. Combining those two analytes improved the
clinical sensitivity on those samples. For past infection samples, VCA
IgG clinical sensitivity was 97%. Sensitivity on clinical samples for
EBNA-1 and EA-D IgG was respectively 98 and 87%. Concordance
calculation demonstrated overall agreement of 90% for VCA IgM,
93% for heterophile antibody and 77% for VCA IgG (especially due
to difference in the antibodies kinetic during primary infection). The
correlation between samples classiﬁcation based on BioPlex 2200 results
and status determined with the lab routine assays was of 83% including
atypical proﬁles and immunocompromised patients.
Conclusion: the BioPlex 2200 EBV IgG and IgM Panels showed very
good interpretation concordance with the routine lab assays. Further-
more, the BioPlex 2200, the ﬁrst and only fully-automated, random
access multiplex EBV testing platform offers practical advantages that
allow for rapid and simultaneous evaluation of the ﬁve most clinically
relevant antibodies including heterophile for accurate assessment of EBV
Immunologic Status.
P1170 Rapid, sensitive and speciﬁc lateral-ﬂow
immunochromatographic device to measure antibodies to
HSV-2 in serum and whole blood
E.I. Laderman, E. Dumaual, E. Whitworth, M. Jones, J. Gonzalez,
A. Hudak, J. Carney, J. Groen (Cypress, US; Cardiff, UK)
Objectives: Herpes simplex virus-2 is a common human pathogen
that causes a variety of clinical manifestations. Adequate identiﬁcation
of anti-HSV-2 IgG is important for clinical management and sero-
epidemiological studies. HSV-2 serology tests currently used include
Western Blot, Immunoblot and ELISA; however, all are laboratory
based. In order to provide near-patient results to allow for faster
counseling and treatment, a rapid assay that is accurate and simple to
use is desirable. Here we describe the development of a lateral ﬂow
immunochromatographic assay (LFIA) using gold colloid nanoparticles
as the detection reagent.
Methods: Samples: A panel of 359 patient sera consecutively submitted
for HSV-1 and -2 type-speciﬁc serology tests was collected. In addition,
sera positive for CMV (n = 11), EBV (n = 16), VZV (n = 14), rubella
(n = 34) or HSV-1 (n = 196) but negative for HSV-2 IgG by ELISA were
also selected for cross-reactivity testing. One hundred volunteer donors
were recruited and heparinised-ﬁngerstick blood, venous whole blood,
and serum samples were collected to measure concordance of results
across sample types. Samples positive or negative for HSV-2 were spiked
with 10mg/mL triglycerides, 60mg/mL albumin, 0.2mg/mL bilirubin
or 220mg/mL haemoglobin for interference testing. Reference ELISA:
Samples were tested using the HerpeSelect-2 type-speciﬁc IgG ELISA
per the package insert. An HSV-2 inhibition test was used to evaluate
specimens with discordant ELISA versus LFIA results. LFIA: After
addition of sample and buffer, the antibody-gold conjugate and sample
migrate across the test strip. Antibodies (if present) and gold conjugate
sequentially contact the test and control lines and cause speciﬁc coloured
lines to form within 15 minutes.
Results: The sensitivity of the HSV-2 LFIA compared with ELISA was
100% (89/89), and the speciﬁcity was 97.3% (257/264). Cross-reactivity
in HSV-1 positive samples was 2.6% (5/196), 2.9% (1/34) for Rubella
and 6.2% (1/16) for EBV. No cross-reactivity in VZV or CMV positive
samples was observed. No interference was observed from bilirubin,
triglycerides, albumin or haemoglobin added to samples. Concordance of
LFIA results between capillary whole blood, EDTA and heparin venous
whole blood and serum was 99% (99/100).
Conclusion: The lateral ﬂow immunochromatographic assay for HSV-2
IgG demonstrated excellent sensitivity, speciﬁcity, and concordance
compared to type-speciﬁc ELISA assay.
P1171 Multiplex bead-based assays for Epstein-Barr virus, IgG
and IgM serum antibody detection
H. Gregson, N. Liu, H. Truong, X. Su, E. Laderman, J. Groen (Cypress,
US)
Objectives: Epstein-Barr Virus (EBV) is a common virus that can cause
a wide variety of symptoms from asymptomatic to severe infectious
mononucleosis. The symptoms of the disease can be similar to that
of other viruses or haematologic cancers. Most important for EBV
diagnosis is the distinction of acute infection, past infection, and no
infection for differential diagnosis. EBV serology methods currently
include IFA, ELISA and multiplex assays; however, IFA and ELISA
are labour intensive and each has their limitations. A multiplexed
assay with better performance is highly desirable. Here we describe the
development of an IgG and an IgM EBV multiplexed assay using the
xMAP technology (Luminex Inc., Austin, TX).
Methods: A panel of 426 patient sera consecutively submitted for
EBV testing and 159 patient sera samples that were classiﬁed as
EBV negative or EBV IgM positive were collected. EBV IgG assay:
Recombinant EA-D and EBNA-1, and native afﬁnity puriﬁed VCAgp-
125, and goat-anti-human IgG (internal control) were covalently linked to
the xMAP polystyrene bead sets. EBV IgM assay: Native afﬁnity puriﬁed
VCAgp125 and heterophile antigen were covalently linked to polystyrene
bead sets. The bead mix was incubated with test serum followed by
washing, and then incubated with anti-human IgG or IgM conjugated
with phycoerythrin (PE). The ﬂuorescence intensity of PE, representing
the amount of IgG or IgM in the target sample, was measured by a
Luminex 100 system. The same samples were tested using the EA IgG,
EBNA IgG, VCA IgG and VCA IgM ELISA system and a rapid test for
heterophile antibodies per the manufacturer’s suggested protocol.
Results: Because reactivity to each antigen represents a speciﬁc stage
in the EBV infection, each sample was classiﬁed by a FDA approved
ELISA and rapid test for heterophile as acute, no infection, past infection,
or indeterminate using the deﬁned FDA algorithm. The sensitivity and
speciﬁcity of each antigen in the multiplex based bead assay was
determined by comparison to the relevant ELISA classiﬁcation. See
attached table for the results of sensitivity and speciﬁcity analysis.
Antigen Acutea Past Infectiona No infectiona
% agreement 95%CI % agreement 95%Cl % agreement 95%Cl
VCA IgG Sens. 100%
(49/49)
92.7–100% Sens. 94.8%
(307/324)
91.8–96.7% Spec. 94.8%
(92/97)
88.5–97.8%
EA IgG Sens. 97.7%
(42/43)
87.9–99.6% Spec. 96.3%
(233/242)
93.1–98.0% Spec. 96.7%
(88/91)
90.8–98.9%
EBNA IgG Spec. 100%
(77/77)
95.3–100% Sens. 97.5%
(316/324)
95.2–98.7% Spec. 100%
(97/97)
96.2–100%
VCA IgM Sens. 93.5%
(72/77)
85.7–97.2% Spec. 92.6%
(300/324)
89.2–95.0% Spec. 95.9%
(93/97)
89.9–98.4%
Heterophile IgM Sens. 98.0
(50/51)
89.7–99.7% Spec. 98.8%
(320/324)
96.9–99.5% Spec. 96.9%
(94/97)
91.3–98.9%
aAbbreviations: Sens., sensitivity; Spec., speciﬁcity; 95%CI, 95% conﬁdence interval.
Conclusion: The multiplex bead-based assay for EBV IgG and
IgM demonstrated excellent sensitivity, speciﬁcity, and concordance
compared to type-speciﬁc ELISA assays.
P1172 New enzyme immunoassay “DS-EIA-HIV-AG-SCREEN”
for early diagnostics of HIV infection
I. Sharipova, E. Baranova, M. Levina, A. Burkov, A. Oriadina,
T. Ulanova (Nizhniy Novgorod, RU)
Objective: The problem of early diagnostics of HIV infection still
remains very important and can be solved by using highly sensitive
tests for detection HIV-1 p24 antigen. Improvements in assay sensitivity
have been achieved constantly since introduction of the ﬁrst commercial
S320 17th ECCMID / 25th ICC, Posters
test. The mostly sensitive current EIA for the detection of HIV p24 have
an analytical sensitivity equal 3 pg/mL. Despite the high performance of
screening assays, transfusion-associated HIV infection is still reported.
The aim of this present study was to develop and evaluate EIA test for
p24 detection with analytical sensitivity equal 0.5 pg/mL.
Methods: New EIA one-step diagnostic test based on biotin-streptavidin
ampliﬁcation. Sensitivity of new test was estimated by testing serial
dilutions of the HIV 1 ANTIGEN STANDARD (Bio-Rad Laboratories,
Hercules, CA, USA) and serum samples from HIV Antigen Sensitivity
Panel No. 801 (Boston Biomedica Inc. (BBI), West Bridgewater, MA,
USA). Seroconversion panels No. 62238 and 64578 (ZeptoMetrix Corp.
(ZMC), Buffalo, NY, USA), No. 931, 939, 942, and 948 (BBI) have been
additionally tested. To challenge the speciﬁcity of the new assay, serum
samples of healthy blood donors (n = 1,990), pregnant women (n = 400),
patients with other infections (n = 256) and patients with noninfectious
diseases (n = 305) were investigated.
Results: Analytical sensitivity of the «DS-EIA-HIV-AG-SCREEN»
assay was estimated equal 0.5 pg/mL. All positive samples from
commercial panels demonstrated much higher signal to cutoff ratios
than with alternative tests. The results obtained during the study of sera
samples from seroconversion panels No. 64578 (ZMC, USA), No. 931,
939, 942, and 948 (BBI, USA) showed that the test “DS-EIA-HIV-AG-
SCREEN” able to detect p24 antigen either simultaneously or two days
later (ZMC, USA, panel No. 62238) than HIV RNA by PCR, but on an
average 3 days earlier than lower sensitive tests. General speciﬁcity of
the new test among different samples cohort was equal 99.95%.
Conclusion: Development of EIA tests for detection an HIV p24 antigen
in concentration lower than 3−5 pg/mL is not technically insuperable
problem. The obtained results showed high diagnostic efﬁciency of the
“DS-EIA-HIV-AG-SCREEN” test which can be used for blood donor
screening and examination of patients from risk groups of with the aim
of early diagnostics of HIV infection.
P1173 Evaluation of a competitive quantitative RT-PCR-ELISA
system for quantiﬁcation of HIV-1 RNA in plasma:
comparison with COBAS Amplicor HIV-1 monitor test
S. Amel jamehdar, F. Sabahi, M. Forouzandeh, M. Haji Abdolbaghi,
A. Kazemnejad, F. Mahboudi, R. Edalat, M. Ravanshad (Tehran, IR)
Objectives: Quantiﬁcation of the human immunodeﬁciency virus type 1
RNA levels (viral load) has become an indispensable tool for the
assessment of patient prognosis and for the monitoring of antiretroviral
therapy. The access to commercial assays for viral load monitoring in
IRAN is still limited due to the high costs. The aim of this study was to
design a competitive quantitative RT-PCR-ELISA system for sensitive
ampliﬁcation of HIV-1 pol gene and evaluation of the treatment of 80
HIV-1 seropositive patients. Results of this assay were compared with
the COBAS Amplicor HIV-1 monitor test.
Methods: Whole blood samples from 80 HIV-1 seropositive and 40
seronegative blood donors were collected in vaccutainer tube. Plasma
was separated and stored at −80ºC. Total RNA was extracted according
to the protocol supplied by the commercial viral RNA kit (Qiagen). A
quantitative HIV-1 test is described based on competitive quantitative
RT-PCR assay combine with hybridisation as a detection system. The
internal RNA standard (IS) was designed by SOEing mechanism,
speciﬁcally to be competitive during the ampliﬁcation step. Sample viral
load determination was carried out with one RT-PCR in the presence of
103 IS copies. The HIV-1 copy number was calculated by reference to
an external standard curve performed on known and increasing amounts
of the reference HIV-1 RNA co-ampliﬁed with a constant amount of the
IS RNA.
Results: The results demonstrated that this technique detected 5 HIV-1
RNA copies per milliliter of plasma. The assay had a linear range from
103 to 106 HIV-1 copies. A positive linear correlation between the two
tests (r2 = 0.88) was found. Overall, no signiﬁcant differences were found
in plasma viral load quantitation between both assays, therefore this assay
is suitable for viral load quantitation of HIV-1 plasma samples.
Conclusions: Our data demonstrates that our competitive quantitative
RT-PCR-ELISA system is a fast and reliable method for the detection
and quantitation of HIV-1 RNA and this technique could be applied
during the monitoring of HAART treatment.
P1174 Analysis of AtheNA Multi-Lyte HIV-1 Test for conﬁrmation
of HIV-1 infection
Y. Wang, A. Suantio, Y. Pogue (Atlanta, US)
Background: The Western Blot test for Human Immunodeﬁciency Virus
Type 1 (HIV-1) is routinely required to detect antibodies against one or
more HIV-1 antigens in the human serums that were tested positive by
using the enzyme immunoassay (EIA) screening method for HIV-1/2.
New HIV-1 Bead Blot (AtheNA Multi-Lyte HIV-1) test is a multiplexed,
microparticle-based immunoassay for conﬁrmation of antibodies against
HIV-1 viral proteins in the Luminex system.
Methods: A total of 115 blood samples that were tested positive by
Abbott HIV-1/2 EIA method were used for comparison of the HIV-1
conﬁrmation by using the AtheNA HIV-1 method on Luminex system
with the conventional manual HIV-1 Western Blot (WB) method.
Results: Of 56 non-duplicated samples tested positive by HIV-1 WB,
all 56 (100%) were tested positive by the AtheNA HIV-1 method. Of 59
HIV-1 unconﬁrmed or negative samples, 46 (78%) resulted in the same
interpretation by both methods: 41 samples were conﬁrmed as negative,
and 5 samples as indeterminant, respectively. Minor discrepant results
were identiﬁed in 13 out of 59 samples (22%). Of 9 samples negative
by the AtheNA method but were indeterminant by WB method, 7 were
either positive or weak positive for p24. Of 4 samples tested negative by
WB method but were indeterminant by AtheNA method, 3 were positive
for p55.
Conclusions: Even with minor discrepancy noticed in the HIV-1
unconﬁrmed or negative samples, the new multiplexed AtheNA Multi-
Lyte HIV-1 Bead Blot assay can provide the same conﬁrmation as the
HIV-1 Western Blot method in the HIV-1 positive serum samples.
P1175 Multi-centre evaluation of a new hepatitis B surface antigen
(HBsAg) assay on the family of Access® immunoassay
systems
A. Pivert, A. Ducancelle, T. Levayer, F. Descamps, M. Maniez-Montreuil,
A. Artus, C. Heinen, D. Woodrum, F. Lunel-Fabiani (Angers,
Montpellier, Lille, Marseilles, Marnes la coquette, FR; San Diego, US)
Background: Accurate detection of Hepatitis B Surface Antigen
(HBsAg) is an important goal for the diagnosis of patients infected
with the hepatitis B virus (HBV). A multi-centre study was conducted
to characterise the clinical performance of the new HbsAg assay on
the family of Access immunoassay systems from Beckman Coulter
currently in development. The Access HBsAg and HBsAg Conﬁrmatory
assays are based on paramagnetic particle, solid phase technology and
chemiluminescent signal detection.
Methods: Percent negative agreement (relative speciﬁcity) was calcu-
lated from 5,020 prospectively enrolled blood donors from two blood
donation centres and 566 subjects from a university hospital for whom
the HBsAg assay was requested by their physician as a part of their
routine medical evaluation (due to suspected exposure or increased risk
of HBV, signs and symptoms of infection, or prenatal screening of
pregnant women). Percent positive agreement (relative sensitivity) was
calculated from 290 subjects with a diagnosis of acute or chronic HBV
infection who were prospectively enrolled or whose samples had been
archived in a sample repository. Percent negative and positive agreements
were calculated relative to the Abbott PRISM® and Abbott AxSYM®
immunoassay systems.
Results: Negative percent agreement for the Access HBsAg assay in
a blood donor population was 99.96% (5,018/5,020) [95%CI: 99.86–
100%]. Negative percent agreement for the Access HBsAg assay
at the university hospital was 99.65% (564/566) [95%CI: 98.73–
99.96%]. Discrepant samples were not conﬁrmed in the Access HBsAg
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Conﬁrmatory assay and agreement between methods after conﬁrmatory
testing was 100%. Positive percent agreement for subjects with known
HBV infection in the Access HBsAg assay was 100% (290/290)
[95%CI: 98.69–100%]. All positive samples were conﬁrmed in the
Access HBsAg Conﬁrmatory assay. Excellent separation of positive and
negative populations was observed.
Conclusion: The Access HBsAg and the Access HBsAg Conﬁrmatory
assays provide excellent sensitivity and speciﬁcity for the detection of
HBsAg in hospital and blood donor populations with the advantage of
a rapid, automated, random-access immunoassay system.
®All trademarks are property of their respective owners.
P1176 Performance of an automated chemiluminescent assay for
the detection of anti-hepatitis A virus IgM antibodies:
Access® HAV IgM assay
Y. Buisson, C. Masson, F. Bouniort (Paris, FR; Nyon, CH)
Background: The diagnosis of acute hepatitis A is based on the detection
of anti-HAV IgM antibodies. A fully automated assay for the qualitative
detection of anti-HAV IgM in human serum and plasma developed on
the family of Access immunoassay systems from Beckman Coulter was
studied and included imprecision, clinical sensitivity and speciﬁcity,
comparison with a reference method and negative samples distribution.
Methods: Intra-assay imprecision based on 30 replicates of 4 samples
(1 negative and 3 positive). Inter-assay imprecision based on the same 4
samples tested in 5 replicates, twice a day, 5 different days. Sensitivity
was studied with a population of 210 individual samples from patients
with acute hepatitis A and with 157 samples from 26 cases of clinical
follow-up or seroconversion. Results obtained with the Access HAV IgM
assay were compared with a commercially available EIA technique;
discrepant results were conﬁrmed using a third EIA method. The
speciﬁcity of the Access HAV IgM assay was evaluated on a normal
population (n = 1,535) and a population with a potentially interfering
pathologies (HBV Ab, HIV Ab, HCV Ab, CMV, EBV, HSV, VZV,
Yellow fever, Mumps, Measles, Polio, Rubella, Toxoplasmosis or auto-
immune disorders (n = 429). A comparison study with a commercialised
automated HAV IgM assay was performed with 620 samples. Discrepant
results were conﬁrmed using a third EIA method. The negative samples
repartition was studied with 706 blood donor samples.
Results: Imprecision was less than 10% CV for the positive samples.
Sensitivity was 99.04% with individual samples and 100% with
seroconversion or clinical follow-up cases. The Access HAV IgM assay
demonstrated a speciﬁcity of 99.93% with a normal population and
99.53% with the population of potentially interfering pathologies. The
comparison study exhibited an overall agreement of 98.40%, a relative
speciﬁcity of 99.35% and a relative sensitivity of 97.40%. After further
analysis with a third EIA method, 7 from the 10 discrepant results were
correctly tested with the Access HAV IgM assay. The negative sample
distribution showed that 93.90% of the results are lower than 0.3 S/CO.
Conclusion: The Access HAV IgM assay combines robust analytical and
clinical performance with good precision, sensitivity, speciﬁcity and a
good distribution of the negative samples far away from the cut-off value:
with the advantage of a rapid, automated, random access immunoassay
system.
P1177 Detection of hepatitis B surface antigen (HBsAg) subtypes,
genotypes, mutants and evaluation of potential hook effect
using the new Access® HBsAg and conﬁrmatory assays
X. Duburcq, A. Clement, D. Duhamel, D. Leirens, F. Margotteau,
F. Bouniort, S. Taskar, O. Flecheux (Paris, FR; Nyon, CH; Chaska, US)
Background and Objectives: Detection of genetic variability of the
HBsAg protein represents signiﬁcant challenges to the accurate detection
of HBsAg. Genetic variants may escape immunoassay detection leading
to erroneous results which could endanger patients’ health and the
blood supply. Another risk for misdetection in an immunological assay
is a false negative result due to high concentration of HBsAg (hook
effect). A study was conducted to characterise the detection of subtypes,
genotypes and mutants; and to investigate the potential hook effect of the
new HBsAg and HBsAg Conﬁrmatory assays on the family of Access
immunoassay systems from Beckman Coulter currently in development.
The Access HBsAg and HBsAg Conﬁrmatory assays are based on
paramagnetic particle, solid phase technology and chemiluminescent
signal detection.
Methods: The STFS 2004 Subtype Panel, containing 8 different HBsAg
subtypes (adw2, adw4, adr, ayw1, ayw2, ayw3, ayw4, and ayr), was
tested to investigate reactivity towards subtype recognition. Seven
genotypes, A-G from the Teragenix HBV Genotype Panel (HBVGTP-
002), were tested to investigate reactivity towards genotype recognition.
A panel of 15 recombinant mutant proteins, each containing single or
multipoint mutations located at 22 different amino acid positions in
the S protein ectodomain, was tested to investigate reactivity towards
genetic mutations. Five very high positive samples, containing 200
to 300mg/mL of HBsAg and a spiked mixture of Ad + Ay HBsAg
(approximately 5mg/mL), were tested to investigate interference due to
high concentration of antigen.
Results: All 8 subtypes in the STSF 2004 Subtype Panel, all 7 genotypes
of the Teragenix HBV Genotype Panel, and all 15 recombinant HBsAg
mutant proteins were detected without ambiguity with the Access HBsAg
assay and conﬁrmed positive with the Access HBsAg Conﬁrmatory
assay using multiple lots of assay kits. No false negative results, due to
high amount of antigen (~5mg/mL in the highest case), were observed
among the 6 samples tested and all samples were conﬁrmed positive
after dilution.
Conclusion: The Access HBsAg and Conﬁrmatory assays provide
excellent sensitivity for the detection of HBsAg mutants, subtypes and
genotypes; and are not impacted by high concentration of antigen.
P1178 A comparative study of the new Access® HBs Ag assay and
the HBs Ag conﬁrmatory assay from Beckman Coulter
X. Duburcq, A. Pouzet, L. Marant, A. Cle´ment, D. Duhamel, Y. Leirens,
F. Margotteau, R. Falcou-Briatte, F. Bouniort, S. Taskar, O. Flecheux
(Paris, FR; Nyon, CH; Chaska, US)
Background: Hepatitis B virus infection is a worldwide problem of
clinical signiﬁcance. The virus is transmitted via parenteral contact,
through the exchange of blood and blood products, by sexual contact, and
by perinatal spread from mother to child. In this study, we compared the
relative sensitivity and speciﬁcity performances of the new Access HBs
Ag assay currently in development and the Abbott AxSYM§ HBsAg V2.
Methods: Analytical sensitivity was compared by testing the BBI PHA
106 panel composed of 15 points with low HBs Ag titer within 0.05 and
0.6 IU/mL. Clinical sensitivity was investigated using commercialised
panels for subtypes and genotypes or in-house panel for variants, 30
commercialised seroconversion panels (including 177 samples), and 100
positive samples from recent, acute or chronic phase infected patients.
Negative sample repartition was compared with 577 negative samples
collected in a hospital in France.
Results: All low titer panel members up to 0.05 IU/mL were recognized
by the Access HBs Ag assay, whereas AxSYM HBs Ag failed to
recognize 2 of them up to 0.1 IU/mL. All subtypes, genotypes and
variants tested were recognized by both methods. The Access HBs Ag
assay showed equivalent results to AxSYM HBs Ag for 18 panels among
the 30 tested. The Access HBs Ag assay was more sensitive with 10
panels and less sensitive with 2 panels. Among the 100 positive samples,
all were found positive, displaying 100% of agreement between the
Access HBs Ag and AxSYM assays. The speciﬁc margin (SM), deﬁned
as the number of SD between the negative sample mean and the cut-off,
was determined equal to 21 for the Access HBsAg assay and 5.5 for
AxSYM HBs Ag.
Conclusion: The performance of the Access HBsAg and the Access
HBsAg Conﬁrmatory assays are at least equivalent to that of the AxSYM
HBsAg V2. The Access HBsAg and the Access HBsAg Conﬁrmatory
assays can be used either with the Access Immunoassay System or with
the high-throughput UniCel® DxI 800 Immunoassay System offering
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rapid and accurate results whatever the throughput requirement of the
lab.
§All trademarks are property of their respective owners.
P1179 Speciﬁcity studies of the new Access® HBs Ag and HBs Ag
conﬁrmatory assays from Beckman Coulter
X. Duburcq, A. Pouzet, A. Cle´ment, L. Marant, D. Duhamel, Y. Leirens,
F. Margotteau, R. Falcou-Briatte, F. Bouniort, S. Taskar, O. Flecheux
(Paris, FR; Nyon, CH; Chaska, US)
Background and Objectives: The challenge for a new HBs Ag assay is
to detect genetic variability in the HBs Ag protein (mutation, subtypes,
and genotypes) in order to avoid false negative results. Nevertheless,
assay speciﬁcity remains essential, as false positives lead to erroneous
results and trouble for the patient. A speciﬁcity study was conducted
using blood bank samples, and the potentially interfering reactions were
investigated using the new Access HBs Ag and HBs Ag Conﬁrmatory
assays currently in development. The Access HBsAg and HBsAg
Conﬁrmatory assays are based on paramagnetic particle, solid phase
technology and chemiluminescent-signal detection.
Methods: Internal evaluation of speciﬁcity was performed with 4,343
samples from blood donors collected by blood banks in France. Potential
cross-reactivity was evaluated by testing a panel of 293 samples
from patients with 21 potentially cross-reactive infections and auto-
immune disorders. Samples with high concentrations of human albumin,
haemoglobin, bilirubin, triolein and biotin were also tested. To evaluate
anticoagulant and SST impacts, matched sets of negative samples
containing serum, EDTA K2, EDTA K3, Citrate, Lithium Heparin, ACD
and SST were tested.
Results: The speciﬁcity for blood donor samples was determined at
99.98% [99.87–100%] (CI 95) and the speciﬁc margin, deﬁned as the
number of SD between the negative samples mean and the cut-off
was equal to 22. Among all the samples tested for cross-reactivity,
two (0.68%) gave positive results in the screening assay, but were
not conﬁrmed with the Access HBs Ag Conﬁrmatory assay. Sample
components and different anticoagulants tested had no impact on the
assay speciﬁcity.
Conclusion: The Access HBsAg and the Access HBsAg Conﬁrmatory
assays provide excellent speciﬁcity without cross reactivity with
potentially interfering components. Moreover, the assay showed an
excellent speciﬁc margin that prevents speciﬁcity issue due to negative
sample repartition close to the cut off.
P1180 Sensitivity studies of the new Access® HBs Ag and HBs Ag
conﬁrmatory assays from Beckman Coulter
X. Duburcq, A. Pouzet, L. Marant, A. Cle´ment, D. Duhamel, Y. Leirens,
F. Margotteau, R. Falcou-Briatte, F. Bouniort, S. Taskar, O. Flecheux
(Paris, FR; Nyon, CH; Chaska, US)
Background and Objectives: Accurate detection of hepatitis B surface
antigen (HBsAg) is important to aid in the diagnosis of individuals
infected with hepatitis B virus. An automated assay, for qualitative
detection of HBsAg in human serum and plasma on the family of
Access® immunoassay systems from Beckman Coulter is currently
in development. The new Access HBsAg and HBsAg Conﬁrmatory
assays are based on paramagnetic particle, solid phase technology and
chemiluminescent-signal detection. The purpose of this study was to
evaluate the analytical and the clinical sensitivity of the new assays.
Methods: The analytical sensitivity was determined using different
commercialised panels (French SFTS 2004 panel, PEI Ad panel, PEI
Ay panel, WHO 80/549 standard, WHO 00/588 standard). The clinical
sensitivity was veriﬁed with the low titer panel BBI PHA 106 (containing
15 samples with concentration between 0.05 IU/mL and 0.6 IU/mL), 100
commercial HBsAg positive samples and 30 seroconversion panels.
Results: Analytical sensitivity was estimated to be 0.1 ng/mL (French
SFTS panel), 0.020 PEI Units/mL (ad panel), 0.024 PEI Units/mL (ay
panel), 0.092 IU/mL with WHO 80/549 HBsAg standard and 0.056
IU/mL with WHO 00/588 HBsAg standard. All low titer panel members
up to 0.05 IU/mL were recognized by the Access HBsAg assay and
conﬁrmed by the Access HBs Ag conﬁrmatory assay. Among the 100
isolated positive samples, all were found positive displaying 100%
of sensitivity for the Access HBsAg assay and all were conﬁrmed
by the Access HBsAg Conﬁrmatory assay. The Access HBsAg assay
demonstrated equivalent results compared to the Abbott AxSYM§
HBsAg V2 assay for 18 panels among the 30 tested. For the remaining
panels, the Access assay was more sensitive than 10 out of 12 cases.
Conclusion: The Access HBsAg and HBsAg Conﬁrmatory assays
provide excellent analytical and clinical sensitivity performance and
can be used either with the Access Immunoassay System or with the
high-throughput UniCel® DxI 800 Immunoassay System for rapid and
accurate results in the management of HBV infection.
§All trademarks are property of their respective owners.
P1181 Comparison of real-time PCR with conventional bDNA
based assay for quantiﬁcation of HBV, HCV and HIV-1:
possible clinical implications
A. Amendola, M. Solmone, A. Garbuglia, C. Angeletti, N. Lauria,
M. Capobianchi (Rome, IT)
Objectives: We compared two commercial assays [Versant 3.0, System
340 (Bayer Diagnostics), based on branched DNA technology, and
COBAS Ampliprep TaqMan, CAP-TCM (Roche Diagnostics), based on
real-time PCR] in measuring HBV, HCV and HIV viraemia.
Methods: 150 consecutive serum samples from patients with chronic
hepatitis B (divided in HBeAg-positive or Anti-HBeAb-positive), 92
clinical samples from patients eligible to HCV therapy and 46
clinical samples from HIV-seropositive individuals have been analysed.
Moreover, commercially available standard panels of HBV, HCV and
HIV-1 were used to compare the linearity of two assays.
Results: In the overlapping range, an elevated degree of correlation
between the tests was measured for all viruses concentrations:
• HBV: r = 0.9389, p< 0.001;
• all HCV genotypes: r = 0.7702, p< 0.001. HCV genotypes 1−4:
r = 0.721, p< 0.001; r = 0.753, p< 0.001; r = 0.0.873, p< 0.001; and
r = 0.783, p< 0.001, respectively;
• HIV-1: r = 0.9885, p< 0.0001.
The analysis of mean values indicated that HBV DNA values obtained
with bDNA-based assay were higher than those obtained with TaqMan.
On the contrary, HCV and HIV-1 viral load values obtained in
CAP/CTM were generally higher than those obtained in bDNA.
Comparisons conducted according to Bland and Altman method showed
that differences of measurement occurred at higher magnitude of viral
load. Moreover, for all viruses analysed, a considerable proportion of
clinical samples gave results discordant by more than 0.5 or even 1 log
that seemed not genotype-dependent.
Conclusion: These results suggest that quantitative results obtained by
different assays may not be interchangeable, even though expressed
in the same (international) units. In general, CAP/CTM shows higher
sensitivity and broad linear range, but at high magnitudo of viral load
HBV-DNA was under estimated while HCV and HIV-1 were over
estimated.
Therefore, it is recommendable that the same quantitative assay be used
longitudinally in monitoring therapeutic response of individual patients.
Longitudinal studies are necessary to evaluate the impact of the higher
viral load results obtained in the real time PCR-based tests in clinical
decision-making.
P1182 Differences of immunoreactivity of selected antigenic epitope
of tick-borne encephalitis virus envelope protein gE modelled
by different variants of recombinant fusion proteins
A. Obriadina, N. Saveleva, Y. Zagryadskaya, N. Oreshko, V. Pimenov,
V. Puzyrev, A. Burkov, T. Ulanova (Nizhny Novgorod, RU)
Objectives: Tick-borne encephalitis virus (TBEV) is a human
pathogenic member of the genus Flavivirus. TBE virus cause severe
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encephalitis with serious sequelae. Envelope protein (E) of the
ﬂaviviruses is a major target of neutralising antibodies and used as a
diagnostic reagent for ELISA-format tests. The aim of present study
was to evaluate the effect of different N-end tags on immunoreactivity
of antigenic epitope(s) of gE protein modeled by recombinant fusion
proteins.
Methods: Artiﬁcial gene encoded 296−414 aa region of gE TBEV
have been synthesized from oligonucleotides by using PCR reaction.
Recombinant antigen was expressed in E. coli cells as a fusion protein
with four different N-end tags variants: 6-histidines (6His), glutathione-
S-transferase (GST), GST and 6-histidines (GST+6His) and maltose
binding protein (MBP). Recombinant fusion proteins were puriﬁed
by afﬁnity chromatography and tested in enzyme immunoassay with
previously well deﬁned 36 anti-TBEV positive and 56 anti-TBEV
negative serum samples.
Results: Different levels of the protein expression, solubility and
immunoreactivity was observed for all four recombinant constructions.
GST-N-tagged protein was the most immunoreactive: it has detected
IgG anti-TBEV in 97.2% positive serum samples and did not react
with any anti-TBEV negative sera. Average signal to cut off (S/C) level
with positive samples was equal toa 5.4. Fusion proteins with MBP and
6His also had high enough level of immunoreactivity. IgG anti-TBEV
activity was detected in 86.1% and 72.2% of positive sera samples,
and average S/C level with positive samples was somewhat higher –
6.3 and 6.1, respectively. But the speciﬁcities of these fusion variants
were only 96.4% for MBP fusion antigen and 98.2% for 6His fusion
protein. The GST+6His N-end tagged antigen demonstrated lower level
of immunoreactivity. IgG anti-TBEV activity has been detected only in
5.6% of positive sera samples. Average S/C level with positive samples
also was lowest − 2.3.
Conclusions: The achieved results suggest that selection of protein
expression system, location and characteristics of fusion tag plays
important role in successful modeling of antigenic epitopes by
recombinant proteins. Fusion of recombinant antigen comprising TBEV
gE regions at 296−414 aa position with glutathione-S-transferase at the
N-end demonstrated signiﬁcant diagnostic potential for the development
of anti-TBEV ELISA diagnostic assays.
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P1183 Initial hospital management at emergency departments of
community-acquired pneumonia in Spain
V. Alvarez-Rodriguez, D. Martinez, M.J. Gimenez, J. Barberan,
L. Aguilar, M.J. Ruiz-Polaina, J. Prieto (Madrid, ES)
Objectives: To study the initial management of patients with
community-acquired pneumonia (CAP) admitted to hospital through
Emergency departments.
Methods: Clinical records of patients with  14 years of age and
CAP diagnosis admitted to hospital through Emergency departments in
a three-month period (January–March 2003) in 24 Spanish hospitals
were retrospectively reviewed in order to obtain demographic data,
clinical and analytical data necessary to classify them according
to the Pneumonia Severity Index (PSI) category, comorbidity data,
microbiological diagnostic tests performed, initial antibiotic treatment
and outcome. Patients sent for treatment on an ambulatory basis were
excluded from the study.
Results: 341 patients (67.0 ± 24.6 years; 65.3% males) were admitted
to hospital trough the Emergency department: 24.0% were managed
at Short Stay Medical Units (SSMU), 36.4% at Internal Medicine,
30.2% at Pneumology, 1.7% at Intensive Care Units (ICU), 2.1% at
Infectious Diseases and 5.6% were derived to a different hospital.
Patients in high-risk classes (IV-V) were 65.7%, 14.7% were class III
and 19.6% were classes I-II. Blood culture was performed in 50.1%
patients (41% patients class I-III, 53.8% patients class IV, and 56.2%
patients class V), while sputum culture was performed in 35.8% patients
(39.3% patients class I-III, 36.1% patients class IV, and 31.4% patients
class V). Pneumococcal or Legionella urinary antigen detection was
performed in 34% and 42.2%, respectively. Most frequent comorbidities
were: chronic obstructive airway disease (37.2% patients), heart disease
(24.6%), hypertension (17%), diabetes (10.8%), and malignancies (10%).
Initial treatment was ﬂuoroquinolone in 37.5% patients, 3rd generation
cephalosporin + macrolide in 19.4%, amoxicillin/clavulanic acid in
17.9%, amoxicillin/clavulanic acid + macrolide in 7.0%, 3rd generation
cephalosporin in 5.0%, macrolides in 4.7%, and others in 8.5%. Eleven
patients died (3.2%), 100% of them within the high-risk class IV-V.
Conclusions: Microbiological diagnostic tests may be scarcely used. As
severity increased, request of blood culture increased but of sputum cul-
ture decreased. Most frequent treatments applied were ﬂuoroquinolones
as monotherapy followed by 3rd generation cephalosporin + macrolide
or amoxicillin/clavulanic acid. These empirical treatments may reﬂect
resistance rates in Streptococcus pneumoniae in Spain, and/or coverage
of both typical and atypical aetiologies.
P1184 Comparison of ﬁrst with second-line antibiotics for
acute bacterial exacerbations of chronic bronchitis: a
meta-analysis of randomised controlled trials
G. Dimopoulos, I.I. Siempos, I.P. Korbila, K.G. Manta, M.E. Falagas
(Athens, GR)
Background: Although acute bacterial exacerbations of chronic
bronchitis (ABECB) are common, there has been no meta-analysis that
focused on the optimum regimen.
Methods: To evaluate the comparative effectiveness and safety of the
ﬁrst- and second-line antimicrobial agents for the treatment of patients
with acute bacterial exacerbation of chronic bronchitis (ABECB), in
an era of increasing antimicrobial resistance among the responsible
microbes for ABECB, we performed a meta-analysis of randomised
controlled trials (RCTs) retrieved through searches of the PubMed and
the Cochrane databases.
Results: Twelve RCTs, enrolling 2,261 patients, were included in the
analysis. First-line antibiotics were associated with lower treatment
success compared to second-line ones in the clinically evaluable patients
[odds ratio (OR) = 0.51, 95% conﬁdence intervals (CI): 0.34–0.75].
There was no difference between the compared regimens regarding
mortality (OR= 0.64, 95%CI: 0.25–1.66) or treatment success in
microbiologically evaluable patients (OR= 0.56, 95%CI: 0.22–1.43) or
adverse effects in general (OR= 0.75, 95%CI: 0.39–1.45) or diarrhoea in
particular (OR= 1.58, 95%CI: 0.74–3.35). Treatment success was lower
in penicillin- than in macrolide-recipients (CE: OR= 0.36, 95%CI: 0.17–
0.75). On the contrary, in the subgroup analysis of RCTs that enrolled
mainly hospitalised patients, less drug-related adverse effects were
attributed to ﬁrst- than to second-line antibiotics (OR= 0.34, 95%CI:
0.23–0.51). Second-line antibiotics are more effective, but less safe in
the subset of hospitalised patients, than ﬁrst-line ones when administered
in patients with ABECB.
Conclusions: Compared to ﬁrst-line antibiotics, second-line antibiotics
are more effective but less safe in the subset of hospitalised patients,
when administered in patients with ABECB. Although, the implications
of our ﬁndings seem to contradict with the attempt to preserve
new antibiotics and prevent induction of antimicrobial resistance,
treatment directed toward resistant pathogens with inadequately effective
antimicrobials and unnecessary administration of antibiotics in patients
with mild ABECB are more important problems regarding this issue.
P1185 Community-acquired pneumonia: doctors do not follow
guidelines
M.B.J. Beadsworth, P. Collini, P. Deegan, T. Neal, P. Burnham,
J. Anson, N.J. Beeching, A.R.O. Miller (Liverpool, UK)
Objectives: Appropriate assessment of CAP allows accurate severity
scoring and hence optimal management, leading to reduced morbidity
and mortality. British Thoracic Society (BTS) guidelines provide an
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appropriate score. We assessed adherence to BTS guidelines in our
medical assessment unit (MAU) in 2001/2. We re-assessed adherence
in 2005/6, 3 years after introducing an educational programme.
Methods: A retrospective casenote study comparing diagnosis, manage-
ment and outcome of CAP during admission to MAU during 3 months
of winter in 2001/2 and 2005/6. (BTS, CURB-65, scoring was used for
2005/6)
Results: Over 3 months in 2001/2, of 165 patients coded as CAP, 65
were wrongly coded and 100 included in the study. In 2005/6 this had not
signiﬁcantly changed. 130 were coded as CAP, of these 43 were wrongly
coded and 87 enrolled. In 2001/2, 48% did not receive a severity score,
in 2005/6 this had signiﬁcantly increased to 87%. (p< 0.0001)
Parenteral antibiotics were used in 79% in 2001/2 and 77% in 2005/6.
3rd generation cephlosporins were used in 63% in 2001/2 and 54% in
2005/6.
In 2001, 15 different antibiotic regimes were prescribed, in 2005/6 this
had increased to 19.
Conclusions: Coding remains poor. Adherence to CAP management
guidelines was poor and has signiﬁcantly worsened. Educational
programmes, alone, do not improve adherence. Restriction of antibiotic
prescribing should be considered.
P1186 Implementation of national guidelines for good antibiotic
policy of respiratory tract infection in hospitalised children
with community-acquired pneumonia
V. Maresova, Z. Blechova, M. Podojilova´, B. Horova´, K. Soltysova
(Prague, CZ)
Objectives: The consumption of antibiotic (AB) increased in the Czech
Republic in 1993 signiﬁcantly and increased the resistance of pathogens
too. Members of the Czech Medical Association prepared guidelines
for treatment of community-acquired respiratory infections. The aim of
our study was to evaluate the implementation of these guidelines in
hospitalised children with community-acquired pneumonia (CAP).
Methods: 241 children (mean age 6.6 years) were hospitalised in
Bulovka University Hospital (1997–2006) with diagnosis CAP. We
investigated from this group two subgroups: ﬁrst consists of children
admitted before publication of the guidelines in 1997 and the second
consists of children hospitalised in 2005–2006. We evaluated both the
initial antibiotic therapy administered in accordance with the guidelines.
Results: The 1st group were evaluated 33 children (9 m and 24 f); in the
2nd second sub-group were 36 children (22 m and 14 f). All children
were treated with antibiotics. In none patient was taken haemoculture,
and in 6 patients was performed serologic examination: in 3 patients were
positive antibodies against Mycoplasma pneumoniae, in 1case inﬂuenza
virus and in 1child RSV antibodies. Initial therapy with penicillins
antibiotics was used in 14 children, cephalosporins a macrolides in
5 children, 1 child was treated with co-trimoxazol, 8 children were
treated with combination of antibiotics and in 4 cases antibiotic therapy
changer. In the second group was haemoculture performed in 34 and in
3 patients was detected S. pneumoniae, in one case pneumococcal Ag in
urine. S. pneumoniae was good sensitivity to penicillins and macrolides.
Serologic examination was performed in 14 children. In 5 cases was
detected M. pneumoniae, in 2 cases viral infections. Initial therapy with
penicillin antibiotic was used in 18 children, with co-aminopenicillins in
4, macrolides in 6, cephalosporins in 3, in 2 cases doxycycline, 1 patient
had co-trimoxazol. In 6 children was the AB therapy changer during
hospitalisation, in other 6 cases was used combination of AB.
Conclusion: Initial therapy with penicillins used more frequently (22
vs. 14), prescription of macrolides didn’t increase, and the use of
cephalosporins decreased in 2nd group. Signiﬁcantly higher was the
number of aetiologically veriﬁed CAP. Quality of prescription ABs were
better in the 2nd group than the 1st in 1997.
Acknowledgements: This study is supported by grant IGA Ministry of
Health NR/8297−3.
P1187 Physician adherence to pneumonia guidelines regarding
initial regimen choice
T.A. Peppas, P. Matsoukas, H. Vlastari, A. Sotiropoulos, I.D. Binikos,
B.D. Kandyla, I. Tamvakos, S.I. Pappas (Piraeus, GR)
Objective: To assess physicians adherence on pneumonia guidelines (G)
regarding the initial regimen chosen.
Methods: All pneumonia admissions were prospectively entered in
database and all regimens chosen by the attending physicians were
compared to the G available and taught to them by admission date,
namely IDSA 2003, BTS 2004, Hellenic IDS 2005 and ERS 2005, as
well as AJRCCM 2005; 388 for nosocomial and healthcare-associated
pneumonia Outcome and hospital stay (HS) was compared for patients
with regimen G concordant (GCR) and non-concordant (GNCR). SPSS
programme, time: October 2004 to September 2006
Results: A total of 72 patients (M: 44, F: 28) mean age 72.1 yrs were
included. Hospital or nursing home pneumonia consisted 14 of them and
previous antimicrobial usage was recorded in 32 (44%) Concordance to
any G was noted in 47 (65.3%) and the respective percentages were IDSA
G: 65%, BTS G: 64% ERS G: 62% and Hellenic IDS: 46%. Main reason
for low concordance to Hellenic G was choice of respiratory quinolone,
without prior antimicrobial use. Hospital stay was higher for GNCR
(10.2 v 8.4, NS) but mortality was higher (28% v 7% of GCR, p = 0.03,
Yates corrected chi-square).
Conclusions: Physicians choice of regimen in pneumonia was con-
cordant to existing G at 65% of cases. There was higher mortality
among patients with non concordant regimen, and though confounding
factors (mainly severity index) can easily bias a small sample size, this
fact underlines guidelines utility and value, warranting a more strict
adherence
P1188 The hospital admission decision for patients with
community-acquired pneumonia; factors in low-risk PORT-
score categories associated with hospitalisation: would low
risk for death have applied in case of outpatients care?
S. Soto, E. Garcı´a-Va´zquez, J. Go´mez, J.A. Herrero, V. Ban˜os, J. Ruiz,
T. Herna´ndez, M. Valde´s (Murcia, ES)
Objectives: Pneumonia Patient Outcomes Research Team (PORT) has
developed a prediction rule to identify patients with Community-
acquired pneumonia (CAP) who are at risk for death and other adverse
outcomes. The authors recommend outpatient management for Fine
categories I and II and parenteral antimicrobial therapy at home or a short
stay (<24 hours) in a hospital observation unit for group III. However,
many of these patients are hospitalised.
Patients and Methods: Observational study of patients with CAP (class
I, II and III according to PORT-score) admitted at a tertiary general
hospital. Data collection from clinical records has been done according to
a standard protocol study of CAP. We analysed epidemiological, clinical,
radiological and laboratory data and outcome of low-risk hospitalised
patients.
Results: ninety nine (46.9%) out of 211 patients with CAP were
classiﬁed in Fine categories I, II and III (26, 33 and 40 respectively); 99
(100%) were hospitalised in general medical wards. Mean age was 50
years (range, 13 to 85 years); <65 years in 72%, 65−75 years in 19% and
>75 years in 8%. A coexisting condition was present in 32% patients
(congestive heart failure 15%; chronic lung disease 14%). More frequent
physical-examination ﬁndings were systolic blood pressure <90mmgHg
(8%), pulse >125/min (7%) and respiratory rate >30/min (6%). More
prevalent laboratory and radiologic ﬁndings were partial pressure of
arterial oxygen <60mmHg (26%), pleural effusion (9%) and glucose
>250mg/dl (8%). Only 1 patient (1%) in group III died. Mean hospital
stay was 6 days (range, 1−24 days).
Conclusions: In our series, CAP patients in PORT-Score categories
I, II and IIII who were admitted to the hospital represent a very
high rate (46.9%) of all CAP admissions. Our ﬁndings suggest that
additional consideration is provided by physicians to the presence of
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coexisting conditions some of which are not considered in the PORT-
score (chronic lung disease and diabetes) and certain ﬁndings in physical-
examination (homodynamic instability and high respiratory rate) and
laboratory/radiology studies (hyperglycaemia, hypoxaemia and pleural
effusion). Mortality rate was very low (1%). Whether this low risk for
death would have applied in case of outpatients care is a question that
remains to be answered.
P1189 Simpler criteria to assess mortality in patients with
community-acquired pneumonia
S. Soto, E. Garcı´a-Va´zquez, J. Go´mez, J. Herrero, V. Ban˜os, J. Ruiz,
T. Herna´ndez, M. Valde´s (Murcia, ES)
Objectives: Pneumonia Patient Outcomes Research Team (PORT) has
developed a prediction rule to identify patients with Community-
acquired pneumonia (CAP) who are at risk for death and other adverse
outcomes. This score considers too many variables. Simpler criteria are
needed to evaluate the risk of mortality in patients with CAP.
Patients and Methods: Observational study of patients with CAP
admitted at a tertiary general hospital. Data collection from clinical
records has been done according to a standard protocol study of CAP.
We analysed epidemiological, clinical, radiological and laboratory data
associated with mortality.
Results: two hundred and eleven (n = 211) patients with CAP were
evaluated; severity distribution according to PORT score was 12.3% in
group I, 15.6% in group II, 19% in group III, 35.5% in group IV and
17.5% in group V. Mean age was 63 years (range, 13 to 100 years);
<65 years, 43.6%; 65−75 years, 25.6% and >75 years, 30.8%. One or
two coexisting conditions were present in 54.5% patients and more than
2 in 7% (congestive heart failure 33.6%; chronic lung disease 29.9%).
Mortality rate was 0% in groups I-II, 2.5% in group III, 5.3% in group IV
and 27% in group V. All variables considered in PORT-score were
included in a mortality predicting model; factors signiﬁcantly associated
with death were altered mental status, respiratory rate >30/min, arterial
pH <7.35, glucose >250mg/dl, and age >75 years; 99% of patients with
CAP who did not present any of these abnormalities died.
Conclusions: In our series, simpler criteria to assess mortality in patients
with Community-acquired pneumonia were identiﬁed. The non-existence
of altered mental status, respiratory rate >30/min, arterial pH <7.35,
glucose >250mg/dl, and age >75 years predicted a non-fatal outcome
in 99% of patients. Presence of these clinical or laboratory ﬁndings
should be considered as mortality predictors and can be used as a
severity adjustment measure and therefore may help physicians make
more rational decisions about hospitalisation for patients with CAP.
P1190 Pre-admission use of statins and mortality within 90 days
after hospitalisation with pneumonia: population-based
cohort study of 29,900 adult patients
R.W. Thomsen, A. Riis, J.B. Kornum, S. Christensen, S.P. Johnsen,
H.T. Sørensen (Aarhus, DK)
Objectives: Statins may improve outcomes of severe infections due to
antithrombotic, anti-inﬂammatory, and immuno-modulatory effects. We
examined preadmission use of statins as a predictor of 30-day and 90-day
mortality among adult Danish patients hospitalised with pneumonia.
Methods: All patients recorded with a ﬁrst-time discharge diagnosis of
pneumonia between 1997 and 2004 were included in this population-
based cohort study in two Danish counties (population, 1.15 million).
Information on statin use, comorbidities, laboratory ﬁndings, occurrence
of bacteraemia and death was obtained from medical and administrative
databases. We computed mortality rate ratios in preadmission statin users
vs. non-users, adjusted for potential confounders in a regression analysis.
Results: A total of 29,900 adult patients were hospitalised with
pneumonia (median age 73 years); of these, 1,516 patients (5.1%) were
preadmission statin users. Laboratory ﬁndings on admission were similar
among users and non-users of statins. Among patients who were blood
cultured (64% of statin-users and 60% of non-users), the adjusted RR for
bacteraemia in statin-users vs. non-users was 0.99 (95%CI: 0.66–1.50).
Overall mortality in statin-users vs. non-users was 10.8% vs. 15.7% after
30 days and 17.0% vs. 22.4% after 90 days, corresponding to adjusted
30- and 90-day mortality rate ratios of 0.65 (95%CI: 0.56–0.76) and
0.69 (95%CI: 0.61–0.79).
Conclusion: Preadmission use of statins was associated with a sub-
stantially decreased mortality following hospitalisation with pneumonia.
Randomised trials are needed to determine if this association is causal
or caused by uncontrolled confounding.
P1191 Association of proinﬂammatory cytokines with ﬁbrinolytic
enzymes and biochemical parameters in childhood
infectious parapneumonic effusions
C.Y. Chiu, J.L. Huang, K.S. Wong, M.H. Tsai, T.Y. Lin (Keelung,
Taoyuan, TW)
Objectives: To evaluate the relationship of proinﬂammatory cytokines
(tumour necrosis factor-a (TNF-a), interleukin-1b (IL-1b) and IL-6)
with intrapleural ﬁbrinolytic enzymes [tissue-type plasminogen activator
(tPA) and plasminogen activator inhibitor type 1 (PAI-1)] and common
biochemical parameters (pH, glucose, LDH), and to compare various
pleural variables for predicting the need of subsequent aggressive
interventions.
Methods: A total of ﬁfty-seven patients were enrolled in the present
study. Chest ultrasound was performed and results were stratiﬁed
into anechoic ﬂuid (stage 1, n = 28), with ﬂoating ﬁbrin strands
(stage 2, n = 16) and with septated ﬁbrin (stage 3, n = 13). The
correlation of various pleural variables with the formation of complicated
parapneumonic effusions (CPE) was performed and factors for predicting
the need of intervention procedures were also analysed.
Results: Univariate analysis revealed that pH, glucose and LDH in
biochemical parameters, proinﬂammatory cytokines (TNF-a, IL-1b,
IL-6), and ﬁbrinolytic enzymes (tPA, PAI-1) were signiﬁcantly different
between these three stages. Additionally, the trends of these variables
were all signiﬁcantly associated with the ordered stages of parapneu-
monic effusions (Ptrend <0.05). Proinﬂammatory cytokines of TNF-a,
IL-1b and IL-6 were all signiﬁcantly correlated with PAI-1 in non-CPE
and CPE. However, only TNF-a and IL-1b were signiﬁcantly correlated
with tPA in non-CPE. The pleural variables of pH, IL-1b and PAI-1
were the most signiﬁcant factors for predicting the need of intervention
procedures (P< 0.05).
Conclusion: The increased release of proinﬂammatory cytokines, such
as TNF-a, IL-1b, and IL-6 in pleural ﬂuid caused by bacteria may result
in an imbalance of tPA and PAI-1, which may subsequently lead to ﬁbrin
deposition and the development of empyema. In addition to pleural ﬂuid
pH, IL-1b and PAI-1 in pleural ﬂuid may be used as alternative markers
for predicting the need of subsequent aggressive interventions.
P1192 Systemic TNF-a production and severity of disease in
severe pneumococcal pneumonia
E. Calbo, M. Alsina, M. Rodrı´guez-Carballeira, M. Xercavins, E. Cuchi,
J. Garau and The Spanish Pneumococcal Infection Study Network
Introduction: Tumour necrosis factor alpha (TNF-a) is one of the
earliest mediators of the inﬂammatory response. It induces a second
wave of pro and anti-inﬂammatory cytokines which are mediators of
the inﬂammatory process. The aim of our study was to analyse the
correlation between TNF-a and other cytokines plasma concentrations,
clinical variables and severity of disease in patients with pneumococcal
pneumonia (SPP) at hospital admission.
Material and Methods: Consecutive adults with pneumonia classes
III-V of the Pneumonia Severity Index (PSI) developed by the Pneu-
monia Outcome Research Team and with a conﬁrmed pneumococcal
aetiology were included. At admission, demographic characteristics,
smoking and alcohol habits, co morbidities (Charlson score), prognosis
measured by PSI and APACHE II scores, immunosuppressive conditions,
previous or current therapy with statins, use of non steroidal or steroidal
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anti-inﬂammatory drugs, and time between pneumonia onset and hospital
admission were prospectively recorded.
Vital signs, haematological and biochemical parameters were also
assessed. Circulating levels of CRP, serum amyloid A (SAA), C3a, C5a
and cytokines TNF-a, IL-1b, IL-6, IL-8, IL-10, IL-1ra were measured.
Comparisons were done among patients with TNF-a above and below
the median values.
Results: 28 patients with SPP were included; 14 had TNF-a concentra-
tions <20.8 pg/mL and the other half had TNF-a concentrations above
this ﬁgure. Both groups were homogeneous in terms of of demographics,
clinical characteristics, presence of comorbidities, previous use of
statins, severity of disease at presentation, radiological involvement
and time between pneumonia onset and admission. The group with
higher concentrations of TNF-a presented more frequently bacteraemia
(64.3% vs 21.4%; p = 0.027), higher axillary temperature (38.4[SD0.4] vs
37.7[SD0.8]; p = 0.046) and higher concentrations of IL-1 (7.8[SD8.5] vs
2.2[SD3]; p = 0.034), IL-6 (4,952[SD6,498] vs 871[SD1,453]; p = 0.037),
and IL-1ra (11,029[SD7,669) vs 5,327[SD616]; p = 0.044).
Conclusions: In pneumococcal pneumonia, higher TNF-a levels were
associated with the degree of fever and the frequency of bacteraemia;
IL-1, IL-6 and IL-1ra increased in parallel with TNF-a levels. No
correlation could be established between TNF-a and severity of disease.
P1193 Systemic inﬂammatory response and time from onset to
hospital admission in severe pneumococcal pneumonia
E. Calbo, M. Alsina, M. Ro´driguez-Carballeira, E. Cuchi, M. Xercavins,
J. Garau and the Spanish Pneumococcal Infection Study Network
Introduction: The inﬂammatory response triggered by the presence of
invading bacteria is a dynamic process changing over time, and many
factors can inﬂuence the magnitude of this response. The aim of our
study was to analyse the impact of time from onset of symptoms to
hospital admission on the systemic plasmatic cytokine concentrations in
patients with severe pneumococcal pneumonia (SPP).
Material and Methods: Consecutive adults with pneumonia classes
III−V of the Pneumonia Severity Index (PSI) developed by the Pneu-
monia Outcome Research Team and with a conﬁrmed pneumococcal
aetiology were included. At admission, demographics, smoking and
alcohol habits, comorbidities (Charlson score), immunosuppressive
conditions, previous or current therapy with statins, use of non-steroidal
or steroidal anti-inﬂammatory drugs, and prognosis measured by PSI and
APACHE II scores were prospectively recorded. Special attention was
paid to record time between pneumonia onset and hospital admission,
collection of initial blood samples and the initiation of antimicrobial
therapy. Vital signs, haematological and biochemical parameters were
also assessed. Circulating levels of CRP, serum amyloid A (SAA), C3a,
C5a and cytokines TNF-a, IL-1b, IL-6, IL-8, IL-10, and IL-1ra were
measured at inclusion.
Results: 32 patients with SPP were included; 13 patients were seen
and included within the ﬁrst 48 h and the other 19 patients after 48 h
from onset of symptoms. Both groups were homogeneous in terms
of demographics, clinical characteristics, presence of comorbidities,
bacteraemia, previous use of statins, severity of disease at presentation
and radiological involvement. The group with a longer time of
evolution at entry presented higher plasmatic levels of TNF-a
(19.1[SD8.5] vs. 35.5[SD26] pg/mL; p = 0.035), ﬁbrinogen (6[SD1.8] vs.
9[SD2]; p = 0.001); CRP (130[SD85] vs. 327[SD131]; p = 0.000),
SAA (678[SD509] vs. 678[SD391]; p = 0.025) and lower albumin
concentrations (40[SD5] vs. 35[SD4]; p = 0.043).
Conclusions: In pneumococcal pneumonia, the sustained release over
time of pneumococcal antigens strongly correlates with a higher pro-
inﬂammatory pattern and a higher expression of acute phase protein
synthesis.
P1194 C-reactive protein in community-acquired pneumonia
among adults in India: association with aetiology, severity,
treatment and outcome
A. Manoharan, A. Kumar, M.K. Laliltha, D. Mathai (Vellore, IN)
Objectives: To study the utility of serum C-reactive protein (CRP) as a
marker for aetiology, management and prognosis of CAP.
Methods: Adult patients (n = 104) with a diagnosis of acute community-
acquired pneumonia (CAP) by clinical (<2 weeks history of cough with
fever and any two respiratory signs), radiological (new inﬁltrate) and
microbiological (sputum/blood or pleural ﬂuid culture) methods at a
tertiary care hospital in South India during the period January 2002–
December 2004. Patients outcome research team (PORT) score was used
to assess the severity of CAP on admission. Acute and convalescent sera
were evaluated for IgM and IgG response to Chlamydophila pneumoniae
(Thermolab system, Finland),Mycoplasma pneumoniae (IBL, Germany).
Presence of IgM or four fold rise in titre in IgG antibody levels between
acute and convalescent sera was considered to be positive for these
atypical pathogens. Detection of Legionella pneumophila antigen in
acute phase urine samples done by a immunochromatographic method
(Binax, Scarborough, USA). CRP was measured by QuikRead CRP
(Orion Diagnostica, Finland) method in acute phase serum samples
available from 64 patients.
Results: In 64 patients in whom CRP levels were determined, mean
age was 57.6 years (SD-15.9years), with 66% being males. According
to receiver operator curve (ROC), a cut-off point of 40mg/L appeared
to be the best CRP value for deﬁnitive diagnosis of bacterial aetiology
of CAP. Fifty patients had CRP 40mg/L (Group A) while 14 had had
CRP< 40mg/L (Group B). Mean days of hospitalisation was similar in
both these groups. Two patients in group A were blood culture positive
for Streptococcus pneumoniae (mean CRP 49mg/L) while two grew
this pathogen in pleural ﬂuid (CRP> 180mg/L). In group A, 32% and
20% were positive for C. pneumoniae and M. pneumoniae while in
group B it was 27% and 7%. None in both groups were positive for
L. pneumophila. No signiﬁcant difference in mean duration of antibiotic
therapy and correlation to severity of pneumonia existed between both
the groups to their CRP levels. Mortality in group A was 24% (n = 12;
meanCRP-138mg/L; p = 0.042), while none died in group B.
Conclusion: High CRP levels are associated with bacterial aetiology
of CAP. Signiﬁcant association exists between high CRP levels and
mortality. CRP could be used as a surrogate marker for the management
of patients with CAP
P1195 Low functional levels of mannose-binding lectin despite
normal genotypes in Legionella pneumophila pneumonia
B.L. Herpers, E.P.F. IJzerman, B.A.W. de Jong, J.P. Bruin, S. Kuipers,
K.D. Lettinga, E.J. van Hannen, G.T. Rijkers, H. van Velzen-Blad,
B.M. de Jongh (Nieuwegein, Haarlem, Apeldoorn, Amsterdam, NL)
Objectives: Deﬁciency of mannose-binding lectin (MBL) has been
associated with an increased risk of infection, compatible with its role
as a pivotal protein in early complement activation. In infections with
intracellular pathogens this association is more ambiguous, as some
pathogens use MBL to enter their host cell. To study this relation
with Legionella pneumophila, we determined MBL levels and genotypes
in a well-described outbreak of legionellosis at a ﬂower show in the
Netherlands. Since this clonal outbreak has no pathogen variability, this
patient cohort is very suitable to study genetic host factors.
Methods: In a retrospective patient-control study MBL levels were
determined in a haemolytic assay in acute phase serum samples from
122 patients, 59 asymptomatic seroconversion controls and 447 blood
bank donors. Serum levels were classiﬁed as deﬁcient (<0.2 ug/mL) or
normal (>0.2). If multiple serum samples were available from a subject,
the highest measurement was used for classiﬁcation.
Genotyping of MBL was performed with denaturing gradient gel elec-
trophoresis (DGGE) of an amplicon harbouring the three polymorphic
sites in exon 1 (“0” vs wildtype “A” allele) and a SNP-PCR determining
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the promotor X/Y polymorphism. Genotypes were classiﬁed as deﬁcient
(0/0, XA/0) or sufﬁcient (YA/0, A/A). Whole blood DNA isolates were
available from 77 patients, 53 seroconversion controls and 223 healthy
adults. Two different nested PCR-DGGE protocols were performed on
serum DNA isolates from 112 patients. Serum genotyping results were
only considered in analysis when both protocols had corresponding
results (72 patients). No discrepancies were found between serum and
whole blood genotyping of exon 1 (38 patients). In this way 111 patients
could be genotyped reliably.
Results: Compared to 30% of patients only 2% of seroconversion
controls and 3% of blood bank donors had MBL levels less than
0.2 ug/mL (X2 p< 0.01). Deﬁcient genotypes were found in only 14% of
patients compared to 7% and 17% of both control groups (X2 p> .05).
Signiﬁcantly more patients than seroconversion controls with sufﬁcient
genotypes had MBL levels below 0.2 ug/mL (20% vs 0%, X2 p< 0.01).
Conclusion: Patients had signiﬁcantly lower MBL levels at the acute
phase of legionellosis than both control groups. This difference was not
found in genotypes. This discrepancy suggest either an exhaustion of
MBL or an inability to produce MBL in legionellosis, even in patients
with sufﬁcient genotypes.
P1196 Mycoplasma pneumoniae infection – 63 case studies
A. Topan, M. Lupse, V. Zanc, D. Tatulescu, M. Flonta (Cluj-Napoca, RO)
Objective: To evaluate the clinical and laboratory ﬁndings in
Mycoplasma pneumoniae infection.
Methods: A retrospective study was performed upon 63 cases
hospitalised in the university hospital of infectious diseases from
February 2005 to October 2006. The clinical diagnosis was conﬁrmed
by a positive enzyme-linked immunosorbent assay (ELISA) test for IgM
antibodies.
Results: An almost equal gender distribution was found, 55.55%
female (n = 35) and the median age was 25 within the range 1.3−63
years (18 children, 45 adults). The highest proportion of patients was
found between ages 25 and 44 years (36.55%). At the onset of the
disease the most frequent signs and symptoms were: fever in 53 cases
(84.12%), cough in 38 cases (60.31%), headache 18 cases (28.57%),
myalgias in 10 cases (15.87%), nonspeciﬁc arthralgias in 5 cases
(7.93%). The pulmonary auscultation was normal in 28 cases (44.44%).
Abnormal ﬁndings on chest X–ray examination were depicted in 42 cases
(66.66%). Laboratory ﬁndings indicated the presence of leukocytosis
in 23 cases (36.5%) and elevated erythrocyte sedimentation rate in 51
cases (82.25%). Extrapulmonary complications were found in 23 cases
(36.5%): nervous system involvement was present in 6 cases (9.52%),
skin rashes of different severity were found in 8 cases (12.69%) and
cardiac involvement (pericarditis) was present in one single case (1.58%)
and thrombocytopenia also in one case (1.58%).
Conclusions: Mycoplasma pneumonia infection was frequent in young
adults. The onset with fever and cough, respiratory signs and laboratory
ﬁndings are not speciﬁc for atypical pneumonia. The presence of
extrapulmonary complications for more than one third of patients
suggests the aetiology. The empiric antibiotic treatment with macrolides
is strongly required for young adults with respiratory infections
mainly when they have extrapulmonary manifestation. The aetiological
diagnosis remains a problem in the absence of some quick and cost
affordable methods of detection.
P1197 Microbial pathogens and antibiotic susceptibility in
community-acquired lower respiratory tract infection in
Korea
H-J. Kim, Y-J. Park, K-G. Park, E-J. Oh, M.W. Kang (Seoul, KR)
Introduction: Community acquired lower respiratory tract infection is
recognized as a major cause of morbidity, mortality and antibiotic use in
the community. We investigated major microbial pathogen and antibiotic
susceptibility in community acquired lower respiratory tract infection in
Korea.
Methods: This study was conducted using sputum specimens sent to
community hospitals between December, 2002 and February, 2004. The
sputum specimens were tested for adequacy by Gram staining. Microbial
pathogens were identiﬁed by use of VITEK (bioMe´rieux, France), API
® strips (bioMe´rieux, France) and conventional biochemical tests.
Results: Of the 371 sputum specimens tested, 145 (39.1%) were
inadequate, 226 (60.9%) were adequate. Of the 226 adequate specimens,
107 (47.3%) grew microbial pathogens; Streptococcus pneumoniae
18.7% (n = 20), Klebsiella pneumoniae 13.1% (n = 14), Pseudomonas
aeruginosa 13.1% (n = 14), Haemophilus inﬂuenzae 12.1% (n = 13),
Pseudomonas spp. 12.1% (n = 13), Staphylococcus aureus 12.1%
(n = 13), Moraxella catarrhalis 9.4% (n = 10), Streptococcus spp. 5.6%
(n = 6), and Acinetobacter spp. 3.7% (n = 4). Susceptibility of S. pneu-
moniae to penicillin, erythromycin, trimethoprim-sulfamethoxazole,
cefotaxime and vancomycin was 60%, 30%, 25%, 85%, and 100%,
respectively. K. pneumoniae showed high susceptibility (90–100%)
to most antibiotics. Susceptibility of P. aeruginosa to ceftazidime,
aminoglycoside, ciproﬂoxacin, imipenem, meropenem was as high as
92.9–100%. P. ﬂuorescens/putida was 100% susceptible to cipiroﬂoxacin,
gentamicin, piperacillin, piperacillin/tazobactam and 84.6%, 92.3%,
92.3% susceptibility to imipenem, ceftazidime, sulbactam, respectively,
but showed a low susceptibility of 23.1 and 69.2% to aztreonam
and meropenem, respectively. S. aureus showed low susceptibility
(15.4%) to penicillin, but was 84.6%, 92.3%, 92.3% susceptible
to erythromycin, ciproﬂoxacin, oxacillin, respectively, and 100%
susceptible to clindamycin, teicoplanin, and vancomycin.
Conclusion: In addition to S. pneumoniae, H. inﬂuenzae, and
M. catarrhalis, the traditional common pathogens of community
acquired lower respiratory tract infections, various pathogen such as
K. pneumoniae, P. aeruginosa, S. aureus were detected. Antibiotic
susceptibility of S. pneumoniae to erythromycin (30%), trimethoprim-
sulfamethoxazole (25%) and S. aureus to penicillin (15.4%) was low.
Except for these 3 pathogens, most pathogens showed high antibiotic
susceptibility.
P1198 The aetiological agents in adult patients with community-
acquired lower respiratory tract infections in Turkey
I. Koksal, T. Ozlu, O. Bayraktar Saral, K. Aydin, R. Caylan, F. Oztuna,
Y. Bulbul, G. Yilmaz, N. Sucu and the Pneumonia Study Group, Turkey
Objectives: Lower respiratory-tract infections, community-acquired
pneumonia (CAP) and acute exacerbation of chronic obstructive
pulmonary disease (COPD), is recognized as a major cause of morbidity,
mortality, and antibiotic use in the community. The microbiologic agents
of CAP and COPD vary considerably not only worldwide, but regionally
as well.
In this study, it is aimed to investigate typical and atypical aetiological
agents of community-acquired lower respiratory-tract infections.
Methods: The study which was led by Karadeniz Technical University
was conducted prospectively between November 2003 and March 2005.
Eight universities hospitals from seven different geographical regions of
Turkey participated in this study. Sputum, nasopharyngeal aspirate, blood
and urinary samples were taken from the 218 patients diagnosed lower
respiratory-tract infections clinically and radiologically. The samples
were inspected by culturing, Gram’s stains and immunoﬂuorescence
methods.
Results: Aetiological agents were identiﬁed in the 62.8% of the patients.
While 24.3% of them were typical, 26.6% were atypical and 11.9% mix
agents. Major pathogens identiﬁed in lower respiratory-tract infections
were %23.4 S. pneumoniae, 21.9% M. pneumoniae, and 16% RSV.
37.6% of the cases were in the winter, 30.3% in the spring. 56.9% of the
patients were under age 65. While 29.1% S. pneumoniae, 23.6% RSV
and 14.5% M. pneumoniae were identiﬁed in the patients above age 65,
26.8% M. pneumoniae, 19.5% S. pneumoniae, 10.9% H. inﬂuenzae and
10.9% RSV identiﬁed in those under the age of 65. While the major
pathogens in CAP were 24.4% M. pneumoniae, 20.9% S. pneumoniae
and 10.4% RSV, those in COPD were 27.4% S. pneumoniae, 25.5% RSV,
17.6% M. pneumoniae and 17.6% H. inﬂuenzae.
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Conclusion: When the lower respiratory-tract infection agents were
inspected, S. pneumoniae, M. pneumoniae and RSV were found out
in the ﬁrst three positions. Most of the cases are seen in the winter. CAP
and COPD agents are similar. S. pneumoniae is, by the ratio of 23.4%,
the most frequent agent.
P1199 The microbiological isolates in patients with non-CF
bronchiectasis in stable clinical situation and in disease
exacerbation
P. Kecelj, E. Music, V. Tomic, M. Kosnik, R. Erzen (Golnik, SI)
Background: Isolation of potential pathogenic microorganisms (PPM)
help in decision about ﬁrst line antibiotic therapy in exacerbation of
inﬂammation in bronhiectasis.
Methods and Patients: 68 patient (26 female, average age 68.2 years)
with non CF bronchiectasis were included in two years retrospective
study. Bronchectasis were diagnosed with CT scan. Patients were divided
in group with (high CRP and WBC) and without exacerbation of the
disease. Amount, quality and microbiological isolates of sputum were
analysed in all patients. Antibiotic therapy of patients was recorded from
medical documentation. Lung function was determinated by FEV1 and
DLco.
Results: 35 patients (52%) were in group with no signs of inﬂammation.
Average amount of sputum was 17mL per day and purulence grade 1.0
of 3. Average FEV1 was 64% of normal values. Normal ﬂora in sputum
was found in 11% of patients. PPM were isolated in 48% of patients.
Most frequent isolates were: P. aeruginosa in 11.4%, H. inﬂuenzae in
8.6%, Streptococcus spp. in 8.6%, MSSA in 8.6% of patients. Bacteria:
A. baumannii, B. cepacia, A. xylosoxidans, M. catarrhalis, K. oxytoca
were isolated in single patients. 33 patients (48%) were in group
with exacerbation of disease. Average amount of sputum was 45mL
per day with purulence grade 2.5 of 3. Average FEV1 was 38% of
normal. Normal ﬂora in sputum was found in 24% of patients. Most
frequent isolates were: P. aeruginosa in 30%, H. inﬂuenzae in 6%,
Streptococcus spp. in 3%, MSSA in 15%, MRSA in 6% of patients.
P. aeruginosa together with second bacteria was isolated in 10% of
patients. In one patient H. inﬂuenzae and MSSA was isolated. Bacteria:
A. baumannii, B. cepacia, A. xylosoxidans, M. catarrhalis, K. oxytoca,
E. coli, E. cloacae were isolated in single patients.
Ciproﬂoxacin in combination with cephalosporins of 3th and 4th
generation was therapy for all patients with isolated P. aeruginosa. In
other patients AMC was used in 27%, ciproﬂoxacin in 20% of cases,
others antibiotics were used seldom.
Conclusions: Potential pathogenic microorganisms were present in
sputum in 48% of patients with clinically stable bronchiectasis,
comparing to pathogenic microorganisms in 74% of patients with
exacerbation of bronchiectasis. In exacerbation of the disease the
empirical antibiotic therapy should be selected according to pervious
antibiotic resistance pattern of PPM in patient, until the real pathogenic
microorganisms are isolated.
P1200 An epidemiological analysis of Streptococcus pneumoniae
infection in outpatient acute exacerbations of chronic
bronchitis
P. Weber, A. Anzueto, J. Garau, D. Guillemot, J. Gaillat, S. Sethi
(Vaires-sur-Marne, FR; San Antonio, US; Terrassa, ES; Paris, Annecy,
FR; Buffalo, US)
Objectives: Streptococcus pneumoniae (SP) is a major bacterial cause of
acute exacerbations of chronic bronchitis (AECB). This ad hoc analysis
of a large cohort of AECB patients recruited to an ongoing clinical
trial in a usual-care setting (>1,000 sites/8 countries) was conducted to
determine the association between SP carriage and patient demographics
and AECB symptoms.
Methods: Patients (n = 3,869) enrolled in the trial were 35 years of
age with a history of chronic bronchitis and a clinical diagnosis of
AECB. Bacteriologic testing of sputum samples obtained on Day 1
was conducted centrally. Patients were considered SP-positive (SP+)
whenever SP was isolated, irrespective of the number of colony-forming
units. Statistical comparisons of demographic data and AECB symptoms
(mild/moderate/severe) were made between SP+ and SP-negative (SP−;
including negative sputum cultures) patients using Wilcoxon, Fisher, and
Cochran-Mantel-Haenszel tests.
Results: Overall, 13.88% (537/3,869) of evaluable patients were SP+.
The median patient age was 61.0 years in both SP+ and SP− groups.
More patients in the SP+ group were male (78.8% vs 69.5%; p< 0.0001).
The distribution (%) of non-smokers/ex-smokers/current smokers was
9.7/35.8/54.6 in the SP+ group and 17.2/36.3/46.5 in the SP− group
(p< 0.0001). The median number of packets/year smoked by current/ex-
smokers was higher in the SP+ group than in the SP− group (36 vs
33; p = 0.005). Of the AECB-related symptoms assessed, the severity
of dyspnoea, haemoptysis, cyanosis, and wheezing, rales, and rhonchi
were not signiﬁcantly different between the groups, while cough, sputum
production, and sputum purulence were all more severe in the SP+ group
(p = 0.012, p< 0.0001, and p< 0.0001, respectively). Fever was observed
in a greater proportion of patients in the SP+ group than in the SP− group
(36.8% vs 29.2%; p = 0.0004).
Conclusions: A higher than expected proportion of usual-care AECB
patients may be colonised or infected with SP. SP+ patients are more
likely to be male, current or ex-smokers. SP-related AECB appears to be
more symptomatic than other bacterial AECB, as SP+ patients present
with more severe AECB symptoms, purulent sputum and fever than
SP− patients.
P1201 Quantitative detection of Streptococcus pneumoniae from
sputum samples for diagnosis of community-aquired
pneumonia
N. Johansson, M. Kalin, J. Hedlund (Stockholm, SE)
Objectives: To assess sensitivity of real-time quantitative PCR (RQ-
PCR) applied on induced sputum samples to identify Streptococcus
pneumoniae (SP) aetiology in patients admitted to hospital with
community-acquired pneumonia (CAP).
Methods: During a 12-month period, patients admitted with CAP were
included prospectively. Induced sputum samples were obtained with
assistance from a respiratory physiotherapist and analysed by culture
and RQ-PCR.
Results: In total, 70/184 patients (38%) were diagnosed with SP as aetio-
logic agent. Cultures from blood, sputum, and nasopharyngeal secretions
were positive in 27/179 (15%), 19/128 (15%), and 42/158 (27%) cases.
Positive ﬁndings in urine antigen assays were obtained in 33/169 (20%),
and in sputum analysed by RQ-PCR in 34/127 (27%) cases.
Of these 34 sputum samples positive by RQ-PCR, half (17) were negative
by culture. Most of these patients (14/17) had been started on antibiotic
therapy when the samples were collected.
Conclusion: SP pneumonia may be rapidly diagnosed by analysing
induced sputum samples by RQ-PCR, especially in patients in whom
antibiotic therapy has been initiated.
P1202 Severe invasive Streptococcus pneumoniae infection with
cardiac involvement: report of two household cases
H. Hyvernat, P.M. Roger, T. Fosse (Nice, FR)
Objectives: We report two related cases of adults presenting severe
community-acquired invasive infection with the same strain of Strep-
tococcus pneumoniae and discuss the initial cardiologic presentation
mimicking a myocarditis.
Method: Case report
Results: An 81-year-old man presented at the emergency unit with severe
dyspnea. Ultrasound examination demonstrated systolic dysfunction with
septal hypokinesis and 30% left ventricular ejection fraction. Laboratory
values showed elevated C-reactive protein, myoglobin and BNP but
no troponin elevation. Shortly after admission, the patient presented
cardiac arrest with ineffective resuscitation. His 77-year-old wife was
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admitted on the following day because of a thoracic oppression and
hypoxaemia. The ECG had low voltage in the limb leads and showed
ST-segment elevation in the anterior septal apex. Laboratory data
showed no troponin neither myogobin elevation but high CRP level.
Ultrasound examination show major anterior and inferior left ventricular
dysfunction but coronarography was normal. Subsequently, hyperthermia
and unstable haemodynamic condition appeared. Blood culture allowed
isolation of a S. pneumoniae serotype 9v strain susceptible to penicillin.
The patient had a favourable course with amoxicillin treatment and
mechanical ventilation. Cardiac function was gradually restored and the
ECG reverted to normal. Pneumococcal antigens by agglutination test
was found in the initial patient’s serum which had been kept at 4ºC in
a dry tube and culture of the blood clot led to isolation of an identical
S. pneumoniae (same serotype and identical biochemical phenotype).
Conclusion: These cases are unusual in the severity of initial
presentation mimicking myocarditis and in the particular bacterial
isolation method. Pneumococcal infections are rarely localised to
cardiovascular system. Myocarditis seems to be exceptional. Cardiac
dysfunction in the ﬁrst case evokes myocardial depression of septic shock
and the second case could evoke stress cardiomyopathy (takotsubo).
But the two cases evoke both an alteration of myocardium directly by
S. pneumoniae or indirectly in a toxinic way. The patients we present
were not related genetically, suggesting that virulence is solely dependent
on the bacterial strain. The lack of myocardium biopsy does not allow
us to conclude. Nevertheless, this case report has the interest to describe
potential differential diagnosis of myocarditis for invasive pneumococcal
infection.
P1203 Pneumococcal empyema in Toronto, Canada, 1995–2006
T. Lee, K. Green, A. McGeer, D. Low for the Toronto Invasive
Bacterial Diseases Network
Background: Several recent studies have documented increases in the
rate of pneumococcal empyema (PEMP). We examined trends in the
occurrence of PEMP in Toronto, Canada from 1995 to 2005.
Methods: Population based surveillance for invasive pneumococcal
disease (IPD) in residents of Toronto and Peel region, Ontario, Canada
(population 3.9M) has been on-going since 1995. PEMP includes cases
with a positive pleural ﬂuid culture, and bacteraemic cases with a
clinical diagnosis of empyema. Data are collected from patients and
their physicians. Antibiotic histories are available for patients from 2000
on.
Results: From 1995 to 2005, 4,496 episodes of IPD have been identiﬁed:
114 (2.5%) are PEMP. The incidence of empyema increased from
0.22/100,000/y in 1995−7 to 0.34/100,000/y in 2003−5, while the
incidence of all IPD decreased from 13.5 to 7.9/100,000/y. Patients
with PEMP were not signiﬁcantly different from others with IPD in
age (median 56y vs 50y, P=.14), gender (61% vs 55% male, P=.22),
or proportion that were healthcare acquired (6.0% vs 4.2%, P=.34),
but were somewhat more likely to have a chronic underlying illness
(68% vs 59%, P = 0.05). Isolates from PEMP were more likely to
be of serotype (ST) 1 (5/32 PEMP vs 96/3,902 other, P = 0.001) and
ST12F (6/80 vs. 95/3,854, P = 0.02); they were also more likely to be
resistant to levoﬂoxacin (4/101 vs 29/3,933, P = 0.004) and erythromycin
(17/101 vs 439/3,956, P = 0.08) but not penicillin (5/101 vs. 154/3,956,
P = 0.60). Patients with PEMP were more likely to failing out-patient
antibiotic therapy when admitted with IPD (11EMP of 127 cases failing
antibiotics, vs 52EMP of 1,343 other cases, P = 0.01). Patients who were
failing ﬂuoroquinolone (FQ) outpatient therapy were more likely to have
a diagnosis of empyema than other patients (4/26, 15% vs 65/2,275,
3%, P = 0.008). All 4 EMP patients with FQ resistant isolates were
failing FQ: none of these patients died, compared to 14/58 (24%) other
patients (P=.26). Similarly, 2/3 EMP patients with erythromycin resistant
isolates were failing macrolides (ML); neither of these two patients died,
compared to 14/62 (23%) other patients.
Conclusion: The incidence of PEMP is increasing. Some serotypes are
more likely to cause PEMP than others. Patients with pneumococcal
infection who are failing ML or FQ therapy because their isolate is
resistant are more likely to present with empyema, but less likely to die
than other patients, perhaps because these antibiotics control systemic
but not local disease.
P1204 Community-acquired meningococcal pneumonia and
empyema: case report
A. Kyratsa, I. Graphakos, Z. Salem, A. Zaphiropoulou, S. Tragaras,
T. Tzanakaki, T. Kremastinou, E. Trikka-Graphakos (Athens, GR)
The primary clinical manifestations of meningococcal disease are
meningitis and meningococcaemia. However, less frequent primary
presentations may occur such as arthritis, pericarditis, pneumonia and
empyema. We present a rare case of pneumonia and empyema due to
Neisseria meningitidis, serogroup B.
A diabetic, debilitated 64-year-old man was admitted to the emergency
department because of severe dyspnea and left pleuritic chest pain.
Past medical history included congestive heart failure. On admission
physical examination revealed jaundice, ascites, edema of the lower
limbs and signs of left pleural effusion. Laboratory values included
WBC 19.100/mL (90.6% PMNs), Hb 17.4 g/dL, Ht 52.9% and
PLT 107,000/mL, glucose 296mg/dL, T.Bil 7.4mg/dL, SGOT 87IU/L
SGPT 174IU/L, LDH 591IU/L, Na 126mmol/L, K 5.2mmol/L and
CRP 85mg/L. Chest X-ray revealed bilateral pleural effusion more
prominent at the left side. Thoracocentesis was performed and pleural
ﬂuid cultures were drawn. The pleural ﬂuid was turbid, ph 6.97,
WBC 80.000/mL (93.1%PMNs), glucose 3mg/dL, protein 2.4 g/dL and
LDH 3.640IU/L. Gram stain revealed polymorphonuclear leukocytosis
and Gram(−) diplococci. Latex examination test conﬁrmed the presence
of N. meningitidis antigen in pleural ﬂuid. Lumbar puncture was
performed and blood cultures were drawn simultaneously. Intravenous
antibiotic treatment with ceftriaxone was initiated. On the third day of
hospitalisation pleural ﬂuid culture revealed N. meningitidis. Molecular
typing (multiplex-PCR) and antibiotic succeptibility testing (E-test) was
performed in the Reference Center. The isolate belonged to serogroup B,
serotype 4:P1.14 and was sensitive to all tested antimicrobials. CSF
and blood cultures were negative. Improvement of patient’s clinical
condition and laboratory ﬁndings permitted discharge after 20 days of
hospitalisation.
N. meningitidis should be included in the differential diagnosis of
pneumonia. An accurate and rapid aetiologic diagnosis due to the the
severity of the condition, as well as the risk of spread to healthcare
personell and family contacts, is mandatory.
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P1205 Pneumococcal meningitis is a cause of death in patients
with severe liver cirrhosis
P. Pagliano, U. Fusco, V. Attanasio, M. Rossi, M. Conte, F. Faella
(Naples, IT)
Bacterial infections are frequently observed in patients with cirrhosis
because of depression of neutrophil granulocyte functions and humoral
and cell-mediated immunity. Poor data are available about pneumococcal
meningitis in such patients. Aim of the study was to evaluate
characteristics of pneumococcal meningitis in cirrhotic patients.
Methods: Fourteen patients with cirrhosis and pneumococcal meningitis
(mean age 58.5±11 years; 9 males), referred to our tertiary care centre
in the period 1997–2005, were evaluated as part of a prospective
surveillance study of pneumococcal meningitis in adult. Pneumococcal
meningitis was deﬁned by CSF pleocytosis (>10 cells/mL) and positive
CSF and/or blood culture. Diagnosis of cirrhosis had to be recorded
by liver histology or unequivocal clinical, laboratory, ultrasonographic
and endoscopic ﬁndings. Data about clinical presentation, laboratory
investigations, treatment and neurological outcome were collected.
Results: All patients had viral cirrhosis. Other conditions predisposing
to pneumococcal meningitis were present in 10 cases: 6 had diabetes
mellitus, 5 recurrent otitis, 3 asplenia, 3 previous neurosurgery. Three
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patients had pneumonia. All patients were comatose at admission.
Twelve patients reported fever before admission. Meningeal signs were
present in 11 cases. Exam of the cerebrospinal ﬂuid showed always
pleocytosis, low CSF/serum glucose ratio and elevated protein. White
blood cell count was 11,100/mL (range 3,900–30,000). Three of 5
patients presenting with CSF cell count below 500/mL died. Penicillin-
susceptible strains of S. pneumoniae grew in 10 cases; in the remaining 4
cases penicillin-nonsusceptible strains were cultured. Patients received
combined treatment with ceftriaxone associated to ampicillin (5 cases),
vancomycin (5 cases), rifampin (2 cases) or linezolid (2 cases) as
empirical treatment. Four patients died, 2 had neurological sequelae.
Three deaths occurred in patients with Child–Pugh C cirrhosis. Child–
Pugh score improved in surviving cases.
Conclusions: Pneumococcal meningitis should be suspected in cirrhotic
patients with fever and changes in mental status, particularly when
predisposing factors are present. Outcome and mortality are related
to the severity of liver disease. The increasing incidence of penicillin-
nonsusceptible strains must be considered in establishing the empirical
treatment.
P1206 Repeated lumbar puncture in patients with pneumococcal
meningitis: practical or anxiolytic relevance?
A. Alvarez, B. Mourvillier, H. Bout, C. Bruel, L. Ferreira, K. Lakhal,
O. Pajot, L. Bouadma, B. Regnier, M. Wolff (Paris, FR)
Introduction: Repeated lumbar puncture (RLP) is recommanded in
patients with pneumococcal meningitis who have not responded clin-
ically after 48 h of appropiate antimicrobial therapy or in pneumococcal
meningitis caused by penicillin- or cephalosporin-resistant strains
(PNSP). Nevertheless the clinical impact of this practice is uncertain.
Patients and Methods: Retrospective analysis of charts of patients
admitted in our 25-bed university medical ICU between January 2000
and December 2005, for pneumococcal meninigitis. All patients were
appropiately treated according to international guidelines. The following
data were collected at admission: clinical features, CSF characteristics:
leukocyte count, protein and glucose concentrations, Gram stain and
MIC of penicillin G. RLP data and changes in antibiotics dosage after
results, were also noted.
Results: Among 51 included patients, 32 (63%) underwent RLP (RLP+)
and were compared to 19 (37%) without RLP (RLP−). The mean
delay between the ﬁrst lumbar puncture and RLP was 4±2.5 days.
RLP+ patients were older (59±14 vs 48±17 years), more severe at
admission (SAPS II: 43±13 vs 29±4); had a more severely altered
mental status (GCS 8±3 vs 12±3); and ICU length of stay was
longer (23±15 d vs 4±3 d). The number of PNSP strains was 7 and
2 respectively (p = 0.52). Characteristics of the ﬁrst lumbar puncture
were not different in the two groups, except for leucocyte count
(1,766±2,190 vs 4,064±4,080, p< 0.05). There was no difference in
mortality (9% in RLP+ group vs 5% in RLP− group, p = 1) but a
tendency toward a larger number of sequelae in the RLP+ group
(34.4% vs 9.5%, p = 0.08). Gram stain was positive in 47% of RLP
but cultures were always sterile. The comparison between admission and
RLP is shown in the table.
Cefotaxime concentrations in CSF were measured in 14 patients and
showed a level >5MIC in 4 and 10MIC in 9 patients, respectively.
In one case cefotaxime concentration was <5MIC but the outcome
was favourable. In none of the patients, the results of the RLP led to
modiﬁcations of the antibiotic treatment.
Day 1 Repeated
lumbar puncture
p
Temperature (ºC) 39.2±1.2 37.7±1.1 <0.05
Leukocytes/mm3 1,773±2,155 3,713±6,334 0.11
Protein (g/L) 6.7±4.3 3.3±2.6 <0.05
Glucose level (mmol/L) 1.1±2 2.7±2.5 <0.05
Conclusion:When internationals treatment guidelines for pneumococcal
meningitis are applied, based on pneumococcal resistance epidemiology,
bacteriological failure seems improbable. Therefore, RLP may be
unnecessary in this context. This hypothesis needs to be conﬁrmed by a
larger prospective study.
P1207 Treatment outcomes in adult purulent meningitis:
a specialised centre experience in the Czech Republic
O. Dzupova, M. Helcl, J. Prihodova, J. Benes, H. Rohacova (Prague, CZ)
Objectives: Despite the availability of highly effective antimicrobials
and intensive care in the last decades purulent meningitis continues to
be a life-threatening disease burdened with an average mortality rate of
20−40%. The aim of the study is to report on outcomes of patients with
purulent meningitis treated in a specialised centre.
Methods: A prospective study performed in years 1997–2004 which
included all consecutive patients older than 16 years with diagnosis
of purulent meningitis, both community-acquired and hospital-acquired,
treated at the Infectious Diseases Department in Bulovka University
Hospital, Prague. Patients with purulent meningitis are concentrated at
the intensive care unit (ICU) of the Department from the subregion of
c. 2-million population and account for ~20% of all patients admitted
at ICU. The outcomes were classiﬁed using the Glasgow Outcome
Scale (GOS) score: 1, death; 2, vegetative state; 3, severe disability;
4, moderate disability; 5, mild or no disability.
Results: The study group consisted of 241 patients (134 men, 107
women), mean age 47.2 years (range 16−85 years). During the primary
hospitalisation 44 patients died (18.3%). One hundred forty ﬁve patients
(60.1%) were discharged to their homes; 52 patients (21.6%) were
transferred to other healthcare facilities for rehabilitation or long-term
hospital care.
Six months after the onset of disease the outcomes were reassessed.
Twelve patients were lost for the follow-up for various reasons. One
hundred and forty ﬁve patients (58.1%) were assessed with GOS 5; 27
patients (11.2%) with GOS 4; 10 patients (4.2%) with GOS 3; 2 patients
(0.8%) with GOS 2; and 50 patients (20.7%) with GOS 1. Thus, in 62
patients (25.7%) the disease had got unfavourable outcome (GOS 1−3).
Conclusion: Relatively low rate of patients with unfavourable outcome
in our study in comparison with data reported in the literature lead
us to recommendation to centralise and treat patients with purulent
meningitis in specialised centres with fully equipped intensive care unit
and experienced personnel.
P1208 Community-acquired Listeria monocytogenes meningitis in
adults
R. Amaya-Villar, E. Garcia Cabrera, E. Sulleiro, M.E. Jime´nez-Mejı´as,
D. Roriguez, P. Ferna´ndez-Viladrich, A. Coloma, P. Catalan,
C. Rodrigo, D. Fontanals, F. Grill, M.L. Julia´, J.A. Va´zquez, J. Pacho´n,
G. Prats (Seville, Barcelona, Madrid, Valencia, ES)
Methods: A descriptive, prospective, and multicentre study carried out
in 9 hospitals of the Spanish Network for the Research in Infectious
Diseases (REIPI) between 1/11/2003 and 31/07/2006. Patients: Three
hundred and twenty-four adult patients with acute community-acquired
bacterial meningitis were included. Forty-ﬁve episodes of Listeria
monocytogenes meningitis were identiﬁed in 45 adult patients. All these
cases were diagnosed on the basis of a compatible clinical and biological
picture and a positive cerebrospinal ﬂuid (CSF) or blood cultures.
Results: All 45 patients were either immunocompromised or aged over
60 years. The classic triad of fever, neck stiffness and altered mental
status was present in 21 (46.7%) patients, however, almost all patients
(95%) had at least 1 or more of these symptoms. CSF samples obtained
through lumbar puncture showed a median WBC count of 550 per mm3
(interquartile range 0–70.000 per mm3); a glucose level of 39 (0.4–
158)mg/dL; a ratio of CSF glucose to blood glucose of 0.27 (0.0–0.65);
and a protein level of 181 (20–674)mg/dL. Gram stain of CSF samples
was performed for 97.8% patients and it was positive in 12 (27.7%) of
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44 cases. CSF and blood cultures were positive in 88.8% and 67.4%,
respectively. The serotype more frequently found was the 4b in 16
(72.2%) of 22 cases. In 18 (40%) of 45 cases, the patients received
empirical antimicrobial therapy. The initial antimicrobial therapy was
ampicillin based for 35 (77.7%) of 45 patients, in 12 (34.3%) of them
associated to aminoglycosides. Twenty-one patients (46.6%) received
adjunctive therapy with dexamethasone; in 16 cases, the ﬁrst dose was
given previously or concomitantly to the ﬁrst antibiotic dose. The median
length of hospital stay was 20 (7−34) days. The mortality rate was 28.9%
(13 of 45 patients) and 4 (8.9%) developed adverse clinical outcome
(neurological and/or auditory sequels). Inadequate initial antimicrobial
therapy was not related to outcome.
Conclusions: Listeria monocytogenes meningitis predominantly occurs
in elderly or immunocompromised patients. Patients with Listeria
monocytogenes meningitis often present with classic symptoms of
bacterial meningitis. This clinical process also remains a serious disease
that carries high morbidity and mortality rates.
P1209 A risk score for unfavourable outcome in adults with
bacterial meningitis
M. Weisfelt, D. van de Beek, L. Spanjaard, J.B. Reitsma, J. de Gans
(Amsterdam, NL)
Objectives: Clinical deterioration in bacterial meningitis can occur
rapidly and is often difﬁcult to predict. Identiﬁcation of high-
risk patients would be helpful in decision-making regarding the
management of individual patients. The aim of the present study was
to derive and validate a simple risk score to predict the risk for an
unfavourable outcome in individual adults with community-acquired
bacterial meningitis.
Methods: We derived a score for the risk of an unfavourable outcome
by performing a multivariate logistic regression analysis of data from a
prospective nationwide cohort study (Dutch Meningitis Cohort, DMC;
n = 696). A key set of independent prognostic variables was selected
from a starting set of 22 potential predictors by backward elimination
procedure using bootstrap techniques to avoid the inclusion of spurious
variables. A nomogram based on these key variables was constructed to
facilitate the use in clinical practice. For validation, we used data from
a randomised controlled trial of adjunctive dexamethasone therapy for
adults with bacterial meningitis (European Dexamethasone Study, EDS;
n = 301).
Fig. 1.
Results: Of the 696 episodes in the DMC, 237 (34%) had an
unfavourable outcome, including 143 patients (21%) who died. The risk
score was based on 6 routinely available variables: age, heart rate, score
on the Glasgow Coma Scale, cranial nerve palsies, cerebrospinal ﬂuid
leukocyte count, and Gram-positive cocci in cerebrospinal ﬂuid Gram’s
stain (ﬁgure 1). The concordance index for the ﬁnal risk score in the
EDS was 0.73 (95% conﬁdence interval 0.65–0.80).
Conclusion: This bedside risk score can be used to reliably predict
the individual risk for unfavourable outcome in adults with community-
acquired bacterial meningitis.
P1210 Antibiotic resistance among Gram-negative bacilli causing
meningitis in an adult neurosurgical centre in Manchester,
UK: implications for effective antibiotic therapy
N. Doshi, T. Wilson, C. Subudhi (Salford, UK)
Objectives: Gram negative bacillary meningitis (GNBM) is an
uncommon infection in adults and often occurs as a complication of
complex neurosurgical procedure or following head injury. The treatment
of Gram-negative bacillary meningitis remains a major therapeutic
challenge with emergence of antibiotic resistance in many of the
causative organisms and the restricted choice of antibiotics. We reviewed
the aetiology and antimicrobial susceptibility pattern of GNBM in our
centre over a 7 year period.
Methods: Hope Hospital, Salford is a 900 bed tertiary referral hospital,
which houses the regional neurosurgical centre for Greater Manchester.
The case notes and microbiological records of all patients with GNBM
between 2000 and 2006 inclusive were reviewed retrospectively. Only
patients with positive CSF culture and clinical features compatible with
meningitis were included.
Results: During the study period, there were 74 patients who had GNBM
from whom 92 different Gram-negative bacilli were isolated in CSF.
The most common causative organisms were Enterobacter spp. (27.2%),
E. coli (21.7%) and Klebsiella spp. (16.3%).
More than one third (38%) of Gram-negative bacillary isolates were
resistant to third generation cephalosporins. 17% of isolates were
resistant to gentamicin and 10% were resistant to ciproﬂoxacin. All the
isolates were sensitive to meropenem and amikacin.
Conclusions: Third generation cephalosporins have been the mainstay to
treat GNBM over the past 20 years because of high CSF penetrance. This
has resulted in dramatic fall in meningitis related mortality. Emergence of
strains resistant to third generation cephalosporins is a signiﬁcant cause
of concern. This retrospective study has highlighted that surveillance of
local pathogens and resistance patterns are essential to guide empirical
therapy. This study has prompted us to consider initiating empiric therapy
for post neurosurgical GNBM with meropenem pending culture and
susceptibility results.
P1211 Nosocomial meningitis
E. Garcia-Cabrera, M.E. Jime´nez-Mejı´as, J. Serra-Vich, V. Pintado,
F. Grill, M. Portillo, J. Colomina, G. Prats, J. Pacho´n-Diaz (Seville,
Barcelona, Madrid, Valencia, ES)
Objectives: Study of epidemiology, demography and risk factors, clinical
and cerebrospinal ﬂuid (CSF) variables, aetiology and prognosis of a
cohort of patients with nosocomial meningitis/ventriculitis (NM).
Methods: Multicentre and prospective study in six tertiary REIPI
hospitals, from September 2004 to July 2006. Inclusion criteria: adults
undergoing neurosurgical or spinal or facial skull surgical, or head
trauma, with NM. Diagnosis NM: clinical features, CSF ﬁndings
(pleocytosis, hypoglycorrachia or CSF/blood glucose ratio <40%, and
increased protein level) and microbiological criteria (microbial presence
in Gram smears and/or isolation from CSF). Monitoring: 30 days after
treatment withdrawal.
Results: A total of 106 patients (57% males) were studied. Median age:
49.5±26.9 years (15−75). Risk factor: temporal shunt 83 patients (79%),
neurosurgery 75 (71%), CSF ﬁstula 26 (25%), permanent drainage
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of CSF 17 (16%), cranial trauma 10 (9%). Cause of admission: 33
(31%) brain tumour resection, 22 (21%) subarachnoid haemorrhage, 15
(14%) brain haematoma, 10 (9%) cranial trauma, 9 (8%) meningitis,
9 malfunction V-P shunt, and others 13. Clinical features: fever
(mean 38.5±1ºC) 92 (87%) patients, headache 50 (47%), decrease of
Glasgow coma score 39 (37%), and meningismus 26 (24.4%), The
classic triad was present in 13 (12.3%) cases. Microbiological studies:
positive CSF cultures in 89 (84%) patients (71 monomicrobial and 18
polymicrobial infections), CSF Gram’s stain 44 (42%); positive blood
cultures 27 of 77 (35%) and no isolation in 16 (15%). Aetiological
agents: Gram-negative bacilli 53 (49%) (Acinetobacter baumannii 25,
Enterobacter spp. 8, Klebsiella pneumoniae 8, E. coli 6, Serratia
marcescens 2, Citrobacter freundii 2, and others 3); Gram-positive cocci
49 (45%) (coagulase-negative Staphylococcus spp. 34, S. aureus 7,
Enterococcus spp. 4; Streptococcus viridans 2, others 2); anaerobes
4 (Propionibacterium acnes 2, Shewanella spp., Provetella spp.); and
others 2. Outcome: mortality 27 cases (25%) (only 6 related with NM);
morbidity: 34 patients (32.1%). Relapse 2 cases.
Conclusions: Neurosurgery and temporal CSF shunt are the ﬁrst causes
of nosocomial meningitis. The sensitivity of classic triad is very low.
The rate of positive CSF cultures is high. Gram-negative bacilli are the
more frequent aetiological agents. Morbidity and mortality of nosocomial
meningitis are very important; although the related mortality is lower
than others series.
P1212 Hippocampal apoptosis in pneumococcal meningitis:
contribution of decreased cellular NAD+ levels?
C. Bellac, R.S. Coimbra, S. Christen, S. Leib (Berne, CH)
Objectives: Apoptosis in the hippocampus (HC) is a characteristic
feature of neuronal damage in pneumococcal meningitis (PM) and
represents the histomorphological correlate for learning and memory
deﬁcits as a sequel of PM. Depletion of intracellular NAD+ and the
resulting decrease in ATP is known to trigger cell death. Whether
decreased NAD+ levels contribute to apoptosis in PM has not
been demonstrated. NAD+ is either recycled from nicotinic acid or
nicotinamide or is synthesized de novo through the kynurenine (KYN)
pathway, which we have previously shown to be induced in PM. Here
we measured NAD+ levels in the HC during acute PM and modulated
the biosynthetic pathways of NAD+ to assess the role of NAD+ in the
pathogenesis of hippocampal apoptosis in PM.
Methods: An established infant rat model of PM was used to determine
hippocampal NAD+ levels at deﬁned time points of acute PM. NAD+
was measured by ﬂuorescence assay. Pharmacologic interventions were
done with speciﬁc inhibitors of the KYN pathway (Ro-61–8048 for
inhibition of kynurenine 3-hydroxylase, and oMBA for kynureninase)
and nicotinamide. Apoptotic damage in the HC was evaluated by
histomorphometry at 36 h after infection.
Results: Compared to uninfected littermates, PM led to a signiﬁcant
reduction in NAD+ levels at 24 h after infection (100% in mock-
infected controls (n = 6) vs. 45 ± 18% in infected animals (n = 10),
p< 0.01). Simultaneous inhibition of the two major enzymes of the KYN
pathway resulted in increased apoptotic damage in the HC of infected
animals (apoptotic score of 1.5 ± 0.6 in infected double inhibited
animals (n = 8) vs. score 0.5 ± 0.6 in infected vehicle treated animals
(n = 31), p< 0.01). Inhibition of the KYN pathway had no effect on
NAD+ levels in infected animals. Treatment with nicotinamide increased
apoptotic damage, despite high NAD+ levels at 36 h p.i. (195 ± 29%
in infected treated animals (n = 6) vs. 100% in mock-infected controls
(n = 7), p< 0.01).
Conclusion: While pneumococcal meningitis causes a signiﬁcant
depletion in hippocampal NAD+, the exact consequence of this decrease
is presently not clear. Pharmacologic inhibition of de novo synthesis of
NAD+ increased hippocampal apoptosis without affecting NAD+ levels
compared to untreated infected animals at 24 h and 36 h after infection.
We conclude that the activation of the KYN pathway is insufﬁcient to
restore cellular NAD+ in the hippocampus during acute PM.
P1213 Nosocomial meningitis in the NICU population: perinatal
risk factors, aetiology and outcome
J. Behrendt, M. Stojewska, M. Wasek-Buko, B. Krolak-Olejnik,
U. Godula-Stuglik (Zabrze, PL)
Neonatal hospital-acquired meningitis (n.h.m.) is a major cause of
morbidity with high risk of neurological consequences in infants treated
in the NICU.
Aim: to assess the correlation between CSF and blood cultures in n.h.m.
and the outcome according to gender, birth weight, aetiology, perinatal
complications associated with high-risk pregnancy and delivery.
Methods: The study population consisted of 48 infants (36 boys,
12 girls) from 7 to 80 days of life, 38 premature and 10 full-term treated
in NICU due to respiratory or cardiovascular disorders. Birth asphyxia
in 21%, obstetric complications in 96%, VLBW in 54%, VLGA (<29
weeks) in 29% were noted. Urgent cesarean sections were carried out in
62%. N.h.m. was diagnosed after 7th day of life and conﬁrmed by CSF
pleocytosis over 30/mm3 with predominance of PMNs and increase of
protein concentration >1.0 g/L.
Results: N.m. was conﬁrmed by CSF culture in 24 (50%) neonates:
Staph. epidermidis MR (14), Staph. warneri (1), Streptococcus
faecalis (1), Klebsiella pn. (2), E. coli (2), Serratia marcescens (1),
Pseudomonas aeruginosa (1), Candida albicans (1) and Candida
sake (1) were isolated. Among 48 sick neonates 24 had positive blood
culture. Only 8 (17%) neonates had a concomitant-positive (Staph.
epidermidis MR 4, Streptococcus faecalis 1, Serratia marcescens 1,
Klebsiella pn. 2) and 12 concomitant-negative blood cultures. In neonates
with both positive blood and CSF cultures the isolated microorganisms
were discordant in 5 (10%) of 48 cases. Three (6%) neonates died –
all asphyxiated premature born in 25, 26 and 29 weeks of gestation,
with birth weight 800–1,050 g, in the course of nosocomial sepsis due to
Staph. epidermidis MR, Serratia marcescens, Streptococcus faecalis and
with infectious perinatal risk factors (chorionamnionitis), admitted to the
NICU because of RDS and congenital pneumonia. In 19 (40%) neonates
with n.h.m. severe neurological consequence (hydrocephalus 10, PVL 5,
hydrocephalus+PVL 4) was noted. In 26 (54%) infants the outcomes at
age 6 month were satisfactory. The bad prognosis (death or brain injury)
was not related to sex, birth asphyxia, birth weight and mode of delivery.
The signiﬁcant correlation between low GA of newborns with n.h.m. and
neurological sequel was found.
Conclusions: (1) Nosocomial meningitis in neonates may occur in the
absence of bacteraemia and positive CSF cultures. (2) Outcome of
nosocomial meningitis depends on neonatal gestational age and mother’s
perinatal risk factors.
P1214 Succesful treatment of multidrug-resistant Acinetobacter
baumannii meningitis with colistin and rifampicin
K.O. Memikoglu, F. Alver Alkaya, Z. Ko¨ken, H. Serdaroglu, T. C¸akir,
A. Azap (Ankara, TR)
Introduction: The treatment of multidrug-resistant A. baumannii
infections is a serious therapeutic problem, especially in patients
with meningitis because antibiotics have a limited ability to penetrate
cerebrospinal ﬂuid (CSF). Meningitis due to Acinetobacter spp. has
an associated mortality rate of 20−27%. We described here a case
of meningitis caused by multidrug-resistant Acinetobacter baumannii,
which was suspectible to colistin and treated succesfully with intravenous
and intrathecal use of colistin with rifampicin.
Case Report: A 38-year-old male was operated because of schwannoma.
On day 9 external CSF shunt was installed. On day 11 the patient
presented fever, headache, nause and vomitting and somnolance. Physical
examination revealed a severly ill patient with lethargy and meningism.
CSF showed pleocytosis (250 cells/ml; with polymorphonuclear neu-
trophil, dominance (100%), a protein level of 321mg/dl, and a glucose
level of 20mg/dl (blood glucose level was 105mg/dl). Meropenem
(1 g q8h), vancomycin (1 g q12h) and rifampicin 10mg/kg q12h po)
were began. Multidrug-resistant A. baumannii was isolated from the
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CSF. Meropenem was stopped and the treatment changed to colistin
intravenous (2 g q8h) and intrathecal (50.000U for the ﬁrst 3 day and
50.000 U on alternative days). On day 2 of treatment the CSF was sterile.
Treatment was maintained for 21 days and the patient was discharged.
Discussion: High use rates of broad-spectrum antibiotics in critically
ill patients have been corraleted with the emergence of resistance
in Acinetobacter strains. In a large serious of adults with acute
bacterial meningitis Acinetobacter spp. were found to be responsible for
approximately 10% of Gram negative bacillary and 4% of all nosocomial
meningitis. Alternative therapies in multidrug-resistant A. baumannii
infections such as colistin are being increasingly employed. Intrathecal
colistin has been used with good results in case of multidrug-resistant
A. baumannii meningitis. Cure seems to be more frequent among patients
receiving combination systemic and intrathecal therapy.
Conclusion: Intravenous and intrathecal use of colistin with rifampicin
may be a potentially effective therapy in cases of meningitis caused by
A. baumannii resistant to carbapenems and other b-lactam agents.
P1215 Endemic serogroup W135 meningococcal meningitis
possibly originated from 2000 and 2001 Hajj epidemics:
a prospective study for the aetiology of childhood acute
bacterial meningitis in Turkey
M. Ceyhan, I. Yildirim, P. Balmer, R. Borrow, G. Secmeer, B. Dikici,
M. Turgut, N. Kurt, A. Aydogan, C. Ecevit, Y. Anlar, O. Gulumser,
G. Tanir, N. Salman, N. Gurler, N. Aydin, M. Hacimustafaoglu,
S. Celebi, Y. Coskun, E. Alhan, U. Celik, Y. Camcioglu (Ankara, TR;
Manchester, UK)
Determination of bacterial meningitis aetiology is important for decisions
about vaccine policies. Cerebrospinal ﬂuid (CSF) samples taken from
patients with a clinical and laboratory diagnosis of acute bacterial
meningitis were obtained from 12 health centres in 7 different
geographical regions that provide health service to 32% of the population
of Turkey. Streptococcus pneumoniae, Haemophilus inﬂuenzae type b
(Hib) and Neisseria meningitidis were detected by PCR. During a period
of one year, 408 CSF samples were included and bacterial meningitis
was detected in 243 samples. N. meningitidis was detected in 56.5%,
S. pneumoniae in 22.5% and Hib in 20.5% of PCR positive samples.
Among N. meningitidis positive CSF samples, 42.7%, 31.1%, 2.2%
and 0.7% belonged to serogroups W135, B, Y, and A, respectively.
Serogroup W135 was the predominant serogroup in Turkey, except
for the south coast and northwest of the country. This study showed
a shift to serogroup W135 whereas serogroups A and B previously
predominated. Vaccines to prevent meningococcal disease should include
serogroup W135 in Turkey and possibly in other countries where many
muslim pilgrims are travelling annually to the Hajj.
P1216 Epidemiologic study of paediatric bacterial meningitis in
Greece (1998–2006)
E. Lebessi, M. Papadimitriou, N. Paleologou, K. Kallergi, I. Niniou,
K. Malliou, G. Antonaki, S. Ioannidou, M. Foustoukou (Athens, GR)
Objectives: To study the epidemiologic data of bacterial meningitis in
children treated in “P.&A. Kyriakou” Children’s Hospital, one of the two
major paediatric hospitals in Greece, during a nine-year period (1998–
2006).
Methods: The laboratory archives were retrospectively reviewed.
Positive CSF cultures of children hospitalised with diagnosis of
meningitis were recorded. Children with history of neurosurgical
procedures were excluded from the study. Cultures were performed
in blood, chocolate, Levinthal agar and BHI broth and strains were
identiﬁed by standard methods. Susceptibility to antimicrobial agents
was tested according to the CLSI guidelines and MICs of penicillin and
cefotaxime for Neisseria meningitidis and Streptococcus pneumoniae
were determined by E-test.
Results: Overall, 104 strains were isolated from CSF cultures received
from 104 patients (males, 63 and females, 41) aged from 3 days to
14 years (median age; 1.33 y). The most frequent pathogens were
N. meningitidis (n = 61, 58.6%) and S. pneumoniae (n = 21, 20.2%),
followed by Escherichia coli (n = 8, 7.7%), Streptococcus agalactiae
(n = 5, 4.8%), Haemophilus inﬂuenzae (n = 4, 3.8%), Streptococcus
pyogenes (n = 2, 1.9%), Enterobacter cloacae (n = 1, 0.9%), Bacillus
cereus (n = 1, 0.9%) and Candida albicans (n = 1, 0.9%). Gram negative
rods and S. agalactiae are the most frequent isolates in neonates. About
two thirds of cases occurred in infants and children younger than 5
years. There were not signiﬁcant changes in the annual distribution of
cases due to N. meningitidis, although the widespread vaccination. Of
the meningococcal strains, 78.7% were typed as serogroup B, 18.1%
serogroup C, 1.6% A, and 1.6% W135. Two H. inﬂuenzae isolates
were type a and two type b. About one quarter of N. meningitidis and
11% of S. pneumoniae isolates showed moderate resistance to penicillin
(0.094–1mg/L). High-level resistance to penicillin and other antibiotics
was not detected. H. inﬂuenzae isolates were found to be susceptible to
all antibiotics tested. Results from 2006 will be completed at the end of
this year.
Conclusion: N. meningitidis is the most frequent pathogen in bacterial
meningitis in infants and children; serogroup B is far more common
than serogroup C. S. pneumoniae and H. inﬂuenzae strains remain
susceptible to currently used antibiotics. However, N. meningitidis strains
with reduced susceptibility to penicillin accounted for 25% of isolates,
warranting continued monitoring of this problem.
P1217 Pneumococcal meningitis in Taiwanese children: emphasis
on clinical outcomes and prognostic factors
M.H. Tsai, S.H. Chen, C.Y. Hsu, D.C. Yan, M.H. Yen, C.H. Chiu,
Y.C. Huang, T.Y. Lin (Keelung, Taoyuan, Taipei, TW)
Background: Pneumococcal meningitis still causes high morbidity or
mortality in childhood despite the progress in medicine. Factors related
to poor outcomes are needed to be investigated.
Methods: From January 1984 to December 2002, Children with
pneumococcal meningitis admitted to Chang Gung Children’s Hospital
were included in this study. Pneumococcal meningitis was deﬁned
as isolation of S. pneumoniae from cerebrospinal ﬂuid (CSF) or a
blood culture positive for S. pneumoniae in combination with a CSF
pleocytosis (CSF white blood cell count >10/mm3). Demography,
clinical manifestations, laboratory ﬁndings, antimicrobial sensitivity
patterns, managements and clinical outcomes were retrospectively
reviewed. Features and outcome parameters were also compared between
survivors and nonsurvivors.
Results: Forty-four children were eligible, with mortality in 20.5% of all
and neurological sequelae in 37.1% of survivors. In the comparison of
clinical proﬁles between survivors and nonsurvivors, only initial white
blood cell count (/mm3) (mean: 7,666.7 vs 16,187.5, p = 0.022) and
cerebral spinal ﬂuid (CSF) leukocyte count (/mm3) (mean: 187.3 vs
1,408.0, p = 0.001) were found to be signiﬁcantly lower in nonsurvivors.
Features of clinical course associated with neurological sequelae in
survivors were also analysed, and the results revealed that patients with
longer duration of hospital stay (days) (mean: 45.3 vs 19.1, p< 0.001)
or intensive care unit admission (days) (mean: 19.6 vs 3.0, p = 0.031)
may have more neurological sequelae. Besides, initial medication
including vancomycin or dexamethasone usage and severity of illness
did not signiﬁcantly affect the occurrence of neurological sequelae. In
multivariate logistic regression analysis for outcome variables, only CSF
leukocyte count 200/mm3 was a signiﬁcantly risk factor for mortality.
Conclusions: In Taiwan, pneumococcal meningitis causes high morbid-
ity and mortality. We investigated risk factors associated with mortality
and only CSF leukocyte count  200/mm3 (p = 0.021) was found to be
signiﬁcant. Physicians should monitor such patients closely to decrease
possible morbidity or even mortality.
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P1218 Hepatitis A infection in central Tuscany in children and
youths
C. Gentile, I. Alberini, I. Manini, E. Montomoli, S. Rossi, T. Pozzi
(Siena, IT)
In Italy, seroepidemiological studies have demonstrated a decrease in
the circulation of the Hepatitis A virus (HAV). The notiﬁed cases
in the SEIEVA system (Integrated Epidemiological System of Acute
Viral Hepatitis) of HAV show a reduction in cases beginning in 1985
(10/100.000) up to 2004 (3.6/100.000) with a peak in 1997 connected
to the epidemic that occurred in Puglia (19/100.000).
The decline in the circulation of HAV in Italy is linked to the
improvement in hygienic conditions and life style, and above all to the
implementation of vaccination, determining the decrease in the risk of
acquiring infection during childhood.
In order to verify the trend in the diffusion of HAV infection in the
geographical area of Central Italy, a seroepidemiological study on cohorts
of subjects, children and youths, was carried out; the years 1992, 1998
and 2004 were considered, and for each of these years two samples
from around 100 subjects aged, respectively, 0−5 and 15−20 years, were
examined. All sera were refrigerated at −20ºC. Each sample of sera was
tested for the presence of total antibodies against HAV by the ELISA
method (HAV antibody, DIESSE Diag. Senese SpA).
The obtained results show a higher prevalence of anti-HAV in youths
compared to children in both 1992 (2.7% in 0−5 year-olds and 7.4%
in 15−20 year-olds) and in 1998 (6.0% in 0−5 year-olds and 11.1% in
15−20 year-olds), while in 2004, infection was 16.4% in children and
5.4% in youths. The high antibody rate against HAV noted in children in
2004 could be correlated to a higher use of vaccine in this age group as
a consequence of small epidemics in the infant community that occurred
in Central Italy during that period. The statistical analysis of the results
thus shows a signiﬁcant tendency of increase in seroprotection over the
years in children (c2 for linear trend = 10.7; p = 0.0011). However, the
overall decrease of prevalence in subjects protected from HAV in youths
(c2 for linear trend = 0.48; p = 0.49) up to the values shown in 2004
(5.4%), besides conﬁrming the national trend of the past few years, does
not allow us to hypothesise a trend toward an increase in the risk of
acquiring infection in young adults.
This trend must be considered with caution because too much time
probably passed between the intervals of blood collection compared to
the period that is the object of our analysis.
P1219 Seroprevalence of hepatitis E virus antibody in 15−40
year-old Turkish women
T. Demirdal, N. Demirturk, D. Toprak, O. Aktepe, S. Orhan
(Afyonkarahisar, TR)
Objectives: Hepatitits E virus (HEV) infection is the major cause of
enterically transmitted Non-A Non-B hepatitis in many parts of the
world. In this study, which was conducted in Central Anatolia in Turkey,
we investigated the seroprevalence of HEV in women between 15 and
40 years of age.
Methods: The study was done in urban and rural areas of Afyonkarahisar
province in Turkey. The study design was cross-sectional and people
selected randomly in 15−40 years old Turkish women. Samples were
tested for anti-HEV IgG by commercial enzyme-linked immunoassay
(ELISA) tests.
Results: We tested 1,194 women whose ages were between 15 and 40
years. The overall seroprevalence of hepatitis E was 7.1% (85/1,194). We
found 95.5% (81/85) of the low educated people HEV seropositive and
the educational level was statistically signiﬁcant (p< 0.05). According to
the salary with HEV seropositivity there was no signiﬁcant correlation
(p> .05). When we compared urban and rural, the distribution of HEV
seropositivity was 48.2% and 51.8% respectively.
Conclusion: The prevalence rate of HEV seropositivity differ in various
regions of Turkey. Protection from HEV infection, which transmitted
faecal–oral route; education, sanitation precautions and environmental
hygen must be actually considered.
P1220 Cardiomyopathy in patients with chronic hepatitis C virus
T. Demirdal, H. Saglam, N. Demirturk, Z. Asci (Afyonkarahisar, TR)
Objectives: A high prevalence of cardiomyopathy has been reported
in patients with chronic hepatitis C virus (HCV). In this study,
we investigated the relationship between cardiomyopathy and HCV
infection.
Methods: Sixty subjects were included in the study. These were
divided into two groups. In both groups anti-HCV and HCV RNA
were detected and ALT levels were measured. Thirty consecutive
anti-HCV and HCV RNA positive patients who were admitted to
infectious diseases clinic and provided informed consent were evaluated
as study group. The other thirty subjects were assumed control group.
Healty volunteers who were anti-HCV and hCV RNA negative and
whose ALT was normal were included in the control group. Clinical,
electrocardiographic and transthorasic echocardiographic evaluations
were performed to all subjects. Valve functions and sistolo-diastolic
performance were evaluated. The subjects with diastolic disfunction were
evaluated cardiomyopathic.
Results: The age of subjects in both groups ranged from 23 to 78
years. In each group, there were 15 man and 15 women. The groups
displayed no signiﬁcant differences for age and sex distribution. Anti-
HCV was positive in all subjects in the study group. In this group,
average serum alanine transferase (ALT) and HCV-RNA levels were
73.68±46.60 U/L and 1,289,243±2,042,026 copies/mL, respectively.
Valve functions and systolic performance of the subjects in both groups
were normal. Diastolic disfunction was observed in 18 patients in the
study group and in four patients in the control group. The number
of subjects with diastolic disfunction in the study group (n = 18) were
signiﬁcantly higher than the control group (n = 4) (p< 0.05).
Conclusion: Diastolic disfunction is the ﬁnding of early stage
cardiomyopathy. In this study, we observed diastolic disfunction in HCV
infected patients. This result reveals that there may be a relationship
between HCV infection and cardiomyopathy. However, larger scale
studies to investigate this relationship are required for a conclusive result.
P1221 The anicteric form of viral hepatitis A
I. Mehmedi, R. Mehmedi, G. Temelkoski, G. Mehmeti, Z. Xhambazoski
(Kercove, MK)
Objectives: The Anicteric Form of Viral Hepatitis A (HA) is an
uncommon form of benign, where the main symptoms are the
same as those associated with icteric HA, except that there is an
absence of jaundice. The presentation of same clinical-epidemiological
characteristics of anicteric form of HA during the epidemics 1998–2000.
Methodes: The material is taken from the Infectious unit at the G. H.
of Ke¨rc¸ove¨ during the period of September 1st, 1999 to March 30th,
2000. There were 175 cases of hepatitis treated at the Infectious unit
at this G. H. The diagnosis was determined on the basis of: anamnesis,
epidemiological date, Physical examination, functional test of the liver
(the serum aminotransferases AST, ALT) and serological testes anti HAV
IgM done by the ELISA (ORGANONR) method.
Results: HA is a disease found mostly in children of a young age. In
our study we found 175 cases with acute viral hepatitis (avh) at an
average age of 8.86 years (from the age of 3 to 43). Based on the place
of the residence of the patients, the patients from urban area dominate
with 54.9%. Based on the gender of the patients, the masculine gender
dominates with 52.6%. The morbidity for the last ten years is an average
of 60 cases per 100,000 inhabitants (6). According to the aetiological
moment the cases are as follows: anti HAV IgM+, 175 cases (100%);
53 (30.3%) were of anicteric form of HA, and 4 patients (2.02%) were
subclinical forms of HA. The symptoms and the clinical examination in
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the prodromal stage of the anicteric form of HA are similar to the icteric
form of HA, except that the symptoms of the anicteric form are shorter
and less intense. Clinical–biochemical recuperation periods are shorter
in the anicteric form of HA, but the differences were not signiﬁcant
according to statistics of the c2 test (p> 0.1).
Conclusion: There were 53 patients (30.3%) with the anicteric form of
HA. The clinical–biochemical symptoms of the anicteric form are the
same as in the icteric form of HA, except that there is an absence of
jaundice.
P1222 Hypercalcaemia associated with chronic viral hepatitis C
A. Yesilkaya, K.O. Memikoglu, A. Azap, O¨. Demir, I. Balik (Batman,
Ankara, TR)
Introduction: Hypercalcaemia has been reported in the course of
some cases of cirrhosis complicated by hepatocellular carcinoma or
cholangiocarcinoma and in patients with hepatic tumours in the absence
ofcirrhosis. However in the absence of liver tumour, this metabolic
complication has been rarely reported in the course of chronic liver
disease. We described here hypercalcaemia associated with chronic
hepatitis C.
Case report: A 71 year old man was admitted in Febuary 2006
for exploration of back pain. He had had HCV chronic hepatitis
for 15 years. Tests showed hypercalcaemia, bicytopenia and mild
increase in aminotransferases. Serum calcium, ionised calcium were
elevated and serum phosphorus, 24-hour urinary calcium excretion
were normal. The level of serum immunoreactive parathyroid hormone
(PTH) was normal. Nephrogenic cAMP 2.38mmol/L, PTH-related
peptide <0.2 pmol/L and a-fetoprotein were normal whereas plasma
1,25 (OH)2 vitamin D3 (25 pg/mL) was slightly high. There were none
of the major causes of true hypercalcaemia such as any malignancy,
hyperthyroidism, hyperparathyroidism and chronic bone disaese. Serum
protein electrophoresis showed an increase in ammaglobulins with
no monoclonol paraprotein lectrophoresis, total body 99-techntium
radionuclide scan showed no increased uptake; chest X-ray and kidney
ultrasonography were normal. There was no history of excessive
aluminium derivates, milk or alkali intake, thiazide diuretic or vitamin
A and D supplementation.
Discussion: Hypercalcaemia has been reported by Gerhardt et al. in
eleven patients waiting for liver transplantation with chronic liver disease
without hepatic tumour. Resorptive factors like interleukin-1, transform-
ing growth factor, tumour necrotising factor, osteoclast activating factor,
or prostaglandin could be responsible for the hypercalcaemia.
Conclusion: Hypercalcaemia could be a rare metabolic feature of
chronic viral hepatitis C; the underlying mechanisms remain to be
elucidated.
P1223 HCV-associated hereditary haemochromatosis and
porphyria cutanea tarda in monozygotic twins
D. Telehin (Lviv, UA)
Objectives: The aim of this study is to investigate a link between
inherited factors, phenotypic expression of hereditary haemochromatosis
(HH), porphyria cutanea tarda (PCT) and course of chronic hepatitis
C (CHC) and to evaluate the efﬁciency of antiviral therapy on HCV-
associated PCT compared to the course of a similar disease without
antiviral treatment.
Methods: We had a unique opportunity to compare a course of CHC
and PCT in two monozygotic twins. Liver biopsy was performed
for histologic evaluation and iron grading (with Perls Prussian stain).
Iron status was determined from transferrin saturation, serum iron,
serum ferritin and hepatic iron. The degree of porphyrin metabolism
disturbance was evaluated according to the concentration of urine uro-
and coproporphyrins. HCV-RNA and its genotype were detected by RT-
PCR. HLA-type was determined by lymphocyte serologic identiﬁcation
method. We explored four generation of the twins’ family.
Results: 2 patients, monozygotic male twins aged 42, while still being
infants were simultaneously infected with HCV. The ﬁrst symptoms
of the disease appeared after 35 years: marked fatigue, increased skin
fragility, bullons lesions, hypertrichosis and hyperpigmentation of the
face, red colour of the urine. Chronic hepatitis C, (METAVIR score
A2F3) with extrahepatic manifestations: PCT, primary haemochromato-
sis was established. Genealogic exploration of probands revealed clinical
minifestation of HH and PCT only in the ﬁrst generation suggestive
of autosomal recessive inheritance. HLA-typing showed HLA-A3
phenotype of twins. Considering low concordance of monozygotic twins
in relation to HH and PCT, it may be assumed that HCV-infection became
the trigger of the latent forms of HH and PCT. One of twins received
antiviral therapy (IFN-a-2b + Rbvn). A persistent remission of PCT
and discontinued viraemia was achieved. The other one was only given
pathogenetic and phlebotomy treatment. The symptoms of CHC and PCT
in this case have undulating course.
Conclusions: The current study showed that HCV-infection probably
acts as a main triggering factor of HH and PCT in genetically
predisposed subjects. The management of PCT in HCV-infected patients
should include antiviral therapy. An association is established between
HH, PCT and HLA-A3.
P1224 The trend of screening tests from 2000 to 2006 and the
relationship of these with age, gender, occupation and
education of healthy blood donors in Turkey
A. Candevir, Y. Tasova, N.B. Kilic, B. Kurtaran, A.S. Inal, G. Seydaoglu
(Adana, TR)
Introduction: Screening tests are mandatory for blood donations in
Turkey. In this study we aimed to review the annual test results and
look for a relationship between positive test results and age, gender,
occupation and education at healthy blood donors in Turkey.
Material and Methods: Between January 2000 and December 2006
totally 141,928 donors’ data was investigated. ELISA was used for
HBsAg, antiHCV and anti HIV1/2, while VDRL was used for syphilis.
Linear trend qui-square test was used for statistical analysis. A more
thorough research was conducted for the year 2005 to investigate the
relationship between screening test and demographic data like age,
gender, occupation and education. Student t-test was used for continuous
variables and qui-square for categorical variables. SPSS v11.5 was used
for statistical analysis.
Results: The annually change of screening test results are shown on table
1. There were no conﬁrmed positive HIV results during these years.
There was a statistically signiﬁcant decrease at HBsAg positiveness
and decrease at antiHCV and VDRL positiveness (p = 0.0001, p = 0.03,
p = 0.002 respectively). In the year 2005, of the 23,368 donors of whom
95.7% was male, 64.5% was single and the mean age was 33±8. There
was no relationship between seropositivity and gender (P values are
0.926, 0.224, 1.000 respectively for HBs Ag, anti HCV and RPR) or
marital status (P values are 0.128, 0.051, 0.807 respectively for HBs
Ag, anti HCV and RPR). There was a negative correlation between HBs
Ag positiveness and educational status (p = 0.0001). There was also a
relationship between HBs Ag seropositivity and occupation (p = 0.0001).
Mean age was signiﬁcantly higher at HBs Ag and RPR positive donors
(p = 0.002 and p = 0.013 respectively).
HBsAg, anti-HCV and RPR positiveness according to year
Year (N) HBsAg Anti-HCV RPR
(+) (−) (+) (−) (+) (−)
n (%) (OR) n n (%) (OR) n n (%) (OR) n
2000 (20,126) 791 (3.93) (1.00) 19,335 81 (0.40) (1.00) 20,045 21 (0.1) (1.00) 20,105
2001 (20,802) 725 (3.49) (0.98) 20,077 87 (0.42) (1.04) 20,715 43 (0.21) (1.98) 20,759
2002 (21,418) 594 (2.77) (0.70) 20,824 116 (0.54) (1.35) 21,302 61 (0.28) (2.73) 21,357
2003 (21,598) 552 (2.56) (0.64) 21,046 134 (0.62) (1.54) 21,464 34 (0.16) (1.51) 21,564
2004 (21,571) 505 (2.34) (0.59) 21,066 134 (0.62) (1.54) 21,437 27 (0.13) (1.20) 21,544
2005 (23,368) 527 (2.26) (0.56) 22,841 105 (0.45) (1.12) 23,263 18 (0.08) (0.74) 23,350
2006 (13,045) 277 (2.12) (0.53) 12,768 72 (0.55) (1.37) 12,973 13 (0.1) (0.96) 13,032
Linear trend c 177.864 4.486 8.865
p value 0.0001 0.03 0.002
S336 17th ECCMID / 25th ICC, Posters
Conclusion:We found a negative trend for HBs Ag seroprevalence and a
positive trend for anti HCV and RPR prevalence. We may say that we are
having positive results of national vaccination and education programme.
And also we may say that, as the educational status improves decreasing
HBs Ag prevalence shows the beneﬁt of education on development of
conciseness for viral hepatitis and other blood borne infections. But it’s
clear that education at schools may not be enough and more efforts
should be consumed for informing public.
P1225 The relationship between serum ﬁbrosis markers and
ﬁbrosis in liver tissue in patients with chronic viral hepatitis
A. Candevir, H.S.Z. Aksu, B. Kurtaran, A.S. Inal (Adana, TR)
Introduction: In management of chronic hepatitis, measuring the degree
of hepatic ﬁbrosis and inﬂammation is crucial. Today the golden
standard is showing the ﬁbrosis and inﬂammation at the liver tissue
via liver biopsy and pathological scoring systems. In this study, two
of the noninvasive markers of ﬁbrosis, hyaluronic acid (HA) and matrix
metalloproteinase-2 (MMP-2), which can be used instead of liver biopsy,
will be investigated.
Material and Methods: 42 patients of chronic hepatitis (mean age
is 38±12, of which 69% male, n = 29) with activation criteria were
included to our study. Routine biochemical assays and liver biopsies
were performed. The relationship between serum HA, MMP-2 levels
and liver ﬁbrosis and histological activity was investigated.
Results: Serum HA levels were found to be increased by increasing liver
ﬁbrosis. But it was not statistically signiﬁcant (p = 0.148). There was
no signiﬁcant relationship between MMP-2 levels and stage (p = 0.583).
There was an increase, which is not signiﬁcant, at serum HA and
MMP-2 levels while histological activity was increasing from mild
to severe (p = 0.117, p = 0.168 respectively). There was a positive
correlation between HA and age (p = 0.002). HA levels were greater at
cirrhotic patients than non cirrhotic ones (p = 0.075). The sensitivity and
speciﬁcity of the HA assay at a cut off value of 50 ng/mL was 66.6% and
80.5% respectively. The likelihood ratio (LR) was 2.95 while positive
predictive value (PPV) and negative predictive value (NPV) were 36.4%
and 93.6%.
Relationship between serum ﬁbrosis markers (hyaluronic acid [HA] and MMP2)
and pathological assessment
HA (ng/mL) MMP2 (ng/mL)
Cirrhosis
Cirrhotic N 6 4
Median (min–max) 61 (15–160) 100 (100–4,200)
Mean±SD 72.1±50.8 1,125±2,050
Non-cirrhotic N 36 35
Median (min–max) 25 (5–375) 130 (100–18,000)
Mean±SD 57±88.7 2,699±4,688.7
Total N 42 39
Median (min–max) 26 (5–375) 100 (100–18,000)
Mean±SD 59.1±84.0 2,537.0±4,498.4
P-valuea 0.075 0.407
Histological activity
Minimal/absent hepatitis N 6 6
Median (min–max) 20 (10–45) 150 (100–9,000)
Mean±SD 22.5±12.6 2,066.7±3,573.6
Moderate–severe hepatitis N 30 29
Median (min–max) 26 (5–375) 130 (100–18,000)
Mean±SD 63.9±95.7 2,830.0±4930.6
Total N 36 35
Median (min–max) 25 (5–375) 130 (100–18,000)
Mean±SD 57±88.7 2,699±4,688.7
P-valuea 0.406 0.871
aMann–Whitney U-test.
Conclusion: As a conclusion, serum HA and MMP-2 levels can not
be used instead of liver biopsy and histological assessment which is
composed of staging ﬁbrosis and grading inﬂammation. For routine
use of serum ﬁbrosis markers, standard assays and new procedures are
needed.
P1226 Oral manifestations of lichen planus in patients with
hepatitis C virus and HIV/AIDS
E. Giovani, R. Souza, J. Cavasin, S. Egashira, J. Melo, P. Armonia,
R. Andia-Merlin (Sa˜o Paulo, BR)
Objective: The aim of this study was to investigate the prevalence of
oral lichen planus (OLP) in patients with hepatitis C virus (HCV), and
or in the patients with HIV/Aids.
Material and Method: All the patients were investigated on the presence
of antibodies anti-HCV and anti-HIV. The parameters analysed included
prevalence of the oral lichen planus, age, gender, race, and the counting
of the lymphocytes T-CD4.
Results: A total of 165 patients have anti-HCV antibodies and or with
co-infection for HIV/Aids, being 91 patients (55.2% male), and 74
patients (44.8% female). The medium age was 37 years for both sexes,
and they were divided in 2 groups. Group I: 59 patients (35.8%) have
anti-HCV antibodies and negative HIV antibodies, 32 were male (54.2%)
and 27 (45.8%) were female, 5 patients (8.5%) exhibited OLP: 2 patients
in the erosive pattern (1 male and 1 female), 1 in the mixed pattern
(male) and 2 patients with the reticular pattern (1 male and 1 female).
Group II: 106 patients (64.2%) have anti-HCV antibodies and positive
HIV antibodies, 59 were male (55.7%), 47 were female (44.3%), 14
(13.2%) patients exhibited OLP: 5 patients with the erosive pattern (3
male and 2 female), 4 patients with the mixed form (2 male and 2
female), and 5 patients with the reticular pattern (2 male and 3 female),
and all the patients make therapy only or combined of interferon and or
ribavirina. As for the counting of the lymphocytes T-CD4, 33 patients
(31.1%) with values below 200 ce´l/mm3 of blood, 55 patients (51.9%)
they presented values among 200 to 499 ce´l/mm3 of blood, 18 patients
(17%) with values above 500 ce´l/mm3.
Conclusion: The patients with counting of the lymphocytes low T-CD4
and that use ribavirina and the interferon exhibited more exuberant OLP
in the several patterns. We still observed the presence of OLP in the
erosive pattern in patients of the masculine sex.
P1227 Arthritis and chronic hepatitis C virus infection
J. Puerto, M.A. Escobar, A.A. Garcia-Egido, F.J. Fernandez, F.M. Gomez-
Soto, J.A. Bernal, S.P. Romero, F. Gomez (El Puerto Santa Maria, ES)
Arthritis is one of the numerous manifestations of hepatitis C virus
infection (HCV).
Objectives: To determine the prevalence of HCV in patients presenting
with chronic peripheral inﬂammatory artritis (CPIA) and, the clinical
forms of CPIAs associated with HCV in a 425 beds teaching hospital
reference of the Bay of Cadiz (over 250.000 inhabitants).
Methods: Prospective case-control study in 1,972 patients presenting
with CPIA as their predominant symptom (excluding cristal induced
and degenerative arthritis), mean age (± SD) 47.6 ± 17.3 years, 64%
of them women (n = 1,080). Control groups: 759 consecutive patients
with non-inﬂammatory chronic arthritis (NICA), and 6,102 consecutive
ﬁrst time blood donors (BD) matched for age and sex. HCV status was
determined (3rd generation ELISA conﬁrmation by RT-PCR, and HCV
genotype).
Results: The prevalence of HCV antibodies (5.6%) in patients with
CPIA was higher than that in patients with NICA (2.6%) or BD (0.88%)
(p< 0.01 in both cases). The prevalence of chronic HCV infection was
higher in patients with CPIA (4.3%) than in BD (0.88%). The prevalence
of chronic HCV infection by ﬁnal diagnosis as compared to BD was:
3.1% for Rheumatoid arthritis (RA) (p< 0.01), 6.4% for seronegative
RA (p< 0.005), 11.9% for intermitent mono-oligoarthritis (p< 0.001),
6.0% for Sjo¨gren’s syndrome (p< 0.005), and 9.8% for systemic lupus
erythematosus (p< 0.001). The prevalence of chronic HCV infection in
psoriasic arthritis, seronegative spondyloarthropathies, and other ﬁnal
diagnosis was not different than that in BD. CPIA associated to HCV
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infection was non erosive/non deforming in 76% of the patients. Type II
cryoglobulins and, decreased levels of C4/C3 were detected in 37%
and 48%/22% of the patients with CPIA associated to HCV infection,
respectively.
Conclusions: An increased prevalence of HCV infection exists in
patients presenting with chronic peripheral inﬂammatory arthritis. HCV
antibodies (3rd generation ELISA) overestimates the prevalence of HCV
infection in those patients. A search for HCV infection should be
performed in the diagnostic process of both inﬂammatory arthritis and
collagen vascular diseases.
P1228 Seroprevalence of blood-borne infections among blood
donors in Boushehr, Iran
Hossein Esmaeili, Z. Hamidiya, S. Mirlatiﬁ, A. Mankhian, G. Hajiyani,
Hassan Esmaeili, M. Azizzadeh (Tehran, Boushehr, IR)
Background and Objectives: In recent years there have been special
interest in the donor selection strategies in blood banks in order to
provide safer blood supply. Important steps are exclusion of paid and
replacement donation and increase in the number of regular donors. In
this survey the seroprevalence of blood-borne infections among regular,
sporadic (lapsed) and ﬁrst-time blood donors were compared (from
March 2005 to February 2005).
Materials and Methods: In a retrospective study the prevalence of
transfusion transmitted infections was compared among regular, sporadic
(lapsed) and ﬁrst-time blood donors of Boushehr city. The total of 19,627
blood donors donated blood during March 2005 to February 2005 in
Boushehr; out of this number, 7,282 were regular donors (37.1%), 728
sporadic donors (3.7%), and 11,617 ﬁrst-time donors (59.18%). Data
were collected from the computerised data source of Boushehr Blood
Transfusion Center and were then compared by the Chi-square statistical
test.
Results: Out of 7,282 regular donors, 6 (0.082%) were HBsAg positive,
6 (0.08%) were HCV-Ab reactive, and all were HIV-Ab negative.
Whereas, out of 728 sporadic donors one (0.13%) was HBsAg positive,
and all were HCV-Ab and HIV-Ab negative. Out of 11,617 ﬁrst-time
blood donors, 65 (0.55%) were HBsAg positive, 41 (0.35%) HCV-Ab
reactive. and 3 (0.02%) were HIV-Ab reactive. The prevalence of blood-
borne infections (hepatitis B, hepatitis C and HIV) was less in regular
than sporadic and ﬁrst-time blood donors. P value of HBsAg factor
was p = 0.0000 for regular and ﬁrst-time donors, also P value of HCV-
Ab factor was p = 0.0004 for regular and ﬁrst-time donors that these
difference were signiﬁcant.
Conclusions: Regular blood donation is one of the important steps in
blood safety; hence, retention of regular donors, and awareness-raising
and recruitment of sporadic and ﬁrst-time donors can increase the rate
of regular donation leading in turn to higher blood safety.
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P1229 New concerns with human brucellosis in France in the
beginning of the 3rd millenium
A. Mailles, B. Garin-Bastuji, M. Maurin, V. Vaillant (Saint Maurice,
Maisons-Alfort, Grenoble, FR)
Context: Human brucellosis is mandatorily notiﬁable in France. Due to a
veterinary policy based on stamping out and vaccination carried out since
the 1970s, France is considered “ofﬁcially brucellosis free” for cattle
since 2005 and no cases have been identiﬁed in sheep nor goats since
2003. In this context, we studied human brucellosis diagnosed in France
to assess remaining risk factors and make speciﬁc recommendations.
Methods: Our descriptive study included all human cases notiﬁed in
mainland France from 1st June 2002 to 31st May 2004. A case was
deﬁned as any patient with clinical signs consistent with brucellosis.
A conﬁrmed case had a bacterial isolation from any biological sample,
or a fourfold increase in anti-Brucella antibodies in 2 samples taken
at 2-week interval or a seroconversion. A probable case had a single
elevated titre in anti-Brucella antibodies and no alternative diagnosis.
For all patients, data were collected using a standardised questionnaire.
Results: During the 2-year period of the study, 105 patients were notiﬁed,
including 72 cases and 26 false cases who did not meet the case
deﬁnitions’ criteria. The annual incidence of human brucellosis was 0.05
cases per 100,000 inhabitants. Of all cases, 32% had localised infections,
mainly arthritis. The disease was diagnosed by bacterial isolation in 49
cases (65%). Eighty percent of cases were imported, having been infected
while travelling in an enzootic country or by eating raw milk products
imported from an enzootic country. The countries where cases were
most frequently contaminated were Portugal (n = 14), Algeria (n = 7)
and Turkey (n = 6). Cases had more frequent contacts with animals
in enzootic countries than false cases (p = 0.05) and had eaten more
frequently raw milk products from enzootic countries than false cases
(p = 0.004). One case had a laboratory acquired brucellosis.
Conclusions: Our study conﬁrmed the efﬁciency of the veterinary policy
against animal brucellosis. The incidence of human brucellosis has
dramatically decreased and most cases are now imported. Considering
the very low prevalence of brucellosis, the direct diagnosis must be
preferred to serology to avoid false cases. Recommendations are made
to increase the speciﬁcity of the surveillance, such as modifying the
case deﬁnition and consider only bacterial isolation and the increase of
serological titre as reliable tests. Speciﬁc recommendations are made to
prevent the increase of laboratory acquired cases.
P1230 Risk factors for human brucellosis in Iran:
a case−control study
M. Sooﬁan, A. Ramezani, M. Banifazl, M. Mohraz, A.A. Velayati,
A. Aghakhani, A. Eslamifar (Tehran, IR)
Objective: Brucellosis is a health problem in the central province of
Iran (Arak city). The major aim of the present study was to evaluate the
risk factors for acquiring brucellosis in Arak.
Methods: A matched case–control study was conducted in the central
part of Iran. A total of 300 subjects (150 cases and 150 controls) were
enrolled in our investigation. Brucellosis cases were deﬁned on the basis
of epidemiologic, clinical, and laboratory criteria using the Standard
Tube Agglutination (STA) test and 2-mercaptoethanol agglutination.
Subjects were interviewed using a standard questionnaire acquiring
demographic and risk factor information. Data were analysed calculating
the odds ratio and the conﬁdence intervals for the studied variables. A
conditional logistic regression model was used to explore the association
between disease and the studied variables.
Results: The age of patients varied between 2 and 86 years (mean:
33.37±21.3 years); 55.3% were males. There were no signiﬁcant
differences in age, gender, marriage situation, residence area (rural/
urban), education level, knowledge about prevention routes of brucellosis
and occupation between case and control subjects. There was no
statistically signiﬁcant correlation between acquisition of brucellosis,
infertility and abortion in sheep and cattle kept at home. Signiﬁcant
risk factors for infection related to existence of (an)other case(s)
of brucellosis at home (OR= 7.55; CI: 3.91–14.61; P< 0.0001) and
consumption of unpasteurised dairy products (OR= 3.7; 95%CI:
1.64−8.3; P< 0.014). Knowledge of the mode of brucellosis transmission
by fresh cheese appeared to be protective against disease transmission
(OR= 0.44; CI: 0.23–0.85; P = 0.01).
We observed signiﬁcant difference about keeping infected cattle, number
of cattle in the house, cattle vaccination, positive family history of
brucellosis, number of infected members in household, rate of relapse
in family between case and control subjects (P< 0.05).
Conclusion: It is concluded that pasteurisation of dairy products and
education regarding fresh cheese must be pursued for eradication of
human brucellosis from rural areas. The greatest risk factor for acquiring
brucellosis is existence of infected family members.
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P1231 Antagonistic activity of Lactobacillus acidophilus toward
clinical strains of Helicobacter pylori
E. Andrzejewska, A. Szkaradkiewicz (Poznan, PL)
Objectives: Clinical observations document antagonistic activity of
probiotic bacteria of the Lactobacillus genus in the course of
Helicobacter pylori infection. Therefore, in present study the in vitro
effects was evaluated of L. acidophilus strains which produced or did
not produce hydrogen peroxide on clinical isolates of H. pylori.
Methods: The material for studies involved 20 clinical isolates of
H. pylori obtained from mucosa of patients with endoscopically
conﬁrmed duodenal ulcers. The biopsies were plated on Columbia agar
(bioMe´rieux) with 7% shepp blood agar and incubated in microaerophilic
conditions at 37ºC for 4 days. The isolated H. pylori strains were
identiﬁed on the basis of Gram staining and by their production of urease,
catalase and oxidase.
Strains of Lactobacillus acidophilus originated from vaginal smears or
saliva samples of healthy women. Species identiﬁcation was conducted
using API 50 CHL test (bioMe´rieux). For detection of hydrogen peroxide
production by the isolated Lactobacillus acidophilus TMB-Plus agar was
applied. In studies on antagonism the so called columnar technique was
employed measuring H. pylori growth inhibition zone around an agar
column containing 48 h culture of the analysed L. acidophilus strain.
Results: The range of obtained zones of H. pylori growth inhibition
in presence of hydrogen peroxide producing strains of L. acidophilus
ranged from 4.9 to 14.2mm (mean: 9.6±3.6mm). The range of zones
of H. pylori growth inhibition in presence of L. acidophilus strains
which did not produce hydrogen peroxide ranged from 5.7 to 11mm
(mean: 8.0±2.0mm). Analysis of the obtained results disclosed no
signiﬁcant differences between H. pylori growth inhibition induced by
L. acidophilus strains which produced or did not produce hydrogen
peroxide (p> 0.05)
Conclusions: Strains of L. acidophilus induce variable inhibition of
growth in clinical isolates of H. pylori and the effect is not related
only to hydrogen peroxide production by the former strains.
P1232 Oral lactobacilli in dental caries
A.K. Szkaradkiewicz, J. Stopa (Poznan, PL)
Objectives: Caries is a unique multifactorial infectious disease, inducing
local destruction of dental tissues. Bacteria of the Lactobacillus
genus have been well documented to be involved in progress of the
carietic process. Present study aimed at evaluation involvement of
Lactobacillus spp. producing or not producing hydrogen peroxide in
active caries.
Methods: Material for the studies involved samples of the full saliva
obtained from 120 patients (20−49 years of age), in whom clinic,
according to World Health Organization criteria, permitted to diagnose
active caries in 45 patients (group 1) or diagnose patients as caries free
(75 patients; group 2). The samples of saliva were plated on Rogosa agar
and the cultured isolates obtained in anaerobic conditions were identiﬁed
using API 50 CHL (bioMe´rieux). In parallel, for detection of hydrogen
peroxide production by the isolated Lactobacillus spp. TMB-Plus agar
was applied.
Results: In group 1 with active caries saliva of all patients was found
to contain Lactobacillus spp. unable to produce hydrogen peroxide.
On the other hand, in 42 (56%) patients in the caries free group
(group 2) presence of hydrogen peroxide-producing Lactobacillus spp.
was disclosed while no such Lactobacillus spp. were detected in the
remaining 33 (44%) patients of group 2.
Conclusions: Development of caries seems to be linked to presence
of oral lactobacilli which produce no hydrogen peroxide. Detection of
hydrogen peroxides, produced by Lactobacillus spp. in saliva, may be of
diagnostic importance in evaluation of the risk of intense caries.
P1233 Methicillin-resistant Staphylococcus aureus infection in a
community hospital and the impact of a nursing home
opening in its inﬂuence area
J.A. Dı´az-Peromingo, S. Cortizo-Vidal, F. Pardo-Sa´nchez,
J. Sa´nchez-Leira, M.F. Garcı´a-Sua´rez, S. Molinos-Castro,
P. Pesqueira-Fonta´n, M. Iglesias-Gallego, J. Saborido-Froja´n, E. Padı´n
Paz, J. Naveiro-Soneira (Riveira, Santiago, ES)
Objective: To study the incidence of Methicillin resistant Staphylococcus
aureus (MRSA) infection in a new opened hospital and the impact of a
nearby nursing home opening.
Methods: Retrospective analysis of patients infected with MRSA from
November 1998 to October 2006. Our hospital covers a population of
about 66,000 people and lacks of Intensive Care Unit (ICU). Age, sex,
concomitant diseases and mortality were analysed. A nursing home was
opened in the hospital inﬂuence area (April 2002). We analysed the
impact of this in terms of hospital admissions due to MRSA infections.
Nasal culture of the nursing home residents was performed to know the
prevalence of MRSA carriers.
Results: 64 patients were admitted to the department of Internal
Medicine suffering MRSA infections. Blood culture was positive in
10 cases; skin and subcutaneous tissue culture in 7 cases and sputum
culture in 47 cases. Middle age was 73 (range 43−91) years old;
45 patients were men and 19 women. During 1998 and 1999 there
were no SAMR infections reported. In 2000 (3), 2001 (5), 2002
(3), 2003 (8), 2004 (13), 2005 (20), and 2006 (12) cases. The
annual incidence of MRSA infection ranged from 4.54/100,000 (years
2000 and 2002) to 30.30/100,000 habitants (year 2005). The most
common associated diseases were chronic obstructive pulmonary disease
(COPD, 40 patients), hypertension (22 patients), anaemia (16 patients),
hyperlipidaemia (15 patients) and smoking, heart failure and atrial
ﬁbrillation (12 patients each). Thirteen patients (20.31%) died. When
examined nasal culture, a total of 89 cultures were performed (98% of
the total number of residents). From these, 9 were positive for MRSA
(carrier prevalence of 10.11%).
Conclusions:
1. There is an increasing rate of MRSA infections in our hospital,
especially respiratory infections.
2. The most frequent underlying clinical conditions in our patients are
COPD, hypertension, anaemia and hyperlipidaemia. MRSA infection
leads to a considerable death rate (20%).
3. The opening of a nursing home in our hospital inﬂuence area,
probably explains the increasing rate in the following years.
4. The relatively old age of our patients all together with the high rate
of MRSA carriers and the probable previous admissions to other
hospitals (with ICU) of the nursing home residents, points to the
need of eradicating this carriers in order to reduce the rate of hospital
infections for MRSA related conditions in our area.
P1234 Use of an AFLP technique for the discrimination of source
(human or animal) of E. coli
A. Vantarakis, M. Chondrou, M. Efstratiou, M. Papapetropoulou
(Alexandroupolis, Patras, Athens, GR)
Objectives: The development and evaluation of a molecular method
Ampliﬁed Fragment Length Polymorphism technique to ﬁngerprint and
differentiate the source of E. coli was the original scope of this study.
Methods: 50 samples of human and 50 samples of animal E. coli were
used for the development of the method. The method for the AFLP
was adapted by Gibson et al. (1998) with minor modiﬁcations. DNA
extraction of the E. coli isolates was performed by Prot K extraction
method. DNA was digested by Hind III in the buffer provided with
the enzyme with 5mM spermidine trihydrochloride. A 5-mL aliquot
of the reaction was used to a ligation reaction containing 0.2 mg. The
ligated DNA was precipitated with ammonium acetate and ethanol. Then
PCR was performed in a total volume of 50 mL as Gibson et al. (1995)
described. Ampliﬁed fragments were electrophoresed in 1.5% agarose
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gel. Bands were statistically evaluated to select the speciﬁc bands
representative of the source.
Results: Four primers with sequences complementary to the adapter
sequence were tested. The ability of each primer was assessed on the
basis of the results for ease differentiation of speciﬁc bands from animal
and human E. coli strains isolated from human faeces (hospital) and
animal faeces. The human faeces derived from humans (adults and
babies) hospitalised for gastroenteritis; the animal faeces came from
poultry, bovine and goats. Two primers were judged to produce the most
satisfactory results for ease differentiation of origin (human or animal)
of E. coli.
Conclusion: AFLP as described can be applied to E. coli without
the need for expensive equipment or reagents and is relatively rapid,
technically simple, reproducible and speciﬁc. It can be a useful a method
for the discrimination of source of E. coli. It can be proved a very
powerful tool for the evaluation of the origin of unknown E. coli and
help to the sanitary survey of an area as well as to the risk assessment.
Aknowledgements: We thank the European Social Fund (ESF),
Operational Program for Educational and Vocational Training II
(EPEAEK II), and particularly the Program PYTHAGORAS II, for
funding the above work.
P1235 Efﬁcacy of long-term co-trimoxazole in Q fever during
pregnancy
X. Carcopino, D. Raoult, L. Boubli, A. Stein (Marseille, FR)
Background: Q fever is a worldwide zoonosis caused by the obligate
intracellular bacterium Coxiella burnetii. During pregnancy it may result
in obstetrical complications such as spontaneous abortion, low birth
weight, oligoamnios, fetal death and premature delivery.
Objectives: To evaluate the efﬁcacy of long-term co-trimoxazole
treatment in cases of Q fever during pregnancy.
Material and Methods: We evaluated the prognosis of 53 pregnant
women who developed Q fever with and without long-term co-
trimoxazole treatment deﬁned by the oral taken of trimethoprim and
sulfamethoxazole during at least 5 weeks.
Results: In the 37 pregnant women who did not received long-term co-
trimoxazole treatment, we observed a 81.1% obstetrical complications
rate: 5 (13.5%) spontaneous abortion, 10 (27%) low birth weight, 4
(10.8%) oligoamnios, 10 (27%) intra uterine fetal death and 10 (27%)
premature deliveries. Outcome of the pregnancy was found to depend
on the trimester in which patients had been infected (p = 0.032) and
on the placental infection by Coxiella burnetii (p = 0.013). Long-term
co-trimoxazole treatment protected against chronic Q fever (p = 0.001),
placental infection (p = 0.038), and obstetrical complication (p = 0.009)
especially fetal death (0/16) (p = 0.018).
Conclusions: Our results show that Q fever during pregnancy causes
severe obstetrical complications including fetal death. Because of its
ability to protect against obstetrical complications and chronic Q fever,
long-term treatment by co-trimoxazole should be used to treat women
who develop Q fever during pregnancy, speciﬁcally when infected during
the ﬁrst trimester.
P1236 Listeriosis in pregnant women
I. Dumitru, S. Rugina, E. Gorun (Constanta, RO)
Background: Listeriosis is relatively rare and occurs primarily in
newborn, elderly patients, and immunocompromised persons. Incidence
is 7.4 cases per million population. Pregnant women account for 27%
of all cases. Hormonal changes during pregnancy have an effect on
the mother’s immune system that lead to an increased susceptibility to
listeriosis in the mother. According to the CDC, pregnant women are
about 20 times more likely than other healthy adults to get listeriosis.
Listeriosis can be transmitted to the fetus through the placenta even if
the mother is not showing signs of illness. This can lead to premature
delivery, miscarriage, stillbirth, or serious health problems for her
newborn.
Objective: To established the incidence of listeriosis in pregnant women
in Constanta and the consequence concerning to fetus and newborn.
Material and Method: Retrospective study on 280 women with
abortive disease serologically investigated for Listeria monocytogenes
(serotype 1a) in the last ﬁve years (2001–2006).
Results: The most affected age group proved to be that in the range of
20−30 years: 206 (73.9%) cases. 112 (40%) female had the diagnostic
titer ( 1/320); among these, 64 (22.85%) had miscarriages in the IVth-
VIIIth month and 38 (13.57%) gave birth to dead foetuses. During
pregnancy, only 10 female (3.57%) was diagnosticated with listeriosis
and received treatment with Ampicillin. The rest of female (168 cases)
was diagnosticated later to abortion and the titer was low. All Ampicillin
treated female gave birth healthy newborn.
Conclusions: Listeriosis is a serios diseases during pregnancy. In our
study only 10 female patients was diagnosticated with listeriosis during
pregnancy, received early treatment and gave birth healthy newborn.
P1237 Cutaneous anthrax in a teaching hospital, Turkey: a review
of 39 cases
A. Engin, N. Elaldi, I. Dokmetas, M. Bakici, M. Bakir (Sivas, TR)
Objectives: To evaluate the epidemiological, clinical and laboratory
ﬁndings and treatment protocols of patients with cutaneous anthrax
retrospectively.
Methods: Patients diagnosed with cutaneous anthrax and followed up in
the Department of Clinical Bacteriology and Infectious Diseases in the
Cumhuriyet University Hospital, an 800-bed teaching hospital in Sivas,
central Turkey, between January 1983 and December 2005 were included
in the study. The diagnosis of cutaneous anthrax was based upon clinical
ﬁndings and/or microbiological procedures, including Gram stain and
culture of materials obtained from lesions. Patients’ charts were reviewed
and age, sex, occupation, exposure to a sick animal or to animal products,
symptoms, location and type of lesion, clinical and laboratory ﬁndings
and choice of treatment were recorded for each patient.
Results: In this period 39 patients with cutaneous anthrax were
diagnosed and followed up in our clinic. Mean age of the patients
was 44 (15 to 74) years, 12 (31%) of whom were females and 27
(69%) of were males. Twenty-ﬁve cases (64%) had a history of recent
animal slaughtering activity. The clinical presentations were malignant
oedema in 10 (26%) of 39 patients and malignant pustule in 29
(74%). The lesions were mostly located on the hand and forearm. The
diagnosis was conﬁrmed by bacterial isolation in 17 (44%) cases, by
direct examination from the lesion material in 8 (21%) cases. The
diagnosis was established in 14 (36%) cases by the lesion presentation.
Thirty-six patients were treated with penicillin G. Because of the fact
that three patients had a history of penicillin allergy, chloramphenicol,
ciproﬂoxacin and doxycycline was used respectively. A patient with
malignant oedema died on the ﬁrst admission day due to asphyxiation
caused by tracheal compression from the extensive oedema.
Conclusions: Although the incidence of anthrax is decreasing world-
wide, it is still encountered in Turkey. It manifests sporadically in the
eastern, south-eastern and central parts of Turkey where the disease is
endemic. Cutaneous anthrax should be considered in any patient with a
painless ulcer with vesicles, oedema and a history of exposure to animals
or animal products. We think that penicillin is the antibiotic of choice
for the treatment of anthrax in endemic regions.
P1238 New perspectives on the bacteriology and antimicrobial
susceptibility of dog bite wounds
B. Meyers, J. Schoeman, A. Goddard, E. Seakemela, J. Picard
(Pretoria, ZA)
Objectives: In spite of dog bite wounds being a common reason for
dogs requiring veterinary care, there is surprisingly little data on the
bacteriology of bite wounds. Thus, a prospective study was performed
on dogs presenting at the Onderstepoort Veterinary Academic Hospital,
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University of Pretoria, and a nearby animal shelter with various grades
of bite wound.
Methods: Fifty dogs with bite wounds inﬂicted within the previous
72 hours were selected. This represented 104 wounds. Wounds were
clinically graded according to severity and evaluated cytologically. Swabs
were collected from all wounds for bacterial culture. Wounds were
classiﬁed as infected or non-infected. Infection was diagnosed if 2 of
the following 3 criteria were met: macroscopic purulence, phagocytosed
bacteria present or if the wounded dog had pyrexia. Non-infected wounds
were either sterile (established by culture) or contaminated (culture
positive but bacteria not phagocytosed on cytology). All wounds were
cultured aerobically and anaerobically and all aerobic cultures were
evaluated for antibiotic susceptibility.
Table 1. Percentage antibiotic susceptibility of the most common bacteria
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n = 30 n = 13 n = 23 n = 27 n = 10
Amoxycillin-
clavulanate
87 100 91 78 80
Cloxacillin 64 83 90 70 22
Penicillin G 93 92 65 81 10
Cephalothin 93 92 100 86 20
Ceftiofur 93 44 65 81 44
Enroﬂoxacin 93 85 91 7 50
Orbiﬂoxacin 64 90 74 48 50
Doxycycline 93 85 57 67 10
−Sulphamethazole +
trimethoprim
90 100 74 89 60
Gentamicin 43 92 91 19 60
Amikacin 65 90 100 7 89
Kanamycin 83 92 95 11 50
Lincomycin 17 31 40 0 10
Lincospectin 33 50 33 n/a 0
Tylosin 76 92 95 77 10
aShaded areas indicate susceptibility of 50% or less.
bPyogenic streptococci included: S. canis, S. pyogenes, S. agalactiae,
Group-C streptococci.
Results: Of the 104 wounds, 21 were judged to be infected and 83
non-infected. Seventeen (16%) of all wounds were sterile were also
classiﬁed as non-infected. This was statistically signiﬁcant (P = 0.02).
Of the 84% that were culture positive, 16% grew aerobes, 1% anaerobes
and 67% a mixture of aerobes and anaerobes. A total of 211 isolates were
cultured representing a mean of 2.1 isolates per wound. Of the aerobes
cultured, 22%, 20% and 17% belonged to Pasteurella, Streptococcus
and Staphylococcus species, respectively. Within these groups, Pas-
teurella multocida (65%) and Staphylococcus intermedius (70%) were
predominant. Pasteurella canis and pyogenic streptococci were common
in infected wounds, whereas Bacillus spp., Actinomyces spp. and the
oral streptococci were usually found in contaminated wounds. Three
anaerobic genera were cultured, namely, Prevotella, Clostridium and
Peptostreptococcus, and were usually associated with wounds with dead
space. This is also the ﬁrst recorded case of Capnocytophaga canimorsus
in an infected dog bite wound. Signiﬁcantly, clinical examination and
cytological assessment were capable of establishing whether antibiotics
were required or not. Although no single antibiotic was considered to
be effective against all the bacteria, in vitro, potentiated sulphonamides,
ampicillin and amoxycillin plus clavulanic acid gave the best results.
P1239 Patients with chronic fatigue syndrome have higher
numbers of anaerobic bacteria in the intestine compared
to healthy subjects
B. Evenga˚rd, C.E. Nord, A˚. Sullivan (Stockholm, SE)
Objectives: To compare the intestinal microﬂora in patients with chronic
fatigue syndrome with the microﬂora in healthy subjects.
Methods: Ten patients (6 females and 4 men, mean age 38.7, range
30−53 years), fulﬁlling the criteria according to the US Centers for
Disease Control and Prevention (1994) for chronic fatigue syndrome,
were included in the study. The patients had high fatigue severity scores
and high disability scores. Ten healthy subjects, matched for gender and
age, were included as a control group (6 females and 4 men, mean age
37.6, range 29−48 years). None of the patients or the healthy subjects had
taken any antimicrobial agents within the preceding 3 months. Two stool
samples (2 to 5 days apart) were collected from each subject. The stool
specimens were suspended, diluted and inoculated on non-selective and
selective media. The aerobic agar plates were incubated for 24 hours and
the anaerobic plates for 48 h at 37ºC. After incubation different colony
types were counted, isolated in pure cultures and identiﬁed to genus
level. Streptocoocci and aerobic Gram-negative rods were identiﬁed to
species level. Median values from the two samples were used in the
comparisons.
Results: The aerobic genera alpha-haemolytic streptococci, Gram-
positive bacilli, enterobacteria and Candida as well as anaerobic
lactobacilli, biﬁdobacteria, clostridia, veillonella and bacteroides were
found in higher numbers in patients with chronic fatigue syndrome than
in healthy subjects. However, only for biﬁdobacteria the difference was
statistically signiﬁcant (P< 0.05). The difference between the two groups
in total numbers of anaerobic microorganisms was also statistically
signiﬁcant (P< 0.001).
Conclusion: In this study, higher numbers of anaerobic intestinal
microorganisms were identiﬁed in patients suffering from chronic fatigue
syndrome than in healthy subjects. Disturbances in the intestinal ecology
have been implicated as a part of the pathogenesis in chronic fatigue
syndrome. Further work is needed to increase our understanding of the
role of the intestinal microﬂora in this disorder.
P1240 Detection and characterisation of enterotoxigenic Clostrid-
ium perfringens type A isolates in Japanese retail meats
Y. Miki, I. Kaneko-Hirano, K. Miyamoto, K. Fujiuchi, S. Akimoto
(Wakayama, JP)
Objectives: Clostridium perfringens is an important pathogen causing
food-borne gastrointestinal disease. In Japan, C. perfringens is ranked
as the third or forth greatest cause of the disease and sickened
approximately 4,000 people, while the outbreak annually occurred 20 to
40 cases. Previous surveys found that the prevalence of enteropathogenic
C. perfringens in Japanese retail food was approximately 0−4%,
which was similar to that in USA. It is thought that food poisoning
isolates carry cpe on their chromosome, while isolates from other
gastrointestinal diseases, such as antibiotic-associated diarrhoea, carry
cpe on transferable plasmid. In Japan, recently two food-borne outbreaks
by plasmid-cpe isolates were reported, while several C. perfringens food
poisoning isolates carry chromosomal cpe. In this survey, we investigated
the prevalence of enterotoxigenic C. perfringens in Japanese retail meat
samples, and then cpe-positive isolates were tested with multiplex PCR,
which could differentiate chromosomal cpe isolate versus plasmid cpe
isolate.
Methods: We collected two hundred meat samples from grocery stores
and meat shops in Wakayama City. Approximately 100 g of food samples
were anaerobically incubated at 45ºC overnight with TGC II medium in
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stomacher bag, and then cultured samples were tested for the presence of
cpe-positive C. perfringens followed by further incubation on SFP agar
plate for bacterial isolation. DNA were prepared from overnight culture
with InstaGene matrix (BioRad) and then used for PCR reaction for cpe
detection.
Results: In PCR reaction, we detected cpe from 8 samples (4%), from
three of which, we isolated cpe-positive C. perfringens. Interestingly, all
three cpe-positive isolates carry cpe on the plasmid and it is combined
with downstream IS1470-like structure in PCR cpe-genotyping assay.
Conclusion: From these results, C. perfringens carrying cpe on the
plasmid might be a possible pathogen of C. perfringens food poisoning
in Japan.
P1241 Isolation and characterisation of Salmonella from Turkish
avian food samples
D. Avsaroglu, M. Jaber, M. Akcelik, F. Bozoglu, A. Schroeter,
B. Guerra, R. Helmuth (Ankara, TR; Berlin, DE)
Objective: To assess the prevalence of Salmonella (S.) in avian food
samples from Turkey and to characterise the strains according to their
serotypes, phage types and antimicrobial resistance (R) patterns.
Methods: 76 chicken meat samples were collected from different
markets in Ankara, Turkey (2005–2006). Strains were isolated according
to ISO 6579. Biochemical tests were performed with the API20E
system. Serological analyses, and phage typing of S. Enteritidis and
S. Typhimurium, were carried out. All isolates were tested for their
susceptibility to 16 antimicrobial agents by the disk diffusion method.
All resistant isolates were further tested by broth microdilution and for
an extra panel of 11 b-lactams, as well.
Results: 45% of the chicken meat samples analysed (34 out of 76)
were positive for Salmonella. From these samples, 71 isolates were
obtained. After phenotypic characterisation, they were considered as
42 epidemiologically unrelated strains. The 42 strains belonged to 12
different serotypes. The most prevalent was S. Enteritidis (10 strains,
24%) followed by S. Infantis and S. Virchow (7, 17% each); S. Group C1
with antigenic formula [6,7: k: -] (5); S. Kentucky, S. ssp. I rough
form (3); S. Thompson (2); S. Agona, S. Corvallis, S. Nchanga,
S. Senftenberg, and S. Typhimurium (1). Among S. Enteritidis,
phage type PT21 was predominant (6 of 10), followed by PT6, PT1
and PT3 (2, 1, and 1 strain). Forty per cent (17 strains) of the
strains were resistant to some antimicrobial agent. From these, 13
strains were multiresistant and four monoresistant. The most frequent
resistance was to nalidixic acid (36% of all strains, 88% of the
resistant). All these strains showed also decreased susceptibility to
ciproﬂoxacin. Multidrug resistance to more than 6 antimicrobials was
observed in S. Infantis (6 strains showed KAN-NEO-NAL-STR-SPE-
SUL-TET-TMP-SXT resistance), and S. Virchow (1 strain AMP-CEF-
NAL-STR-SUL-TMP-SXT). This Virchow strain showed resistance to
several extended-spectrum b-lactams. All S. Enteritidis were susceptible,
except one PT21 NAL-resistant strain.
Conclusion: Almost half of the food samples analysed were contami-
nated with Salmonella, especially serotypes S. Enteritidis, S. Infantis and
S. Virchow. Antibiotic resistance is also a problem in the contaminated
food from avian origin (40% resistance). The quinolone resistance in all
serotypes and multi-resistance in S. Infantis and S. Virchow need further
attention.
P1242 Is a cholera outbreak a natural disaster? Overview on a
cholera outbreak in Iran in 2005
N. Jonaidi jafari, M. Radfar, H. Ghofrani, M. Izadi (Tehran, IR)
Objectives: There has been a sharp increase in the number of cholera
cases reported to WHO during 2005. A total of 131,943 cases, including
2,272 deaths, have been notiﬁed from 52 countries. Overall, this
represents a 30% increase compared with the number of cases reported
in 2004. During the summer of 2005, an outbreak of choler a struck
Iran, infecting 1,118 individuals and killing 11 patients. The epidemic
started from the Southern regions and rapidly disseminated across the
country.
Methods: In this descriptive, epidemiological research, the related data
about all individuals Diagnosed with cholera during the epidemic of
summer 2005 has been gathered from the Disease Management Center
(DMC). The number of patients in each province, their demographic
data, and the death toll were included.
A stool sample from all patients with the clinical diagnosis of cholera was
sent to the provincial medical laboratory for conﬁrmation, serotyping,
and antibiogram. All conﬁrmed samples were then sent to the central
reference laboratory in Tehran for further conﬁrmation. If both these
tests were positive for V. cholera, the patient was considered a conﬁrmed
case.
Results: It is difﬁcult to pinpoint the ﬁrst case of the recent outbreak.
In 25 June 2005, a 26 month-old Iranian child was admitted in the
Southern city of Bushehr with a possible diagnosis of cholera. Ten days
later, two Pakistanis were reported to have the same symptoms in the
Southeastern city of Chabahar, near the Iran-Pakistan border. Serological
studies showed that the former was caused by O1 biotype El Tor serotype
Ogawa, while in the two latter cases, the Inab a serotype was isolated.
Most cases were reported in Tehran (216 cases), Hamadan (187 cases)
and Qom (152 cases) provinces – all located in central Iran. Almost
all Iranian provinces were struck by the epidemic. The total number of
conﬁrmed cases at the end of the epidemic was 1,118, of which 11 had
died.
Conclusion: There is clear trend that cholera is re-emerging in parallel
with the ever-increasing proportion of vulnerable populations who live
in unsanitary situations. Globally cholera remains a threat for social
development. Almost all of the developing countries in the out world
are facing either a cholera outbreak or the threat of an epidemic.
P1243 Contamination of toothbrushes with Helicobacter pylori, a
possible source of infection transmission
A. Helaly (Alexandria, EG)
Introduction: Helicobacter pylori (HP) infection is a common aetiology
in some gastric disorders such as peptic ulcers. The route of infection
transmission is not clear. The natural reservoir for HP is not known. HP
in dental plaque and saliva had been detected with nested PCR.
Objectives: The aim of this work was to examine the presence of the
organism in the toothbrushes of patients with positive infection and
compare that with controls without HP infection, in an attempt to search
for a possible source of reservoir.
Methods: Forty volunteer patients (10 female, 30 male, mean age 41.2
years) with a positive Helicobacter pylori (HP) infection were included
in the study, and ten negative HP volunteers of matched age and sex. All
patients had positive test for HP during routine endoscopic examination,
those with positive test and those with negative test (biopsy from the
antrum) were included in the study. The toothbrush (at least used for
one weeks by the patients for 3 times per day) was rinsed in 50mL
of 0.9% NaCl for about 30 minutes, then centrifugation was done, the
sediment was examined for HP by CLO test. The result was analysed
using standard statistical analysis and student t table.
Result: positive test is considered when any sign of the presence of the
infection is present. Positive test was in 28 patients with positive HP
infection, no one was positive in the negative volunteers (P> 0.005).
Conclusion: toothbrushes may be a source of HP infection, so that the
use of a new one is essential during HP treatment to avoid re-infection.
Also the change of toothbrushes is a good hygienic habit as regards HP
infection. There may be a possible role for anti HP infection solution to
handle the toothbrushes with it.
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P1244 Point prevalence study of the spectrum of infectious
diseases and antimicrobial drugs use in homogeneous slum
population of Mukuru in Nairobi
K. Kandrava, V. Svabova, M. Bartkovjak, K. Kutna, A. Kolenova,
M. Krumpolcova, M. Pivarnik, A. Svitkova, Z. Njambi, S. Kamoche,
M. Kiwou, V. Krcmery, P. Kisac (Bratislava, Trnava, SK)
Introduction: Aproximately 20−40% of the population of big African
cities lives in slums with limited acces to drinking water, sewage removal,
electricity and healthcare. Our tropical health centre in Mukuru slum in
Nairobi (when aproximately 5 million live in slums) serves about 50,000
people. Since 1999, more than 386,600 patients visits were recorded, and
about 105,000 children and 55,000 adults have been registered within last
8 years. Because of the medical service being free of charge, extremely
high patient ﬂow (100–120 daily) for physicians, 2 nurses and 2 lab
technicians is noted, and it is difﬁcult to perform other than routine
outpatient medicine.
Methods: We performed prospective point prevalence study met a
simple protocol and analysed spectrum of infections (ID) aetiology and
antimicrobial therapy in all cases coming for one month (June 2006).
Results: Majority of cases (312) were RTI, which represented 33% of
all visits, followed by diarrhoeal infections (197 cases) and sexually
transmitted disease (86), skin and soft tissue infection (68), AIDS (40)
and malaria (26). The majority of isolates were Staphylococcus aureus
(of which only 3 MRSA), C. albicans and NAC (19; of which only 2
Fluconazol resistant) and S. pneumoniae (8; 2 penicillin resistant).
Including penicillin resistance in pneumococci (25%), resistance proﬁles
were higher (10% of FLU-R among non-albicans Candida and 13% of
MRSA) in comparison to data published previously. Despite of that, after
treatment with simplex and “old” antimicrobials for RTI, most cases
responded clinically. Second commonest infection was gastroenteritis,
when Giardia lamblia followed by Entamoeba histolytica, followed
by Ascaris lumbricoides, Ankylostoma duodenale and Schistosoma
mansonii. Only few cases of GIT infections were of bacterial origin
(S. typhi). AIDS appeared in about 11% of visit and malaria in
nontravelers about 5%, which is interesting since our clinic is at an
altitude of 1,700m a.s.l. However so called Highlands malaria has been
sporadically refuld, also in Nairobi and even in Eldored (2,200m a.s.l.).
Conclusion: Because of free medical service, extremely high patient
ﬂow (100–120 daily) for physicians, 2 nurses and 2 lab technicians makes
it difﬁcult to perform other than routine outpatient medicine.
P1245 Increased frequency of isolation of Vibrio cholerae O1
serotype Inaba replacing prevailing serotype Ogawa in
Karachi, Pakistan
K. Jabeen, A. Zafar, R. Hasan (Karachi, PK)
Background and Aims: V. cholerae O1 strains can undergo serotype
conversion related to a mutation in the wbeT region. Predominant
cholera serotype in Pakistan is Ogawa and serotype Inaba is rare.
However there is signiﬁcant increase in isolation of serotype Inaba in our
laboratory outnumbering serotype Ogawa and we are now reporting this
observation. Moreover we further analysed previous cholera data from
years 1993–2005 at our institution to assess the trend of occurrence and
resistance pattern of Vibrio cholerae strains.
Material and Methods: This study was conducted at the clinical
laboratory of a tertiary care centre located in Karachi, Pakistan which
receives specimens from all over country. Cholera data was retrieved
from a computerised database at our institution. During the study period
(1993–Sept 2005) all stool samples yielding growth of V. cholerae were
included. V. cholerae isolates were isolated and identiﬁed using standard
methodology. Antimicrobial sensitivities were performed by Kirby Bauer
technique. Data was analysed using SPSS version 10.
Results: In year 2005 up to September, 245/3,292 (7.4%) specimens
yielded growth of V. cholerae. Out of which 243 were Vibrio cholerae
serotype Inaba (VCI) which have outnumbered serotype Ogawa (VCO).
This recent VCI strain is 100% resistant to cotrimoxazole, 3% resistant
to chloramphenicol and no resistance were observed against ampicillin,
tetracycline and oﬂoxacin. This sensitivity pattern is almost similar to
that of previous predominant serotype Ogawa.
Conclusion: We are for the ﬁrst time reporting increased isolation of
VCI from Pakistan and suggest that these VCI strains are wbeT mutants
from the previously predominant VCO and presumably have arisen as
result of selection due to immune response against VCO in Pakistani
population. The effective transmission of this strain in the community
suggests decrease immune response of the population against this mutant
VCI strain.
P1246 EpiScanGIS: a geographical information system for
laboratory surveillance of meningococcal disease in Germany
M. Reinhardt, J. Elias, J. Albert, M. Frosch, U. Vogel, D. Harmsen
(Wu¨rzburg, Mu¨nster, DE)
Objectives: The early detection of meningococcal disease outbreaks
is important in order to minimise morbidity and mortality through
timely enforcement of prevention and control measures. The availability
of temporal, spatial and molecular typing data of cases allows the
implementation of an online geographic information system (GIS)
including objective cluster detection routines. This service should enable
members of the public health community to make more informed
decisions based on the latest surveillance data.
Methods: Specimens or strains from patients with IMD are typed at the
NRZM using a well-proven highly discriminatory approach including
serogrouping and DNA sequence typing of the outer membrane proteins
PorA and FetA (Elias et al., EID 2006). Case data are stored in a
protected, local, custom designed database (MS Access). On a weekly
basis, an anonymised fraction of the data is transferred to a PostgreSQL
database server (Linux OS). The automated visualisation of the data
is handled by the PostGIS and UMN MapServer software components.
OpenLaszlo generates Flash-code to deliver these maps in an interactive
graphical user interface for a geographical information system (GIS)
web server. Additionally, data are scanned weekly for ﬁnetype-speciﬁc
spatiotemporal clusters in a prospective fashion employing the freely
available software SaTScan by Michael Kulldorff (www.satscan.org).
Moreover, the system generates interactive slide shows within freely
selectable time frames.
Results: An online GIS has been set-up, which currently includes data
of 2,300 cases of invasive meningococcal disease. To date, the system
has 55 registered users, mainly from the public health sector. 25−30
visitors of the site are counted daily. The system optimises the ﬂow
of information between public health services, laboratories, healthcare
workers, and the public. This proves to be increasingly useful for the
evaluation of regional and national epidemiologic changes of invasive
meningococcal disease.
Conclusion: The innovative web service EpiScanGIS provides the health
community and the general public with easily accessible enriched maps
displaying current surveillance data from the NRZM. Furthermore, it
implements a national early outbreak detection system. Its inclusion of
several non-commercial software packages following a modular “model-
view-controller” design makes it easily expandable and adaptable to the
surveillance of other infectious agents.
P1247 Clonal spread of Staphylococcus aureus among soldiers in
Latvian contingent in Iraq
M. Pinke, L. Cupane, A. Balode, E. Pujate, U. Dumpis, K. Aksenoka,
E. Miklasevics (Riga, LV)
Aim: Staphylococcus aureus is an important human pathogen. Although
S. aureus is considered to be an opportunistic pathogen, it is possible
that certain clones are more prone to cause invasive disease than others
due to the presence of virulence factors that increase chance of gaining
access to normally sterile sites. The aim of the present work was to study
S. aureus carriers rates, resistance levels and dissemination in Latvian
army.
Community-acquired bacterial infections S343
Methods: S. aureus strains were isolated from 337 military persons
dislocated either in Latvia (Aluˆksne, 126) or being on Peacekeeping
Missions in Iraq (125) and Kosovo (86). S. aureus strains isolated from
nasal swabs were tested antimicrobial susceptibility (PEN, FOX, GEN,
CIP, CHL, CLI, ERY, RIF, STX, TET, VAN) according to CLSI standard.
The presence of the mecA and toxin (PVL, HLG, TSST) genes was
determined by PCR. Strain typing was performed by repetitive extragenic
palindromic sequence PCR (rep-PCR).
Results: While the rates of asymptomatic S. aureus carriers in Aluˆksne
and Kosovo contingents were similar (30.9% and 34.8%, respectively)
the percentage of carriers in Iraq unit was almost doubled (57.6%).
From 141 S. aureus isolates obtained none was methicillin-resistant.
104 isolates were resistant to penicillin, and 5 to erythromycin. As
MSSA was found more often among members of Iraq contingent these
isolates were subjected to more detailed investigation. Molecular analysis
revealed 46 strains harbouring no toxin genes, 11 were hlg positive, 7
were hlg-v positive and two strains produced PVL. Rep-PCR revealed
three major groups of strains with identical chromosomal background.
This strongly points toward clonal spread which may explain high carrier
rate in this group.
Conclusions: Antimicrobial resistance levels of analysed strains were
low. Our study revealed clonal spread of S. aureus among members of
closed community. Personal hygiene is of great importance to reduce
dissemination of S. aureus.
P1248 Outbreaks of shigellosis in England and Wales, 2004: use of
phenotypic and molecular typing for strain differentiation
T. Cheasty, J. Threlfall (London, UK)
Objectives: In the summer of 2004 a number of apparently unrelated
outbreaks of Shigella sonnei infection were observed amongst patients
throughout England and Wales. Infections were identiﬁed throughout
the country but were concentrated in the London area, and the north-
west and north-east of England. Outbreaks were in both religious
communities and in homosexual men. The outbreak among homosexual
men was centred in the London area but outbreaks in the religious
community occurred in London, the north-west and the north-east. For
meaningful epidemiological investigations in real-time discrimination
within the serovar was essential. With this in mind a hierarchical
approach based on phenotypic subdivision by phage typing and
antibiogram, supplemented by molecular typing using plasmid proﬁle
and macrorestriction ﬁngerprinting by pulsed-ﬁeld gel electrophoresis
(PFGE) has been adopted.
Methods: Isolates of Sh. sonnei from infections in England and Wales
in 2004 have been phage typed using the scheme of Hammerstrom,
Kallings and Sjoberg. Isolates have been tested for resistance to a range
of antimicrobials, plasmids identiﬁed and sized following extraction of
plasmid DNA according to Kado and Liu, and PFGE performed by
standard protocols according to Pulse-Net USA.
Results: In all outbreaks the only resistance pattern (R-type) identiﬁed
was that of ASSuSpTTm (A, ampicillin; S, streptomycin; Su, sulfon-
amides, Sp, spectinomycin; T, tetracyclines; Tm, trimethoprim). The
outbreak among homosexual men was characterised by a new Sh. sonnei
phage type (PT), designated PT Q. The isolates from this outbreak were
further characterised by a distinctive plasmid-and pulsed-ﬁeld proﬁle.
Isolates from outbreaks among members of a religious community
were characterised by three other phage types distinct from PT Q, and
by different plasmid- and PFGE proﬁles, indicating the presence of
temporally-associated but independent incidents.
Conclusions: These results indicate that outbreaks of Sh. sonnei can
be subdivided by a combination of phenotypic and molecular typing.
Results can be obtained rapidly, and can be used in real-time for
epidemiological investigations.
P1249 Virulence, pathogenicity, antibiotic resistance and plasmid
proﬁle of Escherichia coli strains isolated from drinking
and recreational waters
C. Balotescu, E. Panus, M. Bucur, R. Cernat, D. Nedelcu, C. Bleotu,
D. Valeanu, V. Lazar (Bucharest, Constanta, RO)
The aim of this study was to investigate the antibioresistance proﬁle and
the virulence and pathogenicity hallmarks of Escherichia coli acquatic
strains.
Material and Methods: 116 environmental Escherichia coli were
isolated from drinking water and marine, salmaster water in Constanta,
Romania. They were identiﬁed both by biochemical and serological tests.
Both disc diffusion susceptibility test and microplate dilution technique
were used to investigate the antibiotic resistance proﬁles. The rapid
test to nitrocephine and isoelectrofocusing techniques were used for the
conﬁrmation of the presence and type of b-lactamases. The analysis of
plasmid DNA was performed using Wizard extraction kit. The virulence
tested features were: adherence and invasion of HeLa cells, adherence
on inert substrata quantiﬁed by slime test, production of extracellular
enzymes and exotoxins (haemolysins and other pore-forming toxins,
amylase, mucinase, gelatinase, caseinase, aesculin hydrolysis).
Results and Discussion: The tested strains, irrespective to their source
of isolation exhibited resistance to ampicillin (28% vs 23%), ticarcillin
(7.7% vs 19.4%), tetracyclines (33.3% vs 37.6%) and sulphametoxazole
(2.5% vs 18.2%) and were susceptible to all other tested antibiotics.
21 strains exhibiting resistance to b-lactam antibiotics (7 isolated from
drinking and 14 from marine waters) proved to be positive for the
presence of b-lactamases when tested by nitrocephine rapid test. The
b-lactamases of the periplasmic extract exhibited an isoelectric point
ranging from 7.5 to 9.6. 10% of the drinking water strains exhibited 1 to
3 plasmids, while 5% of marine strains only 1 plasmid. As concerning
the virulence hallmarks, 90% of the strains isolated from drinking water
exhibited high capacity of adherence to the cellular substrate (adherence
indexes of 85–100% with localised, aggregative and diffuse patterns)
demonstrating the potential of these strains to colonise the animal and
human tissues and to initiate an infectious process as compared to
the marine strains showing low adherence potential. All strains showed
colonisation ability of the inert substrate as demonstrated by the high
positivity rate of slime test. All tested strains produced lipase, which
could act as pore-forming toxin in case of tissue colonisation. Our results
are pointing out the importance of detecting speciﬁc virulence factors
before incriminating water as a source of human diseases.
P1250 Inﬂuence of Lactobacilli probiotic strains on apoptosis of
colon cancer cells lines
A.K. Gonet-Suro´wka, M. Strus, P.B. Heczko (Cracow, PL)
Objectives: Cancerogenesis is often associated with disregulation of
the apoptosis process. Many external stimuli like cytokines, viruses or
bacteria can regulate this process, during which activation of several
different proteins takes place within the cell. The central component of
apoptosis is a cascade of proteolytic enzymes called caspases. The aim
of this study was to investigate how different species of Lactobacilli
inﬂuence this process on human colon cancer cell lines.
Methods: We studied the effect of live or heat-killed Lactobacilli strains
on apoptosis by the pan-caspases activation. We used ESP’s green
ﬂuorescent-labeled inhibitor, FAM-VAD-FMK, to detect active caspase
in living cells. To distinguish apoptosis from necrosis we stained the cells
with propidium iodide. As a positive control we used staurosporine, a
well-known caspase activator. The apoptosis proﬁles were determined by
FACS analysis.
Results: Our ﬁndings indicate that ability to induce apoptosis or necrosis
in cancer cell lines vary between different species of Lactobacilli. Many
of them have positive effect on cell survival even in serum-starved
conditions. On the other hand cell incubation with other Lactobacilli
species strongly activate pan-caspases.
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Conclusion: This result suggests that some species of Lactobacilli, many
used as probiotics, may have positive effect on cancer cell apoptosis.
This process is strongly strain speciﬁc and depends on the species of
Lactobacilli used.
P1251 Prevalence of thermotolerant Campylobacter species in
broilers, eggs, chicken abattoir and human samples in a
Hungarian county
G. Kardos, J. Me´sza´ros, Z. Gala´ntai, I. Turcsa´nyi, A. Bistya´k,
A´. Juha´sz, I. Damjanova, J. Pa´szti, I. Kiss (Debrecen, Budapest, HU)
Objectives:We monitored the prevalence of thermotolerant campylobac-
ters in chickens and chicken-derived food by following a broiler premise
to the abattoir as well as a laying stock and the eggs produced. We also
examined the incidence of human campylobacteriosis in Hajdu´-Bihar
county at the same period.
Methods: Study period was April to October 2006. Twelve pools of
ﬁve droppings were taken at the age of one, three and immediately
prior to slaughter from ﬁve consecutive stocks of a broiler premise.
A laying stock was sampled bimonthly. From the latter ﬁfty and six
pools of ﬁve commercial and reject eggs, respectively, were examined
weekly. Environmental and abattoir samples were collected following the
ofﬁcial guidelines. Human data originated from routine faecal samples,
only individuals older than one year were considered. Animal, egg,
environmental and abattoir samples were enriched in Preston broth and
inoculated onto CAT or CCDA agar. Human samples were inoculated
onto solid medium directly. Identiﬁcation of isolates was performed using
genus- and species-speciﬁc PCRs.
Results: Environmental as well as chicken feed samples were always
negative. Pooled faecal samples collected from three- and six-week-old
broilers were almost uniformly culture as well as PCR positive, excepting
the April rotation. Those collected at the age of one week were negative.
All isolates, excepting two Campylobacter coli, were C. jejuni, though
PCR revealed four cases of mixed carriage. All sample sets from layer
hens were also positive, but not all individual pools; C. jejuni, C. coli
and mixed carriage were found in approximately equal proportion. Out
of 300 reject eggs 17 C. jejuni and 8 C. coli, while out of 570 pools
of ﬁve commercial eggs 10 C. jejuni and 2 C. coli were isolated. From
70 meat samples (including 30 collected from retail shops) 35 C. jejuni
and 23 C. coli isolates were obtained. Twenty C. coli isolates originated
from processing of one stock. Two faecal samples taken from abattoir
staff yielded 2 C. jejuni isolates. Human outbreaks were not detected,
the incidence was 2−5%, the monthly proportion of C. coli was between
13% and 36%.
Conclusions: Both eggs and broilers were contaminated by campylobac-
ters, leading to high contamination of meat, which also passed to the
shops. Human incidence could be lowered considerably by decreasing
Campylobacter carriage of broilers and laying hens.
The work was supported by the GVOP-3.1.1.-2004−05–0472/03 grant.
P1252 Risk factors for nasal carriage of Staphylococcus intermedius
in dog owners and their pets
D. Ko, M. Boost (Kowloon, HK)
Objectives: Recently, attention has been drawn to the role of dogs as a
reservoir of resistant staphylococci. S. intermedius is the most frequently
isolated staphylococcal species from the nares of dogs. We investigated
carriage of S. intermedius in dog owners and their pets, and investigated
risk factors for carriage.
Methods: A cross-sectional study of owners and their dogs was
performed using a convenience sample of 800 pairs recruited at six
veterinary practices. Subjects provided information on demographics of
owner and dog, amount of contact between dog and owner, and recent
antibiotic treatment of the dog. S. intermedius was isolated from nasal
swabs collected from both the owner and dog by culture on blood and
mannitol salt agar and enrichment in 5% salt meat broth and further
subculture. Colonies were conﬁrmed as S. intermedius by catalase and
coagulase tests, VP, polymyxin susceptibility and trehalose fermentation.
Association between colonisation and a range of demographic and
contact factors was determined.
Results: S. intermedius was isolated from 64 of 815 dogs (7.9%) and
8 of 740 owners (1.1%). Of the 8 colonised owners, 4 had colonised
dogs. One owner and two dogs were colonised by both S. aureus
and S. intermedius. Colonisation of the owner was not associated with
multiple dog ownership or with age or sex of the owner, or the number
of persons in the household. Dog colonisation was not associated with
the presence of multiple dogs or the presence of other animals. Sex of
the dog did not inﬂuence carriage, but carriage was signiﬁcantly higher
in small dogs and dogs less than one year old, as well as in dogs with
chronic health problems. Carriage was signiﬁcantly higher in dogs that
spent more time outside. Owners of puppies were more likely to be
colonised than those of older dogs, but occupation was not associated
with colonisation of either dogs or owners. S. intermedius was more
frequently isolated from owners permitting the dog to lie on the bed, but
was not associated with licking the face or carrying.
Conclusion: S. intermedius carriage was higher in younger animals
and may spread to their owners more frequently than from older dogs.
Unlike S. aureus, which more frequently colonises bitches, there was
no difference in sex distribution of carriage. Healthcare workers or their
dogs did not have increased risk of colonisation. Co-colonisation with
S. aureus and S. intermedius highlights the possibility of transfer of
resistance determinants.
P1253 School education in Europe: what are children being taught
about antibiotic use and hygiene?
D.M. Lecky, P. Kostkova, C.A.M. McNulty for the e-Bug Working Group
Objectives: e-Bug is a European-wide European Commission (DG
SANCO) funded antibiotic and hygiene teaching resource. It aims to
reinforce an awareness of the beneﬁts of antibiotics, prudent use and
how inappropriate use can have an adverse effect on an individual’s good
bugs and antibiotics resistance in the community. Prior to production, it
is essential to
a) examine the educational structure across each partner country
b) assess what children are being taught about micro-organisms, good
and bad bugs, hand and respiratory hygiene and antibiotic use across
Europe
Methods: A questionnaire was devised for distribution to each European
partner (Belgium, Czech Republic, Denmark, England, France, Greece,
Italy, Poland, Portugal and Spain), exploring the educational structure
across Europe and examining educational resources/campaigns currently
available.
Results: From the data collected it is evident that the majority of
European schools have structured hand hygiene practices in place from a
young age. The curricula in all countries cover the topic of human health
and hygiene however limited information is provided on antibiotics and
their prudent use. Resources comparable to the Bug Investigators Pack in
England, which reinforce and build on teaching and implement National
Advice to the Public (NAP) campaigns in the classroom, are limited. The
‘Microbes en question’ mobile health education campaign in France is an
example of a successful children’s education campaign and an innovative
programme. Evaluation of the impact of school education on attitude and
behaviour change is also limited throughout many European countries.
Conclusion: Not enough is currently being done across Europe to
educate children on the importance of appropriate antibiotic use and
antibiotic resistance. The data from this research will be used to develop
e-Bug: a pan-European EU funded antibiotic and hygiene teaching
resource.
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P1254 Differences between early and late prosthetic valve
endocarditis in a series of 169 cases
A. Plata, J.M. Reguera, A. Alarcon, J. Galvez, J. Ruiz, J. de la Torre,
J.M. Lomas, C. Hidalgo-Tenorio, J.L. Haro, J.D. Colmenero for the
Andalusian Group for the Study of Cardiovascular Infections
Objectives: To determine the clinical, epidemiological, diagnostic, and
therapeutic differences between early (EP) and late (LP) prosthetic valve
endocarditis in a series of 169 cases of prosthetic valve endocarditis.
Method: Descriptive study of 169 cases of prosthetic valve endocarditis
from a series of 696 left-sided infectious endocarditis from six second-
or third-level Andalusian hospitals from 1985 to 2005. Early prosthetic
endocarditis was considered up to 12 months after surgery.
Results: No major differences in age, gender or valve affected were
found. Clinical presentation was more acute in EP (15.7±18 days)
than in LP (41±107 days) and there were more congestive heart
failure (NYHA III/IV: 22.7% vs 14.8%). Other clinical signs like fever,
splenomegaly and constitutional syndrome were more frequent in LP
than EP.
Clinical complications (CNS affectation, systemic embolisms, ocular
or skin involvement) were more frequently registered in LP, but the
complications related to poorer prognosis (renal failure, septic shock or
distress) were more frequent in EP.
Microbiology: EP: S. coagulase negative (50%), S. aureus (13%). LP:
S. coagulase negative (22.8%), S. viridans (20.8%). Vancomicin was
needed in 63% of EP and 27.7% of LP. Transthoracic echocardiography
reaveled diagnosis more frequently in EP than in LP (66.6% vs
41.2%) and so did transoesophageal echocardiography (91% vs 84.7%).
63.2% of the EP and “only” 41.6% of the LE needed surgery. The most
frequent indication for surgery for both was right ventricular failure. The
complications found in ultrasound or surgery (abscess, ﬁstula, . . . ) were
more frequent in EP (66%) than in LP (27.7%). Related mortality was
55.9% in EP versus 31.7% in LP.
Conclusions: Attending the different physiopathology between EP and
LP we have found the following differences:
1. LP is more insidiosus and needs more days of simptoms for its
diagnosis.
2. Transoesophageal echocardiography is better than transthoracic
echocardiography for the diagnosis in EP and LP.
3. S. coagulase negative is still the most frequent microrganism in EP
and in LP the aetiology is similar to native endocarditis.
4. EP patients develop more complications (annular abscess, ﬁstula, . . . )
leaving them in a worse basal situation (NYHA) and a greater need
for surgery together with an increased mortality.
P1255 Risk factors for polymicrobial blood stream infections of
biliary origin
M. Salvado´, V. Arauzo, E. Calbo, P. Vazquez, N. Freixes, M. Riera,
M. Xercavins, C. Nicola´s, J. Garau (Terrassa, ES)
Introduction: Biliary tract infection is an important source of
bacteraemia. Frequently, polymicrobial blood stream infections (BSI)
are also of biliary origin. The aim of our study was to compare
monomicrobial (M) with polymicrobial (P) BSIs of biliary origin in
terms of epidemiology, aetiology, severity and outcome.
Material and Methods: From Jan 2000 to June 2006, all adult cases
of BSI from a biliary source were identiﬁed through records of the
Clinical Microbiology Laboratory in a 450-bed acute care teaching
hospital. Medical charts were retrospectively reviewed. Variables
included demographics, aetiology, comorbidities, severity of disease, and
mortality.
Results: During the study period, a total of 2,260 BSI were recorded;
of these, 106 (4.7%) were polymicrobial, and one third (31 episodes)
of them were of biliary origin. These 31 episodes represent a 14.8%
of all BSI of biliary origin seen during this period. Men (66% vs
45%; p = 0.028), older age (76 y vs 70 y; p = 0.019), and the presence of
stones (41% vs 19.2%; p = 0.046) were more frequent in the M group.
Comorbidities (Charlson score mean 3.3 vs 2.3; p = 0.039), CPR levels
(198 vs 115; p = 0.008), the presence of biliary neoplasia (14.8% vs
4.2%; p = 0.005) or biliary prostheses (25% vs 6.3%; p = 0.006) were
more frequent in the polymicrobial bacteraemia group. E. coli was the
most frequently isolated microorganism in both groups. Previous surgery
or endoscopic retrograde cholangiopancreatography were identiﬁed in
18.8% in the M group vs. 26.9% in P (NS), and in 35% in M vs.
22.2% in P (NS), respectively. Severity, deﬁned by the presence of shock,
ICU admission or vasoactive drugs requirement, was similar in both
groups. Mortality was higher in the polymicrobial bacteraemia group
[10% in M vs 19% in P; p = 0.217)].
Conclusions: Biliary tract infection is an important cause of polymi-
crobial bacteraemia, a third of all cases of polymicrobial bacteraemias
seen during a six year period were of biliary origin. It is associated
with higher co morbidity as compared with the cases of monomicrobial
bacteraemia from the same source. Finally, biliary neoplasm and biliary
prosthesis appear to be risk factors for polymicrobial bacteraemia among
patients with BSI of biliary origin
P1256 Outbreaks of invasive meningococcal disease caused by Neis-
seria meningitidis group C in two regions of southern Poland
A. Pisula, E. Janczewska-Kazek, A. Szczerba-Sachs, U. Posmyk,
K. Kosciow (Chorzow, Katowice, Opole, PL)
Neisseria meningitidis (Nm) is still an important cause of life-threatening
infections. Infections with group B strains are the most common in
Poland, but infections with group C strain are rare.
Between June and November 2006 in two neighbouring regions, Silesia
and Opole, 13 cases of invasive meningococcal disease (IMD) caused
by Nm group C were noted. First cases were observed in Silesia region
in 3 teenagers (all 16 years old, 1 male, 2 females) and 25-year old
woman who meet together in the same discotheque. The IMD form in
one woman and the man from this group was meningitis, but in 2 women
it was sepsis with disseminated intravascular coagulation (DIC). The
epidemiological investigation has shown the connection between sharing
of glasses or intranasal inhalations of illegal drugs and IMD development
in this group. Prevalence of Neisseria meningitidis group C carriage
in nasopharyngeal cavity among habitual guests of the discotheque
was 24%. One discotheque worker was also a Nm carrier.
The next cases were noted among 3 children (5, 10 and 2 years old) from
families living in the same house in poor household condition. Nobody
from their environment was Nm carrier.
In Opole region 4 cases of meningitis (3 men and 1 woman) and 2 cases
of sepsis with disseminated intravascular coagulation (1 man, 1 woman)
were noted in patients aged 16−57. One case of sepsis and one case
of meningitis caused by C ST11 strain resulted in patients’ death. The
epidemiological investigation has shown no connections between these
patients and their environments. In 2 persons from these patients families
carriage of Nm group C was conﬁrmed.
86 persons from environment received the chemoprophylaxis
(ciproﬂoxacin, rifampicin). There were no new infections till half of
November 2006.
Conclusions: (1) An important risk factor of invasive meningococcal
disease is intranasal inhalation of illegal drugs using the same straw.
(2) Vaccination against Neisseria meningitidis group C should be widely
conducted in children and teenagers.
P1257 Assessment of risk factors in continuous ambulatory
peritoneal dialysis-related peritonitis attacks
G.R. Yilmaz, R. Ozturk, C. Bulut, H. Parpucu, H. Irmak, S. Kinikli,
M. Duranay, A.P. Demiroz (Ankara, TR)
Objectives: Peritonitis is a common clinical problem that occurs in
patients with end stage renal disease and treated by peritoneal dialysis.
The aim of this study was to evaluate the potential risk factors for
continuous ambulatory peritoneal dialysis (CAPD) related peritonitis
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Methods: The study included a study group and a control group.
CAPD related peritonitis patients treated in Infectious Diseases and
Clinical Microbiology Department between February 2006 and July 2006
formed the study group. And the control group included CADP patients
without peritonitis. Demographic characteristics of patients and control
group were recorded. Complete blood count, serum protein, albumin,
procalcitonine (PCT) and C-reactive protein (CRP) levels were tested in
both groups. Cloudiness of the peritoneal dialysis ﬂuid with or without
abdominal pain was considered as a suggestive ﬁnding of peritonitis and
was conﬁrmed by cell count and culture. Patients with more than 100
white blood cells/mL in their dialysate ﬂuid were accepted as having
peritonitis. SPPS 13.0 for Windows was used for statistical analysis.
Results: There were 50 patients in the study group and 50 patients in
the control group. The mean age of the patients was 48.4 years (range
18−83 years) and 44.8 years (range 19−79 years) in the study and control
groups, respectively. The median peritoneal dialysate ﬂuid white blood
cell count was 1,275/mm3 (170–17,900) in study group. There were 56
episodes of peritonitis in 50 patients.
Age, gender, education, living in rural area and profession have not been
found as risk factors for peritonitis attacks. However, ESR, CRP, PCT,
anaemia, hypoalbuminaemia, and hypoproteinaemia were found as risk
factors for attacks (p< 0.05). Serum CRP level was found high in 88% of
study and 26% of control group (p< 0.05). Serum PCT level was found
high in 42% of patient and 16% of control group (p< 0.05). Serum CRP
level greater than 5mg/mL and serum PCT level greater than 2 ng/mL
were found to have 100% positive predictive value for the diagnosis of
CAPD related peritonitis.
Conclusion: In several previous studies, high serum CRP and PCT
levels were reported in CAPD patients without peritonitis. In follow
up period of CAPD patients with anaemia, hypoalbuminaemia, and/or
hypoproteinaemia, high serum CRP and/or PCT level may imply
peritonitis.
P1258 Some aspects of treatment of pneumonia complicated with
the development of septic shock
D. Piskun, V. Semenov, A. Kutuzova (Vitebsk, BY)
The aim of the work was the development of recommendations on
optimisation of treatment of pneumonia complicated with septic shock.
Methods: We used statistical and biochemical methods for the
determination of characteristics of nitrosative (nitrites/nitrates) and
oxidative (diene conjugates) stress in blood taken from 32 patients on 1,
3 and 5−6 days from the moment of hospitalisation. The control group
consisted of 32 healthy donors.
Results: On assessment of kinetics of nitrites/nitrates level reﬂecting
nitrosative stress it was found that on the 1st day of admission its
concentration in the blood serum was 41.10mmol/L, much higher than
in the control group – 21.8mmol/L, on the 3rd and 5−6 days – 39.9
and 38.93mmol/L. The level of nitrites/nitrates on the 1st day from the
moment of admission in the serum of patients receiving cephalosporine
of 3rd generation (C3) and macrolide (M) was 40.1mmol/L, on the
3rd and 5−6 days – 39.4 and 38.45 mmol/L. At the same time, the
concentration of nitrites/nitrates in serum of patients receiving C3 and
ﬂuoroquinolone (F) was higher than in the group of patients receiving
C3 and M: it was 42.09 mmol/L on the 1st day of the disease,
44.89mmol/L on the 3rd day, and 41.98 mmol/L on the 5−6 days.
The level of diene conjugates in the experiment group on the 1st day
of blood collection was 124.52 nM/g lip., and on the 3rd and 5−6
days – 127.5 and 139.42 nM/g lip. In the donor group the level of diene
conjugates was 69.18 nM/g lip. Level of diene conjugates in the group of
patients receiving C3 and M on the 1st day was 123.52 nM/g lip., and on
the 3rd and by the 6th day of the disease was 129.4 and 132.8 nM/g lip.
Meantime, in the group of patients receiving C3 and F the level of
diene conjugates was higher: on the 1st day of hospitalisation it was
131.7 nM/g lip., by the 3rd and 6th days – 173.8 and 172.9 nM/g lip.
Conclusions: Due to the development of nitrosative stress in patients
with septic shock the prescribing of iNO-synthase inhibitors (such as
vitamin B12 and trental) is reasonable, especially for the ﬁrst several
days of the disease. Taking into account the trend to increase of the
characteristics of oxidative stress by the 6th day after shock occurrence,
it is necessary to prescribe antioxidants with the duration of the
treatment course not less than 6 days to this group of patients. We
recommend the combination of C3 and M for treatment of pneumonia
complicated by the development of septic shock.
P1259 Host susceptibility to accute community-acquired bacterial
meningitis: multicentre study of genetic markers
E. Garcı´a-Cabrera, R. Amaya-Villar, S. Barroso, E. Sulleiro,
D. Rodriguez, P. Ferna´ndez-Viladrich, A. Coloma, P. Catalan,
C. Rodrigo, D. Fontanals, F. Grill, M.L. Julia´, J.A. Va´zquez, J. Pachon,
G. Prats (Seville, Barcelona, Madrid, Valencia, ES)
Objective: The aim of this study was to investigate the inﬂuence of host
genetic factors in the susceptibility and clinical outcome in patients with
acute community-acquired bacterial meningitis (ACABM).
Methods: An observational, prospective, and multicentre study carried
out in 9 hospitals of the Spanish Network for the Research in Infectious
Diseases, between the 1/11/2003 and 30/09/05. A total of 102 Spanish
Caucasian patients (paediatrics and adults) with ACABM and 135
healthy controls (blood donors) from the same ethnical origin were
included in the study. The following polymorphisms were genotyped
using PCR-ARMS or PCR-RFLP: promoter and allelic variants of
mannose-binding lectin gene and G1166C polymorphism of complement
component C7 gene. At admission to the hospital, we studied the
presence of the following predicting variables of unfavourable evolution
(Ann Inter Med 1998; 129: 862–869): hypotension, altered mental status,
and/or seizures. Unfavourable outcome was considered in the presence
of neurological and/or auditory sequels to the hospital discharge and
hospital mortality.
Results: Altered mental status was more frequent in patients homozy-
gous for the C allele of C7 than for the other genotypes (76.7% vs 49%,
respectively; p = 0.014). Patients homozygous for the G allele developed
more neurological sequels or auditive deﬁcits at the hospital discharge
than the rest of genotypes (41% vs 16.4%; p = 0.0287). No association
was found between C7 polymorphism and intrahospitalary mortality
(p = 0.841).
Conclusions: Our results show that the presence of genotype CC for
polymorphism G1166C of C7 is associated signiﬁcantly with alteration
of the level of consciousness at admission to the hospital and developing
of neurological or auditive deﬁcit in patients with acute community-
acquired bacterial meningitis, although we have found no association
with increased mortality.
P1260 Existence of Bartonella henselae reservoir in Poland
T. Chmielewski, R. Marczak, E. Sochon, E. Podsiadly,
S. Tylewska-Wierzbanowska (Warsaw, PL)
Infections due to Bartonella species are recently considered emerging
diseases. Bartonella organisms are well adapted to facilitate intracellular
persistence in a wide variety of animal species, including humans.
The aim of the study was to determine the existence of Bartonella
henselae reservoir and vectors of infection in the close surroundings of
human beings. This is the ﬁrst report about the existence of B. henselae
in natural reservoirs and vectors in Poland.
The studied groups included mammals (54 dogs, 137 cats) and
arthropods collected from both cats and dogs (32 ﬂeas, 107 ticks).
Blood samples were collected from each animal and cultured on
chocolate agar plates (Choc V, Oxoid) and in mouse ﬁbroblasts
L-929 cell line culture. The levels of Bartonella henselae IgM and
IgG antibodies were determined by indirect immunoﬂuorescence assay
(Focus diagnostics, USA). Dogs and cats antibodies bound to the antigen
were developed with anti-cat and anti-dog FITC IgG Conjugates (Sigma,
Germany).
Isolated Bartonella spp. strains grown on chocolate agar and in cell
line were detected and identiﬁed by PCR methods. Identiﬁcation of
Epidemiology of fungal infections S347
all PCR products was conﬁrmed by DNA sequencing. Bartonella spp.
strains were isolated from blood cultures of 14 cats (10.2%). Isolates
were identiﬁed as: B. henselae 18 isolates, B. clarridgeiae 1 isolate.
No positive Bartonella spp. cultures were obtained from any of the 54
samples of dog blood.
Fifty-nine (45.0%) of 131 cats had speciﬁc B. henselae antibodies.
Twenty seven of tested dogs (50%) had B. henselae antibodies. The
majority (96.2%) of seroreactive dogs had low titers of the speciﬁc
antibodies (1:32, 1:64).
Bartonella DNA was not found in 32 ﬂeas collected from cats and
from dogs. None of the ticks collected from cats were infected with
Bartonella spp., whereas B. henselae DNA was detected in ﬁve ticks
collected from ﬁve dogs.
These data demonstrate that in the area of central Poland B. henselae is
distributed in environmental sources to which humans might be exposed.
This concerns pets and their arthropod parasites.
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P1261 Epidemiology trends of candidaemia in an adult intensive
care unit in a teaching hospital
J. Garbino, P. Rohner, V. Alencar Nobre, N. Vernaz, C. Garzoni,
J-A. Romand (Geneva, CH)
Objectives: A large proportion of nosocomial infections are acquired in
intensive care units (ICU). Candida spp. are the leading non-bacterial
nosocomial pathogens, and candidaemia carries a high risk of mortality
in critically ill patients. Candida spp. are responsible for the majority of
nosocomial fungal infections.
The study objectives were to describe the local epidemiology of
candidaemia in the ICU of a tertiary care hospital, and to analyse the
impact of the use of the newer antifungal compounds.
Methods: Hospital medical records of adult patients with candidaemia
were reviewed from January 1989 to December 2005. Demographic
information, overall mortality, and predisposing factors for the devel-
opment of fungal infections were retrieved. We tested the susceptibility
of Candida strains after the introduction of the newer antifungal drugs
in the institution.
Results: A total of 443 episodes of candidaemia were reviewed. 150
(34%) developed in critical care: 96 (64%) in surgical ICU and 54
(36%) in medical ICU. The median age of patients with candidaemia
was 56.5 years (range 17−92); 92 (61%) were males. 87 patients (58%)
died within 30 days. Candida albicans was responsible for 73% (n = 109)
of infections acquired in ICUs. Non-albicans Candida species (27%)
were equally distributed throughout the study period. C. glabrata was
identiﬁed in 14 episodes, followed by C. parapsilosis (n = 8), C. tropicalis
(n = 6), C. krusei (n = 2), C. guilliermondii (n = 1), C. lusitaniae (n = 1),
C. pseudotropicalis (n = 1), and unspeciﬁed Candida species (n = 9).
No change in the distribution of C. albicans versus non-albicans
Candida species identiﬁed over years was noted. We observed a trend
toward a decrease in candidaemia from 1989–1994 (n = 77) to 1995–2004
(n = 62). Most strains of C. albicans (94%) remained highly sensitive to
ﬂuconazole and all the newer antifungals tested.
Conclusion: Fungal infection remains a severe disease associated with
high crude mortality. We observed a trend toward a decrease in
candidaemia during the study period out of last year. C. albicans was
the most commonly isolated species, and no shift was observed towards
non-albicans Candida species.
P1262 Ongoing semi-national surveillance of fungaemia in
Denmark: species distribution and antifungal susceptibility
M. Arendrup, K. Fuursted, H. Schønheyder, A. Holm, J. Knudsen,
I. Jensen, B. Bruun, J. Christensen, H. Johansen (Copenhagen, Aarhus,
Aalborg, Odense, Hillerød, DK)
Objective: A seminational surveillance programme of fungaemia was
initiated in 2003 and now includes 2/3 of the Danish population.
Methods: Participants are 8 departments of clinical microbiology
serving the greater Copenhagen area and major parts of Zealand, Funen
and Jutland (population 3,440,000). From each episode of fungaemia,
deﬁned as a unique blood culture isolate within a 21-day period, a
specimen is sent to the National Reference Laboratory of Mycology
for veriﬁcation of species identiﬁcation and susceptibility testing.
Completeness was ensured by comparing lists of referred isolates with
local laboratory records. Species identiﬁcation was done by use of micro
and macro morphology and ID32C (bioMe´rieux, France). Susceptibility
testing for amphotericin B, caspofungin, ﬂuconazole, itraconazole, and
voriconazole (since 2004) was performed according to the CLSI 27-A2
document in 2003−4 and according to the EUCAST discussion document
7.1 in 2004−6.
Results: A total of 1,068 episodes of fungaemia were recorded
during the 3-year study period corresponding to a rate of 11/100,000
population. Candida species accounted for 98% of the fungal pathogens.
Although C. albicans was the predominant species (64%) the proportion
was lower than previously described (85% in 1994−5). The relative
proportion varied considerably among participating departments, i.e.
from 55% at Hvidovre University Hospital, Copenhagen and in the
county of Frederiksborg to 74% in North Jutland County. C. glabrata
was the second most frequently isolated fungus (20%) but again
with considerable variation in frequency (8−32%). C. krusei was
rarely isolated (3%) and not encountered at 3 of the 8 sites. MIC
distributions for amphotericin B and caspofungin were in close
agreement with patterns predicted by species diagnosis. However,
decreased susceptibility to voriconazole deﬁned as MIC>1mg/mL was
detected in 1/54 (1.9%) C. glabrata isolate in 2004−5 and in 8/73
(11.0%) in 2005−6 (P = 0.08); Overall, 25% of the isolates showed
decreased susceptibility to ﬂuconazole and or itraconazole.
Conclusion: The incidence rate of fungaemia in Denmark is 3 times
higher than reported in other Nordic countries. Decreased susceptibility
to ﬂuconazol and/or itraconazole is frequent and a novel trend towards
more C. glabrata isolates with elevated MICs to voriconazole was
observed. This should be kept in mind when prescribing antifungal
agents before species identiﬁcation is known.
P1263 Candida lusitaniae fungaemia in cancer patients: risk
factors, amphotericin B-mutational frequency and killing
and outcome
B. Atkinson, R. Lewis, D. Kontoyiannis (Houston, US)
Introduction: Candida lusitaniae, a Candida species frequently resistant
to amphotericin-B (AMB), is a rare cause of candidaemia, seen typically
in immunocompromised patients (pts). The clinical signiﬁcance of this
in vitro resistance phenotype as well as the risk factors for and clinical
presentation of C. lusitaniae fungaemia in comparison with those of
C. albicans have not been completely characterised.
Methods: We reviewed 13 consecutive cases of C. lusitaniae fungaemia
and compared them with 41 consecutive cases of C. albicans fungaemia
(1990–2004). We also determined mutational frequency of an AMB-
susceptible C. lusitaniae isolate as well as time-kill rates to AMB
(1mg/mL, 2mg/mL) in comparison to C. albicans and C. glabrata
reference strains (controls).
Results: In univariate analysis, pts having C. lusitaniae fungaemia
were more likely to have leukaemia as an underlying disease (54% vs
15%, P = 0.007), higher APACHE II score (median 15.5vs 12, 95%CI;
0.68–8.05), profound neutropenia (38% vs 15%, P = 0.007), sustained
neutropenia (38%vs 7%, P = 0.001), concurrent infections (85%vs 54%,
P = 0.05), received growth factors (70% vs 22%, P = 0.005) and systemic
high dose steroids (38% vs 5%, P = 0.006). These pts had more frequent
exposure to antifungal prophylaxis (38%vs 11%, P = 0.048), higher
treatment failure (38% vs 19%, P = 0.028) and need for ICU transfer
(54%vs 22%, P = 0.04). The two groups did not differ in frequency
of catheter-associated fungaemia. In multivariate analysis, pts having
C. lusitaniae fungaemia were more likely to have underlying neutropenia
(P = 0.001), stem cell transplantation (P = 0.014) and to have received
prior antifungals (P = 0.04). Mutational frequency to AMB for the
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C. lusitaniae isolate was 8×10−5 and <1×10−9 for both C. albicans
and C. glabrata isolates. In addition, kill rates of AMB were low for
C. lusitaniae compared to the other isolates.
Conclusion: (1) Host determinants associated with greater susceptibility
to C. lusitaniae are underlying haematologic malignancy and prolonged
neutropenia, (2) pts having C. lusitaniae fungaemia appeared to be more
ill than those having C. albicans fungaemia, (3) C. lusitaniae isolates,
even originally susceptible to AMB, might be less amenable to AMB
therapy.
P1264 Changing pattern of candidaemia 2001–2005 and consump-
tion of antifungal agents at a university hospital, Vienna
E. Presterl, B. Willinger, R. Gattringer, F. Daxboeck, H. Lagler,
W. Graninger (Vienna, AT)
Background: Invasive fungal infections contribute substantially to the
morbidity and mortality of immunocompromised patients. Although
C. albicans has been the predominant species over years isolated from
blood cultures, a shift to so-called non-albicans Candida species has
taken place varying from hospital to hospital.
Methods: We performed a retrospective survey on candidaemia over
a 5-year period at the University Hospital of Vienna, a 2,200-bed
centre with large organ transplantation and haemato-oncology units. The
numbers of admissions range between 94,000 and 96,000 patients/year
without signiﬁcant change over the years.
Results: The isolation of Candida spp. from blood increased signiﬁ-
cantly from n= 25 in 2001, to n = 38 in 2002, n = 60 in 2004 and n = 55
in 2005 (p< 0.05). Although C. albicans remained the most frequently
isolated pathogen, emergence of non-albicans Candida species, primarily
C. glabrata and C. parapsilosis, was observed. C. albicans (17/22
isolates; 77%) was still the leading pathogen at the haemato-oncology
unit, followed by C. tropicalis (2/22; 9%), C. lusitaniae, C. sake and
C. glabrata (1/22; 5%). At the surgical wards, C. albicans was still
the leading pathogen, but the percentage of the non-albicans Candida
species (33%) was signiﬁcantly higher than at any other specialty.
The consumption of antifungal agents increased continuously from
2001 to 2005 (p< 0.05). Fluconazole was abundantly used followed
by amphotericin B (2005: 24701.5 DDD and 24701.5, respectively).
The overall increase in the consumption of antifungals was due to
increased use of voriconazole and caspofungin while the consumption
of ﬂuconazole and amphotericin B was declining.
Conclusion: Although the number of patients remained unchanged, the
net increase of candidaemia in the University Hospital of Vienna, and
the consequently increased consumption of antifungal agents warrant the
identiﬁcation of new risk factors.
P1265 Candida blood stream infection in paediatric haematology
oncology patients at a Saudi Arabian hospital and research
centre
I. Bin-Hussain, A. Al Aidaroos, D. Sharani, I. Barron, M. Jamal,
A. Belgaumi, H. El Solh (Riyadh, SA)
Background: Candida blood stream infections are the second most
frequent isolates from blood cultures in hospital with large populations
of immunocompromised patients.
Objectives: To study the trend of candida blood stream infection at
KFSH&RC in the haematology oncology patients and to evaluate the
risk factors, the response to antifungal therapy and the outcome of
candidaemia in this patient population.
Method: Retrospective chart review utilising the microbiology &
Infection Control Data-Bases from Jan 1996 till Dec 2004.
Results: Total of 229 patients with positive blood for Candida spp.
Seventy paediatric patients with haematology oncology disorders
(30.5%), 57% are males and the majority in the age group 2−5 years
(38.6%). Forty percent of candidaemia occur in patients with diagnosis
of ALL which constitute the majority of our patients.
Forty eight percent during induction phase of chemotherapy, the majority
(68.6%) were neutropenic. Other risk factors like TPN recorded in
25.7% of the patients and 38.6% of them on greater than equal 3
antibiotics. 85% had central venous lines, which were removed in 80%.
Dissemination of fungal infection occur in 38.6% of the patients and the
mortality because of candidaemia alone is 2.9% and due to candidaemia
and other causes is 8.6%.
Conclusion: Candida is not uncommon blood stream isolates in our
patient population and Candida albicans is the common Candida
species isolated, followed by C. tropicalis in paediatric patients with
haematology oncology disorders. Previous hospitalisation is a risk factor
for candidamia. Presence of CVL and prolonged use of broad spectrum
antibiotics are major risk factor for candidaemia.
P1266 The Scedosporium/Pseudallescheria Database and Culture
Collection
R. Horre, V. Robert, G.S. de Hoog, W. Becker, F. Symoens,
D. Garcia-Hermoso, E. Goettlich for the ECMM Working Group on
Pseudallescheria and Scedosporium Infections
Pseudallescheria and Scedosporium are among the very few fungi that
are truly emerging as opportunistic agents of disease. An analysis of
528 published cases of P. boydii infections in humans revealed marked
changes in its clinical spectrum. Initially the fungus was observed
mainly as a cause of mycetoma after traumatic inoculation. Since the
seventies of the previous century, systemic disease entities have become
preponderant. Two disease entities are particularly notable: the species
regularly colonises lungs of patients with cystic ﬁbrosis, and a unique
syndrome is delayed cerebral infection after near-drowning.
The ECMM/ISHAM Network on Pseudallescheria/Scedosporium Infec-
tions (PSI) unites partners from 20 countries and includes clinicians,
microbiologists and fundamental scientists. With a multidisciplinary
approach we aim to understand virulence and routes of infection, and
develop isolation, detection and treatment protocols.
An infrastructure has been implemented to collect and preserve large
numbers of clinical and environmental strains. These are made freely
available for members of the Working Group by IHEM (Brussels) and
CBS (Utrecht). In addition, a web-accessible database is being built up
(www.Scedosporium-ECMM.com), with a number of interesting features
such as on-line identiﬁcation tools, an interactive phenetic tree option,
a picture gallery, and full literature data. Ample options for regular
updating will be provided. Strain-speciﬁc clinical information combined
with susceptibility and microbiological data will enable retrospective
monitoring of disease processes for precise understanding of virulence
and therapeutic success. The database will be demonstrated.
P1267 Meningitis caused by Candida spp. in a tertiary-care
hospital: a 14-year review
E. Calabuig, J. Pema´n, M. Salavert, L. Amselem, M. Bosch, A. Viudes,
M. Gobernado (Valencia, ES)
Introduction: Meningitis caused by Candida species is a serious
condition that may result in signiﬁcant morbidity and morbility if
not recognized and treated effectively. Although meningitis due to
Candida spp. remains rare, the frequency of this life-threatening
infection has increased in the last years, particularly in patients
undergoing neurosurgical procedures (6−17%).
Methods: We have reviewed retrospectively demographic, clinical and
microbiological data of patients with isolation of Candida spp. from
cerebrospinal ﬂuid (CSF) at the La Fe University Hospital, a tertiary-
care hospital in Valencia, Spain, during the period of 1993–2006.
Results: A total of 18 patients, (10 children and 8 adults, with ages
ranging from 15 days to 78 years) had positive CSF cultures for
Candida spp. accompanied by symptoms consistent with infection. Five
patients were female. All cases of meningitis had a nosocomial origin.
The species isolated (n = 20) were: C. albicans (n = 12), C. parapsilosis
(n = 4), C. tropicalis (n = 3) and C. glabrata (n = 1). Two patients had
two different episodes. All patients presented one or more underlying
conditions predisposing to meningitis (9 hidrocephalus, 12 recent
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neurosurgical procedures and 12 CSF shunt). Shunt removal was
performed in 10 episodes, but all the patients were treated with different
antifungal regimens, including ﬂuconazole, ﬂucytosine, deoxicolate or
liposomal amphotericin B. Ten patients (55.6%) survived the infection,
six patients (33.3%) died from infection (attributable mortality), whereas
two patients (11.1%) died from unrelated causes.
Conclusions: Candida meningitis represents a signiﬁcant nosocomial
infection in at-risk patients and is associated with high mortality rates.
It is more common in children (55.5%) than in adults. C. albicans is
the predominant causative agent (60%), although other Candida spp.
are also associated with these infections. Adequate management of
Candida meningitis includes instauration of adequate antifungal therapy
and removal of contaminated shunts.
This study has been partially ﬁnanced by a Grant (2/2005/0140) from
the Fundacio´n Investigacio´n del HU La Fe and a Grant from the ISCIII
(CM04/00248).
P1268 Invasive mould infections in paediatric cancer and
transplant patients
A. Al-Rezqi, M. Hawkes, J. Doyle, S. Richardson, U. Allen (Toronto, CA)
Objectives: As the number of iatrogenically immunocompromised
patients rises with improved survival after cancer diagnosis, increasing
rates of haematopoietic stem cell transplantation (HSCT) and solid
organ transplantation (SOT), the incidence of mould infections has also
increased. However, mould infections in the paediatric population have
not been well studied. The purpose of this study is to document the
incidence, clinical presentation, risk factors, diagnosis, treatment and
outcomes of invasive mould infections in paediatric patients with cancer,
HSCT and SOT.
Methods: A retrospective chart review was performed of all patients
with a microbiologically conﬁrmed (culture-proven) diagnosis of invasive
mould infection over an eight-year period (1997–2004) at the Hospital
for Sick Children, Toronto, Canada.
Mortality in the ﬁrst year after diagnosis (cancer) or transplantation
(HSCT or SOT).
Results: Twenty-eight patients developed proven invasive mould
infections over the eight-year study period (10 cancer, 12 HSCT,
6 SOT). Mould infection occurred in 2.2% and 2.0% after a median
time of 60 days and 71 days, among HSCT and SOT recipients,
respectively. Aspergillus spp. infection was diagnosed most commonly
(23 patients); other moulds included zygomycetes (2), Alternaria spp. (2)
and Fusarium oxysporum (1). The most common site of infection was the
lung (21 patients), followed by sinus (4) and soft tissue (3). Recipients
of allogeneic unrelated HSCT had 7.7-fold higher risk of infection
compared to allogeneic related and autologous HSCT patients (RR= 7.7;
95%CI: 2.1−27.9; p< 0.001). Lung transplant patients had a 21.2-
fold higher risk compared to other SOT patients (RR= 21.2; 95%CI:
4.7−95.2; p = 0.001). The mortality after one year was 60% among
cancer patients, 58% among HSCT patients and 16% among SOT
patients (Figure). For treatment, amphotericin B (conventional or
liposomal formulation) was used most commonly (93% of patients);
caspofungin (29%) and voriconazole (18%) were also used. Combination
antifungal therapy was used in 25% of patients. The total number
of patient-days of antifungal therapy was 2,409 patient-days. Fifteen
patients with mould infection were admitted to the intensive care unit,
for a total duration of 325 patient-days.
Conclusions: Mould infection is an unusual but frequently fatal compli-
cation among iatrogenically immunocompromised children. Aspergillus
spp. predominate, and patients at increased risk include allogeneic
unrelated HSCT recipients and lung transplantation recipients.
P1269 Species distribution in bloodstream isolates of
Candida species in Bulgaria and their susceptibility to
antifungal agents
L. Boyanova, T. Kantardjiev, A. Kouzmanov, Z. Ivanova, T. Velinov,
M. Petrov (Soﬁa, BG)
Objectives: The aim of this study is to evaluate species distribution and
antifungal susceptibility of Candida bloodstream isolates in Bulgaria.
This is a part of surveillance programme, called BulSTAR, which
researches the aetiological structure of microorganisms and their
susceptibility to antimicrobial agents from 1997 to 2005.
Methods: In the National Reference Laborarory of Mycology, we
collected and investigated 277 Candida blood isolates. Species
identiﬁcation was conﬁrmed with VITEK YBC system or with API 20 C
AUX, followed by antifungal susceptibility testing of isolates, performed
with E-test and microdilution kit Micronaut-AM (Merlin). The results
were conﬁrmed with the referent broth microdilution method NCCLS
(currently CLSI) M27-A2.
Results: The data from BulSTAR showed that, for the period of 1997
to 2005 from all bloodstream isolated microorganisms, Candida strains
are: 2.6% (1997), 1.9% (1998), 2.7% (1999), 3.3% (2000), 2.8% (2001),
2.1% (2002), 2.8% (2003), 2.9% (2004), 5.1% (2005).
In the current study overall species distribution is: 53% Candida
albicans, 21% C. parapsilosis, 10% C. glabrata, 3.2% C. krusei,
3.6% C. tropicalis and other non-albicans species. We report one
interesting case of infective prosthetic endocarditis, caused by C. rugosa,
isolated only from the mitral valve.
Minimal inhibitory concentrations (MICs) of ﬂuconazole, read at
24−48 h are: 0.75−2mg/L for C. albicans, 12−32mg/L for C. glabrata,
1.5−3mg/L for C. parapsilosis, 48−64mg/L for C. krusei. MIC of
voriconazole is: 0.023–0.032mg/L for C. albicans, 3−6mg/L for
C. glabrata, 1−2mg/L for C. parapsilosis, 2−3mg/L for C. krusei.
Conclusion: These data suggest that, in Bulgaria the species distribution
of Candida bloodstream infections and their antifungal susceptibility rate
are similar to those reported in Europe and North America. The highest
percentage of non-albicans species identiﬁed are C. parapsilosis and
C. glabrata.
P1270 Candida albicans versus non-albicans bloodstream infection
in critically ill patients: differences in risk factors and
outcome
G. Dimopoulos, F. Ntziora, G. Rachiotis, A. Armaganidis, M.E. Falagas
(Athens, GR)
Objective: To identify differences of the risk factors and outcome
in critically ill patients with Candida albicans and non-albicans
candidaemia.
Methods: A prospective observational study was performed in a
medical-surgical ICU at a tertiary academic hospital in Athens, Greece.
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Non-immunosuppressed, non-neutropenic patients with candidaemia
diagnosed after ICU admission were included in the study.
Results: During the study period (01/2001–12/2005) 56 candidaemia
episodes among 1,037 ICU admissions were included (5.4%). Among
these patients 36/56 (64.3%) had candidaemia due to C. albicans and
20/56 (35.7%) due to non-albicans species [8/56 (14.3%) C. glabrata,
6/56 (10.7%) C. tropicalis, 3/56 (5.4%) C. parapsilosis, 1/56 (1.8%)
C. lusitaniae, 1/56 (1.8%) C. krusei and 1/56 (1.8%) C. dubliniensis].
Administration of glucocorticosteroids, central venous catheter (CVC)
placement and preexisted candiduria were shown to be independently
associated with candidaemia due to C. non-albicans species (OR 45.1,
95%CI 3.0–669.9; OR 26.2, 95%CI 2.1–334.8; and OR 16.5, 95%CI
1.6–173.9, respectively). Mortality was higher in patients with non-
albicans spp. than C. albicans blood stream infection [18/20 (90%) vs
19/36 (52.8%), p = 0.005]. The multivariable logistic regression analysis
revealed that candidaemia due to non-albicans species was independently
associated with death (OR 6.7, 95%CI 1.2–37.7).
Conclusions: In the subset of critically ill non-immunosupressed
patients, candidaemia caused by non-albicans species occurred more
likely in those with medical devices or receiving steroids. Candidaemia
blood stream infection due to non-albicans species was also associated
with higher mortality.
P1271 An outbreak of fungaemia in a neonatal intensive care
unit in Kuwait caused by Candida haemulonii resistant to
amphotericin B, itraconazole and ﬂuconazole
Z. Khan, N. Al-Sweih, S. Ahmad, N. Al-Kazemi, S. Khan, L. Joseph,
R. Chandy (Kuwait, KW)
Objective: Candida haemulonii is an uncommon species of Candida
that is occasionally isolated from foot lesions, and is rarely reported as a
cause of invasive disease. Here, we describe an outbreak of C. haemulonii
fungaemia in a neonatal intensive care unit (ICU) of a maternity hospital
in Kuwait.
Methods: The diagnosis of C. haemulonii fungaemia involving four
neonates was made by isolating the yeast from blood cultures. Repeat
isolates were obtained from two neonates. Since the phenotypic
characteristics of the isolates were not helpful, molecular methods were
used for species-speciﬁc identiﬁcation. The ampliﬁcation of species-
speciﬁc internally transcribed spacer (ITS)-1 and ITS-2 regions of rDNA
and/or D1/D2 regions of 26S rRNA was performed by using panfungal
primers and the amplicons were sequenced. The antifungal susceptibility
of the isolates was determined by E-test using RPMI 1640 medium
supplemented with 2% glucose.
Results: Of the 4 neonates (2 males and 2 females) diagnosed with
C. haemulonii fungaemia, 3 were born pre-term weighing 710–1,035 g,
and one full-term but with congenital abnormality. All were exposed to
risk factors for Candida infections that included use of broad-spectrum
antibiotics, administration of total parenteral nutrition and placement of
central venous catheters. All the 7 isolates did not assimilate cellobiose,
melibiose, melezitose and salicin but assimilated trehalose, esculin,
and glycerol. The ITS and/or D1/D2 region sequences of all the 7
isolates matched nearly completely (only 2 and 1 nucleotide differences
in the ITS and D1/D2 regions, respectively) with the corresponding
sequences from the reference C. haemulonii strain CBS 5149, thus
conﬁrming their identiﬁcation as C. haemulonii. They were uniformly
resistant to amphotericin B, ﬂuconazole and itraconazole, but susceptible
to 5-ﬂucytosine (0.008–0.064mg/mL), voriconazole (0.047–0.38mg/mL)
and caspofungin (0.023−0.5mg/mL). Despite antifungal therapy, 2 of the
neonates died.
Conclusion: To the best of our knowledge, this is the ﬁrst report
describing an outbreak of C. haemulonii fungaemia in neonates. The
report underscores the emergence of new or rare Candida species,
resistant to polyenes and azoles, as a cause of invasive disease in neonates
or immunocompromised patients.
Supported by KURA grant MI04/05, Department of Microbiology,
Faculty of Medicine Kuwait University and Ministry of Health, Kuwait
P1272 In vitro activity of newer antifungal agents against Candida
albicans bioﬁlms
A. Katragkou, M. Simitsopoulou, E. Diza-Mataftsi, C. Tsantali,
E. Roilides (Thessaloniki, GR)
Objectives: Candida albicans bioﬁlms have been shown to be resistant
to a variety of antifungal agents. We aimed to determine the in
vitro activities of the newer antifungal agents voriconazole (VRC),
posaconazole (PSC), caspofungin (CAS) and anidulafungin (AND)
against C. albicans bioﬁlms and compare them to those against
planktonic C. albicans cells.
Methods: C. albicans GDH2346 and M61, two documented bioﬁlm-
producing clinical isolates, were used. Bioﬁlms were grown by
incubation on silicone elastomer disks in 12-well (macro-method) or
96-well (micro-method) plates at 37ºC under constant shaking for 48 h.
Mature bioﬁlms were then incubated with no drug (controls) and with
two-fold dilutions of VRC (0.125–256mg/L), PSC (0.06−64mg/L), CAS
(0.015−16mg/L) or AND (0.0078−16mg/L) for 24 h. Percent bioﬁlm
damage was then assessed colorimetrically by XTT assay as reduction
in the metabolic activity of bioﬁlms. Bioﬁlm MIC was deﬁned as the
least antifungal concentration causing 50% reduction in the metabolic
activity of bioﬁlm compared to controls. Planktonic MIC was determined
according to CLSI M27-A2 microdilution method. Statistical analysis of
5 experiments for each strain included ANOVA and post hoc analysis
(P< 0.05).
Results: Bioﬁlm MIC of VRC was >256, of PSC >64mg/L for
both strains tested, of CAS 0.031 for GDH2346 and 0.0625mg/L for
M61, and of AND 0.125 for GDH2346 and 0.5mg/L for M61. By
comparison, planktonic MICs of VRC were 4 for GDH2346 and
0.015mg/L for M61, of PSC ?0.0018mg/L for both strains, of CAS
0.031 for GDH2346 and 0.0625mg/L for M61 and of AND 0.003mg/L
for both strains. The maximum VRC-, PSC-, CAS- and AND-induced %
bioﬁlm damage for GDH2346 was 30±2.3% (at 256mg/L), 42±9.5%
(at 16mg/L), 70±3.7% (at 0.0625mg/L) and 60±3.8% (at 0.5mg/L),
respectively. For M61 strain the corresponding values were 24.6±3%
(at 256mg/L), 47±4.3% (at 32mg/L), 62.3±11% (at 2mg/L) and
52±3.4% (at 0.5mg/L). Complete sterility of C. albicans bioﬁlms on
silicone substrate was not achieved even at the highest concentrations of
antifungal agents used.
Conclusions: C. albicans bioﬁlms are >1,000-fold less susceptible
to azole-class antifungal agents than their planktonic counterparts.
On the contrary, echinocandin-class antifungal agents appear to have
enhanced activity against C. albicans bioﬁlms. These ﬁndings may assist
better understanding antifungal drug activity against bioﬁlms and have
therapeutic implications.
P1273 Activity of posaconazole against clinical isolates of Candida
albicans with decreased sensitivity to ﬂuconazole from
autoimmune polyendocrinopathy–candidiasis–ectodermal
dystrophy patients
R. Rautemaa-Richardson, M. Richardson, M. Pfaller, P. Koukila-
Ka¨hko¨la¨, J. Perheentupa, H. Saxen (Helsinki, FI; Iowa City, US)
Objectives: Most patients with APECED (autoimmune polyendocrino-
pathy–candidiasis–ectodermal dystrophy) suffer from chronic oral
candidosis from early childhood. Thus most patients receive repeated
treatment and maintenance courses of azole antifungals, principally
ketoconazole and ﬂuconazole, throughout their lives. This has resulted
in both mycological and clinical resistance. Our aim was to determine
the susceptibility of patient isolates from Finnish patients with APECED
to the new triazole antifungal posaconazole, recently approved for the
treatment of oropharyngeal candidosis, including infections refractory
to ﬂuconazole. In previous studies posaconazole has been shown to be
active against most ﬂuconazole-resistant C. albicans isolates.
Methods: The antifungal susceptibility proﬁles and antifungal usage
of all 56 APECED patients followed in our centre were reviewed for
the period 1994–2004. C. albicans isolates of 11 patients reported to
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have decreased ﬂuconazole sensitivity (n = 27, MIC range: 8−32mg/L)
were tested for their sensitivity to posaconazole using a broth dilution
technique as detailed in the CLSI document M23-A2. C. albicans strains
of 11 patients APECED patients reported to be sensitive to azoles (n = 16,
MIC range: 0.12−2mg/L) were tested in a similar manner.
Results: C. albicans isolates previously shown to be of decreased sus-
ceptibility to ﬂuconazole were uniformly sensitive to posaconazole (MIC
range: 0.03−1mg/L). Isolates previously scored as ﬂuconazole sensitive
were equally sensitive to posaconazole (MIC range: 0.12−1mg/L). The
upper limit of posaconazole sensitivity has been tentatively been set at
1mg/L.
Conclusions: Decrease in the susceptibility of the colonising C. al-
bicans strains to antifungals was noted in the mid-1990s. Currently,
symptomatic patients are prescribed topical polyenes. In some patients
eradication treatment of the ﬂuconazole resistant strains with iv
caspofungin or liposomal amphotericin B has been successful in
combination with topical polyenes and professional oral hygiene
procedures. The present data, which highlights the fungistatic and
fungicidal activity of posaconazole against strains with decreased
ﬂuconazole sensitivity, suggests that oral posaconazole would be
effective for treatment of candidosis caused by strains of C. albicans with
decreased sensitivity to ﬂuconazole in APECED patients. Furthermore,
posaconazole could be used as a ﬁrst-line drug for eradication treatment.
P1274 Decreased sensitivity of Candida albicans for azole
antifungals – a complication of long-term prophylaxis in
APECED patients
R. Rautemaa-Richardson, M. Richardson, M. Pfaller,
P. Koukila-Ka¨hko¨la¨, J. Perheentupa, H. Saxen (Helsinki, FI; Iowa, US)
Objectives: Autoimmune polyendocrinopathy-candidiasis-ectodermal
dystrophy (APECED) is an autosomal recessive disease exceptionally
common in Finland. Most patients have chronic oral candidosis since
early childhood and the infection has been suggested to be carcinogenic.
Thus, most patients receive repeated treatment and prophylactic courses
of antifungals throughout their lives. Since the late 1980s topical and
systemic azole antifungals, mainly ketoconazole and ﬂuconazole have
been used. In Finland 92 patients have been diagnosed with APECED
and 66 of them are alive. Our aim was to study the effect of long
term azole treatment on candidal colonisation of APECED patients and
changes in antifungal susceptibilities.
Methods: We gathered and evaluated the routine fungal culture reports,
antifungal susceptibility proﬁles and antifungal usage from 1994 to
2004 based on patient records of all 56 APECED patients followed
in our institution. Candida albicans strains of eleven patients reported
to have decreased azole antifungal sensitivity (n = 27) were re-analysed
for their species and sensitivity to ﬂuconazole. Candida albicans strains
of another eleven APECED patients reported to be sensitive to azole
antifungals (n = 16) were also re-analysed.
Results: A total of 162 fungal cultures had been performed of the 56
APECED patients during 1994 to 2004. Of these 42 (75%) had been
reported to be positive for Candida and 35 (63%) for C. albicans. Eleven
patients had been found to be colonised with a C. albicans strain with a
decreased sensitivity to ﬂuconazole. Seven patients had been reported to
harbour a non-C. albicans strain but only two of them with a decreased
ﬂuconazole sensitivity. Re-analysing the stored strains with decreased
sensitivity to ﬂuconazole showed that colonisation had evolved already
by the mid 1990s and seems to be persistent. The cessation of the use of
azoles and favouring topical polyenes since the year 2000 has not induced
colonisation with sensitive strains in the eleven patients. However, new
patients have not been reported to have become colonised with Candida
strains with decreased sensitivity to ﬂuconazole.
Conclusions: Due to the life long need for antifungal treatment and the
risk of selection of azole resistant Candida strains the use of topical
polyenes should be preferred and the use of repeated, low dose courses
all azoles should be avoided.
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P1275 Longitudinal trends in candidaemia in England and Wales
G. Gardiner, T. Lamagni (London, UK)
Objectives: In light of reports from many countries documenting
increases in the incidence of candidaemia, data from England and Wales
were analysed to characterise epidemiological patterns and trends in
these infections.
Methods: Laboratories across England and Wales participate in
population-based surveillance of infectious diseases. These data are
collated, managed and stored by the Health Protection Agency. Data were
extracted retrospectively on episodes of candidaemia voluntarily reported
between 1980 and 2005 and analysed for epidemiological patterns
and trends. Rates were calculated using mid-year resident population
estimates based on a national census carried out in 2001.
Results: Between 1990 and 2005, the rate of candidaemia across
England and Wales increased almost ﬁve fold from 0.6 to 3.1 per
100,000 population. In 2005, candidaemia reports accounted for 81% of
all invasive fungal infections. The proportion of bloodstream infections
(bacterial and fungal) due to Candida species increased steadily between
1980 and 2005, from 0.74% to 1.79%. Candidaemia rates were higher
in males than females overall (3.4 vs 2.9/100,000; RR= 1.19; 95%CI:
1.08–1.31). Cases were concentrated in infants (15.4 and 8.7/100,000 in
<1 year old males and females respectively) and the elderly (12.1 and
7.1/100,000 in 75 year old males and females respectively). Candida
albicans accounted for 55% of candidaemia reports in 2005 with the
other common species including C. glabrata (18%) and C. parapsilosis
(10%). The distribution of Candida species changed substantially
between 1986 and 1998 where the proportion of candidaemia reports due
to C. albicans fell from 75% to 54%, with increases observed amongst
C. glabrata, C. parapsilosis and C. tropicalis species.
Conclusion: Analysis of trends in candidaemia in England and Wales
has shown marked increases in the rates of disease, more pronounced
than generally seen for bacteraemic infections over the past two decades.
Surveillance has shown changes in the epidemiology of these infections,
in particular a decrease in the proportion of reports due to C. albicans
between 1986 and 1998. This may be of clinical importance with
many non-albicans species being inherently less susceptible to antifungal
agents.
P1276 Ten years of Candida glabrata and C. krusei fungaemia:
epidemiology and susceptibility patterns in a tertiary-care
hospital
M. Bosch, E. Calabuig, J. Pema´n, A. Valentı´n, A. Viudes, E. Canto´n,
M. Gobernado (Valencia, ES)
Objective: To study the incidence, clinical features and susceptibility
patterns of candidaemia caused by Candida glabrata (CG) and Candida
krusei (CK), two species with diminished ﬂuconazole susceptibility, in
a tertiary care hospital during the last ten years.
Methods: Retrospective study of all candidaemia episodes by CG and
CK diagnosed from January 1995 to December 2004 at La Fe University
Hospital. Mycology, laboratory and clinical records were reviewed. The
susceptibility study was carried out using the M27-A2 document.
Results: In the period studied, 567 episodes of candidaemia were
found, 23 of them were due to CG and 26 to CK. The 93.9
and 69.4% of patients were adults and male, respectively. The most
important underlying conditions were haematological malignancy (49%),
solid organ transplantation (6.1%) and pancreatitis (6.1%). The major
predisposing factors were, respectively, previous antibiotic therapy
(100%), intravascular line (89.5%; 31.6 and 57.6%), neutropenia (55.3%;
5.3 and 50%) and previous chemotherapy (55.26%; 2.63 and 52.63%),
antifungal prophylaxis (44.74%; 2.63 and 42.11%) and parenteral
nutrition (28.9%; 18.4 and 10.5%). 28.6% episodes of candidaemia
occurred in ICU patients, 65.31% in medical department patients
(46.9% haematological) and 4.1% in surgical patients. After diagnosis,
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84.2% of patients received antifungal treatment. Crude mortality rate of
candidaemia due to CG and CK were 50% and 63.64%, respectively. Risk
factors associated with death most frequently observed were previous
chemotherapy (59.1%), acute myelogenic leukaemia (45.4%), pneumonia
in HIV (13.6%) and coronary by-pass (13.6%).
Fluconazole MICs ranges (mg/L) for CK/CG, respectively, were 16−32/
0.5−32; itraconazole, 0.06−2/0.06−4; voriconazole, 0.03−1/0.06−4;
ﬂucytosine, 4−32/0.06−2 and amphotericin B, 0.06−2/0.03−1; and the
respective MIC90 (mg/L) for the same drugs were 32/32, 1/1, 1/1, 32/0.5
and 1/1.
Conclusions: CG plus CK are the third cause of candidaemia in our
hospital. Most of candidaemia episodes occur in adults. Major risk
factors for CG or CK candidaemia include broad-spectrum antibiotics,
intravascular line, neutropenia and chemotherapy. The crude mortality
in patients is high (57.9%). All isolates were susceptible to voriconazole
and amphotericin B.
This study has been partially ﬁnanced by a Grant (2/2005/0140) from
the Fundacio´n Investigacio´n del HU La Fe and a Grant from the ISCIII
(CM04/00248).
P1277 Caspofungin for the treatment of invasive mycoses in
critically ill patients (ProCAS study)
C. Leon for the ProCAS Study Group – Grupo de Trabajo en
Enfermedades Infecciosas (GTEI), SEMICYUC
Introduction: Caspofungin is an echinocandin with proven efﬁcacy
against invasive candidiasis (IC) and aspergillosis (IA). The ProCAS
study is an ongoing multicentre, prospective, noncomparative observa-
tional study co-sponsored by GTEI-SEMICYUC and PETHEMA and
funded by MSD Spain, aimed at estimating the effectiveness and safety
of caspofungin in adults with IC or IA under everyday conditons.
Methods: The interim analysis herein presented focused on the ﬁrst
64 critically ill patients enrolled. Caspofungin was generally dosed
as recommended in the package insert. Favourable outcomes included
complete and partial responses on the last day of caspofungin therapy.
Safety was assessed up to 14 days post-caspofungin.
Results: Thirty-three [52%] medical, 26 [41%] surgical, and 5 [8%]
trauma critically ill patients were analysed. The median age was 58 years
(range, 21−83). Nineteen (30%) patients had candidaemia, 16 (25%)
other types of IC, 14 (22%) suspected IC (11 had a Candida Score
[Crit Care Med. 2006 Mar;34(3):730−7] of >2.5), 14 (22%) suspected
or proven IA, and one (2%) mucormycosis. Candida albicans was the
single most frequently isolated species causing documented IC (54%),
followed by C. glabrata (16%), C. krusei (11%), C. tropicalis (8%),
and C. parapsilosis and Candida spp. (5% each). The median duration
of caspofungin therapy was 15 days (range, 2–337). Caspofungin was
given as ﬁrst line therapy to 40 (63%) patients. The remaining patients
were either refractory (21 [33%]) and/or intolerant (2 [6%]) of other
drugs. Eleven (17%) patients received it in combination with other
antifungals. Favourable response rates were 83% (29/35) for proven IC
and 50% (4/8) for documented (proven or probable per EORTC criteria)
mould infections. Overall, 4 (6%) patients had an adverse reaction to
caspofungin (three non-serious, one serious). No signiﬁcant changes in
serum liver function tests and creatinine occurred during caspofungin
therapy. No relapse was detected among patients with documented IC
or IA who responded favourably to caspofungin (median follow-up, 61
days; range, 1–102). Overall and infection-related mortalities were 44%
(28/64) and 31% (20/64).
Conclusion: The results of this interim analysis of the ProCAS Study
suggest that, under everyday conditions, caspofungin is an effective and
safe alternative for the treatment of invasive mycoses in critically ill
patients.
P1278 Prevalence and epidemiology of onychomychosis in diabetic
patients in Duzce, Turkey
A. Gulcan, I. Sahin, M. Yildirim, S. Oksuz, E. Gulcan, D. Kaya (Duzce,
Kutahya, TR)
Objectives: In comparison with the general population, patient with
diabetes mellitus are predisposed to mycotic infections. The aim of this
study was to determine frequency of onychomycosis in diabetic patients,
to identify causative agents, and to evaluate diabetic and epidemiologic
risk factors.
Materials and Methods: Three hundred and thirty one diabetic patients
were included in the study. Of 331 diabetic patients, there were 217
(65.6%) women and 114 (34.4%) men with an age range of 18 to 88
years (mean: 55.6 ±11.8). Type 1 diabetes was present in 10 (3%)
patients (6 men, 4 women) and type 2 diabetes was in 321 (97%)
patients (108 men, 211 women). The demogaphic and clinical data of
the diabetic patients were interrogated by face to face interview. Samples
from clinically abnormal nails were collected by vigorously scraping the
distal portion of the nail. All specimens collected were analysed by
direct microscopy and culture. Onychomycosis frequences relation with
demographic, epidemiologic and diabetic features in diabetic patients
were evaluated Logistic Regression analysis.
Results: Forty-two (12.6%) patients were diagnosed as onychomycosis
mycologically. Of the isolated fungi, 24 (57.1%) were yeasts (19
Candida spp. and 5 Rhodotorula spp.), 18 (42.9%) dermatophytes
(13 T. rubrum, 4 T. mentagrophytes, and 1 T. tonsurans). The signiﬁcant
correlation was found between the frequency of onychomycosis and
obesity (B = 1.446, p = 0.002), the time of nail growth (B = 1.124,
p = 0.006), wearing nylon socks (B = 1.151, p = 0.009), not drying
extremities after ritual ablution (B = −1.430, p = 0.011), family history
(B = 1.044, p = 0.012), and duration of diabetes (B = 1.002, p = 0.038).
The data are shown in Table 1.
Table 1. Relation between onychomycosis and the risk factors
Risk factor N Onychomycosis P B Exp(B)
n % Exp(B) 95%CI
Duration of diabetes (years)
0−10 244 29 11.9 0.038 1.002 2.724 1.056–7.026
>10 87 13 14.9
Not drying after ablution
yes 87 5 5.7 0.011 −1.430 0.239 0.079–0.720
no 187 35 18.7
Wearing nylon socks
yes 157 32 20.4 0.009 1.151 3.161 1.338–7.470
no 174 10 5.7
BMI (kg/m2)
<30 133 9 6.8 0.002 1.446 4.244 1.694–10.631
30 139 33 23.7
Family History
Yes 104 23 22.1 0.012 1.044 2.840 1.260–6.402
No 227 19 8.4
Time of nail growth (week)
<2mm 242 19 7.9 0.006 1.124 3.076 1.391–6.800
>2mm 89 23 25.8
Conclusions: These results indicated that education of the diabetic
patients about the importance of the simple preventions, foot and nail
care should be essential components of diabetes management.
P1279 Candida dubliniensis in a general hospital over an 8-year
period
M. Guembe, T. Pela´ez, C. Matesanz, M. Torres-Narbona, J. Guinea,
L. Alcala´, E. Bouza, P. Mun˜oz (Madrid, ES)
Objectives: C. dubliniensis is a recognized fungal pathogen causing
mucosal disease in AIDS patients. We investigated the incidence and
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antifungal susceptibility of C. dubliniensis isolated from clinical samples
during an 8-year period in our hospital (1999–2006).
Methods: The antifungal susceptibility patterns for amphotericin B (AB),
ﬂuconazole (FZ), itraconazole (IZ), ketoconazole (KZ), voricona-
zole (VZ), posaconazole (PZ), ﬂucytosine (FC), and caspofungin (CS)
were determined by the broth microdilution method (Sensititre YeastOne
YO7) and E test. The isolates were identiﬁed as C. dubliniensis by their
inability to grow at 45ºC and by rapID 32C (bioMe´rieux).
Results: A total of 76 isolates of C. dubliniensis (49 patients) were
recorded. The distribution of isolates and patients (isolates/patients)
during the study period was as follows: 1999 (1/1), 2000 (0/0), 2001
(4/4), 2002 (11/5), 2003 (6/6), 2004 (30/23), 2005 (6/2) and 2006 (18/8).
Clinical isolates were obtained from mucocutaneous sites (17/22%),
respiratory tract samples (51/67%) and normally-sterile sites (8/11%).
Overall, 35 of our 49 patients were HIV-infected. The MIC ranges (mg/L)
of antifungal agents tested against C. dubliniensis were as follows:
AB (0.008–0.06), FZ (0.06−1), IZ (0.008–0.125), KZ (0.008–0.03), VZ
(0.008–0.016), PZ (0.002–0.25), FC (0.003−0.5), and CS (0.016−0.5).
The overall geometric mean and MIC90 (mg/L) were as follows: AB
(0.034/0.06), FZ (0.117/0.25), IZ (0.020/0.06), KZ (0.010/0.016), VZ
(0.008/0.008), PZ (0.018/0.125), FC (0.043/0.006), and CS (0.096/0.25.
Conclusions: C. dubliniensis is increasingly isolated in our microbiology
laboratory and remains susceptible “in vitro” to the most commonly used
antifungal agents.
P1280 A study on Candida blood stream infection at university
hospitals, Leicester, UK
S.C. Hardman, N. Perera (Leicester, UK)
Objectives: To follow up all new episodes of Candida blood stream
infections (CBSI) with a view to inform the antifungal treatment
guidelines in the Trust.
Methods: All patients with a new episode of Candida blood stream
infection between January 2005 and June 2006 were identiﬁed. Isolates
were identiﬁed by AUXACOLOURTM2, Bio-Rad France and were
tested for antifungal susceptibility to six antifungal drugs by YeastOne™
Sensititre, Trek Diagnostic Systems Ltd, UK. All relevant clinical
information was collated by clinical and case note review.
Results: A total of 60 patients with 61 episodes of CBSI were identiﬁed.
Ages ranged from 28 days to 90 years, and 36 patients were males.
59 isolates were identiﬁed to species level, of which 28 were C. albicans.
The rest were non-albicans: 15 C. glabrata, 9 C. parapsilosis and
2 C. krusei isolates. All C. albicans and 19 non-albicans isolates were
susceptible to ﬂuconazole (MIC 8). The latter included 8 C. glabrata
and 8 C. parapsilosis. Resistance to amphotericin (MIC 2) was seen
in non-albicans isolates only and included one each of C. krusei and
C. inconspicua. 90% of patients with CBSI were adults, of whom
27 were from the intensive care units (ICU), 13 from haematology and
oncology and 5 from the renal ward. 10% were paediatric. These included
3 from paediatric haematology and oncology, and one each from the
paediatric ICU, the neonatal unit and general paediatrics. 10/27 isolates
from the adult ICU were non-albicans, of which two isolates were
resistant to ﬂuconazole, both from haematology patients. 11/13 isolates
from adult haematology and oncology were non-albicans, with 45%
resistant to ﬂuconazole. There were several host factors associated with
CBSI. These included colonisation with Candida, central venous catheter
in situ, neutropenia and antifungal prophylaxis. From the data available
at the time of writing 25 patients were alive at 30 days follow up.
Data on associated factors including the timeliness of line removal,
antifungal prophylaxis, treatment including duration and mortality will
be presented.
Conclusion: The drug of choice for empirical antifungal therapy for
non haematology oncology patients should be ﬂuconazole pending
sensitivities. In view of the higher number of non-albicans isolates with
a signiﬁcant percentage of resistance to ﬂuconazole in adult haematology
and oncology the current practice of ﬂuconazole for empirical therapy
needs to be revisited.
P1281 Analysis of clinical characteristics in 53 patients with
Crypotococcus neoformans meningitis
X.J. Lu (Chengdu, CN)
Objective: To analyse the clinical characteristics of Crypotococcus
neoformans meningitis and provide evidence for clinical diagnosis and
therapy.
Method: The clinical manifestations, data of laboratory examination,
features of CT and MRI, antifungal therapy and prognosis of
Crypotococcus meningitis were analysed retrospectively in 53 patients.
Results: All patients were conﬁrmed by cerebral spinal ﬂuid smear
staining 31 cases were positive at ﬁrst puncture, 6 cases were positive just
at the 6th puncture time, the others were positive at 2nd or 3rd time and
culture. The main clinical manifestations were intracranial hypertension
and signs of meningeal irritation in 53 patients. Thirty out of 53 (56%)
patients had underlying diseases and 30 had the history of contact with
pigeons or poultries. The intracranial pressure increased in 51 (96%)
cases, 49 (54%) cases had intracranial pressure over 200mmH2o. For
treatment, 30 patients accepted intravenus amphotericin B combining
with ﬂuconazole. When patients discharged from hospital, 4 out of 53
cases were cured (the therapy duration were 24 days, 55 days, 76 days
and 245 days respectively), 23 were improved, 5 died and 18 giving up
any further treatment due to poor economic condition.
Conclusion: The clinical manifestations of Crypotococcus meningitis
are mainly progressive intracranial hypertension. When progressive
intracranial hypertension and meningeal irritation syndrome occur,
cerebral spinal ﬂuid should be examined repeatedly by Indian ink
staining and culture so as to prevent misdiagnosis and mistreatment. It is
indicated that amphotericin B combining with ﬂuconazole are effective
and well tolerated in treatment of Crypotococcus meningitis.
P1282 Risk factors and outcome of critical ill patients with
candidaemia
M. Pratikaki, E. Platsouka, C. Routsi, C. Sotiropoulou, A. Priovolos,
E. Angelopoulos, O. Paniara, C. Roussos (Athens, GR)
Objective: To determine the incidence and risk factors of Candida
bloodstream infection in non-neutropenic critically ill patients and to
deﬁne whether nosocomial candidaemia is associated with increased
mortality in intensive care unit (ICU) patients.
Methods: This is a retrospective cohort study, conducted in the
30-bed multidisciplinary ICU of Evangelismos Hospital in Athens,
during a 18-month period (August 2004–January 2006). All patients
with ICU stay more than 48 hours were included. Patients with
microbiologically documented candidaemia were matched to control
patients (1:4). Matching was based on an equivalent APACHE II score
(±2 points), diagnostic category, and length of ICU stay (±2 days).
Results: During the study period, 33 of 855 consecutively admitted
patients developed one or more episodes of candidaemia, giving an
incidence of 3.86 per 100 patients. Candida albicans was identiﬁed in
11 patients (33.3%) and Candida non-albicans species in 22 patients
(66.7%). Population characteristics, included age, gender, underlying
disease, hospitalisation before ICU admission, length of ICU stay and in-
hospital mortality rates of patients with candidaemia and their controls
were compared. We used APACHE II score on ICU admission to
compute the total estimated risk of death for all patients; this was
23% (12.15–50.5), median value. Mortality rates for cases and controls
were 60.6% and 22.0% respectively, giving an attributable mortality of
38.6%. The best independent prognostic factor for the development of
candidaemia was the presence of ARDS (OR, 3.995; 95%CI 1.332–
11.983, p = 0.013). By multivariate analysis, independent predictors of
mortality for cases and their controls were: admission APACHE II
score (OR, 1.168; 95%CI 1.105–1.236, p< 0.001), and the presence
of candidaemia (OR, 9.374; 95%CI 3.479–25.259, p< 0.001). Also
multivariate analysis, showed that independent predictors of mortality
for candidemic patients, were: SOFA score (OR, 1.568; 95%CI 1.000–
2.457, p = 0.05), and hypoalbuminaemia (OR, 0.049; 95%CI 0.005–
0.515, p = 0.012), both on candidaemia day.
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Conclusion: The incidence of bloodstream infections caused by yeasts
was 3.86% in our ICU. There was a predominance of Candida species
other than Candida albicans, and candidaemia was associated with an
excess mortality rate.
P1283 Candidaemia in an intensive care unit
L. Rodriguez-Otero, I. Villamil-Cajoto, S. Cortizo, L. Moldes,
M.A. Garcia-Zabarte, A. Aguilera-Guirao, C. Garcia-Riestra,
B. Regueiro (Santiago de Compostela, ES)
Objectives: The incidence of candidaemia – a common and potentially
fatal nosocomial infection – has risen dramatically, and this increase
has been accompanied by a shift in the infecting pathogen away from
Candida albicans to treatment-resistant non-albicans species (NAS). In
this study, we attempted to identify the risk factors for candidaemia
caused by C. albicans and NAS.
Methods: We reviewed the clinical data on 80 inpatients with
candidaemia at an Intensive Care Unit of our tertiary University Hospital
in Spain, over a 5-year period. We deﬁned mortality as occurring between
days 3 to 30 after candidaemia.
Results: Candida albicans, C. parapsilosis, C. glabrata, C. tropicalis
and C. krusei caused 46%, 38%, 5%, 3% and 3% of the candidaemia
episodes, respectively. The overall mortality was 51% and it was highest
in patients suffering from candidaemia of the albicans species (73%)
compared NAS (40%). The risk factors to candidaemia caused by
C. albicans and NAS respectively included: keeping the catheter in place
more than 5 days 78%, 72%; use of total parenteral nutrition 32%,
51%; postoperative state of gastrointestinal tract surgery 35%, 44%;
administration of broad-spectrum or combination antibiotics 5 days or
more 78%, 77%; under corticosteroid therapy 47%, 36% and antifungal
prophylaxis 19%, 28%. The medium length of hospital stay were 61 and
127 days.
Conclusions: Prophylactic azole antifungals, and the use of parenteral
nutrition, may play an important role not only in the management of
candidaemia but also in the proliferation of hard-to-treat candida species.
P1284 Efﬁcacy and safety of voriconazole in real-life setting in
Belgium: results from the Voribel-1 trial
F. Jacobs, D. Selleslag, M. Aoun, A. Sonnet, A. Gadisseur, P. Damas,
P. Laterre, O. Van Der Meeren (Brussels, Brugge, Yvoir, Antwerp,
Lie`ge, BE)
Objective: Voriconazole (VRC) is standard of care for invasive
aspergillosis (IA) and a key treatment option for candidaemia and
invasive candidiasis (CC). VRC has been granted reimbursement by the
Belgian Health System in 2003 under the condition to conﬁrm its safety,
efﬁcacy and cost-efﬁcacy through an observational study in a local real-
life setting. The clinical results are presented here.
Methods: A national multicentre prospective non-interventional study
was initiated after approval by ethics committees. All patients (p)
receiving VRC and presenting with proven/probable IA or CC were
allowed to enter a 12-week follow-up. A sample size of at least 120p
was needed to test the hypothesis that based on average cost, the real-life
setting is not inferior to the pharmacoeconomic model assumed in the
reimbursement dossier.
Results: 141p started treatment with VRC at 14 sites between 3/2004
and 9/2005. Most p were adults with proven/probable IA (116); 9 adults
had CC, 5p were children (all with CC) and 11p had a primary diagnosis
outside the scope of the study. Most p (90%) were immunocompromised
and suffered from haematological conditions (leukaemia 43%, stem-cell
transplantation 21%) or had undergone solid organ transplantation (9%).
In adult p with IA, a complete or partial clinical response was observed
in 50% of p after median treatment duration of 50 days; the mortality
rates by day 14, 42 and 84 were 14%, 27% and 42% respectively. Most
patients (64%) were treated with VRC only and didn’t switch, combine or
interrupt therapy; 41% of p received the oral formulation only and 29%
received both the IV and oral forms sequentially. Serious adverse events
regarded as possibly drug-related were reported in 3p (2%); 23p (16%)
discontinued VRC for safety issues. No new or unexpected adverse event
was reported.
Discussion: In p with proven/probable IA, the response rate of 50% in
this real-life setting conﬁrms the results of the landmark randomised
trial by Herbrecht et al (53%); this result is achieved despite a shorter
median treatment duration (50 vs 77 days). Not surprisingly, the death
rate at week 12 in our non-selected p population is slightly higher than
in the randomised series (42% vs 29%).
Conclusions: In this large real-life cohort, VRC demonstrates very
similar safety and efﬁcacy for patients with IA than in published
randomised trial. The shorter treatment duration and the broad use of
oral therapy are remarkable from an economic perspective.
P1285 Empirical treatment of Candidaemia in intensive care
units: ﬂuconazole or broad-spectrum antifungal agents?
J. Guinea, T. Pela´ez, M. Torres-Narbona, P. Mun˜oz, L. Alcala´, E. Bouza
(Madrid, ES)
Objectives: The fear of candidaemia by a ﬂuconazole-resistant species
of Candida is causing many ICUs to switch empiric therapy from
ﬂuconazole to broad-spectrum antifungal agents, such as amphotericin B
or caspofungin. Our hypothesis was that the risk of having an episode of
candidaemia or invasive candidiasis by an “in vitro” ﬂuconazole-resistant
strain was low and did not justify the empiric selection of broad-spectrum
antifungal drugs.
Methods:We determined the species of Candida involved in episodes of
invasive candidiasis and/or candidaemia in patients admitted to the three
adult ICUs of our institution and evaluated the ﬂuconazole antifungal
susceptibility of each isolate. We estimated the proportion of episodes
produced by ﬂuconazole-resistant species of Candida from 1988 to 2006.
Results: 271 patients admitted to ICUs had proven invasive candidiasis
or candidaemia and 520 strains were isolated from normally sterile
sites from them. Candida albicans (60.9%), C. tropicalis (5.2%),
C. parapsilosis (15%), and a miscellany of other species (3.7%)
represented 84.8% of the isolates and were uniformly susceptible to
ﬂuconazole. Of the remaining strains, C. glabrata (13.3%) and C. krusei
(1.9%) were responsible for invasive candidiasis in 38 patients, but only
in nine were the isolates ﬂuconazole-resistant in vitro (MIC 64mg/mL).
Overall, only 3.3% of the episodes of candidaemia or invasive candidiasis
in our institution had an isolate resistant to ﬂuconazole in vitro (the 6
C. krusei isolates and 3 of 32 C. glabrata isolates).
Conclusion: The generalised use of broad-spectrum antifungal agents
for the empirical treatment of invasive candidiasis in ICUs may not be
universally justiﬁed.
Jesu´s Guinea Pharm D, PhD, is contracted by the Fondo de Investigacio´n
Sanitaria (FIS), contract number CM05/00171.
P1286 Association between oral candidiasis and immunity level in
a population of drug addicts in a centre for prevention and
treatment of drug addictions in Rome, Italy
L. Rocchi, D. D’Alessandro, M. Fabiani, J.F. Osborn, C. Leonardi,
G. Tarsitani, R. Grillot, N. Vescia (Rome, IT; Grenoble, FR)
Objectives: To evaluate the prevalence of Candida infections in the
oral cavity of a population of drug addicts, in order: (1) to test
the susceptibility of Candida isolates to antifungal compounds;
(2) to evaluate the relationship between history of drug abuse, Candida
infection and CD4 levels.
Methods: Fifty-seven drug addicts were enrolled in the prospective
study: oral samples were collected from each one and cultured for
yeast detection on selective medium. The Candida isolates were
identiﬁed by API 20C AUX® (bioMe´rieux, France) and C. dubliniensis
by BICROMO-DUBLI® (Fumouze Diagnostic, France). Using E-test
(AB Biodisk, Sweeden), the strains’ susceptibility to ﬂuconazole was
determined. Regression analysis and signiﬁcance test were used to
compare means and distributions.
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Results: Heroin (55 subjects, 96.5%) and/or cocaine (31 subjects,
54.4%) were the drugs most used, and 51 subjects (89.5%) were addict
to more than one drug. The duration of the drug addiction varied from 1
to 26 years (mean 13.4). Nine subjects (15.8%) were HIV-infected. The
prevalence of oro-pharyngeal candidiasis was 31.6% (18 subjects): 11
cases >250 CFU and 7 cases 50–250 CFU. C. albicans was the most
common species (n = 16, 88.8%) and infection due to C. dubliniensis
was identiﬁed in 4 subjects (22.2%). 87% of C. albicans and 86% of
C. dubliniensis isolates were susceptible to ﬂuconazole (MIC  8 micro-
g/mL). The CD4 count was less than 500/mL in 8 subjects (14.03%) and
for 3 of them, HIV positive, it was less than 200/mL. The difference
between the mean values of PMNs was statistically signiﬁcant (mean
difference 1,479.3; P = 0.04) in subjects with >150 CFU of Candida
in oral cavity. There was no evidence of an association between CD4
count and years of use of heroin. However the percentage level of CD4
reduced on average by 0.033 for each additional year of heroin use
(P = 0.03). The difference between the mean years of use of heroin in
subjects infected or not by C. dubliniensis (difference: 6.35 years) was
statistically signiﬁcant (P< 0.05).
Conclusion: This work shows an association between oral candidiasis
(>150 CFU) and reduction in the level of PMNs. The percentage of CD4
is lower in patients who abuse heroin together with other drugs, and the
reduction is proportional to the number of years of drug use. The ﬁnding
of C. dubliniensis in the oral cavity is associated with the duration of
heroin abuse.
P1287 Transmission of Pneumocystis jirovecii from the grandparent
immunocompetent carriers to his susceptible granddaughter
L. Rivero, M. Montes-Cano, C. de la Horra, N. Respaldiza, V. Friaza,
F. Munoz-Lobato, R. Morilla, F. Medrano, J. Varela, E. Calderon
(Seville, ES)
Objectives: Pneumocystis jirovecii causes pneumonia in immunocom-
promised host but was ﬁrst identiﬁed as an interstitial pneumonia
involving premature and malnourished children. Asymptomatic forms
of Pneumocystis infection have been described in immunocompetent
persons like patients with chronic respiratory diseases who could play a
role for the transmission to susceptible persons. Clusters of Pneumocystis
pneumonia (PCP) cases among immunosuppressed patients suggesting
person to person transmission have been described. This study was
undertaken to determine if PCP could have been caused by familiar
transmission.
Methods: A six months old female was hospitalised for acute bilateral
pneumonia associated with chronic dry cough. Diagnostic test revealed
severe malnutrition and PCP. Oral wash samples were collected from:
mother, father, brother, grandmother and grandfather who referred a
history of rheumatoid arthritis and chronic bronchitis respectively. None
of them had symptoms at the moment of the study. DNA was extracted
using a commercial kit. The mt LSU rRNA gene was identiﬁed by nested-
PCR; polymorphism at nucleotide position 85 and 248 were stablishing
by direct sequencing.
Non-cohabitant Non-cohabitant Grandmother
Genotype 1
Grandfather
Genotype 1,3
Mother
Negative
Father
Negative
Index case
Genotype 1
Fig. 1. Probable transmission of P. jirovecii infection from grandparents
to infant.
Results: The mt LSU rRNA gene of P. jirovecii was identiﬁed in
three cases: the infant, the grandmother and the grandfather. The child
and grandparents showed the same cluster of P. jirovecii, genotype 1
(85C/248C) was identiﬁed in the three cases, and genotype 3 (85T/248C)
was also detected in the grandfather.
Conclusion: Our ﬁndings support a probable transmission of Pneu-
mocystis infection from the grandparent asymptomatic carrier to his
susceptible granddaughter.
P1288 Trichosporon asahii in hospitalised patients
M. Kanellopoulou, A. Velegraki, D. Adamou, M. Martsoukou,
A. Milioni, N. Skarmoutsou, E. Papafrangas (Athens, GR)
Trichosporon asahii is implicated in a variety of clinical manifestations
ranging from simple superﬁcial cutaneus to severe invasive disease.
Objectives: To assess the incidence of T. asahii in clinical specimens
from patients with different underlying conditions and to retrospectively
compare the molecular subtypes of isolates in a period of three years
(2002–2005) in a tertiary Greek hospital.
Patients and Methods: Isolates originated from 12 males and
5 females, (mean age 69 years) with cerebral completed stroke
(n = 5), diabetes mellitus (n = 4), ureterostomy-nephrostomy (n = 3),
renal dysfunction (n = 2), COPD (n = 2), rheumatoid arthritis (n = 1).
Indwelling catheter was present in all patients. T. asahii identiﬁcation
was performed by API ID32C, bioMe´rieux, France). Complementary
biochemical and physiological tests conﬁrmed characterisation of the
strains. PCR ﬁngerprinting by a minisatellite speciﬁc primer M13 [5′-
GAGGGTGGCGGTTC-3′] was used for strain delineation.
Results: During the study period, 17 T. asahii strains were isolated
from an equal number of patients. Fifteen strains were recovered from
urine specimens, and two from respiratory secretions. The two patients
with T. asahii isolated from respiratory secretions were intubated. Eleven
strains were isolated from the same clinic at different time intervals.
Minisatellite ﬁngerprinting grouped the in time and space related isolates
in a single cluster.
Conclusion: (1) Although T. asahii is classed as an emerging
opportunistic agent, in this study was exclusively associated to
colonisation of the urinary tract. (2) Risk factors for colonisation
included indwelling/endotracheal catheter, diabetes mellitus, and old age.
(3) The low T. asahii prevalence among these high-risk groups of patients
over a period of three years is in accordance with the prevalence recorded
internationally. (4) Pending examination of a larger sample size, M13
minisatellite ﬁngerprinting can be recommended for rapid prospective
identiﬁcation of hospital outbreaks.
P1289 Candida kefyr: a new emerging pathogen?
S. Agudo, J. Navarro, C. De Las Cuevas, M. Moreno, B. Buendia,
D. Domingo, T. Alarcon, M. Lopez Brea (Madrid, ES)
Introduction: Candida species are present as normal microﬂora in
humans, alterations in host defences can lead to the development of
the disease. Candida infections include a wide range of infections,
they are common in immunodepressed patients. Infections with non-
albicans Candida species are becoming more frequent. Candida kefyr
is an uncommon fungal pathogen. It is found in dairy products and in
humans as normal ﬂora of the respiratory tract, but it is rare in the
skin. This organism has been isolated from multiple milk products, for
example bovine milk contains at least 16 different species of yeasts
including C. kefyr. In this study we report 6 cases of C. kefyr isolation.
Methods: All the specimens received at the Department of Microbiology
(Hospital Universitario de la Princesa, Madrid) from January 1st 2004 to
November 8th 2006 were cultured according to standard microbiological
procedures. Yeast identiﬁcation was performed using ChromAgar®,
morphology in Corn Meal Agar and Auxacolor®. Clinical ﬁles of
C. kefyr positive patients were checked.
Results: 6 cases of C. kefyr isolation were found, 5 of which were
obtained in the last year. It was only a 0.1% incidence rate of all
Candida species isolated during these three years. Case 1 was a 82 year-
old woman who had multiorganic failure in the context of respiratory
failure after pulmonary thromboembolism. Case 2 was a 91 year-old
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woman who suffered a stroke with important neurological consequences.
Case 3 was a 83 year-old who had several repetitions of urinary tract
infections. In the ﬁrst and the second cases, C. kefyr was isolated from
urine cultures in May 2006. In the third case, it was found in urine
culture in January 2005. Case 4 was a 73 year-old man with multiorganic
failure caused by hepatic encephalopathy. This case of C. kefyr was
detected in bloodstream in September 2006. Case 5 was a 77 year-old
man with acute renal failure and respiratory failure; C. kefyr was found
in bronchoaspirate in April 2006. Case 6 was a 87 year-old woman with
gastric cancer; C. kefyr was isolated from peritoneal liquid in October
2006.
Conclusion: C. kefyr is an uncommon human pathogen. The three
patients reported here were elderly and had severe physical deterioration;
however the clinical signiﬁcance of these isolates remains unclear.
C. kefyr infections reﬂect the increase in Candida species as responsible
of disseminated infections in immunodepressed patients.
P1290 Fungal keratitis in healthcare area of
Santiago de Compostela (Galicia, NW Spain)
F. Pardo, P. Romero, M. Pe´rez del Molino, L. Martı´nez, S. Cortizo,
B. De Domingo, T. Rodrı´guez-Ares (Santiago de Compostela, ES)
Objective: The aim of this study is to analyse risk factors, incidence,
visual signs and symptoms, treatment in fungal keratitis diagnosed in the
Health Care Area of Santiago de Compostela between November 1998
and May 2006.
Methods: Retrospective study of the 22 fungal keratitis diagnosed in
the Health Care Area of Santiago de Compostela between November
1998 and May 2006. Medical records were reviewed for all patients.
Demographic data, clinical signs and symptoms, microbiologic isolations
and treatment were analysed in SPSS programme.
Results: 22 patients were included in this study, 10 males (45.5%)
and 12 females (54.5%). The mean age were 60.32 years (28−87).
Corneal inﬁltrate: 31.8% (7/22) were 1−2mm and 68.2% (15/22) >2mm.
Peripheric lesions were observed in 22.7% and 77.3% in central corneal
zone. Two patients showed satellite lesions. All patients (100%) had
Thyndall in anterior chamber and 81.8% (18/22) had hypopyon and
keratic precipitate at the same time. Principal local risk factors were:
topical corticoid treatment (27.3%), previous ocular surgery (22.8%),
ocular trauma (18.2%), ocular herpes infection (18.2%), contact-lents
user (9.1%), previous ocular disease (9.1%).
Fungal isolation: 57.1% (13/22) were Candida species, and the
most frequent isolates were Candida albicans (53%, 7/13), followed
by C. parapsilosis (38.4%, 5/13) and C. glabrata (7.6%, 1/13).
Filamentous fungi were isolated in 42.9% (9/22), Fusarium spp. (55.6%,
5/9), Aspergillus spp. (22.2%, 2/9), Dactilaria spp. (11.1%, 1/9),
Alternaria spp. (11.1%, 1/9). Topical and systemic antifungal treatment
was performed in all cases. Amphotericin B was used in 77% of cases,
and in 3 cases inside the anterior chamber. Voriconazol was used in
two cases with no improvement with conventional treatment and showed
clinic amelioration.
Conclusion: (1) Annual incidence in this study was 2.7 cases/year,
higher than European average. We observed the major number of
cases in autumn, probably due to high relative humidity and temperate
temperatures. (2) The most frequent isolate was Candida albicans.
(3) The more frequent local risk factors were: local corticoid therapy,
previous ocular surgery and ocular trauma. (4) Pharmacological and
surgery treatment together were necessary in 25% of the patients to
control the infection. (5) 76% had no posterior relapse due to an
appropiate control of the infection.
P1291 Aspergillus keratomycosis at an eye hospital in south India:
a retrospective study
L. Kredics, P. Manikandan, S. Kocsube´, I. Do´czi, V. Narendran,
J. Varga, Z. Antal, C. Va´gvo¨lgyi, R. Revathi, E. Nagy (Szeged, HU;
Coimbatore, IN)
Objectives: The objectives of this study were to analyse the
epidemiological features of Aspergillus keratitis in South India, to
perform morphology-based and molecular identiﬁcation of Aspergillus
strains isolated from keratomycosis patients, to determine the antifungal
susceptibilities of the isolates and to study their genetic diversity.
Methods: 26 Aspergillus strains isolated from keratomycosis in the
Aravind Eye Hospital between August 2005 and February 2006 were
involved in the study. Epidemiological data were recorded for the
patients. Morphological examination was performed by microscopy,
culture characteristics were studied on malt extract agar. Molecular
identiﬁcation was carried out by sequence analysis of the ITS region.
Antifungal susceptibilities were determined by the E-test method.
Results: The 26 patients included 17 males and 9 females. Rural,
semiurban and urban populations were represented among the patients
with 23, 50 and 27%, respectively. Farmer was the most frequent
occupation among the male patients, while most of the female
patients were housewives. Corneal trauma was reported as the potential
predisposing condition of the infection for 57.7% of the patients, the
traumatising agents were dust or iron particles, insects or plant seeds.
Among the further possible predisposing conditions, systemic diseases
like diabetes mellitus and hypertension proved to be frequent. The
antifungal drugs applied for the therapy of patients included natamycin,
itraconazole, ketoconazole, econazole, clotrimazole and amphotericin B.
Therapeutic keratoplasty was performed in the case of 9 patients. Most
of the isolates proved to belong to the species A. ﬂavus, however, other
species of the genus including A. terreus, A. fumigatus and A. tamarii
were also represented in the sample. The initial identiﬁcation of the
isolates based on conidial- and colony morphology could be conﬁrmed
by ITS sequence analysis. All of the examined strains proved to be
resistant to ﬂuconazole with MIC values above 256mg/L. MIC-ranges
of the other examined antifungal drugs were in the following ranges
(mg/L): 0.064−4 for amphotericin B, 0.25−1 for ketoconazole, 0.064−32
for itraconazole and 0.064−1 for voriconazole.
Conclusions: Our data provide important information on the current
incidence of Aspergillus species in corneal ulcers in South-India
conﬁrmed by molecular diagnosis, as well as useful ideas for the
selection of the appropriate antifungal agents.
P1292 Fatal case of antritis caused by mucormycosis in patient
with diabetes mellitus
S. Tsoutsos, Z. Alexiou, A. Kallitsis, P. Konstantopoulos, T. Loukas,
G. Liappi, G. Panoutsopoulos (Elefsina, GR)
Objectives: Mucormycoses are potentially fatal infections unless they
receive immediate diagnosis, followed by surgical and pharmaceutical
treatment.
Methods: Description of the case. M, 75 y.o., was admitted with
symptoms of diabetic ketoacidosis and fever. He developed within
24 hours a strong headache, confusion, amaurosis of vision on both
sides and aglutition.
Results: Physical examination ﬁndings: Edema and proptosis of
orbits, opthalmoplegia on both sides. ENT examination found an
extensive necrosis of the quadrangular septal cartilage, extending to
the perpendicular plate of the ethmoid, enlargement of nasal chambers
due to necrosis of the inferior and middle nasal conchae on both
sides. An extended necrosis of the hard palate and inhibition of
the pharyngeal rephlex were found from the orphopharynx. The CT
imaging protocol: visceral cranium: Enlargement of nasal chambers
to a large extent, both the anterior and posterior ethmoidal air cells,
the sphenoid sinuses and the left antrum maxillare were affected,
cerebral leukoencephalopathy lesions, microinfarcts of periventricular
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white matter, cerebellum atrophy. Thorax ﬁndings: ascending thoracic
aorta aneurysm. Laboratory examination: WBC 18,900, PMN 89%,
MO 7.5%, HCT 39.9%, ESR 124mm, CRP 108mg/dl, lgG 1,130mg/dl,
lgA 903mg/dl, lgM 219mg/dl, C3 167, C4 32.6. CSF examination:
Protein <20mg/dl, Glu 118mg/dl, LDH 75, cells 35. The nasal mucosa
tissue biopsy revealed a hyphomyces of the genus Mucor. Histological
evaluation show necrotic changes of the superﬁcial layers of the nasal
mucosa and necrosis of many vessels caused by mucor. Alcian blue-
PAS stain accentuated the wide-angle branching hyphae characteristic of
mucor. Diabetic ketoacidosis and respiratory infection were treated with
ceftriaxon and amphotericin B. Surgical treatment of the disease was
contraindicated. The patient died 23 days after admission.
Conclusion: Prognosis of mucormycosis is not favourable despite early
diagnosis and aggressive combined surgical and medical therapy.
P1293 Comparison of plasma trough concentrations of
voriconazole in patients with or without comedication of
ranitidine or pantoprazole
W.J. Heinz, C. Kloeser, A. Helle, C. Guhl, S. Scheuermann, H. Einsele,
H. Klinker (Wu¨rzburg, DE)
Objectives: Voriconazole is a broadly used antifungal agent which
has demonstrated superior efﬁcacy compared with amphotericin B
for long term therapy of invasive aspergillosis. It is often used
especially in haematological patients. The azole is metabolised by the
cytochrome P450 (CYP) isoenzymes 2C9, 2C19 and 3A4. In addition
it shows inhibiting and inducing activity. Due to its good bioavailability
voriconazole is often administered orally. On the other side severely
ill patients often receive proton pump-inhibitors (PPI) or H2-receptor
antagonists (H2RA). These agents may reduce absorption of azoles
by increasing gastric pH, or inhibit hepatic metabolisation by CYP. In
previous trials with healthy volunteers no effect with ranitidine could be
detected. For omeprazole an increase of the AUC could be shown, but
PPIs differ in their afﬁnity to CYP isoenzymes. We therefore analysed
plasma through concentrations (PC) of voriconazole from patients with
or without pantoprazole or ranitidine.
Methods: Plasma samples from haematological patients with oral
voriconazole treatment have been collected and voriconazole concen-
trations determined. The results were analysed in correlation to the
comedication of H2RA and PPI.
Results: We analysed 134 samples from 44 patients, 20 samples without
comedication (group 1), 10 samples from patients receiving ranitidine
(group 2), and 104 from patients also receiving pantoprazole (group 3).
Plasma trough levels showed a broad range from undetectable to a
maximum of 12,708 ng/mL. 37 PC have been below 200 ng/mL, 9 (45%)
of group 1, 2 (10%) of group 2 and 26 (25%) of group 3 and only 4
above 10,000 (all group 3). Average plasma concentrations have been
1,212 ng/mL (1), 923 (2) and 1840 (3).
Conclusion: In this retrospective analysis PC of voriconazole have
shown to be lower in patients receiving ranitidine and higher in patients
with comedication of pantoprazole. The average PC for voriconazole
is twice as high in patients taking pantoprazole than in those with
ranitidine. The increase of voriconazole PC stands in parallel to the
results previously shown for omeprazole. Although few values are rather
high (above 10,000 ng/mL) no dosing recommendation can be made up
to now.
P1294 Determination of caspofungin plasma concentrations in
surgical intensive care unit patients
H. Nguyen, T. Hoppe-Tichy, H. Geiss, M. Weigand (Heidelberg, DE)
Objectives: The aim of the present study was to investigate plasma
caspofungin concentrations in surgical intensive care unit [SICU]
patients.
Methods: According to their demographic data (Table) caspofungin
concentrations of ten adult subjects were compared in a pairwise manner.
All patients received an initial caspofungin loading dose of 70mg
followed by 50mg/day. Caspofungin trough concentrations [C24h] were
determined daily for the duration of therapy using High-Performance-
Liquid-Chromatography.
Results: Plasma caspofungin C24h differed signiﬁcantly between paired
subjects (Table). Importantly, on more than one day, caspofungin C24h
for ﬁve patients were found to have fallen below the target concentration
of 1mg/mL (see data ranges on Table).
Pair Age BW (kg)/BS (m2) Mean C24 h (mg/mL) [range] p-value
1 (F) 47 vs. 46 47/1.45 vs. 48/1.46 1.6 [0.91–2.45] vs. 3.48 [1.54–5.01] 0.028
2 (F) 41 vs. 40 72/1.89 vs. 75/1.82 1.04 [0.7–1.74] vs. 2.22 [2.08–2.36] 0.068
3 (M) 72 vs. 65 75/1.93 vs. 75/1.92 1.24 [0.85–1.62] vs. 2.43 [1.97–2.77] 0.028
4 (M) 60 vs. 69 80/1.98 vs. 80/1.65 0.93 [0.55–1.47] vs. 2.0 [1.68−5.1] 0.043
5 (M) 54 vs. 56 77/19.5 vs. 70/1.76 1.34 [0.74–1.97] vs. 3.0 [1.63–3.63] 0.005
aF, female; M, male. bBW, body weight; BS, body surface.
Conclusion: Our data indicate the importance of C24h monitoring
in SICU patients. Further investigations are needed to evaluate the
parameters which inﬂuence plasma caspofungin concentrations in this
patient group.
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P1295 Clonal characterisation of methicillin-resistant
Staphylococcus aureus isolates at an Innsbruck university
hospital using ﬁve different molecular typing methods
K. Grif (Innsbruck, AT)
Objectives: Methicillin-resistant Staphylococcus aureus (MRSA) has
become one of the most prevalent nosocomial pathogens throughout
the world, capable of causing a wide range of hospital infections.
In recent years, several genotyping methods have been developed for
the characterisation of MRSA strains. Of these, one of most suitable
for epidemiological investigation is PFGE. However, a combination of
different typing methods is often needed to obtain reliable analysis of
strains that are suspected to be epidemiologically related.
The aim of our study was to characterise the MRSA strains at the
University Hospital of Innsbruck and the nearby rehabilitation facilities
and to compare these with the simultaneously circulating MRSA clones
using 5 different molecular typing methods.
Material and Methods: A group of 109 MRSA isolates, collected
from patients at the University Hospital of Innsbruck during 2003–2005
was tested for their antimicrobial susceptibility proﬁles. Clonality was
determined using a combination of PFGE, automated ribotyping, spa-
typing and SCC-mec and agr determination.
Results: Thirteen ribotypes and 18 PFGE types were found. Two main
ribotypes, as well as two PFGE types dominated among MRSA isolates
collected. The majority of isolates gained spa-type t001 (67.9%) and
arg type 2 (85%).
Conclusions: Clonal distribution was found of MRSA isolates collected
at the University Hospital of Innsbruck.
P1296 Molecular characterisation of methicillin-resistant
Staphylococcus aureus in South Africa
W.F. Oosthuysen, A.G. Duse´, E. Marais and the South African MRSA
Surveillance Group
Objective: The clonal prevalence, relatedness and distribution of clinical
MRSA isolates have not yet been determined in the Republic of South
Africa (RSA). This study is the ﬁrst ever undertaken to elucidate the
molecular epidemiology of MRSA in South Africa.
Methods: Clinical MRSA isolates were collected from private and state
laboratories from each of the 9 provinces throughout South Africa.
Standard microbiological techniques were used to conﬁrm both the
identity and their resistance to methicillin. The SCCmec type of each
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isolate was investigated using multiplex PCR. All isolates were screened
by PCR to detect the genes for the toxin Panton-Valentine leukocidin
(PVL). spa typing was performed according to previously described
techniques.
Results: Of the 342 isolates conﬁrmed to be S. aureus, 314 were
methicillin-resistant. The SCCmec types of 302 MRSA isolates
were determined. 36.7% were type IV (Paediatric clone/CA-MRSA);
25.2% were type II (NY/Japan clone) or a variant thereof; 23.2% were
type III (Hungarian clone) or a variant thereof, including type IIIA
(Brazilian clone); 13.2% were SCCmec type I (Archaic clone), including
type IA (Iberian clone); and 1.7% were non-typeable according to this
method.
PVL genes were detected in 2/314 (0.6%) of the MRSA strains.
Of 218 MRSA isolates that were subjected to spa typing, 27 different spa
types were identiﬁed that could be grouped in 5 spa clonal complexes
(spa-CC) (table 1). 53% were clustered in spa-CC 012; 35% were
clustered in spa-CC 064; 8% were clustered in spa-CC 045; 2% were
clustered in spa-CC 032 and 1% were clustered in spa-CC 015. Only 1
singleton was found. Nine spa types identiﬁed were novel.
Conclusion: These results indicate that the population structure of
MRSA is composed of a variety of epidemic clones. To our knowledge
is this the ﬁrst report to document epidemic clones circulating in South
Africa. Furthermore, to the best of our knowledge, this is the ﬁrst report
of MRSA isolates shown to carry genes for the toxin PVL in South
Africa.
Table 1. spa types identiﬁed in South Africa
spa type Number of isolates (n = 128) Percentage of total
spa-CC 012; Brazilian/Hungarian clonality
1012 54 23
1037 50 23
1018 4 2
1021 3 1
1046 2 1
1399 2 1
1840 1 0.45
t1504 1 0.45
spa-CC 064; Archaic/Iberian clonality
1064 44 20
t1257 20 9
t951 3 1
t1443 3 1
t104 1 0.45
t1256 1 0.45
t1555 1 0.45
t1774 1 0.45
t1779 1 0.45
spa-CC 045; NY/Japan clonality
t04514 6
t0013 1
t1154 1 0.45
spa-CC 032
t032 2 1
t891 1 0.45
t1468 1 045
spa-CC 015
t015 1 0.45
t050 1 0.45
t456 1 0.45
Singleton
t174 1 0.45
P1297 Double locus sequence typing, a new fast and unambiguous
typing method to study the epidemiology of MRSA at a
regional level
D.S. Blanc, G. Kuhn, A. Wenger, J. Bille, P. Francioli, G. Zanetti
(Lausanne, CH)
We developed a fast and highly discriminatory typing method for MRSA,
based on partial sequences of 2 polymorphous genes (clfB and spa) (JCM
2006, in press).
Objectives: To use this method to investigate the epidemiology of MRSA
in Western Switzerland, and to compare the results with those obtained
with PFGE.
Material and Methods: From Jan. 05 to June 06, one isolate per
antibiogram proﬁle and per patient was prospectively stored in 96-
well plates (N = 1,126). DNA extraction, PCR and sequencing was also
performed in 96-well plates. Each allele at each sequence was attributed
a number. The composition of the two alleles deﬁned a DLSType labelled
with 2 numbers. Considering single locus variant (SLV), e-BURST was
used to analyse the relationship between DLSTypes. For comparison with
previous MRSA surveillance performed with PFGE, a selection of 153
isolates representative of the major PFGE strains recovered previously
was analysed. In addition, the ﬁrst 150 isolates of 2005 were typed
by PFGE and DLST. MLST was performed on isolates of predominant
DLSTypes.
Results: DLST results showed the presence of the four predominant
genotypes already identiﬁed with PFGE: DLSTypes 1−1 (20 pts, ST45),
2−2 (560 pts, ST105), 3−3 (130 pts, ST247), and 4−4 (83 pts, ST228).
A good congruence was found between PFGE and DLST: 95%, 98%,
85% and 100% of isolates belonging to PFGE clones A, B, C and D,
respectively, were clustered within the respective predominant DLSTypes
and their SLVs. However, different PFGE types could be observed within
the same DLSType, and the reverse was also true. This suggests that
the evolution of both markers was different. The discriminatory index,
calculated from 150 unselected isolates of 2005 typed by both methods,
were 0.82 (41 types) for PFGE and 0.76 (37 types) for DLST.
Snapshot analysis with e-BURST revealed that DLSTypes 2−2, 3−3,
and 4−4 were linked by SLVs 3−2, 2−36 and 4−36, suggesting either
a common ancestor, recombination of alleles, or homoplasy. Analysis
of allele sequences and frequency of types in the population, together
with analysis of ST of predominant DLSTypes, lead us to hypothesise a
recombination in one case (DLSType 3-2), and a clonal evolution from
DLSType 2-2 to DLSType 4-4 in the second case.
Conclusion: DLST gave results comparable with those of PFGE, and
appeared suitable for the epidemiological surveillance of MRSA at a
regional level. Moreover, it allowed to hypothesise the origin of some
predominant genotypes.
P1298 Increase of Simpson’s diversity index parallels the control
of a major regional MRSA outbreak in the Netherlands
P. Gruteke, M.E.O.C. Heck, A.J. de Neeling, W.J.B. Wannet,
H.A. Verbrugh (Amsterdam, Bilthoven, Rotterdam, NL)
Objectives: Health authorities need appropriate incidence ﬁgures to
monitor MRSA control policies. UK national health authorities for
instance set targets for local MRSA bacteraemia rates, although rate
reductions may be difﬁcult to interpret (Spiegelhalter 2005). Typing
of strains is vital in directing MRSA control efforts since it can help
discriminate outbreaks from spurious associations. Because the genetic
diversity among isolates is lower in epidemic versus endemic MRSA
situations scoring the Diversity Index (DI) of consecutive collections of
MRSA may provide an additional monitoring tool.
Methods: All 5,300 MRSA isolates were typed by PFGE at the RIVM.
MRSA strain PFGE typing (PT) patterns differing 1 band from preceding
patterns were ascribed a new PT. The 4 years period from April 1st 2002
was divided into 9 time slots (slots 1 and 9: 3 months, slots 2 through
8: 6 months). During the ﬁrst part of this period the province of Zuid
Holland experienced a large outbreak of healthcare associated MRSA.
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One isolate per patient per referring laboratory was included. Isolates
were labeled according to the province of origin. Simpson’s DI’s were
calculated per time slot for Zuid Holland and compared with data from
the other 11 provinces of the Netherlands.
Results: MRSA isolates in the Netherlands have high DI scores,
reﬂecting the small sizes of most outbreaks. In contrast, the DI’s of
the isolates referred from South Holland in the ﬁrst time slots were
signiﬁcantly below those of the rest of the Netherlands. As the MRSA
epidemic became controlled in South Holland, its DIs increased and
became similar to the rest of the Netherlands.
Conclusions: Simpson’s DI clearly reﬂected the existence and the
control of a large MRSA outbreak in a province of the Netherlands.
In situations where typing results are available and sampling strategies
are comparable, trends in DI scores allow monitoring another dimension
of MRSA epidemiology and control.
P1299 The genetic organisation of staphylococcal cassette
chromosome mec type IVA from invasive methicillin-
resistant Staphylococcus aureus isolates in Korea
C. Park, H-S. Chun, D-G. Lee, S.H. Park, S-M. Choi, J-H. Choi,
J-H. Yoo, W-S. Shin (Seoul, KR)
Objective: It was reported that type II of SCCmec was the most prevalent
in Korea. Our previous study on bacteraemic MRSA showed type IVA
of SCCmec was the second most prevalent type following type II and
type IVA isolates were more commonly isolated among community
acquired MRSA (CA-MRSA) than type II isolates. So we investigated
the genetic organisation and variation of SCCmec IVA by sequencing
and their other epidemiologic characteristics from invasive CA-MRSA
isolates.
Material and Method: From invasive CA-MRSA isolates (n = 84),
SCCmec PCR typing was performed by multiplex- and single-PCR
method described by Oliveira and Okuma et al. The genetic organisation
and variation of SCCmec IVA was analysed by long PCR based
sequencing. The prediction of assembled sequencing results was
performed by ORF Finder (http://www.ncbi.nlm.nih.gov/gorf/gorf.html),
and the homology of each open reading frames (orfs) was analysed
by BLAST search (BLASTN 2.2.13). Each variations of class mecA
complex were compared. Other molecular characteristics and antibiotics
susceptibility were also analysed.
Results: Type IVA isolates accounted for approximate 50% by multiplex
PCR typing and were further classiﬁed into three major groups by single
PCR typing. One group was composed of ccr2-typical class B mec
complex, the other ccr2-class A mec complex, and the third group ccr2-
atypical class B mec complex. The sequencing and assembly results of
the third group showed that its class B mec was composed of IS1272-tnp-
A¨mecR1–mecA IS431 (~1kb insertion compared to other class B). The
total length was ~27 kb, and pUB110 (ble, and aadD) was incorporated
into the right region of SCCmec. There were two kinds of STs (72 and
1) in IVA isolates. And orfs of left region had the high homology of orfs
in the left region of IVc. Antibiotics susceptibility test showed that IVA
isolates of the third group were not multi-drug resistant (mainly resistant
to oxacillin, penicillin, erythromycin, tobramycin) but isolates of ﬁrst
group with typical class B were resistant to more antibiotics (oxacillin,
penicillin, erythromycin, tobramycin, tetracycline, gentamicin).
Conclusion: Although its SCCmec type was classiﬁed to type IVA in
multiplex PCR, type IVA was subsequently classiﬁed into several groups.
In each groups, there were some variations in the genetic organisation
of SCCmec. Future studies should determine the epidemiologic and
molecular factors that might contribute to the high occurrence.
P1300 Characterisation of SCCmec type of methicillin-resistant
Staphylococcus aureus strains from hospitalised patients
admitted in Belgian hospitals
O. Denis, A. Afsar, R. De Mendonc¸a, A. Deplano, C. Nonhoff,
M.J. Struelens (Brussels, BE)
Background: The analysis of SCCmec structure is a key typing tool for
classiﬁcation of clones of methicillin-resistant Staphylococcus aureus.
Several strategies based on multiplex PCR have been developed for this
purpose. We compared the results of two PCR protocols for SCCmec
typing with MRSA strains collected during a national survey in Belgian
hospitals in 2005.
Methods: 321 MRSA isolates collected from 116 hospitals were
identiﬁed by multiplex PCR for mecA, nuc and 16S rDNA genes.
SCCmec type was determined by methods described by Oliveira
DC (PCR A) (AAC 2002;46:2155) and Zhang K (PCR B) (JCM
2005;43:5026). Discrepant results between two methods were resolved
by multiplex PCR for ccr and mec complex determination.
Results: The proportion of non typeable SCCmec was 4% by PCR A
and 26% by PCR B (p< 0.001). Only, 210 (64%) isolates had concordant
results by both methods and were SCCmec type I (n = 7), type II (n = 44)
and type IV (n = 159). 26 isolates were incorrectly typed as SCCmec
type I by PCR B but were classiﬁed as type IV by PCR A as conﬁrmed
by ccr and mec complex analysis. Of 75 isolates which were not typeable
by PCR B, 73 were determined of type IV by PCR A, and conﬁrmed
by ccr and mec complex determination. Two isolates which were not
typeable by PCR A were determined as type IV and type V by PCR B,
ccr and mec complex analysis. Ten isolates were untypeable by both
methods.
Conclusion: The method of Oliveira et al. showed the best performance
for SCCmec typing. However, the presence of untypeable SCCmec vari-
ants warrants the combination of methods for SCCmec characterisation.
P1301 Comparative molecular analysis of veterinary, dairy, and
clinical Staphylococcus aureus isolates by spa typing and
ampliﬁcation of the mecA and the PVL genes
A. Sto¨ger, M. Gonano, A. Pietzka, F. Allerberger, M. Wagner,
W. Ruppitsch (Vienna, AT)
Objectives: The aim of this study was to compare Staphylococcus aureus
isolates of veterinary, dairy and human origin to evaluate a possible
animal-to-food, human-to-animal, and/or human-to-food transmission or
vice versa.
Methods: 1,058 isolates were collected by screening cows suspected
of having mastitis, from vat milk and fresh cheese, from wounds of
ambulant patients and from hospitalised patients. Sequencing of the
variable X-region of the protein A gene (spa typing), detection of
the methicillin resistance gene (mecA), and detection of the Panton-
Valentine leukocidin gene (PVL) were used for molecular comparison
of these isolates.
Results: All tested veterinary isolates (n = 60), dairy isolates (n = 64),
and 11 isolates from the ambulant patients, and 57 isolates from
hospitalised patients were negative for mecA (MSSA). The remaining
860 clinical isolates were positive for mecA (MRSA). The PVL gene
as a marker for CA-MRSA was detected in a single veterinary isolate
of spa type t042, which is closely related to CA-MRSA t044. Typing
yielded 152 spa types. Thirty-four spa types were identiﬁed for the 60
veterinary isolates, 35 for the 64 dairy isolates, 28 for the 59 human
MSSA isolates, and 134 for the 860 clinical MRSA isolates. 24 new
spa types were found among the veterinary and dairy isolates that were
not described in the spa database (RIDOM). In contrast to the clinical
MRSA isolates, where the majority belonged to spa complexes SC I
and SC II the majority of veterinary, dairy and also the MSSA isolates
belonged mainly to spa complexes SC VI and SC VII. 11 spa types of
the human population including t190 and t008 were also found in the
veterinary or in the dairy isolates. Spa type t529 was the only one that
was detectable in all populations. Approximately 50% of veterinary and
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dairy isolates belonged to nine common spa types which were different
from that found in the human isolates.
Conclusion: Typical and very frequent human spa types i.e. t190 or t008
rarely occurred in veterinary and dairy isolates. However, the occurrence
of typical human isolates on cow udders and in milk and fresh cheese
might reﬂect a possible transmission from human to animals and food.
No MRSA was detected among the veterinary and dairy isolates. The
high number of identical spa types in veterinary and dairy isolates
indicated a transmission of Staphylococci from animal reservoirs into
the dairy chain.
P1302 Spa sequence-based typing of MRSA starting directly from
multiplex PCR for grouping of SCCmec elements
C. Cuny, W. Witte (Wernigerode, DE)
Objective: The discriminatory power of sequence based typing of MRSA
can be enhanced by grouping of SCCmec elements. Here we report about
grouping of SCCmec elements by PCR and ampliﬁcation of the relevant
sequence of spa for subsequent sequencing starting immediately from
the same multiplex PCR.
Methods: Multiplex PCR with primers for ccrA1, ccrA2, ccrA3, ccrC,
and kdp for grouping of SCCmec elements, and for ampliﬁcation of the
X region of spa.
The multiplex PCR was designed in such a way that the size of amplimers
indicating the SCCmec group would be either below or above the size
of the spa-amplimers (200 bp for the smallest with only 2 repeat units
and 512 for the largest with 15 repeat units).
Results and Conclusion: We found a complete congruence of results of
spa-sequence typing and of grouping of SCCmec elements by separate
PCR experiments and by multiplex PCR for 75 isolates representing
major lineages of epidemic nosocomial MRSA and of community
MRSA. These isolates are epidemiologically unrelated and originate
from various kinds of infections in different geographical areas of
Germany. The deduction of SCCmec groups is especially useful in cases
where isolates exhibiting the same MLST-types and even spa-types (the
same core genome) contain different SCCmec-elements (e.g. STS with
SCCmec I, II, III, V described so far).
P1303 clfB typing in Staphylococcus aureus: online database for dis-
play, clustering analysis and storage of clfB DNA sequences
A.R. Gomes, J. Carric¸o, S. Vinga, A.L. Oliveira, M. Zavolan,
H. de Lencastre (Oeiras, Lisbon, PT; Basle, CH; New York, US)
Objectives: Typing approaches based on DNA sequencing have provided
robust and unambiguous data for Staphylococcus aureus: multilocus
sequence typing (MLST) is useful for global epidemiology and
evolutionary studies and spa typing has been shown to be efﬁcient
not only for evolutionary studies but also for outbreak investigations.
Recently, typing of S. aureus based on sequencing of the repeat region of
the clumping factor B gene (clfB) was shown to be more discriminatory
than spa typing and capable of distinguishing among seemingly related
strains. However, the nomenclature for this new typing methodology
yielding long sequences of repeated units has not been deﬁned yet.
Here, we propose a free-access online interface for the identiﬁcation
of repeated units in DNA sequences, display of the degree of variation
in the nucleotide sequence of the repeats, and for clustering analysis and
storage of clfB DNA sequences.
Methods: An encoding was devised for the representation of sequences
in which each of the four nucleotides was represented by a
three-dimensional ﬂoating-point vector and a sequence composed of
n-nucleotide repeated units was represented by a set of 3n-dimensional
vectors. In order to visualise the sequences, the 3n-dimensional vectors
were projected onto a 3-dimensional space by single value decomposition
and the three coordinates were used to colour-code each occurrence in
terms of hue, brightness and contrast as well as with a numerical proﬁle.
Sequencing of the clfB repeated region was performed in ninety-six
S. aureus isolates representing some of the major clones recovered from
infection or carriage in several countries over a period of more than forty
years. DNA sequences were subsequently grouped using hierarchical
clustering algorithms based on the numerical values obtained, allowing
for various differences from the consensus for the repeating units. All
this information is stored in a free-access database for comparison with
future submissions.
Results: A clfB typing database containing clfB sequences from the
major S. aureus clones is available online. clfB DNA sequences may be
submitted for both a numerical and a graphical colour representation,
clustering analysis and storage in the database.
Conclusion: The online clfB typing database provides a free-access
interface for representation, analysis and storage of clfB DNA
sequences, and constitutes a highly discriminatory typing tool for the
characterisation of S. aureus isolates.
P1304 Array-based typing of community- and healthcare associated
MRSA and occurrence of epidemic strains in eastern Saxony
S. Monecke, L. Jatzwauk, S. Weber, R. Ehricht (Dresden, Hoyerswerda,
Jena, DE)
Objectives: Objective of the study was to test a diagnostic microarray
under routine conditions and to obtain insights into the epidemiology of
Community- and Healthcare Associated MRSA (CA- and HA-MRSA)
in eastern Saxony.
Methods: Multiplex linear DNA-ampliﬁcation and subsequent mi-
croarray hybridisation were performed which allowed to detect 144
genes or distinct allelic variants simultaneously. All relevant exotoxins,
antimicrobial resistance determinants, the allelic variants of agr, as
well as staphylococcal exotoxin-like genes were included. Hybridisation
proﬁles were used for assignment to epidemic strains. The study was
performed in eastern Saxony including an university hospital, a long-
term rehabilitation facility and three county hospitals. For the study
of HA-MRSA, random samples from routine diagnostics as well as
isolates from outbreak investigations were tested. Additionally, all cases
were included in which PVL-positive CA-MRSA were suspected to be
involved.
Results: Most prevalent HA-MRSA strains are South German EMRSA,
New York/Japan Clone (“Rhine-Hessen EMRSA”), Berlin EMRSA,
and EMRSA-15 (“Barnim Epidemic Strain”). Other strains are by
comparison rather rare. Isolated cases of infections with PVL-negative
ST1 and ST8 MRSA were detected. ST8 Hannover ERMSA which used
to be very common in the 1990s virtually disappeared, and EMRSA 16
was completely absent.
CA-MRSA were not found prior to 2004. Still now, cases are rather
sporadic. The most prevalent strain is the PVL-positive ST80-MRSA
IV (four detected cases in 2004, one outbreak including four cases in
2005, two cases in 2006). First infections with PVL-positive ST8-MRSA
IV (USA300, one case in 2005 and one in 2006) and ST30-MRSA IV
(WSPP strain, one case in 2006) were also diagnosed. PVL-positive
ST1-MRSA IV (USA400) were not detected yet.
Conclusions: The DNA-microarray proved to be a powerful tool for
epidemiological monitoring and identiﬁcation of epidemic strains. In
contrast to other typing methods it facilitated the assessment of virulence
and antibiotic susceptibility of a given isolate within a single experiment.
In the region studied, the majority of HA-MRSA infections was caused
by a few epidemic strains. Emerging strains (New York/Japan Clone as
well as SCCmecIV strains EMRSA-15 and Berlin EMRSA) play a major
role. PVL-positive CA-MRSA are still very rare, and the most important
strain is ST80-MRSA IV.
P1305 Double locus sequence typing a new high through put
typing method for MRSA. Results from a 1.5-year
surveillance in a university hospital
I. Nahimana-Tessemo, G. Kuhn, J. Bille, A. Wenger, P. Francioli,
G. Zanetti, D.S. Blanc (Lausanne, CH)
We developed a high through put and highly discriminatory typing
method for MRSA, based on partial sequences (500bp) of 2 highly
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polymorph genes (clfB and spa) (JCM 2006, in press). This method was
used to investigate the molecular epidemiology of MRSA in a University
tertiary care hospital of 800 beds during a 1.5-year period of time (Jan
2005 to June 2006).
Isolates, one per antibiogram proﬁle per patient and per year, were
prospectively stored in 96-well plates. Once a plate was ﬁlled up, DNA
extraction, PCR and sequencing of the two genes were performed. Each
allele at each sequence was attributed a number. Thus, the composition
of the two alleles deﬁned a DLSType.
From January 2005 to June 2006. 288 isolates from 264 patients
were typed by the new method. Results showed that 67 different
DLSTypes were observed. One predominant DLSType (2−2, 125 pts)
and 2 less predominant DLSTypes (4−4 and 3−3, in 33 and 19 pts,
respectively) accounted for 67% of the patients. These 3 major DLSTypes
corresponded to clones B, D and C previously identiﬁed by PFGE
surveillance. Among the 23 patients for whom 2 isolates were typed,
one harboured single locus variants (SLV): the ﬁrst isolate was 2−65
and the second was 66−2; and another patient harboured two different
DLSTypes (134−59 and 3−3). Transmission was suspected from an index
case to roommates at 20/374 occasions. Among these, 11 harboured the
index case DLSType. Two clusters of cases were identiﬁed (hospitalised
in the same unit during overlapping period of time) accounting for 10
possible transmissions, from which only 7 could be conﬁrmed by DLST.
These results are concordant with previous results in our institution using
PFGE as molecular markers. The value of DLST was found to be similar
to PFGE for epidemiological investigation at a local level, with the major
advantage that the method give unambiguous data.
P1306 Direct repeat unit typing to differentiate methicillin-resistant
Staphylococcus aureus isolates in Ireland indistinguishable
by pulsed ﬁeld gel electrophoresis
A. Rossney, R. Goering (Dublin, IE; Omaha, US)
Objectives: In Ireland, the prevalence of a single MRSA strain exhibiting
antibiogram-resistogram (AR) type AR06, multilocus sequence type (ST)
ST22 and staphylococcal cassette chromosome (SCC) mec type IV has
increased from 22% in 1999 to 80% in 2003. In any one year, 50%
of these isolates yield a single chromosomal pattern by pulsed ﬁeld gel
electrophoresis (PFGE). The present study investigated whether sequence
analysis of the direct repeat unit (dru) in the hyper-variable region of the
SSCmec cassette could aid in differentiating isolates of this strain.
Methods: Twenty-three MRSA isolates from six suspected outbreaks
(Clusters A-E) in four different human hospitals and two veterinary
practices in geographically distinct areas of Ireland were investi-
gated. For dru analysis, 5′-GTTAGCATATTACCTCTCCTTGC-3′ and
5′-GCCGATTGTGCTTGATGAG-3′ forward and reverse PCR primers,
respectively, were employed with an initial denaturation step at 94ºC
for 2min followed by 30 cycles of 94ºC for 1min, 52ºC for 1min,
and 72ºC for 1min. The resulting DNA sequences were aligned and
interrelationships analysed using BioNumerics v. 4.61 (Applied Maths,
Sint-Martens-Latem, Belgium).
Results: All isolates exhibited AR type AR06 (or a closely related AR
pattern) and PFGE types (PFT) that were either indistinguishable or not
differing by >6 bands. By dru typing, isolates from two geographically
distinct veterinary practices (Cluster A and B; all PFT 01018) were
differentiated. In Cluster C, dru analysis grouped all four fusidic acid
resistant isolates together, separated them from fusidic acid susceptible
isolates and further differentiated one isolate in the cluster that originated
from a different source. In Cluster D, dru typing differentiated the isolate
with the least similar PFT from the remaining isolates. In Cluster E, two
PFT 01039 isolates were separated while, in Cluster F, four isolates
exhibiting three PFTs were found to be indistinguishable.
Conclusions: The mec-associated dru region has the potential for
extensive variability both in sequence and in number of 40-bp tandem
repeats yet speciﬁc sequence types appear to be very stable over time.
On the basis of this preliminary study, analysis of dru sequences appears
very promising as a means of tracking difﬁcult to differentiate epidemic
MRSA isolates in Ireland such as AR06, warranting further investigation
with this and potentially other difﬁcult groups of isolates.
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P1307 Does a preliminary surveillance study enhance formulation
of a comrehensive MRSA containment action plan? Study
from a large district hospital in northwest England
S. Ambalkar, R. Palmer, A. Guleri (Blackpool, UK)
Objectives: Hospital MRSA control policy is based on national
guidelines. Certain specialities are associated with higher than desirable
MRSA bacteraemia rates. This requires targeted action plans to be
designed for such areas. This study was carried out to evaluate if
conducting a preliminary surveillance study would help in optimal
planning and design of action plans for MRSA hotspots in the hospital.
Method: 53 MRSA bacteraemia episodes over 1-year (April 2005
through March 2006) were analysed.
Results: 95% of cases were over 50-years of age. Majority (60%) of
cases were from medical wards, 25% from surgical, and 12% from
intensive care. Majority (75%) were males. Clear information from
37 cases revealed 81% were hospital acquired and remaining from
community. Out of 30 cases, 27% were previously known MRSA
carriers. 53% of patients died either with or due to MRSA bacteraemia,
of whom 38% died sometime within 14-days of bacteraemia. 20% of
deaths were before anti MRSA treatment was commenced.
Conclusions: MRSA bacteraemia was more common in >50-years age
group, males, hospital acquired and in medical wards. Medical ward has
a large number of patient throughput and patients are frequently shifted
between wards.
Salient points considered while formulating action plan were: Need
for risk stratiﬁcation, screening of high-risk patients, role of empirical
anti MRSA agents in high-risk group, role of rapid diagnostic tests,
decolonisation regimes for known/identiﬁed MRSA carriers, strict
isolation policy, strict intravenous catheter policy, appointing local
consultant/matron as infection prevention lead with support from hospital
infection control team.
It emerged that conducting a preliminary surveillance study deﬁnitely
helped identify local deﬁcits and risk factors that contribute to the higher
than acceptable MRSA rates in that area.
P1308 Improving the evidence base for the effectiveness of
Staphylococcal healthcare-associated infection interventions
B. Cookson, S.P. Stone, B.S. Cooper, C.C. Kibbler, J.A. Robert,
G.F. Medley, G. Duckworth, R. Lai, S. Ebrahim, P.G. Davey,
E.M. Brown, P.J. Wiffen (London, Warwick, Dundee, Bristol, Oxford, UK)
Introduction: The last decade has seen a move towards evidence based
medicine. The publication of “Consolidated Standards of Reporting
Trials” (CONSORT) statement (1996) did much to improve matters
regarding the transparency needed to improve the quality of reporting,
so that information critical to synthesis of research was not missing.
However, it did not provide items or descriptors easily translatable into
the wide variety of interventions, settings, designs and statistical issues
relating to infectious diseases.
Methods: Our systematic review of MRSA Isolation presented at a
previous ISSS revealed many ﬂaws in study design and presentation.
A working party of the British Society of Antimicrobial Chemotherapy
had used our approach in the ﬁeld of antimicrobial prescribing and
we decided to join forces and form “ORION” (Outbreak Reports and
Intervention studies Of Nosocomial infection). This is presented here.
Results: It comprises a list of items or descriptors easily translatable into
the wide variety of interventions, settings, designs and statistical issues
relating to infectious diseases (including for example Staphylococcal)
intervention studies. They are aimed at researchers, editors, reviewers,
and grant assessment panels. It is intended that they facilitate
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well-designed interventional studies to help choose which methods
are effective in reducing antimicrobial resistance and healthcare
associated infection. This list has been available on the www: http://
www.bsac.org.uk/_db/_documents/Orion_5_(3).doc) and been sent to
several editors of journals for comment. ORION consists of a 22
item checklist, a summary table is recommended for description of the
population, clinical setting, and the precise nature and timing of all
interventions and outcomes and a graphical summary of the main results
is recommended when outcomes are not independent. For intervention
studies we strongly recommend a ﬂow chart to track participants through
each stage of the study.
Conclusion: The ORION Collaboration has produced proposals to
improve the evidence base for infection control and antimicrobial
stewardship interventions. They have been widely consulted and will
be reviewed again with the scientiﬁc community in ~3y time.
P1309 Reduction in the incidence of staphylococcal infections in
hospital environment after the starting of the guideline
of perioperative antibiotic prophylaxis. Conﬁrmation of the
decrease in 2006
G. Gattuso, D. Tomasoni, L. Palvarini, D. Berra, C. Chiarelli,
R. Stradoni, A. Scalzini (Mantua, IT)
Objectives: Comparing the general incidence of staphylococcal and
MRSA infections in the “C. Poma” Hospital versus the incidence of
staphylococcal and MRSA in the surgical wards after the introduction
of guidelines for perioperative antibiotic prophylaxis (PAP).
Methods: The hospital is a 530-bed tertiary care teaching hospital in
Mantova with 30,000 patients admission per year. Two periods have been
compared: 2nd Six Months (S) of 2002–1st S of 2003 (period A) and
2nd S of 2003–1st S of 2004 (period B), respectively before and after the
introduction of the guideline of PAP. Two years later the we re-evaluated
the data, considering the 1st semester 2006, to verify the maintenance
of the trend.
Results: In the period A 10,407 microbiological examinations have
been executed; 637/10,407 cases (6.1%) were positive for S. aureus and
119/637 (18.6%) were MRSA. In the period B 8,421 microbiological
exams have been performed: 315/8,421 (3.7%) S. aureus and 81/315
(25.7%) MRSA.
In the period A a signiﬁcant increase of MRSA was found in the surgical
wards comparing to the other wards: 58.6% vs 22.9% (p = 0.001),
whereas in the period B was checked a relevant decrease of MRSA
in the surgical wards compared to the general data (25.0% vs 25.7%;
p=ns). In the second period the data of MRSA in the surgical wards
were found signiﬁcantly reduced (58.6% vs 25.0%; p = 0.001).
Moreover in the period B the global antibiotic consumption was reduced
with an increment of the cephalosporins of 1st generation (+11.5% of
cephazolin) used correctly in surgical prophylaxis. In the ﬁrst semester
2006 we noticed that the value regarding MRSA keeps unchanged, as
in medical wards and ICU MRSA were 37.7% of the whole and in the
surgical ones were 21.7%. The hospital general data in 2006 show an
average value of MRSA equal to 35% of all the S. aureus.
Conclusions: 12 months after the introduction of PAP a signiﬁcant
reduction of incidence of MRSA infections was found in the surgical
wards; moreover such result can be ascribed to a greater adhesion
to norms of “good clinical practice”. The evaluation after two years
(1st semester 2006) conﬁrms the decreasing trend, pointing out an
MRSA incidence of 21.7% of the whole S. aureus isolates, decreasing
in comparison with 25% of the 2004.
P1310 Healthcare workers – Source, vector or victim of MRSA?
W.C. Albrich, S. Harbarth (Johannesburg, ZA; Geneva, CH)
Objectives: There is ongoing controversy about the role of healthcare
workers (HCWs) in transmission of methicillin-resistant Staphylococcus
aureus (MRSA). We performed a systematic literature search of
electronic databases from 1980 through March 2006 to determine
the likelihood of MRSA colonisation in HCWs, their role in MRSA
transmission and their own subsequent risk of infection.
Methods: We scanned the English, French and German literature and
excluded articles that did not present quantitative data. Two reviewers
independently assessed the relevance of the included studies.
Results: In 121 studies, the prevalence of MRSA carriage among 33,318
screened HCWs was 4.6% (range: 0−65%). Average MRSA carriage in
HCWs working in settings with endemic MRSA was 8.1%, compared
to 3.9% in outbreak settings. Risk factors of MRSA carriage included
chronic skin diseases, poor hygienic practices, close contact with infected
or colonised patients and having worked abroad. Transient or intermittent
colonisation predominated, but persistently colonised HCWs were found
to be responsible for several nosocomial MRSA clusters. Almost 80
reports supported a causal role of HCWs in transmission of MRSA to
patients. Success rates of eradication therapy were high (461/521 HCWs;
88.5%), and independent from duration of therapy. Subclinical infections
and colonisation of extranasal sites were associated with persistent
carriage after eradication therapy. Eradication of the MRSA carrier
status and/or removal of personnel from patient care were successful in
terminating MRSA transmission in most cases. About 4.9% of colonised
HCWs developed infections, primarily of the skin and soft tissues. In
settings with a high prevalence of community-associated MRSA, HCWs
carriage of MRSA was 3.2% (92/2,832) with a high proportion of clinical
infections (4/63; 6.3%).
Conclusion: A non-negligible number of HCWs become colonised with
MRSA and 5% of those develop clinical disease. HCWs most frequently
act as vectors and not as main sources of MRSA transmission. HCWs
as persistent reservoir of MRSA are rare but nonetheless important.
Aggressive screening and eradication policies seem justiﬁed in outbreak
investigations or when MRSA has not reached highly endemic levels
yet.
P1311 Controlling an outbreak of Staphylococcus aureus in a
vascular and cardiac surgery ward
K. Kristo´f, K. Antmann, Z. Szalay, N. Pesti, K. Nagy, F. Rozgonyi
(Budapest, HU)
Objectives: Since January 2001 a ﬂuctual increase in S. aureus
infections has been recognized in a vascular and cardiac surgery ward
of the Semmelweis University. The outbreak has been characterised
and the S. aureus infections were monitored both phenotypically and
genotypically.
Methods: From January 2001 to September 2006 a total of 511 S. aureus
isolates were cultured. Identiﬁcation of S. aureus strains was carried out
on the basis of catalase positivity, gold pigment, beta-haemolysis and
clumping factor. The presence of mecA and nucA genes was detected
by PCR. Both the disc diffusion and the microdilution methods were used
according to NCCLS/CLSI recommendations to determine the antibac-
terial sensitivity to vancomycin, teicoplanin, gentamicin, tobramycin,
amikacin, netilmicin, ciproﬂoxacin, trimethoprim/sulphamethoxasole,
doxycycline and linesolid. The clonal relationship of the isolates was
determined by pulsed ﬁeld gel-electrophoresis using SmaI enzyme
digestion. Multilocus sequence typing of the representative MRSA
isolates is in process.
Results: 511 cases of S. aureus infection were identiﬁed during the
investigation period. The incidence of MRSA was the highest in the
year 2005 (27.6% of all S. aureus isolates), while the earlier frequency
was 7.14%, 5.66%, 7.5% and 6.24% from 2001 to 2004. Twelve
antibiotic resistance patterns were found among the MRSA isolates.
The commonest was the multiple resistance to all aminoglycosides,
erythromycin, clindamycin and ciproﬂoxacin. This phenotype showed a
mean incidence of 59% of all MRSA isolates in 2005–2006. Its evolution
ranging from 0% in 2003 to the alarming proportion of 63.9% in 2005.
The spread of this epidemic strain was stopped after introducing strict
hygienic measures with a close cooperation between microbiologists and
hygienists. In 2006, the MRSA incidence decreased to 10.7%. PFGE
analysis revealed MRSA strains form four types with different frequency.
PFGE type C was the most common.
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Conclusions: Although the outbreak was sufﬁciently controlled in the
point of view of hospital hygiene, however multiple resistant MRSA
strains of similar clonality could select causing a disadvantage in the
entire microbiological eradication of them.
Supported by OTKA No.: T 46186
P1312 The MRSA point-prevalence: an important tool in the
infection control programme
I. Chaberny, A. Bindseil, F. Mattner, P. Gastmeier (Hannover, DE)
Background: Due to the enormous increase in the number of MRSA-
patients, an extended admission screening on ICUs and surgical wards
was implemented at the Hannover Medical university hospital since July
2004 (18.4 nares cultures per 1,000 patient days).
Objectives: To determine the prevalence of MRSA and Panton-Valentine
leukocidin (PVL) among inpatients, to identify other patients at risk for
MRSA colonisation and to evaluate the compliance with the established
admission screening.
Methods: Inpatients were screened by cultures from nose, throat and
broken skin in a point-prevalence survey in the year 2005. S. aureus
isolates were tested for oxacillin susceptibility and for PVL. MRSA
were tested for antimicrobial susceptibility and were analysed by
staphylococcal protein A (spa) typing.
Results: Of 510 inpatients, 145 (28%) were S. aureus carriers. 27 (19%
of all S. aureus isolates) were MRSA, i.e. 5.3% of all inpatients were
MRSA carriers (95%CI: 3.49; 7.70) which was the MRSA prevalence.
With 67% was the spa type t032 or so called “Barnimer” strain
predominant followed by t001 (15%), t004 (4%), t008 (4%), t022 (4%)
and t067 (4%). The PVL gene was present in one (0.2%) methicillin-
susceptible strain. Compared to our MRSA database the MRSA status
of 37% of the patients (pts) was unknown (ten out of 27 pts), e.g. in
2.0% (ten out of 510 pts) of all inpatients the MRSA colonisation was
identiﬁed for the ﬁrst time. In three out of these ten cases the compliance
with the established admission screening had failed. Although the
admission screening had previously led to negative results concerning
three other patients, a nosocomial acquisition was identiﬁed. Four other
newly MRSA patients had been detected on wards without a routinely
admission screening (three cases on neurological and one case on an
internal medicine ward).
Conclusion: The results of our study pointed to a 5.3% prevalence
of MRSA, which proved higher than our previous observations had
suggested and it pointed to a 0.2% prevalence of PVL-positive S. aureus.
Despite an extended admission screening practice 37% of all MRSA-
positive inpatients had been missed. The neurological patients were
identiﬁed as a further risk group for admission screening and were
included in the established admission screening practice. In addition,
a weekly surveillance cultures practice seems to be useful in order not
to miss further MRSA cases.
P1313 Topical treatment with mupirocine/chlorexydine and
long-term risk of methicillin-resistant Staphylococcus
aureus infection
A. Pan, L. Soavi, P. Mondello, P. Catenazzi, S. Lorenzotti, L. Signorini,
S. Testa, G. Carnevale, G. Carosi (Brescia, Cremona, IT)
Objective: To evaluate the long term effect of topical treatment with
mupirocine and chlorexidine on the risk of colonisation/infection in
patients with a previous microbiological isolation of MRSA.
Methods: This prospective study was carried out at the hospital of
Cremona, an 850-bed community hospital, where a MRSA control
programme including topical treatment was ongoing. All hospitalised
patients identiﬁed as being MRSA positive and for whom data
regarding topical treatment with 2% nasal mupirocine ointment and
4% chlorexydine baths/showers and shampoo for 5 days were available,
were included in the study.
Results: from January 1, 1997 through July 30, 2006, we identiﬁed
1,000 MRSA positive patients, for a total of 1,101 admissions. Data
regarding topical treatment were available for 768 patients (77%) for a
total of 853 admissions: 479 (62%) were treated with mupirocine on their
ﬁrst admission while 289 (38%) where not. Sixty-three treated and 78
untreated patients died during the ﬁrst admission. MRSA was identiﬁed
during a second admission in 41/416 treated patients (9.9%) and in
35/211 untreated subjects (16.6%) (P = 0.02). Six patients, 4 previously
treated and 2 not treated, had more than one admission. We observed
17 infections in treated patients (4%) as compared with 7 in the untreated
group (3.3%) (P = 0.8). The 17 infections in treated patients were as
follows: 7 blood-stream infections (BSI), 3 respiratory infections (RTI),
6 skin and soft tissue infections (SSTI), and 1 other infection. Untreated
patients had 7 infections: 1 RTI, 4 SSTI, 2 other infections. No signiﬁcant
difference was observed for any type of infection between treated and
untreated subjects (P> 0.1 in all cases).
Conclusions: Patients treated with topical mupirocine and chlorexydine
have a reduced risk of being identiﬁed as MRSA positive during after
previous infection or colonisation (P = 0.02). Despite this, no reduction
in the overall risk of infection in the follow-up was identiﬁed among
treated vs untreated subjects.
P1314 Susceptibility patterns to oral antimicrobials of PVL+
MRSA from Austria
C. Jebelean, K. Pfeil, C. Luger, S. Stumvoll, M. Stammler, B. Sammer,
H. Mittermayer (Linz, AT)
Objectives: The prevalence of PVL+ MRSA is rising in many European
countries.
The aim of our study was to investigate the prevalence, the genetics and
the susceptibility to oral antimicrobials of PVL + MRSA strains from
Austria.
Materials and Methods: We screened 904 strains out of our collection
of 1,742 strains of MRSA going 10 years back for PVL gene using a
PCR method. For all strains we determined the mecA and femA gene
using a multiplex PCR. For subtyping we performed coagulase gene PCR
with restriction digestion of PCR products with AluI, and we further
analysed the PFGE patterns. We then determined the susceptibility
to: erythromycin (E), clindamycin (LC), rifampin (RI), tetracycline
(T), minocycline (MH), trimethoprim/sulfamethoxazole (TMP/SXT),
fusidic acid (FU) and linezolid (L) using the agar diffusion method as
recommended by CLSI.
Results: We found 78 PVL+ MRSA strains out of the 904 strains tested.
The percentage of PVL+ strains varied along the years 2001 to 2006 as
follows: 1.5%, 1.9%, 7.1%, 5.2%, 3.6%, 5.9%, respectively. The strains
were isolated mainly from abscesses, wounds and noses mainly in Upper
Austria, Salzburg and Vienna. The patients were adults: 51%, older
persons: 31% and children 13%. Among the PVL+ strains we found the
following sequence types (ST): ST8 (33%), ST80 (18%), ST30 (17%),
ST152 (15%), ST5 (10%), ST22 (3%), ST777 (3%), non-typable (1%).
The usual encountered MRSA ST in Austria are: ST228, ST8, ST22 and
ST5. Overall the L, RI, TMP/SXT, MH, LC, FU, E, and T susceptibility
was 100%, 100%, 99%, 99%, 99%, 79%, 59%, 54%, respectively. The
resistance to E was higher in Vienna and Salzburg, to FU and T in
Salzburg and Upper Austria.
Conclusions: This is the ﬁrst report on PVL+ MRSA from Austria to
date. The PVL+ MRSA strains encountered in Austria were isolated
mainly from abscesses in adults. The most encountered ST were: ST8,
ST80, ST30, ST152, and ST5. L, RI, TMP/SXT, MH and LC showed a
good in vitro activity on these strains.
P1315 The emergence of methicillin-resistant Staphylococcus
aureus as a major cause of surgical site infection in England
J. Wilson, S. Elgohari, M. Lillie (London, UK)
Objectives: to explore the role of MRSA as a cause of surgical site
infection (SSI).
Methods: The surgical site infection surveillance service (SSISS)
in England collects data on a complete set of patients undergoing
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speciﬁed surgical procedures. Hospitals participate in the surveillance
for minimum 3-month periods in one or more of the 13 categories of
procedures. Trained staff in each hospital use a standard methodology to
identify those patients that develop a surgical site infection (SSI) meeting
a speciﬁc set of criteria during the patients in-patient stay. Between
1998 and 2005 data on 7,366 SSI from 254,607 surgical procedures by
were collected by 247 hospitals participating in the surveillance. Data
on the causative micro-organisms were available for 5,957 (81%) of SSI
reported.
Results: S. aureus was the most common pathogen causing SSI,
accounting for 52% of infections where a causative organism was
reported. Of these 66% were caused by methicillin-resistant S. aureus
(MRSA), although this proportion varied by type of surgery from 20%
in abdominal hysterectomy to 82% in bowel surgery. One third of the
SSI caused by MRSA involved the deep tissues and MRSA was more
likely to cause deep SSI than methicillin sensitive S. aureus (p = 0.001).
The risk of an SSI being caused by MRSA increased with patient age;
18% of SSI in patients under 45 compared to 46% of SSI in patients of
85 years or over (p< 0.001). MRSA has accounted for more than 60% of
S. aureus SSI since the inception of SSISS in 1997. The proportion
that were MRSA ﬂuctuated from year to year with no evidence of an
increasing or decreasing trend. This may reﬂect between year variations
in hospitals participating in the surveillance.
Conclusions: This analysis has provides evidence for the role of MRSA
as a pathogen of surgical wounds from a large national dataset. The
ﬁnding that MRSA accounts for almost two-thirds of S. aureus SSI across
a range of surgical procedures in England has important implications.
This proportion of MRSA is signiﬁcantly higher than that reported for
bacteraemia. Serious MRSA infections can be difﬁcult to treat, more so
in the presence of prostheses, increasing the risks of chronic sequelae.
The prevalence of MRSA as a cause of SSI identiﬁed by this study
emphasizes the need to identify and treat colonised patients prior to
surgery where possible, and review antimicrobial prophylaxis for patients
at high risk of developing post-operative wound infection.
P1316 Incidence and signiﬁcance of methicillin-resistant
Staphylococcus aureus in ventilator-associated pneumonia:
a prospective study
M. Torres, C. Radice, P. Mun˜oz, E. Bouza (Madrid, ES)
Objectives: MRSA is a growing cause for concern in many hospitals.
Ventilator-associated pneumonia (VAP) is one of the most severe
infections in ICUs at present. The incidence and clinical signiﬁcance
of MRSA-VAP are not well known. We aimed to assess the incidence
of MRSA-VAP and to deﬁne its clinical relevance in our institution.
Method: Prospective cohort study in the 3 ICUs of a general reference
hospital. Lower respiratory tract (LRT) samples of all patients with
suspicion of VAP were cultured from Dec 2003 to Dec 2005. Standard
diagnostic criteria were followed.
Results: Over a two-year period, 1,220 consecutive patients were
cultured (2,779 LRT samples) and VAP was diagnosed in 250 patients.
S. aureus was the most frequent causal agent of the VAP episodes (104:
41.6%). Of these, 66 VAP were caused by MRSA (26.4%) and 38 by
MSSA (15.2%).
MRSA-VAP (66 episodes) was compared with MSSA-VAP (38
episodes). MRSA-VAP patients were older (63 vs. 51 years, p< 0.01),
had a higher Charslon comorbidity score (4 vs. 2.7, p = 0.01), more
severe underlying diseases (48.5% fatal vs. 21.1%, p = 0.01), more
frequent multiorganic failure or septic shock (23.7% vs. 5.3% p= 0.01), a
longer hospital admission before VAP diagnosis (13 vs. 6 days, p = 0.01),
a higher Apache II score on admission to the ICU (13.1 vs. 10.3 p = 0.01),
and had consumed more antibiotics before the VAP episode (1.9 vs.
0.7 p< 0.01). MRSA-VAP had a higher mortality rate than MSSA-
VAP (74% vs. 31%; p< 0.01). However, MRSA was not found to be
an independent risk factor for mortality in our study.
Conclusions: MRSA causes 26.4% of VAP episodes and 64% of VAP
by S. aureus. MRSA is a marker of severity VAP but resistance is not
in itself independently associated with a worse outcome.
P1317 Where is MRSA in an intensive care unit and does it matter?
L. White, S. Dancer, C. Robertson (Glasgow, UK)
Objective: This project set out to evaluate the hygiene status of a six-
bedded surgical intensive care unit (SICU) environment alongside the
occurrence of hospital-acquired infection over a ten-week period.
Methods: Ten sites within SICU were sampled twice weekly using
dipslides applied to a range of hand-touch and other environmental
surfaces. The results were analysed using recently proposed standards for
surface level cleanliness, which specify enumeration of aerobic colony
counts from hand-touch sites as well as the identiﬁcation of speciﬁc
indicator organisms.
Results: The audit exposed hygiene fails in over a quarter of the
200 samples obtained. Most occurred at near-patient hand-touch sites,
particularly curtains, beds and cardiac monitor buttons, and suggested
insufﬁcient cleaning of these areas. Sites three or more metres away
from the patients, such as computer keyboard, telephone and staff
chair, also demonstrated hygiene failures but at less than half the
number. In contrast, non-hand-touch sites (sink and ﬂoor) rarely failed
the hygiene standards. Fourteen staphylococcal isolates associated with
SICU-acquired infection were collected from patients during the study
period. Pulsed-ﬁeld gel electrophoresis revealed ﬁve patient strains to
be indistinguishable from eight environmental strains, with timescales
supporting dynamic staphylococcal transmission in both directions
between patients and the environment in this SICU.
Conclusion: These ﬁndings suggest that hand-touch sites closest to
patients may act as a reservoir for potential pathogens.
P1318 Enhanced surveillance of MRSA bacteraemia in English hos-
pitals: comparison of risk factors in patients with community
onset bacteraemia with cases whose onset was in hospital
A. Pearson, K. Wagner, M. Murray, M. Painter, J. Giltrow, M. Fleming
(London, UK)
Objective: The English Department of Health introduced mandatory
reporting of methicillin resistant (MRSA) and sensitive (MSSA)
Staphylococcus aureus bacteraemia in April 2001. In 2004 a performance
target for a 50% reduction in the numbers of MRSA bacteraemia was set
for April 2008. Enhanced mandatory MRSA bacteraemia surveillance
was introduced in October 2005. This paper compares the patient
characteristics of admission diagnosed cases of MRSA bacteraemia
with hospitalised MRSA bacteraemia cases in acute NHS hospitals in
England.
Methods: The analysis presented was based on information sent to a web
enabled database as part of a national mandatory surveillance scheme
between October 2005 and September 2006. Standardised screen formats
were used to record the mandatory enhanced surveillance data. From
May 2006 an optional data collection screen became available on the
system which enabled entry of additional data on source, risk factors
and prior healthcare contacts for each MRSA bacteraemia case.
Results: During October 2005 to September 2006 approximately 7,000
reports of MRSA bacteraemia were received from 172 English Trusts.
Early enhanced surveillance data collected on a voluntary basis suggest
that the most common source of MRSA bacteraemia in patients with
community onset bacteraemia was skin/soft tissue infection (23%),
followed by UTI (17%). In contrast the most common source of MRSA
bacteraemia in patients who had been admitted for 2 or more days before
their bacteraemia was detected was CVC associated (23%), followed by
PVC associated (20%). The most common risk factors for both groups
were peripheral IV devices, followed by central IV devices.
Conclusion: Data from the MRSA bacteraemia enhanced surveillance
scheme provide an important means of identifying risk factors and
sources of bacteraemia in English patients. Skin/soft tissue infections (the
most common source of bacteraemia in the admission diagnosed group)
may result from the use of peripheral IV devices, the most common
risk factor in this group. It is hypothesised that a large proportion of
those patients presenting to the acute trust hospital with an MRSA
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bacteraemia developed this condition as a result of a prior healthcare
contact. Identiﬁcation of key risk factors and sources of bacteraemia
will allow effective targeting of infection control interventions.
P1319 Clonal analysis of methicillin-resistant Staphylococcus
epidermidis strains isolated from bloodstream infections in
Greece
A. Foka, S. Leveidiotou, S. Vamvakopoulou, E.D. Anastassiou,
I. Spiliopoulou (Patras, Ioannina, GR)
Objectives: Methicillin resistant-coagulase negative staphylococci con-
stitute a major cause of hospital infections. Staphylococcus epidermidis
is the predominant species associated with clinically relevant infections.
The purpose of the present study was to investigate any clonal
relationship among methicillin-resistant S. epidermidis (MRSE) isolated
from different patients hospitalised in two University Hospitals located
in Western and North-western part of Greece.
Methods: A total of 73 MRSE isolated from bloodstream infections
of inpatients were tested for their antibiotic resistance against
representative antibiotics by the disk diffusion method: cefoxitin (Cef),
tobramycin (Tm), gentamicin (Gm), linezolid (Lin), erythromycin
(Em), clindamycin (Cm), ciproﬂoxacin (Cip), fusidic acid (FA),
sulfamethoxazole/trimethoprim (SXT), vancomycin (Va). The MIC of
oxacillin was determined by the agar dilution method with Mueller-
Hinton agar containing 2% NaCl. PBP2a was detected by a Latex
agglutination test in all S. epidermidis. The presence of mecA gene
was investigated by PCR with speciﬁc primers. Slime production was
detected by the qualitative method. Clonal types were identiﬁed by PFGE
of chromosomal DNA SmaI digests.
Results: All 73 MRSE were mecA-positive while 57 (78%) produced
slime. The PFGE analysis revealed ﬁve PFGE types, common between
the two hospitals. Twenty three out of 73 (31.5%) isolates had the same
PFGE type, named a. Thirteen MRSE (18%) belonged to PFGE type b,
six (8%) to type c, ﬁve (7%) to type d and three (4%) to type e. The rest
23 (31.5%) were classiﬁed into 23 different PFGE types. All MRSE of
PFGE type a exhibited the same resistance phenotype to Cef, Tm, FA.
PFGE type b isolates showed a common resistance phenotype to Cef,
Tm, Cip, Gm, SXT. The isolates of the PFGE type c were resistant to
Cef, Em, Cip, Cm, Tm, FA. MRSE of PFGE type d were multi-resistant
to Cef, Em, Cip, Gm, Cm, Tm, FA, while strains of PFGE type e were
resistant to Cef, Em, Cm, FA.
Conclusions: Among hospitalised patients with bloodstream infections
in two University Hospitals, located in adjacent regions of the country,
common MRSE clonal types exhibiting multi-resistant phenotypes are
distributed.
P1320 Mortality following invasive MRSA infection in England,
2004−5
N.A.C. Potz, D. Powell, T. Lamagni, R. Pebody, C. Rooney, C. Grifﬁths,
D. Bridger, P. Goldblatt, J. Dobbs, G. Duckworth (London, UK)
Objectives: To evaluate the public health burden associated with MRSA
infection, information is needed on the incidence of infection and patient
outcome. Given that national surveillance of MRSA bacteraemia in
England does not capture patient mortality, a method was developed
to obtain this information from an external source. Preliminary analyses
of mortality following invasive MRSA infection were undertaken using
this augmented dataset.
Methods: A probabilistic record linkage method was developed to link
death registrations from the Ofﬁce for National Statistics and laboratory
conﬁrmed invasive MRSA records from the Health Protection Agency
(HPA) as unique personal identiﬁers are not uniformly available in the
surveillance data. Surveillance reports from laboratories in England
of MRSA isolated from blood and/or CSF from 1st January 2004
to 31st December 2005 were linked to deaths occurring between
1st January 2004 and 31st March 2006. Individuals with multiple
episodes of invasive MRSA infection were identiﬁed and analysed
separately. Descriptive and multivariable analyses of factors associated
with mortality following invasive MRSA infection were undertaken.
Results: Preliminary results identiﬁed that 97% of the 10,449 invasive
MRSA infection records from 1st January 2004 to 31st December 2005
had sufﬁcient identifying variables available to permit linkage. Of these,
59% were identiﬁed as having died up to 31st March 2006 (maximum
27 months follow-up). The 7-day case fatality ratio following a single
episode of invasive MRSA infection was 0.20 rising to 0.38 within 30
days. With adjustment for age, there was no signiﬁcant difference in
30 day mortality for males compared to females (OR= 1.03: 95%CI
0.94–1.12). Age was a strong predictor of 30 day mortality: compared
to a baseline age group of 0−50 years, the likelihood of mortality was
four-fold higher in 71−80 year olds (OR= 3.80: 95%CI 3.21–4.49), and
six-fold in 81−90 year olds (OR= 6.19: 95%CI 5.22–7.33).
Conclusion: Mortality following invasive MRSA infection was found
to be very high, almost 40% of individuals dying within 30 days
of diagnosis, with the elderly being substantially more likely to die.
However, it is known that these patients are likely to have other
underlying conditions and it is recognized that both the risk of
contracting an invasive MRSA infection and the risk of dying are related
to a patients’ underlying disease and treatment.
P1321 Regional variation in Panton-Valentine leukocidin positivity
smong S. aureus isolates in complicated skin and skin
structure infections
R. Strauss, K. Amsler, M. Jacobs, K. Bush, G. Noel (Raritan, US)
Objectives: Panton-Valentine leukocidin (PVL)-positive methicillin-
resistant S. aureus (MRSA) has been recognized as a virulent pathogen
that can cause severe skin and respiratory tract infections. PVL-positive
methicillin-susceptible S. aureus (MSSA) has also been increasingly
described in severe skin infections. The prevalence of PVL-encoding
genes among S. aureus isolates were analysed from a multicentre trial
comparing ceftobiprole, in investigational broad-spectrum cephalosporin
with anti-MRSA activity, to vancomycin in the treatment of patients with
complicated skin and skin structure infections (cSSSI).
Methods: S. aureus isolates were analysed for PVL by multiplex PCR
(n = 415). In vitro susceptibility (CLSI methodology) and a mecA probe
were used to identify MRSA.
Results: The trial involved 92 sites from 15 countries on 4 continents. Of
the 784 patients enrolled, S. aureus was isolated in 494 baseline samples
obtained from pus, leading edge of cellulitis, or debrided tissue. Overall,
47% (195/415) of S. aureus isolates were PVL positive. There were
large regional differences in the prevalence of MRSA and MSSA among
S. aureus isolates. In Europe, 40/239 (16.7%) S. aureus were MRSA,
compared to the USA, where 129/185 (69.7%) of S. aureus were MRSA
(P< 0.001). PVL results were available for 447/497 S. aureus isolates
(89.9%). PVL-positive MRSA isolates were most commonly seen in the
USA, with signiﬁcantly lower rates of PVL-positive MRSA in Europe
(P< 0.001) (Table). In contrast, PVL-positive MSSA most commonly
occurred in Asia/Africa and Europe. Clinical cure rates of cSSSI due
to PVL-positive S. aureus were comparable between ceftobiprole- and
vancomycin-treated subjects (95.0% vs 95.0%). Cure rates of cSSSI due
to PVL-positive MRSA were 93.9% for ceftobiprole-treated subjects and
86.2% for vancomycin-treated subjects. Frequency of PVL positivity
among S. aureus isolates is shown in the table.
Population PVL (+)
% MRSA % MSSA
Europe 5.3 (2/38) 37.4 (70/187)
USA 86.8 (92/106) 26.7 (12/45)
Asia/Africa 0.0 (0/3) 70.8 (17/24)
Central/South America 25.0 (1/4) 12.5 (1/8)
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Conclusion: Prevalence of PVL-positive MRSA and PVL-positive
MSSA differed widely among geographic regions. In this phase 3 cSSSI
trial, PVL-positive S. aureus isolates from US subjects were substantially
more likely to be MRSA than MSSA. This may be reﬂective of the high
prevalence of USA300 isolates as an important cause of cSSSI in the
USA. Outside the USA, the PVL toxin gene was more likely to be found
in MSSA than in MRSA isolates.
P1322 Environmental contamination in the rooms of
MRSA-colonised patients
H. von Baum, F. Raychevska, A. Mo¨ricke (Ulm, DE)
Objectives: The presence of MRSA in the rooms of MRSA colonised
patients and its relationship to the contamination of healthcare workers’
(HCW) gloves and clothing was examined.
Methods: 10 standardised environmental samples from patients’ rooms
as well as samples from the gloved hands and clothing of HCW
were examined. Samples were incubated for 48 h at 37º. Presumptive
positive colonies were conﬁrmed as S. aureus. Resistance to methicillin
was determined using the Slidex® MRSA Detection (bioMe´rieux). All
environmental MRSA isolates as well as the corresponding patients’
isolates were genotyped using pulsed-ﬁeld-gel-electrophoresis (PFGE).
Results: MRSA was present in the rooms of 18 of 25 MRSA patients
(72%). Contamination of HCWs’ gloved hands and/or clothing was
identiﬁed in 15 of 25 nurses (60%); 3 of 6 physicians (50%), 3 of 3
physiotherapists (100%) and 3 of 15 members of the housekeeping staff
(20%). In the majority of patients more than one MRSA strain was
present.
Environmental MRSA strains indistinguishable from the strains colonis-
ing the patients were detected in only half of the cases.
Conclusion: Healthcare workers must be aware that contamination of
their gloved hands and clothing whilst caring for a MRSA colonised
patient is highly probable. In the environment of MRSA colonised
patients not only the patients’ own strains but additional genotypically
distinct MRSA strains were detected.
P1323 Who’s carrying MRSA? Prevalence of MRSA amongst staff
at a district general hospital and associated risk factors
J. Clark, J. Archibald, A. Kearns, S. Barnass, M. Kyi (Isleworth,
London, UK)
Objectives: Methicillin-resistant Staphylococcus aureus (MRSA) in-
fections are important nosocomial infections in the UK. In efforts to
reduce infection rates, interest has focussed on patient colonisation and
transmission. The aim of this study was to determine the rate of and risk
factors for staff carriage of MRSA in a district general hospital setting.
Methods: Staff who enrolled gave written signed consent. They were
required to complete an anonymous questionnaire and a nasal swab
was taken for MRSA culture (also anonymous, but linked to the
questionnaire). MRSA was identiﬁed using standard laboratory methods,
and tested for antimicrobial susceptibility using the British Society for
Antimicrobial Chemotherapy method. Phage typing and pulsed ﬁeld
gel electrophoresis (PFGE) was conducted at the Centre for Infections,
Colindale, London. Statistical analysis was done using Fisher’s Exact
Test. Approval for the study was granted by the Local Research Ethics
Committee.
Results: Of 120 members of staff (21 medical staff, 54 nursing
staff, 11 healthcare assistants, 15 student nurses, 19 non-clinical
staff) who took part in the study, 10 (8.33%) were found to be
carrying MRSA. All the isolates were from nursing staff of varying
grades. Previous MRSA carriage was associated with current MRSA
colonisation (P value = 0.02), with other symptoms of upper respiratory
tract infection (sore throat, runny nose, cough, “cold”, sneezes, fever
and hay fever) showing no statistically signiﬁcant association. A history
of sinusitis or facial surgery, or having been a hospital in-patient in the
previous year, were not associated with MRSA colonisation. Typing of
the isolates showed most (8/10) were UK EMRSA-15 and the other 2
were EMRSA-16. On PFGE, four isolates were found to be a common
pulsotype, EMRSA-15 variant B3, whilst the other 6 were unique to the
hospital.
Conclusion: MRSA is an important cause of nosocomial infection and
its control is a priority for infection control teams. This study has shown
that even when small numbers of staff are screened for nasal carriage
of MRSA, carriers are found. Therefore, good infection control practice
by staff remains a top priority.
P1324 Control of an outbreak of an unusual ciproﬂoxacin-
susceptible variant of methicillin-resistant Staphylococcus
aureus EMRSA-15 on a neonatal unit
J. Otter, J. Klein, T. Watts, A. Kearns, G. French (London, UK)
Objectives: To report an outbreak and subsequent control of an unusu-
ally antimicrobial-susceptible strain of healthcare-associated MRSA on
a NNU, which was initially mistaken for community-associated MRSA
(CA-MRSA) and was not detected by standard local screening methods.
We also investigated whether environmental contamination may have
contributed to the outbreak.
Methods: All babies are screened for MRSA on admission to our NNU
using ciproﬂoxacin-containing broth media. Isolates were characterised
by antimicrobial susceptibility (by disc diffusion), pulsed-ﬁeld gel
electrophoresis (PFGE), phage type and Panton-Valentine leukocidin
(PVL) status. Forty environmental sites were sampled, plating onto
Baird-Parker agar directly and after broth enrichment.
Results: The index case was a premature baby who developed
MRSA bacteraemia with associated tibial osteomyelitis and multiple
subcutaneous abscesses. Screening with non-selective media identiﬁed
three further colonised babies. All four patient isolates were UK
EMRSA-15 by PFGE, PVL-negative and susceptible to all non-b-lactam
antimicrobials tested, including ciproﬂoxacin. This pattern is rare in our
hospital. Seven (17.5%) of the 40 environmental sites yielded MRSA,
including three that matched the phage type and unusual antibiogram
of the outbreak strain. The outbreak strain was cultured from the door
of the milk expressing room and, in the same room, a different MRSA
strain was isolated from a composite sample from a breast-pump and
associated chair arm.
Outbreak interventions included cohort isolation of affected babies,
thorough cleaning of the unit with a chlorine-containing compound,
introduction of a new cleaning regime for the milk expressing room
and increased emphasis on hand hygiene amongst staff and mothers. No
further cases were reported.
Conclusions: The outbreak strain was an unusual ciproﬂoxacin-
susceptible variant of EMRSA-15 and was initially mistaken for CA-
MRSA. MRSA was identiﬁed on hand-touch sites in the NNU including
communal milk expression areas, and mothers may have contributed
to transmission. Non-outbreak MRSA strains were also found in the
environment and may have survived from previous incidents. The
outbreak was controlled by multiple interventions aimed at improving
hand hygiene and reducing environmental contamination. Ciproﬂoxacin-
containing MRSA screening media are sub-optimal in paediatrics, where
ciproﬂoxacin susceptible strains are increasing in prevalence.
P1325 Methicillin-resistant Staphylococcus aureus carriage in
patients discharged from a teaching hospital in endemic area
V. Tomic, V. Ursic (Golnik, SI)
Introduction: After introducing an aggressive infection control pro-
gramme of transmission of methicillin-resistant Staphylococcus aureus
(MRSA) to our tertiary care, teaching hospital the proportion of MRSA
cases acquired in our institution decreased from 50% to 6.1%. To
better evaluate efﬁciency of infection control measures (screening on
admission, use of alcohol hand rub, barrier precautions) we decided to
determine the MRSA carriage rate at discharge which, to our knowledge,
was not yet performed in a highly endemic setting.
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Methods:We screened all patients admitted to our hospital in the periods
April 1−30, 2004 and April 1−30, 2006. Swabs were obtained from
the anterior vestibule of the nose within 24 hours of admission. We
performed nasal swabs in all these patients on the day of their discharge
from hospital regardless of the month of discharge.
Results: In April 2004 673 patients and in April 2006 643 patients
were admitted to our hospital. Both screening swabs (on admission and
discharge) were available for evaluation in 521/673 patients (77.4%)
in 2004 and in 403/643 (62.7%) in 2006. On admission 8 (1.5%) and
4 (0.6%) patients were already colonised with MRSA in April 2004
and 2006, respectively. Two of 8 patients in 2004 were successfully
decolonised. In 2004 we detected MRSA at discharge in 3 (0.5%)
patients not harbouring MRSA on admission. In April 2006 no
such patients were detected. Patients who acquired MRSA in our
institution during stay in April 2004 were hospitalised on the same
ward and the dates of their stay on the ward partially overlapped. After
screening the staff on the ward a medical nurse with history of non-
compliance to hand disinfection protocol was found colonised with
MRSA in the nose and external ear and was successfully decolonised
afterwards. PFGE pattern of MRSA strain detected in the nurse was
undistinguishable from the PFGE patterns of MRSA strains detected in
3 patients. Through screening of all medical staff on other wards we
detected no additional MRSA carriers.
Conclusions: When screening of patients for MRSA carriage, use of
an alcohol hand rub when necessary and barrier precautions are strictly
implemented even in an endemic setting transmission of MRSA can be
prevented. Undetected colonised healthcare workers pose a great risk,
even more so if hand disinfection is not ﬂawless.
P1326 MRSA spa-typing reveals a newly imported hospital
endemic strain
F. Huenger, S. Klik, H. Haefner, V. Krizanovic, S. Koch, S.W. Lemmen
(Aachen, DE)
Background: One aim of hospital infection control is to minimise
emergence and spread of Methicillin-resistant Staphylococcus aureus
(MRSA). Typing of isolates is used to support infection control
measures by revealing transmission and outbreaks. The analysis of the
staphylococcal protein A (spa) gene repeat sequence is a typing method
to discriminate MRSA strains.
Objective: Evaluation of spa-typing as a tool for hospital MRSA
surveillance.
Methods: Non-replicate MRSA isolates detected by screening or clinical
cultures between January 2004 and September 2006 from patients
admitted to the University Hospital Aachen (1,500 beds) were assayed
by spa-gene repeat sequence analysis and spa-types were assigned using
the Ridom StaphType™ software. Typing results were analysed and used
for standard infection control measures.
Results: Among 573 analysed MRSA isolates 46 different spa-types
were identiﬁed. The majority of 324 (57%) isolates belonged to spa-
type t003. The second most frequent strain was t838 with 58 (10%)
isolates followed by 25 t038; 19 t037; 18 t032; 17 t045; 13 t004;
8 t001; 8 t002; 7 t264; 7 t030; 5 t018; 4 t014; 4 t161; 4 t111; 3
t035. In 3 epidemiological not related patients the Panton-Valentine
leucocidin (PVL) positive Community-Acquired (CA) MRSA strain t044
was detected. Strains t109, t216, t457 and t740 were isolated twice. The
remaining isolates belonged to 25 different spa-types.
During an outbreak in a surgical ICU in June/July 2005 the previously
not detected strain t838 was isolated from 8 patients. The ﬁrst isolate
was detected in blood cultures of a patient transferred from the United
Arabic Emirates with multiple traumatic injuries. Screening of staff and
environment was negative. Although the outbreak was controlled by
immediate standard isolation and prevention measures, this rare strain
t838 was isolated regularly during the following 14 months.
Conclusions: Since the majority of 56% of hospital MRSA isolates
belonged to the regional endemic strain t003, spa-typing showed lim-
itation in differentiation between transmission/outbreak and accidental
accumulation. Nonetheless this method turned out to be a useful tool
in hospital infection control, as 3 CA-MRSA strains could be identiﬁed
by spa-typing and transmission within the hospital was excluded. In
addition the typing revealed that the most likely imported strain t838
has established as a second hospital endemic strain and underlines the
risk of international MRSA spread.
P1327 Spread of a vancomycin-intermediate, methicillin-resistant
Staphylococcus caprae in a neonatal intensive care unit
M. John, D. Kenny, D. Diagre, Z. Hussain (London, CA)
Objectives: We report spread and control of a strain of a methicillin-
resistant and vancomycin intermediate Staphylococcus caprae strain in
a 38 bed neonatal intensive care unit (NICU), following isolation from
a blood culture of one of a triplet.
Methods: Specimens from the nose and respiratory tract were collected
from all neonates and cultured. Coagulase negative staphylococci
(CoNS) were screened for vancomycin resistance using BHI plates
with 6mg/L vancomycin. Susceptibility to vancomycin was conﬁrmed
by E-test (AB Biodisk) according to the manufacturer’s instructions.
Susceptibility to other antimicrobials was determined using the VITEK
system and the presence of the mecA gene was ascertained by an in-
house PCR. CoNS that grew on screen plates were identiﬁed using
long set sugars (Kloos method) and were typed using restriction enzyme
digestion (Sma1) and Pulsed Field Gel Electrophoresis (PFGE). Infected
and colonised neonates were cohorted in the same room and placed on
contact precautions. Staff and families were instructed regarding good
hand hygiene.
Results: CoNS from ﬁve babies grew on screen plates and were
identiﬁed as most closely resembling Staphylococcus caprae. Three were
blood isolates, one was from an endotracheal aspirate and one was a
colonising organism. All displayed vancomycin intermediate resistance
and carried the mecA gene. The isolates had an MIC of 8mg/L of
vancomycin by E-test. The proﬁle of PFGE of all ﬁve isolates was
identical. All ﬁve babies with this strain, including a sibling of the index
case were linked epidemiologically and had been in the same room at
the same time.
Conclusion: CoNS resistant to b-lactam antimicrobials have emerged
as important causes of bloodstream infection in NICUs. Vancomycin is
commonly chosen in the treatment of these infections. The outbreak in
our NICU demonstrates the importance of screening isolates of CoNS
for decreased vancomycin susceptibility, which automated methods and
disc diffusion methods may fail to detect. Institution of strict hand
disinfection and contact precautions was successful in preventing further
spread of this organism within our NICU
P1328 Assessing Staphylococcus aureus nasal colonisation in a
cohort of healthy volunteers
M.E. Wood, D.J. Morse, T.M. Nordby, L.K. Olson, P.A. Mach,
C.J. Jacobson (St. Paul, US)
Objectives: The objective of this analysis was to understand S. aureus
nasal carriage levels and patterns (persistent vs. intermittent) among
healthy volunteers.
Methods: A screening study was conducted to obtain nasal samples
from healthy volunteers for use in the development and assessment of a
new rapid in vitro diagnostic device for S. aureus. Right and left naris
of subjects were sampled separately at two time periods 30 days apart.
Nasal specimens were analysed for S. aureus by standard quantitative
culture methods using a selective and differential medium. Conﬁrmation
testing was conducted using the Tube Coagulase Test. Culture data from
all studies was entered into a database for analysis of persistence vs.
intermittent carriage and log count variability.
Results: A total of 151 subjects were enrolled with a total 147 evaluable
subjects (having samples at both time points). 28% of evaluable subjects
were persistent carriers (S. aureus detected on both sampling days),
16% were intermittent (S. aureus detected on one sampling day) and
56% were non-carriers. Mean log count for a persistent carrier was 3.67
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logs while the mean log count for an intermittent carrier was 1.67 logs.
Mean log count difference between the initial and 30 day screening was
approximately 0.96 logs.
Not all subjects were found to be colonised in both nares. 27% of
persistent carriers were colonised in only one naris. 70% of intermittent
carriers were colonised in only one naris. When counts were observed
in both nares, the average difference between nares was approximately
1.19 logs.
29 persistent carriers were sampled repeatedly over a 3 year period. 83%
of the time S. aureus was detected at subsequent samplings. 45% of the
persistent carriers had S. aureus detected at every sampling.
Conclusions: Staphylococcus aureus accounts for approximately 20% of
surgical-site infections. Different nasal colonisation patterns (persistent,
intermittent, non-carrier) may play a key role in deﬁning the epidemi-
ology and pathogenesis of infection. Understanding the relationship
between quantitative nasal cultures and nasal carriage patterns in healthy
volunteers will allow for the development of relevant clinical diagnostics
to determine patients at risk. New rapid diagnostic tests for S. aureus
will enable clinicians to quickly identify those patients who may be at
elevated risk of developing healthcare acquired infections due to their
nasal S. aureus carriage status.
P1329 A quantitative analysis of clincal nasal swab samples testing
positive for methicillin-resistant Staphylococcus aureus
L. Mermel, J. Lonks, S. Gordon, T. Perl, S. Fadem, M. Acharya,
D. Dacus, S. Eells, G. Maxey, J. Cartony, D.J. Morse, M.E. Wood,
P.A. Mach, C.J. Jacobson (Providence, Cleveland, Baltimore, Houston,
Hudson, Delray Beach, Atlanta, St. Paul, US)
Objective: Approximately 25−30% of the population is asymptomat-
ically colonised with S. aureus, which is an important pathogen
that accounts for approximately 20% of surgical-site infections. Over
the past couple of decades, antibiotic treatment of infections due to
S. aureus has become more difﬁcult because of increasing methicillin
resistance. The objective of this study was to quantify methicillin-
resistant Staphylococcus aureus (MRSA) on clinical nasal swab samples,
which were obtained from patients known to be positive for MRSA, or
suspected to be at increased risk for MRSA carriage.
Methods: This is a prospective, multi-centre US clinical study. Swab
samples were collected from in-patient and out-patient populations, using
a sterilised rayon swab. Samples were obtained from both nares of
patients at 11 sites. Samples were analysed at a central microbiology
laboratory by a standard quantitative method using a selective medium
and enrichment broth. Primary isolate slants were generated from MRSA
samples for strain analysis via pulse ﬁeld gel electrophoresis.
Results: A total of 771 subjects were enrolled, of which 219 (31%) were
positive for MRSA. Fourteen of the 219, (6%), yielded MRSA growth
only by broth enrichment. Quantiﬁcation of MRSA samples resulted in
a mean of 2.9 logs, range 0.4−6.8 logs. MRSA strain analysis of 115
isolates identiﬁed 7 unique MRSA strains, with 72% percent identiﬁed
as USA100. Sites with active surveillance yielded 81% of cultures with
MRSA, due to the fact that potential carriers were ﬂagged upon hospital
admittance. For sites without active surveillance yielded 15%
of cultures yielded MRSA, from potential carriers in general high risk
populations.
Conclusion: Based on swab samples from both nares, there was an
average of 103 logs of MRSA colony forming units (cfu’s) found
in patients from multiple regions of the USA. The USA100 strain
predominated in patients from multiple sites. To increase conﬁdence
in the diagnoses of MRSA, it may be beneﬁcial to include a broth
enrichment step. The yield of MRSA cultures was greater in sites using
active surveillance, compared to sites obtaining samples from a general
high risk population.
Community-acquired genito-urinary tract
infections
P1330 Prevalence of Chlamydia trachomatis and Neisseria
gonorrhoeae among female university students in
Novosibirsk, Russian Federation
A. Khryanin, O. Reshetnikov, A. Anpilogova (Novosibirsk, RU)
Objective: Epidemiology of sexually transmitted infections (STIs) is
largely based on surveillance data. The aim of the present study was
to examine the prevalence of Chlamydia trachomatis and Neisseria
gonorrhoeae infections and risk factors for these infections among young
women in Novosibirsk, Western Siberia.
Methods: Female university students were invited to undergo free
gynecological examination. One hundred students (mean age 20.6 years,
range 16−24) voluntarily participated in the study. After a conﬁdential
interview, a gynecologic examination was performed with collection of
endocervical specimens. A nucleic acid ampliﬁcation method (APTIMA
Combo 2 assay, Gen-Probe Inc, USA) was used for N. gonorrhoeae and
C. trachomatis testing.
Results: The prevalence of C. trachomatis infection was 12.0%, and
N. gonorrhoeae prevalence was 2.0%. Both N. gonorrhoeae-positive
females were also infected with C. trachomatis. Infected women reported
younger age at ﬁrst sexual intercourse (16.1 years vs 17.5 years
among non-infected, p = 0.01) and a higher number of lifetime sexual
partners (6.1 vs 2.8, p = 0.01). Other variables (age, new sexual partner,
condom use, history of STDs etc.) did not differ between infected and
non-infected subjects. Among reported symptoms, vaginal discharge
(p = 0.04) and intensive menstrual bleeding (p = 0.04) were more frequent
in infected women, whereas dysmenorrhea, genital pruritus, burning,
pain, and dyspareunia were not.
Conclusion: The prevalence rates of C. trachomatis and N. gonorrhoeae
infections in young females in Novosibirsk, Russia are higher than those
previously published, possibly due to higher sensitivity of the method
used in our study. As in other populations, age at ﬁrst intercourse and
the number of lifetime sexual partners had a signiﬁcant effect on the
risk of bacterial STIs.
P1331 Can we use erythromycin or clindamycin in penicillin-
allergic patients with vaginal and anorectal carriage of
Streptococcus agalactiae in late pregnancy?
F. Khorvash, A. Javadi, M. Izadi, S. Mobasherizadeh,
K. Mostafavizadeh, M. Ahmadi (Isfahan, Tehran, IR)
Objective: The aim of this study was to establish the incidence and
frequency of Group B Streptococcus (GBS) colonisation in pregnant
women and to determine antibiotic susceptibility and policies for
prevention of neonatal GBS infection in Isfahan, Iran.
Methods: A total of 170 pregnant women at 35−37 weeks of gestation
were screened by placement of a swab in the lower third of the vagina
with subsequent passage across the perineum and anus. GBS was
identiﬁed via colonial morphology, beta-haemolytic, and biochemical
reactions. The antimicrobial susceptibility test was performed by the
agar dilution method.
Results: The prevalence of vaginal and rectal GBS colonisation was
18.2%. Colonisation rates were signiﬁcantly increased among multi
parity (p = 0.04), and antecedent abortion (p = 0.01). There were no
signiﬁcant differences between age, socioeconomic condition and GBS
colonisation. All strains were susceptible to penicillin, ampicillin,
vancomycin, cephazolin and imipenem. Thirteen (41.9%) isolates were
resistant to erythromycin (MIC 1 g/L) and eight (25.8%) were resistant
to clindamycin (MIC 1 g/L). Two strains (6.4%) showed intermediate
susceptibility to clindamycin (MIC= 0.5 g/L). 87% of strains were
resistant to gentamicin.
Conclusion: The colonisation rate of GBS among pregnant women in
the present study is high, and on the basis of documented beneﬁts
of antenatal screening in western countries we recommend routine
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screening, especially for our at risk patients. According to high resistant
to erythromycin and clindamycin in our population we recommended
that for allergic penicillin patients use of these antibiotics should be
done after identifying of sensitivity in laboratory.
P1332 Chlamydial infections of non-pregnant women in a gypsy
population
R. Zaﬁrovska, G. Bosevska, S. Panev, S. Kuzmanovska (Skopje, MK)
Objective: To assess the incidence of chlamydial infections among
non-pregnant women with genital infections of gypsy population, as
a part of the Program of Ministry of Health of R. Macedonia, for
HIV/AIDS prevention supported by Grant of Global Fund to ﬁght AIDS,
Tuberculosis and Malaria.
Material and Methods: During period of 1 April to 1 November
2006, from 471 gynecological examined non-pregnant women with STDs
problems, age of 15 to 64 years, 325 cervical samples were tested
for Chlamydia trachomatis infections with ELFA VIDAS bioMe´rieux
method.
Results: See the Table.
Age Gynecological Cervical Chlamydia test
examined for
STDs
samples (+),
80
(+/−),
>60<80
(−),
60
<19 30(64%) 20(6.1%) 0 0 20 (100%)
20−25 87 (18.5%) 67 (20.6%) 4 (6%) 0 63 (94%)
26−40 218 (46.3%) 146 (44.9%) 6 (4.1%) 1 139 (96%)
>40 136 (28.8%) 92 (28.3%) 1 (1%) 2 89 (96.7%)
Total 471 325 11 (34%) 3 311 (95.6%)
Conclusion: Low incidence of detected genital chlamydial infections,
probably is a result of low prevalence (25%) of adolescent group of
women (up to 25 years of age) as a result of gypsy population tradition
for early marriages, average 4 births and termination of reproduction
around 25 years of age.
P1333 Coinfection of genital mycoplasmas among men with gono-
coccal urethritis and their roles in post-gonococcal urethritis
T. Deguchi, M. Yasuda, S. Maeda, M. Tamaki, S. Ito, M. Nakano,
S. Yokoi (Gifu City, Toyota City, JP)
Objectives: F We determined the prevalence of coinfection with
genital mycoplasmas, including Mycoplasma genitalium, Mycoplasma
hominis, Ureaplasma parvum and Ureaplasma urealyticum, among men
with gonococcal urethritis (GU) and analysed roles of the genital
mycoplasmas in post-gonococcal urethritis (PGU).
Methods: We examined ﬁrst-voided urine samples from 390 men
with gonococcal urethritis (GU) for the presence of C. trachomatis,
M. genitalium,M. hominis, U. parvum and U. urealyticum, by polymerase
chain reaction-based assays. The patients were treated with ceﬁxime,
ceftriaxne, or spectinomycin. PGU was judged to occur if, in spite of
the eradication of Neisseria gonorrhoeae, the urethral smear showed
signiﬁcant numbers of polymorphonuclear leucocytes from 7 days to 14
days after treatment.
Results: C. trachomatis and/or the genital mycoplasmas were coinfected
in 132 (33.8) of 390 men with culture-conﬁrmed N. gonorrhoeae. In
85 (21.8%), C. trachomatis was detected with or without the genital
mycoplasmas. One or two species of the genital mycoplasmas were
detected in 15 men coinfected with C. trachomatis (3.8%) and in 47 men
without chlamydia coﬁnfection (12.1%). Of these 47 men, M. genitalium
and U. urealyticum were detected in 12 and 23, respectively. In 291
men, the eradication of N. gonorrhoeae was conﬁrmed by culture after
treatment. Of these 291 men, 103 men (35.4%) were judged to have PGU.
PGU occurred in 51 (77.3%) of 66 men with chlamydia-positive GU
and in 14 (46.7%) of 30 men with chlamydia-negative but mycoplasma-
and/or ureaplasma-positive GU, whereas it was observed in 38 (19.5%)
of 195 men with GU negative for all of C. trachomatis and the genital
mycoplasmas. C. trachomatis, M. genitalium and U. urealyticum were
signiﬁcantly associated with PGU, but M. hominis or U. parvum was
not.
Conclusion: The prevalence of coinfection with C. trachomatis among
men with GU was 21.8%, whereas that with the genital mycoplasmas
was 15.9%. M. genitalium and U. urealyticum were associated with
PGU as well as C. trachomatis. In clinical settings, the detection of
genital mycoplasmas is frequently difﬁcult so that men with NGU
should be treated presumptively with antimicrobial agents active against
C. trachomatis and genital mycoplasmas.
P1334 Epidemiology of urinary pathogens in adults during
2005–2006
I. Apostolidou, M. Zoumberi, K. Papaefstathiou, E. Koloka,
G. Kouppari (Athens, GR)
Objectives: To ﬁnd out the frequency and antimicrobial susceptibility
of urinary tract pathogens during 2005–2006.
Methods: 10,323 urine samples were examined from 9,399 patients
with median age 75 years. The identiﬁcation of the isolated bacteria
was performed by standard methods and the API systems (bioMe´rieux).
The antimicrobial susceptibility testing was carried out by disk diffusion
method and interpreted according to NCCLS and the MIC with E-test
when was needed.
Results: Positive urine cultures were found in 2,183 patients (23.2%).
The microbial strains most frequently isolated from the positive
urine cultures were: Escherichia coli (52.6%), Enterococcus spp.
(11.1%), Pseudomonas aeruginosa (8.8%), Candida spp. (8.6%),
Proteus mirabilis (6.3%), Klebsiella pneumoniae (4.6%), others (7.9%).
Of Escherichia coli isolates 54.6% were resistant to ampicillin, 19.3% to
amoxicillin+clavulanic acid, 25% to co-trimoxazole, 13.1% to cefaclor,
4.4% to cefotaxime, 4.8% to gentamicin, 8.9% to norﬂoxacin, 0% to
imipenem and 13 (0.9%) produced ESBL. Of Enterococcus spp. isolates
9.7% were resistant to vancomycin and teicoplanin (VanA). In 43 patients
the same strain was isolated and from blood culture (2%).
Conclusions: The most common pathogen among isolates from
positive urine cultures was E. coli followed by Enterococcus spp. and
Pseudomonas aeruginosa. Of E. coli isolates 0.9% produced ESBL.
In 2% of the patients with urine infection there was bacteraemia and
the same strain was isolated in both urine and blood cultures. Of
Enterococcus spp. isolates 29 (9.7%) were resistant to vancomycin and
teicoplanin (VanA).
P1335 Antimicrobial resistance of Escherichia coli urinary isolates
from primary care patients in Greece
M.E. Falagas, M. Polemis, V.G. Alexiou, I. Sarantou, J. Kremastinou,
A.C. Vatopoulos (Athens, Kyparissia, GR)
Objective: Most of antimicrobial susceptibility surveillance studies fo-
cus on isolates from hospitalised patients. We performed a retrospective
analysis of microbiological data of the antimicrobial susceptibility of
Escherichia coli urinary isolates from primary care patients in Greece.
Methods: The in vitro susceptibility to ampicillin, amoxicillin/
clavulanate, cefaclor, cefprozil, trimethoprim-sulfamethoxazole (cot-
rimoxazole), amikacin, and norﬂoxacin of 2,460 E. coli isolates
(01/2005−06/2005) from the urine specimens of patients tested at the
laboratories of 3 Greek primary care diagnostic centres were analysed.
Only the ﬁrst isolates per patient (2,074 females and 386 males) were
included in the analysis.
Results: The proportion of E. coli urinary isolates that were resistant to
cotrimoxazole was 20.8% and 26.4% for females and males, respectively.
There were noteworthy differences between age groups; 37.8% isolates
from females <15 years old were resistant to cotrimoxazole compared
to 21.9% and 16.7% for >45 years old and 15−45 years old females,
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respectively (P< 0.001). The proportion of isolates resistant to ampicillin
was very high (from 32.5% to 43.3% and 31% to 63% for urinary
isolates from females and males, respectively, in the different age groups
examined) while it was relatively low for amikacin (up to 4.8%); 17.8%
and 5.5% of the isolates from males and females, respectively, were
resistant to norﬂoxacin (20.7% for males >45 years).
Conclusions: These ﬁndings offer help to clinicians in deciding the
appropriate empirical treatment for primary care patients with urinary
tract infection and emphasize the increasing problem of antimicrobial
resistance in the primary care setting in Greece.
P1336 A meta-analysis of risk factors for mortality in patients
with emphysematous pyelonephritis
M.E. Falagas, V.G. Alexiou, K.P. Giannopoulou, I.I. Siempos (Athens,
GR)
Objectives: Emphysematous pyelonephritis (EPN), an infection most
commonly seen in patients with diabetes mellitus, is associated with
considerable case fatality. We sought to identify the factors associated
with mortality in patients with EPN and estimate the magnitude of the
associations.
Methods: Pub Med was searched to identify studies reporting on risk
factors of mortality in patients with EPN. A meta-analysis of the eligible
studies was performed.
Results: Seven study cohorts, representing 175 patients with EPN, were
included in the meta-analysis. The overall mortality was 25%, ranging
from 11% to 42%. Conservative treatment alone [odds ratio (OR) = 2.85,
95% conﬁdence interval (CI): 1.19–6.81), bilateral EPN (OR= 5.36,
95%CI: 1.41–20.33), type I EPN (OR= 2.53, 95%CI: 1.13–5.65), and
thrombocytopenia (OR= 22.68, 95%CI: 4.4–116.32) were associated
with increased mortality. Systolic blood pressure <90mmHg, serum
creatinine >2.5mg/dl, and disturbance of consciousness were also found
to be associated with increased mortality, based however on limited
data. On the other hand, there was no association between mortality
and diabetes mellitus (OR= 0.32, 95%CI: 0.05–1.99) in patients with
EPN.
Conclusion: Based on the available evidence, conservative treatment,
type I EPN, bilateral EPN and thrombocytopenia are signiﬁcant risk
factors for mortality in patients with EPN. These data may be taken
under consideration when managing patient with devastating infection.
P1337 Diabetes increases relapses and recurrences of acute urinary
tract infections in adult women but does not evoke a differ-
ence in the pattern of antibiotic prescriptions in primary care
K.J. Gorter, D. van Oostveen, E. Hak, N.P.A. Zuithoff,
A.I.M. Hoepelman, G.E.H.M. Rutten (Utrecht, NL)
Objective:Women with diabetes (DM) have an increased risk for urinary
tract infections (UTI). Aim was to assess diabetes care associated risks
of recurrent episodes of UTI in adult women with diabetes (DM) in
primary care and the pattern of prescribed antibiotics.
Design: Retrospective study. Setting: All women of 30 years or over
registered in two primary healthcare centres (n = 22,000 patients) during
a period of 43 months (1998–2001).
Patients: We compared incidence rates of single and recurrent urinary
tract infections (UTI) in women with diabetes (n = 340) and women
without diabetes (n = 6,618).
Main outcome measures: Independent risk of diabetes characteristics,
indicators of care and complications for relapsed and recurrent UTI;
odds ratio with 95% conﬁdence interval [OR; 95%CI]. The diabetes–
no-diabetes associated pattern of antibiotic prescriptions.
Results: Of the women with diabetes and those without diabetes
relapses and (recurrences) were reported in 7.1 (16.9%) and 2.0 (4.2%)
respectively. After adjustments in a multivariate logistic regression
analysis for age, socio-economic status and history of vaginitis, the risk
of a recurrent episode was 2.0 times higher in women with diabetes than
in controls (95%CI: 1.4−2.9). Risks were higher in women who used
oral hypoglycaemic medication (odds ratio [OR]: 2.1; 95%CI: 1.2−3.5),
insulin (3.0; 1.7−5.1), who had >5 years diabetes (2.9; 1.9−4.4) and
who had retinopathy (4.1;1.9−9.1). A similar pattern of antibiotics was
prescribed in women with and without diabetes, both for one episode of
UTI and for relapses and recurrences.
Conclusions: Women with diabetes of longer duration, on treatment and
with retinopathy have an elevated risk for a recurrent episode of acute
symptomatic UTI’s, but this does not evoke difference in the pattern of
antibiotic prescriptions. Research focussing on preventive and antibiotic
management of UTI is needed in women with DM.
Epidemiology of multi-drug resistant
Gram-negative organisms
P1338 Molecular epidemiology of carbapenem-resistant Acineto-
bacter baumannii in a university hospital, Split, Croatia
I. Goic-Barisic, B. Bedenic, M. Tonkic, S. Katic, A. Novak, S. Kalenic,
V. Punda-Polic (Split, Zagreb, HR)
Objectives: Acinetobacter baumannii is an opportunistic pathogen
that is frequently involved in outbreaks of infection, occurring
mostly in intensive care units. Carbapenem resistance is now being
reported increasingly in A. baumannii isolates in association with
the production of carbapenem-hydrolysing class D b-lactamases or
oxacillinases that have now emerged worldwide. The aim of the present
study was to analyse and compare genotypes of clinical isolates of
carbapenem resistant Acinetobacter baumannii collected from three
different Intensive Care Units in University Hospital Split, Croatia.
Methods: During 2004, twenty-two non-repetitive A. baumannii isolates
with an unusual resistance proﬁle were obtained from patients
hospitalised at three different Intensive Care Units (two adults ICU
and one children ICU) inside University Hospital Split. All collected
isolates of A. baumannii displayed intermediate (MIC> 8mg/L) or
resistant (MIC> 16mg/L) proﬁle to imipenem and/or meropenem.
Minimum inhibitory concentrations were also determined for cef-
tazidime, cefepime, ceftriaxone, amikacin, gentamicin, ciproﬂoxacin
and piperacillin-tazobactam by broth microdilution according to CLSI
(formerly NCCLS) recommendation. All isolates were multidrug-
resistant exhibiting high resistance to tested antimicrobials. The isolates
of A. baumannii were genetically characterised using pulsed-ﬁeld gel
electrophoresis (PFGE). Strain typing was performed by macrorestriction
analysis of chromosomal DNA by use of PFGE (Apa I enzyme, in a
CHEF DR III drive module).
Results: We report the clonal dissemination of pulsotype A between two
different adult intensive care units in University Hospital Split, belonging
to the same pulsed-ﬁeld gel electrophoresis (PFGE) proﬁle, probably
by hospital staff during medical procedures. The strain characterised as
pulsotype B was the only strain isolated from children intensive care
unit without expanding inside the hospital.
Conclusion: The infection control team of the hospital implemented
restriction of carbapenem usage and strict antiseptic techniques, which
included the rigorous use of alcohol-clorhexidine solutions before and
between patient and equipment contact and before leaving the units.
Consequently, incidence and spread of multidrug-resistant A. baumannii
nosocomial infections suggest the necessity of a surveillance programme
and enforcing adequate control measures in different hospital settings.
P1339 Molecular characterisation of carbapenem-resistant
Acinetobacter baumannii isolated in two Turkish medical
centres in 2006: report from the SENTRY Antimicrobial
Surveillance Program
L. Deshpande, H. Sader, D. Gur, V. Korten, G. Soyletir, R. Jones
(North Liberty, US; Ankara, Istanbul, TR)
Objectives: To evaluate the mechanisms of resistance (R) to carbapen-
ems (CARB) and the epidemiologic typing of CARB-R Acinetobacter
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spp. (ASP) isolated in Turkey through the SENTRY Program in 2006. We
also evaluate the antimicrobial susceptibility (S) of ASP strains collected
in Turkey over the last 7 years (2000–2006).
Methods: A total of 304 ASP strains were submitted by two
Turkish medical centres (MCs; Ankara and Istanbul) from 2000
to 2006, 57 in 2006. The isolates were mainly from bloodstream
(64.1%) and respiratory tract (26.0%) infections and were S tested by
reference broth microdilution methods to >30 antimicrobials according
to CLSI guidelines (2006). Strains R to imipenem and meropenem
(MIC> 16mg/L) collected in 2006 were screened for production of
carbapenemases (IMP, VIM, SPM and OXA groups) by PCR and
epidemiologically typed by PFGE.
Results: The most active antimicrobials overall were: polymyxin B
(99.2% S), imipenem (51.3% S), meropenem (51.0% S) and tobramycin
(42.4% S). S to imipenem decreased from 80.4% in 2000 to only
29.8% in 2006. Forty of 57 (70.2%) ASP strains collected in 2006
were CARB-R with high rates of cross-R to all other antimicrobials
tested, except polymyxin B (100.0% S) and tigecycline (100.0% inhibited
at 2mg/L), and 23 of those were randomly selected for molecular
characterisation. All 23 strains were PCR-positive for blaOXA-51,
indicating A. baumannii. Five strains were from one site and these
strains showed identical or similar PFGE patterns and were PCR-positive
for blaOXA-58. The remaining 18 CARB-R strains also showed PFGE
pattern identical/similar to each other and distinct from that of MC 068.
All 18 strains had PCR positive results for blaOXA-23.
Conclusions: Clonal dissemination of R strains caused a signiﬁcant
increase in the prevalence of CARB-R ASP in the Turkish medical
centres evaluated by the SENTRY Program. CARB-R was found to
be largely driven by OXA-type carbapenemases, OXA-58-type being
prevalent in Ankara and OXA-23-like in Istanbul. Polymyxin B and
tigecycline represent the only antimicrobials with reasonable in vitro
activity against ASP in the Turkish MCs evaluated.
P1340 Comparative results of the in vitro efﬁcacy of colistin
and carbapenems against multidrug-resistant strains of
Acinetobacter baumannii isolated from clinical specimens
V. Koulourida, A. Papa, M. Moskophidis (Thessaloniki, GR)
The infectious diseases caused by Acinetobacter baumannii are severe
and need instant and proper therapy. Since 1970, the constantly
increasing resistance of A. baumannii strains to antibiotics, sets up a
great problem, as the “weapons” for the treatment of these infections
have been decreasing dramatically.
The aim of the present study was to determine the in vitro sensitivity of
imipenem and meropenem, as well as colistin.
Material and Methods: Material consisted of 109 non replicated MDR
strains A. baumannii, isolated from patients from various clinics of
Papageorgiou General Hospital in Thessaloniki during the period 2001–
2006: 50 from the ICU, 35 from the surgery wards and 24 from the patho-
logical wards. Strains were isolated from various clinical specimens: 22
from blood cultures, 23 from respiratory samples, 14 from intravenous
catheters, 10 from urines, 26 from surgery wounds, 14 from other
materials. For the culture of the specimens MacConkey agar, Mueller
Hinton agar and Blood agar were used. Identiﬁcation and determination
of susceptibility to 20 antibiotics were performed by the automatic
system WIDER using the MIC/ID Gram-negative panels. The MIC in
colistin, imipenem and meropenem, was determined, by the dilution of
antibiotics in agar method in according the NCCLS standards. PCR for
the integrase genes int1, int2 and int3 was performed in al the strains.
Results: Only 15/109 (14%) strains of A. baumannii were sensitive to
imipenem, and 2/109 (2%) were sensitive to meropenem. The resistance
in the other antibiotics ranged from 87 to 100%. All the strains were
found in vitro sensitive to colistin. Concerning integrons, 89% of the
strains were carrying the int1 gene, while int2 and int3 were not detected.
Conclusions: Most of the A. baumannii strains tested were resistant to
carbapenems, while all of them were sensitive to colistin, suggesting
that clinicians have to take these results into consideration for the
antibacterial treatment.
P1341 Emergence of carbepenem-resistant Acinetobacter
baumannii in a Bulgarian university hospital
R. Dobrewski, T.J.K. van der Reijden, E. van Strijen, E. Keuleyan,
H. Hitkova, E. Savov, M. Lesseva, P.J. van den Broek, L. Dijkshoorn
(Soﬁa, Pleven, BG; Leiden, NL)
Objectives: From 2000 to 2002 a predominant multidrug resistant
(MDR) but carbapenem susceptible Acinetobacter baumannii strain
was identiﬁed in the Military Medical Academy (MMA), a teaching
hospital in Soﬁa, Bulgaria. Since, carbapenem resistant A. baumannii has
emerged in this hospital and in other Bulgarian hospitals. The purpose
of our study was to investigate whether this phenomenon was due to the
spread of a single strain.
Methods: A total of 72 MDR A. baumannii isolates from 72
patients was investigated including 58 isolates from the MMA and 14
from three other hospitals (A-C). Sixty-six isolates were carbapenem
resistant; six were carbapenem susceptible. The 58 MMA isolates
comprised 53 carbapenem resistant and ﬁve carbepenem susceptible
isolates from epidemic episodes from 2004 to 2006. The 14 isolates
from the hospitals A−C were from 2005 to 2006; all but one
were carbapenem resistant. Presumptive identiﬁcation and antibiotic
susceptibility determination was done with the VITEK2 system
(bioMe´rieux). AFLP analysis was used to identify the organisms at
species, clone and strain level using clustering levels of 50%, 80% and
90% respectively.
Results: All isolates were identiﬁed to A. baumannii as they clustered
with A. baumannii reference strains at 50% or above. At the strain
delineation level of 90%, the isolates were allocated to seven clusters
and a single strain, coded 1−8. Two major clusters, no. 1 and no. 7
included 47 and 11 isolates respectively. Five other clusters contained
2−4 isolates each. Eleven isolates from hospital A−C grouped together
in the major cluster 1 with isolates from the MMA; three other isolates
from hospital A−C were in cluster 3, 4 and 7, respectively. Thus, there
was no clear correlation between AFLP clustering and the hospitals of
origin. The four isolates of cluster 4 belonged to EU clone II; three
were carbapenem resistant, one was susceptible. The four carbapenem
resistant isolates that grouped together in cluster 5 belonged to EU clone
I. None of the currently found strains corresponded to the strains found
in the MMA from 2000–2002.
Conclusion: Eight different carbapenem resistant A. baumannii strains
were distinguished by AFLP ﬁngerprint analysis. Most isolates belonged
to two predominant clusters and were considered to represent two major
strains. In particular one strain (corresponding to AFLP cluster 1) was
widely prevalent in the MMA and was also in the three other hospitals.
P1342 Molecular differentiation of multidrug-resistant
Acinetobacter baumannii clinical strains in a Greek hospital
A. Papa, V. Koulourida, M. Moskophidis, A. Antoniadis (Thessaloniki,
GR)
Objectives: Acinetobacter baumannii is an important cause of noso-
comial infections especially among critical ill patients. The number
of multidrug-resistant (MDR) strains of A. baumannii is increasing,
resulting in great problems for choosing the proper treatment. Aim of
the present study was the molecular typing of MDR A. baumannii strains
isolated during the last year in a tertiary Greek hospital.
Material and Methods: Thirty-ﬁve non-replicated multiresistant
A. baumannii strains isolated from patients from various wards of
Papageorgiou General Hospital were tested: 14 patients were hospitalised
in the ICU, 11 in the internal medicine wards and 10 in the surgery wards.
Susceptibility to 20 antibiotics was tested by microdilution method.
RAPD and PFGE using ApaI were used for molecular typing of the
strains. In addition, PCR was applied for the detection of integrase genes
int1, int2 and int3.
Results: The 35 strains were divided into three clonal groups using
RAPD and PFGE. The two methods gave similar results. The ﬁrst group
consisted of 18 strains, the second group of 12 strains, while the third
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one of 5 strains. Strains of the ﬁrst two groups were dispersed in all
wards, while the majority (80%) of the strains of the third group was
isolated from the internal medicine ward. All strains presented similar
multi-resistant patterns, with the exception of the third group which was
susceptible to aminoglycosides. Class 1 integrons were missing from the
strains of the third group, while it was present in all other strains. Class
2 or 3 integrons were not detected.
Conclusions: Three different clonal groups of A. baumannii strains are
present in the hospital during the last year. The main difference among
them is the resistance to aminoglycosides combined with the presence of
intI gene in strains of two of the three groups. Results of this study gave
an insight into the molecular diversity of multiresistant A. baumannii
strains isolated in Papageorgiou hospital during the last year.
P1343 Molecular epidemiology of pandrug-resistant Acinetobacter
baumannii infection at a university hospital in Taiwan
L.H. Su, T.L. Wu, J.H. Chia, A.J. Kuo, C.F. Sun (Taoyuan, TW)
Objectives: Acinetobacter baumannii has constituted as an important
clinical pathogen causing an increasing number of respiratory infections
at the Chang Gung Memorial Hospital, Taiwan. Moreover, approximately
50% of the isolates were multidrug-resistant A. baumannii (MDRAB)
that were multiply resistant to all antibiotics commonly used to treat
infections caused by Gram-negative bacteria except imipenem. The
incidence of pandrug-resistant A. baumannii (PDRAB), which is resistant
to all antibiotics including imipenem, had been kept low at 2.7% before
2002, but a sudden increase to 16%-20% was noticed during 2003–2006.
Methods: A total of 597 isolates of A. baumannii collected
from 287 patients during 1998–2006 were retrospectively studied.
Antimicrobial susceptibilities of A. baumannii isolates to amikacin,
aztreonam, ceftazidime, ciproﬂoxacin, cefepime, gentamicin, imipenem,
and piperacillin were analysed by a standard disk diffusion method
and interpreted according to the criteria suggested by the Clinical
and Laboratory Standard Institutes. Genotypes of the isolates were
determined by pulsed-ﬁeld gel electrophoresis (PFGE) and infrequent-
restriction-site PCR (IRS-PCR).
Results: A total of 303 (50.8%) PDRAB isolates and 135 (22.6%)
MDRAB isolates were identiﬁed from the 597 isolates studied.
Genotyping analysis by PFGE and IRS-PCR produced compatible results
and 82 genotypes, including 17 from the PDRAB isolates and 13
from the MDRAB isolates, were identiﬁed. The majority (78.4%) of
the isolates belonged to a predominant genotype 7, the prevalence
of which was signiﬁcantly higher among the PDRAB (93.4%) and
MDRAB (88.1%) isolates compared to isolates of other antibiograms
(41.5%; P< 0.00000005). Among 50 of the 56 patients from whom
multiple isolates of different antibiograms were available for comparison,
genotypes of their isolates remained the same when MDRAB became
PDRAB (in 38 patients) or vice versa (in 22 patients) during their
hospital stay.
Conclusions: The recent upsurge of PDRAB isolates at this hospital
was closely associated with a predominant clone, genotype 7, which
had been prevalent among MDRAB isolates prior to the PDRAB era.
During the hospital stay, MDRAB from the same patients may become
PDRAB, some of which may subsequently turn back to MDRAB again.
Infection control strategies to contain PDRAB infections may not be
effective if patients with imipenem-susceptible MDRAB infections were
not included in the isolation policies.
P1344 Multidrug-resistant Acinetobacter baumannii susceptible
only to colistin outbreak in a cardiac surgical intensive care
unit
A. Mastoraki, E. Douka, I. Kriaras, G. Stravopodis, G. Saroglou,
H. Manoli, S. Geroulanos (Athens, GR)
Objectives: The aim of this study was to determine the incidence and
mortality of Multi-Drug Resistant Acinetobacter baumannii (MDR-AB)
in patients undergoing cardiac surgery, to elucidate the effectiveness of
treating them with colistin and to identify if the additional measures to
the recommended procedures were able to control the dissemination of
MDR-AB isolates in our institution.
Methods: A prospective study was conducted among 1,451 patients who
were submitted to cardiovascular surgery from 1 September 2005 to 31
August 2006. All case histories of infected patients were objected to
meticulous analysis. We reviewed the prophylactic measures of the SICU
and implemented a two scale multiple programme. Scale 1 included
classical infection control measures, i.e. strict contact and droplet
isolation, surveillance of throat, nasal and anal ﬂora for MDR pathogens
on all patients transferred from other hospitals, separate nursing staff for
each infected or colonised case and strict antibiotic policy, while Scale 2
referred to the geographic isolation of all positive MDR-AB cases in
distinct hospital units with exclusive medical and nursing personnel, use
of separate supplies and facilities and environmental intense surveillance.
Results: Among 121/1,451 infected patients 15 were colonised by strains
of MDR-AB susceptible only to colistin. All patients were mechanically
ventilated; 13 presented respiratory tract infection, 1 patient suffered
deep surgical site infection and 1 patient catheter related infection.
Transmission of the pathogen into the hospital occurred via 2 patients
transferred from 2 other institutions. They were all treated with colistin.
Cure or clinical improvement was observed only in 4 patients (27%).
Scale 1 measures were implemented for the whole 12-month period while
Scale 2 for 2 separate periods of 3 weeks. Environmental specimens
(n> 350) sampled on several occasions proved negative.
Conclusions: The increasing prevalence of MDR-AB in SICU patients
creates demand on strict screening and contact precautions. Following
this infection control strategy we were able to achieve intermittent
eradication of the pathogen during a 12-month period with continuous
function of the SICU. Despite the signiﬁcant “in vitro” activity of colistin
against MDR-AB the results were discouraging. Due to the signiﬁcant
mortality of MDR-AB infected patients additional measurements are
highly recommended.
P1345 Multidrug-resistant Acinetobacter baumannii prosthetic
joint infection treated with colistin
A. Rodrı´guez Guardado, V. Asensi, M. Lantero, M. Castillo, J. Carto´n
(Oviedo, ES)
Background: Description of the characteristics of the prosthetic joint
infection by A. baumannii treated with colistin emphasizing the factors
inﬂuencing their outcome
Methods: All the episodes of prosthetic joint infection by multidrug-
resistant A. baumannii diagnosed between 2004–2006 treated with
colistin were retrospectively reviewed. The Acinetobacter isolate was
deﬁned as MDR if it was resistant to  3classes of antimicrobial agents
as tested by commercial system. The dose of parenteral colistin was
160mg/8 h.
Results: Eight cases were reviewed. All the patients had underwent
surgery. Five patients were carriers of a knee prosthesis and the rest
hip prosthesis. The mean time between the surgery and the onset of
the infection was 26.5 days. Five patients had deep wound cultures and
the rest had bone tissue cultures. Three patients had mixed infections
[methicillin-resistant Staphylococcus aureus (two cases), E. faecium (one
case)] coccus aureus (and case each). All the patients had received
previous antibiotic treatment which were inadequate in all cases Four
patients received IV colistin (160mg/8 hours) monotherapy. Three
received a combined IV therapy with colistin and vancomycin. One
patient development a infection by a A. baumannii resistant to colistin
and he was treated with a combination of IV colistin 160mg/8 hours,
IV rifampicin (600mg/day) and IV imipenem (1 g/8 hours) with good
evolution. In 3 cases the treatment was associated with removal of the
prosthesis and in the rest a surgical drainage was performed. The mean
of treatment was 59.7 days. The follow-up period was 9 months (range
6−18 months). Only one patient died a consequence of the infection and
the rest cured. The renal function was normal in all the cases.
Conclusions: The use of intravenous colistin is safe and effective treat-
ment for prosthetic joint infection due to multiresistant A. baumannii.
Epidemiology of multi-drug resistant Gram-negative organisms S373
P1346 Seventy Enterobacter cloacae bloodstream infections in
central Taiwan during 2001 and 2003: evaluation of the roles
of extended-spectrum b-lactamases and class 1 integron
C. Chen, Y-J. Chang, C-E. Liu, C-C. Huang (Changhua, Taichung, TW)
Objectives: Enterobacter cloacae (E. cloacae) bloodstream infection
is an important cause of morbidity and mortality, with an increasing
incidence at Changhua Christian Hospital (CCH) of Central Taiwan
since 1995. The development and spread of the extended-spectrum
b-lactamases (ESBLs) is one of the most important issues in infection
control. Jiang et al. disclosed speciﬁc clonally related E. cloacae isolates
possessed a novel type b-lactamase, which was located in an integron.
So, we designed this study to investigate the clinical epidemiology of
E. cloacae and to elucidate the roles of the ESBLs and integron.
Methods: We analysed the clinical and microbiological data from
E. cloacae bloodstream infection during January 1st 2001 to Decem-
ber 31st 2003 to delineate the epidemiology as an aid in control.
Antimicrobial susceptibility testing for conﬁrmation of ESBL was
performed on the VITEK2 System (bioMe´rieux, Hazlewood, MO).
Koeleman’s previously described method was used to amplify the target
IntI1 genes. We also performed the pulse ﬁeld gel electrophoresis
(PFGE).
Results: Seventy E. cloacae strains isolated from 70 patients (56
nosocomial infections) between January 1st 2001 and December 31st
2003 were subjected to standard microbiological testing and to methods
of class 1 integron detection and PFGE analysis. Case records were
reviewed and statistical analysis was carried out using the chi-square
test and Fisher’s exact test. The signiﬁcant difference was found
between ESBL-positive and ESBL-negative isolates with regard to risk
factors, including the diseases severity (p = 0.03), category of nosocomial
infection (p = 0.04), prior use of antibiotics (p = 0.023), and prior use of a
ventilator (p = 0.037). Also, there was a signiﬁcant difference in mortality
among two groups (p = 0.004; OR= 4.750; 95%CI: 1.573–14.344). The
predominant clone A in ESBL-positive strains was associated with a
higher mortality rate but not with the presence of the integron.
Conclusion: The study disclosed four major risk factors for ESBL-
positive E. cloacae bloodstream infection and the predominant clone A
in ESBL-positive strains for higher mortality. It is necessary to review
antibiotic prescription practices, and we needed to consider ESBL-
producing strains in empirical treatment of nosocomial bloodstream
infection.
P1347 Prevalence of multiple-resistant Escherichia coli strains in
southern and eastern Mediterranean countries
M.A. Borg, E.A. Scicluna, M. de Kraker, N. van de Sande-Bruinsma,
E.W. Tiemersma, J. Monen, H. Grundmann and ARMed Project
Collaborators
Objective: Resistance to Escherichia coli is fast becoming a major
challenge in many countries. The Antibiotic Resistance Surveil-
lance and Control in the Mediterranean Region (ARMed) project
[www.slh.gov.mt/armed] provided a ﬁrst time opportunity for a
longitudinal multi-year study of trends of antimicrobial resistance
amongst this species within countries of the southern and eastern
Mediterranean.
Methods: ARMed collected routine susceptibility test results of more
than 4,000 invasive isolates of E. coli from blood cultures tested
by laboratories in Algeria, Cyprus, Egypt, Jordan, Lebanon, Malta,
Morocco, Tunisia and Turkey. Identical protocols were used as those of
the European Antimicrobial Resistance Surveillance System (EARSS),
including testing of aminopenicillin, third generation cephalosporins
(3GC), ﬂuoroquinolones (Fq) and aminoglycosides.
Results: The proportion of aminopenicillin resistant E. coli in 2005
varied between 49% (Malta) and 83% (Lebanon), with a signiﬁcant
increase observed in Turkey: 68% to 75% between 2003 and 2005.
The highest proportion of aminoglycoside resistance was observed in
Egypt (57% in 2005), whereas the lowest proportion was reported by
Malta (7%). Between 2003 and 2005 a signiﬁcant increase was seen in
Morocco from 12% to 33%, and a signiﬁcant decrease was reported by
Malta from 18% to 7%.
Resistance to 3GC varied widely from 1% in Malta to 70% in Egyptian
centres in 2005. Between 2003 and 2005, Morocco and Turkey showed
a signiﬁcant increase in resistance from 2% to 28% and 26% to 31%
respectively. Levels of Fq resistance in excess of 40% were reported by
Egypt and Turkey where a signiﬁcant increase was observed.
In excess of 15% of isolates from Turkey, Morocco, Jordan and Egypt
were multi-resistant to all 4 classes of antimicrobials. The Egyptian
centres, in particular, showed consistent increase in multiresistant E. coli
during the 3 years of the project to reach a level in excess of 38% in
the ﬁnal year.
Conclusion: Several southern and eastern countries in the Mediterranean
show evidence of signiﬁcant resistance within E. coli, especially to 3GC
and Fq, which are considerably higher than that reported by EARSS
in the European counterpart countries of the same region. Of particular
importance appear to be strains which are multiresistant to several major
antimicrobial groups and which can potentially spread outside of the
region due to the heavy human trafﬁc in this area of the world.
P1348 Prevalence of an epidemic ESBL-producing Escherichia
coli strain in LTCFs in Belfast
A. Loughrey, P. Rooney, M. O’Leary, M. McCalmont, M. Warner,
E. Karisik, P. Donaghy, B. Smyth, N. Woodford, D. Livermore (Belfast,
London, UK)
Objective: ESBL-producing E. coli (ESBLEC) were isolated rarely in
the Belfast area prior to 2003, but have since increased, particularly
from residents of long-term care facilities (LTCFs). We investigated the
epidemiology of ESBLEC among LTCF residents.
Method: LTCFs in the Belfast area were invited to participate. Residents
consented to supply medical data and a single sample of faeces for
ESBLEC culture. To qualify for inclusion the LTCFs had to provide
complete data plus a faecal sample from at least 10 residents between
July 05 and September 06. Samples were screened on CLED agar
containing 1mg/L ciproﬂoxacin with a cefpodoxime disc. Suspected
ESBLEC colonies were conﬁrmed as E. coli on TBX agar and
ESBL production was conﬁrmed by double disc synergy testing.
Antibiotic susceptibilities were determined and interpreted using BSAC
guidelines. Isolates were grouped broadly by antibiogram. PCR was
used to screen selected isolates for an IS26-blaCTX-M link, which is
characteristic of CTX-M-15 ESBL-producing UK epidemic strain A.
Results: Overall, 120/307 (39%) samples from 13 homes yielded at least
one ESBLEC; range, 0% (2 LTCFs) to 75% (18 of 24 positive samples
from 1 LTCF). Sixty (50%) of 120 ESBLEC-positive residents had no
hospital admissions since January 04. The majority of ESBLEC had
phenotypes consistent with production of a CTX-M enzyme. Isolates
assigned presumptively to strain A by PCR accounted for 59/120 (49%)
ESBLEC. Although distinct from strain A, most of the other 61 isolates
also produced a group 1 CTX-M ESBL; these isolates had varying
antibiograms, suggesting multiple strains. In the eastern district of
Belfast, 50/175 samples were ESBLEC-positive, and 38 (76%) of these
were strain A; in the other districts 70/132 samples were positive, but
only 22 (31%) were strain A. The proportion of strain A isolates varied
widely in different LTCFs, ranging from 0/11 ESBLEC in one centre to
9/9 in another.
Conclusions: Epidemic strain A was the predominant ESBLEC strain
among LCTF residents in Belfast. ESBLEC were found in many
residents with no history of recent hospital admission. LTCF residents
requiring hospital admission tended to be referred to their nearest
hospital. Differences in the distributions of strain A and other ESBLEC
in LTCFs from particular districts are consistent with acquisition in
hospital and introduction into the LTCF on discharge. Our study
highlights the importance of spread within LTCFs in the epidemiology
of ESBLEC.
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P1349 Risk factors for ciproﬂoxacin resistance among ESBL-
producing Escherichia coli isolated from non-hospitalised
patients in Spain
J. Alcala´, J. Rodrı´guez-Ban˜o, J. Cisneros, C. Llanos, R. Canto´n,
F. Grill, G. Navarro, M. Cuenca, C. Pen˜a, M. Esteve, A. Oliver,
B. Mirelis, M. Almela, T. To´rtola, A. Pascual for the Red Espan˜ola
de Investigacio´n en Patologı´a Infecciosa (REIPI)
Objectives: ESBL production is frequently associated with quinolone
(QUIN) resistance. We studied the risk factors associated with
ciproﬂoxacin (CIP) resistance among ESBLEC isolated from non-
hospitalised patients in Spain.
Methods: A double case-control study performed in 11 centres in Spain.
Cases: non-hospitalised patients with isolation of ESBLEC in a clinical
sample. Controls: 2 per case, non-hospitalised patients without ESBLEC.
Variables analysed: demographics, comorbidities, healthcare relation and
previous antimicrobials. Susceptibility was assessed by microdilution
(NCCLS). ESBL were characterised by isoelectric focusing, PCR and
sequencing.
Results:We included 121 cases. In 78 cases (68%) ESBLEC strains were
resistant to CIP (MIC50 = 4mg/mL, MIC90 = 64mg/mL). Resistance
to CIP was higher among strains also resistant to co-amoxiclav
(AMC) (89% vs 60%, p = 0.001), co-trimoxazol (SXT) (80% vs 50%,
p = 0.001), gentamicin (GNT) (85% vs 65%, p = 0.06) and tobramycin
(TOB) (92% vs 65%, p = 0.04). Resistance to CIP was more frequent
among patients with renal insufﬁciency (100% vs 65%, p = 0.012). No
signiﬁcant differences were found with respect to previous antimicrobial
use, including QUIN, or with the type of ESBL produced. When
compared to controls, the following risk factors (OR, 95%CI) for CIP-
resistant ESBLEC were found: female gender (2.32, 1.30–4.16), renal
insufﬁciency (3.12, 1.30–7.49), diabetes mellitus (5.52, 2.80–10.87),
recurrent UTI (7.88, 4.43–14.02), healthcare relation (2.11, 1.24–3.58),
urinary catheterisation (5.11, 2.12–12.29), previous use of QUIN (5.79,
3.15–10.64) and previous use of AMC (7.97, 3.66–17.36). Risk factors
for CIP-susceptible ESBLEC were: recurrent UTI (4.15, 1.09–9.08),
previous use of QUIN (4.73, 2.09–10.71) and previous use of AMC
(5.44, 1.95–15.22).
Conclusions: Resistance to CIP among ESBLEC from non-hospitalised
patients is associated with resistance to other antimicrobial agents,
such as AMC, SXT, GNT and TOB. There is association with renal
insufﬁciency but no association with any other variable, including
previous use of QUIN. Previous use of antimicrobial agents and recurrent
UTI are risk factors for both CIP-resistant and CIP-susceptible ESBLEC;
and female sex, diabetes mellitus, renal insufﬁciency, healthcare relation
and urinary catheterisation are risk factors just for CIP-resistant
ESBLEC. More studies on the epidemiology of this organism are needed
to identify factors related to quinolone resistance.
P1350 Study of an outbreak of imipenem-resistant Klebsiella
pneumoniae infections in the intensive care unit of a Greek
hospital
G. Totos, K. Pappas, V. Mpekos, S. Vourli, M. Polemis, A. Vatopoulos
(Athens, GR)
Objectives: Infections due to imipenem resistant K. pneumoniae, due to
the production of metaloenzymes, particularly in the ICU environment,
represent an emerging major Public Health problem in Greece. In this
report we describe an outbreak of infections due to imipenem resistant
K. pneumoniae that occurred in Athens Naval Hospital from May 2006
to June 2006 and involved six patients, three of whom eventually died.
Methods: K. pneumoniae strains were isolated from all patients; three
strains were isolated from bronchial secretions, one from blood, one
from a central venous catheter and one from urine. Hand cultures were
performed on all ICU personnel and samples from various environmental
sources were also collected. All strains were identiﬁed and tested
for susceptibility using the VITEK® 2 system (bioMe´rieux, France).
Metallo-b-lactamase (MBL) and extended-spectrum b-lactamase (ESBL)
production were screened by the imipenem+EDTA disk synergy test and
the double disk synergy test, respectively. The presence of genes of the
blaVIM family was detected by PCR. PFGE (Xba I) was used for typing.
Results: All isolates exhibited the same antibiotic resistance proﬁle and
were found resistant to all major classes of antibiotics and sensitive
only to colistin. The imipenem+EDTA disk synergy test was positive
in all six isolates and all isolates were found to harbour the blaVIM
gene. All six isolates were also ESBL positive. PFGE revealed that ﬁve
out of the six isolates were indistinguishable, whereas the sixth seemed
genetically different. None of the staff members harboured imipenem-
resistant K. pneumoniae and all samples from environmental sources
were tested negative.
Upon recognition that the outbreak is possibly due to the spread of
a single clone of K. pneumoniae in the ICU, strict infection control
measures were implemented which resulted in no further, so far, isolation
of imipenem-resistant K. pneumoniae.
Conclusion: The emergence of MBL producing K. pneumoniae
infections is a new threat that can lead, particularly in the ICU, to
serious infections and increased mortality. Early recognition of the
problem, collaboration of Clinicians and Laboratory personnel and
timely application of infection control measures are imperative for
addressing this problem.
P1351 Comparison of phenotypic methods for identiﬁcation
of AmpC b-lactamase-producing Escherichia coli and
Klebsiella spp. clinical isolates
A. Poulou, F. Markou, V. Kolliou, A. Karakolios, T. Kallinikidis, P. Rozi
(Serres, Athens, GR)
Objectives: Early and accurate detection of the resistance mediated
by class C b-lactamases in Escherichia coli and Klebsiella spp. is
of utmost importance for the proper antibiotic therapy but also for
providing infection control information. We compared three phenotypic
methods for the detection of AmpC-producing E. coli and Klebsiella
spp. strains in a region with increasing incidence of plasmid-mediated
class C enzymes.
Methods: A total of 2,023 E. coli and 235 Klebsiella spp. nonduplicate
isolates were consecutively recovered from clinical infections. Cefoxitin
insusceptibility (MIC> 8mg/mL) was used as a screen for plasmid-
mediated AmpC enzymes. The three dimensional test, the AmpC disk
test with EDTA disks and the boronic acid disk test were used for
the detection of AmpC enzymes. Additionally, the DDST was used for
detection of ESBLs according to CLSI guidelines.
Results: Forty-seven E. coli and 25 Klebsiella spp. isolates with
reduced susceptibility to cefoxitin were further tested with phenotypic
conﬁrmatory methods. The three dimensional test revealed AmpC
enzymes in 21 (29.1%), the AmpC disk test in 30 (41.6%) and the
boronic acid disk test in 36 (50%) isolates. In addition, the latter test
in accordance with the DDST conﬁrmed coexistence of ESBL in 26
of 36 (72.2%) AmpC-producing isolates. Interestingly, 13 of the 36
(36.1%) AmpC-producing isolates were recovered from community-
acquired infections. Antimicrobial resistance rates among the AmpC
producers were: 55.5% to amikacin, 63.8% to ciproﬂoxacin and 72.2% to
co-trimoxazole. Resistance rates among the AmpC non-producers were:
9.2% to amikacin, 12.9% to ciproﬂoxacin and 17.8% to co-trimoxazole.
Conclusions: Detection of the resistance mediated by class C enzymes
is a challenging issue, particularly when plasmid-mediated AmpC
b-lactamases have been disseminated in the community, as it was
detected herein. In our study, the three dimensional test was the most
time consuming, the AmpC disk test was the easiest to be interpreted
while the boronic acid disk test was the most sensitive assay and allowed
the simultaneous detection of ESBLs, which in our population was
associated with multiple antibiotic resistances.
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P1352 Inﬂux of metallo-b-lactamase- and AmpC-producing
Klebsiella pneumoniae clinical isolates in a regional hospital
A. Poulou, F. Markou, S. Pournaras, S. Sideri, A. Tsakris, P. Rozi
(Serres, Larissa, Athens, GR)
Objectives: Acquired metallo-b-lactamases (MBLs) have been recently
emerged in Klebsiella pneumoniae clinical isolates in our region and
elsewhere. Such strains are mainly detected among ICU patients,
have reduced susceptibility to carbapenems and constitute the cause
of nosocomial infections with high rates of mortality. We report the
emergence of K. pneumoniae clinical isolates that produce both MBLs
and AmpC b-lactamases in a Greek hospital.
Methods: During a two month period (August–September 2006), four
K. pneumoniae isolates were recovered from blood and/or bronchial
samples of separate patients hospitalised in the ICU (two cases) and in
medical wards (two cases). The latter two patients have been previously
hospitalised in the ICU and recently transferred to the medical wards.
Identiﬁcation of the isolates and antimicrobial susceptibility testing
was performed by Microscan system (Dade Behring). MBLs were
phenotypically detected with the E-test MBL (AB Biodisc) and the
Double Disc Synergy Test using disks of IPM and EDTA, while AmpC
were detected with the three dimensional test and AmpC disk test. All
isolates were screened for blaVIM and blaCMY genes using PCR assays.
Random ampliﬁed polymorphic DNA (RAPD) was used for typing.
Results: All four isolates exhibited resistance to imipenem, meropenem,
broad spectrum cephalosporins, cephamycins, ﬂuoroquinolones, aztre-
onam and amikacin but susceptibility to gentamicin, colistin and
tigecycline. In all cases, the phenotypic methods showed production of
MBL and AmpC b-lactamases, while PCR conﬁrmed the presence of
blaVIM and blaCMY genes. RAPD analysis proved the dissemination
of a single clonal strain. One of the patients died from septicaemia
despite the therapeutic treatment with gentamicin and colistin.
Conclusions: The genetic similarity of the isolates in conjunction with
the history of previous ICU hospitalisation suggest that a single MBL-
and AmpC-producing K. pneumoniae strain has been disseminated
within the ICU and subsequently in other hospital wards. Continuous
surveillance and accurate recognition of resistance phenotypes are
needed for the early detection of new patterns of antimicrobial resistance
and new combinations of antimicrobial resistance genes.
P1353 Emergence of metallo-b-lactamase-producing Proteus
mirabilis in the community setting
A. Poulou, F. Markou, V. Kolliou, H. Iliopoulou, A. Tsakris, P. Rozi
(Serres, Athens, GR)
Objectives: Metallo-b-lactamases (MBLs) constitute a growing class of
b-lactamases that readily hydrolyse most b-lactams including carbapen-
ems. Acquired MBLs have emerged among nosocomial Pseudomonas
aeruginosa isolates and more recently among other Gram-negative
pathogens such as Acinetobacter baumannii and several enterobacterial
species. However, their dissemination in the community setting has not
been described. In the present study we report the emergence of MBL-
producing Proteus mirabilis recovered from outpatients in a rural area.
Methods: A total of 202 P. mirabilis isolates were consecutively
recovered from patients with community-onset clinical infections (87%
from urinary tract infections) in a rural Greek region. Identiﬁcation
and susceptibility testing was performed with the Microscan system
(Dade Behring). Among isolates with reduced susceptibility to
imipenem (MIC> 4mg/L), phenotypic detection of MBL production was
performed using the E-test MBL (AB Biodisk). The genes encoding the
MBLs were characterised by PCR and sequencing analysis.
Results: Nine (4.5%) P. mirabilis isolates exhibited reduced susceptibil-
ity to imipenem (MICs ranged from 32 to >256mg/L). All but one of the
isolates, were susceptible to aminoglycosides and aztreonam but resistant
to the other b-lactams, quinolones and trimethoprim; the remaining
isolate was pandrug-resistant. Production of MBL was detected in all
9 isolates with E-test MBL. Furthermore, genetic analysis identiﬁed a
blaVIM-1 gene cassette in a class 1 integron in all cases. The majority
of the isolates (8/9) were recovered from urine specimens of outpatients
who had a history of hospitalisation in the previous three months.
They had treated during their hospitalisation with aminoglycosides,
ticarcillin/clavulanic and ﬂuoroquinolones. Aztreonam was used for the
treatment of MBL-positive infections with successful results.
Conclusions: We detected a high prevalence of infections associated
with MBL-producing P. mirabilis in the community setting of our region.
Previous hospitalisation and exposure to antimicrobials were predictive
of MBL-producing P. mirabilis community-onset infection. Continuous
surveillance is essential for the early recognition and for the preventation
of dissemination of such strains by indicating the proper treatment.
P1354 Prevalence of extended-spectrum b-lactamase-producing
Enterobacteriacae isolates at two Belgian hospitals: a
descriptive study
P. Bogaerts, G. Claeys, C. Bauraing, A. Piette, A. De Vleeschauwer,
G. Verschraegen, Y. Glupczynski (Yvoir, Ghent, BE)
Objectives: To study the prevalence and distribution of extended-
spectrum b-lactamase-producing Enterobacteriacae (ESBLE) isolates
found at two university hospitals geographically located in two different
regions of Belgium.
Material and Methods: Centres A and B are respectively a 1,050-bed
hospital located in North Belgium (Province of East Flanders) and a
300-beds unit located in the Southern part (Province of Namur). During
a 4 (centre A) and 20 month (centre B) period, respectively 1,589
and 2,695 consecutive non-duplicated Enterobacteriaceae isolates were
screened retrospectively for ESBL production. Antimicrobial resistance
phenotypes were conﬁrmed by double disk synergy test. Characterisation
of ESBLs was performed by IEF, multiplex PCR assays targeting
blaTEM, blaSHV and blaCTX-M genes and sequencing when needed. In
centre A, ESBLE were typed to detect the occurrence of clonal outbreaks
during the analysed period.
Results: Ninety-four (6%) and 74 (3%) ESBLE were recovered from
centre A and centre B respectively.
In centre A, the presence of ESBL was equally distributed among
Klebsiella pneumoniae (Kp) (34%), Escherichia coli (Ec) (31%) and
Enterobacter aerogenes (Ea) (30%). In centre B, almost half of the
ESBLE were Ec (47%), followed by Ea (32%) with only very few
Kp isolates (5%). In both centres, ESBLs were only rarely found among
Enterobacter cloacae, K. oxytoca and C. freundii (1 to 7% of the total
ESBLE population). TEM, SHV, and CTX-M type ESBLs were detected
in both centres albeit at a variable frequency depending on the ESBLE
species. In Ea, TEM-24 accounted for 75% of more of all ESBLs in both
centres. For Kp, SHV were found in more than 50% and CTX-M in about
25% in centre A, whereas only TEM-derived ESBLs were detected in
centre B. Concerning Ec, no signiﬁcant differences were found between
the two centres, with CTX-M types accounting for more than 50% of
the ESBLs.
In centre A, PFGE typing revealed the occurrence of limited clonal
outbreaks of ESBLE in Ea, Kp and also in Ec.
Conclusions: This study conﬁrms the variable prevalence and distri-
bution of ESBLE in different hospitals within the same country and
highlights the importance of the knowledge of the epidemiology of
ESBL-mediated resistance in order to optimise therapy and limit the
spread of such organisms inside and outside the hospital. In addition,
the global emergence of CTX-M enzymes is conﬁrmed and the reason
of this spread should be urgently elucidated.
P1355 Epidemiology of extended-spectrum b-lactamase-producing
Enterobacteriaceae in Belgium: preliminary results of a
national multicentre survey in 2006
Y. Glupczynski, C. Berhin, H. Rodriguez-Villalobos, M. Struelens,
B. Jans on behalf of the Belgian Infection Control Society
Objectives: As part of a national two-yearly surveillance, we evaluated
the species distribution of ESBL-producing Enterobacteriaceae (ESBLE)
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isolated in Belgian hospitals and the in vitro activity of 11 antimicrobials
against these isolates.
Materials and Methods: Consecutive, unduplicated clinical isolates of
ESBLE collected in the participating centres (maximum of 5 strains
per centre) between 01/2006 and 06/2006 were sent to the reference
laboratory. All strains were conﬁrmed as ESBL producers by double
combination disk test (DDT) and/or by ESBL E-tests (cefotaxime and
ceftazidime + clavulanic acid). The presence of ESBL among AmpC
hyperproducers was assessed by DDT in the presence of cloxacillin
500mg disks or on cloxacillin (250mg/mL) agar. E-test MICs were
determined and results were interpreted according to CLSI and EUCAST
clinical MIC breakpoints.
Results: 86 hospitals (regional distribution: 42 from Flanders, 29 from
Wallonia and 15 from Brussels) sent 401 potential ESBLE isolates.
Of these, 330 (82%) were conﬁrmed as ESBL producers. The ESBLE
strains originated from patients (mean age 72 years; range 1−97
years) hospitalised in medical wards (39%), ICU (21%), geriatric or
surgical units (13% each); they were mainly isolated from urinary
(50%) and respiratory tracts (25%), wound swabs (19%) and blood
(3%). Enterobacter aerogenes (Ea), Escherichia coli (Ec) and Klebsiella
pneumoniae were the most frequent ESBLE and represented respectively
44%, 39% and 9% of all isolates. 72% of all ESBLE were considered
as nosocomially acquired; however almost 50% of Ec ESBL producers
were deemed to be community-acquired.
97% of all ESBLE were resistant to ceftazidime, 86% to cefotaxime,
and 78% to ciproﬂoxacin. Carbapenems (meropenem, imipenem) were
the most active agents (98−99% susceptibility) followed by temocillin
(93% susceptibility), gentamicin and amikacin (85% susceptibility each)
and tigecycline (82% susceptibility). Higher resistance rates and co-
resistance to ceftazidime and ciproﬂoxacin were observed among Ea
while almost two-third of the Ec ESBL producers had a resistance
phenotype compatible with CTX-M ESBLs. Most Ec strains originated
from urines of elderly patients and were co-resistant to ciproﬂoxacin.
Conclusions: These in vitro data provide new insights in the
epidemiology of resistance among Belgian ESBLE isolates and highlight
the rising importance of community-acquired ESBLs, especially among
Ec strains.
P1356 Epidemiology of ESBL-positive Enterobacteriacae in
Copenhagen, Denmark
H. Fjeldsøe-Nielsen, A. Friis-Møller, D. Schrøder Hansen,
N. Frimodt-Møller, K. Schønning (Hvidovre, Hillerød, Copenhagen, DK)
Objectives: The aim of this study was to describe the epidemiology of
ESBL-producing Enterobacteriacae and the initial molecular typing of
prevailing b-lactamases in Copenhagen, Denmark.
Methods: 79 consecutive incident ESBL positive isolates were detected
between January 1st and June 30th 2006. A 10mg cefpodoxime disc and
other 2nd- and 3rd-generation cephalosporins were used to screen for
b-lactamase production. 32/79 (41%) isolates have subsequently been
further characterised by PCR.
Results: 33/79 (42%) infections were community acquired (diagnosed
in specimens from the primary care sector or emergency departments)
the remaining 46/79 (58%) being nosocomial infections. There was
as expected a gender difference with 58% women and 42% men.
Age ranged from 1−99 years with a median 70 years. Infections were
dominated by the urinary tract 65/79 (82%). 32 incident isolates were
characterised by PCR during this period of which 25 were found CTX-M
type positive. CTX-M was the single b-lactamase detected in 16 of these,
the remaining 9 isolates harbouring CTX-M and other b-lactamases as
well such as TEM and SHV. 2/32 isolates remained uncharacterised.
Conclusion: Many ESBL positive Enterobacteriacae infections are
acquired in the community. The urinary tract alone accounts for 82% of
all incident isolates. Older people and women seem to be more prevalent.
25/32 (78%) isolates were PCR positive for CTX-M type b-lactamase.
CTX-M type b-lactamase seems to be the most prevalent among ESBL-
producing Enterobacteriacae in Copenhagen, Denmark.
P1357 Incidence density of highly resistant Gram-negative bacteria
in a Dutch hospital
I. Willemsen, M. van der Wiel, J. Kluytmans (Breda, NL)
Objective: The objective of this study was to determine the incidence
density of highly resistant Gram-negative bacteria (HRGNB) in a Dutch
hospital.
Method: Between 1 Jan 2005 and 30 Jun 2006 all HRGNB
(Enterobacteriaceae, Acinetobacter spp. and Pseudomonas spp.) from
hospitalised patients in the Amphia hospital were included. The
deﬁnition for highly resistant micro-organisms according to the national
guideline (www.wip.nl) was used. From all patients one isolate of each
species was selected. When multiple isolates from one species were
found in one patient the selection was made based on the susceptibility
pattern. All isolated with major (S<>R) differences in susceptibility
for amoxicilline-clavulanic acid, cefalosporines, quinolones, meropenem,
aminoglycosides or sulfa-trimethoprim were included. HRGNB isolated
more than 72 h after admission or less than 72 h after admission but
within 30 days after discharge were deﬁned as nosocomial. Patients who
were on the ICU or who had been on the ICU in a period of 30 days
before culture were deﬁned as ICU-related. The number of bed days was
collected from the hospital administration.
Results: In a period of 1.5 years, 121 patients with 139 HRGNB
were identiﬁed, including: E. coli (95), Klebsiella spp. (11), Proteus
spp. (9), Enterobacter spp. (7), Citrobacter spp. (5), Pseudomonas
aeruginosa (5), Acinetobacter spp. (3), Morganella spp. (2), Salmonella
spp. (1) and Serratia spp. (1). 106 HRGNB were nosocomial, of which
59 were ICU related and 47 were non-ICU related. The ICU accounts
for 15,427 bed days and the rest of the hospital for 383,070 in 1.5 years.
The incidence density for nosocomial HRGNB on the ICU was 38.2
and that in the rest of the hospital 1.2 per 10.000 bed days (RR: 31.1;
95%CI: 21.3–45.5).
Conclusion: Estimating the incidence density of HRMO according to
well-deﬁned criteria can be used as a benchmarking method. Considering
the enormous difference between the ICU and the rest of the hospital
most attention to control the development and spread of HRMO should
be given to the ICU.
P1358 Prevalence of Mex-mediated resistance in Pseudomonas
aeruginosa isolates from patients with ventilator-associated
pneumonia in 4 Belgian hospitals
N. Mesaros, Y. Glupczynski, D. Pierard, A. Dediste, Y. Van Laethem,
F. Jacobs, M. Struelens, D. De Vos, J. Pirnay, F. Van Bambeke,
P. Tulkens (Brussels, BE)
Objectives: Efﬂux mediated resistance is difﬁcult to detect in
Pseudomonas aeruginosa (Pa) by routine susceptibility testing. Yet, it
may confer cross-resistance to unrelated classes of drugs and contribute
to selection of other resistance mechanisms. Our aim was to determine
the prevalence of Mex efﬂux pumps in Pa isolates obtained from patients
with ventilator-associated pneumonia (VAP).
Methods: Pa isolates were collected as pairs from each patient (ﬁrst
isolate before initiation of antibiotic treatment [pre]; second isolate, after
5 to 10 days of treatment [post]). In three hospitals (A-C), isolates were
collected consecutively from all eligible patients; in the 4th hospital (D),
isolates were selected on the basis of compatible resistance phenotypes.
mexA and mexX transscription levels were quantiﬁed by real time PCR;
mexC and mexE transcription was detected by semi-quantitative PCR
(their basal expression being undetectable in wild-type strains). Isolates
typing was performed by fAFLP.
Results: The table shows the number of isolates in which overexpression
of mex genes was detected (pre and post) by hospital. DNA-based typing
globally conﬁrmed the clonality of the sucessive isolates in each patient,
and excluded the occurrence of epidemic strains in the non-selected
isolates.
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Hospitala No. of strains showing gene overexpression
(no. of pairs) mexA mexC mexE mexX
pre post pre post pre post pre post
Random sampling
A (n = 9) 0 1 1 0 0 0 4 7
B (n = 7) 0 1 5 6 2 3 1 3
C (n = 6) 0 0 0 0 0 0 0 0
Total (n = 22) 0 2 6 6 2 3 5 10
Strains collected on the basis of compatible resistance phenotype
D (n = 17) 2 8 4 5 0 4 7 9
aA, AZ-Vrije Universiteit Brussels, B, CHU Saint-Pierre; C, Hoˆpital
Erasme; D, Clinique universitaire UCL Mont-Godinne.
Conclusions: A variable prevalence of Mex efﬂux pumps is found before
treatment in clinical isolates, and increases in several cases following
antibiotic exposure, particularly for MexX. In samples collected based
on antibiograms, prevalence was very high, conﬁrming the value of the
interpretive algorithms used to detect mechanisms of efﬂux resistance.
These data highlight the need of detecting efﬂux-mediated resistance in
Pa clinical isolates originating from hospitalised ICU patients.
P1359 Clonal types and serotypes of multidrug-resistant
Pseudomonas aeruginosa isolates spread in a university
hospital in Greece
E. Drougka, T. Panagea, V. Chini, A. Foka, M. Christoﬁdou,
I. Spiliopoulou (Patras, GR)
Objectives: Despite the introduction of a wide variety of antimicrobial
agents, Pseudomonas aeruginosa remains a common cause of noso-
comial infections. Typing techniques are essential to investigate clonal
relationship among isolates in the hospital setting, to recognize outbreaks
and to elucidate the source of infection. We have studied by phenotypic
and genotypic methods the spread of multi-resistant P. aeruginosa
isolates recovered during one-year period from different patients at a
University Hospital.
Methods: A total of 126 P. aeruginosa isolates recovered from different
patients admitted at the University Hospital of Patras, Greece during
2004 were studied. Antibiotic susceptibility testing was performed
by the Etest according to CLSI guidelines and the production of
metallo-b-lactamases (MBL) was tested by the use of the strip
containing imipenem and imipenem/EDTA. Serotyping was performed
by 17 monovalent antisera against the O antigen according to the
International Antigenic Typing Scheme. Clones were deﬁned by PFGE
of chromosomal DNA SpeI digests.
Results: Fifty-six isolates (45%) derived from the Dept. of Internal
Medicine (IM), 33 (26%) from the Intensive Care Unit (ICU), 24
(24%) from the Dept. of Surgery (GS), 13 (10%) from the Dept.
of Outpatients (OUTP). Overall, 53.2% of the isolates were resistant
to tobramycin, 52.4% to ciproﬂoxacin, 52.4% to meropenem, 49.2%
to imipenem, 36.3% to piperacillin, 33.9% to aztreonam, 28.2% to
piperacillin/tazobactam, while 61 isolates (48%) were MBL-positive. By
serotyping 58 (46%) isolates were classiﬁed to O:11, 19 (15%) to O:12,
12 (10%) to O:3 and 11 (9%) to O:1. PFGE revealed the presence of
19 clones. Clone A predominated including 10 strains with 7 strains
of serotype O:11; clone B included 9 strains with 6 of O:11; clone C
included 7 strains with 4 of O:12; clone D included 6 strains with 5 of
O:11, while the rest strains were classiﬁed into different clones. Strains
of serotype O:11 were mainly isolated from patients hospitalised at the
IM and the ICU. Clone A was mainly spread in IM and ICU, clone B in
GS, clone C in IM and clone D in GS.
Conclusions: Serotype O:11 predominated but it was not classiﬁed in
one PFGE type, neither MBL-positive strains belonged to a common
clone. Even though multi-resistant P. aeruginosa strains are spread in
our hospital, we have identiﬁed four main clones and a variety of clonal
types related to different departments.
P1360 Evaluation of metallo-b-lactamase producing Klebsiella
pneumoniae epidemiology in a Greek hospital (2004–2006)
H. Moraitou, N. Kentrou, I. Galani, N. Tsagarakis, M. Makarona,
A. Gioga, S. Kanavaki (Athens, GR)
Objectives: Nosocomial infections due to the dissemination of multi-
resistant metallo-b-lactamase producing K. pneumoniae within the
hospital setting are of growing concern worldwide. The aim of this study
was to retrospectively analyse all MBL-positive K. pneumoniae strains
isolated in our laboratory, from 2004 (ﬁrst isolation) to 2006.
Methods: A total of 52 carbapenem resistant K. pneumoniae strains
were isolated and collected since March 2004 to September 2006. 39/52
(75.0%) derived from ICU patients and the rest 13/52 (25.0%) from
patients in different wards of our Hospital. 18/52 (34.6%) strains were
isolated in 2004, 23/52 (44.2%) in 2005 and 11/52 (21.2%) in 2006.
All isolates were tested for imipenem resistance by E-test, and for MBL
production by imipenem/EDTA disk synergy test and PCR. Molecular
typing was performed by REP-PCR.
Results: All isolates showed reduced susceptibility (MIC> 0.25)
or resistance to imipenem (MIC> 8) as well as resistance to all
cephalosporins. In addition, all strains were positive for MBL production
by EDTA synergy test and PCR experiments detected blaVIM gene.
Molecular typing by REP-PCR revealed 14 K. pneumoniae clones (A-N),
with predominant the clone A (17/52, 32.7%) throughout the period
studied. It is interesting that clusters of the same or related clones were
noted in ICU, being responsible for infections appeared in March 2004
(7 strains, clone A), March 2005 (6 strains, clone B), and May 2005
(6 strains, clone J). In addition, the Oncology Unit revealed one small
cluster of infections in July 2006 (2 strains, clone F).
Conclusions: All carbapenem-resistant K. pneumoniae isolated in
our laboratory were blaVIM positive. We observed three clusters
of clonal K. pneumoniae infections as well as six single unrelated
clones throughout the study period. The emergence of MBL-producing
K. pneumoniae is of great concern and measures should be taken in
order to avoid dissemination of highly resistant strains within hospital
setting.
P1361 Metallo-b-lactamase producing P. aeruginosa in a tertiary
hospital, 2004–2006
H. Moraitou, N. Tsagarakis, I. Galani, M. Makarona, N. Kentrou,
A. Gioga, S. Kanavaki (Athens, GR)
Objectives: MBL production has been increasingly reported as a
mechanism conferring carbapenem resistance to P. aeruginosa clinical
isolates. The aim of this study was to retrospectively detect the
MBL-producing multi-drug resistant P. aeruginosa strains isolated and
collected in our Hospital from January 2004 to September 2006 and
determinate the type of MBL they carry.
Methods: A total of 128 MDR P. aeruginosa clinical isolates were
retrospectively investigated for MBL production. The strains were
isolated either from ICU (54/128, 42.2%), or non-ICU (74/128, 57.8%)
patients, from different kinds of clinical samples, from January 2004 to
September 2006. The resistance level to imipenem was determined by
MIC, using E- test (AB Biodisk, Sweden). The isolates were tested for
MBL production by imipenem/EDTA disk synergy test as well as the
MBL E-test (AB Biodisk, Sweden). PCR and PCR-RFLP analysis were
further performed to analyse the blaVIM gene.
Results: All isolates exhibited high level resistance to imipenem
(MIC> 16). Among all MDR P. aeruginosa strains 23/128 (18.0%) were
found blaVIM positive, by PCR. Imipenem/EDTA combined synergy
test identiﬁed 22/23 (95.7%) positive isolates, while only 5/23 (21.7%)
found positive by MBL E-test. PCR-RFLP analysis revealed the presence
of a blaVIM-2-like gene in all positive isolates. 9/23 (39.1%) MBL
(+) strains were isolated from ICU patients (6 bronchial secretions,
2 blood cultures, 1 intravenous catheter) and 14/23 (60.9%) from non-
ICU patients (7 sputum, 4 bronchial secretions, 3 blood cultures, 1 pus).
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Conclusion: MBL-producing isolates are prevalent among MDR
P. aeruginosa clinical isolates in our Hospital. Phenotypic tests may
not be entirely accurate, but are indicative enough for the presence of
MBL production. We found that imipenem/EDTA combined synergy test
is more sensitive in indicating MBL (+) isolates. The high incidence of
MBL-producing strains among non-ICU patients is of great concern, and
measures should be taken to avoid dissemination of these MDR strains
in the community.
P1362 The ﬁrst isolation of PER-1-producing Pseudomonas
aeruginosa and Acinetobacter baumanii strains in Hungary
D. Szabo´, L. Ro´kusz, Z. Juha´sz, J. Szentandra´ssy, K. Katona, K. Nagy
(Budapest, HU)
Objectives: A 45-year-old Hungarian tourist injured in terror-attack
was transferred with serious burn injury from Egypt to the Central
Military Hospital, Budapest, Hungary. Our aim was to characterise the
ß-lactamases produced by the Gram-negative bacteria isolated from the
patient.
Methods: The identiﬁcation and the antimicrobial susceptibility proﬁle
of the Gram-negative bacteria were evaluated using a VITEK2 system.
The isolates were screened for extended-spectrum ß-lactamase (ESBL)
and metallo-ß-lactamase (MBL) production. The minimal inhibitory
concantrations (MICs) were determined using E-test according to
Clinical and Laboratory Standards Institute (CLSI) recommendations.
Isoelectric focusing was performed using crude ß-lactamase extracts in
polyacrylamide gels containing ampholines with a pH range of 3.5 to 9.5.
Pulsed-ﬁeld gel electrophoresis (PFGE) was done with SpeI enzyme to
compare the isolates. DNA ampliﬁcation by PCR was carried out using
primers speciﬁc to the blaTEM gene, the blaSHV gene, the blaPER gene
and the blaVIM gene. Both strands of the ampliﬁcation products were
sequenced by the standard Sanger dideoxynucleotide method.
Results: The ESBL phenotype was detected in Pseudomonas aerug-
inosa, Acinetobacter baumannii, Klebsiella pneumoniae and Enter-
obacter cloacae strains. The PER-1-producing (pI:5.3) P. aeruginosa
and A. baumannii strains were isolated from the bloodculture and the
wound of the pateint on the admission day suggesting that these strains
were transported from Egypt. The PER-1 producing A. baumanii also
produced TEM-1 enzyme. The PER-1 producing P. aeruginosa and
A. baumannii were resistant to the ceftazidime, cefotaxime, cefepime,
aztreonam, but were sensitive to imipenem, meropenem. On the ﬁrst day
TEM-1 and SHV-type ESBL-producing K. pneumoniae strain was also
isolated.
MBL phenotype was also detected in a P. aeruginosa strain. This
VIM-2 producing P. aeruginosa showed resistance to almost all ß-lactam
antibiotics, including penicillins, cephalosporins, and carbapenems, but
it was sensitive to colistin. The PER-1 producing P. aeruginosa and the
VIM-2 producing P. aeruginosa strains were unrelated as determined by
PFGE.
Conclusion: This is the ﬁrst report of the PER-1 and VIM-2-producing
P. aeruginosa and PER-1 producing A. baumannii strains from Hungary.
This work illustrates the inter-country and the inter-continent spread of
PER-1-producing P. aeruginosa and A. baumannii isolates.
Supported by OTKA F048410.
P1363 Carbapenem-resistant Pseudomonas aeruginosa and Acine-
tobacter baumannii isolates in an Iranian 1,000-bed hospital
M. Rahbar, P. Islami, S. Molanaee, M. Deldari (Tehran, IR)
Objective: Carbapenems, including imipenem and meropenem, are
b-lactam antibiotics which widely are used recently in our country.
The aim of this study was to determine resistance of P. aeruginosa,
A. baumannii and Klebsiella pneumoniae to carbapenems in our hospital.
Methods: From April 2006 to October 2006 one hundred nosocomial
isolates including 29 strains of P. aeruginosa, 27 Acinetobacter
baumannii and 44 isolates of Klebsiella pneumoniae were collected from
specimens obtained from hospitalised patients. The MIC f of meropenem
for all isolates was determined by E-test (AB/Bio disk Sweden).
Susceptibility to other antibiotics including Pipracillin/Tazobactam,
Cefepime Ciproﬂoxacin, Amikacin, Imipenem and Ceftazidim were
performed by disk diffusion method as recommended by Clinical
Laboratory Standards institute (CLSI).
Results: MIC for meropenem by E-test ranged from 0.25mg/mL to
32mg/mL. Of 29 isolates of P. aeruginosa, 7 (24%) were resistant to
meropenem (MIC> 32mg/mL). These isolates also were resistant to
imipenem. In Acinetobacter baumannii, of 27 isolates 8 (27%) were
resistant to meropenem. All isolates of K. pneumoniae were susceptible
to meropenem and imipenem. Only one strain had intermediate resistance
(MIC= 6mg/mL). Resistance to other tested antibiotics was very high
and more than 80% of organisms were resistant to Piperacillin/
Tazobactam, Cefepime, Ciproﬂoxacin, Amikacin, and Ceftazidim. All
isolates of Klebsiella pneumoniae were resistant to Ceftazidim.
Conclusion: These studies showed that nearly one fourth of non-
fermenter tested organisms in our study were resistant to carbapenems.
However resistance of K. pneumoniae to carbapenem is not a serious
problem already in our hospital.
P1364 The ﬁrst metallo-b-lactamase producing clinical isolate of
Pseudomonas aeruginosa in Norway
Ø. Samuelsen, M.A. Toleman, N.O. Hermansen, B. Aasnæs, B. Haldorsen,
A. Sundsfjord, T.R. Walsh (Tromsø, NO; Cardiff, UK; Oslo, NO)
Objectives: MBL are of great clinical signiﬁcance as they are able
to hydrolyse virtually all b-lactams limiting therapeutic options. Here
we describe the ﬁrst clinical isolate of MBL-producing Pseudomonas
aeruginosa in Norway and its subsequent genetic characterisation.
Methods: A clinical isolate of P. aeruginosa (K34−7) was recovered
from a patient recently admitted from an African country with a
high-level resistance to carbapenems and was examined for MBL
production. Susceptibility testing was performed using disc diffusion,
VITEK and Etest. The presence of MBL was conﬁrmed by PCR (custom
oligonucleotides for all major blaMBL genes) and by spectrophotometric
analysis of crude cell extracts (with and without EDTA – 25mM for 1 hr)
for the ability to hydrolyse imipenem. Characterisation of the MBL gene
and its genetic support was evaluated by its association with integrons,
transposons and insertion elements (ISCR) using PCR and sequencing.
Results: Susceptibility testing showed that P. aeruginosa K34−7 was
multi-drug resistant, highly resistant to imipenem and meropenem
(MIC> 32mg/L) and positive on the MBL Etest (ratio MIC
imipenem/imipenem + EDTA 8). MBL production was also veriﬁed by
hydrolysis/inhibition assays on crude cell extracts ± EDTA. Sequencing
analysis of the positive blaVIM amplicon revealed it was 100%
identical to blaVIM-2. PCR and sequencing analysis revealed that K34−7
contained 2 very different integrons. The class 1 integron contains 4
antibiotic resistant genes including blaOXA31 and genes encoding novel
multi-drug resistant pumps and aminoglycoside modifying enzymes. The
second integron contained TniCR at the 3′ end instead of qac/sul and
the gene cassette sequence: aacA7-blaVIM-2-aacA5. Although standard
transposons was not detected adjacent to the integrons, we detected a
new ISCR element, designated ISCR10, and the ﬁrst to be found in
P. aeruginosa.
Conclusion: This is the ﬁrst report of an MBL-producing P. aeruginosa
identiﬁed in Norway. Genetic analysis revealed the “new” TniCR
integron associated with the blaVIM-2 MBL gene and the ﬁrst ISCR10
found in P. aeruginosa.
P1365 Dissemination of a VIM-positive Pseudomonas aeruginosa
clone in a university hospital, Ankara, Turkey
N. Gurkan Aydin, G. Metan, B. Altun, P. Zarakolu (Ankara, Kayseri, TR)
Objectives: The aim of this study was to report the dissemination of
a VIM-positive Pseudomonas aeruginosa clone in Hacettepe University
Hospital in Ankara, Turkey.
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Methods: P. aeruginosa strains (n = 26) isolated from various clinical
specimens (4 blood, 7 urine, 12 pus, 1 cerebrospinal ﬂuid, 1
bronchoalveolar lavage, 1 sputum) of patients with nosocomial infections
in Hacettepe University Adult Hospital during January and July 2005
were included in the study. The isolates were identiﬁed by Phoenix
System (Becton Dickinson, USA) and the antimicrobial susceptibility
testing was performed by Etest (AB Biodisk, Sweden) method according
to CLSI criteria. All the isolates were screened for carbapenem
hydrolysing metallo-b-lactamase activity by imipenem-EDTA disk
method phenotypically and genotypic detection was performed by PCR
with bla-IMP and bla-VIM primers. Clonal diversity was examined by
PFGE of SpeI-digested genomic DNA.
Results: The antimicrobial resistance of the isolates to ceftazidime was
27% where as 31% to piperacillin-tazobactam, 35% to imipenem, 38%
to meropenem, 46% to tobramycin, 58% to ciproﬂoxacin. All the isolates
were carrying the blaVIM gene and the blaIMP gene was not detected
in any of them. However, only 8 (31%) were phenotypically positive
for metallo-b-lactamase activity. There were 3 clones with one dominant
clone (n = 22).
Conclusion: P. aeruginosa is a multidrug resistant pathogen of
nosocomial infections. Although metallo-b-lactamase activity as a
resistance mechanism has been reported increasingly worldwide, there
are few reports from Turkey. Our ﬁnding of dissemination of this clone
is pointing out the emergence of this resistance pattern in our country.
P1366 Multiresistant Pseudomonas aeruginosa serogroup O:12
outbreak in an intensive care unit
R. Rodrı´guez, M.M. Gallardo, M.V. Garcı´a, A. Vindel, E. Granados,
F. Ropero, I. Viciana, A. Pinedo (Ma´laga, Madrid, ES)
Objective: Research on an multirresistant P. aeruginosa outbreak among
patients hospitalised in the Intensive Care Unit.
Methods: A retrospective study was carried out where the clinical
reports of those patients with a presence of P. aeruginosa of the
same resistant phenotype, were revised. Antimicrobial suceptibilities
were carried out by the MicroScan automised system and by disk
difussion test and E-test. The results interpretation were according
NCCLS guidelines. The epidemiological characterisation by serotyping
was analysed using an agglutination technique with the antisueros of the
IATS. Clonal relationship of strains were carried out with Pulse Field
Gel Elctrophoresis (PFGE) of the restriction fragments obtained with
XbaI and PCR for blaVIM for the detection of metallo-b-lactamases.
Results: Between September 2002 and February 2003, 45 P. aeruginosa
serotype O:12 were isolated with identical resistant phenotype only
sensitive to amikacin. These 45 strains were obtained from 13 patients
out of which 10 (76.9%) were men and 3 (23.07%) were woman with an
average age of 60 years old. Isolates were produced in two intensive care
units from different hospital areas: General Intensive Care Unit (ICU)
and Anaesthesia Intensive Care Unit (recovery). 9 patients were admitted
in ICU, 3 in recovery and one in both wards. Average hospitalisation
days were 49.23 days. 76.9% of the patients were smoker and the base
pathology most frequently found were cardiopathy, diabetes mellitus
and hypertension (46.2%). Mostly of patients were no fatal underlying
condition (76.9%). Samples where P. aeruginosa was isolated more
frequently were blood in 37.7% of the cases followed by bronchial
aspirations (26.6%). Index case was a patient hospitalised in ICU for
49 days. The last 4 cases were recovery patients, one of them had
been admitted previously in ICU. Bronchial aspiration had been done
in all of them as well as mechanical ventilation and SNG. Mortality
was of 46.15% and the mortality attributable was of 23.1%. Restriction
patterns obtained through PFGE were identical in all strains conﬁrming
isolation clonal relationships. PCR blaVIM for carbapenemas detection
was negative in all cases.
Conclusions: Antibiotic pressure to which these patients are submitted
plus the control measures relaxation of healthcare workers, probably
are the cause of the outbreak appearance and dissemination. Molecular
characterisation is an useful tool for epidemiologic surveillance
programmes.
P1367 Epidemiological and clinical investigation of Gram-negative
anaerobic infections in Greece
A. Katsandri, A. Avlamis, N.J. Legakis, G.L. Petrikkos, A. Pantazatou,
J. Papaparaskevas for The Hellenic Study Group for Gram-Negative
Anaerobic Bacteria*
Objective: Epidemiological and clinical investigation of Gram(−)
anaerobic infections.
Materials and Methods: A prospective multicentre study of 206
Gram(−) anaerobic infections was conducted during the period 2003–
2006. Data collected included gender, age, ward type, duration of
hospitalisation, underlying disease, clinical manifestation, outcome, prior
antimicrobial therapy, infection treatment, and microbiological data
(clinical specimen, species identiﬁcation, other pathogens from the same
specimen). Analysis was performed with the STATA 6.0 programme.
Results: Bacteroides spp. isolates were more frequent in intra-abdominal
infections (p< 0.001). Infections due to B. fragilis compared to other
species of the B. fragilis group were more frequent in surgical ward
patients (p = 0.008), and those who received treatment with second
generation cephalosporins (p = 0.017). In bacteraemic cases, Bacteroides
non-fragilis spp. were more frequent than B. fragilis group spp.
(p = 0.02). B. fragilis group spp. were isolated more frequently than
Bacteroides non-fragilis spp. in polymicrobial infections (p = 0.05), and
younger patients (p = 0.049, for median ages of 47.4 and 61.3 years).
Prevotella spp. strains were more frequent in pulmonary infections
compared to bacteraemias, soft tissue, or intrabdominal infections
(p< 0.001), from outpatients than inpatients (p< 0.05), and from
patients with shorter hospitalisation duration (p = 0.033). Fusobacterium
spp. were isolated more frequently from patients with lung abscess
(p = 0.038), and from those that did not receive any form of antimicrobial
therapy (p = 0.024). Mortality was higher among bacteraemic patients
(p< 0.001), those that were hospitalised in internal medicine dpts.
or ICU (p = 0.001), or those that were treated with aminoglycosides
(p = 0.008). Among polymicrobial infections an association was detected
between Staphylococcus and Prevotella spp. (p = 0.006), and between
Enterobacteriaeae and Bacteroides spp. (p = 0.007).
Conclusions: Epidemiological and clinical differences were detected
among cases of infections due to different Gram(−) anaerobic species,
differences that provide useful information for optimisation of the
respective empirical treatment guidelines.
Acknowledgements: The study was funded by European Social Fund
and National Resources (grant EPEAEK II–Pythagoras II).
*Drs M. Foustoukou, M. Kanellopoulou, C. Koutsia-Karouzou, H.
Malamou-Ladas, A. Pangalis, E. Papafrangas, M. Toutouza, E. Trika-
Grafakos, and A. Vogiatzi.
P1368 Correlation between colonisation and infection with
antibiotic-resistant Gram-negative bacilli in the neonatal
intensive care unit
A. Dedeic Ljubovic, D. Bekic, M. Hukic (Sarajevo, BA)
Objectives: Infection due to Gram-negative bacilli which are often
resistant to multiple antibiotics usually occurs in neonates already
colonised in the pharynx or intestine.
We studied bacterial colonisation in the intestinal and nasopharyngeal
ﬂora and development of severe infection (septicaemia and meningitis)
in colonised neonates admitted to a neonatal intensive care unit.
Methods: The study included 255 neonates admitted to a neonatal
intensive care unit at Clinical Center University of Sarajevo in a six-
month period. Cultures of nose, throat and stool were obtained on
admission and once weekly if the lenght of stay was more than seven
days. A total of 923 nose and throat cultures and 450 stool cultures
were performed. Antibiotic sensitivity pattern and ESBL production were
determined with disc-diffusion methods and E test (AB Biodisk, Solna
Sweden) according to the NCCLS.
Results: 85% (217/255) of patients became colonised in throat/intestine
with antibiotic-resistant Gram-negative bacilli. 37.3% (81/217) of
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neonates became colonised early, in the ﬁrst week of hospitalisation.
Klebsiella pneumoniae, Pseudomonas spp., Acinetobacter baumannii,
Serratia marcescens were isolated more often. 92% (47/51) of colonised
neonates had intestinal colonisation, and 45.7% (76/166) nasopharyngeal
colonisation with Klebsiella pneumoniae. 42.3% (52/123) of isolates
were with same antibiotic sensitivity pattern and biotype (1 and 4).
All Klebsiella pneumoniae isolates from stool, and 69.7% (53/76) from
throat and nose were ESBL producers. Pseudomonas and Acinetobacter
were also isolated from stool, throat and nose in 21% and 12% of
patients, respectively. 47% (22/46) of Pseudomonas and 20% (5/25)
of Acinetobacter isolates were imipenem resistant. Serratia marcescens
was isolated from nose and throat in 13.3% (22/166) of patients, but not
in the stool specimens. Severe infection (septicaemia and meningitis)
occurred in 23% (50/217) of colonised neonates with the same strain
of antibiotic resistant Gram-negative bacilli. A mean of 11.6 days was
between colonisation and infection.
Conclusion: The high percentage of patients in our study developed
infection after colonisation. Multi drug resistant hospital strain of Gram-
negative bacilli are the most frequently isolated in colonised and infected
patients. Screening cultures are necessary to detect colonised neonates
when nosocomial Gram-negative bacilli become epidemic in the neonatal
intensive care unit.
Pharmacokinetics and pharmacodynamics
P1369 Modiﬁcation of cephalexin serum concentration by
grapefruit juice co-administration in rats
M. Cuciureanu, C. Tuchilus, A. Poiata, M. Nechifor, R. Cuciureanu
(Iasi, RO)
Acute ingestion of usual quantities of grapefruit juice or whole fresh fruit
segments can alter oral drug pharmacokinetics by different mechanisms
(including the inhibition of enteric cytochrome P450 3A4 isoenzymes).
As a result, metabolism of co-administred drugs is reduced and oral
bioavailability is increased.
Objective: To assess the interactions between grapefruit juice and
cephalexin, we compared the serum concentration of cephalexin given
alone and in association with grapefruit juice after oral administration
in rats.
Methods:Mature male Wistar rats weighing 180–200 g were randomised
into two groups of 10 animals each. The animals were housed at room
temperature (22±1ºC) and had free acces to food and water except during
the course of the experiment. Group I received cephalexin (30mg/kg,
p.o.) and to group II was administred cephalexin (30mg/kg, p.o.) and
grapefruit juice (5mL/kg, p.o.). Blood sample were collected at 0, 1,
2, 3, 8 and 24 hours after oral administration. Microbiological assay
was performed by the agar plate diffusion technique using Sarcina lutea
ATCC9341 as test organism. Based on the results of the above assay and
on known concentrations of antibiotic solutions we realised the serum
concentration/time curve and we determined the rats’ serum cephalexin
levels at various times after administration.
Results: The mean cephalexin serum concentrations for group I were 14;
6.7; 2; 0,5; 0mg/mL and for group II were 19.5; 8.2; 2.5; 0.7; 0mg/mL
at respectively 1, 2, 3, 8 and 24 hours after the administration.
Conclusion: The serum concentrations of cephalexin of group which
received grapefruit juice are higher compared to group which received
only cephalexin, at all determination times.
P1370 Pharmacokinetics of penicillin G in infants with a
gestational age of less than 32 weeks
A.E. Muller, J. DeJongh, Y. Bult, W.H. Goessens, J.W. Mouton,
M. Danhof, J.N. van den Anker (The Hague, Leiden, Assen, Rotterdam,
Nijmegen, NL; Washington, US)
Objectives: Infectious complications in the immediate postnatal period
are common and especially premature infants are vulnerable. Penicillin
G is often given in such cases, but the pharmacokinetics in premature
infants may differ substantially and is largely unknown, in particular in
infants with a gestational age of less than 32 weeks. We investigated the
pharmacokinetics of penicillin G in this age group.
Methods: Infants with a gestational age of less than 32 weeks on
day 3 of life were eligible for the study. They received 50.000 EH/kg
penicillin G every 12 h intravenously. From each patient 6−9 blood
samples were taken. Antibiotic concentrations were determined by a
validated HPLC method. Pharmacokinetic parameters were estimated by
population pharmacokinetic modeling using NONMEM. Various models
were tested. To discriminate between models the minimum value of
objective function (MVOF) was used.
Results: Twenty intants were included. A two-compartment pharmacoki-
netic model best described the time course of penicillin G. Clearance
(CL), volume of the central compartment (Vc) and intercompartimental
clearance were estimated at respectively 0.103±0.01 L/h, 0.359±0.06 L
and 0.774±0.277 L/h (mean±SE). The residual error was found
to be both proportional and additive to the blood concentrations.
Interindividual variability was found for CL and Vc. The volume of
distribution at steady state was 0.54L and terminal half-life was 3.9 h.
CL increased signiﬁcantly with body weight. The relationship between
gestational age and CL was examined, but found to be inferior to the
relationship between body weight and CL.
Conclusions: The pharmacokinetics of penicillin in infants with a
gestational age of less than 32 weeks differs signiﬁcantly from that
in adults and children with a prolonged mean terminal half-life of
approximately 4 hours. These results warrant a dosing schedule of two
times daily dosing in this age group. CL signiﬁcantly increased with
body weight, rather than with gestational age.
P1371 The inﬂuence of uterine contractions during labour on the
pharmacokinetics of intravenously administered amoxicillin
A.E. Muller, P.J. Do¨rr, J.W. Mouton, J. DeJongh, P.M. Oostvogel,
E.A.P. Steegers, R.A. Voskuyl, M. Danhof (The Hague, Nijmegen,
Leiden, Rotterdam, NL)
Objectives: Amoxicillin is widely used in pregnant women, both in
those who are in labour and those who are not. An effect of labour
on the pharmacokinetics of ampicillin has been shown previously,
but similar data are not available for amoxicillin. Changes in the
pharmacokinetics due to uterine contractions may pose these patients
at risk for inappropriate dosing. We investigated the effects of uterine
contractions on the pharmacokinetics of amoxicillin.
Methods: Healthy women at 30−42 weeks of gestation were eligible for
the study. They received amoxicillin following the local guidelines. From
each patient 5−28 serial blood samples were taken and demographic
data recorded. Serum antibiotic concentrations were determined by a
validated HPLC method. Pharmacokinetic parameters and the inﬂuence
of uterine contractions on these parameters were estimated by population
pharmacokinetic modelling using NONMEM. Various models were
tested. To discriminate between models the minimum value of the
objective function (MVOF) was used.
Results: Thirty women were included, 20 without uterine contractions
and 10 who were in labour. A three-compartment pharmacokinetic
model best described the time course of amoxicillin. The estimated
values (mean ±SE) for the entire population for clearance, volume
of distribution of the peripheral compartments (V2 and V3) and
the intercompartmental clearances (Q1 and Q2) were 21.6±0.99 L/h,
6.63±0.53, 8.65±0.99L, 35.8±5.15 and 5.95±0.65 L/h, respectively.
The terminal half-life was 1.16±0.26 h. There was no effect of uterine
contractions on the parameters, except on the volume of distribution of
the central compartment (Vc). Uterine contractions slightly increased
Vc from 6.93±1.73L to 8.64±2.21L (p< 0.05; mean ±SD). The
residual error was found to be proportional to the blood concentrations.
Interindividual variability was mainly due to differences in clearance
and Vc. The main demographic characteristics did not inﬂuence the
individual posthoc estimates for clearance.
Conclusion: A 3-compartment model best described the data. The
consequential slow elimination is beneﬁcial for the efﬁcacy of
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amoxicillin, especially when it is used to prevent Streptococcus
agalactiae infections in the neonate, because of the relatively low MICs.
Both the absence of effects of uterine contractions and the lack of
inﬂuence of patient characteristics indicate that dose-adjustments in this
critical situation are not necessary.
P1372 Optimal piperacillin/tazobactam dosing against
Pseudomonas aeruginosa: prolonged or continuous infusion?
A. Kim, C. Sutherland, J. Kuti, D. Nicolau (Hartford, US)
Objectives: As a result of increasing resistance among Pseu-
domonas aeruginosa (PSA), alternative dosing strategies to optimise
piperacillin/tazobactam (TZP) pharmacodynamics, such as prolonged
(PI) and continuous infusion (CI), have been advocated; however,
comparative data to aid in deciding which to use are sparse. Monte
Carlo simulation was utilised to compare the bactericidal cumulative
fraction of response (CFR) between PI and CI regimens against a local
population of PSA.
Methods: TZP pharmacokinetics were extrapolated from a published
population pharmacokinetic study in surgical and neutropenic patients.
A 2-compartment model was used to calculate steady-state concentration
time proﬁles for the piperacillin component of the following TZP
dosages: 4.5 g q6h (30 minute infusion), 3.375 g q8h (4 h PI), 4.5 g q8h
(4 h PI), 4.5 g q6h (3 h PI), 10.125 g CI, 13.5 g CI, 18 g CI, 20.25 g CI,
and 22.5 g CI. A 5,000 Monte Carlo simulation with covariance matrix
was conducted. Pharmacodynamic targets were 50% free time above the
MIC (T>MIC) for the 30 minute infusion and PI regimens, and 100%
free T>MIC for CI regimens. MICs for 416 consecutive nonduplicate
PSA collected from our institution over a 6 month period during 2006
were tested via E-test.
Results: 92.3% of PSA were TZP susceptible; the MIC50 and MIC90
were 8 and 32mg/mL, respectively. CFR was 79.6 (4.5 g q6h, 30 minute
infusion), 83.1 (3.375 g q8h, 4 h PI), 86.9 (4.5 g q8h, 4 h PI), 89.6
(4.5 g q6h, 3 h PI), 82.0 (10.125 g CI), 86.3 (13.5 g CI), 89.2 (18 g CI),
90.0 (20.25 g CI), and 90.6 (22.5 g CI).
Conclusion: Both PI and CI dosing strategies improve the pharmaco-
dynamics of TZP over that of standard infusion regimens; moreover,
PI and CI regimens that contain the same daily piperacillin dose will
have similar likelihood of bactericidal exposure. Thus, the choice of
administration strategy depends on the convenience of once daily dosing
versus line access availability. Finally, dosing regimens that contained
greater than 18 g TZP daily did not appear to provide any meaningful
additional exposure for this PSA population.
P1373 Clinical signiﬁcance of pharmacokinetics of ertapenem in
an outpatient setting
S. Garazzino, F.G. De Rosa, A. D’Avolio, M. Michelazzo, G. Di Perri
(Turin, IT)
Objectives: Ertapenem is a novel parenteral carbapenem active
against most pathogens associated with community-acquired and mixed
infections. Given its once daily administration, it is an appealing
option in an outpatient setting. Aim of our study was to evaluate
pharmacokinetic parameters of ertapenem in a cohort of outpatients with
a variety of infections and to compare data with those obtained in healthy
volunteers.
Methods: Outpatients treated with intravenous ertapenem at standard
dosage were analysed. Plasma samples for pharmacokinetic analysis
were obtained after multiple dosing at steady state conditions
immediately before and at the end of the infusion, at 2 h and 24 h.
Plasma concentrations of ertapenem were measured by a validated
HPLC-UV method and Cmax, Cmin and AUC0−24 were determined
by non compartmental analysis (Win Nonlin Professional 4.1).
Results: Twenty-ﬁve patients were studied; 14 of them had a complicated
skin/skin structure infection, 8 an osteo-articular infection (chronic
osteomyelitis, diabetic foot or septic arthritis), 1 a mastitis and 2 had a
genito-urinary tract infection. Median age was 55.5 years (range 27−85).
All patients received intravenous ertapenem 1 g once daily over a 30-min
infusion. Serum creatinine levels were within normal range in all patients
but one (1.3mg/dl). Mean Cmax and Cmin were respectively 97.6mg/L
and 1.8mg/L (range 19.4–438 and 0.1–11.6 respectively); mean AUC
was 536.3. Cmin values were associated with age (p< 0.05); no statistical
association was found between ertapenem concentrations and either body
weight, BMI, sex or creatinine levels.
Conclusion: Mean plasma concentrations of ertapenem exceeded the
MIC of susceptible bacteria for the entire dosing interval, satisfying the
pharmacokinetic requirements of a once daily dosing. Data were similar
to those reported in healthy volunteers: no dose adjustment is required
by body weight and creatinine levels. Higher high trough concentrations
observed in patients with advanced age are probably accounted for by a
reduced renal excretion of ertapenem.
P1374 Comparison of oral dosing regimes for pivampicillin by
Monte Carlo PK/PD simulation
K.S. Jensen, N. Frimodt-Møller (Copenhagen, DK)
Objectives: Compartmental models employed in a Monte Carlo
simulation scheme are frequently used to study PK/PD aspects of
antibiotics given intravenously. In contrast, very few modeling studies
of that kind seem to have been reported for drugs when taken as
oral doses. We therefore wanted to test the ability of a compartmental
model to predict concentration-time proﬁles in serum after PO uptake of
pivampicillin when population PK parameters are estimated with the
NPAG computer programme. Furthermore, we wanted to use Monte
Carlo simulation to ﬁnd optimal dosage regimes for pivampicillin
with respect to Streptococcus pneumoniae and S. pyogenes, since
aminopenicillins are commonly used drugs for treatment of upper-
respiratory tract infections.
Methods: PK-data for ampicillin concentrations after dosing of
pivampicillin 500mg (equivalent to 360mg ampicillin) were kindly
provided by Leo-Pharma Denmark. 7 (n = 12) or 8 (n = 5) measurements
of serum concentration within 8 hours from intake were recorded
in 17 individuals (mean age: 38 years, mean weight: 76 kg). The
NPAG programme was used to ﬁt a linear compartment model (seven
state variables, six PK parameters) to the data whereby mean values
as well as covariance matrix for the PK parameters were obtained.
Monte Carlo simulations (Nsubjects = 100,000) were then made with
the compartment model assuming lognormal as well as nonparametric
(empirical) frequency distributions for the PK parameters. Results
were obtained on the probability of target attainment with respect
to T>MIC 50% for a range of MIC values covering Streptococcus
pneumoniae and S. pyogenes (distribution of MIC’s from the EUCAST
website).
Results: After the parameter estimation process, the compartment model
was able to reproduce the measured serum concentrations with good
precision. For MIC targets of 0.063mg/L (streptococci), T>MIC 50%
(free fraction eq. to 100%) could be reached for 99% of the simulated
population on a 250mg q8h pivampicillin dose (breakpoint: 0.125mg/L),
while the same population coverage (99%) required 1,000mg doses if
using a q12h schedule (breakpoint: 0.125mg/L).
Conclusion: Monte Carlo simulation of oral dosage of antibiotics based
on estimation of population PK parameter values can be applied for
pivampicillin. The simulations indicate that for streptococcal infections
the total daily dose can be reduced to less than 40% if distributing the
intake on three instead of two occations per day.
P1375 Pharmacodynamic comparison of linezolid, teicoplanin,
and vancomycin against clinical isolates of Staphylococcus
aureus and coagulase negative staphylococci collected from
hospitals in Brazil
C. Kiffer, J. Kuti, C. Mendes, S. Sinto, P. Koga, D. Nicolau (Sao Paulo,
BR; Hartford, US)
Objectives: The association of MIC distribution and pharmacokinetic
(PK) data derived from microbiological and human studies through
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the use of pharmacodynamic (PD) models offers a more developed
tool for prediction of infection outcome. The probability of obtaining
critical PD targets was determined and compared by the use of Monte
Carlo simulation for Linezolid (L), Teicoplanin (T), and Vancomycin (V)
against non-duplicate clinical isolates of Staphylococcus spp. collected
from 3 hospitals in Sa˜o Paulo, Brazil between 2003 and 2005.
Methods: MICs were determined for 201 Staphylococcus aureus (SA)
and coagulase negative staphylococci (CNS) isolates by Etest method
for L, T, and V. Interpretations were done according to established
CLSI criteria. Methicillin resistance (MR) was conﬁrmed by oxacillin
and cefoxitin disc diffusion. PD exposures, measured as steady-state
total drug AUC/MIC, were modeled via a 5,000 patient Monte Carlo
simulation for the following: L 600mg q12h, T 400mg q24h (T6),
T 800mg q24h (T8), V 1 g q12h, and V 1 g q8h using PK from patients.
PD targets included AUC/MIC >82.9 for L and >345 for T and V. The
bactericidal cumulative fraction of response (CFR) was calculated for
each regimen against each speciﬁc population: methicillin-susceptible
(MS) and MR, for both SA and CNS.
Results: There were 40/119 MRSA and 74/82 MR-CNS isolates. The
SA isolates were fully susceptible to T (MIC90 = 2mg/mL) and L
(MIC90 = 1mg/mL). There was one SA isolate with intermediate sus-
ceptibility to V (MIC= 3mg/mL) (MIC90 = 1.5mg/mL). The CNS isolates
were fully susceptible to V (MIC90 = 3mg/mL) and L (MIC90 = 1mg/mL),
and 13.4% resistant to T (MIC90 = 32mg/mL). CFR against all SA were
96.0%, 30.1%, 71.6%, 48.0%, and 65.1% for L, T6, T12, V q12h, and
V q8h, respectively. CFR against all CNS were 97.8%, 13.4%, 34.6%,
10.9%, and 31.3% for L, T6, T12, V q12h, and V q8h, respectively.
The CFR was reduced for all compounds among the MR versus the MS
strains, except for L against the MR-CNS (94.9% MS-CNS and 98.1%
MR-CNS).
Conclusion: Although MR was not expected to affect MIC, these isolates
did present with higher MICs than the MS isolates, thereby contributing
to lower CFR for MR strains. These data suggest that L has a greater
probability of attaining its requisite PD target than V and T against these
staphylococci. Although higher doses of V and T increased the CFR
for both SA and CNS, the bactericidal targets achieved still appeared
insufﬁcient.
P1376 Ceftazidime vs cefepime: comparison of two drugs as
empirical therapeutic drugs for febrile neutropenia by
Monte Carlo simulation method
Y. Sumitani, Y. Kobayashi (Tokyo, JP)
Objectives: To evaluate of ceftazidime and cefepime as the empirical
therapeutic drugs for Febrile neutropenia based on pharmacokinet-
ics/pharmacodynamics theory.
Methods: The probabilities of attaining targets (TA%) of time above
the MIC (%T>MIC) were calculated by Monte Carlo Simulation method
with Crystal Ball 2000, and compared TA% of the targets for bactericidal
effects in available maximum dosage of ceftazidime (1,000mg every 6 h)
and cefepime (2,000mg every 12 h) in Japan. The bactericidal target of
Craig was adapted: cefems (70%T>MIC).
The distribution of MICs of antibiotics against 12 strains of P. aeruginosa
isolated from blood of patients admitted to Keio University Hospital
between 2002 and 2004 was used for pharmacodynamic data.
Pharmacokinetic data were obtained from healthy volunteers in each
of interview form of ceftazidime and cefepime.
Results: The results of calculation of TA% of 70%T>MIC was
80.26% with ceftazidime in maximum dosage (1,000mg every 6 h)
and TA% of 70%T>MIC was 56.86% with cefepime maximum dosage
(2,000mg every 12 h) against P. aeruginosa.
Conclusion: Cefepime is the only authorised agent as therapeutic drug
for Febrile neutropenia in Japan. But ceftazidime is also one of the ﬁrst
choice agents for FN in the guideline of HCR (The Infectious Diseases
Society of America). In our study, TA% of 70%T>MIC with CAZ was
much higher than that of CFPM and adaptation expansion as therapeutic
drug for FN in Japan is expected.
P1378 In vivo PK/PD of linezolid against extra- and intracellular
Staphylococcus aureus
A. Sandberg, K.S. Jensen, R.L. Skov, N. Frimodt-Møller (Copenhagen,
DK)
Objectives: Intracellular persistence of S. aureus has been acknowledged
for years but regarding antibiotic treatment, S. aureus infections are still
considered as mainly extracellular. Using antibiotic regimens resulting in
poor intracellular activity might therefore be a cause of treatment failure.
Only few have studied this issue in vivo.
The purpose of this study was to characterise the PK/PD of both the
intra- and extracellular anti-staphylococcal activity of linezolid (LZ)
using a newly developed in vivo model.
Methods: PK-studies: plasma concentrations over time, in female NMRI
mice, were measured by bio-assay after s.c. application of different
doses, to test linearity between doses and the PK-parameters. The protein
binding in plasma from mice was determined by ultraﬁltration. PD-
studies: infection was induced by i.p. inoculation of 2.5×107 CFU
S. aureus E19977 (MIC-LZ= 0.5mg/L) in 5% mucin in mice. Two hours
later mice received the ﬁrst of 1−6 doses of 13 different dosing regimens
designed to give various fAUC/MIC24 (342–30 hr) and fT>MIC 24
(24−82%). 24 hrs after infection, mice were killed, a peritoneal wash in
saline was performed, and the ﬂuid retracted. After quantitative culture
of the total bacterial count (TOT) the cell fraction was isolated by
centrifugation and the extracellular bacterial count (EX) determined in
the supernatant. The remaining extracellular bacteria in the pellet were
killed by resuspension in HBSS containing 100mg/mL of lysostaphin.
The cells were lysed in water and the intracellular count (IN) quantiﬁed.
Data were analysed by the Hill equation.
Results: Linearity between doses and PK-parameters was found. The
protein binding was estimated to around 30%. There was no correlation
between effect and the fT>MIC, while signiﬁcant correlations (R2)
were found between bacterial killing and fAUC/MIC: 0.73 (TOT),
0.75 (EX) and 0.62 (IN). The Emax (logCFU/mL) for fAUC/MIC
ranged from 1.12 (TOT), to 1.9 (EX) and 0.85 (IN), respectively. EC50
(AUC/MIC [hr]) for fAUC/MIC ranged from 147.6 (TOT) to 91.0 (EX)
and 144.9 (IN), respectively. The maximum effect in all compartments
was reached at around an AUC/MIC ratio of 160.
Conclusion: The majority of the effect of LZ was seen in the
extracellular compartment. As expected, best correlations for bacterial
killing were found for fAUC/MIC in all three compartments. fT>MIC
shows no signiﬁcant correlation with anti-staphylococcal killing, neither
in total, nor in extra- or intracellular counts.
P1379 Pharmacokinetics of azithromycin in serum and sinus ﬂuid
after administration of extended release and immediate
release formulations in patients with acute bacterial sinusitis
A. Ehnhage, M. Rautiainen, A. Fang, S. Sanchez (Nacka, SE; Tampere,
FI; New York, US)
Objectives: High drug levels at the site of infection are desirable for
optimal activity. The pharmacokinetic (PK) advantages of azithromycin
(AZ) extended release (AZ-ER) versus azithromycin immediate release
(AZ-IR) have been shown previously in human lung and animal models
(Danesi et al., ATS, 2006; Girard et al., JAC 2005). Hence, the aim of
this study was to determine if a single dose of AZ-ER (2 g) achieved
higher AZ levels in the sinus ﬂuid compared to AZ-IR (500mg daily
for 3 days). The invasive nature of repeated puncture makes sinus ﬂuid
sampling difﬁcult. In this study, an indwelling sinus catheter was used
(Ambrose et al., CID, 2004) for repeated sampling to determine serial
levels of AZ for the ﬁrst time.
Methods: This was a randomised, open-label, multi-centre study.
Subjects received either a single 2-g dose of AZ-ER (n = 5) or AZ-IR
500mg once daily for 3 days (n = 4). Serum samples and sinus aspirates
were collected for up to 120 h after the ﬁrst dose. AZ levels were
analysed by a validated LC/MS/MS method. AZ levels in sinus ﬂuid
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were corrected by urea dilution method. A non-compartmental method
was used for PK analyses.
Results: Within the ﬁrst 24 h after dosing, the mean serum AUC24 and
Cmax values were 4-fold higher for AZ-ER than for AZ-IR. Similarly, the
mean AUC24 and Cmax in sinus ﬂuid were 3-fold higher for AZ-ER than
for AZ-IR. After the ﬁrst 24 h, the average AZ levels in the sinus ﬂuid
were higher with AZ-ER than with repeated AZ-IR dosing. The AUC24
values in the sinus ﬂuid were approximately 4−5-fold higher than serum
with both formulations. The mean(SD) PK parameters are shown in the
table.
Matrix Parametera AZ-ER
(n = 3−5)
AZ-IR
(n = 3−4)
ER/IR ratio
Serum AUC24 7.35 (2.93) 1.77 (0.57) 4.2
Cmax 1.15 (0.38) 0.30 (0.11) 3.8
Sinus ﬂuid AUC24 27.1 (15.5) 8.78 (4.57) 3.1
Cmax 7.34 (10.4) 2.58 (1.71) 2.8
AZ conc.
48 h 5.34 (9.49) 2.00 (1.91) 2.7
72 h 5.57 (11.1) 1.69 (0.85) 3.3
96 h 3.22 (3.09) 2.11 (1.09) 1.5
120 h 3.39 (4.09) 1.68 (1.89) 2.0
Units: AZ conc, ug /mL; AUC, ug·h/mL.
Conclusions: AZ demonstrated good penetration into the sinus ﬂuid
regardless of the formulation. Despite the small sample size, this study
suggests that administration of AZ-ER as a single dose results in
increased exposure in the ﬁrst 24 h and concentrations were maintained
in the sinus ﬂuid for up to 120 h.
P1380 Intraperitoneal penetration of imipenem in patients
undergoing abdominal surgery
K. Ikawa, N. Morikawa, K. Sakamoto, K. Ikeda, H. Ohge, Y. Takesue,
T. Sueda (Hiroshima, JP)
Objectives: Imipenem is used for surgical intra-abdominal infections,
however, the penetration into the abdominal cavity remains unclear. This
study was conducted to examine the intraperitoneal pharmacokinetics of
imipenem to rationalise the dosing regimen.
Methods: Ten patients with inﬂammatory bowel diseases who underwent
abdominal surgery were enrolled. Imipenem-cilastatin sodium 500mg
was administered by intravenous infusion over 30 minutes before the
surgery. Plasma and peritoneal ﬂuid samples were collected at the
end of the infusion and every hour for 6 hours. Pharmacokinetic data
were analysed by the multi-compartment model method, and used for
Monte Carlo simulation with MIC data in postoperative intra-abdominal
infections.
Results: Imipenem in peritoneal ﬂuid reached a peak concentration of
16.7 ± 4.3 (mean ± SD) (mg/L) at 0.72 ± 0.07 (h), whereas the
maximal concentration in plasma was 40.5 ± 13.8 (mg/L) at 0.50
(h), and both concentrations were similar between 1 and 6 hours after
the end of infusion. The volume of distribution and total clearance of
imipenem were 8.58 ± 3.31 (L) and 9.50 ± 2.38 (L/h), respectively.
The penetration ratio from plasma to peritoneal ﬂuid in the area under
the drug concentration-time curve was 0.64 ± 0.11, ranging from
0.49 to 0.92. The probabilities of achieving bacteriostatic/bactericidal
pharmacodynamic target (20/40% of the time above MIC for 24 hours)
were 99/96% in peritoneal ﬂuid and 99/97% in plasma using a regimen
of 500mg every 8 hours against an Escherichia coli population, whereas
a regimen of 1,000mg every 8 hours was needed to produce a values of
90/76% in peritoneal ﬂuid and 93/83% in plasma against a Pseudomonas
aeruginosa population.
Conclusion: This study characterised the intraperitoneal pharma-
cokinetics of intravenously administered imipenem, and provided a
pharmacokinetic-pharmacodynamic rationale for the dosing regimen for
prophylactic or empiric therapy of surgical intra-abdominal infections.
P1381 Pharmacokinetics of teicoplanin in Chinese patients
undergoing CAPD
H. Qi, X. Ma, P. Zhang, L. Gao, H. Cui, F. Hou (Beijing, CN)
Objective: To deﬁne a dose regimen of teicoplanin for Chinese patients
undergoing CAPD (continue ambulatory peritoneal dialysis) so that they
achieve trough drug serum levels above 10mg/L.
Methods: Eight CAPD patients with acute respiratory system infection
(seven with upper respiratory tract infection) of Gram-positive cocci were
included in this study. At least seven dose of 400mg teicoplanin were
administered intravenously. After three 400mg teicoplanin q12h loading
doses, patients were given a repeated dose at 24 hour interval, then
q72h for at least three times. Concentrations of teicoplanin in samples
collected from peripheral vein and excluded dialysis ﬂuid after the fourth
dosages and 48, 72, 96 hours after the last dosage were determined by
a microbiological assay.
Results:Mean Cmax was 63.57±16. 90mg/L, mean AUC0−72 at steady
state (AUCss) was 921.51±147.22mgh/L, mean half life (t1/2) was
76.89±21.06 h, mean total clearance rates (CLt) was7.69±0.61mL/h/kg
clearance rates of peritoneal dialysis (CLPD) was 1.66±0.62/h/kg
Mean volumes distribution at steady state (Vss) was 40.16±9.10 l,
mean serum concentration at steady state (Cav) was 12.69±1.82mg/L,
Trough serum levels above 10mg/L of most patients were found at
48 hr after the administration (10.03±2.41mg/L), and mean serum
concentration at 72 hr after the administration was 9.05±3.81mg/L.
Concentration of 96 h after last dose was 7.70±0.87mg/L. The serum
drug concentration of one patient whose total creatinine clearance rate
was 38l/week (3.77mL/min) showed that the concentration at 72 hours
after administration was higher (17.94mg/L) than the concentration
at 48 hours (12.75mg/L). The Clinical efﬁcacy rate and bacterial
eradication rates was 100%. Two patients experienced anorexia one might
be related to primary diseases. There was no adverse effect observed on
the anuric patient who had been given teicoplanin for a period of 22
days because of complicating G+ coccus panaritium and pneumonia.
Conclusion: It is proposed that teicoplanin is safety and efﬁcacy on
CAPD patient when administered according to the dose recommended
by Sanoﬁ-Aventis for renal failure patients with serious infection.
P1382 Concentrations of moxiﬂoxacin (400mg) in prostatic
secretions and ejaculate after a single oral dose in healthy
volunteers
F. Wagenlehner, F. Kees, W. Weidner, K. Naber (Giessen, Regensburg,
Straubing, DE)
Objectives: The spectrum of bacterial prostatitis comprises Gram-
negative, Gram-positive and atypical pathogens. Prostatic concentrations
of most antibiotics are far below serum levels. Because of its broad
spectrum of activity, moxiﬂoxacin might be a suitable antibiotic for the
treatment of bacterial prostatitis. In this study serum concentrations and
the penetration of moxiﬂoxacin into prostatic secretions and ejaculate of
healthy volunteers after a single oral dose of 400mg were investigated.
Methods: In a prospective phase I study 12 healthy male volunteers
received a single oral dose of 400mg moxiﬂoxacin and at the same
time 3.24 g iohexol intravenuously to determine urinary contamination.
Serum concentrations were determined at 0, 0.5, 1, 2, 3 and 4 h, prostatic
secretions and ejaculate were determined 3 to 4.5 h after administration
of drugs. Urinary concentrations were determined in the collecting
urine 0 to 4.5 h. Concentrations of moxiﬂoxacin and iohexol in serum,
secretions and urine were determined by HPLC.
Results: Serum and urine concentrations of moxiﬂoxacin were evaluated
in 11, prostatic secretions in 8 and ejaculate in 10 volunteers. Interassay
and intraassay precisions varied between 3.0 to 5.4% and 5.5 to 7.8%,
respectively. The pharmacokinetic parameters of moxiﬂoxacin are shown
in table 1. The possible urinary contamination of prostatic secretions and
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ejaculate (determined with iohexol) was less than the precision of the
analytical method. Concentrations were therefore not corrected.
Table 1
Pharmacokinetic parameter N Mean SD Median Min Max
Serum
Cmax (mg/L) 11 2.84 0.52 2.74 2.08 3.55
Tmax (h) 11 1.59 0.86 1.00 0.50 3.00
AUC0−4 (mg/L°h) 11 9.04 1.56 9.02 6.52 11.55
Prostatic secretion
Concentration prostatic secretion (mg/L) 8 3.79 1.24 3.99 2.00 5.57
Ratio prostatic secretion/seruma 8 1.61 0.51 1.57 0.97 2.32
Ejaculate
Concentration ejaculate (mg/L) 10 2.46 0.35 2.49 1.94 2.97
Ratio ejaculate/seruma 10 1.02 0.18 1.01 0.77 1.31
aCorresponding serum concentrations were linearly extrapolated from serum
concentrations at 3 and 4 h.
Conclusion: After a single oral dose of 400mg moxiﬂoxacin the
concentrations in prostatic secretion were 60% higher than in serum and
in ejaculate comparable to serum, 3 to 4 h after administration. Therefore,
moxiﬂoxacin might be a good alternative for the treatment of chronic
bacterial prostatitis.
P1383 Penetration of moxiﬂoxacin and lomeﬂoxacin into the
prostatic tissue and ﬂuid
S. Yakovlev, R. Komarov, G. Izotova, V. Yakovlev (Moscow, RU)
Objectives: The successful treatment of chronic bacterial prostatitis
depends to a large extent on the effective antimicrobial concentrations
in the prostate against the causative microorganisms. Fluoroquinolones
are recommended as ﬁrst-line treatment of bacterial prostatitis due to its
good penetration into the prostate. In the present study we examined
the prostatic tissue and ﬂuid penetration of moxiﬂoxacin (MOX) in
comparison with lomeﬂoxacin (LOM) in patients with chronic bacterial
prostatitis.
Methods: The concentrations of ﬂuoroquinolones in blood and prostatic
ﬂuid were determined in 28 patients with chronic bacterial prostatitis
after a ﬁrst oral 400-mg dose. Blood samples were taken prior to
and 1, 2, 3, 6, 12 and 24 h after drug administration. Prostatic ﬂuid
was obtained after prostatic massage prior to and 3, 6 and 24 h after
drug administration. Thirty patients with benign prostatic hypertrophy
undergoing transurethral resection of the prostate received a single
oral 400-mg dose of MOX or LOM 3 or 24 h before surgery for
prophylaxis. Concentrations of MOX and LOM were measured using a
microbiological plate assay. Minimum inhibitory concentrations (MIC)
of MOX and LOM for causative pathogens were determined by broth
microdilution method.
Results: Maximum serum concentrations of MOX and LOM were 3.4
and 1.3mg/mL. Three, 6, 12 and 24 hours after administration, the mean
serum concentrations of MOX were 3.4, 3.3, 2.2 and 1.1mg/mL and
those of LOM were 1.1, 1.0, 0.7 and 0 mg/mL. Mean prostatic ﬂuid
concentrations of MOX at 3, 6 and 24 hours after administration were
3.3, 4.7 and 3.3mg/mL and those of LOM were 4.5, 2.3 and 0.4 mg/mL.
Mean prostatic tissue concentrations of MOX and LOM at 3 hours after
administration were 0.3 and 0.5mg/g and at 24 hours – 0.3 and 0.3 mg/g.
MIC90 of MOX and LOM for most common pathogens were: E. coli
0.25 and 0.25mg/L, Klebsiella spp. 4 and 16mg/L, Enterobacter spp.
<0.125 and 0.25mg/L, Staphylococcus spp. 0.25 and 1mg/L, E. faecalis
<0.125 and 0.5mg/L, Streptococcus spp. 0.5 and 2mg/L.
Conclusion: The concentrations of MOX were higher in both serum
and prostatic ﬂuid than those of LOM. Prostatic tissue levels of both
quinolones were similar. The concentration of MOX in the prostatic
ﬂuid and tissue in contrast with LOM is high enough to eradicate the
majority of pathogens causing chronic bacterial prostatitis.
P1384 PK-PD parameters ratio of antibiotics released from
antibiotic-loaded spacers in drainage ﬂuids
E. Bertazzoni Minelli, A. Benini, B. Magnan, P. Bartolozzi (Verona, IT)
Objectives: Infection remains a difﬁcult problem in total hip or knee
replacement. Polymethylmethacrylate (PMMA) cements impregnated
with aminoglycosides and/or vancomycin are currently utilised as local
antibiotic carriers in orthopaedic prosthetic infections. Few data are
available on antibiotics release in vivo at the moment of implant as
well as their antimicrobial inhibitory activity.
Methods: The local and systemic release of gentamicin (G) from
temporary spacers (hip and knee) loaded with 2.5% gentamicin (Spacer-
G®) was studied in 13 patients undergoing two-stage revision surgery.
We currently combine the use of spacers with systemic therapy for the
treatment of prosthetic infections. Vancomycin (V) was parenterally (1 g,
b.i.d.) or locally administered (cement, 2.5%). The concentrations of G
and V were determined in drainage ﬂuid (DF) and serum collected in
the ﬁrst 24 hours after implantation of spacers. Microbiological method
and FPIA were utilised. Their inhibitory activity was evaluated against
multiresistant clinical isolates (S. aureus, S. epidermidis, S. hominis,
S. haemolyticus, E. coli, P. aeruginosa) by bactericidal titer and
continuous turbidimetric recording of bacterial growth (Bioscreen,
Labsystem).
Results: The release of G from spacers in the infection site seems
prompt and effective, attaining high local concentrations. Serum levels
of G were very low. Parenteral V showed good penetration in the
infection site. Higher levels in drainage ﬂuids were attained by local
administration. G and V were present in the implant site at inhibitory
concentrations. Drainage bactericidal levels presented great intersubject
variability. Highest concentrations of DFs (from 80% to 20%) inhibited
bacterial growth of all strains tested for 24 h, 10% for 12 h. G and V
in combination showed an additive effect against multiresistant strains
when tested at the same concentration of bactericidal titer; lower levels
of G and V inhibited bacterial strains for 10−14 h. DFs maintained their
inhibitory activity also after ﬁltration and proteins precipitation.
Conclusions: G and V are released from cement at inhibitory
concentrations in the infection site for prolonged periods. V presents a
good and prompt penetration in the infection site after i.v. administration.
The combination of G and V exerts an effective effect against
multiresistant bacteria. PK/PD parameters ratio seems good and can be
considered a predictive value for therapeutic efﬁcacy.
P1385 Antibiotic diffusion in pseudoarthrosic infected bone:
glycopeptides, ﬂuoroquinolones and carbapenems
S. Garazzino, A. Aprato, D. Aloj, F.G. De Rosa, A. D’Avolio, A. Masse´,
G. Di Perri (Turin, IT)
Objectives: Antibiotic concentration in infected bone is a major
determinant of clinical response. As glycopeptides, ﬂuoroquinolones and
carbapenems are widely used for the treatment of bone infections, aim
of our study was to assess their diffusion in infected human bone.
Methods: Patients with a septic pseudoarthrosis undergoing debridement
of infected tissue and treated with either a glycopeptide, a ﬂuoro-
quinolone or a carbapenem iv for >1 week, were studied. Plasma and
bone specimens were collected intraoperatively for PK and microbiologic
assays at a mean of 4.7 h after antibiotic administration. Antibiotic
concentrations were measured by HPLC-UV method.
Results: Twenty patients (pts) were studied. Five received vancomycin:
bone cultures grew E. Faecalis, MRSA and MRSE; bone concentrations
(mean) were 2.4mg/L in cortical and 7.1mg/L in cancellous bone, with
a bone/plasma extraction of 12% and 36%, respectively.
Five pts were treated with teicoplanin for MRSA infection: bone
concentrations were 3.1mg/L and 7.7mg/L respectively for cortical and
cancellous bone (16% and 39% of plasma levels).
Five pts received a ﬂuoroquinolone for E. coli or Enterobacter spp.
infection. Ciproﬂoxacin concentrations were 1.8mg/L in cortical, and
30.2mg/L in cancellous and newly formed bone (respective bone/plasma
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ratios: 1.06, and 8.4). Levoﬂoxacin concentrations were 0.3 and
2.69mg/L in cortical and cancellous bone, with diffusion rates of 12%
and 108% respectively.
Five pts received a carbapenem. Imipenem diffusion rates were
respectively 7.5% and 58.3% for cortical and cancellous bone (bone
concentrations: 0.09mg/L and 0.7mg/L). Meropenem bone levels were
1.2mg/L and 5.2mg/L in cortical and cancellous bone, with respective
diffusion rates of 3.6% and 15%.
Conclusion: Both vancomycin and teicoplanin provided concentrations
exceeding the MIC of infecting agents and displayed a satisfactory bone
diffusion. Ciproﬂoxacin provided tissutal levels higher than levoﬂoxacin,
and both showed a good bone diffusion; ciproﬂoxacin concentrations
in cancellous bone and in bony callus were far higher than in plasma,
suggesting an accumulation into highly vascularised bone. Imipenem had
higher diffusion rates than meropenem, but bone levels were under the
MIC of susceptible agents. Glicopeptides and ﬂuoroquinolones appear
an excellent option for bone infections, while carbapenems should be
considered a second choice treatment.
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P1386 Successful reduction of the use of intravenous ciproﬂoxacin
using a simple protocol
I. Willemsen, C. van Buitenen, M. Winters, P. van Hattum, J. Kluytmans
(Breda, NL)
Objectives: The objective of this study was to reduce the hospital use
of intravenous (iv) ciproﬂoxacin (CIPR) with 50%.
Methods: This project was performed in a 1,400 bed teaching hospital
including all medical specialities. The intensive care unit was excluded
from the intervention. There were three criteria to qualify patients
for a switch to oral medication. First patients should be able to
take oral medication. Second, no switch was allowed when patients
were haemodynamically unstable (systolic bloodpressure <100mmHg
or pulse >100 beats/min) and third, when patients were given parenteral
nutrition. A pharmacy assistant assessed all iv recipes for a switch to
oral medication. The medical staff of the hospital approved with the
switch protocol. The attending physician was informed when a switch
was possible. In complicated cases and when the pharmacy assistant
considered the switch questionable, the microbiologist was consulted.
The intervention started on January ﬁrst 2006. The use was registered
per month in Prescribed Daily Doses (PDD) CIPR iv therapy.
Results: The use in 2006 between January and October was 623 PDD
of CIPR iv. In 2005 in the same period the use was 1,281 PDD. The
reduction was achieved after one month and stable from that moment
on.
Conclusion: Ten months after the start of the project the aim of
the project, reduction of the CIPR iv medication with 50% has been
achieved. This will result in a net saving of approximately €50.000. This
is conservative estimate of the true savings, as it does not include the
costs associated with giving IV treatment, e.g. the infusion system.
P1387 Is treatment with sulfamethizole before admission
associated with poor outcome in bacteraemia patients? A
Danish population-based cohort study
M. Søgaard, M. Nørgaard, H. Sørensen, H. Schønheyder (Aalborg,
A˚rhus, DK)
Objectives: In contrast to most other countries, sulphamethizole is still
used in Denmark for uncomplicated urinary tract infections. Concern has
been raised that sulphamethizole may be associated with a poor outcome
if the clinical course is complicated by bacteraemia. We compared
the impact of preadmission treatment with either sulphamethizole or
a commonly used alternative, pivmecillinam, on the 30-day mortality
following community-acquired bacteraemia (CAB).
Methods: We conducted a 10-y population-based cohort study in North
Jutland County (1995–2004) based on all patients with a ﬁrst-time
episode of CAB. We obtained data from the County Bacteraemia
Registry, Prescription Database, and Hospital Discharge Registry. All
patients were followed for 30 days after hospitalisation through the
Danish Civil Registration System. We compared cumulative mortality
and mortality rates in patients who did and did not redeem at least
one prescription for sulphamethizole or pivmecillinam within 30-days
before admission and controlled for gender, age, comorbidity, and type
of bacteraemia in a Cox regression analysis.
Results: During the study period we identiﬁed 2,858 eligible patients,
108 (3.8%) and 86 (3%) had redeemed at least one prescription for
sulphamethizole or pivmecillinam, and 11 had redeemed prescriptions
for both. Overall cum. 30-day mortality in patients exposed to
sulphamethizole alone or in combination with other antibiotics was
13.4% and 12.2%, respectively, compared with 16.2% among patients
not exposed to antibiotics [adjusted mortality rate ratios, MRRs, 0.9
(95%CI: 0.5−1.7), and 1.0 (95%CI: 0.4−1.5)]. The corresponding
ﬁgures for patients exposed to pivmecillinam alone or pivmecillinam
and other antibiotics was 15.4% and 8.5%, respectively [adj. MRRs 1.1
(95%CI: 0.4−3.0), and 0.6 (95%CI: 0.2−1.4)].
Conclusion: In this study treatment with either sulphamethizole or
pivmecillinam prior to admission did not inﬂuence 30-day mortality.
P1388 Aminoglycosides, mortality and increase of serum-creatinine
in patients with bacteraemia given appropriate empirical
therapy. A Danish hospital-based cohort study
H. Schønheyder, M. Freundlich, L. Pedersen, H. West, R. Thomsen
(Aalborg, DK)
Objectives: Aminoglycoside (AG)-b-lactam combination therapy has
been discouraged after the appearance of metaanalyses which did not
ﬁnd signiﬁcant advantages compared to b-lactam monotherapy. Whether
this conclusion is valid to all patient groups is questionable and
therefore we examined the association between AG therapy, mortality
and increased serum-creatinine in patients with bacteraemia given
appropriate empirical antibiotic therapy.
Methods: Cohort study based on prospective registration of bacteraemias
1996–2002 at a Danish hospital. AG+b-lactam was the recommended
empirical therapy for severe sepsis. We identiﬁed 1,257 patients, 969
of whom received gentamicin or tobramycin (AG cohort), while 288
patients who were not exposed to AGs formed the non-AG cohort.
We performed Cox regression analysis to compare mortality rates
adjusted for potential confounders including comorbidity; the association
between AG therapy and an increase of serum-creatinine >45mmol/L
was analysed by logistic regression.
Results: The cumulative 30-day mortality in the AG cohort was 17.3%
vs. 18.1% in the non-AG cohort (adjusted mortality rate ratio (MRR)
1.02; 95%CI 0.74–1.39). For patients alive after 30 days the cumulative
mortality 31–180 days after the bacteraemia was 20.3% in the AG cohort
vs. 12.3% in the non-AG cohort (adj. 31–180 day MRR 1.72; 95%CI
1.15–2.55). AG therapy was associated with lower 30-day mortality in
patients with an abdominal focus (adj. 30-day MRR 0.52; 95%CI 0.24–
1.10) or a urinary tract focus (adj. 30-day MRR 0.48; 95%CI 0.22–
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1.08), but with a worse prognosis in patients with a respiratory tract
focus (adj. 30-day MRR 2.06; 95%CI 0.93–4.53). The higher mortality
associated with AG therapy beyond day 30 was observed for all major
foci except for the urinary tract where the MRR was close to one. Serum-
creatinine concentration was available at baseline in 983 (78.2%) patients
and repeated measurements within 14 days in 422. An increase of serum-
creatinine >45mmol/L was observed less often in AG treated patients
(5.9% vs. 15.0%, adjusted OR 0.54; 95%CI 0.26–1.15).
Conclusion: Among patients with bacteraemia given appropriate
empirical therapy, AG therapy was neither associated with increased
30-day mortality nor risk of rising serum-creatinine. AG therapy was
associated with a survival beneﬁt during the ﬁrst weeks of infection
in patients with a urinary tract or an abdominal focus. The long-term
outcome warrants further consideration.
P1389 Mortality risk factors in patients admitted to an emergency
unit with severe infection treated with imipenem
N.R. Berenguer Torrijo, S. Grau Cerrato, J. Mateu-de Antonio, S. Luque
Pardos, O. Ferra´ndez, D. Conde-Este´vez, E. Salas (Barcelona, ES)
Objectives: To assess the mortality risk factors in patients with severe
infections treated empirically with imipenem (IMP) when they were
admitted to an emergency unit (EU).
Methods: Prospective observational study carried out in 104 patients
consecutively admitted in a EU from September 2003 to March 2006 in a
450-bed university hospital. Patients included where those who presented
severe infections at admission and started an empirically antimicrobial
therapy with IMP. For the analysis we selected those patients in which
a positive microbiological culture was further obtained (67 patients).
Simpliﬁed Acute Physiology Score II (SAPS-II) was used to stratify the
severity of patients at admission.
In statistical analysis, Fischer exact Test was employed for dichotomic
variables and “U”Mann-Whitney test for continuous variables. A
regression binary logistic was used to evaluate the risk factors of
mortality.
Results: Isolated microorganisms were susceptible to imipenem in 63
(94%) patients. Statistical differences were not observed when the
infection source was compared (p = 0.466).
Surviving
patients
Deceased
patients
p
No. of patients 59 8
SAPS-II at admission 38.3 (95%CI:
35.05–41.58)
47.4 (95%CI:
39.15–55.60)
0.038
Presence of septic shock 5 (8.5%) 3 (37.5%) 0.048
Multiresistant microorganisms isolated 20 (33.9%) 3 (37.5%) 1.00
Type of multiresistant microorganisms 0.652
EBSLa-producing 9 (45%) 1 (33.3%)
Pseudomonas aeruginosab 2 (10%) 0
Other multiresistant Gram(−)b 7 (35%) 1 (33.3%)
Gram(+) microorganismsc 2 (10%) 1 (33.3%)
Polymicrobial infections 12 (20.3%) 3 (37.5%)
Evaluation of mortality Odds ratio 95%CI p
SAPS-II at admission 1.060 0.997–1.127 0.061
Presence of septic shock 6.480 1.184–35.452 0.031
Multiresistant microorganisms 1.170 0.253–5.401 0.841
aEBSL, extended-spectrum b-lactamase.
bResistant to more than 3 antibiotic families.
cPresence of methicillin or vancomycin resistance.
Conclusions: Died patients presented a higher SAPS-II at admission and
a higher frequency of septic shock. The presence of septic shock was
the only factor associated with mortality when logistic regression was
applied.
Neither the isolation of Gram-positive or Gram-negative microorganisms
nor the presence of multirresistant microorganisms was related with
mortality.
Imipenem showed an appropriate microbiological coverage against most
of the isolated microorganisms, including Gram-negative bacilli and
Gram-positive cocci, even in the presence of multirresistant strains.
P1390 Impact of antibiotic referral and management system on
antibiotic expenditure in a hospital
E. Fleet, G. Gopal Rao (London, UK)
Background: Excessive expenditure on antibiotics is frequently a cause
for concern in many hospitals. Prudent and cost-effective prescribing of
antibiotics is necessary to minimise this expenditure.
Objective: To describe the impact of Antibiotic Referral and Manage-
ment System (ARMS) on antibiotic expenditure in a general hospital.
Methods: ARMS was implemented in 2005/6 to promote prudent and
cost effective prescribing of antibiotics in in-patients in our hospital.
ARMS consists of a series of practical measures used to aid in such
prescribing.
The key measures included in ARMS were:
• Restriction of empirical use of antibiotics not included in the hospital
formulary.
• Screening of all antibiotic prescriptions to identify those that did not
comply with hospital guidelines.
• Referral of non-compliant prescriptions to ‘antibiotic pharmacist’.
• Review of non-compliant prescriptions by antibiotic pharmacist and
medical microbiologist (The Antibiotic Management Team [AMT]).
• Discussion with prescribing doctor and recommendation to change to
appropriate antibiotics in line with patients’ latest laboratory results.
• Monitoring by Ward pharmacists to ensure that changes are
implemented and intravenous antibiotics are switched to oral as per
guidelines.
Financial impact was determined by comparing the antibiotic expenditure
before and after ARMS.
Results and Conclusion: There was €211,000 (16%) reduction in
expenditure compared to previous ﬁnancial year (2004/5). Considerable
reductions were seen in the use of IV antibiotics, cephalosporins, IV
ciproﬂoxacin, teicoplanin and linezolid.
Conclusion: Implementation of ARMS leads to substantial reduction in
expenditure on antibiotics. Review of clinical outcomes is necessary to
reassure clinicians.
P1391 The HARMONY antibiotic policy and process tools and
SWAB collaboration
B. Cookson, J. Prins, J. Kullberg, I. Gyssens (London, UK; Rotterdam,
NL)
Objectives: To assess the applicability of the HARMONY tools for
international education and helping to produce a national prescribing
policy.
Methods: The HARMONY tools were developed by BC interacting with
19 hospitals in the UK. It was an iterative process and much was learnt
about differing opinions on prescribing practices and policy writing. For
example, some were of an enormous size and unlikely to be used, authors
were opposed to changing them and often did not seek comments from
users. In a second HARMONY phase the tools were further progressed
in the EU with 14 experts in antibiotic stewardship in ESCMID ESGAP
and 20 others in UK, Malta and German workshops. We describe here
their further progression at international educational meetings and in the
National Netherlands Antibiotic Policy Group (SWAB). 76 professionals
representing 44 hospital committees were sent the tool. Analysis was
performed before the meeting and results were presented at the SWAB
meeting, which coincided with the ARPAC Consensus meeting.
Results: Parts 1 and III of the tool were found to be particularly helpful
in multi-disciplinary discussions at two International Federation of
Infection Control meetings, national consensus meetings in Malta, Oman
and Dubai. In multi-disciplinary meetings there are issues relating to
stop dates for surgical prophylaxis and treatment, rotating of antibiotics
and switching to less expensive antibiotics, these being common audit
targets.
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The whole tool also informed the design of the ARPAC and ARMed EU
projects.
64% of SWAB participants responded: this is very high considering the
large size of the tool and its orientation for local rather than national
policy design. The tool was found to be very useful in progressing a
consensus: for example 52% of prescribing effectiveness statements, and
70 to 85% of other sections were agreed with. There were interesting
discussions including the use of costing data in a national policy. The
spreadsheet approach and Likert qualitative scales were particularly
successful in facilitating the rapid production of useful results that
enabled further discussions at the meeting.
Conclusion: The HARMONY tools have now matured into a stage
where they should be of use in many other countries including the EU
and further discussions are underway to explore this possibility.
P1392 Effects on quality prescription of a prospective
interventional study based on a restrictive antibiotic policy
F. Jover, J.M. Cuadrado, V. Sa´nchez, V. Ortiz de la Tabla, M. Gonzalez,
R. Martinez, E. Lo´pez-Calleja, C. Martin (Alicante, ES)
Objective: To assess the impact of a programme to evaluate the quality
of an antibiotic restriction policy at an University hospital.
Methods: A multidisciplinary antimicrobial management team (AMT)
composed by Infectious Diseases, Microbiology and Pharmacy members
daily evaluated restricted antibiotic prescriptions. We designed a
prospective study with two periods: observational (October 1st 2003–
March 31th 2004) and interventional (April 1st 2004–February 28th
2006). A speciﬁc prescription formulary aiming to evaluate the
usage of broad spectrum antibiotics was introduced. Revision criteria
were according to ID Comittee guidelines and Sanford Guide to
Antimicrobial Therapy. Clinical, microbiological and pharmaceutical
data were collected from each patient. Antibiotic therapy appropiateness,
restricted therapy elegibility and economic outcomes were evaluated.
During interventional period, antibiotic recommendation prescriptions
were formulated. Statistical analysis with non-parametric tests were
performed. A p value of <0.05 was accepted as signiﬁcant.
Results: 1,212 patients were evaluated (21% observational/79% inter-
ventional period). Overall, restricted agents prescribed were imipenem
(26.1%), ceftazidime (23.5%), piperacilin-tazobactam (15.3%), amikacin
(12.3%), vancomicin (10.6%), cefepime (5%). Most frequent diagnostic
groups were sepsis (36.3%), respiratory (16.2%), prophylaxis (14.6%),
gastrointestinal (14.4%), soft-tissue and bone infections (13.7%) and
UTI (4.9%). Any microbiological sample was taken in 78.8% of
cases. Comparing both periods, adequate prescription of antibiotherapy
increased from 90.7% to 97.3%. Restricted antibiotic prescription
signiﬁcantly improved from 59.4% to 88.5%, while concordance to
AMT prescription increased from 54.8% to 81.1%. We found a
signiﬁcant reduction in DDD/1,000 patients-day in two periods (52.36
vs 46.21: p< 0.05). Other several statistically signiﬁcant diferences in
DDD/1,000 patients-day were detected: decrease in ceftazime (15.3 vs
8.9) and teicoplanin (3.11 vs 0.5). Economic outcomes were signiﬁcantly
reduced. In the interventional period, 329 written recommendations were
formulated (27.1%), while 73% of them were accepted.
Conclusions: The development of prophylactic and therapeutics local
guidelines reached by consensus, and the evaluation and interventional
policy by an AMT group have signiﬁcantly improved the quality and
economical costs of restricted antibiotic prescription in our hospital.
P1393 The evaluation of a ﬂuoroquinolone restriction policy at a
university teaching hospital
A. Hilts, D. Fish, M. Barron (Denver, US)
Objectives: Gram-negative bacterial (GNB) resistance has been asso-
ciated with overuse of ﬂuoroquinolones (FQ). At the University of
Colorado Hospital, increasing resistance in Pseudomonas aeruginosa
has occurred concurrent with increased use of FQs. In 1/2005, FQs
were placed on 100% restriction in an effort to curb resistance, with
approval by an Infectious Diseases (ID) physician or Pharm.D. required
prior to use. The objective of this study was to evaluate the impact
of this restriction policy on FQ use [deﬁned daily doses (DDD)/
1,000 admissions] and appropriateness, patient outcomes, and GNB
resistance.
Methods: Hospital records were used to evaluate FQ use, cost, and
GNB resistance. Randomly selected charts of 139 hospitalised patients
receiving FQs (65 pre- and 74 post-restriction) were reviewed for
indications and appropriateness of FQ use and patient characteristics.
Appropriateness was determined by a consensus panel of 2 ID PharmDs
and 1 ID MD based on indications, pathogen susceptibilities, dose, route
of administration, and availability of other suitable drugs. FQs were also
deemed appropriate if allergies or renal dysfunction made the use of
other agents undesirable. Statistical signiﬁcance was deﬁned as P< 0.05.
Results: Compared to 2004 (pre-restriction), patients receiving FQs
in 2005 (post-restriction) were more often transferred from outside
facilities (P = 0.04), had previously received antimicrobials (P = 0.001),
were treated for hospital-acquired pneumonia (P = 0.01), were infected
with P. aeruginosa or MRSA (P = 0.03), and had history of penicillin
allergy (P = 0.01). FQ use in 2005 was reduced 66% compared to 2004
(64 DDD/1,000 vs. 188 DDD/1,000). Appropriateness of empiric FQ
use was 92% post-restriction vs. 68% pre-restriction (P = 0.0008). FQ
acquisition cost was reduced 60%, a savings of US$151,000. Other
outcomes (length of FQ therapy, hospital length of stay, mortality) were
not signiﬁcantly different. Resistance of P. aeruginosa to FQ decreased
from 49% to 39% (P = 0.02) while susceptibilities of other drug classes
remained stable.
Conclusion: Implementation of a rigorous restriction policy signiﬁcantly
increased appropriateness of FQ use while decreasing overall use, cost,
and P. aeruginosa resistance. Other patient outcomes were unchanged
despite apparently higher-risk patients receiving FQ in the post-
restriction period. Increased FQ susceptibility of P. aeruginosa was
achieved with no adverse effects on susceptibility to other drug classes.
P1394 Therapeutic approach to upper respiratory tract infections
among primary healthcare physicians
W.L. Lukas, L.P. Panasuik, I.S. Szymczyk, J.S. Skorupka (Zabrze, Lublin,
PL)
Objective: Appraisal of factors underming the decision about antibiotic
use.
Methods: 152 Primary Health Care (PHC) physicians (70% of women),
mean age 42y, mean PHC work’s span 12y participated in the
questionnaire-based study, namely: 38 physicians without any specialty
degree, 67 family physicians, 5 general practitioners, 17 internists, 18
paediatricians, 7 other specialits. Subjects were asked about their work-
span in the PHC, area of practising (village, town, city), awareness of
current guidelines on antibiotic usage, previous attending of any training
courses concerning antibiotic-therapy. Two case report questions with
options for further treatment were presented.
Results: As for the factors enhancing antibiotic use of highest
consequence were: clinical picture, previous experience, awareness
of guidelines, while of least were: patients’ claims, pharmaceutical
companies’ suggestions, consultation with specialists. Acute upper
respiratory tract infections (URI) was found to be an indication for
antibiotic-therapy in 46% of repondents (only 26% considered viral
aetiology) while its purulent stage did in 92%. Gender, work span
in PHC, previous attending of training courses did not affected the
therapeutic decision signiﬁcantly. Physicians under 40 administered
antibiotics at the purulent stage rarely, were more adherent to guidelines
and attentive to patients’ demands. Rural doctors prescribed antibiotics
for URIs signiﬁcantly more frequently than those from urban areas.
Comparing to colleaques without any specialty degree family physicians
showed less regard to recommendations and consultations and aimed at
optimal duration of therapy.
Conclusions: Despite the introduction of relevant recommendations
(2003) and common participation in training courses, vast majority of
PHC physicians proved not to adhere to current guidelines.
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P1395 Controlling costs in the intensive care unit: role of daily
microbiology rounds
A. Kothari, V. Sagar, B. Panigrahi, N. Selot, A. Bhan (New Delhi, IN)
Objective: Spiralling costs of procedures and drugs have led to an
increasing emphasis on controlling costs in hospitals, with a special focus
towards ICUs. Historically, antimicrobial control policies have been used
to control costs, with a side beneﬁt of reduced selective pressure and thus
less antimicrobial resistance.
We did a retrospective analysis looking at the impact of daily clinical
microbiology bedside rounds in our cardiothoracic surgical ICU on
antibiotic consumption patterns of expensive, broad spectrum agents.
Methods: Data regarding usage of antimicrobial agents before (Jan–
Feb 2005) and after (Mar–Dec 2005) the introduction of clinical
microbiology rounds was analysed. Deﬁned daily doses (DDD) per
1,000 patient bed days was calculated for carbapenems, antipseudomonal
penicillins, glycopeptides, and 3rd generation cephalosporins using the
National Nosocomial Infection Surveillance deﬁnitions. Drug acquisition
costs of these antibiotics were used to calculate antibiotic cost (in USD)
per patient day in the ICU. The statistical signiﬁcance of the difference
between the 2 groups was calculated using the unpaired t-test.
Results: The DDD per 1,000 patient bed days in the period before the
introduction of clinical microbiology rounds was 146.4 for carbapenems,
308.1 for antipseudomonal penicillins, 127.8 for glycopeptides and 235.2
for 3rd generation cephalosporins. After the introduction of clinical
microbiology rounds, the DDD per 1,000 patient bed days was 35.6
(p = 0.0153) for carbapenems, 150.9 (p = 0.0137) for antipseudomonal
penicillins, 140.4 (p = 0.78) for glycopeptides and 119.5 (p = 0.3) for 3rd
generation cephalosporins. The antibiotic cost per patient day reduced
from 48.5 USD before introduction of clinical microbiology rounds
to 20.6 USD in the subsequent period (p = 0.0023). Sepsis associated
morbidity and mortality did not change during the same period.
Antibiotic cost in USD per patient day in Cardiothoracic ICU.
Conclusions: There was a signiﬁcant decrease in the costs associated
with antibiotic usage after the introduction of clinical microbiology
rounds in the ICU. Our experience, which is a novel experiment in
India, showed that daily clinical microbiology bedside rounds helped
in optimising antibiotic therapy of patients, reducing the cost of therapy
with no adverse impact on morbidity and mortality from sepsis in the
same period.
P1396 Impact of an infectious disease service on the quality of the
management of infections and the usage of antimicrobials
S. Lemmen, S. Koch, F. Huenger, H. Haefner (Aachen, DE)
Objective: The aim of the study was to evaluate the impact of
an infectious-disease consult service on the quality of medical care
especially concerning the usage of antimicrobials in mainly severe
infections.
Method: From January till June 2006 1,000 consults were documented
by 4 infectious-disease specialists at the University Hospital Aachen,
Germany with an elaborated standardised questionaire. Since 1997 the
infectious disease service is implemented and written guidelines for the
usage of antibiotics exist.
Results: 92% of the consults were performed at 7 different ICUs and
8% at normal wards, respectively. In 78% the consult was performed
during the routine weekly infectious disease ward round together with
the attending physicians; 15% were telephone consults; and in 7% the ID
specialist was called. The locations of the infections were as follows: 310
respiratory tract, 201 sepsis, 101 S-ST, 83 endocarditis, 60 abdominal,
35 CNS, 33 each urogenital and bone and joint. In 201 cases there was
no obvious infection diagnosed and in 117 patients there was deﬁnitely
no infection present.
In 430 consults additional microbiological work up and in 170 further
diagnostic procedures (e.g. ultrasound, echo, endoscopy or radiology)
were recommended, respectively. In 49 patients antimicrobials were
started due to the advice of the ID specialist, however in 50 cases the
physician could be convinced not to start any antimicrobials.
In 837 patients antimicrobials were already administered at the time of
the consult; in 336 cases the therapy was considered adequate. However
in 501 cases interventions were performed: 134× stopping of the therapy,
129× deescalation to monotherapy, 60× decrease and 71× increase
of the antimicrobial spectrum, 60× decrease and 21× increase of the
duration, and 10× increase and 16× decrease of the dosage.
It could be calculated that a total of 3,500 antibiotic days were not given
in comparison to if no intervention had happened. According to the data
of our pharmacy the average cost for one antibiotic day is 45€, thus a
total of 157,500€ could be saved.
Conclusion: This study documents that an infectious-disease service had
an impact on the quality of medical care by suggesting further diagnostic
procedures and reducing the usage of antimicrobials. Since antibiotics
are a major driver for bacterial resistance, their limited administration is
necessary. The saving outweighs by far the expenses for the personnel
and the recommended diagnostic.
P1397 The economical impact of new anti-infective drugs on the
drug budget of a surgical intensive care unit
T. Hoppe-Tichy, M.A. Weigand (Heidelberg, DE)
Background: New antiinfective drugs are usually expensive. In many
cases the new antiinfectives will replace older and cheaper drugs.
We studied antiinfective drug consumption in a surgical ICU with 14
beds to show the impact of new antiinfectives on the overall drug
costs and to show the changes in consumption of deﬁned daily doses
(DDD; according to the WHO ATC/DDD methodology), costs and costs
per DDD in the years 2000 to 2005 regarding different ATC classes,
respectively.
Methods: Antiinfective drug consumption data were taken from the
pharmacy ﬁles. New antiinfective drugs were deﬁned as Tigecycline
(ﬁrst appearance in hospital: 2005), Ertapenem (2005), Synercid (2000),
Linezolid (2001), Voriconazole (2003) and Caspofungin (2002). Changes
in consumptions were calculated on the basis of data for 2000.
Results: There is an increase in overall drug costs in the ICU of 140%
(years 2000 to 2005). The costs of antiinfective therapy increased by
570%. More than 50% of the additional costs were due to antifungal
drug therapy. In contrast numbers of DDD only increased slightly to
44%. The rate in costs for new antiinfectives within all antiinfectives
rose from 16 to 45%, the rate in DDD only from 0 to 16%. The cost of
DDD of new antibiotics is 4 times higher, of new antifungals 20 times
higher than the old drugs in those groups. The use of new antiinfectives is
highly connected to the length of stay in the ICU (Regression coefﬁcient:
0.977).
Conclusion: New antiinfective drugs are responsible for disproporti-
nately higher costs in the ICU setting due to the high costs of DDD.
Primarily, the pricing for new antibiotics is based upon the cost
of DDD for Linezolid and for the new antifungals to Caspofungin.
Within the group of antiinfectives the new antifungal agents are the
primary cost drivers. Therefore new antiinfective drugs should be
controlled by methods such as patient based prescribing, counselling
by multidisciplinary antibiotic management teams, restricted prescribing
or written recommendations. Length of stay is associated with the use
of new antiinfectives in our surgery ICU.
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P1398 The impact of empiric antimicrobial treatment and the
clinical microbiological guidance in sepsis
U.S. Jensen, D.L. Monnet, N. Frimodt-Møller, J.D. Knudsen
(Copenhagen, DK)
Objectives: The recommendations for antibiotic therapy are based on
local ﬁndings of microorganisms and the resistance patterns found.
The recommendations for empiric sepsis treatments are of especial
importance for the outcome and of patients. The recommended empiric
treatment for community-acquired sepsis with undocumented focus is
cefuroxime, usually 1.5 g tid, together with gentamicin 3−5mg/kg od
(for max three days), and metronidazole 500mg tid if an abdominal
focus is suspected.
Evaluation of the coverage of the recommended empiric treatment
and the impact of microbiological guidance is sought by continuous
electronic registration.
Materials and Methods: The ﬁndings in blood cultures at a centralised
clinical microbiology laboratory serving 2,500 beds in 5 somatic
hospitals in Copenhagen were electronically recorded together with
information regarding the signs and symptoms and the treatment
guidance given by the clinical microbiological consultants, in a new
electronic recording system from January 2006. Only cases of sepsis with
ﬁndings of signiﬁcant microorganisms were included, and cases with
coagulase negative staphylococci, Corynebacteria, and other possible
less important ﬁndings were excluded. Only one episode per patient
was included.
Results: In the six month period, Jan–Jun 2006, the ﬁndings of a total
of 582 sepsis patients were considered signiﬁcant, and the electronic
records were evaluated for 362 (70%) of these patients. The overall
30 days mortality was 18%, varying from 62% for fungaemia, and
8% for pneumococcus sepsis, respectively. Escherichia coli was the
most frequent ﬁnding, in 39% of all cases, followed by Staphylococcus
aureus in 10% and Pneumococcus in 9%. Among the E. coli, 98% were
fully susceptible to cefur, 5% of the Pneumococci were intermediate
susceptible to penicillin, and all S. aureus were MSSAs. Cefur alone
covered 77% of the blood culture ﬁndings. The guidance by the
consulting microbiologist modiﬁed the treatments if necessary, in almost
all cases within two days after the blood cultures were drawn. The
group of patients (N = 277) with bacteria in blood cultures susceptible
for cefuroxime had a signiﬁcantly better outcome with 30 days mortality
of 16% compared to patients (N = 64) with bacteria not susceptible to
cefur (Fisher’s exact test, p = 0.03).
Conclusions: The coverage of the empiric antimicrobial treatment was
sufﬁcient and clinical microbiological guidance had a major impact on
the outcome of bacteraemia.
P1399 Cost-effectiveness of ertapenem vs. piperacillin/tazobactam
in the treatment of diabetic foot infections in the United
Kingdom accounting for development of antibiotic resistance
J. Jansen, R. Kumar, Y. Carmeli (Houten, NL; Whitehouse Station,
US; Tel Aviv, IL)
Objective: Increased antibiotic use is associated with a greater likelihood
of reduced effectiveness due to resistance development in the future. The
objective of this study was to evaluate the cost-effectiveness of ertapenem
versus piperacillin/tazobactam in the treatment of diabetic foot infections
in the UK, accounting for development of antibiotic resistance over time.
Methods: A decision tree model was developed to estimate the cost-
effectiveness of ertapenem vs piperacillin/tazobactam at different time
points following introduction of treatment. Development of antibiotic
resistance was incorporated in the analysis using a previously published
compartment (SIS) model (Laxminarayan and Brown et al., 2000).
The development of resistance was a function of the eradication rate
of pathogens and prescription of the antibiotic. The microbiological
eradication rate and clinical success rates were assumed to be related
and were obtained from the SIDESTEP study (Lipsky et al., 2005).
These data included the impact of resistant pathogens (either acquired or
intrinsic resistance) such as Enterobacteriaceae, MRSA, enterococci and
P. aeruginosa. Model outcomes over time included quality-adjusted life
years (QALYs), direct medical costs and cost per QALY saved. Clinical
efﬁcacy of second-line treatment, direct medical costs, and utilities were
derived from other existing studies. Probabilistic sensitivity analyses
were undertaken to estimate the uncertainty of model outcomes.
Results: The model suggested savings of £406 (95% uncertainty interval
£−381; £1,468) per patient when diabetic foot infections are treated with
ertapenem instead of piperacillin/tazobactam. Probabilistic sensitivity
analysis found a 93% probability of the incremental cost per QALY
saved being within £20,000. After 3 years, it is expected that the
antibiotic resistance proﬁle with piperacillin/tazobactam has increased
with a greater rate than with ertapenem. As a result, the cost-savings
with ertapenem are expected to increase to £2,694 (£1,856–3,616), and
ertapenem will additionally result in greater clinical success rates and
QALY savings (0.90; 0.34–1.58).
Conclusion: Ertapenem appears to be an economically dominant therapy
over piperacillin/tazobactam for the treatment of patients with diabetic
foot infections in the UK.
P1400 Pharmaco-economic impact accounting for future resistance
of ertapenam vs. piperacillin/tazobactam in the treatment
of community-acquired complicated intra-abdominal
infections in the Netherlands
J. Jansen, R. Kumar, Y. Carmeli (Houten, NL; Whitehouse Station,
US; Tel Aviv, IL)
Objective: Ertapenam and piperacillin/tazobactam are commonly used
in the treatment of complicated intra-abdominal infections. However,
increased antibiotic use is associated with a greater likelihood of
resistance development. The objective of this study was to evaluate
the cost-effectiveness of ertapenem versus piperacillin/tazobactam
accounting for development of antibiotic resistance using treatment costs
from the Dutch setting.
Methods: A decision tree model was developed to estimate the cost-
effectiveness of ertapenem vs piperacillin/tazobactam. Development of
resistance was incorporated in the analysis using a previously published
compartment model (Laxminarayan and Brown et al., 2000). Resistance
was a function of the eradication rate of pathogens and prescription of the
antibiotic. Model outcomes over time included quality-adjusted life years
(QALYs), direct medical costs and cost per QALY saved. Microbiological
eradication rate, clinical success rates of ﬁrst and second line treatment,
direct medical costs, and utilities were derived from the literature.
These included pathogens intrinsically resistant to ertapenam such as
enterococci and P. aeruginosa, and those with intrinsic or acquired
resistance to piperacillin/tazobactam. Probabilistic sensitivity analyses
were undertaken to estimate the uncertainty of the model outcomes.
Results: The model suggested overall savings of €355 (95% uncertainty
interval €−501; €1,189) per patient when abdominal infections are
treated with ertapenem instead of piperacillin/tazobactam. These results
were derived based on including ﬁrst line treatment (ertapenam or
piperacillin/tazobactam) and switches in therapy for resistant pathogens.
Probabilistic sensitivity analysis found a 94% probability of the
incremental cost per QALY saved being within the generally accepted
threshold for cost-effectiveness (€20,000). After 5 years, it is expected
that the antibiotic resistance with piperacillin/tazobactam has increased
with a greater rate than with ertapenem. As a result, the cost-savings
with ertapenem are expected to increase to €430 (€−286; €1129), and
ertapenem will result in greater clinical success rates and QALY savings
(0.12; 0.04–0.24).
Conclusion: Given the underlying assumptions and data, ertapenem is
an economically dominant therapy over piperacillin/tazobactam for the
treatment of community acquired complicated abdominal infections in
the Netherlands.
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P1401 Pharmaeconomics of aspergillosis after liver
transplantation: a descriptive evaluation
M. Rosenhagen, R. Feldhues, H.K. Geiss, T. Hoppe-Tichy (Heidelberg,
DE)
Objectives: Invasive aspergillosis (IA) causes signiﬁcant morbidity and
mortality. New antifungal agents have been introduced which improve
the management of invasive fungal infections. But therapy of IA is still
associated with poor outcome and extremely high costs.
We evaluated the costs associated with cases of IA in patients undergoing
liver transplantation in a university hospital.
Methods: According to a retrospective investigation of all liver
transplant patients (Dec 01 to Dec 04) in the transplantation unit of the
University of Heidelberg, Germany, patients developing IA were pair
wise matched with controls on the basis of SAPS II and age.
IA was classiﬁed in accordance with EORTC/MSG criteria. The
economic impact of antiinfective treatment was assessed taking into
account the prices of deﬁned daily doses (DDD). Prices were taken from
the hospital formulary.
Results: A total of 195 liver transplantations were performed on 170
patients. 14 patients developed IA (8.2%). One patient was excluded
from economic analysis due to poor documentation. The mortality rate
for patients with IA (n = 13) and matched controls (n = 46) were 92.8%
and 19.2%, respectively (p = 0.001). There was no signiﬁcant difference
between the age and SAPS II score of cases and controls.
The mean costs of antifungal plus antibacterial treatment in patient with
IA was 19.006 € vs 1.136 € in the control group, with an average increase
of 59% per patient.
In two patients IA was proven. The costs of these patients were 49.692
€ and 10.759 €, respectively (controls: 454 €/2.324 €). The criteria
for probable IA were fulﬁlled by six patients, recieving medication for
€8,486 on average (controls: €1,844). The percentage of antifungal drugs
in patients with proven and probable IA mostly exceeded 70%.
Conclusions: IA is associated with increased use of antibiotic and
antifungal drugs which invoke high costs. Considering this data the
primary focus should be the prevention of IA in high risk patients.
Techniques in molecular bacteriology
P1402 Comparison of two commercial multiplex and two
commercial single PCR Kits for detection of atypical
pathogens causing pneumonia
V. Ursic, J. Stokic, V. Tomic (Golnik, SI)
Objectives: Atypical bacterial pathogens Mycoplasma pneumoniae,
Chlamydophila pneumoniae, Legionella pneumophila cause lower
respiratory tract infections (LRTI) and the rate of atypical LRTI is
probably underestimated due to detection difﬁculties. In our study the
presence of these pathogens was investigated in patients with clinical
symptoms of atypical pneumonia, by single PCR kits (Onar® Ls and
Venor® Mp kits, Minerva Biolabs, Germany, GeneKam Biotechnology
AG, Germany) and multiplex PCR kits (Pnemoplex, Prodesse Inc., USA
and Chlamylege, Argene Inc., France).
Methods: We collected 250 sputum samples and throat swab specimens
and used three single and two multiplex PCR kits available commercially
for detection. QIAamp® DNA Mini Kit (QIAGEN, Hilden, Germany)
was used to extract DNA and was performed as recommended by the
manufacturer. PCR was performed with conventional cycler (Biometra
T3000, Biometra, Germany), PCR products were detected by standard
agarose gel electrophoresis (single PCR kits) or by hybridisation in
microtiter plate (multiplex PCR kits). Every specimen was analysed in
parallel with two different kits. For analysis and evaluation, each testing
method was considered a separate experiment.
Results: 135 sputum samples (54%) and 115 throat swab specimens
(46%) were tested prospectively for the presence of the DNA of
C. pneumoniae, M. pneumoniae and Legionella spp. The overall
agreement between the four tests was 100%. Negative samples showed no
inhibition. No discrepancies were found. Since Pneumoplex assay allows
detection of the DNA of Bordetella pertussis, screening for the presence
of the DNA of that pathogen was performed, as well. 32 samples
(12.8%) were positive for at least one pathogen and 218 (87.2%) samples
were negative. Among positive, 17 (53.1%) were sputum sample, 15
(46.9%) were throat swabs. 20 (62.5%) samples showed presence of
M. pneumoniae, 6 (18.8%) showed presence of Legionella spp., 6
(18.8%) were positive for B. pertussis. No specimen showed presence of
C. pneumoniae. Serological data wasn’t avaible for all patients.
Conclusion: Multiplex PCR offers a rapid, sensitive, and easy method
to simultaneously detect several atypical bacterial pathogens, while with
single PCR we detect only one causative microbial agent. Furthermore,
in our hands Pneumoplex multiplex assay proved to be faster and less
labour intensive than Clamylege multiplex assay.
P1403 Extended evalution of the NucliSens easyMAG sytem
(BioMe´rieux) for automated extraction of microbiological
DNA/RNA
K. Beuselinck, E. Verschueren, J. Van Eldere (Leuven, BE)
Objective: Nucleic acid (NA) extraction is the most critical and labour-
intensive step in NA based diagnostics. Performance of NA based
diagnostics is primarily dependent on NA extraction yield, purity and the
amount of sample that can be extracted. Recently, BioMe´rieux introduced
the Nuclisens easyMAG, an automated extraction system with magnetic
micro-particle processing allowing extraction of up to 24 samples in
1 hour.
Methods: Performance of the easyMAG as a front-end extraction system
for our ‘in-house’ Taqman PCR assays (HSV-1, HSV-2, VZV, CMV,
EBV, enterovirus, polyomavirus, Toxoplasma gondii, Chlamydophila
pneumoniae, Mycoplasma pneumoniae, Legionella pneumophila and
Pneumocystis jirovecii) was analysed and compared to manual Qiagen
extraction for the following sample matrices: cerebrospinal ﬂuid,
amniotic ﬂuid, phosphate buffer (swabs), plasma and bronchoalveolair
lavage samples.
Results: Dilution series of the evaluated micro-organisms were spiked
in the appropriate sample matrices and divided into two aliquots. One
aliquot was manually extracted with QIAamp Viral RNA kit (enterovirus)
or QIAamp DNA Mini kit (all other organisms) simultaneously with
automated extraction of the other aliquot with the generic protocol on the
easyMAG. Of 38 dilutions, 10 aliquots were made to test reproducibility
of both extraction methods on 5 different days. Out of 424 duplicate
extractions, 289 were positive and 113 negative for both extractions
(94.8% concordance). 22 discrepant results all had one weak positive
result close to the detection limit of the PCR with 4 manual extractions
leading to a false positive result. The correlation coefﬁcient between
automated and manual extraction was 0.98; the mean difference in cycle
treshold (Ct) was + 0.08 Ct for the easyMAG. The mean variability with
5 repeats for the 38 dilutions was 0.50 Ct (SD: 0.38 Ct) for easyMAG and
0.57 Ct (SD: 0.55 Ct) for manual extraction. No cross-contamination was
observed with easyMAG when strongly positive polyomavirus samples
(15.4 Ct) and polyomavirus negative samples were tested. Turn-around
time on easyMAG for 24 samples was one hour and hands-on time was
15 minutes compared to 95 minutes for manual extraction. The reduced
hands-on time partially compensates the higher easyMAG reagents list
price.
Conclusion: Automated easyMAG extraction offers NA yield similar
to manual Qiagen extraction with reduced cross-contamination risk and
reduced hands-on time.
P1404 A semi-automated procedure for monitoring of
cytomegalovirus
V. To¨rma¨nen, J. Prieto, N. Finnstro¨m, B. Jansson (Bromma, SE)
Objectives: Monitoring of cytomegalovirus (CMV) in transplanted and
other immunocompromised patients can efﬁciently be performed using
molecular diagnostics based on real-time PCR, such as the CE-labelled
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afﬁgene® CMV trender assay (Sangtec, Bromma, Sweden). In high
throughput laboratories it is not always possible or convenient to use
manual sample preparation systems for the analysis of large amount of
samples. Today, there are a number of automated sample preparation
systems on the market. An interesting instrument for automated sample
preparation is the easyMAG from Biome´rieux (Lyon, France) which
is CE-labelled for in-vitro diagnostic use. The aim of this study is to
evaluate the easyMAG instrument in combination with afﬁgene® CMV
trender.
Methods: The parameters limit of detection (LOD) and quantitative
range were determined using the AD169 strain from the well recognized
VQC (Acrometrix, The Netherlands). The strain was diluted to different
concentrations in human plasma.
For LOD ﬁve different levels of CMV in the range from 5 c/mL to 100
c/mL were prepared and ampliﬁed in each of 24 replicates. The probit
statistical analysis was used for determination of LOD. For quantitative
range six different levels of CMV, in the range from 100 c/mL to
2×107 c/mL were prepared and ampliﬁed in twelve replicates. The
imprecision was determined by repeating four replicates at two different
CMV levels on three consecutive runs.
For each preparation 500 microliter of plasma sample was used and the
elution volume was 60 microliter.
Results: As determined using probit analysis the LOD of the semi-
automated system was 57 c/mL (conﬁdence interval 36–134 c/mL). The
quantitative range of the system is from at least 100 c/mL to 2×107 c/mL
with a total imprecision of less than 0.2 log standard deviation.
Conclusions: Automation of sample preparation, using the easyMAG
instrument, in combination with the standardised afﬁgene® CMV trender
PCR assay is an attractive option for quick CMV monitoring in
laboratories requiring high throughput.
P1405 Unique pre-analytic tool for microbial diagnosis
S. Sachse, K.H. Schmidt, M. Lehmann, H.P. Deigner, S. Russwurm,
E. Straube (Jena, DE)
Objectives: Speed is the essence when evaluating a patient with
symptoms consistent with sepsis. Because of the high morbidity and
mortality associated with sepsis, patients receive multiple, broad-
spectrum antibiotics before receiving ﬁnalised blood culture results.
Rapid assay to detect bacteria directly from Blood would facilitate timely
diagnosis and appropriate care.
That is why culture independent pathogen detection methods become
increasingly interesting. However, suitable methods for DNA isolation is
direfully important precondition for further nucleic acid-based detection
(NA) methods. DNA samples can show reduced sensitivity due to very
low amounts of bacterial DNA compared to the human DNA background
as well as inhibitors like hemin or immunoglobulin. Therefore, an
improvement of NA methods can be achieved by an innovative sample
preparation procedure, which reduce the human DNA background
signiﬁcantly and enrich the bacterial DNA simultaneously as well as
inhibitors are removed.
Methods: A recombinant protein with speciﬁc binding afﬁnity for
prokaryotic DNA is the keystone of our innovative and easy-to-use
sample preparation method. To validate the properties of this protein,
we performed classical gel retardation, radioactive experiment, classical
as well as real time PCR experiments using artiﬁcial DNA mixtures
containing pro- and eukaryotic DNA as well as spiked blood samples.
Results: Our experiments showed that prokaryotic DNA is speciﬁcally
retained by the described protein. The protein can be immobilised to
matrices and transferred to spin columns for enrichment experiments.
The DNA preparation procedure using such columns enables a change
of the eukaryotic–prokaryotic DNA ratio in favour for the bacterial DNA.
Furthermore, by means of radioactive and real time PCR experiments,
it could be shown that the application of this procedure decreases
the background of human DNA signiﬁcantly, leading to an increased
sensitivity of the PCR methods for bacterial detection in blood samples.
Conclusion: The proposed unique pre-analytic method improves NA
methods for the detection of small amounts of bacterial DNA in complex
samples (e.g. human whole blood), by a signiﬁcant reduction of the
eukaryotic DNA background. This might be a milestone allowing “same
day diagnosis” of sepsis and SIRS as well.
P1406 Direct detection of bacterial DNA in clinical samples;
evaluating a 4 12 year period of sample collection and analysis
K.R. van Slochteren, E. van Zanten, G.J. Wisselink, R.F. de Boer,
T. Schuurman, A.M.D. Kooistra-Smid (Groningen, NL)
Objective: Four and a half years ago the department of Research and
Development (R&D) of the Laboratory for Infectious Diseases (LvI)
started to analyse direct clinical specimens on request for the presence
of bacterial DNA.
This study shows an evaluation of 4 12 years of detecting bacterial DNA
in direct clinical specimens.
Methods: During the last 4 12 years 480 specimens (that contain no
bacteria in healthy individuals) were send to the LvI with suspicion
of bacterial involvement, where culturing bacteria was not possible or
unlikely to yield results, e.g. because antibiotic treatment had already
commenced.
Putative bacterial DNA was isolated from these samples by means of
mechanical disruption of cells followed by a Boom extraction. If the
specimen consisted of tissue it was ﬁrst digested in order to form a
cell homogenate. A PCR was performed on these samples to detect the
presence of bacterial DNA coding for 16S ribosomal RNA. Positive PCR
products were subsequently sequenced to determine which organism was
present in the clinical specimen. (ref. T. Schuurman et al., JCM 42;2,
2004, p734)
Results: Of these 480 specimens 101 were found to contain a single
bacterial species. In 351 specimens no bacterial DNA was found. In the
remaining 28 specimens a single bacterial micro-organism could not be
identiﬁed either because of the presence of more than 1 strain in which
case sequencing yields an uninterpretable signal, or the PCR remained
negative due to inhibiting factors in the specimen.
Specimens had a wide variety of origins but 67% of requests pertained
to only 4 biological locations: joints 25%, blood 19%, central nervous
system 16% and lung 7%. From these organs came 62% of the positive
results with a single bacterial strain. None of the specimen types from
the different organs submitted for bacterial DNA detection produced only
negative results.
Many different species were found: the identiﬁed strains belonged to 30
different known genera. Streptococci were found by far the most: Of the
positive specimens 33% contained streptococci, whereas the next most
frequently found genus was Bacteroides with only 7% of all positive
results.
Conclusion: Even though the number of positives isolated from various
biological sites differs, every organ could yield a positive result.
Therefore in cases where bacterial infection of normally sterile biological
sites is suspected, determining whether bacterial DNA is present provides
useful information.
P1407 Cultivation versus PCR analysis of joint ﬂuid samples in
prosthetic joint infection
J. Gallo, M. Kolar, D. Koukalova, P. Sauer, Y. Loveckova,
J. Zapletalova (Olomouc, CZ)
Objectives: Successful treatment of prosthetic joint infection (PJI)
requires correct diagnosis, preferably established presurgically. At this
time, aspiration of joint ﬂuid is easily performed and for this reason
widely practised. The goal of this study was to evaluate the role of
cultivation and PCR in joint ﬂuid analysis.
Methods: Joint ﬂuid samples (JFS) were obtained as a part of a
prospective study of 115 failed total joint arthroplasties between January
2003 and June 2005. Of these 49 were considered to be PJI according
to strictly fulﬁlled inclusion criteria. The PCR assay aimed at 16S rRNA
was performed in 35 PJI and 66 controls while cultivation of JFS was
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done in 46 PJI and 48 controls. Standard techniques were used for
microbial identiﬁcations of pathogen.
Results: PCR was positive in 71% of PJI cases (25/35) and in 2
controls (3%). Cultivation of JFS was positive in 44% of investigated
PJI (20/46) while the false positive rate was 6% (3/48). A signiﬁcantly
higher sensitivity, accuracy and negative predictive value was calculated
for PCR analysis of JFS compared to cultivation of JFS (p = 0.014,
p = 0.0014, and p = 0.0016). In 42 cases (85.7%), infectious pathogens
were identiﬁed by cultivation of intraoperative samples. Coagulase-
negative staphylococci and Staphylococcus aureus strains were proved
to be aetiologic agents in 62% of all strains. The concordance between
PCR and intraoperative cultivation methods with regard to identiﬁcation
of causative pathogens could be evaluated in 23 patients. In 19 cases
(82.6%) the same bacteria was reported by the methods under study
at the species-level whereas in 4 patients the results from PCR and
cultivation assays were different.
Conclusion: In this study we found a very low sensitivity of joint ﬂuid
cultivation in contrast to PCR analysis based on detection of 16S rDNA
in the same material. Furthermore, PCR was more accurate and had
much higher negative predictive value and likelihood ratio for positive
result. For this reason, the PCR protocol must be regarded as progress.
In addition, more than 80% of PJI pathogens were correctly identiﬁed
by means of PCR detection.
The study was supported by the Internal Grant Agency of the Czech
Ministry of Health projects No. NR/9065−3.
P1408 Demonstration of the application of the tmRNA transcript
of the bacterial ssrA gene as a molecular diagnostic target
using a combination of NASBA and BiaCore technologies
B. Glynn, K. Lacey, P. Palta, L. Kaplinski, M. Remm, T. Barry,
T. Smith, M. Maher (Galway, IE; Tartu, EE)
Objectives: The tmRNA transcript of the bacterial ssrA gene exhibits
several properties that make it suitable as a molecular target in Nucleic
Acid Diagnostics (NAD). Sequence homology at the 5′ and 3′ ends
of the gene facilitate universal PCR ampliﬁcation for characterisation
of tmRNA from different species, while sequence heterogeneity in the
internal portions of the gene enable the design of oligonucleotide probes
to identify bacteria at genus and species level. We have previously
demonstrated that tmRNA is present at approximately 1,000 copies/cfu
in a range of pathogens. The natural ampliﬁcation of this target has the
potential to improve the detection capability of an NAD test.
The objective of this study was to demonstrate the utility of tmRNA as
a molecular diagnostic target using a combination of BiaCore biosensor
and Nucleic Acid Sequence Based Ampliﬁcation (NASBA) technologies.
Streptococcus pneumoniae was chosen as a model organism for these
evaluations.
S. pneumoniae is a leading cause of morbidity and mortality worldwide.
Infants and young children are most at risk, presenting with meningitis,
pneumonia, bacteraemia, and other infections.
Methods: The ssrA gene was sequenced in geographically distinct
S. pneumoniae strains and in related species of the streptococcus genus
and other bacterial species that may be present in the same clinical
environment as S. pneumoniae. Species-speciﬁc probes were designed by
sequence alignment and by the SLICsel bioinformatics software package.
Initial evaluation of probe speciﬁcity was performed on microarrays
using ﬂuorescently labelled in vitro transcribed cRNAs. Selected probes
were immobilised onto Biacore sensor chips and further evaluated using
a series of unlabelled tmRNA containing targets including; cRNA, total
RNA, and NASBA products.
Results: Using selected S. pneumoniae speciﬁc probes, 1012 cRNA
copies of the tmRNA target were detected on the BiaCore. It was not
possible to detect tmRNA from total S. pneumoniae RNA using this
system. Inclusion of a NASBA step enabled BiaCore detection of a
single S. pneumoniae cell. Speciﬁcity was demonstrated using NASBA
products from a panel of clinically relevant bacteria.
Conclusion: We have demonstrated that the tmRNA transcript of the
ssrA gene in S. pneumoniae is suitable for use as a molecular diagnostic
target. Application of a combination of NASBA and BiaCore biosensor
technologies enabled speciﬁc detection of a single S. pneumoniae cell.
P1409 PCR of the 16S rRNA gene and DNA sequencing in
establishing the aetiology of bacterial infections in children
A. Gleesen, C. Grarup (Copenhagen, DK)
Objectives: Bacterial infections are common in children and an exact
microbiological diagnosis is crucial for speciﬁc antimicrobial treatment,
especially in serious cases. Standard culture of clinical specimens may
not always result in determination of the aetiological organism. In these
cases PCR of bacterial DNA has shown to be an excellent supplement
to culture. As the literature on the use of molecular diagnostics of
bacterial infections in individuals of young age is sparse, we found it
relevant to review results of samples from this population, obtained in
our laboratory.
Methods: The samples were examined using the QIAamp DNA Mini
Kit and the Quantitect SYBR Green kit. Samples were tested in real-time
PCR. Both DNA strands of the amplicons were sequenced using BSF-8
and BSR-534 as sequencing primers and the BigDye v.3.1 sequencing
kit. Data were compared using the BLAST search engine to deposited
sequences in the NCBI database.
Table 1. Bacterial identiﬁcation of the 20 samples positive by PCR
ID Age Specimen Clinical tentative
diagnosis
Bacterial
identifcation
1 11 years Pus Osteomyelitis GAS
2 13 years Joint ﬂuid Coxitis GAS
3 19 months Pus from a lymph node Not speciﬁed GAS
4 2 years Joint ﬂuid Coxitis GAS
5 20 days Joint ﬂuid Coxitis S. agalactiae
6 8 years Biopsy, brain Not speciﬁed S. intermedius
7 2 years Spinal ﬂuid Not speciﬁed S. pneumoniae
8 15 years Spinal ﬂuid Meningitis S. pneumoniae
9 37 days Inoculation from eye Not speciﬁed S. pneumoniae
10 9 months Joint ﬂuid Septic arthritis K. kingae
11 3 years Spinal ﬂuid Not available N. meningitidis
12 9 years Biopsy, lymph node Tularaemia F. tularensis
13 4 years Pus Abscess F. necrophorum
14 8 years Joint ﬂuid Septic arthritis P. acnes
15 10 years Spinal ﬂuid Not available P. acnes
16a 7 months Joint ﬂuid Septic arthritis P. acnes
16b 7 months Joint ﬂuid Septic coxarthritis Polymicrobial
17a 10 years Pus, Femur Ewings sarcoma, ostitis Polymicrobial
17b 10 years Biopsy, Femur Ewings sarcoma, ostitis Polymicrobial
18 12 months Spinal ﬂuid Meningitis Polymicrobial
Results: During a three year period between 2003 and 2006, 62 samples
from 58 patients less than 16 years old were analysed. Bacterial DNA
was detected in 20 of the samples, displayed in Table 1. These included
nine different pathogens of which Streptococcus pyogenes (GAS) and
Streptococcus pneumoniae were the most frequent. The other pathogens
identiﬁed were Streptococcus agalactiae, Kingella kingae, Neisseria
meningitidis, Streptococcus intermedius, and Francisella tularensis.
DNA from Propionibacterium acnes was detected in three samples.
In four samples a positive PCR reaction was found, but a particular
identiﬁcation could not be determined by DNA sequencing as
examination of the electropherogram suggested the presence of DNA
from more than one bacterial species.
Conclusion: In the present material PCR of the 16S rRNA gene could
detect bacterial DNA in 20 out of 62 clinical specimens from paediatric
patients. A deﬁnite microbial diagnosis of a recognized pathogen
was obtained in 13 of these. The bacterial identiﬁcations were in
agreement with characteristic clinical presentations, age of the patients,
and sites from which the specimens were obtained: meningococci and
pneumococci in cerebrospinal ﬂuid with meningitis, S. intermedius in a
brain abscess, S. agalactiae in a 20 days old baby, and K. kingae in joint
ﬂuid.
Techniques in molecular bacteriology S393
We conclude that PCR ampliﬁcation with subsequent DNA sequencing
is a useful diagnostic supplementary tool on various specimens in
establishing the cause of bacterial infections in paediatric patients.
P1410 Comparison of real-time PCR and blood culture for the
diagnosis of bloodstream infections in onco-haematologic
patients: microbiological and clinical assessment
S. Varani, M. Stanzani, L. Nardi, M. Paolucci, N. Vianelli,
M. Baccarani, M. Landini, P. Dal Monte, F. Cavrini, B. Giannini,
F. Melchionda, A. Pession, V. Sambri (Bologna, IT)
Objectives: Sepsis is a syndrome that results from a dysregulated
host response to infection which can rapidly lead to organ dysfunction
and death. The aim of this study was the microbiological and
clinical assessment of a new real-time PCR test (SeptiFast: SF, Roche
Diagnostics) for the diagnosis of blood stream infections (BSI) in a
population of neutropenic patients. The results of SF were compared
with blood cultures (BC) obtained on the same specimens and the clinical
signiﬁcance of the two methods was assessed.
Methods: This single-centre study was conducted from the beginning of
May 2006 until the end of July 2006. Eighty-six samples were obtained
simultaneously for culture and SF from peripheral blood of 51 onco-
haematologic patients with clinical suspicion of bacterial or fungal BSI.
All patients included in the study exhibited leukopenia (WBC< 200/mL).
The SF was performed following manufacturer’s instructions. BC was
performed by using an automated system (BacTAlert, bioMe´rieux).
Standard laboratory procedures were employed for identiﬁcation and
antimicrobial susceptibility testing of the bacterial isolates from BC.
Table 1. Comparative identiﬁcation of bacteria from blood culture and
SeptiFast (febrile episodes/blood specimens)
PCR Bacteria Blood culture
Negative Positive
C
oN
S
S.
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e
Negative 41/57 6/6a 0 1/1b 1/1c 8/8
Positive CoNS 1/1 9/11 0 0 0 9/11
S. aureus 1/3 0 3/3 0 0 3/3
E. coli 1/1 0 0 0 0 0
S. maltophilia 1/1 0 0 0 0 0
A. baumannii 1/1 0 0 0 0 0
Total positive 5/7 9/11 3/3 0 0 12/14
*in 3 out of 6 cases a contamination by CoNS was indicated by
SeptiFast; **SeptiFast indicated the presence of contamination by CoNS;
***SeptiFast indicated the presence of contamination by streptococci
spp.
Results: Fourteen and 57 samples were identiﬁed, respectively, as
positive and negative by both the methods. 8 specimens were found
positive by BC, but negative by SF and 7 samples were detected
as negative by BC, but positive when tested by SF. The agreement
between the two tests was 16.3% and 66.3% for the positive and the
negative specimens, respectively. The overall agreement between the
two methods was 82.6%. In 3 out of 6 cases that resulted positive
for coagulase-negative staphylococci (CoNS) at BC, SF showed the
presence of contamination by CoNS. A clinical surveillance of these
cases suggested that the detection of CoNS by culture was a false
positive result probably due to contamination in the collection procedure.
A comparative identiﬁcation of bacteria from BC and SF was performed
and we found that SF identiﬁed Gram-negative bacteria more efﬁciently
than BC. The average time to identiﬁcation of different bacteria was
85.1±7.9 hours (mean±standard error mean) for BC versus 27.7±4.3
for SF (p< 0.000001).
Conclusion: The capability to identify “contaminating” low bacterial
load, together with the fast availability of clinical relevant results suggest
that SF should be performed together with standard BC in neutropenic
febrile patients to improve the sensitivity and speciﬁcity of the laboratory
diagnosis of BSI.
P1411 PCR with universal primers targeting the small ribosomal
RNA (16S rRNA) gene of bacteria as a diagnostic tool in
15 hospitalised patients with infectious diseases
E. Longhi, A. Foschi, G. Bestetti, V. Acquaviva, A. Radice,
C. Parravicini, S. Antinori, M. Corbellino (Milan, IT)
Objectives: To evaluate the utility of 16S rRNA gene PCR followed
by sequencing of the ampliﬁed products for the in vivo detection and
identiﬁcation of bacteria in clinical specimens and to compare it with
conventional in vitro isolation.
Patients and Methods: Presence of bacterial DNA was sought for by
16S rRNA gene PCR with broad-range primers in 18 clinical specimens
collected from 15 selected patients hospitalised at Luigi Sacco Hospital
(Milano, Italy). The patients had miscellaneous clinical syndromes at
presentation: sepsis, sepsis and meningitis, lymphadenitis, localised
abscess, osteomyelitis, pleural effusion and latero-cervical mass. The
biological specimens analysed were: EDTA-anticoagulated whole blood
(n = 5), cerebro-spinal ﬂuid (n = 1), pleural ﬂuid (n = 2), lymph-node
aspirate (n = 1), lymph-node biopsy (n = 1), skeletal muscle (n = 2), bone
(n = 1) and purulent exudate obtained from abscess (n = 5). In 13 of the
15 patients, coeval samples were tested both by PCR and by traditional
in vitro isolation.
After DNA extraction, PCR was carried out using primers 515F-806R
that amplify a 328 base pair region of the bacterial 16S rRNA gene.
PCR products were directly sequenced and analysed using the BLAST
programme.
Results: 16S rRNA gene PCR allowed the identiﬁcation of the bacterial
pathogen in all cases while in vitro isolation was diagnostic in 8 out
of 13 (61%) cases. Bacterial culture and molecular identiﬁcation were
concordant in 7/13 (54%) patients while PCR was the only method that
yielded a diagnosis in 5/13 patients (40%). 8/15 (53%) individuals were
receiving antimicrobial treatment when PCR and culture were performed:
16S rRNA gene PCR allowed pathogen identiﬁcation in all of them,
while in vitro isolation was positive in only 3/8 cases (37%).
Conclusions: Broad-Range 16S rRNA PCR allowed rapid identiﬁcation
not only of common bacterial pathogens such as Neisseria meningi-
tidis, Streptococcus pneumoniae, Staphylococcus aureus, Streptococcus
pyogenes and other Streptococci but also of fastidious bacteria such as
Bartonella henselae and Mycobacterium genavense.
PCR proved to be superior to bacterial culture in two clinical situations:
infections caused by bacteria with unusual growth requirements and
specimens collected during antimicrobial treatment of the patient.
P1412 Use of denaturing gradient gel electrophoresis for
polymicrobial sample analysis
B. Zaloudikova, M. Slany, T. Freiberger (Brno, CZ)
Objectives: In clinical microbiology most polymerase chain reactions
(PCRs) for the detection of bacteria are designed speciﬁcally to one
organism. This provides high sensitivity and speciﬁcity but detects
only the microorganism we are looking for. To screen for a wide
spectrum of bacterial pathogens, broad-range PCR assays based on the
detection of the 16S rRNA gene were designed. The identity of the
bacterium is revealed by nucleotide sequencing of the PCR product
and comparison of the obtained sequence with the GenBank database.
In contrast to standard culturing techniques, the methods of broad-
range PCR and sequencing have a potential to rapidly detect also
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fastidious or unculturable bacteria. However, applying this approach
to clinical samples containing more than one bacterial species may
result in multisequence signal, which disables exact identiﬁcation of
particular bacteria. Denaturing gradient gel electrophoresis (DGGE)
might overcome this problem. This method is based on separation of
fragments of the same length with different base-pair sequences in
polyacrylamide gel containing a linearly increasing gradient of DNA
denaturant. DGGE results in a pattern of bands each corresponding to
speciﬁc bacterial species. The aim of our study was to optimise the
method of universal molecular detection of pathogens in polymicrobial
materials.
Methods: Samples of DNA extracted from different bacteria were mixed
and used as a template for broad-range PCR. The PCR product was
subsequently analysed using DGGE. Separated bands were cut from
polyacrylamide gel, reampliﬁed and sequenced. Basic Local Alignment
Search Tool (BLAST) programme has been used to compare the
sequences with the GenBank database. The approach was tested on
synovial ﬂuid sample that showed a multiple signal after routine broad-
range PCR and sequencing analysis.
Results: All sequences obtained from arteﬁcial template corresponded
to GenBank sequences of bacteria used for DNA extraction. DGGE
analysis of the clinical material resulted in two bands. Their sequences
showed 99% similarity with Enterobacter cloacae (Accession number
DQ202394) and 98% similarity with Staphylococcus aureus (Accession
number DQ997837), respectively.
Conclusion: Broad-range PCR combined with DGGE and sequencing
seems to be a promissing tool for molecular detection of pathogens in
polymicrobial clinical samples.
P1413 Analysis of mixed microbial species in clinically relevant
bioﬁlms using denaturing HPLC
F. Jury, A. Bueid, W. Ollier, A. Fox, M. Upton (Manchester, UK)
Objective:Many infections have a multi-species aetiology with causative
agents existing in bacterial bioﬁlms. Differentiation of these organisms
usually is possible using culture based approaches. However, in an
age when molecular detection and typing methods are being heralded
as the future of diagnostic microbiology, they are not optimal for
analysis of mixed species populations. We have previously shown that
denaturing HPLC (DHPLC) has utility for rapid identiﬁcation and typing
of Staphylococcus aureus strains. Here we investigate the application of
DHPLC to analysis of mixed bacterial species from culture and clinical
swabs.
Methods: DNA recovered from cultured cells and wound or screening
swabs was used as template in PCR using universal primers. The primers
target the 16S rRNA genes and the forward primer carried a 40bp
GC clamp to allow optimal separation during DHPLC. Conditions for
DHPLC were based on those shown to be useful for separation of
amplicons from environmental samples. DHPLC separation was carried
out using fragments ampliﬁed from swabs known to carry single and
mixed species.
Results: Ampliﬁcation of 16S rDNA from strains and swabs was
successful following some minor modiﬁcations. Separation of multiple
peaks representing individual rDNA species was possible.
Conclusions: DHPLC has potential to be a powerful tool for separation
of mixed ampliﬁcation products for species identiﬁcation and for
analysing population dynamics in bacterial bioﬁlms. The method could
have a signiﬁcant impact on direct detection of clinically relevant
organisms and rapid identiﬁcation for targeted patient management and
antimicrobial therapy selection.
P1414 Use of FTA paper and PCR for detection of bacterial DNA
in clinical swabs
A. Bueid, A. Barhameen, J. Jones, M. Upton (Manchester, UK)
Objective: Detection of bacterial pathogens in clinical samples is being
greatly enhanced by the use of real-time PCR based approaches. The
rate limiting step in such approaches is often extraction of DNA. The
aim of the current study was to investigate possible means of reducing
sample processing time and labour.
Methods: FTA paper was originally developed for storage of human
DNA samples and has been widely used in forensic science. The
paper cards have recently been shown to stabilise bacterial and viral
DNA. Following a simple wash procedure, DNA can be stored at room
temperature for prolonged periods.
We have assessed the utility of FTA paper cards for extraction of bacterial
DNA from clinical swabs carrying between one and four bacterial
species. Swabs were applied to the surface of the cards and washed,
dried and stored prior to use in PCR. Data from PCR reactions were
compared with those obtained by conventional culture based approaches.
Results: DNA was suitable for ampliﬁcation by PCR using universal
and speciﬁc primers and the approach killed all organisms that were
present. Good correlation was seen between results from the molecular
and culture based approaches. This approach has signiﬁcant implications
for making safe samples that contain highly pathogenic organisms.
Conclusions: It is possible that FTA paper cards could be introduced into
routine molecular diagnostic assays to greatly reduce sample preparation
time and make high risk samples safe for handling by lab personnel.
P1415 Improvements in the molecular detection of pathogens
through participation in international external quality
assessment schemes
W. MacKay, C. Scott, C. Steel, H.G.M. Niesters, P. Wallace,
A.M. van Loon (Glasgow, UK)
Objectives: Quality Control for Molecular Diagnostics (QCMD) is
an independent not-for-proﬁt organisation whose primary aim is to
establish and develop External Quality Assessment (EQA) Programmes
for the evaluation of nucleic acid ampliﬁcation techniques (NATs) in
the diagnostic laboratory. QCMD collects and analyses a wealth of
information on the performance of NATs and is uniquely placed to
comment on trends in their performance worldwide.
Methods: Data for all of the EQA programmes offered by QCMD
(including those for MRSA, Mycobacterium tuberculosis, Neisseria
gonorrhoeae, Chlamydia trachomatis and Legionella pneumophila) were
analysed to determine trends in the number of participants contributing
to the EQA programmes, changes in the types of NATs being used and
performance over time.
Results: The number of EQA programmes offered increased from eight
in 2001 to 32 in 2006. Panels were distributed to over 2,500 participants
in more than 50 countries worldwide in 2006. Commercial assays, when
available from major diagnostic companies, were the favoured method
of choice. However a large number of laboratories developed and used
in-house methods. A move towards the use of real time assays was also
evident whilst the use of non-PCR methods was uncommon.
Conclusion: Considerable differences in performance were noted
between laboratories, particularly when in-house methods were used.
False-positive results are still a problem. Nevertheless, the general trend
was towards an improvement in performance.
QCMD is now the primary provider of EQA programmes for the
evaluation of NATs in molecular diagnostics throughout Europe and the
rest of the World. We continue to maintain and develop a comprehensive
portfolio of programmes covering a wide range of pathogens.
P1416 Statistical modelling of the performance of nucleic acid
ampliﬁcation technologies in clinical diagnostic applied to
quality control for molecular diagnostics hepatitis B virus
programmes
L.M. Garcia Fernandez, P. Wallace, H. Staines (Glasgow, Dundee, UK)
Objectives: Pathogen load estimation provided by Nucleic Acid
Technologies (NATs) used to diagnose and manage patients with
infectious disease gives more information than positive/negative results
available from earlier techniques. Generalised Linear Models (GLM) are
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currently used to analyse NAT users’ performance. However, these ignore
the censored quantities lying outside the detection limits of the assays.
We introduce an approach that identiﬁes signiﬁcant factors associated
with lab performance including censored values. The model is tested on
data from 4 years of QCMD HBV programmes.
Methods: We propose a GLM allowing a censored mechanism and
Bayesian parameter inferences using Markov Chain Monte Carlo
(MCMC) methods. The model assumes that the log10 copies/mL
pathogen load estimates are normally distributed.
Results: Potential explanatory variables in the model include NAT
technology used, year of programme and sample genotype. Lab
performance was assessed by the difference between the lab’s and the
target estimate of the pathogen load
The proportion of censored data was higher for samples with lower viral
load.
Users of Commercial PCR technologies were compared with other
technology groups and results depended on viral load. HBV genotype
was a signiﬁcant factor for some sample categories whilst programme
year was signiﬁcant for almost all sample categories.
Conclusions: The model deals with multiple parameters and censored
values in a simpler way than traditional statistical techniques.
Information from the censored values (outside the assay limits of
detection) is incorporated in the model and further modelling of the
censored values can be made.
P1417 Modelling performances of quality control for molecular di-
agnostics participants in Enterovirus programmes over time
L. Garcia Fernandez, P. Wallace, H. Staines, A. van Loon (Glasgow,
Dundee, UK)
Objectives: To analyse data from Enterovirus (EV) Quality Control (QC)
programmes over time to provide a better feedback to participants and
improve the design of future QC programmes. These should help improve
the performance of molecular diagnostic technologies users.
Methods: Homogeneity tests and Generalised Linear Models (GLM)
are used to model the positive/negative responses provided in the
QC programmes. Homogeneity tests are performed on the ratio of
correct results over time for the different category of samples. GLM
(logistic regression) is used to ﬁnd signiﬁcant factors on the estimated
probabilities of correct/incorrect results over time and sample categories.
Results: Data from the 1999 to 2005 QCMD EV programmes were
analysed. The EV proﬁciency panel compositions varied by year although
they contained series of similar samples (sample category): negative,
non-EV and EV samples with different serotype and viral load.
Labs were categorised on whether they had been in previous EV
programmes, if they had returned a correct result in that previous
programme and whether they were accredited. The technology used was
one amongst other factors included as potential explanatory variables.
The difference in the proportions of false positives and false negatives
results over time varied depending on sample and lab category. The
proportion of false positives for non-EV samples varied on the virus
included in the sample. Laboratories that had a correct result in the
previously panel are signiﬁcantly less likely to obtain a false positive that
those that are new to the programme. However, no signiﬁcant differences
were found when analysing negative samples. No signiﬁcance difference
was found between the performances of accredited and non-accredited
participants. Performances from different technology users varied over
time and sample category. In 2004/05 commercial assay users were less
likely to detect low dilution samples than in 2002/03. The proportion of
correct result over time decreased, as the dilution series are lower.
Conclusions: Performance of participants to the EV QC programme
depended on the virus. These results suggest that participating in an EV
QC programme helps improve the performance of laboratories. However
no difference was found between the performance of accredited and
non-accredited labs.
P1418 Evaluation of ﬂuorescence in situ hybridisation for the
identiﬁcation of clinically relevant Candida species
S. Poppert, A. Lakner, M. Bartel, A. Essig (Ulm, DE)
Objectives: Rapid identiﬁcation of Candida albicans is highly warranted
in order to adapt antifungal therapy. Aim of the study was to establish
and evaluate a Fluorescence in situ Hybridisation (FIAH) assay for this
purpose.
Methods: We evaluated FISH using a previously published and a
newly developed C. albicans probe for the identiﬁcation of C. albicans
in comparison to API 20 C, the chromogenic Candida ID-Agar and
determination of ﬁlamentous colony morphology. 17 reference strains,
182clinical isolates and 41 blood cultures showing yeasts in the
Gram stain were included.
Results: All tests produced highly concordant results. The Candida
ID-Agar however was not able to discriminate C. albicans and
C. dubliniensis. Reliable identiﬁcation of C. albicans by API and by
determination of ﬁlamentous colony morphology took 48 hours. FISH
allowed identiﬁcation of C. albicans within 3 hours with a speciﬁcity
and sensitivity of 100% from subculture as well as directly from blood
cultures.
Conclusion: As a robust, simple and over all extraordinarily fast method,
FISH is an appropriate tool for the identiﬁcation of C. albicans isolates,
especially from blood cultures.
P1419 Tri-colour PNA FISH detection of ﬁve Candida species
directly from positive blood culture bottles
F. Wu, S. Whittier, P. Della-Latta (New York, US)
Objectives: Candidaemia is associated with signiﬁcant morbidity and
mortality. C. albicans has historically been the most frequent cause
of candidaemia. However, the frequency of candidaemia due to non-
albicans species such as C. tropicalis, C. glabrata, C. parapsilosis and
C. krusei has risen dramatically. Rapid detection of the most common
Candida species can optimise selection of antifungal therapy.
Methods: A peptide nucleic acid probe ﬂuorescence in situ hybridisation
(PNA FISH) assay was developed and evaluated by using multicolour
labeled ﬂuorescent PNA probes targeting speciﬁc 26S rRNA sequences
of C. albicans (CA), C. glabrata (CG), C. krusei (CK), C. parapsilo-
sis (CP) and C. tropicalis (CT). The probe reagent was applied to smears
made directly from positive blood culture (BC) bottles. After a 90min.
incubation at 55º C, unbound probe was removed by washing at 55ºC for
30min. Smears were then examined by ﬂuorescence microscopy. CA and
CP were identiﬁed as bright green, CG and CK as red and CT as gold
ﬂuorescent cells, respectively. Results were compared to identiﬁcation by
conventional methods. PNA FISH was also challenged with lab strains of
Candida, phylogenetically related species and other organisms frequently
recovered from BC.
Results: A total of 50 blood cultures were tested, including 40 positive
for yeast and 10 positive for bacteria. The assay accurately identiﬁed
14 CA, 13 CG, 2 CK, 2 CP and 6 CT. Positive and negative predictive
values were 100% for all yeast isolates. One BC was negative for CA by
PNA FISH but reported as culture positive for C. albicans. Sequencing
analysis identiﬁed the isolate as Candida dubliniensis. All challenge
strains were PNA FISH negative except for one blood culture positive
for Acinetobacter haemolyticus which initially tested positive for CG/CK
but was negative upon repeat testing. Further investigation is in progress.
Conclusion: The current evaluation of the Yeast Trafﬁc Light PNA FISH
assay demonstrates that this new test can provide rapid and reliable
detection results for ﬁve clinically relevant Candida species, leading to
improvements in antifungal therapy.
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P1420 Expression of IgA-speciﬁc endopeptidases from Neisseria
meningitidis in E. coli
V. Khamiankou, T. Kazeeva, A. Shevelev (Moscow, RU)
Objective: Immunoglobulin A1-speciﬁc proteinase (Igase) is a
pathogenicity factor of meningococcus (Neisseria meningitidis). These
enzymes belong to trypsin-like clan of serine proteinases. They exhibit
a high substrate selectivity being able to discriminate between IgA1 and
IgA2 and, on the other hand, to distinguish human IgA1 and IgA1 from
non-primate species. Taking in account conservancy of hinge region
subjected to cleavage in human and other vertebrates, these means
that Igases exhibit two-level substrate-recognition control which can be
denoted as a primary and non-primary speciﬁcity. Structural basis of
such a high speciﬁcity remains obscure due to unavailability of native
recombinant IgA1 good for crystallographic and enzymatic studies.
Methods:We carried out expression in E. coli of two separate fragments
of Igase corresponding to theoretically predicted domains, refolded and
puriﬁed the proteins.
Results: N-terminal domain harboured the clearly recognized triad of
residues homologous to the active centre of kallikrein, a serine protease
involved to haemostasis. After two-step chromatographical puriﬁcation
and refolding, this protein exhibited a protease activity towards human
myeloma IgA1. C-terminal portion of IgAse corresponds to a putative
substrate-binding domain. This protein was expressed as a peptide
with N-terminal 6His-tag in form of inclusion bodies, puriﬁed by to-
step anion-exchange chromatography and refolded. As expected, the
refolded protein exhibited a high binding capacity towards IgA1 from
both normal and myeloma patient plasma. Besides, the binding domain
tightly bound human IgA2 as conﬁrmed in both ELISA-type and afﬁnity
chromatography tests. Likely to the native IgAse, its separated catalytic
domain attacked a single peptide bound in the native IgA1, as visualised
by immunoblotting with anti-IgA heavy chain antibodies under non-
reducing conditions. However, similar experiment accompanied with
immunoblotting under non-reducing conditions revealed slight shifting
of the processing site of the isolated catalytic domain versus ones of the
native enzyme.
Conclusion: We ﬁrst succeeded to predict occurrence of separate
domains in IgA-protease, to refold and purify them as separate proteins
and to demonstrate their activity.
P1421 Expression of human serum albumin–L7/L12 (Brucella
abortus ribosomal protein) fusion protein in Saccharomyces
cerevisiae
I. Pakzad, A. Rezaee, M. Rasaee, A. Hosseini, A. Kasemnejad,
B. Tabaraiee (Ilam, IR)
Brucella abortus is a facultative interacellular Gram-negative bacterial
pathogen that causes abortion in pregnant cattle and undulant fever in
humans. The immunogenic B. abortus ribosomal protein L7/L12 is a
promising candidate antigen for the development of subunit vaccines
against brucellosis. It has already been expressed in several bacteria and
has been used as DNA vaccine. In order to construct yeast expressing
vector for the tHSA-L7/L12 fusion protein, the l7/L12 ribosomal gene
was ampliﬁed by PCR. The expression plasmid pYtHSA-L7/L12 was
constructed by inserting the L7/L12 gene into the pYHSA5 shuttle vector
(Containing inulinase signal sequence, HSA gene and Gal10 promoter).
The recombinant vector was transformed into S. cerevisiae and was
then induced by galactose. The secreted recombinant fusion protein was
detected in supernatant by SDS-PAGE and conﬁrmed by western blot
analysis using anti-HSA and Anti-L7/L12 antibodies. Fusion protein was
puriﬁed by afﬁnity chromatography and its amount was approximately
500mg/L. These results indicate that both fragments have antigenic
property and they do not have structural (or antigenic) overlapping.
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P1422 Development and validation of a real-time PCR assay for
the detection of group B Streptococcus in pregnant women
M. Wernecke, C. Mullen, M. Maher, T. Barry, T. Smith (Galway, IE)
Objectives: Group B Streptococcus (GBS) (Streptococcus agalactiae) is
one of the leading causes of neonatal sepsis, meningitis and death in the
developed world. Approximately 10−40% of pregnant women carry GBS
in their vagina or rectum. Transmission to the infant occurs vertically
during labour. Of the colonised infants, 1−3% develop disease, usually
within the ﬁrst 24 h after birth.
The objective of this study was to develop a rapid diagnostic test for GBS
that can be performed in a wide variety of labour and delivery settings
using a proprietary NUI Galway technology. Nucleic acid diagnostic tests
for GBS have the potential to overcome the limitations associated with
culture-based detection enabling timely assessment of GBS colonisation
status in pregnant women at the time of delivery. As a result, intrapartum
antibiotic prophylaxis can be administered more effectively leading to
lower infant morbidity and mortality rates.
Methods: The real-time PCR test, performed on the Roche LightCycler®
instrument, uses a proprietary National University of Ireland, Galway
target, RiboSEQ based on the bacterial ssrA gene and includes a
GBS-speciﬁc hybridisation probe. An internal ampliﬁcation control
(IAC) has been incorporated in the test. Sensitivity of detection was
established using serially diluted GBS genomic DNA in the real-time
PCR test. Speciﬁcity studies were performed using a panel of 48 related
streptococci and other species found in the genital tract environment.
The performance of the test is currently being evaluated in a clinical
study and compared to the CDC-approved microbiological method for
the detection of GBS. For this study, sample preparation is performed
using commercially available nucleic acid extraction kits followed by
PCR ampliﬁcation and detection on the LightCycler®.
Results: The detection limit for the GBS real-time PCR test was
determined to be 1−10 cell equivalents. The test was 100% speciﬁc
for GBS. Clinical evaluation of the PCR test is ongoing and a progress
report on test performance will be presented.
Conclusion: We have developed a rapid, sensitive and speciﬁc real-time
PCR test based on an NUI Galway proprietary target, RiboSEQ for the
detection of GBS in pregnant women.
P1423 The importance of signal recognition particle for viability
of Streptococcus pneumoniae
E. Pinto, P. Andrew, L. Faleiro (Faro, PT; Leicester, UK)
S. pneumoniae is an important Gram-positive bacteria responsible for
high levels of human morbidity and mortality, at all ages, around the
world, causing pneumonia, meningitis, otitis media and septicaemia.
The dramatic increase in worldwide incidence of antibiotic resistant
pneumococcal strains required a better understanding of bacterial
physiology to facilitate the development of new antibacterial drugs.
The best targets are those essential for cell function. In other Gram-
positive and Gram-negative bacteria, deletion of components of the
signal recognition particle (SRP) has been shown to cause cell death.
The aim of this research is to conﬁrm that the SRP is essential
for pneumococcus viability and its exploitation as a new target for
therapy. To achieve this genes ffh and ftsY were ampliﬁed by PCR and
cloned using the vector pGEM-T Easy. For S. pneumoniae mutagenesis
these genes were subcloned into the integrational vector pRKO2
under the control of a tetracycline inducible promoter. S. pneumoniae
transformants of strains D39 and TIGR 4 were analysed in order to
conﬁrm the plasmid integration and viability dependence of tetracycline.
Forward the mariner mutagenesis in vitro was used for transformation
of S. pneumoniae D39 to conﬁrm the previous results. A mutant of
S. pneumoniae D39A¨ffh was obtained and no phenotypical differences
with the wild type strain were found. The mutation on gene ftsY seems
to have a crucial role in S. pneumoniae D39 viability.
This work is supported by the project POCTI/58702/2004.
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P1424 Cloning and puriﬁcation of a sortase-like protein in
Streptococcus suis type 2
C.J. Wang, Y.Q. Dong, J.Q. Tang (Nanjing, CN)
Objective: Streptococcus suis 2 is an important zoonotic pathogen, lead
to two serious outbreaks with hallmark of human STSS in Jiangsu and
Sichuan province in China in 1998 and 2005, respectively. The molecular
mechanism of STSS is poorly understood. Sortase, an enzyme cleaves
the LPXTG sequence in surface proteins and catalyses the transfer of
the processed protein to target site. There is little doubt that some
surface proteins of bacteria might play important roles during infection.
As an enzyme which functions during some cell wall surface proteins
covalently anchored to the cell wall, sortase might help some virulent
factors to function during infection. To deﬁne the role of sortase in the
pathogenesis of S. suis infections, cloning and expressing the sortase
gene of S. suis type 2 ZYH33 that isolated from Streptococcal Toxic
Shock Syndrome outbreak patients in China.
Methods: The srtA gene of S. suis was cloned and sequenced. The
recombinant vector pGEX-4T-2-srtA was constructed and the expression
of recombinant protein was analysed by SDS-PAGE and Western
blotting.
Results: For the ﬁrst time, we obtained the recombinant vector pGEX-
4T-2-srtA and a recombinant sortase protein of S. suis2 ZYH33 in China.
Conclusion: From the results of sequencing and homology searches,
we found srtA shows strong conservation and exhibits a high level of
homology with the sortases of most European and domestic isolates.
Polyclonal antiserum from rabbit immunised with S. suis2ZY05719 was
used against the Sortase protein antigen, a brown band of approximately
55 kDa was visualised on the nitrocellulose membranes by Western
blot, demonstrating that the expressed Sortase protein possessed good
immunogenicity (Fig. 1). On account of a transmembrane domain
existing within the Sortase protein, the protein produced by prokaryotic
expression mainly presented in the form of inclusion bodies. A
recombinant Sortase protein removing of the transmembrane domain was
presented by Docter Youjun Feng of Chinese Academy of Sciences, that
the recombinant protein was highly expressed as the form of solvend.
a protein with an apparent molecular mass of 22 KDa by Western
blot that was reacted strongly with polyclonal antiserum from swine
and rabbit immunised with ZY05719, suggesting that the recombinant
Sortase protein had speciﬁc antigenicity. Further work will be needed to
really appreciate the role of sortase in the infections generated by S. suis.
P1425 Distribution of emm genotypes among S. pyogenes isolates
from Serbia
V. Mijac, N. Opavski, L. Ranin, C. Heeg, R. Reinert (Belgrade, RS;
Aachen, DE)
Objective: S. pyogenes is a major human pathogen that causes suppu-
rative and nonsuppurative infections, including pharyngitis, necrotising
fasciitis, and streptococcal toxic shock syndrome. The emm gene which
encodes the major virulence factor, the M protein, is used as the basis
for the characterisation of S. pyogenes. The aim of this study was to
investigate the distribution of emm genotypes in Serbia.
Methods: Seventy seven isolates of S. pyogenes collected from various
regions throughout Serbia were included in the study. Fifty-ﬁve isolates
originated from patients with pharyngitis, while remaining 22 were
isolated from patients with skin and soft tissue infections. The presence
of emm genes was determined by PCR using “all M” primers following
a previously published protocol by Podbielski and co-workers.
Results: A total of 17 different emm types were identiﬁed among the
tested isolates. The most frequent ones were emm 6 (25%), emm 12
(16%), emm 1 (13%) and emm 50 (9%). We observed an association
between emm types and isolation site: among pharyngeal strains the most
common types were emm 6 (33%), followed by emm 12 (22%) and emm
1 (18%), whereas in skin and soft tissue group the most frequent isolates
were emm 50 (27%), emm 58 (27%) and emm 78 (14%).
Conclusion: To the best of our knowledge, this is the ﬁrst report on
the emm type distribution in Serbia. Our results conﬁrm the association
between particular types and isolation site. The high incidence of emm
6 in patients with pharyngitis is a remarkable ﬁnding of the present
investigation and not in concordance with reports from other parts of
the world. Moreover, the present investigation underscores the need for
a future active population-based surveillance programme in Serbia.
P1426 Microbiological aspects of a Streptococcus pyogenes
outbreak causing invasive disease in children attending a
day care centre in Cantabria, Spain
J. Agu¨ero, M. Ortega, M. Cano, A. Gonza´lez de Aledo, J. Calvo,
L. Viloria, P. Mellado, T. Pelayo, L. Martı´nez-Martı´nez (Santander,
Cantabria, ES)
Objectives: To study microbiological aspects of S. pyogenes isolates
cultured from children (5 to 40 month old) attending a day care centre
in Cantabria (Northern Spain), and to compare these isolates with
those from contacts of the affected children and with epidemiologically
unrelated isolates from the same area.
Methods: Pharyngotonsillar swabs from 40 children, 4 day care staff and
258 contacts were cultured according to standard methods. Samples from
multiple organs were cultured from a child who died from streptococcal
toxic shock syndrome (STSS). Blood cultures were obtained from 2 other
children with STSS. Nine S. pyogenes isolated from pharyngotonsillar
samples unrelated with the outbreak were included for comparison.
Clonal relationship of the isolates was assessed by PFGE. Protein M
typing was performed by sequencing of the region of the emm gene
coding for the N-terminal zone of the protein. Susceptibility testing
was performed with Etest strips on Mueller-Hinton blood agar plates.
A multiplex PCR was used for detecting the presence of genes: speA,
speB, speC, speF, speG, speH, speJ, ssa and smeZ.
Results: S. pyogenes was isolated from pharyngotonsillar samples of
11 children and 14 contacts, and from invasive samples of 2 out of 3
children with STSS. All isolates from children at the day care centre
were of emm type 4, presented the same PFGE pattern and contained
speB, speC, speF, ssa and smeZ. Isolates from contacts corresponded to
emm types 1, 2, 12 or 22 and to 5 PFGE patterns unrelated to that of
the children isolates. Isolates from epidemiologically unrelated patients
were of emm types 3, 11, 12, 18 or 22 and presented 5 PFGE unrelated
to that of the outbreak strain. All isolates were susceptible to penicillin,
clindamycin, levoﬂoxacin and tetracycline and, except 1 isolate from an
unrelated patient, to erythromycin.
Conclusions: A strain of S. pyogenes of emm type 4 caused an outbreak
in children attending a day care centre. The organism was also cultured
from two children who developed STSS, one of which died. This strain
was unrelated to other S. pyogenes isolated from contacts of the children
or from epidemiologically unrelated patients from the same area
P1427 Molecular identiﬁcation of Streptococcus bovis group
isolates causing bacteraemia by sodA gene (superoxide
dismutase gene) PCR and sequencing
M. Marin, M.J. Goyanes, E. Cercenado, M. Rodrı´guez-Cre´ixems,
P. Mun˜oz, E. Bouza (Madrid, ES)
Objective: To describe the distribution of species in our S. bovis-group
isolates causing bacteraemia and to evaluate the utility of sodA PCR
associated with sequencing to identify them.
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Methods: 36 S. bovis-group strains (36 patients) isolated from blood
cultures or heart-valve tissue between 2000 and 2006 were studied.
Phenotypic identiﬁcation was by conventional microbiological methods
and API 20 Strep. Molecular identiﬁcation was performed by sodA
gene PCR (superoxide dismutase gene) followed by sequencing. The
sequences obtained were compared with those included in Genebank.
Only alignments with similarities higher than 99% were considered.
Sequences of our S. bovis-group isolates were compared with type
strains deposited in Genebank and well characterised phenotypically
using Clustal X 1.8 software.
Results: The distribution of species after sodA PCR and sequencing
was S. gallolyticus (19), S. pasteurianus (13), S. lutetiensis (3) and
S. infantarius (1). A review of the clinical records of patients revealed 11
cases of infective endocarditis (all but one caused by S. gallolyticus) and
10 cases of S. bovis bacteraemia associated with abdominal malignancies
(5 S. gallolyticus and 5 S. pasteurianus). For 6 patients with infective
endocarditis, S. gallolyticus and S. infantarius were detected by sodA
PCR directly in heart-valve tissue, but traditional culture was positive in
only two patients.
Conclusions: sodA PCR followed by sequencing is a useful and rapid
molecular tool for the identiﬁcation of S. bovis-group clinical isolates.
This method could provide more accurate results than the conventional
methods used routinely in our laboratory. Sequence analysis of the
sodA gene has enabled us to recognize recently described species
among our S. bovis-group isolates that would have gone unnoticed using
non-sequencing-based methods. S. gallolyticus was the most frequently
identiﬁed species.
P1428 Preliminary evaluation of a PCR protocol to directly detect
Streptococcus equi ssp. zooepidemicus in equine specimens
S. Preziuso, L. Bastianini, F. Laus, V. Cuteri (Matelica, Perugia, IT)
Objectives: Streptococcus equi ssp. zooepidemicus (S. zooepidemicus)
are beta-haemolytic streptococci of the Lanceﬁeld group C. These
bacteria are responsible for several diseases of animals and are though
to be infrequent in humans, although cases of cervical lymphadenitis,
pneumonia, meningitis, endocarditis, nephritis, septicaemia, cellulitis,
and deaths due to S. zooepidemicus are not rarely described in
humans. Animal to human transmission by respiratory or milk route are
strongly suggested, but few studies in veterinary sciences are aimed at
S. zooepidemicus detection, although reproductive disorders and strangle-
like diseases due to S. zooepidemicus infection in horses are increasing
in importance.
The objective of this work was to evaluate a PCR protocol to detect
S. zooepidemicus in clinical equine specimens.
Methods: Twenty uterine swabs, 60 nasopharyngeal swabs and 4 milk
samples collected from symptomatic horses were tested blindly by
bacteriology and PCR.
After incubation of swabs in enrichment broth for 6 hours, two aliquots
of the broth were used respectively for culture on equine blood agar
(Oxoid-Milan) or for DNA extraction and PCR. Latex-agglutination test
(Oxoid-Milan) was used to identify the Lanceﬁeld group of the beta-
haemolytic streptococci grown on agar, and API Strep was used for
the biochemical identiﬁcation of the group C colonies. Furthermore,
a loop of beta-haemolytic streptococci of group C was processed for
DNA extraction and PCR. Primers for sodA and for seeI genes were
used as previously reported by Alber et al (2004). PCR conditions were
optimised using reference strains.
Results: S. zooepidemicus was cultured from 5/20 (25.0%) uterine
swabs, 4/60 (6.7%) nasopharyngeal swabs and 1/4 (25.0%) milk samples.
The same results were obtained by PCR on broth samples, with the
difference that 7/60 (11.7%) nasopharyngeal swabs were positive. PCR
on colonies conﬁrmed API Strep (bioMe´rieux-Milan) identiﬁcation in
all cases except 1 case where a wrong API lecture was done.
Conclusions: PCR represents a rapid, sensitive and speciﬁc method
to directly detect S. zooepidemicus in respiratory and genital samples
of symptomatic horses. This protocol could represent a basis for the
development of multiplex PCR method to differentiate the respiratory
and genital pathogenic streptococci.
Further investigation will be aimed at verifying if this PCR protocol can
be used also on human samples for diagnosis or epidemiological studies.
P1429 Serotyping of Streptococcus pneumoniae by PCR – expansion
of the method to identify the Hungarian serotypes
O. Dobay, K. Nagy, S. Amyes, F. Rozgonyi (Budapest, HU; Edinburgh,
UK)
Objectives: Streptococcus pneumoniae has 90 different serotypes, and
as certain serotypes are linked with antibiotic resistance, virulence
or different types of diseases, it is essential for the epidemiological
studies to determine the serotype of the isolates, in addition to
genotyping. The conventional method is to use antisera, but it is time
consuming, expensive and difﬁcult to evaluate. Some workers have
started determining the serotype by PCR and we have expanded this
methodology to characterise the strains normally found in Hungary.
Methods: Conventional serotyping was performed with MAST antisera
on glass slides. For the PCR, the grouping primers and primers for
several individual serotypes described by Brito et al. (1, 3, 4, 6, 14,
18C, 19F, 19A, 23F) were used, but we designed a set of new primers
to other serotypes that are also relatively common in Hungary (9V,
6A, 6B, 7F, 11A, 15A, 15B). The PCR was done in two stages. The
ﬁrst multiplex PCR reaction divided the strains into 6 different groups,
based on the gel pattern. Then a second multiplex PCR reaction, which
included the primers for the individual serotypes of each group (3 or 4),
was performed.
Results: Isolates of known serotypes were tested ﬁrst with the individual
primers in single PCR reactions. Then the grouping reactions were tried
with these strains. The multiplex PCR worked best with Tth polymerase,
but in Taq buffer. We had to alter the annealing temperature and other
parameters as well. After improving the method, we designed the new
primers. These had to be suited for the existing reaction, i.e. had to work
under the same cycling parameters that had originally been used; however
these primers also had to be unique for the new serotype within the group
and provide PCR products of different sizes for each serotype. When
invasive isolates of unknown serotypes were tested by this method and
the results compared with the conventional method, the same serotypes
were identiﬁed.
Conclusions: The new 7-valent conjugate vaccine was introduced in
Hungary very recently, therefore the examination of invasive strains is
of great importance. We have extended the method of Brito et al. to
identify Hungarian isolates, by designing primers for new serotypes.
Serotyping of large numbers of isolates by the conventional method
requires expensive resources, while the capability to identify serotypes
by PCR is much simpler, is as sensitive and is more cost effective than
conventional serotyping.
P1430 Quantiﬁcation of Streptococcus pneumoniae DNA in blood
samples from patients with invasive pneumococcal infection
R.P.H. Peters, R.F. de Boer, T. Schuurman, M.A. van Agtmael,
M. Kooistra-Smid, C.M.J.E. Vandenbroucke-Grauls, M.C. Persoons,
P.H.M. Savelkoul (Amsterdam, NL)
Objectives: Streptococcus pneumoniae is the most prevalent cause
of community-acquired pneumonia (CAP) and meningitis (CAM) in
adults in the Netherlands. Invasive infection is associated with increased
mortality, and rapid diagnosis is essential. Blood cultures, the diagnostic
gold standard, have a relatively low yield and may take two days to
become positive. We evaluated the clinical use of real-time PCR for
direct detection and quantiﬁcation of bacterial DNA in blood samples,
without prior cultivation.
Methods: Whole blood samples were obtained simultaneously with
blood cultures from patients suspected of CAP or CAM. Bacterial DNA
was isolated blood samples with the QIAamp DNA Mini Kit (Qiagen,
Germany). PCR ampliﬁcations were done on a TaqMan 7000 System
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(Applied Biosystems, USA) with a PCR assay that targeted the autolysin
A gene of Streptococcus pneumoniae. A quantitation curve was included
to calculate the bacterial DNA load (BDL). PCR results were compared
to blood culture outcome and clinical data.
Results: In total, 130 blood samples from 63 patients were tested with
PCR. The sensitivity of PCR for detection of Streptococcus pneumoniae
in blood samples was 80% and the speciﬁcity 94%, Table 1. PCR
ampliﬁcations were positive in 11/14 patients (79%) with bacteraemia
and negative in 44/48 patients (92%) without bacteraemia. With PCR, 4
additional cases were identiﬁed compared to blood culture, all of whom
had a microbiologically proven source of Streptococcus pneumoniae
infection (including 1 case of meningitis). Blood samples from patients
with a positive PCR signal and negative blood culture result had been
obtained more frequently under antimicrobial treatment than blood
samples from patients with positive blood cultures (p = 0.04). When PCR
results were combined with blood culture outcome, the detection rate
of invasive Streptococcus pneumoniae infection increased from 22% to
29%. The median BDL was 24 cfu equivalents/mL (range 3.9–683). No
association was found between BDL and clinical characteristics.
Table 1. Comparison of PCR and blood culture for detection of
Streptococcus pneumoniae in blood samples.
Blood culture result
PCR result Positive Negative Total
Positive 16 6 22
Negative 4 101 105
Total 20 107 127
Conclusion: Quantiﬁcation of bacterial DNA in blood samples adds
to the diagnosis of invasive pneumococcal disease, also in patients
receiving antibiotics, but sensitivity of the PCR assay should be
improved to ensure clinical applicability. The clinical value of BDL in
invasive pneumococcal infection seems promising but needs to be further
evaluated.
P1431 Quantiﬁcation of bacterial DNA during bacteraemia: a
possible marker of severity of infection
R.P.H. Peters, M.A. van Agtmael, C.M.J.E. Vandenbroucke-Grauls,
P.H.M. Savelkoul (Amsterdam, NL)
Objectives: We evaluated the clinical value of determination of
Staphylococcus aureus and Enterococcus faecalis bacterial DNA load
(BDL) during bacteraemia in critically ill patients. BDL was related to
clinical and laboratory variables, and to microbiological culture results.
Methods: Blood samples for PCR were obtained whenever blood was
drawn for culture from patients admitted to the intensive care unit of
our hospital. After extraction of DNA from 200mL blood with the
QIAamp DNA Mini Kit, real-time PCR ampliﬁcation was performed
on a TaqMan 7000 System with speciﬁc primers and probe targeting the
16S rRNA gene of S. aureus and E. faecalis. A quantitation curve was
included to determine the BDL.
Results: In total, 175 blood samples for S. aureus PCR and 180 for
E. faecalis PCR, both from 80 patients, were included. The S. aureus
PCR was positive in 31 blood samples from 18 patients; the E. faecalis
PCR in 18 blood samples from 14 patients. Blood cultures were negative
in 7/18 (39%) patients with a positive S. aureus PCR and 4/14 (29%)
with a positive E. faecalis PCR result. Antimicrobial therapy had been
administered to 10/11 patients with a positive PCR and negative blood
culture result prior to blood sampling, which is signiﬁcantly more
frequent than patients with growth-positive blood cultures (p< 0.01). The
median (range) S. aureus BDL was 440 (3–3,370) cfu equivalents/mL;
median E. faecalis BDL was 130 (12–6,582). The E. faecalis BDL was
signiﬁcantly lower in patients with negative blood cultures compared
to a positive culture result (p = 0.03), while a tendency was observed
for S. aureus BDL in this regard (p = 0.07). Furthermore, patients with
only a positive PCR result for S. aureus were less likely to have a
microbiologically proven source of infection (p< 0.01) than patients with
a positive blood culture.
We observed a signiﬁcant correlation between BDL and C-reactive
protein concentration, ﬁgure 1.
Fig. 1. Correlation between bacterial DNA load and C-reactive protein.
Individual correlations of S. aureus BDL (r = 0.60) and E. faecalis
BDL (r = 0.75) with CRP were also signiﬁcant (p< 0.05). No other
associations were observed between BDL and clinical or laboratory
variables.
Conclusion: Determination of BDL can be used to quantify bacteraemia
in ICU patients, also when blood samples are obtained under
antimicrobial treatment or when there is no clear focus of infection. The
positive correlation that we observed between BDL and CRP suggests
that BDL may be a promising marker of severity of infection.
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P1432 Comparative analysis of three different regions of hepatitis
C virus for genotyping Romanian strains
A. Oprisoreanu, C. Szmal, V. Thiers, G. Oprisan (Bucharest, RO;
Paris, FR)
Objective: to compare the three different genomic regions (5′UTR,
core and NS5B) for hepatitis C virus (HCV) identiﬁcation and
characterisation to analyse the strains in relation to those circulating
worldwide in order to have a larger view of the epidemiology of HCV
infection in Romania
Methods: the RNA from sera was extracted using QIAmp viral RNA
extraction kit (Qiagen) and SV Total RNA Isolation System (Promega).
The RT-PCR was done in 20ul with random primers and AMV (4U/ul)
revers transcriptase enzymes. The obtained cDNAs were ampliﬁed in
three genomic regions (5′UTR, core and NS5B) by nested-PCR. RFLP
was realised in 5′UTR region with three restriction enzymes: Mva I,
Mvn I and Sau3A I. The sequencing was performed on an automated
sequencer ABI Prism 3100 Avant (Applied Biosystems). The analysis of
sequences was performed using BLAST, BioEdit 7.0, Mega3 softwares.
Results: We analysed 153 sera from patients and blood donors in
three genomic regions by all three methods: PCR, RFLP, sequencing
and philogenetic analysis. The molecular analysis in the 5′UTR by
RFLP gave very good information about the discrimination between
1b (the predominant subtype) and other genotypes and subtypes. The
sequencing was done in all three regions (5′UTR, core and NS5B). In
all three sequenced region the results indicated the same genotype, the
most reliable being NS5B and core region. Some samples identiﬁed as
subtype 1a by RFLP were identiﬁed later by sequencing as genotype 1b
in all regions. In Romania, so far we have identiﬁed genotype 1b 96%,
1a 2.6% and 4a 1.4%. In relations to other 1b genotype circulating in
S400 17th ECCMID / 25th ICC, Posters
Europe, our strains do not form a speciﬁc cluster. Strains of genotype 1a
are becoming more and more predominant in our country due to drug
abuse, piercing, tattooing, etc. The presence of genotype 4a might
indicate a possible root of circulation from Egypt.
Conclusions: In conclusion RFLP in 5′UTR region is the ﬁrst test
that allows a rapid and relatively cheap method for identiﬁcation of
the genotype but it has a low sensibility towards some subtypes.
The distribution of genotype 1 in Romanian population reveal that
genotype 1b is predominant in all ages while genotype 1a is found
especially in younger populations, which might be an evidence of a shift
between these two genotypes. Interestingly for Romania is the presence
of genotype 4a, which is an endemic subtype for Egypt.
P1433 In vitro replication of hepatitis D virus using a new
construct containing a dimer of HDV genome
F. Behzadian, F. Sabahi, M. Karimi, M. Sadeghi Zadeh, N. Maghsodi
(Tehran, IR)
Objectives: There is no cell line susceptible to Hepatitis D Virus (HDV)
infection. Therefore several genetic based models have been introduced
being able to initiate HDVRNA replication which bypass needs of HDV
particle to attachment, entrance and uncoating stages. Because of circular
nature of HDV genome and its resemblance to plants viroids, the cloned
HDVcDNA generally employed were constructed in tandem repeats of
dimer or trimer genomes. Two ribozyme sequences on the HDV cDNA
are necessary to generate a unit-length HDV RNA after transcription.
Methods: in this study a replicative dimeric construction of HDV cDNA
was made from a single copy of full-length genome through a four-step
cloning scheme (Figure 1). In the resulting recombinant plasmid named
pcDNA3.1D2, two head-to-tail tandem repeats of genomic HDVcDNA
transcript under CMV promoter control. pcDNA3.1D2 was transfected
into the Huh7 and Cos7 cell lines, as cells with liver and non-liver origin
respectively. The cells then were subjected for analysis of replication
markers. Initiation of HDV replication was assessed by two markers,
formation of antigenomic RNA strands and expression of HDAg, the
only HDV encoded protein. RT-nested PCR was performed on DNA-
removed total RNA samples from transfected cells and untransfected
ones (as negative control) to show presence of HDV antigenomic RNA.
Immunoﬂuorescence and Western blotting also were done to detect
expressed HDAg in the mentioned cell lines.
Results: Seven days after transfection, both replication markers in Cos7
and Huh7 were positive.
Conclusion: Since pcDNA3.1D2 is made from genomic HDV cDNA,
antigenomic RNA would be raised exclusively after HDV genome
replication. The results indicate that pcDNA3.1D2 could serve as a
template for DNA-directed RNA synthesis and the transcribed RNA
molecules were processed via ribozyme regions to form circular genomic
RNAs which in turn proceeded HDV replication events. pcDNA3.1D2
can be used conveniently in transfection experiments to explore HDV
biology further. Since this model is made of single unique HDV
genome, there is possibility of using different isolates from different
genotypes or pre-mutated HDV genomes to construct this kind of model
and studying the capacity of their corresponded dimeric vectors for
replication efﬁciency.
P1434 Incidence of double positive ampliﬁcations from
immunocompetent patients screened for active human
herpesvirus replication
A. Manna, A. Di Girolamo, D. Racciatti, L. Manzoli, G. D’Amico,
E. Pizzigallo, A. Balbinot, F. Febbo, D. D’Antonio, G. Parruti (Pescara,
Chieti, IT)
Objectives: In 2003 we introduced into clinical practice the use of
molecular tools for diagnosing active Human Herpes Virus replication
on various clinical specimens from immunocompetent patients. Since
2005, parallel quantitative ampliﬁcations were carried out for each virus
by Real Time PCR. We report on the incidence of double-positive
ampliﬁcations and their possible clinical signiﬁcance.
Methods: DNA extraction from plasma, urine, saliva and vesicular
eluates was performed using the QIAamp DNA Mini Kit (QIAgen
GmbH, Hilden, Germany) according to manufacturer’s instructions.
A qualitative PCR ampliﬁcation was carried out for VZV (Nested–
PCR; Amplimedical Bioline), whereas for the remaining Herpes Viruses
screened (HSV1, HSV2, EBV, CMV, HHV6 and HHV8) quantitative
ampliﬁcations were carried out, using TaqMan probes and primers in an
ABI PRISM 7000 Sequence Detection Systems (Real Time System –
Applied Biosystems).
Results: Since January, 2005 through October, 2006, 820 samples from
immunocompetent patients were collected. Thirty-one double positive
samples (3.7%) were detected from 22 patients, 8 of whom with
persistent fever, 8 with recurrent stomatitis, the remaining 6 with other
herpetic recurrences. All double positive reactions were repeated from
the same source, with 100% conﬁrmatory results; for 9 patients parallel
or serial samples could be analysed, showing >80% concordance. Double
positive ampliﬁcations showed a non-random pattern. The 3 patients
with atypical zoster lesions yielded VZV associated with either HSV1
or HSV2; patients with stomatitis yielded HSV1 or HSV2 in association
with either EBV or HHV6; in patients with persistent fever, HSV1
and CMV were more frequently isolated from plasma, co-isolated in
2 cases and associated with either EBV or HHV6 in the other 6 patients.
HHV8 was never ampliﬁed. Molecular diagnosis had a clinical impact in
patients with atypical zoster-like lesions and in most cases of stomatitis.
Conclusion: In immunocompetent patients, double positive ampliﬁca-
tions of Herpes Viruses seem to be rather frequent from selected clinical
specimens. Our results suggest that they reﬂect true and complex patterns
of viral re-activation, associated with frequently encountered clinical
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conditions. Molecular analysis of these patterns by Real Time PCR
ampliﬁcations may be useful to guide clinical management in selected
cases.
P1435 Monitoring of Epstein-Barr virus DNA in whole-blood
samples of paediatric liver transplant recipients
M.P. Romero, M.P. Gonza´lez, E. Frauca, P. Jara, M.P. Pen˜a,
A. Gutierrez (Madrid, ES)
Introduction: Quantitative analysis of the Epstein–Barr virus (EBV)
genome has been recently reported to be helpful for early identiﬁcation
of EBV viraemia which could reduce the risk of post-transplantation
lymphoproliferative disorder (PTLD). The aim of this study was to
determine circulating EBV DNA after transplantation in paediatric
patients in relation to primary EBV infection and developing of PTLD.
Methods:We retrospectively analysed EBV-DNAemia in paediatric liver
transplant patients by a quantitative real-time PCR assay (afﬁgene® EBV
trender, Sangtec, Sweden).
The EBV genome load in whole blood was measured serially in a total
of 9 recipients of liver transplantation. The mean number of samples
analysed per patient was 6.4 (range 4−8).
All patients were treated prophylactically with ganciclovir IV during
the ﬁrst month after transplantation and continued with oral Aciclovir
or Valganciclovir during three months. Only in the patients with
positive EBV-DNAemia were continued with treatment oral. The
immunussuppressive protocol including tacrolimus and steroids was used
during the ﬁrst year post-transplantation.
Results: Before transplantation 3 patients were EBV seropositive
and 6 were EBV seronegative. Five of the six patients who were
EBV seronegative before transplantation developed positive EBV DNA
samples and the levels were high (mean level 2.38×105 copies/mL, range
6.88×103–4.67×105 copies/mL). In these patients the primary infection
developed between 12−16 weeks after transplantation.
In patients who were seropositives before the transplantation the EBV
DNA levels were low (mean 1.48×103 copies/mL, range 7.14×102–
1.90×103 copies/mL).
Patients with symptomatic EBV infections had higher EBV DNA
levels than those with asymptomatic infection (median 3.70×105 vs
1.74×103 copies/mL). The frequent symptoms were fever, elevated
aminotransferases and neutropenia.
One of the patients developed PTLD grade 1. In this patient the
EBV DNA levels, retrospectively investigated were the highest (mean
1.48×106 copies/mL, range 5.24×105–2.00×106 copies/mL). In this
patient when the levels of immunosuppressives agents were gradually
lowered the hypertrophic amygdala disappeared.
Conclusions: Serial measurement of EBV viral load by quantitative
PCR is a useful tool for monitoring the course of EBV infection
and to help detect the patients who are at the highest risk for PLTD.
Frequent monitoring can by used to make modiﬁcation in the levels of
immunosuppressives and/or antiviral agents.
P1436 Cytomegalovirus reactivation in inﬂammatory bowel disease
F. Hanses, B. Salzberger, J. Scho¨lmerich, C. Franzen (Regensburg, DE)
Objectives: Clinical signiﬁcant cytomegalovirus infection or (re)-
activation is rare in immunocompetent patients, however, much more
frequent in immunocompromised patients. CMV reactivation occurring
in patients with inﬂammatory bowel disease (IBD) has been insufﬁciently
characterised so far concerning frequency and clinical signiﬁcance.
Patients with IBD (ulcerative colitis, Crohn’s disease) are supposed to
be less immunodeﬁcient than patients after solid organ or bone marrow
transplantation or patients with HIV. However, previous studies suggest
a more severe course of the disease in CMV positive patients, eventually
pointing to a local immune imbalance.
Methods: After establishing highly sensitive PCR methods to detect
both CMV DNA and mRNA of immediate-early, early and late CMV
genes (using RT-PCR after DNA digestion), we investigated tissue from
IBD patients and controls. So far, 12 IBD patients (7 of whom reveived
immunosuppressive therapy) were studied.
Results: IBD patients with disease activity under moderate to strong
immunosuppressive therapy (n = 7, on local or systemic steroids,
methotrexate, azathioprin, TNF-a-inhibitor) showed a higher degree of
CMV activity than IBD patients with routine control biopsies or patients
with disease activity under no immunosuppressive therapy or mesalazine
alone (n = 5). Both DNA positivity in tissue biopsies and the degree of
CMV speciﬁc mRNA transcripts were higher in the patient group under
immunosuppressive therapy (83% vs. 60% for CMV DNA and 43% vs.
20% for CMV mRNA.
Conclusion: CMV (re-)activation seems to be associated with IBD
disease activity and immunosuppressive therapy. It is not clear yet
whether this is due to immunosuppression or a refractory disease
course. Although the total number of patients studied so far is small,
these ﬁndings warrant the investigation of the role of CMV associated
complications in a larger patient cohort.
P1437 Real time PCR for monitoring herpes simplex virus load
in tracheal aspirates of intensive care unit patients
N. De Vos, A. Vankeerberghen, A. Boel, I. Demeyer, L. Van Hoovels,
H. De Beenhouwer (Aalst, BE)
Objectives: Detection of Herpes Simplex Virus (HSV) in respiratory
secretions of ventilated patients by culture is described but the
signiﬁcance of these ﬁndings remains unclear. Publications with fast and
reliable methods for quantitative detection of HSV in lower respiratory
tract samples are lacking. We started an observational study in which
HSV viral load was monitored in tracheal aspirates of ventilated ICU
patients by a quantitative real time PCR (Q-PCR).
Methods: Successive tracheal aspirate samples of ventilated adults
(n = 65) staying at the ICU were collected. Sampling was started on
day 3 of intubation. Nucleic acid extraction was performed on the
NucliSens-EasyMAG® (bioMe´rieux). DNA-extract was used for Q-PCR
with primers and probe targeting the DNA polymerase gene of HSV-1
as well as HSV-2 (ABI 7000 Sequence Detection System).
Results: The Q-PCR gave very stable and reproducible results with
minimal intra- and inter-run variability. The assay could detect 102
copies/mL of HSV and no interferences were observed with bacteria,
fungi or other viruses.
Of the included patients 32% were mechanically ventilated for at least
12 days. In 65% of these patients HSV was detected at any point. In
these long term intubated patients often a sharp increase was observed in
consecutive samples coinciding with clinical deterioration and bacterial
Ventilator Associated Pneumonia (VAP). Q-PCR could demonstrate in
some of these patients extremely high viral loads (>108 copies/mL
tracheal aspirate). Administration of acyclovir treatment resulted in
gradual decrease of the viral load.
Conclusion: Q-PCR can be used to monitor the HSV viral load
quantitatively in tracheal aspirates of intubated patients. An increase
in HSV viral load is often observed in ICU patients who are intubated
for a long time. Under acyclovir administration a decrease of HSV viral
load can be observed. Further studies need to be done to investigate
whether antiviral treatment can inﬂuence the incidence of VAP or the
ﬁnal outcome in ICU long term intubated patients.
P1438 Seroprevalence and genotyping of Varicella zoster virus
strains in the Russian Federation
O. Vankova, T. Ulanova, V. Loparev (Nizhny Novgorod, RU; Atlanta, US)
Background: Varicella zoster virus (VZV) is distributed worldwide and
is associated with diseases both in children and in adults. In Russia, data
on VZV seroprevalence in adults and children in different parts of the
country is limited, and the genetic variability of circulating VZV strains
is unknown.
Objectives: We aimed to study the seroprevalence of VZV in population
in various age groups, and characterise VZV strains from known
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chickenpox and varicella zoster cases. Further, all known genotyping
methods were compared.
Materials and Methods: The IgG antibodies to VZV were measured
from 2,000 serum samples by using commercial EIA test for VZV.
Specimens for VZV genotyping were obtained from skin lesions of 61
paediatric and adult patients. PCR ampliﬁed fragments of virus DNA
were examined with three different genotyping methods. Genotyping was
being carried out by sequencing analysis on ABI 3100 Avant Genetic
Analyzer instrument (ABI, Foster City, CA, USA) and by Real-Time
PCR with Light Cycler instrument (Roche, Indianapolis, IN, USA).
Results: Seroprevalence to VZV varied from 45% in children aged 2
months (maternal antibodies) or 30% in children of 1 year old rising to
more than 90% towards the age of 10 years and remaining then about
at the same level to older age. All VZV DNA samples were Pst+Bgl−
(in ORF38 and 54, accordingly) and did not have Sma I site in VZV
ORF 62. These data showed that Russian VZV strains are not related
to Japanese (J) VZV vaccine-like variants. All analysed VZV strains
belonged to European (E1 and E2) genotype identical to Europenian
reference Dumas and HJO strains or to C and B genotype according
to Breuer classiﬁcation system. Similar VZV strains were found in
countries which border Russian Federation in Europe and Asia.
Conclusion: These data gave a reference to immunisations strategies and
can be useful to predict possible consequences after carrying out mass
vaccination against VZV, with vaccine created on the basis the Japanese
genotype strain.
P1439 Mutagenesis analysis of the NS2B determinants of a
tick-borne ﬂavivirus NS2B-NS3 protease activation
B. Pastorino (Marseille, FR)
The genus Flavivirus, family Flaviviridae, contains more than 70 viruses,
many of which are arthropod-borne pathogens of humans and animals.
Being critical for virus replication, the viral protease NS2B-NS3 is
an interesting target for inhibitors with possible use as antiviral drugs
especially by inhibiting the complex formation. Alkhurma virus (ALKV)
is a tick-borne class-4 ﬂavivirus responsible for several human cases
of haemorrhagic fever in Saudi Arabia and a protease assay, using a
p-nitroanilide substrate (BAPNA) had been previously developed in our
laboratory (Bessaud et al., 2005).
In the present work, in an attempt to identify conserved residues
and motifs essential for the NS2B-NS3 protease activity, we ﬁrst
compared ALKV NS2B sequence with the corresponding sequences
of other ﬂaviviruses. The deltaNS2B sequence alignment analysis
revealed that only a few residues (L50, W60, G68, G81 and E89) are
conserved and the differences observed between viruses studied were
regularly distributed along the deltaNS2B region affecting all the motifs
previously described for NS3 protease activation. Based on this sequence
comparison, alanine substitutions were introduced in the NS2B sequence
at residues W60, G68, L73, Q77, G81 by site-directed mutagenesis.
In addition, substitution mutants V88D and V88K were generated as
well as a deletion one called A¨V88. Two chimeric proteases were also
constructed, with the NS2B cofactor from Langat virus and Dengue virus
type 3 replacing the ALKV sequence. The kinetic parameters of the
deltaNS2B-NS3pro mutant proteases was measured and compared with
the activity of the wild-type ALKV enzyme. Finally, four mutants and
the two chimeric proteins exhibited reduction of protease activity against
BAPNA showing that tight complementarity of the proteins sequences
is necessary for NS2B-dependant activation of NS3.
In conclusion and for the ﬁrst time, the enzyme-cofactor interactions
of a tick-borne ﬂavivirus were analysed and two critical NS2B residues
for ALKV NS3 activation V88 and Q77 were identiﬁed. This study
also highlighted the need to enlarge and accumulate the experimental
identiﬁcation of NS2B important residues with protease complex
belonging to different ﬂavivirus cluster
P1440 Human papillomavirus genotyping by DHPLC and
sequencing
E. Dimitriadis, N. Pandis, E. Kada, F. Lazaraki, E. Kouri-Bairaktari,
A. Kourtis, M. Karakoulaki, S. Kanakakis (Athens, GR)
Objectives: Since HPV is the central causal factor in cervical cancer,
understanding the epidemiology and geographical area distribution of
the most prevalent HPV genotypes constitutes an important step towards
development of prevention strategies. This study was aimed to a detailed
HPV genotyping with a combination of molecular techniques, in women
attended the Cervical Pathology Department of “Helena Venizelou”
Hospital.
Methods: HPV Hybrid Capture applied to all samples. All the samples
were also genotyped using PCR with a set of consensus primes
(L1C1/L1C2M, Gp5+/Gp6+, PU-1M/PU-2R), combined with High-
Performance Liquid Chromatography and direct sequencing.
Results: Up to now, 154 samples have been tested. 22.7% was
found positive for High Risk genotypes with the Hybrid Capture.
39.6% was positive by the PCR methods. 15 different genotypes were
identiﬁed, 14 of these being High-risk genotypes. HPV56 was the most
frequent genotype (22.9%) followed by HPV33 (14.7%), HPV31 (9.8%),
HPV39 (9.8%) and HPV58 (8.1%). In 14.7% of the samples double
infection was found.
Conclusion: HPV genotyping by extensive molecular techniques allows
a more precise estimation of the most frequent HPV genotypes in a
given population. To the best of our knowledge this is the ﬁrst study in
a Greek population with these techniques.
P1441 Oncogenic human papillomavirus type distribution by L1
and E6/E7 sequencing
S. Perez, I. Lopez, M.J. Lamas, M.J. Alvarez, F.J. Vasallo, F. Ulloa,
J. Torres (Vigo, ES)
Objectives: A subgroup of human papillomavirus (HPV) termed “high-
risk” is associated with more than 90% of cervical cancers. The aim of
this study was to know the high-risk HPV distribution in women and its
relationship with cytology in our environment.
Methods: 197 samples of endocervical scrapes (January to September,
2006) from 193 patients with recent cytological/histological data were
selected. 3 PCRs per sample were carried out for the ampliﬁcation of
L1 and E6/E7 regions and the human b-globine gene, using consensus
primers (MY09/MY11, HPCF/HPCR, HBBF/HBBR respectively). The
PCR products of L1 and E6/E7 regions were analysed by sequencing
using the same primers (Big Dye Terminator sequencing kit. Applied
Biosystems. GenBank database).
Results: 2 samples (1%) were excluded because they were inhibited.
HPV was detected in 59/195 samples (30.3%): 45/195 (23.1%) high-risk
HPV, 2/195 (1%) low-risk HPV, 6/195 (3.1%) undetermined risk, 2/195
(1%) non-genotypable and 4/195 (2.1%) co-infections. The distribution
of high risk genotypes according to cytological data was: normal
cytology 17/140 (12.1%), atypical squamous cells of undetermined
signiﬁcance (ASC-US) 7/21 (33.3%), low grade squamous intraepithelial
lesion (LSIL) 11/22 (50%), high grade squamous intraepithelial lesion
(HSIL) 8/10 (80%), carcinoma 2/2 (100%). 20 of these 45 high-risk HPV
(44.4%) were detected by only one of the two especiﬁc PCRs used.
50 patients were infected by only one HPV type: HPV 16: 17/50 (34%),
HPV 31: 5/50 (10%), HPV 52: 3/50 (6%), HPV 56: 3/50 (6%), HPV
33: 3/50 (6%), HPV 66: 3/50 (6%), HPV 58: 2/50 (4%), HPV 82: 2/50
(4%), HPV 35, 39, 45, 53, 68: 1 of each type (2% each). It is important
that certain genotypes undetected by commercial methods (HPV 53, 66,
82) were found in 12% of the patients. HPV 16 was the most frequent
genotype detected in the patients with high-grade lesions (7/10 with
HPV 16), however we have not found one predominant genotype in the
patients with low-grade lesions (10/32 with HPV 16).
Conclusions: (1) PCR and DNA sequencing of part of L1 and
E6/E7regions of HPV have a good sensitivity and diagnostic utility
for the screening of uterine cervix cancer. (2) The ampliﬁcation of
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both E6/E7 and L1 genes was necessary for the accurate detection and
genotyping of HPVs. (3) HPV 16 was the most frequent genotype found
in our population, followed by HPV 31. (4) HPV 16 represents most of
the high-risk HPVs associated with HSIL and carcinoma.
P1442 Ampliﬁcation and sequencing of a 190bp segment containing
nucleotide 6240 from prototype human papillomavirus16
L1 gene and 10 clinical isolates from the UK
H. Al Zoubi, P. Vallely, A. Turner, M. Guiver (Manchester, UK)
Previous studies have shown that all HPV16 clinical isolates, for which
sequence data is available, have a cytosine to guanosine (C to G)
nucleotide change at position 6240 relative to the prototype HPV16
sequence. The coordinate L1 amino acid 202 resulting from this change
is aspartic acid instead of histidine (D202H). This change has been
suggested to be important to escape the immune response and was
also found to be important for the efﬁcient assembly of HPV16L1
recombinant proteins into virus-like particles which are currently being
used as a vaccine against HPV infections. An HPV16 genome cloned
into pAT153 plasmid was obtained by our laboratory in 1986. However,
no information on the source of the cloned isolate was available. In an
attempt to identify the cloned HPV16 isolate for further L1 proteins
expression study, we ampliﬁed and sequenced a 190bp segment of L1
gene which contained the coding region for the nucleotide of interest
(6240). In this isolate nucleotide 6240 was found to be C and the
correspondent amino acid at codon 202 in which the C nucleotide is
found was therefore histidine. Based on the previously published data
and on the NCBI BLAST alignment, we identiﬁed the cloned HPV16 to
be the prototype HPV16 isolate. To ﬁnd an appropriate HPV16 isolate for
protein expression and to conﬁrm the presence of the D202H observation
in clinical isolates, 10 clinical isolates collected from UK patients with
different degrees of cytological abnormality were also ampliﬁed and
sequenced using the same PCR and sequencing conditions. All clinical
isolates were found to contain nucleotide G at position 6240 coding for
aspartic acid at position 202 in the L1 gene.
The established PCR and sequencing conditions could be used to conﬁrm
the presence of D202H in HPV16 isolates before proceeding to protein
expression of HPV16L1. It could also be used to sequence larger
numbers of clinical isolates from patients with different degrees of
cytological abnormality, which will further help in understanding the
HPV16 associated pathology.
P1443 Isolation of a canine-like human rotavirus strain G3P[3]
from a child with acute gastroenteritis hospitalised in
Palermo, Italy
S. De Grazia, G.M. Giammanco, S. Ramirez, A. Cascio, V. Martella,
S. Arista (Palermo, Messina, Bari, IT)
Objectives: Group A rotavirus are the most common aetiologic agents
of acute gastroenteritis in children and infants worldwide. They are
ubiquitous viruses, also infecting the young of many animal species.
There are a number of reports of atypical human rotavirus strains, that
show some genetic and antigenic features of rotavirus isolated from
various animal species. Such features suggest that the occurrence of
rotavirus genetic reassortment and interspecies transmission may occur
in nature. In the present study, we report the molecular analysis of
VP7, VP4, VP6 and NSP4 genes of an unusual human rotavirus strains
G3P[3], detected in a young child with acute gastroenteritis in Palermo,
South of Italy, during 1997.
Methods: The rotavirus strain PA260 was isolated from a 2 year-old
child admitted with severe diarrhoea at the “G. Di Cristina” Children’s
Hospital of Palermo, Italy during an epidemiological surveillance study.
As it showed a G3 type, VP7 related, a P, VP4 related, not determinable
type, and a subgroup I speciﬁcity, it was considered atypical and it was
submitted to VP7, VP4, VP6 and NSP4 characterisation by sequence
analysis.
Results: The viral strain was characterised as G3P[3] rotavirus, showing
a 99% and 98% identity in the VP7 and VP4 proteins, respectively, to
the canine rotavirus RV52/96 strain isolated in Bari in 1996. Also the
analysis of VP6 and NSP4 proteins revealed an high amino acid identity,
95% and 98.8% respectively, of PA260/97 to the canine RV52/96 strain.
No human G3 strain, available in GenBank, appeared as closely related
to PA260 strain as RV52/96 strain.
Conclusions: Since the VP7, VP4, VP6 and NSP4 sequences of
the PA260/97 strain are located very close to canine RV52/96 strain
sequences, it is likely that the infection of the Italian child was the result
of canine-to-human transmission. The PA260 strain is the third rotavirus
strain with G3P[3] type described throughout the world and the ﬁrst in
Italy.
P1444 Evaluation of a real-time RT-PCR assay for the diagnosis of
measles virus infections during a measles outbreak in Greece
S. Kokotas, M. Giannaki, E. Horefti, D. Sgouras, M. Logothetis,
P. Panagiotopoulos, T. Georgakopoulou, A. Kansouzidou,
M. Theodoridou, A. Pangalis, A. Mentis (Athens, Thessaloniki, GR)
Objectives: The aim of the study was to evaluate a real-time RT-PCR
(RRT-PCR) for the detection of measles virus (MeV) RNA in clinical
specimens collected during a measles outbreak in Greece.
Materials and Methods: Serum samples and at least one of the
following samples, namely, heparinised blood, pharyngeal exudate and
urine, were collected from suspected measles cases. All cases came
from the measles outbreak in Greece, (October 2005–August 2006).
The presence of MeV-speciﬁc IgM in patient sera was analysed by
a commercial indirect ELISA (Enzygnost, Dade Behring). Equivocal
results were re-tested with an IF method (BIOS). Viral RNA was
extracted from peripheral blood mononuclear cells (PBMC), pharyngeal
exudates and urine by Qiagen Viral RNA mini kit. A quantitative RRT-
PCR (Schalk et al, 2004) was utilised for the detection of MeV-RNA
in all three types of samples, based upon ampliﬁcation of a 413 bp
amplicon in the carboxyterminal region of measles nucleoprotein gene,
detected by a FRET hybridisation probe pair on the Light-Cycler.
Results: In total, 94 specimens from measles suspected cases were
included in the study. In 87 patients, at least one method (serology
and/or RRT-PCR) was positive for MeV infection. Of those cases, 78
were positive and 7 negative by both methods, while 9 cases were
positive solely by RRT-PCR. However, in six of the 9 cases positive
by RRT-PCR and negative by serology, all specimens had been collected
during the ﬁrst two days after onset of the rash, which might lead to
false-negative results by IgM serology. After exclusion of these cases,
sensitivity, speciﬁcity, positive and negative predictive values for the
RRT-PCR were calculated at 100% (95%CI 95.4–100.0), 70% (95%CI
34.8–93.3), 96% (95%CI 89.5–99.2) and 100% (95%CI 59.0–100.0)
respectively. Pharyngeal exudates yielded a higher proportion of MeV
RNA detection, followed by PBMC and urine samples.
Conclusion: A higher detection rate was observed for MeV RNA in
pharyngeal exudates and PBMC than for speciﬁc IgM in serum. RRT-
PCR is a useful method for MeV infection conﬁrmation and should
supplement serology, especially when the specimens for MeV infections
are collected within 2−3 days after rash onset and a second visit of the
patient is not practical.
P1445 Molecular diagnostics of noroviruses detected in Apulia,
Italy
M. Santantonio, C. Rizzo, M.F. Coscia, D. Rizzi, G. Favia, M. Barile,
R. Bavarese, D. De Vito (Bari, IT)
Objectives: Human caliciviruses have been considered one of the most
common causes for nonbacterial acute gastroenteritis outbreaks and
sporadic cases in adults and children worldwide.
A research network set up to study food-borne viruses covering ten
European countries found that norovirus was responsible for over 85%
of all non-bacterial outbreaks. Their role as the second cause of sporadic
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cases of viral gastroenteritis has also been reported by several studies
carried out in other European countries.
Italy has no speciﬁc surveillance system for viral gastroenteritis and
laboratory diagnosis is only carried out in a few cases. Therefore the
impact of NV infection is currently unknown and little information is
available about circulating strains.
The aim of this study was to evaluate the relative contribution of
noroviruses to sporadic cases in adults and children of acute nonbacterial
gastroenteritis in Apulia and to investigate the genotype of the strains
involved.
Methods: A panel of 273 stool specimen collected over a two years
period of time (2004–2005), were derived from cases of gastroenteritis
and included in this study.
Information, collected by means of a standardised questionnaire,
included: age, sex, hospital and division, diagnosis.
All faecal samples have been tested for NLVS by RT-PCR.
The primer used in this study were JV12 and JV13 located in the ORF1
region, and amplify region of 327 bases, of the RNA-dependent RNA
polymerase gene of NLVs.
Results: Among the 273 stool specimens studied, 43 cases (15.7%) were
associated to noroviruses infection.
The seasonal distribution of the episodes showed that acute gastroenteri-
tis caused by norovirus were distributed in winter months.
The age of the individuals was one of the factors analysed: norovirus
were more common among children under 5 years and in those 15 to 19
years old.
The frequent diagnosis associated were gastroenteritis (38%) and
diarrhoea (23%), and the virus was more frequently detected in paediatric
division.
Sequence analysis using the database Food-borne Viruses Europe
revealed strains belonging to the Lordsdale genotype (GGII.4) and
Rotterdam genotype (GGII.3).
Conclusion: The high detection rate of norovirus as the cause of
gastroenteritis in adults and children reported in this study supports
their inclusion in routine screening to diagnose sporadic cases of acute
gastroenteritis.
P1446 Detection of polyomaviruses and herperviruses in human
adrenal tumours
L. Barzon, M. Trevisan, G. Masi, A. Porzionato, M. Iacobone, G. Palu`
(Padua, IT)
Objectives: The presence of polyomaviruses and herpesviruses in
adrenal tumours and their role in adrenal tumorigenesis has never been
investigated, even though the adrenal gland seems to be a preferential
site of infection by these viruses and adrenal steroid hormones have
been shown to activate their replication. Aim of this study was to
investigate whether there is an association between viral infection and
adrenal tumours.
Methods: A total of 128 human adrenal tissue samples, including 20
normal adrenal tissues, 37 nonfunctioning adrenocortical adenomas,
16 cortisol-producing adenomas, 12 aldosterone-producing adenomas,
3 androgen-producing adenomas, 16 adrenocortical carcinomas (14
functioning and 2 nonfunctioning), and 24 adrenal medullary tumours
(including 21 benign pheochromocytomas, 1 malignant pheochromocy-
toma, 2 ganglioneuromas) was investigated for the presence of viral
DNA sequences of the herpesviruses EBV, HCMV, HSV1, HSV2, VZV,
HHV6, HHV7, and HHV8 and the polyomaviruses JCV, BKV, and SV40
by real-time quantitative PCR assays on DNA estracted from frozen or
formalin-ﬁxed parafﬁn-embedded samples. Expression of viral genes was
investigated by immunohistochemistry.
Results: Herpesviruses and polyomaviruses sequences and gene
expression, which were detected in a high proportion of both
normal and neoplastic adrenal samples (overall, viruses were found
in 15% normal adrenals, 25% benign adrenal tumours, and 31%
malignant tumours). The polyomaviruses SV40 and BKV were more
frequently found in adrenocortical carcinomas and in the malignant
pheochromocytoma, whereas herpesviruses, especially EBV and HCMV,
were more frequently detected in functioning benign adrenocortical
tumours, often as coinfection. Moreover, tumours from patients with
severe hypercortisolism frequently showed herpesvirus co-infections at
high viral copy number. In positive samples, immunohistochemical
analysis demonstrated EBV and CMV lytic gene expression, but
no expression of latent genes, suggesting virus reactivation. As for
polyomavirus-positive tumours, expression of T antigen was conﬁrmed
by immunostaining.
Conclusions: Our study suggests that the adrenal gland could be a
reservoir of infection for these viruses and that hormone overproduction
by the adrenal gland could represent a trigger for virus reactivation.
On the other hand, these viruses could also contribute to adrenal cell
proliferation and tumorigenesis.
P1447 Prospective evaluation of a commercial enzyme
immunoassay for the rapid antigenic detection of inﬂuenza
A and B virus from paediatric respiratory samples in ﬁve
consecutive inﬂuenza epidemics seasons
J. Reina, E. Ruiz de Gopegui, A. Mena, M. Macia (Palma de Mallorca,
ES)
Objectives: We report a prospective study of the efﬁcacy of a
commercial enzymoimmunoassay (EIA) compared with the shell-vial
culture method (MDCK cell line) in the rapid antigen detection of
Inﬂuenza A (IA) and Inﬂuenza B (IB) viruses in the respiratory samples
of paediatric patients obtained in ﬁve consecutive ﬂu seasons (2000–
2005).
Material and Methods: Each of the respiratory samples (nasopha-
ryngeal aspirates) was subjected to antigen detection against IA and
IB viruses using the rapid differential EIA membrane test (Directigen
FluA+B, Becton & Dickinson Co., Sparks Maryland, USA) following
the manufacturer’s recommendations. At the same time each sample was
inoculated in two shell vials of the MDCK cell line, incubated at 36ºC
for 3 days and stained with speciﬁc monoclonal antibodies against each
virus (Monoﬂuokit Inﬂuenza A and B, Sanoﬁ Diagnostics, France).
Results: In this period we studied 1,077 samples (30.8% were considered
as positive) and we isolated 331 inﬂuenza viruses (234 IA, 70.7% and
97 IB, 29.3%) (p< 0.05). The percentage of inﬂuenza viruses isolated
in the different epidemic periods varies signiﬁcantly. The overall data
of EIA method compared with the shell-vial culture show for the
overall antigenic assay (IA + IB) a sensitivity of 65.8%, speciﬁcity 100%,
positive predictive value 100% and negative predictive value 86.8%.
There were no stastically signiﬁcant differences between the overall
sensitivity values (62.4% vs 74.2%) nor between the negative predictive
values (89.4% vs 96.7%) for the IA and IB viruses. Statistically
signiﬁcant differences were observed only in the sensitivity values for
the IA and IB viruses in the 2000–2001 (18 IA and 4 IB isolates) and
2001–2002 (50 IA and 20 IB isolates) seasons. We detected higher
overall sensitivity overall values for the detection of IB viruses than
for IA viruses. In the 2003–2004 season we only isolated IA viruses
(29.7% of positivity).
Conclusions: In spite of the low overall sensitivity of the commercial
EIA method studied, it must be regarded as an acceptable (high
speciﬁcity), simple and rapid method for use in the antigenic detection
of IA and IB viruses in paediatric respiratory samples.
P1448 Flocked swabs and UTM-RT are pre-analytical tools
suitable for rapid antigen kits, direct immunoﬂuorescence,
culture and PCR diagnostics assay for viral infections
S. Castriciano, A. Petrich, M. Smieja, M. Chernesky (Brescia, IT;
Hamilton, CA)
Objective: Detection of antigens, nucleic acids, and isolation of mi-
crobes depend on pre-analytical devices used for specimen’s collection.
Diagnostic sensitivity varies with the number of cells and free organisms
released in the transport system. It was reported that Flocked Swabs (FS)
and UTMRT (Copan, BS, Italy) enhances analytical sensitivity of antigen
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detection, culture and nucleic acid ampliﬁcation assays. To compare the
Copan FS and UTMRT to the Remel Dacron swabs (DS) and M4RT for
virus culture, epithelial cells recovery for direct immunoﬂuorescence
assay (DFA), antigens and nucleic acids stability for rapid kits and
ampliﬁcation assays from nasopharyngeal swabs (NPS) for the diagnose
of respiratory viruses.
Methods: 5,002 consecutive NPS, collected with FS and UTMRT,
submitted to the Virology Laboratory from November 1, 2004 to
April 30, 2006, were compared to 4,288 NPS collected with DS and
M4RT from November 1, 2002 to April 30, 2004. Of the NPS collected
with FS and UTMRT, 261 were analysed for Flu A/B and 375 for hMPV
by PCR, 291 were tested with 4 rapid antigen kits for RSV, ﬂu A and B.
All NPS were tested by DFA, cells pellets were spotted on glass slides,
ﬁxed and stained with the para 1, 2 and 3, ﬂu A and B, RSV, adenovirus
and hMPV FITC antibodies. NPS were inoculated into R-Mix shell vial
cultures. After 48 h, cells were ﬁxed, and stained with the Pool and
hMPV reagents. Pool positives were typed. For PCR, nucleic acids were
extracted with the miniMAG system. 5 ul puriﬁed nucleic acid was tested
with the RealArt® kit for Inﬂuenza A/B or with an hMPV speciﬁc RT-
PCR.
Results: 1,318/4,288 were positive in the NPS collected with DS and
M4RT: DFA/culture had 538 ﬂu A, 635 RSV, 10 para 1−3, 35 adenovirus;
2,099/5,002 were positive in the NPS collected with FS and UTMRT:
DFA/culture had 663 ﬂu A, 277 ﬂu B, 879 RSV, 171 para 1−3,
109 adenovirus; 101 positive out of 868 tested for hMPV. Antigen tests
had 121 RSV, 33 ﬂu A, 37 ﬂu B and 100 negatives. The PCR detected
102/261 Flu, 66/375 hMPV. NPS collected with FS and UTMRT detected
2,009/5,002 (42%) positive compared to 1,318/2,288 (31%) positive
detected in NPS collected with DS and M4RT.
Conclusions: NPS collected with ﬂocked swabs in UTMRT detected a
higher number of positives than NPS collected with DS and M4RT. The
Copan ﬂocked swabs and UTMRT collection and transport system is a
universal system compatible with rapid antigen kit, DFA, culture and
PCR and supports the detection/growth of hMPV.
P1449 Assessment of the Immulite systems CMV IgM assays in
comparison to the Vidas assay in a clinical evaluation
F. Vlaspolder, P. Singer (Alkmaar, NL)
Objective: Cytomegalovirus (CMV) belongs to the herpesvirus family
with other well-known viruses such as Herpes Simplex Virus (HSV),
Varicella Zoster Virus (VZV) and Epstein-Barr Virus (EBV). CMV
is found throughout the world and although the infection can be
asymptomatic in the general population, it can cause severe infections in
immunocompromised individuals and in newborns of infected pregnant
women. The objective of this study was to evaluate the clinical
performance of the DPC IMMULITE® systems’ CMV IgM assay to that
of the bioMe´rieux VIDAS® for detection of IgM antibodies to CMV.
Methods: A total of 523 samples were analysed on the two DPC
IMMULITE platforms and the bioMe´rieux VIDAS system. Included in
the sample population were 158 pregnancy samples, 37 samples from
transplant cases, 68 samples deﬁned as primary CMV infections, 153
known negatives, 15 BBI panel, 44 cross-reactives (RFand toxoplasma
IgM) and 48 samples deﬁned as EBV infections.
Results: The overall agreement to the VIDAS assay was 92.3%
for IMMULITE and 92.8% for IMMULITE 2000. In assessing the
performance of the IMMULITE assays within the speciﬁc populations
tested, the Mikrogen® CMV recombinant immunoblot, clinical ﬁndings
if available, and EBV serology were used to further analyse the true
IgM reactivity to CMV. Upon resolution of discordant results with these
additional methods, the IMMULITE assays and the VIDAS assay showed
acceptable agreement within the speciﬁed patient populations.
Based on the blot results, some samples originally identiﬁed with
the VIDAS assay as CMV reactive cases, were reclassiﬁed as EBV
infections. Of the 48 samples identiﬁed as reactive to EBV and non-
reactive to CMV, the IMMULITE (2000/One) assays resulted correctly
in up to 37/39 of the 48 cases, while the VIDAS assay resulted correctly
in up to 23 of the 48 cases
Conclusion: Overall analysis of the IMMULITE and VIDAS results
indicates that the IMMULITE CMV IgM assays are comparable in
performance to the VIDAS assay in all sample populations tested.
Additionally, the IMMULITE assays have a lower level of cross reactivity
interference to EBV, suggesting a higher level of accuracy in reporting
a true CMV IgM result.
P1450 Evaluation of real-time PCR based assays for the detection
and quantitation of CMV DNA
M. Rudolph, B. Willert, T. Grewing, J. Fuhrmann (Hamburg, Berlin, DE)
Introduction: Infections with human cytomegalovirus (CMV) are
usually asymptomatic or related with harmless symptoms. But severe
problems occur if embryos, transplant patients, patients under immuno-
suppressive therapy or AIDS patients get infected. CMV infection in this
risk group can even be fatal. The aim of this work was the evaluation
of real-time PCR assays for the fast, sensitive and speciﬁc detection of
CMV DNA and the reliable quantitation of the viral load. These assays
are important and useful for testing organ donors, monitoring of CMV
patients under antiviral therapy, and for the protection of unborn children.
Materials and Methods: The artus® PCR Kits were designed and
optimised for different real-time PCR instruments: LightCycler®, the
Rotor Gene™ 3000 and the ABI PRISM®7000–7900 Instruments.
The analytical sensitivity was determined by probit analysis. Using
negative human EDTA-plasma was spiked with pre-quantiﬁed CMV.
Serial dilutions were prepared, puriﬁed using the QIAamp® DSP Virus
Kit and analysed with the respective artus CMV PCR Kit. The analytical
speciﬁcity was tested with isolates of related viruses and other human
pathogens. The diagnostic speciﬁcity and sensitivity was determined by
analysing 177 samples in comparison with the COBAS AMPLICOR™
CMV MONITOR System.
Results: The determined analytical sensitivity was 65, 57 and 64
copies/mL for the LightCycler Instrument, the Rotor-Gene 3000, and the
ABI PRISM assay, respectively. Cross reactivity was excluded testing
isolates of other pathogens. The diagnostic sensitivity and speciﬁcity
of the artus CMV PCR Kits was determined by comparison with the
COBAS AMPLICOR CMV MONITOR System. Clinical sensitivity of
100% was determined.
Conclusions: The results demonstrate that the artus CMV PCR Kits,
fulﬁl all requirements for a fast, sensitive, and speciﬁc detection of CMV
DNA and the reliable quantitation of the CMV viral load. Therefore,
the artus CMV PCR Kits can be perfectly used for the successful
management of CMV disease, especially in immunocompromised
patients and pregnant women.
Trademarks: QIAGEN®, artus®, QIAamp®, (QIAGEN Group),
ABI PRISM® (Applera Corporation), CORBAS AMPLICORTM,
LightCycler® Instruments (Roche Group), Rotor-GeneTM (Corbett
Research)
P1451 Pitfalls in molecular detection of human respiratory
syncitial virus
A. Vankeerberghen, A. Boel, H. De Beenhouwer (Aalst, BE)
Objective: Molecular detection techniques take, due their speed,
speciﬁcity and sensitivity, a major place in the detection of viruses on
clinical samples. We started 2 years ago with the detection of human
respiratory syncitial virus (hRSV) by real time PCR (RT PCR) on
aspirates. The PCR technique proved to be more sensitive than the
antigen test. In the autumn of 2006 hRSV antigen positive samples that
were negative by RT PCR were found. Further experiments were done
to resolve the problem.
Methods: Antigen testing was performed with the hRSV Respistrip®
(Coris Bioconcept). RNA was extracted (EasyMAG, bioMe´rieux) from
the aspirates, converted in cDNA (Applied Biosystems) and analysed by
RT PCR on an ABI 7000 (Applied Biosystems) with primers and probe
located in the Nucleoprotein (N) gene of hRSV-A and hRSV-B. Primers
and probe were designed on the basis of BLAST analysis of all sequences
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available in Genbank (October 2004). PCR products of antigen positive,
RT PCR negative samples were analysed by agarosegel electrophoresis
and sequenced with the CEQ Dye terminator cycle sequencing Quick
start kit on the CEQ 8000 capillary sequencer (Beckman Coulter).
Results: Agarosegel electrophoresis of the RT PCR products of hRSV
antigen positive, RT PCR negative samples showed the presence of a
PCR product indicating that the RT ampliﬁcation was normal. Sequence
analysis of the PCR product revealed the presence of 3 extra mismatches
in the binding site of the probe which apparently results in insufﬁcient
binding of the probe. BLAST-analysis showed that the “new” hRSV
variant sequence was not present in Genbank (November 2006). The RT
PCR products of 5 hRSV antigen positive, RT PCR negative samples
were sequenced and they all showed the same nucleotide sequence. RT
PCR with a new probe complementary to the binding site of the “new”
hRSV variant gave a strong positive ampliﬁcation signal. All together,
these results indicate that a new hRSV variant arose with mutations in
the binding site of the probe in the N-gene. This gene is thought to be
one of the more conserved genes of hRSV.
Conclusion: PCR is a powerful technique that detects targets with a high
speciﬁcity and sensitivity. Exactly this speciﬁcity can also be a drawback.
All living creatures are prone to evolution and the mutagenesis rate of
viruses is high. Therefore, care must be taken with the use of PCR as
golden standard. The use of a two-target PCR might decrease the chance
of missing mutated viruses.
P1452 Microarray analysis of liver cells containing a full-length
hepatitis C virus replicon
A. Ciccaglione, C. Marcantonio, R. Bruni, E. Tritarelli, A. Costantino,
P. Tataseo, M. Rapicetta (Rome, Sulmona, IT)
Objectives: Infection with hepatitis C virus (HCV) represents the major
cause of liver disease, affecting more than 170 million individuals
worldwide. Several data indicate that HCV replication can inﬂuence the
progression and the severity of liver diseases by a modulation of cellular
gene expression. To evaluate HCV-induced modiﬁcation in the global
expression proﬁle, we compare gene expression of the human hepatoma
cell line 21−5 carrying the full-length HCV replicon with the parental
cell line Huh7 and the cured replicon cells in which the HCV replicon
was removed by IFN-a´ treatment.
Methods: Gene expression was examined using Applied Biosystems
Human Genome Survey Arrays containing 31,700 60-mer oligonu-
cleotides probes representing a set of 27,868 individual human genes
and more than 1,000 control probes. The study was designed to analyse
gene expression for three biological replicates for each cell line and
two technical replicates for each biological replicate, for a total of 18
microarrays. The fold change of HCV replicon vs. parental or cured
cell lines was analysed by ﬁltering the dataset of normalised signals
(using p value <0.01 and <0.05 and a signal-to-noise ratio >3) and
performing ANOVA statistical analysis. PANTHER Classiﬁcation system
(Celera Genomics) was used to interpret gene expression data obtained
comparing HCV replicon vs parental or cured cells. Alteration of speciﬁc
genes was conﬁrmed by Real-time PCR.
Results: Data obtained from this study indicated that HCV replication
results in a speciﬁc and signiﬁcant alteration of genes involved in
cellular process such as endoplasmic reticulum (ER) and oxidative stress,
apoptosis, lipid metabolism, immune defence and cell cycle.
Conclusion: The data from the microarray analysis are relevant for the
deﬁnition of HCV pathogenesis and possibly related molecular markers.
P1453 Enterovirus meningitis in south west Greece: clinical
manifestations and CSF laboratory ﬁndings
F. Frantzidou, A. Agelatou, K. Dumaidi, J. Kaleyias, A. Papa,
A. Antoniadis, A. Spiliopoulou (Thessaloniki, Patras, GR)
Introduction: Enteroviruses are common human viruses associated
with various clinical syndromes, from minor febrile illness to severe,
potentially fatal conditions such as aseptic meningitis, myocarditis and
neonatal enterovirus sepsis. The method of molecular identiﬁcation
not only provides rapid diagnosis of enterovirus infection, but also
information about the genetic character of the viruses.
Objective: The aim of the study was the assessment of the enteroviral
(EV) RNA detection by reverse transcription polymerase chain reaction
(RT-PCR) in the diagnosis of enteroviral meningitis.
Methods: All consecutive cases of aseptic meningitis that were admitted
at the Children Hospital of Patras during the study period (December
2004–June 2006) were including in the study. Clinical data were
analysed. Rapid detection of EV RNA was directly carried out in the
cerebrospinal ﬂuid CSF using RT-PCR targeting to VP1−2A region and
nucleotide sequence analysis.
Results: Thirty cases of aseptic meningitis were including during the
study period. RT-PCR for EV RNA was positive in 12/30 (40%) of
cases. The ratio male: female was 2:1. The main clinical manifestations
were: fever (100%), headache (42%) nuchal rigidity (40%), skin rash
(30%) and vomiting (30%). The CSF leukocyte count was elevated in
all the cases and revealed a lymphocytic-monocytic predominance. The
identiﬁed virus were found to be HEV-B group: 1 strain echovirus 11
(8.3%), 1 echovirus 14 (8.3%), 2 strains echovirus 9 (16.7%), 3 strains
echovirus 6 (25%) and 5 new strains (41.7%) of the HEV-B species.
Five cases (41.7%) were taken place at the end of October–November
2005 (HEV-B) and three cases (25%) with echovirus 6 in January.
Conclusions: The predominant strains during the study period were the
new strain of the species HEV-B and echovirus 6. The new strain of
the species HEV-B had prominent fall seasonality; in addition, there
was a perennial distribution of EV meningitis cases. The molecular
techniques (RT-PCR/VP1−2A) seem to be accurate and rapid methods
for the detection and identiﬁcation of enterovirus.
Molecular detection of rare pathogens
P1454 First molecular detection of Rickettsia sibirica ssp. sibirica
in skin biopsies from patients with north Asian tick typhus
S. Shpynov, P.-E. Fournier, M. Granitov, I. Arsen’eva, N. Rudakov,
A. Matushchenko, I. Tarasevich, D. Raoult (Omsk, Barnaul, Moscow,
RU; Marseille, FR)
Objectives: The tick-borne North Asian tick typhus (NATT) caused by
Rickettsia sibirica ssp. sibirica (R. sibirica), has been described in Russia
in 1935. Currently, active foci of this communicable disease are spread
in 18 administrative territories of Siberia and Far East, in the Asiatic
part of Russia. Approximately one of half registered cases occur in the
Altay region. From 1936 to 2005, more than 64,000 NATT cases have
been registered in Russia. However, the diagnosis is mostly based on
clinical and serological data, and no direct conﬁrmation is available.
Methods: In Spring 2005, 12 inoculation eschar biopsies were taken
from patients with clinically typical NATT in the city of Barnaul, Altay.
Rickettsiae were detected using partial ampliﬁcation of the 5′-end of the
ompA gene with the 190−70 and 190–701 primers, and ampliﬁcation
of the gltA gene using the CS1d-CS535r and CS409d-RP1258n primer
pairs. PCR reactions were carried out in a PTC-200 thermal cycler (MJ
Research, Inc, Watertown, MA). Positive PCR products were sequenced
using the d-Rhodamine Terminator Cycle Sequencing Ready Reaction
kit (Applied Biosystems, Warrington, UK) and an ABI 3100 PRISM
automated sequencer (Applied Biosystems). Obtained sequences were
compared to the GenBank database.
Results: Ten of the 12 skin biopsies were positive by PCR amplifying
both genes. Inferred sequences were identical and were 100% similar
to those of R. sibirica ssp. sibirica (gltA, GenBank accession number
U59734; ompA, U43807).
All 10 proven NATT cases were characterised by a mild clinical picture
different from that of Far-Eastern rickettsiosis caused by Rickettsia
heilongjiangensis in Russian Far East.
Conclusions: We demonstrate for the ﬁrst time by direct identiﬁcation
of the aetiological agent in skin biopsies the aetiological role
of R. sibirica ssp. sibirica in NATT in the Altay territory of
Russia. Other tick-borne members of the order Rickettsiales, such as
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R. heilongjiangensis, R. helvetica, R. slovaca, R. aeschlimannii, and
Anaplasma phagocytophilum are distributed in natural NATT foci in
the Altay territory as well as in territories free from NATT. Our results
highlight the need to pursue molecular identiﬁcation of tick-borne human
infections in different regions of Russia.
P1455 Learning from mistakes: Taq-polymerase contaminated
with b-lactamase sequences provides false ﬁndings of
Streptococcus pneumoniae containing TEM
R. Koncan, A. Valverde, M. Morosini, R. Canto´n, G. Cornaglia,
F. Baquero, R. del Campo (Verona, IT; Madrid, ES)
Background: In 2004 an Asiatic group published in a local journal an
article entitled “Study on the molecular epidemiology of b-lactamase
TEM gene in isolated Streptococcus pneumoniae” (PMID: 15769331).
In this article the authors referred about S. pneumoniae isolates carrying
TEM genes, never described before. Furthermore, the authors described
new TEM sequences (TEM-129) which were included in the GenBank
data base under the numbers AY452662 and AY392531. The aim of this
work was to explore the reasons for such abnormal ﬁndings.
Methods:We used total DNA extracted from a S. pneumoniae collection
of 24 isolates with MIC values for penicillin of 2−4mg/mL. The
strains were serotyped, PFGE-typed, and the PBP2x, 2b and 1a
were characterised. Total DNA from TEM-4 harbouring Klebsiella
pneumoniae F40 and S. pneumoniae R6 strains were used as positive
and negative controls. To evaluate the presence of TEM genes, PCR
experiments with speciﬁc primers were performed with two different
Taq-polymerase enzymes: FastStart (12032945001 from Roche) and
Taq-Core (Qbiogene, MpBIO). PCR products were further sequenced.
Hydrolysis assays using nitroceﬁn as subtract were also performed in
crude extracts of S. pneumoniae isolates.
Results: Using the FastStart polymerase, a clear positive ampliﬁcation
corresponded to the bla-TEM size were observed in all strains
tested, including the negative control. With this enzyme, ampliﬁcations
occurred also in absence of pneumococcal DNA. Four different
amplicons were sequenced, which corresponded to the ESBL TEM-116
previously described. When the other Taq-polymerase was used, positive
ampliﬁcations were not detected in any of the isolates, except the positive
control. Nitroceﬁn test was consistently negative in all isolates.
Conclusion: Caution should be required to accept data about the
presence of TEM-b-lactamases based only on PCR-based results in the
absence of controls that might reveal TEM sequences contamination of
ampliﬁcation reagents.
P1456 Periodontal pathogenic bacteria in oral microﬂora of
halitosis patients in Latvia
D. Rostoka, J. Kroica, A. Reinis, V. Kuznecova (Riga, LV)
Objectives: Halitosis, commonly referred to as bad breath, may be
due to physiological and/or pathological causes of oral, gastroinstenal,
nasopharingeal or other origin. Oral bacteria hydrolyse proteins and
further degrade the amino acids, which leads to halitosis. Oral anaerobes,
such as Porphyromonas, Prevotella, Treponema spp., produce volatile
sulphur compounds (VSC) from amino acids.
Methods: The recent investigation began in 1997 and included 260
untreated halitosis patients (43.1 year, 167 females, 93 males). Due to
the fact that a tactful approach to a patient is very important detailed
patient’s questionaire was prepared. This questionnaire was approved
by the Committee of Ethics of the Ministry of Welfare of Latvia and
covered questions about the use of antibiotics and other medicine,
especially which affect the quality and quantity of saliva, as well as
questions concerning smoking, the use of alcohol, etc. The oral odour
or bad breath was conﬁrmed by the measurements made by the portable
sulphide monitor or halimeter (Interscan Corporation, Model RH-17E).
The halimeter quantiﬁes breath measurements in parts-per-billion (ppb)
of VSC. Periodontal pocket and dorsal part of tongue microﬂora was
analysed by quantitative PCR (micro-IDent®, Hain Lifescience) for
amounts of periodontal pathogenic bacteria: A. actinomycetemcomitans,
P. gingivalis, T. forsyth, T. denticola, and P. intermedia. The patients
were examined for individual genetic periodontal risk. Polymorphisms
of the IL-1A− 889 and IL-1B+ 3953 gene cluster was checked
(GenoType®PST, Hain Lifescience). ANOVA, t-test, and chi-square were
used to detect statistically signiﬁcant differences.
Results: Halimeter measurements of 260 patients showed increased VSC
(210–340 ppb compared with control group 40−70 ppb).
GenoType®PST results showed that individual genetic periodontal risk
of chronic periodontal diseases was positive in 66.9% out of 260.
Conclusions: Halitosis is mainly an oral problem (94.7%) in Latvia.
Halitosis is a disease which can be diagnosed by a proper examination.
Halitosis can be diagnosed and controlled using different methods. Since
protein degradation is present in oral cavity and increased amount of
VSC, there are changes in oral microﬂora with big prevalence of oral
anaerobes. That can explain often incidence of periodontal diseases
in Latvia. Periodontal disease diagnosis can be based on presence of
periodontal pathogens.
P1457 Streptobacillus moniliformis endocarditis diagnosed by
16S rRNA gene PCR and direct sequencing applied to a
resected heart valve
D.H. Forster, A. Becker, P. Stahlhut, M. Elgas, E. Kniehl (Karlsruhe, DE)
Objective: S. moniliformis is a facultatively anaerobic, fastidious Gram-
negative rod that may develop into long ﬁlaments containing granules,
bulbs and bands; coccal forms may also be observed. It occurs naturally
in the nasopharynx of rats and other rodents. Human infections result
either from bites of rodents (rat bite fever) or from consumption of
contaminated food or water. The most common manifestations are
fever, arthralgias and rash. Endocarditis is a rare complication of
S. moniliformis infection, underlying cardiac valve abnormalities have
been reported in most cases. Though S. moniliformis is a fastidious
organism, diagnosis is usually made by culture. We describe a case of
S. moniliformis endocarditis leading to valve replacement. Diagnosis was
made by 16S rRNA gene PCR and direct sequencing applied to the
resected heart valve and a typical Gram stain ﬁnding of the resected
valve.
Case report: A 74-year-old female patient was admitted for mitral valve
replacement. She presented with a history of fever since 3 weeks and
reduced general condition due to mitral valve insufﬁciency grade IV
with endocarditis. The cause of endocarditis was unknown at the time
of admission.
Gram stain of the resected heart valve revealed pleomorphic, ﬁlamentous
Gram-negative rods, culture remained sterile. Partial 16 S rRNA gene
PCR was performed on the resected valve, the received amplicon was
sequenced. Comparison of the sequence (GenBank accession number:
DQ914526) with the GenBank database showed a 100% sequence
homology with two published S. moniliformis sequences. Together with
the typical Gram stain ﬁnding, this can be considered as unambiguous
identiﬁcation of S. moniliformis as causative agent of endocarditis.
Empirical broad antibiotic therapy was then changed to penicillin G
4×5 Million U for 4 weeks. The postoperative course was uneventful.
Rodent contact or a rodent bite was denied by the patient, the modus of
aquiring the agent is therefore unclear.
Conclusion: Identifying the causative agent of endocarditis cases by
16S rRNA gene PCR and direct sequencing applied on resected heart
valves is in the meantime an established method in culture-negative
endocarditis. The sequencing result in this unusal case is supported by
the Gram stain ﬁnding.
To the best of our knowledge, this is the ﬁrst report of S. moniliformis
endocarditis in Germany and the ﬁrst worldwide diagnosed by the means
of molecular biology.
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P1458 Molecular and serologic evidence of Anaplasma
phagocytophilum and Borrelia burgdorferi sensu lato in dogs
in the Czech Republic
K. Kybicova, Z. Kurzova, L. Uherkova, P. Schanilec, S. Spejchalova,
Z. Svobodova, D. Hulinska (Prague, Brno, CZ)
Objectives: Dogs have been considered important domestic host of
Anaplasma phagocytophilum and Borrelia burgdorferi sensu lato. The
aim of this study was to assess the prevalence of these microorganisms
among dogs from the Czech Republic.
Methods: A total of 192 samples of dog blood and 65 ticks (43 female,
12 male) from 35 dogs collected in Moravia and North Bohemia over
the year 2006 were investigated. Blood samples were obtained from (i)
health dogs naturally exposed to ticks (38.5%), (ii) imunosuppressed
dogs (30.7%), (iii) dogs with oncological disease (5.7%) or (iv) dogs
with neurological disorder or arthritis (25%). DNA was isolated from
blood plasma and buffy coat or from whole ticks. All DNA samples
were analysed by PCR with the LD primer set (Borrelia) and the Ehr
521–790 primer set (Anaplasma) targeting 16S rDNA. The samples
PCR positive for Borrelia were retested by real-time PCR with primer
sets also targeting 16S rDNA (VS, BG, BB) and with a recA primer
set to conﬁrm the positivity and to identify the Borrelia species. The
samples PCR positive for Anaplasma were retested with G3-G4 primers.
Serological study was carried out using ELISA detection of speciﬁc
IgG and IgM antibodies against Borrelia afzelii. Antibodies against
A. phagocytophilum were examined by IFA test with the ﬂuorescein
isothiocyanate-conjugated goat anti-dog IgG diluted at 1:320.
Results: One dog (0.5%) and nine ticks (13.8%) were positive for
B. burgdorferi sensu lato while four dogs (2.1%) and four ticks (6.2%)
were positive for A. phagocytophilum. ELISA demonstrated that 9.7%
and 5.6% of samples contained anti-Borrelia IgG and IgM antibodies,
respectively. If borderline values were considered, the positivity would
be 11.1% and 13.2% for the IgG and IgM antibodies, respectively. The
A. phagocytophilum-speciﬁc IgG were found in 11.4% of dogs.
Conclusions: The ﬁndings of the present study partly conﬁrm results
of other European studies. The difference between the PCR results for
ticks and dogs may come from the fact that most ticks are from healthy
hunting dogs.
P1459 Application of hybridisation probe-based real-time PCR
assay to monitor the Brucella DNA load in patients with
brucellosis throughout different stages of the disease
G. Vrioni, E. Priavali, G. Pappas, C. Gartzonika, S. Levidiotou
(Ioannina, GR)
Different methods have been described for diagnosis of human
brucellosis. Among them, peripheral blood real-time PCR assay
(RTPCR) seems to be a very promising technique not only for the
initial diagnosis of the disease, but also for the post-treatment follow-up
by the accurate quantiﬁcation of Brucella DNA. A quantitative RTPCR
assay using the LightCycler instrument (Roche Diagnostics, Mannheim,
Germany) was employed for the monitoring of bacterial DNA load in
patients with brucellosis throughout different stages of the disease.
A total of 130 peripheral blood specimens were examined from 39
patients with acute brucellosis as determined by blood culture, serologic
tests, and the patients’ clinical picture. A minimum of 3 specimens (one
at diagnosis, one at the end of treatment and at least one during the
post-therapy follow-up period) were obtained per patient. RTPCR assay
was based on direct ampliﬁcation of a 207-bp DNA sequence of a gene
that codes for the synthesis of an immunogenetic 31-kDa protein speciﬁc
for Brucella genus (BCSP31). The ampliﬁcation product was detected
by using as ﬂuorescence technique hybridisation probes labelled with
LightCycler Red 640 (detected in channel F2). Primers and probes were
designed by TIB MOLBIOL (Berlin, Germany) and ﬂuorescence curves
were analysed with LightCycler software v. 3.5. Following ampliﬁcation,
melting curve analysis was performed to verify the speciﬁcity of PCR
products. A standard curve, comprising 10-fold dilutions of Brucella
BCSP31 DNA from 101 to 107 target equivalents, allowed quantiﬁcation
of unknown samples.
RTPCR assay was 100% sensitive and speciﬁc for B. melitensis at
the time of diagnosis. Despite the decrease of bacterial DNA load at
the completion of treatment, the RTPCR results for 87% of patients
remained positive. Six months after therapy, 77% of patients presented
with residual bacterial DNA without experiencing relapse. From 21
patients who were monitored for >1 year after therapy, 13 continued
to have positive RTPCR results, albeit asymptomatic.
In conclusion, B. melitensis DNA may persist on ﬁnalising and after
therapy, despite of the appropriate treatment and apparent recovery from
infection. The signiﬁcance of these ﬁndings remains to be elucidated in
reference with their pathogenic and therapeutic implications.
P1460 Proof of speciﬁc DNA using nested-PCR in patiens with
different clinical form of Lyme borreliosis
D. Picha, L. Moravcova, D. Holeckova, K. Sedivy, E. Zdarsky,
V. Maresova (Prague, CZ)
Objectives: This study was aimed to the direct proof of borrelial DNA
with polymerase chain reaction (PCR) in patients with lyme borreliosis
(LB) and to estimate the speciﬁty of individual primers in the diagnostic
of its clinical forms.
Methods: Into the prospective study 71 patients with LB were enrolled
(35 patients with neuroborreliosis, 14 with joint involvement and 22 with
skin form). The criteria for inclusion were recent clinical symptoms of
LB and the presence of speciﬁc antibodies in the blood, CSF, joint ﬂuid
(conﬁrmed by Western blotting) or proof of DNA in body ﬂuids. Before
the treatment the presence of borrelial DNA was tested in plasma, CSF,
joint ﬂuid and urine, after the treatment in plasma, urine and joint ﬂuid.
A system with ﬁve newly derived primers has been used, with three
primers speciﬁc for chromozomal genes coding 16SrDNA, ﬂagellin and
p66 and two for plasmid genes which are coding the outer membrane’s
protein OspA, OspC. The presence of borrelial DNA was tested by
nested-PCR in parallel with all the primers.
Results: From the total number of 71 examined patients the borrelial
DNA was proved in 42 patients (59.2%) before the treatment; 23 positive
patients (65.7%) were found in group of neuroborreliosis, 10 positives
(45.5%) showed signs of skin involvement and 9 patients (64.3%) were
positive in arthritis. After the treatment the borrelial DNA was proved
in half of the patients with neuroborreliosis (13×) and in the skin
form patients (4×). In patients with the joint form the proof was the
same as before the treatment. From the 105 positive ampliﬁcations
the most frequently positive primer was 16SrDNA 54× (51.4%). Less
sensitive were primers OspA (20×;19%), OspC (14×;13.3%) and
ﬂagellin (14×;13.3%). In 14 patients (31.1%) with skin and joint form
of LB only borrelial DNA without speciﬁc antibodies was proved.
Conclusion: This study has shown that in the period before treatment
the sensitivity of PCR was 59.2% using 5 primers and including all
the clinical forms of borreliosis. The most positive result has been
found by using the primer 16SrDNA (51.4%). The same reactivity was
being shown in plasmid sequences coding genes OspA and OspC and
chromosomal sequence for ﬂagellin. Examination of the borrelial DNA
in urine displayed the same sensitivity as in CSF.
The study was supported by grants of Ministry of Health and Education
(IGA-8293, MSM 0021620812)
P1461 Performance of a new molecular assay for detection and
differentiation of Bordetella spp. DNA
C. Koidl, M. Bozic, H.H. Kessler, E. Marth (Graz, AT)
Objective: To investigate the performance of the new molecular artusTM
Bordetella LC PCR Kit (QIAGEN Hamburg GmbH, Germany) assay
that provides detection and differentiation of Bordetella spp. DNA in a
routine diagnostic laboratory.
Methods: The assay was performed according to the manufacturer’s
package insert. A total of 85 nasopharyngeal swabs obtained from
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patients with a clinical presentation compatible to B. pertussis infection
were tested with the new assay in an International Standards Organization
(ISO9001, 2000)-certiﬁed routine clinical laboratory.
Results: Sixteen of 85 samples were found positive for Bordetella
DNA. Differentiation by melting curve analysis yielded B. pertussis
in 7 samples, B. parapertussis in 1 sample, and B. bronchiseptica
in another one. In the remaining 7 samples, Bordetella DNA was
detected by analysis of ﬂuorescence curves of IS481 and IS1001
ampliﬁcation products only. The heterologous internal control was
consistently detected. In 7 specimens inhibition of the assay was found.
Conclusion: In conclusion, the new molecular assay includes all features
required for molecular detection and differentiation of Bordetella spp.
DNA. It proved to be suitable for the routine diagnostic laboratory
allowing a rapid and safe diagnosis of pertussis.
P1462 Sensitivity of Legionella pneumophila DNA detection in
serum samples in relation to disease severity
B.M.W. Diederen, J.P. Bruin, J.W. den Boer, M.F. Peeters,
E.P.F. Yzerman (Tilburg, Haarlem, NL)
Objectives: Legionella pneumonia can be difﬁcult to diagnose. Existing
laboratory tests all have shortcomings, especially the ability to diagnose
all Legionnella spp. in a specimen that is readily obtainable. The aim
of this study was to assess the sensitivity of PCR as a rapid diagnostic
method and to investigate a possible relation between test sensitivity and
the severity of disease.
Methods: In this study 68 outbreak-related patients (Bovenkarspel, The
Netherlands) with a conﬁrmed Legionnaires’ disease (LD) according to
the European Working Group for Legionella Infections (EWGLI) criteria
were investigated. To investigate the relation between test sensitivity and
severity of disease, the patients were divided into two clinical categories
for pneumonia. Patients were classiﬁed as category 1 (mild pneumonia
and moderately severe) and category 2 (severe pneumonia). LD was
deﬁned as severe when two or more of the following conditions were
present: (1) respiratory rate >30/min, (2) chest radiograph showing
bilateral involvement or involvement of multiple lobes, (3) shock,
(4) PaO2 < 60mmHg or arterial oxygen saturation <92%. A real-time
assay targeted at speciﬁc regions within the 5S rRNA gene was used.
Results: Samples included 136 serum samples from 68 patients with
proven LD. In one sample inhibition of PCR occurred; this patient was
excluded from the analysis. Among the patients with LD 39% (26/67)
tested positive in PCR in the ﬁrst available serum sample, and this
number increased to 54% (36/67) if all serum samples were included
in the calculations. The detection rate for all non-inhibited samples was
35% (47/135). For 58 patients data on disease severity was available. In
patients with severe pneumonia, 49% (19/39) tested positive in the ﬁrst
available serum sample, increasing to 67% (26/39) if all serum samples
were included in the calculations. In patients with mild and moderately
severe pneumonia, 37% (7/19) tested positive in the ﬁrst available serum
sample, increasing to 53% (10/19) if all serum samples were included.
Conclusion: The sensitivity of PCR on serum samples found in our
study was relatively low compared to previous studies. Although we
observed a higher sensitivity in patients with more severe disease (49%
vs 37%, p = 0.4), these differences did not reach statistical signiﬁcance.
P1463 A real-time PCR protocol to detect Neisseria meningitidis
in formalin-ﬁxed parafﬁn-embedded tissues
A. Fernandez-Rodriguez, B. Alcala, G. Vallejo, J. Go´mez,
R. Alvarez-Lafuente (Madrid, ES)
Objectives: Invasive meningococcal infection is a well-established cause
of sudden death. However, symptoms are often vague and postmortem
ﬁndings may be either indistinguishable from any other infection or
overlooked. For these reasons, the differential diagnosis in sudden deaths
should include Neisseria meningitidis detection. Since cultures may not
be available in fulminant fatal cases, the diagnosis of meningococcus
has to rely on PCR assays. CSF and serum are not always taken as
postmortem samples, and sometimes the only specimens collected at
autopsy are tissues. The aim of this study was to evaluate the usefulness
of a real-time PCR protocol to detect meningococcus in formalin-ﬁxed
parafﬁn-embedded tissues from patients with meningococcal disease.
Methods: Our protocol included: (i) detection of meningococcal DNA,
targeting the ctrA gene, (ii) genogrouping to identify serogroups B and C
(siaD gene) in a multiplex format, and (iii) a rapid conﬁrmation of PCR
products with a microchip CE device. We analysed 15 cases of sudden
death due to meningococcal disease where formalin-ﬁxed parafﬁn-
embedded tissues were available. In all those cases meningococcus
had been detected by real-time PCR in fresh samples. Formalin-ﬁxed
parafﬁn-embedded tissues from 5 cases with other infections and from
5 healthy individuals were considered as negative controls. Optimisation
of real-time PCR conditions was performed, as well as validation studies
with other microorganisms.
Results: In all positive cases Meningococcus was detected in at least one
tissue sample. Meningococcus could be detected in skin, spleen, heart,
liver, lung, kidney, bone marrow, brain and adrenal. Positive results were
obtained in ten-year old parafﬁn-embedded tissues. No false-positive
results were detected in negative controls.
Conclusion: Meningococcus can be detected in formalin-ﬁxed parafﬁn-
embedded tissues from fulminant fatal cases when no other samples are
available. However, a thorough protocol is needed to deal with DNA
degradation and PCR inhibition.
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P1464 Trends in the diagnosis of osteomyelitis at the National
Pathology Reference Center of Venezuela, 1996–2006
S. Dickson-Gonzalez, J. Mota-Gamboa, A. Rodriguez-Morales
(Caracas, Trujillo, VE)
Objectives: To describe and analyse the patterns and trends in the
diagnosis of osteomyelitis at the Instituto Anatomopatolo´gico Jose´
A. O’Daly (the National Pathology Reference Center of Venezuela),
Caracas, Venezuela, 1996–2006.
Methods: A total of 613 patients from our pathological database were
included in this report, since January 1996 to May 2006 (10 years). The
samples processing procedure was through parafﬁn blocks, with tissular
sections (3 um), stained with haematoxylin-eosyn, Ziehl-Nielsen, Gram
and Grocott, then the microscopic evaluation is made. Epidemiological,
clinical and pathological features are also described.
Results: During the study period there was a clear increase in the
diagnosis of osteomyelitis, from 25 cases in 1996 to 92 cases in 2005
(r2 = 0.85, p< 0.05), with a mean of 59±21 cases per year. According
to the trends model (y = 6.497x + 23.267), we could expect for year
2006 a record of 95 cases, during the ﬁrst 5 months of this year
we have diagnosed 23 cases. The sex distribution of these cases is
predominantly male (68.1%) over female cases (31.9%) (p< 0.05).
The histopathological features will furtherly discussed, as well the
aetiological agents.
Conclusion: As we have observed, the incidence of osteomyelitis
is increasing; although the sex and age distribution not. Different
reasons could be attributable to this increase, the number of orthopaedic
surgeries, vehicle accidents and new type of injuries which are more
often seen.
P1465 Long-term clinical and radiological (MRI) outcome
of abscess-associated spontaneous pyogenic vertebral
osteomyelitis under conservative management
G. Euba, J.A. Narvaez, J.M. Nolla, O. Murillo, J. Narvaez, C. Gomez,
J. Ariza (Barcelona, ES)
Objectives: Spontaneous Pyogenic Vertebral Osteomyelitis (SPVO) is
classically considered a medical management disease. Surgical approach
is widely accepted for spinal cord compression or vertebral instability,
but controversial for abscess-associated SPVO. Magnetic Resonance
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Imaging (MRI) is the test of choice at diagnosis, most patients (pts)
showing Soft Tissue Involvement (STI); it seems also helpful for follow-
up, but MRI and clinical outcome interrelation is often unclear. The aim
of this study is to evaluate clinical and MRI outcome of SPVO with STI
under conservative treatment.
Methods: Prospective study (PS, period 2000−05) and retrospective
review (RR, period 1995−99) including pts with SPVO in a 1,000 bed
tertiary hospital, treatment according to medical protocol and follow-up
evaluation considering clinical, biological and MRI ﬁndings at diagnosis,
Early Response (ER, end of planned antibiotic therapy) and Late
Response (LR,  6 months from end of therapy). Inclusion criteria: MRI
at diagnosis showing STI; follow-up MRI; initial non-surgical approach.
MRI images were reviewed by an expert radiologist; STI was classiﬁed
as inﬂammatory reaction (IR) or abscess, and abscesses were measured.
Results: Twenty-seven pts (19 PS, 8 RR) were included, 20 men
(74%), mean age 65 ± 14. All had pain, 17 (63%) fever and 6 (22%)
mild neurological impairment. Main aetiology was Staphylococcus spp.
(11, 41%); no microorganism was identiﬁed in 4 (22%). Bacteraemia
was documented in 21 (81%) and epidural/paraspinal abscess in 18
(67%). Antibiotics were given for median of 9 weeks, orally for
6 weeks. ER: only 3 pts were considered as therapeutic failure (1
underwent laminectomy for paraparesis development; 2 had therapy
extended for persistent clinical ﬁndings) with good ﬁnal outcome;
clinical and biological improvement was seen in the remainder; MRI
showed persistent STI, which diminished in all but 2 pts, whereas
bone and disc ﬁndings hardly improved or worsened. LR: median
follow-up was 29 months, no relapse or related death occurred; all
pts were considered clinical and biologically cured, with mild sequels
in 8 (pain/dysesthesia); MRI still showed bone/disc abnormalities, but
residual IR was infrequent (6 pts).
Conclusion:Most pts with abscess-associated SPVO cure with a medical
approach and 8−10 week antibiotic therapy, STI reduction being found
in MRI at ER point. Bone/disc MRI worsening alone during follow-up
should not suggest therapeutic failure.
P1466 Comamonas testosteroni spondylodiscitis
G. Carolo, M. Ganau, E. De Micheli, M. Gerosa, M. Solbiati (Verona, IT)
Introduction: We describe the ﬁrst case in literature of spondylodiscitis
caused by Comamonas testosteroni. It is a Gram-negative rod, present
in soil, water and animal; rarely involved in human pathology, to our
knowledge until now were described 23 cases in the world medical
literature.
Case: A 63 year-old male, following lumbar discectomy for a L2-
L3 disc herniation (prophylaxis with Cefazoline 1 g 1 hour before
surgery), presented with a persistent ﬁve-week untreatable lumbar pain,
accentuated by walking. On admission, he was apiretic, neurological
examination was normal. Plain Rx rays of lumbar spine showed reduction
of L2 body; MRI of the spine conﬁrmed crush of the L2 body with
vertical line of fracture from the superior to the inferior edge plate of
the vertebra accompanied by an uptake of gadolinium in the epidural
and paraverterbal areas of the L2-L3 interbody space. Full blood, and
urinary tests, showed a normocromic normocitic anaemia, associated to
sideropenia, elevated ESR (72 s) and CPR (1.82mg/dl). Tumour markers
were negative, as well as Total Body CT. Blood culture was positive
for Comamonas testosteroni, therefore he started antibiotic therapy with
teicoplanine (600mg e.v./day) and ciproﬂoxacin (400mg 2times/day)
(therapy supported by the evidence at antibiogram of sensibility to
aforementioned drugs). He performed a CT guided biopsy of L3:
anatomopathologic, immunohystochemical and cytological examination
of the biopsy were all negative; from cultures grew Comamonas
testosteroni. Teicoplanin was stopped and the therapy prosecuted with
ciproﬂoxacin and cotrimoxazole After 3 months of sustained therapy a
control MRI of the lumbar spine showed initial resolution of the L2-L3
discitis and Xrays conﬁrmed the stability of the L2 body. The patient kept
on observing rest, and drug protocol until the 9th month, serial blood
test conﬁrmed CPR and ESR within normal ranges, MRI conﬁrmed
the completely resolution of the inﬂammation and X-rays showed good
healing of the L2 vertebral body fracture.
Conclusion: Discitis is a rare complication of disc operation (0.2−0.8%);
direct contamination during surgical time is far more frequent than
haematogenous contamination. In our patient the pathogenic role of
C. testosteroni was suggested by two facts: ﬁrst the organism was isolated
from both the peripheral blood and CVC cultures; second the evolution
was favourable when the patient was treated with adapted antimicrobial
agents.
P1467 Mixed infection of the lower limb caused by rare bacterial
and fungal pathogens in a patient with multiple traumatic
injuries
G. Corti, N. Mondanelli, M. Losco, L. Bartolini, A. Fontanelli,
F. Paradisi (Florence, IT)
Objectives: Enterobacter amnigenus and Leclercia adecarboxylata are
Gram-negative aerobic bacilli of the family Enterobacteriaceae that have
been isolated from water and, rarely, from various clinical specimens.
Absidia is a ﬁlamentous fungus of the class Zygomycetes that is
ubiquitous in nature and can cause infection, primarily in compromised
hosts. Here we describe a case of mixed infection of the left lower
limb caused by E. amnigenus and L. adecarboxylata and subsequent
superinfection by Absidia in a patient with severe traumatic injury.
Methods: Multiple surgical samples of the wound were collected for
microbiological cultures. The identiﬁcation of bacteria was carried out
by standard techniques (isolation on blood agar plates and subsequent
biochemical identiﬁcation). The susceptibility testing was performed by
an automated method (VITEK2, BioMerie´ux, France). The identiﬁcation
of the fungus was carried out after direct microscopic examination and
inoculation onto Sabouraud dextrose agar for culture.
Case report: A 37-year-old male with multiple traumatic injuries
(open fractures of the left distal femur and tibia with bone loss,
multiple fractures of the left foot with soft-tissue involvement) following
motorcycle accident was admitted to our emergency department after ﬁrst
aid on the road. He was treated with irrigation and debride´ment, open
reduction and internal ﬁxation of the tibia and foot fractures, and external
ﬁxation of the femur fracture. Intravenous antibiotics (tobramycin,
teicoplanin, metronidazole) were empirically initiated on the basis of a
hospital protocol. After 14 days, a below-knee amputation was performed
as there was no possibility for limb salvage. Following isolation of two
isolates of E. amnigenus and L. adecarboxylata, piperacillin/tazobactam
was substituted for tobramycin. After seven days, a novel amputation
on a more proximal level was needed for control of stump infection.
Following isolation of a strain of the genus Absidia, a 15-day course of
liposomal amphotericin B was started, and control of stump infection
was ﬁnally achieved. At ﬁve months from ﬁnal surgery, no signs of
infection are present.
Conclusion: E. amnigenus and L. adecarboxylata are multi-susceptible
environmental Enterobacteriaceae and Absidia an ubiquitous zy-
gomycete, and all of them are rare agents of infection. Nevertheless,
they can cause severe life-threatening infections that require complex
and sometimes devastating treatments.
P1468 Predictive risk factors for amputation in diabetic fetid foot
infections
J. Barberan, B. Sanchez, M.A. Menendez, J.R. Toral, A. Fe, I. Fraile,
R. Alguacil, D. Martinez, J. Prieto (Madrid, ES)
Objective: Lower extremity amputation (LEA) is one of the most
disabling complications of diabetes. We report a serie of diabetic
foot infections treated with antibiotic therapy and surgery, to examine
the association of usual tests in its management with incidence of
amputation.
Methods: All enrolled patients had a previously history of diabetes
and infection deﬁned by clinical symptoms and signs. Infections were
categorised by size and depth. Usual test in management were determined
at baseline in all patients.
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Results: Seventy eight patients (68.8 ± 2.3 years) were included (55
had vascular insufﬁciency, 7 neuropathy, and 15 both). Amputation
was performed in 26 (33.3%) cases, and it was associated signiﬁcantly
more frequently with previous ulcers (p = 0.001), vascular insufﬁciency
(P = 0.011), size depth of tissue involeved (P = 0.001), Wagner’s
classiﬁcation (P = 0.00001), purulent secretions (P = 0.048), and fetid
smell (p = 0.033). In a multivariant analysis doppler arterial pressure,
Wagner’s classiﬁcation, and ESR (erythrocyte sedimentation rate) were
found the best variables to indicate the risk of LEA.
Conclusions: With this logistic model and once known three usual tests,
easy to obtain (ESR, doppler arterial and Wagner’s classiﬁcation), we
could predict correctly, in about 90% of cases, the survival of lower
limb afected. These results suggest that single usual tests the low cost
can be very useful to ﬁnd out the risk of amputation in the diabetic fetid
foot.
P1469 Liver abscesses: changes in aetiology associated with
inmigration
A. Salinas, J. Troya, M. De Go´rgolas, I. Gadea, M. Ferna´ndez-Guerrero
(Madrid, ES)
Background: Liver abscesses are relatively common intrabdominal
infections which aetiology, diagnosis and treatment are well-known.
However, changes on the microbiology and prognosis over the years have
not been assessed and speciﬁcally, the role of immigration of people from
South America on microbial aetiology has not been assessed.
Methods: Retrospective study of 60 patients seen by the authors from
1985–2005. For comparison, patients were classiﬁed into 2 groups: those
studied from 1985–1995 and those seen from 1996–2005. Demographics,
clinical ﬁndings, microbiology, treatment and prognosis were compared.
Results: Patients were 40 men and 20 women (male/female ratio
2:1) with a mean age of 53.7 years; 85% were spaniards and 15%
from other countries, mainly from Central and South America. The
most frequent symptons were fever (80%) followed by abdominal pain
(71.6%) in both periods. Diagnosis was made by sonography in 83.3%
of cases. A single abscess was found in 70%. The right lobe of the
liver was the most frequent involved site (55%). The mean diameter of
abscess was 7.83 cm. A bacterial aetiology was found in 61.6% of cases
and the microorganisms most frequently found were Escherichia coli
(9 cases) and Streptococcus anginosus (9 casos). Amoebic abscess were
diagnosed in 5 cases. Diagnosis was reached by serology in most of these
cases (91.6%). Empirically patients were treated with a combination of
b-lactam and metronidazol. A surgical or percutaneous drainage was
performed in 76.6% of cases. Complete cure was attained in 93.3%
of cases. However, 4 patients died in spite of therapy (2 sepsis, 1
gall bladder adenocarcinoma and 1 perforated diverculitis with sepsis).
The clinical presentation was almost identical in the two periods. The
time from presentation to diagnosis was 3.5 weeks (minimum 3 days;
maximum 8 weeks). Eight out of 9 cases seen in foreigners occurred from
1996–2005 and all amoebic hepatic abscesses occurred in this period.
The most common drainage procedure in the ﬁrst period was open
laparotomy (50%), whereas percutanous ultrasound-guided drainage was
most frecuent in second period (94%).
Conclusions: Advances in knowledge of liver abscess has led a more
rapid diagnosis of infection and drainage by means of percutaneous
techniques with less morbidity and mortality. Immigration may introduce
changes in the microbial aetiology of liver abscess in Europe.
P1470 Changing clinical features of severe odontogenic infections
L. Seppa¨nen, A. Lauhio, C. Lindqvist, R. Rautemaa-Richardson
(Helsinki, FI)
Objectives: The number of patients requiring hospital care due to
odontogenic infection has increased in the Helsinki and Uusimaa
Hospital District, Finland. Our aim was to evaluate the clinical features
of the patients hospitalised due to an odontogenic infection.
Methods: In this retrospective study two patient cohorts (years 1994–
1996 and 2004) admitted to the Helsinki University Central Hospital due
to an odontogenic infection were analysed. This patient series covers
all cases of severe odontogenic infections in the region of Helsinki
University Central Hospital (1.4 million inhabitants in year 2004).
99 (1994–1996) and 102 (2004) consecutive patients were included.
Age, gender, fever at admission, WBC counts, CRP levels, focus, fascial
spaces involved, need for re-operation and length of hospital stay were
reviewed.
Results: The incidence of these severe infections increased from 5.3
to 7.2 per 100,000 inhabitants since 1994 to 2004. The two patient
cohorts (1994−96 and 2004) did not differ in age (mean 40 and 43 years,
respectively), gender (60.6% and 63.7% males, respectively), WBC
count on admission (mean 12.4 and 12.5×103/mL, respectively), focus
(mandibular molar 76.8% and 81.4%, respectively) or fascial spaces
(submandibular space involvement 46.5% and 49.0%, respectively).
However, the proportion of patients with WBC greater than 11×103/mL
(49.5% and 53.9%, respectively) and CRP levels greater than 90mg/L
(36.3% and 54.9%, respectively), CRP level on admission (mean 89.2
and 112.0mg/L, respectively) and maximal CRP levels (mean 93.4
and 153.7mg/L, respectively), fever on admission (37.4% and 43.1%,
respectively), need for re-operation (8% and 16.7%, respectively) and
intensive care (18.2% and 31.4%, respectively) were markedly higher
in 2004. In addition, the proportion of patients with mental disorders,
cardiovascular diseases and diabetes had also increased.
Conclusion: This study shows that in the Hospital District of Helsinki
and Uusimaa odontogenic infections require hospital care more often
although the admission criteria have not changed. The increase in the
need for intensive care implicates that the infections have become
potentially more severe. The incidence of underlying systemic diseases
has also increased.
P1471 Pyomyositis. A current review
F.J. Ferna´ndez-Ferna´ndez, S. Pe´rez-Ferna´ndez, M. Rubianes-Gonza´lez,
L. Gonza´lez-Va´zquez, R. Puerta-Louro, J. De la Fuente-Aguado (Vigo,
ES)
Objectives: To describe the epidemiological, clinical, microbiological
and therapeutical features of pyomyositis.
Methods: Retrospective descriptive study of the medical records of all
patients diagnosed of pyomyositis in POVISA and CHUVI between 1996
and 2005. Patients with gas gangrene and necrotising fasciitis were
excluded, as well as psoas abscesses due to its different characteristics.
Results: Forty-one patients were included, 27 males and 14 women, with
a mean age of 50 years. An underlying disease was present in 63% of
the patients: diabetes mellitus in 12 patients, human immunodeﬁciency
virus (HIV) infection and injection drug use in 6, chronic kidney disease
in 5, alcoholism in 4 and cancer in 3. The most common affected sites
were thigh (49%) and gluteal regions (22%). Primary pyomyositis was
diagnosed in 36 patients (88%). Evidence of endocardial involvement
was not demonstrated in any patient in whom echocardiography was
performed. The most frequent clinical manifestations at diagnosis were
muscle pain (90%), swelling (66%) and fever (66%). Clinical symptoms
were present between 2 and 60 days before diagnosis. In laboratory
studies leukocytosis was found in 58%, anaemia in 46% and elevated
erythrocyte sedimentation rate in 96% of patients in which they were
analysed.
Diagnosis was performed by ultrasound (with one false negative result),
computed tomography or magnetic resonance imaging. Aetiologic agent
was known in 31 patients (76%). Staphylococcus aureus was found in
23 patients, streptococci in 6 and Salmonella in 3. Four patients have a
polymicrobial infection. Culture of the abscess was positive in 78%, and
blood cultures in 38%. Drainage of the muscle abscess was performed
in 31 patients, open surgical in 14 patients, percutaneous in 13, and both
types in 4 patients, all of them combined with antimicrobial therapy.
Mortality rate was 7%. Advanced age was the only poor prognostic
factor.
Conclusion: Pyomyositis usually has a primary origin and it is caused
by S. aureus. HIV infection and injection drug use are important
predisposing factors. In some patients there are neither leukocytosis nor
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fever, so diagnosis can delay. Patients with pyomyositis and bacteraemia
seem not to require echocardiography to rule out infective endocarditis.
We report a good outcome only with antibiotics in 10 patients, though
more studies should be performed in this direction because of the small
number of patients. Advanced age was related with higher mortality.
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P1472 Enterococcal endocarditis: a comparison of patients with
native and prosthetic valve endocarditis and analysis of risk
factors of mortality
M. Ferna´ndez-Guerrero, A. Goyenechea, A. Salinas, R. Ferna´ndez
Roblas, J. Fraile, M. De Go´rgolas (Madrid, ES)
Background: Enterococci are the third leading cause of infectious
endocarditis. Mortality of enterococcal endocarditis although relatively
low, has not changed in the last decades. We investigated the risk factors
of mortality in a single institution and whether infections occurring on
prosthetic valves are associated with a poorer prognosis.
Methods: Retrospective review of 44 consecutive episodes of entero-
coccal endocarditis with strict case deﬁnitions according to the modiﬁed
Duke’s criteria from a prospective observational cohort of cases of
infectious endocarditis. The main outcome measure was in-hospital
mortality. Stepwise logistic regression analysis was applied to identify
risk factors for mortality.
Results: 27 patients (61.3%) had NVE and 17 (38.6%) PVE.
Predisposing heart conditions were observed in 77.7% of patients
with NVE. A portal of entry was suspected or determined in 38.2%
and the genitourinary tract was the most common source of the
infection (29.7%). Comorbidities were present in 52.2% of cases. Twelve
episodes (25.5%) were acquired during hospitalisation (7 NVE and 5
PVE). Only 3 isolates of Enterococcus faecalis were highly-resistant to
aminoglycosides. Eighteen patients (40.9%) needed valve replacement
due to cardiac failure or relapse. The comparison between cases of NVE
and PVE did not show differences regarding symptoms, complications,
or the need of surgical treatment (12/44% vs 6/35%; ns). The mean time
to diagnosis was shorter in patients with PVE than NVE (30±18 days
vs 9±6 days) and murmurs were more commonly found in patients with
NVE (25/96% vs 10/59%; p 0.02). Eight out of 47 (17%) episodes
were fatal. The mortality rate of patients with PVE and NVE were
not signiﬁcantly different (2/11.7% vs 6/22% respectively; ns). Age
over seventy (p 0.05), heart failure (OR 1.61;CI:1.15–2.25; p 0.001)
and nosocomial acquisition (OR 8.05; 95%CI:1.50–43.2; p 0.01) were
associated with mortality. In the multivariate analysis, only nosocomial
acquisition increased the risk of mortality.
Conclusions: Enterococcal endocarditis occurring on prosthetic valves
are not associated with an increased need of valve replacement nor
mortality. In this series, nosocomial acquisition of endocarditis was the
most important factor determining outcome.
P1473 Current trends of infective endocarditis caused by
Staphylococcus aureus and coagulase negative staphylococci
in Greece: results from the Hellenic Endocarditis Study
Group, 2000–2004
E. Giannitsioti, A. Antoniadou, S. Tsiodras, I. Skiadas, K. Kanavos,
H. Triantafyllidi, H. Giamarellou on behalf of the Hellenic
Endocarditis Study Group
Objectives: Infective endocarditis (IE) of staphylococcal aetiology
emerges worldwide. Current trends of Staphylococcus aureus IE and
coagulase negative staphylococci (CNS) IE were investigated through a
large epidemiological survey in Greece.
Patients and Methods: Cases of IE fulﬁlling the Duke criteria were
prospectively recorded in 20 general hospitals at the metropolitan area
of Athens from 2000–2004. Both S. aureus and CNS cases of IE were
assessed regarding epidemiological issues, and outcome. Chi-square test
was used for statistical analysis of categorical variables.
Results: From 195 eligible IE cases, 34 (17.4%) and 19 (9.7%) were
caused by S. aureus and CNS respectively. S. aureus IE more often than
other causative agents of IE affected patients younger that 40 years old
(11/34, p< 0.001), intravenous drug users-IVDU (9/34, p< 0.001) and
the tricuspid valve (8/34 p< 0.001. Cardiac predisposition for S. aureus
IE was not frequent (5/34, p = 0.005). CNS (11/19, p< 0.001) but not
S. aureus (5/34, p = 0.3) IE cases were nosocomially acquired. CNS
more often affected aortic valve and patients with prosthetic valve IE
(p< 0.001). Mortality at day 28 was higher for CNS (10/19, p = 0.009)
than for S. aureus (11/34, p = 0.2). Surgical rates for CNS were lower
than for other IE causes (1/16 vs 52/118, p = 0.04). On the contrary, there
was no difference in rates of surgery for S. aureus IE (10/24, p = 1.0).
Conclusion: CNS IE was mostly hospital acquired, affecting prosthetic
valves and presenting higher mortality rates. S. aureus IE affected native
valves in younger patients and IVDU. These trends generate the need for
a continuous investigation of risk factors of acquisition of nosocomial
and community acquired staphylococcal IE in Greece in order to better
apply prevention and treatment.
P1474 Risk factors for infective endocarditis and outcome of
patients with Staphylococcus aureus bacteraemia
E. Hill, S. Vanderschueren, J. Verhaegen, P. Herijgers, P. Claus,
M-C. Herregods, W. Peetermans (Leuven, BE)
Objectives: Staphylococcus aureus bacteraemia (SAB) carries a risk for
the development of infective endocarditis (IE). This study investigated
risk factors for S. aureus IE (SAIE) and 6-month mortality in patients
with SAB.
Methods: A nested case-control study including 66 patients with
S. aureus IE (39 community-acquired (CA) and 27 nosocomial) and
132 ad random selected patients with SAB (78 CA and 54 nosocomial)
from June 2000 to December 2005.
Results: The median age of patients with SAB and SAIE was 66 and
68 years respectively. Bivariable analysis showed that unknown origin
of SAB, cutaneous origin, a foreign body, a valvular prosthesis, a
pacemaker, persistent fever, persistent bacteraemia and prior IE were
signiﬁcantly associated with SAIE. In multivariable analysis, unknown
origin of SAB (OR, 4.8; 95%CI, 1.7–13.1; P = 0.003), a valvular
prosthesis (OR, 8.8; 95%CI, 2.8–28.6; P< 0.001), persistent fever
(OR, 3.4; 95%CI, 1.1−10; P = 0.03) and persistent bacteraemia (OR,
7.2; 95%CI, 2.4–21.7; P< 0.001) remained independently associated
with SAIE. Six-month mortality was 8% in patients with SAB versus
35% in SAIE (P< 0.001). In bivariable analysis, MRSA and persistent
bacteraemia were associated with 6-month mortality in patients with
SAB. In multivariable analysis, persistent bacteraemia (OR, 4; 95%CI
1.6–10.1; P = 0.004) remained independently associated with mortality.
Conclusion: Persistent bacteraemia was independently associated with
SAIE and 6-month mortality in patients with SAB. Unknown origin of
SAB, a valvular prosthesis and persistent fever were associated with
SAIE. SAIE has a signiﬁcantly higher mortality than SAB. The optimal
management of SAB and SAIE deserves further study.
P1475 PET-CT scan in patients with infective endocarditis for
early detection of embolisation and metastatic infection
E. Hill, E. D’Hondt, J.H.G. Crevits, S. Vanderschueren,
M-C. Herregods, P. Herijgers, S. Dymarkowski, L. Mortelmans,
W.E. Peetermans (Leuven, BE)
Objectives: In infective endocarditis (IE), the risk for embolisation
and metastatic infection is the highest during the ﬁrst 2 weeks after
initiation of therapy. Before surgical intervention, it is important to
exclude metastatic foci to reduce the risk of relapse bacteraemia in the
presence of a prosthetic valve.
Methods: From March to August 2006, 13 patients (14 episodes) with
deﬁnite IE according to modiﬁed Duke criteria were included. PET-CT
scan was performed within 2 weeks after diagnosis of IE. This study
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investigated whether PET-CT should be recommended in all patients
with IE to detect early peripheral embolisation and metastatic infection.
Results: The mean age was 62 years and 54% were males. The
causative microorganisms were Staphylococcus aureus in 3 episodes,
streptococci in 5, enterococci in 4 and others in 2. Nine episodes involved
native valves and 5 prosthetic. In 3/14 episodes (21%) PET-CT was
positive for peripheral embolisation without clinical suspicion. In 5/14
episodes (36%), PET-CT was positive for metastatic infection, whereof
in 1 episode without clinical suspicion. In 7/14 episodes with clinical
suspicion of metastatic infection, it was not conﬁrmed by PET-CT in 3
episodes. In 1 patient with clinical suspicion of metastatic infection and
a positive PET-CT (spondylodiscitis), it was not conﬁrmed on MRI.
Overall, PET-CT was positive in 4/14 episodes (29%) without previous
clinical suspicion.
Conclusion: Overall, 50% of IE episodes had a positive PET-CT result
for peripheral embolisation and/or metastatic infection. Early detection
of peripheral embolisation and/or metastatic infection by PET-CT in
episodes without clinical suspicion occurred in nearly one third.
P1476 Streptococcus agalactiae endocarditis: improved prognosis
of a severe infection
A. Salinas, A. Goyenechea, M. De Go´rgolas, R. Ferna´ndez Roblas,
M. Ferna´ndez-Guerrero (Madrid, ES)
Background: Streptococcus agalactiae endocarditis is not commonly
found but its mortality has ranged from 34 to 56%, similar to that
observed in most severe forms of endocarditis. However, a better
knowledge of the disease and a more aggressive use of cardiac surgery
may have improved prognosis.
Methods: Review of cases of Streptococcus agalactiae endocarditis seen
by the authors between 1990 and 2005. The diagnosis of endocarditis
was done following the modiﬁed Duke’ criteria. Identiﬁcation of
S. agalactiae and susceptibility tests were performed by conventional
methods.
Results: 10 cases were reviewed: 3 men and 7 women; mean age
61.3 years. Streptococcus agalactiae endocarditis accounted for 1.7%
of all the cases of endocarditis seen during the study period. Fifty per
cent of patients had underlying valvulopathy: 2 previous endocarditis,
1 rheumatic mitral disease, 1 mitral mixoid, 1 mitral calciﬁed. 80% had
a chronic disease: liver cirrhosis 3, cancer of cervix 2, breast cancer 1,
diabetes mellitus 1, parenteral drug abuse 1. The origin of the infection
was the skin (4), cervix (2) and peritoneum (1). The presentation was
acute in all the cases (average duration: 3.3 days) with fever and heart
murmur. Skin lesions and brain embolism were detected in 30%. 4
patients had heart failure. TTE showed vegetations in 50% of cases.
TEE showed vegetations in all the cases that was performed. The size
of vegetations ranged from 5 to 16mm in diameter (average 11.5mm).
The heart valves involved were: mitral valve 60%, aortic 40% and mitral-
aortic 10%. All the isolates were penicillin-susceptible (MIC< 0.1mg/L)
and patients were treated with b-lactam (penicillin or 3rd-generation
cephalosporins) and gentamicin was associated in 60% of cases. Heart
surgery was indicated in all patients with heart failure. Mortality was
20%.
Conclusions: Endocarditis due to Streptococcus agalactiae is an
uncommon, opportunistic infection in patients with severe chronic
diseases. In comparison with historical series, mortality has decreased.
A rapid diagnosis and a judicious use of cardiac surgery are of paramount
importance to improved prognosis
P1477 Nosocomial endocarditis due to Gram-negative bacteria
A. Demitrovicova, L. Findova, V. Krcmery, V. Hricak, M. Karvaj
(Bratislava, Trnava, Nove Zamky, SK)
Objectives: Common cause of infective endocarditis (IE) are Gram-
positive bacteria: staphylococci, viridans streptococci and enterococci,
which represent 50 to 70% of all bacterial isolates from blood cultures
in patients with IE. Culture negative IE represents 25 to 40% and Gram-
negative bacteria 5 to 10%, 90% of them are of nosocomial origin.
Objective of the study was to investigate IE due to Gram-negative
bacteria.
Methods: We assessed the proportion, aetiology, risk factors and
mortality of IE due to Gram-negative bacteria (GNB) within our database
of IE in 23 years in Slovakia. Forty-two (42) cases of IE due to GNB
appeared within 606 cases (6.9%). Most frequently isolated organisms in
42 cases were Pseudomonas aeruginosa (8), Haemophilus inﬂuenzae (7),
Acinetobacter baumannii (6), Klebsiella pneumoniae (6), S. enteritis
(5), E. agglomerans (4), E. coli (4), Citrobacter freundii (1), Serratia
marcescens (1), Pseudomonas ﬂuorescens (1). All of the cases appeared
in hospital.
Results: Comparison of 42 cases (one was polymicrobial) to all
606 cases from the national database in univariate analysis showed
that diabetes mellitus type 1 (6.2% vs. 11.4%, p< 0.045), previous
cardiosurgery (19.4% vs. 9.9%, p< 0.05), prior endoscopy (31% vs.
8.1%, p< 0.04) and vitium cordis (11.9% vs. 3.3%, p< 0.04) were
signiﬁcantly more frequent, and vice versa, prosthetic valve insertion
(2.4% vs. 14.9%, p< 0.01) less frequently observed in IE due to GNB
than among all the cases. Mortality rate was similar in both groups
(11.5% vs. 15%). Proportion of IE due to GNB (6.9%) within 23 years
in Slovakia was similar to proportion of GNIE (5 to 10%) from other
national studies in Europe.
Conclusion: Patients with diabetes mellitus type 1, after cardiac
surgery and/or endoscopy of gastrointestinal or genitourinal tract are at
higher risk of GNIE. Therefore, initial therapy with anti-Gram-negative
antibiotic until aetiology/susceptibility is not determined is advisable.
P1478 Case report: Granulicatella elegans causing native valve
endocarditis
S. Nayman Alpat, I. Ozgunes, S. Nemli, N. Erben, E. Doyuk Kartal,
G. Usluer (Eskisehir, TR)
Objectives: Infective endocarditis (IE) is a life threatening disease of
endocardium of the heart. It is reported that viridans streptococci as
the most common isolates among patients with IE. Abiotrophia and
Granulicatella species form part of the normal ﬂora of the oral cavity.
They are infrequently isolated in patients with IE.
Case report: We report a case of native valve endocarditis attributed to
Granulicatella elegans. A 60 year old man was admitted to our hospital
with malaise and history of fever. He experienced fever 6 days prior
to admission. Fever was maximal in the afternoons without chills and
sweating. He had no history of underlying heart disease. He had a history
of cholecystectomy due to cholelithiasis 3 weeks ago. He was admitted
to another hospital with fever (40ºC) and unconsciousness 4 days prior
to admission. Transthoracic echocardiography was performed and an
intracardiac motile mass was noted on the posterior part of mitral valve.
On physical examination he had a temperature of 37.8ºC, a 3/6 systolic
murmur was heard at all cardiac focuses on chest. No organomegaly
and rashes were detected during examination. Two sets of blood cultures
were taken with BACTEC blood culture bottles and a urine culture was
taken because of pyuria. Both of blood cultures yielded Gram-positive
coccoids. They were identiﬁed as Granulicatella elegans by VITEC II
identiﬁcation system. Urine culture was negative. Physical examination
and laboratory data showed 1 major and 3 minor criteria according to
DUKE criteria for IE. He was successfully treated with ceftriaxone and
gentamycin.
Conclusion: Twelve cases of IE caused by G. elegans have been reported
in the literature up to October, 2006. Senn et al. reported that bacteraemia
caused by immunosuppressed patients compared to other NVS species.
Therefore our patient was immuncompetant and had no underlying
problem that can suppress immune system. It was our limitation not
to perform antimicrobial susceptibility tests for our clinical G. elegans
isolates. We believe that clinical and laboratory departments should work
closely and communicate continuously especially when microorganisms
such as G. elegans that can also be a part of normal ﬂora are isolated in
specimens. Laboratory department should warn clinicians, get clinical
information about patient and consider it can also be pathogen not a
contaminant.
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P1479 Propionibacterium acnes endocarditis
A.L. Gray, M.R. Sohail, L.M. Baddour, A. Virk (Rochester, US; Al
Ain, AE)
Objectives: Propionibacterium acnes is a rare cause of bacterial
endocarditis. When identiﬁed in blood cultures, it is usually considered
a skin contaminant. The purpose of this study is to describe the clinical
presentation, management and outcome of the patients with P. acnes
endocarditis based on our institutional experience and review of the
published medical literature.
Methods: We retrospectively reviewed all cases of P. acnes endocarditis
identiﬁed at Mayo Clinic Rochester and searched the English language
medical literature for all previously published reports.
Results:We identiﬁed 34 cases in the medical literature and 5 cases from
our institutional database (clinical details were available in only 27of
these cases). Mean age of the patients was 53 years (range15−78) and
89% were males. Most of the cases (90%) presented with non-speciﬁc
symptoms including fever, malaise and weakness while 3 patients had
severe valvular insufﬁciency and 2 presented with embolic strokes. Blood
cultures were positive in 81% (22/27) of the cases. All 5 cases with
negative blood cultures were conﬁrmed by positive valve tissue cultures.
In 85% of the cases (29/34), the infection was in associated with
presence of a foreign body (25 patients with prosthetic valves (PV),
1 left ventricular Teﬂon patch, 1 Carpentier mitral valve ring, and 2
involved pacemaker leads). Prosthetic valve infection was complicated
by abscess formation in 50% of the cases and 17% demonstrated valve
dehiscence on echocardiogram. Infection of the Carpentier mitral ring
resulted in detachment of the ring in one case. Only 4 cases had native
valve endocarditis with P. acnes. Majority of the patients (85%) required
surgery; either valve replacement or removal of the pacemaker apparatus.
Eleven percent (3/27) cases died secondary to the infection. In two of
these, death was described as being secondary to splenic rupture and
valve dehiscence. Penicillin resistant isolated was recovered in only one
case. Median duration of post-operative antibiotics was 6 weeks (mean
7.1 weeks). Patients were typically treated with a penicillin derivative
alone or in combination with gentamicin.
Conclusions: P. acnes endocarditis should be considered when this
organism is isolated from multiple blood cultures especially in the
presence of a foreign cardiovascular device. Morbidity is high, and
aggressive medical and surgical interventions are required to achieve
cure.
P1480 Persistent bacteraemic infective endocarditis
L. Findova, A. Demitrovicova, V. Krcmery, P. Kisac, P. Marks (Trnava,
Bratislava, SK; London, UK)
Objectives: Persistent bacteraemic infective endocarditis (PBIE) is
deﬁned as persistence of positive blood cultures for 3 or more days
despite antibiotic therapy. The reason for persistence of bacteraemia is
deﬁcient or inappropriate selection of antimicrobials, resistant organism,
foreign body or prosthetic endocarditis. Objective of the study was to
analyse persistent IE.
Methods: Within 606 cases of IE in last 23 years in Slovakia, 85 (14%)
fulﬁlled the deﬁnition and had positive blood cultures for 3 or more days
(3 to 7 positive blood cultures). We compared these 85 cases of PBIE
to 606 cases of all IE from the database of the national survey.
Results: Several risk factors were observed more frequently among
persistent IE: elderly age (60% vs. 33%, p< 0.045), diabetes mellitus
(26.9% vs. 11.4%, p< 0.03), prior cardiosurgery (20% vs. 9.9%), prior
surgery (19.4% vs. 42.7%), p for both is 0.04, right side IE (17.6%
vs 11.4%, p< 0.01) and prosthetic valve (32.9% vs 2.4%, p< 0.001).
Also aetiology was different in persistent IE in comparison to all IE.
Viridans streptococci (37.5% vs. 15.2%, p< 0.01), coagulase-negative
staphylococci (51.8% vs. 21.9%, p< 0.02) and enterococci (23.5% vs.
7.6%, p< 0.01) were observed more frequently among persistent IE and
vice versa, embolisation (7.1% vs. 35.5%, p< 0.01), rheumatic fever
(9% vs 22.3%, p< 0.05) were less frequent. However, mortality and
type of intervention (surgery, antimicrobials only) were similar in both
groups. This surprising ﬁnding is difﬁcult to explain because persistent
bacteraemia in IE should be logically related with increased death rate.
Conclusion: Diabetics or elderly patients after prior surgery as well as
those with prosthetic or right side endocarditis may suffer from PBIE
with multiple positive blood cultures. However, risk of embolisation as
well as mortality rate were surprisingly lower.
P1481 10-year epidemiology of operated endocarditis patients at
a tertiary university hospital in Germany – a preliminary
analysis
F. Zauner, T. Glu¨ck, B. Salzberger, B. Ehrenstein, D. Birnbaum,
H.J. Linde, F.X. Audebert (Regensburg, DE)
Objectives: To describe retrospectively the epidemiology and clinical
presentation among patients receiving heart valve surgery for endocardi-
tis at the Regensburg University Medical Center and to compare these
data with other national and international cohort studies. To correlate
pathogen types with anatomic location and histopathologic damage
patterns of affected heart valves.
Methods: 211 intraoperatively conﬁrmed endocarditis episodes of 205
patients were reviewed from September 1994 to February 2005. Data
was obtained from surgical records, microbiology results, histopathology
reports, in-house charts, and medical charts of admitting hospitals.
Results: Altogether 252 valves were replaced or reconstructed. The
median age at the time of operation was 61 years with female patients
accounting for 25% of all patients. Heart valves were affected as follows:
aortic valve (49.3%), mitral valve (28%), aortic and mitral valve (17.5%),
and valves of the right heart (5.2%). Mechanical valves were inserted
in 58%, biological valves in 19% of the episodes. Valve reconstruction
without replacement was performed in 13% and any kind of combined
multiple valve operation was done in 9% of the operations. Postoperative
diagnoses were classiﬁed into ﬂorid natural valve endocarditis (NVE;
58%), ﬂorid prosthetic valve endocarditis (PVE; 12%), status after NVE
(26%), and status after PVE (4%). As predisposing factor, diabetes
mellitus was elicitable in 24% of all patients. Causative organisms
could be delineated in 70% of the episodes. Streptococcus viridans spp.
accounted for 30.8%, Staphylococcus aureus for 28.7%, Enterococcus
spp. for 14.7%, Staphylococcus epidermidis for 9.8%, infections with
any two pathogens at a time for 5.6%, Streptococcus spp. for 3.5% and
other species for the remaining 7% of episodes with delineation of a
causative organism. Among the episodes with conﬁrmed Staphylococcus
aureus, the aortic or mitral valves were approximately equally affected.
In-hospital mortality after cardiac surgery was 10.4% from the day of
surgery and the following 14 days. After 30 days, the mortality rate
slightly increased by 3.3% and accounted for 13.7%.
Conclusions: The distribution of affected valves and the 30-days
mortality rate in our cohort is consistent with results from current
international studies. The spectrum of causative organsims represents
spectra observed in similar studies, although Staph. aureus was
delineated at a lower rate.
P1482 Risk factors for systemic emboli in infective endocarditis
N. Esmailpour, M. Rasoolinejad, A. Ghoochani (Tehran, IR)
Objectives: As one of the complications of infective endocarditis,
embolisation has a great impact on prognosis. This study was undertaken
to analyse the risk factors for systemic emboli in infective endocarditis.
Methods: A retrospective study was conducted during 2001–2004 in two
teaching hospitals in Iran, included patients with infective endocarditis
as deﬁned by Duke Criteria. Demographic, clinical, echocardiographic
and microbiological data were entered in data base, and the relationship
between emboli and these variables was reviewed.
Results:We studied 76 cases (80.5% male, 19.7% female) with infective
endocarditis according to Duke Criteria. Mean age of patients was
37.42 years. In 27.6% mitral valve was induced. The most common
organism was Staph. aureus (14.5%). Systemic embolus was seen in
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32.9% of patients. Most emboli (15.8%) affected the central nervous
system. Mortality in patients with emboli was higher than cases without
emboli (36% vs. 12.8% respectively, P = 0.03). The risk of emboli was
80% when the vegetation measured larger than 10mm and only 15%
when vegetation size was smaller than 10mm (P< 0.05). There was
no relationship between age, gender, kind of induced valve, site of
vegetation, kind of pathogen and duration of symptoms and embolus
formation.
Conclusion: Mortality was higher in infective endocarditis patients with
emboli. According to this study, vegetation size (larger than 10mm) was
the only factor that was associated with an increased risk of embolic
episodes.
P1483 Permanent pacemaker and implantable cardioverter-
deﬁbrillator-related infective endocarditis
M. Sohail, D. Uslan, A. Khan, P. Friedman, D. Hayes, W. Wilson,
J. Steckelberg, S. Stoner, L. Baddour (Al Ain, AE; Rochester, Atlanta, US)
Objectives: Endocarditis is an uncommon but serious complication of
permanent pacemaker (PPM) and implantable cardioverter-deﬁbrillator
(ICD) implantation. Purpose of this study is to describe the management
and outcome of patients with PPM/ICD-related endocarditis.
Methods: Retrospective review of all cases of PPM/ICD infection
presenting to Mayo Clinic Rochester between 1991 and 2003. Device-
related endocarditis was deﬁned using modiﬁed Duke’s criteria.
Results: We identiﬁed 189 PPM/ICD infections during study period.
Forty-four (23%) of these met the case-deﬁnition for device-related
endocarditis (33 PPM, 11 ICD). Mean age of patients was 68 years.
(77% were males). Mean duration from device implantation to infection
was 739 (median 419) days. Coagulase-negative staphylococci (18, 41%)
and Staphylococcus aureus (18, 41%) were the most commonly isolated
organisms. Blood cultures were positive in 77% of cases. Twenty-six
(59%) patients had lead vegetations, 6 (14%) had valvular vegetations
and 12 (27%) had both lead and valvular vegetations (tricuspid valve
11, pulmonic valve 1, mitral valve 3, aortic valve 5). The mean
diameter of vegetations was 16mm (median 11mm). Forty-three (98%)
patients were treated with a combined approach of hardware removal
and parenteral antibiotics. Mean duration of systemic antibiotics after
device explantation was 45 days (median, 28 days). Electrode leads
were percutaneously removed in 34 (77%) cases using manual traction
(7), locking stylet (13) or laser sheath (16); 7 (16%) cases underwent
surgical lead extraction. Fifteen patients had lead diameter 10mm and
percutaneous lead extraction was complicated by pulmonary embolism
in 5 cases as demonstrated per radiographic procedures. However, none
of these patients were clinically symptomatic. Mean time from removal
of an infected device to placement of new system was 14.7 days (median,
9.5 days). A replacement device was not necessary in 17 (39%) cases.
Follow-up data were available for 33 (75%) cases (mean duration,
75 weeks); 27 (82%) of them were cured with device removal and
antibiotics. Six (14%) patients died during index hospitalisation (4 sepsis,
1 nosocomial pneumonia, 1 tricuspid valve rupture).
Conclusions: Device-related endocarditis is associated with severe
morbidity and mortality. Electrode leads can be removed percutaneouly
even in cases with large sized (10mm) lead vegetations without
increasing the risk of symptomatic pulmonary embolism.
P1484 Diagnosis difﬁculties of infective endocarditis in children,
adolescents and young adults without cardiac predisposing
factors – results of a case series
A. Radulescu, A. Slavcovici, M. Flonta, D. Tatulescu, V. Zanc
(Cluj-Napoca, RO)
Objectives: To evaluate infective endocarditis (IE) in previously healthy
children, adolescents and young adults within a retrospective case study
in a tertiary infectious diseases hospital.
Methods: Between 1988 and 2006, 212 cases of infective endocarditis
were documented based on the Duke criteria (range of age 7−83 years).
Medical charts were reviewed for demographic and clinical data (age,
clinical status at admission, signs and symptoms of endocardial infection,
predisposing factors, echocardiographic documentation, predisposing
factors, treatment and outcome).
Results: There were 166 episodes of native valve IE (78%), the aetiology
dominated by streptococci, staphylococci and Gram-negative bacteria
being established in 122 cases (57%). Sixteen cases of IE occurred in
children and young adults without known predisposing factor (median:
25.5 years, range 7 to 35 years, gender ratio1:1). Persistent fever, fatigue,
malaise and heart murmurs were present at admission in all cases,
vascular and immunological phenomena in 4 (splinter haemorrhages,
Osler’s node). A 7 year old boy presented a meningitis clinical picture
with petechial lesions. Dental procedures, poor dental condition and mild
upper respiratory infections were described in all cases. All patients
underwent transthoracic two-dimensional and Doppler transthoracic
echocardiography, 10 patients underwent additional transoesophageal
echocardiography. The initial echocardiogram suggested IE in 14 cases.
Main ﬁndings were vegetations in 14, perivalvular abscesse in 2
and valvular leaks in 3 cases. Despite repeated blood cultures the
aetiology was established in only 7 cases (44%): oral streptococci (4),
Streptococcus bovis (1), S. agalactiae (1) and polymicrobial endocarditis
(1), mainly due to empirical antibiotic treatment. Mitral and aortic
valve involvement was prominent – 13 cases. Antimicrobial therapy
was completed by cardiac surgery in 5 cases. All patients went well,
one relapse was documented. Applying the modiﬁed Duke criteria to
our patient series 11 were considered deﬁnite and 5 possible. Major
echographic ﬁndings became particularly helpful in the cases without
bacteriologic evidence.
Conclusion: Diagnosis of IE is challenging especially in the absence
of predisposing cardiac factors. Delayed diagnosis, empirical antibiotic
treatments signiﬁcantly limit the chance of positive blood cultures.
Modiﬁed Duke classiﬁcation is to be used in children and young adults.
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P1485 Performance evaluation of VIDIA HBs Ag, a new
automated immunoassay test for the qualitative detection
of HBs antigen in serum and plasma human samples
B. Seigne`res, N. Ripoll, P. Gradon, P. Desmottes (Marcy l’Etoile, FR)
Objective: The VIDIA system is a new automated, primary tube
immunoassay instrument designed to reinforce traceability, simplifying
the daily workload for routine testing. The qualitative detection of HbsAg
is used as a ﬁrst-line diagnostic test for hepatitis B infection or for the
follow-up of HBV chronic carriers.
Then, we performed an evaluation of VIDIA HbsAg (bioMe´rieux)
compared to VIDAS HbsAg Ultra (bioMe´rieux) and AxSYM HBsAg
(V2) (Abbott).
Methods: The VIDIA HbsAg assay principle combines a two-step
enzyme immunoassay sandwich method with a ﬁnal chemiluminescence
detection. HBsAg present in the sample binds with monoclonal anti-
HBs antibodies coated on the magnetic particles and with a mixture
of monoclonal anti-HBs conjugates used in the revelation phase. The
antibodies have been selected for their binding ability towards wild type
and variant HBs antigen.
The comparative study was performed by testing 180 positive samples
from Chronic HBV carriers and 213 negative samples including blood
donors and pregnant women. The serological status of 3 samples
was established according to the results obtained with 3 CE-Marked
immunoassays. In case of discrepant samples, the positive samples were
retested and conﬁrmed if repeatedly positive.
Results: In the comparative study, speciﬁcity and sensitivity of VIDIA
HBsAg was assessed according to the clinical status of the samples and
compared to VIDAS HBsAg Ultra and AxSYM HbsAg (V2). VIDIA
HBsAg sensitivity was tested on 30 seroconversion panels. According
to NCCLS recommendations, VIDIA HBsAg precision was evaluated
inferior at 15%.
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180 Positive
samples
213 Negative
samples
VIDIA Positive results 179 3
Negative results 1 210
MIDAS Positive results 179 0
Negative results 1 213
AxSYM Positive results 178 25
Negative results 2 189
MONOLISA Positive results 179 1
Negative results 1 210
Doubtful results - 2
Conclusions:
– VIDIA HBsAg display a better speciﬁcity than Abbott AxSYM HbsAg
(V2) and performed similarly to VIDAS and MONOLISA.
– The evaluation of VIDIA HBsAg sensitivity tested on seroconversion
panels and the comparative data results obtained on positive samples
demonstrated that VIDIA HbsAg is as sensitive as other already CE-
Marked test and present good precision performances.
P1486 Associated factors and viral DNA in isolated hepatitis B
core antibody group among healthcare workers
S. Chiarakul, S. Vuttiopas, K. Eunumjitkul, J. Kaewkungwal,
Y. Poovorawan (Bangkok, TH)
Objectives: To determine the factors associated with healthcare workers
(HCWs) who had isolated hepatitis B core antibody (anti-HBc), and to
determine HBV-DNA result of isolated anti-HBc group.
Methods: HCWs at Prasat Neurological Institute (PNI), Thailand who
had serology HBV proﬁling (HBsAg, anti-HBs and anti-HBc) result of
isolated anti-HBc were conﬁrmed by repeated Microparticle Enzyme
Immunoassay (MEIA) methods. Associated factors were evaluated by
using interview and self-administered questionnaires covering historical,
personal and occupational risk factors. Alanine aminotransferase (ALT),
aspartate aminotransferase (AST) and HBV DNA by nested PCR were
performed in isolated antiHBc group.
Results: Among 548 HCWs, 39 were in isolated anti-HBc group
consisting of 20 had anti-HBc positive and 19 had anti-HBc positive
with low anti-HBs. Twelve (30.8%) were male and 27 (69.2%) were
female, age ranges between 27 and 60 year (mean 47.1). Twenty-three
were in the high occupational risk group, 4 were in moderate risk, 12
in low risk group. Comparing between isolated anti-HBc group and the
other groups, there were statistically signiﬁcant differences in sex (male:
15.2% vs. female: 5.7%, p = 0.002), marital status (single: 3.8% vs.
married/divorce: 9.1%, p = 0.021), education (undergraduate: 10.4% vs.
postgraduate: 3.9%, p = 0.038), history of HB vaccine (vaccinated: 2.5%
vs. non-vaccinated: 9.1%, p = 0.041), history of viral hepatitis (25.9%
vs. 6.1%, p = 0.000), alcohol drinking (drinker: 15.8% vs. non-drinker:
4.7%, p = 0.000).
In isolated anti-HBc group, mean AST was 30.1 u/L (range from 16 to
84 u/L) and mean ALT was 27.4 u/L (range from 4 to 114 u/L). Six
(15.4%) had elevated transaminase levels. Five had elevated both AST
and ALT. 1 with heavy alcohol drinking had elevated only ALT.
Four cases of 39 (10.3%) had HBV DNA detected; 2 were male, 2 were
female; 1 in high occupational risk group with no history of hepatitis; 1
had hepatitis C cirrhosis and post liver transplantation; 1 had past history
of acute hepatitis; and 1 was a heavy alcohol drinker.
Conclusion: Signiﬁcant factors associated with isolated anti-HBc were
found among male, non-vaccinated, history of viral hepatitis, low level of
education, and alcohol drinking. The study results indicated that 15.4%
had elevated liver transaminase; and occult HBV infection (HBV DNA)
were detected in 10.3% of isolated anti-HBc group.
P1487 Studying the association between X gene mutations with
hepatocellular carcinoma and liver cirrhosis in HBsAg-
positive patients referring to medical centres in Tehran
S. Hekmat, M. Ahmadi Pour, S. Amini, F. Roohvand, S. Alavian,
M. Joulaie, S. Andalibi Mahmoudabadi (Tehran, IR)
Objectives: The viral transactivator HBVX (HBx) gene plays a critical
role in the molecular pathology of HBV-related HCC. This study
investigated the possible HBx mutations in Iranian patients with HCC or
liver cirrhosis, especially identiﬁcation of a point mutation at codon 31
from xORF.
Methods: Sera from 30, 10 and 12 patients with acute hepatitis B, HBV-
related HCC and liver cirrhosis, respectively, were analysed by nested-
PCR and RFLP methods to detect (HBx-A31) mutation. In addition
we also cloned the PCR products from second round of nested PCR
in TA cloning vector from 3 HCC, 2 cirrhosis and 2 acute hepatitis
subjects followed by sequencing and aligned them with the downloaded
sequences from GeneBank. We use neighbour-joining method to make
phylogenetic trees.
Results: Two common HBx variants in wild-type HBV, serine-31 (TCG)
and praline-31 (CCG), were digested by AvaI in the presence of
(T) or (C) at the ﬁrst nucleotide position of codon 31, the same PCR
products were not digested by MwoI in lack of Alanine amino acid
(GCG) (a common point mutation at the East Asia). We found two point
mutations (nt.1762, nt.1764) and one point mutation into HBV genome
from serum of all patients with cirrhosis and HCC. These mutations at
both codons 130 (AAG to ATG, lysine to methionine) and 131 (GTC
to ATC, valine to isoleucine) were observed in all available HCC cases
and located at Basal Core Promoter (BCP) which regulate transcription
and production of core and precore RNA. All cases had D genotype and
D1 subgenotype (The common genotype in Iran).
Conclusions: Core promoter region have been associated with more-
severe liver damage, inﬂammation and ﬁbrosis. But the implications of
these ﬁndings in the pathogenesis of HBV are discussed.
P1488 Prevalence of hepatitis B virus genotypes in patients with
chronic hepatitis B virus infection in Madrid
A. Fernandez-Olmos, M. Mercadillo, V. Moreira, M. Mateos (Madrid, ES)
There is evidence that HBV genotypes play a role in several aspects
of HBV infection, such as disease proﬁle or response to treatment. The
eight genotypes of HBV (A-H) have a distinct geographic distribution.
Objectives: To study the prevalence of hepatitis B virus genotypes
among hepatitis B chronic patients and their relationship with age and
the presence of HBeAg and anti-HBe in serum.
Methods: HBV genotypes were determined in serum from 76 patients,
by direct sequencing of a 137-nucleotide fragment from the S region of
the HBV genomal (Trugene HBV Genotyping kit, Bayer Health Care,
New York, USA).
Results: Prevalence of HBV genotypes in the 76 cases was as follows:
41 genotype D (53.9%), 23 genotype A (30.3%), 8 genotype F (10.5%)
and 4 genotype E (5.3%). After stratiﬁcation of patients by age, we found
that genotype D was signiﬁcantly more prevalent among patients over 45
years (71.4% vs. 37.5%, P = 0.021) Comparison of the distribution of the
most common genotypes, A and D, showed that genotype D was present
more often in HBeAg(−) (ratio A:D = 0.5) than in HBeAg(+) (A:D= 1.6),
although the difference was not signiﬁcant (P = 0.142). Distribution of
genotypes F and E was similar among the two groups.
Conclusion: Genotype D is the most common HBV genotype found
in our patients in Madrid, in keeping with other studies in Western
Europe. Interestingly, genotype F was found in a high number of Spanish
patients and this ﬁnding points to the introduction of strains from
South America to the Spanish population and posibly to Europe due
to the high immigration rate. In contrast, no genotype E was found
among autochthonous patients. All four genotype E infected patients
were immigrants from Africa. Our study did not include Asian patients,
therefore, genotype B or C were not found as expected. We did not
Hepatitis B virus S417
ﬁnd genotype G. In agreement with other studies, we conclude that
genotype D is the most prevalent, the presence of genotypes E and F
may be due to demographic movements and genotype G is uncommon
in Spain. As stated by other authors genotype D was more prevalent than
A in patients aged over 45 years.
P1489 Primary resistance and treatment associated resistance to
adefovir in four chronic hepatitis B patients
A. Fernandez-Olmos, M. Tato, V. Moreira, M. Mateos (Madrid, ES)
Background and Objectives: Adefovir dipivoxil is used for the
treatment of patients with chronic hepatitis B infection who are infected
with lamivudine-resistant hepatitis B virus. Mutations A181V, N236T,
L217R, I233V, V214A and Q215S confer resistance to adefovir. We
studied four patients in whom adefovir associated mutations were
detected (N236T, V214A and Q215S). Two of these mutations were
considered as primary resistance since patients had never received
adefovir.
Methods: Serum samples of patients were studied by sequencing a 137-
nucleotide fragment of the retrotranscriptase region of the hepatitis B
virus (Trugene HBV Genotyping kit, Bayer Health Care, New York,
USA). Clinical data are shown in Table 1.
Case AST
(U/I)
ALT
(U/I)
Geno-
type
Adefovir resistance
mutation
Viral load
(UI/mL)
Treatment
1 129 76 D N236T 30,000,000 Lamivudine,
adefovir
2 47 29 D N236T 5,484 Lamivudine,
adefovir
3 32 66 F N236T 3,284 Lamivudine
4 43 53 D V214A, Q215S 39,152 No
Discussion: In cases 1 and 2 adefovir was ineffective since no decrease
in the viral load was observed after 16 and 17 months of treatment,
respectively. Resistance to adefovir is considered unusual but it must be
considered in patients who do not respond to adefovir. In cases 3 and
4, mutations N236T, V214A and Q215S were found when studying the
genotype of the HBV in the patients. These patients had not received
adefovir for the chronic hepatitis B and, therefore, these variants should
be considered as primarily resistant to adefovir. In conclusion, the
detection of resistance mutations is necessary to monitor and anticipate
possible treatment failure.
P1490 Lamivudin treatment in patients with acute severe hepatitis
B
L. Roznovsky, I. Orsagova, A. Kloudova, J. Mrazek, I. Lochman
(Ostrava, CZ)
Objectives: Severe acute hepatitis B in immunocompetent patients may
progress to fulminant hepatitis and death. Lamivudin has been approved
for the treatment of chronic hepatitis B but experience with lamivudin
treatment for acute severe hepatitis B is still limited.
Methods: In the period of 1999–2006 years, 15 immunocompetent
patients (10 women, 5 men, age 18−83 years) with severe acute hepatitis
B were treated with lamivudin. Fourteen patients received lamivudin at
a dose 100mg per day, one patient 150mg daily. Prior to treatment,
all patients were positive for hepatitis B surface antigen (HBsAg) and
IgM antibodies to hepatitis B core antigen; 12 patients were positive
for hepatitis B e antigen (HBeAg); all patients had evidence of severe
hepatocyte lysis; all patients had total bilirubin 230 micromole per litre
or higher (above 14mg per decilitre). Nine patients had rapid increase
of total bilirubin and contemporary decrease of alanine aminotransferase
level, which escalate risk of development of fulminant hepatitis B.
Results: Fourteen patients responded to treatment. Therapy induces a
prompt clinical and biochemical response and was well tolerated in all
cases. HBsAg disappearance was criterion for termination of lamivudin
treatment. HBsAg was undetectable in 11 patients, and protective anti-
HBs antibodies developed in 4 of them. Lamivudin was administered in
these 11 patients for 4−13 months. Three patients still receive lamivudin,
but the therapy is shorter than 6 months. The 12 patients who were
HBeAg positive before treatment seroconverted within 2 months, and
anti-HBe antibodies developed in 11 of them.
One patient with severe encephalopathy developed fulminant hepatitis
B and underwent urgent liver transplantation 7 days after initiation of
lamivudin treatment. Seven years after transplantation, the patient is
without recurrence of hepatitis B and the treatment with lamivudin and
hepatitis B immunoglobulin still continues.
Conclusion: Lamivudin induces a prompt clinical, biochemical and
serological response in immunocompetent patients with severe acute
hepatitis B. Timing of lamivudin administration is crucial, early
lamivudin treatment of severe acute hepatitis B may prevent the
progression to fulminant hepatitis.
P1491 Interferon plus lamivudine in treatment of chronic hepati-
tis B in patients unresponsive to lamivudine monotherapy
M. Panahi, A. Heydari (Mashad, IR)
Introduction: Interferon a-2b has anti-viral and immunomedulatory
effects that can induce virologic and biochemical remission in chronic
hepatitis B (CHB) infection.
Methods: Lamivudine 100mg per day and interferon a-2b 10mega ut
three times per week were given for 26 weeks to 22 adult patients
with liver biopsy-proved chronic hepatitis B who had been treated with
lamivudine for at least 52 weeks. The virologic, immunophoresis, liver
function tests and haematologic assays were evaluated.
Aim: The aim of this study was to evaluate the efﬁcacy of high dosages
of interferon a-2b combined with standard dosages of lamivudine in
precore mutant or lamivudine resistant chronic hepatitis B.
Results: We selected patients to three groups:
Group I: HBeAg(−), HBeAb(+), HBVDNA PCR(+) CHB (6 patients).
Group II: HBeAg(+), HBeAb(−), HBVDNA PCR(+) CHB (11 patients).
Group III: HBeAg(−), HBeAb(−), HBVDNA PCR(+) CHB (5 patients).
Clearance of HBVDNA occurred in three patients in Group II and in
one patient in each of Groups I and III. Aminotrasferase normalisation
occurred in nine patients in Group II and four patients in Groups I and III.
Conclusions: A six-month course administration of 10mega ut of
interferon a-2b 3 times per week in combination with lamivudine in
patients with chronic hepatitis B infection made a sustained depression
of CHB in HBeAg(+) patients. Signiﬁcant studies with more patients
are needed to conﬁrm this study.
P1492 Acute hepatitis B virus infection by genotype F despite suc-
cessful vaccination in an immune-competent German patient
S. Amini-Bavil-Olyaee, A. Heim, T. Luedde, M. Manns, C. Trautwein,
F. Tacke (Aachen, DE)
Background and Aims: Hepatitis B Virus (HBV) infection is a leading
cause of chronic hepatitis and liver cirrhosis worldwide, and efﬁcient
protection can usually be achieved by vaccination that is based on
recombinant HBsAg protein from HBV genotype A and D. We report
the case of a fully immune-competent German patient that acquired a
symptomatic acute HBV infection during adulthood despite a complete
and formally successful vaccination, which had resulted in anti-HBs
titers considered protective.
Case presentation and Methods: A 32 year old, fully immune-
competent German male was referred with classical symptoms of acute
hepatitis, including jaundice, fatigue and generalised skin rash. Initial
aminotransferase activities were AST 525 U/L (normal <50) and ALT
567 U/L (normal <30), HBsAg and HBeAg were positive, and the
copy number of HBV DNA was 26,700 copies/mL by real-time PCR
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(Roche). The HBV infection was most likely acquired in Spain during
a business trip as a mining engineer, and resolved without speciﬁc
therapy within 6 months. The patient had completed a full three-doses-
course of vaccination about 10 months prior to infection. HBV DNA
was extracted, ampliﬁed, sequenced and subjected for sequence and
phylogenetic analyses.
Results: At the time of acute HBV infection, ‘protective’ anti-HBs
antibody titers of 50 IU/L (AxSYM AUSAB, Abbott Diagnostics) or 82
IU/L (Enzygnost, Dade Behring) were determined using two independent
test systems. Phylogenetic analysis revealed that the isolated HBV strain
classiﬁed into genotype F, sub-genotype F1 and cluster Ib with bootstrap
values of 99, 98 and 85%, respectively. Interestingly, this genotype is
extremely rare in Europe. The HBsAg sequence showed no apparent
aberrations in the immunodominant ‘a’ determinant domain of the
envelope gene. However, sequence comparisons revealed that all reported
genotype F isolates display marked differences from the other genotypes
in this domain which serves as an epitope for humoral immune responses.
Conclusions: Current vaccines may not confer full protection against
rare genotypes, even if no speciﬁc mutations in the ‘a’ determinant
epitope are present. It should be considered for future HBV vaccines to
comprise immunodominant proteins from all HBV genotypes to cover
genetic variability ﬂaw among different HBV genotypes.
P1493 Hepatitis B virus genotypes and the response to antiviral
treatment in children with chronic hepatitis B
K. Dzierzanowska-Fangrat, M. Woynarowski, J. Socha,
D. Dzierzanowska (Warsaw, PL)
Objectives: Hepatitis B virus infection remains a serious health problem
worldwide. One of the viral factors believed to be associated with the
clinical outcome of the infection is the genetic variability of the virus.
The aim of this study was to analyse the correlation between HBV
genotype and the response to antiviral therapy in children with chronic
hepatitis B.
Patients and Methods: A total of 92 children and adolescents who
completed IFN-a therapy due to chronic HBV infection 1−13 years
(mean 6 years) earlier were included in the study. A blood sample was
collected from each child for biochemical (ALT) testing and serological
markers of HBV infection, including HBV DNA levels (Cobas Amplicor
HBV Monitor). HBV genotyping was performed in archive serum
samples by a nested-multiplex-PCR.
Results: One to thirteen years after IFN-a therapy 77/92 (84%) patients
were positive for HBsAg, but only 5 (5%) had detectable HBeAg.
ALT levels ranged from 15 to 208U/L (mean 45.7U/L). HBVDNA
testing was performed in 83 children, and 66 (80%) were found positive.
HBVDNA levels ranged from <300 (10 patients) to >200,000 copies/mL
(5 patients). HBeAg was detected only in children with high viraemia
(>200,000 copies/mL). HBV genotypes were available in 49 patients,
41 (84%) of whom were infected with the genotype A, whereas the
remaining 8 had the genotype D. There was no association between the
viral genotype and either serological or biochemical parameters in the
long post-interferon therapy follow-up.
Conclusions: The response to IFN treatment in children with chronic
hepatitis B is not signiﬁcantly inﬂuenced by HBV genotypes A or D,
and the rate of serum HBVDNA clearance a few years after treatment
remains low.
P1494 Viral clearance, lamivudine resistant mutants appearance
and HBV reactivation in patients with chronic hepatitis B
in end-stage renal disease treated with lamivudine
D. Telehin, I. Tychka, M. Lulchuk (Lviv, Kiev, UA)
Objectives: The fact of HBV-infection in patients with end-stage renal
disease (ESRD) is common and ranges 20−30% in some eastern
European countries. Schemes and effectiveness of treatment of chronic
hepatitis B (CHB) in this cohort were not established. The aim of our
study was to evaluate course of CHB at the patients with ESRD treated
with Lamivudine in the haemodialysis department.
Methods: 55 patients with HBV-related chronic liver disease (CLD) and
ESRD were studied: 28 males, 15 females. Mean age 41 years. Median
ALT was 98 IU/L, all of them HBV-DNA+. 72% patients were with
wild-type, 28% with mutant HBV (HBeAg-negative). High virulence
HBV was characterised by high level virus circulation (21.5%). 37
patients have taken Lamivudine in creatinine clearance depending doses
(10−50mg/day) during 24 weeks. Serum HBV-DNA was detected using a
PCR by “Amplisens HBV” (>1,000 cp/mL). Lamivudine resistance was
presumed by virological and biochemical worsening during treatment.
HCV-, HDV-superinfection was excluded.
Results: At the end of treatment with Lamivudine 17 patients (46%)
achieved HBV-DNA clearance. Decreasing of ALT was notiﬁed in
52%. HBeAg seroconversion took place in 19% of HBeAg-seropositive
patients. Sustained virological response (SVR) within 12 months after
treatment was revealed in 13 patients (35%). In 4 patients (24% of
responders) HBV reactivation was noted. Kidney transplantation was
made in 12 patients with SVR. In this group 8 patients (66%) develop
HBV reactivation within the ﬁrst year after surgery. In 18 patients
without Lamivudine therapy late CHB sequences were present: mild
and average CLD − 28%, severe CLD and cirrhosis − 50%, fatal
outcome in 22% of patients was due to chronic liver failure. In patients
nonresponders and/or in those with HBV reactivation the late sequences
rate was accordingly 55%, 45%, 0%.
Conclusions: Peculiarities of clinical course and treatment in immuno-
compromised patients with ESRD strictly depend on the fact of HBV
virulence. In this cohort SVR (6 month duration Lamivudine therapy
course) is 35%. In 66% kidney recipients reactivation of CHB is
experienced even if surgery was after HBV disappearance. Severe course
and mortality rate in Lamivudine treated patients, including those without
conﬁrmed virologic response were more rear then in non treated patients.
P1495 One-year follow-up of adefovir dipivoxil treatment in
chronic hepatitis B patients
B. Kurtaran, H. Aksu, Y. Tasova, N. Saltoglu, A. Inal, A. Candevir,
G. Seydaoglu (Adana, TR)
Objective: The aim of this study is to evaluate the results of adefovir
dipivoxil treatment in hepatitis B e antigen-positive and negative chronic
hepatitis B patients. We conducted this study to investigate the efﬁcacy
of 48 week treatment with this drug at a dose 10mg once daily.
Methods: This study was conducted in C¸ukurova University Hospital.
Patients were enrolled between March 2005 and July 2006. Patients were
manner to receive 10mg of oral adefovir dipivoxil daily for 48 weeks.
Virologic and biochemical assessments (serum HBVDNA and alanine
aminotransferase [ALT] levels) were conducted every four weeks.
Results: The mean age of 36 patients was 34.8±10.3 years and 26
(72.2%) were male. Of the total, 32 (84%) had interferon and/or
lamivudin treatment before administration. Of patients, 17 were HBeAg-
negative and 19 were HBeAg-positive. Both the median of level of
HBVDNA and median of ALT levels was signiﬁcantly decreasing both
in hepatitis B e antigen-positive and negative group during 48 weeks.
The median change of HBVDNA was higher in HBeAg(+) group than
HBeAg(−) group at every four weeks, however no signiﬁcant differences
between two groups at the end of 48 weeks. At the end of the 48 weeks,
28 of 36 (77.7%) patients had improvement in serum HBVDNA levels.
Reductions in serum HBVDNA levels were 1.7, 2.3 and 2.7 log at 12th,
24th and 48th week respectively. Hepatitis B e antigen seroconversion
rate in HBeAg(+) group was 15.8% (3/19). Treatment has been found to
be safe and effective and well tolerated, with a low incidence of adverse
events.
Conclusion: In patients with HBeAg-negative and positive chronic
hepatitis B, 48 weeks of adefovir dipivoxil treatment resulted in
signiﬁcant virologic, and biochemical improvement.
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P1496 Determination of lamivudine and adefovir resistance in
acute hepatitis B virus infections
C. Eroglu, H. Leblebicioglu (Samsun, TR)
Introduction: The most widely used antivirals for treatment of hepatitis
B virus (HBV) infection is lamivudine and adefovir. Reduced virologic
response to therapy with nucleos(t)ide analogues can occur due to the
emergence of mutation. Mutations conferring resistance to lamivudine
and adefovir occur particularly in the reverse transcriptase gene.
Importance of antiviral resistance to nucleos(t)ide analogues in the naive
HBV infected patients is not known.
Methods: Sequencing, restriction fragment length polymorphism, line
probe assay, and real-time PCR can be used in the detection of drug
resistance. In this study, the reverse transcriptase region of polymerase
gene has been sequenced to detect antiviral resistance. 158 serum
samples of patients with acute HBV infection have been investigated
to detect antiviral resistance to lamivudine and adefovir. Mutations at
the codons rtM204, rtL180, and rtV173 for lamivudine resistance, and
mutations at the codons rtN236 and rtA181 for adefovir resistance have
been examined.
Results: Sequences have been obtained in 118 samples. Resistance for
lamivudine in codon V173L has been revealed only in one case. No
resistance to lamivudine at codons 180 and 204 or to adefovir at codons
181 and 236 has been detected.
Conclusion: This study demonstrated the presence of mostly wild type
strains in patients with acute HBV infection. It has been concluded that
lamivudine or adefovir resistance is not an important problem in acute
naı¨ve HBV infected patients.
P1497 Cytokine levels in patients with chronic hepatitis B infection
F. Yildiz, H. Irmak, G. Tuncer Ertem, M.A. Yetkin, U. Onde, C. Bulut,
S. Kinikli, A.P. Demiroz (Ankara, TR)
Objectives: Hepatitis B virus (HBV) infection may progress to liver
failure and cancer, for this reason it is a serious health problem.
The mechanisms of chronicity are poorly understood. The balances in
cytokine production proﬁles may play a crucial role in determining
the resolution or persistence of infection. In this study, we aimed to
determine various cytokine levels in patients with chronic HBV infection
and to reveal the relationship between levels of cytokines and different
clinical phases.
Methods: HBsAg positive patients with a duration of positivity longer
than six months who applied to outpatient clinic of Infectious Diseases
and Clinical Microbiology Department of Ankara Training and Research
Hospital between October 2005 and June 2006 were included into
the study. There were 57 cases in patient group and 24 healthy
individuals in control group. Serum of interleukin (IL)-4, IL-6, IL-10 and
interferon (IFN)-g levels were detected by ELISA and compared between
patients and controls. Additionally, correlation between serum alanine
aminotransferase (ALT) levels and cytokine levels were also examined.
SPSS version 11.5 for Windows was used for the analyses.
Results: In patient group, there were 25 chronic hepatitis and 32 inactive
carrier patients. The mean of serum IL-6 levels in patients with chronic
HBV infection (8.496 pg/mL) was higher than those of the control group
(6.850 pg/mL) and the difference was statistically signiﬁcant (p = 0.022).
Serum IL-10 levels were 0.784 pg/mL and 0.052 pg/mL in patient and
control group, respectively. There was a statistically signiﬁcant difference
between these groups (p = 0.019). Although, serum IL-4 and IFN-g levels
were higher in patients than controls, the difference was insigniﬁcant
(p> 0.05). There was not any correlation between the levels of IL-4,
IL-6, IL-10, IFN-g with ALT in patients.
Conclusion: As a conclusion, increased IL-10 levels may be associated
with persistence of hepatitis B infection. Testing the level of serum IL-6
may be helpful to determine the liver inﬂammation in patients with
chronic hepatitis B infection.
P1498 The value of interleukin-6 as a predictor of tissue injury
due to hepatitis B virus replication
M. Cojocaru, I. Cojocaru, I. Matei, S. Iacob, G. Ene, M. Delagramatic
(Bucharest, RO)
Objectives: Interleukin 6 (IL-6) is a critical mediator for various host
responses. IL-6 also plays the principle roles in the induction of the
hepatic acute phase responses. The purpose of the present study is to
clarify (1) the relationship between the magnitude of tissue injury and
the elevation of serum IL-6, and (2) the change in serum IL-6 and acute
phase reactants.
Methods: Serum samples were obtained from 33 patients with chronic
HBsAg positive hepatitis diagnosed by ultrasonography, liver biopsy and
histopathology. Their ages ranged from 29 to 58 years with a mean of
46±5 years. Another 20 healthy, age and sex matched adults with no
evidence of liver disease were also included as a control group. For all
cases and controls, full history taking, thorough clinical examination
and the following routine laboratory tests were done: Complete
blood count; liver function tests including measurement of alanine
aminotransferase (ALT), aspartate aminotransferase (AST), alkaline
phosphatase, g-glutamyltransferase (GGT), total proteins, albumin and
bilirubin serum. Hepatitis B surface antigen (HbsAg) and HCV antibody
were detected in the sera of patients and control subjects by an enzyme
linked immunosorbent assay (ELISA).
Results: Serum IL-6 was measured with an ELISA using a monoclonal
antibody against IL-6. The normal range of serum IL-6 was less than
4 pg/mL, CRP less than 0.5mg/dL. Serum IL-6 was elevated in 28
patients (1,400.8±383.4 pg/mL), and serum CRP was elevated in 30
patients (68±8mg/dL). The elevation of serum IL-6 was signiﬁcantly
correlated with the elevation of serum CRP (r = 0.84).
Conclusion: Serum IL-6 is an informative and sensitive marker to show
the extent of tissue injury due to hepatitis B virus (HBV) replication.
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P1499 Comparison between Enzygnost® Lyme link VlsE/IgG and
LIAISON® Borrelia IgG for the laboratory diagnosis of
Lyme disease
A. Marangoni, A. Moroni, V. Mondardini, S. Accardo, R. Cevenini
(Bologna, Belluno, IT)
Objectives: We evaluated diagnostic performances of Enzygnost® Lyme
link VlsE/IgG (DADE Behring, Marburg, Germany), in comparison with
those obtained by LIAISON® Borrelia IgG (DiaSorin, Saluggia, Italy).
Methods: In this study a total of 183 human serum specimens were
retrospectively studied. Sera were serially collected from 72 Lyme
disease patients suffering from EM following a tick bite.
A skin punch biopsy was obtained from each patient when entering the
study and cultivated in BSKII medium; the tubes were examined weekly
by dark-ﬁeld microscopy over a period of 45 days.
PCR was performed by using ﬁve different sets of primers: FL6-FL7
(amplifying a fragment of the ﬂagellin gene, conserved in all the Borrelia
burgdorferi s.l. strains); LD (amplifying a 16S rRNA genomic fragment
common to the three genospecies); BB, BG, BA (each one amplifying a
species-speciﬁc 16S rRNA genomic fragment).
Enzygnost® Lyme link VlsE/IgG is a quantitative immunoenzymatic
method based on a mix of native Borrelia antigens from B. afzelii
strain PKo and recombinant VlsE obtained from all the three genospecies
pathogenic to humans (B. burgdorferi s.s., B. garinii, B. afzelii).
LIAISON® Borrelia Screen is a one step sandwich CLIA. Recombinant
speciﬁc VlsE antigen obtained from the PBi strain of B. garinii is used
for coating magnetic particles.
Results and Conclusion: 66/72 cultures obtained from the biopsies
were identiﬁed as B. afzelii by PCR; the remaining 6 cultures presented
borreliae belonging to more than one genospecies.
Enzygnost® Lyme link VlsE/IgG was more sensitive than LIAISON®
Borrelia IgG. In particular, considering the 66 sera obtained at ﬁrst
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presentation that were available for this study, Enzygnost® Lyme link
VlsE/IgG scored 27 sera as reactive, 10 as border line and the remaining
29 as negative. LIAISON® Borrelia IgG identiﬁed 21 sera as positive,
5 as border line and 40 as negative. No seroconversion was observed by
both methods during the follow-up of all the patients found initially
negative. Moreover, all the patients initially IgG positive showed a
decrease in the serological titre within 3−6 months.
Results obtained by Enzygnost® Lyme link VIsE/IgG and LIAISON®
Borrelia IgG, respectively, when the 66 sera obtained at the ﬁrst
presentation were tested.
Enzygnost® Lyme link
VlsE/IgG
LIAISON® Borrelia IgG
Positive 27 (40.9%) 21 (31.8%)
Border line 10 (15.2%) 5 (7.6%)
Negative 29 (43.9%) 40 (60.6%)
Total 66 (100%) 66 (100%)
P1500 Neuroborreliosis and tick-borne encephalitis – same vector,
but different clinical course
K. Soltysova, D. Smiskova, D. Picha, N. Sojkova, M. Podojilova,
K. Roubalova, K. Sedivy, V. Maresova (Prague, CZ)
Objectives: Aetiology of aseptic meningitis in childhood remains often
unclear. Czech Republic is endemic area for Lyme borreliosis and
tick born encephalitis. Both of them belong to the most common
neuroinfections in children and have the same vector – a tick.
Aim of our retrospective study was to characterise dominant neurological
symptoms in children with neuroborreliosis (NB) in comparison with
tick born encephalitis (TBE).
Methods: 38 children (mean age 10 years) hospitalised in Bulovka
University Hospital (2002–2006) with ﬁnal diagnosis neuroborreliosis
and corresponding number of age-matched children suffering from
TBE were enrolled to the study. The diagnosis was established on the
presence of intrathecal antiborrelial IgG synthesis and/or PCR positivity
in cerebrospinal ﬂuid (CSF). TBE diagnosis was determined on the
presence of anti-TBE IgM in blood and signs of aseptic inﬂammation
in CSF. Patients were screened for history of tick bite, ECM, clinical
course, results of laboratory testing including CSF examination, EEG,
neurological complication and sequelae. Patients were monitored at
admission and after 1, 3 and 6 months. Statistical analysis was performed
using a paired t-test.
Results: All NB children except one have signs of aseptic inﬂammation
in CSF. NB patients were more likely to have mononeuritis (NVII in
most cases), afebrile or subfebrile course of the disease, shorter duration
of headache and absence of meningeal irritation. When compared to the
children with NB and TBE, there was no signiﬁcant difference in white
blood cell count, C reactive protein level, red blood cells sedimentation
rate, number of lymphocytes and neutrophils in CSF and total protein
level in CSF. Length of hospitalisation was longer in the NB group due
to antimicrobial therapy. No permanent sequelae were observed in both
groups.
Conclusion: NB had mild afebrile course in children and facial palsy
was the most frequent clinical syndrome. No permanent sequelae where
observed when treated with correct antimicrobial therapy.
Supported by grant No. 1166/2005-IV-GAUK of the Charles University
Grant Agency
P1501 The level of morbidity of Lyme borreliosis after antibiotic
preventive treatment
A. Yagodina (Perm, RU)
Objectives: Intensive research into the problem of ITBB has started just
after the discovery of the causative agent since 1980s. These diseases
hold the leading place by their level of morbidity and dissemination
compared with the other zoonotic diseases with the particular locality
of distribution. The purpose or my research work is to compare the
efﬁciency of doxycycline and azythromycin for antibiotic preventive
treatment of Lyme disease.
Materials and Methods: In Perm region where Lyme disease is
hyperendemic we conducted a trial of treatment with antibiotics in
subjects who had removed attached ticks from their bodies within the
previous 72 hours. Direct microscopic analysis of live preventions of the
material obtained from the gut of a tick removed from the patient’s body
after tick bite helps to reveal the borrelia contamination of the vector
and is the indication for medical prevention. During the period of 2001
to 2006 year 1,782 patients received antibiotic preventive treatment of
ITBB, 1,421 patients bitten by borrelia-infected ticks received 100mg
of oral doxycycline twice daily for 5 days, 381 patients received 500mg
azythromycin once daily for 3 days.
Results: The data obtained after antibiotic preventive course have shown
that 19 out of 1,782 patients developed ITBB. The disease developed at
the site of the tick bite in a signiﬁcantly smaller proportion of the subjects
in the group that received preventive treatment (1%) than of those in the
placebo group (12%). In the group receiving preventive doxycycline
13 patients fell ill, in the group receiving preventive azythromycin
6 patients fell ill. The clinical characteristics of the cases of the
disease are as follows: I. Localised stage, manifested form, associated
with erythema migrans – 7 patients; II. Disseminated stage, erythema
free form – 12 patients. The patients with unfavourable premorbid
background developed the disease. The disease developed in a same
proportion of the subjects in the doxycycline group (0.9±0.2%) and
those in azytromycin (1.5±0.6%) group.
Conclusion: The trial revealed the efﬁciency of antibiotic preventive
treatment. Both antibiotics are efﬁcient in preventive treatment. In the
group receiving preventive doxycycline treatment the level of adverse
reactions is higher.
P1502 Epidemiological aspects of Borrelia spielmanii from
Germany with special respect to its genetic heterogeneity
V. Fingerle, U. Schulte-Spechtel, E. Ruzic-Sabljic, F. Strle, S. Leonhard,
H. Hoffmann, K. Weber, K. Pﬁster, B. Wilske (Munich, DE; Ljubljana, SI)
The Borrelia burgdorferi sensu lato complex comprises at least 11
different species. Three of them – B. burgdorferi sensu stricto (s.s.),
B. afzelii, and B. garinii – are known to cause human disease. In 1999
Wang et al. isolated a new B. burgdorferi genospecies – designated
A14S – from a patient with erythema migrans which was recently
conﬁrmed as a new species and named B. spielmanii. Here we give
data on the prevalence of this new species among European human
isolates and in the tick vector collected from several Bavarian regions
and provide data on its genetic heterogeneity.
A total of 2,155 ticks (136 larvae, 612 nymphs, 1,407 adults) from
8 Bavarian regions and 242 European patient isolates, primarily from
Germany, were investigated by ospA-PCR followed by RFLP and/or
sequencing of the amplicon. Out of 507 B. burgdorferi infected ticks 28
(6%) harboured B. spielmanii. Notably this genospecies was exclusively
present in adult ticks. The by far highest B. spielmanii prevalence (18%
of infected ticks) was present in the English Garden, a recreational area
in the centre of Munich. In the 242 European patient isolates 4 (2%)
B. spielmanii could be identiﬁed. Interestingly all isolates were cultured
from Erythema migrans and all from patients from the Munich area.
To gain deeper insight into the genetic diversity of B. spielmanii,
patient isolates (4 from Germany and 2 additional from Slovenia)
and tick materials (n = 28) were subjected to further genetic analysis.
Sequence identities were 99–100% for rrs, the inner part of ﬂa and
ospA, respectively, 96–100% for rrf-rrl, 66%-100% for dbpA, and
84%-100% for ospC. Four separate ospC and two dbpA clusters were
distinguishable. Compared to the few sequences which have been to our
disposal this heterogeneity is noteworthy and reveals that the new species
B. spielmanii did not evolve just recently.
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The results show that B. spielmanii is present possibly in a focal manner
in Southern Germany and Slovenia and is able to cause human disease.
Further studies on the prevalence of this species in ticks and clinical
material are necessary to clarify its role.
P1503 Protein proﬁle determination of Borrelia afzelii and Borrelia
garinii isolated from skin and cerebrospinal ﬂuid
U. Glinsek, T. Udovic, E. Ruzic-Sabljic, F. Strle (Ljubljana, SI)
Lyme borreliosis is endemic in Slovenia. B. afzelii is most often isolated
species, associated with erythema migrans. Other clinical disorders like
nervous system invasion and musculoskeletal manifestations are usually
associated with B. garinii. The aim of our study was to compare protein
expression of B. afzelii and B. garinii isolated from skin of patients
with erythema migrans and from cerebrospinal ﬂuid of patients with
neuroborreliosis. In the study we analysed 187 samples of borrelia
isolates, 74 were B. afzelii and 113 B. garinii. Protein proﬁle was
performed by sodium dodecyl sulfat polyacrilamid electrophoresis (SDS-
PAGE). We found differences between protein proﬁles of B. afzelii and
B. garinii isolates and between skin and cerebrospinal ﬂuid isolates.
The protein proﬁles showed differences in the number and the amount
of analysed proteins. OspB was expressed by 70 (95%) B. afzelii
strains and by 32 (28%) B. garinii strains. OspC was expressed by 36
(49%) B. afzelii strains and by 93 (82%) B. garinii strains. There were
differences in protein expression regarding to the origin of isolates. OspB
was expressed by 68 (69%) isolates from skin and by 34 (39%) isolates
from cerebrospinal ﬂuid. OspC was expressed by 58 (59%) isolates
from skin and by 71 (81%) ioslates from cerebrospinal ﬂuid. We found
heterogeneity in expression of borrelial proteins, heterogeneity was found
between species as well as within particular species. B. afzelii from skin
and from cerebrospinal ﬂuid had 11 different protein proﬁles. B. garinii
from skin and cerebrospinal ﬂuid had 19 different proﬁles. Differences in
expression of Osp proteins can be important for bacterial dissemination
and colonisation of the host.
P1504 Evaluation of PlateliaTM Lyme IgM and PlateliaTM Lyme
IgG assays for Lyme borreliosis diagnosis
B. Jaulhac, S. De Martino, M. Tabouret (Strasbourg, Marnes la
Coquette, FR)
Objectives: Lyme borreliosis (LB) is a non contagious infection caused
by Borrelia burgdorferi sensu lato and is transmitted by ticks of
the Ixodes genus. It is the most prevalent tick-borne zoonosis and
is considered as an important emerging infection in Europe, North
America and Far Eastern countries. Due to limitations of direct detection,
antibodies screening remains the mainly used method to support a
clinical diagnosis of LB. Objective of the study is to evaluate the
performances of Platelia™ Lyme IgM and Platelia™ Lyme IgG (Bio-
Rad Laboratories) for an accurate diagnosis of Lyme disease.
Methods: Platelia™ Lyme IgM and IgG assays are two step assays
using respectively immunocapture and indirect ELISA formats. Obtained
results were compared to Enzygnost® Borreliosis IgM and IgG (Dade
Behring).
Speciﬁcity was calculated on 200 healthy blood donors from eastern
region of France and on 206 patient samples with potential cross-
reactive conditions (syphilis, leptospirosis, rheumatoid factor, CMV or
EBV infections, etc. . . ). Sensitivity was determined on 70 conﬁrmed LB
sera from early and late stages of the disease.
Results: By comparison with reference ELISA methods, speciﬁcities
on blood donors were 99.0% and 99.5% for respectively IgM and IgG
assays. On potential interfering samples, speciﬁcities were 94.6% for
IgM and 97.5% for IgG (100% and 97.8% for syphilis IgM and IgG
positive samples). Sensitivity results are presented in the table below for
assays considered individually or in combination.
LB stage IgM IgG IgM+IgG
Erythema migrans (n = 17) 58.8% 66.7% 82.4%
Neuroborreliosis (n = 33) 40.0% 100.0% 100.0%
Lyme arthritis/Acrodermatitis (n = 20) 5.0% 100.0% 100.0%
Conclusion: Performances of Platelia™ Lyme assays are adequate for
diagnosis of infected LB patients and fulﬁll recommended criteria for
screening. Using same protocols, both IgM and IgG assays can be run
in parallel.
P1505 Detection of antibodies to Anaplasma phagocytophilum in
Lyme disease patients
J. Chmielewska-Badora, J. Zwolinski, E. Cisak, A. Wo´jcik-Fatla
(Lublin, PL)
The aim of this study was to evaluate the possibility of coinfection with
Anaplasma phagocytophilum in Lyme disease patients.
Material and Methods: 180 persons with diagnosed Lyme disease were
examined for serum antibodies to Borrelia burgdorferi with ELISA kits
(Borrelia IgM Rekombinant and Borrelia IgG Rekombinant, Biomedica
Medizinprodukte, Austria) and to Anaplasma phagocytophilum with IFA
kit (Anaplasma phagocytophilum IFA IgG, Focus Diagnostics, USA).
Chi-square test was used for statistical analysis.
Results: In 159 persons (88.3%) antibodies to Borrelia burgdorferi were
found and in 38 persons (21.1%) antibodies to A. phagocytophilum were
detected. 34 (18.9%) persons possesed antibodies to both infectious
agents. A chi-square analysis was used to test the association between
prevalence of antibodies to Borrelia and antibodies to Anaplasma and it
was found as statistically insigniﬁcant.
Conclusion: Results of these ﬁndings indicate the possibility of
coinfection with Anaplasma phagocytophilum in Lyme disease patients.
P1506 Prevalence of Borrelia burgdorferi, Anaplasma
phagocytophilum and Babesia microti in Ixodes ricinus ticks
collected from the Lublin region (eastern Poland)
E. Cisak, J. Chmielewska-Badora, A. Wo´jcik-Fatla, J. Zwolinski
(Lublin, PL)
The objective of the study was to evaluate the risk of acquaring
infection of Borrelia burgdorferi, Anaplasma phagocytophilum and
Babesia microti for residents and visitors of the Lublin region
Material and Methods: 1,813 ticks were examined for the presence
of B. burgdorferi sensu lato by PCR and for particular genospecies
by nested PCR, in 1,378 ticks the prevalence of Babesia microti DNA
was determined by PCR and nested PCR and 1,079 ticks were checked
for Anaplasma phagocytophilum by PCR. All ticks were collected from
forest areas of six districts of the Lublin region.
Results: The total infection rate of Borrelia burgdorferi s. lato, Babesia
microti and Anaplasma phagocytophilum amounted: 5.4%, 5.4% and
8.4% respectively.
The total occurrence of individual Borrelia burgdorferi genospecies
in infected ticks with regard to the summarised single and mixed
infection amounted 62.8% for Borrelia burgdorferi sensu stricto, 39.8%
for Borrelia afzelii and 17.7% for Borrelia garinii.
Conclusion: The results conﬁrm that Borrelia burgdorferi, Anaplasma
phagocytophilum and Babesia microti are present in forest areas of
the Lublin region and indicate a potential risk for the residents of
surrounding territories as well as for visitors to acquire infections caused
by these pathogens.
The research were supported ﬁnancially by Ministry of Science and
Higher Education (grant no. 2PO5D054 27).
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P1507 Serologic and molecular-genetic data for infection with
Borrelia burgdorferi sensu lato, Anaplasma phagocytophilum
and Francisella tularensis in wild rodents
T. Gladnishka, I. Christova, E. Taseva (Soﬁa, BG)
Objectives: The aim of this study was to generalise serologic and
molecular-genetic data for infectious of wild rodents with aetiological
agents of Lyme disease (B. burgdorferi sensu lato), Human granulocytic
anaplasmosis (A. phagocytophilum) and tularaemia (F. tularensis).
Methods: A total of 70 rodents from whole country from the species
Rattus rattus, Mus musculus and Apodemus agrarius were studied by
PCR and serological methods – ELISA and agglutination.
Results: Our PCR results demonstrated that the most common pathogen
was B. burgdorferi sensu lato – a total of 18 positive samples (18/70;
25.71%). Infection with F. tularensis was on the second place only from
rodents in Meshtitza – a total of 9 positive samples (9/42; 21%) of
spleens of the rodents. The infection with A. phagocytophilum was the
most rare – a total of 5 positive samples (5/70; 7.14%). Twenty-three
positive samples (23/70; 32.86%) of B. burgdorferi sensu lato and 15
positive samples (15/70; 21.43%) of A. phagocytophilum were detected
by ELISA. Nine positive samples (9/42; 21%) of F. tularensis were
detected by agglutination in Meshtitza.
Conclusions: Molecular-genetic methods demonstrated DNA of the
infectious agents before antibody-responses of the macroorganism.
Combining of PCR and serological methods of diagnosis was adequate
tool for quick and effective surveillance on circulation of different
infectious agents among populations of the rodents. Data for infections
of wild rodents with B. burgdorferi sensu lato, A. phagocytophilum and
F. tularensis showed prevalence with different pathogens among main
reservoirs of tick borne infections and warning possible contraction for
human population in different regions in the country.
P1508 Usefulness of C6 peptide antibody assay in early localised
Lyme borreliosis
R.W. Vreede (Delft, NL)
Objectives: In early localised Lyme borreliosis (erythema migrans, EM),
ELISA’s detecting antibodies against ﬂagellin of Borrelia burgdorferi,
followed by immunoblot, usually have a sensitivity of about 50%.
Recently, ELISA’s have been developed detecting antibodies against C6
peptide, a conserved and immunodominant region of the VlsE antigen
of B. burgdorferi. Initial reports showed a speciﬁcity of this assay equal
to that of immunblot and a sensitivity in disseminated Lyme borreliosis
of more than 90%. In a recent Dutch study, the sensitivity in 40 patients
with EM was 22.5% (AP van Dam et al Abstract. Bussiness Meeting
Dutch Society of Medical Microbiology, April 2004).
Methods: We evaluated the performance of the C6 peptide (Immunetics
Inc, Boston, USA) six months after introduction in our laboartory,
which is connected to a large, regional hospital in the Western part
of the Netherlands. In a preliminary study using 39 sera of patients
with disseminated Lyme-borreliosis, the correlation between C6 assay
and ﬂagellin ELISA (Dade Behring, Marburg, Germany) combined
with immunoblot (Mikrogen GMBH, Neuried, Germany) was 90%. All
aforementioned assays were performed in 90 selected sera.
Results: Thirteen of the 15 patients showing a seroconversion in the
ﬂagellin ELISA were also positive in the C6 assay. In 39 patients with
EM, the C6 assay showed a sensivity of 69%. Sensitivity in 20 patients
with disseminated Lyme-borreliosis was 100%. Speciﬁcity of the C6
assay was 95%. No crossreactive antibodies were detected in 20 sera
with positive rheumafactor, IgM antibodies to Epstein-Barr virus or
cytomegalovirus, or speciﬁc antibodies against Treponema pallidum.
Conclusion: The C6 assay showed a high speciﬁcity, an excellent
sensivity in late Lyme-borreliosis and a sensitivity of nearly 70% in
EM, making immunoblot unneccasary and the C6 assay suitable for
use in diagnostic laboratories to detect both disseminated and localised
stages of Lyme disease. Performance of the updated version of the C6
peptide ELISA and validation of the assay for cerebrospinal ﬂuid are
under evaluation.
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P1509 Impact of pretravel medical consultation on behaviour and
health status of travellers
A. Wagenknecht, D. Drescher, A. Knaust, M. Eikenberg, T. Eikmann,
C. Herr (Giessen, DE)
Background: The Center for Travel Medicine and Yellow Fever Vac-
cination, Institute for Hygiene and Environmental Medicine, University
of Giessen (Germany) offers special consultation and immunisation for
travellers. This centre advises approximately 400 travellers every year.
A trained physician provides standardised advice about their particular
destination, general as well as local health-risks, and administers any
necessary vaccination. Some travellers use further information sources
to ﬁnd out more about their destination (for example the internet, books
and locals), therefore status of information varies interindividually.
Methods: We study the quality of pretravel information and measures
in relation to behaviour during travel as well as post travel health status
and medical consultations.
Two trained medical students recruit travellers during pretravel
consultation with an informed consent and a ﬁrst data assessment using
a specially developed form on general travel and personal information,
the content of medical consultation/measures in the Center for Travel
Medicine and Yellow Fever Vaccination and from other information
sources. Travellers are followed-up six to eight weeks after their journey
to capture post-travel health status. The questionnaire applied at this time
point has some similarities to the pretravel assessment form and contains
additional items on during travel health status, physician consultations,
medication and risk behaviours as well as preventive measures. Post
travel medical history is also assessed. The questionnaire comprises
forty items offering the option of completition via telephone, print-out
or internet.
Results: About seventy-ﬁve percent of the travellers agreed to participate
in the study. The posttravel follow-up questionnaire has been completed
by twenty-ﬁve travellers so far. The travellers were 17 to 64 years old,
eight men and 17 women. Travel destinations were in and outside Europe
(e.g. Africa, Uganda). The mean duration of travel was 29 days. Results
of this ﬁrst assessment will be presented.
P1510 Traveller diarrhoea. Aetiological study in a tropical
medicine unit
R. De Julia´n, J. Ruiz, M. Lago, S. Puente, M. Baquero, J. Gasco´n,
J. Go´nzalez-Lahoz (Madrid, Barcelona, ES)
Introduction: The number of international travels is increasing
continuously. 12 million Spaniards travelled abroad last year; 900,000 of
them had tropical countries as ﬁnal destination. Over 10% of travellers
went to a doctor at their arrival. Diarrhoea was the most frequent cause
(over 40%).
Material and Method: 43 patients incoming to Tropical Medicine Unit
were under study, in a four months period, showing diarrhoea after a
travel to the tropic as main symptom. 24 (55.8%) female and 19 (44.2%)
male. Final travel destination by continent was 25 (58.4%) to Africa,
10 (23.26%) to Asia and 8 (18.6%) to Latin America. 3 faeces samples
from different times were collected from all of them, and microbiological
study (bacteriologic and parasitic) was done. When Escherichia coli was
diagnosed by coproculture we tried to identify the strain diarrhogenic
character using PCR, looking for ETEC, EAEC and EPEC-EHEC strains.
Results: 100% exhibit diarrhoea, with a duration of:
<7 days, 9 cases (20.9%, average 4.8 days). Aetiology: E. coli (8):
1 ETEC + Entamoeba histolytica, and 1 EAEC. Parasites (1): Giardia
intestinalis.
7−30 days, 19 cases (44.2%, average 18 days). Aetiology: E. coli (14):
2 ETEC (1 +Blastocystis hominis); 4 EAEC (1 +Cyclospora cayeta-
nensis, 1 +B. hominis) and 1 EPEC. Parasites (2): Cryptosporidium
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parvum, Endolimax nana + B. hominis. Others: Shigella ﬂexneri (1),
Dengue (1), Rickettsiosis (1).
>30 days, 15 cases (34.9%, average 54 days). Aetiology: E. coli (11):
1 ETEC + E. histolytica and 1 EAEC. Parasites (4): G. intestinalis
(1 +B. hominis).
In 3 cases of the last group diarrhoea lasted more than 300 days.
From the beginning of the travel, diarrhoea started in <7 days in 10 cases
(23.3%), between 7−15 days in 21 cases (48.8%) and >15 days in 12
cases (27.9%). 20 cases (46.5%) developed invasive diarrhoea. Fever in
16 cases (37.2%) and abdominal pain in 31 cases (72.1%) appeared as
associated symptom.
Conclusions: Escherichia coli was the most frequent isolated germen
in a important number of parasite-associated cases (multifactorial
aetiology?). E. coli diarrhogenic strain was not able to be conﬁrmed
by PCR in some cases. In this study we cannot conclude that chronic
diarrhoeas are of parasitical aetiology. Microbiological study of faeces of
travellers with diarrhoea arriving from tropical countries must be done
to rule out potentially treatable bacterial and parasitical aetiology.
P1511 A retrospective study of 230 consecutive patients
hospitalised after transcontinental travel
H. Leroy, C. Arvieux, J. Biziragusenyuka, J. Chapplain, C. Guiguen,
C. Michelet, P. Tattevin (Rennes, FR)
Objectives:With the current craze for transcontinental travels, infectious
diseases consultants practicing in Europe or Northern America hospitals
need to be well aware of the distribution of diseases in hospitalised
returning travelers and migrants. Our study adds to the previous which
tried to characterise causes of consultation and/or hospital admission
after traveling. Its purpose is to better deﬁne preventive measures
in patients who consult before traveling and to guide diagnostic
investigations in patients who return ill after traveling abroad.
Methods: We reviewed 230 consecutive patients who were hospitalised
in our infectious diseases unit between January 2000 and March 2006
after traveling to another continent. We conducted a retrospective
observational study. Cases were identiﬁed by our computerised database
system. Data were extracted from medical charts, including demographic
variables, travel conditions, diagnostic workout, treatment and outcome.
Results: Male to female ratio was 1.58; median age was 33 years
and median time from travel to hospitalisation was 13 days. Among
the travelers, 52% were tourists, 28% were long term expatriates, 8%
worked for humanitarian organisations, 10% visited their relatives or
friends, and 26% couldn’t be classiﬁed. The main destination of travel
was sub-Saharan Africa (70.9%), much more frequent than Southern
Asia (8.2%) or Northern Africa (8.2%). Malaria was the most common
diagnosis (49.1%), followed by gastroenteritis (13.0%), viral hepatitis
(6.1%), and bacterial pneumonia (4.3%). A signiﬁcant proportion of
patients were diagnosed with tuberculosis (5.2%) or HIV infection
(4.3%) but the link between recent travel and these pathologies could
not be ascertained. Rare diseases with potential nosocomial transmission
were also observed, including severe acute respiratory syndrome (SARS)
and Crimean-Congo haemorrhagic fever.
Conclusion: Even if the study was not limited to febrile illnesses,
malaria remains the ﬁrst cause of hospitalisation after traveling to another
continent. Owing to the diversity of tropical pathologies and to the
increase of travel to developing countries, this study underscores the
need to maintain tropical expertise for physicians in charge of patients
who return ill from travel. A substantial proportion of these diseases
may be prevented by validated protective measures.
P1512 Wave of undocumented migrants in the Canary Islands:
new challenges for European microbiologists
I. Montesinos, M. Miguel, S. Campos, Y. Pedroso, A. Torres, A. Sierra
(La Laguna, ES)
Introduction: From June to October 2006, 25,000 undocumented
immigrants from West Africa have reached the Canary Islands by boat
from the coast of Senegal and Mauritania, i.e. 3 times the number during
the ﬁrst 5 months of 2006 and around ﬁve times the total for the whole
of last year. Most have arrived in Tenerife. The aim of this work was
to evaluate the impact of this immigrants’ wave for the laboratory of
microbiology of the University Hospital of Canary Islands (HUC).
Methods: The samples received and the results obtained in the section
of parasitology were assessed differentiating two periods: January–May
and June–October, 2006. Parasite examination was performed in faecal
specimens, urine and broncho-alveolar lavage (BAL) after concentration
by microscopic exam with iodine, trichrome and Kinyoun staining.
Graham test to pinworm screening was also performed. Blood samples
were analysed by thin and thick blood ﬁlms stained with Giemsa stain.
Results: During the ﬁrst period of study (January–May) approximately
8,000 undocumented immigrants arrived to Canary Islands. During this
period the parasitology section of the HUC received a total of 953
samples for detection of parasites: 783 stool samples, 160 Graham
tests and 10 blood samples. Only 3 samples were positives for Giardia
lamblia (1) and Entamoeba coli (2) and no cases of malaria were
detected. From June to October the number of immigrants rose 25,000
individuals. The total number of samples received for detection of
parasites ascended to 1,527: 1,239 stool samples, 221 Graham tests,
7 urines, 2 BAL and 58 blood samples. Signiﬁcant increase in the
number of isolates and diversity of pathogens were observed comparing
to the ﬁrst period: Ancylostoma duodenale (2), Ascaris lumbricoides (7),
Giardia lamblia (6), Entamoeba coli (29), Endolimax nana (8),
Iodamoeba bu¨tschlii (2), Enterobius vermicularis (5), Schistosoma
haematobium (2) and Plasmodium falciparum (12).
Conclusion: Both the number and the variety of samples and techniques
realised as well as the parasites observed have increased in the last ﬁve
months coinciding with a new wave of undocumented migrants arrived
this summer to the Canary Islands. This should make us think about the
need to guarantee the necessary human and material resources as well
as training and update courses in parasitology.
P1513 KAP evaluation about travel medicine in international
travellers and medical students in Chile
L. Guerrero-Lillo, J. Medrano-Diaz, C. Pe´rez, R. Chaco´n, J. Silva-Urra,
A. Rodriguez-Morales (Antofagasta, CL; Trujillo, VE)
Objectives: To determinate knowledge, attitude and practices (KAP)
about Travel Medicine on International Travelers and Medical Students.
Methods: A KAP instrument was designed, constituted by 24
questions (questionnaire), answered by 100 international travelers (at
the “Arturo Merino Benı´tez” International Airport of Santiago), and
100 Antofagasta’s Medical Students (randomly selected), exploring
knowledge about Travel Medicine, traveler diseases, morbidity and
prevention of them among interviewed people. Analyses were made with
SPSS 10 and Epi Info 6 (conﬁdence 95%).
Results: Mean age was 44.9±12.3 y-old (travelers) and 22.6±3.0
y-old (medical students) (p< 0.001). In travelers 83% were universitary
professionals. Medical students, 49% were at 3º year. From the total,
78.5% stated as unknowners of Travel Medicine (90% travelers, 67%
medical students; p< 0.001); 92% perceived health risks traveling (94%
and 90% respectively). Malaria was the disease recognized as more risky
(10%; 13% medical students and 7% travelers). From the total, 5% stated
get sick during international trips (6% and 4%, respectively). Travelers
stated in 56% being non-informed about sanitary conditions of their
destinations and 3% have some vaccination (2% YF, 1% HBV). Travelers
were 93% chilean going in 60% to tropical countries.
Conclusions: These results indicated the importance of Travel Medicine
in those countries where the knowledge of tropical diseases (malaria,
dengue, yellow fever, etc), is lower given their inexistence, and where
the traveling pattern indicates a great proportion of people visiting risk
zones for the acquisition of these pathologies, and without the prevention
due to lack of knowledge and immunisation against them.
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P1514 Recurrent pyoderma caused by Staphylococcus aureus with
Panton-Valentine leukocidin production in a young, male
traveller who infected his non-travelling partner and in a
young, female traveller returned from a tropical country
R. Schleucher, M. Gaessler, B. Schulte, M. Marschal, J. Knobloch
(Tu¨bingen, DE)
Objectives: Pyoderma associated with visits to tropical countries is well
known. In most of the cases pyoderma is caused by Staphylococcus
aureus. After a sufﬁcient antibiotic treatment the skin infections
resolve without any sequelae. But several patients suffer from recurrent
pyoderma. The reason is not elucidated so far. Panton-Valentine
leukocidin is a cytotoxin produced by Staphylococcus aureus. It is
associated with severe necrotic lesions involving skin and mucosa. Inter
alia Panton-Valentine leukocidin was isolated in several outbreaks of
community-acquired methicilin-resistant Staphylococcus aureus caused
infections which were associated with a high contagiosity.
Methods: We describe two cases of travellers returned from tropical
countries with recurrent pyoderma. In the ﬁrst case within nine month
after returning from Fiji a young, male, healthy patient relapsed seven
times on different parts of the body. Seven month after the ﬁrst skin
infection the girl friend of this patient developed a pyoderma as well.
In the second case a young, female, healthy patient suffered eight times
from a recurrent conjunctivitis accompanied by pyoderma within one
year after returning from Ghana.
Results: In all cases Staphylococcus aureus producing Panton-Valentine
leukocidin was isolated. In the skin lesions of the ﬁrst patient and
his girl friend Staphylococcus aureus of the same strain was detected.
In the second case the same strain and Panton-Valentine leukocidin
production were found in Staphylococcus aureus of the nasal mucosa
and conjunctival swab.
Conclusion: For the ﬁrst time recurrent pyoderma in young, healthy
travellers caused by Staphylococcus aureus with Panton-Valentine
leukocidin production is described. The relapses and the infection of
the partner demonstrate the high contagiosity and virulence. Additional
nasal carriage represents a source of reinfection. Further studies are
necessary to elucidate the part of Panton-Valentine leukocidin positive
Staphylococcus aureus in the increasing problem of recurrent pyoderma
in healthy travellers. The results could be highly important for the public
health worldwide.
Infections in the tropics
P1515 Relapses versus reactions in multibacillary leprosy:
proposal of new relapse criteria
K. Linder, M. Zia, W.V. Kern, R.K.M. Pfau, D. Wagner (Freiburg,
DE; Karachi, PK)
Objective: The WHO criteria for the diagnosis of relapses in leprosy
rely on a marked increase in the bacterial index at any single site and
evidence of clinical deterioration. Conﬁrmation of the diagnosis would
require growth of Mycobacterium leprae in the mouse footpad system
(MFP) which rarely is available in the ﬁeld. Relapses and isolated late
reactions have different times of onset after the end of treatment, but are
difﬁcult to distinguish by clinical examination. A simple, practical and
sensitive scoring system that circumvents these problems is needed for
a reliable diagnosis of relapses in leprosy. In 2006 the WHO suggested
to include time after stopping treatment as distinguishing feature for
the diagnosis of paucibacillary leprosy. We hypothesised that criteria
to diagnose multi-bacillary (MB) relapses should also include a time
criterion.
Methods:We collected data on all relapses diagnosed between 1998 and
2004 at the Marie-Adelaide-Centre in Karachi, Pakistan, including case
histories, clinical manifestations, follow-up, bacterial indices, treatment
and contacts. We developed a simple scoring system for the diagnosis of
MB-relapses and validated it on a data-set of MFP-conﬁrmed relapses
(Shetty et al. 2005; Lepr Rev 76, 241). Its sensitivity was further
evaluated in the Karachi relapse cohort. The p value was calculated
with McNemar’s test with continuity correction.
Results: The new scoring system that combines time factor, risk factors
and clinical presentation at relapse (see table), had a higher sensitivity
in MFP-conﬁrmed relapses than the WHO-criteria (95% versus 65%,
p< 0.01). The sensitivity of the scoring system was also signiﬁcantly
higher than the WHO criteria in the 57 cases of MB-relapses diagnosed
in Karachi (75% versus 54%, p< 0.05).
Proposed diagnostic scoring system for MB-relapses in leprosy
Factor Scorea
I. Time factor
Time after release from treatment [months]
12 0
12−24 1
25−60 2
>60 3
II. Risk factor
If the initial bacterial index [BI] is 3+ 1
Ill. Clinical presentation at relapse
If the BI in a single lesion is 2+ higher than expectedb 1
If the average BI is 2+ higher than the expected BI 1
If no signs of a reactionc are present 1
aRelapses are diagnosed with a score of 3; the maximal score = 7:
the maximal score for the time factor = 3, the maximal score for the
additional factors = 4, these scores are added to give the ﬁnal score.
bExpected BI = calculated BI with an assumed fall of 1 log-unit/year; if
the initial BI was negative, a positive BI at relapse is sufﬁcient to score.
cClinical signs of inﬂammation of the nerve or the skin or erythemata
nodosa leprosa.
Conclusion: This new simple scoring system for diagnosing MB-
relapses in leprosy should be further validated in a prospective study
to conﬁrm its superior sensitivity and to evaluate the speciﬁcity of these
criteria by using MFP-conﬁrmation for patients presenting with signs of
activity after treatment.
P1516 Spectrum of gastrointestinal infections among 420 cases
in population without regular access to drinking water in
Kenya
Z. Kniezova, V. Sˇva´bova´, M. Bartkovjak, M. Kiwou, J. Johnson,
Z. Njambi, V. Krcmery, M. Krumpolcova, S. Kamoche (Bratislava, SK)
Objectives: The purpose of the study was to describe aetiology, risk
factors, therapy and outcome of gastrointestinal infections (GI) in slum
population in Mukuru without adequate access to drinking water.
Patients and Methods: Community clinic in Mukuru slum serves
the poorest population. The number of patients visiting the clinic is
approximately 30,000 pts per year and 2,500 per month. Within June
420 cases of diarrhoeal diseases have been documented. Microscopic
evaluation of stool for ova and cysts was performed in every patient
with diarrhoea or anaemia.
Results: Majority of cases (120) were due to Giardia (29%),
40 (10%) due to Entamoeba histolytica. Serology for Salmonella
typhimurium was positive in 42 patients (10%). Ascaris lumbricoides
(20 cases, 5%) was the most common worm pathogen, followed by
Ankylostoma duodenale (9 cases, 2%).
Metronidazol for giardia and amoeba diarrhoea (243 pts) and
mebendazol (45 pts) were the most commonly used antiparasitic agents
and TMP/SMX in 65 cases and chloramphenicol in 40 cases resulted to
100% efﬁcacy in treated cases.
Conclusion: Only 23 of 420 cases were HIV positive (5%), however only
120 of 420 pts tested (14% HIV prevalence among tested). Surprisingly,
despite of high HIV prevalence, no cryptosporidium cysts were found.
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P1517 An unusual presentation of acute brucellosis with
thrombocytopenia and maculopapular rash
O. Alici, B. Kasapoglu, R. Alkan, E. Sarifakioglu, R. Akgedik,
R. Bozalan, A. Kosar, H. Sahin (Ankara, TR)
Purpose: We report a case of brucellosis together with severe thrombo-
cytopenia and skin rash that does not related to thrombocytopenia.
Case report: A 69-year-old woman, who was a housewife, was
seen for complaints of extensive pruritic skin lesions over the trunk
and extremities, knee pain and generalised myalgia over the previous
one month. These symptoms were accompanied by sweating, fatigue,
anorexia, bleeding of gum tissues and nosebleed. There was no preceding
episode of any kind of infection or any medication use. She used to eating
cheese made from raw milk.
Physical examination revealed that her temperature was 36.7ºC. She had
modarate splenomegaly (2 cm palpable below the costal margin). The
characteristic feature of skin rash was as maculopapular exanthema and
covered the trunk, arms and legs. The intensity of the rash was more
over trunk than extremities and the lesions were pruritic.
Laboratory analysis yielded a platelet count of 15,000 g/L. Erythrocyte
sedimentation rate of 8mm/h, C-reactive protein level of 9.21mg/L (0 to
8), alanine aminotransferase level of 56.34 IU/L (1 to 31), and aspartate
aminotransferase level of 33 IU/L (1 to 32). Abdominal ultrasonography
showed only splenomegaly. Bone marrow biopsy was normocellular.
Because of the patient’s sweating, generalised myalgia and being from a
rural community Brucella agglutination test was performed and revealed
1/2,560 positivity. Blood cultures were sterile. Doxycycline (200mg/day)
and rifampin (600mg/day) were started. According to dermatology
consultation, skin rash was thought as brucellar dermatitis. The patient
rejected skin biopsy.
The rash began to disappear within two days and thrombocytopenia
began to resolve within three days of therapy commencement. The
patient was discharged from the hospital 7 days later in good health
on rifampicin and doxycycline therapy. At the 6-week follow up, the
patient had came to control and had made a full clinical recovery; skin
rash recovered completely and platelet count increased to normal levels.
Conclusions: It is known that cutaneous lesions and thrombocytopenia
are not speciﬁc to brucellosis. Although this event could be considered
rare, brucellosis should be kept in mind in the investigation of aetiology
of thrombocytopenia and maculopapular rash with absence of fever in
Brucella-endemic areas.
P1518 Serum copper and zinc levels in patients with brucellosis
M.F. Geyik, C. Ustun, I. Tegin, S. Hosoglu, C. Ayaz (Diyarbakir, TR)
Objective: The aim of this study is to compare the serum Copper (Cu)
and Zinc (Zn) levels of patients with brucellosis and healthy individuals.
Material and Methods: In this study, 43 patients with brucellosis, and
32 healthy individuals in the control group were included. From totally
75 individuals, 5mL of venous blood was taken after fasting 10 hours
at night. Serum samples were decomposed by centrifugeting at 5,200
turn for 5 minutes. Serum samples were diluted with deionised water.
Cu and Zn levels were measured in all serum samples by using Unicam
929 Atomic Absorption Spectrophotometer. All data entry and analysis
were performed using SPSS 10.0 for Windows Version programme.
Results: The average age of 43 patients with brucellosis was 39 years; 21
were males (49%), 22 were females (51%). The average age of 32 healthy
individuals was 32 years; 16 were males (50%), 16 were females (50%).
Serum Cu and Zn levels of patients with brucellosis were found to be
89mg/dL and 38.6mg/dL, respectively. Serum Cu and Zn levels of healthy
individuals were found to be 57.2mg/dL and 55.9mg/dL respectively.
A statistically signiﬁcant (p = 0.0001) increase at serum Cu levels and
decrease in Zn levels of patient with brucellosis were detected, when
compared with the control group.
Conclusion: The current evidence suggests that, Cu and Zn levels may
be helpful as indicator in the course of brucellosis.
P1519 Brucella as a rare cause of cirrhosis in a southern Italy
endemic area
T. Ascione, M. Iannece, P. Rosario, M. Onofrio, S. Quaranta,
R. Pempinello (Naples, IT)
Background: Brucella infection may be manifest by nonspeciﬁc hepatic
inﬂammation or by granulomatous hepatitis. Cirrhosis may be a rare
complication of an untreated Brucellosis. Liver and spleen involvement
is commonly described during Brucella infection. We reported a case of
cirrhosis whose only cause was Brucella infection.
Case report: A 60-year-old woman was referred to our hospital
because of gastrointestinal bleeding caused by use of FANS for a
10 months history of unknown origin fever. At admission the patient
presented elevated liver enzymes (ALT, GGT, ALP) and elevated
bilirubin levels. Low level of albumin (2.5 g/dl) and prothrombin were
present. PLT count was 97,000/mmc. HBsAg, HBcAb, anti-HCV, anti-
HIV, HBV-DNA and HCV-RNA were negative. Immunologic markers of
AIH (ANA, AMA, ASMA, p-ANCA, anti-LKM1) were negative too.
Haemochromatosis was excluded of the basis of genotyping testing.
No history of alcohol abuse was reported. Abdominal ultrasonography
showed enlarged spleen (longitudinal diameters of spleen was 157mm)
and ascites. An endoscopic exam showed gastric ulceration related to
FANS use and F2 varices of the distal tract of the oesophagus. Serologic
tests for Brucellosis was positive (1/640) and Brucella melitensis
grew from blood cultures. The patient was treated with doxycycline
and ciproﬂoxacin for six weeks. Fever disappeared after 2 weeks of
therapy. Liver enzymes and bilirubin level improved returning within the
normal range after 8 weeks. Three months after the end of therapy an
ultrasonographic exam showed disappearance of ascites, reduced spleen
longitudinal diameter (132mm), low platelets (150,000/mmc) and an
improved level of albumin (3.7 g/dl).
Conclusions: Although liver involvement is frequent in patients with
brucellosis because of both the direct brucella infection effect and the
host immune response, progression to cirrhosis is rarely reported. In this
case diagnosis of Brucellosis was obtained only after a severe impairment
of liver function and portal hypertension appeared. We suggest that
brucellosis has to be considered both in cases with criptogenetic cirrhosis
or when a progressive worsening of liver functions occurs in patients with
an otherwise stable liver disease, if a history of exposure in endemic
areas is reported.
P1520 The evaluation of 23 anthrax patients: dilemmas in
diagnosis and our experiences from 2004 to 2006
H. Ozcan, U. Kayabas, Y. Bayindir, M. Bayraktar (Malatya, TR)
Objectives: Anthrax is a potentially fatal, zoonotic disease. Naturally
occurring anthrax in humans is acquired from contact with infected
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animals or contaminated animal products. The diagnosis of cutaneous
anthrax (CA) may be very difﬁcult especially in rarely seen regions or
in atypical presentations. The aim of this study is to evaluate the clinical
features of 23 CA cases between May 2004 to September 2006.
Methods: Twenty-three patients with CA were included in this study.
The diagnosis of the CA was based upon clinical ﬁndings and/or
microbiological procedures.
Results: Of the 22 cases followed up with CA and one patient with CA
resulted to anthrax sepsis, 13 (56.5%) were male and 10 (43.5%) were
female. The mean age of the patients was 36.04±14.67 years. All of the
patients have been living in the rural area of Malatya province in Turkey.
Twenty-two patients had a history of slaughtering, skin peeling, meat
and bone processing or helping in one of these activities. One patient
did not have any history of contact with animals or animal products.
He was a construction worker in the village where an attack of CA was
seen a year ago. He had only contacted with soil. Clinical presentation
of CA was typical in 20 patients. Two patients were misdiagnosed as
insect bite and one patient as angioedema.
The vesicular ﬂuid cultures were positive for Bacillus anthracis in seven
(30.43%) cases and Gram stain revealed Gram-positive rods in eight
(34.78%) cases. The diagnosis of CA in remained 15 (65.21%) cases
was made by clinical presentation and history of contact with the sick
animal. Nine of these cases have history of contact with same sick cow.
And also, B. anthracis was detected in the spleen of this cow.
Conclusion: CA is a very contagious and important infectious disease
in worldwide. Early and accurate diagnosis can dramatically affect the
prognosis of the disease. So, CA should be kept in mind especially in
endemic regions.
P1521 Enteric fever due to Brucella melitensis: a case report
A. Erbay, H. Bodur, E. Akinci, A. Bastug, M.A. Cevik (Ankara, TR)
Objectives: Although pathogenetically qualifying as an enteric fever, the
gastrointestinal manifestations of brucellosis in humans are relatively
uncommon. Alimentary tract complaints such as anorexia, nausea,
vomiting, abdominal pain, diarrhoea or constipation are elicited in
patients with brucellosis but systemic symptoms generally are more
common than symptoms localised to the gastrointestinal tract. A patient
with enteric fever caused by Brucella melitensis is reported.
Case: A previously healthy 16 year old male was admitted with fever,
vomiting, diarrhoea and skin rash. His initial complaint was started
with fever six days before admission. He was living at a village
and had a history of consumption of unpasteurised dairy products.
Physical examination revealed an acutely ill boy with a temperature
of 39.9ºC. Blood pressure was 110/60mmHg and pulse was 96/min.
He had abdominal tenderness and hepatosplenomegaly. Maculopapuler
rashes with a diameter of 1−2mm were present on the trunk and arms.
After admission, vomiting, abdominal pain and melena were observed.
Pertinent laboratory ﬁndings were as follows: white blood cell (WBC)
count 3,000/mm3 haemoglobin 12.6 g/dl, platelet count 44,000/mm3,
erythrocyte sedimentation rate 9mm/h, ALT 230 U/L, AST 169 U/L,
CRP 77.4mg/dl. The direct microscopic examination of faecal smear
showed prevalent leukocytes. A faecal occult blood test was positive.
Initial and follow up Widal tests were negative. Serological tests for
acute viral hepatitis were negative. A brucella serum agglutination
test was positive, with a titre of 1:1,280. Stool culture revealed no
evidence of bacterial pathogens. Brucella melitensis was isolated from
the cultures of blood. An upper gastrointestinal endoscopic examination
revealed bulbitis. Combined therapy with rifampicin (600mg/d p.o.)
and doxycycline (100mg p.o., b.i.d.) was started. On the 3rd day of
therapy the patient became afebrile. In the following days the patient
improved clinically. The faecal occult blood test became negative on the
7th day. A repeated CRP was 18.9mg/dl. On the 12th day of the therapy
laboratory test were as follows; WBC count 5,100/mm3, haemoglobin
12.8 g/dl, platelet count 275,000/mm3, alanine aminotransferase 19 U/L
and aspartate aminotransferase 41 U/L. Antibiotic therapy was stopped
on day 42.
Conclusion: Brucellosis is an infection with multiple presentations,
and in an endemic region a thorough history of exposure and clinical
suspicion are required.
P1522 Preferential sites of eschar for scrub typhus
D.M. Kim, S.H. Lee (Gwang-Joo, Nam-won, KR)
Background: Eschar has been shown to be an important ﬁnding for
the diagnosis of scrub typhus patients, and other mite-born rickettsiosis
patients. However, any reports on systemic studies, including the
difference of the gender regarding the preferential site of eschar as well
as a schematic diagram showing the preferential site of eschar, have been
rarely reported.
Materials and Methods: IFA test using serum for scrub typhus was
performed on the adult patients who visited Chosun University hospital
and its branches for diagnosing their acute febrile diseases that developed
within the previous 4 weeks. The presence or absence of eschar was
thoroughly examined.
Results: Eschars were preferentially formed on the front of body. The
sites in the male where eschars were primarily detected was the area
within 30 cm below the umbilicus (19 patients, 34.5%). The lower
extremities and the front chest above the umbilicus were 23.6% (13
patients) and 20.0% (11 patients) respectively. However, on the females
and different from the males, the most prevalent area was the front chest
above the umbilicus for 40.4% (46 patients) of all the detected eschars.
Conclusions: For both the males and the females, the front and the rear
30 cm below the umbilicus should be examined thoroughly, and it is
thought to be important to carefully examine the lower extremities of
the males, and the front chest as well as the back area of the females.
Our study is the ﬁrst report that shows the difference between the males
and the females in regard to the area of developing eschars on scrub
typhus patients.
P1523 Diagnosis of scrub typhus by immunohistochemical staining
of Orientia tsutsugamushi in cutaneous lesions
D.M. Kim, S.H. Lee, S.C. Lim (Gwang-Joo, KR)
Introduction: The aim of this study is to assess the clinical usefulness
of an immunohistochemical staining on parafﬁn-embedded skin biopsy
specimens for the diagnosis of scrub typhus with a comparison of indirect
immunoﬂuorescent antibody (IFA) assay.
Method: A prospective study of patients with possible scrub typhus
was conducted from September, 2005 to August, 2006. The patients
participating in the study were thoroughly examined for the presence or
absence of eschar like lesions and maculopapular lesions. Skin biopsy
specimens for immunohistochemical staining (IHC) were obtained using
a 3mm punch upon the consent of the patient.
Result: 125 potential scrub typhus patients were studied prospectively.
Skin biopsy specimens were obtained from 63 patients. To minimise
the effects caused by antibiotics on the IHC, 46 patients were assessed
prior to the administration of antibiotics (except for the 4 patients who
had received prior antibiotic therapy before admission and 13 patients
who were underwent skin biopsy after administration of antibiotics at
our hospital). Compared with the result of IFA which is the deﬁnite
diagnostic method for scrub typhus, the result of IHC of maculopapular
skin lesions demonstrated a sensitivity of 65% (95% conﬁdence interval
0.38–0.85) and a speciﬁcity of 100% (95% conﬁdence interval 0.6−1).
The result of IHC of eschars demonstrated a sensitivity of 100% (95%
conﬁdence interval 0.82−1) and a speciﬁcity of 100% (95% conﬁdence
interval 0.40−1). IHC of eschar from one of the 13 patients who was
administered antibiotics at our hospital showed negative results on the
13th day of the initial antibiotic administration. IHC done within 3 to
4 days following the initial antibiotic treatment in the remaining 12
patients showed almost the same results as that of the patients who did
not receive prior antibiotics.
Oriential antigens, discrete coccobacilli were primarily located within
the cytoplasm of the infected endothelial cells, and they were also
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identiﬁed within macrophages around the blood vessels on IHC staining.
Intracytoplasmic positive staining of the lining epithelia of the sweat
ducts and glands in the mid- and deep-dermis were also found.
Conclusion: The immunohistochemical staining of skin biopsy speci-
mens, particularly from eschars is sensitive and speciﬁc, which can be a
reliable test for conﬁrmation of the diagnosis of scrub typhus.
P1524 Preparation of recombinant antigen from Orientia
tsutsugamushi Ptan strain and development of rapid
diagnostic reagent of scrub typhus
J. Tang (Nanjing, CN)
Objectives: Preparation of recombinant antigen from O. tsutsugamushi
Ptan strain and then a mixture of the r56 of Gilliam and Ptan strain
was used as the diagnostic antigen to develop a rapid colloidal-gold
immunochromatographic assay (CIA) for diagnosis of scrub typhus.
Methods: A 1,352 bp fragment encoding a truncated 56kD outer
membrane protein of Ptan strain, was ampliﬁed by PCR and then was
cloned into the pET28a vector for expression. The recombinant protein
containing six his tag was puriﬁed by Ni2+ chromatography column,
analysed by SDS-PAGE and identiﬁed by western-blot. A rapid colloidal-
gold immunochromatographic assay (CIA) was developed to detect the
serum anti-O. tsutsugamushi total antibodies, IgG and IgM by employing
the mixture of the truncated 56kD recombinant antigen from Gilliam and
Ptan strain as the diagnostic antigen.
Results: Resulted by SDS-PAGE the expression of a protein with
approximately 52 kD MW was detected when the recombinant plasmid
was transformed into the host E. coli BL21 and no similar protein was
observed when the empty plasmid of pET28a was transformed into the
same host.
Resulted by western-blot the recombinant protein can be recognized by
patient’s positive serum while the negative serum cannot have the same
blot band, showing a good antigenicity. The performance of CIA was
evaluated with a panel of 112 sera from clinical conﬁrmed cases of scrub
typhus. The CIA’s detection sensitivities against anti-O. tsutsugamushi
total antibodies, IgM and IgG were 98.2%, 81.2% and 94.6% respectively
while IFA’s sensitivity against IgG was 85.7%. The speciﬁcity of CIA
against anti-O. tsutsugamushi total antibodies, IgM and IgG were 98.1%,
100% and 98.9% respectively while the speciﬁcity of IFA against IgG
was 98.9%.
Left: CIA strip for detecting anti-O. tsutsugamushi total antibodies in
serum: (a) positive and (b) negative result. Right: CIA strip for diagnosis
of anti-O. tsutsugamushi IgG and IgM in serum: (a) IgG+/IgM+,
(b) IgG+/IgM−, (c) IgG−/IgM+, (d) IgG−/IgM−.
Conclusion: CIA was a good assay and could substitute the conventional
IFA method in the diagnosis of scrub typhus.
P1525 Brucella multi-organ involvement in a patient with negative
serologic tests: case report
F. Khorvash, A. Hassanzadeh Keshteli, M. Behjati, M. Salehi, B. Ataei
(Isfahan, IR)
Background: Brucellosis is a multi-system disease that may present with
a broad spectrum of clinical manifestations. Whilst hepatic involvement
in brucellosis is not rare, it may rarely, involve the kidney or present
with cardiac manifestations. Central nervous involvement in brucellosis
some times can cause demyelinating syndromes. Here we present a case
of brucella hepatitis, myocarditis, acute disseminated encephalomyelitis,
and renal failure.
Case presentation: A 26 year old man presented with fever, ataxia,
and dysarthria. He was a shepherd and gave a history of low grade
fever, chilly sensation, cold sweating, loss of appetite, arthralgia and 10
Kg weight loss during previous 3 months. He had a body temperature
of 39ºC at the time of admission. On laboratory tests he had elevated
levels of liver enzymes, blood urea nitrogen, Creatinine, Creatine
phosphokinase (MB), and moderate proteinuria. He had abnormal
echocardiography and brain MRI too. Coombs test and enzyme-linked
immunosorbent assay for IgG, IgM were negative. Standard tube
agglutination test (STAT) and 2-mercaptoethanol (2-ME) titers were
1:80 and 1:40 respectively. Finally he was diagnosed with brucellosis
by positive blood culture and polymerase chain reaction for Brucella
melitensis.
Conclusion: Brucella infection should be ruled out in patients with
multi-organ involvement, especially in ones from endemic regions. We
can come to this conclusion that we may not be in the safe side from
brucellosis only with low STAT and 2-ME titers and other diagnostic
methods like blood culture and PCR should be administered to rule out
brucellosis.
P1526 Two immunological test to diagnostic Carrion’s disease
(bartonellosis) in patients of endemic areas in Peru
S. Palma, M. Villar, M. Gonzales, C. Prause, P. Ventosilla (Lima, PE)
Bartonella bacilliformis is the aetiological agent of human bartonellosis,
which has the acute phase (with fever, severe haemolytic anaemia) and
chronic phase (with bacillary angiomatosis-like lesions). The methods
of diagnosis are smears (27% of sensibility) and culture (take from 7 to
45 days).
The main goal of this study was detected inmunoglobulins anti-
Bartonella bacilliformis using enzyme linked inmunoabsorbent assay
(ELISA) and Western Blot.
Methods: Bartonella bacilliformis strain ATCC35685 was cultured on
Columbia Agar supplemented with 10% sheep desﬁbrinated blood. The
cells were harvested, sonicated and diluted in solution buffer, this was
the antigen. For ELISA (to detection of Ig G) we had 34 sera of acute,
chronic patients and control negative. And for Western Blot, we used
pool sera of 9 acute and chronic patients, and 8 negative control sera.
Results: In ELISA the sensitivity was 82% and speciﬁcity was 70% in
acute phase patients, and in chronic phase patients was 91% and 76%
respectively.
For Western Blot, we found 26 protein bands (2.5–132 kDa), and 3
antigenic bands (12−47 kDa) for acute phase and 2 antigenic bands
(11, 12 kDa) for chronic phase.
Conclusions: ELISA could be used as screening test because the
sensitivity is higher than current methods employed for the diagnosis
of bartonellosis. In Western blot founded differences between acute and
chronic phase as preliminary results.
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P1527 A new type of TT virus in eastern Taiwanese indigenes
H.-F. Liu, K.-L. Hsiao, H.-H. Lee, C.-L. Lin, Y.-J. Lee, L.-Y. Wang
(Taipei-Tamshui, Keelung, Hualien, TW)
Objectives: Torque Teno virus (TTV), the ﬁrst circular negative-stranded
human DNA virus, has a very high prevalence among general population.
Early studies of prevalence were mostly based on the N22 region which
has now been shown to strongly underestimate the prevalence of TTV
infection. Although TTV infection has been reported in Taiwanese
populations, they were all based on the N22 region. In the present study,
we investigated the prevalence of TTV in eastern Taiwanese indigenes
by using newly designed PCR primers deduced from a highly conserved
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untranslated region (UTR) and performed phylogenetic analysis using
almost entire open reading frame (ORF).
Methods: Serum or plasma samples from 140 eastern Taiwanese
indigenes were included in this study. PCR were performed on the
highly conserved UTR region (about 150 nucleotides) to detect the
prevalence and a long one amplifying the entire ORF (around 3.2Kb)
for phylogenetic analysis. Phylogeny reconstruction was performed using
the Phylip software package, with the neighbour-jointing, the maximum
parsimony, and the maximum likelihood methods. The robustness of
the neighbour-jointing and maximum parsimony trees was statistically
evaluated by bootstrap analysis with 1,000 bootstrap samples.
Results: A very high prevalence (95%) of TTV infection was found in
the eastern Taiwanese indigenes based on the highly conserved UTR
region. Direct sequencing of these PCR products found a severe mixed
infection of many different TTV strains. By cloning, at least 13 isolates
belonging to 3 different TTV groups could be identiﬁed from one
individual. Phylogenetic analysis showed a consistent tree topology by all
3 methods suggesting that TTV could be classiﬁed into 6 monophyletic
groups including a new one consisted of 11 isolates from an eastern
Taiwanese indigene.
Conclusion: TTV are highly prevalent in eastern Taiwanese indigenes
and a new TTV group was identiﬁed from this population. Severe mixed
infection of many different TTV strains in one individual was observed.
Since TTV can cause persistent infection and various different strains
can be found within one individual, this suggested that TTV might have a
quasispecies-like nature which was only observed in some RNA viruses
before.
P1528 Comparison of human metapneumovirus strains from Alto
Adige with strains from surrounding regions in Italy and
Austria
E. Pagani, C. Petters, D. Secolo, P. Rossi, M. Casini, I. Cavattoni,
E. Morello, L. Pescolderungg, G. Campanini, E. Percivalle,
H.P. Huemer, C. Larcher (Bolzano, Pavia, IT)
Human Metapneumovirus (HMPV), in addition to paediatric patients, has
been increasingly described in elderly people and has been found to cause
more severe infections in immunosuppressed patients. In our laboratory
in Bolzano serving a regional hospital routine HMPV diagnosis is based
on direct immunoﬂuorescence assay (DFA) using monoclonal antibodies.
Species diagnosis is conﬁrmed by reverse transcriptase-PCR. During
2005 we performed a preliminary epidemiological survey to compare the
local strains to those of surrounding regions by doing also sequencing
analysis of the N-Genes as well as the L-genes of the obtained isolates.
By alignment with established Dutch reference strains we identiﬁed
three different genotypes circulating in our region with predominantly
type B strains being detected in this season. This is in contrast to
published data from nearby Italian regions from the 2003/2004 winter
season where predominantly A2 strains have been characterised. Also
our study in the Austrian Tyrol region from the same season detected
A-type strains only. Whether this is a further indication for similar strains
cycling in a wider geographic area with the respective types replacing
each other on a seasonal basis remains to be clariﬁed although absolute
sequence identity due to the high variability of RNA viruses was rarely
detected. Similar HMPV types circulated in both the paediatric and adult
patients and, of interest, the two isolates originating from bone marrow
transplant recipients (BMT) were of different genotypes. Both ﬁndings
rather exclude hospital transmission in our BMT patients as has been
suspected in lung transplant patients (Larcher et al., J Heart & Lung
Transplant, 2005).
P1529 The distribution of human papillomavirus infection in the
male urogenital tract in Russian urological patients
V. Smelov, A. Gorelov, J. Pleijster, A. Savicheva, S. Morre
(Saint-Petersburg, RU; Amsterdam, NL)
Objectives: The prevalence of symptomless genital human papillo-
mavirus (HPV) infection among men is not well established. This is
partly due to a poor understanding of which sites should be tested. Up
to now there is no published study regarding the HPV distribution in
Russian male population. HR-HPV types are accepted to be involved
in the aetiology of cervical cancer and this has lead to new vaccine
approaches. The inﬂuence of HPV infection on the risk of cancers among
men, i.e. prostate cancer, is still under investigations. The goal of this
study was to investigate the HPV infection presence in the urethral and
prostate samples in the Russian urological patients.
Methods: The urethral and prostate samples of 210 men (mean age 31.7,
range 16−60 years), who visited 2 urology clinics in St-Petersburg, were
sequentially collected from May through to October 2006 to be tested
against sexually transmitted infections and HPV. No speciﬁc selection
was made to the obtained this study group.
The presence of high- and low-risk HPV (HR- and LR-HPV, respectively)
DNA in the distal urethra and expressed prostate secretion (EPS) was
investigated in Amsterdam by the GP5+/6+ PCR assay followed by
subsequent HR- vs LR-HPV typing using EIA (enzyme immunoassay).
The oligoprobe cocktails for 24 HR-HPVs (i.e., 16, 18, 31, 33, 35) and
21 LR-HPVs (i.e., 6, 11, 32, 40, 42) were used for the group-speciﬁc
detection.
Results: The results are presented in the Table. The HPV distribution
in the urethra and prostate was detected as 16.2% and 13.3% for HR-
and 6.2% and 5.7% for LR-HPV infection, respectively. Concordance
between LR- and/or HR-HPV distribution in both anatomical sites was
observed in only 20−25%. We observed “grey zone” values in 5.7%;
these samples will be re-tested.
Table 1. HPV distribution and HR/LR concordance in the distal urethra
and expressed prostate secretion (EPS) samples in the Russian male
urological patients
HPV distribution, n (%)
HR LR
Urethra 34 (16.2%) 13 (6.2%)
EPS 28 (13.3%) 12 (5.7%)
HR/LR concordance
Urethra/EPS HPV+/210
HR/LR 4
HR/HR 11/49 (22.5%) 23.3%
LR/HR 2
LR/LR 5/21 (23.8%) 10.0%
HR+LR/HR+LR 2
Conclusions: The presence of HR- and LR-HPV types in the distal
urethra and EPS of men was investigated and compared in this study for
the ﬁrst time.
The total HR- and LR-HPV prevalence was detected in this group as
23.3% and 10.0%, respectively; with a low concordance rate between
the two anatomical sites studied.
At the moment we are in progress to: (1) determine HPV types
distribution; (2) extend the study group; and to investigate the HPV
distribution in men with: (3) co-infection, i.e. Chlamydia trachomatis,
and (4) chronic urological disease, i.e. chronic prostatitis.
P1530 CMV reactivation and antiviral immune response in
patients with septic shock
L. von Mu¨ller, M. Principi, A. Klemm, N. Durmus, M. Schneider,
M. Weiß, H. Suger-Wiedeck, T. Mertens (Homburg/Saar, Ulm, DE)
Cytomegalovirus (CMV) is discussed as a pathogen of emerging
evidence in critically ill patients without immunosuppressive therapy.
Sixty-ﬁve patients patients with septic shock were recorded and
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prospectively monitored for active CMV infections using quantitative
pp65-antigenaemia and viral isolation. Forty-three CMV seropositive
patients with a prolonged ICU stay (<7 days) were included. Within two
weeks fourteen patients (32.6%) developed an active CMV infection
with low pp65-antigenaemia (median 3 positive per 500,000 WBCs).
CMV reactivations occurred despite CMV speciﬁc Th1-cell functions.
The active CMV infections turned negative without antiviral therapy after
twenty days, on average. Following active CMV infection the frequency
of CMV and of superantigen (SEB) reactive Th1-cells signiﬁcantly
increased which means that patients with septic shock were capable
to mount an antiviral immune response and to repress active CMV
infection. In patients without active CMV infection the frequencies
of reactive Th1-cells remained low. In parallel active herpes simplex
virus (HSV) infections were detected in sixteen patients using bronchial
aspirates. The HSV and CMV reactivations were associated and occurred
at the same time. ICU treatment and the need of mechanical ventilation
was signiﬁcantly prolonged in the group with active CMV infection and
we suggest that viral reactivation could increase morbidity of patients
with septic shock. Early antiviral therapy aimed at preventing viral
associated morbidity of CMV seropositive patients with septic shock
should be evaluated in future clinical as a new treatment option.
P1531 Persistence of the poliovirus genome in the cerebrospinal
ﬂuid of patients affected by post-polio syndrome
A. Baj, S. Monaco, G. Zanusso, F. Molteni, A. Toniolo (Varese, Verona,
Costamasnaga, IT)
Objectives: Polioviruses (PV; three types) are small, non-enveloped,
positive-strand RNA viruses belonging to the Enterovirus genus of
Picornaviridae. Twenty to thirty years after being hit by paralytic
poliomyelitis, over 50% of patients develop the so called “post-polio
syndrome” (PPS). PPS is characterised by slowly progressing muscular
weakness, chronic pain, fatigue, and other symptoms. The cause of PPS
is likely due to distal degeneration of enlarged post-poliomyelitis motor
units. Virus persistence in the central nervous system (CNS) has long
been investigated with controversial results.
Methods: PPS patients aged 50−65 years have been investigated. The PV
genome has been searched for in cerebrospinal ﬂuid (CSF) samples using
RT-PCR with primers directed to different genomic regions. The utilised
ampliﬁcation methods were capable of detecting <10 genome equivalents
per reaction tube. Direct sequencing of puriﬁed amplicons allowed
identifying the persisting PV serotype. CSF samples from patients with
non-infectious pathologies were used as controls.
Results: All investigated patients (11/11) were positive for the presence
of PV genomic fragments. The 5′ untranslated sequence represented
the most sensitive target for molecular detection. Sequencing of VP1
and 2A tracts revealed that the PV type-1 genome was present in most
patients. Infectious virus was isolated in cell culture from a single patient
undergoing orthopaedic surgery. Complete sequencing of the isolate is
expected to shed light on molecular mechanisms of PV persistence. No
PV amplicons were detected in CSF samples from control patients.
Conclusion: By gene ampliﬁcation and genome sequencing, we have
shown that PV genomes are able to persist for long periods of time
(i.e., >30 years) in the CNS of PPS patients. Though the contribution of
viral persistence to PPS pathogenesis is still undeﬁned, our ﬁndings may
contribute to introducing new molecular tools for PPS diagnosis. The
ﬁnding of persistent PVs also indicates the need of exploring innovative
therapeutic methods for PPS patients. PPS, in fact, represents the most
prevalent motor neuron disease today.
Support from Cariplo Foundation, Varese and Milano (Italy) is gratefully
acknowledged.
P1532 Serological evidence of hantavirus and arbovirus infections
among acute febrile patients in Uzbekistan
A. Soliman, K. Earkart, E. Mohareb, E. Musabaev, S. Vafakulov,
N. Yarmuhamedova, M. Monteville (Cairo, EG; Tashkent, Samarqand,
RU)
Objectives: Hantavirus and arbovirus infections are known to occur
in Eastern Europe and Central Asia, particularly in Kazakhstan and
Turkmenistan. These viral agents have not, however, been reported in
neighbouring Uzbekistan.
Methods: We are currently conducting hospital based surveillance
for undifferentiated fever in Tashkent and Samarqand, Uzbekistan.
Following study enrollment, acute sera was collected from 817 patients
presenting with acute febrile illness between October 2004 and May
2006. Convalescent sera were collected upon discharge or 2−3 weeks
after the ﬁrst specimen was drawn. Sera were screened at 1:100 dilutions
for IgM antibodies to Hantavirus, West Nile (WN), Sindbis (SIN),
Sandﬂy Naples (SFN) and Sandﬂy Sicilian (SFS) viruses using Focus®
IgM-EIA kits (Cypress, California) for Hantavirus and an IgM capture-
ELISA developed at the U.S. Naval Medical Research Unit-3, Cairo,
Egypt. Samples testing positive by ELISA for arbovirus were conﬁrmed
by a plaque reduction neutralisation test (PRNT).
Results: A total of 127 (15.5%) patients were determined IgM positive
to Hantavirus with rates of 6.1% (11/181) and 18.2% (116/636) in
Tashkent and Samarqand, respectively. Six patients (0.7%) had anti-SFS
IgM antibodies (titers ranged 1:400 to 1:6,400), all conﬁrmed by PRNT.
All specimens had no IgM titers against the other viruses tested. Clinical
and epidemiological data of patients will be described.
Conclusions: Hantavirus infection may constitute a signiﬁcant propor-
tion of undiagnosed acute febrile illness particularly in Samarqand (rural
area) in Uzbekistan. This is the ﬁrst report of Hantavirus and SFS virus
infections in Uzbekistan.
P1533 Crimean-Congo haemorrhagic fever and haemorrhagic
fever with renal syndrome in Kazakhstan
B. Ospanov, R. Hewson, J. Hay (Almaty, KZ; Porton Down, UK;
Buffalo, US)
Objectives:We are undertaking a survey of the incidence of two endemic
viral diseases in Kazakhstan. Both diseases are caused by bunyaviruses:
CCHF is spread by ticks, while haemorrhagic fever with renal syndrome
(HFRS), caused by hantaviruses, is contracted through contact with
infected rodent host excreta. Our plan is to integrate studies of human
disease with viral incidence in ticks and reservoir animals.
Methods: To achieve this, we are examining the strain characteristics of
viruses (CCHFV and hantaviruses) that we identify through PCR, and
are assessing incidence of antibody positivity by ELISA against viral
antigens.
We have developed ELISA assays for six strains of both viruses using
cloned, puriﬁed nucleocapsid protein, and PCR assays using detailed
sequence analysis of strains that are likely to be circulating in this part
of central Asia.
Results: We have collected ﬁeld samples as follows: 350 human serum
samples, 2,500 organ samples from over 1,000 rodents and 15,000 ticks
(13,800 H. asiaticum and 1,200 other Ixoides spp.). In preliminary
screening experiments, approximately 40% of ticks tested were positive
for CCHF viral antigen by ELISA. Five percent of rodents were positive
for hantavirus (Puumala) antigen by ELISA.
Conclusion: We anticipate that these numbers are substantial underesti-
mates of the true incidence of viral infection in both ticks and rodents,
and our current PCR and ELISA (for antibodies) studies are designed
to be both more sensitive and speciﬁc than tests used in the past.
S430 17th ECCMID / 25th ICC, Posters
Paediatric bacterial infections
P1534 Comparison of sulbactam/ampicillin and
tazobactam/piperacillin for the treatment of lower
respiratory tract infection in paediatric patients
N. Ishiwada, T. Hoshino, Y. Kohno (Chiba, JP)
Objectives: Paediatric lower respiratory tract infections (LRTI) are
common causes of morbidity and mortality worldwide. Haemophilus in-
ﬂuenzae (Hi), Streptococcus pneumoniae (Pn) and Moraxella catarrhalis
(Mc), the major bacterial aetiologic agents are responsible for cases of
paediatric LRTI. The prevalence of penicillin resistant Pn and ampicillin
(ABPC) resistant Hi has remarkably increased in recent years in Japan.
Furthermore, almost all Mc isolated from patients with LRTI are
b-lactamase-producing strains. Therefore, it becomes more difﬁcult to
treat with antibiotic therapy for LRTI in children. The purpose of this
study is to evaluate the efﬁcacy and safety of two types of penicillin
with an addition of a b-lactamase inhibitor (tazobactam/piperacillin –
TAZ/PIPC – and sulbactam/ampicillin – SBT/ABPC) for the initial
treatment of hospitalised infants and children with LRTI.
Methods: A total 108 paediatric inpatients with LRTI were enrolled in
the study. Of 108 patients, 64 treated with TAZ/PIPC and 44 treated
with SBT/ABPC. We retrospectively analysed clinical efﬁcacy, adverse
events and antibiotic susceptibility of the causative agents isolated from
sputum samples of the patients.
Results: For the patients who received TAZ/PIPC, the overall favourable
clinical response rate was 89.1% (57/64). On the other hand, for
the patients who received SBT/ABPC, the overall favourable clinical
response rate was 86.4% (38/44). Adverse events were reported by two
TAZ/PIPC treated patients and one SBT/ABPC treated patient, but no
severe incidence was observed. In the TAZ/PIPC group, the three most
frequently isolated bacteria from sputum samples were Hi (34 samples),
Pn (14 samples), and Mc (8 samples). Of the 35 Hi strains cultured from
34 samples, 24 strains (66.7%) were ABPC resistant strains including 6
b-lactamase producing strains. In the SBT/ABPC group, the three most
frequently isolated bacteria from sputum samples were Hi (16 samples),
Mc (13 samples), Pn (10 samples). Of the 16 Hi strains, 5 strains (31.3%)
were ABPC resistant strains including 1 b-lactamase producing strain.
Conclusions: Both SBT/ABPC and TAZ/PIPC produced a satisfactory
therapeutic outcome and they are good candidate for initial treatment for
LRTI in children. Especially, TAZ/PIPC was effective for the treatment of
LRTI due to b-lactamase non-producing ABPC resistant Hi. Therefore,
TAZ/PIPC could be a useful agent for treatment of LRTI due to
antimicrobial resistant Hi in children.
P1535 Risk factors for Stenotrophomonas maltophilia isolation
from patients with cystic ﬁbrosis
H. Alexandrou-Athanasoulis, S. Doudounakis, I. Loucou,
A. Sergounioti, M. Georgara, A. Pangalis (Athens, GR)
The number of patients with cystic ﬁbrosis (CF) whose airway secretions
yielded Stenotrophomonas maltophilia (Sm) has been increasing during
the last years.
The aim of our study is to determine risk factors for the initial recovery
of Sm from respiratory secretions of patients with Cystic Fibrosis.
Material and Method: We reviewed retrospectively the clinical and
laboratory data of 87 patients with CF who have been colonised with
Sm between 01/2000 and 11/2006 and 87 matched controls of similar
age (±1 yr) who never had a positive culture for Sm. Variables included
age, gender, mean values of FEV as well as the use of oral, intravenous
or inhaled antibiotics in the three months prior to the ﬁrst isolation of
S. maltophilia from airway secretions.
Results: (1) Eighty-seven out of the 428 patients who have attended
our departments were found to be colonised with Sm. The incidence
rate of Sm acquisition has increased from 3.6% in 2000 to 4.5% in
2006. (2) The mean age at the initial recovery of Sm was 6.9±4.6 years.
(3) Patients positive for Sm were not found to have signiﬁcantly worse
spirometric values than Sm-negative matched controls. (4) Consumption
of oral antibiotics (amoxicillin + clavulate/ciproﬂoxacin/macrolides) as
well as the number of days on intravenous antibiotics were signiﬁcantly
higher in Sm-positive patients. (5) Treatment with inhaled antibiotics
was not found to be a signiﬁcant risk factor for Sm acquisition in our
patients.
Conclusions: Patients with CF with Sm in their airway secretions
do not have an overall worse clinical status at the time of initial
Sm acquisition than Sm-negative patients. Although oral antibiotics or
days of intravenous antibiotic therapy seems to be a signiﬁcant risk factor
for initial Sm acquisition the inhaled antibiotic therapy was not.
P1536 High occurrence of staphylococcal toxins among S. aureus
isolated from children with cystic ﬁbrosis
H. Alexandrou-Athanasoulis, E. Petinaki, S. Nikolaou, S. Doudounakis,
A. Sergounioti, A. Maniatis, A. Pangalis (Athens, GR)
Objectives: S. aureus exerts its pathogenicity by production of
staphylococcal toxins such as toxic-shock syndrome toxin (TSST-1),
Panton-Valentine leucocidin, enteroto-xins etc. In this study, the
occurrence of staphylococcal toxins in S. aureus stains isolated from
children with cystic ﬁbrosis was evaluated.
Material and Methods: A total of 65 S. aureus were collected between
1/1/2005 and 30/6/2006 from sputum of 65 children with cystic ﬁbrosis
(CF), aged 6.9y SD±3.7. Cultures were performed using conventional
methods, while the identiﬁcation of isolates was done by Gram-
stain, catalase and Dnase-activity. Antimicrobial susceptibility to various
antimicrobial agents was tested by the automated VITEK2 system
and the Kirby-Bauer method according to CLSI recommendations.
Methicillin resistance was conﬁrmed by the PB2a detection (Slidex
bioMe´rieux). The detection of genes coding the toxins TSST-1, PVL,
and enterotoxins (seu, sei, seg, sen, seo) was assessed by PCR. A total of
100 S. aureus, collected from different specimens of patients free cystic
ﬁbrosis were also examined.
Results: All 65 isolates were MRSA. The great majority of isolates
expressed a sensitive phenotype (only resistance to oxacillin); only
twelve isolates were resistant to more than three different antimicrobial
agents. All isolates were found to carry at least one gene of the
enterotoxin gene cluster (egc), including the genes sem, sei, seg, sen, seo;
42.5% were found to carry entire the egc operon with the co-existence
of tsst-1 gene. However, none isolate was found to carry the PVL-gene.
Among S. aureus from patients free cystic ﬁbrosis, 13.7% were found
to carry entire the egc operon with the co-existence of tsst-1 gene, while
the presence of PVL-gene was detected in 20% of isolates.
Conclusions: These results clearly indicate that S. aureus from cystic
ﬁbrosis are potentially more virulent than other S. aureus isolates.
P1537 Antimicrobial susceptibility of the pathogens of bacteraemia
in a tertiary neonatal intensive care unit in Bogota,
Colombia, 2001–2006
G. Contreras, R. Prieto, A. Leal (Bogota, CO)
Objectives: Determine the most common pathogens isolated from blood
and characterised their antimicrobial susceptibility pattern
Methods: A descriptive retrospective study was performed. The data of
the Neonatal Intensive Care Unit was collected from the Microbiology
laboratory. Bacterial identiﬁcation and the antimicrobial susceptibility
were determined by the MicroScan system. The data was transferred to
WHONET 5.4 with the aid of BacLink software and were interpreted
according to the criteria of the CLSI. Duplicated isolates were identiﬁed
and deleted. Quality assurance was performed by the National Institute
of Health.
Results: Of 1,210 blood cultures examined in this investigation, 206
(17%) were positive for bacterial growth. The frequency of isolation of
Gram-positive bacteria was 72% (149 of 206) of all isolated pathogens,
26% (621 of 206) were for Gram-negative and 2% for fungi (2 of
206). The 45% of all Gram-positive organisms recovered from our
Paediatric bacterial infections S431
blood cultures coagulase negative staphylococci were the group of
organisms most frequently isolated, the 19% of all Gram-negative
organism Enterobacter cloacae were the most common organism isolated
and Candida albicans was the fungi most common isolated. Table 1
shows the antimicrobial susceptibility rates for Gram-positive and Gram-
negative bacterial species recovered from blood cultures.
Table 1.
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Antibiotic % S % S % S % S % S % S % S % S
Ampicillin N/A N/A 100 0 50 100 40 0
Aztreonam N/A N/A N/A 100 100 100 70 100
Cefepime N/A N/A N/A 100 100 100 100 100
Cefotaxime N/A N/A N/A 100 100 100 60 100
Ceftazidime N/A N/A N/A 100 66.7 100 80 100
Ceftriaxone N/A N/A N/A 100 100 100 70 100
Ciproﬂoxacin 68.2 80.2 100 100 100 100 100 100
Clindamycin 54.5 52.5 N/A N/A N/A N/A N/A N/A
Erythromycin 50 32.7 N/A N/A N/A N/A N/A N/A
Gentamicin 50 31.7 0 77.8 75 100 90 33.3
Gentamicin-high N/A N/A 88.9 N/A N/A N/A N/A N/A
Imipenem N/A N/A N/A 100 100 100 100 100
Meropenem N/A N/A N/A 100 100 100 100 100
Oxacillin 54.5 19.8 N/A N/A N/A N/A N/A N/A
Piperacillin/tazobactam N/A N/A N/A 71.4 100 100 80 100
Rifampin 95.5 94.1 N/A N/A N/A N/A N/A N/A
Trimethoprim/sulfamethoxazole 86.4 76.2 N/A N/A 8.7 N/A N/A 100
Vancomycin 100 100 100 N/A N/A N/A N/A N/A
N/A, not applicable.
Conclusions: This study show the greatest importance of CoNS, which
have higher percentage of resistance to oxacillin and the progressive
increase in the resistance in Staphylococcus aureus in our Unit. The
development of this type of studies in developing countries will facilitate
to guide the empirical antimicrobial treatment in our Institution and
stables control strategies to antimicrobial use.
P1538 The severity of Streptococcus pyogenes infections in
children is signiﬁcantly associated with plasma levels of
inﬂammatory cytokines
S. Wang (Tainan City, TW)
Objectives: Cytokines are intimately involved with the innate and
adaptive immune response to bacterial infections and sepsis. This study
was designed to determine the expression of pro-inﬂammatory and
regulatory cytokines in children according to the severity of infections
caused by Streptococcus pyogenes (group A streptococcus, GAS).
Methods: The study population consisted of 81 children. This included
20 with noninvasive (pharyngitis 7; scarlet fever 13), 16 with invasive
GAS infections (toxic shock syndrome 11; necrotising fasciitis 4;
pneumonia 1), 24 with GAS pharyngeal colonisation and 21 healthy
controls with negative pharyngeal cultures. Plasma levels of interleukin
(IL)-1b, IL-2, IL-6, IL-8, IL-10, IL-12, IL-18, tumour necrosis factor
(TNF)-a, and interferon (IFN)-g were measured by ELISA and ﬂow
cytometry in a particle-based immunoassay.
Results: Patients with invasive GAS diseases had signiﬁcantly higher
IL-1-b, IL-6, IL-8, IL-10, IL-18, and IFN-g than those with noninvasive
diseases, colonisation, and healthy controls. There was no difference in
IL-2, IL-12 and TNF-a levels among the groups. Elevated levels of white
blood cell counts, C-reactive protein and C3 were detected only patients
with invasive diseases.
Conclusions: Children with invasive GAS infections exhibited sig-
niﬁcant up-regulation of plasma levels of IL-1-b, IL-6, IL-8, IL-10,
IL-18, IFN-g during the acute phase of their illness compared to those
with noninvasive infections, pharyngeal colonisation and controls. An
exuberant cytokine response was associated with the severity of illness.
P1539 Laboratory investigation of acute otitis media in children
K. Papavasileiou, H. Papavasileiou, A. Makri, I. Varzakakos, E. Nika,
A. Voyatzi (Athens, GR)
Introduction: Acute Otitis Media (AOM) is a common disease of
childhood, and quite often the children attend the outpatient clinic for this
reason. Risk factors for the development of AOM are: low socioeconomic
status, gender and the use of various hygienic items.
Purpose: To evaluate the incidence of bacterial pathogens responsible
for AOM in children and to monitor the change of their antimicrobial
susceptibility through the ﬁve years of testing (2001–2005).
Material and Methods: A total of 960 middle-ear ﬂuid samples
were collected from infants and children with AOM symptomatology,
who either were hospitalised or attended the ENT outpatient Clinic.
The examined material study was divided in two different time
periods: (A) 2001–2002: 260 samples and (B) 2003–2005: 700 samples.
Identiﬁcation and susceptibility tests were based on classical laboratory
methods, according to NCCLS instructions. In all S. pneumoniae strains
the MICs were deﬁned with automated system (VITEK2, bioMe´rieux).
Results: Out of 960 cultures, 725 (75.5%) were positive to one of
more bacteria. The most prevalent bacteria were: S. aureus (25%),
Ps. aeruginosa (16%), H. inﬂuenzae (14%), S. pneumoniae (10%) and
Streptococcus pyogenes (GAS) (9%). A seasonal distribution has been
detected in the incidence of AOM. In winter–spring time, especially
S. pneumoniae, GAS and H. inﬂuenzae were most predominant.
Comparing the A and B periods, the resistance of S. pneumoniae to
penicillin increased from 36% to 40%, to erythromycin from 26% to
28% whereas to cotrimoxazole it decreased from 52% to 40%. The
determination of MICs showed that there has been a steady increase in
the high-level resistance to penicillin of S. pneumoniae (MIC 2mg/L)
and frequently the strains were multiple resistant. Among S. aureus a
signiﬁcantly lower prevalence of resistance to oxacillin (36% versus
15%) and to erythromycin (25% versus 21%) was observed. The
incidence of erythromycin resistance reduced among H. inﬂuenzae
(25% versus 3%) and GAS (16% versus 14%) during the ﬁve-year
period.
Conclusions: 1. S. aureus was the most predominant causative organism
of AOM in children, followed by H. inﬂuenzae and S. pneumoniae.
2. Signiﬁcant increased resistance of S. pneumoniae strains was not
noted in the last years. 3. The variation on the pattern of antimicrobial
resistance of H. inﬂuenzae and GAS is probably due to the more prudent
use of antibiotics.
P1540 Evaluation of Haemophilus inﬂuenzae isolates from children
with respiratory tract infections
A. Makri, K. Papavasileiou, E. Panagiotaki, H. Papavasileiou,
I. Varzakakos, A. Voyatzi (Athens, GR)
Purpose: The aim of this study was to characterise isolates of
Haemophilus inﬂuenzae (H.i) with respect to serotype and the in vitro
susceptibility to ﬁrst-line antibiotics used for lower respiratory tract
infections.
Material and Methods: A total of 518 samples were collected during
a three-year period (2004–2006) from the lower respiratory tract of
children (327 sputum and 191 bronchoalveolar lavage). Isolates of
H.i were conﬁrmed by using conventional criteria and serotyping was
performed by a slide agglutination procedure with all types antiserum
(Denka seiken). Susceptibility testing was carried out by the disk
diffusion method and the E test (AB Biodisk), while the interpretation
was performed according to CLSI breakpoints. H.i ATCC49247 and
H.i ATCC49766 were used as quality control strains. Beta-lactamase
production was assessed by the nitroceﬁn stick assay.
Results: A total of 212 (40.9%) isolates of H.i were characterised in
this study. Biotypes II and III were the most prevalent types (31.2% and
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25.8% respectively) followed by biotypes I (20.5%), IV (12.9%),
V (4.3%), VIII (3.3%), VI (1%) and VII (1%). The majority of
these isolates (59.4%) were not typeable, whereas serogroups b, a,
and d represented 18.9%, 7.9% and 6%, respectively. The serotypes
c, e and f were rarely found (1%). All isolates were susceptible
to amoxicillin-clavulanate, cefotaxime, meropenem and ciproﬂoxacin.
Ampicillin resistance was observed in 36 strains (17%) and all isolates
were identiﬁed as b-lactamase producers. Resistance to trimethoprim-
sulfamethoxazole and clarithromycin was 26% and 13.7% respectively.
The rank order of activity based on the MIC50 and MIC90 of the
macrolide agents was: azithromycin (0.50−1.5mg/L) > erythromycin
(1.5−4mg/L) > roxithromycin (2−4mg/L) > clarithromycin (2−6mg/L).
Conclusions: (1) Azithromycin was consistently four-fold more active
than the others macrolides. (2) No BLNAR (b-lactamase-negative
ampicillin resistance) isolates were found in our study. (3) The vast
majority of our isolates were non-typeable after the widespread of
conjugate vaccines. (4) Continued surveillance is necessary to monitor
trends with the H.i disease.
P1541 Characteristics of Staphylococcus aureus isolated from the
respiratory tract of cystic ﬁbrosis patients
K. Semczuk, K. Dzierzanowska-Fangrat, D. Borowiec,
D. Dzierzanowska (Warsaw, PL)
Objectives: Staphylococcus aureus is one of the most important causes
of respiratory tract infections in cystic ﬁbrosis (CF) patients. Formation
of small colony variants (SCVs) is usually associated with recurrent
infections refractory to antimicrobial treatment. The aims of this study
were: (1) to determine the frequency of spontaneous and inducible
SCVs formation in CF patients, and (2) to analyse the relation between
antibiotic therapy used and SCVs development.
Material and Methods: During 2003–2005 a total of 107 S. aureus
strains were isolated from 56 deep throat swabs and 61 sputum
samples of 20 CF patients with respiratory tract infections. S. aureus
was identiﬁed by positive catalase, coagulase, DNAase and latex
agglutination tests (Staphytect, Oxoid). Bacteria growing exclusively as
small, non-haemolytic, non-pigmented colonies were considered SCVs.
The ability to form SCVs was evaluated by an in vitro passage in the
medium containing subinhibitory concentration of gentamicin (1mg/L).
Susceptibility to antimicrobial agents was determined by the Etest
method. Forty S. aureus isolates obtained from the upper respiratory
tract of patients without CF were used as control strains.
Results: Eight S. aureus isolates growing as SCVs were cultured from
61 sputum samples. They came from 5 CF patients chronically colonised
with S. aureus. All SCVs isolates were resistant to aminoglycosides (MIC
range 8−32mg/L), 5 isolates were resistant to macrolides (MIC range
2–256mg/L, 4 had MLSB phenotype), 2 were resistant to tetracycline
(MIC range 8−12mg/L) and 1 was resistant to ciproﬂoxacin (MIC-
8mg/L). Among the remaining 99 isolates, 69 (64%) formed SCVs in the
subinhibitory gentamicin concentration, as compared to 20% of control
strains.
Resistance rates of all S. aureus isolates cultured from CF patients
to methicillin, erythromycin, tetracycline, clindamycin, gentamicin,
ciproﬂoxacin and co-trimoxazole were 11, 38, 35, 21, 8, 4 and 3%,
respectively. All isolates were susceptible to vancomycin. Macrolides,
b-lactams and inhaled aminoglycosides were the most frequently used
antimicrobials in CF patients studied.
Conclusions: Chronic S. aureus colonisation in CF patients may be
associated with the bacterial ability to form SCVs. Inhaled gentamicin
may stimulate SCVs formation since these variants were cultured
predominantly from CF patients treated with this form of the drug.
P1542 Arcanobacterium haemolyticum as a cause of
pharyngotonsillitis in Santander (Spain): incidence, clinical
features and antimicrobial susceptibility
C. Garcia, A.B. Campo-Esquisabel, F. Unda, C. Ruiz de Alegrı´a,
J. Agu¨ero (Santander, ES)
Objectives: Arcanobacterium haemolyticum (AH) is considered to be a
cause of infections clinically similar to those caused by beta-haemolytic
streptococci. There have been few published studies on the prevalence
of AH in patients with pharyngotonsillitis. To our knowledge, no data
regarding its frequency in Spain have been published. We reviewed the
46 cases of positive AH isolations from throat samples which occurred
at our institution from Jan 2005 to Oct 2006.
Methods: Throat samples (n = 10.346) from patients with pharyngo-
tonsillitis attending primary healthcare centres and emergency services
in our area (215.000 inhabitants) were studied. Samples were cultured
on sheep blood agar plates for 48 h at 35ºC in 5% CO2. Identiﬁcation
of AH was based on Gram stain, catalase test, a-mannosidase, reverse
CAMP and API-Coryne (bioMe´rieux, France). Deﬁnitive identiﬁcation
was accomplished by sequencing of 16S rDNA. Susceptibility testing
was performed by microdilution with cation-adjusted Mueller-Hinton
broth supplemented with 3% laked horse blood (CLSI guidelines).
Results: AH was recovered from 46 patients, representing 1.54% of all
samples yielding clinically relevant pathogens (n = 2.973). The median
age was 13 years (range 4 to 32). Tonsillar exudate was detected
in 78.2% of patients, rash in 86.9%, fever in 76% and cervical
lymphadenopathy in 78.2%. Recurrent episodes of pharyngitis and/or
exantema occurred in 91.3%. One patient, who presented a peritonsillar
abscess required hospitalisation. Beta-haemolytic streptococci were
concomitantly isolated from 6/46 (13%) samples positive for AH. All AH
strains were susceptible to: penicillin (MIC90 0.06mg/mL), cefuroxim
(MIC90 0.25mg/mL), erythromycin (MIC90 0.01mg/mL), clindamycin
(MIC90 0.03mg/mL), vancomycin (MIC90 0.5mg/mL) and levoﬂoxacin
(MIC90 1mg/mL). Fourteen strains were tetracycline resistant (range of
MICS from 8 to >16mg/mL).
Conclusions: Pharyngotonsillitis by AH tended to occur more frequently
in adolescents, being the incidence similar to those reported from
other European countries. The symptoms of infection by this organism
closely mimiced those of acute streptococcal pharyngitis, including a
scarlatiniform rash in most patients. A history of recurrent pharyngitis
was also present in many cases.
P1543 Anaerobic microbiology of peritoneal cavity specimens in
childhood
M. Vlachou, D. Garantziotou, J. Kaleyias, L. Galanopoulou, V. Rouli,
T. Apostolaki, O. Koureli, A. Spiliopoulou, A. Gatopoulou (Patras, GR)
Introduction: Even though anaerobic organisms are part of the normal
ﬂora, they are associated with several infections with signiﬁcant
morbidity and mortality.
Objectives: The aim of the study was the assessment of incidence of
the anaerobic organisms isolated from peritoneal cavity specimens in
children.
Material and Methods: Setting: Children Hospital of Patras
“Karamandanio”. Study period: June 2003–June 2006 (3 years).
Material: Smears from the peritoneal cavity and the lumen of the
appendix vermiformis. All the positive anaerobic culture were included
in the further analysis of the study. The anaerobic bottles were incubated
with the automatic system BacT-Alert (bioMe´rieux). The culture of
specimens was performed using the appropriate material (Schaedler)
for Gram(+) and Gram(−), incubated under anaerobic conditions for
48−72 hours. The identiﬁcation of the organisms was performed with
API-20A (bioMe´rieux) and BBL Crystal Anaerobe (BD).
Results: One hundred forty-two positive anaerobic cultures during the
three years study period were identiﬁed and included in the further
analysis. The bacteria isolated were: Bacteroides spp. 46/142 (32.39%),
Peptostreptococcus 45/142 (31.69%), Clostridium spp. 21/142 (14.78%),
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Biﬁdobacterium 15/142 (10.6%), Actinomyces israeli 9/142 (6.33%),
Propionibacterium 6/142 (4.22%).
Conclusions: Among the isolated anaerobic microorganisms the most
common Gram-negative was Bacteroides spp. (32.39%), while the most
common Gram-positive was Peptostreptococcus (31.69%). Even though
the anaerobic microorganisms constitute a part of the normal ﬂora of
the human, they may cause severe and sometimes lethal infections. The
appropriate conditions of sampling and transportation of the specimens
are mandatory for the accurate evaluation of each patient.
P1544 Survey of Clostridium difﬁcile infection and faecal lactoferrin
in Polish paediatric patients with inﬂammatory bowel disease
D. Wultanska, A. Banaszkiewicz, A. Radzikowski, P. Obuch-
Woszczatynski, J. Brazier, A. van Belkum, F. Meisel-Mikolajczyk,
H. Pituch, M. Luczak (Warsaw, PL; Cardiff, UK; Rotterdam, NL)
A total of 64 faecal samples submitted from 28 paediatric outpatients
with inﬂammatory bowel disease (IBD) such as Crohn disease (CD) and
ulcerative colitis (UC) between January 2005 and February 2006 were
screened simultanously for detection of C. difﬁcile toxins TcdA/TcdB,
culture of C. difﬁcile strains and faecal lactoferrin (FL). Occurrence of
C. difﬁcile TcdA/TcdB and FL was determined as 70% and 44% of all
cases, respectively. The proportion of positive specimens as well as for
toxins and faecal lactoferrin was not different in CD and UC. Isolates
of C. difﬁcile strains (16 in total) obtained over a 1 year period were
characterised by toxigenicity proﬁle, PCR-ribotyping and susceptibility
to 7 antimicrobial agents. PCR-ribotyping showed six different ribotypes
among 16 C. difﬁcile strains: three toxigenic (014, 018, 046) and four
non-toxigenic (010, 035). The most predominant ribotype in paediatric
patients with IBD was ribotype 014 (A+B+) accounting for 50% (8/16).
No resistance to metronidazole and vancomycin was found. Investigation
of C. difﬁcile infection should be taken into account in group of
paediatric patients with IBD and reccurences of diarrhoea.
This work was supported by Polish Ministry of Education and Science,
Grant No. 2P05D 074 27.
P1545 Prevalence and antimicrobial resistance of bacterial isolates
in neonatal blood-stream infections
E. Ikonomopoulou, M. Vlachou, P. Michail, S. Paratiras,
G. Stavropoulou, C. Verra, A. Regli (Patras, GR)
Objectives: The aim of this study was to determine the prevalence and
the antibiotic resistance of bacterial isolates from blood-stream infections
in the neonatal care unit of our hospital.
Methods: During a three year period (2003–2005) a total of 1,152
blood cultures were obtained from neonates that were suspect of
infection. Blood cultures were performed using the Bactec 9120 (Becton
Dickinson) and Bact–alert (bioMe´rieux) during 2003 and 2004–2005,
respectively. The identiﬁcation and the antimicrobial resistance of
bacterial isolates were carried out by the VITEK system (bioMe´rieux)
or the mini API system (bioMe´rieux).
Results: A total of 90 (7.8%) neonates had positive blood culture. The
most common pathogens were: Coag(−) staphylococci 38, Escherichia
coli 24, Klebsiella pneumoniae 10. Other Gram-negative bacteria were:
Serratia marcescens 3, Proteus mirabilis 2, Enterobacter cloacae 1,
Citrobacter freundii 1 and Stenotrophomonas maltophilia 1. Other Gram-
positive bacteria were: Staphylococcus aureus 3, Enterococcus faecalis 2,
Streptococcus viridans 2, Streptococcus group C 1, and Candida kru-
sei 1. E. coli strains were 50% resistant to ampicillin, 29% to piperacillin,
33% to ticarcillin, 17% to cefalothin, 8% to nalidixic acid and
ciproﬂoxacin, 12.5% to gentamicin and trimethoprim/sulfamethoxazole
and 0% to amikacin, netilmicin, tobramycin, amoxycillin/clavulanic
acid, cefotaxime, ceftriaxone ceftazidime, imipenem, meropenem and
aztreonam. K. pneumoniae strains were 100% resistant to ampicillin
and ticarcillin, 50% to cefalothin and 0% to piperacillin, amoxy-
cillin/clavulanic acid, cefotaxime, ceftriaxone ceftazidime, imipenem,
meropenem, aztreonam, nalidixic acid, ciproﬂoxacin, gentamicin,
amikacin, netilmicin, tobramycin and trimethoprim/sulfamethoxazole.
E. coli and K. pneumoniae strains were ESBL negative. Although
Coag(−) staphylococci sometimes considered to be a contaminant were
17% resistant to oxacillin, 29% to erythromycin, 5% to gentamycin,
16% to fusidic acid and trimethoprim/sulfamethoxazole.
Conclusions: Considering the most common pathogens and their
antibiotic resistance especially to ampicillin perhaps we should revise
the present choise of empirical treatment of ampicillin and one
aminoglycoside until a pathogen has been isolated.
P1546 Serum chemokin RANTES as a immunological indicator
of early-onset neonatal sepsis
M. Wasek-Buko, J. Behrendt, M. Stojewska, B. Krolak-Olejnik,
J. Karpe, U. Godula-Stuglik (Zabrze, PL)
Objectives: Intensive studies on improving the early diagnosis of
neonatal sepsis are ongoing, but only a few of them have focused on
the role of serum chemokine RANTES (s.ch.R). Aim: to establish the
s.ch.R. concentrations in septic neonates, to ﬁnd the relationship between
their gestational age, gender, birth asphyxia, mode of delivery, selected
haematological and biochemical parameters and ch.R. in sick neonates.
Methods: The study comprised 41 septic neonates (28 boys, 13 girls;
18 full-term and 23 preterm). Low birth weight (LBW) was noted
in 13 neonates, extremely LBW in 3, and birth asphyxia in 11.
Cesarean section in 53%, chorioamnionitis in 10% and high-risk
pregnancy in 78% of cases were stated. The most common isolate from
blood was Staph. epidermidis MR (51%). Pseudomonas aeruginosa
was cultured in 9 cases, Klebsiella pn. in 4, E. coli in 3, Staph.
aureus in 2, and Serratia marcescens in 2. Septic neonates presented:
pneumonia (65%), severe gastrointestinal disorders (60%), jaundice with
hepatosplenomegaly (41%), shock (49%), purulent meningitis (17%),
metabolic acidosis and thrombocytopenia in 21%, elevated serum CRP
in 63%. The control group consisted of 40 newborns (25 full-term,
15 preterm, 21 boys, 19 girls) healthy, born vaginally, without perinatal
risk factors. The ch.R. concentration in peripheral vein blood was
measured between the 2nd and 4th day of life by ELISA method using
the Quantikine set (R&D Systems, Minneapolis, USA).
Results: The mean s.ch.R. concentration in full-term septic neonates
was 73.9±25.9 (31.5–17.9) ug/mL and differed signiﬁcantly (p< 0.001)
from the mean value in healthy neonates (28.25±14.0, 12.6–68.4).
Septic prematures had signiﬁcantly (p< 0.001) higher mean s.ch.R.
concentration (59.2±28.2, 12.2–118.2) than healthy preterm newborns
(25.6±8.2, 14.3–41.2). There were no differences between the mean
s.ch.R. value in neonates with Gram(+) sepsis (64.5±22.0, 12.2–96.3)
and neonates with Gram(−) sepsis (67.5±33.9, 22.9–118.2), both in full-
term and preterm neonates. No statistically signiﬁcant difference was
noted in mean s.ch.R. value regarding gender, birth weight, mode of
delivery, or Apgar score in septic neonates. A positive correlation was
found between s.ch.R. concentration and band cells count in peripheral
vein blood (r = 0.249) and serum CRP value (r = 0.301).
Conclusion: Serum chemokine RANTES concentrations increase in
early-onset sepsis in neonates, independently of their gestational age,
gender, Apgar score or mode of delivery, and may be useful in diagnosis
of this congenital bacterial disease.
P1547 Antimicrobial susceptibility of bacteria causing early onset
sepsis
E. Zisovska, L. Lazarevska, J. Zivkovik (Skopje, MK)
Introduction: Neonatal sepsis has high morbidity and mortality, so rapid
and accurate detection and treatment with initial antibiotic therapy, before
the microbiological evaluation ﬁnished, is necessary and is based on
empirical data in regard to sensitivity of prevalent bacterial strains. AIM
of our investigation was to present the spectrum of prevalent bacteria
and their susceptibility to the antibiotics used by the standard protocols,
based on evidence.
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Methods: Our prospective study included all neonates with suspected
sepsis born in our Department of neonatology in a two year’s period
(2004 and 2005). Microbiological identiﬁcation and susceptibility were
performed with routine methods.
Results: A total of 8,356 neonates were evaluated during this study
period and 167 patients fulﬁlled the eligible criteria. Three most
frequent bacterial strains were Staphylococcus epidermidis, Escherichia
coli and Group B streptococci. Less frequent were Staphylococcus
aureus, Klebsiella pneumoniae and Pseudomonas aeruginosa. In 21/167
(12.57%) patients initial antibiotic treatment was inappropriate, and the
most resistant strains were S. aureus (8) followed by K. pneumoniae (7),
E. coli (4) and P. aeruginosa (2).
Discussion: the initial use of appropriate antibiotics, before the detection
of bacteria, is very useful, it reduces the time of therapy, length of stay
and costs of treatment.
Conclusion: It is recommended for each neonatal department to
determine their own spectrum of bacteria and to adjust the initial
antibiotic treatment to the ﬁndings which are typical for the unit. But,
also repeated surveillance is necessary in order to follow the longitudinal
changes of the bacterial spectra due to the resistance acquired.
P1548 Rapid molecular detection of bacterial species and
resistance determination in paediatric blood cultures
D. Menichella, P. Bernaschi, B. Lucignano, C. Manfredini, C. Russo
(Rome, IT)
Bacteraemia is one of the most serious and potentially life-threatening
infection disease in children, specially in case of septic shock. Signs or
symptoms of bacteraemia are highly variable in childhood and diagnosis
is routinely supported by blood culture.
In our study, we evaluated a new molecular genetic assay (GenoType BC
Gram-positive® and GenoType BC Gram-negative® – Hain Lifescience)
as rapid tool for identiﬁcation of most of bacteria involved in blood-
stream infections in children suspected to have bacteraemia, hospitalised
at “Bambino Gesu`” Children Hospital (Rome, Italy) and to improve the
work-ﬂow TAT in a microbiology laboratory.
At instrumental positive time (BACTEC 9240 Becton Dikinson) all the
bottles (PEDS PLUS/F) were evaluated with microscopy Gram stain
and subcultured in agar standard media. Phenotypic identiﬁcation was
obtained on colonies grown after 24 hours of incubation by using the
VITEK® 2 (bioMe´rieux) automated system. For molecular identiﬁcation
20mL of blood positive culture were spotted on GENO-CARD® and
after a drying step, a punch of 1mm in diameter was transferred into
the PCR mix followed by thermal-cycling ampliﬁcation. Hybridisation
protocol was performed as recommended using a shaking incubator and
results were obtained by comparison of the hybridisation pattern present
on the test strip with the ones of the provided evaluation sheet.
148 positive blood culture bottles representing 106 Gram-positive cocci,
28 Gram-negative bacilli and 14 mixed infections were included in
this study. At start time we performed all of the proceduring steps
as manufacturing instructions and the GenoType BC system correctly
ampliﬁed and identiﬁed 41/49 Gram-positive cocci (sensitivity 83%);
8 Staphylococci were not ampliﬁed. 17/17 Gram-negative bacilli were
correctly ampliﬁed and identiﬁed (sensitivity 100%).
In the effort to optimised the GenoType assay we improved by in house
steps the direct DNA extraction. Finally all of 53 Gram-positive cocci,
11 Gram-negative bacilli were correctly ampliﬁed, 4 K. kristinae were
correctly not ampliﬁed (sensitivity and speciﬁcity 100%). About 14
mixed cultures were correctly identiﬁed and for 1 of them the
GenoType BC assay recognized a double infection (P. aeruginosa and
S. maltophilia) demonstrated only after this result by a new subculturing.
GenoType BC assay is very helpful in the rapid diagnosis of paediatric
blood stream infections in effort to prevent severe sepsis and mortality.
P1549 Genetic factors in the development of unfavourable effects
of intrauterine infections on the course of neonatal periods
in neonates
N. Gorovenko, Z. Rossokha, S. Podolskaya (Kiev, UA)
Objectives: Intrauterine infection in neonates is an important factor
of perinatal risk in the development of complications during neonatal
period. The latent forms of these infections are not always when
effecting neonates. In a great number of studies the genes deletion
polymorphism of glutathione-S-transferases was associated with higher
sensitivity to the inﬂuence of many factors. The aim of this research
was to study the prevalence of intrauterine infections and GSTT1 genes
allelic polymorphism in neonates.
Methods: The prevalence of Toxoplasma gondii, Chlamydia trachomatis,
Mycoplasma hominis, Herpesvirus I/II types, Cytomegalovirus in the
blood of neonates with perinatal pathologies and neonates from the
comparative group (clinical healthy neonates) was tested by polymerase
chain reaction (PCR) method. The allelic polymorphism of GSTT1 genes
was investigated by means of multiplex PCR in neonates. Differences in
these groups were assessed by the Pearson chi-square analyses.
Results: There were detected latent forms of intrauterine infections in
74 of 117 neonates with perinatal pathologies (63.24%) as compared
to the comparative group of the neonates where the frequency of latent
forms accounted for 9 of 70 neonates (12.85%). In our investigation we
have observed an increased frequency of GSTT1 null genotypes among
infected neonates (31.32%; 26 of 83 individuals were homozygous
for GSTT1 deletion genotype) as compared to uninfected neonates
(16.98%; 18 of 104 individuals were homozygous for GSTT1 deletion
genotype). The frequency of deletion polymorphism of GSTT1 genes
was signiﬁcantly increased among infected neonates of both groups
(4.59, P< 0.05), i.e. GSTT1 null genotype was associated with the
development of intrauterine infections. The GSTT1 frequency of
deletion polymorphisms was signiﬁcantly (6.66, P< 0.01) increased
among infected neonates with perinatal pathologies (33.78%; 25 of
74 individuals were homozygous for GSTT1 deletion genotype) as
compared to uninfected clinical healthy neonates (13.11%; 8 of 61
individuals were homozygous for GSTT1 deletion genotype).
Conclusion: Thus, the deletion polymorphism of GSTT1 genes in
neonates stipulates the predisposition to the intrauterine infections causes
its effect with further development of perinatal pathologies.
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P1550 Features of norovirus and rotavirus infections in small
children
I. Narkeviciute, I. Tamusauskaite, G. Bernatoniene (Vilnius, LT)
Objectives: No comparison studies of clinical presentation of norovirus
and rotavirus infection in small children were ever made. We investigated
norovirus infection features in children under three year’s age and
compared the results with rotavirus infection in the children of the same
age.
Methods: The random selection and retrospective analysis of 70
norovirus and 70 rotavirus-infected children‘s case notes were done.
All children were treated in Vilnius University Children Hospital in
2005. The norovirus antigen was assayed using ELISA, rotavirus – using
immunochromatography diagnostic assay.
Results: In small children norovirus infection manifested as vomiting
(94.3%), diarrhoea (81.4%) and pyrexia (65.7%). It manifested as either
gastroenteritis with pyrexia (47%) or gastroenteritis alone (30% of all
cases) while 18.6% cases were without diarrhoea. Granulocytosis was
found in 72.7% of blood results. Pyrexia was present in 97.1% case of
rotavirus infection and 80.9% were >38ºC. However, in norovirus infec-
tion accordingly 65.7% and 47.8% (p< 0.0001). Diarrhoea (4 times/d)
more frequently appeared in children with rotavirus infection than with
norovirus (p< 0.0001). Repeated vomiting (4 times/d) has been more
common for children with norovirus infection. As opposed to norovirus
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infection, rotavirus infection usually presented just as one syndrome of
gastroenteritis with pyrexia (p< 0.0001).
Conclusion: Norovirus infection can present either as gastroenteritis or
gastroenteritis with pyrexia. However, diarrhoea was absent in almost
1/5 of all patients. Norovirus and rotavirus infections had statistically
signiﬁcant differences in a degree of pyrexia, intensity of diarrhoea and
vomiting as well as syndromes frequency.
P1551 Clinical proﬁle of dengue infection in children versus adults
N. Othman (Selangor, MY)
Objectives: To compare the clinical proﬁle between children and adults
with serologically conﬁrmed dengue infection.
Methods: A cross-sectional retrospective study comprising 581 adults
and 372 children admitted with dengue infection was carried out from
July to December 2004. Children was deﬁned as <13 years old and
adults as 13 years. Diagnosis of dengue infection was established by
detection of speciﬁc dengue IgM ELISA.
Results: Out of 953 cases, there were 528 (55.4%) males and 425
(44.6%) females. The mean ages were 26.5 and 7.00 years for adults
and children respectively. Children were found to be more prone
to have dengue shock syndrome (DSS). Fever, respiratory symptoms
(cough and coryza) and abdominal pain were commonly present in
children. On the other hand, adults were more likely to complain of
retro-orbital pain, myalgia, athralgia and anorexia. Reported bleeding
manifestations were signiﬁcantly higher in adults. In terms of signs,
hepatomegaly and lymphadenopathy were commoner in children, while
ﬂushing and abdominal tenderness were seen more in adults. The most
remarkable ﬁnding on laboratory investigation was adults had higher
alanine transferase levels as compared to children, implicating a higher
tendency for liver impairment. Both groups showed thrombocytopenia
on admission (71.4×109/L in adults versus 99.05×109/L in children);
thrombocytopenia was found to be statistically lower in adults. No
mortality outcome was noted.
Conclusion: Children tend to be inﬂicted with a more severe form of
dengue infection. Both age groups present different clinical features. In
addition, complication such as liver impairment is more seen in adults
P1552 Myocarditis heart failure associated with Adenovirus
infection
O. Valdes, B. Acosta, C. Savon, A. Pin˜o´n, A. Goyenechea, L. Palerm,
G. Gonza´lez, V. Kouri, A. Martı´nez, L. Sarmiento, D. Rosario,
M. Guzma´n (Havana City, CU)
Objective: Rapid detection of aetiological agent causing myocarditis
using molecular tools.
Methods: During an atypical outbreak of acute febrile syndrome of
viral aetiology, 8 children ranged between 5 months aged to 12 years
old have died in cardiogenic shock due to myocarditis, on July and
August, 2005, in Havana city, Cuba. Nested polymerase chain reaction
(nPCR) was used to detect the genomic sequences of Enterovirus,
Adenovirus, Cytomegalovirus (CMV), Herpes simplex virus (HSV),
Epstein Barr virus (EBV), Varicella zoster virus (VZV), Human Herpes
virus 6 (HHV6), Flavivirus, Alphavirus, human Respiratory syncytial
virus (hRSV) and Inﬂuenza virus (A, B and C) in tissue samples (heart,
lung, brain and tonsil), cerebrospinal ﬂuid and faeces specimens.
Results: We found evidence for the Adenovirus genome in a signiﬁcant
proportion of patients, 6 (75%) of them. Non others viruses were
detected. The predominant clinical picture was characterised by acute
cardiac decompensation and progress to death. In these cases the organs
most common detected were lung (83%) and myocardium (67%). In
three cases adenovirus was detected in both organs. Electrocardiography
changes suggestive of myocarditis were detected in all patients.
Histopathology ﬁndings characterised by an inﬁltrate of inﬂammatory
cells and myocardial necrosis, established the anatomapathologic
diagnosis of myocarditis post-mortem.
Conclusion: After exclusion of other possible causes of death, our
results indicate that viral myocardial affection is the cause of death in
Adenovirus positive cases. It should be noted that this is the ﬁrst report
about the molecular diagnosis of Adenovirus in myocarditis cases in
Cuba.
P1553 Rotaviral and noroviral infections among children inpatients
of a clinic of infectious diseases in Pilsen, Czech Republic
P. Pazdiora, M. Sˇvecova´, J. Ta´borska´ (Plzeo`, Plzen, CZ)
Objectives: Rotaviruses are the most frequent aetiological agent among
patients with diarrhoeal diseases. Data about community-acquired
noroviral infections is sporadic, there is the ﬁrst data from the Czech
Republic.
Methods: The importance of rotaviruses was analysed among childrenœ
inpatients during years 1986–2005, the importance of noroviruses during
years 2003–2006.
Results: In years 1986–2005 were examined 6,416 younger children with
gastrointestinal diseases. Rotaviruses were observed among 26.4% pa-
tients, their occurrence changed in different years between 14−41%. The
incidence of rotavirus acute gastroenteritis among different age groups
was as follows: children under 7 months 16.3%, 7−12 months 28.7%,
13−24 months 32.2%, 25−36 months 28.0%, older 24.4%. The highest
incidence rate was during March (44.8%), the lowest during September
(17.3%). Among 1,385 patients without gastrointestinal symptoms
rotaviruses were detected 57x (4.1%). Nosocomial rotaviral infection was
laboratory detected in 290 of 5,714 infants repeatedly examined during
the hospitalisation (i.e. 5.1%). These infections protracted hospitalisation
on average by 4 days. In years 2003–2006 were examined 248 children
with gastrointestinal diseases. Noroviruses were detected EIA test among
6.8% patients. The highest incidence of norovirus acute gastroenteritis
was among children 7−12 months 18.5%.
Conclusion: The results conﬁrm frequent occurrence of rotaviral and
noroviral infections among hospitalised children.
Grant support: MSM 0021620819 VZ 6096
P1554 Increased prevalence of genotype G2P(4) among children
with rotavirus-associated gastroenteritis in Honduras
A. Ferrera, D. Quan, F. Espinoza (Tegucigalpa, HN; Leo´n, NI)
Background: Rotavirus is a major cause of gastroenteritis among young
children worldwide and is associated with signiﬁcant morbidity and
mortality, particularly in developing countries. From January to March
2006, a large outbreak of gastroenteritis occurred in Honduras that was
associated with hospitalisation and death among children.
Objective: To characterise by molecular methods the rotavirus A
genotypes G and P involved in the outbreak of 2006.
Methods: Faecal samples positive for rotavirus by enzyme-linked
immunosorbent assay were collected from 45 children under 5 years
of age from two geographically distinct regions of Honduras where the
epidemic had occurred. G- and P-types were determined in a two-step
procedure using reverse transcription followed by a standard multiplex
PCR.
Results: The infection G2P(4) (43.3%) appeared to be the most frequent
cause of the rotavirus outbreak, occurring mainly in children less than
one year of age. Other genotypes encountered were G4P(8) (16.7%),
G9P(8) (13.3%) and G2P(10) (3.3%). Co-infection with more than one
G genotype occurred in 5 children, and co-infection with more than one
P genotype occurred in 2 children.
Conclusion:We found for the ﬁrst time genotypes not reported before in
the population, suggesting a great diversity of rotavirus strains circling
in the country. Further molecular surveillance could provide a sound
basis for improving the response to epidemic gastroenteritis and could
provide data needed for the introduction of vaccination programmes in
the country.
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P1555 Human herpes virus 6 infection in children in Northern
Greece
P. Sidira, S. Mitka, D. Karabaxoglou, K. Politi, A. Kansouzidou,
A. Papa (Thessaloniki, GR)
Objective: Human Herpes virus 6 (HHV-6) is a human pathogen of
emerging clinical signiﬁcance. Two genetically distinct variants of the
virus exist, HHV-6A and HHV-6B. HHV-6 has been identiﬁed as a
causative agent of exanthem subitum. HHV-6 infection is common
in the ﬁrst 3 years of life and the disease has a variety of clinical
presentations. The aim of this study was the estimation of the incidence
of the HHV-6 infection in children in northern Greece and the evaluation
of the contribution of PCR in the early and speciﬁc diagnosis of the
disease.
Materials and Methods: A total of 27 patients (children aged under 3
years) with signs and symptoms suggestive of exanthem subitum were
studied. A total of 39 serum specimens from the patients were examined
for the detection of speciﬁc IgM and IgG antibodies against HHV-6
by ELISA and 27 blood specimens were tested for the HHV-6 DNA
by polymerase chain reaction (PCR). In the PCR, a fragment of U67
gene (homology 96.5% between HHV-6A and HHV-6B) was used as
DNA target (fragment 223 bp). HHV-6A U1102 strain was used as a
positive-control.
Results: In total, HHV-6 primary infection was diagnosed in 10 patients
out of 27 patients examined, who presented seroconvertion and/or had
HHV-6 DNA detectable in the acute blood specimen. Past HHV-6
infection was diagnosed in 6 patients who had IgG antibodies against
HHV-6 in the acute serum, while PCR was negative in the acute blood
specimen. Absence of HHV-6 infection was diagnosed in 11 patients
who presented negative results in HHV-6 PCR and IgG serology.
Conclusions: HHV-6 primary infection is a signiﬁcant causative agent
of illness in children aged under 3 years presenting with fever and
exanthem. PCR assay contributes signiﬁcantly in the early diagnosis
of HHV-6 primary infection, as serology alone proved to have many
limitations.
P1556 Varicella-related hospitalisation in children: a seven-year
retrospective study in the pre-vaccine era, in Ankara, Turkey
N. Belet, A. Tapisiz, E. C¸iftc¸i, E. Ince, U¨. Dogru (Ankara, TR)
Objectives: Varicella is predominantly a childhood disease in non-
vaccinated populations. Although varicella infection is more severe
in immunocompromised people, most cases of severe morbidity and
mortality are seen in healthy individuals. The purpose of the study was
to evaluate the indications of hospital admissions and complications of
varicella infection in a tertiary care hospital, in Ankara, Turkey.
Methods: Hospital records of children hospitalised for varicella between
January 2000 and October 2006 were reviewed. Demographics, immune
status, clinical features, microbiological ﬁndings, informations on
varicella complications and the outcomes of patients were analysed.
Results: A total of 30 children were hospitalised during the study
period. The mean age was 53.1±42.1 months. The mean hospital
stay was 7.0±6.5 days. There was a male predominance with 20
(66%) males and 10 (34%) females. The indications of hospitalisation
were immunocompromised status in 46%, varicella-related complications
in 40%, malnutrition in 4%, and isolation requirement during
hospitalisation for another reason in 10%. At admission, 63% of patients
had fever, 80% profused vesicular rash, 20% skin lesions less than
10, and 16% mucosal involvement. There were 29 complications in 14
patients and the majority of patients had more than one complications.
Pneumonia and secondary skin or soft tissue infections were the most
common complications in 6 (20%), followed by hepatitis in 5 (17%),
thrombocytopenia and dehydration in 3 (10%), arthritis and sepsis in
2 (6%), and DIC and feeding difﬁculty in 1 (3%). All patients who
developed complications were healthy except for two. Four patients
(13%) had positive bacterial isolates, including 2 Staphylococcus aureus,
one group A beta-haemolytic Streptococcus, and one Haemophilus
inﬂuenzae type b. Sixteen patients (53%, 14 immunocompromised and
two immunocompetent children) were treated with acyclovir and the
duration of therapy was 7.2±2.2 days. No fatality was reported during
the study period. Only one patient who had pneumonia, hepatitis and
DIC was admitted to the intensive care unit.
Conclusion: Varicella complications are believed to be rare in
immunologically healthy children. However, our results indicate that
varicella complications occurred mainly in immunocompetent children.
Thus, a universal childhood varicella immunisation may reduce the rate
of varicella-related complications and admissions in our country.
P1557 Human metapneumovirus in paediatric viral respiratory
infections
J. Alexandre, M. Alves, G. Rocha, A. Magalha˜es-Sant’Ana,
A. Melic¸o-Silvestre, C. Nogueira (Coimbra, PT)
Objectives: Respiratory infection in infants and young children is a
signiﬁcant public health problem worldwide. Infection with respiratory
syncytial virus (RSV) is the most common known cause of lower
respiratory tract infection in young children. Human metapneumovirus
(hMPV), a member of Pneumovirinae subfamily of the Paramyxoviridae
family, ﬁrst discovered in 2001, has recently been described as a casual
agent of acute respiratory disease. The virus is widely distributed and
has been detected in Japan, China, Australia, USA and several European
countries, and is responsible for about 2 to 25% of cases of acute
respiratory tract infections in infants. This relatively high incidence and
the fact that hMPV associated disease may be severe, emphasized the
need for a reliable, sensitive and rapid diagnostic test for detection of
hMPV.
Methods: From November 2005 to October 2006, 157 respiratory
samples were collected from paediatrics patients with symptoms of
respiratory tract disease. For the hMPV study total RNA was extracted
by MagNA Pure Compact (Roche) using the MagNA Pure Compact
Nucleic Acid Isolation Kit I (Roche), according to the manufacter’s
instructions. cDNA was synthesized with random hexamer primer
from the Transcriptor cDNA synthesis Kit (Roche) according to the
manufacter’s instructions. The detection of hMPV was performed by
a real time PCR assay using primers targeting the nucleoprotein
gene (N) and a ﬂuorogenic endonuclease oligoprobe (Taqman) for
detection. Samples were also tested for screening and identiﬁcation of
Adenovirus (ADV), Parainﬂuenza (P) 1, 2 and 3, and RSV by an indirect
immunoﬂuorescence assay (Respiratory Virus Panel, Biotrin) according
to the manufacter’s instructions.
Results: hMPV was detected in 20 (13%), RSV in 87 (55%), ADV
in 6 (4%), P3 in 3 (2%), respiratory samples. Co infections were also
identiﬁed: 3 hMPV +/RSV + and 1 RSV +/ADV+.
Conclusions: RSV is still the leading cause of respiratory tract illness
in infants and children and our ﬁndings agree with detections rates
(50−90%) published in literature. Nevertheless, hMPV was found in a
signiﬁcant number of cases (13%) as reported by other authors.
P1558 Human bocavirus infections in children in Hong Kong
S.K.P. Lau, P.C.Y. Woo, C.C.Y. Yip, R.A. Lee, L.Y. So, T.L. Que,
K.H. Chan, K.Y. Yuen (Hong Kong, HK)
Objectives: Human bocavirus (HBoV) is a recently discovered human
parvovirus associated with respiratory tract infections in children. We
carried out a one-year prospective study on the clinical spectrum of
disease and epidemiology of HBoV infections in children in Hong Kong.
Methods: A total of 1,200 nasopharyngeal aspirates, negative for
respiratory viruses by immunoﬂuorescence tests, from patients  18
years old with acute respiratory tract infections were subjected to PCR
for HBoV. Clinical records of patients positive for HBoV were analysed
to determine the clinical presentations and outcome.
Results: HBoV was detected in 96 (8%) patients. Of the 96 patients, 11
were 9 years old. The male to female ratio was 1.5: 1. HBoV infections
were associated with both upper and lower respiratory tract disease,
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including pneumonia, acute bronchiolitis and asthmatic exacerbation.
All patients survived. As in other reports, HBoV infections in children
peaked in winter, although cases also occurred in other seasons.
Conclusions: HBoV circulates in children in Hong Kong and is
detected in nasophayngeal aspirates of those with acute respiratory tract
infections. Further studies should be performed o assess the role of
HBoV in respiratory tract infections in children.
Public health aspects of viral infections
P1559 Biological risk stemming from the long-term burial of NDV
vaccinal strains
S. Bianchi, A. Amendola, M. Canuti, A. Zappa, E. Tanzi, R. Koncan,
G. Cornaglia (Milan, Verona, IT)
Objective: Large areas are often used as uncontrolled pits for
pharmaceutical waste. No worldwide-accepted criteria deﬁne the extent
and persistence of the consequent biological risk, related, for instance,
to vaccines and their by-products. The objectives of the present study
were:
1. To study the residual viability of Newcastle Disease Virus (NDV)
vaccine strains stored in sealed vials and recovered after burial for 30
years.
2. To determine the persistence of the NDV genome in embryonated
chicken eggs, i.e. the substrate used for producing the vaccine.
Methods: Vaccines against Newcastle Disease (avian pseudoplague)
were analysed both in lyophilised form and as specimens of eggs
recovered from the same area. To evaluate the competence and integrity
of the viral genome, gene ampliﬁcation was performed by nested RT
PCR speciﬁc for a 275 bp fragment of NDV gene F. The PCR-
positive specimens were submitted to viability tests through preparation
of permissive cell cultures (Vero, African green monkey kidney) and
detection of the cytopathic effect. To conﬁrm the speciﬁcity of the
cytopathic effect, an haemadsorption test was performed. As a positive
control, we used a vaccine currently being used against the avian
pseudoplague (Izovac, Brescia, Italy) containing live NDV strains (titre,
>106 EID50).
Results and Conclusions: Nested RT PCR permitted detection of
the NDV genoma in the lyophilised vaccine vials, but not in the egg
specimens. This suggests that the NDV viral RNA can persist for several
years even under uncontrolled environmental conditions if preserved in
sealed vials, but is not able to persist in substrates undergoing chemical
and bacteriological modiﬁcations, such as the eggs. The recovered
viruses were endowed with the speciﬁc NDV cytopathic effect, thus
showing that they retained their replicative ability. As a consequence,
an NDV infection risk is actually involved in the manipulation of
pharmaceutical waste. The lack of studies aimed at evaluating the
environmental infection risk from the uncontrolled burial of industrial
bio-material, such as vaccines and their by-products, constitutes a serious
gap in our knowledge.
P1560 Reappraisal of the Berg method to assess viral
contamination of the soil
S. Bianchi, A. Amendola, M. Canuti, A. Zappa, E. Tanzi, R. Koncan,
G. Cornaglia (Milan, Verona, IT)
Objectives: Some viruses are able to contaminate the soil and persist
in it. Nevertheless, at present, no widely accepted standards exist for
the evaluation of viral contamination in this environment. The recent
scientiﬁc literature is not particularly informative, since most studies
on this subject date back to roughly 30 years ago and focus on
soil contamination by sewage and on controlling the circulation and
transmission of oro-faecal agents. The Berg method was developed in
1980 for ‘recovering viruses from sludges’, and the following years did
not witness any evolution in that technique or its application to other
types of viral contamination. Thus, we have re-examined it in order to
extend its applicability to soil.
Methods: Known amounts of enteric viruses (namely Coxsackie B6
virus and Echovirus 12) were used to infect the dry soil. The viral
particles were subsequently eluted with 10% beef extract, by means of
centrifuging and serial passages through 3-mm, 0.45-mm and 0.22-mm
ﬁlters, respectively. All tests were performed in the absence of sterility
and under standardised environmental conditions, namely aerobiosis,
23ºC and pH 7. Following every step of the elution procedure, the
presence of the virus was tested by means of gene ampliﬁcation assays
speciﬁc for the enteroviruses used. The viability of the viruses in the
eluates was assessed on the basis of their cytopathic effect on permissive
cells (human rhabdomyosarcoma cell line RD).
Results and Conclusions: Optimal parameters were identiﬁed as regards
quantity of soil and beef extract (100 g and 100mL, respectively).
Titration of the ﬁltrates obtained from each single step made it possible
to assess the efﬁciency of viral recovery, which exceeded by 50%
that envisaged in the original Berg method (reported recovery values,
35−40%). The application of this revised technique to the soil may permit
effective monitoring of different viruses with alleged high environmental
resistance.
P1561 Study of immunity level to measles and mumps in women
of reproductive age in Northern Greece
A. Fylaktou, M. Goutaki, S. Kalamitsou, A. Haidopoulou,
G. Atmatzidis, E. Papadopoulou (Thessaloniki, GR)
Objectives: The aim of our study was to examine the immunity status
to measles and mumps in women of reproductive age.
Methods: Our specimen consists of 198 women between 16−45 years
old who were examined in our hospital during the years 2004–2006.
Our specimen was divided in two groups according to vaccination status.
IgG and IgM antibodies titers for measles and mumps was determined
in blood serum by Elisa Virotech (genzyme diagnostics) semiquantitive
method.
Results: 91.9% of women are immune to measles whereas for mumps the
percentage presents signiﬁcant decrease to 75.76%. In the overwhelming
majority the immunity is due to infection. This is justiﬁed because the
MMR vaccine was introduced to the National Immunization Program at
1989 while previously the immunisation rate either with MMR (after the
mid seventies) or with the monovalent vaccines for measles and mumps
was less than 30%.
IgG+ IgG−
n (%) n (%)
Measles
Group A (after vaccination) 29 (14.65) 0 (0)
Group B (no vaccination) 163 (77.27) 16 (8.08)
Total 182 (91.92) 16 (8.08)
MUMPS
Group A (after vaccination) 29 (14.65) 0 (0)
Group B (no vaccination) 121 (61.11) 48 (24.24)
Total 150 (75.76) 48 (24.24)
Conclusion: A signiﬁcant percentage of women of reproductive age
(24.24% of specimen) is susceptible to mumps. Although these women
are protected by the community’s immunity it would be wise to be alert
since mumps during the ﬁrst trimester of pregnancy is associated with
an increased rate of spontaneous abortion. Also we note that infants
of these mothers will be at high risk for serious infection from mumps
and measles virus with an increased frequency for complications, having
obtained no immunity by transported maternal IgG.
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P1562 Role of exposure to HPV infection and genetic susceptibility
for cervical neoplasia in Italy
A. Agodi, M. Barchitta, N. La Rosa, R. Cipresso, M. Guarnaccia,
M. Cultrera, M. Caruso, M.G. Castiglione, G. Ettore, S. Travali
(Catania, IT)
Objectives: Although cervical infection sustained by high-risk human
papillomaviruses (HPV) is considered a necessary event in the
development of cervical cancer, it is clear that it is not sufﬁcient.
Thus, other factors are likely involved in inﬂuencing the persistence and
progression of an HPV infection towards malignant disease. One such
inﬂuence may be genetic susceptibility, although this issue continues to
be a focus of debate. A cross-sectional study was conducted in order to:
i) estimate the prevalence of cervical HPV infection and ii) investigate
the role of the p53 codon 72, GSTM1 and GSTT1 polymorphisms in
cervical neoplasia.
Methods: During the period 2004–2006, all women attending the
Service for Colposcopy of an Italian Hospital were consecutively
enrolled. Cases were women with high-grade cervical intraepithelial
lesion (H-SIL). Controls were women without a history of cervical
abnormalities or with low-grade cervical intraepithelial lesion (L-SIL).
The presence of various HPV types was examined using the HPV
Screen Kit (Nuclear Laser Medicine). Polymorphisms of p53 gene
were evaluated with PCR with primers encompassing the polymorphic
site at codon 72. The GSTM1 and GSTT1 genetic polymorphisms
were evaluated using multiplex PCR techniques. In all subjects, gene
polymorphisms were determined and results were analysed according
to HPV infection status and histological feature, in comparison to the
control group.
Results: A total of 232 women were enrolled. The overall HPV
prevalence was 71.1% patients. High-risk types were found in 89.7%
of infected women and multiple infections in 47.9% of infected women.
HPV 16 was by far the most common type (51.5% of HPV positive
women), followed by HPV 6 (32.1% of HPV positive women), and HPV
56 (29.7% of HPV positive women); type 18 was found in only 2.4%
of HPV positive women. No signiﬁcant differences in the p53 and GST
polymorphisms distribution were found in relation to the infection with
HPV. On the contrary, our study showed a signiﬁcant association between
the arginine homozygous genotype and H-SIL, corresponding to an odds
ratio of 5.6 (95%CI: 1.515–20.880).
Conclusion: Our study showed a higher HPV prevalence compared with
other European populations. Besides, it revealed a possible susceptibility
role of the p53 codon 72 polymorphism at an early carcinogenetic
stage in cervical cancer. However further research is needed with close
attention to study design and methodological features.
P1563 An investigation of a cluster of parapoxvirus cases in
Missouri, February–May 2006
E. Lederman, M. Tao, H. Pue, M. Reynolds, S. Smith, Y. Li, H. Zhao,
L. Sitler, A. Mahmutovic, G. Emerson, C. Hutson, D. Bensyl, R. Regnery,
B. Zhu, I. Damon (Atlanta, Hyattsville, Jefferson City, Troy, US)
Background: Human infections with “barnyard parapoxvirus” (i.e. orf
virus and pseudocowpox virus) are rarely reported to health departments.
From February to May 2006, four cases were reported in Missouri, two
of which were evaluated for anthrax infection.
Methods: Survey of the four cases, family members, county veterinari-
ans and a convenience sample of local farmers were conducted. Samples
were collected from implicated animals and animal environments
(barnyards) for laboratory analysis.
Results: Two additional cases of human orf infection were identiﬁed
at a community farm. Five of the six cases sought medical care; none
of the primary care providers included parapoxvirus infection in their
initial diagnosis. The presence of parapoxvirus DNA was conﬁrmed by
real time polymerase chain reaction (DNA polymerase gene-ORF25) in
100% of symptomatic animals (n = 9) and 21% of asymptomatic animals
(n = 14). Phylogenetic analysis was performed on virus strains, utilising
the virion core protein gene (ORF-27) and the extracellular envelope
protein genes (ORFs 109 and 110). Twenty-two percent of local farmers
surveyed (n = 58) reported having a parapoxvirus infection at least once
in their lifetime. Of these 39% sought medical care for their lesion and
67% of them received antibiotic therapy. Of local veterinarians surveyed
(n = 14), 43% were consulted for human cases of orf during their practice
and 29% reported that they had been consulted for orf virus infections
in sheep/goats at least once a year. Fewer veterinarians were consulted
for pseudocowpox virus infections in dairy cattle (0% in the last year;
21% ever).
Conclusions: Parapoxvirus infections are common in Missouri livestock
handlers and their animals. The use of nonporous gloves while handling
any animals in an infected herd/ﬂock is prudent as parapoxvirus DNA
was detected in the oral cavities of asymptomatic animals. Human
infections may have a clinical appearance similar to cutaneous anthrax,
however the mild illness associated with parapoxvirus infected animals
provides a key point of differentiation.
P1564 Mortality and hospitalisations related to inﬂuenza and
respiratory syncytial virus in the Netherlands
A. Jansen, E. Sanders, A. van Loon, A. Hoes, E. Hak (Utrecht, NL)
Objective: To estimate inﬂuenza virus- and respiratory syncytial
virus (RSV)-related excess mortality and hospitalisation in the Dutch
population, with special attention to inﬂuenza-virus-related excess
among 0−1-year-olds and non-high-risk 50−64-year olds.
Methods: Retrospective study over the years 1997–2003. Inﬂuenza-
virus- and RSV-active periods were deﬁned according to virus surveil-
lance data. Nationwide all-cause mortality and hospitalisation ﬁgures
were collected. The average excess mortality and hospitalisation were
determined during periods of inﬂuenza-virus and RSV predominance
(i.e. weeks with 5% or more of the season’s total number of reported
inﬂuenza-virus- or RSV-positive patients) over peri-seasonal and summer
baseline periods.
Results: No evident excess mortality was found among persons younger
than 50 years during inﬂuenza-virus active periods. In all 50−64-year-
olds together, inﬂuenza-virus-active periods were associated with excess
mortality (on average yearly around 1.3−4.7 per 100,000 persons over
respectively peri-seasonal and summer baseline period). Among elderly
excess mortality was on average around 102–152 per 100,000 persons
yearly. Inﬂuenza-related excess hospitalisation was highest in 0−1-year-
olds, namely around 79–271 per 100,000 children yearly. For non-
high-risk 50−64-year olds and elderly these ﬁgures were 18−38 and
111–208 per 100,000 persons yearly. The highest RSV-related excess
hospitalisation was demonstrated in 0−1-year-olds (on average around
523–699 per 100,000 yearly). Among elderly this excess was on average
around 50–140 per 100,000 persons yearly.
Conclusion: Inﬂuenza-virus-active periods were associated with excess
mortality in 50−64-year-olds but not in 0−1-year olds. Also a clear
inﬂuenza-virus-related excess hospitalisation was demonstrated among
both 0−1- and non-high-risk 50−64-year-olds. Inﬂuenza-virus-related
mortality among elderly appeared however far highest. RSV-active
periods were associated with excess hospitalisation particularly in the
youngest and to a lesser extent also in the oldest.
P1565 Seroprevalence of HIV, hepatitis B and hepatitis C among
intravenous drug users, men who have sex with men and
commercial sex workers in Kosova
G. Mulliqi, A. Kurti, L. Raka, L. Begolli, L. Berisha, A. Jaka, H. Fejza,
S. Mehmeti (Pristina, RS)
Objectives: Intravenous drug users (IDU), men who have sex with
men (MSM) and female commercial sex workers (CSW) are known to
be at high risk of acquiring blood-borne infections. The objective of this
study was to determine the seroprevalence of HIV, hepatitis B (HBV)
and hepatitis C (HCV) infections among these risk groups.
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Methods: A prospective study was performed among total of 422 IDU,
MSM and CSW at three cities of Kosova (Prishtina [capital], Prizren
and Ferizaj). The study was carried out during the year 2006. The
subjects consisted of randomly selected 199 intravenous drug users
(IVDU), 154 commercial sex workers (CSW) and 69 men who have
sex with men (MSM). The blood samples were tested for HBsAg, anti-
HCV antibodies and anti-HIV antibodies using ELISA commercial kits
(Nubenco Diagnostics, USA).
Results: Of the 199 IDU, 161 (80.1%) were male and 38 (19.9%) female.
The mean age was 23.2 years. The mean length of self-reported injecting
drug use was 3.4 years. Among 199 IDU, in 36 (18.1%) of them were
detected anti-HCV antibodies, whereas HBsAg as a marker of HBV was
found in 29 of them (14.6%). All tested persons among this risk group
were HIV negative. One fourth of them shared needles. Prevalence rates
of hepatitis B among MSM and CSW were 8.7% and 18.1%, respectively.
Five CSW were positive for anti-HCV antibodies (3.2%). Of all tested
samples 48% were positive for Chlamydia infection.
Conclusion: Prevalence rates of HIV and hepatitis in Kosova remain low
at present, but risk behaviours are present already and renewed efforts
are necessary to intervene effectively in these groups.
P1566 HIV infection and the immigration phenomenon.
Consequences on inpatient hospitalisation in a large Italian
hospital, 2000–2006
R. Manfredi, L. Calza (Bologna, IT)
Introduction: Immigration is a recent phenomenon in Italy, mainly
caused by the sudden and unexpected arrival of wawes of foreign citizens,
refugees, and individuals escaping from war. This phenomenon is of
great concern due to its serious socio-economic and healthcare impact.
Patients and Methods: A prospective survey of all charts of patients
(p) hospitalised or followed on day-hospital (DH) basis at our Infectious
Disease ward until mid-2006, allowed us to assess the frequency of
admission of immigrants from extra-Western Europe (eWE), and to
analyse multiple variables related to epidemiologic-clinical features.
Results: The rate of p immigrated from eWE showed a signiﬁcant
increase among our inpatients, and at a lesser extent and later for DH
admissions: 7.7% and 3.1% during the year 2000, 10.1% and 4.6% in
2001, 13.2% and 6.2% in 2002, 17.9% and 7.9% in 2003, 21.3% and
8.9% in 2004, 17.7% and 10.8% in 2005, up to 17.9% and 11.3% in
the year 2006 (p< 0.0001 for inpatients; p< 0.001 for DH p). Over
60% of p came from Africa, followed by Eastern Europe, Asia, and
Central-Southern America. When comparing the admission features of
WE citizens with those of p coming from abroad, no differences were
found as to duration-intensity of assistance, with HIV disease prevailing
among regular admissions (35.1%), and DH access (33.8%), followed
by acute-chronic hepatitis, pulmonary or other-site tuberculosis, central
nervous system and respiratory tract infection, and sexually-transmitted
diseases. HIV-infected immigrants were frequently (60.1% of cases)
AIDS presenters, and less than 5% of them were already on anti-
HIV therapy upon admission. While the frequency of HIV-associated
admissions did not show differences in the considered 7-year period,
p from eWE had an increasing frequency of tuberculosis, skin-soft
tissue infection, exanthems, gastroenteric-parasitic diseases, and malaria
(p< 0.05 to <0.0001).
Conclusions: A continued monitoring of this phenomenon is strongly
warranted, to improve a sustainable social-cultural network, to plan
health resource allocation, and to deﬁne adequate and well-targeted
prevention and public health measures.
P1567 Improving handling of blood exposure incidents: a 3-year
prospective study
P.T.L. van Wijk, M. Pelk-Jongen, C. Wijkmans, A. Voss,
P.M. Schneeberger (’s-Hertogenbosch, Nijmegen, NL)
Objectives: Handling and counselling of blood exposure incidents can
be complicated, time costing and cause a lot of anxiety and stress for the
injured. Incidents occur at all hours, both inside and outside the hospital.
Depending on the kind of injury and the infectivity of the source, they
pose a risk for transmission of hepatitis B (HBV), hepatitis C (HCV) en
HIV.
Methods: To assess quality improvement, all blood exposure incidents
registered throughout 2003–2005 by a 24 hour accessible expert
telephone centre in a Dutch region (500.000 inhabitants) were analysed.
The expert-centre was established for blood exposure incidents in
and outside the hospital. Infection control practitioners make a risk-
assessment and arrange all logistic requirements, treatment and follow-
up according to standardised procedures. Weekly feed back was given
to counsellors to achieve adherence to the protocol.
We analysed occurrence of injuries, HBV vaccination level of the
injured, identiﬁcation of sources, the time in which a HIV test could
be accomplished when risk of HIV transmission was involved and the
adherence to the protocol by the expert centre.
Results: In average 465 reports were registered per year, 50% took
place outside the hospital and 33% of the reports were not during ofﬁce
hours. Sources for blood analysis could be identiﬁed in 85% of the
cases. HBV vaccination level in healthcare workers outside the hospital
rose from 34% to 70% during the three years. This caused reduction
of administering immunoglobulines and unnecessary laboratory testing.
HIV tests could progressively be performed more rapidly during the
registration period due to earlier reporting and improvement of logistics.
No PEP had to be administered unnecessary. In assessing the quality of
the handling by the expert centre, in 2003, in 37% of the reports ﬂaws
in the protocol were identiﬁed, in 2005 this was 8%.
Conclusion: Handling of blood exposure incidents should logistically
also be optimised outside ofﬁce hours and outside hospitals. Higher
level of HBV vaccination makes handling far more simple. Faster
reporting of incidents extends the necessary time for laboratory tests
and administering medication. Quicker HIV testing prevents unnecessary
administering of medication. Less ﬂaws in applying the protocol,
prevents unnecessary interventions and is cost-effective. Through a 24/7
centralised counselling facility for handling of blood exposures we
achieved signiﬁcant improvements.
P1568 Enrollment of women in HIV clinical trials in Rwanda
L. Ackerson, F. Abalikumwe, M. Goble, R. Horsburgh (Kigali, RW)
Objective: To evaluate the proportion of women enrolled in clinical trials
of investigational HIV therapies and assess factors that may inﬂuence
enrollment of women.
Methods: Protocols were identiﬁed from a search of the AIDS Clinical
Trials Information Service (ACTIS), a database that provides detailed
information, including entry and exclusion criteria, on federally and
privately sponsored clinical trials for HIV/AIDS therapies initiated
between 2000 and 2004. Demographic and enrollment information was
requested by letter from trial sponsors of all protocols.
Results: A total of 221 privately sponsored protocols were identiﬁed
from the ACTIS database. Sponsors of 156 protocols provided
demographic data stratiﬁed by gender. Enrollment of women in this
sample ranged from 0% to 64% (mean 11.6%). Twenty-four trials
enrolled no women. All were in phase 1 or 2 of development. All 24
protocols permitted enrollment of non-pregnant women. Sixteen of 24
studies required some form of birth control, including barrier methods,
abstinence, and/or oral contraceptives. Eight of 24 protocols did not
specify any reproductive-related inclusion/exclusion criteria. None of
the 24 protocols had laboratory-based exclusion criteria that appeared
to exclude women.
Conclusion: Factors other than gender-based eligibility criteria appear
to be responsible for the failure of women to enroll in this sample of
HIV clinical trials. To further explore this, The Project San Francisco
(psf), Project UBUZIMA (with microbicide) and We-ACT, all located
in Kigali, are developing an HIV investigational new drugs database to
assess the recruitment and to promote the retention of women in current
and future HIV clinical trials.
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P1569 Strategies for containment of biological risk in reclaiming
a large urban area used as a waste pit by a serum and
vaccine factory
A. Amendola, S. Bianchi, M. Canuti, R. Koncan, A. Zanetti,
G. Tridente, G. Cornaglia (Milan, Verona, IT)
Objectives: The 12,000m2 waste pit of the former Istituto Sieroterapico
Milanese, in the urban centre of Milan, Italy, has recently been reclaimed
after nearly a decade of complete abandonment. Since the early 1900s,
different bio-pharmacological products – vaccines, prophylactic sera,
blood ﬂasks, waste of various animal origins – had been buried at a
depth not exceeding 1.5m. Some material, such as animal waste, had
decomposed in direct contact with the soil for a variable number of
years, and therefore dispersed pathogens are likely to have interacted
with the soil’s own microbicidal properties. Other materials, such as
human or veterinary vaccines, were recovered as sealed vials, and there
was presumably a risk that their contents (either liquid or lyophilised)
might have been totally or partially preserved. The aim of the whole
exercise was to carry out a thorough reclamation whilst minimising the
potential biological risks.
Methods: A preliminary electro-magnetometric investigation was
performed on the whole area, identifying those sub-areas with uneven
soil homogeneity attributable to the alleged presence of heterologous
materials. A pilot intervention zone, the so-called ‘ﬁrst experimental
module’, was used to set up and test all the procedures. All the operations
were conducted under a special tensostructure (base, 30×30m), with
air exchangers and extractors endowed with both ‘absolute’ (i.e., high-
speciﬁcation ﬂuid ﬁlters used to remove small solid particles) and
activated carbon ﬁlters. Removal of the soil was done using excavators
over the whole area.
Results and Conclusions: Given the obvious impossibility of treating
the whole area either by autoclaving or incineration, vibratory sifting
of the possibly contaminated soil was necessary, permitting gross
separation of the foreign materials. The sifted soil was subsequently
put back in the original areas and submitted to 120-days’ quarantine.
The bio-pharmacological products isolated were stored in special
containers and incinerated, after careful sampling for future studies
of their residual biological activities related to both bacteria (Brucella
abortus, Salmonella spp., Streptococcus spp., Bacillus anthracis) and
viruses (Newcastle Disease Virus, Rhabdovirus, Canine Distemper Virus,
Pestivirus, Poliovirus). Despite the lack of similar experience worldwide,
the whole procedure was carried out under optimal conditions and with
adequate levels of both environmental and human safety.
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P1570 Isolation of methicillin-resistant Staphylococcus aureus
strains carrying Panton-Valentine leukocidin genes in a
tertiary hospital in Greece
G. Ganderis, E. Vagiakou, M. Orfanidou, D. Petropoulou, S. Vourli,
A. Vatopoulos, H. Malamou-Lada (Athens, GR)
Objectives: To isolate and investigate strains of methicillin-resistant
Staphylococcus aureus for the presence of the lukS-PV, lukF-PV
determinant of Panton-Valentine leukocidin from specimens obtained
from adult patients with soft tissue abscesses and purulent skin
infections.
Methods: Between 4 January and 17 October 2006, a total of 135
S. aureus strains were revealed from soft tissue abscesses and purulent
skin infections.
S. aureus was identiﬁed by conventional methods. Antimicrobial
susceptibility was tested by Kirby–Bauer method and the MICs by
automated system VITEK 2. Polymerase chain reaction (PCR) was
performed to detect the genes for PVL from the MRSA strains (lukS-PV,
lukF-PV).
Results: Fifty-nine MRSA out of 135 S. aureus strains (59/135, 44%)
were isolated from specimens and 12 MRSA strains were PVL-positive
(12/59, 20%) shared a type IV SCCmec cassette (lukS-PV, lukF-PV
genes). The sources of MRSA-PVL-positive strains were: soft tissue
abscesses (8), furunculosis (2), cellulites (1), pyomyocitis (1). Eight
MRSA-PVL positive strains were isolated from immunocompetent
patients, two from patients with diabetes mellitus (all were community-
acquired) and two from patients with persistent purulent infection in the
site of previous orthopaedic surgery and history of hospitalisation during
the last six months (hospital-acquired). The mean age of 12 patients
(10 male/2 female) was 41 years (range 22−58 years). All MRSA-
PVL positive strains were susceptible to macrolides, ﬂuoroquinolones,
tobramycin and glycopeptides, while they were resistant to oxacillin,
kanamycin, tetracycline, and intermediate-susceptible to fusidic acid.
The MICs of 12 strains to resistant antibiotics were: oxacillin 16mg/L,
tetracycline 16mg/L, and fusidic acid between 8mg/L and 16mg/L.
Conclusions: (1) Twelve MRSA-PVL positive strains (carrying lukF,
lukS genes, SCC mec type IV) were isolated from 12 patients during
the last 10 months from soft tissue abscesses, furunculosis, cellulites,
pyomyocitis. (2) The MRSA-PVL-positive strains had the same unique
resistance pattern to antibiotics (resistance to kanamycin, oxacillin,
tetracycline, and intermediate susceptibility to fusidic acid). (3) MRSA-
PVL-positive strains is now an emerging problem in Greece.
P1571 Characterisation of methicillin resistant Staphylococcus
aureus strains isolated in a tertiary care hospital in the
United Arab Emirates
A. Sonnevend, T. Pal, E. Ungvari, J. Paszti, P. Jumaa, K. al-Dhaheri
(Pecs, Budapest, HU; Al Ain, AE)
Objectives: The incidence of methicillin resistant Staphylococcus aureus
(MRSA) is generally perceived to be low in the United Arab Emirates
(UAE) compared to that of most western countries where its high
prevalence is due, to a large extent, to the spread of epidemic MRSA (E-
MRSA) clones. Our main aim was to type the local MRSA isolates and to
compare them to the worldwide known E-MRSA strains. We investigated
50 MRSA strains isolated from individual patients between July 2002
and July 2003 at a tertiary care referral hospital, Tawam Hospital, Al
Ain, UAE.
Methods: The presence of the mecA gene, and those coding for
enterotoxin A-E, toxic shock syndrome toxin and exfoliativ toxin A and
B were investigated by PCR. Furthermore, the antibiotic sensitivity and
phage type of the isolates and the macro-restriction proﬁle subsequent
to SmaI digestion of the genom were also determined.
Results: All isolates harboured the mecA gene, 54% of them possessed
at least one of the toxin genes. None of the strains exhibited reduced
susceptibility to vancomycin, while resistance to other antibiotics varied.
Surprisingly, as pheno-, and genotyping revealed, 26% of the isolates
(13 strains) were identical or nearly identical to E-MRSA15, and 12%
(6 strains) showed more than 80% similarity by PFGE to the USA100
clone, i.e. the most widespread MRSA clones in the United Kingdom
and the United States, respectively.
Conclusion: The lack of detailed epidemiological data prevented us to
determine the origin of these MRSA strains. However, patients receiving
medical care outside of the UAE may serve as potential sources, although
the extent of local spread remains to be investigated. The possibility of
carrying E-MRSA strains either by patients or by healthcare workers
between continents and countries calls for a well co-coordinated effort
of authorities to limit the further spread of this pathogen.
P1572 Emergence of EMRSA-15 in a university hospital, Canary
Islands
I. Montesinos, T. Delgado, B. Castro, M. Cuervo, M. Lecuona,
M. Ramos, A. Sierra (La Laguna, ES)
Objectives: Since 2000, the rate of MRSA infections has increased
at the University Hospital of Canary Islands (HUC) coinciding with
the emergence and spread of EMRSA-16 clone and replacement of the
Iberian one. In 2003, a new digestion proﬁle by PFGE was observed.
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The aim of this study is the characterisation of this new PFGE type
emerged in the HUC.
Methods: Between 2003 to 2004 29 MRSA isolates showed this new
PFGE proﬁle and were obtained from clinical samples from hospitalised
patients and out-patients at the HUC. Susceptibility testing and bacterial
identiﬁcation were performed using VITEK2 System (bioMe´rieux,
France) and susceptibility testing for vancomycin, teicoplanin, linezolid
and quinupristin-dalfopristin was assessed with E-test (AB BIODISK,
Sweden). Molecular typing was performed by PFGE, MLST, SCCmec
typing and protein A gen ampliﬁcation (spa).
Results: All MRSA isolates studied were susceptible to gentamicin,
tetracycline, rifampim, trimethoprim-sulfamethoxazole and tobramycin.
They were all resistant to ciproﬂoxacin and 45% of them were susceptible
to clindamycin and erythromycin. All of them were also susceptible
to vancomycin, teicoplanin, linezolid and quinupistrin-dalfopristin by
E-test. The SmaI digestion patterns obtained by PFGE were different to
those obtained previously and included 4 PFGE subtypes. The sequence
type of this clone was 22 by MLST and it revealed cassette IV by
SCCmec typing, this corresponding with the pandemic clone EMRSA-
15. The number of repeats obtained by spa typing was also different to
those obtained up to date. Thirteen isolates had 17 repeats, ﬁve had 16
repeats and one of them 18 repeats. The ﬁrst isolation of EMRSA-15
appeared in the HUC in April, 2003 isolated from a patient hospitalised
in internal medicine with a respiratory colonisation. In 2003 and 2004
the 10% and the 13% of the MRSA isolated in the HUC were EMRSA-
15 respectively.
Conclusions: Starting 2000, EMRSA-16 emerged at our hospital and
soon became the predominant clone. In April 2003, a new MRSA clone,
EMRSA-15, appeared in this changing panorama of MRSA clones at
HUC. The EMRSA-15 and EMRSA-16 are the two predominant clones
circulating in the UK.
P1573 Characterisation of an MRSA clone in Denmark similar
to USA300 in PFGE pattern but with different properties:
a potential pitfall when identifying USA300 isolates
A. Larsen, R. Goering, M. Stegger, K. Boye, M. Sørum, H. Westh,
R. Skov (Copenhagen, DK; Omaha, US)
Objectives: In recent years, Denmark has experienced a dramatic
increase in the incidence of MRSA, from 100 to 864 cases in 2002
and 2005, respectively. A comparison of PFGE patterns of the Danish
MRSA isolates with the USA100–1100 reference isolates identiﬁed a
large number of MRSA isolates with a PFGE proﬁle similar to USA300.
However, further analysis revealed that a signiﬁcant number of these
isolates were actually of a previously undescribed strain variant being
indistinguishable from the classical USA300 by PFGE. The aim of
this study was to characterise this USA300 variant with respect to
epidemiology and a variety of important genetic markers.
Methods: All Danish MRSA isolates from 1999–2005 were collected
at Statens Serum Institut. Discharge summaries for each patient/carrier
were screened for epidemiological information regarding acquisition
(hospital or community) and types of infection. All MRSA isolates were
characterised by PFGE, SCCmec type, spa type, analysis of the mec-
associated direct repeat unit (dru), presence or absence of the arginine
catabolic mobile element (ACME), and genes encoding Panton-Valentine
leukocidin (PVL).
Results: A total of 90 MRSA isolates was found to have PFGE patterns
identical to USA300. This group, although indistinguishable by PFGE,
was found to contain two distinctly different subtypes. Forty-two isolates
were classical USA300, spa type t008, PVL positive, and SCCmec
type IVa. However, 48 isolates were spa type t024 and lacked the PVL
genes although still SCCmec type IVa. Further examination revealed
that the t008 and t024 subtypes differed substantially, with dru type 9g
and ACME present in all examined t008 isolates while the t024 isolates
were dru type 10a with ACME absent from several isolates. In addition,
a majority of the t008 (typical USA300) isolates were community
acquired, while the t024 isolates were primarily associated with hospitals
and residential homes.
Conclusion: An MRSA clone that could not be differentiated from
USA300 by PFGE was detected in high numbers as a cause of infections
in Denmark. However, this clone was found to differ substantially from
typical USA300 in epidemiology. Proper identiﬁcation of these isolates
requires the use of tests beyond PFGE, such as spa typing with analysis
of pvl genes, dru and ACME as additional markers.
P1574 Molecular epidemiology of methicillin-resistant
Staphylococcus aureus from Swiss healthcare institutions in
Northeastern Switzerland, 1992–2006
A. Imhof, G. Senn, C. Ruef (Zurich, CH)
Objectives: The emergence of methicillin-resistant Staphylococcus
aureus (MRSA) has generated considerable concern among medical and
public health professionals. We conducted this study to investigate the
antimicrobial susceptibility and the molecular epidemiology of MRSA
strains from Swiss healthcare institutions of Northeastern Switzerland
between 1992 and 2006.
Methods:MRSA isolates (n = 1982) were susceptibility tested according
to CLSI guidelines. PCR for Panton-Valentine leukocidin (PVL) genes
were done from MRSA isolates from outpatient clinics and from isolates
belonged to the 9 predominant PFGE types. Analysis of epidemiological
and molecular typing data (PFGE) of MRSA strains were used to
examine epidemiologic trends for MRSA.
Results: The proportion of MRSA strains resistant to gentamicin was
30%. 48% of the MRSA isolates were resistant to erythromycin and 46%
to clindamycin. 17% revealed macrolide-lincosamide-streptogramin B
resistance (MLS). More than 75% of strains were susceptible to
tetracycline, rifampicin and cotrimoxazole; 62% of isolates were resistant
to ciproﬂoxacin. Annual trends of the susceptibility pattern showed a
signiﬁcant decrease of resistance of ciproﬂoxacin (100% (1992) to 60%
(2006), p< 0.001), tetracyline (98% (1992) to 16% (2006), p< 0.001),
and rifampicin (83% (1992) to 8% (2006), p< 0.001). A signiﬁcant
increase of MLS was found (12% (1993) to 25% (2006), p = 0.029).
All isolates were susceptible to linezolid and glycopeptides. Fifty-one
percent of the isolates belonged to 9 PFGE types, of which three were
predominant: USZ19 (20%), USZ20 (12%) and USZ21 (5%). PVL gene
was found in 3% of the tested MRSA isolates. Interestingly, no PVL
was found in a MRSA clone, which is epidemic in drug addicted people
in the north-eastern Switzerland. However, PVL gene was found in a
MRSA clone which was isolated during an outbreak in a dermatological
clinic.
Conclusions: Speciﬁc clones of MRSA are circulating in hospitals and
communities in north-eastern Switzerland. The susceptibility pattern of
the isolates changed signiﬁcantly during the observation period: Fewer
isolates with resistance to non-b-lactam antibiotics was found. However,
MLS resistance increased signiﬁcantly during the last years.
P1575 Molecular characterisation of hospital-acquired methicillin-
resistant Staphylococcus aureus in a Turkish university
hospital
H. Akoglu, P. Zarakolu, B. Altun, G. Hascelik, S. Unal (Ankara, TR)
Objective: The aim of this study is to evaluate the molecular charac-
terisation of hospital-acquired (HA) methicillin-resistant Staphylococcus
aureus (MRSA) isolates by analysing the presence of PVL genes and
SCCmec typing.
Methods: A total of 110 MRSA isolates from clinical samples (35 blood,
37 pus, 23 deep tracheal aspiration, 5 catheter, and 10 other samples)
of inpatients with nosocomial infections at Hacettepe University Adult
Hospital between January 2004 and December 2005 were included
in the study. Only one isolate from each patient was included. The
identiﬁcation of the isolates was made by Sceptor automated system
(Becton Dickinson, USA). The isolates were retested for methicillin
resistance by oxacillin (1mg, Oxoid, UK) disk diffusion test according to
CLSI and for the presence of mecA gene by polymerase chain reaction
(PCR). The presence of PVL genes and SCCmec types were detected
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also by PCR analysis. Isolates were stored at −80ºC until studied.
S. aureus ATCC29213, S. aureus 27R and S. aureus 8328 were included
as control strains.
Results: All 110 HA-MRSA isolates were positive for mecA gene. Of
the isolates, 68 (56%) were harbouring SCCmec type III, 38 (30%)
SCCmec variant IIIB, and 3 (2.5%) SCCmec type IV. One isolate positive
for mecA gene, could not be typed for SCCmec gene. PVL was positive
in 14 (12.7%) of 110 HA-MRSA isolates. Ten of PVL positive strains
carried SCCmec III; whereas 4 of them carried SCCmec type variant
IIIB. None of the strains harbouring SCCmec type IV were positive for
PVL genes.
Conclusion: Majority of the HA-MRSA isolates in our hospital are
carrying SCCmec III, or variant IIIB. Although PVL is a common
virulence factor of community acquired-MRSA, HA-MRSA isolates in
our centre have a considerable rate of PVL positivity pointing out the
fact of changing epidemiology of MRSA isolates.
P1576 Molecular epidemiology of hospital-acquired methicillin-
resistant Staphylococcus aureus in Russia
M.V. Afanas’ev, S.V. Karakashev, E.N. Ilina, S.A. Grudinina,
A-S. Salem, S.V. Sidorenko, V.M. Govorun (Moscow, RU)
Objectives: Methicillin-resistant Staphylococcus aureus (MRSA) is a
common cause of nosocomial infection. The purpose of this study was to
evaluate clonality of hospital-acquired MRSA (HA-MRSA) circulating
in Russian Federation and to compare different multiplex PCR techniques
with SNP-based approach for MRSA typing.
Methods: Epidemiologically unrelated MRSA isolates (n = 62) from
Moscow hospitals have been selected for typing. Genomic DNA
from clinical isolates was puriﬁed using “DNA express” kit (Lytech
Ltd, Russia). Staphylococcus chromosomal cassette mec (SCCmec)
typing and detection of Panton-Valentine leukocidin (PVL) gene were
performed by PCR using previously described methods. Seven loci from
ﬁve housekeeping genes (arcC162, arcC210, aroE132, gmk123, tpi241,
tpi243 and yqiL333) were used for SNP-typing. Detection of particular
nucleotides in selected loci was carried out in thermocyclic primer
extension reaction, followed by mass-spectrometric detection of the
products. Standard MLST-typing procedure was preformed as reference
method.
Results: Results of SCCmec, SNP-typing and MLST-typing are
presented in the Table. The majority of MRSA isolates (93.6%) belong to
world-wide disseminated clonal complex (CC) 8, Three isolates (4.8%)
belong to CC 1. All ST 239 isolates were found to carry SCCmec
type III, and ST 8 isolates carried SCCmec type IV. No PVL genes
were detected in SCCmec type IV isolates included in this study.
No. of
isolates
(%)
Traditional
typing
Olivera’s
M-PCR
typing
Zhang’s
M-PCR
typing
SNP-typing MLST
51 (82.3) Type IV Type IV mecA gene T-A-T-G-T-A-C ST 8
3 (4.8) Type IV Type IV mecA gene C-A-T-G-C-A-C ST 1
1 (1.6) mecA gene mecA gene Type III C-A-T-G-T-A-T n/d
1 (1.6) Type III Type IIIa Type III T-A-A-G-T-A-C ST 239
6 (9.7) Type III+V Type IIIa Type III T-A-A-G-T-A-C ST 239
ST: sequence type; n/d: not determined
Conclusion: Among Russian MRSA CC8 isolates carrying SCCmec
IV type are predominant. SNP-typing is powerful tool for studies of
molecular epidemiology of MRSA.
P1577 SCCmec type and epidemiological characteristics of MRSA
isolates in the Netherlands
I. Van den Broek, X. Huijsdens, E. Tiemersma, I. van Loo, J. Kluytmans
(Bilthoven, Tilburg, Amsterdam, NL)
Objectives: To investigate the development of SCCmec types of
Methicillin Resistant Staphylococcus aureus (MRSA) in the Netherlands
in relation to epidemiological characteristics.
Methods: 76 MRSA isolates were randomly selected from the national
MRSA database at the National Institute for Public Health and the
Environment, in the period January 2003 to September 2005. We
compared the epidemiological characteristics of the SCCmec types I,
II and III (‘Hospital Acquired’) with types IV and V (‘Community
Acquired’). Patient information was provided by the referring hospitals.
MRSA isolates from the Netherlands, 2003–2006.
Results: Of the 76 isolates, 43 could be typed by SCCmec and 17 of
these had the ‘HA’-type (4 I, 7 II and 6 III) whereas 26 had the ‘CA’-type
(21 IV and 5 V). The development of these two groups over the years
is shown in the ﬁgure. Of the HA-type isolates 82% were attributable
to healthcare exposure while this was the case for only 35% of CA-type
isolates; the ﬁrst were more likely to originate from patients who had
been admitted to a foreign hospital than the latter (65% versus 12%,
p< 0.01). HA-isolates were found by intentional MRSA screening more
frequently than CA-isolates (88% vs 42%, p< 0.01). CA-type isolates
were more often associated with clinical signs of MRSA infection than
HA-type isolates (46% vs 18%, p = 0.1), most of which were skin
infections (92% vs 100%, ns). The living circumstances (degree of
urbanisation) and occupation of the patient had no clear link to SCCmec
type, though CA-type isolates more frequently originated from jobless
persons than HA-type isolates (39% vs 18%).
Conclusion: The increase of MRSA in the Netherlands seems to be
attributable to the CA-type isolates. The HA-type isolates are mainly
derived from patients who have been hospitalised abroad and found by
intentional screening. The majority of CA-types cannot be related to
the healthcare setting and are coincidental ﬁndings indicating that the
patients were not considered to be at increased risk. Further studies are
warranted to identify the patients at risk for CA-MRSA.
P1578 Comparative genome hybridisation of epidemic and
sporadic methicillin-resistant Staphylococcus aureus strains
did not reveal a speciﬁc genetic factor
G. Kuhn, T. Koessler, P. Francois, A. Huyghe, J. Schrenzel, P. Francioli,
D.S. Blanc (Lausanne, Geneva, CH)
Introduction: Staphylococcus aureus has proven an outstanding capacity
to adapt to hospital environmental conditions. This behaviour included
the evolution of Methicillin resistant S. aureus (MRSA) clones which
have spread among hospital settings worldwide with fatal consequences
for health institutions.
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Objectives: Identiﬁcation of the speciﬁc presence or absence of genetic
factors associated with epidemic behaviour of Methicillin resistant
Staphylococcus aureus.
Methods: We have collected 12 genetically diverse strains which have at
local or at international level caused epidemic outbreaks, and 8 sporadic
isolates which have never been transmitted between patients despite
colonisation during several weeks. Genetic analysis was performed using
comparative genome hybridisation with an S. aureus multi-strain oligo
microarray, which was constructed on the basis of published genome
sequences of strains COL, MW2, Mu50, N315. The datasets obtained
for both collections were subtracted.
Results and Discussion: No genetic factor was associated by its
speciﬁc presence or absence with epidemic behaviour. This was also
true, when stringency for data collection was relaxed, i.e. when values
of estimated probability of presence (EPP, an estimate for the risk
of false positive signals) were increased from 1% to 20%. Several
hypotheses can be derived to explain this ﬁnding. First, speciﬁc factors
might have been missed during analysis, because no epidemic strains
have been considered for construction of the microarray. Second,
epidemic behaviour might be associated with speciﬁc alleles or a speciﬁc
transcriptional pattern and not with accessory genetic elements. Third,
epidemic behaviour might have evolved independently and with different
genetic determinants in different phylogenetic lineages.
P1579 Low prevalence of methicillin-resistant Staphylococcus
aureus with reduced susceptibility to glycopeptides in two
West German hospitals
K. Ko¨sters, I. Greiffendorf, E. Schemken-Birk, E. Becker-Boost,
C. Becker (Krefeld, DE)
Objectives: To determine the prevalence of reduced glycopeptide
susceptibility in methicillin-resistant Staphylococcus aureus (MRSA)
strains isolated in two German teaching hospitals between January 2002
and October 2006.
Methods: Vancomycin and teicoplanin minimal inhibitory concen-
trations (MIC) of clinical MRSA strains were determined with the
Etest macromethod on brain heart infusion agar in addition to routine
susceptibility testing with VITEK2.
Results: 671 MRSA strains collected between January 2002 and October
2006 were analysed. MICs for vancomycin and teicoplanin ranged
from 1.5 to 6mg/mL and 0.5 to 8mg/mL, respectively. According to
Etest interpretation guidelines no glycopeptide resistent or intermediate
strains were found. Mean vancomycin MIC was consistently higher than
teicoplanin MIC. An increase in mean glycopeptide MICs over the study
period could not be demonstrated.
Conclusion: Reduced glycopeptide susceptibility could not be detected
with the Etest macromethod in MRSA strains isolated from patients in
two West German hospitals over a four and a half year period. Additional
quantitative determination of glycopeptide resistance such as the Etest
macromethod should be reserved for cases where unusual susceptibility
is suspected or VITEK2 detects high glycopeptide MICs ( 4mg/mL).
P1580 Characterisation of hospital- and community-acquired
methicillin-resistant Staphylococcus aureus in Hong Kong
G. Siu, M. Boost, M. O’Donoghue (Kowloon, HK)
Objectives: In the past, methicillin-resistant Staphylococcus aureus
(MRSA) was mainly a pathogen associated with hospital acquired
infections (HA-MRSA), but in recent years community-acquired strains
(CA-MRSA) causing infections with high morbidity and mortality have
emerged. In Hong Kong, although almost 50% of hospital isolates of
S. aureus are HA-MRSA community isolation of HA-MRSA remains
low. However, in the last year, there have been several reports of
infections with CA-MRSA. This study aimed to characterise both
hospital and community isolates of MRSA.
Methods: The presence of the mecA resistance gene was conﬁrmed
in 139 hospital isolates (clinical isolates) and 13 community isolates
(nasal carriage) of MRSA. The mecA gene was further characterised
by multiplex PCR. Those found to harbour the SCCmec IV element
were investigated for the presence of genes coding for Panton-Valentine
leucocidin and for agr to determine their prototypic or archaic type.
Results: 95% of HA-MRSA strains were found to be multi-drug
resistant, displaying resistance to an average of 6 non-b-lactam drugs. 91
strains (65%) harboured SCCmec variant IIIA and 22 (16%) SCCmec
III. One strain was PVL positive. CA-MRSA remains uncommon in
hospital isolates with only 3 (2%) of isolates harbouring the SCCmec
IV element. These belonged to the less virulent archaic type only one
being a PVL producer. In contrast, over 50% of community isolates
were CA-MRSA, 3 strains with the SCCmec IV element and 4 with
new SCCmec patterns. Fusidic acid and erythromycin resistance was
present in >80% of community isolates. Characterisation revealed the
presence of both archaic strains and a highly resistant PVL-producing
prototypic strain.
Conclusions: CA-MRSA remains rare in hospital infections in Hong
Kong, with most HA-MRSA strains harbouring type III subtypes of the
SCCmec element. One healthy community dwelling person was found to
be colonised by a highly virulent agr type 3 positive strain, which has not
previously been reported from nasal carriage. As colonisation typically
precedes infection, the potential of increased incidence of severe CA-
MRSA-associated infections is likely.
P1581 Genetic analysis of high- and low-level Mupirocin-resistant
MRSA isolated in Kuwaiti hospitals
E. Udo, N. Al-Sweih, B. Mathew, C. Noronha (Kuwait, KW)
Background: Mupirocin resistance in Staphylococci is expressed
either as high-level (MIC >512mg/L) or low-level (MIC 8−256mg/L)
resistance. The prevalence of high-level mupirocin resistance has been
increasing in MRSA isolated in Kuwait in recent years. This necessitated
monitoring MRSA isolated in Kuwaiti hospitals at regular intervals for
changes in their mupirocin resistance patterns.
Objective: To monitor the prevalence of mupirocin resistance in MRSA
isolated in Kuwait hospitals and determine its genetic location.
Methods: MRSA isolated from six hospitals between January 2000 and
December 2005, were tested for susceptibility to antibacterial agents by
disk diffusion. Mupirocin MICs was determined with Etest strips. The
presence of mupA genes that encodes high-level mupirocin resistance
(mupH) was investigated by PCR. Pulsed-ﬁeld gel electrophoresis
(PFGE) was used to study their genetic relatedness. Curing and transfer
experiments were used to determine the plasmid or chromosomal
location of mupirocin resistance.
Results: A total of 4,982 MRSA isolates were investigated. The
prevalence of mupH declined from 22% in 2000 to 1.8% in 2005. In
contrast, the prevalence of low-level resistance increased from 3.6% in
2000 to 90.8% in 2004 before decreasing to 65.7% in 2005. Transfer
experiments revealed that mupH was located on a 38-kb conjugative
plasmid while the low-level resistance was chromosomal. The mupA
gene was detected only in the mupH isolates. PFGE analysis revealed
that the low-level mupirocin-resistant isolates belonged to six different
clones. Two of these clones, constituting 87.6% of the isolates, were
detected in all six hospitals and were related to isolates that expressed
high-level resistance.
Conclusions: This study revealed a dramatic shift in the prevalence of
high- and low-level mupirocin resistance among Kuwait MRSA isolates.
The relatedness of some low-level mupirocin-resistant isolates to those
expressing high-level resistance suggests that these isolates have arisen
by the loss of the 38-kb mupA plasmid. The study also highlights the
value of regular surveillance in detecting changes in resistance and clonal
patterns of MRSA isolates in healthcare environments
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P1582 Molecular characterisation of community-associated and
healthcare-associated methicillin-resistant Staphylococcus
aureus in Korea
E.S. Kim, H.B. Kim, J.S. Song, K.U. Park, S. Shin, H.J. Choi, D.M. Kim,
M.S. Lee, W.B. Park, N.J. Kim, M.D. Oh, E.C. Kim, K.W. Choe
(Goyang, Seoul, Gwangju, KR)
Objectives: Methicillin-resistant Staphylococcus aureus (MRSA), a
leading cause of nosocomial infections worldwide, has become a big
problem in the community as well. Despite the high prevalence of MRSA
in tertiary hospitals, there were only a few reports of MRSA infections
in the community in Korea. This study was performed to determine the
molecular characteristics of community-associated MRSA (CA-MRSA)
in Korea.
Methods: Seventy-two CA-MRSA strains and 72 healthcare-associated
MRSA strains (HA-MRSA) were collected from 7 hospitals between
January and June 2005. To ascertain the presence of the risk factors for
MRSA acquisition, the medical records and the database of the Health
Insurance Review Agency were reviewed. Antibiotic susceptibility tests
were done by the disk diffusion method. Staphylococcal cassette
chromosome mec (SCCmec) typing and multilocus sequence typing
(MLST) were performed as previously described, and the genetic
relationship was analysed by the eBURST programme. The Panton-
Valentine leukocidin (PVL) gene was screened by polymerase chain
reaction.
Results: Nineteen and 24 CA-MRSA strains were classiﬁed as pathogens
and colonisers, respectively. Twenty-nine CA-MRSA isolates from
patients with chronic otitis media (COM) were categorised as a separate
group due to the uncertainty of their clinical signiﬁcance. Multi-drug
resistance was observed in 9 (47%), 9 (38%), and 28 (97%) isolates
of the 3 above-mentioned groups, respectively. Sequence type 72 and
SCCmec type IVA (ST72-MRSA-IVA) were most prevalent among CA-
MRSA. However, most of the COM isolates belonged to the ST5-MRSA-
II or the ST239-MRSA-IIIA strains, which are common among HA-
MRSA in Korea. While only 1 of 25 ST72-MRSA strains showed multi-
drug resistance, all of the ST5-MRSA and the ST239-MRSA strains
were multi-drug resistant. None of the CA-MRSA and the HA-MRSA
strains had the PVL gene.
Conclusion: This study shows that there are some CA-MRSA clones
in Korea which are different from HA-MRSA clones in Korea and CA-
MRSA clones in other countries.
P1583 Molecular patterns of community-acquired methicillin-
resistant Staphylococcus aureus strains in Malaysian carriers
V. Neela, N. Mariana, S. Zamberi (Selangor, MY)
Objective: The ultimate aim of the study is to perform molecular
characterisation of methicillin-resistant Staphylococcus aureus (CA-
MRSA) strains to understand the drug resistance and virulent properties.
Knowledge on the molecular properties is important for the correct
treatment and efﬁcient management of CA-MRSA strains. Speciﬁc
objectives are to determine the molecular patterns of local strains
focusing on the SCCmec (Staphylococcal cassette chromosome mec
element) types, presence of Panton-Valentine leukocidin (PVL) gene and
the strain types (ST).
Methods: Twenty-two S. aureus isolates isolated from 100 university
students screened during November 2005 to February 2006 were
identiﬁed as MRSA. Phenotypic conﬁrmation was carried out by
antibiotic susceptibility test against various antibiotics (vancomycin,
gentamicin, erythromycin, and mupirocin). All isolates were conﬁrmed
genotypically as MRSA using mecA primers. Each isolate was further
investigated for CA-MRSA by SCCmec typing using published primers.
Presence of PVL genes in all CA-MRSA isolates was also determined.
Multi locus sequence typing (MLST) analysis of each CA-MRSA
isolates was carried out to identify the strain type (ST).
Results: Of the twenty-two MRSA isolates, three isolates were identiﬁed
as CA-MRSA. The molecular pattern of the three CA-MRSA isolates
analysed by SCCmec typing revealed two SCCmec types. Two isolates
were positive for SCCmec type V and one isolate was positive for
SCCmec type IVa. The two SCCmec type V isolates were sensitive to
non b-lactams while the SCCmec type IVa positive isolate was resistant
to non b-lactam antibiotics and also carried the PVL gene. Positive
signal for PVL gene was not observed in the SCCmec type V isolates.
MLST analysis of the three CA-MRSA strains showed the strain type
for SCCmec type 1Va isolate as ST-80, while SCCmec type V isolates
belonged to ST-34.
Conclusion: The molecular patterns of the local CA-MRSA strains
studied give valuable information on the SCCmec type, virulent gene
carried and the clonal type circulating in local communities. The
molecular information of the local strains could be very useful in
prescribing correct antibiotics enhancing appropriate treatment and
successful management of the CA-MRSA strains in Malaysia.
P1584 Community-acquired methicillin-resistant Staphylococcus
aureus in Stockholm with increased genetic diversity
H. Fang, G. Hedin, G. Li, C. Nord (Stockholm, SE)
Objectives: Methicillin-resistant Staphylococcus aureus (MRSA) has
become a worldwide problem. Infections caused by MRSA have now
also been found in the community. The ﬁrst community-acquired MRSA
(CA-MRSA) in the southern Stockholm region was documented in 2000.
The present study is aimed to investigate the molecular epidemiology of
CA-MRSA in the southern Stockholm region during the period 2000 to
2005.
Methods: One hundred and fourteen consecutive non-repeated CA-
MRSA isolates from the southern Stockholm region between 2000
and 2005 were included in the study. All strains were analysed by
pulsed-ﬁeld gel electrophoresis (PFGE) and staphylococcal chromosomal
cassette mec (SCCmec) typing. At least one isolate of each PFGE
pattern combined with varied SCCmec types was selected for multi-
locus sequence typing (MLST). The presence of the Panton-Valentine
leukocidin (PVL) genes was detected by PCR.
Results: During the 6-year period, 114 CA-MRSA isolates were
collected, and the majority (66%) of them were isolated in the recent 2
years (32 strains and 44 strains for 2004 and 2005, respectively). Thirty-
six different PFGE patterns and 16 sequence types (STs) were identiﬁed
among the strains. Among these genotypes, ST80-MRSA-IV carrying
the PVL genes was the most prominent MRSA clone (34%) during all 6
years. However, increased genetic diversity of the CA-MRSA strains in
the region was observed during the last years. Only eight sequence types
were identiﬁed during 2000–2003 when MRSA was emerging in the
community, while 13 STs were observed during 2005. Furthermore, the
MRSA clones previously regarded as hospital-associated have also been
identiﬁed in the community, i.e., STs 22 and 45. Regarding SCCmec
typing, types IV and V were detected in 83% (95/114) and 15% (17/114)
of the strains, respectively. One SCCmec pattern found in two isolates
with ST 150 could not be classiﬁed as a known type. The same PFGE
banding proﬁle was presented by both ST 150 isolates with SCCmec
V and the new SCCmec pattern. The PVL genes were found in 53%
(60/114) of the strains.
Conclusion: The frequency of CA-MRSA has been increasing in
Stockholm during the last years. ST 80 predominated while a polyclonal
tendency was observed. SCCmec IV and V were present with different
genetic backgrounds. The study also indicated that cross-talking between
the hospital and community strains of MRSA have started in the region.
P1585 First cases of infections caused by community-associated
methicillin-resistant Staphylococcus aureus in Bulgaria
D. Nashev, L. Bizeva, K. Toshkova, I. Alexiev, D. Beshkov (Soﬁa, BG)
Objectives: We report ﬁrst cases of skin infections caused by Panton-
Valentine leukocidin (PVL) positive cMRSA strains in Bulgaria.
Methods: During 2005 and 2006 ﬁve cases of infection caused by
MRSA with unusual susceptibility patterns and community onset were
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documented in our institution. The patients were young people with no
history of previous MRSA isolation, no history of hospitalisation or
invasive manipulations in the past year and without permanent medical
devices. The skin infections were represented by furunculosis in 4
patients and cutaneous abscesses in one patient. MRSA were isolated
from skin lesions as well as from anterior nares of 4 patients with
furunculosis. Antibiotic susceptibility testing was performed according
to CLSI. Methicillin-resistance was conﬁrmed by latex agglutination test
for PBP 2a and PCR detection of mecA gene. The presence of PVL genes
(lukS-PV-lukF-PV) were assessed by PCR. The isolates were further
analysed by spa-sequence typing, spa types were designated using Ridom
Staphtype software®.
Results: All isolates in the present study were found positive for PVL
genes. MRSA isolates from 4 patients belonged to spa type t008 and from
one patient to spa type t044. In all 4 cases caused by t008 strain, nasal
carriage of the strain with the same spa type was detected. The isolates
belonging to t008 showed resistance to erythromycin, kanamycin,
tetracycline and ciproﬂoxacin and were susceptible to fusidic acid. The
isolate belonging to t044 were resistant to kanamycin, tetracycline as well
as to fusidic acid. The existing sequence databases for spa types allowed
speciﬁc spa types to be associated with particular MLST sequence
type (ST). The isolates belonging to spa type t044 represent the major
European cMRSA clone ST 80. MRSA isolates with spa type t008 are
frequently associated with ST8. However, cMRSA isolates belonging to
ST8 cannot be discriminated from hospital MRSA isolates of this lineage
by spa sequence typing alone; they also exhibit t008. All patients were
succefully treated with clindamycin or trimethoprim-sulfamethoxazole in
combination with rifampin. Nasal carriage was supressed with intranasal
mupirocin, but 3 months later in one patient recolonisation with the same
t008, PVL positive strain occurred.
Conclusion: The appearance of the ﬁrst cMRSA strains should raise
a great concern about diagnosis and treatment of these infections in
Bulgaria.
P1586 Community-associated MRSA clone encoding toxic shock
syndrome toxin 1 (TSST-1) in England
M.J. Ellington, M. Ganner, C. East, M.A. Ganner, M. Warner,
A.M. Kearns (London, UK)
Objectives: TSST-1 is a superantigenic toxin associated with toxic
shock syndrome and staphylococcal scarlet fever amongst other
diseases. Traditionally, TSST-1 has been associated with ST30, agr
type 3 methicillin-susceptible S. aureus but, recently, new community-
associated MRSA (CA-MRSA) clones have been reported as TSST-1-
positive in Europe (ST30, agr3 & ST5 agr2). We aimed to detect and
characterise TSST-1-positive MRSA referred to the England and Wales
Staphylococcal Reference Unit (SRU).
Methods: All putative CA-MRSA isolates referred to SRU in 2005 were
tested by PCR for the presence of toxin genes including for PVL and
TSST-1. TSST-1 (encoded by tst) positive isolates were characterised
further by spa typing and SmaI PFGE. Further PCRs were used to detect:
mecA and the SCCmec cassette type, ccr type and agr allotype. MICs of
a range of antibiotics were determined. Patient demographic and clinical
data were retained for analysis.
Results: Ten tst-positive MRSA isolates were similar to a new clone
described in France and Switzerland; they were agr type 2, harboured
SCCmecIVa, were related by pulsotype and spa typing; 8/10 were spa
type t002, the remaining two were closely related to spa type t002
(t1737). All 10 isolates were b-lactam resistant and 9/10 were fusidic
acid resistant. Unlike tst-negative, PVL-positive spa type t002 CA-
MRSA isolates, these 10 isolates were susceptible to tetracycline in
addition they were susceptible to ciproﬂoxacin, gentamicin, clindamycin,
trimethoprim, vancomycin, linezolid and mupirocin. Five of the 10
patients were community based, 5 were females, 4 were male and
1 patient was of undisclosed sex. The age range was <1 to 76 y
(mode 1 y, median 33 y). Four isolates were from nasal swabs, the
remainder were taken from: bacteraemia, wound infection, urinary tract
infection, red umbilicus, line related infection and a skin and soft tissue
infection. Three of the 10 cases were sporadic, a further three were
from a healthcare associated outbreak, the remaining four were related
geographically.
Conclusion: TSST-1-positive MRSA similar to the ST5 clone found in
Europe, are present, albeit in small numbers, in England. Currently, these
isolates show low levels of antibiotic resistance. Worryingly, like PVL
positive MRSA, the emergence of these TSST-1 positive MRSA strains
portends higher MRSA rates among the young with attendant impact on
infection control and empiric therapeutic strategies.
P1587 The molecular epidemiology of community-associated
methicillin-resistant Staphylococcus aureus at a London
teaching hospital
J. Otter, G. French (London, UK)
Objectives: Community-associated MRSA (CA-MRSA) are common in
some parts of the world such as the USA, but comparatively few have
been reported in the UK. We retrospectively analysed a collection of
MRSA from our London Teaching Hospital to determine whether CA-
MRSA have emerged in our patient population.
Methods: We used ciproﬂoxacin-susceptibility as a phenotypic marker
of CA-MRSA because nearly all healthcare-associated MRSA in
our hospital are ciproﬂoxacin-resistant (CIP-R) and most CA-MRSA
reported in the UK have been ciproﬂoxacin-susceptible (CIP-S). We
therefore analysed surviving CIP-S MRSA isolates for antimicrobial
susceptibility, possession of mecA, staphylococcal cassette chromosome
mec (SCCmec) type, spa type and presence of Panton-Valentine
leukocidin (PVL) genes. Multilocus sequence typing (MLST) was
performed on representative spa types.
Results: CIP-S MRSA were isolated from 414 unique patients during
2000–2005. Only 122 (29%) were available for testing and therefore
the results should be interpreted with caution. However, compared with
CIP-R isolates, CIP-S MRSA were associated with signiﬁcantly younger
patients (average age 39.8y, (95%CI 35.3–44.3) vs. 62.6y (95%CI 62.1–
63.1), unpaired t-test p< 0.0001) (ﬁgure), were isolated more frequently
from wound infections and were more frequently susceptible to non-
b-lactam antimicrobials. These features are consistent with CA-MRSA.
CIP-S MRSA were isolated from adult in-patients (40% of cases), out-
patients (23%), patients from A&E (16%) and paediatric in-patients
(14%).
The majority of the isolates were SCCmec type IV, with IVa accounting
for 54% of the total. The most frequent spa type was t127 (which
was PVL-negative, ST1 and matches the Australian WA-MRSA-1
Age distribution of 122 ciproﬂoxacin-susceptible MRSA isolates from
2000–2005 compared with all 27,422 MRSA isolates at Guy’s and
St. Thomas’ NHS Foundation Trust from 2001–2004.
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community-associated clone), accounting for 39% of isolates. 7% of the
isolates matched the European CA-MRSA clone (PVL-positive ST80-
t044 isolates). 16% of all isolates were PVL-positive, 80% of which were
from wounds. PVL-positive isolates also included CA-MRSA-containing
genotypes such as ST8-t008, ST1-t131 and ST30-t012.
Conclusions: Although many of these CIP-S isolates were from
in-patients, a combination of epidemiological, microbiological and
molecular data deﬁned most of them as CA-MRSA, including common
clones previously reported in the UK and Europe. Thus, CA-MRSA have
emerged in our patient population over the last six years. Prospective
studies are needed to deﬁne the true size of the problem in London.
P1588 Community-acquired methicillin-resistant Staphylococcus
aureus in Austria: prevalence and clinical features
A.J. Grisold, G. Feierl, E. Leitner, A. Badura, L. Masoud, U. Wagner,
I. Wendelin, E. Marth (Graz, AT)
Objective: Infections due to community acquired Staphylococcus aureus
(CA-MRSA) are a recent worldwide phenomenon. Aim of the present
study was to determine the current prevalence of CA-MRSA in Austria.
Methods: A total of 2,433 non-duplicated S. aureus strains, isolated
in 2005 at the Institute of Hygiene, Medical University Graz, Austria,
were investigated. The isolates were characterised by routine laboratory
standard methods and determination of the resistance pattern according
the CLSI (formerly NCCLS) guidelines. Additionally polymerase chain
reaction tests for S. aureus-speciﬁc genes, the mecA gene and the Panton-
Valentine leukocidin (PVL) gene were performed. Patients with MRSA
were analysed for their clinical features, with a main focus on the PVL-
gene positive MRSA.
Results: 83 (3.4%) out of the 2,433 S. aureus isolates were MRSA,
approved by the resistance to oxacillin, evidence of S. aureus speciﬁc
genes and detection of the mecA-gene. 29 (34.9%) of the MRSA
originated from non-hospitalised patients, including patients from long-
term care facilities, from practitioners or from ambulances. 17 (20.5%)
out of the 83 MRSA-strains were deﬁned as CA-MRSA, afﬁrmed by a
positive reaction for the PVL gene and the clinical appearance. Clinical
features of the CA-MRSA patients were superﬁcial to deep soft tissue
abscess formation with single through multiple abscesses. After surgical
intervention and/or antibiotic therapy all patients recovered without
sequelae. Pneumonia could not be observed in any case.
In addition to the resistance to oxacillin CA-MRSA strains exhibited
resistance to tetracycline, ciproﬂoxacin and gentamycin with 35.3%,
29.4% and 17.6%, respectively. Resistance to fusidic acid could be
detected in 6 CA-MRSA strains (35.3%).
Conclusions: The results of this study indicate that MRSA even in
Austria more and more spread into the community, with 34.9% of the
detected MRSA originated from non-hospitalised patients in the year
2005. The occurrence of PVL-positive CA-MRSA is more frequent than
suspected, with 20.5% of the investigated MRSA isolates containing
the PVL gene. In consideration of these facts the worldwide trend of
emergence of CA-MRSA could be conﬁrmed in Austria, which supports
once more the necessity of systematic surveillance.
P1589 Report of a hospital outbreak of CA-MRSA
I.M. Gould, F.M. MacKenzie, D. Morrison, R. Browning, G. Edwards
(Aberdeen, Glasgow, UK)
Objectives: True community-acquired methicillin resistant Staphylococ-
cus aureus (CA MRSA) with the type IV Staphylococcal Chromosomal
Cassette mec (SCCmec) is rarely reported as being acquired in hospital.
We report a hospital outbreak of 8 cases of skin and soft tissue infections
due to such a strain.
Methods: From 23/09/03 to 11/03/04 a cluster of skin and soft tissue
infections due to MRSA involved neonatal and maternity patients in
a Grampian community hospital 30 miles north of Aberdeen. After
recognition of the outbreak, nursing and medical staff were reminded
of the ways in which staphylococci spread and contact precautions were
reinforced. The availability of alcohol hand gel was increased and the
importance of hand washing stressed. All patients had been in the labour,
delivery and maternity units of a small community hospital during a
7-month period. Routine clinical cultures on blood agar identiﬁed all
cases. Contact tracing, environmental cultures and follow up cultures
were plated on ORSAB agar. PFGE and PCR for toxin genes were
carried out at the Scottish MRSA reference laboratory.
Results: 8 patients presented with minor skin infections, mostly
blistering. None of the patients was seriously ill and their condition
only necessitated the use of systemic antibiotics in one case. None
required surgical draining. None of the patients had relevant past
hospital exposure, predisposing medical conditions for MRSA carriage
or had received prior antibiotic therapy except for one infected mother.
Typing by Pulsed Field Gel Electrophoresis showed the isolates to
be a single strain closely related to the USA800 lineage (Paediatric
Clone) and additional typing conﬁrmed it as ST5-MRSA-IV. Genes
for exfoliative toxin A (ETA) and enterotoxin D were detected in
all the isolates although none carried the Panton-Valentine Leukocidin
gene. The uniforms of 7 staff members were cultured and found to be
MRSA negative – as were the hands of staff, all contact screens and all
45 environmental and equipment swabs.
Conclusions: CA-MRSA strain ST5-MRSA-IV with the ETA gene has
been present in the region since 1999 at the latest but has not been seen
elsewhere in Scotland. We describe the spread of this strain within a
group of healthy newborns and one of their mothers. It was probably a
self-limiting outbreak.
P1590 Prevalence of methicillin-resistant Staphylococcus aureus in
veterinarians: an international view
M. Wulf, M. Sorum, A. van Nes, R. Skov, W. Melchers, C. Klaassen,
A. Voss (Nijmegen, NL; Copenhagen, DK; Utrecht, NL)
Objective: In the Netherlands, veterinarians in contact with pigs and
pig farmers were found to have a higher risk of methicillin resistant
S. aureus (MRSA) carriage than the general population. Identical strains
were found in pig farmers, pig veterinarians and pigs. The objective of
this study was to investigate if contact with pigs is a risk factor for
MRSA carriage in an international setting.
Design: 272 attendants of an international conference on pig health were
screened for MRSA carriage by nasal and throat swabs. A questionnaire
was included about the type of animal contacts and possible exposure
to known MRSA risk factors and the protective measures taken while
entering stables.
Results: Thirty-four participants from nine countries carried MRSA
(12.5%). Thirty-one of these strains were non-typable by PFGE using
SmaI. With the exception of ﬁve isolates with spa-type 899, the non-
typable strains belonged to closely related spa-types (t011, t034, t108,
t571, t567) which correspond to MLST 398. All of the above mentioned
spa-types have also been found either in Dutch pigs, pig farmers and/or
veterinarians. Protective measures such as masks, gowns and gloves did
not protect against acquiring MRSA.
Conclusions: Transmission of MRSA from pigs to care-takers appears
to be an international problem, creating a new reservoir for community
acquired MRSA in humans in Europe, and possibly worldwide. The
rise of a new zoonotic source of MRSA can have a severe impact
on the epidemiology of community acquired MRSA and may have
consequences for the control of MRSA, especially in the current low
prevalence countries using search and destroy policies.
P1591 Increase of pig- and calf-related MRSA in a Dutch hospital
M. van Rijen, P. van Keulen, J. Kluytmans (Breda, NL)
Objectives: Methicilline-resistant Staphylococcus aureus (MRSA) has
become an increasingly important pathogen in hospitals and recently also
in the community. In Dutch hospitals the ’Search and Destroy’ policy
is applied successfully. Recently a new risk category was added to this
control policy. This category includes patients who have professionally
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direct contact with living pigs or fatting calves. Patients who live at a
cattle farm are included too. The objective of this study was to determine
the sources of the MRSA’s found in the Amphia hospital over the years
2002 until November 2006.
Methods: Data of the Infection Control Department was used to retrieve
the number of newly introduced MRSA’s and the sources of these
MRSA’s.
Results: During 2002 until November 2006 61 newly introduced MRSA’s
were found. Thirty-six percent was related to a foreign hospital, 10% to
another Dutch hospital, in 31% the source was unknown and in 23%
of the cases the MRSA was related to pig/cattle breeding. This last
category was seen for the ﬁrst time in 2005. In total, 28 patients with
direct contact with pigs/fatting calves were screened. 14 of them were
found to be MRSA positive (50%). Eight pig farmers, one pig farmer’s
wife, one veterinary surgeon, one artiﬁcial inseminator, one calf farmer
and one calf farmer’s daughter were colonised with MRSA and 1 calf
farmer suffered from an MRSA-related osteomyelitis.
Conclusion: The incidence of MRSA over the year 2006 increased more
than 100% compared to previous years. This is caused by MRSA related
to pig and calf farmers. Patients in this risk category have an extremely
high carriage rate of MRSA (14/28 positive).
P1592 Low prevalence of non-typable methicillin-resistant
Staphylococcus aureus in meat products in the Netherlands
B.M.W. Diederen, P. Savelkoul, J.H.C. Woudenberg, R. Roosendaal,
C. Verhulst, P.H.J. Verkeulen, J.A.J.W. Kluytmans (Tilburg, Amsterdam,
Breda, NL)
Objective: A new clone of methicillin resistant Staphylococcus aureus
(MRSA) emerged in the Netherlands that was related to pigfarming. A
survey in pigs showed that nearly 40% carried this new clone. This study
was undertaken to determine the prevalence and genetic relationship of
S. aureus and MRSA in meat products.
Methods: Samples were collected between February and May 2006. A
total of 79 raw pork and cow meat products were collected from 31
different shops (butcheries n = 5, supermarkets n = 26) in the South of
The Netherlands. The samples were cultured using three procedures.
Identiﬁcation of the strains as S. aureus and methicillin resistance were
determined by Martineau PCR assay for species identiﬁcation and PCR
for the presence of the mecA gene. Susceptibility to cefoxitin and
doxycycline was determined using disk diffusion according to CLSI
standards. All isolated S. aureus strains were genotyped by ampliﬁed
fragment gel electrophoresis (AFLP).
Results: Direct plating yielded no MRSA positive isolates. Single-
enrichment microbial culture identiﬁed 8 (10%) S. aureus isolates, of
which 1 isolate was an MRSA. Combining the results of single-and
double-enrichment broth culture systems identiﬁed a total of 35 (44%)
S. aureus isolates of which 2 isolates (5%) were found to be methicillin
resistant. A total of 19 shops (61%) were found to be positive for
S. aureus in at least one meat sample. The AFLP results indicated
that there were 8 genetic lineages, covering 80% [28/35] of the isolated
strains, and a smaller number of unique sporadic isolates (20% [7/35]
of isolated strains). In 5 out of 6 shops (83%) in which more than one
S. aureus isolate was found, there was evidence for a clonal relationship
within the shop. One MRSA isolate was untypable by PFGE using Sma1
digestion and identical to a pigfarming related isolate found in a patient.
The other was identical to the USA 300 clone.
Conclusion: This is the ﬁrst report of MRSA prevalence that is available
for meat products in the Netherlands. 2.5% of the meat contained MRSA.
Furthermore, S. aureus is found regularly in low amounts in meat as it
is sold to consumers. The high rate of clonal relatedness of different
strains within a shop indicates cross contamination of the meat at some
point during processing. Considering the low amounts of contamination
these ﬁndings suggest that under normal conditions meat consumption is
very unlikely to be a hazard to consumers for the acquisition of MRSA.
P1593 Investigation of the genetic basis of erythromycin resistance
in Staphylococcus intermedius and MRSA isolates of
household pets
M. Rich, L. Roberts, A.M. Snelling, J.I. Ross (Wetherby, Bradford, UK)
Objectives: There is increasing concern about the potential transfer of
antibiotic-resistant bacterial strains between the human and veterinary
world. The aim of this study was to determine the prevalence of
the main genes responsible for erythromycin (ERY) resistance in
coagulase-positive staphylococci from household pets, and compare in-
vitro antibiotic susceptibility proﬁles.
Methods: Fifty strains of S. intermedius and 68 strains of MRSA isolated
from clinical infections of UK household pets were studied. Strains
were isolated at a veterinary diagnostic laboratory between 2005−6. All
isolates demonstrated resistance to ERY (8mg/L). Resistance proﬁles
were determined for a range of antibiotics. Isolates were tested for the
presence of erm(A), erm(B), erm(C) and msr(A) genes by PCR.
Results: At least one ERY resistance gene was detected in all isolates.
The predominant resistance gene in S. intermedius was erm(B) (72%),
whereas only a single MRSA strain carried erm(B) (1.5%). In
MRSA isolates erm(C) predominated (97%), whereas just 18% of
S. intermedius carried erm(C). The distribution of erm(A) was similar
in both groups (10−12%). There was a higher prevalence of msr(A)
amongst the S. intermedius (14%) than MRSA strains (1.5%). Only one
S. intermedius isolate contained msr(A) as the only ERY resistance gene.
Multiple ERY resistance genes were detected in 14% of S. intermedius
and 12% of MRSA strains. Incidence of resistance in the S. intermedius
group was higher for clindamycin, tetracycline and neomycin compared
to the S. aureus group (P< 0.001). Resistance to the ﬂuoroquinolones,
marboﬂoxacin and ciproﬂoxacin was 100% in the MRSA group versus
just 4% in S. intermedius. Multiple resistance (resistance to 3 drug
classes in addition to the pre-selected ERY-resistance) was detected in
19% of MRSA strains and 32% of S. intermedius strains.
Conclusion: The ERY resistance determinant most commonly associated
with animals strains, erm(B), is rare in MRSA isolates from household
pets. There is evidence of erm(A) and erm(C), genes usually associated
with ERY-resistance in human strains, amongst S. intermedius isolates.
Surprisingly, twice as many S. intermedius strains were multiply resistant
as MRSA strains. The possibility of exchange of resistance determinants
between these two groups, and the potential for MRSA strains to acquire
resistance determinants from S. intermedius in pets exits.
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P1594 Evaluation of MLVA and spa-typing as a rapid method for
studying relationships of human and bovine Staphylococcus
aureus
R. Ikawaty, J. Verhoef, A.C. Fluit (Utrecht, NL)
Objectives: At present, there is a need for a simple, efﬁcient and
high-resolution molecular typing method for S. aureus to rapidly
detect outbreaks and to study evolutionary relationships. Therefore,
we developed and evaluated a Multiple Locus Variable-number tandem
repeat Analysis (MLVA) system combined with spa-typing on human
and bovine S. aureus (HSA and BSA respectively).
Methods: Six loci (SIRU01, 05, 07, 13, 15 and 21) of 103 and 88
S. aureus isolated from humans and bovine mastitis were ampliﬁed. The
number of repeat units of each locus was calculated from each amplicon.
Multi Locus Sequence Typing (MLST) was used as a reference method.
All HSA isolates have a known sequence type (ST) and they were well
distributed within the population of S. aureus. MLST of BSA isolates
was performed as part of this study. Spa-type was determined by PCR
and sequencing.
Results: Almost all isolates yielded a product for the MLVA PCR. Some
isolates yielded no locus-speciﬁc products. These loci were assigned an
X. Variations in repeat units were observed in all loci. Large variation
in the number of repeat units suggests a greater discriminatory power
as shown for SIRU05, 13 and 21 of HSA isolates, and for SIRU21 of
BSA isolates. It seems that HSA and BSA can be differentiated by the
presence or absence of SIRU05 and 07. The absence of locus-speciﬁc
PCR products and the presence of repeat numbers for each locus are
shown in the table. HSA isolates revealed 46 spa-types and 3 new spa-
types, whereas BSA isolates showed 5 spa-types and 1 new spa-type.
When we compared the data obtained from MLVA combined with spa-
type and the data from MLVA, variations within sequence types (ST)
were observed indicating the MLVA combined with spa-type has better
discriminatory power.
HAS (n = 103) BSA (n = 88)
LOCUS % of
PCR neg.
No. of
repeats
% of
PCR neg.
No. of
repeats
SIRU01 6.8 0−5 0 1−6
SIRU05 23.3 1−22 100
SIRU07 1.9 1−3 92 2−3
SIRU13 1.9 0−26 42 1−5
SIRU15 0.9 0−5 0 0−3
SIRU21 0 1−18 0 2−12
Conclusions: The majority of S. aureus isolates can be typed by MLVA
and spa-typing. The discriminatory power to detect outbreaks for HSA
is good, but questionable for BSA.
P1595 Antimicrobial resistance in Staphylococcus intermedius from
dogs in Norway
M. Norstro¨m, H. Tharaldsen, H. Solheim, T. Mørk, B. Bergsjø,
M. Sunde (Oslo, NO)
Objectives: Staphylococcus intermedius is the most common bacterial
pathogen involved in skin and ear infections in dogs. It is questioned
whether antimicrobial resistance genes in S. intermedius from dogs might
be transferred to other staphylococci, including those causing infections
in humans, and thereby lead to further problems with resistance in
such bacteria. The Norwegian monitoring programme for antimicrobial
resistance in bacteria from feed, food and animals, NORM-VET,
investigated S. intermedius causing skin and ear infections in dogs in the
years 2000, 2002 and 2004. The results suggest an increased frequency
of antimicrobial resistance among S. intermedius from dogs in Norway
(NORM-VET 2004).
The aim of the present study was to examine if the high occurrence of
resistance in S. intermedius from dogs in Norway is due to a limited
number of resistant clones circulating among dogs in Norway, and to
examine the genetic background for resistance.
Methods: A total of 59 S. intermedius isolates from 95 samples obtained
in NORM-VET 2004 were subjected for further analyses. These isolates
were sampled from dogs with no antimicrobial treatment during the
last six months prior sampling. The isolates were sampled from dogs
spread geographically over the whole country. In total, 18.6% of the
isolates were susceptible to all antimicrobial agents included, 28.8% were
resistant to one (mainly penicillin), 23.7% to two (mainly penicillin and
oxytetracycline/fusidic acid), 18.6% to three (penicillin, oxytetracycline
and fusidic acid) and 10.2% to four or more antimicrobial agents. The
isolates were subjected to polymerase chain reaction (PCR) for detection
of resistance genes and to pulsed ﬁeld gel electrophoresis (PFGE).
Results: A multitude of S. intermedius clones are involved in skin and
ear infectious in dogs. PCR showed that resistance to tetracycline was
mediated by tet(M) in all strains expressing resistance to tetracycline,
and that all penicillin resistant strains, except one, harboured the blaZ
b-lactamase gene. Strains resistant to fusidic acid were screened for the
fusB gene, all strains were negative.
Conclusion: The many different clones found in this study indicate
a high diversity of S. intermedius from skin and ear-infections
in Norwegian dogs. The occurrence of antimicrobial resistance is
widespread among all clones.
P1596 Occurrence and enterotoxic characterisation of methicillin-
resistant Staphylococcus aureus from raw milk in southern
Italy
A. Dambrosio, G. La Salandra, M. Corrente, N.C. Quaglia, V. Lorusso,
G.L. Germinario, G. Mula, G. Normanno, G.V. Celano (Valenzano,
Foggia, Barletta, IT)
Objectives: Methicillin-resistant Staphylococcus aureus (MRSA) strains
are a global health concern. Infection could be associated with
the ingestion of contaminated foods. In addition the ingestion of
food contaminated by enterotoxins (SEs) synthesized by S. aureus is
responsible of one of the most common foodborne intoxication. Since
S. aureus is often involved in subclinical mastitis of ruminants, milk
may results contaminated. In fact, the dairy products are frequently
related to cases of Staphylococcal Food Poisoning (SFP), expecially in
areas characterised by a high level of consumption of dairy products.
Consequently an active microbiological surveillance of milk and dairy
products is desirable in order to control the risk of MRSA foodborne
infections and SFP and to allow the improvement of the public health
standards. In this work are reported the results of a survey conducted on
the occurrence and enterotoxic characterisation of MRSA in bulk milk
from Apulia region (Southern Italy).
Methods: In the present study are reported the results obtained from
the investigation of 560 bulk milk samples produced in Apulia region in
order to detect MRSA strains. The S. aureus isolates (one per positive
sample) were characterised by detecting the mecA gene by polymerase
chain reaction, and the production of type A to D staphylococcal
enterotoxins (SEs), using the reverse passive latex agglutination method.
Results: Of the 560 samples 90 (16%) were contaminated with S. aureus
and among the positive samples one showed the presence of a MRSA
(mecA positive) strain. The MRSA strain resulted able to produce
staphylococcal enterotoxin C plus enterotoxin D (SEC plus SED).
Conclusions: Despite its low prevalence in the samples analysed, the
presence of MRSA constitutes a serious health hazard, especially for
immunocompromised individuals. Such a ﬁnding calls for better hygiene
in milk production along the food-chain, especially at the primary
production level. The presence of antibiotic resistance in potentially
harmful bacteria in foods of animal origin warrants further investigations
into the role of antibiotics when they are used for therapeutic purposes
or as growth promoters in food-producing animals.
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P1597 Prevalence of methicillin-resistant Staphylococcus aureus
carriage in Italian long-term care facilities
P. Brugnaro, J. Mantero, R. Cazzaro, U. Fedeli, P. Mantoan,
G. Pellizzer, A. Tomasini, M. Zoppelletto, P. Spolaore (Castelfranco
Veneto, Vicenza, IT)
Objective: Data on the prevalence of Methicillin-Resistant Staphylo-
coccus aureus (MRSA) carriers in long term care facilities are lacking
in Italy, being 11% the prevalence reported in the only available
investigation conducted in a single facility. Aim of the study is to
determine prevalence and risk factors for MRSA carriage in nursing
home residents in Vicenza (North-Eastern Italy).
Methods: Nasal swabs were obtained in late June-early July 2006
from residents of the two largest long term care facilities of the city.
Laboratory screening for MRSA was performed by means of the MRSA
Select Agar (Bio-Rad) and full antibiotic susceptibility was assessed in
MRSA isolates. Demographic and clinical data, dependency, cognitive
function, length of stay, current and previous antibiotic treatment,
presence of medical devices, previous hospital admission, presence of
infection according to Association for Professionals in Infection Control
criteria were assessed in each subject on the same day of sample
collection. The factors signiﬁcantly associated to MRSA carriage at
univariate analysis were introduced in a multiple logistic regression
model, and the corresponding odds ratio (OR) with 95% Conﬁdence
Intervals (CI) were estimated.
Results: Out of 570 residents nasal swabs were obtained in 551 subjects
(96.7%). Among the latter, 73% were females; the mean age was 83
years (31% of residents being aged 90 or more). 118 residents (21%)
had at least one hospital admission in the previous year. 63% of subjects
received systemic antibiotic treatments in the previous 12 months: 37%
were treated with ﬂuoroquinolones, 26% with cephalosporins. Overall
43 MRSA carriers were detected (7.8%; CI: 5.7–10.4%). All MRSA
isolates showed ﬂuoroquinolones resistance. At logistic regression the
risk of MRSA carriage was increased in patients with cancer (OR= 6.1;
CI: 2.5–15.0), with previous hospitalisation (OR= 2.0; CI: 1.0−4.0), and
raised with the number of previous antibiotic treatments, reaching an
OR= 3.9 (CI: 1.6−9.1) in those with 3 or more treatments.
Conclusion: To date the present study is the largest Italian survey
of MRSA carriage in elderly people outside the hospital setting. The
prevalence resulted higher than that reported from nursing homes in
other European countries like Germany. Both comorbidities (cancer) and
pattern of care (previous hospitalisation and antibiotic treatment) were
associated with MRSA carriage.
P1598 Tracking the epidemiology of methicillin-resistant
Staphylococcus aureus strains producing Panton-Valentine
leukocidin in Greece
V. Chini, A. Foka, E. Petinaki, H. Meugnier, F. Kolonitsiou,
D. Garantziotou, M. Bes, J. Etienne, I. Spiliopoulou (Patras, Larissa,
GR; Lyon, FR)
Objectives: Methicillin-resistant Staphylococcus aureus (MRSA) is
recently associated with an increasing number of community-acquired
infections (CA-MRSA), including superﬁcial, deep-seated infections
and pneumonia. CA-MRSA harbours the Staphylococcal Cassette
Chromosome IV or V (SCCmec) and the genes encoding the Panton-
Valentine leukocidin (PVL). We have investigated the distribution and
clonal evolution of CA-MRSA during 2005–2006 in Greece.
Methods: S. aureus isolates from three hospitals in Western and
Central Greece were identiﬁed by conventional tests, followed by the
determination of MIC of oxacillin by the agar dilution method. PBP2a
production was investigated by a Latex agglutination test (bioMe´rieux).
SCCmec types, agr groups and the presence of lukS and lukF genes
(encoding PVL) were deﬁned by PCRs. Clonal types were determined by
MLST. CA-MRSA were isolated from patients without any predisposing
risk factors and identiﬁed on the basis of their genotypes.
Results: A total of 1,541 S. aureus isolates were collected from different
patients from January 2005 until June 2006. Among them 697 isolates
(45%) were MRSA (495 from the Department of Outpatients, OUTP)
and 490 (70%) PVL-positive (443 from the OUTP). An increasing rate
of the total S. aureus infections was observed with a parallel increase
of PVL-positive CA-MRSA. The great majority of CA-MRSA was
associated with skin and soft tissue infections, but ﬁve cases of acute
osteomyelitis and one pneumonia were diagnosed. The majority of CA-
MRSA (432) belonged to the major European clone, which is ST80,
agr 3, SCCmec IV, while the rest 11 belonged to a new emerging
clone, spread also in Europe, ST377, agr 1 and SCCmec type V. Most
of the PVL-positive MRSA were associated with community-acquired
infections, but 47 PVL-positive MRSA of ST80 were isolated from
hospital-acquired infections, mainly at the departments of Orthopaedics
and Surgery.
Conclusions: There is an unusual epidemiology of PVL-positive CA-
MRSA in Greece where, we are encountering an increasing rate of
S. aureus infections, due to CA-MRSA producing PVL and causing
mainly superﬁcial but also deep-seated infections. The European CA-
MRSA clone seems to be spread rapidly, but a new clone is also showing
up.
P1599 A CA-MRSA strain with decreased vancomycin
susceptibility as a cause of serious invasive infection in an
immunocompetent adolescent
M. Tronci, G. Parisi, A. Pantosti, M. Monaco, P. Valentini (Rome, IT)
Obiectives: CA-MRSA are primarily associated with skin and soft tissue
infection although they can also cause more serious infections such as
necrotising pneumonia and septicaemia. This report describes a severe
invasive infection in a immunocompetent adolescent with isolation of an
CA-MRSA strain with decreased susceptibility to vancomycin.
Methods: Blood and CSF cultures were obtained from a 16-year
old Italian boy admitted to the Paediatric Emergency room with
a temperature of 40.5ºC, stiff neck, headache and vomiting. The
patient was previously healthy with no recent hospitalisation story;
he played football and had a purulent skin lesion in the back. An
empiric therapy with a 3rd generation cefalosporin was started. The
identiﬁcation and susceptibility tests were performed by PHOENIX
instrument. Susceptibilities were conﬁrmed by E-test. The presence of
the Panton-Valentine Leucocidin (PVL) toxin genes lukS-PV-lukF-PV
was determined by PCR. The structural type of the Staphylococcal
chromosomal cassette mec (SCCmec) was performed by multiplex PCR.
Multi-locus sequence typing (MLST) was performed to characterise the
clonal group.
Results: Blood and CSF cultures grew an MRSA. In vitro susceptibility
tests showed that both the isolates from blood and from CSF were
resistant to oxacillin, and were sensitive to gentamycin, kanamycin,
erythromycin, clindamycin, rifampicin, tetracycline, ciproﬂoxacin, chlo-
ramphenicol and linezolid. MIC to vancomycin was 4 mg/mL. The
isolates contained SCCmec type IV and were positive for PVL. By
MLST the isolates were found to belong to the European clone.
The patient was transferred to another hospital where vancomycin
was started. On the third day, his condition deteriorated and he
was admitted to the ICU for respiratory distress and hypoxaemia.
The chest X-ray revealed inﬁltrates and the CT scan showed severe
necrotising pneumonia. The antimicrobial regimen was switched to
linezolid, rifampicin and teicoplanin. His conditions improved and he
was discharged after four weeks.
Conclusions: To our knowledge this is the ﬁrst case of an invasive
infection due to a CA-MRSA strain with decreased susceptibility to
vancomycin. We emphasize the importance of an early laboratory
diagnosis for an appropriate and successful therapy. An epidemiological
surveillance system is needed to characterise and monitor CA-MRSA
infections and to understand how MRSA are transmitted in the
community.
S450 17th ECCMID / 25th ICC, Posters
P1600 Methicillin-resistant Staphylococcus aureus from the lower
respiratory tract: a cause for concern?
J. Wadula, S. Vally, T. Adams, M. Khoosal (Johannesburg, ZA)
Background: Methicillin-resistant Staphylococcus aureus has emerged,
as a signiﬁcant cause of pneumonia and infection caused by this organism
has been associated with high mortality.
Recent reports allude to the fact that Staphylococcus aureus strains
carrying the Panton-Valentine Leukocidin gene are highly associated
with lethal necrotising pneumonia in healthy individuals. Community-
associated methicillin-resistant Staphylococcus aureus strains have been
implicated speciﬁcally to harbour the Panton-Valentine Leukocidin gene.
Objectives: To substantiate Methicillin-resistant Staphylococcus aureus
(MRSA) strains in relation to whether, they are community-associated
or hospital-acquired as deﬁned by molecular deﬁnition of speciﬁcally
looking for the panton-valentine leukocidin gene.
To document the reported antimicrobial sensitivity patterns of MRSA
strains.
Methods: Retrospective laboratory data collection of all MRSA cultured
from good quality sputum and tracheal aspirates during a nine-month
period commencing July 2005 through to March 2006. Majority of these
MRSA cultures were from patients in intensive care unit.
Sixty-seven cultures of MRSA from July 2005 to March 2006 were
evaluated to conﬁrm the identiﬁcation, establish the presence of mecA
and PVL genes (Hain Lifescience, Germany).
Results: Sixty-four (97%) of the 66 strains harboured the MecA gene
while none of the 66 carried the PVL gene.
These strains exhibited multiple antibiotic resistance in keeping with
hospital-acquired MRSA strains.
Conclusion: There is a predominance of hospital-acquired MRSA strain
in our hospital, which highlights the need to constantly adhere to
infection control measures.
“Classical” MRSA detection
P1601 Evaluation the cefoxitin 30mG disk diffusion method for
detection of methicillin-resistance in selected Staphylococcus
aureus isolates
M. Lara, N. Batista, F. Laich, S. Me´ndez-A´lvarez (Santa Cruz de
Tenerife, ES)
Objective: To evaluate the discriminative capacity of the CLSI disk
diffusion method with a cefoxitin 30mg disk on S. aureus isolates with
unusual phenotypic characteristics of antimicrobial resistance.
Material and Methods: We studied 53 clinical S. aureus isolates
from N.S. Candelaria Hospital, Tenerife, Spain. The antimicrobial
susceptibility of all isolates was routinely studied by the VITEK2 System
(bioMe`rieux). The methicillin resistance was also studied by CLSI
oxacillin method, and conﬁrmed by a previously described multiplex
PCR method which permitts S. aureus identiﬁcation and simultaneous
detection of methicillin resistance.
MecA positive isolates presenting a diffuse growth within the zone of
inhibition when exposed to oxacillin, were considered heteroresistant;
mecA negative, oxacillin intermediate or resistant isolates were
considered borderline.
All the isolates were tested with a cefoxitin 30 mg disk, according
to the CLSI guidelines (susceptibility: 20mm; resistance: 19mm).
Control strains for all assays included MRSA strain ATCC43300, MSSA
ATCC25923, and MRSA B/3/02 SEIMC. Secondly, we also considered
the criterium of Skov et al (J Clin Microbiol, Oct 2006) who proposes
a zone diameter for cefoxitin susceptibility (22mm).
Results: The isolates formed four groups. The ﬁrst one comprised 20
multi-resistant but oxacillin susceptible and mecA negative isolates; the
second group
was a series of 16 borderline isolates; the third group comprised a
selection of 11 heteroresistant isolates, and the fourth group was a series
of six mecA positive isolates with atypical resistance proﬁles (penicillin
and oxacillin, or ciproﬂoxacin and erythromycin resistance).
The 36 mecA negative isolates included in groups 1 and 2 showed
susceptibility to cefoxitin disk. Fifteen mecA positive isolates from
groups 3 and 4 showed inhibition zones 19mm; two isolates from these
groups (one of each), showed 20 and 21mm respectively. So, sensitivity
was 96.3% (51 of 53 isolates). After applying the Skov proposal, the
susceptibility was 100%.
Conclusions: The 30mg cefoxitin disk diffusion method is proposed
as an efﬁcient method for the detection of methicillin resistance and
permitts a clear determination for S. aureus isolates with atypical
antimicrobial characteristics.
P1602 Comparison of chromogenic agar in the detection of MRSA
A. Curry, M. Walsh, M. Matheson, A. O’Reilly, S. Knowles (Dublin, IE)
To compare two different chromogenic agars for the isolation of MRSA
in order to ﬁnd the most appropriate agar for use in our laboratory.
Nasal, umbilical and groin screening swabs from each neonate in the
NICU were pooled together. Each screen was put in Brain Heart Infusion
enrichment broth, which was incubated for 24 hours aerobically at 37ºC
and subsequently subcultured onto both MRSA ID agar and MRSA
Select agar. Both agars were incubated for 48 hours aerobically at 37ºC
and checked for the presence of green (MRSA ID) or pink (MRSA
Select) colonies at 24 and 48 hours. All green or pink colonies had
conﬁrmatory tests for MRSA.
In total 300 screens were tested on both agars. The same 10 screens
were identiﬁed MRSA positive on both agars after 24 hours. Incubation
for 48 hours did not yield any additional MRSA isolates. Therefore
both agars were comparable in sensitivity and speciﬁcity for MRSA
identiﬁcation. Other factors inﬂuenced our decision to choose a
chromogenic agar for our laboratory. MRSA ID agar grew as large green
colonies on a clear agar and was considered easy to read. MRSA Select
grew as small pink colonies on an opaque agar, which were easy to
read in large numbers. However they could easily be missed when a
scanty growth was present under our laboratory lighting conditions. Also
on both agars, Enterococci grew as a green or pink ﬁne growth after
24 hours and it distorted white colonies that grew coagulase negative
Staphylococci (CoNS) giving them a green or pink hue. On MRSA ID
agar it was easy to distinguish between true MRSA and CoNS that
appeared green due to the presence of Enterococci, however on MRSA
Select, as CoNS were also small colonies, the pink from the Enterococci
distorted the CoNS, giving them the appearance of MRSA and resulted
in them having to be conﬁrmed as CoNS. Cefoxitin resistant Gram-
negative bacilli also grew on both agars after 48 hours incubation and in
some cases a wet prep was required to exclude them as possible MRSA.
One strain of methicillin sensitive Staphylococcus aureus also grew on
both agars after 48 hours incubation.
In conclusion, both agars were comparable in sensitivity and speciﬁcity
for identifying MRSA. MRSA ID agar was chosen as the preferred agar
in our laboratory due to the ease in distinguishing true MRSA from
CoNS affected by the presence of Enterococci and also the ease of
reading the agar under our laboratory conditions.
P1603 Performance of MRSA ID chromogenic medium for
detection of methicillin-resistant Staphylococcus aureus
directly from blood cultures and clinical specimens
S. Colakoglu, H. Uncu, S. Senger, T. Turunc, Y. Demiroglu, H. Arslan
(Ankara, TR)
Objectives: Rapid identiﬁcation of methicillin-resistant Staphylococcus
aureus (MRSA) in clinical samples are an important part of the
infection control measures taken to control the spread of MRSA. The
purpose of this study is to evaluate the performance of MRSA ID
chromogenic medium compared with nonspeciﬁc media routinely used
for the detection of MRSA directly from blood cultures and clinical
specimens.
Methods: We analysed 774 blood cultures from 471 patients and 94
clinical samples (wounds or abscesses) from 71 patients. Each positive
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blood culture bottle (Bactec Plus/F;BD) and clinical sample were directly
inoculated to primary culture media and MRSA ID (bioMe´rieux, France).
All cultures were incubated in aerobic condition at 370C for 24−48 h.
Suspect colonies were identiﬁed as MRSA based on positive reaction on
the tube coagulase test with rabbit plasma, the detection of DNase and
growth on Mueller-Hinton (MH) oxacillin agar (6mg of oxacillin/mL,
according to CLSI). Inoculated MRSA ID plates were interperated in
accordance with the manufacturer’ s instructions. Growth of colonies
showing distinctive green coloration was considered to be positive.
No growth or colonies with colours other than green were considered
negative. Discordant results were conﬁrmed by mecA gene PCR.
Results: The results obtained with MRSA ID are summarised in Tables
1 and 2. Three methicillin-susceptible S. aureus (MSSA) isolates gave
false-positive results on MRSA ID and these strains gave negative result
with the mecA PCR.
Table 1. Results for MRSA ID medium after 24 h and 48 h of incubation
No. strains with a positive test result/total
no. of strains (%) after:
Organism 24 h 48 h
MSSA 2/34 (5.9) 3/34 (8.8)
MRSA 54/56 (96.4) 56/56 (100)
Table 2. Strains producing green colonies which have a different
appearance from MRSA colonies
Organism No. of strains detected on medium
Aerococcus viridans 1
Acinetobacter baumannii 1
Bacillus sp 1
Brucella sp 2
Candida sp 4
Enterococcus sp 2
Enterobacter gergovias 1
Stenotrophomonas maltophilia 4
Conclusions: (1) MRSA ID is highly effective for the isolation and
presumptive identiﬁcation of MRSA directly from wound samples and
blood cultures. (2) The use of MRSA ID with primary culture media
should decrease the time (18−24 h) to reporting positive results compared
with conventional methods.
P1604 Evaluation of a new chromogenic medium SaSelect for
identiﬁcation of Staphylococcus aureus
C. Daurel, R. Leclercq (Caen, FR)
Objectives: The objectives were to compare the sensitivities and
speciﬁcities of SaSelect, a new chromogenic medium, and Mannitol salt
agar medium (MSA, Chapman) associated with a slide coagulase test,
for rapid and direct identiﬁcation of Staphylococcus aureus from cultures
of various clinical samples.
Methods: 322 clinical specimens of various natures were studied:
suppurations (n = 126), upper and lower respiratory tract secretions
(n = 54), faecal samples (n = 31), blood cultures with mixed Gram strains
(n = 30), nasal samples (n = 41), urines (n = 20), catheters (n = 8) and
others (n = 12). All samples were isolated on SaSelect (incubation 24 h)
and MSA (incubation time: 24 and 48 h). The identiﬁcation of pink
colonies on SaSelect and colonies with a yellow halo on MSA was
conﬁrmed by a slide coagulase test.
Results: Most clinical samples were polymicrobial. 152 samples
contained S. aureus with SaSelect (24 h of incubation) and 144 with
MSA (48 h of incubation). 153 S. aureus were isolated on either medium.
Speciﬁcity and sensitivity were calculated, considering that a sample was
positive if any of the two tested media showed the presence of S. aureus.
When only the pink colour of the colonies at 24 h of incubation on
SaSelect was taken as a criterion of identiﬁcation for S. aureus, the
speciﬁcity (100%) was similar to that obtained on MSA combined with
coagulase test at 24 and 48 h of incubation (99.4%). The sensitivity
values were different. At 24 h, the sensitivity was 90.8% for MSA and
98% for SaSelect. At 48 h incubation time, the sensitivity determined on
MSA increased to 94.7%.
Conclusion: The sensitivity and speciﬁcity of the SaSelect medium were
close to 100% in our study. This medium can be used in routine for the
identiﬁcation of S. aureus on the basis of the pink colour of the colonies
without requiring a complementary coagulase test for conﬁrmation.
SaSelect makes it possible to reduce the cost of the test and the working
time.
P1605 Comparison of three chromogenic media for rapid
detection of methicillin-resistant Staphylococcus aureus
from screening swabs in hospitalised patients
C. Nonhoff, O. Denis, A. Brenner, P. Buidin, C. Thiroux, M. Struelens
(Brussels, BE)
Objectives: To evaluate the performance of MRSA-ID (bioMe´rieux),
MRSA Chromogenic Agar (MRSA-Screen, Oxoid) and MRSA-Select
(Bio-Rad) media for detection of methicillin-resistant Staphylococcus
aureus (MRSA) in muco-cutaneous swab samples from patients admitted
to a 860-bed teaching hospital.
Methods: Hospitalised patients (n = 639) were screened for MRSA
carriage by sampling swabs from nares (n = 726), throat (n = 116),
perineum (n = 109 and skin (n = 51). Swabs were inoculated into nutrient
broth (SB) supplemented with 7.5% NaCl, MRSA-ID, MRSA-Screen
and MRSA-Select agar at 35ºC. SB broths were sub-cultured after 24 h
onto the three chromogenic media. S. aureus isolates were identiﬁed by
coagulase test. Susceptibility to oxacillin was determined by cefoxitin
disk method according to CLSI. Identiﬁcation and oxacillin resistance
were conﬁrmed by PCR for 16S rRNA, nuc and mecA genes.
Results:MRSA strains were isolated from 68 (6.8%) specimens from 45
patients: nares (n = 28), throat (n = 16), perineum (n = 13), skin (n = 11).
Performance results of the three chromogenic media are shown in
Table 1. Seven (10.8%) MRSA isolates grew only on primary agar plates
while 10 (15.4%) were only isolated after the enrichment procedure. The
speciﬁcity of MRSA-Screen decreased after 36 h incubation and with the
enrichment step because of growth of pigmented methicillin-susceptible
S. aureus (MSSA) (23 and 24 isolates, respectively).
Sensitivity (%) Speciﬁcity (%)
Medium 16−18 h 36 h Enrichment 16−18 h 36 h Enrichment
MRSA-ID 45.6 75.0 85.3 100 99.9** 99.8
MRSA-Screen 44.1 80.9* 85.3 99.4 97.5** 97.4
MRSA-Select 45.6 72.1* 85.3 100 100** 100
*p = 0.045; **p< 0.001
Conclusion: The three chromogenic media demonstrated equivalent
performance after 16−18 h. The use of an enrichment broth was
necessary to optimise sensitivity but was associated with decreased
speciﬁcity for MRSA-ID and MRSA-Screen. In this study, we observed
equivalent sensitivity after 16−18 h and marginal difference in sensitivity
after 36 h between the three media but signiﬁcant lower speciﬁcity for
MRSA-Screen after 36 h and enrichment (p< 0.001).
P1606 In vitro evaluation of MRSA screening methods
S. Bo¨cher, R. Smyth, G. Kahlmeter, R. Leo Skov (Copenhagen S,
DK; Va¨xjo¨, SE)
Objectives: Chromogenic agars for detection of MRSA carriers are
now widely available. Enrichment broths have been shown to increase
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sensitivity. Studies of enrichment broths in combination with these new
selective agars, using diverse MRSA strains, are needed. This study has
been designed to meet that need.
Materials and Methods: Isolates: 99 well characterised MRSA strains,
representing 13 clonal complexes, including many highly heterogenic
isolates, 50 methicillin sensitive Staphylococcus aureus (MSSA) and 50
methicillin resistant coagulase negative staphylococci (MRCNS) were
tested. Selective agars: MRSA SSI (Statens Serum Institut), MRSA ID®
(bioMe´rieux), MRSA Select® (Biorad), Mannitol salt agar with 4mg/L
cefoxitin (MSA) and 5% blood agar (BA). Enrichment broths: TSB with
2.5% salt, 20mg/L aztreonam and 3.5mg/L cefoxitin (TSB), phenol red
mannitol broth with 75mg/L aztreonam and 5mg/L ceftizoxime (MB).
Method: 20 CFU of each strain was inoculated directly onto each of the
agar media and into the broths. After 18 and 48 h incubation at 35−36ºC,
colonies on the solid media were counted. After 18−24 h incubation of
the broths, 20mL was subcultured onto each of the selective agars and
a blood agar control.
Results: For direct inoculation and 18−24 h incubation the sensitivities
and speciﬁcities were: MRSA SSI: 97%/100%, MRSA ID: 96%/95%,
MRSA Select: 95%/99%, MSA 75%/71%. (88%/71% after 48 hours).
For chromogenic agars 48 h incubation only served to lower selectivity,
especially for MRCNS. Using turbidity or colour change as a growth
indicator, the sensitivities and speciﬁcities of the broths were: TSB:
97%/74%, MB: 47%/100% and after subculture to BA: TSB: 97%/57%,
MB: 74%/58%
After enrichment in broths the sensitivity of MRSA ID and MRSA Select
rose by 1−2%. The sensitivity of MSA increased from 75% to 97% after
enrichment in TSB.
All strains grew on blood agar.
Discussion and Conclusions: In this in vitro evaluation, all 3
chromogenic MRSA agars supported growth of this diverse collection
of MRSA using low inocula and had high speciﬁcity. Enrichment using
TSB gave no overall advantage. MB enrichment displayed low sensitivity
suggesting that the antibiotic content is too high. Incubation of the
chromogenic agars beyond 24 hours had no effect on sensitivity. For
the MSA plate, comparable sensitivity was obtained only after pre-
enrichment.
P1607 Evaluation of a direct cefoxitin disc diffusion test for the
presumptive identiﬁcation of MRSA from clinical specimens
J. Fuller, B. Lui, L. Rosmus, J. Johnson, R. Rennie (Edmonton, CA)
Objective: Despite intensive patient screening programmes, the preven-
tion of methicillin-resistant Staphylococcus aureus (MRSA) nosocomial
transmission continues to challenge many Canadian hospitals. This study
evaluated the predictive capacity of a non-standardised direct cefoxitin
disk test to presumptively identify MRSA isolates from routine clinical
specimens.
Methods: For a six-month period routine clinical isolates collected from
any patient site that resembled S. aureus morphologically at 24 hr of
incubation were subcultured onto sheep blood agar, as per laboratory
protocol. A 30mg cefoxitin disk (Oxoid) was placed in the ﬁrst quadrant
of the subculture plate, which was incubated at 35 degrees C for 18
to 24 hours. The inhibitory zone size of each isolate was measured
and categorised as susceptible (S) or resistant (R) according to current
Clinical Laboratories Standards Institute (CLSI) breakpoint values (S
 20mm, R  19mm). Comparatively, a standard cefoxitin Kirby-
Bauer disk diffusion (CLSI) was performed for each S. aureus isolate.
Conﬁrmatory MRSA identiﬁcation was performed using a PBP2A assay
(Denka Seiken).
Results: 518 S. aureus isolates were collected from 372 patients that
were evenly distributed across common specimen sites, including blood,
respiratory, skin, and wounds. The direct and CLSI disk methods showed
100% breakpoint agreement (S, 79%) and cefoxitin R isolates were
conﬁrmed MRSA by PBP2A. However, the direct method provided
presumptive MRSA results 24 hours sooner. Interestingly, only one
isolate (0.2%) that was S by the CLSI method had an inhibitory zone
between 20 and 23mm. In contrast, using the direct cefoxitin method
72 isolates (14%) had a reduced S zone between 20 and 23mm. Similar
results were observed when the data was restricted to one isolate per
patient.
Conclusion: In this study, a non-standardised cefoxitin disk test reliably
predicted cefoxitin susceptibility for clinical S. aureus isolates 24 hours
sooner than that provided by CLSI disk diffusion. If adopted, this would
allow faster laboratory reporting and infection control interventions
for presumptive MRSA-positive patients. As a precautionary measure,
infection control precautions could also be considered for patients with
an isolate exhibiting a reduced S inhibitory zone size (20 to 23mm)
until conﬁrmatory testing was complete.
Tuberculosis and other mycobacterial
infections: clinical epidemiology
P1608 Tuberculosis case ﬁnding and treatment in the central
prison of Qazvin province
S. Salehi Shahidi, M. Assefzadeh, R.Gh. Barghi (Qazvin, IR)
Objectives: This study is aimed at determining tuberculosis prevalence
in the central prison of Qazvin province.
Methods: It was a cross-sectional study started from April 2004 to July
2005 which use active case ﬁnding based on clinical signs and symptoms
(persistent cough more than 2 weeks, weight loss, fever, night sweats,
decreased appetite) and a minimum of 3 morning sputum samples of TB
suspects for microscopic exam.
Results: A total number of 768 prisoners including 95% males and
5% females were examined. 75% of them were in 21−40 age-group.
5.3% of total examined were tuberculosis suspects. 7 smear-positive TB
cases were found who were all males. 6 cases were in 21−40 age group.
All of the cases were addicted to cigarette and drug. In general the
tuberculosis prevalence was 911 per 100,000. Directly observed short
course treatment was started for all 7 patients. 4 cases were cured, 1
case treatment completed and 2 cases were failed who one of them was
cured after prescription of Category2 regimen, the other one interrupted
his treatment after having been released from the prison.
Conclusion: In our study, the tuberculosis prevalence in evaluated
prisoners was 911 per 100,000. It was 227 times more than smear positive
tuberculosis prevalence and 113 times more than total tuberculosis
prevalence of the province in the same year. In a separate study in Central
Qazvin prison in 1999, it was found out that the tuberculosis prevalence
was 136 per 100,000. This increasing trend of tuberculosis in Central
Qazvin Prison from 136 to 911 per 100,000 in about 5 years is possibly
because of an increased accuracy of active case ﬁnding and increased
predisposing factors for tuberculosis infection/reactivation in the prison.
Since there are no limitation and physical barriers for tuberculosis as
restricting factors this increasing trend can be an alarm for spreading
the disease in the society. Therefore there should be continuous training
programmes for both staff and prisoners.
We had two cases of treatment failure (28.5%) which were higher
than the same result in non-prisoner patients (2.9%) may be due to
noncompliance of the prisoners to the treatment, multiple lung cavities
which were found in chest X-rays of both failure of treatment cases,
smoking and drug addiction. Therefore arrangements should be made in
such a way that all inmates must refrain from smoking and drug abuse
and their treatment should be performed under more supervision and
care.
P1609 Extrapulmonary tuberculosis in central Tunisia: a review
of 114 cases
N. Kaabia, F. Bellezreg, M. Khalifa, E. ben Jazia, A. Braham, F. Bahri,
A. Letaief (Sousse, TN)
Tuberculosis continues to be a serious public health problem in Tunisia.
The aim of this study was to identify epidemiological and clinical
characteristics of extrapulmonary tuberculosis (EPT) in a tertiary care
setting.
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Methods: A retrospective case series was carried out of all cases
diagnosed and treated as EPT during January 2000 to September 2006
at Farhat Hached Hospital, Sousse, Tunisia. Demographic, clinical,
laboratory data and outcome were abstracted from medical records.
Results: 114 cases of EPT were included. The average age of patients
was 47.5 years, 61 (53.5%) were men and 59% were rural dwellers.
Isolated EPT was identiﬁed in 86 (75.5%) patients, 28 cases had
both pulmonary and EPT. 41 patients (36%) had co-morbidities,
most commonly diabetes mellitus in 9.5% of patients. Diagnosis
delay was 16.5 days. The most frequent form was lymphadenitis
in 30 cases (26.5%), followed by digestive (23), osteoarticular (17),
genitourinary (13), pleural (11) and meningeal (11) forms. More than
one location was noted in 24 patients (21%). EPT was diagnosed
by histopathologic methods in 64 (56%) cases and by microbiologic
methods in 33 (29%). Tuberculin skin test was signiﬁcantly positive in
35% of patients. The average hospital stay was 24.5 days. No case had a
relapse or recurrence of disease in the period of follow up, 4 patients with
meningeal tuberculosis died. All patients were treated by antituberculosis
drug, 21 (18.5%) presented adverse effects, most commonly hepatitis in
16 cases.
Conclusion: Although this study did not show the real frequency of EPT
in our region, it noted the high frequency of lymph nodes localisation
and the principal diagnostic method was the biopsy.
P1610 Clinical analysis of tuberculous meningitis cases hospitalised
from 1993 to 2006
M. Bociaga-Jasik, A. Garlicki, A. Kalinowska-Nowak (Cracow, PL)
Objectives: The aim of the study was the retrospective analysis of TB
meningitis cases.
Material: On the basis of medical records 25 cases of TB meningitis
hospitalised in the Department of Infectious Diseases CMUJ from 1993
to 2006 were analysed (1.98% of all meningitis cases hospitalised at this
time).
Results: 18 (72%) men and 7 (28%) women, age range 21−76 years
(mean age 39) with TB meningitis were hospitalised. 5 (20%) were
infected with HIV. Other risk factors included: alcoholism 6 (24%),
diabetes mellitus 2 (8%). 6 (24%) had previous TB lung infection,
1 had involvement of perihilar lymph nodes. There was 1 case (4%)
of milliary TB and 3 (12%) of UT tuberculosis. Mean time since the
onset of symptoms to ﬁnal diagnosis was 13.3 days (min 6, max 26).
Most common complains were: headache 24 (96%), fever 23 (92%),
nausea 22 (88%), upper RTI 20 (80%), haematuria 3 (12%). On
PE: meningeal signs 23 (92%), changes in consciousness 2 (88%),
hemiparesis 4 (16%), Horner sign 3 (12%), cranial nerve palsy 3 (12%),
spastic paresis of lower extremities 2 (8%) were detected.
Changes in CSF differ signiﬁcantly among patients. Number of cells in
CSF range from 40 to 1,117 cells/mm3, with lymphocyte predominance.
Also protein, glucose and chlorine concentration differ signiﬁcantly and
range from 1.0 to 27.7 g/L, 0.69 to 2.2mmol/L and 94 to 119.2mmol/L.
The conﬁrmation from CSF (PCR, BACTEC) was achieved in 13 (52%)
cases. 8 (32%) patients had positive cultures from respiratory tract,
3 (12%) from urinary tract and 1 (4%) from blood. In the rest of cases
the diagnosis was established on the basis of clinical picture, changes in
CSF and response for therapy with antituberculous drugs. All patients
were treated with 4 drugs and steroids. The mean hospitalisation time
was 107 (min 17, max 188). 3 (12%) patients died. 11 (44%) developed
hydrocephalus, 5 of whom required shunts. In 2 (8%) cases brain
ischaemia was detected. 2 (8%) developed epilepsy, 1 (4%) tuberculomas
of the brain, and 1 (4%) mental retardation. 9 (36%) patients recovered
completely.
Conclusions: (1) Tuberculous meningitis in Poland is not forgotten
disease, and should be taken into consideration in diagnostic work up
also of immunocompetent individuals. (2) The diagnosis is usually
delayed because of uncharacteristic clinical presentation and different
pattern of changes in CSF. (3) In spite of therapy tuberculous meningitis
is associated with high risk of complications.
P1611 Clinical and paraclinical aspects of tuberculous meningitis
in a hospital of infectious diseases, Iasi, Romania
C. Luca, C. Dorobat, D. Mihalache, C. Petrovici, E. Nastase,
R. Nemescu, O. Caliman-Sturdza, V. Luca (Iasi, RO)
Objectives: The aim of this study is presentation of tuberculous
meningitis in the department of Iasi Infectious Diseases Hospital, where
patients from all North-East Romania are attended to.
Materials and Method: We retrospectively studied the cases
of tuberculous meningitis during 2005–2006 regarding clinical and
laboratory methods of diagnosis. We used the classic laboratory methods
together with new ones, the quantiﬁcation of gamma-interferon in blood,
in presence of M. tuberculosis speciﬁc antigens.
Results: A total of 58 patients (41 male [71%] and 17 female [29%])
were included. The mean age was 31 years (age range: 10 months–
80 years) with 12 patients (21%) over 50 years old and 15 under
14 years old (26%). 15 (26%) patients had a history of tuberculosis.
The clinical symptoms and signs on the admittance were compatible
with tuberculous meningitis: consciousness alteration in 18 cases (31%),
focal neurological signs in 11 cases (19%), paraplegia and/or hemiplegia
in 7 cases (12%) and extra-neurological tuberculosis was associated in
32 cases (55%).
The patients fulﬁlled some of following diagnosis criteria: CSF
(cerebrospinal ﬂuid) pleocytosis (with <100 elements/mL for 15 cases,
101–300 elements/mL for 25 cases and >300 elements/mL for 17 cases);
high CSF protein level (45 cases, 78%); low CSF glucose level
(32, 55%); favourable response to antituberculous therapy and steroids
(51 cases, 88%); and a mortality of 12% (7 cases).
Microbiological diagnosis was done through culture in CSF with positive
results in 18 cases: 6 cases (10%) were with negative CSF cultures
and 12 (21%) had positive M. tuberculosis CSF cultures and positive
Quantiferon TB Gold results. Also, in 3 cases (5%) we had multidrug
resistant strains of M. tuberculosis.
We used quadruple association of antituberculous drugs for treatment,
with favourable response in 48 cases (83%) and with a mortality of 12%
(7 cases). Sequels were present in 18 cases (31%), with: hydrocephalus
in 10 cases (56%), arachnoiditis in 3 cases (16%) and tuberculomas in
5 cases (28%).
Conclusion: Tuberculous meningitis is still a very serious disease in
Romania, with high morbidity and mortality, especially among children
and elders. Early diagnosis should be considered to improve prognosis.
This study indicates that a new and rapid diagnosis method is highly
needed and improves the prognosis of tuberculous meningitis, shorting
the time needed for an early and accurate treatment initiation.
P1612 Impact of pneumonia in pregnancy on maternal and
neonatal outcomes in Durban, South Africa
M. Khan, J. Moodley, M. Adhikari (Durban, ZA)
Introduction: Pneumonia in pregnancy occurs in <1% of antenatal
attendees; an incidence rate not dissimilar to that reported in non-
pregnant adults. However the pregnant state and risk factors associated
with the development of pneumonia adversely inﬂuence the outcome of
pregnancy. It is the third leading cause of indirect maternal mortality
during pregnancy, labour and the puerperium in the USA and in South
Africa, it was the leading cause of maternal deaths due to non-pregnancy
related infections.
The contribution of pneumonia and HIV-1 co infection in pregnancy has
been poorly documented in South Africa. The aim of our study was to
determine the clinical and demographic proﬁle of women admitted to
the maternity unit of a tertiary centre in Kwa Zulu-Natal, South Africa
and to evaluate the association between pneumonia, HIV-1 infection and
maternal and perinatal outcomes.
Methods: The study was performed between January and December
2000 in the antenatal clinic and labour ward of a tertiary centre. The
investigation of pneumonia by the attending obstetrician was prompted
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by symptoms and clinical signs. All women were offered pre and post
test counseling for HIV-1.
A control arm of HIV infected and uninfected women without
pneumonia were randomly selected from the antenatal population.
Results: Twenty nine pregnant women were diagnosed with pneumonia.
Mycobacterium tuberculosis (MTB) was the only causative organism
isolated from sputum samples. Of the 14 MTB samples, 10 were smear
positive and 8 were culture positive, with one case of drug resistant
MTB. EPTB accounted for 9 of the 14 MTB cases. As a result, 3
categories developed: women with probable or conﬁrmed PTB, women
with suspected PTB and women with suspected bacterial pneumonia.
There were 7 maternal deaths which occurred in women with pneumonia.
There were 18 live born neonates, one intra uterine death and 6 stillbirths.
In the control arm of 112 women, a greater number of obstetric co
morbidities occurred. There were no maternal or neonatal deaths.
Conclusion: Pneumonia in pregnancy has a low incidence rate yet carries
signiﬁcant maternal and neonatal morbidity and mortality. Risk factors
for the development of pneumonia were identiﬁed in our study and
almost two thirds of the mothers had a chronic cough. In resourced
constrained settings with high HIV and TB prevalence, it might be cost
effective to do screening chest radiographs in pregnancy.
P1613 Tuberculosis in the area of Barcelona: the increasing
inﬂuence of immigration
R. Gu¨erri, R. Perello´, F. Sa´nchez, J.L. Gimeno-Bayon, G. Vallecillo,
J.L. Lo´pez, J.A. Kayla´ (Barcelona, ES)
Introduction: The epidemiology of tuberculosis (TB) in urban
populations is on dynamic change. The density of TB in a certain country
or area is determined by (1) the TB prevalence background over the
previous 40 years; (2) the socio-economic situation of the new diagnosed
patients; (3) the migratory movements, and (4) the programmes for
TB control.
Aim: To describe the new epidemiological proﬁle of tuberculosis in
Barcelona (Spain).
Methods: A retrospective-prospective study of the TB cases declared
in the 2002–2005 period has been performed in the University-afﬁliated
Hospital del Mar. The variables included are epidemiological as well as
microbiological.
Results: Within 399 cases registered, 47.8%t were foreign-born, 19.5%
of them coming from south-eastern Asia (India, Pakistan, Afghanistan)
and 12.6% from South America. HIV co-infection was present in 16.8%
of all patients, and in 35% of those coming from South America.
The most frequent clinical presentations were toxic syndrome (22.7%),
prolonged fever (17.9%) and respiratory symptoms (14.6%); 6.5%
of patients presented haemoptisis. Those presentations were different
between autochthonous and foreign-born, being the pulmonary form
identiﬁable in the 59.1% of cases. From those, 27.6% presented cavities,
and 52.6% presented abnormal radiography without cavities. The culture
for mycobacteria was positive in 71.7% of cases, and negative in 28.3%
(M. tuberculosis was identiﬁed in 62.7%). The susceptibility tests showed
5% strains resistant to rifampin among patients coming from South
America, and 4.8% strains resistant to pyrazinamide in those coming
from south-eastern Asia.
Conclusion: TB is now an emerging epidemic in Barcelona, and it is
strongly related to increasing immigration. It is necessary to improve
the diagnostic tools that could help to rapidly identify new TB cases
among foreign-born presenting fever and toxic syndrome, as well as to
prescribe accurate treatments in patients with high suspect of resistance
to ﬁrst-line drugs.
P1614 Tuberculosis among immigrants: our experience
A. Antypa, M. Pouyiouka, E. Spanos, K. Petrochilou, V. Karabassi,
K. Paraskeva, N. Alexandropoulos, M. Toutouza (Athens, GR)
Tuberculosis is an airborne pathogen, propelled through tiny droplets via
sneezing, talking or coughing. The disease is extremely widespread: one
person in three worldwide has the infection and two million die annually
from TB. Mass immigration from developing countries entails the risk
of an increased rate of tuberculosis in our country.
Aim: The aim of this study was to assess the prevalence of tuberculosis
among legal immigrants who asked for lawful permanent residency
Green Cards.
Methods: The study population consisted of 1,460 (638 males and 822
females) immigrants aged 15−65 years old, who came to our hospital for
examination, the period from 12.10.2005 to 02.05.2006. Their countries
of origin were mainly Albania, Bulgaria, Romania, ’the former Soviet
Union’, countries of Africa and South-Eastern Asia.
Tuberculin skin testing was performed on all study subjects upon
enrollment, according to the routine procedures. A tuberculin skin test
reaction size >10mm was considered positive for all study participants.
They were all examined with a posterior-anterior chest radiograph to
detect chest abnormalities. A short history of TB exposure, infection, or
disease was asked though in many cases it was difﬁcult to communicate
with them.
Results: 96 persons found tuberculin skin test positive with negative
history of B.C.G. and 69 (4.9% of all the examined) of them had positive
ﬁndings for pulmonary active Tb, from their chest radiograph. We sent
the positives to the hospital of Chest diseases to be cured.
Conclusions: Screening for TB on arrival should be strengthened,
and preventive therapy for those with recent TB infection should be
considered. Healthcare professionals need to be aware that immigrants
from countries with a relatively high prevalence of TB are a risk for
countries with low prevalence of TB.
P1615 No evidence for hypoadrenalism as a cause of early
mortality in a high HIV/TB prevalence population starting
anti-tuberculosis treatment in Malawi
M.B.J. Beadsworth, J.J. van Oosterhout, M. Diver, A. Shenkin,
H.C. Mwandumba, S. Khoo, T. O’Dempsey, S.B. Squire, E.E. Zijlstra
(Liverpool, UK; Blantyre, MW)
Mortaliy is high in the ﬁrst 2 months after commencing anti-tuberculosis
treatment (ATT), especially in areas with high HIV prevalence, such
as Malawi, where case fatality rates are 23−26%. (40% of these are
in the ﬁrst month.) Various causes have been proposed, including
delayed treatment, other co-infections, advanced HIV disease and severe
malnutrition. Another proposed aetiology is adrenal crisis precipitated by
rifampicin. The commonest cause of hypoadrenalism worldwide is still
described as TB and in addition rifampicin induces cytochrome p450,
which metabolises endogenous glucocorticoid. We tested the hypotheses;
that corticosteroid metabolism is deranged after starting ATT and that
this disturbance is linked to early mortality.
Methods: Consenting consecutive smear positive adults admitted to
Queen Elizabeth Central Hospital, Malawi were enrolled. Adrenal
function was assessed using a short Synacthen (synthetic ACTH) test.
Adequate adrenal function was deﬁned as a rise above 550 nmol/L
at 30 minutes. Testing was carried out at baseline and two weeks
after commencing rifampicin (as part of ATT). Follow-up was for 3
months. All patients were offered HIV testing, as per national guidelines.
Treatment for TB followed national guidelines.
Results: 51 smear-positive patients were enrolled of whom 29 (57%)
were female, median age 32 years (range 18−62). 41 patients consented
to HIV testing, of whom 88% were seropositive. The median time from
onset of symptoms to starting ATT was 48 days (range 7–365 days).
Case fatality in the ﬁrst month was 16%. Hypoadrenalism was found
in 2 patients on admission and none on day 14. Both of these were
discharged and one was followed up at 3 months, the other was well,
but declined further follow up.
Conclusions: Hypoadrenalism is not common and is not a cause of
early mortality after commencement of ATT. Further studies are urgently
required to identify other possible aetiologies.
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P1616 XDR tuberculosis in Lisbon health region
L. Brum, R. Macedo, P. Cristova˜o, L. Reis, E. Fernandes, E. Pereira,
A. Garcia (Lisbon, PT)
Introduction: Portugal is still the European country with the highest
incidence of notiﬁed tuberculosis cases (31/100,000 in 2005 compared
to 12.8/100,00 habitants in Central and Eastern E.U.). Despite MDR-TB
strains isolated in hospital and public health laboratories being currently
notiﬁed to Portuguese Health authorities, the true magnitude of this
problem remains unknown. In fact, even though only 17 MDR-TB cases
were notiﬁed in 2003, the National Institute of Health Dr. Ricardo Jorge
in Lisbon, usually receives around 80 MDR-TB strains per year from
the Health Region of Lisboa e Vale do Tejo (which represent 6−8% of
the total of isolated strains in this region).
Recently it has been described MDR-TB strains that have mutated into an
even stronger forms designated as extremely drug resistant tuberculosis
(XDR-TB). This form of TB is deﬁned as resistance to both isoniazid
and rifampicin (deﬁnition of MDR-TB) in addition to resistance to any
ﬂuoroquinolone and to at least one of the three injectable second-line
anti-TB drugs used in treatment (capreomycin, kanamicin and amikacin).
Material and Methods: In this study we evaluated the prevalence
of XDR-TB strains among strains isolated in Lisbon laboratories and
hospitals, in the years 2002 to 2006.
Susceptibility testing to ﬁrst line drugs (Isoniazid, rifampicin, ethamb-
utol, pyrazinamid, streptomycin) and second line drugs (ethionamide,
capreomycine, oﬂoxacyn, kanamycin, amikacin and PAS), was per-
formed in Bactec 460 Tb in the critical concentrations indicated in the
Bactec manual or according to Pfyffer et al.
Results: Among the MDR-TB strains isolated in our laboratory we found
that about half of them are also XDR-TB (table 1).
Table 1. Number of XDR/MDR patients per year
Year No. of XDR No. of MDR %(XDR/MDR)
2002 41 86 48
2003 50 87 57
2004 49 86 57
2005 49 94 52
2006a 18 46 39
aData until September 2006.
Conclusion: These numbers are extremely high comparing to other
European countries such as France, Belgium or UK that have 3−11%
of XDR-TB cases. This problem is particularly worse for the HIV
population as the rate death for HIV/AIDS patients with XDR-TB is
nearly 100%.
The emergence of XDR-TB calls for a vigorous international response
to fully implement proper TB control, to limit their public health impact
and to ensure that countries at risk from the disease are prepared for it.
P1617 Impact of latent and overt tuberculosis on HIV-infected
patients in southern Iran
M. Davarpanah, A.A. Sohrabpour, R. Neirami, M. Darvishi (Shiraz, IR)
Objectives: Tuberculosis (TB) is an important and potentially fatal
opportunistic infection in the HIV-infected population. It is especially
prevalent in the developing countries, including Iran. This study was
aimed at determining the impact of latent TB infection and overt
tuberculosis among a group of HIV infected clients attending a
university afﬁliated clinic caring for voluntarily participants with high
risk behaviours.
Methods: 572 HIV-infected persons including 60 females (11.4%) were
registered. They all inhabit in the city of Shiraz, with around one
million population located in the Southern Province of Fars, Iran. All
had baseline and annual standard 5-tuberculin unit PPD (Puriﬁed Protein
Derivative) skin tests performed. The patients were followed for a mean
period of 29.2 ± 5.1 months.
Results: 114 patients (19.9%) had positive PPD tests (deﬁned as >5mm
induration) at baseline. 10 more patients (1.7%) with negative baseline
PPD developed positive skin test in follow-up annual tests. During
the follow-up period, 13 patients (2.3%) suffered clinical tuberculosis
including 9 patients with smear-positive pulmonary TB, 2 with biopsy-
proven TB lymphadenitis, and 2 with TB pericarditis as evidenced by
pericardial ﬂuid analysis and complete response to anti-tuberculosis
therapy. 6 out of 13 patients with overt tuberculosis died during the
follow up. Death was directly TB-associated in four, all of whom had
smear positive pulmonary tuberculosis.
Conclusion: There is a high rate of tuberculin reactivity in HIV-infected
patients in southern Iran. The importance of PPD testing and providing
isoniazid preventive therapy deserves more attention in the HIV-infected
population.
P1618 Treatment outcome of tuberculosis patients diagnosed with
human immunodeﬁciency virus infection in Iran
P. Tabarsi, P. Baghaei, M. Amiri, H. Emami, D. Mansouri, M. Masjedi
(Tehran, IR)
Background: Concomitant treatment of tuberculosis (TB) and human
immunodeﬁciency virus (HIV) faces many problems due to pill burden,
drug/drug interactions and toxicity. As there are yet no reports made on
the treatment outcome of TB-HIV patients in Iran, this study aims to
evaluate the outcome of treatment at the Masih Daneshvari Hospital, the
National Referral Center for Tuberculosis and Lung Diseases in Tehran.
Methods: TB patients who were admitted to the hospital between the
years 2002–2004 and tested positive for HIV were included in the study.
61 variables were chosen for comparison. All analysis was done using
SPSS and signiﬁcance was deduced via chi-square testing.
Results: 56 patients were included in the study. The mean CD4 count
was 193 + 181 while the mean count at which death occurred was 128
+ 41. Fifty percent of the cases were cured while mortality occurred
in 15 cases (26.8%). The rate of mortality in patients who developed
AIDS deﬁning illnesses (ADI) was higher (35.1%). The most common
adverse drug effect observed was hepatitis (14.3%). A Kaplan Meier
of survival showed 50% of deaths occurring in the ﬁrst four months of
TB treatment. Comparison of patients who were receiving highly active
antiretroviral therapy (HAART) and mortality did not yield signiﬁcant
results.
Conclusion: Even though the sample size of this study was limited, it
can be suggested that mortality of TB/HIV patients is high. Starting
HAART early for TB-HIV patients whose CD4 count is less than 130
can reduce the rate of mortality.
P1619 Unusual association of tuberculous meningitis and cerebral
toxoplasmosis in a HIV-negative patient. Case report
A. Slavcovici, C. Marcu, M. Lupse, C. Itu, D. Carstina (Cluj-Napoca, RO)
Objective: To underline the concordance/discordance of aetiologic
diagnosis with neuroimagistic assesments.
Case report: A 7-year-old child, with prolonged neonatal jaundice,
non-investigated and without any subsequent results, was admitted in
our clinic for high fever, headaches, vomiting, second degree coma,
nuchal rigidity and left hemiparesis. The cerebral magnetic resonance
imaging (MRI) was negative. The examination of the cerebrospinal ﬂuid
(CSF) revealed discreet lymphocytic pleocytosis, a moderately increased
protein concentration and a very low glucose level (12mg%), suggesting
a tuberculous meningitis. The usual CSF cultures, Gram stain and Ziehl–
Neelsen stain examinations were negative, as well as the HIV test. After
doing CSF culture using MB/BacT system, a speciﬁc tuberculostatic
therapy was initiated (isoniasid, rifampicin, ethanbutol, pyrazinamide),
associated with cerebral depletion (manitol), dexamethasone, and
vitamins B1 and C. 30 days later, the M. tuberculosis strain was isolated
and identiﬁed with susceptibility to classical antituberculosis drugs. The
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clinical status worsened with the persistence of the fever, coma and
the neurologic signs, and with the occurrence of seizures. After 14
days of treatment, the neuroimaging assesment (cranial CT) described
important cerebral edema and multiple round hypodensity areas in the
frontal and parietal lobes, and in the caudatus and lentiform nucleus;
these ﬁndings needed other serological examinations. Toxoplasmosis
Ig M antibodies were detected in high level (ELISA method). We
reevaluated the diagnosis as a proven tuberculous meningitis and a
probable cerebral toxoplasmosis, with unknown time of infection, which
might be either a recent one, or a reactivation of a congenital one. The
treatment was continued with antituberculosis drugs in association with
trimethoprim/sulfamethoxazole, pyrimethamine and folinic acid. The
adjunctive therapy consisted of cerebrolisine, and vitamins B1 and C.
After 4 days of antituberculosis and antitoxoplasmosis treatment, the
outcome was rapidly favourable, without fever and with substantial
remission of the neurological signs.
Conclusions: The risk factor for cerebral toxoplasmosis was the
immunodepression induced by M. tuberculosis. The association of
mycobacterial infection with cerebral toxoplasmosis in a HIV negative
patient is rare. The importance of cranial CT in an unfavourable evolution
of the central nervous system infections is relevant.
P1620 Primary tuberculosis of the breast mimicking breast cancer
B. Nasr, B. Borzouei, A. Nasserabadi, M. Ahmadi (Hamedan, IR)
Background: Tuberculosis of the breast is seen quite rarely. It is mainly
classiﬁed as primary and secondary forms. Primary form is rarer.
The gold standard for diagnosis of the disease is detection of the
aetiologic agent, Mycobacterium tuberculosis, by using Ziehl–Neelsen
staining or culture. However, smear positivity for acid-fast bacilli by
Ziehl–Neelsen staining is low, and in most cases, tuberculosis of the
breast can only be accurately diagnosed by histological identiﬁcation of
the typical necrotising granulomatous lesion.
Case report: A 49-year-old woman with complaints of breast lump
and swelling of her right breast, which had appeared 40 days earlier,
was admitted in our hospital. Her medical history was unremarkable.
On physical examination, a hard mass (5×5 cm), which caused nipple
retraction in the upper outer quadrant of the right breast, was
observed. In laboratory ﬁndings she had WBC=9,000 (neu = 38%,
lym= 60%, mono = 2%), Hb = 12.7 g/dL and HCT= 38. Ultrasonography
examination revealed hypoechoic mass with signiﬁcant ductal dilatation,
without collection and lymphadenopathy, which suggested mastitis.
Mammography, which was performed in another clinical setting,
suggested a malignant tumour (70×50mm) with irregular border. Tc-
99m sestamibi scan revealed abnormal large focal sestamibi uptake with
T/N ratio = 1.45 which suggested malignant lesion.
The mass was excised by using surgery. After surgery, pathologic
examination reported necrotising granulomatous lesion, which conﬁrmed
breast tuberculosis. The patient had no abnormal ﬁndings on computer
tomography (CT) of chest but the result of a tuberculin skin
test was positive. After conﬁrmation of the diagnosis, the patient
received antituberculosis therapy (rifampin, isoniazid, ethambutol, and
pyrazinamide). She was currently being followed-up and the disease was
showed no signs of recurrence one year after treatment.
Discussion: Breast tuberculosis is classiﬁed as primary and secondary
forms. CT is useful in differentiation of primary and secondary breast
tuberculosis. Pathologic conﬁrmation is required for diagnosis. Although
tuberculosis of the breast is rare, it should be considered as a possible
diagnosis, particularly in countries where tuberculosis is endemic. The
prognostic of breast tuberculosis is favourable.
P1621 Early effective treatment of cutaneous infection with
Mycobacterium chelonae complex after rapid molecular
identiﬁcation
J. Hopman, A. Langewouters, T. Kroese, P.D.J. Sturm (Nijmegen, NL)
Objectives: Slow-growing as well as rapid-growing Mycobacteria can
cause cutaneous infection. The latter speciﬁcally in immunocompro-
mised patients. The clinical diagnosis may be delayed due to recurrent
skin lesions. Rapid diagnosis and identiﬁcation aids in the initiation of
appropriate therapy.
Methods and Results: A 50 y.o. male patient had received a renal
transplant 10 years ago for which he used azathioprine and prednison.
He presented to a dermatologist with a 2 month history of recurrent skin
lesions on his right lower leg and pain of his right foot. A diagnosis of
gout was suspected and allopurinol was administered. After a few days,
brownish nodules appeared on the right leg which eventually ulcerated
with purulent discharge. Subsequently, the lesions healed slowly, leaving
behind violaceous maculae with crusts. Flucloxacillin and clindamycin
respectively were started empirically with improvement of the skin
lesions. New purulent nodules developed after cessation of therapy. Now,
a clinical diagnosis of pyoderma gangrenosum was considered which
was conﬁrmed histologically. However, prednison improved symptoms
only temporarily. Histological examination of new skin biopsies showed
acid-fast bacilli. Meanwhile the foot was swollen with increased redness
and tenderness and an abscess was suspected. Acid fast staining of
surgically drained pus showed numerous PMNs and AFBs. A molecular
identiﬁcation of M. chelonae complex was available within 48 hours
and treatment could be initiated with clarithromycin. Amikacin was not
considered an option with respect to his renal function and tigecycline
was added as second agent.
Conclusion: Spontaneously resolving lesions have been described
previously in cutaneous mycobacterial infection and unfamiliarity with
this clinical presentation may result in a delayed diagnosis. Because a
rapid identiﬁcation was established with molecular methods, effective
antimicrobial therapy could be started early. Newer drugs, such as
tigecycline and linezolid, with in-vitro activity against rapid-growing
mycobacteria may be useful in future treatment of these infections.
P1622 Mycobacterium mucogenicum pulmonary infection in an
immunocompromised patient
Z. Gitti, I. Neonakis, E. Stylianoudaki, E. Papadopoulou, S. Maraki,
D. Spandidos (Heraklion, Crete, GR)
Background: Infections caused by non-tuberculous mycobacteria are
continuously increasing. Mycobacterium mucogenicum is a recently
characterised, rapidly-growing mycobacteria, rarely seen in human
infections. Here we report the clinical and laboratory ﬁndings of
a M. mucogenicum pulmonary infection in an immunocompromised
patient.
Case presentation: The patient was a 70-year-old male with non-
Hodgkin’s lymphoma. He was admitted with a low-grade fever of
37.7º C and dyspnea of two months duration. Clinical examination
revealed pulmonary involvement. A chest X-ray showed pulmonary
inﬁltrates, multiple nodular lesions, and perihilar adenopathy. Mantoux
skin test was negative. His past medical history was signiﬁcant
for chronic obstructive pulmonary disease and arterial hypertension.
Ziehl–Neelsen acid fast staining of the gastric ﬂuid was positive.
Liquid and solid cultures of the sample yielded mycobacteria. The
identiﬁcation of the isolate as M. mucogenicum was performed by
Genotype AS diagnostic reverse hybridisation strip test assay (Hain
Lifescience, Germany). Antimicrobial susceptibility was determined
by the E-test. The isolate was sensitive to cefoxitin, imipenem,
clarithromycin, azithromycin, doxycycline, linezolid, cotrimoxazole,
ciproﬂoxacin, sparﬂoxacin, moxiﬂoxacin, tobramycin. Combined therapy
with clarithromycin and ciproﬂoxacin for 4 months was proved effective.
Conclusion: Non-tuberculous mycobacteria can cause considerable
pulmonary infections in immunocompromised patients.M. mucogenicum
is most frequently found in the environment but is also incriminated for
human infections. Early diagnosis is important for the determination of
the appropriate treatment.
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P1623 Granulomatous hepatitis due to intravesical therapy by
BCG for superﬁcial bladder cancer
A. Hristea, V. Arama, R. Moroti, D. Nae, E. Angelescu, R. Sandu,
C. Tiliscan, V. Molagic, D. Munteanu (Bucharest, RO)
Between January 1996 and January 2006, 680 patients with superﬁcial
urinary bladder cancer were admitted to the Urology Department of
Clinical Institute Fundeni, Bucharest. After endoscopic resection they
received BCG immunotherapy according to international guidelines. The
following side effects have been noted: cystitis 92.3%, early macroscopic
haematuria (24−48 h after instillation) 53.8%, low-grade fever (24−36 h
after instillation) 46.1%, fever and chills for more than 7 days 7.6%,
BCG-related visceral granulomas or BCG sepsis 1.8%.
We report a case of disseminated BCG infection causing granulomatous
hepatitis in a 58-year-old man. His medical history included a non-
invasive transitional-cell carcinoma treated by surgery followed by
intravesicular instillation of BCG. The ﬁrst 6 weekly and the following
5 monthly BCG treatments were well tolerated. Two days after his
12th instillation he developed 39ºC fever and weakness followed
by jaundice. On admission he had 38.5ºC fever, a pulse rate of
104/min, jaundice and hepatosplenomegaly. Liver enzymes were elevated
(ALT 2N, AP 2.4N), bilirubin level of 7.6mg/dl (conjugated 7.3),
moderate inﬂammatory syndrome, proteinuria above 3 g/L, albumin level
of 2.2 g/L. Abdominal CT scan showed hepatosplenomegaly without
changing of bile ducts. He was started on empiric broad-spectrum
antibiotic. We noted the persistence of his symptoms and an increasing
cholestasis. A hepatic biopsy was performed and antibiotic therapy was
changed to corticosteroids. The patient’s condition improved over the
next 7 days. The result of the hepatic biopsy showed non-caseating
granulomas, suggesting mycobacterial spread, although the acid-fast
bacillus stains on tissue specimens were negative. In situ PCR conﬁrmed
the mycobacterial dissemination, despite the negative culture of blood
and urine for M. bovis. Antituberculous drugs were added to his
treatment and prednisone was discontinued within 3 weeks. Clinical and
laboratory improvement were marked and sustained so the patient could
be discharged home for a six-month course with an isoniazid–rifampin
combination.
Conclusion: The development of granulomatous lesion in distant organs
is an uncommon complication of immunotherapy with BCG vaccine.
Clinical and laboratory ﬁndings in our patient suggest the haematogenous
spread of mycobacteria to liver, as well as a hypersensitivity response.
P1624 Tenosynovitis caused by Mycobacterium haemophilum in a
patient with rheumatoid arthritis
P.C.A.M. Buijtels, P.A. vd Lubbe, E.J. Kuijper, L.E. Bruijnesteijn
van Coppenraet, P.L.C. Petit (Rotterdam, Schiedam, Leiden, NL)
Introduction: M. haemophilum can present with an array of symptoms
ranging from focal involvement to widespread disease. M. haemophilum
is a fastidious organism. Due to its speciﬁc growth requirements in vitro,
infections were not recognized until 1978.
Objective: Description of M. haemophilum infection diagnosed by real-
time PCR on clinical material.
Methods and Results: We describe a 71-year-old female patient with
rheumatoid arthritis who presented with chronic dorsal tenosynovitis
of the ﬁnger one month after intra-articular injection of steroids. Two
months after the manifestation of the tenosynovitis, a synovectomy
was performed. Histological examination revealed a granulomatous
necrotising inﬂammation by acid-fast bacteria. The culture for mycobac-
teria remained negative, but application of a Mycobacterium genus-
speciﬁc real-time polymerase chain reaction (PCR) in combination
with a M. haemophilum-speciﬁc PCR resulted in the recognition of
M. haemophilum as the causative agent.
The patient recovered completely after synovectomy and a 6 months
treatment by clarithromycin, ciproﬂoxacin and rifampicin.
Conclusion: M. haemophilum infections may be relatively under-
recognized and underreported. Only three patients with rheumatoid
arthritis and M. haemophilum infection have been reported in the
literature. The development of tenosynovitis after intra-articular injection
in the patient we described, is very suggestive for inoculation of
M. haemophilum via contaminated ﬂuid. The real-time PCR has shown
to be a signiﬁcant assay for detecting and identifying M. haemophilum
in clinical samples and may provide insight in the prevalence of
this nontuberculous mycobacterial infection and its clinical relevance.
Because autoimmune diseases like rheumatoid arthritis are increasingly
treated with immunosuppressive drugs clinicians should be aware of this
infection as it may become clinically more important in the future.
P1625 Using ELISPOT to expose false positive skin test conversion
in tuberculosis contacts
P. Hill, D. Jeffries, R. Brookes, A. Fox, D. Jackson-Sillah, M. Lugos,
S. Donkor, B. de Jong, T. Corrah, R. Adegbola, K. McAdam (Banjul, GM)
Objectives: Repeat tuberculin skin tests may be false positive due
to boosting of waned immunity to past mycobacterial exposure.
We evaluated whether an the booster ELISPOT test could be
used to distinguish new Mycobacterium tuberculosis infection from
phenomenon.
Methods: We conducted tuberculin and ELISPOT tests in 1,665 TB
contacts: 799 were tuberculin test negative and were offered a repeat
test after 3 months. Those test positive with 6mm increased induration
had an ELISPOT, chest X-ray and sputum analysis if appropriate. We
compared converters with non-converters and assessed the probability of
each of 4 combinations of ELISPOT results.
Results: 704 (72%) contacts had a repeat tuberculin test; 176 (25%) had
test conversion, which increased with exposure to a case (p = 0.002),
increasing age (p = 0.0006) and BCG scar (p = 0.06). 114 tuberculin
test converters had ELISPOT results: 16 (14%) were recruitment
positive/follow up positive, 9 (8%) positive/negative, 34 (30%) negative/
positive, and 55 (48%) were negative/negative. Approximately 38% of
skin test converters were estimated to have boosting. There was a
signiﬁcant non-linear effect of age for ELISPOT results in skin test
converters (p = 0.038). Three converters were diagnosed with TB, 2 had
ELISPOT results: both were positive, including one at recruitment.
Conclusions: We estimate that approximately 38% of tuberculin skin
test conversion in Gambian TB case contacts is due to boosting. This
varies with age. Use of ELISPOT only in tuberculin converters may lead
to delayed diagnosis of M. tuberculosis infection and disease. Further
studies are required to determine the relevance of ELISPOT reversion.
Methods for antimicrobial susceptibility
testing
P1626 Detection of resistance to linezolid in Enterococcus spp. by
ﬂuorescence in situ hybridisation using locked nucleic acid
probes
G. Werner, A. Essig, M. Bartel, N. Wellinghausen, I. Klare, W. Witte,
S. Poppert (Wernigerode, Ulm, DE)
Objectives: Resistance to linezolid, caused by mutation of one or
multiple alleles of the 23S rRNA gene, is emerging in Enterococcus spp.
especially in vancomycin-resistant Enterococcus faecium. Aim of the
study was to establish and evaluate a ﬂuorescence in situ hybridisation
(FISH) assay for the detection of the resistance mutation.
Methods: FISH probes containing a locked nucleic acid at the
mutation locus were labelled with FITC respectively Cy3 and used in
conjunction (LNA wild type: CCCAGCTCGCGTGC; LNA resistant:
CCAGCTAGCGTGC).
In a ﬁrst step a panel of 30 linezolid-sensitive (15) and -resistant (15)
Enterococcus strains was tested two times in a blinded manner. The
minimal inhibitory concentration (MIC) of enterococci to linezolid
was determined by microbroth dilution using Iso-Sensitest broth as
nutrient medium. In resistant isolates the number of mutated alleles was
determined using LabChip technology and BioAnalyzer 2100.
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In the second step 83 clinical isolates from blood cultures and VRE
screening agar plates were investigated by FISH in parallel to broth
dilution using the Merlin Micronaut System.
Results: FISH consistently correctly recognized all 30 well characterised
isolates as susceptible respectively resistant. Concerning the clinical
isolates seventy-nine isolates were rated susceptible and one isolate as
resistant by both methods. Three E. faecium isolates that were measured
repeatedly susceptible by broth dilution, gave a positive result with
the linezolid-resistance as well as with the wild type probe indicating
presence of mutated and non mutated alleles. All three isolates showed a
single mutated 23S rDNA allele when pooled 23S rDNA PCR fragments
were digested with NheI and resolved on a LabChip 1000.
Conclusion: FISH using LNA probes is a rapid, cheap and easy
performable method that showed 100% sensitivity and speciﬁcity for
determination of presence of resistance genes to linezolid in E. faecium.
P1627 Comparison between MicroScan system and agar dilution
method for quinupristin/dalfopristin susceptibility of
Enterococcus faecium
Y-R. Kim, Y.J. Kim, S.I. Kim, Y.J. Park, M.W. Kang (Seoul, KR)
Objectives: Quinupristin/dalfopristin (Q/D) is one of the effective
antimicrobials in treating vancomycin resistant E. faecium, but Q/D
resistant E. faecium was observed frequently using MicroScan as a tool
for routine antibiotic susceptibility test. We compared the results of Q/D
susceptibility test by the Positive Combo Panel Type11 of the MicroScan
Walk Away 96 (Dade Behringer) with those obtained by reference agar
dilution method.
Methods: We collected consecutively 65 E. faecium isolates non-
susceptible to Q/D (42 resistant, 23 intermediate), and selected randomly
32 E. faecium isolates susceptible to Q/D by MicroScan system from
September 2003 to August 2004. All isolates were identiﬁed in Kangnam
St. Mary’s Hospital Clinical Microbiology Laboratory using MicroScan
system. For Q/D non-susceptible isolates, MIC of Q/D, vancomycin and
teicoplanin for were determined by agar dilution method according to
the CLSI guidelines, and for Q/D-susceptible (by MicroScan), MIC of
Q/D was measured by agar dilution method.
Results: The agreement rates are shown in Table 1. The MIC of Q/D
resistant isolates by agar dilution method were all 4 ug/mL except one,
that is low-grade resistant. Of the Q/D-resistant isolates, most were
susceptible to vancomycin and teicoplanin (78% and 82%) respectively.
Conclusion: Of the Q/D resistant E. faecium, the major error rate
was 11.9%, which is over the acceptable range (3%). If the Q/D
susceptibility test to Q/D results ’resistance’ by MicroScan, it is needed
to conﬁrm the results using reference method. There may be another
factor except Q/D use in hospitals or virginiamycin use in animals for
high rates of glycopeptide-susceptible and Q/D resistant E. faecium.
Table 1. Comparison of Q/D susceptibility test by Microscan and agar
dilution method
No of isolates according
to susceptibility category
Susceptibility category by Microscan
(No. of isolates)
by agar dilution method Susceptible
(32)
Intermediate
(23)
Resistant
(42)
Resistant 0/32 (0%) 14/23 (60.9%) 36/42 (85.7%)
Intermediate 0/32 (0%) 6/23 (26.1%) 1/42 (100%)
Susceptible 32/32 (100%) 3/23 (13.0%) 5/42 (11.9%)
P1628 Fluoroquinolone resistance in nalidixic acid-resistant
Escherichia coli
S. Bengtsson, M. Sundqvist, O. Samuelsen, N. Krrh, A. Sundsfjord,
G. Kahlmeter (Va¨xjo¨, SE; Tromsoe, NO)
Objectives: The Swedish Reference Group on Antibiotics (SRGA) and
the Norwegian Working Group on Antibiotics (NWGA), recommend
the use of a nalidixic acid (NAL) 30mg disc for the detection of
ﬂuoroquinolone (FQ) resistance in Enterobacteriacae. Recently the
European Committee on Antimicrobial Susceptibility Testing (EUCAST)
harmonised European ﬂuoroquinolone breakpoints. We wanted to
determine to what extent NAL overestimates clinical resistance to FQ
in Escherichia coli as deﬁned by EUCAST and Clinical Laboratory
Standards Institute (CLSI) and compare these breakpoints with EUCAST
epidemiological cut-off values.
Methods: 149 consecutive NAL-resistant E. coli from urine samples
collected in Kronoberg county, Sweden, June 2004–January 2005
were investigated. The antibiotics included were ciproﬂoxacin (CIP),
levoﬂoxacin (LVX), moxiﬂoxacin (MXF), norﬂoxacin (NOR) and
oﬂoxacin (OFX). The minimum inhibitory concentrations (MIC) were
determined by Etest (AB Biodisk, Solna), qnr genes and aac(6′)-Ib
with PCR and all strains were typed with PhP-typing. EUCAST and
CLSI breakpoints (2006) and epidemiological cut-off values were used
to deﬁne resistance.
Results: All NAL-resistant isolates showed reduced susceptibility
(higher MIC than epidemiological cut-off values) to the studied FQs
except for LVX and MXF where 37% and 66% of the isolates showed
MIC values inside respective wild type distribution. NAL-resistant
strains would be reported susceptible for CIP in 52% of the isolates,
LVX 55%, MXF 52%, NOR 24% and OFX 27% using EUCAST clinical
breakpoints. With CLSI clinical breakpoints, CIP would be reported
susceptible in 54% of the isolates, LVX 55%, MXF (no CLSI approved
breakpoints), NOR 54% and OFX 52%.
Conclusion: The EUCAST and CLSI breakpoints showed good
agreement for CIP and LVX. However, using CLSI breakpoints for
NOR and OFX would result in reporting 30% and 25%, respectively,
as susceptible while EUCAST would have classiﬁed them as non-
susceptible. In situations where there are few treatment alternatives,
the FQ-susceptibility should be further investigated in NAL-resistant
isolates. FQ-resistance is increasing rapidly and the risk that during
therapy these strains may develop more pronounced FQ resistance must
be weighed against the therapeutic beneﬁts. The fact that so many of
the NAL-resistant E. coli isolates appeared devoid of all signs of any
resistance mechanisms to LVX and MXF is probably due to the higher
activity against topoisomerase IV of these agents.
P1629 Comparison of antimicrobial susceptibility tests for the
detection of KPC-positive strains of Klebsiella pneumoniae
S. Whittier, F. Wu, P. Della-Latta (New York, US)
Objective: The emergence of multi-drug resistant organisms is a tremen-
dous challenge for New York City hospitals. As the armamentarium of
antibiotics for Gram-negative bacteria [GNB] remains stable, resistance
is on the rise, leaving clinicians limited choices for treatment regimens.
Accurate and rapid detection of these multi- or pan-resistant GNB by the
microbiology laboratory is critical both for therapy and infection control
purposes. We examined the performance of 3 antimicrobial susceptibility
tests [AST] and one screening method for the detection of carbapenem
resistance due to KPC production by Klebsiella pneumoniae [KP].
Methods: Forty clinical isolates of KP were identiﬁed as KPC positive
by PCR, which was designed to detect two mutation points in
the purported blaKPC coding region. These isolates were tested for
imipenem [IM] and meropenem [MP] susceptibilities by the following
methods: Microscan Walkaway (Dade Behring, West Sacramento, CA),
VITEK2 (bioMeriuex, Durham, NC) and E test (AB Biodisk, Solna,
Sweden). 2006 CLSI guidelines were utilised for interpretation of MIC
data. The ertapenem disk (BD, Sparks, MD) was also used as a screen
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for carbapenem resistance. Ten KPC negative isolates of KP were also
included as negative controls.
Results: Of the 40 KP isolates, 36 were identiﬁed by PCR as KPC
type 2 and 4 were KPC type 3. Ten carbapenem susceptible isolates
were KPC negative by PCR. When IM and MP results were examined,
the abilities of Microscan, VITEK and E test to correctly determined
resistance were 90%, 85% and 20%, respectively. The ertapenem disk
screen correctly identiﬁed 100% of KPC positive strains. All systems
accurately determined MIC values for the 10 KPC negative isolates.
Conclusions: We evaluated 3 AST systems for their ability to
accurately detect carbapenem resistance. This study demonstrated that
the Microscan and E test performed favourably when compared to PCR,
however VITEK2 did not. We also found that the ertapenem disk test is
a reliable predictor of CB resistance.
P1630 Moraxella catarrhalis susceptibility testing; development of
a CLSI disc diffusion method
J.M. Bell, L.J. Walters, J.D. Turnidge (North Adelaide, AU)
Objectives: At present there is only CLSI susceptibility testing
standards for the species Moraxella catarrhalis (MCAT) for a broth
microdilution (BMD) method. MCAT is isolated frequently from
respiratory specimens, and resistance to a variety of agents has
emerged or is emerging. It is implicated in a range of clinical
syndromes, especially acute otitis media, acute bacterial sinusitis and
acute exacerbations of chronic bronchitis. It has established that broth
microdilution susceptibility testing works reliably. The aim of this study
was to develop a disk diffusion method, and interpretative zone diameter
correlates for the tentative MIC breakpoints, including molecular data
on resistance mechanisms.
Methods: Three hundred well characterised MCAT isolates were tested
against penicillin, ampicillin, amoxicillin/clavulanic acid (2:1 ratio),
ampicillin/sulbactam (2:1 ratio), meropenem, cephalexin, cefaclor, tetra-
cycline, trimethoprim/sulfamethoxazole, erythromycin, clarithromycin,
azithromycin, telithromycin, cefuroxime, rifampin, chloramphenicol,
moxiﬂoxacin, ceftriaxone, ciproﬂoxacin, gentamicin; using CLSI sus-
ceptibility standards for broth microdilution and disc diffusion. Custom
made dry-form BMD panels (Trek Diagnostic Systems) were used.
The disk diffusion method used Mueller-Hinton agar without blood
supplementation, CLSI standard disk strengths and incubation in 5%
CO2 for 20−24 h.
All isolates were conﬁrmed as MCAT and b-lactamase enzymes typed
by PCR. Isolates with elevated tetracycline MICs were tested for the
presence of tet(B) or tet(M) efﬂux genes.
Results: A signiﬁcant number of isolates did not grow on Mueller-
Hinton Agar in air. Disc diffusion tests were therefore incubated in 5%
CO2. On-scale MIC values were obtained for all antimicrobials tested,
except for meropenem where the majority of MICs were 0.004mg/L.
Using the current CLSI disc strengths many of the antimicrobials
tested produced large zone diameters. Eighteen isolates were b-lactamase
negative. Of the b-lactamse positive isolates, 18 typed as BRO-2; all
had lower ampicillin/penicillin MICs than those strains typed as BRO-1.
All isolates with tetracycline MIC> 1mg/L harboured tet(B). Twelve
isolates had elevated (0.25mg/L) ciproﬂoxacin MICs. No erythromycin
resistant strains were found.
Conclusion: Although incubation in 5% CO2 was necessary, and large
zones were obtained, zone diameter correlates could be estimated based
on the current CLSI breakpoints.
P1631 Moxiﬂoxacin MIC results for Neisseria gonorrhoeae
(ATCC49226) for an eight lab study by CLSI agar dilution
methodology
L. Koeth, J. DiFranco (Westlake, US)
Objectives: This study was performed in order to establish a MIC
quality control range for N. gonorrhoeae (ATCC49226) according to
CLSI M23-A2 for agar dilution methodology.
Methods: Moxiﬂoxacin was tested at concentrations of 0.002–
0.25mg/mL using 3 different manufacturers of GC agar base media
(Remel, Accumedia and PML) and 1% deﬁned growth supplement
(Remel). Ciproﬂoxacin was also tested as the control drug at
concentrations of 0.0025 to 0.03 ug/mL using 1 lot of media. 10
replicates of the QC strain were tested for each of the media lots by
eight U.S. laboratories on each of two days.
Results: Of the total 434 moxiﬂoxacin MICs evaluated, 100% were
within a four well range of 0.004 to 0.03 ug/mL and 97% were within
a three well range of 0.008 to 0.03 mg/mL. All ciproﬂoxacin MICs were
within the CLSI established range of 0.001 to 0.008 mg/mL (90.6% of
MICs at 0.004 ug/mL). The modal moxiﬂoxacin MIC for 7 of the 8 labs
and 2 of the 3 media lots was 0.016 mg/mL. The moxiﬂoxacin MICs
for 1 lab and PML media were slightly lower (mode of 0.008mg/mL.).
There was also a higher incidence of poor or no growth with the PML
media. The average inoculum concentration was 5×104 CFU/spot. MIC
distributions for all labs are shown in the table.
Antimicrobial agent MIC (mg/mL) number of occurrences: Total n
0.001 0.002 0.004 0.008 0.016 0.030
Moxiﬂioxacin 13 58 334 29 434
Ciproﬂoxacin 1 12 145 2 160
Conclusions: When performing agar dilution MIC testing according
to CLSI methodology, a quality control range for N. gonorrhoeae
(ATCC49226) versus moxiﬂoxacin of 0.004 to 0.03mg/mL is recom-
mended.
P1632 Comparison of BD Phoenix Automated System and Etest to
broth microdilution method for antimicrobial susceptibility
testing of multiple resistant Pseudomonas aeruginosa and
Acinetobacter spp.
P. Zarakolu, O. Ozcakir, G. Hascelik, S. Unal (Ankara, TR)
Objectives: To compare the BD Phoenix Automated System (Becton
Dickinson Diagnostic Systems, Sparks, MD, USA) and Etest (AB
Biodisk, Solna, Sweden) to broth microdilution method for antimicrobial
susceptibility testing of multiresistant Pseudomonas aeruginosa and
Acinetobacter spp. for some of the commonly used antibiotics in our
hospital.
Methods: Pseudomonas aeruginosa (n = 61) and Acinetobacter spp.
(n = 61) strains isolated from different clinical samples of patients
with hospital infections in Hacettepe University Adult Hospital in
January 2004–July 2005 were included in the study. The isolates were
identiﬁed by BD Phoenix Automated System and stored at −80ºC
until study time. Antimicrobial susceptibility testing by Phoenix System
and Etest method were performed according to the manufacturers’
instructions and interpretive categories (resistant, intermediate, sus-
ceptible) were determined. Broth microdilution method, according to
CLSI guidelines was used as the reference method. The antimicrobials
tested in the study were piperacillin, cefepim, ceftazidim, meropenem,
ciproﬂoxacin and tobramycin. For evaluation, essential and categorical
agreements were determined.
Results: The isolates were multiple ( 3) resistant to the antimicrobials
tested. The overall category agreement was 63.7%; with the very major,
major and minor error rates 2.8%, 19.1%, 14.5%, respectively when
Phoenix System were compared to microdilution method. However,
when Etest antimicrobial susceptibility results were compared to the
reference method, the overall essential agreement was 58.9%; the
category agreement was 69.0% with the very major, major and minor
error rates 3.3%, 15.3%, 12.3% respectively.
Conclusion: Clinicians should be aware of the conﬂicting antimicrobial
susceptibility results by different testing methods while facing difﬁculties
with the infections due to multiresistant nonfermentative bacteria.
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P1633 Accuracy of b-lactam susceptibility testing results from
VITEK and VITEK2 systems when testing Pseudomonas
aeruginosa
V. LaBombardi, V. Rekasius, P. Schreckenberger, R. Jones (New York,
Maywood, North Liberty, US)
Objectives: To critically assess VITEK and VITEK2 accuracy for
determining b-lactam susceptibility (S) when testing P. aeruginosa
(PSA). Recent publications have questioned the interpretative and
quantitative agreement of various automated systems especially for
piperacillin/tazobactam (P/T), cefepime (FEP), and aztreonam (AZM).
A collaborative multi-site study tested local (LOC) clinical strains and
selected challenge (CH) strains.
Methods: This study was performed in 3 sites (Emory University/CDC,
Atlanta, GA; St. Vincent’s Hospital [STV], New York, NY; Loyola
University Medical Center [LUMC], Maywood, IL) with each site
testing strains by one or more automated methods e.g. VITEK by
CDC and LUMC; and VITEK2 by CDC and STV. Each processed
30 PSA (15 LOC and 15 CH) that included an equal distribution of
isolates S and resistant (R) to b-lactams. The tested agents were AZM,
FEP, ceftazidime (CAZ), imipenem (IPM), piperacillin (PIP) and P/T.
Utilised cards/software were: for VITEK (GNS-122/WSVTK-R10.01)
and for VITEK2 (AST-6N09/WSVT2-R04.02). Reference methods were
reference frozen-form panels, Etest and disk diffusion methods using
standardised CLSI procedural details or manufacturer instructions.
Quality Control (QC) was assured via concurrent testing, and all
presented data were associated with acceptable QC results.
Conclusions: PSA were tested by VITEK and VITEK2 and results were
observed as unacceptable for all 6 agents. VME was common with IPM,
PIP and P/T (15.0–21.7%), and mE with signiﬁcant skewing toward false
R (11.0–21.0%) was noted for AZM, FEP and CAZ. These systematic
errors adversely affect local antibiograms (empiric choices), individual
patient care, and require corrective action by the manufacturer.
Results: Analyses compared VITEK and VITEK2 results to those
produced by the reference broth microdilution test, and consensus
categorical results from all reference methods. A signiﬁcant bias toward
S or R was deﬁned as a shift of 10% for S rate when using the
commercial product. Unacceptable levels of intermethod error were
found using both applied analyses. Elevated minor error (mE; limit 10%)
was noted for both systems with AZM (18.3–33.3%), FEP (13.3–36.7%),
CAZ (16.7–23.3%) and IPM (13.3–26.7%). Serious, very major error
(VME; false-S) several-fold greater than acceptable limit (1.5%) was
detected for P/T with lesser degrees of ME and VME for PIP. Error
rates by each system were distributed among LOC and CH strains and
test sites.
Errors produced when testing 30 P. aeruginosa against 6 b-lactam agents by VITEK
and VITEK2 automated systems.
System/Antimicrobial agent (no. tested) Percentage of errora
Compared to
BMD result
Compared to
consensus result
VME VM ME VME VM ME
VITEK
Aztreonam (60) 0.0 3.3 18.3 0.0 5.0 31.7
Cefepime (60) 1.7 0.0 36.7 1.7 0.0 36.7
Ceftazidime (60) 1.7 0.0 20.0 1.7 3.3 16.7
Imipenem (60) 8.3 0.0 13.3 6.7 0.0 10.0
Piperacillin (60) 0.0 8.3 NA 0.0 6.7 NA
Piperacillin/tazobactam (60) 15.0 5.0 NA 15.0 5.0 NA
VITEK2
Aztreonam (60) 1.7 0.0 28.3 0.0 0.0 33.3
Cefepime (60) 0.0 0.0 13.3 1.7 0.0 16.7
Ceftazidime (60) 3.3 0.0 23.3 1.7 0.0 21.7
Imipenem (60) 6.7 0.0 25.0 5.0 0.0 26.7
Piperacillin (60) 5.0 0.0 NA 6.7 0.0 NA
Piperacillin/tazobactam (60) 21.7 1.7 NA 20.0 0.0 NA
Unacceptable levels of error are underlined. NA = not applicable.
P1634 Critical assessment of P. aeruginosa susceptibility testing
results for six b-lactams using the BD Phoenix system
S. Juretschko, T. Beavers-May, C. Essmyer, R. Jones (Little Rock,
Kansas City, North Liberty, US)
Objectives: To study the accuracy of commercial automated systems
when testing P. aeruginosa (PSA) due to escalating and recent reports
of interpretive error. Documented high error rates were recorded for
b-lactams tested by MicroScan WalkAway, VITEK and VITEK2 when
compared to CLSI methods ranging from false-resistant (ME; major) to
false-susceptible (VME; very major) results. Although in depth studies
comparing automated systems have been reported, the BD Phoenix
System has limited intermethod data for PSA, with susceptibility (S)
test results often interpreted by non-CLSI criteria; thus, a 2-laboratory
study was designed to validate Phoenix PSA results.
Methods: 60 tests were produced by local processing of 15 recent
clinical strains (RCS) from each site (Arkansas Children’s Hospital
and St. Luke’s Regional Laboratories) and 15 challenge strains (CS)
representing equal numbers of PSA that were S and resistant (R) to the
tested b-lactams (aztreonam[AZM], cefepime[FEP], ceftazidime[CAZ],
imipenem[IPM], piperacillin[PIP] and piperacillin/tazobactam[P/T]).
Each strain was tested by Phoenix (panel NMIC-112; software
V5.15A/04.11B) and compared to CLSI broth microdilution (BMD)
results or to the consensus result from BMD, disk diffusion test (DD) and
Etest. Errors were deﬁned as VME, ME and minor (mE; intermediate
by one method) guided by M23-A2.
Results: The table compares Phoenix categorical results and the
consensus results from 3 validated methods. Unacceptable rates of
mE (16.7–36.7%) occurred with AZM, FEP and CAZ, regardless of
reference result utilised for analysis. Results were consistent between
sites, RCS or CS subsets, and with prior publications that showed
compromised categorical agreement. For AZM, the mE level was
associated with systematic bias toward false-R. In contrast, IPM, PIP
and P/T had generally acceptable error rates or were only marginally
elevated.
Conclusions: This rigorous challenge of the Phoenix to assess the PSA
susceptibility versus key b-lactams displayed error rates indicating a
modest need for re-evaluation (AZM). Automated systems have been
documented to produce inaccurate results with trending toward false S
as well as R. Clinical laboratories should be aware of these interpretive
problems for PSA testing and seek alternative, validated methods such
as simple agar diffusion tests (DD and Etest). Among the automated
systems evaluated to date, the Phoenix appears to possess the fewest
b-lactam/PSA testing discords.
Types of intermethod errors when testing 30 P. aeruginosa isolates by
the automated Phoenix system in two laboratoriesa.
Antimicrobial agent (no. tested) % error types compared to consensusb
Very Major Major Minor
Aztreonam (60) 0.0 1.7 36.7
Cefepime (60) 0.0 1.7 18.3
Ceftazidime (60) 1.7 0.0 16.7
Imipenem (60) 0.0 0.0 1.7
Piperacillin (30) 0.0 3.3 NA
Piperacillin/tazobactam (60) 1.7 5.0 NA
aResults from two laboratories (Arkansas Children’s Hospital and St.
Luke’s Regional Laboratories). bConsensus of broth microdilution, disk
diffusion and Etest categorical results. Unacceptable levels of error
are underlined and mE was associated with a systematic trend toward
false-R. NA = not applicable.
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P1635 An evaluation of MicroScan WalkAway results for broad-
spectrum b-lactams when testing Pseudomonas aeruginosa
S. Lerner, H. Salimnia, L. Steed, J. Bosso, R. Jones (Detriot,
Charleston, North Liberty, US)
Objectives: To compare contemporary clinical (CL) and challenge
(CH) strains of Pseudomonas aeruginosa (PSA) susceptibility (S)
test results from an automated system (MicroScan WalkAway; 2
laboratories) against 6 broad-spectrum b-lactams-to-results of reference
broth microdilution (BMD) and consensus results from 3 validated
methods (BMD, Etest, disk diffusion[DD]). Previous reports have
documented high minor (mE; 10−32%) and very major (VME; false-S;
19%) errors among anti-PSA b-lactams.
Methods: Each centre tested CH (15) strains of PSA that included
equally represented S and resistant (R) MICs across a wide range
for tested agents (aztreonam[AZM], cefepime[FEP], ceftazidime[CAZ],
imipenem[IPM], piperacillin[PIP], piperacillin/tazobactam[P/T]). 15 CL
strains were also tested by MicroScan WalkAway (panel no. NEGMIC30
or NC32 and software no. LabPro 2.01) and 3 reference methods
(BMD, Etest, DD). Categorical results from MicroScan WalkAway were
compared to CLSI BMD results (see Table) as well as the consensus
of all tests. Error limits for acceptability were those listed in M23-A2
guideline.
Error rates for the MicroScan WalkAway system when testing 30 P. aeruginosa
isolatesa
Antimicrobial agent (no. tested) Percentage of errorb
Compared to
BMD result
Compared to
consensus result
VME ME mE VME ME mE
Aztreonam (60) 0.0 3.3 21.7 0.0 3.3 23.3
Cefepime (60) 0.0 3.3 48.3 0.0 3.3 45.0
Ceftazidime (60) 1.7 6.7 23.3 0.0 6.7 20.0
Imipenem (60) 0.0 1.7 11.7 1.7 1.7 10.0
Piperacillin (60) 10.0 3.3 NA 15.0 3.3 NA
Piperacillin/tazobactam (60) 5.0 1.7 NA 10.0 0.0 NA
aResults from University of South Carolina (Charleston, SC) and Wayne State
University, Detroit Medical Center (Detroit, MI).
bBMD: reference broth microdilution MIC results. Consensus result was
determined from the BMD, disk diffusion and Etest values. Unacceptable levels of
error are underlined.
NA, not applicable.
Results: The table shows the comparisons of categorical agreement and
the listed error rates occurred equally between participant sites and
organism populations (CH, CL). Markedly elevated rates of mE were
observed for AZM (21.7–23.3%), FEP (45.0–48.3%) and CAZ (20.0–
23.3%), regardless of reference result selected for comparative analysis.
More serious errors by MicroScan WalkAway of false-R (major-error;
ME) were also noted for the same agents, but false-S (VME) was
detected (5.0–15.0%) for PIP and P/T. For drugs showing unacceptable
mE or serious interpretive errors (ME), a systematic bias toward false-R
MicroScan WalkAway results was found for AZM (10.0%), FEP (48.3%)
and CAZ (16.7%). The skewing toward R was most extreme for FEP
(3-fold greater than CAZ). PIP and P/T results trended toward false-S
(VME) at a level of 10.0–11.7%.
Conclusions: These results corroborate ﬁndings of others that some
automated susceptibility testing systems perform poorly when testing
b-lactam agents against PSA. Error rates documented in our medical
centres for MicroScan WalkAway, using diverse PSA collections clearly
indicates false-S and -R trends that seriously compromise patient care as
well as misdirecting empiric treatment choices and formulary decisions.
We recommend that our colleagues employ alternative methods such as
agar diffusion tests (DD, Etest) to more accurately assess antimicrobial
S among PSA.
P1636 Pilot evaluation of Innovotech bioFILM PA susceptibility
test for clinical utility in the treatment of cystic ﬁbrosis
patients infected with Pseudomonas aeruginosa
R.P. Rennie, L. Turnbull, C. Brosnikoff, N.E. Brown, D.C. Lien,
B. Rawal, M. Olson (Edmonton, Alberta, Calgary, Alberta, CA)
Objective: To compare the Innovotech bioFILM PA susceptibility kit
designed for planktonic and sessile susceptibility testing with standard
broth micro-dilution susceptibility testing for application in the treatment
of cystic ﬁbrosis (CF) patients infected with Pseudomonas aeruginosa
(Pa).
Methods: 25 strains of Pa isolated from CF patients were tested by
CLSI broth microdilution for susceptibility. The same strains were
then tested with the Innovotech bioFILM PA kit. Isolates were grown
ﬁrst in trypticase soy broth (TSB) and inoculated into wells of the
Innovotech bioFILM PA kit. The sessile inoculating peg lid was placed
on top of the tray containing inoculum and TSB and rocked gently
on a rocker overnight at 35ºC. The sessile inoculating 96 peg lid
was then placed into a 96 well tray containing anti-pseudomonal
antimicrobials in cation-adjusted Mueller Hinton broth (CAMHB) at
CLSI breakpoint concentrations. This tray also contained combinations
of agents commonly used for Pa therapy. After overnight incubation,
the planktonic susceptibility was recorded, and the 96 peg lid was then
placed on a second recovery tray containing CAMHB. After overnight
incubation, the bioﬁlm susceptibilities were determined.
Results: Standard CLSI broth microdilution MICs and Innovotech
planktonic breakpoints (S, I, R) were within the same range. There were
no major or very major errors. For sessile organisms, the Innovotech
MICs were often greater than for the planktonic forms. Tobramycin
combined with colistin, ciproﬂoxacin or meropenem were active against
many of the bioﬁlm cultures. These combinations may be useful for
treatment of bioﬁlm infections in these CF patients. When tested alone,
standard planktonic MICs often indicated resistance to these agents.
The breakpoints of the susceptible combinations were within the ranges
clinically achievable with standard therapeutic doses of these agents.
Conclusions: These ﬁrst attempts to utilise a susceptibility test system
(Innovotech bioFILM PA kit) that better mimics the bioﬁlms of Pa in
the respiratory tract of CF patients provide early support for the use
of this device to assist with appropriate antimicrobial therapy in CF
treatment. In a small number of CF patients our results have suggested
that combination bioﬁlm MICS may have clinical utility. Further studies
are underway to conﬁrm these observations. (This device has been
approved for use by Health Canada; FDA clearance is pending.)
P1637 Evaluation of the in vitro activity of levoﬂoxacin and
moxiﬂoxacin tested against Stenotrophomonas maltophilia:
can moxiﬂoxacin activity be predicted by levoﬂoxacin MIC
results?
A. Gales, R. Jones, M. Janechek, H. Sader (Sao Paulo, BR; North
Liberty, US)
Objective: To evaluate the in vitro activity of levoﬂoxacin (LEV) and
moxiﬂoxacin (MXF) tested against S. maltophilia and the correlation
between MIC values for these ﬂuoroquinolones (FQ) compounds in order
to assess if LEV susceptible (S) strains could be categorised as MXF-S.
Methods: A total of 763 unique S. maltophilia strains collected
worldwide through the SENTRY Antimicrobial Surveillance Program
(2002–2005) were tested for S against LEV, MXF and selected
antimicrobials by broth microdilution methods according to CLSI
guidelines. MIC results were interpreted according to CLSI and
EUCAST breakpoints. CLSI has LEV breakpoints of (S/resistant [R] in
mg/L) 2/8 for S. maltophilia and other Gram-negative bacilli (GNB)
and no MXF breakpoints except for Gram-positive pathogens; while
EUCAST has GNB breakpoints for LEV (1/4 for Enterobacteriaceae
[ENT], Acinetobacter and P. aeruginosa) and MXF (0.5/2 for ENT
only).
S462 17th ECCMID / 25th ICC, Posters
Results: LEV showed good in vitro activity against S. maltophilia
(MIC50, 1mg/L and MIC90, 2mg/L) with 85.8% S at the CLSI
breakpoint, but only 70.3% if EUCAST breakpoints were applied.
Scattergram with the correlation between the MXF and LEV MIC results
is shown in the comparison Figure.
By applying the CLSI LEV breakpoints (2/8mg/L) and MXF
breakpoints at1/4mg/L, the overall categorical agreement was 95.5%
with only 0.1% very major (VM; false-S), no major (MA; false-R)
and 4.3% minor (MI) errors. Using EUCAST ENT breakpoints (LEV
includes P. aeruginosa and Acinetobacter spp.), the overall agreement
was 93.3% with no VM or MA error and 7.7% MI error. S rates for
ciproﬂoxacin were 29.5 and 10.0% when GBN S breakpoints of CLSI
and EUCAST were applied, respectively.
Scattergram showing correlation between levoﬂoxacin and moxiﬂoxacin
MIC results for S. maltophilia. Solid lines indicate CLSI breakpoints,
dashed lines indicates EUCAST breakpoints.
Conclusions: The spectrum of LEV against S. maltophilia decreases
signiﬁcantly if EUCAST breakpoints are used in preference to CLSI
breakpoints. There was an excellent correlation (r = 0.93) between LEV
and MXF MIC results and categorical results for LEV may be used to
predict categorical results for MXF if breakpoints were one doubling
dilution lower than that of LEV. However, clinical studies may be
necessary to establish the role of these FQs in the treatment of
S. maltophilia infections, but achieving a critical number of case studies
would be difﬁcult.
P1638 Comparison of methods for penicillinase detection in
S. aureus
M. Kaase, S. Lenga, F. Szabados, T. Sakinc, A. Anders, S. Friedrich,
S.G. Gatermann (Bochum, DE)
Background: Penicillin resistance in S. aureus is mediated by four
types of Penicillinases encoded by the blaZ gene. Because penicillin is
considered superior to oxacillin in those rare isolates with true penicillin
susceptibility, correct determination of penicillinase is important.
Laboratories using the VITEK2 for susceptibility testing of S. aureus
have to use an additional test for b-lactamase detection for those isolates
with an MIC of  0.12mg/L.
Methods: We investigated several methods for penicillinase detection,
like size and character of penicillin inhibition zones, nitroceﬁn testing,
cloverleaf assay, starch iodine plates and an in-house blaZ-PCR for
isolates with an MIC  0.12mg/L in the VITEK2.
An isolate was considered penicillinase positive if either the blaZ-PCR,
the nitroceﬁn test read after 15min, the cloverleaf assay or the penicillin
zone edge appearance suggested the presence of a penicillinase.
Results: Of 274 isolates 50 (18.2%) were penicillinase positive.
Sensitivities were 80% for penicillin zone edge appearance, 62% for
an penicillin inhibition zone diameter 28mm, 52% for the nitroceﬁn
test read after 15min, 74% for the cloverleaf assay, 58% for starch iodine
plates and 88% for the blaZ-PCR. Isolates with a MIC of 0.12mg/L and
0.06mg/L in the VITEK2, respectively were penicillinase positive in
24.2% and 6.2%.
Conclusion: Cloverleaf assays, penicillin zone edge determination and
blaZ-PCR are superior to starch iodine plate and nitroceﬁn testing for
the detection of penicillinase in S. aureus.
P1639 Assessment of cefoxitin MICs with the BD Phoenix® system
to detect methicillin-resistant Staphylococcus aureus isolates
M.I. Morosini, M. Garcı´a-Castillo, E. Loza, F. Baquero, R. Canto´n
(Madrid, ES)
Cefoxitin (FOX) disks have demonstrated to enhance MRSA detection
when compared with oxacillin (OXA) disks but information with FOX
MICs is scarce. Automated systems are often used in clinical laboratories
but, in some cases, they are not proﬁcient enough to recognize
heterogeneous MRSA (especially low level resistant populations).
Objectives: BD Phoenix was evaluated for the detection of methicillin
resistance in clinical S. aureus with both OXA and FOX MICs. Results
were compared with those of reference microdilution and disk diffusion
(CLSI), and Etest methods. In addition, BD Phoenix was challenged
to detect OXA resistance (R) in artiﬁcially mixed cultures containing
different proportions of OXA-susceptible (S) and OXA-R populations.
Methods: A total of 159 S. aureus isolates prospectively recovered
from blood cultures along 1998–2005 were studied. S. aureus ATCC
(29213, 43300, 33591, and 25923) strains were used as quality controls.
PCRs for mecA detection were performed in isolates with OXA
MIC range of 1–16mg/L representing isolates close to the OXA
susceptibility breakpoints. Detection of PBP2a with the MRSA latex
agglutination test (Slidex®, bioMe´rieux) was carried out. Mixed broth
cultures with different proportions [75:25, 90:10 and 99:1] of OXA-S
(29213) and OXA-R (43300, heterogeneous) or (33591, homogeneous)
strains, respectively, were used to challenge the BD Phoenix.
Results: A total 27% of MRSA isolates was detected. When considering
OXA results, 100% of categorical agreement was observed between
all methods. All OXA-R strains were mecA positive. However, a false
methicillin–S strain (but mecA and PBP2a positive) was detected with
FOX data obtained only with BD Phoenix and disk diffusion. Overall
mean time to methicillin results availability was of 6 hours. Interestingly,
BD Phoenix was able to detect the presence of methicillin-R bacteria
even in the 99:1 mixture (lowest proportion of OXA-R population)
through OXA and FOX MICs.
Conclusion: BD Phoenix compared favourably to reference tests.
Although all methods failed to detect a MRSA strain, only BD Phoenix
and disk diffusion FOX results phenotypically revealed such resistance.
BD Phoenix, when challenged with mixed OXA-S/OXA-R populations,
was able to detect methicillin-R irrespective of bacterial proportions. BD
Phoenix system enhances routine detection of MRSA, particularly those
with low level expression of resistance.
P1640 Evaluation of cefoxitin disks to detect methicillin-resistant
coagulase negative staphylococci
J.W. Mouton, M.T. Bohne, C.H. Klaassen, A.M. Horrevorts,
H.A. de Valk, A. Voss (Nijmegen, NL)
Objectives: For S. aureus, the use of cefoxitin disks is the recommended
method to screen for methicillin resistance (MetR). A similar method has
been suggested for coagulase negative staphylococci (CNS) but it is not
clear which method performs best. Speciﬁcity is compromised since CNS
consists of multiple species and every species has its own characteristics,
including the discriminatory effect on zone diameters. We investigated
4 different methods (2 disks and 2 media) to determine the cut-off zone
diameters to achieve a high speciﬁcity and sensitivity to distinguish metR
from metS CNS. These values were also determined at the species level.
Methods: 250 CNS were isolated from blood cultures or other relevant
sites of infection and stored at −70ºC. Strains were revived by plating
on blood agar. The next day, colonies were suspended to obtain an
adequate inoculum to result in semiconﬂuent growth (Iso Sensitest agar)
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or conﬂuent growth (Mueller Hinton agar). A 10 and 30mg cefoxitine
disk (Oxoid) was placed on each 9 cm agar plate and incubated for 24 h at
35ºC. Zone diameters (mm) were read in two directions to one decimal.
Identiﬁcation was performed by AFLP and partial 16S rRNA gene
sequencing. The mecA gene was identiﬁed by a LightCycler method.
Results: 167 strains were metR and 83 metS. Of the four methods, the
30mg disk on MH performed best, but there was considerable overlap
in zone size between metR and metS strains. Setting the sensitivity at
100% resulted in a speciﬁcity of 67%. At the species level, the median
zone diameter for metS S. epidermidis (N = 128) and S. hominis (N = 38)
was 30.7mm and 26.6mm respectively. A 100% sensitivity as well as
speciﬁty at the species level was obtained at cut offs of 27.5mm and
17mm, respectively.
Conclusion: The method best discriminating between metR and metS
strains was MH with conﬂuent growth and a 30mg disk but with a
relatively poor speciﬁcity of 67%. Speciation increased both sensitivity
and speciﬁcity to 100% for S. epidermidis and S. hominis.
P1641 Validation of Etest for susceptibility testing of moulds with
posaconazole
A. Yusof, A. Engelhardt, P. Ho, A˚. Karlsson, A. Wanger (Solna, SE;
Texas, US)
Background: Posaconazole is a new broad spectrum triazole shown to
be highly active against many species of ﬁlamentous fungi including
Aspergillus, Fusarium, Penicillium and Trichophyton. The performance
of Etest Posaconazole was compared to the CLSI broth microdilution
method (BMD) using a study design to fulﬁl the CE marking require-
ments according to the European Directive for in vitro diagnostic devices.
Method: Etest Posaconazole was compared to BMD in a two site
study involving clinical, stock and challenge organisms. A total
of 217 strains were tested: A. fumigatus (52), A. ﬂavus (40),
A. nidulans (6), A. terreus (16), A. niger (18), A. versicolor (9),
A. ustus (5), A. sydowii (3), Aspergillus spp. (10), F. oxytoca (5),
F. solani (4), Fusarium spp. (13), Rhizopus spp. (11), P. boydii (7),
S. apiospermum (12), Acremonium spp. (3), Alternaria spp. (2) and
Cladosporium spp. (1). 25 identical strains were used to examine
inter-laboratory reproducibility, and 4 ATCC reference strains to
generate quality control speciﬁcations. Inoculum density checks to
verify CFU/mL were done using the quality control and reproducibility
organisms and 10% of clinical isolates. Etest was used according to the
manufacturer’s instructions and BMD according to M38A, Vol 22, No16.
Results: Essential agreement found between Etest and BMD are shown
in the table.
Species N MIC range EA± 2 dilution
Aspergillus spp. 10 0.002–0.125 100
A. niger 18 0.008–0.38 100
A. terreus 16 0.008–0.19 100
A. ﬂavus 40 0.032–0.25 100
A. fumigatus 52 0.023−1.5 98
A. nidulans 6 0.047–0.125 100
A. versicolor 9 0.023−32 100
A. sydonii 3 0.064–0.125 100
A. ustus 5 0.25−32 100
F. oxytoca 5 0.125−2 100
F. solani 4 0.047−32 100
Fusarium spp. 13 0.5−32 100
S. apiospermum 12 0.094−2 100
Rhizopus spp. 11 0.047−32 91
P. boydii 7 0.125−2 100
Aeremonium spp. 3 0.023−2 100
Cladosporium spp. 1 0.094 100
Alternaria spp. 2 0.047–0.094 100
Conclusion: Etest Posaconazole was found to be reproducible for testing
of ﬁlamentous fungi and MIC results were substantially equivalent to the
CLSI reference method. In the absence of interpretive breakpoints for
new agents such as posaconazole, Etest provides a practical alternative
for full range MIC testing.
P1642 Evaluation of the BACT/ALERT 3D system for testing
susceptibility of Mycobacterium tuberculosis to ﬁrst-line
antituberculosis agents: comparison with BacTec MGIT
960 and Lowenstein-Jensen proportion method
C. Guney, A. Suel, T. Karagoz, Y. Yorulmaz (Istanbul, TR)
Objectives: The performance of the BACTALERT 3D (BTA) system for
the testing of Mycobacterium tuberculosis susceptibility to streptomycin
(STR), isoniazid (INH), rifampin (RIF) and ethambutol (ETH) was
evaluated with 101 clinical isolates and compared with BACTEC MGIT
960 (M960) system and Lowenstein-Jensen (L-J) proportion method
(currently used) from clinical specimens at Sureyyapasa Chest Disease
Hospital.
Methods: A series of different samples recovered from patients in
hospital were cultivated in three systems at the same time according
to NaOH %3+NALC decontamination protocol. BTA and M960
susceptibility testing was performed as described by instructions of
manufacturers. M. tuberculosis H37Rv (ATCC27294) standard strain
was used for quality control of the all tests.
Results: In all, there were 404 test combinations with a total of 19
discrepancies (4.7%) between M960 and BTA results. Total agreements
were 95.3%. The discrepancies resolved in favour of the M960 system
in 11 cases and in favour of the BTA system in 8 cases according to
L-J proportion method. The BTA system produced 3 very major errors
(VME) and 8 major errors (ME), while the M960 showed 2 VME and
6 ME. No statistically signiﬁcant differences were found. The mean
times of detection for BTA and M960 were 16.3 days and 12.2 days,
respectively. Two smear negative sputums detected by BTA in 26 and
36 days were not detected by M960. Turnaround times from detection
to reporting SIRE results for BTA and M960 were 12.8 and 11.4
days, respectively. No statistically signiﬁcant differences were found.
The contamination rate for BTA, MGIT and L-J were 2%, 4%, 3%
respectively.
Conclusion: Some discordant results between the standard test and
the test method could be attributed to the presence of borderline-
resistant strains, mainly in relation to LJ tests where the ﬁnal results
depend on an accurate count of colonies. These results suggest that
BACTALERT 3D system is a valid alternative to the BACTEC MGIT
960 for M. tuberculosis susceptibility testing.
P1643 Comparison of quality of drug susceptibility testing of
Mycobacterium tuberculosis by absolute concentration
method and BACTEC 460
A. Baranov, S. Presnova, N. Nizovtseva, I. Trekin, L. Gvozdovskaja,
L. Yendaurova, A. Mariandyshev, G. Bjune, E. Heldal, T. Mannsaker
(Oslo, NO; Murmansk, Archangel, Syktyvkar, Petrozavodsk, RU)
The study has been carried out in 4 administrative territories of the
North-western federal region of Russia. Namely, in Archangel oblast,
Murmansk oblast, Republic of Karelia and Republic of Komi.
Objectives: The aim of our study was to ﬁnd rates of agreement of
DST between absolute concentration method, routinely performed at
the Russian laboratories, and the reference method – BACTEC 460,
performed at the National Reference Laboratory for Mycobacteria of
the Norwegian Institute of Public Health (NIPH).
Laboratory at the Archangel Regional Anti-tuberculosis dispensary has
been involved in DST quality assurance programmes on different levels
for many years. The main component of these programmes was the
collaboration with the reference laboratory at NIPH. Data on this
collaboration from previous years is not presented in this manuscript.
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Methods: In total, 88 strains ofM. tuberculosis were analysed and results
for these strains were compared for both methods. In addition to the
computing of the overall percent agreement for each drug, kappa test
has been used. The following arbitrary divisions for interpreting the
results of kappa test have been used: under 0.20 is negligible; from 0.21
to 0.40 is minimal; from 0.41 to 0.60 is fair; from 0.61 to 0.80 is good;
and over 0.81 is excellent.
Results: The highest rates of agreement were observed for isoniazid
and rifampicin, 95.5% (CI; 88.8–98.8) and 97.7% (CI; 92.0–99.7),
respectively. They also had the highest k-values 0.90 (CI; 0.80−1.0) and
0.96 (CI; 0.89−1.0), which correspond to excellent agreement beyond
chance between investigating methods. Streptomycin and kanamycin
had agreements in 93.2% (CI; 85.8–97.5) and 90.9% (CI; 82.9–96.0)
in all tested strains, respectively, with k-values 0.85 (CI; 0.73–0.97)
and 0.78 (CI; 0.64–0.92). These k-values mean from good to excellent
agreements. The lowest rate of agreement was found for ethambutol, in
85.2% (CI; 76.1–91.9) of cases. This is consistent with relatively low
k-value for this drug 0.70 (CI; 0.56–0.85), which means from fair to
good agreement between investigating methods.
Conclusion: These ﬁndings suggest that, currently, the results of
absolute concentration method for isoniazid and rifampicin can serve
as a reliable diagnostic tool. This is very important for diagnosis and
treatment of MDR tuberculosis.
P1644 Sensitivity to colistin: evaluation of available interpretive
criteria of disc diffusion test
I. Galani, F. Kontopidou, P. Rekatzina, J. Deliolanis, M. Souli,
A. Antoniadou, H. Giamarellou (Athens, GR)
Objectives: Increased antibiotic resistance in Gram-negative bacteria
isolated in ICUs of tertiary-care hospitals, has augmented the use of
colistin (CL) in recent years, since it is the only available active agent
against these isolates. However CLSI and EUCAST does not currently
provide interpretive criteria for disc susceptibility as there is very little
data on the accuracy of disc testing methods for CL. In this study,
we evaluate the accuracy of two available interpretive criteria of disc
susceptibility testing for CL, compared to E-test.
Methods: A total of 409 clinical isolates of Acinetobacter baumannii
[AB] (178), K. pneumoniae [KP] (185) and Escherichia coli [EC] (46)
were included in the study. All strains were isolated from hospitalised
patients in 11 different tertiary hospitals. Isolates were tested by E-test
for susceptibility to CL, and results were compared with those obtained
by disc susceptibility testing method (DD). Two breakpoints were
evaluated, Gales et al. (JCM, 2001; 39: 183−90) (11 and 14mm)
and BSAC 2006 (14 and 15mm) and compared to MIC breakpoints
established by BSAC (>4 and 4mg/L) for Enterobacteriaceae and
Acinetobacter spp.
Results: CL displayed good activity against AB (MIC90 0.5mg/L), and
EC (MIC90 0.625mg/L) but was less active against KP (MIC90 32mg/L).
Forty-six (24.9%) KP, six (3.4%) AB and two (4.3%) EC strains were
resistant (R) to CL according to the E-test method. Totally, 16.4% and
5.5% of CL-resistant isolates were falsely reported as susceptible (S)
when evaluated by the two available criteria, respectively. Applying the
BSAC breakpoints decreased the very major error (R by E-test but S by
DD) to 1.5% from 2.9% compared to Gales et al criteria. On the contrary
major discrepancies (S by E-test but R by DD) were found in 45% of
strains tested with BSAC recommendations while 11.5% of minor errors
(R by E-test and intermediate by DD) were found during application of
Gales et al criteria.
Conclusion: Use of the BSAC criteria decreased the very major errors
but signiﬁcantly increased the major errors when compared with the
breakpoints proposed by Gales et al. Disc susceptibility testing methods
are unreliable at detecting CL resistance. E-test or dilution methods
should be the method of choice for susceptibility testing of CL as
zone diameter interpretive criteria exhibiting good correlation with MICs
seems difﬁcult to establish.
P1645 Comparative evaluation of the VITEK2, disk diffusion,
E-test, and agar dilution susceptibility testing methods
for colistin in clinical isolates (including heteroresistant
E. cloacae and A. baumannii strains)
J. Lo-Ten-Foe, A. de Smet, B. Diederen, J. Kluytmans, P. van Keulen
(Tilburg, Utrecht, Breda, NL)
Objectives: The increasing use of colistin necessitates the availability
of rapid and reliable methods for colistin susceptibility testing. We
compared four methods of colistin susceptibility testing.
Methods: Disk diffusion (Rosco), agar dilution, E-test (Biodisk) and
VITEK2 (bioMe´rieux) colistin susceptibility testing methods were used
in 102 clinical isolates collected from patient materials during a Selective
Digestive Decontamination or Selective Oral Decontamination trial in
an intensive care unit. The agar-based tests were performed on both
Mueller-Hinton (MH) agar and Isosensitest (IS) agar. All isolates were
tested and compared to the agar dilution reference method. BSAC
breakpoints for colistin were used for media containing IS agar. For MH
agar containing media CLSI breakpoints were used for interpretation.
Results: The error rates of the different colistin testing methods
compared to the reference agar dilution method are summarised in
table 1.
Table 1. Error rates compared to the reference agar dilution methoda.
VM M MI
Disk diffusion MH 18% 4% 25%
E-test MH 4% 0% 0%
E-test Isosensitest 0% 3% 7%
VITEK2 8% 0% 0%
aVM, very major error; M, major error; MI, minor error.
High error rates and low levels of reproducibility were observed in
the disk diffusion test. The colistin E-test and the VITEK2 showed
>90% agreement with the agar dilution reference method. We found no
signiﬁcant differences in the performance of either of these test media.
Heteroresistance for colistin was observed in 6 E. cloacae isolates and
in 1 A. baumannii isolate. Heteroresistant isolates could be detected in
the agar dilution, E-test, or disk diffusion tests. The VITEK2 displayed
a low sensitivity in the detection of heteroresistant subpopulations of
E. cloacae. Heteroresistance was easier detected using Isosensitest agar
and seemed to be induced upon exposure to colistin rather than being
caused by stable mutations.
Conclusion: Disk diffusion method is an unreliable method to measure
the susceptibility to colistin. The VITEK2 colistin susceptibility test is
a reliable tool to determine the susceptibility to colistin in isolates that
do not exhibit heteroresistance. The E-test is also a reliable method
to measure colistin susceptibility and detect heteroresistant isolates.
Heteroresistance was observed in several E. cloacae and in A. baumannii
isolates. It is not clear whether these colistin resistant subpopulations are
truly clinically signiﬁcant or are representing in vitro artifacts.
P1646 Detection of low-level resistance to carbapenems using the
VITEK2 and the advanced expert system
Z. Afkou, K. Kontopoulou, D. Soﬁanou, M. Tsivitanidou (Thessaloniki,
GR)
Objectives: Metallo-b-lactamases (MBLs) are plasmid mediated ß-
lactamases conferring resistance to all ß-lactams except aztreonam.
These acquired MBLs recently have been spread among Enterobacte-
riaceae. Many of enterobacteria, possessing MBL genes exhibit low-
level resistance to carbapenems or appear susceptible by the routine
techniques and pass unnoticed in most cases. Our objective was the
evaluation of VITEK2 automated system to detect low-level resistance
to carbapenems.
Methods: A total of 33 Enterobacteriaceae isolates (2 Escherichia coli,
9 Enterobacter cloacae, 22 Klebsiella pneumoniae) recovered from
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clinical specimens at Hippocration General Hospital were studied. The
identiﬁcation and susceptibility testing were performed by using the
VITEK2 automated system (bioMe´rieux, France).
All isolates resistant to ceftazidime, cefoxitin and cefotaxime were
characterised as resistant or intermediate to imipenem (IMP) by the
automated system. The strains were tested by disk-diffusion method ac-
cording to CLSI breakpoint criteria. IMP-EDTA double disk synergy test
was carried out to screen the production of MBL. Molecular investigation
was used to conﬁrm the presence of plasmid-mediated MBL.
Results: By the VITEK2 automated system 18 isolates (54.5%) were
characterised as intermediate to imipenem (MIC= 8mg/mL) while the
remaining 15 (45.5%) were resistant (MIC> 16). By the disk diffusion
method 1 isolate (3%) was intermediate (diameter 14−15mm), 9 strains
(27.2%) were resistant (diameter 13mm) and 23 strains (69.8%) were
susceptible (diameter >16mm). Double disk synergy test using an
imipenem disk and an EDTA disk was positive in all strains
indicating the MBL production. Additionally, all isolates were positive
in PCR assays with blavim speciﬁc oligonucleotides.
Conclusions: This study demonstrated the capacity of VITEK2 to detect
low-level resistance to carbapenems. This automated system combined
with EDTA synergy test is able to detect MBL producers in clinical
laboratories. The early detection of MBLs permits the selection of
appropriate treatment and the implementation of strict infection control
measures in order to prevent their spread in the hospital.
P1647 Evaluation of Etests for determining tigecycline MICs by
BSAC methodology
R. Hope, S. Mushtaq, D. Livermore (London, UK)
Introduction: Etests are calibrated against MICs determined using
Clinical and Laboratory Standards Institute (CLSI) methods, with
Mueller Hinton media. Most UK laboratories however use British Society
for Antimicrobial Chemotherapy (BSAC) susceptibility testing methods,
with IsoSensitest agar. We tested the agreement between tigecycline
MICs determined by Etest and BSAC agar dilution methods.
Method: Isolates (n = 558) were selected from the BSAC 2004
bacteraemia surveillance collection and other collections held at
the reference laboratory. They comprised: 63 Acinetobacter spp.,
44 alpha-haemolytic streptococci, 45 beta-haemolytic streptococci, 35
coagulase-negative staphylococci, 55 Enterobacter, 40 enterococci,
35 E. coli, 46 Haemophilus, 54 Klebsiella, 55 Proteeae, 21 Serratia,
35 S. pneumoniae, and 30 S. aureus, selected to cover the broadest
range of tigecycline MICs and to span the EUCAST/BSAC S/I/R
breakpoints. Tigecycline MICs were determined in parallel using Etests,
with conﬂuent growth on IsoSensitest agar, and by the BSAC agar
dilution method.
Results: MICs by agar dilution and Etest were within experimental
error (i.e. one doubling dilution) in 527/558 (94%) of cases and within
two dilutions in all cases. MICs by Etest nevertheless tended to be
slightly lower than by agar dilution (lower in 33% of cases vs. higher
in 10.5%), with this effect most evident for S. pneumoniae and other
alpha-haemolytic streptococci, all of which were very susceptible, (MIC
 0.5mg/L). alpha-haemolytic streptococci accounted for 22/27 cases
where MICs by Etest were 2 tubes lower than by agar dilution, despite
using a hand lens to seek microcolonies and the ﬁnal termination of
growth. Among Gram-negative isolates (n = 113) with agar dilution MICs
in the range 1−4mg/L (i.e. spanning the “top” end of susceptible,
through intermediate, to the “bottom” end of resistant with respect to
EUCAST/BSAC breakpoints), catergorisation agreement between agar
dilution and Etest MICs was 86%, with 14% minor errors and no major
or very major errors.
Conclusion: Tigecycline Etests used on IsoSensitest agar gave good
agreement with MICs determined using BSAC methodology. Categori-
sation agreement was good for isolates with borderline susceptibility or
resistance – a group where Etests are likely to be used to verify disc
based results. MICs for highly-susceptible alpha-haemolytic streptococci
tended to be underestimated by Etest, but this seems unlikely to be
consequential.
P1648 A new mass-spectrometric approach to antibacterial
susceptibility testing
V. Vereshchagin, E. Ilina, M. Atroshkina, M. Serebryakova, T. Maier,
M. Kostrzewa, V. Govorun (Moscow, RU; Leipzig, DE)
Objectives: Matrix-assisted laser desorption ionisation time-of-ﬂight
mass spectrometry (MALDI-TOF MS) is an established technique
for proﬁling bacterial proteins directly from cell extracts, providing
a reproducible spectrum within minutes. This technique is applied
for different microorganisms identiﬁcation and subtyping. We report
potentialities of this technique for the antibiotic susceptibility testing
remaining one of the principal assays of clinical microbiology.
Methods: All experiments were performed using laboratory strain
of Escherichia coli DH5a (E. coli). After cultivation during 14 h
at 37ºC using SOB agar, bacterial cells were transferred into liquid
media and cultured during 3 h. Then 1mL of bacterial culture
(106–107 cells/mL) was exposed to different concentrations (10–
100mg/mL) of the antibiotics ampicillin (AMP), ceftriaxone (CEF)
or tetracycline (TET) during 1, 2 or 3 hours. A sample without
antibiotics was used as control. Protein extraction was performed as
follows: (1) samples were centrifuged, pellet was solved with pure
water and then ethanol was added; (2) after centrifugation pellet was
added with 70% formic acid and pure acetonitrile, solution was mixed
well and centrifuged again. Supernatant was co-crystallised with matrix
(a-cyano-4-hydroxycinnamic acid) on a steel target plate. Using a
microﬂex MALDI-TOF mass-spectrometer (Bruker Daltonics, Germany)
reproducible spectra for different cultivating conditions were collected.
Results: After antibiotic treatment both small and signiﬁcant changes in
E. coli proﬁle were observed. They depend on the time of exposure,
antibiotic concentration and differ for different antibiotics. E. coli
spectra after AMP treatment show a signiﬁcant new peak (m/z 3822).
Similar results were obtained for TET: spectra show another new peak
(m/z 6970). The more exposure time increased, the worse spectra (AMP,
TET, CEF) were obtained. As for CEF, dramatic suppression of spectra
for 2- and 3-hour exposures was observed.
Conclusion: The suggested approach has great advantages such as
requiring only a small amount of biological material, easy sample
preparation, highly accurate measurement with low cost per analysis.
Mass spectra have speciﬁc alterations under antibiotics exposure. Very
likely these changes reﬂect some molecular events accompanying
cell death. Thus direct mass-spectrometric analysis of whole bacterium
cell has great potential to be used as rapid technique for antibiotic
susceptibility testing.
P1649 Determination of antibiotic breakpoints using a novel
electrochemical respiratory activity assay
T. Mann, O. Hammarstrom, D. Burca, L. O’Hagan, D. Sparkes,
S. Mikkelsen (Kitchener, Waterloo, CA)
Objective: We have developed a rapid respiration-based electrochemical
method for determining antibiotic breakpoint susceptibility of microor-
ganisms, including Gram-positive, Gram-negative, aerobic and anaerobic
bacteria. Respiratory activity measurements made on a suspended
bacterial isolate in the absence/presence of an antibiotic provide results
in 35 minutes.
Methods: Measurements of respiratory activity have been made on
25 microorganisms to date using a biamperometric method and
an electrochemical mediator cocktail containing ferricyanide and
dichlorophenolindophenol. A bacterial isolate was initially incubated for
20 minute with various biochemicals and the antibiotics. Ferricyanide
was then added to the suspension where it was reduced to ferrocyanide
by the microorganism’s respiratory activity, during a 10 minute reaction
time. The ferrocyanide was quantitated by a 2 minute biamperometric
measurement made with two platinum electrodes and a 100 mV
applied potential. In parallel with these measurements, standardised disk-
diffusion tests were undertaken to determine whether the organism was
to be classiﬁed as resistant, intermediate or susceptible. These standard
microbiological results were then compared to electrochemical results
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obtained with the new method, and were used to build up a correlation
database. Predictive algorithms were created to determine susceptibility
results, based on the database values.
Results: Classiﬁcation of the bacteria as susceptible, resistant or
intermediate was possible based on the new respiratory activity
measurements. Preliminary results (n = 2,000) using simple discriminate
models predicted either susceptibility or resistance with greater than
80% categorical agreement between the biamperometric respiratory
activity method and the disk-diffusion method for a range of 25
bacteria to 30 antibiotics from several classes having different modes
of action. The scientiﬁc basis for the new respiratory measurements
and the results obtained with the new respiratory activity–disk diffusion
correlation database will be presented along with the statistical methods
for breakpoint susceptibility determination.
Conclusions: Antibiotic breakpoint testing based on respiratory activity,
measured electrochemically following exposure of bacteria to an
antibiotic, allowed classiﬁcation with greater than 80% categorical
agreement. Further development is underway to examine statistical
methods that will improve classiﬁcation accuracy.
P1650 Use of clustering techniques for the prediction of micro-
biologic breakpoints, in well established bacteria-antibiotic
pairs and in the Acinetobacter spp.–tigecycline combination
F. Fernandez, D. Curcio, M. Galas (Capital Federal, AR)
Objectives: Evaluate the potential of data-mining clustering techniques
in the detection of strains with different behaviour with respect to
its susceptibility measured by size of inhibition zone (SIZ), and in
the prediction of microbiologic breakpoints. Secondarily, we explore
its application to set a proposed breakpoint for Acinetobacter spp.–
Tigecycline (ASP−TIG).
Methods: We used 5 datasets, 4containing the values of SIZ of
bacteria-antibiotic pairs with well-deﬁned breakpoints, Escherichia coli-
ciproﬂoxacin (ECO-CIP; n = 19,857).
Staphylococcus aureus-oxacillin (SAU-OXA; n = 7,006), enterococci-
ampicillin (ENT-AMP; n = 2417), Klebsiella pneumoniae-ceftazidime
(KPN-CAZ; n = 3,064) and 1 with no established breakpoint, ASP-TIG
(n = 336).
Subpopulation Pair Value type Mean SD Breakpoint
Susceptible SAU-OXA Predicted 20.6132 3.2112 12.34
Actual 20.5380 3.2834 13
ECO-CIP Predicted 32.6523 4.0805 22.14
Actual 32.6520 4.0806 21
ENT-AMP Predicted 26.8536 3.7885 17.09
Actual 26.8540 3.7894 17
KPN-CAZ Predicted 28.6576 2.4451 22.35
Actual 26.3330 4.3723 18
ASP-TIG Predicted 21.5549 1.8532 16.78
Actual NAa NA NA
Resistant SAU-OXA Predicted 6.3353 1.2834 9.64
Actual 6.1299 0.6584 10
ECO-CIP Predicted 7.6686 3.5242 16.75
Actual 6.9649 2.1790 15
ENT-AMP Predicted 6.2493 1.3373 9.69
Actual 6.2493 1.3391 16
KPN-CAZ Predicted 16.2532 7.6563 35.97
Actual 8.4537 2.8475 14
ASP-TIG Predicted 17.8589 1.3420 21.32
Actual NA NA NA
aNA, not available.
K-means algorithm was used to divide subpopulations and a normal
probability distribution was ﬁtted to each one. The 99% probability
inferior limit of the subpopulation with greater values was selected to
predict susceptibility breakpoint. First, we had evaluated that established
breakpoints was near that limit in the distribution of susceptible bacteria-
antibiotic pairs.
Results: We could obtain 2 clusters clearly deﬁned in the 5 subsets.
Values of mean, standard deviation (SD), and predicted breakpoints
for susceptible subpopulations sharply corresponded to the values of
subpopulations deﬁned by well-established breakpoints, except for KPN-
CAZ (Table 1). For ASP-TIG we show predicted values since actual ones
are not available.
Conclusion: By this method we could discriminate susceptible from
resistant subpopulations when the histogram of SIZ shows a normal
shape by visual inspection. When the shape is not normal, predicted
values were far from actual ones, as in the case of KPN-CAZ. In the
case of ASP-TIG pair, the histogram has normal shape, and the predicted
value was between 16−17.
In vitro susceptibility of
Gram-negatives/ESBLs/anaerobes
P1651 Determination of PK/PD parameters of moxiﬂoxacin
against Bacteroides thetaiotaomicron in vitro at static and
at varying drug concentrations
A. Mayer-Bartschmidt, J. Schuhmacher, S. Do¨rlemann, M. Haas
(Wuppertal, DE)
Objectives: Moxiﬂoxacin (MXF) is the only marketed ﬂuoroquinolone
approved by the FDA as monotherapy for complicated intra-abdominal
infections. This study evaluated the antibacterial effect of MXF against
B. thetaiotaomicron, an obligate anaerobic bacterium implicated in intra-
abdominal abscesses. The PD parameters determined from in vitro data
were used to simulate the clinical therapeutic effect.
Methods: Time-kill curves with B. thetaiotaomicron ATCC29741 were
performed with a range of static concentrations between 0.25 and
20mg/mL of MXF under anaerobic conditions. Using a sigmoidal Emax
model, the PD parameters (maximal kill rate, EC50 value, Hill slope) as
well as derived parameters e.g. static concentration were calculated. In
addition, PD parameters were determined at varying drug concentrations
by using an in vitro one-compartment PK model. Starting concentrations
ranged between 0.25 and 4mg/mL, t1/2 was set to 13 h. Simulation of
number of colony-forming units (CFU) vs time-course in man following
MXF 400mg IV was performed using the PD parameters as determined
in vitro and the known PK parameters in man.
Results: MXF showed an MIC of 2mg/mL against B. thetaiotaomicron
ATCC29741 representing the susceptible breakpoint recommended by
CSLI. PD parameters for MXF derived from kill curves at static
drug concentrations or from a one-compartment model at varying drug
concentrations are summarised in the table. Simulation of the CFU vs
time course in humans after MXF 400mg IV predicts clinical success
against B. thetaiotaomicron ATCC29741: an approximate 1,000-fold
reduction in CFU is expected after 13 h.
PD parameter One-compartment Kill curves
Estimate CV (%) Estimate CV (%)
k0 (h−1) 0.781 4.54 0.84 9.74
zmax (CFU/mL) 2.66×109 37.1 2.4×109 10.8
kmax (h−1) 1.81 3.96 2.48 7.28
EC50 (mg/mL) 0.561 3.52 1.10 20.5
S 2.74 9.98 1.19 20.5
Static concentration (mg/mL) 0.507 n.c. 0.626 n.c.
Conclusions: MXF is highly active against B. thetaiotaomicron
ATCC29741. PK/PD simulations indicate likely clinical efﬁcacy in man.
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The MXF susceptible CSLI breakpoint of 2mg/mL for anaerobes is
supported by this study.
Research funding: Bayer HealthCare Pharmaceuticals
P1652 Susceptibility of extended-spectrum b-lactamase-producing
Escherichia coli strains causing nosocomially- and
community-acquired bacteraemia
E. Picon, J. Rodriguez-Bano, P. Gijon, J.R. Hernandez, M. Ruiz,
C. Pena, B. Almirante, M. Almela, R. Canton, A. Guerrero, M. Gimenez,
A. Oliver, J. Horcajada, G. Navarro, A. Coloma, A. Pascual on behalf
of the Red Espan˜ola de Investigacion en Patologia Infecciosa (REIPI)
Background: Community and nosocomially acquired bacteraemias
caused by extended-spectrum b-lactamase-producing Escherichia coli
(ESBL-Ec) are increasing in Spain. Therapeutic options for these
infections are scarce.
Methods: Prospective cohort study including all episodes of bacteraemia
due to ESBL-Ec from October/04 to January/06 in 13 hospitals from
6 areas in Spain. E. coli isolates were identiﬁed with API20E and
ESBL production was conﬁrmed according to CLSI guidelines. Sus-
ceptibility to 18 antimicrobial agents including ceftazidime, cefotaxime,
cefepime, piperacillin-tazobactam, amoxicillin-clavulanate, ticarcillin-
clavulanate, imipenem, meropenem, ertapenem, ciproﬂoxacin, nalidixic
acid, amikacin, gentamicin, tobramycin, trimethoprim-sulfamethoxazole,
fosfomycin, and tigecycline was determined by broth microdilution
following CLSI recommendations. For tigecycline EUCAST guidelines
were followed.
Results: We included 190 episodes of bacteraemia; 49.5% were
nosocomially-acquired and 50.5% were community-acquired. No dif-
ferences were found in the MIC and clinical category distribution
between community and nosocomial isolates. All the strains were
susceptible to the three carbapenems studied (imipenem, meropenem
and ertapenem) and tigecycline. The MIC50 and MIC90 of tygecycline
were 0.06mg/L. Among b-lactam/b-lactamase inhibitor combinations
piperacillin-tazobactam was the most active agent with 92% susceptible
strains, followed by amoxicillin-clavulanate and ticarcillin-clavulanate
(61% and 18% respectively). Aminoglycosides activity was as follows:
amikacin 98%, tobramycin 82% and gentamicin 80% of susceptible
strains, respectively. Ciproﬂoxacin and trimethoprim-sulfamethoxazole
were the less active agents with 33% and 39% of susceptible strains,
respectively.
Conclusions: ESBL-Ec is a relevant cause of community and
nosocomially acquired bacteraemia in Spain. The most active agents
against ESBL-Ec were carbapenems and tigecycline with 100% of
susceptible strains. No difference in susceptibility to antimicrobial agents
were found between nosocomial or community acquired isolates.
P1653 Determination of the minimum inhibitory and mutant
prevention concentration of tigecycline against clinical
isolates of E. coli and Klebsiella species
J. Blondeau, S. Borsos, C. Hesje (Saskatoon, CA)
Objectives: Tigecycline is the ﬁrst of the glycylcycline class of
antimicrobials and has reported in vitro activity against E. coli and
Klebsiella spp. The mutant prevention concentration (MPC) deﬁnes the
antimicrobial drug concentration threshold that block the growth of
resistant bacterial subpopulations that may be present in high density
bacterial populations such as those causing infection. We determined
MIC and MPC values for tigecycline against clinical isolates of E. coli
and Klebsiella spp.
Methods: Minimum inhibitory concentration (MIC) was in accordance
with the recommended Clinical and Laboratory Standards Institute
procedure by microbroth dilution using 105 cfu/mL tested against
doubling drug dilutions in appropriate media. For MPC testing 1010
CFUs were added to drug containing agar plates and incubated in
ambient temperature and atmosphere. The lowest drug concentration
preventing growth was recorded as the MIC or MPC depending on
method.
Results: For 24 E. coli clinical isolates, MIC50 (mg/L), MIC90 (mg/L)
and MIC (mg/L) range values were 0.031, 0.063, 0.031–0.125 with 96%
of strains having MICS 0.063; MPC50 (mg/L), MPC90 (mg/L) and
MPC (mg/L) range values were 0.5, 1, 0.05−1 with 96% of strains having
MPCs  1. For 24 Klebsiella spp. clinical isolates, MIC50, MIC90 and
MIC range values were 0.125, 0.5,  0.016−1 with 96% of strains having
MICs  0.5; MPC50, MPC90 and MPC range values were 8, 8, 2−8.
Conclusion: Tigecycline was active in vitro against E. coli and
Klebsiella spp. isolates having MIC90 values of 0.063 and 0.5mg/L
respectively. MPC90 values were 8-fold lower for E. coli (1mg/L) than
for Klebsiella spp. (8mg/L), however, therapeutic drug concentrations
exceed both of these values. Tigecycline appears to have a low propensity
to select for resistance for the organisms studied.
P1654 Determination of the minimum inhibitory and mutant
prevention concentrations of moxiﬂoxacin against clinical
isolates of E. coli and Klebsiella spp.
J. Blondeau, S. Borsos, C. Hesje (Saskatoon, CA)
Objective: The ﬂuoroquinolone (FQ) moxiﬂoxacin has in vitro potency
against Gram-negative bacilli – particularly the Enterobacteriaceae. The
mutant prevention concentration (MPC) deﬁnes the antimicrobial drug
concentration threshold that would require an organism to simultaneously
acquire two resistance mutations for growth in the presence of a FQ. We
measured the minimum inhibitory concentration (MIC) and MPC values
of moxiﬂoxacin against clinical isolates of E. coli and Klebsiella spp.
Method: MIC was determined in accordance with the recommended
CLSI procedure by microbroth dilution using 105 CFU/mL tested against
doubling drug dilutions in appropriate media. For MPC testing 1010 CFU
were added to drug-containing agar plates and incubated at ambient
temperature and atmosphere. The lowest drug concentration preventing
growth was recorded as the MIC or MPC depending on the method used.
Results: Data are shown in the Table. For E. coli, 91% of strains had
MIC values 0.031 and 86% of strains had MPC values 0.5. For
Klebsiella spp., 96% of strains had MIC values 0.25mg/L and 92% of
strains had MPC values 1mg/L.
MIC (mg/L) MPC (mg/L)
MIC50 MIC90 Range MPC50 MPC90 Range
E. coli (n = 23) 0.016 0.031 0.008−2 0.12 1 0.12−2
Klebsiella spp.
(n = 24)
0.031 0.12 0.016−2 1 1 0.25−2
Conclusion: Moxiﬂoxacin is highly active in vitro against E. coli and
Klebsiella spp. with MIC90 values of 0.031 and 0.12mg/L respectively.
By MPC testing, MPC90 values were 1mg/L – a value that is below
achievable serum drug concentration over the duration of the dosing
interval. Moxiﬂoxacin shows low propensity to select for resistance in
these organisms based on MPC measurements.
P1655 Time trends in odds ratios of antimicrobial susceptibility in
nosocomial and non-nosocomial Gram-negative infections
in Israel
A. Zalounina, M. Paul, S. Andreassen, L. Leibovici (Aalborg, DK;
Petah Tikva, IL)
Objectives: To study the changes in difference between antimicrobial
susceptibilities in hospital environment and community over time.
Methods: Clinically signiﬁcant, patient and episode unique, bloodstream
isolates (n = 5,790) were collected prospectively from adults between
1988–2004 at Rabin Medical Center, Israel. Bacteraemia was deﬁned
as nosocomial if it occurred 48 h or more following hospital
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admission. We analysed in-vitro susceptibilities of Escherichia coli,
Klebsiella spp., Pseudomonas spp. and Acinetobacter spp. For each
pathogen and antibiotic we calculated the Odds Ratios (OR) with 95%
conﬁdence intervals (CI) for susceptibility comparing non-nosocomial
vs. nosocomial isolates. ORs were plotted in blocks of 3 years.
Heterogeneity of the ORs across time was assessed by the Breslow-Day
test.
Results: Nosocomial infections comprised 47% of all cases. The results
for the most prevalent pathogen E. coli (44%) and 5 antibiotics
are shown in the chart below. The highest OR for non-nosocomial
E. coli being more susceptible than nosocomial was obtained for
ceftazidime during 1997–1999 (9.9, CI: 3.4–29.0). We observed 2 main
patterns of ORs changes over time. In the ﬁrst, ORs increased over
time followed by a decrease (observed for E. coli and all antibiotics
except quinolones; Acinetobacter and amikacin; Klebsiella spp. and
ceftriaxone or aminoglycosides). In the second pattern, ORs decreased
with time (observed for Pseudomonas and piperacillin; Acinetobacter
and imipenem). ORs for quinolones ﬂuctuated over time. The test on
heterogeneity disclosed signiﬁcant changes in ORs over time for E. coli
with ceftazidime and ceftriaxone, Pseudomonas spp. and ciproﬂoxacin
(p< 0.05).
Conclusion: For the majority of the pathogen/antibiotic combinations
the OR starts relatively low, indicating low resistance both in community
and in the hospital, then rises due to the appearance of resistance in the
hospital and ﬁnally descends again, indicating diffusion of resistance
from the hospital to the community.
P1656 Susceptibility of Acinetobacter spp. to antimicrobial agents
with respect to their susceptibility to carbapenems
M. Sredkova, S. Mihaylova, V. Edreva, S. Pachkova, V. Grigorova,
H. Hitkova, V. Popova, K. Dragoev (Pleven, BG)
Objective: To compare susceptibility of carbapenem-resistant and
carbapenem-susceptible isolates of genus Acinetobacter to nine antimi-
crobial agents.
Methods: Four hundred and eighty-ﬁve clinical isolates of genus
Acinetobacter were tested. The in vitro activities of ampicillin/sulbactam,
azlocillin, piperacillin, ceftazidime, cefepime, imipenem, meropenem,
gentamicin, tobramycin, amikacin and ciproﬂoxacin were determined by
the disk diffusion method according to guidelines of the CLSI. In order to
be included in the study, Acinetobacter strains had to meet the following
criteria: to be isolated during the period 2002–2006, to be the ﬁrst isolate
from a patient and to be either susceptible or resistant to both imipenem
and meropenem. Student’s t test was used to compare groups.
Results: Carbapenem-resistant Acinetobacter spp. were more resistant
to all antibiotics tested in comparison to carbapenem-susceptible
isolates (p< 0.05). In general, A. baumannii showed superior resistance
than A. non-baumannii. The difference was signiﬁcant between
carbapenem-resistant A. baumannii and carbapenem-resistant A. non-
baumannii in case of susceptibility to ceftazidime, cefepime, gentamicin,
tobramycin and ciproﬂoxacin (p< 0.05). Carbapenem-susceptible strains
of A. non-baumannii possessed greater susceptibilities to azlocillin,
piperacillin, ceftazidime, cefepime, gentamicin, tobramycin, amikacin
and ciproﬂoxacin than did strains of carbapenem-susceptible A. bauman-
nii (p< 0.05). Ampicillin/sulbactam was the only agent towards which
carbapenem-susceptible isolates of A. baumannii were resistant in lower
percentage than carbapenem-susceptible isolates of A. non-baumannii
(p< 0.05).
Conclusion: Carbapenem-resistant Acinetobacter spp. tend to ex-
hibit multidrug resistance. Beta-lactams, aminoglycosides and ﬂuo-
roquinolones demonstrate different activity to carbapenem-susceptible
Acinetobacter spp., with respect to their species afﬁliation.
P1657 Antimicrobial susceptibility of Peptostreptococcus
anaerobius and Peptostreptococcus stomatis
E. Ko¨no¨nen, P. Niemi, A. Kanervo-Nordstro¨m (Helsinki, Kotka, FI)
Objective: Peptostreptococcus anaerobius ‘sensu lato’ currently includes
two closely related species, P. anaerobius and P. stomatis. In the present
study, we tested their in vitro antimicrobial susceptibilities to eight
antimicrobials potentially used to treat anaerobic infections.
Methods: Sixty-ﬁve Gram-positive anaerobic coccal isolates sensitive
to SPS (inhibition zone around the disk >12mm) were available from
various human sources. Thirty isolates were conﬁrmed as P. anaerobius
and 32 isolates re-identiﬁed as P. stomatis based on phenotypic
differential characteristics described by Downes and Wade (Int J Syst
Evol Syst Microbiol 2006;56:751−4), whereas the identiﬁcation of three
isolates remained uncertain. The susceptibilities were tested by Etest (AB
Biodisk) and drugs included amoxicillin (AC), amoxicillin/clavulanic
acid (XL), cefoxitin (FX), ertapenem (ETP), azithromycin (AZ),
clindamycin (CM), metronidazole (MZ), and moxiﬂoxacin (MX). Beta-
lactamase production was tested using nitroceﬁn (AB Biodisk).
Results: In general, the drugs exhibited good activities against most
isolates. However, P. anaerobius had constantly higher MIC50 and MIC90
values (mg/L) than P. STOMATIS: 0.125 and 0.38 vs. <0.016 and 0.064
to AC, 0.125 and 0.5 vs. <0.016 and 0.094 to XL, 0.38 and 0.75 vs.
0.064 and 0.38 to FX, 0.25 and 0.38 vs. 0.047 and 0.19 to ETP, 0.5 and
1.0 vs. 0.125 and 0.75 to AZ, 0.19 and 0.75 vs. <0.016 and 0.016 to
CM, 0.094 and 0.19 vs. <0.016 and 0.047 to MZ, and 0.125 and 0.125
vs. 0.094 and 0.125 to MX, respectively. None of the isolates produced
b-lactamases. Three (10%) P. anaerobius isolates were resistant to several
drugs.
Conclusion: The possibility of antimicrobial resistance should be taken
into account when treating infections with the involvement of P.
anaerobius ‘sensu stricto’.
P1658 Occurrence and mechanisms of resistance to b-lactam an-
tibiotics in multiresistant Acinetobacter spp. clinical isolates
E. Sodomova, D. Michalkova-Papajova, B. Gottwaldova, D. Rovna
(Bratislava, SK)
Objectives: The aim of the study was to determine the occurrence and
mechanisms of resistance to b-lactam antibiotics in multiresistant clinical
isolates of the genus Acinetobacter.
Methods: Clinical isolates included in the study (n = 111) were obtained
from University Hospital Ruzinov, Bratislava (Slovakia) and identiﬁed
by NEFERMtest24 (Pliva-Lachema, Czech Republic). Resistance to
antimicrobial agents was determined by standard disk diffusion method
according to NCCLS. The production of ESBL was detected by
combination disk method with disk combinations: ceftazidime (30mg)
and ceftazidime-clavulanic acid (30/10mg), cefotaxime (30mg) and
cefotaxime-clavulanic acid (30/10mg), cefepime (30mg) and cefepime-
clavulanic acid (30/10mg). The presence of the genes coding for
TEM- and SHV-type b-lactamases was determined by PCR.
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Results: In the set of 111 Acinetobacter spp. isolates 100.0% were
resistant to mezlocillin, 81.1% to ticarcillin, 99.1% to piperacillin, 99.1%
to carbenicillin, 35.1% to ampicillin-sulbactam, 55.9% to piperacillin-
tazobactam, 64.0% to ticarcillin-clavulanic acid, 81.1% to ceftazidime,
47.7% to cefepime, 100.0% to cefoperazone, 91.9% to cefotaxime,
91.0% to ceftriaxone, 94.6% to ceftizoxime, 91.9% to moxalactam,
0.0% to imipenem, 20.7% to meropenem, 73.9% to aztreonam, 96.4%
to gentamicin, 55.0% to amikacin, 15.3% to tobramycin, 20.7% to
netilmicin, 96.4% to tetracycline, 72.1% to doxycycline, 74.8% to
minocycline, 98.2% to ciproﬂoxacin, 91.9% to levoﬂoxacin, 99.1%
to lomeﬂoxacin, 99.1% to norﬂoxacin, 80.2% to oﬂoxacin, 92.8%
to gatiﬂoxacin, 99.1% to chloramphenicol, 77.5% to trimethoprim-
sulfamethoxazole and 90.1% to sulfonamides. In the presence of
cloxacillin (inhibitor of class C cephalosporinases, 200mg/mL) at
least 5mm increase in a zone diameter in 67.6% of the isolates
for ceftazidime, 82.9% for cefotaxime and 17.1% for cefepime was
observed. Only one isolate (0.9%) was detected as ESBL-producer. The
presence of the genes coding for TEM-type b-lactamases was determined
in all clinical isolates tested, but the presence of the genes coding for
SHV-type b-lactamases was determined only in two clinical isolates
(1.8%).
Conclusion: Most of the Acinetobacter spp. clinical isolates (91.0%)
were resistant to 20 or more from 33 antimicrobial agents tested. Only
imipenem was effective to all isolates. The production of b-lactamases
contributed to frequent occurrence of resistance to b-lactam antibiotics.
P1659 Resistance to a wide spectrum of antimicrobial agents in
ESBL-producing Klebsiella pneumoniae clinical isolates
S. Resetarova, D. Michalkova-Papajova, E. Sodomova, B. Gottwaldova,
D. Rovna (Bratislava, SK)
Objectives: The purpose of the presented study was to determine
the occurrence of in vitro resistance to 37 antimicrobial agents in
the set of extended-spectrum b-lactamase (ESBL)-producing Klebsiella
pneumoniae clinical isolates obtained from University Hospital Ruzinov,
Bratislava (Slovak Republic) during the years 2004–2006.
Methods: Clinical isolates included in the study (n = 47) were identiﬁed
by ENTEROtest24 (Pliva-Lachema, Czech Republic). The production
of extended-spectrum b-lactamases was veriﬁed by combination disk
method (NCCLS 2003) with following disk combinations: ceftazidime
(30mg) and ceftazidime-clavulanic acid (30/10 mg), cefotaxime (30mg)
and cefotaxime-clavulanic acid (30/10mg). Resistance to selected
antimicrobial agents was determined by standard disk diffusion method
according to the NCCLS recommendations.
Results: All of the 47 ESBL-producing Klebsiella pneumoniae clinical
isolates were in vitro resistant to ampicillin, mezlocillin, piperacillin,
carbenicillin and minocycline, 93.6% of the isolates were in vitro
resistant to amoxicillin-clavulanic acid, 85.1% to ampicillin-sulbactam,
2.1% to piperacillin-tazobactam, 93.6% to ticarcillin-clavulanic acid,
97.9% to cefazolin, 38.3% to cefepime, 89.4% to cefoperazone, 6.4%
to cefoxitin, 83.0% to cefotaxime, 10.6% to ceftizoxime, 85.1% to
ceftriaxone, 55.3% to ceftazidime, 97.9% to cefpodoxime, 0.0% to
imipenem, 2.1% to meropenem, 83.0% to aztreonam, 78.7% to gen-
tamicin, 0.0% to amikacin, 14.9% to netilmicin, 97.9% to tobramycin,
89.4% to tetracycline, 31.9% to doxycycline, 85.1% to ciproﬂoxacin,
68.1% to levoﬂoxacin, 23.4% to gatiﬂoxacin, 95.7% to lomeﬂoxacin,
87.2% to oﬂoxacin, 51.1% to trimethoprim-sulfamethoxazole, 40.4% to
sulfonamides, 51.1% to trimethoprim, 31.9% to chloramphenicol and
80.9% to nitrofurantoin.
Conclusion: The production of extended-spectrum b-lactamases in
Klebsiella pneumoniae is often associated with resistance to other
antibiotics. In the presented study, 87.2% of the isolates were resistant
to 20 or more from 37 antimicrobial agents tested. Most of the
isolates (93.6%) were simultaneously resistant to some of the b-lactams,
aminoglycosides and ﬂuoroquinolones. Imipenem and amikacin were the
only antibiotics effective to all ESBL-producing Klebsiella pneumoniae.
P1660 The activity of mecillinam vs Enterobacteriaceae resistant
to 3rd-generation cephalosporins in Bristol, UK
G. Weston, K. Bowker, A. Noel, A. MacGowan, R. Howe (Bristol,
Cardiff, UK)
Objectives: Resistance in coliforms to 3rd generation cephalosporins
(3GC) is an increasing problem both in hospitals and the community.
Oral options for the treatment of these organisms is often limited
due to resistance to multiple antimicrobial classes. Mecillinam, an
amidinopenicillin that is available in Europe as the oral pro-drug
pivmecillinam, is stable to many b-lactamases. We aim to establish the
activity of mecillinam against Enterobacteriaceae resistant to 3GC.
Methods: Coliforms isolated from urine samples routinely submitted to
North Bristol NHS Trust were screened for resistance to 3GC by disc
testing with cefpodoxime on Isosensitest agar. Resistant isolates were
identiﬁed using the BBL Crystal ID system. Further susceptibility testing
was performed by agar dilution MIC using an inoculum of 104 cfu/spot
on Mueller-Hinton agar. Phenotypic characterisation of 3GC resistance
was determined from MICs for cefotaxime (CTX) and Ceftazidime
(CAZ) with and without clavulanate at a ﬁxed concentration of 2mg/L.
MIC of mecillinam +/− clavulanate for ESBL-producing E. coli.
Results: 127 isolates were identiﬁed by screening of which 123 were
conﬁrmed as resistant to either CTX or CAZ by BSAC criteria.
The majority of 3GC-resistant strains were E. coli 74/123 (60.2%),
followed by Enterobacter spp. 16.2%, Klebsiella spp. 12.2%, and others
11.4%. Overall 98.4% of 3GC-resistant coliforms tested sensitive to
mecillinam (BSAC breakpoint S64mg/L). Of 30 strains that were
multiply-resistant to 3GC, trimethoprim, nitrofurantoin, gentamicin, and
ciproﬂoxacin, 96.7% tested sensitive to mecillinam. As shown in the
ﬁgure, all 67 ESBL-producing E. coli tested sensitive to mecillinam
with a 4-fold or greater decrease in MIC in the presence of clavulanate
in most cases.
Conclusions: Mecillinam maintains good activity against Enterobac-
teriaceae resistant to 3GC. This includes prevalent strains of ESBL-
producing E. coli. Oral formulations of mecillinam should be considered
as possible agents for the treatment of uncomplicated urinary tract
infections caused by such organisms.
P1661 Beta-lactamase production and antibiotic susceptibility
testing of anaerobic Gram-negative bacilli isolated from
oral and maxillofacial infections
G. Bancescu, A. Bancescu, S. Dumitriu, E. Preoteasa, M. Pana,
M. Andrei (Bucharest, RO)
Objectives: The aim of the present study was to identify at species level
and to test in vitro the susceptibility to antibiotics of the anaerobic Gram-
negative bacilli strains isolated from 60 pus samples collected by needle
aspiration from Rumanian patients with different oral and maxillofacial
infections.
Methods: Microscopy of Gram-stained direct smears and cultures
on selective and non-selective media incubated both aerobically and
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anaerobically, were performed in each pus specimen. The strictly
anaerobic bacteria were identiﬁed to genus and species level using
the conventional methods of diagnosis and the Rapid ID 32 A system
(bioMe´rieux, Marcy-l’Etoile, France). The anaerobic Gram-negative rods
isolates were tested for b-lactamase production by nitroceﬁn disk.
The susceptibility of these strains was tested against: metronidazole,
penicillin G, ampicillin, amoxicillin/clavulanic acid and clindamycin by
disk diffusion method and E-test (Ab Biodisk, Solna, Sweden).
Results: The Gram-negative bacilli isolates represented 73% of the
64 strictly anaerobic bacteria strains and belonged to Fusobacterium
nucleatum and different species of Prevotella and Bacteroides. The
Prevotella isolates were the most frequently identiﬁed anaerobic Gram-
negative bacilli (31 strains), with P. melaninogenica predominating.
Correlating the direct microscopy with the culture results, Prevotella
was found to be the only bacteria involved in the aetiology of two
cases of submandibular space abscess. All anaerobic Gram-negative
bacilli isolates were susceptible to metronidazole, clindamycin and
amoxicillin/clavulanic acid. The b-lactamase production was detected
among the Prevotella isolates (13%), while the other Gram-negative
bacilli strains were susceptible to all tested b-lactam antibiotics.
Conclusion: The most frequently isolated anaerobic species was
P. melaninogenica. As antibiotics are often prescribed empirically in
the treatment of acute oral and maxillofacial infections – which are
usually mixed infections, involving anaerobic bacteria that may be
b-lactamase producers – it is recommended to choose an association
of a penicillin with a b-lactamase inhibitor. Clindamycin might be a
good alternative, especially in patients allergic to penicillin. Monitoring
of local susceptibility patterns of anaerobic bacteria is necessary for
antibiotic selection in the initial therapy.
P1662 Emerging colimycin resistance in Gram-negative strains
isolated from intensive care unit patients
F.V. Kontopidou, A. Antoniadou, G. Poulakou, E.D. Papadomichelakis,
I. Galani, A. Armaganidis, H. Giamarellou (Athens, GR)
Background: Infections due to multidrug resistant (MDR) Gram(−)
microorganisms in the ICUs has prompted the use of Colimycin (COL)
an antibiotic forgotten for decades. The mechanism of COL resistance
(COLR) has not been well deﬁned. Until now resistance to COL is
uncommon. While emergence of COLR in vivo, has not yet been
reported.
Patients and Methods: The study was performed in a new
6-bed general ICU from November 2003 to October 2006. Empirical
antimicrobial treatment was guided by weekly active surveillance of
patients ﬂoras (faecal and respiratory). Resistance of the isolated
pathogens prompted COL use as part of empirical antimicrobial regimens
or in microbiologically documented infections. COLR was deﬁned as
<14mm diameter by the disk diffusion method and was conﬁrmed as
an MIC> 4mg/mL by the agar dilution and E test method (according to
BSAC).
Results: Among 146 patients with more than 10 days hospitalisation,
72% was colonised by A. baumannii, 61% by P. aeruginosa, 50% by
K. pneumoniae, 17% by Enterobacter spp., 28% by E. coli, 27% by
S. maltophilia. The resistant strains to COL were 3.8%, 4.5%, 32.4%,
4%, 7.3%, 35% respectively. Using REP-PCR six distinct clones
were identiﬁed among K. pneumoniae Col resistant strains. Most of
K. pneumoniae strains were pan-drug resistant, produsing ESBL and
MBL susceptible only to tetracyclines or and gentamycin. The majority
represented colonisation; only 7 cases of infection were recorded (six
with K. pneumoniae and one with Enterobacter sp), all of them with fatal
outcome. 83 patients had exposure to colistin, 29 of them harbouring a
colistin resistant Gram(−) strain. All patients treated prolonged (>20 d)
with Col developed normal ﬂoras colonisation with K. pneumoniae,
P. aeruginosa, S. maltophilia R to Col plus of intrinsically resistant
to Col enterobacteriaceae (ie. Pr. mirabilis, M. morgani, Serratia spp.,
and Providencia spp.). Colonisation with more than one Col resistant
pathogen correlated with length of stay, severity of illness and a
signiﬁcant exposure to colistin.
Conclusions: Selective pressure due to extensive COL use seems to
lead to the emergence of COL resistance among Gram(−) strains,
jeopardising treatment choices in the ICU, increasing morbidity and
mortality. Therefore it is urgent intensivists to avoid unecessar or/and
prolonged therapy with colistin.
P1663 Baseline proﬁle of RO4908463 (CS-023) against recent
isolates of target Gram-negative pathogens exhibiting
b-lactam-resistant phenotypes from Europe, 2003–2006
N. Brown, D. Draghi, M. Jones, D. Sahm, B. Dannemann (Herndon,
US; Breda, NL; Nutley, US)
Objectives: RO4908463 (CS-023), a carbapenem with a unique
guanidine-pyrrolidine side chain, has broad-spectrum activity against
both Gram-positive and Gram-negative pathogens. As such, this study
was done to establish an in vitro activity baseline of RO4908463
against Europe (EU) isolates of P. aeruginosa (PA), Acinetobacter spp.
(AS), Enterobacteriaceae (EN), and H. inﬂuenzae (HI), including those
exhibiting resistance to currently available b-lactams.
Methods: RO4908463 and comparator agents were tested by broth
microdilution (CLSI; M7-A7, 2006) against 735 Gram-negative isolates
selected to include organisms resistant to b-lactams. Isolates were
collected (2003–2006) from hospitals in 18 European countries and
included ceftazidime-resistant EN and PA, imipenem-resistant PA, and
b-lactamase positive HI.
Results: For ceftazidime-susceptible (n = 83) and ceftazidime non-
susceptible (NS; n = 23) PA isolates, the RO4908463 MIC range/MIC90
(mg/L) was 0.06−16/2 and 0.25−>32/32, respectively. Among
imipenem-S AS (n = 45) and imipenem-NS AS (n = 8) the MIC ranges
were 0.12−16 and 4−>32mg/L, respectively. The MIC90 for all EN
species combined (n = 523) was 0.12mg/L. For ceftazidime NS EN
(n = 90) the MIC range was 0.015 to 1mg/L. The MIC range for HI
(n = 53) was 0.008 to 0.5mg/L with an MIC90 of 0.12mg/L for both
b-lactamase-positive and -negative strains combined.
Conclusion: RO4908463 demonstrated good in vitro activity against
a wide spectrum of Gram-negative pathogens, including Enterobacteri-
aceae with resistance to ceftazidime. These baseline data will provide
an important reference for detecting any changes in the activity of
RO4908463 among target Gram-negative pathogens from European
countries as the clinical development proceeds.
P1664 Baseline surveillance proﬁle of doripenem against key
Gram-negative pathogens encountered in Europe
M.K. Aranza, D.C. Draghi, M.E. Jones, C. Thornsberry, D.F. Sahm
(Herndon, US; Breda, NL)
Background: DOR, is an investigational parenteral broad-spectrum 1-b-
methyl carbapenem that is refractory to hydrolysis by most Gram-
negative b-lactamases. It is under clinical development for complicated
urinary tract infections, complicated intra-abdominal infections, and hos-
pital acquired pneumonia (including ventilator-associated pneumonia).
As a key component of the development programme, this surveillance
initiative was done to establish baseline data on DOR activity against
recent Gram-negative pathogens relative to other key b-lactam agents.
Methods: During 2005–2006, Citrobacter spp. (CP; n = 387), E. cloacae
(EA; n = 406), E. coli (EC;n = 1213), K. pneumoniae (KP;n = 854),
P. mirabilis (PM;n = 443), S. marcescens (SM; n = 291), P. aeruginosa
(PA;n = 621), and Acinetobacter spp. (AC;n = 278) collected from 31
institutions in 12 European countries were centrally tested by broth
microdilution (CLSI; M7-A6). Testing included DOR, imipenem (IMP),
ceftazidime (CAZ), cefepime (FEP), piperacillin-tazobactam (PTZ) and
other relevant agents.
Results: See the table.
New antimicrobials II S471
MICb (mg/L)
Orga DOR IMP CAZ FEP PTZ
Range M90 Range M90 Range M90 Range M90 Range M90
CP 0.015−8 0.06 0.06−32 2 0.03–>32 >32 0.015–>32 1 0.25–>128 64
EA 0.015−1 0.12 0.015−4 2 0.03–>32 >32 0.015–>32 8 0.25–>128 >128
EC 0.015−0.5 0.03 0.015−4 0.5 0.03–>32 2 0.015–>32 1 0.25–>128 64
KP 0.015−8 0.06 0.06−16 1 0.03–>32 >32 0.015−32 >32 0.5–128 >128
PM 0.015−2 0.25 0.06−32 4 0.03–>32 0.12 0.015–>32 0.12 0.25–128 2
SM 0.015−1 0.25 0.25−4 4 0.03–>32 2 0.015–>32 1 1–>128 64
PA 0.015–>32 4 0.25–>32 32 0.06–>32 >32 0.015–>32 16 0.5–>128 >128
AC 0.015–>32 32 0.015–>32 >32 0.06–>32 >32 0.06–>32 >32 0.25–>128 >128
aOrg, Organism; bM90: MIC90.
Conclusions: Based on MIC90s, for every organism group surveyed,
including PA, DOR’s in vitro activity was comparable or more active than
a carbapenem (IMP), the cephalosporins (CAZ, FEP), and a b-lactam
(PTZ). These ﬁndings establish an important baseline for continued
tracking of DOR activity as clinical development continues.
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P1665 Mode of action and resistance of the new ﬂuoroquinolone
BOL-303224-A
E. Cambau, J.F. Lepage, S. Matrat, X.S. Pan, R. Roth dit Bettoni,
C. Corbel, T. Daniel, N. Darchy, A. Aubry, C. Lascols, L.M. Fisher
(Cre´teil, Montpellier, Paris, FR; London, UK)
Objectives: To investigate the mode of action and mechanisms of
resistance to the new quinolone BOL-303224-A.
Methods: The new quinolone BOL-303224-A was investigated for (1) its
inhibition of DNA gyrases and topoisomerases IV from Streptococcus
pneumoniae, taken as the targeted bacterial species, and Escherichia
coli, taken as the reference species, and induction of DNA cleavage by
these type II topoisomerases, (2) mutations in the type II topoisomerase
genes occurring in resistant mutants of S. pneumoniae, S. aureus and
E. coli selected in vitro, and (3) activity on gyrase and topoisomerase
IV deﬁned mutants. These experiments were conducted in comparison
to ciproﬂoxacin.
Results: At low concentrations, BOL-303224-A inhibited supercoiling
activity of DNA gyrases of S. pneumoniae and E. coli (IC50s of
1mg/L for both species) and decatenation by topoisomerase IV (IC50
of 0.4 and 10mg/L, respectively), and induced formation of cleavable
complexes at concentrations of 2.5 and 1mM for DNA gyrase and
topoisomerase IV of S. pneumoniae and 0.1 and 1.4mM for those of
E. coli, respectively. IC50s of BOL-303224-A were 5- to 16-fold lower
than those of ciproﬂoxacin against pneumococcal topoisomerases. The
main mechanism of resistance to SS734 was mutation in the DNA gyrase
genes, mostly gyrA mutation at position 81, 83 and 87, but also gyrB
mutation at positions 426 and 466 (numbering system used in E. coli).
From the results on in vitro selection of resistant mutants, DNA gyrase
was the primary target in E. coli, S. aureus and S. pneumoniae, and
topoisomerase IV was the secondary target. However, a dual targeting is
likely since the selection of resistant mutants of S. aureus could not be
obtained in a single step and inhibitory concentrations were in the same
range for DNA gyrase and topoisomerase IV of S. pneumoniae. MICs
of BOL-303224-A were similarly affected by parC or gyrA mutations
in the deﬁned mutants of these two species, and they remained below
1mg/mL in double gyrA-parC mutants of S. aureus and S. pneumoniae
whereas ciproﬂoxacin MICs were up to >32mg/L.
Conclusion: BOL-303224-A is a good inhibitor of bacterial type II
topoisomerases in vitro, and is one of the rare quinolones to be as active
against DNA gyrase as against topoisomerase IV of S. pneumoniae.
P1666 Daptomycin therapy for Gram-positive infections in cancer
patients
H. Hogan, I. Raad, K. Rolston (Texas, US)
Objectives: To assess the clinical outcomes of daptomycin in cancer
patients.
Methods: Daptomycin is a novel cyclic lipopeptide antibacterial agent
approved in the USA for treatment of Staphylococcus aureus bacteraemia
and skin and skin structure infections caused by susceptible Gram-
positive organisms. Clinical data in cancer patients are limited. Dapto-
mycin usage for documented and/or suspected Gram-positive infections
in cancer patients was retrospectively reviewed at a comprehensive
cancer centre.
Results: Forty-eight patients, 26 males and 22 females were treated
from 1/04 to 5/06. Nineteen (40%) patients received 6mg/kg/day,
27 patients received 4mg/kg/day, and 1 patient received 6mg/kg/Q48h.
Twenty-ﬁve (52%) had haematological malignancies and 23 (48%)
had solid tumours (17 leukaemia, 8 lymphoma, 7 breast cancer
were the most common). The average age was 50 years (range
12−74). Seventeen (35%) were neutropaenic. The infections treated
were cellulitis (23; 48%), abscess (8; 17%), bacteraemia (11; 23%),
UTI (2; 4%), cellulitis + bacteraemia (1; 2%), abscess + bacteraemia
(2; 4%) and UTI + bacteraemia (1; 2%). The organisms isolated were
S. aureus (18, including 14 MRSA), Enterococcus spp. (10, including
7 VRE), coagulase-negative staphylococci (7) and alpha-haemolytic
streptococcus (1). Twenty-three patients (48%) had failed vancomycin
(14 cellulitis, 9 bacteraemia), 4 failed linezolid (2 cellulitis, 1 VRE
bacteraemia, 1 E. faecalis bacteraemia) and 1 discontinued linezolid to
prevent toxicity. All isolates from clinical failures were susceptible to
prior antimicrobial regimens. The overall response to daptomycin (42 of
48 patients) was 87.5%. Thirteen of the seventeen neutropaenic patients
responded to daptomycin therapy. The mean duration of therapy was
13.5 days. No CPK elevations were observed. One patient developed a
rash on day 13 of treatment. Six patients failed to respond to daptomycin
(2 leukaemics with cellulitis/abscess that responded to alternative agents;
2 Sweet’s Syndrome; 2 died due to pancytopenia/pneumonia/refractory
leukaemia).
Conclusions: Daptomycin appears to be a promising agent for
the treatment of Gram-positive infections in neutropaenic and non-
neutropaenic cancer patients and needs further clinical evaluation in this
setting.
P1667 In vitro activity of daptomycin and tigecycline against
Staphylococcus epidermidis blood isolates from bone marrow
transplant patients
E. Presterl, F. Thalhammer, S. Reichmann, W. Rabitsch, A.M. Hirschl,
W. Graninger (Vienna, AT)
Background: Daptomycin (DAP), a new lipopeptide antibiotic, and
tigecycline (TGC) have activity against Gram-positive bacteria including
methicillin-resistant staphylococci and vancomycin-resistant enterococci.
Staphylococcus epidermidis isolated from bone marrow transplant
(BMT) recipients were multiresistant due to exposure to multiple
antibiotics and protection by bioﬁlm formation on implanted catheters.
Moreover, they are signiﬁcant pathogens in this particularly vulnerable
patient population. We present a study on the in-vitro activity of DAP
and TGC against S. epidermidis isolates from blood of 74 bone marrow
transplant patients.
Methods: 107 non-duplicate blood stream isolates of S. epidermidis were
collected in 2000–2006. All patients had the clinical signs and symptoms
of sepsis. All isolates were susceptibility (S) tested using CLSI methods
against DAP, TGC, vancomycin (VAN) and fosfomycin (FOS).
Results: The MIC50 and MIC90, were 0.125mg/mL and 0.125mg/mL
for DAP, 0.25 and 0.25mg/mL for TGC, 1mg/mL and 1mg/mL for VAN,
and 8mg/mL and >256mg/mL for FOS, respectively. The cumulative
numbers inhibited at MIC are given in the table. At established CLSI
breakpoints for VAN (4mg/mL) and for TGC (1mg/mL), 100% and 98%,
respectively, of the S. epidermidis blood stream isolates were susceptible.
For FOS, 41% of the isolates exhibited a MIC 64mg/mL, considered
to be resistant. For DAP, the MICs of all isolates) were 1mg/mL.
Conclusions: Despite considerable antibiotic pressure at a BMT unit
S. epidermidis blood isolates are still susceptible to VAN. Caution and
resistance testing is warranted with TGC. DAP will be useful for the
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treatment of S. epidermidis infection in case of hypersensitivity or
emergence of resistance against VAN.
Inhibition of S. epidermidis isolates (n = 106)
Cumulative numbers inhibited at MIC (mg/mL)
<0.01 0.03 0.06 0.25 0.5 1 2 4 8 16 64 128 256
Vancomycin 5 9 72 105
Fosfomycin 1 2 8 20 41 55 56 57 60 63
Tigecycline 1 7 25 48 84 101 105
Daptomycin 7 10 16 65 103 105
P1668 Evaluation of NAD+-dependent DNA ligase of mycobacteria
as a potential target for antibiotics
E. Rychta, M. Korycka-Machala, A. Brzostek, H. Sayer, A. Rumijowska-
Galewicz, R. Bowater, J. Dziadek (Lodz, PL; Norwich, UK)
Objectives: The aim of this study was veriﬁcation of the essentiality of
NAD+-dependent DNA ligase (LigA) in mycobacteria and its evaluation
as a putative target for new antituberculosis drugs.
Methods: A homologous recombination system was used to assess
essentiality of the mycobacterial gene for NAD+-dependent DNA ligase
(ligA). Conditional mutants carrying a single ligA gene controlled with
chemically inducible promoters were constructed. The protein level was
measured with western blot using antibodies raised against LigA of
Mycobacterium tuberculosis.
Results: Since NAD+-dependent DNA ligase was postulated as a useful
target for new antibiotics, we evaluated if ligA is essential for the
viability of mycobacteria. Using a homologous recombination system we
found that wild type ligA gene cannot be deleted from the chromosome
of Mycobacterium smegmatis. We were able to delete the native ligA in
M. smegmatis by integrating in to the attB site of chromosomal DNA
an extra copy of M. smegmatis or M. tuberculosis ligA, with expression
controlled by chemically inducible promoters. The resultant conditional
mutants allow studies of the effect of LigA depletion on growth of
mycobacteria. Interestingly, the LigA protein from M. smegmatis can be
substituted with the NAD+-dependent DNA ligase of Escherichia coli or
the ATP-dependent ligase of bacteriophage T4. The investigation of LigA
conditional mutants revealed that mycobacterial cells are not affected
by large changes to the levels of LigA. The strong overproduction or
depletion of LigA did not affect the growth or survival of mycobacteria.
Conclusion: NAD+-dependent DNA ligase is essential for mycobacterial
viability, but only low levels of protein are required. Thus, further
investigations are required to determine if NAD+-dependent DNA ligase
could be useful as an antibiotic target in mycobacteria.
P1669 In vitro activity against Staphylococcus aureus, including
MRSA, of soluble copper silicate, a new topical antimicrobial
K.C. Carson, J.G. Bartlett, T-J. Tan, T.V. Riley (Perth, AU)
Objectives: People who are colonised on the skin or in the nares with
Staphylococcus aureus have an increased risk of subsequent infection.
Topical mupirocin has been used for decolonisation therapy, but with the
emergence of both low- and high-level resistance, and increased nasal
carriage of community acquired methicillin resistant S. aureus (MRSA),
impetus has been given to the search for alternatives. Mankind has used
copper as an antimicrobial for thousands of years, and a novel solubilised
form of copper silicate (CS) has been developed by Conve plc for use
as a topical antimicrobial.
Methods: The minimum inhibitory concentration (MIC) and minimum
bactericidal concentration (MBC) of CS were determined for 200 isolates
(100 MRSA and 100 methicillin susceptible S. aureus (MSSA) in
Mueller Hinton Broth with 2% NaCl following Clinical and Laboratory
Standards Institute methodology. Time-kill studies, post antibiotic effect
(PAE) and resistance were also investigated.
Results: All 200 S. aureus isolates had a MIC for CS of 175mg Cu/L.
The MBC range was 175–700mg Cu/L, with an MBC for 90% of
isolates of 350mg Cu/L. In time-kill assays of MRSA strain 101, CS
at a concentration of 700mg Cu/L gave a 3-log reduction at approx.
30min. For S. aureus ATCC® 29213, 350mg Cu/L and 700mg Cu/L a
3-log reduction was predicted to be achieved in approx. 30min and
1min, respectively. A PAE was seen in two MRSA isolates after
exposure to CS at 350mg Cu/L (0.99 h and 2.53 h), while with S. aureus
ATCC® 29213 a PAE was seen at 175mg Cu/L (1.65 h) and 350mg Cu/L
(2.10 h). The S. aureus mutation frequency for resistance to CS was
<1 per 109. Rifampicin at a concentration of 0.5mg/L gave frequencies
of 5−17×10−8.
Conclusion: CS had similar in vitro antimicrobial activity against all
S. aureus isolates. In time kill and PAE assays, MRSA appeared slightly
less susceptible than MSSA; however these differences may be due
to minor variations in susceptibility between the isolates tested. In
S. aureus, there was no evidence of individual cells being resistant,
or becoming tolerant, to CS. Clinical trials are needed to determine if
CS is an efﬁcacious therapy for decolonisation of and dermatological
infections with S. aureus.
P1670 PZ-601 is active against both Gram-positive and Gram-
negative bacterial pathogens causative for complicated skin
and skin structure infections, and community-acquired
pneumonia
J. Pace, T. Stevens, B. Ruth, A. Chua, K. Kanazawa, C. Young, L. Xerri
(Malvern, Schaumberg, US; Osaka, JP)
Background: PZ-601 (SMP-601) is an investigational parenteral
carbapenem with potent activity against both Gram-positive and Gram-
negative pathogens. The projected role for this antibiotic is empirical
monotherapy of infections where drug-resistant staphylococci and
enterococci or Gram-negative pathogens may be encountered. Indications
might include complicated skin and skin structure infections (cSSSI), and
community-acquired pneumonia (CAP).
Methods: Numerous Staphylococcus aureus, coagulase-negative staphy-
lococci, Streptococcus pyogenes, Streptococcus agalactiae, Enterococcus
faecalis, Escherichia coli, and Klebsiella pneumoniae, as well as strains
of Haemophilus inﬂuenzae, Moraxella catarrhalis, and Streptococcus
pneumoniae were obtained from various U.S. and European hospitals.
These bacteria were subjected to susceptibility testing with PZ-601
and comparator antibiotics using broth microdilution minimal inhibitory
concentration (MIC) method according to CLSI guidelines.
Results: PZ-601 was highly active against all bacterial species tested.
This exploratory carbapenem was most active against Staphylococ-
cus spp., Streptococcus spp., H. inﬂuenzae, and M. catarrhalis. Modal
MICs of 1mg/L were observed against the least susceptible species
E. faecalis and K. pneumoniae. When bacteria were grouped by
susceptibility to antibiotic classes, PZ-601 was substantially more active
than imipenem against the methicillin-resistant S. aureus (MRSA) for
example with modal MIC values of 2 and >32mg/L, respectively.
Table 1. Modal MIC (mg/L) values and range for PZ-601 and comparator antibiotics against bacterial Gram-positive
species cumulative for cSSSI and CAP
Species (no.) PZ-601 Vancomycin Linezolid Daptomycin Imipenem
S. aureus (208) 0.03
0.004−4
1
0.5−1
2
1−4
0.5
0.15−1
0.06
0.06−>32
S. epidermidis (201) 0.015
0.004−3
2
0.5−2
1
0.25−4
0.5
0.25−1
0.06
0.06−>32
S. pyogenes (105) 0.004
0.004−0.015
0.5
0.03−0.5
1
0.5−2
0.03
0.03−0.5
0.06
0.015−0.03
S. agalactiae (98) 0.015
0.004−0.5
0.5
0.25−0.5
1
0.03−2
0.12
0.03−1
0.015
0.015−1
E. faecalis (101) 1
0.25−2
1
0.5−>32
2
1−4
2
0.5−4
1
0.25−8
S. pneumoniae (106) 0.008
0.004−1
0.25
0.03−0.5
1
0.25−2
0.06
0.03−0.25
0.015
0.015−1
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Table 2. Modal MIC (mg/L) values and range for PZ-601 and comparator antibiotics against bacterial Gram-negative
species cumulative for cSSSI and CAP
Species (no.) PZ-601 Ceftriaxone Amp/Sulb Levoﬂoxacin Imipenem
H. inﬂuenzae (107) 0.03
0.008−0.12
0.03
0.03−0.6
0.5
0.5−8
ND 0.5
0.08−8
M. catharralis (98) 0.004
0.004−0.06
0.03
0.03−4
4
0.12−16
ND 0.06
0.008−0.12
E. coli (105) 0.25
0.06−32
0.25
0.25−>64
>32
2−>32
>8
0.5−>8
0.12
0.12−0.5
K. pneumoniae (103) 1
0.015−>64
>64
0.25−>64
>32
1−>32
0.5
0.5−>8
0.12
0.12−64
Conclusion: PZ-601 is broadly active in-vitro against antibiotic-
susceptible and -resistant Gram-positive and Gram-negative pathogens
causative for cSSSI and CAP.
P1671 PZ-601 antibiotic and bactericidal activity against
multidrug-resistant Gram-positive bacteria
J. Pace, L. Xerri (Malvern, US)
Background: PZ-601 (SMP-601) is an investigational parenteral
carbapenem with potent activity against both Gram-positive and Gram-
negative pathogens. Its enhanced afﬁnity for PBP2a has extended
its spectrum to include multidrug-resistant Gram-positive bacterial
pathogens. The projected role for this antibiotic is empirical monotherapy
of infections where drug-resistant staphylococci and enterococci may be
encountered.
Methods: Numerous Staphylococcus aureus strains including methi-
cillin-resistant (MRSA) and community acquired (CAMRSA), and
vancomycin-intermediate susceptible and resistant (VISA and VRSA)
strains, coagulase-negative staphylococci, both vancomycin-susceptible
and -resistant enterococci including ampicillin-susceptible and -resistant
strains, and select linezolid-, daptomycin-, and tigecycline-resistant
isolates were obtained from NARSA or various U.S. and European
hospitals. These bacteria were subjected to susceptibility testing with
PZ-601 and comparator antibiotics using broth microdilution minimal
inhibitory concentration (MIC, mg/L) method according to CLSI
guidelines. In some instances minimal bactericidal concentrations
(MBCs) and bactericidal killing by time-kill assay were also evaluated.
MIC (mg/L) values and range for PZ-601 and comparator antibiotics
against select clinical isolates and reference strains of Gram-positive
species
Species Phenotype MIC (mg/L)
PZ-601 V
an
co
m
yc
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L
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em
Staphylococcus aureus
ATCC29213 MSSA 0.015 0.5 2 1 0.5 0.09
COL MRSA 1 1 4 2 1 32
USA300 CA-MRSA 0.5 0.5 8 1 1 4
USA400 CA-MRSA 0.25 1 4 2 0.5 0.5
GC7647 TIG-R 2 2 4 4 16 >32
HIP5836 VISA 1 8 4 4 1 32
Mu-50 VISA 2 8 4 4 1 32
VRSA1 VRSA 1 >256 4 1 2 >32
Enterococcus faecium
J4026 DAP-R 4 128 8 32 ND >32
I225 LIN-R 4 128 32 1 ND >32
Results: MICs of PZ-601 were superior to other carbapenems tested
against most MRSA strains and enterococci. PZ-601 modal MIC was
2 and MIC range was 0.004−4 for MRSA, and 1 and 0.25−2
for Enterococcus faecalis, respectively. PZ-601 was active against
bacteria intermediate-susceptible or resistant to vancomycin, linezolid,
daptomycin, or tigecycline.
Conclusion: PZ-601 is broadly active in-vitro against drug-resistant
Gram-positive pathogens including MRSA and CAMRSA, VISA,
VRSA, VRE, and those isolates resistant to linezolid, daptomycin, or
tigecycline. PZ-601 is bactericidal and reduces bacterial counts to a
greater degree than vancomycin at early time-points.
P1672 PZ-601 antibacterial activity against well-characterised and
fresh Enterobacteriaceae isolates
M. Mezzatesta, M. Trovato, F. Gona, M. Santagati, F. Campanile,
S. Stefani (Catania, IT)
Objectives: The in vitro activity of PZ-601, formerly SMP-601,
an investigational broad-spectrum carbapenem antibiotic, with potent
activity against multi-drug resistant Gram-positive and Gram-negative
bacteria, was tested in comparison with other drugs against a group of
well-characterised and fresh Enterobacteriaceae isolates.
Methods: The strains included in the study – Escherichia coli, Klebsiella
spp. and Enterobacter spp. – were the ﬁrst 70 Enterobacteriaceae con-
secutive non-repetitive strains collected from urine and respiratory tract
specimens of inpatients and outpatients, isolated from the Policlinico
of Catania (I) in a 4-month period, and 23 strains of Enterobacteriaceae
previously molecularly characterised for their ESBL production (Luzzaro
et al. JCM 2006; 44: 1659). All bacterial isolates were identiﬁed at the
species level using standard procedures. Antibiotic susceptibility was
determined by the standard broth microdilution method (MICs) following
CLSI guidelines. The antibiotics used were: PZ-601, imipenem (IMI),
ceftriaxone (CRO), cefepime (CPE), piperacillin/tazobactam (PIP/TAZ),
levoﬂoxacin (LEVO) and tobramycin (TOBRA). PZ-601 was freshly
prepared and maintained in ice.
Results: PZ-601 was highly active against Enterobacteriaceae and
ESBL-producing strains with MIC90 of 2mg/L, comparable with that of
imipenem, and superior to that of the other drugs tested. Among ESBL
isolates, PZ-601 showed a variable activity against the strains possessing
different enzymes, with a MIC90 value of 0.5mg/L in SHV-containing
strains, while it showed MIC90 values of 2 in strains containing CTX-M-
type enzyme.
Table 1. MIC90 (mg/L) of PZ-601 and comparators against Enterobacteriaceae
Strains MIC90 (mg/L)
P
Z
-6
01
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R
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C
P
E
P
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A
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L
E
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T
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I
Enterobacteriaceae (n = 70) 2 128 4 512 4 32 2
ESBLs producers (n = 23) 2 >128 128 >512 16 64 2
SHV strains (n = 7) 0.5 64 4 256 16 64 1
CTX-M (n = 16) 2 >128 128 >512 16 64 1
Conclusion: In this small sample, PZ-601 was highly active against
Enterobacteriaceae and ESBL-producing isolates, demonstrating that this
carbapenem is a potentially outstanding alternative drug in the empiric
treatment of infections caused by these multiresistant microrganisms
resistant to cephalosporins, protected penicillins, quinolones, and
aminoglycosides.
P1673 Safety and pharmacokinetics of single-dose intravenous ad-
ministration of PZ-601: a novel investigational carbapenem
C. Young, A. Rusca, A. Di Stefano, M. Radicioni, D. Binelli, L. Xerri
(Malvern, US; Arzo, CH)
Objective: PZ-601 (SMP-601) is a novel carbapenem with an
antimicrobial spectrum that includes multidrug-resistant Gram positive
(methicillin-resistant Staphylococcus aureus, Enterococcus faecium) and
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extended-spectrum b-lactamase producing Gram negative organisms. We
studied the pharmacokinetics and safety of single ascending doses in
otherwise healthy male volunteers.
Methods: Fifty-six subjects (42 PZ-601, 14 placebo) were randomised
in seven cohorts (6 PZ-601, 2 placebo) to ascending doses of PZ-601:
30, 100, 300, 600, 1,000, 1,500, 2,000mg or placebo by infusion over
30 minutes. Assessments included adverse events, laboratory, ECGs and
PZ-601 plasma levels and urinary excretion.
Results: Adverse events were infrequently noted in 5/42 PZ-601 and
in 1/14 placebo recipients. The most common events were headache (3
PZ-601, 1 placebo) and dyspepsia (1 PZ-601). There were no serious
adverse events. There were no laboratory or ECG ﬁndings of clinical
concern. PZ-601 exposure was linear for the administered doses with a
half-life of 1.4 hours at a dose of 1,000mg. A summary of key PZ-601
pharmacokinetic parameters is presented.
Parameter PZ-601 dose (mg)
30 100 300 600 1,000 1,500 2,000
Cmax (mg/L) 2.1 7.8 20 51 72 122 143
AUC0−∞ (mg·h/L) 3 12 26 68 97 165 220
Volume of distribution (L) 15.5 13.6 16.5 14.2 16.5 14.1 14.7
Clearance (mL/min) 175 137 195 152 250 154 154
T1/2 (h) 1.1 1.2 1.2 1.3 1.4 1.4 1.5
Conclusion: PZ-601 in single doses up to 2 g was generally well-
tolerated in normal healthy male subjects. These results suggest the
potential for twice daily dosing and support progression to repeat dosing.
P1674 Broad spectrum anti-Candida activities of a new
indolyl-triazole, NL114
F. Pagniez, N. Le Bouvier, Y. Na, M. Le Borgne, M. Pfalzer,
R. Hartmann, P. Le Pape (Nantes, FR; Saarbru¨cken, DE)
Objectives: During the last decades, the frequency of fungal infections
has increased. Azole drug activities against systemic fungal infections
have not to be demonstrated. However, azole resistance of Candida spp.,
such as C. krusei and C. glabrata, has been reported. In this work we
present the potent anti-Candida activity of NL114, an indolyl-triazole,
against C. albicans, C. krusei and C. glabrata.
Azole antifungals are known to interfere with fungal but also mammalian
cytochrome P450 (CYP). In view of future development, inhibition of
these CYPs was investigated as well as the cellular toxicity of NL114.
Methods: 39 strains of Candida belonging to the species C. parapsilosis,
C. krusei, C. albicans, C. glabrata and C. lusitaniae were used.
Antifungal drugs were NL114 [2-(2,4-dichlorophenyl)-3-(1H-indol-
1-yl)-1-(1,2,4−1H-triazol-1-yl)-propan-2-ol], ketoconazole, ﬂuconazole
and voriconazole. Antifungal activity was evaluated with a ﬂuorometric
microdilution method. MICs are the concentrations that inhibit 80% of
fungal growth and MIC90s are the concentrations that inhibit growth
of 90% of strains. Cytotoxicity of compounds was studied with human
ﬁbroblast (MRC5) with a ﬂuorometric microdilution method. In vitro
human cytochrome interactions were tested on aromatase (CYP19) and
17 a-hydroxylase/17,20-lyase (CYP17).
Results: Antifungal activity of NL114 is higher than ﬂuconazole and
voriconazole on C. albicans (MIC90 = 1.5, 20 and 2.8mg/mL, respec-
tively), C. glabrata (MIC90=0.26, 31 and 2.1mg/mL, respectively) and
C. krusei (MIC90 = 0.23, 20 and 0.23mg/mL, respectively). Fluconazole-
resistant or less-susceptible Candida strains were susceptible to NL114.
Results of the cellular toxicity assay showed that NL114 is more toxic
than ﬂuconazole and voriconazole. Nevertheless geometric mean of
MICs against Candida is 190 times lower than the toxic concentration
on MRC5 cells.
Human cytochrome interaction study showed that NL114 at a
concentration of 36mM did inhibit CYP19 as well as ketoconazole.
NL114 did not interact with CYP17 at a concentration of 2.5 mM.
Conclusion: In conclusion, these promising results point out that NL114
is a new lead antifungal candidate. Cellular toxicity and interaction with
human P-450 cytochrome studies let predict a good safety.
P1675 QTc measurements during a placebo- and actively
controlled multiple dose study of two different dosing
regimens of isavuconazole
M. Heep, B. Roos, M. Sochor, A. Schmitt-Hoffmann, S. Van Merle,
D. Kappers, P. Voiriot (Basle, CH; Zuidlaren, NL; Nancy, FR)
Background: Isavuconazole (BAL8557/BAL4815, ISA) is a new water-
soluble triazole which has broad in-vitro activity against yeasts, moulds
(including zygomycetes) and dermatophytes. The oral formulation
is almost completely bioavailable and the i.v. formulation can be
administered to renally impaired patients because it does not contain
cyclodextrins. ISA is currently in phase III clinical development. This
study was designed to investigate the cardiac safety of ISA at two dose
levels.
Methods: A total of 80 healthy subjects received a single dose of
400mg moxiﬂoxacin as a positive control for prolongation of QTc, and
subsequently were randomised to groups A and B:
Group A: Staggered oral loading doses of 400, 300 and 200mg ISA
were administered on Days 4, 5 and 6, followed by 100mg qd ISA on
Days 7 to 10, and one IV infusion of 100mg ISA on Day 11. Three
staggered oral loading doses of BAL8557 of 300, 250 and 200mg
ISA equivalents were administered on Days 12 to 14, followed by
once daily oral maintenance doses of 150mg ISA on Days 15−18,
and one i.v. infusion of 150mg ISA as a 1-hour infusion on Day 19.
Group B: 40 subjects receiving placebos.
Time-matched, baseline-subtracted QTc measure was used for analysis.
Results: Moxiﬂoxacin effect was statistically signiﬁcant and increased
QTcF in both groups (6ms in Group A, 7ms in Group B) compared
to baseline, as expected. During the remainder of the study period a
reduction of QTcF from baseline was observed both after ISA and in
the placebo control arm. Reduction of QTc from baseline was generally
more pronounced in the ISA group. There was no apparent difference
in QTc results between the oral or i.v. treatment phase, nor between the
100mg steady state or 150mg steady-state dose level. Dosing was well
tolerated.
Conclusion: In contrast to the moxiﬂoxacin positive control, no QTc
increase was observed for two dosing regimen of isavuconazole. The
decrease of QTcI in comparison with placebo was slight (between 5 and
10 msec) and does not preclude of the safety of the drug.
P1676 Evaluation of isavuconazole (BAL8557/BAL4815)
Etest compared to broth microdilution antifungal
susceptibility testing against quality control strains and
ﬂuconazole-susceptible clinical Candida isolates
M. Heep, P. Grover, N.P. Brown, D. Sahm, M.E. Jones (Basle, CH;
Herndon, US)
Background: Isavuconazole (ISA, BAL8557/BAL4815) is a new broad-
spectrum triazole. In preparation of clinical trials in primary and salvage
treatment of invasive fungal infections, options allowing susceptibility
testing were evaluated. Agar-based methods such as Etest may be
preferred by some clinical laboratories for their simplicity and ease of
use. Broth microdilution (BMD) is a reference method for antifungal
susceptiblity testing (AFST) against which the Etest method was
validated.
Methods: Etest was performed according to manufacturer’s instructions
(AB Biodisk) and BMD according to CLSI M27-A2 guideline. Organ-
isms tested were C. parapsilosis ATCC22019, C. krusei ATCC6258
and 4 clinical isolates of C. parapsilosis, C. glabrata, C. tropicalis,
C. krusei. On three separate days a total of 14 individual inoculum
suspensions for each test organism was prepared and used concomitantly
for Etest and broth microdilution; voriconazole and ﬂuconazole were
included as reference. Both Etest and BMD results were read at 24
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and 48 hours incubation. Concordance between methods was deﬁned as
within 1 doubling dilution of the BMD MIC.
Results: For ISA 100% concordance was detected between BMD
and Etest at 24 h for C. parapsilosis ATCC22019 (BMD MIC range
0.015 ug/mL; Etest MIC range 0.012–0.016mg/L) and C. krusei
ATCC6258 (BMD MIC range 0.06–0.12mg/L; Etest MIC range
0.0125mg/L); and at 48 h for C. parapsilosis ATCC22019 (BMD
MIC range 0.03mg/L; Etest MIC range 0.016–0.023mg/L) and C. krusei
ATCC6258 (BMD MIC range 0.25mg/L; Etest MIC range 0.0125–
0.19mg/L).
Similarly for all clinical isolates 100% of results were concordant at
both 24 h and 48 h with the exception of one 24 h inoculum suspension
(BMD 0.06mg/L versus Etest 0.25mg/L), one 48 h inoculum suspension
(BMD 2mg/L versus Etest 0.75mg/L) of C. glabrata 1547507; and two
inoculum suspensions (both BMD 1mg/L versus 0.38mg/L Etest) of
C. krusei 1547509.
Conclusions: For the ATCC quality control strains and susceptible
clinical isolates ISA Etest results correlated well with the CLSI M27-A2
BMD method. This agar-based method represents a simple and reliable
method for determining ISA susceptibility of Candida spp. Additional
testing will establish concordance between methods for ISA-resistant
isolates.
P1677 Natural coumarins from the plants Seseli devenyense and
Peucedanum luxurians as in vitro antibacterial agents
J. Widelski, K. Craikou, K. Glowniak, E. Chinou, I. Chinou (Lublin,
PL; Athens, GR)
Objectives: Coumarins constitute a major category of secondary plant
products that are widely distributed in the plant Kingdom. Very
interesting subclasses of this category are the linear or angular pyrano
and furanocoumarins that have been found to possess antiproliferative,
antiviral and antibacterial activities. The antimicrobial activity of a series
of 24 natural coumarins isolated from the plants Seseli devenyense and
Peucedanum luxurians from Poland, is evaluated against six pathogenic
bacteria.
Methods: The antimicrobial activities of the tested compounds were
determined, using the diffusion and dilution techniques and measuring
their MICs against Gram-positive bacteria (S. aureus, S. epidermidis),
Gram-negative bacteria (E. coli, E. cloacae, K. pneumoniae, P. aerug-
inosa) all of them strains of ATCC. Standard antibiotics were used in
order to control the sensitivity of the test organisms.
Results: Through the antimicrobial screening, the 24 tested com-
pounds showed a broad diversity regarding growth inhibitory activity.
Twelve compounds among the tested ones (cis-khellactone, laserpitine,
3′-angeloyl-khellactone, praeroside II, devenyol, denyosides A, B and C,
peucedanin, xanthotoxin, stenocarpin and isoimperatorin) appeared to
be signiﬁcantly active against all six tested bacteria (zones of inhibition
16−20mm, MIC values 0.05−3.5mg/mL), six others showed moderate
activity while a variety of six medium chain (C6-C12) aliphatic esters
of (+)-lomatin and (+)-cis-khellactone coumarins appeared completely
inactive.
Conclusions: The results of the assays suggest that the activity of the
tested coumarins can be attributed, to the existence of linear furan ring or
to oxygenated substituents to simple coumarins, while the derivatives of
the angular pyranocoumarins showed increased activities in comparison
with all the rest coumarins possessing another pattern of substitution.
P1678 New antiprotozoal drugs refered as antimicrotubular
haloacetamidobenzoates
P. Le Pape, A. Fellous, A. Valentin, S. Andrade, J. Kalil, M. Veauvy,
M. Le Borgne (Nantes, Toulouse, FR; Salvador de Bahia, Sao Paulo, BR)
Objectives: Protozoal diseases constitute a major world public
health problem. Malaria conveyed in the yearly deaths of 2,000,000
children and there would be 300 millions of new cases per year.
Concerning leishmaniasis, it is estimated that approximately up to
20−30 million people in 88 countries are infected. Chagas’ disease
is an anthropozoonosis due to Trypanosoma cruzi. Chagas’ disease is
widespread in Latin America where it strikes 20 millions of people.
The growing problem of drug resistance has greatly complicated the
treatment for these parasitic diseases. There is still a real need for active
new compounds that would provide therapeutic beneﬁts with less side
effects and a deﬁned cell target.
Methods: A new family of patented antimicrotubule drugs named
haloacetamidobenzoates (MF and GR derivatives) was designed and
evaluated against three protozoa, Plasmodium, Leishmania and Try-
panosoma. In vitro and in vivo models were developed. Mechanism of
action was studied by scanning electron microscopy, immunocytochem-
istry and microtubule assembly assay.
Results: MF29 and GR37 were found to be cytotoxic in vitro on
chloroquine resistant Plasmodium falciparum strains, Leishmania spp.
and Trypanosoma with IC50 values about 0.1mM. These compounds
were shown to be very poor inhibitors of in vitro mammal brain
microtubule assembly indicating parasite speciﬁcity. Parasite MAP2-like
proteins may increase strongly the sensitivity of parasite tubulins to the
drug. Concerning Plasmodium, the in vitro data have been conﬁrmed
in an in vivo murine model using Plasmodium berghei showing a
high reduction in mortality percentage and a moderate activity on
parasitaemia. In the visceral and cutaneous murine leishmaniasis models,
the reference drug antimoniate meglumine (Glucantime) showed a less
marked reduction in parasite organ load that the MF 29 compound.
Moreover a signiﬁcant reduction of mortality was observed when
infected mice by Trypanosoma cruzi are treated by MF 29 compound.
Conclusion: These data demonstrated the high level of antiprotozoal
activity of MF derivatives compared to other antimicrotubule agents
or other antileshmanial drugs. An interesting point of our work is
related to the fact that we have established the mechanism of action
of haloacetamidobenzoates with the precise identiﬁcation of the cellular
target.
P1679 In vitro activity of SS734, a novel ﬂuoroquinolone, against
pathogens associated with bacterial conjunctivitis
L.S. Brunner, S.E. Norton, J.M. Blondeau (Rochester, US; Saskatoon,
CA)
Objectives: SS734 is a novel ﬂuoroquinolone (FQ) compound being
investigated for the treatment of bacterial conjunctivitis (BC). We tested
the in vitro activity of SS734 against Gram-positive and negative
bacterial pathogens – including those resistant to various antimicrobial
agents – associated with BC.
Methods: Minimum Inhibitory Concentrations (MICs) were determined
on 627 clinical isolates following the recommended procedure of the
Clinical and Laboratory Standards Institute. MICs were performed by
broth microdilution: Brieﬂy, approximately 105 CFU/mL were exposed
to doubling dilutions of drug and following incubation in the appropriate
atmosphere and temperature for 18−24 hours, the lowest concentration
preventing growth was the MIC. Neisseria gonorrhoeae was tested by
agar dilution.
Results: The following MIC50 (mg/mL), MIC90 (mg/mL) and MIC range
(mg/mL) values respectively were recorded: N. gonorrhoeae (n = 107)
0.008, 0.015, 0.004–0.03; MICs to 2 quinolone resistant strains were 2
(mg/mL); H. inﬂuenzae (n = 105) 0.03, 0.06, 0.015–0.25; H. inﬂuenzae
b-lactamase (BL) positive, ampicillin resistant strains (n = 25) 0.03,
0.12, 0.015–0.25; E. cloacae extended-spectrum b-lactamase (ESBL)
negative (n = 92) 0.25, 8, 0.06−>8 and MICs tended to be higher
against ESBL positive isolates; S. aureus methicillin sensitive (MS) and
ciproﬂoxacin sensitive (CS) (n = 28) 0.03, 0.06, 0.015–0.25; S. aureus
methicillin resistant (MR) and ciproﬂoxacin resistant (n = 24) 1, 8, 0.5−8;
S. aureus MR CS (n = 25) 0.03, 0.06, 0.015−1; S. epidermidis MS
(n = 38) 0.03, 0.5, 0.03−1; S. epidermidis MR (n = 64) 0.5, 8, 0.015−>8;
S. aureus vancomycin intermediate (n = 23) 1, 2, 0.03−2; S. pneumoniae
(n = 78), 0.12, 0.12, 0.06−2, MIC values were not different for penicillin
susceptible or resistant strains and 1, 2, 0.5−8 against levoﬂoxacin
resistant strains (n = 25).
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Conclusion: SS734, a novel FQ being investigated for BC, is active
in vitro against Gram-negative and positive organisms including those
resistant to other antimicrobial agents. MICs for SS734 were well below
the expected drug concentrations delivered to the eye during therapy
even for ciproﬂoxacin or levoﬂoxacin resistant organisms.
P1680 Bactericidal activity of SS734, a novel ﬂuoroquinolone,
against pathogens associated with bacterial conjunctivitis
L.S. Brunner, P.A. Walsh, S.E. Norton, J.M. Blondeau (Rochester,
US; Saskatoon, CA)
Objectives: SS734 is a novel ﬂuoroquinolone (FQ) currently under
development for the treatment of bacterial conjunctivitis. We performed
time kill studies on SS734, norﬂoxacin (NRFX), and ciproﬂoxacin
(CPFX) against a variety of ocular isolates from clinical sources.
Methods: Two isolates of each organism were chosen for time kill
analysis based on their range of NRFX and CPFX activity. SS734,
NRFX, and CPFX at concentrations of 1 (1×), 2 (2×), and 4 (4×)
times the MIC90 values were inoculated with approximately 105 cfu/mL
challenge organisms. At each sampling time point, the test samples were
diluted in physiologic saline and spread plated onto appropriate agar.
After aerobic incubation, the colonies were counted and the viable cells
per milliliter were calculated.
Results: SS734 has rapid bactericidal activity against Streptococcus
pneumoniae (Sp), Staphylococcus aureus (Sa), coagulase-negative
Staphylococcus (cnS), and Haemophilus inﬂuenzae (Hi). The percent
reduction in viable cells (and log10 reduction) following exposure of
2−4× the MIC90 for SS734, NRFX and CPFX, respectively, was as
follows: Sp at 60 minutes (min) 57−77 (0.4−0.7), 43−68 (0.3−0.5),
46−56 (0.3−0.4); Sa at 30min 74−97 (0.6−1.8), −7–+7 (0−0.1),
38−43 (0.3−0.4); cnS at 30min 88−90 (0.9−1), 5−10 (0.1−0.1), 27−23
(0.2−0.1); and Hi at 45min 63−88 (0.5−1), 35−59 (0.2−0.4), 68−74
(0.6−0.6). MIC90 values for SS734 were 4−128 fold lower than CPFX
and NRFX for Gram-positive organisms and equivalent for Haemophilus
inﬂuenzae.
Conclusion: SS734 was rapidly bactericidal against all strains tested
and showed a more rapid killing rate than NRFX and CPFX. Based on
the time kill studies against these pathogens associated with bacterial
conjunctivitis, SS734 looks to be a suitable ﬂuoroquinolone compound
for further clinical investigation.
P1681 In vitro activity of three echinocandins (caspofungin,
micafungin and anidulafungin) against Aspergillus spp.
A.I. Martos, C. Martin de la Escalera, E. Lopez-Oviedo, A.I. Aller,
A. Romero, C. Serrano, A. Valverde, E. Martı´n-Mazuelos (Seville, ES)
Objective: Echinocandins are a novel class of antifungal agents with
an excellent activity against Aspergillus spp. The in vitro activity of
caspofungin (CF), micafungin (MF) and anidulafungin (AF) were tested
against clinical isolates of Aspergillus spp.
Material and Methods: Forty-one clinical isolates of Aspergillus spp.
were used in the study: 28 isolates of A. fumigatus, 10 isolates of A. ﬂavus
and 3 A. terreus. The susceptibility testing to these three echinocandins
were performed by the broth microdilution (MD) procedure according
to the CLSI M-38A document. The ranges of drugs dilution were
0.03−8mg/L. Inoculum suspensions were prepared recovering the
conidia from a 7-day culture growth on Potato Dextrose Agar at
35ºC (ﬁnal inoculum: 0.5−5×104 CFU/mL). MECs (Minimal Effective
Concentrations) were determined and the readings were performed at
48 h (Kurtz et al. 1994, AAC 38: 1480–1489). Candida parapsilosis
22019, C. krusei 6258, A. fumigatus 204305 and A. ﬂavus 204304 were
included as Quality Control strains.
Results: MECs50, MECs90 and ranges of MECs (mg/L) of CF, MF and
AF are shown in Table 1. The MECs were  0.25mg/mL for all strains
tested. MF and AF shown similar MECs ( 0.03mg/L) while CF MECs
range were from 0.03 to 0.25mg/L. The Quality Control strains were
within the published range.
Table 1.
Speciesa MEC (mg/L)
Caspofungin Micafungin Anidulafungin
Range MEC50 MEC90 Range MEC50 MEC90 Range MEC50 MEC90
A. fumigatus (28) 0.03–0.25 0.06 0.125 0.03 0.03 0.03 0.03 0.03 0.03
A. ﬂavus (10) 0.03–0.25 0.06 0.06 0.03 0.03 0.03 0.03 0.03 0.03
A. terreus (3) 0.125 0.03 0.03
Total (41) 0.03–0.25 0.06 0.25 0.03 0.03 0.03 0.03 0.03 0.03
aNumber of isolates given in parentheses.
Conclusion: These three echinocandins shown an excellent in vitro
activity against all clinical isolates of Aspergillus spp. tested.
P1682 In vitro activity of tigecycline against multiresistant
Acinetobacter baumannii clinical isolates
A. Stylianakis, A. Koutsoukou, S. Tsiplakou, S. Sardiniari, A. Vourtsi,
A. Kolokouri (Athens, GR)
Objectives: The purpose of our study was to evaluate the in vitro activity
of tigecycline against multiresistant Acinetobacter baumannii clinical
isolates.
Methods:We examined 276 non duplicated multiresistant Acinetobacter
baumannii isolates recovered from blood cultures, bronchoalveolar
excretions and pus and urine samples derived from ICU-patients of our
hospital during a one year-time period. The identiﬁcation of the isolates
and the susceptibility testing were performed by the automated VITEK2
system (bioMe´rieux, France). The susceptibility testing for tigecycline
was performed by Kirby-Bauer disk diffusion method and done by
direct colony suspension according to CLSI guidelines. Paper disks
containing tigecycline at 15mg per disk were used (Becton-Dickinson,
USA). The determination of tigecycline-MIC values was performed by
E-test strips according to the manufacturer’s guidelines (AB-Biodisk,
Sweden). Isolates with an inhibition zone diameter of 19mm and with
an MIC level  1mg/L were considered as susceptible to tigecycline
(MIC-susceptibility limits determined by EUCAST).
Results: All the Acinetobacter baumannii clinical isolates were resistant
to aminoglycosides, b-lactams, carbapenems, monobactames, furanes,
cinolones except colistin. The tigecycline was found absolute active to
all the examined multiresistant isolates. The inhibition diameter zones
were found of  20mm and the MIC levels of  0.5mg/L
Conclusion: Tigecycline is absolute active to all the multiresistant
Acinetobacter baumannii isolates and it is consisted a very important
option for treatment of serious infections caused by these isolates.
Clinical laboratories should be aware of testing tigecycline susceptibility
in Acinetobacter baumannii isolates; so that any emergence of
tigecycline-resistance may be detected as soon as possible.
P1683 Analysis of reports of Clostridium difﬁcile infection in phase
2 and 3 studies of tigecycline
M. Wilcox, J. Freeman (Leeds, UK)
Objectives: Antibiotics vary in their propensity to induce C. difﬁcile
infection (CDI). Anaerobic and/or broad spectrum activity may be
associated with increased risk of CDI, although these associations are
not clear. We reviewed the reports of possible CDI in tigecycline pre-
registration studies to determine whether this extended broad spectrum
activity antibiotic has increased risk of inducing CDI.
Methods: Clinical trial database searches were performed on all
completed Phase 2 (n = 4) and 3 (n = 9) studies; 7 of the 9 phase 3
studies were originally blinded. To identify subjects who may have
had CDI associated with tigecycline or comparator therapy, searches
were performed for adverse event terms, indications for receipt of
concomitant antibiotics, and the results of local hospital faecal sample
investigations. A diagnosis of CDI required symptoms (diarrhoea,
abdominal pain/distension, colitis) to be present for at least 48 h; 2
cases (1 tigecycline and 1 comparator), who also received no antibiotic
treatment for CDI, were excluded on this basis. Cases who had symptoms
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of (n = 1) or were being treated for (n = 5) CDI at the time that study
antibiotic was started were also excluded.
Results: Records of 2,402 tigecycline and 1,892 comparator (825
imipenem, 589 vancomycin ± aztreonam, 422 levoﬂoxacin, 52
ciproﬂoxacin and 4 linezolid) recipients were searched for evidence of
CDI. After the above exclusions there were 9 possible cases of CDI.
Of these, 5 received tigecycline, 3 comparator and 1 tigecycline (5
days) and then oral comparator (levoﬂoxacin) for 5 days. The latter
case developed symptoms of CDI 4 days after stopping levoﬂoxacin,
and therefore causality with either antibiotic could not be established.
The tigecycline associated CDI cases received 3−6 (median 3) other
antibiotics before onset of symptoms. Of the comparator associated CDI
cases, 2 (imipenem) each received 3 other antibiotics before onset of
symptoms; the remaining case received only the comparator antibiotic
(levoﬂoxacin). All of the cases were mild-moderate in severity.
Conclusion: CDI was uncommon following tigecycline administration,
was associated with prior exposure to other antibiotics, and was of a
similar frequency to that seen with comparator antibiotics (~0.2% of
study recipients). The extended broad spectrum activity of tigecycline
does not appear to result in increased risk of CDI.
P1684 Tigecycline in vitro activity against often difﬁcult to treat
European pathogens
D. Hoban, B. Johnson, R. Badal, S. Bouchillon, M. Hackel, J. Johnson,
M. Dowzicky (Schaumburg, Collegeville, US)
Background: Enhanced activity agents such as tigecycline (TIG) may
offer antibacterial coverage of common pathogens including multi-drug
resistant Gram-negatives/positives. The T.E.S.T. programme monitored
the in vitro activity of TIG and comparators against current European
pathogens.
Methods: 62 hospital sites in 19 European countries collected over
11,494 clinical isolates from community/hospital infection sites. MICs
were determined to TIG and comparators using broth microdilution
panels, interpreted according to EUCAST guidelines.
Results: Selected European pathogens tested against tigecycline are
shown in the table.
Tigecycline MIC % inhibited at MIC %S*
Organism (#) MIC50 MIC90 0.5 1 2 4
A. baumannii (669) 0.25 1 80.3 96.3 99.0 100 na
E. faecalis (679) 0.12 0.25 100 100
EC, KO, KPa (3,056) 0.25 1 89.8 95.5 97.8 99.7 95.5
ESBLb (276) 0.5 2 75.4 86.2 93.1 97.8 86.2
Enterobacter spp. (1,455) 0.5 2 74.9 88.5 94.6 99.2 88.5
H. inﬂuenzae (814) 0.12 0.25 96.6 98.6 100 na
P. aeruginosa (1,236) 8 >16 1.5 3.2 7.8 25.4 na
S. agalactiae (520) 0.03 0.12 100 100
S. aureus (MR) (1,340) 0.12 0.25 100 100
S. pneumoniae (752) 0.03 0.5 100 na
aEC: E. coli, KO: K. oxytoca, KP: K. pneumoniae.
bESBL-producing EC, KO and KP.
cEUCAST approved breakpoints (2006) where available; na = not yet available.
Conclusions: European isolates of both Gram-positive and -negative
community/hospital pathogens (excluding Pseudomonas) demonstrated
very good TIG MIC90s and % susceptible. For most organ-
isms/phenotypes, TIG MIC90s were 1mg/mL and % susceptible >95%.
TIG activity was reduced against European ESBL-producing Enterobac-
teriaceae isolates (MIC90 = 2; %S= 86.2). TIG promises expanded broad
spectrum activity against multiply resistant European pathogens.
P1685 In vitro activity of tigecycline and 10 common therapeutic
agents against methicillin-resistant Staphylococcus
aureus and vancomycin-resistant Enterococcus species –
Global Data, 2004−2006
R. Badal, J. Johnson, D. Hoban, B. Johnson, S. Bouchillon, M. Hackel,
M. Dowzicky (Schaumburg, Collegeville, US)
Background: Tigecycline (TIG), a member of a new class of
antimicrobials (glycylcyclines), has been shown to have potent activity
against community and hospital acquired staphylococcal and entero-
coccal pathogens. The T.E.S.T. programme determined the in vitro
activity against methicillin-resistant S. aureus and vancomycin-resistant
Enterococcus spp. of TIG and 10 antimicrobials commonly prescribed
for serious Gram-positive infections: amoxicillin-clavulanic acid (AUG),
piperacillin-tazobactam (PT), levoﬂoxacin (LVX), ceftriaxone (CAX),
linezolid (LZD), minocycline (MIN), vancomycin (VAN), ampicillin
(AMP), penicillin (P), and imipenem (IMP). Study strains were collected
from 272 laboratories in 34 countries globally throughout 2004–2006.
Methods: A total of 9,806 clinical isolates (3,925 enterococci, 5,881
S. aureus) were identiﬁed to the species level at each participating
site and conﬁrmed by a central laboratory. Minimum Inhibitory
Concentrations (MICs) were determined by the local laboratory using
broth microdilution panels. Antimicrobial resistance was interpreted
according to CLSI breakpoints with TIG susceptible breakpoints deﬁned
as 0.5mg/mL for S. aureus and 0.25mg/mL for enterococci.
Results: 14.4% (565/3,925) of enterococci were resistant to vancomycin
(VRE), and 45.4% (2,669/5,881) of S. aureus were resistant to oxacillin
(MRSA). Among the VRE, % resistance rates to other study drugs were
LVX 99.6, P 99.1, AMP 97.9, VAN 96.6, MIN 11.9, and LZD 0.0.
Resistance rates for MRSA were P 100, AMP 100, AUG 99.8, LVX
100, PT 99.3, CAX 98.9, IMP 100, MIN 0.7, LZD 0.0, and VAN 0.0.
TIG inhibited 100% of the enterococci and S. aureus resistant to other
drugs. Modal TIG MICs for VRE/nonVRE were 0.03/0.06, and 0.12/0.12
for MRSA/MSSA).
Conclusions: TIG retained potent activity against drug-resistant
S. aureus and enterococcal isolates, inhibiting 100% of all strains tested
at their deﬁned breakpoints of 0.5 and 0.25mg/mL, respectively. TIG
should prove to be a useful drug for therapy of infections with these
resistant Gram-positive pathogens.
P1686 Resistance to tigecycline and other non b-lactam antimicro-
bials of MRSA strains collected in Austria in 2005/2006
C. Jebelean, K. Pfeil, C. Luger, S. Stumvoll, M. Stammler, B. Sammer,
H. Mittermayer (Linz, AT)
Objectives: The prevalence of MRSA is rising in many European
countries.
The aim of our study was to investigate the epidemiology and the
prevalence of resistance to tigecycline (TG) and other non b-lactam
antimicrobials of Austrian MRSA strains.
Materials and Methods:We determined the resistance to: erythromycin
(E), clindamycin (LC), gentamicin (G), fosfomycin (FOS), fusidic acid
(FU), tetracycline (T), vancomycin (V), teicoplanin (TE) using the agar
dilution method as recommended by CLSI, the resistance to linezolid
(L) and TG by E-Test method and the resistance to mupirocin (MUP)
by disk diffusion method of 128 MRSA strains collected allover Austria
during 2005–2006.
Additionally, we screened for heterogeneous VISA using a BHI agar
plate containing 4mg/L TE and the E-Test Macromethod with V and
TE. For all the strains we determined the mecA and femA gene using a
multiplex PCR. For subtyping we performed coagulase gene PCR with
restriction digestion of PCR products with AluI, and we further analysed
the PFGE patterns.
Results: Overall the E, LC, G, FOS, T, FU, L, V, TE, TG and MUP
resistance was 71%, 54%, 59%, 27%, 11%, 7%, 0%, 0%, 0%, 0%, 12%,
respectively, with higher prevalence in Carinthia and Lower Austria and
lower prevalence in Upper Austria and Salzburg. 3 MRSA strain were
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sent for hVISA conﬁrmation by PAP-analysis. Among the MRSA strains
we found following sequence types (ST): ST228 (30%), ST8 (29%),
ST22 (15%), ST5 (12%), and other types under 3% each.
Conclusions: In comparison with resistance data up to 2003 from Upper
Austria we observed an increase in G and T resistance, a decrease in
FOS resistance and a stable resistance rate to LC and FU. All strains
were susceptible to L and TG. The ST distribution was more diverse in
Vienna and Salzburg and with strong dominant types in Carynthia and
Lower Austria were the resistance rate was also higher.
P1687 Marked tigecycline and colistin synergistic bactericidal
effect against a nosocomial epidemic carbapenemase
(VIM-1) producing Klebsiella pneumoniae clone
M.I. Morosini, M. Garcı´a-Castillo, M. Tato, V. Pintado, F. Baquero,
J. Cobo, R. Canto´n (Madrid, ES)
Tigecycline, a new available glycylcycline derivative, is one of the
few alternatives for the treatment of Gram negative bacilli harbouring
extended-spectrum b-lactamases and its role against carbapenemase-
producing strains is also advocated. Colistin comprises another option
in these cases.
Objectives: The activity of tigecycline and colistin, alone or in
combination, was assessed in time-kill studies against a multiresitant
VIM-1-producing Klebsiella pneumoniae epidemic clone recovered in
Madrid (Spain) in 2005.
Methods: Tigecycline and colistin sulphate MICs were determined
by the standard broth macrodilution method (CLSI). Duplicate killing
curves (Lorian, 1991) with each compound alone or in combination at
1xMIC and 2xMIC and at the serum peak concentration achievable after
standard dosing regimens (1mg/L for tigecycline and 4mg/L for colistin)
were performed.
Results: MICs were 0.5mg/L for tigecycline and 1mg/L for colistin.
Tigecycline was bacteriostatic at all tested concentrations whereas col-
istin exhibited concentration-dependent bactericidal activity. Tigecycline
and colistin combinations were markedly synergistic at 3 hours (106
drop in CFU per mL). Moreover, consistent regrowth at 6 hours
observed with single-colistin exposure with all tested concentrations was
delayed with tigecycline until 12 hours, even with the lowest tigecycline
concentration.
Conclusion: Tigecycline and colistin act synergistically rendering
complete killing of a VIM-1 producing K. pneumoniae epidemic clone at
3 hours. Tigecycline abolishes consistent regrowth observed with single-
colistin exposure. In vitro synergistic activity of both compounds gives
support to the possible treatment of infections caused by carbapenemase-
producing isolates. Addition of tigecycline may allow reducing colistin
doses lowering secondary toxicity. Optimal regimens remain to be
determined.
P1688 In vitro activity of tigecycline and other antimicrobial agents
against extended-spectrum b-lactamase E. coli producers
C. Rodriguez-Avial, O. Lo´pez, I. Rodriguez-Avial, E. Hernandez,
J. Picazo (Madrid, ES)
Objective: Tigecycline is likely to have a role in the treatment of
infections due to multirresistant pathogens. ESBL-producing E. coli are
being recognized as an increasing problem. When they are isolated from
patients with urinary tract infections (UTI), they leave few therapeutical
options. We sought to determine the incidence and susceptibility patterns
of ESBL-E. coli isolated in urine samples in our laboratory in 2005.
Methods: A total of 5.053 E. coli were isolated from urine samples.
The MICs of the b-lactamic agents: cefotaxime, ceftazidime, aztreonam
and cefepime, with and without clavulanic acid, amoxycillin-clavulanate,
cefoxitin, imipenen (I) and ertapenem (E), and the non b-lactamic:
ciproﬂoxacin (CIP), tetracycline (T), tigecycline (TY), gentamycin (G)
and nitrofurantoin (N) were determined by agar dilution method (CLSI
guidelines), fosfomycin (F) and co-trimoxazol (SXT) were tested by Etest
method. The origin (hospital or community) was also determined.
Results: Of the 5.053 E. coli isolates, 216 (4, 2%) were ESBL producers
(CLSI Conﬁrmatory test). ESBL-E. coli (n = 192, one isolate per
patient) showed also elevated resistance percentages to non-b-lactamic
agents: CIP 83%, T 69%, SXT 58% and G 15%. Resistance was low
for N 3% (MIC90: 64mg/L), and F 3, 7% (MIC90: 16mg/L). No
resistance was found to the b-lactamic agents I (MIC90: 0.25mg/L)
and E (MIC90: 0.12mg/L) and to TY (MIC90: 2mg/L). We observed a
greater proportion (67%) of ESBL-E. coli isolates from non-hospitalised
patients.
Conclusions: F and N showed good activity against ESBL-E. coli,
and are options for the treatment of uncomplicated UTI in the greater
proportion of ESBL-E. coli isolated in non-hospitalised patients. I and
E showed very high activity, making carbapenems a good option for the
treatment of complicated UTI. TY was very active against our ESBL-
E. coli producers. Tigecycline is likely to have a role in the treatment
of infections due to multirresistant pathogens including ESBL-E. coli
producers.
P1689 Antimicrobial activity of tigecycline and daptomycin against
Gram-positive cocci: a multicentre study in Greek hospitals
F. Kolonitsiou, A. Pratti, I. Spiliopoulou, M. Karanika,
S. Alexiou-Daniel, D. Bakola, M. Vergi, M. Oeconomou,
C. Koutsia-Karouzou, H. Malamou-Lada, L. Zerva, E. Petinaki (Patras,
Larissa, Thessaloniki, Lamia, Athens, GR)
Objectives: During the last decades, the emergence of Gram-positive
strains resistant to different antimicrobial agents has become a serious
medical problem. New compounds that are effective against infections
caused by multi-resistant Gram-positive cocci are urgently needed. In
the present study we tested the activity of tigecycline and daptomycin
against a large number of recent Gram-positive cocci, collected in seven
Greek hospitals located in different regions
Methods: From January 2005 to August 2006 a total of 3,160 Gram-
positive cocci (870 Staphylococcus aureus, 700 coagulase-negative
staphylococci, 400 Enterococcus faecalis, 320 Enterococcus faecium,
200 Streptococcus pneumoniae, 200 Streptococcus agalactiae, 300
Streptococcus pyogenes and 170 viridans streptococci) were isolated in
seven different Greek hospitals, from clinically signiﬁcant specimens
(blood, pus, pleural ﬂuid, etc). MICs to tigecycline and daptomycin were
determined by the E-test. Susceptibility for tigecycline and daptomycin
was deﬁned as approved by US-FDA.
Results: Table 1 summarises the MICs modal, MIC50 and MIC90
of the isolates tested. According to the US-FDA criteria, six MSSA
were not susceptible to tigecycline, having MICs 0.75mg/L; on the
other hand among E. faecalis, twelve isolates had MICs greater than
the breakpoints proposed (four with MICs 0.5mg/L, ﬁve with MICs
0.75mg/L and three with MICs 1mg/L). Among E. faecium, 30 isolates
had MICs greater than 0.25mg/L, while among coagulase-negative
staphylococci 35 isolates had MIC greater than 0.5mg/L. Based on the
FDA breakpoints for daptomycin, all S. pyogenes, S. agalactiae, and
E. faecalis were susceptible to daptomycin. However, 52 MRSA and 59
MSSA had MICs greater than 1mg/L.
Table 1. MICs of isolates tested against tigecycline and daptomycin
Tigecycline Daptomycin
Isolates No MICmodal Range MIC50 MIC90 MICmodal Range MIC50 MIC90
MRSA 348 0.125 0.016−0.5 0.069 0.109 0.909 0.125−3 0.438 0.791
MSSA 522 0.133 0.064–0.38 0.077 0.112 0.8 0.19−3 0.234 0.624
E. faecalis 400 0.311 0.047−1 0.16 0.255 1.49 0.19−3 1.005 1.363
E. faecium 320 0.26 0.064−1.5 0.118 0.204 2.17 0.5−4 1.36 1.905
CoNS-ME 120 0.187 0.064–0.75 0.104 0.141 0.317 0.023−1.5 0.123 0.241
CoNS-MR 580 0.215 0.094−1.5 0.076 0.151 0.57 0.125−5 0.244 0.436
S. pneumoniae 200 0.185 0.094−0.5 0.125 0.155 0.78 0.125−1 0.5 0.62
S. agalactiae 200 0.137 0.047−0.5 0.073 0.103 0.15 0.064–0.75 0.089 0.118
S. pyogenes 300 0.157 0.047−0.5 0.082 0.132 0.148 0.125−1 0.125 0.35
S. viridans 170 0.123 0.015–0.38 0.114 0.120 0.86 0.06−1 0.5 0.7
Conclusions: This is the ﬁrst multi-centre study in Greece, conﬁrming
the good in vitro activity of tigecycline and daptomycin against a range
of Gram-positive pathogens.
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P1690 In vitro activity of tigecycline against multidrug resistant
A. baumannii isolates
G. Yilmaz Bozkurt, K.O. Memikoglu, H. Kutlu, A. Azap, F. C¸okc¸a
(Ankara, TR)
Objectives: Acinetobacter baumannii is one of the important pathogens
of the hospital infections. The evaluation of the in vitro activity of tige-
cycline in comparison to imipenem, meropenem, tazobactam-piperacillin
and cefoperazone-sulbactam against Acinetobacter baumannii strains.
Methods: A total of 100 Acinetobacter baumannii clinical strains
isolated during the period of September 2005–September 2006 were
tested. The isolates originated from a wide variety of clinical specimens
including tracheal aspirate (30), sputum (6), blood (17), central venous
catheter (4), abscess-wound swabs (30), abdominal drain ﬂuid (4),
cerebrospinal ﬂuid (1), pleural ﬂuid (1), bile (1), urine (5). Sixty
percent of these isolates was from clinics of surgery where as 40% was
from internal medicine clinics. Their Minimum Inhibitory Concentration
(MICs) were determined by using E-Test according to CLSI (Clinical
Laboratories Standarts Institute) guidelines.
Results: Overall MIC90 to tigecycline, imipenem, meropenem,
tazobactam-piperacillin and cefoperazone-sulbactam were 6mg/L,
>32mg/L, >32mg/L, >256mg/L, >256mg/L, respectively, whereas
MIC50 were 2mg/L, >32mg/L, >32mg/L, >256mg/L, 32mg/L,
respectively.
Conclusion: In general, tigecycline showed better in vitro activity
than imipenem, meropenem, tazobactam-piperacillin and cefoperazone-
sulbactam against Acinetobacter baumanii strains. The results show
that tigecycline should be considered as a possible alternative for the
treatment of Acinetobacter baumannii infections.
P1691 Activity of tigecycline against ESBL-producing
enterobacteria spreading in Italy
F. Luzzaro, C. Mugnaioli, S. Gualandris, L. Pallecchi, G. Brigante,
B. Pini, G.M. Rossolini, A. Toniolo (Varese, Siena, IT)
Background: Tigecycline is a new glycylcycline active against a variety
of Gram-positive and Gram-negative resistant pathogens. We evaluated
tigecycline activity against a collection of clinical isolates of multidrug-
resistant (MDR) enterobacteria producing different types of extended-
spectrum b-lactamases (ESBL) from a recent Italian nationwide survey.
Methods: ESBL-producing enterobacteria were tested for susceptibility
to tigecycline and other agents by broth microdilution (Microscan panels,
Dade-Behring). The collection included isolates of Escherichia coli
(n = 138), Klebsiella pneumoniae (n = 64), Klebsiella oxytoca (n = 14),
Enterobacter aerogenes (n = 25), Enterobacter cloacae (n = 12), Serratia
marcescens (n = 12), and Citrobacter spp. (n = 15), producing TEM, SHV
and/or CTX-M type ESBLs. Detection of tetracycline resistance genes
[tet(A), tet(B), tet(C) and tet(D)] was performed by PCR.
Results: Overall, 275/280 ESBL-positive isolates (98.2%) were sus-
ceptible to tigecycline (MIC 2mg/L). Susceptibility rates were
100% among E. coli, including members of the CTX-M-15-producing
E. coli clones causing major outbreaks in some Italian hospitals.
Susceptibility rates were 97.4% among Klebsiella spp. and 95.3%
among other Enterobacteriaceae. Overall, MIC50/90 of tigecycline were
0.25/1.0mg/L. E. coli showed MIC50/90 values (0.25/0.5mg/L) lower
than those of other species (0.5/2.0mg/L). The presence of tet(A),
(B), and/or (D) determinants did not affect susceptibility to tigecycline
(MIC50/90 0.25/1.0mg/L for both tet-negative and tet-positive isolates).
Conclusion: Tigecycline showed potent in vitro activity against the vast
majority of ESBL-producing enterobacteria circulating in Italy. It might
thus represent a valid therapeutic option for treating selected infections
caused by these MDR pathogens.
Support from Wyeth Lederle Italia SpA is gratefully acknowledged.
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P1692 Environmental decontamination of an intensive care unit
to control outbreaks of multidrug-resistant Gram-negative
rods using hydrogen peroxide vapour
M. Schouten, J. Otter, A. van Zanten, G. Houmes-Zielman,
M. Nohlmans-Paulssen (Ede, NL; London, UK)
Objectives: 25 patients on our 12-bed intensive care unit (ICU)
acquired multidrug-resistant Gram-negative rods (MDR-GNR) over an
8-month period, comprising Enterobacter cloacae (7) and Acinetobacter
baumannii (18). Transmission continued despite the implementation of
standard infection control measures including an emphasis on hand and
environmental hygiene. We investigated the microbiological and clinical
impact of hydrogen peroxide vapour (HPV) decontamination of the entire
ICU.
Methods: All patients were temporarily relocated from the ICU and
the entire unit was decontaminated using HPV. 100 cm2 sterile cotton
gauzes were moistened in sterile water and used to sample 41×1m2
areas after cleaning (which included 1,000 ppm sodium hypochlorite
for surfaces and 70% alcohol for equipment) but before HPV. Nine
matched adjacent areas were sampled after HPV decontamination.
Gauzes were subcultured on blood and MacConkey agar after
overnight broth enrichment. Thirty commercially-available Geobacillus
stearothermophilus biological indicators (BIs) with an inoculum of
>1.0×106 were located around the periphery of the unit, collected at
the end of the HPV cycle and cultured according to the manufacturer’s
instructions.
Results: HPV decontamination of the unit took approximately 12 hours
and was completed without incident or damage to the materials and
equipment in the ICU. 9 (22%) of 41 areas cultured after cleaning but
before HPV yielded MDR-GNR, including patient strains of E. cloacae
and A. baumannii. These areas were sampled after HPV and yielded
no MDR-GNR; however Bacillus sp. was cultured from 5 sites and
Staphylococcus aureus (sensitive to methicillin) from 1 site. All BIs were
killed by the process. No acquisition of MDR-GNR occurred on the unit
for approximately two months after HPV decontamination. However,
transmission of MDR-GNR has since been identiﬁed on the unit.
Conclusions: HPV proved to be more efﬁcacious than conventional
cleaning methods for reducing the bio-burden on our ICU. Although
several sites remained contaminated following HPV, none were
contaminated with MDR-GNR and we sampled large areas, including
surfaces which may have been occluded from HPV. HPV appeared to
break the cycle of transmission on the unit, but MDR-GNR re-occurred
a few months later. The source of reintroduction is currently unknown.
P1693 Comparative incidence of fungal and bacterial infections in
haematological patients occurring before, during and after
the installation of HEPA ﬁlters in individual patient rooms
R. Araujo, A. Carneiro, J. Guimaraes, A. Rodrigues (Porto, PT)
Objective: Extensive intervention was undertaken in the Haemato-
Oncology Unit of the Department of Clinical Haematology, Hospital
S. Joao, in June 2005: 8 rooms with high efﬁciency particulate air
(HEPA) ﬁlters and two 3-bed rooms were built, in order to prevent
infections in high risk neutropenic patients. The objective of this study
was to evaluate the incidence of fungal and bacterial infections in
haematological patients admitted before, during and after the installation
of the new wards.
Methods: All patients admitted in the department from April 2004
to December 2005 were enrolled. Data regarding haematological
disease, length of stay, reason of admission, hospital acquired-infections,
therapeutic options and, whenever, origin of infection were registered.
Air surveillance was simultaneously performed using the Andersen one
stage sieve impactor.
Results: A total of 287 admissions were registered in the department,
corresponding to 171 patients, during the surveillance period. The
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incidence of fungal and bacterial infections was higher in the group
of patients with acute leukaemia and aplastic anaemia, infections being
associated to prolonged neutropenia. Mould infections, mostly due to
Aspergillus spp., were reduced after the renovation works and installation
of HEPA ﬁlters, as well as Staphylococcus infections. The period after
renovation works also revealed a reduction of 16.7% of central venous
catheter related infections and of 47.9% of microbial agents isolated
from bronchial secretions of patients with acute leukaemia and aplastic
anaemia. Interestingly, in the last period Candida infections were more
common in patients admitted in wards with no air ﬁltration system versus
rooms with HEPA ﬁlters. The new rooms with HEPA ﬁlters showed large
improvements on air quality, especially after the ﬁrst week.
Conclusions: Patients with hospital stays longer than 3−4 weeks and
with prolonged neutropenia are more susceptible to develop fungal
infections, usually associated to the isolation of other microbial agents
and the administration of wide spectrum antibiotics. The improvement
of indoor air quality in hospital environment after the installation
of HEPA ﬁlters in individual rooms effectively reduced invasive
infections in haematology patients, mainly caused by Aspergillus spp.
and Staphylococcus spp.
P1694 Risk of occupational infections due to occupational
exposures in healthcare workers
S.A. Nemli, I. Ozgunes, S.N. Alpat, E.D. Kartal, N. Erben, G. Usluer
(Eskisehir, TR)
Healthcare workers (HCWs) are exposed to the risk of occupational
infections due to accidental exposures such as needlestick injuries
(NSIs), sharps injuries (SIs) and contaminated blood or body ﬂuids
(CBBFs).
The objectives of this study were to determine the rates of bloodborne
exposures and related risk factors experienced by HCWs at a University
Hospital during 2005–2006.
One hundred and thirty HCWs ﬁlled out a questionnaire devised to
determine the numbers of occupational exposures they had experienced
and reported, condition of hepatitis B virus (HBV) immunisation,
behaviours on performing procedures that can cause occupational
exposures. 26.2% of them were male, 73.8% were female. 50% of
participants were physicians and rests of them were nurses. 60% of
participants had been working in internal medicine departments, 40% in
surgical departments. 95.4% of participants determined at least one
or more occupational exposure during their whole career. 79.2% of
participants determined at least one or more occupational exposure
during the preceding 1 year. 31.5% of them experienced SIs, 71.5% NSIs,
33.8% mucosal exposure of CBBFs. 90.4% of participants working in
surgical departments experienced any occupational exposure during the
preceding year and this was statistically signiﬁcantly more compared
to internal departments. Therefore 17.5% of participants exposed to
accidental exposure during last one year reported these exposures, 12.3%
of NSIs, 4.6% of CBBFs.
10% of participants had a history of previous HBV infection. 83.8%
of participants had a history of vaccination and 70.7% were vaccinated
three doses of HBV vaccine. 73.8% of participants were tested for HBV
and 92.7% of them had protective anti HBV level 10 IU/mL or above.
59.6% of vaccinated participants had a history of vaccination after they
started working.
Despite 83.1% of HCWs agreeing that using gloves decreases the
risk of transmission of bloodborne pathogens, only 16.2% of HCWs
reported they always wore gloves prior to any IV applications. 79.2%
of HCWs reported that they feel themselves at risk about transmission
of bloodborne pathogens. The ratio was signiﬁcantly higher for nurses
(58/65; 89.2%) compared to physicians (45/65; 69.2%).
These ﬁndings show that HCWs are at high risk for occupational
injuries. Providing education about universal precautions and bloodborne
pathogen exposure is crucial for the safety of HCWs. But it is difﬁcult
to change behaviours.
P1695 Hepatitis C virus kinetics during the acute phase of
infection after occupational exposure in healthcare workers
M. Pape, K. Mandraveli, A. Politou, I. Isticoglou, S. Alexiou-Daniel
(Thessaloniki, GR)
Objective: The aim of our study was to estimate the host immune
response in the initial phase of infection after occupational exposure
in healthcare workers (HCWs) and to evaluate HCV-RNA, anti-HCV
and ALT levels as markers of acute infection and reliable predictors of
infectivity.
Methods: Over a 4-year period (1998–2002), 134 occupational
exposures of HCWs to possible infectious for HCV material, were
reported in AHEPA University Hospital. Blood specimens from HCWs
and source patients were drawn for the identiﬁcation of their immune
status to HBV, HCV and HIV. The HCWs were also followed up at 3, 6, 9,
16 weeks with repeated tests for anti-HCV, HCV-RNA and ALT. Anti-
HCV immunoreactivity was conﬁrmed by a line immunoassay. HCV-
RNA was detected by using the Cobas Amplicor HCV v2.0 assay. HCV
genotyping was performed in all HCV-RNA positive HCWs.
Results: Forty-six source patients were found to be anti-HCV positive.
None of these were positive for HIV or HbsAg. In the remaining 88
of the injuries the source of the contact was not known. Among the 46
anti-HCV(+) patients, twelve (26%) had detectable HCV-RNA levels,
with 1b genotype being the predominant one. One HCW demonstrated
elevated ALT on 6th, 9th and 16th, two on 6th and one on 9th week,
respectively. ALT levels were normalised during the remaining follow-up
period. One HCW seroconverted for anti-HCV antibodies on 16th week
and 6 months after exposure. Anti-HCV antibodies were also detected
in two others HCWs on 6th and 9th and on 9th week, respectively.
Two HCWs had detectable HCV-RNA on 6th, 9th, 16th and on 6th
and 9th week, respectively. HCV RNA was detected in four HCWs
only on the 6th week after exposure. All HCWs 6 and 12 months
after exposure were HCV-RNA negative. Three HCWs were assigned to
genotypes 1b, 2 and 3 respectively. Genotype could not be determined
in the remaining HCWs. One HCW with detectable HCV-RNA received
antiviral therapy (combination of ribavirin and interferon) and sustained
virological response was deﬁned by a negative HCV-RNA measurement
until the end of the follow up.
Conclusion: The risk of acquiring HCV through occupational exposure
is very low. It is difﬁcult to establishe diagnosis of acute HCV infection
with both serological and virological tests. HCV RNA is temporarily
detectable during the follow up examination. Treatment decisions cannot
be based only on HCV RNA measurements since a self-limiting infection
is a possible outcome.
P1696 Prevalence and diversity of bacteria in root-ﬁlled teeth
associated with periradicular lesions
A. Al-Ahmad, A-L. Liebenow, A. Wittmer, K. Pelz, E. Hellwig,
J-F. Schirrmeister (Freiburg, DE)
Objectives: Persistence of microorganisms or reinfection are the main
reasons for failure of root canal treatment. The knowledge of bacterial
diversity in root-ﬁlled teeth can help to ﬁnd the adequate treatment plan
to eradicate microorganisms associated with periradicular lesions. The
aim of this study was to isolate and identify microorganisms of twenty
different root-ﬁlled teeth associated with periradicular lesions.
Methods: All teeth studied had been previously root-ﬁlled and showed
radiographic evidence of periradicular disease. After removal of the
root-ﬁlling material, samples of 20 cases undergoing retreatment were
collected using paper points which were immediately transferred to
reduced transport ﬂuid (RTF). A quality control was performed to
exclude contamination of the samples with saliva or dental plaque.
Serial dilutions were plated on Columbia Blood Agar (CBA) and on
Yeast-Cystein Blood Agar (HCB) to isolate aerobic and anaerobic
microorganisms, respectively. Bile Esculin Agar was used to cultivate
enterococci. The bacteria were identiﬁed by morphological and
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biochemical analysis. Additionally, identiﬁcation by 16S rRNA-gene
sequencing was applied.
Results: The samples of eight patients did not contain bacteria. In
samples of 12 patients microorganisms could be isolated. The colony
forming units/mL (CFU/mL) were in the range of 103–107 on CBA and
of 103–109 on HCB, respectively. A mixed culture was found in the
samples of 10 patients. Species of Enterococcus, Streptococcus, Pep-
tostreptococcus, Campylobacter, Veillonella, Fusobacterium, Dialister,
Bulleidia, Bacteroides, Eubacterium, Actinomyces, Propionibacterium,
Serratia, Klebsiella, Porphyromonas,Mycoplasma, Gemella, Corynebac-
terium, Capnocytophaga, Vagococcus, Megasphaera, Atopobium, and
Flexistipes were detected. In samples of two patients E. faecalis was
the only isolated species. In two samples similar bacterial species were
also found in the quality control which indicates a contamination of the
revision samples by saliva or dental plaque.
Conclusions: Microorganisms could not be isolated from all teeth. The
majority of positive samples revealed a mixed culture of 2 to 9 species.
E. faecalis was the only detected agent in two patients underlining its
suggested important role in endodontic infections. A quality control was
essential to avoid false positive results which could be easily caused the
contamination with saliva or dental plaque.
P1697 Reduced rates of vancomycin-resistant enterococci coloni-
sation after implementation of infection control measures
L. Galani, V. Sakka, S. Tsiodras, M. Pantelaki, I. Galani, M. Souli,
A. Antoniadou, S. Athanasia, F.V. Kontopidou, H. Nikolaou, H. Fytrou,
N. Siafakas, L. Zerva, H. Giamarellou (Athens, GR)
Objective: The aim of the study was to evaluate the effect of infection
control measures that were applied during one year period after an
outbreak of ancomycin resistant enterococci (VRE) colonisation in our
hospital.
Methods: A hospital wide prevalence study was performed during the
20 April–30 May 2005 period, recording faecal carriage and clinical
VRE isolation. Presence of vancomycin resistance genes and species
identiﬁcation was assessed by multiplex PCR and clonality of isolates
by PFGE. A case-control design, using two randomly selected VRE(−)
controls for each positive case, was performed to identify cases with
VRE colonisation and to evaluate risk factors for such colonisation.
Control measures including patient cohorting, education efforts about
hand hygiene and control of vancomycin use were instituted. An active
surveillance problem was established for high risk patients identiﬁed
through the case control study. A new survey was conducted in October
2006 in order to evaluate all control efforts.
Results: During the initial outbreak of colonisation 460 samples were
evaluated from 367 patients. Total mean VRE carriage was initially
19.7%. All isolates were identiﬁed as E. faecium, with vanA genotype.
Multivariate analysis identiﬁed immunodeﬁciency (OR 3.7, 95%CI:
1.4−9.3), any invasive device (OR 5.5, 95%CI: 2.2–13.9), and duration
of antimicrobial treatment prior to VRE isolation (OR 1.2, 95%CI:
1.1−1.3) as the most important predictors for VRE positivity. During
the 2nd screening 132 patients were screened and 11 were found to be
positive for VRE colonisation (8.3%, p = 0.01). Of these, 4 (3%) were
hospitalised in the orthopaedics department, 4 (3%) in the haematology
unit and the other 3 in internal medicine wards. VRE colonisation was
detected only in patients at high risk who had been already put in cohort
for other multidrug resistance pathogens.
Conclusions: The implementation of infection control measures and
an active surveillance screening programme targeting high risk patients
resulted in a signiﬁcant decrease of VRE isolation rates. High rates of
VRE colonisation can be controlled by timely and intensively applied
infection control and antibiotic use measures, preventing the emergence
of clinical infections.
P1698 Intravenous cannulation in patients: room for improvement?
A.T. George, P. Turner, D. Defriend (Torquay, UK)
More than 90% of all patients admitted to hospital will have a peripheral
cannula inserted. Complications associated with this procedure include
extravasation, thrombosis and infection. The latter represents one of the
most common preventable causes of MRSA bacteraemia.
To investigate both compliance with national guidelines on cannula
insertion and care, as well as complications associated with use,
130 randomly selected medical/surgical patients with a peripheral venous
cannula in situ were monitored daily for 8 days or until removal of
the cannula. A non-interventional study was undertaken by gathering
information on all aspects of care including site, size, use and indications,
level of documentation, status of dressings, infection/thrombosis risk
using the VIPS (Visual Infusion Phlebitis Score) as well as cannula
changes.
Analysis demonstrated poor compliance with choice of non-dominant
hand, cannula size, continuing indications for use. 95% of cannulae had
no documentation regarding insertion, removal or changes. Compliance
of cannulae maintenance was poor, with most of the cannula dressings
becoming contaminated with blood and ﬂuid or the cannulae being
inappropriately secured with non-sterile adhesive tape and bandage
dressings. A non-compliance with best practice for cannulae removal
was seen even when the VIPS score was 2 or more, with a signiﬁcant
group being left in with a score of 3 – indicating active thrombophlebitis.
Frank pus was seen on 2 dressings – in spite of which it was still being
used. 22% of the inserted cannulae were never used. Most cannulae
were left in situ for 48 or more hours after its use had stopped with a
signiﬁcant minority being left in for more than 120 hours.
This study shows that though protocols and national guidelines exist
for use, maintenance and removal of peripheral cannulae, they may be
overlooked and tend not to be followed. As a result, the potential for
serious consequences such as nosocomial MRSA bacteraemia remain.
The lack of documentation is also concerning, given that there is a legal
requirement to do so. An improvement in peripheral cannula use, care
and documentation is essential to ensure best clinical practice and reduce
complications in vulnerable patients.
P1699 Inexpensive interventions can signiﬁcantly reduce the
number of unnecessary intravenous devices present in
medical inpatients
D. Partridge, S. McBride, D. Scott, S. Briggs (Shefﬁeld, UK; Auckland,
NZ)
Objectives: Local and bloodstream infections are common compli-
cations of intravascular devices with signiﬁcant associated morbidity
and mortality. Many such devices are either inserted unnecessarily
or their removal is delayed. Previous attempts to reduce the number
of unnecessary devices have commonly centred around the education
of medical and nursing professionals but rapid staff turnover and a
multitude of other priorities impact negatively upon their effectiveness.
We assessed the impact of the following inexpensive interventions on
the prevalence of unnecessary intravenous devices amongst medical
inpatients:
1. A short notice handed to patients with their breakfast menus
emphasizing the potential need for intravenous cannulae but also
mentioning the associated risks and urging the recipient to ask their
physician whether the device could be removed.
2. A sticker inserted in the medical notes requiring the medical team
to indicate whether a device inserted en route to hospital or in the
Emergency Department should or should not be removed.
Methods: Strict criteria were deﬁned to determine whether individual
intravenous devices were necessary. Inpatients occupying a total of 100
beds on 4 General Medical wards were assessed on a daily basis for
two weeks to identify the number of intravascular devices present and
to determine how many of these devices were unnecessary. After a 5
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week period, the above interventions were instigated and the assessment
process was repeated for a further two weeks.
Results: Data was gathered on 1,144 patient days in the pre-intervention
period. 592 of these were associated with a vascular access day, 233 of
which were deemed unnecessary. Data was gathered on 1,153 patient
days during the intervention. 436 of these were associated with a
vascular access day, 144 of which were deemed unnecessary. The relative
reduction in unnecessary vascular access device days was 39%, and an
absolute reduction of 8% (p< 0.01), with an NNT of 12.
Conclusion: Inexpensive interventions targeted at patients as well
as medical staff can signiﬁcantly reduce the number of unnecessary
intravenous devices present in general medical inpatients. We would
suggest that these interventions would also, therefore, be likely to
reduce the morbidity and mortality associated with intravascular device
associated infections.
P1700 Use of intravenous catheters in a general hospital: results
of a day-prevalence survey
C. Loupa, K. Vamvakoula, H. Demetriadi, E. Katsiki-Divari,
K. Romanos, G. Petrou, M. Lelekis (Athens, GR)
Objectives: Intravenous (IV) catheters are considered a potential cause
of problems such as thrombosis, fever and/or septicaemia. The aim of the
present study was the evaluation of the conditions under which they are
used, as well as of the appropriateness of their use in a general hospital
of Athens, Greece.
Methods: On a speciﬁc day all hospitalised patients were examined
for use of IV catheters. For every patient with such a catheter, an
investigation was performed, concerning reason for use, duration of
catheterisation, appropriateness of use and possible complications.
Results: Peripheral IV catheters were found in 116/203 hospitalised
patients (age 70.9+15.4 years, 52% men). Eight patients had 2 catheters.
There were no central venous catheters. The majority (69%) of the
116 catheterised patients were hospitalised in medical wards. The
catheterised/hospitalised patients ratio was 63% vs. 57% for medical and
surgical wards, respectively. Total days of catheter presence were 1−25
[5.4+5.1 in all catheterised patients, 6.0+5.6 and 3.9+3.2 for medical
and surgical wards respectively, (x+SD, p = 0.01)]. Current catheter was
in place already for 1−5 days (1.7+0.8 in total, 1.8+0.7 and 1.5+0.9
for medical and surgical wards, NS). Eighty-six per cent of catheterised
patients had no restriction for food by mouth and 27% were not receiving
IV medications or IV ﬂuids on that day. In 27 IV catheters (23%) the date
of insertion was not recorded, and in 11 cases (9%) local inﬂammation
was observed. No signiﬁcant difference regarding proportion of patients
with inﬂammation signs was recorded, but insertion date was more
frequently recorded in medical wards (p< 0.001).
Conclusions: (1) Peripheral IV catheter was present in more than half
of hospitalised patients and (2) in a signiﬁcant proportion of cases it was
there “just in case . . . ”. (3) IV catheters were used in a larger proportion
of patients and remained for more days in medical wards compared
to surgical ones. (4) Inﬂammation signs were noted in approximately
10% of IV catheters. (5) Education of hospital staff on proper use of IV
catheters is probably needed.
P1701 Implementation of chlorhexidine gluconate for central
venous catheter site care at a Bangkok hospital, Thailand
B. Balamongkhon, V. Thamlikitkul (Bangkok, TH)
Background: Central venous catheter-related blood stream infections
(CRBSIs) are an important cause of patient morbidity, mortality,
and increased healthcare costs. A meta-analysis and cost-effectiveness
analysis of randomised controlled trials comparing chlorhexidine
gluconate with povidone-iodine solutions for venous catheter site care
found that the use of chlorhexidine gluconate signiﬁcantly reduced the
risk for CRBSIs and it was cost-effective. The objective of the study was
to implement chlorhexidine gluconate for central venous catheter (CVC)
site care in intensive care units (ICUs) at Siriraj Hospital.
Methods: The study was conducted in three ICUs at Siriraj Hospital
from January to July 2006. One hundred and twenty adult patients who
needed CVC insertions and received 2% chlorhexidine gluconate in 70%
alcohol as the antiseptic solution for CVC site care were followed up
daily for CVC related infections until the CVC had been removed for
48 hours and for any adverse effects of 2% chlorhexidine gluconate in
70% alcohol.
Results: The incidence of CRBSIs in the indwelling CVC patients who
received 2% chlorhexidine gluconate in 70% alcohol was less than those
who received 10% povidone-iodine during the same period, 3.2 vs 6.4
episodes per 1,000 CVC days (p = 0.06). The incidence of CRBSIs in
the indwelling CVC patients who received 2% chlorhexidine gluconate
in 70% alcohol was reduced by 36% to 43%. No adverse effects related
to using 2% chlorhexidine gluconate in 70% alcohol were observed.
Conclusion: The locally produced 2% chlorhexidine gluconate in 70%
alcohol was safe, effective and efﬁcient for CVC site care in ICUs at
Siriraj Hospital.
P1702 Prospective, randomised trial of three antiseptic solutions
for prevention of central venous or arterial catheter
colonisation in intensive care unit patients
J. Valle´s, I. Ferna´ndez, D. Alcaraz, E. Chaco´n, A. Cazorla, M. Canals,
D. Mariscal, D. Fontanals, A. Moro´n (Sabadell, ES)
Objectives: Povidone-iodine is the most common catheter-site disin-
fectant, but accumulating evidence has indicated that chlorhexidine
gluconate may be a more effective agent. On the other hand, 2% aquous
clorhexidine gluconate is not available in our country.
The aim of this study was to compare the effectiveness in preventing
central venous and arterial catheter colonisation of three protocols
of skin antisepsis using 10% aqueous povidone-iodine (PI), 2%
aqueous chlorhexidine gluconate (AC), and 0.5% alcoholic chlorhexidine
gluconate (ALC) solutions.
Methods: Prospective and randomised trial in a medical-surgical
intensive care unit (ICU) in a teaching hospital. All patients admitted to
the ICU and requiring the insertion of a central venous and/or arterial
catheter from January 1, 2005 to June 30, 2006 were included in the
study. Patients were randomised assigned to each group according to
the antiseptic solution used for insertion the catheter. Catheter distal tips
were quantitatively cultured when catheters were no longer necessary and
if there was a suspicion of catheter-related infection. Rates of catheter
colonisation and catheter-related bacteraemia were compared in the three
groups.
Results: A total of 631 catheters were included in the study (194 in
PI group, 211 in AC group, and 226 in ALC group). The incidence of
catheter colonisation was signiﬁcantly lower in the ALC and AC groups
than in PI group (14.2% vs 24.7% [RR 0.5, 95%CI 0.3 to 0.8, p< 0.01]
and 16.1% vs 24.7% [RR 0.6, 95%CI 0.4 to 0.9, p:0.03], respectively).
The incidence-rate per 1,000 catheter-days were also signiﬁcantly lower
in the ALC and AC groups than PI group (19.8 vs 31.8; p:0.02 and 21.8
vs 31.8; p:0.02, respectively). There were not difference among ALC
and AC groups. Catheter-related bacteraemia were similar in the three
groups. Both types of chlorhexidine solutions were superior to povidone-
iodine solution in preventing catheter colonisations due to Gram-positive
bacteria (p:0.03), whereas there were not difference in preventing Gram-
negative bacteria colonisation.
Conclusions: We conclude that use of both ALC and AC solutions
for disinfection of intravascular catheter sites reduces the incidence of
catheter colonisation compared with 10% aqueous PI solution in an adult
ICU. This effect seems to be related to the more efﬁcacious prevention
of colonisation with Gram-positive bacteria.
P1703 Mortality associated with bloodstream infection
R.A. Leth, J.K. Møller (Aarhus, DK)
Objectives: To analyse the seven-, thirty-days, and one year crude
mortality rate of patients having had a blood-stream infection (BSI) with
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major groups of micro-organisms. Furthermore, to construct a survival
curve for patients having had BSI with selected micro-organisms.
Material and Methods: All patients with a positive blood-culture at
Skejby Hospital during the period 2001–2005 were included in the
study. An episode of BSI was deﬁned as a positive blood-culture with a
signiﬁcant pathogen and concomitant antibiotic treatment of the patient.
A new BSI episode was deﬁned as a new culture of the same micro-
organism after seven days or later or as growth of a new microbial
species two days or more after previous positive blood-culture.
Crude mortality was analysed in relation to the date of the ﬁrst
positive blood-culture. Seven, thirty-days and one year mortality rates
were calculated. Blood-cultures representing positive repeat cultures or
contaminants were excluded. Patient charts were checked for prescription
of antibiotics and indications that the patient was regarded as having a
true BSI. The date of death of patients was compiled from the patient
administrative system. For the survival curves the Kaplan-Meier method
was chosen.
Results: A total of 1,711 episodes of BSI were found. Thirteen patients
were lost to follow-up. The overall crude mortality rates were: seven-
days 5.4%, thirty-days 11.1%, and one year 24.4%. For E. coli (319
episodes) and S. aureus (300 episodes), the rates were: seven-days 7.8%
and 5.7%, thirty-days 11.9% and 14.7%, and one year 26.6% and 30.7%,
respectively. For fungi (81 episodes) the mortality rates were: seven-days
14.8%, thirty-days 27.2%, and one year 42.0%.
The crude mortality rates in relation to BSI episodes from various
medical specialities A: cardiology and nephrology; B: urology and
thoracic surgery; C: intensive care were: seven-days A: 4.7%, B: 7.3%,
and C: 14.7%; thirty-days A: 11.3%, B: 15.2%, and C: 27.5%; and one
year A: 32.7%, B: 33.4%, and C: 42.2%.
Conclusions: BSI is still associated with substantial short and long-
term crude mortality rates. BSI caused by fungi seems to be associated
with a higher crude mortality compared to E. coli and S. aureus. The
mortality rates seem partly to reﬂect the population of the patients
(medical specialities). The high mortality rates of patients in the intensive
care unit coincide with a high rate of fungal BSI.
P1704 First outbreak of carbapenem-resistant Klebsiella
pneumoniae in an Israeli university hospital
K. Hussein, H. Sprecher, T. Mashiach, G. Rabino, O. Eluk, I. Kassis,
E. Braun, I. Oren, R.A. Fenkelstein (Haifa, IL)
Objective: To describe a preliminary data related to the emergence and
spread of a Klebsiella pneumoniae (CRKP) strain in a large tertiary care
university hospital in Haifa, Israel
Methods: Case-control study.
Results: Starting in January 2006, the prevalence of carbapenem-
resistance (CR) among isolates of K. pneumoniae (KP) increased
signiﬁcantly in our hospital. Among 867 patients infected or colonised
with KP during the ﬁrst 10 months of this year, 48 (5.5%) were CR
(cases). All isolates were susceptible to colistin and gentamicin but
resistant to all other tested antibiotics. Fifteen isolates that underwent
pulse-ﬁeld gel electrophoresis were genetically related and different from
two CRKP isolates previously identiﬁed at our institution. The outbreak
was ﬁrst identiﬁed in April 2006. Four possible index cases included 3
patients hospitalised in 2 geographically close orthopaedic wards and
one transferred to our institution after renal transplant abroad. This
patient had on admission a surgical site infection due to CRKP. By
October 2006, the outbreak has spread to 16 wards. CRKP was isolated
during or after admission to the General ICU in 32 of 48 cases (66.6%).
Several characteristics (longer length of stay (LOS) before isolation of
Klebsiella, admission to the General ICU, mechanical ventilation, central
venous catheterisation, imipenem and vancomycin treatment) were found
to be signiﬁcantly (p< 0.05) more common among cases than among 48
infected or colonised carbapenem-susceptible KP control patients. In
multivariable analysis, admission to the General ICU (OR, 3.5; [95%CI,
1.3−9.5]; p = 0.01), LOS of >7 days (OR, 3.2; [95%CI, 1.0–11.0];
p = 0.05), and previous treatment with vancomycin (OR, 5.1; [95%CI,
1.5–17.9]; p = 0.01) remained signiﬁcantly associated with acquisition of
CRKP.
Conclusions: CRKP has emerged as an important pathogen in our
institution. Despite implementation of several important infection control
measures, the outbreak has not been contained. Because these isolates are
resistant to almost all commonly used antibiotics, control of their spread
is crucial. In this study, prolonged LOS, admissions to ICU and previous
use of vancomycin were signiﬁcantly associated with the acquisition of
CRKP at our hospital.
P1705 A pseudo-outbreak with Mycobacterium intracellulare
M. Van De Vyvere, J. Vanpellicom, M. Verschueren, K. Camps,
L. Winnepenninckx, P. Bomans (Antwerp, BE)
Problem: In the autumn of 2005 we noticed a sharp increase in the
isolation of Mycobacterium avium complex (MAC).
Objectives: Finding the cause of this increase to obtain a solution to
stop the outbreak or pseudo-outbreak.
Methods:
• investigation of the culture data
• mycobacterial culture of the bronchoscopes (secondary on the results
of the data investigation)
• mycobacterial culture of the rinsing water of our two washers
(decontamination procedure with peracetic acid)
Results: Because of the slow growth of the strain and the isolation of it
in samples of immunocompromised patients (which is not exceptional)
it took us a (too) long time before we were aware of the problem.
Meanwhile a lot of other samples were taken. 32 MACs were isolated
from September 2005 until February 2006, with a peak in november.
All strains (minus 1) were isolated from samples of patients of the
same hospital (delivering 35% of the samples for mycobacterial culture).
All samples were acquired by bronchoscopy. All MACs were later
identiﬁed as Mycobacterium intracellulare (MI). Only samples taken
from the bronchoscopes after decontamination in the most recently
bought washer showed growth of MAC(MI). In the same period a
warning of possible contamination of the rinsing water of this type of
washer was given by the manufacturer. It was recommended to extend
the length of the procedure until the washer was ‘upgraded’ by the
company. The automatic decontamination procedure was changed by
a manual procedure. Samples of the rinsing water of the new washer
showed growth of MAC(MI). After the upgrading of the washer all
cultures taken from scopes and rinsing water were negative. No growth
of MAC(MI) in patient samples was seen from the time the cause of the
problem was suspected and measures were taken.
Conclusion: Rinsing water of automatic washers can be contaminated
with mycobacteria. This contamination can be the cause of a pseudo-
outbreak. It is not excluded that it could be the cause of real infection
by installing mycobacteria directly in the lungs during bronchoscopy,
especially in immunocompromised patients. An automatic warning
system should be implemented to give an early warning of an increase
in isolation of speciﬁc strains. If surveillance cultures of scopes and
washers are done: culture of mycobacteria in the rinsing water is most
important.
P1706 A case of Ralstonia paucula septicaemia in an intensive
care patient following blood transfusion via a level-1 fast
ﬂow ﬂuid warmer, successfully treated with meropenem
B.M. Clark, R. Townsend, P. Norman (Shefﬁeld, UK)
Case: An 80-year-old woman on warfarin therapy underwent emergency
surgery for a suspected leaking aortic aneurysm. Instead a tear in the
lower pole of the right kidney was found and repaired. She had 2 cardiac
arrests during the operation and was resuscitated with ﬂuid infused via a
Level-1 Fast Flow Fluid Warmer, including 7 units of blood. Following
the operation it was noted that the water bath of the ﬂuid warmer,
which warms the infused ﬂuid, had been contaminated with blood. IV
(Intravenous) cefuroxime and metronidazole were commenced.
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She was transferred to the ICU (Intensive Care Unit) for invasive
ventilation and inotropic support. On the second day she became pyrexial
and blood cultures were taken, from which a Gram-negative bacteria
was grown. Antibiotics were changed to IV pipericillin-tazobactam. On
the third day she developed septic shock. The bacteria had now been
identiﬁed as a likely environmental organism, but given the possible
contamination of the patient’s blood transfusion this was thought to be
relevant and IV meropenem was commenced. She improved clinically
and received a total of 6 days of meropenem. She was eventually
discharged home after a lengthy hospital stay, including 41 days on the
ICU.
Subsequently the organism was identiﬁed as Ralstonia paucula using
API and conﬁrmed by the reference laboratory (Colindale, UK).
Unfortunately the ﬂuid warmer used in the operation was sterilised
immediately after the operation. However, the water bath from a second
ﬂuid warmer was sampled. This was in the same operating theatre as the
other ﬂuid warmer, and had been ﬁlled from the same water source and
maintained in the same way. From this we also cultured R. paucula.
Discussion: We propose that contamination of transfused blood possibly
occurred during the operation via the Level-1 Fast Flow Fluid Warmer.
The water bath of the ﬂuid warmer used in the operation was blood
stained, and we believe conversely that ﬂuid from the non-sterile water
bath, containing R paucula, was infused into the patient. We will illustrate
how this may have occurred and will also describe the organism R.
paucula in greater detail.
This case has wide reaching implications as fast ﬂow ﬂuid warmers are
used in hospitals across the UK and Europe. Whilst they have contributed
to the saving of countless lives during medical and surgical emergencies
we believe that this case illustrates an important infection control issue
regarding the use of this equipment.
P1707 Report of multicentre outbreak of Buffalopox virus
infection in burn units, Karachi, Pakistan
A. Zafar, R. Swanepoel, R. Hewson, M. Nizam, A. Ahmed, A. Husain,
A. Grobbelaar, K. Bewley, V. Mioulet, B. Dowsett, L. Easterbrook,
R. Hasan (Karachi, PK; Sandringham, ZA; Salisbury, UK)
Objectives: Sporadic outbreaks of Buffalopox (BPV) and its transmis-
sion among farmers have been reported from the subcontinent. We
describe the ﬁrst multi-centre nosocomial outbreak of BPV infection
amongst burns patients in a major city of Pakistan.
Method: Notiﬁcation of outbreak: Atypical lesions involving burns
wound were ﬁrst noted in a patient at a burns unit in Karachi.
Similar lesions rapidly affected other patients within this unit. During
infection control investigation, patients with similar infections were
being reported from other burns centres in the city. Investigation: Clinical
specimens from the lesions were submitted for routine culture and for
histopathology. Impression smears, material from the lesions and biopsy
tissue were used for electron microscopy, DNA sequencing and in-vitro
culture.
The epidemiological ﬁnding suggested a common origin of infection. To
investigate this, practices at the affected burns units were observed and
materials in common use for cleaning and dressing wounds at all the
various centres were collected for testing.
Results: Clinical samples submitted for bacteriological and mycological
culture proved negative. On histopathological examination no Molluscum
bodies were found. Electron microscopy revealed the presence of
orthopox virus particles. Examination of ultrathin sections of infected
Vero cells demonstrated classic orthopox virus maturation with
intracytoplasmic ‘virus factories’. Portions of the gene were sequenced
and analysed. The resulting phylogenetic tree grouped the sample
within the Buffalopox sequences. All surveillance was reported negative.
Nevertheless, clinical samples submitted from several centres revealed
the existence of the same pox virus.
To control nosocomial transmission in the units, a number of measures
were taken including staff education, reinforcement of infection control
practices and strict isolation measures which successfully controlled the
disease spread within the primary unit.
Conclusion: We report ﬁrst nosocomial outbreak of BPV infection
among patients admitted to different burns units located signiﬁcant
distances apart. Initial investigation could not reveal the source but it is
very likely that nosocomial transmission of the viral infection was due
to frequent transfer of exposed patients between the different units. This
hypothesis is supported by the fact that strict infection control measures
in one unit succeeded in controlling transmission.
P1708 Colonisation by resistant Staphylococcus epidermidis strains
in patients qualiﬁed for routine vascular reconstructions
E. Mazur, J. Niedzwiadek, A. Niwinska, P. Terlecki, J. Wronski,
M. Koziol-Montewka (Lublin, PL)
Objectives: The aim of our study was to examine S. epidermidis
colonisation of the anterior nares in patients qualiﬁed for routine vascular
reconstructions on the day of admission to the hospital and after a week
of staying there and to evaluate antimicrobial susceptibility of isolated
strains, including detection of resistance mechanisms.
Methods: The study included 35 patients with PAOD (peripheral
occlusive arterial disease) qualiﬁed for routine vascular reconstruction.
Nasal swabs were obtained on the day of admission and on 8th day of
hospital stay. Classiﬁcation to the species was done on the ground of the
biochemical properties of isolated strains. Susceptibility to antibiotics
was assessed by disc-diffusion method.
Results: S. epidermidis was present in all but one admission culture,
in 8th day cultures this species was isolated from 33 patients. In every
performed culture 1 to 3 different strains of S. epidermidis were isolated.
In 6 patients no changes in S. epidermidis strains were noticed comparing
ﬁrst and second culture, in 7 ones a total change of isolated strains
occurred during hospital stay. As a total 73 strains of S. epidermidis were
isolated, 26 strains were present in both cultures, 23 strains were acquired
in the hospital, 24 strains were lost during hospitalisation. 17 resistant
strains were brought into the hospital, among them 10 MR (methicillin-
resistant), 10 MDR (multidrug-resistant) and 6 MLSB (some resistance
mechanisms were present in the same strain simultaneously). During
hospital stay the examined patients were colonised with 12 resistant
strains of S. epidermidis, among them 11 MR, 8 MDR, 4 MLSB.
28.8% of strains were resistant to methicillin (MRSE), all of them were
fully susceptible to vancomycin, teicoplanin, and mupirocin. 13.7% of
isolated S. epidermidis strains possessed MLSB resistance mechanism.
24.7% of S. epidermidis strains were multiresistant, 72.2% of them were
simultaneously methicillin-resistant.
Conclusions: Due to high rate of resistant strains among S. epidermidis
isolated from patients prepared for routine vascular reconstructions it
seems useful to evaluate nasal colonisation in every subject before and
after such intervention to:
1. have the opportunity to verify perioperative antibiotic prophylaxis in
selected cases and to prevent possible complications;
2. limit the expansion of resistant strains of S. epidermidis in the
hospital.
P1709 The activity of ﬁve commonly used topical antiseptic agents
on epidemic and sporadic strains of Acinetobacter baumannii
E. Demertzi, G. Avraamides, B. Azadian, R.L.R. Hill, J. Turton,
T.L. Pitt (London, UK)
Objectives: Acinetobacter baumannii is increasingly being recognized as
a cause of outbreaks of opportunist infections in intensive care patients
in hospitals. These organisms contaminate the inaminate environment
and may survive for prolonged periods on surfaces. Contact with these
surfaces by healthcare personnel may lead to contamination of their
hands and facilitate the transmission of the organisms to others. A
number of topical antibacterial agents are used for hand hygiene or as
surgical disinfectants and so we questioned whether selected agents were
equally effective against strains of A. baumannii prevalent in British and
European hospitals.
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Materials and Methods: A panel of 30 strains was assembled
comprising 11 characterised epidemic strains (SE clone, Oxa-23 clones
1 and 2, European clones, etc.) 12 representatives of more minor
outbreak strains, and 7 sporadic isolates. The following products (active
agent) were tested:
1. Purell gel (62% ethyl alcohol),
2. Desderman gel (78.2% ethanol + 0.1% phenylphenol),
3. Sterzac bath liquid (2% Triclosan, isopropyl alcohol etc.),
4. Hydrex (0.5% chlorhexidine gluconate w/v in 70% v/v DEB),
5. Betadine (10% povidone-iodine).
Agents were tested for activity using the prEN 12054 European standard
method. Standardised bacterial test suspensions (1mL) were mixed with
products (9mL) and survival at 30 s, 1min and 5min was determined
by viable counts on agar.
Results: The minimum requirement for bactericidal activity for
compliance with prEN 12054 is a 10(5)-fold reduction in viable count
within 1min. Each product tested fulﬁlled prEN 12054.
We conclude that A. baumannii are killed by commonly used topical
antiseptics and hand hygiene should be effective in limiting their spread
in hospitals.
P1710 Infection risk for ﬁlamentous fungi in water in a paediatric
haematology/oncology ward
H. Kennedy, C. Williams (Glasgow, UK)
Objectives: Filamentous fungi from the air, particularly Aspergillus spp.,
cause severe opportunistic infection in immunocompromised patients.
However, there is now some data to suggest that hospital water may also
be a potential source of these organisms. The present study examined
tap water in a paediatric haematology/oncology unit for the presence of
fungi.
Methods: Tap water (hot and cold) samples from three rooms in the
haematology/oncology ward were collected and passed through sterile
0.45um ﬁlters (Millipore). Filters were then transferred to Sabouraud
dextrose agar plates supplemented with chloramphenicol and incubated
for one week. Fungal isolates were identiﬁed by macroscopic and
microscopic characteristics. This procedure was repeated one month
later. Any fungal isolates, which could not be identiﬁed in-house,
were sent to the HPA Mycology Reference Laboratory, Bristol, UK for
identiﬁcation.
Results: Filamentous fungi were cultured from eleven of the twelve
water samples. Exophiala was isolated from 83% of the water samples,
Fusarium (not F. solani or F. oxysporum) from 25%, Verticillium from
17%, Phoma from 25%, Penicillium from 8% and a phialidic mould
which could not be identiﬁed precisely but which resembled Fusarium
was isolated from 92%. The distribution of fungi from the two sampling
periods was similar. There was no evidence of Aspergillus spp.
Conclusion: This study demonstrated that various ﬁlamentous fungi
were present in the water system but that the major opportunistic
pathogen Aspergillus was absent. Exopiaila, Fusarium and Verticullium
spp. are widely distributed in soil and plants and may be found in
aqueous environments. The absence of Aspergillus spp. is desirable
and is probably inﬂuenced by the water storage and distribution system
(following chlorination), which prevents exposure to large volumes of
air from which Aspergillus spores could potentially cause contamination.
Further studies on ﬁlamentous fungi in hospital water systems are
required to investigate the organisms’ ability to persist, their role in
bioﬁlm formation and their clinical signiﬁcance.
P1711 Reduction of healthcare-associated infection rates in a
Swiss university hospital following hand hygiene promotion
I. Uc¸kay, D. Pittet, C. Ginet, H. Sax (Geneva, CH)
Background: Hand hygiene is considered the single most effective
measure to reduce healthcare-associated infection.
Objective: To measure the prevalence of healthcare-associated infection
at the University of Geneva Hospitals before and during participation in a
national hand hygiene promotion campaign (www.swisshandhygiene.ch).
Methods: Two hospital-wide period-prevalence studies including all
healthcare-associated infections according to CDC deﬁnitions were
conducted in May 2004 and May 2006. The assessment took place
two years before and four month after the launch of a multimodal
promotional hand hygiene campaign. An experienced infection control
team collected data from all hospitalised patients (except for the
psychiatric service) according to a standard, unchanged protocol. Other
major infection control strategies were ongoing unchanged in parallel
since 2003.
Results: In 2004, 1,494 patients were included in the study; in 2006,
there were 1,560 patients. Overall compliance with hand hygiene
recommendations improved from 57% to 64% (p< 0.001). Patient’s case
mix between the periods was equivalent based on McCabe score (p = 0.2).
The prevalence of nosocomial infections decreased by 20% hospital-
wide, from 12.8% to 10.2% (OR, 0.77; p = 0.03; 95%CI, 0.61–0.97). It
decreased from 11.8% to 9.6% in the acute care sectors, and from 13.9%
to 11.0% in the long-term sectors. The three most prevalent infections in
2006 were urinary tract (26%), respiratory tract (26%) and surgical site
infections (19%). By assuming an average attributable cost of €2,200
per infection, saving equalled at least €1.8 million in 2006.
Conclusion: A multimodal hand hygiene promotion campaign was
associated with a successful reduction of healthcare-acquired infections,
in both acute and long-term care sectors. Long-term follow-up is required
to assess the continuous impact of the strategy.
P1712 Layperson’s technique of hand washing: is it effective in
reducing bacterial carriage?
Z. Sekawi, F. Jamal (UPM Serdang, MY)
Introduction: In spite of major advances in the diagnosis, treatment
and prevention of infectious diseases, cross infections in hospitals
continue to be a major problem worldwide. Frequent hand washing
among healthcare personnel using a proper prescribed technique has been
shown to reduce the spread of causative agents of these infections. More
often, this technique comprising several systematic steps is considered a
nuisance to some personnel and therefore, compliance to this technique
may not be desirable and will pose problems such as increase in
hospital acquired infections. To encourage compliance, a simple routine
household technique of hand washing may be considered as an alternative
albeit less superior. Is a layperson’s technique of hand washing effective
in reducing bacterial carriage?
Objectives: To determine bacterial ﬂora of hands of staff and students in
Faculty of Medicine and Health Sciences, Universiti Putra Malaysia and
to determine the effectiveness of layperson’s hand washing on bacterial
carriage.
Method: A cross-sectional study with non-probability convenience
sampling was carried out at the faculty premises. Two hundred and
twenty eight participants were asked to inoculate their right hand
ﬁngertips on the blood agar plates before and after washing their
hands with antimicrobial soap using their own usual routine technique.
Instruction on proper hand washing was not given. The agar plates
were then incubated at 37ºC for 18−24 hours and inspected by standard
methods.
Results: All participants but four (98.2%) had Staphylococcus aureus on
their hands while 80 (35.1%) participants had Bacillus spp. before wash-
ing. Other organisms such as Streptococcus spp., Corynebacterium spp.,
unidentiﬁed Gram-negative bacteria and fungus were found on four
participants. One hundred and sixty-three (71.5%) of 228 participants
had reduction in bacterial hand ﬂora after hand washing. Socio-
demographic factors such as gender, age, ethnic groups, occupation and
income were analysed and found to be statistically insigniﬁcant.
Conclusion: It is shown that simple routine household technique of hand
washing can reduce the carriage of bacteria on the hands considerably.
This implies that healthcare worker’s ignorance on the proper hand
washing technique but using their routine layman’s technique of hand
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washing is better than not washing hands at all during their course of
their duty.
P1713 Evaluation of a new ultra-rapid hand drier in relation to
hand hygiene
A.M. Snelling, T. Saville, D.G. Stevens, C.B. Beggs (Bradford,
Malmesbury, UK)
Objectives: Handwashing is a key element of infection control in
the clinical and domestic settings. Whilst much research focuses on
antibacterial wash products, or increasing compliance, little attention has
been paid to the drying step. However, washing does not always remove
100% of contaminants, and can increase levels of commensal bacteria
on the skin surface. The new AirbladeTM drier uses two high pressure
air ‘knives’ to strip water from still hands. Drying takes ~10 seconds.
Conventional warm air driers rely on evaporation from the skin and often
take 30 s with rigorous hand rubbing to achieve a satisfactory effect.
The study aimed to compare the two types of drier in terms of residual
bacterial load on hands.
Methods: The Airblade (Dyson Ltd) was tested against 2 conventional
warm air driers widely used in the UK. 14 (7M, 7F) volunteers took
part. In study (A) hands were contaminated by handling uncooked
chicken. Washing was performed using the Euro-standard handwash
(EN1499:1997) + non-medicated liquid soap. After using a drier, the
ﬁngers of each hand were pressed onto a strip (10×4 cm) of sterile
aluminium foil. Bacteria transferred to foil were eluted into MRD +
soap inactivator, and enumerated on TSA plates. Volunteers repeated the
protocol with each machine, in random order. Study (B): clean hands
were washed in the same way but without soap. Drying was performed
with the machines +/− hand rubbing. Agar contact plates were used to
enumerate bacteria on palms, ﬁngers, ﬁngertips before and after drying.
Results: In study (A) bacterial transfers of 0−107 cfu/hand were
observed. For a set drying time of 10 s the Airblade led to signiﬁcantly
less bacterial transfer than with the other driers (p< 0.05). When the
latter were used for longer (30−35 s) the trend was for the Airblade to
still perform better, but results were not as signiﬁcant (p> .05). In study
(B) rubbing hands whilst using the driers counteracted the reduction in
overall bacterial numbers at all anatomical sites. When hands were held
still, there was no statistical difference between the driers.
Conclusions: If hands are not dried properly after washing, transfer of
commensals or remaining contaminants to other surfaces is more likely to
occur. The Airblade was superior to the conventional driers for reducing
transfer. Its short drying time should encourage greater compliance with
hand drying and hence help reduce the spread of infectious agents by
the hand-borne route.
P1714 Compliance of healthcare workers with hand hygiene rules
in the emergency room of two tertiary hospitals in the area
of Athens
S. Athanasia, E. Giannitsioti, A. Kolias, O. Koulouri, H. Fitrou,
H. Giamarellou (Athens, GR)
Background: The aim of this study is to compare the inﬂuence of hand
hygiene policies on Healthcare workers (HCWs) in the emergency rooms
between two tertiary general hospital at the area of Athens. Hand hygiene
policies were launched in both Institutions.
Patients and Methods: To evaluate the impact of hand hygiene policies
in the emergency rooms of two tertiary hospitals named A (400 beds)
and B (330 beds), behaviour of physicians and nurses regarding the use
of gloves and the use of alcohol-based hand-rubs was assessed by two
independent observers via a standardised registry form. The study was
conducted during a two month period. Alcohol based hand-rubs have
been installed on the tables in every room. Results were analysed by
chi-square and ﬁsher exact tests for categorical variables.
Results: Physicians of Hospital A were more prompt to use gloves than
physicians of Hospital B [26/53 (49%) vs 55/182 (30.2%), p = 0.01].
No difference in the use of gloves was observed between nurses of
Hospital A (27/47, 57.4%) and nurses of Hospital B (72/109, 66%).
Nearly all HCWs were changing gloves between each patient. Among
physicians who did not wear gloves, the rates of those that did not use
antiseptic were similar in both hospitals [Hospital A, 13/27 (48.2%),
Hospital B, 87/127 (68.5%), pNS]. Nurses were equally not using
antiseptic before and after contact with the patients in both Hospitals.
However, in Hospital A, nurses applied more frequently antiseptic after
contact with the patient than nurses in hospital B [Hospital A, n = 11/20
5 (55%), Hospital B, 2/109 (1.8%), p< 0.001].
Conclusions: Despite the same policies regarding hand hygiene which
were applied in both hospitals A and B, compliance of HCWs with
the appropriate use of antiseptic on hands was extremely low in the
emergency rooms. Special issues for the emergency room and continuous
surveillance and education are required in order to change compliance
of HCWs with hand hygiene and enhance the infection control.
P1715 Questionnaire results of a survey on health workers’
knowledge and attitudes to nosocomial infections
A. Dogru, P. Kaymaz, S. Baris, N. Kilicarslan, T. Zengin Elbir
(Istanbul, TR)
Objectives: Our aim is to search the knowledge capacity and behaviour
types of healthcare workers about nosocomial infections and indicate the
wrongs and defects in applications.
Materials and Methods: We applied our questionnaire of 24 questions
on 200 health workers of whom 70 (35%) were doctors, 107 (53.5%)
were nurses and 23 (11.5%) were other healthcare workers (pharmacists,
biologists, technicians, laboratory asistants).
Results: Most of the participants (98%) deﬁned AIDS as the most
important blood-transmitted illness, and 66.3% of them said “i’ll be more
careful about the hygiene rules” while giving care to the patients with
blood-transmitted infectious diseases. 55.1% of nurses express that they
“always” adhere to the rules aimed at avoiding nosocomial infections,
and 55.74% of doctors responded to this question as “frequently”. It
was thought that (77.04%) intensive care units were the most risky
units about nosocomial infections, and handwashing with 55.73% was
thougth to be the most important precaution in avoiding the nosocomial
infections. According to participants, with 82.67% pneumonia was the
most important nosocomial infection and most important agent was
Pseudomonas genus bacterias with 86.95%. 35.71% of doctors and
40.75% of nurses deﬁned that they “always” wash hands before and
after touching a patient. 62.12% of participants indicated that “they are
not able to ﬁnd material everytime when it is needed” as a reason for
not using barriers while contacting with patients. 62.31% of doctors and
77.58% of nurses expressed that they had contact with patients’ blood
and/or extracts during their professional life. With 62.5% “tapping the
injectors plastic cover” became the most important process as injury/
contact reason.
Conclusions: Participants have enough knowledge about nosocomial
infections and precautions. We determined that those who had education
about the subject gave correct answers in higher proportions. Thus, we
decided to increase the portion of education and seminars in addition to
the routine duties of infection control committee, aiming to avoid the
defects that we determined during our applications. Additionally, using
notice boards we will hang in every service, we are planning to acquaint
the healthcare workers with different subjects every month. So, in one
year duration, we are planning to lower the nosocomial infection rates
of our hospital.
P1716 The impact of an intervention on nurses’ HIV/AIDS knowl-
edge and compliance with universal precaution procedures in
emergency department in a university hospital, Shiraz, Iran
N. Pasyar, S. Gholamzadeh (Shiraz, IR)
Introduction: Emergency department nurses are potentially exposed to
blood in the course of their work and therefore are at risk of infection
with bloodborne pathogens, including HIV.
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Methods: A quasi-experimental survey was carried out amongst 120
nurses. The intervention consisted of 1-day training workshop, that
consisted of lecture, and focus group discussion. Each of these nurses
was asked to answer pre- and postsession knowledge questions during
three periods of time (before training, immediately after training and
three months later). Compliance with universal precaution (UP) was
measured through 11 items and data were gathered from observation.
Paired t-tests were used to compare differences between the pre- and
postsession knowledge scores and compliance with UP.
Results: The comparison in three periods revealed that the knowledge
of personnel signiﬁcantly increased immediately and three months after
the intervention compared with before (P< 0.0001). The nurses’ knowl-
edge scores increased from 68.9% before training to 100% immediately
after and 95% 3 months after the training programme (p< 0.0001).
There was a statistically signiﬁcant difference in the knowledge of
HIV and the implementation of universal precaution (P< 0.0001).
Observed compliance with universal precaution procedures before and
after training workshop ranged from 71.7% to 98% for glove use,
75.5% to 99% for handwashing after glove removal, 53.8% to 83% for
wearing mask, 78.3% to 87.7% for not making use of needle cutter. The
results also indicated that some nurses (37.7%) still recapped needles.
Conclusion: The training session signiﬁcantly improved the nurses’
knowledge and implementation of universal precautions among nurses
in emergency department.
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P1717 Comparison of the Plus Aerobic/F and Plus Anaerobic/F
media using the BacTec 9240 system with an in-house
agar-broth biphasic selective fungal culture media (modiﬁed
from the BACTEC Myco/F Lytic media) for the diagnosis
of fungaemia
C.Y. Low, A.L. Tan, B.H. Tan (Singapore, SG)
Objectives: To compare the Plus Aerobic/F and Plus Anaerobic/F media
using the BACTEC 9240 system with our in-house agar-broth biphasic
selective fungal culture media (modiﬁed from the BACTEC Myco/F
Lytic media) for the diagnosis of fungaemia.
Methods: This is a retrospective study of patients admitted to the
Singapore General Hospital over a 27-month period, from April 2004 to
June 2006, who had at least one positive blood culture for fungi using
the Plus Aerobic/F, Plus Anaerobic/F or the agar-broth biphasic fungal
culture media. Comparative analyses were made exclusively on blood
culture sets, a set being made up of one pair of BACTEC Aerobic and
Anaerobic vials and one agar-broth biphasic fungal culture vial, sampled
from the patient at the same time, from the same site, and processed
simultaneously in the laboratory. We compared the following: Positivity
rate by bottles – either BACTEC bottle in the set detecting fungaemia
was taken as positive and compared with the selective fungal culture
media. Positivity rate by patient – cases of fungaemia by the patient were
compared. Time to positivity based on preliminary laboratory reporting –
the earliest day reported by the laboratory for the detection of yeast
or mould was compared. Time to positivity based on ﬁnal laboratory
reporting – the day of the ﬁnal report by the laboratory for the detection
of fungaemia was compared.
Results: There were 141 sets of blood cultures from 86 patients available
for comparison. There were no statistical differences in the positivity
rates between the BACTEC media and the selective fungal culture media,
either by bottle (75.9% versus 69.5%, p = 0.285) or by patient (69.8%
versus 75.6%, p = 0.494). There was poor agreement (kappa, measure of
agreement = −0.369) between the two culture media for the diagnosis
of fungaemia. The mean time to positivity on the BACTEC media
was signiﬁcantly shorter than on the selective fungal culture media,
both in preliminary (3.3±1.9 days versus 8.0±6.2 days, p< 0.0005)
and in ﬁnal laboratory reporting (5.6±1.9 days versus 9.7±6.1 days,
p< 0.0005). The fungaemia-related mortality in the same admission was
54.7% (47/86).
Conclusion: The Plus Aerobic/F and Plus Anaerobic/F BACTEC media
have similar sensitivities to our in-house agar-broth biphasic fungal
culture media in detecting fungaemia but does so in a signiﬁcantly
shorter time. The poor agreement between the two culture media suggests
that they complement each other in the diagnosis of fungaemia.
P1718 Evaluation of the VITEK® 2 system for testing of Gram-
negative bacilli directly from BacT/Alert Fan blood cultures
M. Ullberg, J. Bergstro¨m (Uppsala, SE)
Objectives: The usefulness of the VITEK2 system for rapid diagnosis
of Gram-negative bacilli in blood cultures was evaluated. The aim was
to deliver species identiﬁcation and susceptibility results to the wards
one day earlier than would be feasible using conventional methods.
Methods: Blood cultures were processed by a BacT/ALERT 3D system
using FA and FN bottles. Bacteria from cultures showing Gram-
negative bacilli on the smears were concentrated by centrifugation
in two steps (150g and 2200g for 10 min respectively) and then
analysed in the VITEK2 system. The new colorimetric GN cards were
used for identiﬁcation and AST-N029 cards for antibiotic susceptibility
testing. Results were compared with standard procedures using an in-
house fermentation system for identiﬁcation and disc diffusion for
susceptibility testing.
Results: A total of 67 Gram-negative cultures were investigated. 96%
of the collected strains were correctly identiﬁed. Complete susceptibility
results were obtained within the time limit of 8 hours for 76% of
the strains. Susceptibility results in general correlated well with disc
diffusion data. Nineteen of 67 (28%) patients were found to receive an
inappropriate antibiotic therapy considering Gram smear and VITEK2
results. Twelve of those patients would have remained on improper
therapy for one more day if standard therapeutic regimen had been
applied. These cases included 5 ESBL-producing Klebsiella pneumoniae,
2 multiresistant Escherichia coli, one multiresistant Citrobacter braakii,
one Stenotrophomonas maltophilia, one Pseudomonas aeruginosa and 2
Salmonella sp.
Conclusions: The VITEK2 system proved to be a valuable tool for
direct identiﬁcation and susceptibility testing of Gram-negative bacilli
recovered from BacT/ALERT FAN blood cultures. By using the VITEK2
system, 12 of 67 patients could receive an appropriate antibiotic
treatment one day earlier than if standard in-house diagnostic procedures
had been implemented.
P1719 Validation of VITEK2 GN Cards and VITEK2 Version 4.02
Software for identiﬁcation and antimicrobial susceptibility
testing of nonfermenting Gram-negative bacilli from cystic
ﬁbrosis patients
I.M. Otto-Karg, S. Jandl, T. Mu¨ller, B. Stirzel, U. Vogel, M. Frosch,
H. Hebestreit, M. Abele-Horn (Wu¨rzburg, DE)
Objectives: Accurate identiﬁcation (ID) and antimicrobial susceptibility
(AST) testing of bacterial isolates from cystic ﬁbrosis (CF) patients
is known to pose problems. Commercially automated test systems are
available, but have not been recommended so far. Aim of this study
was to evaluate the VITEK2 GN card for ID and the new VITEK2
version 4.02 software for AST of nonfermenting Gram-negative bacilli
from CF-patients compared to reference methods.
Methods: A total of 168 strains for ID and 117 strains for AST were
investigated. Clinical isolates from CF-patients were identiﬁed with
the VITEK2 GN card and with the API NE system. If ID results
differed, molecular methods were used for deﬁnitive identiﬁcation. Broth
microdilution method served as reference method for AST against
nine antibiotic agents including cefepime, ceftazidime, piperacillin,
imipenem, meropenem, gentamicn, tobramycin, ciproﬂoxacin, and
cotrimoxazole. Interpretation of the AST results was performed
according to the DIN 58940 standard.
Results: Of the 168 strains tested 143 yielded concordant results.
The discordant 25 strains underwent 16S rRNA gene sequencing. The
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VITEK2 GN card identiﬁed 12 of 25 strains correctly to the species
level (155/168, 92%) and nine strains correctly to the genus level
(164/168; 98%); 4 (2%) strains were misidentiﬁed. In contrast, the API
NE correctly identiﬁed 4 of those strains to species level (147/168; 88%),
9 strains to genus level (154/168; 93%) and misidentiﬁed 12 (7%) strains.
Regarding AST, overall categorical agreement of VITEK2 compared to
the reference method was 97% for all antibiotics. Minor errors were
found in 8%.
Conclusion: The new VITEK2 GN card appears to be a reliable
method for identiﬁcation of nonfermenting Gram-negative bacilli from
CF patients. Moreover, the new VITEK2 version 4.02 software showed
good results when compared to reference method for AST and appears
to be applicable for routine clinical use in AST of nonfermenting Gram-
negative bacilli of CF patients.
P1720 Evaluation of the new VITEK2 NH identiﬁcation card
G. Valenza, C. Ruoff, U. Vogel, M. Frosch, M. Abele-Horn (Wu¨rzburg,
DE)
Objectives: The purpose of this study was to evaluate the ability of the
new VITEK2 NH card (bioMe´rieux, Nu¨rtingen, Germany) to identify
fastidious Gram-negative bacteria in comparison to reference methods.
Methods: A total of 149 strains belonging to the species listed in the
data base of the VITEK2 software were investigated, including Neisseria
spp., Haemophilus spp., Campylobacter spp., Capnocytophaga spp.,
Cardiobacterium hominis, Eikenella corrodens, Gardnerella vaginalis,
Kingella denitriﬁcans, and Moraxella catarrhalis. Thirty-one strains were
originated from the strain collection of the German National Reference
Centre for Meningococci (NRZM), from the American Type Culture
Collection (ATCC), and from the German Collection of Microorganisms
and Cell Culture (DSM). The remaining 118 strains were own clinical
isolates, which previously had been identiﬁed by API NH system or
other conventional methods. The new VITEK2 NH cards were used
according to the manufacturer’s recommendations. The cards were ﬁlled
with organism suspensions made in 0.45% aqueous NaCl to turbidity
equivalent to a McFarland #3 standard. Identiﬁcation results were
generated by a computer-assisted algorithm. In the case of conﬂicting
results, 16S rRNA gene sequencing (16 S) method was used for genetic
identiﬁcation.
Results: The new VITEK2 NH card was able to identify 142 (95%)
strains to the genus level and 138 (92.7%) strains to the species level.
Six (4%) strains were misidentiﬁed and ﬁve (3.3%) strains could not
be identiﬁed. 19 of 21 pathogenic Neisseria isolates were correctly
identiﬁed.
Conclusion: The new VITEK2 NH card appears to be a useful method
for the identiﬁcation of fastidious Gram-negative bacteria and seems to
be an improvement over the conventional diagnostic methods of some
fastidious microorganisms. More work is needed to ﬁnally evaluate the
performance of VITEK2 with regard to pathogenic Neisseria.
P1721 Species identiﬁcation with the BD Phoenix® System at low
and high inoculum in a routine laboratory
F. Geppert, N. Kempter (Vienna, AT)
Objectives:Most automated systems require inoculation with McFarland
0.5 (1.5×108 CFU/mL). In the routine laboratory sometimes only few
colonies resulting in lower applicable inocula are available. Becton &
Dickinson has thus developed a new software allowing a lower density of
McFarland 0.25 (7.5×107 CFU/mL). We compared the results obtained
with these two inoculation modes under routine conditions.
Methods: 181 Gram-positive and Gram-negative isolates including
fastidious and difﬁcult to identify strains from clinical material were
analysed. Reference diagnoses were made by conventional methods using
the API- and ID 32 system, tube coagulase (RAPIDEC®) and molecular
typing (GenoType MRSA®, Hain Lifescience). Using the Phoenix®, all
strains were tested in parallel at the standard inoculum of McFarland
0.5 (P 0.5) and 0.25 (P 0.25), respectively, after suspension in 4.5 ml
of identiﬁcation broth. The P 0.25 panels were marked for automatic
identiﬁcation by the system and the results were evaluated in separate
data bases.
Results: 80% of the ID results were available within 4 hours. Accurate
identiﬁcation (ID) at species level was achieved in 94.5% at P 0.5 and
in 93.4% at P 0.25, respectively. Details of discordant results (n = 18)
are presented in the table.
Reference ID Phoenix 0.5 Phoenix 0.25
Enterobacter amnigenus Enterobacter cloacae no ID
Klebsiella ozeanae Klebsiella ozeanae no ID
Kluyvera ascorbata Kluyvera ascorbata no ID
Salmonella abortus equi Salmonella typhi Salmonella paratyphi A
Shigella boydii Shigella sonnei Shigella boydii
Yersinia enterocolitica Yersinia frederiksenii Yersinia frederiksenii
Bordetella bronchiseptica no ID Bordetella bronchiseptica
Bordetella bronchiseptica Moraxella spp. Bordetella bronchiseptica
Pasteurella pneumotropica Pasteurella multocida Pasteurella multocida
Pasteurella multocida Pasteurella multocida no ID
Delftia acidovorans Delftia acidovorans no ID
Pseudomonas stutzeri Pseudomonas spp. Pseudomonas stutzeri
Staphylococcus aureus SCV Staphylococcus aureus no ID
Staphylococcus aureus SCV Staphylococcus warneri Staphylococcus aureus
Staphylococcus intermedius Staphylococcus aureus Staphylococcus intermedius
Staphylococcus lentus Staphylococcus lentus Macrococcus caseolyticus
Streptococcus equi Streptococcus equi no ID
Streptococcus pneumoniae Streptococcus pneumoniae no ID
Conclusion: The new software accurately identiﬁed strains at a lower
inoculum, interestingly in some cases even better than with McFarland
0.5. Since susceptibility testing can be done simultaneously and there is
no need for subculturing in case of low biomass, a report is completed
18−24 hours earlier.
P1722 Accuracy of the VITEK2 system to identify
coagulase-negative staphylococci
A. Sa´ez, B. Ruiz del Castillo, J. Agu¨ero, L. Martı´nez-Martı´nez
(Santander, ES)
Objective: We have determined the reliability of the identiﬁcation
of coagulase-negative staphylococci (CoNS) with the VITEK2 system
at species level, considering as a reference the results of molecular
identiﬁcation.
Methods: One hundred and sixty-six clinical isolates of CoNS (Oct.
2003-May 2005) and 7 ATCC type strains were evaluated. Bacteria were
identiﬁed with the VITEK2 system using ID GP cards. Absence of
coagulase was determined with a latex assay (Pastorex® staph-plus, Bio-
Rad). Reference identiﬁcation was established by 16S rDNA sequence
analysis; when identiﬁcation with VITEK2 and 16S rDNA disagreed,
deﬁnitive identiﬁcation was deﬁned after sequencing of the sodA and tuf
genes, as previously described (Drancourt et al. JCM 2000; 38: 3623−30
and Heikens el al. JCM 2005; 43: 2286−90). For species assignation,
the sequences of 16S rDNA, sodA and tuf were compared with those in
GenBank. Homology values above 97% were considered reliable.
Results: All 7 ATCC strains were correctly identiﬁed by 16S
rDNA sequencing. Among the 166 clinical isolates, the molecular
method identiﬁed the following species (number): S. hominis (39),
S. haemolyticus (35), S. saprophyticus (30), S. epidermidis (25), S.
lugdunensis (12), S. schleiferi (7), S. capitis (7), S. simulans (4), S.
pasteuri (2), S. warneri (2), S. intermedius (2) and S. equorum (1).
VITEK2 correctly identiﬁed 6 out of the 7 ATCC strains and 151/166
(91%) clinical isolates, including 38/39 S. hominis, 11/12 S. lugdunensis,
5/7 S. capitis, 3/4 S. simulans. Most misidentiﬁcations occurred with
S. epidermidis (4/25: 3 as S. hominis and 1 as S. intermedius/S.
chromogenes), S. saprophyticus (3/30: 1 as S. hominis, 1 as S. warneri
and 1 as S. cohnii) and S. haemolyticus (3/32: 1 as S. hominis, 1 as
S. warneri and 1 as S. warneri/S. haemolyticus). All isolates of S.
schleiferi, S. intermedius, S. pasteuri, S. warneri and S. equorum were
correctly identiﬁed by the VITEK2 system.
Conclusions: The VITEK2 system allows reliable identiﬁcation of
CoNS at species level, but additional improvement would be necessary
for identifying S. epidermidis, S. saprophyticus and S. haemolyticus.
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P1723 Evaluation of the 3M Rapid Detect Staph aureus: an in
vitro diagnostic device for direct detection of Staphylococcus
aureus nasal colonisation
L.G.M. Bode, Y. Hendriks, M.C. Vos, H.A. Verbrugh, J.A.J.W. Kluytmans,
D.J. Morse, M.E. Wood (Rotterdam, Breda, NL; St. Paul, US)
Objectives: Staphylococcus aureus is the leading cause of surgical site
infection, and roughly 25−30% of the population are colonised. In
general, colonised patients have a 2−14 fold increased risk of infection,
but those patients that carry at higher levels are at highest risk. The
patient’s own nasal ﬂora account for 80% of S. aureus infections. Rapidly
identifying colonised patients provides the ability to proactively manage
S. aureus carriers for the prevention of infection. The objective of this
pilot study was to investigate the clinical performance of a new rapid
diagnostic test system (for proposed introduction in 2007 under the
trade designation 3M Rapid Detect Staph aureus) to identify high level
carriage of S. aureus directly from nasal swabs.
Methods: This was a multi-centre, prospective, comparative pilot study.
There were a total of four sites, two in Europe and in the United
States that screened and sampled healthy subjects. One nasal sample
was collected from both nares using a swab. The sample was analysed
by the 3M Rapid Detect diagnostic test system, which provides results
in approximately 20 minutes and a standard quantitative culture method
using a selective medium. Conﬁrmation testing was conducted using the
Tube Coagulase Test.
Results: A total of 1044 subjects were enrolled across four sites with a
total of 999 evaluable subjects (having both culture and detector results).
33.6% of all evaluable subjects were S. aureus carriers, while 12.4%
carried 5000 cfu (high level carriers). The mean level of carriage
for those who were positive was 3.23 Logs (Range 0.63–6.50 Logs).
The sensitivity of the test at 5000 cfu was 87% (95%CI: 80−92%).
The overall sensitivity of the test system was 51% (95%CI: 46−57%).
The overall speciﬁcity was 92% (95%CI: 90−94%). At 5000 cfu
the negative predictive value was 98% (95%CI: 97−99%) while the
positive predictive value for all levels of carriage was 76% (95%CI:
70−82%). Based on a positive test result 77% of all patients are not
treated preemptively.
Conclusions: The proposed 3M Rapid Detect diagnostic test system
proved to be a sensitive tool to identify subjects carrying high numbers
of S. aureus in the nares. Especially, the high negative predictive value
provides a screening tool to rapidly and accurately identify patients who
are at low risk of developing a S. aureus infection after surgery, thus
allowing for more targeted use of antibiotics and other infection control
measures.
P1724 Performance evaluation of the Vidia™ toxoplasmosis IgG
and IgM assays
A. Calderaro, G. Piccolo, S. Peruzzi, G. Dettori, C. Chezzi (Parma, IT)
Objective: The aim of the present study was to compare the clinical
performance of the new VIDIA® Toxoplasmosis assays (bioMe´rieux,
France) to VIDAS (bioMe´rieux, France), Axsym (Abbott, USA) and
Liaison (DiaSorin, Italy) assays for both IgG and IgM, using clinical
specimens.
Methods: A total of 405 frozen and fresh serum samples from 243
pregnant women, 6 pregnant women-HIV infected, 39 healthy adults, 31
infants, 71 immuno-compromised patients and 15 blood donor was used
for this retrospective and prospective study.
The samples for which at least one equivocal result have been found
whatever the method have been excluded for the analysis, as well as the
non resolved samples.
Sensitivity and speciﬁcity of the VIDIA TOXO IgM and IgG were
determined, on all sera, in comparison with the VIDAS (routinely used
in our laboratory), Axsym and Liaison systems.
Results: For clinical samples, sensitivity was found to be 100% for
all the four systems for the detection of Toxoplasmosis IgG; regarding
Toxoplasmosis IgM, sensitivity was established at 100% for both VIDIA
and VIDAS systems, with Axsym we obtained 82.35 and 94.12% with
Liaison.
The speciﬁcity was 99.25% for VIDIA, 98.49% for Axsym and 100%
for both VIDAS and Liaison for the detection of toxoplasmosis IgG;
regarding TOXO IgM. Regarding the speciﬁcity we obtained 100% for
VIDIA, VIDAS and LIAISON and 99.73% for Axsym.
Conclusion: According to the results obtained during this study, the
VIDIA TOXO IgG and VIDIA TOXO IgM assays show an excellent
sensitivity and a good speciﬁcity.
P1725 Comparison of two automated systems (WalkAway and
VITEK2) for identiﬁcation of Gram-negative bacteria
K. Becker, B. Gru¨nastel, G. Peters, C. von Eiff (Mu¨nster, DE)
Objectives: The major advantages of automated systems widely used
for species identiﬁcation in the clinical laboratory are their speed,
high throughput, and expedient interfaces with laboratory and hospital
information systems. Since each system has its inherent strengths as well
as recognized restrictions, the performance of two automated systems
was studied with special respect to the time necessary for processing the
isolates.
Methods: A total of 375 clinical isolates comprising 277 enterobacterial,
94 non-fermenter and other Gram-negative isolates (e.g. Pasteurellaceae)
were used to compare the identiﬁcation accuracies of the Dade Behring
MicroScan WalkAway 96 and the Biome´rieux VITEK2 automated
systems. Isolates showing differences in identiﬁcation were subjected
to 16S rRNA gene sequencing.
Results: Overall, 81.6% (n = 306) of the identiﬁcation results were
identical in both systems on the species level, reaching an accordance
of 93.9% if the genus level was considered. Differences on the
family level (n = 10) occurred for Alcaligenaceae, Enterobacteriaceae,
Flavobacteriaceae, Moraxellaceae, and Pseudomonadaceae, whereas
differences on the genus and species level were mainly observed for
enterobacterial genera, such as Citrobacter, Enterobacter, Klebsiella,
and Serratia. In contrast to the ﬁxed processing time of the MicroScan
WalkAway system (2.5 hrs), the time of the VITEK2 system spanned
from 2.5 to 9.75 hrs necessary for identiﬁcation. However, the MicroScan
WalkAway system required in some cases repeats to get a ﬁnal
identiﬁcation result.
Conclusion: Both automated systems allow a timely identiﬁcation
of Gram-negative isolates. Moreover, they constitute an accurate and
reliable method for identiﬁcation of Gram-negative rods. Nevertheless,
the use of automated systems does not supersede the need for
determination of basic criteria for bacterial identiﬁcation in order to
discover major errors in identiﬁcation.
P1726 Direct identiﬁcation and susceptibility testing of
staphylococci from positive BacTec blood cultures with
WalkAway system
E. Gardun˜o, O´. Herra´ez, I. Ma´rquez-Laffo´n, R. Sa´nchez-Silos,
J. Blanco-Palenciano (Badajoz, ES)
Objectives: To evaluate the combination of the automated BACTEC
9240 blood culture system (Becton Dickinson) and the WalkAway/96
instrument (Dade Behring) for the direct identiﬁcation and antimicrobial
susceptibility testing of staphylococci from positive blood cultures
without subculture.
Methods: Positive blood cultures collected between Nov 2005 and
March 2006 from patients at our institution were examined by Gram
stain. Specimens containing Gram-positive cocci in clusters were
included in the study. The direct method was done using a suspension
made by two differential centrifugations of positive blood culture broth
for inoculation of the MicroScan Pos Combo Type 2SA panels. Standard
identiﬁcation and susceptibility were done using an inoculum made from
an overnight culture on solid media.
Results: A total of 88 positive blood cultures were evaluated. 81
isolates showed concordant identiﬁcation between the direct and standard
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methods, and the discrepancies were 3 S. epidermidis, 2 S. hominis and
one isolate of S. simulans identiﬁed by the standard method that were
respectively identiﬁed as S. hominis, S. epidermidis and S. epidermidis
by the direct method.
We found a rate of 92.04% correct identiﬁcation of staphylococci. There
were 87.4% categorical agreements; the major error (false resistance)
rate was 2.1%, and the very major error (false susceptibility) rate was
3.7%. The drugs with the most very major errors were trimethoprim-
sulfamethoxazole and ampicillin, and only vancomycin and cefazolin
showed total agreement with the reference method. Overall, 97.72%
blood cultures found to be positive for oxacillin-resistant were correctly
detected by direct method, while all oxacillin-resistant S. aureus isolates
were correctly detected.
Conclusion: Our results showed that the direct method provided
acceptable bacterial identiﬁcation, but cannot replace the standard
method for susceptibility testing due to unacceptable major and very
major errors rates. Oxacillin resistance is reliably detected by direct
method and could provide earlier information to clinicians.
P1727 Analysis of the comparative work-ﬂow and accuracy
of the VITEK2 Compact and the combination
mini-API/Agar diffusion SIRSCAN method
V. Doat, M. Roubille (Bourgoin-Jallieu, FR)
Objectives: The aim of this study was to analyse the impact
of introducing the VITEK®2 Compact, (bioMe´rieux, France), an
automated identiﬁcation (ID) and susceptibility testing (AST) system
into our laboratory that is currently using a semi-automated method
(identiﬁcation with mini-API® and AST by agar diffusion with results
expertised by SIRSCAN® (Dos version 1999, I2A).
Methods: This study was performed in the laboratory of a 390 bed
hospital from January to April 2006. A total of 300 strains isolated from
various clinical specimens were tested in parallel with the VITEK®2
Compact and our routine technique. The distribution of the strains,
representative of our routine workload, is as follows: 190 Gram-
negative bacilli (15% non-fermenters) and 110 Gram-positive cocci (66%
staphylococci). No fastidious organisms were included in the study
The workﬂow and productivity of each system were evaluated by
measuring the manipulation time for one operator to test 5 strains
repeated 3 times on each system. The total cost to perform one test,
including materials, repeats and waste disposal, were calculated. The
patient beneﬁt of rapid results was estimated by a retrospective analysis
of 10 patient ﬁles in collaboration with an Infectious Disease physician.
Results: The identiﬁcation agreement obtained between the systems
was 98% for the Enterobacteriaceae, 97% for the non-fermenters, and
95% for Staphylococcus and Streptococcus spp. The AST category
agreement was 93% with both systems.
The beneﬁts of introducing VITEK®2 Compact are as follows:
– Rapid results and rapid on-line result validation
– One third less manipulation time
– Reduced cost of reagents and consumables
– Reduction of waste disposal
– Reduced risk of biohazard exposure
Rapid result availability to the clinician is of interest especially in cases
of S. aureus and for P. aeruginosa in severe infections. Time saved is
dependent on laboratory organisation and direct communication with the
ward.
Conclusion: Both systems gave good results for the majority of strains
encountered in our medium size hospital. The reduced manipulation
times, rapid time to results, as well as the easy to use platform of
the VITEK2 Compact provide beneﬁts for both the laboratory and the
patient.
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P1728 Multiplexed molecular testing for the detection of human
respiratory viruses using the TM Bioscience ID-Tag RVP
assay
R. Manji, M. Lotlikar, C. Ginocchio (Lake Success, US)
Introduction: The effective, reliable, and timely identiﬁcation of
respiratory viral infections is of tremendous importance for diagnosis,
infection control, and for epidemiology and surveillance studies. This
study evaluated Tm Bioscience’s (Toronto, CA) respiratory virus test,
ID-TagTM RVP for the detection of the majority of strains and subtypes
of respiratory viruses, including respiratory syncytial virus A and B,
inﬂuenza A (H1, H3), inﬂuenza B, parainﬂuenza 1, 2, 3, 4, adenovirus,
coronavirus (229E, OC43, NL63, HKU1), human metapneumovirus, and
enterovirus/rhinovirus (E/R).
Methods: In total, 253 respiratory samples (nasopharyngeal [NP]
washes, NP aspirates, NP swabs in VTM and bronchial alveolar lavages)
collected during the 2005–2006 viral respiratory season were tested.
Samples (0.2 ml) were extracted using the NucliSENS easyMAG
instrument (bioMe´rieux, Durham, NC). RVP results were compared to
direct immunoﬂuorescence (DFA) and/or viral culture (VC). Discordant
samples were analysed by additional nucleic acid ampliﬁcation assays
and sequencing.
Results: Detection rates (% of total tested) for the 3 comparator methods
(DFA, VC, RVP) for each virus are as follows (ND=not done): Inﬂu A:
13.4, 17.8, 21.0; Inﬂu B: 2.8, 3.2, 4.8: RSV: 18.2, 15.0, 17.9; Para-1:
2.0, 2.8, 2.8; Para-2: 1.2, 2.8, 2.8; Para-3: 0.8, 0.8, 0.8; Para-4: ND,
ND, 2.4; Adeno: 2.8, 7.5, 6.0 (RVP increases to 7.2 with 3 low level
equivocal results): Corona: ND, ND, 1.6; hMPV: ND, ND, 1.2; E/R: ND,
ND, 9.5. The overall detection rate for each test for all viruses was: DFA
= 29%, VC = 49.9%, RVP = 60.4%. Mixed infections were found in 11
samples (4.35%) including 3 E/R+RSV; 2 E/R+Para-1; 1 E/R+ Para-2;
2 E/R+Adeno; 1 RSV+NL63, 1 RSV+Adeno; 1 Adeno+NL63.
Conclusions: ID-TagTM RVP assay can efﬁciently detect the major
respiratory viruses, including mixed infections. This assay will
provide insight on other respiratory pathogens (ex. coronavirus and
metapneumovirus) that are not routinely cultured in most laboratories,
the prevalence of mixed viral infections, and their role in disease severity
and outcome.
P1729 Clinical evaluation of the NucliSENS analyte speciﬁc
reagents for the detection of respiratory syncytial virus
and human metapneumovirus in paediatric respiratory
specimens
R. Manji, F. Zhang, M. Lotlikar, C. Ginocchio (Lake Success, US)
Background: Respiratory syncytial virus (RSV) and human metap-
neumovirus (hMPV) are signiﬁcant causes of lower respiratory tract
infection in infants and young children with bronchiolitis and pneumonia.
The rapid diagnosis of RSV and hMPV infections is important for
patient management and infection control measures. This study evaluated
the NucliSENS RSV and hMPV analyte speciﬁc reagents (ASRs)
(bioMe´rieux, USA) for the detection of RSV and hMPV in paediatric
respiratory samples. The prevalence of RSV and hMPV was determined
by age group and compared to other common viral respiratory pathogens.
Methods: Samples included: frozen respiratory specimens (nasopharyn-
geal aspirates, washes or swabs in VTM) from 653 children (<2 yr:
n = 433; 2−5 yr: n = 220) evaluated for respiratory disease. Specimens
and target speciﬁc RNA inhibition controls (IC) for RSV and hMPV
were co-extracted using the NucliSENS miniMAG and/or easyMAG
instruments (bioMe´rieux). NASBA ampliﬁcation and molecular beacon
detection of either RSV or hMPV and their speciﬁc IC were performed
using a NucliSENS EasyQ analyser (bioMe´rieux). Results for RSV
were compared to direct immunoﬂuorescence (DFA) and/or viral culture
(VC) using R-Mix cells (DHI, USA). hMPV and RSV discordant
results were arbitrated using Pro-hMPV and Pro-ﬂu 1 ASRs (Prodesse,
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USA). Pathogen prevalence was determined by patient age and location
(outpatient [OP], emergency department discharge (EDD), paediatric unit
[PU], intensive care unit [PICU]).
Results: For the comparison methods (DFA, VC, RSV ASRs) sensitivity
was 85.5%, 45.4%, 96.4%; speciﬁcity was 98.6%, 100%, 98.6%, PPV
was 92.9%, 100%, 93.9%, NPV was 96.2%, 91.4%, 99.0%.
NucliSENS hMPV positives were conﬁrmed with Pro-hMPV assay.
Prevalence rates (%) by age were as follows:
– Age <2 yr: Inﬂu A =4.84; Inﬂu B =2.77; Parainﬂu-1 =1.15; Parainﬂu-2
=0; Parainﬂu-3 =1.15; Adenovirus =2.77; Enterovirus =0; RSV
=27.48; hMPV =5.77.
– <2−5 yr:Inﬂu A =8.18; Inﬂu B =2.73; Parainﬂu-1 =0.91; Parainﬂu-2
=0; Parainﬂu-3 =0; Adenovirus =6.36; Enterovirus =0.45; RSV
=12.73; hMPV =4.55.
Distribution (%) of positive samples by patient location for RSV:
OP =43.9, EDD =35.4, PU =9.2, PICU =11.5; for hMPV: OP =2.9,
EDD =37.1, PU= 40, PICU =20.
Conclusions: The NucliSENS ASRs provided rapid (<3.5 hr) and
sensitive methods for the detection of RSV and hMPV in respiratory
samples. RSV remains the most isolated virus among those tested in
this study. RSV and hMPV infections required hospitalisation in 21%
and 60% of the patients in which virus was detected.
P1730 Efﬁciency of RNA isolation from respiratory samples
using the NucliSENS miniMAG and easyMAG extraction
procedures
R. Manji, F. Zhang, C. Ginocchio (Lake Success, US)
Objectives: The semi-automated NucliSENS miniMAG (MM) and the
automated NucliSENS easyMAG (EM) (bioMe´rieux, Durham, NC) are
platforms for the extraction of total nucleic acids (NAs) from clinical
samples. The method used by both is based on the established Boom
chemistry but utilises magnetic silica particles. The purpose of this
study was to evaluate both systems for the removal of inhibitors and the
efﬁciency of isolation of respiratory syncytial virus (RSV) and human
metapneumovirus (hMPV) RNA from paediatric respiratory samples.
Methods: NAs were extracted from 656 samples (nasopharyngeal [NP]
washes, NP aspirates, NP swabs in VTM) using either MM (n = 390)
or EM (n = 181) or both systems (n = 85). Samples (0.2 ml) were
pretreated with DNAse, transferred to a NucliSENS lysis buffer tube,
and target speciﬁc Inhibition Controls for RSV and hMPV were added
to assess the efﬁciency of extraction, ampliﬁcation and the presence of
inhibitors. Each NA extract was tested for RSV and hMPV using a
laboratory validated protocol and NucliSENS analyte speciﬁc reagents
(bioMe´rieux). Sensitivity of each method was compared using aliquots
of serially diluted in vitro transcribed RSV RNA.
Results: For RSV testing, initial inhibition rates for samples extracted
with EM was 0% (0/266) and for MM 2.11% (10/475). Inhibition was
resolved for all samples after repeat MM extraction from a new aliquot.
For hMPV testing, initial inhibition rates for samples extracted with
EM was 1.88% (5/266) and for MM 2.95% (14/475). Inhibition was
resolved for all EM samples and for 10/14 MM samples after repeat
extraction from a new sample aliquot for a ﬁnal inhibition rate of 0%
for EM and 0.84% for MM. RSV assay sensitivity using MM and EM
extraction was 66.7% and 87.5%, respectively, for detecting 10 RSV
RNA copies/isolation. RSV and hMPV were detected in 22.5% and
5.36% of the samples, respectively.
Conclusions: MM and EM provided highly puriﬁed NAs and efﬁciently
removed inhibitory substances from difﬁcult respiratory samples. A
slightly better performance seen with EM may relate to the fuller extent
of the automation and less operator error as compared to the semi-
automated MM. Other beneﬁts of the EM were better throughput per
run (EM:24 samples vs MM:12 samples) and less hands on time (EM:15
min vs MM:45 min). In addition, better assay sensitivity was achieved
with EM extraction. Both systems provide a generic extraction method
for a variety of analytes and sample types.
P1731 HBVDNA extraction from serum using the NucliSENS
easyMAG platform
P. van Deursen, G. Onland, A. van den Brule, A. Verhoeven, M. Jacobs
(Boxtel, Veldhoven, NL)
Background: The NucliSENS easyMAG platform (bioMe´rieux) is
designed for nucleic acid extraction from a broad range of different
sample specimens. However, for some speciﬁc applications additional
pre-extraction procedures and/or a speciﬁc extraction protocols might be
needed. Recently a new extraction protocol (Speciﬁc A) was introduced
for whole blood specimens.
Objectives: The aim of the study was to measure the recovery efﬁciency
of HBVDNA from serum using ﬁve different extraction protocols. Four
of these protocols were performed in combination with the NucliSENS
easyMAG platform and one other manual method was included as
reference.
Methods: A panel of 12 samples, including 4 standards (obtained
from VQC, Amsterdam), 7 HBVDNA positive serum samples and 1
negative control, were tested with ﬁve different extraction protocols.
Identical input (200 ul) and output volumes (110 ul) were used for the
different methods. Brieﬂy, for the NucliSENS easyMAG the following
procedures were tested; (1) no pre-incubation and Generic extraction
protocol, (2) pre-incubation with proteinase K and Generic extraction
protocol, (3) no pre-incubation and Speciﬁc A extraction protocol, and
(4) pre-incubation with proteinase K and Speciﬁc A extraction protocol.
The High Pure PCR Template Preparation kit (Roche diagnostics) was
used as reference method. To all samples control virus (PhHV) was
added to measure overall extraction performance. Extracted samples
were analysed by real time PCR.
Results: PhHV DNA was detected in all samples. Mean Ct values
were 29.6, 29.8, 29.5, 29.3, and 31.4 for protocols 1, 2, 3, 4, and 5,
respectively. HBVDNA was not detected in the negative control samples.
For the remaining samples HBVDNA was detected in 100% (protocols
1, 2, 4, and 5) and 91% (protocol 3). For the samples scored positive
with all ﬁve methods the mean Ct values were 32.8, 31.0, 32.9, 30.5,
and 31.3, respectively.
Conclusion: Best results, for both HBVDNA and control PhHV
DNA detection, were obtained in combination with protocol 4 that
uses proteinase K pre-incubation, followed by extraction with the
NucliSENS easyMAG platform using the Speciﬁc A protocol. The
proteinase K pre-incubation resulted in on average −2.1 lower Ct values
for HBVDNA detection, whereas for this application the Speciﬁc A
protocol contributed minimal (on average −0.2 Ct) to the overall
improvement measured.
P1732 Evaluation of an automated sample preparation system
(MDx) in combination with afﬁgene CMV trender
I. Abbate, N. Finnstrom, A. Garbuglia, M. Solmone, S. Selvaggini,
E. Bennici, S. Neri, C. Brega, M. Capobianchi (Rome, IT; Bromma,
SE; Milan, IT)
Background: Monitoring of Cytomegalovirus (CMV) viral load is
efﬁciently performed by using molecular diagnostics based on PCR,
such as the CE-labelled afﬁgene CMV trender assay (Sangtec, Bromma,
Sweden). Today, a number of automated nucleic acid sample preparation
systems are available for a high throughput laboratory. One of them is
the BioRobot MDx Workstation (MDx) from Qiagen (Hilden, Germany).
This study aims to evaluate the MDx in combination with the PCR
system afﬁgene CMV trender. Moreover, on a small number of clinical
samples a comparative analysis was conducted between afﬁgene CMV
trender assay and an house nested PCR method.
Materials and Methods: For the evaluation, the 2005 QCMD panel for
CMV was used. To mimic the laboratory routine for analysing whole
blood patient sample, freeze-dried samples from the QCMD panel were
diluted into whole blood, or in water and diluted in the lysis buffer of
the extraction kit. Each of the panel member was extracted twice on the
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MDx and thereafter each extraction was ampliﬁed in duplicates using
afﬁgene CMV trender.
Fiftyfour clinical whole blood samples were also included in the study.
Extraction was performed as above and the ampliﬁcation was done in
parallel with afﬁgene CMV trender assay and with nested PCR.
Results: The average results from each of the QCMD samples showed a
less than 0.25 log difference compared to the average reported value in
the QCMD report based on 30 different datasets. One sample varied more
than 0.25 log compared to the reported values. However, this sample was
in the area of the limit of detection for the assay. The negative sample was
reported negative in all four replicates. The comparison between afﬁgene
CMV trender assay and nested PCR showed a good concordance. Only
3 out of 54 patients showed discordant results, being 2 of them CMV
DNA positive only in nested PCR and 1 positive only when using CMV
trender. Moreover, the afﬁgene CMV trender assay was able to quantify
the CMV DNA present in the positive samples with a mean value of
43750 ± 26265 CMV DNA copies/mL.
Conclusions: The BioRobot MDx Workstation works well in combi-
nation with the afﬁgene CMV trender PCR assay as veriﬁed on both
QCMD panel and clinical samples. This opens up the possibilities for
quicker and accurate CMV monitoring for high-throughout laboratories.
P1733 Comparison of three different diagnostic tests for
HCV-RNA viral load: Cobas Amplicor Monitor HCV 2.0,
Versant b-DNA HCV 3.0, and Cobas TaqMan HCV
P. Ravanini, A. Nicosia, M. Crobu, E. Grossini, V. Quaglia,
M. Cagliano, C. Cusaro, F. Milano, F. Caviglia (Novara, Vercelli, IT)
Objectives: The correct quantiﬁcation of HCV-RNA viral load is an
important parameter for the assessment and monitoring of antiviral
therapy.
In this work, the possibility to obtain comparable results by different
standardised tests for HCV-RNA viral load has been veriﬁed. To perform
this aim we veriﬁed if there is an acceptable difference (<0.5 Log) among
three different tests and if there are differences of quantiﬁcation due to
viral genotypes.
Methods: In the last years we performed two similar studies of
comparison. The ﬁrst one compared Bayer Versant HCV 3.0 and Roche
Cobas Monitor HCV 2.0. 44 HCV-RNA positive samples of different
genotype were collected and analysed by both methods between October
2001 and May 2002. A new study was performed between November
2005 and May 2006 on further 70 samples, comparing Bayer Versant
HCV 3.0 and Roche Cobas TaqMan HCV.
Results: In the ﬁrst study the median ratio between the results obtained
by the two tests showed a value of 1.22 with a light overestimate of Cobas
Monitor in comparison to Versant HCV. In the second study the median
ratio was clearly higher: Cobas TaqMan showed an overestimate of 7.39
folds in comparison to Versant HCV. The cases with not acceptable
differences (>0.5 Log) were 5/44 (11%) in the ﬁrst study, and 60/70
(86%) in the second one.
The ﬁrst study showed a good correspondence for genotype 1 (ratio
0.99), a light overestimate for genotypes 2 and 3 (ratio 1.86 and 1.46)
and an underestimate for genotype 4 (ratio 0.79).
In the second study the only genotype with acceptable differences (<0.5
Log) was genotype 4 (ratio 2.0). The other genotypes showed poorer
acceptability because of greater differences (genotype 1 ratio 7.87;
genotype 2 ratio 6.30; genotype 3 ratio 13.11).
Conclusions: According to these data there is an important difference
between the viral loads by Versant HCV and Cobas TaqMan. In the
86% of the cases these differences are not acceptable. The scattering of
the results appears wider in the second study than in the ﬁrst one. The
comparison of different tests underwent a worsening.
Moreover there are great differences of quantiﬁcation according to
genotype. The only genotype with acceptable differences, in the second
comparison, was genotype 4.
In our opinion the standardisation of molecular methods for HCV-RNA
viral load testing is not yet concluded, and have to be resumed for new
Real Time methods which seem to be not perfectly comparable with the
other standardised methods.
P1734 Performance evaluation of the QIAGEN EZ1 DSP virus kit
with Abbott RealTime HIV-1, HCV and HBV assays
G. Schneider, K. Kuper, K. Abravaya, C. Mullen, M. Schmidt,
M. Sprenger-Haussels (Des Plaines, US; Hilden, DE)
Objectives: Automated systems must meet the demands of routine
diagnostics laboratories with regard to performance characteristics and
compatibility with downstream assays. The EZ1 DSP Virus system
is a generic sample preparation system utilising QIAGEN’s second
generation magnetic-bead technology on the QIAGEN BioRobot EZ1
DSP workstation for isolation and puriﬁcation of viral nucleic acids
from human plasma or serum. The improved EZ1 DSP Virus protocol
is taking advantage of optimised lysis conditions as well as increased
binding and washing efﬁciencies. The performance of the QIAGEN EZ1
DSP Virus Kit was evaluated in combination with the Abbott RealTime
HIV-1, HCV and HBV assays.
Methods: RNA viruses (HIV-1 and HCV) and a DNA virus (HBV) were
spiked into negative human plasma or serum and processed in batches of
six. An internal control was added to each sample to control for recovery
and inhibition. Nucleic acids were extracted from 0.4 ml of plasma or
serum using the EZ1 DSP Virus Kit and were eluted in a volume of 90
microliters. The resulting nucleic acids were analysed by the appropriate
RealTime assay on the Abbott m2000rt thermalcycler/reader according to
the package inserts. Run controls were included on every thermalcycler
run.
Results: RealTime assay results were linear over the ranges tested. The
observed inter-assay SDs were less than or equal to 0.13 log except
at the lowest concentration tested in each assay. The EZ1 DSP Virus
kit enabled detection of low levels of virus. Good correlation between
the BioRobot EZ1 and the Abbott m2000sp was observed. EZ1 DSP
Virus kit reagent lot-to-lot variability was evaluated. No detectable
false positives among negative samples were detected in six carryover
challenge runs. No inhibition was observed in the presence of potentially
interfering substances.
Conclusions: The QIAGEN EZ1 DSP Virus system enables reproducible
puriﬁcation of viral nucleic acids from human plasma or serum and
allows for reliable, sensitive and speciﬁc detection and quantiﬁcation of
RNA and DNA viruses by the Abbott RealTime HIV-1, HCV and HBV
assays.
*Under development for in-vitro-diagnostic use in Europe. The EZ1 DSP
Virus Kit as described in this poster will not be available in the USA.
** Abbott RealTime HIV-1 and HCV are CE marked, not available in
the USA. Abbott RealTime HBV is in development. Abbott Molecular
makes no Abbott RealTime assay performance claims using the EZ1
DSP Virus Kit.
P1735 The EZ1 DSP Virus Kit for use in molecular viral
diagnostics: performance veriﬁcation of kit and instrument
M. Schmidt, C. Kupfer, M. Hess, A. Burmeister, M. Sprenger-Haußels
(Hilden, Hamburg, DE)
Objectives: The generic EZ1 DSP Virus Kit* utilises magnetic-bead
technology on the QIAGEN BioRobot EZ1 workstation for isolation
and puriﬁcation of viral nucleic acids from human plasma and serum
samples. In this study, the performance of the EZ1 DSP Virus Kit was
evaluated in combination with several diagnostic downstream assays.
Validation parameters determined for DNA and RNA viruses are limit
of detection, linear ranges, lack of cross-contamination, robustness and
stability of eluates.
Methods: Known quantities of viruses were spiked into negatively tested
human plasma or serum pools. Diagnostic downstream assays used
during the performance veriﬁcation included in-house HCV RT-PCR
assay, artus CMV PCR Kits§ (LC, RG, and TM), artus HBV PCR Kits§
(LC, RG and TM), artus Parvo B19 RG PCR Kit§, COBAS Amplicor
Monitor HIV-1§, COBAS TaqMan HBV§, HCV§, and HIV-1§ (Roche).
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Results:We present some of the results of the performance evaluation of
the EZ1 DSP Virus Kit. The 95% probit value for HIV-1 was determined
to be 114.5 IU/mL using the COBAS Amplicor Monitor HIV-1 Test
(v1.5) and the preliminary 95% probit value for HBV 6.4 IU/mL using
the COBAS TaqMan 48 HBV Test. Plasma samples generated from
different blood collection tubes performed within the acceptance ranges
using an in-house HCV RT-PCR assay and the artus HBV RG PCR Kit.
Cross-contamination was not detected using plasma samples containing
1.00E+08 IU/mL parvovirus B19 processed in a checkerboard pattern in
9 runs on the BioRobot EZ1 DSP workstation.
Conclusion: The results of the performance veriﬁcation of the EZ1 DSP
Virus Kit conﬁrm the generic application of the EZ1 DSP Virus Kit
for fully automated sample preparation in combination with different
diagnostic downstream assays.
The EZ1 DSP Virus Kit and all of the artus PCR Kits as described in
this poster will not be available in the USA.
*Under development for in-vitro-diagnostic use in Europe. §CE-marked
for in-vitro-diagnostic use in Europe.
Pathogenesis of intracellular bacterial
infections
P1736 A proteomics approach to understanding the pathogenesis
mechanisms of the obligate intracellular pathogen Coxiella
burnetii
G. Samoilis, A. Psaroulaki, K. Vougas, A. Gikas, Y. Tselentis, G. Tsiotis
(Heraklion, Athens, GR)
Objectives: Coxiella burnetii is an obligate intracellular pathogen with
nearly worldwide distribution. It is the pathogenic agent of Q-fever in
man [1], and it has been classiﬁed as a Class-B possible agent for
bioterrorism [2]. Coxiella burnetii enters target cells by phagocytosis
and forms within the infected cell phagosomes that fuse with lysosomal
compartments to form the phagolysosome. Within the harsh environment
of the phagolysosome Coxiella burnetii manages to survive and replicate.
In this work we have attempted to construct a 2-dimensional map of
the proteome of intracellular Coxiella burnetii Phase II strain Nine
Mile. Identifying proteins being expressed by the intracellular form
of the bacterium can provide us with vital information concerning its
pathogenesis.
Methods: Intracellular Coxiella burnetii Phase II strain Nine Mile was
cultivated in Vero cell lines, isolated and separated from host cell
components in a renographin density gradient [4]. Total protein extracts
were analysed by conventional 2-dimensional PAGE. Trypsinised protein
spots were analysed in a MALDI-TOF MS instrument. Peptide analysis
and protein identiﬁcation were performed as previously described [5].
Peptide matching and protein searches were performed automatically
using the Mascot Software.
Results: We have detected 600 protein spots in 2-DE gels, and MS
allowed us the identiﬁcation of 168 Coxiella burnetii proteins. Identiﬁed
species seem to be involved in a wide range of bacterial processes,
whereas 12% of them were hypothetical.
Conclusion: The present study allowed the identiﬁcation of 168 different
proteins and, as far as we know, represents the ﬁrst proteome analysis
of Coxiella burnetii Phase II strain Nine Mile. Genome analysis has
predicted that Coxiella burnetii possesses components of the Secretion
IV System [3], and in our work we have conﬁrmed the expression of
DotB. This pathogen expresses an extensive network of chaperones,
which also seems to be coupled to the secretory pathway. We have also
found several other proteins that may be essential virulence or survival
factors for Coxiella burnetii. This work opens the way to characterise
the proteome of Coxiella burnetii, and to compare protein proﬁles of
different isolates.
Reference(s)
[1] M. Maurin and D. Raoult, 1999, Clin Micro Re, 12, 518.
[2] M. Maurin et al., 1992, Inf and Immu, 60, 5013.
[3] R. Seshadri et al., 2003, PNAS USA, 100, 5455.
[4] I. Spyridaki et al., 2002, J Anti Chem, 49, 379.
[5] L. Jiang et al., 2003, Amino Acids, 25, 49.
P1737 Identiﬁcation of Chlamydophila pneumoniae heat shock
protein 60 on atherosclerotic carotid plaque by RT-PCR
R. Cultrera, V. Crapanzano Minichello, S. Seraceni, M. Coen,
F. Mascoli, C. Contini (Ferrara, IT)
Objectives: Some difﬁcult microorganisms, including Chlamydophila
pneumoniae or Mycoplasma spp., are associated with the atheroscletotic
tissue damage. The aim of this study was to evaluate the employment
of culture together with PCR and RT-PCR to identify C. pneumoniae
in atheromatous carotid plaques (ACP) in order to deﬁne their possible
role in the pathogenesis of the arterial tissue damage.
Materials and Methods: ACPs were obtained by endoarterectomies
from 10 patients with severe stenosis of the internal carotid artery. Each
specimen was divided in three parts: a proximal tract to heart, healthy,
without stenosis, a medial tract, corresponding to the atheromatous
plaque, and a distal tract above the plaque. Each sample obtained in
aseptic conditions was immediately homogenised by freezing to −80ºC.
Aliquots were employed to perform cultures for C. pneumoniae on Hep-2
cell line in DMEM. DNA and total RNA were obtained from aliquots of
each tissue sample and from Hep-2 cultures. C. pneumoniae 16S, momp
and hsp60 genes were investigated.
Results: The PCR and RT-PCR for momp and 16S genes of
C. pneumoniae resulted negative in all samples. PCR and RT-PCR for the
hsp60 gene of C. pneumoniae resulted positive in the proximal portion
of one ACP with haemorrhagic evolution of a patient with a retinal
tromboembolic outcome. The molecular analyses on C. pneumoniae
growing in the culture are in progress.
Conclusions: The DNA and RNA ampliﬁcation of different portions
from ACP seems to be useful to evidence the effective localisation
of C. pneumoniae in the atheromatous arterial tissue. The evidence
of the gene expression of C. pneumoniae hsp60 in a patient with
acute haemorrhagic evolution of the carotid plaque may suggest that
C. pneumoniae might partecipate in the atherogenesis and to induce
atherosclerosis complications by inﬂammatory pathways (activation of
cytokines, endothelial factors and matrix-degrading metalloproteinases).
P1738 The role of Chlamydophila pneumoniae in pathogenesis of
adenoiditis in children
I. Choroszy-Kro´l, M. Frej-Madrzak (Wroclaw, PL)
Objective: The aim of the study was to determine a correlation
between the presence of Chlamydophila pneumoniae EB antygen and
the appearance of the ompA gene in pharyngeal tonsil tissue.
Materials and Methods: 162 different samples such as: tonsil swab
(n = 57), sera (n = 57), tonsil tissue (n = 48) were analysed. The samples
were taken from 57 patients aged from 3 to 15 years hospitalised
in Paediatric Otorhinopharyngeal Department of The Lower Silesian
Specialistic Hospital – Center of Medical Emergency in Wroclaw. The
control group consisted of 31 chldren aged from 3 to 15 years with no
symptoms from respiratory tract. Pharyngeal tonsil swabs were analysed
by direct immunoﬂuorescent method by Cp IFT reagent manufactured
by Cellabs Pty Ltd. and by ﬂuorescent microscope made by Olympus.
The level of speciﬁc anti-Cp IgG antibodies was determined by ELISA
assay using diagnostic test made by Vircell SL, Cp IgG ELISA Granada,
Spain. The opmA gene fragment in tonsil tissue was detected by nested
PCR using PCR diagnostic made by DNA – Gdan´sk II s.c.
Results: Infection caused by Chlamydophila pneumoniae was detected
in tonsil swabs by direct immunoﬂuorescent method in 13 of 57 (22.8%)
examinde children whereas in control group the presence of Cp was not
observed. The increased level of anti-Chlamydophila IgG antibodies was
indicated by ELISA in 10/57 (17.5%) examined subjects while in control
group this parameter was not performed for reasons of economy. OmpA
gene of Chlamydophila pneumoniae was detected by PCR in 28 of 48
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(58.3%) patients; in control group this parameter was not evaluated for
reasons already mentioned. The analysis of the frequency of Cp infection
in children of different age showed that the highest rate of infection was
present in group of age ranging from 6 to 10 years: 26.9% of cases with
detection of Cp antigen and 72.2% of cases with detection of Cp DNA
respectively.
Conclusions: In children with adenoiditis the presence of Cp antigens
in tonsil swabs did not correlate with the appearance of IgG antibodies
in sera. The association between the C. pneumoniae antigens observed
in examined patients with the presence of ompA gene in tonsil
tissue of those patients was also excluded. A common appearance
of C. pneumoniae in adenoids could suggest that tonsil tissue may
act as natural reservois for many pathogens of respiratory tract.
The signiﬁcance of detection of Cp in children who underwent
adenoidectomy remains still difﬁcult to deﬁne.
P1739 Looking for evidence of Chlamydia pneumoniae presence in
atherosclerotic and non-atherosclerotic segments of arteries
obtained from autopsies at a forensic unit in a Kuala
Lumpur hospital, by both rtPCR to detect omp A VD4
base sequences and immunohistoch
P.S. Puvaneswaren, M.I.A. Mustafa, N.B. Abdullah, M. Inuzukam,
Q. Haque, A.H. Mansor (Kuantan, MY; Fukui, JP; Kuala Lumpur, MY)
Background and Objective: A plethora of conﬂicting reports regarding
the link between Chlamydia pneumoniae (CP) and atherosclerosis exist,
however few are available from Malaysia and Southeast Asia. This study
was performed to look for evidence of CP presence in atherosclerotic as
well as non-atherosclerotic arteries of the same human cadaver.
Methods: Both a molecular method using real-time PCR to look for the
presence of VD4 sequences, a highly conserved domain of CP ompA
gene, as well as immunohistochemical method using CP species-speciﬁc
antibody ab13941 purchased from DakoCytomation were conducted.
Ampliﬁcation of human beta actin gene, a housekeeping gene, acted as
an endogenous control. Fifty-two atherosclerotic arterial segments and
thirty-three non-atherosclerotic segments were obtained from 33 fresh
cadavers at the Forensic Unit, Hospital Kuala Lumpur for the purpose
of the study.
Results: Both the immunohistochemistry assay as well as the real-time
PCR assay failed to detect any C. pneumoniae from all the tested tissue
samples.
Conclusion: Thus, this study could not demonstrate any molecular or
immunohistochemical evidence for the presence of CP in any of the
arterial tissues tested whether atherosclerotic or non-atherosclerotic.
P1740 Beta-2-microglobulin-deﬁcient mice: increased susceptibility
to Mycobacterium avium infection
S. Gomes Pereira, P. Rodrigues, R. Appelberg, S. Gomes (Porto, PT)
Iron availability is critical for mycobacterial survival and multiplication,
with host iron overload favouring bacterial growth and increasing
susceptibility. Previous studies have shown that beta-2-microglobulin-
deﬁcient mice (b2m KO) are highly susceptible to M. tuberculosis
infection, which was in part due to the absence of CD8+ T cells but
also to the iron overload typical of b2m KO hepatocytes. In M. avium
infection, CD8+ T cells are not fundamental for the control of bacterial
growth, whereas an excess of iron is beneﬁcial for its proliferation. Hfe-
knock-out animals, on the other hand, represent a model of systemic
iron overload, in the absence of any known immune deﬁciency.
In this study, we evaluated the susceptibility to M. avium infection of
both b2mKO and HfeKO mice.
Age-matched animals from C57Bl/6 (wild-type), b2m KO and Hfe KO
mouse strains were infected with M. avium strain 2447 SmT by the
intravenous route. At different times post-infection, blood was collected
for the quantiﬁcation of serum iron and transferrin saturation. Spleen
and liver were recovered for mycobacteria CFU counts, iron content
determination and histological analysis (Ziehl-Nielssen, Perl’s staining).
Two months after infection, b2m KO mice began to show higher
hepatic mycobacteria counts when compared to wild-type animals. This
difference was even more pronounced 4 months post-infection. In the
liver, non-hemic iron values were about four-times higher in b2m KO
animals than in wild-type controls, Serum iron and transferrin saturation
were also higher in b2m-deﬁcient mice. Spleen iron content did not
show signiﬁcant differences between these two strains. The increased
susceptibility of b2mKO mice to M. avium infection does not result
exclusively from the iron overload status of b2m KO mice. Hfe KO mice,
which show similar iron levels and tissue distribution, also exhibited
higher mycobacterial counts than wild-type animals, but did not show
the same degree of susceptibility as b2m KO mice. In order to understand
if CD8 T cells deﬁciency is contributing to the increased susceptibility
in b2m KO animals, experiments with CD8 T cells depletion in Hfe KO
mice are being carried out.
P1741 Association of apolipoprotein E polymorphism with
tuberculosis
T.N. Farivar, P. Johari (Zahedan, IR)
Apolipoprotein E (ApoE) is a 34-kDa glycoprotein involved in
lipoprotein transport through interaction with the low-density lipoprotein
and related receptors and exists as three isoforms, designated E2,
E3, and E4. Recently, it has become clear that ApoE binding to its
receptors plays a role both in development and in control of the immune
system. Also, it has been showed that ApoE modulates the rate of
uptake of apoptotic cells by macrophages. Studies in several populations
have indicated that genetic variation at the apolipoprotein E structural
locus inﬂuences amplitude to infectious diseases. The possible role of
apolipoprotein E polymorphism in the development of Tuberculosis has
not been investigated sufﬁciently. In this study, we aimed to determine
the signiﬁcance of association between Tuberculosis and apolipoprotein
E genotypes.
The apolipoprotein E genotypes were assayed in 82 tuberculosis patients
by polymerase chain reaction followed by enzymatic digestion with Hha
I and compared with previously reported Apo E genotype frequencies.
Our results showed that the incidence of E2 and E4 allelic frequencies
were signiﬁcantly higher in patients (0.34 and 0.12) than in controls (0.03
and 0.06 respectively). Also, the incidence of E3 allelic frequency was
lower in patients (0.54) than in controls (0.91). Also, our study revealed
an association of apolipoprotein E locus with Tuberculosis. However,
large population-based studies are needed to understand the exact role
played by the locus in causing the condition.
P1742 Rapid systemic propagation of Legionella longbeachae lung
infection in A/J mice
I. Gobin, M. Sarec, K. Selenic, M. Doric, M. Susa (Rijeka, HR)
Objectives: Legionnaire’s disease was considered to be exclusively a
lung disease and limited informations were available concerning the
progression of the disease. It was shown that mice intratracheally
inoculated with 105 CFU L. longbeachae serogroup 1 developed an
acute disease and died within six days. Pathohistological changes in the
lungs of infected animals were typical for multifocal bronchopneumonia.
Therefore, we were interested to explore whether a systematisation of
the primary process in the lungs may occur. In this study we analysed
the intensity of bacterial multiplication and pathohistological changes in
liver, spleen and kidney.
Methods: Pathogen-free female 6- to 10-weeks-old A/J mice were
infected by intratracheal inoculation with L. longbeachae serogroup 1
using a dose of 105 CFU. We determined the CFU of bacteria in the
lung, liver, spleen and kidney of A/J mice 2, 24, 48 and 72 hours post
infection. We also followed the patohistological changes in these organs
72 hours post infection (HE, PAS, Mallory and Gomory stain).
Results: Increasing multiplication of L. longbeachae in the lung was
associated with increased colony counts in analysed organs reaching
the concentration between 103 CFU (kidney) and 105 CFU (liver) at
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72 hours post infection. We never detected an excessive proliferation
of bacteria in these organs, which would be independent of the
bacterial proliferation that has been seen in the lungs. Pathohistology
of liver, spleen and kidney analysed 72 hours post infection showed
mainly mild inﬂammatory cellular inﬁltrates and degenerative changes.
In the liver, beyond the degeneration of the hepatocytes, the most
prominent observation was focal inﬁltrations within portal triads by
mononuclear and polymorphonuclear leukocytes. The architecture of
the white and red pulp of the spleen showed all signs of severe
destructive splenitis. In kidney the glomerules were reduced in size and
the juxtaglomerular apparatus showed decreased cellularity. Additionally,
a signiﬁcant degeneration of particular proximal tubule and collagen
increase in the intertubular spaces was observed.
Conclusion: We conﬁrmed that L. longbeachae serogroup 1 rapidly
disseminate in the liver, spleen and kidney causing severe systemic
disease in mice. At the moment we do not know if the observed
pathohistological changes are caused by local bacterial multiplication
and their virulent factor(s) or by uncontrolled host immune response.
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P1743 Predicting sepsis mortality in the emergency department:
a comparison among mortality in emergency department
sepsis (MEDS) score, procalcitonin, and C-reactive protein
C-C. Lee, S-Y. Chen, P-R. Hsueh (Taipei, TW)
Objectives: To compare the prognostic value of a validated clinical
prediction score, Mortality in Emergency Department Sepsis (MEDS)
score, and two labratory markers, procalcitonin (PCT), and C-reactive
protein (CRP), in ED sepsis patients.
Methods: The study is a prospective observational cohort design,
carried out at the emergency department (ED) of an urban, university-
based medical centre. Consecutive adult patients admitted to the ED
fulﬁlling the ACCP/SCCM Consensus Conference deﬁnition of sepsis
were prospectively enrolled. PCT and CRP were evaluated for each
enrolled patient on ED admission. Clinical characteristics and laboratory
results were recorded using a standardised form. Each patient was
followed for at least 30 days. The main outcome was 30-day all cause
mortality. The PCT level and MEDS scores were correlated with clinical
severity of sepsis. Areas under the receiver operating characteristic curve
(ROC curve) were calculated for each prognostic marker.
Results: A total of 525 patients were included in the analysis. The overall
30-day mortalty was 10.5% (55/525). All three markers, PCT, CRP, and
MEDS score, were higly correlated with the severity classiﬁcation of
ROC curves of three predictive markers for mortality in patients with
sepsis.
sepsis (sepsis, severe sepsis, septic shock). The area under the ROC
curve in the prediction of mortality was 0.82 for MEDS, 0.73 for PCT,
and 0.64 for CRP. Controlling for MEDS score variables, elevated serum
level of PCT ( 0.5 ng/mL) was independently associated with 30-day
mortality (odd ratio 2.82; 95%CI, 1.26–6.33). Incorporation of PCT as
an item of MEDS score increases the area under curve from 0.82 to 0.88.
Conclusions:MEDS score was the best predictor of mortality in patients
with sepsis in the ED setiing. PCT provided a better estimate of clinical
severity and prognosis than CRP. Incorporation of PCT into the MEDS
scoring system will enhance its capability to predict mortality in patients
with sepsis.
P1744 Procalcitonin as a parameter for the early recognition of
severe bacterial infections
A. Georgouli, E. Chinou, D. Manavoglou, P. Ntavlouros, E. Skouteli,
P. Golemati (Athens, GR)
Objectives: The aim of our study was to conﬁrm the diagnostic value of
procalcitonin (PCT) levels in the discrimination between severe bacterial
infections and other conditions such as localised infections, superﬁcial
bacterial colonisation or viral infections.
Methods: We examined 166 patients divided into four groups: control
group (n = 85, patients with no sign of infection); patients with
conﬁrmed sepsis (n = 12); patients with localised infections (n = 32);
patients with bacterial colonisation (n = 26); and patients with conﬁrmed
viral infection (n = 11). Plasma PCT levels were determined by an
immunochromatographic test for the semi-quantitative detection of PCT
(normal range of PCT values <0.5 ng/mL).
Results: The following results were obtained:
– Control group (n = 85): PCT levels <0.5 ng/mL.
– Sepsis (n = 12): PCT levels 10.0 ng/mL.
– Localised infection (n = 32): PCT levels 0.5−2.0 ng/mL.
– Bacterial colonisation (n = 26): PCT levels 0.0−2.0 ng/mL.
– Viral infection (n = 11): PCT levels 0.0−0.5 ng/mL.
Conclusions: Our study conﬁrmed that PCT is a sensitive parameter that
is higly elevated only in severe bacterial infections as opposed to viral
infections, localised infections and superﬁcial bacterial colonisation.
P1745 Are procalcitonin and C-reactive protein accurate
prognostic markers in sepsis?
N. Komitopoulos, E. Giakoymaki, V. Tsiavos, D. Charitos,
A. Komitopoulou, A. Kanavou, E. Varsamis (Athens, GR)
The initial presentation of sepsis is often non speciﬁc and its severity is
sometimes underestimated. Procalcitonin is the prohormone of calcitonin
produced by several cell types and many organs in response to pro-
inﬂamatory stimuli, in particular by bacterial products. High values of
Procalcitonin (PCT) and C-Reactive Protein (CRP) are considered useful
and reliable markers for the diagnosis of sepsis, but their association with
sepsis severity is still debated.
Aim: To evaluate whether PCT and CRP serum levels could be correlated
with APACHE II score in septic elderly patients.
Subjects and Methods: 48 patients, 23 females and 25 males, with
sepsis of various origin, aged 74 ± 15 years, were included in this study.
PCT levels (semi-quantitative immunochromatographic test, DIACHEL),
high sensitivity CRP levels (DADE BEHRING) and APACHE II score
were measured within 6 hours after hospital admission.
Results: PCT values were found >0.5 ng/dl in 78% of the patients. The
mean value of APACHE II score in patients with PCT >2 ng/dl (cut off
of severe sepsis) was compared with that of patients with PCT< 2ng/dl
and no statistically signiﬁcant difference was found (20.7 ± 8.2 vs 17.9
± 8.3, respectively, student t-test, p = 0.3). Although the CRP values
in septic patients were high (150 ± 107mg/L), no correlation between
CRP and APACHE score was observed (Regression analysis, p = 0.19).
No signiﬁcant differences were also found in the PCT and CRP levels
between patients who survived and succumbed.
In conclusion, the high levels of PCT and CRP could contribute to the
diagnosis of sepsis in elderly patients but might lack prognostic accuracy.
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P1746 Serum procalcitonin and organ failure in critically ill
patients with sepsis
M. Kompoti, C. Kostopoulos, M. Daganou, P. Bakakos, A. Gonis,
A. Rassidakis, J. Nanas (Athens, GR)
Sequential Organ Failure Assessment (SOFA) score is applied by
internists for daily description of organ dysfunction in critically ill
patients.
Objective: Our study investigates any association between SOFA score
and serum procalcitonin during the ﬁrst 48 h of clinically detectable
sepsis in critically ill patients.
Patients and Methods: Forty-four consecutive patients with sepsis
admitted in the intensive care unit (ICU) of the ﬁrst hospital were
included in our study. At 0 h (baseline), 24 h and 48 h serum procalcitonin
was measured and SOFA score was calculated in all patients. Pearson’s
correlation coefﬁcients were used to quantify the association between
serum procalcitonin and the corresponding SOFA scores. Statistical
signiﬁcance level was set at p< 0.05
Results: Age (mean±SD) was 66.7±11.2 years and APACHE score
at admission in the ICU was 15.2±5.8. SOFA score was 5.5±2.8 at
baseline, 5.5±2.4 at 24 h and 5.5±2.6 at 48 h. Serum procalcitonin
[median (interquartile range)] was 0.53 (0.23–0.85) ng/mL at baseline,
0.48 (0.22–0.76) ng/mL at 24 h and 0.44 (0.25–0.61) ng/mL at 48 h.
SOFA score at all three time-points was linearly associated with
the natural logarithm of serum procalcitonin (Pearson’s correlation
coefﬁcients: r(0 h) = 0.564 (p< 0.001), r(24 h) = 0.486 (p< 0.001) and
r(48 h) = 0.611 (p< 0.001).
Conclusions: In critically ill patients with sepsis, serum procalcitonin
serial measurements reﬂect the degree of organ failure and are linearly
associated with the corresponding SOFA scores.
P1747 The impact of insulin therapy on inﬂammatory markers in
critically ill patients with sepsis
M. Kompoti, C. Kostopoulos, M. Daganou, P. Bakakos, A. Rassidakis,
J. Nanas (Athens, GR)
Objective: To assess the impact of insulin therapy on serum
concentration of C-reactive protein (CRP) and ﬁbrinogen (FBG) in
intensive care unit (ICU) patients.
Patients and Methods: We studied 44 consecutive patients who were
admitted with sepsis in the ICU and who had a known history of type 2
diabetes or presented with stress hyperglycaemia at admission. Blood
glucose was controlled with continuous intravenous insulin infusion.
Serum levels of FBG and CRP were measured at 0 h, 24 h and
48 h. Regression models were ﬁtted describing the association between
changes of CRP and FBG serum concentrations from baseline to 24 h
and 48 h and the total insulin dose administered during the corresponding
time periods. Data analysis was performed with repeated measures test
and linear regression. Statistical signiﬁcance level was set at p< 0.05.
Results: CRP (mean±SD) at 0 h, 24 h and 48 h was 13.9±8.5, 13.8±8.1
and 13.8±8.8mg/L, respectively and FBG was 561±190, 544±181 and
567±196mg/dl, respectively. Insulin dose [median (interquartile range)]
administered over the ﬁrst 24 h and over the ﬁrst 48 h was 40 (13−80)
and 98 (28–179) IU, respectively.
Serum concentration changes of CRP and FBG were linearly associated
with the administered insulin dose after adjustment for age, BMI and
mean blood glucose (CRP: adjusted R-square = 0.199, p = 0.025 for
0−24 h and adjusted R-square = 0.124, p = 0.022 for 0−48 h; FBG: model
for 0−24 h not signiﬁcant and for 0−48 h adjusted R-square = 0.111,
p = 0.023).
Conclusions: Insulin administered with continuous intravenous infusion
in critically ill patients during the ﬁrst 48 h of sepsis produces a
signiﬁcant effect on CRP and FBG serum concentrations.
P1748 Protein Z, other natural anticoagulan and procalcitonin
levels in adult patients with sepsis
N. Tasdelen Fisgin, T. Fisgin, F. Ulger, S. Esen, E. Tanyel,
M. Zivalioglu, H. Leblebicioglu (Samsun, TR)
Objectives: Severe sepsis is one of the major causes of mortality in
intensive care unit patients. Protein Z (PZ) is a vitamin K-dependent
glycoprotein synthesized in the liver that serves as a cofactor for the
inhibition of factor Xa (FXa) in the presence of Ca+2. In some reports
low PZ levels were reported to be a risk factor for thrombosis including
coronary artery disease, ischemic stroke, but, there is no data about
PZ levels in adult with sepsis. Elevated procalcitonin levels have been
reported in acute bacterial infections and sepsis. It is known that a long
term sustained elevation of PCT associated with poor prognosis. In this
study we evaluated levels of protein Z, other natural anticoagulants (PC,
PS, antithrombin III) and procalcitonin levels in patients with sepsis.
Methods: From 2004 through 2005, eligible patients were included in
this study. Twenty patients were diagnosed as having sepsis. Patients
with sepsis (group 1, n:20) and healthy control (group 2, n:16). Patients
were evaluated for age, clinical ﬁndings, laboratory data, treatment, and
prognosis. Two groups were described in this study.
Results: Protein C levels were signiﬁcantly decreased than normal range
in sepsis group (48.9 ± 14.4%, n:50 – 150%). Protein Z levels were
signiﬁcantly decreased in sepsis group (76.9 ng/mL) when compared
to control patients (98.1 ng/mL) (p = 0.02). Procalcitonin levels were
signiﬁcantly increased in sepsis group (98.1 ng/mL) when compared to
control patients (0.23 ng/mL) (p = 0.000).
Conclusions: We found that PZ and PC levels were signiﬁcantly
decreased in patients with sepsis, but we did not observe correlation
between mortality and decreased levels of PZ, PC and increased
procalcitonin levels. In additionally, we found that there was no positive
or negative correlation between PZ and, PC, procalcitonin levels
P1749 Detection of the Factor V Leiden mutation in septic patients
E. Gorodnova, S. Grachev, V. Beloborodov, V. Malov (Moscow, RU)
Objective: To investigate clinical and pathogenic value of identiﬁcation
of activated protein C (APC) resistance associated with Factor V
Leiden mutation in adult patients with bacterial sepsis. Study design is
“Case–Control” = 2(23):1(10), “Control” was the group of comparison,
CI = 95, power = 80% (EPI INFO 6, CDC.gov). Outcome: severe bacterial
sepsis; bias: sampling; confounders: icteric, lipemic and haemolyze
plasma samples; deﬁciencies of coagulations factors VII, VIII, IX, XII;
limitations: enrollment.
Methods: Case: 23 patients with meningococcal sepsis, serotypes of
N. meningitidis- – A 78%, B 18%, C 4% (mortality 22%, average age 44,
m/f 13/10). Control:10 patients with sepsis caused by other bacterias, like
Kl. pneumoniae 34%, Str. pneumoniae 22%, E. coli 22% and Staph.
aureus (mortality 50%, average age 53, m/f 7/3). Inclusion criteria:
adults from 18 to 75 years old with bacterial sepsis; intensive Care Unit
patients; human blood samples were obtained after informed consent,
genders – both. Exclusion criteria: heparin therapy, viral infections;
cancer; pregnancy and lactation. 100% Cases and part of Control patients
displayed skin and mucous haemorrhagic rash, and they were bleeding
of various sites. All patients were characterised by APACHE II score as
severe (M= 21.5; SD= 7.3). Exposure: APCr – Quik test bioMe´rieux,
France.
Results: The Leiden mutation is revealed in 30.5% (n = 7) of Cases and
in 40% (n = 4) of Controls (OR= 0.7). Irrespective of sepsis aetiology, in
case of sepsis lethal outcome, the given genetic defect came to light in
60%. All of these cases are revealed at patients of 40 years or senior. Its
in 100% of cases has been registered in Control group only at persons
of a male.
Conclusion: Detection of Factor V Leiden mutation in adult patients
with severe sepsis is an additional and potent criterion of estimation
of DIC severity (one important component of MOF). Presence of this
genetic defect is an adverse background for development of severe DIC.
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Our study data provide the expediency and utility of Leiden mutation
detection to choose the proper medical approach for DIC correction in
patients with sepsis, because whether patients with the mutation would
beneﬁt from more intense or prolonged anticoagulation is unknown. It
includes the replaceable therapy by an APC drug; and administration of
different anticoagulants for septic patients with Leiden mutation is not
proved because of pathogenetical, clinical and cost-effectiveness reasons.
P1750 Community-acquired Gram-positive sepsis
M. Lupse, M. Flonta, A. Slavcovici, A. Bica, V. Zanc, D. Tatulescu
(Cluj-Napoca, RO)
Community acquired sepsis is an important cause of morbidity and
mortality. Clinical characteristics of Gram-positive sepsis could suggest
the aetiology, being useful for empirical antimicrobial treatment.
Material and Method: We performed a retrospective study based
on case records over a 4-year period (2001–2005). We selected adult
patients having at admittance in ICU Teaching Hospital of Infectious
Diseases the diagnosis criteria of community-acquired sepsis, according
to ACCP/SCCM expert panel recommendation and Gram-positive
aetiology. We made a descriptive statistics regarding: SIRS criteria,
multiple organ dysfunction syndrome (MODS), aetiology and survival
using Excel statistical analysis.
Results: From 209 adult patients non-HIV with community acquired
sepsis we selected 53 cases (25%) with conﬁrmed Gram-positive
aetiology, median age 51.6 years, 26 males (49%). The aetiology was:
66% S. aureus (34% of these were methicillin-resistant MRSA), 14%
Enterococcus spp., 9% Streptococcus pneumoniae, 9% Streptococcus
viridans, 2% others. SIRS criteria were: fever in 74% patients,
tachypneea in 62%, tachycardia in 62% and leukocytosis/leukopenia
in 42% patients. The percent of patients with Gram-positive sepsis
was: 40% for 2 SIRS criteria, 40% for 3 SIRS criteria and 20% for
4 SIRS criteria. The organ dysfunction: 70% respiratory dysfunction
(most of them acute lung injury), septic shock 22%, renal dysfunction
20%, metabolic dysfunction 18%, neurological dysfunction 18%, liver
dysfunction 12% and coagulopathy 8%. 47% of patient had MODS: 21%
with 2-organ dysfunction, 17% with 3-organ dysfunction and 9% with
more than 3 organ dysfunction. Fatality rate was 28%.
Conclusions: S aureus is the most important aetiology of community
acquired Gram-positive sepsis with an important percent of methicillin
resistance. Clinical course of community acquired Gram positive sepsis
is characterised by: 2 or 3 SIRS criteria, frequent with respiratory
involvement, few severe criteria and a good prognostic.
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P1751 DARC and MBL2 polymorphisms in Kenya
J.K. Nganga, J.N. Waitumbi (Nairobi, KE)
Objectives: The clinical outcome of malaria infection depends
on multiple factors. Certain polymorphisms within speciﬁc parasite
recognition receptors (PRRs) confer a selective advantage during malaria
infection. Mannose binding rectin (MBL2) which activates complementis
an important PRR. The Duffy antigen receptor for chemokines (DARC)
on the other hand acts as a receptor for P. vivax and mops up cytokines
during a malarial infection. This study therefore sort to determine the
degree and frequency of single nucleotide polymorphisms within DARC
and MBL2 genes in subjects with severe malarial anaemia versus age
matched controls, determine SNP allele distribution within the promoter
and coding domains within each of the selected genes and ﬁnally
determine the effect of selection pressure on the distribution of the
alleles.
Methods: In this Case-control study, 30 children typed severe malaria
anaemia were recruited as well as 30 of each age and sex-matched
asymptomatic P. falciparum infected and healthy children. Venous blood
was collected for DNA extraction and malaria parasites counted on
Giemsa-stained thick blood ﬁlms. P. falciparum infection was aslso
ascertained by speciﬁc PCR assays. A 376 base pair fragment in
the neighbourhood of MBL2 Arg52Cys, MBL2 Gly57glu and MBL2
Gly54Asp mutations was ampliﬁed and cycle sequenced. Data was
analysed against the human genome data base for this and other
mutations. Frequencies and proportions were compared by c2 test for
trend. The study was approved by Kenya Medical Research Institute
Ethics Committees and had written consent from the participants’ parents
and or guardians.
Results: Initial analysis indicate that all the individuals genotyped were
ﬁxed for the FY0 allele as expected of a population with an African
descent. This is in agreement with the earlier described effects of
intense selection pressure exerted by malaria in the region of western
Kenya leading to ﬁxation of the null B allele. Though the three MBL2
mutations were common they did not seem to segregate differently in
the symptomatic P. falciparum infected and healthy children except for
one novel mutation as represented in Figure 1.
Fig. 1.
Conclusion: Carrier trait analysis involving a combination of SNPs will
help to determine the role of different SNPs in disease susceptibility and
severity as a result of their synergistic action. the speciﬁc SNP identiﬁed
on MBL2 will be further analysed for it role in malaria pathogenesis.
P1752 Mannan-binding lectin in neonates
A. Szala, S. MacDonald, I. Domzalska-Popadiuk, A. Atkinson,
M. Cedzynski, A. Swierzko, J. Szemraj, M. Borkowska, J. Szczapa,
M. Matsushita, M. Turner, D. Kilpatrick (Lodz, PL; Edinburgh, UK;
Gdansk, PL; Poznan, PL; Kanagawa, JP)
Objectives: The mannan-binding lectin (MBL) protects the host from
infection by lysis of microorganisms involving complement activation
via the lectin pathway (LP). MBL may enhance phagocytosis by direct
opsonisation. MBL deﬁciency may lead to the increased susceptibility to
infection. It has been suggested to contribute to unexplained miscarriages
and preterm births. We report some preliminary ﬁndings from ongoing
prospective study of MBL levels, LP activities and mbl2 genotypes in
Polish neonates.
Methods: MBL level in cord serum samples was determined in ELISA
using speciﬁc monoclonal antibody (HYB 131−01, AntibodyShop). LP
activity was determined as the ability to C4d deposition on mannan-
coated plates. Genotyping was performed with the help of INNO-LIPA
MBL2 kits (Innogenetics NV).
Results: The median MBL level in babies with suspected perinatal
infections was 965 ng/mL (n = 203), and did not differ from that
determined in newborns with no symptoms of infection (1093 ng/mL,
n = 890). However, LP activity was signiﬁcantly lower in the ﬁrst group
(181 mU/mL vs 267 mU/mL, p = 0.0017). The incidence of mbl2 gene
defective alleles’ (O/O) homozygosity (5.9%) was found to be almost
twice that of the cohort in general (3.4%). The median MBL level in
low birthweight ( 2500 g) babies (n = 86) did not differ from that of
neonates with birthweights over 2500 g (n = 1006) (1048 vs 1076 ng/mL),
however, LP activity was lower in low birthweight babies (161 vs 258
mU/mL, p = 0.006). Neither MBL nor LP differed between preterm and
term babies, however the frequency of O/O genotypes among premature
neonates was almost twice that of the cohort in general (6.2% and 3.2%,
respectively).
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Conclusion: The low LP activity may increase the risk of infection in
perinatal period.
This study is partially supported by Ministry of Science and Higher
Education (Poland), grant 2 P05E 011 28. Authors are very grateful to
Innogenetics NV for providing INNO-LIPA MBL2 tests.
P1753 Mortality and time for detection of blood growth in patients
with Staphylococcus aureus bacteraemia; implication of
mannose-binding lectin
A. Smithson, A. Mun˜oz, B. Suarez, R. Perello, J.A. Martinez, J. Mensa,
F. Lozano (Barcelona, ES)
Background: Structural and promoter MBL2 gene polymorphisms,
responsible for low mannose-binding lectin (MBL) levels, are associated
with a higher incidence and severity of infections. The aim of the study is
to asses the possible association between mortality and time for detection
of blood growth in patients with S. aureus bacteraemia and the presence
of low expression MBL2 genotypes (O/O and LXA/O).
Methods: Blood samples from 49 Caucasoid patients with S. aureus
bacteraemia (mean age 63 ± 16.7 years) admitted in our hospital were
prospectively collected. For further comparison samples from 104 blood
donors were also included in the study. Forty-two bacteraemic patients
(85.7%) had associated comorbidity: 1 (2%) was a liver transplant
recipient, 7 (14.2%) had cirrhosis, 17 (34.7%) had past history of heart
failure or chronic lung disease, 1 (2%) had AIDS, 13 (26.5%) had
underlying neoplasic diseases, 8 (16.3%) had chronic kidney failure,
13 (26.5%) had diabetes mellitus and 6 (12.24%) were receiving
immunossupressive or corticosteroid therapy. Six single nucleotide
polymorphisms (−550 G/C, −221 C/G, +4 C/T, codon 52 CGT/TGT,
codon 54 GGC/GAC and codon 57 GGA/GAA) in the MBL2 gene
were genotyped using a sequence-based typing technique.
Results: No signiﬁcant differences were observed in the frequencies
for low expression MBL2 genotypes between healthy controls (15.4%)
and patients with S. aureus bacteraemia (10.2%) (P= 0.38; Chi square
test). Nine patients (19.1%) died due to the infection, 1 of whom had
a low expression MBL2 genotype (LXA/O). In the univariate analysis,
chronic kidney failure was the only variable associated to death (P=
0.004; Fisher test). When time for detection of growth in blood culture
vials was analysed, the existence of underlying neoplasic disease was the
only variable associated to a lower average time to hemoculture positivity
(P= 0.022; U Mann-Whitney), while a tendency towards a lower time was
observed in patients with low expression MBL2 genotypes (P= 0.078;
U Mann-Whitney).
Conclusions: Low expression MBL2 genotypes have no signiﬁcant
impact in survival of patients with S. aureus bacteraemia and have no
relationship to the time to positivity of blood growth.
P1754 Pathogen-related association of mannose-binding lectin
deﬁciency with community-acquired pneumonia
B.L. Herpers, H. Endeman, B.A.W. de Jong, E.J. van Hannen,
G.T. Rijkers, H. van Velzen-Blad, D.H. Biesma, J.C. Grutters,
G.P. Voorn, B.M. de Jongh (Nieuwegein, NL)
Objectives: Mannose-binding lectin (MBL) is an activating protein of
the lectin complement pathway. As a pattern recognition receptor of
innate immunity, it binds to a variety of microorganisms including
respiratory pathogens like pneumococci and inﬂuenza A virus. The
association of MBL deﬁciency and pneumococcal disease has been
studied with varying outcome. Less is known about the association with
other pathogens in pneumonia. We studied the role of MBL deﬁciency
as a risk factor for community acquired pneumonia (CAP) in relation to
the causative agent and clinical course of disease.
Methods: In a prospective case-control study 193 immunocompetent
patients with conﬁrmed CAP were included. Severity of disease at
presentation and clinical endpoints (intubation, death) were scored.
Blood cultures, respiratory specimen cultures for bacteria and viruses,
urinary tests for pneumococcal and Legionella antigen, serology
and PCR for atypical pathogens were performed. MBL genotypes
were determined by denaturing gradient gel electrophoresis of an
amplicon harbouring the three polymorphic sites in exon 1 (“0” versus
wildtype “A” allele) and a SNP-PCR determining the promotor X/Y
polymorphism. Genotypes were classiﬁed deﬁcient (0/0, XA/0) or
sufﬁcient (YA/0, A/A). 223 healthy adults served as a control population.
Results: S. pneumoniae was found in 60 patients, viruses in 16 and
Legionella and Mycoplasma both in 9. Signiﬁcantly more patients with
viral pneumonia were MBL deﬁcient compared to controls (40% vs
17%). In contrast, none of the atypical pneumonia patients showed MBL
deﬁciency. Patients with pneumococcal pneumonia did not differ from
controls in MBL deﬁciency (18% vs 17%). However, MBL deﬁciency
was associated with more severe disease at presentation in this subgroup.
More MBL deﬁciency was found in patients with concomitant viral
and pneumococcal infections than with pneumococcal infections alone.
No effect of MBL was seen on mortality of CAP, independent of the
pathogen.
Conclusion: MBL deﬁciency is associated with susceptibility to
community acquired viral pneumonia. No association was found with
susceptibility to pneumococcal pneumonia, although MBL deﬁcient
patients presented with more severe disease. The absence of MBL
deﬁciency in 18 patients with atypical pneumonia is intriguing, as some
other intracellular pathogens use MBL to enter their host cell. A larger
study is required to conﬁrm this relationship.
P1755 Coding and non-coding polymorphisms in the lectin pathway
activator L-ﬁcolin gene in 188 Dutch blood bank donors
B.L. Herpers, M.M. Immink, B.A.W. de Jong, H. van Velzen-Blad,
B.M. de Jongh, E.J. van Hannen (Nieuwegein, NL)
Objective: Human L-ﬁcolin (FCN) is a serum lectin characterised
by a collagen-like and a ﬁbrinogen-like domain that can activate the
lectin pathway of complement. Structural and functional similarities to
mannose-binding lectin (MBL) suggest a role for L-ﬁcolin in innate
immunity similar to MBL. Structural polymorphisms in the MBL2 gene,
leading to functional deﬁciency of MBL, have been associated with
disease. We screened the coding regions of the FCN2 gene for similar
polymorphisms and determined their frequencies in a Dutch population.
Methods: We developed 10 denaturing gradient gel electrophoresis
(DGGE) assays to screen a total of 188 Dutch Caucasians for poly-
morphisms in all exons of FCN2 and their ﬂanking regions. Sequence
variations detected with DGGE were conﬁrmed with sequencing.
Results: Total gene screening in this large cohort revealed 10 single
nucleotide polymorphisms (SNPs) in the FCN2 gene (table; (a) location
and allele names, (b) nucleotide substitutiuon, (c) frequency and allele
count). Non-coding SNPs were found in the 5’-UTR and 3’-UTR, in
introns 2, 3 and 6 and in exons 3 and 8. Two highly conserved coding
SNPs were found in exon 8, leading to amino acid substitutions within
the ﬁbrinogen-like domain
Conclusion: A total of ten polymorphisms were identiﬁed. Non-coding
SNPs were found in the 5’-UTR and the 3’-UTR, in the introns 2, 3 and 6
and in exons 3 and 8. Although such polymorphisms have been described
to inﬂuence translation or splicing events in other genes, the relevance
of these SNPs in this particular gene has to be further investigated.
Three coding SNPs were found in exon 5 and exon 8 encoding the
ﬁbrinogen-like domain of L-ﬁcolin. Fibrinogen-like domains are highly
conserved throughout several proteins in many species. These domains
consists of approximately 220–250 residues with 26 invariant, mostly
hydrophobic residues and at least 46 highly conserved residues. The two
SNPs found in exon 8 respectively result in the substitution of threonine
with the hydrophobic methionine and alanine with serine in the near
proximity of several conserved residues.
As the ﬁbrinogen-like domain of L-ﬁcolin is responsible for pattern
recognition, it is of interest to investigate whether the genetic variation
in this domain alters the afﬁnity or speciﬁcity of carbohydrate binding.
Such possible inﬂuence could affect the recognition of invading
microorganisms and thereby inﬂuence one of the ﬁrst lines of defence
in innate immunity.
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Location, amino acid substitution and frequency of SNPs in FCN2
Locationa SNPb Substitution Frequencyc
5′-UTR (1B) c.−4A>G – 0.27 (101)
Intron 2 (3B) c.213−7A>G – 0.33 (123)
Exon 3 (3B) c.222T>C Synonymous 0.33 (123)
Intron 3 (3C) c.269+10G>A – 0.26 (91)
Exon 5 (5B) c.337C>T p.His113Tyr 0.01 (2)
Intron 6 (6B) c.560+44G>A – 0.14 (52)
Exon 8 (8.1B) c.707C>T p.Thr236Met 0. 277
(103)
Exon 8 (8.1C) c.772G>T p.Ala258Ser 0.14 (51)
3′-UTR (8.2B) c.987T>G – 0.45 (169)
3′-UTR (8.2C) c.987_988insG – 0.01 (2)
P1756 Low mannose-binding lectin complement activation function
is associated with predisposition to Legionnaires’ disease
D. Eisen, J. Stubbs, D. Spilsbury, J. Carnie, J. Leydon, B. Howden
(Parkville, Brisbane, Melbourne, Clayton, AU)
Objectives: Innate immune system deﬁciency may predispose to severe
infections such as Legionnaires’ disease. Mannose-binding lectin (MBL)
is a pattern recognition molecule of the innate immune system that
mediates killing of microorganisms through complement activation and
opsonophagocytosis. There is a high frequency of MBL deﬁciency states.
We have investigated whether MBL deﬁciency affects susceptibility
to Legionella pneumophila through study of the Melbourne Aquarium
Legionnaires’ disease outbreak.
Methods: Serum samples from patients and controls that were exposed
but shown to be uninfected from the Melbourne Aquarium Legionnaires’
disease outbreak were tested for MBL function (C4 deposition) and level
(mannan-binding). The absence of stored cellular material precluded
determination of MBL2 genotype.
Results: MBL function was lower in Legionnaires’ disease cases than
in age and sex matched uninfected, exposed controls (0.09 U/ul vs. 0.13
U/ul, p< 0.02). The frequency of MBL deﬁciency with C4 deposition
<0.2U/ul was signiﬁcantly higher in Legionnaires’ disease cases (OR
2.60 [95%CI, 1.28–5.36]). This also applied to Legionnaires’ disease
cases requiring hospital care. Amongst all the Legionnaires’ disease
cases, the hospitalised patients had a higher frequency of MBL deﬁciency
(OR 4.10 [95%CI 1.08 – 17.11]) than those who were well enough to not
require hospitalisation. There was no difference in age between these two
groups. There was no difference in MBL mannan-binding levels between
Legionnaires’ disease patients and controls (0.81 ug/mL vs. 0.86 ug/mL)
and no signiﬁcant interval change in MBL function or level after a mean
of 46 days.
Conclusions: In contrast to the role MBL may play in protecting against
other intracellular pathogens like TB, MBL complement activation
functional deﬁciency appears to predispose to Legionnaires’ disease.
There was no acute phase change in MBL found in these patients with
severe infection. MBL-mediated opsonophagocytosis may be shown to
increase intracellular killing, potentially through efﬁcient delivery of
L. pneumophila to lysosomes. Additionally, lectin pathway complement
activation may directly kill L. pneumophila. More study of these
pathways is required.
P1757 Role of Toll-like receptor 2 in immunomodulation by
lactobacilli
V. Vankerckhoven, S. Van Voorden, H. Goossens, E. Wiertz (Wilrijk,
BE; Leiden, NL)
Objectives: Different lactobacilli have been shown to differentially
inﬂuence immune responses. The aim of this study was to evaluate Toll-
like receptor 2 (TLR2) signalling of clinical and probiotic Lactobacillus
strains.
Methods: A total of 37 Lactobacillus strains (17 L. paracasei,
19 L. rhamnosus, and 1 L. murines) of different origin (18 probiotic,
2 faecal, 15 clinical, and 2 unknown) were tested for TLR2 signalling.
Strains were grown in MRS broth to OD620=1 and killed by exposure
to UV light. TLR2 signalling was measured as relative IL-8 promotor
activation in transfected human embryonic kidney (HEK) 293 cells. IL-8
concentrations were measured using an enzyme-linked immunosorbent
assay. Heat-killed Listeria monocytogenes (HKLM) and PAM3 were used
as positive controls. All assays were performed at least in duplicate.
Statistical analysis was performed using an unpaired T-test. P< 0.05 was
considered statistically signiﬁcant.
Results: Lactobacilli were shown to signal through TLR2. However,
the production of IL-8 was shown to be variable for the different
Lactobacillus isolates. IL-8 production ranged from 374 pg/mL to
>22,000 pg/mL. More speciﬁcally IL-8 production ranged from 733
pg/mL to 21372 pg/mL for the probiotic isolates and a similar range was
seen for the clinical isolates (from 1021 pg/mL to 18946 pg/mL). No
signiﬁcant differences in IL-8 production were seen between clinical and
probiotic isolates. Also when analysing L. paracasei and L. rhamnosus
isolates separately, no signiﬁcant difference was seen in IL-8 production
between clinical and probiotic isolates. On the contrary, L. rhamnosus
isolates induced a signiﬁcantly higher IL-8 production compared to
L. paracasei isolates.
Conclusions: The results indicate that different lactobacilli may induce
different levels of IL-8 production through TLR2. Lactobacilli have been
found to modulate the immune response in various ways. This variation
may be related to differential signalling through TLRs, including TLR2.
P1758 IL-8 and anti-Chlamydia trachomatis speciﬁc mucosal IGA as
the best marker of Chlamydia trachomatis chronic prostatitis
S. Mazzoli, T. Cai, R. Bartoletti (Florence, IT)
Introduction: Chronic infections of the upper genital tract in males
are impacting pathologies leading to severe sequelae up to infertility.
Chronic prostatitis/chronic pelvic pain syndromes (Cat III NIH)
remains the most frequently detected especially in young fertile
men. Chlamydia trachomatis (CT) DNA was associated with “chronic
abacterial prostatitis” starting from 1996. Cytokines content has been
analysed in prostatitis patients.
Aim of our study was to correlate IL-8 production to CT infection in
a population of 78 CP/CPPS patients positive for C.t. DNA and in a
negative control group.
Materials and Methods: Selected patients (N. 78) were positive
for CT genomic DNA and some for plasmidic DNA and/or secretory
speciﬁc IgA in total ejaculate, but negative for common bacteria,
yeasts, mycoplasmas and viruses. Control population (N. 20) was a non
prostatitis healthy population. Natural human produced IL-8 was detected
in total ejaculate by Quantikine IL-8 Immunoassay, (R&D Systems, MN,
USA). CT plasmidic DNA was detected by Cobas Amplycor CT/NG test,
(Roche Molecular systems, NJ, USA); chromosomal DNA by an in-
house omp-1 Real-Time PCR. Mucosal IgA were detected by IPAzyme
Chlamydia IgG/IgA by Savyon Diagnostics, Ashdod, Israel. Westen Blot
anti-CT IgA was performed by CT Westen Blot kit by AID Autoimmun
Diagnostika GmbH, Straberg, Germany.
Results: 98 subjects were enrolled, 78 with prostatitis and 20 healthy
negative controls. 35 subjects were pDNA positive (35.7%), 54 were
sIgA positive (55.1%)
IL-8 was detected in 59 out of the studied subjects (60.2%). IL-8 showed
an efﬁcient separation between patients with CT prostatitis and those
without prostatitis (sensitivity 75% and speciﬁcity 100%; PPV 100%
and NPV 51%) (p< 0.001). Patients with negative pDNA showed a more
presence of IgA than those with pDNA positive (p< 0.001). The same
correlation for IL-8 was reported (p< 0.001).
Conclusion: Mucosal immune system activation may represent a critical
point in the determinism of adverse consequences associated with
chronic Chlamydial infection. This activation was proved in these CT
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prostatitis patients by high production of speciﬁc anti-CT IgA and
iperproduction of IL-8 which positively correlated with the IgA response.
The continuous inﬂammatory reaction leads to persistent tissue damages,
ﬁbrosis and pelvic pains in these patients. In conclusion IL-8 and sIgA
to CT antigens are the best immunological markers of chronic CT
prostatitis.
P1759 Host defence control in children with chronic sinusitis:
recolonisation of nasal microﬂora
I. Kuznecovs, I. Joksta, K. Jegina (Riga, LV)
Objective: Staphylococcus aureus (SA) enterotoxins are associated
with host defences mechanism disturbances by elevated speciﬁc IgE
production in nasal polyps (NP). It is the main cause of disbacteriosis
in upper airways. Certain alpha-streptococci have been shown to have
growth inhibitory activity against common pathogens in the upper
respiratory tract in vitro (K. Roos, 2000). The role of normal ﬂora of
upper respiratory tract and its interference with SA in host defences in
children with chronic sinusitis (CS) and NP was the aim of present study.
Methods: Nasopharyngeal swabs and nasal tissue samples were taken
from 120 patients with NP and CS. Antibiotic resistance of the strains
was determined with the disc diffusion method. Recolonisation with
selected alpha-streptococcal strains was used in 58 patients with nasal
polyposis. Method of Nonlinear diagnostic was used for demonstration
Results: The rates of nasal carriage of SA were found to be 15% in
control group and 89% in patients with NP and 58% with CS. A lower
number of alpha-streptococci have been found in patients with NP and
CS, compared to control. Colonisation rates of alpha-streptococci strains
were 90% in control and 10% in patients with nasal polyposis. MRSA
was found in 2% in control and in 51% in patients with NP and 74%
with CS. It was demonstrated that nasal carriage of MRSA in patients
recolonised with alpha-streptococci was lower (8%) than in nontreated
patients with NP and CS.
Conclusions: The results, obtained in this investigation can be used in
chronic staphylococcal sinusitis treatment in children by recolonisation
of nasal microﬂora with selected alpha-streptococcal strains. It was
shown that patients recolonised with alpha streptococci with interfering
activity against Staphylococcus aureus, get less recurrences of NP and
CS symptoms than nonrecolonised persons. Recolonisation of microﬂora
is a new effective method for host defence control in children with
chronic sinusitis.
P1760 Immune evasion mechanisms of Aspergillus sp. in cerebral
aspergillosis
G. Rambach, I. Mohsenipour, M. Dierich, C. Speth (Innsbruck, AT)
Objectives: Cerebral aspergillosis is the most dangerous complication
of human Aspergillus infections with a death rate of more than 90%.
The central nervous system (CNS) is separated from the periphery
by the blood-brain-barrier, leaving the local innate immunity with
its main components complement, cytokines/chemokines and resident
immune cells (microglia, astrocytes) the only defence system. We
examined putative evasion strategies of Aspergillus against these
weapons: reduction of antigen presentation, inhibition of phagocytosis
and degradation of complement proteins.
Methods: Immune cells were incubated with fungal secretory factors.
Antigen presentation was analysed by quantiﬁcation of subsequent T-
cell activation. Phagocytosis was measured microscopically. Complement
degradation was investigated by incubation of puriﬁed complement
proteins with cerebrospinal ﬂuid (CSF) wherein Aspergillus was grown.
Results: The fungal factor patulin signiﬁcantly reduced the capacity
of cells to efﬁciently present antigens and thus to stimulate immune
cells. Furthermore, the presence of different fungal toxins resulted in
diminished phagocytosis by brain-resident astrocytes. The growth of
Aspergillus sp in CSF resulted in secretion of proteolytic factors which
degraded various complement factors. The extent of the proteolysis was
dependent of the time period of fungal growth and the used Aspergillus
species. A. fumigatus, the predominant cause of cerebral aspergillosis,
showed a rather quick and strong degradation, whereas the proteolysis
by A. terreus was weaker and rather slow.
Conclusion: These data indicate a broad spectrum of immune evasion
mechanisms executed by Aspergillus species. These processes may
signiﬁcantly contribute to the pathogenesis of cerebral aspergillosis.
Diminished antigen presentation, attenuation of phagocytosis and
probably of further immunological activities of resident defence cells as
well as the degradation of complement proteins act as striking weapons
against the local immunity of the CNS. On the one hand, these facts in
addition to other known escape mechanisms explain the high fatality
of this fungal disease, otherwise this plurality shows new optional
therapeutical targets to support the established antifungal treatments.
Neuroprotective substances or antagonists might neutralise or decrease
the harmful effects of mycotoxins; speciﬁc protease inhibitors could
strengthen the attack of complement against the fungal pathogens.
P1761 Extraction, puriﬁcation and detoxiﬁcation of Brucella
abortus lipopolysaccharide and biological activity evaluation
I. Pakzad, A. Rezaee, M. Rasaee, A. Hosseini, A. Kasemnejad,
T. Bahman, R. Saied (Ilam, IR)
Lipopolysaccharide (LPS) of Brucella abortus is important in brucellosis
diagnosis and as one of the components for developing a subunit
vaccine against brucellosis. Biological evaluation of B. abortus LPS
and it’s protection have been considered as the goal of this research.
Brucella abortus LPS was extracted by n-butanol, then it was puriﬁed by
ultracentrifugation and it was detoxiﬁed by alkaline treatment. Toxicity of
LPS and detoxiﬁed LPS (D-LPS) by LAL (Limulus Amoebocyte Lysate)
method, and pyrogenicity in Rabbit was compared. Immunological
evaluation in animal model was carried out.
Puriﬁed LPS from B. abortus by butanol extraction was shown to have
<2% (wt/wt) contamination by protein and <1% (wt/wt) contamination
by nucleic acids. Pyrogenicity test of B. abortus LPS (10mg/mL) and
E. coli LPS (0.5mg/mL) was positive, but for D-LPS (10, 50mg/mL)
it was negative. In LAL test, 10 ng/mL of D-LPS was negative, but
0.04 ng/mL of B. abortus LPS was positive and endotoxin unit of
B. abortus LPS was less than E. coli LPS. Antibody titer of LPS group
was higher than that of D-LPS group. The difference of protection among
LPS group, DLPS group comparing with negative control was signiﬁcant
(p0.05), In addition, the difference of protection ratio between LPS and
D-LPS groups was not signiﬁcant.
Results show that D-LPS toxicity is severely decreased; we can use
several as many as B. abortus LPS for stimulating immune system.
Besides, ability of B. abortus LPS is likely much less than the LPS
from E. coli to evoke endotoxic shock, and it can be used directly as
immunogen. In addition, protection of LPS and D-LPS probably is due
to humoral important role in secondary infection of brucellosis.
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P1762 Effect of moxiﬂoxacin and human beta-defensin 2 on
ICAM-1 and cytokines expression in human lung epithelial
cell line
M. Tufano, I. Paoletti, B. Perfetto, M. Iovene, L. Tudisco,
G. Donnarumma (Naples, IT)
Interaction of pathogenic bacteria with airway epithelium is usually an
essential step in the infectious process. Epithelia in the human airways,
from the nasal aperture to the alveoli, are covered in a protective ﬁlm
of ﬂuid containing a number of antimicrobial proteins.
Antimicrobial peptides have been identiﬁed as key elements in the
innate host defence against infection. Defensins are single chain strongly
cationic peptides of molecular weight 3000–4500 and are one of the most
extensively studied classes of antimicrobial peptides. In the airways, the
antimicrobial peptide human beta-defensin 1 (HBD1) is constitutively
expressed by epithelia at low levels while the related peptide human beta-
defensin 2 (HBD2) is predominantly induced at sites of inﬂammation.
A number of antibiotics have been found to have signiﬁcant
immunomodulatory properties both in vitro and in vivo in animal models.
Moxiﬂoxacin (MXF) is a ﬂuoroquinolone with activities against both
Gram-positive and Gram-negative bacteria. It has been suggested that
MXF has inhibitory and stimulatory effects on the immune system. Our
data demonstrate that HBD2 stimulation produces a remarkable increase
of ICAM-1 protein expression, but does not induce proinﬂammatory
cytokines expression. In contrast, the costimulation with MXF/HBD2
induces a different production of proinﬂammatory cytokines (IL-8, IL-1
and IL-6). Moreover, the adhesion of PMN to airway epithelium is
increased over either baseline when stimulated with HBD2 or with
MXF/HBD2. These data indicate that the association of MXF/HBD2
can play a crucial role during the infectious processes determining a
balanced release of proinﬂammatory cytokines and adhesion molecules,
possessing chemotactic activity for neutrophils.
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P1763 Bacillus smithii TBMI12 spores as a potential competitive
exclusion agent against Salmonella enteritidis
I. Suitso, E. Jo˜gi, E. Talpsep, P. Naaber, A. Nurk (Tartu, EE)
Objectives: Our work-group has isolated thermopilic sporogenous
bacteria Bacillus smithii TBMI12 (B. TBMI12) from human gut and
supposed it to be a potential probiotic. An objective of the current
research was to investigate the following hypothesis:
1. B. TBMI12 spores are able to colonise intestinal tract of mice.
2. Mice colonised previously with B. TBMI12 spores will not become
infected with pathogen Salmonella enteritidis wt (S. enteritidis).
Methods: In total 25 mice were divided into three groups. The group
A was intragastrically inoculated with one dosage of S. enteritidis
cells 106 CFU. The group B was treated daily for three days with
B. TBMI12 spores 108 CFU and after that inoculated with one dosage of
S. enteritidis cells 106 CFU. The group C was inoculated intragastrically
with B. TBMI12 spores 108 CFU on the 1st and the 8th day. Samples of
faeces were taken maximally over 72 hours and plated on selective media
to count B. TBMI12 or S. enteritidis colonies. Whole A and B group
were executed on the 18th day (group C: 30th day) and the samples from
liver and spleen were plated on selective media too.
Results: All mice from the group A were infected with S. enteritidis.
The ﬁrst colony was detected from faeces on the very next day after
inoculation.
Meantime the group B mice were successfully colonised by B. TBMI12
but the count of B. TBMI12 found in faeces decreased during two weeks
about ten times. S. enteritidis was detected in faeces ﬁrst time on the
13th day and 40% of mice were infected.
First dosage of B. TBMI12 spores colonised the group C mice only for a
couple of days. However, stabile population of B. TBMI12 in intestinal
tract of mice was caused by the second dosage. B. TBMI12 did not cause
any harm to mice.
Conclusion: The current research showed that it is possible to colonise
intestinal tract of mice with several dosages of B. TBMI12 spores.
Unfortunately the number of bacteria fell about ten times in two weeks.
60% of the mice colonised with B. TBMI12 spores were not infected
with S. enteritidis. Therefore we suggest Bacillus smithii TBMI12 spores
as a potential competitive exclusion agent against Salmonella enteritidis.
Figure 1. Infected mice. Infection of the group A (triangle) and the
group B (quadrate) mice with pathogen S. enteritidis was detected by
plate count of faeces, liver or spleen onto selective media XLD.
P1764 In vitro efﬁcacy of moxiﬂoxacin, levoﬂoxacin,
piperacillin/tazobactam and metronidazole in a murine
model of complicated intra-abdominal infection
R. Endermann, K. Ehlert (Wuppertal, DE)
Objectives: Complicated intra-abdominal Infections cIAIs) are usually
polymicrobial, with aerobic and anaerobic bacteria. Moxiﬂoxacin
(MXF), a broad-spectrum antibiotic given once daily orally or
intravenously, has recently been approved in the US and other countries
for the treatment of cIAIs. Here we studied the efﬁcacy of MXF,
levoﬂoxacin (LVX), piperacillin/tazobactam (TZP) and metronidazole in
the murine cecal ligation and puncture model (CLP). CLP represents a
peritonitis model with clinical features comparable to human peritonitis.
Methods: Mice were anaesthetised and the peritoneum opened with a
small cut. The cecum was taken out of the peritoneum without harming
the surrounding intestine. A ligation was set at the proximal end of
the cecum and thereafter the ligated part punctured using an injection
needle (21G). Then, the ligated part of the intestine was put back in the
peritoneum and the wound closed. Mice were treated at 4, 18 and 24 h
after operation (10 animals/group). Survival of treated and non-treated
mice was determined daily.
Results: After ligation and puncture, 70% of the untreated control
animals died by day 3, in the stage of early sepsis. A further 20% of the
control group died on day 8−9. No improvement in survival was achieved
with 3×10 or 3×25mg/kg metronidazole. In contrast, treatment with
MXF, LVX or TZP at dosages of 3×10mg/kg IV resulted in a survival
rate of 70−80% on day 3 and 50−60% on day 14.
Conclusions:
– MXF is effective in this model of polymicrobial peritonitis.
– The efﬁcacy of MXF is comparable to broad spectrum antibiotics like
LFX and TZP.
– Metronidazole showed no therapeutic efﬁcacy.
– The failure of this strictly anti-anaerobic agent and the successful
outcomes with levoﬂoxacin might be because the early mortality in
this model is due to Gram-negative aerobic infection.
Research funding: Bayer HealthCare Pharmaceuticals
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P1765 Clarithromycin enhances the effect of
piperacillin/tazobactam in an experimental model of
empyema by multidrug-resistant Pseudomonas aeruginosa
T. Tsaganos, T. Adamis, I. Txepi, I. Tsovolou, G. Zografos,
H. Giamarellou, E. Giamarellos-Bourboulis (Athens, GR)
Objective: Clarithromycin (CL) is considered to present immunomod-
ulatory properties for chronic inﬂammatory disorders of the lung. Its
effect was tested in combination with piperacillin/tazobactam (PT) in
experimental pleuritis by multidrug-resistant P. aeruginosa (MDRPA).
Methods: 0.3 ml of tuberntine were injected in the right pleura of 32
rabbits followed by the inoculation of 7log10 cfu/mL of one isolate
of MDRPA on the next day. Isolate was resistant to PT, ceftazidime,
imipenem and ciproﬂoxacin. Rabbits were then equally divided into
four groups: A, controls; B, intravenous 80mg/kg CL followed by a
second dose of 30mg/kg two hours after; C, intravenous 400mg/kg of
PT; D: both agents. Therapy was administered only the next day of
bacterial challenge. Pleura was punctured each second day; ﬂuid was
quantitatively cultured. On the seventh day, rabbits were sacriﬁced and
the segments of the lower lobe of the right lung were quantitatively
cultured.
Results: Mean values of bacteria are given in the Table. Mean log10 of
bacteria in lung after sacriﬁce of groups A, B, C and D was 4.63, 5.53,
4.23 and 2.77.
Time log10 cfu/mL
(days) A B C D
1 5.12 6.15 6.18 4.17
3 6.68 6.00 4.64 6.59
5 3.98 4.80 5.00 2.22
7 4.10 4.06 3.95 1.49
Conclusions: Co-administration of CL and PT decreased considerably
bacterial load in lung and pleural ﬂuid. There co-administration is
proposed for the management of nosocomial pneumonia and empyema
by MDRPA.
P1766 Echinococcus cyst of liver and lung in animal models
treated by radio-frequency thermal ablation. An ex vivo
pilot experimental study
V. Lamonaca, L. Maruzzelli, M. Minervini, N. Virga, R. Di Stefano,
P. Tagliareni, A. Luca, G. Sardina, G. Vizzini, U. Palazzo, B. Gridelli
(Palermo, IT)
Background: Echinococcus cyst (EC) usually involves liver and lung.
Treatment is surgery or PAIR (Percutaneous Aspiration, ethanol Injection
and Reaspiration); infective complications and biliary ﬁstulae, mainly
due to proligera detachment, easily occur. Radio-frequency thermal
ablation (RITA) is currently used for treatment of neoplasms, primarily
HCCs.
Aim: evaluate RITA for treatment of EC of liver and lung, in animal
models (explanted organs).
Materials and Methods: infected livers and lungs from slaughtered
animals were studied. Cysts were photographed, classiﬁed, measured
and had ultrasounds (US). Some of the cysts had RITA: 150 watt, 80ºC,
7 minutes; just 1 liver and 2 lung cysts: 70ºC, 7 minutes. During RITA,
temperature was monitored in and outside. A second needle, placed
inside the cyst, stabilised pressure. Both treated and untreated cysts were
sectioned and examined by histology. Viability deﬁnition; alive cyst:
clear ﬂuid plus well preserved scolici and/or preserved germinal layer at
histology; killed cyst: necrotic scolici and/or necrotic germinal layer at
histology.
Results: 28 cysts were studied, 16 hepatic and 12 lung. US showed
proligera adhese in 100% of hepatic and 75% of lung; focally detached
in 25% of lung cysts. 17 cysts, 9 hepatic (average volume 40.5 ml)
and 8 lung (average volume 137 ml) had RITA. The average of highest
temperatures outside the cyst was 41.2ºC (22.3–68.3) for liver and 49.3ºC
(38.8–55.0) for lung. The average extension of parenchymal necrosis
outside the cyst was 0.64 cm (0−2) for liver, 1.57 cm (0.8−2.5) for lung.
After RITA pathology showed: rate of killing 100% in hepatic (9/9)
and 100% in lung cysts (8/8); proligera adhese in 67% (6/9) of hepatic
and 75% (6/8) of lung cysts; focally detached in 33% (3/9) of hepatic
and 25% of lung. 2 cysts, adjacent to treated ones, were killed despite
no direct treatment; 1 more cyst was partially alive but the procedure
was non-optimal (cyst broken). 11 cysts, 7 hepatic and 4 lung (average
volume 30 ml), had no treatment. Pathology showed all of them alive
and with proligera adhese.
Conclusion: Our study showed RITA is very effective in killing EC
of explanted liver and lung. It causes limited damage to normal tissue,
biliary duct damage, and keeps proligera attached. In vivo, RITA could
be therapeutic with a lower incidence of post-procedure complications
and probably also effective on external daughter/adjacent cysts. In vivo
studies are required to conﬁrm and validate such a new therapeutic
approach.
P1767 Probiotic inﬂuence of Bacillus smithii TBMI 12 against
Clostridium difﬁcile infection in mice and hamster model
E. Jo˜gi, I. Suitso, E. Talpsep, P. Naaber, K. Lo˜ivukene, A. Nurk (Tartu,
EE)
The objective of our study is a investigation about the possibilities to
use sporogenic lactic acid producing bacilli as preventive agency to avoid
Clostridium difﬁcile associated diseases in murine and hamster model.
Possible probiotic bacteria Bacillus smithii TBMI 12 (sporogenic, lactic
acid producing) was isolated from human gut and so we try this train
probiotic ability against Clostridium difﬁcile associated diseases.
Clostridium difﬁcile (CD) is a common nosocomical pathogen that
is the causative agent of pseudomembraneous colitis and a major
cause of antibiotic-associated diarrhoea. Usual therapy in these cases
is metronidazole or vancomycine oral treatment. But in this way there’s
also a chance of recurrences of therapy, estimably up to 50% of cases
In vivo were used for Clostridium difﬁcile infection two models:
cefoxitine treated mice model and ampicilline treated hamster model.
In mice model experimental animals were treated during 5 days with
cefoxitine, and then inoculated intragastrically with C. difﬁcile strain
VPI 10463 (107 cells). Next day 4 groups were treated; B. smithii TBMI
12 (108 spores); B. smithii TBMI 12 (108 spores) + metronidazole;
metronidazole and control group.
In hamster model experimental animals were treated with single dose
ampicilline, inoculated with B. smithii TBMI 12 (108 spores) and after
4 hours were group infected with C. difﬁcile strain VPI 10463 (105 cells).
After C. difﬁcile infection hamsters received again 2 doses spores next
2 days. Control group was infected without probiotic treatment (without
B. smithii TMBI 12 spores).
Results in CD mice model does not indicate good effectivity of B. smithii
TBMI 12 spores. Signiﬁcant positive inﬂuense was only in between
comparison of metronidazol or metronidazol+ TBMI 12 groups. This
indicates that mouse model is complicated in such investigation.
Bacillus smithii TBMI 12 inﬂuence in antibiotic-compromised ham-
sterCD infection model was more promising. As hamsters are extremly
sensitive to CD toxins, the in vivo experiments are more trustable than
experiments with mice. B. smithii TBMI 12 was maintained in hamsters
during a month, and all hamsters colonised with spores (3 days 108),
survived the infection with 104 CD cells. Hamsters in control group who
received only 104 CD cells died with 48 hours.
Conclusion: Bacillus smithii TBMI 12 spores could be demonstrate
probiotic effect against Clostridium difﬁcile infection especially in
hamster model.
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P1768 Pertactin evaluation as immunogen in murine model
E. Rosales, A. Fernandez-Ramirez, G. Barcenas-Morales,
J. Montaraz-Crespo (Cuautitlan Izc., Edo de Mexico, MX)
Pertactin (PRN) is an antigen involved in protective immunity against
whooping cough, caused by Bordetella pertussis. The presence of
antibodies against pertactin correlates with protection in humans.
B. pertussis is closely related with B. bronchiseptica, aetiological agent
of respiratory tract infections in animal species. The aim of the present
work was to obtain and purify pertactin from B. bronchiseptica and
evaluate it as an immunogen in a murine model.
Previously, infection murine model has been employed using three
different mouse strains (NIH, Hsd:ICR and BALB/c) and four
B. bronchiseptica strains by aerosol via. In the present work, three
methods were tested in order to obtain PRN from two different
B. bronchiseptica strains: I. By sonicate and acetone precipitation;
II. By acid extraction method (pH= 3) and, III. By ultracentrifugal
series and ethanol precipitation. The product of each method was
corroborated by SDS-PAGE and western blot (BB07 and BB05
monoclonal antibodies) assays. Groups of mice were immunised
with PRN, PRN+FCA or B. bronchiseptica bacterin (day zero) and
immunisations were repeated at day 15. All mice were challenged with
B. bronchiseptica at 21st day; cfu/lung were determined at days 0, 3,
5, 7, 10, 15 and 21 after challenge. Additionally, the two groups of
immunised mice with each pertactin preparation was tested in a cross-
challenge experiment.
Hsd:ICR and BALB/c mouse strains were susceptible to infection by
LBF (isolated from pig) and ESP1 (from human) B. bronchiseptica
strains, respectively. PRN was found to be protective for both mouse
strains, and this protection was even better than that conferred by whole
cell bacterin. Finally, cross protection effect was not observed when the
animals were immunised with the pertactin preparations.
In conclusion, the animal test described in this work could be considered
as a good option for future studies of comparison the protection grade
using different commercial pertactin vaccines.
P1769 Comparative efﬁcacies of telavancin, vancomycin and
linezolid in a rabbit model of methicillin-resistant
Staphylococcus aureus osteomyelitis
L-Y. Yin, J. Calhoun, T. Thomas, E. Wirtz (Columbia, US)
Objectives: Staphylococcus aureus is the most common pathogen
isolated in osteomyelitis. However, therapeutic options are limited for os-
teomyelitis infections caused by methicillin-resistant S. aureus (MRSA)
strains. Telavancin is a novel, rapidly bactericidal lipoglycopeptide with
a multifunctional mechanism of action against Gram-positive bacteria,
including MRSA. The aim of the current study was to evaluate the
efﬁcacies of telavancin, vancomycin and linezolid in a rabbit model of
MRSA osteomyelitis.
Methods: Localised osteomyelitis was induced in New Zealand White
rabbits by percutaneous injection of 106 colony-forming units of MRSA
clinical isolate 168−1 through the lateral aspect of the left tibial
metaphysis into the intramedullary cavity. The infection was allowed
to progress for 2 weeks, at which time rabbits with radiographically
conﬁrmed, localised proximal tibial osteomyelitis were randomised
into four treatment groups (n = 15 per group): untreated controls,
telavancin 30mg/kg subcutaneously every 12 hours, vancomycin
30mg/kg subcutaneously every 12 hours, and linezolid 60mg/kg orally
every 8 hours. Antibiotic treatment was continued for 4 weeks, followed
by 2 weeks without treatment. The rabbits were then euthanised, and the
left and right tibias were recovered from each animal. Bone matrix and
bone marrow from each tibia were cultured on blood agar plates, and
bacterial counts per gram of tissue were determined.
Results: For the MRSA strain used in the study, the MIC was 0.25 mg/mL
for telavancin, 0.5mg/mL for vancomycin and 0.5mg/mL for linezolid.
The left tibias of rabbits from each treatment group yielded positive
cultures for MRSA as follows: untreated controls, 9 of 15 (60%);
telavancin-treated, 3 of 15 (20%); vancomycin-treated, 3 of 15 (20%),
and linezolid-treated, 4 of 14 (29%).
Conclusion: Rabbits with tibial MRSA osteomyelitic lesions treated with
either telavancin or vancomycin showed 80% infection clearance, and
those treated with linezolid showed 71% clearance. Untreated controls
demonstrated only 40% clearance. These results indicate that telavancin
is efﬁcacious in a rabbit model of MRSA osteomyelitis, with efﬁcacy
comparable to that of vancomycin and to linezolid.
P1770 Lack of robust neuroprotection by erythropoietin in acute
experimental pneumococcal meningitis
D. Grandgirard, O. Steiner, R. Ga¨umann, S. Leib (Berne, CH)
Objectives: Erythropoietin (EPO) is neuroprotective in models of brain
injury e.g. ischaemia, hypoxia, experimental autoimmune encephalitis,
and subarachnoid haemorrhage. Bacterial meningitis causes brain injury
including cortical necrosis and hippocampal apoptosis. Here, the effect
of erythropoietin was evaluated in an infant rat model of acute
pneumococcal meningitis (PM).
Methods: PM was induced in 11 day old Wistar rats by intracisternal
injection of Streptococcus pneumoniae (serotype 3). Eighteen hours
after infection, antibiotic therapy (ceftriaxone, 100mg/kg s.c. bid) was
initiated. Animals were randomised for treatment with EPO or an
identical volume (150 microL) of saline. Different treatment regimens
were tested i.e. pre-treatment studies (administration of EPO at the
time of infection) and post-treatment studies (administration of EPO
simultaneous to antibiotic therapy) and different doses were evaluated
i.e. 5, 50 and 500 Units/kg/d EPO i.p). Survival was monitored
and hippocampal apoptosis and cortical necrosis were assessed by
histomorphometry at 36 h after infection.
Results: Survival, evaluated by Kaplan-Meier curves, was not signif-
icantly inﬂuenced by administration of EPO, for all regimens tested.
While pre-treatment regimens showed a non-signiﬁcant trend towards a
decrease in hippocampal apoptosis (Table 1), post-treatment regimens
had no effect on brain injury.
Table 1: Hippocampal apoptosis score (mean±SD), in animals 36 h after
infection. Animals were randomised for different dosage regimens of
EPO or saline.
Dosage of EPO in Hippocampal apoptosis score (n) t-test
pre-treatment Saline EPO P-value
5U 1.0±0.8 (12) 0.8±0.6 (13) 0.46
50U 0.8±0.5 (21) 0.5±0.5 (14) 0.096
500U 0.6±0.4 (27) 0.5±0.4 (25) 0.21
Conclusions: In contrast to other models of brain injury, EPO had
no robust neuroprotective effect in this infant rat model of PM. The
multifactorial disease mechanisms that include inﬂammatory, ischemic,
excitotoxic and pathogen-derived mechanisms may explain the lack of
neuroprotection. A beneﬁcial effect of EPO in the regenerative phase of
PM is however not excluded.
P1771 The effects of probiotics on allergy
R. Can, B. Aridogan, M. Demirci (Samsun, Isparta, TR)
In this study, we aimed to investigate the effects of the probiotic
mixture which we prepared from Lactobacillus and Enterococcus strains
isolated from healthy human gut ﬂora and the standard Lactobacillus
GG (ATCC 53103) probiotic strain on immune responses in allergy in
an experimental animal model.
We prepared a mixture from a total of 13 probiotic strains composed of
10 Lactobacilli (8 Lactobacillus plantarum, 2 Lactobacillus rhamnosus)
and 3 Enterococcus faecalis which are isolated from the gut ﬂora of
healthy people. We administered the probiotic mixture, standard strain
LGG and skim milk suspension orally to Balb-c mice in the study and
control groups for 28 days. The mice in the study groups were immunised
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by intraperitoneal injection of Ovalbumin on days 14 and 21 and the mice
in the control groups were injected PBS only.
The OVA speciﬁc IgE levels were assayed by ELISA method in serum
in each group. The OVA speciﬁc IgE levels of the study groups which
were administered probiotic and standard strain were found lower than
the skim milk fed groups. The difference was statistically signiﬁcant
(p< 0.001).
The OVA speciﬁc IgE levels in the group which was given the probiotic
mixture were found lower than the group which was fed by a standard
probiotic diet but the difference was insigniﬁcant. There was statistically
no difference between the OVA speciﬁc IgE levels of the control groups
which were not immunised (p> 0.05). The OVA speciﬁc IgE levels of
the study groups were found signiﬁcantly higher than the control groups
(p< 0.001).
In conclusion, probiotics may put forward to treatment of allergic
diseases as a new alternative but speciﬁc strains of probiotics with
immunoregulatory effects need to be clearly identiﬁed and their
mechanisms of action will have to be well characterised.
OVA-speciﬁc IgE levels in study and control group.
P1772 Pathogenicity of viridans streptococci in three murine in
vivo models
G. Genzel, J. Beer, T. Ru¨diger, R. Schaumann, P.D. Nitsche-Schmitz,
G.S. Chhatwal, A.C. Rodloff (Leipzig, Braunschweig, DE)
Objectives: To establish a murine model of infection, which allows to
study the pathogenic potential of various viridans streptococci.
Methods: Three different models of infection were ﬁrst established using
Staphylococcus aureus (ATCC 25923) as reference: (i) intravenous (i.v.)
application into the tail vein; (ii) intramuscular (i.m.) application into
the thigh; (iii) application into a preformed pouch. The same models
were then used to assay the pathogenic potential of Streptococcus
oralis, S. anginosus, and S. salivarius that had been isolated from
relevant clinical samples. The infection dose was 108 cfu. Seven days
post infection surviving mice were killed and bacterial loads in liver,
spleen, kidney, blood, abscesses in the muscles and in granulomas were
determined. If not indicated otherwise, 20 mice per infection model and
bacterial species were infected.
Results: In the i.v.-model, S. aureus was isolated in different organs
of 11 mice: liver (n = 9), kidney (n = 4), spleen (n = 6), blood (n = 2)
while S. oralis was detected in organs of 4 animals: spleen (n = 3); blood
(n = 1). In the i.m.-model S. aureus was isolated out of 18 muscles,
infections of other organs occurred in 9 animals. In this model, S. oralis
was isolated from the thighs of 15 animals and S. anginosus in 15 and
S. salvarius in 19 cases, respectively. CFU found in the abscesses ranged
from 106 to 108 for S. aureus while only 102 to 106 viridans streptococci
were recovered. In the granuloma pouch-model (n = 18) S. aureus was
detected in 16 granulomas. Six mice had additional organ infections. By
comparison S. oralis was isolated from the granulomas of 17 animals.
Conclusion: The i.m.-model and the granuloma pouch-model showed
that viridans streptococci have the potential for abscess formation
in immuno-competent mice. However, all 3 models showed that the
virulence of the tested strains was drastically reduced as compared to
S. aureus. The i.m.-inoculation seems to be a suitable model for studying
abscess formation of viridans streptococci and is easy and timesaving to
perform.
P1773 The role of interleukin-1 during Pseudomonas aeruginosa
bacteraemia in compromised host
T. Horino, T. Matsumoto, M. Uramatsu, M. Tanabe, K. Tateda,
S. Miyazaki, Y. Aramaki, Y. Iwakura, K. Yamaguchi (Tokyo, JP)
Objectives: The roles of Interleukin (IL)-1 in infectious diseases are
ﬂuctuated by the experimental conditions, especially in the difference
of pathogens and immunological disorders. Therefore in this study,
we evaluated the role of IL-1 in bacteraemia due to Pseudomonas
aeruginosa, by comparing IL-1-deﬁcient mice and WT (WT) mice, with
or without cyclophosphamide pretreatment.
Methods: P. aeruginosa bacteraemia was induced by intravenous
injection of P. aeruginosa strain D4 via retro-orbital plexus. To evaluate
the role of IL-1 under various immune conditions, we used compromised
host following cyclophosphamide treatment, neutropenic mice by anti-
Gr-1 antibody and macrophage-depleted mice by liposomes containing
dichloromethylene diphosphonate. Furthermore, to investigate bacterial
clearance under macrophage-depleted condition, mice were sacriﬁced
after bacterial inoculation, and cardiac blood, liver and spleen samples
were obtained aseptically. In addition, we compared Tumour necrosis
factor alpha, IL-6 and interferon-gamma productions between IL-1-
deﬁcient mice and WT mice in early and late phase sepsis.
Results: Survival rates after P. aeruginosa bacteraemia did not show
signiﬁcant difference between IL-1-deﬁcient mice and WT mice. On the
other hand, cyclophosphamide pretreatment in both groups of mice cause
signiﬁcantly higher mortality in IL-1-deﬁcient mice compared to WT
mice (P< 0.01). Bacterial counts in the blood, liver, spleen, kidney and
lungs were signiﬁcantly higher in IL-1-deﬁcient mice than in WT mice
following cyclophosphamide treatment. These signiﬁcant differences
were represented in macrophage-depleted mice, but not in neutropenic
mice. Under macrophage-depleted condition, bacterial counts in blood,
liver, and spleen were higher in IL-1-deﬁcient mice than in WT mice,
and Tumour necrosis factor alpha in the liver in early phase sepsis were
signiﬁcantly lower in IL-1-deﬁcient mice than in WT mice.
Conclusion: Our results indicated that the role of IL-1 during
bacteraemia due to P. aeruginosa was enhanced in immunocompromised
conditions, especially in the devastation of macrophage functions.
P1774 Vitamin B6 attenuates cellular energy depletion and
hippocampal apoptosis in experimental pneumococcal
meningitis
M. Wittwer, C. Bellac, R. Coimbra, S. Leib (Berne, CH)
Objectives: In pneumococcal meningitis (PM) the cellular energy status
may contribute to neuronal apoptosis in the hippocampal dentate gyrus.
In experimental PM we evaluated the effect of vitamin B6 on cellular
energy status in the hippocampus by assessment of NAD+ levels and on
apoptosis in the hippocampal dentate gyrus.
Methods: Eleven day old Wistar rats were infected intracisternally
with 10 microL of saline containing 1.00E+06 cfu/mL Streptococcus
pneumoniae (SP; serogroup 3). Animals were randomised for treatment
with vitamin B6 (600mg/kg s.c. 0 and 18 h after infection, n = 20) or an
equal volume (360 microL) of saline (n = 17). Brains were analysed for
the extent of hippocampal apoptosis by histomorphometry at 36 h after
infection. For assessment of cellular energy status NAD+ levels were
measured at 0, 12, 18, 24 and 36 h after infection in hippocampal tissue
from animals with PM treated with vitamin B6 or with saline and in
uninfected age matched littermates (n = 3 for each experimental group
and time).
Results: Compared to saline, vitamin B6 signiﬁcantly (p< 0.02)
increased cellular NAD+ in hippocampal tissue at 24 h after infection
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from (mean ± SD) 1756.4 ± 350.0 to 2484.4 ± 146.5 (ﬁgure 1A) and
signiﬁcantly (p< 0.03; ﬁgure 1B) reduced hippocampal apoptosis from
[median score (range)] 0.44 (0–1.67) to 0.12 (0–0.79).
Fig. 1.
Conclusion: In experimental PM vitamin B6 prevents the decrease in
cellular energy in the hippocampus during the acute disease phase,
when hippocampal apoptosis develops. This improved energy status is
associated with a signiﬁcant attenuation of neuronal apoptosis in the
hippocampal dentate gyrus at 36 h after infection. Thus, vitamin B6, a
well tolerated and readily available compound may represent a promising
candidate for the adjunctive therapy of PM.
P1775 Efﬁcacy of telavancin in a murine model of pneumonia
induced by methicillin-susceptible Staphylococcus aureus
S. Hegde, N. Reyes, R. Skinner, S. Difuntorum (South San Francisco, US)
Objectives: Telavancin, a novel, rapidly bactericidal lipoglycopeptide
with a multifunctional mechanism of action against Gram-positive bac-
teria (including methicillin-resistant Staphylococcus aureus [MRSA]),
exhibited efﬁcacy in a murine model of pneumonia caused by MRSA in a
previous study. The objective of the current investigation was to evaluate
the efﬁcacy of telavancin in a murine model of pneumonia induced by
methicillin-susceptible S. aureus (MSSA) in comparison with three other
antimicrobial agents.
Methods: Female Bagg inbred albino c-strain (BALB/c) mice, weighing
18−20 g, were rendered neutropenic with two intraperitoneal doses
of cyclophosphamide 250mg/kg administered 4 and 2 days prior to
infection. Mice were infected with an intranasal inoculation (50 microL)
of 107 colony-forming units of MSSA strain ATCC 29213. Infected mice
were then allocated to one of ﬁve treatment arms: telavancin 40mg/kg
subcutaneously (SC) every 12 hours, nafcillin 40mg/kg SC every 4
hours, linezolid 80mg/kg intravenously every 12 hours, vancomycin
110mg/kg SC every 12 hours, or no drug (control group). Treatment was
initiated at either 4 or 8 hours post-inoculation. Drug doses were calcu-
lated to simulate human exposures (area under the curve or time >MIC)
at therapeutic doses. Lungs were harvested and homogenised 24 and 48
hours after inoculation to determine the bacterial titre using trypsin-soy
agar plates containing aztreonam 1.0 mg/mL (to select for MSSA).
Table. MICs and lung bacterial titresa
Treatment MIC
(mg/mL)
Change in lung bacterial titre (logCFU/g)
(n = 6)
4 hb 8 hb
Telavancin 0.5 −4.3†‡ −3.2†§
Nafcillin 0.25 −1.4† −1.8†
Linezolid 2 −0.4 0.3
Vancomycin 1 −2.9† −2.2†
aMIC, minimum inhibitory concentration; CFU, colony-forming units.
bTime (post-inoculation) of treatment initiation.
†P< 0.05 vs pre-treatmen titre; ‡P< 0.05 vs nafcillin, vancomycin and
linezolid; §P< 0.05 vs nafcillin and vancomycin.
Results: Telavancin demonstrated potent bactericidal activity against
MSSA strain ATCC 29213 in vitro in terms of MIC, and in vivo in terms
of reduction in lung bacterial titre, compared with nafcillin, linezolid and
vancomycin (Table).
Conclusion: The data from the present study demonstrate the efﬁcacy
of telavancin in reducing lung bacterial burden in an MSSA model of
pneumonia in neutropenic mice. The reduction in lung bacterial titre
with telavancin was signiﬁcantly greater than with nafcillin, vancomycin
and linezolid.
P1776 Efﬁcacy of linezolid alone and in combination with rifampin
in staphylococcal experimental foreign-body infection
O. Murillo, G. Euba, A. Domenech, A. Garcia, F. Tubau, C. Cabellos,
F. Gudiol, J. Ariza (Barcelona, ES)
Objectives: To test the efﬁcacy of linezolid alone (L) or combined with
rifampin (R) against methicillin-susceptible Staphylococcus aureus (Sa)
in comparison with cloxacillin (O) +R and R alone in vitro and in vivo
in a rat tissue cage model of foreign-body infection.
Methods: In vitro studies: MICs (mg/L) of Sa (ATCC 29213) were
L 4, O 0.5 and R 0.015. MBCs and 24 h kill-curves were performed in
both the log-phase (EXP) and stationary phase (STP). Drugs were tested
for a range of concentrations according to their MICs and achievable
levels in human serum. Animal studies: Two Teﬂon tissue cages with 2
PMMA cover-slips each were subcutaneously implanted in rats. Three
weeks after surgery, tissue-cage ﬂuid (TCF) was inoculated with Sa
and three weeks later, therapy was started and administered for 7 or
10 days. Therapeutic groups were (mg·kg/h): L (35/12), R (25/12),
O (200/12) +R, L+R and controls (C). All groups were compared at days
7 and 10 (except for the O+R group, which was only evaluated at day 7)
after the initiation of therapy. Quantitative cultures of TCF before and
at the end of therapy were performed and differences between bacterial
counts used as criteria of efﬁcacy. Screening of R- or L-resistant strains
was performed with culture of samples in agar plates containing R or L
at 4mg/mL.
Results: MBCs (mg/L) in the EXP and in the STP of Sa were
respectively: 1,>256 (O); 64,>256 (L) and >8,>8 (R). Time-kill studies
in the STP showed indifference and no bactericidal activity for any
combination of L+R and O+R. Bacterial killing in TCF (means of
decrease in log cfu/mL) at day 7 was (n): L 0.63 (26), R 1.2 (26),
L+R 1.01 (28), O+R 1.29 (20) and C 0.33 (20). All groups showed better
result than C (p< 0.05, ANOVA) and O+R and R were also better than L
(p< 0.05). After 10 days of therapy the killing in TCF was L 1.22 (15),
L+R 1.44 (16), R 0.1 (13) and C 0.4 (18); L and L+R were better than
R and C (p< 0.05). Neither R- nor L-resistant strains were detected in
TCF for combined therapies, whereas R-resistant Sa using R alone was
observed in 90% and 100% of cases at days 7 and 10, respectively.
Conclusions: Combinations L+R and O+R were likely efﬁcacious and as
active as R alone, but both prevented the emergence of R-resistant Sa.
L+R increased the efﬁcacy with time in contrast with the decreased
activity of R alone due to the growth of resistant strains. L alone was
less effective although development of L-resistant Sa was not observed.
P1777 Investigation on efﬁcacy of garlic extract (Allium sativa)
against burn wound infection by Pseudomonas aeruginosa
in burned animal model
M. Erzanlou, R. Arab, R. Alaei (Ardabil, IR)
Objective: Despite advances in medical cares, infections are the
major causes of death in patients with sever burn. Gram negative
rod, P. aeruginosa, is among the leading causes of burn wound
infection. The situation for patients with P. aeruginosa infections is
particularly problematic, because this organism rapidly evolves to multi-
drug resistant forms and spreads through hospital wards and burn units.
So it could not be eradicated readily with common antibiotic therapies.
Methods: Burn was induced on the back of anaesthetised animals
by heated brass bar, after the hair removal. Bacterial infection was
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established by topical applying of highly pathogenic clinical isolate of
P. aeruginosa. Potential of garlic extract on reduction of mortality was
evaluated by topical application of 10 percent (V/V) garlic extract on
burned and infected animals, and was compared with two control groups:
burned and infected animals either treated with topical silver sulfadiazine
(SSD) (1%) or left untreated. The same groups were subjected to evaluate
bacterial counts in organs (blood, liver, spleen and skin).
Results: Our results indicated that topical administration of garlic
extract (10%) extended the survival of mice for 3−6 days, compared
with survival of the untreated group. Both garlic extract and SSD
treatments reduced the microbial loads in vital organs (blood, liver,
spleen), compared to that of untreated control group (P< 0.05).
Conclusion: The preliminary results presented in this study suggest that
garlic extract may offer a promising and novel means for the treatment
of P. aeruginosa burn wound infection and open new insight into further
investigation on this area.
P1778 Different frequency of N-myc2 activation in liver tumours
from male and female woodchucks chronically infected by
WHV
R. Bruni, A. Paganelli, I. Conti, U. Villano, R. Giuseppetti,
M. Rapicetta (Rome, IT)
Objectives: WHV/woodchuck is a model of HBV infection. In liver
tumours induced by chronic WHV infection, the N-myc2 gene is
frequently activated. In most cases, transcriptional activation is due to
WHV insertion either nearby the gene, or in two downstream loci, b3n
and win. N-myc2 is located into the X chromosome. Mutation of several
X-linked genes involved in cancer is known to show different outcome
according to the gender. No previous studies investigated the distribution
of N-myc2 positive (i.e. showing transcriptional activation and/or WHV
integration in known target loci of the N-myc2 chromosomal domain)
liver tumours in relation with woodchuck gender. Aim of the present
work was to investigate the frequency of N-myc2 positive liver tumours
from male and female woodchucks.
Methods: Tumours were classiﬁed as N-myc2 positive or negative by
studying (A) rearrangement and WHV insertion in N-myc2, b3n and
win loci by Southern blotting and (B) N-myc2 transcription by Northern
blotting.
Results: A survey of 46 not clonally related liver tumours naturally
developed in chronically WHV infected woodchucks was analysed. 16
tumours were from 8 male and 30 from 14 female animals. Southern
and Northern blotting data showed that N-myc2 positive tumours were
7/16 (44%) from male animals vs. 27/30 (90%) from females (p = 0.002
with Fisher’s exact test).
Conclusions: Though statistically signiﬁcant, the biological reasons for
the observed gender related difference remain to be investigated. As
N-myc2 is an X-linked gene, two gene copies per diploid genome are
present in female cells vs. one copy in male cells: thus, as the simplest
explanation, female cells would provide a two-fold more abundant target
for WHV integration. However, in female cells one X chromosome is
functionally inactivated, heterochromatic and, thus, expected to be a poor
substrate for host enzymatic machinery responsible for illegitimate WHV
integration. So, the actual X chromosome target for WHV integration
would not differ between male and female cells. Because of the multistep
nature of tumour development, it is possible that other female speciﬁc
factors might select for N-myc2 positive cells, leading to the observed
higher frequency of tumours with N-myc2 activation in females.
P1779 Rapid insurgence of a viral-resistant mutant in WHV
chronically infected woodchucks treated with lamivudine
and a PRE-S/S CHO-derived hepatitis B virus vaccine
E. D’Ugo, L. Kondili, A. Canitano, S. Catone, R. Giuseppetti,
B. Gallinella, G. Palmieri, S. Orobello, C. Argentini, M. Rapicetta
(Rome, IT)
Objectives: The woodchuck hepatitis virus (WHV) and its host,
the Eastern woodchuck (Marmota monax) are predictive models for
evaluating HBV antiviral therapy. To determine whether the addition
of a pre-S/S human vaccine, previously shown to protect woodchucks
from productive WHV infection, could increase the antiviral activity of
a high-dosage of lamivudine in the woodchuck model.
Methods: The 4 woodchucks were administered a daily dose of
100mg/kg body weight of lamivudine for 40 weeks and were vaccinated
with four doses (50mg each) of CHO–HBsAg vaccine at 14, 18, 22, and
34 weeks after starting lamivudine. WHV-DNA were determined using
a TaqMan Real-Time PCR (sensitivity of 10 genome equivalents/mL);
the positive samples were considered for the sequence analysis. The A,
B, C and D domains of the WHV polymerase region were ampliﬁed
by speciﬁc primers. Serial liver biopsies were performed and numerical
score according to the Ishak system was used.
Results: WHV DNA titres decreased up to two logarithms in 3
woodchucks. Since week 4 the sequence analysis in 3 of the 4 animals
showed a heterogeneous viral population, with the predominant strain
containing a single nucleotide change at position 1696 (from A to T)
in the sequence coding of FLLA motif (domain B). In 2 of the last 3
woodchucks, the increase in WHV DNA titres was observed, though
not immediately after the FLLT mutation appearance. No mutations in
the other domains were observed. Vaccination did not further suppress
WHV DNA, despite anti-HBs production in three animals. In one animal
WHV DNA levels increased immediately after the ﬁrst dose of pre-S/S
vaccine and the grading score increased from 2 to 10.
Conclusions: The emergence of the lamivudine-resistant mutation in the
B domain was observed within 4 weeks of starting lamivudine, which
is much earlier than previously reported. Vaccination could trigger the
immune system and liver inﬂammation in the context of high WHV DNA
levels resistant to lamivudine. Under the conditions used, a transient
effect of combination lamivudine and anti HBs vaccine therapy was
observed.
P1780 Antimicrobial biodegradable composition based on
high-molecular weight polyvinylpyrrolidone for the
prophylaxis of experimental osteomyelitis
G. Aﬁnogenov, R. Tikhilov, A. Mironenko, T. Bogdanova, A. Aﬁnogenova,
I. Kozlov, M. Krasnova, L. Anisimova (St. Petersburg, RU)
Objectives: The problem of the post-surgical osteomyelitis prophylaxis
after metal-osteosuture is still actual now. The local application of
collagen with gentamycin used to prolong the antibiotic activity in tissues
of wound area. Modern technologies allow to obtain high-molecular
weight PVP with different biodegradation terms to use it as a matrix
for various medicines.
The aim was to evaluate the efﬁcacy of antimicrobial composition of
amikacin with activator and polyvinylpyrrolidine as a biodegradable
prolonging agent for the post-surgery infections prophylaxis.
Methods: The rabbit shin-bone was bared under the aseptical
intravenous anaesthesia and two bone defects were formed with 0.1 N
NaOH to obtain surface necrosteosis. The microbial culture of S. aureus
(0.5 ml of 2×08 CFU/mL) was introduced into the bone defects twice
before and after the K-wires were placed. 5 ml of amikacin with activator
and PVP were placed directly on the bone and wound area before made
a suture. The total condition, body temperature and wound view were
valued. The animals were sacriﬁced on the 7th, 14th and 21st days
after the surgery. The clinical evidences of irritation, the pus and tissue
necrosis presence were valued as well as bacteriological and histological
researches were made with muscle and marrow biopsies and implanted
K-wires.
Results: An acute osteomyelitis with expressed tissue microbial
contamination was obtained in the control group. The animals with
prophylaxis introduction of antibacterial composition didn’t display
clinical evidences of osteomyelitis. The tissues microbial contamination
proved to be the same during the experiment in the control group.
The experimental animals showed a reliable decreased microbial
contamination of tissues involved in infectious process. The whole
eradication of S. aureus was obtained by the 21st day in muscle and
marrow biopsies. Testing the K-wires the microbial growth was displayed
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in control group and only by the 7th day – in experimental group.
The bactericidal composition showed a residual antimicrobial activity
in animal tissues during the experiment.
Conclusions: The data obtained show the efﬁcacy of the amikacin com-
bination with activator based on high-molecular weight polyvinylpyrroli-
dine and an opportunity to it’s application for the post-surgery infections
prophylaxis in traumatology, orthopaedics and other surgery areas.
P1781 Efﬁcacy of oritavancin in a mouse model of Streptococcus
pneumoniae pneumonia
D. Lehoux, G. McKay, I. Fadhil, K. Laquerre, M. Malouin, V. Ostiguy,
G. Moeck, T. Parr Jr. (St-Laurent, CA)
Objective: Streptococcus pneumoniae is one of the leading causes of
community-acquired bacterial infections such as pneumonia. Oritavancin
(ORI) is a semi-synthetic glycopeptide with bactericidal activity against
Gram-positive cocci. We investigated the activity of ORI in vitro in the
presence of surfactant and in vivo in a mouse model of S. pneumoniae
pneumonia.
Methods: 1) Broth microdilution assays with ORI, daptomycin (DAP)
and ceftriaxone (CTX) used Staphylococcus aureus ATCC 29213 follow-
ing CLSI guidelines either without modiﬁcation or including 0.5 to 5%
commercially-available surfactant in parallel. 2) In vivo efﬁcacy studies
were performed in an immunocompetent mouse pneumonia model.
CD-1 mice (n = 10/group) were challenged intranasally with 106 colony-
forming units (CFU) of penicillin-sensitive S. pneumoniae (PSSP) ATCC
6303. In a study to assess efﬁcacy resulting from administration of two
doses of ORI and comparators, agents were administered at 1 and 4 h
post-infection as follows: ORI, 32mg/kg, intravenously; DAP, 100mg/kg
subcutaneously; CTX, 50mg/kg, subcutaneously. In a dose-ranging
study, ORI was administered at 1 h post-infection in single intravenous
doses ranging from 0.25 to 32mg/kg. For both the single- and two-
dose studies, lungs were harvested 24 h post-infection, homogenised,
and plated for bacterial counts. A maximal effect (Emax) model was
used to examine the relationship between dose and efﬁcacy.
Results: (1) The addition of 5% surfactant resulted in a 2- to 4-fold
increase in ORI MIC compared to a 64-fold increase for DAP MIC
and no shift for CTX MIC. (2) ORI (2× 32mg/kg) was more active
in the mouse pneumonia model than CTX (2× 50mg/kg) and DAP
(2× 100mg/kg): no detectable CFU were recovered from the lungs of
100% of mice treated with ORI while 40% and 0% of mice treated with
CTX and DAP, respectively, had sterile lungs. Single-dose dose-response
studies of ORI yielded an Emax of 6.49±0.18mg/kg and an ED50 (dose
resulting in 50% of the maximal killing) of 2.76±0.3mg/kg.
Conclusions: (1) Surfactant affected only minimally the antibacterial
activity of ORI in vitro. (2) ORI is highly active in the mouse pneumonia
model and it may have potential utility in the treatment of pneumonia
caused by PSSP.
P1782 Pneumococcal meningitis: is disease severity related to
capsular or clonal types?
S. Ribes, F. Taberner, C. Cabellos, J. Gerber, F. Tubau, C. Ardanuy,
J. Lin˜ares, R. Nau, F. Gudiol (Hospitalet de Llobregat, ES; Gottingen,
DE)
Objectives: Capsular serotype of Streptococcus pneumoniae (Sp) strains
is an important virulence factor. A single pneumococcal serotype
includes a number of genetically divergent clones. Using the rabbit model
of meningitis, we tested whether ﬁve different pneumococcal clones
belonging to serotypes 23F and 3 caused different disease severity.
Methods: Meningitis was induced by intracisternal inoculation of 106
CFU/mL of ﬁve invasive strains of Sp in ﬁve groups of rabbits (n
10/group). We used three strains of serotype 23F with different degree
of penicillin (PEN) susceptibility and sequence type (ST): strain A
(ST311, PEN-S), strain B (ST81, PEN-R) and strain C (ST37, PEN-I)
and two PEN-S strains of serotype 3: strain D (ST260) and strain
E (ST180). Eighteen hours after infection, serial CSF samples were
collected over 24 h to determine bacterial counts and inﬂammatory
data levels: lactate, protein and lipoteichoic/teichoic acids (LTAs).
Bacteraemia at 0 h and mortality at 24 h were also assessed. Fisher’s
exact test was used in bacteraemia/mortality studies. ANOVA/T-Student
test or Kruskal Wallis/Mann-Whitney tests were performed dependent
on whether data were normally distributed or not.
Results: Bacteraemia at 0 h was found in 10/10, 11/13, 8/12, 5/13 and
3/11 of rabbits infected with strains A, B, C, D and E, respectively.
Bacterial concentrations at 0 and 6 h were lower in serotype 3 strains
than in serotype 23F isolates (p< 0.05). Bacterial counts at 24 h were
above 4.5 log CFU/mL in all strains. Lactate at 0, 6 and 24 h, and
protein levels at 6 and 24 h were higher in serotype 23F than in serotype
3 strains. Mortality was 50, 30.8, 58.3, 15.4 and 0% for strains A,
B, C, D and E, respectively. Among strains belonging to serotype
23F, there were neither marked differences in bacterial counts nor in
inﬂammatory activity. On the contrary, there were statistical differences
in CSF bacterial concentrations and in lactate, protein and LTAs levels
among strains belonging to serotype 3.
Conclusions: In the rabbit meningitis model, serotype 23F strains
(independently of their PEN susceptibility patterns), produced higher
bacteraemia and mortality rates, and higher CSF levels of inﬂammatory
parameters than serotype 3 strains. On the other hand, differences noted
between two clones of serotype 3 indicated that additional genetic loci
other than capsular serotype could be involved in pneumococcal disease
severity.
P1783 Levoﬂoxacin-rifampin combination is highly bactericidal in
experimental methicillin-susceptible Staphylococcus aureus
prosthetic joint infection
C. Muller-Serieys, A. Saleh Mghir, L. Massias, A. Andremont,
B. Fantin (Paris, FR)
Objectives: Staphylococcus aureus is the most common pathogen
responsible for bacterial joint infections. Levoﬂoxacin (LEV) and
rifampin (RIF) are highly active in vitro against susceptible strains of
MSSA; nevertheless no data are available on the in vivo relevance of
this combination for treating MSSA prosthetic joint infection.
Methods: A partial knee replacement was performed in rabbits with a
silicone implant ﬁtting into the intramedullary canal of the tibia, and
107 CFU of a MSSA strain (MICs and MPCs: 0.125 and 1mg/L for
LEV and  0.016 and 256mg/L for RIF, respectively) were injected
into the knees. Treatment was started 7 days after inoculation and lasted
for 7 days. Infected animals were randomly assigned to: either no Rx
(controls), or LEV (25mg/kg IV b.i.d.), or RIF (10mg/kg IM b.i.d.) or
LEV+RIF. Surviving bacteria were counted in bone 2 days after the end
of Rx, and resistant mutants were detected on antibiotic-containing agar.
Results: LEV AUC was comparable to that achieved in human after a
750mg daily dose. The mean log10 CFU/g of bone were signiﬁcantly
reduced with LEV (2.92 ± 1.33, 5/12 sterile animals) and RIF (3.20
± 2.12, 5/11 sterile animals) versus controls (6.36 ± 1.33, 0/10 sterile
animals) (p< 0.05). RIF+LEV combination (mean log10 CFU/g of bone:
1.99 ± 0.52, 6/12 sterile animals) was signiﬁcantly more effective
than RIF alone (p< 0.05) and prevented the emergence of RIF-resistant
mutants as observed in 4/6 positive bones in RIF treated animals and
2/6 controls. No LEV-resistant mutants were detected in any group of
animals.
Conclusion: In this MSSA joint prosthesis infection, LEV combined
with RIF was highly bactericidal and prevented the selection of mutant
resistant to RIF. LEV+RIF should be of interest for treating MSSA
prothetic joint infection in human.
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P1784 Standarisation of a rabbit model of methicillin-susceptible,
methicillin-resistant and glycopeptide intermediate
Staphylococcus aureus meningitis
F. Taberner, S. Ribes, E. Force, C. Cabellos, M.A. Dominguez, J. Ariza,
F. Gudiol (Hospitalet, ES)
Staphylococcus aureus meningitis is a rare but severe disease with high
mortality rates. It is usually nosocomial-acquired and associated with
neurosurgical procedures.
Objective: To study the ability of three strains of S. aureus with different
susceptibility to b-lactams and glycopeptides to induce meningitis and
inﬂammatory activity in CSF and to standardise the rabbit meningitis
model to study the efﬁcacy of different antibiotics against them.
Methods: Three different staphylococcal strains were used: Strain A,
methicillin-susceptible S. aureus (MSSA) with MICs (in mg/L) to
cloxacillin (CLOXA) 0.25 and to vancomycin (VAN) 1; strain B,
methicillin-resistant S. aureus (MRSA): CLOXA 512, VAN 2; and strain
C, glycopeptide-intermediate S. aureus (GISA): CLOXA 1024, VAN
4. Meningitis was induced in New Zealand white rabbits (n  6 per
group) by intracisternal inoculation of an inoculum of 107 CFU/mL for
MSSA strain and of 108 for MRSA and GISA strains. Bacterial growth
curve was assessed in CSF of rabbits after 10 h and 20 h of inoculation.
Additionally, CSF samples were used to quantify CSF leukocyte counts,
lactate and protein concentrations. Statistical analysis was performed
using T-student for bacterial counts and for inﬂammatory activity.
Results: All tested animals developed meningitis after 10 hours of
inoculation. Bacterial titers (median ± SD) with all tested strains
at different time points are shown in the table. Some inﬂammatory
activity is shown in the table. All blood cultures were negative. Without
treatment, all animals survived at least 24 h after the inoculation point.
10 h after inoculation 20 h after inoculation
0 h 2 h 6 h 24 h 0 h 2 h 6 h 24 h
Log cfu/mL
Strain A 4.1±0.8 4±0.8 3±0.81 3±1.9 4.7±1.4 4.2±1.6 3.8±2.9 4.8±2.0
Strain B 5.2±0.4* 4.8±0.7* 4.2±0.4* 3.7±1.1* 3.8±0.5 3.5±0.8 2.8±0.7 2.2±1
Strain C 4.8±0.4* 4.7±0.4* 4.5±0.6* 2.9±0.7* 2.6±1.3 2.2±1.7 2±1.6 1.4±1.5
[Lactate] mmol/L
Strain A 10.1±3* 10.7±3* 10.3±2.5* 5.6±2.7 6±0.3 4.2±0.2 6±3.2 3.5
Strain B 12.5±1.4* 11.1±1.7* 9.3±1.1* 7.2±2.7* 6.2±2.4 5.1±1.5 4.7±1.6 4.4±1.3
Strain C 11.6±1.6* 9.7±1.5* 7.5±1* 5.9±1.2* 5.7±0.9 4.9±1.6 4.1±1.6 3.5±1.1
*Statistical difference 10 h vs 20 h.
Conclusion: All three Staphylococcus aureus strains were able to induce
meningitis and inﬂammatory activity without statistically signiﬁcant
differences at 10 h. Log CFU/mL and inﬂammatory parameters were
higher (with statistical signiﬁcance) and more homogeneous at 10 h time
point than at 20 h. This time point has been choosed to begin therapeutic
schedules.
P1785 Efﬁcacy of voriconazole versus anidulafungin alone and in
combination in a guinea pig model of invasive pulmonary
aspergillosis
W.R. Kirkpatrick, L.K. Najvar, R. Bocanegra, A.C. Vallor, M.C. Olivo,
D. Molina, J.R. Graybill, T.F. Patterson (San Antonio, US)
Objectives: Combination therapy for invasive aspergillosis with an
echinocandin and a triazole antifungal is attractive due to distinct
mechanisms of action. Possible antagonism of some drug combinations
and the potential paradoxical “eagle” effect of higher doses of
echinocandins have been suggested; thus, combination therapy remains
controversial. The antifungal activities of voriconazole (VRC) and
anidulafungin (ANID) alone or in combination were evaluated in a
guinea pig model of invasive pulmonary aspergillosis (IPA).
Methods: Guinea pigs were immunosuppressed with cortisone acetate
and made temporarily neutropenic with cyclophosphamide 2 days prior
to, and 3 days following aerosolised challenge with 12 ml 109 CFU/mL
Aspergillus fumigatus AF293 in an acrylic chamber. Therapy with
oral VRC at 2.5 or 10mg/kg/bid, ip ANID at 1, 6 or 12mg/kg/d, or
combinations of VRC 2.5+ANID 1 or VRC10+ANID6 or 12 was begun
24 hr after challenge and continued for 8 d.
Results: Both doses of VRC and the low dose combination of
VRC2.5+ANID1 showed signiﬁcantly increased survival vs controls.
Decreased mortality, expressed as mean day of death, was also shown in
a dose dependent manner with all 3 doses of ANID with longer survival
seen with higher doses of ANID. Semi-quantitative assessment of lung
tissue burden by colony forming units (CFU) revealed that therapy
with VRC10 and both VRC10/ANID combinations yielded signiﬁcant
reductions in counts as compared to controls. Similarly, therapy with
VRC10 or VRC10+ANID12 yielded signiﬁcant reductions in counts as
compared to either ANID6 or 12. Assessment of lung tissue burden
by Q-PCR (Conidial equivalents ”CE”) revealed that VRC10 and both
VRC10/ANID combinations yielded signiﬁcant reductions in counts
as compared to controls. Similarly, Q-PCR showed that therapy with
VRC10 yielded signiﬁcant reductions in counts as compared to ANID12
as did VRC10+ANID12 as compared to either ANID 1 or 12.
Conclusion: Therapy with VRC yielded greater survival than did ANID,
and VRC10 or the combination of VRC10+ANID12 were superior in
reducing tissue burden as assessed by either CFU or CE. In this model of
IPA, VRC10 alone was superior to any dose of ANID tested alone. ANID
combined with low dose VCR reduced lung CE. Combination therapy
with the higher VRC doses demonstrated similar efﬁcacy to VRC alone
although no evidence of a paradoxical effect in tissue burden was seen.
P1786 Dispersin B therapy of Staphylococcus aureus experimental
port-related bloodstream infection
A. Serrera, J.L. del Pozo, A. Martinez, M. Alonso, R. Gonzalez,
J. Leiva, M. Vergara, I. Lasa (Pamplona, ES)
Objectives: S. aureus is a common cause of port-related bloodstream
infections (PRBI). Treatment of these infections typically consists of
surgical removal of the port and prolonged therapy with adequate antimi-
crobials. Dispersin B (Dsp-B) is an enzyme produced by Actinobacillus
actinomycetemcomitans that cleaves beta 1−6 N-Acetylglucosamine
polymers in S. aureus bioﬁlm. We analysed the activity of Dsp-B
(administered as a lock solution inside the port with teicoplanin) in
a sheep model of PRBI.
Methods: Experimental PRBI was established in 24 female sheeps.
Three days after initialing the infection, animals were randomised
into three equal groups and antimicrobial therapy was initiated as
follows: (i) no treatment, (ii) iv teicoplanin (loading dose of 6mg/k/12 h
× 3 doses and then 4mg/k/24 h) plus teicoplanin locks (10mg/mL)
and (iii) iv teicoplanin plus Dsp-B-teicoplanin locks (40mg/mL and
10mg/mL respectively). This treatment was administered every day for
ten days. Blood cultures were extracted (venipuncture and port) every
day. Three days after completion of therapy, sheeps were sacriﬁced and
ports were aseptically removed and cultured (swabbing of the internal
port lumen, septum sonication and catheter tip sonication).
Results: All the animals in no treatment group died due to septic
complications and all blood and port cultures were positive for S. aureus.
In group ii, 75% of the animals got sterile blood cultures during treatment
(mean: 7, range: 3−10 days), but all the port cultures were positive after
removal. In group iii 100% of the animals got sterile blood cultures
during treatment (mean: 3, range: 3−8 days), and catheter cultures were
completely negative in 50% of the animals.
Conclusion: Our results indicate that a combination lock of Dsp-B with
teicoplanin besides systemic antibiotherapy is active in a sheep model of
PRBI. Application of this therapy in the human setting could eliminate
the need for port removal in related infections.
This work was supported by a grant from Proy. Inst. Carlos III ref.
03/1102
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P1787 Morphological substantiation of antibacterial therapy in
acute cystitis
T. Perepanova, J. Kudrjavtcev, V. Kirpatovski, P. Hazan (Moscow, RU)
Objectives: To study the impact of antibacterial medications on the
mucus of bladder in the cases of acute bacterial cystitis in animal testing.
Methods: The experiments were made on 15 white outbreed female rats
with a mass of 280–320g. Acute bacterial cystitis was modeled in all 15
rats. The rats were divided into 5 groups, 3 rats to a group. The ﬁrst group
was a control one – without antibiotics; in the second group the rats were
given furazydin (0.5−1mg to a rat; 1.5mg/kg) with food 3 times a day
during 7 days; the third group took fosfomycin (15mg to a rat; 45mg/kg)
in one dose; in the forth group – norﬂoxacin (2mg to a rat; 6mg/kg) 2
times a day during 3 days; the ﬁfth group was given norﬂoxacin in the
same dose during 5 days. By means of microscope studies of the bladder
preparations morphometrics of a number of parameters was carried
out which allowed to evaluate quantatively the expressed inﬂammatory
reaction. All rats were done away with by putting to sleep on the 7th
day from the beginning of the experiment.
Results: 3 rats from the 1st group revealed visual evidence of cystitis.
The 2nd-5th groups didn’t show any visual evidence of cystitis.
Epithelium alteration showed minimal evidence in groups 4th and 5th.
Development of mesenhematic reaction revealed itself by the evidence of
inﬂammation of hystiocytic cells. The biggest concentration of these cells
showed in the ﬁrst group. The contents of these cells dropped sharply
in the 4th and the 5th groups. There was practically no difference in the
concentration of lymphocytes and macrophages in different groups. The
biggest concentration of polymorphonuclear leucocytes was revealed in
the 4th and the5th groups.
Conclusion: The necessity of antibacterial therapy of acute bacterial
cystitis proved to be crucial. Norﬂoxacin showed better bacterial
efﬁciency compared to fosfomycin and furazydin. Alteration of
urothelium in treatment with norﬂoxacin decreases to a more extent
than that with fosfomycin and furazydin. The application of norﬂoxacin
shortens the reparation phase while long-term antibacterial therapy
course shows moderate suppression of mesenhematic reaction. Three-
day treatment course with norﬂoxacin has certain advantages compared
to ﬁve-day treatment course by this medication to reparation phase.
P1788 Experimental studies with T. pallidum Nichols strain –
Efﬁcacy of treatment in late infection
A.C. Magalha˜es Sant‘Ana, G. Rocha, J. Poiares da Silva (Coimbra,
Porto, PT)
Objective: More than one hundred years since the identiﬁcation by
Schaudinn and Hoffman of Treponema pallidum, the inability to grow
it has limited the knowledge of syphilis physiopathology. In the last
decades, there has been a marked increase in the number of cases
of syphilis and there are still doubts about the total elimination of
T. pallidum in the late syphilis. These factors justify the need to continue
the studies on T. pallidum infection. To study the efﬁcacy of penicillin
and ampicillin treatment in infected
Methods: Rabbits not infected with Treponema paraluiscuniculli were
intratesticular inoculated with T. pallidum Nichols strain. They were
treated with intramuscullar penicillin and/or ampicillin and monitored
by qualitative and quantitative FTAabs. Dark-Field and Transmission
Electron Microscopy (ME) was done in testis, popliteus adenitis and
ocular aqueous humour.
Results: We detected: (i) In early treatment, FTAabs reverts to negative
and in testis the T. pallidum shows lytic aspects with total cure of orchitis.
(ii) If the treatment was initiated after 3 months, FTAabs persist positive.
However with the maintenance of treatment with ampicillin the title of
Ig G decreases to 1/5. (iii) In rabbits that survive until 3 years FTA
abs persists positive, but in autopsy we can see in popliteus adenitis
but not in testis or in aqueous humor some cells, that in ME shows the
morphology of T. pallidum.
Conclusion: We don‘t understand the complete meaning of persistence
of T. pallidum in late infection because it was not possible to obtain
infection with this products in other rabbits. In patients with HIV
infection we ﬁnd an unusual incidence of neurosyphilis, despite adequate
therapy. It is of utmost importance to proceed with these studies with
new biothecnology.
P1789 Moxiﬂoxacin versus ampicillin+gentamicin in the therapy
of experimental Listeria monocytogenes meningitis
O. Sipahi, T. Turhan, H. Pullukcu, S. Calik, M. Tasbakan, H. Sipahi,
B. Arda, T. Yamazhan, S. Ulusoy (Izmir, TR)
Objective: Listeria monocytogenes (LM) is an important pathogen
causing meningitis in immunocompromised and and immunocompetent
host, The main therapeutic choice is ampicillin+gentamicin which is
shown to be synergic in experimental meningitis model in rabbits,
Moxiﬂoxacin is effective against LM in vitro and in machrophages, There
is no human or animal study comparing ampicillin+gentamicin versus
moxiﬂoxacin in LM meningitis, In this study it was aimed to compare
the antibacterial activity of moxiﬂoxacin and ampicillin+gentamicin in
the treatment of LM meningitis in rabbit meningitis model.
Methods: Meningitis was induced by direct inoculation of a clinical
strain isolated from an immunocompromised patient (107cfu/mL), into
cisterna magna of New Zealand rabbits, After 16 h of incubation
time, rabbits were separated into three groups moxiﬂoxacin (M),
ampicillin+gentamicin (A) and control, (C), Group M received 20mg/kg
moxiﬂoxacin (Bayer, Germany) at the end of the incubation time and 5 h
later by IV route, Ampicllin (Mustafa Nevzat, Turkey, 30mg/kg/h) and
gentamicin (IE Ulagay, Turkey, 2.5mg/kg/h) were also given by IV route
with continuous infusion for 8 h in 36 cc 0.9% NaCl and group C did not
receive any treatment, CSF samples (0.1–0.25 mL) were obtained 16 h
and 24 h after induction of meningitis, At the end of the study period
(24 h after the induction of meningitis), animals were humanely killed by
intravenous infusion of high dose nembutal, The bacterial count in CSF
was measured by standard serial dilutions of 10mL CSF in 0.9% NaCl
and incorporation into sheep blood agar (Oxoid, Basingstoke, UK) pour
plates, Data were evaluated by SPSS 11.0 package programme using
Mann-Whitney U-test, Kruskal-Wallis test and Fisher’s c2 test, A P-
value less than 0.05 was considered signiﬁcant.
Results: At the end of 16 h of incubation time, CSF bacterial counts were
similar in all groups (p> 0.05), When three groups were compared (table
1), bacterial counts in both treatment groups 24 h after the induction
of meningitis were signiﬁcantly lower (p< 0.05) than control group,
When two treatment groups were compared bacterial counts were similar
(Table 1).
Table 1. Bacterial counts in CSF of rabbits during study period.
Group No. of rabbits Log10 cfu.mL
16 h after induction
of meningitis
End of treatment
Group C 9 5.309±0.461 6.346±0.623
Group M 9 5.375±0.356 3.830±0.518
Group A 7 5.512±0.712 4.193±0.794
Conclusion: These data suggest that antibacterial activity of mox-
iﬂoxacin is similar with ampicillin+gentamicin in the treatment of
experimental LM meningitis of rabbits
P1790 Dose-dependent effects of octreotide on oxidant-antioxidant
imbalance during experimental sepsis in rat
A. Seydanoglu, M. Gu¨l, M. Ayan, I. Erayman, H. Toy, S. Girisgin
(Konya, TR)
Objective: Sepsis remains one of the leading causes of death in intensive
care units, despite recent acquired knowledge on pathophysiology and
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treatment. Oxidant-antioxidant balance involves different pathways and
yet, there is no ideal drug able to affect all of them. The aim of this study
was to investigate whether Octreotide (OCT), a synthetic somatostatin
analogue, has antioxidative effects in experimental sepsis.
Methods: Forty Sprague-Dawley rats were randomly divided into four
groups. Group I was the control group. Group II received no treatment.
Group III and group IV received subcutanously (sc) OCT 50mg/kg
and 100mg/kg after Cecal Ligation and Perforation (CLP) respectively.
White blood cell (WBC) count, erythrocyte glutathione (GSH), leucocyte
myeloperoxidase (MPO) and plasma malondialdehyde (MDA) were
assessed in all groups.
Results: In group sepsis, while MDA increased in sepsis periods, GSH
decreased when compared with group Sham (p< 0.05). Increase in
MDA levels and decrease in GSH levels after CLP-induced sepsis was
signiﬁcantly prevented by OCT 100mg/kg sc administration (p< 0.05).
Conclusion: Octreotide seems to have a dose-dependent antioxidative
effect in CLP-induced sepsis in rats. As a drug with the wide magrin of
safety and less adverse reaction proﬁle merits consideration as a choice
of treatment in sepsis and septic shock.
P1791 Comparison of the effects of erdosteine and n-acetylcysteine
on the levels of glutathione, myeloperoxidase, plasma and
tissue malondialdehyde in experimental sepsis model
M. Ayan, M. Gu¨l, A. Seydanoglu, I. Erayman, S. Erdem, B. Cander
(Konya, TR)
Objective: The aim of this study was to determine the effects of N-
Acetylcysteine (NAC) and Erdosteine as antioxidant agents on the free
radicals and their plasma levels.
Methods: Forty Sprague-Dawley rats were randomly divided into four
groups. Group I was the control group. Group II received no treatment.
Group III and group IV received orally NAC (20mg/kg/24 h) and
Erdosteine (20mg/kg/24 h) after Cecal Ligation and Perforation (CLP)
respectively. White blood cell (WBC) count, erythrocyte glutathione
(GSH), leucocyte myeloperoxidase (MPO) and plasma malondialdehyde
(MDA) were assessed in all groups.
Results: In groups III; WBC, erythrocyte GSH, and plasma MDA levels
were measured higher than control group (p< 0.05). However, in groups
IV; WBC, erythrocyte GSH, and plasma MDA levels were measured
higher than control group, but not statistically signiﬁcant (p> 0.05). The
lung tissue MDA levels decreased in group III and IV according to
control group (p< 0.05).
Conclusion: By the administration of NAC and Erdosteine as antioxidant
agents al lower doses many meaningful positive effects were detected on
the levels of WBC, erythrocyte GSH, and plasma MDA. These ﬁndings
suggest that NAC and Erdosteine could be a possible therapeutic agent
for sepsis and its mortality. However, further studies are needed to
elucidate the effects of these drugs at higher doses.
P1792 The effect of Ipsat P1A, a novel drug for prevention of
antibiotic-induced intestinal pathogenic colonisation, on
the gut antibiotic levels after intravenous administration of
b-lactam antibiotic/b-lactamase inhibitors in the dog
K. Raatesalmi, T. Korkolainen (Helsinki, FI)
Background: Novel therapies for the prevention of antibiotic (AB)-
induced intestinal pathogenic colonisation and gastrointestinal side-
effects such as diarrhoea, colitis and abdominal discomfort are needed.
In preclinical studies and clinical trials, Ipsat P1A, a recombinant
class A b-lactamase, was shown to prevent ampicillin-induced intestinal
pathogenic colonisation and diarrhoea after intravenous (i.v.) administra-
tion of AB.
Objective: The aim of the study was to test the effect of Ipsat P1A
treatment to prevent the increase in intestinal AB levels after i.v.
b-lactam/b-lactamase inhibitor administration.
Methods: Experiments were carried out on 6 beagle dogs (appr.17 kg),
which were fed with food pellets 20 minutes before AB administration.
During the ﬁrst treatment the dogs received two doses of AB/b-lactamase
inhibitor i.v. six hours apart. In the second treatment the dogs received a
dose of Ipsat P1A (0.1mg/kg, per os) and after 10 minutes an i.v. dose
of AB/b-lactamase inhibitor. After six hours the treatment was repeated.
The chyme samples were collected at different time points for 9 h by
inserting a silicon hose through the jejunal ﬁstula (170 cm from the
pylorus). Jejunal antibiotic concentrations were determined by an HPLC
method.
Results: Administration of ampicillin-sulbactam (40+20mg/kg), amoxi-
cillin-clavulanic acid (25+5mg/kg) and piperacillin-tazobactam (100+
12.5mg/kg) resulted in AUC0–360 values of 38,100, 5,700 and
441,000mgmin/g, respectively, for the intestinal concentration/time
curves of the ABs. When the dogs were treated with Ipsat P1A the
AUC0–360 of ampicillin-sulbactam, amoxicillin-clavulanic acid and
piperacillin-tazobactam were statistically signiﬁcantly reduced by 89, 77
and 36%, respectively.
Conclusion: Ipsat P1A degraded effectively the residues of ABs in the
intestine after i.v. AB administration.
P1793 Emergence of ﬂuoroquinolone resistance in the murine
model of tuberculosis
A. Aubry, A. Chauffour, C. Truffot-Pernot, V. Jarlier, N. Veziris (Paris,
FR)
Objective: Fluoroquinolone (FQ) are key antibiotics in the treatment of
multidrug-resistant tuberculosis, and are under investigation for ﬁrst line
treatment. However, FQ resistance is emerging in M. tuberculosis. We
aim to determine whether selection of FQ-resistant mutants occurs in
the murine model among mice treated with clinically used FQ.
Methods: 80 swiss mice were inoculated in the tail vein with 107 CFU
of M. tuberculosis virulent strain H37Rv. When the CFU count reached
7.9 log10 in the lungs, mice were randomly allocated to 4 groups: a
negative control group in which mice were infected but untreated (10
mice), and 3 tests groups in which 10 mice were treated with oﬂoxacin
(OFX 200mg/kg), levoﬂoxacin (LVX 200mg/kg) or moxiﬂoxacin (MXF
100mg/kg) for 6 months. All mice surviving after 6 months of treatment
were sacriﬁced. Lungs were plated on medium containing or not OFX
2mg/L. Resistant strains selected in vivo were submitted to sequencing
of the QRDRs of gyrA and gyrB genes.
Results: Survival rates after 1 and 6 months of treatment were 1/10 and
0/10 for OFX, 9/10 and 3/10 for LVX, and 9/10 and 7/10 for MXF.
Bacilli recovered from mice treated with OFX were still susceptible to
FQ, suggesting that OFX failed to prevent multiplication of the bacilli,
consistently with low in vivo efﬁcacy.
Among, the 13 strains resistant to FQ isolated from the lungs of mice
treated with LVF (5/6) and MXF (8/9), 11 harboured already described
mutations in GyrA (A83V, S84P or D87G, N, Y), 1 harboured an
unusual mutation in GyrB (D426N) and one strain harboured no mutation
in GyrA or GyrB. Among mutated strains, the majority (83%) were
constituted by a mixture of different clones, 2 different single mutants
in 4 cases and mutant plus wild-type clones in 6 cases.
Conclusion: In the murine model of tuberculosis, under FQ therapy,
we observed the emergence of heterogeneous populations of bacilli with
different resistance mutations, as well as mixtures of drug-susceptible
and drug-resistant genotypes. These data, that are in concordance
with recent observation in human tuberculosis, are informative for the
understanding of the selection of FQ-resistant mutants in tuberculosis
and can be used as a model to assess how to prevent selection of resistant
mutants by second line antituberculous agents. These data will also be
useful for designing molecular diagnosis of resistance to FQ in case of
mixture of resistant and sensitive strains.
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P1794 The protective effect of doxycyclin against Mycobacterium
avium infection in mice
S. Ikegame, M. Fujita, E. Harada, H. Ouchi, I. Inoshima, Y. Nakanishi
(Fukuoka, JP)
Objective: Mycobacterium avium causes chronic and progressive
respiratory infection. Therapeutic regimen including clarithromycin,
rifanpin and ethambutol has been commonly employed, but the effect
of such anti-bacterial therapy is not satisfactory and new approach for
this disease is needed. Doxycyclin (DOXY) is an antibiotic known to
have immunomodulating effects as well as anti-bacterial activity. In this
study, we investigated the effect of DOXY administration on M. avium
infection in mice. It is well known that TNF-alpha plays central roles in
immunity against mycobacteriosis. We investigated the effect of DOXY
in TNF-alpha 1 receptor knock out mice as well.
Methods: Clinically isolated strains of M. avium were used. Either
wild type of C57Bl/6 mice (wt) or TNF receptor 1 knock out
(TNF-R1 KO) mice on same background was administered of
M. avium (1×107 cfu/body) intratracheally. 2mg/kg/day of DOXY was
administered orally to mice after M. avium administration. Mice were
sacriﬁced on day 21, 60 after M. avium administration. The lung
homogenates were inoculated on Middlebrook 7H10 agar plates for
counting the number of colonies. Tissue sections of the lungs were
stained by haematoxylin and eosin or Ziehl–Neelsen (Z-N) methods.
Results: Administration of DOXY attenuated lung inﬂammation caused
byM. avium. Moreover, DOXY administration improved the survival rate
of M. avium infected TNF-R1 KO mice. However, DOXY administration
did not affect the number of M. avium in the lungs.
Conclusion: This study suggests that DOXY administration may have
protective effects against M. avium infection in mice. The effects
of DOXY are probably due to its biological effect apart from its
antimicrobial function.
Pathogenesis of Gram-positive bacterial
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P1795 The prevalence of Staphylococcus aureus bioﬁlm formers
in Scotland
A. Perez, S. Lang, C. Gemmell, G. Ramage (Glasgow, UK)
Background: Staphylococcus aureus has the ability to attach and
colonise implanted biomaterials such as catheters and indwelling medical
devices. These bioﬁlm structures are notoriously difﬁcult to treat with
antibiotics, and this characteristic combined with an increased prevalence
of methicillin resistant S. aureus clones has thwarted our ability to
successfully treat these infections.
Objectives: The aim of this study was to investigate the ability of both
methicillin sensitive and resistant S. aureus (MSSA and MRSA) strains
to form bioﬁlms in an in vitro model.
Methods: One thousand characterised clones of MSSA and MRSA from
the Scottish healthcare environment were obtained from the Scottish
MRSA Reference Laboratory. Each isolate was grown overnight in brain
heart infusion (BHI) broth in a 96-well microtitre plate, which also
contained an appropriate control (8 replicates). Subsequently, a Nunc
Immuno Maxisorp 96 peg plate was immersed in the cultures to inoculate
the individual pegs. This was transferred to a microtitre plate containing
BHI broth, which was incubated for 48 h under shear-force conditions.
Pegs containing bioﬁlms were removed, washed and air dried prior to
staining in 0.5% crystal violet (CV). Excess CV was removed and each
peg decolourised in 100% ethanol which was measured at 570 nm in a
microtitre plate reader. Bioﬁlms were compared to the positive control
(100%):  75% = +++; 25 – 75% = ++;  25% = +. Representative
strains from each section were also examined in a clinically relevant
catheter model using this quantitative methodology.
Results: Of the 1000 isolates screened approximately 82% were MRSA
isolates. Of these 20% displayed an optimal bioﬁlm phenotype (+++),
50% displayed a good bioﬁlm (++), 30% displayed a less than average
bioﬁlm (+). On closer inspection of the MRSA phenotypes in relation
to their genotypes the following was observed: +++ (67% = EMRSA15,
20% = EMRSA16); ++ (65% = EMRSA15, 30% = EMRSA16); + (52%
= EMRSA15, 41% = EMRSA16). In addition, each strain tested in a
catheter model displayed bioﬁlm growth similar to that of the peg plate
model.
Conclusions: This study has shown that EMRSA15 clones from
Scotland appear to have a greater propensity than other MRSA clones
to form tenacious bioﬁlm structures. This may indicate that these
strains have a novel virulence factor that confers a selective advantage
for adhesion and bioﬁlm formation. This is the subject of ongoing
investigations.
P1796 A comparative study on the frequency of genes encoding
cytotoxins in Austrian, Hungarian and Macedonian
methicillin-resistant and sensitive Staphylococcus aureus
strains
E. Kocsis, N. Pesti, K. Kristo´f, K. Nagy, Z. Cekovska, H. Lagler, K. Stich,
W. Graninger, F. Rozgonyi (Budapest, HU; Skopje, MK; Vienna, AT)
Objectives: The aim of this study was to detect the presence of genes
encoding cytotoxins in Staphylococcus aureus strains isolated from
invasive infections, and compare according to country and methicillin
resistance.
Methods: The phenotypical identiﬁcation of the strains was done by
classical microbiological methods. The genetical conﬁrmation of the
strains was done by detecting genes for thermostabile endonuclease
(nucA) and 23S rRNA. According to the presence of the gene
encoding methicillin resistance (mecA) 48 MRSA and 128 MSSA from
Austria (AT), 110 MRSA and 94 MSSA from Hungary (HU), 73
MRSA and 29 MSSA strains from Macedonia (MK) were examined.
The genes responsible for cytotoxins were detected by polymerase chain
reaction. The pulsed-ﬁeld gel electrophoresis of the strains was also
done, evaluation of results is in progress.
Results: The Panton-Valentine leukocidin genes (lukS-PV, lukF-PV)
were only found in 2.3% of AT MSSA, in 4.3% of HU MSSA and
in 1.4% of MK MRSA strains. The genes of the alpha- and delta-
haemolysins (hla, hld) were present in all HU and MK strains. AT
MRSA and MSSA strains harboured the hla gene in 94% and 86%,
respectively. The hld gene was carried in 96% and 98% of AT MRSA
and of MSSA strains. The hlb gene coding beta-haemolysin was found
in 33% and 52% of HU MRSA and MSSA, in 68% and 76% of MK
MRSA and MSSA strains, and in 58% and 40% in AT MRSA and
MSSA strains, respectively. The gamma-haemolysin gene (hlg) carriage
was 96% and 93% in MK MRSA and MSSA, 88% and 68% in HU
MRSA and MSSA, 69% and 74% in AT MRSA and MSSA strains. The
haemolysin gamma variant gene (hlgv) was found in 100% in the MK
strains, 100% and 84% in HU MRSA and MSSA, 100% and 56% in
AT MRSA and MSSA strains. Comparing all the MRSA with MSSA
strains independently from country origin the presence of hlg and hlgv
genes was signiﬁcant for MRSA strains (p< 0.05). The presence of 5-
gene combination pattern composed of hla, hlb, hlg, hlgv, hld genes was
signiﬁcant in both MSSA and MRSA strains (p< 0.05).
Conclusions: Signiﬁcant differences in harbouring cytotoxin genes were
found between S. aureus strains of different countries and between
MRSA and MSSA strains. The low frequency of beta-haemolysin gene in
MRSA strains can explain the high organ persistence experienced in our
former study and the delayed or incomplete development of haemolytic
zone around the MRSA colonies.
Supported by O¨AAD and Te´T grant No.: A-19/02 and OTKA T046186
P1797 Prevalence of different virulence factors and in vitro
adherence of Enterococcus spp. to urinary catheters
J. Dlugaszewska (Poznan˜, PL)
Objectives: There is little information about the virulence properties
of enterococci. Bacterial adherence to plastic biomaterials is the initial
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step necessary for the colonisation of the catheter surface. Hemolysins,
gelatinase and some phenotypic markers have been proposed as possible
virulence factors of Enterococcus strains. This study aimed to determine
the incidence of hemolysin, gelatinase, lipase among enterococi isolated
from patient with UTI and their adherence to urinary catheters.
Methods: For detection of hemolysin activity brain heart infusion agar
supplemented with 5% horse blood was used. Gelatinase activity was
detected using BHI broth containing 3% gelatin. For detection of lipase
activity enterococci were inoculated on Spirit Blue agar supplemented
with Lipase reagent.
Adherence to latex siliconised Foley and PCV Nalaton catheters were
analysed. For the adherence assays, it was used the method by Joyanes
et al., in which the number of adherent bacteria is estimated by agar
plate method.
Results: 78 enterococcal strains: E. faecalis (43) and E. faecium (35),
from UTI were investigated. Sixty-six (84%) isolates were hemolysin
producing (70% of E. faecalis; 79% of E. faecium), twelve (15%) were
gelatinase producing (E. faecalis). The production of lipase was observed
in 13 (17%) isolates (7% of E. faecalis, 14% of E. faecium).
Adherence of enterococci to biomaterials occurred very rapidly. It was
observed after 1 h already but the highest number of bacteria was
isolated after 24 h. The adherence of E. faecalis to both biomaterials
was signiﬁcantly greater (p< 0.05) than that of E. faecium. Moreover,
after 24 h of incubation the adherence of both E. faecalis and E. faecium
to PCV was signiﬁcantly greater (respectively: mean 8.4×106 cfu/mL
and 6.2×105) than that to siliconised latex (respectively: mean 5.7×105
cfu/mL and 1.2×105).
Conclusion: Further studies of the prevalence of hemolysin, gelatinase,
lipase production and adherence to biomaterials in enterococcal isolates
from infectious and noninfectious sites are necessary to elucidate the
role of these factors in human infections.
P1798 Association between opaque variants and serotypes in
invasive isolates of Streptococcus pneumoniae
I. Serrano, J. Melo-Cristino, M. Ramirez (Lisbon, PT)
Objectives: Determine the opacity phenotype of Streptococcus pneumo-
niae responsible for invasive human infections and probe the relationship
between serotype and opacity phenotype.
Methods: The phenotype of 304 invasive isolates from Portugal (1999–
2002) analysed previously and representing the 10 most prevalent
serotypes was determined. Three possible phenotypes were considered,
opaque (O), transparent (T) and intermediate (I). For the scoring of
the dominant phenotype, 104 cfu were plated on a transparent medium
and incubated at 37ºC in a candle extinction jar for 16 h. The colony
morphology was determined using a stereomicroscope and oblique
transmitted illumination.
Results: The visual inspection of the plates allowed unambiguous
identiﬁcation of the phenotype of the strain, which was considered to
be the phenotype exhibited by >70% of the colonies. 18 strains could
not be classiﬁed according to this criterium. The majority of the isolates
classiﬁed (52%, n = 158) were O variants and only 26% (n = 79) were T
variants while the remaining 16% (n = 49) were I phenotype. We found
a striking difference in prevalence of each phenotype among serotypes,
therefore serotype speciﬁc empirical odds ratio (OR) and 95% conﬁdence
intervals (CI) were calculated by reference to all other serotypes. In this
analysis strains classiﬁed as I variants were excluded. Serotypes 1, 4
and 23F presented a higher association with the opaque phenotype than
expected by chance (OR> 1), whereas serotypes 3 and 14 were more
associated with the T phenotype than expected (OR< 1). The serotypes
9V, 8, 19A and 7F were not statistically associated with the O phenotype
and the calculation of OR was not applicable to serotype 12B. We
found no relationship between the O phenotype and the different genetic
backgrounds of the isolates as determined by PFGE and MLST.
Conclusion: The O phenotype dominated on a 2:1 ratio over T
phenotype among our collection of invasive isolates representing 10
serotypes, suggesting a role for phase variation in pneumococcal human
infections. This observation highlights the heterogeneity of opacity
phenotypes in invasive isolates and lends further support to the proposal
that other factors, in addition to the site of isolation, determine the
opacity phenotype of a given isolate. The association between serotype
and colonial opacity could help explain epidemiological differences
observed among pneumococcal serotypes such as a higher invasive
disease potential.
P1799 Antibodies against LTA isolated from E. faecalis 12030 recog-
nize LTA from heterologous enterococcal strains but mediate
opsonophagocytic killing only to CPS-A and CPS-B strains
I. Toma, C. Theilacker, I. Sava, A. Kropec, F. Hammer, J. Huebner
(Freiburg, DE)
Objectives: Enterococci are among the most common causes of
infections in hospitalised patients. Alternative treatment strategies are
needed since these bacteria commonly exhibit resistances to multiple
antibiotics. We have shown previously that LTA is the target of opsonic
antibodies against Enterococcus faecalis strain 12030. Here we present
new data extending our knowledge of the basis of serodiversity of
E. faecalis and E. faecium.
Methods: LTA from E. faecalis and E. faecium strains was prepared as
described previously. Rabbit antiserum raised against LTA from strain
12030 was tested by ELISA using LTA isolated from the four prototype
strains of the serotyping system by Hufnagel et al. as coating antigens.
An opsonophagocytic assay (OPA) was used to asses killing mediated by
the anti-LTA serum. Inhibition of opsonophagocytic killing with puriﬁed
LTA was employed to conﬁrm that LTA was the target of opsonic
antibodies. Protection mediated by rabbit anti-LTA serum was evaluated
in a mouse bacteraemia model.
Results: Rabbit anti-LTA serum promoted killing of E. faecalis strain
12030 in the OPA (>90% killing at a serum concentration of 1:200).
Mice immunised with rabbit anti-LTA serum and challenged i.v. with
E. faecalis strain 12030 had signiﬁcantly lower bacterial counts (99%
reduction). Anti-LTA serum was broadly cross-reactive with LTA isolated
from heterologous E. faecalis serotypes by ELISA. The antiserum also
reacted with heterologous strains of E. faecalis and E. faecium in a whole
cell ELISA. In the OPA, anti-LTA serum killed not only strains belonging
to the same serogroup as strain 12030 (CPS-A), but also strains of the
CPS-B serotype and two vancomycin-resistant E. faecium strains. Killing
activity of anti-LTA serum against these strains was fully inhibited by
homologous LTA as well as LTA derived from a CPS-B strain. Strains
of the CPS-C and CPS-D serotype were not opsonised by anti-LTA. The
opsonophagocytic killing mediated by antisera raised against CPS-C and
CPS-D prototype strains were not inhibited by LTA from strain 12030
or homolgous LTA despite the presence of anti-LTA antibodies in these
antisera.
Conclusions: Antibodies against LTA bind ubiquitiously to enterococcal
LTA, but mediate opsonophagocytic killing only to E. faecalis CPS-A
and CPS-B strains as well as to some E. faecium strains. Despite binding
to LTA of CPS-C and CPS-D strains these strains are not killed, maybe
due to the presence of an antiphagocytic capsule.
P1800 Do enterotoxins and toxic shock syndrome toxin-1 of
Staphylococcus aureus contribute in the pathogenesis of
septic arthritis?
M. Chitsaz, M. Barton, M. Bazargan, N. Badami, R. Sedaghat (Tehran,
IR; Adelaide, AU)
Background: Septic arthritis is one of the most destructive joint
diseases in humans. Staphylococcus aureus is the most common cause
of infectious arthritis and its rate is about 60−80% in many reports.
To elucidate the probable involvement of enterotoxins and toxic shock
syndrome toxin-1 (TSST-1) in the pathogenesis of S. aureus septic
arthritis, production of these superantigens (SupAg) were determined
in 42 clinical isolates of S. aureus obtained from patients with septic
arthritis and the arthritogenicity of SupAg positive and SupAg negative
isolates were studied.
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Methods: Reversed passive latex agglutination, and isoelectricfocusing
were used for detection of enterotoxins A, B, C, and D, and TSST-1
in culture supernatants. Arthritogenicity was evaluated by using an
established rat model of septic S. aureus arthritis. Experimental groups
of Sprague Dawely rats (n= 5) for each type of toxin producing strains
(enterotoxins A, B, C, and D, and TSST-1), and non-SupAg producing
strains were evaluated (totally 6 group). A suspension of bacterial strains
(107 live cells/rat) were injected through tail (intravenously) and rats were
evaluated clinically and histopathologically for development and severity
of arthritis.
Results: From 42 S. aureus isolates, 35 (83.3%) were positive for SupAg
production. Among SupAg positive strains, 24 strains (57.1%) produced
only one type of toxin and 11 strains (26.2%) produced a combination
of two types of superantigen toxins and we did not detect any of these
super-antigens in 6 strains. Almost all rats who received SupAg positive
strains injection, developed arthritis (93.75%). In contrast, only 43.5%
of rats with SupAg negative strains displayed arthritis. Also there was
signiﬁcant difference in the severity of arthritis developed by SupAg
positive (Arthritic Index =7.2) with SupAg negative strains (Arthritic
Index =2.65).
Conclusion: The results indicate that super-antigen production is
possibly an important virulence factor in the development and severity
of S. aureus septic arthritis.
P1801 Signiﬁcance of Streptococcus bovis biotype II/2 bacteraemia
in patients with chronic liver diseases
O. Putcharoen, G. Suwanpimolkul, M. Pongkumpai, S. Nilgate,
W. Kulwichit, T. Tantawichien, M. Hanvanich, C. Suankratay (Bangkok,
TH)
Background: The association between bacteraemia caused by Strepto-
coccus bovis and colonic malignancy is well documented. However, most
studies have not focused on the relationship between S. bovis biotypes
and colonic malignancy and hepatobiliary diseases. We conducted a
retrospective study of patients with S. bovis bacteraemia in King
Chulalongkorn Memorial Hospital, Bangkok, Thailand from 2002 to
2005. S. bovis biotypes were determined with the API Rapid Strep
system (Analytab Products, Plainview, NY). Demographic data, clinical
manifestations, and mortality were obtained for statistical analysis.
Results: During the study period, a total 106 S. bovis strains were
isolated. Of 88 isolates causing bacteraemia, 8 (8.9%) were biotype I, 1
(1.1%) were biotype II/1, and 79 (90%) were biotype II/2. The sex and
age distributions of patients infected with different S. bovis biotypes were
not different. Data of 52 patients with clinically signiﬁcant bacteraemia
were reviewed. Primary bacteraemia was the most common clinical
feature (67%), followed by biliary tract infection (13.5%), spontaneous
bacterial peritonitis (7.7%), infective endocarditis (4%), meningitis (4%),
and skin and soft tissue infection (4%). Of 52 patients, the prevalence of
S. bovis from each biotype was 90%, 7.6%, and 2.4% for biotype II/2,
I, and II/1, respectively. Of 48 patients infected with S. bovis biotype
II, 28 (53%) had underlying hepatobiliary diseases, and 12 (25%) had
hepatocellular carcinoma. In addition, no patients infected with biotype
Underlying diseases of 52 patients with Streptococcus bovis bacteraemia
by biotype. HCC, hepatocellular carcinoma; DM, diabetes mellitus; CRF,
chronic renal failure.
II in our study had colonic malignancy. All isolates were susceptible
to penicillin and the third-generation cephalosporins. Overall in-hospital
mortality rate from S. bovis bacteraemia was 37%. The mortality rate
was 50% and 24% in cirrhotic and non-cirrhotic patients, respectively
(p< 0.05).
Discussion: This study demonstrated that S. bovis biotype II, especially
biotype II/2, is the most common isolate in our institute, compared with
the previous studies conducted in western countries. All patients with S.
bovis biotype II bacteraemia had underlying diseases, and hepatobiliary
diseases are the commonest underlying condition.
P1802 Detection of Panton-Valentine leucocidin gene in some
clinical isolates of methicillin-resistant Staphylococcus
aureus: relation to virulence
N. Rizk, S. El-Fiky, E. El-Gamal, E. Badawy (Alexandria, Al Mansoura,
EG)
Objectives: To assess the prevalence of Panton-Valentine leucocidin
(PVL) encoding genes lukF and lukS among methicillin-resistant
Staphylococcus aureus (MRSA) clinical isolates, and to investigate its
association with various types of staphylococcal diseases.
Methods: Forty seven MRSA isolates were recovered from unique
patient clinical specimens: skin and soft tissue infections (SSTI),
n = 18; broncho-alveolar lavage (BAL) from clinically diagnosed cases
of pneumonia, n = 20; surgical site infections (SSI), n = 7; and central
venous line (CVL) catheter tip, n = 2. Specimens were collected during
the period between June 2005 and May 2006. All isolates were tested
for the presence of mecA and PVL genes (lukS/F) by single target
polymerase chain reaction (PCR).
Results: All isolates were mecA gene positive. The PVL genes were
detected in 8 (17.02%) of the 47 MRSA isolates included in the
study. The prevalence of PVL genes varies with the type of specimen
from which MRSA isolates were recovered; 27.78% (5/18) among
isolates associated with SSTI, 15% (3/20) among isolates responsible
for community-acquired pneumonia; one of them was recovered from
a case of acute necrotising pneumonia. No PVL genes were detected
from MRSA isolates recovered from cases of hospital acquired infections
including SSI or CVL catheter tips.
Conclusion: PVL genes are prevalent among community-acquired
MRSA strains with no prevalence among hospital acquired strains. The
presence of PVL genes is related to disease severity especially acute
necrotising pneumonia. Close surveillance of these strains is essential
to monitor their spread, antimicrobial resistance proﬁle, and association
with disease severity.
P1803 Capsular and surface polysaccharide serotypes of
methicillin-susceptible and methicillin-resistant Staphylo-
coccus aureus strains currently circulating in Germany
C. von Eiff, K.L. Taylor, A. Mellmann, A.I. Fattom, A.W. Friedrich,
G. Peters, K. Becker (Mu¨nster, DE; Rockville, US)
Objectives: Due to its ability to cause serious and fatal infections,
Staphylococcus aureus remains one of the most feared microorganisms.
The severe consequences of staphylococcal infection heighten the
importance of prevention. Currently, a capsular polysaccharide (CP)
bivalent conjugate vaccine with type 5 and type 8 polysaccharides
chemically conjugated is being developed as a new tool for infection
prevention of S. aureus infections. In addition, a S. aureus 336-conjugate
vaccine is aimed to prevent those infections which are caused by serotype
336 and were previously referred to as nontypeable.
Methods: To analyse the potential applicability of a putative S. aureus
polysaccharide conjugate vaccine, 714 German methicillin-susceptible
(MSSA) and methicillin-resistant (MRSA) S. aureus strains collected in
various multi-centre studies were tested for their capsular and surface
polysaccharide serotype by slide agglutination with speciﬁc antibodies
(anti-T5-DT, anti-T8-DT, anti-336-rEPA). The strain serotypes were
conﬁrmed by immunodiffusion using lysostaphin-digested cell lysates.
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Results: Studying MRSA strains representing 86 unique spa types and
thus covering >90% of European MRSA spa types registered, 39 (45.3%)
were type 5 and 36 (41.9%) were type 8. Eleven isolates (12.8%) were
serotype 336. Among 400 MRSA isolates collected from ten different
laboratories covering university hospitals, general hospitals and clinics,
serotype 336 was the second most common serotype (16.5%) throughout
Germany. In a multi-centre study mostly comprising MSSA, type 8
positive strains were more prevalent among isolates recovered from
anterior nares of patients who did not subsequently develop S. aureus
bacteraemia compared to those who became bacteraemic and S. aureus
could be isolated from blood.
Conclusion: Capsular and surface polysaccharide serotyping showed that
the majority of German MSSA and MRSA isolates are comprised of
serotypes 5 and 8, although a higher than expected percentage of type
336 strains were observed. The addition of the newly described type 336
to a capsular polysaccharide-protein conjugate vaccine could extend the
coverage substantially and would include virtually all MSSA and MRSA
strains currently circulating in Germany.
P1804 The ACME-associated arcA gene occurs in diverse strain
types of MRSA in England and Wales
M.J. Ellington, L. Yearwood, M. Ganner, C. East, M.A. Ganner,
M. Warner, A.M. Kearns (London, UK)
Objectives: The ST8-SCCmecIVa (USA300) MRSA clone is highly
successful and prevalent, most notably, in the USA. This clone can
harbour the Arginine Catabolism Metabolic Element (ACME) suggested
as contributing to pathogenicity. To date, the ACME associated arcA
gene has not been reported outside the ST8 genetic background
of S. aureus. We sought to determine the distribution of ACME-
arcA amongst common community associated (CA)- and healthcare
associated (HA)-MRSA strains in England and Wales.
Methods: Previously characterised CA-MRSA isolates, and representa-
tives of HA-MRSA clones occurring in the UK (total n = 215), were
PCR screened for ACME-arcA. MICs of a range of antibiotics were
determined; SmaI PFGE, spa sequence based typing and toxin gene
proﬁling were also performed. Patient demographic and clinical data
were collated.
Results: The ACME-arcA gene was detected in 23 isolates. Seventeen
isolates were spa type t008 and the same pulsotype as known ST8
isolates. These 17 isolates were resistant to b-lactams with variable
ciproﬂoxacin and erythromycin resistance. Four of the remaining six
ACME-arcA positive isolates were closely related to each other by
PFGE ( 2 band changes) and spa typing (t359 and t267 – differing
by only one repeat). These four isolates were resistant to b-lactams,
and had variable resistance to erythromycin, ciproﬂoxacin, clindamycin,
gentamicin, tetracycline and fusidic acid. One of the remaining two
isolates was ST1 by pulsotype, agreeing with the t127 spa type, the other
was an EMRSA-15 variant; spa type t020 and ST22 by pulsotype. The
ST1 isolate was resistant to b-lactams only, whilst the ST22 isolate was
resistant to b-lactams, ciproﬂoxacin and erythromycin. The 17 ACME-
arcA, ST8 isolates were PVL-positive and mostly associated with skin
and soft tissue infections. In addition PVL-positive ST1 isolate and the
four PVL-negative spa t359 isolates were associated with skin and soft
tissue infections.
Conclusions: Whilst the ACME-arcA gene is most prevalent amongst
ST8-like (equivalent to USA300) isolates in the UK, to our knowledge
this is the ﬁrst time it has been identiﬁed in other genetic backgrounds.
The emergence of strains with acquired elements associated with the ‘ﬁt’
USA300 strain is a signiﬁcant public-health concern.
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P1805 Susceptibility analysis of gastroenteritis and beta-haemolytic
streptococcal pathogens collected during a decade of
SENTRY Antimicrobial Surveillance Program Monitoring
in Europe (1997–2006)
D. Biedenbach, T. Fritsche, H. Sader, R. Jones (North Liberty, US)
Objectives: To determine the antimicrobial susceptibility (S) of beta-
haemolytic streptococci (BHS) and gastroenteritis (GI) pathogens in
Europe (EUR) over 10 years. Infections caused by BHS can be relatively
mild or severe and invasive due to suppurative sequelae. Although
infections caused by GI pathogens are mostly self-limiting (diarrhoea),
invasive disease such as bacteraemia due to Salmonella spp. (SAL) or
Aeromonas. (ASP) can be more common among the very young, elderly
and immunocompromised persons.
Methods: During 1997–2006, the following pathogens (no.) were
collected from SENTRY Program (EUR) objectives and tested for S:
ASP (154), Y. enterocolitica (YET; 52), Shigella spp. (SHIG; 283),
SAL (1,526) and BHS (2,553). CLSI broth microdilution test methods
and interpretive criteria were utilised with appropriate concurrent quality
assurance practices.
Results: ASP/YET isolates were resistant (R) to ampicillin (AMP) but
S to penicillin with a b-lactamase inhibitor (85/>99%), cefuroxime
(CXM; 80/95%) and ceftriaxone (CRO), cefepime (FEP), and gentamicin
(GENT) at >95%. Tetracycline (TET) and trim/sulfa (T/S) R in ASP
was 15%, and nalidixic acid (NA)-R was 28% associated with a
high ciproﬂoxacin (CIP) MIC90 to 1mg/L compared to the wildtype
population (0.03mg/L). The AMP-S of SHIG in 2001 (63%) was only
23% in 2003 inﬂuenced by Russian epdemic isolates (>95% AMP-R).
R to NA was 0% in 2001 but 4.3% in 2003; and TET-R increased >7%
during the sampled interval. S among SAL and BHS were compared
during the ﬁrst and the second ﬁve year samples. There was a decline
in S among SAL during the last ﬁve years with AMP-R (24.7%), NA-R
(17.4%) and TET-R (20.3%). A signiﬁcant increase in ESBL phenotypes
(2002–2006) followed a clonal S. typhimurium (CTX-M-5) outbreak in
Russia. We noted a 5−7% decline in S to erythromycin (ERY) among
Group A and B BHS during the second sampled period. ERY-R rates for
BHS varied between nations with highest rate in Italy (37%). TET-S was
stable between years, but varied among serogroups (A and C/70−80%,
G/50% and B/20%). All BHS were S to linezolid, vancomycin, quin/dalfo
and were very S to levoﬂoxacin and penicillin.
Antimicrobial activity of 9 drugs versus Salmonella spp. (1,526)
Salmonella spp./ Year (no.)
Antimicrobial 1997–2001(664) 2002–2006 (862)
% Sa % Ra % Sa % Ra
AMP 77.4 21.8 74.6 24.7
CXM 69.6 0.2 53.1 2.7
CRO 100.0 0.0 (0.2)b 98.1 1.9 (2.7)b
FEP 100.0 0.0 98.4 0.3
NA 85.4 14.6 82.6 17.4
CIP 99.9 0.1 (13.7)c 99.7 0.1 (16.1)c
TET 76.8 22.0 78.7 20.3
T/S 93.8 6.2 93.6 6.4
GENT 98.3 1.4 97.1 1.3
aCriteria as published by the CLSI (M100-S16).
b% of strains with ESBL screen-positive (MIC 2mg/L for CRO).
c% strains with elevated CIP MIC (0.12mg/L).
Conclusions: GI pathogens and BHS contribute a signiﬁcant amount of
morbidity in EUR and worldwide. Antimicrobial surveillance of these
species in EUR shows a trend toward declining S to several drug classes
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and continued monitoring is necessary to track the R proﬁles of these
important bacterial species.
P1806 Prevalence and antimicrobial susceptibility proﬁles of skin
and skin structure infection pathogens in Europe: report
from the SENTRY Antimicrobial Surveillance Program
(1997–2005)
J. Ross, R. Jones, H. Sader, M. Stilwell, T. Fritsche (North Liberty, US)
Objectives: To present a 9-year summary of bacterial pathogens
(prevalence and S trends; SENTRY Program) recovered from EUR
patients experiencing skin and skin structure infection (SSSI). Rising
resistance (R) rates are being observed globally in both Gram-
positive and -negative SSSI pathogens, challenging accepted approaches
to clinical management, especially empiric antimicrobial therapy
guidelines.
Methods: Non-duplicate, clinically-signiﬁcant SSSI isolates (6,828)
were collected from >25 medical centres in Europe participating in the
SENTRY Program from 1997–2005 (exception, 2001). Identiﬁcations
were conﬁrmed by the central monitoring laboratory and all isolates
were S tested using CLSI methods and interpretive criteria (M100-S16)
against antimicrobial agents commonly utilised as empiric or directed
therapy.
Results: The ten ranking EUR SSSI pathogens for all years were:
S. aureus (SA; 38.8%), P. aeruginosa (PSA; 11.8%), E. coli (EC; 10.4%),
Enterococcus spp. (ENT; 5.8%), coagulase-negative staphylococcus
(5.0%), Enterobacter (ESP; 4.9%), Klebsiella spp. (KSP; 4.3%),
beta-haemolytic streptococcus (BHS; 3.8%), P. mirabilis (3.1%), and
Acinetobacter spp. (ASP; 2.6%). Analysis of intervals 1997–2000 and
2002–2005 showed that BHS moved from 10th to 4th in prevalence and
erythromycin (ERY)-R increased from 12.3 to 22.5%. While prevalence
of SA varied widely between countries (highest in the UK [86.1%] and
lowest in Turkey [40.5%]) overall EUR methicillin-R (MRSA) rates
remained unchanged between intervals (22.8 and 24.3%, respectively)
and ERY-R decreased slightly (31.2 to 27.2%). Vancomycin-R rates in
ENT increased slightly between intervals (2.7 and 3.9%, respectively).
R increases were most notable for imipenem (IPM) with PSA and ASP,
and also with levoﬂoxacin (LEV) for KSP and EC. ESBL-phenotypes
were detected in 12.7% of EC and 20.0% of KSP in 2002–2005; both
were increased signiﬁcantly from the previous monitored interval.
Organism (no.) R pattern % Inhibited at CLSI
breakpoints
1997–2000 2002–2005
SA (2,652) MRSA 22.8 23.0
PSA (807) IPM-R 9.5 12.4
Ceftazidime (CAZ)-R 17.8 16.8
LEV-R 28.2 26.2
Amikacin (AMK)-R 10.4 5.5
EC (711) CAZ-R 2.2 (8.3)b 5.7 (12.7)b
LEV-R 6.5 12.3
ESP (338) IPM-NSa 0.6 1.7
CAZ-R 22.4 17.5
LEV-R 7.5 6.2
KSP (283) CAZ-R 14.9 (20.3)b 11.9 (20.0)b
LEV-R 3.4 9.6
AMK-R 1.4 1.5
ASP (179) IPM-R 7.9 11.5
CAZ-R 46.5 41.0
LEV-R 28.7 30.8
AMK-R 55.4 28.2
aNS, non-susceptible.
bNumber in parentheses reﬂects the ESBL-phenotype rate (MIC values
2mg/L).
Conclusions: With key exceptions (ERY-R in BHS; IPM-R in PSA
and ASP; LEV-R in Enterobacteriaceae), R proﬁles for leading SSSI
pathogens did not change signiﬁcantly during the ﬁrst decade of
SENTRY Program data collection. The continued spread of virulent
MRSA into the community setting and increases being detected in ESBL
and carbapenem-R rates are, however, cause for concern and require
continued monitoring to guide contemporary antimicrobial therapies and
searches for new compounds.
P1807 Resistance rates among selected Gram-positive and
-negative isolates from European medical centres: a decade
of SENTRY Program Surveillance (1997–2006)
D. Biedenbach, T. Fritsche, H. Sader, R. Jones (North Liberty, US)
Objectives: To study the prevalence and resistance (R) trends among
selected Gram-positive and -negative pathogens. The increase in R to
antimicrobials can occur soon after introduction into clinical practice,
evolve slowly, or be sporadic without a clear trend. Mupirocin (MUP)-R
occurred soon after it was released onto the market (associated with
increased use). A high level of quinupristin/dalfopristin (Q-D)-R in some
countries has been said to be associated with the use of related agents
in animal husbandry. Trimethoprim/sulfamethoxazole (T/S) is the drug
of choice for the treatment of S. maltophilia (SM) and T/S-R SM are
perceived as rare in occurrence. Carbapenemases and high-level class
C chromosomal cephalosporinase production combined with altered
outer membrane permeability are primarily responsible for carbapenem
[CARB]-R among enteric bacilli which occur at varying frequency.
Methods: Countries in the European region (14−16) contributed isolates
for reference broth microdilution testing using CLSI (2006) methods
and interpretive criteria (2007). MUP was tested over a seven-year
period (2000–2006) against S. aureus (SA) and coagulase-negative
staphylococci (CoNS), and Q-D (1997–2006) against SA, CoNS and
E. faecium (EFM). T/S was analysed against 736 SM and CARB
(imipenem [IPM]) against >30,000 enteric bacilli during 1997–2006.
Results: The highest % of Q-D non-susceptible (S) SA/CoNS were
recovered in France and Austria (10/3%) and Greece (2/4%) compared
to other countries (1%). All monitored countries detected (Q-D)-non-S
EFM at a rate of 10−>70%. Clonal dissemination inﬂuenced the rate of
non-S Q-D SA, CoNS and EFM during some monitored years. High
MUP-R rates among MRSA were noted in Belgium, Ireland, Sweden
and the UK (18.2–25.6%) and CoNS in Belgium, Ireland and Turkey
(40%). T/S-R SM (4.5% overall) were detected in nearly all countries,
but at very low prevalence and CARB-R among enterics was also rare
in Europe with IPM-R at <0.1%.
Occurrences of resistance to Q-D and MUP among staphylococci and E. faecium
(1997–2006)
Org./Antim.-R (no.) Year (%non-S)a
19
97
19
98
19
99
20
00
20
01
20
02
20
03
20
04
20
05
20
06
SA
OX-S/Q-D (11.967) 0.3
(1.0)b
0.1 0.0 0.3 0.2 <0.1 <0.1 0.3 0.2 0.2
OX-R/Q-D (4,813) 4.3 4.9 5.9 4.3 3.7 2.2 0.8 1.1 1.3 1.3
OX-S/MUP (9,399) – – – 0.6 0.5 1.0 0.9 1.0 0.6 0.7
OX-R/MUP (3,903) – – – 14.6 11.1 12.1 10.6 7.7 7.2 6.2
CoNS
OX-S/Q-D (1,822) 1.0c 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
OX-R/Q-D (5,517) 1.3 1.0 0.5 3.1 0.6 1.1 0.7 0.7 0.7 2.1
OX-S/MUP (1,269) – – – 5.1 10.5 5.4 4.2 3.5 5.2 2.0
OX-R/MUP (3,994) – – – 16.7 21.8 25.4 17.7 18.8 18.3 21.4
EFM/Q-D (1,361) 20.3 26.1
(50.0)d
22.7 18.7 25.5 26.3 23.6 27.4 29.5 30.2
aNon-susceptibility % based upon the CLSI interpretive criteria for Q-D (M100-
S16) and MUP at MIC values 16mg/L (high- and low-level rates combined).
bClonal outbreak in France increased the prevalence to 1%.
cThree isolates from different countries with intermediate MIC values (2mg/L). dA
large number of clonally disseminated strains in Austria, Germany, Italy, Portugal
and Spain produced a higher percentage of non-susceptible isolates.
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Conclusions: MRSA and CoNS were more resistant to Q-D and MUP
compared to methicillin-S strains with R rates remaining stable or
declining over the tested SENTRY Program time period. In contrast,
(Q-D)-non-S among EFM has steadily increased in Europe and is
presently over 30%. Continued monitoring of regional pathogens is
essential to determine the longitudinal efﬁcacy of older and more recently
introduced antimicrobial agents.
P1808 Update on potency and spectrum of activity of meropenem
and selected broad-spectrum agents: testing results from
the USA MYSTIC Program (2006)
P. Rhomberg, J. Kirby, T. Fritsche, H. Sader, R. Jones (North Liberty, US)
Objectives: To monitor the potency and spectrum of meropenem
(MEM) and 10 other broad-spectrum agents against pathogens collected
from hospitalised patients within USA medical centres actively using
carbapenems (CARBs) for the treatment of serious infections. The
Meropenem Yearly Susceptibility Test Information Collection (MYSTIC)
Program is a longitudinal resistance (R) surveillance network with >100
sites worldwide. In the USA (2006), 15 sites continued participation by
submitting 200 consecutive, non-duplicate clinical isolates from deﬁned
pathogen groups.
Methods: 2,841 isolates (95% compliance) including 1,260 Enterobac-
teriaceae (ENT), 606 P. aeruginosa (PSA), 456 oxacillin-susceptible
S. aureus (MSSA), 300 streptococci, 149 E. faecalis, and 70 Gram-
positive anaerobes were tested using CLSI reference broth microdilution
or agar dilution susceptibility (S) methods and associated interpretative
criteria. Extended-spectrum b-lactamase (ESBL) phenotype strains were
conﬁrmed using Etest methods, negative strains were then screened for
acquired AmpC genes (8 classes) by PCR. Serine carbapenemase (C-ase)
production was screened by disk approximation and characterised by
PCR. All ﬂuoroquinolone (FQ)-R ENT isolates were tested for a qnr
using PCR.
Results: The CARB class had the lowest R rates against ENT (3.3–
4.0%) and the FQs had the highest R rates (21.7–22.5%). MEM was
the most potent agent tested with an 8-fold lower MIC90 compared to
imipenem against ENT strains and was 2-fold more potent against PSA
strains (MIC90, 8 vs. 16mg/L). Among Klebsiella spp. (KSP), 9.5% (59)
possessed KPC-type serine C-ase from sites in New York (2), New Jersey,
and Ohio at rates of 49.2, 22.2, 32.5, and 2.4%, respectively. Conﬁrmed
ESBL rates among E. coli (EC) and KSP were only 4.8 and 5.0%.
Unconﬁrmed ESBL R was due to FOX (5) and CMY (8) in 57% of
strains. The qnr gene was detected in only 2.5% of 283 FQR ENT
strains. Among PSA, cefepime, MEM, and tobramycin had lowest R rates
(5.6−7.9%). All comparator agents were >98% S against MSSA except
the FQs (only 88.6–90.4%).
Ten monitored USA MYSTIC Program pathogens in 2006
Organisma (no. tested) Meropenern MIC (mg/L) % Sb % Rb
MIC50 MIC90 Range
EC (641) 0.015 0.03 0.015–0.06 100.0 0.0
KSP (619) 0.03 0.5 0.015–>32 91.0 8.2
PSA (606) 0.5 8 0.015–>32 86.5 6.4
MSSA (456) 0.12 0.12 0.03–0.25 100.0 0.0
EF (149) 4 8 0.5–16 – –
SPN (138) 0.015 1 0.015–1 78.3 10.1
BST (113) 0.03 0.06 0.015–0.25 100.0 –
VGS (49) 0.03 0.25 0.015–4 95.9 –
CSP (37) 0.06 2 0.015–4 100.0 0.0
PEP (33) 0.06 0.25 0.015–0.5 100.0 0.0
aEF, E. faecalis; SPN, S. pneumoniae; BST, beta-haemolytic streptococci;
VGS, viridians group streptococci; CSP, Clostridium spp.; PEP, Pep-
tostreptococcus spp.
bCLS1 M100-S16 or M11-A6 breakpoints applied.
Conclusions: MYSTIC Program MIC results demonstrate continued
CARB potency and spectrum of activity against ENT, PSA and MSSA,
however the escalating presence of serine C-ase among KSP is a
serious concern. Continued surveillance in the USA MYSTIC sites
appears warranted to monitor the activity of the CARBs and other
broad-spectrum agents used as empiric or directed therapy against key
pathogens for the treatment of serious infections.
P1809 Ongoing activity of meropenem against European isolates:
report on the MYSTIC 2005 results
P. Turner (Macclesﬁeld, UK)
Objectives:MYSTIC (Meropenem Yearly Suceptibility Test Information
Collection) is a longitudinal global surveillance Study that has examined
annually the in vitro activity of meropenem and other broad spectrum
agents against clinically signiﬁcant, non-copy isolates since 1997. The
data presented here covers the year 2005 and deals with isolates from
Europe.
Methods: A total of 7710 isolates from centres in Belgium, Bulgaria,
Croatia, Czech Republic, Finland, Germany, Greece, Malta, Poland,
Russia, Spain, Sweden, Turkey and the UK were tested by CLSI
reference methodology (either agar dilution or broth microdilution)
and associated interpretative criteria. Extended-spectrum b-lactamase
(ESBL) were conﬁrmed by synergy with clavulanic acid and AmpC
by lack of synergy with this compound.
Results: See the table.
Organism (n) Percent suceptibility
MEM IPM P+T CAZ CPM CIP GM
Staphylococci (1326) 99 99 96 58 97 86 93
Enterobacteriaceae (3718) 99 98 82 82 87 82 87
P. aeruginosa (1098) 75 67 78 72 61 66 62
A. baumannii (408) 60 58 23 22 20 27 41
aMEM, meropenem; IPM, imipenem; P+T: piperacillin + tazobactam;
CAZ, ceftazidime; CPM, cefepime; CIP, ciproﬂoxacin; GM, gentamicin.
Conclusions: Meropenem, as in 1997, remains the antibiotic with the
broadest spectrum of activity followed by imipenem. Many of the
other comparators are experiencing considerable drops in their in vitro
effectiveness indicating the need for continued surveillance.
P1810 Bulgarian Surveillance Tracking Antimicrobial Resistance –
BulSTAR: bloodstream infections in 2005
M. Petrov, T. Velinov, T. Kantardjiev, A. Bachvarova, N. Hadjieva
(Soﬁa, BG)
Bulgarian Surveillance Tracking Antimicrobial Resistance – BulSTAR
monitors the isolation and antimicrobial susceptibility of all clinically
signiﬁcant microorganisms from blood cultures, cerebrospinal ﬂuid,
upper and lower respiratory tract, urine and wound samples. One hundred
and thirty six (136) microbiological laboratories – 25 public, 70 hospital
and 41 private laboratories from all 28 counties of the Republic of
Bulgaria participated in BulSTAR in 2005.
Objectives: The aims of this study are to analyse the aetiological
structure of bloodstream infections and the susceptibility to antimicrobial
agents of the most frequently isolated bacteria from blood among the
participants.
Methods: All the participating laboratories used the CLSI methodology.
Results: Data on bloodstream infections in 2005 are based on 68 083
samples, 2 980 from which were positive. Most frequently isolated
bacteria from blood are: S. aureus – 19.3% followed by E. coli
– 15.4%, Coagulase-negative staphylococci – 9.9%, A. baumannii –
7.2%, P. aeruginosa – 6.3%, K. pneumoniae – 6.2%, Candida spp. –
5.1% etc. In 2005 the prevalence of methicillin-resistant Staphylococcus
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aureus was 18.8% and the resistance of the species to erythromycin,
clindamicin, gentamicin and ciproﬂoxacin was higher than 20%. Among
the Gram-negative bacteria: the prevalence of ESBL-producing E. coli
was 14.1% and among K. pneumoniae was 28.8%. Ceftazidime–resistant
P. aeruginosa reached 32.9% and the resistance to ciproﬂoxacin among
the species was similar – 31.5%. Resistance to imipenem among
A. baumannii was 16%.
Conclusion: The aetiological structure of bloodstream infections is
similar to those in most European countries and also with that in
the previous years in Bulgaria. Remarkable is the stable presence of
P. aeruginosa and A. baumannii among the leading pathogens causing
sepsis in the country. There is a decrease in the proportion of S. aureus
and E. faecalis and an increase in the proportion of Candida spp.
compared with 2004. Main therapeutical problems are ESBL-positive
K. pneumoniae and multiresistant P. aeruginosa and A. baumannii.
P1811 In vitro activity of tigecycline against Gram-positive and
Gram-negative bacteria cultured from blood samples,
wound swabs and intra-abdominal specimens: results of the
German T.E.S.T. Surveillance Program 2005
M. Kresken, J. Brauers, H. Geiss, E. Halle, E. Leitner, G. Peters,
H. Seifert (Rheinbach, Heidelberg, Berlin, Mu¨nster, Cologne, DE)
Objectives: Tigecycline (TGC), the ﬁrst glycylcycline antibacterial
agent, is indicated for the treatment of complicated intra-abdominal
and complicated skin and skin structure infections. G.-T.E.S.T. is a
surveillance programme comprising 15 German laboratories which
monitors the susceptibility of bacterial pathogens to TGC. The objective
of this study was to evaluate the in vitro activity of TGC against bacterial
isolates cultured from blood samples, wound swabs and intraabdominal
specimens.
Methods: A total of 1,464 isolates including Staphylococcus aureus
(Sa, n = 204), S. epidermidis (Se, n = 162), Enterococcus faecalis (Es,
n = 107), E. faecium (Em, n = 112), Escherichia coli (Ec, n = 170),
Enterobacter (En, n = 126), Klebsiella spp. (Kl, n = 125) were studied.
Susceptibility testing with TGC, doxycycline (DOX), cefotaxime (CTX),
ciproﬂoxacin (CIP), oxacillin (OXA), vancomycin (VAN) and other
drugs was performed by broth microdilution according to German DIN
guidelines in a central laboratory. MICs of TGC were interpreted by
EUCAST and FDA criteria.
Results: The majority of isolates was recovered from wound swabs
(52.3%), followed by blood samples (29.4%) and intra-abdominal
specimens (18.2%). Among Sa and Se, 54% and 77% of the isolates,
respectively, were resistant to OXA. The rate of VAN resistance in
Em was 7%. TGC was highly active against Gram-positive species.
All strains were inhibited at 0.5mg/L, except two OXA-resistant
staphylococci (MICs 1mg/L). In case of Ec, all strains were inhibited
by TGC at the EUCAST breakpoint (bp) of 1mg/L. In contrast, 41%
of strains were resistant to DOX, 19% were resistant to CIP, and 6%
were putative ESBL producers (MIC of CTX >1mg/L). Among the
Kl isolates, 87% were susceptible to TGC, 2% were intermediate and
10% were resistant, when EUCAST bp were applied. Similar results
were observed for En isolates, of which 87% were susceptible, 4%
intermediate, and 9% resistant to TGC. However, only two strains one
each of Kl and En were resistant at the FDA bp of resistance (4mg/L),
with MICs of 8mg/L. Kl strains intermediate or resistant to TGC were
all resistant to DOX, as were 12 of 16 En isolates.
Conclusion: TGC demonstrated excellent in vitro activity against
organisms recovered from blood, wounds and the intra-abdominal tract,
including multiple resistant organisms. Therefore, TGC seems to be a
suitable drug for the treatment of complicated intra-abdominal as well
as complicated skin and skin structure infections.
P1812 In vitro activity of tigecycline against pathogens from
Turkey – T.E.S.T. Program 2006
V. Korten, G. So¨yletir, H. Leblebicioglu, G. Usluer, D. Du¨ndar,
D. O¨gu¨nc¸ on behalf of the TEST Study Group – Turkey
Objective: The Tigecycline Evaluation Surveillance Trial (TEST) is
a global surveillance programme to determine in vitro activity of
Tigecycline (TIG), a new glycylcycline, compared to various antibiotics
for Gram-positive/negative species. As part of global TEST programme
a multicentre surveillance study was performed to evaluate the activity
of TIG in Turkey.
Methods: A total of 994 non-duplicate clinically signiﬁcant isolates
collected in 2006 were analysed in this survey. The isolates were
identiﬁed to the species level at 10 participating centres and conﬁrmed
by the central laboratory. MICs were determined by each centre using
supplied E-test and interpreted according to CLSI guidelines for com-
parators (vancomycin, ampicillin, amoxicillin/clavulanate, moxiﬂoxacin,
linezolid, erythromycin, ceftazidime, piperacillin/tazobactam, amikacin,
imipenem, levoﬂoxacin). Breakpoints deﬁned by FDA were used for
tigecycline where applicable.
Results: Selected pathogens tested against tigecycline are shown in the
table. No resistance was observed against TIG and linezolid in Gram-
positive isolates. Tigecycline presented MIC50/MIC90 of 0.125/0.5mg/L
against MRSA isolates and MIC90 of  0.25mg/L against Enterococcus
spp. including isolates with high-level gentamicin and vancomycin
resistance. Tigecycline, at an MIC of 2mg/L, inhibited 100% and 97% of
E. coli and K. pneumoniae respectively, including ESBL producers. Of
153 acinetobacter isolates, 88 and 57 were non-susceptible to imipenem
and all antibiotics tested, respectively. TIG, with an MIC90 of 2mg/L,
was especially active against Acinetobacter spp. including imipenem-
and pan-resistant isolates.
Organism n Tigecycline (mg/L)
MIC50 MIC90 Range Susceptibi-
lity (%)
S. aureus (MR) 99 0.125 0.5 0.03−0.5 100
S. aureus (MS) 58 0.125 0.38 0.03–0.38 100
Enterococcus spp. 86 0.064 0.19 0.01–0.19 100
S. pneumoniae 57 0.023 0.094 0.01–0.19 100
E. coli 164 0.19 0.5 0.047−1 100
Klebsiella spp. 155 0.5 1 0.047−12 97
Enterobacter spp. 127 0.5 1 0.032−6 94
Citrobacter spp. 25 0.19 0.5 0.047−2 96
Morganella morganii 29 1 1.5 0.38−3 97
Serratia spp. 41 1 2 0.032−4 93
Acinetobacter spp. 153 1 2 0.064−8 na
MR, methicillin-resistant; MS, methicillin-susceptible; na, not applica-
ble.
Conclusions: The study validates the potent inhibitory activity of
TIG against hospital pathogens in Turkey including strains resistant to
antimicrobials currently used to treat nosocomial infections. The data
suggest that tigecycline may be a therapeutic option for Acinetobacter
spp. including multidrug resistant strains that pose a particular problem
in Turkish hospitals.
P1813 A pharmacodynamic analysis of resistance trends in
pathogens from patients with infection in intensive care
units in the USA between 1993 and 2004
K. Eagye, D. Nicolau, K. Heilmann, J. Quinn, G. Doern, G. Gallagher,
M. Abramson (Hartford, Iowa City, Chicago, Upper Gwynedd, US)
Objectives: Increasing resistance (R) to available antimicrobial agents
is an area of concern, particularly with respect to nosocomial pathogens.
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While higher minimum inhibitory concentrations (MICs) can inhibit
antimicrobial effectiveness, dose adjustments can often mitigate this
effect. The purpose of this study was to ascertain whether reported
R in intensive care units (ICUs) to several commonly used agents
has increased enough to signiﬁcantly impact their ability to achieve a
bactericidal effect.
Methods: We evaluated 74,235 Gram negative bacilli obtained in the
Merck ICU Surveillance Program in the United States of America (USA)
between 1993 and 2004. MICs to cefepime (FEP), ceftriaxone (CRO),
imipenem (IMP) and piperacillin-tazobactam (TZP) were grouped into
four 3-year periods. Patient-derived pharmacokinetics with Monte Carlo
simulation were used to predict microbiological success in each period,
as measured by cumulative fraction of response (CFR). Trends in
CFR over the four 3-year periods of this survey were assessed using
the Cochran-Armitage trend test. The primary analysis included all
organisms aggregated; P. aeruginosa (PSA) and Acinetobacter spp.
(ACNB) were also evaluated individually.
Results: In the primary analysis, IMP 1g q8 h showed %CFRs from 87
to 90 across all four study periods, a trend toward slightly improved
susceptibility (p< 0.0001). %CFR for FEP 2g q12 h declined from 87
to 85, showing increasing R over time (p< 0.01). The %CFR for TZP
4.5g q6 h declined from 80 to 78, showing increasing R (p< 0.05). CRO
had <52% CFR for all regimens in all periods, with no signiﬁcant trend.
Against PSA, signiﬁcant declines in CFR were seen for (%CFR range,
p-value): IMP 1g q8 h (82−79, <0.0001), FEP 1g q12 h (70−67, <0.01),
FEP 2g q12 h (84−82, <0.05), TZP 3.375g q6 h (76−73, <0.01), TZP 4.5
q8 h (71−68, <0.01), and TZP 4.5 q6 h (80−77, <0.01). Against ACNB,
all regimens of IMP, FEP and TZP showed signiﬁcant declines in CFR
over time (p< 0.0001).
Conclusions: These data suggest that increasing R in ICU pathogens is
indeed present in the USA, and that drug effectiveness as measured
by ability to attain pharmacodynamic targets has declined. Declines
against PSA are signiﬁcant, though FEP 2g q8 h remains potent and
more aggressive dosing of IMP and TZP can preserve some viability for
those compounds. The most relevant declines were seen against ACNB;
only IMP remains a viable option against this pathogen.
P1814 Susceptibility to tigecycline and to an extended panel
of antimicrobials of contemporary Gram-positive and
Gram-negative Portuguese isolates
C. Silva-Costa, M. Ramirez, J. Melo-Cristino (Lisbon, PT)
Objectives: Antibacterial resistance is a frequent ﬁnding in common
bacterial isolates from Portugal. Availability of new agents offer
clinicians novel options for therapy. Tigecycline has a broad spectrum
of activity, including strains resistant to other drugs. Strains collected
in Portugal in 2005 were evaluated for susceptibility to tigecycline and
several other antimicrobials.
Methods: A total of 1575 clinically signiﬁcant isolates were collected
and identiﬁed at 15 hospitals in Portugal. MICs were determined at
the coordinating laboratory using E-tests, and interpreted according
to CLSI guidelines. The antimicrobials tested against Gram positive
bacteria were: tigecycline, vancomycin, teicoplanin, linezolid, quin-
upristin/dalfopristin, levoﬂoxacin, gentamicin, streptomycin, rifampicin,
erythromycin, benzylpenicillin, ampicillin, cefotaxime. The antimi-
crobials tested against Gram negative bacteria were: tigecycline,
imipenem, trimethoprim/sulphamethoxazole, ciproﬂoxacin, levoﬂoxacin,
gatiﬂoxacin, gentamicin, amikacin, ampicillin, cefotaxime, ceftazidime,
cefepime, piperacillin/tazobactam, amoxicillin/clavulanic acid, ampi-
cillin/sulbactam and sulbactam.
Results: Among Gram-positive isolates (n = 825), all Staphylococcus
spp. isolates (n = 375), including methicillin-resistant strains, had
tigecycline MIC90 0.5mg/L. All Enterococcus spp. isolates (n=
150), including vancomycin-resistant strains, had tigecycline MIC90 
0.25mg/L. Streptococcus pneumoniae (n = 150), Streptococcus pyogenes
(n = 75) and Streptococcus agalactiae (n = 75) had tigecycline MIC90 
0.25mg/L.
Among Gram-negative isolates (n = 750), ESBL-producing or quinolone
resistant Escherichia coli (n = 225), Klebsiella spp. (n = 225) and
Enterobacter (n = 75) isolates had tigecycline MIC90  2mg/L.
Haemophilus inlfuenzae (n = 75) had tigecycline MIC90  0.5mg/L,
Stenotrophomonas maltophilia (n = 75) had tigecycline MIC90 
1.5mg/L and Acinetobacter baumannii (n = 75) had tigecycline MIC90
 4mg/L.
Conclusion: Most of the pathogens analysed in this study were resistant
to many broad-spectrum antibiotics. Tigecycline presented consistently
low MIC90 values and broad spectrum of activity, including otherwise
resistant strains. These characteristics should make tigecycline a useful
option for difﬁcult-to-treat infections.
P1815 Micronet: an Italian automatised laboratory based
surveillance and early warning system for infectious diseases
F. D’Ancona, C. Rizzo, V. Alfonsi, M.L. Cioﬁ degli Atti on behalf
of the Micronet Group
Objectives: In Italy several diseases speciﬁc surveillance systems have
been in use to support mandatory notiﬁcation of infectious diseases.
These systems are mainly based on reporting by clinicians and they
require additional resources also from clinical microbiologists. In 2005,
the Istituto Superiore di Sanita`, supported by Ministry of Health,
began to create Micronet, the ﬁrst Italian automatised laboratory based
surveillance system.
Methods: Micronet is designed to be a sentinel surveillance system
that collect all laboratory test results (positive and negative) from
a convenience sample of peripheral microbiological laboratories. The
approach is based on the clinical requests. All data are collected from
the informative system (LIS) of each laboratory. Before the transmission
to the central server, all data are converted automatically in Micronet data
format using standardised tables. The data transmission is designed to
be on daily basis.
Results: A group of microbiologists and epidemiologists produced 11
standardised tables, regularly updated. The Micronet team released the
speciﬁcs for the exchange of the data in XLM format. Seven laboratories,
as pilot test, implemented the tables and the speciﬁcs at local level,
sending 3 months of data, corresponding, removing duplicates, to more
than 50,000 records. All the data are stored into the Micronet central
database and a web site was set up to provide feedback in terms of
analysis on aggregated data. For speciﬁc requirements, data could be
exported on statistical packages for analysis.
Conclusion: The potential users of Micronet are Regional Authorities
(integrating existing clinical and laboratories surveillance system)
National authorities (trend analysis, alert and support of the infectious
diseases notiﬁcation system) and participant laboratories (comparing
local data with regional/national average). Micronet could also represents
an important a national network providing instruments for rapid detection
of outbreaks and assessment of microbiological trends. Micronet should
be fully operative from January 2007 when it is also planned to recruit
other laboratories in order to improve the representativeness of the
system. The project is now facing some difﬁculties and criticalities
such as the representativeness, comparability of data and methods for
duplicates clearing, management of the standardised tables at local level,
but the results obtained in the pilot phase show its potentialities.
P1816 Matching criteria in case-control studies in the ﬁeld of
antimicrobial resistance
M.E. Falagas, E.G. Mourtzoukou, K. Giannopoulou, V.G. Alexiou,
P.I. Rafailidis (Athens, GR)
Objectives: Although the effect of confounding factors on the studied
outcome may be taken under consideration in stratiﬁed or multivariable
analysis of the data, another approach is to adjust for the effect of
such factors in the design of the study. We evaluated the available
evidence from case-control studies in the ﬁeld of antimicrobial resistance
to identify the degree that matching was performed and the criteria used
to do so.
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Methods: We performed a systematic search of the PubMed database
(articles archived by 08/2006) to identify relevant studies. Studies that
used the individual matching technique were further analysed.
Results: 115 case-control studies with a focus on antimicrobial
resistance were identiﬁed; 28 regarding A. baumannii, 25 regarding
P. aeruginosa, and 62 for other bacteria. Individual matching was
performed in 32 (27.8%) out of the 115 studies. Age was the most
frequently used matching criterion in 22 of 32 (69%) evaluated matched
case-control studies, while gender was used in 11 (34%), presence of
underlying illness in 8 (25%), site of infection in 5 (16%), and area of
residence in 4 studies (12.5%). Other criteria were used in less than 10%
of the studies.
Conclusion: The available evidence from the analysed data from case-
control studies in the ﬁeld of antimicrobial resistance shows that
individual matching is employed only in a proportion of such studies and
only for a few characteristics, when it was used. The practical difﬁculties
in ﬁnding appropriately matched control patients may contribute to
this ﬁnding. Although there is a discussion regarding the risks of
adjustment, we believe that methodological advances and more utilisation
of the individual matching technique in case-control studies will help
in answering important speciﬁc research questions in the ﬁeld of
antimicrobial resistance.
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P1817 Changes in antibacterial resistance patterns in
Staphylococcus aureus strains which are related to
microbiologically conﬁrmed nosocomial bacteraemia in a
tertiary care educational hospital in Turkey
O. Sipahi, H. Pullukcu, S. Aydemir, M. Tasbakan, A. Tunger, B. Arda,
T. Yamazhan, S. Ulusoy (Izmir, TR)
Objective: In this study it was aimed to evaluate the resistance patterns
of microbiologically conﬁrmed nosocomial bacteraemia (MCNB) related
S. aureus strains between 2001–2005 retrospectively.
Method: Any patient in whom S. aureus was isolated in at least
one set of blood cultures (Sent to the bacteriology laboratory 72 h
after hospital admission) was considered to have MCNB. Data of
antibacterial resistance and hospital admission dates were extracted from
hospital patient record database. Double or more isolates during each
episode were counted as one episode. Resistance patterns in the 2001–
2002 and 2004–2005 periods were compared by Chi-square test. 2003
data was excluded to see the probable effect governmental antibiotic
restriction policy, which was started in March 2003. Blood cultures
were performed on Bact/Alert (bioMe´rieux, Durham, NC). Bacterial
identiﬁcations were performed by automated API (bioMe´rieux, Durham,
NC). Oxoid antibiotic dics (England) were used to test antibacterial
susceptibility by disc diffusion method following the recommendations
of CLSI. Results were interpreted as described by CLSI.
Results: Oxacillin resistance in 2001 was 73.8% and 55.2% in 2005.
When 2001–2002 and 2004–2005 periods were compared, resistance
to oxacillin, levoﬂoxacin, gentamicin, erythromycin and clindamycin
decreased signiﬁcantly (p< 0.05) (Table 1). There was no glycopeptide
resistance.
Table 1. Resistance patterns of S. aureus strains and comparison of resistance patterns in 2001–2002 and 2004–2005
periods
2001 2002 2003 2004 2005 2001–
2002
2004–
2005
P
Methicillin 73.8% 70.5% 76.7% 63.2% 55.2% 72.2% 59.0% <0.001
(186/252) (124/177) (89/116) (119/188) (115/208) (310/429) (234/396)
Levoﬂoxacin 76.1% 76.2% 64.4% 57.5% 51.4% 76.1% 54.2% <0.001
(118/155) (93/122) (67/104) (99/172) (106/206) (211/277) (205/378)
Gentamicin 61.4% 61.0% 69.5% 54.2% 49.0% 61.2% 51.0% <0.001
(153/249) (108/177) (80/115) (102/188) (100/208) (261/426) (202/396)
Erythromycin 66.9% 61.0% 62.9% 48.4% 33.6% 64.4% 40.6% <0.001
(168/251) (108/177) (73/116) (91/188) (70/208) (276/428) (161/396)
Clindamycin 43.4% 36.7% 50.8% 37.9% 28.8% 59.3% 33.0% <0.001
(109/251) (65/177) (59/116) (71/187) (60/208) (254/428) (131/396)
Penicillin 92.8% 93.2% 96.5% 93.0% 92.3% 92.9% 92.6% NS
(233/251) (165/177) (112/116) (175/188) (192/208) (398/428) (367/396)
Conclusion: Decrease in the resistance rates after the 2003 budget
application suggests that the application is useful not only in decreasing
the cost of antibiotics but the antimicrobial resistance in several bacteria.
P1818 Emergence of linezolid-resistant methicillin-resistant
Staphylococcus aureus in Japan
H. Hanaki, C. Yanagisawa, Y. Hososaka, K. Ishibashi, S. Yamamoto,
Y. Imamura, S. Taniwaki, T. Nakae, K. Sunakawa (Tokyo, Hukuoka, JP)
Objectives: The linezolid (LZD)-resistant methicillin-resistant Stapylo-
coccus aureus (MRSA) has been reported from USA (8 cases), UK
(1), and Brazil (1) yet not from Japan. We isolated the LZD-resistant
MRSA from a case of septicaemia patient in June 2006 only four months
after LZD had been introduced to clinical use in Japan. Five strains of
LZD-resistant MRSA were isolated from the same patient and they were
characterised by means of bacteriology and DNA technology.
Methods: Minimum inhibitory concentration (MIC) of antimicrobial
agent was determined according to the guideline of Clinical and
Laboratory Standard Institutes. Occurrence of the genes encoding
staphylococcal cassette chromosome mec (SCC mec), hemolysin (hla,
hlb), exofoliative toxin (eta, etb) enterotoxin (sea, seb), toxic shock
syndrome toxin-1 (tss, TSST-1), panton-valentain leukocidin (pvl,
PVL) and b-lactamase (blaZ) were examined by polymerase chain
reaction (PCR). Identity of the strains was veriﬁed by pulsed-ﬁeld gel
electrophoresis (PFGE) of the SmaI treated DNA.
Results: MIC of oxacillin, imipenem, pazuﬂoxacin, vancomycin,
teicoplanin, arbekacin, minocycline, rifampin, sulfametoxazole/torimeto-
prim was >128, 64, 1, 1, 4, 16, 0.25, and 2mg/mL, respectively, and
that was identical in all ﬁve strains. MIC of LZD was highest in the
latest isolates of MRSA, 32mg/mL, though that in all the LZD-unexposed
MRSA was 2mg/mL. SCCmec in all ﬁve strains isolated from the patient
was type II, which is common in the MRSA in Japan. Chromosomal
DNA encoding enterotoxin, heamolysine, and b-lactamase was detected
in all the strains, but that was undetectable encoding TSST-1, exofoliative
toxin and panton-valentine leukocidin. PFGE of SmaI-treated DNA in
all the LZD-resistant MRSAs showed identical DNA proﬁle suggesting
the identical origin for all. Only the difference from the DNA proﬁle of
the LZD-susceptible strains was that 120 bp band was shifted to 160 bp
in the resistant strain.
Conclusion: LZD was licensed in clinical use in Japan since April 2006
as an anti-MRSA drug, and the LZD-resistant MRSA emerged only
four months later. LZD was intermittently administered intravenously or
orally for 48 days to the patient with MRSA septicaemia, and the LZD-
resistant MRSA was isolated from blood on the day the patient passed
away. We reported a very ﬁrst case of LZD-resistant MRSA in Japan
and called for precaution for proper use of this powerful antimicrobial
agent.
P1819 Heterogeneous vancomycin intermediate resistance within
methicillin-resistant Staphylococcus aureus clinical isolates
in Alexandria province, Egypt
N. Rizk, S.A. Zaki (Alexandria, EG)
Objectives: To explore the prevalence of heterogeneous vancomycin
intermediate resistant Staphylococcus aureus (hVISA) among methicillin
resistant S. aureus (MRSA) strains isolated from hospitalised patients in
Alexandria University Hospital over a 2 years period, and to investigate
the mechanism of vancomycin resistance.
Methods: Sixty two MRSA isolates were screened by using brain heart
infusion agar supplemented with 4 ug/mL vancomycin (BHI-V4) and
macro Etest. Minimum inhibitory concentrations (MICs) of vancomycin
was determined by broth microdilution and standard Etest. Population
analysis proﬁle (PAP) was performed for detecting the frequency of
heterogeneous resistance for isolates grown on BHI-V4. Vancomycin
intermediate resistant subpopulations of hVISA were viewed with
scanning electron microscopy, and tested for the presence of vanA gene
by PCR.
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Results: Twenty one (33.87%) MRSA isolates grew on BHI-V4,
7 (11.29%) isolates were suspected of having reduced susceptibility to
vancomycin by the macro Etest. PAP conﬁrmed 6 (9.68%) isolates as
hVISA since they produced subpopulations with MIC of vancomycin
of more than 4ug/mL at frequency of 1 in 106 cfu/mL or higher.
Vancomycin MIC values for all isolates were  4ug/mL. Electron
microscopy of vancomycin intermediate resistant subpopulations of
hVISA showed enhanced cell wall thickness with evidence of increased
extra-cellular material and irregular shape compared to vancomycin
susceptible cells. All hVISA isolates were vanA gene negative by PCR.
Conclusion: This study is an early warning that MRSA strains with full
resistance to vancomycin might emerge in Egypt in the future. Due to
the increased use of vancomycin for treatment of MRSA infections,
screening for hVISA in MRSA strains should be considered as a
necessary part of infection control practice emphasizing the importance
of a laboratory capability of its identiﬁcation.
P1820 High prevalence of inducible clindamycin resistance among
community-associated methicillin resistant Staphylococcus
aureus in Europe
D. Farrell, J. Shackloth, L. Cossins, A. Quintana, P. Hogan (London,
UK; New York, US)
Background: Community-associated methicillin resistant Staphylococ-
cus aureus (CA-MRSA) is known to cause serious skin and soft structure
infections (SSTI) and is increasingly reported in Europe. Although CA-
MRSA are often susceptible to many antibiotic classes, clindamycin
(CLIN) is often the preferred antibiotic because of previously demon-
strated clinical efﬁcacy. CLIN resistance is underestimated because
testing for inducible clindamycin resistance (ICR) is not performed
routinely in many clinical laboratories. The aim of this study was to
assess the prevalence of ICR in CA-MRSA from Europe.
Methods: A total of 750 clinically signiﬁcant S. aureus from the
UK (n = 163), Germany (n = 187), Italy (n = 139), Spain (n = 133), and
France (n = 128) were selected and were collected either in 2003–2005
(n = 522) or 1994 (n = 228). Isolates were classiﬁed as CA-MRSA,
healthcare associated MRSA (HA-MRSA), or MSSA based on antibiotic
susceptibility patterns. MICs were determined and interpreted according
to CLSI methodology. ICR was determined by the double disc diffusion
method.
Results: ICR was prevalent in both 1994 and 2003–2005. All 750
isolates were 100% susceptible to vancomycin, teicoplanin and linezolid.
Erythromycin resistant isolates
N Ery-R % CLIN-S % ICR
n %
CA-MRSA 227 108/227 48 95.4 38
HA-MRSA 360 360/360 100 7.8 6.7
MSSA 163 22/163 13.5 63.6 63.6
Conclusions: ICR prevalence was very high in macrolide resistant
CA-MRSA (and MSSA) in 5 European countries suggesting that
empirical treatment with CLIN for serious SSTI may not be appropriate.
Because recent research provides evidence that, as with CLIN, linezolid
also suppresses toxin production in S. aureus whilst vancomycin and
teicoplanin do not, linezolid may be a more suitable empiric therapeutic
option to consider for serious SSTI in Europe until ICR is excluded. This
data also suggests that testing for ICR should be routinely performed in
Europe.
P1821 Staphylococcus aureus bacteraemia in the south-east of
Ireland 2002–2006
K. Burns, S. Fitzgerald, D. O’Brien, E. O’Neill, D. Keady, A. Moloney,
M. Hickey (Waterford, IE)
Background and Objectives: There are 1236 acute hospital beds in
the southeast of Ireland. During the period from 1998 to 2001, our
laboratory surveillance recorded an annual increase in the number of
cases of S. aureus bacteraemia. A decision was made to establish a
database and prospectively record clinical information and outcome on
all cases of S. aureus bacteraemia commencing in July 2002 for a four-
year period.
Methods: Each patient with a blood culture positive for S. aureus was in-
cluded in a database. We recorded demographic and clinical information,
source of bacteraemia, laboratory ﬁndings, clinical outcome, whether or
not there was evidence of relapse, reinfection and whether complications
arose following each infection. Only patients with genuine S. aureus
bacteraemia were included in the database. Centre for disease control
deﬁnitions of infection were utilised in this study. Bacteraemia was
deﬁned as either community or hospital-acquired based on recognized
deﬁnitions.
Results: There were 317 cases of S. aureus bacteraemia over the forty-
eight months of the study. 182 cases were due to methicillin-sensitive
S. aureus (MSSA). Age range was 3 days to 97 years with a mean age of
67 years. 59% of patients were male. We recorded 261 cases of hospital-
acquired infection and 56 cases of community-acquired infection. There
were no cases of bacteraemia due to community-acquired methicillin-
resistant S. aureus (MRSA) in our study. The underlying source of each
episode of bacteraemia was recorded as follows:
– 33% secondary to infection of central venous catheter
– 15% due to infection of peripheral vascular catheter
– 9% due to skin or soft tissue infection
– 4.5% due to septic arthritis
– 4% due to pneumonia
– 3% due to surgical site infection
– 3% due to urinary tract infection
In 20% of cases, the underlying source of infection was not uncovered
despite investigation or because a patient was unﬁt for invasive
investigation.
62% of patients recovered fully without complications. 25% of patients
died. For 22% of total deaths, S. aureus was the underlying cause of
death. In 10% of cases, complications arose secondary to the infection.
In 3% of cases, the outcome was unknown.
Conclusion: In our patient population, 47% of all cases of S. aureus
bacteraemia were due to infection of either a central or peripheral
venous catheter. We have targeted measures to prevent catheter-related
bloodstream infection. We hope to reduce the incidence of S. aureus
bacteraemia in our region in the future.
P1822 Resistance pattern of community-acquired S. aureus
infections in children
T. Panagea, G. Ikonomopoulos, A. Makri, A. Vatopoulos, P. Koukou,
A. Voyatzi (Athens, GR)
Introduction: Community-acquired (CA) methicillin-resistant S. aureus
(MRSA) infections in healthy children and young adults are a recent
worldwide phenomenon. Most CA-MRSA strains are producing Panton
Valentine Leukocidin (PVL), a highly potent toxin, associated with skin
lesions, soft tissue infections and necrotising pneumoniae.
Objectives: The purpose was to determine the incidence, the antibiotic
resistance pattern and the prevalence of PVL producing S. aureus isolates
in children suffering from skin or soft tissue infections in the community.
Material and Methods: A total of 285 strains S. aureus were isolated
from 960 samples obtained from children aged 0−14 years old, during the
last 2 years (October 2004–October 2006). All children suffered from
skin or soft tissue infections and attended the outpatient department
for medical advice. Samples were obtained from skin lesions (520),
abscesses (290), wounds (120), and umbilical swabs (30).
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Identiﬁcation of S. aureus was achieved by conventional methods.
Antibiotic susceptibility testing was performed according to the CLSI
guidelines. Twenty randomly selected CA-MRSA strains were further
examined by PCR technique for the presence of lukF-PV and lukS-PV
genes.
Results: S. aureus was responsible for 29.7% of community acquired
skin and soft tissue infections in children. Antibiotics resistance
pattern was as follow: penicillin 91%, methicillin 22.9%, fusidic
acid 19%, tetracycline 23.6%, clindamycin 2.3%, gentamicin 0.9%,
erythromycin 13.1%, rifampicin 0.9%, trimethoprim-sulfamethoxazole
0.9%, chloramphenicol 1.2% and ciproﬂoxacin 0.9%. None of the strains
was resistant to vancomycin, teicoplanin and amikacin. MRSA accounted
for 22.9% of all CA-S. aureus infections. Out of 65 MRSA strains,
48 (73.8%) were also resistant to fusidic acid and tetracycline. The genes
lukF-PV and lukS-PV were detected in 18 out of 20 (90%) CA-MRSA
strains.
Conclusion: In our paediatric population, 22.9% CA-MRSA infections
were observed. Ninety percent of examined CA-MRSA isolates were
found to be PVL producers. A signiﬁcant number of MRSA isolates
(73.8%) were resistant to fusidic acid and tetracycline. This unusual
antibiotic resistance pattern has been associated with the presence
of PVL producing ST80 CA-MRSA clone, that has previously been
described in Greece.
P1823 The impact of multiple-resistant Staphylococcus
haemolyticus in intensive care units – acquired infection
K. Kristo´f, S. Kardos, V. Cser, E´. Volter, K. Nagy, F. Rozgonyi
(Budapest, HU)
Objectives: The aims of the study was to investigate the susceptibility to
antistaphylococcal agents and the presence of genes encoding adhesins of
S. haemolyticus strains isolated from invasive infections between January
2001 and December of 2005.
Methods: Identiﬁcation of S. haemolyticus strains was performed by
the API Staph 32 (bioMe´rieux). Disc diffusion test, minimum inhibitory
concentration (MIC) of antibiotics and analysis of heteroresistance to
glycopeptides was carried out according to the NCCLS/CLSI guidelines.
Oxacillin resistance was conﬁrmed showing the presence of mecA
by PCR technique. The icaA, icaC, icaD, icaR, fbnA, fbnB genes
responsible for adhesion were detected by PCR.
Results: S. haemolyticus is the second (after S. epidermidis) most
frequently isolated coagulase negative Staphylococcus from clinically
veriﬁed bacteraemias in patients treated at the intensive care units of
our University. During the investigation period 356 strains were isolated
from blood cultures amounting to 5.8% of all positive cases. Most of the
strains were methicillin resistant (94%). The MIC90 was 512mg/L. Each
of them had the mecA gene. 98%, 96%, 57%, and 41% of the strains
were resistant to gentamicin, tobramycin, netilmicin and amikacin,
MIC90 for them were 256mg/L, 256mg/L, 128mg/L and 64mg/L
respectively. Only 12% of the strains were sensitive to ﬂuoroquinolones,
ciproﬂoxacin, levoﬂoxacin and moxiﬂoxacin. All strains were sensitive
to vancomycin. The rate of heteroresistant strain to teicoplanin was 79%
(MIC90 = 16mg/L). Concerning genes for adhesins icaC was present in
8.6% and icaD in 1.2% of the strains. None of the strains contained
genes for ﬁbronectin binding proteins.
Conclusions: The proportion of multiresistant S. haemolyticus strains in
blood stream infections of patients treated at the ICU was relatively high.
The quantitative antibiotic resistance of these strains was extraordinary
high. Vancomycin is the only choice of the treatment. Intercellular
polysaccharide adhesins and ﬁbronectin binding protein genes seem not
to be responsible for the attachment of these strains to indwelling devices.
Supported by OTKA No.: T 46186
P1824 Present situation of antimicrobial resistance of
Staphylococcus in Spain: Sixth Nationwide Prevalence
Study and the in vitro activity of new antimicrobial agents
O. Cuevas, E. Cercenado, M. Goyanes, M. Marin, A. Vindel, E. Bouza
(Madrid, ES)
Objective: Data regarding the evolution of Staphylococcus resistance in
a whole country have a deﬁnite inﬂuence in the design of empirical
treatment regimens. For the last 20 years we have been performing
prevalence studies in order to ascertain the situation of the antimicrobial
resistance of Staphylococcus in our country. In this study we present the
results of the sixth point prevalence study performed in 2006.
Methods: In a selected day of October 2006, we collected all
staphylococci isolated in 145 Spanish hospitals. All microorganisms were
sent to a reference laboratory where identiﬁcation and antimicrobial
susceptibility testing was performed against 15 antimicrobial agents
using and automated microdilution method (MicroScan). Additional E-
test susceptibility testing was performed for the new antimicrobials
daptomycin and tigecycline. We present the data of 75 hospitals, and
260/223 S. aureus/coagulase negative staphylococci (CoNS) isolates
analysed to date and compare the results with these of the ﬁfth study
performed in 2002.
Results: The percentages of resistance of S. aureus/CoNS against
selected antimicrobials (PEN=penicilin, OXA=oxacillin, ERY=erythro-
mycin, CLI=clindamycin, GEN = gentamicin, TOB = tobramycin, CIP =
ciproﬂoxacin, RIF = rifampin, T/S = trimethoprim/sulfamethoxazole,
VAN = vancomycin), are summarised in the table. Resistance to linezolid,
daptomycin, and vancomycin was found among CoNS (one isolate each).
All strains were susceptible to tigecycline. The most frequent phenotypes
of resistance among methicillin-resistant S. aureus were: ERY+CIP+TOB
(75%); ERY+CIP+TOB+CLI (11%); ERY+CIP+TOB+CLI+GEN (14%).
Fenotype M was present in 40% of isolates.
Percentage of resistance of S. aureus/CoNS to selected antimicrobials
Year Resistance (%), S. aureus/CoNS
PEN OXA ERY CLI GEN TOB CIP RIF T/S VAN
2002 88/79 31/63 33/64 20/35 18/35 ND/ND 37/50 2/7 2/22 0/0
2006 88/90 28/70 32/65 18/44 10/43 26/50 37/53 1/6 0/30 0/0.5
Conclusions: The resistance of S. aureus to methicillin in Spain seems
to be stabilised (28% in 2006 versus 31% in 2002), and strains are
more susceptible to other antimicrobials, mainly to gentamicin and
clindamycin. However, resistance of CoNS to all antimicrobials is
increasing and emerging resistance to the new antimicrobial agents has
been detected
P1825 Antimicrobial resistance of S. aureus strains isolated in
2005 from nosocomial infections in Romania
C.C. Dragomirescu, I. Codita, M. Oprea (Bucharest, RO)
Objectives: obtain information on antimicrobial resistance patterns of
nosocomial S. aureus (S.a.) strains; provide feed-back to participant
laboratories; build a national data base for further action.
Methods: Nosocomial infections case deﬁnitions recommended by the
National Centre for Prevention and Control of Communicable Diseases;
Identiﬁcation of S.a. by tube coagulase test and APIStaph; disc difusion
AST cf. CLSI (formerly NCCLS) standard M100-S15; conﬁrmation
of methicillin resistance by cefoxitin disc difusion and oxacillin MIC;
vancomycin susceptibility by testing for MIC; statistical analysis only
when studied cathegory numbered >30 items.
Results:
– 6 from 17 sentinel hospitals in the National Nosocomial Infections
Sentinel Surveillance System sent 1 to 34 S. aureus strains; the total
number of S.a. strains was 84.
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– 78% of S.a. strains were MRSA.
– Distribution by specimen type of MRSA strains: 18 blood, 27 wound,
7 catheter, 5 umbilical cord and 8 other sites isolates.
– Distribution of all strains by oxacillin MIC’s was trimodal, with peaks
at: 4mg/L (heteroresistant strains), 64mg/L and 512mg/L
– 86% of MRSA strains harboured a KTG aminoglycoside phenotype
– MRSA strains were co-resistant to other antimicrobials: 90.76% to
erythromycin; 52.30% to ciproﬂoxacin, 50.76% to rifampicin, 9.23%
to trimethoprim-sulfamethoxazole and 6.15% to chloramphenicol.
– It was not possible to make separate analysis by hospital, but for
3 hospitals. Proportion of MRSA, MLSBi strains, distribution of
oxacillin MIC’s varied between these hospitals, as did KTG phenotype,
ciproﬂoxacin and rifampicin resistance proportions.
Conclusions:
1. Functioning of the sentinel system in the ﬁrst year yielded to
heterogenous participation of hospitals expressed in heterogeneous
composition of S.a. strains sample received at the national laboratory.
2. Only 3 from 17 hospitals sent a sufﬁcient number of S.a. to be
analysed for the local level.
3. Differences were noticed between the 3 hospitals as to the MRSA
proportions, distribution of oxacillin MIC’s, MLSBi strains, KTG
phenotype, ciproﬂoxacin and rifampicin resistance proportions. These
differences suggest different ways to implement antimicrobials use
policies.
4. Taking precaution on the limited number of strains, these very ﬁrst
data could play a cathalist role to continue the surveillance at the
local, county and national level in order to formulate and adopt
antimicrobial resistance use policies.
P1826 Investigation of erythromycin-resistant staphylococci from
the skin of Egyptian acne patients
T.S.M. El-Mahdy, M.M. Abd-Elaziz, M.H. El-Sayed, J.I. Ross, S. Abd-
Allah, H. Radwan, A.M. Snelling (Bradford, UK; Cairo, Ismailia, EG)
Objectives: Long courses of antibiotics remain the mainstay of
acne treatment. Whilst Propionibacterium acnes is being targeted,
selective pressure is also exerted on other members of the commensal
skin ﬂora, including coagulase negative staphylococci (CNS) such as
Staphylococcus epidermidis. These bacteria may then act as reservoirs
of resistance genes for more pathogenic strains or species. Erythromycin
(ERY) is widely used in Egypt to treat acne, and available over the
counter, but it is not known how this is affecting the commensal ﬂora.
This study sought to determine the prevalence of ERY resistant CNS,
and the genes responsible, from acne patients attending clinics in Cairo.
Methods: Fifty-two acne patients, 13 dermatology staff and 36 controls
were studied. Facial skin swabs were taken, and inoculated onto Mueller
Hinton agar containing 4mg/L ERY (breakpoint concentration). Plates
were incubated at 35ºC for 48hrs. ERY resistant staphylococci were
identiﬁed by standard tests. MIC proﬁles for other drugs commonly
used in dermatology were determined using CLSI criteria. Resistance
determinants were identiﬁed by PCR using primer pairs speciﬁc for
erm(A), erm(B), erm(C), and msr(A).
Results: The prevalence of ERY resistant CNS amongst patients, clinic
staff, and controls was 80.8%, 69.2%, and 66.7%, respectively. These
differences were not signiﬁcant (p> 0.05) and patients on current or
very recent antibiotic treatment were no more likely than those using
other or no medication to carry ERY-R strains. A total of 42 ERY-R
strains were isolated from 42 different patients. 54.5% of these had
high level resistance (MIC> 1024mg/L). The most widely-distributed
erythromycin resistance determinants were erm(C) alone (42.9% strains),
msr(A) (40.5%) or both together (16.7%). Erm(A) and erm(B) were
not detected. Amongst the 42 strains, cross-resistance to tetracycline
(64.3%), clindamycin (9.5%), or fusidic acid (45.2%) was detected.
Conclusions: Although high (80.8%) carriage of ERY resistant CNS
amongst Egyptian acne patients is comparable to that reported from
Western countries, and was not signiﬁcantly different from carriage
amongst the non-patients. Prevalence of msr(A) (>half strains tested)
was much higher than expected, and the driver for this remains to be
elucidated. Carriage of CNS with multiple resistances to drugs used
to treat dermatological conditions was common, and is of concern for
treatment of staphylococcal skin infections in Egypt.
P1827 Prevalence of methicillin-resistant Staphylococcus aureus
with reduced susceptibility to glycopeptides in Belgian
hospitals: results of a multicentre survey
Y. Glupczynski, C. Behrin, D. Allemeersch, M. Andre´,
H. De Beenhouwer, R. Cartuyvels, J. Frans, D. Govaerts, R. Joseph,
I. Phillipart, I. Surmont, A-M. Van den Abeele, J. Verhaegen,
C. Nonhoff, O. Denis, M. Struelens (Yvoir, Brussels, BE)
Objectives: MRSA isolates with decreased susceptibility to glycopep-
tides (GISA/h-GISA) have been reported worldwide. Several studies have
shown that such strains could be associated with a poor clinical outcome.
The aim of the present study was to determine the prevalence of GISA/h-
GISA strains among Belgian MRSA isolates collected from hospitalised
patients.
Methods: Consecutive non duplicate MRSA clinical isolates prospec-
tively collected between 01/2005 and 07/2005 in 13 hospitals were
screened locally for reduced susceptibility to glycopeptides by the
modiﬁed Macromethod Etest according to Walsh et al. (JCM 2001)
and by teicoplanin (5mg/L) agar screen (TAS). Etest MICs of both
vancomycin (VA) and teicoplanin (TP)  8mg/L or of TP alone
>12mg/L and growth on TAS were indicative of potential GISA/h-GISA
or of hetero-teicoplanin intermediate S. aureus (h-TISA). All suspected
strains were sent to the reference laboratory for conﬁrmation by Etest
MIC determination on MH agar as well as by VA and TP population
analysis proﬁles (PAP). Conﬁrmed GISA/h-GISA isolates were also
analysed by PFGE in order to delineate their clonality.
Results: Of 573 MRSA strains tested (mean number of isolates by
centre: 44; range: 30−54), 31 (5.4%) met the phenotype screen criteria
of GISA/h-GISA. Putative GISA strains were found in 10 of the 13
participating labs and their frequency by centre ranged between 0 and
13%. 24 isolates (4.2%) were conﬁrmed as h-TISA and 2 (0.3%) as
GISA or h-GISA by MIC testing (VA MIC of 4 and 8mg/L) and by
PAPs. Origins of the isolates were: lower respiratory tract (11), wounds
(7), blood (4) and urine (2). Fourteen of the 24 h-TISA strains were
resistant to gentamicin by disk diffusion. By molecular analysis, all h-
TISA isolates clustered in two epidemic PFGE groups (A and D) which
were previously reported in h-GISA or in h-TISA isolates in Belgium.
The two GISA strains were clearly unrelated to each other and to the
h-TISA strains. Dissemination of h-TISA isolates belonging to the same
clone resulted in small local outbreaks in six of the centres.
Conclusion: Overall GISA/h-GISA isolates were found in 4.5% of
the Belgian MRSA isolates from hospitalised patients. Most of the
isolates had a h-TISA phenotype. Although uncommon, the occurrence
of GISA/h-GISA among MRSA strains is higher than reported previously
in other surveys in Belgium and could possibly be attributed to the spread
of certain epidemic clones within and across hospitals.
Resistance surveillance in Gram-positives
P1828 Update on daptomycin activity and spectrum when tested
against Gram-positive strains collected in European medical
centres (2006)
H. Sader, P. Rhomberg, T. Fritsche, R. Jones (North Liberty, US)
Objective: As part of the Daptomycin Surveillance Program, we
evaluated the in vitro activity of daptomycin against recent clinical
isolates collected in Europe (2006). Daptomycin is a novel cyclic
lipopeptide recently approved by European Medicines Agency (EMEA)
for the treatment of complicated skin and soft structure infections
(cSSSI).
Methods: A total of 2,907 consecutive strains were collected in 24
medical centres located in nine European countries, Turkey and Israel.
The organisms were isolated mainly from bloodstream infections (52%)
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and cSSSI (18%). The following pathogens were evaluated: S. aureus
(SA; 31% oxacillin [OXA]-resistant [R]); coagulase-negative staphylo-
cocci (CoNS; 75% OXA-R), E. faecalis (EF; 1% vancomycin [VAN]-R),
E. faecium (EFM; 14% VAN-R), beta-haemolytic Streptococcus spp.
(BHS; 235), and viridans group Streptococcus spp. (VGS; 119). The
strains were susceptibility (S) tested by broth microdilution methods
in cation-adjusted Mueller-Hinton broth, additionally supplemented to
50mg/L of calcium for daptomycin tests. Numerous comparators were
also tested.
Results: Daptomycin activity is summarised in the table. Daptomycin
was highly active against SA and CoNS (MIC90, 0.5mg/L) and its
activity was not adversely affected by resistance to OXA or VAN. All
staphylococcal strains were inhibited at the daptomycin S breakpoint of
1mg/L. Daptomycin and linezolid were the only compounds active
against all enterococci. Daptomycin was highly active against BHS
(MIC90, 0.25mg/L) as were most comparison agents tested. Daptomycin
was also very active against VGS (MIC90, 0.5mg/L).
Organism
(no. tested)
Cumulative % inhibited at daptomycin
M IC (mg/L) of:
% Sa
0.25 0.5 1 2 4
SA OXA-S (1,014) 88.4 99.5 100.0 – – 100.0
OXA-P (465) 75.7 99.4 100.0 – – 100.0
CoNS OXA-S (132) 72.0 96.2 100.0 – – 100.0
OXA-R (388) 68.3 98.7 100.0 – – 100.0
Enterococcus spp.
VAN-S (526) 4.0 44.6 87.1 99.4 100.0 100.0
VAN-R (28) 7.1 14.3 71.4 100.0 – 100.0
BHS (235) 100.0 – – – – 100.0
VGS (119) 75.8 97.5 100.0 – – 100.0
aUS-FDA/CLSI interpretive criteria.
Conclusions: Daptomycin showed signiﬁcant potency and broad-
spectrum activity against recent clinical isolates of Gram-positive
organisms isolated in European medical centres, including MDR subsets.
All organisms tested were S to daptomycin and R to other compounds did
not adversely inﬂuence the daptomycin potency against staphylococci,
enterococci or streptococci.
P1829 Activity of daptomycin and selected antimicrobial agents
tested against Gram-positive organisms isolated from
European patients with complicated skin and skin structure
infections
H. Sader, T. Fritsche, P. Strabala, R. Jones (North Liberty, US)
Objective: To evaluated the activity of daptomycin tested against Gram-
positive organisms isolated from patients with complicated skin and skin
structure infections (cSSSI) hospitalised in European hospitals in the last
4 years (2003–2006). Daptomycin has been used for the treatment of
cSSSI in the United States since October 2003 and was recently approved
for clinical use in European countries by the European Medicines Agency
(EMEA).
Methods: A total of 2,725 bacterial strains causing cSSSI were collected
from 24 medical centres located in 12 European countries, Turkey and
Israel. The strains were susceptibility (S) tested against daptomycin
and numerous comparator agents by reference broth microdilution
methods performed according to CLSI documents (M7-A7; M100-S16).
Test medium was supplemented with calcium (50mg/L) for testing
daptomycin only. All quality control results were within published CLSI
ranges.
Results: Daptomycin and selected comparator activities (vancomycin
[VAN], quinupristin/dalfopristin [Q/D], linezolid [LZD] and levoﬂoxacin
[LEVO]) are summarised in the table. Rates of oxacillin-resistant
S. aureus (MRSA) varied widely from 0.7% in Sweden to more than
40% in Greece (41.0%) and Ireland (47.8%). Vancomycin-resistant
Enterococcus (VRE) was observed in Germany, Greece, Ireland, Italy,
Turkey and the United Kingdom, and prevalence remains low in most
European countries relative to the USA. Daptomycin was active against
all strains at the S breakpoint and its activity remained stable over the 4
years evaluated. Daptomycin and LZD showed the broadest spectrum of
activity (100.0% S) among the antimicrobials tested, but daptomycin
was generally more potent (lower MIC50 and MIC90) than LZD.
Non-S to Q/D has increased signiﬁcantly among E. faecium (42.2%;
27.5% at 2mg/L) and also emerged among staphylococci (0.4−0.5%).
LEVO showed limited activity against staphylococci and enterococci.
Resistance (R) to other antimicrobial classes did not adversely affect
daptomycin activity against staphylococci, enterococci or streptococci.
Daptomycin was very active against ORSA (MIC50, 0.25mg/L) and
VAN-R E. faecium (MIC50, 2mg/L).
Organism (no.) MIC90 (mg/L) /% S
Daptomycin VAN Q/D LZD LEVO
S. aureus (1,878) 0.5/100.0 1/100 0.5/99.5 2/100.0 >4/75.5
Coag.-negative staphylococci (235) 0.5/100.0 2/100 0.5/99.6 1/100.0 >4/56.2
E. faecalis (198) 1/100.0 2/98.0 >2/0.0 2/100.0 >4/61.1
E. faecium (51) 4/100.0 1/90.2 >2/58.8 2/100.0 >4/27.5
Beta-haemolytic streptococci (306) 0.25/100.0 0.5/100.0 0.5/100.0 1/100.0 1/100.0
Viridans group streptococci (38) 0.5/100.0 1/100.0 1/100.0 2/100.0 1/97.4
Conclusions: Daptomycin was highly active (100.0% S) against the most
clinically important Gram-positive pathogens causing cSSSI in European
medical centres, including multi-drug resistant organisms. Continued
wide geographic monitoring would be preferred to detect emerging
daptomycin-R strains, especially among strains with compromised VAN
activity.
P1830 Susceptibility of Gram-positive pathogens to daptomycin
and other antimicrobial agents: ﬁrst results from the
DAPTOGERM Surveillance Study
M. Kresken, J. Brauers (Rheinbach, DE)
Objectives: Drug resistance in Gram-positive bacteria has become an
increasing problem over the past 20 years. New antibacterial agents
such as the lipopeptide daptomycin (DPC), which was recently approved
in the EU, have been developed to address this problem. Shortly after
the approval, a surveillance study was started by a network of clinical
microbiology laboratories to monitor the susceptibility of Gram-positive
pathogens to DPC in Germany. This report comprises the results of
isolates of ﬁve frequently encountered Gram-positive species collected
in 49 laboratories during the time period from March to June 2006.
Methods: A total of 1,520 isolates including oxacillin-susceptible
Staphylococcus aureus (MSSA, n = 360), oxacillin-resistant S. aureus
(MRSA, n = 286), Staphylococcus epidermidis (Se, n = 262), Entero-
coccus faecalis (Es, n = 209), Enterococcus faecium (Em, n = 208),
and Streptococcus pyogenes (Sp, n = 195) were tested against DPC,
linezolid (LZD), vancomycin (VAN) and other drugs. First isolates
obtained from hospitalised patients with skin and soft tissue infections,
respiratory tract infections, foreign body/catheter infections, or sepsis
were included. MICs were determined in a central laboratory using the
broth microdilution procedure according to the standard of the German
DIN (Deutsches Institut fu¨r Normung) 58940 guidelines. MICs of DPC
were interpreted by the EUCAST criteria.
Results: The majority of isolates was recovered from wound swabs
(57.7%), blood samples (21.9%) and respiratory tract specimens (8.2%).
MIC50/90 values of DPC for MSSA, MRSA, and Se each were
0.5/1mg/L. All strains were inhibited by DPC at the EUCAST breakpoint
of 1mg/L. LZD and VAN were also active against all staphylococci.
However, based on MIC50/90 values, DPC was up to 4fold more active
than LZD or VAN. Of the Em isolates, 23 (10.9%) were resistant to
VAN. In contrast, none of the Ef isolates exhibited resistance to VAN.
DPC inhibited all strains at 4mg/L. MIC50/90 values of DPC for either
enterococcal species were 2/4mg/L. One Em strain was resistant to LZD
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(MIC 32mg/L). DPC was more active than LZD or VAN against Sp.
MIC50/90 values were 0.125/0.25 for DPC compared to 0.25/0.5 and
1/1 for VAN and LZD, respectively. The highest MICs of DPC for Sp
isolates were 0.5mg/L.
Conclusion: DPC demonstrated excellent in vitro activity against
frequently encountered Gram-positive species including multi-resistant
isolates such as MRSA and VRE. Resistent strains were not detected.
P1831 Comparative in vitro activity of tigecycline against
staphylococci and enterococci from patients on ICU- and
non-ICU wards: results of the German T.E.S.T. Surveillance
Program 2005
M. Kresken, J. Brauers, H. Geiss, E. Halle, E. Leitner, G. Peters,
H. Seifert on behalf of the German T.E.S.T. Surveillance Program
Objectives: Tigecycline (TGC), the ﬁrst glycylcycline antibacterial
agent, has been shown to be highly effective against a wide range
of bacteria including methicillin (oxacillin)-resistant staphylococci
and vancomycin-resistant enterococci. G.-T.E.S.T. is a surveillance
programme comprising 15 German laboratories which monitors the
susceptibility of bacterial pathogens to TGC. The objective of this
study was to evaluate the in vitro activity of TGC against both
ICU- and non-ICU isolates of four clinically important Gram-positive
pathogens, namely Enterococcus faecalis (Es), Enterococcus faecium
(Em), Staphylococcus aureus (Sa) and Staphylococcus epidermidis (Se).
Methods: A total of 271 ICU isolates (52 Ef, 67 Em, 77 Sa, 75
Se) and 452 non-ICU isolates (88 Ef, 69 Em, 208 Sa, 87 Se) were
tested against TGC, doxycycline (DOX), oxacillin (OXA), moxiﬂoxacin
(MXF), gentamicin (GEN), linezolid (LZD), vancomycin (VAN) and
other drugs. MICs were determined by broth microdilution according
to German DIN guidelines in a central laboratory. The MICs of TGC
and LZD were interpreted by EUCAST criteria. DIN breakpoints were
applied to the other drugs.
Results: The rates of OXA resistance in ICU/non-ICU isolates of Sa
and Se were 61/57% and 81/74%, respectively. The susceptibility rates
of ICU/non-ICU isolates to MXF and GEN were 47/45% and 81/87% for
Sa compared to 57/60% and 32/39% for Se. In contrast, all staphylococci
were susceptible to VAN and LZD. TGC exhibited excellent in vitro
activity against all staphylococci including OXA-resistant isolates. It
was equally active against ICU- and non-ICU isolates. Only one OXA-
resistant Sa strain isolated from an ICU patient was resistant to TGC
(MIC 1mg/L). Compared to DOX, MIC90s of TGC were 16- and 2-
fold lower for ICU- and non-ICU isolates of Sa, respectively, and 8fold
lower for both ICU- and non-ICU isolates of Se. TCG also exhibited
excellent activity against enterococci. All strains were inhibited by TGC
at 0.25mg/L. In contrast, 7% and 14% of the ICU/non-ICU Em isolates
were resistant to VAN. High-level resistance to GEN in ICU/non-ICU
isolates of Ef and Em ranged from 30 to 54%.
Conclusion: TGC demonstrated excellent in vitro activity against
staphylococci and enterococci isolated from both ICU- and non-ICU
patients. TGC seems to be a useful drug for the treatment of infections
caused by multiple resistant enterococci and staphylococci, even in
patients on intensive care units.
P1832 Gram-positive bacteraemia due to Enterococcus spp. in
Russian intensive care units: results of a 2-year surveillance
D. Galkin, A. Veselov, O. Kretchikova, E. Riabkova, A. Dekhnich
(Smolensk, RU)
Objectives: Bacteraemia caused by Gram-positive microorganisms is
increasing in prevalence and antimicrobial resistance surveillance is
necessary to optimise antibiotic therapy of the corresponding condition
both at the local and national levels. ICUs are characterised by
accumulation of patients with severe infections and compromising
underlying condition. Hence, it makes adequate empiric therapy crucial
for favourable clinical outcomes.
Methods: A multicentre study was conducted in the period of 2002–
2004 in ICUs of 17 Russian cities to collect Gram-positive blood
isolates and evaluate resistance of Enterococcus spp. to commonly
used antimicrobials. Strains were tested using agar dilution method in
accordance with CLSI 2006 (M100-S16) performance standards.
Results: A total of 205 Gram-positive microorganisms were isolated,
of which Enterococcus spp. accounted for 29.7% (n = 61). Enterococcus
faecalis and Enterococcus faecium constituted for 44.3% (27) of strains
each. Enterococcus species were isolated primarily from the patients with
sepsis – 54.1% (33), pneumonia – 13.1% (8), and bacterial endocarditis –
8.2% (5). Susceptibility of the strains was evaluated to ampicillin,
chloramphenicol, gentamicin, ciproﬂoxacin, levoﬂoxacin, moxiﬂoxacin,
tetracycline, streptomycin, vancomycin, teicoplanin, linezolid. All
the strains (100%) were susceptible to glycopeptides and linezolid.
Resistance rates (I+R) of E. faecalis to ampicillin was 11% with
MIC50/MIC90 of 1/16. Gentamicin, tetracycline, ciproﬂoxacin and
chloramphenicol were not active against these strains with resistance
rates of 100%, 74.1%, 77.7%, and 55.6%, respectively. Levoﬂoxacin and
moxiﬂoxacin were slightly more active with resistance rates of 25.9%
and 18.5%. All (100%) E. faecium strains were resistant to ampicillin,
ciproﬂoxacin, gentamicin and streptomycin. Resistance to levoﬂoxacin,
moxiﬂoxacin, chloramphenicol, and tetracycline was 92.5%, 88.8%,
62.9%, and 37.1%, respectively.
Conclusion: Glycopeptides and linezolid are recommended to use for
empiric therapy of bacteraemia caused by Enterococcus species in ICU
patients. Ampicillin is another option for the therapy of E. faecalis
bacteraemia.
P1833 A cost-effective study of VRE surveillance in a Greek
university hospital
N. Charalambakis, M. Pantelaki, K. Chatzigeorgiou, M. Kapi,
N. Siafakas, L. Galani, L. Zerva (Athens, GR)
Objectives: Enterococci with acquired resistance to the glycopeptides
(VRE) have emerged in European hospitals necessitating prompt
identiﬁcation. Enterococcal speciation and susceptibility determination
by automated systems (including Phoenix by Becton Dickinson) remains
problematic. While performing a VRE surveillance study, a cost-effective
approach of rapid and accurate pathogen identiﬁcation was developed.
Methods: A rectal swab was collected from all consenting hospitalised
patients (n = 132) and was inoculated into vancomycin (6mg/mL)
containing Enterococcosel Agar and Broth (BD). Phoenix was used
for speciation and susceptibility testing supplemented by PYR, motility
and pigment production. When indicated, vanco and teico E-tests
were performed (Biodisk). A PCR assay conﬁrmed speciation and
glycopeptide resistance of VRE strains. Reagent cost and number of
performed tests were recorded; test results were analysed in order
to develop the most cost-effective approach for performing a VRE
surveillance study.
Results: A total of 99 isolates were obtained but only 57 were
Enterococci (44.4% colonisation rate). They were speciated as E. faecalis
(n = 4), E. faecium (n = 11) and E. cass.//gallinarum (n = 42) by Phoenix.
All E. faecium strains demonstrated high level glycopeptide resistance
and were conﬁrmed as E. faecium vanA by E-test and PCR. VRE carriage
rate corresponded to 8.3%. The majority of strains (81%, including all
VRE strains) were isolated from both agar and broth cultures. Among
E. cass./gallinarum strains 78% were motile and 21% produced pigment.
All E. faecalis isolates were vanco-S and teico-S by Phoenix, however,
one dilution lower vanco MICs were obtained by the E-test. Non-motile
E. cass./gallinarum strains demonstrated vanco-S, I or R and teico-S
MICs by Phoenix, while vanco E-testing showed lower MICs. Three
E. cass./gallinarum isolates revealing high level glycopeptide resistance
by Phoenix were vanco-I and teico-S MICs by the E-test. Total reagent
cost for “extended testing” corresponded to 2,760 Euros, but the analysis
of obtained results allowed the development of a “minimally required
testing” approach reducing costs by 29%.
Conclusion: These results show high rates of enterococcal and non-
enterococcal strain isolation on selective media, an overestimation of
vanco MICs by Phoenix, while solid media inoculation sufﬁces for
VRE strain isolation. Signiﬁcantly, cost reduction for performing a VRE
surveillance study is possible.
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P1834 Detection of linezolid-resistant, vancomycin-resistant
Enterococcus strain in Iran
R. Hosseini Doust, S. Yasliany Fard, A. Mohabati Mobarez (Tehran, IR)
Enterococci, and especially the vancomycin-resistant enterococci (VRE),
are recognized as one of the most important causes of nosocomial
infections in seriously ill and immunocompromised patients. Linezolid
has been used in clinical practice for a relatively short period of time;
there are already several reports of linezolid-resistant enterocci. The
sensitivity of Enterococci, isolated from clinical samples, to vancomycin,
linozolide and teicoplanin were determined by disk diffusion. Then the
existence of VanA and vanB genes were assessed by PCR.
We isolated 195 Enterococci of human clinical specimens. Forty (20.5%)
isolates were resistant to vancomycin. Fifteen percent of VRE isolates
were resistant to linezolide. Eighteen percent of VRE strains possessed
the VanA and 10% of them possessed the VanB gene, which confers
high level resistance to vancomycin. When the PCR reactions were
carried out speciﬁc and predicted size amplicons of vanA (734 bp)
and VanB 420bp were observed. Of six linezolid resistant isolates, 2
(33.3%), 1 (16.6%) and 1 (16.6%) were E. casseliﬂavus, E. gallinarum
and E. faecium respectively.
These results are important for developing control strategies point of
view. The spreading of glycopeptide and lineozolid resistance strains of
Entrococci is becoming more serious in the healthcare institutions.
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P1835 Genotypic characterisation of Mycobacterium tuberculosis
isolates from Bogota´, Colombia based on IS6110-based
restriction fragment length polymorphism
J. Hernandez, F. de la Hoz, M. Murcia (Bogota, CO)
Objective: The aim of this study was to provide the ﬁrst insight of the
molecular epidemiology of Tuberculosis in Bogota´ – Colombia.
Methods: A total of 137 M. tuberculosis complex strain obtained were
systematically cultured from pathological samples from 1995 to 2006.
The data for each patient included sex, age, HIV serological status, and
the following microbiological data: data of sampling, smear microscopy
results and strain identiﬁcation. All isolates were tested for susceptibility
to antimicrobial agents according to the proportional method. Extraction
of DNA from mycobacterial strains and DNA ﬁngerprinting with
standard IS6110-based RFLP method were performed on all isolates.
RFLP ﬁngerprint images were analysed by using Gelcompar II software
(Applied Maths) version 4.6. Clusters were deﬁned as isolates showing
identical restriction fragment length polymorphism patterns.
Results: RFLP analysis was performed on 129 isolates from Bogota´.
The numbers of IS6110 copies per isolate varied from 5 to 25. A total
of 96 (74%) different IS6110 ﬁngerprints patterns were identiﬁed and
35 isolates (26%) were clustered into 17 groups consisting of two to
four isolates. Direct epidemiological links could no be established from
most of the cases in clusters. Age, sex, drug resistance and positive
sputum smear were not signiﬁcant associated with molecular clustering
(p> 0.05). In contrast HIV-1 was associated with molecular clustering
(p< 0.05).
Conclusion: The results of our study show a high genetic variation of
M. tuberculosis in Bogota´ Colombia, suggesting that the transmission
results from reactivation of infection adquired in the distant past. In
consequence additional molecular epidemiologic studies are necessaries
to improve the knowledge of transmission dynamics of tuberculosis in
Colombia
P1836 Characterisation of multidrug-resistant Mycobacterium
tuberculosis isolates from Johannesburg, South Africa, by
spoligotyping
C. Mlambo, R. Warren, T. Victor, A. Duse, E. Streicher, E. Marais
(Johannesburg, Tygerberg, ZA)
Objective: The development of drug resistance and the emergence of
multidrug-resistant tuberculosis (MDR-TB) is a threat to TB control
globally. The estimated proportion of MDR-TB cases in South Africa
ranges from a median of 1.6% (range 1−2.6%) among new cases
to a median of 6.6% (range 4–13.9%) among re-treatment cases,
depending on the Province. There is however, limited information
on Mycobacterium tuberculosis genotypes currently circulating in the
country. The objective of the study was to determine the population
structure of MDR-TB strains in the greater Johannesburg area, using
molecular techniques.
Methods: Spacer oligonucleotide typing (spoligotyping) was used to
analyse 270 consecutive MDR-TB isolates collected from June 2004 to
February 2006 at the National Health Laboratory Service TB division,
which receives the bulk of samples in the region. The spoligotyping
results were compared to the World Spoligotyping Database of the
Institut Pasteur de Guadelope.
Results: A total of 247 (92%) different spoligotypes were found in the
spoligotyping database, whereas the remaining 23 (8%) were orphan
types. A major proportion of the strains (23%) belonged to the LAM
family. The proportions of the strains that belonged to the remaining
families are as follows: 20% to T, 14% to Beijing, 9% to EAI and
8% to the S/F28 family. The remaining strains belonged either to the
CAS family, X family or the U family. Strains from the Beijing family
are spread throughout the world and are often associated with drug
resistance.
The drugs recommended for treatment of TB in South Africa are
isoniazid, rifampicin, ethambutol and streptomycin. Our study showed
that the majority of strains (57%) from patients who have MDR-TB were
resistant to all the ﬁrst-line drugs.
Conclusion: This is the ﬁrst study to detail the molecular types of MDR-
TB strains in Johannesburg. It highlights the diversity of the strains
that are circulating in the area and the high proportion of MDR-TB
strains that are resistant to all the ﬁrst line anti-TB drugs. These ﬁndings
could have a signiﬁcant impact on TB disease control programmes in
the region, especially as these strains are the precursors to extensively
resistant strains (XDR TB).
P1837 Three years of universal molecular epidemiology of
tuberculosis in Almeria (Spain), a setting with a high
proportion of TB in immigrants
M. Martı´nez, D. Garcı´a de Viedma, M. Sa´nchez, M. Rogado,
M. Cabezas, W. Sa´nchezYebra, M. Herranz, R. Ferna´ndez, J. Martı´nez,
M. Lucerna, P. Barroso, I. Cabeza-Barrera, F. Dı´ez, M. Rodriguez,
M. Esca´mez, P. Marı´n, A. Lazo, J. Gamir, J. Vazquez, C. Gutierrez
on behalf of the INDAL-TB group
Objective: To evaluate the TB transmission patterns in a population with
a high proportion of immigrant cases.
Background: Almeria has a high intensive agriculture production,
responsible of a calling effect for immigrants.
Methods: 469 TB cases were communicated in the period 2003–
2005, among them 283 (60.3%) microbiologically conﬁrmed and
233 (49.7%) in foreigners [Africa-Magreb 94 (40.3%) cases, Africa
Sub-Saharan 56 (24.0%), East-Europe 38 (16.3%), Latin-America
33 (14.2%)]. Microbiology: Samples were inoculated on to Lo¨wenstein
and BacT/ALERT®MP (bioMe´rieux) media. The isolates were identiﬁed
by means of a genomic probe (Gen Probe, USA). Genotyping:
M. tuberculosis (MTB) isolates were ﬁngerprinted by IS6110 RFLP,
Spoligotyping, and MIRU-VNTR with the set of 15 loci. MTB isolates
were considered to be clustered if their MTB genotypes shared identical
RFLPtypes (for patterns with more than 6 bands) or also identical
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spoligotypes and MIRUtypes (for cases with less than 6 RFLP bands).
Cases with suspicious of being false positive due to laboratory cross-
transmission were excluded. Epidemiology: data were obtained from the
Register of the “Sistema de Vigilancia Epidemiolo´gica de Andalucı´a”
and from standardised interviews of the clustered cases.
Results: At least one MTB isolate from each of 256 (90.5%) patients
were genotyped. Seventy-eight cases (30.6%) were grouped into 26
clusters (range 2−6 members) and the remaining cases (69.4%) were
infected with isolates not shared by other members in the population.
Thirty-eight (27.0%) of 141 foreign-born patients and 40 (34.8%) of 115
Spaniard cases were clustered (p 0.176). Nine clusters (34.6%) included
only autochthonous cases; eight (30.8%) only foreign patients and the
remaining nine clusters included both autochthonous and foreign cases
(34.6%). The standard contact tracing identiﬁed epidemiological links in
only 2 of the 8 clusters constituted by four or more members. However,
the standardised interview of clustered cases could reveal links for 7
clusters.
Conclusions: Our data suggest the occurrence of TB transmission among
the foreign-born population and between the autochthonous and foreign
cases in Almeria. Molecular epidemiology is required in addition to the
traditional contact tracing to reveal novel TB transmission routes in this
area with a high socio-epidemiological complexity.
Finance: Fondo Inv. Sanitaria (PI030986-PI030654), J. Andalucı´a
(248−03, 151−05) and F. Progreso y Salud (14033)
P1838 Molecular analysis of Clostridium difﬁcile by PCR-ribotyping
N. Sadeghifard, B. Kazemi, M. Salari (Ilam, Tehran, IR)
Objectives: This study was aimed to determine the prevalence and
molecular typing by PCR ampliﬁcation of rRNA intergenic spacer
regions (PCR ribotyping) of C. difﬁcile in patients and the hospital
environment in three teaching hospitals in Tehran, Iran.
Methods: During the study period, the stool samples of 1822
hospitalised patients with nosocomial diarrhoea and 100 environmental
samples were cultured and tested by stool cytotoxin assay, toxigenic
culture and enzyme immunoassay. Biochemical identiﬁcation of the
isolates was performed by conventional tests then Chromosomal DNA
was extracted from colonies of C. difﬁcile and PCR ampliﬁcation of
the ISR was carried out using two universal primers complementary to
conserved regions in the 16S and 23S rRNA genes.
Results: Toxigenic C. difﬁcile was isolated from 124 of 1822 (6.8%)
patients analysed and recovered from 17 of 100 (17%) environmental
sites cultured. Among patients with Clostridium difﬁcile –associated di-
arrhoea, 69 patients were male (7.1%) and 55 patients were female (6.5).
There was no signiﬁcant relationships between C. difﬁcile associated
diarrhoea and age of patients. According to PCR-ribotyping results, 27
different PCR-ribotyping patterns were observed among clinical isolates,
4 different PCR-ribotyping patterns among environmental toxigenic
C. difﬁcile isolates and 1 PCR-ribotyping pattern was common among
clinical and environmental isolates. Ribotypes 1−5 were isolated only
from hospitalised patients and some of environmental isolates at Emmam
hospital; ribotypes 6−9 were detected only at Children Medical Center
and ribotypes 10−12 were restricted at Shariati hospital. Ribotypes
13−17 were four distinct clones that were circulating in all three
hospitals. The following ribotypes were common among two hospitals;
ribotypes 18−21 were common among Emmam and Shariati hospitals,
22−25 among Emmam hospital and Children Medical Center and
ribotypes 26−28 among Shariati hospital and Children Medical Center.
Ribotypes 29−32 were observed among environmental isolates.
The predominant ribotypes from the clinical isolates were types 13 and
14, which accounted for 29.9% of all isolates in three hospitals.
Conclusion: Our results suggest that CDAD is an emerging nosocomial
problem in Iran and it will be necessary to evaluate the epidemiology
and measures to control nosocomial spread. These ﬁndings show that
the isolates associated with CDAD in Iran have different PCR-ribotyping
patterns.
P1839 Characterisation of virulence factors in Vibrio cholerae
isolates from the recent cholera outbreak in Senegal
(Sub-Saharan Africa)
M.H. Diallo, A.I. Sow, C.S. Boye, A. Aidara Kane, A. Gassama Sow
(Dakar, SN)
Cholera is an epidemic diarrhoeal disease generally caused by toxigenic
O1 or O139 Vibrio cholerae. Senegal has in last two years experienced
major cholera epidemic with a number of cases totalling more than
23, 325 with approximately 303 fatal outcomes. The most important
virulence factor produced by V. cholerae is cholera toxin (CT) encoded
by ctx gene. The genes encoding zonula occludens toxin (Zot) and
accessory enterotoxin (Ace) are located upstream to the ctx gene on
a dynamic region of V. cholerae chromosome termed virulence cassette.
Toxin co-regulated pilus (Tcp) is a colonisation factor. The aim of our
study is to characterise virulence genes among 50 of O1 clinical V.
cholerae isolates from the last V. cholerae outbreak occurring in 2004–
2005 in Senegal. Virulence genes were characterised by polymerase
chain reaction (PCR) using speciﬁcs primers. Ctx, zot, ace genes were
present respectively in 98%, 88%, and 92%. Most of V. cholerae isolates
have an intact virulence cassette (86%) (ctx, zot, ace genes). This
virulence cassette is absent in one isolate; it was deleted (zot, ace genes)
in two isolates. Both ZOT and ACE play synergetic role with CT in the
epidemic V. cholerae toxicity. Strains did not harbour Tcp gene.
P1840 Double digest selective label: a fast and discriminatory
molecular typing technique for clinical isolates of
Pseudomonas aeruginosa
V. Terletskiy, G. Kuhn, P. Francioli, D. Blanc (Lausanne, CH)
Objectives: To develop a new molecular typing technique for
P. aeruginosa, Double Digest Selective Label (DDSL), which could
be used as an alternative to currently widely accepted pulsed-ﬁeld gel
electrophoresis (PFGE).
Methods: In the DDSL approach, large DNA fragments (produced
by SpeI restriction) which were normally analysed by PFGE were
trimmed by a second frequently cutting restriction enzyme (StuI) to
give smaller fragments. Fragments containing SpeI enzyme overhangs
were selectively tagged with biotinylated dCTP (single-tube digestion/
labelling reaction) and then separated on a conventional agarose gel.
Transfer of resolved double-stranded DNA fragments to a nylon support
was performed immediately after electrophoresis in a vacuum blotter.
Subsequent detection of DNA fragments was mediated with alkaline
phosphatase by colour reaction.
Results: 40 isolates collected during a period of 8 years at the intensive
care units of the hospital were typed by both DDSL and PFGE. Turn
around time was only 12 hours in contrast to 4 days required by PFGE
typing. DDSL gave rise to bands which were generally sharper than those
observed by PFGE typing. Both methods discriminated isolates into 34
different types, resulting in discriminatory power values of 0.990 and
0.989 for DDSL and PFGE, respectively. Two major clusters (8 and 6
related isolates in each) were recognized by both methods, segregation
of subclusters within these groups was however different. Minor clusters
containing two closely related isolates observed with PFGE were also
identiﬁed by DDSL.
Conclusion: DDSL typing of P. aeruginosa in a hospital setting was
found to be as discriminatory as PFGE while time required for analysis
was signiﬁcantly reduced. The technique does not require expensive
specialised equipment and is easy to set up in a microbiological
laboratory.
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P1841 On-site molecular typing of Pseudomonas aeruginosa as an
adjunct to infection control in a paediatric cystic ﬁbrosis
centre
C. Lucas, M. McMillan, D. Brown, C. Williams (Glasgow, UK)
Introduction: Cystic Fibrosis (CF) is a genetically inherited disease
affecting around 1 in 3,000 children and young adults in the UK.
It is characterised by a progressive decline in pulmonary function,
exacerbated by the acquisition of speciﬁc micro-organisms, in particular
Pseudomonas aeruginosa. To date, no cure is available and the life
span of sufferers is directly inﬂuenced by the effectiveness of local
infection control practices. However, at the present time, detection of
cross-infection episodes is entirely dependent on the genotyping service
provided off-site.
Methods: Isolates of Ps. aeruginosa grown from CF patients were
collected throughout 2005. An in-house molecular typing method using
the Random Ampliﬁcation of Polymorphic DNA (RAPD) technique was
developed and genetic proﬁles of the isolates were analysed compared
using BioNumerics v.4.0 computer software.
Results: DNA extracts from 90 Ps. aeruginosa strains grown from 19
CF patients have been analysed using RAPD. Strains determined to
be unique to a single patients by the Reference Laboratory clustered
together, demonstrating >80% homology using RAPD. Transmissible
strains known to be genotypically related, which were cultured from
different patients, demonstrated a similar degree of homology. The
advantage for infection control purposes is the rapid availability of results
with on-site molecular screening.
Conclusions: Initial data indicate that RAPD allows recognition of
unique Ps. aeruginosa strains and allows discrimination between diverse
strains, to a level which is adequate for routine screening purposes.
Introduction of on-site RAPD typing will clarify the relatedness between
local strains, hasten detection of cross infection episodes and facilitate
timely and effective infection control action.
P1842 Epidemiology of Candida krusei and Candida inconspicua
infections in haematology-oncology ward
M. Sikora, E. Swoboda-Kopec, E. Stelmach, B. Interewicz,
A. Domaszewska, A. Majewska, W. Olszewski, M. Luczak (Warsaw, PL)
The need for adequate molecular typing is especially relevant in cases
of pathogens that either increase in clinical prevalance or gain speciﬁc
features increasing their disease-causing capacity. Both factors became
appearent for fungy upon the rise in number of infections in immuno-
incomponent.
Objectives: Analysis of epidemiology of the clinical isolates of
C. krusei and C. inconspicua cultured in 2004 from patients hospitalised
in haematology-oncology ward of the Central Clinical Hospital of
the Medical University in Warsaw and molecular characterisation of
selected strains by RAPD (Random ampliﬁcation of polymorphic DNA)
technique.
Methods: The fungal strains were cultured from stool specimens,
sputum, urine, blood, bile as well as swabs of the throat, mouth, wounds
and perioneum of hospitalised patients. The isolation and identiﬁcation
of cultured fungi was done according to standard mycological procedures
and commercially available tests (bioMe´rieux, Sanoﬁ Diagnostics
Pasteur). Sixty nine selected strains of C. krusei and seventeen strains of
C. inconspicua were further characterised by RAPD technique. PCR
products were analysed by PAGE electrophoresis, silver stained and
evaluated using Syngene software.
Results: The strains were most often isolated from stool samples 60.8%,
sputum 15.7%, and throat swabs 9.8%. Molecular analysis of C. krusei
strains revealed three groups (14, 12 and 7 isolates) with 98% of
relatedness between strains, and 80% for 13 strains. 6 and 2 isolates
of C. inconspicua were similar in 98% and 4 in 80%.
Conclusions: We report a high frequency of C. krusei isolations from
patients hospitalised in the haematology–oncology ward. Molecular
analysis of selected strains points to nonsocomial spread of this pathogen.
P1843 Distribution of Ure C, cagA and vacA genes in Helicobacter
pylori isolated from patients with gastroduodenal disease
in Tehran, Iran
F. Jafari, M. Aslani, L. Shokrzadeh, K. Baghai, H. Dabiri, H. Zojaji,
V. Razavilar, P. Kharaziha, M. Haghazali, M. Molaei, M.R. Zali
(Tehran, IR)
Objective: The aim of this study was to investigate the prevalence of
H. pylori infection and the frequency of UreC, cagA and vacA genes in
H. pylori infection in Iran.
Methods: A total of 280 gastric biopsies from patients who were
qualiﬁed for endoscopies of the upper gastrointestinal tract from
February 2006 to September 2006 were included in this study. These
samples were cultured for H. pylori by conventional methods. The
genomic DNA was extracted from biopsy samples by standard method.
UreC (glmM) gene was ampliﬁed by polymerase chains reaction (PCR),
then genotyping was done based on cagA and vacA (s1/s2/m1a/m1b/m2)
genes.
Results: Out of 280 biopsy samples, 179 (63.9%) patients with
gastroduodenal disease were infected with H. pylori. The number of
positive culture in patients with gastric cancer and duodenal ulcer were
8 (4.5%) and 27 (15.1%) respectively. The cagA gene was ampliﬁed in
133 (74.3%) of the isolated strains. The frequency of vacA genotypes
for s1 (signal region) and m2 (middle region) genotypes were 63.5% and
61.2%, respectively. In 67 (38%) of strains s1m2 genotype was found.
Conclusion: The study demonstrated that vacA s1and m2 genotypes
dominant in Iranian strains were also predominant strains in North
America (60−70%), but not in Middle-East (39%), suggesting the
relation between Iranian strains and European strains. The VacA s1
genotype is the most frequent genotype and there was a correlation
between infections with H. pylori strains carried cagA gene. Moreover
vacA s1/m2 genotypes found the frequent genotype responsible for the
development of gastroduodenal diseases.
P1844 Detection and genotyping of Borrelia burgdorferi sensu lato
in Ixodes ricinus ticks collected in Lithuania
D. Ambrasiene, A. Paulauskas, J. Turcinaviciene (Kaunas, Vilnius, LT)
Lyme borreliosis is the most common tick-borne infectious disease in
humans and domestic animals. The Ixodes ricinus ticks are well known
as major vector of the causative agents of Lyme borreliosis and others
infections diseases. In Europe, Lyme borreliosis is associated with three
genospecies of Borrelia burgdorferi sensu lato: B. burgdorferi sensu
stricto, B. garinii and B. afzelii. These species can cause distinct clinical
manifestations of Lyme disease. B. burgdorferi s.s. can cause arthritis,
B. garinii serious neurological manifestations and B. afzelii a distinctive
skin condition known as acrodermatitis chronica atrophicans. I. ricinus
is a widely distributed tick in Lithuania and may transmit pathogens to
mammalian hosts, including human beings.
The aim of this study: to genotype B. burgdorferi genospecies in
I. ricinus ticks and to determinate dominant Borrelia genospecies by
molecular genetics methods.
Methods: More than 2000 I. ricinus ticks were collected by the ﬂagging
method in Lithuania. Examination of ticks (n = 1679) for the presence
of B. burgdorferi s.l. DNA was performed by PCR with ﬂa gene speciﬁc
primers. For Borrelia genotyping (B. burgdorferi s.s., B. garinii and
B. afzelii) were used multiplex PCRs with genospecies-speciﬁc primers.
Results: The overall prevalence of B. burgdorferi s.l. was 13.3%
(223/1679). 190 samples positive for B. burgdorferi s.l. were used
for genotyping. B. afzelii was found in 141 ticks (74%), B. garinii
in 19 (10%), B. burgdorferi s.s. in 14 (7%). Double infections were
observed in 1% of the infected ticks, other 14 samples (7%) of the
Borrelia infections were non typed.
Conclusions: The molecular tools allow identifying different Borrelia
genospecies which can be maintained in nature and are important for
pathogenesis, diagnostic and preventative implications. It was detected
B. afzelii was the dominant genospecies in Lithuanian ticks. Prevalence
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of genospecies is similar to neighbour country Latvia (B. afzelii 64.9%),
but different from western Germany (B. afzelii 39.9%) and Slovakia and
Southern Poland, where B. garinii is predominant genospecies (45.5%).
It is necessary to have a closer look at the local vertebrate biocenosis
in epidemiological studies of Lyme borreliosis, because reservoir host
population is to be held responsible for special distribution of certain
genospecies.
This study was supported by ENLINO (Environmental Studies in
Lithuania and Norway) and the Lithuanian State Science and Studies
Foundation.
P1845 Borrelia burgdorferi species isolated from different natural
sources in Slovenia
A. Zore, E. Ruzic-Sabljic, F. Strle, T. Trilar, T. Avsic-Zupanc (Ljubljana,
SI)
Objectives: Species of Borrelia burgdorferi sensu lato complex are
differently disposed in nature. The aim of this study was to determinate
Borrelia burgdorferi species in various natural sources: humans with
Lyme borreliosis, vectors – Ixodes ricinus ticks found in woods or on
birds, different reservoir animals: small mammals and birds.
Methods: We tested 103 Borrelia human strains isolated from skin, 148
free living ticks from the meadows or forests and 40 ticks removed from
birds, 12 strains isolated from birds (skin or blood) and 141 urinary
bladders from small mammals. For detection of Borrelia species we
used direct methods: PCR or cultivation and determination with PFGE
or RFLP of PCR products.
Results: In our human isolates we identiﬁed frequently B. afzelii (84%),
rarely B. garinii (14%) and only exceptionally B. burgdorferi sensu
stricto (1%) or B. spielmanii (less than 1%). From ticks collected from
meadows or forests we determined with PCR most frequently B. garinii
(56%), often together with B. afzelii (41%), rarely with B. garini and
B. burgdorferi sensu stricto (32%). Engorged ticks from birds were
infected most frequently with B. garinii, exceptionally with B. afzelii in
only one species of birds (Prunella modularis). In birds we found also
B. valaisiana in blackbird (Turdus merula) and in ticks on the blackbirds
(53%). The most frequently infected birds species were blackbirds (50%).
In this species we detected also mixed infections with B. garinii and
B. valaisiana. B. valaisiana is probably not pathogenic species for
human. We never isolated B. valaisiana from human specimens. In
urinary bladders of small mammals we detected B. burgdorferi sensu
lato in 60% of animals with PCR, frequently B. afzelii (39%), in
almost the same frequency B. burgdorferi sensu stricto (33%) and
only exceptionally in mixed infections B. garinii (8%). In isolates of
B. burgdorferi from urinary bladder in small mammals we determinate
with PFGE always only B. afzelii.
Conclusion: Our study demonstrated that different Borrelia burgdorferi
sensu lato species are adapted to speciﬁc reservoir species. PFGE or
RFLP of PCR products are good tools for determination of different
species of Borrelia burgdorferi sensu lato.
P1846 A real-time PCR assay for typing emerging pneumococcal
serotypes
D. Tarrago, A. Fenoll, I. Obando, D. Sanchez-Tatay, L. Arroyo, J. Casal
(Majadahonda, Madrid, ES)
The need for rapid, reliable, and highly sensitive methods for the
diagnosis and serotyping of invasive pneumococcal disease (IPD) is
becoming more urgent due to the emergence of non-vaccine serotypes
after the introduction of 7-valent conjugate vaccine. Conventional
methods of serotyping as the gold standard Quellung Reaction are
hampered by the need of clinical isolates. PCR based assays could be
used in typing Streptococcus pneumoniae directly from clinical samples
and may be helpful in the epidemiological surveillance of invasive
pneumococcal disease.
Objectives: Development of PCR assays based on Streptococcus
pneumoniae capsular genes for typing pneumococci directly from
clinical samples. Assessment of the assay as diagnostic and pronostic
marker of IPD.
Methods: DNA was extracted from blood, pleural ﬂuid and cerebrospinal
ﬂuid using Qiamp DNA kit (Qiagen). Pneumococcus DNA was detected
using a previously described PCR based on pneumolysin gene. Aligment
of cpsb, cpsf and, cpsk genes of the capsular operon of pneumococci
from most of the 90 serotypes was used to design primers and probes
with Primer Express software v3.0 (Applied Biosystems). TaqMan
probe-based chemistry was used for Real-Time PCR. Ampliﬁcations
were performed on an Applied Biosystems 7300 Fast Real-Time PCR
System and absolute quantiﬁcation plate documents were created and
analysed by Sequence Detection Software v1.3.1
Results: A real-time PCR assay using TaqMan-MGB probes based on
the ampliﬁcation of the capsular genes fragments directly from blood,
pleural ﬂuid and cerebrospinal ﬂuid has been developed for detecting
and serotyping Streptococcus pneumoniae in IPD caused by 1, 5, 14,
19A and 19F serotypes.
The assay is able to detect 10 DNA copies/PCR tube and it has been
tested with clinical isolates and clinical samples including blood and
pleural ﬂuid with reliable results for 1, 3, 5, 19A and 19F serotypes.
In a pilot study to investigate the usefulness of the assay, 55 negative-
culture pleural ﬂuids from empyema cases in children <14 who were
admitted to hospitals in southern Spain were analysed by real-time PCR.
Pneumococcus DNA was detected and typed by PCR in 89% (49/55)
and 58% (32/55) of samples, respectively.
Conclusions: Molecular epidemiological analyses are imperative for the
surveillance of IPD. The results indicate that PCR based assays are
needed to know the actual contribution of the different serotypes to
IPD.
P1847 Detection of phage-associated virulence/resistance genes in
induced prophages of Streptococcus pyogenes clinical isolates
S. D’Ercole, D. Petrelli, S. Rombini, M. Prenna, S. Ripa, L. Vitali
(Camerino, IT)
Objectives: The genome of each sequenced Streptococcus pyogenes
strain shows to contain many prophages encoding proven or putative
extracellular virulence factors and antibiotic resistance determinants.
In this work we determined the presence of prophage-associated
virulence/resistance genes (F-vir) and the induction proﬁle of prophages
harbouring virulence/resistance genes in ﬁfty-nine S. pyogenes pharyn-
geal isolates.
Methods: PCR was used to assess the presence of those genes (i.e. speA,
speC, speH, speI, speK, speL, speM, ssa, spd1, spd3, spd4, sdn, sda, sla,
mefA and TetO) known to be prophage-associated in S. pyogenes.
Each strain was treated with mitomycin C to induce release of functional
phages, and the corresponding unrestricted total DNA was then analysed
by pulsed ﬁeld gel electrophoresis (PFGE). S. pyogenes SF370 and
strain-6 (mefA/TetO) were used as control strains. Single or multiple
bands, corresponding to phage DNA, were obtained only in mitomycin-
treated cells. They were excised and analysed by PCR to detect the
speciﬁc F-vir.
Results: Five percent of the strains did not contain any of the known
F-vir, while 76% had at least two. The distribution of F-vir was greatly
variable and the overall mean number of F-vir per isolate was 3.8 (±
2.3). The release of phage DNA was achieved in 17 strains. Among
these, PCR analysis detected a single F-vir in the phage DNA released
by 35.3% of the strains, and three F-vir in 17.6%. One strain released
phage DNA containing two F-vir, whereas another strain released phage
DNA positive to ﬁve F-vir.
The F-vir most frequently associated with released phage DNAs were
sdn, spd4, speC, spd1 and spd3.
Conclusion: The pharynx is colonised by S. pyogenes harbouring a
variable number and assortment of F-vir. A limited number of virulence
genes are hosted by functional prophages and, therefore, have the
potentiality to be horizontally transferred. Many strains possess different
important F-vir that, at least in the conditions used, cannot be detected
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in released phage DNAs. These results suggest that the population of F-
vir-lacking functional prophages is vast and that the polylysogeny would
be the product of the accumulation of temperate phages that eventually
become defective.
P1848 Molecular epidemiology of Streptococcus pneumoniae asso-
ciated with paediatric invasive disease in the Czech Republic
H. Zemlickova, V. Jakubu, P. Urbaskova, M. Musilek, J. Motlova
(Prague, CZ)
Objectives: To characterise invasive isolates of S. pneumoniae associated
with paediatric invasive disease in Czech children under 6 years of
age by multilocus sequence typing (MLST) and to study the clonality
of the causative serotypes collected prior to the introduction of the
pneumococcal conjugate vaccine into the Czech Republic.
Methods: The strains (n = 124) isolated from blood or cerebrospinal
ﬂuid of children under 6 years of age between 1996 and 2003 were
referred to the National Institute of Public Health by 39 microbiology
labs from 28 cities. Serotyping was performed by Quellung reaction. The
minimal inhibitory concentrations (MIC) of penicillin, erythromycin,
tetracycline and chloramphenicol were determined by the CLSI broth
microdilution method. MLST typing was carried out for all available
isolates (n = 80) of the major predominant serotypes 6B, 14, and 23F.
Results: Overall, 5 (4.0%) strains exhibited reduced susceptibility to
penicillin but only one of these was highly resistant. The resistance
rates to erythromycin, tetracycline and chloramphenicol were 5.6%, 8.1%
and 4.8%, respectively. The most frequent serotypes were 6B (19), 14
(15), 23F (12), 19F (11), 9V (9), 18C (9) and 1 (8). MLST typing was
performed on 80 (64.5%) viable isolates of the above named serotypes.
Nine of 32 revealed sequence types (STs) were newly identiﬁed. Isolates
of serotype 6B were quite diverse: 17 strains yielded 8 clonal lineages
(10 STs). In contrast, isolates of serotypes 1, 9V and 14 were highly
homogenous. Serotypes 1 and 9V were classiﬁed into a single clone
each. Thirteen of 15 isolates of serotype 14 had the same sequence type
(ST124).
Conclusion: The vaccine-included serotypes 6B, 14, 23F, 19F, 9V and
18C are most frequently associated with paediatric invasive disease in
the Czech Republic. Clonality varies between serotypes. The continued
presence of previously described invasive clones of S. pneumoniae was
demonstrated for serotypes 1, 9V and 14.
P1849 Molecular typing of clinical isolates of Escherichia coli by
a new PCR MP method
B. Krawczyk, A. Sledzinska, A. Samet, M. Bronk, J. Komarnicka,
J. Leibner, J. Kur (Gdansk, PL)
Background: Epidemiological typing of bacteria is a routine procedure
used in the investigation of infectious outbreaks and requires accurate
molecular typing methods with high discriminatory power. We had
performed evaluation of a new PCR melting proﬁle (PCR MP) technique
for E. coli strain differentiation. Results were compared with PFGE
method.
Methods: Epidemiologic investigation was shown for E. coli isolates
from patients of the Hematological Unit of Clinical Hospital in Gdansk.
A total of 90 isolates from 36 patients were included. The E. coli were
recovered from blood (66), stool (15), urine (8) of patients with suspected
bloodstream infection. To study the genetic similarities between E. coli
isolates, a new PCR MP method and REA-PFGE were used.
Results: PCR MP analysis distinguished 44 types (H1-H44) among
all isolates studied. One genotype was markedly predominant (H2),
as this was represented by 10 isolates from 4 patients. This genotype
probably represents E. coli strain from hospital infection. The molecular
typing by REA-PFGE found also 44 unique proﬁles. Clustering of REA-
PFGE ﬁngerprinting data matched exactly PCR MP data. The PCR MP
was next investigated for the similarities of the E. coli isolated from
different sites of examined patients. PCR MP ﬁngerprinting analysis
exhibited usefulness for bacterial spread monitoring. As expected, the
related epidemiologically isolates show a high degree of similarity.
Genotype similarity was documented in 10 of 36 patients with E. coli
bacteraemia for whom paired blood and faecal or urine isolates were
available for genomic typing, and probably was the major source of
these bacteraemias.
Conclusion: We found that PCR MP technique is a rapid method that
offers good discriminatory power, excellent reproducibility and may be
applied for epidemiological studies. We suggested that there is at least a
similar power of discrimination between the present gold-standard REA-
PFGE and a PCR MP method. Data presented here demonstrate the
complexity of the epidemiological situation concerning E. coli that may
occur in a hospital.
P1850 The analysis Y. pestis strains from Kazakhstan and USA
by PFGE method
T. Meka-Mechenko, R. Tashmetov, B. Atshabar, L. Nekrassova (Almaty,
KZ)
Objectives: Y. pestis strains from plague foci of Republic of Kazakhstan
differ on phenotypic properties. The differences in plasmid proﬁle and
structure of genes are marked also. The comparative analysis Y. pestis
strains isolated from the natural plague foci of Kazakhstan and USA by
PFGE method are of interest.
Methods: Are investigated by PFGE method Y. pestis 48 strains isolated
in 1938–2002 from the natural plague foci of Kazakhstan and 12 strains
from USA. Strains are isolated from ﬂeas, ticks, wild rodents, domestic
animals and from the plague patients.
Results: Y. pestis strains isolated from autonomous plague of Central
Asian desert natural focus, Volga-Ural steppe autonomous focus, Volgo-
Ural sandy natural focus have identity at the genetic level from
82.6% up to 100%, biotype of these strains is mediaevalis. Only 1
strain from Ustyurt autonomous focus (strain’s biotype is antigua) is
generically close (84.5%) to strain from Tian-Shanian natural plague
focus (Sarydzhas autonomous focus). Two plague strains by genetic
structure are closer to strains isolated in USA (83%) in comparison
with others strains isolated from plague foci of Kazakhstan (77.2%).
In strains isolated from Sarydzhas autonomous focus (Tian-Shanian
natural focus) percent of similarity rather low – 77.2%. One strain with
positive fermentation of glycerine and negative denitriﬁcation 95.7%
of similarity of genetic picture with strain isolated from Moinkum
autonomous focus (Central Asian desert natural plague focus). Others
investigated strains are typical and percent of genetic identity makes
84.5%. The similarity of genetic structure strains isolated from USA
varies from 88.8% up to 100%. Rather low percent of identity plague
strains isolated in plague foci of Kazakhstan (77.2% up to 100%),
is caused landscape-epizootological feature of sites and characteristic
properties of circulating populations of the activator of plague.
Conclusion: The identity plague strains on genetic level depend on
geographical region and from strain’s biotype. In strains concerning
to one biotype and isolated from one natural plague focus percent
of identity at molecular level is high. The received results of
computer analysis and dendrogram of phylogenetic connections between
investigated strains allow to determine their origin that increases
efﬁciency of epidemiological of supervision of plague.
P1851 Molecular diversity of Bacillus anthracis in Kazakhstan
A. Aikimbayev, L. Lukhnova, S. Zakaryan, G. Temiraliyeva, Y. Pazylov,
T. Meka-Mechenko, W. Easterday, M. Van Ert, P. Keim, T. Hadﬁeld,
S. Francesconi, J. Blackburn, M. Hugh-Jones (Almaty, KZ; Flagstaff,
Palm Bay, Washington D.C., Baton Rouge, US)
Objectives: In the central Asian republic of Kazakhstan, anthrax is
endemic and represents a public health concern. In this study we
used high resolution genotyping to examine Bacillus anthracis strain
dynamics among historical outbreaks in Kazakhstan and to understand
Kazakh B. anthracis genetic diversity on a regional and global scale.
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Methods: Isolates were cultured from clinical and environmental
samples from anthrax outbreaks in Kazakhstan spanning a 55 year
period. Archival Bacillus anthracis cultures (N = 92) were grown on
Hottinger blood agar and a QIAamp DNA mini kit (Qiagen) was used
to extract DNA from colonies using the manufacturer’s protocol. Eight
VNTR (MLVA-8) markers were ampliﬁed using primers and conditions
according to Keim et al. (2000). Electrophoresis of PCR products was
performed on an ABI 310 genetic analyser and data was analysed
using Genemapper software (ABI, Foster City, CA). UPGMA cluster
analysis of VNTR data from the 92 Kazakh isolates and the ‘diverse
89’ genotypes presented by Keim et al. was used to establish genetic
relationships (Mega 3.1).
Results: UPGMA cluster analysis of isolates with complete MLVA-8
data (N = 88) identiﬁed 12 MLVA subtypes and comparison with the
‘diverse 89’ genotypes revealed that the majority of isolates (n = 74)
belonged to the A1a genetic cluster, 6 isolates belonged to the A3b
cluster, and 2 isolates belonged to the A4 cluster. Over half of the A1a
isolates belong to previously described genotypes (38/74), including G3
(N= 15), G6 (N= 2) and G13 (N= 21). Two Kazakh MLVA types (N= 6)
appear to represent new sub lineages in the ‘A’ branch.
Conclusion: This study provides the ﬁrst description of the genetic
diversity of B. anthracis in this Central Asian region. The data
presented here are useful for retrospective epidemiological analyses
and are valuable baseline data for future epidemiological investigations.
The genetic data describes novel lineages and genotypes and furthers
our understanding of the global diversity and evolutionary history of
B. anthracis.
This research was made possible by ﬁnancial support from the U.S.
Defense Threat Reduction Agency (DTRA) under the project KZ-1 and
administered by U.S. Civilian Research and Development Foundation.
P1852 Direct comparison of pulsed-ﬁeld gel electrophoresis and
multilocus sequence typing
O. Dobay, F. Rozgonyi, F. Walsh, M. Diggle, K. Nagy, S. Amyes
(Budapest, HU; Edinburgh, Glasgow, UK)
Objectives: Pulsed-ﬁeld Gel Electrophoresis (PFGE) and Multilocus
Sequence Typing (MLST) are thought to have similar discriminatory
power. However, although the results from MLST may be more
transportable which may be useful in global epidemiological studies,
PFGE is more sensitive to smaller genomic arrangements and potentially
more discriminatory. In this study, we compare the two methods directly
with Streptococcus pneumoniae.
Methods: PFGE was performed on 30 routine Scottish clinical isolates
of serotype 14 with identical MLST pattern (sequence type, ST). MLST
was performed on 26 Hungarian isolates of very similar PFGE patterns,
12 of serotype 6A and 14 of 23F. Serotyping was performed with the
MAST antisera.
Results: PFGE examination of the 30 isolates with identical ST revealed
small differences in the banding pattern indicating very little diversity
in this group. On the other hand, MLST of the 26 strains with similar
PFGE pattern resulted in two main STs (i.e. differences in 6 loci out of
7). One ST comprised the 12 isolates of serotype 6A with identical PFGE
type. The other ST contained 11 isolates of serotype 23F, but these had
1−3 PFGE band differences. The remaining 3 strains (23F) belonged to
two further STs, but these had also only 1−3 band differences from the
others.
Conclusions: Strains identiﬁed as a single ST, did show some diversity
when tested by the more sensitive discriminator of PFGE. Also in the
other way around, strains with 1−3 PFGE band differences, resulted
mostly in identical ST. Our results suggest that for more diverse bacteria
such as pneumococci, MLST categorises them into sharply distinct
groups, as it is based on sequences, while PFGE allows a bit more
genetic variation, being based on fragment differences. Therefore, PFGE
seems to be better at identifying smaller changes that occur at a
certain geographical region within a shorter time period, while MLST
is probably more useful for international comparisons. Interestingly
clustering by both methods showed little diversity within individual
serotypes. However, although the two techniques are very different in
principle, they are equally important in epidemiology.
P1853 Chlamydia trachomatis genotypes and infection rates in
Lisbon, 1991–2005
S. Viegas, J. Gomes, C. Florindo, A. Nunes, M. Ferreira, A. Paulino,
M. Borrego (Lisbon, PT)
Objective: To establish the infection rate of Chlamydia trachomatis (CT)
and CT genotype distribution in Lisbon.
Methods: Urethral, cervical or urine samples were collected (1991–
2005) from 10550 (3810 men, 6740 women) attendees of the major
Portuguese sexually transmitted diseases (STD) clinic.
9783 (1578 men, 8205 women) non-STD attendees from general
practice, family planning or urology clinics of the Lisbon area were
also evaluated.
The laboratory diagnose of CT was performed in Instituto Nacional de
Sau´de Dr. Ricardo Jorge (INSA), Lisbon, through direct immunoﬂuo-
rescence or culture in McCoy cells (1991–1994), and PCR-Amplicor
(Roche) (1994–2005). Isolates were genotyped through a modiﬁed
protocol of the nested-PCR ﬁrst described by Lan et al, 1994.
Results: During the study period, CT positivity rates [9.1% (965/10550)]
were 2.1-fold higher among STD attendees, than in non-STD attendees
[4.3% (421/9783)]. Overall, this bacterial STI were found more often in
men (9%) than in women (5%).
The mean positivity of CT infection didn’t exhibit a major evolution
since 1991 in both STD (7.8% in 1993 to 7.7% in 2004) and non-STD
populations (7.4% in 1991 to 7.1% in 2004).
Genotype E was the most frequent among STD and non-STD attendees
(41.8% and 42.9% respectively) followed by F (13.1% and 19.7%
respectively). Genotype D/Da was the 3rd most frequent in STD
attendees (12.3%) and G (12.3%) among the non-STD’s. The 4th most
frequent was G for STD attendees (11%) and D/Da for the non-STD’s
(11.3%). Genotypes H, I, and J/Ja were found at lower percentages
and genotypes A, B/Ba, C, K and L2 were rarely found. Mixed and
untypeable infections were found more often among STD’s (3.1%) than
in non-STD’s (1%).
Conclusions: Surprisingly, the number of diagnosed chlamydial
infections didn’t exhibit a major evolution since 1991, despite a slight
decline more obvious among STD-attendees.
The distribution of CT genotypes is similar to the described in the
literature and to previous results of our laboratory (Borrego et al,
1997); however, in the 1991−7 period there was an unusual prevalence
of genotype H among STD clinics female attendees that is no longer
observed. We speculate that the higher occurrence of mixed infections
among STD attendees could relate to sexual risk behaviours. Genotype
E remains the most frequent either because is the best adapted to the
host or because is the most disseminated; this issue is currently under
evaluation in our laboratory.
P1854 Rethinking the applicability of Tenover criteria: a model
algorithm and a new dendrogram approach for the direct
and wider application
I.C. Acuner, C. Eroglu (Samsun, TR)
Objectives: Modiﬁed Tenover criteria (MTC) propose the difference
that is greater than two genetic events (i.e. >eight band difference)
as the criterion for unrelated isolates. However, in the investigation of
outbreaks, PFGE patterns of the isolates are mostly evaluated on the basis
of various similarity indexes to construct similarity matrices, and then to
generate dendrograms through various methods. One of the most used
dendrogram generation methods, UPGMA, together with the assured
statistical signiﬁcance by bootstrapping, is claimed to produce results in
concordance with MTC. Although their biological basis is more relevant
than the other methods, Tenover criteria didn’t ﬁnd much ground for
direct application. In this study, direct applicability of MTC by the use
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of an algorithm to detect the related isolates within the limit of one
genetic event difference has been investigated.
Methods: Based on the variables such as genetic variation mechanism
with or without affecting the restriction site existence or emergence,
relative event position and length, genetic event number, band difference,
position, and intensity, in a set of hypothetical PFGE genotypes and in the
Escherichia coli strains with known whole genome sequences, random
and calculated PFGE patterns are generated, respectively. Consequently,
related genotypes up to three genetic event differences have been
investigated by the application of an algorithm that compares each
PFGE genotype, to the “index” PFGE genotype and a new dendrogram
approach has been adapted.
Results: One genetic event differences that may occur with different
mechanisms as described by MTC were succesfully detected by the
developed algorithm and shown to be distinguishable from each other.
MTC display a special pairwise symmetry in the genetic event types.
MTC cause triangle inequality and hidden histories like the other above
mentioned methods. The selection of the index isolate of an epidemic
seems critical. MTC can not exclude the probability of the occurrence of
PFGE genotypes that may have greater than two genetic event differences
with lower than nine band differences. Direct application of MTC in two
and more genetic events may become so complex that it does not allow
clear-cut interpretation.
Conclusion: It has been shown that MTC can be applicable for
automated direct use in the analysis of large sets of epidemic isolates
by PFGE through an algorithm within the limit of one genetic event
difference.
P1855 Heterogeneity of Chlamydia trachomatis L2 strains involved
in the current outbreak of Lymphogranuloma venereum
T. Meyer, H.J. Stellbrink, S. Fenske, G. Stary, A. Geusau,
A. von Krosigk, A. Plettenberg (Hamburg, DE; Vienna, AT; Munich, DE)
Objectives: Since 2003 an outbreak of lymphogranuloma venereum
(LGV) among men having sex with men (MSM) was recognized,
which has been reported ﬁrst in Rotterdam, and then was also detected
in other European countries and in North America. The disease
mainly represented with anal/rectal symptoms, less frequently with
genital/inguinal manifestations, and rarely with oral/pharyngeal lesions.
The aim of the study was to analyse whether one or multiple Chlamydia
trachomatis strains are involved in the current LGV outbreak.
Methods: C. trachomatis infections were diagnosed by detection of
bacterial DNA using PCR (TaqMan, Roche) and SDA (ProbeTec,
Becton-Dickinson). C. trachomatis genotypes (serotypes) were identiﬁed
by sequence analysis of the VS4 region of outer membrane protein
(Omp) 1. To characterise different strains of LGV genotypes the VS1
and VS2 region of Omp1 were also analysed.
Results: Between July 2003 and October 2006 we have identiﬁed 126
patients with LGV, conﬁrmed by detection of genotype L2. Most of
these patients resided in Hamburg (n = 65), followed by Berlin (n = 29),
Munich (n = 19), and Vienna (n = 10). The majority of the patients were
infected with HIV (n = 69), only two patients were HIV negative. Of the
remaining 55 patients no information about HIV-status was available.
Most of the patients had anal or rectal disease manifestations (98/126,
77.8%). Inguinal lesions (genital ulcer or inguinal lymph node swellings)
occurred in 11/126 (8.7%) of the patients. In one patient LGV manifested
as oral ulcerative lesion. For 16 patients we did not receive informations
about disease manifestations. In 10 patients with anorectal symptoms
the same L2 sequence was identiﬁed, which was 100% identical to
L2b, previously described in Amsterdam. The L2b sequence was also
identiﬁed in one patient with inguinal disease manifestation, but in
another 4 patients with genital or inguinal lesions the L2 sequence was
different from L2b.
Conclusion: Sequence analysis of Omp1 regions indicates that more than
one L2 strain is involved in the current LGV outbreak. Our preliminary
data may further indicate preferential association of individual L2 strains
with different disease manifestations.
P1856 INCF-replicon typing: a study on a widely spread group
of plasmids carrying both virulence and resistance genetic
determinants
L. Villa, A. Garcia, A. Bertini, A. Carattoli (Rome, IT)
Objectives: Plasmids belonging to the incompatibility (Inc) group
F are widespread in the family of Enterobacteriaceae, providing
advantageous traits to their host, encoding antibiotic resistance and
virulence determinants. Recently, they have been found associated to
clinically relevant b-lactamases such as CTX-M-15, CTX-M-9, SHV-5,
SHV-12, DHA-1. The PCR-based replicon typing method (Carattoli et
al. 2005) allows a rapid identiﬁcation of the FII, FIA, FIB and FIC
replicons, however the high level of heterogeneity of the IncF plasmids
requires a further characterisation to better identify and trace their spread.
Methods: Alignment analyses in the region of the FII replicons were
performed on thirty IncF plasmid DNA sequences, including E. coli,
Salmonella, Shigella and Yersinia virulence plasmids, obtained from
reference and clinical strains. Primer pairs were devised on the highly
conserved region of the regulatory antisense RNA, CopA and on the
replicase repA gene to set up a speciﬁc IncF-replicon typing. Plasmids
were typed by these PCRs and DNA sequence analysis of the amplicons.
Results: Three different groups of IncF plasmids were analysed,
classiﬁed and compared by the IncF-replicon typing: (1) CTX-M-15
carrying plasmids isolated in UK and Italy; (2) plasmids from a
collection of human clinical E. coli strains from Spain related to
those previously described in avian pathogenic E. coli; (3) Salmonella,
Shigella, Yersinia, E. coli O157:H7 virulence plasmids. Interesting
correlations were obtained among emerging plasmids circulating in
human clinical isolates with respect to well known reference plasmids
or to plasmids isolated from E. coli from animals.
Conclusion: Resistance plasmids have been described to carry virulence
factors (bacteriocins, siderophores, cytotoxins, or adhesion factors) and
virulence plasmids have been described to carry resistance genes. For
plasmids carrying virulence and resistance linked determinants, an
infective population may be selected for antimicrobial resistance, and
antimicrobial resistance pressure will select the virulence traits. The
acquisition of antimicrobial resistance genes on virulence plasmids,
could represent a novel tool in bacterial evolution, implementing adaptive
strategies to explore and colonise novel hosts and environments. A rapid
method to detect these kind of plasmids could be of great relevance to
monitor their spread and diffusion in relevant clinical isolates.
P1857 Molecular epidemiology of extended-spectrum b-lactamases-
producing organisms of the family Enterobacteriaceae in
Soﬁa, Bulgaria
D. Ivanova, R. Markovska, D. Iordanov, I. Mitov (Soﬁa, BG)
Objectives: High prevalence of nosocomial ESBL-producing Enter-
obacteriaceae in Bulgarian hospitals has been shown previously, but
epidemiological typing of such strains has never been conducted. The
aims of this study were to investigate ESBL-producing isolates of the
family Enterobacteriaceae collected in Queen Joanna hospital, Soﬁa for
phenotypical and genotypic characteristics.
Methods: 160 ESBL-producing clinical isolates: K. pneumoniae
(n = 80), E. coli (n = 68) and S. marcescens (n = 12) were selected and
were characterised by Sceptor MIC/ID system. The ESBL production
was conﬁrmed. The detection and molecular characterisation of the
ESBL-encoding genes of the SHV and CTX-M family were performed
by PCR and PCR-RFLP. RAPD analysis has been used to type a diversity
of microorganisms.
Results: Antimicrobial proﬁles were demonstrated high degree of
diversity of resistance phenotype. All K. pneumoniae strains were
examined by PCR for the presence of blashv genes and a positive
ampliﬁcation was observed for 60 tested isolates. The data from PCR-
RLFP analysis with NheI were showed point mutation at position 238
in all cases. PCR ampliﬁcation with CTX-M-type speciﬁc primers was
positive from 68 E. coli, 30 K. pneumoniae and 12 S. marcescens. As
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was demonstrated PCR-RLFP analysis with PstI and PvuII, all CTX-M
b-lactamases found in tested strains was belonged to the CTX-M-1
cluster. 22 distinct RAPD pattern were obtained for K. pneumoniae, 18
for E. coli and 2 for S. marcescens, respectively. Isolates from the same
wards mostly belonged to 1 or 2 major clones, but we also observed a
number strains with unique patterns. Cases of clonal relatedness between
strains from distinct wards were found.
Discussion: In this study we presented the results of typing ESBL-
producing Enterobacteriaceae strains by combination of phenotypic
and genomic markers. Antimicrobial proﬁles have revealed the high
degree of diversity of resistance phenotype of ESBL-producing strains.
SHV ESBLs have been found predominantly in K. pneumoniae, while
CTX-M in E. coli and S. marcescens. All CTX-M-producung strains
were belonged to the CTX-M-1 cluster. The results of genotypic
typing (RAPD) were indicated that several clones of ESBL-producing
Enterobacteriaceae were associated with either sporadic infection or
cross-infections or outbreaks. The results indicate that ESBL-producing
bacteria are present a signiﬁcant problem and that clonal spread within
hospital may be occurred.
P1858 Molecular typing and pathogenic potential of Listeria
monocytogenes isolates from food and clinical origin
N. Papageorgiou, E. Scoulica, C. Panoulis, S. Maraki, A. Christidou,
Y. Tselentis (Heraklion, GR)
Objectives: The purpose of this study was to correlate the molecular
characters and pathogenic phenotype of Listeria monocytogenes isolates,
of both food and clinical origin which are temporarily and geographically
related. Typing included Pulse Field Gel Electrophoresis (PFGE),
ribotyping and genetic polymorphism of the prfA, plcA, actA and hly
genes. The haemolytic activity of the strains was used for the assessment
of pathogenicity.
Methods: 92 Listeria monocytogenes strains isolated from food and food
processing environment from Massive Feeding Systems in the island
of Crete in Greece and 5 clinical isolates cultivated from 5 patients
hospitalised in the University Hospital of Heraklion Crete. For the PFGE,
the AscI and ApaI restriction enzymes were used. Automated ribotyping
was performed with EcoRI restriction enzyme and the region that
includes the prfA, plcA, hly, and actA virulence genes was completely
sequenced.
The haemolytic activity of the strains was investigated by measuring
spectrophotometrically the lysis of human red blood cells.
Results: A total of 11 different Ribotypes and 23 Pulsotypes were found
among 93 different Listeria monocytogenes isolates analysed.
ActA gene was highly polymorphic. Phylogenetic analysis of ActA
protein sequences showed that Listeria monocytogenes isolates arranged
into 2 main clusters that could be further divided into 12 subclusters.
According to their haemolytic activity strains grouped into a high,
intermediate and low cytotoxicity.
Strains with zero haemolysis had accumulated mutations in the PrfA
protein.
Conclusion: Listeria monocytogenes strains belong to different clonal
groups. Both food and clinical isolates showed differences in haemolytic
activity in vitro. As actA gene was highly polymorphic the DNA
sequencing of this gene can be used as a useful tool for epidemiological
studies. Mutations in the PrfA protein seem to correlate with variability
in haemolytic potential of the strains.
P1859 Variable number of tandem repeats of S. typhimurium in
Ireland
G. Doran, N. DeLappe, J. O’ Connor, D. Morris, M. Cormican,
B. Lindstedt (Galway, IE; Oslo, NO)
Objectives: The discriminatory power of variable number of tandem
repeats (VNTR) was compared to that Pulsed Field Gel Electrophoresis
(PFGE) for the analysis of isolates of DT104 and related phage types.
The current “gold standard” method for molecular typing of Salmonella
spp. is PFGE. This has poor discriminatory power within certain phage
types e.g. DT104 and DT104b. As these phage types account for most
S. Typhimurium isolates a more discriminatory method is desirable.
Methods: Isolates of DT104 (161) DT104b (107) and U302 (2) were
analysed by PFGE according to the Pulse-Net standardised procedure and
by VNTR according to Lindstedt et al. Isolates were collected from 2000
to 2006 and were from human (207), poultry (27), bovine (19), swine
(13) and other sources (4). Fifty isolates were from 15 known small
outbreaks. Proﬁles were analysed by Bionumerics. VNTR proﬁles were
forwarded to the Norwegian Institute of Public Health, for comparison
with known VNTR proﬁles.
Results: PFGE of the 270 isolates yielded 7 patterns, with 95%
belonging to a single pattern. VNTR yielded 88 distinct proﬁles. All
isolates from within a particular outbreak were of the same VNTR
proﬁles. The number of isolates in each proﬁle ranged from single
isolates to 34 isolates. No VNTR proﬁle was conﬁned to a particular
animal source. Some VNTR proﬁles encompassed isolates which were
isolated during a short period of time and therefore may represent
previously undetected outbreaks. VNTR proﬁles were compared to those
in the Norwegian database. Thirty eight Irish proﬁles were new to the
Norwegian bank. Irish proﬁles were indistinguishable to human isolates
from Norway (10), Cyprus (2), Spain (5), Romania (1), Poland (1) and
a canine isolate from Norway.
Conclusion: VNTR was more discriminatory, less time consuming
and less labour intensive than PFGE. It clustered together known
outbreak strains and highlighted other clusters which were also probable
outbreaks. The proﬁles were comparable to proﬁles from other European
countries and many were unique to Ireland.
P1860 Use of multilocus enzyme electrophoresis to examine genetic
relationships among isolates of Klebsiella pneumoniae
M. Rahmati, G. Etemadi, S. Asadi, A. Abdi-Ali, M. Feizabadi (Tehran, IR)
Objectives: Multilocus enzyme electrophoresis was carried out in order
to epidemiological studies and to evaluate the genetic relationships of
Klebsiella pneumoniae in Tehran. The characterisation of electrophoretic
variants of metabolic enzymes reﬂects allelic variations at the
corresponding structural gene locus, and deﬁnes as electrophoretic types
(ET) which correspond to genotypes. The aim of this study was to
determine the antibiotic susceptibility pattern, detection of ESBLs and
analyse the genetic relationships between the strains by Multilocus
Enzyme Electrophoresis (MEE). No information to date is available on
the population genetic analysis of K. pneumoniae in Iran
Methods: 100 isolates of K. pneumoniae were collected from different
clinical samples in two hospitals in Tehran. In addition to antibiotic
susceptibility testing, Extended spectrum b-lactamase enzymes were
detected by both Double Disk Synergy Test (DDST) and Phenotype
Conﬁrmatory Test (PCT). Population genetic of isolates was determined
by Multilocus Enzyme Electrophoresis.
Results: Of 100 isolates, 56% and 20% were from urinary and
respiratory tracts infections, respectively. The other 24% were from other
sources such as blood, wound, CSF, ear, eye, vagina, bone and stool
infections. The highest resistance of isolates was to ampicillin (97%) and
aztreonam (77%), respectively. All strains were susceptible to imipenem
and meropenem. 46% of isolates were ESBLs positive and the resistance
of these strains to ampicillin and cephalexin was 97.83% and 80.43%
respectively. Analysis of the strains with 17 metabolic enzymes produced
51 electrophoretic types (ETs) There was more than one strain in 13
ETs, whereas other strains classiﬁed in separate ETs. Genetic diversity
among strains varied from leucin-tyrisin peptidase (0.733) to Glucose 6-
phosphate dehydrogenase (0.387). Mean genetic diversity among these
strains were determined 0.515.
Conclusion: This present work shows high rate of infections with ESBL
strains in Tehran. MEE revealed the close relationship among isolates of
K. pneumoniae from patients at Tehran hospitals. However polymorphic
loci such as leucin-tyrosin peptidas with a high genetic diversity (0.733)
were observed, MEE differentiated the strains with ESBL phenotype.
MEE as a chromosomal marker is a reliable technique for typing and
discriminating of bacterial population.
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P1861 Genetic proﬁles of intestinal Escherichia coli isolates from
Romanian subjects
C. Usein, A. Palade, N. Popovici, L. Grigore, D. Tatu-Chitoiu,
S. Ciontea, M. Damian, M. Nica (Bucharest, RO)
Objectives: The intestinal microbiota is routinely regarded as a
natural reservoir of strains that might inﬂuence morbidity in humans.
Escherichia coli is a complex species comprising several clones that
could either harmlessly colonise or aggress the host, causing intestinal
and extraintestinal illness. The bulk of E. coli population is divided into
four main phylogenetic groups, namely A, B1, B2 and D, and a link
between phylogeny and virulence was observed.
In an attempt to gain insight into the composition of autochthonal E. coli
human population, we investigated some genotypic characteristics of
strains isolated from the intestinal reservoir of 27 healthy subjects (135
isolates), and 49 subjects with intestinal symptoms (141 isolates).
Methods: The phylogenetic grouping, and the presence of determinants
speciﬁcally associated with E. coli intestinal pathovars were assessed
by PCR-based methods. Pulsed-ﬁeld gel electrophoresis of XbaI
macrorestriction DNA fragments was used for evaluating the clonal
relatedness among circulating strains.
Results: Only 4 of the subjects with diarrhoea carried pathogenic
E. coli strains identiﬁed as EPEC and VTEC. These strains belonged
to B1 and A phylogroups. Strains of phylogenetic group A signiﬁcantly
predominated in both healthy subjects and individuals with acute
diarrhoea (66% vs. 63%). In contrast, strains belonging to B1
phylogenetic group were rare (7%), and were restricted to faecal isolates
from diarrhoea stools. A comparable number of group B2 (14% vs.
20%) and D (18% vs. 11%) strains was identiﬁed in both intestinal
collections. The PFGE patterns analysis revealed the genomic diversity
present among the intestinal isolates of E. coli.
The PCR negative results obtained when targeting virulence determinants
associated with intestinal pathogenicity of E. coli could exclude this
cause of the symptoms, and the great majority of the tested E. coli
faecal isolates in this study could be considered as representing the
normal colonic ﬂora. At the same time, if ExPEC strains are considered
to belong mainly to group B2, and to a lesser extent to group D, one sixth
of the studied isolates could possess the capability of causing infections
when exitting the intestinal niche.
Conclusion: The speciﬁc phylogenetic distribution of E. coli isolates
from Romanian subjects supports the importance of understanding the
structuring of E. coli population as a result of adaptation to various hosts
and geographic environments.
P1862 Evaluation by molecular tools of Brucella persistence in soil
R. Koncan, R. del Campo, S. Bianchi, A. Amendola, A. Mazzariol,
R. Canto´n, F. Baquero, G. Cornaglia (Verona, IT; Madrid, ES; Milan, IT)
Background: Persistence in soil of pathogens such as Brucella has never
been explored with the newly available molecular tools. The aim of this
work was to investigate the biological risk in the waste pit of a vaccine-
producing factory, in which a number of vials originally containing viable
Brucella were being buried over 30 years and subsequently disrupted and
spilt in the soil during the reclamation procedures.
Methods: The contents of the unbroken vials found in the waste
pit were inoculated in Brain-Heart broth, and incubated for 7 days.
Positive cultures were sub-cultivated onto Columbia agar plates, and
a morphological analysis of the resulting colonies was performed. For
bacterial identiﬁcation, DNA was extracted from the different colonies
and ampliﬁed by PCR with general primers based on conservative region
of the 16S ribosomal. Positive amplicons were sequenced and compared
by Clustal analysis with the Genbank data. Speciﬁc primers for Brucella
spp. were also used with the DNA extracted from the vials’ content.
Total soil DNA was extracted by the FastDNA® SPIN Kit for soil
(Qbiogene, Carlsabd, CA, USA). Qualitative bacteriological analysis of
the soil was performed by DGGE experiments, using clinical isolates of
Brucella as the positive controls. Dot-blot assays were also performed
with both the total DNA from soil and the bacteria grown on Brain-Heart.
Results: A total of sixty-nine unbroken vials were studied, six of
them labelled as containing Brucella. Positive cultures were obtained
in twenty-nine vials (42%), and they yielded in all cases contaminant
environmental bacteria, namely Paenibacillus barengoltzii, Paenibacillus
dendritiformis Bacillus thuringensis, Bacillus licheniformis, Bacillus
benzoeorarus, and Ochrobactrum spp. Positive ampliﬁcation with the
speciﬁc primers for Brucella was not successful in any case. This
result was also conﬁrmed by the dot blot experiments. In the DGGE
experiments with the DNA extracted from soil, no band corresponding
to the Brucella size was detected.
Conclusion: Modern molecular tools might help to carry out a
thorough reclamation of putative contaminated areas whilst minimising
the potential biological risks. In particular, they allow assessment of
possible soil contamination by highly infectious bacterial pathogens
such as Brucella, avoiding risk exposure related to the classical culture
techniques.
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P1863 Speciﬁc detection of Candida albicans using real-time PCR
on the LightCycler™
L. O’Connor, M. Ruttledge, M. Maher (Galway, IE)
Objectives: Candida albicans is the fourth most common cause of
bloodstream sepsis in humans. It is estimated that the annual incidence
of severe sepsis in Europe is in the range of 44000–95000 cases.
The ability to diagnose and identify sepsis arising from C. albicans
blood stream infections in the clinical setting is greatly enhanced by
the use of nucleic acid diagnostics (NAD). It is important to rapidly
identify C. albicans as the cause of sepsis in order to rule out bacterial
infection and quickly facilitate the administration of appropriate therapy.
Traditional diagnosis of C. albicans infections can take from 3 to 5
days and requires specialised and experienced staff. Broad spectrum
antibiotics are often administrated before these results are available, and
along with their ineffectiveness against C. albicans, they also increase
the risk of microbial antibiotic resistance characteristics. To aid in rapid
detection of C. albicans a nucleic acid diagnostic test using real-time
PCR on the LightCycler™ has been developed.
Methods: A speciﬁc labelled primer-probe combination was designed
to amplify and detect a segment of the HWP1 gene. The speciﬁcity of
the test was veriﬁed using DNA extracted from geographically distinct
C. albicans reference strains and clinical isolates. In addition, DNA
from other Candida and non-Candida fungal species was also tested.
The speciﬁcity of the test was further cross-checked against DNA from
a panel of bacterial species and human DNA. The detection limit of the
test was established using as template both DNA extracted from serially
diluted overnight culture of C. albicans and DNA from blood spiked
with known numbers of C. albicans cells. DNA for all experiments
was extracted on the MagNA Pure system using DNA isolation kit III
(Roche).
Results: The test was 100% speciﬁc for C. albicans with no cross
reaction with any other non-albcians Candida species, other fungal
species, bacterial or human DNA. The test was also found to be highly
sensitive, reliably detecting between 1 and 10 copies of the target gene
from both culture and spiked blood samples.
Conclusion: A rapid, sensitive nucleic acid test for detection of the
clinical pathogen C. albicans has been developed for use on the
LightCycler™. The key advantage of the test is its speciﬁcity for
C. albicans since over 50% of fungal infections are caused by the
organism.
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P1864 A real-time PCR assay for detection of six common species of
Candida from blood, validated in adult critically ill patients
R. McMullan, L. Metwally, P. Coyle, S. Hedderwick, B. McCloskey,
H. O’Neill, H. Webb, R. Hay (Belfast, UK)
Objectives: One of the major obstacles to improving patient outcomes
in invasive Candida infection is lack of a sensitive, speciﬁc and rapid
test to conﬁrm the diagnosis and provide an early guide to the species
implicated. Such a tool, from which prescribers may infer the likely
antifungal susceptibility proﬁle within a few hours of collecting a
specimen of blood, has the potential to inﬂuence therapy at an early
stage and may improve patient outcomes. We have developed such a
diagnostic test and have evaluated its reliability in adult critically ill
patients.
Methods: Three Taqman-based real-time PCR assays were developed
for identifying up to six Candida species. Target sequences in the
rRNA gene complex were ampliﬁed, using a consensus nested PCR
protocol, to identify Candida albicans, C. parapsilosis, C. tropicalis,
C. dubliniensis, C. glabrata and C. krusei. These take approximately six
hours to complete.
The assays were validated in a single adult intensive care unit (ICU)
over a 16-month period. All patients remaining in the ICU for at least 48
hours were eligible for inclusion and consent was sought from all. Whole
blood and clotted blood specimens were obtained from participants twice
weekly and on each occasion, participants were categorised either as
‘unlikely’ fungal infection, ‘probable’ or ‘proven’, based on published
consensus deﬁnitions endorsed by an EORTC group for use in clinical
trials.
Results: During the study period, 203 patients were evaluated and
were categorised as follows: unlikely = 178, probable = 6, proven = 19.
All patients in the unlikely and probable categories tested PCR negative.
Fifteen of the 19 patients with proven Candida infection tested PCR
positive with four testing negative, although one of these had C. famata
infection. Using the deﬁnitions of ‘proven‘ and ‘unlikely’ infection
as the reference standards (excluding the more ambiguous ‘probable’
group) the assays had sensitivity of 79% and speciﬁcity of 100%. In
this population, when no stringent selection criteria for applying this
diagnostic test were applied, the NPV was 98%, with a PPV of 100%.
Conclusions: These assays provide a reliable diagnostic modality for
rapidly detecting invasive Candida infection in this population as an
adjuct to standard care. Furthermore, speciation, which allows prediction
of azole susceptibility is available on the same day, helping prescribers
to optimise antifungal therapy at an early stage.
P1865 Detection and identiﬁcation of Aspergillus spp. and Candida
spp. by real-time PCR in clinical samples
M.J. Torres, A. Aller, M. Ramı´rez, C. Castro, M. Ruiz, J.M. Cisneros,
I. Espigado, J. Aznar, E. Martı´n-Mazuelos, J.C. Palomares (Seville, ES)
Objective: To develop and evaluate prospectively a real-time PCR assay
for detection and identiﬁcation of Aspergillus spp. and Candida spp. in
patients with suspected IFI.
Methods: Referenced cultures of Aspergillus species and Candida
species were included to determine the analytical sensitivity and
speciﬁcity of the assay.
The ampliﬁcation method used the 18S rRNA genes and the
identiﬁcation of the genus was made by two speciﬁc pair of probes.
The analytical sensitivity of the process was evaluated with suspensions
of A. fumigatus and Candida albicans in ﬁve concentrations (101 to 105
cfu. per ml), and serially diluted DNA of the referred species.
Total genomic DNA extracted from 948 blood samples obtained from
127 patients suspected of having IFI were used.
Results: No cross-reactivity was obtained with any of the collection of
pathogenic and non-pathogenic bacteria and fungi used in the study.
Species identiﬁcation was determined by analysing the Tm of the melting
curves obtained with the speciﬁc probes, ranging from 67.34ºC to
70.7ºC for Aspergillus spp. and from 51.3ºC to 64.5ºC for Candida spp.
Analytical sensitivity for Aspergillus fumigatus was 60 fg using DNA
and 15 conidia using conidial suspensions; and 100 fg and 3 cells for
Candida albicans.
There were 2 cases of proven IA, 3 cases of probable IA and 14 cases of
possible IA. One patient was classiﬁed as having probable Candidiasis,
and 6 cases possible Candidiasis. Only patients with serial positive results
were considered to be PCR positive.
The 2 IA proven cases and 2 of 3 IA probable cases were PCR positive
for Aspergillus and all the cases with probable/possible Candidiasis had
positive PCR results for Candida albicans.
Conclusions: The Light Cycler technique is rapid, accurate, and
reproducible and combines rapid in vitro ampliﬁcation with real-time
species determination and quantiﬁcation of the fungal load. The linear
range of the assay was from 6 to 6×107 fg of Aspergillus DNA and
from 10 to 107 fg of Candida DNA. The assay used provides high
sensitivity and speciﬁcity for fungal detection but more cases are needed
to elucidate the true potential of the technique.
P1866 Comparison of PCR-Reverse Line Blot analysis and
traditional culture of dermatophytes in clinical samples
G. Wisselink, E. van Zanten, K. van Slochteren, M. Kooistra-Smid,
A. Bergmans, R. Wintermans (Groningen, Roosendaal, NL)
Objectives: Traditionally, laboratory detection and identiﬁcation of
dermatophytes consists of culture on selective media and potassium
hydroxide (KOH) tests. This process yields positive results within
approximately 2−6 weeks, and negative results are generated after 6
weeks of incubation. Using PCR followed by Reverse Line Blot (PCR-
RLB) analysis it becomes possible to obtain positive and negative results
within 2−3 days. In this study we compared traditional culture with PCR-
RLB analysis.
Methods: One hundred clinical samples (92 nail, 8 skin) were analysed
retrospectively by PCR-RLB after traditional culture. Samples were
processed using QIAamp® DNA mini kit (Qiagen, Germany) with a
separate pre-lysis step. PCR targeted the ITS region between the genes
coding for 18S and 5.8S rRNA. PCR products were analysed using RLB
[Bergmans et al., in preparation]. The membrane harboured 13 different
probes to identify and discriminate between 9 different dermatophyte
species within 3 genera, namely; T. rubrum, T. mentagrophytes,
T. interdigitale, T. tonsurans, T. violaceum, T. verrucosum, M. canis
(complex), M. audouinii and E. ﬂoccosum.
Results: Culture, KOH and PCR-RLB analysis yielded 18/100, 39/99
and 58/100 positive results respectively. Six samples showed inhibition
in the PCR-RLB; one of these samples was KOH positive and all
were culture negative. All 18 culture positive samples scored positive
in the PCR-RLB. Seventeen of these 18 samples were identiﬁed as
T. rubrum both by PCR-RLB and by culture; one sample was identiﬁed as
T. mentagrophytes by culture, whereas PCR-RLB identiﬁed this sample
as T. interdigitale. Forty samples scored positive in PCR-RLB but
negative in culture. In these samples PCR-RLB identiﬁed 27 T. rubrum,
8 T. interdigitale, 2 Trichophyton spp. and 3 unidentiﬁed fungi. In twenty
samples PCR-RLB scored positive where both culture and KOH scored
negative. Sensitivity for the PCR-RLB compared to culture is 100%
(18/18), compared to the KOH the sensitivity of PCR-RLB is 92%
(35/38)
Conclusion: These data show PCR-RLB to be a fast and very sensitive
method to detect and identify dermatophytes compared to traditional
culture methods. Molecular assays are known to be more sensitive than
culture or microscopic techniques. Therefore it is very likely that the
PCR-RLB positive, culture negative samples are in fact positive.
P1867 Detection of fungi in hospital water supplies using
molecular beacons
P. Bowyer, L. Hoare, D. Denning (Manchester, UK)
Objective: Immunocompromised patients are susceptible to fungal
disease and it is thus extremely important to both prevent exposure
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to fungi via hospital water supplies and monitor possible sources of
exposure in units dealing with such individuals. Sensitive, rapid detection
and identiﬁcation of fungi in these environments is therefore important.
Black materials were demonstrated in water in a single leukaemia
ward and an investigation was launched to identify the source of the
contamination.
Methods: Samples were prepared by ﬁltration of 1l of water through
a 0.4 micron ﬁlter followed by direct extraction from the ﬁlter using
a MoBio Ultraclean Soil DNA kit and the presence of fungus was
determined using RT-PCR with a fungal speciﬁc molecular beacon.
The beacon was constructed so as to recognize all fungi and provide
a basic measure of the level of fungal contamination. Fungal biomass
was quantiﬁed using a standard curve based on cloned Aspergillus target
DNA and a further curve based on serial dilutions of genomic DNA.
Results: 26 water samples were processed. Results show presence
of high levels of fungal DNA in water from 3 particular tap and
shower sources on particular days. The fungus was identiﬁed as
Ochroconis by standard mycological methods. No infections were
documented. Subsequently the mains water was provided from a separate
uncontaminated source.
Conclusion: These results show the usefulness of beacon based
molecular diagnostics for the rapid detection of contaminating fungi.
This provides a rapid and sensitive method to identify fungal
contaminants.
P1868 Identiﬁcation of dermatophytes by using in-house databases
of sequences of the ribosomal DNA internal transcribed
spacers
H.C. Li, J.P. Bouchara, M.M. Hsu, R. Barton, T.C. Chang (Tainan,
TW; Angers, FR; Leeds, UK)
Objectives: The aetiologic agents of the dermatophytoses are classiﬁed
in three anamorphic (asexual) genera, Epidermophyton, Microsporum,
and Trichophyton. The traditional identiﬁcation of dermatophytes is
sometimes delayed or problematic because of atypical microscopic
structures or colony appearances. This study evaluated the feasibility
of sequence analysis of the ribosomal DNA internal transcribed spacer
1 (ITS1) and 2 (ITS2) for identiﬁcation of dermatophytes.
Methods: The ITS regions of 71 reference strains (19 species) were
ampliﬁed by PCR and sequenced. The determined sequences and
reference sequences available in GenBank were used to construct the
in-house ITS1 and ITS2 databases. The efﬁcacies of the databases were
then validated by testing 131 clinical isolates of dermatophytes that
were identiﬁed to species level by morphological characteristics. Strains
producing discrepant identiﬁcations between the conventional methods
and ITS sequence analysis were further analysed by sequencing of the
D1-D2 domain of the large-subunit rRNA gene for species clariﬁcation.
Results: By sequence comparison with the in-house ITS1 and ITS2
databases, the correct identiﬁcation rates of clinical isolates by ITS1 and
ITS2 sequence analysis were 98.7% and 100%, respectively. In addition,
signature sequences were found in the ITS1 regions of Trichophyton
rubrum and T. violaceum, and in the ITS2 regions of Microsporum
audouinii and M. ferrugineum. These signature sequences are useful
for species delineation in case of the result of sequence comparison is
ambiguous.
Conclusion: Identiﬁcation of medically relevant dermatophytes by ITS
sequencing, especially the ITS2 region, is reliable and can be used as
an accurate alternative to the conventional identiﬁcation methods. The
present method could be ﬁnished within approximately 24 h starting from
isolated colonies.
P1869 Evaluation of a new commercial real-time PCR for the de-
tection of Aspergillus spp. in serum and respiratory samples
M.P. Hayette, C. Meex, R. Boreux, P. Huynen, P. Melin, P. De Mol
(Liege, BE)
Objectives: Diagnosis of invasive aspergillosis is still disappointing
and often delayed because of the lack of sensitivity of diagnostic
tools. DNA detection based-methods have been developed, but differ
widely and comparisons are difﬁcult to assess. The objective of the
study is to compare a new commercial real-time PCR kit, afﬁgene®
Aspergillus tracer assay, with an in house nested PCR targeting 18S
rRNA Aspergillus sp. gene.
Methods: Twelve patients at risk for invasive aspergillosis were included
in the study. They were classiﬁed to have possible (5 cases), probable
(1 case) or proven (6 cases) invasive aspergillosis following E.O.R.T.C.
criteria. Fifteen serum and respiratory paired samples were collected.
The DNA extraction was performed by using the QIAmp DNA mini
kit® (Qiagen, Germany). All samples were tested by both PCR assays
and respiratory samples were cultured.
Results: Respiratory samples. A. fumigatus, A. niger and A. ﬂavus were
isolated from 10/15 samples; both PCR methods were positive for these
samples except one that was positive for afﬁgene® and equivocal for the
nested PCR. The real-time PCR assay reported cycle thresholds ranging
from 25 to 38. Three of the ﬁve culture-negative samples were negative
by both PCR methods; one of three was negative in afﬁgene® assay
and equivocal by nested PCR; the last sample was positive in afﬁgene®
assay and negative by nested PCR. Serum. Thirteen of ﬁfteen blood
samples were negative by both PCR methods. One sample was equivocal
by nested PCR and was inhibited in afﬁgene® assay despite a culture-
positive paired respiratory sample. The last case was inhibited by the
real-time PCR assay and negative by nested PCR. Nor the nested PCR,
nor afﬁgene® assay could detect any Aspergillus DNA in serum. In total,
there was 93% of agreement between the two PCR assays.
Conclusion: Both methods are in good agreement and can detect at
least three different species of Aspergillus. However, the sensitivity of
both assays does not permit the detection of Aspergillus DNA in serum.
afﬁgene® assay can easy replace the “in house” assay: it allows a fast
and standardised detection of Aspergillus sp. DNA in respiratory samples
without inconvenient due to the handling of PCR products.
Community-acquired bacterial respiratory
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P1870 Prediction of the tuberculosis reinfection rate from the local
incidence
P.R. Hsueh, J.Y. Wang, L.N. Lee, H.C. Lai, H.L. Hsu, Y.S. Liaw,
P.C. Yang (Taipei, TW)
Background: Reinfection is a major contributor to the development
of tuberculosis (TB). It seems that the higher the local incidence, the
higher the frequency of reinfection. Based on a systematic review of the
literature, we established a regression model to predict the reinfection
rate from the local incidence and veriﬁed it using our local data.
Methods: We ﬁrst reviewed the literature for population-based studies.
The relationship between the reinfection rate and local incidence was
examined to generate a regression model. We then used our local data,
obtained by genotyping the clinical isolates from recurrent patients from
1999 through 2004, to verify the algorithm developed.
Results: Of the 24 studies reporting the contributions of reinfection
in recurrent TB, ﬁve were population-based. Statistical analysis
showed that the reinfection rate was signiﬁcantly correlated with the
local incidence (Reinfection Rate = −32.636 + 44.061 Log Incidence)
(p = 0.010, R2 = 0.906). Accordingly, the reinfection rate in Taiwan
(incidence: 62.4 per 100,000 people) was estimated to be 46.5%. In
our hospital from 1999 through 2004, 25 (51.0%) of the 49 recurrent
patients were reinfection.
Conclusions: The regression model we have developed could possibly
predict the TB reinfection rate from the local incidence. This reinfection
prediction algorithm is important and probably helpful in planning and
policy making for TB control programmes. In endemic areas, such as
Taiwan, reinfection might be responsible for >50% of TB cases, and
aggressive surveillance to detect asymptomatic carriers (case ﬁnding)
could be a more important strategy than direct observed therapy for
controlling the disease.
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P1871 Fluctuation in Legionella pneumophila counts and
persistence of DNA subtypes in 15 cooling towers over a
one-year period
S. Ragull, M. Garcia-Nun˜ez, N. Sopena, M. Pedro-Botet, M. Esteve,
R. Montenegro, M. Sabria (Badalona, Barcelona, ES)
Introduction: The presence of Legionella in cooling towers has been
well documented and implicated in most community outbreaks. However,
Legionella counts seem to vary over time. The genotypic variability and
the persistence of Legionella DNA subtypes in cooling towers can help
to identify the source of the outbreak.
Objectives: The aims of this study were to describe the ﬂuctuation in
Legionella counts in cooling towers over a one-year period, the variability
of the chromosomal DNA subtypes and their persistence.
Methods: Fifteen cooling towers, located within a 3-km radius were
selected. All the cooling towers underwent the same maintenance
regimen. The towers were sampled fortnightly over one year. Water
samples were concentrated by ﬁltration and seeded on agar Legionella
GVPC. Four to 10 colonies were selected from each positive culture and
analysed by Pulsed Field Gel Electrophoresis.
Results: Legionella pneumophila was isolated in 13 out of 15 cooling
towers. Five cooling towers were positive only once (range: 66–
306,666CFU/L) and one cooling tower was positive twice (500CFU/L,
3,333CFU/L). In the remaining 7 towers, concentrations of Legionella
ﬂuctuated during the study period ranging from negative cultures up to
2×106 CFU/L in some samples.
Sixteen different DNA subtypes were obtained among the 13 positive
cooling towers. Seven cooling towers had a single DNA subtype. Three
showed two different DNA subtypes and another 3 showed three different
DNA subtypes. The same DNA subtype persisted in the 8 cooling towers
which were positive in more than one sample.
Conclusions: Concentrations of Legionella pneumophila in cooling
towers ﬂuctuate considerably over time. The temporal variation of
Legionella counts in cooling towers limits the usefulness of infrequent
sampling to know the Legionella status. In small geographical areas the
same indistinguishable DNA subtypes may be shared among different
cooling towers and persist over time.
P1872 Study of the possible casual effect of Chlamydophila
pneumoniae on COPD exacerbation
S. Shokouhi, B. Hajikhani, M. Godazgar, M. Samanabadi, M. Sattari,
H. Jamaati, S. Sazgar (Tehran, IR)
Objectives: Chlamydophila pneumoniae is one of the common causative
agents of respiratory system infections. The present study aims to
ﬁnd out the role of Chlamydophila pneumoniae infection in infectious
exacerbation of chronic obstructive pulmonary disease (COPD).
Methods: 65 nasopharyngeal swab specimens of chronic obstructive
pulmonary disease (COPD) patients were studied using ﬂuorescent
antibody staining with Chlamydia speciﬁc conjugated antibody and with
ﬂuorescent microscopes. The patient’s data was analysing by using SPSS
Software (version 13).
Results: A total number of 65 COPD patients (as deﬁned by the
American thoracic society), 53 (81.5%) male and 12 (18.5%) female
were included in the study. 46 (70.7%) subjects had COPD in
exacerbation period, 19 (29.3%) were stable COPD patients. We found
4 positive cases of Chlamydophila infection (6.15%), 3 of which (2 men
and 1 woman) belonged to the exacerbation group and 1 to the stable
COPD patients.
Conclusion: Data analysis revealed that there wasn’t any signiﬁcant
correlation between Chlamydophila infection and COPD exacerbation
(P = 0.848).
P1873 Complaints of cough in patient older than 50 in general
practice: an exacerbation of COPD
L. Broekhuizen (Utrecht, NL)
Objectives: to determine whether COPD (Chronic Obstructive Pul-
monary Disease) is present in patients, older than 50, who present
themselves with complaints of cough at the general practitioner and
are not yet known with COPD.
This objective is one of the objectives of the FRESCO-project. The main
objective of this project is to determine the cost-effectiveness of the most
optimal diagnostic strategy to diagnose COPD in patients older than 50
with complaints of cough in general practice.
Methods: This is a an observational, prospective diagnostic study.
The study population consists of four hundred patients who are older
than 50 years of age and present themselves with a new episode of
cough at the general practitioner and are not known by their general
practitioner with COPD. Inclusion of these patients started in January
2006 by 48 general practitioners in the eastern part of the Netherlands.
Information on signs and symptoms as well as results of additional
tests, namely lung function tests and repeated blood tests (C-reactive
protein and Brain Natriuretic Peptide) are gathered by the general
practitioners, both during the episode of acute cough as six weeks later,
when the patient is in a stable condition concerning cough and other
respiratory symptoms. In addition, the effect of a diagnostic treatment
with prednisolone in stable condition is assessed. Finally, at day 90, all
patients visit an out-patient clinic where state-of-the-art lung function
measurements are done. After this, for all patients the ﬁnal diagnosis,
namely COPD or no COPD and/or other diagnoses like for example
pneumonia or lung carcinoma, is determined by an expert panel, which
consists of a pulmonologist and a general practitioner. This diagnosis is
based on the results of all diagnostic tests.
Results: At this moment, 100 patients have been included in the study.
The ﬁrst results of these patients show that 40 percent of the included
patients with cough have a chronic lung disease, namely mainly COPD
and in fewer cases asthma, that was unknown before.
Other relevant diagnoses were heart failure in one patient, pneumonia in
two patients and one patient had disseminated lung cancer.
Conclusion: in a large part of the patients that are not known with the
diagnosis COPD that present themselves with cough in general practice,
these complaints are in fact an exacerbation of COPD.
P1874 Clinical characteristics of patients with Haemophilus
inﬂuenzae meningitis in Denmark, 1994–2005
T.I. Pedersen, M. Howitz, C. Østergaard (Herlev, Copenhagen, DK)
Objectives: When a new vaccine is introduced in vaccination
programmes the epidemiology of the disease covered by the vaccine
is expected to change (e.g. disease in other age groups, infection
with other non-vaccine types). Our aim is to present clinical and
paraclinical information on Haemophilus inﬂuenzae (Hi) meningitis
cases in Denmark (pop. ~5mio.) after the introduction of the Hi type b
vaccine in the Danish childhood vaccination programme in 1993.
Methods: Information on cases with Hi meningitis has been collected
consecutively since 1980 in the Danish national notiﬁcation system.
Additional clinical and laboratory ﬁndings, including vaccination status,
were collected retrospectively from medical records from the period
1994–2005.
Results: In the period 1994–2005 52 cases with Hi meningitis were
notiﬁed. 24 cases (46%) were less than 5 years of age; median age 14
months (range 0−45), and 28 cases (54%) were 5 years or older; median
age 54 years (range 5−88). No cases were in the age group 8 to 24 years.
Signiﬁcantly more cases under the age of 5 years were infected with
Hi type b (54%, 13/24) as compared to cases 5 years or older (18%,
5/28, Fisher’s exact test P< 0.01). In the age group under 5 years of
age 39% (5/13) of cases with Hi type b meningitis were known to have
received one or more doses of Hi type b vaccine and 3 of these cases
(60%, 3/5) could be deﬁned as vaccine failures. The remaining 8 children
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had either not been vaccinated or had unknown status. Among children
under 5 years of age, a predisposing condition was found in 29% (7/24)
of cases; 6 cases with otogenic focus and 1 case with CSF leakage. Hi
type b accounted for 71% (5/7) of these cases. In cases 5 years or older
a predisposing condition was found in 46% (13/28); 9 with an otogenic
focus, 1 with sinusitis and 3 with CSF leakage.
3 patients (6%) died due to meningitis; 1 premature infant and 2 adults
at 84 and 86 years of age. None of these cases were due to Hi type b.
Hearing impairment among survivors was reported for 23% (6/26) of
cases 5 years or older; 60% (3/5) after a type b and 14% (3/21) after a
Hi type non b meningitis.
Conclusion: Meningitis caused by Hi type b is rare in Denmark after
implementation of the vaccine in the childhood vaccination programme.
Those cases with Hi meningitis we observed had a clinical presentation
and disease outcome as expected, with regards to case fatality rate,
frequently an otogenic focus and a signiﬁcant risk of hearing loss.
P1875 Evolution of H. inﬂuenzae resistance in a chest diseases
hospital, for the period 2001–2006
N. Tsagarakis, A. Gioga, M. Makarona, H. Moraitou, N. Kentrou,
M. Panagi, A. Pefanis, S. Damianidou, S. Kanavaki (Athens, GR)
Objectives: The aim of this study was to investigate the resistance
patterns of H. inﬂuenzae, from strains isolated in ‘Sotiria’ Chest Diseases
Hospital of Athens, within the period September 2001 to September
2006.
Material and Methods: 700 H. inﬂuenzae strains were isolated from
respiratory samples (sputum and bronchial secretions). The culture and
antibiotic susceptibility tests (Kirby-Bauer) were performed according to
NCCLS 2004 guidelines, including the following antibiotics: ampicillin,
amoxicillin/clavulanic acid, cefalothin, cefuroxime, erythromycin, co-
trimoxazole, tetracycline and ciproﬂoxacin. The b-lactamase production
was tested with nitroceﬁne disks (OXOID, UK).
Results: Among all isolates: 152/700 strains were b-lactamase positive
(21.7%), while a gradual increase of the percentage of b-lactamase
positive strains was noted from 2001 (10.9%) to 2006 (27.93%).
167/700 strains were ampicillin-resistant (23.8%). The percentage of
the ampicillin-resistant strains was gradually increased from 10.9% in
2001−02 to 29.73% in 2005−06. Within the total of ampicillin-resistant
strains, 152/167 (91%) were b-lactamase positive (BLPAR), whereas
15/167 (9%) were b-lactamase negative (BLNAR). A consistent increase
of the percentage of BLNAR strains is noted from 0% in 2001−02,
to 9% in 2005−06. A low rate of ciproﬂoxacin resistance was noted
for the study period (0.9%). The percentage of the strains resistant to
erythromycin was almost doubled from 49.5% in 2001−02 to 90.01% in
2005−06
Conclusions: It is interesting that the prevalence of b-lactamase
positive H. inﬂuenzae isolates has been signiﬁcantly increased (3×) and
BLNAR strains have also emerged throughout the decade. In addition,
erythromycin resistance is of great concern, since it has been double
raised recently.
The evolution of H. inﬂuenzae resistant patterns should be taken under
consideration, when empiric antibiotic treatment is offered for upper
respiratory system infections.
P1876 Epidemiology of Haemophylus inﬂuenzae and meningococcal
invasive diseases in a Spanish hospital (1987–2006)
R. Blanco, M. Unzaga, C. Ezpeleta, J. Alava, I. Guerediaga,
B. Amezua, V. Cabezas, R. Cisterna (Bilbao, ES)
Objective: To describe the epidemiology of serogroup C meningococcal
and Haemophilus inﬂuenzae invasive diseases and evaluate the efﬁcacy
of vaccination against them in Basurto Hospital.
Material and Methods: In the Basque Country scheduled vaccination
with meningococcal conjugate vaccine (MCV4) began in 2000, previous
sporadic campaigns of vaccination were performed since 1997. In 1996
the vaccine against Haemophilus inﬂuenzae was implemented too.
We evaluated the number of cases of CSF and bloodstream infections
in the pre-vaccination period compared with those in post-vaccination
period.
Results: The number of cases of serogroup B meningococcal invasive
disease was 62 and 77 in the prevaccination period and post-vaccination
period, respectively. The number of cases of serogroup C meningococcal
invasive disease (SCMID) in the pre-vaccination period were 59 and 29
in the post-vaccination period; only 5 of them were detected in CSF.
Among persons of 18 years and younger, the number of cases of SCMID
reduced from 49 cases in the pre-vaccination period to 9 cases during
the post-vaccination period. Three patients out of them were vaccinated,
one of them was not and in the remaining 5 patients no data were
available. The number of SCMID cases among persons older than 18
years increased from 3 to 16 cases in the post-vaccination period.
The number of cases of Haemophilus Inﬂuenzae invasive infections
(HIID) in the prevaccination period was 65 and 35 in post-vaccination
period, only 2 of them were detected in CSF. Among persons of 18 years
and younger the number of HIID cases reduced from 25 cases in the
pre-vaccination period to 6 cases during the post-vaccination period. One
patient out of them was previously vaccinated, no data of vaccination
were available in the others. The number of HIID among persons older
than 18 years was reduced from 39 to 24 cases in the post-vaccination
period.
Conclusion: Since the introduction of vaccination, the incidence of
meningitis and bloodstream infections by Haemophilus Inﬂuenzae and
serogroup C meningococci in the Basque Country is declining, which is
partly caused by the natural ﬂuctuation in the incidence of serogroup
B meningococci. Nevertheless, the vaccination against serogroup C
meningococcal disease as well as Haemophilus were very effectives and
contributed signiﬁcantly to the decline in the incidence of meningitis.
P1877 Control programme of an outbreak of pneumococcal
pneumonia among residents of a rest home in southern Spain
J. Delgado de la Cuesta, A. Luna, M. Chavez, R. de la Rosa,
J. Fernandez Rivera, S. Gomez, S. Exposito, B. Romero (Seville, ES)
Objective: To assess the effectiveness of a prophylactic programme,
including vaccination against Streptoccus pneumoniae and antimicrobial
therapy, to control an pneumococcal pneumonia outbreak (PPO) among
elder residents in a Spanish retirement home.
Methods: A prospective study to determine epidemiological charac-
teristics of bacterial pneumonia is being developed in our secondary-
care hospital. From January 24–February 24, 2006, seven (21.4%)
out of twenty-nine patients admitted to our hospital with diagnosis of
pneumococcal pneumonia were residents of the same retirement home.
A positive urinary Streptococcus pneumoniae antigen test (BINAX-
NOW®) was demonstrated in all of them. In order to control a possible
PPO, on February 24, 2006 all residents of this rest-home underwent an
epidemiological questionnaire and an exhaustive physical examination.
All healthy 37 residents were treated with a prophylactic antimicrobial
therapy with Amoxicillin (500mg tid 14 days) and vaccinated with 23-
valent pneumococcal capsular polysaccharide vaccine (Pneumovax®).
Oro-nasal samples from all 24 retirement home workers were obtained
for bacterial culture. All residents and workers were followed for three
months after this intervention.
Results: Median age [range] of residents was 83 [61−94] years.
Fourteen (40.4%) were males. None of patients admitted to hospital for
pneumococcal pneumonia died. All of them were discharged to complete
therapy as out-patients. None of the healthy residents had been ever
vaccinated against Streptococcus pneumoniae. All of them accepted to be
vaccinated and received prophylactic antimicrobial therapy (Intervention
rate 100%). No statistical differences were found with respect to age
(Student t-test; p = 0.95) or gender (Mann-Whitney U test; p = 0.43)
between hospitalised patients and healthy residents. None of patients
diagnosed with pneumococcal pneumonia were roommates or were
attended by the same care-worker. All oronasal cultures were negative for
Streptococcus pneumoniae. There were no further cases of pneumonia
after these control measures during the follow-up period.
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Conclusions: Prophylactic intervention programme performed, includ-
ing antimicrobial chemotherapy and vaccination against Streptococcus
pneumoniae, allowed to control an PPO in a retirement home for elder
people. The present study enforced the vaccination againts Streptococcus
pneumoniae among this epidemiological group in our environment
strikingly poorly used instead of its high effectiveness.
P1878 Validation and optimisation of a prediction rule for
hospitalisation or death from lower respiratory tract
infections in elderly patients in primary care
J. Bont, E. Hak, A. Hoes, T. Verheij on behalf of ESPRIT
Objective: Acute lower respiratory tract infections (LRTIs) in elderly
patients often follow a more complicated course. Prediction rules may
support physicians in their treatment options. So far, most prediction
rules have been derived and validated in a hospital setting, while risk
stratiﬁcation is also of great importance to general practitioners. Earlier
we retrospectively derived and externally validated a prediction rule to
estimate the probability of 30-day hospitalisation or death in elderly
patients with LRTI in primary care. The objective of the current study
is to prospectively validate and optimise this prediction rule.
Methods: 1,158 patients aged 65 years or older visiting the general
practitioner with LRTI were included. The main outcome measure was
30-day hospitalisation or death. First the prediction rule was validated.
Next the rule was optimised with data on signs and symptoms by multiple
logistic regression analysis. A new scoring system was derived with the
use of the regression coefﬁcients of the original prediction rule and new
data. The area under the receiver operating curve (AUC) was calculated
for the validated and optimised prediction model.
Results: The original prediction rule performed almost as good in the
prospective cohort as in the retrospective cohort, with an AUC of 0.73
and 0.75 respectively. The optimised prediction rule performed better
with an AUC of 0.81. A low score (11 points) corresponded with a
96% probability of absence and a high score (19 points) with a 28%
probability of presence of the outcome.
Conclusions: Validation shows that the original prediction rule
differentiates well between high- and low-risk patients with LRTI in
primary care. It may support general practitioners in their decision
treating elderly patients at home or referring them to the hospital.
Although the optimised prediction rule has better discriminative power,
it should be validated in another cohort.
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P1879 Aspartate aminotransferase to platelet ratio index for the
evaluation of ﬁbrosis in chronic viral hepatitis
M.A. Yetkin, C. Bulut, M. C¸aydere, F.S. Erdinc, G. Ertem, S. Kinikli,
N. Tu¨lek, H. U¨stu¨n, A.P. Demiroz (Ankara, TR)
The aspartate aminotransferase to platelet ratio index (APRI), developed
for the diagnosis of signiﬁcant liver ﬁbrosis, is calculated by the simple
parameteres used for the routine follow-up of the chronic hepatitis
patients. The aim of this study is to evaluate the value of APRI for
predicting signiﬁcant ﬁbrosis in chronic hepatitis B and chronic hepatitis
C patients.
Chronic hepatitis B and chronic hepatitis C patients who were admitted
to our clinic and performed liver biopsy between 1999 to 2005 were
inclueded into the study. APRI values of 0.50 or less and greater than
1.50 were evaluated for predicting signiﬁcant ﬁbrosis. Fibrosis was
considered to be insigniﬁcant in cases with scores 0 to 1 and signiﬁcant
in cases with scores 2 and 3.
Ninty-seven male and 58 female patients were inclueded into the study.
Chronic hepatitis B was present in 114 patients and chronic hepatitis
C was present in 41 patients. Avarage Knodell and ﬁbrosis score of
the patients were 8.5±3.6 and 1.3±1.0, respectively. Signiﬁcant ﬁbrosis
was detected in 50 of 155 patients and 34 of them were infected
with chronic hepatitis B. Chronic hepatitis C were detected in rest of
them. Avarage age, serum gama-glutamyl-transpeptidase, Knodell scores
and trombocytopenia were detected statistically high in patients with
signiﬁcant ﬁbrosis (p< 0.05). Signiﬁcant ﬁbrosis was observed in 8/43
patients with APRI  0.5, 29/87 (%33) patients with 0.50<APRI 1.5
and 13/23 (%57) patients with APRI> 1.50 (p< 0.05). The combination
of APRI 0.50 and APRI> 1.50 classiﬁed correctly %31 of patients
with and without signiﬁcant ﬁbrosis.
In conclusion APRI can not replace liver biopsy for the detection of
signiﬁcant ﬁbrosis in chronic hepatitis patients, but it might be helpful
in cases in which liver biopsy could not be performed.
P1880 Immunisation of mice with HCV core protein formulated in
montanide-ISA720 and CpG primes CD+8 CTLs and elicits
Th1-Th2 responses
M. Aghasadeghi, M. Sadat, A. Khabiri, F. Rouhvand (Tehran, IR)
Objectives: Hepatitis C (HCV) core protein (HCVcp) is a prime
candidate for a HCV vaccine. HCVcp is the most conserved gene
in HCV genotypes with several well characterised B cell, T cell and
CTL determinants and target cells expressing HCVcp can be identiﬁed
and destroyed by Core-speciﬁc CTLs. Immunisation with recombinant
proteins however, requires formulation in proper adjuvants. Herein we
describe results of evaluating adjuvant effect of M720 (Montanide ISA
720), CPG ODNs and F127 (Pluronic acid) in different formulations
on induction of HCVcp-speciﬁc Th1/Th2 responses and CD+8 CTLs to
HCVcp in BALB/C mice.
Methods: The HCVcp (amino acids 2–122) was expressed in a
T7/arabinose induction system in E. coli and puriﬁed in native condition
on Ni-NTA agarose. Mice were immunised with HCVcp as antigen (Ag)
in following formulations; Ag, Ag-Freund (IFA), Ag-CpG, Ag-M720,
Ag-F127, Ag-CpG-F127, Ag-CpG-M720. Total IgG, IgG-isotypes and
cytokines were quantiﬁed by ELISA. Re-stimulated spleenocytes of
immunised mice by CD8-speciﬁc-HCVcp peptides were analysed for
CTLs by LDH release cytotoxic assay.
Results: expressed HCVcp was identiﬁed as a 21 kd band by SDS-PAGE
and western blotting using anti-penta His and HCV-core mAb and sera
of HCV infected patients. All Immunised mice developed anti HCV-
core antibodies of IgG class but the mean value for M720 and IM720-
CpG groups was signiﬁcantly higher than for other groups. Cytokine
measurement indicated that although CpG and F127-CpG groups showed
the highest IFN-g:IL-4 ratio, the levels of each cytokine separately was
highest for M720 and M720-CpG adjuvated groups. The CLTs of mice
immunised with HCVcp formulated in M720-CpG, M720 and CpG
shpwed the highest percent of speciﬁc lysis at the effector: target ratio
of 20:1, respectively. In contrast, in other HCVcp formulated groups
(F127, F127-CpG, IFA, free HCVcp and control adjuvats) no detectable
HCVcp-speciﬁc CTL responses could be mounted.
Conclusion: HCVcp puriﬁed in native from is capable to elicit different
level of Th1 and Th2 immune responses when administered in a
combination with selected adjuvants. HCVcp administered with M720
or M720-CpG as adjuvants seem to elicit strong and balanced immune
responses and HCVcp-speciﬁc CD+8 CTL.
P1881 High expression of HCV core protein: a comparative study
on effect of 6xHis-tag location (N- versus C-terminal) and
puriﬁcation method for various properties
M. Sadat, M. Aghasadeghi, G. Bahramali, F. Rouhvand (Tehran, IR)
Objectives: Hepatitis C virus (HCV) core protein (HCVcp) as a
multifunctional and conserved protein among various HCV genotypes
is important for diagnosis, vaccine formulation experiments and studies
on HCVcp-mediated pathogenesis. For such studies high amounts of pure
HCVcp might be prepared by heterologous expression. Insertion of His-
tag for puriﬁcation of recombinant proteins has found great application in
different laboratories; however, this procedure may have unwanted effects
on conformation and antigenic properties. In this study, characterisation
of a new E. coli-derived HCVcp as N- or C-terminally His-tagged protein
(N- or C-HCVcp), puriﬁed in both native and denatured condition is
provided.
Methods: The hydrophilic section of HCVcp gene (aa 2–122) was
inserted into pIVEX 2.3 and 2.4a which provided a 6xHis-tag at C- or
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N-terminal of the protein, respectively. E. coli BL21-AI harbouring
constructs were induced by addition of L-Arabinose. HCVcp was
puriﬁed in both native and denatured condition by NI-NTA agarose
and characterised by SDS-PAGE, Immunoblotting and SELDI-TOF mass
spectrometry. Antigenic and immunogenic properties of HCVcp were
evaluated with HCV-infected human and immunised mice sera by ELISA
respectively. Ability of particulate formation of proteins was examined
by immuno-gold electron microscopy.
Results: The yields of protein expression were 25 and 16mg/L in
denatured versus 7 and 4mg/L in native puriﬁcation for N- versus
C-HCVcp, respectively. N-terminal fragmented products of 9 and 11
Kd, which were not due to proteolytic activity but apparently result of
ribosomal release were identiﬁed. However, these fragmented products
were not puriﬁed with C-HCVcp. Diagnostic properties of natively
puriﬁed proteins were predominant and still better for C-HCVcp,
However N-HCVcp reacted with C-HCVcp-Immunised mice sera in
lower titers. Only natively puriﬁed proteins were capable of particulate
formation and assembling to generate VLPs.
Conclusion: Puriﬁcation in denatured/refolding condition may not result
to proper conformation of HCVcp, thereby native puriﬁcation may be
undertaken for any kind of applications. C-HCVcp which can be puriﬁed
as a homogenous product is predominant for diagnostic and pathogenic
studies while N-HCVcp that is puriﬁed as both fragmented and complete
products may be used for generation of antibodies because of better
presentation of linear epitopes which are mostly located on the N-
terminal of HCVcp.
P1882 Hepatitis C virus genotyping: correlation between real-time
PCR and probe hybridisation assays
A. Rossi, A. Bassani, A. Berrone, A. Baj, R. Pulvirenti, A. Toniolo
(Varese, Rome, IT)
Background: In the US, HCV is responsible of 3.1−4.8 million people
chronically infected and of 8−10 thousand deaths per year. Genetic
heterogeneity of virus may account for differences in clinical outcome
and response to treatment. Factors inﬂuencing treatment outcome are
HCV genotype, baseline viral load, liver ﬁbrosis and inﬂammation.
Patients infected with HCV genotype 1 tend to have reduced response
rates in comparison to patients infected with genotypes 2 or 3.
Study design: A conventional HCV genotype method (line probe
hybridisation, LiPA assay) was compared with a real time PCR
genotyping assay (Abbott-Celera) targeting the 5’UTR and NS5B
genomic regions. In the latter method, HCV genotype is obtained by
comparison of cycle threshold values obtained in three PCR reactions
each containing different primer/probe combinations. Probes are labeled
with FAM, VIC, or NED. In reaction 1, the HCV genome is detected
by FAM, genotype 1a by VIC, 1b by NED. In reaction 2, genotype 2a
by FAM, 2b by VIC, 3 by NED. In reaction 3, genotype 4 by FAM, 5
by VIC, 6 by NED. Genotypes other than those mentioned above, are
detected in reaction 1 (FAM) and give an indeterminate result. Sera of
chronically-infected Italian patients were investigated.
Figure 1. HCV genotyping: agreement between results of LiPA and real-
time PCR assays.
Results: 88 samples were genotyped by real-time PCR and conventional
LiPA. Results are summarised in Figure 1. Of 88 samples that had been
genotyped by LiPA, 58 belonged to genotype 1, 11 to genotype 2, 8
to genotype 3, 9 to genotype 4, 1 to genotype 5, 1 contained the 1&4
genotypes. Real-time PCR and LiPA gave concordant results in 86/88
samples (97.7%). The real-time PCR method correctly identiﬁed (at the
subtype level) 56/58 samples (1a and 1b genotypes). LiPA identiﬁed
the above samples as genotype 1. The correct subtype (1a or 1b) was
attributed in only 39/58 cases. One case with mixed infection (1&4) was
identiﬁed by both methods. One case attributed to genotype 1 by LiPA
was given as indeterminate by real time PCR. One case was identiﬁed as
genotype 4 by real-time PCR and as genotype 1 by LiPA. By sequencing
the 5’UTR region it was shown to contain both genotypes 1 and 4.
Conclusions: Results of HCV genotyping by real-time PCR were in
consistent agreement with LiPA results (97.7% of cases). The Abbott-
Celera genotyping assay appeared to allow better discrimination of
subtypes 1a and 1b (p< 0.05). The assay was fast and easy to perform
and allowed to detect mixed infections.
P1883 Evaluation of a new combined hepatitis C antigen/antibody
assay for routine HCV testing of patient samples
P. Vermeersch, B. Van Meensel, M. Van Ranst, K. Lagrou (Leuven, BE)
Objective: To evaluate a new combined hepatitis C antigen/antibody
assay (HCV Ultra, Bio-Rad) in patient samples that were borderline
positive or positive with AxSYM anti-HCV EIA (version 3, Abbott) in
a routine hospital setting. This test was shown to have a smaller window
phase for the detection of acute HCV infection compared to anti-HCV
assays that only detect antibodies.
Methods: The performance of HCV Ultra was determined in 257 sera
that were borderline positive (S/CO= 0.8−1.0) or positive (S/CO> 1.0)
on AxSYM. The group of positive sera consisted of 82 of the 2408 in-
house sera tested over a 2.5 month period and 175 sera referred for con-
ﬁrmatory testing. We also tested 18 sera that were negative on AxSYM.
All sera were tested with Monolisa Plus Anti-HCV EIA (version 2, Bio-
Rad). Sera that were AxSYM S/CO> 1.0 and Monolisa S/CO> 3 were
considered positive. Otherwise immunoblot analysis was performed with
INNO-LIA HCV Score (Innogenetics). When INNO-LIA did not allow
a conclusion (indeterminate), the sample was tested with PCR for the
presence of HCV RNA when enough serum was available.
Results: All 118 sera that were positive with both AxSYM and Monolisa
were positive with HCV Ultra. The results of the 111 other sera that were
not positive with both AxSYM and Monolisa are shown in table 1. A
signiﬁcant number of sera were undetermined with INNO-LIA (13.5%).
These 15 sera were excluded for the calculation of the performance of
HCV Ultra. In 13 of these samples, HCV Ultra gave a correct result.
The sensitivity and speciﬁcity of HCV Ultra on AxSYM borderline and
positive sera was 99% and 95%, respectively. The 18 sera that were
negative on AxSYM were also negative on Monolisa and Ultra. All
sera that were HCV Ultra S/CO 2.5 were from HCV-positive patients.
The positive predictive value for in-house samples was 0% for AxSYM
borderline positive sera and 54% for AxSYM positive sera. The only
serum that was negative with HCV Ultra and positive with INNO-LIA
was from a patient with normal liver enzymes and was negative with
PCR. The 4 sera that were positive with HCV Ultra and negative with
INNO-LIA could be from seroconverters as was conﬁrmed by PCR in
the only patient from which serum was available.
Table 1. Results in samples that were positive with AxSYM and Monolisa
Plus
HCV Ultra\INNO-LIA Negative Positive Undetermined
Negative 78 1 12
Positive 4 13 3
Conclusion: The performance of HCV Ultra in sera that were AxSYM
borderline or positive was excellent. Conﬁrmation testing with INNO-
LIA has little or no added value in sera tested with HCV Ultra.
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P1884 Early prediction of response during high-dose interferon
induction therapy in difﬁcult-to-treat chronic hepatitis C
patients
H.C. Gelderblom, H.L. Zaaijer, C.J. Weegink, M.G.W. Dijkgraaf,
P.L.M. Jansen, M.G.H.M. Beld, H.W. Reesink (Amsterdam, NL)
Background and Aims: The aims of our study were to determine (i) if
early viral kinetics could predict treatment outcome in “difﬁcult-to-treat”
hepatitis C patients during high dose interferon induction treatment, (ii)
if fast-responders ( 3 log drop in HCV RNA at week 4) could stop
treatment at week 24.
Methods: We treated 100 hepatitis C patients (46 previous non-
responders/relapsers (any genotype), 54 treatment-naı¨ve genotype 1
and 4) with triple antiviral therapy: Amantadine hydrochloride and
ribavirin, combined with 6 weeks interferon alfa2b induction (week 1−2:
18 MU/day, week 3−4: 9 MU/day, week 5−6: 6 MU/day), thereafter
combined with weekly peginterferon alfa-2b, for 24 or 48 weeks. Fast-
responders (3 log drop in HCV RNA at week 4) were randomised to
24 or 48 weeks. Patients with <3 log drop in HCV RNA at week 4
(slow-responders) were treated for 48 weeks. Patients with HCV RNA
detectable by PCR at week 24 stopped treatment.
Results: 36 patients achieved SVR: 19 fast-responders after 24
weeks of treatment, 9 fast-responders and 8 slow-responders after 48
weeks of treatment. 64 patients became non-SVR (27 non-response, 9
breakthrough, 15 relapse, 13 dropout). Predictive values of early viral
kinetics were different for treatment naı¨ve patients and previous non-
responders/relapsers. In treatment-naı¨ve patients, PPV for SVR was
100% if HCV RNA was <5 IU/mL at week 1 or 2; PPV for non-SVR
was 100% if HCV RNA was  615 IU/mL at week 12, or  5 IU/mL at
week 16. In previous non-responders/relapsers PPV for non-SVR was
100% if HCV RNA was  615 IU/mL at week 4, or  5 IU/mL
at week 8. Relapse rates among fast-responders treated for 24 or 48
weeks were 27% and 20%, respectively (P=ns). SVR in fast-responders
treated for 24 or 48 weeks was independent of baseline HCV RNA 
or <800,000 IU/mL.
Conclusion: With high dose interferon induction therapy: (i) early viral
kinetics can predict SVR and NR in treatment naı¨ve patients and previous
non-responders/relapsers, (ii) SVR is independent of baseline HCV
RNA.
P1885 Similar early viral kinetics of hepatitis C virus genotypes
1 and 4
H.C. Gelderblom, H.L. Zaaijer, C.J. Weegink, P.L.M. Jansen,
H.W. Reesink, M.G.H.M. Beld (Amsterdam, NL)
Background: Patients infected with hepatitis C virus genotype 2
(HCV-2) or HCV-3 respond better to interferon alfa (IFN-alfa) treatment
than HCV-1 or HCV-4 patients. The mean initial decline in HCV RNA
during IFN-alfa therapy is faster for HCV-2 and HCV-3 compared to
HCV-1 patients. Little is known about early viral kinetics in patients
with HCV-4.
Aims: The aim of our study was to determine genotype speciﬁc
differences in early viral kinetics in HCV-1 and HCV-4 patients during
a modiﬁed treatment regimen with a high initial dose of interferon
(induction).
Methods: We treated naı¨ve patients with HCV-1 (n = 42) or HCV-4
(n = 12) with triple antiviral therapy consisting of amantadine hydrochlo-
ride and ribavirin, combined with 6 weeks of IFN-alfa2b induction (week
1−2: 18 MU/day, week 3−4: 9 MU/day, week 5−6: 6 MU/day), thereafter
combined with weekly Peg-IFN-alfa2b, for 24 or 48 weeks. HCV RNA
was assessed at baseline, day 1, 2, week 1, 2, 4, 6, 8, and then every 4
weeks until end of treatment by: quantitative bDNA (LLD 615 IU/mL),
qualitative PCR (LLD 50 IU/mL), and TMA (Transcription-Mediated
Ampliﬁcation, LLD 5 IU/mL). Viral dynamics were estimated using the
bi-phasic model for HCV during treatment with IFN-alfa.
Results: Baseline HCV RNA levels, and the 1st and 2nd phase decline
in HCV RNA, were similar in HCV-1 and HCV-4 patients (Figure).
Mean time to reach a TMA negative status in patients with subsequent
SVR was shorter in HCV-4 (4.3 ± 2.3 weeks) compared to HCV-1 (6.4
± 4.5 weeks), this difference was not signiﬁcant. SVR was achieved by
43% of HCV-1 and 50% of HCV-4 patients.
Conclusion: Early viral kinetics are similar in HCV-1 and HCV-4
patients, these results conﬁrm that HCV-4 patients should be treated
as HCV-1.
P1886 Meta-analysis of blood scores for liver ﬁbrosis in chronic
hepatitis C
F. Lunel-Fabiani, P. Cale`s, P. Halfon, Y. Bacq, V. Leroy, M.C. Rousselet,
M. Bourlie`re, A. de Muret, Y. Gallois, N. Sturm, G. Penaranda,
M.C. Bre´chot, C. Trocme (Tours, Grenoble, Angers, FR)
Blood scores of liver ﬁbrosis are alternative tools to liver biopsy or
imaging. The aims of this meta-analysis with individual data were to
evaluate the diagnostic accuracy, the centre effect (reproducibility) of
scores and to compare them.
Methods: The populations from 4 independent centres (dosages, liver
interpretation) included 300, 217, 159, and 149 patients with chronic
hepatitis C, i.e. 825 patients. Blood scores included Fibrotest (FT),
FibroMeter (FM), Hepascore (HS) and APRI.
Results: The global characteristics were the following: 44±12 yr, males:
59.5%, Metavir stages: F0: 4.8%, F1: 46.7%, F2: 25.0%, F3: 12.5%,
F4: 11.0%. The 4 populations were signiﬁcantly different for: age, sex,
Metavir score and prevalence of clinically signiﬁcant ﬁbrosis (F2),
severe ﬁbrosis (F3), and cirrhosis (F4). AUROC are listed in the
following table
FM AUROC for F2 was superior to that of FT (p = 0.049), APRI
(p = 0.001) and HS (p< 10−3). AUROC were different according to
centre, e.g. for FM from 0.773±0.042 to 0.883±0.026. The score
proﬁle signiﬁcantly varied as shown by the comparison of disagreement
rate between blood score and liver biopsy (misclassiﬁed patients) as a
function of Metavir stage: this rate was signiﬁcantly superior for FM vs
FT in F1 (22.9 vs 14.7%, p< 10−3) but signiﬁcantly inferior for FM vs
FT in F2 (40.8 vs 62.8%, p< 10−3), F3 (13.3 vs 27.6%, p = 0.003) and F4
(1.3 vs 9.0%, p = 0.07). This disagreement rate blood vs liver signiﬁcantly
varied according to centre, e.g. for F2 and FM from 18.3 to 28.6%
(ANOVA, p = 0.02). By logistic regression, the centre had an independent
role for this disagreement. Likewise, the disagreement rate between
blood scores signiﬁcantly varied according to centre, e.g. for F2, FT vs
FM from 16.9 to 26.3% (ANOVA, p = 0.05). By contrast, Metavir stage,
but not centre, had an independent role for this disagreement.
F2 F3 F4
FibroMeter 0.831±0.014 0.887±0.014 0.923±0.013
Fibrotest 0.803±0.016 0.853±0.016 0.892±0.015
APRI 0.784±0.017 0.836±0.017 0.874±0.019
Hepascore 0.775±0.017 0.834±0.017 0.886±0.019
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Conclusion: This meta-analysis with individual data validates the
published data of accuracy for blood scores of liver ﬁbrosis (except for
HS) and shows signiﬁcant differences between blood scores for global
accuracy and even more as a function of Metavir stage which explains
a population effect.
P1887 Three-year study of hepatitis A, B and C infection
prevalence in a major Greek hospital
V. Karabassi, M. Poujioyka, K. Petrochilou, C. Achilleos, V. Dimitriou,
M. Toutouza (Athens, GR)
Objectives: The purpose of this study was to perform a serological
analysis of Hepatitis A, B and C virus (HAV, HBV and HCV) infection
prevalence in the patients of a Greek major hospital within a three-year
period.
Methods: During the three last years 1/7/2003–30/6/2006, sera from
15,790 patients (13,090 in-patients and 2,700 out-patients), were tested
for the detection of HAV, HBV and HCV markers. There were
4 groups of patients: Group A, 5,065 patients (3,745 in-patients,
1,320 out-patients) who were controlled for HBV surface antigen
(HBsAg); Group B, 10,725 patients (9,345 in-patients and 1,380 out-
patients) who were controlled for the HBV markers HBsAg, HBeAg,
antiHBe, antiHBcore, antiHBs; Group C, 11,160 patients (9,600 in-
patients, 1,560 out-patients) who were controlled at the same time
for HCV-antibodies (HCVAb); and Group D, 1,610 patients (1,230
in-patients, 380 out-patients) who were controlled for HAV-antibodies
(HAVAb, total and IgM). All tests were performed during 2003–2004 by
MEIA methodology (AXSYM – ABBOTT) and during 2005–2006 by
immunoluminometric assay method (ARCHITECT – ABBOTT).
Results: In Group A, of the 3,745 in-patients and 1,320 out-patients,
75 (2%) and 41 (3.1%). respectively, were found to be positive for
HBsAg. In Group B, of the 9,345 in-patients and 1,380 out-patients
there were, respectively, 4364 (46.7%) and 610 (44.2%) seronegative
for HBV markers, 607 (6.5%) and 173 (12,5%) positive for HBsAg,
1,476 (15.8%), 87 (6.3%) positive for antiHBs due to HBV vaccination,
2,897 (31%) and 510 (37%) negative for HBsAg and positive for the
rest HBV markers. In Group C, of the 9,600 in-patients and 1,560
out-patients, HCVAb-positivity was found in 221 (2.3%) and 94 (6%),
respectively. 2% of them were at the same time positive for HBsAg.
In Group D, of the 1,230 in-patients and 380 out-patients HAVAb total
positivity was found in 652 (53%) and 194 (51%) and HAVAb IgM
positivity was found in 25 (2%) and 5 (1.3%) respectively.
Conclusions: This study showed that there is a signiﬁcant prevalence
of HAV, HBV and HCV infection in the patients of our hospital
(53%, 37.5%, 2.3% for in-patients; 51%, 49.5%, 6% for out-patients,
respectively). The effort for the prevention must be continual and the
control measures with the systematic Hepatitis A and Hepatitis B
vaccination should be strictly enforced.
P1888 Spread of hepatitis B and C viruses among healthy people
in Bulgaria
K. Mekouchinov, E. Marinova, A. Kalchev (Soﬁa, BG)
Background: The viral Hepatitis B and C are infections of great social
importance because of their worldwide spread, severe complications and
big economic loss. Bulgaria belongs to the Middle Endemic World Zone
of Hepatitis B Virus (HBV) carriers, with a rate of 3.5%, and to the
Zone with a low rate (1.11%) of Hepatitis C Virus (HCV). Some HBV
and most HCV infections are subclinical or asymptomatic and remain
undiscovered, causing chronic diseases with irreversible complications.
Objectives: To determine HBV and HCV carriers among healthy people
and to udertake an appropriate treatment.
Methods: During the period of 1 year (2005) we investigated 3,387
healthy people, divided in 2 groups: 1,641 in Military Medical Academy,
Soﬁa and 1,746 in Military Hospital, Plovdiv. The detection and
conﬁrmation of speciﬁc antigens and antibodies we performed with
ELISA and Blot tests, respectively.
Results: We found
– HBV carriers 3.05% and 1.78%, respectively in Soﬁa and Plovdiv,
mean 2.39%.
– HCV carriers 0.91% and 0.05%, respectively in Soﬁa and Plovdiv,
mean 0.47%.
Conclusions: Compared with the results obtained in 2004, the 2.39% of
HBV carriers is higher than 2004 (1.11%), but is still lower than whole
Bulgarian population of 3.5%. The 0.47% of HCV arriers is the same
as in 2004, lower than whole Bulgarian population 1.11%.
P1889 Pharmacokinetic proﬁles in chronic hepatitis C patients
treated with high-dose pegylated interferon
A. van der Eijk, J. Vrolijk, R. de Knegt, S. Schalm, A. Osterhaus,
B. Haagmans (Rotterdam, NL)
Objectives: Therapeutic drug monitoring has been implicated in many
antiviral therapies, but not those involving interferon-alpha (IFN-alpha).
We determined early pharmacokinetic and viral kinetic proﬁles in
difﬁcult-to-treat chronic HCV patients treated with high-dose pegylated
(PEG)-IFN-alpha-2a.
Methods: Nine patients were treated with high dose PEG-IFN-alpha-
2a (360mg/week) during the ﬁrst four weeks. We measured PEG-IFN-
alpha levels using a quantitative sandwich IFN-alpha enzyme-linked
immunosorbent assay and quantitated HCV RNA levels (detection limit
103 copies/mL) in plasma for each individual patient at 0, 1, 2, 4, 7, 14,
21 and 28 days after start of therapy.
Results: We observed large variation in pharmacokinetic proﬁles
between individual patients. PEG-IFN-alpha-2a levels were virtually
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undetectable in one virological nonresponder (patient 2). In this case
IFN-alpha speciﬁc antibodies were detected at low levels before start of
treatment and increased after the ﬁrst week of therapy. Using a sensitive
HCV replicon-based IFN bioassay we conﬁrmed that antiviral activity
of PEG-IFN-alpha-2a was abrogated by serum from this patient.
Conclusion: Our study showed two important aspects. First, individual
PEG-IFN-alpha PK proﬁles can be used to identify non-responders to
antiviral therapy. Secondly, the presentation of the ﬁrst patient with
antibodies that neutralise PEG-IFN-alpha in vivo. Future studies need
to address the extent of autoantibody induction by PEG-IFNs. Our
preliminary results from different HBV and HCV PEG-IFN-alpha trials
indicate that 10−20% of the patients developed antibodies against the
different forms of PEG-IFN-alpha.
P1890 Serum adiponectin in chronic hepatitis C and B
D. Siagris, A. Lekkou, G. Vaﬁadis, M. Michalaki, I. Starakis, M. Makri,
V. Margaritis, A. Tsamandas, C. Labropoulou-Karatza (Patras, GR)
Objectives: Adiponectin possesses anti-inﬂammatory, insulin sensitis-
ing, and anti-atherosclerotic properties. The aim of this study was to
assess the levels of adiponectin in patients with chronic viral hepatitis C
and B and correlate them with parameters exploring insulin resistance
and indices of chronic liver disease.
Methods: Seventy-two patients with chronic HCV infection and 73
patients with chronic HBV infection, matched for age and sex were
studied. All individuals were examined for serum concentrations of
adiponectin, insulin, C-peptide and insulin resistance index (HOMA-IR).
Viral parameters and liver histology were also evaluated.
Results: Serum adiponectin levels were found signiﬁcantly higher
in HCV compared to HBV-infected patients. Correlation analysis in
the whole group, demonstrated that serum adiponectin was positively
correlated with aspartate aminotransferase (AST), alkaline phosphatase,
globulins, high-density lipoprotein cholesterol (HDL-C) and staging
score, while it was negatively correlated with body mass index (BMI),
insulin, C-peptide HOMA-IR. Logistic regression analysis identiﬁed type
of infection (HCV versus HBV), alcohol consumption more than 25 g
daily, serum total globulin and low C-peptide as signiﬁcant predictive
variables associated with high adiponectin levels.
Conclusion: Higher levels of serum adiponectin in HCV compared
to HBV patients could have a role in the slower disease progression
of chronic HCV infection. In addition, alcohol intake more than 25g
daily seems to be a signiﬁcant predictor for hyperadiponectinaemia in
patients with chronic viral hepatitis C or B. Finally in this study, a clear
positive association between adiponectin and hepatic necroinﬂammation
or staging score was not found.
P1891 Effect of intrahepatic hepatitis C virus internal ribosomal
entry site activity on the outcome of infection
M. Motazakker, E. McCruden, P. Preikschat, J. Elliott, C. Smith,
K. Oien, E. Spence, R. Elliott, P. Mills (Uromieh, IR; Glasgow, UK)
Introduction: The course of chronic hepatitis C virus (HCV) infection
is variable and unexplained. Hepatic steatosis has been linked to the
progression of ﬁbrosis in HCV and is known to be more common
in genotype (gt) 3 infected patients. This study explores variation
in intrahepatic HCV internal ribosomal entry site (IRES) nucleotide
sequences and outcome of infection.
Method: The translation efﬁciencies of eight gt 1a and eight gt 3a
5™UTR sequences derived from 16 liver biopsies were measured in
cell culture using a dual luciferase reporter system. The values obtained
were then compared to the liver biopsy scores for steatosis and for
inﬂammation and ﬁbrosis (Ishak system) score and serum viral load.
Results: The steatosis scores correlated positively with the presence of
gt 3a (Mann-Whitney test, p = 0.008), increasing viral load (correlation
coefﬁcient (r) = 0.49, p= 0.02) and ﬁbrosis stage (r = 0.47, p= 0.03).
The IRES activity did not correlate with severity of steatosis (r = −0.3,
p = 0.1), inﬂammation grade (r = 0.09, p = 0.6), stage of ﬁbrosis (r = 0.1,
p = 0.5) or with serum HCV RNA levels (r = −0.11, p = 0.6).
Conclusion: The previously reported association of steatosis with
genotype 3, viral load and stage of ﬁbrosis is conﬁrmed. No correlation
was seen between IRES activity and these parameters. The efﬁciency
with which the IRES directs translation of the polyprotein appears not
to be the limiting factor governing the rate of replication of HCV and
pathological features seen in the liver
P1892 Management of pegylated interferon alpha and ribavirin
induced neutropenia and thrombocytopenia in patients with
chronic hepatitis C
T. Htwe, D. Blessman, M. Spain, A. Adamski, A. Mushtaq, J. Koirala,
N. Khardori (Springﬁeld, US)
Objective: Pegylated IFN-alpha and ribavirin is the standard treatment
for chronic Hepatitis C and bone marrow suppression is a major
side effect of that combination treatment. Treating with GCSF
(Granulocyte Colony Stimulating Factor) for Hepatitis C treatment
induced neutropenia is an option while maintaining the effective dose
of pegylated IFN-alpha and ribavirin to reach sustained virologic
response. We use GCSF prospectively in those patients when the absolute
neutrophil count becomes less than 1000/mL and evaluate its efﬁcacy for
neutropenia and its stabilising effect on platelet count.
Method: We did a retrospective chart review of our Hepatitis C patient
population. We identiﬁed a total of 222 patients from our hepatitis C
database and 60 patients with thrombocytopenia (platelet count less
than 140,000/uL) at any point of treatment were identiﬁed. Of these 60
patients, 30 received GCSF. In GCSF group, only 27 became eligible for
evaluation. One patient had incomplete medical records and two patients
were started on GCSF prior to starting treatment. In the Non-GCSF
group, 23 patients were evaluated. Two patients never received Hepatitis
C treatment; one patient stopped treatment due to intolerance and four
patients did not have pre treatment platelet value. Both groups were
divided into sub groups according to prior to GCSF treatment platelet
values (less than 100,000/uL, between 100,000/uL and 139,000/uL,
between 140,000/uL and 200,000/uL, and greater than 200,000/uL). The
monthly platelet values in GCSF group were plotted on a line graph
and trends of platelet count variations were studied. The platelet values
in Non-GCSF group were followed prior to and during Hepatitis C
treatment and are also plotted on a line graph.
Results: See the graph.
Average platelet values in GCSF group.
Conclusion: As shown in the graph, GCSF treatment stabilises the
platelet count in patients on pegylated interferon alpha and ribavirin
treatment for chronic Hepatitis C. The comparison with control will be
discussed also.
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P1893 Changing of hepatitis C virus genotypes patterns in
HIV-positive and -negative patients in Northern Spain
M. Basaras, M.J. Ferna´ndez, M. Sota, P. Liendo, R. Cisterna (Bilbao, ES)
Hepatitis C virus (HCV) genotypes show speciﬁc geographic distribution
and association with particular risk factors. Nevertheless, differences in
genotype distribution can be observed in different areas of the same
region as well as different areas within a country.
The aim of the present study was to analyse differential distribution
of HCV genotypes in Northern Spain along a six-year period in HIV-
negative and -positive patients.
Patients and Methods: a retrospective analysis was carried out in
2301 serum samples from HCV RNA-positive patients during a six-year
period (from 2000 to 2005). HCV genotyping was determined by reverse
hybridisation of PCR amplicons (Versant HCV Genotype Assay, LIPA).
Human immunodeﬁciency virus antigen was detected by INNOTEST
and hepatitis B virus HBsAg and anti-HBs were detected by ADVIA
Centaur (Bayer).
Results: More than a half of the study group (1248 serum samples,
54.23%) were HIV-negative patients. Of them, the predominant genotype
was 1 (71.39%), followed by 3 (16.98%) and 4 (9.13%), being the most
prevalent subtype 1b (50.64%). On the other hand, 1053 (45.76%) of
serum samples were HCV-HIV co-infected. In that group, the most
frequent HCV genotype was 1 (48.71%), followed by 3 (29.25%) and
4 (19.56%); however, subtype 3a was the most prevalent (29.15%). Co-
infection with several genotypes was infrequent (1.61%). There was a
decline in subtype 1a over time and conversely an increase in subtype
4c/d. In all the study group, subtype 1b was detected preferentially in
patients with history of blood transfusion or no known exposure to risk
factors, whereas subtypes 1a, 3a and genotype 4 are related with injection
drug users. Year after year, subtype 4c/d was detected in younger patients
than subtype 3a. On the other hand, genotype 2 was almost imperceptible
(1.76% in HIV-negative and 0.85% in HIV-positive). Moreover, HBsAg
was detected in 0.7% of serum samples and anti-HBs in 1.34%.
Conclusions: HCV-HIV co-infection was very frequent in the study
group due to these viruses share similar transmission routes. Although
genotype 1 is the most frequent HCV variant, subtype 1a has declined
over time and subtype 4c/d has increased. This last subtype and subtype
3a were related with injection drug use. Subtype 1b was introduced
before than subtype 1a or 3a and is related with history of blood
transfusion or no known exposure to risk factors. Subtype 1a and 3a,
and more recently 4 c/d, are related with HIV co-infection.
P1894 Therapeutical aspects and predictors of outcome for
HIV/HCV co-infected patients treated with pegylated inter-
feron plus ribavirin. Survey in an Italian university hospital
E. Righi, M. Bassetti, A. Di Biagio, C. Dentone, R. Rosso, A. Beltrame,
G. Mazzarello, S. Ratto, C. Viscoli (Genoa, IT)
Introduction: One third of HIV-infected individuals worldwide suffers
from chronic hepatitis C virus (HCV) infection. HCV therapy is a priority
in coinfected patients because they have faster liver disease progression.
We assess the impact of interferon and ribavirin combination therapy in
a cohort of coinfected patients analysing speciﬁcally prognostic factors
for outcome.
Methods: Patients enrolled in the study were all HIV/HCV patients
who received HCV treatment between 2002 and 2006. Clinical data
included: demographical data, HAART sitauation, HCV genotype and
viral load (considering high rates >800,000UI/mL). Primary outcome
were early virological response (EVR) at week 12 and sustained
virological response (SVR) 6 months after stopping treatment.
Results: Forty-four patients were treated for chronic hepatitis C during
the four years period. Mean age was 41 years (SD±6.7) and 74% were
males. Risk factors for co-infection were mainly related to intravenous
drug abusers 32/43 (74%). Regarding immuno-virological situation, 51%
had T-CD4+ count >500/mm3 at baseline, 79% showed no more than
four HAART changes and only 19% had a CD4 nadir <200 cells/mm3.
Genotype 3a represented 51%, while 40% were infected by genotype 1
and 9% by genotype 4. Only 16/43 (37%) were on HAART at baseline
and half of the patients showed high HCV-RNA levels. Liver steatosis
was present in 14/43 (33%) patients. Mean T-CD4+ count reduction
was 175 cells/mm3 (33%), compared a T-CD4+ percentage reduction
of 11%. High rates of HCV treatment discontinuation were present
(63%), due to voluntary interruptions (52%), virological failure (26%),
adverse events as cytopenia (11%) and others. Total EVR was 51%.
The SVR was 30% in total, 38% and 24% for genotypes 3a and 1,
respectively. Positive and negative predicting values of EVR were
60% and 90%. SVR was signiﬁcantly lower in high HCV-RNA viral
load group (c2 = 6, P< 0.0025), CD4 nadir <350 cells/mm3 (c2 = 3.26,
P< 0.01) and <500 cells/mm3 (c2 = 3.94, P< 0.005) and in patients with
genotype 1 and high viral load (c2 = 4.8, P< 0.005).
Conclusions: Factors as HCV viral load rates and genotype 1 have been
conﬁrmed to threaten the response to therapy. Patients with no EVR did
not have any probability of SVR. There is a signiﬁcant response rate if
patients have a history of nadir >350 T-CD4+/mm3. High dropouts rates
reported due to adverse event and voluntary discontinuations complicate
HIV/HCV therapeutic management.
P1895 Low prevalence of HCV co-infection in HIV/HBV
co-infected teenagers from Romania
L. Manolescu, C. Sultana, P. Marinescu, S. Ruta (Bucharest, Giurgiu,
RO)
Objectives: In Romania there was the biggest paediatric HIV infection
acquired by parenteral route. The prevalence of HBV markers at these
children was of 78.3% at HIV infected versus 21.8% in HIV negative
controls. The teenagers acquired HIV and HBV infection horizontally.
This study was performed to examine the impact of HCV co infection
in HIV/HBV co infected teenagers from Romania.
Methods: Two groups of patients with HIV infection, from different
Romanian regions (161 from Constanta, 198 from Giurgiu), average
age 13.8±1.3, were retrospectively analysed 2 years for clinical and
virological parameters. Clinical liver function parameters (AST, ALT,
total bilirubin, albumin), CD4 count, and virological parameters (HCV,
HBV and HIV viral load by Roche Amplicor), HBsAg, HBeAg, HBsAb,
HBcAb were performed twice a year.
Results: Prevalence of HCV antibodies was low and similar in both
groups 2.04% respectively 2.5%. All HCV/HIV co infected patients
were also HBV infected and treated with potent antiretroviral therapy
(HAART), but never experienced speciﬁc antiviral anti HCV treatment.
We noticed in both groups similar correlations. HBV/HCV/HIV co
infection with active HBV replication revealed through the presence of
HBeAg and DNA-HBV high titer (40.000.000 copies DNA-HBV/mL)
in both groups: 33.3% respectively 40%, was associated with worsened
HIV-related parameters (CD4 count under 100 cell/microL, average HIV
titer above 750.000 copies RNA HIV/mL), and increased transaminase
(average values 156mg/dl) but undetectable HCV titers, compared to
patients without active HBV replication that presented detectable HCV
titers (average of 11550 copies RNA-HCV/mL) and undetectable HIV
and HBV titers and transaminase. Patients co infected with HIV/HCV
and without HBeAg appeared to have a good response to HAART
in terms of CD4 count changes, with a CD4 count average of 532
cells/microL.
Conclusions: A surprisingly low prevalence of HCV co infection was
found in HIV/HBV co infected patients despite the commune route of
transmition. HIV disease outcomes following HAART do not appear to
be adversely affected by HCV co infection and reveal good CD4 count
responses. Active chronic HBV co infection in HCV/HIV co infected
patients is associated with worsened liver disease and worsened HIV
condition.
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P1896 Relationship between virological evolution and acute
exacerbation of chronic hepatitis C (A-E-CHC) and during
the natural history of infection
E. Sagnelli, C. Argentini, D. Genovese, M. Pisaturo, C. Sagnelli,
S. Taffon, C. Alteri, N. Coppola, M. Rapicetta (Naples, Rome, IT)
Objectives: To evaluate the relationship between symptomatic a-e-CHC
and virological evolution during the natural course of the disease.
Methods: 49 consecutive patients with acute hepatitis C (AHC) (55%
IVDA) and 57 with a-e-CHC (43.8% IVDA) were observed. AHC was
diagnosed on the basis of seroconversion to anti-HCV and of the increase
in ALT serum levels of at least 5 times the normal value. The diagnosis
of a-e-CHC was based on the presence of anti-HCV and HCV-RNA in
the blood at least 6 months before the onset of symptoms and during
exacerbation and of increased ALT serum values of at leas 5 times
the baseline at exacerbation. Several plasma samples were obtained and
stored frozen at −80ºC. Three patient followed-up for 40−68 months
showed both AHC and a-e-CHC 3−24 months later. In these patients we
evaluated clinical characteristics, viral variability and the variation of
known predicted epitopes in the consensus sequence in the Core, E1/E2,
and NS5b regions, during the different phases of infection.
Result: The ﬁrst patient (genotype 3) presented a high rate of genetic
and epitopic variability which could be related to the maintenance of a
chronic HCV infection state. The second patient (genotype 1b) presented
an apparent resolution of the infection with absence of detectable
viraemia after a symptomatic acute phase; the phylogenetic and epitopic
analysis of the virus isolate during a-e-CHC presented little variation
with the isolate of AHC, indicating a phase of occult presence of
the virus in the period between AHC and a-e-CHC. The third patient
presented two different HCV genotypes, 2c and 2a, associated with the
initial phase of AHC and with a-e-CHC, respectively.
Conclusion: The follow up analysis revealed that, despite similar clinical
presentation, the viral variability and the differences in the ability to
develop or select epitopic variants may drive HCV infection toward
different outcomes.
P1897 Spontaneous virus clearance in perinatally HCV-infected
children: is it a way to escape the risk of chronicisation?
A. Maccabruni, E. Minola, B. Mariani, G. Bossi (Pavia, Bergamo, IT)
Introduction: Vertical transmission of HCV is proved to be the most
frequent route of infection in children, although only 5−7% of infected
mothers are thought to transmit the virus to their offspring. Perinatal
infections occur at a time when the immune system is still immature,
so their chronicisation rate may be very high (>80%); although chronic
HCV hepatitis is generally a mild disease in paediatric patients a slow
and insidious progression of liver disease may occur over the course
of years and cases of severe activity and cirrhosis may be observed in
adolescents and young adults.
The clearance of viraemia, reported in about 16% of vertically infected
children, could represent a spontaneous way out of the risk of
chronicisation, but whether or not they have forever eliminated the virus
is still controversial.
Methods: We conducted a retrospective study on paediatric HCV
infected subjects followed from 1995 in our Department and in the
Infectious Diseases Department of Ospedali Riuniti – Bergamo to
evaluate how many cases of spontaneous clearance of viraemia occurred
and how the natural history of infection has changed from then on.
Results: In our cohort, including 48 perinatally infected children, virus
clearance occurred in 9 of them (17.8%), aged from 10 months to 6
years. In only one of them HCV-RNA was intermittently detected during
a follow-up period of 36 months, while in three cases the clearance of
viraemia was persistent and associated with loss of speciﬁc antibodies
and normal ALT values, without any clinical manifestations (follow-up
38−60 months).
Conclusion: Although in our cases we weren’t able to individuate any
maternal or viral factors predictive of virus clearance in children we can
conclude that perinatally infected children are likely to have successfully
resolved their status of infection when spontaneous clearance of viraemia
with antibody loss and ALT normalisation are persistent for at least 48
months.
As virus clearance can be observed also >5 years after the diagnosis
a prolonged and close monitoring of vertically HCV-infected infants to
evaluate the course of infection is mandatory; the concept of chronicity
in this population should moreover be reconsidered.
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P1898 HIV-related morbidity in the HAART era
M.A. Escobar, A.A. Garcia-Egido, S.P. Romero, J.A. Bernal, J.L. Puerto,
J. Gonzalez-Outon, C. Asencio, F. Gomez (El Puerto Santa Maria, ES)
AIDS related hospital admissions and morbidity have decreased after the
introduction of HAART.
Objective: To assess the changes in hospital admissions and morbidity
with the improvement of HARRT.
Methods: We studied the hospital admissions and morbidity over three
different periods pre-HAART (January 1992 to December 1994), early-
HAART (January 1995 to December 1998) and post-HAART (January
1999 to October 2004), in HIV infected patients followed at our centre.
Results are expressed for periods pre-HAART, early HAART, and post-
HAART respectively. Mean (SD) CD4/mL were: 16±5, 37±11 and
118±33 (p< 0.0001). Undetectable plasma viral load (%) were: 0, 16
and 43 (p< 0.0001). Patients with a prior diagnosis of AIDS were:
91%, 68% and 36% (p< 0.001). The rate (%) of women/heterosexuals
was: 6/2, 11/5 and 21/11 (p< 0.01) and, that of IVDA (%) was:
96, 88 and 75 (p = 0.03). Hospital admissions due to AIDS-deﬁning
illnesses decreased (p< 0.001) with a signiﬁcant increase in the rate
of respiratory tract infections (p< 0.005), digestive tract (p< 0.01) and
liver diseases (p< 0.001). The proportion of AIDS-deﬁning illnesses
decreased after HAART (p< 0.01), whereas the rate of liver diseases
increased (p< 0.001).
Conclusions: The HAART era has been associated with a progressive
decrease in hospital admissions due to AIDS-deﬁning conditions, and
a steady enhancement of the spectrum of admissions by non-AIDS-
deﬁning conditions has increased.
P1899 Assessment of liver cirrhosis by elastography in HCV/HIV
co-infected patients
C. Castellares, L. Martı´n-Carbonero, P. Barreiro, B. Ramos, J. Sheldon,
P. Labarga, S. Novoa-Rodrı´guez, J. Gonza´lez-Lahoz, V. Soriano
(Madrid, ES)
Introduction: Chronic hepatitis C is now one of the leading causes of
morbidity and mortality among HIV-infected individuals. The evaluation
of liver injury in HIV/HCV co-infected patients should follow the same
principles as monoinfected ones.
Methods: Retrospective analysis of all HCV/HIV co-infected patients in
our institution assessed by FibroScan since Oct 2004 to June 06. Patients
with F4 METAVIR ﬁbrosis score estimates (>12.5 kPa) by elastography
(FibroScan) were compared to patients without liver cirrhosis.
Results: A total of 772 HIV/HCV co-infected patients were examined,
20% of whom had F4. The mean liver stiffness in them was 25.7 kPa.
Overall, 42% of cirrhotics admitted current and/or past alcohol abuse.
Their distribution according to Child-Pugh score was: A 68%, B 28% and
C 4%. Plasma HIV RNA was undetectable in 67% of cirrhotics and 62%
of the rest [p =NS], and CD4 counts <200 cells/mL were present in 27%
of cirrhotics vs. 12% of the rest [p< 0.01]. Overall, 25% of patients who
had received HCV treatment showed liver ﬁbrosis improvement. During
the study period, mortality was 16.5% in cirrhotics.
Conclusions: liver cirrhosis is quite prevalent in HCV/HIV-coinfected
patients. Transient elastography may help to recognize subclinical
cirrhosis and design more appropriate therapeutic and prophylactic
strategies for this population.
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Cirrhotics Non-
cirrhotics
P
No. 158 614
Male gender (%) 79 69 0.02
Mean age (years) 43±5 42±5 NS
Mean HCV load (IU/mL) 4.71±2.28 5.26±2.05 NS
HCV genotype (%)
1 64 56 NS
2 2 2 NS
3 21 26 NS
4 13 16 NS
Any IFN-based therapy (%) 69 47 <0.01
HCV clearance after
IFN-based therapy (%)
6 30 <0.01
Currently on therapy 7 NA NA
Chronic hepatitis B (%) 7 1 <0.01
P1900 HIV infection in an intensive care unit
S. Silva, A. Ferreira, C. Pin˜eiro, S. Xerinda, L. Santos, A. Sarmento
(Porto, PT)
Objectives: Evaluation of demography, immunologic state, severity
(SAPS II), causes of acute respiratory failure (ARF) and mortality rate in
HIV infected patients (pts) admitted in an Infectious Diseases Intensive
Care Unit (ICU).
Methods: Retrospective study of HIV infected pts admitted between
January 1991 and July 2006. Mortality rates were compared using the
Fisher test.
Results: 210 pts were admitted, 153 (73%) males. The mean age was
36.5±12.7 years (3 months–78 years). The routes of transmission of HIV
were intravenous drug use in 129 (61.4%), sexual in 68 (32.4%), mother
to child in 7 (3.3%), transfusional in 3 (1.4%) and unknown in 3 (1.4%).
The mean CD4 count in admission was 116.8±162.4 cells/mL. SAPS II
was 45.62±16.56 (median 43). 132 (63%) pts were admitted by ARF.
The mortality rate in ICU was 48.5% and inside the hospital 51.5%.
Causes of ARF are listed in the table. PCP and cancer diagnosis
were associated with a superior death risk (p = 0.003 and p = 0.002
respectively).
Disease Total Mechanical
ventilation
Death
Pneumocystis jiroveci pneumonia (PCP) 43 (32.6%) 36 (81.4%) 29 (67.4%)
Tuberculosis 28 (21.2%) 19 (67.9%) 10 (35.7%)
Viral and bacterial pneumonia 17 (12.9%) 16 (94.%) 6 (35.3%)
Pneumonia by unidentiﬁed agent 30 (22.7%) 24 (80.0%) 11 (36.7%)
Cancer 8 (6.1%) 6 (62.6%) 8 (100%)
Others 6 (4.5%) 1 (16.7%) 1 (16.7%)
Conclusion: ARF is the main cause of admission in ICU. PCP is the
most common cause of ARF.
P1901 Factors associated with the level of HIV-1 proviral DNA in
HIV-infected persons
J.Y. Choi, Y.G. Song, Y.K. Kim, M.S. Kim, Y.S. Park, S.Y. Shin,
Y.H. Kim, J.M. Kim (Seoul, KR)
Background: HAART does not eliminate the persistently replicating,
latent HIV-1 reservoir in patients, despite the viral suppression associated
with the therapy. The ability to generate anti-HIV-1 cytotoxic T
lymphocyte response is considered to be a critical component of the
host immune response to HIV-1.
Patients and Methods: To evaluate the factors associated with the level
of HIV-1 proviral DNA and the relationship between the level of HIV-1
proviral DNA and CTL responses in chronically HIV-infected Koreans,
we conducted cross-sectional study of eighty-two chronically HIV-1-
infected Koreans who had been admitted to Severance Hospital, Yonsei
University College of Medicine. In order to determine the proviral HIV
DNA copies per 106 peripheral blood mononuclear cells, real-time PCR
was carried out. An ELISPOT assay, using HIV-1 peptides, was done
in order to evaluate the HIV-1-speciﬁc CTL response. Multiple linear
regression analysis was used for analysing factors associated with the
HIV-1 proviral DNA level.
Results: There was a statistically signiﬁcant inverse correlation between
the proviral DNA level and the CD4+ T cell counts in the peripheral
blood of subjects (P = 0.01, r = −0.307). Among the patients receiving
HAART, the proviral DNA level was lower in patients in whom viral
load had been suppressed to levels below 25 copies/mL, than in patients
in whom viral load had not been suppressed (P = 0.01). The proviral
DNA level did not correlate with the CTL response (P = 0.36). However,
using multivariate analysis, factors associated with the proviral DNA
level were plasma HIV RNA, HAART, and CTL responses (P< 0.05).
Conclusions: The HIV-1 proviral DNA level was associated with plasma
HIV RNA, HAART, and CTL responses. Intensiﬁcation of HAART and
cellular immune-based therapy could affect the proviral reservoir.
P1902 Relationship between the C3435T and G2677A/T single
nucleotide polymorphisms of the P-glycoprotein in the
mdr-1 gene and efavirenz plasma concentration in patients
with HIV infection
G. Peralta, M.B. Sanchez, E. Valdizan, S. Echevarria, J. Nicola´s,
R. Segura, V. Badı´a, J.A. Armijo (Torrelavega, Santander, ES)
Objectives: P-glycoprotein is a drug transporter recognized to be
important to drug disposition and response. This protein is of particular
clinical relevance due to a broad substrate speciﬁcity and expression
in multiple tissues. The C3435T AND G2677A/T single nucleotide
polymorphisms (SNPs) have been associated with altered transporter
function or expression (higher function/expression of P-glycoprotein for
CC or GG genotypes, and less for TT genotype). Its role in antiretroviral
drug pharmacokinetics is still to be clariﬁed.
Methods: For the study we selected 40 patients in treatment with
Efavirenz (600mg qd) for at least six weeks. We analysed the
relationship between the C3435T and G2677A/T SNPs genotypes and
efavirenz plasma concentrations twelve hours after oral administration.
We excluded those patients in treatment with other drugs with
potential interaction with Efavirenz. The genotypes were determined
with the use of polymerase chain reaction-restriction fragment length
polymorphisms (PCR-RFLP) assays and with allelic discrimination by
PCR assays. Efavirenz plasma levels were measured by high pressure
liquid chromatography. To compare means an ANOVA and t-test were
used.
Results: For the 40 patients studied, the genotype distribution was:
CC: 25%, CT: 52.5%, TT: 20%, for the C3435T SNP; and GG: 35%,
GT: 55%, TT: 10% for the G2677A/T SNP. We did not ﬁnd a statistically
signiﬁcant difference between the C3435T SNP genotypes and efavirenz
plasma concentrations (CC: 1.73±0.80mg/L; CT: 3.11±2.42mg/L; TT:
2.63±1.24mg/L). But when we compared patients with genotype CC
with patients with genotype CT and TT all together, the difference
tended to signiﬁcance (P = 0.083). We did ﬁnd statistically signiﬁcant
difference between the G2677A/T SNP genotypes and efavirenz
plasma concentrations (GG: 1.62±0.76mg/L; GT: 3.20±2.28mg/L; TT:
3.13±1.60mg/L; P = 0.047).
Conclusions: Although the sample is small, in our patients the efavirenz
concentrations seems to be in relation with the G2677A/T SNP, and
probably with C3435T SNP too. These data have to be conﬁrmed in a
bigger group of patients.
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P1903 Performance evaluation of VIDIA HIV DUO, a new
automated immunoassay test for the qualitative HIV
antigen/antibodies detection in serum and plasma human
samples
H. Briand, F. Vayssie´, O. Breton-Laval, J.M. Dugua, X. Lacoux,
N. Battail-Poirot, P. Gradon, J. Piche (Marcy l’Etoile, FR)
Objective: The VIDIA system is a new automated, primary tube
immunoanalyser designed to reinforce traceability and simplify the
daily workload for routine testing. The qualitative 4th generation
combined antigen/antibodies detection is the most appropriate solution
for routine screening of HIV infection. During this study, we evaluated
the performance of the VIDIA HIV DUO (bioMe´rieux, France) test in
terms of sensitivity and speciﬁcity.
Methods: The VIDIA HIV DUO assay principle combines a two-
step enzyme immunoassay sandwich method with chemiluminescence
detection.
The kit uses:
– HIV antigen, HIV synthetic peptides and HIV p24 monoclonal
antibodies coated on microparticles,
– biotin-labelled conjugates: HIV synthetic peptides and HIV p24
monoclonal antibodies,
– and alkaline phosphatase conjugates: HIV antigen and streptavidin.
The raw materials selected enable us to detect HIV1, HIV1 group O, and
HIV2 for IgG, IgM as well as Antigen. Speciﬁcity was studied using 800
blood donor samples collected from French blood banks. Sensitivity was
established using:
• 255 conﬁrmed HIV-positive samples from our collection (200 HIV1
group M, 30 HIV1 group O, 16 HIV 2 and 9 HIV 1 non B subtypes)
• 20 commercial seroconversion panels from BBI (Boston, USA) and
Zeptometrix (Buffalo, USA)
• HIV antigen sensitivity has been established according to the French
SFTS (French Blood Transfusion Society) Panel
The performance characteristics of this new product were established in
our R&D laboratory during the development of the test.
Results: The speciﬁcity determined using 800 blood donors was 99.88%
[99.28%; 99.98%] for VIDIA HIV DUO. Sensitivity was 100% [98.46%;
100%] for the VIDIA HIV DUO assay on the 255 conﬁrmed positive
samples. As regards the seroconversion panels, the results with VIDIA
HIV DUO were comparable to those provided by the panel manufacturer
and other collected results. HIV antigen sensitivity of VIDIA HIV DUO
was determined against the SFTS panel and found to be 16.5 pg/mL of
HIV antigen.
Conclusion: This new HIV 4th generation assay shows excellent
performance in terms of sensitivity as well as speciﬁcity. The kit’s
early detection was conclusively demonstrated on the seroconversion
panels which is an added value for patient diagnosis. The combination
of automation and high performance makes this product an excellent
test for routine screening. These results must be conﬁrmed on the ﬁnal
commercialised product.
P1904 Trends in HIV incidence in Siberia, Russian Federation
(1987–2005)
A. Khryanin, O. Zhukovskaya, O. Reshetnikov (Novosibirsk, RU)
Objective: Currently the spread of HIV infection is acquiring an
epidemic pattern in Russia. Thus, HIV incidence rates increased 24-fold
in 2001, and the cumulative number of HIV cases reported in the country
increased tenfold compared to 1997–1998. The aim of the present study
was to analyse the epidemiology of HIV infection in Western (WS) and
Eastern (ES) Siberia over the period from 1987 through 2005.
Methods: Siberia consists of 14 administrative regions with total
population of 32,115,697 citizens, which is about one fourth of total
Russian population. The data from district STD clinics were obtained
and registered in the departments of social statistics of the regional
committees of statistics.
Results: HIV incidence rate in Siberia accounts for 17.0% of all HIV
infected persons in Russian Federation. Additionally, the HIV incidence
rate is higher than average in Russia by 13.1 percent. Trends in the
incidence of HIV infection are shown in the Table (number of reported
cases in Russia). In 2002, HIV incidence rates in Irkutsk and Novosibirsk
were 102.1 and 8.9 (per 100 000 inhabitants), respectively. More than
50% of all HIV cases were reported from intravenous drug users aged
19−29 years in 2004 (in comparison 80% in 2000). Males comprise
70% of newly diagnosed HIV cases. Sexual transmission was reported
in 4.7% in 1999 and 54.3% in 2004. The sexual/intravenous routes ratio
was 1/1.7 in 2004 (in comparison with 1/21 in 1999).
1987–
1997
1998 1999 2000 2001 2002 2003 2004 2005
Russia 7,024 10,952 26,414 79,881 173,000 226,003 264,996 303,274 331,559
Siberia 226 493 5,456 12,881 24,396 31,287 35,693 39,968 44,406
Novosibirsk (WS) 16 29 48 167 361 600 768 918 1,080
Irkutsk (ES) 22 47 3,285 7,997 11,563 14,060 15,650 17,382 19,429
Conclusion: At present, HIV epidemic unevenly spreads in the Siberian
region. The reservoirs of infection are already formed in some
administrative territories such as Irkutsk (ES). As for Novosibirsk (WS),
the process of formation is under way. Local intervention programmes
are urgently needed to prevent the forthcoming HIV epidemic in Siberia.
P1905 HIV prevalence and risk behaviours among international
truck drivers in Azerbaijan
B.A. Botros, Q. Aliyev, M. Saad, M. Monteville, A. Michael, Z. Nasibov,
H. Mustafaev, P. Scott, J. Sanchez, J. Carr, K. Earhart (Cairo, EG;
Baku, AZ; Rockville, Frederick, Baltimore, US)
Objectives: Assess HIV prevalence and high-risk behaviours among
international truck drivers (TDs) traveling between Azerbaijan and
Russia, Europe, China, Central/West Asia and Middle East.
Methods: Clinics were established near two major truck terminals in
Baku. TDs who volunteered to participate signed consent in his language
and received pre- and post-test counseling. Each participant completed
a questionnaire that included demographics and information about his
personal sexual behaviour, use of condoms and international travel
history. A blood sample was obtained by ﬁnger stick and tested using
2 different rapid HIV tests: 1) Determine (Abbott Laboratories, Abbott
Park, IL USA) and 2) Oraquick (Orasure Technologies Inc., Bethlehem
PA USA). Test result was provided within 30 minutes. Enrollment was
performed between July 2004 and October 2005. Data was analysed
using SPSS version 11.1 statistical package (SPSS Inc, Chicago, IL,
USA).
Results: A total of 3,763 TDs from 21 countries were enrolled. All were
males between the age of 24 and 67 (median, 45 years). Majority came
from Turkey (n = 1369), Russia (n = 1145), Ukraine (n = 662), Georgia
(n = 234) and Azerbaijan (n = 184). 58 TD (1.54%) (95%CI: 1.17–1.99)
tested HIV positive. Highest prevalence was among Russians (2.88%),
then Ukrainians (1.66%), Azerbaijani (1.09%), Georgians (0.85%) and
Turkish (0.73%). 1.9% of participants were injecting drug users (IDUs)
and 60% of these tested HIV positive compared to 0.4% of non IDU
(P< 0.001). Of those using condoms with FSW, 0.7% were HIV positive,
whereas of those not using condoms 3.6% were positive (p< 0.001). Men
having sex with men (MSM) had higher (p< 0.001) HIV prevalence
(42.9%). TD that had STD had higher (P< 0.001) HIV prevalence
(4.4%) than those not having STD (1.2%). Circumcised TD had lower
(p = 0.001) HIV prevalence (0.8%) than non-circumcised (2.2%).
Conclusions: TDs may engage in risky behaviours and are a bridge
population for transmission of HIV to the community. This study
demonstrates that HIV is present among international TDs in Azerbaijan.
As is true for other countries of former Soviet Union, HIV infection
was highly associated with IDU. Other associated factors for HIV
included not using condoms, MSM and STDs. TDs transiting Azerbaijan
should be considered a high risk group and should be a target for
HIV: antiviral treatment S547
surveillance and prevention programmes. Prevention programmes in this
region should target knowledge and risk behaviours of TDs.
P1906 No re-imbursement for statins, ﬁbrates, and omega-3
derivatives for HIV-infected patients with HAART-related
dyslipidaemia in Italy
R. Manfredi, L. Calza (Bologna, IT)
Introduction: The signiﬁcant HAART-prompted advances achieved in
the management of HIV disease may be frustrated by the modiﬁed
reimbursement modalities of all lipid-lowering drugs (LLD) available
in Italy. The remarkably increased life expectancy attained thanks
to HAART, is borne by signiﬁcant risks to develop an uncontrolled
hypercholesterolaemia and/or hypertriglyceridaemia, often concomitant
with insulin resistance and visceral adiposity, which strongly predispose
to cardiovascular events and stroke.
Methods and Results: The present prescribing rules of LLD based on
a computer-generated score, were matched with the present situation
of around 1000 HIV-infected patients (p) treated with HAART, to
assess the frequency and type of dyslipidaemia, and the estimated
rate of need of LLD prescriptions. The rate of hypertrigyceridaemia
and hypercholesterolaemia exceeded 28% and 19% of p respectively,
while around 22% of p had a mixed dyslipidaemia. Over 200 p were
currently treated with statins and/or ﬁbrates, with the eventual adjunct
of omega-3 fatty polyunsaturated acids (PUFA). When applying the risk
score proposed for the general population, <10% of these p reached
the threshold of a >20% risk of major vascular events in the next
decade (due to the proportionally lower mean age, the absence of familial
dyslipidaemia, diabetes, elevated systolic pressure, and anti-hypertension
therapy, vs. the general population), while only very few p needed a
secondary prophylaxis, due to a prior, major cardio-cerebro-vascular
accident. As a result, more than 90% of HIV-infected p presently treated
with LLD due to present antiretroviral therapy recommendations have
lost all rights to LLD re-imbursement in Italy, and are at serious risk to
give up LLD due to not sustainable linked costs.
Discussion: The recent dispositions of the Italian Health Care System
ignore the situation of HIV-infected p, who are exposed to a frequent,
severe, drug-induced dyslipidaemia, and an elevated major vascular risk
despite their lower mean age, and the lack of multiple generic risk
factors. At mid-term, the majority of HAART-induced beneﬁts might be
blunted by the sudden lack of LLD re-imbursement, which is estimated
to regard most of treated HIV-infected p. A comparison with LLD re-
imbursement facilities in other countries is also warranted, to draw some
epidemiologic and pharmacoeconomic issues suggesting a re-extension
of reimbursement facilities of these life-saving drugs to HIV-infected p.
P1907 Immune markers of HIV disease progression are not
modiﬁed by long-term statin administration
R. Manfredi, L. Calza (Bologna, IT)
Introduction: Statins were recently hypothesized to act unfavourably
on the immune system through an altered cytokine pattern and
a Th1/Th2 imbalance, as shown in non-HIV-infected patients (p)
[JAIDS 2005;39:503], while a small experience claimed a p< 0.05
loss of absolute CD4+ lymphocyte count of p treated with a protease
inhibitor (PI)-based HAART, in a 6−18-month period [HIV Clin Trials
2003;4:164].
Patients and Methods: From over 1,000 HIV-infected p, we identiﬁed
all p on HAART since at least 12 months, with compliance levels of
at least 90%, and with altered fasting cholesterol (>200mg/dL) and/or
triglycerides (>250mg/dL), of at least six-month duration.
Results: When comparing the quarterly immunological trend of the
88 p prospectively taking statins (either pravastatin, ﬂuvastatin, or
rosuvastatin) for a predominant hypercholesterolaemia, versus the 103
p receiving ﬁbrates (either bezaﬁbrate, or fenoﬁbrate, or gemﬁbrozil)
for a prevailing hypertriglyceridaemia, versus the 76 p who underwent a
diet/exercise programme only, no signiﬁcant difference in mean-median
CD4+ lymphocyte count occurred among the three p groups during a
mean follow-up which now reachs 15.3±6.7 (range 6−26) months. All p
remained evaluable when still on an HAART regimen ensuring virologic
suppression, and an unchanged hypolipidemic therapy.
Discussion: Examining the broad-spectrum pleiotropic activities at-
tributed to statins, also the virologic course of HIV infection received
limited evidences from a study claiming a direct anti-HIV activity
of statins by down-regulating the small signaling Rho protein [J Exp
Med 2004;200:541], while neither virologic failure nor viral blips
occurred among 78 HAART-stable p who started a statin [JAIDS
2005;39:637]. Also the anti-triglyceride ﬁbrates may have extensive
pleiotropic effects [Curr Vasc Pharmacol 2005;3:87]. In fact, both
ﬁbrates and other molecules interacting with the peroxisome proliferator-
activated receptors (PPAR) (e.g. rosiglitazone and pioglitazone, whose
use is clained by experimental studies on HIV-infected p suffering from
the lipodystropy syndrome), may affect major T-lymphocyte cytokine
mediators [Circ Res 2002;90:703; J Immunol 2004;172:5790]. Based
on our preliminary, simple experience, and waiting for enlarged in vivo
studies conducted on affordable p samples, we remain prudent and wait
for further studies of both basic and clinical sciences in this ﬁeld.
P1908 The assessment of knowledge about AIDS and its prevention
on Isfahan high school students
I. Karimi, B. Ataei (Isfahan, IR)
Introduction: Since there isn’t any effective vaccination against AIDS,
the best way for prevention is to increase the knowledge in society;
especially adolescents and students in high schools, as the most common
location for accumulation of young men and women, has a special
importance. The target of this study was to evaluate knowledge about
AIDS in high school students of Isfahan, in 2003.
Methods: 1,200 validated questionnaires consisting of 20 questions di-
vided between students of six regions of Isfahan education organisation.
In each region 100 male and 100 female students from different ﬁelds
and grades answered the questions. Then the data were obtained and
the result analysed by SPSS 11 software with different statistical tests
including spearman c2 and Student’s t.
Results: The knowledge score increased with increasing educational
level of parents, especially mother (P< 0.001). There is a relationship
between knowledge score and ﬁeld of education and grade of students.
The knowledge level in female students was signiﬁcantly higher than
in males. It was shown to increase with increasing age (P< 0.001) and
mean scores of students (P = 0.006).
Among the resources of obtaining information, the most was radio
and TV (83.6%) then newspapers and magazines (63.3%); the most
uncommon sources were educational programmes in their schools
(24.2%) and textbooks (24.3%).
Discussion: Overall the highest level of knowledge was among females,
older, high grade, students of experimental sciences ﬁeld, rich regions
and educated parents.
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P1909 Incidence and risk factors of nevirapine-associated skin
rashes and hepatitis among naı¨ve HIV-infected patients
with CD4 cell counts <250 cells/mL
W. Manosuthi, A. Chaovavanich, Y. Inthong, W. Prasithsirikul,
S. Chottanapund, C. Sittibusaya, V. Moolasart, P. Termvises,
S. Sungkanuparph (Nonthaburi, Bangkok, TH)
Objectives: To determine incidences and risk factors of nevirapine
(NVP)-associated skin rashes and clinical hepatitis that lead to NVP
discontinuation among antiretroviral naı¨ve HIV-infected patients who had
baseline CD4 cell counts <250 cells/mL
Methods: A retrospective cohort study was conducted among naı¨ve
HIV-infected patients with baseline CD4 cell counts <250 cells/mL who
were initiated NVP-based antiretroviral therapy (ART) between January
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2001 and January 2004. All patients were followed until 180 days after
initiation of ART. Incidence of skin rashes and clinical hepatitis after
1, 2, 3 and 6 months of ART were studied. Cox’s proportional hazard
model was used to analyse the possible risk factors.
Results: There were 785 patients with a mean age of 35.2±7.4 years
and 44% female. Median (IQR) CD4 cell count was 26 (8−76) cells/mL
and median (IQR) baseline plasma HIV RNA was 268,000 (101,250–
548,000) copies/mL. Incidence of NVP-associated skin rash grade II-
IV at 1, 2, 3 and 6 months after ART were 5.7%, 7.4%, 7.7% and
7.7%, respectively. Incidence of clinical hepatitis at 1, 2, 3 and 6
months after ART were 0.5%, 0.8%, 0.9% and 1.2%, respectively.
Cox’s proportional hazard was used after adjusting for gender, baseline
CD4 cells, log plasma HIV RNA and serum alkaline phosphatase; the
result showed that every increment of baseline CD4 50 cells/mL was
associated with higher incidence of NVP-associated skin rashes that lead
to NVP discontinuation (HR= 1.431, 95%CI: 1.006–2.036, P = 0.046).
The number of CD4 cell counts was not associated with NVP-associated
clinical hepatitis.
Conclusions: HIV-infected patients with baseline CD4 <250 cells/mL
had incidences of NVP-associated skin rashes grade II-IV and hepatitis
that lead to NVP discontinuation approximately 8% and 1.2%,
respectively. Almost all of events occurred within the ﬁrst 3 months after
ART. Even in HIV-infected patients with baseline CD4< 250 cells/mL,
the higher number of baseline CD4 cells is associated with a higher risk
for skin rashes
P1910 Potential role of TDM in dosing protease inhibtors in
HIV-HCV co-infected patients with or without cirrhosis
F. Gatti, S. Pagni, P. Nasta, C. Boldrin, A. Matti, A. Loregian, L. Biasi,
M. Puoti, S.G. Parisi, K. Prestini, G. Palu`, G. Carosi (Brescia, Padua, IT)
Objectives: to evaluate the inﬂuence of liver cirrhosis on pharmacoki-
netics (PK) of the main protease inhibitors (PIs) in HIV/HCV co-infected
patients (pts) treated with atazanavir/ritonavir (ATV/r), fosamprenavir/r
(FAPV/r) or lopinavir/r (LPV/r).
Methods: 39 HIV/HCV co-infected pts receiving ATV/r (14), LPV/r
(13) and FAPV±r (12) were included.
According to liver stiffness (LS) value obtained by ﬁbroscan® at the
moment of PK determination or histological diagnosis patients were
classiﬁed in 2 groups:
• NC, no cirrhosis (24) if LS< 12 kPa or Knodell ﬁbrosis score (Kfs)
1−3;
• C, cirrhosis (15) if LS 12 kPa or Kfs 4.
PIs plasma levels (PL) were determined by High Performance Liquid
Chromatography. Samples for determination of Ctrough (Ct) PL were
collected before the morning or the daily dose at the steady state. Results
are expressed as median (interquartiles); parametric and non parametric
tests have been used for comparison of continuous variables between
groups when appropriate (p< 0.05 was considered as signiﬁcant).
Results: 35 pts had HIV-RNA< 50 and 4 <2500 c/mL; 29/39 pts were
on TDF+3tc/FTC. According to CHILD-PUGH score 10/15 C pts were
classiﬁed as A5, 2 as A6 and 3 as B7.
LS in pts taking ATV/r, LPV/r and FAPV/r was respectively 6 (5−8), 6
(4−9) and 6.3 (5.9−6.9) kPa in NC and 17 (12−22), 34 (21−50) and 53.2
(48−75) kPa in C pts.
LS of C pts on FAPV was signiﬁcantly higher than LS of C pts on
ATV (p = 0.0004); C pts on FAPV were taking 700mg BID according
to DHHS guidelines.
Median Ct levels were 540 (170–990) in NC and 340 (100–460) ng/mL
in C pts (p = 0.3) for ATV; 3020 (1020–4910) in NC and 3250 (1490–
10100) ng/mL in C pts (p = 0.6) for LPV; 1350 (1020–1740) in NC and
210 (180–420) ng/mL in C pts (p = 0.01) for FAPV. Moreover PIs Ct was
above minimum target concentration for wild-type virus (as suggested
by DHHS guidelines) in all pts taking ATV/r, LPV/r and FAPV/r; this
concentration was reached only in 2/5 C pts taking unboosted FAPV,
both with a LS< 50 kPa.
Conclusions: ATV and LPV Ct doesn’t seem to be affected by liver
cirrhosis, while Ct of FAPV was found signiﬁcantly lower in C with
respect to NC pts. Of note C pts on FAPV had a median LS signiﬁcantly
higher than others C pts and this may cause a reduction and/or diversion
of the liver blood ﬂow related to initial portal hypertension: dosing FAPV
in C pts with a very high LS (>50 kPa) may therefore require TDM.
P1911 Immmune recovery in treatment-naı¨ve patients under
HAART according to baseline CD4 count: the Chilean
AIDS Cohort (ChiAC) experience
J. Aranciabia, D. Gallardo, C. Beltra´n, O. Morales, M. Wolff for the
Chilean AIDS Group
Background: Immune recovery is one of the achievable goals of modern
antiretroviral therapy (HAART) and is measured through CD4 counts
which increase after successful viral suppression. The magnitude of
recovery also seems to depend on baseline (BL) CD4 count, the higher
the later, the better the results. Present guidelines recommend treatment
before severe immunosuppresion is present but many patients begin
HAART with CD4 levels much lower than the recommended due to
advanced disease at diagnosis.
Objective: To evaluate the rate of immune recovery in treatment
naı¨ve pts (TxN) initiating HAART at various levels of clinical and
immunologic disease cared for in the Chilean Public Health System and
followed by the ChiAC.
Methods: ChiAC has 4,500 pts under follow up, 52% TxN who initiated
HAART between 10/2001 and 01/2004. Results from 2,429 TxN with
information updated to 08/2006, with an average follow up period of 3.5
years were available. Variables studied were BL CD4 and CDC clinical
staging, (A, B and C) HAART regimens and results. CD4 response
was compared according to BL CD4 (Group [G] 1: 0–100, G2: 101–
200 and G3: 201–300/mm3) both in absolute number (median) and
slope and CDC BL clinical stage; CD4 results were measured every
6 months; Patients on HAART with BL CD4> 300/mm3 were excluded;
for statistical analysis SPSS 14 was used.
Results: At the beginning of HAART the number of patients in G1
was 1106; in G2, 712 and in G3, 304. Median baseline CD4 counts for
each group were: 36 (SD ±29.0), 151 (SD ±28.4) and 232 (SD ±27)
cells/mm3, respectively for groups 1, 2, and 3. Median CD4 rise were
137, 125, 188, 242 and 260 cells/mm3, at 0.5, 1, 2, 3 and 4 years of
treatment respectively for G1; 69, 95, 193 and 239 cells/mm3 for G2, and
72, 74, 148, 228, 280 cells/mm3 for G3, respectively for these periods.
The higher the BL CD4 the higher the CD4 rise over time but the slopes
of the CD4 rise curves were comparable between groups. There was no
difference in CD4 rise according to BL clinical status.
Conclusions: CD4 rise after successful HAART in treatment naı¨ve pts
was obtained at different levels of BL CD4 count, without signiﬁcant
difference according to BL clinical staging or viral load. The magnitude
of the rise but not its rate is dependent on the BL CD4.
P1912 Efﬁcacy and safety of tenofovir, abacavir and efavirenz in
treatment-naı¨ve patients: 48-week results (The ABATE Trial)
A. Leon, J. Pich, E. Ferrer, J. Murillas, I. Garcı´a, F. Segura, F. Vidal,
F. Gutierrez, D. Podzamczer, J.M. Miro (Barcelona, Palma de Mallorca,
Hospitalet, Sabadell, Tarragona, Elche, ES)
Background: There are few data on the activity of tenofovir (TDF)
plus abacavir (ABC) as a nucleotide/nucleoside backbone regimen in
combination with efavirenz (EFV). The aim of this study was to evaluate
the efﬁcacy and safety of this combination.
Methods: This is a prospective and multicentre cohort study performed
in nine Spanish HIV Units. Patients came from a randomised,
multicentre, open-label, induction-maintenance clinical trial (the ABATE
trial) in naı¨ve HIV-1-infected patients with >100 CD4 cells/mm3
designed in 2002 and started in May 2003. Induction therapy was
performed with TDF (300mg, QD) plus ABC (300mg, BID) plus EFV
(600mg, QD). Randomisation to maintaining or stopping EFV was
planned at 6 months in patients with undetectable plasma RNA HIV-1
viral load (PVL) (<100 copies/mL). However, the DSMB recommended
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not starting the maintenance phase in September 2003 due to the
high rate of early virologic non-response in treatment-naı¨ve patients
with the combination of TDF plus ABC plus lamivudine (ESS300009
trial). Endpoints of the study were proportion of patients with PVL of
<50 copies/mL, CD4 cell increase and drug-related adverse events (AE)
leading to treatment discontinuation at 48 weeks.
Results: The 52 patients included in the study were followed for at least
48 weeks. Mean (IQR) age was 35 (32−43) years, 73% were males.
Only 15% of patients were former drug users. At baseline, median
(IQR) CD4 and PVL were 287 (238–391) cells/mm3 and 4.9 (4.3−5.3)
log10/mL, respectively. None of the patients died or had C events. Three
patients were lost to follow-up and 13 patients (26%; 95%CI, 14−39%)
discontinued therapy due to AE. Two patients had virological failure.
K65R mutation emerged in one patient. The proportion of patients
(95%CI) with PVL below 50 copies/mL at week 48 by intention-
to-treat (ITT) or per protocol (OT) analysis was 65% (51−78%) and
94% (81−99%), respectively. Median CD4 cell increase (ITT/OT) at
12 months was +201/+232 cells/mm3. AE were due to hypersensitivity
reaction (HSR) to ABC in 5 cases, to either CNS disturbances or skin
rash associated with EFV in 4 cases, to GI alterations in 2 cases and to
skin rash (ABC or EFV) in another 2 cases. 85% of AE appeared within
the ﬁrst month of therapy.
Conclusions: This combination had a high rate of early AE but was
highly effective in naı¨ve patients who were able to tolerate it. Genetic
screening (HLA-B*5701) to prevent ABC HSR could select in the future
those patients who can beneﬁt from this treatment.
P1913 Genotypic drug resistance mutations among HIV-1-infected
patients failing an initial non-nucleoside reverse
transcriptase inhibitor-based antiretroviral regimen in a
resource-limited setting
S. Sungkanuparph, S. Kiertiburanakul, K. Malathum, N. Saekang,
W. Pairoj, W. Chantratita (Bangkok, TH)
Objectives: To determine genotypic drug resistance patterns and optimal
initial antiretroviral regimens in a resource-limited setting after failing
an initial non-nucleoside reverse transcriptase inhibitor (NNRTI)-based
antiretroviral therapy (ART).
Methods: A retrospective study was conducted among HIV-infected
patients who failed an initial ART of NNRTI-based regimen and had
genotype resistance testing between January 2002 and December 2005
in a medical school hospital.
Results: There were 63 patients with a mean (SD) age of 38.3 (7.4)
years and 76% were male. Of these, 60% received nevirapine and
40% received efavirenz. For nucleoside reverse transcriptase inhibitor
(NRTI) backbone, 79% received lamivudine (3TC) + stavudine (d4T) or
zidovudine (AZT) and 21% received didanosine (ddI) + AZT or d4T.
Median (IQR) duration of ART was 21 (12−32) months. Median (IQR)
CD4 cell count and HIV RNA at the time of virological failure was
193 (107–301) cells/mm3 and 4.0 (3.7−4.4) log copies/mL, respectively.
The prevalence of patients with  1 major mutation conferring drug
resistance to NRTIs and NNRTIs were 89% and 95%, respectively. For
NNRTI resistance, K103N was found more often in patients receiving
efavirenz (80% vs. 32%, p< 0.001) whereas Y181C was more common
in patients receiving nevirapine (40% vs 4%, p = 0.002). For NRTI-
resistance mutations, M184V, TAMs, K65R and Q151M were observed
in 73%, 38%, 5% and 8%, respectively. Patients receiving 3TC+AZT or
d4T had a higher frequency of M184V than patients receiving ddI + AZT
or d4T (90% vs 8%, p< 0.001). Q151M, a multinucleoside resistance
mutation, was found more often in patients receiving ddI+AZT or d4T
than that in patients receiving ddI+AZT or d4T (23% vs 4%, p = 0.050).
The frequencies of TAMs and K65R were not different between the two
groups of NRTI backbone. By logistic regression, receiving ddI+AZT
or ddI was the only factor associated with occurrence of Q151M (OR
13.4, p = 0.039). NNRTI drug, CD4 cell count, HIV RNA at failure and
duration of ART were not associated with Q151M. No predicting factors
for the occurrence of TAMs and K65R were found from the analyses.
Conclusion: In a resource-limited setting where the options for the
second regimen are limited, 3TC with AZT or d4T should be a preferred
NRTI backbone for an initial ART regimen. Genotype resistance testing
is still needed to optimise the second ART regimen. The accessibility of
this tool needs to be scaled-up along with accessibility of ART.
P1914 The coexistence of secondary PR mutations M36I, K20I and
L63H predominates in CRF06-cpx and its next generation
recombinant viruses circulating in Estonian treatment-naı¨ve
patients
R. Avi, K. Huik, T. Karki, M. Sadam, P. Paap, J. Smidt, K. Ainsalu,
T. Krispin, I. Lutsar (Tartu, EE)
Objectives: The naturally occurring HIV secondary drug resistance
mutations (DRM) in widely spread subtypes (A, B and C) have been
adequately described and a high variability between different subtypes
has been demonstrated. Such data on circulating recombinant forms
(CRF), however, are often missing. We aimed to describe the proﬁle
of DRMs in Estonian treatment naive HIV positive subjects carrying
predominantly CRF06-cpx viruses or their next generation recombinants.
Methods: A total of 76 treatment-naive subjects (median ages 26 y;
59 male) infected with HIV-1 between 2000 and 2005 were analysed.
Of these 62 (82%) were or had been IV drug users and 14 acquired
infection via heterosexual route. A direct sequencing of plasma viral
RNA was performed in protease (PR), reverse transcriptase (RT), p7
and V3 regions. DRMs were detected by submitting PR and RT
sequences to Stanford University HIV Drug Resistance Database; p7 and
V3 sequences were subtyped using HIV-Blast application. A footprint
analysis of sequenced regions was applied to map recombination patterns
between CRF06-cpx and subtype A viruses.
Results: The majority of subjects (96%) carried rare recombinant viruses
(CRF06-cpx by 53/76; various recombinant forms of former and A
subtype [A06] by 20/76) and only 3/76 had Eastern European subtype
A. On footprint analysis of A06 viruses almost all recombination
breakpoints were situated in p7 region. A secondary PR resistance
mutation M36I was present in all strains. The mutation L63H and K20I
were seen in >90% of CRF06-cpx and in approximately 75% of A06
strains. In addition mutations L33V, I93L and L10I were found in 5%,
5%, 7% of CRF06-cpx viruses, respectively. Of all recombinant viruses
more than 80% carried 3 or more PR mutations.
Conclusions: The vast majority of CRF06-cpx and its next generation
recombinants with Eastern-European subtype A in Estonia carry number
of secondary protease mutations of which the combination of M36I,
K20I, L63H was most commonly seen.
P1915 Immunological reconstitution in severely immunosuppressed
antiretroviral-naı¨ve patients (<100 CD4+ T cells/mm3)
using a non-nucleoside reverse transcriptase inhibitor-based
or boosted protease inhibitor-based ART regimen: 3-year
results
J.M. Miro, J. Pich, P. Domingo, D. Podzamczer, J.R. Arribas, E. Ribera,
J. Arrizabalaga, M. Lonca, E. De Lazzari, M. Plana and the ADVANZ
Study Group
Background: There are few randomised clinical trials involving severely
immunosuppressed patients. The aim of this study was to analyse
whether there are differences in the timing of immune reconstitution
in patients with <100 CD4+ cells/mm3 on non-nucleoside reverse
transcriptase inhibitor (NNRTI)- vs. boosted protease inhibitor (PI)-based
antiretroviral therapies.
Methods: Multicentre, randomised, prospective, open-label clinical
trial in naı¨ve HIV-1-infected patients with <100 CD4 cells/mm3.
Enrollment period: Nov. 2001 – Jan. 2003. Treatment regimens were
two NRTIs plus an NNRTI (efavirenz [EFV] 600mg QD, with
nevirapine [NVP] as the second option for EFV-intolerant patients)
or a boosted PI (indinavir/ritonavir [IDV/r] 800/200mg BID, which,
once approved in Spain, could be changed lopinavir/ritonavir [LPV/r]
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or atazanavir/ritonavir [ATZ/r] as the second option for IND/r-intolerant
patients). Analysis was by intention-to-treat (ITT) and per protocol (OT),
allowing changes of NNRTI or boosted PI within the same class of
antiretrovirals.
Results: Sixty-six patients were randomised: 34 received an NNRTI-
based regimen and 32 received a boosted PI-based regimen. 50% had
had C events. Median (range) CD4+ and PVL at baseline were 40
(1−99) cells/mm3 and 5.5 (4.0−>6) log10/mL, respectively. All patients
completed 3 years of follow-up. Five patients died (NNRTI, 4; PI, 1) and
12 developed a C event (NNRTI, 6; boosted PI, 6), most of them within
the ﬁrst six months. Seventeen patients changed EFV (NVP, 3; LPV/r
1) or IDV/r (LPV/r 9, ATZ/r 3, EFV 3, NVP 1) because of adverse
events and eight patients stopped HAART or were lost for follow-up
(NNRTI, 1; PI, 7). There were 12 virological failures (NNRTI, 5; PI,
7). PVL< 200 copies/mL for NNRTI/PI arms at 1, 2 and 3 years was
71%/65%, 68%/49% and 65%/29% (p = 0.05 at the last time point) by
ITT (M=F) and 73%/77%, 73%/69% and 73%/49% (p=NS at all time
points) by OT analysis, respectively. Median CD4+ cell increase after 1,
2 and 3 years by OT analysis was +186/+136, +226/+162 and +303/+220
cells/mm3 (p=NS for all time points) for NNRTI/PI groups, respectively.
At 1 and 2 years, immune activation (CD8+CD38+) was signiﬁcantly
lower in the NNRTI group (p = 0.004). There were no differences in
T-cell subsets, proliferative responses to mitogens and recall antigens
between both study arms.
Conclusions: At 3 years, the virological response and the magnitude of
the immune reconstitution induced by an NNRTI-based regimen was at
least as potent as that induced by a boosted PI-based regimen.
P1916 The evolution of the avidity of HIV-1-speciﬁc antibodies is
prevented by early treatment started during primary HIV-1
infection
M. Selleri, M. Zaniratti, N. Orchi, A. Corpolongo, P. Zaccaro,
G. Ippolito, M. Capobianchi, E. Girardi (Rome, IT)
Objectives: Avidity of anti-HIV antibodies progressively increases after
primary HIV-1 infection (PHI). It has been reported that an Avidity
Index (AI) <0.80 identiﬁes recent (<6 months) infections, whereas anti-
HIV antibodies with an AI  0.90 indicates long-standing infections.
We evaluated if the administration of highly active antiretroviral therapy
(HAART) during PHI may affect AI evolution.
Methods: The AI and Western blot (WB) evolution patterns were
retrospectively analysed on serial serum/plasma samples from 13
individuals with symptomatic PHI, deﬁned as detectable viral load and
negative or indeterminate HIV-1 antibody tests. Five patients have never
been treated, eight individuals had initiated HAART at the time of
diagnosis (range 0−46 days after presentation), of whom, 4 discontinued
HAART after a variable time lapse from PHI ( 1 year).
Results: At diagnosis, the range of HIV viraemia was 0.003−38×106
copies/mL. In untreated patients viraemia reached the set-point in 4−6
months, while in all patients receiving HAART complete suppression
of viraemia (<50 RNA copies/mL) was achieved early, lasting for the
entire observation period (12 months). At presentation, the median AI
was 0.42 (range 0.33–0.43) in untreated patients, and 0.44 (range 0.40–
0.72) in subsequently treated patients. At 3, 6 and 12 months the median
AI was 0.75, 0.89, 0.97 in untreated patients, and 0.42, 0.49, 0.54 in
treated patients. In the 4 patients who stopped HAART, AI increased
after interruption, reaching the value of 0.80 in 6 months. WB pattern
transiently/partially reversed during HAART in 2 patients.
Conclusions: During PHI, early HAART, accompanied by rapid
virologic suppression, prevents the gradual increase of AI, while
resumption of viral replication is paralleled by a prompt increase of AI.
This altered pattern of maturation of the antibody response in patients
achieving rapid control of viral replication may suggest a complex
mechanism of immune response to HIV not yet fully investigated.
P1917 Antiretrovirals adverse reactions from a prospective
HIV/AIDS cohort study in Bogota´, Colombia
J.F. Vesga, C. Alvarez, J.R. Tamara, J.A. Cortes, P. Guerrero, F. Gil
(Bogota, CO)
Background: Adverse Drug Reactions (ADR), lead not just to a high
percentage of therapy abandonment, but also to a poor adherence to
treatment instructions resulting in failure of therapy. The purpose of this
study was to show the relation between the use of drugs and ADRs,
their impact on treatment and the severity of reaction as deﬁned by the
DAIDS scale.
Methods: Making use of a database designed in Access (ver 11.5 2003,
Microsoft, USA), information from ADR to Antiretrovirals from 384
HIV positive patients between June 2005 and June 2006 was analysed.
Patients were seen routinely every 4 weeks, and data was collected from
such consults. Patient was asked about the presence of ADRs, lot and
drug manufacturer, the active commencement of the antiretroviral, the
effect of the reaction on the overall treatment scheme, and laboratories
related to the negative reaction. For abnormal laboratory results a DAIDS
grade was established. Data was then analysed using programme Stata
(Ver 9.0).
Results: In the consequent year (4608 month/patient), 672 ADRs were
reported to have occurred with the following frequency: metabolic
reactions 28.1%, haematologic 28%, gastrointestinal 26.5%, neurologic
and psychological 13.5%, dermatological 3.28%, hepatic 2.39%, renal
and urological 0.9%.
Regarding intensity of ADRs, 85.2% were mild, 14.4% moderate and
1.7% severe. The most frequent ADRs were macrocytosis, nausea,
hypertrygliceridaemia, combined dyslipidaemia and diarrhoea. Among
all ADRs 89.5% were classiﬁed as DAIDS grade I, 8.8% grade II,
1% grade III and 0.4% grade IV. The 89.9% of ADRs mean no change in
the scheme of treatment, 6.3% required a change of the drug, 1.3% quit
the treatment, and 2.4% of treatments were transitorily suspended.
Conclusions: ADRs were frequent in our study, however the most
of it were reported as mild reactions and didnt necessitate change
or suspension of the treatment. As expected, metabolic reactions like
dyslipidaemia where most frequently found among protease inhibitors
and NNRTs than in NRTs.
P1918 Pharmacokinetic parameters of 400/100mg
indinavir/ritonavir in HIV-infected Thai patients
S. Jaruratanasirikul (Songkhla, TH)
Introduction: The dosage recommendations of 800/100mg indi-
navir/ritonavir in the Thai population may lead to more severe side
effects. This may be due to higher drug levels.
Objective: The aim of this study was to assess the steady state
pharmacokinetics of reduced doses of indinavir boosted with ritonavir
in HIV infected Thai patients.
Methods: Our study was conducted in ten HIV infected patients.
All patients received 400/100mg indinavir/ritonavir combined with
lamivudine and stavudine or zidovudine every 12 h. After 4 weeks of
starting antiretroviral therapy, indinavir pharmacokinetics studies were
carried out and HIV-1 RNA viral load was determined at 24 weeks.
Results: The pharmacokinetic parameters are shown as below and all
patients had a HIV-1 viral load less than 400 copies/mL after 24 weeks
follow up.
Parameter Mean (SD) Units
Cmax 7.51 (3.57) mg/L
Cmin 0.86 (0.59) mg/L
AUC0−12 38.14 (15.17) mg·h/L
T1/2 2.94 (0.90) h
Tmax 2.10 (1.31) h
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Conclusion: The dosage of 400/100mg indinavir/ritonavir can maintain
adequate indinavir plasma concentrations and suppression of viral
replication was observed in all ten patients at 24 weeks follow up.
P1919 Factors correlated with adherence to HAART: a multicentre
study from an HIV-infected Greek population
N. Pitsounis, S. Peristeraki, N. Tsogas, N. Mangafas, M. Chini,
A. Lioni, A. Skoutelis, P. Nikolaides, P. Gargalianos, G. Panos,
T. Kordosis, V. Paparizos, A. Gikas, M. Moschou, G. Chrysos,
G. Koratzanis, M. Lazanas (Athens, GR)
Objectives: Poor adherence to HAART can result in treatment failure
and the development of resistant strains of HIV. We examined the
association between adherence to HAART and various factors in an HIV
infected population.
Methods: A structured questionnaire was distributed to the patients
regularly attending 11 Infectious Diseases Units in Greece (~2200
patients). Adherence to HAART was measured by self report. A single
question measuring frequency of dose omission within the previous
4 months was administered. Adherence was deﬁned as <10% of
doses missed. Statistical analysis involved non parametric correlations
(Spearman’s-Rho and Pearson’s c2). Statistical signiﬁcance was set
at 0.05.
Results: 482 patients completed the questionnaire, of whom 409 (84.9%)
were male and 73 (15.1%) were female. Mean age was 41 years
(range 20−80 years). Age, gender, adjustment to their new health status,
satisfaction with the number of pills taken and psychological support
received were not associated with adherence.
Factors correlated with adherence were length of known HIV infection
(rho = −0.16, p = 0.002), length of antiretroviral treatment (rho = −0.13,
p = 0.001), side effects of HAART (rho = −0.11, p = 0.0035), belief about
radical cure for HIV infection (rho = 0.11, p = 0.0034), and frequency of
condom use (rho = 0.14, p = 0.010).
Conclusion: Adherence to HAART correlates behaviorally positively
with the use of condoms (indicating risk aversion), as well as
psychologically positively with optimism about radical cure for HIV.
Simultaneously adherence to HAART is negatively correlated with
disease duration, measured by length of HIV seropositivity and length
of treatment, as well as with occurrence of side effects from HAART.
P1920 Increase in prevalence of primary mutations in naive HIV
patients in Spain
M. Cianchetta, A. Paravissini, S. Raso, A. Machuca, A. Goyenechea,
M. Gorgolas, R. Garcı´a, M. Fernandez-Guerrero (Madrid, ES)
Objective: Recent studies demonstrate the increase in the prevalence of
genotypic mutations of primary resistance to antiretroviral drugs among
drug naive HIV patients. The objective of the present work is to evaluate
the changes in the prevalence of primary and secondary mutations in
protease (P) and reverse transcriptase (RT) in drug naı¨ve HIV patients
in one year in our country
Methods: In 85 HIV infected patients, with no previous antiretroviral
treatment, viral RNA was extracted by Ampliprep system (Roche) and
genotypic testing was performed using Trugene (Bayer).
Results: Mutations of primary resistance to anti-retrovirals were found
in 9.4% of patients (5/53) till the end of 2005, with 4 patients with
mutations in RT and 1 in IP. However, this number increases till 14%
(12/85) at the end of 2006, with 5 patients with mutations in IP, 4 patients
with mutations in RT and 4 in both. In patients with no evidence of
primary mutations, secondary mutations in P were found in 28 out of
73 patients (38%), being the most common the changes in position L63.
Secondary mutations in RT were found in 15 out of 73 (20%) patients,
being changes in positions A98 and V179 the most frequents. Silent
mutation and polymorphisms were found in all patients.
Conclusions: Primary mutations that confer drug resistance in drug
naı¨ve HIV infected patients increased in our country from 9.4% to 14%
demonstrating a increment in the transmission of mutated virus
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P1921 Exogenous ventilator associated pneumonia incidence in a
medical-surgical intensive care unit: a four-year surveillance
M. Lecuona, L. Lorente, M. Miguel, B. Castro, S. Campos, Y. Pedroso,
A. Sierra (La Laguna, ES)
Objective: To evaluate the ventilator associated pneumonia (VAP)
incidence in an ICU, their aetiology and the exogenous VAP incidence.
Method: A 51 month duration prospective study, between July 1,
2000 to September 30, 2004 in a 24-bed medical-surgical Intensive
Care Unit (ICU) of a 650-bed tertiary hospital. Patients requiring
mechanical ventilation during more than 24 hours were included. The
following variables were taken from each patient: sex, age, APACHE II,
length of stay in ICU, days of mechanical ventilation, mortality and
diagnosis group. Diagnosis of VAP was established according CDC
guidelines. Throat swab and tracheal aspirate were taken at the moment
of admission and twice a week until discharge for bacterial ﬂora study
and/or respiratory infection and colonisation. Respiratory infections
and colonisation events were classiﬁed regarding the throat ﬂora, in
endogenous and exogenous.
Results: A total of 1434 patients were included: 65.1% male, mean
age 58.1±16.9, mean length of stay 19.14±21.49 days, APACHE II
15.28±6.82, mortality 23.8%. VAP incidence (I) was 18.96% (272/1434)
and VAP incidence by 1000 days of MV (DI) was 15.69‰ (279/18926).
Exogenous pneumonia was 7.22% of total VAP (20/277), with an I
of 1.39% of total patients and DI of 1.05‰. When we evaluated the
temporal evolution of exogenous VAP, we could appreciate a decrease
in I (from 3% to 1.4%) and in DI (from 2.4‰ to 1.05‰). More
frequently aetiological agents were non-fermenting Gram-negative bacilli
(31.3%), Staphylococcus aureus (23.6%) (48% of them were MRSA) and
Enterobacteriaceae (21.1%). There were no differences in the exogenous
VAP aetiology.
Conclusions: In our ICU exogenous VAP represents a little part of the
total amount of VAP. The decrease in the incidence could be due to
the effects that continuous surveillance makes in the staff when they
manipulate the patient airway.
P1922 Can routine microbiology data be used as a proxy marker
for infection?
M. Heginbothom (Cardiff, UK)
Objectives: Currently MRSA bacteraemia data is used as a proxy marker
for healthcare associated infections in England and Wales. However this
association has not been validated. The aims of the study were to assess
if routinely collected laboratory data could be readily retrieved from
laboratory systems, and to validate whether such data could provide a
proxy marker for infection.
Methods: The study was performed in six District General Hospitals
in Wales over a 12 month period in 2004. All microbiology data was
transferred into a relational database management system (DataStore)
and a programme was developed to mark the infection class of isolates:
• Invasive infection – blood culture, Cerebrospinal ﬂuid, sterile ﬂuid or
tissue.
• Non-Invasive infection – pus, sputum, urine, non-sterile ﬂuid, medical
device, mouth swab, ulcer swab, wound swab, genital swab, eye swab,
or other (miscellaneous specimens).
• Colonisation – ear swab, nose swab, screening swab or throat swab.
Clinical evaluations were performed by infection control nurses using
CDC deﬁnitions for nosocomial infections (Garner et al. 1988) to assign
a clinical infection class to each MRSA isolate. DataStore information
was then compared with the ICN-validated data to determine the degree
to which the data sets matched.
Results: Clinical evaluations were achieved for 3,924 MRSA isolates
(43 were excluded from the analysis as they did not match the study
criteria; data for 3,881 isolates were analysed). For those isolates classed
by DataStore as ‘Invasive infection’, clinical evaluation agreed with
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86.7% of the classiﬁcations. For those classed as ‘Non-invasive infection’
the agreement was 55.6% and for those classed as ‘Colonisation’ the
agreement was 85.7%.
Conclusions: This study shows that isolation of MRSA from speciﬁc
specimen types can provide a reasonably accurate indication invasive
infection or colonisation. Thus microbiological data from selected
specimen types could be used as a proxy marker for infection. However
the lack of agreement between clinical evaluation and specimen types
classed as indicating non-invasive infection suggests that caution should
be exercised in the selection of proxy infection markers.
P1923 Characterisation and management of healthcare onset
Clostridium difﬁcile associated diarrhoea in a hyperendemic
region in Germany
H-P. Weil, F. Mattner, R. van den Berg, P. Gastmeier, E. Kuijper,
U. Fischer-Bru¨gge (Nordhorn, Hannover, DE; Leiden, NL)
Objectives: To investigate whether intensifying infection control
measures or an antibiotic use programme is effective to reduce C. difﬁcile
incidence rates in three German hospitals (geriatrics [A], diabetology [B]
and internal medicine [C]).
Methods: A case of CDAD was deﬁned as a patient with diarrhoea and a
positive assay for C. difﬁcile toxin A/B. Medication use was subtracted
from an electronic pharmacy database. The strains were analysed by
PCR-ribotyping and pulsed-ﬁeld gel electrophoresis (PFGE) and the
antibiotic susceptibility was determined by E-test.
Results: In 2005, 120, 57 and 123 patients developed CDAD in hospital
A, B, or C, respectively. Isolated strains (n = 54) belonged to the two
PCR ribotypes 001 (A and C) and/or 046 (A and B), whereas typing
by PFGE (n = 38) revealed 9 different strains. Three strains accounted
for at least 6, 10, and 9 transmissions in A, B, or C, respectively. The
strains were resistant towards erythromycin (89%), clindamycin (96%)
and all quinolones (95%). In April 2006 A and B installed infection
control measures and reduced the ﬂuoroquinolone use, B also reduced
the use of clindamycin. A reduced the incidence rate by 70%, whereas
B could not lower the incidence rate. C switched from cefotaxime to
ampicillin/sulbactam without special infection control measures, thereby
reducing the incidence rate by 76%.
Hospital Incidence
ratesa
Transmission
rateb
Control
measures
Quino-
lonesc
Clinda-
mycinc
Cephalo-
sporinsc
2005 p.i.d PFGE (%) 2005 p.i. 2005 p.i. 2005 p.i. 2005 p.i.
A 58 17 6/12 (50) no yes 106 46 54 36 131 142
B 48 51 10/13 (77) no yes 176 66 134 70 119 166
C 38 9 9/13 (69) no no 78 56 29 27 184 54
a(CDAD/10,000PD); b(DDD/1000PD); cEstimated; dAfter intervention.
Conclusions: Multiresistant C. difﬁcile PCR ribotypes 001 and 046
are hyperendemic in northwest Germany. PFGE typing, rather than
PCR-ribotyping, allows the study of nosocomial transmissions. Infection
control measures should be installed and the use of ﬂuoroquinolones,
clindamycin and cephalosporins should be restricted.
P1924 Study on Clostridium difﬁcile-associated diarrhoea in a
hospital in Japan
Y. Ito, T. Matsushita, Y. Takahashi, T. Nakamura, K. Hayashi,
E. Morita, H. Kato (Gifu, Tokyo, JP)
Objectives: In Europe and North America, several outbreaks due to
NAP1/027 Clostridium difﬁcile have been reported. In our hospital
the number of patients with C. difﬁcile-associated diarrhoea (CDAD)
increased after January 2005. Our aim of this study is to know
nosocomial transmission of speciﬁc strains including NAP1/027 among
these patients.
Methods: Subjects were 15 patients who suffered from CDAD between
January 2005 and March 2006 in Gifu Red Cross hospital, general
hospital of 310 beds. The occurrence of CDAD did not concentrate
on a single ward, and extended to 5 wards. Five patients had recurrent
episodes of CDAD. CDAD was deﬁned as diarrhoea associated with
positive for toxigenic culture and/or toxin A assay. The toxin-producing
type of isolates was determined by PCR and PCR ribotyping of isolates
was performed.
Results: Twenty-two strains of C. difﬁcile were isolated from 22
episodes. Twenty strains of C. difﬁcile were toxin-A positive, toxin-B
positive and 2 strains were toxin-A negative, toxin-B positive. PCR
detecting the binary toxin gene was positive in 3 isolates from 2 patients.
Twenty-two isolates were typed into 9 different PCR ribotypes. Type smz,
which has been recognized as an epidemic type causing outbreaks in
multiple hospitals in Japan, was recovered from 7 episodes of 4 patients
and dominant in our hospital. Other three types were isolated from 2 or
3 patients each. Of 5 patients with recurrent CDAD, 4 patients relapsed
with the original strain and 1 patient acquired a new strain. PCR ribotype
gc8 (Brazier’s PCR ribotype 027) was isolated from one patient with
pseudomembranous colitis, who had recurrent diarrhoea caused by the
same type. This type was recovered from no other patients.
Conclusions: Not a wide spread of a single C. difﬁcile strain but a small
scale transmission of several C. difﬁcile strains was found to be related
to the occurrence of CDAD. Although nosocomial spread of NAP1/027
strain was not recognized in our hospital, the isolation of the strain in
Japan indicates the potential for wide spread of the strain in Japanese
hospitals.
P1925 Teicoplanin versus cefuroxime as prophylaxis in prosthetic
joint implant surgery
M. Galie`, E. Pistella, F. Napoleoni, G. Condarelli, C. Santini (Rome, IT)
Objectives: Infections after joint replacement require prolonged
antibiotic therapy and often graft removal. Staphylococci cause up to
70−90% of these infections. Antistaphylococcal prophylaxis decrease
the infection rate and Iº or IIº generation cephalosporins are routinary
employed. Glycopeptides (teicoplanin and vancomycin) represent a valid
alternative for the centres where methicillin-resistant staphylococci are
prevalent. Due to the risk of reduced susceptibility to glycopeptides and
to the lower activity against methicillin-susceptible strains the use of
glycopeptides for prophylaxis is recommended only as alternative and
for short periods. Aim of the study was to compare the efﬁcacy of
cefuroxime and teicoplanin in a hospital with high (60−80%) incidence
of methicillin-resistant staphylococci.
Methods: All the patients undergoing elective total joint replacement
over a 12-month period were randomly assigned to receive one of the
following prophylactic regimen: teicoplanin (a single dose of 400mg i.v.
preoperatively) or cefuroxime (2 g i.v. preoperatively and 1g i.v. every 8 h
postoperatively for 24 hours). Patients where daily controlled for wound
infection and antibiotics side effects. Gram stains and cultures of wound
secretions were routinary performed.
Results: Ninety consecutive patients were enrolled; 48 received
cefuroxime and 42 teicoplanin. The 2 groups were comparable with the
exception of a higher rate of patients >75 years, with femoral fractures
and with diabetes mellitus in the cefuroxime group. Three patients
(7.1%) in the teicoplanin group and 1 patient (2.0%) in cefuroxime group
developed a surgical wound infection. Methicillin-sensitive S. aureus
(2) and Corynebacterium spp. (1) were isolated from wound infections
in teicoplanin group and methicillin-resistant S. epidermidis (1) was
isolated from wound infection in cefuroxime group.
Conclusion: Our study conﬁrms the prevalent staphylococcal aetiology
and the efﬁcacy of cefuroxime. Two infections caused by methicillin
sensitive S. aureus occurred in the teicoplanin group. The present study
conﬁrms that by virtue of their excellent activity against methicillin-
sensitive Staphylococci, Iº and IIº generation cephalosporins should
be preferred for routinary perioperative prophylaxis in orthopaedic
surgery. Teicoplanin may represent a reasonable option when the risk
of methicillin-resistant staphylococcal infection is high.
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P1926 Surgical wound infections after median sternotomy: clinical
and microbiologic preliminary results of a large multicentre
study in Italy
C. Santini on behalf of the GIS-INCARD (Gruppo Italiano per lo
Studio delle Infezioni in Cardiochirurgia)
Objectives: Sternal wound infections (SWIs) after median sternotomy
are associated with high mortality and morbidity. Prevention, early
diagnosis and adeguate treatment are essential, but consensus abiut the
preoperative management and the best surgical treatment strategy is still
lacking. The aim of the study was to evaluate the incidence of SWI, the
occurrence of the known risk factors, the clinical and microbiologic
features and the current therapeutic approaches in a large series of
patients.
Methods: Nineteen divisions of Cardiac Surgery spread all over Italy
participated in a prospective, observational study. Pre, intra and post-
operative risk factors of all the patients undergoing median sternotomy
in the ﬁrst week of every month from October 2005 to July 2006 were
recorded. Further data were recorded for all the patients who developed
SWI.
Results: Overall, 1,746 patients were evaluated. Characteristics of
the patients are reported in Table 1. All patients received antibiotic
prophylaxis for a mean duration of 46.5 hours. Overall 76.1% received
cefazolin, cefuroxime or cefamandole, 24.7% had glycopeptides (8.1% as
single dose combined to other regimens) and 4.8% received ampicillin-
sulbactam or amoxicillin-clavulanate, 1.1% carbapenems and 1.2% other
antibiotics. Forty-six patients developed SWIs (2.7%); 78.5% were due
to Staphylococci. Deep SWIs were 26 (19 sternal osteomyelitis and
7 mediastinitis) and required reoperation (73%), mediastinal irrigation
(30.7%), closed mediastinal drainage (19.2%), vacuum continuous
aspiration (30.7%) and plastic surgery (23%). Forty-four patients
recovered (95.6%) and 1 died for mediastinitis.
Table 1
Mean age (years) 65.9
Mean preoperative hospitalisation (days) 5.5
Mean ASA score 2.95
Coronary artery bypass graft/valve replacement (%) 58.4/
34.9
Elective procedures (%) 88
Cardiopulmonary bypass (%) 90.9
Length of surgery >3 hours (%) 86.3
Preoperative hyperglycaemia (%) 22.7
Cigarette smoking (%) 21.3
Patients with cultures for staphylococcal nasal colonisation (%) 52.1
Staphylococcal nasal carrier (% of cultured patients) 8.6
Shaving of operative site (%) 97.8
Shaving of operative site at day of surgery (%) 40.6
Mechanical ventilation >24 hours (%) 19.5
Central venous catheter >72 hours (%) 32.7
MediastinaI drainage >72 hours (%) 19.4
Conclusions: The rate of SWI was acceptably low. However, efforts
for shorter hospitalisations before surgery, better control of preoperative
hyperglycaemia and for preoperative shaving closer in time to surgery
should be considered. The low rate of staphylococcal nasal carriers
suggests further evaluations for the routinary preoperative nasal cultures.
Although perioperative prophylaxis was mostly adequate for choice
of regimen and duration, only 76% of our patients received Iº or IIº
generation cephalosporins as recommended, the remaining receiving
vancomycin. Deep involvement was frequent and required re-operation
in 75% of cases. Mediastinal irrigation or drainage, vacuum aspiration
and plastic surgery were frequently required. One out of 7 patients with
mediastinitis died, conﬁrming the severe prognosis of this event.
P1927 Matching criteria in case-control studies in postoperative
infections
M.E. Falagas, E.G. Mourtzoukou, F. Ntziora, G. Peppas, P.I. Rafailidis
(Athens, GR)
Background: Matching is commonly used in case-control studies to
control for the effect of major confounding factors. We sought to evaluate
the available evidence from case-control studies regarding postoperative
infections to identify how frequently matching was performed and with
what speciﬁc variables.
Methods: We searched for relevant case-control studies archived by
PubMed until August 2006. Only studies regarding postoperative
infections were included in our review. We further evaluated studies
that used individual matching between cases and controls.
Results: We identiﬁed and evaluated 42 relevant studies. Age was used
as a matching criterion in 27 of these 42 (64.3%) case-control studies.
The speciﬁc type of surgical procedure was the second most commonly
used criterion, in 17 of 42 studies (40.5%). Gender was used in 14 of
42 studies (33.3%) as a matching criterion between case and control
patients. The period at risk for development of surgical site and/or other
postoperative infections, that is the time from surgery to the diagnosis
of infection was used in 9 of 42 studies (21.4%), as was the date
of operation, and the primary diagnosis that led the case and control
patients to surgery. Same surgeon or surgical team was used in 7 studies
(16.7%), while matching according to the National Nosocomial Infection
Surveillance system risk score was performed in 5 studies (11.9%).
Discussion: The ﬁndings of our analysis suggest that various characteris-
tics have been used for matching in case-control studies of postoperative
infections. A more consistent use of matching with the speciﬁc type
of surgical procedure may help in increasing the internal validity of a
case-control study in this ﬁeld of clinical research.
P1928 Risk factor analysis for surgical site infections following
vascular surgery
F. Mattner, E. Ott, I. Chaberny, P. Gastmeier, O. Teebken (Hannover, DE)
Objective: To determine surgical site infection (SSI) rates in abdominal
and peripheral vascular surgery and to perform a risk factor analysis
Methods: Between Jan 2002 and Dec 2005 all patients (pts) receiv-
ing vascular surgery (thoraco-abdominal, abdominal, retroperitoneal,
iliaco-femoral, femoral, femoro-distal replacements, patches, stents or
bypasses) were included in our cohort study. SSIs were determined
according to CDC deﬁnitions. Postdischarge data were included when
available. Risk factor analysis was performed including indications for
surgery, emerging procedures, intervention procedures, demographic
data, and material of vascular grafts as variables.
Results: In 750 pts, 73 thoraco-abdominal, 276 abdominal, 24
retroperitoneal, 172 femoral and 53 femoro-distal surgical procedures,
99 stent-graftings and 112 embolectomies were performed (combined
intervention are included). 42 (5.6%) pts developed SSIs in average 11.5
days (range 5 to 33 days) after surgery. 28 (3.7%) superﬁcial, 10 (1.3%)
deep SSIs and 4 (0.5%) organ space infections occurred. S. aureus
[13 (31%), out of which 8 (19%) were MRSA], CoNS [17 (40%)],
enterococci [14 (33%)], and P. aeruginosa [7 (17%)] were the most
prevalent pathogens [other pathogens (21 (26%)]. Vascular surgery in
pts with femoral interventions (relative risk (RR) 2.3, 95%CI 1.6;3.4,
p< 0.001), operative revisions (RR 1.2, 95%CI 1.1;1.4, p< 0.001),
peripheral vascular disease class Fontaine III (OR 3.5, 95%CI 1.5;8.2,
p = 0.002) and the use of autologous vessels (RR 2.0, 95%CI 1.3;3.3,
p = 0.008) increased the infection risk signiﬁcantly. Elective aneurysm
repair (OR 0.4; 95%CI 0.21;0.77, p = 0.008), and the use of stents (RR
n.d., p = 0.01) was associated with a decreased infection risk.
Conclusion: In vascular surgery postoperative surgical site infections
occur frequently (incidence 5.6%). The choice of surgical access,
graft material and the grade of peripheral vascular disease at the
time of surgery were found crucial risk factors for the development
of surgical site infection in vascular surgery. Future studies should
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address modiﬁcations of surgical access, graft materials, and whether
the decision for an intervention in earlier stages of peripheral vascular
disease would prevent surgical site infections.
P1929 Joint implant infections in a general hospital
F. Moreno, J. Aguilar, M. Noureddine, J. De la Torre, J.L. Prada,
A. Del Arco, L. Merida, J.D. Ruiz-Mesa (Marbella, ES)
Objectives: to analyse features and sources of joint implant (JI)
infections and the medical and surgical treatment in our hospital.
Method: Retrospective study of patients admitted suffrering from JI
infections from 1997 to 2005. Hospital data base and discharge reports
were used.
Results: 89 patients were admitted. 15 had 2 admissions and 8 three
admisions with a total of 121 cases of JI infection. The mean-age was 73
± 12.39 years. 64% were female. 22% were diabetic, 25% heart patients
and 11% COAF patients. In 57% artrosis was the cause of JI indication,
and 32% by fracture. 60% were hips (96% by fracture), and 38% from
knee (63% by artrosis). 85% were the ﬁrst JI: 81% complete/16% parcial.
In 45% ﬁrst symptom started in ﬁrst month after surgery, 34% between
1 month and 2 years and 20% more than 2 years after surgery. Only
20% had risk factors for infection, 10% surgical wound infection and
10% haemorrhage and haematoma. The more recurrent symptoms were
local inﬂamation or wound drainage in 50%, joint pain in 31% and
fever in 14%, a ﬁstula in 8% and in 2% joint effusion. Bacteria were
isolated in 57%, in 36% from ﬁstula or injure 9% from joint ﬂuid
and the others from surgical samples or blood stream. Only a bacteria
was isolated in 82%. In 12% were 2 bacterias and in 6% more than
2. In 57% Staphylococcus was isolated (37% S. aureus, and 20% S.
coagulase negative), in 19% Bacillus Gram-negatives (P. aeruginosa and
E. coli), and 14% Streptococcus (beta-haemolytic streptococcus, viridans
and enterococcus), and 6% were with more than 2. About therapy,
surgical cleaned and antibiotical treatments were performed in 66%.
JI was removed in 15% with reinstatement of a new JI. JI removed
without a new implant and antibiotics in 9%. In the others, parcial JI
were removed, cronic antibiotical treatment was indicated or amputation
was made. The mean length of stay was 24 days (TD 19.33). Only
2 died. The common antibiotical combination was aminoglicosides plus
cloxacilin or cefazoline, vancomycin or ciproﬂoxacin (44%), and cocktail
with ciproﬂoxacin plus cloxacilin, rifampicin or vancomycin (16%). One
case was treated only with one antibiotic. Ciproﬂoxacin was the wide
used (12%). After discharged therapy was prolonged between 3 and 16
weeks with a mean of 7 weeks.
Conclusions:More than 50% were late JI infections but in less than 50%
JI was removed. In the causes, S. aureus is the main bacteria followed
by Staph coagulase negatives and Gram-negatives.
P1930 A nosocomial outbreak due to Serratia marcescens in a
West-Tallinn hospital
I. Zolotuhhina, R. Voiko, P. Albri, V. Adamson, K. Allik (Tallinn, Tartu,
EE)
Objectives: A nosocomial outbreak due to S. marcescens in neonatal
unit of West-Tallinn Central Hospital involving 7 neonate patients was
investigated.
Materials and Methods: During 2005 and 2006 total of 1796 specimens
(369 blood cultures and 1427 swabs taken from nasopharynx, eyes, ears
and umbilical wounds) from patients with clinical signs of infection were
examined. First isolation of S. marcescens from blood of twins, one of
whom developed meningitis (S. marcescens was also isolated from the
cerebrospinal ﬂuid) and another sepsis was registered in November
2005. 6 following isolates were obtained in the period from April
to May 2006 from 5 patients – 2 from blood cultures and 4 from
nasopharyngeal swabs. All these patients manifestated clinical symptoms
of true infection (purulent rhinitis, sepsis). A nosocomial infection was
suspected. The epidemiological investigation included the review of
medical records and of medical and nursing practices in the department.
40 environmental samples from surfaces and medical equipment were
examined. All cultures were identiﬁed initially by BBL Crystal and
conﬁrmed by other biochemical tests. Susceptibility of all strains against
6 antibiotics was determined by the CLSI agar dilution method. Pulse-
ﬁeld gel electrophoresis (PFGE) was used for genotyping of 6 strains.
Results: During epidemiological investigations a single S. marcescens
strain was isolated from the inner surface of the bottle with 0.05%
xylomethazoline drops used for the patients with nasal congestion.
The bottle had been in use during several months. All investigated
strains of S. marcescens had similar antibiotic susceptibility proﬁles.
6 cultures recovered from clinical material and from the bottle showed
indistinguishable PFGE patterns. This led to conclusion that the bottle
with nasal drops contaminated with S. marcescens was the likely
reservoir from which the spread of infection occurred. The bottle was
eliminated and that put a rapid end to the outbreak. No new recovery of
S. marcescens from patients and unit environment has been registered
since May 2006.
Conclusions: The outbreak was related to the bottle with nasal drops
contaminated with S. marcescens. From November 2005 till May
2006 7 neonates in the unit developed clinical manifestations of true
S. marcescens infection. The outbreak stopped after the elimination of the
bottle. The importance of following good medical practice and standard
hygienic precautions should be stressed out.
P1931 Microbiological epidemiology of infections related to
pace-makers and indwelling cardiac deﬁbrillator
C. Tascini, M. Bongiorni, G. Gemignani, E. Soldati, A. Leonildi,
G. Arena, S. Capolupo, F. Menichetti (Pisa, IT)
Background: The cardiology Unit at Cisanello Hospital in Pisa is the
Italian reference centre for non invasive, transvenous removal of infected
pace-makers (PM) or indwelling cardiac deﬁbrillator (ICD). The aim of
the study is to review microbiological ﬁndings of PM and ICD infections
observed at this Unit in ﬁve years period (2000–2005).
Materials and Methods: Retrospective observational study on
consecutive patients. All patients with clinically documented PM or ICD
infections were enrolled in the study. To deﬁne the aetiology of the
infections. Catheter leads and/or the infected material from the pocket
upon removal were cultured in aerobic and anaerobic solid media.
Results: In the study period PM and ICD leads and generators were re-
moved transvenously from 602 patients. Microbiological documentation
was obtained from 451 patients (75%) and 560 different microorganisms
were isolated; therefore we had negative culture in 151 patients. In
99 patients infections were polymicrobial. Staphylococci were the most
frequently isolated pathogens (474/560−84%). The coagulase-negative
staphylococci (CNS) resulted the ﬁrst pathogen (380) followed by
S. aureus (94), methicillin-resistant strains, among staphylococci, were
123/474 (26%). Gram negative rods and fungi are relatively rare. Overall
susceptibility were also studied; the classes of antibiotic with good
activity were newer quinolones (moxiﬂoxacin and levoﬂoxacin followed
by aminoglycosides and glycopeptides).
Year Total
2000–2001 2002–2003 2004 2005
Patients 121 228 136 127 602
Microrganisms isolated 132 180 128 120 560
CNS 93 (70%) 117 (65%) 89 (69%) 81 (67%) 380 (68%)
S. aureus 19 (14%) 35 (19%) 19 (15%) 21 (18%) 94 (17%)
Total MR staphylococci 33 (29%) 36 (30%) 29 (22%) 25 (25%) 123 (26%)
Gram-negative rods 16 14 3 2 35 (6%)
Yeasts/moulds 1 4 2 5 12 (2%)
Others 4 10 15 11 40 (8%)
Conclusions: In our experience PM and ICD infections were mainly
caused by Staphylococci, especially CNS, other microorganisms (Gram-
negative rods and fungi) were also documented in few cases. The
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knowledge of the epidemiology of these infections and the susceptibility
to antibiotics might be useful for clinicians to start an adequate empiric
antibiotic therapy.
P1932 REA-RAISIN: microbiology of national surveillance
network of ICU-acquired infections, France, 2005
R. Gauzit, A. Savey, A. Lepape, B. Tressieres, N. Garreau, T. Lavigne,
F. L’Heriteau, P. Parneix, J. Fabry, B. Coignard on behalf of the
National Nosocomial Infection Alert, Investigation & Surveillance
Network (RAISIN), France
Background: The objective of nosocomial infections (NI) surveillance
in intensive care units (ICU) is to assess and compare rates, microbiology
and resistance over time and amongst ICUs, in order to provide an
evidence-based approach for improving infection control practices.
Methods: In France in 2004, surveillance methods were standardised
through a national surveillance project (raisin). The national REA-
RAISIN network conducts 6 months a year a patient-based NI
surveillance in ICU. Surveillance (on a voluntary basis and using
a standardised methodology) focuses on device related-infections:
ventilator-associated pneumonia (PNE), urinary tract infections (UTI),
central venous catheter colonisation (COL) with or without catheter-
associated infections and bacteraemia (BAC). A maximum of 2 bacteria
are recorded for each infection with, for the most relevant of them,
resistance markers.
Results: From January to June 2005, 151 ICUs included 20,632 patients.
A total of 5 159 events were documented concerning 2 569 patients
(12.4%). The distribution of micro-organisms per site under surveillance
is illustrated in the table. The resistance markers were: MRSA 47.5%,
Enterococcus ampicillin-R 18.5%, Enterococcus vancomycin-R 1.8%,
Enterobacteriaceae cefotaxime-R 17.2%, A. baumannii ceftazidime-R
78.6%, P. aeruginosa ceftazidime-R 22.6%, and S. maltophilia
ceftazidime-R 48.5%.
PNE
(n = 2,314)
COL
(n = 840)
BAC
(n = 785)
UTI
(n = 1,428)
Enterobacteriaceae 29.1% 24.3% 26.7% 45.6%
Other GNB 3.3% 0.2% 1.9% 0.2%
P. aeruginosa 19.7% 14.4% 8.5% 15.9%
A. baumannii 2.2% 2.4% 1.0% 1%
Haemophilus sp. 5.4% – – –
S. aureus 22.8% 13.5% 18.6% 1.8%
CNS 2.4% 35.7% 21.2% 2.1%
Enterococcus sp. 0.7% 3.5% 8% 12%
Other GPC 6% 0.5% 3.9% 1.7%
Candida sp. 5.4% 3.7% 5.2% 18.1%
Anaerobes 0.2% – 3.7% –
Others 2.7% 1.5% 0.9% 1.4%
Conclusion: This report on microbiology and resistance markers of NI
surveillance in ICU from a large sample of French hospitals will serve as
a national reference and will allow describing, evaluating and monitoring
resistance level in ICUs. Feedback to ICUs provides them with relevant
information to monitor and target antimicrobial use and infection control
policies.
http://www.invs.sante.fr/raisin/
P1933 Clinical outcomes of Clostridium difﬁcile ribotype 027
infection versus other ribotypes at a UK hospital
R. Whiting, J.C. O’Driscoll (Aylesbury, UK)
Objectives: Stoke Mandeville Hospital came to prominence due to a
large outbreak of Clostridium difﬁcile disease over a two-year period. It
was the ﬁrst site in the UK where ribotype 027 was identiﬁed, and the
initial clinical impression was that infections due to this ribotype were
more severe and resulted in more relapses and deaths than had been
experienced previously.
The objective of this study was to study patient records retrospectively
to determine whether or not infection with ribotype 027 resulted in a
poorer outcome than that with other ribotypes grouped together.
Methods: A survey form was designed. Notes of patients whose
C. difﬁcile strains had been typed between February 04 and October
05 were reviwed. The results were analysed statistically.
Results: The notes of 77 patients were studied. Forty-ﬁve of these (58%)
had ribotype 027 infection, infection was due to ribotype 001 in 13 cases,
ribotype 106 in 12 cases, ribotype 026 in 2 cases, and the following
ribotypes were found in 1 patient each; 005, 017, 050, 078 and 081.
The median age of patients in both the 027 and non-027 groups was 79
years.
There was no statistical difference in any of the following between
ribotype 027 strains and non-027 strains: duration of diarrhoea (ﬁrst
episode), number of relapses, and crude mortality. In addition, there was
no statistical difference in any of the following parameters between the
2 groups (as measured on admission to hospital, at onset of symptoms,
and 1 week after onset of symptoms): white cell count, haemoglobin,
sodium, potassium, creatinine, C-reactive protein, or albumin.
Conclusion: This study suggests that, despite initial perceptions to the
contrary, C. difﬁcile ribotype 027 infection is no more severe than that
due to other ribotypes.
P1934 Ointments as a source of methicillin-resistant Staphylococcus
aureus spread
D. Orth (Innsbruck, AT)
Objectives:Methicillin-resistant Staphylococcus aureus (MRSA) has for
several years been increasingly spreading at inpatient and outpatient
healthcare facilities and constitutes a great epidemiological problem.
Colonised and infected patients represent the most important reservoir
and MRSA is transmitted by direct person-to-person contact, usually
on the hands of healthcare workers. Long term carrier and recurrent
infections/colonisations occur despite optimal preventive hygienic
measurements. The source of MRSA spread is unknown in such cases.
The aim of this study was to investigate the contamination of ointments
as a source of MRSA spread in the University Hospital of Innsbruck.
Methods: During a six month period, ointments of MRSA-positive
patients were screened for MRSA contamination. MRSA strains
collected from patients and ointments were tested for in vitro
susceptibility and the automated ribotyping was used for molecular
typing. Ointments primary for skin care and other medical indications
were applied for one patient only and used during hospitalisation.
Results: A total of 101 ointments from19 MRSA-positive patients
were examined. Seven ointments specimens (6.9%) (Bepanthen®,
Candio-Hermal® soft paste, Spoendlin’sche® nasal ointment and even
Bactroban®) from 3 patients were found positive for MRSA. Four
different ribotypes (RT 2, 6, 10, 12) were occurred in patients and 2
in ointments (RT2, 6). MRSA from the ointments were identical to
MRSA collected from patients as shown by ribotypes and antimicrobial
susceptibility proﬁle in all cases.
Conclusions: Ointments, in use for patients care were contaminated with
MRSA and could therefore contribute to MRSA spread in the patient-
setting.
P1935 Retrospective analysis of multidrug-resistant Acinetobacter
baumannii isolates recovered during a 3-year period in a
Portuguese hospital
G.J. Da Silva, T. Ferreira, A. Duarte (Coimbra, Lisbon, PT)
In Portugal, an A. baumannii multi-resistant strain belonging to European
clone II is disseminated since 1998 and is endemic in some hospitals.
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Objective: In recent years, the Hospital dos Capuchos, a hospital
located in Lisbon, has increasingly observed the isolation of resistant
A. baumannii. The main goal was to study the epidemiology of
A. baumannii infection during 2004–2006 and to determine whether the
European clone II strain was, at present, endemic.
Methods: During the period of December 2003 until September 2006,
49 non-duplicate A. baumannii isolates were collected. Antibiotic
susceptibility was determined by VITEK2 Advanced Expert System.
Clinical epidemiologic study of A. baumannii isolates was performed
by combination of antibiotyping and randomly ampliﬁed polymorphic
DNA analysis (RAPD).
Results and Conclusions: Isolates were more frequently recovered from
older patients (55 to 70 years old, 26.5%; 71 and more, 55%). Fifty
seven per cent of the isolates were collected from intensive care units
samples, 32.7% from Medicine wards, 8.2% from Surgery wards and 2%
from Haematology. They were isolated mainly from bronchial secretions
(40.8%), urine (24.5%) and blood (22.4%). Ten different antibiotypes
were found, according to antibiotic susceptibility proﬁles. The majority
of isolates collected since January 2004 showed multidrug-resistance.
Only one isolate from January 2004 showed a susceptibility proﬁle, with
a unique DNA ﬁngerprint. During 2004, it was observed an increasingly
higher genetic diversity (ﬁve genotypes), replaced at the end of the
year, and subsequent years, by two major clusters. Both were multidrug
resistant, including resistance to carbapenems and quinolones. Cluster
A isolates were consistently susceptible to gentamycin and amikacin,
showing intermediate susceptibility to ceftazidime, while isolates from
cluster B were resistant to all antibiotics except to tobramycin and
amikacin (variable susceptibility). Phenotypic and genotypic proﬁles of
cluster B isolates were compatible with those of European clone II strain.
At our knowledge, cluster A is found for the ﬁrst time in Portugal in this
hospital. Although, considering antibiogram and DNA ﬁngerprinting, it
cannot be considered as a clone. It is possible that these isolates may
have evolved independently from a common ancestor, forming a recent
lineage. The study shows that several multidrug-resistant clusters of EU
clone II can coexist endemically for several years.
P1936 Assessment of the risk factors for mortality in
hospital-acquired Acinetobacter baumannii infections in a
teaching hospital
C. Bulut, M.A. Yetkin, F.S. Erdinc, C. Ataman Hatipoglu, U. Onde,
E.A. Karakoc, N. Tu¨lek (Ankara, Samsun, TR)
Objectives: Acinetobacters are increasingly involved as aetiological
agents of hospital acquired infections in seriously ill patients, in recent
years. The aim of this study was to evaluate the hospital acquired
Acinetobacter baumannii infections and to assess the risk factors
associated with mortality.
Methods: Prospective laboratory based active surveillance has been
performed in our hospital between January 2000 and December 2004.
Hospital acquired infections were diagnosed according to the CDC
criterias. Conventional methods were used for the identiﬁcation of
Acinetobacter isolates. Disc diffusion method was used for antimicrobial
susceptibility test of the microorganisms.
Results: Hospital acquired Acinetobacter baumannii infections were
detected in 95 male and 71 woman patients. The mean age of
the patients were 58.0±17.8 years. Acinetobacter baumannii was
isolated mainly from the ICU patients (32.5%), from the patients on
the orthopaedy wards (16.3%) and on the neurology ward (11.4%)
consecutively. Predisposing factors detected in the patients infected
with Acinetobacter baumannii were urinary catheter insertion (81.3%),
mechanical ventilation (25.3%) and central venous catheter (21.1%)
consecutively. The mean duration of time between hospitalisation and
occurrence of infection were 17.2±14.8 days. Urinary tract infection,
surgical site infection, primary bloodstream infection and hospital
acquired meningitis were the most common infections and existed in
30.1%, 29.5%, 17.5% and 7.3% of patients respectively. Carbapenems
and netilmicin were the most effective antimicrobials agents against
Acinetobacter isolates and an evident decrease in amicasin resistance
was detected overall the ﬁve year period.
Crude mortality rate was 36.5%. Older age (60 years), mechanical
ventilation, presence of central venous catheter, tracheostomy, being an
ICU patient, presence of coma and having a carbapenem resistance
were found to be associated with mortality due to A baumannii
infection by univariate analysis. Of these factors older age ( 60 years),
mechanical ventilation, presence of coma and being an ICU patient
were independently associated with mortality on multivariate analysis
(p< 0.05).
Conclusion: These data suggest that, clinical efforts aimed at the
improvements in the medical management of ICU patients with severe
A. baumannii infection especially those who need mechanical ventilation,
are required for further improvement in patient outcome.
P1937 Multidrug-resistant Acinetobacter baumannii in a surgical
intensive care unit
J.M. Sahuquillo Arce, E. Colombo Gainza, A. Gil Brusola, P. Ramirez
Galleymore, M. Bosch Alepuz, J. Cordoba, M. Gobernado (Valencia, ES)
Objective: To study the changes in the population of Acinetobacter
baumannii in a period of two years (2003–2005) in an endemic situation
of a surgical ICU.
Materials and Methods: We contrasted the antibiotic susceptibility
(Rosco Disk diffusion and bioMe´rieux VITEK2) and the genetic
polymorphism (Amersham Biosciences Random Ampliﬁed Polymorphic
DNA [RAPD]) data of two environmental studies conducted in
February 2003 and January 2005 in a surgical ICU to determine the
colonisation pressure of multidrug-resistant A. baumannii. The antibiotic
consumption of this department and the percentage of patients who
suffered a bacteraemia by this microorganism were analysed as well.
Results: Nineteen strains of A. baumannii were isolated in the
ﬁrst study, this represented 20% of all the samples included. They
were classiﬁed into three different clones by the RAPD: clone 1 (5
isolates) was susceptible to sulbactam/ampicillin (SAMP), colistin (CS),
sulfamethoxazole trimethoprim (SXT), and two of the isolates were also
susceptible to amikacin (AMK); clone 2 (13 isolates) was susceptible
to SAMP, CS, AMK, and ﬁve isolates were intermediate to cefepime
(CEFP); clone 3 (1 isolate) was only susceptible to CS.
Thirty seven strains of A. baumannii were isolated in the second study,
this meant 31% of all the samples included. They were classiﬁed into the
three original clones by the RAPD: clone 1 (18 isolates) was susceptible
to SAMP, CS, SXT and two of these were also susceptible to AMK;
clone 2 (3 isolates) was susceptible to CL, AMK, intermediate to CEFP
and SAMP; clone 3 (16 isolate) was only susceptible to CS.
The consumption of SXT during that period of time did not vary, while
that of CEFP decreased to half its previous value. On the other hand, the
use of SAMP and AMK reached three times its initial level. Bacteraemia
by A. baumannii increased constantly from 2.8% to 4%.
Conclusions: A population of multidrug-resistant A. baumannii has
settled at our surgical ICU. Three different clones comprise all the
isolates found in both studies with a two-year delay, which points to
an endemic colonisation. The antibiotic pressure over this population
due to the increased use of AMK and SAMP favoured the expansion of
clones 1 and 3, whereas clone 2 almost disappeared. An extensive use
of antibiotics against this microorganism did not improve the situation,
moreover, the number of bacteraemia cases augmented and the treatment
options dimished.
P1938 Use of nested PCR for evaluation of Helicobacter pylori
transmission by endoscopies
H. Mikkelsen, L.P. Andersen (Copenhagen, DK)
Objective: Helicobacter pylori colonise the gastric mucosa of almost
half the world population and have been recognized as the main cause
of gastritis. Additionally, it is considered to play a major role in
development of duodenal ulcers, gastric ulcers and gastric lymphoma
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as well as gastric cancer. Infection is usually acquired in childhood
and it is speculated that infections occurs primarily from person to
person via faecal-oral routes. However, the precise route of transmission
remains undocumented and so far no reservoir for the bacteria has been
identiﬁed outside the human stomach. Endoscopy is a potential source
of nosocomical infection and several studies have described transmission
of infectious agents via contaminated endoscopes. Different approaches
have been applied in order to prevent such iatrogenic infections,
and have resulted in the formulation of strict guidelines for cleaning
and disinfections of endoscopes after use. At Copenhagen University
Hospital, Rigshospitalet endoscopes are cleaned in endoscopic washing
machines after use. The quality of cleaning and disinfections is
monitored by routine inspections. During the last 5 years the measured
germ number have been very low and H. pylori has not been identiﬁed
in these samples.
Methods: To assess the efﬁcacy of cleaning of endoscopes water samples
were collected from both the air channel and biopsy channel of 20
endoscopes. In the latter case a brush was passed through the channel
followed by cleaning of the brush in sterile water. The water samples
were processed and a Helicobacter pylori-speciﬁc PCR targeting the 16S
rDNA gene was conducted to determine the presence or absence of the
bacteria in the water samples.
Results: Samples from all endoscopes were found to be negative with
respect to the presence of H. pylori.
Conclusion: Based on the absence of H. pylori it is concluded that the
present cleaning practise is sufﬁcient to prevent iatrogenic infections in
relation to endoscopes.
P1939 Catheter-associated urinary tract infections: distribution of
uropathogens and patterns of antimicrobial resistance in
an Italian hospital (2000–2006)
M. Bonadio, T. Tartaglia, S. Fondelli, G. Andreotti (Pisa, IT)
Objectives: To evaluate some risk factors which could affect the isolation
rates of various uropathogens and their in vitro antibiotic resistance in
patients with catheter-associated urinary tract infection (CAUTI) at an
Italian teaching hospital.
Methods: A prospective study was conducted in an Urinary Tract
Infections Clinic at Pisa General Hospital. Two hundred twenty-
nine patients (72 males and 157 females) with documented CAUTI
(104 CFU in a catheter sample of urine) were enrolled from January
2000 to October 2006. One hundred eighty-four (81.3%) of all patients
were over the age of 70. The distribution of uropathogens and their in
vitro susceptibility to antimicrobials were evaluated.
Results: The causative microorganism of CAUTIs were the following:
Escherichia coli (28.4%), Enterococcus spp. (18.3%), Pseudomonas
spp. (12.6%), KES group spp. (10.0%), fungi (10.0%). E. coli was
more frequently isolated in women than in men (31.8% vs 20.8%
respectively; p = 0.1). An increased trend of fungi (mostly Candida spp.)
isolation rate throughout the whole study period was observed. E. coli
patterns of antibiotic resistance were the following ones: cotrimoxazole
(35.0%), ampicillin (51.6%), ciproﬂoxacin (18.6%), nitrofurantoin
(12.7%). Enterococci were all susceptible to vancomycin and teicoplanin.
Pseudomonas spp. were frequently resistant to ciproﬂoxacin (40.7%); the
most active antibiotics against Pseudomonas were imipenem, amikacin,
piperacillin-tazobactam and aztreonam. E. coli showed a signiﬁcant
increase of resistance (p = 0.03) to ciproﬂoxacin during the study
period. E. coli and Enterococcus spp. isolated in patients who received
antimicrobials within the 2 months prior to their enrollment were often in
vitro resistant to ciproﬂoxacin and gentamycin. Nitrofurantoin remained
the most active drug against E. coli and Enterococcus in both groups of
patients whether or not they received antimicrobial drugs.
Conclusions: The type of uropathogens associated with CAUTI have
changed over the last 7 yrs at our hospital. The gender of patients seems
to inﬂuence the isolation rate of E. coli. An increased trend of isolation
rate of fungi has been observed during the study period. A previous
antimicrobial treatment in patients with CAUTI increases the risk of
isolation of uropathogens resistant to the antimicrobials.
P1940 Epidemiology of MRSA colonisation in a university hospital
and a cardiosurgical hospital in Hessen, Germany
A. Knaust, K. Madlener, N. Tschernych, J. Barekzai, T. Eikmann,
C. Herr (Giessen, Bad Nauheim, DE)
Objectives: Infections caused by methicillin resistant Staphylococcus
aureus (MRSA) are a major health problem in German hospitals,
causing increased duration of hospital stay and incidence of mortality.
In 2004 the Paul-Ehrlich Institute published a rate of 22.6 percent
methicillin resistant isolates amongst all S. aureus isolates sent in
by reference laboratories. Since rates of methicillin resistance have
constantly increased during the last decades strategies to prevent a further
spread of MRSA are urgently needed. Screening of incoming patients
became more and more evident to be an effective method to decrease
rates of colonisation and infection with MRSA in hospital patients. In
previous studies various designs were used for MRSA screening and
each strategy needs careful evaluation for each hospital or healthcare
facility.
Methods: In the current study based in a university hospital and a
cardiosurgical hospital, different strategies were used to screen incoming
patients for colonisation or infection with MRSA: (i) patients who belong
to risk groups (history or MRSA, wounds, haemodialysis, submission
from healthcare facilities); (ii) patients who were admitted to selected
departments or wards (intensive care units); (iii) all patients were
screened upon admission. Microbiological diagnostics were performed
either by bacterial cultures or by a real time PCR based method.
Results and Conclusion: The total prevalence of MRSA colonisation
and/or infection was about 3 percent during the initial four month period
comprising more than 1000 screening samples. Most of the classical
risk factors showed only weak correlation to an enhanced risk of MRSA
colonisation. Screening of risk groups will miss many asymptomatic
MRSA carriers as could be shown when complete screening of all
admissions was performed. A fast microbiological veriﬁcation is of great
advantage for patient management on the wards to reduce preventive
isolation measures, i.e. single rooms. Each hospital needs to evaluate its
individual patient population to establish an effective and save screening
strategy to prevent MRSA transfer and infection.
P1941 A practical approach to post-discharge surveillance of
surgical site infections
A. Knaust, A. Moussa, T. Eikmann, C. Herr (Giessen, DE)
Objectives: Surgical site infections account for about 30 percent of all
nosokomial infections, resulting in prolonged hospital stay, increased
rate of morbidity and mortality and additional costs for hospitals and
public health systems. Systematic surveillance of infections has been
shown to serve as an effective tool to improve hygiene management
and consecutively to reduce infection rates and costs. As, in times of
increasing cost pressure, duration of hospital stay after many surgical
interventions is minimised to a few days, surveillance during hospital
stay is suspected to miss a major part of infections.
Methods: In the current study surgical site infections in ﬁve surgical
departments were monitored during hospital stay by a computer assisted
on-ward surveillance system and after discharge from the hospital by a
questionnaire and personal communication by telephone.
Results and Conclusion: The vast majority of surgical site infections
were found by post-discharge surveillance. Infection rates were up to
8-fold higher than during on-ward surveillance. About 90 percent of
infections became evident within 10 days after surgical intervention.
The evaluation of the symptoms pain and tumour by the questionnaire
were shown to be a fairly good screening tool. The combination of these
two questions led to a positive likelihood ratio of 4.75 and negative
likelihood ratio of 0.29 for the detection of a surgical site infection,
taken the telephone interview as gold standard. These results demonstrate
a simple and time saving approach for the surveillance of surgical site
infections which overcomes the bias caused by shortened hospital stays
after surgical interventions.
S558 17th ECCMID / 25th ICC, Posters
P1942 A low nurse-to-patient ratio is an independent risk factor
for late-onset VAP
I. Uc¸kay, S. Hugonnet, H. Sax, D. Pittet (Geneva, CH)
Background: The economic and clinical burden of ventilator-associated
pneumonia (VAP) is uncontested. The role of nurses’ understafﬁng is
poorly understood.
Objective: To assess whether low nurse-to-patient ratio increases the risk
of VAP and whether this effect is similar for early-onset and late-onset
VAP.
Methods: Prospective, observational, single-centre cohort study con-
ducted in the medical intensive care unit (ICU) of the University of
Geneva Hospitals. All patients at risk of ICU-acquired infection admitted
from January 1999 to December 2002 were followed from admission to
discharge. Collected variables included patient characteristics, admission
diagnosis, APACHE II score, comorbidities, exposure to invasive devices,
daily number of patients and nurses on duty, nurse training level and all-
site nosocomial infections. VAP was diagnosed according to standard
deﬁnitions. VAP was deﬁned as early-onset when occurring 1 to 5 days
after intubation, and late-onset when occurring from day 6. Respiratory
infections other than VAP were excluded.
Results: Of 2470 patients who were followed during their ICU
stay, 262 VAP episodes were diagnosed in 209/936 patients (22.3%)
receiving mechanical ventilation. Late-onset VAP accounted for 61%
of all episodes. Median duration of mechanical ventilation was 3 days
(interquartile range, 3−11). VAP rate was 37.6 episodes per 1000 days
at risk (95%CI, 33.2–42.4). ICU mortality among patients with and
without VAP was 33.5% and 31.2%, respectively (p = 0.54), whereas
hospital mortality was 45.0% and 39.5%, (p = 0.154). Neither the nurse
training level nor the APACHE II score had any effect on the hazard of
VAP.
The median daily nurse-to-patient ratio over the study period was
1.9 (interquartile range, 1.8−2.2). Results were similar in multivariate
analysis for all VAP (adjusted HR 0.66, p = 0.11) and early-onset VAP
(adjusted HR, 0.78, 95%CI, 0.42–1.45). For late-onset VAP, a higher
nurse-to-patient ratio was independently associated with a reduced risk in
multivariate Cox regression analysis (adjusted HR, 0.42, 95%CI, 0.18–
0.99).
Conclusions: A low nurse-to-patient ratio is an independent risk factor
for late-onset VAP.
P1943 Intensity of care is the major determinant of coagulase-
negative staphylococcal bacteraemia in NICU: implications
for risk adjusted surveillance of hospital-acquired infections
P.H. Phillips, M. Cortina Borja, M. Millar, L. Thalib, S. Kempley,
R. Gilbert (London, UK; Kuwait City, KW)
Coagulase-negative staphylococcus (CNS) is the commonest cause of
bacteraemia in UK Neonatal Intensive Care Units (NICU), accounting
for two-thirds of positive blood cultures[1]. CNS bacteraemia is related to
the use of invasive devices and can be reduced by up to 50% by improved
hygienic practices [2]. We propose that the rate of CNS bacteraemia
could be used as a marker for the quality of care related to hospital
acquired infection in NICUs. To be interpretable across different units,
surveillance must be risk adjusted to take into account the vulnerability
of babies and the invasive procedures used. We examined how risk
factors including intensity of care predicted CNS bacteraemia in a
London NICU.
Methods: The study population included all NICU inpatients in the
hospital over 9 years. Admission data were linked with the laboratory
database for all blood cultures. Levels of care, used for resource
allocation throughout the UK, were deﬁned as Special Care, High
Dependency or Intensive Care, and were used as surrogate markers
for invasive procedures. Dates of admission to each level were used
to determine the total days at risk at each level of care. Analyses
determined the rates of CNS infection stratiﬁed by various risk factors
and intensity of care. Multivariate Poisson regression was then used to
estimate adjusted incidence rate ratios for CNS bacteraemia.
Results: 2492 infants were admitted to NICU. 393 infections were
recorded, of which 164 (42%) were recurrent. The overall rate of
CNS bacteraemia was 5.79 per 1000 baby days, with crude rates of
2.95, 9.63 and 8.92 in Special Care, High Dependency and Intensive
Care respectively. Intensity of care was strongly associated with CNS
infection, with those in High Dependency being most at risk: the
incidence rate ratios adjusted for gestation at birth were 3.48 (95%CI
2.43–4.96) and 2.24 (95%CI 1.54–3.29) for High Dependency and
Intensive Care compared with Special Care. Babies born between 32
and 37 weeks were signiﬁcantly less likely to develop bacteraemia than
term infants, but the adjusted rate ratios for lower gestations were not
signiﬁcant.
Conclusion: Level of care was the main determinant of the incidence of
CNS bacteraemia. These predictors warrant evaluation in other datasets
with a view to developing a marker for risk adjusted monitoring of
hospital acquired bacteraemia.
P1944 Reducing hospital infection rates in burn unit thanks to
compliance with infection control measures
Z. Ozkurt, M.N. Akcay, S. Erol, A. Aras (Erzurum, TR)
Objective: Because infections are easily develop on burn wound,
hospital infection rates usually high in burn units. The aim of the study
is to show affect of compliance with infection control measures on burn
wound infections.
Methods: The study was conducted a 14-bed burn unit hospitalised
paediatric and adult case in a 1200-bed university hospital. Previously
infection rates and antibiotic resistance rates were high. Sometimes
educations had been made related infection control measures at unit.
Imipenem resistant P. aeruginosa strains were increased and 5 pan-
resistant strains observed. Environmental surveillance cultures were
performed. Shutting the unity would be planned if pan-resistant strains
can not be eradicated Education related infection control precaution was
repeated and strictly adherence was advised the unity staff.
Results: Compliance with infection control measures was increased.
Adherence of hand hygiene, asepsis and antisepsis improved. Envi-
ronmental culture results show that hydrotherapy tank is hydrotherapy
tank is an important source of P. aeruginosa infections. Because of
previous experience we had learned that completely disinfection of the
tank was very hard, and sometimes it may be impossible. For this
reason hydrotherapy tank use was abandoned. Environmental cleaning
and disinfections were made more frequently. Isolation and contact
precautions were applied colonised and infected patients. Different rooms
were used for surgical operation of colonised or infected patients and
others. Empiric antibiotic use was not received at admission, antibiotics
use was limited only by infectious diseases specialist at short periods.
At this period burn wound infection rates sharply decreased. Infection
rates were reduced: 28.3% in 2003, 16.8% in 2004, 9.8% in 2005
and 7.4% in 2006. Pan resistant P. aeruginosa strains were not seen.
Antibiotic susceptibility in the Gram-negative microorganisms was
improved to some degree.
Conclusion: Adherence of universal infection control practice reduced
the burn wound infections. Antibiotic use should be based on evidence,
and duration of the antimicrobial drugs should be short. Hydrotherapy
tank should use only if necessity is available.
P1945 European surveillance of surgical site infections
(HELICS-SSI), 2004–2005
J. Wilson, C. Suetens, I. Ramboer, J. Fabry for the HELICS-SSI
working group
Introduction: Surgical site infections (SSI) account for up to 26%
of healthcare associated infection (HCAI) and cause considerable
morbidity. There is a perception that the risk of acquiring HCAI varies
between countries because of different standards in infection control
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practice. The Hospitals in Europe Link for Infection Control through
Surveillance (HELICS) has formed a ‘network of networks’ enabling
data from hospitals contributing to national surveillance networks to
also be submitted to the HELICS database. This database provides an
opportunity to evaluate inter-country differences in rates and explore the
problems associated with making such comparisons.
Methods: HELICS SSI surveillance is targeted at 7 deﬁned groups
of procedures. A standard protocol is used by partner countries to
collect a deﬁned set of demographic and operation data on all patients
undergoing an eligible procedure (http://ipse.univ-lyon1.fr). Additional
data is provided on those that subsequently develop an SSI that meets
the case-deﬁnition.
Results: Data on a total of 255 999 operations were received from 15
countries from 2004 to 2005 (641 hospitals in 2004, 776 hospitals in
2005). The coverage of national networks varies and hence a considerable
proportion of the HELICS dataset comprises data from countries with
well-established networks (41% from Germany, 24% England and 15%
France). All countries submitted data on hip prosthesis Rates of SSI are
conventionally expressed as a cumulative incidence. However, there are
important differences between countries in the use and intensity of post-
discharge surveillance and length of post-operative inpatient stay. In hip
prosthesis the length of postoperative stay varies from 7 to 14 days and
therefore incidence density of SSI/1000 post-operative inpatient days is
a more valid measure for making inter-country comparisons (see Figure
1). The incidence density can only be calculated when the discharge date
is known. Despite the standard HELICS protocol, there is evidence of
differences in interpretation of case deﬁnitions and sensitivity of case
ﬁnding that need to be taken into account when making comparisons.
Fig. 1. Incidence density of surgical site infections/1000 post-op inpatient
days in HPRO (+95%CI) by country, HELICS-SSI, cumulative data for
2004–2005.
Conclusions: The HELICS network represents a unique opportunity to
measure the occurrence of clinically deﬁned HCAI across European
countries using standard deﬁnitions of infection, methods of data
collection and analysis. The data shows inter-country differences in rates
of SSI but also provides evidence of variation in methodology that needs
to be considered when comparing rates.
P1946 Effectiveness of the antibiotic policy by bed-side consultation
A.K. Alzubaidy, W. Bronsveld, A. Steenhoek, F. Vlaspolder, J.H. Sloos
(Alkmaar, NL)
Objectives: Restrictive use of antibiotics is important in the prevention
of resistance against these medicaments in hospitals. This study describes
the effect of bed-side consultations on the maintenance of antibiotic
guidelines. In the MCA a medical doctor under supervision of the
consultant microbiologist is comparing the antibiotic use with the
hospital guide lines of each individual admitted patient on the wards
internal medicine, geriatrics, and cardiology. After physical examination
a written advice is given to the clinician. In case of discrepancy
between this advice and the initially started antibiotics, the consultant
microbiologists advices the clinician additionally.
Results: From March-July 2005, and the same period in 2006 a total
number of 469 consultations were performed (318 internal medicine
ward, 97 geriatrics, 48 cardiology, and 6 of other wards). For 360
(76.8%) cases guidelines for antibiotic treatment were available, whereas
for 28 (6.0%) cases no indication for antibiotics existed. 389 (82.9%)
of the given advices were directly followed and 24 (5.1%) additional
consultation were necessary for success. In 25 (5.3%) cases the clinician
has deviated from the guidelines rightly. In 216 (46.1%) cases continuing
the initially chosen antibiotics was the option chosen, whereas in 160
(34.1%) antibiotic has to be changed, and in 82 (17.5%) to stop the
antibiotic treatment.
Conclusion: Bed-side consultations results in uniformity and reduction
of the use of antibiotics on clinical wards.
P1947 Isolation of Microbacterium species in a case of
dialysis-associated peritonitis
I. Wybo, D. Pie´rard, M. Ichiche, K. Vandoorslaer, O. Soetens,
P. Rosseel, S. Lauwers (Brussels, BE)
Objectives: To present a case of dialysis-associated peritonitis due
to Microbacterium species with a poor response to intraperitoneal
vancomycin. This genus has occasionally been reported as human
pathogen.
Methods: Case report. A 48-year-old woman with chronic renal failure
treated by continuous ambulatory peritoneal dialysis since June 2002
was hospitalised in April 2004 with peritonitis. The patient improved
with intraperitoneal aztreonam 2 g and vancomycin 1 g in 2 L dialysate
and was discharged after four days with amoxicillin/clavulanic acid
875mg twice a day orally. She was readmitted with recurrence of
peritonitis on day 8. Cultures of peritoneal dialysate became positive
with coryneform Gram-positive rods. In spite of a new course of
intraperitoneal vancomycin, the cellular count of peritoneal efﬂuent
remained elevated and the implanted catheter was removed on day 15.
Peritoneal dialysis was restarted without further problems 2 months later.
Microbiological examination: Specimens were cultured after concen-
tration of the efﬂuent by Millipore ﬁltration according to standard
protocols. The following identiﬁcation techniques were used: conven-
tional phenotypic tests, whole-cell fatty acids (CFA) analysis with the
Microbial identiﬁcation System (MIS-Microbial ID, Newark, Del) and
DNA sequencing of the 16 S rRNA gene. Susceptibility testing was
performed by disk diffusion (Rosco) and by EtestR (Oxoid).
Results: A yellow pigmented, catalase positive, oxidase negative,
coryneform Gram positive rod was repeatedly recovered from con-
centrated peritoneal dialysate efﬂuent. The CFA proﬁle showed
predominance of anteiso C15:0 (35%) and anteiso C17:0 (40.1%). This
pattern ﬁtted with Microbacterium species as did presence of gelatinase
activity and lack of xylose fermentation. 16 S rRNA gene sequence
analysis (1393 bp) showed 99.8% similarity with M. oxydans DSM
20578T and 99.6% with M. liquefaciens DSM 20638T. According to
disk diffusion the isolate was susceptible to ampicillin, ciproﬂoxacin
and vancomycin. However, the vancomycin MIC determined by E-test
was 8mg/L, suggesting a diminished susceptibility.
Conclusions: The failure of vancomycin treatment in this case of
CAPD-peritonitis caused by Microbacterium species was probably due
to decreased susceptibility of this organism and presence of the foreign
body. Cure was obtained after removal of the implanted catheter.
P1948 Infectious complications of monoclonal antibodies used in
cancer therapy
P.I. Rafailidis, O.K. Kakisi, K.Z. Vardakas, M.E. Falagas (Athens, GR)
Objectives: The introduction of monoclonal antibodies in the treatment
of cancer has led to improvement in patients’survival. However, little
attention has been paid to the infectious complications associated with
their use.
Methods: We performed a systematic review of the literature to identify
randomised controlled trials (RCTs) that included in their outcomes
comparison of the infectious complications of a monoclonal antibody
plus a chemotherapy regimen versus the chemotherapy alone.
Results: 20 RCTs with relevant data were retrieved. They regarded
the use of monoclonal antibodies in patients with haematological
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malignancies (10 RCTs) and solid tumours (10 RCTs). Six RCTs
compared rituximab in conjunction with CHOP versus CHOP alone for
the treatment of B-cell non-Hodgkin lymphoma (NHL). No signiﬁcant
additive effect to the frequency of development of infection was caused
by the addition of rituximab to chemotherapy (data from 5 RCTs).
However, in HIV seropositive patients rituximab seems to augment the
possibility of a serious infection event or an opportunistic infection and
was associated with a 12% higher infection-related mortality (data from
1 RCT). Six RCTs compared trastuzumab in addition to chemotherapy
versus chemotherapy alone in patients with solid tumours (4 in breast
cancer). The addition of trastuzumab to the various chemotherapy
regimens caused a slight increase in the frequency of infectious
complications when compared to chemotherapy regimens alone.
Conclusion: Monoclonal antibodies added to chemotherapy have
comparable infectious complications with the chemotherapy alone
regimen when administered for the treatment of patients with NHL, with
the exception of HIV seropositive patients.
P1949 The utility of vitamin K3 for local injection therapy against
advanced pancreas cancer
S. Osada, S. Komori, S. Matsui, Y. Tokuyama, F. Sakashita (Gifu, JP)
Background: The molecular mechanism of Vitamin K3 (VK3)-induced
cellular growth inhibitory effect was characterised to evaluate its efﬁcacy
by local injection for application against unresectable pancreatic cancer.
Methods: Cell viability was determined by test method with MTT.
Expressions of cellular proteins were evaluated by Western blott analysis.
Results: The IC50 of VK3 for pancreas cancer cells was calculated to
be 42.1 ± 3.5 microM. By Western blot analysis, VK3 was shown to
induce phosphorylation of extracellular signal-regulated kinase (ERK)
and c-Jun NH2-terminal kinase (JNK) for 30 minutes. Expression
of apoptosis by VK3, as shown by caspase-3 activation, and poly
ADP-ribose polymerase cleavage is found. Treatment with the thiol-
antioxidant (>0.2mM) completely abrogated VK3-induced ERK but not
JNK phosphorylation or inhibition of proliferation. A caspase-3 inhibitor
had no inhibitory effect on the proliferative activity of VK3. As a
comparison with agent to mediate cellular molecular phosphorylation,
oxidative stress (H2O2) at concentrations >5.0mM was found to inhibit
cell proliferation at 24 hours. H2O2 also induced phosphorylation of
JNK or ERK, and activation of Caspase-3. And H2O2-induced these
activations were completely abrogated by non-thiol-antioxidant, but not
thiol-antioxidant. Because H2O2 mediated growth inhibitory effect was
quite hasty, high toxicity was anxious for in vivo study. By contrast,
VK3 was found to induce extensive tumour tissue necrosis. By Western
blot, ERK phosphorylation, but not JNK, was clearly detected only in
response to VK3 injection into tumour tissue.
Conclusion: The local injection with VK3 may be useful in the
curative treatment of unresectable tumours, and the detection of ERK
phosphorylation in tissue is important to predict the effect.
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P1950 In vivo efﬁcacy of the triazole BAL8557 against disseminated
Candida albicans in mice assessed by survival and tissue bur-
den in temporarily and persistently neutropenic mice treated
with 1−7 doses of drug over a dose range of 20−80% of Emax
P.A. Warn, A. Parmar, A. Sharp, M. Heep, J. Spickermann,
D.W. Denning (Manchester, UK; Basle, CH)
Objectives: Isavuconazole (BAL8557/BAL4815, ISA) is a water-soluble
broad-spectrum antifungal triazole. We determined the efﬁcacy of ISA
in temporarily (TN) and persistently neutropenic (PN) mice infected IV
with C. albicans. Mice were given ISA covering 20−80% of the Emax,
3 to 50mg/kg, determined by a dose response curve after a single dose
of ISA.
Methods: Male CD1 mice and a clinical strain of C. albicans FA6862
were used. Mice were compromised using either 1 dose of 200mg/kg
cyclophosphamide (TN) or multiple doses (PN). Mice were infected IV
with an LD50 (8×103 cfu/mouse) or LD90 inoculum (2×104 cfu/mouse)
in the TN and PN models of C. albicans then were treated 5 hours later
with solvent, 3, 7, 25 or 50mg/kg ISA 1× daily (20, 40, 60 & 80%
Emax). 3 mice had kidney burden assessed 24 hours post 1, 3, 5 and 7
days treatment. Groups of 6 mice were treated 1× daily for 1, 3, 5 & 7
days with ISA or solvent & survival assessed for 11 days post infection.
Results: (A) TN model: tissue burdens after 1 dose of 25 or 50mg/kg
were signiﬁcantly lower (p< 0.05) than controls & 3mg/kg at all time
points up to 11 days post infection. Mortality was signiﬁcantly lower
with 25&50mg/kg than solvent treatment even after 1 dose (p< 0.05).
(B) PN model: tissue burden was signiﬁcantly lower than solvent controls
after a single dose 25 & 50mg/kg (p< 0.05). Mortality in solvent treated
controls was 100% reducing to 0% after 25 & 50mg/kg. Survival in all
ISA treatments (including a single dose of 3mg/kg) was signiﬁcantly
superior to solvent controls.
Conclusions: ISA demonstrated impressive efﬁcacy against dissem-
inated C. albicans in both temporarily and persistently neutropenic
models measured by both tissue burden and survival. Highly signiﬁcant
improvements in outcome were achieved by single doses of ISA which
were still evident 10 days later indicating high efﬁcacy and prolonged
protection.
P1951 Dose response in neutropenic mice with disseminated infec-
tion of multiple strains of Aspergillus fumigatus with widely
varying MIC and MFC values treated with isavuconazole
P.A. Warn, A. Parmar, A. Sharp, D.W. Denning (Manchester, UK)
Objectives: Isavuconazole (BAL4815, ISA) a broad spectrum triazole
antifungal is administered as its water soluble prodrug BAL8557. Dose
response curves to treatment with ISA were determined in murine models
against strains of Aspergillus fumigatus with low and high MIC (<0.5
and mg/L respectively) and low and high MFC (<1 and >4mg/L
respectively). Strains were selected that had previously demonstrated
either treatment success or failure when treated with itraconazole.
Methods: In vitro susceptibility tests were performed according to the
CLSI guidelines. A. fumigatus strains isolated from clinical samples
were selected with ISA MIC/MFC values classed as either Low/Low,
Low/High or High/High (including AF91 which has previously been
shown as resistant in vitro and in vivo to itraconazole). Male CD1
mice 21−24g were immunosuppressed with a single dose of 200mg/kg
cyclophosphamide IV then 3 days later infected IV with a sub-lethal
inoculum of Aspergillus (4 strains of fumigatus). 5 hours after infection
mice were treated orally once daily with either solvent or ISA (2.5–
250mg/kg) for 4 days (ISA 1.33–132mg/kg active compound). 100
hours post infection mice were killed and the kidneys removed for
quantitative culture.
Results: All strains generated moderately severe non-lethal infections
with moderate/heavy tissue burdens in the kidneys of infected
animals (Cmax 3.4−4.5 log10 cfu/g). Treatment resulted in Emax of
1.2−1.9 log10 cfu/g. Increasing efﬁcacy occurred over
the entire dose range. In all cases the steepest part of the dose response
curve was in the range of 5.3−40mg/kg ISA (regardless of the MIC
or MFC of the isolate). The magnitude of the drug effect was up to
1.2 log10 cfu/g and similar regardless of the ISA MIC (AF10 MIC =
0.25mg/L and AF91 MIC = 2mg/L both had an Emax 1.2 log10 cfu/g).
Conclusion: ISA was effective in reducing the tissue burden of all
isolates of A. fumigatus including a strain with an MIC of 4mg/L that
demonstrates in vivo resistance to itraconazole. Increased efﬁcacy was
noted over a wide therapeutic range (up to 250mg/kg). In this model
once a day therapy with ISA was effective despite a half life in mice
<2 hours.
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P1952 Identiﬁcation of hsp90 in Cryptococcus neoformans and
examination of the effect of Mycograb® on hsp90 gene
expression in cells exposed to various stress factors
R. Al-Akeel, A. Curry, E. Hoyes, L. Nooney, R. Matthews, J. Burnie
(Manchester, UK)
Cryptococcus neoformans is the causative agent of cryptococcosis,
a chronic and life-threatening infection common in AIDS patients.
Mycograb® is a recombinant antibody derived against the LKVIRKNIV
epitope of candidal heat shock protein 90. Hsp90 is an important
molecular chaperone in all eukaryote cells. Its interaction with groups
of proteins involved in cellular regulatory processes helps to maintain
their active conformation. Little is known about the function of
Hsp90 in C. neoformans in protection against cryptococcosis. A
monoclonal antibody speciﬁc for Hsp90 was used to detect Hsp90
in C. neoformans cells grown in sub-inhibitory concentrations of
amphotericin B and to identify the effects of amphotericin B on
Hsp90 expression. We have examined the expression of the hsp90
gene in C. neoformans and the ability of Mycograb® to inhibit its
expression under various stress factors, including heat shock and
treatment with various antifungal agents. Cells were exposed to sub-
inhibitory concentrations of anti-fungal agents alone and plus three
different concentrations of Mycograb®. The expression of Hsp90 in
presence of these antifungal agents and the effect of Mycograb® on
its expression was examined. Total RNA was isolated from stressed
cells and analysed by RT-PCR. Immuno-electron microscopy showed
that Hsp90 was mainly located on the outer membrane surface of the
cells. The electrophoretic outer membrane protein patterns indicated
14 major protein bands within a molecular weight range varying from
19 to 188 kDa. All isolates displayed similar protein patterns irrespective
of the test conditions although band intensity was clearer when cells
were grown in the presence of amphotericin B than those were not.
Western blotting with anti-Hsp90 monoclonal antibody revealed that
the 90kDa was present in the outer membrane fraction of disrupted
cells. Results of RT-PCR showed that the treatment of C. neoformans
with sub-inhibitory concentrations of amphotericin B and ﬂuconazole
induced Hsp90 mRNA expression, while treatment with caspofungin did
not. Hsp90 gene expression was inhibited by different concentrations of
Mycograb®. The presence of Hsp90 in the capsule of C. neoformans
supports the idea of using this protein as a target for new antifungal
or antibody therapy. Inhibition of Hsp90 mRNA gives the potential to
investigate the use of Mycograb® in the treatment of cryptococcosis.
P1953 In vitro activity of ﬂuconazole and voriconazole against
invasive Candida parapsilosis, Candida tropicalis and
Candida glabrata isolates in patients with candidaemia from
2001–2005 in Hong Kong
M. Hui, M-L. Chin, L-K. Chan, K-C. Chu, C-Y. Chan (Shatin, HK)
Objectives: Candidaemia is one of the commonest nosocomial blood
stream infection and is associated with high mortality. Non-albicans
Candida organisms had been repeatedly reported to emerge in high
risk patients. In particular, Candida parapsilosis, Candida tropicalis and
Candida glabrata are among the most frequently encountered invasive
isolates. These organisms often raised a concern on reduced antifungal
susceptibility. Therefore, it is important to monitor for the trend of
antifungal resistance. In this study, we aimed to investigate the in
vitro activities of ﬂuconazole and voriconazole against invasive Candida
parapsilosis, Candida tropicalis and Candida glabrata isolates in patients
with candidaemia from 2001 – 2005 in Hong Kong.
Methods: Non-duplicate Candida parapsilosis, Candida tropicalis and
Candida glabrata isolates collected from candidaemic patients from
2001 – 2005 were tested against ﬂuconazole and voriconazole in accor-
dance to the NCCLS(CLSI) standard M44-A by disk diffusion method.
Fluconazole and voriconazole susceptibility results were interpreted
according to NCCLS(CLSI) criteria into susceptible, susceptible dose
dependent (SDD) and resistant categories. Tests were done in duplicates.
Results: A total of 84 isolates were collected over the 5-year period.
27 were Candida parapsilosis, 32 were Candida tropicalis and 25
were Candida glabrata. All Candida parapsilosis were susceptible to
ﬂuconazole and voriconazole. Only 10 isolates (40%) of the Candida
glabrata were susceptible to ﬂuconazole, 12 (48%) showed decreased
susceptibility (SDD) and 3 (12%) were resistant to ﬂuconazole.
Whereas 24 (96%) Candida glabrata were susceptible to voriconazole
(p< 0.05). For Candida tropicalis, 24 (75%) isolates were susceptible to
ﬂuconazole, and 21 (65%) were susceptible to voriconazole (p> 0.05).
Conclusion: Candida parapsilosis remains very susceptible to both
ﬂuconazole and voriconazole. Voriconazole has signiﬁcantly more
activity than ﬂuconazole against Candida glabrata. Both drugs showed
similar activities against Candida tropicalis. Although some cross-
resistance may be expected for the two azole agents, their activities
were different with various species. Antifungal susceptibility testing is
warranted to guide the choice of antifungal agents and to monitor the
trend of resistance.
P1954 Trends in species distributions and susceptibilities of fungal
pathogens recovered from European medical centres:
a report from the SENTRY Antimicrobial Surveillance
Program (1999–2006)
T. Fritsche, M. Stilwell, H. Sader, R. Jones (North Liberty, US)
Objectives: To understand changes occurring with the prevalence of
fungal pathogens in European patients and characterise key susceptibility
(S) proﬁles of the predominant species utilising results from the fungal
surveillance component of the SENTRY Program (1999 to 2006).
Development of standardised testing methodologies now allows the
tracking of resistance (R) emergence to numerous old and new antifungal
agents.
Methods: A total of 965 Candida spp. (CSP; 94.8%), 33 Aspergillus
spp. (ASP; 3.2%), 8 C. neoformans (0.8%) and 12 other isolates (1.2%)
from infected sterile-site sources (primarily bloodstream) were submitted
from >20 European (EUR) medical centres to the central monitor (JMI
Laboratories, IA) for identiﬁcation and S testing. S for 5-ﬂuorocytosine
(FC), ﬂuconazole (FLU), itraconazole (ITR) and voriconazole (VOR)
were determined as part of the SENTRY Program for the intervals 1999–
2001 and 2003 using NCCLS/CLSI reference methods and interpretive
criteria (M38-A and M27-A2).
Results: Species rank order of CSP occurrence was: C. albicans
(CA; 49.6%), C. parapsilosis (CP; 10.1%), C. glabrata (CG; 7.9%),
C. tropicalis (CT; 6.9%), C. krusei (CK; 2.1%) and uncharacterised
CSP (3.0%). Prevalence of CA declined slightly over the years 1999
to 2006 from 51 to 48%, whereas CP and CG both increased during
the monitored interval (9.3 to 11.8% and 2.8 to 11.8%, respectively);
CT and CK also increased slightly during the study (5.4 to 8.3% and
1.0 to 2.9%, respectively). Among ASP, A. fumigatus was predominant
(63.6%). Comparison of MIC90 values for CA, CP and CT, respectively,
demonstrated few differences between the intervals of 1999–2001 (13th
ECCMID, abstract P713) and 2003 (44th ICAAC, abstract M1797)
for FC (0.25−0.5, 0.12−0.5 and >64mg/L), FLU (0.25−0.5, 1−2 and
2−4mg/L), and ITR (0.06–0.12, 0.25−0.5 and 0.5mg/L). Increases in
MIC90 values ( four-fold) of VOR were seen between these intervals
with CP (0.015 to 0.06mg/L), CG (0.25 to 2mg/L) and CT (0.06 to
0.25mg/L). CG also displayed the highest MICs against FLU (MIC90
values, 16–128mg/L) and ITR (2mg/L).
Conclusions: CSP accounted for 94.8% of fungal isolates recovered
from patients in EUR medical centres from 1999–2006. While most
were CA, increases were detected among other species, particularly CG,
that display reduced S to azoles. The potential for emergence of species
with R to recently marketed antifungal agents (echinocandins) warrants
continued monitoring.
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P1955 Killing kinetics of caspofungin and anidulafungin against
Candida krusei
E. Canto´n, J. Pema´n, A. Viudes, A. Espinel-Ingroff, A. Valentı´n,
M. Bosch, M. Gobernado (Valencia, ES; Richmond, US)
Introduction: C. krusei is isolated with low frequency from blood
culture with the frequency of candidaemia caused by this species ranging
from 2 to 3%. Treatment of these infections presents problems, especially
in the immunocompromised patient. A fungicidal agent should be the
optimal choice to treat these patients.
Objective: To determine the killing kinetics of caspofungin and
anidulafungin against C. krusei.
Materials and Methods: Three strains of C. krusei were tested.
MICs were determined following M27-A2 method. Caspofungin and
anidulafungin MIC2 and MIC0 (minimum concentration that produces
a growth reduction 50% and 100%, respectively) were determined at
24 h.
Time-killing studies were performed in RMPI 1640 medium (5 mL)
by using an inoculum size of 1 to 7×105 CFU/mL. Concentrations
tested ranged from 0.03 to 32mg/L. Aliquots were removed to determine
CFUs at 0, 2, 4, 6, 12, 24 and 48 h. Time-killing data were ﬁtted to an
exponential equation (Nt =N0 × e−kt) to determine the time (hours) to
achieve 50, 90, 99 and 99.9% (T50, T90, T99 and T99.9, respectively)
of growth reductions from the starting inoculum at each concentration
tested.
Results: Caspofungin MICs0 were 0.5 to 2mg/L and those of
anidulafungin were 0.25 to 0.5mg/L for the three strains tested. The
fungicidal activity of both echinocandins against the three C. krusei
isolates was strain dependent. With 2mg/L, the T50 and T99.9 ranges
for anidulafungin were 1.4 to 4.3 h and 14.1 to 42.9 h, respectively and
for caspofungin 0.06 to 2.48 h and 24.73 to 48 h, respectively.
Conclusions: Anidulafungin and caspofungin display strain and
concentration dependent fungicidal activity against C. krusei, but more
than 24 h were required to reach a three log decrease in CFU with both
agents. The in vitro vs. in vivo correlation of these results is yet to be
determined in clinical trials.
P1956 In vitro activity of amphotericin B and anidulafungin
against Candida albicans bioﬁlms
A. Valentı´n, E. Canto´n, J. Pema´n, M. Bosch, E. Eraso, M. Gobernado
(Valencia, Bilbao, ES)
Objectives: A great number of Candida spp. infections are related to
the formation of bioﬁlms on inert or biological surfaces. One of the
main consequences of Candida spp. bioﬁlms is the increased resistance
to antifungal agents. The purpose of this study was to determine the
activity of amphotericin B (AMB) and anidulafungin (AND) against
C. albicans free-living cells and bioﬁlms.
Methods: Twelve C. albicans isolates from catheter were studied. MICs
of planktonic cells were determined following the M27-A2 document.
MIC0 corresponded to the lowest drug concentration that support no
visible growth (a clear well) and MIC2 was the lowest drug concentration
that showed a reduction of growth  50% compared with the growth
control. Bioﬁlms were formed following the method described by
Ramage et al.* AMB and AND at concentrations ranging from 16–
0.03mg/L were added to microplates containing C. albicans bioﬁlms
of 24 and 48 h of maturation. Sessile MICs (SMICs) 50 and 80
corresponded to the lowest drug concentration that support an OD 
50% and an OD  20%, respectively compared with the growth control.
Results: The 12 isolates were able to form bioﬁlms. Geometric
mean SMICs 50 and SMICs 80 of AMB against bioﬁlms of 24/48 h
of maturation were 0.5/0.7mg/L and 16/16mg/L, respectively.
Geometric mean SMICs 50 and SMICs 80 of AND against bioﬁlms
of 24/48 h of maturation were 0.4/3.5mg/L and 16/16mg/L,
respectively.
Conclusions: C. albicans bioﬁlms showed more resistance to AMB and
AND than their planktonic counterparts. Complete killing of bioﬁlms
was never achieved, even at the highest concentrations of the drugs
tested. In general, similar results were obtained for 24 and 48 h of bioﬁlm
maturation.
AMB and AND exhibited activity against bioﬁlms as indicated by SMICs
50, but SMICs 80 fell into the resistant range 16 in all cases except
for one isolate for which the AMB SMICs 80 was 1/1mg/L.
Reference(s)
*Gordon Ramage, Kacy Vande Walle, Brian L. Wickles, and Jose´
L. Lo´pez-Ribot. Standardised method for in vitro antifungal
susceptibility testing of Candida albicans.
P1957 Growth inhibition of bioﬁlm-associated Candida albicans by
voriconazole in long-term continuous ﬂow cultures
H. Bernhardt, M. Knoke, G. Schwesinger, J. Buﬂer, V. Czaika, K. Ludwig,
J. Bernhardt (Greifswald, Karlsruhe, Bad Saarow, Rostock, DE)
Objectives:We investigated the antifungal effect of voriconazole (VORI)
on bioﬁlm and MIC values of C. albicans (C.a.) in a miniature ﬂow cell
system.
Methods: Several C.a. strains (SC5314 and 3 blood culture isolates)
were grown in miniature ﬂow cells (160mL; Stovall Life Science
Inc.) incubated at 37ºC. Peptone-yeast extract (0.5%/0.2%) + 50 mM
glucose ± VORI (16mg/L) was supplied at very low ﬂow rates (1.3
and 2.5 mL/h). Bioﬁlm and biomass production, glucose metabolism,
pH, morphological features and planktonic cell counts of C.a. were
investigated. MIC testing was performed according to DIN 58940−84
at inocula of 0.5−2.5×104 cfu/mL. Etest® on RPMI or Mueller-
Hinton methylene blue agar and NCCLS/CLSI methods were used
for resuspended bioﬁlms. These were removed from the ﬂow cells
and immediately transferred into phosphate-buffered saline. Statistical
analysis (Wilcoxon rank test) was based on AUCs. Morphology and
viability of fungal cells were assessed by FUN®1 staining.
Results: Each C.a. strain was incubated for up to 10 d in 12 ﬂow cells
with 3 channels. In all experiments, metabolic activities in the established
bioﬁlms (1 or 2 d old) ceased within 24 h after addition of VORI. We
found a strong decrease of biomass production, elevated concentrations
of glucose (p = 0.043) and an increase in pH. None of the C.a. recovered
from resuspended bioﬁlms subject to 1 passage on Sabouraud glucose
agar (SDA) showed changes in their MICs vs. baseline (0.032mg/mL).
C.a. from resuspended bioﬁlms remained susceptible 24 h and 48 h after
input of VORI. After longer incubation, growth was so poor that reliable
results could not be obtained. C.a. from the residual bioﬁlms could be
recultured by several SDA passages and remained sensitive to VORI as
well.
Conclusion: The heterogeneity of C.a. bioﬁlms in different test models
results in divergent experimental results. Continuous-ﬂow models should
be preferred to stationary cultures for the evaluation of antifungal
sensitivity of fungi in bioﬁlms. This setting more closely mimicks the
conditions encountered on catheter surfaces in vivo.
P1958 Parallel- and cross-resistance of the azoles ﬂuconazole,
itraconazole, kezoconazole, voriconazole, and of ﬂuconazole
to clinical yeast isolates
A.F. Schmalreck, K. Becker, W. Fegeler (Munich, Mu¨nster, DE)
Objectives: From a collaborative study of the antifungal study group
of the German Speaking Society of Mycology (DMykG), a subset
(n = 3703) of the database of clinical yeast isolates was evaluated for
their susceptibility/resistance to antifungal agents (AM) ﬂuconazole
(FLC), itraconazole (ITR), ketoconazole (KET), voriconazole (VOR),
and ﬂucytosine (FCY) by analysis of susceptible–intermediate–resistant
(S-I-R) strains and susceptibility pattern analysis (SPA) to determine
the amount and type of parallel- (between azoles) and cross-resistance
(between azoles and FCY).
Methods: Susceptibility testing was performed by the test centres
according to a common test protocol, the same lot of culture
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media (YST medium, with 2% glucose and 0.5mg methylene blue/L;
Siﬁn GmbH, Berlin), by microdilution according to DIN. MIC
assessment was performed by categorisation of MICs into suscepti-
ble (S), intermediate (I), or resistant (R) by applying the following
S/R breakpoints: FLC, 4mg/L and 32mg/L; ITR, 0.125mg/L and
1mg/L; KET and VOR, 1mg/L and 4mg/L; FCY, 4mg/L and
32mg/L. SPA analysis was performed in order to compare speciﬁc
susceptibility/resistance-patterns (SP) for each individual strain based
on a pair-to-pair analysis of S-I-R results.
Results: Of the 3703 clinical yeast isolates, 30.4% demonstrated
resistance to the individual antifungal agents (R Sigma-AM identical
number or resistances by S-I-R), which resulted in 737 patterns with 1
to 5 AM in sequence (RSPA), of which 1% were parallel resistant to all
4 azoles (RPARA), and 0.4% cross-resistant to the azoles and ﬂucytosine
(Table 1).
To the individual AM, 10.2% of the yeast collective were resistant to
FLC, 7.3% to ITR, 2.8% to KET, 1% to VOR, and 9.1% to ITR.
The amount of parallel- and cross-resistance for the individual AM
was calculated by considering R Sigma-AM, and was in the following
order – parallel: VOR (21.3%), KET (11.7%), FCY (6.4), ITR (5.7), and
FLC (4.4%); cross: VOR (9.4%), KET (5.2%), FCY (2.8), ITR (2.5%),
and FLC (2.0%).
Table 1. Number (N) and percentage (%) of clinical isolates tested,
together with the frequency of occurrence (n = number; %= percentage)
of AM-resistances within the isolates (RS-AM), their SP, each containing
1 to 5 resistant AM (RSPA), and the amount of parallel- and cross
resistance (RPARA; RCROSS)
Organisms Frequency RS-AM RSPA RPARA RCROSS
N % n % n % n % n %
Total isolates 3703 100.0 1126 30.4 737 19.9 34 1.0 15 0.4
Candida albicans 1661 44.6 157 9.5 90 5.5 12 0.7 0 0.0
non-C. albicans 1505 40.6 702 46.6 466 31.0 8 0.5 4 0.3
C. glabrata 554 15.0 184 33.2 135 24.4 4 0.7 4 0.7
C. guilliermondii 97 2.6 99 102.1 54 55.7 0 0.0 0 0.0
C. krusei 254 6.9 314 126.6 178 70.0 4 1.6 4 1.6
C. lusitaniae 92 2.5 22 23.9 22 23.9 0 0.0 0 0.0
C. parapsilosis 196 5.3 2 1.0 2 1.0 0 0.0 0 0.0
C. tropicalis 312 8.4 81 26.0 75 24.0 1 0.3 0 0.0
other Candida spp. 118 3.2 8 6.8 8 6.8 0 0.0 0 0.0
not-Candida spp. 140 3.8 72 51.4 54 38.6 3 2.1 2 1.4
Cryptococcus spp. 287 7.8 185 64.5 117 39.4 9 3.1 9 3.1
Cr. neoformans 236 6.4 82 34.8 74 31.3 0 0.0 0 0.0
Conclusion: As demonstrated, total parallel- (1.0%) and cross-
resistance (0.4%) is very low, and found in a signiﬁcant amount only
in C. glabrata, C. krusei, and Cryptococcus albidus. The higher FLC-
resistance rates are due to the “lower” DIN breakpoints. Overall, the
isolates were in vitro most susceptible to voriconazole (99.0%).
P1959 Antifungal susceptibility of Candida clinical isolates in
Canada: a ten-year review
J. Fuller, C. Sand, R. Rennie (Edmonton, CA)
Objective: The Canadian National Centre for Mycology (NCM) provides
susceptibility testing of yeast and ﬁlamentous fungi for Canadian
laboratories submitting specimens for routine mycology or isolates for
conﬁrmatory testing. The purpose of this study was to determine the
antifungal susceptibility rates of clinical Candida isolates submitted to
the NCM over the past ten years.
Methods: Susceptibility testing of Candida isolates was performed
according to the Clinical Laboratories Standards Institute (CLSI)
M27A-2 document for broth microdilution (BMD) testing of yeast. BMD
panels containing RPMI broth with MOPS buffer, and doubling dilutions
of antifungal agents, were inoculated with 10e3 CFU/mL of the test
isolate and incubated at 35 degrees C for 48 hours. Antifungal agents
included amphotericin B, 5-ﬂuorocytosine, ﬂuconazole, intraconazole,
voriconazole, and caspofungin; the latter two agents were tested against
2004 and 2005 isolates only. The 90% minimum inhibitory concentration
(MIC90) averaged from total annual isolates was recorded to monitor
temporal trends.
Results: From 1995 to 2005 the most common species submitted to the
NCM annually included C. albicans, C. glabrata, C. parapsolosis, and
C. tropicalis with 801, 421, 188, and 96 total isolates, respectively, and
primarily consisted of invasive isolates. Overall, MIC90 values remained
unchanged and showed little evidence of reduced susceptibility to the
antifungal agents tested; amphotericin B  4mg/L, 5-ﬂuorocytosine
 8mg/L, intraconazole 16mg/L, voriconazole  2mg/L, and
caspofungin  2mg/L. However, for ﬂuconazole the C. albicans MIC90
decreased from 16mg/L to 4mg/L while C. glabrata MIC90 increased
from 8mg/L to 64mg/L.
Conclusion: Despite reported increases of invasive candidiasis, this
passive surveillance of Candida susceptibility rates indicates that
recommended antifungal agents remain quite active against the most
common infecting species. However, C. glabrata resistance to the
azoles is increasing in Canada. As new antifungal agents become
available, continued and increased surveillance is necessary to monitor
the emergence of resistance.
P1960 Fluconazole resistance in C. parapsilosis, no evidence for
ERG11 mutation
M.A. Alkhalaf, K.J. Dodgson, E. Sarvikivi, A.R. Dodgson (Manchester,
UK; Helsinki, FI)
Objectives: C. parapsilosis is a well recognized cause of systemic
infection in premature neonates, fortunately the isolates of this species
demonstrate almost universal sensitivity to ﬂuconazole. However, a
12 year clonal outbreak with a C. parapsilosis strain that developed
ﬂuconazole resistance has recently been described While many
mechanisms of ﬂuconazole resistance have been described in C. albicans,
resistance mechanisms in C. parapsilosis have not been documented. We
sequenced the ERG11 gene in a number of isolates from the outbreak
to determine whether mutation in the target of ﬂuconazole played a role
in the development of resistance.
Methods: As only a fragment of the C. parapsilosis ERG11 gene
is available in GenBank, we searched for fragments in the Genomic
Sequence Survey database that displayed homology to C. albicans
ERG11. These fragments were assembled to produce a template from
which primers were designed. This putative CpERG11 gene was
ampliﬁed and sequenced in seven isolates, representing ﬂuconazole
MIC’s ranging from 0.5 to 64 ug/mL. Sequences obtained were compared
to known ERG11 sequences and to each other to determine if any
mutations were likely to contribute to resistance.
Results: Sequence was obtained in all seven isolates. Up to 1317 bp of
the coding region of the putative CpERG11 was sequenced, comparison
of the translated protein showed 73% identity and 86% similarity
with C. albicans ERG11 (Accession no. XP716761) suggesting that
the sequences obtained were indeed the C. parapsilosis ERG11 gene.
However, no differences were detected in any of the sequences obtained.
Conclusions: Fluconazole resistance in other Candida species has been
shown to be mediated by a number of mechanisms. Whilst upregulation
of efﬂux pumps appears to be the most common mechanism of resistance
in most species, mutations in the ERG11 gene that encodes the target of
ﬂuconazole has also been described. It appears that in the set of isolates
used in this study, ﬂuconazole resistance is not mediated by ERG11
mutations. A number of other possibilities such as ERG11 expression
and efﬂux pump expression remain to be investigated.
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P1961 Effects of vasoactive amines and albumin upon yeast
susceptibility to antifungals
S. Costa-de-Oliveira, A. Silva Dias, C. Pina-Vaz, A. Gonc¸alves
Rodrigues (Porto, PT)
Critically-ill patients are often administered a variety of therapeutical
drugs namely vasoactive amines and albumin. Following a prospective
study about fungaemia conducted at our University hospital, several
risk factors for invasive fungal disease and unfavourable outcome
were detected. A signiﬁcant correlation was found between fungaemia
and those prescriptions. Previous studies showed the promotion of
germination of A. fumigatus and the increase of antifungal resistance
following incubation with albumin (Rodrigues et al, 2005).
Objective: To evaluate the effect of albumine and vasoactive amines
like adrenaline, noradrenaline, dopamine and dobutamine upon the
susceptibility of Candida to several antifungals.
Methods: 15 clinical strains (3 C. glabrata, 4 C. parapsilosis, 5
C. albicans and 3 C. tropicalis) plus 3 control strains belonging to
American Type Culture Collection (ATCC) were studied. Susceptibility
tests, according by the microdilution protocol M27-A2 from CLSI, were
performed to amphotericin B, ﬂuconazole, voriconazole and posacona-
zole; minimal inhibitory concentrations (MIC) were determined. MIC
values were re-determined in the presence of 2% and 4% of albumin
(Octapharma, Viena, Austria), 10, 25 and 100 mg/mL of adrenaline
(Braun), 2.5, 5 and 100mg/mL of noradrenaline (Braun) and 10, 50
and 200mg/mL of both dobutamine (Sigma, Germany) and dopamine
(Sigma).
Results: All strains showed initial low MIC values to the antifungals
tested. In the presence of 2% and 4% of albumin, MIC of all antifungal
drugs increased from 2 to 10 dilutions. The MIC values of azoles
increased from 2 to 4 dilutions in the presence of adrenaline and
noroadrenaline. These effects were more consistent observed with the
non-albicans strains tested.
Conclusion: Vasoactive and inotropic amines have the potential to pro-
mote antifungal resistance when administered to patients simultaneously
receiving antifungal therapy, especially in non-albicans species. Such
fact may help to explain the increasing incidence of invasive fungal
disease caused by such species among critical care patients.
Reference(s)
Rodrigues et al, Med Mycol 43: 711−7 2005.
P1962 Comparison of Etest and microdilution method for anti-
fungal susceptibility testing of C. neoformans to four azoles
A.I. Aller, R. Claro, E. Lo´pez-Oviedo, A. Romero, E. Martı´n-Mazuelos
(Seville, ES)
Objective: The purpose of this study is to compare the results
obtained by the reference broth microdilution method (MDM) with
those obtained with Etest system (ET) (Ab Biodisk, Solna, Sweden) for
antifungal susceptibility testing of C. neoformans to ﬂuconazole (Pﬁzer
Central Research, UK), itraconazole (Janssen Pharmaceutica, UCA),
voriconazole (Pﬁzer Central Research, UK) and posaconazole (Shering-
Plough Research Institute, USA).
Methods: We have studied retrospectively 80 clinical isolates of
C. neoformans. The susceptibility to four azoles were performed by
the MDM according to the CLSI guidelines (M27-A2 document)
modiﬁed by Ghannoum et al (J Clin Microbiol 1992; 30:2881−86).
The ﬁnal concentrations were of 0.12−64mg/L for ﬂuconazole and
0.015−8mg/L for the rest of antifungal agents. The ﬁnal inoculum size
was 104 CFU/mL. The MICs were deﬁned as the lowest concentration
in which a prominent decrease in turbidity was observed.
The ET was performed according to manufacturer’s instructions. The
inoculum suspensions of C. neoformans isolates matched the turbidity
of nº1 McFarland standard. The incubation time was 48−72 h. The MIC
was read where the border of the elliptical inhibition zone intersected
the scale on the antifungal strip. C. krusei ATCC 6258, C. parapsilosis
ATCC 22019, C. neoformans 90112 and C. neoformans 90113 were
included as control strains. Essential agreement (EA) was deﬁned as
MIC results by ET and MDM in exact agreement or within two dilutions.
Results: The MICs obtained by the two methods after different
incubation times varied by no more than one two-fold dilutions. The
MIC ranges, MIC50 and MIC90 obtained at 72 h are summarised in table
1. The EA was 75% for ﬂuconazole, 63.4% for posaconazole, 30% for
voriconazole and 6.3% for itraconazole.
Table 1
Antifungal agent Method MIC (mg/L)
Range MIC50 MIC90
Fluconazole MDM 0.5−32 4 8
ET 0.032–256 4 32
Itraconazole MDM 0.06−1 0.5 1
ET <0.002–0.25 0.064 0.25
Posaconazole MDM 0.03−4 0.25 0.5
ET <0.02−1 0.023 0.125
Voriconazole MDM 0.25−1 0.5 0.5
ET 0.008−1.5 0.094 0.19
Conclusions:
1. Fluconazole MICs by ET showed good correlation with MDM (75%)
2. Itraconazole showed the lowest agreement (6.3%)
3. It would be necessary to carry out further studies including
interlaboratory agreement and correlation of MICs by different
methods with “in vivo” response.
P1963 Effects of MG3290, a selective histone deacetylase inhibitor,
on azole resistance in Candida glabrata
B. Yeung, N. Georgopapadakou (Montreal, CA)
Objectives: To examine whether MG3290, a highly active potentiator of
azole antifungals against Aspergillus and Candida species, potentiates
azoles against azole-resistant C. glabrata mutants and lowers resistance
frequency when combined with azoles.
Methods: Synergy of MG3290 with azoles was determined by two-
fold dilutions of each compound alone and in combination in 96-well
plates (checkerboard format). Ergosterol synthesis was measured by the
absorbance of lipid extracts at 281 nm; azole transport by the transport
of Rhodamine123 (excitation max, 485 nm; emission max, 535 nm).
Results: C. glabrata mutants resistant to itraconazole and ﬂuconazole
were detected at 3×10−7 and 5×10−6 frequencies respectively on agar
plates containing 4×MIC of the relevant azole. Mutants resistant to
itraconazole/MG3290 were detected at 1×10−7 frequency on plates
containing 4×MIC of itraconazole/MG3290 (none at 2×MIC), while
mutants resistant to ﬂuconazole/MG3290, at 2×10−7 frequency at
4×MIC of ﬂuconazole/MG3290. Three of seven itraconazole- and
13 of 14 ﬂuconazole-resistant mutants isolated and examined had
altered transport and were cross resistant. Basal ergosterol levels in
the azole-resistant mutants were unchanged from the parent. MG3290,
at 4mg/mL, lowered itraconazole MICs against itraconazole-resistant
mutants and ﬂuconazole MICs against ﬂuconazole-resistant mutants.
Conclusion: MG3290 potentiates azoles currently used in the clinic
against resistant mutants and lowers resistance frequency when combined
with azoles. It is therefore an attractive candidate for further development
in combination with azoles.
P1964 Enhancement of yeast susceptibility to antifungals
J. Subik, J. Cernicka, Z. Kozovska, M. Valachovic, I. Hapala, G. Hajos
(Bratislava, Ivanka pri Dunaji, SK; Budapest, HU)
Objectives: Decreased susceptibilities to azole antifungals in Candida
species were resulting from combination of several molecular mech-
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anisms involving the enhanced expression of drug transporter genes
(MDR1, CDR1/2) and over-expression or mutations in the ERG11
gene encoding the 14-a-lanosterol demethylase. To overcome multidrug
resistance in yeast pathogens, antifungals with novel cellular targets as
well as multidrug resistance reversal agents rendering drug resistant
strains sensitive to commercially used antifungals are being developed. In
this report one polyfused heterocyclic compound was found to enhance
the activity of several antifungals in different yeast species.
Methods: A library of polyfused heterocyclic compounds was tested
for multidrug resistance modulating activity in a screening system
using the agar diffusion method. Drug susceptibilities were assayed by
microbroth dilution method in 96-well plates according to the proposed
NCCLS M27-A standard guidelines. RP-HPLC analysis of sterols was
conducted on Eclipse XDB-C8 column using an Agilent 1100 series
instrument. Accumulation of rhodamine 6G (Sigma) was measured by
ﬂow cytometry in a FACS Calibur ﬂuorescence-activated cell cytometer
(Becton Dickinson).
Results: We identiﬁed one compound able to enhance the susceptibility
to cycloheximide and other drugs in the drug resistant Saccharomyces
cerevisiae mutant strain. In the presence of this organic compound an
increased antifungal activity of ﬂuconazole was demonstrated in yeast
mutant strains deleted in genes encoding the major multidrug resistance
transcription factors Yap1p, Pdr1p and Pdr3p, as well as the drug
efﬂux pumps Pdr5p and Snq2p in S. cerevisiae or their counterparts
in C. albicans and C. glabrata, named Cdr1p and Mdr1p, respectively.
Importantly, the compound increased the sensitivity to ﬂuconazole
also in multidrug resistant cells over-expressing the efﬂux pumps.
Yeast cells grown in the presence of sub-inhibitory concentrations of
the compound exhibited an altered sterol composition and a slightly
enhanced accumulation of rhodamine 6G, which suggests that plasma
membrane plays a role in yeast sensitisation to drugs.
Conclusion: The activity of a new compound that can overcome
multidrug resistance in yeast may prove useful in combined treatment of
infections caused by drug resistant fungal pathogens.
P1965 Antifungal drug susceptibility testing of Candida sp. by
two methods: CLSI(M27-A2) broth microdilution and the
image analyser method Wider-I
M. Rodriguez-Dominguez, G. Ayala, A. Fernandez-Olmos,
M. Mercadillo, M. Alvarez, A. Sanchez-Sousa, A. Espinel-Ingroff
(Madrid, ES; Richmond, US)
Introduction: Accurate as well as faster methods than CLSI method-
ology are needed for in vitro susceptibility testing of yeasts. WIDER
I (Francisco Soria Melguizo S.A., Madrid, Spain) is a less labour-
intensive and much simpler to perform assay than the CLSI broth
microdilution M27-A2 method. Wider I is a computer-assisted image
processing system, optimised for microdilution susceptibility testing of
yeasts.
Objectives: To evaluate the suitability of the WIDER I system for testing
the in vitro susceptibility of Candida spp. to four antifungal agents.
We compared results by this automated method to those by the CLSI
reference method for yeasts (M27-A2 document).
Methods: We tested 101 yeasts isolates from transplant recipients
(C. albicans 71, C. glabrata 13, C. parapsilosis 8, C. lusitaniae 4,
C. krusei 2, C. famata 1, C. guilliermondii 1, C. tropicalis 1) against
amphotericin B, voriconazole, itraconazole and ﬂuconazole with both
CLSI (M27-A2) and WIDER I methods.
Results: Agreement (within three dilutions) between methods for
voriconazole and ﬂuconazole was 90% and 87%, respectively 74% for
itraconazole. For amphotericin B, the agreement between both methods
was excellent at 24 h (97%). By breakpoint category, the agreement
was 91% for ﬂuconazole (VME=1% [very major errors, susceptible
by new method and resistant by reference method], ME= 3% [major
errors, resistant by new method and susceptible by reference method]
and M=5% [minor errors, shifting between categories]. The agreement
by category was 93% for voriconazole (ME= 5%, M=2%) and lower
(87.1%) for itraconazole (VME=3%, ME= 1% and M=8.9%).
Conclusion: Although MIC results varied between the methods, we
found a high level of agreement by breakpoint categories. Further
evaluations are needed to assess the suitability of this method.
P1966 FKS mutation in echinocandin-resistant C. glabrata
K.J. Dodgson, B. Kaur, A.Y. Sharafadein, S.A. Messer, M.A. Pfaller,
A.R. Dodgson (Manchester, UK; Iowa City, US)
Objectives: Taking a range of isogenic isolates from 43 year old
AML patient, one of which developed resistance whilst on Caspofungin
therapy, we aimed to elucidate the mechanism of resistance in this isolate.
The isolate was shown to be resistant to all the available echinocandins
(Caspofungin, Micafungin and Anidulafungin) and the resistance was
demonstrated to be stable. Given other descriptions of mutations in
the FKS genes we aimed to clarify whether similar mutations were
responsible for the development of resistance in this clinical isolate of
C. glabrata
Methods: To assess whether the echinocandin resistance was due to
a mutation in a glucan synthase (FKS) gene, the portions of the FKS
gene previously shown harbour mutations known to mediate resistance
in C. glabrata and other species were sequenced from the each of the
three FKS homologues in the C. glabrata genome (CAGL0G01034g,
CAGL0K04037g and CAGL0M13827g). Sequences were obtained from
and compared between the resistant isolate (145.088) and the sensitive
isolates.
Results: No differences were found between the sequences obtained
from the resistant or sensitive isolates in the sequenced portions of
the CAGL0G01034g or CAGL0M13827g ORFs. However the sequence
from the CAGL0K04037g locus revealed a single base pair mutation
from T to C at position 1987, which resulted in a change of amino acid
from serine to proline at position 663.
Conclusions: We describe the development of echinocandin resistance
in a series of isogenic isolates of C. glabrata obtained from a patient
treated with caspofungin. We detected a single base pair mutation
in one of the glucan synthase genes sequenced from the resistant
isolates, this mutation resulted in a change of amino acid for serine
to praline. A number of point mutations in glucan synthase genes have
been associated with echinocandin resistance in a number of Candida
species. In C. glabrata, the only mutation described to date is F659V,
however a S645P mutation has been described previously in a number
of C. albicans isolates. The S663P mutation described in this study
corresponds to that at position 645 in C. albicans and we believe this to
the ﬁrst description of this mutation in C. glabrata.
P1967 Mycograb increases Candida sensitivity to ﬂuconazole in
vitro
L. Nooney, R. Al-Akeel, S. Awad, I. AlShami, R. Matthews, J. Burnie
(Manchester, UK)
Introduction: Hsp90 has been implicated in the development of anti-
fungal drug resistance and has been shown to play an important role
in the development and continuation of resistance. The role of hsp90
in resistance to ﬂuconazole (FLC) is exerted through calcineurin. The
blocking of either hsp90 or calcineurin results in enhanced drug activity
or reversed drug resistance. We hypothesize that Mycograb, an inhibitor
of hsp90, may act in a similar way to geldanamycin and delay or block
the development of high level resistance to ﬂuconazole in Candida.
Methods: Six isolates of Candida were exposed to FLC at a range of
0.03125 to 512ug/mL in the presence of 4, 8 and 16ug/mL Mycograb in
a broth macrodilution assay. Colonies from each of the isolates that grew
at the concentration just prior to culture sterilisation were also examined
in the same assay.
Results: Five of the six isolates displayed increased sensitivity to FLC
with the addition of 4, 8 or 16ug/mL Mycograb, the MIC-2 was reduced
by one or more dilution. A ﬂuconazole sensitive strain of Candida
albicans was the most sensitive with a FLC MIC-2 of 2ug/mL before the
addition of Mycograb and an MIC-2 of 0.5ug/mL in the presence of 8
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and 16mg/mL Mycograb. Comparisons of CFU/mL between cultures with
FLC only and those that contained Mycograb demonstrated additivity
(>1 log reduction in CFU/mL) between ﬂuconazole and Mycograb in
four isolates and synergy, 2log reduction in CFU/mL, in a single
isolate. Repetition of the assay using resistant colonies also showed that
Mycograb increased sensitivity to FLC in four isolates. A ﬂuconazole
resistant strain of C. albicans was the most sensitive isolate to the
activity of Mycograb with an MIC-2 of 16mg/mL and an MIC-2 of
0.03125ug/mL in the absence and presence of Mycograb respectively.
Additivity was observed in two isolates and synergism in a single isolate.
No antagonism was demonstrated.
Conclusion: Candida species exposed to ﬂuconazole (FLC) in
combination with Mycograb were found to have increased sensitivity
to ﬂuconazole in vitro. The MIC-2 to FLC in ﬂuconazole sensitive and
in ﬂuconazole resistant sub-populations of Candida species was found
to be reduced
P1968 Determination of the antifungal susceptibility of
zygomycetes by the ETest and Sensititre YeastOne: a
comparison with the CLSI M-38 A procedure
M. Torres Narbona, J. Guinea, J. Martı´nez-Alarco´n, T. Pela´ez,
M. Guembe, E. Bouza (Madrid, ES)
Objectives: Zygomycetes are emerging as a main cause of invasive
fungal infections in immunocompromised patients, but the in vitro
antifungal susceptibility proﬁles have not been widely investigated. The
few studies that have evaluated the antifungal susceptibility of clinical
isolates of zygomycetes are mainly based on CLSI M38-A, a time-
consuming procedure. We evaluated the correlation of two rapid methods
(E-test and Sensititre YeastOne) with CLSI M38-A for zygomycetes
susceptibility testing.
Methods: We studied 45 clinical strains of zygomycetes collected
during an 18-year period in our institution. We evaluated the activity
of amphotericin B (AMB), itraconazole (ITC), voriconazole (VC),
caspofungin (CAS) and posaconazole (POS) by the E-Test procedure
(AMB, ITC, VC, POS and CAS), by Sensititre YeastOne (AMB, ITC, VC
and CAS), and by the CLSI M38-A procedure (AMB, ITC, POS, VC and
CAS). The plates and trays were incubated at 35ºC. We compared CLSI
M-38 A results (incubation at 24 hours) with the alternative methods
(incubations at 16, 24, 36, 48 and 72 hours). The E-Test minimal
inhibitory concentration (MIC) was read as the drug concentration at
which the border of the elliptical inhibition zone intercepted the scale on
the strip. The microdilution MIC was deﬁned as the lowest concentration
producing complete inhibition of growth (MIC-0) for all the antifungal
drugs studied. Both methods were considered to agree when the results
of the MICs by Sensititre or the E-test were within 2 dilutions of the
MICs obtained by CLSI M38-A.
Results: The highest agreement between AMB, ITC and POS E-test and
the reference MICs (70.5%; 70.5%; 88.6%) was at 48, 16 and 16 hrs
of incubation, respectively. The highest agreement between AMB and
ITC Sensititre YeastOne and reference MICs (40.9%; 79.5%) was at 36
and 24 hrs of incubation, respectively. Although the E-test and Sensititre
YeastOne presented a good correlation with CLSI M-38A for VC and
CAS, both agents presented very poor activity.
Conclusions: The E-test and Sensititre YeastOne are rapid alternative
methods to determine the susceptibility proﬁles of zygomycetes, but the
correlation (within 2 dilutions) with CLSI M-38A was moderate (below
80%), with the exception of POS. The MICs of POS obtained by the
E-test showed a good correlation at 16 hours of incubation.
P1969 Susceptibility of Candida spp. clinical isolates to antifungal
drugs
S. Tyski, M. Staniszewska, B. Rozbicka, A. Rajnisz, E. Bocian,
E. Wasinska, W. Kurzatkowski (Warsaw, PL)
Objectives: The purpose of this investigation was to determine the
susceptibility of clinical isolates of different Candida species to
antifungal therapeutics.
Methods: Altogether 106 clinical isolates of Candida spp. obtained from
different clinical materials were under investigation: 53 C. albicans,
23 C. glabrata, 10 C. tropicalis, 10 C. parapsilosis, 5 C. krusei and
single strains: C. kefyr, C. globosa, C. dubliniensis, C. lipolytica and
C. inconspicua.
Strains susceptibility to: amphotericin B (A), 5-ﬂuorocytosine (5),
itraconazole (I) and ﬂuconazole (F) was determined by ATB Fungus
system, while susceptibility to ketoconazole (K), voriconazole (V),
caspofungin (C) and posaconazole (P) was assayed with the usage of
E-tests, according to manufacturer’s recommendation.
Results: The strains were divided into 3 groups: C. albicans (53),
C. glabrata (23), and other Candida isolates (30).
• All C. albicans isolates were susceptible to (A) and (5), while 5 and
3 of them were resistant to (I) and (F), respectively.
(K) MIC (mg/mL) range (<0.002–>32); MIC50 = 0.012, MIC90 > 32.
(V) MIC (mg/mL) range (<0.002 –>32) MIC50 = 0.016, MIC90 > 32.
(C) MIC (mg/mL) range (0.006–0.25) MIC50 = 0.125, MIC90 = 0.19.
(P) MIC (mg/mL) range (0.003–>32) MIC50 = 0.047, MIC90 > 32.
• All C. glabrata isolates were susceptible to (A), 2 were intermediate
and 21 susceptible to (5), while 21 and 19 C. glabrata were not
susceptible to (I) and (F), respectively.
(K) MIC (mg/mL) range (0.016–8) MIC50 = 0.75, MIC90 = 3.
(V) MIC (mg/mL) range (0.019–12) MIC50 = 0.38, MIC90 = 1.
(C) MIC (mg/mL) range (0.094–0.25) MIC50 = 0.19, MIC90 = 0.25.
(P) MIC (mg/mL) range (0.19 –>32) MIC50 = 12, MIC90 > 32.
• Among other Candida isolates, all but one were susceptible to (A),
two were resistant to (5), while 16 and 21 were susceptible to (I) and
(F), respectively.
(K) MIC (mg/mL) range (0.004–1.5) MIC50 = 0.016, MIC90 = 0.38.
(V) MIC (mg/mL) range (0.006–2) MIC50 = 0.023, MIC90 = 0.125.
(C) MIC (mg/mL) range (0.064–1) MIC50 = 0.25, MIC90 = 1.
(P) MIC (mg/mL) range (0.08–4) MIC50 = 0.047, MIC90 = 1.
Conclusion: Candida spp. isolates showed to be very susceptible to
amphotericin B and 5-ﬂuorocytosine. C. glabrata isolates were more
frequently, then other strains, resistant to itraconazole and ﬂuconazole.
Among analysed strains, number of isolates, showed high resistance (>32
ug/mL) to ketoconazole, voriconazole and posaconazole.
P1970 In vitro susceptibility of clinical isolates of Cryptococcus
gattii
A. Gomez-Lopez, L. Bernal-Martinez, A. Alastruey-Izquierdo,
J. Rodriguez-Tudela, M. Cuenca-Estrella (Majadahonda, ES)
Background: A recent outbreak of C. gattii infection of Vancouver
Island (Canada) emphasize the role of this specie as causal agent of
infections in temperate climate. In addition, Cryptococcus gattii has
shown less in vitro susceptibility than C. neoformans to amphotericin
B and ﬂucytosine although contradictory results have been obtained
in other studies. We have analysed the antifungal susceptibility proﬁle
of clinical isolates of C. neoformans var. gatti and compared with
C. neoformans var. neoformans.
Methods: A collection of 20 isolates of C. neoformans var. gatti was
included in the study. Nineteen of the strains were obtained from
colleagues. In addition, the in vitro susceptibility of 323 strain of
C. neoformans var. neoformans received in our institution between 1995
and 2006 was evaluated.
The isolates were identiﬁed by routine physiological tests. The
susceptibility testing followed strictly the recommendations proposed
by the Antifungal Susceptibility testing Subcommittee of the European
Committee on Antibiotic Susceptibility Testing for fermentative yeast.
The antifungal agents used in the study were as follow: amphotericin
B, ﬂucytosine, ﬂuconazole, itraconazole, voriconazole, ravuconazole,
posaconazole and caspofungin.
Results: The table displays susceptibility results.
Conclusions: (i) C. gattii was less susceptible in vitro to amphotericin
B and ﬂuocytosine than C. neoformans (p< 0.01). (ii) C. gattii showed
signiﬁcantly higher MICs to azole agents (p< 0.01). (iii) Both species
seems intrinsically resistant to caspofungin (GM 16mg/mL).
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Antifungal agent C. neoformans var. gattii
(n = 20)
C. neoformans var.
neoformans (n = 333)
GM MIC90 MIC50 GM MIC90 MIC50
Amphotericin B 0.09 0.125 0.125 0.24 1 0.25
Flucytosine 1.07 2 1 4.38 16 4
Fluconazole 14.93 16 16 7.44 16 8
Itraconazole 0.45 1 0.5 0.25 1 0.25
Voriconazole 0.47 1 0.5 0.12 0.5 0.125
Ravuconazole 0.53 2 0.5 0.15 1 0.125
Posaconazole 0.26 0.5 0.25 0.16 0.5 0.25
Caspofungin 16 16 16 18.02 32 16
P1971 Induction of resistance and cross-resistance of ﬂuconazole,
voriconazole, caspofungin and cationic antimicrobials
against Candida species
S. Tobudic, C. Kratzer, W. Graninger, A. Georgopoulos (Vienna, AT)
Objectives: The purpose of this study was to compare the in vitro
selection of resistance and cross-resistance of ﬂuconazole, voriconazole,
caspofungin and the cationic antimicrobials chlorhexidine digluconate
and Akacid plusR against Candida species.
Methods: For the in vitro selection of resistance Candida albicans
ATCC 10231, C. albicans ATCC 90029, Candida glabrata ATCC
90030, Candida krusei ATCC 6258 and Candida tropicalis ATCC
750 were subcultured in liquid RPMI medium containing selected
concentrations of active substances during 30 passages. Minimal
inhibitory concentrations (MICs) of antimicrobials were performed after
each passage using broth microdilution method according to the CLSI
guidelines (M27/A2).
Results: Subcultivation of C. tropicalis in RPMI containing 32mg/L
ﬂuconazole resulted in a 256–fold increase in the MICs of ﬂuconazole
and voriconazole after less than 10 passages. Following exposure to
4mg/L voriconazole, comparable MIC increases of voriconazole and
lower increases of ﬂuconazole were found (128 and 16 times of the
MIC) in C. tropicalis. Preexposure to subinhibitory concentrations
of caspofungin induced a 64-fold MIC-increase of caspofungin in
C. tropicalis following 10 passages, but no cross-resistance to azoles
or cationic antimicrobials was observed. Subcultivation of both strains
of C. albicans in 2mg/L voriconazole induced a high MIC increase
(>256×) after 10 passages, whereas no cross-resistance to other
antimicrobials could be induced. MICs of active substances against
C. glabrata and C. krusei remained constant during 30 passages.
Development of resistance or cross-resistance to Akacid plusR or
chlorhexidine was not observed in any of the tested isolates.
Conclusion: Repeated exposure to subinhibitory concentrations of
cationic antimicrobials had no effects on selection of resistance or
cross-resistance in Candida spp., whereas resistance and cross-resistance
to azoles and resistance to caspofungin could be easily induced in
C. tropicalis. In vitro resistance of voriconazole was also developed
in both strains of C. albicans.
P1972 Broth microdilution, Etest and disk diffusion methods for
Trichosporon asahii susceptibility testing against established
and new antifungal agents
M. Kanellopoulou, D. Adamou, M. Martsoukou, N. Skarmoutsou,
E. Alexopoulos, A. Milioni, G. Arsenis, A. Velegraki, E. Papafrangas
(Athens, Patras, GR)
The genus Trichosporon is a basidiomycetous yeast phylogenetically
close to Cryptococcus. T. asahii is an emerging cause of disseminated
trichosporonosis. Isolation of T. asahii from patient indwelling devices
and biological secretions, without related dissemination, is hitherto of
ambiguous clinical signiﬁcance.
Objectives: (a) To monitor over 3 years (2002–2005) T. asahii
susceptibility to antifungals isolated from urinary tract and bronchial
secretions of patients without trichosporonosis; (b) to compare broth
microdilution (BMD), Etest and disk diffusion (DD) methods for
determining susceptibility to established antifungals and to posaconazole.
Methods: Seventeen urine specimen isolates from patients with
indwelling catheter (n = 15) and from respiratory secretions with
endotracheal catheter (n = 2) were tested against posaconazole (POS;
Schering Plough Research Institute, New Jersey, USA), amphotericin
(AB; Sigma, St. Louis, MO, USA), ﬂucytosine (FC; Sigma), itraconazole
(IT; Janssen, Beerse, Belgium) ﬂuconazole and voriconazole (FLU and
VOR; Pﬁzer, Sandwich, Kent, UK). Strains were tested by BMD (CLSI,
M-27A2) and Etest (AB Biodisk, Solna, Sweden). FLU and POS were
also tested by DD (CLSI, M-44A, 2004) using commercially prepared
disks (OXOID, Basingstoke, UK). Incubations were performed at 35ºC
and read at 24, 48 and 72 hours. The QC isolates used were: Candida
krusei ATCC6258 and C. parapsilosis ATCC22019.
Results: MIC ranges (mg/mL) were AB: 0.5−16, FC: 2−64, IT: 0.25−2,
FLU: 2−32, VO: 0.215−1 and POS: 0.125−0.5. No intrazonal growth
was observed in the DD method. Inhibition zone diameters ranged
from 5 to 35mm (FLU) and 10 to 20mm (POS). Interclass correlation
coefﬁcients (ICCs) and 95% conﬁdence intervals for comparing the
methods were calculated using log2 transformed data. ICC for BMD
versus Etest ranged from 0.98 to 0.99 (P< 10−4) for all drugs. Pearson’s
correlation coefﬁcient used as a measure of linear associations for FLU
and POS BMD versus Etest, versus disk diffusion was 0.944 (P< 0.01).
Conclusion: High AB, FC, IT and FLU MICs warrant clinical alertness
for breakthrough Trichosporon infections when used for prophylaxis.
Pending clinical studies, the low VOR and POS MICs suggest that they
may be a better alternative for prophylaxis in patients at risk. Disk
diffusion is an option for rapidly testing T. asahii isolates, provided
it is further evaluated. Standardised susceptibility testing can aid the
selection of the most relevant antifungal therapy for the management of
trichosporonosis.
P1973 Comparison of RPMI and AM3 medium for in vitro
susceptibility testing of caspofungin against Candida spp.
by EUCAST broth microdilution method
E. Dannaoui, O. Lortholary, D. Raoux, D. Hoinard, F. Dromer (Paris,
FR)
Objectives: To compare two media, RPMI and AM3, for antifungal
susceptibility testing of caspofungin against Candida spp.
Methods: A total of 863 Candida spp. isolates belonging to 25
different species were evaluated. All isolates were tested for caspofungin
susceptibility in RPMI and AM3. All isolates were identiﬁed according
to standard procedures. Susceptibility testing was performed according
to the EUCAST broth microdilution reference method. Both media were
supplemented with 2% glucose with a ﬁnal inoculum size of 1×105
CFU/mL. Microplates were read spectrophotometrically after 24 h of
incubation at 35ºC. MICs were deﬁned as the lowest concentration
resulting in 50% or more reduction of growth compared to the drug-
free growth control. Quality control strains were included in each set of
MIC determination.
Results: Overall, lower caspofungin MICs were obtained in AM3
(CMI50 = 0.03mg/mL) compared to RPMI (CMI50 = 0.5mg/mL) and
this was true for all tested species. There was a broader range (i.e.
number of log2 dilutions between the highest and the lowest MIC) of
MICs in AM3 than in RPMI for C. albicans (11, and 6 dilutions for
AM3 and RPMI, respectively), C. glabrata (11, and 6), C. parapsilosis
(6, and 4), and C. tropicalis (7, and 4). Moreover, more isolates exhibited
MIC>MIC90 when AM3 was used compared to RPMI for C. albicans,
C. glabrata, and C. parapsilosis, suggesting that AM3 is more suitable
than RPMI for detection of resistance to caspofungin.
Conclusions: For caspofungin susceptibility testing with the EUCAST
reference method, the use of AM3 instead of RPMI yielded lower MICs
as well as a broader range of MICs. Our results suggest that AM3 could
allowed better detection of caspofungin resistant isolates. Further studies
are needed to conﬁrm these preliminary results.
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Table 1. Detection of Candida spp. isolates with high caspofungin MICs
in RPMI and AM3 medium
Species (n) Caspofungin
MIC90
(mg/mL)
No. of isolates with
MIC>MIC90
RPMI AM3 RPMI AM3
C. albicans (404) 0.5 0.03 14 23
C. glabrata (157) 1 0.06 1 11
C. parapsilosis (109) 2 0.5 5 6
C. tropicalis (62) 1 0.06 3 2
C. krusei (21) 2 0.125 1 1
P1974 In vitro activity of caspofungin and micafungin against 1038
yeasts isolates from France by EUCAST reference method
E. Dannaoui, O. Lortholary, D. Raoux, D. Hoinard, F. Dromer and
the YEASTS Group (Paris, FR)
Objectives: To assess the in vitro antifungal susceptibility to caspofungin
and micafungin of yeast clinical isolates received at the National Center
for Mycoses and Antifungals (CNRMA) from 2003 to 2006.
Methods: All isolates were identiﬁed according to standard procedures.
Susceptibility testing was performed according to the EUCAST broth
microdilution reference method. RPMI with 2% glucose was used as test
medium with a ﬁnal inoculum size of 1×105 CFU/mL. Microplates were
read spectrophotometrically after 24 h of incubation at 35ºC. MICs were
deﬁned as the lowest concentration resulting in 50% or more reduction
of growth compared to the drug-free growth control. Quality control
strains were included in each set of MIC determination.
Results: 1038 yeast isolates belonging to 31 different species were
included. Most of the isolates were recovered from blood. Five
species (C. albicans, C. glabrata, C. parapsilosis, C. tropicalis,
and Cryptococcus neoformans) accounted for 86% of all isolates.
Overall, there was a positive correlation between MICs of both drugs.
C. albicans, C. glabrata, and C. tropicalis, were the most susceptible
species with Gmean MIC of <1 and <0.1mg/mL for caspofungin and
micafungin, respectively. Among other Candida spp. C. parapsilosis,
C. guilliermondii, and C. fermentati showed the highest MICs. No
activity was found against C. neoformans with Gmean MIC of >9mg/mL
for both echinocandins. Overall, micafungin showed lower MICs than
caspofungin.
Table 1. MIC values for species with at least 10 tested isolates
Species MIC (mg/mL)
Caspofungin Micafungin
Na Range MIC50 MIC90 GMIC
b Na Range MIC50 MIC90 GMIC
b
C. albicans 404 0.125−4 0.5 0.5 0.38 161 0.015−1 0.03 0.03 0.027
C. glabrata 157 0.25−8 0.5 1 0.51 60 0.015−8 0.03 0.03 0.033
C. parapsilosis 109 0.5−4 2 2 1.57 49 0.25−2 1 2 1.29
C. tropicalis 62 0.25−2 0.5 1 0.60 23 0.03–0.125 0.06 0.06 0.052
C. guilliermondii 27 0.06−2 2 2 1.32 13 0.25−1 1 1 0.77
C. krusei 21 0.5−8 1 2 1.10 13 0.125−4 0.25 0.25 0.26
Cr. neoformans 158 1−16 8 16 9.59 64 2−16 16 16 9.62
aNumber of isolates tested. bGeometric mean MIC.
Conclusions: Caspofungin and micafungin exhibited good in vitro
activity by EUCAST method in RPMI medium against most clinical
isolates of Candida spp. Although micafungin showed lower MIC values,
there was a positive correlation between MICs of both echinocandins.
P1975 Detection of Fusarium oxysporum DNA and (1-3)-b-D-glucan
in serum specimens of experimentally infected mice
Z.U. Khan, S. Ahmad, A. Theyyathel (Kuwait, KW)
Objective: Invasive Fusarium infection is an emerging opportunistic
mycosis associated with high mortality. Its diagnosis is difﬁcult due to
non-speciﬁc signs and symptoms and similarity in tissue morphology
with Aspergillus species. The aim of this study was to develop a
sensitive and speciﬁc diagnostic procedure based on ampliﬁcation of
Fusarium oxysporum DNA by nested (n) PCR and to compare the
results with (1-3)-b-D-Glucan detection in serum samples obtained from
experimentally infected mice.
Methods: Sixty mice immunosuppressed with intraperitoneal injections
of cyclophosphamide were infected intravenously with a dose of 1×107
F. oxysporum conidia/mouse. Six mice were sacriﬁced every day post-
infection. Blood specimens were collected by cardiac puncture. One
hundred mL of blood was used for culture and the rest was processed for
separation of serum. The lung homogenate was cultured and was also
used for direct microscopic examination. The genomic DNA from the
reference strains of F. oxysporum and 9 other fungi including Fusarium
solani, Aspergillus fumigatus, A. ﬂavus and A. terreus was isolated and
used as template for nPCR speciﬁcity. The species-speciﬁc primers were
derived from the internally transcribed spacer (ITS)-1 and ITS-2 regions
of rDNA and their speciﬁcity was conﬁrmed by BLAST searches. The
DNA from serum specimens was extracted using standard procedures.
The PCR amplicons were detected by agarose gel electrophoresis. The
(1-3)-b-D-Glucan was detected by Fungitell (Cape Cod Inc. E. Falmouth,
MA, USA).
Results: The nPCR was speciﬁc for F. oxysporum and detected nearly
440 fg of Fusarium DNA which is roughly equivalent to 10 genome
copies. Of the 60 serum samples tested, 55 (92%) were positive for
(1-3)-beta-D-Glucan and 47 (78%) were positive for F. oxysporum DNA.
The lung homogenates of all the infected animals yielded F. oxysporum
in culture. The fungus was also discernible in KOH-calcoﬂuor mount of
40 (67%) of the animals.
Conclusions: A sensitive and species-speciﬁc nPCR assay has been
developed for the detection of F. oxysporum DNA in serum samples
of experimentally-infected mice. During a follow-up of 14 days post-
infection, 92% and 78% of serum samples were positive for (1-3)-b-
D-Glucan and F. oxysporum DNA, respectively. The data suggest that
detection of F. oxysporum DNA by nPCR combined with (1-3)-b-D-
Glucan may help in early diagnosis of invasive fusariosis.
Supported by KURA Grant MI 04/02.
P1976 Comparative evaluation of Aspergillus terreus DNA and
galactomannan in serum and bronchoalveolar lavage of
intravenously infected mice
S. Ahmad, A. Theyyathel, Z. Khan (Kuwait, KW)
Objective: Invasive aspergillosis is a growing problem in immunocom-
promised individuals. Although Aspergillus fumigatus is the principal
aetiologic agent of the disease, infections caused by Aspergillus terreus
have shown an increased occurrence in recent years. Additionally,
A. terreus is more resistant to amphotericin B and is probably also
associated with higher mortality in humans. Therefore, an early diagnosis
is imperative for reduced mortality and better prognosis. The aim
of this study was to develop sensitive and speciﬁc diagnosis of
invasive aspergillosis by detecting A. terreus-speciﬁc DNA by nested
PCR (nPCR) in serum and bronchoalveolar lavage (BAL) specimens
of intravenously infected mice and to compare the results with
galactomannan (GM) levels.
Methods: Sixty BALB/c mice, immunosuppressed with four intraperi-
toneal injections of cyclophosphamide (200mg/kg) on day −1, 0, +1,
+3 were infected intravenously with 1×106 conidia of A. terreus. The
mice were sacriﬁced on day 1, 3, 5, 7 and 9 post-infection in groups
of twelve each and their BAL, blood, and lungs were cultured. The
A. terreus-speciﬁc DNA and GM in serum and BAL were detected by
New antifungals and antifungal resistance S569
nPCR and Platelia Aspergillus (BioRad, Marnes-la-Coquette, France),
respectively.
Results: The nPCR developed with primers derived from internally
transcribed spacer (ITS)-1 and ITS-2 regions of rDNA was speciﬁc for
A. terreus as genomic DNA from other Aspergillus species or other fungi
was not ampliﬁed. The lung homogenates of all the infected mice yielded
A. terreus in culture, while the blood and BAL specimens were uniformly
negative. The % positivity of serum samples for GM and nPCR were
78% and 73%, respectively. In contrast, among BAL samples, 71% were
positive for GM and 81% for A. terreus-speciﬁc DNA. The combined
detection of A. terreus DNA and/or GM enhanced the positivity to 95%
in serum and 98% in BAL.
Conclusions: The data suggest that GM and A. terreus DNA are easily
detected in both, serum and BAL, during the entire course of infection
and their combined detection could be useful in the early diagnosis of
invasive aspergillosis.
Supported by Kuwait University Research Grant MI04/02
P1977 In vitro activity of isavuconazole (BAL4815/8557) compared
with six other antifungal agents against 180 Cryptococcus
neoformans meningitis isolates from the Netherlands
I. Curfs-Breuker, M. Illnait-Zaragozi, J. Mouton, B. Janssen, F. Hagen,
L. Spanjaard, T. Boekhout, J. Meis (Nijmegen, NL; Havana, CU;
Utrecht, Amsterdam, NL)
Background: Data regarding the antifungal susceptibility of Cryptococ-
cus neoformans (CNE) isolates from The Netherlands are limited. We
determined and compared the in vitro activity of the new azole antifungal
drug isavuconazole (BAL4815/8557) with six other antifungals against
CNE isolates from patients with menigitis.
Methods: 180 CNE strains isolated from cerebrospinal ﬂuid and
blood were used. MICs were determined for amphotericin B (AMB),
ﬂucytocine (5FC), ﬂuconazole (FLU), itraconazole (ITC), voriconazole
(VOR), posaconazole (POS) and isavuconazole (ISA). Microdilution
testing was done in accordance with CLSI M27-A2 guidelines in RPMI
1640 MOPS broth with L-glutamine without bicarbonate. Plates were
incubated at 35oC for 72 hours. The MIC was determined visually
and spectrophotometrically as the lowest concentration of drug showing
absence of growth or  50% reduction of growth compared with that of
the growth control for AMB, and 5FC and azoles, respectively.
Results: No signiﬁcant differences between visual and spectrophotomet-
ric reading was observed. Over all strains, MIC90s of AmB, 5FC, FLU,
IT, VOR, POS, CAS and ISA were 0.5, 8, 8, 0.25, 0.25, 0.125, >64, and
0.125mg/L respectively.
Conclusions: Emergence of drug resistance to AmB, 5FC, FLC, and IT
against CNE, as reported from other regions, were not conﬁrmed in this
study from the Netherlands. Overall, the activity of ISA was at least
equal to FLU and equal to IT, VOR and POS. IT, VOR, POS, and ISA
are the most active antifungal agents in vitro against CNE.
P1978 In vitro activity of isavuconazole (BAL4815) compared
with seven other antifungal agents against 309 prospectively
collected clinical Candida isolates from the Netherlands
I. Curfs-Breuker, J. Mouton, Y. Debets-Ossenkopp, H. Endtz, P. Verweij,
J. Meis (Nijmegen, Amsterdam, Rotterdam, NL)
Background: Isavuconazole (ISA;BAL 4815/8557) is an antifungal drug
of a new generation of triazoles including posaconazole, voriconazole
and ravuconazole. We compared the in vitro activity of ISA against
Candida species isolated from invasive infections with seven other
antifungal drugs.
Methods: 309 strains were prospectively isolated during a 6-month
period (07-2005 to 01-2006). MICs were determined for amphotericin B
(AmB), ﬂucytocine (5FC), ﬂuconazole (FLU), itraconazole (ITC),
voriconazole (VOR), posaconazole (POS), caspofungin (CAS) and ISA.
Microdilution testing was done in accordance with CLSI M27-A2 in
RPMI 1640 MOPS broth with L-glutamine without bicarbonate and
incubated at 35ºC for 24 hours. The MIC was determined visually
and spectrophotometrically as the lowest concentration of drug showing
absence of growth or 50% reduction of growth compared with that of
the growth control for AMB, and 5FC and azoles, respectively.
Results: Species distribution was C. albicans (61%), C. glabrata (21%),
C. tropicalis (5%) and C. parapsilosis (4%). Only 1% of C. albicans was
resistant to FLU compared to 10% of the non-albicans Candida species
isolates.
Among the FLU susceptible (MIC 8) non-albicans Candida species
isolates (n = 103) the MIC90 and MIC range for ISA, CAS, FLU, ITC,
POS, VOR, 5FC and AmB was 0.016, <0.002–0.125; 0.5, 0.016−2; 4,
0.125−4; 0. 25, <0.016−0.5; 0.125, <0.016–0.25; 0.125, <0.016–0.25;
0.063, <0.063−>64; 0.5, 0.063−1mg/L, respectively.
Among the FLU less susceptible (MIC 16) non-albicans isolates
(n = 10) the MIC90 and MIC range for ISA, CAS, FLU, ITC, POS, VOR,
5FC and AmB was 0.125, 0.004–0.125; 0.5, 0.016−0.5; 64, 16−64; 0.5,
0.031−0.5; 0.5, 0.031−0.5; 1, 0.125−1;4, <0.063−8;1, 0.125−1mg/L,
respectively.
Among the FLU susceptible C. albicans isolates (n = 193) the MIC90 and
MIC range for ISA, CAS, FLU, ITC, POS, VOR, 5FC and AmB was
<0.002, <0.002–0.63; 1, 0.016−2; 0.25, <0.063−8; 0.063, <0.016−0.5;
<0.016, <0.016−0.5; <0.016, <0.016–0.125; 0.063, <0.063−2; 1,
0.125−2mg/L, respectively.
Conclusion: Isavuconazole has a high in vitro activity against invasive
Candida isolates with lower MICs than the seven comparator drugs.
Isavuconazole is a potential attractive new agent to treat invasive Candida
infections.
P1979 Risk factors for voriconazole resistance in non/albicans
candida in HIV-positive children
A. Shahum, V. Krcmery, A. Liskova, P. Kisac, V. Hricak, M. Karvaj,
A. Augustinova, E. Kalavsky, J. Benca, S. Seckova, K. Holeckova,
Z. Havlikova, V. Sladeckova, D. Horvathova, H. Havrilova (Phnom
Penh, KH; Bratislava, Trnava, Nove Zamky, SK)
Introduction: Resistance to voriconazole (VOR) has been observed in
C. glabrata and mucorales. However in Candida spp. is still rare and
represents less than 1% of all Candida spp.
Methods: We have analysed VOR and ﬂuconazole (FLU) resistant
candida in HIV-positive children in Cambodia. 8 cases occurred in 2006
after 3 years of HAART among 52 HIV-positive children at antiretroviral
therapy (2 C. krusei, 2 C. glabrata, 2 C. famata, 1 C. lusitaniae,
1 C. kefyr).
Results: Non-albicans Candida (NAC) resistant to VOR appeared
with no different distribution among children with different degree
of immunosuppression. There was unproved signiﬁcant association
with HAART, antituberculotic drug, or pretreatment with antibiotics or
antifungals. We did not record any resistance to VOR among C. tropicalis
and C. parapsilosis, but resistance to both VOR and FLU were found
among C. famata, C. glabrata, C. krusei and C. lusitaniae. VOR-resistant
NAC were more likely resistant also to itraconazole and ketokonazole in
contrast to FLU-susceptible NAC (P< 0.02 and P< 0.002 respectively).
More frequent concomitant resistance to itraconazole, ketokonazole,
5-FC and voriconazole was also seen among FLU-resistant NAC
(P< 0.0175, P< 0.004, P< 0.011 and P< 0.02).
Conclusion: VOR-R was related neither to low CD4 count nor to length
of HAART or TMP/SMX prophylaxis and also not to antituberculotic
and antibiotic therapy. We did not prove any risk factor for VOR
resistance among NAC yeasts in HIV-positive children. Resistant NCA
to VOR and/or FLU were more likely also resistant to other antifungals.
P1980 Identiﬁcation of a mating-type region in the opportunistic
fungus Pneumocystis carinii
B. Sanyal, P. Vohra, C. Thomas (Rochester, US)
Pneumocystis carinii (PC) is an intractable opportunistic fungus
which causes severe pneumonia in patients with AIDS or other
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immunosuppressive conditions. PC alternates between distinct life cycle
forms comprised of trophic forms and multinucleated cysts. The
mechanism of cellular differentiation from the trophic form to the
cyst is unknown. PC is phylogenetically related to the non-pathogenic
ascomycetes S. cerevisiae and S. pombe. The mating-type locus of
ascomycetes control key events in their life cycles. In S. pombe, full
meiotic competence of haplotypes is conferred by the mating-type
region which consists of mat1, mat2 and mat3 loci. The mat3-M loci
contains 2 open-reading frames (ORFs) encoding mat-Mc and mat-Mi
proteins. We identiﬁed and cloned this analogous region in PC using
PCR techniques. This 4956-bp region contains 2 ORFs: PCmatMc is a
699-bp ORF encoding a predicted 232 amino acid protein and PCmatM1
is a 1080-bp ORF encoding a predicted 359 amino acid protein. Both
ORFs are on opposite DNA strands similar to the conﬁguration in S.
pombe. PCmatMc contains an HMG-box domain postulated to bind
DNA sequences necessary for life cycle regulation. We have expressed
this gene as a recombinant protein and are determining the PC DNA
sequences to which PCmatMc binds. Our investigations may provide new
insights into the pathogenesis of PC and potential new therapeutics for
treating PC pneumonia through identiﬁcation of mechanisms involved
in PC life cycle regulation.
Supported by NIH grant 2R01 AI-48409 to CFT.
P1981 Antifungal activity of miconazole against recent clinical
isolates of Candida spp., as determined by minimum
inhibitory concentration
M.A. Ghannoum (Cleveland, US)
Objectives: Miconazole (MICON) has long been used for the topical
treatment of Candida vaginitis and other fungal infections of the skin.
As such, existing susceptibility data for MICON is quite old and
was generated before standard methodology was established. Currently
there is an increased incidence of oropharyngeal candidiasis among
immunocompromised patients, especially in the HIV positive population,
for which a new delivery system of MICON has been developed. With
Miconazole Lauriad® tablets currently in Phase III clinical trials, it is
important to establish a susceptibility proﬁle for MICON against recent
clinical Candida isolates using standard methodology. The objective of
this study was to test MICON against a large number of Candida isolates
to determine whether there has been any development of resistance
to this antifungal in the patient population. The antifungal activity of
MICON, as determined by minimum inhibitory concentration (MIC) was
compared to amphotericin B (AM), caspofungin (CAS), clotrimazole
(CLOT), ﬂuconazole (FLU), itraconazole (ITRA), nystatin (NYS), and
voriconazole (VOR).
Methods: MICs were determined according to CLSI M27A2. Inhibition
endpoints were read as a 50% reduction in growth compared to the
growth control after 24 hours incubation (AM was read at 100%
inhibition).
Results: MICON demonstrated potent inhibitory activity against all of
the Candida strains tested. The overall MIC range for MICON was
0.004−1.0mg/mL, while the MIC50 and MIC90, deﬁned as the minimum
concentration that inhibited 50% and 90% of isolates tested, were 0.06
and 0.5mg/mL, respectively. With the exception of FLU, all of the
comparator drugs demonstrated activity against the panel of test isolates.
The MICON MIC90 for all species was comparable to that of AM,
CAS, CLOT, ITRA, NYS, and VOR (within three dilutions), and was
four dilutions lower than FLU. Importantly, MICON demonstrated MICs
three to eight fold lower than FLU against FLU-resistant strains.
Conclusion: Our data showed that MICON demonstrated potent
inhibitory activity against all of the Candida isolates tested, including
those with known FLU resistance. This indicates that recent clinical
isolates remain susceptible to this antifungal and do not reﬂect increased
resistance. This has important implications to the new application of
MICON in the treatment of oropharyngeal candidiasis.
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P1982 Evaluation of partial 16S rRNA gene sequencing for
identiﬁcation of clinical isolates of non-tuberculous
mycobacteria in a routine mycobacterial laboratory
R. Insa, M. Marı´n, M.J. Ruiz Serrano, M. del Rosal, M.J. Goyanes,
D. Garcı´a de Viedma, E. Bouza (Madrid, ES)
Objectives: Conventional identiﬁcation of non-tuberculous mycobacteria
(NTM) is based on biochemical characteristics, PCR-RFLP (PRA)
or a combination of both. Both techniques are time consuming and
occasionally produce discordant identiﬁcation. The aim of this study
is to evaluate the utility of the ampliﬁcation and sequencing of the 5’
end 16S rRNA gene (16S-PCR) in the identiﬁcation of clinical isolates
of NTM in comparison with both conventional techniques.
Methods: NTM were characterised by: (i) biochemical and phenotypical
characteristics, (ii) PRA and (iii) 16S-PCR. The 16S sequences were
compared with those included in Genebank and Ridom. Only alignments
with similarities higher than 99% were considered. Results obtained by
16S-PCR were compared with our gold standard (biochemical test plus
PRA results)
Results: Overall we evaluated 52 isolates from different patients.
Biochemical tests and PRA matched exactly in 42 isolates: M. fortuitum
(6), M. abscessus (1), M. chelonae (2), M. xenopi (5), M. gordonae
(6), M. avium–intracellulare (5), M. celatum (3), M. kansasii (5),
M. peregrinum (1), M. lentiﬂavum (3), M. simiae (2), M. smegmatis
(2) and M. thermorresistibile (1). Results obtained by 16S-PCR agree
with that gold standard in 90.5% (38/42). In 10 isolates there was
disagreement between biochemical test and PRA. Among these cases,
16S-PCR supported the result obtained by biochemical test in 5/6
and PRA in 1/6. In 4 isolates each of the three methods provided a
different identiﬁcation. 16S-PCR was able to recognize two new species:
M. wolinskyi and M. mageritense.
Conclusions: 16S-PCR could be useful for a preliminary and rapid
identiﬁcation of NTM but needs to be complemented by one of the
conventional methods, preferably biochemical tests. The analysis of other
conserved genes could contribute to a more accurate identiﬁcation.
P1983 Molecular detection of Mycobacterium tuberculosis by
tHDA-ELISA DIG detection system
P. Gill, H. Abdul-Tehrani, A. Ghaemi, T. Hashempour, M. V-p Amiri,
M. Ghalami, N. Eshraghi, M. Noori-Daloii (Tehran, IR)
Objectives: The recent resurgence in tuberculosis (TB) cases poses
a serious public health problem. Effective TB management require
the simple detection and rapid identiﬁcation of the aetiologic agent.
The nucleic acid ampliﬁcation methods have proven to be very
useful tools in the rapid diagnosis of Mycobacterium tuberculosis.
Several PCR-based colorimetric methods such as PCR-ELISA have
been previously described for molecular diagnosis of tuberculosis.
However this study, we designed and developed a novel non-PCR-based
colorimetric assay for speciﬁc and sensitive detection of rrs gene of
Mycobacterium tuberculosis, is named enzyme-linked immunosorbent
assay of thermophilic helicase-dependent DNA ampliﬁcation (tHDA-
ELISA).
Methods: In this procedure, like PCR-ELISA, the tHDA reaction
selectively ampliﬁed a target sequence deﬁned by two primers
and simultaneously incorporated digoxigenin-deoxyuridine triphosphate
(DIG-dUTP) in the resulting ampliﬁed DNAs. However, unlike PCR-
ELISA, the tHDA uses an additional enzyme called a thermophilic
helicase to separate DNA rather than heat. Thus the entire tHDA reaction
can be performed at isothermal temperature which is optimised for
synthesis and it needs no an expensive and power-hungry thermocycler.
Then the DIG-labeled amplicons were detected using species-speciﬁc
probe (biotin-modiﬁed), and colorimetric ELISA method.
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Results: Our results were shown an equal sensitivity and speciﬁcity
between this method and ELISA colorimetric assay of PCR products.
Conclusions: THDA-ELISA DIG detection system can be used
more cost-effectively than PCR-ELISA for molecular detection of
Mycobacterium tuberculosis in developing countries. The other formats
of this technology are under study in real-time format and mobile format.
P1984 Utility of the Gen-Probe ampliﬁed MTD test for the
tuberculosis diagnosis in formalin-ﬁxed, parafﬁn-embedded
histologic specimens
M. Ros, D. Mariscal, P. Ferreros, N. Combalia, R. Orellana,
J.A. Va´zquez, D. Fontanals, M. Torra, M. Rey (Sabadell, ES)
Objective: To value the relationship among the mycobacteria culture,
clinical and histopathologic ﬁndings compatible with tuberculosis (TBC)
and the results of the Gen-Probe ampliﬁed MTD test (MTDT) in
formalin-ﬁxed, parafﬁn-embedded histologic specimens.
Methodology: The affected anatomic sites of 24 biopsies were: lymph
nodes (9); skin (3); synovial (2); colon (2); lung (1); pleural (1);
peritoneal (1), parotid gland (1); bone marrow (1); spleen (1); breast
(1); vertebral (1). All had presence of granuloma with multinucleated
giant cells and/or caseous necrosis. To detect AFB, all smears were
stained by Ziehl–Neelsen (ZN). Only 9 (37.5%) of the specimens were
cultured for mycobacteria. A MTDT was considered positive when the
result was greater than 500.000 RLU. The clinical information of the
24 patients was reviewed and those that have received antituberculous
treatment or/and grew mycobacteria in the culture were considered cases
of TBC.
Results: 23 of the biopsies had chronic granulomatous inﬂammation
and 1 caseous necrosis. Only the specimen with necrosis presented
ZN positive. In 7 specimens (29.1%) MTDT was positive, clinical
information was suggestive of TBC and in 3 mycobacteria grew. One
patient had MTDT negative, clinical information suggestive of TBC and
a positive culture. In two cases, MTDT was negative, there was no culture
but they were treated as TBC. Sensibility, speciﬁcity, PPV and NPV are
70%, 100%, 100% and 82.3% respectively.
Conclusions: Considering that there are cases in which the correspond-
ing tissues are not sent for TBC culture, the MTDT can be a useful
technique for the diagnosis of TBC in formalin-ﬁxed specimens when
clinical or histopathologic suspicion exists.
P1985 Direct identiﬁcation of mycobacteria from BacTec MGIT
960 system tubes: comparative evaluation of INNO-LiPA
Mycobacteria v2 and DNA AccuProbe assays
E. Mokaddas, S. Ahmad (Dasma, Kuwait, KW)
Objective: Species-speciﬁc identiﬁcation of mycobacteria is of clinical
relevance since treatment varies according to the species causing
infection. This study evaluated the performance of two commercial
probe assays; INNO-LiPA MYCOBACTERIA v2 (LiPA) and AccuProbe
for species-speciﬁc identiﬁcation of mycobacterial isolates in Kuwait
directly from MGIT 960 system tubes.
Methods: Seventy-three respiratory and extrapulmonary specimens
ﬂagged positive for growth by MGIT 960 system and smear-positive for
mycobacteria were evaluated for identiﬁcation. The AccuProbe assay was
performed and interpreted according to the manufacturer’s instructions.
The DNA extraction, PCR ampliﬁcation and hybridisation steps were
performed by following the instructions supplied with the LiPA kit. The
results were validated by PCR ampliﬁcation and DNA sequencing of
16S-23S internal transcribed spacer (ITS) region.
Results: Each of the 73 tubes grew one mycobacterial culture.
Both AccuProbe and LiPA identiﬁed 47 isolates as Mycobacterium
tuberculosis complex (MTC) members and ITS region sequences of 8
randomly selected isolates were concordant. AccuProbe assay identiﬁed
26 isolates as non-tuberculous mycobacteria (NTM) with species-speciﬁc
identiﬁcation of 9 isolates. The ITS region sequences were concordant
with the NTM status for 17 isolates and species-speciﬁc identiﬁcation
of 7 of 9 isolates while two M. intracellulare strains were actually
M. chimaera and M. avium complex sequevar MAC-C isolates. The
LiPA identiﬁed 21 isolates as NTM with species (or complex)-speciﬁc
identiﬁcation of 19 isolates while no result was obtained for 5 isolates (no
amplicons with LiPA primers). The ITS region sequencing conﬁrmed the
species (or complex)-speciﬁc identiﬁcation by LiPA of all the 19 isolates
while 2 isolates detected only as NTM by LiPA were identiﬁed as M.
immunogenum and M. lentiﬂavum. The DNA sequencing also identiﬁed
4 isolates yielding no result in LiPA as M. kansasii and one isolate as
M. chimaera.
Conclusions: All the MTC isolates are correctly identiﬁed by both, the
LiPA and AccuProbe assays. Although, AccuProbe assay identiﬁed only
some (9 of 26) while LiPA identiﬁed most (19 of 26) NTM isolates to the
species or complex level, the 4M. kansasii isolates correctly identiﬁed by
AccuProbe assay were not even detected by LiPA indicating variations
in sequences targeted for LiPA ampliﬁcation in M. kansasii strains in
Kuwait.
Supported by KURA grant MI02/04.
P1986 Evaluation of real-time PCR assays, based in molecular
beacon technology, for detection and quantiﬁcation of
Mycobacterium tuberculosis DNA
D.P. Houhoula, A. Siatelis, N.J. Legakis, A. Tsakris, J. Papaparaskevas
(Athens, GR)
Objective: The evaluation of a conventional and two real-time PCR
assays, in comparison to the standard culture for tuberculosis (Tb), and
the patients’ clinical data.
Materials and Methods: A total of 60 clinical samples submitted for
Tb diagnosis, were tested using three PCR assays targeting IS6110.
The samples were 30 (7 pulmonary and 23 extra-pulmonary) from 22
patients, for which Tb diagnosis was based either on positive culture,
or clinical presentation, and 30 from 30 patients with other non-Tb
diagnoses. The assays were a previously reported (Kox et al, JCM 1994)
conventional PCR (C-PCR), a real-time PCR (RT1) using previously
reported nested-PCR inner primers (Caws et al, JCM 2000) with a
newly designed molecular beacon, and a novel real-time PCR (RT2). The
Beacon Designer 5.0 software was used for all newly designed beacons
(RT1, RT2) and primers (RT2). DNA quantiﬁcation was performed using
a standard curve of ﬁve positive concentrations (3.4 pg/mL, and 340, 34,
3.4, and 0.34 fg/mL) of DNA extracted from M. tuberculosis H37Rv
strain. All samples were tested neat and diluted 1/10 for PCR inhibition.
Real-time PCR runs were acceptable when the negative controls had
undetectable cycle threshold (CT) values, and the ﬁrst two positive DNA
concentrations had CT values of 27 to 30 cycles.
Results: Out of 30 samples from conﬁrmed Tb cases, 28, 19 and 27
were positive using C-PCR, RT1, and RT2, respectively, corresponding
to diagnostic sensitivities of 93%, 63% and 90%, respectively. Based on
the DNA quantiﬁcation performed, analytical sensitivities were 10 and
1 fg of DNA, for RT1 and RT2, respectively. When diluted specimens
were examined, 5 inhibition cases were detected (1, 1 and 3 for C-PCR,
RT1, and RT2, respectively). Combined performance of C-PCR+RT2
increased overall sensitivity to 100%. All 30 samples from non-Tb cases
were negative with all assays (speciﬁcity 100%). RT2 quantiﬁcation
indicated that DNA extraction from tissue biopsies resulted in the lowest
DNA yield compared to pleural/sputum samples (DNA load range 0.7–
659 fg, and 4.4–576 pg, respectively). However, a single pus specimen
with DNA load of 2.7 ng was identiﬁed.
Conclusions: RT2 and C-PCR were the most sensitive assays tested, and
their combination resulted in 100% diagnostic sensitivity. Speciﬁcity
was 100%. Real Time PCR, based on molecular beacon technology,
seems to be a rapid and sensitive procedure for Tb diagnosis and DNA
quantiﬁcation in clinical samples.
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P1987 Rapid diagnosis of tuberculous pleuritis by real-time PCR
K. Baba, S. Pathak, L. Sviland, A.M. Dyrhol-Riise, N. Langeland,
A.A. Hoosen, B. Asjø, T. Mustafa (Bergen, NO; Pretoria, ZA)
Tuberculosis is a public health problem. The hallmark of tuberculosis
control is prompt diagnosis and treatment. This is even more important in
suspected tuberculosis pleuritis (TP) for which accurate diagnosis is very
crucial since delay in chemotherapeutic intervention is associated with
poor prognosis. Diagnosis of TP requires microscopy and culture both of
which has limitation, microscopy is not sensitive and culture takes time.
The nested PCR (N-PCR) is used to detect M. tuberculosis complex
organisms and genus speciﬁc real time PCR is used for detection
of a broader spectrum of mycobacteria since atypical mycobacteria is
common in HIV-TB coinfected patients. The real-time PCR (RT-PCR)
has the advantage of not being prone to contamination and quicker
because it does not require post ampliﬁcation detection.
The aim of this study was to assess the diagnostic potential of nested
PCR of the IS6110 gene to detect M. tuberculosis complex organisms
and of RT-PCR for genus speciﬁc hsp65 detection in the diagnosis of
TP.
Thirty-six parafﬁn-embedded pleural tissue samples were taken from the
archives of the department of Pathology Dr. George Mukhari Hospital/
Medunsa Campus University of Limpopo Pretoria South Africa. Twenty-
ﬁve biopsies were from patients with clinical TP, and 11 biopsies from
cases with other diseases were used as controls.
Nested PCR was performed using the Mycobacterium tuberculosis
complex speciﬁc IS6110 primer and real-time PCR was performed using
the genus speciﬁc hsp65 primer (ABI 7500 RT-PCR system).
Sixteen samples were positive by N-PCR and 15/16 was positive by RT-
PCR. Out of the 11 non-TB cases 2 were positive by both N-PCR and
RT-PCR while additional 2 cases were positive by only RT-PCR. Using
clinical diagnosis as gold standard the sensitivity of N-PCR and RT-PCR
were 64% and 76% while speciﬁcity was 82% and 64%, respectively.
The sensitivity of RT-PCR using N-PCR as gold standard was 94%.
This study showed that RT-PCR is equally sensitive to N-PCR in
diagnosing TP. Its lower speciﬁcity might be due to presence of
atypical mycobacteria. Therefore RT-PCR is highly sensitive, not prone
to contamination, and its quicker turn around time will lead to rapid
diagnosis of TP.
P1988 Diagnosis of mycobacterium infection by TB-rapid-antigen-
test in patients from Belarus
S. Zaker, L. Titov, A. Bahrmand, E. Sagalchyk, L. Surkova (Tehran,
IR; Minsk, BY)
Background: Tuberculosis (TB) remains an important problem in
the world, but TB diagnosis is often difﬁcult. The routinely used
procedures for TB diagnosis in clinical laboratory either show poor
sensitivity (microscopy) or take several weeks (culture) before results are
obtained. The aim of the study was to estimate sensitivity and speciﬁcity
of developed for indication MTB in sputum kit “Rapid-Test”.
Method: In this study we tested 288 sputum samples from patients
living in different regions of Belarus with aim to detect Mycobacterium
tuberculosis by developed Rapid-Test. Sputum samples from patients
were concentrated and washed in the speciﬁc cassettes containing
nitrocellulose membrane with absorbing pads above it. MBT were
detected by addition anti-TB monospeciﬁc rabbit serum and gold-
protein A solution. Positive samples were characterised by displaying
a red-to brown colour in central area of cassettes in the contrast to the
blue-purple colour in negative cases. This new rapid test was compared
with the results of acid-fast staining microscopy, speciﬁc culture for TB
bacilli and speciﬁc PCR ampliﬁcation of TB DNA segments.
Results: In this study 107 samples from healthy persons were used as
control and 177 sputums from patients with tuberculosis conﬁrmed by
culture method. We found that developed Rapid-Test was more effective
for M. tuberculosis detection compared with specimen microscopy.
Efﬁciency of Rapid-test in compare with “gold standard” of culture
investigation was 88.5% for Belarussian samples. Compared with culture
for Belarussian samples Rapid-Test was false positive in 22 cases,
false negative in 19 cases, sensitivity was 81%, speciﬁcity 93%, positive
predictive value 66.3% and negative predictive value 89.9%. Meanwhile
Ziehl–Neelsen microscopy did not give false positive results, false
negative results were registered in 23 cases, efﬁciency of microscopy
was estimated as 88%, sensitivity 68.5%, speciﬁcity 94.8%, PPV 82%
and NPV 89.7%.
Conclusion: Therefore, we observed 25% more sensitivity and 20%
speciﬁcity of rapid test compared with microscopy for Mycobacterium
tuberculosis detection.
P1989 Evaluation of a rapid automated assay for the isolation
of Mycobacterium tuberculosis DNA directly from clinical
samples, using magnetic particles
J. Lyse´n, H.K. Høidal Berthelsen, M. Espelund, S. Jeansson,
A.T. Mengshoel, U.H. Refseth (Oslo, NO)
Objectives: The objective of this study was to evaluate the performance
of a fully automated DNA preparation system, the BUGS’n BEADS™
MYCOBACTERIUM (Genpoint, Norway), to isolate Mycobacterium
tuberculosis complex DNA from clinical respiratory samples.
Method: The BUGS’n BEADS™ principle was used to develop an
automated customised application. Brieﬂy, the automatic isolation begins
with addition of specially coated magnetic particles to Nalc-NaOH-
treated clinical samples. Following bacterial capture, the sample matrix
is removed. A rapid lysis at RT releases DNA, which is then adsorbed on
to the same magnetic particles. Beads are washed and the puriﬁed DNA
is robotically transferred for NAAT analysis. Samples were analysed
both by using an in-house developed real-time PCR targeting the
M. tuberculosis complex, and the Strand Displacement Ampliﬁcation
(SDA) part of the ProbeTec™ ET Mycobacterium tuberculosis Complex
(DTB) Direct Detection (Becton Dickinson).
Results: Up to 48 samples can be simultaneously analysed using the
automated BUGS’n BEADS™ system, with as little as 20 minutes
of hands-on for each run, and requiring a total time to results of
four hours. For smear positive samples, the results for the automated
BUGS’n BEADS™ system in combination with real-time PCR were
comparable to culture. The combination of SDA with the automated
BUGS’n BEADS™ was comparable to the in-house Real-Time PCR. For
the smear negative samples, we have observed so far that lowering the
predeﬁned BD cut-off from 3400 to 1000, enabled to improve sensitivity
without worsening speciﬁcity. No inhibition was recorded for the SDA.
Conclusions: We here present a fully automated system for preparation
of M. tuberculosis complex DNA from clinical respiratory samples,
compatible with in-house developed and commercial downstream
detection systems. Used with respiratory samples, the system will give
clinically relevant results within one working day, requiring minimal
hands-on.
The combination with SDA demonstrated successful removal of
inhibition, while opening for further improvement of sensitivity. To
further challenge the system, and evaluate lowering cut off, non-
respiratory samples will be included in a more extensive study.
P1990 Genotype MTBDR assay for rapid detection of rifampin and
isoniazid resistance in Mycobacterium tuberculosis isolates
M. Unzaga, R. Blanco, M. Fernandez, A. Morla, L. Garcia, C. Ezpeleta,
J. Alava, R. Cisterna (Bilbao, ES)
Objectives: The rapid determination of drug resistance in clinical
isolates of Mycobacterium tuberculosis is essential for the initiation
of effective chemotherapy and preventing further spread of drug-
resistant isolates. Drug susceptibility testing by conventional methods
takes several weeks although some new liquid medium-based systems
have been commercially introduced with a shortened incubation time.
A commercially DNA strip assay (Genotype MTBDR assay (Hain
Lifescience Nehren, Germany) based on a multiplex PCR in combination
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with reverse hybridisation to identify either wild type or most common
mutations in M. tuberculosis katG and rpoB was evaluated.
Material and Methods: Genotype MTBDR assay was evaluated by
investigating 53 strains isolated in Basurto Hospital. The results were
compared to data obtained by BACTEC MGIT 960 Becton Dickinson
Microbiology Systems, Sparks, MD). Both assays were performed as
recommended by the manufacturer.
Results: According to the results of BACTEC MGIT 960, 49 were fully
susceptible, 2 were resistant to high level isoniazid (0.4mg/mL) (INH), 2
WERE resistant to low level INH (0.1mg/mL), and two was Multidrug-
resistant (MDR).
All the isolates that were phenotypically resistant to high level INH had
a S315T1 mutation in katG codon 315. No mutation was found in the 2
strains which showed a low level of resistance. None of phenotypically
INH-susceptible isolates had the codon 315 mutation.
No mutations were detected in the phenotypically RIF-susceptible.
One of MDR isolate had an rpoB S531L mutation but did not hybridised
with the Genotype MTBDR test probe (S531L), although the test with the
WT 5 probe was negative. The other one had an rpoB S531L mutation
that hybridised with the mutation-speciﬁc probe (MUT3). In both of
MDR the mutation in katG of MDR was the same than the mentioned
in the other strains.
Conclusions: Genotype MTBDR assay allows rapid and speciﬁc
detection to INH and RMP although it cannot totally replace traditional
cultured-based methods basically due there is not molecular test
established targets all possible genes o mechanism and thus a variable
proportion of resistant strains will not be detected.
P1991 Comparison of Gen-Probe A-MTD test and GenoType
Mycobacteria Direct 3.0 test in detecting Mycobacterium
tuberculosis complex and four nontuberculous mycobacteria
in clinical samples
E. Fakiri, E. Papaefstathiou, K. Paulou, A. Charalampopoulou,
D. Bassoulis, A. Kosmopoulou, E. Papafrangas (Athens, GR)
Aim: The comparison of two RNA-ampliﬁcation bassed assays, Gen-
Probe Ampliﬁed Mycobacterium Tuberculosis Direct Test (A-MTD),
Gen-Probe, Inc. San Diego, CA and a newly developed commercial
kit GenoType Mycobacteria Direct 3.0 (GTMD), Hain Lifescience,
Germany, for the detection of ﬁve mycobacterial species (M. tuberculosis
complex, M. avium, M. intracellulare/M. scrophulaceum/M. interjectum,
M. kansasii and M. malmoense) directly from respiratory and
extrapulmonary clinical specimens.
Material and Methods:We tested a total of 120 clinical samples by both
assays: 97 from lungs (sputa, BALs, bronchial washings) and 23 from
extra-pulmonary sites (CSFs, pleural ﬂuids and pericardial effusions,
ascetic ﬂuids, urines and lymph node aspirates)
Results: Positive M.tb complex: A-MTD 42, GTMD 40. False negative
M.tb complex: A-MTD 0, GTMD 2. False positive M.tb complex:
A-MTD 2, GTMD 0. Additionally GTMD assay correctly identiﬁed
6/120 samples as M. intracellulare and 2/120 as M. avium.
Conclusions: 1. The GTMD test detects in one step ﬁve mycobacterial
species including M.tb complex. 2. The ribosomal RNA isolation
and NASBA ampliﬁcation in GenoType test monitors the presence of
ampliﬁcation inhibitors, since the A-MTD does not. 3. The A-MTD test
is quicker (3.5 h) than GTMD test (5−6 h). 4. The A-MTD test seems to
be more sensitive but less speciﬁc than GTMD test.
P1992 Molecular methodologies in identiﬁng mycobacteria isolates
and detecting Mycobacteria spp. directly in clinical samples
E. Fakiri, E. Papaefstathiou, D. Bassoulis, A. Charalampopoulou,
K. Paulou, S. Mamouha, E. Papafrangas (Athens, GR)
Aim: The evaluation of commercially available molecular methodologies
(Hain Lifesciences, Germany) in (1) The identiﬁcation of mycobacteria
from cultures in solid (LJ) and liquid (MGIT) media and (2) the detection
of mycobacteria spp. directly in clinical samples.
Materials and Methods: (1) We tested 520 mycobacteria strains by PCR
and reverse hybridisation in nitrocellulose strips. We used the MTBC kit
and in case of failure consecutively the CM and AS kits.
(2) Additionally, 100 clinical samples (73 sputa, 2 BALs, 10 bronchial
secretions, 3 CSFs, 4 pleural, 1 pericardial & 1 ascetic ﬂuids, 4 urines and
2 lymphnode biopsies) from suspected TB patients, were tested directly
for the ﬁve most frequent mycobacteria spp. by GenoType Mycobacteria
Direct Test (VER 3.0).
Results: (1) 365 Mtb strains were identiﬁed as M. tuberculosis–
M. africanum–M. canetti (363), M. bovis BCG (1) and M. africanum
E´ (1). Of the 155 MOTTs the CM kit identiﬁed 102, of the remaining
strains the AS kit identiﬁed 31, while the last 22 failed to be identiﬁed
by all the three kits.
(2) Of the 100 clinical samples tested with the GenoType Mycobacteria
Direct Test (VER 3.0) kit, 44 tested positive for mycobacteria (41
M. tuberculosis complex, 2 M. intracellulare, 1 M. avium), while the
rest tested negative.
Conclusions: (1) The commercially available kits we used proved to
be fast, reliable and relatively cheap in identifying mycobacteria species
from solid and liquid media. (2) The new kit GenoType Mycobacteria
Direct Test (VER 3.0) is a highly sensitive, speciﬁc and quick method
for the detection of mycobacteria in clinical samples.
P1993 Extrapulmonary mycobacteria isolations
S. Karabela, S. Nikolaou, A. Raftopoulou, S. Anagnostou, I. Kouseris,
N. Makrigiannis, M. Koletou, S. Kanavaki (Athens, GR)
Aim: To study the extrapulmonary mycobacteria isolations, in an eight
years period (1998–2005).
Material: 21177 extrapulmonary clinical specimens.
Methods: Microscopy by Ziehl Neelsen stain. Culture by the classical
method on solid Lo¨wenstein-Jensen (LJ) medium, as well as, by the
automated system Bactec MGIT 960 (Becton Dickinson). Identiﬁcation
by molecular hybridisation, using the commercial kits: InnoLipa V2
(Innogenetics), Accuprobe (Gen Probe, bioMe´rieux) and Genotype
Mycobacterium CM and AS (Hain Life, Science).
Sensitivity testing by the classical method of proportion on LJ solid
medium, as well as, by the automated system, Bactec MGIT 960
(Becton Dickinson) and the molecular hybridisation technique, Geno
Type MTBDR, (Hain Life Science)
Results:
– The number of extrapulmonary specimens tested increased through
out the study period, from 2197 (13%) in 1998 to 3322 (18.2%) in
2005.
– 685/21177 (3.2%) clinical specimens grew a mycobacterium.
– 622/685 (90.8%) of mycobacteria were M. tuberculosis (MTB), while
– 63/685 (9.2%) were Non TB (NTB) mycobacteria.
a. Concerning MTB isolations, most common clinical sources were
pleural ﬂuid 243/622 (39%), urine 91/622 (14.6%), lymph nodes
83/622 (13.3%) and pus 81/622 (13%). Drug resistance of MTB
isolates showed that 35/622 (5.6%) were resistant to isoniazide (INH),
15/622 (2.4%) to rifampicin (RIF) and 12/622 (1.9%) were MDR
(INH+RIF)
b. Concerning NTB isolations, 52/63 (82.5%) were M. avium, 9/63
(14.3%) were M. chelonae, 1/63 (1.6%) was M. peregrinum and 1/63
(1.6%) was M. fortuitum. Most common clinical sites for the NTB
isolates were for M. avium, lymph nodes 21/63 (33.3%), blood 20/63
(31.7%) and pleural ﬂuid 8/63 (12.7%), while for M. chelonae blood
9/9 (100%), for M. peregrinum pleural ﬂuid and for M. fortuitum a
lymph node.
Conclusions: The vast majority of extrapulmonary specimens grew an
MTB. Most common clinical sources for extrapulmonary MTB isolations
were pleural ﬂuid and urine, while for NTB extrapulmonary isolations,
lymph nodes and blood. Concerning drug resistance and multidrug
resistance of MTB, they are signiﬁcantly lower in extrapulmonary
compared to pulmonary specimens, according previous studies of our
laboratory.
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P1994 Extensively drug-resistant tuberculosis (XDR TB) in Athens
S. Karabela, S. Nikolaou, I. Kouseris, N. Makrigiannis, S. Kanavaki
(Athens, GR)
Objectives: The Global XDR TB Task Force (Geneva, October 8−9,
2006) agreed upon a revised case deﬁnition of XDR TB, as those
cases of TB patients, whose responsible M. tuberculosis isolates are
resistant to isoniazide and rifampicin, plus any of the quinolones and
at least one of three injectable second-line drugs (amikacin, kanamycin
or capreomycin). Since transmission of XDR TB strains is an emerging
threat for the world, countries should strengthen TB control measures.
For this reason, we evaluated the presence of the extensively drug
resistant M. tuberculosis (MTB) strains in TB patients in Athens
(January 2004–August 2006).
Methods: 1,415 new TB patients resulted in an equal number of
MTB isolations. Microscopy, culture by the classical method on solid
Lo¨wenstein-Jensen (LJ) medium, and by the automated system Bactec
MGIT 960 (Becton Dickinson), identiﬁcation by hybridisation methods
and commercial kits: InnoLipa V2 (Innogenetics), Accuprobe (Gen
Probe, bioMe´rieux) and Genotype Mycobacterium CM and AS (Hain
Life, Science) and sensitivity testing by the method of proportion on
LJ solid medium, by Bactec MGIT 960 (Becton Dickinson) and by
hybridisation technique, Geno Type MTBDR (Hain Life Science).
Results: 40/1,415 (2.8%) were multi-drug resistant (MDR) and 9/1,415
(0.6%) were XDR, so that percentage of MDR which were XDR was
22.5% (9/40 MTB isolates). Regarding XDR TB patients’ nationality,
3/9 patients (33.3%) were from NE European countries and 6/9 (66.7%)
were native Greeks.
Conclusions: The isolation of XDR MTB strains in TB patients in our
country, should alert public health authorities. Greece, being a common
destination for a great number of immigrants coming from NE Europe,
SE Asia and Africa and a portal to Europe, should immediately respond
to this danger to prevent further spread of XDR TB isolates.
P1995 Incidence of cmaA2 gene in Beijing and non-Beijing strains
of Mycobacterium tuberculosis strains isolated from clinical
specimens
N. Amir Mozaffari (Tehran, IR)
Objectives: The purpose of this investigation was to determine the
prevalence of cmaA2 gene in M. tuberculosis strains of both Beijing
and non-Beijing types isolated and typed by spoligotyping. Related risk
factors among patients with different nationalities residing in Iran were
also determined.
Methods: The study population involved a total of 742 patients that
referred to the NRITLD, the referral tuberculosis centre in Iran; during
March 21, 2003, till March 21, 2005. The isolatedM. tuberculosis strains
have been characterised by performing susceptibility tests against four
ﬁrst-line antituberculosis drugs and were then subjected to spoligotype
characterisation. PCR was used for detection of cmaA2 gene and its
nucleotide sequence was also determined.
Results: Spoligotyping of M. tuberculosis strains resulted in 150
different patterns. One hundred thirty ﬁve (90%) of these spoligotype
isolates were unique and reported for the ﬁrst time. The remaining
15 (10%) spoligotype patterns were previously reported from other
geographical regions of the world. East African Indian (EAI) family was
most prevalent than the other genotypes. Interestingly, 6.1% of the strains
belonged to the Beijing family. Multidrug-resistance M. tuberculosis
isolates were obtained from 13.6% of the patients during this study.
The cmaA2 gene was detected in M. tuberculosis clinical isolates, but
not in saprophytic strains such as M. kansasi. The other risk factors such
as sex and age were also contributing factors to the disease state.
Conclusion: The results showed that multidrug-resistant bacteria were
more prevalent in Iranian tuberculosis patients. In addition, the spread
of M. tuberculosis strains belonging to the Beijing family among
Iranian patients has to be considered seriously. This study conﬁrmed
the widespread existance of cmaA2 gene in almost all clinical isolates.
It is also important to undertake studies to identify which factors are the
most signiﬁcant to consider in tuberculosis control programme.
P1996 Molecular analysis of drug-resistant Mycobacterium
tuberculosis isolates collected from patients with pulmonary
tuberculosis in central Poland
T. Jagielski, E. Augustynowicz-Kopec, M. Kozinska, A. Zabost,
M. Klatt, Z. Zwolska (Warsaw, PL)
Objective: Although the incidence of tuberculosis (TB) in Poland
is steadily decreasing, the prevalence of primary drug-resistant TB,
including multidrug resistance (MDR), has been on the rise over the
last few years. Therefore, continued surveillance and monitoring of TB
epidemiology are required. Currently, molecular typing methods have
become a useful tool for tracking and control of transmission of drug-
resistant TB. The aim of this study was the molecular characterisation
of drug-resistant Mycobacterium tuberculosis clinical isolates.
Materials and Methods: A total of 48 clinical isolates of
M. tuberculosis representing 48 non-related, adult patients with resistant
pulmonary tuberculosis in central Poland in 2004 were analysed by
spoligotyping and newly devised PCR-based method designated IS6110-
Mtb1/Mtb2 PCR. Species identiﬁcation and drug susceptibility testing
had been performed beforehand.
Results: Among strains tested, a total of 26 distinct spoligotypes were
identiﬁed. Unique spoligotype patterns were observed in 19 (39.6%)
isolates and the remaining 29 (60.4%) isolates were grouped within 7
clusters, made up of 2−8 isolates. When compared with an international
spoligotyping database SpolDB4, 13 (27.1%) of the 19 unique proﬁles
shared already described spoligotypes, whereas the rest 6 (12.5%) did
not match any existing spoligotype and were deﬁned as orphans. Of
the 7 recognized clusters, one had not been described in SpolDB4. This
cluster, comprising 4 isolates, seem to be speciﬁc for the study setting.
Interestingly, two members of the Beijing family were identiﬁed.
Of the 7 spoligotyping clusters, 3 were not conﬁrmed and 2 were
partially conﬁrmed by IS6110-Mtb1/Mtb2 PCR. Only two spoligotyping
clusters, comprising 2 and 4 isolates, respectively, were identical both
with spoligotyping and IS6110-Mtb1/Mtb2 analysis.
Table 1. Comparison of discriminating power among two genotyping
methods used in this study
Technique No. of clustered
isolates (%)
No. of
clusters
Size of
cluster
Spoligotyping 29 (60.4) 7 2−8
IS6110-Mtb1/2 PCR 12(25) 4 2−4
Conclusions: Molecular analysis by using two genotyping methods,
undertaken in 48 drug-resistantM. tuberculosis isolates, showed a variety
of different genetic proﬁles. Spoligotyping overestimated by about 2.5
times the number of clustered isolates, compared to IS6110-Mtb1/Mtb2
PCR. A combination of spoligotyping and IS6110-Mtb1/Mtb2 PCR
showed 12 (25%) strains to be clustered, suggesting possible recent
transmission.
P1997 An IS6110-targeting ﬂuorescent ampliﬁed fragment length
polymorphism DNA ﬁngerprinting alternative to IS6110
RFLP: a pilot study
N. Thorne, J. Evans, E.G. Smith, P. Hawkey, S. Gharbia, C. Arnold
(London, Birmingham, UK)
Objectives: A rapid, simple, highly-discriminatory DNA ﬁngerprinting
methodology that produces data that can be easily interpreted, compared
and transported is the ultimate goal for M. tuberculosis infection
control professionals and epidemiologists. The current ‘gold standard’,
IS6110 RFLP, is far from meeting all these requirements; however
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its discriminatory power has not been matched by a rapid, alternative
method that also analyses the IS6110 sequence.
Methods: A panel of 78 blinded isolates from TB cases that were either
epidemiologically linked or distinct were selected for analysis by IS6110
RFLP and FAFLP. A pilot study for a novel Fluorescent Ampliﬁed
Fragment Length Polymorphism (FAFLP) approach to M. tuberculosis
DNA ﬁngerprinting targeting the variable IS6110 marker was tested for
speciﬁcity and reproducibility and compared with IS6110 RFLP typing
results on the panel of isolates. IS6110 RFLP was carried out using the
internationally standardised published method.
Results: IS6110 RFLP deﬁned the 78 isolates into nine clusters
containing 2−32 isolates, with a total of 63 clustered isolates and 15
unique isolates. There were seven low-copy number isolates included
in which four clustered into two, each containing a pair of isolates.
Comparison of in silico analysis with strain H37Rv found FAFLP
detected fragments to be highly speciﬁc in vitro. The reproducibility of
FAFLP fragment proﬁles for ﬁve repeated digestions with strain H37R
was 100%. FAFLP and RFLP clustering results were found to be highly
congruent. FAFLP clustering was highly similar to RFLP discrimination
of the 78 isolates as unique or clustered strains. FAFLP allocated 97%
of RFLP-clustered isolates to the same eight clusters as RFLP. FAFLP
failed to cluster two single-copy strains that had been clustered by RFLP,
however clustering based on a single IS6110 copy is not reliable and
secondary ﬁngerprinting is necessary.
Conclusion: The discriminatory power exhibited by FALP in this initial
collection of isolates indicates that it would be a rapid and speciﬁc
screening alternative to IS6110 RFLP. The accuracy of fragment sizing
by FAFLP has allowed common fragments to be deﬁned that are likely
hot-spots for IS6110 transposition. FAFLP will enable rapid screening
of strains for epidemiological investigations and initiate further research
into the frequency, conservation and consequence of IS6110 hotspots
and speciﬁc transposition sites.
P1998 Determination of the invasiveness of non-pigmented
rapidly growing mycobacteria by means of two different
in vitro assays
J. Esteban, N. Zamora, I. Gadea, R. Ferna´ndez-Roblas,
A. Ferna´ndez-Martı´nez (Madrid, ES)
Objectives: To determine the invasive capacity of non-pigmented rapidly
growing mycobacteria (NPRGM) in clinical isolates and in collection
strains of NPRGM using the ﬁbroblast-microcolony assay and the HEp-2
monolayer invasiveness assay. To correlate the invasive capacity with the
species, colony phenotype and clinical signiﬁcance of the strains.
Methods: Clinical isolates were identiﬁed according recommended
biochemical tests and PCR-RFLP analysis of the hps65 gene. Clinical
signiﬁcance of the strains was evaluated by analysis of the clinical
charts according to commonly accepted criteria. Colony phenotype
was evaluated by culture on Middlebrook 7H10 agar plates during 5
days. The ﬁbroblast-microcolonies assay, previously described by Byrd
and Lyons, was used with minimal modiﬁcations. The relationship
between diameters of the individual microcolonies in ﬁbroblast were
used by determinate the invasive capacity. The invasion assay in HEp-2
monolayers was carried out according to the method described by
Bermudez et al. with an inoculum of 106 CFU. Invasive bacteria in
HEp-2 monolayers were quantiﬁed performing 1:10 serial dilutions of
the sonicate and streaking each dilution in Tryptic Soy Agar with 5%
sheep blood plates. These plates were incubated at 30ºC during 7 days
before counting the colonies.
Results: 92 strains of NPRGM were tested, including 19 collection
isolates of 15 species and 73 clinical isolates of 5 species (M. abscessus,
M. chelonae, M. fortuitum, M. peregrinum and M. mucogenicum).
35 colonies gave rough colonies, and 57 were smooth colonies. 12 strains
showed elongated colonies in the ﬁbroblast microcolonies assay, while
all the other strains showed rounded colonies. All but one strain showed
different degrees of invasiveness of the Hep-2 monolayers, with a range
of 8–22,500UFC recovered. No statistically signiﬁcant differences were
found in relation with colony phenotype, clinical soigniﬁcance and the
presence of elongated colonies or higher counts in the Hep-2 invasiveness
assay.
Conclusions: Almost all strains of NPRGM were able to invade Hep-2
cell monolayers, but only 13% of the strains were able to invade
ﬁbroblasts according to the results of the microcolonies assay. No
relationship were found between these data and colony phenotype or
clinical signiﬁcance.
Acknowledgments: This study was supported by a grant from the Fondo
de Investigaciones Sanitarias (FIS PI030146). N. Zamora was funded by
a grant from the Fundacio´n Conchita Ra´bago de Jime´nez Dı´az (Madrid,
Spain).
P1999 pncA and rpoB mutations in Mycobacterium tuberculosis,
a 3-year experiment in Lyon, France
S. Mignard, G. Carret, M. Chomarat, I. Fredenucci, M. de Montclos,
J. Flandrois (Pierre Benite, FR)
The emergence of drug resistant Mycobacterium tuberculosis is a serious
public health problem. Pyrazinamide and rifampicin are ﬁrst line drugs
and their efﬁcacy can be evaluated by DNA sequencing. We realised
rpoB and pncA sequencing for all MTBC isolated from 2003 to 2006
in order to check the different mutations existing in Lyon, France. The
in vitro susceptibility testing was done in the same time. 330 isolates
of MTBC were studied during this 3-year period. On the rpoB gene, 9
mutations have been reported, 6 have ever been described: H526L (n = 1),
S531L (n = 3), L511P (n = 1) and the deletion of nucleotides 514–516.
3 mutations were unknown N518D (n = 1), S469L (n = 2) but for these
strains isolates were susceptible to rifampicin by in vitro testing. On
the pncA gene 22 mutations have been reported. Among the 17 ever
known in the literature, 10 correspond to the well known H57D mutation
of M. bovis strains and 7 were T87M mutations. This last mutation is
described in the literature associated with a deletion conferring resistance
to pyrazinamide. All our T87M mutated strains were susceptible to
pyrazinamide in vitro (none presented the deletion). Five mutations were
unknown: A146V (n = 1), R2W (n = 1), H43Y (n = 1), L19P (n = 1) and
V21A (n = 1). Only the A146V strain appeared resistant to pyrazinamide.
The conclusion of this study is the emergence of the T87M mutation on
pncA gene among strains that remain susceptible to pyrazinamide in
vitro. No relationships were observed between patients by spoligotypes
and MIRU types’ comparison.
P2000 The muralitic activity of Rpf proteins and their ability to
resuscitate dormant mycobacterial cells
G. Demina, G. Mukamolova, A. Kaprelyants (Moscow, RU)
Objectives: Micrococcus luteus secretes a small protein Rpf, which
plays an important role in the resuscitation of dormant cells of several
species of Gram-positive bacteria, e.g. M. luteus and pathogenic bacteria
Mycobacterium tuberculosis. Latent tuberculosis infection is believed to
connect with the dormant state of M. tuberculosis in the human host.
Rpf-like proteins contain speciﬁc domain which adopts a lysozime-like
fold however enzymatic activity of Rpf proteins is poorly understood.
The purpose of this study is to elucidate an enzymatic activity of Rpf
proteins and its relation to biological activity.
Methods: The muramidase activity was measured ﬂuorimetrically,
4-methylumbelliferyl-beta-D-N,N′N′′-triacetylchitotrioside was used as
a substrate. The efﬁcacy of resuscitated “non-culturable” M. smegmatis
cells in liquid medium was estimated by MPN assay.
Results: Recombinant M. luteus Rpf is able to hydrolise the artiﬁcal
lysozyme substrate which is structurally similar to peptidoglycan of
bacterial cell wall. The invariant catalytic glutamate residue found
in lysozyme and lytic transglycosylases is also conserved in the
Rpf proteins. Replacement of glutamate residue by amino acids
with less structural similarity resulted in a decrease in enzymatic
activity of Rpf and its ability to resuscitate dormant Mycobacterium
smegmatis cells. Rpf possible cleaves glycosidic bonds with inversion
of conﬁguration, but in contrast to lytic transglycosylase, Rpf doesn’t
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form 1,6-anhydromuro derivatives (Keep et al., 2006). The effect of the
some metal ions on the enzymatic activity was studied; the results show
that Mg2+ and Ca2+ slightly activate the enzyme, while Zn2+ inhibits
enzymatic activity.
Conclusions: Rpf proteins are evidently peptidoglycan hydrolase
enzymes. Rpf’s muralitic activity correlates with its ability to stimulate
resuscitation of dormant bacteria, consistent with the view that biological
activity of Rpf molecule is connected directly or indirectly with its ability
to cleave glycosidic bonds in bacterial peptidoglycan.
P2001 Evaluation of the BacT/Alert PZA test for susceptibility
testing of Mycobacterium tuberculosis to pyrazinamide in
comparison with BacTec 460TB
M. Garrigo´, C. Moreno, L. Aragon, P. Coll (Barcelona, ES)
The importance of rapid availability of Mycobacterium tuberculosis
susceptibility testing is universally acknowledged. Although BACTEC
460TB susceptibility testing is considered the gold standard, its major
disadvantages are that it is semiautomatic and uses radioactive material,
with the need for disposal of radioactive waste.
Objectives: The purpose of this investigation was to evaluate the
performance of the BacT/ALERT PZA (Bio-Me`rieux) kit for testing
M. tuberculosis susceptibility to Pyrazinamide (PZA) drug compared to
the radiometric BACTEC 460TB PZA test (Becton-Dickinson)
Methods: A total of 50 M. tuberculosis isolates from human samples
were included in this study. Twenty, from a culture collection of the
Mycobacteria Study Group of Barcelona, were resistant to PZA having
a pncA mutation. The selected clinical strains were tested in parallel with
BacT/ALERT PZA kit and BACTEC 460TB PZA test. Two reference
control strains, ATCC 27294 (PZA sensitive) and ATCC 35745 (PZA
resistant) were included in order to validate the conditions in which the
clinical strains were analysed. Control and clinical strains were prepared
and tested according to the respective test procedure and the reading
and interpretation of each test were performed in accordance with the
manufacturer’s recommendations. Strains with discrepant results were
repeated in the two methods.
Results: No technical problems were detected. Five strains needed to be
repeated: two because of initial discrepant results, two because of lack
of growth in BACTEC 460 and one because of no respect of the test
validation criteria of the BacT/ALERT PZA kit. Final overall agreement
between the two systems was 100%. The total turnaround time was 13.87
days for BacT/ALERT PZA kit versus 12.39 days for BACTEC 460TB
PZA test.
Conclusion: Final overall agreement between the two systems was
100%. That is, there were no differences between the two systems in the
ability to detect the sensitivity to PZA or the expression of the different
resistance molecular mechanisms included. There was no signiﬁcant
difference in the total turnaround time of the two systems. The main
advantages of BacT/ALERT PZA kit are that it is fully automated with
a nonradiometric detection and that it is less labour-intensive than the
BACTEC 460TB system.
P2002 Drug resistance of Mycobacterium tuberculosis in Santiago
de Compostela, Spain (2002–2005)
M. Pe´rez del Molino, V. Tun˜ez, F. Pardo, S. Cortizo, P. Romero
(Santiago de Compostela, ES)
Objective: The aim of the study was investigate the rate of drugs
resistant tuberculosis (DR-TB) in Santiago de Compostela (Galicia,
north-west of Spain, 459.180 inhabitants). In our sanitary area, the
total number of cases per 100.000 population dropping from 51.5 to
28.3 between 2002 to 2005. The rate of TB patients with human
immunodeﬁciency virus (HIV) coinfection remain 1.7% (2002) and
1.5% (2005).
Methods: The study followed the methodology recommended by the
WHO/IUATLD, and included isolates processed between January 2002
and December 2005. Susceptibility testing was performed using the
Bactec 460 method (Becton Dickinson Diagnostic Instrument Systems,
Sparks, MD, USA) with Middlebrook 7H12 medium (Bactec 12B) and
the following ﬁnal drug concentrations: 0.1 mg/mL for INH, 2mg/mL for
RMP, 6mg/mL for streptomycin (SM), and 7.5mg/mL for ethambutol
(EMB). Culture and detection procedures were performed in accordance
with the manufacturer’s instructions. All susceptibility testing was
performed at the Reference Mycobacteria Laboratory in Galicia, was
subjected to quality control checks by the corresponding supranational
reference laboratory.
Results: The sample included 417 strains of M. tuberculosis (379 never
treated cases and 38 previously treated cases). Isolates from 345 of the
379 never treated cases (91.03%) were susceptible to all of the drugs
tested. This percentage was 86.84% for previously treated. Fifteen strains
from never treated patients and four from previously treated patients
were resistant to INH (3.96% and 10.53%, respectively). There were
one case of MDR-TB among never treated patients (0.26%) and two
among previously treated patients (5.26%). The resistance to SM from
never treated patients remain in 4.75%.
Conclusion: The rate of primary resistance (8.97%) are also similar
to the mean published by the WHO in its latest report 10.2% [range0–
57.1%]). The rate of primary MDR-TB (0.26) was slightly lower than the
WHO mean of 1.1% [range 0–14.2%]. Although Santiago de Compostela
has a high incidence of TB, the resistance levels detected by the study
do not currently pose a serious problem for the region.
We believe in the importance of keeping the quality of the TB prevention
and control programmes.
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P2003 Recommendations for the use of interferon-gamma assays
for the diagnosis of tuberculous infection
H. Hoffmann, T. Bodmer, P. Kirschner for the Working Group on
Mycobacteria (Arbeitskreis Mykobakterien – AKM) of Germany,
Austria and Switzerland
Two years ago, CE certiﬁed interferon-gamma release assay (IGRA) has
been launched on the German marked. Ever since, a multitude of studies
have tested the IGRA. Guidelines have been elaborated by national expert
committees for England, the USA and Switzerland. However, standards
of diagnostics and management of tuberculosis may change from country
to country.
This statement was drafted by members of the “Arbeitskreis Mykobak-
terien” (AKM), the expert committee for TB diagnostics of Germany,
Austria and Switzerland on the basis of review of relevant literature
and experience with CE certiﬁed IGRA available so far. The statement
provides practice-relevant guidelines for indication, pre-analytics and
interpretation of IGRA test results in different clinical conditions.
The IGRA are integrated in existing guidelines of the DZK for TB
management.
P2004 Serological rapid test for discrimination between latent
tuberculous infection and active tuberculosis
H. Hoffmann, A. Bosse, A. Neher, M. Singh (Gauting, Braunschweig, DE)
Since 100 years, the tuberculin skin test (TST) is the diagnostic basis
of tuberculous infection. Recently, the interferon-gamma release assays
(IGRA) appeared as new tests with higher speciﬁcity than the TST.
However, neither the TST nor the IGRA are able to discriminate between
latent tuberculous infection (LTBI) and active tuberculosis (TB).
Very recently, the serologic rapid test TB-ST (Lionex GmbH,
Braunschweig, Germany) has been launched functioning similarly to
pregnancy tests. The seven antigens combined in the test are supposed
to conﬁne speciﬁcally active TB versus LTBI.
In the present study, we analysed the validity of the test. 260 patients
with active TB, LTBI or different pneumological disorders were enroled.
The TB-ST was able to detect active TB with a speciﬁcity of 98%. Over-
all sensitivity was 53%, rising to 80% with smear detection rate of acid
fast bacilli.
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TB-ST is easy to perform (hands-on time less than 2 minutes), lasts only
about 20 minutes, and a positive test result is a strong hint for active TB.
The test principle is presented and options for expedient use of TB-ST
are put up for discussion.
P2005 Role of an interferon-gamma based assay (T-SPOT®.TB)
for the diagnosis of tuberculosis in routine clinical practice
J. Santos, M. Cordeiro, T. Hanscheid, E. Valadas, F. Antunes (Lisbon, PT)
Objectives: Diagnosis of tuberculosis (TB) can be difﬁcult and is often
fraught with long delays, which makes the search for new diagnostic
methods very important. This issue is even more relevant in HIV infected
patients. We evaluated the role of a new commercial ELISPOT for the
diagnosis of TB in routine clinical practice.
Methods: T-SPOT.TB was performed in consecutive patients admitted
to the Department of Infectious Diseases at a large teaching Hospital
in Lisbon, in 2006. Twenty healthcare workers (HCW), from the
Departments of Infectious Diseases and Microbiology, agree to
participate as control group. PBMCs, obtained using a Ficoll gradient,
were incubated overnight in a cell culture containing ESAT-6 and CFP-
10. The assay detects individual effector T cells through their secretion
of interferon-gama which results in a spot. A sample was considered
positive if a well showed at least 6 spots more than the negative control
well.
Results: Patients (n = 79) were male, and all were BCG vaccinated. Mean
age was 40 years and 55 (70%) were HIV infected. Fourteen patients
(22.8%) had TB, latter conﬁrmed by culture, and most were HIV infected
(n = 12, 85.7%). Of those, ELISPOT was positive in 11 patients (78.6%),
negative in two (14.3%), and indeterminate in one (7.1%). From the
remaining 55 patients admitted for other infectious cause, 13 (23.6%)
also had a positive ELISPOT. All 20 HCW had a negative result.
Conclusion: ELISPOT was positive in almost 80% of all TB cases,
even in a population with a very high rate of HIV infection and
severe imunodepression. As T-SPOT.TB uses ESAT-6 and CFP-10,
Mycobacterium tuberculosis complex speciﬁc antigens, these results
were expected in TB cases. Over the last few years, several studies have
showed that this test might have an important role on the diagnosis of
latent infection (LTBI). As Portugal has the highest incidence of TB
in Western Europe (~40/100.000), one would expect to ﬁnd a high
prevalence of latent infection. ELISPOT was positive in ~1/3 of all
patients with other diagnosis, results that support the role of this test in
the diagnosis of LTBI. Therefore, T-SPOT.TB is highly likely to become
a useful and sensitive assay for the diagnosis of TB in routine clinical
practice, as well as to identify individual with LTBI. The capacity of this
test to identify patients that might have a worse response to treatment,
as well as those individuals that can progress from infection to disease,
is still to be proven.
P2006 The use of QuantiFERON-TB Gold In-Tube to screen for
tuberculosis infection in employees of a Swiss university
hospital
A. Stebler, K. Franz, T. Bodmer (Berne, CH)
Objectives: Hospital employees and healthcare workers in particular
have a professional risk for contracting Mycobacterium tuberculosis
(Mtb) infection. Traditionally, screening for latent Mtb infection (LTBI)
is done with the tuberculin skin test (TST). However, previous
BCG vaccination has been shown to interfere with TST results. In
contrast, novel interferon-gamma release assays (IGRA), such as the
QuantiFERON-TB Gold In-Tube (QFT-GIT; Cellestis Inc., Carnegie,
Australia) assay, remain unaffected by BCG vaccination. The aim of
this study was to assess the prevalence of LTBI among employees of a
Swiss University Hospital.
Methods: Between June 1, 2005 and May 31, 2006 all employees who
entered service at the University Hospital and employees who had profes-
sional exposure to infectious forms of tuberculosis (TB) were screened
for LTBI by QFT-GIT as recommended by the manufacturer. In addition,
information on country of origin, BCG vaccination status, profession and
potential risk factors for the progression of LTBI to overt TB disease
were gathered. GraphPad Prism 4.0 was used for all data evaluations.
Results: Overall, 1261 employees were enrolled. BCG vaccination status
and country of origin were available in 608; of these, 494 (81.3%)
were Swiss. Thus, the overall BCG vaccination rate among Swiss
was 90.3%. From 1261 employees enrolled, 768 (60.9%) were newly
recruited personnel: 620 were born in countries with a TB incidence
rate <10/100,0000 (group A) and 87 in countries with a TB incidence
rate 10/100,000 (group B). In 61 cases this information was missing.
Overall, 7.7% of newly recruited personnel had a positive QFT-GIT test
result; the respective positivity rates for group A and group B were
5.9% (37/620) and 16.1% (14/87). This difference was signiﬁcant (odds
ratio = 3.01; 95%CI: 1.55–5.84; p = 0.0028).
Conclusions: We found a very high BCG vaccination rate among Swiss
hospital employees. This ﬁnding limits the usefulness of the TST for
the diagnosis of LTBI. The overall positivity rate of QFT-GIT in our
study population was higher than expected. However, employees born in
a country with a high TB incidence had a signiﬁcantly higher positivity
rate than employees born in a country with a low TB incidence rate.
This indicates that QFT-GIT is a useful tool to screen for LTBI in this
population with a very high background of BCG vaccination. The study
of risk factors for a positive QFT-GIT result other than the country of
origin is ongoing.
P2007 Comparison of T-SPOT.TB and QuantiFERON-TB-Gold In
Tube testing with regular tuberculin skin testing in a cohort
of haemodialysis patients
U. von Both, J. Trachsler, R. Zbinden, A. Zellweger, P. Wrighton-Smith,
C. Ruef (Zurich, Lausanne, CH; Abingdon, UK)
Objectives: Tuberculin skin testing (TST) is the current standard for
screening of persons exposed to tuberculosis. In recent years, a higher
speciﬁcity and sensitivity of interferon-based blood testing methods was
reported. Twenty-six hemodialysis patients had been exposed to a case of
open pulmonary TB in our tertiary care hospital. The aim of this study
was to evaluate the use of T-SPOT.TB and QuantiFERON-TB-Gold In
Tube (QFT-G) testing in comparison with regular TST for detection of
TB-infection among this cohort.
Methods: The cohort consisted of 26 adult patients (10 male, 16 female,
median age 57 years, range 25 to 82 years). Eighteen patients were
of Swiss origin, while eight were residents of southern European or
developing countries. Five patients (19.2%) received immunosuppressive
drugs. A total of 11 patients suffered from malignancies or other
additional causes of immunosuppression. Reliable information on former
BCG vaccination could only be collected for 16 individuals. All patients
were screened by TST, T-SPOT.TB and QFT-G. One patient could not
be tested in the T-SPOT.TB assay due to logistic reasons. A positive TST
was deﬁned as an induration of 5mm in diameter.
Results: 19 patients (73%) were anergic to TST, while 7 individuals
showed positive TST with three of them revealing skin induration of
>10mm in diameter. A positive QFT-G was obtained for 8 patients,
while 5 individuals showed a positive T-SPOT.TB result. TST positivity
was neither associated with positive results in QFT-G nor T-SPOT.TB
testing (P> 0.05), as 5 of 8 positive QFT-G results and 2 of 5 T-
SPOT.TB results were found in patients with negative TST. There was
no correlation between age >60, gender, TST positivity and either of the
two new tests (P> 0.05). Quantitative analysis of the QFT-G showed a
stronger reaction in patients with a positive TST. After analysis of all
tests, 9 patients were considered to have subclinical TB infection and
underwent radiological investigation, 6 receiving INH prophylaxis. No
case of active TB was detected.
Conclusions: In the absence of a gold standard to diagnose subclinical
tuberculosis infection, the interpretation of our results is difﬁcult, espe-
cially in light of immunesuppression. The comparison of the three tests
gave discordant results in some patients. Combining TST with either one
of the two interferon-based tests may enhance the sensitivity in detection
of subclinical TB infection in patients with chronic underlying diseases.
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P2008 Evaluation of three media for the cryopreservation of
peripheral blood mononuclear cells for ELISPOT
C. Maier, S. Bigler, T. Bodmer (Berne, CH)
Background: ELISPOT is used in microbiology for the analysis of
the cell-mediated immune response. Typically, this technique requires
sample processing within hours in order to preserve the vitality of
cells. This may limit its application in clinical settings. Therefore,
cryopreservation of vital lymphocytes prior to testing would facilitate a
wider use in clinical laboratories. The aim of this study was to evaluate
an optimised protocol for cryopreservation of vital lymphocytes.
Methods: Blood was obtained from three healthy donors, and peripheral
blood mononuclear cells (PBMC) were isolated using Vacutainer Cell
Preparation Tubes (Becton Dickinson, Franklin Lakes, US). PBMC
were split into four aliquots, one for direct processing and three for
cryopreservation (liquid nitrogen, −160ºC, 4 weeks) in medium A (FCS,
90%; DMSO, 10%), medium B (AIM-V, 50%; FCS, 35%; DMSO,
15%), and medium C (AIM-V, 90%; DMSO, 10%), respectively. Cell
counts of the aliquots were assessed prior to and after four weeks of
cryopreservation using a Cell Dyn 1200 System (Abbott, Laboratories,
US); cell viability and background were tested using mitogen controls
and negative controls of T-Spot.TB (Oxford Immunotec Ltd., Oxford,
UK). The results were compared and the ideal medium formulation
was identiﬁed. For the purpose of further validation, PBMC of three
individuals with previous positive T-Spot.TB results were processed as
described above, and tested including the TB-speciﬁc antigens of T-
Spot TB after eight weeks of cryopreservation. Spot-forming cells were
counted by the AID Elispot Reader System (AID GmbH, Strassberg,
Germany).
Results: With respect of survival rate, cell viability, and technical
requirements medium A was superior: survival rate was 61.7±12.7%
and mitogen response as a surrogate for cell viability remained above
the level of validity of T-SPOT.TB (20spots/well). Background signal
was not inﬂuenced by FCS, as there was no increase in the extent of
background signal (p = 0.19). All specimens, that had previously tested
positive with the T-SPOT.TB, remained positive after cryopreservation
(Panel A, p = 0.91; Panel B, p = 0.30).
Conclusions: We have identiﬁed a reliable protocol for the cryop-
reservation of PBMC to be tested in ELISPOT-assays. Successful
cryopreservation of PBMC’s facilitates a wider application of this
technique in clinical laboratories, and will allow cell banking for
prospective studies.
P2009 Diagnostic value of neopterin in patients with active
pulmonary tuberculosis and relation with CRP
D. Tarhan, S. Aksaray, A. Toyran, D. Ko¨ksal, E. Guvener (Ankara, TR)
Objectives: Macrophages and T cells are responsible for the main
immune response to tuberculosis by secreting many cytokines and
other substances. Neopterin is a marker of cell-mediated immunity,
and it has been demonstrated that in tuberculosis neopterin levels
could be determinated in various body ﬂuids. The aim of this study
was to investigate diagnostic values of serum neopterin evaluation in
tuberculosis infection.
Methods: Sixty-one male patients (ages 17−66 years) with active
pulmonary tuberculosis, conﬁrmed by clinical, radiological and bacte-
riologic examination ﬁndings who hadn’t antituberculosis medication
were included to this study. Sixty-two healthy male subjects (ages
18−67 years) were selected as a control group. Neopterin was measured
by competitive enzyme-linked immunosorbent assay (IBL, Hamburg)
in seras. CRP values were measured by nephelometric method (Dade
Behring, Germany). Results were expressed as mean ±SD and ranges.
Results: Serum neopterin concentrations were 18.28±23.12 (0−83)
nmol/L in patients with tuberculosis infection, 4.53±8.30 (0−37) nmol/L
in the control group. CRP levels were 62.95±51.7 (4–198) mg/L in
patients with tuberculosis infection and 3.13±21.7 (3–156) mg/L in
control group. There was signiﬁcant difference between patient and
control groups on CRP and neopterin values (p< 0.001).
Conclusion: These ﬁndings indicate that measurements of serum
neopterin levels are useful in diagnosis of active tuberculosis.
P2010 Evaluation of cellular immune response against puriﬁed
antigen 85 in patients with tuberculosis
I. Nikokar, M. Makvandi, K. Huygen (Langaroud, Ahwaz, IR; Brussels,
BE)
Objective: Tuberculosis (TB) remains an important health problem
throughout the world. Despite its signiﬁcance in public health, mech-
anisms of protective immunity against Mycobacyerium Tuberculosis in
humans have not yet been understood. In the this study we evaluated
cell mediated immune response against puriﬁed Ag 85, PPDand
Phytohemagglutinin (PHA) in patients with tuberculosis and healthy
tuberculin positive and negative individuals.
Methods: Thirty patients with tuberculosis and 60 healthy tuberculin
skin test positive and negative volunteers were participated in this study.
Cell mediated immunity was assessed by measuring [3H]-thymidine
uptake and detection of IFN-gamma in the culture supernatant using
commercial ELISA test.
Results: In the present study, we showed that IFN-gamma production
and cell proliferation response to Ag 85 were signiﬁcantly higher
in tuberculin positive than tuberculin negative individuals (P< 0.01).
Among tuberculous patients, IFN-gamma production and cell prolif-
erative responses to Ag 85 was signiﬁcantly lower in contrast to
healthy tuberculin positive individuals (P< 0.01). In addition, IFN-
gamma response in patients with cavitary tuberculosis was lower than
patients without cavitation (P< 0.05).
Conclusion: Based on the higher cell mediated immune responses to
Ag 85 in healthy tuberculin positive volunteers compared to patients
(especially with advanced disease), puriﬁed Ag 85 can be used as a
sensitive marker for analysis of cell immune responses in tuberculosis
P2011 Expression of phagocyte Fcg receptors during
anti-tuberculous treatment
M.A. Escobar, A.A. Garcia-Egido, F.M. Gomez-Soto, F.J. Fernandez,
J.L. Puerto, P. Ruiz, C. Rivera, F. Gomez (El Puerto Santa Maria, ES)
Receptors for IgG (FcgRs) on phagocytic cells are important in host
defence against infection.
Objectives:We have studied the expression of FcgRs by peripheral blood
monocytes (M), M cultured for 72 hours (M/Mø), and granulocytes (G)
in patients with active Tuberculosis (TB), during anti-TB therapy (anti-
TB-Rx) and, after completition of anti-TB-Rx.
Methods: The expression of the three type of FcgRs, FcgRI, FcgRII and
FcgRIII, on M, M/Mø and G were analysed by ﬂow cytometry in 103
HIV-negative patients with TB (77 men and 26 women), at diagnosis, and
monthly thereafter until completition of anti-TB-Rx. FcgRs expression
was assessed on resting M, M/Mø and G, and on these cells after
stimulation by culture with IFNg.
Results: The expression of FcgRI and FcgRIII by M, M/Mø and G
was enhanced in patients with active TB by: 42±4% and 22±2% for
M, respectively (p< 0.001), 56±6% and 41±4% for M/Mø, respectively
(p< 0.001) and, 119±9% and 37±3% for G, respectively (p< 0.001).
The expression of FcgRIIA by M, M/Mø and G was decreased by
−31±1% (p = 0.02), −46±3% (p< 0.001), and −23±1% (p = 0.002),
respectively. These alterations of FcgRs expression normalised from
the 8th week until the end of effective anti-TB-Rx. The expression
of FcgRI, FcgRIIA and FcgRIII by M, M/Mø or G from patients
with active TB was signiﬁcantly increased by culture in the presence
of IFNg (p< 0.001), returning to normal after 8 wks of anti-TB-
Rx. Setting a cut-off value =25% of the mean ﬂuorescence intensity
over controls for FcgRs surface expression and, assuming a prevalence
range of active TB between 25 and 80% among patients undergoing
conﬁrmatory tests, results in a range of sensitivity, speciﬁcity, positive
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and, negative predictive values of: 57−96%, 48−97%, 34−74%, and
59−98%, respectively for M-FcgRIIA, 48−73%, 51−96%, 38−74% and
68−97%, respectively for M-FcgRIII, 31−58%, 64−93%, 37−79% and
69−95%, respectively for G-FcgRI and, 52−71%, 88−98%, 49−77% and
81−93%, respectively for G-FcgRIIB.
Conclusions: Mø and G from patients with active TB exhibit an altered
expression of FcgRs that disappear after effective anti-TB-Rx. Thus, Mø
and G FcgRs expression may help in predicting the response to anti-TB
therapy.
P2012 Expression of phagocyte Fcg receptors in HIV infected
patients with tuberculosis
M.A. Escobar, A.A. Garcia-Egido, J.A. Bernal, F.J. Fernandez,
M. Rosety, P. Ruiz, C. Rivera, F. Gomez (El Puerto Santa Maria, ES)
Phagocyte receptors for IgG (FcgRs) are important in host defence
against infection.
Objectives: We have studied the expression of FcgRs by peripheral
blood monocytes (M), monocytes cultured for 72 hours (M/Mø), and
granulocytes (G) in HIV infected patients with active Tuberculosis (TB),
during anti-tuberculous therapy (anti-TB-Rx) and, after completition of
anti-TB-Rx.
Methods: The expression of FcgRI, FcgRII and FcgRIII, on M, M/Mø
and G (resting and cultured with IFNg) were analysed by ﬂow cytometry
in 68 HIV infected patients with active TB (45 men and 6 women), at
diagnosis of TB, and monthly thereafter until completition of anti-TB-
Rx.
Results: The expression of FcgRI and FcgRIII by M, M/Mø and G
was enhanced in HIV infected patients with active TB by: 34±4% and
19±3% for M, respectively (p< 0.001), 43±6% and 29±3% for M/Mø,
respectively (p< 0.001) and, 54±6% and 21±3% for G, respectively
(p< 0.001). The expression of FcgRIIB by M, M/Mø and G was
decreased by −24±3% (p = 0.02), −33±4% and −19±2% (p< 0.005),
respectively. These alterations of FcgRs expression normalised from
week 12th until the end of effective anti-TB-Rx. The expression
FcgRI, FcgRIIA and FcgRIII by M, M/Mø and G from HIV patients
with TB was signiﬁcantly enhanced by culture with IFNg (p< 0.005).
Setting a cut-off value =25% of the mean ﬂuorescence intensity over
controls for FcgRs surface expression and, assuming a prevalence range
of active TB between 25 and 80% among HIV patients undergoing
conﬁrmatory tests, results in a range of sensitivity, speciﬁcity, positive
and, negative predictive values of: 61−86%, 58−96%, 64−89%, and
57−90%, respectively for M-FcgRIIA, 56−84%, 63−91%, 58−79% and
68−97%, respectively for M-FcgRIII, 61−88%, 54−87%, 44−87% and
69−91%, respectively for G-FcgRI and, 42−75%, 88−98%, 49−77% and
86−98%, respectively for G-FcgRIIB.
Conclusions: Our results suggest that, the alterations of Mø and G Fcg
receptors expression in HIV infected patients with active TB can be used
to predict the response to anti-tuberculous therapy.
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P2013 A decade of levoﬂoxacin: summary of the cumulative
clinical trial safety database
J. Peterson, A. Fisher, M. Khashab, J. Kahn (Raritan, US)
Background: The comprehensive safety proﬁle of a drug is not
established until enough subjects are treated to identify rare adverse
events. Levoﬂoxacin was approved by the US Food and Drug
Administration on December 20, 1996. Worldwide patient exposure
to levoﬂoxacin is estimated to be >300 million prescriptions. Of
9,083 patients who were evaluable for safety in comparator-controlled
trials, 5200 were treated with levoﬂoxacin. The safety experience with
levoﬂoxacin includes four dose regimens in oral and IV form and
numerous disease states.
Methods: Adverse events (AEs) that were identiﬁed during clinical
studies were coded using a WHOART dictionary. The incidence of TEAE
from comparator-controlled studies is summarised by body system and/or
preferred term for the overall populations, certain special populations
(e.g., age > or< 65 years) or body systems or events of special interest
(musculoskeletal, cardiac, CNS etc).
Results: In all active-controlled studies, treatment emergent adverse
events occurred in 42.2% of levoﬂoxacin-treated subjects and in
43.5% of comparator-treated subjects. At least one drug-related AE
occurred in 6.6% of levoﬂoxacin-treated patients and in 7.6% of
patients who received control drugs. usculoskeletal system: Tendinitis
or tendon disorder was reported for 5 (0.1%) and 2 (<0.1%) of
levoﬂoxacin-treated subjects and 0 comparator-treated subjects. Central
and Peripheral Nervous System: Convulsions were reported in 0.1% of
levoﬂoxacin treated subjects and in 0.1% of comparator-treated subjects.
Cardiac Arrhythmia: Arrhythmia occurred in 0.1% of levoﬂoxacin-
treated subjects and in 0.1% of comparator-treated subjects. Elderly
Subjects: In subjects >65 years, the incidence of TEAE’s was 45.4% with
levoﬂoxacin and 45.7% in comparator-treated subjects. As compared
with 41.4% of levoﬂoxacin-treated and in 42.7% of comparator-treated
subjects <65 years of age.
Conclusion: After a decade of exposure in patients with a variety of
infections, levoﬂoxacin’s safety proﬁle is well established. In comparator-
controlled studies, the incidence of adverse events, including ones that
have been associated with ﬂuoroquinolones, is similar to those seen with
comparator agents, regardless of the levoﬂoxacin dose or dosing regimen
used.
P2014 Pooled analysis of retrospective and prospective data
on levoﬂoxacin vs. other antibiotics in the treatment of
hospitalised patients with pneumonia
H. Lode (Berlin, DE)
Objectives: The main objective of this study was to compare the efﬁcacy
of levoﬂoxacin with other antibiotic options in hospitalised patients
suffering pneumonia.
Methods: This pooled analysis includes a retrospective data set based on
records of hospitalised patients with hospital-acquired pneumonia (HAP)
or community-acquired pneumonia (CAP) and a prospective data set of
a non-interventional observational study on levoﬂoxacin in the treatment
of hospitalised CAP patients.
Results: 609 patients were included (261 CAP,112 HAP, 236 NOS
[pneumonia not otherwise speciﬁed]). Levoﬂoxacin was part of the initial
antibiotic therapy in 27.8% of the patients (LEV-group) being compared
to patients with an initial antibiotic therapy without levoﬂoxacin
(OTHER-group), who most frequently received a cephalosporin or an
extended-spectrum penicillin. The results indicate a better clinical suc-
cess in the LEV-group: In the total group (84%/66%) and in the subgroup
CAP (93%/79%) and HAP (81%/58%) higher rates of patients with
cure/improvement were found as well as lower mortality rates for LEV-
patients. Analyses stratiﬁed on type of pneumonia and risk factors before
treatment (PSI risk-classes) showed that the higher success rates of the
LEV-patients were not only the result of an unbalanced risk distribution
between treatment groups (adjusted treatment effect p = 0.0121). To
eliminate the effect of treatment changes, the clinical success rates were
evaluated additionally for patients without change of therapy: Even in
this subgroup LEV-patients had better cure/improvements rates (adjusted
treatment effect p = 0.0018) and lower mortality rates than OTHER-
patients. A shorter hospitalisation in LEV- compared to OTHER-patients
(means: CAP 14.7/17.8 d;HAP 22.7/31.6 d; total 17.9/24.8 d) may be a
hint for a pharmacooeconomic impact of an efﬁcacious initial antibiotic
treatment including a ﬂuoroquinolone-like levoﬂoxacin. Tolerability data
were documented only in the prospective data set, showing a low
incidence of adverse drug reactions in only 1 of 135 LEV-patients
(0.74%).
Conclusions: The results of this pooled analysis conﬁrm that
levoﬂoxacin compared to other therapeutic options is a successfull initial
antibiotic treatment of hospitalised patients with pneumonia.
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P2015 Evaluation of clinical dosage of gatiﬂoxacin for respiratory
tract infections in elderly patients
H. Yoneyama, Y. Niki, T. Matsushima (Kasaoka, Kurashiki, JP)
Objectives: We studied the efﬁcacy and safety of gatiﬂoxacin in
elderly patients with respiratory tract infections, in addition of the
pharmacokinetic analysis.
Methods: Thirty four patients, 65−93 years-old, with mild to moderate
acute bronchitis (10 cases), pneumonia (16 cases) and acute exacerbation
of chronic respiratory disease (8 cases) were administered 100mg once
or twice daily for 3 to 14 days. Gatiﬂoxacin was dosed as below, on
based of the body weight and age of patients.
Serum level of gatiﬂoxacin (1 to 3 samples in each patient) was
determined and the AUC and Cmax was calculated by using the Bayesian
method with population pharmacokinetic parameters.
Results: Total efﬁcacy rate was 84.8% (28/33) at day3 and 87.9% (29/33)
at the end of treatment. For each dose, it was 75% (6/8) at 100mg
once daily and 92.0% (23/25) at 100mg b.i.d. For each infection, it
was 90.0% (9/10), 86.7% (13/15) and 87.5% (7/8) for acute bronchitis,
pneumonia and acute exacerbation of chronic respiratory diseases,
respectively. Fifteen pathogens such as S. pneumoniae, B. catarrhalis
and H. inﬂuenzae were isolated from 13 patients. All strains except
for MRSA and E. faecalis were eradicated after administration of
gatiﬂoxacin. Side effect and clinical abnormality was not observed.
The pharmacokinetic parameters were as follows: The AUCs of patients
dosed 100mg once daily and b.i.d. ranged 11.2 to 37.5 and 12.7 to
111mg*h/L, respectively. AUC/MICs for 2 S. pneumoniae isolates were
39 and 67, and for all of H. inﬂuenzae and M. catarrhalis were >250.
Cmax level of gatiﬂoxacin ranged 0.72 to 3.36mg/L, except for one
patient with Cmax of 6.35mg/L.
Body weight (kg) Age (yrs)
65−74 75−84 85
40 100mg× 1 (1) 100mg× 1 (2) 100mg× 1 (1)
41−60 100mg× 2 (6) 100mg× 2 (13) 100mg× 1 (4)
61 100mg× 2 (4) 100mg× 2 (3) 100mg× 2 (0)
( ): No. of cases.
Conclusion: It was suggetsted that gatiﬂoxacin of 100mg once or twice
daily could achieve an adequate AUC and high clinical efﬁcacy and
tolerance in elderly patients with respiratory tract infections.
P2016 Comparative study of garenoxacin vs levoﬂoxacin on
bacterial pneumonia
H. Kobayashi, K. Fujimaki (Tokyo, JP)
Objectives: Garenoxacin, a des-F(6)-quinolone, has strong activity
against respiratory pathogens including multi-drugs resistant S. pneumo-
niae (MDRSP). The objective of the study was to evaluate the clinical
response of 400mg QD (400mg× 1) of garenoxacin (GRN) for 10 days
comparing to 300mg TD (100mg× 3) levoﬂoxacin (LVFX) for 10 days.
Methods: The double-blind, controlled study was conducted, and a total
253 subjects were randomised 1:1 to either study drug. Clinical efﬁcacy
was assessed upon completion of the treatment and 7 days post-treatment.
Safety was assessed up to 7 days post-treatment.
Results: The efﬁcacy rate upon completion of treatment was 99.1%
(111/112) for GRN and 94.3% (82/87) for LVFX (95%CI, −0.3 to 10),
indicating non-inferiority of garenoxacin. The efﬁcacy rate at 7 days
post-treatment was 94.9% (94/99) for GRN and 92.8% (77/83) for LVFX.
The bacterial eradication rate was 100% (53/53) for GRN and 87.8%
(36/41) for LVFX. Garenoxacin was particularly effective against S.
pneumoinae including MDRSP where the eradication rate was 100%
(22/22) for GRN versus 80.0% (16/20) for LVFX. After treatment with
LVFX, 4 strains of S. pneumoniae (2 PRSP, 1 PISP and 1 PSSP) recurred.
The incidence of drug-related adverse events (AEs), including laboratory
abnormalities, was 35.6% (48/135) for GRN and 27.1% (32/118) for
LVFX. The main AEs were diarrhoea (3.0% vs. 3.4%), headache (1.5%
vs. 2.5%), ALT increase (15.9% vs. 14.8%) and AST increase (13.6%
vs. 11.3%). The incidence of AEs was similar in the both study arms.
Conclusions: A 10-day course of oral GRN 400mg QD showed a
high efﬁcacy rate and high eradication rate in the treatment of bacterial
pneumonia.
P2017 Study of oral Garenoxacin in Japanese patients with
secondary infection of chronic respiratory diseases and
penetration into sputum
H. Kobayashi, A. Watanabe, K. Fujimaki (Tokyo, Sendai, JP)
Objectives: Garenoxacin (GRN), a des-F(6)-quinolone, has strong
activity against respiratory tract infection pathogens including multi-
drug resistant S. pneumoniae (MDRSP). The objective of this study was
to evaluate the clinical response of GRN against secondary infection
of chronic respiratory disease namely acute exacerbation of chronic
bronchitis (AECB). Penetration into sputum was also examined.
Methods: An open-label study was conducted to evaluate clinical
response and microbiological response to treatment with oral GRN
400mg QD for 10 days in adults with secondary infection of chronic
respiratory disease in Japan. The study followed another GRN AECB
study conducted in the US and Europe. The clinical efﬁcacy of GRN was
assessed upon completion of treatment and 7 days post-treatment. Safety
was assessed up to 7 days post-treatment. The drug concentration of
GRN in sputum after administration of GRN 400mg was also measured.
Results: 136 subjects were enrolled in this study. The efﬁcacy rate
of GRN 7 days post-treatment in subjects with secondary infection
of chronic bronchitis was 91.3%. A similar efﬁcacy rate (94.3%) was
observed in the AECB study conducted in the US and Europe. The
bacterial eradication rate of GRN against Gram-positive pathogens was
90.9%. Bacterial eradication rates against PRSP, PISP and BLNAR were
100%. Drug related adverse events (AEs) were observed in 14.0% of the
subjects; no serious AEs were found among them. The main AEs were
gastrointestinal disorders, and all events were mild to moderate. The main
laboratory abnormalities were ALT increase and AST increase. Similar
AEs were observed in the US/European study. The drug concentration
of GRN in sputum 3 hours after administration of GRN 400mg was
3.50 ± 1.17 micro g/g (ﬂuid to plasma ratio: 0.536 ± 0.273). This
was regarded as efﬁcient penetration well over the susceptibility level of
major pathogens causing respiratory tract infection.
Conclusions: A 10-day course of oral GRN 400mg QD showed good
efﬁcacy in the treatment of secondary infection of chronic respiratory
disease. Good penetration into sputum was also conﬁrmed.
P2018 Study of oral garenoxacin against respiratory tract
infection and otrhinolaryngological infection caused by
multidrug-resistant S. pneumoniae
S. Kohno, H. Kobayashi, S. Baba, K. Fujimaki (Nagasaki, Tokyo,
Nagoya, JP)
Objectives: Respiratory tract infections caused by multi-drug resistant
S. pneumoniae (MDRSP) are increasing in frequency worldwide. The
objective of this analysis was to evaluate the clinical response of
garenoxacin (GRN) treatment against S. pneumoniae infection (including
MDRSP) to examine GRN susceptibility against S. pneumoniae isolates,
and to analyse the correlation between resistance and gene mutation in
isolates of S. pneumoniae.
Methods: Eight studies conducted in Japan assessed the clinical and
biological efﬁcacy of GRN in subjects with respiratory tract and
otorhinolaryngological infection caused by S. pneumoniae. Treatment
consisted of oral GRN 400mg QD for 7 to 10 days. The minimum
inhibitory concentration (MIC) of GRN against 106 isolates of
S. pneumoniae (27 PRSP, 28 PISP and 51 PSSP, including 3
quinolone-resistant, 47 cephalosporin-resistant, 84 macrolide-resistant,
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85 tetracycline-resistant, 10 trimethoprim-resistant and 83 multi-
drug resistant) was measured using the CLSI method. GRN was
compared with levoﬂoxacin (LVFX), gatiﬂoxacin (GFLX), moxiﬂoxacin
(MFLX), cefroxime (CXM), erythromycin (EM), azithromycin (AZM),
telithromycin (TEL), tetracycline (TC) and trimethoprim/sulfametozalole
(TMP/SMX). In addition, the mutation of the penicillin-binding protein
genes and macrolide-resistant genes of S. pneumoniae isolates was
investigated using electrophoresis analysis.
Results: The clinical efﬁcacy rate of GRN against S. pneumoniae in 106
subjects was 96.2%; the bacterial eradication rate was 100%. MIC90
values of the 106 isolates were GRN 0.125, LVFX 2, GFLX 0.5,
MFLX 0.25, CXM 8, EM >128, AZM >128, TEL 0.25, TC 64
and TMP/SMX 2mg/mL. In the PRSP/PISP, pbp1a + pbp2x + pbp2b
mutations for PBP and ermB presence for the macrolide-resistant gene
were observed most frequently. There appeared to be a correlation
between drug-resistance and gene mutation.
Conclusions: GRN showed high efﬁcacy and eradication rates in
the treatment of respiratory tract infection caused by S. pneumoniae
including MDRSP.
P2019 Study of oral garenoxacin in Japanese patients with
otorhinolaryngological infections and penetration into
otorhinolaryngological tissues
S. Baba, K. Fujimaki (Nagoya, Tokyo, JP)
Objectives: Garenoxacin (GRN), a des-F(6)-quinolone, has strong ac-
tivity against otorhinolaryngological infection pathogens. The objective
of this study was to evaluate the clinical response of garenoxacin (GRN)
in the treatment of otorhinolaryngological infections. Additionally,
penetration into otorhinolaryngological tissues was examined.
Methods: Clinical response was evaluated in 2 studies: GRN 400mg QD
10-day treatment against sinusitis, laryngo-laryngitis and tosillitis, and
GRN 400mg QD 7-day treatment against otitis media. Clinical efﬁcacy
was assessed upon completion of the treatment and safety was assessed
up to 7 days post-treatment after the last dose. Additionally, after the
administration of GRN 400mg, drug concentration in sinus mucosa,
middle ear mucosa, tonsil tissue and plasma was measured in subjects
who required surgery.
Results: In the study involving sinusitis, laryngo-laryngitis and tosillitis,
71 subjects were enrolled. Efﬁcacy rates were 92.0% in sinusitis, 85.0%
in laryngo-laryngitis and 95.2% in tosillitis. In the study for otitis media,
50 subjects including chronic otitis media were enrolled. The efﬁcacy
rate was 87.2%. Bacterial eradication rates were 100% in the sinusitis,
laryngo-laryngitis and tosillitis study, and 93.3% in the otitis media study.
All PRSP, PISP and BLNAR pathogens were eradicated in both studies.
Drug-related adverse events (AEs) were observed 19.7% of the time
in the sinusitis, laryngo-laryngitis and tosillitis study, and 14.0% in the
otitis media study. The main AEs were gastrointestinal disorders, and all
events were mild to moderate. The drug concentration (tissue to plasma
ratio) after administration of GRN 400mg was 6.01 micro g/mL (1.03)
in sinus mucosa, 5.89 micro g/mL (1.04) in middle ear mucosa and 9.44
micro g/mL (1.61) in tonsil tissue. This result was regarded as efﬁcient
penetration well over the susceptibility level against major pathogens
causing otorhinolaryngological infection.
Conclusions: A 7 to 10-day course of oral GRN 400mg QD showed
good efﬁcacy in the treatment of otorhinolaryngological infections. Good
penetration into otorhinolaryngological tissues was conﬁrmed.
P2020 Assessment of electrocardiograms and garenoxacin plasma
concentrations from subjects with acute bacterial infections
G. Krishna, H. Waskin (New Jersey, US)
Background: Treatment with certain ﬂuoroquinolones may increase
the risk of QT interval (QT) prolongation. Garenoxacin is a novel
des-F(6)-quinolone with broad antimicrobial activity against clinically
important pathogens including multidrug-resistant S. pneumoniae. The
relationship between maximal plasma garenoxacin concentration (Cmax)
and QT measurements has been studied in Phase I studies in healthy
(predominantly young male) subjects but not in subjects treated with IV
garenoxacin for an acute bacterial infection. This analysis assessed for
possible correlation between peak plasma garenoxacin values and QT
abnormalities in subject populations that included women, elderly, and
those with underlying electrolyte disturbances.
Methods: Following informed consent, electrocardiographs (ECG)
and plasma samples were collected from subjects enrolled in 5
randomised, comparative, multicentre, double-blind, Phase 3 studies of
IV garenoxacin (400mg or 600mg once daily). Serial ECG data and
blood samples were collected before the ﬁrst dose of study medication
on day 1 (baseline), within 3 h after the end of the ﬁrst infusion, and once
on study day 3, 4, or 5. For this analysis, only data from the garenoxacin
cohorts (unblinded after data lock) are presented. Blood samples (5
mL) were collected immediately following ECG measurements. For this
retrospective analysis, the potential association between changes in ECG
parameters from baseline to post-dose, measured as maximal QTcF
interval at anticipated Cmax, and plasma garenoxacin concentration was
examined using linear regression analysis.
Results: Collectively, 800 subjects (52%/48% M/F, 24% 65 yr old)
received garenoxacin treatment. No association was apparent between
maximum QTcF and garenoxacin plasma concentrations ranging from
0 to >20mg/mL. These results were consistent with data from a previous
analysis of QTc versus garenoxacin concentration in Phase I studies.
There were no trends in interval abnormalities or change from baseline
of 60ms in the various garenoxacin concentration strata, including
the highest concentration stratum (>20mg/mL). Similarly, no statistically
signiﬁcant temporal change in QTc from baseline was observed after the
ﬁrst dose of garenoxacin or after 3 to 5 days of treatment.
Conclusion: Garenoxacin does not demonstrate clinically signiﬁcant
concentration- or time-dependent effects on QT intervals in subjects
receiving IV treatment for acute bacterial infections.
P2021 Clinical and bacteriological efﬁcacy of sequential
intravenous to oral moxiﬂoxacin in hospitalised patients
with community-acquired pneumonia and pneumococcal
bacteraemia
S. Choudhri, P. Arvis, D. Haverstock (West Haven, US; Puteaux, FR)
Objectives: Streptococcus pneumoniae is the leading bacterial pathogen
in patients with community-acquired pneumonia (CAP) and the presence
of pneumococcal bacteraemia in this setting is associated with signiﬁcant
morbidity and mortality. Pooled data from 6 CAP trials were used
to compare the clinical and microbiological efﬁcacy of sequential
intravenous (IV)/oral (PO) moxiﬂoxacin (MXF) with comparator
(COMP) therapy in patients with pneumococcal bacteraemia.
Methods: Data were pooled from all 6 of the sequential trials
carried out on 400mg (IV/PO) MXF in the treatment of CAP in
hospitalised patients. COMP treatment consisted of ceftriaxone +
erythromycin, amoxicillin/clavulanate ± clarithromycin, trovaﬂoxacin,
levoﬂoxacin, ceftriaxone ± azithromycin ± metronidazole or ceftriaxone
+ levoﬂoxacin. All patients had blood cultures performed prior to
initiation of study drug therapy. Severe CAP was deﬁned using the
modiﬁed ATS criteria.
Clinical and bacteriological success rates of MXF and COMP therapy
in patients with pneumococcal bacteraemia
MXF n/N (%) COMP n/N (%)
Overall clinical success 40/48 (83.3%) 49/64 (76.6%)
Clinical success in patients with
severe CAP
13/19 (68.4%) 18/31 (58.1%)
Overall bacteriological success 42/48 (87.5%) 50/64 (78.1%)
Results: The 6 trials randomised 3015 patients (1494 MXF, 1521
COMP) of which 2288 were valid per protocol (PP) (1141 MXF,
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1147 COMP). Of the valid PP patients, 342 MXF and 361 COMP-
treated subjects were also microbiologically valid. Of these 178 (52.0%)
MXF and 192 (53.2%) COMP-treated subjects had CAP due to
S. pneumoniae with 48 (14.0%) MXF and 64 (17.7%) COMP patients
having pneumococcal bacteraemia. Clinical and bacteriological success
rates of MXF and COMP therapy in patients with pneumococcal
bacteraemia.
Conclusions: Sequential therapy with IV/PO MXF resulted in higher
clinical and bacteriological success rates than comparator therapy
in patients with CAP associated with pneumocococcal bacteraemia,
including patients with severe CAP.
Research funding: Bayer HealthCare Pharmaceuticals.
P2022 Clinical and bacteriological efﬁcacy of sequential
intravenous to oral moxiﬂoxacin in hospitalised patients with
community-acquired pneumonia due to Enterobacteriaceae
S. Choudhri, P. Arvis, D. Haverstock (Wuppertal, DE; Puteaux, FR;
West Haven, US)
Objectives: Although S. pneumoniae is the most common bacterial
cause of community-acquired pneumonia (CAP), Enterobacteriaceae
are an important cause of CAP in patients with underlying comorbid
illnesses such as chronic obstructive pulmonary disease. We used pooled
data from 6 CAP trials to compare the clinical and microbiological
efﬁcacy of sequential intravenous (IV)/oral (PO) moxiﬂoxacin (MXF)
with comparator (COMP) therapy in patients with CAP due to
Enterobacteriaceae.
Methods: Data were pooled from 6 sequential (IV/PO) trials of 400mg
IV/PO MXF in the treatment of mild, moderate and severe CAP
in hospitalised patients. COMP treatment consisted of ceftriaxone +
erythromycin, amoxicillin/clavulanate ± clarithromycin, trovaﬂoxacin,
levoﬂoxacin, ceftriaxone ± azithromycin ± metronidazole or ceftriaxone
+ levoﬂoxacin.
Results: The 6 trials randomised 3015 patients (1494 MXF, 1521
COMP) of which 2288 were valid per protocol (PP) (1141 MXF,
1147 COMP). Of the valid PP patients, 342 (30.0%) MXF and
361 (31.5%) COMP-treated subjects were also microbiologically valid.
Of these 27 (7.9%) MXF and 15 (4.2%) COMP-treated subjects
had Enterobacteriaceae isolated from sputum or blood cultures. The
following individual organisms were isolated (MXF, COMP): E. coli
(3, 6), Klebsiella spp. (19, 8), Proteus mirabilis (1, 0), Proteus vulgaris
(1, 0), Serratia marcescens (0, 1) and Enterobacter cloacae (3, 0). The
overall clinical and bacteriological success rates in these patients were
22/27 (81.5%) and 21/27 (77.8%) for MXF and 10/15 (67.0%) and 10/15
(67.0%) for COMP-treated patients.
Conclusions: Sequential therapy with IV/PO moxiﬂoxacin was highly
effective in the treatment of CAP due to Enterobacteriaceae.
Research funding: Bayer Health Care Pharmaceuticals.
P2023 Clinical and bacteriological efﬁcacy of sequential
intravenous to oral moxiﬂoxacin in hospitalised patients
with severe complicated skin and skin structure infections
due to Enterobacteriaceae
J.R. Bogner, S.H. Choudhri, P. Arvis, P. Pertel, J-M. Breilmann
(Munich, DE; West Haven, US; Puteaux, FR; Wuppertal, DE)
Objectives: Enterobacteriaceae species are an important cause of cSSSI
in patients with underlying comorbid illnesses such as diabetes mellitus,
and require empiric therapy with broad spectrum antimicrobials.
Pooled data from 2 cSSSI trials were used to compare the clinical
and microbiological efﬁcacy of sequential intravenous (IV)/oral (PO)
moxiﬂoxacin (MXF) with comparator (COMP) therapy in patients with
cSSSI due to Enterobacteriaceae.
Methods: Data were pooled from 2 trials of sequential MXF (400mg
q.d. IV/PO) in the treatment of cSSSI in hospitalised patients. COMP
treatment consisted of IV piperacillin/tazobactam followed by PO
amoxicillin/clavulanate and sequential IV/PO amoxicillin/clavulanate.
Results: The 2 trials enrolled 1421 patients (712 MXF, 709 COMP) of
which 999 were valid per protocol (495 MXF, 504 COMP). Of these
patients, 286 (57.8%) MXF and 291 (57.7%) COMP-treated subjects
were also microbiologically valid. Of these, 87 (30.4%) MXF and 77
(26.5%) COMP-treated subjects had Enterobacteriaceae isolated from
their skin infection sites. The following organisms were isolated (MXF,
COMP): E. coli (38, 33), Klebsiella spp. (14, 10), Proteus spp. (14, 16),
Morganella spp. (1, 3), Providencia spp. (2, 2), Serratia marcescens (4,
2) and Enterobacter (14, 11). The overall clinical and bacteriological
success rates at test-of-cure among per protocol valid patients who had
a positive skin culture for Enterobacteriaceae were 65/87 (74.7%) and
64/87 (73.6%) for MXF and 56/77 (72.7%) and 56/77 (72.7%) for
COMP-treated patients.
Conclusions: Enterobacteriaceae were cultured frequently from hospi-
talised patients with cSSSI. Monotherapy therapy with IV/PO MXF had
similar clinical and bacteriological efﬁcacy as the standard treatment
regimens in the management of cSSSI due to Enterobacteriaceae.
Research funding: Bayer HealthCare Pharmaceuticals.
In vitro susceptibility: cephalosporins
P2024 Proﬁle of ceftobiprole activity against S. aureus,
S. pneumoniae, Enterobacteriaceae, and P. aeruginosa:
results of the 2005–2006 Surveillance Program
M.K. Aranza, D.C. Draghi, M.E. Jones, C. Thornsberry, D.F. Sahm
(Herndon, US; Breda, NL)
Background: BPR is an investigational broad spectrum cephalosporin
with activity against both Gram-positive organisms (including MRSA)
and Gram-negative (including PA). BPR is under clinical development
for hospital-acquired pneumonia and complicated skin and skin structure
infections. Surveillance of BPR activity against current Gram-positive
organisms, especially those resistant to b-lactams, and Gram-negative
organisms is an important component of the development programme
and was done to establish a database for longitudinal tracking of BPR
activity throughout the development programme and beyond.
Methods: During 2005 – 2006, S. aureus (SA; including both methi-
cillin-susceptible SA [MSSA] and methicillin-resistant SA [MRSA]),
S. pneumoniae (penicillin-susceptible [PEN-S] and penicillin non-
susceptible [PEN-NS]), Citrobacter spp. (CP), E. cloacae (EA), E. coli
(EC), K. pneumoniae (KP), P. mirabilis (PM), S. marcescens (SM), and
P. aeruginosa (PA) were collected from 31 institutions in 12 European
countries and were centrally tested by broth microdilution (CLSI; M7-
A6).
Results: See the table.
Organism Total n BPR (mg/L)
MIC Range MIC Mode MIC50 MIC90
SA all 1203 0.12–>16 1 0.5 2
MSSA 404 0.12−8 0.25 0.25 0.5
MRSA 799 0.25–>16 1 1 2
SP all 526 0.002−1 0.015 0.015 0.25
SP PEN-S 406 0.002–0.06 0.015 0.008 0.015
SP PEN-NS 120 0.008−1 0.5 0.25 0.5
CP 387 0.015–>32 0.06 0.06 2
EA 406 0.03–>32 0.06 0.12 >32
EC 1213 0.015–>32 0.03 0.03 0.25
KID 854 0.015–>32 0.03 0.06 >32
PM 443 0.015–>32 0.03 0.03 0.12
SM 291 0.03–>32 0.06 0.12 2
PA 621 0.03–>32 2 4 16
Conclusions: BPR exhibited potent activity against Gram-positive
organisms, including MRSA, and had activity very similar to currently
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available cephalosporins against Gram-negative organisms. Because
all of these target pathogens can develop resistance to variety of
antimicrobial agents, this baseline surveillance data will be important
for continued tracking of BPR activity throughout clinical development
and beyond.
P2025 Activity of ceftobiprole against US clinical S. pneumoniae
isolates that are ceftriaxone non-susceptible
T. Davies, K. Bush, P. Appelbaum (Raritan, Hershey, US)
Objectives: Ceftobiprole (BPR) is an investigational cephalosporin with
broad-spectrum activity against many Gram-negative rods and Gram-
positive cocci, including methicillin-resistant Staphylococcus aureus
and drug-resistant Streptococcus pneumoniae. In this study the anti-
pneumococcal activity of BPR was further evaluated by testing recent
clinical isolates that were non-susceptible to ceftriaxone.
Methods: BPR, ceftriaxone (CRO), cefotaxime (CTX), cefuroxime
(CXM), and penicillin (PEN) MICs from 95 CRO-non-susceptible (CLSI
non-meningitis breakpoints) S. pneumoniae isolates (94 clinical, 1 lab
mutant) were determined using CLSI methodology. PCR and DNA
sequencing of the penicillin-binding protein genes pbp1a, pbp2b, and
pbp2x were carried out on all isolates with BPR MICs of 2−4mg/L and
some with BPR MICs< 2mg/L.
Results: BPR had MIC90s 2- to 8-fold lower than the other agents against
CRO-intermediate isolates and 8- to 32-fold lower against CRO-resistant
isolates. The highest BPR MIC was 4mg/L (in two strains) compared to
16 to >64mg/L for the other agents. Isolates with BPR MICs of 2mg/L
had similar mutations in the penicillin binding motifs of pbp1a, pbp2b,
and pbp2x as isolates with BPR MICs of 1mg/L. One isolate with a
BPR MIC of 4mg/L had a T338 to G change in the 337STMK motif
of PBP2x while isolates with BPR MICs of 1 to 2mg/L had a T338
to A and M339 to F change. A CRO-resistant lab mutant (CRO MIC
4mg/L) had no changes in pbp1a, pbp2b, and pbp2x compared to the
parent strain (CRO MIC 0.5mg/L).
Drug MIC (gm/L)
CRO-Intermediate (n = 62) CRO-Resistant (n = 33)
MIC50 MIC90 Range MIC50 MIC90 Range
BPR 0.5 1 0.12−1 1 2 0.5−4
CTX 2 2 1−4 8 16 2−32
CXM 8 8 2−16 32 64 4–>64
CRO 2 2 2 4 16 4−16
PEN 4 4 2−16 8 16 4−32
Conclusion: BPR exhibited excellent activity against most CRO-non-
susceptible isolates with an MIC90 of 1mg/L that was 8- to 32-fold lower
than CRO, CTX, CXM, and PEN. Strains with elevated BPR MICs (2
to 4mg/L) contained multiple mutations in pbp1a, pbp2b, and pbp2x.
P2026 Activity of ceftobiprole against Pseudomonas aeruginosa
clinical isolates from Europe collected in 2005–2006
T. Davies, D. Sahm, R. Flamm, K. Bush (Raritan, Herndon, US)
Objectives: Ceftobiprole, an investigational parenteral cephalosporin
exhibiting a broad spectrum of activity against many Gram-positive (in-
cluding methicillin-resistant Staphylococcus aureus) and Gram-negative
organisms, is currently under clinical development for pneumonia and
complicated skin and skin structure infections. P. aeruginosa is one of the
most common Gram-negative pathogens causing these infections. The
activity of ceftobiprole and comparators was tested against P. aeruginosa
isolates from Europe.
Methods: A total of 621 P. aeruginosa isolates were collected from
31 cites in 13 European countries during 2005–2006. Ceftobiprole,
ceftazidime, cefepime, imipenem, piperacillin-tazobactam, gentamicin,
levoﬂoxacin, and tigecycline MICs were determined by broth microdi-
lution according to CLSI methods.
Results: The ceftobiprole MIC50 (4mg/L) was similar to the other
cephalosporins, imipenem, and gentamicin; and was four-fold lower
than piperacillin-tazobactam and tigecycline. Levoﬂoxacin had the lowest
MIC50 (1mg/L), while ceftobiprole and cefepime MIC90s (16mg/L)
were the lowest of all the drugs tested.
Drug MIC (mg/L)
MIC50 MIC90 Range
Ceftobiprole 4 16 0.03–>32
Cefepime 4 16 0.015–>32
Ceftazidime 2 >32 0.06–>32
Piperacillin–tazobactam 16 >128 0.5–>128
Imipenem 4 32 0.25−32
Gentamicin 4 >16 0.12–>16
Levoﬂoxacin 1 >8 0.008–>8
Tigecycline 16 >16 0.015–>16
Conclusion: Ceftobiprole, in addition to its activity against methicillin-
resistant staphylococci (MRS), had anti-pseudomonal activity in vitro,
similar to other advanced generation cephalosporins and imipenem.
Compared to piperacillin-tazobactam, or tigecycline (another anti-MRS
agent with activity against Gram-negative pathogens), ceftobiprole had
greater in vitro potency against P. aeruginosa as determined by the lower
MIC50 and MIC90 values.
P2027 Ceftobiprole activity and resistance patterns in
staphylococcal isolates from a recent complicated skin and
skin structure infection study
K. Amsler, M. Jacobs, S. Bajaksouzian, A. Windau, M. Heep, K. Bush
(Raritan, Cleveland, US; Basle, CH)
Objectives: Ceftobiprole (BPR) is a broad-spectrum investigational
cephalosporin with demonstrated activity against methicillin-susceptible
and methicillin-resistant staphylococci, as well as against most
Enterobacteriaceae. In this study, the geographic variation of BPR
activity and antimicrobial agent resistance patterns are reported from
the staphylococcal baseline pathogens from a recent Phase 3 clinical
trial to treat complicated skin and skin structure infections.
Methods: The baseline pathogens from 784 patients enrolled in a
multicentre clinical trial involving complicated skin infections were
examined for their susceptibility to BPR and selected antimicrobial
agents. MICs were determined using CLSI methodology.
Results: Of the 461 baseline Staphylococcus aureus isolates available for
testing, 178 isolates were from the USA and 283 isolates were from 16
non-USA countries, including 10 European countries. All staphylococcal
isolates had BPR MICs 4mg/L. Resistance patterns varied between the
USA and non-USA isolates. A higher percentage of staphylococcal USA
isolates were resistant to oxacillin (OXA), ceftazidime (CAZ), penicillin
(PEN), erythromycin (ERY), and levoﬂoxacin (LVX). The most common
resistance patterns observed in the S. aureus USA isolates are shown in
the table, including at least three different drug classes.
Resistance proﬁle Source of
S. aureus isolates
% Isolates (n)
OXA, CAZ, PEN, ERY USA 36.5 (65/178)
Non-USA 1.1 (3/283)
OXA, CAZ, PEN, ERY, LVX USA 20.8 (37/178)
Non-USA 2.1 (6/283)
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Conclusion: Against staphylococcal isolates with methicillin resistance
and multiple resistance phenotypes, ceftobiprole MICs were 4mg/L.
Multidrug-resistant strains were found more frequently in USA isolates
compared to other countries.
P2028 Activity of cefditoren versus seven other antimicrobials
against amoxicillin non-susceptible Streptococcus
pneumoniae
E. Perez-Trallero, J. Marimon, M. Erzibengoa, M. Gimenez, P. Coronel,
L. Aguilar (San Sebastian, Madrid, ES)
Objective: Amoxicillin has the highest intrinsic activity against
S. pneumoniae but amoxicillin non-susceptibility is not rarely found
among penicillin-resistant isolates. Antibiotic susceptibility testing
against these isolates can be considered the workhorse to test new and
old compounds.
Methods: Susceptibility to penicillin (PEN), amoxicillin/clavulanic acid
(2:1) (AMC), cefuroxime (CXM), cefpodoxime (CPD), cefotaxime
(CTX), cefditoren (CDN), erythromycin (ERY), and levoﬂoxacin
(LVX) was determined by microdilution with Mueller-Hinton broth
supplemented with 3% lysed horse blood according to CLSI guidelines,
against 244 isolates exhibiting non-susceptibility to amoxicillin (MIC
4mg/mL) and higher amoxicillin vs. penicillin MIC. CLSI susceptibility
breakpoints (mg/mL) were considered.
Results: MIC distribution of the antimicrobials tested: no. of isolates
inhibited (cumulative percentage) at concentration (mg/mL) are shown
in the Table.
MICa (mg/mL)
0.25 0.5 1 2 4 8 16 %S
PEN 51 (20.9) 162 (87.3) 31 (100) 0
AMC 124 (50.8) 117 (98.8) 3 (100) 0
CXM 64 (26.2) 138 (82.8) 42 (100) 0
CPD 1 (0.4) 29 (12.3) 141 (70.1) 40 (86.5) 29 (98.4) 4 (100) 0
CTX 36 (14.8) 146 (74.6) 52 (95.9) 9 (99.6) 1 (100) 74.6
CDN 58 (23.8) 126 (75.4) 51 (96.3) 7 (99.2) 2(100) –
ERY 67 (27.5) 1 (27.9) 3 (29.1) 173 (100) 27.5
LVX 7 (2.9) 99 (43.4) 102 (85.2) 5 (87.3) 1 (87.7) 19 (95.5) 11 (100) 87.3
aMIC90 and MIC50 values are in bold.
Conclusions: On a MIC90 basis, CDN (1mg/mL) exhibited the highest
intrinsic activity followed by CTX (2mg/mL), AMC, CPD and LVX
(8mg/mL), with a clear inadequacy of CXM and ERY (16mg/mL).
CDN activity (twice that of CTX) may be useful against amoxicillin non-
susceptible strains where only CTX and LVX offer signiﬁcant activity
(70−90% susceptibility rates).
P2029 In vitro efﬁcacy of cefditoren against recent isolates of
Streptococcus pneumoniae in Greece
G. Poulakou, I. Katsarolis, L. Lianou, N. Labri, D. Hatzaki,
H. Giamarellou (Haidari, GR)
Purpose: To evaluate the in vitro efﬁcacy of cefditoren, an oral 3rd
generation cephalosporin in licensure phase in Greece, against recently
isolated Streptococcus pneumoniae strains.
Methods: A total of 261 S pneumoniae strains isolated during 2004–
2006 from clinical specimens of adults and children as well as from
nasopharyngeal swabs of preschool healthy children were tested against
penicillin (PEN) and erythromycin (ERY) by E-test, according to CLSI
2005 methodology and breakpoints for non-susceptibility (NS) and
resistance (R). Susceptibility to cefditoren (CFD) was tested by agar
dilution. Strains with MIC> 2mg/L were considered resistant, according
to recent literature.
Results: Against the total tested population of pneumococci, CFD
MIC50/90 were 0.03/1mg/L (range 0.008−4mg/L). Only 1/262 tested
strains (0.4%) exhibited R to CFD (MIC= 4mg/L). For PEN R
strains (N = 47) CFD MIC50/90 were 0.5/1mg/L (range: 0.008−4mg/L).
Among 124 PEN NS strains CFD MIC50/90 were 0.5/1mg/L (range
0.008−4mg/L), while respective values for 137 PEN S strains were
0.015/0.034mg/L (range 0.008−0.5mg/L) (p< 0.001, t-test). Among 142
ERY R isolates CFD MIC50/90 were 0.06/1mg/L (range 0.008−4mg/L),
whereas among 119 ERY S respective values were 0.015/0.5mg/L (range
0.008−2mg/L) (p< 0.001, t-test). CFD MICs for paediatric isolates did
not differ statistically compared to adult isolates, and the same was also
observed for invasive and non-invasive isolates.
Conclusions: CFD exerted an excellent in vitro antibacterial activity
against recently isolated strains of S. pneumoniae in Greece, retaining
low MICs against all strains displaying resistance to PEN and ERY,
although statistically signiﬁcant differences in MIC distribution were
observed between PEN NS and S, as well as ERY R and ERY S isolates.
Cefditoren could prove a valuable alternative to existing drugs for
community acquired pneumococcal infections treated in the outpatient
setting.
In vitro susceptibility: tigecycline
P2030 A prospective study of tigecycline susceptibility of bacteria
isolated from complicated intra-abdominal as well as skin
and soft tissue infections in a large UK hospital
L. Oliver, E. Watson, J. Hovenden, I. Budai, C. Marodi (Middlesbrough,
UK; Budapest, HU)
Objectives: Tigecycline (TIG) is a glycylcycline antibiotic with
expanded activity licensed in the UK for the treatment of complicated
intraabdominal (cIAI) and skin/soft tissue infections (cSSTI) in 2006.
No data have been available about its activity against regional isolates.
TIG had not been used in our hospital prior to this study. We aimed to
collect information about the TIG sensitivity of isolates from cIAI/cSSTI
in our hospital.
Methods: Isolates from cIAI (infections that spread beyond the
hollow viscus of origin into the peritoneal space associated with
abscess formation/peritonitis) and cSSTI (infections involving deeper
soft tissue/requiring surgical intervention) from both in- and outpatients,
processed in line with the UK laboratory and local guidelines, were
collected over 1 month. In polymicrobic infections, each isolate was
tested. No duplicate isolates were included. Pseudomonads and anaerobic
bacteria were not included in this study.
TIG sensitivity was tested using the standard E-test method on
Isosensitest or Columbia blood agar (BSAC). MICs were read after an
incubation of approximately 20 hours at 35−37ºC on air or at 5% CO2
atmosphere (BSAC).
Results: Altogether 97 isolates were tested (21 from cIAI’s, 76 from
cSSTI’s). See Table for results. Two ESBL-producing E. coli were
isolated with TIG MICs of 0.19 and 0.38mg/L respectively. We
found two AmpC positive Enterobacteriaceae, an E. cloaceae and an
S. marcescens, with MICs of 3.0 and 4.0, respectively.
Table 1. Tigecycline sensitivity of clinical isolates recovered from intra-abdominal and skin/soft tissue
Isolates n Breakpoints (mg/L) MIC (mg/L) Sensitive
S R< Range MIC50 MIC90 No. (%)
Streptococcus beta haemolytic 10 0.25 0.5 0.047–0.190 0.064 0.094 10 100
Enterococcus faecalis 1 0.25 0.5 0.125 NA NA 1 NA
MSSA 37 0.5 0.5 0.047–0.47 0.125 0.19 37 100
MRSA 11 0.5 0.5 0.125–0.250 0.19 0.25 11 100
Total Staphylococcus aureus 48 0.5 0.5 0.047–0.47 0.125 0.19 48 100
Escherichia coli 13 1 2 0.125−1.5 0.25 0.5 12 92.3
Enterobacter spp. 5 1 2 0.5−3 0.75 0.75 4 80
Klebsiella spp. 7 1 2 0.380−3.0 0.75 0.75 6 85.7
Proteus mirabilis 2 1 2 1.5−3.0 NA NA 0 NA
Serratia marcescens 4 1 2 2.0−4.0 NA NA 0 NA
Citrobacter koseri 3 1 2 0.380–0.50 NA NA 3 NA
Total Enterobacteriaceae 34 1 2 0.125−4.0 0.5 3 25 73.5
Sphingomonas paucimobiIis 1 0.25 0.5 0.32 NA NA 1 NA
Acinetobacter baumannii 3 NA NA 0.19−0.5 NA NA NA NA
Total isolates 97 NA NA 0.032−4.0 0.19 2 NA NA
S, sensitive; R, resistant; n, number; NA, not applicable.
Conclusions: Our Gram-positive isolates were universally sensitive to
TIG with generally low MIC50 and MIC90, although MRSA strains had
slightly higher MICs than the MSSAs. Among Gram-negative isolates
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sensitivity was not universal; with only 73.5% of Enterobacteriaceae
being susceptible. Despite the short study period, it was shown that
Gram-negatives are frequently isolated in both cIAIs and cSSTIs.
We can conclude that despite its excellent activity against regional Gram-
positive isolates TIG cannot be used universally in cIAI and cSSTI
because of the signiﬁcant number of Gram negatives tested as resistant.
The excellent activity against MRSA makes TIG a good candidate for
outpatient intravenous antibiotic treatment for MRSA infected chronic
ulcers and pressure sores. At present the use of TIG is restricted in
our hospital and can only be prescribed on the advice of a Consultant
Microbiologist or Infectious Disease Physician.
P2031 In vitro activity of tigecycline against multidrug-resistant
Acinetobacter baumannii and enhanced susceptibility to
amikacin selected by exposure to tigecycline
E. Smith Moland, L. Hachmeister, S. Sayed, D. Craft, S. Hong, S. Kim,
K. Thomson (Omaha, Washington DC, US)
Objectives: A study was designed to investigate the in vitro activity
of tigecycline (TGC) and comparison agents against 170 isolates of
multidrug-resistant Acinetobacter baumannii (MRAB). Three isolates
were investigated for drug interactions between TGC and either
polymyxin B (PB) or amikacin (AN) by time-kill methodology.
Methods: Susceptibility was determined in fresh Mueller-Hinton broth
by CLSI microdilution methodology using TREK custom panels contain-
ing doubling dilutions of TGC, minocycline (MIN), imipenem (IPM),
ampicillin/sulbactam (SAM), PB, ceftazidime (CAZ), levoﬂoxacin
(LEV), AN, piperacillin/tazobactam (TZP), and gentamicin (GM).
Some isolates produced IMP-1, VIM-1, and OXA-23 b-lactamases.
The bactericidal activities of TGC, AN, and PB, both alone and in
combinations of TGC with either AN or PB, were evaluated by time-kill
methodology. Three isolates with varying levels of susceptibility to TGC
were investigated using broth cultures inoculated with >5×105 CFU/mL
of each isolate in log phase growth. The concentrations investigated were
chosen to avoid signiﬁcant killing by any drug on its own.
Results: Based on MIC90 values the most potent agent (MIC90 in mg/L)
was PB (2), followed by MIN and TGC (8), IPM and LEV (16). In time-
kill studies, both combinations exhibited enhanced activity against the
isolate that was most susceptible to TGC (MIC 0.06mg/L). TGC and
PB were synergistic and bactericidal against the isolate that was less
susceptible to TGC (4mg/L) and highly resistant to AN (>128mg/L).
Against the most TGC-resistant isolate (64mg/L), TGC and PB exhibited
enhanced activity, while the combination of TGC and AN was synergistic
and bactericidal. It was noteworthy that TGC exposure caused the
development of increased susceptibility of this isolate to AN.
Conclusion: TGC alone is a potential treatment option for infections
caused by some, but not all, MRAB. In combination with an appropriate
agent, it may be effective against most isolates. The capability of TGC
exposure to cause increased susceptibility to potential co-drugs should
be further investigated.
P2032 Determination of the minimum inhibitory concentration
and mutant prevention concentration of tigeycline
against clinical isolates of methicillin-susceptible and
methicillin-resistant Staphylococcus aureus
J. Blondeau, C. Hesje, S. Borsos (Saskatoon, CA)
Objective: Tigecycline, a member of a new class of antimicrobials
(glycocyclines) has been shown to have potent in vitro activity against
clinical isolates of Staphylococcus aureus (SA) by MIC measurements.
We were interested in determining if the low MIC values would translate
into low mutant prevention concentration (MPC) values.
Methods: Minimum inhibitory concentration was in accordance with
the recommended Clinical and Laboratory Standards Institute procedure
by microbroth dilution using 105 cfu/mL tested against doubling drug
dilutions in appropriate media. For MPC testing 1010 CFUs were added
to drug containing agar plates and incubated in ambient temperature
and atmosphere. The lowest drug concentration preventing growth was
recorded as the MIC or MPC depending on method.
Results: For 68 clinical MSSA strains, MIC50, MIC90 and MIC range
values were 0.063mg/L, 0.125mg/L and 0.125mg/L. By MPC testing,
the MPC50, MPC90 and MPCrange was 1mg/L, 2mg/L and 1−4mg/L
(1 strain). A total of 64% of strains had MPCs of 1mg/L and 99% of
strains had MPCs of 1−2mg/L. For 63 MRSA strains MIC50, MIC90, and
MIC range values were 0.125, 0.5 and 0.063−1mg/L; MPC50, MPC90
and MPC range values were 1, 4 and 0.5−8mg/L with 76% of strains
having MPCs 2mg/L.
Conclusion: By MIC testing, tigeycline was highly active in vitro
against MSSA and MRSA strains with MICs 0.125mg/L and 1mg/L
respectively. Tigecycline MPC values were 2mg/L for 97% and 76%
of MSSA and MRSA strains respectively. Tigecycline appears to be
a promising agent for treating Staphylococcus aureus infections and
appears to have a reduced likelihood for selecting for resistance based
on MPC measurements.
P2033 Antimicrobial activity of tigecycline and other broad-
spectrum agents tested against bacterial isolates collected
in European hospitals in 2006
H. Sader, T. Fritsche, M. Stilwell, R. Jones (North Liberty, US)
Objectives: To assess the activity of tigecycline against recent bacterial
isolates from Europe. Tigecycline is a novel glycylcycline antimicrobial
recently approved by the European Medicines Agency for the treatment
of complicated skin and skin structure infections (cSSSI) and intra-
abdominal infections.
Methods: Bacterial isolates (non-duplicates) were consecutively col-
lected in 2006 from documented infections in patients hospitalised
in 24 medical centres located in Europe (9 countries), Turkey and
Israel. The isolates were obtained mainly from patients with bacteraemia
(BSI; 61.9%), pneumonia (16.1%) and cSSSI (11.1%). Frequency
of occurrence of pathogens was determined and their antibiograms
assessed using reference broth microdilution methods according to
the CLSI M7-A7 (2006). Tigecycline-susceptible (S) breakpoints
(US-FDA/EUCAST) were deﬁned as 2/1mg/L for Gram-negative
bacilli; 0.5/0.5mg/L for staphylococci, and 0.25/0.25mg/L for
streptococci and enterococci.
Results: A total of 5,032 strains were evaluated and the frequency
of pathogen occurrence and susceptibility rates to tigecycline are
summarised in the table. Tigecycline was highly active against the top 8
pathogens, except for P. aeruginosa (PSA). Among the 4 most common
indicated pathogens (3,430 strains; 68.0% of the total), tigecycline
was active against >99% at the US-FDA/EUCAST S breakpoints.
The main resistance phenotypes detected were methicillin-resistant (R)
S. aureus (31.4%) and CoNS (74.6%), ciproﬂoxacin-R E. coli (20.6%),
extended-spectrum b-lactamase (ESBL)-screen-positive Klebsiella spp.
(22.8%) and E. coli (6.3%), imipenem-R PSA (IRPSA; 24.2%) and
vancomycin-R enterococci (5.0%). Tigecycline showed excellent activity
against these R pathogens, except IRPSA.
0rganism (no. tested) Cumulative % inhibited at tigecycline MIC (mg/L): %Susceptiblea
0.12 0.25 0.5 1 2 4 >4
S. aureus (1,479) 80.0 99.5 99.5 – – – – 99.5/99.6
E. coli (854) 77.0 98.0 99.9 100.0 – – – 100.0/100.0
Enterococcus spp. (577) 83.4 100.0 – – – – – 100.0/100.0
Coagulase-negative staphylococci (520) 64.0 97.3 99.8 100.0 – – – 99.8/99.8
P. aeruginosa (302) 0.3 1.0 1.7 3.0 9.3 49.3 100.0 −b/−b
Klebsiella spp. (263) 14.4 73.0 92.4 98.5 100.0 – – 100.0/90.5
Beta-haemolytic streptococci (236) 100.0 – – – – – – 100.0/100.0
Enterobacter spp. (167) 4.2 58.7 84.4 95.2 98.8 100.0 – 98.8/95.2
aUS-FDA/EUCAST criteria.
bNo breakpoints have been established by the US-FDA or EUCAST.
Conclusions: Tigecycline exhibited a wide-spectrum of activity and
potency versus contemporary BSI isolates collected in Europe. R to
tetracycline or other antimicrobial classes did not adversely inﬂuence
tigecycline activity. Treatment options for serious infections in the
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nosocomial environments should beneﬁt from the availability of the new
antimicrobial class agent, tigecycline.
P2034 In vitro antibacterial activity of tigecycline in comparison
with doxycycline, ciproﬂoxacin and rifampin against
Brucella species
H. Turan, H. Arslan, H. Uncu, O. Azap, K. Serefhanoglu (Konya,
Ankara, Adana, TR)
Objectives: Human brucellosis affecting any organ system is a prevalent
public health problem with worldwide distribution. The high rate of
relapse after treatment with conventional drugs underlines the need for
new anti-Brucella antibiotics. We therefore measured the in vitro activity
of a new antimicrobial agent, tigecycline and compared it with the
activity of established antimicrobials. No data exists regarding this issue.
Methods: A total of 82 strains of Brucella species were tested. All of
these were obtained from blood and bone marrow cultures. The in vitro
antimicrobial activities of tigecycline, doxycycline, ciproﬂoxacin, and
rifampin were determined by E-test method.
Results: Doxycycline demonstrated the lowest MIC50 and MIC90 values,
followed by tigecycline, ciproﬂoxacin, and rifampin. The MIC50 and
MIC90 values of antibiotics for the strains of B. melitensis are shown
in the Table. While all isolates were susceptible to ciproﬂoxacin and
doxycycline, intermediate resistance to rifampin was detected in 19
(23%) isolates.
In vitro activities of tigecycline, doxycycline, ciproﬂoxacin and rifampin
against 82 strains of B. melitensis
Antibiotic Range (mg/mL) MIC50 MIC90
Tigecycline <0.016–0.125 0.064 0.125
Doxycycline <0.016–0.125 0.016 0.047
Ciproﬂoxacin 0.047–0.25 0.094 0.19
Rifampin 0.25−2 0.75 1.50
Conclusion: In conclusion, in the present in vitro study, the MIC values
of tigecycline, a novel tetracycline analogue, were assessed for the ﬁrst
time against strains of Brucella, and the MIC values of tigecycline
were found to be lower than those of rifampin and ciproﬂoxacin, but
were greater than those of doxycycline, a major component of currently
available regimens in Brucella infections. Considering the fact that
Brucellae are intracellular pathogens, in vivo studies are needed to fully
evaluate therapeutic potential of tigecycline in brucellosis.
P2035 In vitro activity of tigecycline and linezolid against
nosocomial MRSA strains
O. Kaya, F. Akcam, E. Temel (Isparta, TR)
Objective: Methicillin-resistant Staphylococcus aureus (MRSA) has
become one of the most widespread causes of nosocomial infections
worldwide. Moreover, it has been recovered from community-acquired
infections. Therapeutic options for these infections are limited.
Research for new antimicrobial agent is perpetuated for treatment of
this infections. Tigecycline is the ﬁrst drug in the glycylcycline class
of antibiotics. Linezolid is a synthetic antimicrobial agent of the an
oxazolidinone class. The aim of this study is to evaluate MIC50 and
MIC90 values of tigecycline and linezolid against MRSA strains.
Methods: A total of 60 MRSA strains isolated from various clinical
specimens and at different times were included in the study. All the
isolates were stored at −80ºC when they had been isolated. These
isolates were identiﬁed as S. aureus by phenotypic characteristics,
Gram staining, catalase and coagulase tests. Resistance to methicillin
was conﬁrmed using the Mueller-Hinton agar diffusion procedure with
1mg oxacillin disks, as recommended by the Clinical and Laboratory
Standards Institute (CLSI). Minimal inhibitory concentrations (MIC)
were determined by the E-test method, according to the CLSI criteria.
Results: All isolates were sensitive to linezolid and tygecycline. The
MIC levels of both antibiotics are listed in the table.
Antibiotic Range (mg/mL) MIC50 (pg/mL) MIC90 (mg/mL)
Tigecycline 0.032−1.0 0.125 0.38
Linezolid 0.094−4 0.50 1
Conclusion: In conclusion, given the limited therapeutic options for
serious MRSA infections, tigecycline and linezolid may offer additional
options as they demonstrated good activity against clinical strains of
MRSA infections.
P2036 In vitro antibacterial activity of tigecycline against hospital
isolates: comparison of two methods and proposal for zone
diameter breakpoints in France: a multicentre study
C.J. Soussy, S. Bremont, J.D. Cavallo, M. Chomarat, H.B. Drugeon,
V. Jarlier, M.D. Kitzis, C. Lascols, R. Leclercq, C. Muller-Serieys,
J. Rolain, M. Roussel-Delvallez, A. Dubanchet (Creteil, Paris, Saint
Mande, Lyon, Nantes, Caen, Marseille, Lille, FR)
Objectives: The aim of the study was to compare the MICs of tigecycline
(TIG) by agar dilution (A) using the Comite´ de l’Antibiogramme de la
Socie´te´ Franc¸aise de Microbiologie (CA-SFM) method and by broth
microdilution (B) using the Clinical Laboratory Standards Institute
(CLSI) method and to propose zone diameter breakpoints for clinical
categorisation in France.
Methods:MICs of TIG were determined by A and B against 1478 strains
collected in 10 university hospitals in France in 2006. Antibiograms
were performed with 15mg disks, according to the CA-SFM method. An
internal quality control was carried out with genetically deﬁned strains.
Results: According to the European Committee on Antimicrobial
Susceptibility Testing (EUCAST) MIC breakpoints (mg/L): Enter-
obacteriaceae 1/>2, Staphylococcus 0.5/>0.5; Enterococcus and
Streptococcus A, B, C, G. 0.25/>0.5 and zone diameter breakpoints
were (mm): Enterobacteriaceae 22/<20, Staphylococci: 22/<22,
Enterococci: 22/<18, Streptococci: 21/<18. However in Enterobac-
teriaeceae, it was difﬁcult to discriminate isolates with zone diameter
<22mm.
Bacterial species (no. of strains) MIC50 (mg/L) MIC90 (mg/L)
A B A B
Enterobacteriaceae except
Proteus spp. (400)
0.5 0.5 2 2
Proteus spp. (100) 2 1 8 4
Pseudomonas aeruginosa (100) 16 8 32 32
Acinetobacter baumannii (100) 0.5 0.25 2 2
Stenotrophomonas maltophilia (50) 0.5 0.25 2 2
MSSA (100) 0.12 0.06 0.5 0.5
MRSA (150) 0.12 0.06 0.5 0.5
GISA (30) 0.25 0.12 0.5 0.5
MSCNS (50) 0.12 0.06 0.5 0.5
MRCNS (50) 0.25 0.12 0.5 0.5
Enterococcus faecalis (100) 0.12 0.06 0.5 0.5
Enterococcus faecium (50) 0.12 0.06 0.25 0.25
Streptococci A, C and G (100) 0.06 0.03 0.25 0.25
PSSP (50) 0.03 0.03 0.12 0.12
PRSP (45) 0.03 0.03 0.12 0.12
In vitro susceptibility: tigecycline S587
Conclusion: MICs of TIG obtained by both methods (A and B)
appeared identical or very similar. The susceptibility zone diameter
breakpoint recommended in France by using the 15 mg TIG disks could
be 22mm for all species. However, for Enterobacteriaceae, except
Proteus, Morganella and Providencia showing a poor susceptibility
to TIG, MICs should be determined on isolates with zone diameter
<22mm.
P2037 In vitro antibacterial activity of tigecycline against
anaerobic hospital isolates; comparison of two methods in
France: a multicentre study
L. Dubreuil, L. Calvet, V. Jarlier, J. Cavallo, M. Chomarat,
H. Drugeon, M. Kitzis, C. Soussy, C. Lascols, M. Roussel-Delvallez,
C. Muller-Serieys, R. Leclercq, J. Rolain, A. Dubanchet (Lille, Paris,
Saint-Mande´, Lyon, Nantes, Cre´teil, Caen, Marseilles, FR)
Objectives: The aim of the study was to compare the MICs of tigecycline
(TIG) by agar dilution (A) using the Clinical Laboratory Standards
Institute (CLSI) M11 A6 method and a disk-diffusion test using the
Comite´ de l’Antibiogramme de la Socie´te Franc¸aise de Microbiologie
(CA-SFM) method and to propose zone diameter breakpoints for clinical
categorisation in France.
Methods: MICs of TIG were determined by the reference agar method
M11A6 against 230 strains collected in 10 university hospitals in France
in 2006. Antibiograms were performed with 15mg disks, according to
the CA-SFM method on Brucella blood agar. An internal quality control
was carried out with B. fragilis ATCC25285, B. thetaiotaomicron ATCC
29741 and Eggerthella lenta ATCC 43055.
Results: Results for TIG are shown in the table. By disk-diffusion test the
range for the inhibition zones were 28−41mm for GPAC, 21−37mm for
clostridia (with exception of C. perfringens inhibition zone 14−35mm),
and 11−40mm for the B. fragilis group. Considering the 4mg/L CLSI
breakpoint, the susceptibility zone diameter breakpoint recommended in
France by using the 15mg TIG disks could be ? 21mm for all species
except C. perfringens. MIC should be determined on isolates with zone
size diameter <20mm.
Bacterial species MIC (mg/L)
Range MIC50 MIC90
Bacteroides fragilis (84) 0.06−16 0.5 2
Bacteroides thetaiotaomicron (14) 0.06−16 2 16
Other Bacteroides (19) 0.06−2 0.25 1
All Bacteroides of the fragilis group (117) 0.06−16 0.5 2
Prevotella spp. (4) 0.06–0.125 ND ND
C. perfringens (48) 0.06−2 0.5 1
C. difﬁcile (18) 0.06–0.25 0.125 0.25
Other clostridia (6) 0.06−0.5 0.5 0.5
Finegoldia magna (13) 0.06−0.5 0.125 0.25
Micromonas micros (10) 0.06−0.5 0.125 0.25
Other GPAC: Gram-positive cocci (14) 0.06−0.5 0.125 0.25
All Gram-positive anaerobes (109) 0.06−2 0.125 1
All anaerobes (230) 0.06−16 0.25 2
Conclusion: Categorisation by disk-diffusion test remains difﬁcult for
anaerobes. Among the B. fragilis group, resistance to metronidazole
or imipenem could not be detected, but decreased susceptibility to
metronidazole (4.3%) was observed. TIG 4mg/L inhibited 111/117
strains of the B. fragilis group meanwhile TIG 2mg/L was able to inhibit
all Gram-positive anaerobes. Thus, at a concentration of 4mg/L, TIG
inhibited 97.3% of the investigated strains.
P2038 In vitro activity of tigecycline against linezolid-resistant
Staphylococcus cohnii ssp. urealiticum clinical isolates
A. Stylianakis, A. Koutsoukou, S. Tsiplakou, S. Sardiniari, A. Vourtsi,
I. Merianos (Athens, GR)
Objectives: The purpose of our study was to evaluate the in vitro
activity of tigecycline against linezolid-resistant Staphylococcus cohnii
ssp. urealiticum clinical isolates.
Methods: We examined 18 non duplicated linezolid-resistant Staphy-
lococcus cohnii ssp. urealiticum clinical isolates. These isolates were
recovered from blood cultures of ICU patients of our hospital during a
12 months time period. The identiﬁcation and the susceptibility testing
of the isolates were performed by the automated VITEK2 system
(boiMe´rieux, France). The susceptibility testing for tigecycline was
performed by Kirby-Bauer disk diffusion method and done by direct
colony suspension according to CLSI guidelines. Paper disks containing
tigecycline at 15mg per disk were used (Becton-Dickinson, USA). The
determination of tigecycline and linezolid MIC values was performed
by using E-test strips according to the manufacturer’s guidelines (AB-
Biodisk, Sweden). Isolates with an inhibition zone diameter of  19mm
and with an MIC level  0.5mg/L were considered as susceptible to
tigecycline. (MIC-susceptibility limits determined by EUCAST). Isolates
with an MIC level  8mg/L were considered as resistant to linezolid.
Results: All the Staphylococcus cohnii ssp. urealiticum clinical isolates
were resistant to linezolid with an MIC level 24mg/L. The tigecycline
was found absolute active to all the examined linezolid-resistant
Staphylococcus cohnii ssp. urealiticum clinical isolates. The inhibition
diameter zones for tigecycline were found of 22mm and the
tigecycline-MIC levels of 0.125mg/L.
Conclusion: Tigecycline is absolute active to all linezolid-resistant
Staphylococcus cohnii ssp. urealiticum clinical isolates. This new
glycycline is consisted an alternative option for treatment of infections
caused by these isolates. Clinical laboratories should be routinely testing
tigecycline susceptibility in all clinically signiﬁcant Staphylococci; so
that any changes to the current status may be detected as soon as possible.
P2039 Evaluation of tigecycline in vitro activity against
panresistant Klebsiella pneumoniae clinical isolates
A. Stylianakis, A. Koutsoukou, S. Tsiplakou, V. Garavella, M. Taxtatzis,
I. Merianos (Athens, GR)
Objectives: The purpose of our study was to evaluate the in vitro
activity of tigecycline against panresistant Klebsiella pneumoniae clinical
isolates.
Methods: We examined 68 non duplicated panresistant Klebsiella
pneumoniae isolates recovered from blood cultures, bronchoalveolar
excretions and pus and urine samples derived from ICU-patients of our
hospital during a one year-time period. The identiﬁcation of the isolates
and the susceptibility testing were performed by the automated VITEK2
system (boiMe´rieux, France). The susceptibility testing for tigecycline
was performed by Kirby-Bauer disk diffusion method and done by
direct colony suspension according to CLSI guidelines. Paper disks
containing tigecycline at 15mg per disk were used (Becton-Dickinson,
USA). The determination of tigecycline-MIC values was performed by
E-test strips according to the manufacturer’s guidelines (AB-Biodisk,
Sweden). Isolates with an inhibition zone diameter of  19mm and with
an MIC level  1mg/L were considered as susceptible to tigecycline
(MIC-susceptibility limits determined by EUCAST).
Results: All the Klebsiella pneumoniae clinical isolates were resistant
to aminoglycosides, b-lactams, carbapenems, monobactames, furanes,
cinolones and colistin. The tigecycline was found absolute active to all
the examined isolates. The inhibition diameter zones were found of 
21mm and the MIC levels of 0.5mg/L
Conclusion: Tigecycline is absolute active to panresistant Klebsiella
pneumoniae isolates and holds great promise as a therapeutic agent to
combat or limit desperate infections caused by these panresistant isolates.
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P2040 Activity of tigecycline versus carbapenem-resistant strains
of Acinetobacter spp.
P. Khanna, D. Krahe, D. Bean, D. Wareham (London, UK)
Objectives: Acinetobacter sp have emerged worldwide as important
noscomial pathogens responsible for ventilator associated pneumonia,
bacteraemia and sepsis in the critically ill. In the UK, infection and
colonisation with carbapenem resistant strains have been reported since
2001 and have been responsible for 65 episodes of bacteraemia in
our institution from April 2002 – September 2006. The glycylcyline
antibiotic tigecycline has been proposed as a useful therapeutic agent for
the treatment of multidrug Acinetobacter infection. In order to determine
the potential usefulness of this agent in our population we carried out
susceptibility testing using Etest versus 32 recent multidrug resistant
isolates.
Methods: Multidrug resistant Acinetobacter were isolated from clinical
specimens and identiﬁed to genus level by API 20NE. Antimicrobial
susceptibility testing to ampicillin, cefuroxime, ceftriaxone, trimetho-
prim, amikacin, ceftazidime, ciproﬂoxacin, gentamicin, imipenem,
piperacillin/tazobactam, aztreonam, colistin, sulbactam and minocycline
was performed by the BSAC disc diffusion method and MIC’s to
imipenem, meropenem and tigecyline by Etest. Carbapenem resistant
isolates were assayed for the OXA-51, OXA-23, OXA-58 and OXA-
24 genes to identify A. baumannii isolates and strains belonging to the
OXA-23 clonal group.
Results: All strains were sensitive to colistin. Sensitivity to ciproﬂoxacin,
amikacin, sulbactam and minocycline varied. Imipenem MIC’s ranged
from 0.19−>32mg/L and meropenem MIC’s from 0.25−>32mg/L. Tige-
cycline MIC’s ranged from <0.016−2mg/L with an MIC50 = 0.5mg/L
and an MIC90 = 1.0mg/L. All but one isolate were PCR positive for the
OXA-51 gene and negative for both OXA-58 and OXA-24. The presence
of OXA-23 varied.
Conclusion: Tigecycline demonstrates good activity against the preva-
lent strains of multidrug resistant strains of Acinetobacter isolated in
our institution. The majority of our isolates are A. baumannii exhibiting
marked carbapenem associated with OXA carbapenemases. Although our
practice has been to use colistin for the treatment of serious infections
with these organisms, tigecyline is an attractive alternative option. Its
broad spectrum of activity, in comparison to colistin, combined with its
activity versus A. baumannii, in comparison to carbapenems, make it
especially suitable for empirical treatment of nosocomial infections in
critical care.
P2041 In vitro antimicrobial activity of tigecycline against
multidrug-resistant Acinetobacter baumannii strains
O¨. Kurt Azap, F. Timurkaynak, S. Karaman, H. Arslan (Ankara, TR)
Introduction: Acinetobacter baumannii strains are important multidrug-
resistant nosocomial pathogens especially in the intensive care unit.
Tigecycline, member of glycylcylines, exhibits antibacterial activity
against multidrug-resistant Gram-negative strains.
The aim of this study is to determine the antibacterial activity of
tigecycline against the multidrug-resistant A. baumannii strains isolated
from the blood cultures of the patients hospitalised in the intensive care
unit.
Materials and Methods: Multidrug-resistant A. baumannii strains
isolated from the patients hospitalised in the intensive care unit
between the period January 2005-April 2006 were included in the
study. Bacteria were identiﬁed to the species level by conventional
methods and automated identiﬁcation kits. Each isolate was obtained
from one patient. Antimicrobial activities of ceftazidime, cefepime,
piperacillin-tazobactam, amikacin, ciproﬂoxacin and imipenem were
studied according to the CLSI criteria. Minimal inhibitory concentrations
of tigecycline against 39 A. baumannii strains of which were resistant to
at least four of the drugs above were studied by E test strips.  2mg/L
was chosen as the susceptibility breakpoint according to the other studies.
Results:MIC50 and MIC90 values were found to be 1.5mg/L and 2mg/L
respectively, within a range of 0.75−4mg/L. The susceptibility rate of
the strains were determined to be 94.7%.
Conclusion: MIC50 and MIC90 values of tigecycline against multidrug-
resistant A. baumannii strains were found to be high as in the other
studies. However, tigecycline seems to be an alternative for the infections
caused by resistant pathogens because of the high susceptibility rate
(94.2%). Further studies including higher numbers of strains are needed
to determine the value of tigecycline in the treatment of the infections
caused by multidrug-resistant A. baumannii strains.
P2042 In vitro activity of tigecycline against the multidrug-resistant
bacteria isolated from burn patients
O¨. Kurt Azap, F. Timurkaynak, S. Karaman, H. Arslan (Ankara, TR)
Introduction: Infections in burn patients are usually caused by
multidrug-resistant microorganisms. Tigecycline, a derrivative of glycyl-
cyclines, is an effective antibiotic against the resistant strains. The aim
of this study is to determine the in vitro activity of tigecycline against
the multi-drug resistant bacteria isolated from burn patients.
Materials and Methods: Forty-ﬁve bacteria isolated from 118 patients
hospitalised in the burn unit during 2003–3005 were included in the
study. Gram-negative bacteria that were resistant to at least two classes
of antibiotics among the b-lactam, quinolone, aminoglycoside classes,
methicillin-resistant staphylococci, ampicillin-resistant enterococci were
studied. Minimal inhibitory concentration values of tigecycline against
these bacteria were tested by E test strips. Susceptibility breakpoints
were determined according to the previous studies; 0.25mg/L for
enterococci,0.5mg/L for staphylococci and2mg/L for Acinetobacter
baumannii.
Results: Forty-seven percent of the materials were obtained from wound,
31% from tissue specimens, 27% from blood and 3% from catheters.
MIC50 and MIC90 values were shown in the Table.
MIC values of tigecycline against the bacteria isolated from burn patients
Bacteria (n) MIC (mg/L)
Range MIC50 MIC90
Enterococcus spp. 0.032−1 0.125 0.25
Methicillin-resistant S. aureus 0.19−2 0.25 1.5
Acinetobacter baumannii 0.50−2 1 2
Conclusion: Susceptibility rates were found to be 94.2%, 85.5%, 100%
for MRSA, enterococci, A. baumannii respectively. These results are in
accordance with the other studies. In conclusion, tigecycline seems to
be a good alternative for the difﬁcult-to-treat infections in burn patients.
P2043 Susceptibility to tigecycline among multidrug-resistant
Acinetobacter baumannii clinical isolates
A. Capone, S. D’Arezzo, P. Visca, N. Petrosillo on behalf of GRAB:
Gruppo Romano Acinetobacter baumannii (Italy)
Introduction: Acinetobacter baumannii is serious clinical challenge in
Intensive Care Units (ICUs). Treatment options for infections caused by
Multi Drug Resistant (MDR) strains are currently limited to colistin,
or to a glycylcycline compound, namely tigecycline (TIG). TIG is a
promising antibacterial agent, active in treatment of complicated intra-
abdominal, skin and skin-structure infections and towards a wide range
of pathogens, including A. baumannii. Few studies on limited numbers
of A. baumanni strains on the in vitro activity of TIG have so far been
conducted in Italy.
Objective: Aim of the present study was to assess the in vitro activity of
tigecycline against 80 MDR clinical isolates of A. baumannii collected
from ICU patients in Rome hospitals in the course of a large urban
nosocomial epidemic.
In vitro susceptibility: tigecycline S589
Materials and Methods: 80 A. baumannii clinical strains were isolated
from hospitalised patients in six ICUs in Rome from January 2004
to June 2005 and analysed at the Molecular Microbiology Unit of
the National Institute for Infectious Diseases “L. Spallanzani”, Rome,
for sensitivity assays. Organisms were identiﬁed to species level by
conventional methods. The minimal inhibitory concentration (MIC)
for TIG was determined by broth microdilution reference method
recommended by the NCCLS. The antimicrobial range tested was 0.031–
0.128mg/L. MIC breakpoints used for this agent were 2, 4, 8mg/L
to designate susceptible, intermediate, and resistant strains, respectively.
Results: We identiﬁed 58 susceptible isolates (72.5%) and 22
unsusceptible isolates (27.5%) of which 3/80 (3.7%) with full resistance
and 19/80 (23.7%) with intermediate susceptibility. Information on
previous antibiotic treatment before isolating A. baumannii was available
on 42 patients. 16/36 (44.4%) and 2/6 (33.3%) were unsusceptible
strains in patients with and without previous antibiotics, respectively
(OR: 1.6, 95%CI: 0.25–9.87). Notably, all MDR A. baumannii strains
were susceptible to colistin but one (1.3%) that showed intermediate
susceptibility.
Conclusion: Study shows that about one quarter of MDR A. baumannii
clinical strains analysed, were unsusceptible to TIG. Even though we
did not provide evidence of a statistically signiﬁcant association with
the previous antibiotic regimen, due to the limited size of our series, low
TIG susceptibility can partly be explained by induction of efﬂux-based
multridrug resistance pathways due to previous antibiotic exposure.
P2044 Comparative in vitro activity of tigecycline according to
carbapenem resistance of different sequential clones of
Acinetobacter baumannii in bacteraemic critically ill patients
J. Camarena, R. Gonzalez, R. Zaragoza, J. Navarro, S. Sancho,
J. Nogueira (Valencia, ES)
Objectives: Multiresistant A. baumannii (MRAb) remains during the
last 10 years like the most important problem in our ICU. In order to
know the activity of antimicrobial agents (ATB), the aim of this study
was to compare, according to carbapenem resistance, in vitro activity
of tigecycline and 11 other ATB against epidemiologically characterised
MRAb isolates from bacteraemic critically ill patients.
Methods: MRAb isolates (196) were collected from 100 bacteraemic
ICU patients (samples: 100 bloodstream, 52 respiratory, 22 catheter,
11 wound and 11 other samples) during the last 10 years. MICs of
tigecycline and 11 other ATB (carbapenems, aminoglycosides, ampi-
sulbactam, piperacillin–tazobactam, ceftazidime, colistin, polimixin,
doxycycline and minocycline) were determined by E-test® (AB-Biodisk,
Solna, Sweden), using CLSI breakpoints, except for tigecycline. All
tested strains were previously characterised by genotipically methods
(REP-PCR) in order to cluster related strains.
Results: Because all the isolates/case had the same feno-genotipically
pattern, the results are showed like the 100 cases patient. We
reported 10 different clones with a lot of fenotipically antimicrobial
patterns. The 80% (158 strains) of epidemiologically deﬁned MRAb
isolates from clinically signiﬁcant ICU bacteraemias were carbapenem
(imipenem and meropenem) resistant (CR-MRAb). The in vitro activity
of tigecycline according to this carbapenem resistance did not show
any differences between both groups, CR-MRAb or carbapenem
susceptible (CS-MRAb) strains: range 0.25−4/8mg/L and MIC50−90
2−2mg/L. Only 8 cases in CR-MRAb (10%) and 2 in CS-MRAb
(10%) had MIC for tigecycline 4mg/L. The MIC50−90 in both groups
(CR-MRAb/CS-MRAb) of the 11 other ATB tested were different
for minocycline (4−32/2−2mg/L), ampi-sulbactam (16−64/2−4mg/L),
tobramycin (16−256/2−256mg/L), and amikacin (256−256/
8−256mg/L). These differences related with the characterizated clonal
outbreaks were not found in tigecycline, with the same MICs in the
different clones.
Conclusion: Tigecycline appears to be a promising agent that remain
active against MRAb and there are not any differences in the activity
according to carbapenem resistance or clonallity of the strains. For
A. baumannii the MIC values imply that bacteraemia infection in
critically ill patients might be treated with tigecycline despite the
breakpoint of this is not clearly allocated.
P2045 Evaluation of expected clinical success of tigecycline and
other commonly used antimicrobials for empiric treatment
of complicated skin and skin structure infections in
Germany, Spain and the United States
R. Mallick, T. Fritsche, R. Jones, A. Kuznik, M. Stilwell, H. Sader
(Collegeville, North Liberty, US)
Objective: To model the expected clinical success of tigecycline and
commonly used antimicrobials for empiric treatment of complicated
skin and skin structure infections (cSSSI) based on evaluation of
antimicrobial susceptibility and frequency of pathogen occurrence from
a global surveillance programme. Tigecycline is a novel semisynthetic
glycylcycline recently approved for parenteral treatment of cSSSI and
intraabdominal infections in the United States (US) and European
countries.
Methods: Consecutive, nonduplicate bacterial isolates collected between
2000 and 2005 from patients with documented cSSSI in 48 medical
centres located in Germany (7), Spain (3), and the US (38) were used
to evaluate the frequency of pathogen occurrence and susceptibility
rates of tigecycline and select parenteral antimicrobials. All isolates
were tested using CLSI broth microdilution methods and interpretive
criteria. Tigecycline breakpoints approved by the USA-FDA were used.
By applying pathogen-speciﬁc susceptibility rates to the frequency of
occurrence of pathogens in each country, we calculated the overall
expected coverage for each antimicrobial agent or combination.
Results: The top 3 pathogens identiﬁed in Germany and Spain were
(frequency [%] by country): S. aureus (35.1 and 33.3%, respectively),
E. coli (11.3 and 12.8%), and P. aeruginosa (11.0 and 12.6%). In the
US, the top 3 pathogens identiﬁed were S. aureus (48.1%), P. aeruginosa
(9.4%) and enterococci (8.8%). Other frequently isolated pathogens
included b-haemolytic streptococci, Enterobacter and Klebsiella spp.,
with some inter-country variation. The rates of oxacillin-resistance
(MRSA) varied from 3.6% in Germany to 17.3% in Spain and 43.5%
in the US. Tigecycline was highly active (>90% S) against the
most common pathogens, except P. aeruginosa and P. mirabilis. The
overall expected coverage of cSSSI for the antimicrobials evaluated is
summarised in the table.
Antimicrobial Overall expected coverage
(% susceptible of all
pathogens)
Germany Spain USA
Tigecycline 87.5 85.1 90.6
Vancomycin 66.9 59.5 73.4
Linezolid 66.9 59.5 74.4
Levoﬂoxacin 88.3 84.6 75.7
Piperacillin/tazobactam 96.0 90.0 75.6
Imipenem 95.8 92.1 74.1
Cefazolin 73.2 66.2 60.1
Ceftriaxone 80.2 74.3 64.0
Vancomycin& Piperacillin/tazobactam 98.2 95.8 95.7
Vancomycin & Levoﬂoxacin 95.5 93.1 93.8
Conclusion: Vancomycin in combination with piperacillin/tazobactam
had the highest overall expected empiric coverage of cSSSI in the
countries evaluated. Among monotherapies, tigecycline had the highest
expected coverage rate in the US, where the prevalence of MRSA was
relatively high. Piperacillin/tazobactam and imipenem had the highest
expected coverage in Germany and Spain, where the prevalence of
MRSA was relatively low. Our results suggest that tigecycline might
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be a viable option for empiric treatment of cSSSI in these countries,
especially in settings with high MRSA rates.
P2046 Analysis of tigecycline activity against Acinetobacter spp.
and Enterobacteriaceae based on clinical specimen source
D. Draghi, M. Dowzicky, M. Jones, N. Brown, C. Thornsberry,
D. Sahm (Herndon, Collegeville, US; Breda, NL)
Objective: TIG, the ﬁrst in class glycylglycine was approved for clinical
in 2005 in the US and 2006 in Europe for treatment of skin and intra-
abdominal infections. Because variations in the in vitro activity of an
antimicrobial can occur against organisms (Org) isolated from different
clinical specimen sources, the activity of TIG was analysed according to
specimen source (SPEC) for recent isolates of Acinetobacter spp. (AC)
and Enterobacteriaceae (EN).
Methods: AC and EN isolates were collected from 52 hospital sites
distributed among all nine US Bureau of Census regions and 15 hospital
sites distributed across 4 countries in Europe (EU; Germany, Italy, Spain,
and France). All AC and EN were isolated from clinical specimens in
2005–2006 and centrally tested against TIG and comparators by broth
microdilution (CLSI guidelines M7-A7). The SPECs studied were blood
[BD], respiratory [RP], skin and soft tissue [SST], and urine [UN]). US
FDA breakpoints (BPs; 2mg/L, susceptible [S]; 4mg/L, intermediate
[I]; 8mg/L, resistant [R]) were applied to results from EN isolates
that originated from the US and EUCAST BPs (1mg/L, S; 2mg/L,
I; 4mg/L, R) were applied to results from EN isolates that originated
from EU. Currently, BPs do not exist for AC.
Results: See the table.
Org SPEC USA EU
N MIC (mg/L) %S %I %R N MIC (mg/L) %S %I %R
Range Mode MIC90 Range Mode MIC90
AC SST 83 0.034 0.25 1 – – – NA NA NA NA – – –
RP 64 0.03−2 0.5 2 – – – 15 0.06−2 2 2 – – –
UN 35 0.03−2 2 2 – – – 16 0.06−2 0.5 1 – – –
BL 25 0.03−1 0.12 1 – – – 15 0.06−1 0.25 1 – – –
EN SST 215 0.06−4 0.5 1 99.1 0.9 0 NA NA NA NA NA NA NA
RP 209 0.06−4 0.25 1 99.0 1.0 0 68 0.06−2 0.25 1 97.1 2.9 0
UN 758 0.064 0.25 0.5 99.9 0.1 0 187 0.03−2 0.25 0.5 98.4 1.6 0
BL 126 0.03−2 0.25 1 100 0 0 71 0.06−2 0.25 0.5 98.6 1.4 0
Conclusions: Based on susceptibility patterns susceptibility patterns
and MIC90s, TIG demonstrated a potent activity against EN and AC,
regardless of either the geographic (US or EU) or clinical source
of the isolates. While TIG currently exhibits potent activity against
these important Gram-negative bacilli, the ability of these organisms
to develop resistance to a variety of antimicrobials warrants continued
surveillance as TIG use to treat infections increases.
P2047 Tigecycline Evaluation Surveillance Trial (T.E.S.T.) –
United States in vitro antibacterial activity against selected
species of Enterococcus spp.
S. Bouchillon, M. Hackel, B. Johnson, J. Johnson, D. Hoban, R. Badal,
M. Dowzicky (Schaumburg, Collegeville, US)
Background: Tigecycline, a member of a new class of antimicrobials
(glycylcyclines), has been shown to have potent expanded broad spec-
trum activity against most commonly encountered species responsible
for community and hospital acquired infections. The T.E.S.T. programme
determined the in vitro activity of tigecycline compared to vancomycin,
linezolid, ampicillin, imipenem, ceftriaxone, levoﬂoxacin, minocycline,
penicillin and piperacillin/tazobactam against members of Enterococcus
spp. collected from hospitals in the USA.
Methods: A total of 2,486 clinical isolates were identiﬁed to the
species level at each participating site and conﬁrmed by the central
laboratory. Isolates were collected throughout 2004. Minimum Inhibitory
Concentration (MICs) were determined by the local laboratory using
broth microdilution panels and interpreted according to NCCLS
guidelines.
Results: Of 1,709 E. faecalis evaluated, vancomycin resistance was
noted in 80 (4.7%) isolates. These isolates were all susceptible to
linezolid, penicillin and tigecycline. Tigecycline presented the lowest
MIC50/MIC90 (0.06/0.12mg/mL) among all antimicrobial agents evalu-
ated. As a typical proﬁle of E. faecalis, ﬂuoroquinolone (levoﬂoxacin)
and tetracycline (minocycline) had limited activities against this species.
Among 713 E. faecium, 477 (66.9%) were resistant to vancomycin, of
which 17 isolates were non-susceptible to linezolid. Tigecycline also
presented the lowest MIC50/MIC90 of 0.03/0.12mg/mL.
Conclusion: Tigecycline’s in vitro activity was comparable to or greater
than most commonly prescribed antimicrobials. The presented data
suggest that tigecycline may be an effective and reliable therapeutic
option against Enterococcus spp. including vancomycin-resistant strains.
P2048 Comparison of in vitro activity of tigecycline against
pathogens from intensive care patients in Europe –
T.E.S.T. Program 2006
S. Bouchillon, B. Johnson, R. Badal, M. Hackel, J. Johnson, D. Hoban,
M. Dowzicky (Schaumburg, Collegeville, US)
Background: Tigecycline, a member of a new class of antimicrobials
(glycylcyclines), has been shown to have potent broad spectrum activity
against most commonly encountered species responsible for community
and hospital acquired infections. The T.E.S.T. Program surveyed the in
vitro activity of tigecycline from ICU and non-ICU pathogens during
2004 to 2006.
Methods: A total of 4,744 clinical isolates from 62 testing sites in 19
European countries. Minimum Inhibitory Concentration (MICs) were
determined by each site using common broth microdilution panels and
interpreted according to EUCAST guidelines.
Results: See the tables.
Drug Enterobacteriaceae
(n = 1,206)
Acinetobacter spp.
(n = 221)
MIC50 MIC90 MIC50 MIC90
Tigecycline 0.5 2 0.25 1
Amikacin 2 8 4 >64
Cefepime 0.5 8 8 32
lmipenem 0.5 1 0.5 >16
Levoﬂoxacin 0.06 8 2 >8
Minocycline 2 8 0.5 4
PipTazo 2 128 16 >128
Drug S. aureus (n = 206) Enterococcus spp. (n = 209)
MIC50 MIC90 MIC50 MIC90
Tigecycline 0.12 0.25 0.12 0.12
Levoﬂoxacin 0.12 16 2 >32
Linezolid 2 4 2 2
Minocycline 0.25 1 8 >8
Vancomycin 1 1 1 2
Conclusion: Tigecycline’s in vitro activity was comparable to or greater
than most commonly prescribed broad spectrum antimicrobials for
all ICU bacterial study strains encountered. Tigecycline’s inhibitory
against Enterobacteriaceae, and Acinetobacter spp. was comparable to
imipenem. Against Gram-positive organisms, Tigecycline’s activity was
comparable to linezolid and vancomycin.
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P2049 In vitro activity of tigecycline against pathogens isolated
from cerebrospinal ﬂuid – T.E.S.T. Program 2006
R. Badal, S. Bouchillon, M. Hackel, J. Johnson, D. Hoban, B. Johnson,
M. Dowzicky (Schaumburg, Collegeville, US)
Background: Tigecycline (TIG), a new glycylcycline, has been shown to
have potent broad spectrum activity against most commonly encountered
species responsible for community and hospital acquired infections.
The T.E.S.T. Program determined the in vitro activity of TIG and 10
comparators against respective Gram-positive/negative species.
Methods: 295 cerebrospinal ﬂuid pathogens from 272 sites and 34
countries were analysed in this survey. The isolates were identiﬁed to
the species level at the participating sites and conﬁrmed by the central
laboratory. MICs were determined by each site using supplied broth
microdilution panels and interpreted according to CLSI guidelines.
Results: TIG activity against pathogens isolated from cerebrospinal ﬂuid
are shown in the table.
Organisms (n = 296) %Sus Tigecycline MIC (mg/mL)
MIC50 MIC90 Range
Acinetobacter spp. (n = 36) n/a 0.25 1 0.03−4
P. aeruginosa (n = 17) n/a 16 >6 4–>16
Enterobacter spp. (n = 29) 100 0.5 1 0.25−2
Enterococcus spp. (n = 22) 100 0.12 0.12 0.03–0.25
E. coli (n = 27) 100 0.12 0.25 0.06−2
Klebsiella spp. (n = 17) 100 0.5 1 0.12−1
ESBLs (n = 6) 100 0.25 0.5 0.12−0.5
H. inﬂuenzae (n = 8) n/a 0.12 0.25 0.06–0.25
S. aureus (n = 30) 100 0.12 0.25 0.06–0.25
MRSA (n = 7) 100 0.12 0.25 0.06–0.25
S. pneumoniae (n = 79) n/a 0.03 0.5 0.008−0.5
S. marcescens (n = 16) 100 1 2 0.5−2
S. agalactiae (n = 15) 100 0.03 0.06 0.03–0.25
n/a, breakpoints not available.
Conclusions: Tigecycline showed excellent inhibitory activity against
all pathogens invading the cerebrospinal ﬂuid in this study with
the exception of P. aeruginosa. Tigecycline demonstrated MIC90
values of 0.5mg/mL against Gram-positive pathogens (including
resistant phenotypes) and MIC90 values of 1mg/mL against the
Enterobacteriaceae and Acinetobacter spp. validate the potent inhibitory
activity of TIG against these invasive pathogens.
P2050 Antimicrobial susceptibility of 2,537 bacteraemia causative
pathogens: Tigecycline Evaluation Surveillance Trial
(TEST) in Europe, 2004–2006
R. Badal, S. Bouchillon, B. Johnson, M. Hackel, J. Johnson, D. Hoban,
M. Dowzicky (Schaumburg, Collegeville, US)
Background: Bacterial resistance patterns vary over both time and
geography. One of the goals of surveillance studies is to identify those
patterns to help guide current therapy. The Tigecycline Evaluation
Surveillance Trial (TEST) is an ongoing global study that can serve to
help recognize current trends in resistance on many levels. This report
evaluates differences in susceptibility of bacterial pathogens isolated
from the blood stream, collected in Europe from 2004 to 2006.
Methods: 2,537 bacteraemic pathogens were collected and identiﬁed
from 2004–2006 at 62 hospitals in 19 countries in Europe. MICs for
each strain were determined per EUCAST guidelines at each facility
using broth microdilution.
Results: Tigecycline MICs are recorded in the table.
Organisms (n = 296) %Susa Tigecycline MIC (mg/mL)
MIC50 MIC90 Range
Acinetobacter spp. (n = 161) IE 0.25 1 0.03−4
P. aeruginosa (n = 208) 8 16 0.5–>1 6
Enterobacter spp. (n = 324) 91.0 0.6 1 0.06−8
Enterococcus spp. (n = 227) 100 0.06 0.12 0.015–0.25
VREs (n = 20) 100 0.06 0.12 0.015–0.12
E. coli (n = 531) 99.8 0.12 0.25 0.03−2
Klebsiella spp. (n = 413) 91.0 0.6 1 0.12−8
ESBLs (n = 71) 85.9 0.6 2 0.06−8
Serratia spp. (n = 118) 91.5 0.5 1 0.12−8
H. inﬂuenzae (n = 19) IE 0.12 0.25 0.03−0.5
S. aureus (n = 282) 100 0.12 0.25 0.03−0.5
MRSA (n = 75) 100 0.12 0.25 0.03−0.5
S. agalactiae (n = 72) 100 0.03 0.12 0.015–0.25
S. pneumoniae (n = 182) IE 0.03 0.5 0.008−0.5
a−− indicates this species is a poor target for therapy with this drug.
IE: Insufﬁcient Evidence that this species is a good target for therapy
with this drug.
Conclusions: Tigecycline showed excellent inhibitory activity against
all causative bacteraemic pathogens with the exception of P. aeruginosa.
Tigecycline demonstrated MIC90 values of 0.5mg/mL against Gram-
positive pathogens (including resistant phenotypes) and MIC90 values
of 2mg/mL against the Enterobacteriaceae and Acinetobacter spp.
validate the potent inhibitory activity of TIG against these invasive
pathogens.
P2051 Antibacterial activity of tigecycline against H. inﬂuenzae
and S. pneumoniae (2004−06) Global Population – T.E.S.T.
Program, 2006
S. Bouchillon, M. Hackel, J. Johnson, R. Badal, D. Hoban, B. Johnson,
M. Dowzicky (Schaumburg, Collegeville, US)
Background: Tigecycline (TIG), a new glycylcycline, has been shown to
have potent broad spectrum activity against most commonly encountered
species responsible for community and hospital acquired infections. The
T.E.S.T. Program determined the in vitro activity of TIG and comparators
against respective Gram-positive/negative species. Isolates were collected
from 272 hospital sites in 34 countries from 2004 to 2006.
Methods: A total of 4,724 clinically signiﬁcant respiratory isolates
collected worldwide were analysed in this survey. The isolates were
identiﬁed to the species level at the participating sites and conﬁrmed
by the central laboratory. MICs were determined by each site using
supplied broth microdilution panels and interpreted according to CLSI
guidelines.
Drug H. inﬂuenzae (n = 3,044) S. pneumoniae (n = 3,264)
%Sus MIC50 MIC90 %Sus MIC50 MIC90
Tigecycline n/a 0.12 0.5 n/a 0.03 0.25
AmoxClav 99.7 0.5 1 95.7 0.03 1
Ceftriaxone 99.9 <0.06 <0.06 98.2 <0.03 0.5
Levoﬂoxacin 100 0.015 0.03 99.8 0.5 1
Imipenem 100 0.5 1 74.6 0.12 0.5
Linezolid – – – 100 0.5 1
Penicillin – – – 63.5 0.06 1
an/a: Breakpoints not yet available.
Results: Activities of tigecycline and comparator antimicrobials are
shown in the table. Overall, 22.6% of H. inﬂuenzae were b-lactamase
producers and 36.5% of S. pneumoniae presented some degree
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to non-susceptibility to penicillin. Tigecycline demonstrated potent
inhibitory activity with MIC90 of 0.5mg/mL and 0.25mg/mL
against b-lactamase positive H. inﬂuenzae and penicillin non-susceptible
S. pneumoniae, respectively.
Conclusions: Tigecycline showed excellent inhibitory activity against
H. inﬂuenzae and S. pneumoniae regardless of the presence of
b-lactamase or penicillin-resistance mechanisms. The results of this study
suggest that Tigecycline may be a reliable therapeutic option for the
treatment of respiratory infections due to these species.
P2052 Variable resistance patterns among tigecycline and 10
comparators against multidrug-resistant Acinetobacter from
the T.E.S.T. Program
B. Johnson, S. Bouchillon, M. Hackel, R. Badal, J. Johnson, D. Hoban,
M. Dowzicky (Schaumburg, Collegeville, US)
Background: Tigecycline (TIG), a member of a new class of
antimicrobials (glycylcyclines), has been shown to have potent expanded
broad spectrum activity against most commonly encountered species
responsible for community and hospital acquired infections. The T.E.S.T.
Program determined the in vitro activity of TIG compared to piperacillin-
tazobactam (PT), levoﬂoxacin (LVX), ceftriaxone (CAX), cefepime
(CPE), amikacin (AK), minocycline (MIN), ceftazidime (CAZ), and
imipenem (IMP) against multi-drug resistant Acinetobacter strains
collected from 272 investigational sites in 34 countries throughout 2004–
2006.
Methods: A total of 3,334 clinical Acinetobacter were identiﬁed to
the species level at each participating site and conﬁrmed by the
central laboratory. Minimum Inhibitory Concentrations (MICs) were
determined by the local laboratory using broth microdilution panels.
Antimicrobial resistance was interpreted according to CLSI breakpoints
where applicable.
Results: Resistance rates to the comparator drugs against all Acineto-
bacter spp. were CAX 33.5%, CAZ 42.8%. LVX 38.3%, CPE 33.5%,
PT 25.5%, AK 14.3%, IMP 12.1%, MIN 2.5%. Strains were grouped by
presence of resistance to 0, 1, 2, 3, 4, or 5 drug classes. TIG inhibited
96% of all 930 multi-drug resistant strains (resistant to 3 or more drug
classes) at 2mg/mL with only 3/930 (0.3%) strains at 8mg/mL. TIG
MIC50/90 for Groups Resistant to 0−5 drug classes were 0.12/0.5, 0.5/1,
0.5/2, 1/2, 1/2 and 1/2 mg/mL, respectively.
Conclusions: It has been seen in some species that existing multi-
drug resistant efﬂux pumps may also pump TIG. In spite of this, TIG
remained effective although resistance to one drug classes increased the
TIG MIC90 by 2-fold, and resistance to 2 classes increased it by 4-fold,
TIG remained active against the great majority (96%) of the multi-drug
resistant Acinetobacter strains at MIC values 2mg/mL. TIG’s in vitro
activity against multi-drug resistant Acinetobacter should prove useful in
therapy of infections caused by such therapeutically challenging strains.
P2053 Evaluation of in vitro activity of tigecycline and ten
comparators against methicillin-resistant Staphylococcus
aureus from 34 countries: TEST Program 2004–2006
R. Badal, S. Bouchillon, M. Hackel, J. Johnson, D. Hoban, B. Johnson,
M. Dowzicky (Schaumburg, Collegeville, US)
Background: Tigecycline (TIG), a member of a new class of
antimicrobials (glycylcyclines), has been shown to have potent expanded
broad spectrum activity against most commonly encountered species
responsible for community and hospital acquired infections. The
T.E.S.T. Program determined the in vitro activity of TIG compared
to amoxicillin-clavulanic acid, piperacillin-tazobactam, levoﬂoxacin,
ceftriaxone, linezolid (LZD), minocycline (MIN), and vancomycin
(VAN), ampicillin, penicillin and imipenem against methicillin-resistant
S. aureus (MRSA) isolates collected from 272 sites in 34 countries
throughout 2004–2006.
Methods: A total of 2,669 clinical isolates of MRSA were identiﬁed to
the species level at each participating site and conﬁrmed by the central
laboratory. Minimum Inhibitory Concentration (MICs) were determined
by the local laboratory using supplied broth microdilution panels and
interpreted according to CLSI guidelines, except for tigecycline, which
used the susceptible breakpoint <0.5mg/mL for S. aureus (including
MRSA) as deﬁned in the FDA approved package insert.
Results: The %S for the study drugs with MRSA activity – TIG, VAN,
LZD, and MIN – was 100, 100, 100, and 97.6 respectively. There were
few signiﬁcant differences among geographic regions, except for lower
activity of MIN in Asia (%S= 80.4) and the Middle East (%S= 13.3)
compared to Europe (97.3%) and North America (99.1%). IMP showed
a broad range of MIC50 results, with North America and Europe at
the low end (0.5 and 2 mg/mL, respectively), and all others 16mg/mL.
TIG inhibited 100% of strains in all regions. MIC50/90 (mg/mL) for TIG,
VAN, LZD, and MIN were 0.12/0.25, 1/1, 2/2, and 0.25/2, respectively.
Conclusions: Global susceptibility patterns of MRSA remain fairly
consistent. TIG was as potent as VAN and LZD, inhibiting 2,669/2,669
(100%) of the MRSA isolates at their respective breakpoints. TIG’s
excellent expanded broad spectrum of activity against MRSA should
make it a very useful drug in treatment of difﬁcult staphylococcal
infections.
P2054 Impact of different FDA and EU breakpoints on bacterial
susceptibility patterns – Analysis of data from the T.E.S.T
Program
R. Badal, S. Bouchillon, B. Johnson, M. Hackel, J. Johnson, D. Hoban,
M. Dowzicky (Schaumburg, Collegeville, US)
Background: The MIC testing methodology recommended by the
Clinical and Laboratory Standards Institute (CLSI) and the European
Committee for Antimicrobial Susceptibility Testing (EUCAST) is nearly
identical, but interpretive MIC breakpoints established by the US FDA,
based on CLSI methods, often differ from those set by EUCAST,
sometimes leading to signiﬁcantly different interpretations of the same
MIC. It is important to understand the impact of these differences when
interpreting susceptibility data reported in the literature. This study
evaluated the impact of discrepant S/I/R breakpoints on susceptibility
data from the global Tigecycline Evaluation Surveillance Trial (T.E.S.T.).
Methods: A total of 48,232 pathogens from 34 countries were identiﬁed
at each site and conﬁrmed at a reference laboratory. MICs were
determined at each site utilising supplied broth microdilution panels and
interpreted according to FDA and EUCAST guidelines.
Results: There were discrepancies for Gram-positive and -negative or-
ganisms with several drugs, but the most signiﬁcant (FDA %S 90%S,
EUCAST <90%) were seen only with the Gram-negative species
summarised in the table.
Organism %S (FDA/EUCAST)
Tigecycline Cefepime Ceftriaxone Meropenem
E. aerogenes – 95.7/87.4 – –
E. cloacae 93.6/88.1 93.5/76.2 – –
E. coli – – 92.3/89.7 –
K. pneumoniae 95.0/88.6 91.3/88.5 – –
K. oxytoca – – 93.1/84.1 – –
S. marcescens 96.8/86.0 – 91.6/81.2 –
A. baumannii – – – 95.3/84.9
Conclusions: Differences between FDA vs. EUCAST MIC interpretive
breakpoints can lead to signiﬁcantly different assessments of an
antimicrobial’s potency vs. various bacterial species. Although the
quantitative differences in %S were usually relatively small, there were
several drug/bug combinations in this analysis for which use of EUCAST
breakpoints caused the %S to fall below 90%. Since 90% susceptibility
is often viewed as the minimum for a drug to be considered useful vs.
a given species of bacteria, it is essential when evaluating reports of a
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drug’s activity to be aware of which interpretive breakpoints were used in
the analysis, and to bear in mind that there can be signiﬁcant differences
when using EUCAST instead of FDA breakpoints.
P2055 The killing of E. coli by tigecycline using the minimum
inhibitory and mutant prevention drug concentration
J. Blondeau, S. Borsos (Saskatoon, CA)
Objective: Tigecycline (TIG) is a new antibacterial agent with low
minimum inhibitory concentration (MIC) and low mutant prevention
concentration (MPC) against clinical isolates of E. coli. We were
interested in determining the rate and extent of killing by Tig using MIC
and MPC drug concentrations against high density inocula of E. coli.
Methods: For MIC testing, 105 cfu/mL of E. coli were exposed to
doubling drug concentration of Tig in Mueller-Hinton (MH) broth and
following incubation under ambient conditions, the lowest concentration
preventing growth was the MIC. For MPC testing, 109 CFUs were
exposed to doubling dilutions of TIG on drug containing MH agar plates
and following incubation for 24−48 hours, the lowest drug concentration
preventing growth was the MPC. For kill experiments, 106 cfu/mL
and 107 cfu/mL were exposed to the measured MIC and MPC drug
concentrations and the reduction in viable cells (log10 and % kill) were
recorded at 30 min, 1, 2, 3, 4, 6, 12 and 24 hours. All experiments were
conducted in triplicate.
Results: For 2 clinical E. coli isolates, MIC values were 0.063mg/L
and MPC values were 1mg/L. When 106 or 107 cfu/mL were exposed
to the MIC drug concentrate, positive growth was seen for the ﬁrst 6
hours of drug exposure; at 106 cfu/mL, a 1.06 log10 reduction (13%
kill) was seen by 12 hours and 1.64 log10 reduction (97.7% kill by 24
hours). Exposure of 106 cfu/mL to the MPC drug concentration yielded
a 0.16 to 0.42 log10 reduction (31−62% kill) by 30 min to 4 hours and
this increased to a 1.16–1.86 log10 reduction (93−98% kill by 12−24
hours). Exposure of 107 cfu/mL to the MPC drug concentration yielded
similar results: 0.13–0.31 log10 reduction (26−51% kill) by 1−4 hours
and 0.71–1.14 log10 reduction (81−99% kill) by 12 hours.
Conclusion: TIG MIC and MPC values were low against E. coli – 0.031
and 1mg/L respectively. Killing using MIC drug concentrations against
higher density inocula was slow and incomplete. Killing was faster
and more complete following exposure to MPC drug concentrations –
51−62% by 4 hours and 81−99% by 12 hours. The low MIC and MPC
values suggest that TIG is less likely to select for resistant E. coli and
dosing to achieve MPC results in the efﬁcient killing of high density
bacterial burdens.
P2056 Determination of the minimum inhibitory concentration
and mutant prevention concentration (MPC) of tigecycline
against clinical isolates of Streptococcus pneumoniae;
impact of media on MPC results
C. Hesje, S. Borsos, J. Blondeau (Saskatoon, CA)
Objective: Tigecycline is the ﬁrst of a new class of compound
– glycylcyclines – with reported potent in vitro activity against
penicillin-susceptible and multi-drug resistant strains of Streptococcus
pneumoniae (SP). The mutant prevention concentration (MPC) deﬁnes
the antimicrobial drug concentration threshold that blocks the growth of
resistant bacterial sub-populations that may be present in high density
bacterial populations such as those present in infection. We measured the
MIC and MPC values for tigecycline against clinical isolates of SP and
compared MPC results on blood agar versus solidifying Todd-Hewett
broth (THB).
Methods: For MIC testing, the recommended Clinical and Laboratory
Standards Institute procedure was followed utilising 105 cfu/mL tested
against doubling drug dilutions in THB with incubation at 35−37 degrees
Celsius in 5% CO2 for 18−24 hours. For MPC testing, 109 CFUs were
added to drug containing agar plates: 1) tryptic soy agar containing 5%
sheep red blood cells (BA), 2) THB solidiﬁed with 1.5% agar. Inoculated
plates were incubated as described for 24−48 hours and screened for
growth. The lowest drug concentration preventing growth was the MIC
or MPC depending on method.
Results: For 140 SP isolates (121/86.4% penicillin susceptible; 19/13.6%
penicillin non-susceptible), MIC50, MIC90 and MIC range values were
0.016mg/L, 0.016mg/L and 0.008–0.31mg/L respectively and these
MIC values were not inﬂuenced by SP susceptibility or resistance to
penicillin nor for isolates recovered from blood or respiratory tract
specimens. MPC50, MPC90 and MPC values were 8mg/L, 16mg/L and
1−16mg/L when tested on BA. MPC testing on solidiﬁed THB yielded
MPC50, MPC90 and MPC range values of 0.063mg/L, 0.12mg/L and
0.063–0.25mg/L.
Conclusion: Tigecycline was highly active in vitro against SP with MICs
0.031mg/L and not different for strains of SP resistant to penicillin.
MPC values ranged from 1−16mg/L on BA but we were substantially
lower on solidiﬁed THB – 0.063–0.25mg/L. This data suggests that SP
testing of tigecycline on BA yields falsely elevated values. Solidiﬁed
THB appears to be a more suitable media for SP MPC testing against
tigecycline. Tigecycline appears to have a low propensity to select for
resistance.
Pharmacodynamics and untoward effects of
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P2057 Susceptibility of various b-lactams to the inoculum effect
V.H. Tam, K.R. Ledesma, K.T. Chang, T.Y. Wang, J.P. Quinn (Houston,
Chicago, US)
Objective: Escherichia coli (EC) is part of the human gastrointestinal
ﬂora and a common pathogen implicated in intra-abdominal infections
such as perforated appendicitis and peritonitis. A heavy bacterial burden
is anticipated in this type of infection and the clinical utility of the
b-lactams may be limited by the inoculum effect. We compared the
bactericidal activity of various b-lactam sub-classes against a standard
and heavy inoculum of EC.
Methods: A wild-type (EC ATCC 25922) and a clinical ESBL-
producing (TEM-26) strain were used. Time-kill studies were performed
using approximately 105 and 108 cfu/mL at baseline. A clinically
achievable concentration range of piperacillin/tazobactam (PIPT),
ceftriaxone (CRO) and ertapenem (ERT) were used, and the drug
concentrations were normalised to multiples of MIC. Serial samples
were obtained in duplicate over 24 hours; viable bacterial burden was
determined by quantitative culture to examine the impact of a higher
inoculum on the bactericidal activity of various b-lactams.
Results: MIC of the wild type strain to PIPT, CRO and ERT were
2/4, 0.125 and 0.008mg/L; for TEM-26 the respective MIC values were
16/4, 64 and 0.06mg/L. All 3 b-lactams demonstrated signiﬁcant killing
with the standard inoculum (except for CRO against TEM-26). However,
with the higher inoculum, the activity of PIPT was drastically reduced
in both strains. CRO remained reasonably bactericidal against the wild
type strain only (at 16×MIC). ERT was the least affected by the
inoculum effect in both strains; bactericidal activity was retained with
concentrations 4−8×MIC.
Conclusion: Our results suggest that different b-lactam sub-classes have
a distinct killing proﬁle against a dense EC population. ERT appeared to
be the least susceptible to the inoculum effect, which might be more
efﬁcacious than other non-carbapenem b-lactams in the treatment of
intra-abdominal infections. Comparative in-vivo/clinical investigations
are warranted to validate our ﬁndings.
P2058 Extracellular and intracellular activities of quinupristin-
dalfopristin (Synercid) against Staphylococcus aureus, with
different resistant phenotypes (MSSA, MRSA, VISA)
P. Baudoux, Y. Glupczynski, P. Tulkens, F. Van Bambeke (Brussels, BE)
Objectives: S. aureus survives and thrives in mild acidic pH
environments, such as found intracellularly in phagolysosomes. Synercid,
a semi-synthetic streptogramin antibiotic composed of quinupristin
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and dalfopristin (30:70 w/w ratio), displays a synergistic antibacterial
activity against S. aureus and other Gram-positive bacteria in vitro.
Synercid also displays activity against S. aureus phagocytised by murine
J774 macrophages (JAC, 1992; 30 Suppl A:107−15), but this has
been examined after short term incubation (2 h) and at a single ﬁxed
concentration (10×MIC) only. Our objective was to assess the activity
of Synercid in a newly developed model of S. aureus-infected human
THP1 macrophages that allows longer exposure periods and a detailed
analysis of dose-responses for extracellular and intracellular activities
(AAC 2006; 50:841–851), and using strains of S. aureus with resistance
phenotypes of clinical signiﬁcance.
Methods: We used an erythromycin-susceptible MSSA strain (ATCC
25923) and two erythromycin-resistant (MLSB) MRSA (ATCC 33591)
and VISA (NRS 126) strains. MICs were determined by arithmetic
dilution in MH Broth adjusted to pH 7.4 and 5.4. Change in CFU,
compared to controls, were examined for bacteria incubated in MH
broth (extracelllar activity) or phagocytised by THP-1 macrophages
(intracellular activity) after 24 h exposure to concentrations from 0.01
to 100× the MIC. Key microbiological and pharmacological parameters
(static concentration [Cs]; concentration yielding 50% of the maximal
effect [EC50]; and maximal effect for drug concentration at inﬁnity
[Emax]) were determined by non-linear regression (Hill equation; slope
factor = 1).
Results: Results are shown in the Table.
Strain MIC at pH Extracellular
activitya
Intracellular
activitya
7.4 5.4 EC50 Cs Emax EC50 Cs Emax
MSSA 0.45 0.40 0.58 0.68 −2.96 3.95 0.43 −3.45
MRSA (MLSB) 0.40 0.40 0.40 0.49 −2.94 0.71 0.16 −1.40
VISA (MLSB) 0.30 0.30 0.31 0.43 −2.36 0.22 0.27 −1.19
aEC50 and Cs in mg/L; Emax is change in CFU (log10) from the original
inoculum (~106 cfu per mL [extracell.] or per mg cell protein [intracell.]).
Conclusion: Synercid (a) shows no increase in MIC at acid pH;
(b) shows comparable activities against extracellular erythromycin-
susceptible MSSA and erythromycin-resistant MRSA and erythromycin-
resistant VISA; (c) shows also activity against their intracellular forms
(but a bactericidal effect [>3 log] is only observed with the erythromycin-
susceptible MSSA).
P2059 Effect of human albumin physiological concentrations
on the in vitro bactericidal activity of daptomycin vs.
vancomycin Cmax concentrations against Gram-positive
isolates exhibiting the main resistance phenotypes
F. Caﬁni, L. Aguilar, N. Gonza´lez, M. Gime´nez, M. Torrico, L. Alou,
D. Sevillano, P. Vallejo, J. Prieto (Madrid, ES)
Objectives: To study the effect of the presence of physiological
concentrations of human albumin on the Time needed to obtain
bactericidal activity (3 log10 – 99.9% – initial inocula reduction) by
concentrations similar to the Cmax obtained in serum after i.v. 4mg/kg
of daptomycin and 1g vancomycin, against quinolone-susceptible (QS)
and -resistant (QR) S. pneumoniae (SP), methicillin-susceptible (MS),
-resistant (MR), and heterogeneous vancomycin-intermediate (hVI)
S. aureus (SA), and vancomycin-susceptible (VS) and -resistant (VR)
E. faecium (E).
Methods: Killing curves were performed with ﬁnal inocula of approx.
107 cfu/mL, and a ﬁnal concentration of daptomycin or vancomycin of
56mg/mL and 25.5mg/mL, respectively in different media: a) Mueller-
Hinton broth with 5% lysed horse blood for S. pneumoniae or without
blood supplement for S. aureus and E. faecium (Cmax-MH), and
b) MH broth with 4 g/dl human albumin (Cmax-HAlb). In parallel,
killing curves with daptomycin or vancomycin concentrations (4.7
and 16.1mg/mL, respectively) corresponding to free-drug Cmax were
performed in Mueller-Hinton broth.
Results: MICs of daptomycin and vancomycin and Time (h) to obtain
bactericidal activity are shown in the Table.
Time to bacterial activitya (h)
Strains: Q
S
S
P
Q
R
S
P
Q
R
S
P
M
S
S
A
M
R
S
A
hV
I
V
S
E
V
R
E
DAP MIC (mg/mL) 0.06 0.06 0.06 0.25 0.5 1 2 4
Cmax-MH 1 1 1 1 2 2 2 2
Cmax-HAIb 2 3 3 3 2 4 8 24
8.3% Cmax 2 2 3 3 2 4 – –
VAN MIC (mg/mL) 0.5 0.5 0.25 1 1 4 1 64
Cmax-MH 10 10 24 24 24 – – –
Cmax-HAIb 10 12 24 24 24 – – –
8.3% Cmax 10 24 24 24 24 – – –
a– no bactericidal activity achieved.
Conclusions: Daptomycin Cmax, despite its high protein binding,
exhibited rapid bactericidal activity (time  2 h) against all strains tested
regardless resistance phenotype, that is delayed in the presence of human
albumin. In contrast, vancomycin Cmax exhibited slow bactericidal
activity (obtained generally at 24 h) against SP, MSSA and MRSA,
but never against hVI, VSE and VRE. Theoretical extrapolation of
active drug from total drug by using the protein binding rate seems
a non accurate method to study antibacterial activity considering the
implications of protein binding.
P2060 Effects of cefditoren, cefuroxime, cefaclor and ceﬁxime on
the competitive growth of Streptococcus pneumoniae, as a
model approach to selection of populations
F. Caﬁni, M. Torrico, N. Gonzalez, O. Echevarria, D. Sevillano,
M.J. Gimenez, L. Alou, L. Aguilar, P. Coronel, M. Gimeno, J. Prieto
(Madrid, ES)
Objectives: To explore how oral cephalosporins inﬂuence the evolution
of S. pneumoniae populations sharing the same ecological niche.
Methods: A computerised pharmacodynamic model (J Antimicrob
Chemother 2006;58:794–801) simulating physiological concentrations
obtained after 400mg b.i.d. cefditoren (CDN), 500mg b.i.d. cefuroxime
(CXM), 500mg t.i.d. cefaclor (CEC), and 400mg o.d. ceﬁxime
(CFM) was used to investigate its effect on a mixed culture of four
S. pneumoniae serotypes (Ser) as an approach to ecology of population
dynamics. MICs (mg/mL) of CDN, CXM, CEC and CFM were: 0.015,
0.03, 0.25, and 0.5 for Ser4 and Ser19A; 0.5, 4, >8 and >8 for Ser19F;
and 1, 4, >8 and >8 for Ser23F, respectively. Initial mixed inocula (time
0) of 5×106 to 107 cfu/mL, including similar percentages of each Ser
were used.
Results: Mean colony counts in antibiotic-free plates (whole pneu-
mococcal population) increased (from 0 to 12 h) from log10 7.0 to
6.3 in drug-free simulations (control), from log10 6.6 to 3.6 in CDN
simulations, from log10 6.6 to 8.0 in CXM simulations, from log10 7.0
to 7.2 in CEC simulations, and from log10 6.7 to 7.4 in CFM simulations.
At 12 h of control drug-free experiments, the dominant population was
Ser4 (70.0%). The small ﬁnal population after CDN simulations included
48% Ser23F and 20% Ser19F. With all other compounds, the ﬁnal
population was higher than initial inocula, and corresponded to 90%
Ser19F after CXM simulations, 61% Ser19F and 35% Ser23F after CEC
simulations, and 96% Ser19F after CFM simulations.
Conclusion: Strain distribution in antibiotic-free environment depends
on bacterial ﬁtness in mono- and multi-strain niches. The selective
pressures of antimicrobial regimens eradicate some populations and
unmask minor populations, thus redistributing the whole population.
CDN was the only cephalosporin showing bactericidal activity (3 log10
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reduction of initial inocula) at 12 h of the whole initial population, with a
small remaining population mainly composed by Ser23F. All other oral
cephalosporins selected populations higher than initial inocula mainly
composed by Ser19F.
P2061 Bactericidal activity of simulated serum concentrations of
bid regimens of 400mg cefditoren and 2000/125mg amox-
icillin/clavunanic acid against ampicillin susceptible and
resistant H. inﬂuenzae: an in vitro pharmacodynamic model
N. Gonzalez, O. Echeverria, M. Torrico, D. Sevillano, M. Gimenez,
L. Alou, L. Aguilar, P. Coronel, J. Prieto (Madrid, ES)
Objective: To explore the serum bactericidal activity over 48 h of
simulated serum concentrations obtained after bid regimens of 400mg
cefditoren (CDN) and 2000/125mg amoxicillin/clavulanic acid (AMC)
against ampicillin (AMP) susceptible and resistant H. inﬂuenzae.
Methods: Three strains were used: a) AMP-susceptible b-lactamase
negative strain (AMP-S) with AMC and CDN MICs of 2 and
0.015mg/mL; b) b-lactamase negative AMP-resistant strain (BLNAR)
with AMC and CDN MICs of 8 and 0.12mg/mL; and c) b-lactamase
positive AMC-resistant strain (BLPACR) with AMC and CDN MICs of
8 and 0.06mg/mL. The changing free and total antibiotic concentrations
were simulated over 48 h (4 doses) in a computerised model based on a
two-compartment model described previously (J Antimicrob Chemother
2004;54:1148−51). Initial inocula was approx. 108 cfu/mL. Antibiotic
concentrations and colony counts were determined (in triplicate) at 0, 1,
2, 3, 4, 6, 8, 10, 12, 24, 25, 26, 27, 28, 30, 32, 34, 36 and 48 h. Limit
of detection was 50 cfu/mL.
Results: Mean differences between log10 cfu/mL initial inocula and
log10 cfu/mL at 24 h and 48 h sampling times are shown in the Table.
Strain 24 h 48 h
CDN AMC CDN AMC
Free Total Free Total Free Total Free Total
AMP S >6.3* >6.3** 4.1 4.3 >6.3* >6.3** 4.3 4.9
BLNAR 3.7 5.0** 3.0 3.1 3.7 5.5** 3.2 3.5
BLPACR 4.5* >6.3** 0.1 0.8 4.6* >6.3** 0.8 1.1
*P< 0.001 free CDN vs. free AMC; **P< 0.001 total CDN vs. total
AMC.
Conclusions: 400mg CDN total drug serum concentrations proﬁle
exhibited at 24 and 48 h signiﬁcantly higher initial inocula reduction
than 2000/125mg AMC against the three strains tested regardless
the resistance phenotype. CDN free-drug concentrations exhibited also
higher initial inocula reduction than AMC against the three strains, with
statistically signiﬁcant reductions against the BLPACR phenotype and
even against the AMP-S phenotype.
P2062 Bacterial strain-independent anti-staphylococcal effects
of telavancin in an in vitro dynamic model that simulates
multiple-dose pharmacokinetics in humans
S. Zinner, E. Strukova, M. Smirnova, I. Lubenko, S. Vostrov, A. Firsov
(Cambridge, US; Moscow, RU)
Objective: Telavancin is a lipoglycopeptide antibiotic with potent,
rapidly bactericidal activity against Gram-positive bacteria including
methicillin-susceptible and methicillin-resistant strains of Staphylococ-
cus aureus. To test the hypothesis of its bacterial strain-independent
pharmacodynamics, telavancin was studied with two strains of S. aureus.
Methods: A methicillin-resistant strain of S. aureus ATCC 43300 (MIC
0.25mg/L) and a glycopeptide-intermediate strain of S. aureus (GISA)
Mu-50 (MIC 0.5mg/L) at a starting inoculum of 8 log CFU/mL were
exposed to telavancin administered daily for ﬁve consecutive days.
Mono-exponential concentration decays of telavancin with a half-life of
8 h were simulated over a wide range of ratios of the 24-h area under the
curve (AUC) to MIC: from 30−50 to 1200 h. Depending on the simulated
AUC/MICs, specimens were sampled from the central compartment of
the dynamic model for 6−8 days. The cumulative antimicrobial effect
was determined as an area between the level corresponding to the starting
inoculum and the time-kill curve (ABBC) from time zero to 144 h.
Results: Killing kinetics of S. aureus ATCC 43300 and GISA Mu-
50 exposed to telavancin were similar: initial reduction of the starting
inoculum was followed by bacterial regrowth. An increase in the
AUC/MIC ratio was accompanied by greater killing and delay in
bacterial regrowth. However, the rate of initial killing did not correlate
with the simulated AUC/MIC ratio. The ABBC versus log AUC/MIC
plots were linear and virtually superimposed for both organisms. A linear
regression ﬁts the combined data with r2 of 0.92.
Conclusion: These ﬁndings suggest a bacterial strain-independent
pattern of telavancin pharmacodynamics with staphylococci. The
established AUC/MIC-response relationship allows clinically relevant
prediction of telavancin effects on a hypothetical strain of S. aureus
with MICs values equal to previously reported MIC50 or MIC90 values.
P2063 Dose ranging and fractionation of moxiﬂoxacin against
Stenotrophomonas maltophilia using an in vitro
pharmacodynamic model
D. Sevillano, L. Alou, F. Caﬁni, M. Lo´pez, N. Gonza´lez, O. Echeverrı´a,
M. Torrico, J. Prieto, M. Go´mez-Lus (Madrid, ES)
Objectives: To explore the antibacterial activity of higher total daily
doses of moxiﬂoxacin (MXF) against S. maltophilia with or without
expression of SmeABC or SmeDEF efﬂux pump systems.
Methods: Eight PFGE characterised isolates of S. maltophilia (MIC to
MXF 0.03−8mg/L) without QRDR mutations in gyrA and parC were
exposed to MXF 200mg o.d., MXF 400mg o.d., MXF 400mg b.i.d.,
and MXF 800mg o.d. (AUC0−24/MIC ratio of 4.4–1186.3 h) using
a two-compartment in vitro pharmacodynamic model with peripheral
units containing a starting inoculum of 1−2×109 CFU of each strain.
A sigmoid dose-response model was used to estimate the required
AUC0−24/MIC to achieve a 50% (ED50) and 80% (ED80) of maximum
antibacterial effect at 24 hours. Concentrations of MXF were determined
by bioassay and were closed to target values.
Results: Only the strain with MIC to MXF of 0.03 (no SmeABC
and SmeDEF expression) was eradicated at MXF 200mg. The three
strains with MIC to MXF of 0.12−0.5mg/L (SmeDEF expression) was
related to regrowth after MXF 400mg administration but eradicated
after MOX 400mg b.i.d. or 800mg o.d. These doses were more active
(2.7−4.3 log cfu/mL reduction) than MXF 400mg o.d. (0.6−1.2 log
cfu/mL reduction) (p< 0.05) against strains with MIC to MXF of
1mg/L (SmeDEF expression) or MIC to MXF of 2mg/L (simultaneous
SmeABC and SmeDEF expression) at 24 h. The activity of the MXF 400
b.i.d. regimen was higher than MXF 800 o.d. against strain with MIC
to MXF >2mg/L (1.7−2.4 vs. 0.7−0.8 log cfu/mL reduction). Sigmoid
relationship between AUC/MIC and measurement of the antibacterial
effect was more adequately described using AUBKC (r2 = 0.95). Values
associated with ED50/ED80 at 24 h were 24/87 h.
Conclusions: Higher total daily doses of moxiﬂoxacin (400mg b.i.d.
and 800mg o.d.) than the usual moxiﬂoxacin clinical dose (400mg
o.d.) improve signiﬁcantly the antimicrobial activity against strains of
S. maltophilia with MIC to MXF  2mg/L independently of the efﬂux
pump expression.
P2064 Evaluation of daptomycin activity against Staphylococcus
aureus following vancomycin exposure in an in vitro phar-
macodynamic model with simulated endocardial vegetations
W. Rose, M. Rybak, S. Leonard, G. Sakoulas, G. Kaatz, M. Zervos,
A. Sheth, C. Carpenter (Detroit, Valhalla, Royal Oak, US)
Objective: Staphylococcus aureus (SA) remains clinically problematic
due to multidrug resistance. Vancomycin (V) has been the primary
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therapy though its efﬁcacy has recently come into question. Daptomycin
(D) is bactericidal against SA and often used following V failure. The
objective of this study was to use an in vitro pharmacodynamic model
with simulated endocardial vegetations (IVPD-SEV) model to evaluate
if V exposure affects D activity.
Methods: 5 clinical isolates were evaluated. 4 isolates (3 MRSA, 1
MSSA) were reported to demonstrate D non-susceptibility following
V exposure and 1 MRSA that was not exposed to V but became D
non-susceptible after suboptimal dosing of D. All pre-V isolates were
susceptible to D with MICs of 0.125−0.5mg/L. Two simulations were
evaluated: (1) 4 d of V 1 g q 12 h (Cmax 30mg/L, Cmin 10mg/L)
followed by 4 d of D 6mg/kg q 24 h, and (2) 8 d of D6 q 24 h.
Time to 99% kill (T99) was calculated for each regimen. Changes in
MIC over 8 d were evaluated using D 1.5, 2 and 3×MIC screening
plates. D Etest MICs were performed for all model samples including
any growth on screening plates to conﬁrm changes in MIC. If changes
in MIC were demonstrated, model experiments of no V treatment × 4 d
(growth control) were followed by D6 q 24 h × 4 d to conﬁrm a possible
relationship to V. Additional regimens of V× 4 d followed by D 10mg/kg
q 24 h × 4 d and D10× 8 d were also analysed.
Results: Pre-exposure MICs for V/D were 2/0.25 for MRSA isolates
and 1/0.125 for the MSSA. The MSSA demonstrated D heteroresistance
at baseline; the MRSA isolates did not. No change in MIC was detected
for any MRSA isolate treated with D following V for any regimen tested.
T99 was 1.39–11.36 h for D6 regimens without V exposure and 3.43–
9.41 h following V. MIC elevations to D> 1mg/L for the MSSA isolate
were noted after 96 h of D6 following V but not when D6 was used alone
during the 8 d simulation. Increases in MIC remained stable to serial
passage for 5 d. D maintained bactericidal activity against the MSSA
isolate even during the post V period with T99 achieved at 9.46–9.91 h.
No resistance was detected when D6 followed 4 d of growth control,
D10 post V, or D10 alone × 8 d.
Conclusion: Exposure to V prior to D therapy resulted in no change
in MIC for all MRSA strains. The MSSA isolate demonstrated MIC
changes post V; however, effective D kill was maintained. The pre-
existing heteroresistance to D with the MSSA isolate suggests that
the exposure to V may not have induced this phenomenon. Further
investigation is warranted to conﬁrm these results.
P2065 Evaluation of various ﬂuoroquinolones against
S. pneumoniae with 1st step mutations of parC
J. Chin, M. Rybak, G. Kaatz (Detroit, US)
Objectives: To compare the resistance (R) potential, AUC/MIC
breakpoints, and activity of moxiﬂoxacin (MOX), gemiﬂoxacin (GEM),
levoﬂoxacin (LEV) and gatiﬂoxacin (GAT) against 1st Step Mutations
of parC (SP1), which have been shown in previous studies to be
predisposed to 2nd-step gyrA mutations (MUT) upon re-exposure to
older ﬂuoroquinolones (FQ) leading to high-level R.
Methods: A clinical strain of SP1 (KD2138) was evaluated in an
in vitro PK/PD model over 96 hours with a starting inoculum of
107 CFU/mL. MOX, GEM, LEV, and GAT were dosed to simulate from
50–800, 60–640, 500–1500, and 100–800mg QD with their respective
fAUC/MIC exposures. Samples were drawn from models to determine
emergence/absence of further R. In the event of R, dose and fAUC/MIC
exposure were increased until R was prevented or a dose was reached
that was not clinically feasible. MICs for resistant organisms (RO)
were determined by Etest or microdilution according to CLSI. ROs
with elevated MICs post FQ-exposure underwent PCR ampliﬁcation of
the gyrA quinolone resistance-determining region for DNA sequence
analysis.
Results: Pre-exposure MICs for LEV, MOX, GEM, & GAT were 2,
0.5, 0.125, & 0.5mg/mL. R occurred with MICs up to 128 mg/mL
from LEV 500–1500mg QD (fAUC/MIC of 21−62mg/mL/h). ROs
emerged as early as 24 h and beyond with a delay in R in the higher
fAUC/MIC (at 96 h with 62mg/mL/h). This was also consistent with
GAT 100–400mg QD (fAUC/MIC of 12−41mg/mL/h) with MICs up
to 32mg/mL. R also occurred with GEM 150–320mg QD (fAUC/MIC
18−32mg/mL/h), resulting in MIC increases at 1−2mg/mL. However,
R was prevented at 2X the therapeutic dose with GEM 640mg
QD (fAUC/MIC of 64mg/mL/h) & GAT 800mg QD (fAUC/MIC of
82mg/mL/h). In addition, ROs were only derived from MOX 200mg QD
(fAUC/MIC of 24mg/mL/h) with MICs up to 32mg/mL, but not from
the therapeutic dose of MOX 400mg QD (fAUC/MIC of 48mg/mL/h).
All MIC increases  4-fold were associated with efﬂux. MIC elevations
32mg/mL were associated with the following MUTs in gyrA: S81L,
S81F, and E85A.
Conclusions: Additional R resulting in gyrA MUTs in SP1 occurred
with LEV and GAT at therapeutic fAUC/MIC but not with MOX.
Changes in MICs to GEM were observed, but this was attributed to
efﬂux, not to gyrA mutations.
P2066 Inﬂuence of newer ﬂuoroquinolones on phagocytosis and
killing of Candida albicans by human polymorphonuclear
neutrophils
C. Mo¨rler, T. Gru¨ger, K. Brandenburg, S. Nidermajer, N. Schnitzler,
R. Horre`, J. Zu¨ndorf (Bonn, DE)
Objectives: The function of the Polymorphonuclear Neutrophils
(PMN) is of high relevance for the prognosis of antibiotic treated
patients. Especially phagocytosis and intracellular killing of pathogenic
microorganisms have large impact on the outcome of infections. Many
antiinfectives have been shown to inﬂuence the function of these cells.
The aim of this project was to achieve more detailed information about
the inﬂuence on phagocytosis and intracellular killing of pathogenic
microorganisms such as Candida albicans by newer ﬂuoroquinolones.
Methods: We analysed the effect of several ﬂuoroquinolones on
phagocytosis and killing of C. albicans by human PMN. C. albicans was
chosen as pathogen for its naturally high resistance to ﬂuoroquinolones
thereby excluding direct inﬂuence of the substances tested on the vitality
of the microorganism.
Whole blood samples from healthy volunteers were incubated with
the ﬂuoroquinolones in concentrations ranging from 0.5 mg/mL up to
1500mg/mL and compared to a drug-free control. Fluorescent-labeled
C. albicans cells were then added in a C. albicans/PMN ratio of at least
2.5:1. Phagocytosis was stopped after incubation of 5, 15, 30 and 60
minutes and the samples were measured by ﬂow cytometry.
Intracellular Killing of C. albicans was analysed after phagocytosis (4 h)
by plate counting the washed probes.
Results: Tested ﬂuoroquinolones in clinical relevant concentrations
(0.5, 5.0, and 100mg/mL) did not have signiﬁcant inﬂuence on
phagocytosis and killing of C. albicans by human PMN. In contrast
higher concentrations (1500mg/mL) of some newer ﬂuoroquinolones do
have negative impact on phagocytosis without inﬂuencing viability of
PMNs.
Conclusion: Newer ﬂuoroquinolones in clinical relevant concentrations
do not affect phagocytosis and killing of Candida albicans. Thus,
antiinfective therapy with newer ﬂuoroquinolones seems to have no
impact on the main human defence mechanism against the opportunistic
pathogenic fungus C. albicans.
P2067 Ciproﬂoxacin and doxorubicin are substrates of different
multidrug resistance-related proteins efﬂux transporters in
J774 macrophages
F. Clesse, M. Mingeot-Leclercq, P. Tulkens, F. Van Bambeke (Brussels,
BE)
Objectives: Ciproﬂoxacin (CIP) and doxorubicin (DOX) are both
substrates of the Multidrug Resistance-related Proteins efﬂux trans-
porters (MRP), a subfamily of the ATP-Binding Cassette transporters
(ABC) in eukaryotic cells. This contributes to a reduction of their
cellular accumulation, and, therefore, of their intracellular activity (Int J
Cancer. 2001;93:107−13; J Antimicrob Chemother. 2003;51:1167−73).
Our objective was to determine whether CIP and DOX could share the
same MRP transporter in macrophages since this could be the basis
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of potential, unanticipated drug interactions in cancer patients receiving
both drugs either simultaneously (by direct competition for transport) or
in succession (trough drug-induced overexpression of the transporter).
Methods: We used J774 macrophages, a cell line that spontaneously
expel CIP (Antimicrob Agents Chemother. 2004;48:2673−82; wild-type
cells) and a cell line derived thereof by continuous exposure to CIP
(CIP-resistant cells) and which overexpresses the corresponding MRP
transporter (Antimicrob Agents Chemother. 2006;50:1689−95). Cells
were incubated with CIP or DOX alone, or in competition with each
other, or in the presence of probenecid (PB), a non-speciﬁc inhibitor
of MRP transporters. Cell-associated CIP and DOX were measured by
ﬂuorimetry and their accumulation recorded as cellular to extracellular
concentration ratios (Cc/Ce).
Results: In wild-type cells, (i) PB increased both CIP and DOX Cc/Ce
but not to the same extent; (ii) excess of CIP but not of DOX caused an
increase in CIP Cc/Ce; (iii) excess of DOX had no effect on CIP and only
a marginal effect on DOX Cc/Ce. In CIP-resistant cells, accumulation
of CIP was markedly reduced compared to wild type cells (and only
partially restored by PB), but not that of DOX (with PB exerting a
similar effect to that observed in wild-type cells).
Condition Cc/Ce (% control in wild-type cells)
wild-type cells CIP-resistant cells
CIP DOX CIP DOX
Control (drug conc. 50mM) 100±1 100±8 10±2* 98±10ns
+ PB (5mM) 335±24* 178±41* 225±41* 195±16ns
+ DOX (total conc. 75 mMa) 101±2ns 135±16*
+ ClP (total conc. 500 mMa) 494±43* 105±6ns
aHighest testable conc. (limit of solubility).
Statistical analysis: (i) wild-type cells: differences with control values;
(ii) CIP-resistant cells: differences with the corresponding values in wild-
type cells; *p< 0.05, nsnon-signiﬁcant.
Conclusions: CIP and DOX are substrates of distinct MRP efﬂux
transporters in J774 cells. Drug interactions related to competition for
transport or overexpression of CIP transporter are, therefore, unlikely.
P2068 Adverse reactions to imipenem therapy in adult patients
with sepsis
D. Ciubotariu, C. Ghiciuc, V. Luca, M. Nechifor (Iasi, RO)
Objective: To assess the incidence of side and adverse effects of
imipenem treatment (alone or in associations with other antibacterial
drugs) in adult patients with sepsis.
Method: The study was performed on 83 cases (48 male and 35 female,
mean age 39.06 years) diagnosed with sepsis and hospitalised in the
Infectious Diseases Hospital Iasi, Romania between 1999 and 2006,
treated with imipenem-cilastatin (Tienam®). Only patients receiving
therapy for at least 7 days were included. Mean therapy duration was
10.78 days and mean doses of imipenem were 0.5g tid. 52 patients
(62.65% of total cases) received imipenem as single antibacterial therapy
and 31 cases (37.34% of total cases) received imipenem associated with
other antibacterial drugs, most frequently used being ﬂuoroquinolones –
14 cases and aminoglycosides – 9 cases. Sepsis aetiological agent was
identiﬁed in 67.46% of cases (56 patients), most frequently encountered
bacteria being Staphylococcus aureus (16 patients, 19.28% cases),
Pseudomonas aeruginosa (5 patients, 6.02% cases), Staphylococcus
epidermidis and Klebsiella penumoniae (4 patients, 4.81% cases).
All identiﬁed bacteria were sensitive to imipenem. Adverse reactions
were evaluated both by clinical and paraclinical evaluation (main
haematological and bio-chemical parameters).
Results: Adverse reactions occurred in 23 patients (27.71% of cases),
most patients experiencing more than 1 adverse effect. Most frequently
encountered reactions were vomiting (15 patients, 18.07% of cases),
abdominal pain and diarrhoea (13 patients, 15.66% of cases), transient
AST elevations (11 cases, 13.25% of cases), eosinophilia (6 patients,
7.22% of cases), coetaneous erythema (4 patients, 4.81% of cases) and
convulsions (2 patients, 2.4% of cases). In patient treated with imipenem
alone, the incidence of digestive effects (nausea and diarrhoea) was
lower compared to the group treated with imipenem + ﬂuoroquinolones:
16.07% vs. 35.71%, p< 0.01). In 55 patients (66.26% of cases) a
transient black colouring of the teeth occurred. None of patients died
due to adverse effects of imipenem.
Conclusions: In patients receiving only imipenem, the incidence of
adverse effects was 18.07%, almost the same as that reported by Sanz
et al., 2005 and other authors (22%). Association of imipenem with
ﬂuoroquinolones signiﬁcantly increases the risk of adverse reactions.
Septic state does not seem to signiﬁcantly modify the incidence of
imipenem adverse reactions.
P2069 Relationship of plasma concentration and changes in the
QTc interval in hospitalised patients receiving intravenous
moxiﬂoxacin for the treatment of community-acquired
pneumonia
M. le Berre, P. Arvis, H. Stass, S. Choudhri (Puteaux, FR; Wuppertal,
DE; West Haven, US)
Background: It is well documented that moxiﬂoxacin can prolong the
QTc interval in some patients, although not to a clinically relevant
degree. In Phase I studies, the magnitude of QTc prolongation showed a
linear correlation with plasma moxiﬂoxacin concentration, although with
high variability. This analysis was designed to assess the relationship
between plasma concentrations and changes in QTc in hospitalised
patients with severe community-acquired pneumonia (CAP) requiring
intravenous (IV) therapy.
Methods: All patients included in this analysis had CAP with a
pneumonia severity index (PSI) Class of III to V and received IV
moxiﬂoxacin 400mg (infused over 60 minutes) once daily. In all patients,
3 standard 12-lead ECG measurements were obtained within 6 hours
prior to ﬁrst infusion, within 30 minutes after the ﬁrst infusion (day
1) and within 30 minutes after the third infusion (day 3). Plasma
moxiﬂoxacin concentrations were determined concomitantly using a
HPLC validated method.
Results: 217 moxiﬂoxacin-treated patients were valid for the analysis
of QTcB changes between baseline and day 1 and 163 patients for the
analysis between baseline and day 3. Mean QTcB (±SD) changes and
the concentration effect relationship for the day 1 and day 3 groups are
shown in the Table.
Group Mean DQTcB Concentration effect relationship
(ms, ±SD)a Slope [s] r2 P
Day 1 10.9±20.8 −0.0001 0.0001 0.88
Day 3 8.5±27.9 +0.0014 0.0134 0.15
aQT interval corrected for heart rate using Bazett’s formula.
Conclusions: The QTcB changes observed were similar to those
observed in previous CAP studies. There was no signiﬁcant correlation
between changes in QTcB and plasma moxiﬂoxacin concentrations.
P2070 DNA characteristics of male generative cells during
treatment of urogenital chlamydiasis with tetracyclines,
macrolides and ﬂuoquinolones
A.G. Zakharenka (Vitebsk, BY)
Objectives: To evaluate the inﬂuence of tetracyclines, macrolides and
ﬂuoquinolones on chromatingeterogenic test (CT) results in young male
patients with urogenital chlamidiasis.
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Methods: 99 male patients (20−25 years old) with veriﬁed non-
complicated urogenital chlamidiasis without initial changes in sperm
characteristics were randomly treated with doxycycline (0.1 g twice a
day 7 days), or azytromycine (1.0 g once), or levoﬂoxacine (0.5 f once a
day 7 days). CT was performed before treatment, immediately after the
treatment course ending and after 3 and 6 months.
Results: Before treatment the mean CT value was 22.3±4.6% (normal
level is up to 30%). Immediately after treatment, this parameter was
56.9±3.2% in doxycycline group, 29.2±2.1% in azytromycine group and
29.1±1.5% in levoﬂoxacine group. In 3 months, the mean CT values in
these groups were 39.6±4.2%, 26.8±3.2% and 26.3±4.2%, respectively.
In 6 months after the ending of a treatment course the mean CT values
were 35.7±3.1% (after doxycycline), 21.3±1.5% (after azytromycine)
and 23.4±3.2% (after levoﬂoxacine).
Conclusion: The data obtained permit to conclude that azytromycine
and levoﬂoxacine have demonstrated the low level of toxicity to male
generative cells and can be the drugs of choice for the treatment
of urogenital chlamidiasis in young male patients. Doxycycline was
characterised by the high level of male generative cells damage and
therefore this fact should be considered during determination of the
treatment strategy of this disease in this special population.
P2071 Characteristics of DNA condition from male generative
cells under doxycycline and macrolides
U.A. Baliasau (Vitebsk, BY)
Objectives: The study of chromatingeterogenic test (CT) results
in sperm of subjects taking doxycycline (D) and some macrolides
[erythromycin (E), josamycin (J), and azythromycin (A)] in moderate
therapeutic doses.
Methods: 40 healthy volunteers (20−23 years) were studied. Daily dose
of D was 0.2; E was administered in dose 0.25 four times per day
10 days; J – 0.5 before meals twice daily 10 days; A – 0.25 before
meals once daily 5 days. CT for evaluation of DNA condition in human
spermatozoids was performed before treatment (twice), on the 5th and
10th days of treatment, as well as 1 and 2 months after treatment course
completion.
Results: CT data analysis revealed that the mean amount of defective
spermatozoids before treatment was 18.5+3.5%. By the 5th day of
D treatment the index of de-natured DNA was 63.4+6.5% (p< 0.001),
by the 10th day – 80.4+7.2% (p< 0.001). 1 month and 2 months after the
D treatment course the amount of generative cells with denatured DNA
was 54.5+4.6% and 42.5+3.8%, respectively (p< 0.001 in both case).
Under E treatment the amount of defective spermatozoids changed as
38.2+4.2 (5th day), 42.4+2.7 (10th day), 35.6+2.5 (after 1 month), and
30.5+4.2% (after 2 months) (p< 0.05 in any case). Under A using the
CT results at the same control points were 39.5+4.7, 46.5+3.2, 40.2+3.5,
25.6+3.2% (p< 0.05 in any case); and under J treatment – 18.2+2.5,
20.3+2.5, 17.2+3.2, 15.2+4.2%, respectively (p> 0.05 in any case).
Conclusions: The data obtained permit to conclude that D demonstrates
a high level of toxicity to male generative cells. This effect persists
during 2 month after the course of D treatment.
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P2072 Bactericidal effect of Ltx peptides against Staphylococcus
aureus in vitro and in murine skin infection model
R.L. Fischer, N. Frimodt-Møller, W. Stensen, J.S. Svendsen
(Copenhagen S, DK; Tromsø, NO)
Objective: Staphylococcus aureus is a major human pathogen with
increasing resistance towards important antimicrobial agents. The Ltx
micropeptides are a novel group of membrane-lysing antimicrobial
compounds, and the aim was to investigate the effect against S. aureus
in vitro and in vivo.
Methods: In vitro time-kill curves for Ltx-5 were tested against
S. aureus FDA486 at 0.5×, 2× and 8×MIC including vancomycin and
dicloxacillin at 8×MIC. The MIC of Ltx-5 was 16mg/L. A suspension
of fresh overnight colonies was grown in broth one hour before test
solutions were added. CFU counts were determined at 0, 10, 30 minutes,
1, 2 and 5 hours after addition of the compounds.
Topical treatment with 2% Ltx-7, Ltx-8 or Ltx-10 formulations was
investigated in the skin infection model including Fucidin®, Bactroban®
and placebo formulation. BALB/c mice were anaesthetized before the
fur was removed in a 2−3 cm2 area on the back of the mice. Next razor
and tape stripping was used to give a ﬁnal skin lesion. A suspension of
S. aureus FDA486 was applied on the lesion, and treatment was initiated
the next day. Mice were treated by topical application over the affected
area with about 45 g of formulation/mouse in groups of 9 mice. Each
mouse was treated for one day at 9 a.m., 12 noon and 3 p.m., followed
by sampling of skin biopsy at 6 p.m. The biopsies were homogenised in
saline with a piston and the CFU was determined in the sample.
Results: Ltx-5 showed dose-dependent killing in the time-kill curve,
and a 5 log reduction in CFU/mL was observed at 8×MIC after 2
hours. The killing of Ltx-5 at 2×MIC was comparable to 8×MIC for
vancomycin and dicloxacillin. A bactericidal effect of the Ltx peptides
was also observed in the skin infection model. The mean log reduction
in CFU/mouse for the Ltx-treated groups compared to placebo was
in the range of 3.1−4.8 after one day treatment. The corresponding
reduction for Fucidin® was 1.2−1.3 log CFU/mouse, and for Bactroban®
0.7−0.9 log CFU/mouse.
Conclusion: A bactericidal effect of the Ltx peptides was observed in
the time-kill curves at 2×MIC and 8×MIC. In addition, topical treatment
with the Ltx petides showed excellent killing of S. aureus after one day
treatment.
P2073 The effect of efﬂux pump inhibitor on MIC values
of nalidixic acit, ﬂouroquinolones and macrolide of
multidrug-resistant Escherichia coli
Y. Tezer, I.T. Filik, O. Memikoglu, H. Kurt (Ankara, TR)
Objective: Efﬂux pumps are found in all living cells and drop toxic
substances and antibiotics from inside to out. As a result, pump system
is responsible for multidrug resistance. So we aimed to investigte the
effect of this system on some antibiotics minimal inhibitor concentration
(MIC) values.
Methods: In this study, we investigated phenyl-arginin-beta-napthyl-
amide (PA-beta-N) effect as an efﬂux pump inhibitor on multidrug
resistant Escherichia coli. For this study during 6 months periods,
100 clinical isolates which were multiple drug resistant pattern that
had been determined via disc diffusion methods collected. With agar
dilution method, MIC values of four antibiotics which were nalidixic
acit, ciproﬂoxacin, levoﬂoxacin, and erytromycin were determined.
After that, having efﬂux pump had been searched by organic solvent
tolerance test. Then we examined nalidixic acit, ﬂouroquinolones and
macrolide MIC values via broth dilution method with PA-beta-N and
without it.
After broth dilution method, different concentrations of PA-beta-N were
studied in tolerant isolates. Results were analysed with Mann-Whitney
U tests.
Results: Fifty ﬁve percent of isolates were tolerant to organic solvents.
It means that, efﬂux pump was overexpressed in these isolates. For
levoﬂoxacin and erytromycin MIC values were decreased with PA-
beta-N. On the other hand there were no change on ciproﬂoxacin and
nalidixic acit MIC values. For ciproﬂoxacin and nalididixic acit there
were no signiﬁcant statistical value on MIC values. But on the other
hand for levoﬂoxacin and erytromycin there were signiﬁcant statistical
change on MIC values.
In addition PA-beta-N has homogenous effect in different concentrations
and no concentration dependent effect was determined.
Conclusions: Effect of efﬂux pump on multidrug resistance mechanisms
was rarely reported from our country and all over the world. So we
thought that studies that made by speciﬁc inhibitors of efﬂux pump, like
using b-lactam/b-lactamases might be innovator in clinical applications.
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P2074 In vitro and in vivo antibacterial activity of novel
nitrile-containing ﬂuoroquinolones
M.D. Huband, P.J. Pagano, R.W. Murray, J.W. Gage, G. Gibson,
S.T. Murphy, K.R. Marotti (Ann Arbor, US)
Objectives: The continuing emergence of resistance in Gram-positive
bacterial species including multi-drug resistant Streptococcus pneu-
moniae, vancomycin-R Enterococci (VRE), ciproﬂoxacin-R MRSA
(CRMRSA), and Vancomycin-intermediate Staphylococcus aureus
(VISA) has created the need for new antibacterial compounds. Two new
nitrile-containing ﬂuoroquinolones (#1966 and #9402) were developed
to treat infections caused by susceptible and multi-drug resistant Gram-
positive and fastidious Gram-negative bacterial strains. This study inves-
tigated the in vitro antimicrobial activity of 1966, 9402, moxiﬂoxacin,
and conventional antibacterials against 1204 geographically diverse
recent bacterial clinical isolates. Compound efﬁcacy was also evaluated
by in vivo testing (PD50s).
Methods: Microbroth dilution MICs followed CLSI guidelines. In vivo
testing was performed in CD1 female mice using protocols approved by
the Pﬁzer Animal Use Committee in compliance with NIH guidelines
for proper care and use of laboratory animals.
Results: See the table. Both of the nitrile ﬂuoroquinolones were highly
active against Gram-positive (MIC90s 0.5−4mg/mL) and fastidious
Gram-negative strains (MIC90s 0.03–0.06 ug/mL). This potent activity
carried over to efﬁcacy in Streptococcus pneumoniae animal infection
models. Acute systemic PD50s (oral dosing) were 3.2 and 1.1mg/kg,
respectively, and pneumonia model PD50s (oral dosing) were 5.93 and
5.48mg/kg.
Organism (# strains) MIC90 (mg/mL)
#1966 #9402 Moxiﬂoxacin
S. aureus CRMRSA (34) 1 1 8
S. aureus VISAa (4) 2 0.5 4
S. epidermidis ORSE (23) 2 1 32
S. pneumoniae FQ-R (26) 0.5 0.5 4
E. faecalis (13) 0.5 0.5 8
E. faecalis Van A (14) 1 0.5 16
E. faecalis Van B (22) 1 0.5 16
E. faecium Van A (45) 4 4 32
Moraxella catarrhalis (30) 0.06 0.06 0.06
Haemophilus inﬂuenzae (67) 0.03 0.06 0.03
aMIC50 (mg/mL).
Conclusion: This study conﬁrms both the in vitro antibacterial potency
and in vivo efﬁcacy of 1966 and 9402 against clinically relevant Gram-
positive and fastidious Gram-negative organisms.
P2075 Screening for medicinal plants with broad spectrum of
antibacterial activity
S.P. Voravuthikunchai, S. Limsuwan, S. Subhadhirasakul (Hatyai,
Songkla, TH)
Objectives: Interest in the study of medicinal plants as a source of
pharmacologically active compounds has increased worldwide. The
objective of this study was to screen for effective plants from 31
plant species commonly used in Thai traditional medicine for bacterial
infections.
Methods: Preliminary screening was performed using agar disc diffusion
method. Minimal inhibitory concentration and Minimal bactericidal
concentration were subsequently carried out on effective plants.
Results: Agar disc diffusion method showed that most plants were more
active against Gram-positive than Gram-negative bacteria. Streptococcus
pyogenes was the most sensitive organism inhibited by nearly all of
the extracts (97.6%), followed by Staphylococcus aureus (61.0%), and
Bacillus cereus (63.4%). We report two plants with very broad spectrum
of activity. The ethanolic extracts from Quercus infectoria demonstrated
signiﬁcant activity against all important pathogens including Acineto-
bacter baumannii, Bacillus cereus, Enterococcus faecalis, Escherichia
coli, Klebsiella pneumoniae, Listeria monocytogenes, Pseudomonas
aeruginosa, Salmonella spp., Shigella ﬂexneri, Staphylococcus aureus,
Streptococcus mutans, and Streptococcus pyogenes. It inhibited the
growth of all pathogens with the MIC values of 62.5 to 1000 ug/mL and
the MBC values of 125 to >1000mg/mL. The ethanolic extracts from
Piper betle showed antibacterial activity against almost all species, except
Enterococcus faecalis. It showed antibacterial activity with the same MIC
and MBC values (125−500mg/mL). The leaf extract of Rhodomyrtus
tomentosa showed extremely good antibacterial activity on most Gram-
positive bacteria with the MICs and MBCs ranging from 3.9 to 15.6 and
7.8 to 125mg/mL.
Conclusion: Further studies on these plant species may result in
discovery of novel natural medicine against pathogenic bacteria.
Acknowledgement: This work was supported by the Thailand Research
Fund: Royal Golden Jubilee (PHD/0029/2548), Fiscal year 2005–2010,
the Thailand Research Fund: Basic Research (BRG4880021), Fiscal year
2005–2008, and Natural Products Research Unit, Faculty of Science,
Prince of Songkla University, Thailand.
P2076 Linezolid versus a glycopeptide or b-lactam for treatment
of Gram-positive bacterial infections: a meta-analysis of
randomised controlled trials
M.E. Falagas, I.I. Siempos, K.Z. Vardakas (Athens, GR)
Objectives: During the last decade, several new antibiotics have been
released to the market for the treatment of patients with infections due to
Gram-positive cocci resistant to traditionally used antibiotics, including
glycopeptides. Among these antibiotics, linezolid has been reported
to have excellent pharmacokinetics and effectiveness. We performed a
meta-analysis of randomised controlled trials (RCTs) to further clarify
the therapeutic role of linezolid.
Methods: Our data sources for relevant RCTS were PubMed, Current
Contents, and Cochrane Central. A total of 12 RCTs comparing linezolid
with vancomycin (6 RCTs), teicoplanin (2 RCTs), and b-lactams
(amoxicillin/clavulanic acid, cephadroxil, and ceftriaxone in 2, 1, and
1 RCT, respectively) that studied 6,093 patients were included in our
analysis.
Results: Two reviewers independently extracted data from published
RCTs. Overall linezolid, as empirical treatment, was more effective
regarding treatment success than the comparator antibiotics (OR=
1.41, 95%CI 1.11–1.81). Mortality was similar between the compared
antibiotics (OR= 0.97, 95%CI 0.79–1.19). Linezolid was more effective
in the subset of patients with skin and soft tissue infections (OR=
1.67, 95%CI 1.31–2.12) and bacteraemia (OR= 2.18, 95%CI 1.10–
4.29). However, there was no difference in treatment success for patients
with pneumonia (OR= 1.03, 95%CI 0.75–1.42). Although treatment
with linezolid was not associated with more adverse effects in general
(OR= 1.40, 95%CI 0.95–2.05), more episodes of thrombocytopenia were
recorded in patients receiving this antibiotic (OR= 9.25, 95%CI 3.52–
25.76).
Conclusion: Linezolid was more effective than a glycopeptide or a
b-lactam for the empirical treatment of patients with skin and soft tissue
infections and bacteraemia due to Gram-positive cocci. However, the
lack of any beneﬁt in the treatment of patients with pneumonia, the
same all-cause mortality, and the higher probability of thrombocytopenia
are major limitations of the antibiotic that should be taken under
consideration and limit the use of linezolid to speciﬁc patient populations
or infections that are difﬁcult to treat with other antibiotics.
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P2077 Bactericidal activity of ertapenem against A. baumannii
T. Schneiders, S. Amyes (Edinburgh, UK)
Ertapenem is a new carbapenem targetted for clinical use against
fermenters such as E. coli and Klebsiella spp. but with reduced or weak
activity against non-fermenting Gram-negative bacteria such as Acine-
tobacter baumannii and Pseudomonas aeruginosa. Both Acinetobacter
spp. and Pseudomonas spp. are established pathogens in the hospital
setting and are resistant to a range of antibiotics which include the
carbapenems. Since the carbapenems (e.g. meropenem) represent the
last line of antibiotics against both Acinetobacter and Pseudomonas
spp., it is imperative that this antibiotic class is preserved. Due to
its reduced activity the introduction and use of ertapenem, suggests a
potential for resistance development in these bacteria. The combination
of increasingly carbapenem-resistant bacteria and a less efﬁcacious
antibiotic such as ertapenem against a rapidly evolving bacterial
population could result in the emergence of completely untreatable
bacteria. The efﬁcacy of ertapenem against three characterised strains
of A. baumannii was determined using time-kill studies at 4 times the
MIC. The three strains of A. baumannii were ATCC 19606, a carbapenem
sensitive clinical A. baumannii isolate, SD16, and another carbapenem
sensitive A. baumannii clinical isolate, E13, which harbours a mutS
mutation. As a comparator antibiotic, meropenem, was used. Against
ATCC 19606 and at 4 times the MIC, ertapenem reduced the viable
count by 2 log10 reduction in 3 hours and extended the killing to
greater than 4 log10 after 24 hours. Against the sensitive clinical isolate
SD16, ertapenem exerted a 3 log10 reduction in 3 hours and after 24
hours reduced the viable count to a 4 log10 reduction. Of note, the
levels of reduction in viable cell counts by ertapenem were comparable
to meropenem. Interestingly against the mutS mutant, E13, the viable
counts obtained with either meropenem or ertapenem, showed little or no
reduction over the 3 hour period which was in contrast to that observed
with ATCC19606 and SD16. However a reduction to 4 log10 was
observed with both ertapenem and meropenem after 24hrs. The results
obtained here clearly demonstrate that ertapenem inhibits non-fermenters
such as A. baumannii with similar efﬁcacy as meropenem. These ﬁndings
are signiﬁcant as it is the ﬁrst to describe the effect ertapenem has on
A. baumannii and serves to re-examine the role of ertapenem either as
a potential therapeutic option or a selector of resistance.
P2078 Novel acyclic substituted (pyridin-3-yl)phenyl
oxazolidinones: antibacterial agents with reduced activity
against monoamine oxidase A and improved solubility
F. Reck, F. Zhou, G. Zainoun, D. Carcanague, C. Eyermann,
M. Gravestock (Waltham, US)
Objectives: Oxazolidinones bearing a (pyridin-3-yl)phenyl moiety
(e.g. 1) generally show increased antibacterial activity compared to
linezolid, but suffer from potent monoamine oxidase A (MAO-A)
inhibition and low solubility. New analogs with acyclic substituents on
the pyridyl moiety were prepared and their antibacterial activity, MAO-A
inhibition, and solubility were determined.
Methods: Compounds were synthesized by Suzuki Coupling of pyridyl-
3-bromides with oxazolidinone phenylboronic acids. Antibacterial
activity, MAO-A inhibition, and solubility were evaluated in vitro. A
homology model of MAO-A was built and used to rationalise the SAR.
Results: Antibacterial potency for many analogs was excellent, with
MICs for linezolid resistant Streptococcus pneumoniae for compound
2 and 3 at 1 and 0.5 ug/mL respectively. Activity against Staphylococcus
aureus was also very good, with MICs of 0.25 ug/mL for 2 and 3.
In addition, compound 2 displayed good activity against Haemophilus
inﬂuenzae, with an MIC of 1 ug/mL. In general, bulkier substituents
yielded signiﬁcantly reduced MAO-A inhibition (Ki = 40 uM for 2;
Ki = 19 uM for 3) relative to the unsubstituted parent 1 (Ki< 0.3 uM).
Solubility was enhanced with incorporation of polar groups.
Conclusion: Acyclic 6-substituted pyridin-3-yl phenyl oxazolidinones
with sufﬁciently bulky substituent such as 2 and 3 are potent
antibacterial compounds against Gram-positive organisms, including
linezolid resistant Streptococcus pneumoniae. The properties of these
compounds include reduced MAO-A activity and increased solubility.
P2079 Synthesis and evaluation of novel (pyridin-3-yl) phenyl
oxazolidinones with improved physicochemical properties
D. Carcanague, M. Gravestock, S. Hauck, F. Reck, G. Zainoun
(Waltham, US)
Objectives: Isoxazolino oxazolidinone 1 has potent microbiological
activity against Gram-positive pathogens, however its in vivo efﬁcacy
is limited by low bioavailability due to high crystallinity and poor
aqueous solubility. Ester prodrugs of 1 with improved DMPK properties
have been described previously. Our further studies of this compound
series focused on the synthesis of novel derivatives that would retain
microbiological potency but exhibit improved solubility. In order to
achieve this goal, the hydroxyl group of 1 was replaced with various
amines or ethers.
Methods: Compounds were synthesized from 1 using standard
functional group manipulations. The antibacterial activity and solubility
of these compounds were measured.
Results: Good antibacterial activity, including against linezolid-resistant
strains, was retained in a number of new compounds with enhanced
solubility, such as the N-methyl amine 16. MICs for linezolid resistant
Streptococcus pneumoniae were in the range 0.5−1mg/L for most
compounds. Excellent activity against Staphylococcus aureus and
linezolid-susceptible Streptococcus pneumoniae was observed, with
MICs for compound 16 of 0.5mg/L and <0.06mg/L respectively.
Conclusion: Novel ether or amine isoxazolino oxazolidinone analogues
of 1 show potent antibacterial activity against Gram-positive pathogens
and signiﬁcantly improved solubility.
P2080 Microbiological activity and efﬁcacy of novel (pyridin-3-yl)
phenyl oxazolidinones
R. Illingworth, K. Coleman, J. Jones (Waltham, US)
Objectives: We describe the in vitro antibacterial activity and in vivo
efﬁcacy of a novel series of oxazolidinones with potent activity against
linezolid-susceptible and –resistant Gram-positive bacteria.
Methods: MICs were determined using CLSI standard broth microdilu-
tion methods on a total of 280 recent clinical isolates with a multitude
of resistance markers. In vivo efﬁcacy against S. pneumoniae was
determined in a mouse lung infection model and against S. aureus
in a neutropenic mouse thigh infection model. To determine the
pharmacodynamic index of the series a dose fractionation study was
carried out with compound II in the S. pneumoniae lung model where
total daily doses up to 160mg/kg p.o. were fractionated over 24 hours.
Results: Analogues in the series were consistently more potent than
linezolid against all Gram-positive species tested and maintained good
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activity against linezolid-resistant isolates. Improved activity was also
observed with most derivatives against strictly anaerobic Gram-negative
bacteria such as B. fragilis, but activity was weak or absent against other
Gram-negative bacteria, such as H. inﬂuenzae and E. coli. Compounds
I and II yielded a >2 log reduction in cfu vs. untreated control at
20mg/kg/day p.o. in the mouse S. pneumoniae lung infection model.
Compound II yielded a 2-log reduction at 40mg/kg in the mouse
S. aureus thigh infection model. The PD index associated with efﬁcacy
was AUC/MIC, consistent with data published for linezolid.
Conclusions: The (pyridin-3-yl) phenyl oxazolidinones reported here
were  4-fold more potent than linezolid against all Gram-positive
organisms and  32-fold more potent against strains resistant to
linezolid. Activity against most Gram-negative species was poor, but
against B. fragilis, most analogues were  4-fold more potent than
linezolid. Analogs in this series exhibited good in vivo efﬁcacy against
S. pneumoniae and S. aureus in mouse models of infection.
P2081 Evaluation of antibacterial activity and bioﬁlm formation
in Klebsiella pneumoniae in contact with essential oil and
alcoholic extract of cumin seed (Cuminum cyminum)
S. Derakhshan, M. Sattari, M. Bigdeli (Tehran, IR)
Introduction: Klebsiella pneumoniae has special importance in nosoco-
mial infection. Because of the acquisition of multiresistant plasmids,
these organisms are resistant to a number of antibiotics, including
extended-spectrum cephalosporins and aminoglycosides.
Methods: In this study essential oil of cumin seeds (Cuminum cyminum)
obtained in a cleavenger system by hydrodistillation method. Antibac-
terial activity of essential oil and alcoholic extract of cumin against
Klebsiella pneumoniae ATCC13883 and clinical Klebsiella pneumoniae
(ceftazidime-resistant strain) were evaluated on the minimum inhibitory
concentration by the broth-dilution method. Synergistic or antagonistic
effect with antibiotic disks were tested in agar media involving sub-MIC
concentration of oil and alcoholic extract. Bioﬁlm assay were performed
by colorimetric method as described by O’Toole in 1998.
Results: The MIC was 1/800 fold of essential oil for K. pneumoniae
ATCC 13883 and 1/200 for clinical K. pneumoniae. Also MIC was
1/32 fold of alcoholic extract for two strain in sub-MIC concentration,
synergistic effect was seen between ciproﬂoxacin and oil (signiﬁcant
increasing of inhibition zone diameter) and antagonistic effect was
seen between trimethoprim and sulfamethoxazol (reversion of colonies
around the antibiotic disk) for the clinical K. pneumoniae. The decrease
or prevention of bioﬁlm formation occurred when oil concentration
increased. Alcoholic extract was low effect in antibiotical activity
and bioﬁlm formation. The oil was analysed by GC and GC/MS.
Main constituent in oil of Cuminum cyminum is cuminaldehyde (4
isopropylbenzaldehyde).
Discussion: The results of this study suggested that the essential oil and
alcoholic extract of cumin seed could be used in medicinal industries
(desinfectant or antiseptic), but in-vivo tests are required to ascertain
fully their medicinal properties and potential toxicity.
P2082 Galanin-message-associated peptide suppresses hyphal
growth of Candida albicans
I. Rauch, L. Lundstro¨m, M. Hell, B. Koﬂer (Salzburg, AT; Stockholm, SE)
Objectives: Several epithelial surfaces are continuously exposed to
potential pathogens but rarely become infected, because speciﬁc
secretions protect them. Antimicrobial peptides (AMPs) participate in
this innate immune response by providing a rapid ﬁrst line defence
against infection. Neuropeptides are expressed by neuronal and non-
neuronal tissues in various organs including the skin, which constitutes
the ﬁrst barrier against external stress. These neuropeptides exert potent
growth- and immunomodulatory effects and few have also been shown
to possess antimicrobial activity. Recently, we have gained evidence
that galanin precursor peptide mRNA (ppGAL) is one of the few
neuropeptide mRNAs expressed in keratinocytes of the human skin. The
galanin gene encodes a precursor peptide that is processed into the 29
amino acid peptide galanin and the 59 amino acid galanin-message-
associated peptide (GMAP). Our objectives where to test whether one
of these two peptides possesses antimicrobial activity.
Methods: A microbial cell viability assay and microscopical evaluation
were used to examine inﬂuences on microbial growth. The effect of
co-culture with C. albicans on ppGAL expression in human cultured
keratinocytes was assessed by quantitative real time PCR.
Results: We were able to demonstrate that GMAP possesses growth-
inhibiting activity against C. albicans, but not Gram-positive and Gram-
negative bacteria. GMAP inhibits the yeast-to-hyphal transition, which is
one of the most important virulence factors of C. albicans. After testing
shorter variants of GMAP, we identiﬁed GMAP 16−41 as the essential
part of the peptide for this antifungal activity. Co-culture of keratinocytes
with C. albicans resulted in a 2-fold upregulation of ppGAL expression.
Conclusion: These studies establish GMAP as a new component of
the innate immune system, which has implications for prophylactic and
therapeutic strategies of Candida infections.
Supported by grants of the Jubila¨umsfonds (Nr. 11996) and the
Paracelsus Private Medical University (Nr.05/01/003).
P2083 Emergence of linezolid resistance of S. epidermidis in a
critical care unit
L. Martı´nez, M. Trevin˜o, S. Cortizo, M. Pen˜alver, M. Garcı´a-Zabarte,
F. Pardo, B. Regueiro (Santiago de Compostela, ES)
Objectives: Linezolid is the ﬁrst member of the oxazolidinone class of
antimicrobials, approved for clinical use in 2000, particularly appropriate
for treating multiresistant staphylococci. In the present work, we
report four cases of linezolid-resistant coagulase-negative staphylococci
(CoNS).
Methods: CoNS strains were isolated from blood and/or wound cultures
from patients belonging to the same clinical unit (postsurgical care unit)
from July to October, 2006. Identiﬁcation and susceptibility testing of the
strains were performed by the VITEK2 System (bioMe´rieux®, France)
and E-test (ABBiodisk®, Sweden).
Results: All strains showed slower growth than linezolid-sensitive
CoNS strains, were identiﬁed as Staphylococcus epidermidis and
were sensitive to glycopeptides, quinupristin-dalfopristin, fosfomycin,
tetracycline, erythromycin, clindamycin and moxiﬂoxacin, and resistant
to oxacillin, rifampicin, fusidic acid, trimethoprim-sulfamethoxazole,
ciproﬂoxacin, gentamicin and tobramycin. CMI range for linezolid was
8−16mg/L. Only one of these patients had been previously treated with
linezolid.
Conclusions: Linezolid resistance in CoNS has emerged at our
institution. We think that, probably, person-to-person spread of linezolid-
resistant CoNS has led to establishment of skin colonisation with the
strain, however, genotypical characterisation methods must be applied
to comﬁrm this approach. In any case, in vitro susceptibility testing of
linezolid is advisable for accurate therapy of CoNS in medical units
where linezolid is habitually used.
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P2084 Antimicrobial activity of apidaecin peptides
P. Czihal, A. Nimptsch, U. Mo¨llmann, P. Zipfel, R. Hoffmann (Leipzig,
Jena, DE)
In recent years there was a dramatical increase in bacteria strains
resistance to one or even several antibiotics. Thus, the development of
antimicrobial compounds with novel modes of action is a major focus
of current pharmaceutical research. A very interesting and promising
approach relies on antibacterial peptides, because bacteria do not develop
any resistance to these antimicrobial peptide families. One of the most
promising among these families are the short, proline-rich antibacterial
peptides originally isolated from insects, such as apidaecin, drosocin, for-
maecin, and pyrrhocoricin. These peptides represent a viable treatment
option for the major pathogens in urinary tract infections, that is, E. coli
and K. pneumoniae, causing 90−95% of all urinary tract infections.
Based on the native sequences of apidaecin 1a and apidaecin 1b,
we have identiﬁed all residues important for the antibacterial activity
with an alanine scan. In a second round, the identiﬁed positions were
selectively modiﬁed with other alpha-amino acids and unnatural amino
acid derivatives to increase the antibacterial activity. Furthermore, the
protease resistance was increased to elongate the peptide activity in
blood. All peptides were synthesized on solid-phase using the Fmoc/tBu-
strategy and puriﬁed by reversed phase HPLC. The activities of the
peptides were determined by an agar diffusion assay and the minimal
inhibition concentration (MIC) was determined on a microtiter plate for
pathogenic E. coli strains (e.g. E. coli 1103) and Klebsiella pneumoniae
ssp. pneumoniae 11678. The ﬁrst results on the antimicrobial activities
and protease resistances of the new apidaecin analogs will be presented.
P2085 A novel antimicrobial peptide with anti-MRSA activity
R. Aunpad, K. Na-Bangchang (Pathumthani, TH)
Objectives: To search and characterise a new antimicrobial peptide
against MRSA.
Methods: Forty-three different water and soil samples were collected
from three different areas from Thailand. The single colony obtained
from each sample was screened for its antagonistic activity against the
indicator strain, methicillin resistant Staphylococcus aureus (MRSA) by
co-culture method. The agar-well diffusion method was used to assess the
antimicrobial activity spectrum of 20 selected bacterial strains against
20 Gram-positive and Gram-negative test microorganisms. The agent
containing antimicrobial peptide (ACAP) prepared from the culture
supernatant of one strain, WAPB4, was tested for its antimicrobial
spectrum, enzyme sensitivity, heat and pH stability and mode of action.
The antimicrobial peptide was puriﬁed from ACAP by a three-step
procedure: solvent extraction, solid phase extraction and followed by
reversed phase chromatography. The molecular mass was determined by
mass spectrometry.
Results: A total of 20 water and soil isolated bacteria can inhibit the
growth of MRSA. It was also found that three Gram-positive isolated
bacteria strain WARY9−1, WARY6−6 and WASM9−25 showed a broad
range of inhibition. Two Gram-negative bacteria strain WARY9−10
and WARY7−4 are active against both Gram-positive and Gram-
negative bacteria. One strain, WAPB4, identiﬁed as Bacillus pumilus
showed remarkable antibacterial activity against MRSA and VRE. The
antimicrobial peptide produced by WAPB4 was heat stable up to 121ºC,
15 min and active within the pH range of 3−9. Its activity disappeared
when treated with pronase E, chymotrypsin and trypsin demonstrating
its proteinaceous nature. ACAP showed bacteriostatic effect to MRSA
in vitro. The antimicrobial peptide could be puriﬁed by a three-step
procedure and the molecular mass as determined by mass spectrometry
was 1994.62 Dalton.
Conclusion: Bacillus pumilus strain WAPB4 produced a new antimicro-
bial peptide with broad spectrum antibacterial activity including MRSA
and VRE. The compound is thermal and pH stable and has potential for
use as an alternative antibacterial agent for the treatment of infection
with MRSA and VRE.
P2086 Clinical efﬁcacy of retapamulin, 1% ointment, in subjects
with antibiotic-resistant Staphylococcus aureus: pooled
Phase III results from Europe, Costa Rica, India, Mexico,
Peru, Russia and South Africa
A. Oranje, O. Chosidow, N. Scangarella, M. Twynholm, R. Shawar,
T. Erb (Rotterdam, NL; Paris, FR; Collegeville, US; Greenford, UK)
Background: Antimicrobial resistance to the oral and topical agents used
in treating skin infections is a growing problem globally, with speciﬁc
regional differences in the prevalence and strains of resistant bacteria.
For instance, 33–50% of S. aureus isolates from European subjects with
skin infections were recently found to be resistant to fusidic acid [1,2].
The problem of resistance demands new antibiotic choices. Retapamulin
is the ﬁrst antibiotic of the novel pleuromutilin class developed for
the treatment of uncomplicated skin and soft tissue infections. It has
a unique mode of action, no known target-speciﬁc cross resistance and
a low propensity for resistance development in vitro. It has excellent
in vitro activity against skin pathogens, including those resistant to
existing antibiotics. Retapamulin, 1% ointment, has demonstrated good
clinical efﬁcacy in the treatment of adults and children with impetigo,
secondarily infected dermatitis (SID) and secondarily infected traumatic
lesions (SITL).
Objectives: To determine the clinical efﬁcacy of retapamulin against
antibiotic-resistant S. aureus recovered from European and international
subjects in Phase III studies.
Methods: Clinical efﬁcacy data for retapamulin were pooled from ﬁve
worldwide studies: 469 (vs placebo) and 224 (vs topical fusidic acid) in
subjects with impetigo; 032 in those with SID (vs oral cephalexin) and
030A and 030B in SITL (vs oral cephalexin). Only subjects from Europe
(Austria, France, Germany, Greece, Italy, Poland, Spain, The Netherlands
and UK) and Costa Rica, India, Mexico, Peru, Russia and South
Africa were included in the analysis. In each study, subjects received
retapamulin, 1% ointment, twice daily for 5 days, or placebo/comparator
(2:1 randomisation). A total of 1527 subjects (ITT population) were
considered.
Results: Pooled data from European and international subjects for
the three indications show excellent clinical efﬁcacy in subjects with
fusidic acid-resistant (FusR), mupirocin-resistant (MupR) or methicillin-
resistant (MR) S. aureus (SA) isolates.
Clinical efﬁcacy of retapamulin by baseline pathogen (ITT population)
Clinical success % (n/N)a
MupRSAb IFusRSAb MRSAb
Europe 100 (2/2) 92.3 (24/26) 80.0 (4/5)
International 92.9 (13/14) 100 (6/6) 92.0 (23/25)
Overall 93.8 (15/16) 93.8 (30/32) 90.0 (27/30)
an/N: number of clinical success/number of subjects with pathogen at
baseline.
bResistance deﬁned as MIC 8 g/L for mupirocin and 4 g/L for fusidic
acid. Oxacillin disk test used to deﬁne methicillin resistance.
Conclusions: Retapamulin achieved high rates of clinical success against
FusRSA, MupRSA or MRSA infections. Retapamulin, 1% ointment,
is therefore a highly effective new treatment option for uncomplicated
skin infections, including those involving pathogens resistant to current
antibacterials.
Reference(s)
[1] Shah et al. Br J Dermatol 2003;148:1018−20.
[2] Afset et al. Scand J Infect Dis 2003;35:84−9.
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P2087 Spectrum and activity of doripenem, an investigational car-
bapenem, tested against bacterial pathogens recovered from
patients hospitalised with pneumonia (Europe; 2004–2006)
T. Fritsche, H. Sader, P. Strabala, R. Jones (North Liberty, US)
Objectives: To summarise the activity of doripenem (DOR), an
investigational broad-spectrum parenteral carbapenem (CARB) in
late stage clinical development, against leading bacterial pathogens
recovered from European patients with HAP. Emerging resistance (R)
among hospital-acquired pneumonia (HAP) pathogens, especially Gram-
negative bacilli, compromises patient management and contributes to
excess morbidity and mortality.
Methods: A total of 2,127 consecutive, non-duplicate isolates de-
termined as the cause of pneumonia in hospitalised patients were
submitted from 24 medical centres in Europe (2004–2006). Included
HAP pathogens are summarised in the Table. Susceptibility (S) testing of
DOR and comparator agents was performed using current CLSI methods
and interpretive criteria, including those for characterisation of ESBL-
phenotypes.
Results: Results for DOR are in the Table. Ranking of the top-eight
occurring HAP isolates and key R characteristics were (see Table): PSA
(21.5% meropenem-non-susceptible [MER-NS]) > SA (441 isolates;
39.7% OXA-R) > EC (11.2% ESBL) > KSP (31.4% ESBL) > ESP
(31.5% ceftazidime-R) > ASP (66% MER-NS) > SER > S. maltophilia
(SM; 68 isolates; not shown). OXA-R SA and SM are inherently R to
CARB and are not discussed further. Overall, DOR inhibited 90.8% of
the 7 top-ranked pathogens within its spectrum of activity at  4mg/L
(equivalent to breakpoints of peer CARB) compared with 86.3% for
imipenem (IPM) and 88.6% for MER. Elevated DOR, MER and IPM
MIC values were detected among PSA (MIC50/90 values, 0.5/8; 1/>8;
and 1/>8mg/L, respectively) and ASP (MIC50/90 values, 8/>8; 4/>8;
and 8/>8mg/L). Strains of metallo-b-lactamase producing PSA (IMP,
VIM series) were detected in Italy, Greece and Turkey.
Organism (no. tested) DOR MIC (mg/L)
50% 90% Range % 2/4
P. aeruginosa (PSA; 488) 0.5 8 0.06–>8 72/85
S. aureus (SA; Oxacillin [OXA]-S; 266) 0.06 0.06 0.06−0.5 100/100
E. coli (EC; 241) 0.06 0.06 0.06–0.25 100/100
Klebsiella spp. (KSP; 229) 0.06 0.06 0.06–>8 >99/100
Enterobacter spp. (ESP; 146) 0.06 0.12 0.06−1 100/100
Acinetobacter spp. (ASP; 134) 8 >8 0.06–>8 38/46
Serratia spp. (SER; 75) 0.12 0.25 0.06−0.5 100/100
Conclusion: The described prevalences of R phenotypes among contem-
porary European HAP pathogens increasingly complicates therapeutic
management decisions. DOR is a promising CARB that may represent
an important choice among broad-spectrum agents for this indication
(HAP) especially given its enhanced activity against ESBLs and PSA.
P2088 Variations and trends in the activity of doripenem and other
broad-spectrum agents against leading bacterial pathogens:
results from a European Surveillance Program (2003–2006)
T. Fritsche, H. Sader, P. Strabala, R. Jones (North Liberty, US)
Objectives: To summarise the results of a European-focused surveillance
programme comparing activity of doripenem (DOR) and other agents
tested against leading contemporary pathogens. DOR is a broad-
spectrum investigational parenteral carbapenem (CARB) in late stage
clinical development that displays enhanced activity against P. aerug-
inosa (PSA) compared to other marketed CARB. As we continue to
evaluate DOR, regional data assessing resistance (R) patterns of targeted
pathogens are needed.
Methods: Non-duplicate bacterial isolates (27,689; 54.5% bloodstream;
21.6% respiratory tract; 8.3% skin and skin structure; others, 15.6%)
were collected from 24 medical centres in Europe during 2003–2006.
Identiﬁcations were conﬁrmed and all isolates were susceptibility (S)
tested using CLSI broth microdilution methods and interpretive criteria
against DOR, meropenem (MEM), imipenem (IPM) and comparators.
Results: At MIC values of 0.25mg/L for SPN, 0.5mg/L for BHS and
HI, and 4mg/L for all others (equivalent to peer agents), DOR inhibited
95.7% of the tabulated pathogens recovered from all sources. DOR was
broadly active against staphylococci, streptococci, and HI, and at least
2-fold more potent against PSA than either MEM or IPM (MIC90/%
4mg/L: 8/85, >8/81 and >8/76, respectively). Only polymyxin B
(>99% S) and amikacin (89%) provided greater PSA coverage than
DOR. While ESBL-phenotype rates varied considerably between 2003
and 2006 (EC, 4.9−8.3%; KSP, 17.8–26.9%), DOR inhibited 100% of
strains conﬁrmed as ESBL-producers at 2mg/L.
Organism (no. tested) MIC (mg/L) Cum. % inhibited at MIC (mg/L)
50% 90% 1 2 4 8
S. aureus (OXA-S; 4,441) 0.06  0.06 >99 100
CoNSa (OXA-S; 588) 0.06 0.06 100
BHSa (836) 0.06 0.06 100
S. pneumoniae (SPN; 2,146) 0.06 0.5 >99 100
H. inﬂuenzae (HI; 1,594) 0.06 0.25 >99 100
E. coli (EC; 4,979) 0.06 0.06 100
Klebsiella spp. (KSP; 1,621) 0.06 0.06 98 99 >99 >99
Enterobacter spp. (1,010) 0.06 0.12 98 99 >99 >99
P. aeruginosa (PSA; 1,934) 0.5 8 69 77 85 92
Acinetobacter spp. (568) 2 >8 48 57 66 81
aCoNS, coagulase-negative staphylococci; BHS, beta-haemolytic streptococci.
Conclusions: Emerging global R has created a critical need for
accelerated development and introduction of new antimicrobials. DOR
inhibited 100% of ESBL-producing strains and was more potent than
other CARB against PSA. DOR is a promising CARB displaying a
broad-spectrum against most common hospital pathogens, especially
Enterobacteriaceae and non-fermentative bacilli.
P2089 Extending structure-activity-relationship studies of bioactive
natural products by novel iminonitroso cycloaddition
chemistry
M. Miller, U. Moellmann, F. Li, B. Yang, T. Zoellner, P. Gebhardt,
H. Dahse, P. Miller (Notre Dame, US; Jena, DE)
Objectives: Healthcare problems caused by multidrug-resistant microbes
are increasing constantly. However, the pipeline for novel drug candidates
is substantially unﬁlled. Natural products and their derivatives remain a
signiﬁcant source of molecular diversity for drug discovery. However,
the development of highly efﬁcient and versatile natural product
derivatisation methods remains a challenge. Classical derivatisation
methods are often limited to standard modiﬁcation of nucleophilic or
electrophilic functional groups and selectivity is problematic.
Here we report the use of stabilised iminonitroso Diels-Alder reactions
for derivatisation of complex diene-containing natural products. This to-
tally atom economical cycloaddition reaction produces conformationally
restricted analogs and introduces new functionality to rarely modiﬁed
centres, diene or polyene components, of bioactive natural products in a
highly regio- and stereoselective and chemically efﬁcient fashion.
Methods: Six natural products (turimycin H3, ergosterol, reductiomycin,
isoforocidin, colchicine and thebaine) were selected for our initial
studies using nitrosopyridine Diels-Alder reactions. The conﬁguration of
cycloadducts was assigned based on 1D and 2D high resolution NMR
studies, 1HNMR analysis, NOE correlations from ROESY experiments
and X-ray crystallographic analyses. Bioactivity of the cycloadducts was
studied against bacteria, yeast and fungi. Different cell lines were used
for antiproliferative and cytotoxicity assays.
Results: The reactions with nitroso dienophiles proceeded in 10−20 min
to afford the corresponding oxazine cycloadducts as single isomers in
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~90% yield and with excellent regio- and stereoselectivity for all of the
substrates examined.
Incorporation of the oxazine heterocycles altered the biological activity
proﬁle of the corresponding parent natural products. While the
cycloaddition products of turimycin retained reduced, but did not
eliminate, antibacterial activity, antiproliferative activity was introduced.
Biological activity studies of related cycloadducts of all of the other
natural products mentioned will be presented as well.
Conclusion: The methodology presented herein provides a highly efﬁ-
cient and atom economical tool for derivatisation and functionalisation of
complex diene-containing bioactive natural products at rarely modiﬁed
centres. It provides a new basis towards structural diversity for drug
discovery.
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P2090 In vitro activity of API-1252, a novel anti-staphylococcal
agent, against 100 genotypically unique Staphylococcus
aureus strains
F. Perdreau-Remington, G. Zhanel, D. Vaughan, N. Kaplan (San
Francisco, US; Winnipeg, Toronto, CA)
Objectives: API-1252 is a novel anti-staphylococcal agent that targets
the key component of bacterial fatty acid synthesis, the enoyl-ACP
reductase (FabI). API-1252 is being developed as a new class of oral
and intravenous agent with a novel mechanism of action. We selected
100 unique Staphylococcus aureus (SA) strains based on a combination
of genotypes and antimicrobial resistance phenotypes and compared
the activity of API-1252 to other antimicrobials commonly used in the
treatment of SA infections
Methods: MRSA and MSSA were selected according to their sequence
type (ST), presence or absence of mecA and Panton Valentine
Leucocidine (PVL) genes, staphylococcal chromosomal cassette element
(SCCmec), pulsed ﬁeld gel electrophoresis (PFGE) proﬁles and
antimicrobial phenotypes. MICs were determined using current CLSI
guidelines.
Results: The 79 MRSA strains belonged to 12 ST’s (SCCmecIV n = 62;
SCCmecII n = 17; PVL+ n = 35) and 47 unique PFGE proﬁles including
USA100–1100. The 21 MSSA strains represented nine ST‘s and 20
unique PFGE proﬁles. All strains represented a combination of 100
unique genotypic/phenotypic proﬁles. Seventy nine percent of the strains
originated from non sterile sites. The percent of SCCmecIV, SCCmec
II and MSSA strains susceptible to comparators were 92%, 29% and
100% (meropenem); 65%, 12% and, 81% (ciproﬂoxacin) and 97%, 76%
and 100% (gentamicin). All strains were susceptible to vancomycin.
The ranges of API-1252 MIC’s (mg/L) were 0.004–0.125 for MRSA
and 0.004–0.015 for MSSA. For MRSA, the MIC90 for API-1252 was
0.015mg/L for all SCCmecII strains as well as all SCCmecIV USA300
strains (n = 26) while all other SCCmec IV (n = 36) recorded an MIC90
of 0.03mg/L. All MSSA strains independent of ST or phenotype had an
MIC90 of 0.015mg/L.
Conclusions: API-1252 demonstrated highly potent in-vitro activity
against the diverse genetic backgrounds included in this study. The
equipotent activity against representatives of all common community
and hospital acquired MRSA strains greatly encourage the further
development of API-1252 for challenging staphylococcal infections.
P2091 In vitro–in vivo clearance correlation of EDP-420,
clarithromycin and telithromycin
L.J. Jiang, D. Wachtel, T. Phan, A. Sonderfan, Y.S. Or (Watertown, US)
Objectives: A signiﬁcant number of drug candidates entering clinical
development are discontinued due to unacceptable pharmacokinetic (PK)
properties and, thus, there is an urgent need to establish and validate
the in vitro and interspecies scaling methods which can accurately
predict human PK before clinical trials. Herein, the in vitro-in vivo
clearance (CL) correlations of two marketed antibiotics, clarithromycin
and telithromycin, are evaluated. Additionally, the human clearance
of EDP-420, a ﬁrst-in-class bicyclolide (bridged bicyclic macrolide)
currently in clinical development, was predicted before clinical trials.
Methods: Clarithromycin, telithromycin, or EDP-420 (1 microM) were
incubated separately in triplicate with human microsomes (0.5mg
protein/mL) in the presence or absence of NADPH at pH 7.4 and 37
degree. Reactions were stopped at designated times, and supernatant
concentrations of clarithromycin, telithromycin and EDP-420 were
determined by LC/MS/MS. Human hepatic CL was calculated from the
intrinsic CL of human liver microsomes using the well-stirred model.
Results: Following 90-minute incubations with human liver microsomes,
98% of telithromycin and 84% of clarithromycin were metabolised while
52% of the initial amount of EDP-420 remained. The in vitro human
liver microsomal half-life of telithromycin, clarithromycin and EDP-420
were calculated to be 18.1, 44.2 and 89.8 minutes, respectively. The
calculated human CL values of clarithromycin and telithromycin based
on in vitro human liver microsomal results were 30.3 and 55.6 L/h,
respectively, which were very close to the observed human CL of
31.1 L/h for clarithromycin and 57.7 L/h for telithromycin. The predicted
human CL of EDP-420 is 12.9 L/h, which is 4-fold and 2-fold lower than
the corresponding values for telithromycin and clarithromycin.
Conclusion: An excellent in vitro-in vivo clearance correlation was
demonstrated for both clarithromycin and telithromycin, indicating that
in vitro microsomal incubations would be a useful tool for predicting
human clearance for this drug class. EDP-420 is predicted to have low
clearance in humans.
P2092 Preclinical pharmacokinetics and interspecies scaling of
EDP-420, a ﬁrst-in-class bicyclolide
L.J. Jiang, G. Wang, L. Phan, A. Sonderfan, M. Paris, Y.S. Or
(Watertown, US)
Objectives: EDP-420 (EP-013420) is a ﬁrst-in-class bicyclolide (bridged
bicyclic macrolide) currently in clinical development for the treatment
of respiratory tract infections (RTI). It exhibits potent activity against
RTI pathogens, including multi-drug resistant streptococci and the
atypical organisms. EDP-420 also demonstrates in vivo efﬁcacy against
S. pneumoniae, S. pyogenes, and S. aureus in mouse protection tests, and
against H. inﬂuenzae in a rat lung infection model. Herein, preclinical
pharmacokinetics (PK) and interspecies scaling of EDP-420 are reported.
Methods: The single-dose intravenous (i.v.) and oral PK of EDP-420
was examined in mice (15mg/kg), rats (10mg/kg), dogs (5mg/kg) and
monkeys (5mg/kg). Plasma EDP-420 concentrations were determined
by LC/MS/MS. Allometric scaling was used to predict human PK
parameters from multiple species animal data by linear least-squares
regression analysis.
Results: Following a single oral dose, the average bioavailability was
low (38.6%) for rats but relatively high for monkeys (50.8%), dogs
(63.8%) and mice (88.6%). The area under the plasma concentration-time
curve in mice, rats, dogs, and monkeys was 16.7, 4.1, 8.9, and 6.8mg-
hr/mL after a single oral dose of 15, 10, 5, and 5mg/kg, respectively.
Plasma clearance was substantially slower in dogs (0.26 L/h/kg) and
monkeys (0.36 L/h/kg) than in mice and rats (0.8 to 0.95 L/h/kg).
Volume of distribution (Vd) exceeded 2.5 L/kg in all species. Dogs had
substantially longer half-life (t1/2, 15.0 and 10.8 hours for i.v. and oral,
respectively) than mice, rats and monkeys (t1/2 ranged from 2.7 to 5.2
hours). The predicted human clearance and Vd are 13 L/h and 300 L,
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respectively, based on multiple species animal data using allometric
scaling (R2 > 0.97). A long t1/2 of ~16 hours is predicted in humans.
Conclusions: EDP-420 is well absorbed and has optimal pre-clinical PK
properties across multiple species. The excellent correlation of allometric
plots of PK parameters in four preclinical species suggests that EDP-420
PK behaviour in humans can be well predicted.
P2093 Tissue distribution of [14C]-EDP-420 in the rat by
quantitative whole-body autoradiography
L.J. Jiang, M. Takeuchi, R. Lewsley, A. Sonderfan, T. Baba, Y.S. Or
(Watertown, US; Osaka, JP; Harrogate, UK)
Objectives: EDP-420 (EP-013420) is a ﬁrst-in-class bicyclolide (bridged
bicyclic macrolide) currently in clinical development for the treatment of
respiratory tract infections (RTI). This study shows the tissue distribution
of radioactivity in the male and female albino rat and the male pigmented
rat following a single oral gavage administration of 10mg/kg of [14C]-
EDP-420 using QWBA.
Methods: Rats were euthanised by cold shock following deep
anaesthesia under isoﬂurane at speciﬁc times after dosing. The carcasses
were frozen in a mixture of hexane and solid carbon dioxide and
were subjected to quantitative whole-body autoradiography (QWBA)
procedures. Radioactivity concentrations in tissues were quantiﬁed from
the whole body autoradiograms using a validated image analysis system.
Results: Radioactivity was widely distributed at 2 hours after
administration to male albino rats with Tmax = 8−10 hours in most
tissues. Cmax in most tissues was greater than plasma Cmax of 0.871mg
equiv/g. Highest concentrations of radioactivity in tissues were generally
associated with the Harderian gland (unique to rodents), lung, pituitary
and spleen, with Cmax = 20−60mg equiv/g, and AUC0−∞ = 671–1940mg
equiv-h/g. Plasma AUC0−∞ was 14.5mg equiv-h/g. The ratios of Cmax
and AUC0−∞ in lung over the corresponding values in plasma were 32.3
and 46.3, respectively. The majority of tissues had terminal half-lives
of radioactivity in the range of 10 to 20 hours. Plasma had the shortest
terminal half-life of 6.15 hours. There was little evidence for any gender
difference in the distribution of radioactivity. Absorbed radioactivity was
eliminated by both the biliary and renal routes. Quantiﬁable radioactivity
was present in melanin-containing tissues (uveal tract and pigmented
skin) of pigmented animals and declined at late sampling times.
Conclusion: EDP-420 has demonstrated good tissue distribution
(especially lung penetration) in rats, suggesting that EDP-420 may be
an effective compound for the treatment of RTI.
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P2094 Association between antibiotic use and incidence of
methicillin-resistant Staphylococcus aureus in general
intensive care unit
E. Pujate, A. Balode, P. Oss, U. Dumpis (Riga, LV)
Objectives: The use of 3rd generation cephalosporins and ﬂuoro-
quinolones has been previously associated with increased risk for
acquisition of MRSA. Active surveillance of all MRSA cases and
infection control programme was started in March, 2003 when the
ﬁrst cases were identiﬁed in our hospital. Most of the outbreaks were
associated with the ICU. Aim of this study was to examine possible
correlation between aggregated antibiotic consumption data and MRSA
incidence in the general ICU.
Method: Retrospective study on antibiotic usage and MRSA incidence
was performed in ICU. Data on MRSA cases were taken from MRSA
surveillance database. Number of new MRSA cases in ICU was
calculated monthly. Antibiotic consumption was measured in DDD per
100 bed days and patient on antibiotic days (PAD) recorded every day
for each antibiotic by the nurse. Statistical analysis was performed with
SPSS 13 software package.
Results: Three hundred sixty ﬁve new MRSA cases were registered
in the hospital by September, 2006. 34.3% (CI: 29.6; 39.3) of cases
were detected in general ICU. 88.8% (CI: 82.1; 93.2) of them received
antibiotics before the cultures were taken of whom 36.0% (CI: 24.5; 40.6)
received ciproﬂoxacin, 31.5% (CI: 23.6; 40.07) ceftriaxone, and 8.1%
(CI: 4.3; 14.7) ceftazidime. In contrast, for the study time period
the proportion in total antibiotic consumption in DDD/bed days for
ciproﬂoxacin was 11.1% (CI: 6.8; 1.8), ceftriaxone 11.7% (CI: 7.3; 18.2),
and ceftazidime 0.83% (CI: 0.2; 4.2). Ciproﬂoxacin was the only
ﬂuoroquinolone used.
Average monthly antibiotic consumption in ICU was 134.37 (CI:
122.2; 146.6) DDD per 100 bed days or 230.1 (CI: 221.54; 252.3) PAD.
There was no correlation or association between monthly variations in
total consumption and MRSA incidence. Time trend analysis showed
association of number of new MRSA cases and PAD for ciproﬂoxacin.
We observed the peak of ciproﬂoxacin consumption measured in PAD
before increase in MRSA cases with the time delay of 2−3 months.
There was no such association with consumption of third generation
cephalosporins and other antibiotics except vancomycin that was used
for treatment.
Conclusions: Use of ciproﬂoxacin and 3rd generation cephalosporins
was identiﬁed as a risk factor for acquisition of MRSA infection and did
not reﬂect the general pattern of antibiotic use in our ICU. Measurement
of antibiotic consumption by using PAD could have advantage for
evaluation of the impact of antibiotic resistance selection pressure.
P2095 Carbapenem consumption and resistance of P. aeruginosa
and K. pneumoniae to carbapenems: results from a 7-year
study in a general hospital
M. Lelekis, C. Loupa, A. Karaitianou, H. Papadaki, I. Tzannou,
E. Katsiki-Divari, K. Papaefstathiou, G. Kouppari (Athens, GR)
Objective: The aim of the present study was to record on one hand
carbapenem consumption and on the other hand carbapenem resistance
of P. aeruginosa and K. pneumoniae strains isolated in our 300-bed
general hospital over a 7 year period.
Methods: Antibiotic consumption for the period 1999 to 2005
was studied retrospectively using data from the pharmacy computer.
Antibiotic use was calculated in DDDs per 1000 patient days (ABC
Calc 3.0). On the other hand data concerning imipenem resistance of
P. aeruginosa and K. pneumoniae strains isolated in our hospital during
the same time period were taken from the microbiology department.
Results: Antibiotic consumption was 572, 647, 678, 675, 710, 785 and
892 DDDs/1000 patient days (years 1999, 2000, 2001, 2002, 2003,
2004, 2005 respectively). Carbapenem consumption was 3.8, 6.7, 6.2,
3.9, 7.1, 9.8, 15.2 DDDs/1000 patient days for the above mentioned
years (ﬁgure). During the same time period P. aeruginosa resistance to
imipenem was 14.5%, 7.8%, 14%, 17.5%, 15.4%, 15.5%, 15.5% and that
of K. pneumonia to imipenem 0, 2.1%, 0, 0, 2%, 2.3%, 7.3% (ﬁgure).
Conclusions: During the study period, total consumption increased
signiﬁcantly in our hospital and this was the case for carbapenem
consumption as well. At the same time while P. aeruginosa resistance to
carbapenems seems to have stabilised around 15%, it is worrisome that
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K. pneumoniae resistance increased signiﬁcantly in the last years. Follow
up studies will reveal if this will be the next serious resistance problem
in our hospital. At the same time resistance mechanisms of carbapenem
resistant Klebsiella are being investigated.
P2096 Are recommendations for antibiotic use related to
antibiotic consumption in hospital? Results from a French
surveillance network
K. Miliani, F. L’Heriteau, I. Arnaud, A. Carbonne, P. Astagneau (Paris,
FR)
Objectives: In France, antibiotics (AB) consumption is dramatically high
in parallel to high rate of multiresistant bacteria. For the last few years,
a well-deﬁned policy has been implemented at the national level to
control and monitor antibiotic consumption. Since 2002, surveillance
networks with voluntary hospitals were set up to evaluate AB policy
and consumption. The aim of the study was to evaluate whether
recommendations for good practices of AB use were related to reduction
of AB consumption.
Methods: Based on data from the Northern France surveillance system,
recommendations for AB use were collected annually on a standardised
questionnaire including 21 items. AB consumption was expressed in
deﬁned daily dose (DDD) per 1000 patient-days. A multivariate logistic
regression analysis was performed with AB consumption categorised
according to low ( percentile 75th) and high consumption (>p75)
as the dependent variable. Whole AB as well as ﬂuoroquinolones
and amoxicillin/clavulanic acid (amoxiclav) consumption were analysed
separately.
Results: Among the 83 hospitals participating in the study, 75%
had a whole AB consumption  669.5 DDDs/1000 patient-days.
The less frequent practices were: educational AB programmes (17%),
request for an antibiotic specialist for second-line antibiotics (26%),
systematic reassessment of AB treatment after 72 hours (27%), and
computerised prescription and dispensation (35%). In the multivariate
analysis, nominative delivery form (whole AB and amoxiclav) and
computerised prescription (ﬂuoroquinolones only) were associated with
lower AB consumption.
Conclusions: Control measure of AB prescription appears to be the key
for lowering consumption. Sustained efforts should focus on AB with
high potential for emerging bacterial resistance.
P2097 Development of resistance toward macrolides in oropharyn-
geal streptococci after administration of azithromycin SR
or clarithromycin XL in comparison to a control group
G. Westphal, M. Schmidt-Ioanas, J. Wagner, H. Lode (Brandenburg,
Berlin, DE)
Objectives: Macrolide antibiotics are thought to enhance the develop-
ment of bacterial resistance. We assessed the resistance development
of oroharyngeal streptococci after a single dose of azithromycin SR
(sustained release fomrula, 2.0 g), a ﬁve day treatment of clarithromycin
XL (extended release formula, 1.0 g/day) and a control group (no
treatment).
Methods: 50 healthy subjects were randomised into three groups. One
group was given a single 2g dose of azithromycin SR (20 volunteers):
the other group received 1g/day of clarithromycin XL for 5 days (20
volunteers). The control group received no treatment and consisted
of 10 healthy volunteers. In a surveillance period of 13 weeks post
administration, oropharyngeal streptococci viridans were tested for their
MIC (minimal inhibitory concentration) of macrolides at 0, 7, 21,
35, 49, 63, and 91 days post administration by eTest®. The bacterial
ﬂora was obtained by oropharyngeal swabs. For each subject and
each visit, ﬁve distinct streptococci viridans strains were selected and
tested. Compliance was conﬁrmed by supervision of administration and
measurement of urinal concentration.
Results: We tested 700 strains in the azithromycin SR group (20
subjects), 665 strains in the clarithromycin XL group (19 subjects) and
280 strains in the control group (8 subjects). The transient development
of resistance was similar in both treated groups. The geometrical mean
erythromycin MICs (in mg/L) in the azithromycin SR group were 0.42
at day 0, 1.82 at day 63 (maximum value) and 0.60 at day 91; in the
clarithromycin XL group 1.40 at day 0, 5.66 at day 63 (maximum
value) and 1.22 at day 91. The control group did not develop any
signiﬁcant changes in the resistance index. In comparison to baseline, the
analysed streptococci showed no signiﬁcant differences in the level of
resistance for erythromycin at day 91 within the three groups (p = 0.09).
Azithromycin SR and Clarithromycin XL showed no severe side effects.
Conclusion: Azithromycin SR administered in a single dose of 2 g has a
similar transient development of resistance as clarithromycin XL. There
is no signiﬁcant development of resistance to erythromycin after 91 days.
In comparison to a control group the changes of the resistance index in
a period of 91 days are not signiﬁcant either.
P2098 Tobramycin resistance in Pseudomonas aeruginosa isolates
from children with cystic ﬁbrosis on nebulised tobramycin
– temporal relationship with antibiotic usage
M. Doyle, P. McNally, G. Leen, J. Dier, P. Greally, P. Murphy (Dublin, IE)
Objectives: High level resistance (HLR) isolates of P. aeruginosa with
a Minimum inhibitory concentration (MIC) >1024 for Tobramycin have
been cultured from patients on Tobramycin Inhaled Solution (TSI). In
the patients with isolates with an MIC> 1024mg/mL, there is a tendency
towards a more rapid fall off in both weight z scores and FEV1 [1].
The aim of this study is to explore the temporal relationship between
use of (TSI) and ﬂuctuations in the (MIC) in P. aeruginosa isolated from
sputum of children with cystic ﬁbrosis receiving inhaled Tobramycin.
Methods: Sputum was collected prospectively from all children with
a persistent growth of P. aeruginosa receiving (TSI). Isolates were
collected from Oct 2005 to Oct 2006. Patients were requested to send
sputum for culture before and after a course of TSI therapy. All isolates
were tested to evaluate the MIC. The timing and duration of TSI usage
was recorded prospectively. The data was examined to establish if a
temporal relationship exists between use of TSI and the changes in
Tobramycin MIC of the P. aeruginosa isolates cultured.
Results: Thirty patients were treated with TSI during the study period.
Two-hundred and twenty isolates were tested. The Tobramycin MIC in
P. aeruginosa isolates from each patient ﬂuctuated during the study
period. No relationship could be demonstrated between the Tobramycin
MIC from the P. aeruginosa isolated and the timing of TSI. Ten of the
patients had a high level resistant (HLR) strain of P. aeruginosa isolated
with a Tobramycin MIC of >1024mg/mL. Seven patients remained
colonised with a HLR isolate. One patient discontinued therapy with TSI
during the study period. This patient continued to culture P. aeruginosa
with a Tobramycin MIC >1024 one year after discontinuing TSI.
Conclusions: Isolates of P aeruginosa cultured from patients on TSI
have a ﬂuctuating Tobramycin MIC. The ﬂuctuations in MIC do not
appear to be related to the timing of therapy with TSI. Once a patient is
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colonised with an isolate with high level resistance to Tobramycin, most
will remain colonised (7/10). The isolation of HLR P aeruginosa didn’t
cease once TSI therapy was stopped.
Reference(s)
[1] Longitudinal development of tobramycin resistance in Pseudomonas
aeruginosa isolates from children with cystic ﬁbrosis on nebulised
tobramycin – effects on clinical outcomes. Doyle M, McNally P,
Leen G, Dier J, Greally P, Murphy P. ECCMID, 2006.
P2099 Strong association between ciproﬂoxacin use and
ciproﬂoxacin resistance within a hospital
I. Willemsen, A. Heijneman, D. Bogaers-Hofman, J. Kluytmans (Breda,
NL)
Objectives: In the last years the use of ciproﬂoxacin in our hospital
has increased signiﬁcantly. The objective of this study was to determine
the increase of resistance over time and to determine if the density of
antibiotic use correlates with the resistance in E. coli within individual
hospital units.
Method: The density of the use of ciproﬂoxacin (cip), amoxicillin +
clavulanic acid (amcl), 1st- and 2nd-generation cephalosporins (cef)
and trimethoprim/Sulfamethoxazole (sxt) was measured in 6 consecutive
one-day prevalence-surveys between 2001 and 2004. The susceptibility
patterns from E. coli were obtained from the Laboratory Information
System between 2003 and 2006. The percentage of resistance to cip,
amcl, cef and sxt in E. coli isolates was calculated per unit and over
time.
Results: A total of 4105 patients were included in the prevalence-
surveys. 23% (938) of the patients were on antibiotics, of whom
12.8% (120) were treated with cip, 39.1% (367) with amcl, 13.2% (124)
with cef and 5.7% (53) with sxt. 4790 E. coli susceptibility patterns were
obtained from hospitalised patients. There was a signiﬁcant increase
of resistance over time for all antibiotics, except for SXT, and a
signiﬁcant correlation between the prevalence of use and the percentage
of resistance for cip (R = 0.795, p = 0.006), amcl (R = 0.860, p = 0.001)
and cef (R = 0.828, p = 0.003). For cip the urology unit rose above the
other units with a use of 9.9% and a resistance rate of 19.8%. Also cip
resistance showed the strongest increase over time.
Conclusion: This study shows that cip resistance is associated with the
density of its use even on the micro-level of a hospital unit, and its
use has the strongest association with resistance of all frequently used
groups of antimicrobial-agents in the hospital.
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P2100 Appropriateness of antibiotic therapy on weekends vs
weekdays
J. Bishara, D. Hershkovitz, S. Pitlik (Petah-Tiqwa, IL)
Background: Several recent reports have raised concerns about the
adequacy of medical care provided by hospitals on weekends. Antibiotic
resistance is an emerging and universal problem and one of its major
contributors is the inappropriate prescription of antibiotics.
Objective: To compare the appropriateness of antibiotic treatment
prescribed in an emergency department (ED) of a tertiary medical centre
on weekdays and weekends.
Methods: During a one month period medical charts of 1029 ED visits,
who were discharged from ED were reviewed. Data of patients that
were discharged with antibiotics was blindly evaluated by two infectious
diseases specialists, and an “appropriateness score” was given to the
antibiotic prescription.
Results: Antibiotics were prescribed at discharge for182 (17.7%)
patients. The appropriateness score was signiﬁcantly better at the
beginning of the week and declined progressively toward the weekend
(p = 0.025). Appropriateness scores were higher for the surgical and
urological wings (p = 0.011), and for diagnoses of pneumonia and urinary
tract infection (p = 0.005). Time of the day, patients age and sex did not
have a signiﬁcant effect on the appropriateness score.
Conclusions: During the week, there is a progressive decay in the
appropriateness of antibiotic prescriptions in the ED. More studies are
needed to clarify measures improving appropriate antibiotic therapy in
weekends.
P2101 Do antibiotic ward rounds improve antibiotic prescribing?
J. Hinton, M.S. Kyi, S. Barnass (Isleworth, Middlesex, UK)
Objectives:
– To review all prescription charts for patients receiving restricted an-
tibiotics to ensure they are in line with the Trust Antibiotic Guidelines
or have been approved by one of the medical microbiologists
– To ensure antibiotics are stopped appropriately.
– To optimise timing and choice of switch from intravenous to oral
antibiotics.
– To provide ongoing education of staff during the review.
– To ensure ward staff are aware that the prescriptions are reviewed.
– To inform guidelines on review of antibiotics for pharmacists new to
the Trust.
Methods: Ward antibiotic charts were reviewed weekly (on different
days of the week and at different times) between May 2005 and October
2006 by the Senior Antibiotic Pharmacist and one of the Consultant
Microbiologists. All patients’ charts for whom restricted antibiotics
had been prescribed were reviewed, and patients were often reviewed
on several occasions. Changes were made or antibiotics stopped, as
appropriate, after consultation with the doctors looking after the patient
and explanation of the rationale. If the medical staff could not be
contacted, a note was left in the medical notes or on the prescription
chart to request review.
Results: A total of 403 patients’ charts were reviewed (mean 22 per
month, range 5−50). Of these, 212 (52.6%) had been approved by
the medical microbiologist or were in line with the Trust Antibiotic
Guidelines. 224/403 (55.5%) antibiotics were continued and 180/403
(44.5%) were changed or stopped. The mean number changed or stopped
per month was 10 (45.5%), with a range of 1−24 (11−69%).
The percentage of restricted antibiotics approved by the medical
microbiologists or in line with the Trust Antibiotic Guidelines, and the
percentage of antibiotics changed or stopped, did not change over the
course of the study or with the experience of the cohort of junior doctors,
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the majority of whom change posts at the beginning of August each
year. Junior ward staff know who we are and we deal with medical
and pharmacy enquiries on our round. Unused restricted antibiotics are
taken back to pharmacy, decreasing the likelihood of their use. Other
prescribing problems which are found are addressed.
Conclusion: We have not seen an improvement in prescribing of
restricted antibiotics, but we expect a continuing need to review charts
and educate staff. We plan to improve the prescription charts with a box
for the indication and duration of treatment. Guidelines to assist new
pharmacists have been compiled.
P2102 Pre-admission penicillin in patients with meningitis or
meningococcal disease
J.M. Darville, A.M. Lovering, A.P. MacGowan (Bristol, UK)
Objectives: UK government guidelines recommend that patients with
suspected meningitis or meningococcal disease receive intra-muscular
penicillin before admission to hospital. This study assesses adherence to
these guidelines by determining the frequency of such antibiotic use in
the area served by North Bristol Trust hospitals in a 6 year period.
Methods: Laboratory computer records were searched for patients
from whom Neisseria meningitidis was isolated from any sample,
and for those from whom Streptococcus pneumoniae or Haemophilus
inﬂuenzae were isolated from CSF samples. Hospital computer records
were searched for patients for whom the ﬁnal diagnosis was infectious
meningitis. Personal, demographic, clinical and therapeutic data were
extracted from patients’ hospital notes. To estimate the extent of pre-
admission illness, 10 presenting symptoms consistent with meningitis
or meningococcal disease were each allocated one point. The data were
transferred to a data-base for analysis.
Results: Mean severity scores are in brackets. 57 patients (2.9) did
not see a doctor (medical practitioner) pre-admission. 7 of these had
meningococcal septicaemia, 46 had meningitis (15 meningococcal) and
2 had meningococcal infection. 149 patients (3.36) did see a doctor.
40 (3.75) of these had antibiotic and 109 (3.21) did not. Of the 40,
4 had septicaemia (all meningococcal) and 35 had meningitis (11
meningococcal). Of the 109, 13 had septicaemia (all meningococcal)
and 90 had meningitis (29 meningococcal).
72 patients (3.15) had meningococcal disease. 48 (3.15) of these saw a
doctor, 24 (3.17) did not. Of the 48, 15 (3.67) had antibiotic, 33 (2.91)
did not.
46 (3.44) patients with rash saw a doctor.18 (3.72) of these had antibiotic,
28 (3.25) did not. Of 32 (3.28) patients with meningococcal disease and
rash seeing a doctor, 13 (3.69) had antibiotic, 19 (3.0) did not.
175 patients (3.3) had meningitis. 125 (3.47) of these saw a doctor, and
of these 35 (3.77) had antibiotic, 90 (3.36) did not.
Conclusions: Patients may be more likely to receive pre-admission
antibiotic the more symptoms they present with, when a rash is present
or when Neisseria meningitidis is subsequently isolated. However, the
majority of patients with meningitis or meningococcal disease seeing a
doctor before admission did not receive antibiotic. Our study suggests
that the guidelines have not been adequately observed and that it may
necessary to revise them.
P2103 Value of early serum assay for dosage adjustment of
vancomycin in continuous infusion
A. Forgeot, A. Carricajo, J. Morel, C. Venet, P. Mahul, S. Guyomarc’h,
N. Fonsale, C. Auboyer, F. Zeni, G. Aubert (Saint-Etienne, FR)
Objective: It is difﬁcult to obtain rapid bactericidal effects with
vancomycin (V) due to the increased MIC for staphylococcal strains
(in particular hetero-glycopeptide intermediate Staphylococcus aureus).
The aim of this study was to obtain a serum concentration for V (SCV)
of between 25 and 30mg/L and a serum concentration/MIC ratio of >8
within ﬁrst 24 hours in patients receiving V in a continuous infusion.
Methods: In 2005 and 2006, all patients requiring treatment with V in
the two study ICUs were given a loading dose of V of 30mg/kg in a
1-hour infusion followed by V at a dosage of 30mg/kg/24 h. Creatinine
clearance (CLc) was required to be >50mL/min. Dosage was adjusted
daily using a predetermined algorithm according to results of SCV:
SCV< 25mg/L, dosage increased by 4 to 8mg/kg/24 h; SCV> 30mg/L,
dosage reduced by 4 to 8mg/kg/24 h. V concentrations were measured
by FPIA kit (Abbott, USA) and the MIC for V was determined using
the E-Test method (AB Biodisk, Sweden).
Results: 21 patients were included in the study, 11 of whom
presented documented infection (coagulase-negative Staphylococcus sp
and Staphylococcus aureus with MIC between 0.5 and 3mg/L). Mean
CLc was 105 mL/min (range 50 to 178), mean body weight was 83 kg
(range 60 to 115), and SAPS II was 42.4 (range 22 to 64). A serum
concentration of V  26.5mg/L within 6 hours of the start of treatment
(best cut-off) was predictive of a concentration of V in excess of 25mg/L
at 24 h. The positive predictive value was 100% for the 14 patients with
CLc< 120mL/min and 90% for all 21 patients.
Conclusion: The target concentration for V of between 25 and 30mg/L
was achieved within 24 hours using our protocol in patients with
CLc< 120mL/min. Concentrations of V below the target level were seen
in patients with CLc> 120mL/min. Assay of V 6 hours after the start
of treatment allowed early dosage adjustment. The serum concentration
target must be reassessed on achievement of the MIC for V with regard
to the offending staphylococcal strain.
P2104 Surgical antibiotic prophylaxis in a Turkish university
hospital
S. Serin Senger, T. Togan, O. Kurt Azap, F. Timurkaynak, H. Arslan
(Ankara, TR)
Objective: Since surgical site infections are important causes of
morbidity, mortality, and healthcare costs, we aimed to assess the
appropriateness of use of surgical antimicrobial prophylaxis at our
institution.
Methods: A retrospective evaluation of the use of antimicrobial
prophylaxis in patients undergoing major surgery at Bas¸kent Uni-
versity Hospital from July to September 2006 was carried out. The
surgical operations included were liver and kidney transplantations,
cardiovascular surgery, urological operations, neurosurgical operations,
head and neck surgeries, orthopaedic surgery, breast surgery, general
abdominal colorectal surgery, and abdominal and vaginal hysterectomy.
Patients having infectious diseases prior to the surgery were excluded.
The guidelines to assess choice of antimicrobial agent and duration
of prophylaxis, were ASHP Therapeutic Guidelines on Antimicrobial
Prophylaxis in Surgery (1999), IDSA (Antimicrobial Prophylaxis for
Surgery: An Advisory Statement from the National Surgical Infection
Prevention Project) (2004), and Sanford Guide (2005).
Results: A total of 148 patients with a mean age of 41.9 years
(ranged 1−89 with SD= 24.5) were included in the study. General
Surgery was the leading department where 50 (33.8%) of the operations
were performed. Cefazolin was the most commonly used antibiotic
(constituting 48.0% of all the antimicrobial agents) during the study
period. In 77 (52.0%) of the cases the prophylaxis decisions were
appropriate, with proper choices of antibiotics in 51 cases and omissions
in 26, in accordance with the guidelines. Unnecessary prolongation of
prophylaxis in the patients of appropriately chosen antibiotics was found
to be 41.0%.
Conclusion: The results showed a signiﬁcantly high level of in-
appropriate use of antimicrobial prophylaxis in our institution. To
improve the proper use of prophylactic antimicrobials, the infection
control committee planned to prepare a local guideline and to organise
educational sessions for the surgeons.
